PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	French, JP; Hamilton, KL; Quindry, JC; Lee, Y; Upchurch, PA; Powers, SK				French, Joel P.; Hamilton, Karyn L.; Quindry, John C.; Lee, Youngil; Upchurch, Patrick A.; Powers, Scott K.			Exercise-induced protection against myocardial apoptosis and necrosis: MnSOD, calcium-handling proteins, and calpain	FASEB JOURNAL			English	Article						ischemia; reperfusion; antioxidant	ISCHEMIA-REPERFUSION INJURY; OXYGEN-FREE-RADICALS; VITAMIN-E; ISCHEMIA/REPERFUSION INJURY; INDUCED CARDIOPROTECTION; CARDIAC MYOCYTES; RAT-HEART; CA2+; PERFORMANCE; TOLERANCE	Exercise provides protection against myocardial ischemia-reperfusion (IR) injury. Understanding the mechanisms of this protection may lead to new interventions for the prevention and/or treatment of heart disease. Although presently these mechanisms are not well understood, reports suggest that manganese superoxide dismutase (MnSOD) and calpain may be critical mediators of this protection. We hypothesized that an exercise-induced increase in MnSOD would provide cardioprotection by attenuating IR-induced oxidative modification to critical Ca2+-handling proteins, thereby decreasing calpain-mediated cleavage of these and other proteins attenuating cardiomyocyte death. After IR, myocardial apoptosis and infarct size were significantly reduced in hearts of exercised animals compared with sedentary controls. In addition, exercise prevented IR-induced calpain activation as well as the oxidative modification and calpain-mediated degradation of myocardial Ca2+-handling proteins (L-type Ca2+ channels, phospholamban, and sarcoplasmic/endoplasmic reticulum calcium ATPase). Further, IR-induced activation of proapoptotic proteins was attenuated in exercised animals. Importantly, prevention of the exercise-induced increase in MnSOD activity via antisense oligonucleotides greatly attenuated the cardioprotection conferred by exercise. These results suggest that MnSOD provides cardioprotection by attenuating IR-induced oxidation and calpain-mediated degradation of myocardial Ca2+-handling proteins, thereby preventing myocardial apoptosis and necrosis.	[French, Joel P.; Hamilton, Karyn L.; Quindry, John C.; Lee, Youngil; Upchurch, Patrick A.; Powers, Scott K.] Univ Florida, Ctr Exercise Sci, Dept Appl Physiol & Kinesiol, Gainesville, FL 32611 USA; [French, Joel P.; Hamilton, Karyn L.; Quindry, John C.; Lee, Youngil; Upchurch, Patrick A.; Powers, Scott K.] Univ Florida, Dept Physiol & Physiol Genom, Gainesville, FL USA; [French, Joel P.; Hamilton, Karyn L.; Quindry, John C.; Lee, Youngil; Upchurch, Patrick A.; Powers, Scott K.] Univ Minnesota, Dept Med, Div Cardiol, Minneapolis, MN 55455 USA; [French, Joel P.; Hamilton, Karyn L.] Colorado State Univ, Dept Hlth & Exercise Sci, Ft Collins, CO 80523 USA; [French, Joel P.; Quindry, John C.; Lee, Youngil; Upchurch, Patrick A.; Powers, Scott K.] Appalachian State Univ, Dept Hlth Leisure & Exercise Sci, Boone, NC 28608 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of Minnesota System; University of Minnesota Twin Cities; Colorado State University; University of North Carolina; Appalachian State University	French, JP (corresponding author), Univ Minnesota, Dept Med, Div Cardiol, MMC 508 Mayo,420 Delaware St SE, Minneapolis, MN 55455 USA.	frenc147@umn.edu	Quindry, John/E-8476-2011; Lee, Youngil/AAX-2787-2021	Lee, Youngil/0000-0003-3819-2469				Adlam VJ, 2005, FASEB J, V19, P1088, DOI 10.1096/fj.05-3718com; AEBI H, 1984, METHOD ENZYMOL, V105, P121; Baines CP, 2005, J MOL CELL CARDIOL, V38, P47, DOI 10.1016/j.yjmcc.2004.11.004; Bajaj G, 2006, BIOCHEM BIOPH RES CO, V345, P1558, DOI 10.1016/j.bbrc.2006.05.059; Bognar Z, 2006, FREE RADICAL BIO MED, V41, P835, DOI 10.1016/j.freeradbiomed.2006.06.004; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; Chen M, 2002, J BIOL CHEM, V277, P29181, DOI 10.1074/jbc.M204951200; Chen ZY, 1998, J MOL CELL CARDIOL, V30, P2281, DOI 10.1006/jmcc.1998.0789; COETZEE WA, 1992, J MOL CELL CARDIOL, V24, P651, DOI 10.1016/0022-2828(92)91049-B; COETZEE WA, 1994, AM J PHYSIOL, V266, pH909, DOI 10.1152/ajpheart.1994.266.3.H909; Coombes JS, 2000, ACTA PHYSIOL SCAND, V169, P261, DOI 10.1046/j.1365-201x.2000.00740.x; Coombes JS, 2000, INT J VITAM NUTR RES, V70, P293, DOI 10.1024/0300-9831.70.6.293; Coombes JS, 2000, AM J PHYSIOL-REG I, V279, pR2149, DOI 10.1152/ajpregu.2000.279.6.R2149; Demirel HA, 2001, J APPL PHYSIOL, V91, P2205, DOI 10.1152/jappl.2001.91.5.2205; FLOHE L, 1984, METHOD ENZYMOL, V105, P114; French JP, 2006, AM J PHYSIOL-HEART C, V290, pH128, DOI 10.1152/ajpheart.00739.2005; Galvez AS, 2007, CIRC RES, V100, P1071, DOI 10.1161/01.RES.0000261938.28365.11; Garg S, 2005, J MOL CELL CARDIOL, V38, P73, DOI 10.1016/j.yjmcc.2004.11.006; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Guerra L, 1996, BRIT J PHARMACOL, V118, P1278, DOI 10.1111/j.1476-5381.1996.tb15534.x; Hamilton KL, 2004, FREE RADICAL BIO MED, V37, P1360, DOI 10.1016/j.freeradbiomed.2004.07.025; Hamilton KL, 2001, AM J PHYSIOL-HEART C, V281, pH1346, DOI 10.1152/ajpheart.2001.281.3.H1346; Hamilton KL, 2003, FREE RADICAL BIO MED, V34, P800, DOI 10.1016/S0891-5849(02)01431-4; Jin ZQ, 2005, AM J PHYSIOL-HEART C, V288, pH2986, DOI 10.1152/ajpheart.01144.2004; KANEKO M, 1989, AM J PHYSIOL, V256, pH368, DOI 10.1152/ajpheart.1989.256.2.H368; KATO M, 1988, MOL CELL BIOCHEM, V83, P15; Kim HD, 2003, J KOREAN MED SCI, V18, P337, DOI 10.3346/jkms.2003.18.3.337; KIM MS, 1987, AM J PHYSIOL, V252, pH252, DOI 10.1152/ajpheart.1987.252.2.H252; Kim SJ, 2001, CIRC RES, V89, P831, DOI 10.1161/hh2101.098547; Kourie JI, 1998, AM J PHYSIOL-CELL PH, V275, pC1, DOI 10.1152/ajpcell.1998.275.1.C1; LAWLER JM, 1993, MED SCI SPORT EXER, V25, P1259; Lebedeva I, 2001, ANNU REV PHARMACOL, V41, P403, DOI 10.1146/annurev.pharmtox.41.1.403; Lennon SL, 2004, ACTA PHYSIOL SCAND, V182, P161, DOI 10.1111/j.1365-201X.2004.01346.x; Lennon SL, 2004, AM J PHYSIOL-HEART C, V287, pH975, DOI 10.1152/ajpheart.01208.2003; Lennon SL, 2004, J APPL PHYSIOL, V96, P1299, DOI 10.1152/japplphysiol.00920.2003; Logue SE, 2005, J MOL CELL CARDIOL, V38, P21, DOI 10.1016/j.yjmcc.2004.11.009; MCCORD JM, 1968, J BIOL CHEM, V243, P5753; Node K, 1997, CIRCULATION, V96, P1257, DOI 10.1161/01.CIR.96.4.1257; Powers SK, 1998, AM J PHYSIOL-REG I, V275, pR1468, DOI 10.1152/ajpregu.1998.275.5.R1468; Quindry J, 2005, EXP GERONTOL, V40, P416, DOI 10.1016/j.exger.2005.03.010; Regula KA, 2005, J MOL CELL CARDIOL, V38, P3, DOI 10.1016/j.yjmcc.2004.11.003; Striessnig J, 1999, CELL PHYSIOL BIOCHEM, V9, P242, DOI 10.1159/000016320; SUZUKI YJ, 1992, AM J PHYSIOL, V262, pH114, DOI 10.1152/ajpheart.1992.262.1.H114; Taylor RP, 2003, CARDIOVASC RES, V58, P575, DOI 10.1016/S0008-6363(03)00285-2; Thierry AR, 2003, CURR OPIN MOL THER, V5, P133; Tokube K, 1998, PFLUG ARCH EUR J PHY, V437, P155, DOI 10.1007/s004240050760; Trumbeckaite S, 2003, BIOCHEM PHARMACOL, V65, P911, DOI 10.1016/S0006-2952(02)01610-6; Wu YL, 1998, TRENDS CARDIOVAS MED, V8, P312, DOI 10.1016/S1050-1738(98)00023-1; Yamashita N, 1999, J EXP MED, V189, P1699, DOI 10.1084/jem.189.11.1699; Yoshikawa Y, 2005, AM J PHYSIOL-HEART C, V288, pH1690, DOI 10.1152/ajpheart.00666.2004; Zima AV, 2006, CARDIOVASC RES, V71, P310, DOI 10.1016/j.cardiores.2006.02.019; ZOLOTARJOVA N, 1994, BBA-BIOMEMBRANES, V1192, P125, DOI 10.1016/0005-2736(94)90152-X	53	96	101	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2862	2871		10.1096/fj.07-102541	http://dx.doi.org/10.1096/fj.07-102541			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18417547	Green Published			2022-12-25	WOS:000258089300026
J	Tseng, RC; Lin, RK; Wen, CK; Tseng, C; Hsu, HS; Hsu, WH; Wang, YC				Tseng, R-C; Lin, R-K; Wen, C-K; Tseng, C.; Hsu, H-S; Hsu, W-H; Wang, Y-C			Epigenetic silencing of AXIN2/betaTrCP and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in lung tumorigenesis	ONCOGENE			English	Article						beta-catenin; AXIN2; betaTrCP; p53; epigenetic alteration; NSCLC	DOWN-REGULATION; EXPRESSION; CANCER; AXIN2; P53; MUTATIONS; ACTIVATION; STABILITY; CARCINOMA; PATHWAY	beta-catenin accumulation is often found in lung tumors, but only a few patients have mutations in beta-catenin gene. In addition, activated p53 downregulates beta-catenin. Therefore, we postulated that alteration of the degradation complex AXIN2 ( axis inhibition protein 2) and betaTrCP (beta-transducin repeat-containing protein) and p53 regulation could result in beta-catenin protein accumulation in lung cancer. Using the immunohistochemical and sequencing analyses, we found that patients with beta-catenin accumulation without mutation were associated with patients with p53 overexpression and low AXIN2 expression (P=0.023 similar to 0.041). Alteration of AXIN2 was associated with poor survival in early stage patients (P=0.016). Low expression of AXIN2 and betaTrCP was significantly associated with promoter hypermethylation and histone deacetylation. Ectopic expression and knockdown of p53, AXIN2 and betaTrCP genes in A549 (p53wild-type) and H1299 (p53 null) lung cancer cell lines showed cooperation between p53 and AXIN2/betaTrCP in the reduction of beta-catenin expression. Our clinical and cell model findings provide new evidence that epigenetic silencing of AXIN2/betaTrCP in the degradation complex and deregulation of p53-mediated control lead to wild-type beta-catenin nuclear accumulation in non-small cell lung cancer tumorigenesis. In addition, a high level of p53 downregulates the beta-catenin expression, but this effect is attenuated by non-functional AXIN2 or betaTrCP in lung cancer.	[Tseng, R-C; Lin, R-K; Wen, C-K; Wang, Y-C] Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, Tainan 70101, Taiwan; [Tseng, C.] Natl Tsing Hua Univ, Dept Life Sci, Hsinchu, Taiwan; [Hsu, H-S] Natl Yang Ming Univ, Inst Emergency & Crit Care Med, Taipei Vet Gen Hosp, Dept Surg,Div Thorac Surg, Taipei 112, Taiwan	National Cheng Kung University; National Tsing Hua University; National Yang Ming Chiao Tung University; Taipei Veterans General Hospital	Wang, YC (corresponding author), Natl Cheng Kung Univ, Coll Med, Dept Pharmacol, 1 Univ Rd, Tainan 70101, Taiwan.	ycw5798@mail.ncku.edu.tw	Wang, Yi-Ching/J-8702-2019	Wang, Yi-Ching/0000-0002-7694-2067				Chen RH, 2000, J BIOL CHEM, V275, P17894, DOI 10.1074/jbc.M905336199; Chu YW, 1997, AM J RESP CELL MOL, V17, P353, DOI 10.1165/ajrcmb.17.3.2837; Chung GG, 2004, CANCER, V100, P2084, DOI 10.1002/cncr.20232; Damalas A, 1999, EMBO J, V18, P3054, DOI 10.1093/emboj/18.11.3054; Derks S, 2004, CELL ONCOL, V26, P291; Gregorieff A, 2005, GENE DEV, V19, P877, DOI 10.1101/gad.1295405; Hughes TA, 2006, CANCER LETT, V233, P338, DOI 10.1016/j.canlet.2005.03.026; Hughes TA, 2005, EXP CELL RES, V303, P32, DOI 10.1016/j.yexcr.2004.09.014; Jones PA, 2007, CELL, V128, P683, DOI 10.1016/j.cell.2007.01.029; Kase S, 2000, CLIN CANCER RES, V6, P4789; KASE S, 2000, CLIN CANC RES; Kim CJ, 2007, APMIS, V115, P127, DOI 10.1111/j.1600-0463.2007.apm_562.x; Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1; Koch A, 2005, CLIN CANCER RES, V11, P4295, DOI 10.1158/1078-0432.CCR-04-1162; Koinuma K, 2006, ONCOGENE, V25, P139, DOI 10.1038/sj.onc.1209009; Lee MN, 2007, CLIN CANCER RES, V13, P832, DOI 10.1158/1078-0432.CCR-05-2694; Levina E, 2004, ONCOGENE, V23, P4444, DOI 10.1038/sj.onc.1207587; Liu J, 2001, MOL CELL, V7, P927, DOI 10.1016/S1097-2765(01)00241-6; Liu WG, 2000, NAT GENET, V26, P146, DOI 10.1038/79859; Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002; Mazieres J, 2005, CANCER LETT, V222, P1, DOI 10.1016/j.canlet.2004.08.040; Minna JD, 2002, CANCER CELL, V1, P49, DOI 10.1016/S1535-6108(02)00027-2; Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Polakis P, 2000, GENE DEV, V14, P1837; Sadot E, 2001, MOL CELL BIOL, V21, P6768, DOI 10.1128/MCB.21.20.6768-6781.2001; Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557; Spiegelman VS, 2000, MOL CELL, V5, P877, DOI 10.1016/S1097-2765(00)80327-5; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Tseng RC, 2005, INT J CANCER, V117, P241, DOI 10.1002/ijc.21178; Wang YC, 2005, J CLIN ONCOL, V23, P154, DOI 10.1200/JCO.2005.03.139; Wodarz A, 1998, ANNU REV CELL DEV BI, V14, P59, DOI 10.1146/annurev.cellbio.14.1.59	32	38	39	2	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4488	4496		10.1038/onc.2008.83	http://dx.doi.org/10.1038/onc.2008.83			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18372914	Bronze			2022-12-25	WOS:000257881700011
J	Garza, JC; Guo, M; Zhang, W; Lu, XY				Garza, Jacob C.; Guo, Ming; Zhang, Wei; Lu, Xin-Yun			Leptin increases adult hippocampal neurogenesis in vivo and in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTENT ANTITUMOR-ACTIVITY; NEURAL PRECURSOR CELLS; LONG-TERM POTENTIATION; DENTATE GYRUS; PROGENITOR CELLS; OBESE GENE; ANTIDEPRESSANT TREATMENT; SIGNAL-TRANSDUCTION; GROWTH-FACTOR; BETA-CATENIN	Leptin, an adipose-derived hormone, has been implicated in several physiological processes involving the hippocampus. However, the role of leptin in adult hippocampal neurogenesis remains unknown. Here we show that leptin regulates neurogenesis in the dentate gyrus of adult mice as well as in cultured adult hippocampal progenitor cells. Chronic administration of leptin to adult mice increased cell proliferation without significant effects on the differentiation and the survival of newly proliferated cells in the dentate gyrus. The expression of the long form leptin receptor, LepRb, was detected in hippocampal progenitor cells by reverse transcription-PCR and immunohistochemistry. Leptin treatment also increased proliferation of cultured adult hippocampal progenitor cells. Analysis of signal transduction pathways revealed that leptin stimulated phosphorylation of Akt and STAT3 but not ERK1/2. Furthermore, pre-treating the cells with specific inhibitors of Akt or STAT3 attenuated leptin-induced cell proliferation in a dose-dependent manner. Taken together, our results support a role for leptin in adult hippocampal neurogenesis and suggest the involvement of the Akt and STAT3 signaling pathways in mediating the actions of leptin on neurogenesis.	[Garza, Jacob C.; Guo, Ming; Zhang, Wei; Lu, Xin-Yun] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Lu, XY (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	lux3@uthscsa.edu	Lu, Xin-Yun/M-8657-2016	Guo, Ming/0000-0002-3698-5580	NATIONAL CANCER INSTITUTE [P30CA054174] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH073844, R01MH076929] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P30AG013319, P01AG019316] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA 54174, P30 CA054174] Funding Source: Medline; NIA NIH HHS [P30 AG013319, P01 AG 19316, P01 AG019316, P30 AG 013319] Funding Source: Medline; NIMH NIH HHS [R01 MH073844-02, R01 MH076929-03, R01 MH073844, MH 076929, R01 MH073844-04, R01 MH076929-01A1, R01 MH076929, R01 MH073844-03, R01 MH076929-02, MH 073844, R01 MH076929-04, R01 MH076929-05, R01 MH073844-05, R01 MH073844-01A2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adachi K, 2007, STEM CELLS, V25, P2827, DOI 10.1634/stemcells.2007-0177; Alonzi T, 2001, MOL CELL NEUROSCI, V18, P270, DOI 10.1006/mcne.2001.1018; Banks WA, 1996, PEPTIDES, V17, P305, DOI 10.1016/0196-9781(96)00025-3; Bjorbaek C, 2004, RECENT PROG HORM RES, V59, P305, DOI 10.1210/rp.59.1.305; Bjorbaek C, 2001, J BIOL CHEM, V276, P4747, DOI 10.1074/jbc.M007439200; Blaskovich MA, 2003, CANCER RES, V63, P1270; Burguera B, 2000, DIABETES, V49, P1219, DOI 10.2337/diabetes.49.7.1219; Burns KA, 2005, EUR J NEUROSCI, V21, P803, DOI 10.1111/j.1460-9568.2005.03907.x; Cameron HA, 2001, J COMP NEUROL, V435, P406, DOI 10.1002/cne.1040; CAMERON HA, 1993, NEUROSCIENCE, V56, P337, DOI 10.1016/0306-4522(93)90335-D; Cooper-Kuhn CM, 2002, DEV BRAIN RES, V134, P13, DOI 10.1016/S0165-3806(01)00243-7; Czeh B, 2002, BIOL PSYCHIAT, V52, P1057, DOI 10.1016/S0006-3223(02)01457-9; Duman RS, 2001, J PHARMACOL EXP THER, V299, P401; Duman RS, 2001, NEUROPSYCHOPHARMACOL, V25, P836, DOI 10.1016/S0893-133X(01)00358-X; Emsley JG, 2003, EXP NEUROL, V183, P298, DOI 10.1016/S0014-4886(03)00129-8; Farr SA, 2006, PEPTIDES, V27, P1420, DOI 10.1016/j.peptides.2005.10.006; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; Gu F, 2005, J NEUROSCI RES, V81, P163, DOI 10.1002/jnr.20561; Guo ZH, 2008, J BIOL CHEM, V283, P1754, DOI 10.1074/jbc.M703753200; HALAAS JL, 1995, SCIENCE, V269, P543, DOI 10.1126/science.7624777; Hayes NL, 2002, DEV BRAIN RES, V134, P77, DOI 10.1016/S0165-3806(01)00324-8; Hirabayashi Y, 2005, NEUROSCI RES, V51, P331, DOI 10.1016/j.neures.2005.01.004; Jacobs BL, 2002, BRAIN BEHAV IMMUN, V16, P602, DOI 10.1016/S0889-1591(02)00015-6; Jiang W, 2005, J CLIN INVEST, V115, P3104, DOI 10.1172/JCI25509; Jung KH, 2006, BRAIN RES, V1073, P190, DOI 10.1016/j.brainres.2005.12.037; Karonen SL, 1998, EUR J NUCL MED, V25, P607, DOI 10.1007/s002590050262; Kempermann G, 2003, DEVELOPMENT, V130, P391, DOI 10.1242/dev.00203; Kim CS, 2006, NEUROPSYCHOPHARMACOL, V31, pS237; Kim JB, 2004, BRAIN RES, V1027, P1, DOI 10.1016/j.brainres.2004.070.93; Learish RD, 2000, DEV BRAIN RES, V122, P97; Lee J, 2002, J NEUROCHEM, V80, P539, DOI 10.1046/j.0022-3042.2001.00747.x; Lee J, 2000, J MOL NEUROSCI, V15, P99, DOI 10.1385/JMN:15:2:99; LENDAHL U, 1990, CELL, V60, P585, DOI 10.1016/0092-8674(90)90662-X; Li XL, 2002, NEUROSCIENCE, V113, P607, DOI 10.1016/S0306-4522(02)00162-8; Li Z, 2004, BRAIN RES, V1021, P8, DOI 10.1016/j.brainres.2004.05.115; Lu B, 1999, J NEUROSCI RES, V58, P76, DOI 10.1002/(SICI)1097-4547(19991001)58:1<76::AID-JNR8>3.0.CO;2-0; Lu XY, 2007, CURR OPIN PHARMACOL, V7, P648, DOI 10.1016/j.coph.2007.10.010; Lu XY, 2006, P NATL ACAD SCI USA, V103, P1593, DOI 10.1073/pnas.0508901103; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; McEwen BS, 1999, ANNU REV NEUROSCI, V22, P105, DOI 10.1146/annurev.neuro.22.1.105; Miller JR, 1996, GENE DEV, V10, P2527, DOI 10.1101/gad.10.20.2527; Munzberg H, 2005, NAT NEUROSCI, V8, P566, DOI 10.1038/nn1454; Naito AT, 2005, CIRC RES, V97, P144, DOI 10.1161/01.RES.0000175241.92285.f8; Nakagawa S, 2002, J NEUROSCI, V22, P3673; Niswender KD, 2001, NATURE, V413, P794, DOI 10.1038/35101657; Oomura Y, 2006, PEPTIDES, V27, P2738, DOI 10.1016/j.peptides.2006.07.001; Overton JM, 2001, HYPERTENSION, V37, P663, DOI 10.1161/01.HYP.37.2.663; PELLEYMOUNTER MA, 1995, SCIENCE, V269, P540, DOI 10.1126/science.7624776; Peltier J, 2007, DEV NEUROBIOL, V67, P1348, DOI 10.1002/dneu.20506; Pham K, 2003, EUR J NEUROSCI, V17, P879, DOI 10.1046/j.1460-9568.2003.02513.x; Raber J, 2004, RADIAT RES, V162, P39, DOI 10.1667/RR3206; Ransome MI, 2007, J NEUROCHEM, V102, P1953, DOI 10.1111/j.1471-4159.2007.04684.x; REYNOLDS BA, 1992, J NEUROSCI, V12, P4565, DOI 10.1523/jneurosci.12-11-04565.1992; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Sun JZ, 2005, ONCOGENE, V24, P3236, DOI 10.1038/sj.onc.1208470; Taupin P, 2007, BRAIN RES REV, V53, P198, DOI 10.1016/j.brainresrev.2006.08.002; Trejo JL, 2001, J NEUROSCI, V21, P1628, DOI 10.1523/JNEUROSCI.21-05-01628.2001; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Wang L, 2006, J CEREBR BLOOD F MET, V26, P556, DOI 10.1038/sj.jcbfm.9600215; Wong EYH, 2006, NEUROSCIENCE, V137, P83, DOI 10.1016/j.neuroscience.2005.08.073; Xu AW, 2005, J CLIN INVEST, V115, P951, DOI 10.1172/JCI200524301; Yoshimatsu T, 2006, DEVELOPMENT, V133, P2553, DOI 10.1242/dev.02419; Zhang EE, 2004, P NATL ACAD SCI USA, V101, P16064, DOI 10.1073/pnas.0405041101; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	67	171	177	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18238	18247		10.1074/jbc.M800053200	http://dx.doi.org/10.1074/jbc.M800053200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18367451	Green Published, hybrid			2022-12-25	WOS:000256949200052
J	Bernasconi, R; Pertel, T; Luban, J; Molinari, M				Bernasconi, Riccardo; Pertel, Thomas; Luban, Jeremy; Molinari, Maurizio			A dual task for the Xbp1-responsive OS-9 variants in the mammalian endoplasmic reticulum - Inhibiting secretion of misfolded protein conformers and enhancing their disposal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ER-ASSOCIATED DEGRADATION; IDENTIFIES YOS9P; QUALITY-CONTROL; GLYCOPROTEINS; COMPLEX; ALPHA-1-ANTITRYPSIN; EXPRESSION; LECTIN; EDEM; MEMBRANES	Normally, non-native polypeptides are not transported through the secretory pathway. Rather, they are translocated from the endoplasmic reticulum (ER) lumen into the cytosol where they are degraded by proteasomes. Here we characterize the function in ER quality control of two proteins derived from alternative splicing of the OS-9 gene. OS-9.1 and OS-9.2 are ubiquitously expressed in human tissues and are amplified in tumors. They are transcriptionally induced upon activation of the Ire1/Xbp1 ER-stress pathway. OS-9 variants do not associate with folding-competent proteins. Rather, they selectively bind folding-defective ones thereby inhibiting transport of non-native conformers through the secretory pathway. The intralumenal level of OS-9.1 and OS-9.2 inversely correlates with the fraction of a folding-defective glycoprotein, the Null(hong kong) (NHK) variant of alpha 1-antitrypsin that escapes retention-based ER quality control. OS-9 up-regulation does not affect NHK disposal, but reduction of the intralumenal level of OS-9.1 and OS-9.2 substantially delays disposal of this model substrate. OS-9.1 and OS-9.2 also associate transiently with non-glycosylated folding-defective proteins, but association is unproductive. Finally, OS-9 activity does not require an intact mannose 6-P homology domain. Thus, OS-9.1 and OS-9.2 play a dual role in mammalian ER quality control: first as crucial retention factors for misfolded conformers, and second as promoters of protein disposal from the ER lumen.	[Bernasconi, Riccardo; Pertel, Thomas; Luban, Jeremy; Molinari, Maurizio] Inst Biomed Res, CH-6500 Bellinzona, Switzerland	Universita della Svizzera Italiana	Molinari, M (corresponding author), Inst Biomed Res, CH-6500 Bellinzona, Switzerland.	maurizio.molinari@irb.unisi.ch	Longo, Kenneth A/A-5631-2010; Molinari, Maurizio/N-2587-2019	Molinari, Maurizio/0000-0002-7636-5829; Pertel, Thomas/0000-0002-2286-6011; Luban, Jeremy/0000-0001-5650-4054	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036199] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI036199] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Baek JH, 2005, MOL CELL, V17, P503, DOI 10.1016/j.molcel.2005.01.011; Bhamidipati A, 2005, MOL CELL, V19, P741, DOI 10.1016/j.molcel.2005.07.027; BLOBEL G, 1975, J CELL BIOL, V67, P835, DOI 10.1083/jcb.67.3.835; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; Brodsky JL, 2007, BIOCHEM J, V404, P353, DOI 10.1042/BJ20061890; Buschhorn BA, 2004, FEBS LETT, V577, P422, DOI 10.1016/j.febslet.2004.10.039; CARLSON JA, 1988, J CLIN INVEST, V82, P26, DOI 10.1172/JCI113580; Carvalho P, 2006, CELL, V126, P361, DOI 10.1016/j.cell.2006.05.043; Christianson JC, 2008, NAT CELL BIOL, V10, P272, DOI 10.1038/ncb1689; Denic V, 2006, CELL, V126, P349, DOI 10.1016/j.cell.2006.05.045; Flashman E, 2005, MOL CELL, V17, P472, DOI 10.1016/j.molcel.2005.02.001; Gauss R, 2006, NAT CELL BIOL, V8, P849, DOI 10.1038/ncb1445; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Hebert DN, 2007, PHYSIOL REV, V87, P1377, DOI 10.1152/physrev.00050.2006; Kanehara K, 2007, SEMIN CELL DEV BIOL, V18, P743, DOI 10.1016/j.semcdb.2007.09.007; Kaneko M, 2007, FEBS LETT, V581, P5355, DOI 10.1016/j.febslet.2007.10.033; Kim W, 2005, MOL CELL, V19, P753, DOI 10.1016/j.molcel.2005.08.010; Kimura Y, 1997, J BIOCHEM-TOKYO, V122, P1190; Kimura Y, 1998, J BIOCHEM-TOKYO, V123, P876; Litovchick L, 2002, J BIOL CHEM, V277, P34413, DOI 10.1074/jbc.M203986200; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; Meusser B, 2005, NAT CELL BIOL, V7, P766, DOI 10.1038/ncb0805-766; Molinari M, 2003, SCIENCE, V299, P1397, DOI 10.1126/science.1079474; Molinari M, 2002, METHOD ENZYMOL, V348, P35, DOI 10.1016/S0076-6879(02)48623-5; Molinari M, 2007, NAT CHEM BIOL, V3, P313, DOI 10.1038/nchembio880; NIELSEN H, 1998, 6 INT C INT SYST MOL, P122; Olivari S, 2005, J BIOL CHEM, V280, P2424, DOI 10.1074/jbc.C400534200; Paganetti P, 2005, J CELL BIOL, V168, P863, DOI 10.1083/jcb.200410047; ROTHMAN JE, 1984, J CELL BIOL, V99, P248, DOI 10.1083/jcb.99.1.248; SIFERS RN, 1988, J BIOL CHEM, V263, P7330; Szathmary R, 2005, MOL CELL, V19, P765, DOI 10.1016/j.molcel.2005.08.015; Wang SY, 2008, NAT CELL BIOL, V10, P251, DOI 10.1038/ncb0308-251; Wang Y, 2007, J BIOL CHEM, V282, P36561, DOI 10.1074/jbc.M703903200; Yoshida H, 2003, DEV CELL, V4, P265, DOI 10.1016/S1534-5807(03)00022-4	34	97	98	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16446	16454		10.1074/jbc.M802272200	http://dx.doi.org/10.1074/jbc.M802272200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18417469	hybrid, Green Published			2022-12-25	WOS:000256497100021
J	Lambert, LJ; Bobkov, AA; Smith, JW; Marassi, FM				Lambert, Lester J.; Bobkov, Andrey A.; Smith, Jeffrey W.; Marassi, Francesca M.			Competitive interactions of collagen and a jararhagin-derived disintegrin peptide with the integrin alpha 2-I domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SNAKE-VENOM METALLOPROTEINASE; DEPENDENT ADHESION SITE; ALPHA-2 I-DOMAIN; CRYSTAL-STRUCTURE; BINDING-SITE; STRUCTURAL BASIS; DIVALENT-CATION; RKKH PEPTIDES; A-DOMAIN; NMR	Integrin alpha 2 beta 1 is a major receptor required for activation and adhesion of platelets, through the specific recognition of collagen by the alpha 2-I domain (alpha 2-I), which binds fibrillar collagen via Mg2+ -bridged interactions. The crystal structure of a truncated form of the alpha 2-I domain, bound to a triple helical collagen peptide, revealed conformational changes suggestive of a mechanism where the ligand-bound I domain can initiate and propagate conformational change to the full integrin complex. Collagen binding by alpha 2-I and fibrinogen-dependent platelet activity can be inhibited by snake venom polypeptides. Here we describe the inhibitory effect of a short cyclic peptide derived from the snake toxin metalloprotease jararhagin, with specific amino acid sequence RKKH, on the ability of alpha 2-I to bind triple helical collagen. Isothermal titration calorimetry measurements showed that the interactions of alpha 2-I with collagen or RKKH peptide have similar affinities, and NMR chemical shift mapping experiments with N-15-labeled alpha 2-I, and unlabeled RKKH peptide, indicate that the peptide competes for the collagen-binding site of alpha 2-I but does not induce a large scale conformational rearrangement of the I domain.	[Lambert, Lester J.; Bobkov, Andrey A.; Smith, Jeffrey W.; Marassi, Francesca M.] Burnham Inst Med Res, La Jolla, CA 92037 USA	Sanford Burnham Prebys Medical Discovery Institute	Marassi, FM (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	fmarassi@burnham.org			NATIONAL CANCER INSTITUTE [P30CA030199] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL072862, U01HL080718] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA030199] Funding Source: Medline; NHLBI NIH HHS [HL080718, U01 HL080718, HL072862] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; Calderwood DA, 1997, J BIOL CHEM, V272, P12311, DOI 10.1074/jbc.272.19.12311; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Cruz MA, 2005, BLOOD, V105, P1986, DOI 10.1182/blood-2004-04-1365; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DELUCA M, 1995, BIOCHEM BIOPH RES CO, V206, P570, DOI 10.1006/bbrc.1995.1081; Elshorst B, 2003, J BIOMOL NMR, V27, P191, DOI 10.1023/A:1024991511799; Emsley J, 1997, J BIOL CHEM, V272, P28512, DOI 10.1074/jbc.272.45.28512; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; Feng YB, 1996, J AM CHEM SOC, V118, P10351, DOI 10.1021/ja961260c; Goddard T.D., 2004, SPARKY 3; Grzesiek S, 1996, NAT STRUCT BIOL, V3, P340, DOI 10.1038/nsb0496-340; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; Hoffman RMB, 2005, BIOCHEMISTRY-US, V44, P15750, DOI 10.1021/bi051583y; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Ivaska J, 1999, J BIOL CHEM, V274, P3513, DOI 10.1074/jbc.274.6.3513; Jung SM, 1998, J BIOL CHEM, V273, P14827, DOI 10.1074/jbc.273.24.14827; KAMATA T, 1994, J BIOL CHEM, V269, P26006; KAMATA T, 1994, J BIOL CHEM, V269, P9659; KAMATA T, 1995, J BIOL CHEM, V270, P12531, DOI 10.1074/jbc.270.21.12531; Kamiguti AS, 1996, TOXICON, V34, P627, DOI 10.1016/0041-0101(96)00017-7; Kamiguti AS, 1996, BIOCHEM J, V320, P635, DOI 10.1042/bj3200635; Kapyla J, 2007, J MED CHEM, V50, P2742, DOI 10.1021/jm070063t; King SL, 1997, J BIOL CHEM, V272, P28518, DOI 10.1074/jbc.272.45.28518; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Laing GD, 2005, TOXICON, V45, P987, DOI 10.1016/j.toxicon.2005.02.013; LEE JO, 1995, CELL, V80, P631, DOI 10.1016/0092-8674(95)90517-0; Legge GB, 2000, J MOL BIOL, V295, P1251, DOI 10.1006/jmbi.1999.3409; Luo BH, 2007, ANNU REV IMMUNOL, V25, P619, DOI 10.1146/annurev.immunol.25.022106.141618; MORI S, 1995, J MAGN RESON SER B, V108, P94, DOI 10.1006/jmrb.1995.1109; Nymalm Y, 2004, J BIOL CHEM, V279, P7962, DOI 10.1074/jbc.M312912200; PAINE MJI, 1992, J BIOL CHEM, V267, P22869; Pentikainen O, 1999, J BIOL CHEM, V274, P31493, DOI 10.1074/jbc.274.44.31493; Qu AD, 1996, STRUCTURE, V4, P931, DOI 10.1016/S0969-2126(96)00100-1; QU AD, 1995, P NATL ACAD SCI USA, V92, P10277, DOI 10.1073/pnas.92.22.10277; RAJAGOPAL P, 1994, BIOCHEMISTRY-US, V33, P15271, DOI 10.1021/bi00255a008; Shimaoka M, 2003, CELL, V112, P99, DOI 10.1016/S0092-8674(02)01257-6; Shimaoka M, 2002, ANNU REV BIOPH BIOM, V31, P485, DOI 10.1146/annurev.biophys.31.101101.140922; Shuker SB, 1996, SCIENCE, V274, P1531, DOI 10.1126/science.274.5292.1531; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Tuckwell DS, 2000, BIOCHEM J, V350, P485, DOI 10.1042/0264-6021:3500485; Yin H, 2006, BIOORG MED CHEM LETT, V16, P3380, DOI 10.1016/j.bmcl.2006.04.037	43	20	24	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16665	16672		10.1074/jbc.M710483200	http://dx.doi.org/10.1074/jbc.M710483200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18417478	hybrid, Green Published			2022-12-25	WOS:000256497100043
J	Resto, VA; Burdick, MM; Dagia, NM; McCammon, SD; Fennewald, SM; Sackstein, R				Resto, Vicente A.; Burdick, Monica M.; Dagia, Nilesh M.; McCammon, Susan D.; Fennewald, Susan M.; Sackstein, Robert			L-selectin-mediated lymphocyte-cancer cell interactions under low fluid shear conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH ENDOTHELIAL VENULES; COLON-CARCINOMA CELLS; TUMOR LYMPHANGIOGENESIS; HOMING RECEPTORS; BINDING-ACTIVITY; ADHESION; LIGAND; METASTASIS; PSGL-1; FLOW	Cell migration in blood flow is mediated by engagement of specialized adhesion molecules that function under hemodynamic shear conditions, and many of the effectors of these adhesive interactions, such as the selectins and their ligands, are well defined. However, in contrast, our knowledge of the adhesion molecules operant under lymphatic flow conditions is incomplete. Among human malignancies, head and neck squamous cell cancer displays a marked predilection for locoregional lymph node metastasis. Based on this distinct tropism, we hypothesized that these cells express adhesion molecules that promote their binding to lymphoid tissue under lymphatic fluid shear stress. Accordingly, we investigated adhesive interactions between these and other cancer cells and the principal resident cells of lymphoid organs, lymphocytes. Parallel plate flow chamber studies under defined shear conditions, together with biochemical analyses, showed that human head and neck squamous cell cancer cells express heretofore unrecognized L-selectin ligand(s) that mediate binding to lymphocyte L-selectin at conspicuously low shear stress levels of 0.07-0.08 dynes/cm(2), consistent with lymphatic flow. The binding of head and neck squamous cancer cells to L-selectin displays canonical biochemical features, such as requirements for sialylation, sulfation, and N-glycosylation, but displays a novel operational shear threshold differing from all other L-selectin ligands, including those expressed on colon cancer and leukemic cells (e. g. HCELL). These data define a novel class of L-selectin ligands and expand the scope of function for L-selectin within circulatory systems to now include a novel activity within shear stresses characteristic of lymphatic flow.	[Resto, Vicente A.; Burdick, Monica M.; Dagia, Nilesh M.; Sackstein, Robert] Harvard Univ, Brigham & Womens Hosp, Skin Dis Res Ctr, Dept Dermatol, Boston, MA 02115 USA; [Sackstein, Robert] Harvard Univ, Brigham & Womens Hosp, Skin Dis Res Ctr, Dept Med, Boston, MA 02115 USA; [Sackstein, Robert] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Resto, Vicente A.; McCammon, Susan D.; Fennewald, Susan M.] Univ Texas Galveston, Med Branch, Dept Otolaryngol, Galveston, TX 77555 USA; [Resto, Vicente A.; Fennewald, Susan M.] Univ Texas Galveston, Med Branch, Dept Biochem & Mol Biol, Galveston, TX 77555 USA; [Resto, Vicente A.; Fennewald, Susan M.] Univ Texas Galveston, Med Branch, Sealy Ctr Canc Cell Biol, Galveston, TX 77555 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston	Sackstein, R (corresponding author), Harvard Univ, Skin Dis Res Ctr, 77 Ave Louis Pasteur,Rm 671, Boston, MA 02115 USA.	rsackstein@rics.bwh.harvard.edu	Resto, Vicente/D-9891-2014	Burdick, Monica/0000-0003-3168-0072	NATIONAL CANCER INSTITUTE [K08CA132988, R01CA121335] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073714, R01HL060528] Funding Source: NIH RePORTER; NCI NIH HHS [K08 CA132988, R01 CA121335] Funding Source: Medline; NHLBI NIH HHS [R01 HL073714, R01 HL060528] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Brodt P, 1997, INT J CANCER, V71, P612, DOI 10.1002/(SICI)1097-0215(19970516)71:4<612::AID-IJC17>3.0.CO;2-D; Burdick MM, 2003, AM J PHYSIOL-CELL PH, V284, pC977, DOI 10.1152/ajpcell.00423.2002; Burdick MM, 2006, J BIOL CHEM, V281, P13899, DOI 10.1074/jbc.M513617200; CHEN AJ, 1995, J EXP MED, V182, P519, DOI 10.1084/jem.182.2.519; Diacovo TG, 1996, SCIENCE, V273, P252, DOI 10.1126/science.273.5272.252; Dimitroff CJ, 2000, P NATL ACAD SCI USA, V97, P13841, DOI 10.1073/pnas.250484797; Dimitroff CJ, 2001, J BIOL CHEM, V276, P47623, DOI 10.1074/jbc.M105997200; Fischer M, 1996, AM J PHYSIOL-HEART C, V270, pH358, DOI 10.1152/ajpheart.1996.270.1.H358; Forastiere A, 2001, NEW ENGL J MED, V345, P1890, DOI 10.1056/NEJMra001375; Fuhlbrigge RC, 1996, J CELL BIOL, V135, P837, DOI 10.1083/jcb.135.3.837; Fuhlbrigge RC, 2002, J IMMUNOL, V168, P5645, DOI 10.4049/jimmunol.168.11.5645; Gulubova MV, 2002, HISTOCHEM J, V34, P67; Hanley WD, 2005, CANCER RES, V65, P5812, DOI 10.1158/0008-5472.CAN-04-4557; He YL, 2002, J NATL CANCER I, V94, P819, DOI 10.1093/jnci/94.11.819; Hoshida T, 2006, CANCER RES, V66, P8065, DOI 10.1158/0008-5472.CAN-06-1392; Johnson LA, 2006, J EXP MED, V203, P2763, DOI 10.1084/jem.20051759; JUNG TM, 1990, J IMMUNOL, V144, P3130; Kannagi R, 2002, CURR OPIN STRUC BIOL, V12, P599, DOI 10.1016/S0959-440X(02)00365-2; KISHIMOTO TK, 1989, SCIENCE, V245, P1238, DOI 10.1126/science.2551036; Lawrence MB, 1997, J CELL BIOL, V136, P717, DOI 10.1083/jcb.136.3.717; LAWRENCE MB, 1990, BLOOD, V75, P227; Mandriota SJ, 2001, EMBO J, V20, P672, DOI 10.1093/emboj/20.4.672; Puri KD, 1998, NATURE, V392, P930, DOI 10.1038/31954; PURI KD, 1995, J CELL BIOL, V131, P261, DOI 10.1083/jcb.131.1.261; Rocco JW, 2006, CANCER CELL, V9, P45, DOI 10.1016/j.ccr.2005.12.013; Rosen SD, 2004, ANNU REV IMMUNOL, V22, P129, DOI 10.1146/annurev.immunol.21.090501.080131; Sackstein R, 2000, BLOOD, V96, P2765, DOI 10.1182/blood.V96.8.2765.h8002765_2765_2774; Sackstein R, 1997, BLOOD, V89, P2773, DOI 10.1182/blood.V89.8.2773; Sackstein R, 2005, CURR OPIN HEMATOL, V12, P444, DOI 10.1097/01.moh.0000177827.78280.79; SCHER RL, 1993, ARCH OTOLARYNGOL, V119, P432; Schramm R, 2006, INFLAMM RES, V55, P160, DOI 10.1007/s00011-006-0066-0; Skobe M, 2001, NAT MED, V7, P192, DOI 10.1038/84643; Spertini O, 1996, J CELL BIOL, V135, P523, DOI 10.1083/jcb.135.2.523; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; von Andrian UH, 2003, NAT REV IMMUNOL, V3, P867, DOI 10.1038/nri1222; Walcheck B, 1996, J CLIN INVEST, V98, P1081, DOI 10.1172/JCI118888	36	32	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15816	15824		10.1074/jbc.M708899200	http://dx.doi.org/10.1074/jbc.M708899200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18385135	Green Published, hybrid			2022-12-25	WOS:000256332500039
J	Takahashi, S; Matsuno, H; Furusawa, H; Okahata, Y				Takahashi, Shuntaro; Matsuno, Hisao; Furusawa, Hiroyuki; Okahata, Yoshio			Direct monitoring of allosteric recognition of type IIE restriction endonuclease EcoRII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUARTZ-CRYSTAL MICROBALANCE; SITE-SPECIFIC RECOMBINATION; TARGET RECOGNITION; DNA; ADSORPTION; SURFACES; BINDING; PROTEIN; MECHANISM; CLEAVAGE	EcoRII is a homodimer with two domains consisting of a DNA-binding N terminus and a catalytic C terminus and recognizes two specific sequences on DNA. It shows a relatively complicated cleavage reaction in bulk solution. After binding to either recognition site, EcoRII cleaves the other recognition site of the same DNA (cis-binding) strand and/or the recognition site of the other DNA (trans-binding) strand. Although it is difficult to separate these two reactions in bulk solution, we could simply obtain the binding and cleavage kinetics of only the cis-binding by following the frequency (mass) changes of a DNA-immobilized quartz-crystal microbalance (QCM) responding to the addition of EcoRII in aqueous solution. We obtained the maximum binding amounts (Delta m(max)) the dissociation constants (K-d), the binding and dissociation rate constants (k(on) and k(off)), and the catalytic cleavage reaction rate constants (k(cat)) for wildtype EcoRII, the N-terminal-truncated form (EcoRII N-domain), and the mutant derivatives in its C-terminal domain (K263A and R330A). It was determined from the kinetic analyses that the N-domain, which covers the catalytic C-domain in the absence of DNA, preferentially binds to the one DNA recognition site while transforming EcoRII into an active form allosterically, and then the secondary C-domain binds to and cleaves the other recognition site of the DNA strand.	[Takahashi, Shuntaro; Matsuno, Hisao; Furusawa, Hiroyuki; Okahata, Yoshio] Tokyo Inst Technol, Frontier Res Ctr, Dept Biomol Engn, Midori Ku, Yokohama, Kanagawa, Japan	Tokyo Institute of Technology	Okahata, Y (corresponding author), Tokyo Inst Technol, Frontier Res Ctr, Dept Biomol Engn, Midori Ku, B-53 4259 Nagatsuda, Yokohama, Kanagawa, Japan.	yokahata@bio.titech.ac.jp	Takahashi, Shuntaro/AFM-6339-2022	Takahashi, Shuntaro/0000-0002-7569-1761				Bozic D, 1996, J MOL BIOL, V255, P176, DOI 10.1006/jmbi.1996.0015; Chinen A, 2000, MOL BIOL EVOL, V17, P1610, DOI 10.1093/oxfordjournals.molbev.a026260; Deibert M, 2000, NAT STRUCT BIOL, V7, P792, DOI 10.1038/79032; Fant C, 2002, BIOMACROMOLECULES, V3, P732, DOI 10.1021/bm025506j; Ferrell JE, 1998, SCIENCE, V280, P895, DOI 10.1126/science.280.5365.895; Gopaul DN, 1998, EMBO J, V17, P4175, DOI 10.1093/emboj/17.14.4175; Graneli A, 2003, LANGMUIR, V19, P842, DOI 10.1021/la026231w; Guo F, 1999, P NATL ACAD SCI USA, V96, P7143, DOI 10.1073/pnas.96.13.7143; Guo F, 1997, NATURE, V389, P40, DOI 10.1038/37925; Hook F, 2002, COLLOID SURFACE B, V24, P155, DOI 10.1016/S0927-7765(01)00236-3; Hook F, 1998, P NATL ACAD SCI USA, V95, P12271, DOI 10.1073/pnas.95.21.12271; KOSYKH V G, 1982, Biokhimiya, V47, P619; KRUGER DH, 1988, NUCLEIC ACIDS RES, V16, P3997; KRUGER DH, 1995, FEMS MICROBIOL REV, V17, P177; Larsson C, 2003, ANAL CHEM, V75, P5080, DOI 10.1021/ac034269n; Lewis M, 1996, SCIENCE, V271, P1247, DOI 10.1126/science.271.5253.1247; Matsuno H, 2001, BIOCHEMISTRY-US, V40, P3615, DOI 10.1021/bi001699o; Mucke M, 2003, NUCLEIC ACIDS RES, V31, P6079, DOI 10.1093/nar/gkg836; Mucke M, 2002, EMBO J, V21, P5262, DOI 10.1093/emboj/cdf514; Mucke M, 2000, J BIOL CHEM, V275, P30631, DOI 10.1074/jbc.M003904200; Munro JC, 2004, MACROMOLECULES, V37, P925, DOI 10.1021/ma030297w; Nishino H, 2004, J AM CHEM SOC, V126, P14752, DOI 10.1021/ja046583k; Nishino H, 2004, J AM CHEM SOC, V126, P2264, DOI 10.1021/ja0361805; Otzen DE, 2003, COLLOID SURFACE B, V29, P67, DOI 10.1016/S0927-7765(02)00186-8; Ozeki T, 2007, ANAL CHEM, V79, P79, DOI 10.1021/ac060873x; Petrauskene OV, 1998, FEBS LETT, V425, P29, DOI 10.1016/S0014-5793(98)00184-7; Pingoud A, 2005, CELL MOL LIFE SCI, V62, P685, DOI 10.1007/s00018-004-4513-1; Pingoud A, 2001, NUCLEIC ACIDS RES, V29, P3705, DOI 10.1093/nar/29.18.3705; Pingoud A, 1997, EUR J BIOCHEM, V246, P1, DOI 10.1111/j.1432-1033.1997.t01-6-00001.x; Pingoud V, 2003, J MOL BIOL, V329, P913, DOI 10.1016/S0022-2836(03)00523-0; Reuter M, 1998, J BIOL CHEM, V273, P8294, DOI 10.1074/jbc.273.14.8294; Reuter M, 1999, J BIOL CHEM, V274, P5213, DOI 10.1074/jbc.274.8.5213; Rickert J, 1997, ANAL CHEM, V69, P1441, DOI 10.1021/ac960875p; SAUERBREY G, 1959, Z PHYS, V155, P206, DOI 10.1007/BF01337937; SCHLEIF R, 1992, ANNU REV BIOCHEM, V61, P199, DOI 10.1146/annurev.bi.61.070192.001215; Siksnys V, 1999, J MOL BIOL, V291, P1105, DOI 10.1006/jmbi.1999.2977; Takahashi N, 2002, J BACTERIOL, V184, P6100, DOI 10.1128/JB.184.22.6100-6108.2002; Takahashi S, 2007, ANAL BIOCHEM, V361, P210, DOI 10.1016/j.ab.2006.11.030; Zhou XYE, 2004, J MOL BIOL, V335, P307, DOI 10.1016/j.jmb.2003.10.030	39	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15023	15030		10.1074/jbc.M800334200	http://dx.doi.org/10.1074/jbc.M800334200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18367450	Green Published, hybrid			2022-12-25	WOS:000256232000015
J	Clement, EA; Richard, A; Thwaites, M; Ailon, J; Peters, S; Dickson, CT				Clement, Elizabeth A.; Richard, Alby; Thwaites, Megan; Ailon, Jonathan; Peters, Steven; Dickson, Clayton T.			Cyclic and Sleep-Like Spontaneous Alternations of Brain State Under Urethane Anaesthesia	PLOS ONE			English	Article								Background: Although the induction of behavioural unconsciousness during sleep and general anaesthesia has been shown to involve overlapping brain mechanisms, sleep involves cyclic fluctuations between different brain states known as active (paradoxical or rapid eye movement: REM) and quiet (slow-wave or non-REM: nREM) stages whereas commonly used general anaesthetics induce a unitary slow-wave brain state. Methodology/Principal Findings: Long-duration, multi-site forebrain field recordings were performed in urethane-anaesthetized rats. A spontaneous and rhythmic alternation of brain state between activated and deactivated electroencephalographic (EEG) patterns was observed. Individual states and their transitions resembled the REM/nREM cycle of natural sleep in their EEG components, evolution, and time frame (similar to 11 minute period). Other physiological variables such as muscular tone, respiration rate, and cardiac frequency also covaried with forebrain state in a manner identical to sleep. The brain mechanisms of state alternations under urethane also closely overlapped those of natural sleep in their sensitivity to cholinergic pharmacological agents and dependence upon activity in the basal forebrain nuclei that are the major source of forebrain acetylcholine. Lastly, stimulation of brainstem regions thought to pace state alternations in sleep transiently disrupted state alternations under urethane. Conclusions/Significance: Our results suggest that urethane promotes a condition of behavioural unconsciousness that closely mimics the full spectrum of natural sleep. The use of urethane anaesthesia as a model system will facilitate mechanistic studies into sleep-like brain states and their alternations. In addition, it could also be exploited as a tool for the discovery of new molecular targets that are designed to promote sleep without compromising state alternations.	[Clement, Elizabeth A.; Peters, Steven; Dickson, Clayton T.] Univ Alberta, Ctr Neurosci, Edmonton, AB, Canada; [Richard, Alby; Thwaites, Megan; Ailon, Jonathan; Dickson, Clayton T.] Univ Alberta, Dept Psychol, Edmonton, AB, Canada; [Dickson, Clayton T.] Univ Alberta, Dept Physiol, Edmonton, AB, Canada	University of Alberta; University of Alberta; University of Alberta	Dickson, CT (corresponding author), Univ Alberta, Ctr Neurosci, Edmonton, AB, Canada.	cdickson@ualberta.ca	Sanguansri, Luz/B-6630-2011; Peters, Steven/AAT-5974-2021	Sanguansri, Luz/0000-0003-1908-7604; Peters, Steven/0000-0002-4799-1265; Dickson, Clayton/0000-0002-3849-8110; Clement, Elizabeth/0000-0001-8222-4048	Canadian Institutes of Health [MOP 77625]; Alberta Heritage Foundation for Medical Research (AHFMR) [summer studentships]; Natural Sciences and Engineering Research Council of Canada [summer studentships]	Canadian Institutes of Health(Canadian Institutes of Health Research (CIHR)); Alberta Heritage Foundation for Medical Research (AHFMR)(Alberta Heritage Foundation for Medical Research); Natural Sciences and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC)CGIAR)	This study was supported by a Canadian Institutes of Health Research grant (MOP 77625 to CTD). CTD is a Scholar of the Alberta Heritage Foundation for Medical Research (AHFMR). SRP and JA were supported by Natural Sciences and Engineering Research Council of Canada summer studentships. SRP was additionally supported by an AHFMR summer studentship.	ASERINSK.E, 1965, SCIENCE, V150, P763, DOI 10.1126/science.150.3697.763-a; ASERINSKY E, 1953, SCIENCE, V118, P273, DOI 10.1126/science.118.3062.273; BLAND BH, 1986, PROG NEUROBIOL, V26, P1, DOI 10.1016/0301-0082(86)90019-5; BLAND BH, 1993, PROG NEUROBIOL, V41, P157, DOI 10.1016/0301-0082(93)90007-F; BORBELY AA, 1976, BRAIN RES, V114, P305, DOI 10.1016/0006-8993(76)90673-9; BUENO JR, 1968, PSYCHOPHARMACOLOGIA, V12, P400, DOI 10.1007/BF00401345; CARLSSON A, 1957, NATURE, V180, P1200, DOI 10.1038/1801200a0; Carvalho RC, 2006, BRAIN RES, V1122, P179, DOI 10.1016/j.brainres.2006.09.008; CHAPUT M, 1980, J PHYSIOL-PARIS, V76, P551; Contreras D, 1997, J NEUROSCI, V17, P1179; Datta S, 2000, BEHAV NEUROSCI, V114, P1239, DOI 10.1037/0735-7044.114.6.1239; DEMENT W, 1957, ELECTROEN CLIN NEURO, V9, P673, DOI 10.1016/0013-4694(57)90088-3; Detari L, 1997, BRAIN RES, V759, P112, DOI 10.1016/S0006-8993(97)00252-7; DICKSON C, 2007, CAN J NEUROL SCI S, V3; DICKSON C, 2007, SOC NEUROSCI; Dringenberg HC, 1998, NEUROSCI BIOBEHAV R, V22, P243, DOI 10.1016/S0149-7634(97)00012-2; Eschenko O, 2006, J NEUROSCI, V26, P12914, DOI 10.1523/JNEUROSCI.3175-06.2006; Ferrara M, 1999, Sleep Res Online, V2, P15; GRAHN DA, 1989, AM J PHYSIOL, V256, pR840, DOI 10.1152/ajpregu.1989.256.4.R840; Hara K, 2002, ANESTH ANALG, V94, P313, DOI 10.1097/00000539-200202000-00015; Hobson JA, 2002, NAT REV NEUROSCI, V3, P679, DOI 10.1038/nrn915; HOBSON JA, 1975, SCIENCE, V189, P55, DOI 10.1126/science.1094539; Horner RL, 1999, NEUROSCIENCE, V93, P215, DOI 10.1016/S0306-4522(99)00126-8; Hunter JD, 1998, RESP PHYSIOL, V112, P71, DOI 10.1016/S0034-5687(98)00018-8; JONES BE, 1993, PROG BRAIN RES, V98, P61; Jones BE, 2003, FRONT BIOSCI-LANDMRK, V8, pS438, DOI 10.2741/1074; Kinney GG, 1998, BRAIN RES, V809, P307, DOI 10.1016/S0006-8993(98)00878-6; Koblin DD, 2002, ANESTH ANALG, V94, P241, DOI 10.1097/00000539-200202000-00002; Lee J, 2004, P NATL ACAD SCI USA, V101, P18195, DOI 10.1073/pnas.0408089101; Lu J, 2006, NATURE, V441, P589, DOI 10.1038/nature04767; MCCARLEY RW, 1975, SCIENCE, V189, P58, DOI 10.1126/science.1135627; Molle M, 2006, J NEUROPHYSIOL, V96, P62, DOI 10.1152/jn.00014.2006; Murakami M, 2005, NEURON, V46, P285, DOI 10.1016/j.neuron.2005.02.025; Nelson LE, 2003, ANESTHESIOLOGY, V98, P428, DOI 10.1097/00000542-200302000-00024; Nelson LE, 2002, NAT NEUROSCI, V5, P979, DOI 10.1038/nn913; Nelson LE, 2004, ANESTHESIOLOGY, V100, P1341, DOI 10.1097/00000542-200406000-00003; NOMEIR AA, 1989, TOXICOL APPL PHARM, V97, P203, DOI 10.1016/0041-008X(89)90326-8; Ocampo-Garces A, 2000, J NEUROPHYSIOL, V84, P2699; Pace-Schott EF, 2002, NAT REV NEUROSCI, V3, P591, DOI 10.1038/nrn895; Rechtschaffen A, 2002, SLEEP, V25, p68B, DOI 10.1093/sleep/25.1.68; Rechtschaffen A, 2002, SLEEP, V25, P18, DOI 10.1093/sleep/25.1.18; Rechtschaffen A, 1999, SLEEP, V22, P11, DOI 10.1093/sleep/22.1.11; ROBINSON TE, 1977, BRAIN RES, V124, P544, DOI 10.1016/0006-8993(77)90954-4; ROBINSON TE, 1978, EXP NEUROL, V61, P485, DOI 10.1016/0014-4886(78)90018-3; Sceniak MP, 2006, J NEUROPHYSIOL, V95, P3865, DOI 10.1152/jn.01196.2005; SHAFER A, 1995, ANESTHESIOLOGY, V83, P1331, DOI 10.1097/00000542-199512000-00024; SHOUSE MN, 1992, BRAIN RES, V571, P50, DOI 10.1016/0006-8993(92)90508-7; Siapas AG, 1998, NEURON, V21, P1123, DOI 10.1016/S0896-6273(00)80629-7; SIEGEL JM, 2005, PRINCIPLES PRACTICE; Sinton CM, 2004, SEMIN NEUROL, V24, P211, DOI 10.1055/s-2004-835067; SOTOMAYOR RE, 1990, TOXICOL IND HEALTH, V6, P71, DOI 10.1177/074823379000600106; STERIADE M, 1987, J NEUROPHYSIOL, V57, P260, DOI 10.1152/jn.1987.57.1.260; STERIADE M, 1993, J NEUROSCI, V13, P3266; Steriade M., 1999, ELECTROENCEPHALOGRAP, P28; Tung A, 2004, ANESTHESIOLOGY, V100, P1419, DOI 10.1097/00000542-200406000-00014; Tung A, 2004, SLEEP MED REV, V8, P213, DOI 10.1016/j.smrv.2004.01.003; Tung A, 2002, ANESTHESIOLOGY, V97, P906, DOI 10.1097/00000542-200210000-00024; Tung A, 2001, ANESTH ANALG, V92, P1232; Tung A, 2001, BRAIN RES, V908, P155, DOI 10.1016/S0006-8993(01)02629-4; Tung A, 2001, LIFE SCI, V69, P855, DOI 10.1016/S0024-3205(01)01179-1; VANDERWOLF CH, 1988, INT REV NEUROBIOL, V30, P225; VERTES RP, 1982, PROG NEUROBIOL, V19, P159, DOI 10.1016/0301-0082(82)90005-3; Whelan PJ, 2003, METHODS, V30, P127, DOI 10.1016/S1046-2023(03)00074-4; Wolansky T, 2006, J NEUROSCI, V26, P6213, DOI 10.1523/JNEUROSCI.5594-05.2006; YLINEN A, 1995, J NEUROSCI, V15, P30	65	243	243	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e2004	10.1371/journal.pone.0002004	http://dx.doi.org/10.1371/journal.pone.0002004			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414674	Green Published, gold, Green Submitted			2022-12-25	WOS:000260867300023
J	Atwal, GS; Rabadan, R; Lozano, G; Strong, LC; Ruijs, MWG; Schmidt, MK; van't Veer, LJ; Nevanlinna, H; Tommiska, J; Aittomaki, K; Bougeard, G; Frebourg, T; Levine, AJ; Bond, GL				Atwal, Gurinder Singh; Rabadan, Raul; Lozano, Guillermina; Strong, Louise C.; Ruijs, Marielle W. G.; Schmidt, Marjanka K.; van't Veer, Laura J.; Nevanlinna, Heli; Tommiska, Johanna; Aittomaki, Kristiina; Bougeard, Gaelle; Frebourg, Thierry; Levine, Arnold J.; Bond, Gareth L.			An Information-Theoretic Analysis of Genetics, Gender and Age in Cancer Patients	PLOS ONE			English	Article								Germline genetics, gender and hormonal-signaling pathways are all well described modifiers of cancer risk and progression. Although an improved understanding of how germline genetic variants interact with other cancer risk factors may allow better prevention and treatment of human cancer, measuring and quantifying these interactions is challenging. In other areas of research, Information Theory has been used to quantitatively describe similar multivariate interactions. We implemented a novel information-theoretic analysis to measure the joint effect of a high frequency germline genetic variant of the p53 tumor suppressor pathway (MDM2 SNP309 T/G) and gender on clinical cancer phenotypes. This analysis quantitatively describes synergistic interactions among gender, the MDM2 SNP309 locus, and the age of onset of tumorigenesis in p53 mutation carriers. These results offer a molecular and genetic basis for the observed sexual dimorphism of cancer risk in p53 mutation carriers and a model is proposed that suggests a novel cancer prevention strategy for p53 mutation carriers.	[Atwal, Gurinder Singh; Rabadan, Raul; Levine, Arnold J.; Bond, Gareth L.] Inst Advanced Study, Princeton, NJ USA; [Levine, Arnold J.] Canc Inst New Jersey, New Brunswick, NJ USA; [Lozano, Guillermina; Strong, Louise C.] MD Anderson Canc Ctr, Univ Texas, Houston, TX USA; [Ruijs, Marielle W. G.; van't Veer, Laura J.] Netherlands Canc Inst, Family Canc Clin, Amsterdam, Netherlands; [Schmidt, Marjanka K.] Netherlands Canc Inst, Dept Epidemiol, Amsterdam, Netherlands; [Ruijs, Marielle W. G.] Vrije Univ Amsterdam, Med Ctr, Dept Clin Genet & Human Genet, Amsterdam, Netherlands; [Nevanlinna, Heli; Tommiska, Johanna] Helsinki Univ, Central Hosp, Dept Obstet & Gynaecol, Helsinki, Finland; [Aittomaki, Kristiina] Helsinki Univ, Central Hosp, Dept Clin Genet, Helsinki, Finland; [Bougeard, Gaelle; Frebourg, Thierry] Rouen Univ Hosp, Inst Biomed Res, Dept Genet, Inserm U614, Rouen, France	Institute for Advanced Study - USA; Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers Cancer Institute of New Jersey; University of Texas System; UTMD Anderson Cancer Center; Netherlands Cancer Institute; Netherlands Cancer Institute; Vrije Universiteit Amsterdam; University of Helsinki; University of Helsinki; CHU de Rouen; Institut National de la Sante et de la Recherche Medicale (Inserm)	Atwal, GS (corresponding author), Inst Advanced Study, Princeton, NJ USA.	gareth.bond@ndm.ox.ac.uk	Rabadan, Raul/AAZ-7367-2020; Schmidt, Marjanka K/G-9058-2011; BOUGEARD, Gaëlle/ABI-6642-2020; Frebourg, Thierry/AAK-8390-2020	Schmidt, Marjanka K/0000-0002-2228-429X; BOUGEARD, Gaëlle/0000-0002-1475-0254; Nevanlinna, Heli/0000-0002-0916-2976; Tommiska, Johanna/0000-0001-7958-8262; Rabadan, Raul/0000-0001-7946-9255; Frebourg, Thierry/0000-0003-0399-4007	Breast Cancer Research Foundation; Simons Foundation; Leon Levy Foundation; French National Cancer Institute; Cancer Center [CA16672]; NIH [P01 CA034936]; NATIONAL CANCER INSTITUTE [P30CA016672, P01CA034936] Funding Source: NIH RePORTER	Breast Cancer Research Foundation; Simons Foundation; Leon Levy Foundation; French National Cancer Institute(Institut National du Cancer (INCA) France); Cancer Center; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Support of this work comes from the Breast Cancer Research Foundation, The Simons Foundation, the Leon Levy Foundation and the French National Cancer Institute. Further support of this work comes from a Cancer Center Support Grant, CA16672, and a NIH Grant to Louise Strong, P01 CA034936.	Alhopuro P, 2005, J MED GENET, V42, P694, DOI 10.1136/jmg.2005.031260; Arva NC, 2005, J BIOL CHEM, V280, P26776, DOI 10.1074/jbc.M505203200; Bond GL, 2007, ONCOGENE, V26, P1317, DOI 10.1038/sj.onc.1210199; Bond GL, 2006, J MED GENET, V43, P950, DOI 10.1136/jmg.2006.043539; Bond GL, 2006, CANCER RES, V66, P5104, DOI 10.1158/0008-5472.CAN-06-0180; Bond GL, 2005, CANCER RES, V65, P5481, DOI 10.1158/0008-5472.CAN-05-0825; Bond GL, 2005, CURR CANCER DRUG TAR, V5, P3, DOI 10.2174/1568009053332627; Bond GL, 2004, CELL, V119, P591, DOI 10.1016/j.cell.2004.11.022; Bougeard G, 2006, J MED GENET, V43, P531, DOI 10.1136/jmg.2005.037952; Brenner N, 2000, NEURAL COMPUT, V12, P1531, DOI 10.1162/089976600300015259; Chompret A, 2000, BRIT J CANCER, V82, P1932; Cordell HJ, 2002, AM J HUM GENET, V70, P124, DOI 10.1086/338007; GAT I, 1999, NEURAL INFORM PROCES; Gronwald J, 2006, INT J CANCER, V118, P2281, DOI 10.1002/ijc.21536; Hirata H, 2007, CLIN CANCER RES, V13, P4123, DOI 10.1158/1078-0432.CCR-07-0609; Hong Y, 2005, CANCER RES, V65, P9582, DOI 10.1158/0008-5472.CAN-05-1460; Hu WW, 2007, CANCER RES, V67, P2757, DOI 10.1158/0008-5472.CAN-06-2656; Hwang SJ, 2003, AM J HUM GENET, V72, P975, DOI 10.1086/374567; Khan S, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.026209; KLEIN KO, 1994, J CLIN INVEST, V94, P2475, DOI 10.1172/JCI117616; Lain S, 2003, EUR J CANCER, V39, P1053, DOI 10.1016/S0959-8049(03)00063-7; Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006; LI FP, 1992, J NATL CANCER I, V84, P1156, DOI 10.1093/jnci/84.15.1156; Lind H, 2006, INT J CANCER, V119, P718, DOI 10.1002/ijc.21872; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; Narod SA, 2000, LANCET, V356, P1876, DOI 10.1016/S0140-6736(00)03258-X; Nelson MR, 2001, GENOME RES, V11, P458, DOI 10.1101/gr.172901; Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004; Paris F, 2002, J CLIN ENDOCR METAB, V87, P791, DOI 10.1210/jc.87.2.791; Province MA, 2001, ADV GENET, V42, P273, DOI 10.1016/S0065-2660(01)42028-1; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; Ritchie MD, 2001, AM J HUM GENET, V69, P138, DOI 10.1086/321276; Ruijs MWG, 2007, EUR J HUM GENET, V15, P110, DOI 10.1038/sj.ejhg.5201715; Sherriff A, 2001, ADV GENET, V42, P287, DOI 10.1016/S0065-2660(01)42029-3; SLONIM NS, 2005, ARXIVCSIT0502017; Tabori U, 2007, CANCER RES, V67, P1415, DOI 10.1158/0008-5472.CAN-06-3682; Tahri-Daizadeh N, 2003, GENOME RES, V13, P1952, DOI 10.1101/gr.1254203	37	17	17	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1951	10.1371/journal.pone.0001951	http://dx.doi.org/10.1371/journal.pone.0001951			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398474	gold, Green Published, Green Submitted, Green Accepted			2022-12-25	WOS:000260795500025
J	Li, H; Gu, S; Cai, XY; Speed, WC; Pakstis, AJ; Golub, EI; Kidd, JR; Kidd, KK				Li, Hui; Gu, Sheng; Cai, Xiaoyun; Speed, William C.; Pakstis, Andrew J.; Golub, Efim I.; Kidd, Judith R.; Kidd, Kenneth K.			Ethnic Related Selection for an ADH Class I Variant within East Asia	PLOS ONE			English	Article								Background: The alcohol dehydrogenases (ADH) are widely studied enzymes and the evolution of the mammalian gene cluster encoding these enzymes is also well studied. Previous studies have shown that the ADH1B*47His allele at one of the seven genes in humans is associated with a decrease in the risk of alcoholism and the core molecular region with this allele has been selected for in some East Asian populations. As the frequency of ADH1B*47His is highest in East Asia, and very low in most of the rest of the world, we have undertaken more detailed investigation in this geographic region. Methodology/Principal Findings: Here we report new data on 30 SNPs in the ADH7 and Class I ADH region in samples of 24 populations from China and Laos. These populations cover a wide geographic region and diverse ethnicities. Combined with our previously published East Asian data for these SNPs in 8 populations, we have typed populations from all of the 6 major linguistic phyla (Altaic including Korean-Japanese and inland Altaic, Sino-Tibetan, Hmong-Mien, Austro-Asiatic, Daic, and Austronesian). The ADH1B genotyping data are strongly related to ethnicity. Only some eastern ethnic phyla or subphyla (Korean-Japanese, Han Chinese, Hmong-Mien, Daic, and Austronesian) have a high frequency of ADH1B*47His. ADH1B haplotype data clustered the populations into linguistic subphyla, and divided the subphyla into eastern and western parts. In the Hmong- Mien and Altaic populations, the extended haplotype homozygosity (EHH) and relative EHH (REHH) tests for the ADH1B core were consistent with selection for the haplotype with derived SNP alleles. In the other ethnic phyla, the core showed only a weak signal of selection at best. Conclusions/Significance: The selection distribution is more significantly correlated with the frequency of the derived ADH1B regulatory region polymorphism than the derived amino-acid altering allele ADH1B*47His. Thus, the real focus of selection may be the regulatory region. The obvious ethnicity-related distributions of ADH1B diversities suggest the existence of some culture-related selective forces that have acted on the ADH1B region.	[Li, Hui; Gu, Sheng; Speed, William C.; Pakstis, Andrew J.; Golub, Efim I.; Kidd, Judith R.; Kidd, Kenneth K.] Yale Univ, Sch Med, Dept Genet, Lab Human Polymorphism Studies, New Haven, CT 06510 USA; [Li, Hui; Cai, Xiaoyun] Fudan Univ, Ctr Evolutionary Biol, Sch Life Sci, Inst Biomed Sci, Shanghai, Peoples R China	Yale University; Fudan University	Li, H (corresponding author), Yale Univ, Sch Med, Dept Genet, Lab Human Polymorphism Studies, New Haven, CT 06510 USA.	Kenneth.Kidd@Yale.edu	Li, Hui/A-2014-2010		US NIH [AA009379]; USPHS [GM057672]; NSF [BCS0096588]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM057672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA009379] Funding Source: NIH RePORTER	US NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); USPHS(United States Department of Health & Human ServicesUnited States Public Health Service); NSF(National Science Foundation (NSF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This research was funded primarily by US NIH grant AA009379 to KKK, and in part by USPHS grant GM057672 and NSF grant BCS0096588.	AGARWAL DP, 1992, PHARMACOGENETICS, V2, P48, DOI 10.1097/00008571-199204000-00002; Baker Chris, 2005, HIST THAILAND; Bandelt HJ, 1999, MOL BIOL EVOL, V16, P37, DOI 10.1093/oxfordjournals.molbev.a026036; Borras E, 2000, HEPATOLOGY, V31, P984, DOI 10.1053/he.2000.5978; Charlton KE, 2005, EUR J CARDIOV PREV R, V12, P355, DOI 10.1097/01.hjr.0000170265.22938.d1; Chen CC, 1999, AM J HUM GENET, V65, P795, DOI 10.1086/302540; Chen JG, 2006, INT J CANCER, V119, P1447, DOI 10.1002/ijc.21952; Chen WJ, 1996, BRIT J PSYCHIAT, V168, P762, DOI 10.1192/bjp.168.6.762; Chen WJ, 1997, BIOL PSYCHIAT, V41, P703, DOI 10.1016/S0006-3223(96)00072-8; Cheung C, 1999, BIOCHEM BIOPH RES CO, V261, P100, DOI 10.1006/bbrc.1999.0943; Cichoz-Lach H, 2006, ALCOHOL ALCOHOLISM, V41, P14, DOI 10.1093/alcalc/agh225; Dannenberg LO, 2006, ALCOHOL CLIN EXP RES, V30, P928, DOI 10.1111/j.1530-0277.2006.00107.x; Dean FB, 2002, P NATL ACAD SCI USA, V99, P5261, DOI 10.1073/pnas.082089499; Dodd PR, 2004, ADDICT BEHAV, V29, P1295, DOI 10.1016/j.addbeh.2004.06.010; Edenberg HJ, 2006, HUM MOL GENET, V15, P1539, DOI 10.1093/hmg/ddl073; Endo T, 1996, MOL BIOL EVOL, V13, P685, DOI 10.1093/oxfordjournals.molbev.a025629; ERIKSSON CJ, 2001, ALCOHOL CLIN SISBRA, pS157; Fallin D, 2000, AM J HUM GENET, V67, P947, DOI 10.1086/303069; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; GOEDDE HW, 1992, HUM GENET, V88, P344; GOLDMAN D, 1990, WORLD REV NUTR DIET, V63, P143; Gordon R. G., 2005, ETHNOLOGUE LANGUAGES, V15th; Gu S, 2005, BIOINFORMATICS, V21, P3938, DOI 10.1093/bioinformatics/bti649; GU WN, 2001, AGR ARCHAEOLOGY, V21, P1; Han Y, 2007, AM J HUM GENET, V80, P441, DOI 10.1086/512485; Hasin D, 2002, AM J PSYCHIAT, V159, P1432, DOI 10.1176/appi.ajp.159.8.1432; He P, 2003, J YUNNAN U NATIONALI, V20, P45; HIGUCHI S, 1995, AM J PSYCHIAT, V152, P1219; Homann N, 2006, INT J CANCER, V118, P1998, DOI 10.1002/ijc.21583; Inoue K, 2000, XENOBIOTICA, V30, P285, DOI 10.1080/004982500237677; Issell BF, 2005, CANCER INVEST, V23, P497, DOI 10.1080/07357900500201442; Jia CQ, 2007, THROMB RES, V120, P679, DOI 10.1016/j.thromres.2006.12.023; Jin L, 2000, NAT REV GENET, V1, P126, DOI 10.1038/35038565; Kim JJ, 2005, HUM GENET, V117, P511, DOI 10.1007/s00439-005-1334-8; Kong QP, 2003, AM J HUM GENET, V73, P671, DOI 10.1086/377718; Li H, 2007, HUM GENET, V122, P383, DOI 10.1007/s00439-007-0407-2; Li H, 2007, AM J HUM GENET, V81, P842, DOI 10.1086/521201; LIU ZX, 1985, HIST UIGHUR, V1; LIVAK KJ, 1995, NAT GENET, V9, P341, DOI 10.1038/ng0495-341; Long JC, 1998, AM J MED GENET, V81, P216, DOI 10.1002/(SICI)1096-8628(19980508)81:3<216::AID-AJMG2>3.0.CO;2-U; Ma LL, 2005, HEREDITAS, V142, P103, DOI 10.1111/j.1601-5223.2005.01910.x; Mackerras Colin, 1972, UIGHUR EMPIRE ACCORD; Matsuo K, 2007, HUM MUTAT, V28, P506, DOI 10.1002/humu.20477; Mulligan CJ, 2003, HUM GENET, V113, P325, DOI 10.1007/s00439-003-0971-z; MURAMATSU T, 1995, HUM GENET, V96, P151, DOI 10.1007/BF00207371; Neumark YD, 1998, J STUD ALCOHOL, V59, P133, DOI 10.15288/jsa.1998.59.133; Osier M, 1999, AM J HUM GENET, V64, P1147, DOI 10.1086/302317; Osier MV, 2002, AM J HUM GENET, V71, P84, DOI 10.1086/341290; Peters ES, 2005, CANCER EPIDEM BIOMAR, V14, P476, DOI 10.1158/1055-9965.EPI-04-0431; Ramchandani VA, 2001, PATHOL BIOL, V49, P676, DOI 10.1016/S0369-8114(01)00232-2; Raymond M, 1995, EVOLUTION, V49, P1280, DOI 10.1111/j.1558-5646.1995.tb04456.x; Reich T, 1998, AM J MED GENET, V81, P207, DOI 10.1002/(SICI)1096-8628(19980508)81:3<207::AID-AJMG1>3.3.CO;2-X; Roemer H. R., 2000, HIST TURKIC PEOPLES; Sabeti PC, 2007, NATURE, V449, P913, DOI 10.1038/nature06250; Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140; Saccone NL, 2000, AM J MED GENET, V96, P632, DOI 10.1002/1096-8628(20001009)96:5<632::AID-AJMG8>3.0.CO;2-#; Seitz HK, 2005, DIGEST DIS, V23, P297, DOI 10.1159/000090177; Shen YC, 1997, ALCOHOL CLIN EXP RES, V21, P1272, DOI 10.1111/j.1530-0277.1997.tb04448.x; Shi Y., 1989, QUESTION QUATERNARY; Sinor D., 1990, CAMBRIDGE HIST EARLY; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Su B, 2000, HUM GENET, V107, P582, DOI 10.1007/s004390000406; Tajima A, 2002, HUM GENET, V110, P80, DOI 10.1007/s00439-001-0651-9; THOMASSON HR, 1994, ALCOHOL CLIN EXP RES, V18, P640, DOI 10.1111/j.1530-0277.1994.tb00923.x; Tiemersma EW, 2003, CANCER EPIDEM BIOMAR, V12, P419; Tishkoff SA, 2004, NAT GENET, V36, pS21, DOI 10.1038/ng1438; TONG EZ, 1984, AGR ARCHAEOLOGY, V4, P29; Triano EA, 2003, CANCER RES, V63, P3092; Uhl GR, 2004, NEUROPHARMACOLOGY, V47, P140, DOI 10.1016/j.neuropharm.2004.07.029; Voight BF, 2006, PLOS BIOL, V4, P446, DOI 10.1371/journal.pbio.0040072; WANG MK, 1999, PRIMORDIAL HIST BROT; Wen B, 2004, NATURE, V431, P302, DOI 10.1038/nature02878; WENG QH, 1998, TROPICAL GEOGRAPHY, V18, P72; Whitfield JB, 1998, ALCOHOL CLIN EXP RES, V22, P1463; Wilf H.S, 1977, STAT METHODS DIGITAL; Wright S, 1931, GENETICS, V16, P0097; Yao Chung-Tay, 1997, Proceedings of the National Science Council Republic of China Part B Life Sciences, V21, P106; Yin SJ, 1997, GASTROENTEROLOGY, V112, P766, DOI 10.1053/gast.1997.v112.pm9041238; Yokoyama A, 2003, JPN J CLIN ONCOL, V33, P111, DOI 10.1093/jjco/hyg026; YOSHIDA A, 1991, PROG NUCLEIC ACID RE, V40, P255	81	31	32	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1881	10.1371/journal.pone.0001881	http://dx.doi.org/10.1371/journal.pone.0001881			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382665	Green Published, Green Submitted, gold			2022-12-25	WOS:000260795400016
J	Smith, GI; Atherton, P; Villareal, DT; Frimel, TN; Rankin, D; Rennie, MJ; Mittendorfer, B				Smith, Gordon I.; Atherton, Philip; Villareal, Dennis T.; Frimel, Tiffany N.; Rankin, Debbie; Rennie, Michael J.; Mittendorfer, Bettina			Differences in Muscle Protein Synthesis and Anabolic Signaling in the Postabsorptive State and in Response to Food in 65-80 Year Old Men and Women	PLOS ONE			English	Article							AMINO-ACID-CONCENTRATIONS; ELDERLY-MEN; WHOLE-BODY; GENE-EXPRESSION; TESTOSTERONE; YOUNG; MASS; AGE; METABOLISM; LEUCINE	Women have less muscle than men but lose it more slowly during aging. To discover potential underlying mechanism(s) for this we evaluated the muscle protein synthesis process in postabsorptive conditions and during feeding in twenty-nine 65-80 year old men (n = 13) and women (n = 16). We discovered that the basal concentration of phosphorylated eEF2(Thr56) was similar to 40% less (P < 0.05) and the basal rate of MPS was similar to 30% greater (P = 0.02) in women than in men; the basal concentrations of muscle phosphorylated Akt(Thr308), p70s6k(Thr389), eIF4E(Ser209), and eIF4E-BP1(Thr37/46) were not different between the sexes. Feeding increased (P < 0.05) Akt(Thr308) and p70s6k(Thr389) phosphorylation to the same extent in men and women but increased (P < 0.05) the phosphorylation of eIF4E(Ser209) and eIF4E-BP1(Thr37/46) in men only. Accordingly, feeding increased MPS in men (P < 0.01) but not in women. The postabsorptive muscle mRNA concentrations for myoD and myostatin were not different between sexes; feeding doubled myoD mRNA (P < 0.05) and halved that of myostatin (P < 0.05) in both sexes. Thus, there is sexual dimorphism in MPS and its control in older adults; a greater basal rate of MPS, operating over most of the day may partially explain the slower loss of muscle in older women.	[Smith, Gordon I.; Villareal, Dennis T.; Frimel, Tiffany N.; Mittendorfer, Bettina] Washington Univ, Sch Med, St Louis, MO 63130 USA; [Atherton, Philip; Rankin, Debbie; Rennie, Michael J.] Univ Nottingham, Sch Grad Entry Med & Hlth, Derby, England	Washington University (WUSTL); University of Nottingham	Smith, GI (corresponding author), Washington Univ, Sch Med, St Louis, MO 63130 USA.	mittendb@wustl.edu		Hilton, Tiffany/0000-0001-5869-201X; Smith, Gordon/0000-0003-0063-046X; Atherton, Philip/0000-0002-7286-046X	US National Institutes of Health [AR 49869, AG 025501, RR 00036, RR 00954, DK 56341]; University of Nottingham; UK Biotechnology and Biological Sciences Research Council [BB/XX510697/1, BB/C516779/1]; European Union EXEGENESIS program; Research Councils UK fellow; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000036, P41RR000954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR049869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025501] Funding Source: NIH RePORTER; Biotechnology and Biological Sciences Research Council [BB/C516779/1] Funding Source: researchfish	US National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Nottingham; UK Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); European Union EXEGENESIS program; Research Councils UK fellow(UK Research & Innovation (UKRI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	The study was supported by US National Institutes of Health grants AR 49869, AG 025501, RR 00036 (General Clinical Research Center), RR 00954 (Biomedical Mass Spectrometry Resource), and DK 56341 (Clinical Nutrition Research Unit), the University of Nottingham, the UK Biotechnology and Biological Sciences Research Council grants BB/XX510697/1 and BB/C516779/1, and a European Union EXEGENESIS program grant. Philip Atherton is a designated Research Councils UK fellow.	ADIBI SA, 1973, J CLIN INVEST, V52, P1586, DOI 10.1172/JCI107335; BERGSTROM J, 1990, CLIN SCI, V79, P331, DOI 10.1042/cs0790331; Bhasin S, 2001, J ENDOCRINOL, V170, P27, DOI 10.1677/joe.0.1700027; Bohe J, 2003, J PHYSIOL-LONDON, V552, P315, DOI 10.1113/jphysiol.2003.050674; Bohe J, 2001, J PHYSIOL-LONDON, V532, P575, DOI 10.1111/j.1469-7793.2001.0575f.x; Boirie Y, 2001, J CLIN ENDOCR METAB, V86, P638, DOI 10.1210/jc.86.2.638; Brodsky IG, 1996, J CLIN ENDOCR METAB, V81, P3469, DOI 10.1210/jc.81.10.3469; BURESOVA M, 1971, J ENDOCRINOL, V50, P643, DOI 10.1677/joe.0.0500643; CELERMAJER DS, 1994, J AM COLL CARDIOL, V24, P471, DOI 10.1016/0735-1097(94)90305-0; Chevalier S, 2005, METABOLISM, V54, P1529, DOI 10.1016/j.metabol.2005.05.021; Cid-Ruzafa J, 1999, J AM DIET ASSOC, V99, P564, DOI 10.1016/S0002-8223(99)00140-6; Clark MG, 2006, CURR OPIN CLIN NUTR, V9, P185, DOI 10.1097/01.mco.0000222097.90890.c2; Crozier SJ, 2005, J NUTR, V135, P376, DOI 10.1093/jn/135.3.376; Cuthbertson D, 2004, FASEB J, V18, P422, DOI 10.1096/fj.04-2640fje; DIETRICHSON P, 1987, J NEUROL NEUROSUR PS, V50, P1461, DOI 10.1136/jnnp.50.11.1461; Ferrando AA, 2003, J CLIN ENDOCR METAB, V88, P358, DOI 10.1210/jc.2002-021041; Ferrando AA, 1998, AM J PHYSIOL-ENDOC M, V275, pE864; FORBES GB, 1970, METABOLIS, V19, P653, DOI 10.1016/0026-0495(70)90062-4; Frost RA, 2007, J APPL PHYSIOL, V103, P378, DOI 10.1152/japplphysiol.00089.2007; Fujita S, 2007, AM J PHYSIOL-ENDOC M, V292, pE77, DOI 10.1152/ajpendo.00173.2006; Gallagher D, 2000, AM J PHYSIOL-ENDOC M, V279, pE366, DOI 10.1152/ajpendo.2000.279.2.E366; Garlick PJ, 2005, J NUTR, V135, p1553S, DOI 10.1093/jn/135.6.1553S; GRIGGS RC, 1989, J APPL PHYSIOL, V66, P498, DOI 10.1152/jappl.1989.66.1.498; GRIGSBY JS, 1976, GROWTH, V40, P303; Guttridge DC, 2004, CURR OPIN CLIN NUTR, V7, P443, DOI 10.1097/01.mco.0000134364.61406.26; Horowitz JF, 2001, AM J CLIN NUTR, V73, P517; Hughes VA, 2002, AM J CLIN NUTR, V76, P473, DOI 10.1093/ajcn/76.2.473; Jahn LA, 1999, J CLIN ENDOCR METAB, V84, P1007, DOI 10.1210/jc.84.3.1007; Jensen-Urstad K, 2001, J INTERN MED, V250, P29, DOI 10.1046/j.1365-2796.2001.00843.x; Kobayashi H, 2003, AM J PHYSIOL-ENDOC M, V284, pE488, DOI 10.1152/ajpendo.00094.2002; Kraegen E W, 1990, Horm Metab Res Suppl, V24, P41; Ledikwe JH, 2004, J AM GERIATR SOC, V52, P589, DOI 10.1111/j.1532-5415.2004.52167.x; Lee SJ, 2001, P NATL ACAD SCI USA, V98, P9306, DOI 10.1073/pnas.151270098; Lind L, 2002, CLIN SCI, V102, P241, DOI 10.1042/CS20010013; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; LONG CL, 1981, AM J CLIN NUTR, V34, P1087, DOI 10.1093/ajcn/34.6.1087; McCormick KM, 2004, J MUSCLE RES CELL M, V25, P21, DOI 10.1023/B:JURE.0000021398.78327.39; McMahon CD, 2003, AM J PHYSIOL-ENDOC M, V284, pE377, DOI 10.1152/ajpendo.00282.2002; McPherron AC, 2002, J CLIN INVEST, V109, P595, DOI 10.1172/JCI200213562; MILLWARD DJ, 1973, NATURE, V241, P204, DOI 10.1038/241204a0; Mingrone G, 2001, METABOLISM, V50, P1004, DOI 10.1053/meta.2001.25650; Mittendorfer B, 2005, J PHYSIOL-LONDON, V563, P203, DOI 10.1113/jphysiol.2004.077180; MOORE D, 2008, EXPT BIOL 2008; Morais JA, 1997, AM J CLIN NUTR, V66, P880, DOI 10.1093/ajcn/66.4.880; Parise G, 2001, J APPL PHYSIOL, V91, P1041, DOI 10.1152/jappl.2001.91.3.1041; Partridge T, 2000, NEUROL SCI, V21, pS939; Patterson BW, 1997, METABOLISM, V46, P943, DOI 10.1016/S0026-0495(97)90084-6; Piccone CM, 2005, EXP PHYSIOL, V90, P87, DOI 10.1113/expphysiol.2004.028373; Pitkanen HT, 2003, AMINO ACIDS, V24, P413, DOI 10.1007/s00726-002-0338-0; Proud CG, 2007, BIOCHEM J, V403, P217, DOI 10.1042/BJ20070024; Radegran G, 1999, J APPL PHYSIOL, V87, P2375, DOI 10.1152/jappl.1999.87.6.2375; Remond D, 2007, AM J CLIN NUTR, V85, P1286, DOI 10.1093/ajcn/85.5.1286; Rennie MJ, 2006, J NUTR, V136, p264S, DOI 10.1093/jn/136.1.264S; Rieu I, 2006, J PHYSIOL-LONDON, V575, P305, DOI 10.1113/jphysiol.2006.110742; Rooyackers OE, 1997, ANNU REV NUTR, V17, P457, DOI 10.1146/annurev.nutr.17.1.457; Roubenoff R, 2003, CURR OPIN CLIN NUTR, V6, P295, DOI 10.1097/01.mco.0000068965.34812.62; Rousset S, 2003, BRIT J NUTR, V90, P1107, DOI 10.1079/BJN20031004; Sarabi M, 1999, J INTERN MED, V246, P265, DOI 10.1046/j.1365-2796.1999.00542.x; Schaap LA, 2006, AM J MED, V119, DOI 10.1016/j.amjmed.2005.10.049; Sheffield-Moore M, 1999, J CLIN ENDOCR METAB, V84, P2705, DOI 10.1210/jc.84.8.2705; Toth MJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE883, DOI 10.1152/ajpendo.00353.2004; Toth MJ, 2001, AM J PHYSIOL-ENDOC M, V280, pE496, DOI 10.1152/ajpendo.2001.280.3.E496; Tsai PJ, 2000, J FORMOS MED ASSOC, V99, P151; Umpleby AM, 1996, BAILLIERE CLIN ENDOC, V10, P551, DOI 10.1016/S0950-351X(96)80711-7; URBAN RJ, 1995, AM J PHYSIOL-ENDOC M, V269, pE820, DOI 10.1152/ajpendo.1995.269.5.E820; Vary TC, 1999, AM J PHYSIOL-ENDOC M, V277, pE1077, DOI 10.1152/ajpendo.1999.277.6.E1077; Visser M, 2002, J GERONTOL A-BIOL, V57, pM326, DOI 10.1093/gerona/57.5.M326; Volpi E, 2001, JAMA-J AM MED ASSOC, V286, P1206, DOI 10.1001/jama.286.10.1206; WATT PW, 1991, P NATL ACAD SCI USA, V88, P5892, DOI 10.1073/pnas.88.13.5892; Welle S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001385; Zamboni M, 2003, AGING CLIN EXP RES, V15, P321, DOI 10.1007/BF03324517; Zierler K, 1999, AM J PHYSIOL-ENDOC M, V276, pE409, DOI 10.1152/ajpendo.1999.276.3.E409	72	109	111	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1875	10.1371/journal.pone.0001875	http://dx.doi.org/10.1371/journal.pone.0001875			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365020	Green Published, gold			2022-12-25	WOS:000260762400026
J	Zhu, Q; Youn, H; Tang, J; Tawfit, O; Dennis, K; Terranova, PF; Du, J; Raynal, P; Thrasher, JB; Li, B				Zhu, Q.; Youn, H.; Tang, J.; Tawfit, O.; Dennis, K.; Terranova, P. F.; Du, J.; Raynal, P.; Thrasher, J. B.; Li, B.			Phosphoinositide 3-OH kinase p85 alpha and p110 beta are essential for androgen receptor transactivation and tumor progression in prostate cancers	ONCOGENE			English	Article						prostate cancer; PI3K; androgen receptor; siRNA; tumor progression; mouse xenograft	PROTEIN-COUPLED RECEPTORS; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASES; BETA-GAMMA; ACTIVATION; CELLS; TRANSCRIPTION; PATHWAY; P110-ALPHA; SUBUNITS	Phosphoinositide 3-OH kinases (PI3Ks) are a group of major intracellular signaling molecules. In our previous study, we found that inhibition of PI3K activity suppressed the androgen receptor (AR)-mediated gene expression in prostate cancer cells. The AR has been considered as a critical determinant for the development and progression of human prostate cancers. In this study, we sought to identify the PI3K isoforms involved in AR transactivation. Using a gene-specific small interference RNA (siRNA) approach, we determined that the regulatory isoform p85 alpha and the catalytic isoform p110 beta, but not p110 alpha, were required for androgen-stimulated AR transactivation and cell proliferation in prostate cancer cells. Consistently, overexpression of wild-type p110b but not p110 alpha gene led to androgen-independent AR transactivation. Silencing p110 beta gene in prostate cancer cells abolished tumor growth in nude mice. Of the dual (lipid and protein) kinase activities, p110 beta's lipid kinase activity was required for AR transactivation. Further analysis by a chromatin immunoprecipitation assay showed that p110 beta is indispensable for androgen-induced AR-DNA interaction. Finally, gene expression analysis of clinical specimens showed that both p85 alpha and p110 beta were highly expressed in malignant prostate tissues compared to the nonmalignant compartments, and their expression levels correlated significantly with disease progression. Taken together, our data demonstrated that p85 alpha and p110 beta are essential for androgen-stimulated AR transactivation, and their aberrant expression or activation might play an important role in prostate cancer progression.	[Zhu, Q.; Youn, H.; Tang, J.; Thrasher, J. B.; Li, B.] Univ Kansas, Med Ctr, Dept Urol, Kansas City, KS 66160 USA; [Zhu, Q.; Li, B.] Xian Jiaotong Univ, Affiliated Hosp 1, Dept Med Oncol, Xian 710049, Peoples R China; [Tawfit, O.; Dennis, K.; Li, B.] Univ Kansas, Med Ctr, Dept Pathol, Kansas City, KS 66160 USA; [Tawfit, O.; Dennis, K.; Li, B.] Univ Kansas, Med Ctr, Lab Med, Kansas City, KS 66160 USA; [Terranova, P. F.; Li, B.] Univ Kansas, Med Ctr, Deptt Mol & Integrated Physiol, Kansas City, KS 66160 USA; [Du, J.] Baylor Coll Med, Dept Med, Houston, TX 77030 USA; [Raynal, P.] Hop Purpan, INSERM, U563, Bat C, Toulouse, France	University of Kansas; University of Kansas Medical Center; Xi'an Jiaotong University; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; University of Kansas; University of Kansas Medical Center; Baylor College of Medicine; CHU de Toulouse; Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm)	Li, B (corresponding author), Univ Kansas, Med Ctr, Dept Urol, 3901 Rainbow Blvd,Lied 2045, Kansas City, KS 66160 USA.	bli@kumc.edu	Raynal, Patrick/O-1926-2018	Youn, Hyewon/0000-0003-1006-2689; Raynal, Patrick/0000-0002-6731-3007	NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015563] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR015563, P20 RR015563-096219, 1P20RR15563] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bader AG, 2005, NAT REV CANCER, V5, P921, DOI 10.1038/nrc1753; Chini B, 2004, J MOL ENDOCRINOL, V32, P325, DOI 10.1677/jme.0.0320325; Cinar B, 2007, J BIOL CHEM, V282, P29584, DOI 10.1074/jbc.M703310200; Czauderna F, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng127; Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879; Hayakawa M, 2006, BIOORGAN MED CHEM, V14, P6847, DOI 10.1016/j.bmc.2006.06.046; Heinlein CA, 2004, ENDOCR REV, V25, P276, DOI 10.1210/er.2002-0032; Holzbeierlein J, 2004, AM J PATHOL, V164, P217, DOI 10.1016/S0002-9440(10)63112-4; Jackson SP, 2005, NAT MED, V11, P507, DOI 10.1038/nm1232; Kasbohm EA, 2005, J BIOL CHEM, V280, P11583, DOI 10.1074/jbc.M414423200; Latil A, 2001, CANCER RES, V61, P1919; Lee SO, 2003, ONCOGENE, V22, P7981, DOI 10.1038/sj.onc.1206735; Li BY, 2007, ASIAN J ANDROL, V9, P41, DOI 10.1111/J.1745-7262.2007.00226.x; Li BY, 2007, CARCINOGENESIS, V28, P572, DOI 10.1093/carcin/bgl193; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Liao XB, 2004, ENDOCRINOLOGY, V145, P2941, DOI 10.1210/en.2003-1519; Liao XB, 2005, MOL CANCER THER, V4, P505, DOI 10.1158/1535-7163.MCT-04-0313; Lu ML, 2001, J BIOL CHEM, V276, P13442, DOI 10.1074/jbc.M006598200; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Mellinghoff IK, 2004, CANCER CELL, V6, P517, DOI 10.1016/j.ccr.2004.09.031; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; Murillo H, 2001, ENDOCRINOLOGY, V142, P4795, DOI 10.1210/en.142.11.4795; Scher HI, 2005, J CLIN ONCOL, V23, P8253, DOI 10.1200/JCO.2005.03.4777; Shang YF, 2002, MOL CELL, V9, P601, DOI 10.1016/S1097-2765(02)00471-9; Shanmugam I, 2007, CELL DEATH DIFFER, V14, P2085, DOI 10.1038/sj.cdd.4402227; Sharma M, 2002, J BIOL CHEM, V277, P30935, DOI 10.1074/jbc.M201919200; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Sun AJ, 2007, PROSTATE, V67, P976, DOI 10.1002/pros.20586; Sun A, 2007, PROSTATE, V67, P203, DOI 10.1002/pros.20521; Sun M, 2003, J BIOL CHEM, V278, P42992, DOI 10.1074/jbc.M306295200; Yart A, 2002, J BIOL CHEM, V277, P21167, DOI 10.1074/jbc.M110411200; Zhao JJ, 2005, P NATL ACAD SCI USA, V102, P18443, DOI 10.1073/pnas.0508988102	33	68	73	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4569	4579		10.1038/onc.2008.91	http://dx.doi.org/10.1038/onc.2008.91			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18372911	Green Accepted			2022-12-25	WOS:000258077300006
J	Dong, LF; Low, P; Dyason, JC; Wang, XF; Prochazka, L; Witting, PK; Freeman, R; Swettenham, E; Valis, K; Liu, J; Zobalova, R; Turanek, J; Spitz, DR; Domann, FE; Scheffler, IE; Ralph, SJ; Neuzil, J				Dong, L-F; Low, P.; Dyason, J. C.; Wang, X-F; Prochazka, L.; Witting, P. K.; Freeman, R.; Swettenham, E.; Valis, K.; Liu, J.; Zobalova, R.; Turanek, J.; Spitz, D. R.; Domann, F. E.; Scheffler, I. E.; Ralph, S. J.; Neuzil, J.			alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II	ONCOGENE			English	Article						alpha-tocopheryl succinate; complex II; ubiquinonebinding sites; reactive oxygen species; apoptosis; anti-cancer drug target	VITAMIN-E SUCCINATE; BREAST-CANCER CELLS; ELECTRON-TRANSPORT; E ANALOGS; 3-NITROPROPIONIC ACID; OXIDATIVE STRESS; LIVER-CANCER; OXYGEN; DEHYDROGENASE; ANTIOXIDANT	alpha-Tocopheryl succinate (alpha-TOS)is a selective inducer of apoptosis in cancer cells, which involves the accumulation of reactive oxygen species (ROS). The molecular target of alpha-TOS has not been identified. Here, we show that alpha-TOS inhibits succinate dehydrogenase (SDH) activity of complex II (CII) by interacting with the proximal and distal ubiquinone (UbQ)-binding site (Q(P) and Q(D), respectively). This is based on biochemical analyses and molecular modelling, revealing similar or stronger interaction energy of a- TOS compared to that of UbQ for the QP and QD sites, respectively. CybL-mutant cells with dysfunctional CII failed to accumulate ROS and underwent apoptosis in the presence of alpha-TOS. Similar resistance was observed when CybL was knocked down with siRNA. Reconstitution of functional CII rendered CybL-mutant cells susceptible to alpha-TOS. We propose that alpha-TOS displaces UbQ in CII causing electrons generated by SDH to recombine with molecular oxygen to yield ROS. Our data highlight CII, a known tumour suppressor, as a novel target for cancer therapy.	[Low, P.; Ralph, S. J.] Griffith Univ, Sch Med Sci, Genom Res Ctr, Southport, Qld 4215, Australia; [Dong, L-F; Wang, X-F; Freeman, R.; Swettenham, E.; Liu, J.; Zobalova, R.; Neuzil, J.] Griffith Univ, Sch Med Sci, Apoptosis Res Grp, Southport, Qld 4215, Australia; [Dyason, J. C.] Griffith Univ, Inst Glycom, Southport, Qld 4215, Australia; [Prochazka, L.; Turanek, J.] Vet Res Inst, Dept Immunol, CS-62132 Brno, Czech Republic; [Witting, P. K.] Concord Hosp, Med Res Inst, ANZAC, Sydney, NSW, Australia; [Valis, K.; Zobalova, R.; Neuzil, J.] Acad Sci Czech Republ, Inst Biotechnol, Mol Therapy Grp, Prague, Czech Republic; [Spitz, D. R.; Domann, F. E.] Univ Iowa, Dept Radiat Oncol, Free Rad & Radiat Biol Program, Iowa City, IA USA; [Scheffler, I. E.] Univ Calif San Diego, Div Biol, San Diego, CA 92103 USA	Griffith University; Griffith University; Griffith University; Czech Veterinary Research Institute; Concord Repatriation General Hospital; Czech Academy of Sciences; Institute of Biotechnology of the Czech Academy of Sciences; University of Iowa; University of California System; University of California San Diego	Ralph, SJ (corresponding author), Griffith Univ, Sch Med Sci, Genom Res Ctr, Southport, Qld 4215, Australia.	s.ralph@grif.th.edu.au; j.neuzil@grif.th.edu.au	Vališ, Karel/D-6463-2017; Neuzil, Jiri/H-7204-2014; Zobalova, Renata/H-7242-2014; Witting, Paul/ABD-2053-2020; DONG, LANFENG/S-8805-2019; Ralph, Stephen J./AAE-4888-2019; Witting, Paul/L-9786-2019; Dyason, Jeffrey C/L-5534-2014; Prochazka, Lubomir/J-5284-2014	Vališ, Karel/0000-0002-3036-4345; Neuzil, Jiri/0000-0002-2478-2460; Witting, Paul/0000-0003-2237-7004; Ralph, Stephen J./0000-0002-4335-092X; Dong, Lanfeng/0000-0002-9857-6352; Zobalova, Renata/0000-0002-9097-4700; Domann, Frederick/0000-0002-0489-2179; Spitz, Douglas/0000-0002-1254-8765	NATIONAL CANCER INSTITUTE [R01CA100045, R01CA073612] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA073612-07, R01 CA100045-03, R01-CA73612, R01-CA100045, R01 CA073612, R01 CA073612-08, R01 CA100045, R01 CA100045-05, R01 CA100045-04] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*ACC INC, 2001, INS, V2; Adam-Vizi V, 2006, TRENDS PHARMACOL SCI, V27, P639, DOI 10.1016/j.tips.2006.10.005; Albayrak T, 2003, MOL BIOL CELL, V14, P3082, DOI 10.1091/mbc.e02-10-0631; Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890; Allen RG, 2003, EXP CELL RES, V289, P307, DOI 10.1016/S0014-4827(03)00279-9; Alleva R, 2001, FEBS LETT, V503, P46, DOI 10.1016/S0014-5793(01)02694-1; BERRIDGE MV, 1993, ARCH BIOCHEM BIOPHYS, V303, P474, DOI 10.1006/abbi.1993.1311; Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020; BURNELL JN, 1975, BIOCHEM J, V150, P527, DOI 10.1042/bj1500527; Case D.A., 2002, AMBER, V7; Cheng VWT, 2006, J BIOL CHEM, V281, P27662, DOI 10.1074/jbc.M604900200; CHOUDHRY ZM, 1985, FEBS LETT, V182, P171, DOI 10.1016/0014-5793(85)81177-7; CHOUDHRY ZM, 1986, BIOCHIM BIOPHYS ACTA, V850, P131, DOI 10.1016/0005-2728(86)90017-4; CHURCH SL, 1993, P NATL ACAD SCI USA, V90, P3113, DOI 10.1073/pnas.90.7.3113; Degterev A, 2001, NAT CELL BIOL, V3, P173, DOI 10.1038/35055085; Dias N, 2005, BIOCHEM PHARMACOL, V70, P1, DOI 10.1016/j.bcp.2005.03.021; Don AS, 2004, TRENDS MOL MED, V10, P372, DOI 10.1016/j.molmed.2004.06.005; Dong LF, 2007, CANCER RES, V67, P11906, DOI 10.1158/0008-5472.CAN-07-3034; Fariss MW, 2001, FREE RADICAL BIO MED, V31, P530, DOI 10.1016/S0891-5849(01)00615-3; Geschwind JFH, 2002, CANCER RES, V62, P3909; Gottlieb E, 2005, NAT REV CANCER, V5, P857, DOI 10.1038/nrc1737; GUY CT, 1992, P NATL ACAD SCI USA, V89, P10578, DOI 10.1073/pnas.89.22.10578; Hail N, 2005, APOPTOSIS, V10, P687, DOI 10.1007/s10495-005-0792-8; Hartshorn MJ, 2002, J COMPUT AID MOL DES, V16, P871, DOI 10.1023/A:1023813504011; Huang LS, 2006, J BIOL CHEM, V281, P5965, DOI 10.1074/jbc.M511270200; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; Ishii T, 2005, CANCER RES, V65, P203; James AM, 2005, J BIOL CHEM, V280, P21295, DOI 10.1074/jbc.M501527200; James AM, 2007, J BIOL CHEM, V282, P14708, DOI 10.1074/jbc.M611463200; Kang YH, 2004, INT J CANCER, V112, P385, DOI 10.1002/ijc.20424; Kelso GF, 2001, J BIOL CHEM, V276, P4588, DOI 10.1074/jbc.M009093200; Ko YH, 2004, BIOCHEM BIOPH RES CO, V324, P269, DOI 10.1016/j.bbrc.2004.09.047; Ko YH, 2001, CANCER LETT, V173, P83, DOI 10.1016/S0304-3835(01)00667-X; Kogure K, 2002, CANCER LETT, V186, P151, DOI 10.1016/S0304-3835(02)00344-0; Lahouel M, 2007, BIOCHEM BIOPH RES CO, V355, P252, DOI 10.1016/j.bbrc.2007.01.145; Le SB, 2007, J BIOL CHEM, V282, P8860, DOI 10.1074/jbc.M611777200; MAEHARA Y, 1988, ONCOLOGY-BASEL, V45, P434, DOI 10.1159/000226660; McLennan HR, 2000, J BIOENERG BIOMEMBR, V32, P153, DOI 10.1023/A:1005507913372; Milanesi E, 2006, J BIOL CHEM, V281, P10066, DOI 10.1074/jbc.M513708200; Morris GM, 1998, J COMPUT CHEM, V19, P1639, DOI 10.1002/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B; Neuzil J, 2005, BIOCHEM BIOPH RES CO, V327, P1024, DOI 10.1016/j.bbrc.2004.12.115; Neuzil J, 2001, FASEB J, V15, P403, DOI 10.1096/fj.00-0251com; Neuzil J, 2001, BRIT J CANCER, V84, P87, DOI 10.1054/bjoc.2000.1559; Neuzil J, 2007, J BIOENERG BIOMEMBR, V39, P65, DOI 10.1007/s10863-006-9060-z; Neuzil J, 2007, MOL PHARMACOL, V71, P1185, DOI 10.1124/mol.106.030122; Neuzil J, 2006, FEBS LETT, V580, P5125, DOI 10.1016/j.febslet.2006.05.072; Newmeyer DD, 2003, CELL, V112, P481, DOI 10.1016/S0092-8674(03)00116-8; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; OOSTVEEN FG, 1995, J BIOL CHEM, V270, P26104, DOI 10.1074/jbc.270.44.26104; Rice J.E., 1997, SUBCELLULAR FRACTION, V1st, P107; Robinson BWS, 2005, LANCET, V366, P397, DOI 10.1016/S0140-6736(05)67025-0; SAFFORD SE, 1994, CANCER RES, V54, P4261; SANBORN BM, 1971, BIOCHIM BIOPHYS ACTA, V227, P219, DOI 10.1016/0005-2744(71)90055-6; Sanner MF, 1999, J MOL GRAPH MODEL, V17, P57; Scallet AC, 2003, ANN NY ACAD SCI, V993, P305, DOI 10.1111/j.1749-6632.2003.tb07538.x; Seo BB, 1998, P NATL ACAD SCI USA, V95, P9167, DOI 10.1073/pnas.95.16.9167; Sever N, 2004, J BIOL CHEM, V279, P43136, DOI 10.1074/jbc.M406406200; Shiau CW, 2006, J BIOL CHEM, V281, P11819, DOI 10.1074/jbc.M511015200; SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152; Slane BG, 2006, CANCER RES, V66, P7615, DOI 10.1158/0008-5472.CAN-06-0833; Soller M, 2007, MOL PHARMACOL, V71, P1535, DOI 10.1124/mol.107.034371; SPENCER TL, 1976, BIOCHEM J, V160, P121, DOI 10.1042/bj1600121; Stapelberg M, 2005, J BIOL CHEM, V280, P25369, DOI 10.1074/jbc.M414498200; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Swettenham E, 2005, J NEUROCHEM, V94, P1448, DOI 10.1111/j.1471-4159.2005.03298.x; Trachootham D, 2006, CANCER CELL, V10, P241, DOI 10.1016/j.ccr.2006.08.009; Tran QM, 2006, J BIOL CHEM, V281, P32310, DOI 10.1074/jbc.M607476200; Trounce I A, 1996, Methods Enzymol, V264, P484, DOI 10.1016/S0076-6879(96)64044-0; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wang XF, 2005, BIOCHEM BIOPH RES CO, V326, P282, DOI 10.1016/j.bbrc.2004.11.028; Wang XF, 2007, CANCER RES, V67, P3337, DOI 10.1158/0008-5472.CAN-06-2480; Weber T, 2003, BIOCHEMISTRY-US, V42, P4277, DOI 10.1021/bi020527j; Weber T, 2002, CLIN CANCER RES, V8, P863; Word JM, 1999, J MOL BIOL, V285, P1735, DOI 10.1006/jmbi.1998.2401; Xu RH, 2005, CANCER RES, V65, P613; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605; YU L, 1983, BIOCHIM BIOPHYS ACTA, V723, P139, DOI 10.1016/0005-2728(83)90113-5; Zhang JG, 2001, ARCH BIOCHEM BIOPHYS, V393, P87, DOI 10.1006/abbi.2001.2486; Zhao ZW, 2006, BIOCHEM CELL BIOL, V84, P1013, DOI 10.1139/O06-188	79	225	235	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4324	4335		10.1038/onc.2008.69	http://dx.doi.org/10.1038/onc.2008.69			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372923	Green Accepted, Green Published			2022-12-25	WOS:000257691100007
J	Cox, JH; Dean, RA; Roberts, CR; Overall, CM				Cox, Jennifer H.; Dean, Richard A.; Roberts, Clive R.; Overall, Christopher M.			Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMOKINE RECEPTOR; MULTIPLE-SCLEROSIS; CXC CHEMOKINE; GELATINASE-A; IN-VIVO; 1-MATRIX METALLOPROTEINASE; HEPARIN-BINDING; CC-CHEMOKINE; T-CELLS; PROTEIN	The CXCR3 chemokine receptor regulates the migration of Th1 lymphocytes and responds to three ligands: CXCL9/MIG, CXCL10/IP-10, and CXCL11/I-TAC. We screened for potential regulation of T cell responses by matrix metalloproteinase (MMP) processing of these important chemokines. The most potent of the CXCR3 ligands, CXCL11, was identified by matrix-assisted laser desorption ionization time-of-flight mass spectrometry as a substrate of the PMN-specific MMP-8, macrophage-specific MMP-12, and the general leukocyte MMP-9. The 73-amino acid residue CXCL11 is processed at both the amino and carboxyl termini to generate CXCL11-(5-73),-(5-63), and-(5-58) forms. NH2-terminal truncation results in loss of agonistic properties, as shown in calcium mobilization and chemotaxis experiments using CXCR3 transfectants and human T lymphocytes. Moreover, CXCL11-(5-73) is a CXCR3 antagonist and interestingly shows enhanced affinity to heparin. However, upon COOH-terminal truncation to position 58 there is loss of antagonist activity and heparin binding. Together this highlights an unexpected site for receptor interaction and that the carboxyl terminus is critical for glycosaminoglycan binding, an essential function for the formation of chemokine gradients in vivo. Hence, MMP activity might regulate CXCL11 tissue gradients in two ways. First, the potential of CXCL11-(5-73) to compete active CXCL11 from glycosaminoglycans might lead to the formation of an antagonistic haptotactic chemokine gradient. Second, upon further truncation, MMPs disperse the CXCL11 gradients in a novel way by proteolytic loss of a COOH-terminal GAG binding site. Hence, these results reveal potential new roles in down-regulating Th1 lymphocyte chemoattraction through MMP processing of CXCL11.	[Cox, Jennifer H.; Overall, Christopher M.] Univ British Columbia, Dept Biochem & Mol Biol, Vancouver, BC V6T 1Z3, Canada; [Dean, Richard A.; Roberts, Clive R.; Overall, Christopher M.] Univ British Columbia, Dept Oral Biol & Med Sci, Vancouver, BC V6T 1Z3, Canada	University of British Columbia; University of British Columbia	Overall, CM (corresponding author), Life Sci Inst 4401, 2350 Hlth Sci Mall, Vancouver, BC V6T 1Z3, Canada.	chris.overall@ubc.ca						Abraham M, 2005, J NEUROIMMUNOL, V163, P157, DOI 10.1016/j.jneuroim.2005.02.001; Ajami K, 2008, FEBS LETT, V582, P819, DOI 10.1016/j.febslet.2008.02.005; Balbin M, 2003, NAT GENET, V35, P252, DOI 10.1038/ng1249; Bar-Or A, 2003, BRAIN, V126, P2738, DOI 10.1093/brain/awg285; Booth V, 2004, PROTEIN SCI, V13, P2022, DOI 10.1110/ps.04791404; Burrage PS, 2006, FRONT BIOSCI-LANDMRK, V11, P529, DOI 10.2741/1817; BUSBY TF, 1995, J BIOL CHEM, V270, P18558, DOI 10.1074/jbc.270.31.18558; Butler GS, 2004, J BIOL CHEM, V279, P15615, DOI 10.1074/jbc.M312727200; Cauwe B, 2007, CRIT REV BIOCHEM MOL, V42, P113, DOI 10.1080/10409230701340019; Clark-Lewis I, 2003, J BIOL CHEM, V278, P289, DOI 10.1074/jbc.M209470200; ClarkLewis I, 1997, METHOD ENZYMOL, V287, P233; Cole KE, 1998, J EXP MED, V187, P2009, DOI 10.1084/jem.187.12.2009; COX JH, 2008, CANC DEGRADOME PROTE; Dean RA, 2007, MOL CELL BIOL, V27, P8454, DOI 10.1128/MCB.00821-07; Dean RA, 2007, MOL CELL PROTEOMICS, V6, P611, DOI 10.1074/mcp.M600341-MCP200; Fernandez EJ, 2002, ANNU REV PHARMACOL, V42, P469, DOI 10.1146/annurev.pharmtox.42.091901.115838; Fricker SP, 2006, BIOCHEM PHARMACOL, V72, P588, DOI 10.1016/j.bcp.2006.05.010; Gerard C, 2001, NAT IMMUNOL, V2, P108, DOI 10.1038/84209; Hamilton TA, 2007, J LEUKOCYTE BIOL, V82, P213, DOI 10.1189/jlb.1206754; Hancock WW, 2003, CURR OPIN IMMUNOL, V15, P479, DOI 10.1016/S0952-7915(03)00103-1; Handel TM, 2005, ANNU REV BIOCHEM, V74, P385, DOI 10.1146/annurev.biochem.72.121801.161747; Hasan L, 2006, J IMMUNOL, V176, P6512, DOI 10.4049/jimmunol.176.11.6512; Hensbergen PJ, 2004, J BIOL CHEM, V279, P13402, DOI 10.1074/jbc.M312814200; Herman GA, 2007, CLIN PHARMACOL THER, V81, P761, DOI 10.1038/sj.clpt.6100167; Kakehi K, 2001, ANAL BIOCHEM, V297, P111, DOI 10.1006/abio.2001.5309; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; Kouwenhoven M, 2001, J AUTOIMMUN, V16, P463, DOI 10.1006/jaut.2001.0505; Kuschert GSV, 1998, BIOCHEMISTRY-US, V37, P11193, DOI 10.1021/bi972867o; Lau EK, 2004, J BIOL CHEM, V279, P22294, DOI 10.1074/jbc.M311224200; Li QL, 2002, CELL, V111, P635, DOI 10.1016/S0092-8674(02)01079-6; Lim JK, 2006, J LEUKOCYTE BIOL, V80, P1395, DOI 10.1189/jlb.0406290; Locati M, 2005, CYTOKINE GROWTH F R, V16, P679, DOI 10.1016/j.cytogfr.2005.05.003; Loetscher M, 1996, J EXP MED, V184, P963, DOI 10.1084/jem.184.3.963; Ludwig A, 2002, J LEUKOCYTE BIOL, V72, P183; LustiNarasimhan M, 1996, J BIOL CHEM, V271, P3148, DOI 10.1074/jbc.271.6.3148; Matias-Roman S, 2005, BLOOD, V105, P3956, DOI 10.1182/blood-2004-06-2382; McQuibban GA, 2000, SCIENCE, V289, P1202, DOI 10.1126/science.289.5482.1202; McQuibban GA, 2002, BLOOD, V100, P1160, DOI 10.1182/blood.V100.4.1160.h81602001160_1160_1167; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Moser B, 2004, TRENDS IMMUNOL, V25, P75, DOI 10.1016/j.it.2003.12.005; Neel NF, 2005, CYTOKINE GROWTH F R, V16, P637, DOI 10.1016/j.cytogfr.2005.05.008; Ogilvie P, 2001, BLOOD, V97, P1920, DOI 10.1182/blood.V97.7.1920; Overall CM, 2007, NAT REV MOL CELL BIO, V8, P245, DOI 10.1038/nrm2120; Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821; Overall CM, 2002, MOL BIOTECHNOL, V22, P51, DOI 10.1385/MB:22:1:051; Overall CM, 2002, BIOL CHEM, V383, P1059, DOI 10.1515/BC.2002.114; Page-McCaw A, 2007, NAT REV MOL CELL BIO, V8, P221, DOI 10.1038/nrm2125; Parks WC, 2004, NAT REV IMMUNOL, V4, P617, DOI 10.1038/nri1418; Petit I, 2002, NAT IMMUNOL, V3, P687, DOI 10.1038/ni813; Proost P, 2001, BLOOD, V98, P3554, DOI 10.1182/blood.V98.13.3554; Proost P, 2007, BLOOD, V110, P37, DOI 10.1182/blood-2006-10-049072; Proudfoot AEI, 2001, J BIOL CHEM, V276, P10620, DOI 10.1074/jbc.M010867200; QUANTIN B, 1989, BIOCHEMISTRY-US, V28, P5327, DOI 10.1021/bi00439a004; Sauty A, 2001, J IMMUNOL, V167, P7084, DOI 10.4049/jimmunol.167.12.7084; SCHILLING O, 2008, NAT BIOTECH IN PRESS, P26; Schulte A, 2007, BIOCHEM BIOPH RES CO, V358, P233, DOI 10.1016/j.bbrc.2007.04.100; Shapiro SD, 2003, EUR RESPIR J, V22, p30S, DOI 10.1183/09031936.03.00000903a; SHAPIRO SD, 1993, J BIOL CHEM, V268, P23824; Sorensen TL, 1999, J CLIN INVEST, V103, P807, DOI 10.1172/JCI5150; Takahashi A, 1999, PHYSIOL REV, V79, P1089, DOI 10.1152/physrev.1999.79.4.1089; Tam EM, 2004, J BIOL CHEM, V279, P43336, DOI 10.1074/jbc.M407186200; Tam EM, 2004, P NATL ACAD SCI USA, V101, P6917, DOI 10.1073/pnas.0305862101; Tester AM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000312; Turk BE, 2001, NAT BIOTECHNOL, V19, P661, DOI 10.1038/90273; Unneberg P, 2001, PROTEINS, V42, P460, DOI 10.1002/1097-0134(20010301)42:4<460::AID-PROT50>3.0.CO;2-U; Van Damme J, 1999, Chem Immunol, V72, P42, DOI 10.1159/000058725; Van den Steen PE, 2003, EUR J BIOCHEM, V270, P3739, DOI 10.1046/j.1432-1033.2003.03760.x; Van den Steen PE, 2003, BIOCHEM BIOPH RES CO, V310, P889, DOI 10.1016/j.bbrc.2003.09.098; Van den Steen PE, 2000, BLOOD, V96, P2673, DOI 10.1182/blood.V96.8.2673.h8002673_2673_2681; Vergote D, 2006, P NATL ACAD SCI USA, V103, P19182, DOI 10.1073/pnas.0604678103; Will H, 1996, J BIOL CHEM, V271, P17119, DOI 10.1074/jbc.271.29.17119; Wolf K, 2003, BLOOD, V102, P3262, DOI 10.1182/blood-2002-12-3791; Yang MX, 2006, IMMUNOL CELL BIOL, V84, P557, DOI 10.1111/j.1440-1711.2006.01465.x; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127	74	80	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19389	19399		10.1074/jbc.M800266200	http://dx.doi.org/10.1074/jbc.M800266200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18411283	hybrid			2022-12-25	WOS:000257387600025
J	Samanta, M; Iwakiri, D; Takada, K				Samanta, M.; Iwakiri, D.; Takada, K.			Epstein-Barr virus-encoded small RNA induces IL-10 through RIG-I-mediated IRF-3 signaling	ONCOGENE			English	Article						EBV; Burkitt's lymphoma; EBER; RIG-I; IRF-3; IL-10	LYMPHOMA CELL-LINE; BURKITTS-LYMPHOMA; GROWTH TRANSFORMATION; (EBV)-ENCODED RNA; T-CELLS; EBV; PROTEIN; TRANSCRIPTION; EXPRESSION; INDUCTION	Epstein-Barr virus-encoded small RNA (EBER) is nonpolyadenylated, noncoding RNA, forms stem-loop structure by intermolecular base-pairing giving rise to double-stranded RNA (dsRNA)-like molecule and exists abundantly in EBV-infected cells. EBER induces IL-10 and thus supports the growth of Burkitt's lymphoma (BL) cells. In this study, the mechanism of IL-10 induction by EBER was analysed in the context of dsRNA signaling pathway. Knockdown of retinoic acid-inducible gene I (RIG-I) by small interfering RNA (siRNA), and expression of dominant-negative RIG-I downregulated IL-10 induction in EBER(+) EBV-infected and EBER plasmid-transfected BL cells. Transfection of EBER-expressing plasmid or in vitro synthesized EBER induced IL-10 in RIG-I-expressing cell clones, and activation of IL-10 promoter by EBER was blocked by dominant-negative RIG-I. Blocking of nuclear factor (NF)-kappa B by dominant-negative I kappa B-alpha plasmid did not block IL-10 expression, whereas knockdown of IRF-3 by siRNA resulted in downregulation of IL-10 in EBER(+) BL cells. NF-kappa B is reported to function downstream of RIG-I signaling pathway and is involved in the induction of proinflammatory cytokines. Our results indicate that EBER induces an anti-inflammatory cytokine IL-10 through RIG-I-mediated IRF-3 but not NF-kappa B signaling. These findings suggest a new mechanism of dsRNA signaling pathway that triggers the expression of IL-10, which acts as an autocrine growth factor in BL cells.	[Samanta, M.; Iwakiri, D.; Takada, K.] Hokkaido Univ, Dept Tumor Virol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan	Hokkaido University	Takada, K (corresponding author), Hokkaido Univ, Dept Tumor Virol, Inst Med Genet, Kita Ku, Sapporo, Hokkaido 0600815, Japan.	kentaka@igm.hokudai.ac.jp	Takada, Kenzo/A-6666-2012					AB RICKINSON, 2001, FIELDS VIROLOGY, P2575; ARRAND JR, 1989, J VIROL, V63, P983, DOI 10.1128/JVI.63.2.983-986.1989; CLARKE PA, 1991, NUCLEIC ACIDS RES, V19, P243, DOI 10.1093/nar/19.2.243; GLICKMAN JN, 1988, J VIROL, V62, P902, DOI 10.1128/JVI.62.3.902-911.1988; GREGORY CD, 1990, J GEN VIROL, V71, P1481, DOI 10.1099/0022-1317-71-7-1481; HEITBROCK LZ, 2003, J IMMUNOL, V171, P285; Imaizumi T, 2004, LIFE SCI, V75, P1171, DOI 10.1016/j.lfs.2004.01.030; Iwakiri D, 2005, ONCOGENE, V24, P1767, DOI 10.1038/sj.onc.1208357; Iwakiri D, 2003, CANCER RES, V63, P7062; Kato H, 2005, IMMUNITY, V23, P19, DOI 10.1016/j.immuni.2005.04.010; KIEFF E, 2001, FIELDS VIROLOGY, P2511; Kitagawa N, 2000, EMBO J, V19, P6742, DOI 10.1093/emboj/19.24.6742; KLEIN E, 1968, CANCER RES, V28, P1300; Komano J, 1999, J VIROL, V73, P9827, DOI 10.1128/JVI.73.12.9827-9831.1999; LERNER MR, 1981, P NATL ACAD SCI-BIOL, V78, P805, DOI 10.1073/pnas.78.2.805; Lin RT, 1999, MOL CELL BIOL, V19, P959; MALEFYT RD, 1991, J EXP MED, V174, P915; MALEFYT RD, 1993, J IMMUNOL, V150, P4754; MITCHELL T, 1995, J VIROL, V69, P2968, DOI 10.1128/JVI.69.5.2968-2976.1995; NAKAGOMI H, 1994, INT J CANCER, V57, P240, DOI 10.1002/ijc.2910570218; Nanbo A, 2002, EMBO J, V21, P954, DOI 10.1093/emboj/21.5.954; ROSA MD, 1981, MOL CELL BIOL, V1, P785, DOI 10.1128/MCB.1.9.785; Ruf IK, 2000, J VIROL, V74, P10223, DOI 10.1128/JVI.74.21.10223-10228.2000; Samanta M, 2006, EMBO J, V25, P4207, DOI 10.1038/sj.emboj.7601314; SHARP TV, 1993, NUCLEIC ACIDS RES, V21, P4483, DOI 10.1093/nar/21.19.4483; SHIMIZU N, 1994, J VIROL, V68, P6069, DOI 10.1128/JVI.68.9.6069-6073.1994; TAKADA K, 1991, VIRUS GENES, V5, P147, DOI 10.1007/BF00571929; TOCZYSKI DP, 1994, P NATL ACAD SCI USA, V91, P3463, DOI 10.1073/pnas.91.8.3463; TOCZYSKI DPW, 1991, EMBO J, V10, P459, DOI 10.1002/j.1460-2075.1991.tb07968.x; Tone M, 2000, J IMMUNOL, V165, P286, DOI 10.4049/jimmunol.165.1.286; Wagoner J, 2007, J VIROL, V81, P309, DOI 10.1128/JVI.01411-06; Wu Y, 2007, J VIROL, V81, P11236, DOI 10.1128/JVI.00579-07; Yajima M, 2005, J VIROL, V79, P4298, DOI 10.1128/JVI.79.7.4298-4307.2005; Yamamoto N, 2000, FEBS LETT, V484, P153, DOI 10.1016/S0014-5793(00)02145-1; Yang LX, 2004, CANCER RES, V64, P5332, DOI 10.1158/0008-5472.CAN-04-0733; Yoneyama M, 2004, NAT IMMUNOL, V5, P730, DOI 10.1038/ni1087	36	117	125	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2008	27	30					4150	4160		10.1038/onc.2008.75	http://dx.doi.org/10.1038/onc.2008.75			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18362887				2022-12-25	WOS:000257496800002
J	Schoch, GA; Yano, JK; Sansen, S; Dansette, PM; Stout, CD; Johnson, EF				Schoch, Guillaume A.; Yano, Jason K.; Sansen, Stefaan; Dansette, Patrick M.; Stout, C. David; Johnson, Eric F.			Determinants of cytochrome P4502C8 substrate binding - Structures of complexes with montelukast, troglitazone, felodipine, and 9-cis-retinoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIVER-MICROSOMES; RETINOIC ACID; RECEPTOR ANTAGONIST; ARACHIDONIC-ACID; DRUG INTERACTION; LIGAND-BINDING; METABOLISM; 3A4; 2C8; PHARMACOKINETICS	Although a crystal structure and a pharmacophore model are available for cytochrome P450 2C8, the role of protein flexibility and specific ligand-protein interactions that govern substrate binding are poorly understood. X-ray crystal structures of P450 2C8 complexed with montelukast (2.8 angstrom), troglitazone (2.7 angstrom), felodipine (2.3 angstrom), and 9-cis-retinoic acid (2.6 angstrom) were determined to examine ligand-protein interactions for these chemically diverse compounds. Montelukast is a relatively large anionic inhibitor that exhibits a tripartite structure and complements the size and shape of the active-site cavity. The inhibitor troglitazone occupies the upper portion of the active-site cavity, leaving a substantial part of the cavity unoccupied. The smaller neutral felodipine molecule is sequestered with its dichlorophenyl group positioned close to the heme iron, and water molecules fill the distal portion of the cavity. The structure of the 9-cis-retinoic acid complex reveals that two substrate molecules bind simultaneously in the active site of P450 2C8. A second molecule of 9-cis-retinoic acid is located above the proximal molecule and can restrain the position of the latter for more efficient oxygenation. Solution binding studies do not discriminate between cooperative and noncooperative models for multiple substrate binding. The complexes with structurally distinct ligands further demonstrate the conformational adaptability of active site-constituting residues, especially Arg-241, that can reorient in the active-site cavity to stabilize a negatively charged functional group and define two spatially distinct binding sites for anionic moieties of substrates.	[Schoch, Guillaume A.; Yano, Jason K.; Sansen, Stefaan; Johnson, Eric F.] Scripps Res Inst, Dept Mol & Expt Med, La Jolla, CA 92037 USA; [Stout, C. David] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Dansette, Patrick M.] Univ Paris 05, CNRS, Chim & Biochim Pharmacol & Toxicol Lab, UMR 8601, F-75270 Paris 06, France	Scripps Research Institute; Scripps Research Institute; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite Paris Cite	Johnson, EF (corresponding author), Scripps Res Inst, Dept Mol & Expt Med, 10550 N Torrey Pines Rd,MEM-255, La Jolla, CA 92037 USA.	johnson@scripps.edu	DANSETTE, Patrick/B-8384-2014; Dansette, Patrick/AFQ-0661-2022	DANSETTE, Patrick/0000-0002-3694-3348; Yano, Jason/0000-0002-9774-2611	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031001] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM031001, R01 GM031001-27, R01 GM031001] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAARNHIELM C, 1986, ACTA PHARMACOL TOX, V59, P113; Balani SK, 1997, DRUG METAB DISPOS, V25, P1282; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chiba M, 1997, DRUG METAB DISPOS, V25, P1022; Collaborative Computational Project, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI DOI 10.1107/S0907444994003112; Cupp-Vickery J, 2000, P NATL ACAD SCI USA, V97, P3050, DOI 10.1073/pnas.050406897; DAIKH BE, 1994, J PHARMACOL EXP THER, V271, P1427; Delaforge M, 2005, DRUG METAB DISPOS, V33, P466, DOI 10.1124/dmd.104.002097; Denisov IG, 2007, J BIOL CHEM, V282, P7066, DOI 10.1074/jbc.M609589200; Ekroos M, 2006, P NATL ACAD SCI USA, V103, P13682, DOI 10.1073/pnas.0603236103; ERIKSSON UG, 1991, DRUG METAB DISPOS, V19, P889; Giaginis C, 2007, J CHROMATOGR B, V857, P181, DOI 10.1016/j.jchromb.2007.07.013; HURVICH CM, 1995, BIOMETRICS, V51, P1077, DOI 10.2307/2533006; Jaakkola T, 2006, EUR J CLIN PHARMACOL, V62, P503, DOI 10.1007/s00228-006-0136-9; Jefcoate C R, 1978, Methods Enzymol, V52, P258; Johnson EF, 2005, BIOCHEM BIOPH RES CO, V338, P331, DOI 10.1016/j.bbrc.2005.08.190; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; Kajosaari LI, 2006, CLIN PHARMACOL THER, V79, P231, DOI 10.1016/j.clpt.2005.11.002; Korzekwa KR, 1998, BIOCHEMISTRY-US, V37, P4137, DOI 10.1021/bi9715627; Kumar S, 2002, J PHARMACOL EXP THER, V303, P969, DOI 10.1124/jpet.102.038992; Kuzmic P, 1996, ANAL BIOCHEM, V237, P260, DOI 10.1006/abio.1996.0238; Lampe JN, 2006, BIOCHEMISTRY-US, V45, P12204, DOI 10.1021/bi060083h; LEO MA, 1989, ARCH BIOCHEM BIOPHYS, V269, P305, DOI 10.1016/0003-9861(89)90112-4; Li HY, 1997, NAT STRUCT BIOL, V4, P140, DOI 10.1038/nsb0297-140; Marill J, 2000, MOL PHARMACOL, V58, P1341, DOI 10.1124/mol.58.6.1341; Marill J, 2002, BIOCHEM PHARMACOL, V63, P933, DOI 10.1016/S0006-2952(01)00925-X; McSorley LC, 2000, BIOCHEM PHARMACOL, V60, P517, DOI 10.1016/S0006-2952(00)00356-7; Melet A, 2004, BIOCHEMISTRY-US, V43, P15379, DOI 10.1021/bi0489309; Ogilvie BW, 2006, DRUG METAB DISPOS, V34, P191, DOI 10.1124/dmd.105.007633; RAHMAN A, 1994, CANCER RES, V54, P5543; RICHARDSON TH, 1995, ARCH BIOCHEM BIOPHYS, V323, P87, DOI 10.1006/abbi.1995.0013; Roberts AG, 2005, BIOCHEMISTRY-US, V44, P1353, DOI 10.1021/bi0481390; SCHENKMAN JB, 1967, MOL PHARMACOL, V3, P113; Schoch GA, 2004, J BIOL CHEM, V279, P9497, DOI 10.1074/jbc.M312516200; Shitara Y, 2004, J PHARMACOL EXP THER, V311, P228, DOI 10.1124/jpet.104.068536; STERN JO, 1973, ARCH BIOCHEM BIOPHYS, V156, P404, DOI 10.1016/0003-9861(73)90289-0; Tornio A, 2008, DRUG METAB DISPOS, V36, P73, DOI 10.1124/dmd.107.018010; Totah RA, 2005, CLIN PHARMACOL THER, V77, P341, DOI 10.1016/j.clpt.2004.12.267; TSAI R, 1970, P NATL ACAD SCI USA, V66, P1157, DOI 10.1073/pnas.66.4.1157; Walsky RL, 2005, DRUG METAB DISPOS, V33, P413, DOI 10.1124/dmd.104.002766; Walsky RL, 2005, J CLIN PHARMACOL, V45, P68, DOI 10.1177/0091270004270642; Yamazaki H, 1999, DRUG METAB DISPOS, V27, P1260; ZELDIN DC, 1995, ARCH BIOCHEM BIOPHYS, V322, P76, DOI 10.1006/abbi.1995.1438; Zhao B, 2005, J BIOL CHEM, V280, P11599, DOI 10.1074/jbc.M410933200	44	130	131	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17227	17237		10.1074/jbc.M802180200	http://dx.doi.org/10.1074/jbc.M802180200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18413310	Green Published, hybrid			2022-12-25	WOS:000256720600032
J	Radhakrishnan, Y; Maile, LA; Ling, Y; Graves, LM; Clemmons, DR				Radhakrishnan, Yashwanth; Maile, Laura A.; Ling, Yan; Graves, Lee M.; Clemmons, David R.			Insulin-like growth factor-I stimulates Shc-dependent phosphatidylinositol 3-kinase activation via Grb2-associated p85 in vascular smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE PHOSPHATASE SHP-2; PROTEIN-KINASE; HIGH GLUCOSE; RECEPTOR SUBSTRATE-1; ALPHA-V-BETA-3 INTEGRIN; HYPERGLYCEMIA ALTERS; SIGNALING PATHWAYS; LIGAND OCCUPANCY; DOCKING PROTEIN; PHOSPHORYLATION	Insulin-like growth factor-I (IGF-I) stimulates vascular smooth muscle cell proliferation and migration by activating both MAPK and phosphatidylinositol 3-kinase (PI3K). Vascular smooth muscle cells (VSMCs) maintained in 25mM glucose sustain MAPK activation via increased Shc phosphorylation and Grb2 association resulting in an enhanced mitogenic response compared with cells grown in 5 mM glucose. PI3K plays a major role in IGF-I-stimulated VSMC migration, and hyperglycemia augments this response. In contrast to MAPK activation the role of Shc in modulating PI3K in response to IGF-I has not been determined. In this study we show that impaired Shc association with Grb2 results in decreased Grb2-p85 association, SHPS-1-p85 recruitment, and PI3K activation in response to IGF-I. Exposure of VSMCs to cell-permeable peptides, which contained polyproline sequences from p85 proposed to mediate Grb2 association, resulted in inhibition of Grb2-p85 binding and AKT phosphorylation. Transfected cells that expressed p85 mutant that had specific prolines mutated to alanines resulted in less Grb2-p85 association, and a Grb2 mutant (W36A/W193A) that attenuated p85 binding showed decreased association of p85 with SHPS-1, PI3K activation, AKT phosphorylation, cell proliferation, and migration in response to IGF-I. Cellular exposure to 25 mM glucose, which is required for Shc phosphorylation in response to IGF-I, resulted in enhanced Grb2 binding to p85, activation of PI3K activity, and increased AKT phosphorylation as compared with cells exposed to 5 mM glucose. We conclude that in VSMCs exposed to hyperglycemia, IGF-I stimulation of Shc facilitates the transfer of Grb2 to p85 resulting in enhanced PI3K activation and AKT phosphorylation leading to enhanced cell proliferation and migration.	[Radhakrishnan, Yashwanth; Maile, Laura A.; Ling, Yan; Clemmons, David R.] Univ N Carolina, Div Endocrinol, Sch Med, Dept Med, Chapel Hill, NC 27599 USA; [Graves, Lee M.] Univ N Carolina, Sch Med, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Clemmons, DR (corresponding author), Univ N Carolina, Div Endocrinol, Sch Med, Dept Med, CB 7170,5030 Burnett Womack, Chapel Hill, NC 27599 USA.	endo@med.unc.edu	Graves, Lee/AAG-5470-2021		NHLBI NIH HHS [HL56850, R01 HL056850] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL056850] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Anitha M, 2006, J CLIN INVEST, V116, P344, DOI 10.1172/JCI26295; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; Baughn LB, 2005, J VIROL, V79, P2325, DOI 10.1128/JVI.79.4.2325-2334.2005; Buren J, 2003, EUR J ENDOCRINOL, V148, P157, DOI 10.1530/eje.0.1480157; Campbell M, 2005, CIRC RES, V96, P197, DOI 10.1161/01.RES.0000152966.88353.9d; Campbell M, 2003, DIABETES, V52, P519, DOI 10.2337/diabetes.52.2.519; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Cantrell DA, 2001, J CELL SCI, V114, P1439; Clemmons DR, 2007, NAT REV DRUG DISCOV, V6, P821, DOI 10.1038/nrd2359; Gadina M, 2000, J BIOL CHEM, V275, P26959; Gavrieli M, 2006, BIOCHEM BIOPH RES CO, V345, P1440, DOI 10.1016/j.bbrc.2006.05.036; Gotoh N, 1996, EMBO J, V15, P6197, DOI 10.1002/j.1460-2075.1996.tb01008.x; Gu HH, 2000, MOL CELL BIOL, V20, P7109, DOI 10.1128/MCB.20.19.7109-7120.2000; Hawkins PT, 2006, BIOCHEM SOC T, V34, P647, DOI 10.1042/BST0340647; Heinrich JN, 2006, CELL SIGNAL, V18, P795, DOI 10.1016/j.cellsig.2005.07.004; Ho A, 2001, CANCER RES, V61, P474; HolgadoMadruga M, 1996, NATURE, V379, P560, DOI 10.1038/379560a0; Huang C, 2002, DIABETES, V51, P2090, DOI 10.2337/diabetes.51.7.2090; Imai Y, 1999, ENDOCRINOLOGY, V140, P4228, DOI 10.1210/en.140.9.4228; Jones JI, 1996, P NATL ACAD SCI USA, V93, P2482, DOI 10.1073/pnas.93.6.2482; KAPELLER R, 1994, J BIOL CHEM, V269, P1927; Kim BS, 1998, J BIOL CHEM, V273, P34543, DOI 10.1074/jbc.273.51.34543; Kwon M, 2006, ENDOCRINOLOGY, V147, P1458, DOI 10.1210/en.2005-1115; Lai KMV, 2000, GENE DEV, V14, P1132; Lee MJ, 2007, AM J PHYSIOL-RENAL, V292, pF617, DOI 10.1152/ajprenal.00278.2006; Lieskovska J, 2006, J BIOL CHEM, V281, P25041, DOI 10.1074/jbc.M602866200; Ling Y, 2005, MOL BIOL CELL, V16, P3353, DOI 10.1091/mbc.E04-10-0918; Ling Y, 2003, MOL ENDOCRINOL, V17, P1824, DOI 10.1210/me.2003-0143; Lock LS, 2000, J BIOL CHEM, V275, P31536, DOI 10.1074/jbc.M003597200; Lord JD, 1998, J IMMUNOL, V161, P4627; Maile LA, 2002, J BIOL CHEM, V277, P8955, DOI 10.1074/jbc.M109258200; Maile LA, 2007, ENDOCRINOLOGY, V148, P2435, DOI 10.1210/en.2006-1440; MYERS MG, 1993, ENDOCRINOLOGY, V132, P1421, DOI 10.1210/en.132.4.1421; Nakajima K, 2000, J BIOL CHEM, V275, P20880, DOI 10.1074/jbc.M905410199; Nam TJ, 2000, ENDOCRINOLOGY, V141, P1100, DOI 10.1210/en.141.3.1100; Paez-Espinosa V, 2001, ENDOCRINE, V14, P295, DOI 10.1385/ENDO:14:3:295; PARKER A, 1995, ENDOCRINOLOGY, V136, P2470, DOI 10.1210/en.136.6.2470; Pillay TS, 1996, J CLIN INVEST, V97, P613, DOI 10.1172/JCI118457; PLEIMAN CM, 1994, SCIENCE, V263, P1609, DOI 10.1126/science.8128248; Pratt JC, 1999, J IMMUNOL, V163, P2586; Ravichandran KS, 2001, ONCOGENE, V20, P6322, DOI 10.1038/sj.onc.1204776; RodriguezViciana P, 1996, PHILOS T ROY SOC B, V351, P225, DOI 10.1098/rstb.1996.0020; SALCINI AE, 1994, ONCOGENE, V9, P2827; Salt IP, 2003, J BIOL CHEM, V278, P18791, DOI 10.1074/jbc.M210618200; Sasaoka T, 2001, ENDOCRINOLOGY, V142, P5226, DOI 10.1210/en.142.12.5226; Sayeski PP, 2003, EXP CELL RES, V287, P339, DOI 10.1016/S0014-4827(03)00154-X; Taouis M, 1998, MOL CELL ENDOCRINOL, V137, P177, DOI 10.1016/S0303-7207(97)00245-1; Tesseraud S, 2007, DOMEST ANIM ENDOCRIN, V33, P123, DOI 10.1016/j.domaniend.2006.06.002; Tzatsos A, 2006, MOL CELL BIOL, V26, P63, DOI 10.1128/MCB.26.1.63-76.2006; Tzatsos A, 2007, J BIOL CHEM, V282, P18069, DOI 10.1074/jbc.M610101200; Varma S, 2005, AM J PHYSIOL-HEART C, V289, pH1744, DOI 10.1152/ajpheart.01088.2004; WANG J, 1995, J BIOL CHEM, V270, P12774, DOI 10.1074/jbc.270.21.12774; YAMAUCHI K, 1994, J BIOL CHEM, V269, P31107; Yu JH, 1998, J BIOL CHEM, V273, P30199, DOI 10.1074/jbc.273.46.30199; Zheng B, 1998, P NATL ACAD SCI USA, V95, P11217, DOI 10.1073/pnas.95.19.11217; Zheng XL, 2007, DIABETOLOGIA, V50, P881, DOI 10.1007/s00125-006-0543-6; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	57	50	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16320	16331		10.1074/jbc.M801687200	http://dx.doi.org/10.1074/jbc.M801687200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18420583	Green Published, hybrid			2022-12-25	WOS:000256497100008
J	Taylor, AI; Gould, HJ; Sutton, BJ; Calvert, RA				Taylor, Alexander I.; Gould, Hannah J.; Sutton, Brian J.; Calvert, Rosaleen A.			Avian IgY binds to a monocyte receptor with IgG-like kinetics despite an IgE-like structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC; CHICKEN; COMPLEX; CELLS; EVOLUTION; FRAGMENT; ANTIBODY; IDENTIFICATION; CLONING; REGION	An ancestor of avian IgY was the evolutionary precursor of mammalian IgG and IgE, and present day chicken IgY performs the function of human IgG despite having the domain structure of human IgE. The kinetics of IgY binding to its receptor on a chicken monocyte cell line, MQ-NCSU, were measured, the first time that the binding of a non-mammalian antibody to a non-mammalian cell has been investigated (k(+1) = 1.14 +/- 0.46 x 10(5) mol(-1)sec(-1), k(-1) = 2.30 +/- 0.14 x 10(-3) s(-1), and K-a = 4.95 x 10(7) M-1). This is a lower affinity than that recorded for mammalian IgE-high affinity receptor interactions (K-a similar to 10(10) M-1) but is within the range of mammalian IgG-high affinity receptor interactions (human: K-a similar to 10(8)-10(9) M-1; mouse: K-a similar to 10(7)-10(8) M-1). IgE has an extra pair of immunoglobulin domains when compared with IgG. Their presence reduces the dissociation rate of IgE from its receptor 20-fold, thus contributing to the high affinity of IgE. To assess the effect of the equivalent domains on the kinetics of IgY binding, IgY-Fc fragments with and without this domain were cloned and expressed in mammalian cells. In contrast to IgE, their presence in IgY has little effect on the association rate and no effect on dissociation. Whatever the function of this extra domain pair in avian IgY, it has persisted for at least 310 million years and has been co-opted in mammalian IgE to generate a uniquely slow dissociation rate and high affinity.	[Taylor, Alexander I.; Gould, Hannah J.; Sutton, Brian J.; Calvert, Rosaleen A.] Kings Coll London, Randall Div Cell & Mol Biophys, London SE1 1UL, England	University of London; King's College London	Calvert, RA (corresponding author), Kings Coll London, Randall Div Cell & Mol Biophys, Guys Campus, London SE1 1UL, England.	rosy.calvert@kcl.ac.uk		Gould, Hannah/0000-0003-0411-688X; Taylor, Alexander/0000-0001-7684-1437	Medical Research Council [G0400503B] Funding Source: researchfish; BBSRC [BB/D011418/1] Funding Source: UKRI; MRC [G0501494] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/D011418/1] Funding Source: Medline; Medical Research Council [G0501494] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Abi-Rached L, 2007, J IMMUNOL, V178, P7943, DOI 10.4049/jimmunol.178.12.7943; AMEMIYA CT, 1989, NUCLEIC ACIDS RES, V17, P5388, DOI 10.1093/nar/17.13.5388; BELLAVIA A, 1992, IMMUNOPHARM IMMUNOT, V14, P233, DOI 10.3109/08923979209009222; Bininda-Emonds ORP, 2007, NATURE, V446, P507, DOI 10.1038/nature05634; Caldwell CC, 2001, ARCH BIOCHEM BIOPHYS, V387, P107, DOI 10.1006/abbi.2000.2216; CHAND N, 1978, AVIAN DIS, V22, P639, DOI 10.2307/1589640; CHAND N, 1976, BRIT J PHARMACOL, V57, P399, DOI 10.1111/j.1476-5381.1976.tb07680.x; Cook JPD, 1997, BIOCHEMISTRY-US, V36, P15579, DOI 10.1021/bi9713005; Davis RS, 2007, ANNU REV IMMUNOL, V25, P525, DOI 10.1146/annurev.immunol.25.022106.141541; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; ELLMAN GL, 1958, ARCH BIOCHEM BIOPHYS, V74, P443, DOI 10.1016/0003-9861(58)90014-6; FAITH RE, 1973, IMMUNOLOGY, V25, P151; Fayngerts SA, 2007, IMMUNOGENETICS, V59, P493, DOI 10.1007/s00251-007-0208-8; FELLAH JS, 1988, MOL IMMUNOL, V25, P1377, DOI 10.1016/0161-5890(88)90054-5; Flajnik MF, 2002, NAT REV IMMUNOL, V2, P688, DOI 10.1038/nri889; Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; GEHA RS, 1985, NATURE, V315, P577, DOI 10.1038/315577a0; GOODRICH JA, 2007, BINDING KINETICS MOL, P88; Gould HJ, 2003, ANNU REV IMMUNOL, V21, P579, DOI 10.1146/annurev.immunol.21.120601.141103; Hedges SB, 2002, NAT REV GENET, V3, P838, DOI 10.1038/nrg929; Henry AJ, 1997, BIOCHEMISTRY-US, V36, P15568, DOI 10.1021/bi971299+; HULETT MD, 1994, ADV IMMUNOL, V57, P1, DOI 10.1016/S0065-2776(08)60671-9; IKEYAMA S, 1987, MOL IMMUNOL, V24, P231; ISHIZAKA T, 1986, P NATL ACAD SCI USA, V83, P8323, DOI 10.1073/pnas.83.21.8323; Karagiannis SN, 2003, EUR J IMMUNOL, V33, P1030, DOI 10.1002/eji.200323185; Karagiannis SN, 2008, CANCER IMMUNOL IMMUN, V57, P247, DOI 10.1007/s00262-007-0371-7; KENTEN JH, 1982, P NATL ACAD SCI-BIOL, V79, P6661, DOI 10.1073/pnas.79.21.6661; KULCZYCK.A, 1974, J EXP MED, V140, P1676, DOI 10.1084/jem.140.6.1676; KYHSEANDERSEN J, 1984, J BIOCHEM BIOPH METH, V10, P203, DOI 10.1016/0165-022X(84)90040-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Laun K, 2006, PLOS GENET, V2, P707, DOI 10.1371/journal.pgen.0020073; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Lynch Michael, 2003, Journal of Structural and Functional Genomics, V3, P35, DOI 10.1023/A:1022696612931; Maenaka K, 2001, J BIOL CHEM, V276, P44898, DOI 10.1074/jbc.M106819200; MAGOR KE, 1992, J IMMUNOL, V149, P2627; Martin AM, 2002, TRENDS IMMUNOL, V23, P81, DOI 10.1016/S1471-4906(01)02155-X; Maruoka T, 2004, IMMUNOGENETICS, V55, P712, DOI 10.1007/s00251-003-0626-1; MCCONAHEY P, 1980, IMMUNOCHEMICAL TEC A, V70, P210; McDonnell JM, 2001, NAT STRUCT BIOL, V8, P437, DOI 10.1038/87603; MURPHY KM, 2008, JANEWAYS IMMUNOBIOLO, P566; OGAWA M, 1983, P NATL ACAD SCI-BIOL, V80, P4494, DOI 10.1073/pnas.80.14.4494; PARVARI R, 1988, EMBO J, V7, P739, DOI 10.1002/j.1460-2075.1988.tb02870.x; Pleass RJ, 2001, J BIOL CHEM, V276, P8197, DOI 10.1074/jbc.M009396200; QURESHI MA, 1990, VET IMMUNOL IMMUNOP, V26, P237, DOI 10.1016/0165-2427(90)90094-9; Qureshi MA, 2000, DEV COMP IMMUNOL, V24, P103, DOI 10.1016/S0145-305X(99)00067-1; Reischl IG, 1996, CLIN EXP ALLERGY, V26, P630, DOI 10.1046/j.1365-2222.1996.1047408.x; Reisz RR, 2004, TRENDS GENET, V20, P237, DOI 10.1016/j.tig.2004.03.007; ROSE ME, 1980, INT ARCH ALLER A IMM, V63, P21; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; SEGAL DM, 1977, J IMMUNOL, V118, P1338; Shi JG, 1997, BIOCHEMISTRY-US, V36, P2112, DOI 10.1021/bi961231e; SHOPES B, 1990, J IMMUNOL, V145, P3842; Suzuki N, 2004, GLYCOBIOLOGY, V14, P275, DOI 10.1093/glycob/cwh031; Taylor AI, 2007, IMMUNOGENETICS, V59, P323, DOI 10.1007/s00251-007-0195-9; UNKELESS JC, 1975, J EXP MED, V142, P1520, DOI 10.1084/jem.142.6.1520; Vernersson M, 2004, DEV COMP IMMUNOL, V28, P61, DOI 10.1016/S0145-305X(03)00084-3; Vernersson M, 2002, EUR J IMMUNOL, V32, P2145, DOI 10.1002/1521-4141(200208)32:8<2145::AID-IMMU2145>3.0.CO;2-I; Viertlboeck BC, 2007, P NATL ACAD SCI USA, V104, P11718, DOI 10.1073/pnas.0702011104; WARR GW, 1995, IMMUNOL TODAY, V16, P392, DOI 10.1016/0167-5699(95)80008-5; WILSON AB, 1976, INT ARCH ALLER A IMM, V51, P68, DOI 10.1159/000231579; Woof JM, 2004, NAT REV IMMUNOL, V4, P89, DOI 10.1038/nri1266; YOUNG RJ, 1995, PROTEIN ENG, V8, P193, DOI 10.1093/protein/8.2.193; ZHANG GP, 1995, J IMMUNOL, V155, P1534; Zhao Y, 2000, IMMUNOLOGY, V101, P348, DOI 10.1046/j.1365-2567.2000.00106.x	64	29	34	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16384	16390		10.1074/jbc.M801321200	http://dx.doi.org/10.1074/jbc.M801321200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18400746	hybrid			2022-12-25	WOS:000256497100014
J	Kim, HR; Lee, GH; Ha, KC; Ahn, T; Moon, JY; Lee, BJ; Cho, SG; Kim, S; Seo, YR; Shin, YJ; Chae, SW; Reed, JC; Chae, HJ				Kim, Hyung-Ryong; Lee, Geum-Hwa; Ha, Ki-Chan; Ahn, Taeho; Moon, Ji-Yong; Lee, Bong-Jin; Cho, Ssang-Goo; Kim, Sanguk; Seo, Young-Rok; Shin, Yong-Joo; Chae, Soo-Wan; Reed, John C.; Chae, Han-Jung			Bax inhibitor-1 is a pH-dependent regulator of Ca2+ channel activity in the endoplasmic reticulum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR PH; CALCIUM STORES; ION-CHANNEL; CELLS; APOPTOSIS; MACROPHAGES; MECHANISMS; EXPRESSION; BINDING; STRESS	In this study, Bax inhibitor-1 (BI-1) overexpression reduces the ER pool of Ca2+ released by thapsigargin. Cells overexpressing BI-1 also showed lower intracellular Ca2+ release induced by the Ca2+ ionophore ionomycin as well as agonists of ryanodine receptors and inositol trisphosphate receptors. In contrast, cells expressing carboxyl-terminal deleted BI-1 (C Delta-BI-1 cells) displayed normal intracellular Ca2+ mobilization. Basal Ca2+ release rates from the ER were higher in BI-1-overexpressing cells than in control or C Delta-BI-1 cells. We determined that the carboxyl-terminal cytosolic region of BI-1 contains a lysine-rich motif (EKDKKKEKK) resembling the pH-sensing domains of ion channels. Acidic conditions triggered more extensive Ca2+ release from ER microsomes from BI-1-overexpressing cells and BI-1-reconsituted liposomes. Acidic conditions also induced BI-1 protein oligomerization. Interestingly subjecting BI-1 overexpressing cells to acidic conditions induced more Bax recruitment to mitochondria, more cytochrome c release from mitochondria, and more cell death. These findings suggest that BI-1 increases Ca2+ leak rates from the ER through a mechanism that is dependent on pH and on the carboxyl-terminal cytosolic region of the BI-1 protein. The findings also reveal a cell death-promoting phenotype for BI-1 that is manifested under low pH conditions.	[Reed, John C.] Burnham Inst Med Res, La Jolla, CA 92037 USA; [Lee, Geum-Hwa; Ha, Ki-Chan; Moon, Ji-Yong; Chae, Soo-Wan; Chae, Han-Jung] Chonbuk Natl Univ, Dept Pharmacol, Sch Med, Jeonju 561181, Chonbuk, South Korea; [Lee, Geum-Hwa; Ha, Ki-Chan; Moon, Ji-Yong; Chae, Soo-Wan; Chae, Han-Jung] Chonbuk Natl Univ, Inst Cardiovasc Res, Sch Med, Jeonju 561181, Chonbuk, South Korea; [Kim, Hyung-Ryong] Wonkwang Univ, Dept Dent Pharmacol, Sch Dent, Iksan 570749, Chonbuk, South Korea; [Kim, Hyung-Ryong] Wonkwang Univ, Wonkwang Biomat Implant Res Inst, Sch Dent, Iksan 570749, Chonbuk, South Korea; [Chae, Soo-Wan; Chae, Han-Jung] Chonbuk Hosp, Clin Trial Ctr Funct Foods, Jeonju 561712, Chonbuk, South Korea; [Ahn, Taeho] Chonnam Natl Univ, Dept Biochem, Coll Vet Med, Kwangju 500757, South Korea; [Lee, Bong-Jin] Seoul Natl Univ, Coll Pharm, Seoul 151742, South Korea; [Cho, Ssang-Goo] Konkuk Univ, Dept Anim Biotechnol, Seoul 143701, South Korea; [Kim, Sanguk] Pohang Univ Sci & Technol POSTECH, Div Mol & Life Sci, Pohang 790784, South Korea; [Seo, Young-Rok] Kyung Hee Univ, Dept Pharmacol, MRC, Coll Med, Seoul 130701, South Korea; [Shin, Yong-Joo] Catholic Univ Korea, Div Rheumatol, Dept Internal Med, Catholic Res Inst Med Sci,Sch Med, Seoul 150010, South Korea	Sanford Burnham Prebys Medical Discovery Institute; Jeonbuk National University; Jeonbuk National University; Wonkwang University; Wonkwang University; Chonnam National University; Seoul National University (SNU); Konkuk University; Pohang University of Science & Technology (POSTECH); Kyung Hee University; Catholic University of Korea	Reed, JC (corresponding author), Burnham Inst Med Res, 10901 N Torrey Pines Rd, La Jolla, CA 92037 USA.	jreed@burnham.org; hjchae@chonbuk.ac.kr	Lee, Bong-Jin/AAQ-1609-2020	Lee, Bong-Jin/0000-0001-7896-2961; Cho, Ssang-Goo/0000-0002-0968-7932; Kim, Sanguk/0000-0002-3449-3814; Chae, Han-Jung/0000-0003-4190-9889	NIA NIH HHS [AG15393] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG015393] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akiba Y, 1999, AM J PHYSIOL-GASTR L, V276, pG293, DOI 10.1152/ajpgi.1999.276.1.G293; Berridge MJ, 2002, CELL CALCIUM, V32, P235, DOI 10.1016/S0143416002001823; BEZPROZVANNY I, 1991, NATURE, V351, P751, DOI 10.1038/351751a0; Bolduc N, 2007, BIOCHIMIE, V89, P961, DOI 10.1016/j.biochi.2007.02.004; Bootman MD, 2002, FASEB J, V16, DOI 10.1096/fj.02-0037rev; Boyarsky G, 1996, AM J PHYSIOL-CELL PH, V271, pC1146, DOI 10.1152/ajpcell.1996.271.4.C1146; Chae HJ, 2004, MOL CELL, V15, P355, DOI 10.1016/j.molcel.2004.06.038; Chae HJ, 2003, GENE, V323, P101, DOI 10.1016/j.gene.2003.09.011; Chen CC, 1998, P NATL ACAD SCI USA, V95, P10240, DOI 10.1073/pnas.95.17.10240; Choi J, 1999, ANAL BIOCHEM, V274, P118, DOI 10.1006/abio.1999.4261; Clapham DE, 2007, CELL, V131, P1047, DOI 10.1016/j.cell.2007.11.028; Corbett EF, 1999, J BIOL CHEM, V274, P6203, DOI 10.1074/jbc.274.10.6203; Cowling RT, 1998, MOL MEMBR BIOL, V15, P177, DOI 10.3109/09687689709044319; Dasso LLT, 2000, AM J PHYSIOL-LUNG C, V279, pL36, DOI 10.1152/ajplung.2000.279.1.L36; Deau JTY, 2003, ANESTH ANALG, V97, P1325, DOI 10.1213/01.ANE.0000082240.74557.6D; Dhein S, 2006, ADV CARDIOL, V42, P198, DOI 10.1159/000092570; FARR M, 1985, CLIN EXP RHEUMATOL, V3, P99; GILL DL, 1989, CELL CALCIUM, V10, P363, DOI 10.1016/0143-4160(89)90062-6; GRIFFITHS JR, 1991, BRIT J CANCER, V64, P425, DOI 10.1038/bjc.1991.326; Hardingham GE, 1997, NATURE, V385, P260, DOI 10.1038/385260a0; Hofer AM, 1996, FASEB J, V10, P302, DOI 10.1096/fasebj.10.2.8641563; HOLZ RW, 1992, METHOD ENZYMOL, V219, P165; Ihara-Ohori Y, 2007, PLANT PHYSIOL, V143, P650, DOI 10.1104/pp.106.090878; Kingsley LA, 2007, MOL CANCER THER, V6, P2609, DOI 10.1158/1535-7163.MCT-07-0234; Kloda A, 2006, BIOPHYS J, V90, P1992, DOI 10.1529/biophysj.105.075481; Koo MK, 2007, CYTOM PART A, V71A, P87, DOI 10.1002/cyto.a.20361; Lambers TT, 2007, MOL CELL BIOL, V27, P1486, DOI 10.1128/MCB.01468-06; Leake DS, 1997, ATHEROSCLEROSIS, V129, P149, DOI 10.1016/S0021-9150(96)06035-2; MAIDORN RP, 1993, BRIT J CANCER, V67, P297, DOI 10.1038/bjc.1993.56; Matsuyama S, 2000, CELL DEATH DIFFER, V7, P1155, DOI 10.1038/sj.cdd.4400779; Picloplichko VI, 2006, P NATL ACAD SCI USA, V103, P11376, DOI 10.1073/pnas.0600768103; POZZAN T, 1994, PHYSIOL REV, V74, P595, DOI 10.1152/physrev.1994.74.3.595; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; SILVER IA, 1988, EXP CELL RES, V175, P266, DOI 10.1016/0014-4827(88)90191-7; TAPPER H, 1992, BIOCHEM J, V281, P245, DOI 10.1042/bj2810245; Van Coppenolle F, 2004, J CELL SCI, V117, P4135, DOI 10.1242/jcs.01274; Wang W, 2006, J BIOL CHEM, V281, P2497, DOI 10.1074/jbc.M507123200; Wang ZL, 2004, J BIOL CHEM, V279, P48168, DOI 10.1074/jbc.M405022200; Xu QL, 1998, MOL CELL, V1, P337, DOI 10.1016/S1097-2765(00)80034-9; Zanke BW, 1998, CANCER RES, V58, P2801	40	86	89	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15946	15955		10.1074/jbc.M800075200	http://dx.doi.org/10.1074/jbc.M800075200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18378668	Green Published, hybrid			2022-12-25	WOS:000256332500053
J	Arito, M; Horiba, T; Hachimura, S; Inoue, J; Sato, R				Arito, Mitsumi; Horiba, Taro; Hachimura, Satoshi; Inoue, Jun; Sato, Ryuichiro			Growth factor-induced phosphorylation of sterol regulatory element-binding proteins inhibits sumoylation, thereby stimulating the expression of their target genes, low density lipoprotein uptake, and lipid synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED RECEPTOR-GAMMA; TRANSCRIPTIONAL REPRESSION; SUMO-1 MODIFICATION; PROTEASOME PATHWAY; DEGRADATION; (SREBP)-1A; MOTIF	The destiny and activity of sterol regulatory element-binding proteins (SREBPs) in the nucleus are regulated by modification with ubiquitin, small ubiquitin-like modifier (SUMO), or phosphorus. ERK-dependent phosphorylation causes an increase in their transcriptional activity, whereas SUMO modification halts it. We hypothesized a causal linkage between phosphorylation and sumoylation because their sites are very closely located in SREBP-1 and -2 molecules. When Ser(455) a phosphorylation site in SREBP-2, was substituted with Ala, this SREBP-2 mutant was more efficiently modified by SUMO-1. On the other hand, substitution of Asp inhibited SUMO conjugation, mimicking phosphoserine. When cells were cultured with insulin-like growth factor-1, sumoylation of SREBP-2 was decreased with an increase in its phosphorylation, but SREBP-2(S455A) was continuously sumoylated. An ERK cascade inhibitor, U0126, inversely augmented SUMO modification of SREBP-2. Insulin-like growth factor-1 treatment stimulated the expression of SREBP target genes such as the low density lipoprotein (LDL) receptor, squalene synthase, and hydroxymethylglutaryl-CoA synthase genes. These results indicate that growth factor-induced phosphorylation of SREBP-2 inhibits sumoylation, thereby facilitating SREBP transcriptional activity. Glutathione S-transferase pulldown assays revealed that wild-type SREBP-2, but not a mutant lacking Lys(464), interacts with HDAC3 preferentially among the histone deacetylase family members. HDAC3 small interfering RNA induced gene expression of the LDL receptor and thereby augmented fluorescently labeled LDL uptake in HepG2 cells. In summary, growth factors inhibit sumoylation of SREBPs through their phosphorylation, thus avoiding the recruitment of an HDAC3 corepressor complex and stimulating the lipid uptake and synthesis required for cell growth.	[Arito, Mitsumi; Horiba, Taro; Hachimura, Satoshi; Inoue, Jun; Sato, Ryuichiro] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan; [Inoue, Jun; Sato, Ryuichiro] Basic Res Activ Innovat Biosci, Tokyo 1050001, Japan	University of Tokyo	Sato, R (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Appl Biol Chem, Tokyo 1138657, Japan.	aroysato@mail.ecc.u-tokyo.ac.jp	INOUE, Jun/O-7352-2016	INOUE, Jun/0000-0003-4145-3754	Grants-in-Aid for Scientific Research [19108002] Funding Source: KAKEN	Grants-in-Aid for Scientific Research(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI))		Arimura N, 2004, J BIOL CHEM, V279, P10070, DOI 10.1074/jbc.M308522200; Bengoechea-Alonso MT, 2005, P NATL ACAD SCI USA, V102, P11681, DOI 10.1073/pnas.0501494102; Bies J, 2002, J BIOL CHEM, V277, P8999, DOI 10.1074/jbc.M110453200; Demoulin JB, 2004, J BIOL CHEM, V279, P35392, DOI 10.1074/jbc.M405924200; Girdwood D, 2003, MOL CELL, V11, P1043, DOI 10.1016/S1097-2765(03)00141-2; Goldstein JL, 2006, CELL, V124, P35, DOI 10.1016/j.cell.2005.12.022; Hietakangas V, 2006, P NATL ACAD SCI USA, V103, P45, DOI 10.1073/pnas.0503698102; Hirano Y, 2003, J BIOL CHEM, V278, P16809, DOI 10.1074/jbc.M212448200; Hirano Y, 2001, J BIOL CHEM, V276, P36431, DOI 10.1074/jbc.M105200200; Kanayama T, 2007, J BIOL CHEM, V282, P10290, DOI 10.1074/jbc.M700270200; Kotzka J, 2000, J LIPID RES, V41, P99; Kotzka J, 2004, J BIOL CHEM, V279, P22404, DOI 10.1074/jbc.M401198200; Martin S, 2007, NATURE, V447, P321, DOI 10.1038/nature05736; Nakahara M, 2005, J BIOL CHEM, V280, P42283, DOI 10.1074/jbc.M507454200; Nishida T, 2002, J BIOL CHEM, V277, P41311, DOI 10.1074/jbc.M206741200; Ohshima T, 2004, J BIOL CHEM, V279, P29551, DOI 10.1074/jbc.M403866200; Park J, 2007, P NATL ACAD SCI USA, V104, P17028, DOI 10.1073/pnas.0609852104; Punga T, 2006, J BIOL CHEM, V281, P25278, DOI 10.1074/jbc.M604983200; Roth G, 2000, J BIOL CHEM, V275, P33302, DOI 10.1074/jbc.M005425200; Sato R, 1999, J BIOL CHEM, V274, P24714, DOI 10.1074/jbc.274.35.24714; Shin HJ, 2003, ONCOGENE, V22, P3853, DOI 10.1038/sj.onc.1206502; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Sundqvist A, 2005, CELL METAB, V1, P379, DOI 10.1016/j.cmet.2005.04.010; Swinnen JV, 2000, ONCOGENE, V19, P5173, DOI 10.1038/sj.onc.1203889; Uchimura Y, 2004, ANAL BIOCHEM, V331, P204, DOI 10.1016/j.ab.2004.04.034; Yang SH, 2004, MOL CELL, V13, P611, DOI 10.1016/S1097-2765(04)00060-7; Yang SH, 2003, MOL CELL, V12, P63, DOI 10.1016/S1097-2765(03)00265-X	27	54	59	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15224	15231		10.1074/jbc.M800910200	http://dx.doi.org/10.1074/jbc.M800910200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18403372	Green Published, hybrid			2022-12-25	WOS:000256232000040
J	Lasorsa, FM; Pinton, P; Palmieri, L; Scarcia, P; Rottensteiner, H; Rizzuto, R; Palmieri, F				Lasorsa, Francesco Massimo; Pinton, Paolo; Palmieri, Luigi; Scarcia, Pasquale; Rottensteiner, Hanspeter; Rizzuto, Rosario; Palmieri, Ferdinando			Peroxisomes as novel players in cell calcium homeostasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL CA2+ HOMEOSTASIS; TARGETED RECOMBINANT AEQUORIN; GREEN FLUORESCENT PROTEINS; ENDOPLASMIC-RETICULUM; MAMMALIAN PEROXISOMES; CYTOSOLIC PH; INTACT-CELLS; MEMBRANE; TRANSPORT; DETERMINANTS	Ca2+ concentration in peroxisomal matrix ([Ca2+](perox)) has been monitored dynamically in mammalian cells expressing variants of Ca2+-sensitive aequorin specifically targeted to peroxisomes. Upon stimulation with agonists that induce Ca2+ release from intracellular stores, peroxisomes transiently take up Ca2+ reaching peak values in the lumen as high as 50-100 mu M, depending on cell types. Also in resting cells, peroxisomes sustain a Ca2+ gradient, [Ca2+](perox) being similar to 20-fold higher than [Ca2+] in the cytosol ([Ca2+](cyt)). The properties of Ca2+ traffic across the peroxisomal membrane are different from those reported for other subcellular organelles. The sensitivity of peroxisomal Ca2+ uptake to agents dissipating H+ and Na+ gradients unravels the existence of a complex bioenergetic framework including V-ATPase, Ca2+/H+, and Ca2+/Na+ activities whose components are yet to be identified at a molecular level. The different [Ca2+](perox) of resting and stimulated cells suggest that Ca2+ could play an important role in the regulation of peroxisomal metabolism.	[Pinton, Paolo; Rizzuto, Rosario] Univ Ferrara, Sect Gen Pathol, Dept Expt & Diagnost Med, I-44110 Ferrara, Italy; [Lasorsa, Francesco Massimo; Palmieri, Luigi; Scarcia, Pasquale; Palmieri, Ferdinando] Univ Bari, Dept Pharmacobiol, Biochem & Mol Biol Lab, I-70125 Bari, Italy; [Lasorsa, Francesco Massimo; Palmieri, Luigi; Scarcia, Pasquale; Palmieri, Ferdinando] Inst Biomembranes & Bioenerget, CNR, I-70125 Bari, Italy; [Rottensteiner, Hanspeter] Ruhr Univ Bochum, Inst Physiol Chem, D-44780 Bochum, Germany	University of Ferrara; Universita degli Studi di Bari Aldo Moro; Consiglio Nazionale delle Ricerche (CNR); Ruhr University Bochum	Rizzuto, R (corresponding author), Univ Ferrara, Sect Gen Pathol, Dept Expt & Diagnost Med, I-44110 Ferrara, Italy.	r.rizzuto@unife.it; fpalm@farmbiol.uniba.it	lasorsa, francesco massimo m/B-7931-2008; Pinton, Paolo/J-8025-2012; Scarcia, Pasquale/O-9550-2019; Scarcia, Pasquale/A-8830-2010	lasorsa, francesco massimo m/0000-0001-8418-5222; Pinton, Paolo/0000-0001-7108-6508; Scarcia, Pasquale/0000-0001-6216-0411; Scarcia, Pasquale/0000-0001-6216-0411; Rizzuto, Rosario/0000-0001-7044-5097	Telethon [GGP05284] Funding Source: Medline; Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Telethon(Fondazione Telethon); Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Abad MFC, 2004, J BIOL CHEM, V279, P11521, DOI 10.1074/jbc.M306766200; Aboushadi N, 1998, J LIPID RES, V39, P1781; Alvarez J, 2002, CELL CALCIUM, V32, P251, DOI 10.1016/S0143416002001860; Baron KT, 1997, EUR J PHARMACOL, V340, P295, DOI 10.1016/S0014-2999(97)01433-7; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRINI M, 1995, J BIOL CHEM, V270, P9896, DOI 10.1074/jbc.270.17.9896; BRINI M, 1993, EMBO J, V12, P4813, DOI 10.1002/j.1460-2075.1993.tb06170.x; Chiesa A, 2001, BIOCHEM J, V355, P1, DOI 10.1042/0264-6021:3550001; Coakley RJ, 2002, BLOOD, V100, P3383, DOI 10.1182/blood.V100.9.3383; COX DA, 1993, J BIOL CHEM, V268, P938; Dansen TB, 2000, NAT CELL BIOL, V2, P51, DOI 10.1038/71375; DOUMA AC, 1990, YEAST, V6, P45, DOI 10.1002/yea.320060105; HEMING TA, 1995, J EXP BIOL, V198, P1711; IMANAKA T, 1993, BIOCHEM BIOPH RES CO, V195, P1027, DOI 10.1006/bbrc.1993.2147; Jankowski A, 2001, J BIOL CHEM, V276, P48748, DOI 10.1074/jbc.M109003200; KASS GEN, 1989, J BIOL CHEM, V264, P15192; KENDALL JM, 1992, BIOCHEM BIOPH RES CO, V187, P1091, DOI 10.1016/0006-291X(92)91309-E; Kim PK, 2006, J CELL BIOL, V173, P521, DOI 10.1083/jcb.200601036; Lasorsa FM, 2004, BIOCHEM J, V381, P581, DOI 10.1042/BJ20040856; Lasorsa FM, 2003, J BIOL CHEM, V278, P38686, DOI 10.1074/jbc.M304988200; Lazarow PB, 1989, CURR OPIN CELL BIOL, V1, P630, DOI 10.1016/0955-0674(89)90026-4; Llopis J, 1998, P NATL ACAD SCI USA, V95, P6803, DOI 10.1073/pnas.95.12.6803; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Mitchell KJ, 2001, J CELL BIOL, V155, P41, DOI 10.1083/jcb.200103145; MONTERO M, 1995, EMBO J, V14, P5467, DOI 10.1002/j.1460-2075.1995.tb00233.x; Nelson N, 1999, PHYSIOL REV, V79, P361, DOI 10.1152/physrev.1999.79.2.361; NICOLAY K, 1987, ARCH MICROBIOL, V147, P37, DOI 10.1007/BF00492902; Niikura K, 2004, BRIT J PHARMACOL, V142, P558, DOI 10.1038/sj.bjp.0705812; Palmieri L, 2001, EMBO J, V20, P5049, DOI 10.1093/emboj/20.18.5049; Pinton P, 1998, EMBO J, V17, P5298, DOI 10.1093/emboj/17.18.5298; Pinton P, 2007, METHOD CELL BIOL, V80, P297, DOI 10.1016/S0091-679X(06)80015-4; Pizzo P, 1997, J CELL BIOL, V136, P355, DOI 10.1083/jcb.136.2.355; REDDY JK, 1994, ANNU REV NUTR, V14, P343, DOI 10.1146/annurev.nu.14.070194.002015; Rizzuto R, 1998, SCIENCE, V280, P1763, DOI 10.1126/science.280.5370.1763; RIZZUTO R, 1994, J CELL BIOL, V126, P1183, DOI 10.1083/jcb.126.5.1183; RIZZUTO R, 1992, NATURE, V358, P325, DOI 10.1038/358325a0; Rizzuto R, 2006, PHYSIOL REV, V86, P369, DOI 10.1152/physrev.00004.2005; Rottensteiner H, 2006, BBA-MOL CELL RES, V1763, P1527, DOI 10.1016/j.bbamcr.2006.08.012; Serowy S, 2003, BIOPHYS J, V84, P1031, DOI 10.1016/S0006-3495(03)74919-4; Southall TD, 2006, PHYSIOL GENOMICS, V26, P35, DOI 10.1152/physiolgenomics.00038.2006; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; Theodoulou FL, 2006, FEBS LETT, V580, P1139, DOI 10.1016/j.febslet.2005.12.095; Titorenko VI, 2004, J CELL BIOL, V164, P641, DOI 10.1083/jcb.200312081; van Roermund CWT, 2004, J CELL SCI, V117, P4231, DOI 10.1242/jcs.01305; Visser WF, 2007, BIOCHEM J, V401, P365, DOI 10.1042/BJ20061352; Walker JE, 2006, BBA-BIOENERGETICS, V1757, P286, DOI 10.1016/j.bbabio.2006.01.001; Wanders RJA, 2004, AM J MED GENET A, V126A, P355, DOI 10.1002/ajmg.a.20661; Wanders RJA, 2006, ANNU REV BIOCHEM, V75, P295, DOI 10.1146/annurev.biochem.74.082803.133329	49	40	40	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15300	15308		10.1074/jbc.M800648200	http://dx.doi.org/10.1074/jbc.M800648200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18364350	hybrid, Green Published			2022-12-25	WOS:000256232000048
J	Frederick, ED; Ramos, SBV; Blackshear, PJ				Frederick, Elizabeth D.; Ramos, Silvia B. V.; Blackshear, Perry J.			A unique C-terminal repeat domain maintains the cytosolic localization of the placenta-specific tristetraprolin family member ZFP36L3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; NUCLEAR EXPORT SIGNAL; PRIMARY RESPONSE GENE; AU-RICH ELEMENTS; MESSENGER-RNA; TRANSCRIPTION FACTOR; NUCLEOTIDE-SEQUENCE; TIS11 FAMILY; MECHANISMS; BINDING	Members of the tristetraprolin family of CCCH tandem zinc finger proteins bind to AU-rich elements in certain cellular mRNAs, leading to their deadenylation and destabilization. Studies in knock-out mice demonstrated roles for three of the family members, tristetraprolin, ZFP36L1, and ZFP36L2, in inflammation, chorioallantoic fusion, and early embryonic development, respectively. However, little is known about a recently discovered placenta-specific tristetraprolin family member, ZFP36L3. Tristetraprolin, ZFP36L1, and ZFP36L2 have been shown to shuttle between the nucleus and cytoplasm, using typical hydrophobic amino acid-rich nuclear export sequences, and nuclear localization sequences located within the tandem zinc finger domain. In contrast, we previously showed that green fluorescent protein-labeled ZFP36L3, expressed in HEK293 cells, remained cytosolic, even in the presence of the nuclear export blocker leptomycin B. We show here that the conserved tandem zinc finger domain contains an active nuclear localization signal. However, the sequence corresponding to the nuclear export signal in the other family members was nonfunctional, and thus did not contribute to the cytosolic localization. The unique C-terminal repeat domain could override the activity of the nuclear localization sequence, preventing the import of ZFP36L3 into the nucleus. Immunostaining of mouse placenta demonstrated that ZFP36L3 was located only in the cytoplasm of trophoblast cells. Thus, in contrast to the other mammalian members of this protein family, ZFP36L3 is a "full-time" cytosolic protein, rather than a nucleocytoplasmic shuttling protein. The significance of this difference in subcellular localization to the physiology of placental trophoblast cells, where ZFP36L3 is selectively expressed, remains to be determined.	[Frederick, Elizabeth D.; Ramos, Silvia B. V.; Blackshear, Perry J.] NIEHS, Res Triangle Pk, NC 27709 USA; [Frederick, Elizabeth D.; Blackshear, Perry J.] Duke Univ, Med Ctr, Dept Biochem, Durham, NC 27710 USA; [Blackshear, Perry J.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Duke University; Duke University	Blackshear, PJ (corresponding author), NIEHS, A2-05 111 Alexander Dr, Res Triangle Pk, NC 27709 USA.	black009@niehs.nih.gov	Blackshear, Perry J./C-6206-2019	Blackshear, Perry J./0000-0002-9561-8529; Frederick, Elizabeth/0000-0001-5596-5094	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [ZIAES090080] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 ES090080-10] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Blackshear PJ, 2005, BIOL REPROD, V73, P297, DOI 10.1095/biolreprod.105.040527; Bogerd HP, 1996, MOL CELL BIOL, V16, P4207; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; Brook M, 2006, MOL CELL BIOL, V26, P2408, DOI 10.1128/MCB.26.6.2408-2418.2006; BUSTIN SA, 1994, DNA CELL BIOL, V13, P449, DOI 10.1089/dna.1994.13.449; Cao HP, 2004, J BIOL CHEM, V279, P21489, DOI 10.1074/jbc.M400900200; DUBOIS RN, 1990, J BIOL CHEM, V265, P19185; FISCHER U, 1995, CELL, V82, P475, DOI 10.1016/0092-8674(95)90436-0; GOMPERTS M, 1990, ONCOGENE, V5, P1081; HEXIMER SP, 1993, DNA CELL BIOL, V12, P73, DOI 10.1089/dna.1993.12.73; Kudo N, 1999, P NATL ACAD SCI USA, V96, P9112, DOI 10.1073/pnas.96.16.9112; Kudo N, 1998, EXP CELL RES, V242, P540, DOI 10.1006/excr.1998.4136; Lai WS, 2001, J BIOL CHEM, V276, P23144, DOI 10.1074/jbc.M100680200; Lai WS, 2000, J BIOL CHEM, V275, P17827, DOI 10.1074/jbc.M001696200; LAI WS, 1990, J BIOL CHEM, V265, P16556; Lai WS, 1999, MOL CELL BIOL, V19, P4311; MA QF, 1991, ONCOGENE, V6, P1277; Maclean KN, 1998, BRIT J BIOMED SCI, V55, P184; MACLEAN KN, 1995, GENOMICS, V30, P89, DOI 10.1006/geno.1995.0014; Murata T, 2002, BIOCHEM BIOPH RES CO, V293, P1242, DOI 10.1016/S0006-291X(02)00363-7; NIE XF, 1995, GENE, V152, P285, DOI 10.1016/0378-1119(94)00696-P; Nigg EA, 1997, NATURE, V386, P779, DOI 10.1038/386779a0; Ning ZQ, 1996, EUR J IMMUNOL, V26, P2356, DOI 10.1002/eji.1830261013; Pemberton LF, 2005, TRAFFIC, V6, P187, DOI 10.1111/j.1600-0854.2005.00270.x; Phillips RS, 2002, J BIOL CHEM, V277, P11606, DOI 10.1074/jbc.M111457200; Ramos SBV, 2004, DEVELOPMENT, V131, P4883, DOI 10.1242/dev.01336; Stumpo DJ, 2004, MOL CELL BIOL, V24, P6445, DOI 10.1128/MCB.24.14.6445-6455.2004; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Taylor GA, 1996, MOL ENDOCRINOL, V10, P140, DOI 10.1210/me.10.2.140; TAYLOR GA, 1991, NUCLEIC ACIDS RES, V19, P3454, DOI 10.1093/nar/19.12.3454; VARNUM BC, 1991, MOL CELL BIOL, V11, P1754, DOI 10.1128/MCB.11.3.1754; VARNUM BC, 1989, ONCOGENE, V4, P119; Yoneda Y, 2000, GENES CELLS, V5, P777, DOI 10.1046/j.1365-2443.2000.00366.x	33	22	23	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14792	14800		10.1074/jbc.M801234200	http://dx.doi.org/10.1074/jbc.M801234200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18367448	Green Accepted, hybrid, Green Published			2022-12-25	WOS:000255941400067
J	Oikawa, Y; Matsuda, E; Nishii, T; Ishida, Y; Kawaichi, M				Oikawa, Yu; Matsuda, Eishou; Nishii, Tomonori; Ishida, Yasumasa; Kawaichi, Masashi			Down-regulation of CIBZ, a novel substrate of caspase-3, induces apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC-FINGER PROTEINS; SKELETAL-MUSCLE DIFFERENTIATION; C2C12 MYOBLASTS; TRANSCRIPTIONAL REPRESSOR; CTBP; EXPRESSION; DNA; COREPRESSOR; ACTIVATION; INTERACTS	We previously identified and characterized a murine BTB domain-containing protein, CIBZ (ZBTB38 in human), that interacts with CtBP and binds to methylated CpGs. However, its physiological function remained unknown. As CtBP is reportedly involved in p53-independent programmed cell death, we examine here whether CIBZ is associated with apoptosis. We found that CIBZ was highly expressed in proliferating C2C12 cells but that its expression levels decreased upon induction of apoptosis by serum starvation. Knockdown of CIBZ by small interfering RNA in C2C12 cells induced apoptosis, as determined by an increase of annexin V/propidium iodide labeling, activation of caspase-3, and cleavage of poly( ADP-ribose) polymerase. CIBZ inhibition also activated caspase-7 and caspase-9, suggesting that CIBZ-associated apoptosis occurs through the mitochondrial pathway. Notably, knockdown of CIBZ in p53(-/-) mouse embryonic fibroblast cells also activated caspase-3 and cleavage of poly( ADP-ribose) polymerase, indicating that CIBZ-associated apoptosis is mediated by a p53-independent pathway; however, because both common and distinct targets are regulated by CIBZ- and CtBP-associated apoptosis, we conclude that more than one pathway is involved. Finally, using mutagenesis and an in vitro caspase cleavage assay, we show that CIBZ is a novel substrate of caspase-3 and identify two caspase-3 recognition sites. These findings indicate, collectively, that CIBZ plays an important role by participating in the negative regulation of apoptosis in murine cells.	[Oikawa, Yu; Matsuda, Eishou; Nishii, Tomonori; Ishida, Yasumasa; Kawaichi, Masashi] Nara Inst Sci & Technol, Div Gene Funct Anim, Nara 6300192, Japan	Nara Institute of Science & Technology	Matsuda, E (corresponding author), Nara Inst Sci & Technol, Div Gene Funct Anim, 8916-5 Takayama, Nara 6300192, Japan.	ematsuda@bs.naist.jp						Agata Y, 1999, J BIOL CHEM, V274, P16412, DOI 10.1074/jbc.274.23.16412; Chang HY, 2000, MICROBIOL MOL BIOL R, V64, P821, DOI 10.1128/MMBR.64.4.821-846.2000; Fernando P, 2002, P NATL ACAD SCI USA, V99, P11025, DOI 10.1073/pnas.162172899; Fesik SW, 2001, SCIENCE, V294, P1477, DOI 10.1126/science.1062236; Filion GJP, 2006, MOL CELL BIOL, V26, P169, DOI 10.1128/MCB.26.1.169-181.2006; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Grooteclaes M, 2003, P NATL ACAD SCI USA, V100, P4568, DOI 10.1073/pnas.0830998100; Hildebrand JD, 2002, MOL CELL BIOL, V22, P5296, DOI 10.1128/MCB.22.15.5296-5307.2002; Kamradt MC, 2002, J BIOL CHEM, V277, P38731, DOI 10.1074/jbc.M201770200; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kiefer H, 2005, MOL CELL BIOL, V25, P1713, DOI 10.1128/MCB.25.5.1713-1729.2005; Matsuda E, 2004, P NATL ACAD SCI USA, V101, P4170, DOI 10.1073/pnas.0400604101; Matsuda E, 2001, J BIOL CHEM, V276, P14222, DOI 10.1074/jbc.M010663200; Mercer SE, 2005, J BIOL CHEM, V280, P25788, DOI 10.1074/jbc.M413594200; Paliwal S, 2006, MOL CELL BIOL, V26, P2360, DOI 10.1128/MCB.26.6.2360-2372.2006; Parrado A, 2004, P NATL ACAD SCI USA, V101, P1898, DOI 10.1073/pnas.0308358100; Prokhortchouk A, 2001, GENE DEV, V15, P1613, DOI 10.1101/gad.198501; Sasai N, 2005, GENES CELLS, V10, P871, DOI 10.1111/j.1365-2443.2005.00885.x; SCHAEPER U, 1995, P NATL ACAD SCI USA, V92, P10467, DOI 10.1073/pnas.92.23.10467; Shen X, 2003, DEV DYNAM, V226, P128, DOI 10.1002/dvdy.10200; Shi YG, 2004, PROTEIN SCI, V13, P1979, DOI 10.1110/ps.04789804; Song ZW, 1999, TRENDS CELL BIOL, V9, pM49, DOI 10.1016/S0968-0004(99)01485-1; Tannu NS, 2004, MOL CELL PROTEOMICS, V3, P1065, DOI 10.1074/mcp.M400020-MCP200; Wang J, 1996, SCIENCE, V273, P359, DOI 10.1126/science.273.5273.359; Wang SY, 2006, J BIOL CHEM, V281, P34810, DOI 10.1074/jbc.M607484200; Wang Y, 2007, FASEB J, V21, pA1343; Zhang OH, 2003, CELL, V115, P177, DOI 10.1016/S0092-8674(03)00802-X; Zhang QH, 2005, P NATL ACAD SCI USA, V102, P2802, DOI 10.1073/pnas.0409373102	28	33	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14242	14247		10.1074/jbc.M802257200	http://dx.doi.org/10.1074/jbc.M802257200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18375381	hybrid			2022-12-25	WOS:000255941400010
J	Shimokawa, T; Tostar, U; Lauth, M; Palaniswamy, R; Kasper, M; Toftgard, R; Zaphiropoulos, PG				Shimokawa, Takashi; Tostar, Ulrica; Lauth, Matthias; Palaniswamy, Ramesh; Kasper, Maria; Toftgard, Rune; Zaphiropoulos, Peter G.			Novel human glioma-associated oncogene 1 (GLI1) splice variants reveal distinct mechanisms in the terminal transduction of the hedgehog signal	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL ACTIVITY; TUMOR-SUPPRESSOR; MESSENGER-RNA; 1ST EXON; GENE; EXPRESSION; GROWTH; INTERFERENCE; REQUIREMENT; INHIBITION	Hedgehog (HH) signaling is one of the key pathways with major significance for embryogenesis, tumorigenesis, and stem cell maintenance. Glioma- associated oncogene 1 (GLI1) is a transcription factor that acts as the terminal signaling effector but also represents a pathway target gene. Here we report the identification and functional properties of novel GLI1 splice variants generated by skipping exons 2 and 3 and encoding an N-terminal truncated GLI1 protein (GLI1 Delta N). Analysis of the GLI1 Delta N mRNAs in adult human tissues revealed comparable expression levels to the full-length GLI1 (GLI1FL), whereas in tumor cell lines a generally lower and more variable expression pattern was observed. Furthermore, GLI1 Delta N is up-regulated by HH signaling to the same extent as GLI1FL but has a weaker capacity to activate transcription. However, in specific cellular contexts GLI1 Delta N may be more potent than GLI1FL in activating endogenous gene expression. Moreover, the dual-specificity tyrosine phosphorylation-regulated kinase 1 ( Dyrk1) potentiates the transcriptional activity of GLI1FL but not GLI1 Delta N. Interestingly, GLI1FL, in contrast to GLI1 Delta N, is localized solely at the nucleus, in line with its increased transcriptional capacity. The negative regulator of the pathway, Suppressor of Fused ( SUFU), elicits a cytoplasmic retention of the GLI1 isoforms, which is more pronounced for GLI1FL, as this contains an N-terminal SUFU binding domain. Collectively, our findings reveal that the activation mechanism of the terminal transducer of the pathway, GLI1, is mediated not only by GLI1FL but also by the GLI1 Delta N variant.	[Shimokawa, Takashi; Tostar, Ulrica; Lauth, Matthias; Palaniswamy, Ramesh; Kasper, Maria; Toftgard, Rune; Zaphiropoulos, Peter G.] Karolinska Inst, Dept Biosci & Nutr, SE-14157 Huddinge, Sweden	Karolinska Institutet	Shimokawa, T (corresponding author), Karolinska Inst, Dept Biosci & Nutr, SE-14157 Huddinge, Sweden.	tash@biosci.ki.se	Shimokawa, Takashi/AAA-5870-2020; Kasper, Maria/Q-6318-2016	Shimokawa, Takashi/0000-0001-6549-9277; Palaniswamy, Ramesh/0000-0003-4322-2407; Kasper, Maria/0000-0002-6117-2717; Lauth, Matthias/0000-0001-5922-5384; Zaphiropoulos, Peter/0000-0003-4298-3861				Agren M, 2004, GENE, V330, P101, DOI 10.1016/j.gene.2004.01.010; Auboeuf D, 2007, TRENDS ENDOCRIN MET, V18, P122, DOI 10.1016/j.tem.2007.02.003; Berman DM, 2003, NATURE, V425, P846, DOI 10.1038/nature01972; Blencowe BJ, 2006, CELL, V126, P37, DOI 10.1016/j.cell.2006.06.023; Chen JK, 2002, P NATL ACAD SCI USA, V99, P14071, DOI 10.1073/pnas.182542899; Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033; Del Prete MJ, 2007, RNA, V13, P414, DOI 10.1261/rna.79407; Dunaeva M, 2003, J BIOL CHEM, V278, P5116, DOI 10.1074/jbc.M209492200; Eichberger T, 2006, GENOMICS, V87, P616, DOI 10.1016/j.ygeno.2005.12.003; Frank-Kamenetsky Maria, 2002, J Biol, V1, P10, DOI 10.1186/1475-4924-1-10; Hahn H, 1996, CELL, V85, P841, DOI 10.1016/S0092-8674(00)81268-4; Hallikas O, 2006, CELL, V124, P47, DOI 10.1016/j.cell.2005.10.042; He J, 2006, J BIOL CHEM, V281, P35598, DOI 10.1074/jbc.C600200200; Hoppler S, 2007, J CELL SCI, V120, P385, DOI 10.1242/jcs.03363; Ingham PW, 2006, NAT REV GENET, V7, P841, DOI 10.1038/nrg1969; Johnson JM, 2003, SCIENCE, V302, P2141, DOI 10.1126/science.1090100; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kasper M, 2006, EUR J CANCER, V42, P437, DOI 10.1016/j.ejca.2005.08.039; Kasper M, 2006, MOL CELL BIOL, V26, P6283, DOI 10.1128/MCB.02317-05; KINZLER KW, 1988, NATURE, V332, P371, DOI 10.1038/332371a0; Kogerman P, 1999, NAT CELL BIOL, V1, P312, DOI 10.1038/13031; Kogerman P, 2002, ONCOGENE, V21, P6007, DOI 10.1038/sj.onc.1205865; Lauth M, 2007, P NATL ACAD SCI USA, V104, P8455, DOI 10.1073/pnas.0609699104; Mao JH, 2002, J BIOL CHEM, V277, P35156, DOI 10.1074/jbc.M206743200; Merchant M, 2004, MOL CELL BIOL, V24, P8627, DOI 10.1128/MCB.24.19.8627-8641.2004; Nagao K, 2005, GENOMICS, V85, P462, DOI 10.1016/j.ygeno.2004.11.014; Nilsson M, 2000, P NATL ACAD SCI USA, V97, P3438, DOI 10.1073/pnas.050467397; Nybakken K, 2005, NAT GENET, V37, P1323, DOI 10.1038/ng1682; Pajares MJ, 2007, LANCET ONCOL, V8, P349, DOI 10.1016/S1470-2045(07)70104-3; Rahnama F, 2006, BIOCHEM J, V394, P19, DOI 10.1042/BJ20050941; Rahnama F, 2004, BIOCHEM J, V378, P325, DOI 10.1042/BJ20031200; Regl G, 2002, ONCOGENE, V21, P5529, DOI 10.1038/sj.onc.1205748; Roessler E, 2005, HUM MOL GENET, V14, P2181, DOI 10.1093/hmg/ddi222; Ruiz i Altaba A, 2007, TRENDS CELL BIOL, V17, P438, DOI 10.1016/j.tcb.2007.06.007; Sanchez P, 2004, P NATL ACAD SCI USA, V101, P12561, DOI 10.1073/pnas.0404956101; Shimokawa T, 2007, ONCOGENE, V26, P4889, DOI 10.1038/sj.onc.1210301; Shimokawa T, 2004, FEBS LETT, V578, P157, DOI 10.1016/j.febslet.2004.11.006; Speek M, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-13; Uchikawa H, 2006, BIOCHEM BIOPH RES CO, V349, P277, DOI 10.1016/j.bbrc.2006.08.046; Wang GS, 2007, NAT REV GENET, V8, P749, DOI 10.1038/nrg2164; Wang XQ, 2001, J BIOL CHEM, V276, P1311, DOI 10.1074/jbc.M005191200; Wang Y, 2007, CURR OPIN CELL BIOL, V19, P159, DOI 10.1016/j.ceb.2007.02.005; Yuan Z, 2007, ONCOGENE, V26, P1046, DOI 10.1038/sj.onc.1209860	43	59	63	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14345	14354		10.1074/jbc.M800299200	http://dx.doi.org/10.1074/jbc.M800299200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18378682	Green Published, hybrid			2022-12-25	WOS:000255941400021
J	Jones-Carson, J; Laughlin, J; Hamad, MA; Stewart, AL; Voskuil, MI; Vazquez-Torres, A				Jones-Carson, Jessica; Laughlin, James; Hamad, Mohammed A.; Stewart, Amanda L.; Voskuil, Martin I.; Vazquez-Torres, Andres			Inactivation of [Fe-S] Metalloproteins Mediates Nitric Oxide-Dependent Killing of Burkholderia mallei	PLOS ONE			English	Article								Background: Much remains to be known about the mechanisms by which O-2-dependent host defenses mediate broad antimicrobial activity. Methodology/Principal Findings: We show herein that reactive nitrogen species (RNS) generated by inducible nitric oxide (NO) synthase (iNOS) account for the anti-Burkholderia mallei activity of IFN gamma-primed macrophages. Inducible NOS-mediated intracellular killing may represent direct bactericidal activity, because B. mallei showed an exquisite sensitivity to NO generated chemically. Exposure of B. mallei to sublethal concentrations of NO upregulated transcription of [Fe-S] cluster repair genes, while damaging the enzymatic activity of the [Fe-S] protein aconitase. To test whether [Fe-S] clusters are critical targets for RNS-dependent killing of B. mallei, a mutation was constructed in the NO-induced, [Fe-S] cluster repair regulator iscR. Not only was the iscR mutant hypersusceptible to iNOS-mediated killing, but its aconitase pool was readily oxidized by NO donors as compared to wild-type controls. Although killed by authentic H2O2, which also oxidizes [Fe-S] clusters, B. mallei appear to be resilient to NADPH oxidase-mediated cytotoxicity. The poor respiratory burst elicited by this bacterium likely explains why the NADPH oxidase is nonessential to the killing of B. mallei while it is still confined within phagosomes. Conclusions/Significance: Collectively, these findings have revealed a disparate role for NADPH oxidase and iNOS in the innate macrophage response against the strict aerobe B. mallei. To the best of our knowledge, this is the first instance in which disruption of [Fe-S] clusters is demonstrated as cause of the bactericidal activity of NO congeners.	[Jones-Carson, Jessica; Laughlin, James; Hamad, Mohammed A.; Stewart, Amanda L.; Voskuil, Martin I.; Vazquez-Torres, Andres] Univ Colorado, Dept Microbiol, Hlth Sci Ctr, Aurora, CO 80045 USA; [Jones-Carson, Jessica] Univ Colorado, Hlth Sci Ctr, Dept Med, Aurora, CO USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado System; University of Colorado Anschutz Medical Campus	Vazquez-Torres, A (corresponding author), Univ Colorado, Dept Microbiol, Hlth Sci Ctr, Aurora, CO 80045 USA.	andres.vazquez-torres@uchsc.edu	Hamad, Mohammed/HCH-0914-2022		Rocky Mountain Regional Center of Excellence	Rocky Mountain Regional Center of Excellence(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Support of this work was provided by the Rocky Mountain Regional Center of Excellence	Babior BM, 2004, CURR OPIN IMMUNOL, V16, P42, DOI 10.1016/j.coi.2003.12.001; Bergman MA, 2005, INFECT IMMUN, V73, P7226, DOI 10.1128/IAI.73.11.7226-7235.2005; Breitbach K, 2006, INFECT IMMUN, V74, P6300, DOI 10.1128/IAI.00966-06; Brett PJ, 2007, MOL MICROBIOL, V63, P379, DOI 10.1111/j.1365-2958.2006.05519.x; BRETT PJ, 2007, CELL MICROBIOL; BRUNELLI L, 1995, ARCH BIOCHEM BIOPHYS, V316, P327, DOI 10.1006/abbi.1995.1044; CASTRO L, 1994, J BIOL CHEM, V269, P29409; CRAIG FF, 1989, J GEN MICROBIOL, V135, P2885; DEGROOTE MA, 1995, P NATL ACAD SCI USA, V92, P6399, DOI 10.1073/pnas.92.14.6399; DeGroote MA, 1997, P NATL ACAD SCI USA, V94, P13997, DOI 10.1073/pnas.94.25.13997; DENIS M, 1991, CELL IMMUNOL, V132, P150, DOI 10.1016/0008-8749(91)90014-3; DRAPIER JC, 1986, J CLIN INVEST, V78, P790, DOI 10.1172/JCI112642; Fang FC, 2004, NAT REV MICROBIOL, V2, P820, DOI 10.1038/nrmicro1004; FIGURSKI DH, 1979, P NATL ACAD SCI USA, V76, P1648, DOI 10.1073/pnas.76.4.1648; Gardner PR, 1997, J BIOL CHEM, V272, P25071, DOI 10.1074/jbc.272.40.25071; Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038; HAUSLADEN A, 1994, J BIOL CHEM, V269, P29405; Johnston RB, 2001, CURR OPIN HEMATOL, V8, P17, DOI 10.1097/00062752-200101000-00004; Jones AL, 1996, INFECT IMMUN, V64, P782, DOI 10.1128/IAI.64.3.782-790.1996; LaCourse R, 2002, INFECT IMMUN, V70, P7179, DOI 10.1128/IAI.70.12.7179-7181.2002; Lehavi O, 2002, HAREFUAH, V141, P88; Lopez J, 2003, MICROBES INFECT, V5, P1125, DOI 10.1016/j.micinf.2003.07.004; Lopez-Jaramillo P, 1998, LANCET, V351, P1176, DOI 10.1016/S0140-6736(05)79119-4; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MacMicking JD, 2003, SCIENCE, V302, P654, DOI 10.1126/science.1088063; McCollister BD, 2005, J EXP MED, V202, P625, DOI 10.1084/jem.20050246; Miyagi K, 1997, INFECT IMMUN, V65, P4108, DOI 10.1128/IAI.65.10.4108-4113.1997; Molofsky AB, 2006, J EXP MED, V203, P1093, DOI 10.1084/jem.20051659; Nathan C, 2000, P NATL ACAD SCI USA, V97, P8841, DOI 10.1073/pnas.97.16.8841; Pick E, 1986, Methods Enzymol, V132, P407; POLLOCK JD, 1995, NAT GENET, V9, P202, DOI 10.1038/ng0295-202; Reeves EP, 2002, NATURE, V416, P291, DOI 10.1038/416291a; Ribot WJ, 2006, INFECT IMMUN, V74, P4349, DOI 10.1128/IAI.01939-05; Rowland CA, 2006, INFECT IMMUN, V74, P5333, DOI 10.1128/IAI.02046-05; Schell MA, 2007, MOL MICROBIOL, V64, P1466, DOI 10.1111/j.1365-2958.2007.05734.x; Segal BH, 2003, INFECT IMMUN, V71, P205, DOI 10.1128/IAI.71.1.205-210.2003; Shiloh MU, 1999, IMMUNITY, V10, P29, DOI 10.1016/S1074-7613(00)80004-7; Stevens JM, 2005, J BACTERIOL, V187, P7857, DOI 10.1128/JB.187.22.7857-7862.2005; Stevens MP, 2002, MOL MICROBIOL, V46, P649, DOI 10.1046/j.1365-2958.2002.03190.x; STUEHR DJ, 1985, P NATL ACAD SCI USA, V82, P7738, DOI 10.1073/pnas.82.22.7738; Swanson MS, 2005, AUTOPHAGY, V1, P174, DOI 10.4161/auto.1.3.2067; Tortora V, 2007, FREE RADICAL BIO MED, V42, P1075, DOI 10.1016/j.freeradbiomed.2007.01.007; Utaisincharoen P, 2004, CLIN EXP IMMUNOL, V136, P277, DOI 10.1111/j.1365-2249.2004.02445.x; Utaisincharoen P, 2001, MICROBIOL IMMUNOL, V45, P307, DOI 10.1111/j.1348-0421.2001.tb02623.x; Utaisincharoen P, 2000, CLIN EXP IMMUNOL, V122, P324, DOI 10.1046/j.1365-2249.2000.01386.x; VazquezTorres A, 1996, INFECT IMMUN, V64, P3127, DOI 10.1128/IAI.64.8.3127-3133.1996; VAZQUEZTORRES A, 1995, INFECT IMMUN, V63, P1142, DOI 10.1128/IAI.63.3.1142-1144.1995; VAZQUEZTORRES A, 1999, NITRIC OXIDE INFECT, P475; Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205; YABUUCHI E, 1992, MICROBIOL IMMUNOL, V36, P1251, DOI 10.1111/j.1348-0421.1992.tb02129.x; Zamboni DS, 2006, NAT IMMUNOL, V7, P318, DOI 10.1038/ni1305	51	37	38	1	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1976	10.1371/journal.pone.0001976	http://dx.doi.org/10.1371/journal.pone.0001976			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398486	Green Submitted, Green Published, gold			2022-12-25	WOS:000260795500039
J	Wang, FP; Wang, JB; Jian, HH; Zhang, B; Li, SK; Wang, F; Zeng, XW; Gao, L; Bartlett, DH; Yu, J; Hu, SN; Xiao, X				Wang, Fengping; Wang, Jianbin; Jian, Huahua; Zhang, Bing; Li, Shengkang; Wang, Feng; Zeng, Xiaowei; Gao, Lei; Bartlett, Douglas Hoyt; Yu, Jun; Hu, Songnian; Xiao, Xiang			Environmental Adaptation: Genomic Analysis of the Piezotolerant and Psychrotolerant Deep-Sea Iron Reducing Bacterium Shewanella piezotolerans WP3	PLOS ONE			English	Article								Shewanella species are widespread in various environments. Here, the genome sequence of Shewanella piezotolerans WP3, a piezotolerant and psychrotolerant iron reducing bacterium from deep-sea sediment was determined with related functional analysis to study its environmental adaptation mechanisms. The genome of WP3 consists of 5,396,476 base pairs (bp) with 4,944 open reading frames (ORFs). It possesses numerous genes or gene clusters which help it to cope with extreme living conditions such as genes for two sets of flagellum systems, structural RNA modification, eicosapentaenoic acid (EPA) biosynthesis and osmolyte transport and synthesis. And WP3 contains 55 open reading frames encoding putative c-type cytochromes which are substantial to its wide environmental adaptation ability. The mtr-omc gene cluster involved in the insoluble metal reduction in the Shewanella genus was identified and compared. The two sets of flagellum systems were found to be differentially regulated under low temperature and high pressure; the lateral flagellum system was found essential for its motility and living at low temperature.	[Wang, Fengping; Jian, Huahua; Li, Shengkang; Wang, Feng; Xiao, Xiang] State Ocean Adm, Key Lab Marine Biogenet Resources, Xiamen, Peoples R China; [Wang, Fengping; Jian, Huahua; Li, Shengkang; Wang, Feng; Xiao, Xiang] State Oceanic Admin, Third Inst Oceanography, Xiamen, Peoples R China; [Wang, Jianbin; Zhang, Bing; Yu, Jun; Hu, Songnian] Chinese Acad Sci, Beijing Inst Genom, Beijing, Peoples R China; [Wang, Jianbin; Zhang, Bing; Zeng, Xiaowei; Yu, Jun; Hu, Songnian] Zhejiang Univ, James D Watson Inst Genome Sci, Hangzhou, Peoples R China; [Gao, Lei] Fudan Univ, T Life Res Ctr, Shanghai, Peoples R China; [Bartlett, Douglas Hoyt] Univ Calif San Diego, Scripps Inst Oceanography, Ctr Marine Biotechnol & Biomed, Marine Biol Res Div, La Jolla, CA USA	State Oceanic Administration; State Oceanic Administration; Chinese Academy of Sciences; Beijing Institute of Genomics, CAS; Zhejiang University; Fudan University; University of California System; University of California San Diego; Scripps Institution of Oceanography	Wang, FP (corresponding author), State Ocean Adm, Key Lab Marine Biogenet Resources, Xiamen, Peoples R China.	husn@genomics.org.cn; xxwfp@public.xm.fj.cn	xiao, xiang/GWU-6035-2022; Jian, Huahua/E-6732-2016; Wang, Feng/O-8202-2016; 郑, 征/C-8514-2011; Gao, Lei/I-4159-2013; Wang, Jianbin/B-8973-2016; Hu, Songnian/C-6509-2013	Gao, Lei/0000-0002-6488-0292; Wang, Jianbin/0000-0003-3155-894X; Hu, Songnian/0000-0003-3966-3111; Jian, Huahua/0000-0001-5507-497X	China COMRA foundation [DYLY0202-03]; NSFC fund [40625016, 40776095]	China COMRA foundation; NSFC fund(National Natural Science Foundation of China (NSFC))	This work was financially supported by China COMRA foundation DYLY0202-03, NSFC fund (40625016, 40776095).	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Bao QY, 2002, GENOME RES, V12, P689, DOI 10.1101/gr.219302; Bartlett DH, 2002, BBA-PROTEIN STRUCT M, V1595, P367, DOI 10.1016/S0167-4838(01)00357-0; Bartlett Douglas H., 1999, Journal of Molecular Microbiology and Biotechnology, V1, P93; BELAS R, 1986, J BACTERIOL, V167, P210, DOI 10.1128/jb.167.1.210-218.1986; Benson DA, 2006, NUCLEIC ACIDS RES, V34, pD16, DOI 10.1093/nar/gkj157; Charette M, 2000, IUBMB LIFE, V49, P341; Chiu CH, 2005, NUCLEIC ACIDS RES, V33, P1690, DOI 10.1093/nar/gki297; Delcher AL, 1999, NUCLEIC ACIDS RES, V27, P4636, DOI 10.1093/nar/27.23.4636; DIANNE KN, 2002, SCIENCE, V296, P1071; Eisen JA, 2000, GENOME BIOL, V1; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Gao HC, 2006, INT J SYST EVOL MICR, V56, P1911, DOI 10.1099/ijs.0.64354-0; Gao HC, 2004, J BACTERIOL, V186, P7796, DOI 10.1128/JB.186.22.7796-7803.2004; Glockner FO, 2003, P NATL ACAD SCI USA, V100, P8298, DOI 10.1073/pnas.1431443100; Gordon D, 1998, GENOME RES, V8, P195, DOI 10.1101/gr.8.3.195; Gutgsell NS, 2005, RNA, V11, P1141, DOI 10.1261/rna.2550105; Heidelberg JF, 2002, NAT BIOTECHNOL, V20, P1118, DOI 10.1038/nbt749; Hou SB, 2004, P NATL ACAD SCI USA, V101, P18036, DOI 10.1073/pnas.0407638102; Kanehisa M, 2004, NUCLEIC ACIDS RES, V32, pD277, DOI 10.1093/nar/gkh063; Kato C, 1997, EXTREMOPHILES, V1, P111, DOI 10.1007/s007920050023; Kato C, 2001, FEMS MICROBIOL ECOL, V35, P223, DOI 10.1016/S0168-6496(00)00100-8; Kato Chiaki, 1999, Journal of Molecular Microbiology and Biotechnology, V1, P87; Khachane AN, 2005, NUCLEIC ACIDS RES, V33, P4016, DOI 10.1093/nar/gki714; Leaphart AB, 2006, J BACTERIOL, V188, P1633, DOI 10.1128/JB.188.4.1633-1642.2006; Li SK, 2006, EXTREMOPHILES, V10, P97, DOI 10.1007/s00792-005-0476-x; Lobry JR, 1996, MOL BIOL EVOL, V13, P660, DOI 10.1093/oxfordjournals.molbev.a025626; Lowe TM, 1997, NUCLEIC ACIDS RES, V25, P955, DOI 10.1093/nar/25.5.955; MCCARTER L, 1988, CELL, V54, P345, DOI 10.1016/0092-8674(88)90197-3; Medigue C, 2005, GENOME RES, V15, P1325, DOI 10.1101/gr.4126905; Methe BA, 2005, P NATL ACAD SCI USA, V102, P10913, DOI 10.1073/pnas.0504766102; Metz JG, 2001, SCIENCE, V293, P290, DOI 10.1126/science.1059593; Meyer TE, 2004, OMICS, V8, P57, DOI 10.1089/153623104773547499; MYERS CR, 1988, SCIENCE, V240, P1319, DOI 10.1126/science.240.4857.1319; Ofengand J, 2001, COLD SPRING HARB SYM, V66, P147, DOI 10.1101/sqb.2001.66.147; Ofengand J, 2000, RIBOSOME: STRUCTURE, FUNCTION, ANTIBIOTICS, AND CELLULAR INTERACTIONS, P175; Qi J, 2004, J MOL EVOL, V58, P1, DOI 10.1007/s00239-003-2493-7; Roh Y, 2006, APPL ENVIRON MICROB, V72, P3236, DOI 10.1128/AEM.72.5.3236-3244.2006; Russel M, 1997, GENE, V192, P23, DOI 10.1016/S0378-1119(96)00801-3; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Saunders NFW, 2003, GENOME RES, V13, P1580, DOI 10.1101/gr.1180903; Tamegai H, 2005, EXTREMOPHILES, V9, P247, DOI 10.1007/s00792-005-0439-2; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Venkateswaran K, 1999, INT J SYST BACTERIOL, V49, P705, DOI 10.1099/00207713-49-2-705; Vezzi A, 2005, SCIENCE, V307, P1459, DOI 10.1126/science.1103341; Wang F, 2007, J BACTERIOL, V189, P7151, DOI 10.1128/JB.00569-07; Wang FP, 2004, EXTREMOPHILES, V8, P165, DOI 10.1007/s00792-003-0365-0; Xiao X, 2007, INT J SYST EVOL MICR, V57, P60, DOI 10.1099/ijs.0.64500-0; Xu MX, 2005, BIODIVERS CONSERV, V14, P3363, DOI 10.1007/s10531-004-0544-z	51	112	460	3	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1937	10.1371/journal.pone.0001937	http://dx.doi.org/10.1371/journal.pone.0001937			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398463	Green Submitted, Green Published, gold			2022-12-25	WOS:000260795500014
J	Greco, D; Somervuo, P; Di Lieto, A; Raitila, T; Nitsch, L; Castren, E; Auvinen, P				Greco, Dario; Somervuo, Panu; Di Lieto, Antonio; Raitila, Tuomas; Nitsch, Lucio; Castren, Eero; Auvinen, Petri			Physiology, Pathology and Relatedness of Human Tissues from Gene Expression Meta-Analysis	PLOS ONE			English	Article								Background: Development and maintenance of the identity of tissues is of central importance for multicellular organisms. Based on gene expression profiles, it is possible to divide genes in housekeeping genes and those whose expression is preferential in one or a few tissues and which provide specialized functions that have a strong effect on the physiology of the whole organism. Results: We have surveyed the gene expression in 78 normal human tissues integrating publicly available microarray gene expression data. A total amount of 1601 genes were identified as selectively expressed in one or more tissues. The tissue-selective genes covered a wide range of cellular and molecular functions, and could be linked to 361 human diseases with Mendelian inheritance. Based on the gene expression profiles, we were able to form a network of tissues reflecting their functional relatedness and, to certain extent, their development. Using co-citation driven gene network technique and promoter analysis, we predicted a transcriptional module where the co-operation of the transcription factors E2F and NF-kappaB can possibly regulate a number of genes involved in the neurogenesis that takes place in the adult hippocampus. Conclusions: Here we propose that integration of gene expression data from Affymetrix GeneChip experiments is possible through re-annotation and commonly used pre-processing methods. We suggest that some functional aspects of the tissues can be explained by the co-operation of multiple transcription factors that regulate the expression of selected groups of genes.	[Greco, Dario; Somervuo, Panu; Raitila, Tuomas; Auvinen, Petri] Univ Helsinki, Inst Biotechnol, Helsinki, Finland; [Di Lieto, Antonio; Castren, Eero] Univ Helsinki, Neurosci Ctr, Helsinki, Finland; [Nitsch, Lucio] Univ Federico 2, Dipartimento Biol Patol Cell Mol, Naples, Italy	University of Helsinki; University of Helsinki; University of Naples Federico II	Greco, D (corresponding author), Univ Helsinki, Inst Biotechnol, Helsinki, Finland.	dario.greco@helsinki.fi	Castrén, Eero/A-4618-2010; Auvinen, Petri/AAP-8117-2021; Greco, Dario/T-7113-2019; Auvinen, Petri/D-5044-2009	Greco, Dario/0000-0001-9195-9003; Auvinen, Petri/0000-0002-3947-4778; Castren, Eero/0000-0002-1402-2791	Institute of Biotechnology, University of Helsinki; Academy of Finland [117968]	Institute of Biotechnology, University of Helsinki; Academy of Finland(Academy of Finland)	This research was funded by the Institute of Biotechnology, University of Helsinki, and by the Academy of Finland (grant 117968).	Abbas A., 2017, CELLULAR MOL IMMUNOL, P281; Attwooll C, 2004, EMBO J, V23, P4709, DOI 10.1038/sj.emboj.7600481; Benson DW, 1999, J CLIN INVEST, V104, P1567, DOI 10.1172/JCI8154; Castillo-Davis CI, 2002, NAT GENET, V31, P415, DOI 10.1038/ng940; Dai MH, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni179; Denis-Donini S, 2005, DEV BRAIN RES, V154, P81, DOI 10.1016/j.devbrainres.2004.10.010; Duret L, 2000, MOL BIOL EVOL, V17, P68, DOI 10.1093/oxfordjournals.molbev.a026239; Eerola I, 2003, AM J HUM GENET, V73, P1240, DOI 10.1086/379793; Freilich S, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-7-r56; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Garg V, 2003, NATURE, V424, P443, DOI 10.1038/nature01827; Goldmuntz E, 2001, CIRCULATION, V104, P2565, DOI 10.1161/hc4601.098427; Gould E, 2007, NAT REV NEUROSCI, V8, P481, DOI 10.1038/nrn2147; Hirayama-Yamada K, 2005, AM J MED GENET A, V135A, P47, DOI 10.1002/ajmg.a.30684; Irizarry RA, 2003, BIOSTATISTICS, V4, P249, DOI 10.1093/biostatistics/4.2.249; Janeway CA, 2001, IMMUNOBIOLOGY; Krivan W, 2001, GENOME RES, V11, P1559, DOI 10.1101/gr.180601; Liang S, 2006, PHYSIOL GENOMICS, V26, P158, DOI 10.1152/physiolgenomics.00313.2005; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Liu DX, 2001, NEURON, V32, P425, DOI 10.1016/S0896-6273(01)00495-0; Meffert MK, 2005, TRENDS NEUROSCI, V28, P37, DOI 10.1016/j.tins.2004.11.002; Olson EN, 2006, SCIENCE, V313, P1922, DOI 10.1126/science.1132292; Sandberg R, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-48; Schott JJ, 1998, SCIENCE, V281, P108, DOI 10.1126/science.281.5373.108; Su AI, 2004, P NATL ACAD SCI USA, V101, P6062, DOI 10.1073/pnas.0400782101; Swanson LW, 1998, TRENDS NEUROSCI, V21, P323, DOI 10.1016/S0166-2236(98)01265-X; Swanson LW, 2003, ANN NY ACAD SCI, V985, P174; Timens W, 1997, MICROSC RES TECHNIQ, V39, P387, DOI 10.1002/(SICI)1097-0029(19971201)39:5<387::AID-JEMT1>3.0.CO;2-E; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Vinogradov AE, 2004, TRENDS GENET, V20, P248, DOI 10.1016/j.tig.2004.03.006; Vinogradov AE, 2003, NUCLEIC ACIDS RES, V31, P5212, DOI 10.1093/nar/gkg699; Wasserman WW, 1998, J MOL BIOL, V278, P167, DOI 10.1006/jmbi.1998.1700; Watanabe Y, 2002, J MED GENET, V39, P807, DOI 10.1136/jmg.39.11.807; Winter EE, 2004, GENOME RES, V14, P54, DOI 10.1101/gr.1924004; Yu XP, 2006, NUCLEIC ACIDS RES, V34, P4925, DOI 10.1093/nar/gkl595	35	21	21	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1880	10.1371/journal.pone.0001880	http://dx.doi.org/10.1371/journal.pone.0001880			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382664	Green Submitted, Green Published, gold			2022-12-25	WOS:000260795400015
J	Dudek, P; Picard, D				Dudek, Peter; Picard, Didier			Genomics of Signaling Crosstalk of Estrogen Receptor alpha in Breast Cancer Cells	PLOS ONE			English	Article							ACTIVATED PROTEIN-KINASE; CYCLIC ADENOSINE-MONOPHOSPHATE; GROWTH-FACTOR RECEPTOR; GENE-EXPRESSION; DEPENDENT TRANSCRIPTION; TAMOXIFEN RESISTANCE; MEDIATED TRANSCRIPTION; PROGESTERONE-RECEPTOR; COUPLED RECEPTOR; RESPONSE ELEMENT	Background: The estrogen receptor alpha (ER alpha) is a ligand-regulated transcription factor. However, a wide variety of other extracellular signals can activate ER alpha in the absence of estrogen. The impact of these alternate modes of activation on gene expression profiles has not been characterized. Methodology/Principal Findings: We show that estrogen, growth factors and cAMP elicit surprisingly distinct ER alpha-dependent transcriptional responses in human MCF7 breast cancer cells. In response to growth factors and cAMP, ER alpha primarily activates and represses genes, respectively. The combined treatments with the anti-estrogen tamoxifen and cAMP or growth factors regulate yet other sets of genes. In many cases, tamoxifen is perverted to an agonist, potentially mimicking what is happening in certain tamoxifen-resistant breast tumors and emphasizing the importance of the cellular signaling environment. Using a computational analysis, we predicted that a Hox protein might be involved in mediating such combinatorial effects, and then confirmed it experimentally. Although both tamoxifen and cAMP block the proliferation of MCF7 cells, their combined application stimulates it, and this can be blocked with a dominant-negative Hox mutant. Conclusions/Significance: The activating signal dictates both target gene selection and regulation by ER alpha, and this has consequences on global gene expression patterns that may be relevant to understanding the progression of ER alpha-dependent carcinomas.	[Dudek, Peter; Picard, Didier] Univ Geneva, Dept Biol Cell, Geneva, Switzerland	University of Geneva	Dudek, P (corresponding author), Univ Geneva, Dept Biol Cell, Geneva, Switzerland.	didier.picard@cellbio.unige.ch			Fondation Medic; Swiss National Science Foundation; Canton de Geneve	Fondation Medic; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Canton de Geneve	Funding for this project was provided by the Fondation Medic, the Swiss National Science Foundation, and the Canton de Geneve.	Ahn S, 1998, MOL CELL BIOL, V18, P967, DOI 10.1128/MCB.18.2.967; Al-Dhaheri MH, 2007, MOL ENDOCRINOL, V21, P439, DOI 10.1210/me.2006-0059; Ali S, 2002, NAT REV CANCER, V2, P101, DOI 10.1038/nrc721; Anzick SL, 1997, SCIENCE, V277, P965, DOI 10.1126/science.277.5328.965; ARONICA SM, 1993, MOL ENDOCRINOL, V7, P743, DOI 10.1210/me.7.6.743; BENZ CC, 1992, BREAST CANCER RES TR, V24, P85, DOI 10.1007/BF01961241; Bourdeau V, 2008, NUCLEIC ACIDS RES, V36, P76, DOI 10.1093/nar/gkm945; Bunone G, 1996, EMBO J, V15, P2174, DOI 10.1002/j.1460-2075.1996.tb00571.x; Cascio S, 2007, J BIOL CHEM, V282, P3498, DOI 10.1074/jbc.M606244200; Chadwick CC, 2005, P NATL ACAD SCI USA, V102, P2543, DOI 10.1073/pnas.0405841102; Chen DS, 1999, MOL CELL BIOL, V19, P1002; Chen HX, 2003, CANCER BIOL THER, V2, P524, DOI 10.4161/cbt.2.5.525; Creighton CJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r28; Cui Y, 2004, CANCER RES, V64, P9199, DOI 10.1158/0008-5472.CAN-04-2126; Cunliffe HE, 2003, CANCER RES, V63, P7158; Curtis SW, 1996, P NATL ACAD SCI USA, V93, P12626, DOI 10.1073/pnas.93.22.12626; de Mora JF, 2000, MOL CELL BIOL, V20, P5041, DOI 10.1128/MCB.20.14.5041-5047.2000; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; Donze O, 2001, EMBO J, V20, P3771, DOI 10.1093/emboj/20.14.3771; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; FONTANA JA, 1987, J NATL CANCER I, V78, P1107; Frasor J, 2004, CANCER RES, V64, P1522, DOI 10.1158/0008-5472.CAN-03-3326; Frasor J, 2003, ENDOCRINOLOGY, V144, P4562, DOI 10.1210/en.2003-0567; Frech K, 1997, J MOL BIOL, V270, P674, DOI 10.1006/jmbi.1997.1140; FUJIMOTO N, 1994, MOL ENDOCRINOL, V8, P296, DOI 10.1210/me.8.3.296; Gburcik Valentina, 2006, Nucl Recept Signal, V4, pe005; Gee JMW, 2001, INT J CANCER, V95, P247, DOI 10.1002/1097-0215(20010720)95:4<247::AID-IJC1042>3.0.CO;2-S; Hewitt SC, 2005, MOL ENDOCRINOL, V19, P657, DOI 10.1210/me.2004-0142; Hom YK, 1998, ENDOCRINOLOGY, V139, P913, DOI 10.1210/en.139.3.913; IGNARTROWBRIDGE DM, 1992, P NATL ACAD SCI USA, V89, P4658, DOI 10.1073/pnas.89.10.4658; IGNARTROWBRIDGE DM, 1993, MOL ENDOCRINOL, V7, P992, DOI 10.1210/me.7.8.992; Kalkhoven E, 1996, INT J CANCER, V65, P682, DOI 10.1002/(SICI)1097-0215(19960301)65:5<682::AID-IJC20>3.0.CO;2-8; Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188; KATZENELLENBOGEN BS, 1990, ENDOCRINOLOGY, V126, P891, DOI 10.1210/endo-126-2-891; Kininis M, 2007, MOL CELL BIOL, V27, P5090, DOI 10.1128/MCB.00083-07; Klotz DM, 2002, J BIOL CHEM, V277, P8531, DOI 10.1074/jbc.M109592200; Kurokawa H, 2000, CANCER RES, V60, P5887; Lavinsky RM, 1998, P NATL ACAD SCI USA, V95, P2920, DOI 10.1073/pnas.95.6.2920; Lazennec G, 2001, J STEROID BIOCHEM, V77, P193, DOI 10.1016/S0960-0760(01)00060-7; Lin CY, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-9-r66; Ma XJ, 2004, CANCER CELL, V5, P607, DOI 10.1016/j.ccr.2004.05.015; MA ZQ, 1994, MOL ENDOCRINOL, V8, P910, DOI 10.1210/me.8.7.910; Maggiolini M, 2004, J BIOL CHEM, V279, P27008, DOI 10.1074/jbc.M403588200; Michalides R, 2004, CANCER CELL, V5, P597, DOI 10.1016/j.ccr.2004.05.016; Miller WR, 1997, CLIN CANCER RES, V3, P2399; MILLER WR, 1990, BRIT J CANCER, V61, P263, DOI 10.1038/bjc.1990.48; Nettles KW, 2008, MOL ENDOCRINOL, V22, P263, DOI 10.1210/me.2007-0324; NEWTON CJ, 1994, J STEROID BIOCHEM, V48, P481, DOI 10.1016/0960-0760(94)90197-X; Nutt SL, 1998, EMBO J, V17, P2319, DOI 10.1093/emboj/17.8.2319; Osborne CK, 2003, J NATL CANCER I, V95, P353, DOI 10.1093/jnci/95.5.353; Picard D, 2003, PURE APPL CHEM, V75, P1743, DOI 10.1351/pac200375111743; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; Prossnitz ER, 2007, MOL CELL ENDOCRINOL, V265, P138, DOI 10.1016/j.mce.2006.12.010; Shim WS, 2000, ENDOCRINOLOGY, V141, P396, DOI 10.1210/en.141.1.396; Shou J, 2004, JNCI-J NATL CANCER I, V96, P926, DOI 10.1093/jnci/djh166; Siu YT, 2007, FEBS J, V274, P3224, DOI 10.1111/j.1742-4658.2007.05884.x; Sivaraman VS, 1997, J CLIN INVEST, V99, P1478, DOI 10.1172/JCI119309; VINTERMYR OK, 1995, ENDOCRINOLOGY, V136, P2513, DOI 10.1210/en.136.6.2513; Zwart W, 2007, EMBO J, V26, P3534, DOI 10.1038/sj.emboj.7601791	60	27	28	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1859	10.1371/journal.pone.0001859	http://dx.doi.org/10.1371/journal.pone.0001859			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365014	Green Published, gold			2022-12-25	WOS:000260762400020
J	Veerapathran, A; Joshi, R; Goswami, K; Dogra, S; Moodie, EEM; Reddy, MVR; Kalantri, S; Schwartzman, K; Behr, MA; Menzies, D; Pai, M				Veerapathran, Anandharaman; Joshi, Rajnish; Goswami, Kalyan; Dogra, Sandeep; Moodie, Erica E. M.; Reddy, M. V. R.; Kalantri, Shriprakash; Schwartzman, Kevin; Behr, Marcel A.; Menzies, Dick; Pai, Madhukar			T-Cell Assays for Tuberculosis Infection: Deriving Cut-Offs for Conversions Using Reproducibility Data	PLOS ONE			English	Article							INTERFERON-GAMMA ASSAY; HEALTH-CARE WORKERS; LATENT TUBERCULOSIS; SKIN-TEST; RESPONSES; TESTS; AGREEMENT; DIAGNOSIS; ELISPOT; INDIA	Background: Although interferon-gamma release assays (IGRA) are promising alternatives to the tuberculin skin test, interpretation of repeated testing results is hampered by lack of evidence on optimal cut-offs for conversions and reversions. A logical start is to determine the within-person variability of T-cell responses during serial testing. Methodology/Principal Findings: We performed a pilot study in India, to evaluate the short-term reproducibility of QuantiFERON-TB Gold In Tube assay (QFT) among 14 healthcare workers (HCWs) who underwent 4 serial QFT tests on day 0, 3, 9 and 12. QFT ELISA was repeated twice on the same sets of specimens. We assessed two types of reproducibility: 1) test-retest reproducibility (between-test variability), and 2) within-person reproducibility over time. Test-retest reproducibility: with dichotomous test results, extremely high concordance was noticed between two tests performed on the same sets of specimens: of the 56 samples, the test and re-test results agreed for all but 2 individuals (k = 0.94). Discordance was noted in subjects who had IFN-gamma values around the cut-off point, with both increases and decreases noted. With continuous IFN-gamma results, re-test results tended to produce higher estimates of IFN-gamma than the original test. Within-person reproducibility: when continuous IFN-gamma data were analyzed, the within-person reproducibility was moderate to high. While persons with negative QFT results generally stayed negative, positive results tended to vary over time. Our data showed that increases of more than 16% in the IFN-gamma levels are statistically improbable in the short-term. Conclusions: Conservatively assuming that long-term variability might be at least twice higher than short-term, we hypothesize that a QFT conversion requires two conditions to be met: 1) change from negative to positive result, and 2) at least 30% increase in the baseline IFN-gamma response. Larger studies are needed to confirm our preliminary findings, and determine the conversion thresholds for IGRAs.	[Veerapathran, Anandharaman; Joshi, Rajnish; Goswami, Kalyan; Reddy, M. V. R.; Kalantri, Shriprakash] Mahatma Gandhi Inst Med Sci, Dept Biochem, Sevagram, Maharashtra, India; [Veerapathran, Anandharaman; Joshi, Rajnish; Goswami, Kalyan; Reddy, M. V. R.; Kalantri, Shriprakash] Mahatma Gandhi Inst Med Sci, Dept Med, Sevagram, Maharashtra, India; [Joshi, Rajnish] Univ Calif, Sch Public Hlth, Div Epidemiol, Berkeley, CA USA; [Dogra, Sandeep] Acharya Shri Chander Coll Med Sci & Hosp, Jammu, India; [Moodie, Erica E. M.; Schwartzman, Kevin; Behr, Marcel A.; Menzies, Dick; Pai, Madhukar] McGill Univ, Dept Epidemiol, Biostat & Occupat Hlth, Montreal, PQ, Canada; [Schwartzman, Kevin; Menzies, Dick; Pai, Madhukar] McGill Univ, Montreal Chest Inst, Resp Epidemiol & Clin Res Unit, Montreal, PQ, Canada; [Behr, Marcel A.] McGill Univ Hlth Ctr, Div Infect Dis & Med Microbiol, Montreal, PQ, Canada	Mahatma Gandhi Institute of Medical Sciences, Sevagram; Mahatma Gandhi Institute of Medical Sciences, Sevagram; University of California System; University of California Berkeley; McGill University; McGill University; McGill University	Veerapathran, A (corresponding author), Mahatma Gandhi Inst Med Sci, Dept Biochem, Sevagram, Maharashtra, India.	madhukar.pai@mcgill.ca	Goswami, Kalyan/H-2825-2019; Dogra, Sandeep/AAS-6079-2021; Kalantri, Shriprakash/ABG-9318-2021; PAL, MRINAL/ABG-9676-2020; Pai, Madhukar/AAX-9901-2021	Kalantri, Shriprakash/0000-0002-1633-1029; PAL, MRINAL/0000-0002-1032-272X; Pai, Madhukar/0000-0003-3667-4536; Joshi, Rajnish/0000-0002-4702-0522	Canadian Institutes of Health Research (CIHR) [MOP-81362, New Investigator Award]; training fellowship Fogarty AIDS International Training Program [AITRP] [1-D43-TW00003-17]; Fonds de la Recherche en Sante du Quebec (FRSQ), Canada; FOGARTY INTERNATIONAL CENTER [D43TW000003] Funding Source: NIH RePORTER	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); training fellowship Fogarty AIDS International Training Program [AITRP]; Fonds de la Recherche en Sante du Quebec (FRSQ), Canada(Fonds de la Recherche en Sante du Quebec); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC))	This project was supported in part by a grant from the Canadian Institutes of Health Research (MOP-81362). MP is supported by a New Investigator Award from the Canadian Institutes of Health Research (CIHR). RJ is a recipient of a training fellowship from the Fogarty AIDS International Training Program [AITRP] (grant 1-D43-TW00003-17), USA. KS, MB and DM are recipients of career awards from the Fonds de la Recherche en Sante du Quebec (FRSQ), Canada. Cellestis Limited (Victoria, Australia) donated the QuantiFERON-TB Gold In Tube kits. This company did not provide funding for this study and was not involved in the preparation, review or submission of this manuscript.	*AM THOR SOC, 2000, AM J RESP CRIT CARE, V161, pS221, DOI DOI 10.1164/AJRCCM.161.SUPPLEMENT_; Andersen P, 2007, TRENDS MOL MED, V13, P175, DOI 10.1016/j.molmed.2007.03.004; Bland JM, 2007, J BIOPHARM STAT, V17, P571, DOI 10.1080/10543400701329422; BLAND JM, 1986, LANCET, V1, P307, DOI 10.1016/s0140-6736(86)90837-8; CORBETT EL, 2006, INT J TUBERC LUNG D, V10, pS231; DIGGLE PJ, 1988, BIOMETRICS, V44, P959, DOI 10.2307/2531727; Dogra S, 2007, J INFECTION, V54, P267, DOI 10.1016/j.jinf.2006.04.007; Ewer K, 2006, AM J RESP CRIT CARE, V174, P831, DOI 10.1164/rccm.200511-1783OC; Farhat M, 2006, INT J TUBERC LUNG D, V10, P1192; Hill PC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000183; Hill PC, 2007, PLOS MED, V4, P1061, DOI 10.1371/journal.pmed.0040192; LAIRD NM, 1982, BIOMETRICS, V38, P963, DOI 10.2307/2529876; Mazurek Gerald H., 2005, Morbidity and Mortality Weekly Report, V54, P49; Menzies D, 1999, AM J RESP CRIT CARE, V159, P15, DOI 10.1164/ajrccm.159.1.9801120; Menzies D, 2007, ANN INTERN MED, V146, P340, DOI 10.7326/0003-4819-146-5-200703060-00006; National Association of State Public Health Veterinarians Inc. (NASPHV), 2005, MMWR Recomm Rep, V54, P1; Pai M, 2005, JAMA-J AM MED ASSOC, V293, P2746, DOI 10.1001/jama.293.22.2746; Pai M, 2007, INFECTION, V35, P98, DOI 10.1007/s15010-007-6114-z; Pai M, 2007, LANCET INFECT DIS, V7, P428, DOI 10.1016/S1473-3099(07)70086-5; Pai M, 2007, PLOS MED, V4, P980, DOI 10.1371/journal.pmed.0040208; Pai M, 2006, J OCCUP MED TOXICOL, V1, DOI 10.1186/1745-6673-1-7; Pai M, 2006, EMERG INFECT DIS, V12, P1311, DOI 10.3201/eid1209.051663; Pai M, 2006, INT J TUBERC LUNG D, V10, P942; Pai M, 2006, AM J RESP CRIT CARE, V174, P349, DOI 10.1164/rccm.200604-472OC	24	86	87	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1850	10.1371/journal.pone.0001850	http://dx.doi.org/10.1371/journal.pone.0001850			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365006	Green Submitted, gold, Green Published			2022-12-25	WOS:000260762400012
J	Grubb, DR; Vasilevski, O; Huynh, H; Woodcock, EA				Grubb, David R.; Vasilevski, Oliver; Huynh, Huy; Woodcock, Elizabeth A.			The extreme C-terminal region of phospholipase C beta 1 determines subcellular localization and function; the "b" splice variant mediates alpha(1)-adrenergic receptor responses in cardiomyocytes	FASEB JOURNAL			English	Article						proline-rich domain; Gq; PLC; myristoylated peptides; signaling specificity	MYOCARDIAL HYPERTROPHY; CARDIAC-HYPERTROPHY; BETA ISOZYMES; G-PROTEINS; 2 FORMS; ACTIVATION; CELLS; RHO; G-ALPHA(Q); C-BETA(1)	Phospholipase C beta 1 (PLC beta 1) exists as two splice variants, PLC beta 1a (150 kDa) and PLC beta 1b (140 kDa), which differ only in their C-terminal sequences of 64 and 31 amino acids, respectively. The 3 C-terminal amino acid residues of PLC beta 1a comprise a PDZ-interacting domain, whereas the PLC beta 1b sequence has no PDZ- interacting domain but contains unique proline-rich domain 5 residues from the C terminus. PLC beta 1a is localized in the cytoplasm, whereas PLC beta 1b targets to the sarcolemma and is enriched in caveolae. Deletion of 3 amino acids from the C terminus of PLC beta 1b did not alter its sarcolemmal localization, but deletion of the entire unique 31 amino acid sequence caused cytosolic localization. A myristoylated 10 amino acid peptide from the C terminus of PLC beta 1b selectively dissociated N-terminally GFP-tagged PLC beta 1b from the sarcolemma and inhibited PLC responses to alpha 1-adrenergic agonists, with a half maximal effective concentration of 12 +/- 1.6 mu M (mean +/- SE, n = 3). A similar peptide from PLC beta 1a was without effect at concentrations below 100 mu M. Thus, the extreme C-terminal sequences of the PLC beta 1 splice variants determine localization and, thus, function. In cardiomyocytes, responses initiated by alpha(1)-adrenergic receptor activation involve only PLC beta 1b, and the selective targeting of this splice variant to the sarcolemma provides a potential therapeutic target to reduce hypertrophy, apoptosis, and arrhythmias.	[Grubb, David R.; Vasilevski, Oliver; Huynh, Huy; Woodcock, Elizabeth A.] Baker Heart Res Inst, Cellular Biochem Lab, Melbourne, Vic 8008, Australia	Baker Heart and Diabetes Institute	Woodcock, EA (corresponding author), Baker Heart Res Inst, Cellular Biochem Lab, POB 6792,St Kilda Rd Cent, Melbourne, Vic 8008, Australia.	liz.woodcock@baker.edu.au						Adams JW, 1998, P NATL ACAD SCI USA, V95, P10140, DOI 10.1073/pnas.95.17.10140; Akhter SA, 1998, SCIENCE, V280, P574, DOI 10.1126/science.280.5363.574; Arthur JF, 2001, J BIOL CHEM, V276, P37341, DOI 10.1074/jbc.M106572200; Bahk YY, 1998, BBA-LIPID LIPID MET, V1389, P76, DOI 10.1016/S0005-2760(97)00128-8; BAHK YY, 1994, J BIOL CHEM, V269, P8240; BRISTOL JA, 1994, TRENDS ENDOCRIN MET, V5, P402, DOI 10.1016/1043-2760(95)92522-K; Bush EW, 2006, J BIOL CHEM, V281, P33487, DOI 10.1074/jbc.M605536200; Cai Y, 2005, ONCOGENE, V24, P4293, DOI 10.1038/sj.onc.1208593; CannonCarlson S, 1997, ANAL BIOCHEM, V246, P146, DOI 10.1006/abio.1997.2002; Dorn GW, 1999, TRENDS CARDIOVAS MED, V9, P26, DOI 10.1016/S1050-1738(99)00004-3; Dowal L, 2006, J BIOL CHEM, V281, P23999, DOI 10.1074/jbc.M512330200; Exton JH, 1996, ANNU REV PHARMACOL, V36, P481, DOI 10.1146/annurev.pa.36.040196.002405; Faenza I, 2000, J BIOL CHEM, V275, P30520, DOI 10.1074/jbc.M004630200; Fiume R, 2005, J BIOL CHEM, V280, P24221, DOI 10.1074/jbc.M411833200; Gonzales ML, 2006, J CELL BIOCHEM, V97, P252, DOI 10.1002/jcb.20655; Illenberger D, 2003, J BIOL CHEM, V278, P3006, DOI 10.1074/jbc.M208282200; Jezyk MR, 2006, NAT STRUCT MOL BIOL, V13, P1135, DOI 10.1038/nsmb1175; Kay BK, 2000, FASEB J, V14, P231, DOI 10.1096/fasebj.14.2.231; Kelley GG, 2006, J BIOL CHEM, V281, P2639, DOI 10.1074/jbc.M507681200; Kim MJ, 1998, J BIOL CHEM, V273, P3618, DOI 10.1074/jbc.273.6.3618; Morris JB, 2006, J MOL CELL CARDIOL, V41, P17, DOI 10.1016/j.yjmcc.2006.03.011; Morris JB, 2004, J BIOL CHEM, V279, P8740, DOI 10.1074/jbc.M310012200; Onohara N, 2006, EMBO J, V25, P5305, DOI 10.1038/sj.emboj.7601417; Putney JW, 2007, BIOCHEM SOC SYMP, V74, P37, DOI 10.1042/BSS2007c04; Rebecchi MJ, 2000, PHYSIOL REV, V80, P1291, DOI 10.1152/physrev.2000.80.4.1291; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Sah VP, 1996, J BIOL CHEM, V271, P31185, DOI 10.1074/jbc.271.49.31185; Saunders CM, 2007, BIOCHEM SOC SYMP, V74, P23, DOI 10.1042/BSS2007c03; Schmidt M, 1996, N-S ARCH PHARMACOL, V354, P87, DOI 10.1007/BF00178707; Schnabel P, 2000, BIOCHEM BIOPH RES CO, V275, P1, DOI 10.1006/bbrc.2000.3255; Spassova MA, 2006, P NATL ACAD SCI USA, V103, P16586, DOI 10.1073/pnas.0606894103; Sudol M, 1996, TRENDS BIOCHEM SCI, V21, P161, DOI 10.1016/0968-0004(96)30018-2; Suh PG, 2001, BIOCHEM BIOPH RES CO, V288, P1, DOI 10.1006/bbrc.2001.5710; Sun LS, 2007, PLATELETS, V18, P217, DOI 10.1080/09537100601016133; Venkatakrishnan G, 1996, J BIOL CHEM, V271, P5066; Wettschureck N, 2001, NAT MED, V7, P1236, DOI 10.1038/nm1101-1236; Xu AM, 2001, MOL CELL BIOL, V21, P2981, DOI 10.1128/MCB.21.9.2981-2990.2001; Zhang W, 2006, J BIOL CHEM, V281, P5811, DOI 10.1074/jbc.M507871200	38	36	38	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2768	2774		10.1096/fj.07-102558	http://dx.doi.org/10.1096/fj.07-102558			7	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18390926				2022-12-25	WOS:000258089300017
J	Liu, P; Kao, TP; Huang, H				Liu, P.; Kao, T. P.; Huang, H.			CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factor	ONCOGENE			English	Article						FOXO1; CDK1; phosphorylation; cell cycle; apoptosis; prostate cancer	PROSTATE-CANCER CELLS; PROTEIN-KINASE-B; CYCLIN-DEPENDENT KINASES; FACTOR FKHR; TUMOR SUPPRESSION; PROTEASOMAL DEGRADATION; INCREASED EXPRESSION; NUCLEAR EXCLUSION; BCL-2 EXPRESSION; DOWN-REGULATION	The forkhead box O (FOXO) transcription factor FOXO1 functions as a tumor suppressor by regulating expression of genes involved in apoptosis, cell cycle arrest and oxidative detoxification. Here, we demonstrate that cyclin-dependent kinase 1 (CDK1) specifically phosphorylates FOXO1 at serine 249 (S249) in vitro and in vivo. Coimmunoprecipitation assays demonstrate that both endogenous CDK1 and ectopically expressed CDK1 form a protein complex with FOXO1 in prostate cancer (PCa) cells. In vitro protein binding assays reveal that CDK1 interacts directly with FOXO1. Accordingly, overexpression of CDK1 inhibits the transcriptional activity of FOXO1 in PCa cells through S249 phosphorylation on FOXO1. Consistent with the roles of FOXO3a and FOXO4 (two other members of the FOXO family) in cell cycle regulation, forced expression of FOXO1 causes a delay in the transition from G2 to M phase. This effect is blocked completely by overexpression of CDK1 and cyclin B1. Ectopic expression of constitutively active CDK1 also inhibits FOXO1-induced apoptosis in PCa cells. Moreover, we demonstrate that the inhibitory effect of FOXO1 on Ras oncogene-induced colony formation in fibroblasts is diminished by overexpression of CDK1. Given that CDK1 and cyclin B1 are often overexpressed in human cancers including PCa, our findings suggest that aberrant activation of CDK1 may contribute to tumorigenesis by promoting cell proliferation and survival via phosphorylation and inhibition of FOXO1.	[Liu, P.; Kao, T. P.; Huang, H.] Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; [Liu, P.; Kao, T. P.; Huang, H.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Huang, H (corresponding author), Univ Minnesota, Ctr Canc, MMC 806,420 Delaware St SE, Minneapolis, MN 55455 USA.	huang253@umn.edu						Aoki M, 2004, P NATL ACAD SCI USA, V101, P13613, DOI 10.1073/pnas.0405454101; Biggs WH, 1999, P NATL ACAD SCI USA, V96, P7421, DOI 10.1073/pnas.96.13.7421; Borkhardt A, 1997, ONCOGENE, V14, P195, DOI 10.1038/sj.onc.1200814; Brunet A, 2001, MOL CELL BIOL, V21, P952, DOI 10.1128/MCB.21.3.952-965.2001; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Chen SY, 2006, P NATL ACAD SCI USA, V103, P15969, DOI 10.1073/pnas.0604193103; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; Fernandez-Zapico ME, 2003, EMBO J, V22, P4748, DOI 10.1093/emboj/cdg470; Furukawa-Hibi Y, 2002, J BIOL CHEM, V277, P26729, DOI 10.1074/jbc.C200256200; GALILI N, 1993, NAT GENET, V5, P230, DOI 10.1038/ng1193-230; Gilley J, 2003, J CELL BIOL, V162, P613, DOI 10.1083/jcb.200303026; Goga A, 2007, NAT MED, V13, P820, DOI 10.1038/nm1606; Gray NS, 1998, SCIENCE, V281, P533, DOI 10.1126/science.281.5376.533; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; Greer EL, 2005, ONCOGENE, V24, P7410, DOI 10.1038/sj.onc.1209086; Hillion J, 1997, BLOOD, V90, P3714, DOI 10.1182/blood.V90.9.3714; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Huang H, 2005, P NATL ACAD SCI USA, V102, P1649, DOI 10.1073/pnas.0406789102; Huang H, 2001, J BIOL CHEM, V276, P38830, DOI 10.1074/jbc.M103632200; Huang HJ, 2007, J CELL SCI, V120, P2479, DOI 10.1242/jcs.001222; Huang HJ, 2006, SCIENCE, V314, P294, DOI 10.1126/science.1130512; Huang HJ, 2004, ONCOGENE, V23, P2161, DOI 10.1038/sj.onc.1207326; Huang HJ, 2004, J BIOL CHEM, V279, P13866, DOI 10.1074/jbc.M314143200; Kallakury BV, 1998, J CLIN ONCOL, V16, P1302, DOI 10.1200/JCO.1998.16.4.1302; Kallakury BVS, 1997, CANCER-AM CANCER SOC, V80, P753, DOI 10.1002/(SICI)1097-0142(19970815)80:4<753::AID-CNCR15>3.0.CO;2-S; Knockaert M, 2002, TRENDS PHARMACOL SCI, V23, P417, DOI 10.1016/S0165-6147(02)02071-0; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; Kops GJPL, 2002, MOL CELL BIOL, V22, P2025, DOI 10.1128/MCB.22.7.2025-2036.2002; Maddison LA, 2004, PROSTATE, V58, P335, DOI 10.1002/pros.10341; Mashal RD, 1996, CANCER RES, V56, P4159; Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; Medema RH, 2000, NATURE, V404, P782, DOI 10.1038/35008115; Modur V, 2002, J BIOL CHEM, V277, P47928, DOI 10.1074/jbc.M207509200; Nakamura N, 2000, MOL CELL BIOL, V20, P8969, DOI 10.1128/MCB.20.23.8969-8982.2000; Ozen M, 2005, CLIN CANCER RES, V11, P4701, DOI 10.1158/1078-0432.CCR-04-2551; Paik JH, 2007, CELL, V128, P309, DOI 10.1016/j.cell.2006.12.029; PARKER LL, 1992, SCIENCE, V257, P1955, DOI 10.1126/science.1384126; Pinkston JM, 2006, SCIENCE, V313, P971, DOI 10.1126/science.1121908; Pinkston-Gosse J, 2007, NAT GENET, V39, P1403, DOI 10.1038/ng.2007.1; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Ramaswamy S, 2002, CANCER CELL, V2, P81, DOI 10.1016/S1535-6108(02)00086-7; Rena G, 1999, J BIOL CHEM, V274, P17179, DOI 10.1074/jbc.274.24.17179; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; Santamaria D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046; Schmidt M, 2002, MOL CELL BIOL, V22, P7842, DOI 10.1128/MCB.22.22.7842-7852.2002; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Sherr CJ, 2004, GENE DEV, V18, P2699, DOI 10.1101/gad.1256504; Soria JC, 2000, CANCER RES, V60, P4000; Stahl M, 2002, J IMMUNOL, V168, P5024, DOI 10.4049/jimmunol.168.10.5024; Stanbrough M, 2006, CANCER RES, V66, P2815, DOI 10.1158/0008-5472.CAN-05-4000; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Tran H, 2002, SCIENCE, V296, P530, DOI 10.1126/science.1068712; Woods YL, 2001, BIOCHEM J, V355, P597, DOI 10.1042/bj3550597; Wu XL, 2006, HUM MUTAT, V27, P742, DOI 10.1002/humu.20321; Wu XY, 1998, P NATL ACAD SCI USA, V95, P15587, DOI 10.1073/pnas.95.26.15587	57	114	120	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4733	4744		10.1038/onc.2008.104	http://dx.doi.org/10.1038/onc.2008.104			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408765	Bronze			2022-12-25	WOS:000258236300011
J	Magnelli, P; Cipollo, JF; Ratner, DM; Cui, J; Kelleher, D; Gilmore, R; Costello, CE; Robbins, PW; Samuelson, J				Magnelli, Paula; Cipollo, John F.; Ratner, Daniel M.; Cui, Jike; Kelleher, Daniel; Gilmore, Reid; Costello, Catherine E.; Robbins, Phillips W.; Samuelson, John			Unique Asn-linked oligosaccharides of the human pathogen Entamoeba histolytica	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUALITY-CONTROL; N-GLYCANS; GOLGI; OLIGOSACCHARYLTRANSFERASE; PARASITE; PROTIST; BINDING; LECTIN	N-Glycans of Entamoeba histolytica, the protist that causes amebic dysentery and liver abscess, are of great interest for multiple reasons. E. histolytica makes an unusual truncated N-glycan precursor (Man(5)GlcNAc(2)), has few nucleotide sugar transporters, and has a surface that is capped by the lectin concanavalin A. Here, biochemical and mass spectrometric methods were used to examine N-glycan biosynthesis and the final N-glycans of E. histolytica with the following conclusions. Unprocessed Man(5)GlcNAc(2), which is the most abundant E. histolytica N-glycan, is aggregated into caps on the surface of E. histolytica by the N-glycan-specific, anti-retroviral lectin cyanovirin-N. Glc(1)Man(5)GlcNAc(2), which is made by a UDP-Glc: glycoprotein glucosyltransferase that is part of a conserved N-glycan-dependent endoplasmic reticulum quality control system for protein folding, is also present in mature N-glycans. A swainsonine-sensitive alpha-mannosidase trims some N-glycans to biantennary Man(3)GlcNAc(2). Complex N-glycans of E. histolytica are made by the addition of alpha 1,2-linked Gal to both arms of small oligomannose glycans, and Gal residues are capped by one or more Glc. In summary, E. histolytica N-glycans include unprocessed Man(5)GlcNAc(2), which is a target for cyanovirin-N, as well as unique, complex N-glycans containing Gal and Glc.	[Samuelson, John] Boston Univ, Med Ctr, Goldman Sch Dent Med, Dept Mol & Cell Biol, Boston, MA 02118 USA; [Cipollo, John F.; Costello, Catherine E.] Boston Univ, Med Ctr, Dept Biochem, Boston, MA 02118 USA; [Kelleher, Daniel; Gilmore, Reid] Univ Massachusetts, Sch Med, Dept Biochem & Mol Pharmacol, Worcester, MA 01605 USA	Boston University; Boston University; University of Massachusetts System; University of Massachusetts Worcester	Samuelson, J (corresponding author), Boston Univ, Med Ctr, Goldman Sch Dent Med, Dept Mol & Cell Biol, 715 Albany St,Evans 426, Boston, MA 02118 USA.	jsamuels@bu.edu		Samuelson, John/0000-0001-9533-3040; Costello, Catherine/0000-0003-1594-5122; Robbins, Phillips/0000-0002-5121-1524	NATIONAL CENTER FOR RESEARCH RESOURCES [S10RR015942, P41RR010888] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044070] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM031318, R01GM043768, R01GM031318] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR 10888, S10 RR 15942] Funding Source: Medline; NIAID NIH HHS [AI 44070] Funding Source: Medline; NIGMS NIH HHS [GM 43768, GM 31318] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams EW, 2004, CHEM BIOL, V11, P875, DOI 10.1016/j.chembiol.2004.04.010; ADLER P, 1995, J BIOL CHEM, V270, P5164, DOI 10.1074/jbc.270.10.5164; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ARHETS P, 1995, INFECT IMMUN, V63, P4358, DOI 10.1128/IAI.63.11.4358-4367.1995; Atrih A, 2005, J BIOL CHEM, V280, P865, DOI 10.1074/jbc.M411061200; Banerjee S, 2007, P NATL ACAD SCI USA, V104, P11676, DOI 10.1073/pnas.0704862104; Barboza M, 2005, FEBS J, V272, P3803, DOI 10.1111/j.1742-4658.2005.04787.x; Betenbaugh MJ, 2004, CURR OPIN STRUC BIOL, V14, P601, DOI 10.1016/j.sbi.2004.09.001; Bredeston LM, 2005, J BIOL CHEM, V280, P32168, DOI 10.1074/jbc.M507035200; CHAPPELL TG, 1994, MOL BIOL CELL, V5, P519, DOI 10.1091/mbc.5.5.519; CIUCANU I, 1984, CARBOHYD RES, V131, P209, DOI 10.1016/0008-6215(84)85242-8; Clark CG, 2002, CLIN MICROBIOL REV, V15, P329, DOI 10.1128/CMR.15.3.329-341.2002; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; DOMON B, 1998, BIOCHEMISTRY-US, V27, P1534; ELBEIN AD, 1991, FASEB J, V5, P3055, DOI 10.1096/fasebj.5.15.1743438; Funk VA, 1997, MOL BIOCHEM PARASIT, V84, P33, DOI 10.1016/S0166-6851(96)02780-6; Guha-Niyogi A, 2001, GLYCOBIOLOGY, V11, p45R, DOI 10.1093/glycob/11.4.45R; Haque R, 2003, NEW ENGL J MED, V348, P1565, DOI 10.1056/NEJMra022710; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Herscovics A, 1999, BBA-GEN SUBJECTS, V1473, P96, DOI 10.1016/S0304-4165(99)00171-3; Kelleher DJ, 2007, J CELL BIOL, V177, P29, DOI 10.1083/jcb.200611079; Kelleher DJ, 2006, GLYCOBIOLOGY, V16, p47R, DOI 10.1093/glycob/cwj066; KELLEHER DJ, 1992, CELL, V69, P55, DOI 10.1016/0092-8674(92)90118-V; Kelleher DJ, 2001, GLYCOBIOLOGY, V11, P321, DOI 10.1093/glycob/11.4.321; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kwong PD, 2002, NATURE, V420, P678, DOI 10.1038/nature01188; Loftus B, 2005, NATURE, V433, P865, DOI 10.1038/nature03291; Lowe JB, 2003, ANNU REV BIOCHEM, V72, P643, DOI 10.1146/annurev.biochem.72.121801.161809; LUBAS WA, 1987, J BIOL CHEM, V262, P3775; Moody-Haupt S, 2000, J MOL BIOL, V297, P409, DOI 10.1006/jmbi.2000.3577; Nielsen H, 1999, PROTEIN ENG, V12, P3, DOI 10.1093/protein/12.1.3; Petri WA, 2002, ANNU REV MICROBIOL, V56, P39, DOI 10.1146/annurev.micro.56.012302.160959; Samuelson J, 2005, P NATL ACAD SCI USA, V102, P1548, DOI 10.1073/pnas.0409460102; Scanlan CN, 2002, J VIROL, V76, P7306, DOI 10.1128/JVI.76.14.7306-7321.2002; Stanley SL, 2003, LANCET, V361, P1025, DOI 10.1016/S0140-6736(03)12830-9; Trombetta ES, 2003, ANNU REV CELL DEV BI, V19, P649, DOI 10.1146/annurev.cellbio.19.110701.153949; YAMASHITA K, 1980, J BIOL CHEM, V255, P5635	37	27	27	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18355	18364		10.1074/jbc.M800725200	http://dx.doi.org/10.1074/jbc.M800725200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18417475	Green Published, hybrid			2022-12-25	WOS:000256949200063
J	Myles, T; Leung, LLK				Myles, Timothy; Leung, Lawrence L. K.			Thrombin hydrolysis of human osteopontin is dependent on thrombin anion-binding exosites	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRUCTURAL REQUIREMENTS; CRYSTAL-STRUCTURE; CELL-MIGRATION; FACTOR-VIII; PROTEIN-C; FACTOR-V; PHOSPHORYLATION; INTEGRIN; IDENTIFICATION; ACTIVATION	The cytokine osteopontin (OPN) can be hydrolyzed by thrombin exposing a cryptic Phi(4)beta(1)/alpha(9)beta(1) integrin-binding motif (SVVYGLR), thereby acting as a potent cytokine for cells bearing these activated integrins. We show that purified milk OPN is a substrate for thrombin with a k(cat)/K-m value of 1.14 x 105 M(-1)s(-1). Thrombin cleavage of OPN was inhibited by unsulfated hirugen (IC50 = 1.2 +/- 0.2 mu M), unfractionated heparin (IC50 = 56.6 +/- 8.4 mu g/ml) and low molecular weight (5 kDa) heparin (IC50 = 31.0 +/- 7.9 mu g/ml), indicating the involvement of both anion-binding exosite I (ABE-I) and anion-binding exosite II (ABE-II). Using a thrombin mutant library, we mapped residues important for recognition and cleavage of OPN within ABE-I and ABE-II. Apeptide (OPN-(162-197)) was designed spanning the OPN thrombin cleavage site and a hirudin-like C-terminal tail domain. Thrombin cleaved OPN-(162-197) with a specificity constant of k(cat)/K-m = 1.64 x 10(4) M(-1)s(-1). Representative ABE-I mutants (K65A, H66A, R68A, Y71A, and R73A) showed greatly impaired cleavage, whereas the ABE-II mutants were unaffected, suggesting that ABE-I interacts principally with the hirudin-like OPN domain C-terminal and contiguous to the thrombin cleavage site. Debye-Huckel slopes for milk OPN (-4.1 +/- 1.0) and OPN-(162-197) (-2.4 +/- 0.2) suggest that electrostatic interactions play an important role in thrombin recognition and cleavage of OPN. Thus, OPN is a bona fide substrate for thrombin, and generation of thrombin- cleaved OPN with enhanced pro-inflammatory properties provides another molecular link between coagulation and inflammation.	[Myles, Timothy; Leung, Lawrence L. K.] Stanford Univ, Sch Med, Div Hematol, Stanford, CA 94305 USA; [Leung, Lawrence L. K.] Palo Alto Vet Affairs Hlth Care System, Palo Alto, CA 94304 USA	Stanford University	Myles, T (corresponding author), Maxygen Inc, 515 Galveston Dr, Redwood City, CA 94063 USA.	timothy.myles@maxygen.com			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL057530] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 057530] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adams TE, 2006, ARTERIOSCL THROM VAS, V26, P1738, DOI 10.1161/01.ATV.0000228844.65168.d1; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; Baerga-Ortiz A, 2000, J MOL BIOL, V296, P651, DOI 10.1006/jmbi.1999.3447; Barry ST, 2000, EXP CELL RES, V258, P342, DOI 10.1006/excr.2000.4941; Barry ST, 2000, BIOCHEM BIOPH RES CO, V267, P764, DOI 10.1006/bbrc.1999.2032; Bayless KJ, 2001, J BIOL CHEM, V276, P13483, DOI 10.1074/jbc.M011392200; Bayless KJ, 1997, PROTEIN EXPRES PURIF, V9, P309, DOI 10.1006/prep.1996.0699; BODE W, 1992, PROTEIN SCI, V1, P426; BRAUN PJ, 1988, BIOCHEMISTRY-US, V27, P6517, DOI 10.1021/bi00417a048; Carter WJ, 2004, J BIOL CHEM, V279, P26387, DOI 10.1074/jbc.M402364200; Chabas D, 2001, SCIENCE, V294, P1731, DOI 10.1126/science.1062960; Christensen B, 2005, BIOCHEM J, V390, P285, DOI 10.1042/BJ20050341; Denda S, 1998, MOL BIOL CELL, V9, P1425, DOI 10.1091/mbc.9.6.1425; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; DENNIS S, 1990, EUR J BIOCHEM, V188, P61, DOI 10.1111/j.1432-1033.1990.tb15371.x; Fortenberry YM, 2007, J THROMB HAEMOST, V5, P1486, DOI 10.1111/j.1538-7836.2007.02574.x; Fortenberry YM, 2004, J BIOL CHEM, V279, P43237, DOI 10.1074/jbc.M406716200; Gandhi PS, 2008, P NATL ACAD SCI USA, V105, P1832, DOI 10.1073/pnas.0710894105; Green PM, 2001, FEBS LETT, V503, P75, DOI 10.1016/S0014-5793(01)02690-4; Hall SW, 1999, J BIOL CHEM, V274, P25510, DOI 10.1074/jbc.274.36.25510; HIGGINS DL, 1983, J BIOL CHEM, V258, P9276; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; Ishijima M, 2001, J EXP MED, V193, P399, DOI 10.1084/jem.193.3.399; Jono S, 2000, J BIOL CHEM, V275, P20197, DOI 10.1074/jbc.M909174199; KARSHIKOV A, 1992, PROTEIN SCI, V1, P727, DOI 10.1002/pro.5560010605; Katayama Y, 1998, J CELL PHYSIOL, V176, P179, DOI 10.1002/(SICI)1097-4652(199807)176:1<179::AID-JCP19>3.3.CO;2-M; Kazanecki CC, 2007, J CELL BIOCHEM, V102, P912, DOI 10.1002/jcb.21558; Koh A, 2007, IMMUNOLOGY, V122, P466, DOI 10.1111/j.1365-2567.2007.02682.x; Lane DA, 2005, BLOOD, V106, P2605, DOI 10.1182/blood-2005-04-1710; LeBonniec BF, 1996, BIOCHEMISTRY-US, V35, P7114, DOI 10.1021/bi952701s; LIAW L, 1995, J CLIN INVEST, V95, P713, DOI 10.1172/JCI117718; Liaw L, 1998, J CLIN INVEST, V101, P1468; Mazzali M, 2002, QJM-INT J MED, V95, P3, DOI 10.1093/qjmed/95.1.3; MONKOVIC DD, 1990, BIOCHEMISTRY-US, V29, P1118, DOI 10.1021/bi00457a004; Myles T, 2002, BLOOD, V100, P2820, DOI 10.1182/blood-2002-03-0843; Myles T, 2001, BIOCHEMISTRY-US, V40, P4972, DOI 10.1021/bi0023549; Myles T, 2001, J BIOL CHEM, V276, P25143, DOI 10.1074/jbc.M011324200; Parry MAA, 1996, BIOCHEM J, V320, P335, DOI 10.1042/bj3200335; Philippou H, 2003, J BIOL CHEM, V278, P32020, DOI 10.1074/jbc.M305364200; RYDEL TJ, 1991, J MOL BIOL, V221, P583, DOI 10.1016/0022-2836(91)80074-5; Senger DR, 1996, BBA-MOL CELL RES, V1314, P13, DOI 10.1016/S0167-4889(96)00067-5; SENGER DR, 1994, MOL BIOL CELL, V5, P565, DOI 10.1091/mbc.5.5.565; Smith LL, 1998, EXP CELL RES, V242, P351, DOI 10.1006/excr.1998.4108; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; Tsiang M, 1997, J BIOL CHEM, V272, P12024, DOI 10.1074/jbc.272.18.12024; Tsiang M, 1996, BIOCHEMISTRY-US, V35, P16449, DOI 10.1021/bi9616108; Vindigni A, 1996, BIOCHEMISTRY-US, V35, P4417, DOI 10.1021/bi952834d; Wade RC, 1998, P NATL ACAD SCI USA, V95, P5942, DOI 10.1073/pnas.95.11.5942; Wai PY, 2004, J SURG RES, V121, P228, DOI 10.1016/j.jss.2004.03.028; Weber GF, 2002, J LEUKOCYTE BIOL, V72, P752; Weber GF, 1996, SCIENCE, V271, P509, DOI 10.1126/science.271.5248.509; WELLS CM, 1992, BIOCHEMISTRY-US, V31, P11721, DOI 10.1021/bi00162a008; Yokosaki Y, 1999, J BIOL CHEM, V274, P36328, DOI 10.1074/jbc.274.51.36328; Yun TH, 2003, J BIOL CHEM, V278, P48112, DOI 10.1074/jbc.M306925200	55	22	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17789	17796		10.1074/jbc.M708629200	http://dx.doi.org/10.1074/jbc.M708629200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18413297	hybrid, Green Published			2022-12-25	WOS:000256949200006
J	Le, HY; Zhang, Y; Liu, H; Ma, LH; Jin, Y; Huang, QH; Chen, Y; Deng, M; Chen, Z; Chen, SJ; Liu, TX				Le, Huang-Ying; Zhang, Yong; Liu, Han; Ma, Li-Heng; Jin, Yi; Huang, Qiu-Hua; Chen, Yi; Deng, Min; Chen, Zhu; Chen, Sai-Juan; Liu, Ting Xi			eena promotes myeloid proliferation through stimulating ERK1/2 phosphorylation in zebrafish	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; RECEPTOR ENDOCYTOSIS; BINDING PARTNERS; GENE-EXPRESSION; MLL; DYNAMIN; FAMILY; SYNAPTOJANIN; ENDOPHILIN; ENCODES	The EEN (extra eleven nineteen) gene is one of the fusion partners of mixed-lineage leukemia, located on chromosome 19p13. Here we cloned two een genes (designated as eena and eenb) in zebrafish, which are assigned to linkage groups 8 and 2, respectively. Whole-mount in situ hybridization assay showed that eena and eenb have overlapping but distinct expression patterns during embryogenesis. Ubiquitous or targeted overexpression of eena, but not eenb, into wild-type or transgenic embryos (green fluorescent protein-labeled myeloid progenitors) induced a significant proliferation and ectopic distribution of myeloid progenitors in the yolk sac. Using a morpholino antisense gene knockdown approach, we showed that the number of myeloid progenitors and their downstream mature myelomonocytic cells was significantly decreased in the eena-deficient embryos. Mechanistically, overexpression of eena selectively stimulated ERK phosphorylation and increased the level of transcription factor c-Fos in vitro and in vivo, whereas eena lacking the Src homology 3 domain completely abolished these effects. Furthermore, a MAPK/ERK kinase (MEK) inhibitor, PD98059, blocked the eena-induced cell proliferation and activation of ERK signaling. The results suggest that eena plays an important role in the development of the myeloid cell through activation of the ERK pathway and may provide a valuable reference for future studies of the role of EEN in leukemogenesis.	[Le, Huang-Ying; Zhang, Yong; Liu, Han; Ma, Li-Heng; Jin, Yi; Huang, Qiu-Hua; Chen, Yi; Deng, Min; Chen, Zhu; Chen, Sai-Juan; Liu, Ting Xi] Chinese Acad Sci, Shanghai Inst Biol Sci, Lab Dev & Dis, Shanghai 200025, Peoples R China; [Le, Huang-Ying; Zhang, Yong; Liu, Han; Ma, Li-Heng; Jin, Yi; Huang, Qiu-Hua; Chen, Yi; Deng, Min; Chen, Zhu; Chen, Sai-Juan; Liu, Ting Xi] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, State Key Lab Med Genom, Shanghai 200025, Peoples R China; [Le, Huang-Ying; Zhang, Yong; Liu, Han; Ma, Li-Heng; Jin, Yi; Huang, Qiu-Hua; Chen, Yi; Deng, Min; Chen, Zhu; Chen, Sai-Juan; Liu, Ting Xi] Shanghai Jiao Tong Univ, Sch Med, RuiJin Hosp, Shanghai Inst Hematol, Shanghai 200025, Peoples R China; [Chen, Zhu; Chen, Sai-Juan] Shanghai Jiao Tong Univ, Sch Med, Shanghai Ctr Syst Biomed, Shanghai 200240, Peoples R China; [Liu, Ting Xi] Shanghai Jiao Tong Univ, Sch Med, E Inst Shanghai Univ, Model Organism Div, Shanghai 200240, Peoples R China	Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai Jiao Tong University	Chen, SJ (corresponding author), RuiJin Hosp, State Key Lab Med Genom, 197 RuiJin Rd 2, Shanghai 200025, Peoples R China.	sjchen@stn.sh.cn	Chen, Yi-Chen/GVU-0551-2022					Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Ayton PM, 2001, ONCOGENE, V20, P5695, DOI 10.1038/sj.onc.1204639; Bennett CM, 2001, BLOOD, V98, P643, DOI 10.1182/blood.V98.3.643; Chen Y, 2003, CELL, V115, P37, DOI 10.1016/S0092-8674(03)00726-8; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; Corral J, 1996, CELL, V85, P853, DOI 10.1016/S0092-8674(00)81269-6; Daaka Y, 1998, J BIOL CHEM, V273, P685, DOI 10.1074/jbc.273.2.685; Daser A, 2005, SEMIN CANCER BIOL, V15, P175, DOI 10.1016/j.semcancer.2005.01.007; Davidson AJ, 2004, ONCOGENE, V23, P7233, DOI 10.1038/sj.onc.1207943; de Jong JLO, 2005, ANNU REV GENET, V39, P481, DOI 10.1146/annurev.genet.39.073003.095931; Della Rocca GJ, 1999, J BIOL CHEM, V274, P4749, DOI 10.1074/jbc.274.8.4749; DETRICH HW, 1995, P NATL ACAD SCI USA, V92, P10713, DOI 10.1073/pnas.92.23.10713; Garrington TP, 1999, CURR OPIN CELL BIOL, V11, P211, DOI 10.1016/S0955-0674(99)80028-3; Giachino C, 1997, GENOMICS, V41, P427, DOI 10.1006/geno.1997.4645; Gong HY, 2004, GENE, V338, P35, DOI 10.1016/j.gene.2004.05.003; Gupta S, 2006, DEVELOPMENT, V133, P2177, DOI 10.1242/dev.02386; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; Hirsh AE, 2001, NATURE, V411, P1046, DOI 10.1038/35082561; Hsu K, 2004, BLOOD, V104, P1291, DOI 10.1182/blood-2003-09-3105; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Huttner WB, 2000, CURR OPIN NEUROBIOL, V10, P543, DOI 10.1016/S0959-4388(00)00126-4; Jaillon O, 2004, NATURE, V431, P946, DOI 10.1038/nature03025; KARIN M, 1995, J BIOL CHEM, V270, P16483, DOI 10.1074/jbc.270.28.16483; KIMMEL CB, 1995, DEV DYNAM, V203, P253, DOI 10.1002/aja.1002030302; Kobiyama A, 1998, J EXP BIOL, V201, P2801; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Link V, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-1; Liu H, 2004, ONCOGENE, V23, P3385, DOI 10.1038/sj.onc.1207402; Liu TX, 2007, EXP HEMATOL, V35, P230, DOI 10.1016/j.exphem.2006.10.008; Lotfi CFP, 2000, BRAZ J MED BIOL RES, V33, P1133, DOI 10.1590/S0100-879X2000001000002; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; Lua BL, 2005, J CELL SCI, V118, P2707, DOI 10.1242/jcs.02383; Ma LH, 2007, BLOOD, V109, P769, DOI 10.1182/blood-2006-02-003517; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Micheva KD, 1997, J BIOL CHEM, V272, P27239, DOI 10.1074/jbc.272.43.27239; Modregger J, 2003, J BIOL CHEM, V278, P4160, DOI 10.1074/jbc.M208568200; Paffett-Lugassy NN, 2004, METH MOLEC MED, V105, P171; Patel AS, 1998, ONCOGENE, V16, P3227, DOI 10.1038/sj.onc.1201850; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; Pierrat B, 2001, GENOMICS, V71, P222, DOI 10.1006/geno.2000.6378; Postlethwait J, 2004, TRENDS GENET, V20, P481, DOI 10.1016/j.tig.2004.08.001; Rhodes J, 2005, DEV CELL, V8, P97, DOI 10.1016/j.devcel.2004.11.014; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Ringstad N, 2001, J BIOL CHEM, V276, P40424, DOI 10.1074/jbc.M106338200; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; So CW, 1997, P NATL ACAD SCI USA, V94, P2563, DOI 10.1073/pnas.94.6.2563; So CW, 2000, BIOCHEM J, V348, P447, DOI 10.1042/0264-6021:3480447; So CW, 2000, LEUKEMIA, V14, P594, DOI 10.1038/sj.leu.2401692; Song HD, 2004, P NATL ACAD SCI USA, V101, P16240, DOI 10.1073/pnas.0407241101; Tang YT, 1999, P NATL ACAD SCI USA, V96, P12559, DOI 10.1073/pnas.96.22.12559; Thermes V, 2002, MECH DEVELOP, V118, P91, DOI 10.1016/S0925-4773(02)00218-6; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Volff Jean-Nicolas, 2003, Journal of Structural and Functional Genomics, V3, P139, DOI 10.1023/A:1022678305005; Wei Y, 1999, CELL, V97, P99, DOI 10.1016/S0092-8674(00)80718-7; WESTERFIELD M, 1995, ZEBRAFISH BOOK GUIDE; Widmann C, 1999, PHYSIOL REV, V79, P143, DOI 10.1152/physrev.1999.79.1.143; Wiellette EL, 2003, DEVELOPMENT, V130, P3821, DOI 10.1242/dev.00572; Woods IG, 2000, GENOME RES, V10, P1903, DOI 10.1101/gr.10.12.1903; Xue LZ, 1998, CELL SIGNAL, V10, P339, DOI 10.1016/S0898-6568(98)00011-4; Yam JWP, 2004, BLOOD, V103, P1445, DOI 10.1182/blood-2003-07-2452	62	6	6	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17652	17661		10.1074/jbc.M710517200	http://dx.doi.org/10.1074/jbc.M710517200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18413315	hybrid			2022-12-25	WOS:000256720600071
J	Nairn, AV; York, WS; Harris, K; Hall, EM; Pierce, JM; Moremen, KW				Nairn, Alison V.; York, William S.; Harris, Kyle; Hall, Erica M.; Pierce, J. Michael; Moremen, Kelley W.			Regulation of glycan structures in animal tissues - Transcript profiling of glycan-related genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-ADHESION MOLECULE; UDP-GALACTOSE; EXPRESSION ANALYSIS; CORE 2; CLONING; GLYCOSYLATION; BIOSYNTHESIS; CHAIN; SULFOTRANSFERASE; ROLES	Glycan structures covalently attached to proteins and lipids play numerous roles in mammalian cells, including protein folding, targeting, recognition, and adhesion at the molecular or cellular level. Regulating the abundance of glycan structures on cellular glycoproteins and glycolipids is a complex process that depends on numerous factors. Most models for glycan regulation hypothesize that transcriptional control of the enzymes involved in glycan synthesis, modification, and catabolism determines glycan abundance and diversity. However, few broad-based studies have examined correlations between glycan structures and transcripts encoding the relevant biosynthetic and catabolic enzymes. Low transcript abundance for many glycan-related genes has hampered broad-based transcript profiling for comparison with glycan structural data. In an effort to facilitate comparison with glycan structural data and to identify the molecular basis of alterations in glycan structures, we have developed a medium-throughput quantitative real time reverse transcriptase-PCR platform for the analysis of transcripts encoding glycan-related enzymes and proteins in mouse tissues and cells. The method employs a comprehensive list of > 700 genes, including enzymes involved in sugar-nucleotide biosynthesis, transporters, glycan extension, modification, recognition, catabolism, and numerous glycosylated core proteins. Comparison with parallel microarray analyses indicates a significantly greater sensitivity and dynamic range for our quantitative real time reverse transcriptase-PCR approach, particularly for the numerous low abundance glycan-related enzymes. Mapping of the genes and transcript levels to their respective biosynthetic pathway steps allowed a comparison with glycan structural data and provides support for a model where many, but not all, changes in glycan abundance result from alterations in transcript expression of corresponding biosynthetic enzymes.	[Nairn, Alison V.; York, William S.; Harris, Kyle; Hall, Erica M.; Pierce, J. Michael; Moremen, Kelley W.] Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30602 USA; [Nairn, Alison V.; York, William S.; Harris, Kyle; Hall, Erica M.; Pierce, J. Michael; Moremen, Kelley W.] Univ Georgia, Dept Biochem & Mol Biol, Athens, GA 30602 USA	University System of Georgia; University of Georgia; University System of Georgia; University of Georgia	Moremen, KW (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, 315 Riverbend Rd, Athens, GA 30602 USA.	moremen@uga.edu	Moremen, Kelley/AAD-4661-2019	Nairn, Alison/0000-0002-4453-7593	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR018502] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062116] Funding Source: NIH RePORTER; NCRR NIH HHS [RR018502] Funding Source: Medline; NIGMS NIH HHS [U54 GM062116] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Akama TO, 2002, SCIENCE, V295, P124, DOI 10.1126/science.1065570; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Amado M, 1998, J BIOL CHEM, V273, P12770, DOI 10.1074/jbc.273.21.12770; Angata K, 1998, J BIOL CHEM, V273, P28524, DOI 10.1074/jbc.273.43.28524; Aoki K, 2007, J BIOL CHEM, V282, P9127, DOI 10.1074/jbc.M606711200; Bakker H, 1997, J BIOL CHEM, V272, P29942, DOI 10.1074/jbc.272.47.29942; Bax M, 2007, J IMMUNOL, V179, P8216, DOI 10.4049/jimmunol.179.12.8216; BHAUMIK M, 1995, GENE, V164, P295, DOI 10.1016/0378-1119(95)00260-D; Brenner S, 2000, NAT BIOTECHNOL, V18, P630, DOI 10.1038/76469; BROCKHAUSEN I, 1989, J BIOL CHEM, V264, P11211; Brockhausen I, 1998, ACTA ANAT, V161, P36; Bustin SA, 2004, A Z QUANTITATIVE PCR; Chen GY, 2005, MOL CELL BIOL, V25, P7828, DOI 10.1128/MCB.25.17.7828-7838.2005; Chen JJ, 2002, P NATL ACAD SCI USA, V99, P12257, DOI 10.1073/pnas.192436499; Comelli EM, 2006, GLYCOBIOLOGY, V16, P117, DOI 10.1093/glycob/cwj048; Coutinho PM, 1999, ROY SOC CH, P3; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; DALLNER G, 1966, J CELL BIOL, V30, P73, DOI 10.1083/jcb.30.1.73; de Martin PE, 2005, BIOCHEM CELL BIOL, V83, P752, DOI 10.1139/O05-159; Dennis JW, 1999, BIOESSAYS, V21, P412, DOI 10.1002/(SICI)1521-1878(199905)21:5<412::AID-BIES8>3.0.CO;2-5; Diehn M, 2003, NUCLEIC ACIDS RES, V31, P219, DOI 10.1093/nar/gkg014; DOHI T, 1990, J BIOL CHEM, V265, P7880; Eveland AL, 2008, PLANT PHYSIOL, V146, P32, DOI 10.1104/pp.107.108597; Garcia-Vallejo JJ, 2006, J CELL PHYSIOL, V206, P203, DOI 10.1002/jcp.20458; Garcia-Vallejo Juan J., 2006, V347, P187; Haltiwanger RS, 2004, ANNU REV BIOCHEM, V73, P491, DOI 10.1146/annurev.biochem.73.011303.074043; Hashimoto M, 2007, GLYCOBIOLOGY, V17, P994, DOI 10.1093/glycob/cwm068; Helenius A, 2004, ANNU REV BIOCHEM, V73, P1019, DOI 10.1146/annurev.biochem.73.011303.073752; Hemmoranta H, 2007, EXP HEMATOL, V35, P1279, DOI 10.1016/j.exphem.2007.05.006; Hennet T, 1998, J BIOL CHEM, V273, P58, DOI 10.1074/jbc.273.1.58; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; Imiya K, 2002, GENE, V296, P29, DOI 10.1016/S0378-1119(02)00840-5; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Ishii A, 2007, GLYCOBIOLOGY, V17, P261, DOI 10.1093/glycob/cwl076; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Kanehisa M, 2008, NUCLEIC ACIDS RES, V36, pD480, DOI 10.1093/nar/gkm882; Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102; Kawashima H, 2006, BIOL PHARM BULL, V29, P2343, DOI 10.1248/bpb.29.2343; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; Kubista Mikael, 2006, Molecular Aspects of Medicine, V27, P95, DOI 10.1016/j.mam.2005.12.007; KUI WN, 2003, J BIOL CHEM, V278, P28619, DOI DOI 10.1074/JBC.M302741200; Li LH, 1998, J ANDROL, V19, P365; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Liu WH, 2002, ANAL BIOCHEM, V302, P52, DOI 10.1006/abio.2001.5530; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lo NW, 1998, GLYCOBIOLOGY, V8, P517, DOI 10.1093/glycob/8.5.517; Lockhart DJ, 1996, NAT BIOTECHNOL, V14, P1675, DOI 10.1038/nbt1296-1675; Lowe JB, 2003, ANNU REV BIOCHEM, V72, P643, DOI 10.1146/annurev.biochem.72.121801.161809; Lowe JB, 2001, CELL, V104, P809, DOI 10.1016/S0092-8674(01)00277-X; Lu J, 2004, GENOMICS, V84, P631, DOI 10.1016/j.ygeno.2004.06.014; Maglott D, 2007, NUCLEIC ACIDS RES, V35, pD26, DOI 10.1093/nar/gkl993; Morrison TB, 1998, BIOTECHNIQUES, V24, P954; MORTON JA, 1988, IMMUNOL INVEST, V17, P217, DOI 10.3109/08820138809052961; Nairn AV, 2007, J PROTEOME RES, V6, P4374, DOI 10.1021/pr070446f; Naito Y, 2007, MOL CELL BIOL, V27, P3008, DOI 10.1128/MCB.02047-06; Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019; Okuda T, 2003, J BIOCHEM, V134, P111, DOI 10.1093/jb/mvg118; Ong E, 1998, J BIOL CHEM, V273, P5190, DOI 10.1074/jbc.273.9.5190; Orth JM, 2000, CURR TOP DEV BIOL, V50, P103, DOI 10.1016/S0070-2153(00)50006-4; Provenano M, 2007, ADV EXP MED BIOL, V593, P66; Ramakers C, 2003, NEUROSCI LETT, V339, P62, DOI 10.1016/S0304-3940(02)01423-4; Rozen S, 2000, Methods Mol Biol, V132, P365; Rutishauser U, 1996, TRENDS NEUROSCI, V19, P422; Saier MH, 2006, NUCLEIC ACIDS RES, V34, pD181, DOI 10.1093/nar/gkj001; Schachter H, 2000, GLYCOCONJUGATE J, V17, P465; SCHACHTER H, 1991, Glycobiology, V1, P453, DOI 10.1093/glycob/1.5.453; SCHACHTER H, 1984, BIOL CELL, V51, P133, DOI 10.1111/j.1768-322X.1984.tb00292.x; SCHACHTER H, 1984, CLIN BIOCHEM, V17, P3, DOI 10.1016/S0009-9120(84)90360-6; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; SCHWARTING GA, 1987, DEV BIOL, V120, P65, DOI 10.1016/0012-1606(87)90104-7; Seiki T, 1999, BIOCHEM BIOPH RES CO, V255, P182, DOI 10.1006/bbrc.1999.0151; Senn C, 2002, MOL CELL NEUROSCI, V20, P712, DOI 10.1006/mcne.2002.1142; Smith FI, 2005, GENE EXPR PATTERNS, V5, P740, DOI 10.1016/j.modgep.2005.04.006; Sutton-Smith M, 2002, BIOCHEM SOC SYMP, V69, P105; Takamiya K, 1998, P NATL ACAD SCI USA, V95, P12147, DOI 10.1073/pnas.95.21.12147; Taniguchi N., 2002, HDB GLYCOSYLTRANSFER; Taniguchi N, 2006, CURR OPIN STRUC BIOL, V16, P561, DOI 10.1016/j.sbi.2006.08.011; Taylor M.E., 2006, INTRO GLYCOBIOLOGY, P122; Terayama K, 1997, P NATL ACAD SCI USA, V94, P6093, DOI 10.1073/pnas.94.12.6093; Togayachi A, 2006, METHOD ENZYMOL, V416, P91, DOI 10.1016/S0076-6879(06)16006-1; Togayachi A, 2007, P NATL ACAD SCI USA, V104, P15829, DOI 10.1073/pnas.0707426104; Tremblay LO, 2007, J BIOL CHEM, V282, P2558, DOI 10.1074/jbc.M608661200; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Uchimura K, 2006, TRENDS IMMUNOL, V27, P559, DOI 10.1016/j.it.2006.10.007; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; Varki A., 1999, ESSENTIALS GLYCOBIOL; VELCULESCU VE, 1995, SCIENCE, V270, P484, DOI 10.1126/science.270.5235.484; WANG X, 2006, ADV METHODS, P93; Wheeler DL, 2007, NUCLEIC ACIDS RES, V35, pD5, DOI 10.1093/nar/gkl1031; Xia GQ, 2000, J BIOL CHEM, V275, P38402, DOI 10.1074/jbc.M007821200; Yamamoto A, 1996, J NEUROCHEM, V66, P26; Yamamoto H, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001232; Yamamoto M, 2001, J BIOL CHEM, V276, P13701, DOI 10.1074/jbc.M010805200; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; Young WW, 2003, GLYCOBIOLOGY, V13, P549, DOI 10.1093/glycob/cwg062	96	143	149	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17298	17313		10.1074/jbc.M801964200	http://dx.doi.org/10.1074/jbc.M801964200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18411279	Green Published, hybrid			2022-12-25	WOS:000256720600039
J	Bin Fang, W; Brantley-Sieders, DM; Hwang, Y; Ham, AJL; Chen, J				Bin Fang, Wei; Brantley-Sieders, Dana M.; Hwang, Yoonha; Ham, Amy-Joan L.; Chen, Jin			Identification and functional analysis of phosphorylated tyrosine residues within EphA2 receptor tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID-SEQUENCES; IN-VIVO; TUMOR MICROENVIRONMENT; INDUCED ANGIOGENESIS; PROTEIN DATABASE; CELL-MIGRATION; GROWTH-FACTOR; ACTIVATION; LIGAND; MICE	EphA2 is a member of the Eph family of receptor tyrosine kinases. EphA2 mediates cell-cell communication and plays critical roles in a number of physiological and pathologic responses. We have previously shown that EphA2 is a key regulator of tumor angiogenesis and that tyrosine phosphorylation regulates EphA2 signaling. To understand the role of EphA2 phosphorylation, we have mapped phosphorylated tyrosines within the intracellular region of EphA2 by a combination of mass spectrometry analysis and phosphopeptide mapping using two-dimensional chromatography in conjunction with site-directed mutagenesis. The function of these phosphorylated tyrosine residues was assessed by mutational analysis using EphA2-null endothelial cells reconstituted with EphA2 tyrosineto-phenylalanine or tyrosine-to-glutamic acid substitution mutants. Phosphorylated Tyr(587) and Tyr(593) bind to Vav2 and Vav3 guanine nucleotide exchange factors, whereas Tyr(P)(734) binds to the p85 regulatory subunit of phosphatidylinositol 3-kinase. Mutations that uncouple EphA2 with Vav3 guanine nucleotide exchange factors or p85 are defective in Rac1 activation and cell migration. Finally, EphA2 mutations in the juxtamembrane region (Y587F, Y593F, Y587E/Y593E), kinase domain (Y734F), or SAM domain (Y929F) inhibited ephrin-A1-induced vascular assembly. In addition, EphA2-null endothelial cells reconstituted with these mutants were unable to incorporate into tumor vasculature, suggesting a critical role of these phosphorylation tyrosine residues in transducing EphA2 signaling in vascular endothelial cells during tumor angiogenesis.	[Brantley-Sieders, Dana M.; Hwang, Yoonha; Chen, Jin] Vanderbilt Univ, Dept Med, Sch Med, Div Rheumatol & Immunol, Nashville, TN 37232 USA; [Bin Fang, Wei; Chen, Jin] Vanderbilt Univ, Dept Canc Biol, Sch Med, Nashville, TN 37232 USA; [Ham, Amy-Joan L.] Vanderbilt Univ, Prote Lab, Sch Med, Mass Spectrometry Res Ctr, Nashville, TN 37232 USA; [Chen, Jin] Vanderbilt Univ, Dept Cell & Dev Biol, Sch Med, Nashville, TN 37232 USA; [Chen, Jin] Vanderbilt Univ, Vanderbilt Ingram Canc Ctr, Sch Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University	Chen, J (corresponding author), Vanderbilt Univ, Dept Med, Sch Med, Div Rheumatol & Immunol, A-4323 MCN,1161 21st Ave S, Nashville, TN 37232 USA.	jin.chen@vanderbilt.edu		Chen, Jin/0000-0002-5557-2079; Hwang, Yoonha/0000-0001-7420-4477	NCI NIH HHS [CA114301, CA1179151, CA95004] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA114301, R01CA095004] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams RH, 2002, SEMIN CELL DEV BIOL, V13, P55, DOI 10.1006/scdb.2001.0289; Bin Fang W, 2005, ONCOGENE, V24, P7859, DOI 10.1038/sj.onc.1208937; Binns KL, 2000, MOL CELL BIOL, V20, P4791, DOI 10.1128/MCB.20.13.4791-4805.2000; Brantley DM, 2002, ONCOGENE, V21, P7011, DOI 10.1038/sj.onc.1205679; Brantley-Sieders D, 2004, CURR PHARM DESIGN, V10, P3431, DOI 10.2174/1381612043383160; Brantley-Sieders DM, 2006, CANCER RES, V66, P10315, DOI 10.1158/0008-5472.CAN-06-1560; Brantley-Sieders Dana M., 2004, Angiogenesis, V7, P17, DOI 10.1023/B:AGEN.0000037340.33788.87; Brantley-Sieders DM, 2005, FASEB J, V19, P1884, DOI 10.1096/fj.05-4038fje; Brantley-Sieders DM, 2004, J CELL SCI, V117, P2037, DOI 10.1242/jcs.01061; Cheng N, 2002, MOL CANCER RES, V1, P2; Cheng N, 2003, NEOPLASIA, V5, P445, DOI 10.1016/S1476-5586(03)80047-7; Chiarugi P, 1997, BIOCHEM BIOPH RES CO, V238, P676, DOI 10.1006/bbrc.1997.7355; Daniel TO, 1996, KIDNEY INT, V50, pS73; Dobrzanski P, 2004, CANCER RES, V64, P910, DOI 10.1158/0008-5472.CAN-3430-2; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Erber R, 2006, EMBO J, V25, P628, DOI 10.1038/sj.emboj.7600949; Fang BW, 2008, J CELL SCI, V121, P358, DOI 10.1242/jcs.017145; Foo SS, 2006, CELL, V124, P161, DOI 10.1016/j.cell.2005.10.034; Gale NW, 1996, NEURON, V17, P9, DOI 10.1016/S0896-6273(00)80276-7; Gerety SS, 2002, DEVELOPMENT, V129, P1397; Ham A., 2005, ENCY MASS SPECTROMET, V2, P10; Hansen BT, 2005, J PROTEOME RES, V4, P358, DOI 10.1021/pr0498234; Hunter SG, 2006, MOL CELL BIOL, V26, P4830, DOI 10.1128/MCB.02215-05; JAT PS, 1991, P NATL ACAD SCI USA, V88, P5096, DOI 10.1073/pnas.88.12.5096; Kalo MS, 1999, BIOCHEMISTRY-US, V38, P14396, DOI 10.1021/bi991628t; Kalo MS, 2001, J BIOL CHEM, V276, P38940, DOI 10.1074/jbc.M105815200; Kikawa KD, 2002, J BIOL CHEM, V277, P39274, DOI 10.1074/jbc.M207127200; Lawrenson ID, 2002, J CELL SCI, V115, P1059; Miao H, 2003, J CELL BIOL, V162, P1281, DOI 10.1083/jcb.200304018; Miao H, 2000, NAT CELL BIOL, V2, P62, DOI 10.1038/35000008; Nor JE, 2001, LAB INVEST, V81, P453, DOI 10.1038/labinvest.3780253; Noren NK, 2004, P NATL ACAD SCI USA, V101, P5583, DOI 10.1073/pnas.0401381101; Ogawa K, 2000, ONCOGENE, V19, P6043, DOI 10.1038/sj.onc.1204004; PANDEY A, 1994, J BIOL CHEM, V269, P30154; PANDEY A, 1995, J BIOL CHEM, V270, P19201, DOI 10.1074/jbc.270.33.19201; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Pasquale EB, 2005, NAT REV MOL CELL BIO, V6, P462, DOI 10.1038/nrm1662; Pratt RL, 2002, ONCOGENE, V21, P7690, DOI 10.1038/sj.onc.1205758; Ridley AJ, 2001, J CELL SCI, V114, P2713; Stein E, 1996, J BIOL CHEM, V271, P23588, DOI 10.1074/jbc.271.38.23588; Stein E, 1998, GENE DEV, V12, P667, DOI 10.1101/gad.12.5.667; Walker-Daniels J, 2002, MOL CANCER RES, V1, P79; Wang YJ, 2002, BIOCHEM BIOPH RES CO, V296, P214, DOI 10.1016/S0006-291X(02)00806-9; Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2; YATES JR, 1995, ANAL CHEM, V67, P1426, DOI 10.1021/ac00104a020	45	93	99	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16017	16026		10.1074/jbc.M709934200	http://dx.doi.org/10.1074/jbc.M709934200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18387945	hybrid, Green Published			2022-12-25	WOS:000256332500060
J	Makarava, N; Baskakov, IV				Makarava, Natallia; Baskakov, Ilia V.			The same primary structure of the prion protein yields two distinct self-propagating states	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYLOID FIBRILS; IN-VITRO; SYNTHETIC PRIONS; MAMMALIAN PRIONS; MOLECULAR-BASIS; MOUSE SCRAPIE; STRAIN; CONFORMATION; POLYMORPHISM; CONVERSION	The question of whether distinct self-propagating structures could be formed within the same amino acid sequence in the absence of external cofactors or templates has important implications for a number of issues, including the origin of prion strains and the engineering of smart, self-assembling peptide-based biomaterials. In the current study, we showed that chemically identical prion protein can give rise to conformationally distinct, self-propagating amyloid structures in the absence of cellular cofactors, post-translational modification, or PrPSc-specified templates. Even more surprising, two self-replicating states were produced under identical solvent conditions, but under different shaking modes. Individual prion conformations were inherited by daughter fibrils in seeding experiments conducted under alternative shaking modes, illustrating the high fidelity of fibrillation reactions. Our study showed that the ability to acquire conformationally different self-propagating structures is an intrinsic ability of protein fibrillation and strongly supports the hypothesis that conformational variation in self-propagating protein states underlies prion strain diversity.	[Makarava, Natallia; Baskakov, Ilia V.] Univ Maryland, Maryland Biotechnol Inst, Ctr Med Biotechnol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore	Baskakov, IV (corresponding author), Univ Maryland, Maryland Biotechnol Inst, Ctr Med Biotechnol, 725 W Lombard St, Baltimore, MD 21201 USA.	Baskakov@umbi.umd.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045585] Funding Source: NIH RePORTER; NINDS NIH HHS [NS045585] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Anderson M, 2006, J MOL BIOL, V358, P580, DOI 10.1016/j.jmb.2006.02.007; Baskakov IV, 2007, BBA-MOL BASIS DIS, V1772, P692, DOI 10.1016/j.bbadis.2006.07.007; Baskakov IV, 2002, J BIOL CHEM, V277, P21140, DOI 10.1074/jbc.M111402200; Baskakov IV, 2004, PROTEIN SCI, V13, P586, DOI 10.1110/ps.03457204; BESSEN RA, 1994, J VIROL, V68, P7859, DOI 10.1128/JVI.68.12.7859-7868.1994; Bocharova OV, 2005, PROTEIN SCI, V14, P1222, DOI 10.1110/ps.041186605; Bocharova OV, 2005, J MOL BIOL, V346, P645, DOI 10.1016/j.jmb.2004.11.068; Breydo L, 2005, BIOCHEMISTRY-US, V44, P15534, DOI 10.1021/bi051369+; Breydo L, 2007, BIOCHEMISTRY-US, V46, P852, DOI 10.1021/bi061923v; Caughey B, 1998, J BIOL CHEM, V273, P32230, DOI 10.1074/jbc.273.48.32230; Cordeiro Y, 2001, J BIOL CHEM, V276, P49400, DOI 10.1074/jbc.M106707200; Deleault NR, 2007, P NATL ACAD SCI USA, V104, P9741, DOI 10.1073/pnas.0702662104; Deleault NR, 2003, NATURE, V425, P717, DOI 10.1038/nature01979; Dzwolak W, 2005, BIOCHEMISTRY-US, V44, P8948, DOI 10.1021/bi050281t; Heise H, 2005, P NATL ACAD SCI USA, V102, P15871, DOI 10.1073/pnas.0506109102; Jones EM, 2005, CELL, V121, P63, DOI 10.1016/j.cell.2005.01.034; KIMBERLIN RH, 1987, J GEN VIROL, V68, P1875, DOI 10.1099/0022-1317-68-7-1875; KIMBERLIN RH, 1989, J GEN VIROL, V70, P2017, DOI 10.1099/0022-1317-70-8-2017; Legname G, 2004, SCIENCE, V305, P673, DOI 10.1126/science.1100195; Legname G, 2005, P NATL ACAD SCI USA, V102, P2168, DOI 10.1073/pnas.0409079102; Makarava N, 2006, PROTEIN SCI, V15, P1334, DOI 10.1110/ps.052013106; Novitskaya V, 2006, J BIOL CHEM, V281, P15536, DOI 10.1074/jbc.M601349200; Peretz D, 2002, NEURON, V34, P921, DOI 10.1016/S0896-6273(02)00726-2; Peretz D, 1997, J MOL BIOL, V273, P614, DOI 10.1006/jmbi.1997.1328; Peretz D, 2001, PROTEIN SCI, V10, P854, DOI 10.1110/ps.39201; Petkova AT, 2005, SCIENCE, V307, P262, DOI 10.1126/science.1105850; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Safar J, 1998, NAT MED, V4, P1157, DOI 10.1038/2654; Safar JG, 2005, J VIROL, V79, P10796, DOI 10.1128/JVI.79.16.10796-10806.2005; Sun Y, 2007, J BIOL CHEM, V282, P9090, DOI 10.1074/jbc.M608623200; Telling GC, 1996, SCIENCE, V274, P2079, DOI 10.1126/science.274.5295.2079; Tomzig A, 2004, J BIOL CHEM, V279, P33847, DOI 10.1074/jbc.M403730200; Uptain SM, 2001, EMBO J, V20, P6236, DOI 10.1093/emboj/20.22.6236; Vanik DL, 2004, MOL CELL, V14, P139, DOI 10.1016/S1097-2765(04)00155-8; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0	35	86	86	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15988	15996		10.1074/jbc.M800562200	http://dx.doi.org/10.1074/jbc.M800562200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18400757	hybrid, Green Published			2022-12-25	WOS:000256332500057
J	Chambers, JW; Kearns, MT; Morris, MT; Morris, JC				Chambers, Jeremy W.; Kearns, Margaret T.; Morris, Meredith T.; Morris, James C.			Assembly of heterohexameric trypanosome hexokinases reveals that hexokinase 2 is a regulable enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-STREAM FORM; PHOSPHATE DIKINASE; BRUCEI HEXOKINASE; DEPENDENT ENZYME; CRUZI HEXOKINASE; PYROPHOSPHATE; GLYCOLYSIS; GLUCOSE; PHOSPHOFRUCTOKINASE; BISPHOSPHONATES	Glycolysis is essential to Trypanosoma brucei, the protozoan parasite that causes African sleeping sickness in humans and nagana in cattle. Hexokinase (HK), the first enzyme in glycolysis, catalyzes the phosphorylation of glucose to form glucose 6-phosphate. T. brucei harbors two HKs that are 98% identical at the amino acid level, T. brucei hexokinase 1 (TbHK1) and TbHK2. Recombinant TbHK1 (rTbHK1) has HK activity, whereas rTbHK2 does not. Unlike other eukaryotic HKs, TbHK1 is not subject to inhibition by ADP and glucose 6-phosphate. However, TbHK1 is inhibited by myristate, a critical fatty acid in T. brucei biology. We report here that rTbHKs, similar to authentic TbHK, form oligomers. Myristate dissociated these assemblies when incubated with either ATP or glucose. Furthermore, oligomer disruption was reversible by removal of myristate. Mixing of rTbHK1 and rTbHK2 monomers followed by reassembly yielded enzyme with an similar to 3-fold increase in specific activity compared with similarly treated rTbHK1 alone. Surprisingly, reassembly of rTbHK2 with an inactive rTbHK1 variant yielded an active HK, revealing for the first time that rTbHK2 is competent for HK activity. Finally, pyrophosphate inhibits active reassembled rTbHK2 oligomers but not oligomeric rTbHK1, suggesting that the two enzymes have distinct regulatory mechanisms.	[Chambers, Jeremy W.; Kearns, Margaret T.; Morris, Meredith T.; Morris, James C.] Clemson Univ, Dept Biochem & Genet, Clemson, SC 29634 USA	Clemson University	Morris, JC (corresponding author), Clemson Univ, Dept Biochem & Genet, 214 BRC,51 New Cherry St, Clemson, SC 29634 USA.	jmorri2@clemson.edu	Morris, James/L-7253-2019	Chambers, Jeremy/0000-0002-6143-3091; Morris, James/0000-0003-2515-5714				Acosta H, 2004, COMP BIOCHEM PHYS B, V138, P347, DOI 10.1016/j.cbpc.2004.04.017; Albert MA, 2005, J BIOL CHEM, V280, P28306, DOI 10.1074/jbc.M502403200; Bringaud F, 1998, P NATL ACAD SCI USA, V95, P7963, DOI 10.1073/pnas.95.14.7963; Cardenas ML, 1998, BBA-MOL CELL RES, V1401, P242, DOI 10.1016/S0167-4889(97)00150-X; Chambers JW, 2008, MOL BIOCHEM PARASIT, V158, P202, DOI 10.1016/j.molbiopara.2007.12.013; Chambers JW, 2008, BIOCHEM BIOPH RES CO, V365, P420, DOI 10.1016/j.bbrc.2007.10.192; Colasante C, 2006, PROTEOMICS, V6, P3275, DOI 10.1002/pmic.200500668; Drew ME, 2003, J BIOL CHEM, V278, P46596, DOI 10.1074/jbc.M309320200; Er E, 2007, J BIOL CHEM, V282, P24938, DOI 10.1074/jbc.M703823200; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; Furuya T, 2002, P NATL ACAD SCI USA, V99, P14177, DOI 10.1073/pnas.222454899; Hudock MP, 2006, J MED CHEM, V49, P215, DOI 10.1021/jm0582625; Lamour N, 2005, J BIOL CHEM, V280, P11902, DOI 10.1074/jbc.M414274200; Michels PAM, 1997, EUR J BIOCHEM, V250, P698, DOI 10.1111/j.1432-1033.1997.00698.x; MISSET O, 1986, EUR J BIOCHEM, V157, P441, DOI 10.1111/j.1432-1033.1986.tb09687.x; Morris JC, 2002, EMBO J, V21, P4429, DOI 10.1093/emboj/cdf474; Morris MT, 2006, EUKARYOT CELL, V5, P2014, DOI 10.1128/EC.00146-06; NWAGWU M, 1982, ACTA TROP, V39, P61; Sanz-Rodriguez CE, 2007, J BIOL CHEM, V282, P12377, DOI 10.1074/jbc.M607286200; Subramanya S, 2006, FEBS J, V273, P2110, DOI 10.1111/j.1742-4658.2006.05225.x; TSAI HJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P206, DOI 10.1006/abbi.1995.1029; VEECH RL, 1980, FEBS LETT, V117, pK65, DOI 10.1016/0014-5793(80)80571-0; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; Willert EK, 2007, P NATL ACAD SCI USA, V104, P8275, DOI 10.1073/pnas.0701111104; Willson M, 2002, CHEM BIOL, V9, P839, DOI 10.1016/S1074-5521(02)00169-2	25	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					14963	14970		10.1074/jbc.M802124200	http://dx.doi.org/10.1074/jbc.M802124200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18387941	Green Published, hybrid			2022-12-25	WOS:000256232000008
J	Ha, VL; Bharti, S; Inoue, H; Vass, WC; Campa, F; Nie, ZZ; de Gramont, A; Ward, Y; Randazzo, PA				Ha, Vi Luan; Bharti, Sanita; Inoue, Hiroki; Vass, William C.; Campa, Fanny; Nie, Zhongzhen; de Gramont, Armand; Ward, Yvona; Randazzo, Paul A.			ASAP3 is a focal adhesion-associated Arf GAP that functions in cell migration and invasion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING-PROTEIN; ADP-RIBOSYLATION FACTOR; RHO GTPASES; PODOSOMES; IDENTIFICATION; REQUIREMENT; INVADOPODIA; REGULATORS; KINASES; COMPLEX	ASAP3, an Arf GTPase-activating protein previously called DDEFL1 and ACAP4, has been implicated in the pathogenesis of hepatocellular carcinoma. We have examined in vitro and in vivo functions of ASAP3 and compared it to the related Arf GAP ASAP1 that has also been implicated in oncogenesis. ASAP3 was biochemically similar to ASAP1: the pleckstrin homology domain affected function of the catalytic domain by more than 100-fold; catalysis was stimulated by phosphatidylinositol 4,5-bisphosphate; and Arf1, Arf5, and Arf6 were used as substrates in vitro. Like ASAP1, ASAP3 associated with focal adhesions and circular dorsal ruffles. Different than ASAP1, ASAP3 did not localize to invadopodia or podosomes. Cells, derived from a mammary carcinoma and from a glioblastoma, with reduced ASAP3 expression had fewer actin stress fiber, reduced levels of phosphomyosin, and migrated more slowly than control cells. Reducing ASAP3 expression also slowed invasion of mammary carcinoma cells. In contrast, reduction of ASAP I expression had no effect on migration or invasion. We propose that ASAP3 functions nonredundantly with ASAP1. to control cell movement and may have a role in cancer cell invasion. In comparing ASAP1. and ASAP3, we also found that invadopodia are dispensable for the invasive behavior of cells derived from a mammary carcinoma.	[Ha, Vi Luan; Bharti, Sanita; Inoue, Hiroki; Campa, Fanny; Nie, Zhongzhen; Randazzo, Paul A.] NCI, Cellular & Mol Biol Lab, Bethesda, MD 20892 USA; [Vass, William C.] NCI, Cellular Oncol Lab, Bethesda, MD 20892 USA; [Ward, Yvona] NCI, Canc Cell Biol Branch, Canc Res Ctr, Bethesda, MD 20892 USA; [de Gramont, Armand] NIDDK, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Randazzo, PA (corresponding author), Bldg 37,Rm 2042, Bethesda, MD 20892 USA.	Randazzo@helix.nih.gov			Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC007365, ZICBC010947, Z01BC007365, Z01BC010947] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Amerongen GPV, 2004, CIRC RES, V94, P1041, DOI 10.1161/01.RES.0000125627.77235.0C; Andreev J, 1999, MOL CELL BIOL, V19, P2338; Ayala I, 2006, EUR J CELL BIOL, V85, P159, DOI 10.1016/j.ejcb.2005.09.005; Balasubramanian N, 2007, NAT CELL BIOL, V9, P1381, DOI 10.1038/ncb1657; Bharti S, 2007, MOL CELL BIOL, V27, P8271, DOI 10.1128/MCB.01781-06; Brown MC, 2005, MOL BIOL CELL, V16, P4316, DOI 10.1091/mbc.E05-02-0131; Brown MT, 1998, MOL CELL BIOL, V18, P7038, DOI 10.1128/MCB.18.12.7038; Brunton VG, 2004, BBA-MOL CELL RES, V1692, P121, DOI 10.1016/j.bbamcr.2004.04.010; Buccione R, 2004, NAT REV MOL CELL BIO, V5, P647, DOI 10.1038/nrm1436; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Chen CS, 2004, ANNU REV BIOMED ENG, V6, P275, DOI 10.1146/annurev.bioeng.6.040803.140040; Cotton M, 2007, MOL BIOL CELL, V18, P501, DOI 10.1091/mbc.E06-06-0567; de Curtis I, 2001, EMBO REP, V2, P277, DOI 10.1093/embo-reports/kve072; Donaldson JG, 2005, BBA-MOL CELL RES, V1744, P364, DOI 10.1016/j.bbamcr.2005.03.001; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Donaldson JG, 2000, CURR OPIN CELL BIOL, V12, P475, DOI 10.1016/S0955-0674(00)00119-8; Ehlers JP, 2005, CLIN CANCER RES, V11, P3609, DOI 10.1158/1078-0432.CCR-04-1941; Fang ZY, 2006, MOL CELL PROTEOMICS, V5, P1437, DOI 10.1074/mcp.M600050-MCP200; Frank SR, 2006, EMBO J, V25, P1848, DOI 10.1038/sj.emboj.7601092; Furman C, 2002, J BIOL CHEM, V277, P7962, DOI 10.1074/jbc.M109149200; Hashimoto S, 2006, P NATL ACAD SCI USA, V103, P7036, DOI 10.1073/pnas.0509166103; Hashimoto S, 2004, P NATL ACAD SCI USA, V101, P6647, DOI 10.1073/pnas.0401753101; Inoue H, 2007, TRAFFIC, V8, P1465, DOI 10.1111/j.1600-0854.2007.00624.x; Koo TH, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-29; Krugmann S, 2006, J CELL SCI, V119, P425, DOI 10.1242/jcs.02755; Krugmann S, 2004, CURR BIOL, V14, P1380, DOI 10.1016/j.cub.2004.07.058; Krugmann S, 2002, MOL CELL, V9, P95, DOI 10.1016/S1097-2765(02)00434-3; Linder S, 2003, TRENDS CELL BIOL, V13, P376, DOI 10.1016/S0962-8924(03)00128-4; Liu YH, 2005, J BIOL CHEM, V280, P8884, DOI 10.1074/jbc.M412200200; Liu YH, 2002, MOL BIOL CELL, V13, P2147, DOI 10.1091/mbc.E02-01-0018; Logsdon JM, 2003, PROTEINS CELL REG, V1, P1; Luo RB, 2007, BIOCHEM J, V402, P439, DOI 10.1042/BJ20061217; Manabe R, 2002, J CELL SCI, V115, P1497; Miura K, 2002, MOL CELL, V9, P109, DOI 10.1016/S1097-2765(02)00428-8; Moss J, 1998, J BIOL CHEM, V273, P21431, DOI 10.1074/jbc.273.34.21431; Oda A, 2003, J BIOL CHEM, V278, P6456, DOI 10.1074/jbc.M210817200; Okabe H, 2004, INT J ONCOL, V24, P43; Onodera Y, 2005, EMBO J, V24, P963, DOI 10.1038/sj.emboj.7600588; Palacios F, 2003, J BIOL CHEM, V278, P17395, DOI 10.1074/jbc.M300998200; PELLIGRIN S, 2007, CELL SCI, V120, P3491; Petit V, 2000, BIOL CELL, V92, P477, DOI 10.1016/S0248-4900(00)01101-1; Radhakrishna H, 1999, J CELL SCI, V112, P855; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Randazzo PA, 2000, P NATL ACAD SCI USA, V97, P4011, DOI 10.1073/pnas.070552297; Randazzo PA, 2004, CELL SIGNAL, V16, P401, DOI 10.1016/j.cellsig.2003.09.012; RANDAZZO PA, 2000, SCI STKE, V59, pRE1; Randazzo PA, 2007, BIOL CELL, V99, P583, DOI 10.1042/BC20070034; Ridley AJ, 2001, J CELL SCI, V114, P2713; Sabe H, 2003, J BIOCHEM, V134, P485, DOI 10.1093/jb/mvg181; Sabe H, 2006, CURR OPIN CELL BIOL, V18, P558, DOI 10.1016/j.ceb.2006.08.002; Spinardi L, 2006, EUR J CELL BIOL, V85, P191, DOI 10.1016/j.ejcb.2005.08.005; Stacey TTI, 2004, J CELL SCI, V117, P6071, DOI 10.1242/jcs.01526; Turner CE, 1999, J CELL BIOL, V145, P851, DOI 10.1083/jcb.145.4.851; Turner CE, 2001, CURR OPIN CELL BIOL, V13, P593, DOI 10.1016/S0955-0674(00)00256-8; Walker JL, 2005, CYTOKINE GROWTH F R, V16, P395, DOI 10.1016/j.cytogfr.2005.03.003; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Wehrle-Haller B, 2002, TRENDS CELL BIOL, V12, P382, DOI 10.1016/S0962-8924(02)02321-8; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; Yamaguchi H, 2006, EUR J CELL BIOL, V85, P213, DOI 10.1016/j.ejcb.2005.10.004; Yoon HY, 2006, J CELL SCI, V119, P4650, DOI 10.1242/jcs.03237; Zhao ZS, 2000, MOL CELL BIOL, V20, P6354, DOI 10.1128/MCB.20.17.6354-6363.2000	62	39	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					14915	14926		10.1074/jbc.M709717200	http://dx.doi.org/10.1074/jbc.M709717200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18400762	hybrid, Green Published			2022-12-25	WOS:000256232000003
J	Walseng, E; Bakke, O; Roche, PA				Walseng, Even; Bakke, Oddmund; Roche, Paul A.			Major histocompatibility complex class II-peptide complexes internalize using a clathrin- and dynamin-independent endocytosis pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; HLA-DR MOLECULES; INVARIANT CHAIN COMPLEXES; DENDRITIC CELL MATURATION; ANTIGEN PRESENTATION; PLASMA-MEMBRANE; SURFACE EXPRESSION; LIPID RAFTS; INTRACELLULAR-TRANSPORT; TARGETING SIGNALS	Major histocompatibility complex (MHC) class II molecules (MHC-II) function by binding antigenic peptides and displaying these peptides on the surface of antigen presenting cells (APCs) for recognition by peptide-MHC-II (pMHC-II)-specific CD4 T cells. It is known that cell surface MHC-II can internalize, exchange antigenic peptides in endosomes, and rapidly recycle back to the plasma membrane; however, the molecular machinery and trafficking pathways utilized by internalizing/recycling MHC-II have not been identified. We now demonstrate that unlike newly synthesized invariant chain-associated MHC-II, mature cell surface pMHC-II complexes internalize following clathrin-, AP-2-, and dynamin-independent endocytosis pathways. Immunofluorescence microscopy of MHC-II expressing HeLa-CIITA cells, human B cells, and human DCs revealed that pMHC enters Arf6(+) Rab35(+) EHD1(+) tubular endosomes following endocytosis. These data contrast the internalization pathways followed by newly synthesized and peptide-loaded MHC-II molecules and demonstrates that cell surface pMHC-II internalize and rapidly recycle from early endocytic compartments in tubular endosomes.	[Walseng, Even; Roche, Paul A.] NCI, Expt Immunol Branch, Natl Inst Hlth, Bethesda, MD 20892 USA; [Walseng, Even; Bakke, Oddmund] Univ Oslo, Dept Mol Biosci, Ctr Immune Regulat, N-0316 Oslo, Norway; [Bakke, Oddmund] Univ Bergen, Gade Inst, N-5021 Bergen, Norway	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Oslo; University of Bergen	Roche, PA (corresponding author), Bldg 10 Rm 4B36, Bethesda, MD 20892 USA.	paul.roche@nih.gov		Bakke, Oddmund/0000-0003-4843-7626; Roche, Paul/0000-0002-8949-9172	Intramural NIH HHS Funding Source: Medline; NATIONAL CANCER INSTITUTE [ZIABC011035, Z01BC009404, ZIABC009404, ZICBC009255, Z01BC009255, Z01BC011035] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ackerman AL, 2003, J IMMUNOL, V170, P4178, DOI 10.4049/jimmunol.170.8.4178; Anderson HA, 2000, NAT IMMUNOL, V1, P156, DOI 10.1038/77842; ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; ANDERSON MS, 1993, J EXP MED, V178, P1959, DOI 10.1084/jem.178.6.1959; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BARNES KA, 1995, J EXP MED, V181, P1715, DOI 10.1084/jem.181.5.1715; Becart S, 2003, J CELL SCI, V116, P2565, DOI 10.1242/jcs.00449; BIKOFF EK, 1993, J EXP MED, V177, P1699, DOI 10.1084/jem.177.6.1699; Boes M, 2002, NATURE, V418, P983, DOI 10.1038/nature01004; Bonifacino JS, 2003, ANNU REV BIOCHEM, V72, P395, DOI 10.1146/annurev.biochem.72.121801.161800; Busch R, 2005, IMMUNOL REV, V207, P242, DOI 10.1111/j.0105-2896.2005.00306.x; Caplan S, 2002, EMBO J, V21, P2557, DOI 10.1093/emboj/21.11.2557; Chow A, 2002, NATURE, V418, P988, DOI 10.1038/nature01006; Delamarre L, 2006, J EXP MED, V203, P2049, DOI 10.1084/jem.20052442; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; Dugast M, 2005, J BIOL CHEM, V280, P19656, DOI 10.1074/jbc.M501357200; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; FRA AM, 1994, J BIOL CHEM, V269, P30745; Gupta SN, 2006, EUR J CELL BIOL, V85, P457, DOI 10.1016/j.ejcb.2006.02.001; Hansen HJ, 1996, BIOCHEM J, V320, P293, DOI 10.1042/bj3200293; Hiltbold EM, 2003, J IMMUNOL, V170, P1329, DOI 10.4049/jimmunol.170.3.1329; Hofmann MW, 1999, J BIOL CHEM, V274, P36153, DOI 10.1074/jbc.274.51.36153; Kirkham M, 2005, J CELL BIOL, V168, P465, DOI 10.1083/jcb.200407078; KLEIJMEER MJ, 1995, J IMMUNOL, V154, P5715; KLEIJMEER MJ, 1994, J INVEST DERMATOL, V103, P516, DOI 10.1111/1523-1747.ep12395666; Kouranti I, 2006, CURR BIOL, V16, P1719, DOI 10.1016/j.cub.2006.07.020; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; Maldonado-Baez L, 2006, TRENDS CELL BIOL, V16, P505, DOI 10.1016/j.tcb.2006.08.001; Matsuki Y, 2007, EMBO J, V26, P846, DOI 10.1038/sj.emboj.7601556; Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216; McCormick PJ, 2005, P NATL ACAD SCI USA, V102, P7910, DOI 10.1073/pnas.0502206102; Muntasell A, 2007, EMBO J, V26, P4263, DOI 10.1038/sj.emboj.7601842; NABAVI N, 1989, J IMMUNOL, V142, P1444; Naslavsky N, 2004, MOL BIOL CELL, V15, P3542, DOI 10.1091/mbc.E04-02-0151; Pathak SS, 2001, J IMMUNOL, V167, P632, DOI 10.4049/jimmunol.167.2.632; PIETERS J, 1993, J CELL SCI, V106, P831; PINET V, 1995, NATURE, V375, P603, DOI 10.1038/375603a0; Pinet VM, 1998, EUR J IMMUNOL, V28, P799, DOI 10.1002/(SICI)1521-4141(199803)28:03<799::AID-IMMU799>3.0.CO;2-5; Poloso NJ, 2006, J IMMUNOL, V177, P5451, DOI 10.4049/jimmunol.177.8.5451; Poloso NJ, 2004, J IMMUNOL, V173, P4539, DOI 10.4049/jimmunol.173.7.4539; REID PA, 1992, IMMUNOLOGY, V77, P539; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROCHE PA, 1992, EMBO J, V11, P2841, DOI 10.1002/j.1460-2075.1992.tb05351.x; Rodionov DG, 1998, J BIOL CHEM, V273, P6005, DOI 10.1074/jbc.273.11.6005; Rovere P, 1998, P NATL ACAD SCI USA, V95, P1067, DOI 10.1073/pnas.95.3.1067; Santambrogio L, 2006, IMMUNITY, V25, P857, DOI 10.1016/j.immuni.2006.11.007; SHACKELFORD DA, 1981, J IMMUNOL, V127, P1403; Shin JS, 2006, NATURE, V444, P115, DOI 10.1038/nature05261; Simonsen A, 1999, J IMMUNOL, V163, P2540; SIMONSEN A, 1993, INT IMMUNOL, V5, P903, DOI 10.1093/intimm/5.8.903; Simonsen A, 1997, J CELL SCI, V110, P597; Sinnathamby G, 2003, J IMMUNOL, V170, P3504, DOI 10.4049/jimmunol.170.7.3504; Stumptner-Cuvelette P, 2001, P NATL ACAD SCI USA, V98, P12144, DOI 10.1073/pnas.221256498; Trombetta ES, 2005, ANNU REV IMMUNOL, V23, P975, DOI 10.1146/annurev.immunol.22.012703.104538; van Niel G, 2006, IMMUNITY, V25, P885, DOI 10.1016/j.immuni.2006.11.001; VIVILLE S, 1993, CELL, V72, P635, DOI 10.1016/0092-8674(93)90081-Z; von Delwig A, 2005, SCAND J IMMUNOL, V62, P243, DOI 10.1111/j.1365-3083.2005.01664.x; von Delwig A, 2003, EUR J IMMUNOL, V33, P2353, DOI 10.1002/eji.200323559; Wang K, 1997, J BIOL CHEM, V272, P17055, DOI 10.1074/jbc.272.27.17055; Zhong GM, 1997, J EXP MED, V185, P429, DOI 10.1084/jem.185.3.429	63	101	102	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14717	14727		10.1074/jbc.M801070200	http://dx.doi.org/10.1074/jbc.M801070200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18378669	hybrid, Green Published			2022-12-25	WOS:000255941400060
J	Yang, CH; Murti, A; Pfeffer, SR; Fan, MY; Du, ZY; Pfeffer, LM				Yang, Chuan He; Murti, Aruna; Pfeffer, Susan R.; Fan, Meiyun; Du, Ziyun; Pfeffer, Lawrence M.			The role of TRAF2 binding to the type I interferon receptor in alternative NF kappa B activation and antiviral response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROMOTES CELL-SURVIVAL; IKK-ALPHA; NF-KAPPA-B2 P100; GENE-EXPRESSION; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL-TRANSDUCTION; LIVER DEGENERATION; IFNAR1 CHAIN; MICE LACKING; PATHWAYS	Type I interferons ( IFNs) play critical roles in the host defense by modulating gene expression through the IFN-dependent activation of STAT and NF kappa B transcription factors. Previous studies established that IFN activates NF kappa B through a classical NF kappa B pathway that results in I kappa B alpha degradation and formation of p50-containing NF kappa B complexes, as well as an alternative pathway that involves NF kappa B-inducing kinase and TRAF2, which results in the formation of p52-containing NF kappa B complexes. In this study, we examined the interaction of TRAF proteins with the type I IFN receptor. We found that TRAF2 was directly coupled to the signal-transducing IFNAR1 subunit of the IFN receptor. By immunoprecipitation, overexpression of epitope-tagged IFNAR1 constructs, and glutathione S-transferase pull-down experiments, we demonstrate that TRAF2 rapidly binds to the IFNAR1 subunit of the IFN receptor upon IFN binding. The membrane proximal half of the IFNAR1 subunit was found to directly bind TRAF2. Moreover, analysis of mouse embryo fibroblasts derived from TRAF2 knock-out mice demonstrated that TRAF2 plays a critical role in the activation of the alternative NF kappa B pathway by IFN, but not the classical NF kappa B pathway, as well as in the antiviral action of IFN. Our results place TRAF2 directly in the signaling pathway transduced through the IFNAR1 subunit of the IFN receptor. These findings provide an important insight into the molecular mechanisms by which IFN generates signals to induce its biological effects.	Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Memphis, TN 38163 USA; Ctr Canc Res, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Pfeffer, LM (corresponding author), Univ Tennessee, Ctr Hlth Sci, Dept Pathol & Lab Med, Rm 530,930 Madison Ave, Memphis, TN 38163 USA.	lpfeffer@utmem.edu			NCI NIH HHS [CA 73753] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA073753] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baeuerle PA, 1998, CELL, V95, P729, DOI 10.1016/S0092-8674(00)81694-3; Basu L, 1998, VIROLOGY, V242, P14, DOI 10.1006/viro.1997.9002; Billie Au PY, 2007, ADV EXP MED BIOL, V597, P32; Bonizzi G, 2004, EMBO J, V23, P4202, DOI 10.1038/sj.emboj.7600391; Chung JY, 2002, J CELL SCI, V115, P679; Claudio E, 2002, NAT IMMUNOL, V3, P958, DOI 10.1038/ni842; COLAMONICI OR, 1994, J BIOL CHEM, V269, P9598; CONSTANTINESCU SN, 1995, P NATL ACAD SCI USA, V92, P10487, DOI 10.1073/pnas.92.23.10487; CONSTANTINESCU SN, 1994, P NATL ACAD SCI USA, V91, P9602, DOI 10.1073/pnas.91.20.9602; Coope HJ, 2002, EMBO J, V21, P5375, DOI 10.1093/emboj/cdf542; Dejardin E, 2002, IMMUNITY, V17, P525, DOI 10.1016/S1074-7613(02)00423-5; EISENKRAFT BL, 1991, CANCER RES, V51, P5881; Grech AP, 2004, IMMUNITY, V21, P629, DOI 10.1016/j.immuni.2004.09.011; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Kumar KGS, 2004, J BIOL CHEM, V279, P46614, DOI 10.1074/jbc.M407082200; Lee TH, 2004, J BIOL CHEM, V279, P33185, DOI 10.1074/jbc.M404206200; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Li QT, 2005, TRENDS IMMUNOL, V26, P318, DOI 10.1016/j.it.2005.04.003; Li ST, 2006, MOL CELL, V24, P497, DOI 10.1016/j.molcel.2006.10.015; Li XX, 1997, MOL CELL BIOL, V17, P2048, DOI 10.1128/MCB.17.4.2048; Luftig M, 2004, P NATL ACAD SCI USA, V101, P141, DOI 10.1073/pnas.2237183100; Meraz MA, 1996, CELL, V84, P431, DOI 10.1016/S0092-8674(00)81288-X; Muller JR, 2003, J BIOL CHEM, V278, P12006, DOI 10.1074/jbc.M210768200; Park YC, 1999, NATURE, V398, P533, DOI 10.1038/19110; Pfeffer LM, 2004, J BIOL CHEM, V279, P31304, DOI 10.1074/jbc.M308975200; Pfeffer LM, 1997, SCIENCE, V276, P1418, DOI 10.1126/science.276.5317.1418; Pomerantz JL, 2002, MOL CELL, V10, P693, DOI 10.1016/S1097-2765(02)00697-4; Runkel L, 1998, J BIOL CHEM, V273, P8003, DOI 10.1074/jbc.273.14.8003; Saha SK, 2006, EMBO J, V25, P3257, DOI 10.1038/sj.emboj.7601220; Saitoh T, 2003, J BIOL CHEM, V278, P36005, DOI 10.1074/jbc.M304266200; Senftleben U, 2001, SCIENCE, V293, P1495, DOI 10.1126/science.1062677; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Tanaka M, 1999, IMMUNITY, V10, P421, DOI 10.1016/S1074-7613(00)80042-4; Wallach D, 1997, FEBS LETT, V410, P96, DOI 10.1016/S0014-5793(97)00553-X; Wei L, 2006, J BIOL CHEM, V281, P11678, DOI 10.1074/jbc.M513286200; Xiao GT, 2004, J BIOL CHEM, V279, P30099, DOI 10.1074/jbc.M401428200; Xiao GT, 2001, MOL CELL, V7, P401, DOI 10.1016/S1097-2765(01)00187-3; Yang CH, 2005, J BIOL CHEM, V280, P25849, DOI 10.1074/jbc.M413721200; Yang CH, 2005, J BIOL CHEM, V280, P31530, DOI 10.1074/jbc.M503120200; Yang CH, 1998, P NATL ACAD SCI USA, V95, P5568, DOI 10.1073/pnas.95.10.5568; Yang CH, 2001, J BIOL CHEM, V276, P13756, DOI 10.1074/jbc.M011006200; Yang CH, 1996, J BIOL CHEM, V271, P8057, DOI 10.1074/jbc.271.14.8057; Yang CH, 2000, P NATL ACAD SCI USA, V97, P13631, DOI 10.1073/pnas.250477397; Yang CH, 2007, J IMMUNOL, V178, P986, DOI 10.4049/jimmunol.178.2.986; Yeh WC, 1997, IMMUNITY, V7, P715, DOI 10.1016/S1074-7613(00)80391-X	49	23	23	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14309	14316		10.1074/jbc.M708895200	http://dx.doi.org/10.1074/jbc.M708895200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18362156	hybrid, Green Published			2022-12-25	WOS:000255941400017
J	Guyader, S; Burch, CL				Guyader, Sebastien; Burch, Christina L.			Optimal Foraging Predicts the Ecology but Not the Evolution of Host Specialization in Bacteriophages	PLOS ONE			English	Article								We explore the ability of optimal foraging theory to explain the observation among marine bacteriophages that host range appears to be negatively correlated with host abundance in the local marine environment. We modified Charnov's classic diet composition model to describe the ecological dynamics of the related generalist and specialist bacteriophages phi X174 and G4, and confirmed that specialist phages are ecologically favored only at high host densities. Our modified model accurately predicted the ecological dynamics of phage populations in laboratory microcosms, but had only limited success predicting evolutionary dynamics. We monitored evolution of attachment rate, the phenotype that governs diet breadth, in phage populations adapting to both low and high host density microcosms. Although generalist phi X174 populations evolved even broader diets at low host density, they did not show a tendency to evolve the predicted specialist foraging strategy at high host density. Similarly, specialist G4 populations were unable to evolve the predicted generalist foraging strategy at low host density. These results demonstrate that optimal foraging models developed to explain the behaviorally determined diets of predators may have only limited success predicting the genetically determined diets of bacteriophage, and that optimal foraging probably plays a smaller role than genetic constraints in the evolution of host specialization in bacteriophages.	[Guyader, Sebastien; Burch, Christina L.] Univ N Carolina, Dept Biol, Chapel Hill, NC 27515 USA	University of North Carolina; University of North Carolina Chapel Hill	Guyader, S (corresponding author), Univ N Carolina, Dept Biol, Chapel Hill, NC 27515 USA.	cburch@bio.unc.edu	Guyader, Sébastien/A-8980-2012	Guyader, Sébastien/0000-0001-5438-8790; Burch, Christina/0000-0001-7830-0124	NSF	NSF(National Science Foundation (NSF))	This work was supported by an NSF grant to CLB.	ABEDON ST, 1989, MICROB ECOL, V18, P79, DOI 10.1007/BF02030117; Abedon ST, 2001, APPL ENVIRON MICROB, V67, P4233, DOI 10.1128/AEM.67.9.4233-4241.2001; BERGH O, 1989, NATURE, V340, P467, DOI 10.1038/340467a0; Boivin G, 2004, OECOLOGIA, V138, P640, DOI 10.1007/s00442-003-1469-z; Bull JJ, 1997, GENETICS, V147, P1497; CHARNOV EL, 1976, AM NAT, V110, P141, DOI 10.1086/283054; Charnov EL, 1973, THESIS U WASHINGTON; Chen F, 2002, APPL ENVIRON MICROB, V68, P2589, DOI 10.1128/AEM.68.5.2589-2594.2002; FUTUYMA DJ, 1988, ANNU REV ECOL SYST, V19, P207, DOI 10.1146/annurev.es.19.110188.001231; GAREN A, 1951, J EXP MED, V94, P177, DOI 10.1084/jem.94.3.177; GARNICK E, 1992, THEOR POPUL BIOL, V42, P62, DOI 10.1016/0040-5809(92)90005-E; Holder KK, 2001, GENETICS, V159, P1393; Jiang SC, 1998, APPL ENVIRON MICROB, V64, P535; Kemp PF, 2004, FEMS MICROBIOL ECOL, V47, P161, DOI 10.1016/S0168-6496(03)00257-5; KREBS JR, 1977, ANIM BEHAV, V25, P30, DOI 10.1016/0003-3472(77)90064-1; LENSKI RE, 1985, AM NAT, V125, P585, DOI 10.1086/284364; McDaniel L, 2002, NATURE, V415, P496, DOI 10.1038/415496a; McPeek MA, 1996, AM NAT, V148, pS124, DOI 10.1086/285906; Middelboe M, 2001, MICROBIAL ECOL, V42, P395, DOI 10.1007/s00248-001-0012-1; MOEBUS K, 1980, HELGOLANDER MEERESUN, V34, P1, DOI 10.1007/BF01983537; MOEBUS K, 1981, HELGOLANDER MEERESUN, V34, P375, DOI 10.1007/BF02074130; MOEBUS K, 1992, HELGOLANDER MEERESUN, V46, P275, DOI 10.1007/BF02367099; MOEBUS K, 1992, HELGOLANDER MEERESUN, V45, P411; PYKE GH, 1977, Q REV BIOL, V52, P137, DOI 10.1086/409852; Ripp S, 1998, MICROBIOL-UK, V144, P2225, DOI 10.1099/00221287-144-8-2225; Stent G., 1963, MOL BIOL BACTERIAL V; STEWART FM, 1984, THEOR POPUL BIOL, V26, P93, DOI 10.1016/0040-5809(84)90026-1; Sullivan MB, 2003, NATURE, V424, P1047, DOI 10.1038/nature01929; SUTTLE CA, 1993, MAR ECOL PROG SER, V92, P99, DOI 10.3354/meps092099; TESSMAN I, 1968, VIROLOGY, V35, P330, DOI 10.1016/0042-6822(68)90275-4; VIA S, 1990, ANNU REV ENTOMOL, V35, P421, DOI 10.1146/annurev.en.35.010190.002225; Wang IN, 1996, EVOL ECOL, V10, P545, DOI 10.1007/BF01237884; Weinbauer MG, 2004, FEMS MICROBIOL REV, V28, P127, DOI 10.1016/j.femsre.2003.08.001; Wells LE, 2006, AQUAT MICROB ECOL, V45, P15, DOI 10.3354/ame045015; WERNER EE, 1981, ECOLOGY, V62, P116, DOI 10.2307/1936675; WERNER EE, 1974, ECOLOGY, V55, P1042, DOI 10.2307/1940354; Wichels A, 1998, APPL ENVIRON MICROB, V64, P4128; WIKNER J, 1993, FEMS MICROBIOL ECOL, V12, P237; Williamson SJ, 2002, APPL ENVIRON MICROB, V68, P4307, DOI 10.1128/AEM.68.9.4307-4314.2002; Wilson WH, 1996, J PHYCOL, V32, P506, DOI 10.1111/j.0022-3646.1996.00506.x; Wolf A, 2004, AQUAT MICROB ECOL, V35, P131, DOI 10.3354/ame035131; Wommack KE, 2000, MICROBIOL MOL BIOL R, V64, P69, DOI 10.1128/MMBR.64.1.69-114.2000; WRIGHT DH, 1983, OIKOS, V41, P496, DOI 10.2307/3544109; Yoshida T, 2006, APPL ENVIRON MICROB, V72, P1239, DOI 10.1128/AEM.72.2.1239-1247.2006	44	27	27	0	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1946	10.1371/journal.pone.0001946	http://dx.doi.org/10.1371/journal.pone.0001946			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414655	Green Published, Green Submitted, gold			2022-12-25	WOS:000260867300004
J	Zychlinska, M; Herrmann, H; Zimber-Strobl, U; Hammerschmidt, W				Zychlinska, Magdalena; Herrmann, Heidrun; Zimber-Strobl, Ursula; Hammerschmidt, Wolfgang			Restricted Expression of Epstein-Barr Virus Latent Genes in Murine B Cells Derived from Embryonic Stem Cells	PLOS ONE			English	Article								Background: Several human malignancies are associated with Epstein-Barr virus (EBV) and more than 95% of the adult human population carries this virus lifelong. EBV efficiently infects human B cells and persists in this cellular compartment latently. EBV-infected B cells become activated and growth transformed, express a characteristic set of viral latent genes, and acquire the status of proliferating lymphoblastoid cell lines in vitro. Because EBV infects only primate cells, it has not been possible to establish a model of infection in immunocompetent rodents. Such a model would be most desirable in order to study EBV's pathogenesis and latency in a suitable and amenable host. Methodology/Principal Findings: We stably introduced recombinant EBV genomes into mouse embryonic stem cells and induced their differentiation to B cells in vitro to develop the desired model. In vitro differentiated murine B cells maintained the EBV genomes but expression of viral genes was restricted to the latent membrane proteins (LMPs). In contrast to human B cells, EBV's nuclear antigens (EBNAs) were not expressed detectably and growth transformed murine B cells did not arise in vitro. Aberrant splicing and premature termination of EBNA mRNAs most likely prevented the expression of EBNA genes required for B-cell transformation. Conclusions/Significance: Our findings indicate that fundamental differences in gene regulation between mouse and man might block the route towards a tractable murine model for EBV.	[Zychlinska, Magdalena; Herrmann, Heidrun; Hammerschmidt, Wolfgang] German Res Ctr Environm & Hlth, Helmholtz Ctr Munich, Dept Gene Vectors, Munich, Germany; [Zimber-Strobl, Ursula] German Res Ctr Env & Hlth, Helmholtz Ctr Munich, Inst Clin Mol Biol & Tumor Genet, Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Hammerschmidt, W (corresponding author), German Res Ctr Environm & Hlth, Helmholtz Ctr Munich, Dept Gene Vectors, Munich, Germany.	hammerschmidt@helmholtz-muenchen.de	Hammerschmidt, Wolfgang/ABG-3921-2021; Zimber-Strobl, Ursula/M-4618-2014	Hammerschmidt, Wolfgang/0000-0002-4659-0427; Zimber-Strobl, Ursula/0000-0002-9765-5251	Deutsche Forschungsgemeinschaft [SPP 1230, SFB 455, SFB-Transregio 36]; Krebshilfe [107277]; National Institutes of Health [CA70723-11]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Krebshilfe(Deutsche Krebshilfe); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This work was supported by institutional intramural grants, grants by the Deutsche Forschungsgemeinschaft (grants SPP 1230, SFB 455, SFB-Transregio 36), Krebshilfe grant 107277, and the National Institutes of Health grant CA70723-11.	Altmann M, 2006, P NATL ACAD SCI USA, V103, P14188, DOI 10.1073/pnas.0605985103; Boiani M, 2005, NAT REV MOL CELL BIO, V6, P872, DOI 10.1038/nrm1744; Bornkamm GW, 2001, PHILOS T R SOC B, V356, P437, DOI 10.1098/rstb.2000.0781; Cho SK, 1999, P NATL ACAD SCI USA, V96, P9797, DOI 10.1073/pnas.96.17.9797; Delecluse HJ, 1998, P NATL ACAD SCI USA, V95, P8245, DOI 10.1073/pnas.95.14.8245; GREGORY CD, 1987, EUR J IMMUNOL, V17, P1199, DOI 10.1002/eji.1830170818; Haan KM, 2001, J VIROL, V75, P3016, DOI 10.1128/JVI.75.6.3016-3020.2001; Hammerschmidt Wolfgang, 2006, V47, P687; HANSSON M, 1983, J EXP MED, V158, P616, DOI 10.1084/jem.158.2.616; Humme S, 2003, P NATL ACAD SCI USA, V100, P10989, DOI 10.1073/pnas.1832776100; KATAMINE S, 1984, NATURE, V309, P369, DOI 10.1038/309369a0; KEMPKES B, 1995, P NATL ACAD SCI USA, V92, P5875, DOI 10.1073/pnas.92.13.5875; KEMPKES B, 1995, J VIROL, V69, P231, DOI 10.1128/JVI.69.1.231-238.1995; Kieff E, 2007, FIELDS VIROLOGY, P2603; KRYSAN PJ, 1993, GENE, V136, P137, DOI 10.1016/0378-1119(93)90457-E; Lemischka IR, 2006, CELL CYCLE, V5, P347, DOI 10.4161/cc.5.4.2424; Li QX, 1997, J VIROL, V71, P4657, DOI 10.1128/JVI.71.6.4657-4662.1997; Maeda A, 2001, J HUMAN VIROL, V4, P227; Mancao C, 2007, BLOOD, V110, P3715, DOI 10.1182/blood-2007-05-090142; Mansilla A, 2005, EMBO REP, V6, P1182, DOI 10.1038/sj.embor.7400539; Marchbank KJ, 2000, J IMMUNOL, V165, P2354, DOI 10.4049/jimmunol.165.5.2354; MILLER G, 1972, P NATL ACAD SCI USA, V69, P383, DOI 10.1073/pnas.69.2.383; Minarovits J, 2006, CURR TOP MICROBIOL, V310, P61; NAKANO T, 1994, SCIENCE, V265, P1098, DOI 10.1126/science.8066449; NEMEROW GR, 1989, CELL, V56, P369, DOI 10.1016/0092-8674(89)90240-7; Olivadoti M, 2007, COMPARATIVE MED, V57, P44; Pulvertaft JV, 1964, LANCET, V1, P238; Ren CP, 2006, STEM CELLS, V24, P1338, DOI 10.1634/stemcells.2005-0338; RICKINSON AB, 2007, FIELDS VIROLOGY, P2655; Schneider F, 2008, PLOS BIOL, V6, P86, DOI 10.1371/journal.pbio.0060008; Shultz LD, 2007, NAT REV IMMUNOL, V7, P118, DOI 10.1038/nri2017; Son GH, 2003, J BIOL CHEM, V278, P18037, DOI 10.1074/jbc.M209850200; Surani MA, 2007, CELL, V128, P747, DOI 10.1016/j.cell.2007.02.010; Thomae AW, 2008, P NATL ACAD SCI USA, V105, P1692, DOI 10.1073/pnas.0707260105; Young LS, 2004, NAT REV CANCER, V4, P757, DOI 10.1038/nrc1452; Zambrowicz BP, 1997, P NATL ACAD SCI USA, V94, P3789, DOI 10.1073/pnas.94.8.3789; 1997, EPSTEIN BARR VIRUS K, V8	37	2	2	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1996	10.1371/journal.pone.0001996	http://dx.doi.org/10.1371/journal.pone.0001996			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414672	Green Published, Green Submitted, gold			2022-12-25	WOS:000260867300021
J	Peters, EJ; Slager, SL; Kraft, JB; Jenkins, GD; Reinalda, MS; McGrath, PJ; Hamilton, SP				Peters, Eric J.; Slager, Susan L.; Kraft, Jeffrey B.; Jenkins, Greg D.; Reinalda, Megan S.; McGrath, Patrick J.; Hamilton, Steven P.			Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample	PLOS ONE			English	Article								Background: We sought to determine whether clinical response or tolerance to the Selective Serotonin Reuptake Inhibitor (SSRI) citalopram is associated with genetic polymorphisms in potentially relevant pharmacokinetic enzymes. Methodology: We used a two-stage case-control study design in which we split the sample of 1,953 subjects from the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial into a discovery (n = 831) and validation set (n = 1,046). Fifteen polymorphisms from five (CYP2D6, ABCB1, CYP2C19, CYP3A4, and CYP3A5) pharmacokinetic genes were genotyped. We examined the associations between these polymorphisms and citalopram response and tolerance. Significant associations were validated in the second stage for those polymorphism found to be statistically significant in the first stage. Conclusions: No genetic polymorphism in the pharmacokinetic genes examined was significantly associated with our response or tolerance phenotypes in both stages. For managing pharmacological treatment with citalopram, routine screening of the common pharmacokinetic DNA variants that we examined appears to be of limited clinical utility.	[Peters, Eric J.; Kraft, Jeffrey B.; Hamilton, Steven P.] Univ Calif San Francisco, Inst Human Genet, Dept Psychiat, San Francisco, CA USA; [Slager, Susan L.; Jenkins, Greg D.; Reinalda, Megan S.] Mayo Clinic, Dept Hlth Sci Res, Rochester, MN USA; [McGrath, Patrick J.] Columbia Univ Coll Physicians & Surgeons, New York State Psychiat Inst, Dept Psychiat, New York, NY USA	University of California System; University of California San Francisco; Mayo Clinic; Columbia University; New York State Psychiatry Institute	Peters, EJ (corresponding author), Univ Calif San Francisco, Inst Human Genet, Dept Psychiat, San Francisco, CA USA.	SteveH@lppi.ucsf.edu	McGrath, Patrick/I-6410-2013	McGrath, Patrick/0000-0001-7217-7321; Hamilton, Steven/0000-0001-8106-6260	National Institute of Mental Health [MH072802, N01MH90003]; HHMI Pre-Doctoral Fellowship; State of New York; National Cancer Institute [CA94919]; NATIONAL CANCER INSTITUTE [K07CA094919] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [N01MH090003, R01MH072802] Funding Source: NIH RePORTER	National Institute of Mental Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); HHMI Pre-Doctoral Fellowship(Howard Hughes Medical Institute); State of New York; National Cancer Institute(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by the National Institute of Mental Health (SPH, MH072802), HHMI Pre-Doctoral Fellowship (EJP), and by the State of New York (PJM), and the National Cancer Institute (SLS, CA94919). STAR*D was funded by NIMH contract N01MH90003 to the University of Texas Southwestern Medical Center at Dallas (A. John Rush, PI). The funding agencies played no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, and in the preparation, review, or approval of the manuscript.	Berg AO, 2007, GENET MED, V9, P819, DOI 10.1097/GIM.0b013e31815bf9a3; Bondolfi G, 1996, PSYCHOPHARMACOLOGY, V128, P421, DOI 10.1007/s002130050152; Bradford LD, 2002, PHARMACOGENOMICS, V3, P229, DOI 10.1517/14622416.3.2.229; Brosen K, 2004, THERAPIE, V59, P5, DOI 10.2515/therapie:2004003; Brosen K, 2001, EUR NEUROPSYCHOPHARM, V11, P275, DOI 10.1016/S0924-977X(01)00101-8; Cascorbi I, 2001, CLIN PHARMACOL THER, V69, P169, DOI 10.1067/mcp.2001.114164; De Leon J, 2006, PSYCHOSOMATICS, V47, P75, DOI 10.1176/appi.psy.47.1.75; Eichelbaum M, 2006, ANNU REV MED, V57, P119, DOI 10.1146/annurev.med.56.082103.104724; Goldstein DB, 2003, NEW ENGL J MED, V348, P553, DOI 10.1056/NEJMe020173; Grasmader K, 2004, EUR J CLIN PHARMACOL, V60, P329, DOI 10.1007/s00228-004-0766-8; Gutierrez MM, 2003, CLIN THER, V25, P1200, DOI 10.1016/S0149-2918(03)80076-0; Herrlin K, 2003, BRIT J CLIN PHARMACO, V56, P415, DOI 10.1046/j.1365-2125.2003.01874.x; Hersberger M, 2000, CLIN CHEM, V46, P1072; Hoffmeyer S, 2000, P NATL ACAD SCI USA, V97, P3473, DOI 10.1073/pnas.050585397; Illmer T, 2002, CANCER RES, V62, P4955; Kirchheiner J, 2004, MOL PSYCHIATR, V9, P442, DOI 10.1038/sj.mp.4001494; Kraft JB, 2007, BIOL PSYCHIAT, V61, P734, DOI 10.1016/j.biopsych.2006.07.017; Lunshof JE, 2006, PHARMACOGENOMICS, V7, P237, DOI 10.2217/14622416.7.2.237; McMahon FJ, 2006, AM J HUM GENET, V78, P804, DOI 10.1086/503820; Mrazek DA, 2006, CNS SPECTRUMS, V11, P1; MRAZEK DA, 2004, CURR PSYCHAIAT, V3, P11; Murphy GM, 2003, AM J PSYCHIAT, V160, P1830, DOI 10.1176/appi.ajp.160.10.1830; QUITKIN FM, 1987, ARCH GEN PSYCHIAT, V44, P259; Rasmussen BB, 2000, THER DRUG MONIT, V22, P143, DOI 10.1097/00007691-200004000-00001; Rau T, 2004, CLIN PHARMACOL THER, V75, P386, DOI 10.1016/j.clpt.2003.12.015; Reis M, 2003, THER DRUG MONIT, V25, P183, DOI 10.1097/00007691-200304000-00007; Rodriguez-Antona C, 2005, BIOCHEM BIOPH RES CO, V338, P299, DOI 10.1016/j.bbrc.2005.09.020; Ross DC, 2002, J CLIN PSYCHOPHARM, V22, P414, DOI 10.1097/00004714-200208000-00013; Rudberg I, 2006, THER DRUG MONIT, V28, P102, DOI 10.1097/01.ftd.0000189899.23931.76; Rush AJ, 2003, BIOL PSYCHIAT, V54, P573, DOI 10.1016/S0006-3223(02)01866-8; Rush AJ, 2004, CONTROL CLIN TRIALS, V25, P119, DOI 10.1016/S0197-2456(03)00112-0; Satagopan JM, 2004, BIOMETRICS, V60, P589, DOI 10.1111/j.0006-341X.2004.00207.x; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Suzuki Y, 2006, NEUROPSYCHOPHARMACOL, V31, P825, DOI 10.1038/sj.npp.1300919; Tang H, 2005, AM J HUM GENET, V76, P268, DOI 10.1086/427888; Tate SK, 2005, P NATL ACAD SCI USA, V102, P5507, DOI 10.1073/pnas.0407346102; Tomalik-Scharte D, 2008, PHARMACOGENOMICS J, V8, P4, DOI 10.1038/sj.tpj.6500462; Trivedi MH, 2006, AM J PSYCHIAT, V163, P28, DOI 10.1176/appi.ajp.163.1.28; Uhr M, 2003, J PSYCHIAT RES, V37, P179, DOI 10.1016/S0022-3956(03)00022-0; Uhr M, 2008, NEURON, V57, P203, DOI 10.1016/j.neuron.2007.11.017; Yin OQP, 2006, J CLIN PSYCHOPHARM, V26, P367, DOI 10.1097/01.jcp.0000227355.54074.14; Yu BN, 2003, DRUG METAB DISPOS, V31, P1255, DOI 10.1124/dmd.31.10.1255	42	131	137	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1872	10.1371/journal.pone.0001872	http://dx.doi.org/10.1371/journal.pone.0001872			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382661	Green Submitted, Green Published, gold			2022-12-25	WOS:000260795400012
J	Hassan, M; Alaoui, A; Feyen, O; Mirmohammadsadegh, A; Essmann, F; Tannapfel, A; Gulbins, E; Schulze-Osthoff, K; Hengge, UR				Hassan, M.; Alaoui, A.; Feyen, O.; Mirmohammadsadegh, A.; Essmann, F.; Tannapfel, A.; Gulbins, E.; Schulze-Osthoff, K.; Hengge, U. R.			The BH3-only member Noxa causes apoptosis in melanoma cells by multiple pathways	ONCOGENE			English	Article						apoptosis; melanoma; Noxa; BH3-only proteins	ENDOPLASMIC-RETICULUM; BCL-2 FAMILY; TRIGGERS APOPTOSIS; SIGNALING PATHWAY; GENE-EXPRESSION; UP-REGULATION; C-JUN; DEATH; ACTIVATION; INDUCTION	The molecular causes for resistance of melanoma to apoptosis are currently only partly understood. In the present study, we examined gene transfer and expression of the proapoptotic BH3-only protein Noxa as an alternative approach to chemotherapy and investigated the molecular mechanisms regulating Noxa-induced apoptosis. Noxa gene transfer caused dysregulation of both mitochondria and, as shown for the first time, also the endoplasmic reticulum, resulting in the accumulation of reactive oxygen species. Interestingly, expression of Noxa not only triggered the classical mitochondrial caspase cascade, but also resulted in the activation of apoptosis signal-regulating kinase1 and its downstream effectors c-Jun N-terminal kinase and p38. The activation of these kinases was abolished by antioxidants. Moreover, inhibition of the kinases by RNA interference or pharmacological inhibitors significantly attenuated Noxa-induced apoptosis. Thus, our data provide evidence for the involvement of multiple pathways in Noxa-induced apoptosis that are triggered at mitochondria and the endoplasmic reticulum, and suggest Noxa gene transfer as a complementary approach to chemotherapy.	[Hassan, M.; Alaoui, A.; Mirmohammadsadegh, A.; Hengge, U. R.] Univ Dusseldorf, Dept Dermatol, D-40225 Dusseldorf, Germany; [Feyen, O.] Univ Dusseldorf, Dept Pediat Immunol & Oncol, D-40225 Dusseldorf, Germany; [Essmann, F.; Schulze-Osthoff, K.] Univ Dusseldorf, Inst Mol Med, D-40225 Dusseldorf, Germany; [Tannapfel, A.] Ruhr Univ Bochum, Dept Pathol, Bochum, Germany; [Gulbins, E.] Univ Duisburg Essen, Dept Mol Biol, Essen, Germany	Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Heinrich Heine University Dusseldorf; Ruhr University Bochum; University of Duisburg Essen	Hengge, UR (corresponding author), Univ Dusseldorf, Dept Dermatol, Moorenstr 5, D-40225 Dusseldorf, Germany.	ulrich.hengge@uni-duesseldorf.de	Essmann, Frank/ABG-7409-2020; Hassan, Mohamed/AHE-7565-2022; Schulze-Osthoff, Klaus/N-9025-2013	Essmann, Frank/0000-0003-4369-8456; Schulze-Osthoff, Klaus/0000-0003-1443-2720				Adler V, 1999, ONCOGENE, V18, P6104, DOI 10.1038/sj.onc.1203128; AKAO Y, 1994, CANCER RES, V54, P2468; Cai JY, 1998, BBA-BIOENERGETICS, V1366, P139, DOI 10.1016/S0005-2728(98)00109-1; Chen L, 2005, MOL CELL, V17, P393, DOI 10.1016/j.molcel.2004.12.030; Chun ACS, 2003, J BIOL CHEM, V278, P37439, DOI 10.1074/jbc.M307185200; Daniel PT, 2003, ESSAYS BIOCHEM, V39, P73, DOI 10.1042/bse0390073; DENIAUD A, 2007, ONCOGENE, V27, P274; Duan WR, 2003, J PATHOL, V199, P221, DOI 10.1002/path.1289; Eferl R, 2003, NAT REV CANCER, V3, P859, DOI 10.1038/nrc1209; Essmann F, 2005, J BIOL CHEM, V280, P37169, DOI 10.1074/jbc.M502052200; Essmann F, 2003, CELL DEATH DIFFER, V10, P1260, DOI 10.1038/sj.cdd.4401301; ESTUS S, 1994, J CELL BIOL, V127, P1717, DOI 10.1083/jcb.127.6.1717; Fernandez Y, 2005, CANCER RES, V65, P6294, DOI 10.1158/0008-5472.CAN-05-0686; Gillissen B, 2003, EMBO J, V22, P3580, DOI 10.1093/emboj/cdg343; Gomez-Bougie P, 2007, CANCER RES, V67, P5418, DOI 10.1158/0008-5472.CAN-06-4322; Hassan M, 2005, CELL MOL LIFE SCI, V62, P2015, DOI 10.1007/s00018-005-5172-6; Hassan M, 2005, VIROLOGY, V333, P324, DOI 10.1016/j.virol.2005.01.008; Hassan M, 2004, CELL SIGNAL, V16, P1375, DOI 10.1016/j.cellsig.2004.04.005; Hassan M, 2007, CELL SIGNAL, V19, P301, DOI 10.1016/j.cellsig.2006.07.002; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Horiuchi D, 2003, NEUROSCI RES, V47, P209, DOI 10.1016/S0168-0102(03)00216-5; Hossini AM, 2006, ONCOGENE, V25, P2160, DOI 10.1038/sj.onc.1209253; Hossini AM, 2003, FEBS LETT, V553, P250, DOI 10.1016/S0014-5793(03)01017-2; Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Labi V, 2006, CELL DEATH DIFFER, V13, P1325, DOI 10.1038/sj.cdd.4401940; Lee AS, 2001, TRENDS BIOCHEM SCI, V26, P504, DOI 10.1016/S0968-0004(01)01908-9; Lindsten T, 2000, MOL CELL, V6, P1389, DOI 10.1016/S1097-2765(00)00136-2; LOS M, 1995, EMBO J, V14, P3731, DOI 10.1002/j.1460-2075.1995.tb00043.x; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Oppermann M, 2005, ONCOGENE, V24, P7369, DOI 10.1038/sj.onc.1208890; Pardo J, 2006, J CELL BIOL, V174, P509, DOI 10.1083/jcb.200604044; Perez-Galan P, 2007, BLOOD, V109, P4441, DOI 10.1182/blood-2006-07-034173; Qin JZ, 2006, CANCER RES, V66, P9636, DOI 10.1158/0008-5472.CAN-06-0747; Qin JZ, 2004, MOL CANCER THER, V3, P895; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Samraj AK, 2007, MOL BIOL CELL, V18, P84, DOI 10.1091/mbc.E06-04-0263; Scorrano L, 2003, SCIENCE, V300, P135, DOI 10.1126/science.1081208; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Soengas MS, 2003, ONCOGENE, V22, P3138, DOI 10.1038/sj.onc.1206454; Soengas MS, 2001, NATURE, V409, P207, DOI 10.1038/35051606; Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Willis SN, 2007, SCIENCE, V315, P856, DOI 10.1126/science.1133289; Zanke BW, 1996, CURR BIOL, V6, P606, DOI 10.1016/S0960-9822(02)00547-X; Zong WX, 2003, J CELL BIOL, V162, P59, DOI 10.1083/jcb.200302084	47	49	51	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4557	4568		10.1038/onc.2008.90	http://dx.doi.org/10.1038/onc.2008.90			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18408751				2022-12-25	WOS:000258077300005
J	Logunov, DY; Scheblyakov, DV; Zubkova, OV; Shmarov, MM; Rakovskaya, IV; Gurova, KV; Tararova, ND; Burdelya, LG; Naroditsky, BS; Ginzburg, AL; Gudkov, AV				Logunov, D. Y.; Scheblyakov, D. V.; Zubkova, O. V.; Shmarov, M. M.; Rakovskaya, I. V.; Gurova, K. V.; Tararova, N. D.; Burdelya, L. G.; Naroditsky, B. S.; Ginzburg, A. L.; Gudkov, A. V.			Mycoplasma infection suppresses p53, activates NF-kappa B and cooperates with oncogenic Ras in rodent fibroblast transformation	ONCOGENE			English	Article						oncogene; tumor suppressor; p21; senescence; transactivation	INSTABILITY; CHECKPOINT; PATHWAY; MICE	Prokaryotes of the genus Mycoplasma are the smallest cellular organisms that persist as obligate extracellular parasites. Although mycoplasma infection is known to be associated with chromosomal instability and can promote malignant transformation, the mechanisms underlying these phenomena remain unknown. Since persistence of many cellular parasites requires suppression of apoptosis in host cells, we tested the effect of mycoplasma infection on the activity of the p53 and nuclear factor (NF)-kappa B pathways, major mechanisms controlling programmed cell death. To monitor the activity of p53 and NF-kappa B in mycoplasma-infected cells, we used a panel of reporter cell lines expressing the bacterial beta-galactosidase gene under the control of p53- or NF-kappa B-responsive promoters. Cells incubated with media conditioned with different species of mycoplasma showed constitutive activation of NF-kappa B and reduced activation of p53, common characteristics of the majority of human tumor cells, with M. arginini having the strongest effect among the species tested. Moreover, mycoplasma infection reduced the expression level and inducibility of an endogenous p53- responsive gene, p21(waf1), and inhibited apoptosis induced by genotoxic stress. Infection with M. arginini made rat and mouse embryo fibroblasts susceptible to transformation with oncogenic H-Ras, whereas mycoplasma-free cells underwent irreversible p53- dependent growth arrest. Mycoplasma infection was as effective as shRNA-mediated knockdown of p53 expression in making rodent fibroblasts permissive to Ras-induced transformation. These observations indicate that mycoplasma infection plays the role of a p53- suppressing oncogene that cooperates with Ras in cell transformation and suggest that the carcinogenic and mutagenic effects of mycoplasma might be due to inhibition of p53 tumor suppressor function by this common human parasite.	[Burdelya, L. G.; Gudkov, A. V.] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA; [Logunov, D. Y.; Scheblyakov, D. V.; Zubkova, O. V.; Shmarov, M. M.; Rakovskaya, I. V.; Naroditsky, B. S.; Ginzburg, A. L.] NF Gamalei Inst Epidemiol & Microbiol, Moscow, Russia; [Gurova, K. V.; Tararova, N. D.; Burdelya, L. G.; Gudkov, A. V.] Cleveland BioLabs Inc, Buffalo, NY USA	Roswell Park Cancer Institute; Russian Academy of Medical Sciences; Gamaleya National Research Center for Epidemiology & Microbiology, RAMS	Gudkov, AV (corresponding author), Roswell Pk Canc Inst, Dept Cell Stress Biol, MRC N 212,Elm & Carlton St, Buffalo, NY 14263 USA.	bsnar1941@yahoo.com; andrei.gudkov@roswellpark.org	Naroditsky, Boris S/F-9135-2012; Shmarov, Maxim M/D-8662-2014; Zubkova, Olga/E-4168-2014	Zubkova, Olga/0000-0001-7893-8419; Gintsburg, Alexander/0000-0003-1769-5059; Shmarov, Maxim/0000-0002-5268-1296; Gudkov, Andrei/0000-0003-2548-0154; Naroditsky, Boris/0000-0001-5522-8238	NCI NIH HHS [CA75179, R01 CA075179, CA098374, CA60730, R01 CA060730, R01 CA098374] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA098374, R01CA075179, R01CA060730] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baek KH, 2003, J LEUKOCYTE BIOL, V73, P850, DOI 10.1189/jlb.1202607; Boiko AD, 2006, GENE DEV, V20, P236, DOI 10.1101/gad.1372606; Bubici C, 2006, HISTOL HISTOPATHOL, V21, P69, DOI 10.14670/HH-21.69; Burgert HG, 2002, CURR TOP MICROBIOL, V269, P273; Chu HW, 2005, J IMMUNOL, V174, P5713, DOI 10.4049/jimmunol.174.9.5713; Cimolai N, 2001, CAN J MICROBIOL, V47, P691, DOI 10.1139/cjm-47-8-691; Correa P, 2007, GASTROENTEROLOGY, V133, P659, DOI 10.1053/j.gastro.2007.06.026; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Donehower LA, 1996, PROG CLIN BIOL RES, V395, P1; Efeyan A, 2007, CELL CYCLE, V6, P1006, DOI 10.4161/cc.6.9.4211; Feng SH, 1999, MOL CELL BIOL, V19, P7995; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Gartel AL, 1999, EXP CELL RES, V246, P280, DOI 10.1006/excr.1998.4319; Gurova KV, 2004, CANCER RES, V64, P1951, DOI 10.1158/0008-5472.CAN-03-1541; Gurova KV, 2005, P NATL ACAD SCI USA, V102, P17448, DOI 10.1073/pnas.0508888102; JIANG S, 2007, J CELL BIOCH; Karin M, 2006, CELL, V124, P823, DOI 10.1016/j.cell.2006.02.016; Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870; Komarova EA, 1997, EMBO J, V16, P1391, DOI 10.1093/emboj/16.6.1391; Lee CH, 2007, BIOFACTORS, V29, P19, DOI 10.1002/biof.5520290103; Lisowska K, 2003, ARCH IMMUNOL THER EX, V51, P367; Lu T, 2004, ONCOGENE, V23, P2138, DOI 10.1038/sj.onc.1207332; Lu T, 2004, P NATL ACAD SCI USA, V101, P7112, DOI 10.1073/pnas.0402048101; Mantovani F, 2001, ONCOGENE, V20, P7874, DOI 10.1038/sj.onc.1204869; McCormick F, 2000, SEMIN CANCER BIOL, V10, P453, DOI 10.1006/scbi.2000.0336; Nelyudova AM, 2004, CELL CYCLE, V3, P1427, DOI 10.4161/cc.3.11.1204; ORIEL JD, 1983, SEX TRANSM DIS, V10, P263; Poyurovsky MV, 2006, GENE DEV, V20, P125, DOI 10.1101/gad.1397506; PROZOROVSKIY SV, 1995, MED MYCOPLASMOLOGY, P187; Razin S, 1998, MICROBIOL MOL BIOL R, V62, P1094, DOI 10.1128/MMBR.62.4.1094-1156.1998; Rottem S, 2003, PHYSIOL REV, V83, P417, DOI 10.1152/physrev.00030.2002; Sablina AA, 1999, CELL BIOL INT, V23, P323, DOI 10.1006/cbir.1999.0362; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Takeda K, 2002, J ENDOTOXIN RES, V8, P459, DOI 10.1179/096805102125001073; TSAI S, 1995, P NATL ACAD SCI USA, V92, P10197, DOI 10.1073/pnas.92.22.10197; Yaswen P, 2007, CELL, V128, P233, DOI 10.1016/j.cell.2007.01.005; Zhang BX, 1997, P SOC EXP BIOL MED, V214, P359	37	54	62	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4521	4531		10.1038/onc.2008.103	http://dx.doi.org/10.1038/onc.2008.103			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18408766	Green Accepted			2022-12-25	WOS:000258077300002
J	Finkin, S; Aylon, Y; Anzi, S; Oren, M; Shaulian, E				Finkin, S.; Aylon, Y.; Anzi, S.; Oren, M.; Shaulian, E.			Fbw7 regulates the activity of endoreduplication mediators and the p53 pathway to prevent drug-induced polyploidy	ONCOGENE			English	Article						polyploidy; Fbw7; p53; spindle inhibitors	F-BOX PROTEIN; PHOSPHORYLATION-DEPENDENT DEGRADATION; CYCLIN-E; AURORA-A; UBIQUITIN LIGASE; CHROMOSOMAL INSTABILITY; ENDOMETRIAL CANCER; TUMOR SUPPRESSION; OVARIAN-CANCER; C-MYC	Fbw7 is a tumor suppressor that is mutated in numerous cancers. It encodes an E3 ubiquitin ligase, whose ability to decrease the levels of pivotal regulators of cell growth and proliferation underlies its tumor suppressor function. Here, we explore the consequences of Fbw7 inactivation on the outcome of chemotherapeutic treatments. When exposed to spindle toxins such as vinblastine and taxol, Fbw7-deficient cells undergo extensive mitotic slippage and endoreduplication, rendering them polyploid. A combined deregulation of several Fbw7 target proteins is required for this phenotype. Specifically, elevated expression of cyclin E and Aurora A in Fbw7-deficient cells is required for drug-induced polyploidy. However, overexpression of either cyclin E or Aurora A alone is not sufficient for drug-induced polyploidy. In addition, we demonstrate that Fbw7 deficiency limits the ability of p53 to respond to mitotic toxins but not to DNA damage. Furthermore, Fbw7 expression regulates the p53-dependent induction of genes such as Lats2 and p21 in response to vinblastine. Hence, we suggest that Fbw7 serves as a master regulator of the mitotic and tetraploidy checkpoints.	[Finkin, S.; Anzi, S.; Shaulian, E.] Hebrew Univ Jerusalem, Sch Med, Dept Expt Med & Canc Res, Jerusalem, Israel; [Aylon, Y.; Oren, M.] Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel	Hebrew University of Jerusalem; Weizmann Institute of Science	Shaulian, E (corresponding author), Hebrew Univ Jerusalem, Sch Med, Dept Expt Med & Canc Res, Jerusalem, Israel.	eshaulian@md.huji.ac.il		Oren, Moshe/0000-0003-4311-7172; Shaulian, Eitan/0000-0001-6242-6849	NATIONAL CANCER INSTITUTE [R37CA040099] Funding Source: NIH RePORTER; NCI NIH HHS [R37 CA40099] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Aylon Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Cassia R, 2003, J PATHOL, V201, P589, DOI 10.1002/path.1474; Chen SS, 2002, EMBO J, V21, P4491, DOI 10.1093/emboj/cdf409; DEFFIE A, 1995, MOL CELL BIOL, V15, P3926; Di Leonardo A, 1997, CANCER RES, V57, P1013; Doxsey S, 2005, TRENDS CELL BIOL, V15, P303, DOI 10.1016/j.tcb.2005.04.008; Fujii Y, 2006, CANCER SCI, V97, P729, DOI 10.1111/j.1349-7006.2006.00239.x; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Gupta-Rossi N, 2001, J BIOL CHEM, V276, P34371, DOI 10.1074/jbc.M101343200; Hubalek MM, 2004, ONCOGENE, V23, P4187, DOI 10.1038/sj.onc.1207560; Katayama H, 2004, NAT GENET, V36, P55, DOI 10.1038/ng1279; Kimura T, 2003, CANCER SCI, V94, P431, DOI 10.1111/j.1349-7006.2003.tb01460.x; Koepp DM, 2001, SCIENCE, V294, P173, DOI 10.1126/science.1065203; Kwak EL, 2005, GYNECOL ONCOL, V98, P124, DOI 10.1016/j.ygyno.2005.04.007; Libertini SJ, 2005, CANCER RES, V65, P10700, DOI 10.1158/0008-5472.CAN-05-1666; Liu Q, 2004, J BIOL CHEM, V279, P18210, DOI 10.1074/jbc.M400678200; Mao JH, 2004, NATURE, V432, P775, DOI 10.1038/nature03155; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Minella AC, 2007, ONCOGENE, V26, P6948, DOI 10.1038/sj.onc.1210518; Minella AC, 2005, CELL CYCLE, V4, P1356, DOI 10.4161/cc.4.10.2058; Minella AC, 2005, P NATL ACAD SCI USA, V102, P9649, DOI 10.1073/pnas.0503677102; Minella AC, 2002, CURR BIOL, V12, P1817, DOI 10.1016/S0960-9822(02)01225-3; Moberg KH, 2004, CURR BIOL, V14, P965, DOI 10.1016/j.cub.2004.04.040; Moberg KH, 2001, NATURE, V413, P311, DOI 10.1038/35095068; Montagnoli A, 1999, GENE DEV, V13, P1181, DOI 10.1101/gad.13.9.1181; Nakayama K, 2004, DEV CELL, V6, P661, DOI 10.1016/S1534-5807(04)00131-5; Nateri AS, 2004, SCIENCE, V303, P1374, DOI 10.1126/science.1092880; Oberg C, 2001, J BIOL CHEM, V276, P35847, DOI 10.1074/jbc.M103992200; Parisi T, 2003, EMBO J, V22, P4794, DOI 10.1093/emboj/cdg482; Rajagopalan H, 2004, NATURE, V428, P77, DOI 10.1038/nature02313; Reed SE, 2004, CANCER RES, V64, P795, DOI 10.1158/0008-5472.CAN-03-3417; Sheaff RJ, 1997, GENE DEV, V11, P1464, DOI 10.1101/gad.11.11.1464; Spruck CH, 2002, CANCER RES, V62, P4535; Spruck CH, 1999, NATURE, V401, P297, DOI 10.1038/45836; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Strohmaier H, 2001, NATURE, V413, P316, DOI 10.1038/35095076; Takahashi T, 2000, JPN J CANCER RES, V91, P1007, DOI 10.1111/j.1349-7006.2000.tb00878.x; Tanaka T, 1999, CANCER RES, V59, P2041; Toji S, 2004, GENES CELLS, V9, P383, DOI 10.1111/j.1356-9597.2004.00732.x; Vlach J, 1997, EMBO J, V16, P5334, DOI 10.1093/emboj/16.17.5334; Waldman T, 1996, NATURE, V381, P713, DOI 10.1038/381713a0; Wei WY, 2005, CANCER CELL, V8, P25, DOI 10.1016/j.ccr.2005.06.005; Welcker M, 2005, J BIOL CHEM, V280, P7654, DOI 10.1074/jbc.M413377200; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wu GY, 2001, MOL CELL BIOL, V21, P7403, DOI 10.1128/MCB.21.21.7403-7415.2001; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217	50	38	40	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4411	4421		10.1038/onc.2008.77	http://dx.doi.org/10.1038/onc.2008.77			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18391985				2022-12-25	WOS:000257881700004
J	Riek, U; Scholz, R; Konarev, P; Rufer, A; Suter, M; Nazabal, A; Ringler, P; Chami, M; Muller, SA; Neumann, D; Forstner, M; Hennig, M; Zenobi, R; Engel, A; Svergun, D; Schlattner, U; Wallimann, T				Riek, Uwe; Scholz, Roland; Konarev, Peter; Rufer, Arne; Suter, Marianne; Nazabal, Alexis; Ringler, Philippe; Chami, Mohamed; Mueller, Shirley A.; Neumann, Dietbert; Forstner, Michael; Hennig, Michael; Zenobi, Renato; Engel, Andreas; Svergun, Dmitri; Schlattner, Uwe; Wallimann, Theo			Structural properties of AMP-activated protein kinase - Dimerization, molecular shape, and changes upon ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATIONS; BIOLOGICAL MACROMOLECULES; SOLUTION SCATTERING; CRYSTAL-STRUCTURE; UPSTREAM KINASE; SKELETAL-MUSCLE; ALPHA-SUBUNITS; GAMMA-SUBUNITS; DOMAIN; BETA	Heterotrimeric AMP-activated protein kinase (AMPK) is crucial for energy homeostasis of eukaryotic cells and organisms. Here we report on (i) bacterial expression of untagged mammalian AMPK isoform combinations, all containing gamma(1), (ii) an automated four-dimensional purification protocol, and (iii) biophysical characterization of AMPK heterotrimers by small angle x-ray scattering in solution (SAXS), transmission and scanning transmission electron microscopy (TEM, STEM), and mass spectrometry (MS). AMPK in solution at low concentrations (< similar to 1 mg/ml) largely consisted of individual heterotrimers in TEM analysis, revealed a precise 1: 1: 1 stoichiometry of the three sub-units in MS, and behaved as an ideal solution in SAXS. At higher AMPK concentrations, SAXS revealed concentration-dependent, reversible dimerization of AMPK heterotrimers and formation of higher oligomers, also confirmed by STEM mass measurements. Single particle reconstruction and averaging by SAXS and TEM, respectively, revealed similar elongated, flat AMPK particles with protrusions and an indentation. In the lower AMPK concentration range, addition of AMP resulted in a significant decrease of the radius of gyration by similar to 5% in SAXS, which indicates a conformational switch in AMPK induced by ligand binding. We propose a structural model involving a ligand-induced relative movement of the kinase domain resulting in a more compact heterotrimer and a conformational change in the kinase domain that protects AMPK from dephosphorylation of Thr(172), thus positively affecting AMPK activity.	[Riek, Uwe; Scholz, Roland; Suter, Marianne; Neumann, Dietbert; Schlattner, Uwe; Wallimann, Theo] Univ Grenoble 1, INSERM, U884, Lab Fundamental & Appl Bioenerget, F-38041 Grenoble 9, France; [Riek, Uwe; Scholz, Roland; Suter, Marianne; Neumann, Dietbert; Schlattner, Uwe; Wallimann, Theo] ETH, Inst Cell Biol, CH-8093 Zurich, Switzerland; [Riek, Uwe; Scholz, Roland; Suter, Marianne; Neumann, Dietbert; Zenobi, Renato; Schlattner, Uwe; Wallimann, Theo] ETH, Dept Analyt Chem, Organ Chem Lab, CH-8093 Zurich, Switzerland; [Konarev, Peter; Svergun, Dmitri] DESY, EMBL, D-22603 Hamburg, Germany; [Konarev, Peter; Svergun, Dmitri] Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia; [Rufer, Arne; Hennig, Michael] F Hoffmann La Roche & Cie AG, CH-4070 Basel, Switzerland; [Ringler, Philippe; Chami, Mohamed; Mueller, Shirley A.; Engel, Andreas] Univ Basel, M E Muller Inst Struct Biol, CH-4056 Basel, Switzerland; [Forstner, Michael] Zurich Financial Serv, CH-8002 Zurich, Switzerland	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; European Molecular Biology Laboratory (EMBL); Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS; Roche Holding; University of Basel	Schlattner, U (corresponding author), Univ Grenoble 1, INSERM, U884, Lab Fundamental & Appl Bioenerget, BP 53, F-38041 Grenoble 9, France.	uwe.schlattner@ujf-grenoble.fr; theo.wallimann@cell.biol.ethz.ch	Scholz, Roland W./AAH-8385-2020; Wallimann, Theo/C-6047-2008; Zenobi, Renato/F-1113-2010; Konarev, Petr V/W-1380-2017; Schlattner, Uwe/D-1267-2009	Scholz, Roland W./0000-0003-2506-3254; Wallimann, Theo/0000-0003-4957-5836; Schlattner, Uwe/0000-0003-1159-5911; Konarev, Petr/0000-0002-5606-1596; Neumann, Dietbert/0000-0002-4316-684X; Svergun, Dmitri/0000-0003-0830-5696				Amodeo GA, 2007, NATURE, V449, P492, DOI 10.1038/nature06127; Andersson Y, 2006, MOL CANCER THER, V5, P1050, DOI 10.1158/1535-7163.MCT-05-0318; Ashrafian H, 2006, LANCET, V367, P618, DOI 10.1016/S0140-6736(06)68228-7; Baron SJ, 2005, CIRC RES, V96, P337, DOI 10.1161/01.RES.0000155723.53868.d2; Bolster DR, 2002, J BIOL CHEM, V277, P23977, DOI 10.1074/jbc.C200171200; BOULIN CJ, 1988, NUCL INSTRUM METH A, V269, P312, DOI 10.1016/0168-9002(88)90895-9; Carattino MD, 2005, J BIOL CHEM, V280, P17608, DOI 10.1074/jbc.M501770200; Carling D, 2005, BIOCHIMIE, V87, P87, DOI 10.1016/j.biochi.2004.10.017; Carretero J, 2007, ONCOGENE, V26, P1616, DOI 10.1038/sj.onc.1209951; Davies JK, 2006, AM J PHYSIOL-HEART C, V290, pH1942, DOI 10.1152/ajpheart.01020.2005; Day P, 2007, ACTA CRYSTALLOGR D, V63, P587, DOI 10.1107/S0907444907009110; Dolinsky VW, 2006, AM J PHYSIOL-HEART C, V291, pH2557, DOI 10.1152/ajpheart.00329.2006; Elbing K, 2006, J BIOL CHEM, V281, P26170, DOI 10.1074/jbc.M603811200; Gollob MH, 2003, BIOCHEM SOC T, V31, P228, DOI 10.1042/bst0310228; Guinier A., 1955, SMALL ANGLE SCATTERI; Hardie DG, 2007, NAT REV MOL CELL BIO, V8, P774, DOI 10.1038/nrm2249; Hardie DG, 2007, ANNU REV PHARMACOL, V47, P185, DOI 10.1146/annurev.pharmtox.47.120505.105304; Hardie DG, 2006, J PHYSIOL-LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944; Hardie DG, 2001, BIOESSAYS, V23, P1112, DOI 10.1002/bies.10009; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hardie DG, 2005, CURR OPIN CELL BIOL, V17, P167, DOI 10.1016/j.ceb.2005.01.006; Hardie DG, 2006, PHYSIOLOGY, V21, P48, DOI 10.1152/physiol.00044.2005; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Horman S, 2006, J BIOL CHEM, V281, P5335, DOI 10.1074/jbc.M506850200; Hudson ER, 2003, CURR BIOL, V13, P861, DOI 10.1016/S0960-9822(03)00249-5; Iseli TJ, 2005, J BIOL CHEM, V280, P13395, DOI 10.1074/jbc.M412993200; Kahn BB, 2005, CELL METAB, V1, P15, DOI 10.1016/j.cmet.2004.12.003; Konarev PV, 2006, J APPL CRYSTALLOGR, V39, P277, DOI 10.1107/S0021889806004699; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Luo ZJ, 2005, TRENDS PHARMACOL SCI, V26, P69, DOI 10.1016/j.tips.2004.12.011; MCGILVERY RW, 1974, J BIOL CHEM, V249, P5845; Minokoshi Y, 2002, NATURE, V415, P339, DOI 10.1038/415339a; Mitchelhill KI, 1997, J BIOL CHEM, V272, P24475, DOI 10.1074/jbc.272.39.24475; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P317, DOI 10.1016/0304-3991(92)90022-C; Muller SA, 2001, MICRON, V32, P21, DOI 10.1016/S0968-4328(00)00022-6; Nayak V, 2006, STRUCTURE, V14, P477, DOI 10.1016/j.str.2005.12.008; Nazabal A, 2006, ANAL CHEM, V78, P3562, DOI 10.1021/ac0519108; Neumann D, 2003, PROTEIN EXPRES PURIF, V30, P230, DOI 10.1016/S1046-5928(03)00126-8; Neumann D, 2003, BIOCHEM SOC T, V31, P169, DOI 10.1042/bst0310169; Neumann D., 2007, MOL SYSTEMS BIOENERG, P303; Neumann D, 2007, MOL BIOTECHNOL, V36, P220, DOI 10.1007/s12033-007-0029-x; Pang T, 2007, J BIOL CHEM, V282, P495, DOI 10.1074/jbc.M605790200; Polekhina G, 2005, ACTA CRYSTALLOGR F, V61, P39, DOI 10.1107/S1744309104025059; Polekhina G, 2003, CURR BIOL, V13, P867, DOI 10.1016/S0960-9822(03)00292-6; Porod G., 1982, SMALL ANGLE XRAY SCA, P17, DOI DOI 10.1002/ACTP.1985.010360520; RIEK U, 2008, BIOTECHNIQU IN PRESS; Roessle MW, 2007, J APPL CRYSTALLOGR, V40, pS190, DOI 10.1107/S0021889806055506; Ruderman NB, 2003, ENDOCRINOLOGY, V144, P5166, DOI 10.1210/en.2003-0849; Rudolph MJ, 2007, STRUCTURE, V15, P65, DOI 10.1016/j.str.2006.11.014; Rudolph MJ, 2005, BIOCHEM BIOPH RES CO, V337, P1224, DOI 10.1016/j.bbrc.2005.09.181; Sanders MJ, 2007, J BIOL CHEM, V282, P32539, DOI 10.1074/jbc.M706543200; Sanders MJ, 2007, BIOCHEM J, V403, P139, DOI 10.1042/BJ20061520; Schlattner U, 2004, ENCY BIOL CHEM, P646; Scott JW, 2004, J CLIN INVEST, V113, P274, DOI 10.1172/JCI200419874; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Suter M, 2006, J BIOL CHEM, V281, P32207, DOI 10.1074/jbc.M606357200; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Taylor EB, 2006, AM J PHYSIOL-ENDOC M, V290, pE661, DOI 10.1152/ajpendo.00313.2005; Taylor EB, 2005, AM J PHYSIOL-ENDOC M, V288, pE1055, DOI 10.1152/ajpendo.00516.2004; Townley R, 2007, SCIENCE, V315, P1726, DOI 10.1126/science.1137503; Treebak JT, 2006, DIABETES, V55, P2051, DOI 10.2337/db06-0175; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; Warden SM, 2001, BIOCHEM J, V354, P275, DOI 10.1042/0264-6021:3540275; Wong KA, 2006, J BIOL CHEM, V281, P36434, DOI 10.1074/jbc.M607410200; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Xiao B, 2007, NATURE, V449, P496, DOI 10.1038/nature06161; Xie ZL, 2006, J BIOL CHEM, V281, P6366, DOI 10.1074/jbc.M511178200; Zou MH, 2004, J BIOL CHEM, V279, P43940, DOI 10.1074/jbc.M404421200	73	73	75	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18331	18343		10.1074/jbc.M708379200	http://dx.doi.org/10.1074/jbc.M708379200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18372250	Green Published, hybrid			2022-12-25	WOS:000256949200061
J	Sunesson, L; Hellman, U; Larsson, C				Sunesson, Lovisa; Hellman, Ulf; Larsson, Christer			Protein kinase C epsilon binds peripherin and induces its aggregation, which is accompanied by apoptosis of neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMYOTROPHIC-LATERAL-SCLEROSIS; MOTOR-NEURON DISEASE; NERVE GROWTH-FACTOR; INTERMEDIATE-FILAMENT PROTEIN; SUPEROXIDE-DISMUTASE GENE; NEURITE OUTGROWTH; PKC-EPSILON; REGULATORY DOMAIN; MOUSE MODEL; EXPRESSION	A hallmark of the afflicted nervous tissue in amyotrophic lateral sclerosis is the presence of protein aggregates, which to a large extent contain the intermediate filament protein peripherin. Here we show that activation of protein kinase C (PKC) or overexpression of PKC epsilon induces the aggregation of peripherin in cultured neuroblastoma cells with elevated amounts of peripherin. The formation of aggregates was coupled to an increased apoptosis, suggesting a functional link between these events. Both induction of aggregates and apoptosis were suppressed in cells that had been transfected with small interfering RNAs targeting PKC epsilon. PKC epsilon and peripherin associate as shown by co-immunoprecipitation, and the interaction is dependent on and mediated by the C1b domain of PKC epsilon. The interaction was specific for PKC epsilon since corresponding structures from other isoforms did not co-precipitate peripherin, with the exception for PKC eta and-theta, which pulled down minute amounts. PKC epsilon interacts with vimentin through the same structures but does not induce its aggregation. When the PKC epsilon C1b domain is expressed in neuroblastoma cells together with peripherin, both phorbol ester-induced peripherin aggregation and apoptosis are abolished, supporting a model in which PKC epsilon through its interaction with peripherin facilitates its aggregation and subsequent cell death. These events may be prevented by expressing molecules that bind peripherin at the same site as PKC epsilon.	[Sunesson, Lovisa; Larsson, Christer] Lund Univ, Malmo Univ Hosp, Ctr Mol Pathol, UMAS, SE-20502 Malmo, Sweden; [Hellman, Ulf] Uppsala Univ, Ludwig Inst Canc Res, SE-75124 Uppsala, Sweden	Lund University; Skane University Hospital; Ludwig Institute for Cancer Research; Uppsala University	Larsson, C (corresponding author), Lund Univ, Malmo Univ Hosp, Ctr Mol Pathol, UMAS, Entrance 78,3rd Floor, SE-20502 Malmo, Sweden.	Christer.Larsson@med.lu.se						ALETTA JM, 1989, J BIOL CHEM, V264, P4619; Beaulieu JM, 1999, J CELL BIOL, V147, P531, DOI 10.1083/jcb.147.3.531; Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; Colon-Gonzalez F, 2006, BBA-MOL CELL BIOL L, V1761, P827, DOI 10.1016/j.bbalip.2006.05.001; CORBO M, 1992, J NEUROPATH EXP NEUR, V51, P531, DOI 10.1097/00005072-199209000-00008; ESCURAT M, 1990, J NEUROSCI, V10, P764; Fagerstrom S, 1996, CELL GROWTH DIFFER, V7, P775; Gervasi C, 2000, J COMP NEUROL, V423, P512; Gros-Louis F, 2004, J BIOL CHEM, V279, P45951, DOI 10.1074/jbc.M408139200; Gros-Louis F, 2006, BBA-MOL BASIS DIS, V1762, P956, DOI 10.1016/j.bbadis.2006.01.004; Gruzman A, 2007, P NATL ACAD SCI USA, V104, P12524, DOI 10.1073/pnas.0705044104; Guegan C, 2003, J CLIN INVEST, V111, P153, DOI 10.1172/JCI200317610; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hardy J, 2002, SCIENCE, V297, P353, DOI 10.1126/science.1072994; He CZ, 2004, J NEUROL SCI, V217, P47, DOI 10.1016/j.jns.2003.08.016; Hellman U, 2002, MASS SPECTROMETRY AND HYPHENATED TECHNIQUES IN NEUROPEPTIDE RESEARCH, P259; HUNDLE B, 1995, J BIOL CHEM, V270, P30134; Ivaska J, 2005, EMBO J, V24, P3834, DOI 10.1038/sj.emboj.7600847; Jackson M, 1997, ANN NEUROL, V42, P803, DOI 10.1002/ana.410420518; Julien JP, 2000, J NEUROL SCI, V180, P7, DOI 10.1016/S0022-510X(00)00422-6; Lariviere RC, 2003, NEUROBIOL DIS, V13, P158, DOI 10.1016/S0969-9961(03)00036-6; Leung CL, 2004, BRAIN PATHOL, V14, P290, DOI 10.1111/j.1750-3639.2004.tb00066.x; Ling M, 2005, J BIOL CHEM, V280, P17910, DOI 10.1074/jbc.M412036200; Ling M, 2004, EXP CELL RES, V292, P135, DOI 10.1016/j.yexcr.2003.08.013; Ling M, 2007, J MOL BIOL, V368, P951, DOI 10.1016/j.jmb.2007.02.073; Mellor H, 1998, BIOCHEM J, V332, P281, DOI 10.1042/bj3320281; MIGHELI A, 1993, LAB INVEST, V68, P185; Millecamps S, 2006, J NEUROCHEM, V98, P926, DOI 10.1111/j.1471-4159.2006.03932.x; Nguyen TA, 2004, J BIOL CHEM, V279, P52714, DOI 10.1074/jbc.M403040200; OBLINGER MM, 1989, J NEUROSCI, V9, P3766; PARYSEK LM, 1988, J NEUROSCI, V8, P555; PORTIER MM, 1984, DEV NEUROSCI-BASEL, V6, P335, DOI 10.1159/000112360; RIPPS ME, 1995, P NATL ACAD SCI USA, V92, P689, DOI 10.1073/pnas.92.3.689; Robertson J, 2001, J CELL BIOL, V155, P217, DOI 10.1083/jcb.200107058; Robertson J, 2003, J CELL BIOL, V160, P939, DOI 10.1083/jcb.200205027; Robertson J, 2002, BIOCHIMIE, V84, P1151, DOI 10.1016/S0300-9084(02)00025-1; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Schultz A, 2003, CELL DEATH DIFFER, V10, P662, DOI 10.1038/sj.cdd.4401235; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Strong MJ, 2005, J NEUROPATH EXP NEUR, V64, P649, DOI 10.1097/01.jnen.0000173889.71434.ea; Sundberg C, 2004, J BIOL CHEM, V279, P51601, DOI 10.1074/jbc.M403753200; TROY CM, 1990, BRAIN RES, V529, P232, DOI 10.1016/0006-8993(90)90832-V; TROY CM, 1990, NEUROSCIENCE, V36, P217, DOI 10.1016/0306-4522(90)90364-A; Walton JD, 2004, NEOPLASIA, V6, P838, DOI 10.1593/neo.04310; Wang HB, 2002, J BIOL CHEM, V277, P4541, DOI 10.1074/jbc.M107150200; WONG PC, 1995, NEURON, V14, P1105, DOI 10.1016/0896-6273(95)90259-7; Xiao SX, 2006, BBA-MOL BASIS DIS, V1762, P1001, DOI 10.1016/j.bbadis.2006.09.003; Yao LB, 1997, J BIOL CHEM, V272, P13033, DOI 10.1074/jbc.272.20.13033; Zeidman R, 1999, INT J CANCER, V81, P494, DOI 10.1002/(SICI)1097-0215(19990505)81:3<494::AID-IJC26>3.0.CO;2-L; Zeidman R, 1999, J CELL BIOL, V145, P713, DOI 10.1083/jcb.145.4.713	50	14	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16653	16664		10.1074/jbc.M710436200	http://dx.doi.org/10.1074/jbc.M710436200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18408015	hybrid			2022-12-25	WOS:000256497100042
J	Crublet, E; Andrieu, JP; Vives, RR; Lortat-Jacob, H				Crublet, Elodie; Andrieu, Jean-Pierre; Vives, Romain R.; Lortat-Jacob, Hugues			The HIV-1 envelope glycoprotein gp120 features four heparan sulfate binding domains, including the co-receptor binding site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; SEXUAL TRANSMISSION; ANTIBODY-BINDING; V3 REGION; CELLS; CD4; PROTEOGLYCANS; RECEPTOR; ATTACHMENT; MECHANISM	It is well established that the human immunodeficiency virus-1 envelope glycoprotein surface unit, gp120, binds to cell-associated heparan sulfate (HS). Virus infectivity is increased by such interaction, and a variety of soluble polyanions efficiently neutralize immunodeficiency virus-1 in vitro. This interaction has been mainly attributed to the gp120 V3 loop. However, although evidence suggested that this particular domain does not fully recapitulate the binding activity of the protein, the ability of HS to bind to other regions of gp120 has not been completely addressed, and the exact localizations of the polysaccharide binding sites are not known. To investigate in more detail the structural basis of the HS-gp120 interaction, we used a mapping strategy and compared the heparin binding activity of wild type and mutant gp120 using surface plasmon resonance-based binding assays. Four heparin binding domains (1-4) were identified in the V2 and V3 loops, in the C-terminal domain, and within the CD4-induced bridging sheet. Interestingly, three of them were found in domains of the protein that undergo structural changes upon binding to CD4 and are involved in co-receptor recognition. In particular, Arg(419), Lys(421), and Lys(432), which directly interact with the co-receptor, are targeted by heparin. This study provides a complete account of the gp120 residues involved in heparin binding and identified several binding surfaces that constitute potential target for viral entry inhibition.	[Crublet, Elodie; Andrieu, Jean-Pierre; Vives, Romain R.; Lortat-Jacob, Hugues] Univ Grenoble 1, CNRS, Inst Biol Struct, Commissariat Energie Atom,UMR 5075, F-38027 Grenoble, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA	Lortat-Jacob, H (corresponding author), Univ Grenoble 1, CNRS, Inst Biol Struct, Commissariat Energie Atom,UMR 5075, 41 Rue Horowitz, F-38027 Grenoble, France.	Hugues.Lortat-Jacob@ibs.fr	Vives, Romain/I-9372-2012					Argyris EG, 2003, J VIROL, V77, P12140, DOI 10.1128/JVI.77.22.12140-12151.2003; Banks WA, 2004, NEUROSCIENCE, V128, P143, DOI 10.1016/j.neuroscience.2004.06.021; Barbouche R, 2005, MOL PHARMACOL, V67, P1111, DOI 10.1124/mol.104.008276; Basmaciogullari S, 2002, J VIROL, V76, P10791, DOI 10.1128/JVI.76.21.10791-10800.2002; BATINIC D, 1992, J BIOL CHEM, V267, P6664; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Bernfield M, 1999, ANNU REV BIOCHEM, V68, P729, DOI 10.1146/annurev.biochem.68.1.729; Bobardt MD, 2004, J VIROL, V78, P6567, DOI 10.1128/JVI.78.12.6567-6584.2004; Bobardt MD, 2003, IMMUNITY, V18, P27, DOI 10.1016/S1074-7613(02)00504-6; Bomsel M, 2003, NAT REV MOL CELL BIO, V4, P57, DOI 10.1038/nrm1005; BOSCH V, 1990, J VIROL, V64, P2337, DOI 10.1128/JVI.64.5.2337-2344.1990; Bugatti A, 2007, ANTIMICROB AGENTS CH, V51, P2337, DOI 10.1128/AAC.01362-06; CALLAHAN LN, 1991, J VIROL, V65, P1543, DOI 10.1128/JVI.65.3.1543-1550.1991; Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327; Cormier EG, 2002, J VIROL, V76, P8953, DOI 10.1128/JVI.76.17.8953-8957.2002; de Parseval A, 2005, J BIOL CHEM, V280, P39493, DOI 10.1074/jbc.M504233200; Este JA, 1997, MOL PHARMACOL, V52, P98, DOI 10.1124/mol.52.1.98; Harrop HA, 1998, GLYCOBIOLOGY, V8, P131, DOI 10.1093/glycob/8.2.131; Hartley O, 2005, AIDS RES HUM RETROV, V21, P171, DOI 10.1089/aid.2005.21.171; Hollister J, 2002, BIOCHEMISTRY-US, V41, P15093, DOI 10.1021/bi026455d; Huang CC, 2005, SCIENCE, V310, P1025, DOI 10.1126/science.1118398; Huang CC, 2007, SCIENCE, V317, P1930, DOI 10.1126/science.1145373; KING LA, 1992, BACULOVIRUS EXPRESSI, P111; Klimstra WB, 1999, J VIROL, V73, P6299, DOI 10.1128/JVI.73.8.6299-6306.1999; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; Laguri C, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001110; LI Y, 1994, VIROLOGY, V204, P266, DOI 10.1006/viro.1994.1531; Liu J, 2002, MED RES REV, V22, P1, DOI 10.1002/med.1026; Losada SA, 2002, NEUROBIOL DIS, V11, P469, DOI 10.1006/nbdi.2002.0566; Luscher-Mattli M, 2000, ANTIVIR CHEM CHEMOTH, V11, P249, DOI 10.1177/095632020001100401; Mondor I, 1998, J VIROL, V72, P3623, DOI 10.1128/JVI.72.5.3623-3634.1998; Moulard M, 2000, BBA-REV BIOMEMBRANES, V1469, P121, DOI 10.1016/S0304-4157(00)00014-9; Moulard M, 2000, J VIROL, V74, P1948, DOI 10.1128/JVI.74.4.1948-1960.2000; Murphy KJ, 2004, J BIOL CHEM, V279, P27239, DOI 10.1074/jbc.M401774200; OKADA T, 1995, BIOCHEM BIOPH RES CO, V209, P850, DOI 10.1006/bbrc.1995.1577; Olinger GG, 2000, J VIROL, V74, P8550, DOI 10.1128/JVI.74.18.8550-8557.2000; Pasquato A, 2007, FEBS LETT, V581, P5807, DOI 10.1016/j.febslet.2007.11.050; Poignard P, 2001, ANNU REV IMMUNOL, V19, P253, DOI 10.1146/annurev.immunol.19.1.253; RIDER CC, 1994, BIOCHEMISTRY-US, V33, P6974, DOI 10.1021/bi00188a029; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; RODERIQUEZ G, 1995, J VIROL, V69, P2233, DOI 10.1128/JVI.69.4.2233-2239.1995; Saidi H, 2007, VIROLOGY, V358, P55, DOI 10.1016/j.virol.2006.07.029; Saphire ACS, 2001, J VIROL, V75, P9187, DOI 10.1128/JVI.75.19.9187-9200.2001; Spillmann D, 2001, BIOCHIMIE, V83, P811, DOI 10.1016/S0300-9084(01)01290-1; THALI M, 1993, J VIROL, V67, P3978, DOI 10.1128/JVI.67.7.3978-3988.1993; Vives RR, 2006, CURR GENE THER, V6, P35, DOI 10.2174/156652306775515565; Vives RR, 2005, J BIOL CHEM, V280, P21353, DOI 10.1074/jbc.M500911200; Vives RR, 2004, J BIOL CHEM, V279, P54327, DOI 10.1074/jbc.M409760200; Vives RR, 2002, BIOCHEMISTRY-US, V41, P14779, DOI 10.1021/bi026459i; Whitelock JM, 2005, CHEM REV, V105, P2745, DOI 10.1021/cr010213m; Wu H, 1996, P NATL ACAD SCI USA, V93, P15030, DOI 10.1073/pnas.93.26.15030; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wu ZW, 2003, J INFECT DIS, V188, P1473, DOI 10.1086/379248; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884; Zhang WT, 2001, BIOCHEMISTRY-US, V40, P1662, DOI 10.1021/bi001397m	55	66	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15193	15200		10.1074/jbc.M800066200	http://dx.doi.org/10.1074/jbc.M800066200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18378683	Green Published, hybrid			2022-12-25	WOS:000256232000036
J	Shishova, EY; Yu, FL; Miller, DJ; Faraldos, JA; Zhao, YX; Coates, RM; Allemann, RK; Cane, DE; Christianson, DW				Shishova, Ekaterina Y.; Yu, Fanglei; Miller, David J.; Faraldos, Juan A.; Zhao, Yuxin; Coates, Robert M.; Allemann, Rudolf K.; Cane, David E.; Christianson, David W.			X-ray crystallographic studies of substrate binding to aristolochene synthase suggest a metal ion binding sequence for catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRICHODIENE SYNTHASE; TERPENOID CYCLASE; ISOPRENOID BIOSYNTHESIS; ASPERGILLUS-TERREUS; CYCLIZATION; DIPHOSPHATE; DIVERSITY; PYROPHOSPHATES; CONVERSION; EXPRESSION	The universal sesquiterpene precursor, farnesyl diphosphate (FPP), is cyclized in an Mg2+-dependent reaction catalyzed by the tetrameric aristolochene synthase from Aspergillus terreus to form the bicyclic hydrocarbon aristolochene and a pyrophosphate anion (PPi) coproduct. The 2.1-angstrom resolution crystal structure determined from crystals soaked with FPP reveals the binding of intact FPP to monomers A-C, and the binding of PPi and Mg-B(2+) to monomer D. The 1.89-angstrom resolution structure of the complex with 2-fluorofarnesyl diphosphate (2F-FPP) reveals 2F-FPP binding to all subunits of the tetramer, with Mg-B(2+) accompanying the binding of this analogue only in monomer D. All monomers adopt open active site conformations in these complexes, but slight structural changes in monomers C and D of each complex reflect the very initial stages of a conformational transition to the closed state. Finally, the 2.4-angstrom resolution structure of the complex with 12,13-difluorofarnesyl diphosphate (DF-FPP) reveals the binding of intact DF-FPP to monomers A-C in the open conformation and the binding of P(P)i, Mg-B(2+), and Mg-C(2+) to monomer D, in a predominantly dosed conformation. Taken together, these structures provide 12 independent "snapshots" of substrate or product complexes that suggest a possible sequence for metal ion binding and conformational changes required for catalysis.	[Shishova, Ekaterina Y.; Christianson, David W.] Univ Penn, Dept Chem, Roy & Diana Vagelos Labs, Philadelphia, PA 19104 USA; [Yu, Fanglei; Miller, David J.; Allemann, Rudolf K.] Cardiff Univ, Sch Chem, Cardiff CF10 3AT, Wales; [Faraldos, Juan A.; Zhao, Yuxin; Coates, Robert M.] Univ Illinois, Dept Chem, Urbana, IL 61801 USA; [Cane, David E.] Brown Univ, Dept Chem, Providence, RI 02912 USA	University of Pennsylvania; Cardiff University; University of Illinois System; University of Illinois Urbana-Champaign; Brown University	Christianson, DW (corresponding author), Univ Penn, Dept Chem, Roy & Diana Vagelos Labs 2001, 231 S 34th St, Philadelphia, PA 19104 USA.	chris@sas.upenn.edu	Faraldos, Juan/A-7311-2014; Miller, David/A-6377-2009	Faraldos, Juan/0000-0003-0738-0838; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030301, R01GM030301, R01GM056838] Funding Source: NIH RePORTER; EPSRC [EP/D069580/1] Funding Source: UKRI; NIGMS NIH HHS [GM 13956, R01 GM030301, GM 56838, GM 30301] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EPSRC(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Calvert MJ, 2002, J AM CHEM SOC, V124, P11636, DOI 10.1021/ja020762p; CANE DE, 1990, CHEM REV, V90, P1089, DOI 10.1021/cr00105a002; CANE DE, 1985, ACCOUNTS CHEM RES, V18, P220, DOI 10.1021/ar00115a005; Cane DE, 2000, ARCH BIOCHEM BIOPHYS, V376, P354, DOI 10.1006/abbi.2000.1734; Christianson DW, 2006, CHEM REV, V106, P3412, DOI 10.1021/cr050286w; Felicetti B, 2004, J AM CHEM SOC, V126, P7212, DOI 10.1021/ja0499593; GOODMAN DS, 1960, J LIPID RES, V1, P286; Hyatt DC, 2007, P NATL ACAD SCI USA, V104, P5360, DOI 10.1073/pnas.0700915104; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LESBURG CA, 1988, CURR OPIN STRUC BIOL, V8, P695; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27; Miller DJ, 2007, CHEMBIOCHEM, V8, P1819, DOI 10.1002/cbic.200700219; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pichersky E, 2006, SCIENCE, V311, P808, DOI 10.1126/science.1118510; PROCTOR RH, 1993, J BIOL CHEM, V268, P4543; Rynkiewicz MJ, 2002, BIOCHEMISTRY-US, V41, P1732, DOI 10.1021/bi011960g; Rynkiewicz MJ, 2001, P NATL ACAD SCI USA, V98, P13543, DOI 10.1073/pnas.231313098; Shishova EY, 2007, BIOCHEMISTRY-US, V46, P1941, DOI 10.1021/bi0622524; Starks CM, 1997, SCIENCE, V277, P1815, DOI 10.1126/science.277.5333.1815; TIDD BK, 1971, J CHEM SOC B, P1168, DOI 10.1039/j29710001168; Vedula LS, 2007, ARCH BIOCHEM BIOPHYS, V466, P260, DOI 10.1016/j.abb.2007.06.016; Wendt KU, 1998, STRUCTURE, V6, P127, DOI 10.1016/S0969-2126(98)00015-X; Whittington DA, 2002, P NATL ACAD SCI USA, V99, P15375, DOI 10.1073/pnas.232591099; Yu FL, 2007, CHEM COMMUN, P4155, DOI 10.1039/b709562g	27	62	66	1	19	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15431	15439		10.1074/jbc.M800659200	http://dx.doi.org/10.1074/jbc.M800659200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18385128	hybrid, Green Published			2022-12-25	WOS:000256232000061
J	Gopalakrishna, R; Gundimeda, U; Schiffman, JE; Mcneill, TH				Gopalakrishna, Rayudu; Gundimeda, Usha; Schiffman, Jason Eric; Mcneill, Thomas H.			A direct redox regulation of protein kinase C isoenzymes mediates oxidant-induced neuritogenesis in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NERVE GROWTH-FACTOR; INDUCED NEURONAL DIFFERENTIATION; PHORBOL ESTER BINDING; SPINAL-CORD-INJURY; NEURITE OUTGROWTH; N-ACETYLCYSTEINE; RAT-BRAIN; TYROSINE PHOSPHORYLATION; OXIDATIVE MODIFICATION; POSSIBLE INVOLVEMENT	In this study, we have used the PC12 cell model to elucidate the mechanisms by which sublethal doses of oxidants induce neuritogenesis. The xanthine/xanthine oxidase (X/XO) system was used for the steady state generation of superoxide, and CoCl2 was used as a representative transition metal redox catalyst. Upon treatment of purified protein kinase C (PKC) with these oxidants, there was an increase in its cofactor-independent activation. Redox-active cobalt competed with the redoxinert zinc present in the zinc-thiolates of the PKC regulatory domain and induced the oxidation of these cysteine-rich regions. Both CoCl2 and X/XO induced neurite outgrowth in PC12 cells, as determined by an overexpression of neuronal marker genes. Furthermore, these oxidants induced a translocation of PKC from cytosol to membrane and subsequent conversion of PKC to a cofactor-independent form. Isoenzyme-specific PKC inhibitors demonstrated that PKC epsilon plays a crucial role in neuritogenesis. Moreover, oxidant-induced neurite outgrowth was increased with a conditional overexpression of PKC epsilon and decreased with its knock-out by small interfering RNA. Parallel with PKC activation, an increase in phosphorylation of the growth-associated neuronal protein GAP-43 at Ser(41) was observed. Additionally, there was a sustained activation of extracellular signal-regulated kinases 1 and 2, which was correlated with activating phosphorylation (Ser(133)) of cAMP-responsive element-binding protein. All of these signaling events that are causally linked to neuritogenesis were blocked by antioxidant N-acetylcysteine (both L and D-forms) and by a variety of PKC-specific inhibitors. Taken together, these results strongly suggest that sublethal doses of oxidants induce neuritogenesis via a direct redox activation of PKC epsilon.	[Gopalakrishna, Rayudu; Gundimeda, Usha; Schiffman, Jason Eric; Mcneill, Thomas H.] Keck Sch Med, Dept Cell & Neurobiol, Los Angeles, CA 90089 USA; [Mcneill, Thomas H.] Keck Sch Med, Dept Neurol, Los Angeles, CA 90089 USA; [Mcneill, Thomas H.] Univ So Calif, Grad Program Neurosci, Los Angeles, CA 90089 USA	University of Southern California	Gopalakrishna, R (corresponding author), Keck Sch Med, Dept Cell & Neurobiol, BMT 403,1333 San Pablo St, Los Angeles, CA 90089 USA.	rgopalak@usc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR020700] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046538] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR020700-01] Funding Source: Medline; NINDS NIH HHS [NS 046538] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bae YS, 1997, J BIOL CHEM, V272, P217, DOI 10.1074/jbc.272.1.217; BAKER MA, 1990, ANAL BIOCHEM, V190, P360, DOI 10.1016/0003-2697(90)90208-Q; Barrett WC, 1999, J BIOL CHEM, V274, P34543, DOI 10.1074/jbc.274.49.34543; BONNI A, 1995, MOL CELL NEUROSCI, V6, P168, DOI 10.1006/mcne.1995.1015; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brodie C, 1999, CELL GROWTH DIFFER, V10, P183; Burry RW, 1998, J NEUROSCI RES, V53, P214, DOI 10.1002/(SICI)1097-4547(19980715)53:2<214::AID-JNR10>3.0.CO;2-6; CHEN SJ, 1993, BIOCHEMISTRY-US, V32, P1032, DOI 10.1021/bi00055a006; Chiueh CC, 2005, ANN NY ACAD SCI, V1042, P403, DOI 10.1196/annals.1338.034; COGGINS PJ, 1989, J NEUROCHEM, V53, P1895, DOI 10.1111/j.1471-4159.1989.tb09259.x; Fagerstrom S, 1996, CELL GROWTH DIFFER, V7, P775; GERDIN MJ, 2007, SCI STKE, pE15; Gopalakrishna R, 1999, ARCH BIOCHEM BIOPHYS, V363, P246, DOI 10.1006/abbi.1999.1100; GOPALAKRISHNA R, 1994, P NATL ACAD SCI USA, V91, P12233, DOI 10.1073/pnas.91.25.12233; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P6438; Gopalakrishna R, 1997, ARCH BIOCHEM BIOPHYS, V348, P25, DOI 10.1006/abbi.1997.0334; GOPALAKRISHNA R, 1989, P NATL ACAD SCI USA, V86, P6758, DOI 10.1073/pnas.86.17.6758; GOPALAKRISHNA R, 1992, ANAL BIOCHEM, V206, P24, DOI 10.1016/S0003-2697(05)80006-5; Gopalakrishna R, 2000, FREE RADICAL BIO MED, V28, P1349, DOI 10.1016/S0891-5849(00)00221-5; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Griner EM, 2007, NAT REV CANCER, V7, P281, DOI 10.1038/nrc2110; GSCHWENDT M, 1994, BIOCHEM BIOPH RES CO, V199, P93, DOI 10.1006/bbrc.1994.1199; Guyton KZ, 1996, J BIOL CHEM, V271, P4138, DOI 10.1074/jbc.271.7.3604; Hannun YA, 1996, SCIENCE, V274, P1855, DOI 10.1126/science.274.5294.1855; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; He Q, 1997, J NEUROSCI, V17, P3515; Hughes-Davis EJ, 2005, NEUROSCIENCE, V135, P1231, DOI 10.1016/j.neuroscience.2005.07.017; HUNDLE B, 1995, J BIOL CHEM, V270, P30134; Ito Y, 1997, J NEUROCHEM, V69, P729; Johnson JA, 1996, J BIOL CHEM, V271, P24962, DOI 10.1074/jbc.271.40.24962; Kamata H, 1996, J BIOL CHEM, V271, P33018, DOI 10.1074/jbc.271.51.33018; Katoh S, 1997, BIOCHEM BIOPH RES CO, V241, P347, DOI 10.1006/bbrc.1997.7514; Katoh S, 1999, BIOCHEM J, V338, P465, DOI 10.1042/0264-6021:3380465; KAZANIETZ MG, 1995, J BIOL CHEM, V270, P21852, DOI 10.1074/jbc.270.37.21852; KIKKAWA U, 1987, FEBS LETT, V223, P212, DOI 10.1016/0014-5793(87)80291-0; Klusman I, 1997, BRAIN RES, V762, P173, DOI 10.1016/S0006-8993(97)00381-8; KOSAKA Y, 1988, BIOCHEM BIOPH RES CO, V151, P973, DOI 10.1016/S0006-291X(88)80461-3; Kotake-Nara E, 2006, THESCIENTIFICWORLDJO, V6, P176, DOI 10.1100/tsw.2006.37; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; LIN WH, 1993, J NEUROSCI RES, V34, P546, DOI 10.1002/jnr.490340507; LORBER A, 1973, J CLIN PHARMACOL, V13, P332, DOI 10.1002/j.1552-4604.1973.tb00220.x; Mallis RJ, 2001, BIOCHEM J, V355, P145, DOI 10.1042/bj3550145; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; Markus A, 2002, CURR OPIN NEUROBIOL, V12, P523, DOI 10.1016/S0959-4388(02)00372-0; MARTINYBARON G, 1993, J BIOL CHEM, V268, P9194; Masutani H, 2004, MOL NEUROBIOL, V29, P229, DOI 10.1385/MN:29:3:229; Mobarak CD, 2000, MOL BIOL CELL, V11, P3191, DOI 10.1091/mbc.11.9.3191; Moskovitz J, 2002, ARCH BIOCHEM BIOPHYS, V397, P354, DOI 10.1006/abbi.2001.2692; Neet KE, 2001, CELL MOL LIFE SCI, V58, P1021, DOI 10.1007/PL00000917; Newton AC, 1997, CURR OPIN CELL BIOL, V9, P161, DOI 10.1016/S0955-0674(97)80058-0; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBERMEIER A, 1994, EMBO J, V13, P1585, DOI 10.1002/j.1460-2075.1994.tb06421.x; ODRISCOLL KR, 1995, MOL BIOL CELL, V6, P449, DOI 10.1091/mbc.6.4.449; Oehrlein SA, 1996, BIOCHEM J, V317, P219, DOI 10.1042/bj3170219; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OLAH Z, 1994, ANAL BIOCHEM, V221, P94, DOI 10.1006/abio.1994.1384; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Parker Peter J, 2003, Methods Mol Biol, V233, P159; PEUNOVA N, 1995, NATURE, V375, P68, DOI 10.1038/375068a0; Prekeris R, 1998, J BIOL CHEM, V273, P26790, DOI 10.1074/jbc.273.41.26790; SAIDO TC, 1992, BIOCHEM, V21, P482; SALGO MG, 1992, BIOCHIM BIOPHYS ACTA, V1127, P131, DOI 10.1016/0005-2760(92)90268-Z; Schwab ME, 2002, SCIENCE, V295, P1029, DOI 10.1126/science.1067840; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; Soltoff SP, 2001, J BIOL CHEM, V276, P37986; STADTMAN ER, 1991, J BIOL CHEM, V266, P2005; Sun XZ, 2003, ANTIOXID REDOX SIGN, V5, P655, DOI 10.1089/152308603770310338; Suzukawa K, 2000, J BIOL CHEM, V275, P13175, DOI 10.1074/jbc.275.18.13175; Tsuji M, 2001, J BIOL CHEM, V276, P32779, DOI 10.1074/jbc.M101403200; Uemura K, 2003, LIFE SCI, V72, P1595, DOI 10.1016/S0024-3205(02)02450-5; VANHOOFF COM, 1989, J CELL BIOL, V108, P1115, DOI 10.1083/jcb.108.3.1115; Vaudry D, 2002, SCIENCE, V296, P1648, DOI 10.1126/science.1071552; Wagner S, 2004, WOUND REPAIR REGEN, V12, P368, DOI 10.1111/j.1067-1927.2004.012315.x; Ward NE, 2000, BIOCHEMISTRY-US, V39, P10319, DOI 10.1021/bi000781g; Watson JA, 1999, BIOCHEM J, V343, P301, DOI 10.1042/0264-6021:3430301; Weinreb O, 2004, FASEB J, V18, P1471, DOI 10.1096/fj.04-1916fje; Witte S, 2000, J BIOL CHEM, V275, P1902, DOI 10.1074/jbc.275.3.1902; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; YAN CYI, 1995, J BIOL CHEM, V270, P26827, DOI 10.1074/jbc.270.45.26827; Yang CF, 2007, BIOCHEM J, V403, P1, DOI 10.1042/bj20061750; Zeidman R, 2002, MOL BIOL CELL, V13, P12, DOI 10.1091/mbc.01-04-0210; Zou WG, 2001, J NEUROSCI RES, V64, P646, DOI 10.1002/jnr.1118	82	35	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14430	14444		10.1074/jbc.M801519200	http://dx.doi.org/10.1074/jbc.M801519200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18375950	hybrid, Green Published, Green Accepted			2022-12-25	WOS:000255941400030
J	Cabral, LG; Foley, BR; Nuzhdin, SV				Cabral, Larry G.; Foley, Brad R.; Nuzhdin, Sergey V.			Does Sex Trade with Violence among Genotypes in Drosophila melanogaster?	PLOS ONE			English	Article								The evolutionary forces shaping the ability to win competitive interactions, such as aggressive encounters, are still poorly understood. Given a fitness advantage for competitive success, variance in aggressive and sexual display traits should be depleted, but a great deal of variation in these traits is consistently found. While life history tradeoffs have been commonly cited as a mechanism for the maintenance of variation, the variability of competing strategies of conspecifics may mean there is no single optimum strategy. We measured the genetically determined outcomes of aggressive interactions, and the resulting effects on mating success, in a panel of diverse inbred lines representing both natural variation and artificially selected genotypes. Males of one genotype which consistently lost territorial encounters with other genotypes were nonetheless successful against males that were artificially selected for supernormal aggression and dominated all other lines. Intransitive patterns of territorial success could maintain variation in aggressive strategies if there is a preference for territorial males. Territorial success was not always associated with male mating success however and females preferred 'winners' among some male genotypes, and 'losers' among other male genotypes. This suggests that studying behaviour from the perspective of population means may provide limited evolutionary and genetic insight. Overall patterns of competitive success among males and mating transactions between the sexes are consistent with mechanisms proposed for the maintenance of genetic variation due to nonlinear outcomes of competitive interactions.	[Cabral, Larry G.] Calif State Univ Sacramento, Dept Biol Sci, Sacramento, CA 95819 USA; [Foley, Brad R.; Nuzhdin, Sergey V.] Univ Calif Davis, Evolut & Ecol, Davis, CA USA; [Nuzhdin, Sergey V.] Univ Southern Calif, Mol & Comp Biol, Los Angeles, CA USA	California State University System; California State University Sacramento; University of California System; University of California Davis; University of Southern California	Cabral, LG (corresponding author), Calif State Univ Sacramento, Dept Biol Sci, Sacramento, CA 95819 USA.	Cabral@csus.edu; s4020793@student.uq.edu.au			NSF [1R24GM065513, DEB 0548991]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R24GM065513] Funding Source: NIH RePORTER	NSF(National Science Foundation (NSF)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	NSF grants 1R24GM065513, DEB 0548991	Baier A, 2002, J EXP BIOL, V205, P1233; Boake CRB, 2002, AM NAT, V160, pS143, DOI 10.1086/342902; Brooks R, 2001, EVOLUTION, V55, P1644, DOI 10.1111/j.0014-3820.2001.tb00684.x; Chen S, 2002, P NATL ACAD SCI USA, V99, P5664, DOI 10.1073/pnas.082102599; Coleman SW, 2004, NATURE, V428, P742, DOI 10.1038/nature02419; Dierick HA, 2006, NAT GENET, V38, P1023, DOI 10.1038/ng1864; DOW MA, 1975, NATURE, V254, P511, DOI 10.1038/254511a0; Droney DC, 2001, J INSECT BEHAV, V14, P621, DOI 10.1023/A:1012275201320; Edwards AC, 2006, PLOS GENET, V2, P1386, DOI 10.1371/journal.pgen.0020154; Garcia LV, 2004, OIKOS, V105, P657, DOI 10.1111/j.0030-1299.2004.13046.x; Greenspan RJ, 2000, ANNU REV GENET, V34, P205, DOI 10.1146/annurev.genet.34.1.205; Harris WE, 2008, EVOLUTION, V62, P337, DOI 10.1111/j.1558-5646.2007.00302.x; Hine E, 2004, EVOLUTION, V58, P2754, DOI 10.1111/j.0014-3820.2004.tb01627.x; HOFFMANN AA, 1987, ANIM BEHAV, V35, P807, DOI 10.1016/S0003-3472(87)80117-3; HOFFMANN AA, 1990, ANIM BEHAV, V40, P526, DOI 10.1016/S0003-3472(05)80533-0; HOFFMANN AA, 1988, ANIM BEHAV, V36, P1180, DOI 10.1016/S0003-3472(88)80077-0; HOFFMANN AA, 1989, ANIM BEHAV, V38, P23, DOI 10.1016/S0003-3472(89)80062-4; Lasbleiz C, 2006, ANIM BEHAV, V72, P1001, DOI 10.1016/j.anbehav.2006.01.027; Matthews IM, 1997, P ROY SOC B-BIOL SCI, V264, P695, DOI 10.1098/rspb.1997.0099; Moore AJ, 1997, EVOLUTION, V51, P1352, DOI 10.1111/j.1558-5646.1997.tb01458.x; Nilsen SP, 2004, P NATL ACAD SCI USA, V101, P12342, DOI 10.1073/pnas.0404693101; Sih A, 2005, BEHAVIOUR, V142, P1417, DOI 10.1163/156853905774539454; Sih A, 2004, Q REV BIOL, V79, P241, DOI 10.1086/422893; Sinervo B, 1996, NATURE, V380, P240, DOI 10.1038/380240a0; Stamps J, 2005, ANIM BEHAV, V70, P609, DOI 10.1016/j.anbehav.2004.11.018; Stamps JA, 2007, ECOL LETT, V10, P355, DOI 10.1111/j.1461-0248.2007.01034.x; Tomkins JL, 2004, TRENDS ECOL EVOL, V19, P323, DOI 10.1016/j.tree.2004.03.029; Wolf JB, 1999, AM NAT, V153, P254, DOI 10.1086/303168; Yang HP, 2003, MOL BIOL EVOL, V20, P800, DOI 10.1093/molbev/msg087	29	12	12	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1986	10.1371/journal.pone.0001986	http://dx.doi.org/10.1371/journal.pone.0001986			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414669	Green Published, gold, Green Submitted			2022-12-25	WOS:000260867300018
J	Gammie, SC; Edelmann, MN; Mandel-Brehm, C; D'Anna, KL; Auger, AP; Stevenson, SA				Gammie, Stephen C.; Edelmann, Michelle N.; Mandel-Brehm, Caleigh; D'Anna, Kimberly L.; Auger, Anthony P.; Stevenson, Sharon A.			Altered Dopamine Signaling in Naturally Occurring Maternal Neglect	PLOS ONE			English	Article							MEDIAL PREOPTIC AREA; INNERVATED BRAIN-REGIONS; TYROSINE-HYDROXYLASE PHOSPHORYLATION; PROGESTIN RECEPTOR EXPRESSION; WHEEL-RUNNING BEHAVIOR; NUCLEUS-ACCUMBENS; CHILD NEGLECT; ARTIFICIAL SELECTION; COCAINE TREATMENT; VENTRAL PALLIDUM	Background: Child neglect is the most common form of child maltreatment, yet the biological basis of maternal neglect is poorly understood and a rodent model is lacking. Methodology/Principal Findings: The current study characterizes a population of mice (MaD1) which naturally exhibit maternal neglect (little or no care of offspring) at an average rate of 17% per generation. We identified a set of risk factors that can predict future neglect of offspring, including decreased self-grooming and elevated activity. At the time of neglect, neglectful mothers swam significantly more in a forced swim test relative to nurturing mothers. Cross-fostered offspring raised by neglectful mothers in turn exhibit increased expression of risk factors for maternal neglect and decreased maternal care as adults, suggestive of possible epigenetic contributions to neglect. Unexpectedly, offspring from neglectful mothers elicited maternal neglect from cross-fostered nurturing mothers, suggesting that factors regulating neglect are not solely within the mother. To identify a neurological pathway underlying maternal neglect, we examined brain activity in neglectful and nurturing mice. c-Fos expression was significantly elevated in neglectful relative to nurturing mothers in the CNS, particularly within dopamine associated areas, such as the zona incerta (ZI), ventral tegmental area (VTA), and nucleus accumbens. Phosphorylated tyrosine hydroxylase (a marker for dopamine production) was significantly elevated in ZI and higher in VTA (although not significantly) in neglectful mice. Tyrosine hydroxylase levels were unaltered, suggesting a dysregulation of dopamine activity rather than cell number. Phosphorylation of DARPP-32, a marker for dopamine D1-like receptor activation, was elevated within nucleus accumbens and caudate-putamen in neglectful versus nurturing dams. Conclusions/Significance: These findings suggest that atypical dopamine activity within the maternal brain, especially within regions involved in reward, is involved in naturally occurring neglect and that MaD1 mice are a useful model for understanding the basis of naturally occurring neglect.	[Gammie, Stephen C.; Mandel-Brehm, Caleigh; D'Anna, Kimberly L.; Stevenson, Sharon A.] Univ Wisconsin, Dept Zool, Madison, WI 53706 USA; [Gammie, Stephen C.; Edelmann, Michelle N.; Auger, Anthony P.] Univ Wisconsin Madison, Neurosci Training Program, Madison, WI USA; [Auger, Anthony P.] Univ Wisconsin Madison, Dept Psychol, Madison, WI USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Gammie, SC (corresponding author), Univ Wisconsin, Dept Zool, Madison, WI 53706 USA.	scgammie@wisc.edu		D'Anna-Hernandez, Kimberly/0000-0001-7647-1640; mandel-brehm, caleigh/0000-0001-7764-6529	National Institutes of Health [R01 MH066086, R01 MH072956]; National Research Service Award (NRSA) [GM007507]; University of Wisconsin Hilldale Undergraduate Research Fellowship; American Psychological Association Diversity Program in Neuroscience Fellowship; Ford Foundation Dissertation Fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007507] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH072956, R01MH066086] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); National Research Service Award (NRSA)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); University of Wisconsin Hilldale Undergraduate Research Fellowship; American Psychological Association Diversity Program in Neuroscience Fellowship; Ford Foundation Dissertation Fellowship; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This work was supported by National Institutes of Health grants R01 MH066086 to S.C.G. and R01 MH072956 to A.P.A., by the National Research Service Award (NRSA) GM007507 to M.N.E., a University of Wisconsin Hilldale Undergraduate Research Fellowship to C. M.-B, and an American Psychological Association Diversity Program in Neuroscience Fellowship and Ford Foundation Dissertation Fellowship to K.L.D.	ABLER B, 2007, NEUROPSYCHOPHARMACOL; Afonso VM, 2008, BRAIN RES, V1198, P115, DOI 10.1016/j.brainres.2007.12.042; Aragona BJ, 2006, NAT NEUROSCI, V9, P133, DOI 10.1038/nn1613; Bakowska JC, 1995, BRAIN RES, V703, P191, DOI 10.1016/0006-8993(95)01097-1; Bale TL, 2003, J NEUROSCI, V23, P5295; Bouwknecht J. Adriaan, 2002, Behavioural Brain Research, V136, P489, DOI 10.1016/S0166-4328(02)00200-0; BRAYDEN RM, 1992, J PEDIATR-US, V120, P426, DOI 10.1016/S0022-3476(05)80912-6; Byrnes EM, 2002, PHARMACOL BIOCHEM BE, V73, P869, DOI 10.1016/S0091-3057(02)00941-3; Carelli Regina M, 2002, Behav Cogn Neurosci Rev, V1, P281, DOI 10.1177/1534582302238338; Champagne F, 2001, Prog Brain Res, V133, P287; Champagne FA, 2006, ENDOCRINOLOGY, V147, P2909, DOI 10.1210/en.2005-1119; Cryan JF, 2005, PSYCHOPHARMACOLOGY, V182, P335, DOI 10.1007/s00213-005-0093-5; Cryan JF, 2004, MOL PSYCHIATR, V9, P326, DOI 10.1038/sj.mp.4001457; D'Anna KL, 2006, J NEUROENDOCRINOL, V18, P553, DOI 10.1111/j.1365-2826.2006.01448.x; D'Anna KL, 2005, BEHAV NEUROSCI, V119, P1061, DOI 10.1037/0735-7044.119.4.1061; De Bellis MD, 2005, CHILD MALTREATMENT, V10, P150, DOI 10.1177/1077559505275116; Dunkley PR, 2004, J NEUROCHEM, V91, P1025, DOI 10.1111/j.1471-4159.2004.02797.x; Ferris CF, 2005, J NEUROSCI, V25, P149, DOI 10.1523/JNEUROSCI.3156-04.2005; Francis DD, 2002, J NEUROENDOCRINOL, V14, P349, DOI 10.1046/j.0007-1331.2002.00776.x; Fresiello A, 2002, BEHAV BRAIN RES, V130, P111, DOI 10.1016/S0166-4328(01)00426-0; GAFFORI O, 1979, PHYSIOL BEHAV, V23, P317, DOI 10.1016/0031-9384(79)90373-1; Gammie SC, 2005, BEHAV BRAIN RES, V160, P169, DOI 10.1016/j.bbr.2004.11.026; Gammie SC, 2004, BEHAV NEUROSCI, V118, P805, DOI 10.1037/0735-7044.118.4.805; Gammie SC, 2003, HORM BEHAV, V44, P209, DOI 10.1016/S0018-506X(03)00140-5; Gammie SC, 2006, BEHAV GENET, V36, P713, DOI 10.1007/s10519-006-9071-x; Gimenez-Llort L, 2002, EUR J NEUROSCI, V16, P547, DOI 10.1046/j.1460-9568.2002.02122.x; Girard I, 2002, BEHAV PROCESS, V57, P37, DOI 10.1016/S0376-6357(01)00206-6; HANSEN S, 1991, BEHAV NEUROSCI, V105, P588, DOI 10.1037/0735-7044.105.4.588; HANSEN S, 1991, PHARMACOL BIOCHEM BE, V39, P71, DOI 10.1016/0091-3057(91)90399-M; Harada K, 1996, J NEUROCHEM, V67, P629; Hasen NS, 2005, PHYSIOL BEHAV, V84, P681, DOI 10.1016/j.physbeh.2005.02.010; HEMMINGS HC, 1984, J NEUROSCI, V4, P99; Henry B, 2006, J NEUROSCI, V26, P9142, DOI 10.1523/JNEUROSCI.1494-06.2006; Hildyard KL, 2002, CHILD ABUSE NEGLECT, V26, P679, DOI 10.1016/S0145-2134(02)00341-1; Johns JM, 2005, BEHAV NEUROSCI, V119, P1605, DOI 10.1037/0735-7044.119.6.1605; JOHNS JM, 1994, BEHAV NEUROSCI, V108, P107, DOI 10.1037/0735-7044.108.1.107; Kelley AE, 2002, J NEUROSCI, V22, P3306; Kumer SC, 1996, J NEUROCHEM, V67, P443; Lang AJ, 2006, CHILD ABUSE NEGLECT, V30, P17, DOI 10.1016/j.chiabu.2005.07.006; Langley KC, 1997, NEUROSCIENCE, V78, P977, DOI 10.1016/S0306-4522(96)00583-0; Lavi-Avnon Y, 2008, PSYCHOPHARMACOLOGY, V196, P281, DOI 10.1007/s00213-007-0961-2; Lee A, 2000, BEHAV BRAIN RES, V108, P213, DOI 10.1016/s0166-4328(98)00109-0; Light KC, 2004, ADDICT BEHAV, V29, P1541, DOI 10.1016/j.addbeh.2004.02.062; Lindgren N, 2002, EUR J NEUROSCI, V15, P769, DOI 10.1046/j.1460-9568.2002.01901.x; LOOKINGLAND KJ, 1985, BRAIN RES, V348, P205, DOI 10.1016/0006-8993(85)90438-X; Lounds JJ, 2004, CHILD MALTREATMENT, V9, P371, DOI 10.1177/1077559504269536; Lounds JJ, 2006, CHILD MALTREATMENT, V11, P281, DOI 10.1177/1077559506289864; Maestripieri D, 1998, PSYCHOL BULL, V123, P211, DOI 10.1037/0033-2909.123.3.211; Mani SK, 2000, SCIENCE, V287, P1053, DOI 10.1126/science.287.5455.1053; Mattson BJ, 2001, BEHAV NEUROSCI, V115, P683, DOI 10.1037/0735-7044.115.3.683; Miller SM, 2005, BEHAV NEUROSCI, V119, P1072, DOI 10.1037/0735-7044.119.4.1072; Murray C, 2006, J ABNORM PSYCHOL, V115, P52, DOI 10.1037/0021-843X.115.1.52; Numan M, 2005, BEHAV NEUROSCI, V119, P1588, DOI 10.1037/0735-7044.119.6.1588; NUMAN M, 1984, BEHAV NEUROSCI, V98, P712, DOI 10.1037/0735-7044.98.4.712; Numan M, 2005, BEHAV BRAIN RES, V158, P53, DOI 10.1016/j.bbr.2004.08.008; Numan M., 2003, HORM BR BEHAV; Olesen KM, 2007, J NEUROENDOCRINOL, V19, P481, DOI 10.1111/j.1365-2826.2007.01554.x; Olesen KM, 2005, ENDOCRINOLOGY, V146, P3705, DOI 10.1210/en.2005-0498; Olesen KM, 2005, J NEUROENDOCRINOL, V17, P255, DOI 10.1111/j.1365-2826.2005.01302.x; OUIMET CC, 1984, J NEUROSCI, V4, P111; Prickaerts J, 2006, J NEUROSCI, V26, P9022, DOI 10.1523/JNEUROSCI.5216-05.2006; Rhodes JS, 2005, INTEGR COMP BIOL, V45, P438, DOI 10.1093/icb/45.3.438; Rhodes JS, 2003, BEHAV NEUROSCI, V117, P1243, DOI 10.1037/0735-7044.117.6.1243; Risinger FO, 2001, J NEUROSCI, V21, P340, DOI 10.1523/JNEUROSCI.21-01-00340.2001; Shipman K, 2005, CHILD ABUSE NEGLECT, V29, P1015, DOI 10.1016/j.chiabu.2005.01.006; Silva MRP, 2001, PHARMACOL BIOCHEM BE, V68, P461, DOI 10.1016/S0091-3057(01)00471-3; Sita LV, 2003, BRAIN RES, V970, P232, DOI 10.1016/S0006-8993(03)02345-X; Solanto MV, 2002, BEHAV BRAIN RES, V130, P65, DOI 10.1016/S0166-4328(01)00431-4; Stolzenberg DS, 2007, BEHAV NEUROSCI, V121, P907, DOI 10.1037/0735-7044.121.5.907; Strathearn L, 2001, PEDIATRICS, V108, P142, DOI 10.1542/peds.108.1.142; Swallow JG, 1998, BEHAV GENET, V28, P227, DOI 10.1023/A:1021479331779; *US DEP HHS, 2004, CHILD MALTR 2002 SUM; WAGNER CK, 1995, BRAIN RES, V677, P229, DOI 10.1016/0006-8993(95)00128-D; WALAAS SI, 1984, J NEUROSCI, V4, P84; Wilson SL, 2005, CHILD ABUSE NEGLECT, V29, P985, DOI 10.1016/j.chiabu.2005.03.007; Zachariou V, 2006, NEUROPSYCHOPHARMACOL, V31, P555, DOI 10.1038/sj.npp.1300832; ZIGMOND RE, 1989, ANNU REV NEUROSCI, V12, P415, DOI 10.1146/annurev.ne.12.030189.002215	77	22	22	2	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1974	10.1371/journal.pone.0001974	http://dx.doi.org/10.1371/journal.pone.0001974			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	370XD	18398484	Green Published, gold, Green Submitted			2022-12-25	WOS:000260795500037
J	Semyonov, J; Park, JI; Chang, CL; Hsu, SYT				Semyonov, Jenia; Park, Jae-Il; Chang, Chia Lin; Hsu, Sheau Yu Teddy			GPCR Genes Are Preferentially Retained after Whole Genome Duplication	PLOS ONE			English	Article							PROTEIN-COUPLED RECEPTORS; ADAPTIVE EVOLUTION; PROVIDES EVIDENCE; TELEOST FISH; PSI-BLAST; REPERTOIRE; IDENTIFICATION; SENSITIVITY; ROBUSTNESS; DIVERGENCE	One of the most interesting questions in biology is whether certain pathways have been favored during evolution, and if so, what properties could cause such a preference. Due to the lack of experimental evidence, whether select gene families have been preferentially retained over time after duplication in metazoan organisms remains unclear. Here, by syntenic mapping of nonchemosensory G protein-coupled receptor genes (nGPCRs which represent half the receptome for transmembrane signaling) in the vertebrate genomes, we found that, as opposed to the 8-15% retention rate for whole genome duplication (WGD)-derived gene duplicates in the entire genome of pufferfish, greater than 27.8% of WGD-derived nGPCRs which interact with a nonpeptide ligand were retained after WGD in pufferfish Tetraodon nigroviridis. In addition, we show that concurrent duplication of cognate ligand genes by WGD could impose selection of nGPCRs that interact with a polypeptide ligand. Against less than 2.25% probability for parallel retention of a pair of WGD-derived ligands and a pair of cognate receptor duplicates, we found a more than 8.9% retention of WGD-derived ligand-nGPCR pairs-threefold greater than one would surmise. These results demonstrate that gene retention is not uniform after WGD in vertebrates, and suggest a Darwinian selection of GPCR-mediated intercellular communication in metazoan organisms.	[Semyonov, Jenia; Park, Jae-Il; Hsu, Sheau Yu Teddy] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA; [Chang, Chia Lin] Chang Gung Memorial Hosp, Dept Obstet & Gynecol, Chang Gung Univ, Sch Med, Tao Yuan, Taiwan	Stanford University; Chang Gung Memorial Hospital; Chang Gung University	Semyonov, J (corresponding author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA.	teddyhsu@stanford.edu			SCCPRR Center at the Stanford University School of Medicine; NIH [HD31398, R21 HD47606, RO1 DK70652]; March of Dimes research grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [U54HD031398, R21HD047606] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK070652] Funding Source: NIH RePORTER	SCCPRR Center at the Stanford University School of Medicine; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); March of Dimes research grant(March of Dimes); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	J. Semyonov is supported by the Bioinformatics Core of the SCCPRR Center at the Stanford University School of Medicine (NIH, HD31398). The authors also acknowledge the support of NIH awards (R21 HD47606 and RO1 DK70652, SYH) and the March of Dimes research grant (SYH).	Alioto TS, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-173; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Amores A, 1998, SCIENCE, V282, P1711, DOI 10.1126/science.282.5394.1711; Aparicio S, 2002, SCIENCE, V297, P1301, DOI 10.1126/science.1072104; Ben-Shlomo Izhar, 2003, Sci STKE, V2003, pRE9, DOI 10.1126/stke.2003.187.re9; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Brunet FG, 2006, MOL BIOL EVOL, V23, P1808, DOI 10.1093/molbev/msl049; Chen NS, 2005, P NATL ACAD SCI USA, V102, P146, DOI 10.1073/pnas.0408307102; Choi SS, 2003, GENOME RES, V13, P2252, DOI 10.1101/gr.1431603; Christoffels A, 2004, MOL BIOL EVOL, V21, P1146, DOI 10.1093/molbev/msh114; Courseaux A, 2001, SCIENCE, V291, P1293, DOI 10.1126/science.1057284; Feldman M, 1997, GENETICS, V147, P1381; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Foord SM, 2005, PHARMACOL REV, V57, P279, DOI 10.1124/pr.57.2.5; Force A, 1999, GENETICS, V151, P1531; Francino MP, 2005, NAT GENET, V37, P573, DOI 10.1038/ng1579; Fredriksson R, 2005, MOL PHARMACOL, V67, P1414, DOI 10.1124/mol.104.009001; FRYXELL KJ, 1995, J MOL EVOL, V41, P85, DOI 10.1007/BF00174044; Gilad Y, 2005, GENOME RES, V15, P224, DOI 10.1101/gr.2846405; Gimelbrant AA, 2004, P NATL ACAD SCI USA, V101, P9019, DOI 10.1073/pnas.0401566101; Gloriam DEI, 2005, MOL PHYLOGENET EVOL, V35, P470, DOI 10.1016/j.ympev.2004.12.003; Goodstadt L, 2006, PLOS COMPUT BIOL, V2, P1134, DOI 10.1371/journal.pcbi.0020133; Grus WE, 2005, P NATL ACAD SCI USA, V102, P5767, DOI 10.1073/pnas.0501589102; Gu ZL, 2003, NATURE, V421, P63, DOI 10.1038/nature01198; He XL, 2005, CURR BIOL, V15, P1016, DOI 10.1016/j.cub.2005.04.035; Hillier LW, 2004, NATURE, V432, P695, DOI 10.1038/nature03154; Hoegg S, 2004, J MOL EVOL, V59, P190, DOI 10.1007/s00239-004-2613-z; Hsu SY, 1999, MOL ENDOCRINOL, V13, P2163, DOI 10.1210/me.13.12.2163; Hsu SY, 2000, MOL ENDOCRINOL, V14, P594, DOI 10.1210/me.14.5.594; Hsu SY, 2002, MOL ENDOCRINOL, V16, P1538, DOI 10.1210/me.16.7.1538; Hsu SY, 2000, MOL ENDOCRINOL, V14, P1257, DOI 10.1210/me.14.8.1257; Hsu SY, 2001, NAT MED, V7, P605, DOI 10.1038/87936; Hubbard T, 2005, NUCLEIC ACIDS RES, V33, pD447, DOI 10.1093/nar/gki138; Huerta-Cepas J, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-r109; Hughes AL, 2005, P NATL ACAD SCI USA, V102, P8791, DOI 10.1073/pnas.0503922102; Jaillon O, 2004, NATURE, V431, P946, DOI 10.1038/nature03025; Jeong H, 2001, NATURE, V411, P41, DOI 10.1038/35075138; Kasprzyk A, 2004, GENOME RES, V14, P160, DOI 10.1101/gr.1645104; Kellis M, 2004, NATURE, V428, P617, DOI 10.1038/nature02424; Kent WJ, 2002, GENOME RES, V12, P656, DOI 10.1101/gr.229202; Kocher TD, 2004, NAT REV GENET, V5, P288, DOI 10.1038/nrg1316; Liberles SD, 2006, NATURE, V442, P645, DOI 10.1038/nature05066; Lindblad-Toh K, 2005, NATURE, V438, P803, DOI 10.1038/nature04338; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Mombaerts P, 1999, SCIENCE, V286, P707, DOI 10.1126/science.286.5440.707; Mulley J, 2004, NATURE, V431, P916, DOI 10.1038/431916a; Ohno S., 1970, EVOLUTION GENE DUPLI; Papp B, 2003, NATURE, V424, P194, DOI 10.1038/nature01771; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; Rodriguez I, 2005, P NATL ACAD SCI USA, V102, P6639, DOI 10.1073/pnas.0502318102; Roest Crollius H, 2005, GENOME RES, V15, P1675, DOI 10.1101/gr.3735805; Roh J, 2004, J BIOL CHEM, V279, P7264, DOI 10.1074/jbc.M305332200; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; Schaffer AA, 2001, NUCLEIC ACIDS RES, V29, P2994, DOI 10.1093/nar/29.14.2994; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Shiu SH, 2006, P NATL ACAD SCI USA, V103, P2232, DOI 10.1073/pnas.0510388103; Small Kersten M, 2003, Am J Pharmacogenomics, V3, P65, DOI 10.2165/00129785-200303010-00008; Steel M, 2005, TRENDS GENET, V21, P307, DOI 10.1016/j.tig.2005.04.001; Swanson WJ, 2002, NAT REV GENET, V3, P137, DOI 10.1038/nrg733; Tatusova TA, 1999, FEMS MICROBIOL LETT, V174, P247, DOI 10.1016/S0378-1097(99)00149-4; Taylor JS, 2003, GENOME RES, V13, P382, DOI 10.1101/gr.640303; Taylor JS, 2004, ANNU REV GENET, V38, P615, DOI 10.1146/annurev.genet.38.072902.092831; Taylor JS, 2001, PHILOS T R SOC B, V356, P1661, DOI 10.1098/rstb.2001.0975; Taylor JS, 2001, TRENDS GENET, V17, P299, DOI 10.1016/S0168-9525(01)02318-6; Terai Y, 2006, PLOS BIOL, V4, P2244, DOI 10.1371/journal.pbio.0040433; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Thornton JW, 2005, TRENDS GENET, V21, P310, DOI 10.1016/j.tig.2005.04.002; Van de Peer Y, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-12-250; Vandepoele K, 2004, P NATL ACAD SCI USA, V101, P1638, DOI 10.1073/pnas.0307968100; Vassilatis DK, 2003, P NATL ACAD SCI USA, V100, P4903, DOI 10.1073/pnas.0230374100; Wagner A, 2000, NAT GENET, V24, P355, DOI 10.1038/74174; Woods IG, 2005, GENOME RES, V15, P1307, DOI 10.1101/gr.4134305; Yang J, 2003, P NATL ACAD SCI USA, V100, P15661, DOI 10.1073/pnas.2536672100; Yokoyama S, 2002, NAT GENET, V30, P350, DOI 10.1038/ng0402-350; Zylka MJ, 2003, P NATL ACAD SCI USA, V100, P10043, DOI 10.1073/pnas.1732949100	75	18	18	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1903	10.1371/journal.pone.0001903	http://dx.doi.org/10.1371/journal.pone.0001903			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382678	gold, Green Submitted, Green Published			2022-12-25	WOS:000260795400030
J	van Baarsen, LGM; Vosslamber, S; Tijssen, M; Baggen, JMC; van der Voort, LF; Killestein, J; Kraan, TCTMVDP; Polman, CH; Verweij, CL				van Baarsen, Lisa G. M.; Vosslamber, Saskia; Tijssen, Marianne; Baggen, Josefien M. C.; van der Voort, Laura F.; Killestein, Joep; Kraan, Tineke C. T. M. van der Pouw; Polman, Chris H.; Verweij, Cornelis L.			Pharmacogenomics of Interferon-beta Therapy in Multiple Sclerosis: Baseline IFN Signature Determines Pharmacological Differences between Patients	PLOS ONE			English	Article								Background: Multiple sclerosis (MS) is a heterogeneous disease. In order to understand the partial responsiveness to IFN beta in Relapsing Remitting MS (RRMS) we studied the pharmacological effects of IFN beta therapy. Methodology: Large scale gene expression profiling was performed on peripheral blood of 16 RRMS patients at baseline and one month after the start of IFN beta therapy. Differential gene expression was analyzed by Significance Analysis of Microarrays. Subsequent expression analyses on specific genes were performed after three and six months of treatment. Peripheral blood mononuclear cells (PBMC) were isolated and stimulated in vitro with IFN beta. Genes of interest were measured and validated by quantitative realtime PCR. An independent group of 30 RRMS patients was used for validation. Principal Findings: Pharmacogenomics revealed a marked variation in the pharmacological response to IFN beta between patients. A total of 126 genes were upregulated in a subset of patients whereas in other patients these genes were downregulated or unchanged after one month of IFN beta therapy. Most interestingly, we observed that the extent of the pharmacological response correlates negatively with the baseline expression of a specific set of 15 IFN response genes (R = -0.7208; p = 0.0016). The negative correlation was maintained after three (R = -0.7363; p = 0.0027) and six (R = -0.8154; p = 0.0004) months of treatment, as determined by gene expression levels of the most significant correlating gene. Similar results were obtained in an independent group of patients (n = 30; R = -0.4719; p = 0.0085). Moreover, the ex vivo results could be confirmed by in vitro stimulation of purified PBMCs at baseline with IFN beta indicating that differential responsiveness to IFN beta is an intrinsic feature of peripheral blood cells at baseline. Conclusion: These data imply that the expression levels of IFN response genes in the peripheral blood of MS patients prior to treatment could serve a role as biomarker for the differential clinical response to IFN beta..	[van Baarsen, Lisa G. M.; Vosslamber, Saskia; Baggen, Josefien M. C.; Kraan, Tineke C. T. M. van der Pouw; Verweij, Cornelis L.] Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands; [van Baarsen, Lisa G. M.; Vosslamber, Saskia; Tijssen, Marianne; Verweij, Cornelis L.] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands; [van der Voort, Laura F.; Killestein, Joep; Polman, Chris H.] Vrije Univ Amsterdam Med Ctr, Dept Neurol, Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	van Baarsen, LGM (corresponding author), Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, Amsterdam, Netherlands.	c.verweij@vumc.nl	van Baarsen, Lisa G/N-3646-2015	van Baarsen, Lisa G/0000-0003-3346-8921; Killestein, Joep/0000-0002-6347-5957	Dutch MS Research Foundation (Voorschoten, Netherlands) [04-549 MS]; Centre for Medical Systems Biology	Dutch MS Research Foundation (Voorschoten, Netherlands)(Netherlands Government); Centre for Medical Systems Biology	This study was funded in part by the Dutch MS Research Foundation (Voorschoten, Netherlands) and by the Centre for Medical Systems Biology (a center of excellence approved by the Netherlands Genomics Initiative/Netherlands Organization for Scientific Research). Furthermore, the Dutch MS Research Foundation also supports S. Vosslamber (grant 04-549 MS). The funding sources of this study had no involvement in study design, in the collection, analyses and interpretation of data, in the writing of the report, and in the decision to submit the paper for publication.	Alam J, 1997, PHARMACEUT RES, V14, P546, DOI 10.1023/A:1012128406432; Ball CA, 2005, NUCLEIC ACIDS RES, V33, pD580; Baranzini SE, 2005, PLOS BIOL, V3, P166, DOI 10.1371/journal.pbio.0030002; Brierley MM, 2005, J BIOL CHEM, V280, P13029, DOI 10.1074/jbc.M500426200; Der SD, 1998, P NATL ACAD SCI USA, V95, P15623, DOI 10.1073/pnas.95.26.15623; Dupont SA, 2002, J INTERF CYTOK RES, V22, P491, DOI 10.1089/10799900252952280; DUQUETTE P, 1995, NEUROLOGY, V45, P1277; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Feng X, 2002, J NEUROIMMUNOL, V129, P205, DOI 10.1016/S0165-5728(02)00182-0; Ghislain JJ, 1996, J BIOL CHEM, V271, P12408, DOI 10.1074/jbc.271.21.12408; Ghislain JJ, 2001, J INTERF CYTOK RES, V21, P379, DOI 10.1089/107999001750277853; Gilli F, 2005, J NEUROIMMUNOL, V158, P195, DOI 10.1016/j.jneuroim.2004.08.006; GRESSER I, 1990, J INVEST DERMATOL, V95, pS66, DOI 10.1111/1523-1747.ep12874776; Hafler DA, 2005, IMMUNOL REV, V204, P208, DOI 10.1111/j.0105-2896.2005.00240.x; KRAAN TCV, 2007, ARTHRITIS RES; Kracke A, 2000, NEUROLOGY, V54, P193, DOI 10.1212/WNL.54.1.193; Lehtonen A, 1997, J IMMUNOL, V159, P794; Li XX, 1996, J BIOL CHEM, V271, P5790, DOI 10.1074/jbc.271.10.5790; Markowitz CE, 2007, NEUROLOGY, V68, pS8, DOI 10.1212/01.wnl.0000277703.74115.d2; Miller DH, 2002, BRAIN, V125, P1676, DOI 10.1093/brain/awf177; Ravandi F, 1999, CLIN CANCER RES, V5, P3990; Reske D, 2004, ACTA NEUROL SCAND, V109, P66, DOI 10.1034/j.1600-0404.2003.00180.x; Revel M, 2003, PHARMACOL THERAPEUT, V100, P49, DOI 10.1016/S0163-7258(03)00085-8; Rice GPA, 1999, NEUROLOGY, V52, P1277, DOI 10.1212/WNL.52.6.1277; Rudick RA, 2004, ANN NEUROL, V56, P548, DOI 10.1002/ana.20224; Rudick RA, 2006, ANN NEUROL, V60, P236, DOI 10.1002/ana.20883; Salmon P, 1996, J INTERF CYTOK RES, V16, P759, DOI 10.1089/jir.1996.16.759; SIBLEY WA, 1985, LANCET, V1, P1313; Sturzebecher S, 2003, BRAIN, V126, P1419, DOI 10.1093/brain/awg147; Sturzebecher S, 1999, J INTERF CYTOK RES, V19, P1257, DOI 10.1089/107999099312920; Takaoka A, 2003, CANCER SCI, V94, P405, DOI 10.1111/j.1349-7006.2003.tb01455.x; Tusher VG, 2001, P NATL ACAD SCI USA, V98, P5116, DOI 10.1073/pnas.091062498; van Baarsen LGM, 2006, GENES IMMUN, V7, P522, DOI 10.1038/sj.gene.6364324; Vartanian TK, 2004, NEUROLOGY, V63, pS42, DOI 10.1212/WNL.63.11_suppl_5.S42; Weinstock-Guttman B, 2003, J IMMUNOL, V171, P2694, DOI 10.4049/jimmunol.171.5.2694; Zhuang HY, 2006, ARTHRITIS RHEUM-US, V54, P1573, DOI 10.1002/art.21800	36	89	98	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1927	10.1371/journal.pone.0001927	http://dx.doi.org/10.1371/journal.pone.0001927			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382694	Green Published, gold			2022-12-25	WOS:000260795400047
J	Zavan, B; Vindigni, V; Lepidi, S; Iacopetti, I; Avruscio, G; Abatangelo, G; Cortivo, R				Zavan, Barbara; Vindigni, Vincenzo; Lepidi, Sandro; Iacopetti, Ilaria; Avruscio, Giampiero; Abatangelo, Giovanni; Cortivo, Roberta			Neoarteries grown in vivo using a tissue-engineered hyaluronan-based scaffold	FASEB JOURNAL			English	Article						elastin; vascular prosthesis; remodeling; surgery	BLOOD-VESSEL; VASCULAR AUTOGRAFTS; ELASTIN; CELLS	Vascular tissue engineering has emerged as a promising technology for the design of an ideal, responsive, living conduit with properties similar to that of native tissue. The missing link in tissue-engineered blood vessels is elastin biosynthesis. Several biomaterials are currently used but few support elastin biosynthesis in a 3-D array. In previous studies, we demonstrated that a hyaluronan-based scaffold (HYAFF-11 (TM)) grafted in the infrarenal rat aorta successfully guided the complete regeneration of a well-functioning small-diameter (2 mm) neoartery. The aim of the present study was to test the ability of HYAFF-11 biodegradable grafts to develop into neovessels of larger size (4 mm) in a porcine model, focusing on extracellular matrix (ECM) remodeling and elastin biosynthesis. HYAFF-11 tubes (diameter 4 mm, length 5 cm) were implanted in an end-to-end fashion in the common carotid artery. Grafts were analyzed for patency with a Duplex scan every 15 days. ECM components were evaluated by histological and molecular biological methods. All the animals survived the observation period without complications. Intimal hyperplasia (initiating at the anastomotic site) and graft thrombosis led to 3 cases of partial or complete occlusion, as demonstrated by histological examination. There were no signs of stenoses or aneurysms in the remaining grafts. After 5 months, the biomaterial was almost completely degraded and replaced by a neoartery segment composed of mature smooth muscle cells, collagen, and elastin fibers organized in layers and was completely covered on the luminal surface by endothelial cells (vWF(+)). Whereas in previous small animal studies, patency rates were not optimal, those obtained in the present study using hyaluronan-based grafts of larger size confirmed the ability of these constructs to guide the development of a well-functioning neoartery, with the remarkable additional attribute of facilitating the formation of organized layers of elastin fibers.	[Vindigni, Vincenzo] Univ Padua, Clin Plast Surg, I-35100 Padua, Italy; [Zavan, Barbara; Abatangelo, Giovanni; Cortivo, Roberta] Univ Padua, Dept Histol Microbiol & Med Biotechnol, I-35100 Padua, Italy; [Lepidi, Sandro] Univ Padua, Clin Vasc Surg, I-35100 Padua, Italy; [Avruscio, Giampiero] Univ Padua, Unit Angiol, I-35100 Padua, Italy; [Iacopetti, Ilaria] Univ Padua, Dept Vet Sci, I-35100 Padua, Italy	University of Padua; University of Padua; University of Padua; University of Padua; University of Padua	Vindigni, V (corresponding author), Univ Padua, Clin Plast Surg, Via Giustiniani 2, I-35100 Padua, Italy.	vincenzo.vindigni@unipd.it	Vindigni, Vincenzo/K-5059-2016	Vindigni, Vincenzo/0000-0001-6638-9010; Lepidi, Sandro/0000-0003-2201-6081				Alsberg E, 2002, P NATL ACAD SCI USA, V99, P12025, DOI 10.1073/pnas.192291499; Joddar B, 2007, BIOMATERIALS, V28, P3918, DOI 10.1016/j.biomaterials.2007.05.019; Joddar B, 2006, BIOMATERIALS, V27, P5698, DOI 10.1016/j.biomaterials.2006.07.020; Karnik SK, 2003, DEVELOPMENT, V130, P411, DOI 10.1242/dev.00223; Kerdjoudj H, 2007, CLIN HEMORHEOL MICRO, V37, P89; Kielty CM, 2002, J CELL SCI, V115, P2817; L'Heureux N, 2006, NAT MED, V12, P361, DOI 10.1038/nm1364; L'Heureux N, 2007, NEW ENGL J MED, V357, P1451, DOI 10.1056/NEJMc071536; L'Heureux N, 2007, NAT CLIN PRACT CARD, V4, P389, DOI 10.1038/ncpcardio0930; Lepidi S, 2005, FASEB J, V19, P103, DOI 10.1096/fj.05-4802fje; Lepidi S, 2006, EUR J VASC ENDOVASC, V32, P411, DOI 10.1016/j.ejvs.2006.02.012; LHEUREUX N, 1993, J VASC SURG, V17, P499, DOI 10.1016/0741-5214(93)90150-K; Li DY, 1998, NATURE, V393, P276, DOI 10.1038/30522; Long JL, 2003, MATRIX BIOL, V22, P339, DOI 10.1016/S0945-053X(03)00052-0; Mann BK, 2001, ANAT RECORD, V263, P367, DOI 10.1002/ar.1116; Matsumura G, 2003, BIOMATERIALS, V24, P2303, DOI 10.1016/S0142-9612(03)00043-7; *NAT RES COUNC, 1996, GUID CAR US LAB AN; Patel A, 2006, CARDIOVASC RES, V71, P40, DOI 10.1016/j.cardiores.2006.02.021; Ratcliffe A, 2000, MATRIX BIOL, V19, P353, DOI 10.1016/S0945-053X(00)00080-9; Remuzzi A, 2004, TISSUE ENG, V10, P699, DOI 10.1089/1076327041348347; Ross JJ, 2003, MATRIX BIOL, V22, P477, DOI 10.1016/S0945-053X(03)00078-7; Shin'oka T, 2005, J THORAC CARDIOV SUR, V129, P1330, DOI 10.1016/j.jtcvs.2004.12.047; Tonello C, 2003, BIOMATERIALS, V24, P1205, DOI 10.1016/S0142-9612(02)00450-7; Turner NJ, 2004, BIOMATERIALS, V25, P5955, DOI 10.1016/j.biomaterials.2004.02.002; WEINBERG CB, 1986, SCIENCE, V231, P397, DOI 10.1126/science.2934816; Ye Q, 2000, EUR J CARDIO-THORAC, V17, P449, DOI 10.1016/S1010-7940(00)00371-7; Zhang WJ, 2007, J CELL MOL MED, V11, P945, DOI 10.1111/j.1582-4934.2007.00099.x; [No title captured]	28	57	58	0	24	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2853	2861		10.1096/fj.08-107284	http://dx.doi.org/10.1096/fj.08-107284			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18385214				2022-12-25	WOS:000258089300025
J	Yoo, H; Antoniewicz, MR; Stephanopoulos, G; Kelleher, JK				Yoo, Hyuntae; Antoniewicz, Maciek R.; Stephanopoulos, Gregory; Kelleher, Joanne K.			Quantifying reductive carboxylation flux of glutamine to lipid in a brown adipocyte cell line	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADP(+)-DEPENDENT ISOCITRATE DEHYDROGENASE; PENTOSE-PHOSPHATE PATHWAY; TRICARBOXYLIC-ACID CYCLE; OXIDATIVE DAMAGE; KEY ENZYMES; RAT-LIVER; GLYCOLYSIS; METABOLISM; TRANSHYDROGENASE; DISTRIBUTIONS	We previously reported that glutamine was a major source of carbon for de novo fatty acid synthesis in a brown adipocyte cell line. The pathway for fatty acid synthesis from glutamine may follow either of two distinct pathways after it enters the citric acid cycle. The glutaminolysis pathway follows the citric acid cycle, whereas the reductive carboxylation pathway travels in reverse of the citric acid cycle from alpha-ketoglutarate to citrate. To quantify fluxes in these pathways we incubated brown adipocyte cells in [U-C-13] glutamine or [5-C-13] glutamine and analyzed the mass isotopomer distribution of key metabolites using models that fit the isotopomer distribution to fluxes. We also investigated inhibitors of NADP-dependent isocitrate dehydrogenase and mitochondrial citrate export. The results indicated that one third of glutamine entering the citric acid cycle travels to citrate via reductive carboxylation while the remainder is oxidized through succinate. The reductive carboxylation flux accounted for 90% of all flux of glutamine to lipid. The inhibitor studies were compatible with reductive carboxylation flux through mitochondrial isocitrate dehydrogenase. Total cell citrate and alpha-ketoglutarate were near isotopic equilibrium as expected if rapid cycling exists between these compounds involving the mitochondrial membrane NAD/NADP transhydrogenase. Taken together, these studies demonstrate a new role for glutamine as a lipogenic precursor and propose an alternative to the glutaminolysis pathway where flux of glutamine to lipogenic acetyl-CoA occurs via reductive carboxylation. These findings were enabled by a new modeling tool and software implementation (Metran) for global flux estimation.	[Antoniewicz, Maciek R.; Stephanopoulos, Gregory; Kelleher, Joanne K.] MIT, Dept Chem Engn, Bioinformat & Metab Engn Lab, Cambridge, MA 02139 USA; [Yoo, Hyuntae] MIT, Dept Chem, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Kelleher, JK (corresponding author), MIT, Dept Chem Engn, Bioinformat & Metab Engn Lab, 77 Massachusetts Ave,Rm 66-401, Cambridge, MA 02139 USA.	jkk@mit.edu	Antoniewicz, Maciek/D-4015-2009	Antoniewicz, Maciek/0000-0002-0087-2875	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK075850] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 075850] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Antoniewicz MR, 2007, ANAL CHEM, V79, P7554, DOI 10.1021/ac0708893; Antoniewicz MR, 2007, METAB ENG, V9, P68, DOI 10.1016/j.ymben.2006.09.001; Antoniewicz MR, 2006, METAB ENG, V8, P324, DOI 10.1016/j.ymben.2006.01.004; BOARD M, 1990, BIOCHEM J, V265, P503, DOI 10.1042/bj2650503; Brock M, 2002, EUR J BIOCHEM, V269, P6184, DOI 10.1046/j.1432-1033.2002.03336.x; Comte B, 2002, AM J PHYSIOL-HEART C, V283, pH1505, DOI 10.1152/ajpheart.00287.2002; DADAMO AF, 1989, J BIOL CHEM, V240, P613; DALZIEL K, 1968, BIOCHEM J, V110, P223, DOI 10.1042/bj1100223; DEALMEIDA AF, 1989, INT J BIOCHEM, V21, P937, DOI 10.1016/0020-711X(89)90295-4; Fasshauer M, 2001, MOL CELL BIOL, V21, P319, DOI 10.1128/MCB.21.1.319-329.2001; Fiehn O, 2000, ANAL CHEM, V72, P3573, DOI 10.1021/ac991142i; Holleran AL, 1995, MOL CELL BIOCHEM, V152, P95, DOI 10.1007/BF01076071; Jo SH, 2001, J BIOL CHEM, V276, P16168, DOI 10.1074/jbc.M010120200; Kim HJ, 2005, FREE RADICAL RES, V39, P441, DOI 10.1080/10715760500066265; KOCHAN Z, 1993, BIOCHEM PHARMACOL, V46, P1501, DOI 10.1016/0006-2952(93)90118-G; Koh HJ, 2004, J BIOL CHEM, V279, P39968, DOI 10.1074/jbc.M402260200; KOWALCHUK JM, 1988, BIOCHEM J, V249, P705, DOI 10.1042/bj2490705; Mazurek S, 2003, ANTICANCER RES, V23, P1149; MCKEEHAN WL, 1982, CELL BIOL INT REP, V6, P635, DOI 10.1016/0309-1651(82)90125-4; NEWSHOLME EA, 1985, BIOSCIENCE REP, V5, P393, DOI 10.1007/BF01116556; RAO S, 1989, EXP CELL RES, V180, P341, DOI 10.1016/0014-4827(89)90062-1; REYNOLDS CH, 1978, BIOCHEM J, V171, P733, DOI 10.1042/bj1710733; ROSIERS CD, 1995, J BIOL CHEM, V270, P10027, DOI 10.1074/jbc.270.17.10027; SAZANOV LA, 1994, FEBS LETT, V344, P109, DOI 10.1016/0014-5793(94)00370-X; WANDERS RJA, 1981, EUR J BIOCHEM, V116, P609, DOI 10.1111/j.1432-1033.1981.tb05379.x; Yoo H, 2004, J LIPID RES, V45, P1324, DOI 10.1194/jlr.M400031-JLR200	26	216	220	3	28	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 25	2008	283	30					20621	20627		10.1074/jbc.M706494200	http://dx.doi.org/10.1074/jbc.M706494200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	327RL	18364355	hybrid, Green Published			2022-12-25	WOS:000257746100002
J	Green, M; Panesar, NK; Loewenstein, PM				Green, M.; Panesar, N. K.; Loewenstein, P. M.			The transcription-repression domain of the adenovirus E1A oncoprotein targets p300 at the promoter	ONCOGENE			English	Article						adenovirus; Ad E1A; transcription repression; p300; promoter interaction	TATA-BINDING PROTEIN; MAJOR LATE PROMOTER; ACTIVATES TRANSCRIPTION; MAMMALIAN-CELLS; IN-VITRO; COACTIVATOR; DIFFERENTIATION; RECRUITMENT; CHROMATIN; CBP/P300	Extensive mutational/functional analysis of the transcription-repression domain encoded in the N-terminal 80 amino acids of the adenovirus E1A 243R oncoprotein suggests a model for the molecular mechanism of E1A repression: E1A accesses transcriptional co-activators such as p300 on specific promoters and then interacts with TBP to disrupt the TBP - TATA complex. In support of this model, as reported here, a basal core promoter activated by tethering p300 is repressible by E1A at the promoter level as shown by chromatin immunoprecipitation (ChIP) analysis. Sequestration of p300 by E1A does not play a significant role, as indicated by dose-response measurements. Furthermore, when the core promoter is transcriptionally activated by tethering activation domains of several transcription factors that can recruit p300 (p65, MyoD, cMyb and TFE3), transcription is repressible by E1A. However, when the core promoter is activated by factors not known to recruit p300 (USF1 and USF2), transcription is resistant to E1A repression. Finally, tethering p300 to the non-repressible adenovirus major late promoter (MLP) renders it repressible by E1A. ChIP analysis shows that E1A occupies the repressed MLP. These findings provide support for the hypothesis that p300 can serve as a scaffold for the E1A repression domain to access specific cellular gene promoters involved in growth regulation.	[Green, M.; Panesar, N. K.; Loewenstein, P. M.] St Louis Univ, Sch Med, Inst Mol Virol, EA Doisy Res Ctr, St Louis, MO 63104 USA	Saint Louis University	Green, M (corresponding author), St Louis Univ, Sch Med, Inst Mol Virol, EA Doisy Res Ctr, 1100 S Grand Blvd, St Louis, MO 63104 USA.	green@slu.edu			NCI NIH HHS [CA29561] Funding Source: Medline; NIAID NIH HHS [AI-04739] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA029561] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Berk AJ, 2005, ONCOGENE, V24, P7673, DOI 10.1038/sj.onc.1209040; Boyd JM, 2002, J VIROL, V76, P1461, DOI 10.1128/JVI.76.3.1461-1474.2002; Burgers WA, 2007, ONCOGENE, V26, P1650, DOI 10.1038/sj.onc.1209950; CARTHEW RW, 1985, CELL, V43, P439, DOI 10.1016/0092-8674(85)90174-6; Chan HM, 2001, J CELL SCI, V114, P2363; CHINNADURAI G, 2006, NUCLEUS; Chinnadurai G., 2006, CTBP FAMILY PROTEINS, P1; Dorris DR, 2000, MOL CELL BIOL, V20, P4350, DOI 10.1128/MCB.20.12.4350-4358.2000; ECKNER R, 1994, GENE DEV, V8, P869, DOI 10.1101/gad.8.8.869; Frisch SM, 2002, NAT REV MOL CELL BIO, V3, P441, DOI 10.1038/nrm827; Gallimore PH, 2001, ONCOGENE, V20, P7824, DOI 10.1038/sj.onc.1204913; Goodman RH, 2000, GENE DEV, V14, P1553; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GREEN M, 1988, CELL, V53, P921, DOI 10.1016/S0092-8674(88)90429-1; Green M, 2008, VIROLOGY, V371, P1, DOI 10.1016/j.virol.2007.10.021; Lavrrar JL, 2004, J BIOL CHEM, V279, P46343, DOI 10.1074/jbc.M402692200; LILLIE JW, 1987, CELL, V50, P1091, DOI 10.1016/0092-8674(87)90175-9; Loewenstein PM, 2006, VIROLOGY, V351, P312, DOI 10.1016/j.virol.2006.03.041; Luo X, 1996, P NATL ACAD SCI USA, V93, P1308, DOI 10.1073/pnas.93.3.1308; MORAN E, 1993, CURR OPIN GENET DEV, V3, P63, DOI 10.1016/S0959-437X(05)80342-9; Parker SF, 1997, J VIROL, V71, P2004, DOI 10.1128/JVI.71.3.2004-2012.1997; Perkins ND, 1997, SCIENCE, V275, P523, DOI 10.1126/science.275.5299.523; Postigo AA, 1999, MOL CELL BIOL, V19, P7961; Postigo AA, 1999, P NATL ACAD SCI USA, V96, P6683, DOI 10.1073/pnas.96.12.6683; Qyang YB, 1999, MOL CELL BIOL, V19, P1508; Rasti M, 2005, J VIROL, V79, P5594, DOI 10.1128/JVI.79.9.5594-5605.2005; SAWADOGO M, 1985, CELL, V43, P165, DOI 10.1016/0092-8674(85)90021-2; SHENK T, 2001, FUNDAMENTAL VIROLOGY; SONG CZ, 1995, P NATL ACAD SCI USA, V92, P10330, DOI 10.1073/pnas.92.22.10330; SONG CZ, 1995, J VIROL, V69, P2907, DOI 10.1128/JVI.69.5.2907-2911.1995; Song CZ, 1997, MOL CELL BIOL, V17, P2186, DOI 10.1128/MCB.17.4.2186; SONG CZ, 1995, J BIOL CHEM, V40, P23263; Taatjes DJ, 2004, NAT REV MOL CELL BIO, V5, P403, DOI 10.1038/nrm1369; Takahashi Y, 2000, GENE DEV, V14, P804; WEBSTER KA, 1988, NATURE, V332, P553, DOI 10.1038/332553a0; Weilbaecher KN, 2001, MOL CELL, V8, P749, DOI 10.1016/S1097-2765(01)00360-4; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; Yuan WC, 1996, J BIOL CHEM, V271, P9009, DOI 10.1074/jbc.271.15.9009	38	9	10	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2008	27	32					4446	4455		10.1038/onc.2008.85	http://dx.doi.org/10.1038/onc.2008.85			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18408753				2022-12-25	WOS:000257881700007
J	Carlson, BL; Ballister, ER; Skordalakes, E; King, DS; Breidenbach, MA; Gilmore, SA; Berger, JM; Bertozzi, CR				Carlson, Brian L.; Ballister, Edward R.; Skordalakes, Emmanuel; King, David S.; Breidenbach, Mark A.; Gilmore, Sarah A.; Berger, James M.; Bertozzi, Carolyn R.			Function and structure of a prokaryotic formylglycine-generating enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIPLE SULFATASE DEFICIENCY; CRYSTAL-STRUCTURE; PROTEIN MODELS; MECHANISM; ALKYLSULFATASE; REFINEMENT; REPLACEMENT; PHOSPHATASE; INHIBITION; COFACTORS	Type I sulfatases require an unusual co-or post-translational modification for their activity in hydrolyzing sulfate esters. In eukaryotic sulfatases, an active site cysteine residue is oxidized to the aldehyde-containing C-alpha-formylglycine residue by the formylglycine-generating enzyme (FGE). The machinery responsible for sulfatase activation is poorly understood in prokaryotes. Here we describe the identification of a prokaryotic FGE from Mycobacterium tuberculosis. In addition, we solved the crystal structure of the Streptomyces coelicolor FGE homolog to 2.1 A resolution. The prokaryotic homolog exhibits remarkable structural similarity to human FGE, including the position of catalytic cysteine residues. Both biochemical and structural data indicate the presence of an oxidized cysteine modification in the active site that may be relevant to catalysis. In addition, we generated a mutant M. tuberculosis strain lacking FGE. Although global sulfatase activity was reduced in the mutant, a significant amount of residual sulfatase activity suggests the presence of FGE-independent sulfatases in this organism.	[Carlson, Brian L.; Skordalakes, Emmanuel; King, David S.; Gilmore, Sarah A.; Berger, James M.; Bertozzi, Carolyn R.] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; [Ballister, Edward R.; Breidenbach, Mark A.; Bertozzi, Carolyn R.] Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; [Carlson, Brian L.; Ballister, Edward R.; King, David S.; Breidenbach, Mark A.; Gilmore, Sarah A.; Bertozzi, Carolyn R.] Univ Calif Berkeley, Howard Hughes Med Inst, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley; Howard Hughes Medical Institute; University of California System; University of California Berkeley	Bertozzi, CR (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, B84 Hildebrand Hall, Berkeley, CA 94720 USA.	crb@berkeley.edu	Skordalakes, Emmanuel/H-7071-2019	Ballister, Edward/0000-0002-4478-2513; Skordalakes, Emmanuel/0000-0002-7600-2833	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI068135] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM059907] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 051662, AI 068135] Funding Source: Medline; NIGMS NIH HHS [GM 059907] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1997, NUCLEIC ACIDS RES, V25, P3402; Berteau O, 2006, J BIOL CHEM, V281, P22464, DOI 10.1074/jbc.M602504200; Breidenbach MA, 2004, NATURE, V432, P925, DOI 10.1038/nature03123; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Carrico IS, 2007, NAT CHEM BIOL, V3, P321, DOI 10.1038/nchembio878; Cosma MP, 2003, CELL, V113, P445, DOI 10.1016/S0092-8674(03)00348-9; Dickmanns A, 2005, J BIOL CHEM, V280, P15180, DOI 10.1074/jbc.M414317200; Dierks T, 2005, CELL, V121, P541, DOI 10.1016/j.cell.2005.03.001; Dierks T, 1999, EMBO J, V18, P2084, DOI 10.1093/emboj/18.8.2084; Dierks T, 2003, CELL, V113, P435, DOI 10.1016/S0092-8674(03)00347-7; Diez-Roux G, 2005, ANNU REV GENOM HUM G, V6, P355, DOI 10.1146/annurev.genom.6.080604.162334; Ellis HR, 1997, BIOCHEMISTRY-US, V36, P15013, DOI 10.1021/bi972191x; Fetzner S, 2002, APPL MICROBIOL BIOT, V60, P243, DOI 10.1007/s00253-002-1123-4; Hagelueken G, 2006, P NATL ACAD SCI USA, V103, P7631, DOI 10.1073/pnas.0510501103; HAGEMAN TC, 1974, ARCH BIOCHEM BIOPHYS, V164, P707, DOI 10.1016/0003-9861(74)90083-6; Hanson SR, 2004, ANGEW CHEM INT EDIT, V43, P5736, DOI 10.1002/anie.200300632; HATFULL GF, 2000, MOL GENETICS MYCOBAC, P313; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kahnert A, 2000, J BIOL CHEM, V275, P31661, DOI 10.1074/jbc.M005820200; Kertesz MA, 2000, FEMS MICROBIOL REV, V24, P135, DOI 10.1016/S0168-6445(99)00033-9; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemieux GA, 1998, TRENDS BIOTECHNOL, V16, P506, DOI 10.1016/S0167-7799(98)01230-X; Lukatela G, 1998, BIOCHEMISTRY-US, V37, P3654, DOI 10.1021/bi9714924; Mougous JD, 2002, CHEM BIOL, V9, P767, DOI 10.1016/S1074-5521(02)00175-8; Muller I, 2004, BIOCHEMISTRY-US, V43, P3075, DOI 10.1021/bi035752v; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; O'Brien PJ, 1998, J AM CHEM SOC, V120, P12369, DOI 10.1021/ja983390m; Okeley NM, 2000, CHEM BIOL, V7, pR159, DOI 10.1016/S1074-5521(00)00140-X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Parish T, 2000, MICROBIOL-SGM, V146, P1969, DOI 10.1099/00221287-146-8-1969; Roeser D, 2006, P NATL ACAD SCI USA, V103, P81, DOI 10.1073/pnas.0507592102; Sardiello M, 2005, HUM MOL GENET, V14, P3203, DOI 10.1093/hmg/ddi351; Sareen D, 2003, J BACTERIOL, V185, P6736, DOI 10.1228/JB.185.22.6736-6740.2003; SCHMIDT B, 1995, CELL, V82, P271, DOI 10.1016/0092-8674(95)90314-3; STANKIEWICZ PJ, 1988, BIOCHEMISTRY-US, V27, P206, DOI 10.1021/bi00401a031; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Szameit C, 1999, J BIOL CHEM, V274, P15375, DOI 10.1074/jbc.274.22.15375; Terwilliger TC, 2004, ACTA CRYSTALLOGR D, V60, P2144, DOI 10.1107/S0907444904019535; Wentworth P, 2001, SCIENCE, V293, P1806, DOI 10.1126/science.1062722; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; ZHANG L, 1988, INFECT IMMUN, V56, P2876, DOI 10.1128/IAI.56.11.2876-2883.1988	42	80	104	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20117	20125		10.1074/jbc.M800217200	http://dx.doi.org/10.1074/jbc.M800217200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18390551	Green Published, hybrid			2022-12-25	WOS:000257565300028
J	Visanji, NP; Orsi, A; Johnston, TH; Howson, PA; Dixon, K; Callizot, N; Brotchie, JM; Rees, DD				Visanji, Naomi P.; Orsi, Antonia; Johnston, Tom H.; Howson, Patrick A.; Dixon, Kimberly; Callizot, Noelle; Brotchie, Jonathan M.; Rees, Daryl D.			PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP+ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease	FASEB JOURNAL			English	Article						BDNF; GDNF; neurorestorative; striatum; Cogane	NIGRAL DOPAMINE NEURONS; SUBSTANTIA-NIGRA; FUNCTIONAL RECOVERY; PRIMATE MODELS; RAT MODEL; CELL-CULTURES; GENE-TRANSFER; IN-VIVO; 2 PARTS; GDNF	Many experimental data support the enhancement of neurotrophic factors as a means to modify neurodegeneration in Parkinson's disease. However, the translation of this to the clinic has proven problematic. This is likely due to the complex nature of the surgical gene delivery and cell-based approaches adopted to deliver proteinaceous neurotrophic factors to targets within the central nervous system. We investigated the ability of a novel, orally active, nonpeptide neurotrophic factor inducer, PYM50028 (Cogane), to restore dopaminergic function after 1-methyl-4-phenylpyridinium (MPP+) -induced damage to mesencephalic neurons in vitro and in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) -lesioned mice. In rat mesencephalic neurons, administration of PYM50028, either before or after MPP+, significantly prevented and reversed both MPP+ -induced neuronal atrophy and cell loss. These effects were potent and of a magnitude equivalent to those achieved by a combination of brain-derived neurotrophic factor (BDNF) and glial-derived neurotrophic factor (GDNF). Oral administration of PYM50028 (10 mg/kg/day for 60 days) to MPTP-lesioned mice, commencing after a striatal impairment was evident, resulted in a significant elevation of striatal GDNF (297%) and BDNF (511%), and attenuated the loss of striatal dopaminergic transporter levels and dopaminergic neurons in the substantia nigra. PYM50028 did not inhibit monoamine oxidase B in vitro, nor did it alter brain levels of MPP+ in vivo. PYM50028 has neuroprotective and neurorestorative potential and is in clinical development for the treatment of neurodegenerative disorders, including Parkinson's disease.	[Visanji, Naomi P.; Johnston, Tom H.; Dixon, Kimberly; Brotchie, Jonathan M.] Toronto Western Res Inst, Toronto, ON M5T 2S8, Canada; [Orsi, Antonia; Howson, Patrick A.; Callizot, Noelle; Rees, Daryl D.] Phytopharm Plc, Godmanchester, Cambs, England	University of Toronto; University Toronto Affiliates; University Health Network Toronto	Brotchie, JM (corresponding author), Toronto Western Res Inst, MCL 11-419, Toronto, ON M5T 2S8, Canada.	brotchie@uhnres.utoronto.ca	Visanji, Naomi P/AAW-4618-2021; Johnston, Tom H/D-2531-2018	Johnston, Tom H/0000-0002-1537-8175; Brotchie, Jonathan/0000-0003-2337-0816; Visanji, Naomi/0000-0001-5968-7845				ALTAR CA, 1994, J NEUROCHEM, V63, P1021; Bjorklund A, 2003, LANCET NEUROL, V2, P437, DOI 10.1016/S1474-4422(03)00442-3; Chauhan NB, 2001, J CHEM NEUROANAT, V21, P277, DOI 10.1016/S0891-0618(01)00115-6; Connor B, 1998, BRAIN RES REV, V27, P1, DOI 10.1016/S0165-0173(98)00004-6; Dawson TM, 2002, NAT NEUROSCI, V5, P1058, DOI 10.1038/nn941; Ericson C, 2005, EUR J NEUROSCI, V22, P2755, DOI 10.1111/j.1460-9568.2005.04503.x; Eslamboli A, 2005, REV NEUROSCIENCE, V16, P303; Fabbrini G, 2007, MOVEMENT DISORD, V22, P1379, DOI 10.1002/mds.21475; FADDA E, 1993, NEUROSCI LETT, V159, P147, DOI 10.1016/0304-3940(93)90820-B; Feng LY, 1999, MOL BRAIN RES, V66, P62, DOI 10.1016/S0169-328X(99)00015-7; Gash DM, 1996, NATURE, V380, P252, DOI 10.1038/380252a0; Gerhardt GA, 1999, BRAIN RES, V817, P163, DOI 10.1016/S0006-8993(98)01244-X; Gill SS, 2003, NAT MED, V9, P589, DOI 10.1038/nm850; Grandoso L, 2007, INT J PHARMACEUT, V343, P69, DOI 10.1016/j.ijpharm.2007.05.027; Grondin R, 2002, BRAIN, V125, P2191, DOI 10.1093/brain/awf234; Hung H C, 1996, Brain Res Mol Brain Res, V41, P14; Jackson-Lewis V, 2007, NAT PROTOC, V2, P141, DOI 10.1038/nprot.2006.342; KEARNS CM, 1995, BRAIN RES, V672, P104, DOI 10.1016/0006-8993(94)01366-P; Klein RL, 1999, BRAIN RES, V847, P314, DOI 10.1016/S0006-8993(99)02116-2; Kobori N, 2006, BRAIN RES, V1086, P142, DOI 10.1016/j.brainres.2006.02.111; Kordower JH, 2000, SCIENCE, V290, P767, DOI 10.1126/science.290.5492.767; Lang AE, 1998, NEW ENGL J MED, V339, P1130, DOI 10.1056/NEJM199810153391607; Lang AE, 2006, ANN NEUROL, V59, P459, DOI 10.1002/ana.20737; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Levivier M, 1995, J NEUROSCI, V15, P7810, DOI 10.1523/jneurosci.15-12-07810.1995; Lotharius J, 1999, J NEUROSCI, V19, P1284; MartinezSerrano A, 1997, TRENDS NEUROSCI, V20, P530, DOI 10.1016/S0166-2236(97)01119-3; McBride JL, 2006, P NATL ACAD SCI USA, V103, P9345, DOI 10.1073/pnas.0508875103; Nishio T, 1998, NEUROREPORT, V9, P2847, DOI 10.1097/00001756-199808240-00030; Nutt JG, 2003, NEUROLOGY, V60, P69, DOI 10.1212/WNL.60.1.69; Oiwa Y, 2006, NEUROL MED-CHIR, V46, P267, DOI 10.2176/nmc.46.267; Ostergaard K, 1996, EXP NEUROL, V142, P340, DOI 10.1006/exnr.1996.0203; Palfi S, 2002, J NEUROSCI, V22, P4942, DOI 10.1523/JNEUROSCI.22-12-04942.2002; Rosenblad C, 2000, EXP NEUROL, V161, P503, DOI 10.1006/exnr.1999.7296; Saavedra A, 2005, FREE RADICAL BIO MED, V39, P1611, DOI 10.1016/j.freeradbiomed.2005.08.005; SCHINELLI S, 1988, J NEUROCHEM, V50, P1900, DOI 10.1111/j.1471-4159.1988.tb02495.x; Sherer TB, 2006, MOVEMENT DISORD, V21, P136, DOI 10.1002/mds.20861; Singh Shalini, 2006, Indian Journal of Experimental Biology, V44, P699; Slevin JT, 2007, J NEUROSURG, V106, P614, DOI 10.3171/jns.2007.106.4.614; Son JH, 1999, J NEUROSCI, V19, P10, DOI 10.1523/JNEUROSCI.19-01-00010.1999; TOMAC A, 1995, NATURE, V373, P335, DOI 10.1038/373335a0	41	64	72	0	1	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2488	2497		10.1096/fj.07-095398	http://dx.doi.org/10.1096/fj.07-095398			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18364399				2022-12-25	WOS:000257292500040
J	Hossain, MI; Iwasaki, H; Okochi, Y; Chahine, M; Higashijima, S; Nagayama, K; Okamura, Y				Hossain, Md. Israil; Iwasaki, Hirohide; Okochi, Yoshifumi; Chahine, Mohamed; Higashijima, Shinichi; Nagayama, Kuniaki; Okamura, Yasushi			Enzyme domain affects the movement of the voltage sensor in ascidian and zebrafish voltage-sensing phosphatases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							K+ CHANNEL; STRUCTURAL BASIS; SURFACE-CHARGE; MUTANT	The ascidian voltage-sensing phosphatase (Ci-VSP) consists of the voltage sensor domain (VSD) and a cytoplasmic phosphatase region that has significant homology to the phosphatase and tensin homolog deleted on chromosome TEN (PTEN). The phosphatase activity of Ci-VSP is modified by the conformational change of the VSD. In many proteins, two protein modules are bidirectionally coupled, but it is unknown whether the phosphatase domain could affect the movement of the VSD in VSP. We addressed this issue by whole-cell patch recording of gating currents from a teleost VSP (Dr-VSP) cloned from Danio rerio expressed in tsA201 cells. Replacement of a critical cysteine residue, in the phosphatase active center of Dr-VSP, by serine sharpened both ON- and OFF-gating currents. Similar changes were produced by treatment with phosphatase inhibitors, pervanadate and orthovanadate, that constitutively bind to cysteine in the active catalytic center of phosphatases. The distinct kinetics of gating currents dependent on enzyme activity were not because of altered phosphatidylinositol 4,5-bisphosphate levels, because the kinetics of gating current did not change by depletion of phosphatidylinositol 4,5-bisphosphate, as reported by coexpressed KCNQ2/3 channels. These results indicate that the movement of the VSD is influenced by the enzymatic state of the cytoplasmic domain, providing an important clue for understanding mechanisms of coupling between the VSD and its effector.	[Hossain, Md. Israil; Iwasaki, Hirohide; Okochi, Yoshifumi; Higashijima, Shinichi; Okamura, Yasushi] Natl Inst Physiol Sci, Okazaki Inst Integrat Biosci, Dept Dev Neurophysiol, Okazaki, Aichi 4448787, Japan; [Hossain, Md. Israil; Nagayama, Kuniaki] Okazaki Inst Integrat Biosci, Dept Nanoanat, Okazaki, Aichi 4448787, Japan; [Hossain, Md. Israil; Iwasaki, Hirohide; Okochi, Yoshifumi; Higashijima, Shinichi; Nagayama, Kuniaki; Okamura, Yasushi] Natl Inst Nat Sci, Natl Inst Physiol Sci, Okazaki, Aichi 4448787, Japan; [Hossain, Md. Israil; Iwasaki, Hirohide; Higashijima, Shinichi; Nagayama, Kuniaki; Okamura, Yasushi] Grad Univ Adv Studies, Okazaki, Aichi 4448787, Japan; [Okochi, Yoshifumi; Okamura, Yasushi] Osaka Univ, Grad Sch Med, Suita, Osaka 5650871, Japan; [Chahine, Mohamed] Univ Laval, Dept Med, Quebec City, PQ G1J 2G3, Canada; [Chahine, Mohamed] Univ Laval Robert Giffard, Le Ctr Rech, Quebec City, PQ G1J 2G3, Canada	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Okazaki Institute for Integrative Bioscience (OIIB); National Institutes of Natural Sciences (NINS) - Japan; Okazaki Institute for Integrative Bioscience (OIIB); National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Graduate University for Advanced Studies - Japan; Osaka University; Laval University; Laval University	Okamura, Y (corresponding author), Natl Inst Physiol Sci, Okazaki Inst Integrat Biosci, Dept Dev Neurophysiol, Higashiyama 5-1, Okazaki, Aichi 4448787, Japan.	yokamura@phys2.med.osaka-u.ac.jp	Nagayama, Kuniaki/O-2522-2018	Higashijima, Shin-ichi/0000-0001-6350-4992; Iwasaki, Hirohide/0000-0002-7432-5938				Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Alabi AA, 2007, NATURE, V450, P370, DOI 10.1038/nature06266; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Chen FSP, 1997, J GEN PHYSIOL, V110, P87, DOI 10.1085/jgp.110.2.87; GOLDIN AL, 1992, METHOD ENZYMOL, V207, P266; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Horn R, 2000, J GEN PHYSIOL, V116, P461, DOI 10.1085/jgp.116.3.461; Hossain I, 2007, BIOPHYS J, p550A; Hu X, 2006, BIOPHYS J, V91, P948, DOI 10.1529/biophysj.105.080259; JIA ZC, 1995, SCIENCE, V268, P1754, DOI 10.1126/science.7540771; Kohout SC, 2008, NAT STRUCT MOL BIOL, V15, P106, DOI 10.1038/nsmb1320; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2005, SCIENCE, V309, P903, DOI 10.1126/science.1116270; Long SB, 2007, NATURE, V450, P376, DOI 10.1038/nature06265; Maehama T, 1998, J BIOL CHEM, V273, P13375, DOI 10.1074/jbc.273.22.13375; Maehama T, 2000, ANAL BIOCHEM, V279, P248, DOI 10.1006/abio.2000.4497; MOCZYDLOWSKI E, 1985, J MEMBRANE BIOL, V83, P273, DOI 10.1007/BF01868701; Murata Y, 2005, NATURE, V435, P1239, DOI 10.1038/nature03650; Murata Y, 2007, J PHYSIOL-LONDON, V583, P875, DOI 10.1113/jphysiol.2007.134775; OHMORI H, 1977, J PHYSIOL-LONDON, V267, P429, DOI 10.1113/jphysiol.1977.sp011821; Ramsey IS, 2006, NATURE, V440, P1213, DOI 10.1038/nature04700; Reiland J, 1996, BIOCHEM J, V319, P39, DOI 10.1042/bj3190039; Scapin G, 2001, PROTEIN SCI, V10, P1596, DOI 10.1110/ps.11001; Schmidt D, 2006, NATURE, V444, P775, DOI 10.1038/nature05416; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; Thornhill WB, 1996, J BIOL CHEM, V271, P19093, DOI 10.1074/jbc.271.32.19093; Wang HS, 1998, SCIENCE, V282, P1890, DOI 10.1126/science.282.5395.1890; Watanabe I, 2003, J PHYSIOL-LONDON, V550, P51, DOI 10.1113/jphysiol.2003.040337; Xu YP, 2008, NATURE, V451, P826, DOI 10.1038/nature06618; Zhang HL, 2003, NEURON, V37, P963, DOI 10.1016/S0896-6273(03)00125-9; Zhang ZY, 1998, CRIT REV BIOCHEM MOL, V33, P1, DOI 10.1080/10409239891204161; ZHOU W, 1995, J GEN PHYSIOL, V105, P441, DOI 10.1085/jgp.105.4.441	33	88	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18248	18259		10.1074/jbc.M706184200	http://dx.doi.org/10.1074/jbc.M706184200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18375390				2022-12-25	WOS:000256949200053
J	Smolinsky, B; Eichler, SA; Buchmeier, S; Meier, JC; Schwarz, G				Smolinsky, Birthe; Eichler, Sabrina A.; Buchmeier, Sabine; Meier, Jochen C.; Schwarz, Guenter			Splice-specific functions of gephyrin in molybdenum cofactor biosynthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCINE RECEPTOR; PROTEIN GEPHYRIN; INHIBITORY SYNAPSES; CRYSTAL-STRUCTURE; MOLECULAR-BASIS; ACTIVE-SITE; BINDING; GENE; MOLYBDOPTERIN; MECHANISM	Gephyrin is a multifunctional protein involved in the clustering of inhibitory neuroreceptors. In addition, gephyrin catalyzes the last step in molybdenum cofactor (Moco) biosynthesis essential for the activities of Mo-dependent enzymes such as sulfite oxidase and xanthine oxidoreductase. Functional complexity and diversity of gephyrin is believed to be regulated by alternative splicing in a tissue-specific manner. Here, we investigated eight gephyrin variants with combinations of seven alternatively spliced exons located in the N-terminal G domain, the central domain, and the C-terminal E domain. Their activity in Moco synthesis was analyzed in vivo by reconstitution of gephyrin-deficient L929 cells, which were found to be defective in the G domain of gephyrin. Individual domain functions were assayed in addition and confirmed that variants containing either an additional C5 cassette or missing the C6 cassette are inactive in Moco synthesis. In contrast, different alterations within the central domain retained the Moco synthetic activity of gephyrin. The recombinant gephyrin G domain containing the C5 cassette forms dimers in solution, binds molybdopterin, but is unable to catalyze molybdopterin (MPT) adenylylation. Determination of Moco and MPT content in different tissues showed that besides liver and kidney, brain was capable of synthesizing Moco most efficiently. Subsequent analysis of cultured neurons and glia cells demonstrated glial Moco synthesis due to the expression of gephyrins containing the cassettes C2 and C6 with and without C3.	[Smolinsky, Birthe; Schwarz, Guenter] Univ Cologne, Inst Biochem, D-50674 Cologne, Germany; [Smolinsky, Birthe; Schwarz, Guenter] Univ Cologne, Ctr Mol Med, D-50674 Cologne, Germany; [Eichler, Sabrina A.; Meier, Jochen C.] Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany; [Buchmeier, Sabine] Tech Univ Carolo Wilhelmina Braunschweig, Inst Zool, D-38106 Braunschweig, Germany	University of Cologne; University of Cologne; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Braunschweig University of Technology	Schwarz, G (corresponding author), Univ Cologne, Inst Biochem, Otto Fischer Str 12-14, D-50674 Cologne, Germany.	gschwarz@uni-koeln.de	Schwarz, Guenter/ABE-9643-2021	Schwarz, Guenter/0000-0002-2118-9338; Meier, Jochen/0000-0001-5574-3336				Bedet C, 2006, J BIOL CHEM, V281, P30046, DOI 10.1074/jbc.M602155200; BREWER GJ, 1989, BRAIN RES, V494, P65, DOI 10.1016/0006-8993(89)90144-3; David-Watine B, 2001, GENE, V271, P239, DOI 10.1016/S0378-1119(01)00511-X; Feng GP, 1998, SCIENCE, V282, P1321, DOI 10.1126/science.282.5392.1321; Fuhrmann JC, 2002, J NEUROSCI, V22, P5393; Giesemann T, 2003, J NEUROSCI, V23, P8330; Gutzke G, 2001, J BIOL CHEM, V276, P36268, DOI 10.1074/jbc.M105321200; Harvey K, 2004, J NEUROSCI, V24, P5816, DOI 10.1523/JNEUROSCI.1184-04.2004; Hasona A, 1998, J BACTERIOL, V180, P1466, DOI 10.1128/JB.180.6.1466-1472.1998; Kim EY, 2006, EMBO J, V25, P1385, DOI 10.1038/sj.emboj.7601029; Kins S, 2000, NAT NEUROSCI, V3, P22, DOI 10.1038/71096; KIRSCH J, 1995, MOL CELL NEUROSCI, V6, P450, DOI 10.1006/mcne.1995.1033; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; Kneussel M, 2000, P NATL ACAD SCI USA, V97, P8594, DOI 10.1073/pnas.97.15.8594; Kneussel M, 2000, TRENDS NEUROSCI, V23, P429, DOI 10.1016/S0166-2236(00)01627-1; Kuper J, 2000, P NATL ACAD SCI USA, V97, P6475, DOI 10.1073/pnas.110568497; Kuper J, 2004, NATURE, V430, P803, DOI 10.1038/nature02681; Kuper J, 2003, ARCH BIOCHEM BIOPHYS, V411, P36, DOI 10.1016/S0003-9861(02)00714-2; Lardi-Studler B, 2007, J CELL SCI, V120, P1371, DOI 10.1242/jcs.003905; Lee HJ, 2002, HUM MOL GENET, V11, P3309, DOI 10.1093/hmg/11.26.3309; Liu MTW, 2000, J BIOL CHEM, V275, P1814, DOI 10.1074/jbc.275.3.1814; Llamas A, 2004, J BIOL CHEM, V279, P55241, DOI 10.1074/jbc.M409862200; Llamas A, 2006, J BIOL CHEM, V281, P18343, DOI 10.1074/jbc.M601415200; Meier J, 2000, MOL CELL NEUROSCI, V16, P566, DOI 10.1006/mcne.2000.0899; Meier J, 2004, J NEUROSCI, V24, P1398, DOI 10.1523/JNEUROSCI.4260-03.2004; Meier J, 2002, MOL CELL NEUROSCI, V21, P324, DOI 10.1006/mcne.2002.1161; MEYER G, 1995, NEURON, V15, P563, DOI 10.1016/0896-6273(95)90145-0; Nichols JD, 2007, BIOCHEMISTRY-US, V46, P78, DOI 10.1021/bi061551q; Paarmann I, 2006, J BIOL CHEM, V281, P34918, DOI 10.1074/jbc.M607764200; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; Ramming M, 2000, P NATL ACAD SCI USA, V97, P10266, DOI 10.1073/pnas.97.18.10266; Rees MI, 2003, J BIOL CHEM, V278, P24688, DOI 10.1074/jbc.M301070200; Reiss J, 2003, HUM MUTAT, V21, P569, DOI 10.1002/humu.10223; Reiss J, 2001, AM J HUM GENET, V68, P208, DOI 10.1086/316941; Saiyed T, 2007, J BIOL CHEM, V282, P5625, DOI 10.1074/jbc.M610290200; Santamaria-Araujo JA, 2004, J BIOL CHEM, V279, P15994, DOI 10.1074/jbc.M311815200; Schrader N, 2004, J BIOL CHEM, V279, P18733, DOI 10.1074/jbc.M311245200; Schwarz G, 2005, CELL MOL LIFE SCI, V62, P2792, DOI 10.1007/s00018-005-5269-y; Schwarz G, 2001, J MOL BIOL, V312, P405, DOI 10.1006/jmbi.2001.4952; Schwarz G, 2000, PLANT CELL, V12, P2455, DOI 10.1105/tpc.12.12.2455; Sola M, 2004, EMBO J, V23, P2510, DOI 10.1038/sj.emboj.7600256; Sola M, 2001, J BIOL CHEM, V276, P25294, DOI 10.1074/jbc.M101923200; Stallmeyer B, 1999, P NATL ACAD SCI USA, V96, P1333, DOI 10.1073/pnas.96.4.1333; Tretter V, 2008, J NEUROSCI, V28, P1356, DOI 10.1523/JNEUROSCI.5050-07.2008; Zita MM, 2007, EMBO J, V26, P1761, DOI 10.1038/sj.emboj.7601625	46	37	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17370	17379		10.1074/jbc.M800985200	http://dx.doi.org/10.1074/jbc.M800985200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18411266	hybrid			2022-12-25	WOS:000256720600046
J	Solmaz, SRN; Hunte, C				Solmaz, Sozanne R. N.; Hunte, Carola			Structure of complex III with bound cytochrome c in reduced state and definition of a minimal core interface for electron transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BC(1) COMPLEX; RHODOBACTER-SPHAEROIDES; UBIQUINOL OXIDATION; RESPIRATORY-CHAIN; PARAMAGNETIC NMR; PROTEIN; YEAST; C(2); BINDING	In cellular respiration, cytochrome c transfers electrons from cytochrome bc(1) complex (complex III) to cytochrome c oxidase by transiently binding to the membrane proteins. Here, we report the structure of isoform-1 cytochrome c bound to cytochrome bc(1) complex at 1.9 angstrom resolution in reduced state. The dimer structure is asymmetric. Monovalent cytochrome c binding is correlated with conformational changes of the Rieske head domain and subunit QCR6p and with a higher number of interfacial water molecules bound to cytochrome c(1). Pronounced hydration and a "mobility mismatch" at the interface with disordered charged residues on the cytochrome c side are favorable for transient binding. Within the hydrophobic interface, a minimal core was identified by comparison with the novel structure of the complex with bound isoform-2 cytochrome c. Four core interactions encircle the heme cofactors surrounded by variable interactions. The core interface may be a feature to gain specificity for formation of the reactive complex.	[Solmaz, Sozanne R. N.; Hunte, Carola] Max Planck Inst Biophys, Dept Mol Membrane Biol, D-60438 Frankfurt, Germany; [Hunte, Carola] Max Planck Inst Biophys, D-60539 Frankfurt, Germany	Max Planck Society; Max Planck Society	Hunte, C (corresponding author), Univ Leeds, IMSB, Leeds LS2 9JT, W Yorkshire, England.	c.hunte@leeds.ac.uk	Hunte, Carola/E-4071-2015	Hunte, Carola/0000-0002-0826-3986; Solmaz, Sozanne R/0000-0002-1703-3701				Autenrieth F, 2004, J PHYS CHEM B, V108, P20376, DOI 10.1021/jp047994q; Axelrod HL, 2002, J MOL BIOL, V319, P501, DOI 10.1016/S0022-2836(02)00168-7; Banci L, 1999, J BIOL INORG CHEM, V4, P21, DOI 10.1007/s007750050285; Berry EA, 2000, ANNU REV BIOCHEM, V69, P1005, DOI 10.1146/annurev.biochem.69.1.1005; Bogan AA, 1998, J MOL BIOL, V280, P1, DOI 10.1006/jmbi.1998.1843; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Crowley PB, 2002, CHEMBIOCHEM, V3, P526, DOI 10.1002/1439-7633(20020603)3:6<526::AID-CBIC526>3.0.CO;2-N; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Gallivan JP, 1999, P NATL ACAD SCI USA, V96, P9459, DOI 10.1073/pnas.96.17.9459; Guo ML, 2004, P NATL ACAD SCI USA, V101, P5940, DOI 10.1073/pnas.0306708101; Hunte C, 2002, BBA-BIOENERGETICS, V1555, P21, DOI 10.1016/S0005-2728(02)00249-9; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; KIM CH, 1983, J BIOL CHEM, V258, P3543; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lange C, 2002, P NATL ACAD SCI USA, V99, P2800, DOI 10.1073/pnas.052704699; LAZ TM, 1984, P NATL ACAD SCI-BIOL, V81, P4475, DOI 10.1073/pnas.81.14.4475; Lo Conte L, 1999, J MOL BIOL, V285, P2177; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Miyashita O, 2004, P NATL ACAD SCI USA, V101, P16174, DOI 10.1073/pnas.0405745101; Miyashita O, 2003, BIOCHEMISTRY-US, V42, P11651, DOI 10.1021/bi0350250; MURPHY MEP, 1992, J MOL BIOL, V227, P160, DOI 10.1016/0022-2836(92)90689-H; Page CC, 1999, NATURE, V402, P47, DOI 10.1038/46972; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; Pogorelov TV, 2007, J PHYS CHEM B, V111, P618, DOI 10.1021/jp064973i; Reichmann D, 2005, P NATL ACAD SCI USA, V102, P57, DOI 10.1073/pnas.0407280102; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; Schneider TR, 2004, ACTA CRYSTALLOGR D, V60, P2269, DOI 10.1107/S0907444904023492; SCHOPPINK PJ, 1988, EUR J BIOCHEM, V173, P115, DOI 10.1111/j.1432-1033.1988.tb13974.x; SPECK SH, 1979, P NATL ACAD SCI USA, V76, P155, DOI 10.1073/pnas.76.1.155; SPECK SH, 1984, J BIOL CHEM, V259, P1064; Trumpower BL, 2002, BBA-BIOENERGETICS, V1555, P166, DOI 10.1016/S0005-2728(02)00273-6; Ubbink M, 1998, STRUCTURE, V6, P323, DOI 10.1016/S0969-2126(98)00035-5; VANNESTE WH, 1966, BIOCHIM BIOPHYS ACTA, V113, P175, DOI 10.1016/S0926-6593(66)80132-7; Volkov AN, 2006, P NATL ACAD SCI USA, V103, P18945, DOI 10.1073/pnas.0603551103; WALLACE AC, 1995, PROTEIN ENG, V8, P127, DOI 10.1093/protein/8.2.127; Wedler G., 2004, LEHRBUCH PHYS CHEM; Wenz T, 2007, J BIOL CHEM, V282, P3977, DOI 10.1074/jbc.M606482200; Wienk H, 2003, BIOCHEMISTRY-US, V42, P6005, DOI 10.1021/bi027198f; YU CA, 1974, J BIOL CHEM, V249, P4905; Zhang ZL, 1998, NATURE, V392, P677, DOI 10.1038/33612	42	172	176	2	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17542	17549		10.1074/jbc.M710126200	http://dx.doi.org/10.1074/jbc.M710126200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18390544	hybrid			2022-12-25	WOS:000256720600061
J	Fan, YY; Yu, SY; Ito, H; Kameyama, A; Sato, T; Lin, CH; Yu, LC; Narimatsu, H; Khoo, KH				Fan, Yao-Yun; Yu, Shin-Yi; Ito, Hiromi; Kameyama, Akihiko; Sato, Takashi; Lin, Chi-Hung; Yu, Lung-Chih; Narimatsu, Hisashi; Khoo, Kay-Hooi			Identification of further elongation and branching of dimeric type 1 chain on lactosylceramides from colonic adenocarcinoma by tandem mass spectrometry sequencing analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I-EXTENSION ENZYME; CELL-LINES; CARBOHYDRATE-STRUCTURE; N-GLYCANS; ANTIGENS; EXPRESSION; GLYCOLIPIDS; LEA; GLYCOSPHINGOLIPIDS; GLYCOPROTEIN	Mammalian glycan chain elongation is mostly based on extending the type 2 chain, Gal beta 1-4GlcNAc, whereas the corresponding type 1 chain, Gal beta 1-3GlcNAc, is not normally extended. In a broader context of developing high sensitivity mass spectrometry methodologies for glycomic identification of Le(a) versus Le(x) and linear versus branched poly-N-acetyllactosamine (polyLacNAc), we have now shown that the dimeric type 1 glycan chain, as carried on the lactosylceramides of a human colonic adenocarcinoma cell line, Colo205, not only can be further extended linearly but can likewise be branched at C6 of 3-linked Gal in a manner similar to polyLacNAc. A combination of chemical and enzymatic derivatization coupled with advanced mass spectrometry analyses afforded unambiguous identification of a complex mixture of type 1 and 2 hybrids as well as those fucosylated variants founded exclusively on linear and branched trimeric type 1 chain. We further showed by in vitro enzymatic synthesis that extended type 1 and the hybrid chains can be branched by all three forms of the human I branching enzymes (IGnT) currently identified but with lower efficiency and stringency with respect to branching site preference. Importantly, it was found that a better substrate is one that carries a Gal site for branching that is extended at the non-reducing end by a type 2 and not a type 1 unit, whereas the IGnTs are less discriminative with respect to whether the targeted Gal site is itself beta 3- or beta 4-linked to GlcNAc at the reducing end.	[Fan, Yao-Yun; Yu, Shin-Yi; Lin, Chi-Hung; Yu, Lung-Chih; Khoo, Kay-Hooi] Acad Sinica, Inst Biol Chem, Taipei 11529, Taiwan; [Fan, Yao-Yun; Yu, Shin-Yi; Yu, Lung-Chih; Khoo, Kay-Hooi] Natl Taiwan Univ, Inst Biochem Sci, Taipei 106, Taiwan; [Ito, Hiromi; Kameyama, Akihiko; Sato, Takashi; Narimatsu, Hisashi] Natl Inst Adv Ind Sci & Technol, Glycogene Funct Team, Res Ctr Med Glycosci, Tsukuba, Ibaraki 3058568, Japan; [Lin, Chi-Hung] Acad Sinica, CBMB, Taiwan Int Grad Program, Taipei 115, Taiwan; [Lin, Chi-Hung] Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu 30013, Taiwan	Academia Sinica - Taiwan; National Taiwan University; National Institute of Advanced Industrial Science & Technology (AIST); Academia Sinica - Taiwan; National Tsing Hua University	Khoo, KH (corresponding author), Acad Sinica, Inst Biol Chem, 128 Acad Rd,Sec 2, Taipei 11529, Taiwan.	kkhoo@gate.sinica.edu.tw	Sato, Takashi/M-2577-2018; Fan, YaoYun/AAS-5920-2020; Narimatsu, Hisashi/M-4757-2018; Kameyama, Akihiko/A-9641-2008; Khoo, Kay-Hooi/E-1989-2019	Sato, Takashi/0000-0002-9973-8923; Narimatsu, Hisashi/0000-0002-8402-133X; Kameyama, Akihiko/0000-0002-8229-4449; Khoo, Kay-Hooi/0000-0003-2906-406X; YU, Shin-Yi/0000-0003-0197-9575				Angstrom J, 2004, GLYCOBIOLOGY, V14, P1, DOI 10.1093/glycob/cwh003; DELL A, 1983, CARBOHYD RES, V115, P41, DOI 10.1016/0008-6215(83)88133-6; DELL A, 1994, METHOD ENZYMOL, V230, P108; Dennis JW, 1999, BBA-GEN SUBJECTS, V1473, P21, DOI 10.1016/S0304-4165(99)00167-1; FUKUDA M, 1979, J BIOL CHEM, V254, P3700; HOLMES EH, 1987, J BIOL CHEM, V262, P15649; HOLMES EH, 1989, ARCH BIOCHEM BIOPHYS, V270, P630, DOI 10.1016/0003-9861(89)90546-8; Inaba N, 2003, BLOOD, V101, P2870, DOI 10.1182/blood-2002-09-2838; Isshiki S, 1999, J BIOL CHEM, V274, P12499, DOI 10.1074/jbc.274.18.12499; ITO H, 1992, CANCER RES, V52, P3739; ITZKOWITZ SH, 1988, CANCER RES, V48, P3834; Kameyama A, 2005, ANAL CHEM, V77, P4719, DOI 10.1021/ac048350h; KANNAGI R, 1985, J BIOL CHEM, V260, P6410; KARLSSON KA, 1981, J BIOL CHEM, V256, P3512; Koy C, 2003, PROTEOMICS, V3, P851, DOI 10.1002/pmic.200300381; Lin SW, 2006, BIOCHEMISTRY-US, V45, P8108, DOI 10.1021/bi0601297; MARTENSSON S, 1988, CANCER RES, V48, P2125; MIYAKE M, 1989, CANCER RES, V49, P5689; Muto S, 1999, BIOL PHARM BULL, V22, P347; NAKAMORI S, 1993, CANCER RES, V53, P3632; Shiraishi N, 2001, J BIOL CHEM, V276, P3498, DOI 10.1074/jbc.M004800200; Spina E, 2004, RAPID COMMUN MASS SP, V18, P392, DOI 10.1002/rcm.1350; STROUD MR, 1992, EUR J BIOCHEM, V203, P577, DOI 10.1111/j.1432-1033.1992.tb16586.x; STROUD MR, 1991, J BIOL CHEM, V266, P8439; Terada M, 2005, J BIOL CHEM, V280, P10897, DOI 10.1074/jbc.M413092200; Togayachi A, 2001, J BIOL CHEM, V276, P22032, DOI 10.1074/jbc.M011369200; Togayachi A, 2006, METHOD ENZYMOL, V416, P91, DOI 10.1016/S0076-6879(06)16006-1; Ujita M, 2000, J BIOL CHEM, V275, P15868, DOI 10.1074/jbc.M001034200; Ujita M, 1999, J BIOL CHEM, V274, P9296, DOI 10.1074/jbc.274.14.9296; Yu LC, 2003, BLOOD, V101, P2081, DOI 10.1182/blood-2002-09-2693; Yu SY, 2006, GLYCOCONJUGATE J, V23, P355, DOI 10.1007/s10719-006-8492-3	31	16	17	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16455	16468		10.1074/jbc.M707274200	http://dx.doi.org/10.1074/jbc.M707274200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18413313	Green Published, hybrid			2022-12-25	WOS:000256497100022
J	Touze, T; Blanot, D; Mengin-Lecreulx, D				Touze, Thierry; Blanot, Didier; Mengin-Lecreulx, Dominique			Substrate specificity and membrane topology of Escherichia coli PgpB, an undecaprenyl pyrophosphate phosphatase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECOGNITION SEQUENCE PEPTIDES; DOLICHYL PYROPHOSPHATE; ENDOPLASMIC-RETICULUM; MULTIPLE GENES; CARRIER LIPIDS; BACA GENE; PEPTIDOGLYCAN; IDENTIFICATION; BIOSYNTHESIS; COMPLEX	The synthesis of the lipid carrier undecaprenyl phosphate (C-55-P) requires the dephosphorylation of its precursor, undecaprenyl pyrophosphate (C-55-PP). The latter lipid is synthesized de novo in the cytosol and is also regenerated after its release from the C-55-PP-linked glycans in the periplasm. In Escherichia coli the dephosphorylation of C-55-PP was shown to involve four integral membrane proteins, BacA, and three members of the type 2 phosphatidic acid phosphatase family, PgpB, YbjG, and YeiU. Here, the PgpB protein was purified to homogeneity, and its phosphatase activity was examined. This enzyme was shown to catalyze the dephosphorylation of C-55-PP with a relatively low efficiency compared with diacylglycerol pyrophosphate and farnesyl pyrophosphate (C-15-PP) lipid substrates. However, the in vitro C-55-PP phosphatase activity of PgpB was specifically enhanced by different phospholipids. We hypothesize that the phospholipids are important determinants to ensure proper conformation of the atypical long axis C-55 carrier lipid in membranes. Furthermore, a topological analysis demonstrated that PgpB contains six transmembrane segments, a large periplasmic loop, and the type 2 phosphatidic acid phosphatase signature residues at a periplasmic location.	[Touze, Thierry] Univ Paris 11, CNRS, UMR8619, IBBMC,Lab Enveloppes Bacteriennes & Antibiot, F-91405 Orsay, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Touze, T (corresponding author), Univ Paris 11, CNRS, UMR8619, IBBMC,Lab Enveloppes Bacteriennes & Antibiot, Batiment 430, F-91405 Orsay, France.	thierry.touze@u-psud.fr	Touzé, Thierry/GLT-1308-2022	MENGIN-LECREULX, Dominique/0000-0003-3205-0275; Touze, Thierry/0000-0002-2176-6537				Alaimo C, 2006, EMBO J, V25, P967, DOI 10.1038/sj.emboj.7601024; Apfel CM, 1999, J BACTERIOL, V181, P483, DOI 10.1128/JB.181.2.483-492.1999; Bouhss A, 2008, FEMS MICROBIOL REV, V32, P208, DOI 10.1111/j.1574-6976.2007.00089.x; BROOMESMITH JK, 1990, MOL MICROBIOL, V4, P1637, DOI 10.1111/j.1365-2958.1990.tb00540.x; BUGG TDH, 1994, FEMS MICROBIOL LETT, V119, P255; Burda P, 1999, BBA-GEN SUBJECTS, V1426, P239, DOI 10.1016/S0304-4165(98)00127-5; Cadene M, 2000, ANAL CHEM, V72, P5655, DOI 10.1021/ac000811l; CAIN BD, 1993, J BACTERIOL, V175, P3784, DOI 10.1128/JB.175.12.3784-3789.1993; Chang SY, 2004, PROTEIN SCI, V13, P971, DOI 10.1110/ps.03519904; Chang SY, 2003, J BIOL CHEM, V278, P29298, DOI 10.1074/jbc.M302687200; Debarbieux L, 1997, J BACTERIOL, V179, P6692, DOI 10.1128/jb.179.21.6692-6698.1997; DEROPP JS, 1985, J BIOL CHEM, V260, P5669; Dillon DA, 1996, J BIOL CHEM, V271, P30548, DOI 10.1074/jbc.271.48.30548; El Ghachi M, 2005, J BIOL CHEM, V280, P18689, DOI 10.1074/jbc.M412277200; El Ghachi M, 2004, J BIOL CHEM, V279, P30106, DOI 10.1074/jbc.M401701200; Fernandez F, 2001, J BIOL CHEM, V276, P41455, DOI 10.1074/jbc.M105544200; FUNK CR, 1992, J BACTERIOL, V174, P205, DOI 10.1128/jb.174.1.205-213.1992; Guo RT, 2005, J BIOL CHEM, V280, P20762, DOI 10.1074/jbc.M502121200; ICHO T, 1983, J BACTERIOL, V153, P722, DOI 10.1128/JB.153.2.722-730.1983; Ishikawa K, 2000, EMBO J, V19, P2412, DOI 10.1093/emboj/19.11.2412; JOHNSON JG, 1977, J BACTERIOL, V129, P225, DOI 10.1128/JB.129.1.225-236.1977; Kato JI, 1999, J BACTERIOL, V181, P2733, DOI 10.1128/JB.181.9.2733-2738.1999; KENNEDY EP, 1996, ESCHERICHIA COLI SAL, P1064; Klammt C, 2004, EUR J BIOCHEM, V271, P568, DOI 10.1111/j.1432-1033.2003.03959.x; LEMAIRE M, 1986, ANAL BIOCHEM, V154, P525, DOI 10.1016/0003-2697(86)90025-4; Liu D, 1996, J BACTERIOL, V178, P2102, DOI 10.1128/jb.178.7.2102-2107.1996; Marolda CL, 2004, MICROBIOL-SGM, V150, P4095, DOI 10.1099/mic.0.27456-0; MCCLOSKEY MA, 1980, BIOCHEMISTRY-US, V19, P2056, DOI 10.1021/bi00551a008; MCCLOSKEY MA, 1980, BIOCHEMISTRY-US, V19, P2061, DOI 10.1021/bi00551a009; Miller J. H., 1972, EXPT MOL GENETICS, P431; Neuhaus FC, 2003, MICROBIOL MOL BIOL R, V67, P686, DOI 10.1128/MMBR.67.4.686-723.2003; Pompeo F, 1998, J BACTERIOL, V180, P4799, DOI 10.1128/JB.180.18.4799-4803.1998; Press WH, 1986, NUMERICAL RECIPES AR, P521; Raetz CRH, 2002, ANNU REV BIOCHEM, V71, P635, DOI 10.1146/annurev.biochem.71.110601.135414; Ravaud S, 2006, BIOCHEM J, V395, P345, DOI 10.1042/BJ20051719; Rick PD, 1998, GLYCOBIOLOGY, V8, P557, DOI 10.1093/glycob/8.6.557; Rush JS, 2008, J BIOL CHEM, V283, P4087, DOI 10.1074/jbc.M707067200; Rush JS, 2002, J BIOL CHEM, V277, P45226, DOI 10.1074/jbc.M207076200; SCHER M, 1968, P NATL ACAD SCI USA, V59, P1313, DOI 10.1073/pnas.59.4.1313; SIEWERT G, 1967, P NATL ACAD SCI USA, V57, P767, DOI 10.1073/pnas.57.3.767; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Stukey J, 1997, PROTEIN SCI, V6, P469; Tatar LD, 2007, MICROBIOL-SGM, V153, P2518, DOI 10.1099/mic.0.2007/006312-0; TOSCANO WA, 1982, PHARMACOL THERAPEUT, V16, P199, DOI 10.1016/0163-7258(82)90054-7; TOUZE T, 2008, ESCHERICHIA COLI SAL; Touze T, 2008, MOL MICROBIOL, V67, P264, DOI 10.1111/j.1365-2958.2007.06044.x; TROY FA, 1975, J BIOL CHEM, V250, P156; Valvano MA, 2008, MOL MICROBIOL, V67, P232, DOI 10.1111/j.1365-2958.2007.06052.x; van Dam V, 2007, MOL MICROBIOL, V64, P1105, DOI 10.1111/j.1365-2958.2007.05722.x; van Heijenoort J, 2001, NAT PROD REP, V18, P503, DOI 10.1039/a804532a; VANHEIJENOORT Y, 1992, J BACTERIOL, V174, P3549, DOI 10.1128/JB.174.11.3549-3557.1992; WATKINSON RJ, 1971, NATURE-NEW BIOL, V229, P57, DOI 10.1038/newbio229057a0; WRIGHT A, 1967, P NATL ACAD SCI USA, V57, P1798, DOI 10.1073/pnas.57.6.1798; Zhou GP, 2005, GLYCOBIOLOGY, V15, P347, DOI 10.1093/glycob/cwi016; Zhou GP, 2003, GLYCOBIOLOGY, V13, P51, DOI 10.1093/glycob/cwg008	55	56	57	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16573	16583		10.1074/jbc.M800394200	http://dx.doi.org/10.1074/jbc.M800394200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18411271	hybrid			2022-12-25	WOS:000256497100034
J	Chan, YW; On, KF; Chan, WM; Wong, W; Siu, HO; Hau, PM; Poon, RYC				Chan, Ying Wai; On, Kin Fan; Chan, Wan Mui; Wong, Winnie; Siu, Ho On; Hau, Pok Man; Poon, Randy Y. C.			The kinetics of p53 activation versus cyclin E accumulation underlies the relationship between the spindle-assembly checkpoint and the postmitotic checkpoint	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; MITOTIC CHECKPOINT; DNA REREPLICATION; PHOSPHORYLATION; INHIBITION; APOPTOSIS; PROTEIN; TETRAPLOIDY; CENTROSOMES; FAILURE	Although cells can exit mitotic block aberrantly by mitotic slippage, they are prevented from becoming tetraploids by a p53-dependent postmitotic checkpoint. Intriguingly, disruption of the spindle-assembly checkpoint also compromises the postmitotic checkpoint. The precise mechanism of the interplay between these two pivotal checkpoints is not known. We found that after prolonged nocodazole exposure, the postmitotic checkpoint was facilitated by p53. We demonstrated that although disruption of the mitotic block by a MAD2-binding protein promoted slippage, it did not influence the activation of p53. Both p53 and its downstream target p21(CIP1/WAF1) were activated at the same rate irrespective of whether the spindle-assembly checkpoint was enforced or not. The accelerated S phase entry, as reflected by the premature accumulation of cyclin E relative to the activation of p21(CIP1/WAF1), is the reason for the uncoupling of the postmitotic checkpoint. In support of this hypothesis, forced premature mitotic exit with a specific CDK1 inhibitor triggered DNA replication without affecting the kinetics of p53 activation. Finally, replication after checkpoint bypass was boosted by elevating the level of cyclin E. These observations indicate that disruption of the spindle-assembly checkpoint does not directly influence p53 activation, but the shortening of the mitotic arrest allows cyclin E-CDK2 to be activated before the accumulation of p21(CIP1/WAF1). These data underscore the critical relationship between the spindle-assembly checkpoint and the postmitotic checkpoint in safeguarding chromosomal stability.	[Chan, Ying Wai; On, Kin Fan; Chan, Wan Mui; Wong, Winnie; Siu, Ho On; Hau, Pok Man; Poon, Randy Y. C.] Hong Kong Univ Sci & Technol, Dept Biochem, Hong Kong, Peoples R China	Hong Kong University of Science & Technology	Poon, RYC (corresponding author), Hong Kong Univ Sci & Technol, Dept Biochem, Clear Water Bay, Hong Kong, Peoples R China.	rycpoon@ust.hk	Chan, Gary/P-7347-2019	Chan, Gary/0000-0002-6196-7675; Poon, Randy/0000-0001-5571-6231				Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Arooz T, 2000, BIOCHEMISTRY-US, V39, P9494, DOI 10.1021/bi0009643; Ausubel FM, 1991, CURRENT PROTOCOLS MO; Aylon Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006; Blangy A, 1995, CELL, V83, P1159, DOI 10.1016/0092-8674(95)90142-6; Borel F, 2002, P NATL ACAD SCI USA, V99, P9819, DOI 10.1073/pnas.152205299; Casenghi M, 1999, EXP CELL RES, V250, P339, DOI 10.1006/excr.1999.4554; Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127; Chan WM, 2004, MOL CELL BIOL, V24, P3536, DOI 10.1128/MCB.24.8.3536-3551.2004; Chi TY, 2005, CANCER CELL INT, V5, DOI 10.1186/1475-2867-5-27; Chow JPH, 2003, J BIOL CHEM, V278, P40815, DOI 10.1074/jbc.M306683200; Ciciarello M, 2001, J BIOL CHEM, V276, P19205, DOI 10.1074/jbc.M009528200; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; Di Leonardo A, 1997, CANCER RES, V57, P1013; Duelli DM, 2005, J CELL BIOL, V171, P493, DOI 10.1083/jcb.200507069; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Fung TK, 2002, J BIOL CHEM, V277, P35140, DOI 10.1074/jbc.M205503200; Ganem NJ, 2007, CELL, V131, P437, DOI 10.1016/j.cell.2007.10.024; Ganem NJ, 2007, CURR OPIN GENET DEV, V17, P157, DOI 10.1016/j.gde.2007.02.011; Habu T, 2002, EMBO J, V21, P6419, DOI 10.1093/emboj/cdf659; Khan SH, 1998, CANCER RES, V58, P396; Kops GJPL, 2005, NAT REV CANCER, V5, P773, DOI 10.1038/nrc1714; Lanni JS, 1998, MOL CELL BIOL, V18, P1055, DOI 10.1128/MCB.18.2.1055; Li WQ, 1999, CELL GROWTH DIFFER, V10, P769; Liu YW, 2007, CANCER RES, V67, P2603, DOI 10.1158/0008-5472.CAN-06-3436; Lu CR, 2006, MOL CELL, V23, P121, DOI 10.1016/j.molcel.2006.05.023; Mikule K, 2007, NAT CELL BIOL, V9, P160, DOI 10.1038/ncb1529; Musacchio A, 2007, NAT REV MOL CELL BIO, V8, P379, DOI 10.1038/nrm2163; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; Quignon F, 2007, ONCOGENE, V26, P165, DOI 10.1038/sj.onc.1209787; Rajagopalan H, 2003, NAT REV CANCER, V3, P695, DOI 10.1038/nrc1165; Rogakou EP, 2000, J BIOL CHEM, V275, P9390, DOI 10.1074/jbc.275.13.9390; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Sablina AA, 1999, CELL BIOL INT, V23, P323, DOI 10.1006/cbir.1999.0362; Shi QH, 2005, NATURE, V437, P1038, DOI 10.1038/nature03958; Siu WY, 2004, MOL CANCER THER, V3, P621; Siu WY, 1999, EXP CELL RES, V250, P131, DOI 10.1006/excr.1999.4551; Srsen V, 2006, J CELL BIOL, V174, P625, DOI 10.1083/jcb.200606051; Stewart ZA, 1999, MOL CELL BIOL, V19, P205; Tao WK, 2005, CANCER CELL, V8, P49, DOI 10.1016/j.ccr.2005.06.003; Tritarelli A, 2004, MOL BIOL CELL, V15, P3751, DOI 10.1091/mbc.E03-12-0900; Uetake Y, 2004, J CELL BIOL, V165, P609, DOI 10.1083/jcb.200403014; Uetake Y, 2007, J CELL BIOL, V176, P173, DOI 10.1083/jcb.200607073; Vassilev LT, 2006, P NATL ACAD SCI USA, V103, P10660, DOI 10.1073/pnas.0600447103; Vogel C, 2004, ONCOGENE, V23, P6845, DOI 10.1038/sj.onc.1207860; Weaver BAA, 2005, CANCER CELL, V8, P7, DOI 10.1016/j.ccr.2005.06.011; Woo RA, 2004, GENE DEV, V18, P1317, DOI 10.1101/gad.1165204; Xia GH, 2004, EMBO J, V23, P3133, DOI 10.1038/sj.emboj.7600322; Yam CH, 1999, MOL CELL BIOL, V19, P635; Yam CH, 2001, P NATL ACAD SCI USA, V98, P497, DOI 10.1073/pnas.240461397	50	17	19	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15716	15723		10.1074/jbc.M800629200	http://dx.doi.org/10.1074/jbc.M800629200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18400748	Green Published, hybrid			2022-12-25	WOS:000256332500027
J	Denis, M; Landry, YD; Zha, XH				Denis, Maxime; Landry, Yves D.; Zha, Xiaohui			ATP-binding cassette A1-mediated lipidation of apolipoprotein A-I occurs at the plasma membrane and not in the endocytic compartments	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article; Proceedings Paper	80th Annual Scientific Session of the American-Heart-Association (AHA)	NOV 04-07, 2007	Orlando, FL	Amer Heart Assoc (AHA)			TANGIER-DISEASE; APOA-I; ABCA1 TRANSPORTER; PARTICLES; MUTATIONS; PATHWAY; EFFLUX; LOCALIZATION; TRAFFICKING; BIOGENESIS	ATP-binding cassette transporter (ABC) A1 is required for the lipidation of apolipoprotein A-I to generate high density lipoprotein (HDL). This process is proposed to occur through a retro-endocytosis pathway in which apoA-I internalizes with ABCA1 and generates HDL from the endosomal compartments before resecretion. The aim of this study was to determine the route of apoA-I endocytosis and whether endocytosis contributes to HDL biogenesis. Using confocal microscopy, we found that internalized apoA-I only transiently colocalized with transferrin, a retro-endocytosis marker. Instead, apoA-I perfectly colocalized with a bulk phase uptake marker (fluorescein iso-thiocyanate-dextran) and, at later time points, with LysoTracker in several cell models including macrophages, fibroblasts, and baby hamster kidney cells. ABCA1 colocalized poorly with internalized apoA-I. To determine the contribution of internalized apoA-I to HDL biogenesis, we specifically removed apoA-I from the cell surface and analyzed the fate of internalized apoA-I. We found that 23% of cell-associated apoA-I was internalized at steady state. Of internalized apoA-I, only 20% was converted to HDL, and the rest was degraded, consistent with a lysosomal destination. We also found that apoA-I was released approximately five times faster from the plasma membrane than from the intracellular compartments. From these kinetic parameters, we estimated that similar to 5.6% of apoA-I that interacts with cells is degraded and that internalized apoA-I contributes to similar to 1.4% of total HDL production. We also found that blocking endocytosis with sucrose or cytochalasin D did not decrease cholesterol efflux or HDL biogenesis. We therefore conclude that the plasma membrane is the main platform where ABCA1-mediated lipidation of apoA-I occurs.	Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada; Univ Ottawa, Dept Biochem Microbiol & Immunol, Ottawa, ON K1Y 4E9, Canada	University of Ottawa; Ottawa Hospital Research Institute; University of Ottawa	Zha, XH (corresponding author), Univ Ottawa, Ottawa Hlth Res Inst, Ottawa, ON K1Y 4E9, Canada.	xzha@ohri.ca						Batal R, 1998, ARTERIOSCL THROM VAS, V18, P655, DOI 10.1161/01.ATV.18.4.655; Bodzioch M, 1999, NAT GENET, V22, P347, DOI 10.1038/11914; BOJANOVSKI D, 1987, J CLIN INVEST, V80, P1742, DOI 10.1172/JCI113266; Brooks-Wilson A, 1999, NAT GENET, V22, P336, DOI 10.1038/11905; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; Chadda R, 2007, TRAFFIC, V8, P702, DOI 10.1111/j.1600-0854.2007.00565.x; Duong PT, 2006, J LIPID RES, V47, P832, DOI 10.1194/jlr.M500531-JLR200; Fitzgerald ML, 2002, J BIOL CHEM, V277, P33178, DOI 10.1074/jbc.M204996200; Hassan HH, 2007, J LIPID RES, V48, P2428, DOI 10.1194/jlr.M700206-JLR200; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; Kiss RS, 2003, J BIOL CHEM, V278, P10119, DOI 10.1074/jbc.M300137200; Krimbou L, 2005, J LIPID RES, V46, P1668, DOI 10.1194/jlr.M500038-JLR200; Landry YD, 2006, J BIOL CHEM, V281, P36091, DOI 10.1074/jbc.M602247200; Lorenzi I, 2008, J MOL MED, V86, P171, DOI 10.1007/s00109-007-0267-1; Luzio JP, 2007, NAT REV MOL CELL BIO, V8, P622, DOI 10.1038/nrm2217; MAYOR S, 1993, J CELL BIOL, V121, P1257, DOI 10.1083/jcb.121.6.1257; Mayor S, 2007, NAT REV MOL CELL BIO, V8, P603, DOI 10.1038/nrm2216; Mukherjee S, 1998, BIOPHYS J, V75, P1915, DOI 10.1016/S0006-3495(98)77632-5; Mukherjee S, 1997, PHYSIOL REV, V77, P759, DOI 10.1152/physrev.1997.77.3.759; Neufeld EB, 2004, J BIOL CHEM, V279, P15571, DOI 10.1074/jbc.M314160200; Neufeld EB, 2001, J BIOL CHEM, V276, P27584, DOI 10.1074/jbc.M103264200; Nofer JR, 2005, CELL MOL LIFE SCI, V62, P2150, DOI 10.1007/s00018-005-5125-0; Orso E, 2000, NAT GENET, V24, P192, DOI 10.1038/72869; Pagano RE, 1990, CURR OPIN CELL BIOL, V2, P652, DOI 10.1016/0955-0674(90)90107-P; Rust S, 1999, NAT GENET, V22, P352, DOI 10.1038/11921; Sieczkarski SB, 2002, J GEN VIROL, V83, P1535, DOI 10.1099/0022-1317-83-7-1535; SIGAL NH, 1992, ANNU REV IMMUNOL, V10, P519, DOI 10.1146/annurev.iy.10.040192.002511; Takahashi Y, 1999, P NATL ACAD SCI USA, V96, P11358, DOI 10.1073/pnas.96.20.11358; Vaughan AM, 2003, J LIPID RES, V44, P1373, DOI 10.1194/jlr.M300078-JLR200; Vedhachalam C, 2007, J BIOL CHEM, V282, P25123, DOI 10.1074/jbc.M704590200; Vedhachalam C, 2007, ARTERIOSCL THROM VAS, V27, P1603, DOI 10.1161/ATVBAHA.107.145789; Wang N, 2003, J CLIN INVEST, V111, P99, DOI 10.1172/JCI200316808; Zha XH, 2001, J BIOL CHEM, V276, P39476, DOI 10.1074/jbc.M105067200	33	75	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16178	16186		10.1074/jbc.M709597200	http://dx.doi.org/10.1074/jbc.M709597200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	Biochemistry & Molecular Biology	307QD	18385134	hybrid, Green Published			2022-12-25	WOS:000256332500076
J	Vetting, MW; Frantom, PA; Blanchard, JS				Vetting, Matthew W.; Frantom, Patrick A.; Blanchard, John S.			Structural and enzymatic analysis of MshA from Corynebacterium glutamicum - Substrate-assisted catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYCOBACTERIUM-TUBERCULOSIS ERDMAN; POSITIONAL ISOTOPE-EXCHANGE; MYCOTHIOL SYNTHASE MUTANT; CRYSTAL-STRUCTURE; RETAINING GLYCOSYLTRANSFERASES; CONFORMATIONAL-CHANGE; DEACETYLASE MSHB; CHEMICAL RESCUE; BIOSYNTHESIS; MECHANISM	The glycosyltransferase termed MshA catalyzes the transfer of N-acetylglucosamine from UDP-N-acetylglucosamine to 1-L-myo-inositol-1-phosphate in the first committed step of mycothiol biosynthesis. The structure of MshA from Corynebacterium glutamicum was determined both in the absence of substrates and in a complex with UDP and 1-L-myo-inositol-1-phosphate. MshA belongs to the GT-B structural family whose members have a two-domain structure with both domains exhibiting a Rossman-type fold. Binding of the donor sugar to the C-terminal domain produces a 97 degrees rotational reorientation of the N-terminal domain relative to the C-terminal domain, clamping down on UDP and generating the binding site for 1-L-myoinositol-1-phosphate. The structure highlights the residues important in binding of UDP-N-acetylglucosamine and 1-L-myo-inositol-1-phosphate. Molecular models of the ternary complex suggest a mechanism in which the beta-phosphate of the substrate, UDP-N-acetylglucosamine, promotes the nucleophilic attack of the 3-hydroxyl group of 1-L-myo-inositol-1-phosphate while at the same time promoting the cleavage of the sugar nucleotide bond.	[Vetting, Matthew W.; Frantom, Patrick A.; Blanchard, John S.] Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Vetting, MW (corresponding author), Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	vetting@aecom.yu.edu	Frantom, Patrick/GQB-1040-2022		NIAID NIH HHS [AI33696] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033696] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adams PD, 2004, J SYNCHROTRON RADIAT, V11, P53, DOI 10.1107/S0909049503024130; Anderberg SJ, 1998, J BIOL CHEM, V273, P30391, DOI 10.1074/jbc.273.46.30391; Bourne Y, 2001, CURR OPIN STRUC BIOL, V11, P593, DOI 10.1016/S0959-440X(00)00253-0; Breton C, 2006, GLYCOBIOLOGY, V16, p29R, DOI 10.1093/glycob/cwj016; Britton WJ, 2004, LANCET, V363, P1209, DOI 10.1016/S0140-6736(04)15952-7; Buchmeier N, 2006, FEMS MICROBIOL LETT, V264, P74, DOI 10.1111/j.1574-6968.2006.00441.x; Buchmeier NA, 2006, J BACTERIOL, V188, P6245, DOI 10.1128/JB.00393-06; Buschiazzo A, 2004, EMBO J, V23, P3196, DOI 10.1038/sj.emboj.7600324; Campbell JA, 1998, BIOCHEM J, V329, P719, DOI 10.1042/bj3290719; Chen LJ, 2000, BIOCHEMISTRY-US, V39, P12415, DOI 10.1021/bi001517q; Coutinho PM, 2003, J MOL BIOL, V328, P307, DOI 10.1016/S0022-2836(03)00307-3; Demain AL, 1999, APPL MICROBIOL BIOT, V52, P455, DOI 10.1007/s002530051546; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; Gibson RP, 2004, J BIOL CHEM, V279, P1950, DOI 10.1074/jbc.M307643200; Gibson RP, 2002, CHEM BIOL, V9, P1337, DOI 10.1016/S1074-5521(02)00292-2; Goedl C, 2008, FEBS J, V275, P903, DOI [10.1111/j.1742-4658.2008.06254.x, 10.1111/j.1742-4658.2007.06254.x]; Guerin ME, 2007, J BIOL CHEM, V282, P20705, DOI 10.1074/jbc.M702087200; Hand CE, 2005, J NAT PROD, V68, P293, DOI 10.1021/np049685x; Hayward S, 2002, J MOL GRAPH MODEL, V21, P181, DOI 10.1016/S1093-3263(02)00140-7; Hermann T, 2003, J BIOTECHNOL, V104, P155, DOI 10.1016/S0168-1656(03)00149-4; Hu YN, 2003, P NATL ACAD SCI USA, V100, P845, DOI 10.1073/pnas.0235749100; Igura M, 2008, EMBO J, V27, P234, DOI 10.1038/sj.emboj.7601940; KIM SC, 1988, J BIOL CHEM, V263, P10151; KIM SC, 1988, ARCH BIOCHEM BIOPHYS, V267, P54, DOI 10.1016/0003-9861(88)90007-0; Koledin T, 2002, ARCH MICROBIOL, V178, P331, DOI 10.1007/s00203-002-0462-y; Lairson LL, 2004, J BIOL CHEM, V279, P28339, DOI 10.1074/jbc.M400451200; LAIRSON LL, 2004, CHEM COMM CAMB, V21, P2243; Leslie AGW, 2006, ACTA CRYSTALLOGR D, V62, P48, DOI 10.1107/S0907444905039107; Lovering AL, 2007, SCIENCE, V315, P1402, DOI 10.1126/science.1136611; Martinez-Fleites C, 2006, CHEM BIOL, V13, P1143, DOI 10.1016/j.chembiol.2006.09.005; Maynes JT, 2003, J BIOL CHEM, V278, P47166, DOI 10.1074/jbc.M308914200; Monegal A, 2006, J AM CHEM SOC, V128, P16030, DOI 10.1021/ja0659931; Mulichak AM, 2003, P NATL ACAD SCI USA, V100, P9238, DOI 10.1073/pnas.1233577100; Murray BW, 1997, BIOCHEMISTRY-US, V36, P823, DOI 10.1021/bi962284z; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Newton GL, 2006, J BIOL CHEM, V281, P33910, DOI 10.1074/jbc.M604724200; Newton GL, 2005, J BACTERIOL, V187, P7309, DOI 10.1128/JB.187.21.7309-7316.2005; Newton GL, 2003, J BACTERIOL, V185, P3476, DOI 10.1128/JB.185.11.3476-3479.2003; Newton GL, 2002, ARCH MICROBIOL, V178, P388, DOI 10.1007/s00203-002-0469-4; Newton GL, 1996, J BACTERIOL, V178, P1990, DOI 10.1128/jb.178.7.1990-1995.1996; Newton GL, 2000, J BACTERIOL, V182, P6958, DOI 10.1128/JB.182.24.6958-6963.2000; Perrakis A, 1997, ACTA CRYSTALLOGR D, V53, P448, DOI 10.1107/S0907444997005696; Persson K, 2001, NAT STRUCT BIOL, V8, P166, DOI 10.1038/84168; Rawat M, 2002, ANTIMICROB AGENTS CH, V46, P3348, DOI 10.1128/AAC.46.11.3348-3355.2002; Sareen D, 2003, J BACTERIOL, V185, P6736, DOI 10.1228/JB.185.22.6736-6740.2003; Sareen D, 2002, BIOCHEMISTRY-US, V41, P6885, DOI 10.1021/bi012212u; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; SINNOTT ML, 1980, J AM CHEM SOC, V102, P2026, DOI 10.1021/ja00526a043; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; TANAKA Y, 1994, J BIOL CHEM, V269, P32306; Vetting MW, 2006, J BIOL CHEM, V281, P2795, DOI 10.1074/jbc.M510798200; Vetting MW, 2003, PROTEIN SCI, V12, P1954, DOI 10.1110/ps.03153703; Vocadlo DJ, 2001, NATURE, V412, P835, DOI 10.1038/35090602; Vocadlo DJ, 2002, BIOCHEMISTRY-US, V41, P9727, DOI 10.1021/bi020077v	57	92	97	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15834	15844		10.1074/jbc.M801017200	http://dx.doi.org/10.1074/jbc.M801017200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18390549	Green Published, hybrid			2022-12-25	WOS:000256332500041
J	Yakovleva, L; Chen, SX; Hecht, SM; Shuman, S				Yakovleva, Lyudmila; Chen, Shengxi; Hecht, Sidney M.; Shuman, Stewart			Chemical and traditional mutagenesis of vaccinia DNA topoisomerase provides insights to cleavage site recognition and transesterification chemistry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VIRUS TOPOISOMERASE; MUTATIONAL ANALYSIS; ACTIVE-SITE; CATALYTIC MECHANISM; COVALENT; RESIDUES; SPECIFICITY; BASE; ANALOGS; IB	Vaccinia DNA topoisomerase IB (TopIB) relaxes supercoils by forming and resealing a covalent DNA-(3'-phosphotyrosyl)enzyme intermediate. Here we gained new insights to the TopIB mechanism through "chemical mutagenesis." Meta-substituted analogs of Tyr(274) were introduced by in vitro translation in the presence of a chemically misacylated tRNA. We report that a meta-OH reduced the rate of DNA cleavage 130-fold without affecting the rate of religation. By contrast, meta-OCH3 and NO2 groups elicited only a 6-fold decrement in cleavage rate. We propose that the meta-OH uniquely suppresses deprotonation of the para-OH nucleophile during the cleavage step. Assembly of the vaccinia TopIB active site is triggered by protein contacts with a specific DNA sequence 5'-C(+5)C(+4)C(+3)T(+2)T(+1)p down arrow N(where down arrow denotes the cleavage site). A signature alpha-helix of the poxvirus TopIB ((132)GKMKYLKENETVG(144)) engages the target site in the major groove and thereby recruits catalytic residue Arg(130) to the active site. The effects of 11 missense mutations at Tyr(136) highlight the importance of van der Waals interactions with the 3'-G(+4)pG(+3)p dinucleotide of the nonscissile strand for DNA cleavage and super-coil relaxation. Asn(140) and Thr(142) donate hydrogen bonds to the pro-(S-p)-oxygen of the G(+3)pA(+2) phosphodiester of the nonscissile strand. Lys(133) and Lys(135) interact with purine nucleobases in the major groove. Whereas none of these side chains is essential per se, an N140A/T142A double mutation reduces the rate of supercoil relaxation and DNA cleavage by 120- and 30-fold, respectively, and a K133A/K135A double mutation slows relaxation and cleavage by 120- and 35-fold, respectively. These results underscore functional redundancy at the TopIB-DNA interface.	[Yakovleva, Lyudmila; Shuman, Stewart] Sloan Kettering Inst, Program Mol Biol, New York, NY 10065 USA; [Chen, Shengxi; Hecht, Sidney M.] Univ Virginia, Dept Chem, Charlottesville, VA 22901 USA; [Chen, Shengxi; Hecht, Sidney M.] Univ Virginia, Dept Biol, Charlottesville, VA 22901 USA	Memorial Sloan Kettering Cancer Center; University of Virginia; University of Virginia	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10065 USA.	s-shuman@ski.mskcc.org			NATIONAL CANCER INSTITUTE [R01CA077359] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046330, R01GM046330] Funding Source: NIH RePORTER; NCI NIH HHS [CA077359] Funding Source: Medline; NIGMS NIH HHS [GM46330] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Benarroch D, 2006, J VIROL, V80, P314, DOI 10.1128/JVI.80.1.314-321.2006; Cheng CH, 1998, CELL, V92, P841, DOI 10.1016/S0092-8674(00)81411-7; Cheng CH, 1999, BIOCHEMISTRY-US, V38, P16599, DOI 10.1021/bi992001d; Cheng CH, 1997, J BIOL CHEM, V272, P8263, DOI 10.1074/jbc.272.13.8263; Choudhury AK, 2007, BIOCHEMISTRY-US, V46, P4066, DOI 10.1021/bi062042r; Davies DR, 2006, J MOL BIOL, V357, P1202, DOI 10.1016/j.jmb.2006.01.022; Gao R, 2005, J AM CHEM SOC, V127, P3321, DOI 10.1021/ja044182z; Gao R, 2006, BIOCHEMISTRY-US, V45, P8402, DOI 10.1021/bi0605179; HANAI R, 1994, P NATL ACAD SCI USA, V91, P11904, DOI 10.1073/pnas.91.25.11904; Hwang Y, 2006, J BIOL CHEM, V281, P38052, DOI 10.1074/jbc.M608858200; Interthal H, 2004, J BIOL CHEM, V279, P2984, DOI 10.1074/jbc.M309959200; Krogh BO, 2000, MOL CELL, V5, P1035, DOI 10.1016/S1097-2765(00)80268-3; Krogh BO, 2002, P NATL ACAD SCI USA, V99, P1853, DOI 10.1073/pnas.032613199; Krogh BO, 2002, J BIOL CHEM, V277, P5711, DOI 10.1074/jbc.C100681200; Krogh BO, 2001, J BIOL CHEM, V276, P36091, DOI 10.1074/jbc.M102609200; Krogh BO, 2001, J BIOL CHEM, V276, P20907, DOI 10.1074/jbc.M102312200; Minkah N, 2007, VIROLOGY, V365, P60, DOI 10.1016/j.virol.2007.02.037; MORHAM SG, 1990, GENE DEV, V4, P515, DOI 10.1101/gad.4.4.515; Nagarajan R, 2005, BIOCHEMISTRY-US, V44, P11476, DOI 10.1021/bi050796k; Nagarajan R, 2006, BIOCHEMISTRY-US, V45, P5775, DOI 10.1021/bi060133i; Perry K, 2006, MOL CELL, V23, P343, DOI 10.1016/j.molcel.2006.06.015; Petersen BO, 1997, J BIOL CHEM, V272, P3891, DOI 10.1074/jbc.272.7.3891; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; SEKIGUCHI J, 1995, J BIOL CHEM, V270, P11636, DOI 10.1074/jbc.270.19.11636; Sekiguchi J, 1997, NUCLEIC ACIDS RES, V25, P3649, DOI 10.1093/nar/25.18.3649; SHUMAN S, 1991, J BIOL CHEM, V266, P11372; SHUMAN S, 1988, J BIOL CHEM, V263, P16401; SHUMAN S, 1990, J BIOL CHEM, V265, P17826; SHUMAN S, 1993, J BIOL CHEM, V268, P18943; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; STIVERS JT, 1994, BIOCHEMISTRY-US, V33, P15449, DOI 10.1021/bi00255a027; Stivers JT, 2000, BIOCHEMISTRY-US, V39, P5561, DOI 10.1021/bi992429c; Tian LE, 2003, J BIOL CHEM, V278, P9905, DOI 10.1074/jbc.M212468200; Tian LG, 2005, STRUCTURE, V13, P513, DOI 10.1016/j.str.2005.02.001; Tian LG, 2004, J BIOL CHEM, V279, P39718, DOI 10.1074/jbc.M407376200; Tian LG, 2004, STRUCTURE, V12, P31, DOI 10.1016/j.str.2003.11.025; Tian LG, 2003, MOL CELL, V12, P199, DOI 10.1016/S1097-2765(03)00263-6; Tian LG, 2007, VIROLOGY, V359, P466, DOI 10.1016/j.virol.2006.08.056; WITTSCHIEBEN J, 1994, J BIOL CHEM, V269, P29978; Wittschieben J, 1997, NUCLEIC ACIDS RES, V25, P3001, DOI 10.1093/nar/25.15.3001; Yakovleva L, 2003, J BIOL CHEM, V278, P42170, DOI 10.1074/jbc.M308079200; Yakovleva L, 2006, J BIOL CHEM, V281, P35914, DOI 10.1074/jbc.M608349200; Yakovleva L, 2006, BIOCHEMISTRY-US, V45, P7644, DOI 10.1021/bi060158h	43	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16093	16103		10.1074/jbc.M801595200	http://dx.doi.org/10.1074/jbc.M801595200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18367446	hybrid, Green Published			2022-12-25	WOS:000256332500068
J	Alexandrov, IM; Vishnevskaya, AB; Ter-Avanesyan, MD; Kushnirov, VV				Alexandrov, Ilya M.; Vishnevskaya, Aleksandra B.; Ter-Avanesyan, Michael D.; Kushnirov, Vitaly V.			Appearance and propagation of polyglutamine-based amyloids in yeast - Tyrosine residues enable polymer fragmentation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PSI+ PRION; GUANIDINE-HYDROCHLORIDE; PROTEIN; HSP104; AGGREGATION; HUNTINGTIN; CHAPERONE; RNQ1; REPLICATION	In yeast, fragmentation of amyloid polymers by the Hsp104 chaperone allows them to propagate as prions. The prion-forming domain of the yeast Sup35 protein is rich in glutamine, asparagine, tyrosine, and glycine residues, which may define its prion properties. Long polyglutamine stretches can also drive amyloid polymerization in yeast, but these polymers are unable to propagate because of poor fragmentation and exist through constant seeding with the Rnq1 prion polymers. We proposed that fragmentation of polyglutamine amyloids may be improved by incorporation of hydrophobic amino acid residues into polyglutamine stretches. To investigate this, we constructed sets of polyglutamine with or without tyrosine stretches fused to the non-prion domains of Sup35. Polymerization of these chimeras started rapidly, and its efficiency increased with stretch size. Polymerization of proteins with polyglutamine stretches shorter than 70 residues required Rnq1 prion seeds. Proteins with longer stretches polymerized independently of Rnq1 and thus could propagate. The presence of tyrosines within polyglutamine stretches dramatically enhanced polymer fragmentation and allowed polymer propagation in the absence of Rnq1 and, in some cases, of Hsp104.	[Alexandrov, Ilya M.; Vishnevskaya, Aleksandra B.; Ter-Avanesyan, Michael D.; Kushnirov, Vitaly V.] Cardiol Res Ctr, Inst Expt Cardiol, Moscow 121552, Russia	National Medical Research Center of Cardiology	Kushnirov, VV (corresponding author), Cardiol Res Ctr, Inst Expt Cardiol, 3rd Cherepkovskaya St, Moscow 121552, Russia.	vkushnirov@cardio.ru	Vitaly, Kushnirov/AAU-6003-2021	Kushnirov, Vitaly/0000-0003-0316-0766	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bradley ME, 2002, P NATL ACAD SCI USA, V99, P16392, DOI 10.1073/pnas.152330699; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Chiti F, 2006, ANNU REV BIOCHEM, V75, P333, DOI 10.1146/annurev.biochem.75.101304.123901; Derkatch IL, 2004, P NATL ACAD SCI USA, V101, P12934, DOI 10.1073/pnas.0404968101; Derkatch IL, 1997, GENETICS, V147, P507; Derkatch IL, 1996, GENETICS, V144, P1375; Derkatch IL, 2001, CELL, V106, P171, DOI 10.1016/S0092-8674(01)00427-5; Ferreira PC, 2001, MOL MICROBIOL, V40, P1357, DOI 10.1046/j.1365-2958.2001.02478.x; Jung GM, 2001, CURR MICROBIOL, V43, P7, DOI 10.1007/s002840010251; Krobitsch S, 2000, P NATL ACAD SCI USA, V97, P1589, DOI 10.1073/pnas.97.4.1589; Kryndushkin DS, 2003, J BIOL CHEM, V278, P49636, DOI 10.1074/jbc.M307996200; Kushnirov VV, 2006, METHODS, V39, P50, DOI 10.1016/j.ymeth.2006.04.007; Kushnirov VV, 1998, CELL, V94, P13, DOI 10.1016/S0092-8674(00)81216-7; Landles C, 2004, EMBO REP, V5, P958, DOI 10.1038/sj.embor.7400250; Meriin AB, 2002, J CELL BIOL, V157, P997, DOI 10.1083/jcb.200112104; Patino MM, 1996, SCIENCE, V273, P622, DOI 10.1126/science.273.5275.622; Paushkin SV, 1996, EMBO J, V15, P3127, DOI 10.1002/j.1460-2075.1996.tb00675.x; Prusiner SB, 1998, CELL, V93, P337, DOI 10.1016/S0092-8674(00)81163-0; Ross ED, 2005, P NATL ACAD SCI USA, V102, P12825, DOI 10.1073/pnas.0506136102; Ross ED, 2004, MOL CELL BIOL, V24, P7206, DOI 10.1128/MCB.24.16.7206-7213.2004; Salnikova AB, 2005, J BIOL CHEM, V280, P8808, DOI 10.1074/jbc.M410150200; Schlumpberger M, 2001, MOL CELL BIOL, V21, P7035, DOI 10.1128/MCB.21.20.7035-7046.2001; Shewmaker F, 2006, P NATL ACAD SCI USA, V103, P19754, DOI 10.1073/pnas.0609638103; Shorter J, 2004, SCIENCE, V304, P1793, DOI 10.1126/science.1098007; Sondheimer N, 2000, MOL CELL, V5, P163, DOI 10.1016/S1097-2765(00)80412-8; Song YT, 2005, EUKARYOT CELL, V4, P289, DOI 10.1128/EC.4.2.289-297.2005; Tanaka M, 2005, CELL, V121, P49, DOI 10.1016/j.cell.2005.03.008; Tanaka M, 2006, METHOD ENZYMOL, V412, P185, DOI 10.1016/S0076-6879(06)12012-1; Tanaka M, 2006, NATURE, V442, P585, DOI 10.1038/nature04922; TERAVANESYAN MD, 1993, MOL MICROBIOL, V7, P683, DOI 10.1111/j.1365-2958.1993.tb01159.x; Urakov VN, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-34; Vitrenko YA, 2007, J BIOL CHEM, V282, P1779, DOI 10.1074/jbc.M609269200; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170	33	45	45	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15185	15192		10.1074/jbc.M802071200	http://dx.doi.org/10.1074/jbc.M802071200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18381282	Green Published, hybrid			2022-12-25	WOS:000256232000035
J	Tomasiak, TM; Maklashina, E; Cecchini, G; Iverson, TM				Tomasiak, Thomas M.; Maklashina, Elena; Cecchini, Gary; Iverson, Tina M.			A threonine on the active site loop controls transition state formation in Escherichia coli respiratory complex II	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							QUINOL-FUMARATE REDUCTASE; SUCCINATE-UBIQUINONE OXIDOREDUCTASE; WOLINELLA-SUCCINOGENES QUINOL; MEMBRANE-PROTEIN COMPLEX; L-ASPARTATE OXIDASE; SHEWANELLA-FRIGIDIMARINA; DIRECTED MUTAGENESIS; CATALYTIC-ACTIVITY; DEHYDROGENASE; FLAVOCYTOCHROME	In Escherichia coli, the complex 11 superfamily members succinate:ubiquinone oxidoreductase (SQR) and quinol:fumarate reductase (QFR) participate in aerobic and anaerobic respiration, respectively. Complex II enzymes catalyze succinate and fumarate interconversion at the interface of two domains of the soluble flavoprotein subunit, the FAD binding domain and the capping domain. An 11-amino acid loop in the capping domain (Thr-A234 to Thr-A244 in quinol:fumarate reductase) begins at the interdomain hinge and covers the active site. Amino acids of this loop interact with both the substrate and a proton shuttle, potentially coordinating substrate binding and the proton shuttle protonation state. To assess the loop's role in catalysis, two threonine residues were mutated to alanine: QFR Thr-A244 (act-T; Thr-A254 in SQR), which hydrogen-bonds to the substrate at the active site, and QFR Thr-A234 (hinge-T; Thr-A244 in SQR), which is located at the hinge and hydrogen-bonds the proton shuttle. Both mutations impair catalysis and decrease substrate binding. The crystal structure of the hinge-T mutation reveals a reorientation between the FAD-binding and capping domains that accompanies proton shuttle alteration. Taken together, hydrogen bonding from act-T to substrate may coordinate with interdomain motions to twist the double bond of fumarate and introduce the strain important for attaining the transition state.	[Maklashina, Elena; Cecchini, Gary] Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA; [Tomasiak, Thomas M.; Iverson, Tina M.] Vanderbilt Univ, Dept Pharmacol, Nashville, TN 37232 USA; [Tomasiak, Thomas M.; Iverson, Tina M.] Vanderbilt Univ, Dept Biochem, Nashville, TN 37232 USA; [Maklashina, Elena; Cecchini, Gary] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94158 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vanderbilt University; Vanderbilt University; University of California System; University of California San Francisco	Cecchini, G (corresponding author), Vet Affairs Med Ctr, Div Mol Biol, San Francisco, CA 94121 USA.	gary.cecchini@ucsf.edu; tina.iverson@vanderbilt.edu			NIEHS NIH HHS [P30 ES 000267, P30 ES000267] Funding Source: Medline; NIGMS NIH HHS [GM 61606, GM 079419, R01 GM061606, R01 GM079419-01, T32 GM 65086, R01 GM079419-02, R01 GM079419, T32 GM065086] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES000267] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM065086, R01GM061606, R01GM079419] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ackrell BAC, 2000, FEBS LETT, V466, P1, DOI 10.1016/S0014-5793(99)01749-4; ACKRELL BAC, 1989, ARCH BIOCHEM BIOPHYS, V268, P26, DOI 10.1016/0003-9861(89)90561-4; Adams PD, 2002, ACTA CRYSTALLOGR D, V58, P1948, DOI 10.1107/S0907444902016657; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bamford V, 1999, NAT STRUCT BIOL, V6, P1104; BLAUT M, 1989, J BIOL CHEM, V264, P13599; Bossi RT, 2002, BIOCHEMISTRY-US, V41, P3018, DOI 10.1021/bi015939r; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cecchini G, 2003, ANNU REV BIOCHEM, V72, P77, DOI 10.1146/annurev.biochem.72.121801.161700; DeLano W, 2002, PYMOL 0 99; DePristo MA, 2005, STRUCTURE, V13, P1311, DOI 10.1016/j.str.2005.06.008; Doherty MK, 2000, BIOCHEMISTRY-US, V39, P10695, DOI 10.1021/bi000871l; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Huang LS, 2006, BBA-BIOENERGETICS, V1757, P1073, DOI 10.1016/j.bbabio.2006.06.015; Huang LS, 2006, J BIOL CHEM, V281, P5965, DOI 10.1074/jbc.M511270200; Iverson TM, 2002, J BIOL CHEM, V277, P16124, DOI 10.1074/jbc.M200815200; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; Iverson TM, 2000, CURR OPIN STRUC BIOL, V10, P448, DOI 10.1016/S0959-440X(00)00113-5; Jeuken LJC, 2002, J AM CHEM SOC, V124, P5702, DOI 10.1021/ja012638w; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KITA K, 1989, J BIOL CHEM, V264, P2672; Lancaster CRD, 2000, BBA-BIOENERGETICS, V1459, P422, DOI 10.1016/S0005-2728(00)00180-8; Lancaster CRD, 1999, NATURE, V402, P377, DOI 10.1038/46483; Lancaster CRD, 2003, ADV PROTEIN CHEM, V63, P131; Lancaster CRD, 2001, EUR J BIOCHEM, V268, P1820, DOI 10.1046/j.1432-1327.2001.02053.x; Leger C, 2001, BIOCHEMISTRY-US, V40, P11234, DOI 10.1021/bi010889b; Leys D, 1999, NAT STRUCT BIOL, V6, P1113; Luna-Chavez C, 2000, PROTEIN EXPRES PURIF, V19, P188, DOI 10.1006/prep.2000.1238; Madej MG, 2006, EMBO J, V25, P4963, DOI 10.1038/sj.emboj.7601361; Maklashina E, 1998, J BACTERIOL, V180, P5989, DOI 10.1128/JB.180.22.5989-5996.1998; Maklashina E, 2006, J BIOL CHEM, V281, P11357, DOI 10.1074/jbc.M512544200; Maklashina E, 1999, ARCH BIOCHEM BIOPHYS, V369, P223, DOI 10.1006/abbi.1999.1359; Maklashina E, 2001, J BIOL CHEM, V276, P18968, DOI 10.1074/jbc.M011270200; Maklashina E, 2006, J BIOL CHEM, V281, P26655, DOI 10.1074/jbc.M602938200; MASSEY V, 1974, ANN NY ACAD SCI, V227, P446, DOI 10.1111/j.1749-6632.1974.tb14407.x; Mattevi A, 2006, TRENDS BIOCHEM SCI, V31, P276, DOI 10.1016/j.tibs.2006.03.003; Mattevi A, 1999, STRUCTURE, V7, P745, DOI 10.1016/S0969-2126(99)80099-9; Mowat CG, 2001, BIOCHEMISTRY-US, V40, P12292, DOI 10.1021/bi011360h; OHNISHI T, 1981, J BIOL CHEM, V256, P5577; OTWINOWSKI Z, 1993, CCP4 STUDY WEEKEND D, P56; Pankhurst KL, 2006, J BIOL CHEM, V281, P20589, DOI 10.1074/jbc.M603077200; Pankhurst KL, 2002, BIOCHEMISTRY-US, V41, P8551, DOI 10.1021/bi020155e; Reid GA, 2000, BBA-BIOENERGETICS, V1459, P310, DOI 10.1016/S0005-2728(00)00166-3; Rothery EL, 2004, BIOCHEMISTRY-US, V43, P4983, DOI 10.1021/bi030261w; Rothery RA, 2005, FEBS J, V272, P313, DOI 10.1111/j.1742-4658.2004.04469.x; SCHRODER I, 1991, J BIOL CHEM, V266, P13572; Sun F, 2005, CELL, V121, P1043, DOI 10.1016/j.cell.2005.05.025; Taylor P, 1999, NAT STRUCT BIOL, V6, P1108; VEEGER C, 1966, FLAVINS FLAVOPROTEIN, P242; Wardrope C, 2006, FEBS LETT, V580, P1677, DOI 10.1016/j.febslet.2006.02.016; WESTENBERG DJ, 1993, J BIOL CHEM, V268, P815; Yankovskaya V, 2003, SCIENCE, V299, P700, DOI 10.1126/science.1079605	52	22	22	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15460	15468		10.1074/jbc.M801372200	http://dx.doi.org/10.1074/jbc.M801372200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18385138	Green Published, hybrid			2022-12-25	WOS:000256232000064
J	Iguchi, T; Sakata, K; Yoshizaki, K; Tago, K; Mizuno, N; Itoh, H				Iguchi, Tokuichi; Sakata, Kensei; Yoshizaki, Kotaro; Tago, Kenji; Mizuno, Norikazu; Itoh, Hiroshi			Orphan G protein-coupled receptor GPR56 regulates neural progenitor cell migration via a G alpha(12/13) and rho pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPING CEREBRAL-CORTEX; DIEKER LISSENCEPHALY GENE; G-BETA-GAMMA; NEURONAL MIGRATION; ADHESION; BRAIN; ACTIVATION; ENCODES; DISEASE; FAMILY	In the developing forebrain, the migration and positioning of neural progenitor cells (NPCs) are regulated coordinately by various molecules. Mutation of these molecules, therefore, causes cortical malformation. GPR56 has been reported as a cortical malformation-related gene that is mutated in patients with bilateral frontoparietal polymicrogyria. GPR56 encodes an orphan G protein-coupled receptor, and its mutations reduce the cell surface expression. It has also been reported that the expression level of GPR56 is involved in cancer cell adhesion and metastasis. However, it remains to be clarified how GPR56 functions in brain development and which signaling pathways are activated by GPR56. In this study, we showed that GPR56 is highly expressed in NPCs and has the ability to inhibit NPC migration. We found that GPR56 coupled with G alpha(12/13) and induced Rho-dependent activation of the transcription mediated through a serum-responsive element and NF-kappa B-responsive element and actin fiber reorganization. The transcriptional activation and actin reorganization were inhibited by an RGS domain of the p115 Rho-specific guanine nucleotide exchange factor (p115 RhoGEF RGS) and dominant negative form of Rho. Moreover, we have demonstrated that a functional anti-GPR56 antibody, which has an agonistic activity, inhibited NPC migration. This inhibition was attenuated by p115 RhoGEF RGS, C3 exoenzyme, and GPR56 knockdown. These results indicate that GPR56 participates in the regulation of NPC movement through the G alpha(12/13) and Rho signaling pathway, suggesting its important role in the development of the central nervous system.	[Iguchi, Tokuichi; Sakata, Kensei; Yoshizaki, Kotaro; Tago, Kenji; Mizuno, Norikazu; Itoh, Hiroshi] Nara Inst Sci & Technol, Grad Sch Biol Sci, Dept Cell Biol, Nara 6300192, Japan	Nara Institute of Science & Technology	Itoh, H (corresponding author), Nara Inst Sci & Technol, Grad Sch Biol Sci, Dept Cell Biol, 8916-5 Takayama, Nara 6300192, Japan.	hitoh@bs.naist.jp		Iguchi, Tokuichi/0000-0003-4025-8770				Arai K, 2003, MOL PHARMACOL, V63, P478, DOI 10.1124/mol.63.3.478; Behar TN, 2000, CEREB CORTEX, V10, P899, DOI 10.1093/cercor/10.9.899; Behar TN, 2001, CEREB CORTEX, V11, P744, DOI 10.1093/cercor/11.8.744; Bielas S, 2004, ANNU REV CELL DEV BI, V20, P593, DOI 10.1146/annurev.cellbio.20.082503.103047; Bjarnadottir TK, 2007, CELL MOL LIFE SCI, V64, P2104, DOI 10.1007/s00018-007-7067-1; Bjarnadottir TK, 2004, GENOMICS, V84, P23, DOI 10.1016/j.ygeno.2003.12.004; DARCANGELO G, 1995, NATURE, V374, P719, DOI 10.1038/374719a0; DEPORTES V, 1998, CELL, V92, P51; Elies R, 1998, EUR J BIOCHEM, V251, P659, DOI 10.1046/j.1432-1327.1998.2510659.x; Etienne-Manneville S, 2002, NATURE, V420, P629, DOI 10.1038/nature01148; Fesus L, 2002, TRENDS BIOCHEM SCI, V27, P534, DOI 10.1016/S0968-0004(02)02182-5; Fredriksson R, 2003, BIOCHEM BIOPH RES CO, V301, P725, DOI 10.1016/S0006-291X(03)00026-3; Fredriksson R, 2002, FEBS LETT, V531, P407, DOI 10.1016/S0014-5793(02)03574-3; Fukushima N, 2000, DEV BIOL, V228, P6, DOI 10.1006/dbio.2000.9930; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Gleeson JG, 1998, CELL, V92, P63, DOI 10.1016/S0092-8674(00)80899-5; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HIROTSUNE S, 1995, NAT GENET, V10, P77, DOI 10.1038/ng0595-77; Jin ZH, 2007, HUM MOL GENET, V16, P1972, DOI 10.1093/hmg/ddm144; Kabarowski JHS, 2000, P NATL ACAD SCI USA, V97, P12109, DOI 10.1073/pnas.97.22.12109; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; Ke N, 2007, MOL CANCER THER, V6, P1840, DOI 10.1158/1535-7163.MCT-07-0066; Kholmanskikh SS, 2003, J NEUROSCI, V23, P8673; Little KD, 2004, MOL BIOL CELL, V15, P2375, DOI 10.1091/mbc.E03-12-0886; Liu M, 1999, GENOMICS, V55, P296, DOI 10.1006/geno.1998.5644; Makita N, 2007, P NATL ACAD SCI USA, V104, P5443, DOI 10.1073/pnas.0701290104; Marin O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058; Marin O, 2006, TRENDS NEUROSCI, V29, P655, DOI 10.1016/j.tins.2006.10.001; Marinissen MJ, 2001, TRENDS PHARMACOL SCI, V22, P368, DOI 10.1016/S0165-6147(00)01678-3; Milligan G, 2006, BRIT J PHARMACOL, V147, pS46, DOI 10.1038/sj.bjp.0706405; Mizuno N, 2005, P NATL ACAD SCI USA, V102, P12365, DOI 10.1073/pnas.0506101102; Moers A, 2008, MOL CELL BIOL, V28, P1480, DOI 10.1128/MCB.00651-07; Nadarajah B, 2003, CEREB CORTEX, V13, P607, DOI 10.1093/cercor/13.6.607; OGAWA M, 1995, NEURON, V14, P899, DOI 10.1016/0896-6273(95)90329-1; Piao XH, 2004, SCIENCE, V303, P2033, DOI 10.1126/science.1092780; REINER O, 1993, NATURE, V364, P717, DOI 10.1038/364717a0; Schott M, 2005, TRENDS ENDOCRIN MET, V16, P243, DOI 10.1016/j.tem.2005.05.009; Seifert R, 2002, N-S ARCH PHARMACOL, V366, P381, DOI 10.1007/s00210-002-0588-0; Shashidhar S, 2005, ONCOGENE, V24, P1673, DOI 10.1038/sj.onc.1208395; Shinohara H, 2004, J BIOL CHEM, V279, P41141, DOI 10.1074/jbc.M406721200; Stumm RK, 2003, J NEUROSCI, V23, P5123; Sud N, 2006, CANCER LETT, V233, P265, DOI 10.1016/j.canlet.2005.03.018; Sun YJ, 1999, J BIOCHEM, V125, P515, DOI 10.1093/oxfordjournals.jbchem.a022315; Tabata H, 2003, J NEUROSCI, V23, P9996; Takasaki J, 2004, J BIOL CHEM, V279, P47438, DOI 10.1074/jbc.M408846200; Terskikh AV, 2001, P NATL ACAD SCI USA, V98, P7934, DOI 10.1073/pnas.131200898; Xu L, 2006, P NATL ACAD SCI USA, V103, P9023, DOI 10.1073/pnas.0602681103; Yamauchi J, 2001, BIOCHEM BIOPH RES CO, V284, P1199, DOI 10.1006/bbrc.2001.5103; Zendman AJW, 1999, FEBS LETT, V446, P292, DOI 10.1016/S0014-5793(99)00230-6	50	149	151	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14469	14478		10.1074/jbc.M708919200	http://dx.doi.org/10.1074/jbc.M708919200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18378689	hybrid			2022-12-25	WOS:000255941400034
J	Jorgensen, AD; Nohr, J; Kastrup, JS; Gajhede, M; Sigurskjold, BW; Sauer, J; Svergun, DI; Svensson, B; Vestergaard, B				Jorgensen, Anders Dysted; Nohr, Jane; Kastrup, Jette Sandholm; Gajhede, Michael; Sigurskjold, Bent W.; Sauer, Jorgen; Svergun, Dmitri I.; Svensson, Birte; Vestergaard, Bente			Small angle x-ray studies reveal that Aspergillus niger glucoamylase has a defined extended conformation and can form dimers in solution	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STARCH-BINDING DOMAIN; INDIRECT FOURIER TRANSFORMATION; BIOLOGICAL MACROMOLECULES; SOLUTION SCATTERING; BETA-CYCLODEXTRIN; STABILITY; THERMODYNAMICS; RESOLUTION; PROGRAM; CHAINS	The industrially important glucoamylase 1 is an exo-acting glycosidase with substrate preference for alpha-1,4 and alpha-1,6 linkages at non-reducing ends of starch. It consists of a starch binding and a catalytic domain interspersed by a highly glycosylated polypeptide linker. The linker function is poorly understood and structurally undescribed, and data regarding domain organization and intramolecular functional cooperativity are conflicting or non-comprehensive. Here, we report a combined small angle x-ray scattering and calorimetry study of Aspergillus niger glucoamylase 1, glucoamylase 2, which lacks a starch binding domain, and an engineered low-glycosylated variant of glucoamylase 1 with a short linker. Low resolution solution structures show that the linker adopts a compact structure rendering a well defined extended overall conformation to glucoamylase. We demonstrate that binding of a short heterobidentate inhibitor simultaneously directed toward the catalytic and starch binding domains causes dimerization of glucoamylase and not, as suggested previously, an intramolecular conformational rearrangement mediated by linker flexibility. Our results suggest that glucoamylase functions via transient dimer formation during hydrolysis of insoluble substrates and address the question of the cooperative effect of starch binding and hydrolysis.	[Jorgensen, Anders Dysted; Kastrup, Jette Sandholm; Gajhede, Michael; Vestergaard, Bente] Univ Copenhagen, Dept Med Chem, DK-2100 Copenhagen, Denmark; [Sigurskjold, Bent W.] Univ Copenhagen, Dept Biol, DK-2100 Copenhagen, Denmark; [Jorgensen, Anders Dysted; Svensson, Birte] Tech Univ Denmark, Dept Syst Biol, DK-2800 Lyngby, Denmark; [Nohr, Jane] Univ So Denmark, Dept Mol Biol & Biochem, DK-5230 Odense, Denmark; [Svensson, Birte] Carlsberg Res Lab, DK-2500 Valby, Denmark; [Svergun, Dmitri I.] European Mol Biol Lab, D-22603 Hamburg, Germany; [Svergun, Dmitri I.] Russian Acad Sci, Inst Crystallog, Moscow 117333, Russia	University of Copenhagen; University of Copenhagen; Technical University of Denmark; University of Southern Denmark; European Molecular Biology Laboratory (EMBL); Russian Academy of Sciences; FSRC Crystallography & Photonics RAS	Svensson, B (corresponding author), Soltofts Plads,Bldg 224, DK-2800 Lyngby, Denmark.	bis@bio.dtu.dk		Gajhede, Michael/0000-0001-9864-2287; Vestergaard, Bente/0000-0001-8011-6414; Kastrup, Jette Sandholm/0000-0003-2654-1510; Svergun, Dmitri/0000-0003-0830-5696; Svensson, Birte/0000-0002-2993-8196				ALESHIN A, 1992, J BIOL CHEM, V267, P19291; BELSHAW NJ, 1991, BIOCHIM BIOPHYS ACTA, V1078, P117, DOI 10.1016/0167-4838(91)90100-E; Christensen T, 1999, BIOCHEMISTRY-US, V38, P6300, DOI 10.1021/bi990185q; Coutinho PM, 1997, PROTEINS, V29, P334, DOI [10.1002/(SICI)1097-0134(199711)29:3<334::AID-PROT7>3.0.CO;2-A, 10.1002/(SICI)1097-0134(199711)29:3&lt;334::AID-PROT7&gt;3.0.CO;2-A]; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; FRANDSEN TP, 1994, BIOCHEMISTRY-US, V33, P13808, DOI 10.1021/bi00250a035; GILKES NR, 1988, J BIOL CHEM, V263, P10401; GUNNARSSON A, 1984, EUR J BIOCHEM, V145, P463, DOI 10.1111/j.1432-1033.1984.tb08578.x; Hammel M, 2005, J BIOL CHEM, V280, P38562, DOI 10.1074/jbc.M503168200; Hammel M, 2004, J BIOL CHEM, V279, P55985, DOI 10.1074/jbc.M408979200; Hansen S, 2000, J APPL CRYSTALLOGR, V33, P1415, DOI 10.1107/S0021889800012930; Khan SMA, 2000, STARCH-STARKE, V52, P385, DOI 10.1002/1521-379X(200011)52:11<385::AID-STAR385>3.0.CO;2-G; Konarev PV, 2006, J APPL CRYSTALLOGR, V39, P277, DOI 10.1107/S0021889806004699; Konarev PV, 2003, J APPL CRYSTALLOGR, V36, P1277, DOI 10.1107/S0021889803012779; Kozin MB, 2001, J APPL CRYSTALLOGR, V34, P33, DOI 10.1107/S0021889800014126; KRAMER GFH, 1993, J CHEM SOC FARADAY T, V89, P2595, DOI 10.1039/ft9938902595; MEAGHER MM, 1988, CARBOHYD RES, V173, P273, DOI 10.1016/S0008-6215(00)90823-1; Payre N, 1999, ANGEW CHEM INT EDIT, V38, P974, DOI 10.1002/(SICI)1521-3773(19990401)38:7<974::AID-ANIE974>3.0.CO;2-K; PAZUR JH, 1960, J BIOL CHEM, V235, P297; Petoukhov MV, 2002, BIOPHYS J, V83, P3113, DOI 10.1016/S0006-3495(02)75315-0; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; Receveur V, 2002, J BIOL CHEM, V277, P40887, DOI 10.1074/jbc.M205404200; Roessle MW, 2007, J APPL CRYSTALLOGR, V40, pS190, DOI 10.1107/S0021889806055506; Sauer J, 2001, BIOCHEMISTRY-US, V40, P9336, DOI 10.1021/bi010515i; Sauer J, 2000, BBA-PROTEIN STRUCT M, V1543, P275, DOI 10.1016/S0167-4838(00)00232-6; SHEN H, 1991, J BIOL CHEM, V266, P11335; Sigurskjold BW, 1998, BIOCHEMISTRY-US, V37, P10446, DOI 10.1021/bi9807310; Sorimachi K, 1996, J MOL BIOL, V259, P970, DOI 10.1006/jmbi.1996.0374; Southall SM, 1999, FEBS LETT, V447, P58, DOI 10.1016/S0014-5793(99)00263-X; STOFFER B, 1993, BIOCHEM J, V292, P197, DOI 10.1042/bj2920197; SVENSSON B, 1982, CARLSBERG RES COMMUN, V47, P55, DOI 10.1007/BF02907797; SVENSSON B, 1983, CARLSBERG RES COMMUN, V48, P529, DOI 10.1007/BF02907555; SVENSSON B, 1992, CARBOHYD RES, V227, P29, DOI 10.1016/0008-6215(92)85059-9; Svergun D, 1995, J APPL CRYSTALLOGR, V28, P768, DOI 10.1107/S0021889895007047; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1988, ACTA CRYSTALLOGR A, V44, P244, DOI 10.1107/S0108767387011255; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Svergun DI, 2003, REP PROG PHYS, V66, P1735, DOI 10.1088/0034-4885/66/10/R05; Tanaka A, 1998, BIOSCI BIOTECH BIOCH, V62, P2127, DOI 10.1271/bbb.62.2127; Vestergaard B, 2006, J APPL CRYSTALLOGR, V39, P797, DOI 10.1107/S0021889806035291; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; WILLIAMSON G, 1992, EUR J BIOCHEM, V207, P661, DOI 10.1111/j.1432-1033.1992.tb17093.x	42	17	18	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14772	14780		10.1074/jbc.M801709200	http://dx.doi.org/10.1074/jbc.M801709200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18378674	hybrid			2022-12-25	WOS:000255941400065
J	Muhlbauer, M; Chilton, PM; Mitchell, TC; Jobin, C				Muehlbauer, Marcus; Chilton, Paula M.; Mitchell, Thomas C.; Jobin, Christian			Impaired bcl3 up-regulation leads to enhanced lipopolysaccharide-induced interleukin (IL)-23P19 gene expression in IL-10(-/-) mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KAPPA-B P50; INFLAMMATORY-BOWEL-DISEASE; INTERLEUKIN-10-DEFICIENT MICE; DENDRITIC CELLS; KINASE-ACTIVITY; COLITIS; MACROPHAGES; IL-23; IL-12; BACTERIA	Genetic and biochemical analyses show that IL-23p19 plays a central role in mediating bacteria- induced colitis in interleukin-10-deficient (IL-10(-/-)) mice. The molecular mechanisms responsible for the dysregulated innate host response leading to enhanced IL- 23 gene expression in IL- 10(-/-) mice are poorly understood. In this study, we investigated the role of Bcl3 in controlling LPS-induced IL-23p19 gene expression in bone marrow-derived dendritic cells (BMDC) isolated from IL- 10(-/-) mice. We report higher IL-23p19 mRNA accumulation and protein secretion in LPS-stimulated BMDC isolated from IL- 10(-/-) compared with WT mice. Lipopolysaccharide ( LPS)-induced B cell leukemia 3 ( Bcl3) expression was strongly impaired ( 90% decrease) in IL- 10(-/-) BMDC compared with WT BMDC. Chromatin immunoprecipitation demonstrated enhanced RelA binding to the IL-23p19 promoter in IL- 10(-/-) compared with WT BMDC. Bcl3 overexpression decreased LPS-induced IL-23p19 gene expression in IL- 10(-/-) BMDC, which correlated with enhanced NF-kappa B p50 binding and decreased RelA binding to the gene promoter. Conversely, Bcl3 knockdown enhanced LPS-induced IL-23p19 gene expression in WT BMDC. Moreover, LPS-induced IL-23p19 gene expression was significantly enhanced in Bcl3(-/-) BMDC compared with WT BMDC. In conclusion, enhanced LPS-induced IL-23p19 gene expression in IL- 10(-/-) mice is due to impaired Bcl3 expression leading to diminished p50 and enhanced RelA recruitment to the IL-23p19 promoter.	[Muehlbauer, Marcus; Jobin, Christian] Univ N Carolina, Dept Med Pharmacol, Chapel Hill, NC 27599 USA; [Muehlbauer, Marcus; Jobin, Christian] Univ N Carolina, Ctr Gastrointestinal Biol & Dis, Chapel Hill, NC 27599 USA; [Chilton, Paula M.; Mitchell, Thomas C.] Univ Louisville, Dept Microbiol & Immunol, Louisville, KY 40202 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of Louisville	Jobin, C (corresponding author), Univ N Carolina, Dept Med Pharmacol, Chapel Hill, NC 27599 USA.	job@med.unc.edu	Mitchell, Thomas C/B-4193-2013	Chilton, Paula/0000-0002-8749-0975	NIAID NIH HHS [R01 AI071047] Funding Source: Medline; NIDDK NIH HHS [R01 DK047700, R01 DK 47700, R01 DK 73338] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI071047] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047700, R01DK073338] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Becker C, 2006, J IMMUNOL, V177, P2760, DOI 10.4049/jimmunol.177.5.2760; Berg DJ, 1996, J CLIN INVEST, V98, P1010, DOI 10.1172/JCI118861; Bhattacharyya S, 2004, BLOOD, V104, P1100, DOI 10.1182/blood-2003-12-4302; Carmody RJ, 2007, SCIENCE, V317, P675, DOI 10.1126/science.1142953; Carmody RJ, 2007, J IMMUNOL, V178, P186, DOI 10.4049/jimmunol.178.1.186; Dechend R, 1999, ONCOGENE, V18, P3316, DOI 10.1038/sj.onc.1202717; Duerr RH, 2006, SCIENCE, V314, P1461, DOI 10.1126/science.1135245; El Kasmi KC, 2006, J IMMUNOL, V177, P7880, DOI 10.4049/jimmunol.177.11.7880; Elson CO, 2007, GASTROENTEROLOGY, V132, P2359, DOI 10.1053/j.gastro.2007.03.104; Franzoso G, 1998, J EXP MED, V187, P147, DOI 10.1084/jem.187.2.147; Haller D, 2004, J PEDIATR GASTR NUTR, V38, P123, DOI 10.1097/00005176-200402000-00004; Hoentjen F, 2005, BLOOD, V105, P689, DOI 10.1182/blood-2004-04-1309; Hue S, 2006, J EXP MED, V203, P2473, DOI 10.1084/jem.20061099; INOUE J, 1993, ONCOGENE, V8, P2067; Kamada N, 2005, J IMMUNOL, V175, P6900, DOI 10.4049/jimmunol.175.10.6900; Karrasch T, 2007, J IMMUNOL, V178, P6522, DOI 10.4049/jimmunol.178.10.6522; KERR LD, 1992, GENE DEV, V6, P2352, DOI 10.1101/gad.6.12a.2352; Kontoyiannis D, 2001, EMBO J, V20, P3760, DOI 10.1093/emboj/20.14.3760; Kraehenbuhl JP, 2004, SCIENCE, V303, P1624, DOI 10.1126/science.1096222; KUHN R, 1993, CELL, V75, P263, DOI 10.1016/0092-8674(93)80068-P; Kuwata H, 2003, BLOOD, V102, P4123, DOI 10.1182/blood-2003-04-1228; Langrish CL, 2004, IMMUNOL REV, V202, P96, DOI 10.1111/j.0105-2896.2004.00214.x; Lee TS, 2002, NAT MED, V8, P240, DOI 10.1038/nm0302-240; Moore KW, 2001, ANNU REV IMMUNOL, V19, P683, DOI 10.1146/annurev.immunol.19.1.683; Murray PJ, 2005, P NATL ACAD SCI USA, V102, P8686, DOI 10.1073/pnas.0500419102; NOLAN GP, 1993, MOL CELL BIOL, V13, P3557, DOI 10.1128/MCB.13.6.3557; Parham C, 2002, J IMMUNOL, V168, P5699, DOI 10.4049/jimmunol.168.11.5699; Qasimi P, 2006, J BIOL CHEM, V281, P6316, DOI 10.1074/jbc.M508608200; Qin HW, 2006, J IMMUNOL, V177, P7761, DOI 10.4049/jimmunol.177.11.7761; Rakoff-Nahoum S, 2006, IMMUNITY, V25, P319, DOI 10.1016/j.immuni.2006.06.010; Riemann M, 2005, J IMMUNOL, V175, P3560, DOI 10.4049/jimmunol.175.6.3560; Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528; Schottelius AJG, 1999, J BIOL CHEM, V274, P31868, DOI 10.1074/jbc.274.45.31868; Schuetze N, 2005, INT IMMUNOL, V17, P649, DOI 10.1093/intimm/dxh247; Schwarz EM, 1997, GENE DEV, V11, P187, DOI 10.1101/gad.11.2.187; Sellon RK, 1998, INFECT IMMUN, V66, P5224, DOI 10.1128/IAI.66.11.5224-5231.1998; Strober W, 2006, NAT REV IMMUNOL, V6, P9, DOI 10.1038/nri1747; Uhlig HH, 2006, IMMUNITY, V25, P309, DOI 10.1016/j.immuni.2006.05.017; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; Wessells J, 2004, J BIOL CHEM, V279, P49995, DOI 10.1074/jbc.M404246200; Williams L, 2004, J IMMUNOL, V172, P567, DOI 10.4049/jimmunol.172.1.567; Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005; Yen D, 2006, J CLIN INVEST, V116, P1310, DOI 10.1172/JCI21404; Zhang XR, 2007, IMMUNITY, V27, P438, DOI 10.1016/j.immuni.2007.07.017	44	30	31	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14182	14189		10.1074/jbc.M709029200	http://dx.doi.org/10.1074/jbc.M709029200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18375954	Green Published, hybrid			2022-12-25	WOS:000255941400003
J	Nagamatsu, Y; Rikitake, Y; Takahashi, M; Deki, Y; Ikeda, W; Hirata, K; Takai, Y				Nagamatsu, Yuichi; Rikitake, Yoshiyuki; Takahashi, Motonori; Deki, Yuko; Ikeda, Wataru; Hirata, Ken-ichi; Takai, Yoshimi			Roles of Necl-5/poliovirus receptor and rho-associated kinase (ROCK) in the regulation of transformation of integrin alpha(V)beta(3)-based focal complexes into focal adhesions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENHANCES CELL-MIGRATION; XR1 GLIAL-CELLS; MYOSIN; DYNAMICS; PHOSPHORYLATION; INHIBITION; ACTIVATION; INTERACTS; CONTACTS; NECTIN-3	Focal complexes are continuously formed and transformed into focal adhesions during cell movement. We previously demonstrated that Necl-5 co-localizes with integrin alpha(V)beta(3) at focal complexes, whereas Necl-5 does not localize at focal adhesions in moving NIH3T3 cells, suggesting that Necl-5 may be dissociated from integrin alpha(V)beta(3) during the transformation of focal complexes into focal adhesions, but the underlying mechanism remains unknown. Here, we explore the roles of Necl-5 and Rho-associated kinase (ROCK) in the regulation of the transformation of focal complexes into focal adhesions. We found that inhibition of Necl-5 expression and expression of a constitutively active mutant of ROCK1 enhanced, whereas treatment with a ROCK inhibitor Y-27632 inhibited the transformation of focal complexes into focal adhesions. In HEK293 cells ectopically expressing Necl-5 and integrin alpha(V)beta(3), treatment of cells with Y-27632 increased the binding of Necl-5 to clustered integrin alpha(V)beta(3). The experiments using inhibitors of myosin ATPase and actin polymerization revealed that actomyosin-driven contractility exerts a similar function as ROCK. The phosphorylation of integrin beta(3) at Tyr747, which is known to be critical for the formation of focal adhesions, plays a pivotal role for the interaction between Necl-5 and integrin alpha(V)beta(3). These results indicate that the transformation of focal complexes into focal adhesions is negatively and positively regulated by Necl-5 and ROCK, respectively, and that ROCK-dependent actomyosin-driven contractility is a critical determinant for the regulation of the interaction between Necl-5 and integrin alpha(V)beta(3).	[Nagamatsu, Yuichi; Rikitake, Yoshiyuki; Takahashi, Motonori; Deki, Yuko; Takai, Yoshimi] Kobe Univ, Grad Sch Med, Div Mol & Cellular Biol, Dept Biochem & Mol Biol, Kobe, Hyogo 6500017, Japan; [Rikitake, Yoshiyuki; Takahashi, Motonori; Hirata, Ken-ichi] Kobe Univ, Grad Sch Med, Div Cardiovasc Med, Dept Internal Med, Kobe, Hyogo 6500017, Japan; [Ikeda, Wataru; Takai, Yoshimi] Osaka Univ, Grad Sch Med, Fac Med, Dept Mol Biol & Biochem, Suita, Osaka 5650871, Japan	Kobe University; Kobe University; Osaka University	Takai, Y (corresponding author), Kobe Univ, Grad Sch Med, Div Mol & Cellular Biol, Dept Biochem & Mol Biol, Kobe, Hyogo 6500017, Japan.	ytakai@med.kobe-u.ac.jp	Ikeda, Wataru/V-8531-2019	Ikeda, Wataru/0000-0002-6907-9058				Amano M, 1997, SCIENCE, V275, P1308, DOI 10.1126/science.275.5304.1308; Amano M, 1996, J BIOL CHEM, V271, P20246, DOI 10.1074/jbc.271.34.20246; Ballestrem C, 2001, J CELL BIOL, V155, P1319, DOI 10.1083/jcb.200107107; Carragher NO, 2004, TRENDS CELL BIOL, V14, P241, DOI 10.1016/j.tcb.2004.03.011; Clark EA, 1998, J CELL BIOL, V142, P573, DOI 10.1083/jcb.142.2.573; Folsom TD, 1997, GLIA, V20, P348; Folsom TD, 1999, GLIA, V26, P245, DOI 10.1002/(SICI)1098-1136(199905)26:3<245::AID-GLIA6>3.3.CO;2-M; Fujito T, 2005, J CELL BIOL, V171, P165, DOI 10.1083/jcb.200501090; Geiger B, 2001, CURR OPIN CELL BIOL, V13, P584, DOI 10.1016/S0955-0674(00)00255-6; Honda T, 2003, GENES CELLS, V8, P51, DOI 10.1046/j.1365-2443.2003.00616.x; Ikeda W, 2004, J BIOL CHEM, V279, P18015, DOI 10.1074/jbc.M312969200; Ikeda W, 2003, J BIOL CHEM, V278, P28167, DOI 10.1074/jbc.M303586200; Kawakami K, 2001, J CELL SCI, V114, P3125; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; Leopoldt D, 2001, J CELL PHYSIOL, V188, P106, DOI 10.1002/jcp.1102; Liu L, 2002, J IMMUNOL, V169, P2330, DOI 10.4049/jimmunol.169.5.2330; Minami Y, 2007, J BIOL CHEM, V282, P18481, DOI 10.1074/jbc.M611330200; Nakano K, 1999, MOL BIOL CELL, V10, P2481, DOI 10.1091/mbc.10.8.2481; NOBES CD, 1995, BIOCHEM SOC T, V23, P456, DOI 10.1042/bst0230456; Ostap EM, 2002, J MUSCLE RES CELL M, V23, P305, DOI 10.1023/A:1022047102064; Ridley AJ, 2001, TRENDS CELL BIOL, V11, P471, DOI 10.1016/S0962-8924(01)02153-5; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; Schaffner-Reckinger E, 1998, J BIOL CHEM, V273, P12623, DOI 10.1074/jbc.273.20.12623; van der Flier A, 2001, BBA-MOL CELL RES, V1538, P99, DOI 10.1016/S0167-4889(01)00072-6; Wozniak MA, 2004, BBA-MOL CELL RES, V1692, P103, DOI 10.1016/j.bbamcr.2004.04.007; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792	27	12	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14532	14541		10.1074/jbc.M801647200	http://dx.doi.org/10.1074/jbc.M801647200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18364349	hybrid			2022-12-25	WOS:000255941400041
J	Osipov, AV; Kasheverov, IE; Makarova, YV; Starkov, VG; Vorontsova, OV; Ziganshin, RK; Andreeva, TV; Serebryakova, MV; Benoit, A; Hogg, RC; Bertrand, D; Tsetlin, VI; Utkin, YN				Osipov, Alexey V.; Kasheverov, Igor E.; Makarova, Yana V.; Starkov, Vladislav G.; Vorontsova, Olga V.; Ziganshin, Rustam Kh.; Andreeva, Tatyana V.; Serebryakova, Marina V.; Benoit, Audrey; Hogg, Ronald C.; Bertrand, Daniel; Tsetlin, Victor I.; Utkin, Yuri N.			Naturally occurring disulfide-bound dimers of three-fingered toxins - A paradigm for biological activity diversification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; AMINO-ACID-SEQUENCE; KAPPA-BUNGAROTOXIN; CRYSTAL-STRUCTURE; COBRA VENOM; ALPHA-NEUROTOXINS; MASS-SPECTROMETRY; SNAKE-VENOMS; CIRCULAR-DICHROISM; NAJA-KAOUTHIA	Disulfide-bound dimers of three-fingered toxins have been discovered in the Naja kaouthia cobra venom; that is, the homodimer of alpha-cobratoxin (a long-chain alpha-neurotoxin) and heterodimers formed by alpha-cobratoxin with different cytotoxins. According to circular dichroism measurements, toxins in dimers retain in general their three-fingered folding. The functionally important disulfide 26 - 30 in polypeptide loop II of alpha-cobratoxin moiety remains intact in both types of dimers. Biological activity studies showed that cytotoxins within dimers completely lose their cytotoxicity. However, the dimers retain most of the alpha-cobratoxin capacity to compete with alpha-bungarotoxin for binding to Torpedo and alpha 7 nicotinic acetylcholine receptors (nAChRs) as well as to Lymnea stagnalis acetylcholine-binding protein. Electrophysiological experiments on neuronal nAChRs expressed in Xenopus oocytes have shown that alpha-cobratoxin dimer not only interacts with alpha 7 nAChR but, in contrast to alpha-cobratoxin monomer, also blocks alpha 3 beta 2 nAChR. In the latter activity it resembles kappa-bungarotoxin, a dimer with no disulfides between monomers. These results demonstrate that dimerization is essential for the interaction of three-fingered neurotoxins with heteromeric alpha 3 beta 2 nAChRs.	[Osipov, Alexey V.; Kasheverov, Igor E.; Makarova, Yana V.; Starkov, Vladislav G.; Vorontsova, Olga V.; Ziganshin, Rustam Kh.; Andreeva, Tatyana V.; Tsetlin, Victor I.; Utkin, Yuri N.] Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Moscow 117997, Russia; [Serebryakova, Marina V.] Sci Res Inst Physicochem Med, Moscow 119992, Russia; [Benoit, Audrey; Hogg, Ronald C.; Bertrand, Daniel] Ctr Med Univ Geneva, Dept Neurosci, Fac Med, CH-1211 Geneva 4, Switzerland	Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Bioorganic Chemistry of the Russian Academy of Sciences; Lopukhin Federal Research & Clinical Center of Physical-Chemical Medicine of Federal Medical Biological Agency; University of Geneva	Utkin, YN (corresponding author), Russian Acad Sci, Shemyakin Ovchinnikov Inst Bioorgan Chem, Ul Miklukho Maklaya 16-10, Moscow 117997, Russia.	utkin@mx.ibch.ru	Kasheverov, Igor E/F-6024-2014; Serebryakova, Marina/E-2986-2012; Ziganshin, Rustam/Q-7445-2016; Utkin, Yuri N./F-1958-2014; Alexey, Osipov/AAQ-1422-2021; Utkin, Yuri/L-2952-2019; Tsetlin, Victor/X-2491-2018	Serebryakova, Marina/0000-0002-5402-8215; Ziganshin, Rustam/0000-0002-7931-519X; Utkin, Yuri N./0000-0002-4609-970X; Utkin, Yuri/0000-0002-4609-970X; Osipov, Aleksei/0000-0001-7665-4711				Bilgrami S, 2004, J MOL BIOL, V341, P829, DOI 10.1016/j.jmb.2004.06.048; BILWES A, 1994, J MOL BIOL, V239, P122, DOI 10.1006/jmbi.1994.1357; Bourne Y, 2005, EMBO J, V24, P1512, DOI 10.1038/sj.emboj.7600620; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; CHIAPPINELLI VA, 1985, J BIOL CHEM, V260, P6182; CRIMMINS DL, 1995, ANAL BIOCHEM, V226, P355, DOI 10.1006/abio.1995.1236; DEWAN JC, 1994, BIOCHEMISTRY-US, V33, P13147, DOI 10.1021/bi00248a026; Dunn RD, 2001, BBA-MOL CELL BIOL L, V1533, P29, DOI 10.1016/S1388-1981(01)00138-X; Feofanov AV, 2005, BIOCHEM J, V390, P11, DOI 10.1042/BJ20041892; FIORDALISI JJ, 1994, BIOCHEMISTRY-US, V33, P12962, DOI 10.1021/bi00248a004; Forouhar F, 2003, J BIOL CHEM, V278, P21980, DOI 10.1074/jbc.M208650200; Grant GA, 1998, BIOCHEMISTRY-US, V37, P12166, DOI 10.1021/bi981227y; GRANT GA, 1988, BIOCHEMISTRY-US, V27, P3794, DOI 10.1021/bi00410a041; GRANT GA, 1985, BIOCHEMISTRY-US, V24, P1532, DOI 10.1021/bi00327a036; GRAY WR, 1993, PROTEIN SCI, V2, P1732, DOI 10.1002/pro.5560021017; Hansen SB, 2005, EMBO J, V24, P3635, DOI 10.1038/sj.emboj.7600828; Hogg RC, 2003, J BIOL CHEM, V278, P26908, DOI 10.1074/jbc.M212628200; JOUBERT FJ, 1979, H-S Z PHYSIOL CHEM, V360, P1075, DOI 10.1515/bchm2.1979.360.2.1075; Kukhtina VV, 2000, EUR J BIOCHEM, V267, P6784, DOI 10.1046/j.1432-1033.2000.01775.x; Kukhtina VV, 2000, BIOORG KHIM+, V26, P803; Kulkeaw K, 2007, TOXICON, V49, P1026, DOI 10.1016/j.toxicon.2007.01.019; Levandoski MM, 1999, J BIOL CHEM, V274, P26113, DOI 10.1074/jbc.274.37.26113; Li ST, 2004, BIOCHEM J, V384, P119, DOI 10.1042/BJ20040354; Li XL, 2004, ARCH BIOCHEM BIOPHYS, V424, P53, DOI 10.1016/j.abb.2004.01.015; Llinas P, 2005, EMBO J, V24, P1655, DOI 10.1038/sj.emboj.7600635; Loughnan M, 2006, J BIOL CHEM, V281, P24745, DOI 10.1074/jbc.M603703200; LUETJE CW, 1990, J NEUROCHEM, V55, P632, DOI 10.1111/j.1471-4159.1990.tb04180.x; Lyukmanova EN, 2007, J BIOL CHEM, V282, P24784, DOI 10.1074/jbc.M611263200; Makarova YV, 2006, BIOCHEMISTRY-MOSCOW+, V71, P678, DOI 10.1134/S0006297906060125; MANNING MC, 1988, BIOPHYS CHEM, V31, P77, DOI 10.1016/0301-4622(88)80011-5; MARTIN BM, 1983, J BIOL CHEM, V258, P8714; Nirthanan S, 2004, J PHARMACOL SCI, V94, P1, DOI 10.1254/jphs.94.1; Osipov AV, 2005, BIOCHEM BIOPH RES CO, V328, P177, DOI 10.1016/j.bbrc.2004.12.154; Osipov AV, 2004, EUR J BIOCHEM, V271, P2018, DOI 10.1111/j.1432-1033.2004.04115.x; PLUZHNIKOV KA, 1994, BIOORG KHIM+, V20, P857; Quik M, 1996, J NEUROCHEM, V67, P145; RASHEED JK, 1988, MICROB PATHOGENESIS, V5, P333, DOI 10.1016/0882-4010(88)90034-4; SANTOS AD, 1992, J BIOL CHEM, V267, P20701; SCHIPPERS PH, 1981, ANAL CHEM, V53, P778, DOI 10.1021/ac00229a008; Serebryakova MV, 2006, EUR J MASS SPECTROM, V12, P51, DOI 10.1255/ejms.792; Servent D, 1997, J BIOL CHEM, V272, P24279, DOI 10.1074/jbc.272.39.24279; Smit AB, 2001, NATURE, V411, P261, DOI 10.1038/35077000; Smith B J, 1994, Methods Mol Biol, V32, P23; Suckau D, 2003, ANAL BIOANAL CHEM, V376, P952, DOI 10.1007/s00216-003-2057-0; Zamudio FZ, 1997, J BIOL CHEM, V272, P11886, DOI 10.1074/jbc.272.18.11886	45	69	77	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14571	14580		10.1074/jbc.M802085200	http://dx.doi.org/10.1074/jbc.M802085200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18381281	hybrid			2022-12-25	WOS:000255941400045
J	Ronnebaum, SM; Joseph, JW; Ilkayeva, O; Burgess, SC; Lu, D; Becker, TC; Sherry, AD; Newgard, CB				Ronnebaum, Sarah M.; Joseph, Jamie W.; Ilkayeva, Olga; Burgess, Shawn C.; Lu, Danhong; Becker, Thomas C.; Sherry, A. Dean; Newgard, Christopher B.			Chronic suppression of Acetyl-CoA carboxylase 1 in beta-cells impairs insulin secretion via inhibition of glucose rather than lipid metabolism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID OXIDATION; ATP-CITRATE LYASE; MALONYL-COA; COUPLING FACTORS; REGULATORY ROLE; MUTANT MICE; ACTIVATION; GLUTAMATE; INCREASE; SYNTHASE	Acetyl-CoA carboxylase 1 (ACC1) currently is being investigated as a target for treatment of obesity-associated dyslipidemia and insulin resistance. To investigate the effects of ACC1 inhibition on insulin secretion, three small interfering RNA ( siRNA) duplexes targeting ACC1 ( siACC1) were transfected into the INS-1-derived cell line, 832/13; the most efficacious duplex was also cloned into an adenovirus and used to transduce isolated rat islets. Delivery of the siACC1 duplexes decreased ACC1 mRNA by 60-80% in 832/13 cells and islets and enzyme activity by 46% compared with cells treated with a non-targeted siRNA. Delivery of siACC1 decreased glucose-stimulated insulin secretion (GSIS) by 70% in 832/13 cells and by 33% in islets. Surprisingly, siACC1 treatment decreased glucose oxidation by 49%, and the ATP: ADP ratio by 52%, accompanied by clear decreases in pyruvate cycling activity and tricarboxylic acid cycle intermediates. Exposure of siACC1-treated cells to the pyruvate cycling substrate dimethylmalate restored GSIS to normal without recovery of the depressed ATP: ADP ratio. In siACC1-treated cells, glucokinase protein levels were decreased by 25%, which correlated with a 36% decrease in glycogen synthesis and a 33% decrease in glycolytic flux. Furthermore, acute addition of the ACC1 inhibitor 5-(tetradecyloxy)-2-furoic acid ( TOFA) to beta-cells suppressed [C-14] glucose incorporation into lipids but had no effect on GSIS, whereas chronic TOFA administration suppressed GSIS and glucose metabolism. In sum, chronic, but not acute, suppression of ACC1 activity impairs GSIS via inhibition of glucose rather than lipid metabolism. These findings raise concerns about the use of ACC inhibitors for diabetes therapy.	[Ronnebaum, Sarah M.; Joseph, Jamie W.; Ilkayeva, Olga; Lu, Danhong; Becker, Thomas C.; Newgard, Christopher B.] Duke Univ, Med Ctr, Sarah W Stedman Mutr & Metab Ctr, Duke Independence Pk Facil, Durham, NC 27704 USA; [Ronnebaum, Sarah M.; Joseph, Jamie W.; Ilkayeva, Olga; Lu, Danhong; Becker, Thomas C.; Newgard, Christopher B.] Duke Univ, Med Ctr, Dept Pharmacol & Cell Biol, Durham, NC 27704 USA; [Burgess, Shawn C.; Sherry, A. Dean] Univ Texas SW Med Ctr Dallas, Mary Nell & Ralph B Rogers Magnet Resonance Ctr, Dept Radiol & Pharmacol, Dallas, TX 75235 USA; [Burgess, Shawn C.; Sherry, A. Dean] Univ Texas SW Med Ctr Dallas, Adv Imaging Res Ctr, Dallas, TX 75235 USA	Duke University; Duke University; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas	Newgard, CB (corresponding author), Duke Univ, Med Ctr, Sarah W Stedman Mutr & Metab Ctr, Duke Independence Pk Facil, 4321 Med Pk Dr,Suite 200, Durham, NC 27704 USA.	newga002@mc.duke.edu	; Sherry, Dean/P-2348-2018	Ronnebaum, Sarah/0000-0003-4787-754X; Sherry, Dean/0000-0001-7150-8301	NIDDK NIH HHS [DK 58398, DK 42583, P01 DK058398] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058398] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abu-Elheiga L, 2005, P NATL ACAD SCI USA, V102, P12011, DOI 10.1073/pnas.0505714102; Abu-Elheiga L, 2003, P NATL ACAD SCI USA, V100, P10207, DOI 10.1073/pnas.1733877100; Abu-Elheiga L, 2001, SCIENCE, V291, P2613, DOI 10.1126/science.1056843; Antinozzi PA, 1998, J BIOL CHEM, V273, P16146, DOI 10.1074/jbc.273.26.16146; Arden C, 2004, DIABETES, V53, P2346, DOI 10.2337/diabetes.53.9.2346; ASFARI M, 1992, ENDOCRINOLOGY, V130, P167, DOI 10.1210/en.130.1.167; Bain JR, 2004, DIABETES, V53, P2190, DOI 10.2337/diabetes.53.9.2190; Bollheimer LC, 1998, J CLIN INVEST, V101, P1094, DOI 10.1172/JCI420; Boucher A, 2004, J BIOL CHEM, V279, P27263, DOI 10.1074/jbc.M401167200; Briscoe CP, 2003, J BIOL CHEM, V278, P11303, DOI 10.1074/jbc.M211495200; CARLING D, 1987, FEBS LETT, V223, P217, DOI 10.1016/0014-5793(87)80292-2; Chakravarthy MV, 2007, J CLIN INVEST, V117, P2539, DOI 10.1172/JCI31183; Chen JG, 2007, AM J PHYSIOL-ENDOC M, V292, pE1906, DOI 10.1152/ajpendo.00356.2006; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; Corkey BE, 2000, J NUTR, V130, p299S, DOI 10.1093/jn/130.2.299S; EFANOV AM, 2004, DIABETES, V3, P75; Eto K, 1999, SCIENCE, V283, P981, DOI 10.1126/science.283.5404.981; Freeman H, 2006, CELL METAB, V3, P35, DOI 10.1016/j.cmet.2005.10.008; Gaussin V, 1996, BIOCHEM J, V316, P217, DOI 10.1042/bj3160217; Gleason CE, 2007, J BIOL CHEM, V282, P10341, DOI 10.1074/jbc.M610631200; Guay C, 2007, J BIOL CHEM, V282, P35657, DOI 10.1074/jbc.M707294200; Harwood HJ, 2003, J BIOL CHEM, V278, P37099, DOI 10.1074/jbc.M304481200; Hohmeier HE, 2000, DIABETES, V49, P424, DOI 10.2337/diabetes.49.3.424; HUGHES SD, 1993, J BIOL CHEM, V268, P15205; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; Ivarsson R, 2005, DIABETES, V54, P2132, DOI 10.2337/diabetes.54.7.2132; Jensen MV, 2006, J BIOL CHEM, V281, P22342, DOI 10.1074/jbc.M604350200; Joseph JW, 2007, J BIOL CHEM, V282, P31592, DOI 10.1074/jbc.M706080200; Joseph JW, 2006, J BIOL CHEM, V281, P35624, DOI 10.1074/jbc.M602606200; Joseph JW, 2004, J BIOL CHEM, V279, P51049, DOI 10.1074/jbc.M409189200; Kowluru A, 2001, DIABETES, V50, P1580, DOI 10.2337/diabetes.50.7.1580; Lu DH, 2002, P NATL ACAD SCI USA, V99, P2708, DOI 10.1073/pnas.052005699; MacDonald MJ, 2005, AM J PHYSIOL-ENDOC M, V288, pE1, DOI 10.1152/ajpendo.00218.2004; Maechler P, 1999, NATURE, V402, P685, DOI 10.1038/45280; Mao J, 2006, P NATL ACAD SCI USA, V103, P8552, DOI 10.1073/pnas.0603115103; MILBURN JL, 1995, J BIOL CHEM, V270, P1295, DOI 10.1074/jbc.270.3.1295; Mulder H, 2001, J BIOL CHEM, V276, P6479, DOI 10.1074/jbc.M010364200; NABER SP, 1980, DIABETOLOGIA, V19, P439, DOI 10.1007/BF00281823; Nenquin M, 2004, J BIOL CHEM, V279, P32316, DOI 10.1074/jbc.M402076200; NEWGARD CB, 1995, ANNU REV BIOCHEM, V64, P689, DOI 10.1146/annurev.biochem.64.1.689; PRENTKI M, 1992, J BIOL CHEM, V267, P5802; Robertson RP, 2004, DIABETES, V53, pS119, DOI 10.2337/diabetes.53.2007.S119; Roduit R, 2004, DIABETES, V53, P1007, DOI 10.2337/diabetes.53.4.1007; Ronnebaum SM, 2006, J BIOL CHEM, V281, P30593, DOI 10.1074/jbc.M511908200; Schisler JC, 2005, P NATL ACAD SCI USA, V102, P7297, DOI 10.1073/pnas.0502168102; SCHULTZ V, 1993, ANAL BIOCHEM, V215, P302, DOI 10.1006/abio.1993.1591; Szollosi A, 2007, J BIOL CHEM, V282, P1747, DOI 10.1074/jbc.M609875200; Tong L, 2006, J CELL BIOCHEM, V99, P1476, DOI 10.1002/jcb.21077; TREADWAY JL, 2004, AM DIABETES ASS SCI; Zhang SY, 1998, CELL SIGNAL, V10, P35, DOI 10.1016/S0898-6568(97)00070-3	50	44	45	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14248	14256		10.1074/jbc.M800119200	http://dx.doi.org/10.1074/jbc.M800119200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18381287	Green Published, hybrid			2022-12-25	WOS:000255941400011
J	Zhang, MX; Zhang, C; Shen, YH; Wang, J; Li, XN; Zhang, Y; Coselli, J; Wang, XL				Zhang, Ming-Xiang; Zhang, Cheng; Shen, Ying H.; Wang, Jian; Li, Xiao Nan; Zhang, Yun; Coselli, Joseph; Wang, Xing Li			Biogenesis of short intronic repeat 27-nucleotide small RNA from endothelial nitric-oxide synthase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION; MICRORNAS; DISEASE; POLYMORPHISM; GENOTYPE; CELLS	Endothelial nitric-oxide synthase (eNOS) is a constitutively expressed gene in endothelium that produces NO and is critical for vascular integrity. Previously, we reported that the 27-nucleotide (nt) repeat polymorphism in eNOS intron 4, a source of 27-nt small RNA, which inhibits eNOS expression, were associated with cardiovascular risk and expression of the eNOS gene. In the current study, we investigated the biogenesis of the intron 4-derived 27-nt small RNA. Using Northern blot, we showed that the eNOS-derived 27-nt short intronic repeat RNA (sir-RNA) expressed only in the eNOS expressing endothelial cells. Cells containing 10 x 27- or 5 x 27-nt repeats produced higher levels of 27nt sir-RNA and lower levels of eNOS mRNA than the cells with 4 x 27-nt repeats. The 27nt sir-RNA was mostly present within the endothelial nuclei. When the splicing junctions of the 27-nt repeat containing intron 4 in the full-length eNOS cDNA vector were mutated, 27nt sir-RNA biogenesis was abolished. Suppression of Drosha or Dicer diminished the biogenesis of the 27nt sir-RNA. Our study suggests that the 27nt sir-RNA derived through eNOS pre-mRNA splicing may represent a new class of small RNA. The more eNOS is transcribed or higher number of the 27-nt repeats, the more 27nt sir-RNA is produced, which functions as a negative feedback self-regulator by specifically inhibiting the host gene eNOS expression. This novel molecular model may be responsible for quantitative differences between individuals carrying different numbers of the polymorphic repeats hence the cardiovascular risk.	[Zhang, Ming-Xiang; Zhang, Cheng; Shen, Ying H.; Wang, Jian; Li, Xiao Nan; Coselli, Joseph; Wang, Xing Li] Baylor Coll Med, Adult Sect Cardiothorac Surg, Texas Heart Inst,Michael E DeBakey Dept Surg, St Lukes Episcopal Hosp,Div Cardiothorac Surg, Houston, TX 77030 USA; [Zhang, Ming-Xiang; Zhang, Cheng; Li, Xiao Nan; Zhang, Yun] Shandong Univ, Qilu Hosp, Key Lab Cardiovasc Remodeling & Funct Res, Chinese Minist Educ, Jinan 250100, Peoples R China; [Zhang, Ming-Xiang; Zhang, Cheng; Li, Xiao Nan; Zhang, Yun] Shandong Univ, Qilu Hosp, Chinese Minist Publ Hlth, Jinan 250100, Peoples R China	Baylor College of Medicine; Saint Lukes Episcopal Hospital; Texas Heart Institute; Shandong University; Shandong University	Zhang, MX (corresponding author), Baylor Coll Med, Adult Sect Cardiothorac Surg, Texas Heart Inst,Michael E DeBakey Dept Surg, St Lukes Episcopal Hosp,Div Cardiothorac Surg, Houston, TX 77030 USA.	mzhang1@bcm.edu; xlwang@bcm.edu	shen, ying/HHS-5635-2022		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL083794, R01HL071608, R01HL066053] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 066053, R01 HL 071608, P50 HL 083794] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ambros V, 2003, CURR BIOL, V13, P807, DOI 10.1016/S0960-9822(03)00287-2; Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Aravin AA, 2003, DEV CELL, V5, P337, DOI 10.1016/S1534-5807(03)00228-4; Aravin A, 2006, NATURE, V442, P203, DOI 10.1038/nature04916; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Beckman JS, 1996, AM J PHYSIOL-CELL PH, V271, pC1424; Bennettt EA, 2004, GENETICS, V168, P933, DOI 10.1534/genetics.104.031757; Berezikov E, 2007, MOL CELL, V28, P328, DOI 10.1016/j.molcel.2007.09.028; Casas JP, 2004, CIRCULATION, V109, P1359, DOI 10.1161/01.CIR.0000121357.76910.A3; Cullen BR, 2004, VIRUS RES, V102, P3, DOI 10.1016/j.virusres.2004.01.009; Gan YH, 2006, BIOCHEM BIOPH RES CO, V340, P29, DOI 10.1016/j.bbrc.2005.11.151; Gan YH, 2005, J BIOL CHEM, V280, P16467, DOI 10.1074/jbc.M412960200; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; Hausladen A, 1999, METHOD ENZYMOL, V300, P389; Kathiresan S, 2005, CIRCULATION, V112, P1419, DOI 10.1161/CIRCULATIONAHA.105.544619; Kim YK, 2007, EMBO J, V26, P775, DOI 10.1038/sj.emboj.7601512; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Melino G, 1997, NATURE, V388, P432, DOI 10.1038/41237; Oemar BS, 1998, CIRCULATION, V97, P2494, DOI 10.1161/01.CIR.97.25.2494; Ou HS, 2005, ARTERIOSCL THROM VAS, V25, P2509, DOI 10.1161/01.ATV.0000189306.99112.4c; Rajendran AM, 2006, COMPUT MECH, V38, P1, DOI 10.1007/s00466-005-0712-3; Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085; Ruby JG, 2007, NATURE, V448, P83, DOI 10.1038/nature05983; Senthil D, 2005, DNA CELL BIOL, V24, P218, DOI 10.1089/dna.2005.24.218; Wang R, 2002, ARTERIOSCL THROM VAS, V22, pE1, DOI 10.1161/01.ATV.0000016248.51577.1F; Wang XL, 1996, NAT MED, V2, P41, DOI 10.1038/nm0196-41; Wang XL, 2000, MOL GENET METAB, V70, P241, DOI 10.1006/mgme.2000.3033; Zeng Y, 2006, ONCOGENE, V25, P6156, DOI 10.1038/sj.onc.1209908; Zeng Yan, 2006, V342, P49, DOI 10.1385/1-59745-123-1:49; Zhang JH, 2005, CARCINOGENESIS, V26, P1748, DOI 10.1093/carcin/bgi144; Zhang MX, 2005, P NATL ACAD SCI USA, V102, P16967, DOI 10.1073/pnas.0503853102	31	48	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14685	14693		10.1074/jbc.M801933200	http://dx.doi.org/10.1074/jbc.M801933200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18390539	Green Published, hybrid			2022-12-25	WOS:000255941400057
J	Funabashi, M; Funa, N; Horinouchi, S				Funabashi, Masanori; Funa, Nobutaka; Horinouchi, Sueharu			Phenolic lipids synthesized by type III polyketide synthase confer penicillin resistance on Streptomyces griseus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR REGULATORY CASCADE; FATTY-ACID BIOSYNTHESIS; A-FACTOR; MORPHOLOGICAL DEVELOPMENT; SECONDARY METABOLISM; ESCHERICHIA-COLI; GENE; ENZYME; ADPA	Type III polyketide synthases (PKSs) found in plants, fungi, and bacteria synthesize a variety of aromatic polyketides. A Gram-positive, filamentous bacterium Streptomyces griseus contained an srs operon, in which srsA encoded a type III PKS, srsB encoded a methyltransferase, and srsC encoded a flavoprotein hydroxylase. Consistent with this annotation, overexpression of the srs genes in a heterologous host, Streptomyces lividans, showed that SrsA was a type III PKS responsible for synthesis of phenolic lipids, alkylresorcinols, and alkylpyrones, SrsB was a methyltransferase acting on the phenolic lipids to yield alkylresorcinol methyl ethers, and SrsC was a hydroxylase acting on the alkylresorcinol methyl ethers. In vitro SrsA reaction showed that SrsA synthesized alkylresorcinols from acyl-CoAs of various chain lengths as a starter substrate, one molecule of methylmalonyl-CoA, and two molecules of malonyl-CoA. SrsA was thus unique in that it incorporated the extender substrates in a strictly controlled order of malonyl-CoA, malonyl-CoA, and methylmalonyl-CoA to produce alkylresorcinols. An srsA mutant, which produced no phenolic lipids, was highly sensitive to beta-lactam antibiotics, such as penicillin G and cephalexin. Together with the fact that the alkylresorcinols were fractionated mainly in the cell wall fraction, this observation suggests that the phenolic lipids, perhaps associated with the cytoplasmic membrane because of their amphiphilic property, affect the characteristic and rigidity of the cytoplasmic membrane/peptidoglycan of a variety of bacteria. An srs-like operon is found widely among Gram-positive and -negative bacteria, indicating wide distribution of the phenolic lipids.	[Funabashi, Masanori; Funa, Nobutaka; Horinouchi, Sueharu] Univ Tokyo, Dept Biotechnol, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan	University of Tokyo	Horinouchi, S (corresponding author), Univ Tokyo, Dept Biotechnol, Grad Sch Agr & Life Sci, Bunkyo Ku, Tokyo 1138657, Japan.	asuhori@mail.ecc.u-tokyo.ac.jp						Austin MB, 2003, NAT PROD REP, V20, P79, DOI 10.1039/b100917f; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; Blecher M, 1981, Methods Enzymol, V72, P404; BULOCK JD, 1969, J CHEM SOC, V60, P61; Enroth C, 1998, STRUCTURE, V6, P605, DOI 10.1016/S0969-2126(98)00062-8; Funa N, 1999, NATURE, V400, P897, DOI 10.1038/23748; Funa N, 2006, P NATL ACAD SCI USA, V103, P6356, DOI 10.1073/pnas.0511227103; Gruschow S, 2007, CHEMBIOCHEM, V8, P863, DOI 10.1002/cbic.200700026; Herai S, 2004, P NATL ACAD SCI USA, V101, P14031, DOI 10.1073/pnas.0406058101; Horinouchi S, 2007, P JPN ACAD B-PHYS, V83, P277, DOI [10.2183/pjab.83.277, 10.2183/pjab/83.277]; Horinouchi S, 2007, BIOSCI BIOTECH BIOCH, V71, P283, DOI 10.1271/bbb.60627; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; Kieser T., 2000, PRACTICAL STREPTOMYC, V4362; Kozubek A, 1999, CHEM REV, V99, P1, DOI 10.1021/cr970464o; KUMAGAI M, 1971, J ANTIBIOT, V24, P870, DOI 10.7164/antibiotics.24.870; Maniatis T., 1982, MOL CLONING LAB MANU; Miyanaga A, 2008, P NATL ACAD SCI USA, V105, P871, DOI 10.1073/pnas.0709819105; Ohnishi Y, 2005, BIOSCI BIOTECH BIOCH, V69, P431, DOI 10.1271/bbb.69.431; Pertiwiningrum A, 2004, J BIOSCI BIOENG, V98, P214; Rock CO, 1996, BBA-LIPID LIPID MET, V1302, P1, DOI 10.1016/0005-2760(96)00056-2; Saxena P, 2003, J BIOL CHEM, V278, P44780, DOI 10.1074/jbc.M306714200; SIEBERT M, 1992, FEBS LETT, V307, P347, DOI 10.1016/0014-5793(92)80710-X; TAKANO E, 1995, GENE, V166, P133, DOI 10.1016/0378-1119(95)00545-2; WALLACE KK, 1995, FEMS MICROBIOL LETT, V131, P227, DOI 10.1016/0378-1097(95)00263-5; Winter-Vann AM, 2005, NAT REV CANCER, V5, P405, DOI 10.1038/nrc1612; Yamazaki H, 2003, MOL MICROBIOL, V50, P1173, DOI 10.1046/j.1365-2958.2003.03760.x	26	78	83	3	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2008	283	20					13983	13991		10.1074/jbc.M710461200	http://dx.doi.org/10.1074/jbc.M710461200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299AM	18364359	hybrid			2022-12-25	WOS:000255728200052
J	Steinmann, C; Landsverk, ML; Barral, JM; Boehning, D				Steinmann, Camia; Landsverk, Megan L.; Barral, Jose M.; Boehning, Darren			Requirement of inositol 1,4,5-trisphosphate receptors for tumor-mediated lymphocyte apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CANCER IN-VIVO; FAS LIGAND; COLON-CANCER; IMMUNE PRIVILEGE; COUNTERATTACK; EXPRESSION; XESTOSPONGINS; INFLAMMATION; PROGRESSION; PATHWAYS	Tumor cells strategically down-regulate Fas receptor expression to evade immune attack and up-regulate expression of Fas ligand to promote apoptosis of infiltrating T lymphocytes. Many pathways leading to apoptotic cell death require calcium release from inositol 1,4,5-trisphosphate receptors (IP3Rs). Here, we show that Fas-dependent killing of Jurkat T lymphoma cells by SW620 colon cancer cells requires calcium release from IP3R. General suppression of IP3R signaling significantly reduced SW620-mediated Jurkat cell apoptosis. Significantly, a specific inhibitor of apoptotic calcium release from IP3R strongly blocked lymphocyte apoptosis. Thus, selective pharmacological targeting of apoptotic calcium release from IP3R may enhance tumor cell immunogenicity.	[Steinmann, Camia; Barral, Jose M.; Boehning, Darren] Univ Texas Galveston, Med Branch, Dept Cell Biol & Neurosci, Galveston, TX 77555 USA; [Landsverk, Megan L.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA	University of Texas System; University of Texas Medical Branch Galveston; University of Washington; University of Washington Seattle	Boehning, D (corresponding author), Univ Texas Galveston, Med Branch, Dept Cell Biol & Neurosci, 301 Univ Blvd, Galveston, TX 77555 USA.	dfboehni@utmb.edu	Boehning, Darren/I-8539-2015	Boehning, Darren/0000-0001-7920-6922	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081685] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM081685, R01 GM081685] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bebenek M, 2006, MED SCI MONITOR, V12, pCR457; Bennett MW, 2001, J CLIN PATHOL, V54, P598, DOI 10.1136/jcp.54.8.598; Boehning D, 2003, NAT CELL BIOL, V5, P1051, DOI 10.1038/ncb1063; Boehning D, 2005, P NATL ACAD SCI USA, V102, P1466, DOI 10.1073/pnas.0409650102; Gafni J, 1997, NEURON, V19, P723, DOI 10.1016/S0896-6273(00)80384-0; Houston A, 2004, CURR OPIN PHARMACOL, V4, P321, DOI 10.1016/j.coph.2004.03.008; Houston A, 2003, BRIT J CANCER, V89, P1345, DOI 10.1038/sj.bjc.6601240; Houston A, 2003, INT J CANCER, V107, P209, DOI 10.1002/ijc.11392; Igney FH, 2005, CANCER IMMUNOL IMMUN, V54, P1127, DOI 10.1007/s00262-005-0680-7; O'Connell J, 2001, NAT MED, V7, P271, DOI 10.1038/85395; OConnell J, 1996, J EXP MED, V184, P1075, DOI 10.1084/jem.184.3.1075; Reichmann E, 2002, SEMIN CANCER BIOL, V12, P309, DOI 10.1016/S1044-579X(02)00017-2; Reimer T, 2002, BREAST CANCER RES, V4, DOI 10.1186/bcr456; Ryan AE, 2006, CELL CYCLE, V5, P246, DOI 10.4161/cc.5.3.2413; Ryan AE, 2005, CANCER RES, V65, P9817, DOI 10.1158/0008-5472.CAN-05-1462; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Ta TA, 2006, MOL PHARMACOL, V69, P532, DOI 10.1124/mol.105.019125; Wozniak AL, 2006, J CELL BIOL, V175, P709, DOI 10.1083/jcb.200608035; Yamana K, 2005, BRIT J CANCER, V93, P544, DOI 10.1038/sj.bjc.6602732	19	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2008	283	20					13506	13509		10.1074/jbc.C800029200	http://dx.doi.org/10.1074/jbc.C800029200			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299AM	18364356	Green Published, hybrid, Green Accepted			2022-12-25	WOS:000255728200003
J	Azadpour, M; Balaban, E				Azadpour, Mahan; Balaban, Evan			Phonological Representations Are Unconsciously Used when Processing Complex, Non-Speech Signals	PLOS ONE			English	Article								Neuroimaging studies of speech processing increasingly rely on artificial speech-like sounds whose perceptual status as speech or non-speech is assigned by simple subjective judgments; brain activation patterns are interpreted according to these status assignments. The naive perceptual status of one such stimulus, spectrally-rotated speech (not consciously perceived as speech by naive subjects), was evaluated in discrimination and forced identification experiments. Discrimination of variation in spectrally-rotated syllables in one group of naive subjects was strongly related to the pattern of similarities in phonological identification of the same stimuli provided by a second, independent group of naive subjects, suggesting either that (1) naive rotated syllable perception involves phonetic-like processing, or (2) that perception is solely based on physical acoustic similarity, and similar sounds are provided with similar phonetic identities. Analysis of acoustic (Euclidean distances of center frequency values of formants) and phonetic similarities in the perception of the vowel portions of the rotated syllables revealed that discrimination was significantly and independently influenced by both acoustic and phonological information. We conclude that simple subjective assessments of artificial speech-like sounds can be misleading, as perception of such sounds may initially and unconsciously utilize speech-like, phonological processing.	[Azadpour, Mahan; Balaban, Evan] SISSA, Int Sch Adv Studies, Cognit Neurosci Sector, I-34014 Trieste, Italy; [Balaban, Evan] McGill Univ, Behav Neurosci Program, Montreal, PQ, Canada	International School for Advanced Studies (SISSA); McGill University	Balaban, E (corresponding author), SISSA, Int Sch Adv Studies, Cognit Neurosci Sector, I-34014 Trieste, Italy.	evan.balaban@mcgill.ca	Balaban, Evan/AAV-2353-2020	Balaban, Evan/0000-0002-0391-3433; Azadpour, Mahan/0000-0001-5714-7140	Scuola Internazionale Superiore di Studi Avanzati SISSA (Italy); NSERC (Canada); Canadian Fund for Innovation	Scuola Internazionale Superiore di Studi Avanzati SISSA (Italy); NSERC (Canada)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canadian Fund for Innovation	This work was supported by the Scuola Internazionale Superiore di Studi Avanzati SISSA (Italy), NSERC (Canada), and the Canadian Fund for Innovation.	BLESSER B, 1972, J SPEECH HEAR RES, V15, P5, DOI 10.1044/jshr.1501.05; Boersma Paul, 2006, PRAAT DOING PHONETIC; Dehaene-Lambertz G, 2005, NEUROIMAGE, V24, P21, DOI 10.1016/j.neuroimage.2004.09.039; Fava Elisabetta, 1976, STUDI FONETICA FONOL, P35; LIBERMAN AM, 1989, SCIENCE, V243, P489, DOI 10.1126/science.2643163; Manly BFJ, 1997, RANDOMIZATION BOOTST; Maurer D, 2000, INT J NEUROSCI, V100, P39, DOI 10.3109/00207450008999677; Narain C, 2003, CEREB CORTEX, V13, P1362, DOI 10.1093/cercor/bhg083; Obleser J, 2006, CEREB CORTEX, V16, P1069, DOI 10.1093/cercor/bhj047; PETERSON GE, 1952, J ACOUST SOC AM, V24, P175, DOI 10.1121/1.1906875; Pulvermuller F, 2006, P NATL ACAD SCI USA, V103, P7865, DOI 10.1073/pnas.0509989103; ROSEN S, 2002, ARO ABSTR, V25, P50; Scott SK, 2004, COGNITION, V92, P13, DOI 10.1016/j.cognition.2002.12.002; Scott SK, 2000, BRAIN, V123, P2400, DOI 10.1093/brain/123.12.2400; Scott SK, 2006, J ACOUST SOC AM, V120, P1075, DOI 10.1121/1.2216725; SIEGEL S, 1988, NONPARAMETRIC STAT; Whalen DH, 2006, J ACOUST SOC AM, V119, P575, DOI 10.1121/1.2139627; Wright Richard, 2004, PHONETICALLY BASED P, P34, DOI DOI 10.1017/CBO9780511486401.002	18	11	11	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1966	10.1371/journal.pone.0001966	http://dx.doi.org/10.1371/journal.pone.0001966			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414663	Green Submitted, Green Published, gold			2022-12-25	WOS:000260867300012
J	Rebetz, J; Tian, DP; Persson, A; Widegren, B; Salford, LG; Englund, E; Gisselsson, D; Fan, X				Rebetz, Johan; Tian, Dongping; Persson, Annette; Widegren, Bengt; Salford, Leif G.; Englund, Elisabet; Gisselsson, David; Fan, Xiaolong			Glial Progenitor-Like Phenotype in Low-Grade Glioma and Enhanced CD133-Expression and Neuronal Lineage Differentiation Potential in High-Grade Glioma	PLOS ONE			English	Article								Background: While neurosphere-as well as xenograft tumor-initiating cells have been identified in gliomas, the resemblance between glioma cells and neural stem/progenitor cells as well as the prognostic value of stem/progenitor cell marker expression in glioma are poorly clarified. Methodology/Principal Findings: Viable glioma cells were characterized for surface marker expression along the glial genesis hierarchy. Six low-grade and 17 high-grade glioma specimens were flow-cytometrically analyzed for markers characteristics of stem cells (CD133); glial progenitors (PDGFR alpha, A2B5, O4, and CD44); and late oligodendrocyte progenitors (O1). In parallel, the expression of glial fibrillary acidic protein (GFAP), synaptophysin and neuron-specific enolase (NSE) was immunohistochemically analyzed in fixed tissue specimens. Irrespective of the grade and morphological diagnosis of gliomas, glioma cells concomitantly expressed PDGFRa, A2B5, O4, CD44 and GFAP. In contrast, O1 was weakly expressed in all low-grade and the majority of high-grade glioma specimens analyzed. Co-expression of neuronal markers was observed in all high-grade, but not low-grade, glioma specimens analyzed. The rare CD133 expressing cells in low-grade glioma specimens typically co-expressed vessel endothelial marker CD31. In contrast, distinct CD133 expression profiles in up to 90% of CD45-negative glioma cells were observed in 12 of the 17 high-grade glioma specimens and the majority of these CD133 expressing cells were CD31 negative. The CD133 expression correlates inversely with length of patient survival. Surprisingly, cytogenetic analysis showed that gliomas contained normal and abnormal cell karyotypes with hitherto indistinguishable phenotype. Conclusions/Significance: This study constitutes an important step towards clarification of lineage commitment and differentiation blockage of glioma cells. Our data suggest that glioma cells may resemble expansion of glial lineage progenitor cells with compromised differentiation capacity downstream of A2B5 and O4 expression. The concurrent expression of neuronal markers demonstrates that high-grade glioma cells are endowed with multi-lineage differentiation potential in vivo. Importantly, enhanced CD133 expression marks a poor prognosis in gliomas.	[Rebetz, Johan; Tian, Dongping; Widegren, Bengt; Salford, Leif G.; Fan, Xiaolong] Univ Lund Hosp, Div Neurosurg, Rausing Lab, S-22185 Lund, Sweden; [Fan, Xiaolong] Lund Univ, Strategic Res Ctr Stem Cell Biol & Cell Therapy, Lund, Sweden; [Widegren, Bengt] Lund Univ, Dept Cell & Mol Biol, Lund, Sweden; [Gisselsson, David] Lund Univ Hosp, Dept Clin Genet, Lund, Sweden; [Persson, Annette; Englund, Elisabet] Lund Univ Hosp, Dept Pathol, Lund, Sweden	Lund University; Skane University Hospital; Lund University; Lund University; Lund University; Skane University Hospital; Lund University; Skane University Hospital	Rebetz, J (corresponding author), Univ Lund Hosp, Div Neurosurg, Rausing Lab, S-22185 Lund, Sweden.	Xiaolong.Fan@med.lu.se	Rebetz, Johan/AAK-9569-2021	Rebetz, Johan/0000-0003-1673-0684; Englund, Elisabet/0000-0002-2708-2443	Swedish Cancer Society; Swedish Pediatric Cancer Foundation; Swedish Research Council; Lund University Medical Faculty; Hans and Marit Rausing charitable foundation; VFK Krebsforschung gGmbH; Gunnar Nilsson Cancer Foundation; Swedish Foundation for Strategic Research	Swedish Cancer Society(Swedish Cancer Society); Swedish Pediatric Cancer Foundation; Swedish Research Council(Swedish Research CouncilEuropean Commission); Lund University Medical Faculty; Hans and Marit Rausing charitable foundation; VFK Krebsforschung gGmbH; Gunnar Nilsson Cancer Foundation; Swedish Foundation for Strategic Research(Swedish Foundation for Strategic Research)	This study was supported by the Swedish Cancer Society, the Swedish Pediatric Cancer Foundation, The Swedish Research Council, Lund University Medical Faculty, Hans and Marit Rausing charitable foundation, VFK Krebsforschung gGmbH and Gunnar Nilsson Cancer Foundation. Lund Strategic Research Center for Stem Cell Biology and Cell Therapy is supported by a Center of Excellence grant from Swedish Foundation for Strategic Research. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alfei L, 1999, EUR J HISTOCHEM, V43, P29; ARMSTRONG RC, 1992, J NEUROSCI, V12, P1538; Assanah M, 2006, J NEUROSCI, V26, P6781, DOI 10.1523/JNEUROSCI.0514-06.2006; Baeten CIM, 2002, BRIT J CANCER, V87, P344, DOI 10.1038/sj.bjc.6600457; Beier D, 2007, CANCER RES, V67, P4010, DOI 10.1158/0008-5472.CAN-06-4180; BISHOP M, 1989, AM J PATHOL, V135, P517; Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730; Bouvier C, 2003, J NEUROSURG, V99, P344, DOI 10.3171/jns.2003.99.2.0344; Cai JL, 2004, J NEUROCHEM, V88, P212, DOI 10.1046/j.1471-4159.2003.02184.x; Castor A, 2005, NAT MED, V11, P630, DOI 10.1038/nm1253; Dietrich J, 2002, GLIA, V40, P65, DOI 10.1002/glia.10116; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; ELLISON JA, 1994, J NEUROSCI RES, V37, P116, DOI 10.1002/jnr.490370116; Fan XL, 2007, SEMIN CANCER BIOL, V17, P214, DOI 10.1016/j.semcancer.2006.04.002; Frederick L, 2000, CANCER RES, V60, P1383; Gabay L, 2003, NEURON, V40, P485, DOI 10.1016/S0896-6273(03)00637-8; Galli R, 2004, CANCER RES, V64, P7011, DOI 10.1158/0008-5472.CAN-04-1364; Glanz C, 2007, NEUROPATH APPL NEURO, V33, P440, DOI 10.1111/j.1365-2990.2007.00832.x; Glinsky GV, 2005, J CLIN INVEST, V115, P1503, DOI 10.1172/JCI23412; Gregori N, 2002, J NEUROSCI, V22, P248, DOI 10.1523/JNEUROSCI.22-01-00248.2002; Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100; Hill RP, 2006, CANCER RES, V66, P1891, DOI 10.1158/0008-5472.CAN-05-3450; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Kelly PN, 2007, SCIENCE, V317, P337, DOI 10.1126/science.1142596; Kho AT, 2004, GENE DEV, V18, P629, DOI 10.1101/gad.1182504; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kornblum HI, 1998, J NEUROSCI RES, V53, P697, DOI 10.1002/(SICI)1097-4547(19980915)53:6<697::AID-JNR8>3.3.CO;2-M; Ligon KL, 2004, J NEUROPATH EXP NEUR, V63, P499, DOI 10.1093/jnen/63.5.499; Liu Y, 2004, DEV BIOL, V276, P31, DOI 10.1016/j.ydbio.2004.08.018; Liu Y, 2004, BIOL CELL, V96, P279, DOI 10.1016/j.biolcel.2004.02.001; Louis DN, 2001, AM J PATHOL, V159, P779, DOI 10.1016/S0002-9440(10)61750-6; MayerProschel M, 1997, NEURON, V19, P773, DOI 10.1016/S0896-6273(00)80960-5; Murayama A, 2002, J NEUROSCI RES, V69, P837, DOI 10.1002/jnr.10339; Nunes MC, 2003, NAT MED, V9, P439, DOI 10.1038/nm837; Piper DR, 2001, J NEUROSCI RES, V66, P356, DOI 10.1002/jnr.1228; PRINGLE NP, 1992, DEVELOPMENT, V115, P535; PRINGLE NP, 1993, DEVELOPMENT, V117, P525; RAFF MC, 1983, NATURE, V303, P390, DOI 10.1038/303390a0; Rao MS, 1998, P NATL ACAD SCI USA, V95, P3996, DOI 10.1073/pnas.95.7.3996; Reynolds BA, 2005, NAT METHODS, V2, P333, DOI 10.1038/nmeth758; Roy NS, 1999, J NEUROSCI, V19, P9986, DOI 10.1523/jneurosci.19-22-09986.1999; Sakariassen PO, 2006, P NATL ACAD SCI USA, V103, P16466, DOI 10.1073/pnas.0607668103; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Scolding N, 1998, BRAIN, V121, P2221, DOI 10.1093/brain/121.12.2221; Scolding NJ, 1999, NEUROSCIENCE, V89, P1, DOI 10.1016/S0306-4522(98)00548-X; Shoshan Y, 1999, P NATL ACAD SCI USA, V96, P10361, DOI 10.1073/pnas.96.18.10361; Singh SK, 2003, CANCER RES, V63, P5821; Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128; Sirn FJ, 2006, ANN NEUROL, V59, P763, DOI 10.1002/ana.20812; Tamaki S, 2002, J NEUROSCI RES, V69, P976, DOI 10.1002/jnr.10412; Taubert H, 2007, ONCOGENE, V26, P7170, DOI 10.1038/sj.onc.1210530; Temple S, 2001, NATURE, V414, P112, DOI 10.1038/35102174; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; Weissman IL, 2001, ANNU REV CELL DEV BI, V17, P387, DOI 10.1146/annurev.cellbio.17.1.387; Wolswijk G, 1998, J NEUROSCI, V18, P601; WOLSWIJK G, 1989, DEVELOPMENT, V105, P387; Xia CL, 2003, INT J ONCOL, V23, P353; Yuan XP, 2004, ONCOGENE, V23, P9392, DOI 10.1038/sj.onc.1208311; Zeppernick F, 2008, CLIN CANCER RES, V14, P123, DOI 10.1158/1078-0432.CCR-07-0932; Zhang SC, 1999, P NATL ACAD SCI USA, V96, P4089, DOI 10.1073/pnas.96.7.4089	61	91	94	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1936	10.1371/journal.pone.0001936	http://dx.doi.org/10.1371/journal.pone.0001936			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398462	Green Submitted, Green Published, gold			2022-12-25	WOS:000260795500013
J	Ali, NA; Gaughan, AA; Orosz, CG; Baran, CP; McMaken, S; Wang, YJ; Eubank, TD; Hunter, M; Lichtenberger, FJ; Flavahan, NA; Lawler, J; Marsh, CB				Ali, Naeem A.; Gaughan, Alice A.; Orosz, Charles G.; Baran, Chris P.; McMaken, Sara; Wang, Yijie; Eubank, Timothy D.; Hunter, Melissa; Lichtenberger, Frank J.; Flavahan, Nicholas A.; Lawler, Jack; Marsh, Clay B.			Latency Associated Peptide Has In Vitro and In Vivo Immune Effects Independent of TGF-beta 1	PLOS ONE			English	Article								Latency Associated Peptide (LAP) binds TGF-beta 1, forming a latent complex. Currently, LAP is presumed to function only as a sequestering agent for active TGF-beta 1. Previous work shows that LAP can induce epithelial cell migration, but effects on leukocytes have not been reported. Because of the multiplicity of immunologic processes in which TGF-beta 1 plays a role, we hypothesized that LAP could function independently to modulate immune responses. In separate experiments we found that LAP promoted chemotaxis of human monocytes and blocked inflammation in vivo in a murine model of the delayed-type hypersensitivity response (DTHR). These effects did not involve TGF-beta 1 activity. Further studies revealed that disruption of specific LAP-thrombospondin-1 (TSP-1) interactions prevented LAP-induced responses. The effect of LAP on DTH inhibition depended on IL-10. These data support a novel role for LAP in regulating monocyte trafficking and immune modulation.	[Ali, Naeem A.; Baran, Chris P.; McMaken, Sara; Wang, Yijie; Eubank, Timothy D.; Hunter, Melissa; Lichtenberger, Frank J.; Marsh, Clay B.] Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA; [Gaughan, Alice A.; Orosz, Charles G.] Ohio State Univ, Dept Surg, Columbus, OH USA; [Ali, Naeem A.; Gaughan, Alice A.; Orosz, Charles G.; Baran, Chris P.; McMaken, Sara; Wang, Yijie; Eubank, Timothy D.; Hunter, Melissa; Lichtenberger, Frank J.; Marsh, Clay B.] Ohio State Univ, Dorothy M Davis Heart & Lung Res Inst, Columbus, OH USA; [Flavahan, Nicholas A.] Johns Hopkins Univ, Dept Anesthesiol & Critical Care Med, Baltimore, MD USA; [Lawler, Jack] Harvard Med Sch, Beth Israel Deaconess Med Sch, Dept Pathol, Boston, MA USA	University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Johns Hopkins University; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Ali, NA (corresponding author), Ohio State Univ, Dept Internal Med, Columbus, OH 43210 USA.	clay.marsh@osumc.edu	Eubank, Tim/E-3043-2011; Lawler, Jack/AAJ-1379-2020	ALI, NORA'AINI/0000-0003-1391-2757; Eubank, Tim/0000-0002-8225-7824	Davis-Bremer Medical Research Grant;  [K23 RR019544-01A2];  [T32 HL07946-01];  [RO-1HL68003];  [RO-1HL 66108];  [RO-1HL67176];  [RO-1 HL63800];  [PO-1 HL70294-02]; NATIONAL CENTER FOR RESEARCH RESOURCES [K23RR019544] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068003, R01HL063800, R01HL066108, T32HL007946, P01HL070294, R01HL067176] Funding Source: NIH RePORTER	Davis-Bremer Medical Research Grant; ; ; ; ; ; ; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	This work was funded by the following grants: K23 RR019544-01A2, T32 HL07946-01 and Davis-Bremer Medical Research Grant (NAA), RO-1HL68003 (JL), RO-1HL 66108, RO-1HL67176 and RO-1 HL63800 (CBM), and PO-1 HL70294-02 (CGO and CBM). The sponsor played no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.	Annes JP, 2004, J CELL BIOL, V165, P723, DOI 10.1083/jcb.200312172; Annes JP, 2003, J CELL SCI, V116, P217, DOI 10.1242/jcs.00229; Bickerstaff AA, 2000, TRANSPLANTATION, V69, P1517, DOI 10.1097/00007890-200004150-00055; Bickerstaff AA, 2002, AM J TRANSPLANT, V2, P819, DOI 10.1034/j.1600-6143.2002.20903.x; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9; Ebert EC, 2005, CELL IMMUNOL, V237, P106, DOI 10.1016/j.cellimm.2005.10.003; Febbraio M, 2001, J CLIN INVEST, V108, P785, DOI 10.1172/JCI200114006; Fukasawa H, 2004, KIDNEY INT, V65, P63, DOI 10.1111/j.1523-1755.2004.00393.x; Gandhi R, 2007, J IMMUNOL, V178, P4017, DOI 10.4049/jimmunol.178.7.4017; GRAZIANO RF, 1987, J IMMUNOL, V139, P3536; JANSSENS K, 2002, J BIOL CHEM; JANSSENS K, 2005, J MED GENET; KHALIL N, 1993, J CLIN INVEST, V92, P1812, DOI 10.1172/JCI116771; KULKARNI AB, 1993, P NATL ACAD SCI USA, V90, P770, DOI 10.1073/pnas.90.2.770; Lawler J, 1998, J CLIN INVEST, V101, P982, DOI 10.1172/JCI1684; Lu M, 2002, J CELL SCI, V115, P4641, DOI 10.1242/jcs.00145; Massague J, 2000, CELL, V103, P295, DOI 10.1016/S0092-8674(00)00121-5; Munger JS, 1999, CELL, V96, P319, DOI 10.1016/S0092-8674(00)80545-0; Munger JS, 1998, MOL BIOL CELL, V9, P2627, DOI 10.1091/mbc.9.9.2627; Murphy-Ullrich JE, 2000, CYTOKINE GROWTH F R, V11, P59, DOI 10.1016/S1359-6101(99)00029-5; POSTLETHWAITE AE, 1995, J CELL PHYSIOL, V164, P587, DOI 10.1002/jcp.1041640317; Ribeiro SMF, 1999, J BIOL CHEM, V274, P13586, DOI 10.1074/jbc.274.19.13586; SCHULTZCHERRY S, 1994, J BIOL CHEM, V269, P26783; SCHULTZCHERRY S, 1995, J BIOL CHEM, V270, P7304, DOI 10.1074/jbc.270.13.7304; Sheppard D, 2001, CHEST, V120, p49S, DOI 10.1378/chest.120.1_suppl.S49; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; Sirak J, 1997, TRANSPLANTATION, V63, P1300, DOI 10.1097/00007890-199705150-00018; VanBuskirk AM, 2000, J CLIN INVEST, V106, P145, DOI 10.1172/JCI9171; WAHL SM, 1987, P NATL ACAD SCI USA, V84, P5788, DOI 10.1073/pnas.84.16.5788; Wei JY, 1997, J LEUKOCYTE BIOL, V61, P397, DOI 10.1002/jlb.61.4.397; Xiao YQ, 2006, J IMMUNOL, V176, P1209, DOI 10.4049/jimmunol.176.2.1209; Yehualaeshet T, 1999, AM J PATHOL, V155, P841, DOI 10.1016/S0002-9440(10)65183-8; Young GD, 2004, J BIOL CHEM, V279, P47633, DOI 10.1074/jbc.M404918200; Young GD, 2004, J BIOL CHEM, V279, P38032, DOI 10.1074/jbc.M405658200; Zhang Y, 2003, J INVEST DERMATOL, V121, P713, DOI 10.1046/j.1523-1747.2003.12517.x	36	21	25	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1914	10.1371/journal.pone.0001914	http://dx.doi.org/10.1371/journal.pone.0001914			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18392110	Green Published, gold, Green Submitted			2022-12-25	WOS:000260795400038
J	Anestal, K; Prast-Nielsen, S; Cenas, N; Arner, ESJ				Anestal, Karin; Prast-Nielsen, Stefanie; Cenas, Narimantas; Arner, Elias S. J.			Cell Death by SecTRAPs: Thioredoxin Reductase as a Prooxidant Killer of Cells	PLOS ONE			English	Article							MAMMALIAN THIOREDOXIN; GLUTATHIONE-REDUCTASE; ESCHERICHIA-COLI; REDOX REGULATION; HUMAN PLACENTA; ACTIVE-SITE; SELENOCYSTEINE; SELENOPROTEIN; INHIBITION; EXPRESSION	Background: SecTRAPs ((se) under bar lenium (c) under bar ompromised (t) under bar hioredoxin (r) under bar eductase-derived (a) under bar poptotic (p) under bar rotein (s) under bar) can be formed from the selenoprotein thioredoxin reductase (TrxR) by targeting of its selenocysteine ( Sec) residue with electrophiles, or by its removal through C-terminal truncation. SecTRAPs are devoid of thioredoxin reductase activity but can induce rapid cell death in cultured cancer cell lines by a gain of function. Principal Findings: Both human and rat SecTRAPs killed human A549 and HeLa cells. The cell death displayed both apoptotic and necrotic features. It did not require novel protein synthesis nor did it show extensive nuclear fragmentation, but it was attenuated by use of caspase inhibitors. The redox active disulfide/dithiol motif in the N-terminal domain of TrxR had to be maintained for manifestation of SecTRAP cytotoxicity. Stopped-flow kinetics showed that NADPH can reduce the FAD moiety in SecTRAPs at similar rates as in native TrxR and purified SecTRAPs could maintain NADPH oxidase activity, which was accelerated by low molecular weight substrates such as juglone. In a cellular context, SecTRAPs triggered extensive formation of reactive oxygen species (ROS) and consequently antioxidants could protect against the cell killing by SecTRAPs. Conclusions: We conclude that formation of SecTRAPs could contribute to the cytotoxicity seen upon exposure of cells to electrophilic agents targeting TrxR. SecTRAPs are prooxidant killers of cells, triggering mechanisms beyond those of a mere loss of thioredoxin reductase activity.	[Anestal, Karin; Prast-Nielsen, Stefanie; Arner, Elias S. J.] Karolinska Inst, Dept Med Biochem, Med Nobel Inst Biochem, Stockholm, Sweden; [Cenas, Narimantas] Inst Biochem, Vilnius, Lithuania	Karolinska Institutet; Vilnius University	Anestal, K (corresponding author), Karolinska Inst, Dept Med Biochem, Med Nobel Inst Biochem, Stockholm, Sweden.	Elias.Arner@ki.se	Prast-Nielsen, Stefanie/W-6946-2019; Arnér, Elias S.J./J-5832-2012; Arnér, Elias/K-6737-2019	Prast-Nielsen, Stefanie/0000-0001-5877-7988; Arnér, Elias S.J./0000-0002-4807-6114; Arnér, Elias/0000-0002-4807-6114	Karolinska Institutet; The Royal Swedish Academy of Sciences; Swedish Cancer Society	Karolinska Institutet(Karolinska Institutet); The Royal Swedish Academy of Sciences; Swedish Cancer Society(Swedish Cancer Society)	Financial support was received from Karolinska Institutet, The Royal Swedish Academy of Sciences and the Swedish Cancer Society. These funding bodies had no influence on the content of this study beyond that of providing research funding.	Andersson M, 1996, J BIOL CHEM, V271, P10116, DOI 10.1074/jbc.271.17.10116; Anestal K, 2003, J BIOL CHEM, V278, P15966, DOI 10.1074/jbc.M210733200; Arner ESJ, 2006, SEMIN CANCER BIOL, V16, P420, DOI 10.1016/j.semcancer.2006.10.009; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; Arner ESJ, 2002, METHOD ENZYMOL, V347, P226; Arner ESJ, 1996, BIOCHEM BIOPH RES CO, V225, P268, DOI 10.1006/bbrc.1996.1165; Arner ESJ, 2001, FREE RADICAL BIO MED, V31, P1170, DOI 10.1016/S0891-5849(01)00698-0; ARNER ESJ, 2000, CURRENT PROTOCOLS TO; Arscott LD, 1997, P NATL ACAD SCI USA, V94, P3621, DOI 10.1073/pnas.94.8.3621; Bar-Noy S, 2001, FREE RADICAL BIO MED, V30, P51, DOI 10.1016/S0891-5849(00)00448-2; Becker K, 2000, EUR J BIOCHEM, V267, P6118, DOI 10.1046/j.1432-1327.2000.01703.x; Becker K, 2001, J MED CHEM, V44, P2784, DOI 10.1021/jm001014i; Berndtsson M, 2007, INT J CANCER, V120, P175, DOI 10.1002/ijc.22132; Biterova EI, 2005, P NATL ACAD SCI USA, V102, P15018, DOI 10.1073/pnas.0504218102; Cassidy PB, 2006, CARCINOGENESIS, V27, P2538, DOI 10.1093/carcin/bgl111; Cenas N, 2006, J BIOL CHEM, V281, P5593, DOI 10.1074/jbc.M511972200; Cenas N, 2004, J BIOL CHEM, V279, P2583, DOI 10.1074/jbc.M310292200; Cheng Q, 2006, NAT PROTOC, V1, P604, DOI 10.1038/nprot.2006.87; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P2172, DOI 10.1073/pnas.86.7.2172; Cohen GM, 1997, BIOCHEM J, V326, P1, DOI 10.1042/bj3260001; Crosley LK, 2007, ARCH BIOCHEM BIOPHYS, V459, P178, DOI 10.1016/j.abb.2006.12.029; Enoksson M, 2004, J BIOL CHEM, V279, P49575, DOI 10.1074/jbc.C400374200; Fadeel B, 2000, LEUKEMIA, V14, P1514, DOI 10.1038/sj.leu.2401871; Fang JG, 2006, J AM CHEM SOC, V128, P1879, DOI 10.1021/ja057358l; Fang JG, 2005, J BIOL CHEM, V280, P25284, DOI 10.1074/jbc.M414645200; Gan L, 2005, J CELL BIOCHEM, V96, P653, DOI 10.1002/jcb.20585; Gromer S, 2004, MED RES REV, V24, P40, DOI 10.1002/med.10051; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; Gromer S, 1997, FEBS LETT, V412, P318, DOI 10.1016/S0014-5793(97)00816-8; Hofman ER, 1998, MOL CELL BIOL, V18, P6493, DOI 10.1128/MCB.18.11.6493; Johansson L, 2004, NAT METHODS, V1, P61, DOI 10.1038/NMETH707; Johansson L, 2005, BBA-GEN SUBJECTS, V1726, P1, DOI 10.1016/j.bbagen.2005.05.010; Kryukov GV, 2003, SCIENCE, V300, P1439, DOI 10.1126/science.1083516; KUMAR S, 1992, EUR J BIOCHEM, V207, P435, DOI 10.1111/j.1432-1033.1992.tb17068.x; Lee SR, 1999, J BIOL CHEM, V274, P4722, DOI 10.1074/jbc.274.8.4722; Lee SR, 2000, P NATL ACAD SCI USA, V97, P2521, DOI 10.1073/pnas.050579797; Li L, 2004, SCIENCE, V305, P1471, DOI 10.1126/science.1098231; Lillig CH, 2007, ANTIOXID REDOX SIGN, V9, P25, DOI 10.1089/ars.2007.9.25; Lindner DJ, 2000, BBA-MOL CELL RES, V1496, P196, DOI 10.1016/S0167-4889(00)00021-5; Lindner DJ, 2002, CLIN CANCER RES, V8, P3210; Lu J, 2007, P NATL ACAD SCI USA, V104, P12288, DOI 10.1073/pnas.0701549104; LUNDSTROMLJUNG J, 1995, FEBS LETT, V357, P305, DOI 10.1016/0014-5793(94)01386-F; Ma XR, 2002, J BIOL CHEM, V277, P22460, DOI 10.1074/jbc.M202286200; Ma XR, 2001, J BIOL CHEM, V276, P24843, DOI 10.1074/jbc.M100380200; Marzano C, 2007, FREE RADICAL BIO MED, V42, P872, DOI 10.1016/j.freeradbiomed.2006.12.021; May JM, 1997, J BIOL CHEM, V272, P22607, DOI 10.1074/jbc.272.36.22607; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Moos PJ, 2003, J BIOL CHEM, V278, P745, DOI 10.1074/jbc.M211134200; Nakamura H, 1997, ANNU REV IMMUNOL, V15, P351, DOI 10.1146/annurev.immunol.15.1.351; Nalvarte I, 2004, J BIOL CHEM, V279, P54510, DOI 10.1074/jbc.M408494200; Nordberg J, 1998, J BIOL CHEM, V273, P10835, DOI 10.1074/jbc.273.18.10835; Nordberg J, 2001, FREE RADICAL BIO MED, V31, P1287, DOI 10.1016/S0891-5849(01)00724-9; Rengby O, 2004, APPL ENVIRON MICROB, V70, P5159, DOI 10.1128/AEM.70.9.5159-5167.2004; Rengby O, 2007, APPL ENVIRON MICROB, V73, P432, DOI 10.1128/AEM.02019-06; Rigobello MP, 1998, FREE RADICAL BIO MED, V24, P370, DOI 10.1016/S0891-5849(97)00216-5; Robertson JD, 2004, EMBO REP, V5, P643, DOI 10.1038/sj.embor.7400153; Rundlof AK, 2004, FREE RADICAL BIO MED, V36, P641, DOI 10.1016/j.freeradbiomed.2003.12.004; Rundlof AK, 2004, ANTIOXID REDOX SIGN, V6, P41, DOI 10.1089/152308604771978336; Ryter SW, 2007, ANTIOXID REDOX SIGN, V9, P49, DOI 10.1089/ars.2007.9.49; Sandalova T, 2001, P NATL ACAD SCI USA, V98, P9533, DOI 10.1073/pnas.171178698; Sasada T, 1999, FREE RADICAL BIO MED, V27, P504, DOI 10.1016/S0891-5849(99)00101-X; Schweizer A, 2007, STRUCTURE, V15, P625, DOI 10.1016/j.str.2007.03.014; Su D, 2005, J BIOL CHEM, V280, P26491, DOI 10.1074/jbc.M503638200; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Tamura T, 1996, P NATL ACAD SCI USA, V93, P1006, DOI 10.1073/pnas.93.3.1006; Trigona WL, 2006, BIOCHEM J, V394, P207, DOI 10.1042/BJ20050712; Turanov AA, 2006, J BIOL CHEM, V281, P22953, DOI 10.1074/jbc.M604326200; Urig S, 2006, SEMIN CANCER BIOL, V16, P452, DOI 10.1016/j.semcancer.2006.09.004; Urig S, 2006, FEBS LETT, V580, P3595, DOI 10.1016/j.febslet.2006.05.038; WATSON WH, 2008, BIOCH BIOPHYS RES CO; Witte AB, 2005, FREE RADICAL BIO MED, V39, P696, DOI 10.1016/j.freeradbiomed.2005.04.025; Xia L, 2003, J BIOL CHEM, V278, P2141, DOI 10.1074/jbc.M210456200; Yarimizu J, 2000, ANTIOXID REDOX SIGN, V2, P643, DOI 10.1089/ars.2000.2.4-643; Yoo MH, 2006, J BIOL CHEM, V281, P13005, DOI 10.1074/jbc.C600012200; Yoo MH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001112; Zhon LW, 1998, J BIOL CHEM, V273, P8581, DOI 10.1074/jbc.273.15.8581; Zhong LW, 2000, P NATL ACAD SCI USA, V97, P5854, DOI 10.1073/pnas.100114897; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	79	124	124	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1846	10.1371/journal.pone.0001846	http://dx.doi.org/10.1371/journal.pone.0001846			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382651	Green Submitted, Green Published, gold			2022-12-25	WOS:000260795400001
J	Folkesson, A; Haagensen, JAJ; Zampaloni, C; Sternberg, C; Molin, S				Folkesson, Anders; Haagensen, Janus A. J.; Zampaloni, Claudia; Sternberg, Claus; Molin, Soren			Biofilm Induced Tolerance towards Antimicrobial Peptides	PLOS ONE			English	Article								Increased tolerance to antimicrobial agents is thought to be an important feature of microbes growing in biofilms. We address the question of how biofilm organization affects antibiotic susceptibility. We established Escherichia coli biofilms with differential structural organization due to the presence of IncF plasmids expressing altered forms of the transfer pili in two different biofilm model systems. The mature biofilms were subsequently treated with two antibiotics with different molecular targets, the peptide antibiotic colistin and the fluoroquinolone ciprofloxacin. The dynamics of microbial killing were monitored by viable count determination, and confocal laser microscopy. Strains forming structurally organized biofilms show an increased bacterial survival when challenged with colistin, compared to strains forming unstructured biofilms. The increased survival is due to genetically regulated tolerant subpopulation formation and not caused by a general biofilm property. No significant difference in survival was detected when the strains were challenged with ciprofloxacin. Our data show that biofilm formation confers increased colistin tolerance to cells within the biofilm structure, but the protection is conditional being dependent on the structural organization of the biofilm, and the induction of specific tolerance mechanisms.	[Folkesson, Anders; Haagensen, Janus A. J.; Sternberg, Claus; Molin, Soren] Tech Univ Denmark, BioCentrum DTU, Infect Microbiol Grp, DK-2800 Lyngby, Denmark; [Zampaloni, Claudia] Univ Camerino, Dept Mol Cell Anim Biol, Camerino, Italy	Technical University of Denmark; University of Camerino	Folkesson, A (corresponding author), Tech Univ Denmark, BioCentrum DTU, Infect Microbiol Grp, DK-2800 Lyngby, Denmark.	anf@bio.dtu.dk	Sternberg, Claus/Y-1737-2019; Sternberg, Claus/E-4300-2010	Sternberg, Claus/0000-0002-2572-0288; Sternberg, Claus/0000-0002-2572-0288; Folkesson, Anders/0000-0002-2175-830X; Molin, Soren/0000-0002-7973-2639	Danish research councils; FEMS Research Fellowship	Danish research councils(Det Frie Forskningsrad (DFF)); FEMS Research Fellowship	This work was supported by the Danish research councils to Soren Molin and a FEMS Research Fellowship to Claudia Zampaloni.	Amorena B, 1999, J ANTIMICROB CHEMOTH, V44, P43, DOI 10.1093/jac/44.1.43; Andersen JB, 1998, APPL ENVIRON MICROB, V64, P2240; ANWAR H, 1992, ANTIMICROB AGENTS CH, V36, P1208, DOI 10.1128/AAC.36.6.1208; Ausubel FM., 1992, CURRENT PROTOCOLS MO, V3; BERTANI G, 1951, J BACTERIOL, V62, P293, DOI 10.1128/JB.62.3.293-300.1951; Ceri H, 1999, J CLIN MICROBIOL, V37, P1771, DOI 10.1128/JCM.37.6.1771-1776.1999; CHANDLER M, 1983, J MOL BIOL, V170, P61, DOI 10.1016/S0022-2836(83)80227-7; Christensen BB, 1998, APPL ENVIRON MICROB, V64, P2247; CLARK DJ, 1967, J MOL BIOL, V23, P99, DOI 10.1016/S0022-2836(67)80070-6; CONRAD RS, 1989, ANTIMICROB AGENTS CH, V33, P1724, DOI 10.1128/AAC.33.10.1724; COSTERTON JW, 1995, ANNU REV MICROBIOL, V49, P711, DOI 10.1146/annurev.mi.49.100195.003431; DAME JB, 1979, J BACTERIOL, V137, P1043, DOI 10.1128/JB.137.2.1043-1047.1979; Datsenko KA, 2000, P NATL ACAD SCI USA, V97, P6640, DOI 10.1073/pnas.120163297; Desai M, 1998, J ANTIMICROB CHEMOTH, V42, P153, DOI 10.1093/jac/42.2.153; DIEDERICH L, 1992, PLASMID, V28, P14, DOI 10.1016/0147-619X(92)90032-6; Drenkard E, 2002, NATURE, V416, P740, DOI 10.1038/416740a; Drlica K, 1997, MICROBIOL MOL BIOL R, V61, P377, DOI 10.1128/.61.3.377-392.1997; Dudley EG, 2006, INFECT IMMUN, V74, P2102, DOI 10.1128/IAI.74.4.2102-2114.2006; GELLERT M, 1977, P NATL ACAD SCI USA, V74, P4772, DOI 10.1073/pnas.74.11.4772; Ghigo JM, 2001, NATURE, V412, P442, DOI 10.1038/35086581; Gilbert P, 1997, Adv Dent Res, V11, P160; GRISTINA AG, 1989, ANTIMICROB AGENTS CH, V33, P813, DOI 10.1128/AAC.33.6.813; Haagensen JAJ, 2007, J BACTERIOL, V189, P28, DOI 10.1128/JB.00720-06; Hagiwara D, 2004, BIOSCI BIOTECH BIOCH, V68, P1758, DOI 10.1271/bbb.68.1758; Harada K, 2005, J VET MED SCI, V67, P999, DOI 10.1292/jvms.67.999; Heydorn A, 2000, MICROBIOL-SGM, V146, P2395, DOI 10.1099/00221287-146-10-2395; Heydorn A, 2002, APPL ENVIRON MICROB, V68, P2008, DOI 10.1128/AEM.68.4.2008-2017.2002; Hill D, 2005, J CLIN MICROBIOL, V43, P5085, DOI 10.1128/JCM.43.10.5085-5090.2005; Hooper DC, 1999, DRUGS, V58, P6, DOI 10.2165/00003495-199958002-00002; KATHIR P, 1991, PLASMID, V26, P40, DOI 10.1016/0147-619X(91)90035-U; Kim W, 2003, J BACTERIOL, V185, P3111, DOI 10.1128/JB.185.10.3111-3117.2003; Kim Wook, 2003, Biological Procedures Online, V5, P189, DOI 10.1251/bpo61; Kuehn M, 1998, APPL ENVIRON MICROB, V64, P4115; KUMON H, 1995, ANTIMICROB AGENTS CH, V39, P1038, DOI 10.1128/AAC.39.5.1038; Larsen T, 1996, APMIS, V104, P280, DOI 10.1111/j.1699-0463.1996.tb00718.x; Lewis K, 2001, ANTIMICROB AGENTS CH, V45, P999, DOI 10.1128/AAC.45.4.999-1007.2001; Li J, 2005, INT J ANTIMICROB AG, V25, P11, DOI 10.1016/j.ijantimicag.2004.10.001; Littlewood JM, 2000, RESP MED, V94, P632, DOI 10.1053/rmed.2000.0834; Maloy SR., 1996, GENETIC ANAL PATHOGE; Maneewannakul K, 1996, MOL MICROBIOL, V22, P197, DOI 10.1046/j.1365-2958.1996.00087.x; MANEEWANNAKUL K, 1995, J BACTERIOL, V177, P2957, DOI 10.1128/jb.177.11.2957-2964.1995; MANEEWANNAKUL K, 1993, J BACTERIOL, V175, P1384, DOI 10.1128/JB.175.5.1384-1391.1993; Miller J.H., 1992, SHORT COURSE BACTERI, P150; Miller SI, 2005, NAT REV MICROBIOL, V3, P36, DOI 10.1038/nrmicro1068; Molin S, 2003, CURR OPIN BIOTECH, V14, P255, DOI 10.1016/S0958-1669(03)00036-3; MOORE D, 1993, J BACTERIOL, V175, P1375, DOI 10.1128/JB.175.5.1375-1383.1993; NICKEL JC, 1985, ANTIMICROB AGENTS CH, V27, P619, DOI 10.1128/AAC.27.4.619; PANICKER MM, 1985, J BACTERIOL, V162, P584, DOI 10.1128/JB.162.2.584-590.1985; Reisner A, 2003, MOL MICROBIOL, V48, P933, DOI 10.1046/j.1365-2958.2003.03490.x; Reisner A, 2006, J BACTERIOL, V188, P3572, DOI 10.1128/JB.188.10.3572-3581.2006; Reisner A, 2006, J BACTERIOL, V188, P3582, DOI 10.1128/JB.188.10.3582-3588.2006; Schroder G, 2002, J BACTERIOL, V184, P2767, DOI 10.1128/JB.184.10.2767-2779.2002; Spoering AL, 2001, J BACTERIOL, V183, P6746, DOI 10.1128/JB.183.23.6746-6751.2001; Sternberg C, 1999, APPL ENVIRON MICROB, V65, P4108; STORM DR, 1977, ANNU REV BIOCHEM, V46, P723, DOI 10.1146/annurev.bi.46.070177.003451; Trent MS, 2001, J BIOL CHEM, V276, P43132, DOI 10.1074/jbc.M106962200; VAARA M, 1981, FEBS LETT, V129, P145, DOI 10.1016/0014-5793(81)80777-6; Vidal O, 1998, J BACTERIOL, V180, P2442, DOI 10.1128/JB.180.9.2442-2449.1998; VORACHIT M, 1993, ANTIMICROB AGENTS CH, V37, P2000, DOI 10.1128/AAC.37.9.2000; Williams I, 1997, MICROBIOL-UK, V143, P2407, DOI 10.1099/00221287-143-7-2407; Wimpenny J, 2000, FEMS MICROBIOL REV, V24, P661, DOI 10.1111/j.1574-6976.2000.tb00565.x; Winfield MD, 2004, P NATL ACAD SCI USA, V101, P17162, DOI 10.1073/pnas.0406038101; Xu KD, 2000, MICROBIOL-UK, V146, P547, DOI 10.1099/00221287-146-3-547; Xu KD, 1998, APPL ENVIRON MICROB, V64, P4035; Yeaman MR, 2003, PHARMACOL REV, V55, P27, DOI 10.1124/pr.55.1.2	67	63	63	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1891	10.1371/journal.pone.0001891	http://dx.doi.org/10.1371/journal.pone.0001891			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382672	Green Published, gold, Green Submitted			2022-12-25	WOS:000260795400023
J	Funderburg, N; Luciano, AA; Jiang, W; Rodriguez, B; Sieg, SF; Lederman, MM				Funderburg, Nicholas; Luciano, Angel A.; Jiang, Wei; Rodriguez, Benigno; Sieg, Scott F.; Lederman, Michael M.			Toll-Like Receptor Ligands Induce Human T Cell Activation and Death, a Model for HIV Pathogenesis	PLOS ONE			English	Article								Background: Recently, heightened systemic translocation of microbial products was found in persons with chronic HIV infection and this was linked to immune activation and CD4(+) T cell homeostasis. Methodology: We examined here the effects of microbial Toll-like receptor (TLR) ligands on T cell activation in vitro. Conclusions/Findings: We show that exposure to TLR ligands results in activation of memory and effector CD4(+) and CD8(+) T cells. After exposure to each of 8 different ligands that activate TLRs 2, 3, 4, 5, 7, 8, and 9, CD8(+) T cells are activated and gain expression of the C type lectin CD69 that may promote their retention in lymphoid tissues. In contrast, CD4(+) T cells rarely increase CD69 expression but instead enter cell cycle. Despite activation and cell cycle entry, CD4(+) T cells divide poorly and instead, disproportionately undergo activation-induced cell death. Systemic exposure to TLR agonists may therefore increase immune activation, effector cell sequestration in lymphoid tissues and T cell turnover. These events may contribute to the pathogenesis of immune dysfunction and CD4+ T cell losses in chronic infection with the human immunodeficiency virus.	[Funderburg, Nicholas; Lederman, Michael M.] Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA; [Luciano, Angel A.] Rainbow Babies & Childrens Hosp, Dept Pediat, Div Neonatol, Cleveland, OH USA; [Luciano, Angel A.; Jiang, Wei; Rodriguez, Benigno; Sieg, Scott F.; Lederman, Michael M.] Case Western Reserve Univ, Univ Hosp Case Med Ctr, Ctr AIDS Res, Dept Med, Cleveland, OH USA	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; Rainbow Babies & Children's Hospital; Case Western Reserve University; Case Western Reserve University Hospital	Lederman, MM (corresponding author), Case Western Reserve Univ, Dept Mol Biol & Microbiol, Cleveland, OH 44106 USA.	michael.lederman@case.edu	Rodriguez, Benigno/C-3365-2009; Sieg, Scott/AAV-2429-2021; Funderburg, Nicholas/L-8022-2013	Rodriguez, Benigno/0000-0001-9736-7957; Funderburg, Nicholas/0000-0003-3113-1217	Center for AIDS Research [AI 36219, AI 38858]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI036219, U01AI038858] Funding Source: NIH RePORTER	Center for AIDS Research; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	Center for AIDS Research AI 36219 AI 38858. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABRAMS DI, 1984, ANN INTERN MED, V100, P801, DOI 10.7326/0003-4819-100-6-801; Altfeld M, 2002, J CLIN INVEST, V109, P837, DOI 10.1172/JCI0214789; Andersson J, 1998, AIDS, V12, pF123, DOI 10.1097/00002030-199811000-00004; Beignon AS, 2005, J CLIN INVEST, V115, P3265, DOI 10.1172/JCI26032; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Biancotto A, 2007, BLOOD, V109, P4272, DOI 10.1182/blood-2006-11-055764; Brenchley JM, 2006, NAT MED, V12, P1365, DOI 10.1038/nm1511; Brenchley JM, 2004, J EXP MED, V200, P749, DOI 10.1084/jem.20040874; Caron G, 2005, J IMMUNOL, V175, P1551, DOI 10.4049/jimmunol.175.3.1551; CHEYNIER R, 1994, CELL, V78, P373, DOI 10.1016/0092-8674(94)90417-0; Crellin NK, 2005, J IMMUNOL, V175, P8051, DOI 10.4049/jimmunol.175.12.8051; Deeks SG, 2004, BLOOD, V104, P942, DOI 10.1182/blood-2003-09-3333; Giorgi JV, 1999, J INFECT DIS, V179, P859, DOI 10.1086/314660; Heil F, 2004, SCIENCE, V303, P1526, DOI 10.1126/science.1093620; Hornung V, 2002, J IMMUNOL, V168, P4531, DOI 10.4049/jimmunol.168.9.4531; Iwasaki A, 2004, NAT IMMUNOL, V5, P987, DOI 10.1038/ni1112; Jiang W, 2007, EUR J IMMUNOL, V37, P2205, DOI 10.1002/eji.200636984; Kovacs JA, 2001, J EXP MED, V194, P1731, DOI 10.1084/jem.194.12.1731; Lempicki RA, 2000, P NATL ACAD SCI USA, V97, P13778, DOI 10.1073/pnas.250472097; Liu Z, 1998, J ACQ IMMUN DEF SYND, V18, P332, DOI 10.1097/00042560-199808010-00004; Meier A, 2007, J VIROL, V81, P8180, DOI 10.1128/JVI.00421-07; Okoye A, 2007, J EXP MED, V204, P2171, DOI 10.1084/jem.20070567; Pasare C, 2004, IMMUNITY, V21, P733, DOI 10.1016/j.immuni.2004.10.006; Pasare C, 2005, ADV EXP MED BIOL, V560, P11; Picker LJ, 2004, J EXP MED, V200, P1299, DOI 10.1084/jem.20041049; Sancho D, 2005, TRENDS IMMUNOL, V26, P136, DOI 10.1016/j.it.2004.12.006; Shiow LR, 2006, NATURE, V440, P540, DOI 10.1038/nature04606; Sieg SF, 2005, J INFECT DIS, V192, P62, DOI 10.1086/430620; Silvestri G, 2003, IMMUNITY, V18, P441, DOI 10.1016/S1074-7613(03)00060-8; TENNERRACZ K, 1993, AM J PATHOL, V142, P1750; Wilson CM, 2004, AIDS RES HUM RETROV, V20, P263, DOI 10.1089/088922204322996482; Zanin-Zhorov A, 2007, J IMMUNOL, V179, P41, DOI 10.4049/jimmunol.179.1.41	32	102	111	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1915	10.1371/journal.pone.0001915	http://dx.doi.org/10.1371/journal.pone.0001915			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382686	Green Submitted, Green Published, gold			2022-12-25	WOS:000260795400039
J	Lin, JC; Tsao, D; Barras, P; Bastarrachea, RA; Boyd, B; Chou, J; Rosete, R; Long, H; Forgie, A; Abdiche, Y; Dilley, J; Stratton, J; Garcia, C; Sloane, DL; Comuzzie, AG; Rosenthal, A				Lin, John C.; Tsao, David; Barras, Paul; Bastarrachea, Raul A.; Boyd, Bob; Chou, Joyce; Rosete, Rodnie; Long, Hua; Forgie, Alison; Abdiche, Yasmina; Dilley, Jeanette; Stratton, Jennifer; Garcia, Carlos; Sloane, David L.; Comuzzie, Anthony G.; Rosenthal, Arnon			Appetite Enhancement and Weight Gain by Peripheral Administration of TrkB Agonists in Non-Human Primates	PLOS ONE			English	Article								Loss of function mutations in the receptor tyrosine kinase TrkB pathway resulted in hyperphagia and morbid obesity in human and rodents. Conversely, peripheral or central stimulation of TrkB by its natural ligands BDNF or NT4 reduced body weight and food intake in mice, supporting the idea that TrkB is a key anorexigenic signal downstream of the melanocortin-4 receptor (Mc4r) system. Here we show that in non-human primates TrkB agonists were anorexigenic when applied centrally, but surprisingly orexigenic, leading to gain in appetite, body weight, fat deposits and serum leptin levels, when given peripherally. The orexigenic and pro-obesity effects of peripherally administered TrkB agonists appear to be dose dependent, not associated with fluid retention nor with evidence of receptor down regulation. Our findings revealed that TrkB signaling exerts dual control on energy homeostasis in the primates that could be targeted for the treatment of either wasting disorders or obesity.	[Lin, John C.; Tsao, David; Chou, Joyce; Rosete, Rodnie; Long, Hua; Forgie, Alison; Abdiche, Yasmina; Dilley, Jeanette; Stratton, Jennifer; Garcia, Carlos; Sloane, David L.; Rosenthal, Arnon] Pfizer Inc, Rinat, San Francisco, CA USA; [Bastarrachea, Raul A.; Comuzzie, Anthony G.] Southwest Fdn Biomed Res, San Antonio, TX USA; [Barras, Paul] Alpha Genesis Inc, Yemassee, SC USA; [Boyd, Bob] Northern Biomed Res, Muskegon, MI USA	Pfizer; Texas Biomedical Research Institute	Lin, JC (corresponding author), Pfizer Inc, Rinat, San Francisco, CA USA.	john.lin@rinat.pfizer.com	Bastarrachea, Raul/B-5920-2019	Bastarrachea, Raul/0000-0002-4034-3062	Pfizer Inc.	Pfizer Inc.(Pfizer)	Pfizer Inc. funded and approved the publication of this work.	BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; BERKEMEIER LR, 1991, NEURON, V7, P857, DOI 10.1016/0896-6273(91)90287-A; Caro JF, 1996, LANCET, V348, P159, DOI 10.1016/S0140-6736(96)03173-X; Gray J, 2006, DIABETES, V55, P3366, DOI 10.2337/db06-0550; HALLBOOK F, 1991, NEURON, V6, P845, DOI 10.1016/0896-6273(91)90180-8; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; Kernie SG, 2000, EMBO J, V19, P1290, DOI 10.1093/emboj/19.6.1290; KONONEN J, 1994, MOL BRAIN RES, V27, P347, DOI 10.1016/0169-328X(94)90022-1; Lyons WE, 1999, P NATL ACAD SCI USA, V96, P15239, DOI 10.1073/pnas.96.26.15239; Monteleone P, 2005, PSYCHOL MED, V35, P897, DOI 10.1017/S0033291704003368; Monteleone P, 2004, PSYCHOSOM MED, V66, P744, DOI 10.1097/01.psy.0000138119.12956.99; Nakazato M, 2003, BIOL PSYCHIAT, V54, P485, DOI 10.1016/S0006-3223(02)01746-8; Poduslo JF, 1996, MOL BRAIN RES, V36, P280, DOI 10.1016/0169-328X(95)00250-V; Rios M, 2001, MOL ENDOCRINOL, V15, P1748, DOI 10.1210/me.15.10.1748; Schwartz MW, 1996, NAT MED, V2, P589, DOI 10.1038/nm0596-589; Suwa M, 2006, METABOLISM, V55, P852, DOI 10.1016/j.metabol.2006.02.012; Tonra JR, 1999, DIABETES, V48, P588, DOI 10.2337/diabetes.48.3.588; TSAO D, 2008, ENDOCRINOLOGY; Xu BJ, 2003, NAT NEUROSCI, V6, P736, DOI 10.1038/nn1073; YAMAMOTO H, 1990, J NEUROSCI, V10, P3469; Yeo GSH, 2004, NAT NEUROSCI, V7, P1187, DOI 10.1038/nn1336	21	41	45	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1900	10.1371/journal.pone.0001900	http://dx.doi.org/10.1371/journal.pone.0001900			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382675	Green Submitted, gold, Green Published			2022-12-25	WOS:000260795400027
J	Yerushalmi, U; Teicher, M				Yerushalmi, Uri; Teicher, Mina			Inevitable Evolutionary Temporal Elements in Neural Processing: A Study Based on Evolutionary Simulations	PLOS ONE			English	Article								Recent studies have suggested that some neural computational mechanisms are based on the fine temporal structure of spiking activity. However, less effort has been devoted to investigating the evolutionary aspects of such mechanisms. In this paper we explore the issue of temporal neural computation from an evolutionary point of view, using a genetic simulation of the evolutionary development of neural systems. We evolve neural systems in an environment with selective pressure based on mate finding, and examine the temporal aspects of the evolved systems. In repeating evolutionary sessions, there was a significant increase during evolution in the mutual information between the evolved agent's temporal neural representation and the external environment. In ten different simulated evolutionary sessions, there was an increased effect of time - related neural ablations on the agents' fitness. These results suggest that in some fitness landscapes the emergence of temporal elements in neural computation is almost inevitable. Future research using similar evolutionary simulations may shed new light on various biological mechanisms.	[Yerushalmi, Uri; Teicher, Mina] Bar Ilan Univ, Leslie & Susan Gonda Interdisciplinary Brain Res, Ramat Gan, Israel	Bar Ilan University	Yerushalmi, U (corresponding author), Bar Ilan Univ, Leslie & Susan Gonda Interdisciplinary Brain Res, Ramat Gan, Israel.	uri.yerushalmi@gmail.com			DIP	DIP	This research was supported by the DIP grant for compositionality	Abeles M, 2004, J COMPUT NEUROSCI, V17, P179, DOI 10.1023/B:JCNS.0000037682.18051.5f; ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; Abeles M, 2001, J NEUROSCI METH, V107, P141, DOI 10.1016/S0165-0270(01)00364-8; Abeles M, 1991, CORTICONICS NEURAL C, DOI DOI 10.1017/CBO9780511574566; Aharonov-Barki R, 2001, NEURAL COMPUT, V13, P691, DOI 10.1162/089976601300014529; AYERS DR, 2001, EVOLVING COLUMNAR CI; BAILEY WJ, 1991, REPROD BEHAVIOUR INS; Beer RD, 1999, J COMPUT NEUROSCI, V7, P119, DOI 10.1023/A:1008920021246; BIENENSTOCK EGS, 1994, HDB BRAIN THEORY NEU; Cangelosi A, 1997, NEURAL PROCESS LETT, V6, P91, DOI 10.1023/A:1009615807222; Chiel HJ, 1999, J COMPUT NEUROSCI, V7, P99, DOI 10.1023/A:1008923704408; Conway Morris S., 2003, LIFES SOLUTION INEVI; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; GOTOH O, 1982, J MOL BIOL, V162, P705, DOI 10.1016/0022-2836(82)90398-9; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; Hertz J, 1996, NETWORK-COMP NEURAL, V7, P357, DOI 10.1088/0954-898X/7/2/017; Hertz JA, 2018, INTRO THEORY NEURAL; HOLLAND JH, 1975, ADAPTATION NATURAL A, P8; HOPFIELD JJ, 1994, PHYS TODAY, V47, P40, DOI 10.1063/1.881412; HOPFIELD JJ, 1984, P NATL ACAD SCI-BIOL, V81, P3088, DOI 10.1073/pnas.81.10.3088; Ijspeert AJ, 1999, ADAPT BEHAV, V7, P151, DOI 10.1177/105971239900700202; Levy N, 2001, NEURAL NETWORKS, V14, P815, DOI 10.1016/S0893-6080(01)00044-2; Maass W, 1997, NEURAL NETWORKS, V10, P1659, DOI 10.1016/S0893-6080(97)00011-7; McAdams HH, 1998, ANNU REV BIOPH BIOM, V27, P199, DOI 10.1146/annurev.biophys.27.1.199; MJOLSNESS E, 1991, J THEOR BIOL, V152, P429, DOI 10.1016/S0022-5193(05)80391-1; MODDEMEIJER R, 1989, SIGNAL PROCESS, V16, P233, DOI 10.1016/0165-1684(89)90132-1; Riehle A, 1997, SCIENCE, V278, P1950, DOI 10.1126/science.278.5345.1950; Ruppin E, 2002, NAT REV NEUROSCI, V3, P132, DOI 10.1038/nrn729; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.ne.18.030195.003011; THOMAS B, 1993, EVOL COMPUT, V1, P1; VILLA AEP, 1990, BRAIN RES, V509, P325, DOI 10.1016/0006-8993(90)90558-S; Wolpert L, 2002, NATURE, V420, P745, DOI 10.1038/420745a; YERUSHALMI U, 2006, REGULATION NETWORK B; Yerushalmi U, 2007, B MATH BIOL, V69, P2261, DOI 10.1007/s11538-007-9219-8; YERUSHALMI UT, 2007, NEUROCOMPUT IN PRESS	35	1	1	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1863	10.1371/journal.pone.0001863	http://dx.doi.org/10.1371/journal.pone.0001863			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382654	Green Published, Green Submitted, gold			2022-12-25	WOS:000260795400004
J	Zamir, E; Geiger, B; Kam, Z				Zamir, Eli; Geiger, Benjamin; Kam, Zvi			Quantitative Multicolor Compositional Imaging Resolves Molecular Domains in Cell-Matrix Adhesions	PLOS ONE			English	Article								Background: Cellular processes occur within dynamic and multi-molecular compartments whose characterization requires analysis at high spatio-temporal resolution. Notable examples for such complexes are cell-matrix adhesion sites, consisting of numerous cytoskeletal and signaling proteins. These adhesions are highly variable in their morphology, dynamics, and apparent function, yet their molecular diversity is poorly defined. Methodology/Principal Findings: We present here a compositional imaging approach for the analysis and display of multicomponent compositions. This methodology is based on microscopy-acquired multicolor data, multi-dimensional clustering of pixels according to their composition similarity and display of the cellular distribution of these composition clusters. We apply this approach for resolving the molecular complexes associated with focal-adhesions, and the time-dependent effects of Rho-kinase inhibition. We show here compositional variations between adhesion sites, as well as ordered variations along the axis of individual focal-adhesions. The multicolor clustering approach also reveals distinct sensitivities of different focal-adhesion-associated complexes to Rho-kinase inhibition. Conclusions/Significance: Multicolor compositional imaging resolves "molecular signatures'' characteristic to focal-adhesions and related structures, as well as sub-domains within these adhesion sites. This analysis enhances the spatial information with additional "contents-resolved'' dimensions. We propose that compositional imaging can serve as a powerful tool for studying complex multi-molecular assemblies in cells and for mapping their distribution at sub-micron resolution.	[Zamir, Eli; Geiger, Benjamin; Kam, Zvi] Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel	Weizmann Institute of Science	Zamir, E (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, Rehovot, Israel.	benny.geiger@weizmann.ac.il		Zamir, Eli/0000-0001-8226-5480	Israel Science Foundation; US-Israel Bi-National Foundation; Kahn fund for Systems Biology at the Weizmann Institute of Science; The Cell Migration Consortium; NIH [U54 GM64346]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM064346] Funding Source: NIH RePORTER	Israel Science Foundation(Israel Science Foundation); US-Israel Bi-National Foundation(US-Israel Binational Science Foundation); Kahn fund for Systems Biology at the Weizmann Institute of Science; The Cell Migration Consortium; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This study was supported by grants from the Israel Science Foundation, the US-Israel Bi-National Foundation, the Kahn fund for Systems Biology at the Weizmann Institute of Science and The Cell Migration Consortium (NIH Grant U54 GM64346).	Alon U, 1999, P NATL ACAD SCI USA, V96, P6745, DOI 10.1073/pnas.96.12.6745; Altelaar AFM, 2007, NAT PROTOC, V2, P1185, DOI 10.1038/nprot.2007.117; Ballestrem C, 2001, J CELL BIOL, V155, P1319, DOI 10.1083/jcb.200107107; Borrmann CM, 2000, ANN NY ACAD SCI, V915, P144; Cavalcanti-Adam EA, 2007, BIOPHYS J, V92, P2964, DOI 10.1529/biophysj.106.089730; Cluzel C, 2005, J CELL BIOL, V171, P383, DOI 10.1083/jcb.200503017; De Rosa SC, 2001, NAT MED, V7, P245, DOI 10.1038/84701; Gao XH, 2005, CURR OPIN BIOTECH, V16, P63, DOI 10.1016/j.copbio.2004.11.003; Goffin JM, 2006, J CELL BIOL, V172, P259, DOI 10.1083/jcb.200506179; Gygi SP, 1999, NAT BIOTECHNOL, V17, P994, DOI 10.1038/13690; Hutter H, 2004, J MICROSC-OXFORD, V215, P213, DOI 10.1111/j.0022-2720.2004.01367.x; Irish JM, 2004, CELL, V118, P217, DOI 10.1016/j.cell.2004.06.028; Kam Z, 2001, TRENDS CELL BIOL, V11, P329, DOI 10.1016/S0962-8924(01)02067-0; Kingsmore SF, 2006, NAT REV DRUG DISCOV, V5, P310, DOI 10.1038/nrd2006; Lehnert D, 2004, J CELL SCI, V117, P41, DOI 10.1242/jcs.00836; Lichtenstein N, 2003, CYTOM PART A, V54A, P8, DOI 10.1002/cyto.a.10053; Ma B, 2007, MICROSC RES TECHNIQ, V70, P171, DOI 10.1002/jemt.20401; Mallick P, 2007, NAT BIOTECHNOL, V25, P125, DOI 10.1038/nbt1275; Michalet X, 2005, SCIENCE, V307, P538, DOI 10.1126/science.1104274; Padilla-Nash HM, 2006, NAT PROTOC, V1, P3129, DOI 10.1038/nprot.2006.358; Perret E, 2005, CURR OPIN CELL BIOL, V17, P423, DOI 10.1016/j.ceb.2005.06.008; Rhodes DR, 2005, NAT GENET, V37, pS31, DOI 10.1038/ng1570; Riveline D, 2001, J CELL BIOL, V153, P1175, DOI 10.1083/jcb.153.6.1175; Schubert W, 2006, NAT BIOTECHNOL, V24, P1270, DOI 10.1038/nbt1250; Shaner NC, 2005, NAT METHODS, V2, P905, DOI 10.1038/NMETH819; Zaidel-Bar R, 2004, BIOCHEM SOC T, V32, P416, DOI 10.1042/BST0320416; Zaidel-Bar R, 2003, J CELL SCI, V116, P4605, DOI 10.1242/jcs.00792; Zaidel-Bar R, 2007, NAT CELL BIOL, V9, P858, DOI 10.1038/ncb0807-858; Zaidel-Bar R, 2007, J CELL SCI, V120, P137, DOI 10.1242/jcs.03314; Zamir E, 2000, NAT CELL BIOL, V2, P191, DOI 10.1038/35008607; Zamir E, 2001, J CELL SCI, V114, P3583; Zamir E, 1999, J CELL SCI, V112, P1655; Zimmermann T, 2003, FEBS LETT, V546, P87, DOI 10.1016/S0014-5793(03)00521-0	33	31	31	1	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1901	10.1371/journal.pone.0001901	http://dx.doi.org/10.1371/journal.pone.0001901			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382676	gold, Green Submitted, Green Published			2022-12-25	WOS:000260795400028
J	Caut, S; Fossette, S; Guirlet, E; Angulo, E; Das, K; Girondot, M; Georges, JY				Caut, Stephane; Fossette, Sabrina; Guirlet, Elodie; Angulo, Elena; Das, Krishna; Girondot, Marc; Georges, Jean-Yves			Isotope Analysis Reveals Foraging Area Dichotomy for Atlantic Leatherback Turtles	PLOS ONE			English	Article							FEEDING HABITAT USE; STABLE-ISOTOPES; DERMOCHELYS-CORIACEA; SEA-TURTLES; CARETTA-CARETTA; NUTRITIONAL STRESS; MOVEMENT PATTERNS; CARBON ISOTOPES; NESTING NUMBERS; MARINE TURTLES	Background: The leatherback turtle (Dermochelys coriacea) has undergone a dramatic decline over the last 25 years, and this is believed to be primarily the result of mortality associated with fisheries bycatch followed by egg and nesting female harvest. Atlantic leatherback turtles undertake long migrations across ocean basins from subtropical and tropical nesting beaches to productive frontal areas. Migration between two nesting seasons can last 2 or 3 years, a time period termed the remigration interval (RI). Recent satellite transmitter data revealed that Atlantic leatherbacks follow two major dispersion patterns after nesting season, through the North Gulf Stream area or more eastward across the North Equatorial Current. However, information on the whole RI is lacking, precluding the accurate identification of feeding areas where conservation measures may need to be applied. Methodology/Principal Findings: Using stable isotopes as dietary tracers we determined the characteristics of feeding grounds of leatherback females nesting in French Guiana. During migration, 3-year RI females differed from 2-year RI females in their isotope values, implying differences in their choice of feeding habitats (offshore vs. more coastal) and foraging latitude (North Atlantic vs. West African coasts, respectively). Egg-yolk and blood isotope values are correlated in nesting females, indicating that egg analysis is a useful tool for assessing isotope values in these turtles, including adults when not available. Conclusions/Significance: Our results complement previous data on turtle movements during the first year following the nesting season, integrating the diet consumed during the year before nesting. We suggest that the French Guiana leatherback population segregates into two distinct isotopic groupings, and highlight the urgent need to determine the feeding habitats of the turtle in the Atlantic in order to protect this species from incidental take by commercial fisheries. Our results also emphasize the use of eggs, a less-invasive sampling material than blood, to assess isotopic data and feeding habits for adult female leatherbacks.	[Caut, Stephane; Das, Krishna] B6C Liege Univ, MARE Ctr, Lab Oceanol, Liege, Belgium; [Guirlet, Elodie; Angulo, Elena; Girondot, Marc] Univ Paris Sud, Lab Ecol, Syst Evolut, Orsay, France; [Girondot, Marc] Museum Natl Histoire Naturelle Paris, Dept Evolut Syst, Paris, France; [Fossette, Sabrina; Georges, Jean-Yves] CNRS Univ Strasbourg, UMR 7178, Inst Pluridisciplinaire Hubert Curien, Dept Ecol Physiol Ethiol, Strasbourg, France	University of Liege; UDICE-French Research Universities; Universite Paris Saclay; Museum National d'Histoire Naturelle (MNHN); Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute of Nuclear and Particle Physics (IN2P3); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Caut, S (corresponding author), B6C Liege Univ, MARE Ctr, Lab Oceanol, Liege, Belgium.	stephane.caut@u-psud.fr; elodie.guirlet@u-psud.fr	Angulo, Elena/A-8107-2013; Das, Krishna/AAB-7273-2020; Girondot, Marc/A-7663-2010	Angulo, Elena/0000-0001-5545-4032; Das, Krishna/0000-0003-2689-3348; Girondot, Marc/0000-0001-6645-8530	DIREN-Guyane; FNRS-FRS; University of Liege [post-doctoral grant]; ANR-Biodiversite project; French Ministry of Research [studentship]; Programme Amazonie du CNRS; ANR through Projet MIRETTE	DIREN-Guyane; FNRS-FRS(Fonds de la Recherche Scientifique - FNRS); University of Liege(University of Liege); ANR-Biodiversite project(French National Research Agency (ANR)); French Ministry of Research(Ministry of Research, FranceEuropean Commission); Programme Amazonie du CNRS; ANR through Projet MIRETTE(French National Research Agency (ANR))	This work was supported by DIREN-Guyane. Krishna Das received a grant from FNRS-FRS and Stephane Caut received a post-doctoral grant from the University of Liege. Elena Angulo acknowledges funding by the ANR-Biodiversite project. SF was supported by a studentship from the French Ministry of Research. JYG was supported by Programme Amazonie du CNRS and ANR through Projet MIRETTE.	Benson SR, 2007, CHELONIAN CONSERV BI, V6, P150, DOI 10.2744/1071-8443(2007)6[150:PMOLTD]2.0.CO;2; Biasatti DM, 2004, PALAEOGEOGR PALAEOCL, V206, P203, DOI 10.1016/j.palaeo.2004.01.004; BJORNDAL KA, 1997, BIOL SEA TURTLES, P237; Broderick AC, 2001, P ROY SOC B-BIOL SCI, V268, P1481, DOI 10.1098/rspb.2001.1695; Burton RK, 1999, OECOLOGIA, V119, P578, DOI 10.1007/s004420050822; Burton RK, 2001, OECOLOGIA, V128, P107, DOI 10.1007/s004420100631; Cherel Y, 2005, PHYSIOL BIOCHEM ZOOL, V78, P106, DOI 10.1086/425202; Das K, 2003, MAR ECOL PROG SER, V263, P287, DOI 10.3354/meps263287; Davenport J., 1998, British Herpetological Society Bulletin, V62, P4; DeNiro M.J., 1976, GEOL SOC AM ABS PROG, V8, P834; DENIRO MJ, 1978, GEOCHIM COSMOCHIM AC, V42, P495, DOI 10.1016/0016-7037(78)90199-0; DENIRO MJ, 1981, GEOCHIM COSMOCHIM AC, V45, P341, DOI 10.1016/0016-7037(81)90244-1; DOYLE TK, 2007, ENDANGERED SPECIES R, V3, P15; DUNTON KH, 1989, MAR ECOL PROG SER, V56, P89, DOI 10.3354/meps056089; Duron M, 1980, COURRIER NATURE, V69, P37; Eckert SA, 2002, J EXP BIOL, V205, P3689; Eckert SA, 2006, CHELONIAN CONSERV BI, V5, P239, DOI 10.2744/1071-8443(2006)5[239:IAPMAF]2.0.CO;2; Eckert SA, 2006, MAR BIOL, V149, P1257, DOI 10.1007/s00227-006-0262-z; Ferraroli S, 2004, NATURE, V429, P521, DOI 10.1038/429521a; Fossette S, 2007, MAR ECOL PROG SER, V338, P233, DOI 10.3354/meps338233; FRANCE RL, 1995, MAR ECOL PROG SER, V124, P307, DOI 10.3354/meps124307; Georges JY, 2007, MAR ECOL PROG SER, V338, P225, DOI 10.3354/meps338225; Girondot M, 2002, ANIM CONSERV, V5, P75, DOI 10.1017/S1367943002001099; Girondot Marc, 1996, Chelonian Conservation and Biology, V2, P204; Godley BJ, 1998, MAR ECOL PROG SER, V166, P277, DOI 10.3354/meps166277; GODLEY BJ, 2007, ENDANGERED SPECIES R, V3, P16; GOERICKE R, 1994, GLOBAL BIOGEOCHEM CY, V8, P85, DOI 10.1029/93GB03272; Hatase H, 2002, MAR ECOL PROG SER, V233, P273, DOI 10.3354/meps233273; Hatase H, 2006, OECOLOGIA, V149, P52, DOI 10.1007/s00442-006-0431-2; Hays GC, 2004, ANIM BEHAV, V67, P733, DOI 10.1016/j.anbehav.2003.08.011; Hays GC, 2000, J THEOR BIOL, V206, P221, DOI 10.1006/jtbi.2000.2116; Hays GC, 2004, NATURE, V429, P522, DOI 10.1038/429522a; Hilderbrand GV, 1996, CAN J ZOOL, V74, P2080, DOI 10.1139/z96-236; HOBSON KA, 1992, CONDOR, V94, P189, DOI 10.2307/1368808; HOBSON KA, 1995, CONDOR, V97, P752, DOI 10.2307/1369183; HOBSON KA, 1994, J ANIM ECOL, V63, P786, DOI 10.2307/5256; HOBSON KA, 1993, CONDOR, V95, P388, DOI 10.2307/1369361; Hobson KA, 1999, OECOLOGIA, V120, P314, DOI 10.1007/s004420050865; Houghton JDR, 2006, ECOLOGY, V87, P1967, DOI 10.1890/0012-9658(2006)87[1967:JAALTF]2.0.CO;2; James MC, 2006, CAN J ZOOL, V84, P754, DOI 10.1139/Z06-046; James MC, 2005, ECOL LETT, V8, P195, DOI 10.1111/j.1461-0248.2004.00710.x; James MC, 2005, P ROY SOC B-BIOL SCI, V272, P1547, DOI 10.1098/rspb.2005.3110; James Michael C., 2001, Chelonian Conservation and Biology, V4, P202; James MC, 2006, J EXP MAR BIOL ECOL, V335, P221, DOI 10.1016/j.jembe.2006.03.013; Kaplan IC, 2005, CAN J FISH AQUAT SCI, V62, P1710, DOI 10.1139/F05-121; Kelly JF, 2000, CAN J ZOOL, V78, P1, DOI 10.1139/cjz-78-1-1; Kempster B, 2007, OECOLOGIA, V151, P365, DOI 10.1007/s00442-006-0597-7; McCutchan JH, 2003, OIKOS, V102, P378, DOI 10.1034/j.1600-0706.2003.12098.x; Miller Jeffrey D., 1997, P51; MINAGAWA M, 1984, GEOCHIM COSMOCHIM AC, V48, P1135, DOI 10.1016/0016-7037(84)90204-7; Myers AE, 2006, MAR ECOL PROG SER, V322, P259, DOI 10.3354/meps322259; Oelbermann K, 2002, OECOLOGIA, V130, P337, DOI 10.1007/s004420100813; Peckham SH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001041; Post DM, 2002, ECOLOGY, V83, P703, DOI 10.1890/0012-9658(2002)083[0703:USITET]2.0.CO;2; Price E. R., 2006, ENDANGER SPECIES RES, V1, P41, DOI DOI 10.3354/ESR001041; RAU GH, 1982, DEEP-SEA RES, V29, P1035, DOI 10.1016/0198-0149(82)90026-7; Reich KJ, 2007, BIOL LETTERS, V3, P712, DOI 10.1098/rsbl.2007.0394; Reina RD, 2005, J EXP MAR BIOL ECOL, V316, P1, DOI 10.1016/j.jembe.2004.10.002; Revelles M, 2007, J MAR BIOL ASSOC UK, V87, P805, DOI 10.1017/S0025315407054707; Revelles M, 2007, SCI MAR, V71, P87, DOI 10.3989/scimar.2007.71n187; Rivalan P, 2005, OECOLOGIA, V145, P564, DOI 10.1007/s00442-005-0159-4; Rostal DC, 1998, GEN COMP ENDOCR, V109, P232, DOI 10.1006/gcen.1997.7026; Rubenstein DR, 2004, TRENDS ECOL EVOL, V19, P256, DOI 10.1016/j.tree.2004.03.017; Saba VS, 2007, J APPL ECOL, V44, P395, DOI 10.1111/j.1365-2664.2007.01276.x; Sale A, 2006, J EXP MAR BIOL ECOL, V328, P197, DOI 10.1016/j.jembe.2005.07.006; Martinez LS, 2007, CHELONIAN CONSERV BI, V6, P70, DOI 10.2744/1071-8443(2007)6[70:CABOTL]2.0.CO;2; SAS Institute Inc, 2004, SAS 9 1 3 HELP DOC; Seminoff JA, 2006, MAR ECOL PROG SER, V308, P271, DOI 10.3354/meps308271; Seminoff JA, 2007, COPEIA, P534, DOI 10.1643/0045-8511(2007)2007[534:SCANID]2.0.CO;2; Solow AR, 2002, ECOL LETT, V5, P742, DOI 10.1046/j.1461-0248.2002.00374.x; StatSoft Inc. Statistica, 2001, DAT AN SOFTW SYST VE; Takai N, 2000, J MAR BIOL ASSOC UK, V80, P675, DOI 10.1017/S0025315400002502; TIESZEN LL, 1983, OECOLOGIA, V57, P32, DOI 10.1007/BF00379558; Vanderklift MA, 2003, OECOLOGIA, V136, P169, DOI 10.1007/s00442-003-1270-z; VOIGT CC, 2007, J EXP BIOL, V207, P1741; Wallace BP, 2005, J EXP BIOL, V208, P3873, DOI 10.1242/jeb.01860; Wallace BP, 2007, CHELONIAN CONSERV BI, V6, P147, DOI 10.2744/1071-8443(2007)6[147:ATFOBS]2.0.CO;2; Wallace BP, 2006, MAR BIOL, V149, P953, DOI 10.1007/s00227-006-0247-y; Williams CT, 2007, OECOLOGIA, V153, P11, DOI 10.1007/s00442-007-0717-z; Witt MJ, 2007, MAR ECOL PROG SER, V337, P231, DOI 10.3354/meps337231	80	63	67	0	45	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1845	10.1371/journal.pone.0001845	http://dx.doi.org/10.1371/journal.pone.0001845			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365003	Green Published, gold			2022-12-25	WOS:000260762400009
J	De Luigi, A; Colombo, L; Diomede, L; Capobianco, R; Mangieri, M; Miccolo, C; Limido, L; Forloni, G; Tagliavini, F; Salmona, M				De Luigi, Ada; Colombo, Laura; Diomede, Luisa; Capobianco, Raffaella; Mangieri, Michela; Miccolo, Claudia; Limido, Lucia; Forloni, Gianluigi; Tagliavini, Fabrizio; Salmona, Mario			The Efficacy of Tetracyclines in Peripheral and Intracerebral Prion Infection	PLOS ONE			English	Article							MOLECULAR-BIOLOGY; AMYLOID FIBRILS; AMPHOTERICIN-B; MINOCYCLINE; DOXYCYCLINE; MODEL; EPIDEMIOLOGY; QUINACRINE; INFUSION; BEHAVIOR	We have previously shown that tetracyclines interact with and reverse the protease resistance of pathological prion protein extracted from scrapie-infected animals and patients with all forms of Creutzfeldt-Jakob disease, lowering the prion titre and prolonging survival of cerebrally infected animals. To investigate the effectiveness of these drugs as anti-prion agents Syrian hamsters were inoculated intramuscularly or subcutaneously with 263K scrapie strain at a 10(-4) dilution. Tetracyclines were injected intramuscularly or intraperitoneally at the dose of 10 mg/kg. A single intramuscular dose of doxycycline one hour after infection in the same site of inoculation prolonged median survival by 64%. Intraperitoneal doses of tetracyclines every two days for 40 or 44 days increased survival time by 25% (doxycycline), 32% (tetracycline); and 81% (minocycline) after intramuscular infection, and 35% (doxycycline) after subcutaneous infection. To extend the therapeutic potential of tetracyclines, we investigated the efficacy of direct infusion of tetracyclines in advanced infection. Since intracerebroventricular infusion of tetracycline solutions can cause overt acute toxicity in animals, we entrapped the drugs in liposomes. Animals were inoculated intracerebrally with a 10(-4) dilution of the 263K scrapie strain. A single intracerebroventricular infusion of 25 mu g/20 mu l of doxycycline or minocycline entrapped in liposomes was administered 60 days after inoculation, when 50% of animals showed initial symptoms of the disease. Median survival increased of 8.1% with doxycycline and 10% with minocycline. These data suggest that tetracyclines might have therapeutic potential for humans.	[De Luigi, Ada; Colombo, Laura; Diomede, Luisa; Salmona, Mario] Ist Ric Farmacol Mario Negri, Dept Mol Biochem & Pharmacol, Milan, Italy; [Forloni, Gianluigi] Ist Ricerche Farmacol, Dept Neurosci, Milan, Italy; [Capobianco, Raffaella; Mangieri, Michela; Miccolo, Claudia; Limido, Lucia; Tagliavini, Fabrizio] Fdn IRCCS Ist Neurol, Milan, Italy	Istituto di Ricerche Farmacologiche Mario Negri IRCCS	De Luigi, A (corresponding author), Ist Ric Farmacol Mario Negri, Dept Mol Biochem & Pharmacol, Milan, Italy.	salmona@marionegri.it	salmona, mario/AAA-7116-2020; colombo, laura/AAA-6716-2020; Forloni, Gianluigi/AAB-2115-2020; salmona, mario/ABI-4066-2020; Miccolo, Claudia/AAR-8386-2020; Tagliavini, Fabrizio/AAO-7891-2021; Diomede, Luisa/P-3417-2014; De Luigi, Ada/ABF-7913-2020	salmona, mario/0000-0002-9098-9873; colombo, laura/0000-0002-3243-0270; Forloni, Gianluigi/0000-0001-5374-3914; Tagliavini, Fabrizio/0000-0003-1039-7315; Diomede, Luisa/0000-0002-2258-0531; De Luigi, Ada/0000-0001-7907-7139	European Union; Neuroprion and ExpTheraprion; Fondazione Cariplo [NOBEL-Guard]; Italian Ministry of University and Research [RBNE03PX83]; Italian Ministry of Health	European Union(European Commission); Neuroprion and ExpTheraprion; Fondazione Cariplo(Fondazione Cariplo); Italian Ministry of University and Research(Ministry of Education, Universities and Research (MIUR)); Italian Ministry of Health(Ministry of Health, Italy)	This work was supported by the European Union within the frame of Neuroprion and ExpTheraprion, Fondazione Cariplo (Grant NOBEL-Guard), the Italian Ministry of University and Research (FIRB, RBNE03PX83), and the Italian Ministry of Health.	Adjou KT, 2000, J COMP PATHOL, V122, P3, DOI 10.1053/jcpa.1999.0338; Aitken JF, 2003, BIOCHEM J, V374, P779, DOI 10.1042/BJ20030422; Benito-Leon J, 2004, CLIN NEUROPHARMACOL, V27, P201, DOI 10.1097/01.wnf.0000134853.36429.0e; Bruce ME, 2003, BRIT MED BULL, V66, P99, DOI 10.1093/bmb/66.1.99; Caramelli M, 2006, CNS DRUGS, V20, P15, DOI 10.2165/00023210-200620010-00002; Cardoso I, 2006, FASEB J, V20, P234, DOI 10.1096/fj.05-4509com; Cardoso I, 2003, FASEB J, V17, P803, DOI 10.1096/fj.02-0764com; Chopra I, 2001, MICROBIOL MOL BIOL R, V65, P232, DOI 10.1128/MMBR.65.2.232-260.2001; Clarke AR, 2001, PHILOS T ROY SOC B, V356, P185, DOI 10.1098/rstb.2000.0764; Colovic M, 2003, J CHROMATOGR B, V791, P337, DOI 10.1016/S1570-0232(03)00247-2; Cosentino U, 2005, J MOL MODEL, V11, P17, DOI 10.1007/s00894-004-0213-x; DEMAIMAY R, 1994, J GEN VIROL, V75, P2499, DOI 10.1099/0022-1317-75-9-2499; Demaimay R, 1999, J VIROL, V73, P3511, DOI 10.1128/JVI.73.4.3511-3513.1999; Doh-Ura K, 2004, J VIROL, V78, P4999, DOI 10.1128/JVI.78.10.4999-5006.2004; Domercq M, 2004, TRENDS PHARMACOL SCI, V25, P609, DOI 10.1016/j.tips.2004.10.001; Du YS, 2001, P NATL ACAD SCI USA, V98, P14669, DOI 10.1073/pnas.251341998; Forloni G, 2002, P NATL ACAD SCI USA, V99, P10849, DOI 10.1073/pnas.162195499; Forloni G, 2001, FEBS LETT, V487, P404, DOI 10.1016/S0014-5793(00)02380-2; Forloni Gianluigi, 2003, Current Medicinal Chemistry - Immunology Endocrine & Metabolic Agents, V3, P185, DOI 10.2174/1568013033483456; Giaccone G, 2000, BRAIN PATHOL, V10, P31, DOI 10.1111/j.1750-3639.2000.tb00240.x; Hersch S, 2003, ANN NEUROL, V54, P841, DOI 10.1002/ana.21891; Konings AW, 1984, LIPOSOME TECHNOLOGY, P139; Korth C, 2006, ARCH NEUROL-CHICAGO, V63, P497, DOI 10.1001/archneur.63.4.497; Malmo C, 2006, FASEB J, V20, P346, DOI 10.1096/fj.05-4652fje; Mohan J, 2005, IMMUNOLOGY, V114, P225, DOI 10.1111/j.1365-2567.2004.02074.x; Moon JE, 2006, ANTIMICROB AGENTS CH, V50, P1989, DOI 10.1128/AAC.01467-05; Murakami-Kubo I, 2004, J VIROL, V78, P1281, DOI 10.1128/JVI.78.3.1281-1288.2004; Nakajima M, 2004, DEMENT GERIATR COGN, V17, P158, DOI 10.1159/000076350; Ono K, 2006, J NEUROCHEM, V97, P105, DOI 10.1111/j.1471-4159.2006.03707.x; Otto M, 2004, NEUROLOGY, V62, P714, DOI 10.1212/01.WNL.0000113764.35026.EF; Prusiner SB, 2001, NEW ENGL J MED, V344, P1516, DOI 10.1056/NEJM200105173442006; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Ragg E, 1999, EUR J BIOCHEM, V266, P1192, DOI 10.1046/j.1432-1327.1999.00985.x; Rainov NG, 2007, EXPERT OPIN BIOL TH, V7, P713, DOI 10.1517/14712598.7.5.713; Riesner D, 2003, BRIT MED BULL, V66, P21, DOI 10.1093/bmb/66.1.21; Seabrook TJ, 2006, GLIA, V53, P776, DOI 10.1002/glia.20338; Smith DL, 2003, ANN NEUROL, V54, P186, DOI 10.1002/ana.10614; Tagliavini F, 1997, SCIENCE, V276, P1119, DOI 10.1126/science.276.5315.1119; Tagliavini F, 2000, J MOL BIOL, V300, P1309, DOI 10.1006/jmbi.2000.3840; Todd NV, 2005, J INFECTION, V50, P394, DOI 10.1016/j.jinf.2004.07.015; Truccolo J, 2002, ANTIMICROB AGENTS CH, V46, P848, DOI 10.1128/AAC.46.3.848-853.2002; Weissmann C, 2005, ANNU REV MED, V56, P321, DOI 10.1146/annurev.med.56.062404.172936	42	74	78	1	10	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1888	10.1371/journal.pone.0001888	http://dx.doi.org/10.1371/journal.pone.0001888			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365024	Green Published, Green Submitted, gold			2022-12-25	WOS:000260762400030
J	Oyesanya, RA; Lee, ZP; Wu, JH; Chen, J; Song, YD; Mukherjee, A; Dent, P; Kordula, T; Zhou, HP; Fang, XJ				Oyesanya, Regina A.; Lee, Zendra P.; Wu, Jinhua; Chen, Jing; Song, Yuanda; Mukherjee, Abir; Dent, Paul; Kordula, Tomasz; Zhou, Huiping; Fang, Xianjun			Transcriptional and post-transcriptional mechanisms for lysophosphatidic acid-induced cyclooxygenase-2 expression in ovarian cancer cells	FASEB JOURNAL			English	Article						C/EBP; GPCR; HuR; receptor tyrosine kinase	PROTEIN-COUPLED RECEPTOR; GROWTH-FACTOR RECEPTOR; MESSENGER-RNA; C/EBP-BETA; BINDING PROTEINS; OVER-EXPRESSION; GENE-EXPRESSION; IN-VIVO; C-JUN; HUR	Emerging evidence suggests that lysophosphatidic acid (LPA) is a physiological regulator of cyclooxygenase-2 (Cox-2) expression. Herein we used ovarian cancer cells as a model to investigate the molecular mechanisms that link the LPA G protein-coupled receptors (GPCRs) to Cox-2 expression. LPA stimulated Cox-2 expression and release of prostaglandins though the LPA(1), LPA(2), and LPA(5) receptors. The effect of LPA involves both transcriptional activation and post-transcriptional enhancement of Cox-2 mRNA stability. The consensus sites for C/EBP in the Cox-2 promoter were essential for transcriptional activation of Cox-2 by LPA. The NF-kappa B and AP-1 transcription factors commonly involved in inducible Cox-2 expression were dispensable. Dominant-negative C/EPB beta inhibited LPA activation of the Cox-2 promoter and expression. Furthermore, LPA stimulated C/EBP beta phosphorylation and activity through a novel mechanism integrating GPCR signals and a permissive activity from a receptor tyrosine kinase (RTK). This role of RTK was not consistent with LPA activation of C/EBP through transactivation of RTK, as full activation of RTKs with their own agonists only weakly stimulated C/EBP. In addition to the transcriptional activation, the RNA stabilization protein HuR bound to and protected Cox-2 mRNA in LPA-stimulated cells, indicating an active role for HuR in sustaining Cox-2 induction during physiological responses.	[Oyesanya, Regina A.; Lee, Zendra P.; Wu, Jinhua; Chen, Jing; Song, Yuanda; Mukherjee, Abir; Dent, Paul; Kordula, Tomasz; Fang, Xianjun] Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Sch Med, Richmond, VA 23298 USA; [Zhou, Huiping] Virginia Commonwealth Univ, Sch Med, Dept Microbiol, Richmond, VA 23298 USA	Virginia Commonwealth University; Virginia Commonwealth University	Fang, XJ (corresponding author), Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Sch Med, Box 980614,1101 E Marshall St, Richmond, VA 23298 USA.	xfang@vcu.edu	Zhou, Huiping/H-6875-2019; Zhou, Huiping/J-3639-2015	Zhou, Huiping/0000-0002-0050-372X; 	NCI NIH HHS [P30 CA016059, P30 CA16059, CA102196, R01 CA102196] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA102196, P30CA016059] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		An SZ, 1998, J BIOL CHEM, V273, P7906, DOI 10.1074/jbc.273.14.7906; Bandoh K, 1999, J BIOL CHEM, V274, P27776, DOI 10.1074/jbc.274.39.27776; BROWN PH, 1993, ONCOGENE, V8, P877; Cesena TI, 2007, J BIOL CHEM, V282, P956, DOI 10.1074/jbc.M511451200; Chen LC, 2004, BBA-MOL CELL BIOL L, V1683, P38, DOI 10.1016/j.bbalip.2004.04.003; Cok SJ, 2003, J BIOL CHEM, V278, P36157, DOI 10.1074/jbc.M302547200; Daub H, 1997, EMBO J, V16, P7032, DOI 10.1093/emboj/16.23.7032; Dean JLE, 2004, CELL SIGNAL, V16, P1113, DOI 10.1016/j.cellsig.2004.04.006; Denkert C, 2004, CLIN CANCER RES, V10, P5580, DOI 10.1158/1078-0432.CCR-04-0070; Denkert C, 2004, CANCER RES, V64, P189, DOI 10.1158/0008-5472.CAN-03-1987; Denkert C, 2006, MODERN PATHOL, V19, P1261, DOI 10.1038/modpathol.3800645; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; Eaton EM, 2003, J BIOL CHEM, V278, P33416, DOI 10.1074/jbc.M305680200; EICHHOLTZ T, 1993, BIOCHEM J, V291, P677, DOI 10.1042/bj2910677; Erkinheimo TL, 2003, CANCER RES, V63, P7591; Fan XHC, 1998, EMBO J, V17, P3448, DOI 10.1093/emboj/17.12.3448; Fang XJ, 2004, J BIOL CHEM, V279, P9653, DOI 10.1074/jbc.M306662200; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Hahn A, 2002, BIOCHEM J, V362, P33, DOI 10.1042/0264-6021:3620033; Hecht JH, 1996, J CELL BIOL, V135, P1071, DOI 10.1083/jcb.135.4.1071; HOWE LR, 1993, J BIOL CHEM, V268, P20717; Hu YL, 2001, J NATL CANCER I, V93, P762, DOI 10.1093/jnci/93.10.762; Huang MC, 2004, ONCOGENE, V23, P122, DOI 10.1038/sj.onc.1206986; Ki SH, 2007, J BIOL CHEM, V282, P1938, DOI 10.1074/jbc.M606080200; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kitayama J, 2004, BREAST CANCER RES, V6, pR640, DOI 10.1186/bcr935; Lee CW, 2006, J BIOL CHEM, V281, P23589, DOI 10.1074/jbc.M603670200; Lee HK, 2006, NUCLEIC ACIDS RES, V34, P5705, DOI 10.1093/nar/gkl698; Lee Z, 2006, CANCER RES, V66, P2740, DOI 10.1158/0008-5472.CAN-05-2947; Liao ZX, 2007, DRUGS, V67, P821, DOI 10.2165/00003495-200767060-00001; McAllister-Lucas LM, 2007, P NATL ACAD SCI USA, V104, P139, DOI 10.1073/pnas.0601947103; McIntyre TM, 2003, P NATL ACAD SCI USA, V100, P131, DOI 10.1073/pnas.0135855100; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Moolenaar WH, 2000, ANN NY ACAD SCI, V905, P1; Moolenaar WH, 1997, CURR OPIN CELL BIOL, V9, P168, DOI 10.1016/S0955-0674(97)80059-2; Muehlich S, 2004, ATHEROSCLEROSIS, V175, P261, DOI 10.1016/j.atherosclerosis.2004.04.011; NAKAJIMA T, 1993, P NATL ACAD SCI USA, V90, P2207, DOI 10.1073/pnas.90.6.2207; Nie M, 2003, MOL CELL BIOL, V23, P9233, DOI 10.1128/MCB.23.24.9233-9244.2003; Noguchi K, 2003, J BIOL CHEM, V278, P25600, DOI 10.1074/jbc.M302648200; Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018; Oshima M, 1996, CELL, V87, P803, DOI 10.1016/S0092-8674(00)81988-1; Park SY, 2006, CELL SIGNAL, V18, P1063, DOI 10.1016/j.cellsig.2005.08.018; Pontsler AV, 2002, J BIOL CHEM, V277, P13029, DOI 10.1074/jbc.M109546200; Pustilnik TB, 1999, CLIN CANCER RES, V5, P3704; Ristimaki A, 1996, BIOCHEM J, V318, P325, DOI 10.1042/bj3180325; Rubio I, 2003, BIOCHEM J, V376, P571, DOI 10.1042/BJ20031410; Schulte KM, 2001, INT J CANCER, V92, P249, DOI 10.1002/1097-0215(200102)9999:9999<::AID-IJC1166>3.0.CO;2-D; Sengupta S, 2003, J BIOL CHEM, V278, P25227, DOI 10.1074/jbc.M301813200; Shida D, 2005, WORLD J GASTROENTERO, V11, P5638, DOI 10.3748/wjg.v11.i36.5638; Sivashanmugam P, 2004, J BIOL CHEM, V279, P21154, DOI 10.1074/jbc.M313776200; Smith WL, 2000, ANNU REV BIOCHEM, V69, P145, DOI 10.1146/annurev.biochem.69.1.145; Sundfeldt K, 1999, BRIT J CANCER, V79, P1240, DOI 10.1038/sj.bjc.6690199; Symowicz J, 2005, CANCER RES, V65, P2234, DOI 10.1158/0008.5472.CAN-04-2781; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; Wang DH, 2007, P NATL ACAD SCI USA, V104, P145, DOI 10.1073/pnas.0601894104; Wu J, 2002, BBA-MOL CELL BIOL L, V1582, P100, DOI 10.1016/S1388-1981(02)00143-9; Wu KK, 2005, ARTERIOSCL THROM VAS, V25, P679, DOI 10.1161/01.ATV.0000157899.35660.61; Xu J, 2004, J BIOL CHEM, V279, P10459, DOI 10.1074/jbc.M311891200; Ye XQ, 2005, NATURE, V435, P104, DOI 10.1038/nature03505; Zaslavsky A, 2006, BBA-MOL CELL BIOL L, V1761, P1200, DOI 10.1016/j.bbalip.2006.08.011	62	38	38	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2639	2651		10.1096/fj.07-101428	http://dx.doi.org/10.1096/fj.07-101428			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18362203	Green Published			2022-12-25	WOS:000258089300005
J	Xie, B; Shen, JK; Dong, A; Swaim, M; Hackett, SF; Wyder, L; Worpenberg, S; Barbieri, S; Campochiaro, PA				Xie, Bing; Shen, Jikui; Dong, Aling; Swaim, Mara; Hackett, Sean F.; Wyder, Lorenza; Worpenberg, Susanne; Barbieri, Samuel; Campochiaro, Peter A.			An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization	FASEB JOURNAL			English	Article						age-related macular degeneration; angiogenesis; chemokines; diabetic retinopathy; inflammation; stromalderived factor-1; vascular endothelial growth factor	CHOROIDAL NEOVASCULARIZATION; UP-REGULATION; EXPRESSION; METARGIDIN; PROTEIN; DOMAIN; CELLS; MICE; ALPHA(V)BETA(3); RETINOPATHY	Proteins with a disintegrin and a metalloproteinase domain (ADAMs) are a family of membrane-bound proteinases that bind integrins through their disintegrin domain. In this study, we have found modest expression of ADAM15 in pericytes in normal retina and strong up-regulation of ADAM15 in retinal vascular endothelial cells in ischemic retina. Increased expression of vascular endothelial growth factor (VEGF) in the retina in the absence of ischemia also increased ADAM15 levels, and knockdown of Vegf mRNA in ischemic retina reduced Adam15 mRNA. Mice deficient in ADAM15 showed a significant reduction in ischemia-induced retinal neovascularization, choroidal neovascularization at rupture sites in Bruch's membrane, and VEGF-induced subretinal neovascularization. ADAM15-deficient mice also showed reduced levels of VEGF(164), VEGF receptor 1, and VEGF receptor 2 in ischemic retina. These data suggest that ADAM15 and VEGF participate in an amplification loop; VEGF increases expression of ADAM15, which in turn increases expression of VEGF and its receptors. Perturbation of the loop by elimination of ADAM15 suppresses ocular neovascularization in 3 different model systems, and thus ADAM15 provides a new therapeutic target for diseases complicated by neovascularization.	[Xie, Bing; Shen, Jikui; Dong, Aling; Swaim, Mara; Hackett, Sean F.; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Ophthalmol, Baltimore, MD 21287 USA; [Xie, Bing; Shen, Jikui; Dong, Aling; Swaim, Mara; Hackett, Sean F.; Campochiaro, Peter A.] Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21287 USA; [Wyder, Lorenza; Worpenberg, Susanne; Barbieri, Samuel] Expertise Platform Proteases, Novartis Inst Biomed Res, Basel, Switzerland; [Xie, Bing] Shanghai Jiao Tong Univ, Sch Med, Ruijin Hosp, Dept Ophthalmol, Shanghai 200030, Peoples R China	Johns Hopkins University; Johns Hopkins University; Novartis; Shanghai Jiao Tong University	Campochiaro, PA (corresponding author), Johns Hopkins Univ, Sch Med, Dept Ophthalmol, 600 N Wolfe St, Baltimore, MD 21287 USA.	pcampo@jhmi.edu		Xie, Bing/0000-0003-2335-5966	NEI NIH HHS [R01 EY012609, P30 EY001765, P30EY1765] Funding Source: Medline; NATIONAL EYE INSTITUTE [P30EY001765] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Ellis LM, 1998, J BIOL CHEM, V273, P1052, DOI 10.1074/jbc.273.2.1052; Fleming RYD, 1997, SURGERY, V122, P501, DOI 10.1016/S0039-6060(97)90044-1; Gerber HP, 1997, J BIOL CHEM, V272, P23659, DOI 10.1074/jbc.272.38.23659; GOULD RJ, 1990, P SOC EXP BIOL MED, V195, P168, DOI 10.3181/00379727-195-43129B; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Herren B, 1997, FASEB J, V11, P173, DOI 10.1096/fasebj.11.2.9039960; Horiuchi K, 2003, MOL CELL BIOL, V23, P5614, DOI 10.1128/MCB.23.16.5614-5624.2003; Huovila APJ, 2005, TRENDS BIOCHEM SCI, V30, P413, DOI 10.1016/j.tibs.2005.05.006; Komiya K, 2005, ARTHRITIS RES THER, V7, pR1158, DOI 10.1186/ar1796; Kratzschmar J, 1996, J BIOL CHEM, V271, P4593; Kwak N, 2000, INVEST OPHTH VIS SCI, V41, P3158; Lum L, 1998, J BIOL CHEM, V273, P26236, DOI 10.1074/jbc.273.40.26236; Luna J, 1996, LAB INVEST, V75, P563; Mori K, 2001, J CELL PHYSIOL, V188, P253, DOI 10.1002/jcp.1114; Nath D, 1999, J CELL SCI, V112, P579; Nguyen QD, 2005, BRIT J OPHTHALMOL, V89, P1368, DOI 10.1136/bjo.2005.066431; Nguyen QD, 2006, AM J OPHTHALMOL, V142, P961, DOI 10.1016/j.ajo.2006.06.068; Ohno-Matsui K, 2002, AM J PATHOL, V160, P711, DOI 10.1016/S0002-9440(10)64891-2; Okamoto N, 1997, AM J PATHOL, V151, P281; Poghosyan Z, 2002, J BIOL CHEM, V277, P4999, DOI 10.1074/jbc.M107430200; Rosenfeld PJ, 2006, NEW ENGL J MED, V355, P1419, DOI 10.1056/NEJMoa054481; Saunders WB, 2006, J CELL BIOL, V175, P179, DOI 10.1083/jcb.200603176; Sennino B, 2007, CANCER RES, V67, P7358, DOI 10.1158/0008-5472.CAN-07-0293; Shen BQ, 1998, J BIOL CHEM, V273, P29979, DOI 10.1074/jbc.273.45.29979; Shen JK, 2007, INVEST OPHTH VIS SCI, V48, P4335, DOI 10.1167/iovs.07-0113; SMITH LEH, 1994, INVEST OPHTH VIS SCI, V35, P101; Sounni NE, 2004, J BIOL CHEM, V279, P13564, DOI 10.1074/jbc.M307688200; SUNDBERG C, 1993, AM J PATHOL, V143, P1377; Tobe T, 1998, AM J PATHOL, V153, P1641, DOI 10.1016/S0002-9440(10)65753-7; Tobe T, 1998, INVEST OPHTH VIS SCI, V39, P180; Trochon V, 1998, Angiogenesis, V2, P277, DOI 10.1023/A:1009206817829; Trochon-Joseph V, 2004, CANCER RES, V64, P2062, DOI 10.1158/0008-5472.CAN-03-3272; Umeda N, 2006, MOL PHARMACOL, V69, P1820, DOI 10.1124/mol.105.020941; Yannuzzi LA, 2001, RETINA-J RET VIT DIS, V21, P416, DOI 10.1097/00006982-200110000-00003; Zhang XP, 1998, J BIOL CHEM, V273, P7345, DOI 10.1074/jbc.273.13.7345	35	27	29	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2775	2783		10.1096/fj.07-099283	http://dx.doi.org/10.1096/fj.07-099283			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18381816	Green Published			2022-12-25	WOS:000258089300018
J	Clarke, CE; Veale, EL; Wyse, K; Vandenberg, JI; Mathie, A				Clarke, Catherine E.; Veale, Emma L.; Wyse, Ken; Vandenberg, Jamie I.; Mathie, Alistair			The M1P1 loop of TASK3 K2P channels apposes the selectivity filter and influences channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN K+ CHANNELS; CEREBELLAR GRANULE NEURONS; 2-PORE DOMAIN; POTASSIUM CHANNEL; PORE DOMAIN; ALPHA-HELIX; SUBUNITS; PHARMACOLOGY; BLOCK; INACTIVATION	Channels of the two-pore domain potassium (K2P) family contain two pore domains rather than one and an unusually long pre-pore extracellular linker called the M1P1 loop. The TASK (TASK1, TASK3, and TASK5) subfamily of K2P channels is regulated by a number of different pharmacological and physiological mediators. At pH 7.4 TASK3 channels are selectively blocked by zinc in a manner that is both pH(o)- and [K](o)(-) dependent Mutation of both the Glu-70 residue in the M1P1 loop and the His-98 residue in the pore region abolished block, suggesting the two residues may contribute to a zinc binding site. Mutation of one Glu-70 residue and one His-98 residue to cysteine in TASK3 fixed concatamer channels gave currents that were enhanced by dithiothreitol and then potently blocked by cadmium, suggesting that spontaneous disulfide bridges could be formed between these two residues. Swapping the M1P1 loops of TASK1 and TASK3 channels showed that the M1P1 loop is also involved in channel regulation by pH. Therefore, the TASK3 M1P1 loop lies close to the pore, regulating TASK3 channel activity.	[Mathie, Alistair] Univ Kent, Medway Sch Pharm, Chatham ME4 4TB, Kent, England; Univ Greenwich, Medway Sch Pharm, Chatham ME4 4TB, Kent, England; [Veale, Emma L.; Mathie, Alistair] Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Div Cell & Mol Biol, Biophys Sect, London SW7 2AZ, England; [Clarke, Catherine E.; Wyse, Ken; Vandenberg, Jamie I.] Univ New S Wales, Victor Chang Res Inst, Sydney, NSW 2010, Australia	University of Greenwich; University of Kent; University of Greenwich; Imperial College London; University of New South Wales Sydney; Victor Chang Cardiac Research Institute	Mathie, A (corresponding author), Univ Kent, Medway Sch Pharm, Cent Ave, Chatham ME4 4TB, Kent, England.	a.a.mathie@kent.ac.uk	Mathie, Alistair/K-7198-2019; Vandenberg, Jamie I/B-6608-2013; Veale, Emma/AAA-5022-2022	Mathie, Alistair/0000-0001-6094-2890; Vandenberg, Jamie I/0000-0002-3859-3716; Veale, Emma/0000-0002-6778-9929; Gregory, Catherine/0000-0002-3100-2741	MRC [G0200370] Funding Source: UKRI; Medical Research Council [G0200370] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Alexander SPH, 2008, BRIT J PHARMACOL, V153, pS1, DOI 10.1038/sj.bjp.0707746; Aller MI, 2005, J NEUROSCI, V25, P11455, DOI 10.1523/JNEUROSCI.3153-05.2005; Brickley SG, 2007, J NEUROSCI, V27, P9329, DOI 10.1523/JNEUROSCI.1427-07.2007; CAREAGA CL, 1992, BIOPHYS J, V62, P209, DOI 10.1016/S0006-3495(92)81806-4; Clarke CE, 2006, J PHYSIOL-LONDON, V573, P291, DOI 10.1113/jphysiol.2006.108332; Clarke CE, 2004, J PHYSIOL-LONDON, V560, P51, DOI 10.1113/jphysiol.2004.070292; Czirjak G, 2003, MOL PHARMACOL, V63, P646, DOI 10.1124/mol.63.3.646; Doring F, 2006, EUR J NEUROSCI, V24, P2264, DOI 10.1111/j.1460-9568.2006.05102.x; Duprat F, 2007, TRENDS NEUROSCI, V30, P573, DOI 10.1016/j.tins.2007.08.003; Goldstein SAN, 2005, PHARMACOL REV, V57, P527, DOI 10.1124/pr.57.4.12; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; Kang DW, 2004, J PHYSIOL-LONDON, V554, P64, DOI 10.1113/jphysiol.2003.054387; Kim D, 2005, CURR PHARM DESIGN, V11, P2717, DOI 10.2174/1381612054546824; Kim Y, 2000, J BIOL CHEM, V275, P9340, DOI 10.1074/jbc.275.13.9340; Krezel A, 2001, J INORG BIOCHEM, V84, P77, DOI 10.1016/S0162-0134(00)00212-9; Laine M, 2003, NEURON, V39, P467, DOI 10.1016/S0896-6273(03)00468-9; Lauritzen I, 2003, J BIOL CHEM, V278, P32068, DOI 10.1074/jbc.M302631200; Lesage F, 1996, EMBO J, V15, P6400, DOI 10.1002/j.1460-2075.1996.tb01031.x; Lesage F, 2003, NEUROPHARMACOLOGY, V44, P1, DOI 10.1016/S0028-3908(02)00339-8; Liu J, 2002, J GEN PHYSIOL, V120, P723, DOI 10.1085/jgp.20028687; Lopes CMB, 2001, J BIOL CHEM, V276, P24449, DOI 10.1074/jbc.C100184200; Lopes CMB, 2000, J BIOL CHEM, V275, P16969, DOI 10.1074/jbc.M001948200; Lotshaw DP, 2007, CELL BIOCHEM BIOPHYS, V47, P209, DOI 10.1007/s12013-007-0007-8; Mathie A, 2003, CEREBELLUM, V2, P11, DOI 10.1080/14734220310015593; Mathie A, 2007, J PHYSIOL-LONDON, V578, P377, DOI 10.1113/jphysiol.2006.121582; Mathie A, 2006, PHARMACOL THERAPEUT, V111, P567, DOI 10.1016/j.pharmthera.2005.11.004; Millar JA, 2000, P NATL ACAD SCI USA, V97, P3614, DOI 10.1073/pnas.050012597; Morton MJ, 2005, P NATL ACAD SCI USA, V102, P16102, DOI 10.1073/pnas.0506870102; Morton MJ, 2003, PFLUG ARCH EUR J PHY, V445, P577, DOI 10.1007/s00424-002-0901-2; Musset B, 2006, J PHYSIOL-LONDON, V572, P639, DOI 10.1113/jphysiol.2006.106898; Niemeyer MI, 2007, P NATL ACAD SCI USA, V104, P666, DOI 10.1073/pnas.0606173104; O'Connell AD, 2002, BBA-BIOMEMBRANES, V1566, P152, DOI 10.1016/S0005-2736(02)00597-7; Rajan S, 2000, J BIOL CHEM, V275, P16650, DOI 10.1074/jbc.M000030200; Reyes R, 1998, J BIOL CHEM, V273, P30863, DOI 10.1074/jbc.273.47.30863; Sobolevsky AI, 2004, NEURON, V41, P367, DOI 10.1016/S0896-6273(04)00008-X; Talley EM, 2000, NEURON, V25, P399, DOI 10.1016/S0896-6273(00)80903-4; Torres AM, 2003, J BIOL CHEM, V278, P42136, DOI 10.1074/jbc.M212824200; Yuill K, 2004, PFLUG ARCH EUR J PHY, V448, P63, DOI 10.1007/s00424-003-1218-5; Yuill KH, 2007, PFLUG ARCH EUR J PHY, V455, P333, DOI 10.1007/s00424-007-0282-7; Zilberberg N, 2001, NEURON, V32, P635, DOI 10.1016/S0896-6273(01)00503-7	40	33	34	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					16985	16992		10.1074/jbc.M801368200	http://dx.doi.org/10.1074/jbc.M801368200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18417474	Green Accepted, hybrid			2022-12-25	WOS:000256720600004
J	Fyfe, PK; Oza, SL; Fairlamb, AH; Hunter, WN				Fyfe, Paul K.; Oza, Sandra L.; Fairlamb, Alan H.; Hunter, William N.			Leishmania trypanothione synthetase-amidase structure reveals a basis for regulation of conflicting synthetic and hydrolytic activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; GLUTATHIONYLSPERMIDINE SYNTHETASE/AMIDASE; GLUTATHIONE SYNTHETASE; CRITHIDIA-FASCICULATA; FUNCTIONAL SYNTHETASE; TRYPANOSOMA-BRUCEI; CRYSTAL-STRUCTURE; DRUG-RESISTANCE; BIOSYNTHESIS; PURIFICATION	The bifunctional trypanothione synthetase-amidase catalyzes biosynthesis and hydrolysis of the glutathione-spermidine adduct trypanothione, the principal intracellular thiol-redox metabolite in parasitic trypanosomatids. These parasites are unique with regard to their reliance on trypanothione to determine intracellular thiol-redox balance in defense against oxidative and chemical stress and to regulate polyamine levels. Enzymes involved in trypanothione biosynthesis provide essential biological activities, and those absent from humans or for which orthologues are sufficiently distinct are attractive targets to underpin anti-parasitic drug discovery. The structure of Leishmania major trypanothione synthetase-amidase, determined in three crystal forms, reveals two catalytic domains. The N-terminal domain, a cysteine, histidine-dependent amidohydrolase/peptidase amidase, is a papain-like cysteine protease, and the C-terminal synthetase domain displays an ATP-grasp family fold common to C:N ligases. Modeling of substrates into each active site provides insight into the specificity and reactivity of this unusual enzyme, which is able to catalyze four reactions. The domain orientation is distinct from that observed in a related bacterial glutathionylspermidine synthetase. In trypanothione synthetase-amidase, the interactions formed by the C terminus, binding in and restricting access to the amidase active site, suggest that the balance of ligation and hydrolytic activity is directly influenced by the alignment of the domains with respect to each other and implicate conformational changes with amidase activity. The potential inhibitory role of the C terminus provides a mechanism to control relative levels of the critical metabolites, trypanothione, glutathionylspermidine, and spermidine in Leishmania.	[Fyfe, Paul K.; Oza, Sandra L.; Fairlamb, Alan H.; Hunter, William N.] Univ Dundee, Coll Life Sci, Div Biol Chem & Drug Discovery, Dundee DD1 5EH, Scotland	University of Dundee	Hunter, WN (corresponding author), Univ Dundee, Coll Life Sci, Div Biol Chem & Drug Discovery, Dow St, Dundee DD1 5EH, Scotland.	w.n.hunter@dundee.ac.uk	Fairlamb, Alan/A-5272-2009; Hunter, William/AAE-3947-2019	Fairlamb, Alan/0000-0001-5134-0329; Oza, Sandra/0000-0001-9404-7931; Fyfe, Paul/0000-0003-3541-2294	MRC [G0500367] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council Funding Source: Medline; Medical Research Council [G0500367] Funding Source: Medline; Wellcome Trust [079838, 082596, 083481] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Alphey MS, 2006, ACTA CRYSTALLOGR F, V62, P504, DOI 10.1107/S1744309106014849; Alphey MS, 2003, J BIOL CHEM, V278, P25919, DOI 10.1074/jbc.M301526200; Alphey MS, 1999, J BIOL CHEM, V274, P25613, DOI 10.1074/jbc.274.36.25613; Alphey MS, 2000, J MOL BIOL, V300, P903, DOI 10.1006/jmbi.2000.3881; ANANTHARAMAN V, 2003, GENOME BIOL, V4; Ariyanayagam MR, 2005, BIOCHEM J, V391, P425, DOI 10.1042/BJ20050911; Bacchi CJ, 2002, MINI-REV MED CHEM, V2, P553, DOI 10.2174/1389557023405549; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Barrett MP, 2007, BRIT J PHARMACOL, V152, P1155, DOI 10.1038/sj.bjp.0707354; Bateman A, 2003, TRENDS BIOCHEM SCI, V28, P234, DOI 10.1016/S0968-0004(03)00061-6; BOLLINGER JM, 1995, J BIOL CHEM, V270, P14031, DOI 10.1074/jbc.270.23.14031; Bond CS, 1999, STRUCTURE, V7, P81, DOI 10.1016/S0969-2126(99)80011-2; Chaudhary K, 2005, NAT BIOTECHNOL, V23, P1089, DOI 10.1038/nbt0905-1089; Comini M, 2005, J BIOL CHEM, V280, P6850, DOI 10.1074/jbc.M404486200; Comini MA, 2004, FREE RADICAL BIO MED, V36, P1289, DOI 10.1016/j.freeradbiomed.2004.02.008; Croft SL, 2006, CLIN MICROBIOL REV, V19, P111, DOI 10.1128/CMR.19.1.111-126.2006; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Delespaux V, 2007, DRUG RESIST UPDATE, V10, P30, DOI 10.1016/j.drup.2007.02.004; Dinescu A, 2004, J BIOL CHEM, V279, P22412, DOI 10.1074/jbc.M401334200; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Evans P, 2006, ACTA CRYSTALLOGR D, V62, P72, DOI 10.1107/S0907444905036693; FAIRLAMB AH, 1992, ANNU REV MICROBIOL, V46, P695, DOI 10.1146/annurev.micro.46.1.695; Galperin MY, 1997, PROTEIN SCI, V6, P2639; Gasteiger E, 2005, PROTEOMICS PROTOCOLS, P571, DOI [10.1385/1-59259-890-0:571, DOI 10.1385/1-59259-890-0:571]; Gogos A, 2002, STRUCTURE, V10, P1669, DOI 10.1016/S0969-2126(02)00906-1; Hara T, 1996, BIOCHEMISTRY-US, V35, P11967, DOI 10.1021/bi9605245; Heby O, 2007, AMINO ACIDS, V33, P359, DOI 10.1007/s00726-007-0537-9; HENDERSON GB, 1990, BIOCHEMISTRY-US, V29, P3924, DOI 10.1021/bi00468a019; Hiratake J, 2005, CHEM REC, V5, P209, DOI 10.1002/tcr.20045; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Krauth-Siegel RL, 2005, ANGEW CHEM INT EDIT, V44, P690, DOI 10.1002/anie.200300639; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Kwon DS, 1997, J BIOL CHEM, V272, P2429; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leslie A. G. W., 1992, JOINT CCP4 ESF EAMCB, P26; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; MARTON LJ, 1995, ANNU REV PHARMACOL, V35, P55, DOI 10.1146/annurev.pa.35.040195.000415; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Oza SL, 2006, MOL BIOCHEM PARASIT, V149, P117, DOI 10.1016/j.molbiopara.2006.05.001; Oza SL, 2002, BIOCHEM J, V364, P679, DOI 10.1042/BJ20011370; Oza SL, 2002, J BIOL CHEM, V277, P35853, DOI 10.1074/jbc.M204403200; Oza SL, 2005, MOL BIOCHEM PARASIT, V139, P107, DOI 10.1016/j.molbiopara.2004.10.004; Oza SL, 2003, MOL BIOCHEM PARASIT, V131, P25, DOI 10.1016/S0166-6851(03)00176-2; Pai CH, 2006, EMBO J, V25, P5970, DOI 10.1038/sj.emboj.7601440; Qi GY, 2005, BIOINFORMATICS, V21, P2832, DOI 10.1093/bioinformatics/bti420; Ravaschino EL, 2006, J MED CHEM, V49, P426, DOI 10.1021/jm050922i; Reithinger R, 2007, LANCET INFECT DIS, V7, P581, DOI 10.1016/S1473-3099(07)70209-8; Rigden DJ, 2003, TRENDS BIOCHEM SCI, V28, P230, DOI 10.1016/S0968-0004(03)00062-8; SMITH K, 1992, PROTEIN SCI, V1, P874, DOI 10.1002/pro.5560010705; STORER AC, 1994, METHOD ENZYMOL, V244, P486; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Tetaud E, 1998, J BIOL CHEM, V273, P19383, DOI 10.1074/jbc.273.31.19383; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	57	70	70	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17672	17680		10.1074/jbc.M801850200	http://dx.doi.org/10.1074/jbc.M801850200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18420578	Green Published, hybrid			2022-12-25	WOS:000256720600073
J	Mueller-Planitz, F; Herschlag, D				Mueller-Planitz, Felix; Herschlag, Daniel			Coupling between ATP binding and DNA cleavage by DNA topoisomerase II - A unifying kinetic and structural mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-TERMINAL FRAGMENT; STEADY-STATE ANALYSIS; DOUBLE HELIX; GYRASE; TRANSPORT; DOMAIN; INHIBITION; HYDROLYSIS; ALPHA; COMMUNICATION	DNA topoisomerase II is a molecular machine that couples ATP hydrolysis to the transport of one DNA segment through a transient break in another segment. To learn about the energetic connectivity that underlies this coupling, we investigated how the ATPase domains exert control over DNA cleavage. We dissected the DNA cleavage reaction by measuring rate and equilibrium constants for the individual reaction steps utilizing defined DNA duplexes in the presence and absence of the non-hydrolyzable ATP analog 5'-adenylyl-beta,gamma-imidodiphosphate (AMPPNP). Our results revealed the existence of two enzyme conformations whose relative abundance is sensitive to the presence of nucleotides. The predominant species in the absence of nucleotides binds DNA at a diffusion limited rate but cannot efficiently cleave DNA. In the presence of AMPPNP, most of the enzyme is converted to a state in which DNA binding and release is extremely slow but which allows DNA cleavage. A minimal kinetic and thermodynamic framework is established that accounts for the cooperativity of cleavage of the two DNA strands in the presence and absence of bound AMPPNP and includes conformational steps revealed in the kinetic studies. The model unifies available kinetic, thermodynamic, and structural data to provide a description for the reaction in terms of the order and rate of individual reaction steps and the physical nature of the species on the reaction path. Furthermore, this reaction framework provides a foundation for a future in-depth analysis of energy transduction by topoisomerase II, for guiding and interpreting future structural studies, and for analyzing the mechanism of drugs that convert topoisomerase into a cellular poison.	[Mueller-Planitz, Felix; Herschlag, Daniel] Stanford Univ, Dept Biochem, Sch Med, Stanford, CA 94305 USA	Stanford University	Herschlag, D (corresponding author), Stanford Univ, Dept Biochem, Sch Med, Beckman Ctr B400,279 Campus Dr, Stanford, CA 94305 USA.	herschla@stanford.edu	Mueller-Planitz, Felix/P-8461-2014	Mueller-Planitz, Felix/0000-0001-8273-6473	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064798] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM064798, R01 GM064798-04, GM64798] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alberts B, 1998, CELL, V92, P291, DOI 10.1016/S0092-8674(00)80922-8; ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; ALI JA, 1995, BIOCHEMISTRY-US, V34, P9801, DOI 10.1021/bi00030a018; Anderson VE, 2001, CURR PHARM DESIGN, V7, P337, DOI 10.2174/1381612013398013; Baird CL, 1999, P NATL ACAD SCI USA, V96, P13685, DOI 10.1073/pnas.96.24.13685; Baird CL, 2001, J BIOL CHEM, V276, P27893, DOI 10.1074/jbc.M102544200; Benedetti P, 1997, J BIOL CHEM, V272, P12132, DOI 10.1074/jbc.272.18.12132; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Brino L, 2000, J BIOL CHEM, V275, P9468, DOI 10.1074/jbc.275.13.9468; BROWN PO, 1979, SCIENCE, V206, P1081, DOI 10.1126/science.227059; Burden DA, 2000, METH MOL B, V95, P283; Burden DA, 1998, BBA-GENE STRUCT EXPR, V1400, P139, DOI 10.1016/S0167-4781(98)00132-8; Bustamante C, 2001, ACCOUNTS CHEM RES, V34, P412, DOI 10.1021/ar0001719; Classen S, 2003, P NATL ACAD SCI USA, V100, P10629, DOI 10.1073/pnas.1832879100; CORBETT AH, 1992, J BIOL CHEM, V267, P683; Corbett KD, 2005, STRUCTURE, V13, P873, DOI 10.1016/j.str.2005.03.013; Corbett KD, 2004, ANNU REV BIOPH BIOM, V33, P95, DOI 10.1146/annurev.biophys.33.110502.140357; Corbett KD, 2003, EMBO J, V22, P151, DOI 10.1093/emboj/cdg008; Fersht A., 1999, STRUCTURE MECH PROTE, P164; Gardiner LP, 1998, BIOCHEMISTRY-US, V37, P16997, DOI 10.1021/bi9818321; GOTO T, 1984, J BIOL CHEM, V259, P422; Hande KR, 1998, BBA-GENE STRUCT EXPR, V1400, P173, DOI 10.1016/S0167-4781(98)00134-1; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7299, DOI 10.1021/bi9729108; Harkins TT, 1998, BIOCHEMISTRY-US, V37, P7292, DOI 10.1021/bi9729099; Horst M, 1996, PROTEIN SCI, V5, P759; Hu T, 2002, J BIOL CHEM, V277, P5944, DOI 10.1074/jbc.M111394200; Lamour V, 2002, J BIOL CHEM, V277, P18947, DOI 10.1074/jbc.M111740200; LINDSLEY JE, 1993, NATURE, V361, P749, DOI 10.1038/361749a0; LINDSLEY JE, 1993, J BIOL CHEM, V268, P8096; Maxwell A, 1997, TRENDS MICROBIOL, V5, P102, DOI 10.1016/S0966-842X(96)10085-8; Mueller-Planitz F, 2007, NUCLEIC ACIDS RES, V35, P3764, DOI 10.1093/nar/gkm335; Mueller-Planitz F, 2006, J BIOL CHEM, V281, P23395, DOI 10.1074/jbc.M604119200; Olland S, 1999, J BIOL CHEM, V274, P21688, DOI 10.1074/jbc.274.31.21688; OSHEROFF N, 1987, BIOCHEMISTRY-US, V26, P4303, DOI 10.1021/bi00388a018; OSHEROFF N, 1986, J BIOL CHEM, V261, P9944; Roca J, 2004, J BIOL CHEM, V279, P25783, DOI 10.1074/jbc.M402555200; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; SANDER M, 1983, J BIOL CHEM, V258, P8421; Schoeffler AJ, 2005, BIOCHEM SOC T, V33, P1465, DOI 10.1042/BST0331465; Skouboe C, 2003, J BIOL CHEM, V278, P5768, DOI 10.1074/jbc.M210332200; Strumberg D, 2002, ANTIMICROB AGENTS CH, V46, P2735, DOI 10.1128/AAC.46.9.2735-2746.2002; Vale RD, 2003, CELL, V112, P467, DOI 10.1016/S0092-8674(03)00111-9; Vaughn J, 2005, J BIOL CHEM, V280, P11920, DOI 10.1074/jbc.M411841200; Wang JC, 1998, Q REV BIOPHYS, V31, P107, DOI 10.1017/S0033583598003424; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; Wei H, 2005, J BIOL CHEM, V280, P37041, DOI 10.1074/jbc.M506520200; WIGLEY DB, 1991, NATURE, V351, P624, DOI 10.1038/351624a0; ZIMMER C, 1990, J BASIC MICROB, V30, P209, DOI 10.1002/jobm.3620300312	49	21	22	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17463	17476		10.1074/jbc.M710014200	http://dx.doi.org/10.1074/jbc.M710014200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18403371	Green Published, hybrid, Green Accepted			2022-12-25	WOS:000256720600054
J	Onda, M; Nakatani, K; Takehara, S; Nishiyama, M; Takahashi, N; Hirose, M				Onda, Maki; Nakatani, Kazuyo; Takehara, Sayaka; Nishiyama, Mika; Takahashi, Nobuyuki; Hirose, Masaaki			Cleaved serpin refolds into the relaxed state via a stressed conformer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REACTIVE-CENTER LOOP; OVALBUMIN MUTANT R339T; HINGE REGION; ALPHA(1)-ANTITRYPSIN DEFICIENCY; CONFORMATIONAL-CHANGES; CRYSTAL-STRUCTURE; F-HELIX; PROTEIN; MECHANISM; STABILITY	Serine proteinase inhibitors (serpins) are believed to fold in vivo into a metastable "stressed" state with cleavage of their P1-P1' bond resulting in reactive center loop insertion and a thermostable "relaxed" state. To understand this unique folding mechanism, we investigated the refolding processes of the P1-P1'-cleaved forms of wild type ovalbumin (cl-OVA) and the R339T mutant (cl-R339T). In the native conditions, cl-OVA is trapped as the stressed conformer, whereas cl-R339T attains the relaxed structure. Under urea denaturing conditions, these cleaved proteins completely dissociated into the heavy (Gly(1)-Ala(352)) and light (Ser(353)-Pro(385)) chains. Upon refolding, the heavy chains of both proteins formed essentially the same initial burst refolding intermediates and then reassociated with the light chain counterparts. The reassociated intermediates both refolded into the native states with indistinguishable kinetics. The two refolded proteins, however, had a notable difference in thermostability. cl-OVA refolded into the stressed form with T-m = 68.4 degrees C, whereas cl-R339T refolded into the relaxed form with T-m = 85.5 degrees C. To determine whether cl-R339T refolds directly to the relaxed state or through the stressed state, conformational analyses by anion-exchange chromatography and fluorescence measurements were executed. The results showed that cl-R339T refolds first to the stressed conformation and then undergoes the loop insertion. This is the first demonstration that the P1-P1'-cleaved serpin peptide capable of loop insertion refolds to the stressed conformation. This highlights that the stressed conformation of serpins is an inevitable intermediate state on the folding pathway to the relaxed structure.	[Onda, Maki; Nishiyama, Mika] Osaka Prefecture Univ, Grad Sch Sci, Dept Biol Sci, Naka Ku, Sakai, Osaka 5998570, Japan; [Nakatani, Kazuyo] Osaka Womens Univ, Fac Sci, Dept Environm Sci, Naka Ku, Sakai, Osaka 5998531, Japan; [Takehara, Sayaka; Takahashi, Nobuyuki; Hirose, Masaaki] Kyoto Univ, Grad Sch Agr, Div Appl Life Sci, Kyoto 6110011, Japan	Osaka Metropolitan University; Osaka Metropolitan University; Kyoto University	Onda, M (corresponding author), Osaka Prefecture Univ, Grad Sch Sci, Dept Biol Sci, Naka Ku, Gakuencho 1-2, Sakai, Osaka 5998570, Japan.	onda@b.s.osakafu-u.ac.jp		Hirose, Masaaki/0000-0003-2672-4384				Arii Y, 2002, BIOCHEM J, V363, P403, DOI 10.1042/0264-6021:3630403; Arii Y, 1999, BIOSCI BIOTECH BIOCH, V63, P1392, DOI 10.1271/bbb.63.1392; AULAK KS, 1993, J BIOL CHEM, V268, P18088; Boudier C, 2001, BIOCHEMISTRY-US, V40, P9962, DOI 10.1021/bi010701o; Brockwell DJ, 2007, CURR OPIN STRUC BIOL, V17, P30, DOI 10.1016/j.sbi.2007.01.003; Cabrita LD, 2004, BIOCHEMISTRY-US, V43, P9834, DOI 10.1021/bi0491346; Cabrita LD, 2002, BIOCHEMISTRY-US, V41, P4575, DOI 10.1021/bi0158932; CARRELL RW, 1985, NATURE, V317, P730, DOI 10.1038/317730a0; Davis RL, 1999, NATURE, V401, P376, DOI 10.1038/43897; DELANO WL, 2002, PYMOL MOL GRAPHICS G; Desai UR, 2002, ANAL BIOCHEM, V302, P81, DOI 10.1006/abio.2001.5512; Devlin GL, 2005, FRONT BIOSCI-LANDMRK, V10, P288, DOI 10.2741/1528; Elliott PR, 1998, AM J RESP CELL MOL, V18, P670, DOI 10.1165/ajrcmb.18.5.3065; FERNANDEZDIEZ M J, 1964, Arch Biochem Biophys, V107, P449; HERVE M, 1990, EUR J BIOCHEM, V191, P653, DOI 10.1111/j.1432-1033.1990.tb19171.x; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; Huntington JA, 1997, BIOCHEMISTRY-US, V36, P5432, DOI 10.1021/bi9702142; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Im H, 2002, J BIOL CHEM, V277, P46347, DOI 10.1074/jbc.M207682200; Kim DY, 1996, BIOCHEM BIOPH RES CO, V226, P378, DOI 10.1006/bbrc.1996.1364; KITABATAKE N, 1988, AGR BIOL CHEM TOKYO, V52, P967; Klein-Seetharaman J, 2002, SCIENCE, V295, P1719, DOI 10.1126/science.1067680; Li L, 2000, NAT STRUCT BIOL, V7, P336; Liu T, 1999, J BIOL CHEM, V274, P29628, DOI 10.1074/jbc.274.42.29628; Lomas DA, 2004, FRONT BIOSCI-LANDMRK, V9, P2873, DOI 10.2741/1444; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; Lukacs CM, 1996, NAT STRUCT BIOL, V3, P888, DOI 10.1038/nsb1096-888; Onda M, 1997, J BIOCHEM-TOKYO, V122, P83; Onda M, 1997, J BIOL CHEM, V272, P3973, DOI 10.1074/jbc.272.7.3973; Onda M, 2005, J BIOL CHEM, V280, P13735, DOI 10.1074/jbc.M413282200; Onda M, 2003, J BIOL CHEM, V278, P23600, DOI 10.1074/jbc.M300295200; PACE CN, 1995, PROTEIN SCI, V4, P2411, DOI 10.1002/pro.5560041120; POWELL LM, 1992, J MOL BIOL, V224, P241, DOI 10.1016/0022-2836(92)90587-A; PRESS WH, 1988, NUMERICAL RECIPES C, P683; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P379; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; SOENSEN SPL, 1915, M C R TRAV LAB CARLS, V12, P12; STEIN PE, 1991, J MOL BIOL, V221, P941, DOI 10.1016/0022-2836(91)80185-W; STEIN PE, 1990, NATURE, V347, P99, DOI 10.1038/347099a0; TAKAHASHI N, 1995, GENE, V161, P211, DOI 10.1016/0378-1119(95)00234-W; Takahashi N, 2005, J MOL BIOL, V348, P409, DOI 10.1016/j.jmb.2005.02.054; TAKAHASHI N, 1992, J BIOL CHEM, V267, P11565; TAKAHASHI N, 1991, J BIOCHEM-TOKYO, V109, P846, DOI 10.1093/oxfordjournals.jbchem.a123469; Tew DJ, 2001, J MOL BIOL, V313, P1161, DOI 10.1006/jmbi.2001.5104; TONOMURA B, 1978, ANAL BIOCHEM, V84, P370, DOI 10.1016/0003-2697(78)90054-4; Vendruscolo M, 2001, NATURE, V409, P641, DOI 10.1038/35054591; VERPY E, 1995, J CLIN INVEST, V95, P350, DOI 10.1172/JCI117663; Whisstock J, 1998, TRENDS BIOCHEM SCI, V23, P63, DOI 10.1016/S0968-0004(97)01172-9; Whisstock JC, 2006, CURR OPIN STRUC BIOL, V16, P761, DOI 10.1016/j.sbi.2006.10.005; WRIGHT HT, 1984, J BIOL CHEM, V259, P4335; Yamasaki M, 2002, J MOL BIOL, V315, P113, DOI 10.1006/jmbi.2001.5056	51	17	17	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17568	17578		10.1074/jbc.M709262200	http://dx.doi.org/10.1074/jbc.M709262200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18390904	hybrid			2022-12-25	WOS:000256720600064
J	Guillaume, JL; Daulat, AM; Maurice, P; Levoye, A; Migaud, M; Brydon, L; Malpaux, B; Borg-Capra, C; Jockers, R				Guillaume, Jean-Luc; Daulat, Avais M.; Maurice, Pascal; Levoye, Angelique; Migaud, Martine; Brydon, Lena; Malpaux, Benoit; Borg-Capra, Catherine; Jockers, Ralf			The PDZ protein MUPP1 promotes G(i) coupling and signaling of the Mt(1) melatonin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE ENERGY-TRANSFER; BETA(1)-ADRENERGIC RECEPTOR; DOMAIN; INTERACTS; BINDING; TRAFFICKING; ASSOCIATION; EXPRESSION; LIGAND; DESENSITIZATION	Intracellular signaling events are often organized around PDZ (PSD-95/Drosophila Disc large/ZO-1 homology) domain-containing scaffolding proteins. The ubiquitously expressed multi-PDZ protein MUPP1, which is composed of 13 PDZ domains, has been shown to interact with multiple viral and cellular proteins and to play important roles in receptor targeting and trafficking. In this study, we show that MUPP1 binds to the G protein-coupled MT1 melatonin receptor and directly regulates its G(i)-dependent signal transduction. Structural determinants involved in this interaction are the PDZ10 domain of MUPP1 and the valine of the canonical class III PDZ domain binding motif DSV of the MT1 carboxyl terminus. This high affinity interaction (K-d similar to 4 nM), which is independent of MT1 activation, occurs in the ovine pars tuberalis of the pituitary expressing both proteins endogenously. Although the disruption of the MT1/MUPP1 interaction has no effect on the subcellular localization, trafficking, or degradation of MT1, it destabilizes the interaction between MT1 and G(i) and abolishes G(i)-mediated signaling of MT1. Our findings highlight a previously unappreciated role of PDZ proteins in promoting G protein coupling to receptors.	[Guillaume, Jean-Luc; Daulat, Avais M.; Maurice, Pascal; Levoye, Angelique; Brydon, Lena; Jockers, Ralf] Univ Paris 05, Inst Cochin, Dept Cell Biol, CNRS UMR8104, F-75014 Paris, France; [Guillaume, Jean-Luc; Daulat, Avais M.; Maurice, Pascal; Levoye, Angelique; Brydon, Lena; Jockers, Ralf] INSERM, U567, F-75014 Paris, France; [Migaud, Martine; Malpaux, Benoit] Univ Francois Rabelais Tours Haras Nationaux, CNRS, INRA, UMR 6175, F-37380 Nouzilly, France; [Borg-Capra, Catherine] Hybrigenics, F-75014 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); Universite de Tours; INRAE	Jockers, R (corresponding author), Univ Paris 05, Inst Cochin, Dept Cell Biol, CNRS UMR8104, 22 Rue Mechain, F-75014 Paris, France.	jockers@cochin.inserm.fr	Jockers, Ralf/Q-2100-2019; Malpaux, Benoît/GXW-2719-2022; Levoye, Angelique/ABC-7892-2021; Jockers, Ralf/P-2272-2017; Maurice, Pascal/AAM-9126-2021	Jockers, Ralf/0000-0002-4354-1750; Jockers, Ralf/0000-0002-4354-1750; Levoye, Angelique/0000-0002-7125-7327; MAURICE, Pascal/0000-0003-2167-4808; Daulat, Avais/0000-0002-3076-2132; Migaud, Martine/0000-0002-9496-0517				Ayoub MA, 2002, J BIOL CHEM, V277, P21522, DOI 10.1074/jbc.M200729200; Ayoub MA, 2007, MOL PHARMACOL, V71, P1329, DOI 10.1124/mol.106.030304; Balasubramanian S, 2007, J BIOL CHEM, V282, P4162, DOI 10.1074/jbc.M607695200; Barritt DS, 2000, J CELL BIOCHEM, V79, P213, DOI 10.1002/1097-4644(20001101)79:2<213::AID-JCB50>3.0.CO;2-G; Becamel C, 2001, J BIOL CHEM, V276, P12974, DOI 10.1074/jbc.M008089200; Bockaert J, 2004, BIOCHEM SOC T, V32, P851, DOI 10.1042/BST0320851; Bousquet C, 2006, EMBO J, V25, P3943, DOI 10.1038/sj.emboj.7601279; Brydon L, 1999, MOL ENDOCRINOL, V13, P2025, DOI 10.1210/me.13.12.2025; Brydon L, 2001, ENDOCRINOLOGY, V142, P4264, DOI 10.1210/en.142.10.4264; Cao TT, 1999, NATURE, V401, P286, DOI 10.1038/45816; Chen ZJ, 2006, J BIOL CHEM, V281, P12414, DOI 10.1074/jbc.M508651200; Dillon DC, 2002, AM J CLIN PATHOL, V118, P451; Fam SR, 2005, P NATL ACAD SCI USA, V102, P8042, DOI 10.1073/pnas.0408818102; FromontRacine M, 1997, NAT GENET, V16, P277, DOI 10.1038/ng0797-277; Gavarini S, 2006, MOL BIOL CELL, V17, P4619, DOI 10.1091/mbc.E06-03-0218; Gutkind J. S., 2000, SCI STKE, pre1, DOI DOI 10.1126/STKE.2000.40.RE1; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Hamazaki Y, 2002, J BIOL CHEM, V277, P455, DOI 10.1074/jbc.M109005200; He JQ, 2006, J BIOL CHEM, V281, P2820, DOI 10.1074/jbc.M509503200; Hu LYA, 2003, J BIOL CHEM, V278, P26295, DOI 10.1074/jbc.M212352200; Issafras H, 2002, J BIOL CHEM, V277, P34666, DOI 10.1074/jbc.M202386200; Jeanneteau F, 2004, MOL BIOL CELL, V15, P4926, DOI 10.1091/mbc.E04-04-0285; Jelen F, 2003, ACTA BIOCHIM POL, V50, P985; Jockers R, 1998, ENDOCRINOLOGY, V139, P2676, DOI 10.1210/en.139.6.2676; Joubert L, 2004, J CELL SCI, V117, P5367, DOI 10.1242/jcs.01379; Kimber WA, 2002, BIOCHEM J, V361, P525, DOI 10.1042/0264-6021:3610525; Lahuna O, 2005, EMBO J, V24, P1364, DOI 10.1038/sj.emboj.7600616; Lanaspa MA, 2007, P NATL ACAD SCI USA, V104, P13672, DOI 10.1073/pnas.0702752104; Latorre IJ, 2005, J CELL SCI, V118, P4283, DOI 10.1242/jcs.02560; Lee SS, 2000, J VIROL, V74, P9680, DOI 10.1128/JVI.74.20.9680-9693.2000; Li ZR, 2006, J BIOL CHEM, V281, P11066, DOI 10.1074/jbc.M600113200; Mahon MJ, 2002, NATURE, V417, P858, DOI 10.1038/nature00816; Mancini A, 2000, FEBS LETT, V482, P54, DOI 10.1016/S0014-5793(00)02036-6; Massimi P, 2004, ONCOGENE, V23, P8033, DOI 10.1038/sj.onc.1207977; MORGAN PJ, 1989, J MOL ENDOCRINOL, V3, pR5, DOI 10.1677/jme.0.003R005; MORGAN PJ, 1989, NEUROENDOCRINOLOGY, V50, P359, DOI 10.1159/000125245; Nguyen ML, 2003, J VIROL, V77, P6957, DOI 10.1128/JVI.77.12.6957-6964.2003; Oh YS, 2004, MOL CELL BIOL, V24, P5069, DOI 10.1128/MCB.24.11.5069-5079.2004; Paasche JD, 2005, MOL PHARMACOL, V67, P1581, DOI 10.1124/mol.104.007013; Parker LL, 2003, J BIOL CHEM, V278, P21576, DOI 10.1074/jbc.M210973200; Pfleger KDG, 2006, NAT METHODS, V3, P165, DOI 10.1038/nmeth841; Roka F, 1999, MOL PHARMACOL, V56, P1014, DOI 10.1124/mol.56.5.1014; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Shirley RL, 2004, NAT NEUROSCI, V7, P699, DOI 10.1038/nn1271; Sitek B, 2003, BRAIN RES, V970, P178, DOI 10.1016/S0006-8993(03)02338-2; Slominski A, 2005, FASEB J, V19, P176, DOI 10.1096/fj.04-2079rev; Sneddon WB, 2003, J BIOL CHEM, V278, P43787, DOI 10.1074/jbc.M306019200; Stiffler MA, 2007, SCIENCE, V317, P364, DOI 10.1126/science.1144592; Stricker NL, 1997, NAT BIOTECHNOL, V15, P336, DOI 10.1038/nbt0497-336; Ullmer C, 1998, FEBS LETT, V424, P63, DOI 10.1016/S0014-5793(98)00141-0; Xia ZQ, 2003, J BIOL CHEM, V278, P21901, DOI 10.1074/jbc.M301905200; Xiang Y, 2002, J BIOL CHEM, V277, P33783, DOI 10.1074/jbc.M204136200; Yamada T, 2005, J BIOL CHEM, V280, P19358, DOI 10.1074/jbc.M414561200; Yao R, 2004, ONCOGENE, V23, P6023, DOI 10.1038/sj.onc.1207817; Zhou YW, 2005, AM J PHYSIOL-CELL PH, V288, pC377, DOI 10.1152/ajpcell.00279.2004; Zilberfarb V, 1997, J CELL SCI, V110, P801	56	58	60	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16762	16771		10.1074/jbc.M802069200	http://dx.doi.org/10.1074/jbc.M802069200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18378672	hybrid, Green Published			2022-12-25	WOS:000256497100053
J	Li, SKM; Smith, DK; Leung, WY; Cheung, AMS; Lam, EWF; Dimri, GP; Yao, KM				Li, Samuel K. M.; Smith, David K.; Leung, Wai Ying; Cheung, Alice M. S.; Lam, Eric W. F.; Dimri, Goberdhan P.; Yao, Kwok-Ming			FoxM1c counteracts oxidative stress-induced senescence and stimulates Bmi-1 expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M1 TRANSCRIPTION FACTOR; REGULATES CELL-PROLIFERATION; HEMATOPOIETIC STEM-CELLS; TUMOR-SUPPRESSOR; SELF-RENEWAL; MOLECULAR ANALYSIS; TRANSGENIC MICE; FACTOR TRIDENT; GENE-PRODUCT; GLIOMA-CELLS	The Forkhead box transcription factor FoxM1 is expressed in proliferating cells. When it was depleted in mice and cell lines, cell cycle defects and chromosomal instability resulted. Premature senescence was observed in embryonic fibroblasts derived from FoxM1 knock-out mice, but the underlying cause has remained unclear. To investigate whether FoxM1 can protect cells against stress-induced premature senescence, we established NIH3T3 lines with doxycycline-inducible overexpression of FoxM1c. Treatment of these lines with sublethal doses (20 and 100 mu M) of H2O2 induced senescence with senescence-associated beta-galactosidase expression and elevated levels of p53 and p21. Induction of FoxM1c expression markedly suppressed senescence and expression of p53 and p21. Consistent with down-regulation of the p19(Arf)-p53 pathway, p19(Arf) levels decreased while expression of the Polycomb group protein Bmi-1 was induced. That Bmi-1 is a downstream target of FoxM1c was further supported by the dose-dependent induction of Bmi-1 by FoxM1c at both the protein and mRNA levels, and FoxM1 and Bmi-1 reached maximal levels in cells at the G(2)/M phase. Depletion of FoxM1 by RNA interference decreased Bmi-1 expression. Using Bmi-1 promoter reporters with wild-type and mutated c-Myc binding sites and short hairpin RNAs targeting c-Myc, we further demonstrated that FoxM1c activated Bmi-1 expression via c-Myc, which was recently reported to be regulated by FoxM1c. Our results reveal a functional link between FoxM1c, c-Myc, and Bmi-1, which are major regulators of tumorigenesis. This link has important implications for the regulation of cell proliferation and senescence by FoxM1 and Bmi-1.	[Li, Samuel K. M.; Smith, David K.; Leung, Wai Ying; Cheung, Alice M. S.; Yao, Kwok-Ming] Univ Hong Kong, Dept Biochem, LKS Fac Med, Pokfulam, Hong Kong, Peoples R China; [Dimri, Goberdhan P.] Northwestern Univ, Dept Med, Evanston NW Healthcare Res Inst, Feinberg Sch Med, Chicago, IL 60201 USA; [Lam, Eric W. F.] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Oncol, Canc Res United Kingdom Labs, London W12 0NN, England	University of Hong Kong; Northwestern University; Feinberg School of Medicine; Cancer Research UK; Imperial College London	Yao, KM (corresponding author), Univ Hong Kong, Dept Biochem, LKS Fac Med, 3-F Lab Block,LKS Fac Med Bldg,21 Sassoon Rd, Pokfulam, Hong Kong, Peoples R China.	kmyao@hkusua.hku.hk	Yao, Kwok Ming/C-4457-2009; Dimri, Goberdhan/AAO-4210-2021; Lam, Eric W-F/AAW-8566-2020; Cheung, Man Sze/A-4574-2012; Leung, Gloria/C-4189-2009; Cheung, Alice/B-3264-2011	Lam, Eric W-F/0000-0003-1274-3576; Smith, David/0000-0003-3608-0586; Cheung, Alice/0000-0003-2195-4017	NCI NIH HHS [R01 CA094150] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA094150] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; Ben-Porath I, 2005, INT J BIOCHEM CELL B, V37, P961, DOI 10.1016/j.biocel.2004.10.013; Bracken AP, 2007, GENE DEV, V21, P525, DOI 10.1101/gad.415507; Braig M, 2005, NATURE, V436, P660, DOI 10.1038/nature03841; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; Chen QM, 1998, BIOCHEM J, V332, P43, DOI 10.1042/bj3320043; Chen ZB, 2005, NATURE, V436, P725, DOI 10.1038/nature03918; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Dai B, 2007, ONCOGENE, V26, P6212, DOI 10.1038/sj.onc.1210443; Dimri GP, 2005, CANCER CELL, V7, P505, DOI 10.1016/j.ccr.2005.05.025; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Duan HM, 2005, INT J BIOCHEM CELL B, V37, P1407, DOI 10.1016/j.biocel.2005.01.010; Guo WJ, 2007, MOL BIOL CELL, V18, P536, DOI 10.1091/mbc.E06-05-0447; Itahana K, 2004, BIOGERONTOLOGY, V5, P1, DOI 10.1023/B:BGEN.0000017682.96395.10; Iwama A, 2004, IMMUNITY, V21, P843, DOI 10.1016/j.immuni.2004.11.004; Jacobs JJL, 1999, NATURE, V397, P164, DOI 10.1038/16476; Kaestner KH, 2000, GENE DEV, V14, P142; Kalin TV, 2006, CANCER RES, V66, P1712, DOI 10.1158/0008-5472.CAN-05-3138; Kalinichenko VV, 2003, J BIOL CHEM, V278, P37888, DOI 10.1074/jbc.M305555200; Kalinichenko VV, 2004, GENE DEV, V18, P830, DOI 10.1101/gad.1200704; Kalinina OA, 2003, ONCOGENE, V22, P6266, DOI 10.1038/sj.onc.1206640; Kim IM, 2006, CANCER RES, V66, P2153, DOI 10.1158/0008-5472.CAN-05-3003; Kim IM, 2005, J BIOL CHEM, V280, P22278, DOI 10.1074/jbc.M500936200; Korver W, 1998, CURR BIOL, V8, P1327, DOI 10.1016/S0960-9822(07)00563-5; Korver W, 1997, NUCLEIC ACIDS RES, V25, P1715, DOI 10.1093/nar/25.9.1715; Krupczak-Hollis K, 2004, DEV BIOL, V276, P74, DOI 10.1016/j.ydbio.2004.08.022; Laoukili J, 2005, NAT CELL BIOL, V7, P126, DOI 10.1038/ncb1217; Laoukili J, 2007, BBA-REV CANCER, V1775, P92, DOI 10.1016/j.bbcan.2006.08.006; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Leung TWC, 2001, FEBS LETT, V507, P59, DOI 10.1016/S0014-5793(01)02915-5; Liu MG, 2006, CANCER RES, V66, P3593, DOI 10.1158/0008-5472.CAN-05-2912; Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054; Ly DH, 2000, SCIENCE, V287, P2486, DOI 10.1126/science.287.5462.2486; Ma RYM, 2005, J CELL SCI, V118, P795, DOI 10.1242/jcs.01657; Madureira PA, 2006, J BIOL CHEM, V281, P25167, DOI 10.1074/jbc.M603906200; Michaloglou C, 2005, NATURE, V436, P720, DOI 10.1038/nature03890; Molofsky AV, 2003, NATURE, V425, P962, DOI 10.1038/nature02060; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Pomerantz J, 1998, CELL, V92, P713, DOI 10.1016/S0092-8674(00)81400-2; Ramakrishna S, 2007, DEV DYNAM, V236, P1000, DOI 10.1002/dvdy.21113; Tan YJ, 2007, MOL CELL BIOL, V27, P1007, DOI 10.1128/MCB.01068-06; Teh MT, 2002, CANCER RES, V62, P4773; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Ventura A, 2007, NATURE, V445, P661, DOI 10.1038/nature05541; Wang IC, 2005, MOL CELL BIOL, V25, P10875, DOI 10.1128/MCB.25.24.10875-10894.2005; Wang XH, 2002, J BIOL CHEM, V277, P44310, DOI 10.1074/jbc.M207510200; Wang XH, 2001, P NATL ACAD SCI USA, V98, P11468, DOI 10.1073/pnas.201360898; Weber JD, 1999, NAT CELL BIOL, V1, P20, DOI 10.1038/8991; Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944; Wierstra I, 2006, FEBS J, V273, P4645, DOI 10.1111/j.1742-4658.2006.05468.x; Wonsey DR, 2005, CANCER RES, V65, P5181, DOI 10.1158/0008-5472.CAN-04-4059; Xue W, 2007, NATURE, V445, P656, DOI 10.1038/nature05529; Yao KM, 1997, J BIOL CHEM, V272, P19827, DOI 10.1074/jbc.272.32.19827; Ye HG, 1999, MOL CELL BIOL, V19, P8570; Ye HG, 1997, MOL CELL BIOL, V17, P1626, DOI 10.1128/MCB.17.3.1626; Yoshida Y, 2007, GASTROENTEROLOGY, V132, P1420, DOI 10.1053/j.gastro.2007.01.036	56	85	89	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16545	16553		10.1074/jbc.M709604200	http://dx.doi.org/10.1074/jbc.M709604200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18408007	hybrid, Green Published			2022-12-25	WOS:000256497100031
J	Kolisek, M; Launay, P; Beck, A; Sponder, G; Serafini, N; Brenkus, M; Froschauer, EM; Martens, H; Fleig, A; Schweigel, M				Kolisek, Martin; Launay, Pierre; Beck, Andreas; Sponder, Gerhard; Serafini, Nicolas; Brenkus, Marcel; Froschauer, Elisabeth Maria; Martens, Holger; Fleig, Andrea; Schweigel, Monika			SLC41A1 is a novel mammalian Mg2+ carrier	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN SOLUTE CARRIER; MAGNESIUM TRANSPORT; FUNCTIONAL-CHARACTERIZATION; SALMONELLA-TYPHIMURIUM; SMOOTH-MUSCLE; CHANNELS; INFLUX; MGTE; CORA; IDENTIFICATION	The molecular biology of mammalian magnesium transporters and their interrelations in cellular magnesium homeostasis are largely unknown. Recently, the mouse SLC41A1 protein was suggested to be a candidate magnesium transporter with channel-like properties when overexpressed in Xenopus laevis oocytes. Here, we demonstrate that human SLC41A1 overexpressed in HEK293 cells forms protein complexes and locates to the plasma membrane without, however, giving rise to any detectable magnesium currents during whole cell patch clamp experiments. Nevertheless, in a strain of Salmonella enterica exhibiting disruption of all three distinct magnesium transport systems (CorA, MgtA, and MgtB), overexpression of human SLC41A1 functionally substitutes these transporters and restores the growth of the mutant bacteria at magnesium concentrations otherwise non-permissive for growth. Thus, we have identified human SLC41A1 as being a bona fide magnesium transporter. Most importantly, overexpressed SLC41A1 provide HEK293 cells with an increased magnesium efflux capacity. With outwardly directed Mg2+ gradients, a SLC41A1-dependent reduction of the free intracellular magnesium concentration accompanied by a significant net decrease of the total cellular magnesium concentration could be observed in such cells. SLC41A1 activity is temperature-sensitive but not sensitive to the only known magnesium channel blocker, cobalt(III) hexaammine. Taken together, these data functionally identify SLC41A1 as a mammalian carrier mediating magnesium efflux.	[Kolisek, Martin; Brenkus, Marcel; Martens, Holger] Free Univ Berlin, Inst Vet Physiol, D-14163 Berlin, Germany; [Launay, Pierre; Serafini, Nicolas] Equipe Avenir, U699, INSERM, F-75018 Paris, France; [Beck, Andreas; Fleig, Andrea] Queens Med Ctr, Lab Cell & Mol Signalling, Ctr Biomed Res, Honolulu, HI 96813 USA; [Sponder, Gerhard; Froschauer, Elisabeth Maria] Univ Vienna, Max F Perutz Labs, Dept Microbiol & Genet, A-1030 Vienna, Austria; [Schweigel, Monika] Res Inst Biol Farm Anim, Dept Nutr Physiol Oskar Kellner, D-18196 Dummerstorf, Germany	Free University of Berlin; Institut National de la Sante et de la Recherche Medicale (Inserm); The Queen's Medical Center; Medical University of Vienna; University of Vienna; Vienna Biocenter (VBC); Max F. Perutz Laboratories (MFPL); Forschungsinstitut fur Nutztierbiologie (FBN)	Kolisek, M (corresponding author), Free Univ Berlin, Inst Vet Physiol, Oertzenweg 19B, D-14163 Berlin, Germany.	martink@zedat.fu-berlin.de; pierre.launay@bichat.inserm.fr; afleig@hawaii.edu; mschweigel@fbn-dummerstorf.de	SERAFINI, nicolas/S-5675-2019; Launay, Pierre/AAH-7076-2019	SERAFINI, nicolas/0000-0002-7440-4353; Fleig, Andrea/0000-0001-8396-7249	NIGMS NIH HHS [P01GM078195] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM078195] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bara M, 2001, MAGNESIUM RES, V14, P11; Barbagallo M, 2007, NEW PERSPECTIVES IN MAGNESIUM RESEARCH: NUTRITION AND HEALTH, P213, DOI 10.1007/978-1-84628-483-0_17; Bijvelds MJC, 1996, J MEMBRANE BIOL, V154, P217; BULLAS LR, 1983, J BACTERIOL, V156, P471, DOI 10.1128/JB.156.1.471-474.1983; Chubanov V, 2005, PFLUG ARCH EUR J PHY, V451, P228, DOI 10.1007/s00424-005-1470-y; Chubanov V, 2004, P NATL ACAD SCI USA, V101, P2894, DOI 10.1073/pnas.0305252101; Cowan JA, 2002, BIOMETALS, V15, P225, DOI 10.1023/A:1016022730880; Froschauer EM, 2004, FEMS MICROBIOL LETT, V237, P49, DOI 10.1016/j.femsle.2004.06.013; Gadsby DC, 2004, NATURE, V427, P795, DOI 10.1038/427795a; Goytain A, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-48; Goytain A, 2005, PHYSIOL GENOMICS, V22, P382, DOI 10.1152/physiolgenomics.00058.2005; Goytain A, 2005, PHYSIOL GENOMICS, V21, P337, DOI 10.1152/physiolgenomics.00261.2004; Goytain A, 2005, BIOCHEM BIOPH RES CO, V330, P701, DOI 10.1016/j.bbrc.2005.03.037; Goytain A, 2007, J BIOL CHEM, V282, P8060, DOI 10.1074/jbc.M610314200; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; GUNTHER T, 1995, BBA-BIOMEMBRANES, V1234, P105, DOI 10.1016/0005-2736(94)00267-S; Gunthorpe MJ, 2001, J BIOL CHEM, V276, P10977, DOI 10.1074/jbc.M009575200; Hartwig A, 2001, MUTAT RES-FUND MOL M, V475, P113, DOI 10.1016/S0027-5107(01)00074-4; He Y, 2005, CIRC RES, V96, P207, DOI 10.1161/01.RES.0000152967.88472.3e; Hediger MA, 2004, PFLUG ARCH EUR J PHY, V447, P465, DOI 10.1007/s00424-003-1192-y; HMIEL SP, 1989, J BACTERIOL, V171, P4742, DOI 10.1128/jb.171.9.4742-4751.1989; Jin LH, 2007, BIOPHYS CHEM, V128, P185, DOI 10.1016/j.bpc.2007.04.005; Juttner R, 1998, BBA-BIOMEMBRANES, V1370, P51, DOI 10.1016/S0005-2736(97)00242-3; Kisters, 1999, Int J Angiol, V8, P154; Kolisek M, 2003, EMBO J, V22, P1235, DOI 10.1093/emboj/cdg122; Kucharski LM, 2000, J BIOL CHEM, V275, P16767, DOI 10.1074/jbc.M001507200; Meyer K, 1996, J GEN PHYSIOL, V108, P177, DOI 10.1085/jgp.108.3.177; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; NELSON DL, 1971, J BIOL CHEM, V246, P3042; Odblom MP, 1999, BIOCHEM BIOPH RES CO, V264, P334, DOI 10.1006/bbrc.1999.1490; QUAMME GA, 1990, BIOCHEM BIOPH RES CO, V167, P1406, DOI 10.1016/0006-291X(90)90679-H; REDDY MM, 1994, J MEMBRANE BIOL, V140, P57; Sahni J, 2007, BIOCHEM J, V401, P505, DOI 10.1042/BJ20060673; Saris NEL, 2000, CLIN CHIM ACTA, V294, P1, DOI 10.1016/S0009-8981(99)00258-2; Scheel O, 2005, NATURE, V436, P424, DOI [10.1038/nature03860, 10.1038/nature0386O]; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Schweigel M, 2006, AM J PHYSIOL-GASTR L, V290, pG56, DOI 10.1152/ajpgi.00014.2005; Schweigel M, 2000, AM J PHYSIOL-GASTR L, V278, pG400, DOI 10.1152/ajpgi.2000.278.3.G400; Schweigel M, 2003, AM J PHYSIOL-GASTR L, V285, pG45, DOI 10.1152/ajpgi.00396.2002; Smith RL, 1998, J BACTERIOL, V180, P2788, DOI 10.1128/JB.180.10.2788-2791.1998; SMITH RL, 1995, J BACTERIOL, V177, P1233, DOI 10.1128/jb.177.5.1233-1238.1995; SNAVELY MD, 1989, J BACTERIOL, V171, P4761, DOI 10.1128/jb.171.9.4761-4766.1989; SWAMY M, 2006, SCI STKE, V345, P14; TOWSEND DE, 1995, J BACTERIOL, V177, P5350; Urbanowski JL, 1999, J BIOL CHEM, V274, P38061, DOI 10.1074/jbc.274.53.38061; Wabakken T, 2003, BIOCHEM BIOPH RES CO, V306, P718, DOI 10.1016/S0006-291X(03)01030-1; WANG CY, 2004, GENE, V306, P37; WOLF FI, 1997, ADV MAGNESIUM RES S, V1, P490	48	94	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16235	16247		10.1074/jbc.M707276200	http://dx.doi.org/10.1074/jbc.M707276200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18367447	Green Published, hybrid			2022-12-25	WOS:000256332500082
J	Wang, L; Harris, TE; Lawrence, JC				Wang, Lifu; Harris, Thurl E.; Lawrence, John C., Jr.			Regulation of proline-rich Akt substrate of 40 kDa (PRAS40) function by mammalian target of rapamycin complex 1 (mTORC1)-mediated phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P70 S6 KINASE; MAMMALIAN TARGET; PHAS-I; RAPAMYCIN MTOR; INSULIN; PROTEIN; GROWTH; IDENTIFICATION; INHIBITOR; BINDING	The rapamycin-sensitive mammalian target of rapamycin (mTOR) complex 1 (mTORC1) contains mTOR, raptor, mLST8, and PRAS40 (proline-rich Akt substrate of 40 kDa). PRAS40 functions as a negative regulator when bound to mTORC1, and it dissociates from mTORC1 in response to insulin. PRAS40 has been demonstrated to be a substrate of mTORC1, and one phosphorylation site, Ser-183, has been identified. In this study, we used two-dimensional phosphopeptide mapping in conjunction with mutational analysis to show that in addition to Ser-183, mTORC1 also phosphorylates Ser-212 and Ser-221 in PRAS40 when assayed in vitro. Mutation of all three residues to Ala markedly reduces mTORC1-mediated phosphorylation of PRAS40 in vitro. All three sites were confirmed to be phosphorylated in vivo by [P-32] orthophosphate labeling and peptide mapping. Phosphorylation of Ser-221 and Ser-183 but not Ser-212 is sensitive to rapamycin treatment. Furthermore, we demonstrate that mutation of Ser-221 to Ala reduces the interaction with 14-3-3 to the same extent as mutation of Thr-246, the Akt/protein kinase B-phosphorylated site. We also find that mutation of Ser-221 to Ala increases the inhibitory activity of PRAS40 toward mTORC1. We propose that after mTORC1 kinase activation by upstream regulators, PRAS40 is phosphorylated directly by mTOR, thus contributing to the relief of PRAS40-mediated substrate competition.	[Wang, Lifu; Harris, Thurl E.; Lawrence, John C., Jr.] Univ Virginia, Dept Pharmacol, Charlottesville, VA 22908 USA	University of Virginia	Wang, L (corresponding author), Univ Virginia Hlth Syst, Dept Pharmacol, POB 800735,1300 Jefferson Pk Ave, Charlottesville, VA 22908 USA.	lw6j@virginia.edu	wang, lifu/E-1436-2012		NIDDK NIH HHS [DK52753, DK28312] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052753, R01DK028312] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; Burnett PE, 1998, P NATL ACAD SCI USA, V95, P1432, DOI 10.1073/pnas.95.4.1432; Choi KM, 2003, J BIOL CHEM, V278, P19667, DOI 10.1074/jbc.M301142200; Fonseca BD, 2007, J BIOL CHEM, V282, P24514, DOI 10.1074/jbc.M704406200; Hara K, 2002, CELL, V110, P177, DOI 10.1016/S0092-8674(02)00833-4; Harthill JE, 2002, BIOCHEM J, V368, P565, DOI 10.1042/BJ20020838; HU CB, 1994, P NATL ACAD SCI USA, V91, P3730, DOI 10.1073/pnas.91.9.3730; Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839; Kovacina KS, 2003, J BIOL CHEM, V278, P10189, DOI 10.1074/jbc.M210837200; LIN TA, 1995, J BIOL CHEM, V270, P18531, DOI 10.1074/jbc.270.31.18531; Lin Tai-An, 1994, Journal of Biological Chemistry, V269, P21255; Mackintosh C, 2004, BIOCHEM J, V381, P329, DOI 10.1042/BJ20031332; Madhunapantula SV, 2007, CANCER RES, V67, P3626, DOI 10.1158/0008-5472.CAN-06-4234; Manning BD, 2002, MOL CELL, V10, P151, DOI 10.1016/S1097-2765(02)00568-3; Mothe-Satney I, 2000, J BIOL CHEM, V275, P33836, DOI 10.1074/jbc.M006005200; Nascimento EBM, 2006, DIABETES, V55, P3221, DOI 10.2337/db05-1390; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Oshiro N, 2007, J BIOL CHEM, V282, P20329, DOI 10.1074/jbc.M702636200; SABERS CJ, 1995, J BIOL CHEM, V270, P815, DOI 10.1074/jbc.270.2.815; Saito A, 2004, J NEUROSCI, V24, P1584, DOI 10.1523/JNEUROSCI.5209-03.2004; Sancak Y, 2007, MOL CELL, V25, P903, DOI 10.1016/j.molcel.2007.03.003; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Scott PH, 1998, J BIOL CHEM, V273, P34496, DOI 10.1074/jbc.273.51.34496; Tee AR, 2002, MOL CELL BIOL, V22, P1674, DOI 10.1128/MCB.22.6.1674-1683.2002; Thedieck K, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001217; Vander Haar E, 2007, NAT CELL BIOL, V9, P316, DOI 10.1038/ncb1547; Wang LF, 2007, J BIOL CHEM, V282, P20036, DOI 10.1074/jbc.M702376200; Wang LF, 2006, J BIOL CHEM, V281, P24293, DOI 10.1074/jbc.M603566200; Wullschleger S, 2006, CELL, V124, P471, DOI 10.1016/j.cell.2006.01.016; Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64	30	139	142	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15619	15627		10.1074/jbc.M800723200	http://dx.doi.org/10.1074/jbc.M800723200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18372248	hybrid, Green Published			2022-12-25	WOS:000256332500015
J	Takaki, H; Ichiyama, K; Koga, K; Chinen, T; Takaesu, G; Sugiyama, Y; Kato, S; Yoshimura, A; Kobayashi, T				Takaki, Hiromi; Ichiyama, Kenji; Koga, Keiko; Chinen, Takatoshi; Takaesu, Giichi; Sugiyama, Yuki; Kato, Shigeaki; Yoshimura, Akihiko; Kobayashi, Takashi			STAT6 inhibits TGF-beta 1-mediated Foxp3 induction through direct binding to the Foxp3 promoter, which is reverted by retinoic acid receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REGULATORY T-CELLS; NF-KAPPA-B; TRANSCRIPTION FACTOR FOXP3; NECROSIS-FACTOR-ALPHA; GROWTH-FACTOR-BETA; TGF-BETA; INTERFERON-GAMMA; GENE-EXPRESSION; DENDRITIC CELLS; ORAL TOLERANCE	It has been shown that transforming growth factor beta (TGF-beta 1) is critical in the generation of CD4(+)CD25(+)Foxp3(+) -inducible regulatory T cells (iTregs) from naive CD4(+)T cells. However, in contrast to natural Tregs, TGF-beta 1-induced iTregs rapidly lose both Foxp3 expression and suppression activity. We found that TGF-beta 1-induced Foxp3 levelswere maintained by the addition of the anti-interleukin 4 (IL-4) antibody or by STAT6 gene deletion. Thus, IL-4 is an important suppressor of Foxp3 induction, and T helper 2 development is a major cause for the disappearance of iTreg during long culture. Using promoter analysis in EL4 cells and primary T cells, we identified a silencer region containing a STAT6 binding site. STAT6 binding to this site reduced TGF-beta 1-mediated Foxp3 promoter activation and chromatin modification. Retinoic acid has also been shown to suppress loss of Foxp3 induced by TGF-beta 1 Retinoic acid in the presence of TGF-beta 1 reduced STAT6 binding to the Foxp3 promoter and enhanced histone acetylation, thereby reverting the effect of IL-4. We propose that antagonistic agents for neutralizing IL-4 could be a novel strategy to facilitate inducible Treg cell generation and the promotion of tolerance in Th2-dominated diseases such as allergy.	[Takaki, Hiromi; Ichiyama, Kenji; Koga, Keiko; Chinen, Takatoshi; Takaesu, Giichi; Yoshimura, Akihiko; Kobayashi, Takashi] Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, Fukuoka 8128582, Japan; [Sugiyama, Yuki; Yoshimura, Akihiko] Keio Univ, Sch Med, Dept Microbiol & Immunol, Shinjuku Ku, Tokyo 1608582, Japan; [Kato, Shigeaki] Univ Tokyo, Inst Mol & Cellular Biosci, Bunkyo Ku, Tokyo 1130032, Japan	Kyushu University; Keio University; University of Tokyo	Yoshimura, A (corresponding author), Kyushu Univ, Med Inst Bioregulat, Div Mol & Cellular Immunol, Higashi Ku, 3-1-1 Maidashi, Fukuoka 8128582, Japan.	yakihiko@bioreg.kyushu-u.ac.jp; takashik@bioreg.kyushu-u.ac.jp	Yoshimura, Akihiko/K-5515-2013	Ichiyama, Kenji/0000-0002-3340-9799; Takaesu, Giichi/0000-0002-1581-1055				Apostolou I, 2004, J EXP MED, V199, P1401, DOI 10.1084/jem.20040249; Baron U, 2007, EUR J IMMUNOL, V37, P2378, DOI 10.1002/eji.200737594; Bennett BL, 1997, J BIOL CHEM, V272, P10212; Benson MJ, 2007, J EXP MED, V204, P1765, DOI 10.1084/jem.20070719; Bettelli E, 2006, NATURE, V441, P235, DOI 10.1038/nature04753; Chen WJ, 2003, J EXP MED, V198, P1875, DOI 10.1084/jem.20030152; Chen YH, 1996, P NATL ACAD SCI USA, V93, P388, DOI 10.1073/pnas.93.1.388; CLARKE CJP, 1995, EUR J IMMUNOL, V25, P2961, DOI 10.1002/eji.1830251037; Coombes JL, 2007, J EXP MED, V204, P1757, DOI 10.1084/jem.20070590; Davidson TS, 2007, J IMMUNOL, V178, P4022, DOI 10.4049/jimmunol.178.7.4022; Du X, 2005, EUR J IMMUNOL, V35, P3414, DOI 10.1002/eji.200535366; Floess S, 2007, PLOS BIOL, V5, P169, DOI 10.1371/journal.pbio.0050038; Fu S, 2004, AM J TRANSPLANT, V4, P1614, DOI 10.1111/j.1600-6143.2004.00566.x; Hiroi M, 2003, J BIOL CHEM, V278, P651, DOI 10.1074/jbc.M204544200; Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490; Inobe J, 1998, EUR J IMMUNOL, V28, P2780, DOI 10.1002/(SICI)1521-4141(199809)28:09<2780::AID-IMMU2780>3.0.CO;2-J; Joo A, 2004, ONCOGENE, V23, P726, DOI 10.1038/sj.onc.1207174; Kim HP, 2007, J EXP MED, V204, P1543, DOI 10.1084/jem.20070109; Kinjyo I, 2006, J EXP MED, V203, P1021, DOI 10.1084/jem.20052333; Matsumura Y, 2007, J IMMUNOL, V179, P2170, DOI 10.4049/jimmunol.179.4.2170; Mucida D, 2007, SCIENCE, V317, P256, DOI 10.1126/science.1145697; Nakamura K, 2001, J EXP MED, V194, P629, DOI 10.1084/jem.194.5.629; Nelson BH, 2004, J IMMUNOL, V172, P3983, DOI 10.4049/jimmunol.172.7.3983; Nozaki Y, 2006, RHEUMATOL INT, V26, P810, DOI 10.1007/s00296-005-0076-1; Park IK, 2005, J IMMUNOL, V175, P5666, DOI 10.4049/jimmunol.175.9.5666; Roncarolo MG, 2006, IMMUNOL REV, V212, P28; Schambach F, 2007, EUR J IMMUNOL, V37, P2396, DOI 10.1002/eji.200737621; Schwartz RH, 2005, NAT IMMUNOL, V6, P327, DOI 10.1038/ni1184; Seder RA, 1998, J IMMUNOL, V160, P5719; Selvaraj RK, 2007, J IMMUNOL, V178, P7667, DOI 10.4049/jimmunol.178.12.7667; Sun CM, 2007, J EXP MED, V204, P1775, DOI 10.1084/jem.20070602; Takeyama K, 1996, BIOCHEM BIOPH RES CO, V222, P395, DOI 10.1006/bbrc.1996.0755; Taniguchi K, 2007, MOL CELL BIOL, V27, P4541, DOI 10.1128/MCB.01600-06; Tone Y, 2008, NAT IMMUNOL, V9, P194, DOI 10.1038/ni1549; VELDE AAT, 1990, J IMMUNOL, V144, P3046; Wang R, 2005, J BIOL CHEM, V280, P11528, DOI 10.1074/jbc.M413930200; Wei J, 2007, P NATL ACAD SCI USA, V104, P18169, DOI 10.1073/pnas.0703642104; Yao Z, 2007, BLOOD, V109, P4368, DOI 10.1182/blood-2006-11-055756; Zheng SG, 2004, J IMMUNOL, V172, P5213, DOI 10.4049/jimmunol.172.9.5213	39	121	129	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					14955	14962		10.1074/jbc.M801123200	http://dx.doi.org/10.1074/jbc.M801123200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18400747	Green Published, hybrid			2022-12-25	WOS:000256232000007
J	Friedmann, DR; Wilson, JJ; Kovall, RA				Friedmann, David R.; Wilson, Jeffrey J.; Kovall, Rhett A.			RAM-induced allostery facilitates assembly of a Notch pathway active transcription complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							T-CELL LEUKEMIA; CRYSTAL-STRUCTURE; ANKYRIN REPEAT; CSL; MASTERMIND; ACTIVATION; PROTEINS; DOMAINS; ROLES; TURNOVER	The Notch pathway is a conserved cell-to-cell signaling mechanism, in which extracellular signals are transduced into transcriptional outputs through the nuclear effector CSL. CSL is converted from a repressor to an activator through the formation of the CSL-NotchIC-Mastermind ternary complex. The RAM (RBP-J associated molecule) domain of NotchIC avidly interacts with CSL; however, its role in assembly of the CSL-NotchIC-Mastermind ternary complex is not understood. Here we provide a comprehensive thermodynamic, structural, and biochemical analysis of the RAM-CSL interaction for components from both mouse and worm. Our binding data show that RAM and CSL form a high affinity complex in the presence or absence of DNA. Our structural studies reveal a striking distal conformational change in CSL upon RAM binding, which creates a docking site for Mastermind to bind to the complex. Finally, we show that the addition of a RAM peptide in trans facilitates formation of the CSL-NotchIC-Mastermind ternary complex in vitro.	[Friedmann, David R.; Wilson, Jeffrey J.; Kovall, Rhett A.] Univ Cincinnati, Coll Med, Dept Mol Genet Biochem & Microbiol, Cincinnati, OH 45267 USA	University System of Ohio; University of Cincinnati	Kovall, RA (corresponding author), 231 Albert Sabin Way,MSB3102, Cincinnati, OH 45267 USA.	kovallra@ucmail.uc.edu	Kovall, Rhett/A-3106-2008		NATIONAL CANCER INSTITUTE [R01CA120199] Funding Source: NIH RePORTER; NCI NIH HHS [CA 120199] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Aster JC, 2000, MOL CELL BIOL, V20, P7505, DOI 10.1128/MCB.20.20.7505-7515.2000; Bertagna A, 2008, BIOCHEM SOC T, V36, P157, DOI 10.1042/BST0360157; Bonde J, 2004, CURR OPIN HEMATOL, V11, P392, DOI 10.1097/01.moh.0000145672.42503.70; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Del Bianco C, 2008, J MOL BIOL, V376, P131, DOI 10.1016/j.jmb.2007.11.061; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014; Fryer CJ, 2002, GENE DEV, V16, P1397, DOI 10.1101/gad.991602; Garg V, 2005, NATURE, V437, P270, DOI 10.1038/nature03940; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; Gridley T, 2003, HUM MOL GENET, V12, pR9, DOI 10.1093/hmg/ddg052; JARRIAULT S, 1995, NATURE, V377, P355, DOI 10.1038/377355a0; Jeffries S, 2002, MOL CELL BIOL, V22, P3927, DOI 10.1128/MCB.22.11.3927-3941.2002; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kovall RA, 2004, EMBO J, V23, P3441, DOI 10.1038/sj.emboj.7600349; Kovall RA, 2007, CURR OPIN STRUC BIOL, V17, P117, DOI 10.1016/j.sbi.2006.11.004; Krejci A, 2007, GENE DEV, V21, P1322, DOI 10.1101/gad.424607; Kurooka H, 1998, NUCLEIC ACIDS RES, V26, P5448, DOI 10.1093/nar/26.23.5448; Lai EC, 2002, EMBO REP, V3, P840, DOI 10.1093/embo-reports/kvf170; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Leong KG, 2006, BLOOD, V107, P2223, DOI 10.1182/blood-2005-08-3329; Lubman OY, 2007, J MOL BIOL, V365, P577, DOI 10.1016/j.jmb.2006.09.071; Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037; Nam Y, 2003, J BIOL CHEM, V278, P21232, DOI 10.1074/jbc.M301567200; Nam YS, 2007, P NATL ACAD SCI USA, V104, P2103, DOI 10.1073/pnas.0611092104; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Petcherski AG, 2000, NATURE, V405, P364, DOI 10.1038/35012645; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Roehl H, 1996, EMBO J, V15, P7002, DOI 10.1002/j.1460-2075.1996.tb01092.x; Tamura K, 1995, CURR BIOL, V5, P1416, DOI 10.1016/S0960-9822(95)00279-X; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Wallberg AE, 2002, MOL CELL BIOL, V22, P7812, DOI 10.1128/MCB.22.22.7812-7819.2002; Wilson JJ, 2006, CELL, V124, P985, DOI 10.1016/j.cell.2006.01.035; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wu LZ, 2000, NAT GENET, V26, P484, DOI 10.1038/82644; Wyman J, 1990, BINDING LINKAGE FUNC; Zhou SF, 2000, MOL CELL BIOL, V20, P2400, DOI 10.1128/MCB.20.7.2400-2410.2000	39	69	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14781	14791		10.1074/jbc.M709501200	http://dx.doi.org/10.1074/jbc.M709501200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18381292	Green Published, hybrid			2022-12-25	WOS:000255941400066
J	Sachidanandan, C; Yeh, JRJ; Peterson, QP; Peterson, RT				Sachidanandan, Chetana; Yeh, Jing-Ruey J.; Peterson, Quinn P.; Peterson, Randall T.			Identification of a Novel Retinoid by Small Molecule Screening with Zebrafish Embryos	PLOS ONE			English	Article							HEDGEHOG SIGNALING PATHWAY; ACID RECEPTORS; CANCER; HINDBRAIN; GENETICS; PATTERN; TARGET; GENES; DIFFERENTIATION; SPECIFICATION	Small molecules have played an important role in delineating molecular pathways involved in embryonic development and disease pathology. The need for novel small molecule modulators of biological processes has driven a number of targeted screens on large diverse libraries. However, due to the specific focus of such screens, the majority of the bioactive potential of these libraries remains unharnessed. In order to identify a higher proportion of compounds with interesting biological activities, we screened a diverse synthetic library for compounds that perturb the development of any of the multiple organs in zebrafish embryos. We identified small molecules that affect the development of a variety of structures such as heart, vasculature, brain, and body-axis. We utilized the previously known role of retinoic acid in anterior-posterior (A-P) patterning to identify the target of DTAB, a compound that caused A-P axis shortening in the zebrafish embryo. We show that DTAB is a retinoid with selective activity towards retinoic acid receptors gamma and beta. Thus, conducting zebrafish developmental screens using small molecules will not only enable the identification of compounds with diverse biological activities in a large chemical library but may also facilitate the identification of the target pathways of these biologically active molecules.	[Sachidanandan, Chetana; Yeh, Jing-Ruey J.; Peterson, Quinn P.; Peterson, Randall T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA	Harvard University; Massachusetts General Hospital	Peterson, RT (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA.	peterson@cvrc.mgh.harvard.edu		Peterson, Quinn/0000-0001-8701-0575; Yeh, Jing-Ruey Joanna/0000-0002-7768-4901; Peterson, Randall/0000-0003-0727-3469	Novartis Institutes for Biomedical Research NIH - NHLBI [HL079267]; Postdoctoral Fellowship from Massachusetts General Hospital Fund for Medical Discovery; Tosteson Fellowship from the Massachusetts Biomedical Research Corporation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL079267] Funding Source: NIH RePORTER	Novartis Institutes for Biomedical Research NIH - NHLBI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Postdoctoral Fellowship from Massachusetts General Hospital Fund for Medical Discovery; Tosteson Fellowship from the Massachusetts Biomedical Research Corporation; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Funding for R.T.P. from Sponsored Research Agreement from Novartis Institutes for Biomedical Research NIH - NHLBI HL079267. C.S. was supported by Postdoctoral Fellowship from Massachusetts General Hospital Fund for Medical Discovery. J.-R.J.Y. was supported by a Tosteson Fellowship from the Massachusetts Biomedical Research Corporation. None of the funders played any role in the conduct, interpretation, preparation, or approval of the manuscript.	Aerne B, 2004, DEVELOPMENT, V131, P3391, DOI 10.1242/dev.01222; Altucci L, 2001, NAT REV CANCER, V1, P181, DOI 10.1038/35106036; Altucci L, 2007, NAT REV DRUG DISCOV, V6, P793, DOI 10.1038/nrd2397; Asou N, 2007, INTERNAL MED, V46, P91, DOI 10.2169/internalmedicine.46.1780; Bastien J, 2004, GENE, V328, P1, DOI 10.1016/j.gene.2003.12.005; Begemann G, 2001, DEVELOPMENT, V128, P3081; Begemann G, 2001, BIOESSAYS, V23, P981, DOI 10.1002/bies.1142; Chandraratna RAS, 1997, J AM ACAD DERMATOL, V37, pS12, DOI 10.1016/S0190-9622(97)80395-7; Clagett-Dame M, 2002, ANNU REV NUTR, V22, P347, DOI 10.1146/annurev.nutr.22.010402.102745E; Diez del Corral R, 2003, NEURON, V40, P65; Dobbs-McAuliffe B, 2004, MECH DEVELOP, V121, P339, DOI 10.1016/j.mod.2004.02.008; Emoto Y, 2005, DEV BIOL, V278, P415, DOI 10.1016/j.ydbio.2004.11.023; Holmes WF, 2000, J CELL PHYSIOL, V185, P61, DOI 10.1002/1097-4652(200010)185:1<61::AID-JCP5>3.0.CO;2-0; Katano M, 2005, CANCER LETT, V227, P99, DOI 10.1016/j.canlet.2004.11.030; Katoh Y, 2005, CANCER BIOL THER, V4, P1050, DOI 10.4161/cbt.4.10.2184; Kawasumi M, 2007, J INVEST DERMATOL, V127, P1577, DOI 10.1038/sj.jid.5700853; KEELER RF, 1968, TERATOLOGY, V1, P5, DOI 10.1002/tera.1420010103; Langdon SP, 1998, CANCER CHEMOTH PHARM, V42, P429, DOI 10.1007/s002800050841; MacRae CA, 2003, CHEM BIOL, V10, P901, DOI 10.1016/j.chembiol.2003.10.003; MANGELSDORF DJ, 1992, GENE DEV, V6, P329, DOI 10.1101/gad.6.3.329; Mark M, 2006, ANNU REV PHARMACOL, V46, P451, DOI 10.1146/annurev.pharmtox.46.120604.141156; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Mullins MC, 1996, DEVELOPMENT, V123, P81; Njar VCO, 2006, BIOORGAN MED CHEM, V14, P4323, DOI 10.1016/j.bmc.2006.02.041; Ortholand JY, 2004, CURR OPIN CHEM BIOL, V8, P271, DOI 10.1016/j.cbpa.2004.04.011; Purton LE, 2006, J EXP MED, V203, P1283, DOI 10.1084/jem.20052105; REES J, 1992, BRIT J DERMATOL, V126, P97, DOI 10.1111/j.1365-2133.1992.tb07804.x; Robert B, 2006, DEV DYNAM, V235, P2337, DOI 10.1002/dvdy.20890; Ross AC, 2003, J NUTR, V133, p291S, DOI 10.1093/jn/133.1.291S; Savchuk NP, 2004, CURR OPIN CHEM BIOL, V8, P412, DOI 10.1016/j.cbpa.2004.06.003; Schier AF, 2005, ANNU REV GENET, V39, P561, DOI 10.1146/annurev.genet.37.110801.143752; Schreiber SL, 2000, SCIENCE, V287, P1964, DOI 10.1126/science.287.5460.1964; SCHULTEMERKER S, 1994, DEVELOPMENT, V120, P843; Shaw A, 2007, J UROLOGY, V177, P832, DOI 10.1016/j.juro.2006.10.061; Stadler R, 2006, SEMIN ONCOL, V33, pS7, DOI 10.1053/j.seminoncol.2005.12.016; Thisse B., 2001, EXPRESSION ZEBRAFISH; Wagner M, 2007, EXP BIOL MED, V232, P866; Walkley CR, 2007, CELL, V129, P1097, DOI 10.1016/j.cell.2007.05.014; Weindl G, 2006, AM J CLIN DERMATOL, V7, P85, DOI 10.2165/00128071-200607020-00002; Xavier-Neto J, 2001, GENESIS, V31, P97, DOI 10.1002/gene.10009; YU PB, 2008, NAT CHEM BI IN PRESS	41	50	52	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1947	10.1371/journal.pone.0001947	http://dx.doi.org/10.1371/journal.pone.0001947			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398471	gold, Green Published, Green Submitted			2022-12-25	WOS:000260795500022
J	Shamgar, L; Haitin, Y; Yisharel, I; Malka, E; Schottelndreier, H; Peretz, A; Paas, Y; Attali, B				Shamgar, Liora; Haitin, Yoni; Yisharel, Ilanit; Malka, Eti; Schottelndreier, Hella; Peretz, Asher; Paas, Yoav; Attali, Bernard			KCNE1 Constrains the Voltage Sensor of Kv7.1 K+ Channels	PLOS ONE			English	Article								Kv7 potassium channels whose mutations cause cardiovascular and neurological disorders are members of the superfamily of voltage-gated K+ channels, comprising a central pore enclosed by four voltage-sensing domains (VSDs) and sharing a homologous S4 sensor sequence. The Kv7.1 pore-forming subunit can interact with various KCNE auxiliary subunits to form K+ channels with very different gating behaviors. In an attempt to characterize the nature of the promiscuous gating of Kv7.1 channels, we performed a tryptophan-scanning mutagenesis of the S4 sensor and analyzed the mutation-induced perturbations in gating free energy. Perturbing the gating energetics of Kv7.1 bias most of the mutant channels towards the closed state, while fewer mutations stabilize the open state or the inactivated state. In the absence of auxiliary subunits, mutations of specific S4 residues mimic the gating phenotypes produced by co-assembly of Kv7.1 with either KCNE1 or KCNE3. Many S4 perturbations compromise the ability of KCNE1 to properly regulate Kv7.1 channel gating. The tryptophan-induced packing perturbations and cysteine engineering studies in S4 suggest that KCNE1 lodges at the inter-VSD S4-S1 interface between two adjacent subunits, a strategic location to exert its striking action on Kv7.1 gating functions.	[Shamgar, Liora; Haitin, Yoni; Yisharel, Ilanit; Malka, Eti; Schottelndreier, Hella; Peretz, Asher; Attali, Bernard] Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; [Paas, Yoav] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Ramat Gan, Israel	Tel Aviv University; Sackler Faculty of Medicine; Bar Ilan University	Attali, B (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.	battali@post.tau.ac.il	Haitin, Yoni/AAQ-4571-2021	Haitin, Yoni/0000-0002-1648-6792	Israel Science Foundation [ISF 672/05]; Israel Ministry of Science Tashtiot program; Keren Wolfson Family funds	Israel Science Foundation(Israel Science Foundation); Israel Ministry of Science Tashtiot program; Keren Wolfson Family funds	This work is supported by the Israel Science Foundation (ISF 672/05), the Israel Ministry of Science Tashtiot program (2007 2009) and the Keren Wolfson Family funds to BA.	Abbott GW, 1998, Q REV BIOPHYS, V31, P357, DOI 10.1017/S0033583599003467; Ashcroft FM, 2000, ION CHANNELS DIS; Attali B, 1996, NATURE, V384, P24, DOI 10.1038/384024a0; Barhanin J, 1996, NATURE, V384, P78, DOI 10.1038/384078a0; Chen YH, 2003, SCIENCE, V299, P251, DOI 10.1126/science.1077771; Franqueza L, 1999, J BIOL CHEM, V274, P21063, DOI 10.1074/jbc.274.30.21063; Gibor G, 2007, BIOPHYS J, V93, P4159, DOI 10.1529/biophysj.107.107987; Jentsch TJ, 2000, NAT REV NEUROSCI, V1, P21, DOI 10.1038/35036198; Jentsch TJ, 2004, NAT CELL BIOL, V6, P1039, DOI 10.1038/ncb1104-1039; Li-Smerin YY, 2000, J GEN PHYSIOL, V115, P33, DOI 10.1085/jgp.115.1.33; LOPEZ GA, 1991, NEURON, V7, P327, DOI 10.1016/0896-6273(91)90271-Z; Melman YF, 2002, TRENDS CARDIOVAS MED, V12, P182, DOI 10.1016/S1050-1738(02)00158-5; Melman YF, 2004, NEURON, V42, P927, DOI 10.1016/j.neuron.2004.06.001; Nakajo K, 2007, J GEN PHYSIOL, V130, P269, DOI 10.1085/jgp.200709805; Nerbonne JM, 2005, PHYSIOL REV, V85, P1205, DOI 10.1152/physrev.00002.2005; Panaghie G, 2007, J GEN PHYSIOL, V129, P121, DOI 10.1085/jgp.200609612; PAPAZIAN DM, 1991, NATURE, V349, P305, DOI 10.1038/349305a0; Robbins J, 2001, PHARMACOL THERAPEUT, V90, P1, DOI 10.1016/S0163-7258(01)00116-4; Rocheleau JM, 2008, J GEN PHYSIOL, V131, P59, DOI 10.1085/jgp.200709816; Sanguinetti MC, 1996, NATURE, V384, P80, DOI 10.1038/384080a0; Schroeder BC, 2000, NATURE, V403, P196, DOI 10.1038/35003200; Shamgar L, 2006, CIRC RES, V98, P1055, DOI 10.1161/01.RES.0000218979.40770.69; Swartz KJ, 2004, NAT REV NEUROSCI, V5, P905, DOI 10.1038/nrn1559; Tapper AR, 2001, J BIOL CHEM, V276, P38249; Tinel N, 2000, EMBO J, V19, P6326, DOI 10.1093/emboj/19.23.6326; Wang KW, 1996, NEURON, V16, P571, DOI 10.1016/S0896-6273(00)80076-8; Yellen G, 2002, NATURE, V419, P35, DOI 10.1038/nature00978	27	34	34	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1943	10.1371/journal.pone.0001943	http://dx.doi.org/10.1371/journal.pone.0001943			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398469	Green Published, gold, Green Submitted			2022-12-25	WOS:000260795500020
J	Lal, A; Kim, HH; Abdelmohsen, K; Kuwano, Y; Pullmann, R; Srikantan, S; Subrahmanyam, R; Martindale, JL; Yang, XL; Ahmed, F; Navarro, F; Dykxhoorn, D; Lieberman, J; Gorospe, M				Lal, Ashish; Kim, Hyeon Ho; Abdelmohsen, Kotb; Kuwano, Yuki; Pullmann, Rudolf; Srikantan, Subramanya; Subrahmanyam, Ramesh; Martindale, Jennifer L.; Yang, Xiaoling; Ahmed, Fariyal; Navarro, Francisco; Dykxhoorn, Derek; Lieberman, Judy; Gorospe, Myriam			p16(INK4a) Translation Suppressed by miR-24	PLOS ONE			English	Article							TUMOR-SUPPRESSOR; MESSENGER-RNA; REPLICATIVE SENESCENCE; EXPRESSION; MICRORNA; INITIATION; PROTEINS; REPRESSION; INK4A/ARF; INK4/ARF	Background: Expression of the tumor suppressor p16(INK4a) increases during aging and replicative senescence. Methodology/Principal Findings: Here, we report that the microRNA miR-24 suppresses p16 expression in human diploid fibroblasts and cervical carcinoma cells. Increased p16 expression with replicative senescence was associated with decreased levels of miR-24, a microRNA that was predicted to associate with the p16 mRNA coding and 3'-untranslated regions. Ectopic miR-24 overexpression reduced p16 protein but not p16 mRNA levels. Conversely, introduction of antisense (AS)-miR-24 blocked miR-24 expression and markedly enhanced p16 protein levels, p16 translation, and the production of EGFP-p16 reporter bearing the miR-24 target recognition sites. Conclusions/Significance: Together, our results suggest that miR-24 represses the initiation and elongation phases of p16 translation.	[Lal, Ashish; Kim, Hyeon Ho; Abdelmohsen, Kotb; Kuwano, Yuki; Pullmann, Rudolf; Srikantan, Subramanya; Subrahmanyam, Ramesh; Martindale, Jennifer L.; Yang, Xiaoling; Gorospe, Myriam] NIA, IRP, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA; [Lal, Ashish; Ahmed, Fariyal; Navarro, Francisco; Dykxhoorn, Derek; Lieberman, Judy] Harvard Med Sch, CBR Inst Biomed Res, Dept Pediat, Boston, MA USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School	Lal, A (corresponding author), NIA, IRP, Cellular & Mol Biol Lab, NIH, Baltimore, MD 21224 USA.	alal@cbrinstitute.org; myriam-gorospe@nih.gov	Martindale, Jennifer Luethy/AAD-1963-2022; Lieberman, Judy/A-2717-2015; Dykxhoorn, Derek M/D-1357-2015; Subrahmanyam, Ramesh/K-5503-2012; Abdelmohsen, Kotb/AAX-4191-2020	Martindale, Jennifer Luethy/0000-0002-3234-6861; Abdelmohsen, Kotb/0000-0001-6240-5810; srikantan, subramanya/0000-0003-1810-6519	National Institute on Aging - Intramural Research Program; NATIONAL INSTITUTE ON AGING [Z01AG000391, Z01AG000394, ZIAAG000391, ZIAAG000511, ZIAAG000394, Z01AG000511] Funding Source: NIH RePORTER	National Institute on Aging - Intramural Research Program(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	National Institute on Aging - Intramural Research Program	Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Alcorta DA, 1996, P NATL ACAD SCI USA, V93, P13742, DOI 10.1073/pnas.93.24.13742; Anderson P, 2006, J CELL BIOL, V172, P803, DOI 10.1083/jcb.200512082; Ben-Saadon R, 2004, J BIOL CHEM, V279, P41414, DOI 10.1074/jbc.M407201200; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Carmell MA, 2002, GENE DEV, V16, P2733, DOI 10.1101/gad.1026102; Chendrimada TP, 2007, NATURE, V447, P823, DOI 10.1038/nature05841; Easow G, 2007, RNA, V13, P1198, DOI 10.1261/rna.563707; Eulalio A, 2007, NAT REV MOL CELL BIO, V8, P9, DOI 10.1038/nrm2080; Filipowicz W, 2008, NAT REV GENET, V9, P102, DOI 10.1038/nrg2290; GEORGE AD, 2006, RNA BIOL, V3, P2; Gonzalez S, 2006, NATURE, V440, P702, DOI 10.1038/nature04585; HAYFLICK L, 1965, EXP CELL RES, V37, P614, DOI 10.1016/0014-4827(65)90211-9; Humphreys DT, 2005, P NATL ACAD SCI USA, V102, P16961, DOI 10.1073/pnas.0506482102; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Jacobs JJL, 1999, GENE DEV, V13, P2678, DOI 10.1101/gad.13.20.2678; Kim WY, 2006, CELL, V127, P265, DOI 10.1016/j.cell.2006.10.003; Krishnamurthty J, 2004, J CLIN INVEST, V114, P1299, DOI 10.1172/JCI200422475; Lal A, 2005, EMBO J, V24, P1852, DOI 10.1038/sj.emboj.7600661; McConnell BB, 1998, CURR BIOL, V8, P351, DOI 10.1016/S0960-9822(98)70137-X; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Moore MJ, 2005, SCIENCE, V309, P1514, DOI 10.1126/science.1111443; Nielsen GP, 1999, LAB INVEST, V79, P1137; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Olsen PH, 1999, DEV BIOL, V216, P671, DOI 10.1006/dbio.1999.9523; Passegue E, 2000, EMBO J, V19, P2969, DOI 10.1093/emboj/19.12.2969; Petersen CP, 2006, MOL CELL, V21, P533, DOI 10.1016/j.molcel.2006.01.031; Pillai RS, 2007, TRENDS CELL BIOL, V17, P118, DOI 10.1016/j.tcb.2006.12.007; Reed R, 2003, CURR OPIN CELL BIOL, V15, P326, DOI 10.1016/S0955-0674(03)00048-6; Seggerson K, 2002, DEV BIOL, V243, P215, DOI 10.1006/dbio.2001.0563; Serrano M, 1997, EXP CELL RES, V237, P7, DOI 10.1006/excr.1997.3824; Shapiro GI, 2000, CELL BIOCHEM BIOPHYS, V33, P189, DOI 10.1385/CBB:33:2:189; Sharpless NE, 2005, MUTAT RES-FUND MOL M, V576, P22, DOI 10.1016/j.mrfmmm.2004.08.021; Sheth U, 2003, SCIENCE, V300, P805, DOI 10.1126/science.1082320; Thermann R, 2007, NATURE, V447, P875, DOI 10.1038/nature05878; Valencia-Sanchez MA, 2006, GENE DEV, V20, P515, DOI 10.1101/gad.1399806; Wang WG, 2005, EMBO REP, V6, P158, DOI 10.1038/sj.embor.7400346; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Zhu DG, 2002, J CELL PHYSIOL, V193, P19, DOI 10.1002/jcp.10147; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	40	209	222	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1864	10.1371/journal.pone.0001864	http://dx.doi.org/10.1371/journal.pone.0001864			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365017	gold, Green Submitted, Green Published			2022-12-25	WOS:000260762400023
J	Proulx, MJ; Stoerig, P; Ludowig, E; Knoll, I				Proulx, Michael J.; Stoerig, Petra; Ludowig, Eva; Knoll, Inna			Seeing 'Where' through the Ears: Effects of Learning-by-Doing and Long-Term Sensory Deprivation on Localization Based on Image-to-Sound Substitution	PLOS ONE			English	Article							AUDITORY SUBSTITUTION; CORTEX; BLIND; PLASTICITY; PERCEPTION; SYSTEM	Background: Sensory substitution devices for the blind translate inaccessible visual information into a format that intact sensory pathways can process. We here tested image-to-sound conversion-based localization of visual stimuli (LEDs and objects) in 13 blindfolded participants. Methods and Findings: Subjects were assigned to different roles as a function of two variables: visual deprivation (blindfolded continuously (Bc) for 24 hours per day for 21 days; blindfolded for the tests only (Bt)) and system use (system not used (Sn); system used for tests only (St); system used continuously for 21 days (Sc)). The effect of learning-by-doing was assessed by comparing the performance of eight subjects (BtSt) who only used the mobile substitution device for the tests, to that of three subjects who, in addition, practiced with it for four hours daily in their normal life (BtSc and BcSc); two subjects who did not use the device at all (BtSn and BcSn) allowed assessment of its use in the tasks we employed. The impact of long-term sensory deprivation was investigated by blindfolding three of those participants throughout the three week-long experiment (BcSn, BcSn/c, and BcSc); the other ten subjects were only blindfolded during the tests (BtSn, BtSc, and the eight BtSt subjects). Expectedly, the two subjects who never used the substitution device, while fast in finding the targets, had chance accuracy, whereas subjects who used the device were markedly slower, but showed much better accuracy which improved significantly across our four testing sessions. The three subjects who freely used the device daily as well as during tests were faster and more accurate than those who used it during tests only; however, long-term blindfolding did not notably influence performance. Conclusions: Together, the results demonstrate that the device allowed blindfolded subjects to increasingly know where something was by listening, and indicate that practice in naturalistic conditions effectively improved "visual'' localization performance.	[Proulx, Michael J.; Stoerig, Petra; Ludowig, Eva; Knoll, Inna] Univ Dusseldorf, Inst Expt Psychol, Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Proulx, MJ (corresponding author), Univ Dusseldorf, Inst Expt Psychol, Dusseldorf, Germany.	Michael.Proulx@uni-duesseldorf.de	Proulx, Michael J/A-1045-2008	Proulx, Michael/0000-0003-4066-3645	Volkswagen Stiftung [I/80 742]; Anton-Betz-Stiftung	Volkswagen Stiftung(Volkswagen); Anton-Betz-Stiftung	We gratefully acknowledge financial support by the Volkswagen Stiftung (I/80 742) and the Anton-Betz-Stiftung. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Amedi A, 2005, CURR DIR PSYCHOL SCI, V14, P306, DOI 10.1111/j.0963-7214.2005.00387.x; Arno P, 1999, PERCEPTION, V28, P1013, DOI 10.1068/p2607; Auvray M, 2007, PERCEPTION, V36, P416, DOI 10.1068/p5631; Bach-y-Rita P, 2003, TRENDS COGN SCI, V7, P541, DOI 10.1016/j.tics.2003.10.013; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd ed., DOI DOI 10.4324/9780203771587; Cronly-Dillon J, 2000, P ROY SOC B-BIOL SCI, V267, P2231, DOI 10.1098/rspb.2000.1273; Cronly-Dillon J, 1999, P ROY SOC B-BIOL SCI, V266, P2427, DOI 10.1098/rspb.1999.0942; Kauffman T, 2002, NEUROREPORT, V13, P571, DOI 10.1097/00001756-200204160-00007; Killeen PR, 2005, PSYCHOL SCI, V16, P345, DOI 10.1111/j.0956-7976.2005.01538.x; Lessard N, 1998, NATURE, V395, P278, DOI 10.1038/26228; Marr D., 1982, Vision. A computational investigation into the human representation and processing of visual information; MEIJER PBL, 1992, IEEE T BIO-MED ENG, V39, P112, DOI 10.1109/10.121642; Pascual-Leone A, 2001, PROG BRAIN RES, V134, P427; Poirier C, 2006, APPL COGNITIVE PSYCH, V20, P447, DOI 10.1002/acp.1186; Pollok B, 2005, EXP BRAIN RES, V167, P287, DOI 10.1007/s00221-005-0060-8; Ptito M, 2005, BRAIN, V128, P606, DOI 10.1093/brain/awh380; Renier L, 2005, NEUROIMAGE, V26, P573, DOI 10.1016/j.neuroimage.2005.01.047; Segond H, 2005, PERCEPTION, V34, P1231, DOI 10.1068/p3409	18	57	57	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1840	10.1371/journal.pone.0001840	http://dx.doi.org/10.1371/journal.pone.0001840			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	370KZ	18364998	Green Published, gold, Green Submitted			2022-12-25	WOS:000260762400004
J	Frohlich, DA; McCabe, MT; Arnold, RS; Day, ML				Frohlich, D. A.; McCabe, M. T.; Arnold, R. S.; Day, M. L.			The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis	ONCOGENE			English	Article						tumorigenesis; Nrf2; oxidative stress; prostate cancer; DNA damage	GLUTATHIONE-S-TRANSFERASE; GENE-EXPRESSION; INTRAEPITHELIAL NEOPLASIA; OXIDATIVE STRESS; RESPONSE ELEMENT; ENZYME INDUCERS; CANCER; CARCINOGENESIS; MICE; REVEALS	The impact of oxidative stress in human cancer has been extensively studied. It is accepted that elevated reactive oxygen species (ROS) promote mutagenic DNA damage. Even with an extensive armament of cellular antioxidants and detoxification enzymes, alterations to DNA occur that initiate cellular transformation. Erythroid 2p45 (NFE2)-related factor 2 (Nrf2) is a basic-region leucine zipper transcription factor that mediates the expression of key protective enzymes through the antioxidant-response element (ARE). By analysing 10 human prostate cancer microarray data sets, we have determined that Nrf2 and members of the glutathione-S-transferase (GST) mu family are extensively decreased in human prostate cancer. Using the TRAMP transgene and Rb and Nrf2 knockout murine models, we demonstrated that the loss of Nrf2 initiates a detrimental cascade of reduced GST expression, elevated ROS levels and ultimately DNA damage associated with tumorigenesis. Based on overwhelming data from clinical samples and the current functional analysis, we propose that the disruption of the Nrf2-antioxidant axis leads to increased oxidative stress and DNA damage in the initiation of cellular transformation in the prostate gland.	[Frohlich, D. A.; Day, M. L.] Univ Michigan, UMCC, Dept Urol, Ann Arbor, MI 48109 USA; [McCabe, M. T.] Emory Univ, Sch Med, Dept Radiat Oncol, Atlanta, GA USA; [Arnold, R. S.] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA	University of Michigan System; University of Michigan; Emory University; Emory University	Day, ML (corresponding author), Univ Michigan, UMCC, Dept Urol, 6219 CCGC,1500 E Med Ctr Dr, Ann Arbor, MI 48109 USA.	mday@umich.edu			NCI NIH HHS [5T32 CA009674] Funding Source: Medline; NIDDK NIH HHS [DK061488, 5T32 DK07758-05] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007758, R01DK061488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arnold RS, 2001, P NATL ACAD SCI USA, V98, P5550, DOI 10.1073/pnas.101505898; Baker AM, 1997, PROSTATE, V32, P229, DOI 10.1002/(SICI)1097-0045(19970901)32:4<229::AID-PROS1>3.0.CO;2-E; Bostwick DG, 2007, HUM PATHOL, V38, P1394, DOI 10.1016/j.humpath.2007.02.008; Bostwick DG, 2000, CANCER, V89, P123, DOI 10.1002/1097-0142(20000701)89:1<123::AID-CNCR17>3.0.CO;2-9; Brooks JD, 2001, CANCER EPIDEM BIOMAR, V10, P949; Chan KM, 1996, P NATL ACAD SCI USA, V93, P13943, DOI 10.1073/pnas.93.24.13943; Chanas SA, 2002, BIOCHEM J, V365, P405, DOI 10.1042/BJ20020320; Day KC, 2002, J BIOL CHEM, V277, P44475, DOI 10.1074/jbc.M205361200; De Marzo AM, 2007, NAT REV CANCER, V7, P256, DOI 10.1038/nrc2090; Dhakshinamoorthy S, 2000, CURR TOP CELL REGUL, V36, P201; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; GREENBERG NM, 1995, P NATL ACAD SCI USA, V92, P3439, DOI 10.1073/pnas.92.8.3439; GUYTON KZ, 1993, BRIT MED BULL, V49, P523, DOI 10.1093/oxfordjournals.bmb.a072628; Hayes JD, 2005, ANNU REV PHARMACOL, V45, P51, DOI 10.1146/annurev.pharmtox.45.120403.095857; Hayes JD, 1995, CRIT REV BIOCHEM MOL, V30, P445, DOI 10.3109/10409239509083491; Ho SM, 2006, ANN NY ACAD SCI, V1089, P177, DOI 10.1196/annals.1386.005; Iida K, 2004, CANCER RES, V64, P6424, DOI 10.1158/0008-5472.CAN-04-1906; Itoh K, 1999, GENE DEV, V13, P76, DOI 10.1101/gad.13.1.76; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jaiswal AK, 2000, FREE RADICAL BIO MED, V29, P254, DOI 10.1016/S0891-5849(00)00306-3; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Kwak MK, 2004, MUTAT RES-FUND MOL M, V555, P133, DOI 10.1016/j.mrfmmm.2004.06.041; Kwak MK, 2003, J BIOL CHEM, V278, P8135, DOI 10.1074/jbc.M211898200; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; LaTulippe E, 2002, CANCER RES, V62, P4499; Lee JM, 2003, J BIOL CHEM, V278, P12029, DOI 10.1074/jbc.M211558200; Lee JM, 2003, BBA-GENE STRUCT EXPR, V1629, P92, DOI 10.1016/j.bbaexp.2003.08.006; Luo J, 2001, CANCER RES, V61, P4683; Ma Q, 2006, AM J PATHOL, V168, P1960, DOI 10.2353/ajpath.2006.051113; Magee JA, 2001, CANCER RES, V61, P5692; McCabe MT, 2005, NEOPLASIA, V7, P141, DOI 10.1593/neo.04394; McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158; McCabe MT, 2006, CANCER RES, V66, P385, DOI 10.1158/0008-5472.CAN-05-2020; Myhre O, 2003, BIOCHEM PHARMACOL, V65, P1575, DOI 10.1016/S0006-2952(03)00083-2; Osburn WO, 2007, INT J CANCER, V121, P1883, DOI 10.1002/ijc.22943; Ouyang X, 2005, CANCER RES, V65, P6773, DOI 10.1158/0008-5472.CAN-05-1948; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Tam NNC, 2006, PROSTATE, V66, P57, DOI 10.1002/pros.20313; Thimmulappa RK, 2006, BIOCHEM BIOPH RES CO, V351, P883, DOI 10.1016/j.bbrc.2006.10.102; Vanaja DK, 2006, CLIN CANCER RES, V12, P1128, DOI 10.1158/1078-0432.CCR-05-2072; Varambally S, 2005, CANCER CELL, V8, P393, DOI 10.1016/j.ccr.2005.10.001; Venugopal R, 1996, P NATL ACAD SCI USA, V93, P14960, DOI 10.1073/pnas.93.25.14960; Wang YH, 2000, CANCER RES, V60, P6008; Welsh JB, 2001, CANCER RES, V61, P5974; Yates MS, 2006, CANCER RES, V66, P2488, DOI 10.1158/0008-5472.CAN-05-3823; Yu X, 2005, MUTAT RES-FUND MOL M, V591, P93, DOI 10.1016/j.mrfmmm.2005.04.017; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zhu M, 2001, BIOCHEM BIOPH RES CO, V289, P212, DOI 10.1006/bbrc.2001.5944	51	142	151	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2008	27	31					4353	4362		10.1038/onc.2008.79	http://dx.doi.org/10.1038/onc.2008.79			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372916	Bronze			2022-12-25	WOS:000257691100010
J	Sayan, AE; Sayan, BS; Gogvadze, V; Dinsdale, D; Nyman, U; Hansen, TM; Zhivotovsky, B; Cohen, GM; Knight, RA; Melino, G				Sayan, A. E.; Sayan, B. S.; Gogvadze, V.; Dinsdale, D.; Nyman, U.; Hansen, T. M.; Zhivotovsky, B.; Cohen, G. M.; Knight, R. A.; Melino, G.			p73 and caspase-cleaved p73 fragments localize to mitochondria and augment TRAIL-induced apoptosis	ONCOGENE			English	Article						p73; mitochondria; p53; transcription independent; apoptosis; TRAIL	C-ABL; PROTEIN STABILITY; TUMOR-SUPPRESSOR; REGULATES P73; P53; TRANSACTIVATION; ACTIVATION; DEGRADATION; CARCINOMA; ABSENCE	The p73 protein, a member of the p53 family, has both developmental and tumorigenic functions. Here we show that p73 is cleaved by caspase-3 and -8 both in vitro and in vivo during apoptosis elicited by DNA-damaging drugs and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor ligation. TAp73 and some of its cleavage products are localized to mitochondria. siRNA-mediated downregulation of p73 expression induced a small but significant change in the susceptibility of HCT116 cells to TRAIL-induced apoptosis. A transcription-deficient mutant of TAp73 enhanced TRAIL-induced apoptosis suggesting that p73 protein has transcriptionin-dependent functions during death receptor-mediated apoptosis. Additionally, recombinant p73 protein induced cytochrome c release from isolated mitochondria providing evidence that nonnuclear p73 may have additional functions in the progression of apoptosis.	[Sayan, A. E.; Sayan, B. S.; Dinsdale, D.; Hansen, T. M.; Cohen, G. M.; Knight, R. A.; Melino, G.] Univ Leicester, MRC, Toxicol Unit, Leicester LE1 9HN, Leics, England; [Gogvadze, V.; Nyman, U.; Zhivotovsky, B.] Karolinska Inst, Inst Environm Med, Div Toxicol, S-10401 Stockholm, Sweden	University of Leicester; Karolinska Institutet	Melino, G (corresponding author), Univ Leicester, MRC, Toxicol Unit, Hodgkin Bldg,Lancaster Rd,POB 138, Leicester LE1 9HN, Leics, England.	gm89@leicester.ac.uk	Gogvadze, Vladimir/A-4392-2014; Zhivotovsky, Boris/A-4346-2014; Nyman, Ulrika/D-3708-2013; SAYAN, A. EMRE/H-7330-2012	Zhivotovsky, Boris/0000-0002-2238-3482; SAYAN, A. EMRE/0000-0002-5291-1485	MRC [MC_U132670600] Funding Source: UKRI; Medical Research Council [MC_U132670600] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Agami R, 1999, NATURE, V399, P809; Aqeilan RI, 2004, P NATL ACAD SCI USA, V101, P4401, DOI 10.1073/pnas.0400805101; Asher G, 2005, GENE DEV, V19, P316, DOI 10.1101/gad.319905; Bernassola F, 2004, J EXP MED, V199, P1545, DOI 10.1084/jem.20031943; Chipuk JE, 2006, CELL DEATH DIFFER, V13, P994, DOI 10.1038/sj.cdd.4401908; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Chipuk JE, 2003, CANCER CELL, V4, P371, DOI 10.1016/S1535-6108(03)00272-1; Costanzo A, 2002, MOL CELL, V9, P175, DOI 10.1016/S1097-2765(02)00431-8; De Laurenzi V, 1998, J EXP MED, V188, P1763, DOI 10.1084/jem.188.9.1763; Essmann F, 2005, J BIOL CHEM, V280, P37169, DOI 10.1074/jbc.M502052200; Gong JG, 1999, NATURE, V399, P806; Grob TJ, 2001, CELL DEATH DIFFER, V8, P1213, DOI 10.1038/sj.cdd.4400962; Lamkanfi M, 2007, CELL DEATH DIFFER, V14, P44, DOI 10.1038/sj.cdd.4402047; Leu JIJ, 2004, NAT CELL BIOL, V6, P443, DOI 10.1038/ncb1123; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Luthi AU, 2007, CELL DEATH DIFFER, V14, P641, DOI 10.1038/sj.cdd.4402103; MacLachan TK, 2002, P NATL ACAD SCI USA, V99, P9492, DOI 10.1073/pnas.132241599; Mahyar-Roemer M, 2004, ONCOGENE, V23, P6226, DOI 10.1038/sj.onc.1207637; Mantovani F, 2004, MOL CELL, V14, P625, DOI 10.1016/j.molcel.2004.05.007; Marchenko ND, 2000, J BIOL CHEM, V275, P16202, DOI 10.1074/jbc.275.21.16202; Melino G, 2002, NAT REV CANCER, V2, P605, DOI 10.1038/nrc861; Melino G, 2004, J BIOL CHEM, V279, P8076, DOI 10.1074/jbc.M307469200; Melino G, 2003, TRENDS BIOCHEM SCI, V28, P663, DOI 10.1016/j.tibs.2003.10.004; Mihara M, 2003, MOL CELL, V11, P577, DOI 10.1016/S1097-2765(03)00050-9; Muller M, 2005, CELL DEATH DIFFER, V12, P1564, DOI 10.1038/sj.cdd.4401774; Munarriz E, 2005, BIOCHEM BIOPH RES CO, V333, P954, DOI 10.1016/j.bbrc.2005.05.188; Oberst A, 2005, BIOCHEM BIOPH RES CO, V331, P707, DOI 10.1016/j.bbrc.2005.03.158; Ozoren N, 2002, NEOPLASIA, V4, P551, DOI 10.1038/sj.neo.7900270; Rossi M, 2005, EMBO J, V24, P836, DOI 10.1038/sj.emboj.7600444; Sayan AE, 2001, ONCOGENE, V20, P5111, DOI 10.1038/sj.onc.1204669; Sayan AE, 2005, BIOCHEM BIOPH RES CO, V330, P186, DOI 10.1016/j.bbrc.2005.02.145; Sayan BS, 2007, P NATL ACAD SCI USA, V104, P10871, DOI 10.1073/pnas.0700761104; Sayan BS, 2006, J BIOL CHEM, V281, P13566, DOI 10.1074/jbc.M512467200; Schembri L, 2007, NAT METHODS, V4, P107, DOI 10.1038/nmeth0207-107; Sigal A, 2000, CANCER RES, V60, P6788; Stiewe T, 2002, CANCER RES, V62, P3598; Stiewe T, 2000, NAT GENET, V26, P464, DOI 10.1038/82617; Sun XM, 1999, J BIOL CHEM, V274, P5053, DOI 10.1074/jbc.274.8.5053; Takimoto R, 2000, ONCOGENE, V19, P1735, DOI 10.1038/sj.onc.1203489; Toledo F, 2006, NAT REV CANCER, V6, P909, DOI 10.1038/nrc2012; Tomita Y, 2006, J BIOL CHEM, V281, P8600, DOI 10.1074/jbc.M507611200; Yang A, 2000, NATURE, V404, P99, DOI 10.1038/35003607; Zaika AI, 1999, CANCER RES, V59, P3257	43	48	50	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4363	4372		10.1038/onc.2008.64	http://dx.doi.org/10.1038/onc.2008.64			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18362891				2022-12-25	WOS:000257691100011
J	Althage, MC; Ford, EL; Wang, S; Tso, P; Polonsky, KS; Wice, BM				Althage, Matthew C.; Ford, Eric L.; Wang, Songyan; Tso, Patrick; Polonsky, Kenneth S.; Wice, Burton M.			Targeted ablation of glucose-dependent insulinotropic polypeptide-producing cells in transgenic mice reduces obesity and insulin resistance induced by a high fat diet	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GASTRIC-INHIBITORY POLYPEPTIDE; RAT ADIPOSE-TISSUE; ENTEROENDOCRINE CELLS; SMALL-INTESTINE; ENTEROINSULAR AXIS; INCRETIN RECEPTORS; DIABETES-MELLITUS; LINEAGE ABLATION; FEEDBACK-CONTROL; ENDOCRINE-CELLS	The K cell is a specific sub-type of enteroendocrine cell located in the proximal small intestine that produces glucose-dependent insulinotropic polypeptide (GIP), xenin, and potentially other unknown hormones. Because GIP promotes weight gain and insulin resistance, reducing hormone release from K cells could lead to weight loss and increased insulin sensitivity. However, the consequences of coordinately reducing circulating levels of all K cell-derived hormones are unknown. To reduce the number of functioning K cells, regulatory elements from the rat GIP promoter/gene were used to express an attenuated diphtheria toxin A chain in transgenic mice. K cell number, GIP transcripts, and plasma GIP levels were profoundly reduced in the GIP/DT transgenic mice. Other enteroendocrine cell types were not ablated. Food intake, body weight, and blood glucose levels in response to insulin or intraperitoneal glucose were similar in control and GIP/DT mice fed standard chow. In contrast to single or double incretin receptor knock-out mice, the incretin response was absent in GIP/DT animals suggesting K cells produce GIP plus an additional incretin hormone. Following high fat feeding for 21-35 weeks, the incretin response was partially restored in GIP/DT mice. Transgenic versus wildtype mice demonstrated significantly reduced body weight (25%), plasma leptin levels (77%), and daily food intake (16%) plus enhanced energy expenditure (10%) and insulin sensitivity. Regardless of diet, long term glucose homeostasis was not grossly perturbed in the transgenic animals. In conclusion, studies using GIP/DT mice demonstrate an important role for K cells in the regulation of body weight and insulin sensitivity.	[Althage, Matthew C.; Ford, Eric L.; Wang, Songyan; Polonsky, Kenneth S.; Wice, Burton M.] Washington Univ, Sch Med, Dept Internal Med, Div Endocrinol Metab & Lipid Res, St Louis, MO 63110 USA; [Tso, Patrick] Univ Cincinnati, Sch Med, Dept Pathol, Cincinnati, OH 45267 USA	Washington University (WUSTL); University System of Ohio; University of Cincinnati	Wice, BM (corresponding author), Washington Univ, Sch Med, Dept Internal Med, Div Endocrinol Metab & Lipid Res, Campus Box 8127,660 S Euclid Ave, St Louis, MO 63110 USA.	bwice@im.wustl.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK056341, R37DK031842, R01DK088126, P60DK020579, U24DK059630, P30DK052574, U2CDK059630, R01DK031842] Funding Source: NIH RePORTER; NIDDK NIH HHS [P30 DK056341-08, DK 59630, 5 P30 DK 052574, DK 31842, R01 DK088126, P60 DK 020579, P30 DK 056341, P30 DK056341, P30 DK056341-07] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abbott CR, 2006, INT J OBESITY, V30, P288, DOI 10.1038/sj.ijo.0803137; AIKEN KD, 1994, DEV DYNAM, V201, P636; Anlauf M, 2000, J HISTOCHEM CYTOCHEM, V48, P1617, DOI 10.1177/002215540004801205; Asakawa A, 2001, GASTROENTEROLOGY, V120, P337, DOI 10.1053/gast.2001.22158; Baba ASH, 2000, COMP BIOCHEM PHYS B, V127, P173, DOI 10.1016/S0305-0491(00)00249-2; BAILEY CJ, 1986, ACTA ENDOCRINOL-COP, V112, P224, DOI 10.1530/acta.0.1120224; Batterham RL, 2002, NATURE, V418, P650, DOI 10.1038/nature00887; BECK B, 1988, INT J OBESITY, V12, P41; Brand SJ, 1995, TXB GASTROENTEROLOGY, P25; BREITMAN ML, 1989, DEVELOPMENT, V106, P457; BREITMAN ML, 1990, MOL CELL BIOL, V10, P474, DOI 10.1128/MCB.10.2.474; Cani PD, 2007, MOL CELL ENDOCRINOL, V276, P18, DOI 10.1016/j.mce.2007.06.003; CATALAND S, 1974, J CLIN ENDOCR METAB, V39, P223, DOI 10.1210/jcem-39-2-223; Cheung AT, 2000, SCIENCE, V290, P1959, DOI 10.1126/science.290.5498.1959; CREUTZFELDT W, 1978, DIABETOLOGIA, V14, P15, DOI 10.1007/BF00429703; Drucker DJ, 2007, J CLIN INVEST, V117, P24, DOI 10.1172/JCI30076; Drucker DJ, 1998, DIABETES, V47, P159, DOI 10.2337/diabetes.47.2.159; EBERT R, 1991, HORM METAB RES, V23, P517, DOI 10.1055/s-2007-1003745; EBERT R, 1979, EUR J CLIN INVEST, V9, P129, DOI 10.1111/j.1365-2362.1979.tb01678.x; ECKEL RH, 1979, DIABETES, V28, P1141, DOI 10.2337/diabetes.28.12.1141; ELAHI D, 1984, DIABETES, V33, P950, DOI 10.2337/diabetes.33.10.950; FALKO JM, 1975, J CLIN ENDOCR METAB, V41, P260, DOI 10.1210/jcem-41-2-260; FEHMANN HC, 1995, ENDOCR REV, V16, P390, DOI 10.1210/er.16.3.390; Feurle GE, 1998, PEPTIDES, V19, P609, DOI 10.1016/S0196-9781(97)00378-1; FEURLE GE, 1992, J BIOL CHEM, V267, P22305; Feurle GE, 2003, REGUL PEPTIDES, V111, P153, DOI 10.1016/S0167-0115(02)00281-1; Feurle GE, 1997, J PEPT RES, V49, P324; Garabedian EM, 1997, J BIOL CHEM, V272, P23729, DOI 10.1074/jbc.272.38.23729; Hamscher G, 1996, PEPTIDES, V17, P889; Hansotia T, 2007, J CLIN INVEST, V117, P143, DOI 10.1172/JCI25483; HAUNER H, 1988, ANN NUTR METAB, V32, P282, DOI 10.1159/000177467; Heuser M, 2002, REGUL PEPTIDES, V107, P23, DOI 10.1016/S0167-0115(02)00062-9; HIGASHIMOTO Y, 1993, BIOCHEM BIOPH RES CO, V193, P182, DOI 10.1006/bbrc.1993.1607; Itoh H, 1999, J CLIN INVEST, V104, P1539, DOI 10.1172/JCI6211; Jandacek RJ, 2004, GASTROENTEROLOGY, V127, P139, DOI 10.1053/j.gastro.2004.04.007; Knapper Jacqueline M. E., 1993, Biochemical Society Transactions, V21, p135S; Li L, 2005, AM J PHYSIOL-ENDOC M, V288, pE208, DOI 10.1152/ajpendo.00346.2004; Liddle RA, 1997, ANNU REV PHYSIOL, V59, P221, DOI 10.1146/annurev.physiol.59.1.221; Lu WJ, 2007, AM J PHYSIOL-GASTR L, V293, pG963, DOI 10.1152/ajpgi.00146.2007; MAXWELL F, 1987, MOL CELL BIOL, V7, P1576, DOI 10.1128/MCB.7.4.1576; Miller L.J., 1999, TXB GASTROENTEROLOGY, P35; Miyawaki K, 2002, NAT MED, V8, P738, DOI 10.1038/nm727; Miyawaki K, 1999, P NATL ACAD SCI USA, V96, P14843, DOI 10.1073/pnas.96.26.14843; MORGAN LM, 1988, BRIT J NUTR, V59, P373, DOI 10.1079/BJN19880046; Mortensen K, 2003, REGUL PEPTIDES, V114, P189, DOI 10.1016/S0167-0115(03)00125-3; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; OBEN J, 1991, J ENDOCRINOL, V130, P267, DOI 10.1677/joe.0.1300267; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; Pamir N, 2003, AM J PHYSIOL-ENDOC M, V284, pE931, DOI 10.1152/ajpendo.00270.2002; Persson K, 2000, AM J PHYSIOL-ENDOC M, V279, pE956, DOI 10.1152/ajpendo.2000.279.5.E956; Preitner F, 2004, J CLIN INVEST, V113, P635, DOI 10.1172/JCI200420518; Ramshur EB, 2002, J CELL PHYSIOL, V192, P339, DOI 10.1002/jcp.10139; ROTH KA, 1990, P NATL ACAD SCI USA, V87, P6408, DOI 10.1073/pnas.87.16.6408; SALERA M, 1982, J CLIN ENDOCR METAB, V55, P329, DOI 10.1210/jcem-55-2-329; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Silvestre RA, 2003, REGUL PEPTIDES, V115, P25, DOI 10.1016/S0167-0115(03)00147-2; SJOLUND K, 1983, GASTROENTEROLOGY, V85, P1120; STARICH GH, 1985, AM J PHYSIOL, V249, pE603, DOI 10.1152/ajpendo.1985.249.6.E603; SYKES S, 1980, J ENDOCRINOL, V85, P201, DOI 10.1677/joe.0.0850201; Theodorakis MJ, 2006, AM J PHYSIOL-ENDOC M, V290, pE550, DOI 10.1152/ajpendo.00326.2004; THOMAS FB, 1976, GASTROENTEROLOGY, V70, P523; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; TSENG CC, 1994, AM J PHYSIOL, V266, pG887, DOI 10.1152/ajpgi.1994.266.5.G887; TSENG CC, 1995, MOL CELL ENDOCRINOL, V115, P13, DOI 10.1016/0303-7207(95)03665-T; Walsh John H., 1994, P1; Wang SY, 2004, J HISTOCHEM CYTOCHEM, V52, P53, DOI 10.1177/002215540405200106; Wang SY, 2003, AM J PHYSIOL-ENDOC M, V284, pE988, DOI 10.1152/ajpendo.00398.2002; WASADA T, 1981, J CLIN INVEST, V68, P1106, DOI 10.1172/JCI110335; Wice BM, 1998, J BIOL CHEM, V273, P25310, DOI 10.1074/jbc.273.39.25310; Wolfe MM, 2000, AM J PHYSIOL-GASTR L, V279, pG561, DOI 10.1152/ajpgi.2000.279.3.G561; Yip RGC, 1998, ENDOCRINOLOGY, V139, P4004, DOI 10.1210/en.139.9.4004; Zhou L, 2006, AM J PHYSIOL-REG I, V290, pR634, DOI 10.1152/ajpregu.00596.2005	72	135	157	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18365	18376		10.1074/jbc.M710466200	http://dx.doi.org/10.1074/jbc.M710466200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18420580	Green Published, hybrid			2022-12-25	WOS:000256949200064
J	Yanagisawa, M; Huveldt, D; Kreinest, P; Lohse, CM; Cheville, JC; Parker, AS; Copland, JA; Anastasiadis, PZ				Yanagisawa, Masahiro; Huveldt, Deborah; Kreinest, Pamela; Lohse, Christine M.; Cheville, John C.; Parker, Alexander S.; Copland, John A.; Anastasiadis, Panos Z.			A p120 catenin isoform switch affects Rho activity, induces tumor cell invasion, and predicts metastatic disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SNAIL; E-CADHERIN EXPRESSION; EPITHELIAL-MESENCHYMAL TRANSITIONS; FAMILY GTPASES; PROTEIN-KINASE; BREAST-CANCER; CARCINOMA; P120-CATENIN; ADHESION; GROWTH	p120 catenin is a cadherin-associated protein that regulates Rho GTPases and promotes the invasiveness of E-cadherin-deficient cancer cells. Multiple p120 isoforms are expressed in cells via alternative splicing, and all of them are essential for HGF signaling to Rac1. However, only full-length p120 ( isoform 1) promotes invasiveness. This selective ability of p120 isoform 1 is mediated by reduced RhoA activity, both under basal conditions and following HGF treatment. All p120 isoforms can bind RhoA in vitro, via a central RhoA binding site. However, only the cooperative binding of RhoA to the central p120 domain and to the alternatively spliced p120 N terminus stabilizes RhoA binding and inhibits RhoA activity. Consistent with this, increased expression of p120 isoform 1, when compared with other p120 isoforms, is predictive of renal tumor micrometastasis and systemic progression, following nephrectomy. Furthermore, ectopic expression of the RhoA-binding, N-terminal domain of p120 is sufficient to block the ability of p120 isoform 1 to inhibit RhoA and to promote invasiveness. The data indicate that the increased expression of p120 isoform 1 during tumor progression contributes to the invasive phenotype of cadherin-deficient carcinomas and that the N-terminal domain of p120 is a valid therapeutic target.	[Yanagisawa, Masahiro; Huveldt, Deborah; Kreinest, Pamela; Copland, John A.; Anastasiadis, Panos Z.] Mayo Clin, Dept Canc Biol, Jacksonville, FL 32224 USA; [Parker, Alexander S.] Mayo Clin, Dept Urol, Jacksonville, FL 32224 USA; [Lohse, Christine M.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55095 USA; [Cheville, John C.] Mayo Clin, Dept Anat Pathol, Rochester, MN 55095 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Mayo Clinic	Anastasiadis, PZ (corresponding author), Mayo Clin, Ctr Comprehens Canc, Griffin Canc Res Bldg,Rm 307,4500 San Pablo Rd, Jacksonville, FL 32224 USA.	panos@mayo.edu			NCI NIH HHS [R01 CA 100467, R01 CA104505, R01 CA 104505, R01 CA100467] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA100467, R01CA104505] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aho S, 2002, J CELL SCI, V115, P1391; Anastasiadis PZ, 2001, CURR OPIN CELL BIOL, V13, P604, DOI 10.1016/S0955-0674(00)00258-1; Anastasiadis PZ, 2000, NAT CELL BIOL, V2, P637, DOI 10.1038/35023588; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berx G, 2001, BREAST CANCER RES, V3, P289, DOI 10.1186/bcr309; Bible KC, 1999, ANAL BIOCHEM, V267, P217, DOI 10.1006/abio.1998.2980; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Castano J, 2007, MOL CELL BIOL, V27, P1745, DOI 10.1128/MCB.01974-06; Cheville JC, 2003, AM J SURG PATHOL, V27, P612, DOI 10.1097/00000478-200305000-00005; Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X; Conacci-Sorrell M, 2002, J CLIN INVEST, V109, P987, DOI 10.1172/JCI200215429; Cozzolino M, 2003, MOL BIOL CELL, V14, P1964, DOI 10.1091/mbc.E02-08-0469; Davis MA, 2003, J CELL BIOL, V163, P525, DOI 10.1083/jcb.200307111; De Wever O, 2004, FASEB J, V18, P1016, DOI 10.1096/fj.03-1110fje; Grosheva I, 2001, J CELL SCI, V114, P695; Hafez KS, 1997, J UROLOGY, V157, P2067, DOI 10.1016/S0022-5347(01)64675-5; Hajra KM, 2002, CANCER RES, V62, P1613; Ireton RC, 2002, J CELL BIOL, V159, P465, DOI 10.1083/jcb.200205115; Jiang WG, 2003, CLIN CANCER RES, V9, P4274; KATAGIRI A, 1995, BRIT J CANCER, V71, P376, DOI 10.1038/bjc.1995.76; Keirsebilck A, 1998, GENOMICS, V50, P129, DOI 10.1006/geno.1998.5325; Leibovich BC, 2003, CANCER-AM CANCER SOC, V97, P1663, DOI 10.1002/cncr.11234; Li R, 1997, J BIOL CHEM, V272, P4671, DOI 10.1074/jbc.272.8.4671; Mariner DJ, 2001, J BIOL CHEM, V276, P28006, DOI 10.1074/jbc.M102443200; McLaughlin JK, 2000, SEMIN ONCOL, V27, P115; Mo YY, 1996, CANCER RES, V56, P2633; Morell-Quadreny L, 2003, ANTICANCER RES, V23, P5005; Noren NK, 2000, J CELL BIOL, V150, P567, DOI 10.1083/jcb.150.3.567; Ohkubo T, 2004, J CELL SCI, V117, P1675, DOI 10.1242/jcs.01004; Perl AK, 1998, NATURE, V392, P190, DOI 10.1038/32433; Potempa S, 1998, MOL BIOL CELL, V9, P2185, DOI 10.1091/mbc.9.8.2185; REESE J H, 1991, Current Opinion in Oncology, V3, P537, DOI 10.1097/00001622-199106000-00016; Royal I, 2000, MOL BIOL CELL, V11, P1709, DOI 10.1091/mbc.11.5.1709; Russell RC, 2007, CELL CYCLE, V6, P56, DOI 10.4161/cc.6.1.3668; Shimazui T, 2006, ONCOL REP, V15, P1181; SKINNER DG, 1972, J UROLOGY, V107, P705, DOI 10.1016/S0022-5347(17)61121-2; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822; Thoreson MA, 2002, DIFFERENTIATION, V70, P583, DOI 10.1046/j.1432-0436.2002.700911.x; Uehata M, 1997, NATURE, V389, P990, DOI 10.1038/40187; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; Wong AST, 2003, J CELL BIOL, V161, P1191, DOI 10.1083/jcb.200212033; Xia XB, 2003, BIOCHEMISTRY-US, V42, P9195, DOI 10.1021/bi034597h; Xiao KY, 2003, J CELL BIOL, V163, P535, DOI 10.1083/jcb.200306001; Yanagisawa M, 2006, J CELL BIOL, V174, P1087, DOI 10.1083/jcb.200605022; Zhang J, 2004, J BIOL CHEM, V279, P22118, DOI 10.1074/jbc.M400774200	45	118	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18344	18354		10.1074/jbc.M801192200	http://dx.doi.org/10.1074/jbc.M801192200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18407999	Green Published, hybrid			2022-12-25	WOS:000256949200062
J	Greggio, E; Zambrano, I; Kaganovich, A; Beilina, A; Taymans, JM; Daniels, V; Lewis, P; Jain, S; Ding, J; Syed, A; Thomas, KJ; Baekelandt, V; Cookson, MR				Greggio, Elisa; Zambrano, Ibardo; Kaganovich, Alice; Beilina, Alexandra; Taymans, Jean-Marc; Daniels, Veronique; Lewis, Patrick; Jain, Shushant; Ding, Jinhui; Syed, Ali; Thomas, Kelly J.; Baekelandt, Veerle; Cookson, Mark R.			The Parkinson disease-associated leucine-rich repeat kinase 2 (LRRK2) is a dimer that undergoes intramolecular autophosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE ACTIVITY; NEURONAL TOXICITY; GTP-BINDING; ROC DOMAIN; MUTATIONS; G2019S; ACTIVATION; LRRK2/DARDARIN; GENE; LOOP	Mutations in leucine-rich repeat kinase 2 (LRRK2) are a common cause of familial and apparently sporadic Parkinson disease. LRRK2 is a multidomain protein kinase with autophosphorylation activity. It has previously been shown that the kinase activity of LRRK2 is required for neuronal toxicity, suggesting that understanding the mechanism of kinase activation and regulation may be important for the development of specific kinase inhibitors for Parkinson disease treatment. Here, we show that LRRK2 predominantly exists as a dimer under native conditions, a state that appears to be stabilized by multiple domain-domain interactions. Furthermore, an intact C terminus, but not N terminus, is required for autophosphorylation activity. We identify two residues in the activation loop that contribute to the regulation of LRRK2 autophosphorylation. Finally, we demonstrate that LRRK2 undergoes intramolecular autophosphorylation. Together, these results provide insight into the mechanism and regulation of LRRK2 kinase activity.	[Greggio, Elisa; Ding, Jinhui] NIA, NIH, Neurogenet Lab, Bioinformat Facil, Bethesda, MD 20982 USA; [Greggio, Elisa; Zambrano, Ibardo; Kaganovich, Alice; Beilina, Alexandra; Lewis, Patrick; Jain, Shushant; Syed, Ali; Thomas, Kelly J.; Cookson, Mark R.] NIA, NIH, Cell Biol & Genen Express Unit, Bethesda, MD 20982 USA; [Daniels, Veronique; Baekelandt, Veerle] Katholieke Univ Leuven, Dept Mol & Cellular Med, Div Mol Med, Lab Neurobiol & Gene Therapy, B-3000 Louvain, Belgium	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); KU Leuven	Greggio, E (corresponding author), NIA, NIH, Neurogenet Lab, Bioinformat Facil, Bldg 35,Rm 1A1012,MSC 3707,35 Convent Dr, Bethesda, MD 20982 USA.	greggio@mail.nih.gov	Cookson, Mark/AAW-2516-2021; Greggio, Elisa/H-6119-2013; Baekelandt, Veerle/ABB-9736-2020; Lewis, Patrick A./C-3674-2009; Taymans, Jean-Marc/M-9175-2018	Cookson, Mark/0000-0002-1058-3831; Greggio, Elisa/0000-0002-8172-3598; Baekelandt, Veerle/0000-0001-8966-2921; Taymans, Jean-Marc/0000-0001-5503-5524; Lewis, Patrick/0000-0003-4537-0489; Daniels, Veronique/0000-0003-3403-8106	NATIONAL INSTITUTE ON AGING [Z01AG000948, ZIAAG000948] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bonifati V, 2007, NEUROCHEM RES, V32, P1700, DOI 10.1007/s11064-007-9324-y; Bras JM, 2005, MOVEMENT DISORD, V20, P1653, DOI 10.1002/mds.20682; Cheng JK, 2005, J BIOL CHEM, V280, P13477, DOI 10.1074/jbc.M414258200; Dachsel JC, 2007, PARKINSONISM RELAT D, V13, P382, DOI 10.1016/j.parkreldis.2007.01.008; Deng JP, 2008, P NATL ACAD SCI USA, V105, P1499, DOI 10.1073/pnas.0709098105; Funayama M, 2005, ANN NEUROL, V57, P918, DOI 10.1002/ana.20484; Funayama M, 2002, ANN NEUROL, V51, P296, DOI 10.1002/ana.10113; Gloeckner CJ, 2006, HUM MOL GENET, V15, P223, DOI 10.1093/hmg/ddi439; Greggio E, 2007, J NEUROCHEM, V102, P93, DOI 10.1111/j.1471-4159.2007.04523.x; Greggio E, 2006, NEUROBIOL DIS, V23, P329, DOI 10.1016/j.nbd.2006.04.001; Guo LX, 2007, EXP CELL RES, V313, P3658, DOI 10.1016/j.yexcr.2007.07.007; Ito G, 2007, BIOCHEMISTRY-US, V46, P1380, DOI 10.1021/bi061960m; Jaleel M, 2007, BIOCHEM J, V405, P307, DOI 10.1042/BJ20070209; Korr D, 2006, CELL SIGNAL, V18, P910, DOI 10.1016/j.cellsig.2005.08.015; Lesage S, 2006, NEW ENGL J MED, V354, P422, DOI 10.1056/NEJMc055540; Leung IWL, 2001, J BIOL CHEM, V276, P1961, DOI 10.1074/jbc.M004092200; Lewis PA, 2007, BIOCHEM BIOPH RES CO, V357, P668, DOI 10.1016/j.bbrc.2007.04.006; Li XT, 2007, J NEUROCHEM, V103, P238, DOI 10.1111/j.1471-4159.2007.04743.x; Luzon-Toro B, 2007, HUM MOL GENET, V16, P2031, DOI 10.1093/hmg/ddm151; Melrose HL, 2007, NEUROSCIENCE, V147, P1047, DOI 10.1016/j.neuroscience.2007.05.027; Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024; Ohren JF, 2004, NAT STRUCT MOL BIOL, V11, P1192, DOI 10.1038/nsmb859; Ozelius LJ, 2006, NEW ENGL J MED, V354, P424, DOI 10.1056/NEJMc055509; Paisan-Ruiz C, 2004, NEURON, V44, P595, DOI 10.1016/j.neuron.2004.10.023; Shi ZS, 2006, CURR OPIN STRUC BIOL, V16, P686, DOI 10.1016/j.sbi.2006.10.011; Smith WLW, 2006, NAT NEUROSCI, V9, P1231, DOI 10.1038/nn1776; Song JJ, 2003, J BIOL CHEM, V278, P47245, DOI 10.1074/jbc.M213201200; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; West AB, 2005, P NATL ACAD SCI USA, V102, P16842, DOI 10.1073/pnas.0507360102; West AB, 2007, HUM MOL GENET, V16, P223, DOI 10.1093/hmg/ddl471; Whaley NR, 2006, J NEURAL TRANSM-SUPP, P221; Xiang ZX, 2002, P NATL ACAD SCI USA, V99, P7432, DOI 10.1073/pnas.102179699; Zhou HY, 2005, PROTEINS, V61, P152, DOI 10.1002/prot.20732; Zimprich A, 2004, NEURON, V44, P601, DOI 10.1016/j.neuron.2004.11.005	34	230	234	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16906	16914		10.1074/jbc.M708718200	http://dx.doi.org/10.1074/jbc.M708718200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18397888	Green Published, hybrid			2022-12-25	WOS:000256497100068
J	Aghaie, A; Lechaplais, C; Sirven, P; Tricot, S; Besnard-Gonnet, M; Muselet, D; de Berardinis, V; Kreimeyer, A; Gyapay, G; Salanoubat, M; Perret, A				Aghaie, Asadollah; Lechaplais, Christophe; Sirven, Peggy; Tricot, Sabine; Besnard-Gonnet, Marielle; Muselet, Delphine; de Berardinis, Veronique; Kreimeyer, Annett; Gyapay, Gabor; Salanoubat, Marcel; Perret, Alain			New insights into the alternative D-glucarate degradation pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KETOGLUTARIC SEMIALDEHYDE DEHYDROGENASE; ACINETOBACTER SP ADP1; ENZYMATIC-ACTIVITIES; ENOLASE SUPERFAMILY; ESCHERICHIA-COLI; PSEUDOMONAS ACIDOVORANS; GENOME SEQUENCE; EVOLUTION; DEHYDRATASE; IDENTIFICATION	Although the D-glucarate degradation pathway is well characterized in Escherichia coli, genetic and biochemical information concerning the alternative pathway proposed in Pseudomonas species and Bacillus subtilis remains incomplete. Acinetobacter baylyi ADP1 is a Gram-negative soil bacterium possessing the alternative pathway and able to grow using D-glucarate as the only carbon source. Based on the annotation of its sequenced genome (1), we have constructed a complete collection of single-gene deletion mutants (2). High throughput profiling for growth on a minimal medium containing D-glucarate as the only carbon source for similar to 2450 mutants led to the identification of the genes involved in D-glucarate degradation. Protein purification after recombinant production in E. coli allowed us to reconstitute the enzymatic pathway in vitro. We describe here the kinetic characterization of D-glucarate dehydratase, D-5-keto-4-deoxyglucarate dehydratase, and of cooperative alpha-ketoglutarate semialdehyde dehydrogenase. Transcription and expression analyses of the genes involved in D-glucarate metabolism within a single organism made it possible to access information regarding the regulation of this pathway for the first time.	[Aghaie, Asadollah; Lechaplais, Christophe; Sirven, Peggy; Tricot, Sabine; Besnard-Gonnet, Marielle; Muselet, Delphine; de Berardinis, Veronique; Kreimeyer, Annett; Gyapay, Gabor; Salanoubat, Marcel; Perret, Alain] Genoscope Commissariat Energie Atom, CNRS, UMR 8030, F-91057 Evry, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; CEA	Perret, A (corresponding author), Genoscope Commissariat Energie Atom, CNRS, UMR 8030, 2 Rue Gaston Cremieux, F-91057 Evry, France.	aperret@genoscope.cns.fr		Aghaie, Asadollah Alain/0000-0002-3247-7087; de Berardinis, Veronique/0000-0002-3273-4135; PERRET, Alain/0000-0002-8896-1978				ADAMS E, 1967, J BIOL CHEM, V242, P1802; ADAMS E, 1966, BIOCHEM BIOPH RES CO, V23, P633, DOI 10.1016/0006-291X(66)90446-3; Barbe V, 2004, NUCLEIC ACIDS RES, V32, P5766, DOI 10.1093/nar/gkh910; BLUMENTHAL HJ, 1963, BIOCHEM BIOPH RES CO, V11, P239, DOI 10.1016/0006-291X(63)90341-3; Cobessi D, 1999, J MOL BIOL, V290, P161, DOI 10.1006/jmbi.1999.2853; Dagley S, 1975, Methods Enzymol, V42, P272; de Berardinis V, 2008, MOL SYST BIOL, V4, DOI 10.1038/msb.2008.10; EISENSTEIN E, 1991, J BIOL CHEM, V266, P5801; Gulick AM, 1998, BIOCHEMISTRY-US, V37, P14358, DOI 10.1021/bi981123n; Gulick AM, 2000, BIOCHEMISTRY-US, V39, P4590, DOI 10.1021/bi992782i; HASSALL H, 1969, BIOCHEM J, V114, pP78; Hosoya S, 2002, FEMS MICROBIOL LETT, V210, P193, DOI 10.1111/j.1574-6968.2002.tb11180.x; Hubbard BK, 1998, BIOCHEMISTRY-US, V37, P14369, DOI 10.1021/bi981124f; JACOB F, 1961, J MOL BIOL, V3, P318, DOI 10.1016/S0022-2836(61)80072-7; JEFFCOAT R, 1969, BIOCHEM J, V115, P969, DOI 10.1042/bj1150969; JEFFCOAT R, 1969, BIOCHEM J, V115, P977, DOI 10.1042/bj1150977; Kay HD, 1926, BIOCHEM J, V20, P321, DOI 10.1042/bj0200321; KOO PH, 1974, J BIOL CHEM, V249, P1704; Koshland DE, 2002, BIOORG CHEM, V30, P211, DOI 10.1006/bioo.2002.1246; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; Kreimeyer A, 2007, J BIOL CHEM, V282, P7191, DOI 10.1074/jbc.M609829200; MACGEE J, 1954, J BIOL CHEM, V210, P617; Metzgar D, 2004, NUCLEIC ACIDS RES, V32, P5780, DOI 10.1093/nar/gkh881; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Nelson KE, 2002, ENVIRON MICROBIOL, V4, P799, DOI 10.1046/j.1462-2920.2002.00366.x; SHARMA BS, 1973, J BACTERIOL, V116, P1346, DOI 10.1128/JB.116.3.1346-1354.1973; TRUDGILL PW, 1966, NATURE, V211, P1097, DOI 10.1038/2111097a0; Watanabe S, 2007, J BIOL CHEM, V282, P6685, DOI 10.1074/jbc.M611057200; Watanabe S, 2006, J BIOL CHEM, V281, P28876, DOI 10.1074/jbc.M602585200	29	25	30	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15638	15646		10.1074/jbc.M800487200	http://dx.doi.org/10.1074/jbc.M800487200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18364348	hybrid, Green Published			2022-12-25	WOS:000256332500017
J	Nogueira, E; Fidalgo, M; Molnar, A; Kyriakis, J; Force, T; Zalvide, J; Pombo, CM				Nogueira, Emilio; Fidalgo, Miguel; Molnar, Arpad; Kyriakis, John; Force, Thomas; Zalvide, Juan; Pombo, Celia M.			SOK1 translocates from the Golgi to the nucleus upon chemical anoxia and induces apoptotic cell death	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GERMINAL CENTER KINASE; MAMMALIAN STE20-LIKE PROTEIN-KINASE-3; PROTEIN-KINASE; PROMOTES APOPTOSIS; OXIDATIVE-STRESS; STE20-RELATED KINASE; CASPASE ACTIVATION; TUMOR-SUPPRESSOR; OXIDANT STRESS; MAP KINASE	SOK1 is a Ste20 protein kinase of the germinal center kinase (GCK) family that has been shown to be activated by oxidant stress and chemical anoxia, a cell culture model of ischemia. More recently, it has been shown to be localized to the Golgi apparatus, where it functions in a signaling pathway required for cell migration and polarization. Herein, we demonstrate that SOK1 regulates cell death after chemical anoxia, as its down-regulation by RNA interference enhances cell survival. Furthermore, expression of SOK1 elicits apoptotic cell death by activating the intrinsic pathway. We also find that a cleaved form of SOK1 translocates from the Golgi to the nucleus after chemical anoxia and that this translocation is dependent on both caspase activity and on amino acids 275-292, located immediately C-terminal to the SOK1 kinase domain. Furthermore, SOK1 entry into the nucleus is important for the cell death response since SOK1 mutants unable to enter the nucleus do not induce cell death. In summary, SOK1 is necessary to induce cell death and can induce death when over-expressed. Furthermore, SOK1 appears to play distinctly different roles in stressed versus non-stressed cells, regulating cell death in the former.	[Nogueira, Emilio; Fidalgo, Miguel; Zalvide, Juan; Pombo, Celia M.] Univ Santiago de Compostela, Sch Med, Dept Physiol, Lab Cell Signaling & Canc Res, Santiago De Compostela 15705, Spain; [Molnar, Arpad] Massachusetts Gen Hosp, Diabet Res Lab, Charlestown, MA 02129 USA; [Kyriakis, John] Tufts Univ, Sch Med, Tufts New England Med Ctr, Mol Cardiol Res Inst, Boston, MA 02111 USA; [Force, Thomas] Thomas Jefferson Univ, Ctr Translat Med, Philadelphia, PA 19107 USA	Universidade de Santiago de Compostela; Harvard University; Massachusetts General Hospital; Tufts Medical Center; Tufts University; Jefferson University	Pombo, CM (corresponding author), Univ Santiago de Compostela, Sch Med, Dept Physiol, Lab Cell Signaling & Canc Res, San Francisco S-N, Santiago De Compostela 15705, Spain.	fspombo@usc.es	Zalvide, Juan/ABG-4050-2020; Fidalgo, Miguel/I-7006-2019; Pombo, Celia M/L-4479-2014	Fidalgo, Miguel/0000-0003-1134-2674; Zalvide, Juan/0000-0001-7645-156X; Pombo, Celia M/0000-0003-2541-9468; Force, Thomas/0000-0002-0450-8659	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL067371] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL67371] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Benhar M, 2002, EMBO REP, V3, P420, DOI 10.1093/embo-reports/kvf094; Brodie C, 2003, APOPTOSIS, V8, P19, DOI 10.1023/A:1021640817208; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Cheung WL, 2003, CELL, V113, P507, DOI 10.1016/S0092-8674(03)00355-6; Chuang DM, 2005, ANNU REV PHARMACOL, V45, P269, DOI 10.1146/annurev.pharmtox.45.120403.095902; Dan I, 2002, J BIOL CHEM, V277, P5929, DOI 10.1074/jbc.M110882200; Dan I, 2001, TRENDS CELL BIOL, V11, P220, DOI 10.1016/S0962-8924(01)01980-8; Droge W, 2002, PHYSIOL REV, V82, P47, DOI 10.1152/physrev.00018.2001; FRIESEN H, 1994, GENE DEV, V8, P2162, DOI 10.1101/gad.8.18.2162; Graves JD, 1998, EMBO J, V17, P2224, DOI 10.1093/emboj/17.8.2224; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; Hatai T, 2000, J BIOL CHEM, V275, P26576, DOI 10.1074/jbc.M003412200; Huang CYF, 2002, J BIOL CHEM, V277, P34367, DOI 10.1074/jbc.M202468200; Jia JH, 2003, GENE DEV, V17, P2514, DOI 10.1101/gad.1134003; Khokhlatchev A, 2002, CURR BIOL, V12, P253, DOI 10.1016/S0960-9822(02)00683-8; Klein JA, 2003, J CLIN INVEST, V111, P785, DOI 10.1172/JCI200318182; Kultz D, 2005, ANNU REV PHYSIOL, V67, P225, DOI 10.1146/annurev.physiol.67.040403.103635; Kyriakis JM, 1999, J BIOL CHEM, V274, P5259, DOI 10.1074/jbc.274.9.5259; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Lee WS, 2004, FEBS LETT, V572, P41, DOI 10.1016/j.febslet.2004.07.007; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Lin JL, 2001, ONCOGENE, V20, P6559, DOI 10.1038/sj.onc.1204818; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Osada S, 1997, ONCOGENE, V14, P2047, DOI 10.1038/sj.onc.1201043; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Pombo CM, 2007, FRONT BIOSCI-LANDMRK, V12, P850, DOI 10.2741/2107; Pombo CM, 1997, J BIOL CHEM, V272, P29372, DOI 10.1074/jbc.272.46.29372; POMBO CM, 1995, NATURE, V377, P750, DOI 10.1038/377750a0; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; POMBO CM, 1994, J BIOL CHEM, V269, P26546; Praskova M, 2004, BIOCHEM J, V381, P453, DOI 10.1042/BJ20040025; Preisinger C, 2004, J CELL BIOL, V164, P1009, DOI 10.1083/jcb.200310061; Robb GB, 2005, NAT STRUCT MOL BIOL, V12, P133, DOI 10.1038/nsmb886; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Schinkmann K, 1997, J BIOL CHEM, V272, P28695, DOI 10.1074/jbc.272.45.28695; Stegert MR, 2005, MOL CELL BIOL, V25, P11019, DOI 10.1128/MCB.25.24.11019-11029.2005; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Ura S, 2001, GENES CELLS, V6, P519, DOI 10.1046/j.1365-2443.2001.00439.x; Ura S, 2001, P NATL ACAD SCI USA, V98, P10148, DOI 10.1073/pnas.181161698; Veal EA, 2004, MOL CELL, V15, P129, DOI 10.1016/j.molcel.2004.06.021; Wu HY, 2008, APOPTOSIS, V13, P283, DOI 10.1007/s10495-007-0161-x; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X; Zhou TH, 2000, J BIOL CHEM, V275, P2513, DOI 10.1074/jbc.275.4.2513; Zong WX, 2006, GENE DEV, V20, P1, DOI 10.1101/gad.1376506	46	42	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16248	16258		10.1074/jbc.M709724200	http://dx.doi.org/10.1074/jbc.M709724200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18364353	Green Published, hybrid			2022-12-25	WOS:000256332500083
J	Eddine, AN; von Kries, JP; Podust, MV; Warrier, T; Kaufmann, SHE; Podust, LM				Eddine, Ali Nasser; von Kries, Jens P.; Podust, Mikhail V.; Warrier, Thulasi; Kaufmann, Stefan H. E.; Podust, Larissa M.			X-ray structure of 4,4 '-dihydroxybenzophenone mimicking sterol substrate in the active site of sterol 14 alpha-demethylase (CYP51)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AZOLE ANTIFUNGAL AGENTS; RESISTANT CANDIDA-ALBICANS; 14-DEMETHYLASE P450 CYP51; MYCOBACTERIUM-TUBERCULOSIS; LANOSTEROL 14-ALPHA-DEMETHYLASE; ASPERGILLUS-FUMIGATUS; 14-ALPHA-STEROL DEMETHYLASE; FLUCONAZOLE RESISTANCE; TRYPANOSOMA-CRUZI; CHAGAS-DISEASE	A universal step in the biosynthesis of membrane sterols and steroid hormones is the oxidative removal of the 14 alpha-methyl group from sterol precursors by sterol 14 alpha-demethylase (CYP51). This enzyme is a primary target in treatment of fungal infections in organisms ranging from humans to plants, and development of more potent and selective CYP51 inhibitors is an important biological objective. Our continuing interest in structural aspects of substrate and inhibitor recognition in CYP51 led us to determine (to a resolution of 1.95 angstrom) the structure of CYP51 from Mycobacterium tuberculosis (CYP51(Mt)) co-crystallized with 4,4'-dihydroxybenzophenone (DHBP), a small organic molecule previously identified among top type I binding hits in a library screened against CYP51(Mt). The newly determined CYP51(Mt)-DHBP structure is the most complete to date and is an improved template for three-dimensional modeling of CYP51 enzymes from fungal and prokaryotic pathogens. The structure demonstrates the induction of conformational fit of the flexible protein regions and the interactions of conserved Phe-89 essential for both fungal drug resistance and catalytic function, which were obscure in the previously characterized CYP51(Mt)-estriol complex. DHBP represents a benzophenone scaffold binding in the CYP51 active site via a type I mechanism, suggesting (i) a possible new class of CYP51 inhibitors targeting flexible regions, (ii) an alternative catalytic function for bacterial CYP51 enzymes, and (iii) a potential for hydroxybenzophenones, widely distributed in the environment, to interfere with sterol biosynthesis. Finally, we show the inhibition of M. tuberculosis growth by DHBP in a mouse macrophage model.	[Eddine, Ali Nasser; Warrier, Thulasi; Kaufmann, Stefan H. E.] Max Planck Inst Infect Biol, D-10117 Berlin, Germany; [von Kries, Jens P.] Leibniz Inst Mol Pharmacol FMP, Screening Unit, D-13125 Berlin, Germany; [Podust, Mikhail V.; Podust, Larissa M.] Univ Calif San Francisco, Dept Pharmaceut Chem, San Francisco, CA 94158 USA	Max Planck Society; Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP); University of California System; University of California San Francisco	Podust, LM (corresponding author), Univ Calif San Francisco, Dept Pharmaceut Chem, 600 16th St, San Francisco, CA 94158 USA.	larissa.podust@ucsf.edu	Podust, Larissa/ABB-7940-2020; Horstmann, Britta/C-2154-2008; Kaufmann, Stefan HE/I-5454-2014	Podust, Larissa/0000-0002-8537-8760; Kaufmann, Stefan HE/0000-0001-9866-8268	NIGMS NIH HHS [R01 GM 078553] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM078553] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aoyama Y, 1998, J BIOCHEM-TOKYO, V124, P694; Aoyama Y, 2005, FRONT BIOSCI, V10, P1546, DOI 10.2741/1639; Asai K, 1999, ANTIMICROB AGENTS CH, V43, P1163, DOI 10.1128/AAC.43.5.1163; BABOSHIN M, 2008, BIODEGRADAT IN PRESS; Banfi E, 2006, J ANTIMICROB CHEMOTH, V58, P76, DOI 10.1093/jac/dkl182; Bellamine A, 1999, P NATL ACAD SCI USA, V96, P8937, DOI 10.1073/pnas.96.16.8937; Bellamine A, 2004, J LIPID RES, V45, P2000, DOI 10.1194/jlr.M400239-JLR200; Blair RM, 2000, TOXICOL SCI, V54, P138, DOI 10.1093/toxsci/54.1.138; Brezna B, 2006, APPL MICROBIOL BIOT, V71, P522, DOI 10.1007/s00253-005-0190-8; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Casellas M, 1997, APPL ENVIRON MICROB, V63, P819, DOI 10.1128/AEM.63.3.819-826.1997; Chau AS, 2006, ANTIMICROB AGENTS CH, V50, P3917, DOI 10.1128/AAC.00747-06; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Correia M.A., 2005, CYTOCHROME P450 STRU, V3rd ed., P247, DOI DOI 10.1007/0-387-27447-2_7; Cueto M, 2001, J NAT PROD, V64, P1444, DOI 10.1021/np0102713; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; Ekins S, 2007, DRUG METAB DISPOS, V35, P493, DOI 10.1124/dmd.106.013888; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fukuoka T, 2003, ANTIMICROB AGENTS CH, V47, P1213, DOI 10.1128/AAC.47.4.1213-1219.2003; Gan YH, 2006, J ORG CHEM, V71, P5864, DOI 10.1021/jo060481q; Gatfield J, 2000, SCIENCE, V288, P1647, DOI 10.1126/science.288.5471.1647; Gollapudy R, 2004, BIOORGAN MED CHEM, V12, P2937, DOI 10.1016/j.bmc.2004.03.034; GRIFOLL M, 1995, APPL ENVIRON MICROB, V61, P3711, DOI 10.1128/AEM.61.10.3711-3723.1995; HAGEDORNLEWEKE U, 1995, PHARMACEUT RES, V12, P1354, DOI 10.1023/A:1016286026462; Hayden CGJ, 1997, LANCET, V350, P863, DOI 10.1016/S0140-6736(05)62032-6; Hucke O, 2005, J MED CHEM, V48, P5415, DOI 10.1021/jm050441z; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Ji HT, 2003, J MED CHEM, V46, P474, DOI 10.1021/jm020362c; Jiang R, 1999, BRIT J CLIN PHARMACO, V48, P635; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kelly SL, 1999, FEMS MICROBIOL LETT, V180, P171, DOI 10.1111/j.1574-6968.1999.tb08792.x; Kudo M, 2005, J BIOCHEM, V137, P625, DOI 10.1093/jb/mvi073; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lenhart A, 2003, J MED CHEM, V46, P2083, DOI 10.1021/jm0211218; Lepesheva GI, 2006, J BIOL CHEM, V281, P3577, DOI 10.1074/jbc.M510317200; Lopez Z, 2005, J IND MICROBIOL BIOT, V32, P455, DOI 10.1007/s10295-005-0022-y; Lopez Z, 2006, APPL MICROBIOL BIOT, V70, P747, DOI 10.1007/s00253-005-0120-9; Macchiarulo A, 2002, BIOORGAN MED CHEM, V10, P3415, DOI 10.1016/S0968-0896(02)00263-8; Makris TM., 2005, CYTOCHROME P450, P149; Marichal P, 1999, MICROBIOL-SGM, V145, P2701, DOI 10.1099/00221287-145-10-2701; Maya JD, 2007, COMP BIOCHEM PHYS A, V146, P601, DOI 10.1016/j.cbpa.2006.03.004; McLean KJ, 2007, ARCH BIOCHEM BIOPHYS, V464, P228, DOI 10.1016/j.abb.2007.03.026; Mishra J, 2007, CURR MED CHEM, V14, P1153, DOI 10.2174/092986707780362862; MONNA L, 1993, APPL ENVIRON MICROB, V59, P285, DOI 10.1128/AEM.59.1.285-289.1993; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; OMURA T, 1964, J BIOL CHEM, V239, P2379; Opalski KS, 2006, PEST MANAG SCI, V62, P393, DOI 10.1002/ps.1176; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perea S, 2001, ANTIMICROB AGENTS CH, V45, P2676, DOI 10.1128/AAC.45.10.2676-2684.2001; Podust LM, 2007, ANTIMICROB AGENTS CH, V51, P3915, DOI 10.1128/AAC.00311-07; Podust LM, 2001, P NATL ACAD SCI USA, V98, P3068, DOI 10.1073/pnas.061562898; Podust LM, 2001, J INORG BIOCHEM, V87, P227, DOI 10.1016/S0162-0134(01)00388-9; Podust LM, 2004, STRUCTURE, V12, P1937, DOI 10.1016/j.str.2004.08.009; Qi X, 2006, P NATL ACAD SCI USA, V103, P18848, DOI 10.1073/pnas.0607849103; Resnick SM, 1996, APPL ENVIRON MICROB, V62, P4073, DOI 10.1128/AEM.62.11.4073-4080.1996; Roberts CW, 2003, MOL BIOCHEM PARASIT, V126, P129, DOI 10.1016/S0166-6851(02)00280-3; Rupp B, 2005, J COMPUT AID MOL DES, V19, P149, DOI 10.1007/s10822-005-3692-7; Sacchettini JC, 2008, NAT REV MICROBIOL, V6, P41, DOI 10.1038/nrmicro1816; Sanglard D, 1998, ANTIMICROB AGENTS CH, V42, P241, DOI 10.1093/jac/42.2.241; Schiaffella F, 2005, J MED CHEM, V48, P7658, DOI 10.1021/jm050685j; Schmitt MR, 2006, PEST MANAG SCI, V62, P383, DOI 10.1002/ps.1177; Sheehan DJ, 1999, CLIN MICROBIOL REV, V12, P40, DOI 10.1128/CMR.12.1.40; Sheng CQ, 2006, J MED CHEM, V49, P2512, DOI 10.1021/jm051211n; Sheng CQ, 2004, J BIOMOL STRUCT DYN, V22, P91, DOI 10.1080/07391102.2004.10506984; Suzuki T, 2005, TOXICOL APPL PHARM, V203, P9, DOI 10.1016/j.taap.2004.07.005; TRZASKOS JM, 1986, J BIOL CHEM, V261, P6937; Urbina JA, 1996, SCIENCE, V273, P969, DOI 10.1126/science.273.5277.969; Van der Geize R, 2007, P NATL ACAD SCI USA, V104, P1947, DOI 10.1073/pnas.0605728104; Wang Y, 2006, MICROBIOL IMMUNOL, V50, P513, DOI 10.1111/j.1348-0421.2006.tb03821.x; Wattiau P, 2001, RES MICROBIOL, V152, P861, DOI 10.1016/S0923-2508(01)01269-4; Wheat LJ, 2006, J ANTIMICROB CHEMOTH, V57, P1235, DOI 10.1093/jac/dkl133; Xiao L, 2004, ANTIMICROB AGENTS CH, V48, P568, DOI 10.1128/AAC.48.2.568-574.2004; Yao B, 2007, J MED CHEM, V50, P5293, DOI 10.1021/jm0701167; Yoshida Y, 1997, J BIOCHEM-TOKYO, V122, P1122; Zhao L, 2007, FEMS MICROBIOL LETT, V277, P37, DOI 10.1111/j.1574-6968.2007.00929.x; Zhao QJ, 2007, CHEM BIODIVERS, V4, P1472, DOI 10.1002/cbdv.200790125; Zhu J, 2006, BIOORG MED CHEM LETT, V16, P5285, DOI 10.1016/j.bmcl.2006.08.001	77	31	34	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15152	15159		10.1074/jbc.M801145200	http://dx.doi.org/10.1074/jbc.M801145200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18367444	Green Published, hybrid			2022-12-25	WOS:000256232000031
J	Lin, DW; Chang, IC; Tseng, A; Wu, ML; Chen, CH; Patenaude, CA; Layne, MD; Yet, SF				Lin, Da-Wei; Chang, Il-Chi; Tseng, Alan; Wu, Meng-Ling; Chen, Chung-Huang; Patenaude, Cassandra A.; Layne, Matthew D.; Yet, Shaw-Fang			Transforming growth factor beta up-regulates cysteine-rich protein 2 in vascular smooth muscle cells via activating transcription factor 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIM-DOMAIN PROTEIN; CAMP-RESPONSIVE ELEMENT; HEPATIC STELLATE CELLS; TGF-BETA; GENE-EXPRESSION; MOLECULAR-CLONING; MESSENGER-RNA; BINDING; GROWTH-FACTOR-BETA-1; DIFFERENTIATION	CRP2 (cysteine-rich protein) is a vascular smooth muscle cell (VSMC) -expressed LIM-only protein. CRP2 associates with the actin cytoskeleton and interacts with transcription factors in the nucleus to mediate smooth muscle cell gene expression. Using Csrp2 (gene symbol of the mouse CRP2 gene)-deficient mice, we previously demonstrated that an absence of CRP2 enhances VSMC migration and increases neointima formation following arterial injury. Despite its importance in vascular injury, the molecular mechanisms controlling CRP2 expression in VSMC are largely unknown. Transforming growth factor beta (TGF beta), a key factor present in the vessel wall in the early phases of arterial response to injury, plays an important role in modulating lesion formation. Because both CRP2 and TGF beta are mediators of VSMC responses, we examined the possibility that TGF beta might regulate CRP2 expression. TGF beta significantly induced CRP2 mRNA and protein expression in VSMCs. Promoter analysis identified a conserved cAMP-responsive element (CRE)-like site (TAACGTCA) in the Csrp2 promoter that was critical for basal promoter activity and response to TGF beta. Gel mobility shift assays revealed that mainly ATF2 bound to this CRE-like element, and mutation of the CRE sequences abolished binding. TGF beta enhanced the activation of ATF2, leading to increased phospho-ATF2 levels within the DNA-protein complexes. Furthermore, ATF2-transactivated Csrp2 promoter activity and TGF beta enhanced this activation. In addition, a phosphorylation- negative ATF2 mutant construct decreased basal and TGF beta-mediated Csrp2 promoter activity. Our results show for the first time in VSMC that TGF beta activates ATF2 phosphorylation and Csrp2 gene expression via a CRE promoter element.	[Chang, Il-Chi; Wu, Meng-Ling; Chen, Chung-Huang; Yet, Shaw-Fang] Natl Hlth Res Inst, Cardiovasc & Blood Med Res Ctr, Zhunan Town 35053, Miaoli County, Taiwan; [Lin, Da-Wei; Tseng, Alan; Layne, Matthew D.; Yet, Shaw-Fang] Harvard Univ, Sch Med, Boston, MA 02115 USA; [Lin, Da-Wei; Tseng, Alan; Layne, Matthew D.; Yet, Shaw-Fang] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Patenaude, Cassandra A.; Layne, Matthew D.] Boston Univ, Sch Med, Dept Biochem, Boston, MA 02118 USA	National Health Research Institutes - Taiwan; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Boston University	Yet, SF (corresponding author), Natl Hlth Res Inst, Cardiovasc & Blood Med Res Ctr, 35 Keyan Rd R2-5021, Zhunan Town 35053, Miaoli County, Taiwan.	syet@nhri.org.tw	Yet, Shaw-Fang/B-1067-2010; Yet, Shaw-Fang/O-8583-2019	Layne, Matthew/0000-0003-0007-4870; Yet, Shaw-Fang/0000-0001-9097-3962	NHLBI NIH HHS [R01 HL078869, HL 057977, HL 078869] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL078869, R01HL057977] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arber S, 1996, GENE DEV, V10, P289, DOI 10.1101/gad.10.3.289; ARBER S, 1994, CELL, V79, P221, DOI 10.1016/0092-8674(94)90192-9; Arber S, 1997, CELL, V88, P393, DOI 10.1016/S0092-8674(00)81878-4; BENBROOK DM, 1994, NUCLEIC ACIDS RES, V22, P1463, DOI 10.1093/nar/22.8.1463; BENBROOK DM, 1990, ONCOGENE, V5, P295; Chang DF, 2003, DEV CELL, V4, P107, DOI 10.1016/S1534-5807(02)00396-9; Chang YF, 2003, AM J PHYSIOL-HEART C, V285, pH1675, DOI 10.1152/ajpheart.00165.2003; Clark KA, 2007, J CELL SCI, V120, P2066, DOI 10.1242/jcs.000695; CRAWFORD AW, 1994, J CELL BIOL, V124, P117, DOI 10.1083/jcb.124.1.117; Dawid IB, 1998, TRENDS GENET, V14, P156, DOI 10.1016/S0168-9525(98)01424-3; Dibrov A, 2006, GROWTH FACTORS, V24, P1, DOI 10.1080/08977190500365995; DiCamillo SJ, 2006, AM J PHYSIOL-LUNG C, V291, pL232, DOI 10.1152/ajplung.00530.2005; Feinberg MW, 2000, J BIOL CHEM, V275, P25766, DOI 10.1074/jbc.M002664200; FEUERSTEIN R, 1994, P NATL ACAD SCI USA, V91, P10655, DOI 10.1073/pnas.91.22.10655; Fogel-Petrovic M, 2007, INT IMMUNOPHARMACOL, V7, P1924, DOI 10.1016/j.intimp.2007.07.003; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAI T, 1991, P NATL ACAD SCI USA, V88, P3720, DOI 10.1073/pnas.88.9.3720; Henderson JR, 2002, J HISTOCHEM CYTOCHEM, V50, P107, DOI 10.1177/002215540205000112; HERR I, 1994, CARCINOGENESIS, V15, P1105, DOI 10.1093/carcin/15.6.1105; Herrmann J, 2006, BIOCHEM BIOPH RES CO, V345, P1526, DOI 10.1016/j.bbrc.2006.05.076; Ishida A, 2002, J BIOL CHEM, V277, P26217, DOI 10.1074/jbc.M111093200; Jain MK, 1996, J BIOL CHEM, V271, P10194, DOI 10.1074/jbc.271.17.10194; Kadrmas JL, 2004, NAT REV MOL CELL BIO, V5, P920, DOI 10.1038/nrm1499; Kim MJ, 2006, J ENDOCRINOL, V188, P623, DOI 10.1677/joe.1.06480; Kobayashi K, 2005, CIRC RES, V96, P904, DOI 10.1161/01.RES.0000163980.55495.44; Kong YF, 1997, MOL CELL BIOL, V17, P4750, DOI 10.1128/MCB.17.8.4750; Li XY, 1996, GENE DEV, V10, P517, DOI 10.1101/gad.10.5.517; Liu GM, 2006, J BIOL CHEM, V281, P29479, DOI 10.1074/jbc.M600579200; LIVINGSTONE C, 1995, EMBO J, V14, P1785, DOI 10.1002/j.1460-2075.1995.tb07167.x; Louis HA, 1997, J BIOL CHEM, V272, P27484, DOI 10.1074/jbc.272.43.27484; MAEKAWA T, 1989, EMBO J, V8, P2023, DOI 10.1002/j.1460-2075.1989.tb03610.x; MAJESKY MW, 1991, J CLIN INVEST, V88, P904, DOI 10.1172/JCI115393; Meng JF, 2005, INT ARCH ALLERGY IMM, V138, P151, DOI 10.1159/000088437; Najwer I, 2005, AM J PHYSIOL-CELL PH, V289, pC785, DOI 10.1152/ajpcell.00098.2005; NIKOL S, 1992, J CLIN INVEST, V90, P1582, DOI 10.1172/JCI116027; Owens GK, 2004, PHYSIOL REV, V84, P767, DOI 10.1152/physrev.00041.2003; Pomies P, 1997, J CELL BIOL, V139, P157, DOI 10.1083/jcb.139.1.157; Qing J, 2004, MOL CELL BIOL, V24, P1411, DOI 10.1128/MCB.24.3.1411-1425.2004; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; SCHMEICHEL KL, 1994, CELL, V79, P211, DOI 10.1016/0092-8674(94)90191-0; Schmeichel KL, 1998, BIOCHEM J, V331, P885, DOI 10.1042/bj3310885; Sekiguchi K, 2001, CIRC RES, V88, P52, DOI 10.1161/01.RES.88.1.52; Shah NM, 1996, CELL, V85, P331, DOI 10.1016/S0092-8674(00)81112-5; Sinha S, 2004, AM J PHYSIOL-CELL PH, V287, pC1560, DOI 10.1152/ajpcell.00221.2004; Sreeramaneni R, 2005, MOL CELL BIOL, V25, P220, DOI 10.1128/MCB.25.1.220-232.2005; Tedgui A, 2006, PHYSIOL REV, V86, P515, DOI 10.1152/physrev.00024.2005; Tsukada S, 2005, J BIOL CHEM, V280, P10055, DOI 10.1074/jbc.M409381200; van Dam H, 2001, ONCOGENE, V20, P2453, DOI 10.1038/sj.onc.1204239; Watanabe T, 2004, LIFE SCI, V75, P1219, DOI 10.1016/j.lfs.2004.03.004; Wei J, 2005, CIRC RES, V97, P1323, DOI 10.1161/01.RES.0000194331.76925.5c; WEISKIRCHEN R, 1995, J BIOL CHEM, V270, P28946, DOI 10.1074/jbc.270.48.28946; Weiskirchen R, 2003, BIOESSAYS, V25, P152, DOI 10.1002/bies.10226; WEISKIRCHEN R, 1993, ONCOGENE, V8, P2317; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; Yet SF, 1999, J CLIN INVEST, V103, pR23, DOI 10.1172/JCI6163; Yet SF, 1998, J BIOL CHEM, V273, P10530, DOI 10.1074/jbc.273.17.10530; Yokote K, 2006, TRENDS CARDIOVAS MED, V16, P240, DOI 10.1016/j.tcm.2006.04.005; Yoshida T, 2003, CIRC RES, V92, P856, DOI 10.1161/01.RES.0000068405.49081.09; Zhang Y, 1996, NATURE, V383, P168, DOI 10.1038/383168a0	60	29	30	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15003	15014		10.1074/jbc.M801621200	http://dx.doi.org/10.1074/jbc.M801621200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18387947	hybrid, Green Published			2022-12-25	WOS:000256232000013
J	Tachampa, K; Kobayashi, T; Wang, H; Martin, AF; Biesiadeck, BJ; Solaro, RJ; de Tombe, PP				Tachampa, Kittipong; Kobayashi, Tomoyoshi; Wang, Helen; Martin, Anne F.; Biesiadeck, Brandon J.; Solaro, R. John; de Tombe, Pieter P.			Increased cross-bridge cycling kinetics after exchange of C-terminal truncated troponin I in skinned rat cardiac muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; STUNNED MYOCARDIUM; THIN-FILAMENTS; DEGRADATION; HEART; PHOSPHORYLATION; IDENTIFICATION; MYOFILAMENTS; SENSITIVITY; RELAXATION	The precise mechanism of cardiac troponin I (cTnl) proteolysis in myocardial stunning is not fully understood. Accordingly, we determined the effect of cTnI C terminus truncation on chemo-mechanical transduction in isolated skinned rat trabeculae. Recombinant troponin complex (cTn), containing either mouse cTnI-(1-193) or human cTnI-(1-192) was exchanged into skinned cardiac trabeculae; Western blot analysis confirmed that 60-70% of the endogenous cTn was replaced by recombinant Tn. Incorporation of truncated cTnI induced significant reductions (similar to 50%) in maximum force and cooperative activation as well as increases (similar to 50%) in myofilament Ca2+ sensitivity and tension cost. Similar results were obtained with either mouse or human truncated cTn. Presence of truncated cTnI increased maximum actin-activated S1 ATPase activity as well as its Ca2+ sensitivity in vitro. Partial exchange (50%) for truncated cTnI resulted in similar reductions in maximum force and cooperativity; tension cost was increased in proportion to truncated cTnI content. In vitro, to determine the molecular mechanism responsible for the enhanced myofilament Ca2+ sensitivity, we measured Ca2+ binding to cTn as reported using a fluorescent probe. Incorporation of truncated cTnI did not affect Ca2+ binding affinity to cTn alone. However, when cTn was incorporated into thin filaments, cTnI truncation induced a significant increase in Ca2+ binding affinity to cTn. We conclude that cTnI truncation induces depressed myofilament function. Decreased cardiac function after ischemia/reperfusion injury may directly result, in part, from proteolytic degradation of cTnI, resulting in alterations in cross-bridge cycling kinetics.	Univ Illinois, Cardiovasc Res Ctr, Chicago, IL 60612 USA; Univ Illinois, Dept Physiol & Biophys, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	de Tombe, PP (corresponding author), 835 S Wolcott,Physiol & Biophys MC901, Chicago, IL 60612 USA.	pdetombe@uic.edu	Tachampa, Kittipong/AAK-3634-2020	Tachampa, Kittipong/0000-0002-2011-3542	NHLBI NIH HHS [HL 62426, HL 75494, HL 22231, HL 77195, HL 072742, HL 07692, HL 082923, P01 HL062426] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL082923, R01HL022231, P01HL062426, T32HL072742, T32HL007692, R01HL077195, R37HL022231, R01HL075494] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bolli R, 1999, PHYSIOL REV, V79, P609, DOI 10.1152/physrev.1999.79.2.609; BRUTSAERT DL, 1989, PHYSIOL REV, V69, P1228, DOI 10.1152/physrev.1989.69.4.1228; Chandra M, 2001, AM J PHYSIOL-HEART C, V280, pH705, DOI 10.1152/ajpheart.2001.280.2.H705; Colantonio DA, 2004, CARDIOVASC RES, V63, P217, DOI 10.1016/j.cardiores.2004.04.006; de Tombe PP, 2007, AM J PHYSIOL-REG I, V292, pR1129, DOI 10.1152/ajpregu.00630.2006; de Tombe PP, 2003, J BIOMECH, V36, P721, DOI 10.1016/S0021-9290(02)00450-5; Feng J, 2001, CIRCULATION, V103, P2035; Foster DB, 2003, CIRC RES, V93, P917, DOI 10.1161/01.RES.0000099889.35340.6F; Gao WD, 1997, CIRC RES, V80, P393, DOI 10.1161/01.res.0000435855.49359.47; Gao WD, 2006, AM J PHYSIOL-HEART C, V290, pH886, DOI 10.1152/ajpheart.00493.2005; Geeves MA, 2005, ADV PROTEIN CHEM, V71, P161, DOI 10.1016/S0065-3233(04)71005-0; Jweied E, 2007, J MOL CELL CARDIOL, V42, P722, DOI 10.1016/j.yjmcc.2007.02.002; Kobayashi T, 2006, J BIOL CHEM, V281, P13471, DOI 10.1074/jbc.M509561200; Kobayashi T, 2005, ANNU REV PHYSIOL, V67, P39, DOI 10.1146/annurev.physiol.67.040403.114025; Kobayashi T, 2005, J MOL CELL CARDIOL, V38, P213, DOI 10.1016/j.yjmcc.2004.10.014; McDonough JL, 2001, CIRCULATION, V103, P58; Murphy AM, 2000, SCIENCE, V287, P488, DOI 10.1126/science.287.5452.488; Narolska NA, 2006, CIRC RES, V99, P1012, DOI 10.1161/01.RES.0000248753.30340.af; Neagoe C, 2002, CIRCULATION, V106, P1333, DOI 10.1161/01.CIR.0000029803.93022.93; Papp Z, 2000, CARDIOVASC RES, V45, P981, DOI 10.1016/S0008-6363(99)00374-0; Rarick HM, 1997, J BIOL CHEM, V272, P26887, DOI 10.1074/jbc.272.43.26887; Rundell VLM, 2005, AM J PHYSIOL-HEART C, V288, pH896, DOI 10.1152/ajpheart.00407.2004; Stehle R, 2002, BIOPHYS J, V83, P2152, DOI 10.1016/S0006-3495(02)73975-1; Sumandea MP, 2003, J BIOL CHEM, V278, P35135, DOI 10.1074/jbc.M306325200; Thomas SA, 1999, CIRC RES, V85, P446, DOI 10.1161/01.RES.85.5.446; White MY, 2005, PROTEOMICS, V5, P1395, DOI 10.1002/pmic.200400995	26	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15114	15121		10.1074/jbc.M801636200	http://dx.doi.org/10.1074/jbc.M801636200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18378675	hybrid, Green Published			2022-12-25	WOS:000256232000026
J	Firestein, R; Blander, G; Michan, S; Oberdoerffer, P; Ogino, S; Campbell, J; Bhimavarapu, A; Luikenhuis, S; de Cabo, R; Fuchs, C; Hahn, WC; Guarente, LP; Sinclair, DA				Firestein, Ron; Blander, Gil; Michan, Shaday; Oberdoerffer, Philipp; Ogino, Shuji; Campbell, Jennifer; Bhimavarapu, Anupama; Luikenhuis, Sandra; de Cabo, Rafael; Fuchs, Charles; Hahn, William C.; Guarente, Leonard P.; Sinclair, David A.			The SIRT1 Deacetylase Suppresses Intestinal Tumorigenesis and Colon Cancer Growth	PLOS ONE			English	Article								Numerous longevity genes have been discovered in model organisms and altering their function results in prolonged lifespan. In mammals, some have speculated that any health benefits derived from manipulating these same pathways might be offset by increased cancer risk on account of their propensity to boost cell survival. The Sir2/SIRT1 family of NAD(+)-dependent deacetylases is proposed to underlie the health benefits of calorie restriction (CR), a diet that broadly suppresses cancer in mammals. Here we show that CR induces a two-fold increase SIRT1 expression in the intestine of rodents and that ectopic induction of SIRT1 in a beta-catenin-driven mouse model of colon cancer significantly reduces tumor formation, proliferation, and animal morbidity in the absence of CR. We show that SIRT1 deacetylates beta-catenin and suppresses its ability to activate transcription and drive cell proliferation. Moreover, SIRT1 promotes cytoplasmic localization of the otherwise nuclear-localized oncogenic form of beta-catenin. Consistent with this, a significant inverse correlation was found between the presence of nuclear SIRT1 and the oncogenic form of beta-catenin in 81 human colon tumor specimens analyzed. Taken together, these observations show that SIRT1 suppresses intestinal tumor formation in vivo and raise the prospect that therapies targeting SIRT1 may be of clinical use in beta-catenin-driven malignancies.	[Firestein, Ron; Michan, Shaday; Oberdoerffer, Philipp; Campbell, Jennifer; Luikenhuis, Sandra; Sinclair, David A.] Harvard Univ, Sch Med, Dept Pathol, Paul F Glenn Labs Biol Mech Aging, Boston, MA 02115 USA; [Blander, Gil; Bhimavarapu, Anupama; Guarente, Leonard P.] Massachusetts Inst Technol, Dept Biol, Cambridge, MA USA; [Firestein, Ron; Ogino, Shuji] Brigham & Womens Hospital, Harvard Med Sch, Dept Pathol, Boston, MA USA; [Firestein, Ron; Ogino, Shuji] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA; [de Cabo, Rafael] NIH, NIA, Lab Expt Gerontol, Bethesda, MD USA; [Firestein, Ron; Fuchs, Charles; Hahn, William C.] Massachusetts Inst Technol, Broad Inst Harvard, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA	Harvard University; Harvard Medical School; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Harvard University; Dana-Farber Cancer Institute; Massachusetts Institute of Technology (MIT); Broad Institute	Sinclair, DA (corresponding author), Harvard Univ, Sch Med, Dept Pathol, Paul F Glenn Labs Biol Mech Aging, Boston, MA 02115 USA.	david_sinclair@hms.harvard.edu	de Cabo, Rafael/E-7996-2010; de Cabo, Rafael Carlos/J-5230-2016; de Cabo, Rafael/J-5230-2016	de Cabo, Rafael/0000-0003-2830-5693; de Cabo, Rafael Carlos/0000-0003-2830-5693; de Cabo, Rafael/0000-0002-3354-2442; Ogino, Shuji/0000-0002-3909-2323; Sinclair, David/0000-0002-9936-436X	NIH [T32]; Estee Lauder [postdoctoral fellowship]; National Space Biomedical Research Institute; Intramural Research Program of the NIH/NIA; Paul F. Glenn Foundation; NATIONAL INSTITUTE ON AGING [R01AG028730, R01AG019719, Z01AG000363] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Estee Lauder; National Space Biomedical Research Institute; Intramural Research Program of the NIH/NIA(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); Paul F. Glenn Foundation; NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	RF was supported by the NIH T32 Grant. GB by an Estee Lauder postdoctoral fellowship. PO by a National Space Biomedical Research Institute Grant. DAS, SO, CSF and LG by grants from NIH; RD in part by the Intramural Research Program of the NIH/NIA. DS is also supported by a gift from the Paul F. Glenn Foundation.	Alcendor RR, 2007, CIRC RES, V100, P1512, DOI 10.1161/01.RES.0000267723.65696.4a; Bitterman KJ, 2002, J BIOL CHEM, V277, P45099, DOI 10.1074/jbc.M205670200; Brack AS, 2007, SCIENCE, V317, P807, DOI 10.1126/science.1144090; Camp RL, 2002, NAT MED, V8, P1323, DOI 10.1038/nm791; Chen WY, 2005, CELL, V123, P437, DOI 10.1016/j.cell.2005.08.011; Chua KF, 2005, CELL METAB, V2, P67, DOI 10.1016/j.cmet.2005.06.007; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; Dai JM, 2007, J CELL PHYSIOL, V210, P161, DOI 10.1002/jcp.20831; El Marjou F, 2004, GENESIS, V39, P186, DOI 10.1002/gene.20042; Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923; Fu MF, 2006, MOL CELL BIOL, V26, P8122, DOI 10.1128/MCB.00289-06; Guarente L, 2005, CELL, V120, P473, DOI 10.1016/j.cell.2005.01.029; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; LIM CS, 2006, MED HYPOTHESES; Liu HJ, 2007, SCIENCE, V317, P803, DOI 10.1126/science.1143578; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Mai V, 2003, CANCER RES, V63, P1752; Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046; Narala SR, 2008, MOL BIOL CELL; Ogino S, 2006, NEOPLASIA, V8, P458, DOI 10.1593/neo.06247; Pruitt K, 2006, PLOS GENET, V2, P344, DOI 10.1371/journal.pgen.0020040; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; Saunders LR, 2007, ONCOGENE, V26, P5489, DOI 10.1038/sj.onc.1210616; Simcha I, 1998, J CELL BIOL, V141, P1433, DOI 10.1083/jcb.141.6.1433; Sinclair DA, 2005, MECH AGEING DEV, V126, P987, DOI 10.1016/j.mad.2005.03.019; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; Xu WQ, 2007, J CELL SCI, V120, P3337, DOI 10.1242/jcs.013771; Yamamoto H, 2007, MOL ENDOCRINOL, V21, P1745, DOI 10.1210/me.2007-0079; Yeung F, 2004, EMBO J, V23, P2369, DOI 10.1038/sj.emboj.7600244	33	471	494	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e2020	10.1371/journal.pone.0002020	http://dx.doi.org/10.1371/journal.pone.0002020			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414679	gold, Green Published, Green Submitted			2022-12-25	WOS:000260867300029
J	Owen, LA; Kowalewski, AA; Lessnick, SL				Owen, Leah A.; Kowalewski, Ashley A.; Lessnick, Stephen L.			EWS/FLI Mediates Transcriptional Repression via NKX2.2 during Oncogenic Transformation in Ewing's Sarcoma	PLOS ONE			English	Article							HISTONE DEACETYLASE; CHROMOSOME-TRANSLOCATION; GENE; FUSION; PROTEIN; DOMAIN; EXPRESSION; GROUCHO; BINDING; FAMILY	EWS/FLI is a master regulator of Ewing's sarcoma formation. Gene expression studies in A673 Ewing's sarcoma cells have demonstrated that EWS/FLI downregulates more genes than it upregulates, suggesting that EWS/FLI, and/or its targets, function as transcriptional repressors. One critical EWS/FLI target, NKX2.2, is a transcription factor that contains both transcriptional activation and transcriptional repression domains, raising the possibility that it mediates portions of the EWS/FLI transcriptional signature. We now report that microarray analysis demonstrated that the transcriptional profile of NKX2.2 consists solely of downregulated genes, and overlaps with the EWS/FLI downregulated signature, suggesting that NKX2.2 mediates oncogenic transformation via transcriptional repression. Structure-function analysis revealed that the DNA binding and repressor domains in NKX2.2 are required for oncogenesis in Ewing's sarcoma cells, while the transcriptional activation domain is completely dispensable. Furthermore, blockade of TLE or HDAC function, two protein families thought to mediate the repressive function of NKX2.2, inhibited the transformed phenotype and reversed the NKX2.2 transcriptional profile in Ewing's sarcoma cells. Whole genome localization studies (ChIP-chip) revealed that a significant portion of the NKX2.2-repressed gene expression signature was directly mediated by NKX2.2 binding. These data demonstrate that the transcriptional repressive function of NKX2.2 is necessary, and sufficient, for the oncogenic phenotype of Ewing's sarcoma, and suggest a therapeutic approach to this disease.	[Owen, Leah A.; Kowalewski, Ashley A.; Lessnick, Stephen L.] Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA; [Owen, Leah A.; Lessnick, Stephen L.] Univ Utah, Sch Med, Salt Lake City, UT USA; [Lessnick, Stephen L.] Univ Utah, Huntsman Canc Inst, Ctr Children, Salt Lake City, UT USA; [Lessnick, Stephen L.] Univ Utah, Div Pediat Hematol Oncol, Salt Lake City, UT USA	Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah; Huntsman Cancer Institute; Utah System of Higher Education; University of Utah; Utah System of Higher Education; University of Utah	Lessnick, SL (corresponding author), Univ Utah, Dept Oncol Sci, Salt Lake City, UT 84112 USA.	stephen.lessnick@hci.utah.edu		Owen, Leah/0000-0003-3802-3868	Terri Anna Perine Sarcoma Fund; American Cancer Society [MGO-111812]; Huntsman Cancer Institute Director's Translational Research Initiative; NIH [P30 CA42014];  [T32 HD007491]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007491] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P30CA042014] Funding Source: NIH RePORTER	Terri Anna Perine Sarcoma Fund; American Cancer Society(American Cancer Society); Huntsman Cancer Institute Director's Translational Research Initiative; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); ; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	L.A.O. is supported by T32 HD007491. S.L.L. is supported by the Terri Anna Perine Sarcoma Fund, American Cancer Society Research Scholar Grant MGO-111812, and a Huntsman Cancer Institute Director's Translational Research Initiative Grant. We also acknowledge NIH support to Huntsman Cancer Institute via P30 CA42014. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Briscoe J, 1999, NATURE, V398, P622, DOI 10.1038/19315; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; DELATTRE O, 1992, NATURE, V359, P162, DOI 10.1038/359162a0; Doyle MJ, 2007, DEVELOPMENT, V134, P515, DOI 10.1242/dev.02763; Fujimura Y, 1996, ONCOGENE, V12, P159; Grier HE, 1997, PEDIATR CLIN N AM, V44, P991, DOI 10.1016/S0031-3955(05)70541-1; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Guidez F, 1998, BLOOD, V91, P2634, DOI 10.1182/blood.V91.8.2634.2634_2634_2642; Hollenhorst PC, 2007, GENE DEV, V21, P1882, DOI 10.1101/gad.1561707; Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565; Jaboin J, 2002, CANCER RES, V62, P6108; Kinsey M, 2006, MOL CANCER RES, V4, P851, DOI 10.1158/1541-7786.MCR-06-0090; Lambert G, 2000, BIOCHEM BIOPH RES CO, V279, P401, DOI 10.1006/bbrc.2000.3963; Lessnick SL, 2002, CANCER CELL, V1, P393, DOI 10.1016/S1535-6108(02)00056-9; LESSNICK SL, 1995, ONCOGENE, V10, P423; MAY WA, 1993, MOL CELL BIOL, V13, P7393, DOI 10.1128/MCB.13.12.7393; MAY WA, 1993, P NATL ACAD SCI USA, V90, P5752, DOI 10.1073/pnas.90.12.5752; McAllister Nancy R, 2005, Curr Treat Options Oncol, V6, P461, DOI 10.1007/s11864-005-0025-y; Minucci S, 1999, SEMIN CELL DEV BIOL, V10, P215, DOI 10.1006/scdb.1999.0303; Muhr J, 2001, CELL, V104, P861, DOI 10.1016/S0092-8674(01)00283-5; Owen LA, 2006, CELL CYCLE, V5, P2049, DOI 10.4161/cc.5.18.3213; PRASAD DDK, 1994, ONCOGENE, V9, P3717; Prieur A, 2004, MOL CELL BIOL, V24, P7275, DOI 10.1128/MCB.24.16.7275-7283.2004; Rodriguez-Galindo C, 2003, MED PEDIATR ONCOL, V40, P276, DOI 10.1002/mpo.10240; Sakimura R, 2005, INT J CANCER, V116, P784, DOI 10.1002/ijc.21069; Smith R, 2006, CANCER CELL, V9, P405, DOI 10.1016/j.ccr.2006.04.004; Smith SB, 1999, MOL CELL BIOL, V19, P8272; SONNEMANN J, 2007, J CANC RES CLIN ONCO; Stegmaier K, 2007, PLOS MED, V4, P702, DOI 10.1371/journal.pmed.0040122; SUBLETT JE, 1995, ONCOGENE, V11, P545; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Sussel L, 1998, DEVELOPMENT, V125, P2213; Tetsuka T, 2000, J BIOL CHEM, V275, P4383, DOI 10.1074/jbc.275.6.4383; TURCCAREL C, 1988, CANCER GENET CYTOGEN, V32, P229, DOI 10.1016/0165-4608(88)90285-3; Watada H, 2000, P NATL ACAD SCI USA, V97, P9443, DOI 10.1073/pnas.97.17.9443; Wei Q, 2005, J BIOL CHEM, V280, P16284, DOI 10.1074/jbc.M500491200	36	95	100	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1965	10.1371/journal.pone.0001965	http://dx.doi.org/10.1371/journal.pone.0001965			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414662	gold, Green Published, Green Submitted			2022-12-25	WOS:000260867300011
J	van Loggerenberg, F; Mlisana, K; Williamson, C; Auld, SC; Morris, L; Gray, CM; Karim, QA; Grobler, A; Barnabas, N; Iriogbe, I; Karim, SSA				van Loggerenberg, Francois; Mlisana, Koleka; Williamson, Carolyn; Auld, Sara C.; Morris, Lynn; Gray, Clive M.; Karim, Quarraisha Abdool; Grobler, Anneke; Barnabas, Nomampondo; Iriogbe, Itua; Karim, Salim S. Abdool		CAPRISA 002 Acute Infection Study Team	Establishing a Cohort at High Risk of HIV Infection in South Africa: Challenges and Experiences of the CAPRISA 002 Acute Infection Study	PLOS ONE			English	Article								Objectives: To describe the baseline demographic data, clinical characteristics and HIV-incidence rates of a cohort at high risk for HIV infection in South Africa as well as the challenges experienced in establishing and maintaining the cohort. Methodology/Principle Findings: Between August 2004 and May 2005 a cohort of HIV-uninfected women was established for the CAPRISA 002 Acute Infection Study, a natural history study of HIV-1 subtype C infection. Volunteers were identified through peer-outreach. The cohort was followed monthly to determine HIV infection rates and clinical presentation of early HIV infection. Risk reduction counselling and male and female condoms were provided. After screening 775 individuals, a cohort of 245 uninfected high-risk women was established. HIV-prevalence at screening was 59.6% (95% CI: 55.9% to 62.8%) posing a challenge in accruing HIV-uninfected women. The majority of women (78.8%) were self-identified as sex-workers with a median of 2 clients per day. Most women (95%) reported more than one casual sexual partner in the previous 3 months (excluding clients) and 58.8% reported condom use in their last sexual encounter. Based on laboratory testing, 62.0% had a sexually transmitted infection at baseline. During 390 person-years of follow-up, 28 infections occurred yielding seroincidence rate of 7.2 (95% CI: 4.5 to 9.8) per 100 person-years. Despite the high mobility of this sex worker cohort retention rate after 2 years was 86.1%. High co-morbidity created challenges for ancillary care provision, both in terms of human and financial resources. Conclusions/Significance: Challenges experienced were high baseline HIV-prevalence, lower than anticipated HIV-incidence and difficulties retaining participants. Despite challenges, we have successfully accrued this cohort of HIV-uninfected women with favourable retention, enabling us to study the natural history of HIV-1 during acute HIV-infection. Our experiences provide lessons for others establishing similar cohorts, which will be key for advancing the vaccine and prevention research agenda in resource-constrained settings.	[van Loggerenberg, Francois; Mlisana, Koleka; Williamson, Carolyn; Auld, Sara C.; Morris, Lynn; Gray, Clive M.; Karim, Quarraisha Abdool; Grobler, Anneke; Barnabas, Nomampondo; Iriogbe, Itua; Karim, Salim S. Abdool] Univ KwaZulu Natal, Ctr AIDS Programme Res S Africa, Durban, South Africa; [Williamson, Carolyn] Univ Cape Town, Inst Infect Dis & Mol Med, Cape Town, South Africa; [Auld, Sara C.; Karim, Quarraisha Abdool; Karim, Salim S. Abdool] Columbia Univ, New York, NY USA; [Morris, Lynn; Gray, Clive M.] Natl Inst Communicable Dis, Johannesburg, South Africa	University of Kwazulu Natal; University of Cape Town; Columbia University; National Institute for Communicable Diseases (NICD)	van Loggerenberg, F (corresponding author), Univ KwaZulu Natal, Ctr AIDS Programme Res S Africa, Durban, South Africa.	loggerenbergf@ukzn.ac.za	Karim, Salim Abdool/AAE-7118-2019; Karim, Salim Abdool/P-3117-2019; Morris, Lynn/V-3941-2018; Karim, Salim Safurdeen Abdool/N-5947-2013; Abdool Karim, Quarraisha/GVS-1160-2022; Mlisana, Koleka/N-6204-2013	Karim, Salim Abdool/0000-0002-4986-2133; Morris, Lynn/0000-0003-3961-7828; Karim, Salim Safurdeen Abdool/0000-0002-4986-2133; Abdool Karim, Quarraisha/0000-0002-0985-477X; Mlisana, Koleka/0000-0002-8436-3268; Grobler, Anneke/0000-0002-7809-7688; van Loggerenberg, Francois/0000-0001-5317-7983; Gray, Clive/0000-0002-9293-901X; , Carolyn/0000-0003-0125-1226	National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH) [U19 AI51794]; US Department of Health and Human Services (DHHS) [U19 AI51794]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI051794] Funding Source: NIH RePORTER	National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); US Department of Health and Human Services (DHHS); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	CAPRISA received support for the CAPRISA 002 Acute Infection Study from the Comprehensive International Program of Research on AIDS (CIPRA) funded by the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH) and the US Department of Health and Human Services (DHHS) (Grant#1 U19 AI51794). The funders supported the initial development of the protocol but had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ABDOOLKARIM Q, 1995, AM J PUBLIC HEALTH, V85, P1521; Allen TM, 2005, J VIROL, V79, P13239, DOI 10.1128/JVI.79.21.13239-13249.2005; Begaud E, 2006, RETROVIROLOGY, V3, DOI 10.1186/1742-4690-3-35; Bollinger RC, 1997, JAMA-J AM MED ASSOC, V278, P2085, DOI 10.1001/jama.278.23.2085; Costello C, 2005, INT J EPIDEMIOL, V34, P577, DOI 10.1093/ije/dyi023; Deschamps MM, 2000, AIDS, V14, P2515, DOI 10.1097/00002030-200011100-00014; Dunkle KL, 2004, SOC SCI MED, V59, P1581, DOI 10.1016/j.socscimed.2004.02.003; Fowke KR, 1998, AIDS RES HUM RETROV, V14, P1521, DOI 10.1089/aid.1998.14.1521; GOUWS E, 2005, HIV AIDS S AFRICA, P67; Hecht FM, 2002, AIDS, V16, P1119, DOI 10.1097/00002030-200205240-00005; Karim SSA, 2007, AIDS, V21, P653, DOI 10.1097/QAD.0b013e3280327923; Kiepiela P, 2004, NATURE, V432, P769, DOI 10.1038/nature03113; Lavreys L, 2000, CLIN INFECT DIS, V30, P486, DOI 10.1086/313718; Lyles RH, 2000, J INFECT DIS, V181, P872, DOI 10.1086/315339; Martin G, 2004, CLIN IMMUNOL, V111, P275, DOI 10.1016/j.clim.2004.02.004; Mlisana K, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001626; Paxton WA, 1996, NAT MED, V2, P412, DOI 10.1038/nm0496-412; Ramjee G, 1998, SEX TRANSM DIS, V25, P346, DOI 10.1097/00007435-199808000-00004; Ramjee G, 2000, AIDS, V14, P2553, DOI 10.1097/00002030-200011100-00018; Rowland-Jones SL, 1998, J CLIN INVEST, V102, P1758, DOI 10.1172/JCI4314; Saah AJ, 1998, AIDS, V12, P2107, DOI 10.1097/00002030-199816000-00005; SHISANA O, 2005, S AFRICAN NATL HIV P, P33; Steyn K, 2001, J HYPERTENS, V19, P1717, DOI 10.1097/00004872-200110000-00004; Stremlau M, 2004, NATURE, V427, P848, DOI 10.1038/nature02343; Truong LX, 2003, AIDS, V17, P1425, DOI 10.1097/00002030-200307040-00002; Vanhems P, 2003, JAIDS-J ACQ IMM DEF, V32, P542, DOI 10.1097/00126334-200304150-00012; West GR, 2007, AIDS EDUC PREV, V19, P275, DOI 10.1521/aeap.2007.19.4.275	27	145	147	0	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1954	10.1371/journal.pone.0001954	http://dx.doi.org/10.1371/journal.pone.0001954			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414658	gold, Green Published, Green Accepted, Green Submitted			2022-12-25	WOS:000260867300007
J	Boultwood, J; Pellagatti, A; Nikpour, M; Pushkaran, B; Fidler, C; Cattan, H; Littlewood, TJ; Malcovati, L; Della Porta, MG; Jadersten, M; Killick, S; Giagounidis, A; Bowen, D; Hellstrom-Lindberg, E; Cazzola, M; Wainscoat, JS				Boultwood, Jacqueline; Pellagatti, Andrea; Nikpour, Maryam; Pushkaran, Beena; Fidler, Carrie; Cattan, Helen; Littlewood, Tim J.; Malcovati, Luca; Della Porta, Matteo G.; Jadersten, Martin; Killick, Sally; Giagounidis, Aristoteles; Bowen, David; Hellstrom-Lindberg, Eva; Cazzola, Mario; Wainscoat, James S.			The Role of the Iron Transporter ABCB7 in Refractory Anemia with Ring Sideroblasts	PLOS ONE			English	Article							GENE-EXPRESSION; MUTATION; ATAXIA; CELLS; IDENTIFICATION; CANDIDATE; COMPLEX; IMPACT	Refractory Anemia with Ring Sideroblasts (RARS) is an acquired myelodysplastic syndrome (MDS) characterized by an excess iron accumulation in the mitochondria of erythroblasts. The pathogenesis of RARS and the cause of this unusual pattern of iron deposition remain unknown. We considered that the inherited X-linked sideroblastic anemia with ataxia (XLSA/A) might be informative for the acquired disorder, RARS. XLSA/A is caused by partial inactivating mutations of the ABCB7 ATP-binding cassette transporter gene, which functions to enable transport of iron from the mitochondria to the cytoplasm. Furthermore, ABCB7 gene silencing in HeLa cells causes an accumulation of iron in the mitochondria. We have studied the role of ABCB7 in RARS by DNA sequencing, methylation studies, and gene expression studies in primary CD34(+) cells and in cultured erythroblasts. The DNA sequence of the ABCB7 gene is normal in patients with RARS. We have investigated ABCB7 gene expression levels in the CD34(+) cells of 122 MDS cases, comprising 35 patients with refractory anemia (RA), 33 patients with RARS and 54 patients with RA with excess blasts (RAEB), and in the CD34(+) cells of 16 healthy controls. We found that the expression levels of ABCB7 are significantly lower in the RARS group. RARS is thus characterized by lower levels of ABCB7 gene expression in comparison to other MDS subtypes. Moreover, we find a strong relationship between increasing percentage of bone marrow ring sideroblasts and decreasing ABCB7 gene expression levels. Erythroblast cell cultures confirm the low levels of ABCB7 gene expression levels in RARS. These data provide an important link between inherited and acquired forms of sideroblastic anemia and indicate that ABCB7 is a strong candidate gene for RARS.	[Boultwood, Jacqueline; Pellagatti, Andrea; Pushkaran, Beena; Fidler, Carrie; Cattan, Helen; Littlewood, Tim J.; Wainscoat, James S.] John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, LRF Mol Haematol Unit, Oxford OX3 9DU, England; [Nikpour, Maryam; Jadersten, Martin; Hellstrom-Lindberg, Eva] Karolinska Inst, Dept Med, Div Hematol, Stockholm, Sweden; [Malcovati, Luca; Della Porta, Matteo G.; Cazzola, Mario] Univ Pavia, Med Sch, IRCCS Policlinico S Matteo, Pavia, Italy; [Killick, Sally] Royal Bournemouth Hosp, Dept Haematol, Bournemouth, Dorset, England; [Giagounidis, Aristoteles] St Johannes Hosp, Medizinische Klin 2, Duisburg, Germany; [Bowen, David] Leeds Teaching Hosp, Haematol Dept, Leeds, W Yorkshire, England	University of Oxford; Karolinska Institutet; IRCCS Fondazione San Matteo; University of Pavia; St. Johannes Hospital; University of Leeds	Boultwood, J (corresponding author), John Radcliffe Hosp, Nuffield Dept Clin Lab Sci, LRF Mol Haematol Unit, Oxford OX3 9DU, England.	jacqueline.boultwood@ndcls.ox.ac.uk	Cazzola, Mario/AAQ-8854-2021; Malcovati, Luca/CAJ-1695-2022; Giagounidis, Aristoteles/S-7097-2019; Giagounidis, Aristoteles/ABE-3927-2020	Cazzola, Mario/0000-0001-6984-8817; Malcovati, Luca/0000-0002-1460-1611; Giagounidis, Aristoteles/0000-0003-4083-4109; Pellagatti, Andrea/0000-0002-6122-0221; Boultwood, Jacqueline/0000-0002-4330-2928; Della Porta, Matteo Giovanni/0000-0002-6915-5970	Leukaemia Research Fund of the UK; AIRC (Associazione Italiana per la Ricerca sul Cancro), Milan; Fondazione IRCCS Policlinico San Matteo, Pavia	Leukaemia Research Fund of the UK; AIRC (Associazione Italiana per la Ricerca sul Cancro), Milan(Fondazione AIRC per la ricerca sul cancro); Fondazione IRCCS Policlinico San Matteo, Pavia	This work was supported by the Leukaemia Research Fund of the UK, and in part by grants from AIRC (Associazione Italiana per la Ricerca sul Cancro), Milan, and Fondazione IRCCS Policlinico San Matteo, Pavia, to M.C.	Allikmets R, 1999, HUM MOL GENET, V8, P743, DOI 10.1093/hmg/8.5.743; Bekri S, 2000, BLOOD, V96, P3256; BENNETT JM, 1982, BRIT J HAEMATOL, V51, P189, DOI 10.1111/j.1365-2141.1982.tb08475.x; Breccia M, 2006, LEUKEMIA RES, V30, P178, DOI 10.1016/j.leukres.2005.06.015; Cavadini P, 2007, BLOOD, V109, P3552, DOI 10.1182/blood-2006-08-041632; Cazzola M, 2003, BLOOD, V101, P1996, DOI 10.1182/blood-2002-07-2006; COTTER PD, 1994, BLOOD, V84, P3915, DOI 10.1182/blood.V84.11.3915.bloodjournal84113915; Furuyama K, 2002, CELL MOL BIOL, V48, P5; Gibbons RJ, 2003, NAT GENET, V34, P446, DOI 10.1038/ng1213; Greenberg Peter L, 2002, Hematology Am Soc Hematol Educ Program, P136; Heaney ML, 1999, NEW ENGL J MED, V340, P1649, DOI 10.1056/NEJM199905273402107; HINES J D, 1970, Seminars in Hematology, V7, P86; Kim JH, 2002, P NATL ACAD SCI USA, V99, P1241, DOI 10.1073/pnas.251672198; Kispal G, 1997, FEBS LETT, V418, P346, DOI 10.1016/S0014-5793(97)01414-2; Krogan NJ, 2001, MOL CELL BIOL, V21, P8203, DOI 10.1128/MCB.21.23.8203-8212.2001; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Oscarson M, 2006, CLIN PHARMACOL THER, V80, P440, DOI 10.1016/j.clpt.2006.08.013; Pellagatti A, 2007, P NATL ACAD SCI USA, V104, P11406, DOI 10.1073/pnas.0610477104; Pellagatti A, 2006, BLOOD, V108, P337, DOI 10.1182/blood-2005-12-4769; Pondarre C, 2007, BLOOD, V109, P3567, DOI 10.1182/blood-2006-04-015768; Shimada Y, 1998, J HUM GENET, V43, P115, DOI 10.1007/s100380050051; Steensma DP, 2007, LEUKEMIA RES, V31, P623, DOI 10.1016/j.leukres.2006.06.005; Tehranchi R, 2003, BLOOD, V101, P1080, DOI 10.1182/blood-2002-06-1774; Warner MH, 2007, MOL CELL BIOL, V27, P6103, DOI 10.1128/MCB.00772-07; WEATHERALL DJ, 1970, LANCET, V2, P744; Weber M, 2007, NAT GENET, V39, P457, DOI 10.1038/ng1990	26	92	100	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1970	10.1371/journal.pone.0001970	http://dx.doi.org/10.1371/journal.pone.0001970			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398482	Green Published, Green Submitted, gold			2022-12-25	WOS:000260795500035
J	Siegel, M; Strnad, P; Watts, RE; Choi, KH; Jabri, B; Omary, MB; Khosla, C				Siegel, Matthew; Strnad, Pavel; Watts, R. Edward; Choi, Kihang; Jabri, Bana; Omary, M. Bishr; Khosla, Chaitan			Extracellular Transglutaminase 2 Is Catalytically Inactive, but Is Transiently Activated upon Tissue Injury	PLOS ONE			English	Article								Transglutaminase 2 (TG2) is a multifunctional mammalian protein with transamidase and signaling properties. Using selective TG2 inhibitors and tagged nucleophilic amine substrates, we show that the majority of extracellular TG2 is inactive under normal physiological conditions in cell culture and in vivo. However, abundant TG2 activity was detected around the wound in a standard cultured fibroblast scratch assay. To demonstrate wounding-induced activation of TG2 in vivo, the toll-like receptor 3 ligand, polyinosinic-polycytidylic acid (poly(I:C)), was injected in mice to trigger small intestinal injury. Although no TG2 activity was detected in vehicle-treated mice, acute poly(I:C) injury resulted in rapid TG2 activation in the small intestinal mucosa. Our findings provide a new basis for understanding the role of TG2 in physiology and disease.	[Siegel, Matthew; Khosla, Chaitan] Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA; [Strnad, Pavel; Omary, M. Bishr] VA Palo Alto Hlth Care Syst, Dept Med, Palo Alto, CA USA; [Watts, R. Edward; Choi, Kihang; Khosla, Chaitan] Stanford Univ, Dept Chem, Stanford, CA USA; [Jabri, Bana] Univ Chicago, Dept Pathol, Med & Pediat, Chicago, IL USA; [Khosla, Chaitan] Stanford Univ, Dept Biochem, Stanford, CA USA	Stanford University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Palo Alto Health Care System; Stanford University; University of Chicago; Stanford University	Siegel, M (corresponding author), Stanford Univ, Dept Chem Engn, Stanford, CA 94305 USA.	khosla@stanford.edu	Strnad, Pavel/E-8555-2010	Khosla, Chaitan/0000-0001-6529-495X; Omary, Bishr/0000-0002-8624-2347; Choi, Kihang/0000-0001-5196-4107	NIH [DK063158, DK052951, DK067180]; Department of Veterans Affairs; Stanford-NIH Digestive Disease Center [DK056339]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067180, R01DK063158, P30DK056339, R56DK052951, R01DK052951] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Department of Veterans Affairs(US Department of Veterans Affairs); Stanford-NIH Digestive Disease Center; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	This research was jointly supported by NIH grant DK063158 (C.K.), NIH grant DK052951 and the Department of Veterans Affairs (M.B.O.), NIH grant DK067180 (B.J.) and the Stanford-NIH Digestive Disease Center (DK056339). The NIH played no role in the design or conduction of the study.	AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; Akimov SS, 2000, J CELL BIOL, V148, P825, DOI 10.1083/jcb.148.4.825; Akimov SS, 2001, J CELL SCI, V114, P2989; Antonyak MA, 2004, J BIOL CHEM, V279, P41461, DOI 10.1074/jbc.M404976200; Begg GE, 2006, J BIOL CHEM, V281, P12603, DOI 10.1074/jbc.M600146200; Bernassola F, 2002, FASEB J, V16, P1371, DOI 10.1096/fj.01-0689com; Case A, 2003, BIOCHEMISTRY-US, V42, P9466, DOI 10.1021/bi030084z; Choi K, 2005, CHEM BIOL, V12, P469, DOI 10.1016/j.chembiol.2005.02.007; DARGENIO G, 1989, GUT, V30, P950, DOI 10.1136/gut.30.7.950; De Laurenzi V, 2001, MOL CELL BIOL, V21, P148, DOI 10.1128/MCB.21.1.148-155.2001; Esposito C, 2003, AM J GASTROENTEROL, V98, P1813, DOI [10.1016/S0002-9270(03)00431-3, 10.1111/j.1572-0241.2003.07582.x]; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Hoffner G, 2005, FRONT BIOSCI-LANDMRK, V10, P3078, DOI 10.2741/1764; Korponay-Szabo IR, 2003, GUT, V52, P199, DOI 10.1136/gut.52.2.199; Kulka A, 2006, MOL IMMUNOL, V43, P1579, DOI 10.1016/j.molimm.2005.09.019; LORAND L, 1972, ANAL BIOCHEM, V50, P623, DOI 10.1016/0003-2697(72)90074-7; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; Maiuri L, 2005, GASTROENTEROLOGY, V129, P1400, DOI 10.1053/j.gastro.2005.07.054; Mangala LS, 2007, ONCOGENE, V26, P2459, DOI 10.1038/sj.onc.1210035; Mangala LS, 2005, PROG EXP TUMOR RES, V38, P125; Mehta K, 2004, CLIN CANCER RES, V10, P8068, DOI 10.1158/1078-0432.CCR-04-1107; Molberg O, 2001, EUR J IMMUNOL, V31, P1317, DOI 10.1002/1521-4141(200105)31:5<1317::AID-IMMU1317>3.0.CO;2-I; Molberg O, 2000, J PEDIATR GASTR NUTR, V30, P232, DOI 10.1097/00005176-200003000-00005; Nakamaru M, 1998, CANCER CHEMOTH PHARM, V41, P98; NANDA N, J BIOL CHEM, V276, P20678; Naruhashi K, 2000, CLIN EXP PHARMACOL P, V27, P980, DOI 10.1046/j.1440-1681.2000.03380.x; Pinkas DM, 2007, PLOS BIOL, V5, P2788, DOI 10.1371/journal.pbio.0050327; Piper JL, 2004, J PHARMACOL EXP THER, V311, P213, DOI 10.1124/jpet.104.068429; Shan L, 2002, SCIENCE, V297, P2275, DOI 10.1126/science.1074129; Siegel M, 2007, PHARMACOL THERAPEUT, V115, P232, DOI 10.1016/j.pharmthera.2007.05.003; Smethurst PA, 1996, BIOCHEM J, V313, P803, DOI 10.1042/bj3130803; Sollid LM, 2002, NAT REV IMMUNOL, V2, P647, DOI 10.1038/nri885; Strnad P, 2006, FEBS LETT, V580, P2351, DOI 10.1016/j.febslet.2006.03.051; Strnad P, 2007, GASTROENTEROLOGY, V132, P1515, DOI 10.1053/j.gastro.2007.02.020; Szebeni B, 2007, J PEDIATR GASTR NUTR, V45, P187, DOI 10.1097/MPG.0b013e318064514a; Telci D, 2006, FRONT BIOSCI-LANDMRK, V11, P867, DOI 10.2741/1843; UPCHURCH HF, 1991, J CELL PHYSIOL, V149, P375, DOI 10.1002/jcp.1041490304; Watts RE, 2006, J MED CHEM, V49, P7493, DOI 10.1021/jm060839a; Wodzinska JM, 2005, MINI-REV MED CHEM, V5, P279, DOI 10.2174/1389557053175416; Xia J, 2006, J AM CHEM SOC, V128, P1859, DOI 10.1021/ja056423o; Yuan L, 2007, ONCOGENE, V26, P2563, DOI 10.1038/sj.onc.1210048; Yuan L, 2005, MOL CANCER THER, V4, P1293, DOI 10.1158/1535-7163.MCT-04-0328; ZEMSKOV EA, 2006, FRONT BIOSCI, V11, P173; Zhang JW, 1998, J BIOL CHEM, V273, P2288, DOI 10.1074/jbc.273.4.2288; Zhang JW, 1998, J NEUROCHEM, V71, P240; Zhou RB, 2007, J IMMUNOL, V178, P4548, DOI 10.4049/jimmunol.178.7.4548	46	145	145	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1861	10.1371/journal.pone.0001861	http://dx.doi.org/10.1371/journal.pone.0001861			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365016	Green Submitted, Green Published, gold			2022-12-25	WOS:000260762400022
J	Andreeva, AV; Kutuzov, MA; Voyno-Yasenetskaya, TA				Andreeva, Alexandra V.; Kutuzov, Mikhail A.; Voyno-Yasenetskaya, Tatyana A.			G alpha 12 is targeted to the mitochondria and affects mitochondrial morphology and motility	FASEB JOURNAL			English	Article						heterotrimeric G proteins; Bcl-2; Hsp90; mitochondrial fission; organelle motility	PROTEIN-COUPLED RECEPTORS; HETEROTRIMERIC G-PROTEINS; OUTER-MEMBRANE; ANTIAPOPTOTIC FUNCTION; ACTIN-FILAMENTS; BCL-2; FUSION; HSP90; STIMULATION; ACTIVATION	G alpha 12 constitutes, along with G alpha 13, one of the four families of alpha subunits of heterotrimeric G proteins. We found that the N terminus of G alpha 12, but not those of other G alpha subunits, contains a predicted mitochondrial targeting sequence. Using confocal microscopy and cell fractionation, we demonstrated that up to 40% of endogenous G alpha 12 in human umbilical vein endothelial cells colocalize with mitochondrial markers. N-terminal sequence of G alpha 12 fused to GFP efficiently targeted the fusion protein to mitochondria. G alpha 12 with mutated mitochondrial targeting sequence was still located in mitochondria, suggesting the existence of additional mechanisms for mitochondrial localization. Lysophosphatidic acid, one of the known stimuli transduced by G alpha 12/13, inhibited mitochondrial motility, while depletion of endogenous G alpha 12 increased mitochondrial motility. G alpha 12Q229L variants uncoupled from RhoGEFs (but not fully functional activated G alpha 12Q229L) induced transformation of the mitochondrial network into punctate mitochondria and resulted in a loss of mitochondrial membrane potential. All examined G alpha 12Q229L variants reduced phosphorylation of Bcl-2 at Ser-70, while only mutants unable to bind RhoGEFs also decreased cellular levels of Bcl-2. These G alpha 12 mutants were also more efficient Hsp90 interactors. These findings are the first demonstration of a heterotrimeric G protein alpha subunit specifically targeted to mitochondria and involved in the control of mitochondrial morphology and dynamics.	[Andreeva, Alexandra V.; Kutuzov, Mikhail A.; Voyno-Yasenetskaya, Tatyana A.] Univ Illinois, Dept Pharmacol, Chicago, IL 60612 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Voyno-Yasenetskaya, TA (corresponding author), Univ Illinois, Dept Pharmacol, MC 868,909 S Wolcott Ave, Chicago, IL 60612 USA.	tvy@uic.edu		Kutuzov, Mikhail/0000-0003-3386-4350	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065160, R55GM056159, R01GM056159] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL06078] Funding Source: Medline; NIGMS NIH HHS [R55 GM056159, R01 GM065160, R01 GM056159, GM56159, GM65160] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andreeva AV, 2006, MOL PHARMACOL, V69, P975, DOI 10.1124/mol.105.018846; Andreeva AV, 2005, J BIOL CHEM, V280, P30376, DOI 10.1074/jbc.M502844200; BEREITERHAHN J, 1994, MICROSC RES TECHNIQ, V27, P198, DOI 10.1002/jemt.1070270303; Blagosklonny MV, 2001, LEUKEMIA, V15, P869, DOI 10.1038/sj.leu.2402134; Bockaert J, 2002, INT REV CYTOL, V212, P63; Brichese L, 2004, CELL CYCLE, V3, P1312, DOI 10.4161/cc.3.10.1166; Chan DC, 2006, ANNU REV CELL DEV BI, V22, P79, DOI 10.1146/annurev.cellbio.22.010305.104638; Chan DC, 2006, CELL, V125, P1241, DOI 10.1016/j.cell.2006.06.010; Chen HC, 2003, J CELL BIOL, V160, P189, DOI 10.1083/jcb.200211046; Chen HC, 2005, HUM MOL GENET, V14, pR283, DOI 10.1093/hmg/ddi270; Chisari M, 2007, J BIOL CHEM, V282, P24092, DOI 10.1074/jbc.M704246200; Cismowski MJ, 2006, SEMIN CELL DEV BIOL, V17, P334, DOI 10.1016/j.semcdb.2006.03.003; Cohen-Saidon C, 2006, BLOOD, V107, P1413, DOI 10.1182/blood-2005-07-2648; Collins TJ, 2003, J EXP BIOL, V206, P1993, DOI 10.1242/jeb.00244; Cortese JD, 1998, EXP CELL RES, V240, P122, DOI 10.1006/excr.1998.4004; Davidson SM, 2007, CIRC RES, V100, P1128, DOI 10.1161/01.RES.0000261970.18328.1d; Delivani P, 2006, MOL CELL, V21, P761, DOI 10.1016/j.molcel.2006.01.034; Deng XM, 2004, P NATL ACAD SCI USA, V101, P153, DOI 10.1073/pnas.2533920100; Deng XM, 2001, J BIOL CHEM, V276, P23681, DOI 10.1074/jbc.M100279200; DiMauro S, 2003, NEW ENGL J MED, V348, P2656, DOI 10.1056/NEJMra022567; Fan ACY, 2006, J BIOL CHEM, V281, P33313, DOI 10.1074/jbc.M605250200; Gao SJ, 2004, J BIOL CHEM, V279, P15968, DOI 10.1074/jbc.M308504200; Hampoelz B, 2004, CELL, V119, P453, DOI 10.1016/j.cell.2004.10.025; Hollenbeck PJ, 2005, J CELL SCI, V118, P5411, DOI 10.1242/jcs.053850; Krendel M, 1998, CELL MOTIL CYTOSKEL, V40, P368, DOI 10.1002/(SICI)1097-0169(1998)40:4<368::AID-CM5>3.3.CO;2-R; Kurose H, 2003, LIFE SCI, V74, P155, DOI 10.1016/j.lfs.2003.09.003; Kutuzov MA, 2005, J BIOL CHEM, V280, P25388, DOI 10.1074/jbc.M413202200; Kuyznierewicz I, 2002, CELL BIOL INT, V26, P99, DOI 10.1006/cbir.2001.0823; Landry Y, 2006, CURR MED CHEM, V13, P51, DOI 10.2174/092986706775197953; Ligon LA, 2000, J COMP NEUROL, V427, P351, DOI 10.1002/1096-9861(20001120)427:3<351::AID-CNE3>3.0.CO;2-R; McBride HM, 2006, CURR BIOL, V16, pR551, DOI 10.1016/j.cub.2006.06.054; Meigs TE, 2005, J BIOL CHEM, V280, P18049, DOI 10.1074/jbc.M500445200; Minin AA, 2006, J CELL SCI, V119, P659, DOI 10.1242/jcs.02762; Morfini G, 2006, NAT NEUROSCI, V9, P907, DOI 10.1038/nn1717; Nagao M, 1999, ONCOGENE, V18, P4425, DOI 10.1038/sj.onc.1202832; Offermanns S, 2003, PROG BIOPHYS MOL BIO, V83, P101, DOI 10.1016/S0079-6107(03)00052-X; Orrenius S, 2007, ANNU REV PHARMACOL, V47, P143, DOI 10.1146/annurev.pharmtox.47.120505.105122; Patel TB, 2004, PHARMACOL REV, V56, P371, DOI 10.1124/pr.56.3.4; Ponimaskin E, 1998, FEBS LETT, V429, P370, DOI 10.1016/S0014-5793(98)00638-3; Quintero M, 2006, P NATL ACAD SCI USA, V103, P5379, DOI 10.1073/pnas.0601026103; Ramamurthy S, 2006, J NEUROSCI RES, V84, P1402, DOI 10.1002/jnr.21061; Rezaul K, 2005, MOL CELL PROTEOMICS, V4, P169, DOI 10.1074/mcp.M400115-MCP200; Riobo NA, 2005, TRENDS PHARMACOL SCI, V26, P146, DOI 10.1016/j.tips.2005.01.007; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Sabath E, 2008, J CELL SCI, V121, P814, DOI 10.1242/jcs.014878; Sage D, 2005, IEEE T IMAGE PROCESS, V14, P1372, DOI 10.1109/TIP.2005.852787; Schultz BE, 2001, ANNU REV BIOPH BIOM, V30, P23, DOI 10.1146/annurev.biophys.30.1.23; Sharpe JC, 2004, BBA-MOL CELL RES, V1644, P107, DOI 10.1016/j.bbamcr.2003.10.016; STRATHMANN MP, 1991, P NATL ACAD SCI USA, V88, P5582, DOI 10.1073/pnas.88.13.5582; Vaiskunaite R, 2001, J BIOL CHEM, V276, P46088, DOI 10.1074/jbc.M108711200; VOYNOYASENETSKAYA T, 1994, J BIOL CHEM, V269, P4721; Waheed AA, 2002, J BIOL CHEM, V277, P32409, DOI 10.1074/jbc.C200383200; Yaffe MP, 1999, NAT CELL BIOL, V1, pE149, DOI 10.1038/14101; Yamaguchi Y, 2003, J BIOL CHEM, V278, P14936, DOI 10.1074/jbc.M301409200; Yamamoto K, 1999, MOL CELL BIOL, V19, P8469; Yanamadala V, 2007, J BIOL CHEM, V282, P24352, DOI 10.1074/jbc.M702804200; Yi MQ, 2004, J CELL BIOL, V167, P661, DOI 10.1083/jcb.200406038; Young JC, 2003, CELL, V112, P41, DOI 10.1016/S0092-8674(02)01250-3; Zhu DG, 2007, MOL PHARMACOL, V71, P1268, DOI 10.1124/mol.106.033555; Zhu DG, 2004, J BIOL CHEM, V279, P54983, DOI 10.1074/jbc.C400508200	60	30	30	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2821	2831		10.1096/fj.07-104224	http://dx.doi.org/10.1096/fj.07-104224			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18367648	Green Published			2022-12-25	WOS:000258089300022
J	Li, D; Ambrogio, L; Shimamura, T; Kubo, S; Takahashi, M; Chirieac, LR; Padera, RF; Shapiro, GI; Baum, A; Himmelsbach, F; Rettig, WJ; Meyerson, M; Solca, F; Greulich, H; Wong, KK				Li, D.; Ambrogio, L.; Shimamura, T.; Kubo, S.; Takahashi, M.; Chirieac, L. R.; Padera, R. F.; Shapiro, G. I.; Baum, A.; Himmelsbach, F.; Rettig, W. J.; Meyerson, M.; Solca, F.; Greulich, H.; Wong, K-K			BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models	ONCOGENE			English	Article						EGFR; HER2; lung cancer; BIBW2992; therapeutics	GROWTH-FACTOR RECEPTOR; HER2 KINASE DOMAIN; TYROSINE KINASE; EGF RECEPTOR; ACQUIRED-RESISTANCE; MUTATIONS; GEFITINIB; SENSITIVITY; ADENOCARCINOMAS; TRANSFORMATION	Genetic alterations in the kinase domain of the epidermal growth factor receptor (EGFR) in non-small cell lung cancer (NSCLC) patients are associated with sensitivity to treatment with small molecule tyrosine kinase inhibitors. Although first-generation reversible, ATP-competitive inhibitors showed encouraging clinical responses in lung adenocarcinoma tumors harboring such EGFR mutations, almost all patients developed resistance to these inhibitors over time. Such resistance to first generation EGFR inhibitors was frequently linked to an acquired T790M point mutation in the kinase domain of EGFR, or upregulation of signaling pathways downstream of HER3. Overcoming these mechanisms of resistance, as well as primary resistance to reversible EGFR inhibitors driven by a subset of EGFR mutations, will be necessary for development of an effective targeted therapy regimen. Here, we show that BIBW2992, an anilino-quinazoline designed to irreversibly bind EGFR and HER2, potently suppresses the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms. Consistent with this activity, BIBW2992 suppresses transformation in isogenic cell-based assays, inhibits survival of cancer cell lines and induces tumor regression in xenograft and transgenic lung cancer models, with superior activity over erlotinib. These findings encourage further testing of BIBW2992 in lung cancer patients harboring EGFR or HER2 oncogenes.	[Solca, F.] Boehringer Ingelheim Austria, Dept Pharmacol, Vienna, Austria; [Li, D.; Ambrogio, L.; Shimamura, T.; Shapiro, G. I.; Meyerson, M.; Greulich, H.; Wong, K-K] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; [Li, D.] Harvard Univ, Ctr Canc, Ludwig Ctr, Boston, MA 02115 USA; [Ambrogio, L.; Meyerson, M.; Greulich, H.] Broad Inst Harvard, Cambridge, MA USA; [Ambrogio, L.; Meyerson, M.; Greulich, H.] MIT, Cambridge, MA 02139 USA; [Shimamura, T.; Shapiro, G. I.; Meyerson, M.; Greulich, H.; Wong, K-K] Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA; [Shimamura, T.; Shapiro, G. I.; Meyerson, M.; Greulich, H.; Wong, K-K] Harvard Univ, Sch Med, Boston, MA USA; [Kubo, S.; Takahashi, M.] Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA; [Chirieac, L. R.; Padera, R. F.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; [Himmelsbach, F.] Boehringer Ingelheim Pharma GmbH & Co KG, Biberach, Germany	Boehringer Ingelheim; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Brigham & Women's Hospital; Boehringer Ingelheim	Solca, F (corresponding author), Boehringer Ingelheim Austria, Dept Pharmacol, Dr Boehringer Gasse 5-11, Vienna, Austria.	flavio.solca@vie.boehringer-ingelheim.com	Chirieac, Lucian R./AAD-2030-2019; Meyerson, Matthew L/E-7123-2012		NATIONAL CANCER INSTITUTE [P20CA090578, R01CA122794, R01CA090687, P50CA090578] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [K08AG024004, R01AG027757] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA122794, P20 CA90578, R01 CA90687, R01 CA122794-04, P50 CA090578, R01 CA090687, P50 CA090578-06, P20 CA090578] Funding Source: Medline; NIA NIH HHS [R01 AG027757-03, R01 AG2400401, K08 AG024004, R01 AG027757] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bedano PM, 2006, J THORAC ONCOL, V1, P582, DOI 10.1097/01243894-200607000-00015; COUSSENS L, 1985, SCIENCE, V230, P1132, DOI 10.1126/science.2999974; Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Eskens F, 2008, BRIT J CANCER, V98, P80, DOI 10.1038/sj.bjc.6604108; FAN Z, 1993, CANCER RES, V53, P4637; Greulich H, 2005, PLOS MED, V2, P1167, DOI 10.1371/journal.pmed.0020313; Hurwitz E, 2000, CANCER IMMUNOL IMMUN, V49, P226, DOI 10.1007/s002620000112; Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609; Janne PA, 2005, J CLIN ONCOL, V23, P3227, DOI 10.1200/JCO.2005.09.985; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Ji HB, 2006, P NATL ACAD SCI USA, V103, P7817, DOI 10.1073/pnas.0510284103; Ji HB, 2006, CANCER CELL, V9, P485, DOI 10.1016/j.ccr.2006.04.022; Jiang JR, 2005, CANCER RES, V65, P8968, DOI 10.1158/0008-5472.CAN-05-1829; Kobayashi S, 2005, CANCER RES, V65, P7096, DOI 10.1158/0008-5472.CAN-05-1346; Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238; Krypuy M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-295; Kwak EL, 2005, P NATL ACAD SCI USA, V102, P7665, DOI 10.1073/pnas.0502860102; Lee JC, 2006, PLOS MED, V3, P2264, DOI 10.1371/journal.pmed.0030485; Li DN, 2007, CANCER CELL, V12, P81, DOI 10.1016/j.ccr.2007.06.005; Li DN, 2007, J CLIN INVEST, V117, P346, DOI 10.1172/JCI30446; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Mulloy R, 2007, CANCER RES, V67, P2325, DOI 10.1158/0008-5472.CAN-06-4293; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017; Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Rabindran SK, 2004, CANCER RES, V64, P3958, DOI 10.1158/0008-5472.CAN-03-2868; Riely GJ, 2006, CLIN CANCER RES, V12, P839, DOI 10.1158/1078-0432.CCR-05-1846; Schiffer HH, 2007, MOL PHARMACOL, V71, P508, DOI 10.1124/mol.106.027656; Shigematsu H, 2005, CANCER RES, V65, P1642, DOI 10.1158/0008-5472.CAN-04-4235; Shimamura T, 2006, CANCER RES, V66, P6487, DOI 10.1158/0008-5472.CAN-06-0971; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; Vikis H, 2007, CANCER RES, V67, P4665, DOI 10.1158/0008-5472.CAN-07-0217; Wang SZE, 2006, CANCER CELL, V10, P25, DOI 10.1016/j.ccr.2006.05.023; Yuza Y, 2007, CANCER BIOL THER, V6, P661, DOI 10.4161/cbt.6.5.4003	37	1086	1170	6	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2008	27	34					4702	4711		10.1038/onc.2008.109	http://dx.doi.org/10.1038/onc.2008.109			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408761	Green Accepted			2022-12-25	WOS:000258236300008
J	Rzymski, T; Paantjens, A; Bod, J; Harris, AL				Rzymski, T.; Paantjens, A.; Bod, J.; Harris, A. L.			Multiple pathways are involved in the anoxia response of SKIP3 including HuR-regulated RNA stability, NF-kappa B and ATF4	ONCOGENE			English	Article						ATF4; SKIP3; anoxia; RNA stability; NF-kappa B	MESSENGER-RNA; CYCLOOXYGENASE-2 EXPRESSION; GENE-EXPRESSION; HYPOXIA; ACTIVATION; BINDING; CELL; TRB3; PHOSPHORYLATION; STABILIZATION	Under anoxia a coordinated, cytoprotective program is induced, called the unfolded protein response (UPR). Activating transcription factor 4 (ATF4) is a mediator of the UPR and activates a gene expression program, promoting tumour growth and survival under anoxia. A key gene induced by ATF4 under normoxic conditions is SKIP3. We characterized the induction of SKIP3 during anoxic exposure to determine whether UPR alone was sufficient or there was a more complex regulatory response to anoxia. There was temporal separation of acute hypoxia-inducible factor (HIF)-1 alpha- and chronic ATF4-dependent gene expression programs. SKIP3 was regulated by chronic (48 h) rather than acute anoxia (< 24h) by a complex set of pathways and mechanisms, besides ATF4 induced by the classical UPR, there was transcriptional regulation by nuclear factor-kappa B (NF-kappa B)and RNA stabilization by HuR. Temporal activation of the NF-kappa B pathway under anoxia protected cells from negative consequences of the oxygen stress and involved the canonical signalling pathways that promote I kappa BA phosphorylation and degradation, and reduced mRNA level of the inhibitory protein I kappa BA followed by the translational repression of I kappa BA. We also show that SKIP3 acts as an inhibitor of NF-kappa B and ATF4-dependent transcription under anoxia and provides a regulatory feedback loop. Repression of the survival pathway NF-kappa B by SKIP3 sensitized cells to metabolic consequences of the anoxic stress. Thus, the response to anoxia is mediated by three pathways independently of HIF, suggesting that combined therapeutic approaches would be needed to maximize effects against this pathway.	[Rzymski, T.; Paantjens, A.; Bod, J.; Harris, A. L.] Univ Oxford, John Radcliffe Hosp, Mol Oncol Labs, Weatherall Inst Mol Med,Canc Res UK, Oxford OX3 9DS, England	Cancer Research UK; University of Oxford	Harris, AL (corresponding author), Univ Oxford, John Radcliffe Hosp, Mol Oncol Labs, Weatherall Inst Mol Med,Canc Res UK, Oxford OX3 9DS, England.	aharris.lab@cancer.org.uk	Harris, Adrian L/ABA-3343-2020	Harris, Adrian L/0000-0003-1376-8409	Cancer Research UK Funding Source: Medline	Cancer Research UK(Cancer Research UK)		Ameri K, 2004, BLOOD, V103, P1876, DOI 10.1182/blood-2003-06-1859; Atasoy U, 1998, J CELL SCI, V111, P3145; Blais JD, 2004, MOL CELL BIOL, V24, P7469, DOI 10.1128/MCB.24.17.7469-7482.2004; Bowers AJ, 2003, ONCOGENE, V22, P2823, DOI 10.1038/sj.onc.1206367; Brown JM, 2004, NAT REV CANCER, V4, P437, DOI 10.1038/nrc1367; Chen CY, 2001, CELL, V107, P451, DOI 10.1016/S0092-8674(01)00578-5; Cummins EP, 2006, P NATL ACAD SCI USA, V103, P18154, DOI 10.1073/pnas.0602235103; de Silanes IL, 2004, P NATL ACAD SCI USA, V101, P2987, DOI 10.1073/pnas.0306453101; Deng J, 2004, MOL CELL BIOL, V24, P10161, DOI 10.1128/MCB.24.23.10161-10168.2004; Erkinheimo TL, 2005, GYNECOL ONCOL, V99, P14, DOI 10.1016/j.ygyno.2005.04.047; Erkinheimo TL, 2003, CANCER RES, V63, P7591; Evans SM, 2003, CANCER LETT, V195, P1, DOI 10.1016/S0304-3835(03)00012-0; Grosshans J, 2000, CELL, V101, P523, DOI 10.1016/S0092-8674(00)80862-4; Harding HP, 2000, MOL CELL, V6, P1099, DOI 10.1016/S1097-2765(00)00108-8; Harding HP, 2003, MOL CELL, V11, P619, DOI 10.1016/S1097-2765(03)00105-9; Imbert V, 1996, CELL, V86, P787, DOI 10.1016/S0092-8674(00)80153-1; Jousse C, 2007, J BIOL CHEM, V282, P15851, DOI 10.1074/jbc.M611723200; Kiss-Toth E, 2004, J BIOL CHEM, V279, P42703, DOI 10.1074/jbc.M407732200; KOONG AC, 1994, CANCER RES, V54, P5273; Koritzinsky M, 2006, EMBO J, V25, P1114, DOI 10.1038/sj.emboj.7600998; Koritzinsky M, 2005, RADIOTHER ONCOL, V76, P177, DOI 10.1016/j.radonc.2005.06.036; Koumenis C, 2002, MOL CELL BIOL, V22, P7405, DOI 10.1128/MCB.22.21.7405-7416.2002; Levy NS, 1998, J BIOL CHEM, V273, P6417, DOI 10.1074/jbc.273.11.6417; Liang GS, 1997, J BIOL CHEM, V272, P24088, DOI 10.1074/jbc.272.38.24088; Mouritzen P, 2003, EXPERT REV MOL DIAGN, V3, P27, DOI 10.1586/14737159.3.1.27; Nabors LB, 2001, CANCER RES, V61, P2154; Ohoka N, 2005, EMBO J, V24, P1243, DOI 10.1038/sj.emboj.7600596; Ord D, 2005, BIOCHEM BIOPH RES CO, V330, P210, DOI 10.1016/j.bbrc.2005.02.149; Ord D, 2003, EXP CELL RES, V286, P308, DOI 10.1016/S0014-4827(03)00070-3; Pan YX, 2005, J BIOL CHEM, V280, P34609, DOI 10.1074/jbc.M507802200; Patel NS, 2005, CANCER RES, V65, P8690, DOI 10.1158/0008-5472.CAN-05-1208; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Royds JA, 1998, J CLIN PATHOL-MOL PA, V51, P55; Scheuner D, 2001, MOL CELL, V7, P1165, DOI 10.1016/S1097-2765(01)00265-9; Semenza GL, 2001, CELL, V107, P1, DOI 10.1016/S0092-8674(01)00518-9; Sheflin LG, 2004, BIOCHEM BIOPH RES CO, V322, P644, DOI 10.1016/j.bbrc.2004.07.173; TEICHER BA, 1994, CANCER METAST REV, V13, P139, DOI 10.1007/BF00689633; Wu M, 2003, J BIOL CHEM, V278, P27072, DOI 10.1074/jbc.M209814200	38	44	45	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4532	4543		10.1038/onc.2008.100	http://dx.doi.org/10.1038/onc.2008.100			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18408768				2022-12-25	WOS:000258077300003
J	Cornforth, AN; Davis, JS; Khanifar, E; Nastiuk, KL; Krolewski, JJ				Cornforth, A. N.; Davis, J. S.; Khanifar, E.; Nastiuk, K. L.; Krolewski, J. J.			FOXO3a mediates the androgen-dependent regulation of FLIP and contributes to TRAIL-induced apoptosis of LNCaP cells	ONCOGENE			English	Article						FLIP; androgen; Forkhead; TRAIL; prostate cancer; apoptosis	PROSTATE-CANCER CELLS; FORKHEAD TRANSCRIPTION FACTOR; INHIBITORY PROTEIN GENE; RAT VENTRAL PROSTATE; FACTOR FKHR; DEATH; RECEPTOR; AKT; EXPRESSION; PTEN	Androgen-withdrawal-induced apoptosis (AWIA) is deregulated in androgen refractory prostate cancer. Androgens have been shown to positively regulate expression of the antiapoptotic FADD-like interleukin-1 beta-converting enzyme (FLICE)-like inhibitory protein (FLIP), and reduced FLIP expression precedes apoptosis after androgen withdrawal. Here, we show that FLIP protein expression is downregulated in castrated rats, while in LNCaP cells, androgens regulate FLIP in a manner that is dependent on phosphoinositol-3-kinase (PI3K) and Akt signaling. Specifically, treatment of LNCaP cells with LY294002, or expression of either PTEN or a non-phosphorylatable form of FOXO3a (FOXO3aTM), downregulates FLIP protein and mRNA. Conversely, treatment with androgens in the absence of PI3/Akt signaling, or following expression of FOXO3aTM, leads to increased FLIP expression. A FOXO3a binding site was identified in the FLIP promoter and shown necessary for the combined effects of androgens and FOXO3a on FLIP transcription. FOXO3a binds the androgen receptor, suggesting that the transcriptional synergy depends on an interaction between these proteins. Finally, LNCaP cells are sensitized to TRAIL-induced apoptosis by PTEN or LY294002, and rescued by androgens. FOX-O3aTMalso sensitizes cells to androgen-inhibited TRAIL apoptosis. Androgen rescue was diminished when either FOXO3a or FLIP was reduced by siRNA. These data support a role for FOXO3a in AWIA.	[Cornforth, A. N.; Davis, J. S.; Khanifar, E.; Nastiuk, K. L.; Krolewski, J. J.] Univ Calif Irvine, Dept Pathol & Lab Med, Sch Med, Irvine, CA 92697 USA; [Krolewski, J. J.] Univ Calif Irvine, Chao Family Comprehens Canc Ctr, Sch Med, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Krolewski, JJ (corresponding author), Univ Calif Irvine, Dept Pathol & Lab Med, Sch Med, Med Sci 1 D450, Irvine, CA 92697 USA.	jkrolews@uci.edu		Davis, Jennifer/0000-0001-9456-1682	NATIONAL CANCER INSTITUTE [T32CA009054] Funding Source: NIH RePORTER; NCI NIH HHS [5T32CA009054] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ayala G, 2004, CLIN CANCER RES, V10, P6572, DOI 10.1158/1078-0432.CCR-04-0477; Bertram J, 2006, PROSTATE, V66, P895, DOI 10.1002/pros.20411; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819; Daskivich TJ, 2006, CURR OPIN UROL, V16, P173, DOI 10.1097/01.mou.0000193392.77469.e2; de la Taille A, 1999, PROSTATE, V40, P89, DOI 10.1002/(SICI)1097-0045(19990701)40:2<89::AID-PROS4>3.0.CO;2-E; Furutani T, 2002, BIOCHEM BIOPH RES CO, V294, P779, DOI 10.1016/S0006-291X(02)00564-8; Gao S, 2005, MOL ENDOCRINOL, V19, P1792, DOI 10.1210/me.2004-0445; Gao S, 2006, J MOL ENDOCRINOL, V36, P463, DOI 10.1677/jme.1.01991; Hermans KG, 2004, GENE CHROMOSOME CANC, V39, P171, DOI 10.1002/gcc.10311; Huang HJ, 2004, J BIOL CHEM, V279, P13866, DOI 10.1074/jbc.M314143200; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Kimura K, 2001, CANCER RES, V61, P5611; Krueger A, 2001, J BIOL CHEM, V276, P20633, DOI 10.1074/jbc.M101780200; KYPRIANOU N, 1988, ENDOCRINOLOGY, V122, P552, DOI 10.1210/endo-122-2-552; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Li PF, 2003, MOL CELL BIOL, V23, P104, DOI 10.1128/MCB.23.1.104-118.2003; Li PF, 2001, J BIOL CHEM, V276, P20444, DOI 10.1074/jbc.M010226200; Liao YD, 2003, INT J CANCER, V107, P676, DOI 10.1002/ijc.11471; Longley DB, 2006, ONCOGENE, V25, P838, DOI 10.1038/sj.onc.1209122; Lynch RL, 2005, MOL CANCER RES, V3, P163, DOI 10.1158/1541-7786.MCR-04-0163; Majumder PK, 2005, ONCOGENE, V24, P7465, DOI 10.1038/sj.onc.1209096; Marti A, 1999, CELL DEATH DIFFER, V6, P1190, DOI 10.1038/sj.cdd.4400610; MARTIKAINEN P, 1990, ENDOCRINOLOGY, V127, P2963, DOI 10.1210/endo-127-6-2963; Matys V, 2003, NUCLEIC ACIDS RES, V31, P374, DOI 10.1093/nar/gkg108; Nastiuk KL, 2003, J CELL PHYSIOL, V196, P386, DOI 10.1002/jcp.10283; Nesterov A, 2001, J BIOL CHEM, V276, P10767, DOI 10.1074/jbc.M005196200; Nesterov A, 2002, ONCOGENE, V21, P1135, DOI 10.1038/sj.onc.1205151; Panka DJ, 2001, J BIOL CHEM, V276, P6893, DOI 10.1074/jbc.C000569200; Roth W, 2004, VITAM HORM, V67, P189; Shaw G, 2002, FASEB J, V16, P869, DOI 10.1096/fj.01-0995fje; Skurk C, 2004, J BIOL CHEM, V279, P1513, DOI 10.1074/jbc.M304736200; Srikanth S, 1998, CANCER RES, V58, P834; Sugihara A, 2001, IN VIVO, V15, P385; Suzuki A, 1996, ONCOGENE, V13, P31; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; Yuan XJ, 2002, ONCOGENE, V21, P319, DOI 10.1038/sj/onc/1205054; Zhang XP, 2004, CANCER RES, V64, P7086, DOI 10.1158/0008-5472.CAN-04-1498	38	52	54	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4422	4433		10.1038/onc.2008.80	http://dx.doi.org/10.1038/onc.2008.80			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18391984				2022-12-25	WOS:000257881700005
J	Ozgen, N; Obreztchikova, M; Guo, JF; Elouardighi, H; Dorn, GW; Wilson, BA; Steinberg, SF				Ozgen, Nazira; Obreztchikova, Maria; Guo, Jianfen; Elouardighi, Hasnae; Dorn, Gerald W., II; Wilson, Brenda A.; Steinberg, Susan F.			Protein kinase D links G(q)-coupled receptors to cAMP response element-binding protein (CREB)-Ser(133) phosphorylation in the heart	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT CARDIAC MYOCYTES; CREB TRANSCRIPTION FACTOR; C-DELTA; IN-VIVO; DEPENDENT ACTIVATION; SIGNALING PATHWAYS; B-LYMPHOCYTES; MUSCLE-CELLS; PKC-DELTA; D FAMILY	Many growth regulatory stimuli promote cAMP response element-binding protein (CREB) Ser(133) phosphorylation, but the physiologically relevant CREB-Ser(133) kinase(s) in the heart remains uncertain. This study identifies a novel role for protein kinase D (PKD) as an in vivo cardiac CREB-Ser(133) kinase. We show that thrombin activates a PKC delta-PKD pathway leading to CREB-Ser(133) phosphorylation in cardiomyocytes and cardiac fibroblasts. alpha(1)-Adrenergic receptors also activate a PKC delta-PKD-CREB-Ser(133) phosphorylation pathway in cardiomyocytes. Of note, while the epidermal growth factor (EGF) promotes CREB-Ser(133) phosphorylation via an ERK-RSK pathway in cardiac fibroblasts, the thrombin-dependent EGFR transactivation pathway leading to ERK-RSK activation does not lead to CREB-Ser(133) phosphorylation in this cell type. Adenoviral-mediated overexpression of PKC delta(but not PKC epsilon or PKC alpha) activates PKD; PKC delta and PKD1-S744E/S748E overexpression both promote CREB-Ser(133) phosphorylation. Pasteuralla multocida toxin (PMT), a direct G alpha(q) agonist that induces robust cardiomyocyte hypertrophy, also activates the PKD-CREB-Ser(133) phosphorylation pathway, leading to the accumulation of active PKD and Ser(133)-phosphorylated CREB in the nucleus, activation of a CRE-responsive promoter, and increased Bcl-2 (CREB target gene) expression in cardiomyocyte cultures. Cardiac-specific G alpha(q) overexpression also leads to an increase in PKD-Ser(744)/Ser(748) and CREB-Ser(133) phosphorylation as well as increased Bcl-2 protein expression in the hearts of transgenic mice. Collectively, these studies identify a novel G alpha(q)-PKC delta-PKD-CREB-Ser(133) phosphorylation pathway that is predicted to contribute to cardiac remodeling and could be targeted for therapeutic advantage in the setting of heart failure phenotypes.	[Ozgen, Nazira; Obreztchikova, Maria; Guo, Jianfen; Elouardighi, Hasnae; Steinberg, Susan F.] Columbia Univ, Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA; [Dorn, Gerald W., II] Univ Cincinnati, Cincinnati, OH 45229 USA; [Wilson, Brenda A.] Univ Illinois, Dept Microbiol, Urbana, IL 61801 USA	Columbia University; University System of Ohio; University of Cincinnati; University of Illinois System; University of Illinois Urbana-Champaign	Steinberg, SF (corresponding author), Columbia Univ, Coll Phys & Surg, Dept Pharmacol, 630 West,168 St, New York, NY 10032 USA.	sfs1@columbia.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL028958, R01HL067101, R01HL077860] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI038396] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-67101, HL-28958, HL77860, R01 HL077860] Funding Source: Medline; NIAID NIH HHS [R29 AI038396] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Benes CH, 2005, CELL, V121, P271, DOI 10.1016/j.cell.2005.02.019; Blois JT, 2004, J BIOL CHEM, V279, P30123, DOI 10.1074/jbc.M402793200; Cardenas C, 2004, J BIOL CHEM, V279, P39122, DOI 10.1074/jbc.M401044200; DAngelo DD, 1997, P NATL ACAD SCI USA, V94, P8121, DOI 10.1073/pnas.94.15.8121; Darragh J, 2005, BIOCHEM J, V390, P749, DOI 10.1042/BJ20050196; Doppler H, 2007, J BIOL CHEM, V282, P31873, DOI 10.1074/jbc.M703584200; Fentzke RC, 1998, J CLIN INVEST, V101, P2415, DOI 10.1172/JCI2950; Harrison BC, 2006, MOL CELL BIOL, V26, P3875, DOI 10.1128/MCB.26.10.3875-3888.2006; Harrison JG, 2004, BBA-MOL CELL RES, V1644, P17, DOI 10.1016/j.bbamcr.2003.10.008; Haworth RS, 2004, CIRC RES, V95, P1091, DOI 10.1161/01.RES.0000149299.34793.3c; Iglesias T, 1998, J BIOL CHEM, V273, P27662, DOI 10.1074/jbc.273.42.27662; Johannessen M, 2007, J BIOL CHEM, V282, P14777, DOI 10.1074/jbc.M610669200; LAU YH, 1980, CIRC RES, V47, P41, DOI 10.1161/01.RES.47.1.41; Lefkowitz RJ, 2006, MOL CELL, V24, P643, DOI 10.1016/j.molcel.2006.11.007; Markou T, 2004, J MOL CELL CARDIOL, V37, P1001, DOI 10.1016/j.yjmcc.2004.08.002; Matthews SA, 2006, MOL CELL BIOL, V26, P1569, DOI 10.1128/MCB.26.4.1569-1577.2006; Matthews SA, 1999, J BIOL CHEM, V274, P26543, DOI 10.1074/jbc.274.37.26543; Mehrhof FB, 2001, CIRCULATION, V104, P2088, DOI 10.1161/hc4201.097133; Moens MJU, 2007, FRONT BIOSCI-LANDMRK, V12, P1814; Nishikawa K, 1997, J BIOL CHEM, V272, P952, DOI 10.1074/jbc.272.2.952; Oancea E, 2003, DEV CELL, V4, P561, DOI 10.1016/S1534-5807(03)00087-X; Obreztchikova M, 2006, J BIOL CHEM, V281, P20197, DOI 10.1074/jbc.M601859200; Olivot JM, 2001, CIRC RES, V88, P681, DOI 10.1161/hh0701.088769; Patberg KW, 2005, CARDIOVASC RES, V68, P259, DOI 10.1016/j.cardiores.2005.05.028; Pei LM, 2005, J BIOL CHEM, V280, P29256, DOI 10.1074/jbc.M502606200; Rennecke J, 1996, EUR J BIOCHEM, V242, P428, DOI 10.1111/j.1432-1033.1996.0428r.x; Rozengurt E, 2005, J BIOL CHEM, V280, P13205, DOI 10.1074/jbc.R500002200; Rybin V, 1996, CIRC RES, V79, P388, DOI 10.1161/01.RES.79.3.388; Rybin VO, 2003, J BIOL CHEM, V278, P14555, DOI 10.1074/jbc.M212644200; Sabri A, 2002, CIRC RES, V90, P850, DOI 10.1161/01.RES.0000016165.23795.1F; Sabri A, 2002, CIRC RES, V91, P532, DOI 10.1161/01.RES.0000035242.96310.45; Sapkota GP, 2007, BIOCHEM J, V401, P29, DOI 10.1042/BJ20061088; Steinberg SF, 2005, MOL PHARMACOL, V67, P2, DOI 10.1124/mol.104.003103; STEINBERG SF, 1991, CIRC RES, V68, P1216, DOI 10.1161/01.RES.68.5.1216; Storz P, 2004, MOL CELL BIOL, V24, P2614, DOI 10.1128/MCB.24.7.2614-2626.2004; Sturany S, 2001, J BIOL CHEM, V276, P3310, DOI 10.1074/jbc.M008719200; Tan MQ, 2004, ARTERIOSCL THROM VAS, V24, P2271, DOI 10.1161/01.ATV.0000148449.92035.3a; Tan MQ, 2003, J BIOL CHEM, V278, P2824, DOI 10.1074/jbc.M211523200; Trivier E, 1996, NATURE, V384, P567, DOI 10.1038/384567a0; Vega RB, 2004, MOL CELL BIOL, V24, P8374, DOI 10.1128/MCB.24.19.8374-8385.2004; Waldron RT, 1999, J BIOL CHEM, V274, P9224, DOI 10.1074/jbc.274.14.9224; Wiggin GR, 2002, MOL CELL BIOL, V22, P2871, DOI 10.1128/MCB.22.8.2871-2881.2002; Wood CD, 2005, J BIOL CHEM, V280, P6245, DOI 10.1074/jbc.M411564200; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0	44	57	59	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17009	17019		10.1074/jbc.M709851200	http://dx.doi.org/10.1074/jbc.M709851200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18378685	Green Published, hybrid			2022-12-25	WOS:000256720600007
J	Ebina, H; Chatterjee, AG; Judson, RL; Levin, HL				Ebina, Hirotaka; Chatterjee, Atreyi Ghatak; Judson, Robert L.; Levin, Henry L.			The GP(Y/F) domain of TF1 integrase multimerizes when present in a fragment, and substitutions in this domain reduce enzymatic activity of the full-length protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; TERMINAL REPEAT-RETROTRANSPOSON; RETROVIRAL DNA INTEGRATION; TYPE-1 INTEGRASE; HIV-1 INTEGRASE; FISSION YEAST; CONCERTED INTEGRATION; FUNCTIONAL DOMAINS; CATALYTIC DOMAIN; SELF-ASSOCIATION	Integrases (INs) of retroviruses and long terminal repeat retrotransposons possess a C-terminal domain with DNA binding activity. Other than this binding activity, little is known about how the C-terminal domain contributes to integration. A stretch of conserved amino acids called the GP(Y/F) domain has been identified within the C-terminal IN domains of two distantly related families, the gamma-retroviruses and the metavirus retrotransposons. To enhance understanding of the C-terminal domain, we examined the function of the GP(Y/F) domain in the IN of Tf1, a long terminal repeat retrotransposon of Schizosaccharomyces pombe. The activities of recombinant IN were measured with an assay that modeled the reverse of integration called disintegration. Although deletion of the entire C-terminal domain disrupted disintegration activity, an alanine substitution (P365A) in a conserved amino acid of the GP(Y/ F) domain did not significantly reduce disintegration. When assayed for the ability to join two molecules of DNA in a reaction that modeled forward integration, the P365A substitution disrupted activity. UV cross-linking experiments detected DNA binding activity in the C-terminal domain and found that this activity was not reduced by substitutions in two conserved amino acids of the GP(Y/F) domain, G364A and P365A. Gel filtration and cross-linking of a 71-amino acid fragment containing the GP(Y/F) domain revealed a surprising ability to form dimers, trimers, and tetramers that was disrupted by the G364A and P365A substitutions. These results suggest that the GP(Y/F) residues may play roles in promoting multimerization and intermolecular strand joining.	[Ebina, Hirotaka; Chatterjee, Atreyi Ghatak; Judson, Robert L.; Levin, Henry L.] NICHD, Sect Eukaryot Transposable Elements, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Levin, HL (corresponding author), NICHD, Sect Eukaryot Transposable Elements, Lab Gene Regulat & Dev, NIH, 18 Lib Dr, Bethesda, MD 20892 USA.	henry_levin@nih.gov		Levin, Henry/0000-0003-1728-118X	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001009] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001009] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDRAKE MD, 1995, J BIOL CHEM, V270, P29299, DOI 10.1074/jbc.270.49.29299; Atwood A, 1998, J VIROL, V72, P1324, DOI 10.1128/JVI.72.2.1324-1333.1998; Behrens R, 2000, NUCLEIC ACIDS RES, V28, P4709, DOI 10.1093/nar/28.23.4709; Bowen NJ, 2003, GENOME RES, V13, P1984, DOI 10.1101/gr.1191603; BUSHMAN FD, 1993, P NATL ACAD SCI USA, V90, P3428, DOI 10.1073/pnas.90.8.3428; Chiu R, 2003, J VIROL, V77, P6482, DOI 10.1128/JVI.77.11.6482-6492.2003; CHOW SA, 1994, J VIROL, V68, P3896, DOI 10.1128/JVI.68.6.3896-3907.1994; CHOW SA, 1992, SCIENCE, V255, P723, DOI 10.1126/science.1738845; Coleman J, 1999, J BIOL CHEM, V274, P32842, DOI 10.1074/jbc.274.46.32842; Craigie R, 2002, MOBILE DNA, P613; DYDA F, 1994, SCIENCE, V266, P1981, DOI 10.1126/science.7801124; ENGELMAN A, 1993, EMBO J, V12, P3269, DOI 10.1002/j.1460-2075.1993.tb05996.x; ENGELMAN A, 1994, J VIROL, V68, P5911, DOI 10.1128/JVI.68.9.5911-5917.1994; ENGELMAN A, 1991, CELL, V67, P1211, DOI 10.1016/0092-8674(91)90297-C; Esposito D, 1998, EMBO J, V17, P5832, DOI 10.1093/emboj/17.19.5832; FUJIWARA T, 1988, CELL, V54, P497, DOI 10.1016/0092-8674(88)90071-2; Gao X, 2008, GENOME RES, V18, P359, DOI 10.1101/gr.7146408; HICKMAN AB, 1994, J BIOL CHEM, V269, P29279; Hizi A, 2005, J BIOL CHEM, V280, P39086, DOI 10.1074/jbc.M506363200; Jenkins TM, 1996, J BIOL CHEM, V271, P7712, DOI 10.1074/jbc.271.13.7712; JERN P, 2005, RETROVIROLOGY, V2; JONES KS, 1992, J BIOL CHEM, V267, P16037; Jonsson CB, 1996, J VIROL, V70, P4585, DOI 10.1128/JVI.70.7.4585-4597.1996; KHAN E, 1991, NUCLEIC ACIDS RES, V19, P851, DOI 10.1093/nar/19.4.851; KULKOSKY J, 1995, VIROLOGY, V206, P448, DOI 10.1016/S0042-6822(95)80060-3; Lee SP, 1997, BIOCHEMISTRY-US, V36, P173, DOI 10.1021/bi961849o; LEVIN HL, 1993, EMBO J, V12, P4885, DOI 10.1002/j.1460-2075.1993.tb06178.x; Li M, 2006, EMBO J, V25, P1295, DOI 10.1038/sj.emboj.7601005; Li M, 2005, J BIOL CHEM, V280, P29334, DOI 10.1074/jbc.M505367200; Lin JH, 1997, GENE DEV, V11, P270, DOI 10.1101/gad.11.2.270; Lutzke RAP, 1998, J VIROL, V72, P4841, DOI 10.1128/JVI.72.6.4841-4848.1998; LUTZKE RAP, 1994, NUCLEIC ACIDS RES, V22, P4125, DOI 10.1093/nar/22.20.4125; Malik HS, 1999, J VIROL, V73, P5186, DOI 10.1128/JVI.73.6.5186-5190.1999; Singleton TL, 2002, EUKARYOT CELL, V1, P44, DOI 10.1128/EC.01.1.44-55.2002; Sinha S, 2002, J VIROL, V76, P3105, DOI 10.1128/JVI.76.7.3105-3113.2002; Sinha S, 2005, J VIROL, V79, P8208, DOI 10.1128/JVI.79.13.8208-8216.2005; VANGENT DC, 1993, EMBO J, V12, P3261, DOI 10.1002/j.1460-2075.1993.tb05995.x; Villanueva RA, 2003, VIROLOGY, V316, P146, DOI 10.1016/S0042-6822(03)00559-2; VINCENT KA, 1993, J VIROL, V67, P425, DOI 10.1128/JVI.67.1.425-437.1993; VINK C, 1993, NUCLEIC ACIDS RES, V21, P1419, DOI 10.1093/nar/21.6.1419; WOERNER AM, 1993, NUCLEIC ACIDS RES, V21, P3507, DOI 10.1093/nar/21.15.3507	41	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15965	15974		10.1074/jbc.M801354200	http://dx.doi.org/10.1074/jbc.M801354200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18397885	Green Published, hybrid			2022-12-25	WOS:000256332500055
J	Kim, YY; Kim, DY; Shim, D; Song, WY; Lee, J; Schroeder, JI; Kim, S; Moran, N; Lee, Y				Kim, Yu-Young; Kim, Do-Young; Shim, Donghwan; Song, Won-Yong; Lee, Joohyun; Schroeder, Julian I.; Kim, Sanguk; Moran, Nava; Lee, Youngsook			Expression of the novel wheat gene TM20 confers enhanced cadmium tolerance to bakers' yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARABIDOPSIS-THALIANA; DEFICIENT MUTANT; ABC-TRANSPORTER; MECHANISM; GLUTATHIONE; ACCUMULATION; PROTEIN; ROOTS; LEAD; HYPERACCUMULATOR	Cadmium causes the generation of reactive oxygen species, which in turn causes cell damage. We isolated a novel gene from a wheat root cDNA library, which conferred Cd(II)-specific tolerance when expressed in yeast (Saccharomyces cerevisiae). The gene, which we called TaTM20, for Triticum aestivum transmembrane 20, encodes a putative hydrophobic polypeptide of 889 amino acids, containing 20 transmembrane domains arranged as a 5-fold internal repeating unit of 4 transmembrane domains each. Expression of TaTM20 in yeast cells stimulated Cd(II) efflux resulting in a decrease in the content of yeast intracellular cadmium. TaTM20-induced Cd(II) tolerance was maintained in yeast even under conditions of reduced GSH. These results demonstrate that TaTM20 enhances Cd(II) tolerance in yeast through the stimulation of Cd(II) efflux from the cell, partially independent of GSH. Treatment of wheat seedlings with Cd(II) induced their expression of TaTM20, decreasing subsequent root Cd(II) accumulation and suggesting a possible role for TaTM20 in Cd(II) tolerance in wheat.	[Kim, Yu-Young; Kim, Do-Young; Shim, Donghwan; Song, Won-Yong; Lee, Joohyun; Lee, Youngsook] Pohang Univ Sci & Technol, POSTECH UZH Cooperat Lab, Div Mol Life Sci, Pohang 790784, South Korea; [Schroeder, Julian I.] Univ Calif San Diego, Cell & Dev Biol Sect, Div Biol Sci, La Jolla, CA 92093 USA; [Schroeder, Julian I.] Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; [Kim, Sanguk] Pohang Univ Sci & Technol, Struct Bioinformat Lab, Div Mol Life Sci, Pohang 790784, South Korea; [Moran, Nava] Hebrew Univ Jerusalem, Fac Agr Food & Environm Qual Sci, IL-76100 Rehovot, Israel; [Lee, Youngsook] Gyeongsang Natl Univ, Environm Biotechnol Natl Core Res Ctr, Jinju 660701, South Korea	Pohang University of Science & Technology (POSTECH); University of California System; University of California San Diego; University of California System; University of California San Diego; Pohang University of Science & Technology (POSTECH); Hebrew University of Jerusalem; Gyeongsang National University	Lee, Y (corresponding author), Pohang Univ Sci & Technol, POSTECH UZH Cooperat Lab, Div Mol Life Sci, Pohang 790784, South Korea.	ylee@postech.ac.kr	Shim, Donghwan/AAN-3014-2020; Lee, Youngsook/E-6578-2016	Lee, Youngsook/0000-0002-5808-9613; Lee, Joohyun/0000-0003-1696-8991; Kim, Sanguk/0000-0002-3449-3814; Schroeder, Julian/0000-0002-3283-5972	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P42ES010337] Funding Source: NIH RePORTER; NIEHS NIH HHS [P42ES010337] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Boominathan R, 2003, BIOTECHNOL BIOENG, V83, P158, DOI 10.1002/bit.10656; Chao Y, 2004, J BIOL CHEM, V279, P12043, DOI 10.1074/jbc.M313510200; Clemens S, 1998, P NATL ACAD SCI USA, V95, P12043, DOI 10.1073/pnas.95.20.12043; Clemens S, 1999, EMBO J, V18, P3325, DOI 10.1093/emboj/18.12.3325; Covello PS, 1996, PLANT PHYSIOL, V111, P223, DOI 10.1104/pp.111.1.223; Dixit V, 2001, J EXP BOT, V52, P1101, DOI 10.1093/jexbot/52.358.1101; Eun SO, 2000, PHYSIOL PLANTARUM, V110, P357, DOI 10.1034/j.1399-3054.2000.1100310.x; Ha SB, 1999, PLANT CELL, V11, P1153, DOI 10.1105/tpc.11.6.1153; HAMER DH, 1985, SCIENCE, V228, P685, DOI 10.1126/science.3887570; Hart BA, 1999, TOXICOLOGY, V133, P43, DOI 10.1016/S0300-483X(99)00013-X; Hirschi KD, 2000, PLANT PHYSIOL, V124, P125, DOI 10.1104/pp.124.1.125; HOWDEN R, 1995, PLANT PHYSIOL, V107, P1067, DOI 10.1104/pp.107.4.1067; Hsu YT, 2004, PLANT GROWTH REGUL, V42, P227, DOI 10.1023/B:GROW.0000026514.98385.5c; Hunte C, 2005, NATURE, V435, P1197, DOI 10.1038/nature03692; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; Jahrmann T, 2005, PLANTA, V222, P80, DOI 10.1007/s00425-005-1519-3; JARUP L, 1998, SCAND J WORK ENV HEA, V124, P1; Kim DY, 2007, PLANT J, V50, P207, DOI 10.1111/j.1365-313X.2007.03044.x; Kim YY, 2002, PHYSIOL PLANTARUM, V116, P368, DOI 10.1034/j.1399-3054.2002.1160312.x; Koizumi T, 1996, TOXICOLOGY, V114, P125, DOI 10.1016/S0300-483X(96)03477-4; Koren'kov V, 2007, PLANTA, V225, P403, DOI 10.1007/s00425-006-0352-7; Kupper H, 2000, PLANTA, V212, P75, DOI 10.1007/s004250000366; Larsson EH, 2002, J EXP BOT, V53, P447, DOI 10.1093/jexbot/53.368.447; Lee S, 2007, PLANT PHYSIOL, V145, P831, DOI 10.1104/pp.107.102236; Li LG, 2002, J BIOL CHEM, V277, P5360, DOI 10.1074/jbc.M108777200; Li ZS, 1996, J BIOL CHEM, V271, P6509, DOI 10.1074/jbc.271.11.6509; Lindberg S, 2007, PLANT PHYSIOL BIOCH, V45, P47, DOI 10.1016/j.plaphy.2007.01.001; Lux A, 2004, PHYSIOL PLANTARUM, V120, P537, DOI 10.1111/j.0031-9317.2004.0275.x; Meda AR, 2007, PLANT PHYSIOL, V143, P1761, DOI 10.1104/pp.106.094474; Mehdi K, 1997, MICROBIOL-UK, V143, P1885, DOI 10.1099/00221287-143-6-1885; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Moons A, 2003, FEBS LETT, V553, P370, DOI 10.1016/S0014-5793(03)01060-3; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; Nigam R, 2001, PLANT SOIL, V230, P107, DOI 10.1023/A:1004865811529; OIKI S, 1988, P NATL ACAD SCI USA, V85, P8703, DOI 10.1073/pnas.85.22.8703; Palmiter RD, 1998, P NATL ACAD SCI USA, V95, P8428, DOI 10.1073/pnas.95.15.8428; Petrovic S, 2000, YEAST, V16, P561, DOI 10.1002/(SICI)1097-0061(200004)16:6<561::AID-YEA551>3.0.CO;2-L; PREVERAL S, 2006, BIOCH PARIS, V19, P1651; Ranieri A, 2005, PLANT PHYSIOL BIOCH, V43, P45, DOI 10.1016/j.plaphy.2004.12.004; Rea PA, 1998, ANNU REV PLANT PHYS, V49, P727, DOI 10.1146/annurev.arplant.49.1.727; Sandalio LM, 2001, J EXP BOT, V52, P2115, DOI 10.1093/jexbot/52.364.2115; SCHACHTMAN DP, 1994, NATURE, V370, P655, DOI 10.1038/370655a0; Shimizu T, 2004, J MOL BIOL, V339, P1, DOI 10.1016/j.jmb.2004.03.048; Silver S, 2005, J IND MICROBIOL BIOT, V32, P587, DOI 10.1007/s10295-005-0019-6; Song WY, 2003, NAT BIOTECHNOL, V21, P914, DOI 10.1038/nbt850; Stiefel V, 1999, J BIOL CHEM, V274, P27734, DOI 10.1074/jbc.274.39.27734; Sunkar R, 2003, PLANT J, V35, P452, DOI 10.1046/j.1365-313X.2003.01819.x; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; Tommasini R, 1998, PLANT J, V13, P773, DOI 10.1046/j.1365-313X.1998.00076.x; Vatamaniuk OK, 1999, P NATL ACAD SCI USA, V96, P7110, DOI 10.1073/pnas.96.12.7110; Vitoria AP, 2001, PHYTOCHEMISTRY, V57, P701, DOI 10.1016/S0031-9422(01)00130-3; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978	53	22	25	1	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15893	15902		10.1074/jbc.M708947200	http://dx.doi.org/10.1074/jbc.M708947200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18411273	Green Published, hybrid			2022-12-25	WOS:000256332500048
J	Stokes, MJ; Guther, MLS; Turnock, DC; Prescott, AR; Martin, KL; Alphey, MS; Ferguson, MAJ				Stokes, Matthew J.; Guther, M. Lucia S.; Turnock, Daniel C.; Prescott, Alan R.; Martin, Kirstee L.; Alphey, Magnus S.; Ferguson, Michael A. J.			The synthesis of UDP-N-acetylglucosamine is essential for bloodstream form Trypanosoma brucei in vitro and in vivo and UDP-N-acetylglucosamine starvation reveals a hierarchy in parasite protein glycosylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE SUGAR TRANSPORTERS; VARIANT SURFACE GLYCOPROTEINS; AFRICAN SLEEPING SICKNESS; PHOSPHATIDYLINOSITOL MEMBRANE ANCHOR; GDP-MANNOSE PYROPHOSPHORYLASE; DE-NOVO SYNTHESIS; LEISHMANIA-MEXICANA; STRUCTURAL-CHARACTERIZATION; GALACTOSE METABOLISM; LINKED OLIGOSACCHARIDES	A gene encoding Trypanosoma brucei UDP-N-acetylglucosamine pyrophosphorylase was identified, and the recombinant protein was shown to have enzymatic activity. The parasite enzyme is unusual in having a strict substrate specificity for N-acetylglucosamine 1-phosphate and in being located inside a peroxisome-like microbody, the glycosome. A bloodstream form T. brucei conditional null mutant was constructed and shown to be unable to sustain growth in vitro or in vivo under nonpermissive conditions, demonstrating that there are no alternative metabolic or nutritional routes to UDP-N-acetylglucosamine and providing a genetic validation for the enzyme as a potential drug target. The conditional null mutant was also used to investigate the effects of N-acetylglucosamine starvation in the parasite. After 48 h under nonpermissive conditions, about 24 h before cell lysis, the status of parasite glycoprotein glycosylation was assessed. Under these conditions, UDP-N-acetylglucosamine levels were less than 5% of wild type. Lectin blotting and fluorescence microscopy with tomato lectin revealed that poly-N-acetyllactosamine structures were greatly reduced in the parasite. The principal parasite surface coat component, the variant surface glycoprotein, was also analyzed. Endoglycosidase digestions and mass spectrometry showed that, under UDP-N-acetylglucosamine starvation, the variant surface glycoprotein was specifically underglycosylated at its C-terminal Asn-428 N-glycosylation site. The significance of this finding, with respect to the hierarchy of site-specific N-glycosylation in T. brucei, is discussed.	[Stokes, Matthew J.; Guther, M. Lucia S.; Turnock, Daniel C.; Prescott, Alan R.; Martin, Kirstee L.; Alphey, Magnus S.; Ferguson, Michael A. J.] Univ Dundee, Div Biol Chem & Drug Discovery, Wellcome Trust Bioctr, Coll Life Sci, Dundee DD1 5EH, Scotland	University of Dundee	Ferguson, MAJ (corresponding author), Univ Dundee, Div Biol Chem & Drug Discovery, Wellcome Trust Bioctr, Coll Life Sci, Dundee DD1 5EH, Scotland.	m.a.j.ferguson@dundee.ac.uk	Ferguson, Michael A. J./F-7829-2010; Prescott, Alan/Y-5956-2018	Ferguson, Michael A. J./0000-0003-1321-8714; Prescott, Alan/0000-0002-0747-7317	Medical Research Council Funding Source: Medline; Wellcome Trust [071463] Funding Source: Medline	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		Atrih A, 2005, J BIOL CHEM, V280, P865, DOI 10.1074/jbc.M411061200; Azema L, 2004, BIOCHEM PHARMACOL, V67, P459, DOI 10.1016/j.bcp.2003.09.005; BANGS JD, 1988, J BIOL CHEM, V263, P17697; Berninsone PM, 2000, CURR OPIN STRUC BIOL, V10, P542, DOI 10.1016/S0959-440X(00)00128-7; BLUM ML, 1993, NATURE, V362, P603, DOI 10.1038/362603a0; Boehmelt G, 2000, EMBO J, V19, P5092, DOI 10.1093/emboj/19.19.5092; BRICKMAN MJ, 1990, J PROTOZOOL, V37, P219, DOI 10.1111/j.1550-7408.1990.tb01131.x; Caffaro CE, 2006, ACCOUNTS CHEM RES, V39, P805, DOI 10.1021/ar0400239; Chang TH, 2002, J BIOL CHEM, V277, P50176, DOI 10.1074/jbc.M208374200; Davis AJ, 2004, J BIOL CHEM, V279, P12462, DOI 10.1074/jbc.M312365200; DOERING TL, 1989, J BIOL CHEM, V264, P11168; Ferguson MAJ, 1999, J CELL SCI, V112, P2799; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; Garami A, 2001, EMBO J, V20, P3657, DOI 10.1093/emboj/20.14.3657; Garami A, 2001, MOL CELL BIOL, V21, P8168, DOI 10.1128/MCB.21.23.8168-8183.2001; Gerardy-Schahn R, 2001, BIOCHIMIE, V83, P775, DOI 10.1016/S0300-9084(01)01322-0; Guther MLS, 2006, MOL BIOL CELL, V17, P5265, DOI 10.1091/mbc.E06-08-0702; Guha-Niyogi A, 2001, GLYCOBIOLOGY, V11, p45R, DOI 10.1093/glycob/11.4.45R; Jones DC, 2005, J BIOL CHEM, V280, P35929, DOI 10.1074/jbc.M509130200; Kelleher DJ, 2006, GLYCOBIOLOGY, V16, p47R, DOI 10.1093/glycob/cwj066; Krieger S, 2000, MOL MICROBIOL, V35, P542, DOI 10.1046/j.1365-2958.2000.01721.x; Lillico S, 2003, MOL BIOL CELL, V14, P1182, DOI 10.1091/mbc.E02-03-0167; LOW P, 1991, J BIOL CHEM, V266, P19250; MacRae JI, 2006, MOL BIOCHEM PARASIT, V147, P126, DOI 10.1016/j.molbiopara.2006.02.011; Manthri S, 2008, GLYCOBIOLOGY, V18, P367, DOI 10.1093/glycob/cwn014; Martin KL, 2006, MOL MICROBIOL, V61, P89, DOI 10.1111/j.1365-2958.2006.05216.x; Martin KL, 2006, BIOCHEM J, V396, P287, DOI 10.1042/BJ20051825; McConville MJ, 2002, MICROBIOL MOL BIOL R, V66, P122, DOI 10.1128/MMBR.66.1.122-154.2002; Mendonca-Previato L, 2005, CURR OPIN STRUC BIOL, V15, P499, DOI 10.1016/j.sbi.2005.08.011; MENGINLECREULX D, 1994, J BACTERIOL, V176, P5788, DOI 10.1128/JB.176.18.5788-5795.1994; Milne KG, 2001, MOL BIOCHEM PARASIT, V112, P301, DOI 10.1016/S0166-6851(00)00369-8; Mio T, 1998, J BIOL CHEM, V273, P14392, DOI 10.1074/jbc.273.23.14392; Mok MTS, 2005, J BIOL CHEM, V280, P39363, DOI 10.1074/jbc.M509209200; Muraoka M, 2007, J BIOL CHEM, V282, P24615, DOI 10.1074/jbc.M611358200; Nagamune K, 2004, J EXP MED, V199, P1445, DOI 10.1084/jem.20030635; Nagamune K, 2000, P NATL ACAD SCI USA, V97, P10336, DOI 10.1073/pnas.180230697; Nolan DP, 1999, CURR BIOL, V9, P1169, DOI 10.1016/S0960-9822(00)80018-4; Opperdoes FR, 2007, TRENDS PARASITOL, V23, P470, DOI 10.1016/j.pt.2007.08.002; Opperdoes FR, 2006, MOL BIOCHEM PARASIT, V147, P193, DOI 10.1016/j.molbiopara.2006.02.010; Peneff C, 2001, EMBO J, V20, P6191, DOI 10.1093/emboj/20.22.6191; PREVIATO JO, 1995, J BIOL CHEM, V270, P7241, DOI 10.1074/jbc.270.13.7241; Rabina J, 2001, GLYCOCONJUGATE J, V18, P799, DOI 10.1023/A:1021107602535; Roper JR, 2005, J BIOL CHEM, V280, P19728, DOI 10.1074/jbc.M502370200; Roper JR, 2002, P NATL ACAD SCI USA, V99, P5884, DOI 10.1073/pnas.092669999; SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244; Smith TK, 2004, EMBO J, V23, P4701, DOI 10.1038/sj.emboj.7600456; Stewart J, 2005, INT J PARASITOL, V35, P861, DOI 10.1016/j.ijpara.2005.03.008; Thoden JB, 2001, J BIOL CHEM, V276, P15131, DOI 10.1074/jbc.M100220200; Titorenko VI, 2002, J CELL BIOL, V156, P481, DOI 10.1083/jcb.200111075; Tomiya N, 2001, ANAL BIOCHEM, V293, P129, DOI 10.1006/abio.2001.5091; Treumann A, 1997, J MOL BIOL, V269, P529, DOI 10.1006/jmbi.1997.1066; Turnock DC, 2007, J BIOL CHEM, V282, P28853, DOI 10.1074/jbc.M704742200; Turnock DC, 2007, EUKARYOT CELL, V6, P1450, DOI 10.1128/EC.00175-07; Urbaniak MD, 2006, EUKARYOT CELL, V5, P1906, DOI 10.1128/EC.00156-06; Wirtz E, 1999, MOL BIOCHEM PARASIT, V99, P89, DOI 10.1016/S0166-6851(99)00002-X; ZAMZE SE, 1991, J BIOL CHEM, V266, P20244	56	45	46	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16147	16161		10.1074/jbc.M709581200	http://dx.doi.org/10.1074/jbc.M709581200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18381290	hybrid, Green Published			2022-12-25	WOS:000256332500073
J	Niu, J; Azfer, A; Zhelyabovska, O; Fatma, S; Kolattukudy, PE				Niu, Jianli; Azfer, Asim; Zhelyabovska, Olga; Fatma, Sumbul; Kolattukudy, Pappachan E.			Monocyte chemotactic protein (MCP)-1 promotes angiogenesis via a novel transcription factor, MCP-1-induced protein (MCPIP)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ENDOTHELIAL-CELLS; N-CADHERIN; LUMEN FORMATION; VE-CADHERIN; GROWTH; APOPTOSIS; MCP-1; IDENTIFICATION; MORPHOGENESIS; ACTIVATION	Monocyte chemotactic protein-1 (MCP-1) has been recognized as an angiogenic chemokine. The molecular mechanism of MCP-1-mediated angiogenesis remains unknown. We recently identified a novel transcription factor, designated MCP-1-induced protein (MCPIP), in human monocytes after treatment with MCP-1. We investigated whether MCP-1-induced angiogenesis is mediated via MCPIP. Treatment of human umbilical vein endothelial cells (HUVECs) with MCP-1 induced expression of MCPIP and capillary-like tube formation. Knockdown of MCPIP by small interfering RNA (siRNA) suppressed MCP-1-induced angiogenesis-related gene VEGF and HIF-1 alpha expression as well as tube formation. Transfection of HUVECs with an MCPIP expression vector induced angiogenesis-related genes and tube formation. Chromatin immunoprecipitation analysis revealed that cadherin (cdh) 12 and cdh19 are in vivo targets of MCPIP. Transfection of HUVECs with MCPIP expression vector activated the expression of cdh12 and cdh19 genes. Knockdown of cdh12 or cdh19 expression markedly inhibited MCPIP-induced capillary-like tube formation. Moreover, knockdown of MCPIP also significantly suppressed MCP-1-induced cdh12 and cdh19 gene expression. Our data strongly suggest that MCP-1-induced angiogenesis is mediated via MCPIP, at least in part through transcriptional activation of cdh12 and cdh19.	[Niu, Jianli; Azfer, Asim; Zhelyabovska, Olga; Fatma, Sumbul; Kolattukudy, Pappachan E.] Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Orlando, FL 32826 USA	State University System of Florida; University of Central Florida	Kolattukudy, PE (corresponding author), Univ Cent Florida, Coll Med, Burnett Sch Biomed Sci, Bldg 20,Rm 136, Orlando, FL 32826 USA.	pk@mail.ucf.edu	kolattukudy, pappachan e/A-1350-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL069458, R01HL069458] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 69458] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arras M, 1998, J CLIN INVEST, V101, P40, DOI 10.1172/JCI119877; Bidzhekov K, 2006, CIRC RES, V98, P1107, DOI 10.1161/01.RES.0000223483.12225.80; Blaschuk OW, 2000, CANCER METAST REV, V19, P1, DOI 10.1023/A:1026522216059; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 2005, NATURE, V438, P932, DOI 10.1038/nature04478; Charo IF, 2004, CIRC RES, V95, P858, DOI 10.1161/01.RES.0000146672.10582.17; Cheng N, 2002, MOL CANCER RES, V1, P2; Cheng N, 2002, CYTOKINE GROWTH F R, V13, P75, DOI 10.1016/S1359-6101(01)00031-4; Deindl E, 2005, CELL BIOCHEM BIOPHYS, V43, P1, DOI 10.1385/CBB:43:1:001; Duval Helene, 2003, Angiogenesis, V6, P171, DOI 10.1023/B:AGEN.0000021390.09275.bc; Gerhardt H, 2000, DEV DYNAM, V218, P472, DOI 10.1002/1097-0177(200007)218:3<472::AID-DVDY1008>3.0.CO;2-#; Griffioen AW, 2000, PHARMACOL REV, V52, P237; Hamik A, 2006, ARTERIOSCL THROM VAS, V26, P1936, DOI 10.1161/01.ATV.0000232542.42968.e3; Heidemann J, 2003, J BIOL CHEM, V278, P8508, DOI 10.1074/jbc.M208231200; Herold J, 2004, HUM GENE THER, V15, P1, DOI 10.1089/10430340460732517; Hong KH, 2005, BLOOD, V105, P1405, DOI 10.1182/blood-2004-08-3178; ISO T, 2003, ARTERIOSC THROMB VAS, V23, P380; Ito WD, 1997, CIRC RES, V80, P829; KAMPER JT, 1994, J BIOL CHEM, V269, P9195; Kontos CD, 2007, CURR OPIN MOL THER, V9, P145; Luo Y, 2005, J CELL BIOL, V169, P29, DOI 10.1083/jcb.200411127; Moldovan NI, 2000, CIRC RES, V87, P378; Morisada T, 2006, ENDOTHELIUM-J ENDOTH, V13, P71, DOI 10.1080/10623320600697989; Myers C, 2000, J CELL BIOL, V148, P343, DOI 10.1083/jcb.148.2.343; Nelson EA, 2004, J BIOL CHEM, V279, P54724, DOI 10.1074/jbc.M408464200; Oettgen P, 2001, CIRC RES, V89, P380, DOI 10.1161/hh1701.095958; Pandya NM, 2006, VASC PHARMACOL, V44, P265, DOI 10.1016/j.vph.2006.01.005; Peters K, 2002, MICROVASC RES, V64, P334, DOI 10.1006/mvre.2002.2438; Salcedo R, 2000, BLOOD, V96, P34, DOI 10.1182/blood.V96.1.34.013a49_34_40; SALOMON D, 1992, J CELL SCI, V102, P7; Tertemiz F, 2005, BIOL REPROD, V72, P727, DOI 10.1095/biolreprod.104.034975; Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100; Voskuil M, 2003, AM J PHYSIOL-HEART C, V284, pH1422, DOI 10.1152/ajpheart.00506.2002; Zhang J, 2006, J PATHOL, V208, P453, DOI 10.1002/path.1937; Zhou LM, 2006, CIRC RES, V98, P1177, DOI 10.1161/01.RES.0000220106.64661.71	35	185	197	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14542	14551		10.1074/jbc.M802139200	http://dx.doi.org/10.1074/jbc.M802139200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18364357	Green Published, hybrid			2022-12-25	WOS:000255941400042
J	Clark, K; Middelbeek, J; Morrice, NA; Figdor, CG; Lasonder, E; van Leeuwen, FN				Clark, Kristopher; Middelbeek, Jeroen; Morrice, Nick A.; Figdor, Carl G.; Lasonder, Edwin; van Leeuwen, Frank N.			Massive Autophosphorylation of the Ser/Thr-Rich Domain Controls Protein Kinase Activity of TRPM6 and TRPM7	PLOS ONE			English	Article								TRPM6 and TRPM7 are bifunctional proteins expressing a TRP channel fused to an atypical alpha-kinase domain. While the gating properties of TRPM6 and TRPM7 channels have been studied in detail, little is known about the mechanisms regulating kinase activity. Recently, we found that TRPM7 associates with its substrate myosin II via a kinase-dependent mechanism suggesting a role for autophosphorylation in substrate recognition. Here, we demonstrate that the cytosolic C-terminus of TRPM7 undergoes massive autophosphorylation (32 +/- 4 mol/mol), which strongly increases the rate of substrate phosphorylation. Phosphomapping by mass spectrometry indicates that the majority of autophosphorylation sites (37 out of 46) map to a Ser/Thr-rich region immediately N-terminal of the catalytic domain. Deletion of this region prevents substrate phosphorylation without affecting intrinsic catalytic activity suggesting that the Ser/Thr-rich domain contributes to substrate recognition. Surprisingly, the TRPM6-kinase is regulated by an analogous mechanism despite a lack of sequence conservation with the TRPM7 Ser/Thr-rich domain. In conclusion, our findings support a model where massive autophosphorylation outside the catalytic domain of TRPM6 and TRPM7 may facilitate kinase-substrate interactions leading to enhanced phosphorylation of those substrates.	[Clark, Kristopher; Figdor, Carl G.; van Leeuwen, Frank N.] Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Tumor Immunol, NL-6525 ED Nijmegen, Netherlands; [Middelbeek, Jeroen; van Leeuwen, Frank N.] Radboud Univ Nijmegen Med Ctr, Med Ctr, Nijmegen Ctr Mol Life Sci, Lab Pediat Oncol, Nijmegen, Netherlands; [Lasonder, Edwin] Radboud Univ Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Ctr Mol & Biomol Informat, Nijmegen, Netherlands; [Morrice, Nick A.] Univ Dundee, James Black Ctr, MRC Protein Phosphorylat Unit, Dundee, Scotland	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen; University of Dundee	Clark, K (corresponding author), Radboud Univ Nijmegen, Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Tumor Immunol, NL-6525 ED Nijmegen, Netherlands.	FN.vanleeuwen@cukz.umcn.nl	Middelbeek, Jeroen/A-1126-2010; van Leeuwen, Frank/AAQ-6799-2020; Figdor, Carl G/A-4232-2010	van Leeuwen, Frank/0000-0003-1107-6513; Figdor, Carl G/0000-0002-2366-9212; Lasonder, Edwin/0000-0003-2582-3444	FEBS; Dutch Cancer Society [KUN 2002-2593, KUN 2007-3733]	FEBS; Dutch Cancer Society(KWF Kankerbestrijding)	The work was supported by a short-term fellowship from FEBS to KC and grants from the Dutch Cancer Society to FvL (KUN 2002-2593/KUN 2007-3733).	Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; Boedding M., 2007, V179, P299; Clancy CE, 1997, J BIOL CHEM, V272, P11812, DOI 10.1074/jbc.272.18.11812; Clark K, 2006, EMBO J, V25, P290, DOI 10.1038/sj.emboj.7600931; Clark K, 2007, TRENDS CELL BIOL, V17, P178, DOI 10.1016/j.tcb.2007.02.002; Demeuse P, 2006, J GEN PHYSIOL, V127, P421, DOI 10.1085/jgp.200509410; Diggle TA, 1999, FEBS LETT, V457, P189, DOI 10.1016/S0014-5793(99)01034-0; Dorovkov MV, 2004, J BIOL CHEM, V279, P50643, DOI 10.1074/jbc.C400441200; Drennan D, 2004, PROG BIOPHYS MOL BIO, V85, P1, DOI 10.1016/S0079-6107(03)00060-9; Hanano T, 2004, J PHARMACOL SCI, V95, P403, DOI 10.1254/jphs.FP0040273; Hermosura MC, 2005, P NATL ACAD SCI USA, V102, P11510, DOI 10.1073/pnas.0505149102; Kolman MF, 1997, J BIOL CHEM, V272, P16904, DOI 10.1074/jbc.272.27.16904; Kozak JA, 2003, BIOPHYS J, V84, P922, DOI 10.1016/S0006-3495(03)74909-1; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; Krapivinsky G, 2006, NEURON, V52, P485, DOI 10.1016/j.neuron.2006.09.033; Langeslag M, 2007, J BIOL CHEM, V282, P232, DOI 10.1074/jbc.M605300200; Liang WC, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-19; Matsushita M, 2005, J BIOL CHEM, V280, P20793, DOI 10.1074/jbc.M413671200; MEDLEY QG, 1990, BIOCHEMISTRY-US, V29, P8992, DOI 10.1021/bi00490a016; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; Numata T, 2007, AM J PHYSIOL-CELL PH, V292, pC460, DOI 10.1152/ajpcell.00367.2006; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; Pavur KS, 2000, BIOCHEMISTRY-US, V39, P12216, DOI 10.1021/bi0007270; Penner R., 2007, V179, P313; Pinna LA, 1996, BBA-MOL CELL RES, V1314, P191, DOI 10.1016/S0167-4889(96)00083-3; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Ryazanov AG, 2002, FEBS LETT, V514, P26, DOI 10.1016/S0014-5793(02)02299-8; Ryazanov AG, 1999, CURR BIOL, V9, pR43, DOI 10.1016/S0960-9822(99)80006-2; Ryazanova LV, 2004, J BIOL CHEM, V279, P3708, DOI 10.1074/jbc.M308820200; Schlingmann KP, 2002, NAT GENET, V31, P166, DOI 10.1038/ng889; Schmitz C, 2005, J BIOL CHEM, V280, P37763, DOI 10.1074/jbc.M509175200; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; Steimle PA, 2001, J BIOL CHEM, V276, P6853, DOI 10.1074/jbc.M008992200; Su LT, 2006, J BIOL CHEM, V281, P11260, DOI 10.1074/jbc.M512885200; Takezawa R, 2004, P NATL ACAD SCI USA, V101, P6009, DOI 10.1073/pnas.0307565101; Voets T, 2004, J BIOL CHEM, V279, P19, DOI 10.1074/jbc.M311201200; Walder RY, 2002, NAT GENET, V31, P171, DOI 10.1038/ng901; Yamaguchi H, 2001, MOL CELL, V7, P1047, DOI 10.1016/S1097-2765(01)00256-8	39	74	78	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1876	10.1371/journal.pone.0001876	http://dx.doi.org/10.1371/journal.pone.0001876			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365021	Green Published, Green Accepted, gold, Green Submitted			2022-12-25	WOS:000260762400027
J	Kasahara, T; Kubota, M; Miyauchi, T; Ishiwata, M; Kato, T				Kasahara, Takaoki; Kubota, Mie; Miyauchi, Taeko; Ishiwata, Mizuho; Kato, Tadafumi			A Marked Effect of Electroconvulsive Stimulation on Behavioral Aberration of Mice with Neuron-Specific Mitochondrial DNA Defects	PLOS ONE			English	Article								We developed transgenic (Tg) mice modeling an autosomally inherited mitochondrial disease, chronic progressive external ophthalmoplegia, patients with which sometimes have comorbid mood disorders. The mutant animals exhibited bipolar disorder-like phenotypes, such as a distorted day-night rhythm and a robust activity change with a period of 4-5 days, and the behavioral abnormalities were improved by lithium. In this study, we tested the effect of electroconvulsive stimulation (ECS) on the behavioral abnormalities of the model. Electroconvulsive therapy, which has long been used in clinical practice, provides fast-acting relief to depressive patients and drug-resistant patients. We performed long-term recordings of wheel-running activity of Tg and non-Tg mice. While recording, we administrated a train of ECS to mice, six times over two weeks or three times over a week. The treatment ameliorated the distorted day-night rhythm within three times of ECS, but it had no effect on the activity change with a period of 4-5 days in the female mice. To study the mechanism of the action, we investigated whether ECS could alter the circadian phase but found no influence on the circadian clock system. The potent and fast-acting efficacy of ECS in the mutant mice supports the predictive validity of the mice as a model of bipolar disorder. This model will be useful in developing a safe and effective alternative to lithium or electroconvulsive therapy.	[Kasahara, Takaoki; Kubota, Mie; Miyauchi, Taeko; Ishiwata, Mizuho; Kato, Tadafumi] RIKEN, Brain Sci Inst, Lab Mol Dynam Mental Disorders, Wako, Saitama, Japan	RIKEN	Kasahara, T (corresponding author), RIKEN, Brain Sci Inst, Lab Mol Dynam Mental Disorders, Wako, Saitama, Japan.	casa@brain.riken.jp	Kasahara, Takaoki/AAJ-5367-2020; Kato, Tadafumi/J-3583-2014	Kasahara, Takaoki/0000-0002-0953-5146; Kato, Tadafumi/0000-0001-7856-3952	Laboratory for Molecular Dynamics of Mental Disorders, RIKEN BSI; Japanese Ministry of Health and Labor [Grant-in-Aid]; Japanese Ministry of Education, Culture, Sports, Science and Technology [Grant-in-Aid]	Laboratory for Molecular Dynamics of Mental Disorders, RIKEN BSI; Japanese Ministry of Health and Labor; Japanese Ministry of Education, Culture, Sports, Science and Technology(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by grants to the Laboratory for Molecular Dynamics of Mental Disorders, RIKEN BSI; a Grant-in-Aid from the Japanese Ministry of Health and Labor; and Grants-in-Aid from the Japanese Ministry of Education, Culture, Sports, Science and Technology. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Altar CA, 2004, J NEUROSCI, V24, P2667, DOI 10.1523/JNEUROSCI.5377-03.2004; *AM PSYCH ASS, 2001, PRACT ECT RECOMM TRE; Angelucci F, 2003, INT J NEUROPSYCHOPH, V6, P225, DOI 10.1017/S1461145703003468; Angelucci F, 2003, NEUROPEPTIDES, V37, P51, DOI 10.1016/S0143-4179(03)00004-0; Crow TJ, 2007, AM J PSYCHIAT, V164, P13, DOI 10.1176/appi.ajp.164.1.13; Daly JJ, 2001, BIPOLAR DISORD, V3, P95, DOI 10.1034/j.1399-5618.2001.030208.x; Einat H, 2007, NEUROSCI BIOBEHAV R, V31, P850, DOI 10.1016/j.neubiorev.2006.12.001; Fukumoto T, 2001, PSYCHOPHARMACOLOGY, V158, P100, DOI 10.1007/s002130100871; Goodwin F, 1990, MANIC DEPRESSIVE ILL; Gould TD, 2007, NEUROSCI BIOBEHAV R, V31, P825, DOI 10.1016/j.neubiorev.2007.05.007; Honrado GI, 1996, J COMP PHYSIOL A, V178, P563; Ji RR, 1998, P NATL ACAD SCI USA, V95, P15635, DOI 10.1073/pnas.95.26.15635; Kasahara T, 2006, MOL PSYCHIATR, V11, P577, DOI 10.1038/sj.mp.4001824; Kato T, 2007, CNS DRUGS, V21, P1, DOI 10.2165/00023210-200721010-00001; Kato T, 2007, PSYCHIAT CLIN NEUROS, V61, P3, DOI 10.1111/j.1440-1819.2007.01604.x; Kubota M, 2006, J NEUROSCI, V26, P12314, DOI 10.1523/JNEUROSCI.3933-06.2006; Newton SS, 2003, J NEUROSCI, V23, P10841; PERRIS C, 1966, ACTA PSYCHIAT SCAND, VS 42, P153; T, 2007, NEUROSCI BIOBEHAV R, V31, P832; Travnickova Z, 1996, AM J PHYSIOL-REG I, V271, pR825, DOI 10.1152/ajpregu.1996.271.4.R825; Van Goethem G, 2001, NAT GENET, V28, P211, DOI 10.1038/90034	21	8	8	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1877	10.1371/journal.pone.0001877	http://dx.doi.org/10.1371/journal.pone.0001877			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365022	Green Published, gold, Green Submitted			2022-12-25	WOS:000260762400028
J	Tseng, H; Chou, WC; Wang, JW; Zhang, XH; Zhang, SL; Schultz, RM				Tseng, Hung; Chou, Weichin; Wang, Junwen; Zhang, Xiaohong; Zhang, Shengliang; Schultz, Richard M.			Mouse Ribosomal RNA Genes Contain Multiple Differentially Regulated Variants	PLOS ONE			English	Article							POLYMERASE-I TRANSCRIPTION; PROTEIN-SYNTHESIS; LENGTH HETEROGENEITY; MOLECULAR-BASIS; HUMAN RDNA; DNA; METHYLATION; CELL; BASONUCLIN; AMPLIFICATION	Background: Previous cytogenetic studies suggest that various rDNA chromosomal loci are not equally active in different cell types. Consistent with this variability, rDNA polymorphism is well documented in human and mouse. However, attempts to identify molecularly rDNA variant types, which are regulated individually (i.e., independent of other rDNA variants) and tissue-specifically, have not been successful. We report here the molecular cloning and characterization of seven mouse rDNA variants (v-rDNA). The identification of these v-rDNAs was based on restriction fragment length polymorphisms (RFLPs), which are conserved among individuals and mouse strains. The total copy number of the identified variants is less than 100 and the copy number of each individual variant ranges from 4 to 15. Sequence analysis of the cloned v-rDNA identified variant-specific single nucleotide polymorphisms (SNPs) in the transcribed region. These SNPs were used to develop a set of variant-specific PCR assays, which permitted analysis of the v-rDNAs' expression profiles in various tissues. These profiles show that three v-rDNAs are expressed in all tissues (constitutively active), two are expressed in some tissues (selectively active), and two are not expressed (silent). These expression profiles were observed in six individuals from three mouse strains, suggesting the pattern is not randomly determined. Thus, the mouse rDNA array likely consists of genetically distinct variants, and some are regulated tissue-specifically. Our results provide the first molecular evidence for cell-type-specific regulation of a subset of rDNA.	[Tseng, Hung; Chou, Weichin; Zhang, Xiaohong; Zhang, Shengliang] Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA; [Tseng, Hung] Univ Penn, Cell & Dev Biol, Philadelphia, PA USA; [Tseng, Hung; Schultz, Richard M.] Univ Penn, Ctr Res Reproduct & Womens Hlth, Philadelphia, PA USA; [Wang, Junwen] Univ Penn, Ctr Bioinformat, Dept Genet, Philadelphia, PA USA; [Wang, Junwen] Univ Penn, Dept Comp & Informat Sci, Philadelphia, PA USA; [Schultz, Richard M.] Univ Penn, Dept Biol, Philadelphia, PA USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Tseng, H (corresponding author), Univ Penn, Dept Dermatol, Philadelphia, PA 19104 USA.	htsengpe@mail.med.upenn.edu	Wang, Junwen/C-4432-2009; Wang, Junwen/D-3700-2011	Wang, Junwen/0000-0002-4432-4707	NIH [AG14456, EY13637, HD22681]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD022681] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD022681] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY013637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG014456] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))	This work was supported by NIH grants AG14456, EY13637 to HT, and HD22681 to RMS. The funding agencies had no role in the conception, design, conduct, analysis and reporting of this work.	ARNHEIM N, 1979, J MOL BIOL, V134, P743, DOI 10.1016/0022-2836(79)90483-2; ARNHEIM N, 1977, CELL, V11, P363, DOI 10.1016/0092-8674(77)90053-8; ARNHEIM N, 1982, P NATL ACAD SCI-BIOL, V79, P4677, DOI 10.1073/pnas.79.15.4677; Bachvarova R, 1985, Dev Biol (N Y 1985), V1, P453; BIRD AP, 1982, ADV EXP MED BIOL, V158, P375; BROWN DD, 1968, SCIENCE, V160, P272, DOI 10.1126/science.160.3825.272; Caburet S, 2005, GENOME RES, V15, P1079, DOI 10.1101/gr.3970105; Comai L, 2004, ADV PROTEIN CHEM, V67, P123; CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3; CORPET F, 1988, NUCLEIC ACIDS RES, V16, P10881, DOI 10.1093/nar/16.22.10881; CORY S, 1977, CELL, V11, P795, DOI 10.1016/0092-8674(77)90292-6; DECAPOA A, 1985, HUM GENET, V69, P212, DOI 10.1007/BF00293027; DECAPOA A, 1985, J CELL SCI, V74, P21; DEV VG, 1977, GENETICS, V86, P389; ELSEVIER SM, 1975, CHROMOSOMA, V52, P219, DOI 10.1007/BF00332112; ERICKSON JM, 1985, AM J HUM GENET, V37, P311; FLAVELL RB, 1986, PHILOS T ROY SOC B, V314, P385, DOI 10.1098/rstb.1986.0060; Gogel E, 1996, CHROMOSOMA, V104, P511, DOI 10.1007/BF00352115; GONZALEZ IL, 1990, MOL BIOL EVOL, V7, P203; Gonzalez IL, 2001, GENOMICS, V73, P255, DOI 10.1006/geno.2001.6540; GONZALEZ IL, 1985, P NATL ACAD SCI USA, V82, P7666, DOI 10.1073/pnas.82.22.7666; Green H, 2005, MOL B INT U, P207; Grozdanov P, 2003, GENOMICS, V82, P637, DOI 10.1016/S0888-7543(03)00199-X; Grummt I, 2003, GENE DEV, V17, P1691, DOI 10.1101/gad.1098503R; GUNDERSON JH, 1987, SCIENCE, V238, P933, DOI 10.1126/science.3672135; HENDERSON AS, 1974, CHROMOSOMA, V49, P155, DOI 10.1007/BF00348887; HENDERSON AS, 1972, P NATL ACAD SCI USA, V69, P3394, DOI 10.1073/pnas.69.11.3394; KUEHN M, 1983, NUCLEIC ACIDS RES, V11, P211, DOI 10.1093/nar/11.1.211; Kuo BA, 1996, NUCLEIC ACIDS RES, V24, P4817, DOI 10.1093/nar/24.23.4817; LABELLA T, 1989, GENOMICS, V5, P752, DOI 10.1016/0888-7543(89)90117-1; LATHAM KE, 1991, DEVELOPMENT, V112, P921; LATHAM KE, 1994, DEV BIOL, V163, P341, DOI 10.1006/dbio.1994.1153; Lawrence RJ, 2004, MOL CELL, V13, P599, DOI 10.1016/S1097-2765(04)00064-4; Ma J, 2006, DEVELOPMENT, V133, P2053, DOI 10.1242/dev.02371; Mahoney MG, 1998, BIOL REPROD, V59, P388, DOI 10.1095/biolreprod59.2.388; Mauro VP, 2007, CELL CYCLE, V6, P2246, DOI 10.4161/cc.6.18.4739; Mauro VP, 2002, P NATL ACAD SCI USA, V99, P12031, DOI 10.1073/pnas.192442499; McStay B, 2006, GENE DEV, V20, P1207, DOI 10.1101/gad.1436906; McStay B, 2002, GENE EXPRESSION, V10, P263, DOI 10.3727/000000002783992415; MILLER DA, 1976, GENETICS, V84, P67; MILLER KG, 1981, CELL, V27, P165, DOI 10.1016/0092-8674(81)90370-6; MOSS T, 1983, NATURE, V302, P223, DOI 10.1038/302223a0; Moss T, 2002, CELL, V109, P545, DOI 10.1016/S0092-8674(02)00761-4; Oh B, 2000, DEVELOPMENT, V127, P3795; Osheim YN, 1996, J CELL BIOL, V133, P943, DOI 10.1083/jcb.133.5.943; PERKOWSKA E, 1968, NATURE, V217, P649, DOI 10.1038/217649a0; Qin XL, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-4-r63; Ramsahoye BH, 2000, P NATL ACAD SCI USA, V97, P5237, DOI 10.1073/pnas.97.10.5237; REEDER RH, 1984, CELL, V38, P349, DOI 10.1016/0092-8674(84)90489-6; ROCHAIX JD, 1974, J MOL BIOL, V87, P473, DOI 10.1016/0022-2836(74)90098-9; Russell J, 2005, TRENDS BIOCHEM SCI, V30, P87, DOI 10.1016/j.tibs.2004.12.008; Santoro R, 2001, MOL CELL, V8, P719, DOI 10.1016/S1097-2765(01)00317-3; SOGO JM, 1984, J MOL BIOL, V178, P897, DOI 10.1016/0022-2836(84)90318-8; Stancheva I, 1997, NUCLEIC ACIDS RES, V25, P1727, DOI 10.1093/nar/25.9.1727; Su YQ, 2007, DEV BIOL, V302, P104, DOI 10.1016/j.ydbio.2006.09.008; TSENG H, 1988, CELL, V54, P491, DOI 10.1016/0092-8674(88)90070-0; Tseng H, 1998, Front Biosci, V3, pD985; Tseng H, 2006, BIOESSAYS, V28, P719, DOI 10.1002/bies.20430; Wang QX, 1997, MOL REPROD DEV, V47, P265, DOI 10.1002/(SICI)1098-2795(199707)47:3&lt;265::AID-MRD5&gt;3.0.CO;2-J; WATERS AP, 1989, NATURE, V342, P438, DOI 10.1038/342438a0; WELLAUER PK, 1976, J MOL BIOL, V105, P461, DOI 10.1016/0022-2836(76)90229-1; WELLAUER PK, 1976, J MOL BIOL, V105, P487, DOI 10.1016/0022-2836(76)90230-8; White RJ, 2005, NAT REV MOL CELL BIO, V6, P69, DOI 10.1038/nrm1551; Zhang SL, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000902; Zhang XH, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001087	65	42	43	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1843	10.1371/journal.pone.0001843	http://dx.doi.org/10.1371/journal.pone.0001843			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365001	gold, Green Published, Green Submitted			2022-12-25	WOS:000260762400007
J	Baron, R; Nemirovsky, A; Harpaz, I; Cohen, H; Owens, T; Monsonego, A				Baron, Rona; Nemirovsky, Anna; Harpaz, Idan; Cohen, Hagit; Owens, Trevor; Monsonego, Alon			IFN-gamma enhances neurogenesis in wild-type mice and in a mouse model of Alzheimer's disease	FASEB JOURNAL			English	Article						cytokine; immunity; aging; neurodegenerative disease; neuronal repair	CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; AMYLOID BETA-PEPTIDE; INTERFERON-GAMMA; HIPPOCAMPAL NEUROGENESIS; TRANSGENIC MICE; NEURONAL DIFFERENTIATION; ADULT NEUROGENESIS; NEURITE OUTGROWTH; NITRIC-OXIDE	The generation of new neurons and glia from a precursor stem cell appears to take place in the adult brain. However, new neurons generated in the dentate gyrus decline sharply with age and to an even greater extent in neurodegenerative diseases. Here we raise the question whether peripheral immune mechanisms can generate immunity to such deficits in neuronal repair. We demonstrate that in contrast to primarily innate immunity cytokines, such as interleukin-6 and tumor necrosis factor-alpha, the adaptive immunity cytokine IFN-gamma enhances neurogenesis in the dentate gyrus of adult mice and improves the spatial learning and memory performance of the animals. In older mice, the effect of IFN-gamma is more pronounced in both wild-type mice and mice with Alzheimer's-like disease and is associated with neuroprotection. In addition, IFN-gamma reverses the increase in oligodendrogenesis observed in a mouse model of Alzheimer's disease. We demonstrate that limited amounts of IFN-gamma in the brain shape the neuropoietic milieu to enhance neurogenesis, possibly representing the normal function of the immune system in controlling brain inflammation and repair.	[Baron, Rona; Nemirovsky, Anna; Harpaz, Idan; Monsonego, Alon] Ben Gurion Univ Negev, Fac Hlth Sci, Shraga Segal Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel; [Harpaz, Idan; Cohen, Hagit] Ben Gurion Univ Negev, Fac Hlth Sci, Anxiety & Stress Res Unit, Minist Hlth,Mental Hlth Ctr, IL-84105 Beer Sheva, Israel; [Nemirovsky, Anna; Harpaz, Idan; Monsonego, Alon] Ben Gurion Univ Negev, Natl Inst Biotechnol Negev, IL-84105 Beer Sheva, Israel; [Owens, Trevor] Univ So Denmark, Ctr Med Biotechnol, Odense, Denmark	Ben Gurion University; Ben Gurion University; Ben Gurion University; University of Southern Denmark	Monsonego, A (corresponding author), Ben Gurion Univ Negev, Fac Hlth Sci, Shraga Segal Dept Microbiol & Immunol, IL-84105 Beer Sheva, Israel.	alonmon@bgu.ac.il		Owens, Trevor/0000-0001-9315-6036				Abrous DN, 2005, PHYSIOL REV, V85, P523, DOI 10.1152/physrev.00055.2003; Aharoni R, 2005, J NEUROSCI, V25, P8217, DOI 10.1523/JNEUROSCI.1859-05.2005; Aloisi F, 2001, GLIA, V36, P165, DOI 10.1002/glia.1106; Bal-Price A, 2001, J NEUROSCI, V21, P6480; Balabanov R, 2007, J NEUROSCI, V27, P2013, DOI 10.1523/JNEUROSCI.4689-06.2007; Blasko I, 2001, J NEUROIMMUNOL, V116, P1, DOI 10.1016/S0165-5728(01)00279-X; Blasko I, 2000, NEUROBIOL DIS, V7, P682, DOI 10.1006/nbdi.2000.0321; Buckwalter MS, 2006, J NEUROSCI, V26, P11437, DOI 10.1523/JNEUROSCI.2436-06.2006; Buckwalter MS, 2006, AM J PATHOL, V169, P154, DOI 10.2353/ajpath.2006.051272; Butovsky O, 2006, MOL CELL NEUROSCI, V31, P149, DOI 10.1016/j.mcn.2005.10.006; Butovsky O, 2006, P NATL ACAD SCI USA, V103, P11784, DOI 10.1073/pnas.0604681103; Corbin JG, 1996, MOL CELL NEUROSCI, V7, P354, DOI 10.1006/mcne.1996.0026; Fassbender K, 2004, FASEB J, V18, P203, DOI 10.1096/fj.03-0364fje; Franklin K, 2007, MOUSE BRAIN STEROTAX; Gao X, 2000, MOL CELL NEUROSCI, V16, P338, DOI 10.1006/mcne.2000.0883; Golde S, 2002, J NEUROCHEM, V82, P269, DOI 10.1046/j.1471-4159.2002.00973.x; Hallam DM, 2000, J NEUROIMMUNOL, V110, P66, DOI 10.1016/S0165-5728(00)00289-7; Haughey NJ, 2002, J NEUROCHEM, V83, P1509, DOI 10.1046/j.1471-4159.2002.01267.x; Hohlfeld R, 2006, NEUROL SCI, V27, pS1, DOI 10.1007/s10072-006-0537-7; Hsia AY, 1999, P NATL ACAD SCI USA, V96, P3228, DOI 10.1073/pnas.96.6.3228; Imitola J, 2004, P NATL ACAD SCI USA, V101, P18117, DOI 10.1073/pnas.0408258102; Iosif RE, 2006, J NEUROSCI, V26, P9703, DOI 10.1523/JNEUROSCI.2723-06.2006; Jin KL, 2004, P NATL ACAD SCI USA, V101, P13363, DOI 10.1073/pnas.0403678101; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Kaneko N, 2006, NEUROPSYCHOPHARMACOL, V31, P2619, DOI 10.1038/sj.npp.1301137; Kempermann G, 2004, CURR OPIN NEUROBIOL, V14, P186, DOI 10.1016/j.conb.2004.03.001; Kim SJ, 2007, NEUROCHEM RES, V32, P1399, DOI 10.1007/s11064-007-9323-z; Kleinschek MA, 2007, J EXP MED, V204, P161, DOI 10.1084/jem.20061738; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Kwidzinski E, 2005, FASEB J, V19, P1347, DOI 10.1096/fj.04-3228fje; Lee J, 2006, J NEUROSCI RES, V83, P1552, DOI 10.1002/jnr.20831; McGeer EG, 2005, NEUROBIOL AGING, V26, pS94, DOI 10.1016/j.neurobiolaging.2005.08.008; Monje ML, 2003, SCIENCE, V302, P1760, DOI 10.1126/science.1088417; Monsonego A, 2006, P NATL ACAD SCI USA, V103, P5048, DOI 10.1073/pnas.0506209103; Monsonego A, 2003, J IMMUNOL, V171, P2216, DOI 10.4049/jimmunol.171.5.2216; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Phillips LM, 1999, J NEUROIMMUNOL, V96, P218, DOI 10.1016/S0165-5728(99)00034-X; Renno T, 1998, MOL CELL NEUROSCI, V12, P376, DOI 10.1006/mcne.1998.0725; Shaked I, 2005, J NEUROCHEM, V92, P997, DOI 10.1111/j.1471-4159.2004.02954.x; Song JH, 2005, J BIOL CHEM, V280, P12896, DOI 10.1074/jbc.M412139200; Taupin P, 2002, J NEUROSCI RES, V69, P745, DOI 10.1002/jnr.10378; Tran EH, 2000, J IMMUNOL, V164, P2759, DOI 10.4049/jimmunol.164.5.2759; Turnley AM, 2002, NAT NEUROSCI, V5, P1155, DOI 10.1038/nn954; Turnley AM, 2001, NEUROREPORT, V12, P3443, DOI 10.1097/00001756-200111160-00013; Vallieres L, 2002, J NEUROSCI, V22, P486, DOI 10.1523/JNEUROSCI.22-02-00486.2002; Wheeler RD, 2006, IMMUNOLOGY, V118, P527, DOI 10.1111/j.1365-2567.2006.02395.x; WINNER B, 2007, NEUROBIOL A IN PRESS; Wong G, 2004, EXP NEUROL, V187, P171, DOI 10.1016/j.expneurol.2004.01.009; Xie Z, 2002, J NEUROSCI, V22, P3484; Yamamoto M, 2007, AM J PATHOL, V170, P680, DOI 10.2353/ajpath.2007.060378; Zhang CL, 2008, NATURE, V451, P1004, DOI 10.1038/nature06562; Zhang PL, 2006, MOL CELL NEUROSCI, V31, P387, DOI 10.1016/j.mcn.2005.10.014; Ziv Y, 2006, NAT NEUROSCI, V9, P268, DOI 10.1038/nn1629	54	119	123	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2843	2852		10.1096/fj.08-105866	http://dx.doi.org/10.1096/fj.08-105866			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18390924				2022-12-25	WOS:000258089300024
J	Fitzgerald, J; Rich, C; Zhou, FH; Hansen, U				Fitzgerald, Jamie; Rich, Cathleen; Zhou, Fiona H.; Hansen, Uwe			Three novel collagen VI chains, alpha 4(VI), alpha 5(VI), and alpha 6(VI)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONGENITAL MUSCULAR-DYSTROPHY; BETHLEM MYOPATHY; MICROFIBRIL FORMATION; ALPHA-3(VI) CHAIN; EXTRACELLULAR-MATRIX; VONWILLEBRAND-FACTOR; SEQUENCE-ANALYSIS; GLOBULAR DOMAINS; ULLRICH-DISEASE; INTIMA COLLAGEN	We report the identification of three new collagen VI genes at a single locus on human chromosome 3q22.1. The three new genes are COL6A4, COL6A5, and COL6A6 that encode the alpha 4(VI), alpha 5(VI), and alpha 6(VI) chains. In humans, the COL6A4 gene has been disrupted by a chromosome break. Each of the three new collagen chains contains a 336-amino acid triple helix flanked by seven N-terminal von Willebrand factor A-like domains and two (alpha 4 and alpha 6 chains) or three (alpha 5 chain) C-terminal von Willebrand factor A-like domains. In humans, mRNA expression of COL6A5 is restricted to a few tissues, including lung, testis, and colon. In contrast, the COL6A6 gene is expressed in a wide range of fetal and adult tissues, including lung, kidney, liver, spleen, thymus, heart, and skeletal muscle. Antibodies to the alpha 6(VI) chain stained the extracellular matrix of human skeletal and cardiac muscle, lung, and the territorial matrix of articular cartilage. In cell transfection and immuno-precipitation experiments, mouse alpha 4(VI) N6-C2 chain co-assembled with endogenous alpha 1(VI) and alpha 2(VI) chains to form trimeric collagen VI molecules that were secreted from the cell. In contrast, alpha 5(VI) N5-C1 and alpha 6(VI) N6-C2 chains did not assemble with alpha 1(VI) and alpha 2(VI) chains and accumulated intracellularly. We conclude that the alpha 4(VI) N6-C2 chain contains all the elements necessary for trimerization with alpha 1(VI) and alpha 2(VI). In summary, the discovery of three additional collagen VI chains doubles the collagen VI family and adds a layer of complexity to collagen VI assembly and function in the extracellular matrix.	[Fitzgerald, Jamie; Rich, Cathleen; Zhou, Fiona H.] Oregon Hlth & Sci Univ, Dept Orthopaed & Rehabil, Portland, OR 97239 USA; [Hansen, Uwe] Univ Hosp Muenster, Inst Physiol Chem & Pathobiochem, D-48129 Munster, Germany	Oregon Health & Science University; University of Munster	Fitzgerald, J (corresponding author), Oregon Hlth & Sci Univ, Dept Orthopaed & Rehabil, Mail Code OP31, Portland, OR 97239 USA.	fitzgerj@ohsu.edu			NIAMS NIH HHS [R01 AR055957] Funding Source: Medline	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Allen JM, 2006, J BIOL CHEM, V281, P7341, DOI 10.1074/jbc.M513746200; Baker NL, 2005, HUM MOL GENET, V14, P279, DOI 10.1093/hmg/ddi025; Ball S, 2003, J BIOL CHEM, V278, P15326, DOI 10.1074/jbc.M209977200; Ball SG, 2001, J BIOL CHEM, V276, P7422, DOI 10.1074/jbc.M002816200; Bendtsen JD, 2004, J MOL BIOL, V340, P783, DOI 10.1016/j.jmb.2004.05.028; Bengtsson E, 2000, J BIOL CHEM, V275, P40695, DOI 10.1074/jbc.M007917200; CHU ML, 1990, EMBO J, V9, P385, DOI 10.1002/j.1460-2075.1990.tb08122.x; CHU ML, 1988, J BIOL CHEM, V263, P18601; CHU ML, 1987, EUR J BIOCHEM, V168, P309, DOI 10.1111/j.1432-1033.1987.tb13422.x; CHU ML, 1989, EMBO J, V8, P1939, DOI 10.1002/j.1460-2075.1989.tb03598.x; COLOMBATTI A, 1995, J BIOL CHEM, V270, P13105, DOI 10.1074/jbc.270.22.13105; Donoghue PCJ, 2007, TRENDS ECOL EVOL, V22, P424, DOI 10.1016/j.tree.2007.05.005; Fitzgerald J, 2002, FEBS LETT, V517, P61, DOI 10.1016/S0014-5793(02)02579-6; Fitzgerald J, 2001, J BIOL CHEM, V276, P187, DOI 10.1074/jbc.M008173200; FURTHMAYR H, 1983, BIOCHEM J, V211, P303, DOI 10.1042/bj2110303; Irwin WA, 2003, NAT GENET, V35, P367, DOI 10.1038/ng1270; Ishikawa H, 2004, NEUROLOGY, V62, P620, DOI 10.1212/01.WNL.0000113023.84421.00; Ishikawa H, 2002, NEUROLOGY, V59, P920, DOI 10.1212/WNL.59.6.920; Jimenez-Mallebrera C, 2005, CELL MOL LIFE SCI, V62, P809, DOI 10.1007/s00018-004-4510-4; Kassner A, 2003, MATRIX BIOL, V22, P131, DOI 10.1016/S0945-053X(03)00008-8; Khoshnoodi J, 2006, J BIOL CHEM, V281, P38117, DOI 10.1074/jbc.R600025200; Lamande SR, 2006, J BIOL CHEM, V281, P16607, DOI 10.1074/jbc.M510192200; Lamande SR, 2002, J BIOL CHEM, V277, P1949, DOI 10.1074/jbc.M109932200; Lamande SR, 1998, J BIOL CHEM, V273, P7423, DOI 10.1074/jbc.273.13.7423; Lamande SR, 1999, J BIOL CHEM, V274, P21817, DOI 10.1074/jbc.274.31.21817; Lampe AK, 2005, J MED GENET, V42, P673, DOI 10.1136/jmg.2002.002311; Lampe AK, 2005, J MED GENET, V42, P108, DOI 10.1136/jmg.2004.023754; Lucioli S, 2005, NEUROLOGY, V64, P1931, DOI 10.1212/01.WNL.0000163990.00057.66; Michalczyk AA, 2002, BIOCHEM J, V364, P105, DOI 10.1042/bj3640105; Niiyama T, 2002, ACTA NEUROPATHOL, V104, P67, DOI 10.1007/s00401-002-0522-z; ODERMATT E, 1983, BIOCHEM J, V211, P295, DOI 10.1042/bj2110295; Pan TC, 2003, AM J HUM GENET, V73, P355, DOI 10.1086/377107; ROBERTS S, 1991, ANN RHEUM DIS, V50, P787, DOI 10.1136/ard.50.11.787; Sherwin AF, 1999, HISTOCHEM J, V31, P623, DOI 10.1023/A:1003811310619; Soderhall C, 2007, PLOS BIOL, V5, P1952, DOI 10.1371/journal.pbio.0050242; Steiper ME, 2006, MOL PHYLOGENET EVOL, V41, P384, DOI 10.1016/j.ympev.2006.05.021; Timpl R, 1994, EXTRACELLULAR MATRIX, P207, DOI 10.1016/B978-0-12-775170-2.50012-3	37	121	122	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 18	2008	283	29					20170	20180		10.1074/jbc.M710139200	http://dx.doi.org/10.1074/jbc.M710139200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	325CH	18400749	hybrid			2022-12-25	WOS:000257565300033
J	Di Costanzo, L; Drury, JE; Penning, TM; Christianson, DW				Di Costanzo, Luigi; Drury, Jason E.; Penning, Trevor M.; Christianson, David W.			Crystal structure of human liver Delta(4)-3-ketosteroid 5 beta-reductase (AKR1D1) and implications for substrate binding and catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN ALDOSE REDUCTASE; DELTA(4)-3-OXOSTEROID 5-BETA-REDUCTASE; 20-ALPHA-HYDROXYSTEROID DEHYDROGENASE; PROTEIN MODELS; SRD5B1 AKR1D1; DEFICIENCY; REVEALS; TESTOSTERONE; SPECIFICITY; MUTAGENESIS	AKR1D1 (steroid 5 beta-reductase) reduces all Delta(4)-3-ketosteroids to form 5 beta-dihydrosteroids, a first step in the clearance of steroid hormones and an essential step in the synthesis of all bile acids. The reduction of the carbon-carbon double bond in an alpha,beta-unsaturated ketone by 5 beta-reductase is a unique reaction in steroid enzymology because hydride transfer from NADPH to the beta-face of a Delta(4)-3-ketosteroid yields a cis-A/B-ring configuration with an similar to 90 degrees bend in steroid structure. Here, we report the first x-ray crystal structure of amammaliansteroid hormone carbon-carbon double bond reductase, human Delta(4)-3-ketosteroid 5 beta-reductase (AKR1D1), and its complexes with intact substrates. We have determined the structures of AKR1D1 complexes with NADP(+) at 1.79- and 1.35-angstrom resolution (HEPES bound in the active site), NADP(+) and cortisone at 1.90-angstrom resolution, NADP(+) and progesterone at 2.03-angstrom resolution, and NADP(+) and testosterone at 1.62-angstrom resolution. Complexes with cortisone and progesterone reveal productive substrate binding orientations based on the proximity of each steroid carbon-carbon double bond to the re-face of the nicotinamide ring of NADP(+). This orientation would permit 4-pro-(R)-hydride transfer from NADPH. Each steroid carbonyl accepts hydrogen bonds from catalytic residues Tyr(58) and Glu(120). The Y58F and E120A mutants are devoid of activity, supporting a role for this dyad in the catalytic mechanism. Intriguingly, testosterone binds nonproductively, thereby rationalizing the substrate inhibition observed with this particular steroid. The locations of disease-linked mutations thought to be responsible for bile acid deficiency are also revealed.	[Drury, Jason E.; Penning, Trevor M.] Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; [Di Costanzo, Luigi; Christianson, David W.] Univ Penn, Dept Chem, Roy Diana Vagelos Labs, Philadelphia, PA 19104 USA; [Drury, Jason E.; Penning, Trevor M.] Univ Penn, Sch Med, Ctr Excellence Environm Toxicol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Penning, TM (corresponding author), Univ Penn, Sch Med, Dept Pharmacol, 130C John Morgan Bldg,3620 Hamilton Walk, Philadelphia, PA 19104 USA.	penning@pharm.med.upenn.edu; chris@sas.upenn.edu	Di Costanzo, Luigi Franklin/AAL-6761-2020	Di Costanzo, Luigi Franklin/0000-0002-4795-2573; Penning, Trevor/0000-0002-3937-1066	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047015] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES013508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056838] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK047015, R01-DK47015] Funding Source: Medline; NIEHS NIH HHS [P30-ES013508, P30 ES013508] Funding Source: Medline; NIGMS NIH HHS [R01-GM56838] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen FH, 2002, ACTA CRYSTALLOGR B, V58, P380, DOI 10.1107/S0108768102003890; Bennett MJ, 1996, BIOCHEMISTRY-US, V35, P10702, DOI 10.1021/bi9604688; Bennett MJ, 1997, STRUCTURE, V5, P799, DOI 10.1016/S0969-2126(97)00234-7; BERSEUS O, 1967, J BIOL CHEM, V242, P1211; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Charbonneau A, 2001, BBA-GENE STRUCT EXPR, V1517, P228, DOI 10.1016/S0167-4781(00)00278-5; Clayton PT, 1996, GUT, V38, P623, DOI 10.1136/gut.38.4.623; COUSTARD JM, 1975, TETRAHEDRON LETT, P2029; Couture JF, 2004, J MOL BIOL, V339, P89, DOI 10.1016/j.jmb.2004.03.035; Couture JF, 2003, J MOL BIOL, V331, P593, DOI 10.1016/S0022-2836(03)00762-9; DEYASHIKI Y, 1992, BIOCHEM J, V282, P741, DOI 10.1042/bj2820741; Drury J, 2007, ENZYMOLOGY MOL BIOL, P332; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; ELKABBANI O, 1994, ACTA CRYSTALLOGR D, V50, P859, DOI 10.1107/S0907444994005275; GANDOUR RD, 1981, BIOORG CHEM, V10, P169, DOI 10.1016/0045-2068(81)90020-1; Gonzales E, 2004, J HEPATOL, V40, P716, DOI 10.1016/j.jhep.2003.12.024; GRIMSHAW CE, 1995, BIOCHEMISTRY-US, V34, P14374, DOI 10.1021/bi00044a014; HOOG SS, 1994, P NATL ACAD SCI USA, V91, P2517, DOI 10.1073/pnas.91.7.2517; Jez JM, 1998, BIOCHEMISTRY-US, V37, P9695, DOI 10.1021/bi980294p; Jez JM, 1997, BIOCHEM J, V326, P625, DOI 10.1042/bj3260625; Jin Y, 2006, STEROIDS, V71, P380, DOI 10.1016/j.steroids.2005.12.002; Jin Y, 2001, BIOCHEMISTRY-US, V40, P10161, DOI 10.1021/bi010919a; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kimura A, 1998, EUR J PEDIATR, V157, P386, DOI 10.1007/s004310050835; Komoto J, 2004, BIOCHEMISTRY-US, V43, P2188, DOI 10.1021/bi036046x; KONDO KH, 1994, EUR J BIOCHEM, V219, P357, DOI 10.1111/j.1432-1033.1994.tb19947.x; Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemonde HA, 2003, GUT, V52, P1494, DOI 10.1136/gut.52.10.1494; March J., 1984, ADV ORGANIC CHEM REA, P694; McCoy AJ, 2005, ACTA CRYSTALLOGR D, V61, P458, DOI 10.1107/S0907444905001617; Michalak K, 2000, J CHEM SOC PERK T 1, P1587, DOI 10.1039/b000600i; Nahoum V, 2001, J BIOL CHEM, V276, P42091, DOI 10.1074/jbc.M105610200; NORYMBERSKI JK, 1955, J CHEM SOC, P3426, DOI 10.1039/jr9550003426; OKUDA A, 1984, J BIOL CHEM, V259, P7519; ONISHI Y, 1991, FEBS LETT, V283, P215, DOI 10.1016/0014-5793(91)80591-P; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Penning TM, 2000, BIOCHEM J, V351, P67, DOI 10.1042/0264-6021:3510067; RUSSELL DW, 1994, ANNU REV BIOCHEM, V63, P25, DOI 10.1146/annurev.bi.63.070194.000325; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Schlegel BP, 1998, BIOCHEMISTRY-US, V37, P3538, DOI 10.1021/bi9723055; SETCHELL KDR, 1988, J CLIN INVEST, V82, P2148, DOI 10.1172/JCI113837; Sheldrick GM, 1997, METHOD ENZYMOL, V277, P319, DOI 10.1016/S0076-6879(97)77018-6; Steckelbroeck S, 2004, MOL PHARMACOL, V66, P1702, DOI 10.1124/mol.104.004515; TAKEDA K, 1961, YAKUGAKU ZASSHI, V81, P325; Thorn A, 2008, J BIOL CHEM, V283, P17260, DOI 10.1074/jbc.M706185200; TOMKINS GM, 1956, RECENT PROG HORM RES, V12, P125; WILSON DK, 1992, SCIENCE, V257, P81, DOI 10.1126/science.1621098	49	54	58	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16830	16839		10.1074/jbc.M801778200	http://dx.doi.org/10.1074/jbc.M801778200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18407998	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000256497100060
J	Makanji, Y; Walton, KL; Wilce, MC; Chan, KL; Robertson, DM; Harrison, CA				Makanji, Yogeshwar; Walton, Kelly L.; Wilce, Matthew C.; Chan, Karen L.; Robertson, David M.; Harrison, Craig A.			Suppression of inhibin A biological activity by alterations in the binding site for betaglycan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FOLLICLE-STIMULATING-HORMONE; GROWTH-FACTOR-BETA; ALPHA-SUBUNIT ELISA; II RECEPTOR-BINDING; CRYSTAL-STRUCTURE; FEMALE RAT; COMPLEX; FOLLISTATIN; PITUITARY; PROTEIN	Inhibins A and B negatively regulate the production and secretion of follicle-stimulating hormone from the anterior pituitary, control ovarian follicle development and steroidogenesis, and act as tumor suppressors in the gonads. Inhibins regulate these reproductive events by forming high affinity complexes with betaglycan and activin or bone morphogenetic protein type II receptors. In this study, the binding site of inhibin A for betaglycan was characterized using inhibin A mutant proteins. An epitope for high affinity betaglycan binding was detected spanning the outer convex surface of the inhibin alpha-subunit. Homology modeling indicates that key alpha-subunit residues (Tyr(50), Val(108), Thr(111), Ser(112), Phe(118), Lys(119), and Tyr(120)) form a contiguous epitope in this region of the molecule. Disruption of betaglycan binding by the simultaneous substitution of Thr(111), Ser(112), and Tyr(120) to alanine yielded an inhibin A variant that was unable to suppress activin-induced follicle-stimulating hormone release by rat pituitary cells in culture. Together these results indicate that a high affinity interaction between betaglycan and residues Val(108)-Tyr(120) of the inhibin alpha-subunit mediate inhibin A biological activity.	[Makanji, Yogeshwar; Walton, Kelly L.; Chan, Karen L.; Robertson, David M.; Harrison, Craig A.] Prince Henrys Inst Med Res, Clayton, Vic 3168, Australia; [Makanji, Yogeshwar] Monash Univ, Dept Obstet & Gynaecol, Clayton, Vic 3168, Australia; [Wilce, Matthew C.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3168, Australia	Prince Henry's Institute of Medical Research; Monash University; Monash University	Harrison, CA (corresponding author), Prince Henrys Inst Med Res, 246 Clayton Rd, Clayton, Vic 3168, Australia.	craig.harrison@princehenrys.org	Walton, Kelly/ABF-7282-2020; Chan, Karen/E-4041-2015	Walton, Kelly/0000-0003-0627-2958; Harrison, Craig/0000-0003-1059-3682; Chan, Karen/0000-0001-9947-4713				Allendorph GP, 2007, BIOCHEMISTRY-US, V46, P12238, DOI 10.1021/bi700907k; Antenos M, 2007, MOL ENDOCRINOL, V21, P1670, DOI 10.1210/me.2007-0050; Bernard DJ, 2004, MOL ENDOCRINOL, V18, P606, DOI 10.1210/me.2003-0264; Chapman SC, 2003, ENDOCRINOLOGY, V144, P5640, DOI 10.1210/en.2003-0670; De Crescenzo G, 2006, J MOL BIOL, V355, P47, DOI 10.1016/j.jmb.2005.10.022; DeLano WL, 2005, DRUG DISCOV TODAY, V10, P213, DOI 10.1016/S1359-6446(04)03363-X; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Esparza-Lopez J, 2001, J BIOL CHEM, V276, P14588, DOI 10.1074/jbc.M008866200; Ethier JF, 2002, MOL ENDOCRINOL, V16, P2754, DOI 10.1210/me.2002-0014; FINDLAY JK, 1993, BIOL REPROD, V48, P15, DOI 10.1095/biolreprod48.1.15; Graham KE, 1999, J ENDOCRINOL, V162, pR1, DOI 10.1677/joe.0.162R001; Gray PC, 2002, MOL CELL ENDOCRINOL, V188, P253, DOI 10.1016/S0303-7207(02)00037-0; Greenwald J, 2004, MOL CELL, V15, P485, DOI 10.1016/j.molcel.2004.07.011; Greenwald J, 2003, MOL CELL, V11, P605, DOI 10.1016/S1097-2765(03)00094-7; Gregory SJ, 2004, SEMIN REPROD MED, V 22, P253, DOI 10.1055/s-2004-831901; Harrington AE, 2006, EMBO J, V25, P1035, DOI 10.1038/sj.emboj.7601000; Harrison CA, 2004, J BIOL CHEM, V279, P28036, DOI 10.1074/jbc.M402782200; Harrison CA, 2006, ENDOCRINOLOGY, V147, P2744, DOI 10.1210/en.2006-0131; Hart PJ, 2002, NAT STRUCT BIOL, V9, P203, DOI 10.1038/nsb766; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Lewis KA, 2000, NATURE, V404, P411, DOI 10.1038/35006129; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MacConell LA, 2002, ENDOCRINOLOGY, V143, P1066, DOI 10.1210/en.143.3.1066; Magoffin DA, 1997, HUM REPROD, V12, P1714, DOI 10.1093/humrep/12.8.1714; Makanji Y, 2007, ENDOCRINOLOGY, V148, P2309, DOI 10.1210/en.2006-1612; Mason AJ, 1996, MOL ENDOCRINOL, V10, P1055, DOI 10.1210/me.10.9.1055; MAYO KE, 1986, P NATL ACAD SCI USA, V83, P5849, DOI 10.1073/pnas.83.16.5849; Ramaswamy S, 2001, MOL CELL ENDOCRINOL, V180, P93, DOI 10.1016/S0303-7207(01)00498-1; ROBERTSON DM, 1986, MOL CELL ENDOCRINOL, V46, P29, DOI 10.1016/0303-7207(86)90066-3; Robertson DM, 2002, J CLIN ENDOCR METAB, V87, P816, DOI 10.1210/jc.87.2.816; Robertson DM, 2001, MOL CELL ENDOCRINOL, V180, P79, DOI 10.1016/S0303-7207(01)00518-4; Schreuder H, 2005, BIOCHEM BIOPH RES CO, V329, P1076, DOI 10.1016/j.bbrc.2005.02.078; SCOTT RS, 1980, ENDOCRINOLOGY, V107, P1536, DOI 10.1210/endo-107-5-1536; Stenvers KL, 2003, MOL CELL BIOL, V23, P4371, DOI 10.1128/MCB.23.12.4371-4385.2003; Thompson TB, 2005, DEV CELL, V9, P535, DOI 10.1016/j.devcel.2005.09.008; Thompson TB, 2003, EMBO J, V22, P1555, DOI 10.1093/emboj/cdg156; VALE W, 1988, RECENT PROG HORM RES, V44, P1; van Casteren JIJ, 2000, BIOL REPROD, V62, P886, DOI 10.1095/biolreprod62.4.886; Wiater E, 2003, J BIOL CHEM, V278, P7934, DOI 10.1074/jbc.M209710200; Wiater E, 2006, J BIOL CHEM, V281, P17011, DOI 10.1074/jbc.M601459200; WOODRUFF TK, 1993, ENDOCRINOLOGY, V132, P2332, DOI 10.1210/en.132.6.2332; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	42	37	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16743	16751		10.1074/jbc.M801045200	http://dx.doi.org/10.1074/jbc.M801045200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18397882	hybrid			2022-12-25	WOS:000256497100051
J	Pallerla, SR; Lawrence, R; Lewejohann, L; Pan, Y; Fischer, T; Schlomann, U; Zhang, X; Esko, JD; Grobe, K				Pallerla, Srinivas R.; Lawrence, Roger; Lewejohann, Lars; Pan, Yi; Fischer, Tobias; Schlomann, Uwe; Zhang, Xin; Esko, Jeffrey D.; Grobe, Kay			Altered heparan sulfate structure in mice with deleted NDST3 gene function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEOGLYCANS; FGF; BINDING; SULFOTRANSFERASE; BIOSYNTHESIS; DISRUPTION; HYPOPLASIA; DEFICIENT; DIVERSITY; HEDGEHOG	We report the generation and analysis of mutant mice bearing a targeted disruption of the heparan sulfate (HS)-modifying enzyme GlcNAc N-deacetylase/N-sulfotransferase 3 (NDST3). NDST3(-/-) mice develop normally, are fertile, and show only subtle hematological and behavioral abnormalities in agreement with only moderate HS undersulfation. Compound mutant mice made deficient in NDST2; NDST3 activities also develop normally, showing that both isoforms are not essential for development. In contrast, NDST1(-/-); NDST3(-/-) compound mutant embryos display developmental defects caused by severe HS undersulfation, demonstrating NDST3 contribution to HS synthesis in the absence of NDST1. Moreover, analysis of HS composition in dissected NDST3 mutant adult brain revealed regional changes in HS sulfation, indicating restricted NDST3 activity on nascent HS in defined wild-type tissues. Taken together, we show that NDST3 function is not essential for development or adult homeostasis despite contributing to HS synthesis in a region-specific manner and that the loss of NDST3 function is compensated for by the other NDST isoforms to a varying degree.	[Pallerla, Srinivas R.; Schlomann, Uwe; Grobe, Kay] Univ Munster, Dept Gen Zool & Genet, D-48149 Munster, Germany; [Grobe, Kay] Univ Munster, Inst Physiol Chem & Pathobiochem, D-48149 Munster, Germany; [Lewejohann, Lars] Univ Munster, Dept Behav Biol, D-48149 Munster, Germany; [Lawrence, Roger; Esko, Jeffrey D.] Univ Calif San Diego, Dept Cellular & Mol Med, La Jolla, CA 92093 USA; [Pan, Yi; Zhang, Xin] Indiana Univ, Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA; [Fischer, Tobias] Max Planck Inst Expt Med, Dept Neurogenet, D-37075 Gottingen, Germany	University of Munster; University of Munster; University of Munster; University of California System; University of California San Diego; Indiana University System; Indiana University-Purdue University Indianapolis; Max Planck Society	Grobe, K (corresponding author), Univ Munster, Dept Gen Zool & Genet, Schlosspl 5, D-48149 Munster, Germany.	kgrobe@uni-muenster.de	Lewejohann, Lars/H-3717-2013; Schlomann, Uwe/F-6419-2012; Grobe, Kay/F-2399-2011	Lewejohann, Lars/0000-0002-0202-4351; Pallerla, Srinivas reddy/0000-0003-1669-1515	NEI NIH HHS [R01 EY018868] Funding Source: Medline; NHLBI NIH HHS [HL57345] Funding Source: Medline; NIGMS NIH HHS [GM33063] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY018868] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL057345] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM033063, R01GM033063] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abramsson A, 2007, GENE DEV, V21, P316, DOI 10.1101/gad.398207; Aikawa J, 2001, J BIOL CHEM, V276, P5876, DOI 10.1074/jbc.M009606200; Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; Carrasco H, 2005, J CELL BIOCHEM, V96, P831, DOI 10.1002/jcb.20586; Esko JD, 2002, ANNU REV BIOCHEM, V71, P435, DOI 10.1146/annurev.biochem.71.110601.135458; Esko JD, 2001, J CLIN INVEST, V108, P169, DOI 10.1172/JCI200113530; Fan GP, 2000, FEBS LETT, V467, P7, DOI 10.1016/S0014-5793(00)01111-X; Forsberg E, 1999, NATURE, V400, P773, DOI 10.1038/23488; Fuster MM, 2007, J CELL BIOL, V177, P539, DOI 10.1083/jcb.200610086; Grobe K, 2005, DEVELOPMENT, V132, P3777, DOI 10.1242/dev.01935; Grobe K, 2002, BBA-GEN SUBJECTS, V1573, P209, DOI 10.1016/S0304-4165(02)00386-0; Holmborn K, 2004, J BIOL CHEM, V279, P42355, DOI 10.1074/jbc.C400373200; Humphries DE, 1999, NATURE, V400, P769, DOI 10.1038/23481; Inatani M, 2003, SCIENCE, V302, P1044, DOI 10.1126/science.1090497; Ledin J, 2004, J BIOL CHEM, V279, P42732, DOI 10.1074/jbc.M405382200; Ledin J, 2006, J BIOL CHEM, V281, P35727, DOI 10.1074/jbc.M604113200; Lewejohann L, 2006, GENES BRAIN BEHAV, V5, P64, DOI 10.1111/j.1601-183X.2005.00140.x; Lin X, 2000, DEV BIOL, V224, P299, DOI 10.1006/dbio.2000.9798; Lin XH, 1999, NATURE, V400, P281, DOI 10.1038/22343; Lin XH, 1999, DEVELOPMENT, V126, P3715; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; MacArthur JM, 2007, J CLIN INVEST, V117, P153, DOI 10.1172/JCI29154; McLellan JS, 2006, P NATL ACAD SCI USA, V103, P17208, DOI 10.1073/pnas.0606738103; Ornitz DM, 2001, GENOME BIOL, V2; Pallerla SR, 2007, DEV DYNAM, V236, P556, DOI 10.1002/dvdy.21038; Pan Y, 2006, DEVELOPMENT, V133, P4933, DOI 10.1242/dev.02679; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; Ringvall M, 2000, J BIOL CHEM, V275, P25926, DOI 10.1074/jbc.C000359200; Rogers DC, 2001, NEUROSCI LETT, V306, P89, DOI 10.1016/S0304-3940(01)01885-7; Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3; The I, 1999, MOL CELL, V4, P633, DOI 10.1016/S1097-2765(00)80214-2; Toyoda H, 1997, J CHROMATOGR B, V704, P19, DOI 10.1016/S0378-4347(97)00478-7; Wang LC, 2005, NAT IMMUNOL, V6, P902, DOI 10.1038/ni1233	33	49	49	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16885	16894		10.1074/jbc.M709774200	http://dx.doi.org/10.1074/jbc.M709774200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18385133	Green Published, hybrid			2022-12-25	WOS:000256497100066
J	Paruchuri, S; Jiang, YF; Feng, CL; Francis, SA; Plutzky, J; Boyce, JA				Paruchuri, Sailaja; Jiang, Yongfeng; Feng, Chunli; Francis, Sanjeev A.; Plutzky, Jorge; Boyce, Joshua A.			Leukotriene E-4 activates peroxisome proliferator-activated receptor gamma and induces prostaglandin D-2 generation by human mast cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPIRIN-INTOLERANT ASTHMA; CYSTEINYL LEUKOTRIENES; INFLAMMATORY CELLS; AIRWAY HYPERRESPONSIVENESS; PULMONARY INFLAMMATION; C-4 SYNTHASE; EXPRESSION; HISTAMINE; RESPONSES; PROTEIN	Cysteinyl leukotrienes (cys-LTs) are potent inflammatory lipid mediators, of which leukotriene (LT) E-4 is the most stable and abundant in vivo. Although only a weak agonist of established G protein-coupled receptors (GPCRs) for cys-LTs, LTE4 potentiates airway hyper-responsiveness (AHR) by a cyclooxygenase (COX)-dependent mechanism and induces bronchial eosinophilia. We now report that LTE4 activates human mast cells (MCs) by a pathway involving cooperation between an MK571-sensitive GPCR and peroxisome proliferator-activated receptor (PPAR)gamma, a nuclear receptor for dietary lipids. Although LTD4 is more potent than LTE4 for inducing calcium flux by the human MC sarcoma line LAD(2), LTE4 is more potent for inducing proliferation and chemokine generation, and is at least as potent for upregulating COX-2 expression and causing prostaglandin D-2 (PGD(2)) generation. LTE4 caused phosphorylation of extracellular signal-regulated kinase (ERK), p90RSK, and cyclic AMP-regulated-binding protein (CREB). ERK activation in response to LTE4, but not to LTD4, was resistant to inhibitors of phosphoinositol 3-kinase. LTE4-mediated COX-2 induction, PGD2 generation, and ERK phosphorylation were all sensitive to interference by the PPAR gamma antagonist GW9662 and to targeted knockdown of PPAR gamma. Although LTE4-mediated PGD2 production was also sensitive to MK571, an antagonist for the type 1 receptor for cys-LTs (CysLT(1)R), it was resistant to knockdown of this receptor. This LTE4-selective receptor-mediated pathway may explain the unique physiologic responses of human airways to LTE4 in vivo.	[Paruchuri, Sailaja; Jiang, Yongfeng; Feng, Chunli; Boyce, Joshua A.] Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, Boston, MA 02115 USA; [Francis, Sanjeev A.; Plutzky, Jorge] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA 02115 USA; [Paruchuri, Sailaja; Jiang, Yongfeng; Francis, Sanjeev A.; Plutzky, Jorge; Boyce, Joshua A.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; [Boyce, Joshua A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Boyce, JA (corresponding author), Brigham & Womens Hosp, Div Rheumatol Allergy & Immunol, 1 Jimmy Fund Way,Smith Bldg Rm 626, Boston, MA 02115 USA.	jboyce@rics.bwh.harvard.edu	Plutzky, Jorge/V-3410-2019		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036110] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI078908, U01AI031599, R01AI048802, R37AI052353, R56AI052353, U19AI031599, R01AI052353] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB000768] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL036110-24, P01 HL036110, P01 HL036110-240017, HL-36110] Funding Source: Medline; NIAID NIH HHS [R01 AI052353-07S2, AI-52353, R01 AI078908, AI-48802, R01 AI052353, AI-31599] Funding Source: Medline; NIBIB NIH HHS [EB-00768] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))		Adamjee J, 2006, J PATHOL, V209, P392, DOI 10.1002/path.1979; Altman LC, 1998, J ALLERGY CLIN IMMUN, V102, P50, DOI 10.1016/S0091-6749(98)70054-5; ARM JP, 1990, AM REV RESPIR DIS, V142, P1112, DOI 10.1164/ajrccm/142.5.1112; Bagga S, 2004, BLOOD, V104, P4080, DOI 10.1182/blood-2004-03-1166; Beller TC, 2004, J BIOL CHEM, V279, P46129, DOI 10.1074/jbc.M407057200; Beller TC, 2004, P NATL ACAD SCI USA, V101, P3047, DOI 10.1073/pnas.0400235101; Bochenek G, 2003, J ALLERGY CLIN IMMUN, V111, P743, DOI 10.1067/mai.2003.1387; Brown JD, 2007, CIRCULATION, V115, P518, DOI 10.1161/CIRCULATIONAHA.104.475673; Carter BZ, 1998, J BIOL CHEM, V273, P28277, DOI 10.1074/jbc.273.43.28277; CHRISTIE PE, 1993, EUR RESPIR J, V6, P1468; CHRISTIE PE, 1992, AM REV RESPIR DIS, V146, P1506, DOI 10.1164/ajrccm/146.6.1506; Ciana P, 2006, EMBO J, V25, P4615, DOI 10.1038/sj.emboj.7601341; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; DAVIDSON AB, 1987, AM REV RESPIR DIS, V135, P333; DIXON RAF, 1990, NATURE, V343, P282, DOI 10.1038/343282a0; DRAZEN JM, 1992, AM REV RESPIR DIS, V146, P104, DOI 10.1164/ajrccm/146.1.104; DRAZEN JM, 1987, AM REV RESPIR DIS, V136, P985, DOI 10.1164/ajrccm/136.4.985; Figueroa DJ, 2003, CLIN EXP ALLERGY, V33, P1380, DOI 10.1046/j.1365-2222.2003.01786.x; FULLER RW, 1986, AM REV RESPIR DIS, V133, P252; Gardner OS, 2003, J BIOL CHEM, V278, P46261, DOI 10.1074/jbc.M307827200; Gauvreau GM, 2001, AM J RESP CRIT CARE, V164, P1495, DOI 10.1164/ajrccm.164.8.2102033; Gurish MF, 2006, J ALLERGY CLIN IMMUN, V117, P1285, DOI 10.1016/j.jaci.2006.04.017; Hamilton A, 1998, J ALLERGY CLIN IMMUN, V102, P177, DOI 10.1016/S0091-6749(98)70083-1; HARDY CC, 1984, NEW ENGL J MED, V311, P209, DOI 10.1056/NEJM198407263110401; Heise CE, 2000, J BIOL CHEM, V275, P30531, DOI 10.1074/jbc.M003490200; Hirai H, 2001, J EXP MED, V193, P255, DOI 10.1084/jem.193.2.255; Israel E, 1996, JAMA-J AM MED ASSOC, V275, P931, DOI 10.1001/jama.275.12.931; Jiang Y, 2007, BLOOD, V110, P3263, DOI 10.1182/blood-2007-07-100453; Jiang YF, 2006, J IMMUNOL, V177, P2755, DOI 10.4049/jimmunol.177.5.2755; Kanaoka Y, 2004, J IMMUNOL, V173, P1503, DOI 10.4049/jimmunol.173.3.1503; Kim DC, 2006, J IMMUNOL, V176, P4440, DOI 10.4049/jimmunol.176.7.4440; Kim EJ, 2003, J PHARMACOL EXP THER, V307, P505, DOI 10.1124/jpet.103.053876; Kirshenbaum AS, 2003, LEUKEMIA RES, V27, P677, DOI 10.1016/S0145-2126(02)00343-0; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; KLIEWER SA, 1994, P NATL ACAD SCI USA, V91, P7335; Kodera Y, 2000, J BIOL CHEM, V275, P33201, DOI 10.1074/jbc.C000517200; LAITINEN LA, 1993, LANCET, V341, P989, DOI 10.1016/0140-6736(93)91073-U; LAM BK, 1994, P NATL ACAD SCI USA, V91, P7663, DOI 10.1073/pnas.91.16.7663; LEE CW, 1983, IMMUNOLOGY, V48, P27; LEE TH, 1984, P NATL ACAD SCI-BIOL, V81, P4922, DOI 10.1073/pnas.81.15.4922; LEIER I, 1994, J BIOL CHEM, V269, P27807; Lynch KR, 1999, NATURE, V399, P789; MALAVIYA R, 1993, J BIOL CHEM, V268, P4939; Mamedova L, 2005, BIOCHEM PHARMACOL, V71, P115, DOI 10.1016/j.bcp.2005.10.003; Mellor EA, 2003, P NATL ACAD SCI USA, V100, P11589, DOI 10.1073/pnas.2034927100; Mellor EA, 2002, J EXP MED, V195, P583, DOI 10.1084/jem.20020044; Mellor EA, 2001, P NATL ACAD SCI USA, V98, P7964, DOI 10.1073/pnas.141221498; NICHOLSON DW, 1993, P NATL ACAD SCI USA, V90, P2015, DOI 10.1073/pnas.90.5.2015; Ochi H, 1999, J EXP MED, V190, P267, DOI 10.1084/jem.190.2.267; OHICKEY SP, 1991, AM REV RESPIR DIS, V144, P1053, DOI 10.1164/ajrccm/144.5.1053; Olivares-Reyes JA, 2005, MOL PHARMACOL, V68, P356, DOI 10.1124/mol.104.010637; Pawliczak R, 2004, J BIOL CHEM, V279, P48550, DOI 10.1074/jbc.M408926200; Pontsler AV, 2002, J BIOL CHEM, V277, P13029, DOI 10.1074/jbc.M109546200; Rokos CL, 1997, J BIOL CHEM, V272, P13452, DOI 10.1074/jbc.272.20.13452; Sousa AR, 1997, THORAX, V52, P940, DOI 10.1136/thx.52.11.940; Sousa AR, 2002, NEW ENGL J MED, V347, P1493, DOI 10.1056/NEJMoa013508; Wada K, 2006, J BIOL CHEM, V281, P12673, DOI 10.1074/jbc.M513786200; Wedemeyer J, 2000, CURR OPIN IMMUNOL, V12, P624, DOI 10.1016/S0952-7915(00)00154-0; WENZEL SE, 1990, AM REV RESPIR DIS, V142, P112, DOI 10.1164/ajrccm/142.1.112; Zarini S, 2006, J BIOL CHEM, V281, P10134, DOI 10.1074/jbc.M510783200; Ziouzenkova O, 2003, P NATL ACAD SCI USA, V100, P2730, DOI 10.1073/pnas.0538015100	62	81	82	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16477	16487		10.1074/jbc.M705822200	http://dx.doi.org/10.1074/jbc.M705822200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18411276	Green Published, hybrid			2022-12-25	WOS:000256497100024
J	Czirjak, G; Vuity, D; Enyedi, P				Czirjak, Gabor; Vuity, Drazsen; Enyedi, Peter			Phosphorylation-dependent binding of 14-3-3 proteins controls TRESK regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN K+ CHANNELS; POTASSIUM CHANNEL; FUNCTIONAL EXPRESSION; ENDOPLASMIC-RETICULUM; 14-3-3 PROTEINS; DOCKING SITE; CALCINEURIN; ANESTHETICS; KINASE; TASK-1	The two-pore domain K+ channel, TRESK (TWIK-related spinal cord K+ channel) is reversibly activated by the calcium/calmodulin-dependent protein phosphatase, calcineurin. In the present study, we report that 14-3-3 proteins directly bind to the intracellular loop of TRESK and control the kinetics of the calcium-dependent regulation of the channel. Coexpression of 14-3-3 eta with TRESK blocked, whereas the coexpression of a dominant negative form of 14-3-3 eta accelerated the return of the K+ current to the resting state after the activation mediated by calcineurin in Xenopus oocytes. The direct action of 14-3-3 was spatially restricted to TRESK, since 14-3-3 eta was also effective, when it was tethered to the channel by a flexible polyglutamine-containing chain. The effect of both the coexpressed and chained 14-3-3 was alleviated by the microinjection of Ser(P)-Raf259 phosphopeptide that competes with TRESK for binding to 14-3-3. The gamma and eta isoforms of 14-3-3 controlled TRESK regulation, whereas the beta, zeta, epsilon, sigma, and tau isoforms failed to influence the mechanism significantly. Phosphorylation of serine 264 in mouse TRESK was required for the binding of 14-3-3 eta. Because 14-3-3 proteins are ubiquitous, they are expected to control the duration of calcineurin-mediated TRESK activation in all the cell types that express the channel, depending on the phosphorylation state of serine 264. This kind of direct control of channel regulation by 14-3-3 is unique within the two-pore domain K+ channel family.	[Czirjak, Gabor; Vuity, Drazsen; Enyedi, Peter] Semmelweis Univ, Dept Physiol, H-1444 Budapest, Hungary	Semmelweis University	Enyedi, P (corresponding author), Semmelweis Univ, Dept Physiol, POB 259, H-1444 Budapest, Hungary.	enyedi@puskin.sote.hu		Czirjak, Gabor/0000-0002-5485-2327				Aitken A, 2006, SEMIN CANCER BIOL, V16, P162, DOI 10.1016/j.semcancer.2006.03.005; Chemin J, 2003, EMBO J, V22, P5403, DOI 10.1093/emboj/cdg528; Chen XD, 2006, P NATL ACAD SCI USA, V103, P3422, DOI 10.1073/pnas.0507710103; Czirjak B, 2004, J BIOL CHEM, V279, P18550, DOI 10.1074/jbc.M312229200; Czirjak G, 2002, J BIOL CHEM, V277, P5426, DOI 10.1074/jbc.M107138200; Czirjak G, 2001, AM J PHYSIOL-CELL PH, V281, pC700, DOI 10.1152/ajpcell.2001.281.2.C700; Czirjak G, 2006, J BIOL CHEM, V281, P14677, DOI 10.1074/jbc.M602495200; Dobler T, 2007, J PHYSIOL-LONDON, V585, P867, DOI 10.1113/jphysiol.2007.145649; Dodge KL, 2003, BIOCHEM BIOPH RES CO, V311, P1111, DOI 10.1016/j.bbrc.2003.09.040; Gardino AK, 2006, SEMIN CANCER BIOL, V16, P173, DOI 10.1016/j.semcancer.2006.03.007; Heurteaux C, 2004, EMBO J, V23, P2684, DOI 10.1038/sj.emboj.7600234; HOSHI T, 1990, SCIENCE, V250, P533, DOI 10.1126/science.2122519; Kang D, 2004, J BIOL CHEM, V279, P28063, DOI 10.1074/jbc.M402940200; Kang D, 2008, BIOCHEM BIOPH RES CO, V367, P609, DOI 10.1016/j.bbrc.2008.01.008; Kang DW, 2006, AM J PHYSIOL-CELL PH, V291, pC649, DOI 10.1152/ajpcell.00047.2006; Kang D, 2006, AM J PHYSIOL-CELL PH, V291, pC138, DOI 10.1152/ajpcell.00629.2005; Keshavaprasad B, 2005, ANESTH ANALG, V101, P1042, DOI 10.1213/01.ane.0000168447.87557.5a; Li HM, 2004, J MOL BIOL, V342, P1659, DOI 10.1016/j.jmb.2004.07.068; Li HM, 2007, J MOL BIOL, V369, P1296, DOI 10.1016/j.jmb.2007.04.032; Liu CH, 2004, ANESTH ANALG, V99, P1715, DOI 10.1213/01.ANE.0000136849.07384.44; Lotshaw DP, 2007, CELL BIOCHEM BIOPHYS, V47, P209, DOI 10.1007/s12013-007-0007-8; Masino L, 2002, FEBS LETT, V513, P267, DOI 10.1016/S0014-5793(02)02335-9; Mathie A, 2007, J PHYSIOL-LONDON, V578, P377, DOI 10.1113/jphysiol.2006.121582; Muslin AJ, 1996, CELL, V84, P889, DOI 10.1016/S0092-8674(00)81067-3; O'Kelly I, 2002, CELL, V111, P577, DOI 10.1016/S0092-8674(02)01040-1; Patel AJ, 1999, NAT NEUROSCI, V2, P422, DOI 10.1038/8084; Rajan S, 2002, J PHYSIOL-LONDON, V545, P13, DOI 10.1113/jphysiol.2002.027052; Renigunta V, 2006, TRAFFIC, V7, P168, DOI 10.1111/j.1600-0854.2005.00375.x; Roy J, 2007, MOL CELL, V25, P889, DOI 10.1016/j.molcel.2007.02.014; Sano Y, 2003, J BIOL CHEM, V278, P27406, DOI 10.1074/jbc.M206810200; Sen S, 2003, PROTEIN SCI, V12, P953, DOI 10.1110/ps.0224403; Thorson JA, 1998, MOL CELL BIOL, V18, P5229, DOI 10.1128/MCB.18.9.5229; Veale EL, 2007, MOL PHARMACOL, V71, P1666, DOI 10.1124/mol.106.033241; Xiao Bing, 1995, Nature (London), V376, P188, DOI 10.1038/376188a0; Yaffe MB, 1997, CELL, V91, P961, DOI 10.1016/S0092-8674(00)80487-0; Zhang LX, 1997, J BIOL CHEM, V272, P13717, DOI 10.1074/jbc.272.21.13717	36	40	46	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15672	15680		10.1074/jbc.M800712200	http://dx.doi.org/10.1074/jbc.M800712200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18397886	Green Published, hybrid			2022-12-25	WOS:000256332500021
J	Palacios, A; Munoz, IG; Pantoja-Uceda, D; Marcaida, MJ; Torres, D; Martin-Garcia, JM; Luque, I; Montoya, G; Blanco, FJ				Palacios, Alicia; Munoz, Ines G.; Pantoja-Uceda, David; Marcaida, Maria J.; Torres, Daniel; Martin-Garcia, Jose M.; Luque, Irene; Montoya, Guillermo; Blanco, Francisco J.			Molecular basis of histone H3K4me3 recognition by ING4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHD FINGER; ZINC-FINGER; PLANT HOMEODOMAIN; CHROMATIN; BINDING; METHYLATION; RELAXATION; PROTEIN; FAMILY; DOMAIN	The inhibitors of growth (ING) family of tumor suppressors consists of five homologous proteins involved in chromatin remodeling. They form part of different acetylation and deacetylation complexes and are thought to direct them to specific regions of the chromatin, through the recognition of H3K4me3 (trimethylated K4 in the histone 3 tail) by their conserved plant homeodomain (PHD). We have determined the crystal structure of ING4-PHD bound to H3K4me3, which reveals a tight complex stabilized by numerous interactions. NMR shows that there is a reduction in the backbone mobility on the regions of the PHD that participate in the peptide binding, and binding affinities differ depending on histone tail lengths Thermodynamic analysis reveals that the discrimination in favor of methylated lysine is entropydriven, contrary to what has been described for chromodomains. The molecular basis of H3K4me3 recognition by ING4 differs from that of ING2, which is consistent with their different affinities for methylated histone tails. These differences suggest a distinct role in transcriptional regulation for these two ING family members because of the antagonistic effect of the complexes that they recruit onto chromatin. Our results illustrate the versatility of PHD fingers as readers of the histone code.	[Munoz, Ines G.; Marcaida, Maria J.; Montoya, Guillermo] Ctr Nacl Invest Oncol, Macromol Crystallog Grp, Madrid 28029, Spain; [Palacios, Alicia; Blanco, Francisco J.] CIC bioGUNE, Struct Biol Unit, Derio 48160, Spain; [Pantoja-Uceda, David; Torres, Daniel] Ctr Nacl Invest Oncol, NMR Grp, Struct Biol & Biocomp Programme, Madrid 28029, Spain; [Martin-Garcia, Jose M.; Luque, Irene] Univ Granada, Dept Phys Chem, Fac Sci, E-18071 Granada, Spain; [Martin-Garcia, Jose M.; Luque, Irene] Univ Granada, Inst Biotechnol, Fac Sci, E-18071 Granada, Spain	CIC bioGUNE; University of Granada; University of Granada	Montoya, G (corresponding author), Ctr Nacl Invest Oncol, Macromol Crystallog Grp, Melchor Fernandez Almagro 3, Madrid 28029, Spain.	gmontoya@cnio.es; fblanco@cicbiogune.es	Hu, Ruogu/B-2203-2008; Ortega, Alicia Palacios/F-7710-2019; MARTIN GARCIA, JOSE MANUEL/GQA-3160-2022; MARTIN GARCIA, JOSE MANUEL/AAB-6838-2020; cancer, biogune/H-7276-2012; Luque, Irene/K-4758-2012; Pantoja-Uceda, David/J-8097-2014; Ortega, Alicia Palacios/AAD-4449-2020; Munoz, Ines G/M-3285-2014; Garcia, Jose Manuel Martin/V-2043-2018; Marcaida, Maria Jose/I-1644-2017; Luque, Inmaculada/K-9464-2014; Blanco, Francisco J/D-4401-2009	Ortega, Alicia Palacios/0000-0002-7906-1417; MARTIN GARCIA, JOSE MANUEL/0000-0002-4558-3858; MARTIN GARCIA, JOSE MANUEL/0000-0002-4558-3858; Luque, Irene/0000-0003-2757-4779; Ortega, Alicia Palacios/0000-0002-7906-1417; Munoz, Ines G/0000-0001-6732-4059; Garcia, Jose Manuel Martin/0000-0002-4558-3858; Marcaida, Maria Jose/0000-0003-0663-5309; Luque, Inmaculada/0000-0003-1838-2636; Blanco, Francisco J/0000-0003-2545-4319; Pantoja-Uceda, David/0000-0003-4390-6972				AASLAND R, 1995, TRENDS BIOCHEM SCI, V20, P56, DOI 10.1016/S0968-0004(00)88957-4; Bienz M, 2006, TRENDS BIOCHEM SCI, V31, P35, DOI 10.1016/j.tibs.2005.11.001; BRUSCHWEILER R, 1995, SCIENCE, V268, P886, DOI 10.1126/science.7754375; Campos EI, 2004, CELL MOL LIFE SCI, V61, P2597, DOI 10.1007/s00018-004-4199-4; Cohen SX, 2004, ACTA CRYSTALLOGR D, V60, P2222, DOI 10.1107/S0907444904027556; Cole R, 2003, J BIOMOL NMR, V26, P203, DOI 10.1023/A:1023808801134; Downs JA, 2007, NATURE, V447, P951, DOI 10.1038/nature05980; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fischle W, 2005, NATURE, V438, P1116, DOI 10.1038/nature04219; Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290; Groth A, 2007, CELL, V128, P721, DOI 10.1016/j.cell.2007.01.030; Guccione E, 2007, NATURE, V449, P933, DOI 10.1038/nature06166; He GHY, 2005, MOL BIOL EVOL, V22, P104, DOI 10.1093/molbev/msh256; Hirota T, 2005, NATURE, V438, P1176, DOI 10.1038/nature04254; Hughes RM, 2007, P NATL ACAD SCI USA, V104, P11184, DOI 10.1073/pnas.0610850104; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Johnson Bruce A, 2004, Methods Mol Biol, V278, P313; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kirmizis A, 2007, NATURE, V449, P928, DOI 10.1038/nature06160; Kleywegt G. J., 2001, INT TABLES CRYSTALLO, VF, P353, DOI DOI 10.1107/97809553602060000111; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Li B, 2007, CELL, V128, P707, DOI 10.1016/j.cell.2007.01.015; Li HT, 2006, NATURE, V442, P91, DOI 10.1038/nature04802; LIPARI G, 1982, J AM CHEM SOC, V104, P4559, DOI 10.1021/ja00381a010; Luque I, 1998, METHOD ENZYMOL, V295, P100; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Palacios A, 2006, FEBS LETT, V580, P6903, DOI 10.1016/j.febslet.2006.11.055; PALMER AG, 1991, J AM CHEM SOC, V113, P4371, DOI 10.1021/ja00012a001; Pascual J, 2000, J MOL BIOL, V304, P723, DOI 10.1006/jmbi.2000.4308; Pawley NH, 2001, J BIOMOL NMR, V20, P149, DOI 10.1023/A:1011249816560; Pena PV, 2006, NATURE, V442, P100, DOI 10.1038/nature04814; Potterton E, 2002, ACTA CRYSTALLOGR D, V58, P1955, DOI 10.1107/S0907444902015391; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Renner C, 2002, J BIOMOL NMR, V23, P23, DOI 10.1023/A:1015385910220; Rountree MR, 2001, ONCOGENE, V20, P3156, DOI 10.1038/sj.onc.1204339; Russell M, 2006, EXP CELL RES, V312, P951, DOI 10.1016/j.yexcr.2006.01.020; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Shi XB, 2006, NATURE, V442, P96, DOI 10.1038/nature04835; Sigurskjold BW, 2000, ANAL BIOCHEM, V277, P260, DOI 10.1006/abio.1999.4402; Soliman MA, 2007, TRENDS BIOCHEM SCI, V32, P509, DOI 10.1016/j.tibs.2007.08.006; Taverna SD, 2007, NAT STRUCT MOL BIOL, V14, P1025, DOI 10.1038/nsmb1338; Tjandra N, 1995, J AM CHEM SOC, V117, P12562, DOI 10.1021/ja00155a020; Wysocka J, 2006, NATURE, V442, P86, DOI 10.1038/nature04815	45	68	69	0	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15956	15964		10.1074/jbc.M710020200	http://dx.doi.org/10.1074/jbc.M710020200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18381289	Green Published, hybrid			2022-12-25	WOS:000256332500054
J	Li, Y; Suggs, C; Wright, JT; Yuan, ZA; Aragon, M; Fong, H; Simmons, D; Daly, B; Golub, EE; Harrison, G; Kulkarni, AB; Gibson, CW				Li, Yong; Suggs, Cynthia; Wright, J. Timothy; Yuan, Zhi-an; Aragon, Melissa; Fong, Hanson; Simmons, Darrin; Daly, Bill; Golub, Ellis E.; Harrison, Gerald; Kulkarni, Ashok B.; Gibson, Carolyn W.			Partial rescue of the amelogenin null dental enamel phenotype	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYL-D-GLUCOSAMINE; MATRIX PROTEINS; GENE-EXPRESSION; TRANSGENIC MICE; IMPERFECTA; ODONTOBLASTS; MUTATION; BIOLOGY; EXON-8; BINDS	The amelogenins are the most abundant secreted proteins in developing dental enamel. Enamel from amelogenin (Amelx) null mice is hypoplastic and disorganized, similar to that observed in X-linked forms of the human enamel defect amelogenesis imperfecta resulting from amelogenin gene mutations. Both transgenic strains that express the most abundant amelogenin (TgM180) have relatively normal enamel, but strains of mice that express a mutated amelogenin (TgP70T), which leads to amelogenesis imperfecta in humans, have heterogeneous enamel structures. When Amelx null (KO) mice were mated with transgenic mice that produce M180 (TgM180), the resultant TgM180KO offspring showed evidence of rescue in' enamel thickness, mineral density, and volume in molar teeth. Rescue was not observed in the molars from the TgP70TKO mice. It was concluded that a single amelogenin protein was able to significantly rescue the KO phenotype and that one amino acid change abrogated this function during development.	[Li, Yong; Yuan, Zhi-an; Aragon, Melissa; Gibson, Carolyn W.] Univ Penn, Sch Dent Med, Dept Anat & Cell Biol, Philadelphia, PA 19104 USA; [Golub, Ellis E.; Harrison, Gerald] Univ Penn, Sch Dent Med, Dept Biochem, Philadelphia, PA 19104 USA; [Suggs, Cynthia; Simmons, Darrin; Daly, Bill] Univ N Carolina, Sch Dent, Dept Pediat Dent, Chapel Hill, NC 27599 USA; [Fong, Hanson] Univ Washington, Dept Mat Sci & Engn, Seattle, WA 98195 USA; [Kulkarni, Ashok B.] NIDCR, Funct Genom Sect, Lab Cell & Dev Biol, NIH, Bethesda, MD 20892 USA	University of Pennsylvania; University of Pennsylvania; University of North Carolina; University of North Carolina Chapel Hill; University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR)	Gibson, CW (corresponding author), Univ Penn, Sch Dent Med, Dept Anat & Cell Biol, 240 S 40th St, Philadelphia, PA 19104 USA.	gibson@biochem.dental.upenn.edu	Wright, John Timothy/AAX-5755-2020		NIDCR NIH HHS [DE 011089] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [R01DE011089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000698, ZIADE000698] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Bartlett JD, 2006, J DENT RES, V85, P894, DOI 10.1177/154405910608501004; BROOKES SJ, 1995, ARCH ORAL BIOL, V40, P1, DOI 10.1016/0003-9969(94)00135-X; CHAPMAN VM, 1991, GENOMICS, V10, P23, DOI 10.1016/0888-7543(91)90479-X; Chen E, 2003, CALCIFIED TISSUE INT, V73, P487, DOI 10.1007/s00223-002-0036-7; Collier PM, 1997, ARCH ORAL BIOL, V42, P235, DOI 10.1016/S0003-9969(96)00099-4; Delgado S, 2007, J DENT RES, V86, P326, DOI 10.1177/154405910708600405; FEARNHEAD RW, 1960, NATURE, V188, P509, DOI 10.1038/188509a0; FINCHAM AG, 1995, J STRUCT BIOL, V115, P50, DOI 10.1006/jsbi.1995.1029; Fincham AG, 1999, J STRUCT BIOL, V126, P270, DOI 10.1006/jsbi.1999.4130; FINCHAM AG, 1983, BIOCHEM J, V211, P149, DOI 10.1042/bj2110149; Fong H, 2003, J BONE MINER RES, V18, P2052, DOI 10.1359/jbmr.2003.18.11.2052; Gibson CW, 2007, J DENT RES, V86, P331, DOI 10.1177/154405910708600406; Gibson CW, 1995, CONNECT TISSUE RES, V32, P109, DOI 10.3109/03008209509013711; Gibson CW, 1999, CRIT REV EUKAR GENE, V9, P45, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.40; Gibson CW, 2001, J BIOL CHEM, V276, P31871, DOI 10.1074/jbc.M104624200; Hart PS, 2002, ARCH ORAL BIOL, V47, P255, DOI 10.1016/S0003-9969(02)00005-5; Hoang AM, 2002, J DENT RES, V81, P497, DOI 10.1177/154405910208100713; Hu CC, 1997, J DENT RES, V76, P641, DOI 10.1177/00220345970760020401; Li W, 1998, ARCH ORAL BIOL, V43, P497, DOI 10.1016/S0003-9969(98)00013-2; Li W, 2001, MATRIX BIOL, V19, P755, DOI 10.1016/S0945-053X(00)00121-9; Li Y, 2006, EUR J ORAL SCI, V114, P190, DOI 10.1111/j.1600-0722.2006.00286.x; Margolis HC, 2006, J DENT RES, V85, P775, DOI 10.1177/154405910608500902; MOEREMANS M, 1985, ANAL BIOCHEM, V145, P315, DOI 10.1016/0003-2697(85)90368-9; Moradian-Oldak J, 2000, J STRUCT BIOL, V131, P27, DOI 10.1006/jsbi.2000.4237; Moradian-Oldak J, 2005, CELLS TISSUES ORGANS, V181, P202, DOI 10.1159/000091382; Moradian-Oldak J, 2001, MATRIX BIOL, V20, P293, DOI 10.1016/S0945-053X(01)00154-8; Nagano T, 2003, J DENT RES, V82, P982, DOI 10.1177/154405910308201209; NAKAHORI Y, 1991, GENOMICS, V9, P264, DOI 10.1016/0888-7543(91)90251-9; Oida S, 2002, J DENT RES, V81, P103, DOI 10.1177/154405910208100204; OLIVER W, 1992, J MATER RES, V4, P564; Ozdemir D, 2005, J DENT RES, V84, P1031, DOI 10.1177/154405910508401112; Paine ML, 2004, CELLS TISSUES ORGANS, V176, P7, DOI 10.1159/000075023; Papagerakis P, 2003, BONE, V32, P228, DOI 10.1016/S8756-3282(02)00978-X; Papagerakis P, 2005, J DENT RES, V84, P613, DOI 10.1177/154405910508400706; Ravassipour DB, 2000, J DENT RES, V79, P1476, DOI 10.1177/00220345000790070801; Ravindranath RMH, 1999, J BIOL CHEM, V274, P2464, DOI 10.1074/jbc.274.4.2464; Ravindranath RMH, 2000, J BIOL CHEM, V275, P39654, DOI 10.1074/jbc.M006471200; ROBINSON C, 1981, J CRYST GROWTH, V53, P160, DOI 10.1016/0022-0248(81)90062-2; Robinson C, 2003, CONNECT TISSUE RES, V44, P65, DOI 10.1080/03008200390152115; Robinson C, 2000, CRIT REV ORAL BIOL M, V11, P481, DOI 10.1177/10454411000110040601; ROBINSON C, 1979, J DENT RES, V58, P871, DOI 10.1177/00220345790580024101; SALIDO EC, 1992, AM J HUM GENET, V50, P303; SAUK JJ, 1972, AM J HUM GENET, V24, P267; Simmer JP, 2002, CONNECT TISSUE RES, V43, P441, DOI 10.1080/03008200290001159; Smith CE, 1998, CRIT REV ORAL BIOL M, V9, P128, DOI 10.1177/10454411980090020101; Snead ML, 2003, CONNECT TISSUE RES, V44, P47, DOI 10.1080/03008200390152089; TERMINE JD, 1980, J BIOL CHEM, V255, P9760; THESLEFF I, 1995, INT J DEV BIOL, V39, P35; Tucker AS, 1999, J DENT RES, V78, P826, DOI 10.1177/00220345990780040201; Wen HB, 2000, J DENT RES, V79, P1902, DOI 10.1177/00220345000790111501; White SN, 2007, J BIOL CHEM, V282, P5340, DOI 10.1074/jbc.M604814200; Wright JT, 2006, AM J MED GENET A, V140A, P2547, DOI 10.1002/ajmg.a.31358; Wright JT, 2003, CONNECT TISSUE RES, V44, P72, DOI 10.1080/03008200390152124; Wu L, 2003, ARCH ORAL BIOL, V48, P177, DOI 10.1016/S0003-9969(02)00170-X	54	24	24	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15056	15062		10.1074/jbc.M707992200	http://dx.doi.org/10.1074/jbc.M707992200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18390542	Green Submitted, Green Published, hybrid			2022-12-25	WOS:000256232000019
J	Sauvat, F; Capito, C; Sarnacki, S; Poirot, C; Bachelot, A; Meduri, G; Dandolo, L; Binart, N				Sauvat, Frederique; Capito, Carmen; Sarnacki, Sabine; Poirot, Catherine; Bachelot, Anne; Meduri, Geri; Dandolo, Luisa; Binart, Nadine			Immature Cryopreserved Ovary Restores Puberty and Fertility in Mice without Alteration of Epigenetic Marks	PLOS ONE			English	Article							BECKWITH-WIEDEMANN-SYNDROME; ASSISTED REPRODUCTIVE TECHNOLOGY; MONOZYGOTIC TWINS DISCORDANT; BONE-MARROW-TRANSPLANTATION; IN-VITRO FERTILIZATION; TERM-FOLLOW-UP; TISSUE CRYOPRESERVATION; MOUSE OVARIES; CHILDHOOD-CANCER; H19	Background: Progress in oncology could improve survival rate in children, but would probably lead to impaired fertility and puberty. In pre-pubertal girls, the only therapeutic option is the cryopreservation of one ovary. Three births have been reported after reimplantation of cryopreserved mature ovary. Conversely, reimplantation of ovary preserved before puberty (defined as immature ovary) has never been performed in humans. Methodology/Principal Findings: In order to analyze ovarian function, we performed transplantation using fresh or cryopreserved immature grafts in pre-pubertal or adult mice. Puberty as well as cyclic hormonal activity was restored. All follicle populations were present although a significant reduction in follicle density was observed with or without cryopreservation. Although fertility was restored, the graft is of limited life span. Because ex vivo ovary manipulation and cryopreservation procedure, the status of genomic imprinting was investigated. Methylation status of the H19 and Lit1 Imprinting Control Regions in kidney, muscle and tongue of offsprings from grafted mice does not show significant alteration when compared to those of unoperated mice. Conclusions/Significance: These results demonstrate that immature ovarian grafting can restore spontaneous puberty and fertility. However, these data suggest that follicle depletion leads to premature ovarian failure. This study addresses the very important epigenetics issue, and provides valuable information to the study of ovarian transplantation suggesting that these procedures do not perturb normal epigenetics marks. These results are highly relevant to the reimplantation question of immature cortex in women.	[Sauvat, Frederique; Capito, Carmen; Bachelot, Anne; Binart, Nadine] INSERM, Unit 845, Paris, France; [Sauvat, Frederique; Capito, Carmen; Bachelot, Anne; Binart, Nadine] Univ Paris 05, Fac Med Rene Descartes, Paris 5 Necker Site, UMR S845, Paris, France; [Sauvat, Frederique; Sarnacki, Sabine] Hosp Necker Enfants Malades, Dept Pediat Surg, AP HP, Paris, France; [Poirot, Catherine] GH Pitie Salpetriere, Unit Biol Reprod, AP HP, Paris, France; [Bachelot, Anne] GH Pitie Salpetriere, Dept Endocrinol & Reprod Med, AP PH, Paris, France; [Meduri, Geri] Inserm, Unit 693, Le Kremlin Bicetre, France; [Meduri, Geri] GH Bicetre, Dept Mol Biochem, AP PH, Le Kremlin Bicetre, France; [Dandolo, Luisa] Univ Paris 05, Inst Cochin, Dept Genet & Dev, CNRS UMR 8104, Inserm U 567, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Binart, N (corresponding author), INSERM, Unit 845, Paris, France.	binart@necker.fr	Bachelot, Anne/GQZ-0551-2022; Binart, Nadine/F-2949-2013; Sarnacki, Sabine/I-2692-2017	Binart, Nadine/0000-0002-5606-3866; Sarnacki, Sabine/0000-0003-4304-5578	ARC [3695]; Inserm	ARC(Australian Research Council); Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission)	This study was supported by a grant from ARC #3695 and Inserm. F. Sauvat was supported by a fellowship from Inserm.	Akar M, 2005, TRENDS ENDOCRIN MET, V16, P374, DOI 10.1016/j.tem.2005.06.011; Bakker B, 2000, EUR J PEDIATR, V159, P31, DOI 10.1007/s004310050006; Bath LE, 2004, HUM REPROD, V19, P2569, DOI 10.1093/humrep/deh472; BenEzra D, 2005, BRIT J OPHTHALMOL, V89, P393, DOI 10.1136/bjo.2004.056739; Blatt J, 1999, MED PEDIATR ONCOL, V33, P29, DOI 10.1002/(SICI)1096-911X(199907)33:1<29::AID-MPO6>3.0.CO;2-2; BLEYER WA, 1990, CA-CANCER J CLIN, V40, P355, DOI 10.3322/canjclin.40.6.355; Buiting K, 2003, AM J HUM GENET, V72, P571, DOI 10.1086/367926; Candy CJ, 2000, HUM REPROD, V15, P1300, DOI 10.1093/humrep/15.6.1300; Chang AS, 2005, FERTIL STERIL, V83, P349, DOI 10.1016/j.fertnstert.2004.07.964; Constancia M, 2004, NATURE, V432, P53, DOI 10.1038/432053a; Cox SL, 2000, FERTIL STERIL, V74, P366, DOI 10.1016/S0015-0282(00)00635-X; Cox SL, 1996, J REPROD FERTIL, V107, P315, DOI 10.1530/jrf.0.1070315; DeBaun MR, 2003, AM J HUM GENET, V72, P156, DOI 10.1086/346031; Demeestere I, 2007, ONCOLOGIST, V12, P1437, DOI 10.1634/theoncologist.12-12-1437; Desandes E, 2006, EUR J CANCER, V42, P403, DOI 10.1016/j.ejca.2005.07.035; Doherty AS, 2000, BIOL REPROD, V62, P1526, DOI 10.1095/biolreprod62.6.1526; Donnez J, 2004, LANCET, V364, P1405, DOI 10.1016/S0140-6736(04)17222-X; Fedoriw AM, 2004, SCIENCE, V303, P238, DOI 10.1126/science.1090934; Fitzpatrick DR, 2003, CLIN IMMUNOL, V109, P37, DOI 10.1016/S1521-6616(03)00205-5; Frisk P, 2004, BONE MARROW TRANSPL, V33, P205, DOI 10.1038/sj.bmt.1704324; Gicquel C, 2003, AM J HUM GENET, V72, P1338, DOI 10.1086/374824; GOSDEN RG, 1994, HUM REPROD, V9, P597, DOI 10.1093/oxfordjournals.humrep.a138556; GOSDEN RG, 1992, J ASSIST REPROD GEN, V9, P118, DOI 10.1007/BF01203750; Gosden RG, 2007, NEW ENGL J MED, V356, P731, DOI 10.1056/NEJMe068284; Gunasena KT, 1997, HUM REPROD, V12, P101, DOI 10.1093/humrep/12.1.101; Hamish W, 2004, LANCET, V364, P2093, DOI 10.1016/S0140-6736(04)17544-2; Hubinont C, 2004, LANCET, V364, P2093, DOI 10.1016/S0140-6736(04)17543-0; JONES EC, 1960, J ENDOCRINOL, V20, P135, DOI 10.1677/joe.0.0200135; Kim SS, 2006, FERTIL STERIL, V85, P1, DOI 10.1016/j.fertnstert.2005.04.071; Kim SS, 2004, FERTIL STERIL, V82, P930, DOI 10.1016/j.fertnstert.2004.02.137; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; Lewis A, 2006, DEVELOPMENT, V133, P4203, DOI 10.1242/dev.02612; Liu J, 2002, HUM REPROD, V17, P605, DOI 10.1093/humrep/17.3.605; Lo Presti A, 2004, EUR J OBSTET GYN R B, V113, pS33, DOI 10.1016/j.ejogrb.2003.11.008; Lobo RA, 2005, NEW ENGL J MED, V353, P64, DOI 10.1056/NEJMra043475; Lucifero D, 2004, HUM MOL GENET, V13, P839, DOI 10.1093/hmg/ddh104; Ludwig M, 2005, J MED GENET, V42, P289, DOI 10.1136/jmg.2004.026930; Maher ER, 2003, J MED GENET, V40, P62, DOI 10.1136/jmg.40.1.62; Maher ER, 2005, HUM MOL GENET, V14, pR133, DOI 10.1093/hmg/ddi107; Mancini-DiNardo D, 2003, HUM MOL GENET, V12, P283, DOI 10.1093/hmg/ddg024; Mancini-DiNardo D, 2006, GENE DEV, V20, P1268, DOI 10.1101/gad.1416906; Mann MRW, 2003, BIOL REPROD, V69, P902, DOI 10.1095/biolreprod.103.017293; Meirow D, 1999, FERTIL STERIL, V71, P948, DOI 10.1016/S0015-0282(99)00067-9; Meirow D, 2005, NEW ENGL J MED, V353, P318, DOI 10.1056/NEJMc055237; Meirow D, 2007, FERTIL STERIL, V87, DOI 10.1016/j.fertnstert.2006.05.086; Meirow D, 2007, LEUKEMIA LYMPHOMA, V48, P1569, DOI 10.1080/10428190701471957; Migishima F, 2006, FERTIL STERIL, V86, P1080, DOI 10.1016/j.fertnstert.2006.03.023; Muller J, 2002, BEST PRACT RES CL EN, V16, P91, DOI 10.1053/beem.2002.0183; MUSSETT MV, 1961, J REPROD FERTIL, V2, P80, DOI 10.1530/jrf.0.0020080; Myers M, 2004, REPRODUCTION, V127, P569, DOI 10.1530/rep.1.00095; Navarro-Costa P, 2005, HUM REPROD, V20, P1607, DOI 10.1093/humrep/deh787; Niemitz EL, 2004, AM J HUM GENET, V74, P599, DOI 10.1086/382897; Oktay K, 2004, LANCET, V363, P837, DOI 10.1016/S0140-6736(04)15728-0; Oktay K, 2004, LANCET, V364, P2091, DOI 10.1016/S0140-6736(04)17541-7; Oktay K, 2006, HUM REPROD, V21, P1345, DOI 10.1093/humrep/del007; Paulsen M, 2001, J PATHOL, V195, P97, DOI 10.1002/path.890; Poirot C, 2005, Gynecol Obstet Fertil, V33, P799, DOI 10.1016/j.gyobfe.2005.07.032; Poirot CJ, 2007, PEDIATR BLOOD CANCER, V49, P74, DOI 10.1002/pbc.21027; Pritchard-Jones K, 2006, EUR J CANCER, V42, P2183, DOI 10.1016/j.ejca.2006.06.006; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Salle B, 2003, FERTIL STERIL, V80, P172, DOI 10.1016/S0015-0282(03)00554-5; Shaw JM, 2000, MOL CELL ENDOCRINOL, V161, P103, DOI 10.1016/S0303-7207(99)00230-0; Siegel-Itzkovich J, 2005, BRIT MED J, V331, P8, DOI 10.1136/bmj.331.7507.8-a; Silber SJ, 2007, NEW ENGL J MED, V356, P1382, DOI 10.1056/NEJMc066574; Silber SJ, 2005, NEW ENGL J MED, V353, P58, DOI 10.1056/NEJMoa043157; SILBER SJ, 2008, HUM REPROD; Skinner R, 2006, LANCET ONCOL, V7, P489, DOI 10.1016/S1470-2045(06)70724-0; Sklar CA, 2006, J NATL CANCER I, V98, P890, DOI 10.1093/jnci/djj243; THE VL, 1989, MOL ENDOCRINOL, V3, P1310, DOI 10.1210/mend-3-8-1310; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Wallace WHB, 2005, LANCET ONCOL, V6, P209, DOI 10.1016/S1470-2045(05)70092-9; Wang HB, 2002, AM J OBSTET GYNECOL, V187, P370, DOI 10.1067/mob.2002.123606; Young LE, 2003, MECH DEVELOP, V120, P1433, DOI 10.1016/j.mod.2003.09.006	73	28	30	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1972	10.1371/journal.pone.0001972	http://dx.doi.org/10.1371/journal.pone.0001972			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414667	gold, Green Published, Green Submitted			2022-12-25	WOS:000260867300016
J	Haitin, Y; Yisharel, I; Malka, E; Shamgar, L; Schottelndreier, H; Peretz, A; Paas, Y; Attali, B				Haitin, Yoni; Yisharel, Ilanit; Malka, Eti; Shamgar, Liora; Schottelndreier, Hella; Peretz, Asher; Paas, Yoav; Attali, Bernard			S1 Constrains S4 in the Voltage Sensor Domain of Kv7.1 K+ Channels	PLOS ONE			English	Article								Voltage-gated K+ channels comprise a central pore enclosed by four voltage-sensing domains (VSDs). While movement of the S4 helix is known to couple to channel gate opening and closing, the nature of S4 motion is unclear. Here, we substituted S4 residues of Kv7.1 channels by cysteine and recorded whole-cell mutant channel currents in Xenopus oocytes using the two-electrode voltage-clamp technique. In the closed state, disulfide and metal bridges constrain residue S225 (S4) nearby C136 (S1) within the same VSD. In the open state, two neighboring I227 (S4) are constrained at proximity while residue R228 (S4) is confined close to C136 (S1) of an adjacent VSD. Structural modeling predicts that in the closed to open transition, an axial rotation (similar to 190 degrees) and outward translation of S4 (similar to 12 angstrom) is accompanied by VSD rocking. This large sensor motion changes the intra-VSD S1-S4 interaction to an inter-VSD S1-S4 interaction. These constraints provide a ground for cooperative subunit interactions and suggest a key role of the S1 segment in steering S4 motion during Kv7.1 gating.	[Haitin, Yoni; Yisharel, Ilanit; Malka, Eti; Shamgar, Liora; Schottelndreier, Hella; Peretz, Asher; Attali, Bernard] Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel; [Paas, Yoav] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, Ramat Gan, Israel	Tel Aviv University; Sackler Faculty of Medicine; Bar Ilan University	Attali, B (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel.	battali@post.tau.ac.il	Haitin, Yoni/AAQ-4571-2021	Haitin, Yoni/0000-0002-1648-6792	Israel Science Foundation [ISF 672/05]; Israel Ministry of Science Tashtiot program; Keren Wolfson Family	Israel Science Foundation(Israel Science Foundation); Israel Ministry of Science Tashtiot program; Keren Wolfson Family	This work is supported by the Israel Science Foundation (ISF 672/05), the Israel Ministry of Science Tashtiot program and the Keren Wolfson Family funds to BA.	Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Ahern CA, 2004, TRENDS NEUROSCI, V27, P303, DOI 10.1016/j.tins.2004.03.008; Alabi AA, 2007, NATURE, V450, P370, DOI 10.1038/nature06266; Aziz QH, 2002, J BIOL CHEM, V277, P42719, DOI 10.1074/jbc.M207258200; Campos FV, 2007, P NATL ACAD SCI USA, V104, P7904, DOI 10.1073/pnas.0702638104; Elliott DJS, 2004, EMBO J, V23, P4717, DOI 10.1038/sj.emboj.7600484; Gandhi CS, 2002, J GEN PHYSIOL, V120, P455, DOI 10.1085/jgp.20028678; Gibor G, 2004, J GEN PHYSIOL, V124, P83, DOI 10.1085/jgp.200409068; Gibor G, 2007, BIOPHYS J, V93, P4159, DOI 10.1529/biophysj.107.107987; Grabe M, 2007, NATURE, V445, P550, DOI 10.1038/nature05494; Hille B., 2001, IONIC CHANNELS EXCIT, P814; Ledwell JL, 1999, J GEN PHYSIOL, V113, P389, DOI 10.1085/jgp.113.3.389; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Long SB, 2007, NATURE, V450, P376, DOI 10.1038/nature06265; Mannuzzu LM, 2000, J GEN PHYSIOL, V115, P257, DOI 10.1085/jgp.115.3.257; Nerbonne JM, 2005, PHYSIOL REV, V85, P1205, DOI 10.1152/physrev.00002.2005; Nguyen TP, 2002, J GEN PHYSIOL, V120, P419, DOI 10.1085/jgp.20028636; Pathak M, 2005, J GEN PHYSIOL, V125, P57, DOI 10.1085/jgp.200409197; Phillips LR, 2005, NATURE, V436, P857, DOI 10.1038/nature03873; Ruta V, 2005, CELL, V123, P463, DOI 10.1016/j.cell.2005.08.041; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; Starace DM, 2004, NATURE, V427, P548, DOI 10.1038/nature02270; Tombola F, 2005, NEURON, V45, P379, DOI 10.1016/j.neuron.2004.12.047; Tombola F, 2007, NATURE, V445, P546, DOI 10.1038/nature05396; Tombola F, 2006, ANNU REV CELL DEV BI, V22, P23, DOI 10.1146/annurev.cellbio.21.020404.145837; Yang NB, 1997, BIOPHYS J, V73, P2260, DOI 10.1016/S0006-3495(97)78258-4; Yarov-Yarovoy V, 2006, P NATL ACAD SCI USA, V103, P7292, DOI 10.1073/pnas.0602350103	27	20	21	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1935	10.1371/journal.pone.0001935	http://dx.doi.org/10.1371/journal.pone.0001935			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398461	Green Submitted, gold, Green Published			2022-12-25	WOS:000260795500012
J	Scott-Algara, D; Arnold, V; Didier, C; Kattan, T; Pirozzi, G; Barre-Sinoussi, F; Pancino, G				Scott-Algara, Daniel; Arnold, Vincent; Didier, Celine; Kattan, Tarek; Pirozzi, Gianluca; Barre-Sinoussi, Francoise; Pancino, Gianfranco			The CD85j(+) NK Cell Subset Potently Controls HIV-1 Replication in Autologous Dendritic Cells	PLOS ONE			English	Article								Natural killer (NK) cells and dendritic cells (DC) are thought to play critical roles in the first phases of HIV infection. In this study, we examined changes in the NK cell repertoire and functions occurring in response to early interaction with HIV-infected DC, using an autologous in vitro NK/DC coculture system. We show that NK cell interaction with HIV-1-infected autologous monocyte-derived DC (MDDC) modulates NK receptor expression. In particular, expression of the CD85j receptor on NK cells was strongly down-regulated upon coculture with HIV-1-infected MDDC. We demonstrate that CD85j(+) NK cells exert potent control of HIV-1 replication in single-round and productively HIV-1-infected MDDC, whereas CD85j(-) NK cells induce a modest and transient decrease of HIV-1 replication. HIV-1 suppression in MDCC by CD85j(+) NK cells required cell-to-cell contact and did not appear mediated by cytotoxicity or by soluble factors. HIV-1 inhibition was abolished when NK-MDDC interaction through the CD85j receptor was blocked with a recombinant CD85j molecule, whereas inhibition was only slightly counteracted by blocking HLA class I molecules, which are known CD85j ligands. After masking HLA class I molecules with specific antibodies, a fraction of HIV-1 infected MDDC was still strongly stained by a recombinant CD85j protein. These results suggest that CD85j(+) NK cell inhibition of HIV-1 replication in MDDC is mainly mediated by CD85j interaction with an unknown ligand (distinct from HLA class I molecules) preferentially expressed on HIV-1-infected MDDC.	[Scott-Algara, Daniel; Arnold, Vincent; Didier, Celine; Kattan, Tarek; Pirozzi, Gianluca; Barre-Sinoussi, Francoise; Pancino, Gianfranco] Inst Pasteur, Unite Regulat Infect Retrovirales, Paris, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Scott-Algara, D (corresponding author), Inst Pasteur, Unite Regulat Infect Retrovirales, Paris, France.	scott@pasteur.fr	Pancino, Gianfranco/A-5519-2010; Scott, Daniel/AFK-5428-2022; Barre-Sinoussi, Françoise/G-8355-2011	Scott-Algara, Daniel/0000-0003-1851-503X	Sidaction; National Agency for AIDS Research (ANRS), France	Sidaction; National Agency for AIDS Research (ANRS), France(ANRS)	This study was supported by grants from Sidaction and the National Agency for AIDS Research (ANRS), France.	Alter G, 2005, BLOOD, V106, P3366, DOI 10.1182/blood-2005-03-1100; Alter G, 2007, J EXP MED, V204, P3027, DOI 10.1084/jem.20070695; Alter G, 2007, J INFECT DIS, V195, P1452, DOI 10.1086/513878; Alter G, 2006, CURR MOL MED, V6, P621, DOI 10.2174/156652406778195035; Ancuta P, 2006, VIROLOGY, V344, P267, DOI 10.1016/j.virol.2005.10.027; Bottino C, 2006, CURR TOP MICROBIOL, V298, P175; Boyton RJ, 2007, CLIN EXP IMMUNOL, V149, P1, DOI 10.1111/j.1365-2249.2007.03424.x; Bryceson YT, 2006, IMMUNOL REV, V214, P73, DOI 10.1111/j.1600-065X.2006.00457.x; Donaghy H, 2006, J LEUKOCYTE BIOL, V80, P1001, DOI 10.1189/jlb.0306158; Fauci AS, 2005, NAT REV IMMUNOL, V5, P835, DOI 10.1038/nri1711; Fortis C, 2002, J BIOL REG HOMEOS AG, V16, P30; Kottilil S, 2004, J INFECT DIS, V189, P1193, DOI 10.1086/382090; Kottilil S, 2003, J INFECT DIS, V187, P1038, DOI 10.1086/368222; Lopez-Botet M, 2004, TISSUE ANTIGENS, V63, P195, DOI 10.1111/j.1399-0039.2004.00210.x; Marcenaro E, 2006, TRANSPL IMMUNOL, V17, P16, DOI 10.1016/j.trim.2006.09.019; Martin MP, 2007, NAT GENET, V39, P733, DOI 10.1038/ng2035; Mavilio D, 2005, P NATL ACAD SCI USA, V102, P2886, DOI 10.1073/pnas.0409872102; Mavilio D, 2003, P NATL ACAD SCI USA, V100, P15011, DOI 10.1073/pnas.2336091100; Mavilio D, 2006, J EXP MED, V203, P2339, DOI 10.1084/jem.20060894; Moretta A, 2005, TRENDS IMMUNOL, V26, P668, DOI 10.1016/j.it.2005.09.008; Moretta L, 2006, IMMUNOL REV, V214, P219, DOI 10.1111/j.1600-065X.2006.00450.x; O'Connor GM, 2007, CLIN IMMUNOL, V124, P277, DOI 10.1016/j.clim.2007.05.016; Oliva A, 1998, J CLIN INVEST, V102, P223, DOI 10.1172/JCI2323; Perez-Bercoff D, 2003, J VIROL, V77, P4081, DOI 10.1128/JVI.77.7.4081-4094.2003; Ravet S, 2007, BLOOD, V109, P4296, DOI 10.1182/blood-2006-08-040238; Scott-Algara D, 2003, J IMMUNOL, V171, P5663, DOI 10.4049/jimmunol.171.11.5663; SCOTTALGARA D, 1992, CLIN EXP IMMUNOL, V90, P181; Tasca S, 2003, AIDS, V17, P2291, DOI 10.1097/00002030-200311070-00003; Vales-Gomez M, 2005, J VIROL, V79, P2251, DOI 10.1128/JVI.79.4.2251-2260.2005	29	33	33	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1975	10.1371/journal.pone.0001975	http://dx.doi.org/10.1371/journal.pone.0001975			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398485	Green Published, gold, Green Submitted			2022-12-25	WOS:000260795500038
J	Chehab, EW; Kaspi, R; Savchenko, T; Rowe, H; Negre-Zakharov, F; Kliebenstein, D; Dehesh, K				Chehab, E. Wassim; Kaspi, Roy; Savchenko, Tatyana; Rowe, Heather; Negre-Zakharov, Florence; Kliebenstein, Dan; Dehesh, Katayoon			Distinct Roles of Jasmonates and Aldehydes in Plant-Defense Responses	PLOS ONE			English	Article							HYDROPEROXIDE LYASE; BOTRYTIS-CINEREA; ARABIDOPSIS-THALIANA; SALICYLIC-ACID; BIOSYNTHESIS; RESISTANCE; VOLATILES; METABOLITES; HERBIVORES; CAMALEXIN	Background: Many inducible plant-defense responses are activated by jasmonates (JAs), C-6-aldehydes, and their corresponding derivatives, produced by the two main competing branches of the oxylipin pathway, the allene oxide synthase (AOS) and hydroperoxide lyase (HPL) branches, respectively. In addition to competition for substrates, these branch-pathway-derived metabolites have substantial overlap in regulation of gene expression. Past experiments to define the role of C-6-aldehydes in plant defense responses were biased towards the exogenous application of the synthetic metabolites or the use of genetic manipulation of HPL expression levels in plant genotypes with intact ability to produce the competing AOS-derived metabolites. To uncouple the roles of the C-6-aldehydes and jasmonates in mediating direct and indirect plant-defense responses, we generated Arabidopsis genotypes lacking either one or both of these metabolites. These genotypes were subsequently challenged with a phloem-feeding insect (aphids: Myzus persicae), an insect herbivore (leafminers: Liriomyza trifolii), and two different necrotrophic fungal pathogens (Botrytis cinerea and Alternaria brassicicola). We also characterized the volatiles emitted by these plants upon aphid infestation or mechanical wounding and identified hexenyl acetate as the predominant compound in these volatile blends. Subsequently, we examined the signaling role of this compound in attracting the parasitoid wasp (Aphidius colemani), a natural enemy of aphids. Principal Findings: This study conclusively establishes that jasmonates and C-6-aldehydes play distinct roles in plant defense responses. The jasmonates are indispensable metabolites in mediating the activation of direct plant-defense responses, whereas the C-6-aldehyes are not. On the other hand, hexenyl acetate, an acetylated C-6-aldehyde, is the predominant wound-inducible volatile signal that mediates indirect defense responses by directing tritrophic (plant-herbivore-natural enemy) interactions. Significance: The data suggest that jasmonates and hexenyl acetate play distinct roles in mediating direct and indirect plant-defense responses. The potential advantage of this "division of labor'' is to ensure the most effective defense strategy that minimizes incurred damages at a reduced metabolic cost.	[Chehab, E. Wassim; Kaspi, Roy; Savchenko, Tatyana; Dehesh, Katayoon] Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA; [Rowe, Heather; Negre-Zakharov, Florence; Kliebenstein, Dan] Univ Calif Davis, Dept Plant Sci, Davis, CA USA	University of California System; University of California Davis; University of California System; University of California Davis	Chehab, EW (corresponding author), Univ Calif Davis, Plant Biol Sect, Davis, CA 95616 USA.	kdehesh@ucdavis.edu	Savchenko, Tatyana/E-7091-2014; Rowe, Heather C/C-9284-2011	Savchenko, Tatyana/0000-0003-0126-4932; Kliebenstein, Daniel/0000-0001-5759-3175; Zakharov, Florence/0000-0003-3327-6145	NSF [0543904];  [0606838]	NSF(National Science Foundation (NSF)); 	This work was supported by NSF grants 0543904 and 0606838 awarded to KD	Abramoff MD, 2004, BIOPHOTONICS INT, V11, P36, DOI DOI 10.1117/1.3589100; Bate NJ, 1998, PLANT J, V16, P561, DOI 10.1046/j.1365-313x.1998.00324.x; Blee E, 2002, TRENDS PLANT SCI, V7, P315, DOI 10.1016/S1360-1385(02)02290-2; Bruce TJA, 2005, TRENDS PLANT SCI, V10, P269, DOI 10.1016/j.tplants.2005.04.003; Chehab EW, 2006, PLANT PHYSIOL, V141, P121, DOI 10.1104/pp.106.078592; Chen H, 2005, P NATL ACAD SCI USA, V102, P19237, DOI 10.1073/pnas.0509026102; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Creelman RA, 1997, ANNU REV PLANT PHYS, V48, P355, DOI 10.1146/annurev.arplant.48.1.355; Denby KJ, 2004, PLANT J, V38, P473, DOI 10.1111/j.0960-7412.2004.02059.x; Devoto A, 2003, ANN BOT-LONDON, V92, P329, DOI 10.1093/aob/mcg151; Duan H, 2005, PLANT PHYSIOL, V139, P1529, DOI 10.1104/pp.105.067249; Engelberth J, 2004, P NATL ACAD SCI USA, V101, P1781, DOI 10.1073/pnas.0308037100; Engelberth J, 2003, ANAL BIOCHEM, V312, P242, DOI 10.1016/S0003-2697(02)00466-9; Farag MA, 2005, PLANTA, V220, P900, DOI 10.1007/s00425-004-1404-5; Ferrari S, 2003, PLANT J, V35, P193, DOI 10.1046/j.1365-313X.2003.01794.x; Feussner I, 2002, ANNU REV PLANT BIOL, V53, P275, DOI 10.1146/annurev.arplant.53.100301.135248; Halitschke R, 2004, PLANT J, V40, P35, DOI 10.1111/j.1365-313X.2004.02185.x; Halitschke R, 2003, PLANT J, V36, P794, DOI 10.1046/j.1365-313X.2003.01921.x; Heil M, 2002, TRENDS PLANT SCI, V7, P61, DOI 10.1016/S1360-1385(01)02186-0; HERMAN PL, 1989, PLANT CELL, V1, P1051, DOI 10.1105/tpc.1.11.1051; HILDEBRAND DF, 1993, J CHEM ECOL, V19, P1875, DOI 10.1007/BF00983793; Kaspi R, 2006, J ECON ENTOMOL, V99, P1168, DOI 10.1603/0022-0493-99.4.1168; Kessler A, 2001, SCIENCE, V291, P2141, DOI 10.1126/science.291.5511.2141; Kessler A, 2004, SCIENCE, V305, P665, DOI 10.1126/science.1096931; Kishimoto K, 2005, PLANT CELL PHYSIOL, V46, P1093, DOI 10.1093/pcp/pci122; Kliebenstein DJ, 2005, PLANT J, V44, P25, DOI 10.1111/j.1365-313X.2005.02508.x; Li L, 2004, PLANT CELL, V16, P126, DOI 10.1105/tpc.017954; Matsui K, 2006, CURR OPIN PLANT BIOL, V9, P274, DOI 10.1016/j.pbi.2006.03.002; McCarthy DA, 1998, ABSTR PAP AM CHEM S, V216, pU900; Paiva NL, 2000, J PLANT GROWTH REGUL, V19, P131; Pare PW, 1999, PLANT PHYSIOL, V121, P325, DOI 10.1104/pp.121.2.325; Pareja M, 2007, J CHEM ECOL, V33, P695, DOI 10.1007/s10886-007-9260-y; Park JH, 2002, PLANT J, V31, P1, DOI 10.1046/j.1365-313X.2002.01328.x; Rowe HC, 2007, MOL PLANT MICROBE IN, V20, P1126, DOI 10.1094/MPMI-20-9-1126; Royo J, 1999, P NATL ACAD SCI USA, V96, P1146, DOI 10.1073/pnas.96.3.1146; Schmelz EA, 2003, PLANT PHYSIOL, V133, P295, DOI 10.1104/pp.103.024174; SCHOONHOVEN LM, 1998, PLANT GROWTH REGUL, V28, P217; Shiojiri K, 2006, P NATL ACAD SCI USA, V103, P16672, DOI 10.1073/pnas.0607780103; ULLAND S, 2007, CHEM SENSES; van Poecke RMP, 2004, PLANT BIOLOGY, V6, P387, DOI 10.1055/s-2004-820887; Vancanneyt G, 2001, P NATL ACAD SCI USA, V98, P8139, DOI 10.1073/pnas.141079498; Walley JW, 2007, PLOS GENET, V3, P1800, DOI 10.1371/journal.pgen.0030172; Walling LL, 2000, J PLANT GROWTH REGUL, V19, P195; Weber H, 1999, PLANT CELL, V11, P485, DOI 10.1105/tpc.11.3.485; Wei JN, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000852; Zar JH, 1999, BIOSTATISTICAL ANAL; Zhou N, 1999, PLANT CELL, V11, P2419, DOI 10.1105/tpc.11.12.2419	47	102	115	2	54	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1904	10.1371/journal.pone.0001904	http://dx.doi.org/10.1371/journal.pone.0001904			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382679	Green Published, gold, Green Submitted			2022-12-25	WOS:000260795400031
J	Sukhai, MA; Thomas, M; Xuan, Y; Chan, LSA; Hamadanizadeh, SA; Zhang, T; Bharadwaj, RR; Schuh, AC; Wells, RA; Kamel-Reid, S				Sukhai, M. A.; Thomas, M.; Xuan, Y.; Chan, L. S. A.; Hamadanizadeh, S. A.; Zhang, T.; Bharadwaj, R. R.; Schuh, A. C.; Wells, R. A.; Kamel-Reid, S.			Evidence of functional interaction between NuMA-RAR alpha and RXR alpha in an in vivo model of acute promyelocytic leukemia	ONCOGENE			English	Article							ACID RECEPTOR-ALPHA; RETINOIC ACID; FUSION PROTEINS; MYELOID-LEUKEMIA; DNA-BINDING; GENE; VARIANT; PLZF; NPM; DIFFERENTIATION	Acute promyelocytic leukemia (APL) is characterized by reciprocal balanced chromosomal translocations involving retinoic acid receptor-alpha (RAR alpha). RAR alpha heterodimerizes with the retinoid X receptor-alpha (RXR alpha) and transcriptionally regulates myeloid differentiation in response to ATRA (all-trans retinoic acid). Several lines of evidence suggest that APL fusion proteins interact with RXR alpha. To elucidate the role of RXR alpha in APL, we conditionally knocked out RXR alpha in the hCG-NuMA-RAR alpha APL mouse model. Phenotype analysis of NuMA-RAR alpha(+) mice demonstrated that these mice developed a myeloproliferative disease-like myeloid leukemia within 4 months of birth. While hemizygous and homozygous RXR alpha conditional knockout mice were phenotypically normal as late as 12 months of age, we observed that the leukemic phenotype in NuMA-RAR alpha(+) mice was dependent on the presence of functional RXR alpha. Bone marrow promyelocyte counts were significantly reduced in NuMA-RAR alpha(+) mice with RXRa knocked down. Significant differences in the accumulations of Gr-1(+) and Mac-1(+) cells were also seen. We further observed that genes previously identified to be cooperating events in APL were also regulated in an RXR alpha-dependent manner. We therefore propose that the APL fusion protein NuMA-RAR alpha cooperates with RXR alpha in the development of leukemia in hCG-NuMA-RAR alpha transgenic mice and suggest a novel role for RXR alpha in the pathogenesis of APL.	[Sukhai, M. A.; Thomas, M.; Xuan, Y.; Hamadanizadeh, S. A.; Zhang, T.; Bharadwaj, R. R.; Schuh, A. C.; Kamel-Reid, S.] Univ Hlth Network, Ontario Canc Inst, Princess Margaret Hosp, Div Appl Mol Oncol, Toronto, ON M5G 2M9, Canada; [Sukhai, M. A.; Thomas, M.; Chan, L. S. A.; Schuh, A. C.; Wells, R. A.; Kamel-Reid, S.] Univ Toronto, Dept Med Biophys, Toronto, ON, Canada; [Chan, L. S. A.; Wells, R. A.] Sunnybrook Hlth Sci Ctr, Sunnybrook Res Inst, Crashley Myelodysplast Syndrome Res Lab, Toronto, ON M4N 3M5, Canada; [Hamadanizadeh, S. A.; Kamel-Reid, S.] Univ Toronto, Inst Med Sci, Toronto, ON M5S 1A1, Canada; [Kamel-Reid, S.] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada	University of Toronto; University Toronto Affiliates; University Health Network Toronto; Princess Margaret Cancer Centre; University of Toronto; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto	Kamel-Reid, S (corresponding author), Univ Hlth Network, Ontario Canc Inst, Princess Margaret Hosp, Div Appl Mol Oncol, Room 9-622,610 Univ Ave, Toronto, ON M5G 2M9, Canada.	Suzanne.Kamel-Reid@uhn.on.ca	Chan, Lap Shu/AAF-8737-2021	Chan, Lap Shu/0000-0003-1409-8638; Mathew, Mariam/0000-0003-2203-6939; Kamel-Reid, Suzanne/0000-0002-4386-0292				Arnould C, 1999, HUM MOL GENET, V8, P1741, DOI 10.1093/hmg/8.9.1741; BENNETT JM, 1976, BRIT J HAEMATOL, V33, P451, DOI 10.1111/j.1365-2141.1976.tb03563.x; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CASTAIGNE S, 1990, BLOOD, V76, P1704; Catalano A, 2007, BLOOD, V110, P4073, DOI 10.1182/blood-2007-06-095554; Chen J, 1998, DEVELOPMENT, V125, P1943; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; Dong S, 2004, MOL CELL BIOL, V24, P4465, DOI 10.1128/MCB.24.10.4465-4475.2004; Hummel JL, 1999, ONCOGENE, V18, P633, DOI 10.1038/sj.onc.1202357; Hummel JL, 2002, CELL GROWTH DIFFER, V13, P173; Imai T, 2001, P NATL ACAD SCI USA, V98, P4581, DOI 10.1073/pnas.071056098; Kamashev D, 2004, J EXP MED, V199, P1163, DOI 10.1084/jem.20032226; Kamel-Reid S, 2003, ONCOGENE, V22, P6424, DOI 10.1038/sj.onc.1206696; KASTNER P, 1994, CELL, V78, P987, DOI 10.1016/0092-8674(94)90274-7; Kogan SC, 2002, BLOOD, V100, P238, DOI 10.1182/blood.V100.1.238; Kogan SC, 2001, J EXP MED, V193, P531, DOI 10.1084/jem.193.4.531; Li M, 2001, DEVELOPMENT, V128, P675; Li M, 2000, NATURE, V407, P633, DOI 10.1038/35036595; Licht JD, 1996, ONCOGENE, V12, P323; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Loonstra A, 2001, P NATL ACAD SCI USA, V98, P9209, DOI 10.1073/pnas.161269798; Minucci S, 2000, MOL CELL, V5, P811, DOI 10.1016/S1097-2765(00)80321-4; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; Redner RL, 1996, BLOOD, V87, P882, DOI 10.1182/blood.V87.3.882.bloodjournal873882; Reis PP, 2002, ONCOGENE, V21, P6480, DOI 10.1038/sj.onc.1205864; RICOTE M, 2006, J LUEKOC BIOL, V4, P850; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Silva MLM, 2005, ONCOL REP, V14, P663; So CW, 2000, LEUKEMIA, V14, P77, DOI 10.1038/sj.leu.2401643; Stephensen CB, 2007, IMMUNOLOGY, V121, P484, DOI 10.1111/j.1365-2567.2007.02595.x; Sukhai MA, 2004, ONCOGENE, V23, P665, DOI 10.1038/sj.onc.1207073; Taschner S, 2007, BLOOD, V109, P971, DOI 10.1182/blood-2006-04-020552.7; Truong BTH, 2003, BLOOD, V101, P1141, DOI 10.1182/blood-2002-05-1374; Wells RA, 1997, NAT GENET, V17, P109, DOI 10.1038/ng0997-109; Zeisig BB, 2007, CANCER CELL, V12, P36, DOI 10.1016/j.ccr.2007.06.006; Zhu J, 2007, CANCER CELL, V12, P23, DOI 10.1016/j.ccr.2007.06.004	37	11	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4666	4677		10.1038/onc.2008.106	http://dx.doi.org/10.1038/onc.2008.106			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408763				2022-12-25	WOS:000258236300005
J	Fumoto, K; Lee, PC; Saya, H; Kikuchi, A				Fumoto, K.; Lee, P-C; Saya, H.; Kikuchi, A.			AIP regulates stability of Aurora-A at early mitotic phase coordinately with GSK-3 beta	ONCOGENE			English	Article						AIP; GSK-3 beta; Aurora; cell cycle; mitosis	GLYCOGEN-SYNTHASE KINASE-3; ADENOMATOUS POLYPOSIS-COLI; BETA-CATENIN; BICAUDAL-D; NEGATIVE REGULATOR; SIGNALING PATHWAY; PROTEIN-KINASE; CELL-DIVISION; SPINDLE; DYNEIN	Glycogen synthase kinase-3 (GSK-3 beta) regulates microtubule dynamics and cellular polarity through phosphorylating various microtubule associating proteins and plus-end tracking proteins. Although it was also reported that GSK-3 beta is inactivated by protein kinase B at the spindle poles, functions and targets of GSK-3 beta in the mitotic phase are unknown. Here, we identified Aurora-A-interacting protein (AIP), a negative regulator of Aurora-A, as a binding partner of GSK-3 beta. AIP was colocalized with Aurora-A and GSK-3 beta to the spindle poles in metaphase, and its depletion in cells stabilized and activated Aurora-A in early mitotic phase and caused mitotic cell arrest. Treatment of the cells with a GSK-3 beta inhibitor reduced the protein level of Aurora-A and this reduction was suppressed by AIP knockdown. AIP was phosphorylated by GSK-3 beta, and an AIP mutant in which the GSK-3 beta phosphorylation site was mutated could bind and downregulate Aurora-A more efficiently. These results suggest that GSK-3 beta modulates the early mitotic Aurora-A level through binding and phosphorylating AIP.	[Fumoto, K.; Lee, P-C; Kikuchi, A.] Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Minami Ku, Hiroshima 7348551, Japan; [Saya, H.] Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat, Tokyo, Japan	Hiroshima University; Keio University	Kikuchi, A (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Biochem, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	akikuchi@hiroshima-u.ac.jp	Saya, Hideyuki/J-4325-2013; Lee, Ping Chin/AGV-4612-2022	Lee, Ping Chin/0000-0002-4280-0829				Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; Doble BW, 2003, J CELL SCI, V116, P1175, DOI 10.1242/jcs.00384; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Fumoto K, 2006, EMBO J, V25, P5670, DOI 10.1038/sj.emboj.7601459; Gruss OJ, 2002, NAT CELL BIOL, V4, P871, DOI 10.1038/ncb870; Hino S, 2003, J BIOL CHEM, V278, P14066, DOI 10.1074/jbc.M213265200; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Hoogenraad CC, 2001, EMBO J, V20, P4041, DOI 10.1093/emboj/20.15.4041; Hoogenraad CC, 2003, EMBO J, V22, P6004, DOI 10.1093/emboj/cdg592; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Kiat LS, 2002, J BIOL CHEM, V277, P45558, DOI 10.1074/jbc.M206820200; Kimura M, 1997, J BIOL CHEM, V272, P13766, DOI 10.1074/jbc.272.21.13766; Kobayashi T, 2006, MOL CELL BIOL, V26, P898, DOI 10.1128/MCB.26.3.898-911.2006; Kufer TA, 2002, J CELL BIOL, V158, P617, DOI 10.1083/jcb.200204155; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Lim SK, 2007, BIOCHEM J, V403, P119, DOI 10.1042/BJ20061272; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Matanis T, 2002, NAT CELL BIOL, V4, P986, DOI 10.1038/ncb891; Meraldi P, 2004, CURR OPIN GENET DEV, V14, P29, DOI 10.1016/j.gde.2003.11.006; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Sarkissian M, 2004, GENE DEV, V18, P48, DOI 10.1101/gad.1136004; Stenoien DL, 2003, CELL MOTIL CYTOSKEL, V55, P134, DOI 10.1002/cm.10120; SUTER B, 1989, GENE DEV, V3, P1957, DOI 10.1101/gad.3.12a.1957; Tanji C, 2002, J BIOL CHEM, V277, P36955, DOI 10.1074/jbc.M206210200; Tighe A, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-34; Tsai MY, 2003, NAT CELL BIOL, V5, P242, DOI 10.1038/ncb936; Wakefield JG, 2003, J CELL SCI, V116, P637, DOI 10.1242/jcs.00273; Yamamoto H, 2003, EMBO J, V22, P2047, DOI 10.1093/emboj/cdg204; Yamamoto H, 1998, MOL CELL BIOL, V18, P2867, DOI 10.1128/MCB.18.5.2867; Zachariae W, 1999, GENE DEV, V13, P2039, DOI 10.1101/gad.13.16.2039; Zumbrunn J, 2001, CURR BIOL, V11, P44, DOI 10.1016/S0960-9822(01)00002-1	32	16	16	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2008	27	32					4478	4487		10.1038/onc.2008.92	http://dx.doi.org/10.1038/onc.2008.92			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18391981				2022-12-25	WOS:000257881700010
J	Zhang, SYL; Kozak, JA; Jiang, WH; Yeromin, AV; Chen, J; Yu, Y; Penna, A; Shen, W; Chi, V; Cahalan, MD				Zhang, Shenyuan L.; Kozak, J. Ashot; Jiang, Weihua; Yeromin, Andriy V.; Chen, Jing; Yu, Ying; Penna, Aubin; Shen, Wei; Chi, Victor; Cahalan, Michael D.			Store-dependent and -independent modes regulating Ca2+ release-activated Ca2+ channel activity of human Orai1 and Orai3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OPERATED CALCIUM-CHANNEL; CURRENT I-CRAC; PLASMA-MEMBRANE; 2-AMINOETHOXYDIPHENYL BORATE; T-LYMPHOCYTES; CA-2+ CURRENT; MIC CHANNELS; MAST-CELLS; STIM1; DEPLETION	We evaluated currents induced by expression of human homologs of Orai together with STIM1 in human embryonic kidney cells. When co-expressed with STIM1, Orai1 induced a large inwardly rectifying Ca2+-selective current with Ca2+-induced slow inactivation. A point mutation of Orai1 (E106D) altered the ion selectivity of the induced Ca2+ release-activated Ca2+ (CRAC)-like current while retaining an inwardly rectifying I-V characteristic. Expression of the C-terminal portion of STIM1 with Orai1 was sufficient to generate CRAC current without store depletion. 2-APB activated a large relatively nonselective current in STIM1 and Orai3 co-expressing cells. 2-APB also induced Ca2+ influx in Orai3-expressing cells without store depletion or co-expression of STIM1. The Orai3 current induced by 2-APB exhibited outward rectification and an inward component representing a mixed calcium and monovalent current. A pore mutant of Orai3 inhibited store-operated Ca2+ entry and did not carry significant current in response to either store depletion or addition of 2-APB. Analysis of a series of Orai1-3 chimeras revealed the structural determinant responsible for 2-APB-induced current within the sequence from the second to third transmembrane segment of Orai3. The Orai3 current induced by 2-APB may reflect a store-independent mode of CRAC channel activation that opens a relatively nonselective cation pore.	[Zhang, Shenyuan L.; Kozak, J. Ashot; Jiang, Weihua; Yeromin, Andriy V.; Chen, Jing; Yu, Ying; Penna, Aubin; Shen, Wei; Chi, Victor; Cahalan, Michael D.] Univ Calif Irvine, Dept Physiol & Biophys, Irvine, CA 92697 USA	University of California System; University of California Irvine	Cahalan, MD (corresponding author), Univ Calif Irvine, Dept Physiol & Biophys, 285 Irvine Hall, Irvine, CA 92697 USA.	mcahalan@uci.edu	penna, aubin/AAD-2550-2019; PENNA, aubin/E-2208-2018	penna, aubin/0000-0002-1070-5990; PENNA, aubin/0000-0002-1070-5990	NATIONAL CANCER INSTITUTE [P30CA062203] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA062203] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bakowski D, 2002, PFLUG ARCH EUR J PHY, V443, P892, DOI 10.1007/s00424-001-0775-8; Cahalan MD, 2007, CELL CALCIUM, V42, P133, DOI 10.1016/j.ceca.2007.03.002; Chung MK, 2004, J NEUROSCI, V24, P5177, DOI 10.1523/JNEUROSCI.0934-04.2004; DeHaven WI, 2007, J BIOL CHEM, V282, P17548, DOI 10.1074/jbc.M611374200; Fanger CM, 2001, J BIOL CHEM, V276, P12249, DOI 10.1074/jbc.M011342200; Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702; Feske S, 2007, NAT REV IMMUNOL, V7, P690, DOI 10.1038/nri2152; Gwack Y, 2007, J BIOL CHEM, V282, P16232, DOI 10.1074/jbc.M609630200; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; Hu HZ, 2004, J BIOL CHEM, V279, P35741, DOI 10.1074/jbc.M404164200; Huang GN, 2006, NAT CELL BIOL, V8, P1003, DOI 10.1038/ncb1454; Juvin V, 2007, MOL PHARMACOL, V72, P1258, DOI 10.1124/mol.107.037044; Kozak JA, 2002, J GEN PHYSIOL, V120, P221, DOI 10.1085/jgp.20028601; LeppleWienhues A, 1996, BIOPHYS J, V71, P787, DOI 10.1016/S0006-3495(96)79278-0; Lewis RS, 2007, NATURE, V446, P284, DOI 10.1038/nature05637; LEWIS RS, 1989, CELL REGUL, V1, P99, DOI 10.1091/mbc.1.1.99; Li ZZ, 2007, J BIOL CHEM, V282, P29448, DOI 10.1074/jbc.M703573200; Liou J, 2005, CURR BIOL, V15, P1235, DOI 10.1016/j.cub.2005.05.055; Liou J, 2007, P NATL ACAD SCI USA, V104, P9301, DOI 10.1073/pnas.0702866104; Lioudyno MI, 2008, P NATL ACAD SCI USA, V105, P2011, DOI 10.1073/pnas.0706122105; Lis A, 2007, CURR BIOL, V17, P794, DOI 10.1016/j.cub.2007.03.065; Luik RM, 2006, J CELL BIOL, V174, P815, DOI 10.1083/jcb.200604015; Maruyama T, 1997, J BIOCHEM-TOKYO, V122, P498; Mercer JC, 2006, J BIOL CHEM, V281, P24979, DOI 10.1074/jbc.M604589200; Muik M, 2008, J BIOL CHEM, V283, P8014, DOI 10.1074/jbc.M708898200; Neeper MP, 2007, J BIOL CHEM, V282, P15894, DOI 10.1074/jbc.M608287200; Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003; Peinelt C, 2006, NAT CELL BIOL, V8, P771, DOI 10.1038/ncb1435; Prakriya M, 2002, J GEN PHYSIOL, V119, P487, DOI 10.1085/jgp.20028551; Prakriya M, 2001, J PHYSIOL-LONDON, V536, P3, DOI 10.1111/j.1469-7793.2001.t01-1-00003.x; Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122; Roos J, 2005, J CELL BIOL, V169, P435, DOI 10.1083/jcb.200502019; Soboloff J, 2006, J BIOL CHEM, V281, P20661, DOI 10.1074/jbc.C600126200; Vig M, 2006, SCIENCE, V312, P1220, DOI 10.1126/science.1127883; Vig M, 2006, CURR BIOL, V16, P2073, DOI 10.1016/j.cub.2006.08.085; Wu MM, 2006, J CELL BIOL, V174, P803, DOI 10.1083/jcb.200604014; Yamashita M, 2007, J GEN PHYSIOL, V130, P525, DOI 10.1085/jgp.200709872; Yeromin AV, 2006, NATURE, V443, P226, DOI 10.1038/nature05108; Yeromin AV, 2004, J GEN PHYSIOL, V123, P167, DOI 10.1085/jgp.200308982; Zhang SL, 2006, P NATL ACAD SCI USA, V103, P9357, DOI 10.1073/pnas.0603161103; Zhang SYL, 2005, NATURE, V437, P902, DOI 10.1038/nature04147; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; Zweifach A, 1996, J GEN PHYSIOL, V107, P597, DOI 10.1085/jgp.107.5.597; ZWEIFACH A, 1993, P NATL ACAD SCI USA, V90, P6295, DOI 10.1073/pnas.90.13.6295	45	152	156	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17662	17671		10.1074/jbc.M801536200	http://dx.doi.org/10.1074/jbc.M801536200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18420579	hybrid, Green Published			2022-12-25	WOS:000256720600072
J	Hartupee, J; Li, XX; Hamilton, T				Hartupee, Justin; Li, Xiaoxia; Hamilton, Thomas			Interleukin 1 alpha-induced NF kappa B activation and chemokine mRNA stabilization diverge at IRAK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AU-RICH ELEMENTS; POSTTRANSCRIPTIONAL REGULATION; GENE-EXPRESSION; STABILITY; KINASE; TRAF6; INTERLEUKIN-1; ALPHA; KC; TRISTETRAPROLIN	Interleukin 1 alpha(IL-1 alpha) is capable of driving pro-inflammatory gene expression through both the initiation of transcription and by prolonging the half-life of short-lived mRNAs. Although the signaling events linking the IL-1 receptor to the activation of NF kappa B and the initiation of transcription have been well characterized, less is known about the signaling events linking to mRNA stabilization. As a model to study the control of mRNA stability we have used the mouse chemokine KC, expression of which requires both NF kappa B-driven transcription and stabilization of the constitutively unstable mRNA. We have evaluated the role of signaling adaptors known to play a role in IL-1 alpha-driven NF kappa B activation in the generation of mRNA stability. Surprisingly, although TRAF6 is essential for NF kappa B activation, it is not required for IL-1 alpha-induced mRNA stabilization. IRAK1, which is recognized to function upstream of TRAF6, is required for both mRNA stabilization and activation of NF kappa B. Consistent with the previous findings, the TRAF6 interaction sites in IRAK1 are required for NF kappa B activation but do not play a role in mRNA stabilization. These findings indicate that signals from the IL-1 receptor segregate into at least two separate pathways at the level of IRAK1; one couples through TRAF6 to NF kappa B activation while a second utilizes a TRAF6-independent pathway that is responsible for mRNA stabilization.	[Hartupee, Justin; Li, Xiaoxia; Hamilton, Thomas] Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Hamilton, T (corresponding author), Cleveland Clin Fdn, Dept Immunol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.	hamiltt@ccf.org		Hamilton, Thomas/0000-0002-9817-242X	NATIONAL CANCER INSTITUTE [R01CA039621] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007250] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA039621-26, R01 CA039621, CA39621] Funding Source: Medline; NIGMS NIH HHS [T32 GM007250, T32GM007250] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Armstrong DA, 2004, J LEUKOCYTE BIOL, V75, P641, DOI 10.1189/jlb.0803370; Baud V, 1999, GENE DEV, V13, P1297, DOI 10.1101/gad.13.10.1297; Biswas R, 2003, J IMMUNOL, V170, P6202, DOI 10.4049/jimmunol.170.12.6202; Cao ZD, 1996, NATURE, V383, P443, DOI 10.1038/383443a0; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; Carballo E, 1998, SCIENCE, V281, P1001, DOI 10.1126/science.281.5379.1001; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; Dai YL, 2003, BLOOD, V102, P1178, DOI 10.1182/blood-2002-12-3771; Datta S, 2004, J IMMUNOL, V173, P2755, DOI 10.4049/jimmunol.173.4.2755; Datta S, 2008, J IMMUNOL, V180, P2545, DOI 10.4049/jimmunol.180.4.2545; Dean JLE, 1999, J BIOL CHEM, V274, P264, DOI 10.1074/jbc.274.1.264; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; Fan J, 2005, EUR RESPIR J, V26, P933, DOI 10.1183/09031936.05.00120204; Garneau NL, 2007, NAT REV MOL CELL BIO, V8, P113, DOI 10.1038/nrm2104; Hacker H, 2006, NATURE, V439, P204, DOI 10.1038/nature04369; Hartupee J, 2007, J IMMUNOL, V179, P4135, DOI 10.4049/jimmunol.179.6.4135; Holtmann H, 1999, MOL CELL BIOL, V19, P6742; Kim TW, 2007, J EXP MED, V204, P1025, DOI 10.1084/jem.20061825; Kontoyiannis D, 1999, IMMUNITY, V10, P387, DOI 10.1016/S1074-7613(00)80038-2; Li XX, 1999, MOL CELL BIOL, V19, P4643; Lomaga MA, 1999, GENE DEV, V13, P1015, DOI 10.1101/gad.13.8.1015; Newbury SF, 2006, BIOCHEM SOC T, V34, P30, DOI 10.1042/BST0340030; Novotny M, 2005, J BIOL CHEM, V280, P30166, DOI 10.1074/jbc.M502280200; Oganesyan G, 2006, NATURE, V439, P208, DOI 10.1038/nature04374; Qian YC, 2002, P NATL ACAD SCI USA, V99, P9386, DOI 10.1073/pnas.142294499; Saklatvala J, 2003, BIOCHEM SOC SYMP, V70, P95, DOI 10.1042/bss0700095; Seko Y, 2006, AUTOIMMUN REV, V5, P299, DOI 10.1016/j.autrev.2005.10.013; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; Shim J, 2002, MOL CELLS, V14, P323; STOECKLE MY, 1991, NUCLEIC ACIDS RES, V19, P917, DOI 10.1093/nar/19.4.917; Taylor GA, 1996, IMMUNITY, V4, P445, DOI 10.1016/S1074-7613(00)80411-2; Tebo J, 2003, J BIOL CHEM, V278, P12085, DOI 10.1074/jbc.M212992200; Tebo JM, 2000, J BIOL CHEM, V275, P12987, DOI 10.1074/jbc.275.17.12987; Uematsu S, 2005, J EXP MED, V201, P915, DOI 10.1084/jem.20042372; Wang C, 2001, NATURE, V412, P346, DOI 10.1038/35085597; Winzen R, 1999, EMBO J, V18, P4969, DOI 10.1093/emboj/18.18.4969; Ye H, 2002, NATURE, V418, P443, DOI 10.1038/nature00888	37	33	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15689	15693		10.1074/jbc.M801346200	http://dx.doi.org/10.1074/jbc.M801346200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18411265	Green Published, hybrid			2022-12-25	WOS:000256332500023
J	Kim, YI; Park, JE; Martinez-Hernandez, A; Yi, AK				Kim, Young-In; Park, Jeoung-Eun; Martinez-Hernandez, Antonio; Yi, Ae-Kyung			CpG DNA prevents liver injury and shock-mediated death by modulating expression of interleukin-1 receptor-associated kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; ACTIVATED PROTEIN-KINASES; INDUCED HEPATIC-INJURY; NF-KAPPA-B; UP-REGULATION; IRAK-M; CYCLOOXYGENASE-2 EXPRESSION; MOLECULAR-MECHANISMS; NEGATIVE REGULATOR; LIPOTEICHOIC ACID	Tumor necrosis factor-alpha (TNF-alpha) produced by macrophages in response to CpG DNA induces severe liver injury and subsequent death Of D-galactosamine (D-GalN)-sensitized mice. In the present study we demonstrate that mice pre-exposed to CpG DNA are resistant to liver injury and death induced by CpG DNA/D-GalN. CpG DNA/D-GalN failed to induce TNF-alpha production and hepatocyte apoptosis in the mice pre-exposed to CpG DNA. In addition, macrophages isolated from the CpG DNA-pretreated mice showed suppressed activation of MAPKs and NF-kappa B and production of TNF-alpha in response to CpG DNA, indicating that the CpG DNA-mediated protection of CpG DNA/D-GalN-challenged mice is due to the hyporesponsiveness of macrophages to CpG DNA. CpG DNA pretreatment in vivo inhibited expression of interleukin-1 receptor-associated kinase (IRAK)-1 while inducing IRAK-M expression in macrophages. Suppressed expression of IRAK-1 was responsible for the macrophage hyporesponsiveness to CpG DNA. However, increased expression of IRAK-M was not sufficient to render macrophages hyporesponsive to CpG DNA but was required for induction of the optimal level of macrophage hyporesponsiveness. Taken together, reduced expression of IRAK-1 and increased expression of IRAK-M after CpG DNA pretreatment resulted in the hyporesponsiveness of macrophages that leads to the protection of mice from hepatic injury and death caused by CpG DNA/D-GalN.	[Kim, Young-In; Park, Jeoung-Eun; Yi, Ae-Kyung] Univ Tennessee, Hlth Sci Ctr, Dept Pediat, Memphis, TN 38103 USA; [Kim, Young-In; Park, Jeoung-Eun; Yi, Ae-Kyung] Lebonheur Childrens Hosp & Med Ctr, Childrens Fdn Res Ctr, Memphis, TN 38103 USA; [Martinez-Hernandez, Antonio] Univ Tennessee, Hlth Sci Ctr, Dept Pathol & Lab Med, Memphis, TN 38163 USA; [Yi, Ae-Kyung] Univ Tennessee, Hlth Sci Ctr, Dept Mol Sci, Memphis, TN 38163 USA; [Martinez-Hernandez, Antonio] Vet Affairs Med Ctr, Pathol & Lab Med Serv, Memphis, TN 38104 USA	University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; University of Tennessee System; University of Tennessee Health Science Center; US Department of Veterans Affairs; Veterans Health Administration (VHA); Memphis VA Medical Center	Yi, AK (corresponding author), Univ Tennessee, Hlth Sci Ctr, Dept Pediat, 50 N Dunlap St,Rm 315 WPT, Memphis, TN 38103 USA.	ayi@utmem.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI053137] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 053137] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abe T, 2005, J VIROL, V79, P2847, DOI 10.1128/JVI.79.5.2847-2858.2005; Adib-Conquy M, 2000, AM J RESP CRIT CARE, V162, P1877, DOI 10.1164/ajrccm.162.5.2003058; Akira S, 2004, NAT REV IMMUNOL, V4, P499, DOI 10.1038/nri1391; Aste-Amezaga M, 1998, J IMMUNOL, V160, P5936; Barton GM, 2006, NAT IMMUNOL, V7, P49, DOI 10.1038/ni1280; Boone DL, 2004, NAT IMMUNOL, V5, P1052, DOI 10.1038/ni1110; CAR BD, 1994, J EXP MED, V179, P1437, DOI 10.1084/jem.179.5.1437; Chaudhary A, 2007, IMMUNOL CELL BIOL, V85, P249, DOI 10.1038/sj.icb7100030; Crabtree TD, 2001, INFECT IMMUN, V69, P2123, DOI 10.1128/IAI.69.4.2123-2129.2001; Dalpke AH, 2005, IMMUNOLOGY, V116, P203, DOI 10.1111/j.1365-2567.2005.02211.x; Dalpke AH, 2001, J IMMUNOL, V166, P7082, DOI 10.4049/jimmunol.166.12.7082; DECKER K, 1974, REV PHYSIOL BIOCH P, V71, P77, DOI 10.1007/BFb0027661; DECKER K, 1990, EUR J BIOCHEM, V192, P245, DOI 10.1111/j.1432-1033.1990.tb19222.x; Deng JC, 2006, J CLIN INVEST, V116, P2532, DOI 10.1172/JCI28054; Escoll P, 2003, BIOCHEM BIOPH RES CO, V311, P465, DOI 10.1016/j.bbrc.2003.10.019; Fan HK, 2004, J ENDOTOXIN RES, V10, P71, DOI 10.1179/096805104225003997; GALANOS C, 1979, P NATL ACAD SCI USA, V76, P5939, DOI 10.1073/pnas.76.11.5939; Harada K, 2006, LIVER INT, V26, P935, DOI 10.1111/j.1478-3231.2006.01325.x; Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123; Jacinto R, 2002, J IMMUNOL, V168, P6136, DOI 10.4049/jimmunol.168.12.6136; JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G; Jiang W, 2005, P NATL ACAD SCI USA, V102, P17077, DOI 10.1073/pnas.0504570102; Josephs MD, 2000, AM J PHYSIOL-REG I, V278, pR1196, DOI 10.1152/ajpregu.2000.278.5.R1196; Kawai T, 2007, J BIOCHEM, V141, P137, DOI 10.1093/jb/mvm032; Kinjyo I, 2002, IMMUNITY, V17, P583, DOI 10.1016/S1074-7613(02)00446-6; Kobayashi K, 2002, CELL, V110, P191, DOI 10.1016/S0092-8674(02)00827-9; Lehner MD, 2001, J IMMUNOL, V166, P5161, DOI 10.4049/jimmunol.166.8.5161; Liu DY, 2004, J BIOL CHEM, V279, P48434, DOI 10.1074/jbc.M407190200; Louis H, 1997, GASTROENTEROLOGY, V112, P935, DOI 10.1053/gast.1997.v112.pm9041256; Malagarie-Cazenave S, 2004, J BIOL CHEM, V279, P18648, DOI 10.1074/jbc.M314294200; MATSUO R, 1992, ACTA MED OKAYAMA, V46, P345; Medvedev AE, 2002, J IMMUNOL, V169, P5209, DOI 10.4049/jimmunol.169.9.5209; Medvedev AE, 2007, J BIOL CHEM, V282, P16042, DOI 10.1074/jbc.M606781200; Mizel SB, 2002, J BIOL CHEM, V277, P22414, DOI 10.1074/jbc.M201762200; Morita A, 2003, HEPATOL RES, V27, P143, DOI 10.1016/S1386-6346(03)00206-7; MUNOZ C, 1991, J CLIN INVEST, V88, P1747, DOI 10.1172/JCI115493; Nakagawa R, 2002, IMMUNITY, V17, P677, DOI 10.1016/S1074-7613(02)00449-1; Nakayama K, 2004, J BIOL CHEM, V279, P6629, DOI 10.1074/jbc.M308620200; Nowak M, 2000, AM J PHYSIOL-REG I, V278, pR1202, DOI 10.1152/ajpregu.2000.278.5.R1202; Rao N, 2005, MOL CELL BIOL, V25, P6521, DOI 10.1128/MCB.25.15.6521-6532.2005; Ropert C, 2003, J IMMUNOL, V171, P1456, DOI 10.4049/jimmunol.171.3.1456; Sato S, 2002, INT IMMUNOL, V14, P783, DOI 10.1093/intimm/dxf046; Sly LM, 2007, FRONT BIOSCI-LANDMRK, V12, P2836, DOI 10.2741/2276; Sly LM, 2004, IMMUNITY, V21, P227, DOI 10.1016/j.immuni.2004.07.010; Stunz LL, 2002, EUR J IMMUNOL, V32, P1212, DOI 10.1002/1521-4141(200205)32:5<1212::AID-IMMU1212>3.0.CO;2-D; Uematsu S, 2005, J EXP MED, V201, P915, DOI 10.1084/jem.20042372; VOLK HD, 1991, BEHRING I MITT, V88, P208; WYSOCKA M, 1995, EUR J IMMUNOL, V25, P672, DOI 10.1002/eji.1830250307; Yeo SJ, 2003, J BIOL CHEM, V278, P40590, DOI 10.1074/jbc.M306280200; Yeo SJ, 2003, J BIOL CHEM, V278, P22563, DOI 10.1074/jbc.M302076200; Yeo SJ, 2003, J IMMUNOL, V170, P1052, DOI 10.4049/jimmunol.170.2.1052; Yi AK, 2006, J BIOL CHEM, V281, P15001, DOI 10.1074/jbc.M601337200; Yi AK, 1998, J IMMUNOL, V161, P4493; Yi AK, 1998, J IMMUNOL, V160, P4755; Yi AK, 2002, J IMMUNOL, V168, P4711, DOI 10.4049/jimmunol.168.9.4711	55	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15258	15270		10.1074/jbc.M709549200	http://dx.doi.org/10.1074/jbc.M709549200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18378686	Green Published, hybrid			2022-12-25	WOS:000256232000044
J	Rigby, K; Cobine, PA; Khalimonchuk, O; Winge, DR				Rigby, Kevin; Cobine, Paul A.; Khalimonchuk, Oleh; Winge, Dennis R.			Mapping the functional interaction of Sco1 and Cox2 in cytochrome oxidase biogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-OXIDASE; CRYSTAL-STRUCTURE; YEAST SCO1; PROTEIN; ACCUMULATION; GENE	Sco1 is implicated in the copper metallation of the Cu-A site in Cox2 of cytochrome oxidase. The structure of Sco1 in the metallated and apo-conformers revealed structural dynamics primarily in an exposed region designated loop 8. The structural dynamics of loop 8 in Sco1 suggests it may be an interface for interactions with Cox17, the Cu(I) donor and/or Cox2. A series of conserved residues in the sequence Motif (KKYRVYF223)-K-217 on the leading edge of this loop are shown presently to be important for yeast Sco1 function. Cells harboring Y219D, R220D, V221D, and Y222D mutant Sco1 proteins failed to restore respiratory growth or cytochrome oxidase activity in sco1 Delta cells. The mutant proteins are stably expressed and are competent to bind Cu(I) and Cu(II) normally. Specific Cu(I) transfer from Cox17 to the mutant apo-Sco1 proteins proceeds normally. In contrast, using two in vivo assays that permit monitoring of the transient Sco1-Cox2 interaction, the mutant Sco1 molecules appear compromised in a function with Cox2. The mutants failed to suppress the respiratory defect of cox17-1 cells unlike wild-type SCO1. In addition, the mutants failed to suppress the hydrogen peroxide sensitivity of sco1 Delta cells. These studies implicate different surfaces on Sco1 for interaction or function with Cox17 and Cox2.	Univ Utah, Hlth Sci Ctr, Dept Biochem, Salt Lake City, UT 84132 USA	Utah System of Higher Education; University of Utah	Winge, DR (corresponding author), Univ Utah, Hlth Sci Ctr, Dept Med, Salt Lake City, UT 84132 USA.	dennis.winge@hsc.utah.edu	Khalimonchuk, Oleh/AAM-1194-2021; Cobine, Paul/AAH-6619-2020; Winge, Dennis/G-3611-2010; Cobine, Paul A/G-3107-2011	Khalimonchuk, Oleh/0000-0002-3972-8678; Cobine, Paul/0000-0001-6012-0985; Cobine, Paul A/0000-0001-6012-0985	NIDDK NIH HHS [P30 DK 072437] Funding Source: Medline; NIEHS NIH HHS [ES 03817] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK072437] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES003817, R01ES003817] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Abajian C, 2006, J BIOL INORG CHEM, V11, P459, DOI 10.1007/s00775-006-0096-7; Balatri E, 2003, STRUCTURE, V11, P1431, DOI 10.1016/j.str.2003.10.004; Banci L, 2007, STRUCTURE, V15, P1132, DOI 10.1016/j.str.2007.07.011; Banci L, 2007, P NATL ACAD SCI USA, V104, P15, DOI 10.1073/pnas.0606189103; Banci L, 2006, P NATL ACAD SCI USA, V103, P8595, DOI 10.1073/pnas.0601375103; Banting GS, 2006, EUKARYOT CELL, V5, P568, DOI 10.1128/EC.5.3.568-578.2006; Beers J, 2002, J BIOL CHEM, V277, P22185, DOI 10.1074/jbc.M202545200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Cobine PA, 2006, J BIOL CHEM, V281, P12270, DOI 10.1074/jbc.M600496200; Cobine PA, 2006, BBA-MOL CELL RES, V1763, P759, DOI 10.1016/j.bbamcr.2006.03.002; Diekert K, 2001, METHOD CELL BIOL, V65, P37, DOI 10.1016/S0091-679X(01)65003-9; Foltopoulou PF, 2004, MOL GENET METAB, V81, P225, DOI 10.1016/j.ymgme.2003.11.006; Glerum DM, 1996, J BIOL CHEM, V271, P20531, DOI 10.1074/jbc.271.34.20531; Hell K, 2000, J BIOL CHEM, V275, P4571, DOI 10.1074/jbc.275.7.4571; Horng YC, 2005, J BIOL CHEM, V280, P34113, DOI 10.1074/jbc.M506801200; Horng YC, 2004, J BIOL CHEM, V279, P35334, DOI 10.1074/jbc.M404747200; Khalimonchuk O, 2007, J BIOL CHEM, V282, P17442, DOI 10.1074/jbc.M702379200; KRUMMECK G, 1990, CURR GENET, V18, P13, DOI 10.1007/BF00321109; Leary SC, 2004, HUM MOL GENET, V13, P1839, DOI 10.1093/hmg/ddh197; Leary SC, 2007, CELL METAB, V5, P9, DOI 10.1016/j.cmet.2006.12.001; Lode A, 2000, FEBS LETT, V485, P19, DOI 10.1016/S0014-5793(00)02176-1; Maxfield AB, 2004, J BIOL CHEM, V279, P5072, DOI 10.1074/jbc.M311772200; Nittis T, 2001, J BIOL CHEM, V276, P42520, DOI 10.1074/jbc.M107077200; Rigby K, 2007, J BIOL CHEM, V282, P10233, DOI 10.1074/jbc.M610082200; SCHULZE M, 1988, MOL GEN GENET, V211, P492, DOI 10.1007/BF00425706; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; Valnot I, 2000, AM J HUM GENET, V67, P1104; Williams JC, 2005, J BIOL CHEM, V280, P15202, DOI 10.1074/jbc.M410705200	28	39	39	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15015	15022		10.1074/jbc.M710072200	http://dx.doi.org/10.1074/jbc.M710072200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18390903	Green Published, hybrid			2022-12-25	WOS:000256232000014
J	Heiss, A; Eckert, T; Aretz, A; Richtering, W; Van Dorp, W; Schafer, C; Jahnen-Dechent, W				Heiss, Alexander; Eckert, Thomas; Aretz, Anke; Richtering, Walter; Van Dorp, Wim; Schaefer, Cora; Jahnen-Dechent, Willi			Hierarchical role of fetuin-A and acidic serum proteins in the formation and stabilization of calcium phosphate particles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN/FETUIN-A; CRYSTAL-GROWTH; HYDROXYAPATITE; BONE; CALCIFICATION; INHIBITION; SOLUBILITY; COMPLEX; TRAFFICKING; ASSOCIATION	The serum protein fetuin-A is a potent systemic inhibitor of soft tissue calcification. Fetuin-A is highly effective in the formation and stabilization of protein-mineral colloids, referred to as calciprotein particles (CPPs). These particles ripen in vitro in a two-step process, indicated by a morphological conversion from spheres to larger prolate ellipsoids. Using a combined light scattering and electron microscopic imaging approach we determined that the second-stage particles resulted from a highly anisotropic outgrowth of the first-stage particles. Electron microscopy of ascites fluid from a patient with calcifying peritonitis revealed particles reminiscent of secondary CPPs. Thus, CPPs form in the body and undergo the two-step ripening at least in pathological conditions. Unlike in vitro generated CPPs, ascites-derived CPPs contained little fetuin-A but large amounts of albumin. This prompted us to study the role of fetuin-A combined with other serum proteins in CPP formation. Fetuin-A was indispensable for primary CPP formation. Albumin and acidic proteins in general greatly enhanced the fetuin-A triggered formation of secondary CPPs and, thus, substituted substantial amounts of fetuin-A without loss of inhibition of calcium phosphate precipitation. Thus, direct mineral deposition from solute in the body is unlikely even at low fetuin-A serum levels as long as sufficient bulk acidic protein is available. Collectively fetuin-A and other acidic bulk plasma proteins may be considered as mineral chaperones mediating the stabilization, safe transport, and clearance in the body of calcium and phosphate as colloidal complexes, thus, preventing ectopic calcification.	[Heiss, Alexander; Schaefer, Cora; Jahnen-Dechent, Willi] Rhein Westfal TH Aachen Univ, Helmholtz Inst Biomed Engn, Biointerface Grp, D-52074 Aachen, Germany; [Eckert, Thomas; Richtering, Walter] Rhein Westfal TH Aachen Univ, Inst Phys Chem, D-52074 Aachen, Germany; [Aretz, Anke] Rhein Westfal TH Aachen Univ, Cent Facil Elect Microscopy, D-52074 Aachen, Germany; [Heiss, Alexander] Inst Solid State Res, Res Ctr, D-52425 Julich, Germany; [Van Dorp, Wim] Kennemer Gasthuis, NL-2000 AK Haarlem, Netherlands	Helmholtz Association; RWTH Aachen University; RWTH Aachen University; RWTH Aachen University; Spaarne Hospital	Heiss, A (corresponding author), Rhein Westfal TH Aachen Univ, Helmholtz Inst Biomed Engn, Biointerface Grp, Pauwelsstr 30, D-52074 Aachen, Germany.	alexander.heiss@post.rwth-aachen.de	Richtering, Walter/E-4130-2012; Heiss, Alexander/AAK-4928-2020; Heiss, Alexander/C-9698-2009; Jahnen-Dechent, Willi/A-7608-2011	Richtering, Walter/0000-0003-4592-8171; Heiss, Alexander/0000-0002-6033-6636; Eckert, Thomas/0000-0003-4054-2915; Jahnen-Dechent, Willi/0000-0003-1315-4407				ASHTON BA, 1976, CALC TISS RES, V22, P27; BLUMENTHAL NC, 1975, CALC TISS RES, V18, P81, DOI 10.1007/BF02546228; Doherty TM, 2004, ENDOCR REV, V25, P629, DOI 10.1210/er.2003-0015; GARNETT J, 1990, BIOCHEM J, V266, P863; GILMAN H, 1994, J INORG BIOCHEM, V55, P31, DOI 10.1016/0162-0134(94)85130-1; Heiss A, 2007, BIOINTERPHASES, V2, P16, DOI 10.1116/1.2714924; Heiss A, 2003, J BIOL CHEM, V278, P13333, DOI 10.1074/jbc.M210868200; Hendig D, 2006, CLIN CHEM, V52, P227, DOI 10.1373/clinchem.2005.059253; Hunter GK, 1996, BIOCHEM J, V317, P59, DOI 10.1042/bj3170059; Ix JH, 2007, CIRCULATION, V115, P2533, DOI 10.1161/CIRCULATIONAHA.106.682450; Jahnen-Dechent W, 2008, J MOL MED, V86, P379, DOI 10.1007/s00109-007-0294-y; Jersmann HPA, 2003, CLIN SCI, V105, P273, DOI 10.1042/CS20030126; Kajander EO, 1998, P NATL ACAD SCI USA, V95, P8274, DOI 10.1073/pnas.95.14.8274; Ketteler M, 2003, LANCET, V361, P827, DOI 10.1016/S0140-6736(03)12710-9; KOPPEL DE, 1972, J CHEM PHYS, V57, P4814, DOI 10.1063/1.1678153; Kundranda MN, 2004, BBA-MOL CELL RES, V1693, P111, DOI 10.1016/j.bbamcr.2004.06.005; MENANTEAU J, 1982, METAB BONE DIS RELAT, V4, P157, DOI 10.1016/0221-8747(82)90030-3; Nadra I, 2008, ATHEROSCLEROSIS, V196, P98, DOI 10.1016/j.atherosclerosis.2007.02.005; Nagayama S, 2007, INT J PHARMACEUT, V329, P192, DOI 10.1016/j.ijpharm.2006.08.025; Nesbitt SA, 1997, SCIENCE, V276, P266, DOI 10.1126/science.276.5310.266; NEUMAN WF, 1982, CALCIFIED TISSUE INT, V34, P149, DOI 10.1007/BF02411226; Overbeck E, 1999, J MOD OPTIC, V46, P303, DOI 10.1080/095003499149953; PETERS T, 1996, ALL ALBUMIN BIOCH GE, P25; Price PA, 2004, J BIOL CHEM, V279, P1594, DOI 10.1074/jbc.M305199200; Price PA, 2003, J BIOL CHEM, V278, P22153, DOI 10.1074/jbc.M300739200; Price PA, 2003, J BIOL CHEM, V278, P22144, DOI 10.1074/jbc.M300744200; Price PA, 2002, J BIOL CHEM, V277, P3926, DOI 10.1074/jbc.M106366200; Raoult D, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.0040041; Reynolds JL, 2005, J AM SOC NEPHROL, V16, P2920, DOI 10.1681/ASN.2004100895; ROMBERG RW, 1986, BIOCHEMISTRY-US, V25, P1176, DOI 10.1021/bi00353a035; Salo J, 1997, SCIENCE, V276, P270, DOI 10.1126/science.276.5310.270; Schafer C, 2003, J CLIN INVEST, V112, P357, DOI 10.1172/JCI17202; SCHAFER C, 2007, HDB BIOMINERALIZATIO, P317; SCHATZEL K, 1991, J MOD OPTIC, V38, P1849, DOI 10.1080/09500349114551951; Schinke T, 1996, J BIOL CHEM, V271, P20789, DOI 10.1074/jbc.271.34.20789; SPIRO RG, 1963, J BIOL CHEM, V238, P644; Stenbeck G, 2004, J CELL SCI, V117, P827, DOI 10.1242/jcs.00935; Stenvinkel P, 2005, KIDNEY INT, V67, P2383, DOI 10.1111/j.1523-1755.2005.00345.x; SUZUKI M, 1994, J EXP ZOOL, V270, P501, DOI 10.1002/jez.1402700603; Talmage D. W., 2007, Journal of Musculoskeletal & Neuronal Interactions, V7, P108; TANFORD C, 1961, PHYSICAL CHEM MACROM, P327; TERKELTAUB RA, 1988, ARTHRITIS RHEUM, V31, P1081, DOI 10.1002/art.1780310901; TRIFFITT JT, 1976, NATURE, V262, P226, DOI 10.1038/262226a0; Urban C, 1998, J COLLOID INTERF SCI, V207, P150, DOI 10.1006/jcis.1998.5769; Wang AYM, 2005, NEPHROL DIAL TRANSPL, V20, P1676, DOI 10.1093/ndt/gfh891; WILSON JWL, 1985, J UROLOGY, V134, P1255, DOI 10.1016/S0022-5347(17)47706-8; Woltje M, 2006, J MOL ENDOCRINOL, V36, P261, DOI 10.1677/jme.1.02001; Wu J, 1998, HEPATOLOGY, V27, P772, DOI 10.1002/hep.510270319; Wuttke M, 2001, J BIOL CHEM, V276, P36839, DOI 10.1074/jbc.M105689200	49	162	172	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14815	14825		10.1074/jbc.M709938200	http://dx.doi.org/10.1074/jbc.M709938200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18364352	hybrid			2022-12-25	WOS:000255941400069
J	Tringe, SG; Zhang, T; Liu, XG; Yu, YT; Lee, WH; Yap, J; Yao, F; Suan, ST; Ing, SK; Haynes, M; Rohwer, F; Wei, CL; Tan, P; Bristow, J; Rubin, EM; Ruan, YJ				Tringe, Susannah G.; Zhang, Tao; Liu, Xuguo; Yu, Yiting; Lee, Wah Heng; Yap, Jennifer; Yao, Fei; Suan, Sim Tiow; Ing, Seah Keng; Haynes, Matthew; Rohwer, Forest; Wei, Chia Lin; Tan, Patrick; Bristow, James; Rubin, Edward M.; Ruan, Yijun			The Airborne Metagenome in an Indoor Urban Environment	PLOS ONE			English	Article								The indoor atmosphere is an ecological unit that impacts on public health. To investigate the composition of organisms in this space, we applied culture-independent approaches to microbes harvested from the air of two densely populated urban buildings, from which we analyzed 80 megabases genomic DNA sequence and 6000 16S rDNA clones. The air microbiota is primarily bacteria, including potential opportunistic pathogens commonly isolated from human-inhabited environments such as hospitals, but none of the data contain matches to virulent pathogens or bioterror agents. Comparison of air samples with each other and nearby environments suggested that the indoor air microbes are not random transients from surrounding outdoor environments, but rather originate from indoor niches. Sequence annotation by gene function revealed specific adaptive capabilities enriched in the air environment, including genes potentially involved in resistance to desiccation and oxidative damage. This baseline index of air microbiota will be valuable for improving designs of surveillance for natural or man-made release of virulent pathogens.	[Tringe, Susannah G.; Bristow, James; Rubin, Edward M.] Joint Genome Inst, Dept Energy, Walnut Creek, CA 94598 USA; [Tringe, Susannah G.; Bristow, James; Rubin, Edward M.] Lawrence Berkeley Natl Lab, Genomics Div, Berkeley, CA USA; [Zhang, Tao; Liu, Xuguo; Yu, Yiting; Lee, Wah Heng; Yao, Fei; Wei, Chia Lin; Tan, Patrick; Ruan, Yijun] Genome Inst Singapore, Singapore, Singapore; [Yap, Jennifer] Natl Environm Agcy, Environm Hlth Inst, Singapore, Singapore; [Suan, Sim Tiow; Ing, Seah Keng] Natl Univ Singapore, Dept Microbiol, Singapore, Singapore; [Haynes, Matthew; Rohwer, Forest] San Diego State Univ, Ctr Microbial Sci, Biol Dept, San Diego, CA USA	United States Department of Energy (DOE); Joint BioEnergy Institute - JBEI; Joint Genome Institute - JGI; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; Agency for Science Technology & Research (A*STAR); A*STAR - Genome Institute of Singapore (GIS); National University of Singapore; California State University System; San Diego State University	Tringe, SG (corresponding author), Joint Genome Inst, Dept Energy, Walnut Creek, CA 94598 USA.	emrubin@lbl.gov; ruanyj@gis.a-star.edu.sg	Rohwer, Forest/AAC-5315-2019; Yu, Yiting/C-8443-2009; Tringe, Susannah Green/T-9431-2019	Tringe, Susannah Green/0000-0001-6479-8427; Rohwer, Forest/0000-0003-1548-5429	Agency for Science, Technology and Research (A*STAR), Singapore; US Department of Energy's Office of Science, Biological and Environmental Research Program; University of California, Lawrence Livermore National Laboratory [W-7405-Eng-48]; Lawrence Berkeley National Laboratory [DE-AC02-05CH11231]; Los Alamos National Laboratory [DE-AC02-06NA25396]	Agency for Science, Technology and Research (A*STAR), Singapore(Agency for Science Technology & Research (A*STAR)); US Department of Energy's Office of Science, Biological and Environmental Research Program(United States Department of Energy (DOE)); University of California, Lawrence Livermore National Laboratory(University of California System); Lawrence Berkeley National Laboratory(United States Department of Energy (DOE)); Los Alamos National Laboratory(United States Department of Energy (DOE)Los Alamos National Laboratory)	This work was supported by the Agency for Science, Technology and Research (A*STAR), Singapore, and under the auspices of the US Department of Energy's Office of Science, Biological and Environmental Research Program, and by the University of California, Lawrence Livermore National Laboratory under Contract No. W-7405-Eng-48, Lawrence Berkeley National Laboratory under contract No. DE-AC02-05CH11231, and Los Alamos National Laboratory under contract No. DE-AC02-06NA25396.	Abraham WR, 1999, INT J SYST BACTERIOL, V49, P1053, DOI 10.1099/00207713-49-3-1053; Angenent LT, 2005, P NATL ACAD SCI USA, V102, P4860, DOI 10.1073/pnas.0501235102; Brodie EL, 2007, P NATL ACAD SCI USA, V104, P299, DOI 10.1073/pnas.0608255104; Cook GM, 1998, MICROBIOL-UK, V144, P3297, DOI 10.1099/00221287-144-12-3297; DeSantis TZ, 2006, NUCLEIC ACIDS RES, V34, pW394, DOI 10.1093/nar/gkl244; DeSantis TZ, 2006, APPL ENVIRON MICROB, V72, P5069, DOI 10.1128/AEM.03006-05; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Endley S, 2001, J BACTERIOL, V183, P2454, DOI 10.1128/JB.183.8.2454-2462.2001; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; Ewing B, 1998, GENOME RES, V8, P175, DOI 10.1101/gr.8.3.175; Gans J, 2005, SCIENCE, V309, P1387, DOI 10.1126/science.1112665; Gilad J, 2000, SCAND J INFECT DIS, V32, P90, DOI 10.1080/00365540050164290; Han XY, 2005, J ANTIMICROB CHEMOTH, V55, P853, DOI 10.1093/jac/dki139; Hoppe P, 1998, INT J BIOMETEOROL, V42, P1, DOI 10.1007/s004840050075; Huber T, 2004, BIOINFORMATICS, V20, P2317, DOI 10.1093/bioinformatics/bth226; Kawamura Y, 2001, MICROBIOL IMMUNOL, V45, P819, DOI 10.1111/j.1348-0421.2001.tb01321.x; Koski LB, 2001, J MOL EVOL, V52, P540, DOI 10.1007/s002390010184; LANE DJ, 1985, P NATL ACAD SCI USA, V82, P6955, DOI 10.1073/pnas.82.20.6955; OjanenReuhs T, 1997, J BACTERIOL, V179, P1280, DOI 10.1128/jb.179.4.1280-1290.1997; OSTERHOLM M, 2005, EPIDEMIOLOGY INFECT, P161; Paster BJ, 2002, J CLIN MICROBIOL, V40, P2187, DOI 10.1128/JCM.40.6.2187-2191.2002; Radosevich JL, 2002, LETT APPL MICROBIOL, V34, P162, DOI 10.1046/j.1472-765x.2002.01048.x; Ravaoarinoro M, 1999, INT J ANTIMICROB AG, V12, P27, DOI 10.1016/S0924-8579(98)00095-8; Shaffer BT, 1997, MICROBIAL ECOL, V34, P167, DOI 10.1007/s002489900046; Shelton BG, 2002, APPL ENVIRON MICROB, V68, P1743, DOI 10.1128/AEM.68.4.1743-1753.2002; STREIFEL A, 2004, DESIGN MAINTENANCE H, P1577; Tatusov RL, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-41; Torsvik V, 2002, SCIENCE, V296, P1064, DOI 10.1126/science.1071698; Tringe SG, 2005, SCIENCE, V308, P554, DOI 10.1126/science.1107851; Valdezate S, 2004, J CLIN MICROBIOL, V42, P693, DOI 10.1128/JCM.42.2.693-699.2003; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; von Mering C, 2005, NUCLEIC ACIDS RES, V33, pD433, DOI 10.1093/nar/gki005; Way SS, 1999, J BACTERIOL, V181, P1229, DOI 10.1128/JB.181.4.1229-1237.1999; Wu PC, 2005, INDOOR AIR, V15, P19, DOI 10.1111/j.1600-0668.2004.00313.x; Xu J, 2004, J HOSP INFECT, V57, P52, DOI 10.1016/j.jhin.2004.01.011	35	157	168	2	71	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1862	10.1371/journal.pone.0001862	http://dx.doi.org/10.1371/journal.pone.0001862			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382653	Green Submitted, Green Published, gold			2022-12-25	WOS:000260795400003
J	Bethune, MT; Ribka, E; Khosla, C; Sestak, K				Bethune, Michael T.; Ribka, Erin; Khosla, Chaitan; Sestak, Karol			Transepithelial Transport and Enzymatic Detoxification of Gluten in Gluten-Sensitive Rhesus Macaques	PLOS ONE			English	Article								Background and Aims: In a previous report, we characterized a condition of gluten sensitivity in juvenile rhesus macaques that is similar in many respects to the human condition of gluten sensitivity, celiac disease. This animal model of gluten sensitivity may therefore be useful toward studying both the pathogenesis and the treatment of celiac disease. Here, we perform two pilot experiments to demonstrate the potential utility of this model for studying intestinal permeability toward an immunotoxic gluten peptide and pharmacological detoxification of gluten in vivo by an oral enzyme drug candidate. Methods: Intestinal permeability was investigated in age-matched gluten-sensitive and control macaques by using mass spectrometry to detect and quantify an orally dosed, isotope labeled 33-mer gluten peptide delivered across the intestinal epithelium to the plasma. The protective effect of a therapeutically promising oral protease, EP-B2, was evaluated in a gluten-sensitive macaque by administering a daily gluten challenge with or without EP-B2 supplementation. ELISA-based antibody assays and blinded clinical evaluations of this macaque and of an age-matched control were conducted to assess responses to gluten. Results: Labeled 33-mer peptide was detected in the plasma of a gluten-sensitive macaque, both in remission and during active disease, but not in the plasma of healthy controls. Administration of EP-B2, but not vehicle, prevented clinical relapse in response to a dietary gluten challenge. Unexpectedly, a marked increase in anti-gliadin (IgG and IgA) and anti-transglutaminase (IgG) antibodies was observed during the EP-B2 treatment phase. Conclusions: Gluten-sensitive rhesus macaques may be an attractive resource for investigating important aspects of celiac disease, including enhanced intestinal permeability and pharmacology of oral enzyme drug candidates. Orally dosed EP-B2 exerts a protective effect against ingested gluten. Limited data suggest that enhanced permeability of short gluten peptides generated by gastrically active glutenases may trigger an elevated antibody response, but that these antibodies are not necessarily causative of clinical illness.	[Bethune, Michael T.; Khosla, Chaitan] Stanford Univ, Dept Biochem, Stanford, CA 94305 USA; [Ribka, Erin; Sestak, Karol] Tulane Natl Primate Res Ctr, Covington, LA USA; [Khosla, Chaitan] Stanford Univ, Dept Chem, Stanford, CA USA; [Khosla, Chaitan] Stanford Univ, Dept Chem Engn, Stanford, CA USA; [Sestak, Karol] Tulane Univ, Sch Med, Dept Microbiol & Immunol, New Orleans, LA USA	Stanford University; Tulane University; Stanford University; Stanford University; Tulane University	Bethune, MT (corresponding author), Stanford Univ, Dept Biochem, Stanford, CA 94305 USA.	ksestak@tulane.edu		Sestak, Karol/0000-0003-3951-2719; Khosla, Chaitan/0000-0001-6529-495X	Stanford University; TNPRC [P51 RR00164, U24 RR018111];  [R21 AI54146];  [R01 DK063158]; NATIONAL CENTER FOR RESEARCH RESOURCES [U24RR018111, P51RR000164] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI054146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK076653, R01DK063158] Funding Source: NIH RePORTER	Stanford University(Stanford University); TNPRC; ; ; NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	Grant support: This research was jointly supported by R21 AI54146 to K.S., R01 DK063158 to C.K., and grants P51 RR00164 and U24 RR018111 to the TNPRC. M.T.B. was a recipient of an NIH Cellular and Molecular Biology Training Grant through Stanford University at the outset of this work.	Bethune MT, 2006, CHEM BIOL, V13, P637, DOI 10.1016/j.chembiol.2006.04.008; BETHUNE MT, 2008, PLOS ONE IN PRESS; BJARNASON I, 1983, LANCET, V1, P323; BJARNASON I, 1985, GUT, V26, P1214, DOI 10.1136/gut.26.11.1214; BJARNASON I, 1984, GUT, V25, P145, DOI 10.1136/gut.25.2.145; BJARNASON I, 1985, GUT, V26, P579, DOI 10.1136/gut.26.6.579; Cerf-Bensussan N, 2007, GUT, V56, P157, DOI 10.1136/gut.2005.090498; Ciacci C, 2002, DIGESTION, V66, P178, DOI 10.1159/000066757; Cornell HJ, 2005, SCAND J GASTROENTERO, V40, P1304, DOI 10.1080/00365520510023855; DICKE W K, 1953, Acta Paediatr, V42, P34, DOI 10.1111/j.1651-2227.1953.tb05563.x; Esposito C, 2002, GUT, V51, P177, DOI 10.1136/gut.51.2.177; Fleckenstein B, 2002, J BIOL CHEM, V277, P34109, DOI 10.1074/jbc.M204521200; Gass J, 2007, GASTROENTEROLOGY, V133, P472, DOI 10.1053/j.gastro.2007.05.028; Gass J, 2006, J PHARMACOL EXP THER, V318, P1178, DOI 10.1124/jpet.106.104315; Green PHR, 2006, ANNU REV MED, V57, P207, DOI 10.1146/annurev.med.57.051804.122404; Hausch F, 2003, CHEM BIOL, V10, P225, DOI 10.1016/S1074-5521(03)00045-0; Hausch F, 2002, AM J PHYSIOL-GASTR L, V283, pG996, DOI 10.1152/ajpgi.00136.2002; Jabri B, 2005, IMMUNOL REV, V206, P219, DOI 10.1111/j.0105-2896.2005.00294.x; Kim CY, 2004, P NATL ACAD SCI USA, V101, P4175, DOI 10.1073/pnas.0306885101; Korponay-Szabo IR, 2004, GUT, V53, P641, DOI 10.1136/gut.2003.024836; Korponay-Szabo IR, 2003, GUT, V52, P199, DOI 10.1136/gut.52.2.199; MAYER M, 1991, GUT, V32, P881, DOI 10.1136/gut.32.8.881; Pietzak MM, 2005, GASTROENTEROLOGY, V128, pS135, DOI 10.1053/j.gastro.2005.02.025; PINKAS DM, 2007, PLOS BIOL, V327, P2; Piper JL, 2002, BIOCHEMISTRY-US, V41, P386, DOI 10.1021/bi011715x; Qiao SW, 2004, J IMMUNOL, V173, P1757, DOI 10.4049/jimmunol.173.3.1757; Quarsten H, 1999, EUR J IMMUNOL, V29, P2506, DOI 10.1002/(SICI)1521-4141(199908)29:08<2506::AID-IMMU2506>3.0.CO;2-9; Schulzke JD, 1998, PEDIATR RES, V43, P435, DOI 10.1203/00006450-199804000-00001; See Jacalyn, 2006, Nutr Clin Pract, V21, P1, DOI 10.1177/011542650602100101; Shan L, 2005, J PROTEOME RES, V4, P1732, DOI 10.1021/pr050173t; Shan L, 2002, SCIENCE, V297, P2275, DOI 10.1126/science.1074129; Siegel M, 2006, CHEM BIOL, V13, P649, DOI 10.1016/j.chembiol.2006.04.009; Sollid LM, 2002, NAT REV IMMUNOL, V2, P647, DOI 10.1038/nri885; SOLLID LM, 1989, J EXP MED, V169, P345, DOI 10.1084/jem.169.1.345; Spurkland A, 1997, TISSUE ANTIGENS, V49, P29, DOI 10.1111/j.1399-0039.1997.tb02706.x; Stepniak D, 2006, TRENDS BIOTECHNOL, V24, P433, DOI 10.1016/j.tibtech.2006.08.003; Teahon K, 1996, GUT, V38, P864, DOI 10.1136/gut.38.6.864; Vader LW, 2002, J EXP MED, V195, P643, DOI 10.1084/jem.20012028; Vora H, 2007, BIOTECHNOL BIOENG, V98, P177, DOI 10.1002/bit.21423; Xia J, 2005, BIOCHEMISTRY-US, V44, P4442, DOI 10.1021/bi047747c	40	32	33	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1857	10.1371/journal.pone.0001857	http://dx.doi.org/10.1371/journal.pone.0001857			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365012	Green Published, gold, Green Submitted			2022-12-25	WOS:000260762400018
J	Goldin, N; Arzoine, L; Heyfets, A; Israelson, A; Zaslavsky, Z; Bravman, T; Bronner, V; Notcovich, A; Shoshan-Barmatz, V; Flescher, E				Goldin, N.; Arzoine, L.; Heyfets, A.; Israelson, A.; Zaslavsky, Z.; Bravman, T.; Bronner, V.; Notcovich, A.; Shoshan-Barmatz, V.; Flescher, E.			Methyl jasmonate binds to and detaches mitochondria-bound hexokinase	ONCOGENE			English	Article						jasmonate; target; hexokinase; VDAC; mitochondria	DEPENDENT ANION CHANNEL; PERMEABILITY TRANSITION; ENERGY-METABOLISM; ANTICANCER AGENTS; BRAIN HEXOKINASE; CELL-DEATH; RAT-BRAIN; CANCER; APOPTOSIS; GLYCOLYSIS	Cellular bio-energetic metabolism and mitochondria are recognized as potential targets for anticancer agents, due to the numerous relevant peculiarities cancer cells exhibit. Jasmonates are anticancer agents that interact directly with mitochondria. The aim of this study was to identify mitochondrial molecular targets of jasmonates. We report that jasmonates bind to hexokinase and detach it from the mitochondria and its mitochondrial anchor-the voltage-dependent anion channel (VDAC), as judged by hexokinase immunochemical and activity determinations, surface plasmon resonance analysis and planar lipid bilayer VDAC- activity analysis. Furthermore, the susceptibility of cancer cells and mitochondria to jasmonates is dependent on the expression of hexokinase, evaluated using hexokinase-overexpressing transfect ants and its mitochondrial association. Many types of cancer cells exhibit overexpression of the key glycolytic enzyme, hexokinase, and its excessive binding to mitochondria. These characteristics are considered to play a pivotal role in cancer cell growth rate and survival. Thus, our findings provide an explanation for the selective effects of jasmonates on cancer cells. Most importantly, this is the first demonstration of a cytotoxic mechanism based on direct interaction between an anticancer agent and hexokinase. The proposed mechanism can serve to guide development of a new selective approach for cancer therapy.	[Goldin, N.; Heyfets, A.; Flescher, E.] Tel Aviv Univ, Sackler Fac Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel; [Arzoine, L.; Israelson, A.; Shoshan-Barmatz, V.] Ben Gurion Univ Negev, Dept Life Sci, IL-84105 Beer Sheva, Israel; [Zaslavsky, Z.] Tel Aviv Univ, Sackler Fac Med, Interdept Core Facil, IL-69978 Tel Aviv, Israel; [Bravman, T.; Bronner, V.; Notcovich, A.] Bio Rad Haifa, Haifa, Israel	Tel Aviv University; Sackler Faculty of Medicine; Ben Gurion University; Tel Aviv University; Sackler Faculty of Medicine	Flescher, E (corresponding author), Tel Aviv Univ, Sackler Fac Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel.	flascher@post.tau.ac.il		Israelson, Adrian/0000-0002-8289-7653				Al jamal JA, 2005, PROTEIN J, V24, P1, DOI 10.1007/s10930-004-0600-2; Azoulay-Zohar H, 2004, BIOCHEM J, V377, P347, DOI 10.1042/BJ20031465; Boozer C, 2006, CURR OPIN BIOTECH, V17, P400, DOI 10.1016/j.copbio.2006.06.012; Brawer Michael K, 2005, Rev Urol, V7 Suppl 7, pS21; BUSTAMANTE E, 1977, P NATL ACAD SCI USA, V74, P3735, DOI 10.1073/pnas.74.9.3735; Chini A, 2007, NATURE, V448, P666, DOI 10.1038/nature06006; Cuezva JM, 2002, CANCER RES, V62, P6674; Dang CV, 1999, TRENDS BIOCHEM SCI, V24, P68, DOI 10.1016/S0968-0004(98)01344-9; Debatin KM, 2002, ONCOGENE, V21, P8786, DOI 10.1038/sj.onc.1206039; Ehsani-Zonouz A, 2001, MOL CELL BIOCHEM, V223, P81, DOI 10.1023/A:1017952827675; Fingrut O, 2005, BRIT J PHARMACOL, V146, P800, DOI 10.1038/sj.bjp.0706394; Fingrut O, 2002, LEUKEMIA, V16, P608, DOI 10.1038/sj.leu.2402419; Flescher E, 2005, ANTI-CANCER DRUG, V16, P911, DOI 10.1097/01.cad.0000176501.63680.80; Flescher E, 2007, CANCER LETT, V245, P1, DOI 10.1016/j.canlet.2006.03.001; Galluzzi L, 2006, ONCOGENE, V25, P4812, DOI 10.1038/sj.onc.1209598; Gincel D, 2001, BIOCHEM J, V358, P147, DOI 10.1042/0264-6021:3580147; Goldin N, 2007, J BIOENERG BIOMEMBR, V39, P51, DOI 10.1007/s10863-006-9061-y; Green DR, 2004, SCIENCE, V305, P626, DOI 10.1126/science.1099320; Hamilton MD, 2007, NUCLEIC ACIDS RES, V35, P143, DOI 10.1093/nar/gkl1015; Hammerman PS, 2004, TRENDS BIOCHEM SCI, V29, P586, DOI 10.1016/j.tibs.2004.09.008; Heyfets A, 2007, CANCER LETT, V250, P300, DOI 10.1016/j.canlet.2006.10.013; Ishii Y, 2004, LEUKEMIA, V18, P1413, DOI 10.1038/sj.leu.2403421; Isidoro A, 2004, BIOCHEM J, V378, P17, DOI 10.1042/BJ20031541; KEISARI Y, 1992, J IMMUNOL METHODS, V146, P155, DOI 10.1016/0022-1759(92)90224-H; Kroemer G, 2006, ONCOGENE, V25, P4630, DOI 10.1038/sj.onc.1209589; Kroemer G, 2003, CURR MED CHEM, V10, P1469, DOI 10.2174/0929867033457232; Lampidis TJ, 2006, CANCER CHEMOTH PHARM, V58, P725, DOI 10.1007/s00280-006-0207-8; Lemasters JJ, 1998, BBA-BIOENERGETICS, V1366, P177, DOI 10.1016/S0005-2728(98)00112-1; Machida K, 2006, J BIOL CHEM, V281, P14314, DOI 10.1074/jbc.M513297200; Majewski N, 2004, MOL CELL, V16, P819, DOI 10.1016/j.molcel.2004.11.014; Mathupala SP, 2006, ONCOGENE, V25, P4777, DOI 10.1038/sj.onc.1209603; Miccoli L, 1998, CANCER RES, V58, P5777; NAKASHIMA RA, 1986, BIOCHEMISTRY-US, V25, P1015, DOI 10.1021/bi00353a010; OUDARD S, 1995, INT J CANCER, V62, P216, DOI 10.1002/ijc.2910620218; Pastorino JG, 2005, CANCER RES, V65, P10545, DOI 10.1158/0008-5472.CAN-05-1925; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Pedersen P L, 1978, Prog Exp Tumor Res, V22, P190; Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P211, DOI 10.1007/s10863-007-9094-x; Pedersen PL, 2007, J BIOENERG BIOMEMBR, V39, P1, DOI 10.1007/s10863-007-9070-5; PEDERSEN PL, 2002, BIOCHIM BIOPHYS ACTA, V1355, P14; Penso J, 2003, MOL GENET METAB, V78, P74, DOI 10.1016/S1096-7192(02)00203-2; Reischer D, 2007, BRIT J PHARMACOL, V150, P738, DOI 10.1038/sj.bjp.0707146; Robey RB, 2006, ONCOGENE, V25, P4683, DOI 10.1038/sj.onc.1209595; Robey R.B., 2005, DRUG DISCOV TODAY DI, V2, P239, DOI [10.1016/j.ddmec.2005.05.021, DOI 10.1016/J.DDMEC.2005.05.021, DOI 10.1016/j.ddmec.2005.05.021]; Rotem R, 2005, CANCER RES, V65, P1984, DOI 10.1158/0008-5472.CAN-04-3091; Shoshan-Barmatz V, 2005, J MEMBRANE BIOL, V204, P57, DOI 10.1007/s00232-005-0749-4; Sun L, 2008, MOL CELL BIOL, V28, P1007, DOI 10.1128/MCB.00224-07; Varbiro G, 2001, FREE RADICAL BIO MED, V31, P548, DOI 10.1016/S0891-5849(01)00616-5; Warburg O.H., 1930, METABOLISM TUMOURS I; WILSON JE, 1989, PREP BIOCHEM, V19, P13, DOI 10.1080/10826068908544893; Wilson JE, 2003, J EXP BIOL, V206, P2049, DOI 10.1242/jeb.00241; WILSON JE, 1995, REV PHYSIOL BIOCH P, V126, P65, DOI 10.1007/BFb0049776; WILSON JE, 1968, J BIOL CHEM, V243, P3640; WILSON JE, 1989, ARCH BIOCHEM BIOPHYS, V269, P517, DOI 10.1016/0003-9861(89)90135-5; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599	55	151	160	1	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2008	27	34					4636	4643		10.1038/onc.2008.108	http://dx.doi.org/10.1038/onc.2008.108			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408762				2022-12-25	WOS:000258236300002
J	Shi, H; Scheffler, JM; Pleitner, JM; Zeng, C; Park, S; Hannon, KM; Grant, AL; Gerrard, DE				Shi, Hao; Scheffler, Jason M.; Pleitner, Jonathan M.; Zeng, Caiyun; Park, Sungkwon; Hannon, Kevin M.; Grant, Alan L.; Gerrard, David E.			Modulation of skeletal muscle fiber type by mitogen-activated protein kinase signaling	FASEB JOURNAL			English	Article						ERK1/2; MKP-1; plasticity; signal transduction	MYOSIN HEAVY-CHAIN; HEAVY-CHAIN-2 GENE-EXPRESSION; MAP KINASE; GROWTH-FACTOR; SLOW; CALCINEURIN; PATHWAY; DIFFERENTIATION; ISOFORM; PHOSPHORYLATION	Skeletal muscle is composed of diverse fiber types, yet the underlying molecular mechanisms responsible for this diversification remain unclear. Herein, we report that the extracellular signal-regulated kinase (ERK) 1/2 pathway, but not p38 or c-Jun NH2-terminal kinase (JNK), is preferentially activated in fast-twitch muscles. Pharmacological blocking of ERK1/2 pathway increased slow-twitch fiber type-specific reporter activity and repressed those associated with the fast-twitch fiber phenotype in vitro. Overexpression of a constitutively active ERK2 had an opposite effect. Inhibition of ERK signaling in cultured myotubes increased slow-twitch fiber-specific protein accumulation while repressing those characteristic of fast-twitch fibers. Overexpression of MAP kinase phosphatase-1 (MKP1) in mouse and rat muscle fibers containing almost exclusively type IIb or IIx fast myosin heavy chain (MyHC) isoforms induced de novo synthesis of the slower, more oxidative type IIa and I MyHCs in a time-dependent manner. Conversion to the slower phenotype was confirmed by up-regulation of slow reporter gene activity and down-regulation of fast reporter activities in response to forced MKP1 expression in vivo. In addition, activation of ERK2 signaling induced up-regulation of fast-twitch fiber program in soleus. These data suggest that the MAPK signaling, most likely the ERK1/2 pathway, is necessary to preserve the fast-twitch fiber phenotype with a concomitant repression of slow- twitch fiber program.	[Shi, Hao; Scheffler, Jason M.; Pleitner, Jonathan M.; Zeng, Caiyun; Park, Sungkwon; Grant, Alan L.; Gerrard, David E.] Purdue Univ, Dept Anim Sci, W Lafayette, IN 47907 USA; [Hannon, Kevin M.] Purdue Univ, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Purdue University System; Purdue University; Purdue University West Lafayette Campus	Gerrard, DE (corresponding author), Purdue Univ, Dept Anim Sci, 915 W State St, W Lafayette, IN 47907 USA.	dgerrard@purdue.edu	gerrard, david/AAG-7507-2019	Scheffler, Jason/0000-0001-6360-8820; gerrard, david/0000-0002-3482-1400				Allen DL, 2002, J BIOL CHEM, V277, P45323, DOI 10.1074/jbc.M208302200; Arany Z, 2007, CELL METAB, V5, P35, DOI 10.1016/j.cmet.2006.12.003; Bassel-Duby R, 2006, ANNU REV BIOCHEM, V75, P19, DOI 10.1146/annurev.biochem.75.103004.142622; Berchtold MW, 2000, PHYSIOL REV, V80, P1215, DOI 10.1152/physrev.2000.80.3.1215; Camps M, 2000, FASEB J, V14, P6, DOI 10.1096/fasebj.14.1.6; Chang LF, 2001, NATURE, V410, P37, DOI 10.1038/35065000; Charge SBP, 2004, PHYSIOL REV, V84, P209, DOI 10.1152/physrev.00019.2003; Chin ER, 1998, GENE DEV, V12, P2499, DOI 10.1101/gad.12.16.2499; Delling U, 2000, MOL CELL BIOL, V20, P6600, DOI 10.1128/MCB.20.17.6600-6611.2000; Depreux FFS, 2000, MEAT SCI, V56, P261, DOI 10.1016/S0309-1740(00)00051-6; DiMario JX, 2001, EXP CELL RES, V263, P23, DOI 10.1006/excr.2000.5094; Dinev D, 2001, EMBO REP, V2, P829, DOI 10.1093/embo-reports/kve177; Graves LM, 2000, NATURE, V403, P328, DOI 10.1038/35002111; Grifone R, 2004, MOL CELL BIOL, V24, P6253, DOI 10.1128/MCB.24.14.6253-6267.2004; Hagiwara N, 2005, DEV DYNAM, V234, P301, DOI 10.1002/dvdy.20535; Hagiwara N, 2007, DEV DYNAM, V236, P2062, DOI 10.1002/dvdy.21223; Hasegawa K, 1997, CIRCULATION, V96, P3943; Hazzalin CA, 2002, NAT REV MOL CELL BIO, V3, P30, DOI 10.1038/nrm715; Higginson J, 2002, PFLUG ARCH EUR J PHY, V445, P437, DOI 10.1007/s00424-002-0939-1; HUGHES SM, 1992, CELL, V68, P659, DOI 10.1016/0092-8674(92)90142-Y; Jones NC, 2001, J CELL PHYSIOL, V186, P104, DOI 10.1002/1097-4652(200101)186:1<104::AID-JCP1015>3.0.CO;2-0; Jordan T, 2005, J CELL SCI, V118, P2295, DOI 10.1242/jcs.02341; Jordan T, 2004, J CELL SCI, V117, P6175, DOI 10.1242/jcs.01543; Jordan T, 2003, J CELL BIOL, V162, P843, DOI 10.1083/jcb.200303164; Keren A, 2006, MOL CELL ENDOCRINOL, V252, P224, DOI 10.1016/j.mce.2006.03.017; Kramer HF, 2007, J APPL PHYSIOL, V103, P388, DOI 10.1152/japplphysiol.00085.2007; Lin J, 2002, NATURE, V418, P797, DOI 10.1038/nature00904; Lluis F, 2006, TRENDS CELL BIOL, V16, P36, DOI 10.1016/j.tcb.2005.11.002; Long YC, 2004, P NUTR SOC, V63, P227, DOI 10.1079/PNS2004346; Maggs AM, 2000, J MUSCLE RES CELL M, V21, P101, DOI 10.1023/A:1005639229497; Meissner JD, 2007, J BIOL CHEM, V282, P7265, DOI 10.1074/jbc.M609076200; Monje P, 2003, MOL CELL BIOL, V23, P7030, DOI 10.1128/MCB.23.19.7030-7043.2003; Murgia M, 2000, NAT CELL BIOL, V2, P142, DOI 10.1038/35004013; Murphy LO, 2002, NAT CELL BIOL, V4, P556, DOI 10.1038/ncb822; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Palmer A, 1998, EMBO J, V17, P5037, DOI 10.1093/emboj/17.17.5037; Perry RLS, 2001, MOL CELL, V8, P291, DOI 10.1016/S1097-2765(01)00302-1; Pette D, 2001, HISTOCHEM CELL BIOL, V115, P359, DOI 10.1007/s004180100268; Pyronnet S, 1999, EMBO J, V18, P270, DOI 10.1093/emboj/18.1.270; Robinson MJ, 1998, CURR BIOL, V8, P1141, DOI 10.1016/S0960-9822(07)00485-X; Schiaffino S, 1996, PHYSIOL REV, V76, P371, DOI 10.1152/physrev.1996.76.2.371; Shi H, 2007, AM J PHYSIOL-CELL PH, V292, pC1681, DOI 10.1152/ajpcell.00466.2006; Stefanovsky V, 2006, MOL CELL, V21, P629, DOI 10.1016/j.molcel.2006.01.023; Strle K, 2006, ENDOCRINOLOGY, V147, P4363, DOI 10.1210/en.2005-1541; Swoap SJ, 2000, AM J PHYSIOL-CELL PH, V279, pC915, DOI 10.1152/ajpcell.2000.279.4.C915; Swoap SJ, 1998, AM J PHYSIOL-CELL PH, V274, pC681, DOI 10.1152/ajpcell.1998.274.3.C681; Treinies I, 1999, MOL CELL BIOL, V19, P321; Wang YX, 2004, PLOS BIOL, V2, P1532, DOI 10.1371/journal.pbio.0020294; Wu H, 2002, SCIENCE, V296, P349, DOI 10.1126/science.1071163; Wu JJ, 2006, CELL METAB, V4, P61, DOI 10.1016/j.cmet.2006.05.010; Wu JJ, 2005, MOL CELL BIOL, V25, P4792, DOI 10.1128/MCB.25.11.4792-4803.2005; Yeow K, 2002, BIOCHEM BIOPH RES CO, V293, P112, DOI 10.1016/S0006-291X(02)00190-0	52	61	68	0	5	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2990	3000		10.1096/fj.07-097600	http://dx.doi.org/10.1096/fj.07-097600			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18417546				2022-12-25	WOS:000258089300039
J	Benjdia, A; Subramanian, S; Leprince, J; Vaudry, H; Johnson, MK; Berteau, O				Benjdia, Alhosna; Subramanian, Sowmya; Leprince, Jerome; Vaudry, Hubert; Johnson, Michael K.; Berteau, Olivier			Anaerobic sulfatase-maturating enzymes, first dual substrate radical S-adenosylmethionine enzymes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEIN; FORMYLGLYCINE-GENERATING ENZYME; LYASE ACTIVATING ENZYME; COLI BIOTIN SYNTHASE; ESCHERICHIA-COLI; POSTTRANSLATIONAL MODIFICATION; RIBONUCLEOTIDE REDUCTASE; BACTERIAL SULFATASES; 4FE-4S CLUSTERS; SAM ENZYMES	Sulfatases are a major group of enzymes involved in many critical physiological processes as reflected by their broad distribution in all three domains of life. This class of hydrolases is unique in requiring an essential post-translational modification of a critical active-site cysteine or serine residue to C-alpha-formylglycine. This modification is catalyzed by at least three nonhomologous enzymatic systems in bacteria. Each enzymatic system is currently considered to be dedicated to the modification of either cysteine or serine residues encoded in the sulfatase-active site and has been accordingly categorized as Cys-type and Ser-type sulfatase-maturating enzymes. Wereport here the first detailed characterization of two bacterial anaerobic sulfatase maturating enzymes (anSMEs) that are physiologically responsible for either Cys- type or Ser-type sulfatase maturation. The activity of both enzymes was investigated in vivo and in vitro using synthetic substrates and the successful purification of both enzymes facilitated the first biochemical and spectroscopic characterization of this class of enzyme. We demonstrate that reconstituted anSMEs are radical S-adenosyl-L-methionine enzymes containing a redox active [4Fe-4S] 2(+,+) cluster that initiates the radical reaction by binding and reductively cleaving S-adenosyl-L-methionine to yield 5'-deoxyadenosine and methionine. Surprisingly, our results show that anSMEs are dual substrate enzymes able to oxidize both cysteine and serine residues to C'-formylglycine. Taken together, the results support a radical modification mechanism that is initiated by hydrogen abstraction from a serine or cysteine residue located in an appropriate target sequence.	[Benjdia, Alhosna; Berteau, Olivier] INRA, UPR 910, Unite Ecol & Physiol Syst Digestif, F-78352 Jouy En Josas, France; [Subramanian, Sowmya; Johnson, Michael K.] Univ Georgia, Dept Chem, Athens, GA 30602 USA; [Subramanian, Sowmya; Johnson, Michael K.] Univ Georgia, Ctr Metalloenzyme Studies, Athens, GA 30602 USA; [Leprince, Jerome; Vaudry, Hubert] Univ Rouen, UA CNRS, IFRMP23, INSERM U 413, F-76821 Mont St Aignan, France	INRAE; UDICE-French Research Universities; Universite Paris Saclay; University System of Georgia; University of Georgia; University System of Georgia; University of Georgia; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rouen Normandie	Berteau, O (corresponding author), Batiment Jacques Poly, F-78352 Jouy En Josas, France.	Olivier.Berteau@jouy.inra.fr	Subramanian, Sowmya/AAD-7307-2021; Leprince, Jerome/N-9083-2017; Berteau, Olivier/AAF-9080-2019; Benjdia, Alhosna/AAM-7415-2021	Berteau, Olivier/0000-0002-3434-5168; Benjdia, Alhosna/0000-0002-3544-2541; Leprince, Jerome/0000-0002-7814-9927	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM062524, R37GM062524] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM062524, R01 GM062524-08, GM 62524] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agar JN, 2000, BIOCHEMISTRY-US, V39, P7856, DOI 10.1021/bi000931n; Benjdia A, 2007, J AM CHEM SOC, V129, P3462, DOI 10.1021/ja067175e; Benjdia A, 2007, FEBS LETT, V581, P1009, DOI 10.1016/j.febslet.2007.01.076; Berteau O, 2006, J BIOL CHEM, V281, P22464, DOI 10.1074/jbc.M602504200; Broderick JB, 1997, J AM CHEM SOC, V119, P7396, DOI 10.1021/ja9711425; Cheek J, 2002, J AM CHEM SOC, V124, P2860, DOI 10.1021/ja017784g; CHENG Q, 1992, J BACTERIOL, V174, P7185, DOI 10.1128/jb.174.22.7185-7193.1992; Cosma MP, 2003, CELL, V113, P445, DOI 10.1016/S0092-8674(03)00348-9; Cosper MM, 2002, J AM CHEM SOC, V124, P14006, DOI 10.1021/ja0283044; Cosper MM, 2004, BIOCHEMISTRY-US, V43, P2007, DOI 10.1021/bi0356653; DAILEY HA, 1994, BIOCHEMISTRY-US, V33, P403, DOI 10.1021/bi00168a003; Dierks T, 2003, CELL, V113, P435, DOI 10.1016/S0092-8674(03)00347-7; DROZDZEWSKI PM, 1988, APPL SPECTROSC, V42, P1575, DOI 10.1366/0003702884429841; Duin EC, 1997, BIOCHEMISTRY-US, V36, P11811, DOI 10.1021/bi9706430; Fang QH, 2004, J BIOL CHEM, V279, P14570, DOI 10.1074/jbc.M313855200; Fontecave M, 2004, TRENDS BIOCHEM SCI, V29, P243, DOI 10.1016/j.tibs.2004.03.007; Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234; Glockner FO, 2003, P NATL ACAD SCI USA, V100, P8298, DOI 10.1073/pnas.1431443100; Hanson SR, 2004, ANGEW CHEM INT EDIT, V43, P5736, DOI 10.1002/anie.200300632; Kriek M, 2007, J BIOL CHEM, V282, P17413, DOI 10.1074/jbc.M700782200; Layer G, 2005, BIOL CHEM, V386, P971, DOI 10.1515/BC.2005.113; Marquordt C, 2003, J BIOL CHEM, V278, P2212, DOI 10.1074/jbc.M209435200; Ollagnier S, 1999, J AM CHEM SOC, V121, P6344, DOI 10.1021/ja990073m; Ollagnier S, 1997, J BIOL CHEM, V272, P24216, DOI 10.1074/jbc.272.39.24216; Ono K, 2006, J BIOL CHEM, V281, P13672, DOI 10.1074/jbc.M600029200; Peng JH, 2003, J MASS SPECTROM, V38, P80, DOI 10.1002/jms.404; Recksiek R, 1998, J BIOL CHEM, V273, P6096, DOI 10.1074/jbc.273.11.6096; Roeser D, 2006, P NATL ACAD SCI USA, V103, P81, DOI 10.1073/pnas.0507592102; Szameit C, 1999, J BIOL CHEM, V274, P15375, DOI 10.1074/jbc.274.22.15375; Walsby CJ, 2002, J AM CHEM SOC, V124, P3143, DOI 10.1021/ja012034s; Wang SC, 2007, TRENDS BIOCHEM SCI, V32, P101, DOI 10.1016/j.tibs.2007.01.002; Wang WY, 1999, BIOTECHNIQUES, V26, P680, DOI 10.2144/99264st03; Wright DP, 2000, J BACTERIOL, V182, P3002, DOI 10.1128/JB.182.11.3002-3007.2000; Xu J, 2003, SCIENCE, V299, P2074, DOI 10.1126/science.1080029; Xu J, 2007, PLOS BIOL, V5, P1574, DOI 10.1371/journal.pbio.0050156	35	50	54	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17815	17826		10.1074/jbc.M710074200	http://dx.doi.org/10.1074/jbc.M710074200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18408004	Green Published, hybrid			2022-12-25	WOS:000256949200009
J	Singh, AK; Bhattacharyya-Pakrasi, M; Pakrasi, HB				Singh, Abhay K.; Bhattacharyya-Pakrasi, Maitrayee; Pakrasi, Himadri B.			Identification of an atypical membrane protein involved in the formation of protein disulfide bonds in oxygenic photosynthetic organisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; ISOMERASE; DSBA; SYSTEM; GENE; CYANOBACTERIUM; PROTEOMICS; EVOLUTION; MANGANESE; MUTANTS	The evolution of oxygenic photosynthesis in cyanobacteria nearly three billion years ago provided abundant reducing power and facilitated the elaboration of numerous oxygen-dependent reactions in our biosphere. Cyanobacteria contain an internal thylakoid membrane system, the site of photosynthesis, and a typical Gram-negative envelope membrane system. Like other organisms, the extracytoplasmic space in cyanobacteria houses numerous cysteine-containing proteins. However, the existence of a biochemical system for disulfide bond formation in cyanobacteria remains to be determined. Extracytoplasmic disulfide bond formation in non-photosynthetic organisms is catalyzed by coordinated interaction between two proteins, a disulfide carrier and a disulfide generator. Here we describe a novel gene, SyndsbAB, required for disulfide bond formation in the extracytoplasmic space of cyanobacteria. The SynDsbAB orthologs are present in most cyanobacteria and chloroplasts of higher plants with fully sequenced genomes. The SynDsbAB protein contains two distinct catalytic domains that display significant similarity to proteins involved in disulfide bond formation in Escherichia coli and eukaryotes. Importantly, SyndsbAB complements E. coli strains defective in disulfide bond formation. In addition, the activity of E. coli alkaline phosphatase localized to the periplasm of Synechocystis 6803 is dependent on the function of SynDsbAB. Deletion of SyndsbAB in Synechocystis 6803 causes significant growth impairment under photoautotrophic conditions and results in hyper-sensitivity to dithiothreitol, a reductant, whereas diamide, an oxidant had no effect on the growth of the mutant strains. We conclude that SynDsbAB is a critical protein for disulfide bond formation in oxygenic photosynthetic organisms and required for their optimal photoautotrophic growth.	[Singh, Abhay K.; Bhattacharyya-Pakrasi, Maitrayee; Pakrasi, Himadri B.] Washington Univ, Dept Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Pakrasi, HB (corresponding author), Washington Univ, Dept Biol, Campus Box 1137,1 Brookings Dr, St Louis, MO 63130 USA.	Pakrasi@wustl.edu						Bader M, 1999, CELL, V98, P217, DOI 10.1016/S0092-8674(00)81016-8; Bader MW, 2001, EMBO J, V20, P1555, DOI 10.1093/emboj/20.7.1555; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; Bartsevich VV, 1999, J BACTERIOL, V181, P3591, DOI 10.1128/JB.181.11.3591-3593.1999; BARTSEVICH VV, 1995, EMBO J, V14, P1845, DOI 10.1002/j.1460-2075.1995.tb07176.x; CLAROS MG, 1994, COMPUT APPL BIOSCI, V10, P685; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; Emanuelsson O, 2000, J MOL BIOL, V300, P1005, DOI 10.1006/jmbi.2000.3903; Frand AR, 1998, MOL CELL, V1, P161, DOI 10.1016/S1097-2765(00)80017-9; Fulda S, 2000, EUR J BIOCHEM, V267, P5900, DOI 10.1046/j.1432-1327.2000.01642.x; Goodstadt L, 2004, TRENDS BIOCHEM SCI, V29, P289, DOI 10.1016/j.tibs.2004.04.004; Gruber CW, 2006, TRENDS BIOCHEM SCI, V31, P455, DOI 10.1016/j.tibs.2006.06.001; Hirani TA, 2001, PLANT MOL BIOL, V45, P133, DOI 10.1023/A:1006425214168; Huang F, 2002, MOL CELL PROTEOMICS, V1, P956, DOI 10.1074/mcp.M200043-MCP200; HUMPHREYS DP, 1995, J BIOL CHEM, V270, P28210; Jonda S, 1999, EMBO J, V18, P3271, DOI 10.1093/emboj/18.12.3271; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; Kadokura H, 2005, J BACTERIOL, V187, P1519, DOI 10.1128/JB.187.4.1519-1522.2005; Kadokura H, 2004, SCIENCE, V303, P534, DOI 10.1126/science.1091724; Kadokura H, 2003, ANNU REV BIOCHEM, V72, P111, DOI 10.1146/annurev.biochem.72.121801.161459; Kouwen TRHM, 2007, MOL MICROBIOL, V64, P984, DOI 10.1111/j.1365-2958.2007.05707.x; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; Merchant SS, 2007, SCIENCE, V318, P245, DOI 10.1126/science.1143609; MISSIAKAS D, 1993, P NATL ACAD SCI USA, V90, P7084, DOI 10.1073/pnas.90.15.7084; MISSIAKAS D, 1994, EMBO J, V13, P2013, DOI 10.1002/j.1460-2075.1994.tb06471.x; MISSIAKAS D, 1995, EMBO J, V14, P3415, DOI 10.1002/j.1460-2075.1995.tb07347.x; Nakamura Y, 2003, DNA RES, V10, P137, DOI 10.1093/dnares/10.4.137; RIPPKA R, 1988, METHOD ENZYMOL, V167, P3; SAMBROOK J, 2000, MOL CLONING LAB MANU; Sevier CS, 2006, ANTIOXID REDOX SIGN, V8, P797, DOI 10.1089/ars.2006.8.797; Sevier CS, 2005, PROTEIN SCI, V14, P1630, DOI 10.1110/ps.051355705; Sevier CS, 2001, NAT CELL BIOL, V3, P874, DOI 10.1038/ncb1001-874; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4; Wajih N, 2007, J BIOL CHEM, V282, P2626, DOI 10.1074/jbc.M608954200	34	57	58	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15762	15770		10.1074/jbc.M800982200	http://dx.doi.org/10.1074/jbc.M800982200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18413314	hybrid, Green Published			2022-12-25	WOS:000256332500033
J	Audet, N; Gales, C; Archer-Lahlou, E; Vallieres, M; Schiller, PW; Bouvier, M; Pineyro, G				Audet, Nicolas; Gales, Celine; Archer-Lahlou, Elodie; Vallieres, Marc; Schiller, Peter W.; Bouvier, Michel; Pineyro, Graciela			Bioluminescence resonance energy transfer assays reveal ligand-specific conformational changes within preformed signaling complexes containing delta-opioid receptors and heterotrimeric G proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA(2) ADRENERGIC-RECEPTOR; FORM STABLE COMPLEXES; ADENYLYL-CYCLASE; LIVING CELLS; COUPLED RECEPTORS; MOLECULAR PHARMACOLOGY; INVERSE-AGONIST; ACTIVATION; TRAFFICKING; EFFICACY	Heptahelical receptors communicate extracellular information to the cytosolic compartment by binding an extensive variety of ligands. They do so through conformational changes that propagate to intracellular signaling partners as' the receptor switches from a resting to an active conformation. This active state has been classically considered unique and responsible for regulation of all signaling pathways controlled by a receptor. However, recent functional studies have challenged this notion and called for a paradigm where receptors would exist in more than one signaling conformation. This study used bioluminescence resonance energy transfer assays in combination with ligands of different functional profiles to provide in vivo physical evidence of conformational diversity of delta-opioid receptors (DORs). DORs and alpha(i1)beta(1)gamma(2) G protein subunits were tagged with Luc or green fluorescent protein to produce bioluminescence resonance energy transfer pairs that allowed monitoring DOR-G protein interactions from different vantage points. Results showed that DORs and heterotrimeric G proteins formed a constitutive complex that underwent structural reorganization upon ligand binding. Conformational rearrangements could not be explained by a two-state model, supporting the idea that DORs adopt ligand-specific conformations. In addition, conformational diversity encoded by the receptor was conveyed to the interaction among heterotrimeric subunits. The existence of multiple active receptor states has implications for the way we conceive specificity of signal transduction.	[Audet, Nicolas; Archer-Lahlou, Elodie; Vallieres, Marc; Pineyro, Graciela] Hop Louis H Lafontaine, Ctr Rech Fernand Seguin, Montreal, PQ H1N 3V2, Canada; [Audet, Nicolas; Archer-Lahlou, Elodie; Schiller, Peter W.] Univ Montreal, Fac Med, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada; [Bouvier, Michel] Univ Montreal, Fac Med, Dept Biochim, Montreal, PQ H3C 3J7, Canada; [Pineyro, Graciela] Univ Montreal, Fac Med, Dept Psychiat, Montreal, PQ H3C 3J7, Canada; [Archer-Lahlou, Elodie; Bouvier, Michel; Pineyro, Graciela] Grp Rech Univ Medicament, Montreal, PQ H3C 3J7, Canada; [Gales, Celine] INSERM, Inst Louis Bugnard, Unite 858, Equipe 8, F-31432 Toulouse, France; [Schiller, Peter W.] Inst Rech Clin Montreal, Lab Chem Biol & Peptide Res, Montreal, PQ 2W 1R7, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal	Pineyro, G (corresponding author), Univ Montreal, Dept Psychiat, 7331 Rue Hochelaga, Montreal, PQ H1N 3V2, Canada.	graciela.pineyro.filpo@umontreal.ca	Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100; Pineyro, Graciela/0000-0001-9709-651X; GALES, Celine/0000-0002-4938-1583	NIDA NIH HHS [R01 DA004443] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004443] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Abramow-Newerly M, 2006, CELL SIGNAL, V18, P579, DOI 10.1016/j.cellsig.2005.08.010; Alves ID, 2003, J BIOL CHEM, V278, P48890, DOI 10.1074/jbc.M306866200; Angers S, 2000, P NATL ACAD SCI USA, V97, P3684, DOI 10.1073/pnas.060590697; Audet N, 2005, J BIOL CHEM, V280, P7808, DOI 10.1074/jbc.M411695200; Ayoub MA, 2007, MOL PHARMACOL, V71, P1329, DOI 10.1124/mol.106.030304; Azzi M, 2003, P NATL ACAD SCI USA, V100, P11406, DOI 10.1073/pnas.1936664100; Berg KA, 1998, MOL PHARMACOL, V54, P94, DOI 10.1124/mol.54.1.94; Bertrand L, 2002, J RECEPT SIGNAL TR R, V22, P533, DOI 10.1081/RRS-120014619; Bourne HR, 1997, CURR OPIN CELL BIOL, V9, P134, DOI 10.1016/S0955-0674(97)80054-3; Breit A, 2006, MOL PHARMACOL, V70, P686, DOI 10.1124/mol.106.022897; Bunemann M, 2003, P NATL ACAD SCI USA, V100, P16077, DOI 10.1073/pnas.2536719100; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; Dupre DJ, 2007, CELL SIGNAL, V19, P481, DOI 10.1016/j.cellsig.2006.07.021; Dupre DJ, 2006, J BIOL CHEM, V281, P34561, DOI 10.1074/jbc.M605012200; Dupre DJ, 2006, CELL SIGNAL, V18, P1549, DOI 10.1016/j.cellsig.2006.03.009; Ford CE, 1998, SCIENCE, V280, P1271, DOI 10.1126/science.280.5367.1271; Frank M, 2005, J BIOL CHEM, V280, P24584, DOI 10.1074/jbc.M414630200; FURCHGOTT RF, 1966, B NEW YORK ACAD MED, V42, P996; Gales C, 2005, NAT METHODS, V2, P177, DOI 10.1038/NMETH743; Gales C, 2006, NAT STRUCT MOL BIOL, V13, P778, DOI 10.1038/nsmb1134; Ghanouni P, 2001, J BIOL CHEM, V276, P24433, DOI 10.1074/jbc.C100162200; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; Kenakin T, 2004, TRENDS PHARMACOL SCI, V25, P186, DOI 10.1016/j.tips.2004.02.012; KOSHLAND DE, 1966, BIOCHEMISTRY-US, V5, P365, DOI 10.1021/bi00865a047; Kreienkamp HJ, 2002, CURR OPIN PHARMACOL, V2, P581, DOI 10.1016/S1471-4892(02)00203-5; Lachance M, 1999, CELL SIGNAL, V11, P523, DOI 10.1016/S0898-6568(99)00024-8; Lavine N, 2002, J BIOL CHEM, V277, P46010, DOI 10.1074/jbc.M205035200; Li JH, 2007, J BIOL CHEM, V282, P26284, DOI 10.1074/jbc.M704875200; Marullo S, 2007, TRENDS PHARMACOL SCI, V28, P362, DOI 10.1016/j.tips.2007.06.007; Mercier JF, 2002, J BIOL CHEM, V277, P44925, DOI 10.1074/jbc.M205767200; Milligan G, 2005, FEBS J, V272, P2914, DOI 10.1111/j.1742-4658.2005.04731.x; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Nobles M, 2005, P NATL ACAD SCI USA, V102, P18706, DOI 10.1073/pnas.0504778102; Ostrom RS, 2004, BRIT J PHARMACOL, V143, P235, DOI 10.1038/sj.bjp.0705930; Petaja-Repo UE, 2000, J BIOL CHEM, V275, P13727, DOI 10.1074/jbc.275.18.13727; Pineyro G, 2005, MOL PHARMACOL, V67, P336, DOI 10.1124/mol.104.004549; Pineyro G, 2001, MOL PHARMACOL, V60, P816; Pineyro G, 2007, CELL SIGNAL, V19, P8, DOI 10.1016/j.cellsig.2006.05.026; Quock RM, 1999, PHARMACOL REV, V51, P503; Rebois RV, 2006, J CELL SCI, V119, P2807, DOI 10.1242/jcs.03021; Roy AA, 2006, CELL SIGNAL, V18, P336, DOI 10.1016/j.cellsig.2005.05.004; Schiller PW, 1999, BIOPOLYMERS, V51, P411, DOI 10.1002/(SICI)1097-0282(1999)51:6<411::AID-BIP4>3.0.CO;2-Z; Selley DE, 1998, J RECEPT SIGNAL TR R, V18, P25, DOI 10.3109/10799899809039163; Sunahara RK, 1997, SCIENCE, V278, P1943, DOI 10.1126/science.278.5345.1943; Urban JD, 2007, J PHARMACOL EXP THER, V320, P1, DOI 10.1124/jpet.106.104463	45	90	91	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15078	15088		10.1074/jbc.M707941200	http://dx.doi.org/10.1074/jbc.M707941200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18381293	Green Published, hybrid			2022-12-25	WOS:000256232000022
J	Lu, LL; Puri, M; Horvath, CM; Sen, GC				Lu, Lenette L.; Puri, Mamta; Horvath, Curt M.; Sen, Ganes C.			Select paramyxoviral v proteins inhibit IRF3 activation by acting as alternative substrates for inhibitor of kappa B kinase is an element of (IKKe)/TBK1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOUBLE-STRANDED-RNA; INTERFERON REGULATORY FACTOR-3; VIRUS-INFECTED CELLS; IFN-BETA PROMOTER; IKK-EPSILON; SIGNAL-TRANSDUCTION; ANTIVIRAL IMMUNITY; VACCINIA VIRUS; RIG-I; RECEPTOR	V accessory proteins from Paramyxoviruses are important in viral evasion of the innate immune response. Here, using a cell survival assay that identifies both inhibitors and activators of interferon regulatory factor 3 (IRF3)-mediated gene induction, we identified select paramyxoviral V proteins that inhibited double-stranded RNA- mediated signaling; these are encoded by mumps virus ( MuV), human parainfluenza virus 2 ( hPIV2), and parainfluenza virus 5 ( PIV5), all members of the genus Rubulavirus. We showed that interaction between V and the IRF3/7 kinases, TRAF family member-associated NF kappa B activator ( TANK)-binding kinase 1 ( TBK1)/inhibitor of kappa B kinase is an element of ( IKKe), was essential for this inhibition. Indeed, V proteins were phosphorylated directly by TBK1/IKKe, and this, intriguingly, resulted in lowering of the cellular level of V. Thus, it appears that V mimics IRF3 in both its phosphorylation by TBK1/IKKe and its subsequent degradation. Finally, a PIV5 mutant encoding a V protein that could not inhibit IKKe was much more susceptible to the antiviral effects of double-stranded RNA than the wild-type virus. Because many innate immune response signaling pathways, including those initiated by TLR3, TLR4, RIG-I, MDA5, and DNA-dependent activator of IRFs (DAI), use TBK1/IKKe as the terminal kinases to activate IRFs, rubulaviral V proteins have the potential to inhibit all of them.	[Lu, Lenette L.; Sen, Ganes C.] Cleveland Clin, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA; [Lu, Lenette L.; Sen, Ganes C.] Case Western Reserve Univ, Sch Med, Grad Program Mol Virol, Cleveland, OH 44106 USA; [Puri, Mamta; Horvath, Curt M.] Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Cleveland Clinic Foundation; Case Western Reserve University; Northwestern University	Sen, GC (corresponding author), Cleveland Clin, Lerner Res Inst, Dept Mol Genet, 9500 Euclid Ave, Cleveland, OH 44195 USA.	seng@ccf.org		Horvath, Curt/0000-0003-2449-225X	NCI NIH HHS [CA 68782, CA 62220] Funding Source: Medline; NIGMS NIH HHS [T32 GM007250, GM 07250] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA062220, R01CA068782] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Andrejeva J, 2004, P NATL ACAD SCI USA, V101, P17264, DOI 10.1073/pnas.0407639101; Bowie A, 2000, P NATL ACAD SCI USA, V97, P10162, DOI 10.1073/pnas.160027697; Bowie AG, 2007, TRENDS IMMUNOL, V28, P147, DOI 10.1016/j.it.2007.02.002; Chariot A, 2002, J BIOL CHEM, V277, P37029, DOI 10.1074/jbc.M205069200; Cheng G, 2006, P NATL ACAD SCI USA, V103, P8499, DOI 10.1073/pnas.0602957103; Childs K, 2007, VIROLOGY, V359, P190, DOI 10.1016/j.virol.2006.09.023; Fitzgerald KA, 2003, NAT IMMUNOL, V4, P491, DOI 10.1038/ni921; Gainey MD, 2008, J VIROL, V82, P828, DOI 10.1128/JVI.02023-07; Garcia-Sastre A, 2004, CURR TOP MICROBIOL, V283, P249; Guo JJ, 2000, VIROLOGY, V267, P209, DOI 10.1006/viro.1999.0135; Haller O, 2006, VIROLOGY, V344, P119, DOI 10.1016/j.virol.2005.09.024; He B, 2002, VIROLOGY, V303, P15, DOI 10.1006/viro.2002.1738; Hiscott J, 2007, J BIOL CHEM, V282, P15325, DOI 10.1074/jbc.R700002200; Horvath CM, 2004, CYTOKINE GROWTH F R, V15, P117, DOI 10.1016/j.cytogfr.2004.02.003; Hovanessian AG, 2007, CYTOKINE GROWTH F R, V18, P351, DOI 10.1016/j.cytogfr.2007.06.003; HU A, 1993, ARCH VIROL, V133, P201, DOI 10.1007/BF01309756; Kumar KGS, 2004, J BIOL CHEM, V279, P46614, DOI 10.1074/jbc.M407082200; Kumar KP, 2000, MOL CELL BIOL, V20, P4159, DOI 10.1128/MCB.20.11.4159-4168.2000; Li K, 2005, P NATL ACAD SCI USA, V102, P2992, DOI 10.1073/pnas.0408824102; Li XX, 1999, MOL CELL BIOL, V19, P4643; Liew FY, 2005, NAT REV IMMUNOL, V5, P446, DOI 10.1038/nri1630; Lin RT, 1998, MOL CELL BIOL, V18, P2986, DOI 10.1128/MCB.18.5.2986; Loo YM, 2006, P NATL ACAD SCI USA, V103, P6001, DOI 10.1073/pnas.0601523103; Lyles D. S., 2007, FIELDS VIROLOGY, V1, P1364; Medzhitov R, 2007, NATURE, V449, P819, DOI 10.1038/nature06246; Mibayashi M, 2007, J VIROL, V81, P514, DOI 10.1128/JVI.01265-06; MULLER M, 1993, EMBO J, V12, P4221, DOI 10.1002/j.1460-2075.1993.tb06106.x; Navarro L, 1999, J BIOL CHEM, V274, P35535, DOI 10.1074/jbc.274.50.35535; Nishio M, 2002, VIROLOGY, V300, P92, DOI 10.1006/viro.2002.1509; Parisien JP, 2002, J VIROL, V76, P4190, DOI 10.1128/JVI.76.9.4190-4198.2002; Paterson RG, 1993, MOL VIROLOGY PRACTIC, P35; Peters KL, 2002, P NATL ACAD SCI USA, V99, P6322, DOI 10.1073/pnas.092133199; Platanias LC, 2005, NAT REV IMMUNOL, V5, P375, DOI 10.1038/nri1604; Poole E, 2002, VIROLOGY, V303, P33, DOI 10.1006/viro.2002.1737; Rodriguez JJ, 2003, J VIROL, V77, P11842, DOI 10.1128/JVI.77.21.11842-11845.2003; Ronco LV, 1998, GENE DEV, V12, P2061, DOI 10.1101/gad.12.13.2061; Sarkar SN, 2003, J BIOL CHEM, V278, P4393, DOI 10.1074/jbc.C200655200; Shaw ML, 2005, J VIROL, V79, P6078, DOI 10.1128/JVI.79.10.6078-6088.2005; Stack J, 2005, J EXP MED, V201, P1007, DOI 10.1084/jem.20041442; Tenoever BR, 2007, SCIENCE, V315, P1274, DOI 10.1126/science.1136567; tenOever BR, 2004, J VIROL, V78, P10636, DOI 10.1128/JVI.78.19.10636-10649.2004; Ulane CM, 2005, J VIROL, V79, P10180, DOI 10.1128/JVI.79.16.10180-10189.2005; Unterstab G, 2005, P NATL ACAD SCI USA, V102, P13640, DOI 10.1073/pnas.0502883102; Wang D, 2004, P NATL ACAD SCI USA, V101, P16642, DOI 10.1073/pnas.0407233101	44	83	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14269	14276		10.1074/jbc.M710089200	http://dx.doi.org/10.1074/jbc.M710089200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18362155	hybrid, Green Published			2022-12-25	WOS:000255941400013
J	Kawakami, R; Dobi, A; Shigemoto, R; Ito, I				Kawakami, Ryosuke; Dobi, Alice; Shigemoto, Ryuichi; Ito, Isao			Right Isomerism of the Brain in Inversus Viscerum Mutant Mice	PLOS ONE			English	Article								Left-right (L-R) asymmetry is a fundamental feature of higher-order neural function. However, the molecular basis of brain asymmetry remains unclear. We recently reported L-R asymmetry of hippocampal circuitry caused by differential allocation of N-methyl-D-aspartate receptor (NMDAR) subunit GluR epsilon 2 (NR2B) in hippocampal synapses. Using electrophysiology and immunocytochemistry, here we analyzed the hippocampal circuitry of the inversus viscerum (iv) mouse that has a randomized laterality of internal organs. The iv mouse hippocampus lacks L-R asymmetry, it exhibits right isomerism in the synaptic distribution of the epsilon 2 subunit, irrespective of the laterality of visceral organs. This independent right isomerism of the hippocampus is the first evidence that a distinct mechanism downstream of the iv mutation generates brain asymmetry.	[Kawakami, Ryosuke; Ito, Isao] Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 812, Japan; [Kawakami, Ryosuke; Dobi, Alice; Shigemoto, Ryuichi] Grad Univ Advanced Stud, Sch Life Sci, Natl Inst Physiol Sci, Div Cerebral Structure, Okazaki, Aichi, Japan; [Shigemoto, Ryuichi] Japan Sci & Technol Agcy, Solution Oriented Res Sci & Technol, Kawaguchi, Japan	Kyushu University; Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Japan Science & Technology Agency (JST)	Ito, I (corresponding author), Kyushu Univ, Fac Sci, Dept Biol, Fukuoka 812, Japan.	isitoscb@mbox.nc.kyushu-u.ac.jp	Kawakami, Ryosuke/AAU-6087-2020; 良介, 川上/E-2029-2012; Shigemoto, Ryuichi/E-3628-2013	Shigemoto, Ryuichi/0000-0001-8761-9444	Solution Oriented Research or Science and Technology from the Japan Science and Technology Corporation; Brain Science Foundation; Yamada Science Foundation; Ministry of Education, Culture, Sports, Science and Technology of Japan [19300114, 17021032, 18019030, 16300101]; Grant-in-Aid for JSPS Fellows; Cooperative Study Program of National Institute for Physiological Sciences	Solution Oriented Research or Science and Technology from the Japan Science and Technology Corporation; Brain Science Foundation; Yamada Science Foundation; Ministry of Education, Culture, Sports, Science and Technology of Japan(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); Grant-in-Aid for JSPS Fellows(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI)); Cooperative Study Program of National Institute for Physiological Sciences	This work was supported by Solution Oriented Research or Science and Technology from the Japan Science and Technology Corporation (R.S. and I.I.), the Brain Science Foundation (I.I.), the Yamada Science Foundation (I.I.), Grant-in-Aid for Scientific Research Grants 19300114 (R.S.), 17021032, 18019030, 16300101 (I.I.) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, Grant-in-Aid for JSPS Fellows (R.K.), and the Cooperative Study Program of National Institute for Physiological Sciences.	Aizawa H, 2005, CURR BIOL, V15, P238, DOI 10.1016/j.cub.2005.01.014; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; Capdevila J, 2000, CELL, V101, P9, DOI 10.1016/S0092-8674(00)80619-4; Chizh BA, 2001, TRENDS PHARMACOL SCI, V22, P636, DOI 10.1016/S0165-6147(00)01863-0; Fischer G, 1997, J PHARMACOL EXP THER, V283, P1285; Gamse JT, 2005, DEVELOPMENT, V132, P4869, DOI 10.1242/dev.02046; Hirokawa N, 2006, CELL, V125, P33, DOI 10.1016/j.cell.2006.03.002; Hummel K. P., 1959, Journal of Heredity, V50, P9; Ito I, 1996, NEUROSCI LETT, V203, P69, DOI 10.1016/0304-3940(95)12258-3; Kawakami R, 2003, SCIENCE, V300, P990, DOI 10.1126/science.1082609; Matsubara A, 1996, J NEUROSCI, V16, P4457; Mutel V, 1998, J NEUROCHEM, V70, P2147; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; Nonaka S, 2002, NATURE, V418, P96, DOI 10.1038/nature00849; Nusser Z, 1998, J NEUROSCI, V18, P1693; Okada Y, 1999, MOL CELL, V4, P459, DOI 10.1016/S1097-2765(00)80197-5; ROGERS LJ, 1988, EXP BRAIN RES, V70, P378; Shiratori H, 2006, DEVELOPMENT, V133, P2095, DOI 10.1242/dev.02384; Sun T, 2005, SCIENCE, V308, P1794, DOI 10.1126/science.1110324; Supp DM, 1999, DEVELOPMENT, V126, P5495; Supp DM, 1997, NATURE, V389, P963, DOI 10.1038/40140; Takeda S, 1999, J CELL BIOL, V145, P825, DOI 10.1083/jcb.145.4.825; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; Wu Y, 2005, J NEUROSCI, V25, P9213, DOI 10.1523/JNEUROSCI.2134-05.2005	24	33	33	0	18	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1945	10.1371/journal.pone.0001945	http://dx.doi.org/10.1371/journal.pone.0001945			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414654	Green Published, Green Submitted, gold			2022-12-25	WOS:000260867300003
J	Syme, AE; Poore, GCB				Syme, Anna E.; Poore, Gary C. B.			A Supplementary Description of Cypridina mariae and Rediagnosis of the Genus Cylindroleberis (Ostracoda: Myodocopa: Cylindroleberididae)	PLOS ONE			English	Article							CRUSTACEA	The ostracod family Cylindroleberididae is based on the genus Cylindroleberis Brady, 1868, and has a complicated nomenclatural history. The type species of Cylindroleberis is Cypridina mariae Baird, 1850. Baird described only the carapace, which had been considered lost. Thus, there was no reference point for the concept C. mariae or the genus Cylindroleberis. Baird's material has now been found in the Natural History Museum, London, U. K., and is illustrated here. To clarify the taxonomic status of C. mariae and Cylindroleberis, specimens were obtained from near the type locality, and a supplementary description is presented. This includes description of appendages, particularly the first antenna and mandible, which contain important diagnostic characters. This supplementary description provides important information about C. mariae, allowing a revision of the genus Cylindroleberis, and establishing a framework for future biological research on this ostracod group.	[Syme, Anna E.; Poore, Gary C. B.] Victoria & Albert Museum, Melbourne, Vic, Australia		Syme, AE (corresponding author), Victoria & Albert Museum, Melbourne, Vic, Australia.	asyme@museum.vic.gov.au		Syme, Anna/0000-0002-9906-0673				Baird W., 1850, P ZOOL SOC LONDON, V18, P254; Brady G.S., 1896, SCI T ROYAL DUBLIN S, V5, P621; Brady G. S., 1868, INTELLECTUAL OBSERVE, V12, P110; BRADY GS, 1868, T LINN SOC LOND, V26, P353, DOI DOI 10.1111/J.1096-3642.1968.TB00199.X; BRADY GS, 1871, P ZOO SOC LOND, V19, P289; Corbari L, 2005, J EXP BIOL, V208, P661, DOI 10.1242/jeb.01427; Cushman Joseph A., 1906, Boston Proc Soc Nat Hist, V32, P359; HARTMANN G, 1984, Mitteilungen aus dem Hamburgischen Zoologischen Museum und Institut, V81, P117; Juday C., 1907, U CALIFORNIA PUBLICA, V3, P135; JUDAY CH, 1906, U CAL PUBL ZOOL, V3; Kornicker L., 1992, SMITHSONIAN CONTRIBU, V531, P1; Kornicker L.S., 1974, Smithsonian Contributions to Zoology, VNo. 178, P1; Kornicker L. S., 1970, Smithson. Contr. Zool., VNo. 39, P1; Kornicker L.S., 1975, Smithsonian Contributions to Zoology, VNo. 163, P1; Kornicker L. S., 1981, SMITHSONIAN CONTRIBU, V319, P1; KORNICKER LS, 1991, SMITHSONIAN CONTRIBU, V505, P1; Kornicker LS, 1976, SMITHSONIAN CONTRIBU, V214, P1; Kornicker LS, 1974, SMITHSON CONTRIB ZOO, V179, P78; MULLER GW, 1912, TIERREICH, V31, pR33; Muller GW, 1906, SIBOGA EXPEDITION, V30; Oakley TH, 2005, HYDROBIOLOGIA, V538, P179, DOI 10.1007/s10750-004-4961-5; PHILIPPI A, 1840, ARCH NATURGESCHICTE, V6, P186; Poulsen EM, 1965, DANA REPORTS; Skogsberg T., 1920, ZOOLOGISKA BIDRAG FR, V1, P784; STRAND EMBRIK, 1928, ARCH NATURGESCH ABT A, V92, P30; Sylvester-Bradley P. C, 1961, TREATISE INVERTEBR Q, P387; Syme AE, 2006, ZOOTAXA, P51, DOI 10.11646/zootaxa.1305.1.5; Syme Anna E., 2006, Museum Victoria Science Reports, V9, P1	28	1	1	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1960	10.1371/journal.pone.0001960	http://dx.doi.org/10.1371/journal.pone.0001960			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414661	Green Published, gold			2022-12-25	WOS:000260867300010
J	Wasserstrom, A; Adar, R; Shefer, G; Frumkin, D; Itzkovitz, S; Stern, T; Shur, I; Zangi, L; Kaplan, S; Harmelin, A; Reisner, Y; Benayahu, D; Tzahor, E; Segal, E; Shapiro, E				Wasserstrom, Adam; Adar, Rivka; Shefer, Gabi; Frumkin, Dan; Itzkovitz, Shalev; Stern, Tomer; Shur, Irena; Zangi, Lior; Kaplan, Shai; Harmelin, Alon; Reisner, Yair; Benayahu, Dafna; Tzahor, Eldad; Segal, Eran; Shapiro, Ehud			Reconstruction of Cell Lineage Trees in Mice	PLOS ONE			English	Article							DNA MISMATCH-REPAIR; SELF-RENEWAL; BONE-MARROW; FATE; PROGENITORS; POPULATION; NEMATODE	The cell lineage tree of a multicellular organism represents its history of cell divisions from the very first cell, the zygote. A new method for high-resolution reconstruction of parts of such cell lineage trees was recently developed based on phylogenetic analysis of somatic mutations accumulated during normal development of an organism. In this study we apply this method in mice to reconstruct the lineage trees of distinct cell types. We address for the first time basic questions in developmental biology of higher organisms, namely what is the correlation between the lineage relation among cells and their (1) function, (2) physical proximity and (3) anatomical proximity. We analyzed B-cells, kidney-, mesenchymal- and hematopoietic-stem cells, as well as satellite cells, which are adult skeletal muscle stem cells isolated from their niche on the muscle fibers (myofibers) from various skeletal muscles. Our results demonstrate that all analyzed cell types are intermingled in the lineage tree, indicating that none of these cell types are single exclusive clones. We also show a significant correlation between the physical proximity of satellite cells within muscles and their lineage. Furthermore, we show that satellite cells obtained from a single myofiber are significantly clustered in the lineage tree, reflecting their common developmental origin. Lineage analysis based on somatic mutations enables performing high resolution reconstruction of lineage trees in mice and humans, which can provide fundamental insights to many aspects of their development and tissue maintenance.	[Wasserstrom, Adam; Adar, Rivka; Frumkin, Dan; Kaplan, Shai; Shapiro, Ehud] Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel; [Itzkovitz, Shalev; Stern, Tomer; Segal, Eran; Shapiro, Ehud] Weizmann Inst Sci, Dept Comp Sci & Appl Math, Rehovot, Israel; [Shur, Irena; Zangi, Lior; Reisner, Yair; Tzahor, Eldad] Weizmann Inst Sci, Dept Immunol, Rehovot, Israel; [Harmelin, Alon] Weizmann Inst Sci, Dept Vet Resources, Rehovot, Israel; [Shefer, Gabi; Benayahu, Dafna] Tel Aviv Univ, Sackler Sch Med, Dept Cell & Dev Biol, Tel Aviv, Israel	Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Weizmann Institute of Science; Tel Aviv University; Sackler Faculty of Medicine	Wasserstrom, A (corresponding author), Weizmann Inst Sci, Dept Biol Chem, IL-76100 Rehovot, Israel.	Ehud.Shapiro@weizmann.ac.il	Segal, Eran/AAF-4855-2019; Reisner, Yair/AAA-4772-2019; TZAHOR, ELDAD/AAD-9886-2021	Segal, Eran/0000-0002-6859-1164; Reisner, Yair/0000-0002-3354-6945; Stern, Tomer/0000-0003-4279-3558	Israel Academy of Science and Humanities (Bikura); Yeshaya Horowitz association through the center for Complexity Science; Kenneth and Sally Leafman Appelbaum Discovery Fund; Estate of Karl Felix Jakubskind; Clore Center for Biological Physics; Louis Chor Memorial Trust	Israel Academy of Science and Humanities (Bikura); Yeshaya Horowitz association through the center for Complexity Science; Kenneth and Sally Leafman Appelbaum Discovery Fund; Estate of Karl Felix Jakubskind; Clore Center for Biological Physics; Louis Chor Memorial Trust	This research was supported by The Israel Academy of Science and Humanities (Bikura), by The Yeshaya Horowitz association through the center for Complexity Science, by The Research Grant from Dr. Mordecai Roshwald, by The Grant from Kenneth and Sally Leafman Appelbaum Discovery Fund, by The Estate of Karl Felix Jakubskind, by The Clore Center for Biological Physics, and by a Research Grant from The Louis Chor Memorial Trust.	Baker SM, 1996, NAT GENET, V13, P336, DOI 10.1038/ng0796-336; BENAYAHU D, 1991, CALCIFIED TISSUE INT, V49, P202, DOI 10.1007/BF02556119; CAIRNS J, 1975, NATURE, V255, P197, DOI 10.1038/255197a0; CHISHOLM A, 2000, ENCY GENETICS; Clarke JDW, 1999, NAT CELL BIOL, V1, pE103, DOI 10.1038/12105; Cobaleda C, 2007, NAT IMMUNOL, V8, P463, DOI 10.1038/ni1454; Collins CA, 2005, CELL CYCLE, V4, P1338, DOI 10.4161/cc.4.10.2114; Collins CA, 2005, CELL, V122, P289, DOI 10.1016/j.cell.2005.05.010; De Angelis L, 1999, J CELL BIOL, V147, P869, DOI 10.1083/jcb.147.4.869; Dekel B, 2006, J AM SOC NEPHROL, V17, P3300, DOI 10.1681/ASN.2005020195; DEKEL N, 1988, ANN NY ACAD SCI, V541, P211, DOI 10.1111/j.1749-6632.1988.tb22258.x; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Frumkin D, 2005, PLOS COMPUT BIOL, V1, P382, DOI 10.1371/journal.pcbi.0010050; Frumkin D, 2008, BMC BIOTECHNOL, V8, DOI 10.1186/1472-6750-8-17; GRAUR D, 2000, FUNDAMENTALS MOL EVO; Gros J, 2005, NATURE, V435, P954, DOI 10.1038/nature03572; HERMISTON ML, 1993, P NATL ACAD SCI USA, V90, P8866, DOI 10.1073/pnas.90.19.8866; Irvine KD, 2001, ANNU REV CELL DEV BI, V17, P189, DOI 10.1146/annurev.cellbio.17.1.189; Kassar-Duchossoy L, 2005, GENE DEV, V19, P1426, DOI 10.1101/gad.345505; Lasken RS, 2003, TRENDS BIOTECHNOL, V21, P531, DOI 10.1016/j.tibtech.2003.09.010; LAWSON KA, 1991, DEVELOPMENT, V113, P891; Liu ZD, 2000, J CELL BIOCHEM, V76, P509, DOI 10.1002/(SICI)1097-4644(20000301)76:3<509::AID-JCB17>3.0.CO;2-R; Mathis L, 2002, TRENDS GENET, V18, P627, DOI 10.1016/S0168-9525(02)02806-8; NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840; OHLEN C, 1990, J IMMUNOL, V145, P52; Pal R, 2007, STEM CELLS DEV, V16, P3, DOI 10.1089/scd.2006.0109; Relaix F, 2005, NATURE, V435, P948, DOI 10.1038/nature03594; Salipante SJ, 2006, P NATL ACAD SCI USA, V103, P5448, DOI 10.1073/pnas.0601265103; Salipante SJ, 2007, CURR TOP DEV BIOL, V79, P157, DOI 10.1016/S0070-2153(06)79006-8; Shefer G, 2004, J CELL SCI, V117, P5393, DOI 10.1242/jcs.01419; SLACK JMW, 2000, NATURE GENETICS, V24; Stent GS, 1998, INT J DEV BIOL, V42, P237; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; Vilkki S, 2001, CANCER RES, V61, P4541; WALSH C, 1992, SCIENCE, V255, P434, DOI 10.1126/science.1734520; WASSERSTROM A, 2008, PLOS COMPUT IN PRESS; Wei K, 2002, TRENDS MOL MED, V8, P346, DOI 10.1016/S1471-4914(02)02359-6	38	40	41	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1939	10.1371/journal.pone.0001939	http://dx.doi.org/10.1371/journal.pone.0001939			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398465	Green Published, gold			2022-12-25	WOS:000260795500016
J	Neznanov, N; Dragunsky, EM; Chumakov, KM; Neznanova, L; Wek, RC; Gudkov, AV; Banerjee, AK				Neznanov, Nickolay; Dragunsky, Eugenia M.; Chumakov, Konstantin M.; Neznanova, Lubov; Wek, Ronald C.; Gudkov, Andrei V.; Banerjee, Amiya K.			Different Effect of Proteasome Inhibition on Vesicular Stomatitis Virus and Poliovirus Replication	PLOS ONE			English	Article								Proteasome activity is an important part of viral replication. In this study, we examined the effect of proteasome inhibitors on the replication of vesicular stomatitis virus (VSV) and poliovirus. We found that the proteasome inhibitors significantly suppressed VSV protein synthesis, virus accumulation, and protected infected cells from toxic effect of VSV replication. In contrast, poliovirus replication was delayed, but not diminished in the presence of the proteasome inhibitors MG132 and Bortezomib. We also found that inhibition of proteasomes stimulated stress-related processes, such as accumulation of chaperone hsp70, phosphorylation of eIF2 alpha, and overall inhibition of translation. VSV replication was sensitive to this stress with significant decline in replication process. Poliovirus growth was less sensitive with only delay in replication. Inhibition of proteasome activity suppressed cellular and VSV protein synthesis, but did not reduce poliovirus protein synthesis. Protein kinase GCN2 supported the ability of proteasome inhibitors to attenuate general translation and to suppress VSV replication. We propose that different mechanisms of translational initiation by VSV and poliovirus determine their sensitivity to stress induced by the inhibition of proteasomes. To our knowledge, this is the first study that connects the effect of stress induced by proteasome inhibition with the efficiency of viral infection.	[Neznanov, Nickolay; Neznanova, Lubov; Banerjee, Amiya K.] Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, Cleveland, OH 44195 USA; [Dragunsky, Eugenia M.; Chumakov, Konstantin M.] FDA, Ctr Biol Evaluat & Res, Rockville, MD USA; [Wek, Ronald C.] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN USA; [Gudkov, Andrei V.] Roswell Park Canc Inst, Dept Cell Stress Biol, Buffalo, NY USA; [Gudkov, Andrei V.] Cleveland Biolabs Inc, Buffalo, NY USA	Cleveland Clinic Foundation; US Food & Drug Administration (FDA); Indiana University System; Indiana University-Purdue University Indianapolis; Roswell Park Cancer Institute	Neznanov, N (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Mol Genet, 9500 Euclid Ave, Cleveland, OH 44195 USA.	neznann@ccf.org		Gudkov, Andrei/0000-0003-2548-0154	NIH [AI26585, CA60730, CA88071]; Lerner Research Institute; NATIONAL CANCER INSTITUTE [R01CA088071, R01CA060730] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026585] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Lerner Research Institute; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This work was supported by the grant from NIH to Amiya K. Banerjee (AI26585), by the grants from NIH to Andrei V. Gudkov (CA60730 and CA88071), and funds provided by Lerner Research Institute to Nickolay Neznanov.	Ahmed M, 1998, J VIROL, V72, P8413, DOI 10.1128/JVI.72.10.8413-8419.1998; Ahmed M, 2003, J VIROL, V77, P4646, DOI 10.1128/JVI.77.8.4646-4657.2003; Barik S, 2004, VIRUS RES, V102, P27, DOI 10.1016/j.virusres.2004.01.012; Berlanga JJ, 2006, EMBO J, V25, P1730, DOI 10.1038/sj.emboj.7601073; BONNEAU AM, 1985, J CELL BIOL, V100, P1209, DOI 10.1083/jcb.100.4.1209; Bordeleau ME, 2006, NAT CHEM BIOL, V2, P213, DOI 10.1038/nchembio776; BREZINA R, 1975, ACTA VIROL, V19, P496; BUCKLEY B, 1987, J BIOL CHEM, V262, P13599; Caraglia M, 2005, J CELL PHYSIOL, V202, P323, DOI 10.1002/jcp.20137; Clemens MJ, 2005, SEMIN CELL DEV BIOL, V16, P13, DOI 10.1016/j.semcdb.2004.11.011; COLL JM, 1995, ARCH VIROL, V140, P827, DOI 10.1007/BF01314961; Connor JH, 2005, J BIOL CHEM, V280, P13512, DOI 10.1074/jbc.M501156200; Cowan JL, 2004, EUR J BIOCHEM, V271, P3596, DOI 10.1111/j.0014-2956.2004.04306.x; Desforges M, 2001, VIRUS RES, V76, P87, DOI 10.1016/S0168-1702(01)00251-9; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Esser C, 2004, BBA-MOL CELL RES, V1695, P171, DOI 10.1016/j.bbamcr.2004.09.020; Fernandez J, 2002, J BIOL CHEM, V277, P19198, DOI 10.1074/jbc.M201052200; FRIELLE DW, 1989, VIROLOGY, V172, P274, DOI 10.1016/0042-6822(89)90129-3; Gaccioli F, 2006, J BIOL CHEM, V281, P17929, DOI 10.1074/jbc.M600341200; Harty RN, 2001, J VIROL, V75, P10623, DOI 10.1128/JVI.75.22.10623-10629.2001; Hatakeyama S, 2003, J BIOCHEM, V134, P1, DOI 10.1093/jb/mvg106; He B, 2006, CELL DEATH DIFFER, V13, P393, DOI 10.1038/sj.cdd.4401833; HELLEN CUT, 1991, J VIROL, V65, P4226, DOI 10.1128/JVI.65.8.4226-4231.1991; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Hinault MP, 2006, J MOL NEUROSCI, V30, P249, DOI 10.1385/JMN:30:3:249; Holcik M, 2005, NAT REV MOL CELL BIO, V6, P318, DOI 10.1038/nrm1618; Holmberg CI, 2000, CELL STRESS CHAPERON, V5, P219, DOI 10.1379/1466-1268(2000)005<0219:FONHGV>2.0.CO;2; Imai J, 2003, CELL CYCLE, V2, P585, DOI 10.4161/cc.2.6.586; Jackson RJ, 2005, BIOCHEM SOC T, V33, P1231, DOI 10.1042/BST0331231; Jiang HY, 2005, J BIOL CHEM, V280, P14189, DOI 10.1074/jbc.M413660200; Johannes G, 1998, RNA, V4, P1500, DOI 10.1017/S1355838298981080; KAPLAN G, 1985, P NATL ACAD SCI USA, V82, P8424, DOI 10.1073/pnas.82.24.8424; Karin M, 2000, ANNU REV IMMUNOL, V18, P621, DOI 10.1146/annurev.immunol.18.1.621; Klinger Patricia P, 2005, Expert Rev Anti Infect Ther, V3, P61, DOI 10.1586/14787210.3.1.61; Kloetzel PM, 2001, NAT REV MOL CELL BIO, V2, P179, DOI 10.1038/35056572; Komar AA, 2005, J BIOL CHEM, V280, P23425, DOI 10.1074/jbc.R400041200; KRAUSSLICH HG, 1987, J VIROL, V61, P2711; Krebs DL, 2001, STEM CELLS, V19, P378, DOI 10.1634/stemcells.19-5-378; LLOYD RE, 1988, J VIROL, V62, P4216, DOI 10.1128/JVI.62.11.4216-4223.1988; Luo HL, 2003, AM J PATHOL, V163, P381, DOI 10.1016/S0002-9440(10)63667-X; Mathur M, 1996, J VIROL, V70, P2252, DOI 10.1128/JVI.70.4.2252-2259.1996; Melnick J L, 1970, CRC Crit Rev Clin Lab Sci, V1, P87, DOI 10.3109/10408367009014720; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Molina S, 2007, VIROLOGY, V363, P430, DOI 10.1016/j.virol.2007.02.001; Neznanov N, 2005, J BIOL CHEM, V280, P24153, DOI 10.1074/jbc.M502303200; Neznanov N, 2001, J VIROL, V75, P10409, DOI 10.1128/JVI.75.21.10409-10420.2001; ONEILL RE, 1989, J VIROL, V63, P5069, DOI 10.1128/JVI.63.12.5069-5075.1989; Ott DE, 2003, J VIROL, V77, P3384, DOI 10.1128/JVI.77.6.3384-3393.2003; Pickering BM, 2005, SEMIN CELL DEV BIOL, V16, P39, DOI 10.1016/j.semcdb.2004.11.006; Proud CG, 2005, SEMIN CELL DEV BIOL, V16, P3, DOI 10.1016/j.semcdb.2004.11.004; Qian SB, 2006, J BIOL CHEM, V281, P392, DOI 10.1074/jbc.M509126200; Rahmani M, 2005, J BIOL CHEM, V280, P35217, DOI 10.1074/jbc.M506551200; Robert F, 2006, MOL BIOL CELL, V17, P4632, DOI 10.1091/mbc.E06-06-0478; Roos-Mattjus P, 2004, ANN MED, V36, P285, DOI 10.1080/07853890310016324; Rubtsova MP, 2003, J BIOL CHEM, V278, P22350, DOI 10.1074/jbc.M303213200; Sasaki J, 1999, J VIROL, V73, P1219, DOI 10.1128/JVI.73.2.1219-1226.1999; SCHMID M, 1994, ARCH VIROL, P279; Shackelford J, 2005, ESSAYS BIOCHEM, V41, P139, DOI 10.1042/EB0410139; SLEAT DE, 1993, J VIROL, V67, P1334, DOI 10.1128/JVI.67.3.1334-1339.1993; Spataro V, 1998, BRIT J CANCER, V77, P448, DOI 10.1038/bjc.1998.71; Thomas M, 1999, ONCOGENE, V18, P7690, DOI 10.1038/sj.onc.1202953; Wang JS, 2006, CELL MOL IMMUNOL, V3, P255; Watanabe H, 2005, MICROBIOL IMMUNOL, V49, P835, DOI 10.1111/j.1348-0421.2005.tb03672.x; Weissman AM, 2001, NAT REV MOL CELL BIO, V2, P169, DOI 10.1038/35056563; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Wilson JE, 2000, MOL CELL BIOL, V20, P4990, DOI 10.1128/MCB.20.14.4990-4999.2000; Yang Q, 1997, NUCLEIC ACIDS RES, V25, P2800, DOI 10.1093/nar/25.14.2800; YU SF, 1991, VIROLOGY, V182, P615, DOI 10.1016/0042-6822(91)90602-8; Yuan H, 1998, VIROLOGY, V251, P383, DOI 10.1006/viro.1998.9413; Yuan H, 2001, J VIROL, V75, P4453, DOI 10.1128/JVI.75.9.4453-4458.2001; Zhang HG, 2004, ONCOGENE, V23, P2009, DOI 10.1038/sj.onc.1207373	71	34	34	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1887	10.1371/journal.pone.0001887	http://dx.doi.org/10.1371/journal.pone.0001887			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382670	Green Published, gold, Green Submitted			2022-12-25	WOS:000260795400021
J	Spadaro, M; Caorsi, C; Ceruti, P; Varadhachary, A; Forni, G; Pericle, F; Giovarelli, M				Spadaro, Michela; Caorsi, Cristiana; Ceruti, Patrizia; Varadhachary, Atul; Forni, Guido; Pericle, Federica; Giovarelli, Mirella			Lactoferrin, a major defense protein of innate immunity, is a novel maturation factor for human dendritic cells	FASEB JOURNAL			English	Article						adaptive immunity; antigen presentation; T-cell activation	RECEPTOR-RELATED PROTEIN; BOVINE LACTOFERRIN; T-LYMPHOCYTES; IN-VIVO; BINDING; LIPOPOLYSACCHARIDE; ACTIVATION; CYTOKINES; RESPONSES; SURVIVAL	Lactoferrin (LF) is an important protein component of the innate immune system that is broadly distributed within the body fluids. LF is endowed with multiple biological activities. Talactoferrin (TLF), a recombinant human LF, is in clinical development as an anticancer agent and is entering Phase III clinical trials. Here, we show that TLF induces the maturation of human dendritic cells (DCs) derived from monocytes. TLF, at physiologically relevant concentrations ( 100 mu g/ml) up-regulates the expression of human leukocyte antigen (HLA) class II, CD83, CD80, and CD86 costimulatory molecule and CXCR4 and CCR7 chemokine receptors, acting primarily through the p38 MAPK signaling pathway. DCs matured by TLF displayed an enhanced release of IL-8 and CXCL10, as well as a significantly reduced production of IL-6, IL-10, and CCL20. They also display a reduced ability to take up antigen and increased capacity to trigger proliferation and release IFN-gamma in the presence of allogeneic human T cells. TLF-matured DCs are able to prime naive T cells to respond to KLH antigen and display a significantly increased capacity to present Flu-MA(58-66) peptide to HLA-A2-matched T cells. These data suggest that a key immunomodulatory function that may be mediated by TLF is to link the innate with adaptive immunity through DC maturation.	[Caorsi, Cristiana; Ceruti, Patrizia; Giovarelli, Mirella] Univ Turin, Dept Med & Expt Oncol, Ctr Expt Res & Med Studies, I-10126 Turin, Italy; [Spadaro, Michela; Forni, Guido] Univ Turin, Dept Clin & Biol Sci, Ctr Mol Biotechnol, I-10126 Turin, Italy; [Varadhachary, Atul; Pericle, Federica] Agennix Inc, Houston, TX USA	University of Turin; University of Turin	Giovarelli, M (corresponding author), Univ Turin, Dept Med & Expt Oncol, Ctr Expt Res & Med Studies, Corso Raffaello 30, I-10126 Turin, Italy.	mirella.giovarelli@unito.it	Spadaro, Michela/F-1399-2016	Giovarelli, Mirella/0000-0002-7397-3466; Spadaro, Michela/0000-0001-7544-8879				Aerts-Toegaert C, 2007, EUR J IMMUNOL, V37, P686, DOI 10.1002/eji.200636535; Ardeshna KM, 2000, BLOOD, V96, P1039, DOI 10.1182/blood.V96.3.1039.015k04_1039_1046; Arrighi JF, 2001, J IMMUNOL, V166, P3837, DOI 10.4049/jimmunol.166.6.3837; Baker EN, 2005, CELL MOL LIFE SCI, V62, P2531, DOI 10.1007/s00018-005-5368-9; Biragyn A, 2002, SCIENCE, V298, P1025, DOI 10.1126/science.1075565; BIRGENS HS, 1994, ADV EXP MED BIOL, V357, P99; CHIAPPA M, 2007, J EXP MED, V203, P2847; Chorny A, 2006, ANN NY ACAD SCI, V1088, P187, DOI 10.1196/annals.1366.004; COLOMBO MP, 1992, CANCER RES, V52, P4853; Curran CS, 2006, CELL IMMUNOL, V242, P23, DOI 10.1016/j.cellimm.2006.08.006; Edde L, 2001, AM J PHYSIOL-GASTR L, V281, pG1140, DOI 10.1152/ajpgi.2001.281.5.G1140; FABER JM, 1997, J LEUKOCYTE BIOL, V61, P246; Fillebeen C, 1999, J BIOL CHEM, V274, P7011, DOI 10.1074/jbc.274.11.7011; Fischer R, 2006, BIOCHEM CELL BIOL, V84, P303, DOI 10.1139/O06-058; Fujii SI, 2004, J EXP MED, V199, P1607, DOI 10.1084/jem.20040317; GAHR M, 1991, J LEUKOCYTE BIOL, V49, P427, DOI 10.1002/jlb.49.5.427; Gliemann J, 1998, BIOL CHEM, V379, P951; Grey A, 2004, MOL ENDOCRINOL, V18, P2268, DOI 10.1210/me.2003-0456; Groot F, 2005, J VIROL, V79, P3009, DOI 10.1128/JVI.79.5.3009-3015.2005; Guillen C, 2002, J IMMUNOL, V168, P3950, DOI 10.4049/jimmunol.168.8.3950; Hanson L A, 1995, Pediatr Allergy Immunol, V6 Suppl 8, P7; Hayes TG, 2006, INVEST NEW DRUG, V24, P233, DOI 10.1007/s10637-005-3690-6; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hirano N, 2006, BLOOD, V107, P1528, DOI 10.1182/blood-2005-05-2073; Huang RQ, 2007, J BIOMED SCI, V14, P121, DOI 10.1007/s11373-006-9121-7; Humrich JY, 2006, IMMUNOLOGY, V117, P238, DOI 10.1111/j.1365-2567.2005.02292.x; Kane SV, 2003, AM J GASTROENTEROL, V98, P1309, DOI 10.1016/S0002-9270(03)00232-6; Kanyshkova TG, 2001, BIOCHEMISTRY-MOSCOW+, V66, P1, DOI 10.1023/A:1002817226110; Kim KD, 2006, EXP MOL MED, V38, P72, DOI 10.1038/emm.2006.9; Langenkamp A, 2000, NAT IMMUNOL, V1, P311, DOI 10.1038/79758; Legrand D, 2005, CELL MOL LIFE SCI, V62, P2549, DOI 10.1007/s00018-005-5370-2; LEVAY PF, 1995, HAEMATOLOGICA, V80, P252; MAZURIER J, 1994, ADV EXP MED BIOL, V357, P111; MEILINGER M, 1995, FEBS LETT, V360, P70, DOI 10.1016/0014-5793(95)00082-K; Mincheva-Nilsson L, 1997, SCAND J IMMUNOL, V46, P609, DOI 10.1046/j.1365-3083.1997.d01-165.x; Moser M, 2000, NAT IMMUNOL, V1, P199, DOI 10.1038/79734; NIJMAN HW, 1995, J EXP MED, V182, P163, DOI 10.1084/jem.182.1.163; Paesano R, 2006, BIOCHEM CELL BIOL, V84, P377, DOI 10.1139/O06-040; Rescigno M, 1998, J EXP MED, V188, P2175, DOI 10.1084/jem.188.11.2175; SALLUSTO F, 1995, J EXP MED, V182, P389, DOI 10.1084/jem.182.2.389; SHAU HY, 1992, J LEUKOCYTE BIOL, V51, P343, DOI 10.1002/jlb.51.4.343; Sorg RV, 2003, J IMMUNOTHER, V26, P374, DOI 10.1097/00002371-200307000-00010; Sozzani S, 1998, J IMMUNOL, V161, P1083; Spadaro M, 2007, CANCER RES, V67, P6425, DOI 10.1158/0008-5472.CAN-06-4080; SRINIVAS S, 2006, ASCO ANNU MEET P I, V24, P4600; Suzuki YA, 2005, CELL MOL LIFE SCI, V62, P2560, DOI 10.1007/s00018-005-5371-1; Suzuki YA, 2001, BIOCHEMISTRY-US, V40, P15771, DOI 10.1021/bi0155899; Takayama Y, 2003, J BIOL CHEM, V278, P22112, DOI 10.1074/jbc.M300894200; Thomas LL, 2002, J IMMUNOL, V169, P993, DOI 10.4049/jimmunol.169.2.993; Troost FJ, 2002, J NUTR, V132, P2597, DOI 10.1093/jn/132.9.2597; Tsuda H, 2002, BIOCHEM CELL BIOL, V80, P131, DOI 10.1139/o01-239; Ueno H, 2006, CANCER SCI, V97, P1105, DOI 10.1111/j.1349-7006.2006.00274.x; Varadhachary A, 2004, INT J CANCER, V111, P398, DOI 10.1002/ijc.20271; WANG Y, 2006, ASCO ANN M P, V24, P7095; Ward PP, 2005, CELL MOL LIFE SCI, V62, P2540, DOI 10.1007/s00018-005-5369-8; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WRIGHT DG, 1979, J IMMUNOL, V123, P285; Yoneyama H, 2002, J EXP MED, V195, P1257, DOI 10.1084/jem.20011983; Zhu KJ, 2000, CHINESE MED J-PEKING, V113, P1124; Zimecki M, 2002, IMMUNOBIOLOGY, V205, P120, DOI 10.1078/0171-2985-00115	60	101	108	0	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2747	2757		10.1096/fj.07-098038	http://dx.doi.org/10.1096/fj.07-098038			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18364398				2022-12-25	WOS:000258089300015
J	Rybin, VO; Guo, JF; Gertsberg, Z; Feinmark, SJ; Steinberg, SF				Rybin, Vitalyi O.; Guo, Jianfen; Gertsberg, Zoya; Feinmark, Steven J.; Steinberg, Susan F.			Phorbol 12-myristate 13-acetate-dependent protein kinase C delta-Tyr(311) phosphorylation in cardiomyocyte caveolae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE-C-DELTA; ACTIVATION LOOP PHOSPHORYLATION; PROTEIN-COUPLED-RECEPTOR; FOCAL ADHESION KINASE; GROWTH-FACTOR; PKC-DELTA; TYROSINE KINASE; SIGNAL-TRANSDUCTION; SRC; ENDOTHELIN	Protein kinase C delta(PKC delta) activation is generally attributed to lipid cofactor-dependent allosteric activation mechanisms at membranes. However, recent studies indicate that PKC delta also is dynamically regulated through tyrosine phosphorylation in H2O2- and phorbol 12-myristate 13-acetate (PMA)-treated cardiomyocytes. H2O2 activates Src and related Src-family kinases (SFKs), which function as dual PKC delta-Tyr(311) and -Tyr(332) kinases in vitro and contribute to H2O2- dependent PKC delta-Tyr(311)/Tyr(332) phosphorylation in cardiomyocytes and in mouse embryo fibroblasts. H2O2- dependent PKC delta-Tyr(311)/Tyr(332) phosphorylation is defective in SYF cells ( deficient in SFKs) and restored by Src re-expression. PMA also promotes PKC delta-Tyr(311) phosphorylation, but this is not associated with SFK activation or PKC delta-Tyr(332) phosphorylation. Rather, PMA increases PKC delta-Tyr(311) phosphorylation by delivering PKC delta to SFK-enriched caveolae. Cyclodextrin treatment disrupts caveolae and blocks PMA-dependent PKC delta-Tyr(311) phosphorylation, without blocking H2O2 dependent PKC delta-Tyr(311) phosphorylation. The enzyme that acts as a PKC delta-Tyr(311) kinase without increasing PKC delta phosphorylation at Tyr(332) in PMA-treated cardiomyocytes is uncertain. Although in vitro kinase assays implicate c-Abl as a selective PKC delta-Tyr(311) kinase, PMA-dependent PKC delta-Tyr(311) phosphorylation persists in cardiomyocytes treated with the c-Abl inhibitor ST1571 and c-Abl is not detected in caveolae; these results effectively exclude a c-Abl-dependent process. Finally, we show that 1,2-dioleoyl-sn-glycerol mimics the effect of PMA to drive PKC delta to caveolae and increase PKC delta-Tyr(311) phosphorylation, whereas G protein-coupled receptor agonists such as norepinephrine and endothelin-1 do not. These results suggest that norepinephrine and endothelin-1 increase 1,2-dioleoyl-sn-glycerol accumulation and activate PKC delta exclusively in non-caveolae membranes. Collectively, these results identify stimulus-specific PKC delta localization and tyrosine phosphorylation mechanisms that could be targeted for therapeutic advantage.	[Rybin, Vitalyi O.; Guo, Jianfen; Gertsberg, Zoya; Feinmark, Steven J.; Steinberg, Susan F.] Columbia Univ, Dept Pharmacol, Coll Phys & Surg, New York, NY 10032 USA	Columbia University	Steinberg, SF (corresponding author), 630 West 168 St, New York, NY 10032 USA.	sfs1@columbia.edu			NHLBI NIH HHS [HL 77860, R01 HL077860] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL077860] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abu-Ghazaleh R, 2001, BIOCHEM J, V360, P255, DOI 10.1042/0264-6021:3600255; Arimoto T, 2006, CIRCULATION, V113, P60, DOI 10.1161/CIRCULATIONAHA.105.560771; Boivin B, 2005, J MOL CELL CARDIOL, V38, P665, DOI 10.1016/j.yjmcc.2005.02.011; Buchdunger E, 2000, J PHARMACOL EXP THER, V295, P139; Cary LA, 2002, MOL CELL BIOL, V22, P2427, DOI 10.1128/MCB.22.8.2427-2440.2002; Cheng N, 2007, J IMMUNOL, V179, P7720, DOI 10.4049/jimmunol.179.11.7720; Choi SY, 2006, J BIOL CHEM, V281, P7049, DOI 10.1074/jbc.M512000200; CHUN MY, 1994, P NATL ACAD SCI USA, V91, P11728, DOI 10.1073/pnas.91.24.11728; Clarke CJ, 2007, AM J PHYSIOL-HEART C, V292, pH2248, DOI 10.1152/ajpheart.01170.2006; Fujita T, 2001, CARDIOVASC RES, V51, P709, DOI 10.1016/S0008-6363(01)00348-0; Georgiou G, 2003, SCIENCE, V300, P592, DOI 10.1126/science.1084976; Huang Y, 2007, CIRCULATION, V115, P763, DOI 10.1161/CIRCULATIONAHA.106.664862; Jiang K, 2008, BIOCHEMISTRY-US, V47, P787, DOI 10.1021/bi7019782; Kaul S, 2005, J BIOL CHEM, V280, P28721, DOI 10.1074/jbc.M501092200; Kemp TJ, 2003, BIOCHEM BIOPH RES CO, V307, P416, DOI 10.1016/S0006-291X(03)01215-4; Konishi H, 2001, P NATL ACAD SCI USA, V98, P6587, DOI 10.1073/pnas.111158798; KOVALENKO M, 1994, CANCER RES, V54, P6106; Kwon SH, 2003, J MOL CELL CARDIOL, V35, P615, DOI 10.1016/S0022-2828(03)00084-1; LAU YH, 1980, CIRC RES, V47, P41, DOI 10.1161/01.RES.47.1.41; Le Good JA, 1998, SCIENCE, V281, P2042, DOI 10.1126/science.281.5385.2042; Lee H, 2001, J BIOL CHEM, V276, P35150, DOI 10.1074/jbc.M104530200; Lee YJ, 2005, ONCOGENE, V24, P3715, DOI 10.1038/sj.onc.1208440; Leitges M, 2002, MOL CELL BIOL, V22, P3970, DOI 10.1128/MCB.22.12.3970-3980.2002; Liu Y, 2006, J BIOL CHEM, V281, P12102, DOI 10.1074/jbc.M600508200; Lu W, 2007, CELL SIGNAL, V19, P2165, DOI 10.1016/j.cellsig.2007.06.015; Lu W, 2007, BIOCHEM BIOPH RES CO, V352, P431, DOI 10.1016/j.bbrc.2006.11.028; Markou T, 2006, J BIOL CHEM, V281, P8321, DOI 10.1074/jbc.M508398200; Masterson LR, 2008, P NATL ACAD SCI USA, V105, P506, DOI 10.1073/pnas.0709214104; Morita M, 2008, J BIOCHEM, V143, P31, DOI 10.1093/jb/mvm190; Morris DP, 2008, J BIOL CHEM, V283, P2973, DOI 10.1074/jbc.M705795200; Oh P, 2001, MOL BIOL CELL, V12, P685, DOI 10.1091/mbc.12.3.685; Pike LJ, 1996, J BIOL CHEM, V271, P26453, DOI 10.1074/jbc.271.43.26453; Rozengurt E, 2007, J CELL PHYSIOL, V213, P589, DOI 10.1002/jcp.21246; Rybin VO, 2007, J BIOL CHEM, V282, P23631, DOI 10.1074/jbc.M701676200; Rybin VO, 2004, J BIOL CHEM, V279, P19350, DOI 10.1074/jbc.M311096200; Rybin VO, 2003, J BIOL CHEM, V278, P14555, DOI 10.1074/jbc.M212644200; Rybin VO, 1999, CIRC RES, V84, P980, DOI 10.1161/01.RES.84.9.980; Rybin VO, 2000, J BIOL CHEM, V275, P41447, DOI 10.1074/jbc.M006951200; Sakurai Y, 2001, BIOL PHARM BULL, V24, P973, DOI 10.1248/bpb.24.973; Salazar EP, 2001, J BIOL CHEM, V276, P17788, DOI 10.1074/jbc.M100984200; Stahelin RV, 2004, J BIOL CHEM, V279, P29501, DOI 10.1074/jbc.M403191200; Steinberg SF, 2004, BIOCHEM J, V384, P449, DOI 10.1042/BJ20040704; STEINBERG SF, 1991, CIRC RES, V68, P1216, DOI 10.1161/01.RES.68.5.1216; Stempka L, 1999, J BIOL CHEM, V274, P8886, DOI 10.1074/jbc.274.13.8886; Sun XG, 2000, J BIOL CHEM, V275, P7470, DOI 10.1074/jbc.275.11.7470; Takahashi H, 2005, CIRCULATION, V111, P1510, DOI 10.1161/01.CIR.0000159339.00703.22; van Rheenen J, 2005, EMBO J, V24, P1664, DOI 10.1038/sj.emboj.7600655; Waltenberger J, 1999, CIRC RES, V85, P12; Yamaguchi T, 2003, EUR J BIOCHEM, V270, P1816, DOI 10.1046/j.1432-1033.2003.03544.x; Yang N, 2004, J BIOL CHEM, V279, P20898, DOI 10.1074/jbc.M400625200; Zorov DB, 2006, BBA-BIOENERGETICS, V1757, P509, DOI 10.1016/j.bbabio.2006.04.029	51	24	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17777	17788		10.1074/jbc.M800333200	http://dx.doi.org/10.1074/jbc.M800333200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18387943	Green Published, hybrid			2022-12-25	WOS:000256949200005
J	Gauthier, MS; Miyoshi, H; Souza, SC; Cacicedo, JM; Saha, AK; Greenberg, AS; Ruderman, NB				Gauthier, Marie-Soleil; Miyoshi, Hideaki; Souza, Sandra C.; Cacicedo, Jose M.; Saha, Asish K.; Greenberg, Andrew S.; Ruderman, Neil B.			AMP-activated protein kinase is activated as a consequence of lipolysis in the adipocyte - Potential mechanism and physiological relevance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADIPOSE TRIGLYCERIDE LIPASE; HORMONE-SENSITIVE LIPASE; FATTY-ACID OXIDATION; ISOLATED RAT ADIPOCYTES; A-STIMULATED LIPOLYSIS; 3T3-L1 ADIPOCYTES; GLUCOSE-METABOLISM; PERILIPIN-A; MALONYL-COA; INSULIN-RESISTANCE	AMP-activated proteinkinase(AMPK) is activated in adipocytes during exercise and other states in which lipolysis is stimulated. However, the mechanism(s) responsible for this effect and its physiological relevance are unclear. To examine these questions, 3T3-L1 adipocytes were treated with cAMP-inducing agents (isoproterenol, forskolin, and isobutylmethylxanthine), which stimulate lipolysis and activate AMPK. When lipolysis was partially inhibited with the general lipase inhibitor orlistat, AMPK activation by these agents was also partially reduced, but the increases in cAMP levels and cAMP-dependent protein kinase (PKA) activity were unaffected. Likewise, small hairpin RNA-mediated silencing of adipose tissue triglyceride lipase inhibited both forskolin-stimulated lipolysis and AMPK activation but not that of PKA. Forskolin treatment increased the AMP:ATP ratio, and this too was reduced by orlistat. When acyl-CoA synthetase, which catalyzes the conversion of fatty acids to fatty acyl-CoA, was inhibited with triacsin C, the increases in both AMPK activity and AMP:ATP ratio were blunted. Isoproterenol-stimulated lipolysis was accompanied by an increase in oxidative stress, an effect that was quintupled in cells incubated with the AMPK inhibitor compound C. The isoproterenol-induced increase in the AMP: ATP ratio was also much greater in these cells. In conclusion, the results indicate that activation of AMPK in adipocytes by cAMP-inducing agents is a consequence of lipolysis and not of PKA activation. They suggest that AMPK activation in this setting is caused by an increase in the AMP: ATP ratio that appears to be due, at least in part, to the acylation of fatty acids. Finally, this AMPK activation appears to restrain the energy depletion and oxidative stress caused by lipolysis.	[Gauthier, Marie-Soleil; Cacicedo, Jose M.; Saha, Asish K.; Ruderman, Neil B.] Boston Univ, Sch Med, Diabet & Metab Res Unit, Med Ctr,Dept Med,Sect Endocrinol, Boston, MA 02118 USA; [Miyoshi, Hideaki; Souza, Sandra C.; Greenberg, Andrew S.] Tufts Univ, Human Nutr Res Ctr Aging, Jean Mayer US Dept Agr, Boston, MA 02111 USA; [Miyoshi, Hideaki] Hokkaido Univ, Grad Sch Med, Sapporo, Hokkaido 0608638, Japan; [Souza, Sandra C.] Novartis Inst BioMed Res, Cambridge, MA 02139 USA; [Cacicedo, Jose M.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02140 USA	Boston University; Tufts University; United States Department of Agriculture (USDA); Hokkaido University; Novartis; Boston University	Gauthier, MS (corresponding author), Boston Univ, Sch Med, Diabet & Metab Res Unit, Med Ctr,Dept Med,Sect Endocrinol, 650 Albany St,Rm 820, Boston, MA 02118 USA.	msgauth@bu.edu	MIYOSHI, HIDEAKI/G-3971-2012	Ruderman, Neil/0000-0002-6589-6587; Saha, Asish/0000-0003-1001-5110; /0000-0001-8417-9754	NHLBI NIH HHS [P01HL68758] Funding Source: Medline; NIDDK NIH HHS [R01DK067509, R01DK19514, R01DK50647] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL068758] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067509, R01DK019514, R01DK050647] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ajuwon KM, 2005, J NUTR, V135, P1841, DOI 10.1093/jn/135.8.1841; Alam N, 1998, BIOCHEM J, V334, P233, DOI 10.1042/bj3340233; Alba G, 2004, FEBS LETT, V573, P219, DOI 10.1016/j.febslet.2004.07.077; An ZB, 2007, J BIOL CHEM, V282, P26793, DOI 10.1074/jbc.M703701200; ANGEL A, 1971, J LIPID RES, V12, P104; ANGEL A, 1971, METABOLISM, V20, P87, DOI 10.1016/0026-0495(71)90062-X; Beale EG, 2002, FASEB J, V16, P1695, DOI 10.1096/fj.02-0407rev; Brasaemle DL, 2007, J LIPID RES, V48, P2547, DOI 10.1194/jlr.R700014-JLR200; Brasaemle DL, 2000, J BIOL CHEM, V275, P38486, DOI 10.1074/jbc.M007322200; BROOKS B, 1982, FEBS LETT, V146, P327, DOI 10.1016/0014-5793(82)80945-9; Cacicedo JM, 2004, BIOCHEM BIOPH RES CO, V324, P1204, DOI 10.1016/j.bbrc.2004.09.177; Cacicedo JM, 2007, DIABETES, V56, pA515; CAHILL GF, 1960, J BIOL CHEM, V235, P1246; Collins SP, 2000, BIOCHEM J, V345, P673, DOI 10.1042/0264-6021:3450673; Dagon Y, 2006, BIOCHEM BIOPH RES CO, V340, P43, DOI 10.1016/j.bbrc.2005.11.159; Daval M, 2005, J BIOL CHEM, V280, P25250, DOI 10.1074/jbc.M414222200; Daval M, 2006, J PHYSIOL-LONDON, V574, P55, DOI 10.1113/jphysiol.2006.111484; Furukawa S, 2004, J CLIN INVEST, V114, P1752, DOI [10.1172/JCI20042162S, 10.1172/JCI21625]; Gaidhu MP, 2006, J BIOL CHEM, V281, P25956, DOI 10.1074/jbc.M602992200; GARTON AJ, 1989, EUR J BIOCHEM, V179, P249, DOI 10.1111/j.1432-1033.1989.tb14548.x; GREENBERG AS, 1991, J BIOL CHEM, V266, P11341; Haemmerle G, 2006, SCIENCE, V312, P734, DOI 10.1126/science.1123965; HAGEN JH, 1960, J BIOL CHEM, V235, P1545; Hardie DG, 2007, ANNU REV PHARMACOL, V47, P185, DOI 10.1146/annurev.pharmtox.47.120505.105304; Hardie DG, 2006, J PHYSIOL-LONDON, V574, P7, DOI 10.1113/jphysiol.2006.108944; Hardie DG, 1997, EUR J BIOCHEM, V246, P259, DOI 10.1111/j.1432-1033.1997.00259.x; Hawley SA, 2005, CELL METAB, V2, P9, DOI 10.1016/j.cmet.2005.05.009; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; HEPP D, 1968, J BIOL CHEM, V243, P2321; Kamigaki M, 2006, BIOCHEM BIOPH RES CO, V339, P624, DOI 10.1016/j.bbrc.2005.11.059; KATHER H, 1990, J CLIN INVEST, V85, P106, DOI 10.1172/JCI114399; Kawaguchi T, 2002, J BIOL CHEM, V277, P3829, DOI 10.1074/jbc.M107895200; Kelly M, 2004, BIOCHEM BIOPH RES CO, V320, P449, DOI 10.1016/j.bbrc.2004.05.188; Kim JH, 2001, J BIOL CHEM, V276, P24667, DOI 10.1074/jbc.M010793200; Koh HJ, 2007, BIOCHEM J, V403, P473, DOI 10.1042/BJ20061479; KOHANSKI RA, 1986, J BIOL CHEM, V261, P2272; Lee WJ, 2005, ARTERIOSCL THROM VAS, V25, P2488, DOI 10.1161/01.ATV.0000190667.33224.4c; Lin Y, 2005, J BIOL CHEM, V280, P4617, DOI 10.1074/jbc.M411863200; LOWRY OH, 1972, FLEXIBLE SYSTEM ENZY, P147; Luo B, 2007, J BIOL CHEM, V282, P7172, DOI 10.1074/jbc.M607362200; MAIZELS EZ, 1977, BIOCHEM J, V162, P557, DOI 10.1042/bj1620557; Martin SG, 2003, NATURE, V421, P379, DOI 10.1038/nature01296; Mashek DG, 2006, J BIOL CHEM, V281, P945, DOI 10.1074/jbc.M507646200; Miyoshi H, 2007, J BIOL CHEM, V282, P996, DOI 10.1074/jbc.M605770200; Miyoshi H, 2006, J BIOL CHEM, V281, P15837, DOI 10.1074/jbc.M601097200; Momcilovic M, 2006, J BIOL CHEM, V281, P25336, DOI 10.1074/jbc.M604399200; Moule SK, 1998, FEBS LETT, V439, P287, DOI 10.1016/S0014-5793(98)01392-1; Nolan CJ, 2006, DIABETOLOGIA, V49, P2120, DOI 10.1007/s00125-006-0305-5; Park H, 2002, J BIOL CHEM, V277, P32571, DOI 10.1074/jbc.M201692200; Pilon G, 2004, J BIOL CHEM, V279, P20767, DOI 10.1074/jbc.M401390200; Reshef L, 2003, J BIOL CHEM, V278, P30413, DOI 10.1074/jbc.R300017200; RESHEFF L, 1970, J BIOL CHEM, V245, P5979; RODBELL M, 1964, J BIOL CHEM, V239, P375; ROGNSTAD R, 1966, P NATL ACAD SCI USA, V55, P1148, DOI 10.1073/pnas.55.5.1148; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Ruderman NB, 2003, BIOCHEM SOC T, V31, P202, DOI 10.1042/bst0310202; Salt IP, 2000, DIABETES, V49, P1649, DOI 10.2337/diabetes.49.10.1649; Sapkota GP, 2001, J BIOL CHEM, V276, P19469, DOI 10.1074/jbc.M009953200; Self DW, 1998, J NEUROSCI, V18, P1848; Souza SC, 1998, J BIOL CHEM, V273, P24665, DOI 10.1074/jbc.273.38.24665; Souza SC, 2002, J BIOL CHEM, V277, P8267, DOI 10.1074/jbc.M108329200; Subauste AR, 2007, AM J PHYSIOL-ENDOC M, V293, pE159, DOI 10.1152/ajpendo.00629.2006; SULLIVAN JE, 1994, FEBS LETT, V353, P33, DOI 10.1016/0014-5793(94)01006-4; Unoki H, 2007, DIABETES RES CLIN PR, V76, P236, DOI 10.1016/j.diabres.2006.09.016; VALLANO ML, 1983, AM J PHYSIOL, V245, pE266, DOI 10.1152/ajpendo.1983.245.3.E266; VAUGHAN M, 1961, J BIOL CHEM, V236, P2196; VAUGHAN M, 1962, J BIOL CHEM, V237, P3354; Viollet B, 2006, J PHYSIOL-LONDON, V574, P41, DOI 10.1113/jphysiol.2006.108506; Watt MJ, 2006, AM J PHYSIOL-ENDOC M, V290, pE500, DOI 10.1152/ajpendo.00361.2005; WOITCZAK L, 1993, BIOCHIM BIOPHYS ACTA, V1183, P41, DOI 10.1016/0005-2728(93)90004-Y; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Xie ZL, 2006, J BIOL CHEM, V281, P6366, DOI 10.1074/jbc.M511178200; Yamaguchi S, 2005, AM J PHYSIOL-ENDOC M, V289, pE643, DOI 10.1152/ajpendo.00456.2004; Yang JY, 2006, OBESITY, V14, P388, DOI 10.1038/oby.2006.52; Yin W, 2003, J BIOL CHEM, V278, P43074, DOI 10.1074/jbc.M308484200; Zechner R, 2005, CURR OPIN LIPIDOL, V16, P333, DOI 10.1097/01.mol.0000169354.20395.1c; Zhang HH, 2003, J BIOL CHEM, V278, P51535, DOI 10.1074/jbc.M309591200; Zhou GC, 2001, J CLIN INVEST, V108, P1167, DOI 10.1172/JCI200113505; Zimmermann R, 2004, SCIENCE, V306, P1383, DOI 10.1126/science.1100747	80	194	198	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16514	16524		10.1074/jbc.M708177200	http://dx.doi.org/10.1074/jbc.M708177200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18390901	Green Published, hybrid, Green Submitted			2022-12-25	WOS:000256497100028
J	Imamura, D; Zhou, RB; Feig, M; Kroos, L				Imamura, Daisuke; Zhou, Ruanbao; Feig, Michael; Kroos, Lee			Evidence that the Bacillus subtilis SpoIIGA protein is a novel type of signal-transducing aspartic protease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEVELOPMENTAL TRANSCRIPTION FACTOR; REGULATED INTRAMEMBRANE PROTEOLYSIS; IMMUNODEFICIENCY-VIRUS PROTEASE; GENOME-WIDE ANALYSIS; GENE-EXPRESSION; MUTATIONAL ANALYSIS; SIGMA-FACTOR; ACTIVE-SITE; MOTHER-CELL; SUBCELLULAR-LOCALIZATION	The bacterium Bacillus subtilis undergoes endospore formation in response to starvation. or factors play a key role in spatiotemporal regulation of gene expression during development. Activation of or factors is coordinated by signal transduction between the forespore and the mother cell. sigma(E) is produced as pro-sigma(E), which is activated in the mother cell by cleavage in response to a signal from the forespore. We report that expression of SpoIIR, a putative signaling protein normally made in the forespore, and SpoIIGA, a putative protease, is necessary and sufficient for accurate, rapid, and abundant processing of pro-sigma(E) to sigma(E) in Escherichia coli. Modeling and mutational analyses provide evidence that SpoIIGA is a novel type of aspartic protease whose C-terminal half forms a dimer similar to the human immunodeficiency virus type I protease. Previous studies suggest that the N-terminal half of SpoIIGA is membraneembedded. We found that SpoIIGA expressed in E. coli is membrane-associated and that after detergent treatment SpoIIGA was self-associated. Also, SpoIIGA interacts with SpoIIR. The results support a model in which SpoIIGA forms inactive dimers or oligomers, and interaction of SpoIIR with the N-terminal domain of SpoIIGA on one side of a membrane causes a conformational change that allows formation of active aspartic protease dimer in the C-terminal domain on the other side of the membrane, where it cleaves pro-sigma(E)..	[Imamura, Daisuke; Zhou, Ruanbao; Feig, Michael; Kroos, Lee] Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA; [Imamura, Daisuke] Setsunan Univ, Fac Pharmaceut Sci, Osaka 5730101, Japan	Michigan State University; Setsunan University	Kroos, L (corresponding author), Michigan State Univ, Dept Biochem & Mol Biol, E Lansing, MI 48824 USA.	kroos@msu.edu	Zhou, Ruanbao/ABC-6593-2020; Feig, Michael/AAI-9540-2021	Zhou, Ruanbao/0000-0001-9073-999X; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043585, R29GM043585] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM043585-15, R01 GM043585-14, GM 43585, R01 GM043585] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AbadZapatero C, 1996, PROTEIN SCI, V5, P640; ALDEN RA, 1971, BIOCHEM BIOPH RES CO, V45, P337, DOI 10.1016/0006-291X(71)90823-0; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Barak I, 2005, MOL MICROBIOL, V57, P611, DOI 10.1111/j.1365-2958.2005.04687.x; BIRKTOFT JJ, 1972, J MOL BIOL, V68, P187, DOI 10.1016/0022-2836(72)90210-0; BIZUB D, 1991, J BIOL CHEM, V266, P4951; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Campo N, 2007, J BACTERIOL, V189, P6021, DOI 10.1128/JB.00399-07; Campo N, 2006, MOL CELL, V23, P25, DOI 10.1016/j.molcel.2006.05.019; Carlson HC, 1996, J BACTERIOL, V178, P546, DOI 10.1128/jb.178.2.546-549.1996; CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660; CUTFIELD SM, 1995, STRUCTURE, V3, P1261, DOI 10.1016/S0969-2126(01)00261-1; CUTTING S, 1991, J MOL BIOL, V221, P1237; CUTTING S, 1990, CELL, V62, P239, DOI 10.1016/0092-8674(90)90362-I; DILANNI C L, 1990, Journal of Biological Chemistry, V265, P17348; Eichenberger P, 2004, PLOS BIOL, V2, P1664, DOI 10.1371/journal.pbio.0020328; Eichenberger P, 2003, J MOL BIOL, V327, P945, DOI 10.1016/S0022-2836(03)00205-5; Fawcett P, 1998, MOL MICROBIOL, V28, P931, DOI 10.1046/j.1365-2958.1998.00849.x; Feig M, 2004, J MOL GRAPH MODEL, V22, P377, DOI 10.1016/j.jmgm.2003.12.005; Feucht A, 2003, MICROBIOL-SGM, V149, P3023, DOI 10.1099/mic.0.26413-0; Fujita M, 2002, MOL MICROBIOL, V43, P27, DOI 10.1046/j.1365-2958.2002.02732.x; GHOLAMHOSEINIAN A, 1989, J BACTERIOL, V171, P5747, DOI 10.1128/jb.171.10.5747-5749.1989; Ginalski K, 2003, BIOINFORMATICS, V19, P1015, DOI 10.1093/bioinformatics/btg124; Haass C, 2004, EMBO J, V23, P483, DOI 10.1038/sj.emboj.7600061; Harwood C.R., 1990, MOL BIOL METHODS BAC; Heaslet H, 2007, ACTA CRYSTALLOGR D, V63, P866, DOI 10.1107/S0907444907029125; Hofmeister A, 1998, J BACTERIOL, V180, P2426, DOI 10.1128/JB.180.9.2426-2433.1998; HOFMEISTER AEM, 1995, CELL, V83, P219, DOI 10.1016/0092-8674(95)90163-9; Hornak V, 2006, P NATL ACAD SCI USA, V103, P915, DOI 10.1073/pnas.0508452103; Ishima R, 1999, STRUCTURE, V7, P1047, DOI 10.1016/S0969-2126(99)80172-5; Ishima R, 2003, J BIOL CHEM, V278, P43311, DOI 10.1074/jbc.M307549200; JONAS RM, 1988, J BACTERIOL, V170, P507, DOI 10.1128/jb.170.2.507-511.1988; Ju JL, 1998, J BACTERIOL, V180, P1673, DOI 10.1128/JB.180.7.1673-1681.1998; Ju JL, 2003, J BACTERIOL, V185, P5897, DOI 10.1128/JB.185.19.5897-5900.2003; Ju JL, 1997, J BACTERIOL, V179, P4888, DOI 10.1128/jb.179.15.4888-4893.1997; KAROW ML, 1995, P NATL ACAD SCI USA, V92, P2012, DOI 10.1073/pnas.92.6.2012; KENNEY TJ, 1987, J BACTERIOL, V169, P3329, DOI 10.1128/jb.169.7.3329-3339.1987; Kervinen J, 1999, EMBO J, V18, P3947, DOI 10.1093/emboj/18.14.3947; KOLINSKI A, 1994, PROTEINS, V18, P338, DOI 10.1002/prot.340180405; KONVALINKA J, 1995, J VIROL, V69, P7180, DOI 10.1128/JVI.69.11.7180-7186.1995; Kroos L, 2002, J BACTERIOL, V184, P5393, DOI 10.1128/JB.184.19.5393-5401.2002; Kroos L, 1999, MOL MICROBIOL, V31, P1285, DOI 10.1046/j.1365-2958.1999.01214.x; Kroos L, 2007, ANNU REV GENET, V41, P13, DOI 10.1146/annurev.genet.41.110306.130400; Krysan DJ, 2005, EUKARYOT CELL, V4, P1364, DOI 10.1128/EC.4.8.1364-1374.2005; LABELL TL, 1987, P NATL ACAD SCI USA, V84, P1784, DOI 10.1073/pnas.84.7.1784; Laco GS, 1997, BIOCHEMISTRY-US, V36, P10696, DOI 10.1021/bi9707436; Lee MS, 2003, J COMPUT CHEM, V24, P1348, DOI 10.1002/jcc.10272; LOEB DD, 1989, J VIROL, V63, P111, DOI 10.1128/JVI.63.1.111-121.1989; LondonoVallejo JA, 1997, MICROBIOL-UK, V143, P2753, DOI 10.1099/00221287-143-8-2753; LONDONOVALLEJO JA, 1995, GENE DEV, V9, P503, DOI 10.1101/gad.9.4.503; MacKerell AD, 1998, J PHYS CHEM B, V102, P3586, DOI 10.1021/jp973084f; MASUDA ES, 1990, NUCLEIC ACIDS RES, V18, P657, DOI 10.1093/nar/18.3.657; MIYAO A, 1993, J BACTERIOL, V175, P4081, DOI 10.1128/JB.175.13.4081-4086.1993; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; PEARL L, 1984, FEBS LETT, V174, P96, DOI 10.1016/0014-5793(84)81085-6; PEARL LH, 1987, NATURE, V329, P351, DOI 10.1038/329351a0; PETERS HK, 1991, J BACTERIOL, V173, P7821, DOI 10.1128/jb.173.24.7821-7827.1991; PETERS HK, 1994, J BACTERIOL, V176, P7763, DOI 10.1128/JB.176.24.7763-7766.1994; PETERS HK, 1992, J BACTERIOL, V174, P4629, DOI 10.1128/JB.174.14.4629-4637.1992; Pillai B, 2001, PROTEINS, V43, P57, DOI 10.1002/1097-0134(20010401)43:1<57::AID-PROT1017>3.0.CO;2-D; Pogliano K, 1997, J BACTERIOL, V179, P3331, DOI 10.1128/jb.179.10.3331-3341.1997; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P19; Resnekov O, 1998, P NATL ACAD SCI USA, V95, P3162, DOI 10.1073/pnas.95.6.3162; RICCA E, 1992, J BACTERIOL, V174, P3177, DOI 10.1128/jb.174.10.3177-3184.1992; Rudner DZ, 1999, P NATL ACAD SCI USA, V96, P14765, DOI 10.1073/pnas.96.26.14765; Rudner DZ, 2002, GENE DEV, V16, P1007, DOI 10.1101/gad.977702; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SHAZAND K, 1995, EMBO J, V14, P1439, DOI 10.1002/j.1460-2075.1995.tb07130.x; Soding J, 2005, NUCLEIC ACIDS RES, V33, pW244, DOI 10.1093/nar/gki408; Steil L, 2005, MICROBIOL-SGM, V151, P399, DOI 10.1099/mic.0.27493-0; STRAGIER P, 1988, CELL, V52, P697, DOI 10.1016/0092-8674(88)90407-2; Strisovsky K, 2000, PROTEIN SCI, V9, P1631, DOI 10.1110/ps.9.9.1631; Wang ST, 2006, J MOL BIOL, V358, P16, DOI 10.1016/j.jmb.2006.01.059; WEBER IT, 1990, J BIOL CHEM, V265, P10492; WIODAWER A, 1998, ANNU REV BIOPH BIOM, V27, P249; Wolfe MS, 2004, SCIENCE, V305, P1119, DOI 10.1126/science.1096187; YOUNGMAN P, 1984, PLASMID, V12, P1, DOI 10.1016/0147-619X(84)90061-1; Yu YTN, 2000, J BACTERIOL, V182, P3305, DOI 10.1128/JB.182.11.3305-3309.2000; Yudkin MD, 2005, MOL MICROBIOL, V56, P578, DOI 10.1111/j.1365-2958.2005.04594.x; Zhou RB, 2005, MOL MICROBIOL, V58, P835, DOI 10.1111/j.1365-2958.2005.04870.x; Zhou RB, 2004, P NATL ACAD SCI USA, V101, P6385, DOI 10.1073/pnas.0307709101	81	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15287	15299		10.1074/jbc.M708962200	http://dx.doi.org/10.1074/jbc.M708962200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18378688	Green Published, hybrid, Green Accepted			2022-12-25	WOS:000256232000047
J	Kaneiwa, T; Yamada, S; Mizumoto, S; Montano, AM; Mitani, S; Sugahara, K				Kaneiwa, Tomoyuki; Yamada, Shuhei; Mizumoto, Shuji; Montano, Adriana M.; Mitani, Shohei; Sugahara, Kazuyuki			Identification of a novel chondroitin hydrolase in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN LINKAGE REGION; EMBRYONIC-CELL DIVISION; CENTRAL-NERVOUS-SYSTEM; TESTICULAR HYALURONIDASE; OLIGOSACCHARIDE CHAINS; DERMATAN SULFATE; IN-VIVO; PROTEOGLYCANS; GLYCOSAMINOGLYCANS; BIOSYNTHESIS	Hyaluronidases have been postulated to be the enzyme acting at the initial step of chondroitin sulfate (CS) catabolism in vivo. Since chondroitin (Chn) but not hyaluronic acid (HA) has been detected in Caenorhabditis elegans, the nematode is a good model for elucidating the mechanism of the degradation of CS/Chn in vivo. Here we cloned the homolog of human hyaluronidase in C. elegans, T22C8.2. The Chn-degrading activity in vitro was first demonstrated when it was expressed in COS-7 cells. The enzyme cleaved preferentially Chn. CS-A and CS-C were also depolymerized but to lesser extents, and HA was hardly degraded. In order of preference, the substrates ranked Chn >> CS-A > CS-C >> HA. The products of the degradation of Chn by the enzyme were characterized by anion-exchange high performance liquid chromatography and delayed extraction matrix-assisted laser desorption ionization time-of-flight mass spectrometry. The structure of the major component in the digest was determined as GlcUA beta 1-3GalNAc beta 1-4GlcUA beta 1-3GalNAc, where GlcUA and GalNAc represent D-glucuronic acid and N-acetyl-D-galactosamine, respectively, indicating that this enzyme is a Chn hydrolase, an endo-beta-galactosaminidase specific for Chn. Investigation of the effects of pH on the activity revealed the optimum pH of Chn hydrolase to be 6.0. Since Chn in C. elegans has been demonstrated to play critical roles in cell division, Chn hydrolase possibly regulates the function of Chn in vivo. This is the first demonstration of a Chn hydrolase in an animal.	[Kaneiwa, Tomoyuki; Yamada, Shuhei; Mizumoto, Shuji; Sugahara, Kazuyuki] Hokkaido Univ, Grad Sch Life Sci, Lab Proteoglycan Signaling & Therapeut, Kita Ku, Sapporo, Hokkaido 0010021, Japan; [Yamada, Shuhei; Montano, Adriana M.; Sugahara, Kazuyuki] Kobe Pharmaceut Univ, Dept Biochem, Kobe, Hyogo 6588558, Japan; [Mitani, Shohei] Tokyo Womens Med Univ, Sch Med, Dept Physiol, Tokyo 1628666, Japan	Hokkaido University; Kobe Pharmaceutical University; Tokyo Women's Medical University	Yamada, S (corresponding author), Hokkaido Univ, Grad Sch Life Sci, Lab Proteoglycan Signaling & Therapeut, Kita Ku, Nishi 11 Choume,Kita 21 Jo, Sapporo, Hokkaido 0010021, Japan.	tjohej@sci.hokudai.ac.jp; k-sugar@sci.hokudai.ac.jp	Mizumoto, Shuji/F-8313-2018; Montano, Adriana/AHE-8741-2022	Mizumoto, Shuji/0000-0002-4641-1505; 				Csoka AB, 2001, MATRIX BIOL, V20, P499, DOI 10.1016/S0945-053X(01)00172-X; Fieber C, 2004, J CELL SCI, V117, P359, DOI 10.1242/jcs.00831; Frost GL, 1996, TRENDS GLYCOSCI GLYC, V8, P419, DOI 10.4052/tigg.8.419; Guerardel Y, 2001, BIOCHEM J, V357, P167, DOI 10.1042/0264-6021:3570167; HIYAMA K, 1975, J BIOL CHEM, V250, P1824; Hosono K, 2007, AM J PATHOL, V171, P274, DOI 10.2353/ajpath.2007.060828; Hwang HY, 2003, NATURE, V423, P439, DOI 10.1038/nature01634; IMANARI T, 1992, J PHARMACOBIO-DYNAM, V15, P231, DOI 10.1248/bpb1978.15.231; Izumikawa T, 2004, J BIOL CHEM, V279, P53755, DOI 10.1074/jbc.M409615200; Jedrzejas MJ, 2005, PROTEINS, V61, P227, DOI 10.1002/prot.20592; KARAMANOS NK, 1988, BIOCHIM BIOPHYS ACTA, V966, P36, DOI 10.1016/0304-4165(88)90126-2; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kinoshita A, 1999, ANAL BIOCHEM, V269, P367, DOI 10.1006/abio.1999.4027; LOZZO RV, 1998, ANNU REV BIOCHEM, V67, P609; Mikami T, 2003, J BIOL CHEM, V278, P36115, DOI 10.1074/jbc.M306044200; Mizuguchi S, 2003, NATURE, V423, P443, DOI 10.1038/nature01635; Nakagawa H, 2007, GLYCOBIOLOGY, V17, P157, DOI 10.1093/glycob/cwl058; Nandini CD, 2006, ADV PHARMACOL, V53, P253, DOI 10.1016/S1054-3589(05)53012-6; Olson SK, 2006, J CELL BIOL, V173, P985, DOI 10.1083/jcb.200603003; Pavao MSG, 2006, ADV PHARMACOL, V53, P117, DOI 10.1016/S1054-3589(05)53006-0; Petit E, 2006, ADV PHARMACOL, V53, P167, DOI 10.1016/S1054-3589(05)53008-4; Prabhakar V, 2006, ADV PHARMACOL, V53, P69, DOI 10.1016/S1054-3589(06)53005-9; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; Rolls A, 2004, EUR J NEUROSCI, V20, P1973, DOI 10.1111/j.1460-9568.2004.03676.x; SAITOH H, 1995, J BIOL CHEM, V270, P3741, DOI 10.1074/jbc.270.8.3741; Sakaguchi H, 2001, J BIOCHEM-TOKYO, V129, P107, DOI 10.1093/oxfordjournals.jbchem.a002820; Silbert JE, 2002, GLYCOCONJUGATE J, V19, P227, DOI 10.1023/A:1025379812535; SUGAHARA K, 1991, EUR J BIOCHEM, V202, P805, DOI 10.1111/j.1432-1033.1991.tb16436.x; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Sugahara K, 1996, GLYCOCONJUGATE J, V13, P609, DOI 10.1007/BF00731449; Sugahara K, 2007, CURR OPIN STRUC BIOL, V17, P536, DOI 10.1016/j.sbi.2007.08.015; Sugahara KN, 2006, J BIOL CHEM, V281, P5861, DOI 10.1074/jbc.M506740200; Sugiyama E, 1997, GLYCOBIOLOGY, V7, P719, DOI 10.1093/glycob/7.5.719; Toyoda H, 2000, J BIOL CHEM, V275, P2269, DOI 10.1074/jbc.275.4.2269; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Yamada S, 1999, FEBS LETT, V459, P327, DOI 10.1016/S0014-5793(99)01286-7; Yamada S, 2002, J BIOL CHEM, V277, P31877, DOI 10.1074/jbc.M205078200; Yamada S, 2007, GLYCOBIOLOGY, V17, P886, DOI 10.1093/glycob/cwm051; YAMAGATA T, 1968, J BIOL CHEM, V243, P1523	40	21	22	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					14971	14979		10.1074/jbc.M709236200	http://dx.doi.org/10.1074/jbc.M709236200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18390555	Green Published, hybrid			2022-12-25	WOS:000256232000009
J	Li, WQ; Young, SL; King, N; Miller, WT				Li, Wanqing; Young, Susan L.; King, Nicole; Miller, W. Todd			Signaling properties of a non-metazoan Src kinase and the evolutionary history of Src negative regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONRECEPTOR TYROSINE KINASES; SH2 DOMAIN; C-SRC; SUBSTRATE RECOGNITION; FAMILY KINASES; PROCESSIVE PHOSPHORYLATION; PROTEIN-KINASE; HCK; ACTIVATION; BINDING	Choanoflagellates, unicellular organisms that are closely related to metazoans, possess cell adhesion and signaling proteins previously thought to be unique to animals, suggesting that these components may have played roles in the evolution of metazoan multicellularity. We have cloned, expressed, and purified the nonreceptor tyrosine kinase MbSrc1 from the cho-anoflagellate Monosiga brevicollis. The kinase has the same domain arrangement as mammalian Src kinases, and we find that the individual Src homology 3 (SH3), SH2, and catalytic domains have similar functions to their mammalian counterparts. In contrast to mammalian c-Src, the SH2 and catalytic domains of MbSrc1 do not appear to be functionally coupled. We cloned and expressed the M. brevicollis homolog of c-Src C-terminal kinase (MbCsk) and showed that it phosphorylates the C terminus of MbSrc1, yet this phosphorylation does not inhibit MbSrc to the same degree seen in the mammalian Src/Csk pair. Thus, Src autoinhibition likely evolved more recently within the metazoan lineage, and it may have played a role in the establishment of intercellular signaling in metazoans.	[Li, Wanqing; Miller, W. Todd] SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Stony Brook, NY 11794 USA; [Young, Susan L.; King, Nicole] Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; [Young, Susan L.; King, Nicole] Univ Calif Berkeley, Ctr Integrat Genom, Berkeley, CA 94720 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Miller, WT (corresponding author), SUNY Stony Brook, Sch Med, Dept Physiol & Biophys, Basic Sci Tower,T-6, Stony Brook, NY 11794 USA.	todd.miller@stonybrook.edu		Li, Wanqing/0000-0002-4427-2687; Rojahn, Susan/0000-0001-5888-7693	NCI NIH HHS [R01 CA058530, CA 58530, R01 CA058530-14] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058530, R29CA058530] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alexandropoulos K, 1996, GENE DEV, V10, P1341, DOI 10.1101/gad.10.11.1341; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARKER SC, 1995, BIOCHEMISTRY-US, V34, P14843, DOI 10.1021/bi00045a027; Bjorge JD, 2000, ONCOGENE, V19, P5620, DOI 10.1038/sj.onc.1203923; Bradshaw JM, 1998, BIOCHEMISTRY-US, V37, P9083, DOI 10.1021/bi973147k; Briggs SD, 1997, J BIOL CHEM, V272, P17899, DOI 10.1074/jbc.272.29.17899; Briggs SD, 1999, J BIOL CHEM, V274, P26579, DOI 10.1074/jbc.274.37.26579; Brown MT, 1996, BBA-REV CANCER, V1287, P121, DOI 10.1016/0304-419X(96)00003-0; Burnham MR, 1996, ONCOGENE, V12, P2467; CASNELLIE JE, 1991, METHOD ENZYMOL, V200, P115; ERPEL T, 1995, EMBO J, V14, P963, DOI 10.1002/j.1460-2075.1995.tb07077.x; Frame MC, 2002, BBA-REV CANCER, V1602, P114, DOI 10.1016/S0304-419X(02)00040-9; GARCIA P, 1993, J BIOL CHEM, V268, P25146; Gonfloni S, 2000, NAT STRUCT BIOL, V7, P281; Irby RB, 2000, ONCOGENE, V19, P5636, DOI 10.1038/sj.onc.1203912; KEMP BE, 1977, J BIOL CHEM, V252, P4888; King N, 2001, P NATL ACAD SCI USA, V98, P15032, DOI 10.1073/pnas.261477698; King N, 2004, DEV CELL, V7, P313, DOI 10.1016/j.devcel.2004.08.010; King N, 2003, SCIENCE, V301, P361, DOI 10.1126/science.1083853; King N, 2008, NATURE, V451, P783, DOI 10.1038/nature06617; Klinghoffer RA, 1999, EMBO J, V18, P2459, DOI 10.1093/emboj/18.9.2459; Kuriyan J, 1997, ANNU REV BIOPH BIOM, V26, P259, DOI 10.1146/annurev.biophys.26.1.259; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LaFevre-Bernt M, 1998, J BIOL CHEM, V273, P32129, DOI 10.1074/jbc.273.48.32129; Lang BF, 2002, CURR BIOL, V12, P1773, DOI 10.1016/S0960-9822(02)01187-9; Lee S, 2003, P NATL ACAD SCI USA, V100, P14707, DOI 10.1073/pnas.2534493100; Lee SS, 2006, J BIOL CHEM, V281, P8183, DOI 10.1074/jbc.M508120200; Lerner EC, 2002, NAT STRUCT BIOL, V9, P365, DOI 10.1038/nsb782; LIU XQ, 1993, ONCOGENE, V8, P1119; Lukong KE, 2003, BBA-REV CANCER, V1653, P73, DOI 10.1016/j.bbcan.2003.09.001; McPherson RA, 2000, ONCOGENE, V19, P3616, DOI 10.1038/sj.onc.1203678; Miller MA, 2000, ONCOGENE, V19, P3925, DOI 10.1038/sj.onc.1203714; Miller WT, 2003, ACCOUNTS CHEM RES, V36, P393, DOI 10.1021/ar020116v; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Nakamoto T, 1996, J BIOL CHEM, V271, P8959, DOI 10.1074/jbc.271.15.8959; Parsons SJ, 2004, ONCOGENE, V23, P7906, DOI 10.1038/sj.onc.1208160; Patwardhan P, 2006, J BIOL CHEM, V281, P20689, DOI 10.1074/jbc.M602311200; Pellicena P, 1998, J BIOL CHEM, V273, P15325, DOI 10.1074/jbc.273.25.15325; Porter M, 2000, J BIOL CHEM, V275, P2721, DOI 10.1074/jbc.275.4.2721; Qiu HQ, 2004, ONCOGENE, V23, P2216, DOI 10.1038/sj.onc.1207339; Qiu HQ, 2002, J BIOL CHEM, V277, P34634, DOI 10.1074/jbc.M203877200; Scott MP, 2000, BIOCHEMISTRY-US, V39, P14531, DOI 10.1021/bi001850u; Segawa Y, 2006, P NATL ACAD SCI USA, V103, P12021, DOI 10.1073/pnas.0600021103; Sicheri F, 1997, CURR OPIN STRUC BIOL, V7, P777, DOI 10.1016/S0959-440X(97)80146-7; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; Steenkamp ET, 2006, MOL BIOL EVOL, V23, P93, DOI 10.1093/molbev/msj011; Sun GQ, 1997, BIOCHEMISTRY-US, V36, P2139, DOI 10.1021/bi962291n; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; TILL JH, 1994, J BIOL CHEM, V269, P7423; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Young MA, 2001, CELL, V105, P115, DOI 10.1016/S0092-8674(01)00301-4	52	53	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15491	15501		10.1074/jbc.M800002200	http://dx.doi.org/10.1074/jbc.M800002200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18390552	hybrid, Green Published			2022-12-25	WOS:000256232000067
J	Pesavento, JJ; Bullock, CR; Leduc, RD; Mizzen, CA; Kelleher, NL				Pesavento, James J.; Bullock, Courtney R.; LeDuc, Richard D.; Mizzen, Craig A.; Kelleher, Neil L.			Combinatorial modification of human histone H4 quantitated by two-dimensional liquid chromatography coupled with top down mass spectrometry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POSTTRANSLATIONAL MODIFICATIONS; CELL-CYCLE; IN-VIVO; METHYLATION; ACETYLATION; H3; LYSINE-20; METHYLTRANSFERASE; IDENTIFICATION; PROTEINS	Quantitative proteomics has focused heavily on correlating protein abundances, ratios, and dynamics by developing methods that are protein expression-centric (e.g. isotope coded affinity tag, isobaric tag for relative and absolute quantification, etc.). These methods effectively detect changes in protein abundance but fail to provide a comprehensive perspective of the diversity of proteins such as histones, which are regulated by post-translational modifications. Here, we report the characterization of modified forms of HeLa cell histone H4 with a dynamic range > 10(4) using a strictly Top Down mass spectrometric approach coupled with two dimensions of liquid chromatography. This enhanced dynamic range enabled the precise characterization and quantitation of 42 forms uniquely modified by combinations of methylation and acetylation, including those with dimethylated Lys-20, monomethylated Arg-3, and the novel dimethylated Arg-3 (each <1% of all H4 forms). Quantitative analyses revealed distinct trends in acetylation site occupancy depending on Lys-20 methylation state. Because both modifications are dynamically regulated through the cell cycle, we simultaneously investigated acetylation and methylation kinetics through three cell cycle phases and used these data to statistically assess the robustness of our quantitative analysis. This work represents the most comprehensive analysis of histone H4 forms present in human cells reported to date.	[Bullock, Courtney R.; LeDuc, Richard D.; Kelleher, Neil L.] Univ Illinois, Dept Chem, Urbana, IL 61801 USA; [Pesavento, James J.; Kelleher, Neil L.] Univ Illinois, Ctr Biophys & Computat Biol, Urbana, IL 61801 USA; [Mizzen, Craig A.] Univ Illinois, Dept Cell & Dev Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Kelleher, NL (corresponding author), Univ Illinois, Dept Chem, 600 S Mathews,53 Rodger Adams Lab, Urbana, IL 61801 USA.	kelleher@scs.uiuc.edu		LeDuc, Richard/0000-0002-6951-2923; Pesavento, James/0000-0001-6107-3666	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM067193, T32GM008276] Funding Source: NIH RePORTER; NIGMS NIH HHS [5T32 GM 08276, GM 067193-04, R01 GM067193] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANNUNZIATO AT, 1983, J BIOL CHEM, V258, P2675; ANNUNZIATO AT, 1995, BIOCHEMISTRY-US, V34, P2916, DOI 10.1021/bi00009a023; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Berger SL, 2007, NATURE, V447, P407, DOI 10.1038/nature05915; Boyne MT, 2006, J PROTEOME RES, V5, P248, DOI 10.1021/pr050269n; Cuthbert GL, 2004, CELL, V118, P545, DOI 10.1016/j.cell.2004.08.020; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; DELANGE RJ, 1969, J BIOL CHEM, V244, P319; Downs JA, 2007, NATURE, V447, P951, DOI 10.1038/nature05980; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Felsenfeld G, 2003, NATURE, V421, P448, DOI 10.1038/nature01411; Fischer JJ, 2008, GENOMICS, V91, P41, DOI 10.1016/j.ygeno.2007.08.010; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Garcia BA, 2007, NAT METHODS, V4, P487, DOI 10.1038/nmeth1052; Hirs C. H. W, 1967, METHODS ENZYMOL, V11, P197; Horn DM, 2000, J AM SOC MASS SPECTR, V11, P320, DOI 10.1016/S1044-0305(99)00157-9; Huang SM, 2005, GENE DEV, V19, P1885, DOI 10.1101/gad.1333905; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; Jiang L, 2007, J BIOL CHEM, V282, P27923, DOI 10.1074/jbc.M704194200; Kaufman PD, 1996, CURR OPIN CELL BIOL, V8, P369, DOI 10.1016/S0955-0674(96)80012-3; Kelleher NL, 2004, ANAL CHEM, V76, p196A, DOI 10.1021/ac0415657; KNEHR M, 1995, EXP CELL RES, V217, P546, DOI 10.1006/excr.1995.1121; Kourmouli N, 2004, J CELL SCI, V117, P2491, DOI 10.1242/jcs.01238; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; LIEW CC, 1970, NATURE, V226, P414, DOI 10.1038/226414a0; Mizzen CA, 2000, J CHROMATOGR B, V744, P33, DOI 10.1016/S0378-4347(00)00210-3; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Pesavento JJ, 2008, MOL CELL BIOL, V28, P468, DOI 10.1128/MCB.01517-07; Pesavento JJ, 2007, MOL CELL PROTEOMICS, V6, P1510, DOI 10.1074/mcp.M600404-MCP200; Pesavento JJ, 2006, ANAL CHEM, V78, P4271, DOI 10.1021/ac0600050; Pesavento JJ, 2004, J AM CHEM SOC, V126, P3386, DOI 10.1021/ja039748i; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; Sarg B, 2004, J BIOL CHEM, V279, P53458, DOI 10.1074/jbc.M409099200; Sarg B, 2002, J BIOL CHEM, V277, P39195, DOI 10.1074/jbc.M205166200; Schafer KA, 1998, VET PATHOL, V35, P461, DOI 10.1177/030098589803500601; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Siuti N, 2006, J PROTEOME RES, V5, P233, DOI 10.1021/pr050268v; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Song OK, 2003, J BIOL CHEM, V278, P38109, DOI 10.1074/jbc.C300355200; Spada F, 2005, J CELL BIOCHEM, V95, P885, DOI 10.1002/jcb.20416; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Strahl BD, 2001, CURR BIOL, V11, P996, DOI 10.1016/S0960-9822(01)00294-9; Tamaru H, 2003, NAT GENET, V34, P75, DOI 10.1038/ng1143; Taylor GK, 2003, ANAL CHEM, V75, P4081, DOI 10.1021/ac0341721; Thomas CE, 2006, J PROTEOME RES, V5, P240, DOI 10.1021/pr050266a; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; Trievel RC, 2004, CRIT REV EUKAR GENE, V14, P147, DOI 10.1615/CritRevEukaryotGeneExpr.v14.i3.10; TURNER BM, 1989, FEBS LETT, V253, P141, DOI 10.1016/0014-5793(89)80947-0; Turner BM, 2002, CELL, V111, P285, DOI 10.1016/S0092-8674(02)01080-2; Wang HB, 2001, SCIENCE, V293, P853, DOI 10.1126/science.1060781; Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400; Zhang KL, 2002, MOL CELL PROTEOMICS, V1, P500, DOI 10.1074/mcp.M200031-MCP200; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6; Zubarev RA, 1998, J AM CHEM SOC, V120, P3265, DOI 10.1021/ja973478k	57	141	145	0	38	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					14927	14937		10.1074/jbc.M709796200	http://dx.doi.org/10.1074/jbc.M709796200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18381279	Green Published, hybrid			2022-12-25	WOS:000256232000004
J	Zhou, FF; Zhang, L; Wang, AJ; Song, B; Gong, K; Zhang, LH; Hu, M; Zhang, XF; Zhao, NM; Gong, YD				Zhou, Fangfang; Zhang, Long; Wang, Aijun; Song, Bo; Gong, Kai; Zhang, Lihai; Hu, Min; Zhang, Xiufang; Zhao, Nanming; Gong, Yandao			The association of GSK3 beta with E2F1 facilitates nerve growth factor-induced neural cell differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNTHASE KINASE 3-BETA; UBIQUITIN-PROTEASOME PATHWAY; SUBCELLULAR-LOCALIZATION; CYCLIN D1; NUCLEAR ACCUMULATION; GENE-EXPRESSION; AXON GROWTH; DNA-DAMAGE; PC12 CELLS; DEGRADATION	It is widely acknowledged that E2F1 and GSK3 beta are both involved in the process of cell differentiation. However, the relationship between E2F1 and GSK3 beta in cell differentiation has yet to be discovered. Here, we provide evidence that in the differentiation of PC12 cells induced by nerve growth factor (NGF), GSK3 beta was increased at both the mRNA and protein levels, whereas E2F1 at these two levels was decreased. Both wild-type GSK3 beta and its kinase-defective mutant GSK3 beta KM can inhibit E2F1 by promoting its ubiquitination through physical interaction. In addition, the colocalization of GSK3 beta and E2F1 and their subcellular distribution, regulated by NGF, were observed in the process of PC12 differentiation. At the tissue level, GSK3 beta colocalized and interacted with E2F1 in mouse hippocampus. Furthermore, GSK3 beta facilitated neurite outgrowth by rescuing the promoter activities of Cdk inhibitors p21 and p15 from the inhibition caused by E2F1. To summarize, our findings suggest that GSK3 beta can promote the ubiquitination of E2F1 via physical interaction and thus inhibit its transcription activity in a kinase activity independent manner, which plays an important role in the NGF-induced PC12 differentiation.	[Zhou, Fangfang; Zhang, Long; Wang, Aijun; Song, Bo; Gong, Kai; Zhang, Xiufang; Zhao, Nanming; Gong, Yandao] Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrance & Membrane Biotechnol, Beijing 100084, Peoples R China; [Zhang, Lihai; Hu, Min] Chinese Peoples Liberat Army Gen Hosp, Dept Stomatol, Beijing 100853, Peoples R China	Tsinghua University; Chinese People's Liberation Army General Hospital	Gong, YD (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, State Key Lab Biomembrance & Membrane Biotechnol, Beijing 100084, Peoples R China.	gongyd@tsinghua.edu.cn	Zhang, Long/AAT-6571-2021; Wang, Aijun/C-7559-2013	Zhang, Long/0000-0001-8139-0474; Wang, Aijun/0000-0002-2985-3627				Amanullah A, 2000, BLOOD, V96, P475; Apostolova MD, 2002, J BIOL CHEM, V277, P34471, DOI 10.1074/jbc.M205827200; Bijur GN, 2001, J BIOL CHEM, V276, P37436, DOI 10.1074/jbc.M105725200; Campanero MR, 1997, P NATL ACAD SCI USA, V94, P2221, DOI 10.1073/pnas.94.6.2221; Chou AH, 2002, ONCOGENE, V21, P6348, DOI 10.1038/sj.onc.1205791; delaLuna S, 1996, J CELL SCI, V109, P2443; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Espanel X, 1998, ONCOGENE, V17, P585, DOI 10.1038/sj.onc.1201962; Field SJ, 1996, CELL, V85, P549, DOI 10.1016/S0092-8674(00)81255-6; Garcia-Alvarez G, 2007, BBA-MOL CELL RES, V1773, P375, DOI 10.1016/j.bbamcr.2006.09.015; Gill RM, 2000, J CELL BIOL, V148, P1187, DOI 10.1083/jcb.148.6.1187; Goold RG, 2005, MOL CELL NEUROSCI, V28, P524, DOI 10.1016/j.mcn.2004.11.005; Goold RG, 2001, J CELL SCI, V114, P4273; Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9; Hateboer G, 1996, GENE DEV, V10, P2960, DOI 10.1101/gad.10.23.2960; Hofmann F, 1996, GENE DEV, V10, P2949, DOI 10.1101/gad.10.23.2949; Huang W, 2007, ONCOGENE, V26, P2471, DOI 10.1038/sj.onc.1210033; Inoue Y, 2007, EMBO J, V26, P2083, DOI 10.1038/sj.emboj.7601652; Kim MJ, 2005, HYPERTENSION, V45, P552, DOI 10.1161/01.HYP.0000158263.64320.eb; Kishida S, 2004, MOL CELL BIOL, V24, P4487, DOI 10.1128/MCB.24.10.4487-4501.2004; Lee JY, 2007, MOL CELL BIOL, V27, P3187, DOI 10.1128/MCB.01461-06; Lindeman GJ, 1997, P NATL ACAD SCI USA, V94, P5095, DOI 10.1073/pnas.94.10.5095; Milton AH, 2006, EMBO J, V25, P1046, DOI 10.1038/sj.emboj.7600999; Naska S, 2006, J NEUROSCI, V26, P13344, DOI 10.1523/JNEUROSCI.4462-06.2006; NUMA F, 1995, CANCER RES, V55, P4676; Persengiev SP, 1999, MOL CELL BIOL, V19, P6048; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Rossig L, 2002, J BIOL CHEM, V277, P9684, DOI 10.1074/jbc.M106157200; Seng S, 2006, MOL CELL BIOL, V26, P8371, DOI 10.1128/MCB.02167-05; SHACKLEFORD GM, 1993, NEURON, V11, P865, DOI 10.1016/0896-6273(93)90116-9; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; Strachan GD, 2005, EXP NEUROL, V193, P455, DOI 10.1016/j.expneurol.2004.08.038; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Trimarchi JM, 2002, NAT REV MOL CELL BIO, V3, P11, DOI 10.1038/nrm714; Wang Z, 2004, J VIROL, V78, P7523, DOI 10.1128/JVI.78.14.7523-7527.2004; Wu LZ, 2001, NATURE, V414, P457, DOI 10.1038/35106593; Yamasaki L, 1996, CELL, V85, P537, DOI 10.1016/S0092-8674(00)81254-4; Yamasaki L, 1998, Results Probl Cell Differ, V22, P199; YAN GZ, 1995, J NEUROSCI, V15, P6200; Yoshimura T, 2005, CELL, V120, P137, DOI 10.1016/j.cell.2004.11.012; Zhang L, 2006, J BIOL CHEM, V281, P8607, DOI 10.1074/jbc.M600274200; Zhou FQ, 2004, NEURON, V42, P897, DOI 10.1016/j.neuron.2004.05.011	42	33	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14506	14515		10.1074/jbc.M706136200	http://dx.doi.org/10.1074/jbc.M706136200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18367454	hybrid			2022-12-25	WOS:000255941400038
J	Bronmark, C; Skov, C; Brodersen, J; Nilsson, PA; Hansson, LA				Broenmark, Christer; Skov, Christian; Brodersen, Jakob; Nilsson, P. Anders; Hansson, Lars-Anders			Seasonal Migration Determined by a Trade-Off between Predator Avoidance and Growth	PLOS ONE			English	Article							ROACH; FISH; RISK; DIEL; TEMPERATURE; COMMUNITY; REFUGES; SHIFTS; MODEL	Migration is a common phenomenon in many organisms, terrestrial as well as aquatic, and considerable effort has been spent to understand the evolution of migratory behaviour and its consequences for population and community dynamics. In aquatic systems, studies on migration have mainly been focused on commercially important fish species, such as salmon and trout. However, seasonal mass-migrations may occur also among other freshwater fish, e. g. in cyprinids that leave lakes and migrate into streams and wetlands in the fall and return back to the lake in spring. In a conceptual model, we hypothesized that this is an adaptive behaviour in response to seasonal changes in predation (P) and growth (G) and that migrating fish change habitat so as to minimise the ratio between predation mortality and growth rate (P/G). Estimates from bioenergetic modelling showed that seasonal changes in the ratio between predator consumption rate and prey growth rate followed the predictions from the conceptual model and also gave more precise predictions for the timing of the habitat change. By quantifying the migration of more than 1800 individually marked fish, we showed that actual migration patterns followed predictions with a remarkable accuracy, suggesting that migration patterns have evolved in response to seasonally fluctuating trade-offs between predator avoidance and foraging gains. Thus, the conceptual model provides a mechanistic understanding to mass-migration in prey fish. Further, we also show that the dominant prey fish is actually absent from the lake during a major part of the year, which should have strong implications for the dynamics of the lake ecosystem through direct and indirect food-web interactions.	[Broenmark, Christer; Brodersen, Jakob; Nilsson, P. Anders; Hansson, Lars-Anders] Lund Univ, Dept Ecol, S-22362 Lund, Sweden; [Skov, Christian] Danish Inst Fisheries Res, Silkeborg, Denmark	Lund University	Bronmark, C (corresponding author), Lund Univ, Dept Ecol, S-22362 Lund, Sweden.	christer.bronmark@limnol.lu.se	Nilsson, Anders/H-6836-2014; Skov, Christian/X-6511-2019; Hansson, Lars-Anders/HCI-2735-2022	Nilsson, Anders/0000-0002-3541-9835; Skov, Christian/0000-0002-8547-6520; Hansson, Lars-Anders/0000-0002-3035-1317	Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning; Danish National Science Research Council	Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning(Swedish Research Council Formas); Danish National Science Research Council	Funding was received from the Swedish Research Council for Environment, Agricultural Sciences and Spatial Planning. Additional funds were received from the Danish National Science Research Council. These are governmental research councils financing basic and applied research. They have no role in the actual study or preparation of manuscript.	BAKER R R, 1978, P1012; Borcherding J, 2002, J FISH BIOL, V61, P1154, DOI 10.1006/jfbi.2002.2129; BRABRAND A, 1993, OECOLOGIA, V95, P38, DOI 10.1007/BF00649504; BRODERSEN J, 2008, OIKOS IN PRESS; CASSELMAN JM, 1978, AM FISH SOC SPEC PUB, V11, P114; Castro-Santos T, 1996, FISH RES, V28, P253, DOI 10.1016/0165-7836(96)00514-0; CERRI RD, 1983, AM NAT, V121, P552, DOI 10.1086/284082; CLARK CW, 1988, AM NAT, V131, P271, DOI 10.1086/284789; Dingle H, 2007, BIOSCIENCE, V57, P113, DOI 10.1641/B570206; Dodson Julian J., 1997, P10; EKLOV P, 1995, BEHAV ECOL SOCIOBIOL, V37, P169, DOI 10.1007/s002650050178; FRYXELL JM, 1988, TRENDS ECOL EVOL, V3, P237, DOI 10.1016/0169-5347(88)90166-8; GAUTHREAUX SA, 1980, ANIMAL MIGRATION ORI, P387; GILLIAM JF, 1987, ECOLOGY, V68, P1856, DOI 10.2307/1939877; Hansson LA, 2007, LIMNOL OCEANOGR, V52, P696, DOI 10.4319/lo.2007.52.2.0696; HE X, 1990, T AM FISH SOC, V119, P825, DOI 10.1577/1548-8659(1990)119<0825:DAIEOP>2.3.CO;2; Jepsen N, 2002, HYDROBIOLOGIA, V483, P167, DOI 10.1023/A:1021379528719; Jobling M., 1994, FISH BIOENERGETICS, P309; Johnson, 1997, FISH BIOENERGETICS; JONSSON B, 1993, REV FISH BIOL FISHER, V3, P348, DOI 10.1007/BF00043384; JORDAN DR, 1985, J FISH BIOL, V27, P163, DOI 10.1111/j.1095-8649.1985.tb03239.x; KAUFMANN R, 1992, ENVIRON BIOL FISH, V33, P87, DOI 10.1007/BF00002556; Koyama A, 2005, CAN J FISH AQUAT SCI, V62, P518, DOI [10.1139/f04-220, 10.1139/F04-220]; LESSMARK O, 1983, THESIS LUND U LUND; LIMA SL, 1990, CAN J ZOOL, V68, P619, DOI 10.1139/z90-092; Lucas MC., 2001, MIGRATION FRESHWATER, DOI [10.1002/9780470999653, DOI 10.1002/9780470999653]; MAGNUSON JJ, 1985, ENVIRON BIOL FISH, V14, P241, DOI 10.1007/BF00002627; NASLUND I, 1990, J FISH BIOL, V36, P401, DOI 10.1111/j.1095-8649.1990.tb05620.x; Nilsson PA, 2006, OIKOS, V113, P251; Nilsson PA, 2000, OIKOS, V88, P539, DOI 10.1034/j.1600-0706.2000.880310.x; Northcote T.G., 1978, P326; PETTERSSON LB, 1993, OECOLOGIA, V95, P353, DOI 10.1007/BF00320988; Romare P, 2003, LIMNOL OCEANOGR, V48, P1956, DOI 10.4319/lo.2003.48.5.1956; Schindler DE, 1999, CAN J FISH AQUAT SCI, V56, P61, DOI 10.1139/cjfas-56-S1-61; Skov C, 2005, J FISH BIOL, V67, P1195, DOI 10.1111/j.1095-8649.2005.00814.x; Tarling G, 2000, CAN J FISH AQUAT SCI, V57, P38, DOI 10.1139/cjfas-57-S3-38; TURNER AM, 1990, ECOLOGY, V71, P2241, DOI 10.2307/1938636; van Dijk PLM, 2002, OECOLOGIA, V130, P496, DOI 10.1007/s00442-001-0830-3; WERNER EE, 1983, ECOLOGY, V64, P1525, DOI 10.2307/1937507; WERNER EE, 1984, ANNU REV ECOL SYST, V15, P393, DOI 10.1146/annurev.es.15.110184.002141; [No title captured]	41	99	100	2	80	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1957	10.1371/journal.pone.0001957	http://dx.doi.org/10.1371/journal.pone.0001957			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414660	Green Submitted, Green Published, gold			2022-12-25	WOS:000260867300009
J	Rempel, H; Calosing, C; Sun, B; Pulliam, L				Rempel, Hans; Calosing, Cyrus; Sun, Bing; Pulliam, Lynn			Sialoadhesin Expressed on IFN-Induced Monocytes Binds HIV-1 and Enhances Infectivity	PLOS ONE			English	Article								Background: HIV-1 infection dysregulates the immune system and alters gene expression in circulating monocytes. Differential gene expression analysis of CD14(+) monocytes from subjects infected with HIV-1 revealed increased expression of sialoadhesin (Sn, CD169, Siglec 1), a cell adhesion molecule first described in a subset of macrophages activated in chronic inflammatory diseases. Methodology/Principal Findings: We analyzed sialoadhesin expression on CD14+ monocytes by flow cytometry and found significantly higher expression in subjects with elevated viral loads compared to subjects with undetectable viral loads. In cultured CD14(+) monocytes isolated from healthy individuals, sialoadhesin expression was induced by interferon-alpha and interferon-gamma but not tumor necrosis factor-alpha. Using a stringent binding assay, sialoadhesin-expressing monocytes adsorbed HIV-1 through interaction with the sialic acid residues on the viral envelope glycoprotein gp120. Furthermore, monocytes expressing sialoadhesin facilitated HIV-1 trans infection of permissive cells, which occurred in the absence of monocyte self-infection. Conclusions/Significance: Increased sialoadhesin expression on CD14(+) monocytes occurred in response to HIV-1 infection with maximum expression associated with high viral load. We show that interferons induce sialoadhesin in primary CD14(+) monocytes, which is consistent with an antiviral response during viremia. Our findings suggest that circulating sialoadhesin-expressing monocytes are capable of binding HIV-1 and effectively delivering virus to target cells thereby enhancing the distribution of HIV-1. Sialoadhesin could disseminate HIV-1 to viral reservoirs during monocyte immunosurveillance or migration to sites of inflammation and then facilitate HIV-1 infection of permissive cells.	[Rempel, Hans; Calosing, Cyrus; Sun, Bing; Pulliam, Lynn] Vet Affairs Med Ctr, Dept Lab Med, San Francisco, CA 94121 USA; [Pulliam, Lynn] Univ Calif San Francisco, San Francisco, CA USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco	Rempel, H (corresponding author), Vet Affairs Med Ctr, Dept Lab Med, San Francisco, CA 94121 USA.	lynn.pulliam@ucsf.edu			National Institutes of Health (NIMH) [R01MH073478]; University of California, Universitywide AIDS Research Program (UARP) [ID06-NCIRE-245]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH073478] Funding Source: NIH RePORTER	National Institutes of Health (NIMH)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); University of California, Universitywide AIDS Research Program (UARP)(University of California System); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	This research was supported by grants from the National Institutes of Health (NIMH) R01MH073478 (LP) and a University of California, Universitywide AIDS Research Program (UARP) grant ID06-NCIRE-245 (LP).	Baba M, 1999, P NATL ACAD SCI USA, V96, P5698, DOI 10.1073/pnas.96.10.5698; Bobardt MD, 2003, IMMUNITY, V18, P27, DOI 10.1016/S1074-7613(02)00504-6; Boggiano C, 2007, J VIROL, V81, P2519, DOI 10.1128/JVI.01661-06; Burleigh L, 2006, J VIROL, V80, P2949, DOI 10.1128/JVI.80.6.2949-2957.2006; Crocker P R, 1998, Glycobiology, V8, pv; CROCKER PR, 1991, EMBO J, V10, P1661, DOI 10.1002/j.1460-2075.1991.tb07689.x; Delamarre L, 2005, SCIENCE, V307, P1630, DOI 10.1126/science.1108003; Endres MJ, 1996, CELL, V87, P745, DOI 10.1016/S0092-8674(00)81393-8; Fischer-Smith T, 2001, J NEUROVIROL, V7, P528, DOI 10.1080/135502801753248114; FITZGERALDBOCARSLY P, 1993, PHARMACOL THERAPEUT, V60, P39, DOI 10.1016/0163-7258(93)90021-5; Fogg DK, 2006, SCIENCE, V311, P83, DOI 10.1126/science.1117729; Geijtenbeek TBH, 2000, CELL, V100, P587, DOI 10.1016/S0092-8674(00)80694-7; Hartnell A, 2001, BLOOD, V97, P288, DOI 10.1182/blood.V97.1.288; Hendrix CW, 2000, ANTIMICROB AGENTS CH, V44, P1667, DOI 10.1128/AAC.44.6.1667-1673.2000; Kirchberger S, 2005, J IMMUNOL, V175, P1145, DOI 10.4049/jimmunol.175.2.1145; Kwon DS, 2002, IMMUNITY, V16, P135, DOI 10.1016/S1074-7613(02)00259-5; Leon B, 2005, SEMIN IMMUNOL, V17, P313, DOI 10.1016/j.smim.2005.05.013; Liu YL, 2000, J NEUROVIROL, V6, pS70; MCELRATH MJ, 1991, J CLIN INVEST, V87, P27, DOI 10.1172/JCI114981; Mellman I, 2001, CELL, V106, P255, DOI 10.1016/S0092-8674(01)00449-4; Munday J, 1999, J LEUKOCYTE BIOL, V66, P705, DOI 10.1002/jlb.66.5.705; PARSEVAL AF, 2005, J BIOL CHEM, V280, P39493; Pulliam L, 2004, J NEUROIMMUNOL, V157, P93, DOI 10.1016/j.jneuroim.2004.08.039; Saphire ACS, 2001, J VIROL, V75, P9187, DOI 10.1128/JVI.75.19.9187-9200.2001; Schmidt B, 2005, VIROLOGY, V343, P256, DOI 10.1016/j.virol.2005.09.059; SINICCO A, 1993, AIDS, V7, P1167, DOI 10.1097/00002030-199309000-00003; Sonza S, 1996, J VIROL, V70, P3863, DOI 10.1128/JVI.70.6.3863-3869.1996; Stylianou E, 2000, CLIN EXP IMMUNOL, V119, P479, DOI 10.1046/j.1365-2249.2000.01144.x; Sun JF, 2001, VIROLOGY, V284, P26, DOI 10.1006/viro.2001.0889; Tilton JC, 2006, J VIROL, V80, P11486, DOI 10.1128/JVI.00324-06; Trombetta ES, 2003, SCIENCE, V299, P1400, DOI 10.1126/science.1080106; van den Berg TK, 2001, J IMMUNOL, V166, P3637, DOI 10.4049/jimmunol.166.6.3637; van der Kuyl AC, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000257; VANDENBERG TK, 1992, J EXP MED, V176, P647, DOI 10.1084/jem.176.3.647; Vanderheijden N, 2003, J VIROL, V77, P8207, DOI 10.1128/JVI.77.15.8207-8215.2003; VONSYDOW M, 1991, AIDS RES HUM RETROV, V7, P375, DOI 10.1089/aid.1991.7.375; Wang CY, 1999, P NATL ACAD SCI USA, V96, P10367, DOI 10.1073/pnas.96.18.10367; Wei XP, 2002, ANTIMICROB AGENTS CH, V46, P1896, DOI 10.1128/AAC.46.6.1896-1905.2002; WHITELAW DM, 1972, CELL TISSUE KINET, V5, P311, DOI 10.1111/j.1365-2184.1972.tb00369.x; Williams K, 2005, J CLIN INVEST, V115, P2534, DOI 10.1172/JCI22953; Wu LJ, 1997, J EXP MED, V185, P1681, DOI 10.1084/jem.185.9.1681	41	121	122	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1967	10.1371/journal.pone.0001967	http://dx.doi.org/10.1371/journal.pone.0001967			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414664	Green Published, gold, Green Submitted			2022-12-25	WOS:000260867300013
J	Smit, C; Hallett, TB; Lange, J; Garnett, G; de Wolf, F				Smit, Colette; Hallett, Timothy B.; Lange, Joep; Garnett, Geoff; de Wolf, Frank			Late Entry to HIV Care Limits the Impact of Anti-Retroviral Therapy in the Netherlands	PLOS ONE			English	Article								Objective: To explain differences in survival in the first three years of combination anti-retroviral therapy (cART) between HIV treatment centres in the Netherlands. Methodology/Principal Findings: We developed a mathematical simulation model, parameterised using data from the ATHENA cohort that describes patients entering care, being monitored and starting cART. Three scenarios were used to represent three treatment centres with widely varying mortality rates on cART that were differentiated by: (i) the distribution of CD4 counts of patients entering care; (ii) the age distribution of patients entering care; (iii) the average rate of monitoring the patients not on cART. At the level of the treatment centre, the fraction of Dutch MSM dying in the first three years of treatment ranged from 0% to 8%. The mathematical model captured the large variation in observed mortality between the three treatment centres. Manipulating the age-distribution of patients or the frequency of monitoring did not affect the model predictions. In contrast, when the same national average distribution of CD4 count at entry was used in all the scenarios, the variation in predicted mortality between all centres was diminished. Conclusions/Significance: Patients entering care with low CD4 counts appears to be the main source of variation in the mortality rates between Dutch treatment centres. Recruiting HIV-infected individuals to care earlier could lead to substantial improvements in cART outcomes. For example, if patients were to present with at least 400 CD4 cells/mm(3), as they do already in some centres, then our model predicts that the mortality in the first three years of cART could be reduced by approximately 20%.	[Smit, Colette; de Wolf, Frank] HIV Monitoring Fdn Amsterdam, Amsterdam, Netherlands; [Hallett, Timothy B.; Garnett, Geoff; de Wolf, Frank] Imperial College London, London, England; [Lange, Joep] Academic Med Ctr Amsterdam, Amsterdam, Netherlands	Imperial College London; University of Amsterdam; Academic Medical Center Amsterdam	Smit, C (corresponding author), HIV Monitoring Fdn Amsterdam, Amsterdam, Netherlands.	Colette.Smit@amc.uva.nl	Garnett, Geoffrey P/A-9312-2008; Hallett, Timothy/A-2390-2011	Hallett, Timothy/0000-0002-9681-0424	Wellcome Trust; UK Medical Research Council	Wellcome Trust(Wellcome TrustEuropean Commission); UK Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))	TBH thanks the Wellcome Trust; GPG thanks the UK Medical Research Council	Adu-Sarkodie Y, 1998, J CLIN VIROL, V11, P173, DOI 10.1016/S0928-0197(98)00062-2; Badri M, 2006, PLOS MED, V3, P48, DOI 10.1371/journal.pmed.0030004; Braitstein P, 2006, LANCET, V367, P817, DOI 10.1016/S0140-6736(06)68337-2; DEGRUTTOLA V, 1991, J AM STAT ASSOC, V86, P569, DOI 10.2307/2290384; Egger M, 2002, LANCET, V360, P119, DOI 10.1016/S0140-6736(02)09411-4; EGGER M, 2007, 14 C RETR OPP INF; Fraser C, 2001, P ROY SOC B-BIOL SCI, V268, P2085, DOI 10.1098/rspb.2001.1777; GRAS L, 2006, MONITORING HUMAN IMM; Hallett TB, 2008, PLOS MED, V5, P403, DOI 10.1371/journal.pmed.0050053; Lepri AC, 1997, J INFECT DIS, V175, P775, DOI 10.1086/513970; MALONE JL, 1990, J ACQ IMMUN DEF SYND, V3, P144; MARGOLICK JB, 1995, NAT MED, V1, P674, DOI 10.1038/nm0795-674; McNeil AJ, 1997, STAT MED, V16, P2555, DOI 10.1002/(SICI)1097-0258(19971130)16:22&lt;2555::AID-SIM690&gt;3.0.CO;2-Y; RABOUD JM, 1995, J ACQ IMMUN DEF SYND, V10, pS67; Sabin CA, 2004, AIDS, V18, P2145, DOI 10.1097/00002030-200411050-00006; van Sighem AI, 2003, AIDS, V17, P2227, DOI 10.1097/00002030-200310170-00011	16	32	32	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1949	10.1371/journal.pone.0001949	http://dx.doi.org/10.1371/journal.pone.0001949			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398473	gold, Green Published, Green Submitted			2022-12-25	WOS:000260795500024
J	Hennig, BJ; Fielding, K; Broxholme, J; Diatta, M; Mendy, M; Moore, C; Pollard, AJ; Rayco-Solon, P; Sirugo, G; van der Sande, MA; Waight, P; Whittle, HC; Zaman, SM; Hill, AV; Hall, AJ				Hennig, Branwen J.; Fielding, Katherine; Broxholme, John; Diatta, Mathurin; Mendy, Maimuna; Moore, Catrin; Pollard, Andrew J.; Rayco-Solon, Pura; Sirugo, Giorgio; van der Sande, Marianne A.; Waight, Pauline; Whittle, Hilton C.; Zaman, Syed M.; Hill, Adrian V.; Hall, Andrew J.			Host Genetic Factors and Vaccine-Induced Immunity to Hepatitis B Virus Infection	PLOS ONE			English	Article								Background: Vaccination against hepatitis B virus infection (HBV) is safe and effective; however, vaccine-induced antibody level wanes over time. Peak vaccine-induced anti-HBs level is directly related to antibody decay, as well as risk of infection and persistent carriage despite vaccination. We investigated the role of host genetic factors in long-term immunity against HBV infection based on peak anti-HBs level and seroconversion to anti-HBc. Methods: We analyzed 715 SNP across 133 candidate genes in 662 infant vaccinees from The Gambia, assessing peak vaccine-induced anti-HBs level and core antibody (anti-HBc) status, whilst adjusting for covariates. A replication study comprised 43 SNPs in a further 393 individuals. Results: In our initial screen we found variation in IFNG, MAPK8, and IL10RA to affect peak anti-HBs level (GMTratio of <0.6 or >1.5 and P <= 0.001) and lesser associations in other genes. Odds of core-conversion was associated with variation in CD163. A coding change in ITGAL (R719V) with likely functional relevance showed evidence of association with increased peak anti-HBs level in both screens (1st screen: s595_22 GMTratio 1.71, P = 0.013; 2nd screen: s595_22 GMTratio 2.15, P = 0.011). Conclusion: This is to our knowledge the largest study to date assessing genetic determinants of HBV vaccine-induced immunity. We report on associations with anti-HBs level, which is directly related to durability of antibody level and predictive of vaccine efficacy long-term. A coding change in ITGAL, which plays a central role in immune cell interaction, was shown to exert beneficial effects on induction of peak antibody level in response to HBV vaccination. Variation in this gene does not appear to have been studied in relation to immune responses to viral or vaccine challenges previously. Our findings suggest that genetic variation in loci other than the HLA region affect immunity induced by HBV vaccination.	[Hennig, Branwen J.; Fielding, Katherine; Rayco-Solon, Pura; Hall, Andrew J.] London Sch Hyg & Trop Med, London WC1, England; [Hennig, Branwen J.; Broxholme, John; Hill, Adrian V.] Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford, England; [Diatta, Mathurin; Mendy, Maimuna; Rayco-Solon, Pura; Sirugo, Giorgio; van der Sande, Marianne A.; Waight, Pauline; Whittle, Hilton C.; Zaman, Syed M.; Hall, Andrew J.] MRC Labs, Banjul, Gambia; [Moore, Catrin; Pollard, Andrew J.] Univ Oxford, Ctr Clin Vaccinol & Trop Med, Oxford, England	University of London; London School of Hygiene & Tropical Medicine; University of Oxford; Wellcome Centre for Human Genetics; MRC Laboratory Molecular Biology; University of Oxford	Hennig, BJ (corresponding author), London Sch Hyg & Trop Med, London WC1, England.	branwen.hennig@lshtm.ac.uk	Sirugo, Giorgio/L-1628-2016; Hennig, Branwen/M-6444-2014; Moore, Catrin/K-1980-2017; Sirugo, Giorgio/N-9056-2019; Mendy, Maimuna/ABD-5038-2021	Moore, Catrin/0000-0002-8639-9846; van der Sande, Marianne AB/0000-0002-4778-6739; Hennig, Branwen J./0000-0003-4127-8386	Wellcome Trust Advanced Training Fellowship; MRC [MC_U190071516, G0700837] Funding Source: UKRI; Medical Research Council [G0700837, MC_U190071516] Funding Source: researchfish	Wellcome Trust Advanced Training Fellowship(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission)	B.J.H. was supported by a Wellcome Trust Advanced Training Fellowship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALPER CA, 1995, EXP CLIN IMMUNOGENET, V12, P171; Arbour N, 2002, J EXP MED, V195, P801, DOI 10.1084/jem.20011481; CHOTARD J, 1992, J INFECT DIS, V166, P764, DOI 10.1093/infdis/166.4.764; De Silvestri A, 2001, GENES IMMUN, V2, P367, DOI 10.1038/sj.gene.6363792; DESOMBERE I, 1995, J IMMUNOL, V154, P520; Desombere I, 2005, CLIN EXP IMMUNOL, V140, P126, DOI 10.1111/j.1365-2249.2004.02749.x; FORTUIN M, 1994, J INFECT DIS, V169, P1374, DOI 10.1093/infdis/169.6.1374; FORTUIN M, 1993, LANCET, V341, P1129, DOI 10.1016/0140-6736(93)93137-P; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; HATAE K, 1992, EUR J IMMUNOL, V22, P1899, DOI 10.1002/eji.1830220733; Hiraoka A, 2005, PATHOL RES PRACT, V201, P379, DOI 10.1016/j.prp.2004.10.006; Hohler T, 2005, HEPATOLOGY, V42, P72, DOI 10.1002/hep.20740; Hohler T, 2002, J HEPATOL, V37, P387, DOI 10.1016/S0168-8278(02)00205-2; Hohler T, 2002, LANCET, V360, P991, DOI 10.1016/S0140-6736(02)11083-X; Hohler T, 1998, HUM IMMUNOL, V59, P212, DOI 10.1016/S0198-8859(98)00014-7; INSKIP HM, 1991, INT J EPIDEMIOL, V20, P764, DOI 10.1093/ije/20.3.764; Jack AD, 1999, J INFECT DIS, V179, P489, DOI 10.1086/314578; Kimman TG, 2007, COMMUNITY GENET, V10, P201, DOI 10.1159/000106559; Kruger A, 2005, CLIN EXP IMMUNOL, V140, P325, DOI 10.1111/j.1365-2249.2005.02765.x; LIN TM, 1989, ANTICANCER RES, V9, P737; Lindemann M, 2002, VIROLOGY, V297, P245, DOI 10.1006/viro.2002.1467; Lindemann M, 2001, FEBS LETT, V495, P82, DOI 10.1016/S0014-5793(01)02339-0; LOUAGIE H, 1993, VACCINE, V11, P1188, DOI 10.1016/0264-410X(93)90041-U; Martinetti M, 2000, CLIN IMMUNOL, V97, P234, DOI 10.1006/clim.2000.4933; McDermott AB, 1997, TISSUE ANTIGENS, V50, P8, DOI 10.1111/j.1399-0039.1997.tb02827.x; Milich DR, 2003, AUTOIMMUN REV, V2, P248, DOI 10.1016/S1568-9972(03)00031-4; MILLER SA, 1988, NUCLEIC ACIDS RES, V16, P1215, DOI 10.1093/nar/16.3.1215; Newport MJ, 2004, GENES IMMUN, V5, P122, DOI 10.1038/sj.gene.6364051; Ovsyannikova IG, 2004, PHARMACOGENOMICS, V5, P417, DOI 10.1517/14622416.5.4.417; Sleijffers A, 2003, J IMMUNOL, V170, P3423, DOI 10.4049/jimmunol.170.6.3423; Sullivan JS, 1999, J PAEDIATR CHILD H, V35, P412, DOI 10.1046/j.1440-1754.1999.0390k.x; SUN ZT, 1991, CANCER DETECT PREV, V15, P313; Tabor HK, 2002, NAT REV GENET, V3, P391, DOI 10.1038/nrg796; Thursz M, 2001, QJM-MON J ASSOC PHYS, V94, P287, DOI 10.1093/qjmed/94.6.287; van der Sande MAB, 2006, J INFECT DIS, V193, P1528, DOI 10.1086/503433; van der Sande MAB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000753; Vanlandschoot P, 2002, BIOCHEM BIOPH RES CO, V297, P486, DOI 10.1016/S0006-291X(02)02243-X; Vidan-Jeras B, 2000, PFLUG ARCH EUR J PHY, V440, pR188, DOI 10.1007/s004240000059; Viviani S, 1999, VACCINE, V17, P2946, DOI 10.1016/S0264-410X(99)00178-4; Wang CB, 2004, HEPATOLOGY, V39, P978, DOI 10.1002/hep.20142; Weaver LK, 2007, J LEUKOCYTE BIOL, V81, P663, DOI 10.1189/jlb.0706428; Whittle H, 2002, BMJ-BRIT MED J, V325, P569, DOI 10.1136/bmj.325.7364.569; WHITTLE HC, 1991, LANCET, V337, P747, DOI 10.1016/0140-6736(91)91367-4; WHITTLE HC, 1995, LANCET, V345, P1089, DOI 10.1016/S0140-6736(95)90822-6; WHITTLE HC, 1983, LANCET, V1, P1203; *WHO, 2000, HEP B FACT SHEET; Yang SH, 2006, GENE THER, V13, P1110, DOI 10.1038/sj.gt.3302751; Yucesoy B, 2002, VACCINE, V20, P3193, DOI 10.1016/S0264-410X(02)00267-0	48	65	68	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1898	10.1371/journal.pone.0001898	http://dx.doi.org/10.1371/journal.pone.0001898			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365030	Green Published, gold, Green Accepted			2022-12-25	WOS:000260762400036
J	Moya-Larano, J; Vinkovic, D; De Mas, E; Corcobado, G; Moreno, E				Moya-Larano, Jordi; Vinkovic, Dejan; De Mas, Eva; Corcobado, Guadalupe; Moreno, Eulalia			Morphological Evolution of Spiders Predicted by Pendulum Mechanics	PLOS ONE			English	Article								Background: Animals have been hypothesized to benefit from pendulum mechanics during suspensory locomotion, in which the potential energy of gravity is converted into kinetic energy according to the energy-conservation principle. However, no convincing evidence has been found so far. Demonstrating that morphological evolution follows pendulum mechanics is important from a biomechanical point of view because during suspensory locomotion some morphological traits could be decoupled from gravity, thus allowing independent adaptive morphological evolution of these two traits when compared to animals that move standing on their legs; i.e., as inverted pendulums. If the evolution of body shape matches simple pendulum mechanics, animals that move suspending their bodies should evolve relatively longer legs which must confer high moving capabilities. Methodology/Principal Findings: We tested this hypothesis in spiders, a group of diverse terrestrial generalist predators in which suspensory locomotion has been lost and gained a few times independently during their evolutionary history. In spiders that hang upside-down from their webs, their legs have evolved disproportionately longer relative to their body sizes when compared to spiders that move standing on their legs. In addition, we show how disproportionately longer legs allow spiders to run faster during suspensory locomotion and how these same spiders run at a slower speed on the ground (i.e., as inverted pendulums). Finally, when suspensory spiders are induced to run on the ground, there is a clear trend in which larger suspensory spiders tend to run much more slowly than similar-size spiders that normally move as inverted pendulums (i.e., wandering spiders). Conclusions/Significance: Several lines of evidence support the hypothesis that spiders have evolved according to the predictions of pendulum mechanics. These findings have potentially important ecological and evolutionary implications since they could partially explain the occurrence of foraging plasticity and dispersal constraints as well as the evolution of sexual size dimorphism and sociality.	[Moya-Larano, Jordi; De Mas, Eva; Corcobado, Guadalupe; Moreno, Eulalia] CSIC, Estac Expt Zonas Aridas, Dept Ecol Func & Evolut, Almeria, Spain; [Vinkovic, Dejan] Univ Split, Phys Dept, Split, Croatia	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Experimental de Zonas Aridas (EEZA); University of Split	Moya-Larano, J (corresponding author), CSIC, Estac Expt Zonas Aridas, Dept Ecol Func & Evolut, Almeria, Spain.	jordi@eeza.csic.es	Moreno, Eulalia/D-4230-2014; De Mas, Eva/H-9172-2015; Moya-Laraño, Jordi/K-8596-2014	Moreno, Eulalia/0000-0002-7197-5679; De Mas, Eva/0000-0001-8225-5805; Moya-Laraño, Jordi/0000-0001-7141-3206; Vinkovic, Dejan/0000-0001-9082-3921	Spanish Ministry of Science and Culture (MEC) [CGL2004-03153, CGL2007-60520, CGL2005-01771]; FPI scholarship [BES-2005-9234]	Spanish Ministry of Science and Culture (MEC)(Spanish Government); FPI scholarship	This paper has been written under a Ramon y Cajal research contract from the Spanish Ministry of Science and Culture (MEC) to JML and a FPI scholarship (BES-2005-9234) to GC. This work has been funded by MEC grants CGL2004-03153 and CGL2007-60520 to JML and GC, as well as CGL2005-01771 to EM.	Alderweireldt M., 1994, Bulletin of the British Arachnological Society, V9, P300; Alexander RM., 2003, PRINCIPLES ANIMAL LO; Arnedo MA, 2004, MOL PHYLOGENET EVOL, V31, P225, DOI 10.1016/S1055-7903(03)00261-6; ARNOLD SJ, 1983, AM ZOOL, V23, P347, DOI 10.1093/icb/23.2.347; Aviles Leticia, 1997, P476; BAUWENS D, 1995, EVOLUTION, V49, P848, DOI 10.1111/j.1558-5646.1995.tb02321.x; Bertram JEA, 1999, J EXP BIOL, V202, P2609; Coddington JA, 2005, SPIDERS N AM IDENTIF, P18; Dickinson MH, 2000, SCIENCE, V288, P100, DOI 10.1126/science.288.5463.100; FELSENSTEIN J, 1985, AM NAT, V125, P1, DOI 10.1086/284325; Foelix R. F., 2011, BIOL SPIDERS; Foellmer Matthias W., 2007, P71; Framenau VW, 2005, J ARACHNOL, V33, P334, DOI 10.1636/04-57.1; GARLAND T, 1992, SYST BIOL, V41, P18, DOI 10.2307/2992503; Gomes MW, 2005, J THEOR BIOL, V237, P265, DOI 10.1016/j.jtbi.2005.04.014; HALLGRIMSSON B, 1995, J MORPHOL, V224, P111, DOI 10.1002/jmor.1052240112; Hormiga G., 2000, SMITHSONIAN CONTRIBU, V609, P1, DOI [DOI 10.5479/SI.00810282.609, 10.5479/si.00810282.609]; Jones D., 1985, GUIA CAMPO ARACNIDOS; Kaston B. J., 1981, SPIDERS CONNECTICUT; LUBIN Y, 1993, ECOLOGY, V74, P1915, DOI 10.2307/1940835; Lubin Y, 2007, ADV STUD BEHAV, V37, P83, DOI 10.1016/S0065-3454(07)37003-4; Maddison WP, 2003, INVERTEBR SYST, V17, P529, DOI 10.1071/IS02044; Miller JA, 2004, CLADISTICS, V20, P385, DOI 10.1111/j.1096-0031.2004.00033.x; MORENO E, 1993, ECOLOGY, V74, P2037, DOI 10.2307/1940849; Moya-Larano J, 2002, EVOLUTION, V56, P420, DOI 10.1111/j.0014-3820.2002.tb01351.x; Murphy NP, 2006, MOL PHYLOGENET EVOL, V38, P583, DOI 10.1016/j.ympev.2005.09.004; Peters H. M., 1990, ACTA ZOOL FENN, V190, P309; Powers KS, 2003, ETHOLOGY, V109, P725, DOI 10.1046/j.1439-0310.2003.00918.x; RAMOS M, P NATL ACAD SCI US, V101, P4883; Roberts MJ., 1995, COLLINS FIELD GUIDE; Roberts MJ, 1985, SPIDERS GREAT BRITAI, V2; Roberts MJ, 1985, SPIDERS GREAT BRITAI, V1; Srinivasan M, 2006, NATURE, V439, P72, DOI 10.1038/nature04113; SWARTZ SM, 1989, INT J PRIMATOL, V10, P387, DOI 10.1007/BF02736368; Warton DI, 2006, BIOL REV, V81, P259, DOI 10.1017/S1464793106007007; Wise DH, 1993, SPIDERS ECOLOGICAL W	36	35	37	0	19	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1841	10.1371/journal.pone.0001841	http://dx.doi.org/10.1371/journal.pone.0001841			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18364999	gold, Green Submitted, Green Published			2022-12-25	WOS:000260762400005
J	Impens, F; Van Damme, P; Demol, H; Van Damme, J; Vandekerckhove, J; Gevaert, K				Impens, F.; Van Damme, P.; Demol, H.; Van Damme, J.; Vandekerckhove, J.; Gevaert, K.			Mechanistic insight into taxol-induced cell death	ONCOGENE			English	Article						protease substrates; caspase-like activity; taxol; cytotoxic granule	LUNG-CANCER CELLS; INDUCED APOPTOSIS; PACLITAXEL TREATMENT; PROTEOMICS; IDENTIFICATION; PROTEASE; ACTIVATION; INHIBITION; PEPTIDES; PROTEINS	We analysed the involvement of proteases during taxol-mediated cell death of human A549 non-small-cell lung carcinoma cells using a proteomics approach that specifically targets protein N termini and further detects newly formed N termini that are the result of protein processing. Our analysis revealed 27 protease-mediated cleavages, which we divided in sites C-terminal to aspartic acid (Asp) and sites C-terminal to non-Asp residues, as the result of caspase and non-caspase protease activities, respectively. Remarkably, some of the former were insensitive to potent pancaspase inhibitors, and we therefore suggest that previous inhibitor-based studies that report on the caspase-independent nature of taxol-induced cell death should be judged with care. Furthermore, many of the sites C-terminal to non-Asp residues were also uniquely observed in a model of cytotoxic granule-mediated cell death and/or found by in vitro cataloging human mu-calpain substrates using a similar proteomics technique. This thus raises the hypothesis that killing tumor cells by chemotherapy or by immune cells holds similar non-Asp-specific proteolytic components with strong indications to calpain activity.	[Gevaert, K.] Univ Ghent, Fac Med & Hlth Sci, Dept Biochem, B-9000 Ghent, Belgium; [Impens, F.; Van Damme, P.; Demol, H.; Van Damme, J.; Vandekerckhove, J.; Gevaert, K.] Univ Ghent VIB, Dept Med Prot Res, Ghent, Belgium	Ghent University; Flanders Institute for Biotechnology (VIB); Ghent University	Gevaert, K (corresponding author), Univ Ghent, Fac Med & Hlth Sci, Dept Biochem, Baertsoenkaai 3, B-9000 Ghent, Belgium.	kris.gevaert@ugent.be	Gevaert, Kris/D-6489-2017; Van Damme, Petra/C-7269-2008; Impens, Francis/C-3335-2009; Gevaert, Kris/AAE-4212-2019; Gevaert, Kris/H-3637-2013	Gevaert, Kris/0000-0002-4237-0283; Van Damme, Petra/0000-0001-9090-027X; Gevaert, Kris/0000-0002-4237-0283; Gevaert, Kris/0000-0002-4237-0283; Demol, Hans/0000-0001-7595-0148; Impens, Francis/0000-0003-2886-9616				Bidere N, 2003, J BIOL CHEM, V278, P31401, DOI 10.1074/jbc.M301911200; Blagosklonny MV, 1999, INT J CANCER, V83, P151, DOI 10.1002/(SICI)1097-0215(19991008)83:2<151::AID-IJC1>3.0.CO;2-5; Broker LE, 2004, CANCER RES, V64, P27, DOI 10.1158/0008-5472.CAN-03-3060; Broker LE, 2002, CANCER RES, V62, P4081; Day TW, 2006, BIOCHEM PHARMACOL, V71, P1551, DOI 10.1016/j.bcp.2006.02.015; de Bruin EC, 2003, CELL DEATH DIFFER, V10, P1204, DOI 10.1038/sj.cdd.4401296; DIGWEED M, 1995, MOL CELL BIOL, V15, P305, DOI 10.1128/MCB.15.1.305; Ehrlichova M, 2005, ANTICANCER RES, V25, P4215; Enoksson M, 2007, J PROTEOME RES, V6, P2850, DOI 10.1021/pr0701052; Foghsgaard L, 2001, J CELL BIOL, V153, P999, DOI 10.1083/jcb.153.5.999; Garcia-Calvo M, 1998, J BIOL CHEM, V273, P32608, DOI 10.1074/jbc.273.49.32608; Gevaert K, 2006, J PROTEOME RES, V5, P1415, DOI 10.1021/pr060026a; Gevaert K, 2003, NAT BIOTECHNOL, V21, P566, DOI 10.1038/nbt810; Ghesquiere B, 2006, J PROTEOME RES, V5, P2438, DOI 10.1021/pr060186m; Huisman C, 2002, CLIN CANCER RES, V8, P596; Janssen K, 2007, BLOOD, V110, P3662, DOI 10.1182/blood-2007-02-073213; Karmakar S, 2007, APOPTOSIS, V12, P671, DOI 10.1007/s10495-006-0024-x; Kondo H, 1997, NATURE, V388, P75, DOI 10.1038/40411; Krishan A, 1990, Methods Cell Biol, V33, P121; Leers MPG, 1999, J PATHOL, V187, P567, DOI 10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Li R, 2005, CELL DEATH DIFFER, V12, P292, DOI 10.1038/sj.cdd.4401554; Lopez-Otin C, 2002, NAT REV MOL CELL BIO, V3, P509, DOI 10.1038/nrm858; Lu KH, 2005, CLIN CHIM ACTA, V357, P65, DOI 10.1016/j.cccn.2005.02.003; Martens L, 2005, BIOINFORMATICS, V21, P3584, DOI 10.1093/bioinformatics/bti588; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; Ofir R, 2002, CELL DEATH DIFFER, V9, P636, DOI 10.1038/sj.cdd.4401012; Ong SE, 2002, MOL CELL PROTEOMICS, V1, P376, DOI 10.1074/mcp.M200025-MCP200; Park SJ, 2004, J BIOL CHEM, V279, P51057, DOI 10.1074/jbc.M406543200; Pineiro D, 2007, EXP CELL RES, V313, P369, DOI 10.1016/j.yexcr.2006.10.020; PYTELA R, 1980, P NATL ACAD SCI-BIOL, V77, P4808, DOI 10.1073/pnas.77.8.4808; SCHIFF PB, 1980, P NATL ACAD SCI-BIOL, V77, P1561, DOI 10.1073/pnas.77.3.1561; Schotte P, 1999, FEBS LETT, V442, P117, DOI 10.1016/S0014-5793(98)01640-8; Smyth MJ, 2001, J LEUKOCYTE BIOL, V70, P18; Staes A, 2004, J PROTEOME RES, V3, P786, DOI 10.1021/pr049956p; Torres K, 1998, CANCER RES, V58, P3620; Van Damme P, 2005, NAT METHODS, V2, P771, DOI 10.1038/NMETH792; Vande Walle L, 2007, J PROTEOME RES, V6, P1006, DOI 10.1021/pr060510d; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Yan R, 2006, CELL MOL LIFE SCI, V63, P877, DOI 10.1007/s00018-005-5338-2; Zhao JS, 2005, INT J ONCOL, V27, P247; Zhao M, 2000, FEBS LETT, V485, P104, DOI 10.1016/S0014-5793(00)02195-5	42	36	37	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2008	27	33					4580	4591		10.1038/onc.2008.96	http://dx.doi.org/10.1038/onc.2008.96			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18408750				2022-12-25	WOS:000258077300007
J	Bjork, K; Rimondini, R; Hansson, AC; Terasmaa, A; Hyytia, P; Heilig, M; Sommer, WH				Bjork, K.; Rimondini, R.; Hansson, A. C.; Terasmaa, A.; Hyytia, P.; Heilig, M.; Sommer, W. H.			Modulation of voluntary ethanol consumption by beta-arrestin 2	FASEB JOURNAL			English	Article						alcoholism; animal model; brain; gene expression; ethanol preference	C-FOS EXPRESSION; NUCLEUS-ACCUMBENS; ANTISENSE OLIGONUCLEOTIDE; MORPHINE ANALGESIA; ALCOHOL-DRINKING; ANIMAL-MODELS; DOPAMINE; GENES; TRANSMISSION; GENETICS	Beta-arrestin 2 is a multifunctional key component of the G protein-coupled receptor complex and is involved in mu-opiate and dopamine D2 receptor signaling, both of which are thought to mediate the rewarding effects of ethanol consumption. We identified elevated expression of the beta-arrestin 2 gene (Arrb2) in the striatum and the hippocampus of ethanol-preferring AA rats compared to their nonpreferring counterpart ANA line. Differential mRNA expression was accompanied by different levels of Arrb2 protein. The elevated expression was associated with a 7-marker haplotype in complete linkage disequilibrium, which segregated fully between the lines, and was unique to the preferring line. Furthermore, a single, distinct, and highly significant quantitative trait locus for Arrb2 expression in hippocampus and striatum was identified at the locus of this gene, providing evidence that genetic variation may affect a cis-regulatory mechanism for expression and regional control of Arrb2. These findings were functionally validated using mice lacking Arrb2, which displayed both reduced voluntary ethanol consumption and ethanol-induced psychomotor stimulation. Our results demonstrate that beta-arrestin 2 modulates acute responses to ethanol and is an important mediator of ethanol reward.	[Bjork, K.; Hansson, A. C.; Terasmaa, A.; Heilig, M.; Sommer, W. H.] NIAAA, Lab Clin & Translat Studies, NIH, Bethesda, MD 20892 USA; [Bjork, K.; Rimondini, R.] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden; [Hyytia, P.] Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, Helsinki, Finland	National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); Karolinska Institutet; Finland National Institute for Health & Welfare	Sommer, WH (corresponding author), NIAAA, Lab Clin & Translat Studies, NIH, 10 Ctr Dr,B 10,R 15330, Bethesda, MD 20892 USA.	wolfgang.sommer@mail.nih.gov	Terasmaa, Anton/I-3312-2015; Tanda, Gianluigi/Q-4976-2019; Rimondini, Roberto/B-2500-2010; Sommer, Wolfgang H./I-4809-2019; Hansson, Anita C/K-8146-2013; Tanda, Gianluigi/B-3318-2009; roberto, rimondini/AAC-3525-2019	Terasmaa, Anton/0000-0002-5139-1764; Tanda, Gianluigi/0000-0001-9526-9878; Rimondini, Roberto/0000-0003-4099-513X; Sommer, Wolfgang H./0000-0002-5903-6521; Tanda, Gianluigi/0000-0001-9526-9878; roberto, rimondini/0000-0003-4099-513X; Hyytia, Petri/0000-0002-0284-1298	Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Arlinde C, 2004, PHARMACOGENOMICS J, V4, P208, DOI 10.1038/sj.tpj.6500243; Beaulieu JM, 2007, TRENDS PHARMACOL SCI, V28, P166, DOI 10.1016/j.tips.2007.02.006; Beaulieu JM, 2005, CELL, V122, P261, DOI 10.1016/j.cell.2005.05.012; Bjork K, 2006, FASEB J, V20, P1826, DOI 10.1096/fj.06-5896com; Bohn LM, 2000, NATURE, V408, P720, DOI 10.1038/35047086; Bohn LM, 1999, SCIENCE, V286, P2495, DOI 10.1126/science.286.5449.2495; Bohn LM, 2003, J NEUROSCI, V23, P10265; Bontempi B, 1997, J NEUROSCI, V17, P8596; Chesler EJ, 2004, NAT NEUROSCI, V7, P485, DOI 10.1038/nn0504-485; Crabbe JC, 2006, ADDICT BIOL, V11, P195, DOI 10.1111/j.1369-1600.2006.00038.x; Di Chiara G, 2004, NEUROPHARMACOLOGY, V47, P227, DOI 10.1016/j.neuropharm.2004.06.032; Edenberg HJ, 2006, ADDICT BIOL, V11, P386, DOI 10.1111/j.1369-1600.2006.00035.x; Egli M, 2005, ADDICT BIOL, V10, P309, DOI 10.1080/13556210500314550; Enoch Mary-Anne, 2003, Am J Pharmacogenomics, V3, P217, DOI 10.2165/00129785-200303040-00001; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Garcia MM, 2003, NEUROSCIENCE, V119, P787, DOI 10.1016/S0306-4522(02)00975-2; Goldman D, 2005, NAT REV GENET, V6, P521, DOI 10.1038/nrg1635; Gurevich EV, 2002, NEUROSCIENCE, V109, P421, DOI 10.1016/S0306-4522(01)00511-5; Hall FS, 2001, PSYCHOPHARMACOLOGY, V154, P43, DOI 10.1007/s002130000622; Hansson AC, 2003, J NEUROSCI, V23, P6013, DOI 10.1523/JNEUROSCI.23-14-06013.2003; HANSSON AC, 2008, J EUR NEUROSCI, DOI DOI 10.1111/J1460-9568.2008.06159.X; Hansson AC, 2007, NEUROPSYCHOPHARMACOL, V32, P117, DOI 10.1038/sj.npp.1301034; HEILIG M, 1993, EUR J PHARMACOL, V236, P339, DOI 10.1016/0014-2999(93)90610-T; HUGHES P, 1995, PHARMACOL REV, V47, P133; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; Jiang BH, 2006, NEUROSCI LETT, V400, P150, DOI 10.1016/j.neulet.2006.02.071; JOHNSON SW, 1992, J NEUROSCI, V12, P483; KALIVAS PW, 1991, BRAIN RES REV, V16, P223, DOI 10.1016/0165-0173(91)90007-U; KIIANMAA K, 1979, PHARMACOL BIOCHEM BE, V10, P603, DOI 10.1016/0091-3057(79)90240-5; Kohout TA, 2001, P NATL ACAD SCI USA, V98, P1601, DOI 10.1073/pnas.041608198; Koob GF, 2005, NAT NEUROSCI, V8, P1442, DOI 10.1038/nn1105-1442; Kreek MJ, 2002, NAT REV DRUG DISCOV, V1, P710, DOI 10.1038/nrd897; Leftowitz RJ, 2005, SCIENCE, V308, P512, DOI 10.1126/science.1109237; McBride WJ, 1998, CRIT REV NEUROBIOL, V12, P339, DOI 10.1615/CritRevNeurobiol.v12.i4.40; Mokdad AH, 2004, JAMA-J AM MED ASSOC, V291, P1238, DOI 10.1001/jama.291.10.1238; Moller C, 1997, ALCOHOL CLIN EXP RES, V21, P656, DOI 10.1111/j.1530-0277.1997.tb03818.x; Muller MM, 2006, P NATL ACAD SCI USA, V103, P14250, DOI 10.1073/pnas.0606668103; Okvist A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000930; Oswald LM, 2004, PHYSIOL BEHAV, V81, P339, DOI 10.1016/j.physbeh.2004.02.008; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Peirce JL, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-7; Peoples RW, 1996, ANNU REV PHARMACOL, V36, P185, DOI 10.1146/annurev.pa.36.040196.001153; RASSNICK S, 1993, BRAIN RES, V623, P16, DOI 10.1016/0006-8993(93)90004-7; Roberts AJ, 2000, J PHARMACOL EXP THER, V293, P1002; Saba L, 2006, MAMM GENOME, V17, P669, DOI 10.1007/s00335-005-0190-0; SOMMER W, 1993, NEUROREPORT, V5, P277, DOI 10.1097/00001756-199312000-00024; Sommer W, 1996, P NATL ACAD SCI USA, V93, P14134, DOI 10.1073/pnas.93.24.14134; Sommer W, 2006, ADDICT BIOL, V11, P289, DOI 10.1111/j.1369-1600.2006.00037.x; SPANAGEL R, 1992, P NATL ACAD SCI USA, V89, P2046, DOI 10.1073/pnas.89.6.2046; Sumner BEH, 2004, PSYCHOPHARMACOLOGY, V171, P306, DOI 10.1007/s00213-003-1579-7; Tanda GL, 1998, EUR J NEUROSCI, V10, P1179, DOI 10.1046/j.1460-9568.1998.00135.x; ULM RR, 1995, J CLIN PSYCHIAT, V56, P5; Wang JT, 2003, NEUROINFORMATICS, V1, P299, DOI 10.1385/NI:1:4:299; WEISS F, 1993, J PHARMACOL EXP THER, V267, P250	54	30	30	1	8	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2552	2560		10.1096/fj.07-102442	http://dx.doi.org/10.1096/fj.07-102442			9	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18367649				2022-12-25	WOS:000257292500046
J	Ida, K; Kurabayashi, M; Suguro, M; Hiruma, Y; Hikima, T; Yamomoto, M; Suzuki, H				Ida, Koh; Kurabayashi, Masashi; Suguro, Masaya; Hiruma, Yuhta; Hikima, Takaaki; Yamomoto, Masaki; Suzuki, Haruo			Structural basis of proteolytic activation of L-phenylalanine oxidase from Pseudomonas sp P-501	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUCOSE-FRUCTOSE OXIDOREDUCTASE; CRYSTAL-STRUCTURE; ZYMOMONAS-MOBILIS; MACROMOLECULAR STRUCTURES; PRECURSOR FORM; SUBSTRATE; IDENTIFICATION; MONOOXYGENASE; DEHYDROGENASE; HYDROXYLASE	The mature form of L-phenylalanine oxidase (PAOpt) from Pseudomonas sp. P-501 was generated and activated by the proteolytic cleavage of a noncatalytic proenzyme (proPAO). The crystal structures of proPAO, PAOpt, and the PAOpt-o-amino benzoate (AB) complex were determined at 1.7, 1.25, and 1.35 angstrom resolutions, respectively. The structure of proPAO suggests that the prosequence peptide of proPAO occupies the funnel (pathway) of the substrate amino acid from the outside of the protein to the interior flavin ring, whereas the funnel is closed with the hydrophobic residues at its vestibule in both PAOpt and the PAOpt-AB complex. All three structures have an oxygen channel that is open to the surface of the protein from the flavin ring. These results suggest that structural changes were induced by proteolysis; that is, the proteolysis of proPAO removes the prosequence and closes the funnel to keep the active site hydrophobic but keeps the oxygen channel open. The possibility that an interaction of the hydrophobic side chain of substrate with the residues of the vestibule region may open the funnel as a putative amino acid channel is discussed.	[Ida, Koh; Kurabayashi, Masashi; Hiruma, Yuhta; Suzuki, Haruo] Kitasato Univ, Dept Biosci, Sch Sci, Kanagawa 2288555, Japan; [Suguro, Masaya; Suzuki, Haruo] Kitasato Univ, Grad Sch Fundamental Life Sci, Div Biosci, Kanagawa 2288555, Japan; [Ida, Koh; Hikima, Takaaki; Yamomoto, Masaki] RIKEN SPring 8 Ctr, Mikazuki, Hyogo 6795148, Japan	Kitasato University; Kitasato University; RIKEN	Ida, K (corresponding author), Kitasato Univ, Dept Biosci, Sch Sci, Kitasato 1-15-1, Kanagawa 2288555, Japan.	idakoh@sci.kitasato-u.ac.jp						Alfieri A, 2007, P NATL ACAD SCI USA, V104, P1177, DOI 10.1073/pnas.0608381104; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Bryan PN, 2002, CHEM REV, V102, P4805, DOI 10.1021/cr010190b; BULLIS BL, 1994, J BIOL CHEM, V269, P6543; Damborsky Jiri, 2007, Biotechnology Journal, V2, P62, DOI 10.1002/biot.200600208; Enroth C, 2003, ACTA CRYSTALLOGR D, V59, P1597, DOI 10.1107/S0907444903014902; Hallberg BM, 2004, J MOL BIOL, V341, P781, DOI 10.1016/j.jmb.2004.06.033; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Huang QQ, 2005, J MOL BIOL, V348, P951, DOI 10.1016/j.jmb.2005.03.008; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Khan AR, 1998, PROTEIN SCI, V7, P815; KLEYWEGT GJ, 1994, ACTA CRYSTALLOGR D, V50, P178, DOI 10.1107/S0907444993011333; KOYAMA H, 1982, J BIOCHEM-TOKYO, V92, P1235, DOI 10.1093/oxfordjournals.jbchem.a134041; KOYAMA H, 1984, J BIOCHEM-TOKYO, V96, P421, DOI 10.1093/oxfordjournals.jbchem.a134853; KOYAMA H, 1984, CLIN CHIM ACTA, V136, P131; KOYAMA H, 1983, J BIOCHEM, V93, P1313, DOI 10.1093/oxfordjournals.jbchem.a134265; KOYAMA H, 1986, J BIOCHEM-TOKYO, V100, P859, DOI 10.1093/oxfordjournals.jbchem.a121798; Krissinel E, 2004, ACTA CRYSTALLOGR D, V60, P2256, DOI 10.1107/S0907444904026460; Li M, 2006, BIOCHEMISTRY-US, V45, P4775, DOI 10.1021/bi051847g; LOOS H, 1993, FEMS MICROBIOL LETT, V107, P293, DOI 10.1016/0378-1097(93)90325-V; Malito E, 2004, P NATL ACAD SCI USA, V101, P13157, DOI 10.1073/pnas.0404538101; MASSEY V, 1994, J BIOL CHEM, V269, P22459; Mattevi A, 2006, TRENDS BIOCHEM SCI, V31, P276, DOI 10.1016/j.tibs.2006.03.003; Moustafa IM, 2006, J MOL BIOL, V364, P991, DOI 10.1016/j.jmb.2006.09.032; Mukouyama EB, 1998, J BIOCHEM-TOKYO, V123, P1097; MUKOUYAMA EB, 1994, ARCH BIOCHEM BIOPHYS, V308, P400, DOI 10.1006/abbi.1994.1056; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; NAKAJIMA H, 1991, AGR BIOL CHEM TOKYO, V55, P3117, DOI 10.1080/00021369.1991.10857909; Nurizzo D, 2001, BIOCHEMISTRY-US, V40, P13857, DOI 10.1021/bi011355d; Pawelek PD, 2000, EMBO J, V19, P4204, DOI 10.1093/emboj/19.16.4204; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; RAICES M, 1995, FEBS LETT, V369, P233, DOI 10.1016/0014-5793(95)00758-2; SCHREUDER HA, 1988, J MOL BIOL, V199, P637, DOI 10.1016/0022-2836(88)90307-5; SERRA EC, 1995, J BIOL CHEM, V270, P19930, DOI 10.1074/jbc.270.34.19930; Sheldrick GM, 2008, ACTA CRYSTALLOGR A, V64, P112, DOI 10.1107/S0108767307043930; Suzuki H, 2004, J BIOCHEM, V136, P617, DOI 10.1093/jb/mvh169; SUZUKI H, 1991, J BIOCHEM-TOKYO, V110, P169, DOI 10.1093/oxfordjournals.jbchem.a123552; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Terwilliger TC, 2000, ACTA CRYSTALLOGR D, V56, P965, DOI 10.1107/S0907444900005072; Vagin AA, 2001, ACTA CRYSTALLOGR D, V57, P1451, DOI 10.1107/S0907444901012409; Vendrell J, 2000, BBA-PROTEIN STRUCT M, V1477, P284, DOI 10.1016/S0167-4838(99)00280-0; Wiegert T, 1996, ARCH MICROBIOL, V166, P32, DOI 10.1007/s002030050352	43	25	27	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16584	16590		10.1074/jbc.M800366200	http://dx.doi.org/10.1074/jbc.M800366200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18417467	hybrid			2022-12-25	WOS:000256497100035
J	Baden, EM; Owen, BAL; Peterson, FC; Volkman, BF; Ramirez-Alvarado, M; Thompson, JR				Baden, Elizabeth M.; Owen, Barbara A. L.; Peterson, Francis C.; Volkman, Brian F.; Ramirez-Alvarado, Marina; Thompson, James R.			Altered dimer interface decreases stability in an amyloidogenic protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMARY SYSTEMIC AMYLOIDOSIS; LIGHT-CHAIN DIMER; TERTIARY STRUCTURE; AL AMYLOIDOSIS; B1 DOMAIN; MODEL; FEATURES; TOOLS	Amyloidoses are devastating and currently incurable diseases in which the process of amyloid formation causes fatal cellular and organ damage. The molecular mechanisms underlying amyloidoses are not well known. In this study, we address the structural basis of immunoglobulin light chain amyloidosis, which results from deposition of light chains produced by clonal plasma cells. We compare light chain amyloidosis protein AL-09 to its wild-type counterpart, the kappa I O18/O8 light chain germline. Crystallographic studies indicate that both proteins form dimers. However, AL-09 has an altered dimer interface that is rotated 90 from the kappa I O18/O8 dimer interface. The three non-conservative mutations in AL-09 are located within the dimer interface, consistent with their role in the decreased stability of this amyloidogenic protein. Moreover, AL-09 forms amyloid fibrils more quickly than kappa I O18/O8 in vitro. These results support the notion that the increased stability of the monomer and delayed fibril formation, together with a properly formed dimer, may be protective against amyloidogenesis. This could open a new direction into rational drug design for amyloidogenic proteins.	[Baden, Elizabeth M.; Ramirez-Alvarado, Marina] Mayo Clin, Dept Biochem & Mol Biol, Coll Med, Rochester, MN 55905 USA; [Owen, Barbara A. L.] Mayo Clin, Dept Mol Pharmacol & Expt Therapeut, Coll Med, Rochester, MN 55905 USA; [Owen, Barbara A. L.] Mayo Clin, Dept Physiol & Biomed Engn, Coll Med, Rochester, MN 55905 USA; [Peterson, Francis C.; Volkman, Brian F.] Med Coll Wisconsin, Dept Biochem, Milwaukee, WI 53226 USA	Mayo Clinic; Mayo Clinic; Mayo Clinic; Medical College of Wisconsin	Ramirez-Alvarado, M (corresponding author), Mayo Clin, Dept Biochem & Mol Biol, Coll Med, 200 1st St SW, Rochester, MN 55905 USA.	ramirezalvarado.marina@mayo.edu; thompson.james@mayo.edu	Volkman, Brian F./ABE-7306-2020; Owen, Barbara/AAD-2322-2021; Volkman, Brian F./ABE-7312-2020	Volkman, Brian F./0000-0002-6681-5179; Volkman, Brian F./0000-0002-6681-5179; Ramirez-Alvarado, Marina/0000-0003-2325-6773	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071514] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM071514, GM071514] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abraham RS, 2003, BLOOD, V101, P3801, DOI 10.1182/blood-2002-09-2707; ALBINSSON B, 1992, J PHYS CHEM-US, V96, P6204, DOI 10.1021/j100194a023; Alim MA, 1999, CLIN EXP IMMUNOL, V118, P344; Bourne PC, 2002, ACTA CRYSTALLOGR D, V58, P815, DOI 10.1107/S0907444902004183; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cohen FE, 2003, NATURE, V426, P905, DOI 10.1038/nature02265; Dobson CM, 1999, TRENDS BIOCHEM SCI, V24, P329, DOI 10.1016/S0968-0004(99)01445-0; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; EPP O, 1975, BIOCHEMISTRY-US, V14, P4943, DOI 10.1021/bi00693a025; Ferguson N, 1999, J MOL BIOL, V286, P1597, DOI 10.1006/jmbi.1998.2548; GERTZ MA, 1989, MAYO CLIN PROC, V64, P1505, DOI 10.1016/S0025-6196(12)65706-1; Hammarstrom P, 2002, P NATL ACAD SCI USA, V99, P16427, DOI 10.1073/pnas.202495199; HUANG DB, 1994, BIOCHEMISTRY-US, V33, P14848, DOI 10.1021/bi00253a024; Huang DB, 1997, MOL IMMUNOL, V34, P1291, DOI 10.1016/S0161-5890(98)00002-9; Kim YS, 2000, J BIOL CHEM, V275, P1570, DOI 10.1074/jbc.275.3.1570; Koo EH, 1999, P NATL ACAD SCI USA, V96, P9989, DOI 10.1073/pnas.96.18.9989; Krissinel E, 2005, LECT NOTES COMPUT SC, V3695, P163; KYLE RA, 1995, SEMIN HEMATOL, V32, P45; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; McLaughlin RW, 2006, PROTEIN SCI, V15, P1710, DOI 10.1110/ps.051997606; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NOVOTNY J, 1985, P NATL ACAD SCI USA, V82, P4592, DOI 10.1073/pnas.82.14.4592; Olsen KE, 1998, BIOCHEM BIOPH RES CO, V245, P713, DOI 10.1006/bbrc.1998.8515; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Owen BAL, 2005, NAT STRUCT MOL BIOL, V12, P663, DOI 10.1038/nsmb965; Owen BAL, 2002, J BIOL CHEM, V277, P7086, DOI 10.1074/jbc.M111450200; Pace CN, 1997, PROTEIN STRUCTURE PR, P383; Park SH, 1997, BIOCHEMISTRY-US, V36, P14277, DOI 10.1021/bi971914+; Perfetti V, 2002, BLOOD, V100, P948, DOI 10.1182/blood-2002-01-0114; Pokkuluri PR, 1999, AMYLOID, V6, P165, DOI 10.3109/13506129909007322; Pokkuluri PR, 1998, STRUCT FOLD DES, V6, P1067, DOI 10.1016/S0969-2126(98)00107-5; Qin ZJ, 2007, BIOCHEMISTRY-US, V46, P3521, DOI 10.1021/bi061716v; Raman B, 2005, BIOCHEMISTRY-US, V44, P1288, DOI 10.1021/bi048029t; Ramirez-Alvarado M, 2003, PROTEIN SCI, V12, P567, DOI 10.1110/ps.0227403; RAMIREZALVARADO M, 2007, PROTEIN MISFOLDING B, P183; Read RJ, 2001, ACTA CRYSTALLOGR D, V57, P1373, DOI 10.1107/S0907444901012471; Richardson JS, 2003, METHOD ENZYMOL, V374, P385, DOI 10.1016/S0076-6879(03)74018-X; Roussel A, 1999, EUR J BIOCHEM, V260, P192, DOI 10.1046/j.1432-1327.1999.00136.x; SCHORMANN N, 1995, P NATL ACAD SCI USA, V92, P9490, DOI 10.1073/pnas.92.21.9490; Solomon A, 1995, AMYLOID, V2, P269, DOI 10.3109/13506129508999010; Sreerama N, 1999, PROTEIN SCI, V8, P370; Stevens FJ, 2000, AMYLOID, V7, P200, DOI 10.3109/13506120009146835; STEVENS FJ, 1980, P NATL ACAD SCI-BIOL, V77, P1144, DOI 10.1073/pnas.77.2.1144; STEVENS PW, 1995, PROTEIN SCI, V4, P421; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Sunde M, 1997, J MOL BIOL, V273, P729, DOI 10.1006/jmbi.1997.1348; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; Vistica J, 2004, ANAL BIOCHEM, V326, P234, DOI 10.1016/j.ab.2003.12.014; Wall J, 1999, BIOCHEMISTRY-US, V38, P14101, DOI 10.1021/bi991131j; Wall JS, 2004, J MOL RECOGNIT, V17, P323, DOI 10.1002/jmr.681; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736	51	86	87	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15853	15860		10.1074/jbc.M705347200	http://dx.doi.org/10.1074/jbc.M705347200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18400753	Green Published, hybrid			2022-12-25	WOS:000256332500043
J	Lao, QZ; Kobrinsky, E; Harry, JB; Ravindran, A; Soldatov, NM				Lao, Qi Zong; Kobrinsky, Evgeny; Harry, Jo Beth; Ravindran, Arippa; Soldatov, Nikolai M.			New determinant for the Ca-v beta(2) subunit modulation of the Ca(v)1.2 calcium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GATED CA2+ CHANNELS; BETA-SUBUNIT; FUNCTIONAL-PROPERTIES; MOLECULAR DETERMINANTS; ALPHA(1C) SUBUNIT; SPLICE VARIANTS; SKELETAL-MUSCLE; HUMAN HEART; VOLTAGE; INACTIVATION	Ca-v beta subunits support voltage gating of Ca(v)1.2 calcium channels and play important role in excitation-contraction coupling. The common central membrane-associated guanylate kinase (MAGUK) region of Ca-v beta binds to the alpha-interaction domain (AID) and the IQ motif of the pore-forming alpha(1C) subunit, but these two interactions do not explain why the cardiac Ca-v beta(2) subunit splice variants differentially modulate inactivation of Ca2+ currents (I-Ca). Previously we described beta(2 Delta g), a functionally active splice variant of human Ca-v beta(2) lacking MAGUK. By deletion analysis of beta(2 Delta g), we have now identified a 41-amino acid C-terminal essential determinant (beta 2CED) that stimulates ICa in the absence of Ca-v beta subunits and conveys a +20-mV shift in the peak of the I-Ca-voltage relationship. The beta 2CED is targeted by alpha(1C) to the plasma membrane, forms a complex with alpha(1C) but does not bind to AID. Electrophysiology and binding studies point to the calmodulin-interacting LA/IQ region in the alpha(1C) subunit C terminus as a functionally relevant beta 2CED binding site. The beta 2CED interacts with LA/IQ in a Ca2+- and calmodulin-independent manner and need LA, but not IQ, to activate the channel. Deletion/mutation analyses indicated that each of the three Ca-v beta(2)/alpha(1C) interactions is sufficient to support I-Ca. However, beta 2CED does not support Ca2+-dependent inactivation, suggesting that interactions of MAGUK with AID and IQ are crucial for Ca2+-induced inactivation. The beta 2CED is conserved only in Ca-v beta(2) subunits. Thus, beta 2CED constitutes a previously unknown integrative part of the multifactorial mechanism of Ca-v beta(2)-subunit differential modulation of the Ca(v)1.2 calcium channel that in beta(2 Delta g) occurs without MAGUK.	[Lao, Qi Zong; Kobrinsky, Evgeny; Harry, Jo Beth; Ravindran, Arippa; Soldatov, Nikolai M.] NIA, Natl Inst Hlth, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)	Soldatov, NM (corresponding author), 5600 Nathan Shock Dr, Baltimore, MD 21224 USA.	soldatovN@grc.nia.nih.gov	Ravindran, Arippa/AAE-3503-2020	Ravindran, Arippa/0000-0003-2853-5464	Intramural NIH HHS [Z01 AG000294-08] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [ZIAAG000294] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Berjukow S, 1996, BRIT J PHARMACOL, V118, P748, DOI 10.1111/j.1476-5381.1996.tb15463.x; Beurg M, 1999, BIOPHYS J, V76, P1744, DOI 10.1016/S0006-3495(99)77336-4; CARLSSON J, 1978, BIOCHEM J, V173, P723, DOI 10.1042/bj1730723; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Cens T, 1996, PFLUG ARCH EUR J PHY, V431, P771, DOI 10.1007/BF02253842; Cens T, 1999, J BIOL CHEM, V274, P5483, DOI 10.1074/jbc.274.9.5483; Chen YH, 2004, NATURE, V429, P675, DOI 10.1038/nature02641; Colecraft HM, 2002, J PHYSIOL-LONDON, V541, P435, DOI 10.1113/jphysiol.2002.018515; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Foell JD, 2004, PHYSIOL GENOMICS, V17, P183, DOI 10.1152/physiolgenomics.00207.2003; Garcia R, 2002, J PHYSIOL-LONDON, V545, P407, DOI 10.1113/jphysiol.2002.027433; Gerster U, 1999, J PHYSIOL-LONDON, V517, P353, DOI 10.1111/j.1469-7793.1999.0353t.x; Hanlon MR, 1999, FEBS LETT, V445, P366, DOI 10.1016/S0014-5793(99)00156-8; Harry JB, 2004, J BIOL CHEM, V279, P46367, DOI 10.1074/jbc.M409523200; Hullin R, 2003, J BIOL CHEM, V278, P21623, DOI 10.1074/jbc.M211164200; Jiang YX, 2002, NATURE, V417, P523, DOI 10.1038/417523a; Kobrinsky E, 2005, J BIOL CHEM, V280, P12474, DOI 10.1074/jbc.M412140200; Kobrinsky E, 2004, BIOPHYS J, V87, P844, DOI 10.1529/biophysj.104.041152; Koushik SV, 2006, BIOPHYS J, V91, pL99, DOI 10.1529/biophysj.106.096206; Kurejova M, 2007, EUR J PHARMACOL, V567, P10, DOI 10.1016/j.ejphar.2007.04.005; Liang HY, 2003, NEURON, V39, P951, DOI 10.1016/S0896-6273(03)00560-9; Maltez JM, 2005, NAT STRUCT MOL BIOL, V12, P372, DOI 10.1038/nsmb909; Meir A, 2000, BIOPHYS J, V79, P731, DOI 10.1016/S0006-3495(00)76331-4; Morad M, 2005, CELL CALCIUM, V38, P223, DOI 10.1016/j.ceca.2005.06.027; Opatowsky Y, 2004, NEURON, V42, P387, DOI 10.1016/S0896-6273(04)00250-8; Opatowsky Y, 2003, J BIOL CHEM, V278, P52323, DOI 10.1074/jbc.M303564200; Peterson BZ, 2000, BIOPHYS J, V78, P1906, DOI 10.1016/S0006-3495(00)76739-7; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; Qin N, 1998, P NATL ACAD SCI USA, V95, P4690, DOI 10.1073/pnas.95.8.4690; RAVINDRAN A, 2008, P NATL ACAD IN PRESS; Romanin C, 2000, FEBS LETT, V487, P301, DOI 10.1016/S0014-5793(00)02361-9; Seu L, 2006, J GEN PHYSIOL, V128, P605, DOI 10.1085/jgp.200609631; Shi CZ, 2002, J BIOL CHEM, V277, P6813, DOI 10.1074/jbc.M110524200; SOLDATOV NM, 1995, J BIOL CHEM, V270, P10540, DOI 10.1074/jbc.270.18.10540; Stotz SC, 2004, J PHYSIOL-LONDON, V554, P263, DOI 10.1113/jphysiol.2003.047068; Takahashi SX, 2005, J GEN PHYSIOL, V126, P365, DOI 10.1085/jgp.200509354; Van Petegem F, 2004, NATURE, V429, P671, DOI 10.1038/nature02588; Xiang CC, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh185; Zhou JM, 1997, P NATL ACAD SCI USA, V94, P2301, DOI 10.1073/pnas.94.6.2301	40	20	21	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15577	15588		10.1074/jbc.M802035200	http://dx.doi.org/10.1074/jbc.M802035200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18411278	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000256332500011
J	Eudes, A; Bozzo, GG; Waller, JC; Naponelli, V; Lim, EK; Bowles, DJ; Gregory, JF; Hanson, AD				Eudes, Aymerick; Bozzo, Gale G.; Waller, Jeffrey C.; Naponelli, Valeria; Lim, Eng-Kiat; Bowles, Dianna J.; Gregory, Jesse F., III; Hanson, Andrew D.			Metabolism of the folate precursor p-aminobenzoate in plants - Glucose ester formation and vacuolar storage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SUSPENSION-CULTURES; PHENOLIC-COMPOUNDS; ORGANIC-ACIDS; COMPARTMENTATION; MITOCHONDRIA; NUCLEOTIDES; SYNTHASE; BINDING; GLYCOSYLTRANSFERASES; BIOSYNTHESIS	Plants produce p-aminobenzoate (pABA) in chloroplasts and use it for folate synthesis in mitochondria. In plant tissues, however, pABA is known to occur predominantly as its glucose ester (pABA-Glc), and the role of this metabolite in folate synthesis has not been defined. In this study, the UDP-glucose:pABA acyl-glucosyltransferase (pAGT) activity in Arabidopsis extracts was found to reside principally (95%) in one isoform with an apparent K-m for pABA of 0.12 mM. Screening of recombinant Arabidopsis UDP-glycosyltransferases identified only three that recognized pABA. One of these (UGT75B1) exhibited a far higher k(cat)/K-m value than the others and a far lower apparent K-m for pABA (0.12 mm), suggesting its identity with the principal enzyme in vivo. Supporting this possibility, ablation of UGT75B1 reduced extractable pAGT activity by 95%, in vivo [C-14]pABA glucosylation by 77%, and the endogenous pABA-Glc/pABA ratio by 9-fold. The K-eq for the pABA esterification reaction was found to be 3 x 10(-3). Taken with literature data on the cytosolic location of pAGT activity and on cytosolic UDP-glucose/UDP ratios, this K-eq value allowed estimation that only 4% of cytosolic pABA is esterified. That pABA-Glc predominates in planta therefore implies that it is sequestered away from the cytosol and, consistent with this possibility, vacuoles isolated from [C-14]pABA-fed pea leaves were estimated to contain >= 88% of the [C-14]pABA-Glc formed. In total, these data and the fact that isolated mitochondria did not take up [H-3]pABA-Glc, suggest that the glucose ester represents a storage form of pABA that does not contribute directly to folate synthesis.	[Eudes, Aymerick; Bozzo, Gale G.; Waller, Jeffrey C.; Hanson, Andrew D.] Univ Florida, Dept Hort Sci, Gainesville, FL 32611 USA; [Naponelli, Valeria; Gregory, Jesse F., III] Univ Florida, Dept Food Sci & Human Nutr, Gainesville, FL 32611 USA; [Lim, Eng-Kiat; Bowles, Dianna J.] Univ York, Dept Biol, Ctr Novel Agr Prod, York YO10 5DD, N Yorkshire, England	State University System of Florida; University of Florida; State University System of Florida; University of Florida; University of York - UK	Hanson, AD (corresponding author), Univ Florida, Dept Hort Sci, POB 110690, Gainesville, FL 32611 USA.	adha@ufl.edu	Eudes, Aymerick/AAH-4909-2021; Waller, Jeffrey/C-5683-2009	Eudes, Aymerick/0000-0002-1387-6111; Waller, Jeffrey/0000-0003-3903-4059; Gregory, Jesse/0000-0002-9976-2085; naponelli, valeria/0000-0001-5210-1522	NIGMS NIH HHS [R01 GM 071382] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM071382] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bekaert S, 2008, TRENDS PLANT SCI, V13, P28, DOI 10.1016/j.tplants.2007.11.001; BOLLER T, 1979, PLANT PHYSIOL, V63, P1123, DOI 10.1104/pp.63.6.1123; Bowles D, 2006, ANNU REV PLANT BIOL, V57, P567, DOI 10.1146/annurev.arplant.57.032905.105429; Bozzo GG, 2008, PHYTOCHEMISTRY, V69, P29, DOI 10.1016/j.phytochem.2007.06.031; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Charmont S, 2005, PHYTOCHEMISTRY, V66, P453, DOI 10.1016/j.phytochem.2004.12.013; COHEN FS, 1977, J MEMBRANE BIOL, V37, P361, DOI 10.1007/BF01940940; DANCER J, 1990, PLANT PHYSIOL, V92, P637, DOI 10.1104/pp.92.3.637; DANCER J, 1990, PLANT SCI, V66, P59, DOI 10.1016/0168-9452(90)90169-O; DOUCE R, 1987, METHOD ENZYMOL, V148, P403; EDWARDS K, 1991, NUCLEIC ACIDS RES, V19, P1349, DOI 10.1093/nar/19.6.1349; ELTHON TE, 1984, PLANT PHYSIOL, V75, P951, DOI 10.1104/pp.75.4.951; Farre EM, 2001, PLANT PHYSIOL, V127, P685, DOI 10.1104/pp.127.2.685; Gibeaut DM, 1997, PLANT PHYSIOL, V115, P317, DOI 10.1104/pp.115.2.317; Goldraij A, 2000, PLANTA, V210, P652, DOI 10.1007/s004250050056; Goulard F, 1999, EUR J PHYCOL, V34, P21, DOI 10.1017/S0967026298001711; Haferkamp I, 2007, FEBS LETT, V581, P2375, DOI 10.1016/j.febslet.2007.02.020; Hampele IC, 1997, J MOL BIOL, V268, P21, DOI 10.1006/jmbi.1997.0944; Hanson AD, 2002, CURR OPIN PLANT BIOL, V5, P244, DOI 10.1016/S1369-5266(02)00249-2; Hanson AD, 2001, ANNU REV PLANT PHYS, V52, P119, DOI 10.1146/annurev.arplant.52.1.119; Hong ZL, 2001, PLANT CELL, V13, P769, DOI 10.1105/tpc.13.4.769; Kocsis MG, 2003, PLANT PHYSIOL, V131, P1808, DOI 10.1104/pp.102.018846; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li LN, 2007, J MOL BIOL, V370, P951, DOI 10.1016/j.jmb.2007.05.036; Lim EK, 1998, J BIOL CHEM, V273, P34920, DOI 10.1074/jbc.273.52.34920; Lim EK, 2002, J BIOL CHEM, V277, P586, DOI 10.1074/jbc.M109287200; LIPS SH, 1966, PLANT PHYSIOL, V41, P709, DOI 10.1104/pp.41.4.709; LOOMIS WD, 1966, PHYTOCHEMISTRY, V5, P423, DOI 10.1016/S0031-9422(00)82157-3; MARTINOIA E, 2001, CRC SERIES, P221; Nok AJ, 2000, PARASITOL RES, V86, P923, DOI 10.1007/s004360000274; Offen W, 2006, EMBO J, V25, P1396, DOI 10.1038/sj.emboj.7600970; Orsomando G, 2006, PLANT J, V46, P426, DOI 10.1111/j.1365-313X.2006.02685.x; Orsomando G, 2005, J BIOL CHEM, V280, P28877, DOI 10.1074/jbc.M504306200; Panjaitan TS, 2000, JPC-J PLANAR CHROMAT, V13, P114; Peng LC, 2002, SCIENCE, V295, P147, DOI 10.1126/science.1064281; Quinlivan EP, 2003, J BIOL CHEM, V278, P20731, DOI 10.1074/jbc.M302894200; Rea PA, 2007, ANNU REV PLANT BIOL, V58, P347, DOI 10.1146/annurev.arplant.57.032905.105406; Rebeille F, 1997, EMBO J, V16, P947, DOI 10.1093/emboj/16.5.947; Rohman M, 2000, PROTEIN EXPRES PURIF, V20, P45, DOI 10.1006/prep.2000.1271; Ross J, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2001-2-2-reviews3004; Scott J, 2000, J SCI FOOD AGR, V80, P795, DOI [10.1002/(SICI)1097-0010(20000515)80:7&lt;795::AID-JSFA599&gt;3.0.CO;2-K, 10.1002/(SICI)1097-0010(20000515)80:7<795::AID-JSFA599>3.0.CO;2-K]; STERLING TM, 1990, PLANT PHYSIOL, V92, P1121, DOI 10.1104/pp.92.4.1121; Trossat C, 1996, PLANT PHYSIOL, V111, P965, DOI 10.1104/pp.111.4.965; Wink M, 1997, ADV BOT RES, V25, P141, DOI 10.1016/S0065-2296(08)60151-2; WINTER H, 1994, PLANTA, V193, P530, DOI 10.1007/BF02411558	45	36	40	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15451	15459		10.1074/jbc.M709591200	http://dx.doi.org/10.1074/jbc.M709591200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18385129	Green Published, hybrid			2022-12-25	WOS:000256232000063
J	Gheorghe, DM; Aghamohammadzadeh, S; Rooij, LISD; Allwood, EG; Winder, SJ; Ayscough, KR				Gheorghe, Dana M.; Aghamohammadzadeh, Soheil; Rooij, Lwona I. Smaczynska-de; Allwood, Ellen G.; Winder, Steve J.; Ayscough, Kathryn R.			Interactions between the yeast SM22 homologue Scp1 and actin demonstrate the importance of actin bundling in endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT TURNOVER; ARP2/3 COMPLEX; BUDDING YEAST; CELL POLARITY; BINDING; FIMBRIN; PROTEIN; ORGANIZATION; CYTOSKELETON; ACTIVATION	The yeast SM22 homologue Scp1 has previously been shown to act as an actin-bundling protein in vitro. In cells, Scp1 localizes to the cortical actin patches that form as part of the invagination process during endocytosis, and its function overlaps with that of the well characterized yeast fimbrin homologue Sac6p. In this work we have used live cell imaging to demonstrate the importance of key residues in the Scp1 actin interface. We have defined two actin binding domains within Scp1 that allow the protein to both bind and bundle actin without the need for dimerization. Green fluorescent protein-tagged mutants of Scp1 also indicate that actin localization does not require the putative phosphorylation site Ser- 185 to be functional. Deletion of SCP1 has few discernable effects on cell growth and morphology. However, we reveal that scp1 deletion is compensated for by up-regulation of Sac6. Furthermore, Scp1 levels are increased in the absence of sac6. The presence of compensatory pathways to up-regulate Sac6 or Scp1 levels in the absence of the other suggest that maintenance of sufficient bundling activity is critical within the cell. Analysis of cortical patch assembly and movement during endocytosis reveals a previously undetected role for Scp1 in movement of patches away from the plasma membrane. Additionally, we observe a dramatic increase in patch lifetime in a strain lacking both sac6 and scp1, demonstrating the central role played by actin-bundling proteins in the endocytic process.	[Gheorghe, Dana M.; Aghamohammadzadeh, Soheil; Rooij, Lwona I. Smaczynska-de; Allwood, Ellen G.; Ayscough, Kathryn R.] Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England; [Winder, Steve J.] Univ Sheffield, Dept Biomed Sci, Sheffield S10 2TN, S Yorkshire, England	University of Sheffield; University of Sheffield	Ayscough, KR (corresponding author), Univ Sheffield, Dept Mol Biol & Biotechnol, Sheffield S10 2TN, S Yorkshire, England.	k.ayscough@sheffield.ac.uk		Allwood, Ellen/0000-0003-3825-4789	MRC [G117/394] Funding Source: UKRI; Biotechnology and Biological Sciences Research Council [BB/C510091/1] Funding Source: Medline; Medical Research Council [G117/394, G117/394(66695)] Funding Source: Medline; Wellcome Trust [074979, GR077544AIA, 07479/Z/04/Z] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust)		ADAMS AEM, 1991, NATURE, V354, P404, DOI 10.1038/354404a0; Ayscough KR, 1997, J CELL BIOL, V137, P399, DOI 10.1083/jcb.137.2.399; Ayscough KR, 2000, CURR BIOL, V10, P1587, DOI 10.1016/S0960-9822(00)00859-9; Belmont LD, 1999, J CELL SCI, V112, P1325; DRUBIN DG, 1988, J CELL BIOL, V107, P2551, DOI 10.1083/jcb.107.6.2551; DULIC V, 1991, METHOD ENZYMOL, V194, P697; Fu YP, 2000, J APPL PHYSIOL, V89, P1985, DOI 10.1152/jappl.2000.89.5.1985; Gimona M, 1998, CURR BIOL, V8, pR674; Goode BL, 2001, J CELL BIOL, V153, P627, DOI 10.1083/jcb.153.3.627; Goodman A, 2003, MOL BIOL CELL, V14, P2617, DOI 10.1091/mbc.E03-01-0028; Gourlay CW, 2004, J CELL BIOL, V164, P803, DOI 10.1083/jcb.200310148; Hagan IM, 2000, PRACT APPROACH SER, V218, P179; Hettema EH, 2007, METHOD MICROBIOL, V36, P241, DOI 10.1016/S0580-9517(06)36011-4; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HOLTZMAN DA, 1994, J CELL BIOL, V126, P423, DOI 10.1083/jcb.126.2.423; HONTS JE, 1994, J CELL BIOL, V126, P413, DOI 10.1083/jcb.126.2.413; Kaiser C., 1994, METHODS YEAST GENETI; Kaksonen M, 2005, CELL, V123, P305, DOI 10.1016/j.cell.2005.09.024; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; Kudryashov DS, 2005, P NATL ACAD SCI USA, V102, P13105, DOI 10.1073/pnas.0506429102; Lappalainen P, 1997, NATURE, V388, P78, DOI 10.1038/40418; Liu J, 2006, P NATL ACAD SCI USA, V103, P10277, DOI 10.1073/pnas.0601045103; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Madania A, 1999, MOL BIOL CELL, V10, P3521, DOI 10.1091/mbc.10.10.3521; Moseley JB, 2006, MICROBIOL MOL BIOL R, V70, P605, DOI 10.1128/MMBR.00013-06; Moseley JB, 2006, METHOD ENZYMOL, V406, P215, DOI 10.1016/S0076-6879(06)06016-2; Smythe E, 2006, J CELL SCI, V119, P4589, DOI 10.1242/jcs.03247; Toret CP, 2006, J CELL SCI, V119, P4585, DOI 10.1242/jcs.03251; Winder SJ, 2003, BIOCHEM J, V375, P287, DOI 10.1042/BJ20030796; WINDER SJ, 1995, J CELL SCI, V108, P63; Winter D, 1999, CURR BIOL, V9, P501, DOI 10.1016/S0960-9822(99)80218-8	31	31	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15037	15046		10.1074/jbc.M710332200	http://dx.doi.org/10.1074/jbc.M710332200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18400761	hybrid, Green Accepted, Green Published			2022-12-25	WOS:000256232000017
J	Abdulle, S; Hagberg, L; Svennerholm, B; Fuchs, D; Gisslen, M				Abdulle, Sahra; Hagberg, Lars; Svennerholm, Bo; Fuchs, Dietmar; Gisslen, Magnus			Cerebrospinal Fluid Viral Load and Intrathecal Immune Activation in Individuals Infected with Different HIV-1 Genetic Subtypes	PLOS ONE			English	Article								Background: HIV-1 exhibits a high degree of genetic diversity and is presently divided into 3 distinct HIV-1 genetic groups designated major (M), non-M/non-O (N) and outlier (O). Group M, which currently comprises 9 subtypes (A-D, F-H, J and K), at least 34 circulating recombinant forms (CRFs) and several unique recombinant forms (URFs) is responsible for most of the HIV-1 epidemic. Most of the current knowledge of HIV-1 central nervous system (CNS) infection is based on subtype B. However, subtypes other than subtype B account for the majority of global HIV-1 infections. Therefore, we investigated whether subtypes have any influence on cerebrospinal fluid (CSF) markers of HIV-1 CNS infection. Methodology/Principal Findings: CSF HIV-1 RNA, CSF neopterin and CSF white blood cell (WBC) count were measured in patients infected with different HIV-1 subtypes. Using multivariate regression analysis, no differences in the CSF WBC count, neopterin and viral load were found between various HIV-1 subtypes. Conclusions: We did not find any subtype-dependent differences in the markers evaluated in this study.	[Abdulle, Sahra; Hagberg, Lars; Gisslen, Magnus] Univ Gothenburg, Sahlgrenska Acad, Dept Infect Dis, Gothenburg, Sweden; [Svennerholm, Bo] Gothenburg Univ, Sahlgrenska Acad, Dept Virol, Gothenburg, Sweden; [Fuchs, Dietmar] Innsbruck Med Univ, Ludwig Boltzmann Inst AIDS Res, Div Biol Chem, Innsbruck, Austria	University of Gothenburg; University of Gothenburg; Ludwig Boltzmann Institute; Medical University of Innsbruck	Abdulle, S (corresponding author), Univ Gothenburg, Sahlgrenska Acad, Dept Infect Dis, Gothenburg, Sweden.	sahra.abdulle@infect.gu.se	Fuchs, Dietmar/AAL-8011-2021; Gisslen, Magnus/D-7454-2015	Fuchs, Dietmar/0000-0003-1627-9563; Gisslen, Magnus/0000-0002-2357-1020	National Institutes of Health [R01 NS43103-01]; Medical Faculty of Goteborg University [ALFGBG-2874]; Goteborg Medical Society; Research Foundation of Swedish Physicians Against AIDS; government of the State of the Austrian Tyrol; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS043103] Funding Source: NIH RePORTER	National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Medical Faculty of Goteborg University; Goteborg Medical Society; Research Foundation of Swedish Physicians Against AIDS; government of the State of the Austrian Tyrol; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This study was supported by grants from the National Institutes of Health (NINDS R01 NS43103-01), the Medical Faculty of Goteborg University (ALFGBG-2874), the Goteborg Medical Society, the Research Foundation of Swedish Physicians Against AIDS and the government of the State of the Austrian Tyrol.	Alaeus A, 1999, AIDS, V13, P901, DOI 10.1097/00002030-199905280-00005; Albright AV, 2003, J NEUROVIROL, V9, P222, DOI 10.1080/13550280390194073; Amornkul PN, 1999, AIDS, V13, P1963, DOI 10.1097/00002030-199910010-00020; BACELLAR H, 1994, NEUROLOGY, V44, P1892, DOI 10.1212/WNL.44.10.1892; BOGNER JR, 1992, CLIN INVESTIGATOR, V70, P665; Brew BJ, 1996, J INFECT DIS, V174, P294, DOI 10.1093/infdis/174.2.294; Clifford DB, 2007, J NEUROVIROL, V13, P67, DOI 10.1080/13550280601169837; CONRAD AJ, 1995, J ACQ IMMUN DEF SYND, V10, P425, DOI 10.1097/00042560-199512000-00005; Fischer-Smith Tracy, 2005, Expert Reviews in Molecular Medicine, V7, P1, DOI 10.1017/S1462399405010239; Gartner S, 2000, SCIENCE, V287, P602, DOI 10.1126/science.287.5453.602; Geretti AM, 2006, CURR OPIN INFECT DIS, V19, P1, DOI 10.1097/01.qco.0000200293.45532.68; Gisslen M, 1999, J ACQ IMMUN DEF SYND, V21, P271, DOI 10.1097/00126334-199908010-00003; Gonzalez-Scarano F, 2005, NAT REV IMMUNOL, V5, P69, DOI 10.1038/nri1527; HAGBERG LAL, 2004, CLIN APPL CEREBROSPI, P102; HUBER C, 1984, J EXP MED, V160, P310, DOI 10.1084/jem.160.1.310; Kaleebu P, 2002, J INFECT DIS, V185, P1244, DOI 10.1086/340130; Kaleebu P, 2001, AIDS, V15, P293, DOI 10.1097/00002030-200102160-00001; Kanki PJ, 1999, J INFECT DIS, V179, P68, DOI 10.1086/314557; LAEYENDECKER O, 2006, 13 C RETR OPP INF 20; Liner KJ, 2007, J NEUROVIROL, V13, P291, DOI 10.1080/13550280701422383; Mamidi A, 2002, J NEUROVIROL, V8, P158, DOI 10.1080/13550280290049723; McArthur J H, 1986, J Neurosci Nurs, V18, P242; Neilson JR, 1999, J VIROL, V73, P4393, DOI 10.1128/JVI.73.5.4393-4403.1999; Price RW, 1996, LANCET, V348, P445, DOI 10.1016/S0140-6736(95)11035-6; Sacktor N, 2007, NAT CLIN PRACT NEURO, V3, P436, DOI 10.1038/ncpneuro0559; Shafer RW, 2000, NUCLEIC ACIDS RES, V28, P346, DOI 10.1093/nar/28.1.346; Spudich SS, 2005, BMC INFECT DIS, V5, DOI 10.1186/1471-2334-5-98; Vasan A, 2006, CLIN INFECT DIS, V42, P843, DOI 10.1086/499952; Weisman Z, 1999, J ACQ IMMUN DEF SYND, V21, P157; Wong MH, 2007, NEUROLOGY, V68, P350, DOI 10.1212/01.wnl.0000252811.48891.6d; Yepthomi T, 2006, J INT NEUROPSYCH SOC, V12, P424, DOI 10.1017/S1355617706060516	31	2	3	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1971	10.1371/journal.pone.0001971	http://dx.doi.org/10.1371/journal.pone.0001971			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414666	Green Published, gold, Green Submitted			2022-12-25	WOS:000260867300015
J	Hoeft, F; Wu, DA; Hernandez, A; Glover, GH; Shimojo, S				Hoeft, Fumiko; Wu, Daw-An; Hernandez, Arvel; Glover, Gary H.; Shimojo, Shinsuke			Electronically Switchable Sham Transcranial Magnetic Stimulation (TMS) System	PLOS ONE			English	Article							HUMAN MOTOR CORTEX; CURRENT DIRECTIONS; COIL ORIENTATION; WAVE-FORM; BRAIN; THRESHOLDS; ACTIVATION; DISEASE; FIBER; PULSE	Transcranial magnetic stimulation (TMS) is increasingly being used to demonstrate the causal links between brain and behavior in humans. Further, extensive clinical trials are being conducted to investigate the therapeutic role of TMS in disorders such as depression. Because TMS causes strong peripheral effects such as auditory clicks and muscle twitches, experimental artifacts such as subject bias and placebo effect are clear concerns. Several sham TMS methods have been developed, but none of the techniques allows one to intermix real and sham TMS on a trial-by-trial basis in a double-blind manner. We have developed an attachment that allows fast, automated switching between Standard TMS and two types of control TMS (Sham and Reverse) without movement of the coil or reconfiguration of the setup. We validate the setup by performing mathematical modeling, search-coil and physiological measurements. To see if the stimulus conditions can be blinded, we conduct perceptual discrimination and sensory perception studies. We verify that the physical properties of the stimulus are appropriate, and that successive stimuli do not contaminate each other. We find that the threshold for motor activation is significantly higher for Reversed than for Standard stimulation, and that Sham stimulation entirely fails to activate muscle potentials. Subjects and experimenters perform poorly at discriminating between Sham and Standard TMS with a figure-of-eight coil, and between Reverse and Standard TMS with a circular coil. Our results raise the possibility of utilizing this technique for a wide range of applications.	[Hoeft, Fumiko; Hernandez, Arvel] Stanford Univ, Sch Med, Ctr Interdisciplinary Brain Sci Res, Palo Alto, CA 94304 USA; [Hoeft, Fumiko; Wu, Daw-An; Shimojo, Shinsuke] CALTECH, Computat & Neural Syst & Div Biol, Pasadena, CA USA; [Wu, Daw-An] Harvard Univ, Dept Psychol, Cambridge, MA USA; [Glover, Gary H.] Stanford Univ, Sch Med, Dept Radiol, Palo Alto, CA USA	Stanford University; California Institute of Technology; Harvard University; Stanford University	Hoeft, F (corresponding author), Stanford Univ, Sch Med, Ctr Interdisciplinary Brain Sci Res, Palo Alto, CA 94304 USA.			Wu, Daw-An/0000-0003-4296-3369; Hernandez, Arvel/0000-0001-7653-9318	National Science Foundation [BCS-0305276, BCS-0305866]; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [P41EB015891] Funding Source: NIH RePORTER	National Science Foundation(National Science Foundation (NSF)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB))	This study was funded by the National Science Foundation under BCS-0305276 and BCS-0305866. The sponsors did not play any role in the study besides providing funding.	AMASSIAN VE, 1992, ELECTROEN CLIN NEURO, V85, P291, DOI 10.1016/0168-5597(92)90105-K; BARKER AT, 1991, ELECTROEN CLIN NEURO, P227; BARKER AT, 1985, LANCET, V1, P1106; BRASILNETO JP, 1992, J CLIN NEUROPHYSIOL, V9, P132, DOI 10.1097/00004691-199201000-00014; Chen R, 2000, MUSCLE NERVE, pS26; Corthout E, 2001, EXP BRAIN RES, V141, P128, DOI 10.1007/s002210100860; George MS, 2006, TRANSCRANIAL MAGNETI; Green DM, 1966, SIGNAL DETECTION THE; Hallett M, 2000, NATURE, V406, P147, DOI 10.1038/35018000; Hallett M., 2005, MAGNETIC STIMULATION, V2nd; HARRINGTON A, 2002, SCI PLACEBO; Hill AC, 2000, NEUROREPORT, V11, P3257, DOI 10.1097/00001756-200009280-00041; Ilmoniemi RJ, 1999, CRIT REV BIOMED ENG, V27, P241; Jackson J. D, 1998, CLASSICAL ELECTRODYN, VThird; Jang SH, 2005, RESTOR NEUROL NEUROS, V23, P51; Kammer T, 2001, CLIN NEUROPHYSIOL, V112, P2015, DOI 10.1016/S1388-2457(01)00673-3; Kammer T, 2001, CLIN NEUROPHYSIOL, V112, P250, DOI 10.1016/S1388-2457(00)00513-7; Kaptchuk TJ, 2000, ALTERN THER HEALTH M, V6, P18; Kobayashi M, 2003, LANCET NEUROL, V2, P145, DOI 10.1016/S1474-4422(03)00321-1; Lisanby Sarah H, 2004, BRAIN STIMULATION PS; Maeda F, 2003, PSYCHOPHARMACOLOGY, V168, P359, DOI 10.1007/s00213-002-1216-x; MILLS KR, 1992, ELECTROEN CLIN NEURO, V85, P17, DOI 10.1016/0168-5597(92)90096-T; Mulleners WM, 2002, EUR J NEUROL, V9, P35, DOI 10.1046/j.1468-1331.2002.00334.x; Okabe S, 2003, MOVEMENT DISORD, V18, P382, DOI 10.1002/mds.10370; Pascual-Leone A, 2000, CURR OPIN NEUROBIOL, V10, P232, DOI 10.1016/S0959-4388(00)00081-7; PASCUALLEONE A, 1994, ELECTROEN CLIN NEURO, V93, P42, DOI 10.1016/0168-5597(94)90090-6; Paus T, 2005, PHILOS T R SOC B, V360, P1109, DOI 10.1098/rstb.2005.1652; Robertson EM, 2003, J COGNITIVE NEUROSCI, V15, P948, DOI 10.1162/089892903770007344; ROTH BJ, 1990, IEEE T BIO-MED ENG, V37, P588, DOI 10.1109/10.55662; Ruohonen J, 2000, IEEE T BIO-MED ENG, V47, P145, DOI 10.1109/10.821731; Sakai K, 1997, EXP BRAIN RES, V113, P24, DOI 10.1007/BF02454139; Schatzberg AF, 2000, BIOL PSYCHIAT, V47, P736, DOI 10.1016/S0006-3223(00)00846-5; Vucic S, 2006, BRAIN, V129, P2436, DOI 10.1093/brain/awl172; Walsh V, 2005, TRANSCRANIAL MAGNETI; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8	35	19	20	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1923	10.1371/journal.pone.0001923	http://dx.doi.org/10.1371/journal.pone.0001923			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398456	Green Published, Green Submitted, gold, Green Accepted			2022-12-25	WOS:000260795500007
J	Stark, K; Reinhard, W; Neureuther, K; Wiedmann, S; Sedlacek, K; Baessler, A; Fischer, M; Weber, S; Kaess, B; Erdmann, J; Schunkert, H; Hengstenberg, C				Stark, Klaus; Reinhard, Wibke; Neureuther, Katharina; Wiedmann, Silke; Sedlacek, Kamil; Baessler, Andrea; Fischer, Marcus; Weber, Stefan; Kaess, Bernhard; Erdmann, Jeanette; Schunkert, Heribert; Hengstenberg, Christian			Association of Common Polymorphisms in GLUT9 Gene with Gout but Not with Coronary Artery Disease in a Large Case-Control Study	PLOS ONE			English	Article							GENOME-WIDE ASSOCIATION; SERUM URIC-ACID; MYOCARDIAL-INFARCTION; CARDIOVASCULAR-DISEASE; RISK-FACTORS; HYPERURICEMIA; MORTALITY; LOCI; SUSCEPTIBILITY; EPIDEMIOLOGY	Background: Serum uric acid (UA) levels have recently been shown to be genetically influenced by common polymorphisms in the GLUT9 gene in two genome-wide association analyses of Italian and British populations. Elevated serum UA levels are often found in conjunction with the metabolic syndrome. Hyperuricemia is the major risk factor for gout and has been associated with increased cardiovascular morbidity and mortality. The aim of the present study was to further elucidate the association of polymorphisms in GLUT9 with gout and coronary artery disease (CAD) or myocardial infarction (MI). To test our hypotheses, we performed two large case-control association analyses of individuals from the German MI Family Study. Methods and Findings: First, 665 patients with gout and 665 healthy controls, which were carefully matched for age and gender, were genotyped for four single nucleotide polymorphisms (SNPs) within or near the GLUT9 gene. All four SNPs demonstrated highly significant association with gout. SNP rs6855911, located within intron 7 of GLUT9, showed the strongest signal with a protective effect of the minor allele with an allelic odds ratio of 0.62 (95% confidence interval 0.52-0.75; p = 3.2*10(-7)). Importantly, this finding was not influenced by adjustment for components of the metabolic syndrome or intake of diuretics. Secondly, 1,473 cases with severe CAD or MI and 1,241 healthy controls were tested for the same four GLUT9 SNPs. The analyses revealed, however, no significant association with CAD or with MI. Additional screening of genome-wide association data sets showed no signal for CAD or MI within the GLUT9 gene region. Conclusion: Thus, our results provide compelling evidence that common genetic variations within the GLUT9 gene strongly influence the risk for gout but are unlikely to have a major effect on CAD or MI in a German population.	[Stark, Klaus; Reinhard, Wibke; Neureuther, Katharina; Wiedmann, Silke; Sedlacek, Kamil; Baessler, Andrea; Fischer, Marcus; Weber, Stefan; Kaess, Bernhard; Hengstenberg, Christian] Klinikum Univ Regensburg, Klin & Poliklin Innere Med 2, Regensburg, Germany; [Erdmann, Jeanette; Schunkert, Heribert] Univ Schleswig Holstein, Med Klin 2, Lubeck, Germany	University of Regensburg; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Kiel; Schleswig Holstein University Hospital	Hengstenberg, C (corresponding author), Klinikum Univ Regensburg, Klin & Poliklin Innere Med 2, Regensburg, Germany.	christian.hengstenberg@klinik.uni-regensburg.de	Stark, Klaus/D-3813-2009; Erdmann, Jeanette/P-7513-2014	Stark, Klaus/0000-0002-7832-1942; Erdmann, Jeanette/0000-0002-4486-6231; Wiedmann, Silke/0000-0002-4486-6207; Sedlacek, Kamil/0000-0003-1257-1321	National Genome Network [01GS0417]; Deutsche Forschungsgemeinschaft [He1921/9-1]; Vaillant-Stiftung; Deutsche Stiftung fuer Herzforschung; EU sponsored project Cardiogenics [LSH-2005-037593]	National Genome Network; Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Vaillant-Stiftung; Deutsche Stiftung fuer Herzforschung; EU sponsored project Cardiogenics	This study was supported by grants from the National Genome Network (NGFN, 01GS0417), Deutsche Forschungsgemeinschaft (He1921/9-1), the Vaillant-Stiftung (C.H., H.S.), the Deutsche Stiftung fuer Herzforschung, and the EU sponsored project Cardiogenics (LSH-2005-037593).	Annemans L, 2008, ANN RHEUM DIS, V67, P960, DOI 10.1136/ard.2007.076232; Augustin R, 2004, J BIOL CHEM, V279, P16229, DOI 10.1074/jbc.M312226200; Barrett JC, 2005, BIOINFORMATICS, V21, P263, DOI 10.1093/bioinformatics/bth457; Broeckel U, 2002, NAT GENET, V30, P210, DOI 10.1038/ng827; Burton PR, 2007, NATURE, V447, P661, DOI 10.1038/nature05911; Campion E W, 1987, Am J Med, V82, P421, DOI 10.1016/0002-9343(87)90441-4; Choi HK, 2005, ANN INTERN MED, V143, P499, DOI 10.7326/0003-4819-143-7-200510040-00009; Choi HK, 2005, CURR OPIN RHEUMATOL, V17, P341; Choi HK, 2007, CIRCULATION, V116, P894, DOI 10.1161/CIRCULATIONAHA.107.703389; Conen D, 2004, BMC PUBLIC HEALTH, V4, DOI 10.1186/1471-2458-4-9; Culleton BF, 1999, ANN INTERN MED, V131, P7, DOI 10.7326/0003-4819-131-1-199907060-00003; Cupples LA, 2007, BMC MED GENET, V8, DOI 10.1186/1471-2350-8-S1-S1; Dehghan A, 2008, DIABETES CARE, V31, P361, DOI 10.2337/dc07-1276; Fam AG, 2002, J RHEUMATOL, V29, P1350; Fang J, 2000, JAMA-J AM MED ASSOC, V283, P2404, DOI 10.1001/jama.283.18.2404; Faul F, 2007, BEHAV RES METHODS, V39, P175, DOI 10.3758/BF03193146; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Helgadottir A, 2007, SCIENCE, V316, P1491, DOI 10.1126/science.1142842; Hense HW, 1995, J HUM HYPERTENS, V9, P935; Knight JC, 2003, CLIN SCI, V104, P493, DOI 10.1042/CS20020304; Li S, 2007, PLOS GENET, V3, P2156, DOI 10.1371/journal.pgen.0030194; Luk AJ, 2005, AM J MANAG CARE, V11, pS435; Mattick JS, 2004, NAT REV GENET, V5, P316, DOI 10.1038/nrg1321; Mayer B, 2007, CLIN RES CARDIOL, V96, P1, DOI 10.1007/s00392-006-0447-y; McPherson R, 2007, SCIENCE, V316, P1488, DOI 10.1126/science.1142447; Niskanen LK, 2004, ARCH INTERN MED, V164, P1546, DOI 10.1001/archinte.164.14.1546; Pascual E, 2004, CURR OPIN RHEUMATOL, V16, P282, DOI 10.1097/00002281-200405000-00020; Phay JE, 2000, GENOMICS, V66, P217, DOI 10.1006/geno.2000.6195; Purcell S, 2007, AM J HUM GENET, V81, P559, DOI 10.1086/519795; Samani NJ, 2007, NEW ENGL J MED, V357, P443, DOI 10.1056/NEJMoa072366; Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358; Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382; Sedlacek K, 2007, J MOL MED, V85, P997, DOI 10.1007/s00109-007-0211-4; Shoji A, 2004, ARTHRIT RHEUM-ARTHR, V51, P321, DOI 10.1002/art.20405; Sladek R, 2007, NATURE, V445, P881, DOI 10.1038/nature05616; Steinthorsdottir V, 2007, NAT GENET, V39, P770, DOI 10.1038/ng2043; Underwood M, 2006, BMJ-BRIT MED J, V332, P1315, DOI 10.1136/bmj.332.7553.1315; Wallace C, 2008, AM J HUM GENET, V82, P139, DOI 10.1016/j.ajhg.2007.11.001; Wallace KL, 2004, J RHEUMATOL, V31, P1582; Xu JF, 2002, HUM GENET, V111, P573, DOI 10.1007/s00439-002-0819-y; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; Zeggini E, 2007, SCIENCE, V316, P1336, DOI 10.1126/science.1142364	42	67	76	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1948	10.1371/journal.pone.0001948	http://dx.doi.org/10.1371/journal.pone.0001948			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398472	Green Submitted, Green Published			2022-12-25	WOS:000260795500023
J	Grimaldi, A; Bianchi, C; Greco, G; Tettamanti, G; Noonan, DM; Valvassori, R; de Eguileor, M				Grimaldi, Annalisa; Bianchi, Cristiano; Greco, Gabriella; Tettamanti, Gianluca; Noonan, Douglas M.; Valvassori, Roberto; de Eguileor, Magda			In Vivo Isolation and Characterization of Stem Cells with Diverse Phenotypes Using Growth Factor Impregnated Biomatrices	PLOS ONE			English	Article							HIRUDO-MEDICINALIS	Background: The stimulation to differentiate into specific cell types for somatic stem cells is largely due to a series of internal and external signals coming from the microenvironment that surrounds the stem cell. Even though intensive research has been made, the basic mechanisms of plasticity and/or the molecules regulating stem cells proliferation and differentiation are not completely determined. Potential answers concerning the problems could be derived from the studies of stem cells in culture. Methodology/Principle Findings: We combine a new procedure (using the matrigel biopolymer supplemented with a selected cytokine/growth factor) with classic techniques such as light, confocal and electron microscopy, immunohistochemistry and cell culture, to perform an analysis on stem cells involved in the leech (Hirudo medicinalis) repair tissues. The leech has a relative anatomical simplicity and is a reliable model for studying a variety of basic events, such as tissue repair, which has a striking similarity with vertebrate responses. Our data demonstrate that the injection of an appropriate combination of the matrigel biopolymer supplemented with a selected cytokine/growth factor in the leech Hirudo medicinalis is a remarkably effective tool for isolating a specific cell population in vivo. A comparative analysis of biopolymer in vivo sorted stem cells indicates that VEGF recruited cells of a hematopoietic/endothelial phenotype whereas MCP-1/CCL2 isolated cells that were of an early myeloid lineage. Conclusion: Our paper describes, for the first time, a method allowing not only the isolation of a specific cell population in relation to the cytokine utilized but also the possibility to culture a precise cell type whose isolation is otherwise quite difficult. This approach could be broadly applied to isolate stem cells of diverse origins based on the recruitment stimuli employed.	[Grimaldi, Annalisa; Bianchi, Cristiano; Greco, Gabriella; Tettamanti, Gianluca; Valvassori, Roberto; de Eguileor, Magda] Univ Insubria, Dept Struct & Funct Biol, Varese, Italy; [Noonan, Douglas M.] Univ Insubria, Dept Clin & Biol Sci, Varese, Italy; [Noonan, Douglas M.] IRCCS Multimedica, Milan, Italy	University of Insubria; University of Insubria; IRCCS Multimedica	Grimaldi, A (corresponding author), Univ Insubria, Dept Struct & Funct Biol, Varese, Italy.	annalisa.grimaldi@uninsubria.it	Tettamanti, Gianluca/L-8748-2019; Noonan, Douglas M/A-8620-2010; Tettamanti, Gianluca/E-5465-2012	Tettamanti, Gianluca/0000-0002-0665-828X; Noonan, Douglas M/0000-0001-8058-0719; Tettamanti, Gianluca/0000-0002-0665-828X; Grimaldi, Annalisa/0000-0002-9258-7595	(FAR) Fondi dell'Ateneo per la Ricerca; Centro Grandi Attrezzature (CGA) of the University of Insubria; MIUR (Ministero dell'Universita e della Ricerca) PRIN; Associazione Italiana per la Ricerca sul Cancro (AIRC)	(FAR) Fondi dell'Ateneo per la Ricerca; Centro Grandi Attrezzature (CGA) of the University of Insubria; MIUR (Ministero dell'Universita e della Ricerca) PRIN(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Associazione Italiana per la Ricerca sul Cancro (AIRC)(Fondazione AIRC per la ricerca sul cancro)	This work was supported by the FAR (Fondi dell'Ateneo per la Ricerca) and the Centro Grandi Attrezzature (CGA) of the University of Insubria, the MIUR (Ministero dell'Universita e della Ricerca) PRIN, and the Associazione Italiana per la Ricerca sul Cancro (AIRC).	Arsic N, 2004, MOL THER, V10, P844, DOI 10.1016/j.ymthe.2004.08.007; Barbero A, 2001, J CELL PHYSIOL, V186, P183, DOI 10.1002/1097-4652(200102)186:2<183::AID-JCP1020>3.3.CO;2-H; Benelli R, 2000, J INFECT DIS, V182, P1643, DOI 10.1086/317597; de Eguileor M, 2004, CURR PHARM DESIGN, V10, P1979, DOI 10.2174/1381612043384358; De Eguileor M., 2001, Angiogenesis, V4, P299, DOI 10.1023/A:1016025803370; Delorme B, 2006, REGEN MED, V1, P497, DOI 10.2217/17460751.1.4.497; FLAMME I, 1992, DEVELOPMENT, V116, P435; Grimaldi A, 2006, CURR PHARM DESIGN, V12, P3033, DOI 10.2174/138161206777947443; Gritti A, 2002, J PHYSIOL-PARIS, V96, P81, DOI 10.1016/S0928-4257(01)00083-3; Grotendorst GR, 1996, CELL GROWTH DIFFER, V7, P469; Kaushansky K, 2006, NEW ENGL J MED, V354, P2034, DOI 10.1056/NEJMra052706; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; Lagasse E, 2001, IMMUNITY, V14, P425, DOI 10.1016/S1074-7613(01)00123-6; Lu DY, 2005, J NEUROTRAUM, V22, P1011, DOI 10.1089/neu.2005.22.1011; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Sreerekha PR, 2006, CELL PROLIFERAT, V39, P301, DOI 10.1111/j.1365-2184.2006.00389.x; Tamaki T, 2002, J CELL BIOL, V157, P571, DOI 10.1083/jcb.200112106; Tettamanti G, 2006, CURR MED CHEM, V13, P2737, DOI 10.2174/092986706778521986; Tettamanti G, 2004, BIOL CELL, V96, P443, DOI 10.1016/j.biolcel.2004.04.008; Tettamanti G, 2003, CYTOKINE, V22, P168, DOI 10.1016/S1043-4666(03)00176-5; Tettamanti G, 2003, TISSUE CELL, V35, P199, DOI 10.1016/S0040-8166(03)00027-2	21	11	11	1	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1910	10.1371/journal.pone.0001910	http://dx.doi.org/10.1371/journal.pone.0001910			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382683	Green Published, gold, Green Submitted			2022-12-25	WOS:000260795400035
J	Outeiro, TF; Putcha, P; Tetzlaff, JE; Spoelgen, R; Koker, M; Carvalho, F; Hyman, BT; McLean, PJ				Outeiro, Tiago Fleming; Putcha, Preeti; Tetzlaff, Julie E.; Spoelgen, Robert; Koker, Mirjam; Carvalho, Filipe; Hyman, Bradley T.; McLean, Pamela J.			Formation of Toxic Oligomeric alpha-Synuclein Species in Living Cells	PLOS ONE			English	Article								Background: Misfolding, oligomerization, and fibrillization of alpha-synuclein are thought to be central events in the onset and progression of Parkinson's disease (PD) and related disorders. Although fibrillar alpha-synuclein is a major component of Lewy bodies (LBs), recent data implicate prefibrillar, oligomeric intermediates as the toxic species. However, to date, oligomeric species have not been identified in living cells. Methodology/Principal Findings: Here we used bimolecular fluorescence complementation (BiFC) to directly visualize alpha-synuclein oligomerization in living cells, allowing us to study the initial events leading to alpha-synuclein oligomerization, the precursor to aggregate formation. This novel assay provides us with a tool with which to investigate how manipulations affecting alpha-synuclein aggregation affect the process over time. Stabilization of alpha-synuclein oligomers via BiFC results in increased cytotoxicity, which can be rescued by Hsp70 in a process that reduces the formation of alpha-synuclein oligomers. Introduction of PD-associated mutations in alpha-synuclein did not affect oligomer formation but the biochemical properties of the mutant alpha-synuclein oligomers differ from those of wild type alpha-synuclein. Conclusions/Significance: This novel application of the BiFC assay to the study of the molecular basis of neurodegenerative disorders enabled the direct visualization of alpha-synuclein oligomeric species in living cells and its modulation by Hsp70, constituting a novel important tool in the search for therapeutics for synucleinopathies.	[Outeiro, Tiago Fleming; Putcha, Preeti; Tetzlaff, Julie E.; Spoelgen, Robert; Koker, Mirjam; Carvalho, Filipe; Hyman, Bradley T.; McLean, Pamela J.] Harvard Univ, Sch Med, MGH,Alzheimers Res Unit, MassGen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA; [Outeiro, Tiago Fleming] Univ Lisbon, Fac Med, Inst Fisiol, Inst Med Mol,Cell & Mol Neurosci Unit, Lisbon, Portugal	Harvard University; Universidade de Lisboa	Outeiro, TF (corresponding author), Harvard Univ, Sch Med, MGH,Alzheimers Res Unit, MassGen Inst Neurodegenerat Dis, Charlestown, MA 02129 USA.	touteiro@fm.ul.pt; pmclean@partners.org	Tetzlaff, Julie/ABA-3395-2021; Outeiro, Tiago F/C-1067-2008; Outeiro, Tiago/M-8106-2019; Outeiro, Tiago/L-7351-2019	Outeiro, Tiago F/0000-0003-1679-1727; Outeiro, Tiago/0000-0003-1679-1727; McLean, Pamela/0000-0003-4870-5715	American Parkinson's disease association; NIH [5P50-NS38372A-06]; MBRC [Tosteson Award Postdoctoral Fellowship]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS063963, P50NS038372] Funding Source: NIH RePORTER	American Parkinson's disease association; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); MBRC; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was supported by a grant from the American Parkinson's disease association (PJM) and from the NIH 5P50-NS38372A-06 (BTH). T.F.O. was supported by the Tosteson Award Postdoctoral Fellowship from MBRC.	Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Conway KA, 2000, ANN NY ACAD SCI, V920, P42; Cookson MR, 2005, ANNU REV BIOCHEM, V74, P29, DOI 10.1146/annurev.biochem.74.082803.133400; Danzer KM, 2007, J NEUROSCI, V27, P9220, DOI 10.1523/JNEUROSCI.2617-07.2007; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Ding TT, 2002, BIOCHEMISTRY-US, V41, P10209, DOI 10.1021/bi020139h; El-Agnaf OMA, 2003, FASEB J, V17, P1945, DOI 10.1096/fj.03-0098fje; Engelender S, 1999, NAT GENET, V22, P110, DOI 10.1038/8820; Fink AL, 2006, ACCOUNTS CHEM RES, V39, P628, DOI 10.1021/ar050073t; Goedert M, 2001, CLIN CHEM LAB MED, V39, P308, DOI 10.1515/CCLM.2001.047; Hu CD, 2002, MOL CELL, V9, P789, DOI 10.1016/S1097-2765(02)00496-3; Kayed R, 2003, SCIENCE, V300, P486, DOI 10.1126/science.1079469; Kerppola TK, 2006, NAT REV MOL CELL BIO, V7, P449, DOI 10.1038/nrm1929; KLUCKEN J, 2004, J BIOL CHEM; Klucken J, 2006, FASEB J, V20, P2050, DOI 10.1096/fj.05-5422com; Kontopoulos E, 2006, HUM MOL GENET, V15, P3012, DOI 10.1093/hmg/ddl243; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lansbury PT, 2002, CURR OPIN CELL BIOL, V14, P653, DOI 10.1016/S0955-0674(02)00377-0; Lashuel HA, 2002, J MOL BIOL, V322, P1089, DOI 10.1016/S0022-2836(02)00735-0; Lucking CB, 2000, CELL MOL LIFE SCI, V57, P1894, DOI 10.1007/PL00000671; McLean PJ, 2001, NEUROSCIENCE, V104, P901, DOI 10.1016/S0306-4522(01)00113-0; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Outeiro TF, 2007, SCIENCE, V317, P516, DOI 10.1126/science.1143780; Outeiro TF, 2006, BIOCHEM BIOPH RES CO, V351, P631, DOI 10.1016/j.bbrc.2006.10.085; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Remy I, 2006, NAT METHODS, V3, P977, DOI 10.1038/nmeth979; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Wood SJ, 1999, J BIOL CHEM, V274, P19509, DOI 10.1074/jbc.274.28.19509; Zarranz JJ, 2004, ANN NEUROL, V55, P164, DOI 10.1002/ana.10795	31	322	334	1	37	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1867	10.1371/journal.pone.0001867	http://dx.doi.org/10.1371/journal.pone.0001867			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382657	Green Submitted, Green Published, gold			2022-12-25	WOS:000260795400007
J	Rocha-Perugini, V; Montpellier, C; Delgrange, D; Wychowski, C; Helle, F; Pillez, A; Drobecq, H; Le Naour, F; Charrin, S; Levy, S; Rubinstein, E; Dubuisson, J; Cocquerel, L				Rocha-Perugini, Vera; Montpellier, Claire; Delgrange, David; Wychowski, Czeslaw; Helle, Francois; Pillez, Andre; Drobecq, Herve; Le Naour, Francois; Charrin, Stephanie; Levy, Shoshana; Rubinstein, Eric; Dubuisson, Jean; Cocquerel, Laurence			The CD81 Partner EWI-2wint Inhibits Hepatitis C Virus Entry	PLOS ONE			English	Article								Two to three percent of the world's population is chronically infected with hepatitis C virus (HCV) and thus at risk of developing liver cancer. Although precise mechanisms regulating HCV entry into hepatic cells are still unknown, several cell surface proteins have been identified as entry factors for this virus. Among these molecules, the tetraspanin CD81 is essential for HCV entry. Here, we have identified a partner of CD81, EWI-2wint, which is expressed in several cell lines but not in hepatocytes. Ectopic expression of EWI-2wint in a hepatoma cell line susceptible to HCV infection blocked viral entry by inhibiting the interaction between the HCV envelope glycoproteins and CD81. This finding suggests that, in addition to the presence of specific entry factors in the hepatocytes, the lack of a specific inhibitor can contribute to the hepatotropism of HCV. This is the first example of a pathogen gaining entry into host cells that lack a specific inhibitory factor.	[Rocha-Perugini, Vera; Montpellier, Claire; Delgrange, David; Wychowski, Czeslaw; Helle, Francois; Pillez, Andre; Drobecq, Herve; Dubuisson, Jean; Cocquerel, Laurence] Univ Lille 1, CNRS, Inst Biol, UMR8161, Lille, France; [Levy, Shoshana; Cocquerel, Laurence] Stanford Univ, Med Ctr, Dept Med, Div Oncol, Stanford, CA USA; [Le Naour, Francois; Charrin, Stephanie; Rubinstein, Eric] Univ Paris 11, Inst Andre Lwoff, INSERM U602, Villejuif, France	Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); Universite de Lille - ISITE; Universite de Lille; Stanford University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Saclay	Rocha-Perugini, V (corresponding author), Univ Lille 1, CNRS, Inst Biol, UMR8161, Lille, France.	jean.dubuisson@ibl.fr; laurence.cocquerel@ibl.fr	Cocquerel, Laurence/P-1951-2016; Rocha-Perugini, Vera/D-6977-2014; Rubinstein, Eric/B-4650-2019; HELLE, Francois/G-7427-2011; CHARRIN, Stephanie/B-2892-2019; Dubuisson, Jean/E-6813-2016	Cocquerel, Laurence/0000-0002-2136-5178; Rocha-Perugini, Vera/0000-0002-1761-9884; Rubinstein, Eric/0000-0001-7623-9665; HELLE, Francois/0000-0001-6884-2456; Dubuisson, Jean/0000-0003-1626-7693; Drobecq, Herve/0000-0002-4081-1575; Charrin, Stephanie/0000-0002-4942-3990; MONTPELLIER, Claire/0000-0002-3112-8491	Institut Federatif de Recherche-142; CNRS; Agence Nationale de Recherches sur le Sida et les hepatites virales ANRS [fellowship]; Institut Pasteur de Lille/Region Nord Pas-de-Calais [fellowship]; French Ministry of Research; Howard Hughes Medical Institute	Institut Federatif de Recherche-142; CNRS(Centre National de la Recherche Scientifique (CNRS)); Agence Nationale de Recherches sur le Sida et les hepatites virales ANRS(ANRSFrench National Research Agency (ANR)); Institut Pasteur de Lille/Region Nord Pas-de-Calais(Region Hauts-de-France); French Ministry of Research(Ministry of Research, FranceEuropean Commission); Howard Hughes Medical Institute(Howard Hughes Medical Institute)	This work was supported by the Institut Federatif de Recherche-142 (IFR142) and by grants from the CNRS and the Agence Nationale de Recherches sur le Sida et les hepatites virales ANRS. V R-P was supported by a fellowship from the Institut Pasteur de Lille/Region Nord Pas-de-Calais . DD was supported by a fellowship from the ANRS. FH was supported by a fellowship from the French Ministry of Research. JD is an international scholar of the Howard Hughes Medical Institute.	Bartosch B, 2003, J BIOL CHEM, V278, P41624, DOI 10.1074/jbc.M305289200; Bartosch B, 2003, J EXP MED, V197, P633, DOI 10.1084/jem.20021756; Bost AG, 2003, J VIROL, V77, P4401, DOI 10.1128/JVI.77.7.4401-4408.2003; Boucheix C, 2001, CELL MOL LIFE SCI, V58, P1189, DOI 10.1007/PL00000933; Charrin S, 2003, BIOCHEM J, V373, P409, DOI 10.1042/BJ20030343; Charrin S, 2001, J BIOL CHEM, V276, P14329, DOI 10.1074/jbc.M011297200; Clark KL, 2001, J IMMUNOL, V167, P5115, DOI 10.4049/jimmunol.167.9.5115; Cocquerel L, 2006, J GEN VIROL, V87, P1075, DOI 10.1099/vir.0.81646-0; Cocquerel L, 1998, J VIROL, V72, P2183, DOI 10.1128/JVI.72.3.2183-2191.1998; Cocquerel L, 2003, J VIROL, V77, P10677, DOI 10.1128/JVI.77.19.10677-10683.2003; Cocquerel L, 2003, J VIROL, V77, P1604, DOI 10.1128/JVI.77.2.1604-1609.2003; Cocquerel L, 2001, J GEN VIROL, V82, P1629, DOI 10.1099/0022-1317-82-7-1629; COFFEY G, 2006, C FRS TUCS AZ US; Cormier EG, 2004, P NATL ACAD SCI USA, V101, P7270, DOI 10.1073/pnas.0402253101; Crotta S, 2006, EUR J IMMUNOL, V36, P919, DOI 10.1002/eji.200535527; Delgrange D, 2007, J GEN VIROL, V88, P2495, DOI 10.1099/vir.0.82872-0; DUBUISSON J, 2007, CELL MICROB IN PRESS; Evans MJ, 2007, NATURE, V446, P801, DOI 10.1038/nature05654; Flint M, 1999, J VIROL, V73, P6235, DOI 10.1128/JVI.73.8.6235-6244.1999; Flint M, 2006, J VIROL, V80, P11331, DOI 10.1128/JVI.00104-06; Higginbottom A, 2000, J VIROL, V74, P3642, DOI 10.1128/JVI.74.8.3642-3649.2000; Hsu M, 2003, P NATL ACAD SCI USA, V100, P7271, DOI 10.1073/pnas.0832180100; Kapadia SB, 2007, J VIROL, V81, P374, DOI 10.1128/JVI.01134-06; Kato T, 2003, GASTROENTEROLOGY, V125, P1808, DOI 10.1053/j.gastro.2003.09.023; Kazarov AR, 2002, J CELL BIOL, V158, P1299, DOI 10.1083/jcb.200204056; Keck ZY, 2004, J VIROL, V78, P9224, DOI 10.1128/JVI.78.17.9224-9232.2004; Kolesnikova TV, 2004, BLOOD, V103, P3013, DOI 10.1182/blood-2003-07-2201; Koutsoudakis G, 2007, J VIROL, V81, P588, DOI 10.1128/JVI.01534-06; Koutsoudakis G, 2006, J VIROL, V80, P5308, DOI 10.1128/JVI.02460-05; LEMON SM, 2007, FIELDS VIROLOGY, P1253; Levy S, 2005, PHYSIOLOGY, V20, P218, DOI 10.1152/physiol.00015.2005; Levy S, 2005, NAT REV IMMUNOL, V5, P136, DOI 10.1038/nri1548; Lindenbach BD, 2005, SCIENCE, V309, P623, DOI 10.1126/science.1114016; Maillard P, 2001, J VIROL, V75, P8240, DOI 10.1128/JVI.75.17.8240-8250.2001; Manns MP, 2006, GUT, V55, P1350, DOI 10.1136/gut.2005.076646; MEERTENS L, 2008, J VIROL; Molina S, 2008, J VIROL, V82, P569, DOI 10.1128/JVI.01443-07; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Rubinstein E, 1996, EUR J IMMUNOL, V26, P2657, DOI 10.1002/eji.1830261117; Sala-Valdes M, 2006, J BIOL CHEM, V281, P19665, DOI 10.1074/jbc.M602116200; Sandrin V, 2002, BLOOD, V100, P823, DOI 10.1182/blood-2001-11-0042; Stipp CS, 2003, J CELL BIOL, V163, P1167, DOI 10.1083/jcb.200309113; Stipp CS, 2001, J BIOL CHEM, V276, P40545, DOI 10.1074/jbc.M107338200; Stipp CS, 2001, J BIOL CHEM, V276, P4853, DOI 10.1074/jbc.M009859200; Tscherne DM, 2006, J VIROL, V80, P1734, DOI 10.1128/JVI.80.4.1734-1741.2006; Wakita T, 2005, NAT MED, V11, P791, DOI 10.1038/nm1268; YANG W, 2008, J BIOL CHEM; Yang XH, 2006, J BIOL CHEM, V281, P12976, DOI 10.1074/jbc.M510617200; Zhang XA, 2003, CANCER RES, V63, P2665; Zheng AH, 2007, J VIROL, V81, P12465, DOI 10.1128/JVI.01457-07; Zhong J, 2005, P NATL ACAD SCI USA, V102, P9294, DOI 10.1073/pnas.0503596102	51	86	89	0	8	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1866	10.1371/journal.pone.0001866	http://dx.doi.org/10.1371/journal.pone.0001866			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382656	gold, Green Published, Green Submitted			2022-12-25	WOS:000260795400006
J	Tinto, N; Zagari, A; Capuano, M; De Simone, A; Capobianco, V; Daniele, G; Giugliano, M; Spadaro, R; Franzese, A; Sacchetti, L				Tinto, Nadia; Zagari, Adriana; Capuano, Marina; De Simone, Alfonso; Capobianco, Valentina; Daniele, Gerardo; Giugliano, Michela; Spadaro, Raffaella; Franzese, Adriana; Sacchetti, Lucia			Glucokinase Gene Mutations: Structural and Genotype-Phenotype Analyses in MODY Children from South Italy	PLOS ONE			English	Article							YOUNG TYPE-2 MODY-2; INSULIN SENSITIVITY; ONSET; IDENTIFICATION; MECHANISMS; GCK; HYPERINSULINEMIA; HYPERGLYCEMIA; CONSERVATION; NOMENCLATURE	Background: Maturity onset diabetes of the young type 2 (or GCK MODY) is a genetic form of diabetes mellitus provoked by mutations in the glucokinase gene (GCK). Methodology/Principal Findings: We screened the GCK gene by direct sequencing in 30 patients from South Italy with suspected MODY. The mutation-induced structural alterations in the protein were analyzed by molecular modeling. The patients' biochemical, clinical and anamnestic data were obtained. Mutations were detected in 16/30 patients (53%); 9 of the 12 mutations identified were novel (p.Glu70Asp, p.Phe123Leu, p.Asp132Asn, p.His137Asp, p.Gly162Asp, p.Thr168Ala, p.Arg392Ser, p.Glu290X, p.Gln106_Met107delinsLeu) and are in regions involved in structural rearrangements required for catalysis. The prevalence of mutation sites was higher in the small domain (7/12: similar to 59%) than in the large (4/12: 33%) domain or in the connection (1/12: 8%) region of the protein. Mild diabetic phenotypes were detected in almost all patients [mean (SD) OGTT = 7.8 mMol/L (1.8)] and mean triglyceride levels were lower in mutated than in unmutated GCK patients (p = 0.04). Conclusions: The prevalence of GCK MODY is high in southern Italy, and the GCK small domain is a hot spot for MODY mutations. Both the severity of the GCK mutation and the genetic background seem to play a relevant role in the GCK MODY phenotype. Indeed, a partial genotype-phenotype correlation was identified in related patients (3 pairs of siblings) but not in two unrelated children bearing the same mutation. Thus, the molecular approach allows the physician to confirm the diagnosis and to predict severity of the mutation.	[Tinto, Nadia; Capuano, Marina; Capobianco, Valentina; Daniele, Gerardo; Sacchetti, Lucia] Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Naples, Italy; [Zagari, Adriana; De Simone, Alfonso] Univ Napoli Federico II, CEINGE Biotecnol Avanzate, Dipartimento Sci Biol, Naples, Italy; [Giugliano, Michela; Spadaro, Raffaella; Franzese, Adriana] Univ Napoli Federico II, Dipartimento Pediat, Naples, Italy	University of Naples Federico II; CEINGE Biotecnologie Avanzate; University of Naples Federico II; University of Naples Federico II	Tinto, N (corresponding author), Univ Naples Federico II, Dipartimento Biochim & Biotecnol Med, Naples, Italy.	sacchetti@dbbm.unina.it	capuano, marina/GLT-0659-2022	Capobianco, Valentina/0000-0002-9161-1581	CEINGE-Regione Campania; MIUR; Ministero Salute [DL 502/92, DL 229/99]	CEINGE-Regione Campania; MIUR(Ministry of Education, Universities and Research (MIUR)); Ministero Salute(Ministry of Health, Italy)	Work supported by grants from CEINGE-Regione Campania (Convenzione del. G. R. 27/12/2002 N. 6276), from MIUR art.5.2. and from Ministero Salute (ricerca finalizzata - progetto ordinario DL 502/92 and DL 229/99 art.12 and 12 bis).	Aleshin AE, 1998, J MOL BIOL, V282, P345, DOI 10.1006/jmbi.1998.2017; [Anonymous], HUMAN GENE MUTATION; BERENDSEN HJC, 1995, COMPUT PHYS COMMUN, V91, P43, DOI 10.1016/0010-4655(95)00042-E; Berger M, 2005, CLIN CHEM, V51, P791, DOI 10.1373/clinchem.2004.045963; Burke CV, 1999, BIOCHEM J, V342, P345, DOI 10.1042/0264-6021:3420345; den Dunnen JT, 2003, HUM MUTAT, V22, P181, DOI 10.1002/humu.10262; den Dunnen JT, 2001, HUM GENET, V109, P121, DOI 10.1007/s004390100505; Ellard S, 2007, DIABETOLOGIA, V50, P2313, DOI 10.1007/s00125-007-0798-6; Fajans SS, 2001, NEW ENGL J MED, V345, P971, DOI 10.1056/NEJMra002168; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; Fraternali F, 1996, J MOL BIOL, V256, P939, DOI 10.1006/jmbi.1996.0139; Garcia-Herrero CM, 2007, DIABETOLOGIA, V50, P325, DOI 10.1007/s00125-006-0542-7; Glaser F, 2005, PROTEINS, V58, P610, DOI 10.1002/prot.20305; Gloyn AL, 2003, HUM MUTAT, V22, P353, DOI 10.1002/humu.10277; Hattersley AT, 1998, NAT GENET, V19, P268, DOI 10.1038/953; IYNEDJIAN PB, 1993, BIOCHEM J, V293, P1; Kamata K, 2004, STRUCTURE, V12, P429, DOI 10.1016/j.str.2004.02.005; Kuczmarski RJ, 2002, SERIES-J SPAN ECON, V11, P1, DOI DOI 10.1016/J.BBRC.2015.06.114; Mantovani Vilma, 2003, Hum Mutat, V22, P338, DOI 10.1002/humu.9179; Massa O, 2001, DIABETOLOGIA, V44, P898; Miller SP, 1999, DIABETES, V48, P1645, DOI 10.2337/diabetes.48.8.1645; Pinterova D, 2007, CLIN GENET, V71, P95, DOI 10.1111/j.1399-0004.2006.00729.x; Prisco F, 2000, DIABETOLOGIA, V43, P1331; Raeder H, 2006, NAT GENET, V38, P54, DOI 10.1038/ng1708; Rhodes CJ, 2002, EUR J CLIN INVEST, V32, P3, DOI 10.1046/j.1365-2362.32.s3.2.x; Sagen JV, 2006, DIABETES, V55, P1713, DOI 10.2337/db05-1513; Shield JPH, 2004, ARCH DIS CHILD-FETAL, V89, pF341, DOI 10.1136/adc.2003.030502; STOFFEL M, 1992, P NATL ACAD SCI USA, V89, P7698, DOI 10.1073/pnas.89.16.7698; Toaima Dalia, 2005, Hum Mutat, V25, P503, DOI 10.1002/humu.9334; VeigadaCunha M, 1996, J BIOL CHEM, V271, P6292, DOI 10.1074/jbc.271.11.6292; Velho G, 1997, DIABETOLOGIA, V40, P217, DOI 10.1007/s001250050666; Weedon Michael N, 2007, Curr Diab Rep, V7, P131, DOI 10.1007/s11892-007-0022-6; PROTEIN FAMILIES DAT; PRIMER3 INPUT 0 4 0	34	35	38	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1870	10.1371/journal.pone.0001870	http://dx.doi.org/10.1371/journal.pone.0001870			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382660	Green Submitted, gold, Green Published			2022-12-25	WOS:000260795400010
J	Mydlarz, LD; Holthouse, SF; Peters, EC; Harvell, CD				Mydlarz, Laura D.; Holthouse, Sally F.; Peters, Esther C.; Harvell, C. Drew			Cellular Responses in Sea Fan Corals: Granular Amoebocytes React to Pathogen and Climate Stressors	PLOS ONE			English	Article							DISEASE RESISTANCE; TEMPERATURE STRESS; INNATE IMMUNITY; ECOLOGY; PERSPECTIVES; ATTENUATION; RESILIENCE; INFECTION; SURVIVE; MARINE	Background: Climate warming is causing environmental change making both marine and terrestrial organisms, and even humans, more susceptible to emerging diseases. Coral reefs are among the most impacted ecosystems by climate stress, and immunity of corals, the most ancient of metazoans, is poorly known. Although coral mortality due to infectious diseases and temperature-related stress is on the rise, the immune effector mechanisms that contribute to the resistance of corals to such events remain elusive. In the Caribbean sea fan corals (Anthozoa, Alcyonacea: Gorgoniidae), the cell-based immune defenses are granular acidophilic amoebocytes, which are known to be involved in wound repair and histocompatibility. Methodology/Principal Findings: We demonstrate for the first time in corals that these cells are involved in the organismal response to pathogenic and temperature stress. In sea fans with both naturally occurring infections and experimental inoculations with the fungal pathogen Aspergillus sydowii, an inflammatory response, characterized by a massive increase of amoebocytes, was evident near infections. Melanosomes were detected in amoebocytes adjacent to protective melanin bands in infected sea fans; neither was present in uninfected fans. In naturally infected sea fans a concurrent increase in prophenoloxidase activity was detected in infected tissues with dense amoebocytes. Sea fans sampled in the field during the 2005 Caribbean Bleaching Event (a once-in-hundred-year climate event) responded to heat stress with a systemic increase in amoebocytes and amoebocyte densities were also increased by elevated temperature stress in lab experiments. Conclusions/Significance: The observed amoebocyte responses indicate that sea fan corals use cellular defenses to combat fungal infection and temperature stress. The ability to mount an inflammatory response may be a contributing factor that allowed the survival of even infected sea fan corals during a stressful climate event.	[Mydlarz, Laura D.] Univ Texas Arlington, Dept Biol, Arlington, TX 76019 USA; [Holthouse, Sally F.; Harvell, C. Drew] Cornell Univ, Dept Ecol & Evolut Biol, Ithaca, NY USA; [Peters, Esther C.] Tetra Tech Inc, Fairfax, VA USA	University of Texas System; University of Texas Arlington; Cornell University	Mydlarz, LD (corresponding author), Univ Texas Arlington, Dept Biol, Arlington, TX 76019 USA.	Mydlarz@UTA.edu	Peters, Esther C/ABA-5788-2021; Mydlarz, Laura/B-8132-2011	Peters, Esther C/0000-0001-5404-5309; 	NSF/NIH Ecology of Infectious Disease Program [NSF EF- 0326705]	NSF/NIH Ecology of Infectious Disease Program	We would like to acknowledge funding for this project from NSF/NIH Ecology of Infectious Disease Program (NSF EF- 0326705).	ALKER A, 2006, CORAL REEFS, V23, P397; Blackstone NW, 2005, INTEGR COMP BIOL, V45, P605, DOI 10.1093/icb/45.4.605; Brakhage AA, 2005, CURR DRUG TARGETS, V6, P875, DOI 10.2174/138945005774912717; Brown BE, 2005, MAR ECOL PROG SER, V296, P291, DOI 10.3354/meps296291; Bruno JF, 2007, PLOS BIOL, V5, P1220, DOI 10.1371/journal.pbio.0050124; Cerenius L, 2004, IMMUNOL REV, V198, P116, DOI 10.1111/j.0105-2896.2004.00116.x; Cheng W, 2001, FISH SHELLFISH IMMUN, V11, P53, DOI 10.1006/fsim.2000.0293; Cooper EL, 2002, BIOESSAYS, V24, P319, DOI 10.1002/bies.10077; Ellner SP, 2007, AM NAT, V170, pE143, DOI 10.1086/522841; Fine M, 2007, SCIENCE, V315, P1811, DOI 10.1126/science.1137094; Galloway TS, 2001, ECOTOXICOLOGY, V10, P5, DOI 10.1023/A:1008939520263; Griffin SP, 2006, COMP BIOCHEM PHYS A, V144, P155, DOI 10.1016/j.cbpa.2006.02.017; Grottoli AG, 2006, NATURE, V440, P1186, DOI 10.1038/nature04565; Harvell CD, 2002, SCIENCE, V296, P2158, DOI 10.1126/science.1063699; HARVELL CD, 2007, OCEANOGRAPHY, V20, P59; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hughes TP, 2003, SCIENCE, V301, P929, DOI 10.1126/science.1085046; Kim K, 2000, MAR BIOL, V136, P259, DOI 10.1007/s002270050684; Kim K, 2004, AM NAT, V164, pS52, DOI 10.1086/424609; Lesser MP, 2007, P NATL ACAD SCI USA, V104, P5259, DOI 10.1073/pnas.0700910104; LEVY JM, 2006, B AM METEOROL SOC, V87, pS21; Levy O, 2006, J EXP MAR BIOL ECOL, V328, P35, DOI 10.1016/j.jembe.2005.06.018; Li WKW, 1998, LIMNOL OCEANOGR, V43, P1746, DOI 10.4319/lo.1998.43.7.1746; Little AF, 2004, SCIENCE, V304, P1492, DOI 10.1126/science.1095733; Meszaros A, 1999, J INVERTEBR PATHOL, V73, P321, DOI 10.1006/jipa.1999.4851; Miller J, 2006, CORAL REEFS, V25, P418, DOI 10.1007/s00338-006-0125-6; Monari M, 2007, FISH SHELLFISH IMMUN, V22, P98, DOI 10.1016/j.fsi.2006.03.016; Mullen KM, 2004, CORAL HEALTH AND DISEASE, P377; Mydlarz LD, 2006, ANNU REV ECOL EVOL S, V37, P251, DOI 10.1146/annurev.ecolsys.37.091305.110103; Nappi AJ, 2005, INSECT BIOCHEM MOLEC, V35, P443, DOI 10.1016/j.ibmb.2005.01.014; Olano CT, 2000, J INVERTEBR PATHOL, V76, P176, DOI 10.1006/jipa.2000.4974; Ouedraogo RM, 2003, J INVERTEBR PATHOL, V82, P103, DOI 10.1016/S0022-2011(02)00185-4; Ouedraogo RM, 2002, J INVERTEBR PATHOL, V81, P19, DOI 10.1016/S0022-2011(02)00117-9; Oxenford HA, 2008, CLIMATIC CHANGE, V87, P435, DOI 10.1007/s10584-007-9311-y; PATTERSON MJ, 1979, J INVERTEBR PATHOL, V33, P189, DOI 10.1016/0022-2011(79)90152-6; Petes LE, 2003, MAR ECOL PROG SER, V264, P167, DOI 10.3354/meps264167; PORCHETHENNERE E, 1992, CELL TISSUE RES, V269, P167, DOI 10.1007/BF00384737; Rinkevich B, 1996, MAR ECOL PROG SER, V143, P297, DOI 10.3354/meps143297; Sadd BM, 2006, P ROY SOC B-BIOL SCI, V273, P2571, DOI 10.1098/rspb.2006.3574; Sheehan D.C., 1980, THEORY PRACTICE HIST; Sigsgaard L, 2000, ENTOMOL EXP APPL, V95, P173, DOI 10.1023/A:1003993719952; Smith GW, 1996, NATURE, V383, P487, DOI 10.1038/383487a0; SPARKS AK, 1985, SYNOPSIS INVERTEBRAT, P1; Thomas MB, 2003, TRENDS ECOL EVOL, V18, P344, DOI 10.1016/S0169-5347(03)00069-7; TRUSCOTT R, 1990, FUNCT ECOL, V4, P455, DOI 10.2307/2389609; Vargas-Angel B, 2007, J INVERTEBR PATHOL, V95, P140, DOI 10.1016/j.jip.2007.01.003; Ward JR, 2007, MAR ECOL PROG SER, V329, P115, DOI 10.3354/meps329115	47	132	134	1	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1811	10.1371/journal.pone.0001811	http://dx.doi.org/10.1371/journal.pone.0001811			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18364996	gold, Green Published			2022-12-25	WOS:000260762400002
J	Park, D; Veenstra, JA; Park, JH; Taghert, PH				Park, Dongkook; Veenstra, Jan A.; Park, Jae H.; Taghert, Paul H.			Mapping Peptidergic Cells in Drosophila: Where DIMM Fits In	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; TRANSCRIPTION FACTOR MIST1; IMMUNOREACTIVE NEURONS; NEUROSECRETORY-CELLS; SEROTONERGIC NEURONS; EXPRESSING NEURONS; ECDYSIS BEHAVIOR; FEEDING-BEHAVIOR; GENE-EXPRESSION; INNATE BEHAVIOR	The bHLH transcription factor DIMMED has been associated with the differentiation of peptidergic cells in Drosophila. However, whether all Drosophila peptidergic cells express DIMM, and the extent to which all DIMM cells are peptidergic, have not been determined. To address these issues, we have mapped DIMM expression in the central nervous system (CNS) and periphery in the late larval stage Drosophila. At 100 hr after egg-laying, DIMM immunosignals are largely congruent with a dimm-promoter reporter (c929 GAL4) and they present a stereotyped pattern of 306 CNS cells and 52 peripheral cells. We assigned positional values for all DIMM CNS cells with respect to reference gene expression patterns, or to patterns of secondary neuroblast lineages. We could assign provisional peptide identities to 68% of DIMM-expressing CNS cells (207/306) and to 73% of DIMM-expressing peripheral cells (38/52) using a panel of 24 markers for Drosophila neuropeptide genes. Furthermore, we found that DIMM co-expression was a prevalent feature within single neuropeptide marker expression patterns. Of the 24 CNS neuropeptide gene patterns we studied, six patterns are >90% DIMM-positive, while 16 of 22 patterns are >40% DIMM-positive. Thus most or all DIMM cells in Drosophila appear to be peptidergic, and many but not all peptidergic cells express DIMM. The co-incidence of DIMM-expression among peptidergic cells is best explained by a hypothesis that DIMM promotes a specific neurosecretory phenotype we term LEAP. LEAP denotes Large cells that display Episodic release of Amidated Peptides.	[Park, Dongkook; Taghert, Paul H.] Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA; [Veenstra, Jan A.] Univ Bordeaux 1, CNIC UMR 5228 CNRS, Talence, France; [Park, Jae H.] Univ Tennessee Knoxville, Dept Biochem & Cell & Mol Biol, Knoxville, TN USA	Washington University (WUSTL); UDICE-French Research Universities; Universite de Bordeaux; University of Tennessee System; University of Tennessee Knoxville	Park, D (corresponding author), Washington Univ, Sch Med, Dept Anat & Neurobiol, St Louis, MO 63110 USA.	taghertp@pcg.wustl.edu	Veenstra, Jan/B-4610-2008	Veenstra, Jan Adrianus/0000-0002-2783-0018; Park, Jae/0000-0002-4846-2197	NSF [IBN-0133538]; NIH [NS21749, NS057105]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021749, P30NS057105] Funding Source: NIH RePORTER	NSF(National Science Foundation (NSF)); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	The work was supported by a grant from the NSF (IBN-0133538) to JAP, and the NIH (NS21749) to PHT, and by an NIH Neuroscience Blueprint Core Grant (#NS057105) to Washington University	Acampora D, 1999, GENE DEV, V13, P2787, DOI 10.1101/gad.13.21.2787; Allan DW, 2005, NEURON, V45, P689, DOI 10.1016/j.neuron.2005.01.026; ARCH S, 1989, BRAIN RES REV, V14, P181, DOI 10.1016/0165-0173(89)90014-3; Bader R, 2007, J COMP NEUROL, V502, P848, DOI 10.1002/cne.21342; Baggerman G, 2002, J BIOL CHEM, V277, P40368, DOI 10.1074/jbc.M206257200; Baggerman G, 2005, J MASS SPECTROM, V40, P250, DOI 10.1002/jms.744; Baker JD, 2002, J EXP BIOL, V205, P2555; BARGMANN W, 1951, SITE ORIGIN HORMONE; Baumgardt M, 2007, PLOS BIOL, V5, P295, DOI 10.1371/journal.pbio.0050037; Blitz DM, 1999, J NEUROSCI, V19, P6774, DOI 10.1523/JNEUROSCI.19-16-06774.1999; Boonen K, 2007, GEN COMP ENDOCR, V152, P231, DOI 10.1016/j.ygcen.2007.05.002; BROADUS J, 1995, MECH DEVELOP, V53, P393, DOI 10.1016/0925-4773(95)00454-8; Broeck JV, 2001, PEPTIDES, V22, P241, DOI 10.1016/S0196-9781(00)00376-4; BURBACH JPH, 1986, J NEUROCHEM, V47, P1814, DOI 10.1111/j.1471-4159.1986.tb13093.x; Burbach JPH, 2001, PHYSIOL REV, V81, P1197, DOI 10.1152/physrev.2001.81.3.1197; Cabrero P, 2002, J EXP BIOL, V205, P3799; Candy DJ, 2002, INSECT BIOCHEM MOLEC, V32, P1361, DOI 10.1016/S0965-1748(02)00056-5; CHEN YT, 1994, CELL TISSUE RES, V278, P493, DOI 10.1007/BF00331367; Cheng LP, 2004, NAT NEUROSCI, V7, P510, DOI 10.1038/nn1221; CHIN AC, 1990, DNA CELL BIOL, V9, P263, DOI 10.1089/dna.1990.9.263; Choi YJ, 2005, J COMP NEUROL, V482, P372, DOI 10.1002/cne.20419; Clark AC, 2004, J NEUROSCI, V24, P4283, DOI 10.1523/JNEUROSCI.4938-03.2004; COPENHAVER PF, 1986, J NEUROSCI, V6, P1738; CUI X, 1992, DEVELOPMENT, V116, P943; de Velasco B, 2007, DEV BIOL, V302, P309, DOI 10.1016/j.ydbio.2006.09.035; Dewey EM, 2004, CURR BIOL, V14, P1208, DOI 10.1016/j.cub.2004.06.051; Dierick HA, 2007, NAT GENET, V39, P678, DOI 10.1038/ng2029; Ding YQ, 2003, NAT NEUROSCI, V6, P933, DOI 10.1038/nn1104; EIPPER BA, 1992, ANNU REV NEUROSCI, V15, P57, DOI 10.1146/annurev.ne.15.030192.000421; Ewer J, 1996, J COMP NEUROL, V370, P330; Furuya K, 2000, P NATL ACAD SCI USA, V97, P6469, DOI 10.1073/pnas.97.12.6469; Gauthier SA, 2006, J EXP BIOL, V209, P1803, DOI 10.1242/jeb.02202; GORCZYCA MG, 1994, DEVELOPMENT, V120, P2143; Goshu E, 2004, MOL ENDOCRINOL, V18, P1251, DOI 10.1210/me.2003-0372; Hartenstein V, 2006, J ENDOCRINOL, V190, P555, DOI 10.1677/joe.1.06964; Hewes RS, 2006, J NEUROSCI, V26, P7860, DOI 10.1523/JNEUROSCI.1759-06.2006; Hewes RS, 2003, DEVELOPMENT, V130, P1771, DOI 10.1242/dev.00404; HEWES RS, 1994, J NEUROSCI, V14, P1812, DOI 10.1523/JNEUROSCI.14-03-01812.1994; Hewes RS, 2001, GENOME RES, V11, P1126, DOI 10.1101/gr.169901; Hosoya T, 2001, GENES CELLS, V6, P361, DOI 10.1046/j.1365-2443.2001.00421.x; ISABEL G, 2004, AM J PHYSL REGUL INT; Jiang N, 2000, DEV BIOL, V226, P118, DOI 10.1006/dbio.2000.9832; Kaneko M, 1997, J NEUROSCI, V17, P6745; Karcavich R, 2005, J COMP NEUROL, V481, P240, DOI 10.1002/cne.20371; Kean L, 2002, AM J PHYSIOL-REG I, V282, pR1297, DOI 10.1152/ajpregu.00584.2001; Kim SK, 2004, NATURE, V431, P316, DOI 10.1038/nature02897; Kim YJ, 2006, P NATL ACAD SCI USA, V103, P14211, DOI 10.1073/pnas.0603459103; Kim YJ, 2006, CURR BIOL, V16, P1395, DOI 10.1016/j.cub.2006.06.027; Kolhekar AS, 1997, J NEUROSCI, V17, P1363, DOI 10.1523/jneurosci.17-04-01363.1997; Lee GH, 2004, GENETICS, V167, P311, DOI 10.1534/genetics.167.1.311; Lee KS, 2004, J BIOL CHEM, V279, P50781, DOI 10.1074/jbc.M407842200; Lemercier C, 1998, EMBO J, V17, P1412, DOI 10.1093/emboj/17.5.1412; Liu F, 2006, MOL CELL PROTEOMICS, V5, P510, DOI 10.1074/mcp.M400114-MCP200; Luan HJ, 2006, J NEUROSCI, V26, P573, DOI 10.1523/JNEUROSCI.3916-05.2006; Lundell MJ, 1998, DEVELOPMENT, V125, P463; LUNDQUIST T, 1990, J COMP NEUROL, V294, P161, DOI 10.1002/cne.902940202; Macins A, 1999, ARCH INSECT BIOCHEM, V40, P107, DOI 10.1002/(SICI)1520-6327(1999)40:2&lt;107::AID-ARCH5&gt;3.0.CO;2-B; Melcher C, 2005, PLOS BIOL, V3, P1618, DOI 10.1371/journal.pbio.0030305; Michaud JL, 1998, GENE DEV, V12, P3264, DOI 10.1101/gad.12.20.3264; Miguel-Aliaga I, 2004, DEVELOPMENT, V131, P5837, DOI 10.1242/dev.01447; NAKAI S, 1995, GENE DEV, V3121, P2; Nassel DR, 2006, CELL TISSUE RES, V326, P1, DOI 10.1007/s00441-006-0210-8; Nassel DR, 2002, PROG NEUROBIOL, V68, P1, DOI 10.1016/S0301-0082(02)00057-6; NASSEL DR, 1991, CELL TISSUE RES, V266, P511, DOI 10.1007/BF00318593; Neupert S, 2007, ANAL CHEM, V79, P3690, DOI 10.1021/ac062411p; Nitabach MN, 2008, CURR BIOL, V18, pR84, DOI 10.1016/j.cub.2007.11.061; Nitabach MN, 2006, J NEUROSCI, V26, P479, DOI 10.1523/JNEUROSCI.3915-05.2006; O'Brien MA, 1998, J EXP BIOL, V201, P193; Park DK, 2004, DEV BIOL, V269, P95, DOI 10.1016/j.ydbio.2004.01.015; Park D, 2008, MOL CELL BIOL, V28, P410, DOI 10.1128/MCB.01104-07; Park JH, 2003, DEVELOPMENT, V130, P2645, DOI 10.1242/dev.00503; Park Y, 1999, FEBS LETT, V463, P133, DOI 10.1016/S0014-5793(99)01622-1; Pereanu W, 2006, J NEUROSCI, V26, P5534, DOI 10.1523/JNEUROSCI.4708-05.2006; Pin CL, 2000, ANAT REC, V259, P157, DOI 10.1002/(SICI)1097-0185(20000601)259:2<157::AID-AR6>3.0.CO;2-0; Pin CL, 2001, J CELL BIOL, V155, P519, DOI 10.1083/jcb.200105060; Ramsey VG, 2007, DEVELOPMENT, V134, P211, DOI 10.1242/dev.02700; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Roller L, 2003, CELL TISSUE RES, V312, P393, DOI 10.1007/s00441-003-0722-4; Rorsman P, 2003, DIABETOLOGIA, V46, P1029, DOI 10.1007/s00125-003-1153-1; Rulifson EJ, 2002, SCIENCE, V296, P1118, DOI 10.1126/science.1070058; Santos JG, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000695; SCHOLNICK SB, 1986, SCIENCE, V234, P998, DOI 10.1126/science.3095924; Schonemann MD, 1995, GENE DEV, V9, P3122, DOI 10.1101/gad.9.24.3122; SCHOOFS L, 1993, PEPTIDES, V14, P409, DOI 10.1016/0196-9781(93)90126-2; Shiga S, 2003, MICROSC RES TECHNIQ, V62, P114, DOI 10.1002/jemt.10366; Siegmund T, 2001, J COMP NEUROL, V431, P481, DOI 10.1002/1096-9861(20010319)431:4<481::AID-CNE1084>3.0.CO;2-7; STAY B, 1992, CELL TISSUE RES, V270, P15, DOI 10.1007/BF00381875; SUDHOF TC, 2008, NEUROTRANSMITTER REL, P1; TAGER HS, 1976, ANAL BIOCHEM, V71, P367; TAGHERT PH, 1990, J NEUROSCI, V10, P1929; Taghert PH, 2003, ADV GENET, V49, P1, DOI 10.1016/S0065-2660(03)01001-0; Taghert PH, 2001, J NEUROSCI, V21, P6673, DOI 10.1523/JNEUROSCI.21-17-06673.2001; Taylor CAM, 2004, J NEUROBIOL, V58, P379, DOI 10.1002/neu.10301; Terhzaz S, 2007, BIOCHEM BIOPH RES CO, V352, P305, DOI 10.1016/j.bbrc.2006.11.030; Urbach R, 2003, DEVELOPMENT, V130, P3621, DOI 10.1242/dev.00533; Verleyen P, 2004, J NEUROCHEM, V88, P311, DOI 10.1046/j.1471-4159.2003.02161.x; VILLAR MJ, 1988, NEUROSCI LETT, V86, P114, DOI 10.1016/0304-3940(88)90193-0; Wang WD, 2000, DEV BIOL, V227, P432, DOI 10.1006/dbio.2000.9902; Wegener C, 2006, J NEUROCHEM, V96, P1362, DOI 10.1111/j.1471-4159.2005.03634.x; Wu Q, 2003, NEURON, V39, P147, DOI 10.1016/S0896-6273(03)00396-9; Zitnan D, 1996, SCIENCE, V271, P88, DOI 10.1126/science.271.5245.88; ZITNAN D, 1993, DEV BIOL, V156, P117, DOI 10.1006/dbio.1993.1063	102	135	136	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1896	10.1371/journal.pone.0001896	http://dx.doi.org/10.1371/journal.pone.0001896			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365028	Green Submitted, Green Published, gold			2022-12-25	WOS:000260762400034
J	Chen, R; Alvero, AB; Silasi, DA; Kelly, MG; Fest, S; Visintin, I; Leiser, A; Schwartz, PE; Rutherford, T; Mor, G				Chen, R.; Alvero, A. B.; Silasi, D. A.; Kelly, M. G.; Fest, S.; Visintin, I.; Leiser, A.; Schwartz, P. E.; Rutherford, T.; Mor, G.			Regulation of IKK beta by miR-199a affects NF-kappa B activity in ovarian cancer cells	ONCOGENE			English	Article						inflammation; ovarian cancer; IKK beta; MyD88; chemoresistance	TOLL-LIKE RECEPTORS; KINASE-ACTIVITY; INFLAMMATION; ACTIVATION; APOPTOSIS; TUMORIGENESIS; INJURY; CHEMORESISTANCE; PROLIFERATION; STATISTICS	Cancer progression is an abnormal form of tissue repair characterized by chronic inflammation. I kappa B kinase-beta (IKK beta) required for nuclear factor-kappa B (NF-kappa B) activation plays a critical role in this process. Using EOC cells isolated from malignant ovarian cancer ascites and solid tumors, we identified IKKb as a major factor promoting a functional TLR-MyD88-NF-kappa B pathway that confers to EOC cell the capacity to constitutively secrete proinflammatory/protumor cytokines and therefore promoting tumor progression and chemoresistance. Furthermore, we describe for the first time the identification of the microRNA hsa-miR-199a as a regulator of IKK beta expression. Our study describes the property of ovarian cancer cells to enhance the inflammatory microenvironment as a result of the expression of an active IKKb pathway. Identification of these markers in patients' tumor samples may facilitate the adequate selection of treatment and open new venues for the development of effective therapy for chemoresistant ovarian cancers.	[Mor, G.] Yale Univ, Sch Med, Reprod Immunol Unit, Dept Obstet Gynecol & Reprod Sci, New Haven, CT 06520 USA; [Chen, R.] Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA	Yale University; Yale University	Mor, G (corresponding author), Yale Univ, Sch Med, Reprod Immunol Unit, Dept Obstet Gynecol & Reprod Sci, 333 Cedar St,FMB 301, New Haven, CT 06520 USA.	Gil.Mor@yale.edu		Alvero, Ayesha/0000-0002-6593-3595	NATIONAL CANCER INSTITUTE [R01CA127913, R01CA118678] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA127913, R01 CA127913-02, R01 CA118678, R01 CA118678-02, R01 CA127913-01A2] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Balkwill F, 2004, NAT REV CANCER, V4, P540, DOI 10.1038/nrc1388; Balkwill F, 2004, NATURE, V431, P405, DOI 10.1038/431405a; Barnhart BC, 2003, CELL, V114, P148, DOI 10.1016/S0092-8674(03)00561-0; Baumgartner B, 2002, LEUKEMIA, V16, P2062, DOI 10.1038/sj.leu.2402641; Chen R, 2007, AM J REPROD IMMUNOL, V57, P93, DOI 10.1111/j.1600-0897.2006.00441.x; Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322; Duan Z, 2002, CYTOKINE, V17, P234, DOI 10.1006/cyto.2001.1008; Flick MB, 2004, J SOC GYNECOL INVEST, V11, P252, DOI 10.1016/j.jsgi.2003.11.003; Fukata M, 2005, AM J PHYSIOL-GASTR L, V288, pG1055, DOI 10.1152/ajpgi.00328.2004; Greten FR, 2004, CANCER LETT, V206, P193, DOI 10.1016/j.canlet.2003.08.029; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; HARROCH S, 1995, NUCLEIC ACIDS RES, V23, P3539, DOI 10.1093/nar/23.17.3539; Hu MCT, 2004, CELL, V117, P225, DOI 10.1016/S0092-8674(04)00302-2; Jemal A, 2006, CA-CANCER J CLIN, V56, P106, DOI 10.3322/canjclin.56.2.106; Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43; Jiang DH, 2005, NAT MED, V11, P1173, DOI 10.1038/nm1315; Kamsteeg M, 2003, ONCOGENE, V22, P2611, DOI 10.1038/sj.onc.1206422; Karin M, 2002, NAT REV CANCER, V2, P301, DOI 10.1038/nrc780; Kelly MG, 2006, CANCER RES, V66, P3859, DOI 10.1158/0008-5472.CAN-05-3948; Leung CH, 2006, MOL PHARMACOL, V70, P1946, DOI 10.1124/mol.106.028480; Li L, 2004, CANCER-AM CANCER SOC, V101, P2351, DOI 10.1002/cncr.20605; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Li QT, 1999, SCIENCE, V284, P321, DOI 10.1126/science.284.5412.321; Liu BG, 2006, P NATL ACAD SCI USA, V103, P17202, DOI 10.1073/pnas.0604481103; Ludwig L, 2001, CANCER RES, V61, P4526; Luo JL, 2005, J CLIN INVEST, V115, P2625, DOI 10.1172/JCI26322; Maeda S, 2005, CELL, V121, P977, DOI 10.1016/j.cell.2005.04.014; Maeda S, 2003, IMMUNITY, V19, P725, DOI 10.1016/S1074-7613(03)00301-7; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588; ODWYER PJ, 1994, CANCER RES, V54, P724; Pikarsky E, 2004, NATURE, V431, P461, DOI 10.1038/nature02924; Pull SL, 2005, P NATL ACAD SCI USA, V102, P99, DOI 10.1073/pnas.0405979102; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Rakoff-Nahoum S, 2007, SCIENCE, V317, P124, DOI 10.1126/science.1140488; Romieu-Mourez R, 2001, CANCER RES, V61, P3810; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Schwartz Peter E, 2002, Cancer Treat Res, V107, P99; Shishodia S, 2004, BIOCHEM PHARMACOL, V68, P1071, DOI 10.1016/j.bcp.2004.04.026; Tamatani T, 2001, CANCER LETT, V171, P165, DOI 10.1016/S0304-3835(01)00611-5; Yang JM, 2001, CANCER RES, V61, P4901	43	248	269	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4712	4723		10.1038/onc.2008.112	http://dx.doi.org/10.1038/onc.2008.112			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408758	Green Accepted			2022-12-25	WOS:000258236300009
J	Filiano, AJ; Bailey, CDC; Tucholski, J; Gundemir, S; Johnson, GVW				Filiano, Anthony J.; Bailey, Craig D. C.; Tucholski, Janusz; Gundemir, Soner; Johnson, Gail V. W.			Transglutaminase 2 protects against ischemic insult, interacts with HIF1 beta, and attenuates HIF1 signaling	FASEB JOURNAL			English	Article						oxygen and glucose deprivation; hypoxia; neuron	HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; FACTOR-I HIF-1; TISSUE-TYPE TRANSGLUTAMINASE; NEUROBLASTOMA SH-SY5Y CELLS; PIG LIVER TRANSGLUTAMINASE; CEREBRAL-ARTERY OCCLUSION; HUNTINGTONS-DISEASE BRAIN; DELAYED NEURONAL DEATH; CREB-BINDING PROTEIN; CROSS-LINKING	Transglutaminase 2 (TG2) is a multifunctional enzyme that has been implicated in the pathogenesis of neurodegenerative diseases, ischemia, and stroke. The mechanism by which TG2 modulates disease progression have not been elucidated. In this study we investigate the role of TG2 in the cellular response to ischemia and hypoxia. TG2 is up-regulated in neurons exposed to oxygen and glucose deprivation (OGD), and increased TG2 expression protects neurons against OGD-induced cell death independent of its transamidating activity. We identified hypoxia inducible factor 1 beta (HIF1 beta) as a TG2 binding partner. HIF1 beta and HIF1 alpha together form the heterodimeric transcription factor hypoxia inducible factor 1(HIF1). TG2 and the transaminase-inactive mutant C277S-TG2 inhibited a HIF-dependent transcription reporter assay under hypoxic conditions without affecting nuclear protein levels for HIF1 alpha or HIF1 beta, their ability to form the HIF1 heterodimeric transcription factor, or HIF1 binding to its DNA response element. Interestingly, TG2 attenuates the up-regulation of the HIF-dependent proapoptotic gene Bnip3 in response to OGD but had no effect on the expression of VEGF, which has been linked to prosurvival processes. This study demonstrates for the first time that TG2 protects against OGD, interacts with HIF1 beta, and attenuates the HIF1 hypoxic response pathway. These results indicate that TG2 may play an important role in protecting against the delayed neuronal cell death in ischemia and stroke.	[Filiano, Anthony J.; Gundemir, Soner; Johnson, Gail V. W.] Univ Rochester, Dept Anesthesiol, Rochester, NY 14642 USA; [Filiano, Anthony J.; Gundemir, Soner; Johnson, Gail V. W.] Univ Rochester, Dept Physiol & Pharmacol, Rochester, NY 14642 USA; [Filiano, Anthony J.; Johnson, Gail V. W.] Univ Alabama, Dept Cell Biol, Birmingham, AL 35294 USA; [Bailey, Craig D. C.; Tucholski, Janusz] Univ Alabama, Dept Psychiat, Birmingham, AL 35294 USA	University of Rochester; University of Rochester; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Johnson, GVW (corresponding author), Univ Rochester, Dept Anesthesiol, 601 Elmwood Ave,Box 604, Rochester, NY 14642 USA.	gail_johnsonvoll@urmc.rochester.edu	Johnson, Gail V.W./K-4723-2012	Johnson, Gail V.W./0000-0003-3464-0404; Bailey, Craig/0000-0002-4320-6872; Gundemir, Soner/0000-0002-9997-3552	NATIONAL INSTITUTE ON AGING [R01AG012396] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG012396, AG012396] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ACHYUTHAN KE, 1987, J BIOL CHEM, V262, P1901; Akimov SS, 2001, J CELL SCI, V114, P2989; Arany Z, 1996, P NATL ACAD SCI USA, V93, P12969, DOI 10.1073/pnas.93.23.12969; Bailey CDC, 2005, J NEUROCHEM, V92, P83, DOI 10.1111/j.1471-4159.2004.02839.x; Bailey CDC, 2004, MOL CELL NEUROSCI, V25, P493, DOI 10.1016/j.mcn.2003.11.016; Baranova O, 2007, J NEUROSCI, V27, P6320, DOI 10.1523/JNEUROSCI.0449-07.2007; Bergeron M, 1999, EUR J NEUROSCI, V11, P4159, DOI 10.1046/j.1460-9568.1999.00845.x; Berra E, 2003, EMBO J, V22, P4082, DOI 10.1093/emboj/cdg392; Bhattacharya S, 1999, GENE DEV, V13, P64, DOI 10.1101/gad.13.1.64; BIRCKBICHLER PJ, 1981, P NATL ACAD SCI-BIOL, V78, P5005, DOI 10.1073/pnas.78.8.5005; BLANCHARD KL, 1992, MOL CELL BIOL, V12, P5373, DOI 10.1128/MCB.12.12.5373; Boehm JE, 2002, J BIOL CHEM, V277, P20127, DOI 10.1074/jbc.C200147200; Budde A, 2005, ONCOGENE, V24, P1802, DOI 10.1038/sj.onc.1208369; Carrero P, 2000, MOL CELL BIOL, V20, P402, DOI 10.1128/MCB.20.1.402-415.2000; Chen CH, 2007, J NEUROCHEM, V102, P1831, DOI 10.1111/j.1471-4159.2007.04652.x; Chen SH, 1996, J BIOL CHEM, V271, P32385, DOI 10.1074/jbc.271.50.32385; Citron BA, 2002, NEUROCHEM INT, V40, P69, DOI 10.1016/S0197-0186(01)00062-6; Citron BA, 2001, J BIOL CHEM, V276, P3295, DOI 10.1074/jbc.M004776200; Dames SA, 2002, P NATL ACAD SCI USA, V99, P5271, DOI 10.1073/pnas.082121399; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; FACCHIANO F, 1993, J BIOL CHEM, V268, P4588; Fath DM, 2006, J BIOL CHEM, V281, P13612, DOI 10.1074/jbc.M600456200; FESUS L, 1987, FEBS LETT, V224, P104, DOI 10.1016/0014-5793(87)80430-1; Forsythe JA, 1996, MOL CELL BIOL, V16, P4604; Freedman SJ, 2002, P NATL ACAD SCI USA, V99, P5367, DOI 10.1073/pnas.082117899; Gray MJ, 2005, ONCOGENE, V24, P3110, DOI 10.1038/sj.onc.1208513; Guo K, 2001, CELL DEATH DIFFER, V8, P367, DOI 10.1038/sj.cdd.4400810; Halterman MW, 1999, EXP NEUROL, V159, P65, DOI 10.1006/exnr.1999.7160; Halterman MW, 1999, J NEUROSCI, V19, P6818, DOI 10.1523/JNEUROSCI.19-16-06818.1999; Hasegawa G, 2003, BIOCHEM J, V373, P793, DOI 10.1042/BJ20021084; Helton R, 2005, J NEUROSCI, V25, P4099, DOI 10.1523/JNEUROSCI.4555-04.2005; Ientile R, 2004, NEUROSCI LETT, V363, P173, DOI 10.1016/j.neulet.2004.04.003; Ientile R, 2002, NEUROSCIENCE, V115, P723, DOI 10.1016/S0306-4522(02)00482-7; Jiang HB, 2003, HUM MOL GENET, V12, P1, DOI 10.1093/hmg/ddg002; Johnson GVW, 1997, BRAIN RES, V751, P323, DOI 10.1016/S0006-8993(96)01431-X; Joshi S, 2006, ONCOGENE, V25, P240, DOI 10.1038/sj.onc.1209027; Karpuj MV, 1999, P NATL ACAD SCI USA, V96, P7388, DOI 10.1073/pnas.96.13.7388; Kasper LH, 2006, CELL CYCLE, V5, P142, DOI 10.4161/cc.5.2.2353; Kasper LH, 2005, EMBO J, V24, P3846, DOI 10.1038/sj.emboj.7600846; Kasper LH, 2006, MOL CELL BIOL, V26, P789, DOI 10.1128/MCB.26.3.789-809.2006; Kato H, 2004, J BIOL CHEM, V279, P41966, DOI 10.1074/jbc.M406320200; Katoh S, 1996, EXP CELL RES, V222, P255, DOI 10.1006/excr.1996.0032; Kim JY, 2004, J EXP MED, V199, P113, DOI 10.1084/jem.20030613; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; Kobayashi A, 1997, J BIOCHEM, V122, P703; Kress GJ, 2002, J NEUROSCI, V22, P5848; LEE KN, 1989, BIOCHEM BIOPH RES CO, V162, P1370, DOI 10.1016/0006-291X(89)90825-5; Lee MJ, 2004, MOL CELL BIOL, V24, P3918, DOI 10.1128/MCB.24.9.3918-3927.2004; Lesort M, 1999, J NEUROCHEM, V73, P2018; Lorand L, 2003, NAT REV MOL CELL BIO, V4, P140, DOI 10.1038/nrm1014; LU S, 1995, J BIOL CHEM, V270, P9748, DOI 10.1074/jbc.270.17.9748; MACCIONI RB, 1986, MOL CELL BIOCHEM, V69, P161; Marxsen JH, 2004, BIOCHEM J, V381, P761, DOI 10.1042/BJ20040620; Mastroberardino P, 2002, CELL DEATH DIFFER, V9, P873, DOI 10.1038/sj.cdd.4401093; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; MELINO G, 1994, MOL CELL BIOL, V14, P6584, DOI 10.1128/MCB.14.10.6584; Milakovic T, 2004, J BIOL CHEM, V279, P8715, DOI 10.1074/jbc.M308479200; Mishra S, 2004, J BIOL CHEM, V279, P23863, DOI 10.1074/jbc.M311919200; Murthy SNP, 2002, P NATL ACAD SCI USA, V99, P2738, DOI 10.1073/pnas.052715799; NAKAOKA H, 1994, SCIENCE, V264, P1593, DOI 10.1126/science.7911253; Oliverio S, 1999, J BIOL CHEM, V274, P34123, DOI 10.1074/jbc.274.48.34123; PASTUSZKO A, 1986, J NEUROCHEM, V46, P499, DOI 10.1111/j.1471-4159.1986.tb12996.x; PERRY MJM, 1995, NEUROSCIENCE, V65, P1063, DOI 10.1016/0306-4522(94)00556-K; PERRY MJM, 1993, INT J DEV NEUROSCI, V11, P325, DOI 10.1016/0736-5748(93)90004-W; PIACENTINI M, 1991, EUR J CELL BIOL, V54, P246; Piacentini M, 2002, J NEUROCHEM, V81, P1061; Pilpel Y, 2006, J NEUROCHEM, V97, P1379, DOI 10.1111/j.1471-4159.2006.03825.x; Rameau GA, 2000, NEUROPHARMACOLOGY, V39, P2255, DOI 10.1016/S0028-3908(00)00066-6; Sang NL, 2002, MOL CELL BIOL, V22, P2984, DOI 10.1128/MCB.22.9.2984-2992.2002; Semenza GL, 2000, GENE DEV, V14, P1983; Semenza GL, 1996, J BIOL CHEM, V271, P32529, DOI 10.1074/jbc.271.51.32529; Stout AK, 1998, NAT NEUROSCI, V1, P366, DOI 10.1038/1577; Sun YJ, 2003, J CLIN INVEST, V111, P1843, DOI 10.1172/JCI200317977; Szondy Z, 2006, CELL DEATH DIFFER, V13, P1827, DOI 10.1038/sj.cdd.4401889; Tolentino PJ, 2004, J NEUROCHEM, V89, P1301, DOI 10.1111/j.1471-4159.2004.02436.x; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; Tucholski J, 2003, J BIOL CHEM, V278, P26838, DOI 10.1074/jbc.M303683200; Tucholski J, 2002, J NEUROCHEM, V81, P780, DOI 10.1046/j.1471-4159.2002.00859.x; Tucholski J, 2001, NEUROSCIENCE, V102, P481, DOI 10.1016/S0306-4522(00)00482-6; Van Hoecke M, 2007, MOL CELL NEUROSCI, V34, P40, DOI 10.1016/j.mcn.2006.09.009; Verma A, 2006, CANCER RES, V66, P10525, DOI 10.1158/0008-5472.CAN-06-2387; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Zemaitaitis MO, 2003, J NEUROPATH EXP NEUR, V62, P173, DOI 10.1093/jnen/62.2.173	84	60	60	0	8	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2662	2675		10.1096/fj.07-097709	http://dx.doi.org/10.1096/fj.07-097709			14	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18375543	Green Published			2022-12-25	WOS:000258089300007
J	Rotem, S; Radzishevsky, IS; Bourdetsky, D; Navon-Venezia, S; Carmeli, Y; Mor, A				Rotem, Shahar; Radzishevsky, Inna S.; Bourdetsky, Dmitry; Navon-Venezia, Shiri; Carmeli, Yehuda; Mor, Amram			Analogous oligo-acyl-lysines with distinct antibacterial mechanisms	FASEB JOURNAL			English	Article						host defense peptides; peptidomimetics; mechanism of action; intracellular targets	CATIONIC ANTIMICROBIAL PEPTIDES; MEMBRANE-BINDING PROPERTIES; DERMASEPTIN S4 DERIVATIVES; DE-NOVO DESIGN; ESCHERICHIA-COLI; PSEUDOMONAS-AERUGINOSA; STAPHYLOCOCCUS-AUREUS; CYTOPLASMIC MEMBRANE; NEUTROPHIL DEFENSIN; ANTIBIOTIC-ACTIVITY	Bactericidal properties were recently shown to emerge from hydrophobicity and charge buildup in oligo-acyl-lysine (OAK) peptide mimetics. Toward understanding the attributes that govern the activity of this novel antimicrobial system, we compared the functional and mechanistic properties of a known octamer and a newly generated hexamer analog. The data provide strong evidence for multiple similarities that included high tissue stability, low hemolysis, large-spectrum antibacterial activity in vitro, and the ability to prevent Escherichia coli-induced mortality in vivo. Despite these similarities, however, the octamer mode of action involved membrane disruption, unlike the hexamer, which acted predominantly through inhibition of DNA functions with characteristically slower bactericidal kinetics. Collectively, the data support the view that the analogous OAKs induced bacterial death by distinct mechanisms and further suggest that relatively minor differences in the sequence of host defense peptides are responsible for selecting one mechanism over another, possibly in conjunction with differential binding affinities to the external and/or cytoplasmic membrane.	[Mor, Amram] Technion Israel Inst Technol, Dept Biotechnol & Food Engn, LAPI, Haifa, Israel; [Navon-Venezia, Shiri; Carmeli, Yehuda] Tel Aviv Sourasky Med Ctr, Dept Epidemiol, Tel Aviv, Israel	Technion Israel Institute of Technology; Tel Aviv University; Sackler Faculty of Medicine; Tel Aviv Sourasky Medical Center	Mor, A (corresponding author), Technion Israel Inst Technol, Dept Biotechnol & Food Engn, LAPI, Haifa, Israel.	amor@tx.technion.ac.il		Radzishevsky, Inna/0000-0001-7748-7599; Navon-Venezia, Shiri/0000-0002-4916-110X				Avrahami D, 2002, BIOCHEMISTRY-US, V41, P2254, DOI 10.1021/bi011549t; BOMAN HG, 1993, INFECT IMMUN, V61, P2978, DOI 10.1128/IAI.61.7.2978-2984.1993; Bradshaw JP, 2003, BIODRUGS, V17, P233, DOI 10.2165/00063030-200317040-00002; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; Frimodt-Moller N., 1999, HDB ANIMAL MODELS IN, P127, DOI [10.1016/B978-012775390-4/50153-6, DOI 10.1016/B978-012775390-4/50153-6]; Gaidukov L, 2003, BIOCHEMISTRY-US, V42, P12866, DOI 10.1021/bi034514x; Goldman MJ, 1997, CELL, V88, P553, DOI 10.1016/S0092-8674(00)81895-4; Gordon YJ, 2005, CURR EYE RES, V30, P505, DOI 10.1080/02713680590968637; Hancock REW, 1997, LANCET, V349, P418, DOI 10.1016/S0140-6736(97)80051-7; Hancock REW, 2006, NAT BIOTECHNOL, V24, P1551, DOI 10.1038/nbt1267; HOBEN HJ, 1982, APPL ENVIRON MICROB, V44, P1246, DOI 10.1128/AEM.44.5.1246-1247.1982; Iverson BL, 1997, NATURE, V385, P113, DOI 10.1038/385113a0; Jenssen H, 2006, CLIN MICROBIOL REV, V19, P491, DOI 10.1128/CMR.00056-05; Kirshenbaum K, 1998, P NATL ACAD SCI USA, V95, P4303, DOI 10.1073/pnas.95.8.4303; Kragol G, 2001, BIOCHEMISTRY-US, V40, P3016, DOI 10.1021/bi002656a; Lee IH, 1997, INFECT IMMUN, V65, P2898, DOI 10.1128/IAI.65.7.2898-2903.1997; LEHRER RI, 1989, J CLIN INVEST, V84, P553, DOI 10.1172/JCI114198; Liu DH, 2001, J AM CHEM SOC, V123, P7553, DOI 10.1021/ja0107475; Lockwood NA, 2004, BIOCHEM J, V378, P93, DOI 10.1042/BJ20031393; Majerle A, 2003, J ANTIMICROB CHEMOTH, V51, P1159, DOI 10.1093/jac/dkg219; Marynka K, 2007, CHEM BIOL, V14, P75, DOI 10.1016/j.chembiol.2006.11.009; Matsuzaki K, 1998, BIOCHEMISTRY-US, V37, P15144, DOI 10.1021/bi9811617; Minahk CJ, 2003, LETT APPL MICROBIOL, V37, P374, DOI 10.1046/j.1472-765X.2003.01411.x; MOORE RA, 1986, ANTIMICROB AGENTS CH, V29, P496, DOI 10.1128/AAC.29.3.496; MOR A, 1994, J BIOL CHEM, V269, P31635; Morton CO, 2007, MOL MICROBIOL, V65, P494, DOI 10.1111/j.1365-2958.2007.05801.x; Oppenheim JJ, 2005, CURR OPIN IMMUNOL, V17, P359, DOI 10.1016/j.coi.2005.06.002; Park CB, 2000, P NATL ACAD SCI USA, V97, P8245, DOI 10.1073/pnas.150518097; Patch JA, 2003, J AM CHEM SOC, V125, P12092, DOI 10.1021/ja037320d; Patrzykat A, 2002, ANTIMICROB AGENTS CH, V46, P605, DOI 10.1128/AAC.46.3.605-614.2002; Radzishevsky I, 2007, ANTIMICROB AGENTS CH, V51, P1753, DOI 10.1128/AAC.01288-06; Radzishevsky IS, 2007, NAT BIOTECHNOL, V25, P657, DOI 10.1038/nbt1309; Radzishevsky IS, 2005, ANTIMICROB AGENTS CH, V49, P2412, DOI 10.1128/AAC.49.6.2412-2420.2005; Rotem S, 2006, ANTIMICROB AGENTS CH, V50, P2666, DOI 10.1128/AAC.00030-06; Rozek A, 2003, BIOCHEMISTRY-US, V42, P14130, DOI 10.1021/bi035643g; Rydlo T, 2006, ANTIMICROB AGENTS CH, V50, P490, DOI 10.1128/AAC.50.2.490-497.2006; Sahl HG, 2005, J LEUKOCYTE BIOL, V77, P466, DOI 10.1189/jlb.0804452; Schwetz BA, 2001, JAMA-J AM MED ASSOC, V285, P724, DOI 10.1001/jama.285.6.724-a; SELSTED ME, 1993, J BIOL CHEM, V268, P6641; Shai Y, 2002, BIOPOLYMERS, V66, P236, DOI 10.1002/bip.10260; Shalev DE, 2006, J BIOL CHEM, V281, P9432, DOI 10.1074/jbc.M513051200; Tew GN, 2002, P NATL ACAD SCI USA, V99, P5110, DOI 10.1073/pnas.082046199; Tossi A, 1997, Methods Mol Biol, V78, P133; Wu MH, 1999, BIOCHEMISTRY-US, V38, P7235, DOI 10.1021/bi9826299; Xiong YQ, 1999, ANTIMICROB AGENTS CH, V43, P1111, DOI 10.1128/AAC.43.5.1111; Yang D, 2004, ANNU REV IMMUNOL, V22, P181, DOI 10.1146/annurev.immunol.22.012703.104603; Yeaman MR, 1998, J CLIN INVEST, V101, P178, DOI 10.1172/JCI562; Zasloff M, 2002, NATURE, V415, P389, DOI 10.1038/415389a; Zhang LJ, 2000, ANTIMICROB AGENTS CH, V44, P3317, DOI 10.1128/AAC.44.12.3317-3321.2000	50	59	59	0	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2652	2661		10.1096/fj.07-105015	http://dx.doi.org/10.1096/fj.07-105015			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18385215				2022-12-25	WOS:000258089300006
J	Lu, Z; Liu, M; Stribinskis, V; Klinge, CM; Ramos, KS; Colburn, NH; Li, Y				Lu, Z.; Liu, M.; Stribinskis, V.; Klinge, C. M.; Ramos, K. S.; Colburn, N. H.; Li, Y.			MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene	ONCOGENE			English	Article						miR-21; PDCD4; cell transformation; microRNA; tumor suppressor	TUMOR-SUPPRESSOR GENE; INITIATION-FACTOR 4A; BREAST-CANCER; MICRO-RNA; EXPRESSION; PDCD4; TRANSLATION; SIGNATURE; BINDING; PROGRESSION	MicroRNAs (miRNAs) are small noncoding RNA molecules that negatively control expression of target genes in animals and plants. The microRNA-21 gene (mir-21) has been identified as the only miRNA commonly over-expressed in solid tumors of the lung, breast, stomach, prostate, colon, brain, head and neck, esophagus and pancreas. We initiated a screen to identify miR-21 target genes using a reporter assay and identified a potential miR-21 target in the 30-UTR of the programmed cell death 4 (PDCD4) gene. We cloned the full-length 30-UTR of human PDCD4 downstream of a reporter and found that mir-21 downregulated, whereas a modified antisense RNA to miR-21 upregulated report er activity. Moreover, deletion of the putative miR-21-binding site (miRNA regulatory element, MRE) from the 30-UTR of PDCD4, or mutations in the MRE abolished the ability of miR-21 to inhibit reporter activity, indicating that this MRE is a critical regulatory region. Western blotting showed that Pdcd4 protein levels were reduced by miR-21 in human and mouse cells, whereas quantitative real-time PCR revealed little difference at the mRNA level, suggesting translational regulation. Finally, overexpression of mir-21 in MCF-7 human breast cancer cells and mouse epidermal JB6 cells promoted soft agar colony formation by downregulating Pdcd4 protein levels. The demonstration that miR-21 promotes cell transformation supports the concept that mir-21 functions as an oncogene by a mechanism that involves translational repression of the tumor suppressor Pdcd4.	[Lu, Z.; Stribinskis, V.; Klinge, C. M.; Li, Y.] Univ Louisville, Sch Med, Ctr Genet & Mol Med, Louisville, KY 40292 USA; [Liu, M.] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Biochem & Cell Biol, State Key Lab Mol Biol, Shanghai, Peoples R China; [Colburn, N. H.] NCI, Gene Regulat Sect, Lab Canc Prevent, Ctr Canc Res, Frederick, MD 21701 USA	University of Louisville; Chinese Academy of Sciences; Shanghai Institutes for Biological Sciences, CAS; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Li, Y (corresponding author), Univ Louisville, Dept Biochem & Mol Biol, 319 Abraham Flexner Way,Rm 513-A Building, Louisville, KY 40202 USA.	yong.li@louisville.edu		liu, mo fang/0000-0003-1800-466X; Klinge, Carolyn/0000-0002-3358-4378	NATIONAL CANCER INSTITUTE [Z01BC010026, ZIABC010026, R21CA124811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES014443] Funding Source: NIH RePORTER; NCI NIH HHS [R21-CA124811] Funding Source: Medline; NIEHS NIH HHS [P30ES014443] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ASANGANI LA, 2007, ONCOGENE        1029; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Cai XZ, 2004, RNA, V10, P1957, DOI 10.1261/rna.7135204; Calin GA, 2005, NEW ENGL J MED, V353, P1793, DOI 10.1056/NEJMoa050995; Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137; Chen CF, 2005, NUCLEIC ACIDS RES, V33, DOI 10.1093/nar/gni178; Chen Y, 2003, J PATHOL, V200, P640, DOI 10.1002/path.1378; Cmarik JL, 1999, P NATL ACAD SCI USA, V96, P14037, DOI 10.1073/pnas.96.24.14037; Da C, 2004, SPECTROSC SPECT ANAL, V24, P672; Diederichs S, 2006, CANCER RES, V66, P6097, DOI 10.1158/0008-5472.CAN-06-0537; DONG Z, 2002, SCI STKE, pPL7; Frankel LB, 2008, J BIOL CHEM, V283, P1026, DOI 10.1074/jbc.M707224200; Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112; Hilliard A, 2006, J IMMUNOL, V177, P8095, DOI 10.4049/jimmunol.177.11.8095; Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783; Jansen AP, 2005, CANCER RES, V65, P6034, DOI 10.1158/0008-5472.CAN-04-2119; Jansen AP, 2004, MOL CANCER THER, V3, P103; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lawrie CH, 2007, INT J CANCER, V121, P1156, DOI 10.1002/ijc.22800; Lee S, 2006, ONCOL REP, V16, P747; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Li L, 2007, J CELL BIOCHEM, V102, P1368, DOI 10.1002/jcb.21593; Ma Gang, 2005, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V27, P597; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022; Meng FY, 2006, GASTROENTEROLOGY, V130, P2113, DOI 10.1053/j.gastro.2006.02.057; Miranda KC, 2006, CELL, V126, P1203, DOI 10.1016/j.cell.2006.07.031; Roldo C, 2006, J CLIN ONCOL, V24, P4677, DOI 10.1200/JCO.2005.05.5194; Root DE, 2006, NAT METHODS, V3, P715, DOI 10.1038/NMETH924; Si ML, 2007, ONCOGENE, V26, P2799, DOI 10.1038/sj.onc.1210083; Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103; Wang TS, 2007, GENE CHROMOSOME CANC, V46, P336, DOI 10.1002/gcc.20415; Yang HS, 2003, MOL CELL BIOL, V23, P26, DOI 10.1128/MCB.23.1.26-37.2003; Yang HS, 2004, MOL CELL BIOL, V24, P3894, DOI 10.1128/MCB.24.9.3894-3906.2004; Yang HS, 2001, ONCOGENE, V20, P669, DOI 10.1038/sj.onc.1204137; Yu K, 2001, ENDOCR-RELAT CANCER, V8, P249, DOI 10.1677/erc.0.0080249; Zhu SM, 2007, J BIOL CHEM, V282, P14328, DOI 10.1074/jbc.M611393200	39	575	622	1	73	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4373	4379		10.1038/onc.2008.72	http://dx.doi.org/10.1038/onc.2008.72			7	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372920				2022-12-25	WOS:000257691100012
J	Cha, HC; Oak, NR; Kang, S; Tran, TA; Kobayashi, S; Chiang, SH; Tenen, DG; MacDougald, OA				Cha, Hyuk C.; Oak, Nikhil R.; Kang, Sona; Tran, Tuan-Ahn; Kobayashi, Susumu; Chiang, Shian-Huey; Tenen, Daniel G.; MacDougald, Ormond A.			Phosphorylation of CCAAT/enhancer-binding protein alpha regulates GLUT4 expression and glucose transport in adipocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING-PROTEIN; ADIPONECTIN GENE-EXPRESSION; GROWTH-INHIBITORY ACTIVITY; C/EBP-ALPHA; PPAR-GAMMA; 3T3-L1 ADIPOCYTES; TRANSCRIPTIONAL REGULATION; INSULIN-RESISTANCE; PHOSPHOENOLPYRUVATE CARBOXYKINASE; INTRACELLULAR RETENTION	The transcription factor CCAAT/enhancer-binding protein alpha(C/EBP alpha) is required during adipogenesis for development of insulin-stimulated glucose uptake. Modes for regulating this function of C/EBP alpha have yet to be determined. Phosphorylation of C/EBP alpha on Ser-21 has been implicated in the regulation of granulopoiesis and hepatic gene expression. To explore the role of Ser-21 phosphorylation on C/EBP alpha function during adipogenesis, we developed constructs in which Ser-21 was mutated to alanine (S21A) to model dephosphorylation. In two cell culture models deficient in endogenous C/EBP alpha, enforced expression of S21A-C/EBP alpha resulted in normal lipid accumulation and expression of many adipogenic markers. However, S21A-C/EBP alpha had impaired ability to activate the Glut4 promoter specifically, and S21A-C/EBP alpha expression resulted in diminished GLUT4 and adiponectin expression, as well as reduced insulin-stimulated glucose uptake. No defects in insulin signaling or GLUT4 vesicle trafficking were identified with S21A-C/EBP alpha expression, and when exogenous GLUT4 expression was enforced to normalize expression in S21A-C/EBP alpha cells, insulin-responsive glucose transport was reconstituted, suggesting that the primary defect was a deficit in GLUT4 levels. Mice in which endogenous C/EBP alpha was replaced with S21A-C/EBP alpha displayed reduced GLUT4 and adiponectin protein expression in epididymal adipose tissue and increased blood glucose compared with wild-type littermates. These results suggest that phosphorylation of C/EBP alpha on Ser-21 may regulate adipocyte gene expression and whole body glucose homeostasis.	[Cha, Hyuk C.; Oak, Nikhil R.; Kang, Sona; Tran, Tuan-Ahn; Chiang, Shian-Huey; MacDougald, Ormond A.] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA; [Kobayashi, Susumu; Tenen, Daniel G.] Harvard Univ, Sch Med, Boston, MA 02215 USA; [Kobayashi, Susumu; Tenen, Daniel G.] Beth Israel Deaconess Med Ctr, Div Hematol Oncol, Boston, MA 02215 USA	University of Michigan System; University of Michigan; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	MacDougald, OA (corresponding author), 1301 E Catherine St, Ann Arbor, MI 48109 USA.	macdouga@umich.edu		MacDougald, Ormond/0000-0001-6907-7960; Tenen, Daniel/0000-0002-6423-3888	NICHD NIH HHS [5 T32 HD 007505] Funding Source: Medline; NIDDK NIH HHS [DK 62876] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007505] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK062876, R56DK062876] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575; Armoni M, 2007, TRENDS ENDOCRIN MET, V18, P100, DOI 10.1016/j.tem.2007.02.001; Barak Y, 1999, MOL CELL, V4, P585, DOI 10.1016/S1097-2765(00)80209-9; Baumann CA, 2000, NATURE, V407, P202, DOI 10.1038/35025089; Baumann CA, 2001, J BIOL CHEM, V276, P6065, DOI 10.1074/jbc.C000856200; Behre G, 2002, J BIOL CHEM, V277, P26293, DOI 10.1074/jbc.M202301200; Carvalho E, 2005, AM J PHYSIOL-ENDOC M, V289, pE551, DOI 10.1152/ajpendo.00116.2005; Carvalho E, 2004, J BIOL CHEM, V279, P21598, DOI 10.1074/jbc.M312269200; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; Darlington GJ, 1998, J BIOL CHEM, V273, P30057, DOI 10.1074/jbc.273.46.30057; DEFRONZO RA, 1992, DIABETES CARE, V15, P318, DOI 10.2337/diacare.15.3.318; Eguez L, 2005, CELL METAB, V2, P263, DOI 10.1016/j.cmet.2005.09.005; El-Jack AK, 1999, J BIOL CHEM, V274, P7946, DOI 10.1074/jbc.274.12.7946; Erickson RL, 2001, J BIOL CHEM, V276, P16348, DOI 10.1074/jbc.M100128200; Fernandez-Veledo Sonia, 2006, Archives of Physiology and Biochemistry, V112, P13, DOI 10.1080/13813450500508137; FREYTAG SO, 1994, GENE DEV, V8, P1654, DOI 10.1101/gad.8.14.1654; Goodyear LJ, 1998, ANNU REV MED, V49, P235, DOI 10.1146/annurev.med.49.1.235; Gross DN, 2004, MOL CELL BIOL, V24, P7151, DOI 10.1128/MCB.24.16.7151-7162.2004; Hemati N, 1997, J BIOL CHEM, V272, P25913, DOI 10.1074/jbc.272.41.25913; Hernandez R, 2003, BIOCHEM J, V372, P617, DOI 10.1042/BJ20030325; Kahn BB, 2000, J CLIN INVEST, V106, P473, DOI 10.1172/JCI10842; Kane S, 2002, J BIOL CHEM, V277, P22115, DOI 10.1074/jbc.C200198200; Kanzaki M, 2001, J BIOL CHEM, V276, P42436, DOI 10.1074/jbc.M108297200; Kim J, 2002, J BIOL CHEM, V277, P38037, DOI 10.1074/jbc.M207235200; Kovacs KA, 2003, J BIOL CHEM, V278, P36959, DOI 10.1074/jbc.M303147200; Larance M, 2005, J BIOL CHEM, V280, P37803, DOI 10.1074/jbc.M503897200; Li D, 2005, J BIOL CHEM, V280, P26941, DOI 10.1074/jbc.M500463200; LIN FT, 1993, P NATL ACAD SCI USA, V90, P9606, DOI 10.1073/pnas.90.20.9606; Liu HK, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-14; Liu PCC, 2006, J BIOCHEM MOL TOXIC, V20, P79, DOI 10.1002/jbt.20120; MAHONEY CW, 1992, J BIOL CHEM, V267, P19396; Miller RS, 2007, BIOCHEM BIOPH RES CO, V362, P188, DOI 10.1016/j.bbrc.2007.07.176; Minokoshi Y, 2003, J BIOL CHEM, V278, P33609, DOI 10.1074/jbc.R300019200; Mora S, 2002, DIABETES-METAB RES, V18, P345, DOI 10.1002/dmrr.321; Mori T, 2005, J BIOL CHEM, V280, P12867, DOI 10.1074/jbc.M410515200; Oishi Y, 2005, CELL METAB, V1, P27, DOI 10.1016/j.cmet.2004.11.005; Park BH, 2004, MOL CELL BIOL, V24, P8671, DOI 10.1128/MCB.24.19.8671-8680.2004; Pedersen TA, 2007, EMBO J, V26, P1081, DOI 10.1038/sj.emboj.7601563; Pessler-Cohen Dorit, 2006, Archives of Physiology and Biochemistry, V112, P3, DOI 10.1080/13813450500500399; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; PIPER RC, 1993, J CELL BIOL, V121, P1221, DOI 10.1083/jcb.121.6.1221; Qiao LP, 2006, J BIOL CHEM, V281, P24390, DOI 10.1074/jbc.M603038200; Qiao LP, 2006, ENDOCRINOLOGY, V147, P865, DOI 10.1210/en.2005-1030; Radomska HS, 2006, J EXP MED, V203, P371, DOI 10.1084/jem.20052242; Rangwala SM, 2000, ANNU REV NUTR, V20, P535, DOI 10.1146/annurev.nutr.20.1.535; Rosen ED, 2000, GENE DEV, V14, P1293; Rosen ED, 1999, MOL CELL, V4, P611, DOI 10.1016/S1097-2765(00)80211-7; Rosen ED, 2002, GENE DEV, V16, P22, DOI 10.1101/gad.948702; Ross SE, 2004, MOL CELL BIOL, V24, P675, DOI 10.1128/MCB.24.2.675-686.2004; Ross SE, 2002, MOL CELL BIOL, V22, P5989, DOI 10.1128/MCB.22.16.5989-5999.2002; Ross SE, 2000, SCIENCE, V289, P950, DOI 10.1126/science.289.5481.950; Routes JM, 2000, BIOCHEM J, V352, P335, DOI 10.1042/0264-6021:3520335; Saltiel AR, 2001, NATURE, V414, P799, DOI 10.1038/414799a; Shepherd PR, 1999, NEW ENGL J MED, V341, P248, DOI 10.1056/NEJM199907223410406; Steppan CM, 2001, NATURE, V409, P307, DOI 10.1038/35053000; Steppan CM, 2001, P NATL ACAD SCI USA, V98, P502, DOI 10.1073/pnas.98.2.502; Subramanian L, 2003, J BIOL CHEM, V278, P9134, DOI 10.1074/jbc.M210440200; Thurmond DC, 1998, J BIOL CHEM, V273, P33876, DOI 10.1074/jbc.273.50.33876; Wang GL, 2006, MOL CELL BIOL, V26, P2570, DOI 10.1128/MCB.26.7.2570-2582.2006; Wang GL, 2005, MOL CELL BIOL, V25, P1325, DOI 10.1128/MCB.25.4.1325-1338.2005; Wang GL, 2004, GENE DEV, V18, P912, DOI 10.1101/gad.1183304; WANG ND, 1995, SCIENCE, V269, P1108, DOI 10.1126/science.7652557; Wertheim N, 2004, J BIOL CHEM, V279, P41468, DOI 10.1074/jbc.M405088200; Wu ZD, 1999, MOL CELL, V3, P151, DOI 10.1016/S1097-2765(00)80306-8; Xu Y, 2006, J BIOL CHEM, V281, P16090, DOI 10.1074/jbc.M510514200; Yin LY, 2005, MOL CELL ENDOCRINOL, V245, P43, DOI 10.1016/j.mce.2005.10.002; Yoshida Y, 2006, HEPATOLOGY, V43, P276, DOI 10.1002/hep.21044	67	17	19	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18002	18011		10.1074/jbc.M800419200	http://dx.doi.org/10.1074/jbc.M800419200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18408001	Green Published, hybrid			2022-12-25	WOS:000256949200029
J	Xu, SX; Wong, CCL; Tong, EHY; Chung, SSM; Yates, JR; Yin, YB; Ko, BCB				Xu, SongXiao; Wong, Catherine C. L.; Tong, Edith H. Y.; Chung, Stephen S. M.; Yates, John R., III; Yin, YiBing; Ko, Ben C. B.			Phosphorylation by casein kinase 1 regulates tonicity-induced osmotic response element-binding protein/tonicity enhancer-binding protein nucleocytoplasmic trafficking	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CASEIN KINASE-I; NUCLEAR-LOCALIZATION; TRANSCRIPTIONAL REGULATION; STIMULATES TRANSCRIPTION; MASS-SPECTROMETRY; GENE-EXPRESSION; IDENTIFICATION; NFAT; IMPORT; SITES	The osmotic response element-binding protein (OREBP), also known as tonicity enhancer-binding protein (TonEBP) or NFAT5, is the only known osmo-sensitive transcription factor that mediates cellular adaptations to extracellular hypertonic stress. Although it is well documented that the subcellular localization and transactivation activity of OREBP/TonEBP are tightly regulated by extracellular tonicity, the molecular mechanisms involved remain elusive. Here we show that nucleocytoplasmic trafficking of OREBP/TonEBP is regulated by the dual phosphorylation of Ser-155 and Ser-158. Alanine scanning mutagenesis revealed that Ser-155 is an essential residue that regulates OREBP/TonEBP nucleocytoplasmic trafficking. Tandem mass spectrometry revealed that Ser-155 and Ser-158 of OREBP/TonEBP are both phosphorylated in living cells under hypotonic conditions. In vitro phosphorylation assays further suggest that phosphorylation of the two serine residues proceeds in a hierarchical manner with phosphorylation of Ser-155 priming the phosphorylation of Ser-158 and that these phosphorylations are essential for nucleocytoplasmic trafficking of the transcription factor. Finally, we have shown that the pharmacological inhibition of casein kinase 1 (CK1) abolishes the phosphorylation of Ser-158 and impedes OREBP/TonEBP nuclear export and that recombinant CK1 phosphorylates Ser-158. Knockdown of CK1 alpha 1L, a novel isoform of CK1, inhibits hypotonicity-induced OREBP/TonEBP nuclear export. Together these data highlight the importance of Ser-155 and Ser-158 in the nucleocytoplasmic trafficking of OREBP/TonEBP and indicate that CK1 plays a major role in regulating this process.	[Xu, SongXiao; Ko, Ben C. B.] Chinese Univ Hong Kong, State Key Lab Oncol S China, Hong Kong, Hong Kong, Peoples R China; [Xu, SongXiao; Ko, Ben C. B.] Chinese Univ Hong Kong, Dept Anat & Cellular Pathol, Hong Kong, Hong Kong, Peoples R China; [Xu, SongXiao; Yin, YiBing] Chongqing Med Univ, Dept Lab Med, Minist Educ, Key Lab Lab Med Diagnost, Chongqing, Peoples R China; [Wong, Catherine C. L.; Yates, John R., III] Scripps Res Inst, Dept Cell Biol, La Jolla, CA 92037 USA; [Tong, Edith H. Y.; Chung, Stephen S. M.] Univ Hong Kong, Li Ka Shing Fac Med, Dept Physiol, Hong Kong, Hong Kong, Peoples R China	Chinese University of Hong Kong; Chinese University of Hong Kong; Chongqing Medical University; Scripps Research Institute; University of Hong Kong	Ko, BCB (corresponding author), Chinese Univ Hong Kong, State Key Lab Oncol S China, Hong Kong, Hong Kong, Peoples R China.	benko@cuhk.edu.hk	Ko, Chi-bun/ACH-7514-2022; Xu, Songxiao/L-5737-2019	Ko, Ben Chi Bun/0000-0003-2027-5899; Wong, Catherine CL/0000-0001-7270-980X	NCRR NIH HHS [P41 RR011823] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Amanchy R, 2007, NAT BIOTECHNOL, V25, P285, DOI 10.1038/nbt0307-285; Behrend L, 2000, ONCOGENE, V19, P5303, DOI 10.1038/sj.onc.1203939; BEYAERT R, 1995, J BIOL CHEM, V270, P23293, DOI 10.1074/jbc.270.40.23293; BROCKMAN JL, 1992, P NATL ACAD SCI USA, V89, P9454, DOI 10.1073/pnas.89.20.9454; Burg MB, 2007, PHYSIOL REV, V87, P1441, DOI 10.1152/physrev.00056.2006; Burg MB, 1997, ANNU REV PHYSIOL, V59, P437, DOI 10.1146/annurev.physiol.59.1.437; Burg MB, 1996, KIDNEY INT, V49, P1684, DOI 10.1038/ki.1996.247; Cantin GT, 2007, ANAL CHEM, V79, P4666, DOI 10.1021/ac0618730; CHIJIWA T, 1989, J BIOL CHEM, V264, P4924; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P16800, DOI 10.1073/pnas.222659799; Ferraris JD, 2002, P NATL ACAD SCI USA, V99, P739, DOI 10.1073/pnas.241637298; Go WY, 2004, P NATL ACAD SCI USA, V101, P10673, DOI 10.1073/pnas.0403139101; Gross SD, 1997, J CELL SCI, V110, P3083; Gross SD, 1998, CELL SIGNAL, V10, P699, DOI 10.1016/S0898-6568(98)00042-4; Grozinger CM, 2000, P NATL ACAD SCI USA, V97, P7835, DOI 10.1073/pnas.140199597; Ha H, 2003, J BIOL CHEM, V278, P18573, DOI 10.1074/jbc.M212626200; Handler JS, 2001, KIDNEY INT, V60, P408, DOI 10.1046/j.1523-1755.2001.060002408.x; HENNEKES H, 1993, J CELL BIOL, V120, P1293, DOI 10.1083/jcb.120.6.1293; Hogan PG, 2003, GENE DEV, V17, P2205, DOI 10.1101/gad.1102703; Irarrazabal CE, 2004, P NATL ACAD SCI USA, V101, P8809, DOI 10.1073/pnas.0403062101; Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816; Knippschild U, 2005, CELL SIGNAL, V17, P675, DOI 10.1016/j.cellsig.2004.12.011; Ko BCB, 2000, BIOCHEM BIOPH RES CO, V270, P52, DOI 10.1006/bbrc.2000.2376; Ko BCB, 2002, J BIOL CHEM, V277, P46085, DOI 10.1074/jbc.M208138200; Ko BCB, 1997, J BIOL CHEM, V272, P16431, DOI 10.1074/jbc.272.26.16431; Komeili A, 1999, SCIENCE, V284, P977, DOI 10.1126/science.284.5416.977; Lam AKM, 2004, J BIOL CHEM, V279, P48048, DOI 10.1074/jbc.M407224200; Lee H, 2002, MOL CELL BIOL, V22, P5835, DOI 10.1128/MCB.22.16.5835-5845.2002; Link AJ, 1999, NAT BIOTECHNOL, V17, P676, DOI 10.1038/10890; Lopez-Rodriguez C, 1999, P NATL ACAD SCI USA, V96, P7214, DOI 10.1073/pnas.96.13.7214; Lopez-Rodriguez C, 2004, P NATL ACAD SCI USA, V101, P2392, DOI 10.1073/pnas.0308703100; Lu BW, 2007, ANAL CHEM, V79, P1301, DOI 10.1021/ac061334v; McDonald WH, 2002, INT J MASS SPECTROM, V219, P245, DOI 10.1016/S1387-3806(02)00563-8; Miyakawa H, 1999, P NATL ACAD SCI USA, V96, P2538, DOI 10.1073/pnas.96.5.2538; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; O'Connor RS, 2007, J CELL SCI, V120, P149, DOI 10.1242/jcs.03307; Okamura H, 2004, MOL CELL BIOL, V24, P4184, DOI 10.1128/MCB.24.10.4184-4195.2004; Okamura H, 2000, MOL CELL, V6, P539, DOI 10.1016/S1097-2765(00)00053-8; Petronczki M, 2006, CELL, V126, P1049, DOI 10.1016/j.cell.2006.07.029; Pulgar V, 1999, EUR J BIOCHEM, V260, P520, DOI 10.1046/j.1432-1327.1999.00195.x; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rena G, 2002, EMBO J, V21, P2263, DOI 10.1093/emboj/21.9.2263; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; Rim JS, 1998, J BIOL CHEM, V273, P20615, DOI 10.1074/jbc.273.32.20615; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Takano A, 2004, J BIOL CHEM, V279, P32578, DOI 10.1074/jbc.M403433200; TAKENAKA M, 1994, J BIOL CHEM, V269, P29379; Tong EHY, 2006, J BIOL CHEM, V281, P23870, DOI 10.1074/jbc.M602556200; von Blume J, 2007, EMBO J, V26, P4619, DOI 10.1038/sj.emboj.7601891; Wang Y, 2005, J BIOL CHEM, V280, P19986, DOI 10.1074/jbc.M501689200; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Woo SK, 2000, AM J PHYSIOL-RENAL, V278, pF1006; Woo SK, 2002, MOL CELL BIOL, V22, P5753, DOI 10.1128/MCB.22.16.5753-5760.2002; Wu H, 2007, TRENDS CELL BIOL, V17, P251, DOI 10.1016/j.tcb.2007.04.006; YANCEY PH, 1982, SCIENCE, V217, P1214, DOI 10.1126/science.7112124; Zhang F, 2000, P NATL ACAD SCI USA, V97, P12577, DOI 10.1073/pnas.230435597; Zhang YP, 2001, SCIENCE, V292, P1910, DOI 10.1126/science.1058637; Zhao Y, 2004, J BIOL CHEM, V279, P30844, DOI 10.1074/jbc.M404651200; Zhu JY, 1998, CELL, V93, P851, DOI 10.1016/S0092-8674(00)81445-2	60	26	26	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17624	17634		10.1074/jbc.M800281200	http://dx.doi.org/10.1074/jbc.M800281200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18411282	Green Published, hybrid			2022-12-25	WOS:000256720600069
J	Charruyer, A; Bell, SM; Kawano, M; Douangpanya, S; Yen, TY; Macher, BA; Kumagai, K; Hanada, K; Holleran, WM; Uchida, Y				Charruyer, Alexandra; Bell, Sean M.; Kawano, Miyuki; Douangpanya, Sounthala; Yen, Ten-Yang; Macher, Bruce A.; Kumagai, Keigo; Hanada, Kentaro; Holleran, Walter M.; Uchida, Yoshikazu			Decreased ceramide transport protein (CERT) function alters sphingomyelin production following UVB irradiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXYSTEROL-BINDING PROTEIN; GLUCOSYLCERAMIDE SYNTHASE; INDUCED APOPTOSIS; ENDOPLASMIC-RETICULUM; NONVESICULAR TRAFFICKING; SIGNAL-TRANSDUCTION; ACTIVATION; GOLGI; INHIBITORS; EXPRESSION	Increased cellular ceramide accounts in part for UVB irradiation-induced apoptosis in cultured human keratinocytes with concurrent increased glucosylceramide but not sphingomyelin generation in these cells. Given that conversion of ceramide to non-apoptotic metabolites such as sphingomyelin and glucosylceramide protects cells from ceramide-induced apoptosis, we hypothesized that failed up-regulation of sphingomyelin generation contributes to ceramide accumulation following UVB irradiation. Because both sphingomyelin synthase and glucosylceramide synthase activities were significantly decreased in UVB-irradiated keratinocytes, we investigated whether alteration(s) in the function of ceramide transport protein (or CERT) required for sphingomyelin synthesis occur(s) in UVB-irradiated cells. Fluorescently labeled N-(4,4-difluoro-5,7-dimethyl-4-bora-3a, 4a-diaza-s-indacene-3-pentanoyl)-D-erythro-sphingosine (C-5-DMB-ceramide) relocation to the Golgi was diminished after irradiation, consistent with decreased CERT function, whereas the CERT inhibitor N-(3-hydroxy-1-hydroxymethyl-3-phenylpropyl) dodecanamide (1R, 3R isomer) (HPA-12) produced an equivalent effect. UVB irradiation also induced the rapid formation of a stable CERT homotrimer complex in keratinocytes as determined by Western immunoblot and mass spectrometry analyses, a finding replicated in HeLa, HEK293T, and HaCaT cells and in murine epidermis. Ceramide binding activity was decreased in recombinant CERT proteins containing the UVB-induced homotrimer. The middle region domain of the CERT protein was required for the homotrimer formation, whereas neither the pleckstrin homology (Golgi-binding) nor the START (ceramide-binding) domains were involved. Finally like UVB-treated keratinocytes, HPA-12 blockade of CERT function increased keratinocyte apoptosis, decreased sphingomyelin synthesis, and led to accumulation of ceramide. Thus, UVB-induced CERT homotrimer formation accounts, at least in part, for apoptosis and failed up-regulation of sphingomyelin synthesis following UVB irradiation, revealing that inactive CERT can attenuate a key metabolic protective mechanism against ceramide-induced apoptosis in keratinocytes.	[Uchida, Yoshikazu] Vet Adm Med Ctr, Dermatol Serv, San Francisco, CA 94121 USA; [Charruyer, Alexandra; Bell, Sean M.; Douangpanya, Sounthala; Holleran, Walter M.; Uchida, Yoshikazu] Univ Calif San Francisco, No Calif Inst Res & Educ, Dept Dermatol, Sch Med, San Francisco, CA 94121 USA; [Holleran, Walter M.] Univ Calif San Francisco, Dept Pharmaceut Chem, Sch Pharm, San Francisco, CA 94143 USA; [Kawano, Miyuki; Kumagai, Keigo; Hanada, Kentaro] Natl Inst Infect Dis, Dept Biochem & Cell Biol, Tokyo 1628640, Japan; [Yen, Ten-Yang; Macher, Bruce A.] San Francisco State Univ, Dept Chem & Biochem, San Francisco, CA 94132 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Northern California Institute for Research & Education; University of California System; University of California San Francisco; University of California System; University of California San Francisco; National Institute of Infectious Diseases (NIID); California State University System; San Francisco State University	Uchida, Y (corresponding author), Vet Adm Med Ctr, Dermatol Serv, 4150 Clement St, San Francisco, CA 94121 USA.	uchiday@derm.ucsf.edu	Kumagai, Keigo/AAG-1385-2021	Kumagai, Keigo/0000-0002-1663-2905; KAWANO-KAWADA, Miyuki/0000-0002-1168-9291; Uchida, Yoshikazu/0000-0002-4980-3416; Hanada, Kentaro/0000-0003-1383-2781	NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES [P20MD000262] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR051077, P01AR039448] Funding Source: NIH RePORTER	NATIONAL CENTER ON MINORITY HEALTH AND HEALTH DISPARITIES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ABE A, 1995, J LIPID RES, V36, P611; Alpy F, 2005, J CELL SCI, V118, P2791, DOI 10.1242/jcs.02485; Bieberich E, 1999, J NEUROCHEM, V72, P1040, DOI 10.1046/j.1471-4159.1999.0721040.x; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Bonhoure E, 2006, LEUKEMIA, V20, P95, DOI 10.1038/sj.leu.2404023; Charruyer A, 2005, J BIOL CHEM, V280, P19196, DOI 10.1074/jbc.M412867200; Chujor CSN, 1998, J LIPID RES, V39, P277; Claerhout S, 2006, PHOTOCH PHOTOBIO SCI, V5, P199, DOI 10.1039/b504970a; Fugmann T, 2007, J CELL BIOL, V178, P15, DOI 10.1083/jcb.200612017; Fukasawa M, 1999, J CELL BIOL, V144, P673, DOI 10.1083/jcb.144.4.673; Funakoshi T, 2000, J BIOL CHEM, V275, P29938, DOI 10.1074/jbc.M004470200; Grazide S, 2004, J BIOL CHEM, V279, P18256, DOI 10.1074/jbc.M314105200; Halter D, 2007, J CELL BIOL, V179, P101, DOI 10.1083/jcb.200704091; Hanada K, 2003, NATURE, V426, P803, DOI 10.1038/nature02188; Haratake A, 1997, J INVEST DERMATOL, V108, P769, DOI 10.1111/1523-1747.ep12292163; Holleran WM, 1997, PHOTODERMATOL PHOTO, V13, P117, DOI 10.1111/j.1600-0781.1997.tb00214.x; Houben E, 2006, J LIPID RES, V47, P1063, DOI 10.1194/jlr.M600001-JLR200; Huwiler A, 1999, J BIOL CHEM, V274, P7190, DOI 10.1074/jbc.274.11.7190; Itoh M, 2003, CLIN CANCER RES, V9, P415; Kawano M, 2006, J BIOL CHEM, V281, P30279, DOI 10.1074/jbc.M605032200; KOVAL M, 1991, BIOCHIM BIOPHYS ACTA, V1082, P113, DOI 10.1016/0005-2760(91)90184-J; Kudo N, 2008, P NATL ACAD SCI USA, V105, P488, DOI 10.1073/pnas.0709191105; Kumagai K, 2007, J BIOL CHEM, V282, P17758, DOI 10.1074/jbc.M702291200; Larsson P, 2006, BRIT J DERMATOL, V155, P292, DOI 10.1111/j.1365-2133.2006.07347.x; Lee L, 1999, J BIOL CHEM, V274, P14662, DOI 10.1074/jbc.274.21.14662; Li JL, 2007, J BIOMED SCI, V14, P303, DOI 10.1007/s11373-007-9148-4; Liu YY, 1999, J BIOL CHEM, V274, P1140, DOI 10.1074/jbc.274.2.1140; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; Magnoni C, 2002, TOXICOL IN VITRO, V16, P349, DOI 10.1016/S0887-2333(02)00024-3; Malakhova ML, 2005, J BIOL CHEM, V280, P26312, DOI 10.1074/jbc.M500481200; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Mathias S, 1998, BIOCHEM J, V335, P465, DOI 10.1042/bj3350465; Nishigori C, 2006, PHOTOCH PHOTOBIO SCI, V5, P208, DOI 10.1039/b507471a; OBERHAMMER FA, 1992, P NATL ACAD SCI USA, V89, P5408, DOI 10.1073/pnas.89.12.5408; Ohanian J, 2001, CELL MOL LIFE SCI, V58, P2053, DOI 10.1007/PL00000836; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Perry RJ, 2006, MOL BIOL CELL, V17, P2604, DOI 10.1091/mbc.E06-01-0060; PITTELKOW MR, 1986, MAYO CLIN PROC, V61, P771, DOI 10.1016/S0025-6196(12)64815-0; Rabe JH, 2006, J AM ACAD DERMATOL, V55, P1, DOI 10.1016/j.jaad.2005.05.010; Raj D, 2006, J INVEST DERMATOL, V126, P243, DOI 10.1038/sj.jid.5700008; Ruvolo PP, 2003, PHARMACOL RES, V47, P383, DOI 10.1016/S1043-6618(03)00050-1; Schwarz A, 1996, J INVEST DERMATOL, V106, P1187, DOI 10.1111/1523-1747.ep12347944; Uchida Y, 2004, CANCER RES, V64, P6271, DOI 10.1158/0008-5472.CAN-03-1476; Uchida Y, 2003, J INVEST DERMATOL, V120, P662, DOI 10.1046/j.1523-1747.2003.12098.x; Uchida Y, 2002, J LIPID RES, V43, P1293, DOI 10.1194/jlr.M100442-JLR200; Wang YM, 2006, J BIOL CHEM, V281, P11887, DOI 10.1074/jbc.M511309200; Wyles JP, 2002, J BIOL CHEM, V277, P29908, DOI 10.1074/jbc.M201191200; Yasuda S, 2001, J BIOL CHEM, V276, P43994, DOI 10.1074/jbc.M104884200; Zhang WG, 2005, CARCINOGENESIS, V26, P249, DOI 10.1093/carcin/bgh300; ZIEGLER A, 1994, NATURE, V372, P773, DOI 10.1038/372773a0	50	39	45	0	3	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16682	16692		10.1074/jbc.M800799200	http://dx.doi.org/10.1074/jbc.M800799200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18411267	Green Published, hybrid			2022-12-25	WOS:000256497100045
J	Chen, W; Bacanamwo, M; Harrison, DG				Chen, Wei; Bacanamwo, Methode; Harrison, David G.			Activation of p300 histone acetyltransferase activity is an early endothelial response to laminar shear stress and is essential for stimulation of endothelial nitric-oxide synthase mRNA transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; GENE-EXPRESSION; POSTTRANSCRIPTIONAL REGULATION; SIGNAL-TRANSDUCTION; CELLS; PHOSPHORYLATION; MECHANISM; FLOW; ENOS; AKT	Previous studies have shown that the acute stimulation of endothelial nitric-oxide synthase (eNOS) mRNA transcription by laminar shear stress is dependent on nuclear factor kappa B (NF kappa B) subunits p50 and p65 binding to a shear stress response element (SSRE) in the human eNOS promoter and that mutation of the SSRE abrogates the shear-stimulated increase in eNOS promoter activity. In the present study, we found that although shear markedly increased eNOS mRNA, the increase in nuclear translocation of p50 and p65 caused by shear was only 2-fold, suggesting that shear has additional effects on NF kappa B cofactor activity beyond nuclear translocation. Chromatin immunoprecipitation assays showed that virtually no p50 or p65 was bound to the eNOS promoter at base line but that shear increased the binding of these subunits to the human eNOS SSRE by 10- to 20-fold. Co-immunoprecipitation studies demonstrated during the first 30 min of shear p300 bound to p65. Shear also increased p300 histone acetyltransferase (HAT) activity by 2.5-fold and increased acetylation of p65. The increase in eNOS mRNA caused by shear was completely blocked by pharmacological inhibition of p300/HAT activity with curcumin or by p300 small interfering RNA. Chromatin immunoprecipitation assays also showed that shear stimulated acetylation of histones 3 and 4 at the region of the eNOS promoter SSRE and extended 3' toward the eNOS coding region. This was associated with opening of chromatin at the SSRE. In conclusion, these studies reveal a previously unknown role of p300/HAT activation as a very early response to shear that is essential for increasing eNOS mRNA levels.	[Chen, Wei; Harrison, David G.] Emory Univ, Sch Med, Div Cardiol, Dept Med, Atlanta, GA 30022 USA; [Chen, Wei; Harrison, David G.] Atlanta Vet Adm Hosp, Decatur, GA 30033 USA; [Bacanamwo, Methode] Morehouse Sch Med, Cardiovasc Res Inst, Atlanta, GA 30310 USA	Emory University; Morehouse School of Medicine	Harrison, DG (corresponding author), Emory Univ, Sch Med, Div Cardiol, Dept Med, Rm 319 WMRB,1639 Pierce Dr, Atlanta, GA 30022 USA.	dharr02@emory.edu		Chen, Wei/0000-0002-3973-340X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059248, P01HL058000, P01HL075209, R01HL039006, R29HL038206, R01HL038206, R37HL038206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051257] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL59248, HL075209, HL39006, HL58000, HL38206] Funding Source: Medline; NIDDK NIH HHS [DK51257] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Berk BC, 1995, J BIOMECH, V28, P1439, DOI 10.1016/0021-9290(95)00092-5; Blasko E, 2002, J BIOL CHEM, V277, P295, DOI 10.1074/jbc.M105691200; Boo YC, 2002, AM J PHYSIOL-HEART C, V283, pH1819, DOI 10.1152/ajpheart.00214.2002; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; Davis ME, 2004, J BIOL CHEM, V279, P163, DOI 10.1074/jbc.M307528200; de Martin R, 2000, ARTERIOSCL THROM VAS, V20, pE83; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; Drummond GR, 2000, CIRC RES, V86, P347, DOI 10.1161/01.RES.86.3.347; Fleming I, 2005, J CELL SCI, V118, P4103, DOI 10.1242/jcs.02541; Fleming I, 1999, CARDIOVASC RES, V43, P532, DOI 10.1016/S0008-6363(99)00094-2; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Goriely S, 2004, J EXP MED, V199, P1011, DOI 10.1084/jem.20031272; Grumbach IM, 2005, J MOL CELL CARDIOL, V39, P595, DOI 10.1016/j.yjmcc.2005.06.012; Hassa PO, 2002, CELL MOL LIFE SCI, V59, P1534, DOI 10.1007/s00018-002-8527-2; Huang WC, 2005, MOL CELL BIOL, V25, P6592, DOI 10.1128/MCB.25.15.6592-6602.2005; Huddleson JP, 2005, J BIOL CHEM, V280, P23371, DOI 10.1074/jbc.M413839200; JAMES NL, 1995, FASEB J, V9, P968, DOI 10.1096/fasebj.9.10.7615166; Khorasanizadeh S, 2004, CELL, V116, P259, DOI 10.1016/S0092-8674(04)00044-3; LAURINDO FRM, 1994, CIRC RES, V74, P700, DOI 10.1161/01.RES.74.4.700; Li QT, 2002, NAT REV IMMUNOL, V2, P725, DOI 10.1038/nri910; Malek AM, 1995, J BIOMECH, V28, P1515, DOI 10.1016/0021-9290(95)00099-2; Mattart M, 2003, BIORHEOLOGY, V40, P289; NEREM RM, 1993, J CARDIOVASC PHARM, V21, pS6, DOI 10.1097/00005344-199321001-00002; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; Partridge J, 2007, FASEB J, V21, P3553, DOI 10.1096/fj.06-8059com; Rahman I, 2004, BIOCHEM PHARMACOL, V68, P1255, DOI 10.1016/j.bcp.2004.05.042; Ramasamy S, 1998, J LIPID RES, V39, P268; Rothwarf D M, 1999, Sci STKE, V1999, pRE1, DOI 10.1126/stke.1999.5.re1; Searles CD, 2006, AM J PHYSIOL-CELL PH, V291, pC803, DOI 10.1152/ajpcell.00457.2005; Tzima E, 2002, EMBO J, V21, P6791, DOI 10.1093/emboj/cdf688; Tzima E, 2005, NATURE, V437, P426, DOI 10.1038/nature03952; Vanden Berghe W, 2003, ADV EXP MED BIOL, V544, P181; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wang JG, 2006, BLOOD, V107, P558, DOI 10.1182/blood-2005-05-2152	34	63	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16293	16298		10.1074/jbc.M801803200	http://dx.doi.org/10.1074/jbc.M801803200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18397880	hybrid, Green Published			2022-12-25	WOS:000256497100005
J	Leanza, L; Ferraro, P; Reichard, P; Bianchi, V				Leanza, Luigi; Ferraro, Paola; Reichard, Peter; Bianchi, Vera			Metabolic interrelations within guanine deoxynucleotide pools for mitochondrial and nuclear DNA maintenance	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOSIDE-PHOSPHORYLASE DEFICIENCY; THYMIDINE KINASE; NEUROGASTROINTESTINAL ENCEPHALOMYOPATHY; DEOXYRIBONUCLEOSIDE KINASES; RIBONUCLEOTIDE REDUCTION; DEOXYGUANOSINE KINASE; SUBSTRATE-SPECIFICITY; TRIPHOSPHATE POOLS; IMMUCILLIN-H; CELLS	Mitochondrial deoxynucleoside triphosphates are formed and regulated by a network of anabolic and catabolic enzymes present both in mitochondria and the cytosol. Genetic deficiencies for enzymes of the network cause mitochondrial DNA depletion and disease. We investigate by isotope flow experiments the interrelation between mitochondrial and cytosolic deoxynucleotide pools as well as the contributions of the individual enzymes of the network to their maintenance. To study specifically the synthesis of dGTP used for the synthesis of mitochondrial and nuclear DNA, we labeled hamster CHO cells or human fibroblasts with [H-3] deoxyguanosine during growth and quiescence and after inhibition with aphidicolin or hydroxyurea. At time intervals we determined the labeling of deoxyguanosine nucleotides and DNA and the turnover of dGTP from its specific radioactivity in the separated mitochondrial and cytosolic pools. In both cycling and quiescent cells, the import of deoxynucleotides formed by cytosolic ribonucleotide reductase accounted for most of the synthesis of mitochondrial dGTP, with minor contributions by cytosolic deoxycytidine kinase and mitochondrial deoxyguanosine kinase. A dynamic isotopic equilibrium arose rapidly from the shuttling of deoxynucleotides between mitochondria and cytosol, incorporation of dGTP into DNA, and degradation of dGMP. Inhibition of DNA synthesis by aphidicolin marginally affected the equilibrium. Inhibition of DNA synthesis by blockage of ribonucleotide reduction with hydroxyurea instead disturbed the equilibrium and led to accumulation of labeled dGTP in the cytosol. The turnover of dGTP decreased, suggesting a close connection between ribonucleotide reduction and pool degradation.	[Leanza, Luigi; Ferraro, Paola; Reichard, Peter; Bianchi, Vera] Univ Padua, Dept Biol, I-35131 Padua, Italy	University of Padua	Bianchi, V (corresponding author), Univ Padua, Dept Biol, Via Ugo Bassi 58B, I-35131 Padua, Italy.	vbianchi@bio.unipd.it	Leanza, Luigi/K-3060-2016	Leanza, Luigi/0000-0002-5919-7114	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom; Telethon [GGP05001] Funding Source: Medline	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Telethon(Fondazione Telethon)		BERK AJ, 1973, J BIOL CHEM, V248, P2722; BESTWICK RK, 1982, J BIOL CHEM, V257, P9300; Bianchi V, 2003, J BIOL CHEM, V278, P46195, DOI 10.1074/jbc.R300032200; BOGENHAGEN D, 1976, J BIOL CHEM, V251, P2938; Bourdon A, 2007, NAT GENET, V39, P776, DOI 10.1038/ng2040; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chabes AL, 2003, P NATL ACAD SCI USA, V100, P3925, DOI 10.1073/pnas.0330774100; COHEN A, 1978, J CLIN INVEST, V61, P1405, DOI 10.1172/JCI109058; Eriksson S, 2002, CELL MOL LIFE SCI, V59, P1327, DOI 10.1007/s00018-002-8511-x; Ferraro P, 2005, J BIOL CHEM, V280, P24472, DOI 10.1074/jbc.M502869200; Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103; Franzolin E, 2006, BIOCHEM BIOPH RES CO, V344, P30, DOI 10.1016/j.bbrc.2006.03.147; Gazziola C, 2001, J BIOL CHEM, V276, P6185, DOI 10.1074/jbc.M007623200; GIBLETT ER, 1975, LANCET, V1, P1010, DOI 10.1016/S0140-6736(75)91950-9; GRANGER DL, 1982, J CELL BIOL, V95, P527, DOI 10.1083/jcb.95.2.527; Hah SS, 2007, P NATL ACAD SCI USA, V104, P11203, DOI 10.1073/pnas.0701733104; Hakansson P, 2006, J BIOL CHEM, V281, P7834, DOI 10.1074/jbc.M512894200; Huang M, 2008, LEUKEMIA RES, V32, P1268, DOI 10.1016/j.leukres.2007.12.015; HUBERMAN JA, 1981, CELL, V23, P647, DOI 10.1016/0092-8674(81)90426-8; Kicska GA, 2001, P NATL ACAD SCI USA, V98, P4593, DOI 10.1073/pnas.071050798; KRAKOFF IH, 1968, CANCER RES, V28, P1559; Mandel H, 2001, NAT GENET, V29, P337, DOI 10.1038/ng746; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Nordlund N, 2006, ANNU REV BIOCHEM, V75, P681, DOI 10.1146/annurev.biochem.75.103004.142443; Pontarin G, 2003, P NATL ACAD SCI USA, V100, P12159, DOI 10.1073/pnas.1635259100; Pontarin G, 2007, J BIOL CHEM, V282, P16820, DOI 10.1074/jbc.M701310200; Pontarin G, 2006, J BIOL CHEM, V281, P22720, DOI 10.1074/jbc.M604498200; Rampazzo C, 2007, J BIOL CHEM, V282, P34758, DOI 10.1074/jbc.M705923200; REICHARD P, 1988, ANNU REV BIOCHEM, V57, P349, DOI 10.1146/annurev.bi.57.070188.002025; Saada A, 2001, NAT GENET, V29, P342, DOI 10.1038/ng751; Sandrini MPB, 2005, TRENDS BIOCHEM SCI, V30, P225, DOI 10.1016/j.tibs.2005.03.003; SHERMAN PA, 1989, ANAL BIOCHEM, V180, P222, DOI 10.1016/0003-2697(89)90420-X; Sjoberg AH, 1998, MOL PHARMACOL, V53, P270, DOI 10.1124/mol.53.2.270; Spinazzola A, 2005, GENE, V354, P162, DOI 10.1016/j.gene.2005.03.025; Tanaka H, 2000, NATURE, V404, P42, DOI 10.1038/35003506; Usova EV, 1997, EUR J BIOCHEM, V248, P762, DOI 10.1111/j.1432-1033.1997.t01-2-00762.x; Zhu CY, 2000, FEBS LETT, V474, P129, DOI 10.1016/S0014-5793(00)01569-6	37	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16437	16445		10.1074/jbc.M801572200	http://dx.doi.org/10.1074/jbc.M801572200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18417473	hybrid			2022-12-25	WOS:000256497100020
J	Lu, L; Zhu, Y; Huang, JH; Chen, X; Yang, HW; Jiang, SB; Chen, YH				Lu, Lu; Zhu, Yun; Huang, Jinghe; Chen, Xi; Yang, Hengwen; Jiang, Shibo; Chen, Ying-Hua			Surface exposure of the HIV-1 Env cytoplasmic tail LLP2 domain during the membrane fusion process - Interaction with gp41 fusion core	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL TAIL; ENVELOPE GLYCOPROTEIN; BINDING MOTIF; ATOMIC-STRUCTURE; IMMUNODEFICIENCY; PEPTIDE; REGION; ENTRY; TRUNCATION; ECTODOMAIN	HIV-1 gp41 cytoplasmic tail (CT) is highly conserved among HIV-1 isolates, particularly the region designated lentivirus lytic peptide (LLP1-2), which includes two alpha-helical domains LLP1 and LLP2. Although the gp41 CT is recognized as a modulator of viral fusogenicity, little is known about the regulatory mechanism of this region in the viral fusion process. Here we report that anti-LLP1-2 and anti-LLP2 antibodies (IgG) inhibited HIV-1 Env-mediated cell fusion and bound to the interface between effector and target cells at a suboptimal temperature (31.5 degrees C), which slows down the fusion process and prolongs the fusion intermediate state. This suggests that LLP1-2, especially the LLP2 region located inside the viral membrane, is transiently exposed on the membrane surface during the fusion process. Synthetic LLP2 peptide could bind to the gp41 six-helix bundle core with high binding affinity. These results suggest that the gp41 CT may interact with the gp41 core, via the surface-exposed LLP2 domain, to regulate Env-mediated membrane fusion.	[Jiang, Shibo] New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Viral Immunol, New York, NY 10065 USA; [Lu, Lu; Zhu, Yun; Huang, Jinghe; Chen, Xi; Yang, Hengwen; Chen, Ying-Hua] Tsinghua Univ, Dept Biol, Immunol Lab, Beijing Key Lab Prot Therapeut, Beijing 100084, Peoples R China	New York Blood Center; Tsinghua University	Jiang, SB (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Viral Immunol, New York, NY 10065 USA.	sjiang@nybloodcenter.org; chenyh@mail.tsinghua.edu.cn	lu, lu/HII-7530-2022; Lu, Lu/K-7070-2014; Jiang, Shibo/L-4500-2014; lu, lu/HGA-0894-2022; Yang, Hengwen/G-8091-2012; chen, ying/HHS-8254-2022; Huang, Jinghe/O-1986-2015; yang, hengwen/GQH-7922-2022	Lu, Lu/0000-0002-2255-0391; Jiang, Shibo/0000-0001-8283-7135; yang, hengwen/0000-0002-6418-1985; Zhu, Yun/0000-0001-9382-8592	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI046221, R01AI046221] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Abrahamyan LG, 2005, J VIROL, V79, P106, DOI 10.1128/JVI.79.1.106-115.2005; Caffrey M, 1998, EMBO J, V17, P4572, DOI 10.1093/emboj/17.16.4572; Celma CCP, 2001, VIROLOGY, V283, P253, DOI 10.1006/viro.2001.0869; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chen SSL, 2001, J VIROL, V75, P9925, DOI 10.1128/JVI.75.20.9925-9938.2001; CHERNOMORDIK L, 1994, J VIROL, V68, P7115, DOI 10.1128/JVI.68.11.7115-7123.1994; Cleveland SM, 2003, J GEN VIROL, V84, P591, DOI 10.1099/vir.0.18630-0; Comardelle AM, 1997, AIDS RES HUM RETROV, V13, P1525, DOI 10.1089/aid.1997.13.1525; Contreras LM, 2001, BIOCHEMISTRY-US, V40, P3196, DOI 10.1021/bi002613u; Dimitrov AS, 2007, BIOCHEMISTRY-US, V46, P1398, DOI 10.1021/bi062245f; Dimitrov AS, 2003, BIOCHEMISTRY-US, V42, P14150, DOI 10.1021/bi035154g; Eckert DM, 2001, ANNU REV BIOCHEM, V70, P777, DOI 10.1146/annurev.biochem.70.1.777; Edwards TG, 2002, J VIROL, V76, P2683, DOI 10.1128/JVI.76.6.2683-2691.2002; GABUZDA DH, 1992, J VIROL, V66, P3306, DOI 10.1128/JVI.66.6.3306-3315.1992; Golding H, 2002, J VIROL, V76, P6780, DOI 10.1128/JVI.76.13.6780-6790.2002; Huang JH, 2007, BIOCHEM J, V403, P565, DOI 10.1042/BJ20061275; Huang JH, 2007, J BIOL CHEM, V282, P6143, DOI 10.1074/jbc.M607701200; Huang JH, 2006, FEBS LETT, V580, P4807, DOI 10.1016/j.febslet.2006.07.067; HUNTER E, 1990, CURR TOP MICROBIOL, V157, P187; Jiang S, 1998, J VIROL, V72, P10213, DOI 10.1128/JVI.72.12.10213-10217.1998; JIANG SB, 1993, NATURE, V365, P113, DOI 10.1038/365113a0; Jiang SB, 1999, J VIROL METHODS, V80, P85, DOI 10.1016/S0166-0934(99)00041-5; Kalia V, 2003, J VIROL, V77, P3634, DOI 10.1128/JVI.77.6.3634-3646.2003; KENNEDY RC, 1986, SCIENCE, V231, P1556, DOI 10.1126/science.3006246; Kliger Y, 1997, BIOCHEMISTRY-US, V36, P5157, DOI 10.1021/bi962935r; Lee SF, 2000, J BIOL CHEM, V275, P15809, DOI 10.1074/jbc.M000601200; Liu SW, 2007, J BIOL CHEM, V282, P9612, DOI 10.1074/jbc.M609148200; Lu M, 1997, J BIOMOL STRUCT DYN, V15, P465, DOI 10.1080/07391102.1997.10508958; MILLER MA, 1991, AIDS RES HUM RETROV, V7, P511, DOI 10.1089/aid.1991.7.511; Munch J, 2007, CELL, V129, P263, DOI 10.1016/j.cell.2007.02.042; Pascual R, 2005, J VIROL, V79, P5142, DOI 10.1128/JVI.79.8.5142-5152.2005; Peisajovich SG, 2000, BIOCHEMISTRY-US, V39, P1826, DOI 10.1021/bi991887i; Peisajovich SG, 2001, J MOL BIOL, V311, P249, DOI 10.1006/jmbi.2001.4875; Qiao ZS, 2005, J BIOL CHEM, V280, P23138, DOI 10.1074/jbc.M414515200; Root MJ, 2001, SCIENCE, V291, P884, DOI 10.1126/science.1057453; Sackett K, 2002, BIOCHEMISTRY-US, V41, P4678, DOI 10.1021/bi0255322; SPIES CP, 1994, VIROLOGY, V203, P8, DOI 10.1006/viro.1994.1449; Tan KM, 1997, P NATL ACAD SCI USA, V94, P12303, DOI 10.1073/pnas.94.23.12303; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; WILK T, 1992, VIROLOGY, V189, P167, DOI 10.1016/0042-6822(92)90692-I; Wyma DJ, 2000, J VIROL, V74, P9381, DOI 10.1128/JVI.74.20.9381-9387.2000; Wyma DJ, 2004, J VIROL, V78, P3429, DOI 10.1128/JVI.78.7.3429-3435.2004; Wyss S, 2005, J VIROL, V79, P12231, DOI 10.1128/JVI.79.19.12231-12241.2005; Zhu Y, 2007, CHEM BIOL DRUG DES, V70, P311, DOI 10.1111/j.1747-0285.2007.00564.x; ZINGLER K, 1993, J VIROL, V67, P2824, DOI 10.1128/JVI.67.5.2824-2831.1993	46	36	37	0	17	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16723	16731		10.1074/jbc.M801083200	http://dx.doi.org/10.1074/jbc.M801083200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18408000	Green Published, hybrid			2022-12-25	WOS:000256497100049
J	Pascual, JM; Wang, D; Yang, R; Shi, L; Yang, H; De Vivo, DC				Pascual, Juan M.; Wang, Dong; Yang, Ru; Shi, Lei; Yang, Hong; De Vivo, Darryl C.			Structural signatures and membrane helix 4 in GLUT1 - Inferences from human blood-brain glucose transport mutants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTITUTED-CYSTEINE ACCESSIBILITY; MAJOR FACILITATOR SUPERFAMILY; XENOPUS-LAEVIS OOCYTES; SCANNING MUTAGENESIS; DEFICIENCY SYNDROME; LACTOSE PERMEASE; ESCHERICHIA-COLI; 3-DIMENSIONAL STRUCTURE; WATER PERMEABILITY; ADENYLATE-CYCLASE	Exon IV of SLC2A1, a multiple facilitator superfamily (MFS) transporter gene, is particularly susceptible to mutations that cause GLUT1 deficiency syndrome, a human encephalopathy that results from decreased glucose flux through the blood-brain barrier. Genotyping of 100 patients revealed that in a third of them who harbor missense mutations in the GLUT1 transporter, transmembrane domain 4 (TM4), encoded by SLC2A1 exon IV, contains mutant residues that have the periodicity of one face of a kinked alpha-helix. Arg-126, located at the amino terminus of TM4, is the locus for most of the mutations followed by other arginine and glycine residues located elsewhere in the transporter but conserved among MFS proteins. The Arg-126 mutants were constructed and assayed for protein expression, targeting, and transport capacity in Xenopus oocytes. The role of charge at position 126, as well as its accessibility, was investigated in R126H by determining its activity as a function of extracellular pH. The results indicate that intracellular charges at the MFS TM2-3 and TM8-9 signature loops and flanking TMs 3, 5, and 6 are critical for the structure of GLUT1 as are TM glycines and that TM4, located at the catalytic core of MFS proteins, forms a helix that surfaces into the extracellular solution where another proton facilitates transport.	[Pascual, Juan M.] Univ Texas SW Med Ctr Dallas, Dept Neurol, Dallas, TX 75390 USA; [Pascual, Juan M.] Univ Texas SW Med Ctr Dallas, Dept Physiol, Dallas, TX 75390 USA; [Pascual, Juan M.] Univ Texas SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75390 USA; [Wang, Dong; Yang, Ru; Yang, Hong; De Vivo, Darryl C.] Columbia Univ, Coll Phys & Surg, Dept Neurol, New York, NY 10032 USA; [De Vivo, Darryl C.] Columbia Univ, Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; [Shi, Lei] Cornell Univ, Dept Physiol & Biophys, Weill Med Coll, New York, NY 10021 USA; [Shi, Lei] Cornell Univ, Inst Computat Biomed, Weill Med Coll, New York, NY 10021 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Southwestern Medical Center Dallas; Columbia University; Columbia University; Cornell University; Cornell University	Pascual, JM (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Neurol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Juan.Pascual@UTSouthwestern.edu	Shi, Lei/AAV-1321-2020	Shi, Lei/0000-0002-4137-096X; Pascual, Juan/0000-0002-0843-8221	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS037949, K12NS001698] Funding Source: NIH RePORTER; NINDS NIH HHS [NS037949, NS001698] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abramson J, 2003, SCIENCE, V301, P610, DOI 10.1126/science.1088196; Abramson J, 2004, CURR OPIN STRUC BIOL, V14, P413, DOI 10.1016/j.sbi.2004.07.005; Alisio A, 2004, J BIOL CHEM, V279, P26540, DOI 10.1074/jbc.M402303200; Baumgartner W, 1999, BIOPHYS J, V77, P1980, DOI 10.1016/S0006-3495(99)77039-6; Brockmann K, 2001, ANN NEUROL, V50, P476, DOI 10.1002/ana.1222; Busch W, 2002, CRIT REV BIOCHEM MOL, V37, P287, DOI 10.1080/10409230290771528; CHIN JJ, 1986, J BIOL CHEM, V261, P7101; CHIN JJ, 1987, P NATL ACAD SCI USA, V84, P4113, DOI 10.1073/pnas.84.12.4113; CODERRE PE, 1995, BIOCHEMISTRY-US, V34, P9762, DOI 10.1021/bi00030a014; Cunningham P, 2006, J BIOL CHEM, V281, P5797, DOI 10.1074/jbc.M509422200; CURTIS HJ, 1938, J GEN PHYSIOL, V21, P1980; Dwyer DS, 2001, PROTEINS, V42, P531, DOI 10.1002/1097-0134(20010301)42:4<531::AID-PROT110>3.3.CO;2-0; FINIDORI J, 1982, MOL CELL ENDOCRINOL, V28, P211, DOI 10.1016/0303-7207(82)90033-8; FINIDORILEPICARD J, 1981, NATURE, V292, P255, DOI 10.1038/292255a0; FISCHBARG J, 1993, P NATL ACAD SCI USA, V90, P11658, DOI 10.1073/pnas.90.24.11658; Gerstein M, 1998, PROTEIN SCI, V7, P445; GODAL HC, 1980, SCAND J HAEMATOL, V25, P107; Guan L, 2006, ANNU REV BIOPH BIOM, V35, P67, DOI 10.1146/annurev.biophys.35.040405.102005; HEBERT DN, 1992, J BIOL CHEM, V267, P23829; Hirai T, 2002, NAT STRUCT BIOL, V9, P597, DOI 10.1038/nsb821; HRESKO RC, 1994, J BIOL CHEM, V269, P20482; Huang YF, 2003, SCIENCE, V301, P616, DOI 10.1126/science.1087619; Iserovich P, 2002, J BIOL CHEM, V277, P30991, DOI 10.1074/jbc.M202763200; Joost HG, 2001, MOL MEMBR BIOL, V18, P247, DOI 10.1080/09687680110090456; JUNG EKY, 1986, J BIOL CHEM, V261, P9155; Karlin A, 1998, METHOD ENZYMOL, V293, P123; Klepper J, 2005, NEUROPEDIATRICS, V36, P302, DOI 10.1055/s-2005-872843; Klepper J, 2001, FEBS LETT, V498, P104, DOI 10.1016/S0014-5793(01)02463-2; Klepper J, 1999, J CLIN LAB ANAL, V13, P116, DOI 10.1002/(SICI)1098-2825(1999)13:3<116::AID-JCLA5>3.0.CO;2-C; Levine KB, 2002, BIOCHEMISTRY-US, V41, P12629, DOI 10.1021/bi0258997; MAIDEN MCJ, 1987, NATURE, V325, P641, DOI 10.1038/325641a0; Mueckler M, 1999, J BIOL CHEM, V274, P10923, DOI 10.1074/jbc.274.16.10923; Mueckler M, 2002, J BIOL CHEM, V277, P3498, DOI 10.1074/jbc.M109157200; MUECKLER M, 1985, SCIENCE, V229, P941, DOI 10.1126/science.3839598; Mueckler M, 2005, J BIOL CHEM, V280, P39562, DOI 10.1074/jbc.M509050200; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; Pao SS, 1998, MICROBIOL MOL BIOL R, V62, P1; Pascual JM, 2004, EUR J ENDOCRINOL, V150, P627, DOI 10.1530/eje.0.1500627; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; Pascual JM, 2002, ANN NEUROL, V52, P458, DOI 10.1002/ana.10311; PASCUAL JM, 1995, NEURON, V14, P1055, DOI 10.1016/0896-6273(95)90344-5; Pascual JM, 2007, ARCH NEUROL-CHICAGO, V64, P507, DOI 10.1001/archneur.64.4.noc60165; Saier MH, 2006, NUCLEIC ACIDS RES, V34, pD181, DOI 10.1093/nar/gkj001; Salas-Burgos A, 2004, BIOPHYS J, V87, P2990, DOI 10.1529/biophysj.104.047886; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Sato M, 1999, J BIOL CHEM, V274, P24721, DOI 10.1074/jbc.274.35.24721; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Schurmann A, 1997, BIOCHEMISTRY-US, V36, P12897, DOI 10.1021/bi971173c; Seidner G, 1998, NAT GENET, V18, P188, DOI 10.1038/ng0298-188; Shi JY, 2001, J MOL BIOL, V310, P243, DOI 10.1006/jmbi.2001.4762; SHI YW, 1995, J BIOL CHEM, V270, P21772, DOI 10.1074/jbc.270.37.21772; SOGIN DC, 1980, P NATL ACAD SCI-BIOL, V77, P5725, DOI 10.1073/pnas.77.10.5725; Starace DM, 2001, J GEN PHYSIOL, V117, P469, DOI 10.1085/jgp.117.5.469; Uldry M, 2004, PFLUG ARCH EUR J PHY, V447, P480, DOI 10.1007/s00424-003-1085-0; Vannucci SJ, 1997, GLIA, V21, P2, DOI 10.1002/(SICI)1098-1136(199709)21:1<2::AID-GLIA2>3.0.CO;2-C; Vardy E, 2004, PROTEIN SCI, V13, P1832, DOI 10.1110/ps.04657704; Voss J, 2001, BIOCHEMISTRY-US, V40, P3184, DOI 10.1021/bi002333e; Wang D, 2000, HUM MUTAT, V16, P224, DOI 10.1002/1098-1004(200009)16:3<224::AID-HUMU5>3.0.CO;2-P; Wang D, 2006, HUM MOL GENET, V15, P1169, DOI 10.1093/hmg/ddl032; Wang D, 2005, ANN NEUROL, V57, P111, DOI 10.1002/ana.20331; Wang D, 2003, J BIOL CHEM, V278, P49015, DOI 10.1074/jbc.M308765200; Wang D, 2001, ANN NEUROL, V50, pS125; Wilkins ME, 2002, J NEUROSCI, V22, P5328; ZEIDEL ML, 1992, BIOCHEMISTRY-US, V31, P589, DOI 10.1021/bi00117a041; Zeng H, 1996, BIOPHYS J, V70, P14, DOI 10.1016/S0006-3495(96)79560-7; Zuniga FA, 2001, J BIOL CHEM, V276, P44970, DOI 10.1074/jbc.M107350200	66	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16732	16742		10.1074/jbc.M801403200	http://dx.doi.org/10.1074/jbc.M801403200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18387950	Green Published, hybrid			2022-12-25	WOS:000256497100050
J	Villa-Abrille, MC; Sidor, A; O'Rourke, B				Villa-Abrille, Maria Celeste; Sidor, Agnieszka; O'Rourke, Brian			Insulin effects on cardiac Na+/Ca2+ exchanger activity - Role of the cytoplasmic regulatory loop	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SARCOLEMMAL NA+-CA2+ EXCHANGER; SODIUM-CALCIUM EXCHANGER; POSITIVE INOTROPIC ACTION; FAILING HUMAN MYOCARDIUM; SMOOTH-MUSCLE-CELLS; NITRIC-OXIDE; PHOSPHOINOSITIDE 3-KINASES; DIABETIC CARDIOMYOPATHY; INHIBITORY PEPTIDE	Insulin can alter myocardial contractility, in part through an effect on the cardiac sarcolemmal Na+/Ca2(+) exchanger (NCX), but little is known about its mechanism of action. The large cytoplasmic domain (f-loop) of NCX is required for regulation by various intracellular factors, and we have shown previously that residues 562-679 are determinants of NCX inhibition by exchanger inhibitory peptide (XIP). Here we show that the same f-loop deletion eliminates the enhancement of NCX current by insulin, and we examine the signal pathways involved in the insulin response. NCX current (I-NCX) was measured in freshly isolated or cultured (up to 48 h) adult guinea pig myocytes and in myocytes expressing canine NCX1.1 with the 562-679 f-loop deletion (NCX-(Delta 562-679)) via adenoviral gene transfer. I-NCX was recorded by whole-cell patch clamp as the Ni2+-sensitive current at 37 degrees C with intracellular Ca2+ buffered. Insulin (1 mu M) increased I-NCX (at + 80 mV) by 110 and 83% in fresh and cultured myocytes, respectively, whereas in myocytes expressing NCX-(Delta 562-679) the response was eliminated (with 100 mu M XIP included to suppress any native guinea pig INCX). The insulin effect on INCX was not inhibited by wortmannin, a nitricoxide synthase inhibitor, or disruption of caveolae but was blocked by chelerythrine, implicating protein kinase C, but not phosphatidylinositol-3-kinase, in the mechanism. The insulin effect was also not additive with phosphatidylinositol-4,5-bisphosphate-induced activation of INCX. The finding that the 562-670 f-loop domain is implicated in both XIP and receptor-mediated modulation of NCX highlights its important role in acute physiological or pathophysiological regulation of Ca2+ balance in the heart.	[Villa-Abrille, Maria Celeste; Sidor, Agnieszka; O'Rourke, Brian] Johns Hopkins Univ, Dept Med, Div Cardiol, Baltimore, MD 21205 USA	Johns Hopkins University	O'Rourke, B (corresponding author), Johns Hopkins Univ, Dept Med, Div Cardiol, 720 Rutland Ave,1059 Ross Bldg, Baltimore, MD 21205 USA.	bor@jhmi.edu		O'Rourke, Brian/0000-0002-5548-4853	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL081427, R01HL061711] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL61711, P01-HL81427] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aulbach F, 1999, CARDIOVASC RES, V42, P113, DOI 10.1016/S0008-6363(98)00307-1; Baines CP, 1999, BASIC RES CARDIOL, V94, P188, DOI 10.1007/s003950050142; Balijepalli RC, 2006, P NATL ACAD SCI USA, V103, P7500, DOI 10.1073/pnas.0503465103; BALLARD C, 1994, MOL CELL BIOCHEM, V135, P113, DOI 10.1007/BF00925967; Bossuyt J, 2002, ANN NY ACAD SCI, V976, P197; Bossuyt J, 2002, FEBS LETT, V511, P113, DOI 10.1016/S0014-5793(01)03323-3; BROCK TA, 1985, J BIOL CHEM, V260, P4158; DEMOISSAC DL, 2008, BIOPHYS J, V94, P432; DHALLA N S, 1985, Canadian Journal of Cardiology, V1, P263; Dimmeler S, 1999, NATURE, V399, P601, DOI 10.1038/21224; FEIN FS, 1981, CIRC RES, V49, P1251, DOI 10.1161/01.RES.49.6.1251; Fulton D, 1999, NATURE, V399, P597, DOI 10.1038/21218; Golfman L, 1998, MOL CELL BIOCHEM, V188, P91, DOI 10.1023/A:1006824623496; GUPTA MP, 1986, LIFE SCI, V39, P1077, DOI 10.1016/0024-3205(86)90199-2; Hattori Y, 2000, J PHYSIOL-LONDON, V527, P85, DOI 10.1111/j.1469-7793.2000.00085.x; He ZP, 2000, AM J PHYSIOL-CELL PH, V278, pC661, DOI 10.1152/ajpcell.2000.278.4.C661; Hilgemann D W, 2001, Sci STKE, V2001, pre19, DOI 10.1126/stke.2001.111.re19; Hilgemann DW, 1996, SCIENCE, V273, P956, DOI 10.1126/science.273.5277.956; Hoppe UC, 2000, MOL THER, V1, P159, DOI 10.1006/mthe.1999.0023; Hsu CH, 2006, J HEART LUNG TRANSPL, V25, P1126, DOI 10.1016/j.healun.2006.05.010; Iwamoto T, 1998, BIOCHEMISTRY-US, V37, P17230, DOI 10.1021/bi981521q; KATO M, 1988, MOL CELL BIOCHEM, V83, P15; Leevers SJ, 1999, CURR OPIN CELL BIOL, V11, P219, DOI 10.1016/S0955-0674(99)80029-5; LI ZP, 1991, J BIOL CHEM, V266, P1014; LUCCHESI BR, 1972, EUR J PHARMACOL, V18, P107, DOI 10.1016/0014-2999(72)90137-9; Maack C, 2005, CIRC RES, V96, P91, DOI 10.1161/01.RES.0000151334.48676.68; MAKINO N, 1987, AM J PHYSIOL, V253, pE202, DOI 10.1152/ajpendo.1987.253.2.E202; MENE P, 1991, AM J PHYSIOL, V261, pF466, DOI 10.1152/ajprenal.1991.261.3.F466; Nicoll DA, 1999, J BIOL CHEM, V274, P910, DOI 10.1074/jbc.274.2.910; ORELLANA S, 1987, J BIOL CHEM, V262, P1638; OROURKE B, 1994, SCIENCE, V265, P962, DOI 10.1126/science.8052856; Ottolia M, 2001, J BIOL CHEM, V276, P19603, DOI 10.1074/jbc.M101489200; Pan Y, 2000, AM J PHYSIOL-CELL PH, V279, pC393, DOI 10.1152/ajpcell.2000.279.2.C393; Paternostro G, 1999, CARDIOVASC RES, V42, P246, DOI 10.1016/S0008-6363(98)00233-8; Philipson KD, 2000, ANNU REV PHYSIOL, V62, P111, DOI 10.1146/annurev.physiol.62.1.111; RIEKER RP, 1975, YALE J BIOL MED, V48, P353; Schaffer SW, 1997, CARDIOVASC RES, V34, P129, DOI 10.1016/S0008-6363(97)00020-5; SHANNON TR, 1994, AM J PHYSIOL, V266, pC1350, DOI 10.1152/ajpcell.1994.266.5.C1350; Shigekawa M, 2001, CIRC RES, V88, P864, DOI 10.1161/hh0901.090298; Swan JW, 1997, J AM COLL CARDIOL, V30, P527, DOI 10.1016/S0735-1097(97)00185-X; Touyz RM, 1997, HYPERTENSION, V30, P1440, DOI 10.1161/01.HYP.30.6.1440; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; von Lewinski D, 2005, CIRCULATION, V111, P2588, DOI 10.1161/CIRCULATIONAHA.104.497461; Zeng GY, 1996, J CLIN INVEST, V98, P894, DOI 10.1172/JCI118871	44	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16505	16513		10.1074/jbc.M801424200	http://dx.doi.org/10.1074/jbc.M801424200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18387949	Green Published, hybrid			2022-12-25	WOS:000256497100027
J	Tzubery, T; Rimon, A; Padan, E				Tzubery, Tzvi; Rimon, Abraham; Padan, Etana			Structure-based functional study reveals multiple roles of transmembrane segment IX and loop VIII-IX in NhaA Na+/H+ antiporter of Escherichia coli at physiological pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; THIOL CROSS-LINKING; EVOLUTIONARY ORIGINS; MOLECULAR RULERS; ION-TRANSPORT; ALKALINE PH; MEMBRANE; PROTEIN; DOMAIN; OLIGOMERIZATION	The three-dimensional crystal structure of Escherichia coli NhaA determined at pH 4 provided the first structural insights into the mechanism of antiport and pH regulation of a Na+/H+ antiporter. However, because NhaA is activated at physiological pH (pH 6.5-8.5), many questions pertaining to the active state of NhaA have remained open including the structural and physiological roles of helix IX and its loop VIII-IX. Here we studied this NhaA segment (Glu(241)-Phe(267)) by structure-based biochemical approaches at physiological pH. Cysteine-scanning mutagenesis identified new mutations affecting the pH dependence of NhaA, suggesting their contribution to the "pH sensor." Furthermore mutation F267C reduced the H+/Na+ stoichiometry of the antiporter, and F267C/F344C inactivated the antiporter activity. Tests of accessibility to [2-(trimethylammonium) ethyl] methanethiosulfonate bromide, a membrane-impermeant positively charged SH reagent with a width similar to the diameter of hydrated Na+, suggested that at physiological pH the cytoplasmic cation funnel is more accessible than at acidic pH. Assaying intermolecular cross-linking in situ between single Cys replacement mutants uncovered the NhaA dimer interface at the cytoplasmic side of the membrane; between Leu(255) and the cytoplasm, many Cys replacements cross-link with various cross-linkers spanning different distances (10-18 angstrom) implying a flexible interface. L255C formed intermolecular S-S bonds, cross-linked only with a 5-angstrom cross-linker, and when chemically modified caused an alkaline shift of 1 pH unit in the pH dependence of NhaA and a 6-fold increase in the apparent Km for Na+ of the exchange activity suggesting a rigid point in the dimer interface critical for NhaA activity and pH regulation.	[Tzubery, Tzvi; Rimon, Abraham; Padan, Etana] Hebrew Univ Jerusalem, Dept Biol Chem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel	Hebrew University of Jerusalem	Padan, E (corresponding author), Hebrew Univ Jerusalem, Dept Biol Chem, Alexander Silberman Inst Life Sci, IL-91904 Jerusalem, Israel.	etana@vms.huji.ac.il						AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brett CL, 2005, AM J PHYSIOL-CELL PH, V288, pC223, DOI 10.1152/ajpcell.00360.2004; DAVIS BD, 1950, J BACTERIOL, V60, P17, DOI 10.1128/JB.60.1.17-28.1950; DZIOBAWINOGRODZ.J, 2008, J MOL MICRO IN PRESS; Fisher CL, 1997, BIOTECHNIQUES, V23, P570, DOI 10.2144/97234bm01; Galili L, 2004, J BIOL CHEM, V279, P23104, DOI 10.1074/jbc.M400288200; Galili L, 2002, BIOCHEMISTRY-US, V41, P609, DOI 10.1021/bi011655v; Gerchman Y, 1999, J BIOL CHEM, V274, P24617, DOI 10.1074/jbc.274.35.24617; GERCHMAN Y, 1993, P NATL ACAD SCI USA, V90, P1212, DOI 10.1073/pnas.90.4.1212; Gerchman Y, 2001, BIOCHEMISTRY-US, V40, P3403, DOI 10.1021/bi002669o; GOLDBERG EB, 1987, P NATL ACAD SCI USA, V84, P2615, DOI 10.1073/pnas.84.9.2615; Green NS, 2001, PROTEIN SCI, V10, P1293, DOI 10.1110/ps.51201; Hilger D, 2007, BIOPHYS J, V93, P3675, DOI 10.1529/biophysj.107.109769; Hilger D, 2005, BIOPHYS J, V89, P1328, DOI 10.1529/biophysj.105.062232; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hunte C, 2005, NATURE, V435, P1197, DOI 10.1038/nature03692; Kozachkov L, 2007, BIOCHEMISTRY-US, V46, P2419, DOI 10.1021/bi602393s; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; McGaughey GB, 1998, J BIOL CHEM, V273, P15458, DOI 10.1074/jbc.273.25.15458; Ninio S, 2004, FEBS LETT, V562, P193, DOI 10.1016/S0014-5793(04)00240-6; Olami Y, 1997, J BIOL CHEM, V272, P1761, DOI 10.1074/jbc.272.3.1761; Olkhova E, 2006, P NATL ACAD SCI USA, V103, P2629, DOI 10.1073/pnas.0510914103; Olkhova E, 2007, BIOPHYS J, V92, P3784, DOI 10.1529/biophysj.106.098269; Padan E, 2005, BBA-BIOMEMBRANES, V1717, P67, DOI 10.1016/j.bbamem.2005.09.010; Padan E, 2004, BBA-BIOENERGETICS, V1658, P2, DOI 10.1016/j.bbabio.2004.04.018; PADAN E, 1989, J BIOL CHEM, V264, P20297; Padan E, 1998, FEBS LETT, V441, P53, DOI 10.1016/S0014-5793(98)01524-5; PADAN E, 1976, EUR J BIOCHEM, V63, P533, DOI 10.1111/j.1432-1033.1976.tb10257.x; PINNER E, 1993, J BIOL CHEM, V268, P1729; PINNER E, 1994, J BIOL CHEM, V269, P26274; Rimon A, 2002, BIOCHEMISTRY-US, V41, P14897, DOI 10.1021/bi0261342; Rimon A, 1998, J BIOL CHEM, V273, P26470, DOI 10.1074/jbc.273.41.26470; Rimon A, 2007, J BIOL CHEM, V282, P26810, DOI 10.1074/jbc.M704469200; ROSEN BP, 1986, METHOD ENZYMOL, V125, P328; Sal-Man N, 2007, J BIOL CHEM, V282, P19753, DOI 10.1074/jbc.M610368200; SCHULDINER S, 1978, BIOCHEMISTRY-US, V17, P706, DOI 10.1021/bi00597a023; Screpanti E, 2006, J MOL BIOL, V362, P192, DOI 10.1016/j.jmb.2006.07.019; TAGLICHT D, 1991, J BIOL CHEM, V266, P11289; TAGLICHT D, 1993, J BIOL CHEM, V268, P5382; Tsuboi Y, 2003, J BIOL CHEM, V278, P21467, DOI 10.1074/jbc.M301932200; Tzubery T, 2004, J BIOL CHEM, V279, P3265, DOI 10.1074/jbc.M309021200; Williams KA, 1999, EMBO J, V18, P3558, DOI 10.1093/emboj/18.13.3558; Williams KA, 2000, NATURE, V403, P112, DOI 10.1038/47534; Xiang MH, 2007, P NATL ACAD SCI USA, V104, P18677, DOI 10.1073/pnas.0707120104	46	33	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15975	15987		10.1074/jbc.M800482200	http://dx.doi.org/10.1074/jbc.M800482200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18387952	Green Published, hybrid			2022-12-25	WOS:000256332500056
J	Brasen, C; Schmidt, M; Grotzinger, J; Schonheit, P				Braesen, Christopher; Schmidt, Marcel; Groetzinger, Joachim; Schoenheit, Peter			Reaction mechanism and structural model of ADP-forming acetyl-CoA synthetase from the hyperthermophilic archaeon Pyrococcus furiosus - Evidence for a second active site histidine residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A SYNTHETASE; ESCHERICHIA-COLI; AMITOCHONDRIATE PROTIST; ACETATE FORMATION; PURIFICATION; CLONING; ENZYME; METABOLISM; EXPRESSION; SEQUENCE	In Archaea, acetate formation and ATP synthesis from acetylCoA is catalyzed by an unusual ADP-forming acetyl-CoA synthetase (ACD) (acetyl-CoA + ADP + P-i reversible arrow acetate + ATP + HS-CoA) catalyzing the formation of acetate from acetyl-CoA and concomitant ATP synthesis by the mechanism of substrate level phosphorylation. ACD belongs to the protein superfamily of nucleoside diphosphate-forming acyl-CoA synthetases, which also include succinyl-CoA synthetases (SCSs). ACD differs from SCS in domain organization of subunits and in the presence of a second highly conserved histidine residue in the beta-subunit, which is absent in SCS. The influence of these differences on structure and reaction mechanism of ACD was studied with heterotetrameric ACD (alpha(2)beta(2)) from the hyperthermophilic archaeon Pyrococcus furiosus in comparison with heterotetrameric SCS. A structural model of P. furiosus ACD was constructed suggesting a novel spatial arrangement of the subunits different from SCS, however, maintaining a similar catalytic site. Furthermore, kinetic and molecular properties and enzyme phosphorylation as well as the ability to catalyze arsenolysis of acetyl-CoA were studied in wild type ACD and several mutant enzymes. The data indicate that the formation of enzyme-bound acetyl phosphate and enzyme phosphorylation at His-257 alpha, respectively, proceed in analogy to SCS. In contrast to SCS, in ACID, the phosphoryl group is transferred from the His-257 alpha to ADP via transient phosphorylation of a second conserved histidine residue in the beta-subunit, His-71 beta. It is proposed that ACD reaction follows a novel four-step mechanism including transient phosphorylation of two active site histidine residues:.	[Braesen, Christopher; Schmidt, Marcel; Schoenheit, Peter] Univ Kiel, Inst Allgemeine Mikrobiol, D-24118 Kiel, Germany; [Groetzinger, Joachim] Univ Kiel, Inst Biochem, D-24118 Kiel, Germany	University of Kiel; University of Kiel	Schonheit, P (corresponding author), Univ Kiel, Inst Allgemeine Mikrobiol, Botan Garten 1-9, D-24118 Kiel, Germany.	peter.schoenheit@ifam.uni-kiel.de		Brasen, Christopher/0000-0002-8328-9713				Bailey DL, 1999, J MOL BIOL, V285, P1655, DOI 10.1006/jmbi.1998.2325; Binieda A, 1999, BIOCHEM J, V340, P793, DOI 10.1042/0264-6021:3400793; Bock AK, 1999, J BACTERIOL, V181, P1861, DOI 10.1128/JB.181.6.1861-1867.1999; Brasen C, 2004, ARCH MICROBIOL, V182, P277, DOI 10.1007/s00203-004-0702-4; CHEN GC, 1977, ANAL LETT, V10, P1195, DOI 10.1080/00032717708067855; CHISTOSERDOVA LV, 1994, J BACTERIOL, V176, P7398, DOI 10.1128/JB.176.23.7398-7404.1994; ELSHOURBAGY NA, 1992, EUR J BIOCHEM, V204, P491, DOI 10.1111/j.1432-1033.1992.tb16659.x; Fraser ME, 2006, J BIOL CHEM, V281, P11058, DOI 10.1074/jbc.M511785200; Fraser ME, 2000, J MOL BIOL, V299, P1325, DOI 10.1006/jmbi.2000.3807; Fraser ME, 2002, BIOCHEMISTRY-US, V41, P537, DOI 10.1021/bi011518y; Fraser ME, 1999, J MOL BIOL, V285, P1633, DOI 10.1006/jmbi.1998.2324; Joyce MA, 2000, BIOCHEMISTRY-US, V39, P17, DOI 10.1021/bi991696f; Kanao T, 2002, EUR J BIOCHEM, V269, P3409, DOI 10.1046/j.1432-1033.2002.03016.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lehtio L, 2005, ACTA CRYSTALLOGR D, V61, P350, DOI 10.1107/S0907444904034389; Mai XH, 1996, J BACTERIOL, V178, P5897, DOI 10.1128/jb.178.20.5897-5903.1996; MAJUMDAR R, 1991, BIOCHIM BIOPHYS ACTA, V1076, P86, DOI 10.1016/0167-4838(91)90223-M; Marchler-Bauer A, 2005, NUCLEIC ACIDS RES, V33, pD192, DOI 10.1093/nar/gki069; Marchler-Bauer A, 2004, NUCLEIC ACIDS RES, V32, pW327, DOI 10.1093/nar/gkh454; Musfeldt M, 2002, J BACTERIOL, V184, P636, DOI 10.1128/JB.184.3.636-644.2002; Musfeldt M, 1999, J BACTERIOL, V181, P5885, DOI 10.1128/JB.181.18.5885-5888.1999; PEARSON PH, 1975, J BIOL CHEM, V250, P8524; Plaggenborg R, 2001, FEMS MICROBIOL LETT, V205, P9, DOI 10.1111/j.1574-6968.2001.tb10918.x; REEVES RE, 1977, J BIOL CHEM, V252, P726; Sanchez LB, 2000, J BIOL CHEM, V275, P5794, DOI 10.1074/jbc.275.8.5794; Sanchez LB, 1996, FEBS LETT, V378, P240, DOI 10.1016/0014-5793(95)01463-2; Sanchez LB, 1999, GENE, V233, P225, DOI 10.1016/S0378-1119(99)00134-1; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAFER T, 1991, ARCH MICROBIOL, V155, P366; SCHAFER T, 1993, ARCH MICROBIOL, V159, P72, DOI 10.1007/BF00244267; SCHONHEIT P, 1995, WORLD J MICROB BIOT, V11, P26, DOI 10.1007/BF00339135; Shikata K, 2007, J BIOL CHEM, V282, P26963, DOI 10.1074/jbc.M702694200; Siebers B, 2005, CURR OPIN MICROBIOL, V8, P695, DOI 10.1016/j.mib.2005.10.014; SRERE PA, 1963, ACTA CHEM SCAND, V17, P129, DOI 10.3891/acta.chem.scand.17s-0129; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WEITZMAN PDJ, 1978, FEBS LETT, V88, P255, DOI 10.1016/0014-5793(78)80187-2; WOLODKO WT, 1994, J BIOL CHEM, V269, P10883	38	30	31	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15409	15418		10.1074/jbc.M710218200	http://dx.doi.org/10.1074/jbc.M710218200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18372246	Green Published, hybrid			2022-12-25	WOS:000256232000059
J	Kawaguchi, R; Yu, JM; Wiita, P; Honda, J; Sun, H				Kawaguchi, Riki; Yu, Jiamei; Wiita, Patrick; Honda, Jane; Sun, Hui			An essential ligand-binding domain in the membrane receptor for retinol-binding protein revealed by large-scale mutagenesis and a human polymorphism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED SERTOLI CELLS; VITAMIN-A; POTASSIUM CHANNELS; PIGMENT EPITHELIUM; SURFACE RECEPTOR; GENE STRA6; PLASMA; TRANSPORT; MUTATIONS; BLOOD	Plasma retinol-binding protein (RBP), the principal carrier of vitamin A in the blood, delivers vitamin A from liver, the site of storage, to distant organs that need vitamin A, such as the eye, brain, placenta, and testis. STRA6 is a high-affinity membrane receptor for RBP and mediates vitamin A uptake in these target organs. STRA6 is a 74-kDa multi-transmembrane domain protein that represents a new class of membrane transport protein. In this study, we used an unbiased strategy by analyzing > 900 random mutants of STRA6 to study its structure and function, and we identified an essential RBP-binding domain in STRA6. Mutations in any of the three essential residues in this domain can almost completely abolish binding of STRA6 to RBP and its vitamin A uptake activity from holo-RBP without affecting its cell surface expression. We have also functionally characterized the mutations in human STRA6 that cause severe birth defects as well as several human polymorphisms. All STRA6 mutants associated with severe birth defects have largely abolished vitamin A uptake activity, consistent with the severe clinical phenotypes. In addition, we have identified a human polymorphism that significantly reduces the vitamin A uptake activity of STRA6. Interestingly, the residue affected by this polymorphism is located in the RBP-binding domain we identified, and the polymorphism causes decreased vitamin A uptake by reducing RBP binding. This study identifies an essential functional domain in STRA6 and a human polymorphism in this domain that leads to reduced vitamin A uptake activity.	[Kawaguchi, Riki; Yu, Jiamei; Wiita, Patrick; Honda, Jane; Sun, Hui] Univ Calif Los Angeles, David Geffen Sch Med, Dept Physiol, Los Angeles, CA 90095 USA; [Kawaguchi, Riki; Yu, Jiamei; Sun, Hui] Univ Calif Los Angeles, David Geffen Sch Med, Jules Stein Eye Inst, Los Angeles, CA 90095 USA; [Sun, Hui] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Sun, H (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Physiol, 52-231 CHS,650 Charles E Young Dr S, Los Angeles, CA 90095 USA.	hsun@mednet.ucla.edu	Kawaguchi, Riki/AAV-6090-2020		NEI NIH HHS [1R01 EY 018144] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY018144] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		BHAT MK, 1979, BIOCHIM BIOPHYS ACTA, V587, P273, DOI 10.1016/0304-4165(79)90360-X; Bichet D, 2004, P NATL ACAD SCI USA, V101, P4441, DOI 10.1073/pnas.0401195101; BISHOP PD, 1987, BIOCHEMISTRY-US, V26, P7511, DOI 10.1021/bi00397a046; BLANER WS, 1989, ENDOCR REV, V10, P308, DOI 10.1210/edrv-10-3-308; BOK D, 1976, EXP EYE RES, V22, P395, DOI 10.1016/0014-4835(76)90177-9; Bouillet P, 1997, MECH DEVELOP, V63, P173, DOI 10.1016/S0925-4773(97)00039-7; BUCK J, 1990, J EXP MED, V171, P1613, DOI 10.1084/jem.171.5.1613; CHEN CC, 1977, J BIOL CHEM, V252, P5216; Collins MD, 1999, ANNU REV PHARMACOL, V39, P399, DOI 10.1146/annurev.pharmtox.39.1.399; DAVIS JT, 1995, BIOL REPROD, V52, P356, DOI 10.1095/biolreprod52.2.356; Dellis O, 2006, SCIENCE, V313, P229, DOI 10.1126/science.1125203; DENNING GM, 1992, NATURE, V358, P761, DOI 10.1038/358761a0; Folli C, 2005, BIOCHEM BIOPH RES CO, V336, P1017, DOI 10.1016/j.bbrc.2005.08.227; Golzio C, 2007, AM J HUM GENET, V80, P1179, DOI 10.1086/518177; Goodman DS, 1984, RETINOIDS, P41, DOI DOI 10.1016/B978-0-12-658102-7.50008-7; Hagen E, 1999, J NUTR BIOCHEM, V10, P345, DOI 10.1016/S0955-2863(99)00013-3; HELLER J, 1975, J BIOL CHEM, V250, P3613; HELLER J, 1976, EXP EYE RES, V22, P403, DOI 10.1016/0014-4835(76)90178-0; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; KAWAGUCHI R, 2008, BIOCHEMISTR IN PRESS; Kawaguchi R, 2007, SCIENCE, V315, P820, DOI 10.1126/science.1136244; MACDONALD PN, 1990, P NATL ACAD SCI USA, V87, P4265, DOI 10.1073/pnas.87.11.4265; MARAINI G, 1975, INVEST OPHTH VISUAL, V14, P785; Minor DL, 1999, CELL, V96, P879, DOI 10.1016/S0092-8674(00)80597-8; Newcomer ME, 2000, BBA-PROTEIN STRUCT M, V1482, P57, DOI 10.1016/S0167-4838(00)00150-3; Pasutto F, 2007, AM J HUM GENET, V80, P550, DOI 10.1086/512203; RASK L, 1976, J BIOL CHEM, V251, P6360; Seeliger MW, 1999, INVEST OPHTH VIS SCI, V40, P3; Sekine-Aizawa Y, 2004, P NATL ACAD SCI USA, V101, P17114, DOI 10.1073/pnas.0407563101; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9641, DOI 10.1021/bi00451a015; SIVAPRASADARAO A, 1988, BIOCHEM J, V255, P561; SIVAPRASADARAO A, 1994, BIOCHEM J, V302, P245, DOI 10.1042/bj3020245; SMELAND S, 1995, BIOCHEM J, V305, P419, DOI 10.1042/bj3050419; Szeto W, 2001, CANCER RES, V61, P4197; TORMA H, 1984, ARCH DERMATOL RES, V276, P390, DOI 10.1007/BF00413360; Yi BA, 2001, NEURON, V29, P657, DOI 10.1016/S0896-6273(01)00241-0; Zanotti G, 2004, VITAM HORM, V69, P271, DOI 10.1016/S0083-6729(04)69010-8	37	50	50	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15160	15168		10.1074/jbc.M801060200	http://dx.doi.org/10.1074/jbc.M801060200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18387951	Green Published, hybrid			2022-12-25	WOS:000256232000032
J	Nair, VD; Olanow, CW				Nair, Venugopalan D.; Olanow, C. Warren			Differential modulation of Akt/glycogen synthase kinase-3 beta pathway regulates apoptotic and cytoprotective signaling responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; TRANSCRIPTION FACTOR NRF2; PROTEIN-KINASE-B; MITOCHONDRIAL COMPLEX-I; PARKINSONS-DISEASE; OXIDATIVE STRESS; PHOSPHOINOSITIDE 3-KINASE; BETA-CATENIN; DIRECT PHOSPHORYLATION; DOPAMINE NEURONS	We have previously reported that specific dopamine agonists mediate protection against apoptosis induced by oxidative stress by activating the D-2 receptor-coupled phosphoinositide 3-kinase (PI-3K)/Akt pathway. In the present study we examined the downstream effectors of PI-3K/Akt signaling and their role in cell death after oxidative stress and protection provided by ropinirole, a D-2 receptor agonist in PC12 cells and primary cultures of dopamine neurons. Ropinirole treatment was associated with rapid translocation and phosphorylation of the PI-3K substrate Akt and phosphorylation of Akt substrates. One of these Akt downstream substrates was identified as the proapoptotic factor glycogen synthase kinase-3 beta (GSK-3 beta). Ropinirole-induced protection was associated with phosphorylation of GSK-3 beta (inactivation). In contrast, inhibition of PI-3K blocked the phosphorylation of Akt and GSK-3 beta (activation) and prevented the protection mediated by ropinirole. Suppression of Akt with specific short hairpin RNA in normal PC12 cells caused cell death, which was associated with reduced phosphorylation of GSK-3 beta and reduced levels of beta-catenin, a transcriptional activator that is regulated by GSK-3 beta. Knock-out of GSK-3 beta expression with a short hairpin RNA alone was itself sufficient to cause cell death. We further demonstrated that oxidative stress induced by hydrogen peroxide (H2O2) dephosphorylates Akt and GSK-3 beta, increases GSK-3 beta activity, and promotes an interaction with beta-catenin and its degradation. Inhibition of GSK-3 beta activity by inhibitor VIII protects cells from H2O2 similar to ropinirole. These results indicate that GSK-3 beta downstream of Akt plays a critical role in cell death and survival in these models.	[Nair, Venugopalan D.; Olanow, C. Warren] Mt Sinai Sch Med, Dept Neurol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Nair, VD (corresponding author), Mt Sinai Sch Med, Dept Neurol, Box 1137,1 Gustave L Levy Pl, New York, NY 10029 USA.	venugopalan.nair@mssm.edu		Nair, Venugopalan/0000-0002-8231-6230; Nair, Venugopalan/0000-0002-0299-0998				Alessi DR, 1996, EMBO J, V15, P6541, DOI 10.1002/j.1460-2075.1996.tb01045.x; An JH, 2005, P NATL ACAD SCI USA, V102, P16275, DOI 10.1073/pnas.0508105102; Baranano DE, 2002, P NATL ACAD SCI USA, V99, P16093, DOI 10.1073/pnas.252626999; Beal MF, 2003, ANN NY ACAD SCI, V991, P120; Bellacosa A, 1998, ONCOGENE, V17, P313, DOI 10.1038/sj.onc.1201947; Bhat RV, 2000, P NATL ACAD SCI USA, V97, P11074, DOI 10.1073/pnas.190297597; BOUVIER MM, 1995, J NEUROSCI, V15, P7141; Brazil DP, 2002, CELL, V111, P293, DOI 10.1016/S0092-8674(02)01083-8; Brunt ER, 2002, J NEURAL TRANSM, V109, P489, DOI 10.1007/s007020200040; Castelo-Branco G, 2004, J CELL SCI, V117, P5731, DOI 10.1242/jcs.01505; Chalecka-Franaszek E, 1999, P NATL ACAD SCI USA, V96, P8745, DOI 10.1073/pnas.96.15.8745; Chen G, 2004, FASEB J, V18, P1162, DOI 10.1096/fj.04-1551fje; Cohen P, 2001, NAT REV MOL CELL BIO, V2, P769, DOI 10.1038/35096075; DATTA K, 1995, MOL CELL BIOL, V15, P2304; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; DEL PL, 1997, SCIENCE, V278, P687; Dore S, 1999, P NATL ACAD SCI USA, V96, P2445, DOI 10.1073/pnas.96.5.2445; Du F, 2005, EUR J NEUROSCI, V22, P2422, DOI 10.1111/j.1460-9568.2005.04438.x; Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200; Forno LS, 1996, J NEUROPATH EXP NEUR, V55, P259, DOI 10.1097/00005072-199603000-00001; Ikeyama S, 2002, FASEB J, V16, pA1163, DOI 10.1096/fj.01-0409fje; Itoh K, 1999, FREE RADICAL RES, V31, P319, DOI 10.1080/10715769900300881; Jain AK, 2007, J BIOL CHEM, V282, P16502, DOI 10.1074/jbc.M611336200; Joyce JN, 2003, EXP NEUROL, V184, P393, DOI 10.1016/S0014-4886(03)00353-4; Keeney PM, 2006, J NEUROSCI, V26, P5256, DOI 10.1523/JNEUROSCI.0984-06.2006; Koh SH, 2004, NEUROTOXICOLOGY, V25, P793, DOI 10.1016/j.neuro.2004.02.001; Kwak MK, 2001, MOL MED, V7, P135, DOI 10.1007/BF03401947; Lee KY, 2007, BRAIN RES, V1129, P89, DOI 10.1016/j.brainres.2006.10.055; Li HL, 2007, P NATL ACAD SCI USA, V104, P3591, DOI 10.1073/pnas.0609303104; Liang MH, 2007, J BIOL CHEM, V282, P3904, DOI 10.1074/jbc.M605178200; Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2; Martin D, 2002, J BIOL CHEM, V277, P42943, DOI 10.1074/jbc.M201070200; Maurer U, 2006, MOL CELL, V21, P749, DOI 10.1016/j.molcel.2006.02.009; McMahon M, 2001, CANCER RES, V61, P3299; Millan MJ, 2004, J PHARMACOL EXP THER, V309, P921, DOI 10.1124/jpet.103.062414; Mishra R, 2007, J BIOL CHEM, V282, P30393, DOI 10.1074/jbc.M705895200; Moore DJ, 2005, ANNU REV NEUROSCI, V28, P57, DOI 10.1146/annurev.neuro.28.061604.135718; Nair VD, 2006, APOPTOSIS, V11, P955, DOI 10.1007/s10495-006-6316-3; Nair VD, 2004, J BIOL CHEM, V279, P27494, DOI 10.1074/jbc.M312135200; Nair VD, 2003, BIOCHEM J, V373, P25, DOI 10.1042/BJ20030017; Nair VD, 2003, J BIOL CHEM, V278, P47053, DOI 10.1074/jbc.M303364200; Nair VD, 2006, J BIOL CHEM, V281, P39550, DOI 10.1074/jbc.M603950200; Olanow CW, 2006, LANCET NEUROL, V5, P677, DOI 10.1016/S1474-4422(06)70521-X; Olanow CW, 2004, ANNU REV MED, V55, P41, DOI 10.1146/annurev.med.55.091902.104422; Olanow CW, 1998, ANN NEUROL, V44, pS167; PARKER WD, 1989, ANN NEUROL, V26, P719, DOI 10.1002/ana.410260606; Presgraves SP, 2004, EXP NEUROL, V190, P157, DOI 10.1016/j.expneurol.2004.06.021; Rushmore TH, 2002, CURR DRUG METAB, V3, P481, DOI 10.2174/1389200023337171; Salazar M, 2006, J BIOL CHEM, V281, P14841, DOI 10.1074/jbc.M513737200; Sasaki C, 2001, NEUROL RES, V23, P588, DOI 10.1179/016164101101199054; Schafer M, 2004, BRAIN RES, V1005, P84, DOI 10.1016/j.brainres.2004.01.037; SCHAPIRA AHV, 1990, J NEUROCHEM, V54, P823, DOI 10.1111/j.1471-4159.1990.tb02325.x; Shaw M, 1998, BIOCHEM J, V336, P241, DOI 10.1042/bj3360241; Teismann P, 2003, ANN NY ACAD SCI, V991, P272; Wang WY, 2007, NEUROPHARMACOLOGY, V52, P1678, DOI 10.1016/j.neuropharm.2007.03.017; Wei Y, 2003, J BIOL CHEM, V278, P5188, DOI 10.1074/jbc.M207216200; Whone AL, 2003, ANN NEUROL, V54, P93, DOI 10.1002/ana.10609; Woodgett JR, 2005, CURR OPIN CELL BIOL, V17, P150, DOI 10.1016/j.ceb.2005.02.010; Wu Y, 2007, APOPTOSIS, V12, P1365, DOI 10.1007/s10495-007-0065-9; Yu JY, 2003, MOL THER, V7, P228, DOI 10.1016/S1525-0016(02)00037-0	60	77	79	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15469	15478		10.1074/jbc.M707238200	http://dx.doi.org/10.1074/jbc.M707238200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18387957	hybrid, Green Published			2022-12-25	WOS:000256232000065
J	Jayaram, SA; Senti, KA; Tiklova, K; Tsarouhas, V; Hemphala, J; Samakovlis, C				Jayaram, Satish Arcot; Senti, Kirsten-Andre; Tiklova, Katarina; Tsarouhas, Vasilios; Hemphala, Johanna; Samakovlis, Christos			COPI Vesicle Transport Is a Common Requirement for Tube Expansion in Drosophila	PLOS ONE			English	Article								Background: Tube expansion defects like stenoses and atresias cause devastating human diseases. Luminal expansion during organogenesis begins to be elucidated in several systems but we still lack a mechanistic view of the process in many organs. The Drosophila tracheal respiratory system provides an amenable model to study tube size regulation. In the trachea, COPII anterograde transport of luminal proteins is required for extracellular matrix assembly and the concurrent tube expansion. Principal Findings: We identified and analyzed Drosophila COPI retrograde transport mutants with narrow tracheal tubes. gamma COP mutants fail to efficiently secrete luminal components and assemble the luminal chitinous matrix during tracheal tube expansion. Likewise, tube extension is defective in salivary glands, where it also coincides with a failure in the luminal deposition and assembly of a distinct, transient intraluminal matrix. Drosophila gamma COP colocalizes with cis-Golgi markers and in gamma COP mutant embryos the ER and Golgi structures are severely disrupted. Analysis of gamma COP and Sar1 double mutants suggests that bidirectional ER-Golgi traffic maintains the ER and Golgi compartments and is required for secretion and assembly of luminal matrixes during tube expansion. Conclusions/Significance: Our results demonstrate the function of COPI components in organ morphogenesis and highlight the common role of apical secretion and assembly of transient organotypic matrices in tube expansion. Intraluminal matrices have been detected in the notochord of ascidians and zebrafish COPI mutants show defects in notochord expansion. Thus, the programmed deposition and growth of distinct luminal molds may provide distending forces during tube expansion in diverse organs.	[Jayaram, Satish Arcot; Senti, Kirsten-Andre; Tiklova, Katarina; Tsarouhas, Vasilios; Hemphala, Johanna; Samakovlis, Christos] Stockholm Univ, Dept Dev Biol, Wenner Gren Inst, S-10691 Stockholm, Sweden	Stockholm University	Samakovlis, C (corresponding author), Stockholm Univ, Dept Dev Biol, Wenner Gren Inst, S-10691 Stockholm, Sweden.	christos@devbio.su.se	Tsarouhas, Vasilios/AAG-8226-2020; Senti, Kirsten-Andre/AAB-3036-2020	Tsarouhas, Vasilios/0000-0002-2933-1351; Arcot Jayaram, Satish/0000-0002-2479-2669; Senti, Kirsten-Andre/0000-0002-7208-7593	Swedish Research Council; Cancerfonden, SSF; EMBO postdoctoral fellowship	Swedish Research Council(Swedish Research CouncilEuropean Commission); Cancerfonden, SSF(Swedish Foundation for Strategic ResearchSwedish Cancer Society); EMBO postdoctoral fellowship(European Molecular Biology Organization (EMBO))	Swedish Research Council (VR), Cancerfonden, SSF to CS. EMBO postdoctoral fellowship to KAS. The funding agencies had no role in any part of the manuscript.	Abrams EW, 2006, DEVELOPMENT, V133, P3517, DOI 10.1242/dev.02525; Abrams EW, 2005, DEVELOPMENT, V132, P2743, DOI 10.1242/dev.01863; ADAMS DS, 1990, DEVELOPMENT, V110, P115; Affolter M, 2003, DEV CELL, V4, P11, DOI 10.1016/S1534-5807(02)00410-0; Araujo SJ, 2005, DEV BIOL, V288, P179, DOI 10.1016/j.ydbio.2005.09.031; Bagnat M, 2007, NAT CELL BIOL, V9, P954, DOI 10.1038/ncb1621; Bartoszewski S, 2004, MECH DEVELOP, V121, P1259, DOI 10.1016/j.mod.2004.05.006; Beitel GJ, 2000, DEVELOPMENT, V127, P3271; Bethune J, 2006, J MEMBRANE BIOL, V211, P65, DOI 10.1007/s00232-006-0859-7; Bonifacino JS, 2004, CELL, V116, P153, DOI 10.1016/S0092-8674(03)01079-1; Coutinho P, 2004, DEV CELL, V7, P547, DOI 10.1016/j.devcel.2004.07.020; Deak P, 1997, GENETICS, V147, P1697; Devine WP, 2005, P NATL ACAD SCI USA, V102, P17014, DOI 10.1073/pnas.0506676102; Ghabrial A, 2003, ANNU REV CELL DEV BI, V19, P623, DOI 10.1146/annurev.cellbio.19.031403.160043; Hemphala J, 2003, DEVELOPMENT, V130, P249, DOI 10.1242/dev.00218; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; Jazwinska A, 2003, NAT CELL BIOL, V5, P895, DOI 10.1038/ncb1049; Jiang D, 2007, DEV DYNAM, V236, P1748, DOI 10.1002/dvdy.21184; Kuraishi T, 2007, EXP CELL RES, V313, P500, DOI 10.1016/j.yexcr.2006.10.027; Laprise P, 2006, DEV CELL, V11, P363, DOI 10.1016/j.devcel.2006.06.001; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Lubarsky B, 2003, CELL, V112, P19, DOI 10.1016/S0092-8674(02)01283-7; Luschnig S, 2006, CURR BIOL, V16, P186, DOI 10.1016/j.cub.2005.11.072; Martin-Belmonte F, 2007, CELL, V128, P383, DOI 10.1016/j.cell.2006.11.051; Moelleken J, 2007, P NATL ACAD SCI USA, V104, P4425, DOI 10.1073/pnas.0611360104; Olver RE, 2004, ANNU REV PHYSIOL, V66, P77, DOI 10.1146/annurev.physiol.66.071702.145229; Pellikka M, 2002, NATURE, V416, P143, DOI 10.1038/nature721; Perens EA, 2005, DEV CELL, V8, P893, DOI 10.1016/j.devcel.2005.03.009; Pimpl P, 2000, PLANT CELL, V12, P2219, DOI 10.1105/tpc.12.11.2219; Rabouille C, 2005, NAT REV MOL CELL BIO, V6, P812, DOI 10.1038/nrm1735; Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199; Sabri N, 2007, J CELL BIOL, V178, P557, DOI 10.1083/jcb.200612135; SADLER TW, 1985, LANGMANS MED EMBRYOL; Seshaiah P, 2001, DEV BIOL, V239, P309, DOI 10.1006/dbio.2001.0429; Sisson JC, 2000, J CELL BIOL, V151, P905, DOI 10.1083/jcb.151.4.905; Sohn K, 1996, J CELL BIOL, V135, P1239, DOI 10.1083/jcb.135.5.1239; Stemple DL, 2005, DEVELOPMENT, V132, P2503, DOI 10.1242/dev.01812; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; Tian E, 2007, GLYCOBIOLOGY, V17, P820, DOI 10.1093/glycob/cwm056; Tonning A, 2005, DEV CELL, V9, P423, DOI 10.1016/j.devcel.2005.07.012; Tsarouhas V, 2007, DEV CELL, V13, P214, DOI 10.1016/j.devcel.2007.06.008; Uv A, 2003, TRENDS CELL BIOL, V13, P301, DOI 10.1016/S0962-8924(03)00083-7; WADDINGTON CH, 1962, PROC R SOC SER B-BIO, V156, P459, DOI 10.1098/rspb.1962.0050; Wang SQ, 2006, CURR BIOL, V16, P180, DOI 10.1016/j.cub.2005.11.074; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; Yano H, 2005, P NATL ACAD SCI USA, V102, P13467, DOI 10.1073/pnas.0506681102	46	52	53	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1964	10.1371/journal.pone.0001964	http://dx.doi.org/10.1371/journal.pone.0001964			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398480	Green Published, Green Submitted, gold			2022-12-25	WOS:000260795500033
J	Gehrmann, M; Liebisch, G; Schmitz, G; Anderson, R; Steinem, C; De Maio, A; Pockley, G; Multhoff, G				Gehrmann, Mathias; Liebisch, Gerhard; Schmitz, Gerd; Anderson, Robin; Steinem, Claudia; De Maio, Antonio; Pockley, Graham; Multhoff, Gabriele			Tumor-Specific Hsp70 Plasma Membrane Localization Is Enabled by the Glycosphingolipid Gb3	PLOS ONE			English	Article								Background: Human tumors differ from normal tissues in their capacity to present Hsp70, the major stress-inducible member of the HSP70 family, on their plasma membrane. Membrane Hsp70 has been found to serve as a prognostic indicator of overall patient survival in leukemia, lower rectal and non small cell lung carcinomas. Why tumors, but not normal cells, present Hsp70 on their cell surface and the impact of membrane Hsp70 on cancer progression remains to be elucidated. Methodology/Principal Findings: Although Hsp70 has been reported to be associated with cholesterol rich microdomains (CRMs), the partner in the plasma membrane with which Hsp70 interacts has yet to be identified. Herein, global lipid profiling demonstrates that Hsp70 membrane-positive tumors differ from their membrane-negative counterparts by containing significantly higher amounts of globotriaoslyceramide (Gb3), but not of other lipids such as lactosylceramide (LacCer), dodecasaccharideceramide (DoCer), galactosylceramide (GalCer), ceramide (Cer), or the ganglioside GM1. Apart from germinal center B cells, normal tissues are Gb3 membrane-negative. Co-localization of Hsp70 and Gb3 was selectively determined in Gb3 membrane-positive tumor cells, and these cells were also shown to bind soluble Hsp70-FITC protein from outside in a concentration-dependent manner. Given that the latter interaction can be blocked by a Gb3-specific antibody, and that the depletion of globotriaosides from tumors reduces the amount of membrane-bound Hsp70, we propose that Gb3 is a binding partner for Hsp70. The in vitro finding that Hsp70 predominantly binds to artificial liposomes containing Gb3 (PC/SM/Chol/Gb3, 17/45/33/5) confirms that Gb3 is an interaction partner for Hsp70. Conclusions/Significance: These data indicate that the presence of Gb3 enables anchorage of Hsp70 in the plasma membrane of tumors and thus they might explain tumor-specific membrane localization of Hsp70.	[Gehrmann, Mathias; Multhoff, Gabriele] Tech Univ Munich, Klinikum Rechts Isar, Dept Radiotherapy & Radiooncol, D-8000 Munich, Germany; [Liebisch, Gerhard; Schmitz, Gerd] Univ Hosp Regensburg, Inst Clin Chem, Regensburg, Germany; [Anderson, Robin] Peter MacCallum Canc Inst, East Melbourne, Victoria, Australia; [Steinem, Claudia] Univ Gottingen, Inst Organ & Biomol Chem, Gottingen, Germany; [De Maio, Antonio] Univ Calif San Diego, Dept Surg, La Jolla, CA USA; [Pockley, Graham] Univ Sheffield, Sch Med & Biomed Sci, Sheffield, S Yorkshire, England; [Multhoff, Gabriele] Helmholtz Ctr Munich, German Res Ctr Environm Hlth GmbH, Inst Pathol, Munich, Germany	Technical University of Munich; University of Regensburg; Peter Maccallum Cancer Center; University of Gottingen; University of California System; University of California San Diego; University of Sheffield; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health	Multhoff, G (corresponding author), Tech Univ Munich, Klinikum Rechts Isar, Dept Radiotherapy & Radiooncol, D-8000 Munich, Germany.	gabriele.multhoff@lrz.tu-muenchen.de	Anderson, Robin/K-6966-2019; Steinem, Claudia/K-7534-2018; Anderson, Robin/I-2306-2013; Steinem, Claudia/O-4801-2019; Pockley, Alan G/I-4704-2015; Liebisch, Gerhard/G-6130-2010; Anderson, Robin/S-1005-2017	Steinem, Claudia/0000-0001-8778-9283; Pockley, Alan G/0000-0001-9593-6431; Liebisch, Gerhard/0000-0003-4886-0811; Anderson, Robin/0000-0002-6841-7422; Multhoff, Gabriele/0000-0002-2616-3137	Deutsche Forschungsgemeinschaft [MU1238 7/2]; Bundesministerium fur Forschung und Technologie [0312338]; EU [2004-512253]; Helmholtz Gemeinschaft; biotech company multimmune GmbH; NIH [GM 50878]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); Bundesministerium fur Forschung und Technologie; EU(European Commission); Helmholtz Gemeinschaft(Helmholtz Association); biotech company multimmune GmbH; NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)	This study was supported in part by grants of the Deutsche Forschungsgemeinschaft (DFG MU1238 7/2 to G.M.), the Bundesministerium fur Forschung und Technologie (BMBF BioChance plus, 0312338), EU (TRANSNET MRTN 2004-512253), by the Helmholtz Gemeinschaft, the biotech company multimmune GmbH and NIH GM 50878 (to A.D.M.). The sponsors/funders had no input into the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.	Arispe N, 2004, FASEB J, V18, P1636, DOI 10.1096/fj.04-2088com; Arispe N, 2002, CELL STRESS CHAPERON, V7, P330, DOI 10.1379/1466-1268(2002)007<0330:LIDTCA>2.0.CO;2; Asea A, 2001, INT J HYPERTHER, V17, P347, DOI 10.1080/02656730110053146; Barreto A, 2003, CELL IMMUNOL, V222, P97, DOI 10.1016/S0008-8749(03)00115-1; Broquet AH, 2003, J BIOL CHEM, V278, P21601, DOI 10.1074/jbc.M302326200; BROWN DA, 1992, CELL, V68, P533, DOI 10.1016/0092-8674(92)90189-J; Brown G, 2005, VIROLOGY, V338, P69, DOI 10.1016/j.virol.2005.05.004; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; Calderwood SK, 2007, FEBS LETT, V581, P3689, DOI 10.1016/j.febslet.2007.04.044; Chen XH, 2002, IMMUNOL LETT, V84, P81, DOI 10.1016/S0165-2478(02)00042-1; FARKASHIMSLEY H, 1995, P NATL ACAD SCI USA, V92, P6996, DOI 10.1073/pnas.92.15.6996; Gastpar R, 2004, J IMMUNOL, V172, P972, DOI 10.4049/jimmunol.172.2.972; Gehrmann M, 2005, CELL DEATH DIFFER, V12, P38, DOI 10.1038/sj.cdd.4401510; GREGORY CD, 1987, J IMMUNOL, V139, P313; Guzhova I, 2001, BRAIN RES, V914, P66, DOI 10.1016/S0006-8993(01)02774-3; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; HIGHTOWER LE, 1989, J CELL PHYSIOL, V138, P257, DOI 10.1002/jcp.1041380206; Johansson D, 2006, CANCER BIOL THER, V5, P1211, DOI 10.4161/cbt.5.9.3173; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Liebisch G, 1999, J LIPID RES, V40, P1539; Liebisch G, 2006, BBA-MOL CELL BIOL L, V1761, P121, DOI 10.1016/j.bbalip.2005.12.007; Liebisch G, 2004, BBA-MOL CELL BIOL L, V1686, P108, DOI 10.1016/j.bbalip.2004.09.003; LINDBERG AA, 1987, J BIOL CHEM, V262, P1779; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; LINGWOOD CA, 1987, J BIOL CHEM, V262, P8834; Maloney MD, 1999, GLYCOCONJUGATE J, V16, P821, DOI 10.1023/A:1007145420116; MALONEY MD, 1994, J EXP MED, V180, P191, DOI 10.1084/jem.180.1.191; Mambula SS, 2006, J IMMUNOL, V177, P7849, DOI 10.4049/jimmunol.177.11.7849; Mamelak D, 2001, J BIOL CHEM, V276, P449, DOI 10.1074/jbc.M006732200; Multhoff G, 1997, J IMMUNOL, V158, P4341; Multhoff G, 2001, CELL STRESS CHAPERON, V6, P337, DOI 10.1379/1466-1268(2001)006<0337:AMHPSN>2.0.CO;2; MULTHOFF G, 1995, INT J CANCER, V61, P272, DOI 10.1002/ijc.2910610222; NUDELMAN IL, 1987, INT SURG, V72, P104; Nutikka A, 2003, GLYCOCONJUGATE J, V20, P33, DOI 10.1023/B:GLYC.0000016740.69726.fb; Pockley AG, 2003, LANCET, V362, P469, DOI 10.1016/S0140-6736(03)14075-5; Pockley AG, 1998, IMMUNOL INVEST, V27, P367, DOI 10.3109/08820139809022710; Shin BK, 2003, J BIOL CHEM, V278, P7607, DOI 10.1074/jbc.M210455200; Simons K, 1997, NATURE, V387, P569, DOI 10.1038/42408; Theriault JR, 2005, FEBS LETT, V579, P1951, DOI 10.1016/j.febslet.2005.02.046; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Triantafilou M, 2002, J CELL SCI, V115, P2603; Uittenbogaard A, 1998, J BIOL CHEM, V273, P6525, DOI 10.1074/jbc.273.11.6525; van den Eijnde SM, 1998, APOPTOSIS, V3, P9, DOI 10.1023/A:1009650917818; van Engeland M, 1998, CYTOMETRY, V31, P1, DOI 10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R	44	125	128	1	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1925	10.1371/journal.pone.0001925	http://dx.doi.org/10.1371/journal.pone.0001925			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382692	Green Accepted, Green Published, Green Submitted, gold			2022-12-25	WOS:000260795400045
J	van Rijn, BB; Franx, A; Steegers, EAP; de Groot, CJM; Bertina, RM; Pasterkamp, G; Voorbij, HAM; Bruinse, HW; Roest, M				van Rijn, Bas B.; Franx, Arie; Steegers, Eric A. P.; de Groot, Christianne J. M.; Bertina, Rogier M.; Pasterkamp, Gerard; Voorbij, Hieronymus A. M.; Bruinse, Hein W.; Roest, Mark			Maternal TLR4 and NOD2 Gene Variants, Pro-Inflammatory Phenotype and Susceptibility to Early-Onset Preeclampsia and HELLP Syndrome	PLOS ONE			English	Article							TOLL-LIKE RECEPTOR-4; ELEVATED LIVER-ENZYMES; INNATE-IMMUNE-SYSTEM; HEART-DISEASE; LOW PLATELETS; RISK; TOLL-LIKE-RECEPTOR-4; ASSOCIATION; PREGNANCY; HEAT-SHOCK-PROTEIN-60	Background: Altered maternal inflammatory responses play a role in the development of preeclampsia and the hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome. We examined whether allelic variants of the innate immune receptors Toll-like receptor 4 (TLR4) and nucleotide-binding oligomerization domain 2 (NOD2), that impair the inflammatory response to endotoxin, are related to preeclampsia and HELLP syndrome. Methods and Findings: We determined five common mutations in TLR4 (D299G and T399I) and NOD2 (R702W, G908R and L1007fs) in 340 primiparous women with a history of early-onset preeclampsia, of whom 177 women developed HELLP syndrome and in 113 women with a history of only uneventful pregnancies as controls. In addition, we assessed plasma levels of pro-inflammatory biomarkers C-reactive protein, interleukin-6, soluble intercellular adhesion molecule-1, fibrinogen and von Willebrand factor in a subset of 214 women included at least six months after delivery. After adjustment for maternal age and chronic hypertension, attenuating allelic variants of TLR4 were more common in women with a history of early-onset preeclampsia than in controls (OR 2.9 [95% CI 1.2-6.7]). Highest frequencies for TLR4 variants were observed in women who developed HELLP syndrome (adjusted OR 4.1 [95% CI 1.7-9.8]). In addition, high levels of interleukin-6 and fibrinogen were associated with a history of early-onset preeclampsia. Combined positivity for any of the TLR4 and NOD2 allelic variants and high levels of interleukin-6 was 6.9-fold more common in women with a history of early-onset preeclampsia (95% CI 2.1-23.2) compared to controls. Conclusions: We observed an association of common TLR4 and NOD2 gene variants, and pro-inflammatory phenotype with a history of early-onset preeclampsia and HELLP syndrome. These findings suggest involvement of the maternal innate immune system in severe hypertensive disorders of pregnancy.	[van Rijn, Bas B.; Bruinse, Hein W.] Univ Med Ctr Utrecht, Div Perinatol & Gynecol, Utrecht, Netherlands; [van Rijn, Bas B.; Voorbij, Hieronymus A. M.; Roest, Mark] Univ Med Ctr Utrecht, Lab Clin Chem & Hematol, Utrecht, Netherlands; [Pasterkamp, Gerard] Univ Med Ctr Utrecht, Dept Expt Cardiol, Utrecht, Netherlands; [Franx, Arie] St Elisabeth Hosp Tilburg, Dept Obstet & Gynecol, Tilburg, Netherlands; [Steegers, Eric A. P.] Erasmus MC, Div Obstet & Prenatal Med, Rotterdam, Netherlands; [de Groot, Christianne J. M.] Med Ctr Haaglanden, Dept Obstet & Gynecol, Hagen, Germany; [Bertina, Rogier M.] Leiden Univ Med Ctr, Dept Hematol, Leiden, Netherlands	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center; Elisabeth-TweeSteden Ziekenhuis (ETZ); Erasmus University Rotterdam; Erasmus MC; Leiden University; Leiden University Medical Center (LUMC)	van Rijn, BB (corresponding author), Univ Med Ctr Utrecht, Div Perinatol & Gynecol, Utrecht, Netherlands.	brijn2@umcutrecht.nl	Franx, Arie/AAA-1739-2021; van Rijn, Bas/E-2512-2013; van Rijn, Bas/ABZ-1080-2022; Bertina, Rogier/AGQ-5246-2022	van Rijn, Bas/0000-0003-1305-3825; van Rijn, Bas/0000-0003-1305-3825; 	The Netherlands Organization for Scientific Research [920-03-230]	The Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO))	BvR is supported by a stipend from The Netherlands Organization for Scientific Research (ZonMW/NWO grant 920-03-230). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Arechavaleta-Velasco F, 2006, AM J PATHOL, V168, P1951, DOI 10.2353/ajpath.2006.050781; Beutler B, 2001, CRIT CARE MED, V29, pS2, DOI 10.1097/00003246-200107001-00002; Beutler B, 2006, ANNU REV IMMUNOL, V24, P353, DOI 10.1146/annurev.immunol.24.021605.090552; Boggess KA, 2003, OBSTET GYNECOL, V101, P227, DOI 10.1016/S0029-7844(02)02314-1; Borzychowski AM, 2006, SEMIN FETAL NEONAT M, V11, P309, DOI 10.1016/j.siny.2006.04.001; Brown MA, 2001, HYPERTENS PREGNANCY, V20, pIX, DOI 10.1081/PRG-100104165; Bulut Y, 2002, J IMMUNOL, V168, P1435, DOI 10.4049/jimmunol.168.3.1435; Cordell HJ, 2005, LANCET, V366, P1121, DOI 10.1016/S0140-6736(05)67424-7; Costello MJ, 2007, AM J REPROD IMMUNOL, V57, P67, DOI 10.1111/j.1600-0897.2006.00447.x; Crider KS, 2005, GENET MED, V7, P593, DOI 10.1097/01.gim.0000187223.69947.db; CUNNINGHAM DS, 1993, J REPROD MED, V38, P459; D'Agostino RB, 2001, JAMA-J AM MED ASSOC, V286, P180, DOI 10.1001/jama.286.2.180; De Groot CJM, 1999, AM J OBSTET GYNECOL, V181, P975, DOI 10.1016/S0002-9378(99)70335-2; FAAS MM, 1994, AM J OBSTET GYNECOL, V171, P158, DOI 10.1016/0002-9378(94)90463-4; Freeman DJ, 2004, HYPERTENSION, V44, P708, DOI 10.1161/01.HYP.0000143849.67254.ca; Gaya DR, 2006, LANCET, V367, P1271, DOI 10.1016/S0140-6736(06)68345-1; Goddard KAB, 2007, HUM HERED, V63, P1, DOI 10.1159/000097926; Goulis DG, 2005, BJOG-INT J OBSTET GY, V112, P299, DOI 10.1111/j.1471-0528.2004.00423.x; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Hulstein JJJ, 2006, J THROMB HAEMOST, V4, P2569, DOI 10.1111/j.1538-7836.2006.02205.x; Kiechl S, 2002, NEW ENGL J MED, V347, P185, DOI 10.1056/NEJMoa012673; Kim YM, 2005, AM J OBSTET GYNECOL, V193, P921, DOI 10.1016/j.ajog.2005.06.053; Kloosterman G J, 1969, Ned Tijdschr Verloskd Gynaecol, V69, P349; Krishnegowda G, 2005, J BIOL CHEM, V280, P8606, DOI 10.1074/jbc.M413541200; Kurt-Jones EA, 2000, NAT IMMUNOL, V1, P398, DOI 10.1038/80833; Lafayette RA, 1998, KIDNEY INT, V54, P1240, DOI 10.1046/j.1523-1755.1998.00097.x; Levine RJ, 2004, AM J OBSTET GYNECOL, V190, P707, DOI 10.1016/j.ajog.2003.12.019; Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884; MARTIN JN, 1991, AM J OBSTET GYNECOL, V164, P1500, DOI 10.1016/0002-9378(91)91429-Z; Matzinger P, 2002, SCIENCE, V296, P301, DOI 10.1126/science.1071059; MCMASTER MT, 1994, ANN NY ACAD SCI, V734, P122, DOI 10.1111/j.1749-6632.1994.tb21740.x; Mockenhaupt FP, 2006, P NATL ACAD SCI USA, V103, P177, DOI 10.1073/pnas.0506803102; Mockenhaupt FP, 2006, J INFECT DIS, V194, P184, DOI 10.1086/505152; Ohashi K, 2000, J IMMUNOL, V164, P558, DOI 10.4049/jimmunol.164.2.558; Okamura Y, 2001, J BIOL CHEM, V276, P10229, DOI 10.1074/jbc.M100099200; Pestka S, 2004, ANNU REV IMMUNOL, V22, P929, DOI 10.1146/annurev.immunol.22.012703.104622; Rallabhandi P, 2006, J IMMUNOL, V177, P322, DOI 10.4049/jimmunol.177.1.322; Redman CW, 2005, SCIENCE, V308, P1592, DOI 10.1126/science.1111726; Ridker PM, 2004, CIRCULATION, V109, P6, DOI 10.1161/01.CIR.0000133444.17867.56; SIBAI BM, 1986, AM J OBSTET GYNECOL, V155, P501, DOI 10.1016/0002-9378(86)90266-8; Sikkema JM, 2002, PLACENTA, V23, P337, DOI 10.1053/plac.2001.0785; Smith GCS, 2001, LANCET, V357, P2002, DOI 10.1016/S0140-6736(00)05112-6; Stepan H, 2006, NEW ENGL J MED, V354, P1857, DOI 10.1056/NEJMc052721; Terrone DA, 2000, SOUTHERN MED J, V93, P768; Ulevitch R, 2001, CRIT CARE MED, V29, pS6; van Heel DA, 2001, LANCET, V357, P1902, DOI 10.1016/S0140-6736(00)05091-1; van Rijn BB, 2006, AM J OBSTET GYNECOL, V195, P723, DOI 10.1016/j.ajog.2006.06.044; van Rijn BB, 2004, J IMMUNOL METHODS, V289, P81, DOI 10.1016/j.jim.2004.03.013; Heimel PJV, 2006, EUR J OBSTET GYN R B, V128, P187, DOI 10.1016/j.ejogrb.2005.11.041; Visser N, 2007, OBSTET GYNECOL SURV, V62, P191, DOI 10.1097/01.ogx.0000256779.06275.c4; von Dadelszen P, 2003, BJOG-INT J OBSTET GY, V110, P725, DOI 10.1111/j.1471-0528.2003.02481.x; Watanabe T, 2004, NAT IMMUNOL, V5, P800, DOI 10.1038/ni1092; WHO, 2005, MAK EV MOTH CHILD CO; Yang IA, 2006, CURR OPIN ALLERGY CL, V6, P23, DOI 10.1097/01.all.0000200503.77295.bb	55	63	67	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1865	10.1371/journal.pone.0001865	http://dx.doi.org/10.1371/journal.pone.0001865			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382655	Green Published, Green Accepted, Green Submitted, gold			2022-12-25	WOS:000260795400005
J	Akbarzadeh, S; Wheldon, LM; Sweet, SMM; Talma, S; Mardakheh, FK; Heath, JK				Akbarzadeh, Shiva; Wheldon, Lee M.; Sweet, Steve M. M.; Talma, Sonia; Mardakheh, Faraz Khosravi; Heath, John K.			The Deleted in Brachydactyly B Domain of ROR2 Is Required for Receptor Activation by Recruitment of Src	PLOS ONE			English	Article								The transmembrane receptor 'ROR2' resembles members of the receptor tyrosine kinase family of signalling receptors in sequence but its' signal transduction mechanisms remain enigmatic. This problem has particular importance because mutations in ROR2 are associated with two human skeletal dysmorphology syndromes, recessive Robinow Syndrome (RS) and dominant acting Brachydactyly type B (BDB). Here we show, using a constitutive dimerisation approach, that ROR2 exhibits dimerisation-induced tyrosine kinase activity and the ROR2 C-terminal domain, which is deleted in BDB, is required for recruitment and activation of the non-receptor tyrosine kinase Src. Native ROR2 phosphorylation is induced by the ligand Wnt5a and is blocked by pharmacological inhibition of Src kinase activity. Eight sites of Src-mediated ROR2 phosphorylation have been identified by mass spectrometry. Activation via tyrosine phosphorylation of ROR2 receptor leads to its internalisation into Rab5 positive endosomes. These findings show that BDB mutant receptors are defective in kinase activation as a result of failure to recruit Src.	[Akbarzadeh, Shiva; Wheldon, Lee M.; Sweet, Steve M. M.; Talma, Sonia; Mardakheh, Faraz Khosravi; Heath, John K.] Univ Birmingham, Sch Biosci, CR UK Growth Factor Grp, Birmingham, W Midlands, England	University of Birmingham	Akbarzadeh, S (corresponding author), Univ Birmingham, Sch Biosci, CR UK Growth Factor Grp, Birmingham, W Midlands, England.	J.K.Heath@bham.ac.uk	Sweet, Steve/B-5528-2008	Sweet, Steve/0000-0002-3962-0421; akbarzadeh, shivaa/0000-0002-2787-3317; Mardakheh, Faraz/0000-0003-3896-0827; Heath, John/0000-0003-4886-4070	Wellcome Trust; Cancer Research UK; Endotrack (EU FP6)	Wellcome Trust(Wellcome TrustEuropean Commission); Cancer Research UK(Cancer Research UK); Endotrack (EU FP6)(European Commission)	This research was funded by the Wellcome Trust (to JKH, Andrew Wilkie and Gillian Morriss-Kay) and Cancer Research UK. SMMS was funded by Endotrack (EU FP6).	Afzal AR, 2000, NAT GENET, V25, P419, DOI 10.1038/78107; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; Beausoleil SA, 2006, NAT BIOTECHNOL, V24, P1285, DOI 10.1038/nbt1240; Billiard J, 2005, MOL ENDOCRINOL, V19, P90, DOI 10.1210/me.2004-0153; DeChiara TM, 2000, NAT GENET, V24, P271, DOI 10.1038/73488; Forrester WC, 2002, CELL MOL LIFE SCI, V59, P83, DOI 10.1007/s00018-002-8407-9; GORVEL JP, 1991, CELL, V64, P915, DOI 10.1016/0092-8674(91)90316-Q; Hikasa H, 2002, DEVELOPMENT, V129, P5227; Ishizawar R, 2004, CANCER CELL, V6, P209, DOI 10.1016/j.ccr.2004.09.001; Larsen MR, 2005, MOL CELL PROTEOMICS, V4, P873, DOI 10.1074/mcp.T500007-MCP200; Liu J, 2007, MOL BIOL CELL, V18, P1375, DOI 10.1091/mbc.E06-08-0725; Liu Y, 2007, MOL ENDOCRINOL, V21, P3050, DOI 10.1210/me.2007-0323; MASIAKOWSKI P, 1992, J BIOL CHEM, V267, P26181; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115; Nishita M, 2006, J CELL BIOL, V175, P555, DOI 10.1083/jcb.200607127; Oishi I, 1999, GENES CELLS, V4, P41, DOI 10.1046/j.1365-2443.1999.00234.x; Oishi I, 2003, GENES CELLS, V8, P645, DOI 10.1046/j.1365-2443.2003.00662.x; Oldridge M, 2000, NAT GENET, V24, P275, DOI 10.1038/73495; Sammar M, 2004, GENES CELLS, V9, P1227, DOI 10.1111/j.1365-2443.2004.00799.x; Schambony A, 2007, DEV CELL, V12, P779, DOI 10.1016/j.devcel.2007.02.016; Schwabe GC, 2000, AM J HUM GENET, V67, P822, DOI 10.1086/303084; Stricker S, 2006, DEV DYNAM, V235, P3456, DOI 10.1002/dvdy.20993; Takeuchi S, 2000, GENES CELLS, V5, P71, DOI 10.1046/j.1365-2443.2000.00300.x; van Bokhoven H, 2000, NAT GENET, V25, P423, DOI 10.1038/78113; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	26	59	60	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1873	10.1371/journal.pone.0001873	http://dx.doi.org/10.1371/journal.pone.0001873			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365018	gold, Green Published, Green Submitted			2022-12-25	WOS:000260762400024
J	Olmeda, D; Montes, A; Moreno-Bueno, G; Flores, JM; Portillo, F; Cano, A				Olmeda, D.; Montes, A.; Moreno-Bueno, G.; Flores, J. M.; Portillo, F.; Cano, A.			Snai1 and Snai2 collaborate on tumor growth and metastasis properties of mouse skin carcinoma cell lines	ONCOGENE			English	Article						Snai1; Snai2; E-cadherin; EMT; invasion; metastasis	EPITHELIAL-MESENCHYMAL TRANSITIONS; TRANSCRIPTION FACTOR SNAIL; CADHERIN GENE-EXPRESSION; REPRESSES E-CADHERIN; ADHESION MOLECULE; FACTOR SLUG; PROGRESSION; SUPERFAMILY; PATHWAY; OVARIAN	Snai1 (Snail) and Snai2 (Slug), the two main members of Snail family factors, are important mediators of epithelial-mesenchymal transitions and involved in tumor progression. We recently reported that Snai1 plays a major role in tumor growth, invasion and metastasis, but the contribution of Snai2 to tumorigenesis is not yet well understood. To approach this question we have silenced Snai2 and/or Snai1 by stable RNA interference in two independent mouse skin carcinoma (HaCa4 and CarB) cell lines. We demonstrate that Snai2 knockdown has a milder effect, but collaborates with Snai1 silencing in reduction of tumor growth potential of either carcinoma cell line when injected into nude mice. Importantly, Snai1 or Snai2 silencing dramatically influences the metastatic ability of squamous carcinoma HaCa4 cells, inducing a strong reduction in liver and lung distant metastasis. However, only Snai1 knockdown has an effective action on invasiveness and fully abolishes tumor cell dissemination into the spleen. These results demonstrate that Snai1 and Snai2 collaborate on primary tumor growth and specifically contribute to site-specific metastasis of HaCa4 cells. These data also indicate that Snai1 is the major regulator of local invasion, supporting a hierarchical participation of both factors in the metastatic process.	[Olmeda, D.; Montes, A.; Moreno-Bueno, G.; Portillo, F.; Cano, A.] UAM, Inst Invest Biomed Alberto Sols, CSIC, Dept Biochem, Madrid 28029, Spain; [Flores, J. M.] Univ Complutense Madrid, Fac Vet, Dept Cirugia & Med Anim, Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Complutense University of Madrid	Cano, A (corresponding author), UAM, Inst Invest Biomed Alberto Sols, CSIC, Dept Biochem, C Arturo Duperier 4, Madrid 28029, Spain.	acano@iib.uam.es	Moreno-Bueno, Gema/K-9354-2016; Olmeda, David/L-4270-2017	Moreno-Bueno, Gema/0000-0002-5030-6687; Olmeda, David/0000-0001-5513-5621; Portillo Perez, Francisco/0000-0003-4922-346X				Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; BIRCHMEIER W, 1994, BBA-REV CANCER, V1198, P11, DOI 10.1016/0304-419X(94)90003-5; Bolos V, 2003, J CELL SCI, V116, P499, DOI 10.1242/jcs.00224; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Carver EA, 2001, MOL CELL BIOL, V21, P8184, DOI 10.1128/MCB.21.23.8184-8188.2001; Christofori G, 1999, TRENDS BIOCHEM SCI, V24, P73, DOI 10.1016/S0968-0004(98)01343-7; Christofori G, 2006, NATURE, V441, P444, DOI 10.1038/nature04872; Come C, 2006, CLIN CANCER RES, V12, P5395, DOI 10.1158/1078-0432.CCR-06-0478; Elloul S, 2005, CANCER-AM CANCER SOC, V103, P1631, DOI 10.1002/cncr.20946; Elloul S, 2006, VIRCHOWS ARCH, V449, P520, DOI 10.1007/s00428-006-0274-6; Fraga MF, 2004, CANCER RES, V64, P5527, DOI 10.1158/0008-5472.CAN-03-4061; Guaita S, 2002, J BIOL CHEM, V277, P39209, DOI 10.1074/jbc.M206400200; Gupta GP, 2006, CELL, V127, P679, DOI 10.1016/j.cell.2006.11.001; Hajra KM, 2002, CANCER RES, V62, P1613; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; Jiang RL, 1998, DEV BIOL, V198, P277, DOI 10.1016/S0012-1606(98)80005-5; Jorda M, 2005, J CELL SCI, V118, P3371, DOI 10.1242/jcs.02465; Jorda M, 2007, EXP CELL RES, V313, P2389, DOI 10.1016/j.yexcr.2007.04.001; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Llorens A, 1998, LAB INVEST, V78, P1131; Manzanares M, 2001, TRENDS GENET, V17, P178, DOI 10.1016/S0168-9525(01)02232-6; Mehlen P, 2006, NAT REV CANCER, V6, P449, DOI 10.1038/nrc1886; Moreno-Bueno G, 2003, ONCOGENE, V22, P6115, DOI 10.1038/sj.onc.1206868; NAVARRO P, 1991, J CELL BIOL, V115, P517, DOI 10.1083/jcb.115.2.517; Nieto MA, 2002, NAT REV MOL CELL BIO, V3, P155, DOI 10.1038/nrm757; Olmeda D, 2007, ONCOGENE, V26, P1862, DOI 10.1038/sj.onc.1209997; Olmeda D, 2007, CANCER RES, V67, P11721, DOI 10.1158/0008-5472.CAN-07-2318; Peinado H, 2005, EMBO J, V24, P3446, DOI 10.1038/sj.emboj.7600781; Peinado H, 2007, NAT REV CANCER, V7, P415, DOI 10.1038/nrc2131; Perez-Losada J, 2003, ONCOGENE, V22, P4205, DOI 10.1038/sj.onc.1206467; Rodrigo I, 1999, EXP CELL RES, V248, P358, DOI 10.1006/excr.1999.4438; Savagner P, 2005, J CELL PHYSIOL, V202, P858, DOI 10.1002/jcp.20188; Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822	34	90	96	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2008	27	34					4690	4701		10.1038/onc.2008.118	http://dx.doi.org/10.1038/onc.2008.118			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408755				2022-12-25	WOS:000258236300007
J	Whitney, NP; Peng, H; Erdmann, NB; Tian, C; Monaghan, DT; Zheng, JC				Whitney, Nicholas P.; Peng, Hui; Erdmann, Nathan B.; Tian, Changhai; Monaghan, Daniel T.; Zheng, Jialin C.			Calcium-permeable AMPA receptors containing Q/R-unedited GluR2 direct human neural progenitor cell differentiation to neurons	FASEB JOURNAL			English	Article						glutamate; Q/R editing; neurogenesis; dendritic arborization; ADAR2	CENTRAL-NERVOUS-SYSTEM; ADULT-RAT HIPPOCAMPUS; STEM-CELLS; GLUTAMATE RECEPTORS; ACID RECEPTORS; MESSENGER-RNA; SUBUNIT COMPOSITION; RELATIVE ABUNDANCE; CA2+ PERMEABILITY; SPIDER TOXIN	We identify calcium-permeable alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors on human neural progenitor cells (NPCs) and present a physiological role in neurogenesis. RNA editing of the GluR2 subunit at the Q/R site is responsible for making most AMPA receptors impermeable to calcium. Because a single-point mutation could eliminate the need for editing at the Q/R site and Q/R-unedited GluR2 exists during embryogenesis, the Q/R-unedited GluR2 subunit presumably has some important actions early in development. Using calcium imaging, we found that NPCs contain calcium-permeable AMPA receptors, whereas NPCs differentiated to neurons and astrocytes express calcium-impermeable AMPA receptors. We utilized reverse-transcription polymerase chain reaction and BbvI digestion to demonstrate that NPCs contain Q/R-unedited GluR2, and differentiated cells contain Q/R-edited GluR2 subunits. This is consistent with the observation that the nuclear enzyme responsible for Q/R-editing, adenosine deaminase (ADAR2), is increased during differentiation. Activation of calcium-permeable AMPA receptors induces NPCs to differentiate to the neuronal lineage and increases dendritic arbor formation in NPCs differentiated to neurons. AMPA-induced differentiation of NPCs to neurons is abrogated by overexpression of ADAR2 in NPCs. This elucidates the role of AMPA receptors as inductors of neurogenesis and provides a possible explanation for why the Q/R editing process exists.	[Whitney, Nicholas P.; Peng, Hui; Erdmann, Nathan B.; Tian, Changhai; Monaghan, Daniel T.; Zheng, Jialin C.] Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, Omaha, NE 68198 USA; [Whitney, Nicholas P.; Peng, Hui; Erdmann, Nathan B.; Tian, Changhai; Monaghan, Daniel T.; Zheng, Jialin C.] Univ Nebraska, Med Ctr, Dept Pathol & Microbiol, Omaha, NE 68198 USA; [Whitney, Nicholas P.; Peng, Hui; Erdmann, Nathan B.; Tian, Changhai; Zheng, Jialin C.] Univ Nebraska, Med Ctr, Lab Neurotoxicol, Omaha, NE 68198 USA; [Whitney, Nicholas P.; Peng, Hui; Erdmann, Nathan B.; Tian, Changhai; Zheng, Jialin C.] Univ Nebraska, Med Ctr, Ctr Neurovirol & Neurodegenerat Disorders, Omaha, NE 68198 USA	University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center; University of Nebraska System; University of Nebraska Medical Center	Whitney, NP (corresponding author), Univ Nebraska, Med Ctr, Dept Pharmacol & Expt Neurosci, 985800 Nebraska Med Ctr, Omaha, NE 68198 USA.	jzheng@unmc.edu			NATIONAL CENTER FOR RESEARCH RESOURCES [P20RR015635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS043985, R01NS041858] Funding Source: NIH RePORTER; NCRR NIH HHS [P20 RR015635, P20 RR15635] Funding Source: Medline; NINDS NIH HHS [R01 NS041858, R01 NS 41858, P01 NS043985] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bai F, 2003, NEUROPHARMACOLOGY, V44, P1013, DOI 10.1016/S0028-3908(03)00104-7; Barbon A, 2003, MOL BRAIN RES, V117, P168, DOI 10.1016/S0169-328X(03)00317-6; Bertrand N, 2002, NAT REV NEUROSCI, V3, P517, DOI 10.1038/nrn874; Beyersmann D, 2001, BIOMETALS, V14, P331, DOI 10.1023/A:1012905406548; BLASCHKE M, 1993, P NATL ACAD SCI USA, V90, P6528, DOI 10.1073/pnas.90.14.6528; Brorson JR, 1999, J NEUROSCI, V19, P9149; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; Chappell AS, 2007, NEUROLOGY, V68, P1008, DOI 10.1212/01.wnl.0000260240.46070.7c; Dingledine R, 1999, PHARMACOL REV, V51, P7; Emsley JG, 2005, PROG NEUROBIOL, V75, P321, DOI 10.1016/j.pneurobio.2005.04.002; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; Hagg T, 2005, TRENDS NEUROSCI, V28, P589, DOI 10.1016/j.tins.2005.08.009; Higuchi M, 2000, NATURE, V406, P78, DOI 10.1038/35017558; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; Iino M, 1996, J PHYSIOL-LONDON, V496, P431, DOI 10.1113/jphysiol.1996.sp021696; Ingvar M, 1997, EXP NEUROL, V146, P553, DOI 10.1006/exnr.1997.6581; Jia YS, 2002, J PHYSIOL-LONDON, V543, P35, DOI 10.1113/jphysiol.2002.020172; Kask K, 1998, P NATL ACAD SCI USA, V95, P13777, DOI 10.1073/pnas.95.23.13777; Kawahara Y, 2004, NATURE, V427, P801, DOI 10.1038/427801a; Kawahara Y, 2003, EUR J NEUROSCI, V18, P23, DOI 10.1046/j.1460-9568.2003.02718.x; Kohr G, 1998, NEUROPHARMACOLOGY, V37, P1411, DOI 10.1016/S0028-3908(98)00149-X; Konig N, 2001, JPN J PHARMACOL, V86, P1, DOI 10.1254/jjp.86.1; Kung SS, 2001, FEBS LETT, V509, P277, DOI 10.1016/S0014-5793(01)03183-0; Kwak S, 2005, J MOL MED, V83, P110, DOI 10.1007/s00109-004-0599-z; Lee JC, 1998, BRAIN RES PROTOC, V3, P142, DOI 10.1016/S1385-299X(98)00035-X; Luk KC, 2003, J NEUROSCI, V23, P2239; Lynch G, 1997, EXP NEUROL, V145, P89, DOI 10.1006/exnr.1997.6447; Maas S, 2001, P NATL ACAD SCI USA, V98, P14687, DOI 10.1073/pnas.251531398; Mackowiak M, 2002, NEUROPHARMACOLOGY, V43, P1, DOI 10.1016/S0028-3908(02)00066-7; Mansour M, 2001, NEURON, V32, P841, DOI 10.1016/S0896-6273(01)00520-7; Mattson MP, 2004, TRENDS NEUROSCI, V27, P589, DOI 10.1016/j.tins.2004.08.001; Miller FD, 2003, CURR OPIN NEUROBIOL, V13, P391, DOI 10.1016/s0959-4388(03)00072-2; Ming GL, 2005, ANNU REV NEUROSCI, V28, P223, DOI 10.1146/annurev.neuro.28.051804.101459; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; Murray TK, 2003, J PHARMACOL EXP THER, V306, P752, DOI 10.1124/jpet.103.049445; Nacher J, 2006, HIPPOCAMPUS, V16, P267, DOI 10.1002/hipo.20160; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; O'Neill MJ, 2004, CNS NEUROL DISORD-DR, V3, P181, DOI 10.2174/1568007043337508; Palmer CL, 2005, PHARMACOL REV, V57, P253, DOI 10.1124/pr.57.2.7; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Paupard MC, 2000, NEUROSCIENCE, V95, P869; PellegriniGiampietro DE, 1997, TRENDS NEUROSCI, V20, P464, DOI 10.1016/S0166-2236(97)01100-4; PENDE M, 1994, P NATL ACAD SCI USA, V91, P3215, DOI 10.1073/pnas.91.8.3215; Peng H, 2004, J NEUROSCI RES, V76, P35, DOI 10.1002/jnr.20045; Peng PL, 2006, NEURON, V49, P719, DOI 10.1016/j.neuron.2006.01.025; Quirk JC, 2002, CNS DRUG REV, V8, P255; Rosenmund C, 1998, SCIENCE, V280, P1596, DOI 10.1126/science.280.5369.1596; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; Sans N, 2003, J NEUROSCI, V23, P9367; Slavov D, 2002, GENE, V299, P83, DOI 10.1016/S0378-1119(02)01016-8; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; Suzuki M, 2006, EUR J NEUROSCI, V24, P645, DOI 10.1111/j.1460-9568.2006.04957.x; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; Voss OP, 2007, NEUROPHARMACOLOGY, V52, P590, DOI 10.1016/j.neuropharm.2006.09.001; Washburn MS, 1996, J PHARMACOL EXP THER, V278, P669; Webb SE, 2005, CELL CALCIUM, V37, P375, DOI 10.1016/j.ceca.2005.01.005; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Zheng JL, 2004, NEUROINFORMATICS, V2, P303, DOI 10.1385/NI:2:3:303; Zheng JL, 1999, J NEUROIMMUNOL, V98, P185, DOI 10.1016/S0165-5728(99)00049-1	60	71	76	0	6	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2888	2900		10.1096/fj.07-104661	http://dx.doi.org/10.1096/fj.07-104661			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18403631	Green Published			2022-12-25	WOS:000258089300029
J	Chen, Z; Feng, J; Saldivar, JS; Gu, D; Bockholt, A; Sommer, SS				Chen, Z.; Feng, J.; Saldivar, J-S; Gu, D.; Bockholt, A.; Sommer, S. S.			EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids	ONCOGENE			English	Article						EGFR; lung cancer; doublet; somatic mutation	GROWTH-FACTOR RECEPTOR; DRUG-RESISTANCE MUTATION; MULTIPLE MUTATIONS; GENE-MUTATIONS; GEFITINIB; AMPLIFICATION; SENSITIVITY; PATTERNS; MUTANTS; SUSCEPTIBILITY	Doublet mutations in cancer are not well studied. We find that allelic somatic doublet mutations are present at high frequency in the epidermal growth factor receptor (EGFR) tyrosine kinase (TK) domain in lung cancers. When doublets from the literature are added, a total of 96 doublets are available for analysis. The frequency of doublets overall is 6%, which is sevenfold greater than that observed in normal tissue in mouse. All characterized doublets are allelic, and silent mutations occur rarely. About half of all doublets contain one or two of 12 distinct missense mutations at five amino acids: E709, G719, S768, T790 and L861. The mutations at these five amino acids are seldom reported as singlets. Moreover, when the common L858 target is included, more than one-third of EGFR doublets are one of five specific missense pairs: G719/E709, G719/S768, G719/L861, L858/E709 and L858/T790. Structure suggests function: The data imply that most EGFR doublets are NOT consistent with a 'driver and passenger' mutation mechanism. EGFR doublets are highly skewed relative to singlets, consistent with functional selection of two individually suboptimal mutations that, in combination, have enhanced oncogenic potential.	[Chen, Z.; Feng, J.; Saldivar, J-S; Gu, D.; Bockholt, A.; Sommer, S. S.] City Hope Natl Med Ctr, Dept Mol Genet, Duarte, CA 91010 USA	City of Hope	Sommer, SS (corresponding author), City Hope Natl Med Ctr, Dept Mol Genet, 1500 E Duarte Rd, Duarte, CA 91010 USA.	sommerlab@coh.org			NIA NIH HHS [R01-AG19784-02] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG019784] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Arteaga CL, 2002, SEMIN ONCOL, V29, P3, DOI 10.1053/sonc.2002.35642; Bell DW, 2005, NAT GENET, V37, P1315, DOI 10.1038/ng1671; Buettner VL, 2000, MUTAT RES-FUND MOL M, V452, P219, DOI 10.1016/S0027-5107(00)00090-7; Buettner VL, 1999, ENVIRON MOL MUTAGEN, V33, P320, DOI 10.1002/(SICI)1098-2280(1999)33:4<320::AID-EM9>3.0.CO;2-S; Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159; Davies H, 2005, CANCER RES, V65, P7591, DOI 10.1158/0008-5472.CAN-05-1855; Godin-Heymann N, 2007, CANCER RES, V67, P7319, DOI 10.1158/0008-5472.CAN-06-4625; Greenman C, 2007, NATURE, V446, P153, DOI 10.1038/nature05610; Gu D, 2007, HUM MUTAT, V28, P760, DOI 10.1002/humu.20512; Hill KA, 2004, MUTAT RES-FUND MOL M, V554, P223, DOI 10.1016/j.mrfmmm.2004.05.005; Hill KA, 2003, MUTAT RES-GEN TOX EN, V534, P173, DOI 10.1016/S1383-5718(02)00277-2; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Ma ESK, 2007, INT J CANCER, V120, P1828, DOI 10.1002/ijc.22506; Mulloy R, 2007, CANCER RES, V67, P2325, DOI 10.1158/0008-5472.CAN-06-4293; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Regales L, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000810; Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Shintani Satoru, 2003, Am J Clin Oncol, V26, pe150, DOI 10.1097/01.coc.0000091356.25759.69; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; SOMMER SS, 1980, J MOL EVOL, V15, P37, DOI 10.1007/BF01732582; SOMMER SS, 1992, BIOTECHNIQUES, V12, P82; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Strauss BS, 2000, MUTAT RES-FUND MOL M, V457, P93, DOI 10.1016/S0027-5107(00)00135-4; Strauss BS, 1997, CARCINOGENESIS, V18, P1445, DOI 10.1093/carcin/18.8.1445; Takano T, 2005, J CLIN ONCOL, V23, P6829, DOI 10.1200/JCO.2005.01.0793; Tam IYS, 2006, CLIN CANCER RES, V12, P1647, DOI 10.1158/1078-0432.CCR-05-1981; Vikis H, 2007, CANCER RES, V67, P4665, DOI 10.1158/0008-5472.CAN-07-0217; Yokoyama T, 2006, CANCER SCI, V97, P753, DOI 10.1111/j.1349-7006.2006.00233.x; Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017	30	60	67	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2008	27	31					4336	4343		10.1038/onc.2008.71	http://dx.doi.org/10.1038/onc.2008.71			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372921				2022-12-25	WOS:000257691100008
J	De Boer, L; Oakes, V; Beamish, H; Giles, N; Stevens, F; Somodevilla-Torres, M; DeSouza, C; Gabrielli, B				De Boer, L.; Oakes, V.; Beamish, H.; Giles, N.; Stevens, F.; Somodevilla-Torres, M.; DeSouza, C.; Gabrielli, B.			Cyclin A/cdk2 coordinates centrosomal and nuclear mitotic events	ONCOGENE			English	Article						cyclin A/cdk2; G(2)/M; centrosome	XENOPUS EGG EXTRACTS; HUMAN-CELLS; CYTOPLASMIC ACCUMULATION; G2-M TRANSITION; PROTEIN-KINASE; CDK2; ACTIVATION; PHOSPHORYLATION; MITOSIS; CDC25B	Cyclin A/cdk2 has a role in progression through Sphase, and a large pool is also activated in G(2) phase. Here we report that this G(2) phase pool regulates the timing of progression into mitosis. Knock down of cyclin A by siRNA or addition of a specific cdk2 small molecule inhibitor delayed entry into mitosis by delaying cells in G(2) phase. The G(2) phase-delayed cells contained elevated levels of inactive cyclin B/cdk1. However, increased microtubule nucleation at the centrosomes was observed, and the centrosomes stained for markers of cyclin B/cdk1 activity. Both microtubule nucleation at the centrosomes and the phosphoprotein markers were lost with short-term treatment of the cdk1/2 inhibitor roscovitine but not the Mek1/2 inhibitor U0126. Cyclin A/cdk2 localized at the centrosomes in late G(2) phase after separation of the centrosomes but before the start of prophase. Thus G(2) phase cyclin A/cdk2 controls the timing of entry into mitosis by controlling the subsequent activation of cyclin B/cdk1, but also has an unexpected role in coordinating the activation of cyclin B/cdk1 at the centrosome and in the nucleus.	[De Boer, L.; Oakes, V.; Beamish, H.; Giles, N.; Stevens, F.; Somodevilla-Torres, M.; Gabrielli, B.] Univ Queensland, Princess Alexandra Hosp, Diamantina Inst Canc Immunol & Metab Med, Canc Biol Program, Brisbane, Qld 4102, Australia; [DeSouza, C.] Ohio State Univ, Dept Mol Genet, Columbus, OH 43210 USA	University of Queensland; University System of Ohio; Ohio State University	Gabrielli, B (corresponding author), Univ Queensland, Princess Alexandra Hosp, Diamantina Inst Canc Immunol & Metab Med, Canc Biol Program, Brisbane, Qld 4102, Australia.	brianG@uq.edu.au	Gabrielli, Brian G/B-3655-2011	Gabrielli, Brian G/0000-0003-3933-1651; Stevens, Frankie/0000-0002-2556-473X				Andrews PD, 2003, CURR OPIN CELL BIOL, V15, P672, DOI 10.1016/j.ceb.2003.10.013; BAILLY E, 1992, J CELL SCI, V101, P529; Berthet C, 2003, CURR BIOL, V13, P1775, DOI 10.1016/j.cub.2003.09.024; Blomberg I, 1999, MOL CELL BIOL, V19, P6183; BUENDIA B, 1992, J CELL BIOL, V116, P1431, DOI 10.1083/jcb.116.6.1431; CLARKE PR, 1992, EMBO J, V11, P1751, DOI 10.1002/j.1460-2075.1992.tb05227.x; De Souza CPC, 2000, EXP CELL RES, V257, P11, DOI 10.1006/excr.2000.4872; den Elzen N, 2001, J CELL BIOL, V153, P121, DOI 10.1083/jcb.153.1.121; Dutertre S, 2004, J CELL SCI, V117, P2523, DOI 10.1242/jcs.01108; Fung TK, 2007, MOL BIOL CELL, V18, P1861, DOI 10.1091/mbc.E06-12-1092; Furuno N, 1999, J CELL BIOL, V147, P295, DOI 10.1083/jcb.147.2.295; Gabrielli BG, 1996, J CELL SCI, V109, P1081; Goldstone S, 2001, ONCOGENE, V20, P921, DOI 10.1038/sj.onc.1204177; Gong DQ, 2007, CURR BIOL, V17, P85, DOI 10.1016/j.cub.2006.11.066; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; Hu B, 2001, MOL CELL BIOL, V21, P2755, DOI 10.1128/MCB.21.8.2755-2766.2001; Jackman M, 2003, NAT CELL BIOL, V5, P143, DOI 10.1038/ncb918; KNOBLICH JA, 1993, EMBO J, V12, P65, DOI 10.1002/j.1460-2075.1993.tb05632.x; Kramer A, 2004, NAT CELL BIOL, V6, P884, DOI 10.1038/ncb1165; Krauer KG, 2004, ONCOGENE, V23, P1342, DOI 10.1038/sj.onc.1207253; Lindqvist A, 2005, J CELL BIOL, V171, P35, DOI 10.1083/jcb.200503066; Lukas C, 1999, NATURE, V401, P815, DOI 10.1038/44611; Mitra J, 2004, ONCOGENE, V23, P3361, DOI 10.1038/sj.onc.1207446; Ortega S, 2003, NAT GENET, V35, P25, DOI 10.1038/ng1232; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; Qiu L, 2000, MOL BIOL CELL, V11, P2069, DOI 10.1091/mbc.11.6.2069; ROSSOMANDO AJ, 1994, MOL CELL BIOL, V14, P1594, DOI 10.1128/MCB.14.3.1594; Sherr CJ, 2000, CANCER RES, V60, P3689; Stead E, 2002, ONCOGENE, V21, P8320, DOI 10.1038/sj.onc.1206015; Tetsu O, 2003, CANCER CELL, V3, P233, DOI 10.1016/S1535-6108(03)00053-9	31	103	106	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4261	4268		10.1038/onc.2008.74	http://dx.doi.org/10.1038/onc.2008.74			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372919				2022-12-25	WOS:000257691100001
J	Kalakonda, N; Fischle, W; Boccuni, P; Gurvich, N; Hoya-Arias, R; Zhao, X; Miyata, Y; MacGrogan, D; Zhang, J; Sims, JK; Rice, JC; Nimer, SD				Kalakonda, N.; Fischle, W.; Boccuni, P.; Gurvich, N.; Hoya-Arias, R.; Zhao, X.; Miyata, Y.; MacGrogan, D.; Zhang, J.; Sims, J. K.; Rice, J. C.; Nimer, S. D.			Histone H4 lysine 20 monomethylation promotes transcriptional repression by L3MBTL1	ONCOGENE			English	Article						cell cycle; chromatin; L3MBTL1; lysine monomethylation; PR-SET7	POLYCOMB GROUP PROTEIN; CELL-CYCLE; DROSOPHILA-MELANOGASTER; MITOTIC CHROMOSOMES; MAMMALIAN CHROMATIN; METHYLATION STATES; SILENT CHROMATIN; HORMONE-RECEPTOR; TUDOR DOMAIN; HP1 PROTEINS	Lethal 3 malignant brain tumor 1 (L3MBTL1), a homolog of the Drosophila polycomb tumor suppressor l(3) mbt, contains three tandem MBT repeats (3xMBT) that are critical for transcriptional repression. We recently reported that the 3xMBT repeats interact with mono- and dimethylated lysines in the amino termini of histones H4 and H1b to promote methylation-dependent chromatin compaction. Using a series of histone peptides, we now show that the recognition of mono- and dimethylated lysines in histones H3, H4 and H1.4 (but not their trimethylated or unmodified counterparts) by 3xMBT occurs in the context of a basic environment, requiring a conserved aspartic acid (D355) in the second MBT repeat. Despite the broad range of in vitro binding, the chromatin association of L3MBTL1 mirrors the progressive accumulation of H4K20 monomethylation during the cell cycle. Furthermore, transcriptional repression by L3MBTL1 is enhanced by the H4K20 monomethyltransferase PR-SET7 (to which it binds) but not SUV420H1 (an H4K20 trimethylase) or G9a (an H3K9 dimethylase) and knockdown of PR-SET7 decreases H4K20me1 levels and the chromatin association of L3MBTL1. Our studies identify the importance of H4K20 monomethylation and of PR-SET7 for L3MBTL1 function.	[Kalakonda, N.; Boccuni, P.; Gurvich, N.; Hoya-Arias, R.; Zhao, X.; Miyata, Y.; MacGrogan, D.; Zhang, J.; Nimer, S. D.] Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, New York, NY 10021 USA; [Fischle, W.] Rockefeller Univ, Lab Chromatin Biol, New York, NY 10021 USA; [Sims, J. K.; Rice, J. C.] Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA	Memorial Sloan Kettering Cancer Center; Rockefeller University; University of Southern California	Nimer, SD (corresponding author), Sloan Kettering Inst, Lab Mol Aspects Hematopoiesis, 1275 York Ave,Box 575, New York, NY 10021 USA.	nimers@mskcc.org	Rice, Judd C/B-7806-2009; MacGrogan, Donal/E-8604-2016; MacGrogan, Donal/AAR-7392-2021	MacGrogan, Donal/0000-0003-2808-8422; MacGrogan, Donal/0000-0003-2808-8422; Zhao, Xiaolan/0000-0002-8302-6905	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM075094] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM075094, R01 GM075094-01A2, R01 GM075094-02] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Barski A, 2007, CELL, V129, P823, DOI 10.1016/j.cell.2007.05.009; Boccuni P, 2003, J BIOL CHEM, V278, P15412, DOI 10.1074/jbc.M300592200; Bornemann D, 1998, GENETICS, V150, P675; Botuyan MV, 2006, CELL, V127, P1361, DOI 10.1016/j.cell.2006.10.043; Dialynas GK, 2007, J CELL SCI, V120, P3415, DOI 10.1242/jcs.012914; Fang J, 2002, CURR BIOL, V12, P1086, DOI 10.1016/S0960-9822(02)00924-7; Flanagan JF, 2005, NATURE, V438, P1181, DOI 10.1038/nature04290; GATEFF E, 1993, MECH DEVELOP, V41, P15, DOI 10.1016/0925-4773(93)90052-Y; Huang Y, 2006, SCIENCE, V312, P748, DOI 10.1126/science.1125162; Huebert DJ, 2005, CURR OPIN GENET DEV, V15, P476, DOI 10.1016/j.gde.2005.08.001; Ishizuka T, 2003, MOL CELL BIOL, V23, P5122, DOI 10.1128/MCB.23.15.5122-5131.2003; Jacobs SA, 2004, METHOD ENZYMOL, V376, P131; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jorgensen S, 2007, J CELL BIOL, V179, P1337, DOI 10.1083/jcb.200706150; Julien E, 2004, MOL CELL, V14, P713, DOI 10.1016/j.molcel.2004.06.008; Karachentsev D, 2005, GENE DEV, V19, P431, DOI 10.1101/gad.1263005; Kim J, 2006, EMBO REP, V7, P397, DOI 10.1038/sj.embor.7400625; Klymenko T, 2006, GENE DEV, V20, P1110, DOI 10.1101/gad.377406; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; Koga H, 1999, ONCOGENE, V18, P3799, DOI 10.1038/sj.onc.1202732; Kohlmaier A, 2004, PLOS BIOL, V2, P991, DOI 10.1371/journal.pbio.0020171; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lewis PW, 2004, GENE DEV, V18, P2929, DOI 10.1101/gad.1255204; MacGrogan D, 2004, GENE CHROMOSOME CANC, V41, P203, DOI 10.1002/gcc.20087; Martens JHA, 2005, EMBO J, V24, P800, DOI 10.1038/sj.emboj.7600545; Maurer-Stroh S, 2003, TRENDS BIOCHEM SCI, V28, P69, DOI 10.1016/S0968-0004(03)00004-5; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; Mikkelsen TS, 2007, NATURE, V448, P553, DOI 10.1038/nature06008; Nishioka K, 2002, MOL CELL, V9, P1201, DOI 10.1016/S1097-2765(02)00548-8; Pesavento JJ, 2008, MOL CELL BIOL, V28, P468, DOI 10.1128/MCB.01517-07; Peters AHFM, 2003, MOL CELL, V12, P1577, DOI 10.1016/S1097-2765(03)00477-5; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Rice JC, 2003, MOL CELL, V12, P1591, DOI 10.1016/S1097-2765(03)00479-9; Rice JC, 2002, GENE DEV, V16, P2225, DOI 10.1101/gad.1014902; Ruthenburg AJ, 2007, MOL CELL, V25, P15, DOI 10.1016/j.molcel.2006.12.014; Schotta G, 2004, GENE DEV, V18, P1251, DOI 10.1101/gad.300704; Schotta G, 2002, EMBO J, V21, P1121, DOI 10.1093/emboj/21.5.1121; Seet BT, 2006, NAT REV MOL CELL BIO, V7, P473, DOI 10.1038/nrm1960; Sims JK, 2006, J BIOL CHEM, V281, P12760, DOI 10.1074/jbc.M513462200; Stewart MD, 2005, MOL CELL BIOL, V25, P2525, DOI 10.1128/MCB.25.7.2525-2538.2005; Talasz H, 2005, J BIOL CHEM, V280, P38814, DOI 10.1074/jbc.M505563200; Tardat M, 2007, J CELL BIOL, V179, P1413, DOI 10.1083/jcb.200706179; Trojer P, 2007, CELL, V129, P915, DOI 10.1016/j.cell.2007.03.048; Turner BM, 2007, NAT CELL BIOL, V9, P2, DOI 10.1038/ncb0107-2; Vakoc CR, 2006, MOL CELL BIOL, V26, P9185, DOI 10.1128/MCB.01529-06; Wang WK, 2003, STRUCTURE, V11, P775, DOI 10.1016/S0969-2126(03)00127-8; WISMAR J, 1995, MECH DEVELOP, V53, P141, DOI 10.1016/0925-4773(95)00431-9; Yohn CB, 2003, GENETICS, V165, P1889; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zhang LW, 2003, CHROMOSOMA, V112, P77, DOI 10.1007/s00412-003-0244-6	52	117	126	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2008	27	31					4293	4304		10.1038/onc.2008.67	http://dx.doi.org/10.1038/onc.2008.67			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18408754	Green Accepted			2022-12-25	WOS:000257691100004
J	Tikhonov, DB; Zhorov, BS				Tikhonov, Denis B.; Zhorov, Boris S.			Molecular modeling of benzothiazepine binding in the L-type calcium channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							D-CIS-DILTIAZEM; CA2+ CHANNEL; POTASSIUM CHANNEL; SELECTIVITY FILTER; PORE REGION; SLOW INACTIVATION; LOCAL-ANESTHETICS; SODIUM-CHANNELS; SKELETAL-MUSCLE; ENTRY BLOCKERS	Benz(othi) azepine (BTZ) derivatives constitute one of three major classes of L-type Ca2+ channel ligands. Despite intensive experimental studies, no three-dimensional model of BTZ binding is available. Here we have built KvAP-and KcsA-based models of the Ca(v)1.2 pore domain in the open and closed states and used multiple Monte Carlo minimizations to dock representative ligands. In our open channel model, key functional groups of BTZs interact with BTZ-sensing residues, which were identified in previous mutational experiments. The bulky tricyclic moiety occupies interface between domains III and IV, while the ammonium group protrudes into the inner pore, where it is stabilized by nucleophilic C-ends of the pore helices. In the closed channel model, contacts with several ligand-sensing residues in the inner helices are lost, which weakens ligand-channel interactions. An important feature of the ligand-binding mode in both open and closed channels is an interaction between the BTZ carbonyl group and a Ca2+ ion chelated by the selectivity filter glutamates in domains III and IV. In the absence of Ca2+, the tricyclic BTZ moiety remains in the domain interface, while the ammonium group directly interacts with a glutamate residue in the selectivity filter. Our model suggests that the Ca2+ potentiation involves a direct electrostatic interaction between a Ca2+ ion and the ligand rather than an allosteric mechanism. Energy profiles indicate that BTZs can reach the binding site from the domain interface, whereas access through the open activation gate is unlikely, because reorientation of the bulky molecule in the pore is hindered.	[Tikhonov, Denis B.; Zhorov, Boris S.] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada; [Tikhonov, Denis B.] Russian Acad Sci, IM Sechenov Evolutionary Physiol & Biochem Inst, St Petersburg 194223, Russia	McMaster University; North-Western State Medical University named after I.I. Mechnikov; Russian Academy of Sciences; Sechenov Institute of Evolutionary Physiology & Biochemistry	Zhorov, BS (corresponding author), McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON L8N 3Z5, Canada.	zhorov@mcmaster.ca	Zhorov, Boris S./V-8072-2019; Zhorov, Boris/T-9892-2019; Tikhonov, Denis/AAK-9148-2020	Zhorov, Boris/0000-0002-3630-7114; Tikhonov, Denis/0000-0001-8523-4305				ALMERS W, 1984, J PHYSIOL-LONDON, V353, P585, DOI 10.1113/jphysiol.1984.sp015352; BALWIERCZAK JL, 1987, MOL PHARMACOL, V31, P175; Basdevant N, 2007, J PHYS CHEM B, V111, P9390, DOI 10.1021/jp0727190; Berjukow S, 1999, J BIOL CHEM, V274, P6154, DOI 10.1074/jbc.274.10.6154; Berneche S, 2005, STRUCTURE, V13, P591, DOI 10.1016/j.str.2004.12.019; Bruhova I, 2005, BIOPHYS J, V89, P1020, DOI 10.1529/biophysj.105.062240; CHENG RC, 2008, BIOPHYS J, V94; Cosconati S, 2007, J MED CHEM, V50, P1504, DOI 10.1021/jm061245a; DAS J, 1992, J MED CHEM, V35, P2610, DOI 10.1021/jm00092a011; DAS J, 1992, J MED CHEM, V35, P773, DOI 10.1021/jm00082a019; Dilmac N, 2004, MOL PHARMACOL, V66, P1236, DOI 10.1124/mol.104.000893; Dilmac N, 2003, MOL PHARMACOL, V64, P491, DOI 10.1124/mol.64.2.491; Doyle DA, 1998, SCIENCE, V280, P69, DOI 10.1126/science.280.5360.69; Dreker T, 2005, MOL PHARMACOL, V68, P966, DOI 10.1124/mol.105.012401; Dudley SC, 2000, J GEN PHYSIOL, V116, P679, DOI 10.1085/jgp.116.5.679; Findlay I, 2004, J PHYSIOL-LONDON, V554, P275, DOI 10.1113/jphysiol.2003.047902; FLOYD DM, 1992, J MED CHEM, V35, P756, DOI 10.1021/jm00082a018; GALIZZI JP, 1985, BIOCHEM BIOPH RES CO, V132, P49, DOI 10.1016/0006-291X(85)90986-6; GARCIA ML, 1986, J BIOL CHEM, V261, P8146; GLOSSMANN H, 1983, FEBS LETT, V160, P226, DOI 10.1016/0014-5793(83)80972-7; HEINEMANN SH, 1992, NATURE, V356, P441, DOI 10.1038/356441a0; HERING S, 1993, MOL PHARMACOL, V43, P820; HERZIG S, 1992, PHARMACOL TOXICOL, V71, P229, DOI 10.1111/j.1600-0773.1992.tb00552.x; HILLE B, 1977, J GEN PHYSIOL, V69, P497, DOI 10.1085/jgp.69.4.497; Hockerman GH, 1997, ANNU REV PHARMACOL, V37, P361, DOI 10.1146/annurev.pharmtox.37.1.361; Huber I, 2000, BIOCHEM J, V347, P829, DOI 10.1042/0264-6021:3470829; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Hunt J T, 1993, Bioorg Med Chem, V1, P59, DOI 10.1016/S0968-0896(00)82134-3; KIMBALL SD, 1992, J MED CHEM, V35, P780, DOI 10.1021/jm00082a020; KING VF, 1988, J BIOL CHEM, V263, P2238; Kraus RL, 1998, J BIOL CHEM, V273, P27205, DOI 10.1074/jbc.273.42.27205; Kurokawa J, 1997, MOL PHARMACOL, V51, P262, DOI 10.1124/mol.51.2.262; Lacinova L, 2005, GEN PHYSIOL BIOPHYS, V24, P3; Lazaridis T, 1999, PROTEINS, V35, P133, DOI 10.1002/(SICI)1097-0134(19990501)35:2<133::AID-PROT1>3.0.CO;2-N; LEE KS, 1983, NATURE, V302, P790, DOI 10.1038/302790a0; Lenaeus MJ, 2005, NAT STRUCT MOL BIOL, V12, P454, DOI 10.1038/nsmb929; LI ZQ, 1987, P NATL ACAD SCI USA, V84, P6611, DOI 10.1073/pnas.84.19.6611; Lipkind GM, 2003, MOL PHARMACOL, V63, P499, DOI 10.1124/mol.63.3.499; Lipkind GM, 2001, BIOCHEMISTRY-US, V40, P6786, DOI 10.1021/bi010269a; Madeja M, 2003, MOL PHARMACOL, V63, P547, DOI 10.1124/mol.63.3.547; MCCLESKEY EW, 1985, P NATL ACAD SCI USA, V82, P7149, DOI 10.1073/pnas.82.20.7149; NAGIWARA M, 2003, EUR J PHARMACOL, V466, P63; Periole X, 2007, J AM CHEM SOC, V129, P10126, DOI 10.1021/ja0706246; Rossokhin A, 2006, MOL PHARMACOL, V69, P1356, DOI 10.1124/mol.105.017970; Saiz L, 2002, ACCOUNTS CHEM RES, V35, P482, DOI 10.1021/ar010167c; SEYDL K, 1993, PFLUG ARCH EUR J PHY, V424, P552, DOI 10.1007/BF00374922; Shi CZ, 2002, J BIOL CHEM, V277, P6813, DOI 10.1074/jbc.M110524200; Tikhonov DB, 2005, BIOPHYS J, V88, P184, DOI 10.1529/biophysj.104.048173; Tikhonov DB, 2007, BIOPHYS J, V93, P1557, DOI 10.1529/biophysj.106.100248; Tikhonov DB, 2006, FEBS LETT, V580, P6027, DOI 10.1016/j.febslet.2006.10.035; UEHARA A, 1985, J GEN PHYSIOL, V85, P621, DOI 10.1085/jgp.85.5.621; Webster SM, 2004, NATURE, V428, P864, DOI 10.1038/nature02468; WEINER SJ, 1986, J COMPUT CHEM, V7, P230, DOI 10.1002/jcc.540070216; WEINER SJ, 1984, J AM CHEM SOC, V106, P765, DOI 10.1021/ja00315a051; YALE HL, 1959, J MED PHARMACEUT CH, V1, P121, DOI 10.1021/jm50003a001; Yamaguchi S, 2003, MOL PHARMACOL, V64, P235, DOI 10.1124/mol.64.2.235; Zhorov BS, 2004, J NEUROCHEM, V88, P782, DOI 10.1111/j.1471-4159.2004.02261.x; ZHOROV BS, 1981, J STRUCT CHEM+, V22, P4, DOI 10.1007/BF00745970; Zhorov BS, 2001, ARCH BIOCHEM BIOPHYS, V393, P22, DOI 10.1006/abbi.2001.2484; Zhou M, 2004, J MOL BIOL, V338, P839, DOI 10.1016/j.jmb.2004.03.020; Zhou M, 2001, NATURE, V411, P657, DOI 10.1038/35079500	61	46	47	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17594	17604		10.1074/jbc.M800141200	http://dx.doi.org/10.1074/jbc.M800141200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18397890	hybrid			2022-12-25	WOS:000256720600066
J	Glauser, G; Grata, E; Dubugnon, L; Rudaz, S; Farmer, EE; Wolfender, JL				Glauser, Gaetan; Grata, Elia; Dubugnon, Lucie; Rudaz, Serge; Farmer, Edward E.; Wolfender, Jean-Luc			Spatial and temporal dynamics of jasmonate synthesis and accumulation in Arabidopsis in response to wounding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							METHYL JASMONATE; OXYLIPIN SIGNAL; MALE-STERILE; ACID; BIOSYNTHESIS; PATHWAY; PLANTS; RESISTANCE; TRANSPORT; THALIANA	A new metabolite profiling approach combined with an ultrarapid sample preparation procedure was used to study the temporal and spatial dynamics of the wound-induced accumulation of jasmonic acid (JA) and its oxygenated derivatives in Arabidopsis thaliana. In addition to well known jasmonates, including hydroxyjasmonates (HOJAs), jasmonoyl-isoleucine (JA-Ile), and its 12-hydroxy derivative (12-HOJA-Ile), a new wound-induced dicarboxyjasmonate, 12-carboxyjasmonoyl-L-isoleucine (12-HOOCJA-Ile) was discovered. HOJAs and 12-HOOCJA-Ile were enriched in the midveins of wounded leaves, strongly differentiating them from the other jasmonate metabolites studied. The polarity of these oxylipins at physiological pH correlated with their appearance in midveins. When the time points of accumulation of different jasmonates were determined, JA levels were found to increase within 2-5 min of wounding. Remarkably, these changes occurred throughout the plant and were not restricted to wounded leaves. The speed of the stimulus leading to JA accumulation in leaves distal to a wound is at least 3 cm/min. The data give new insights into the spatial and temporal accumulation of jasmonates and have implications in the understanding of long-distance wound signaling in plants.	[Dubugnon, Lucie; Farmer, Edward E.] Univ Lausanne, CH-1015 Lausanne, Switzerland; [Glauser, Gaetan; Grata, Elia; Wolfender, Jean-Luc] Univ Lausanne, Univ Geneva, Lab Pharmacognosy & Phytochem, Sch Pharmaceut Sci, CH-1211 Geneva 4, Switzerland; [Glauser, Gaetan; Grata, Elia; Rudaz, Serge] Univ Lausanne, Univ Geneva, Lab Pharmaceut Analyt Chem, Sch Pharmaceut Sci, CH-1211 Geneva 4, Switzerland	University of Lausanne; University of Geneva; University of Lausanne; University of Geneva; University of Lausanne	Farmer, EE (corresponding author), Univ Lausanne, CH-1015 Lausanne, Switzerland.	edward.farmer@unil.ch	Farmer, Edward E/H-1635-2011; Glauser, Gaetan/K-7574-2017; Jean-Luc, Wolfender JLW/O-2163-2018; Jean-Luc, Wolfender JLW/EWV-1043-2022; Rudaz, Serge/AAB-2861-2021	Glauser, Gaetan/0000-0002-0983-8614; Jean-Luc, Wolfender JLW/0000-0002-0125-952X; Jean-Luc, Wolfender JLW/0000-0002-0125-952X; Rudaz, Serge/0000-0002-4180-5417				Browse J, 2005, VITAM HORM, V72, P431, DOI 10.1016/S0083-6729(05)72012-4; FEYS BJF, 1994, PLANT CELL, V6, P751, DOI 10.1105/tpc.6.5.751; FISHER DB, 1990, PLANT PHYSIOL, V94, P455, DOI 10.1104/pp.94.2.455; Gfeller A, 2004, SCIENCE, V306, P1515, DOI 10.1126/science.1104352; Gidda SK, 2003, J BIOL CHEM, V278, P17895, DOI 10.1074/jbc.M211943200; Glauser G, 2008, J CHROMATOGR A, V1180, P90, DOI 10.1016/j.chroma.2007.12.021; Gottlieb HE, 1997, J ORG CHEM, V62, P7512, DOI 10.1021/jo971176v; Grata E, 2007, J SEP SCI, V30, P2268, DOI 10.1002/jssc.200700143; Guranowski A, 2007, FEBS LETT, V581, P815, DOI 10.1016/j.febslet.2007.01.049; HELDER H, 1993, PHYSIOL PLANTARUM, V88, P647, DOI 10.1111/j.1399-3054.1993.tb01384.x; Holbrook L, 1997, PLANT PHYSIOL, V114, P419, DOI 10.1104/pp.114.2.419; Koch T, 1997, HELV CHIM ACTA, V80, P838, DOI 10.1002/hlca.19970800318; Li CY, 2005, PLANT CELL, V17, P971, DOI 10.1105/tpc.104.029108; Mandaokar A, 2006, PLANT J, V46, P984, DOI 10.1111/j.1365-313X.2006.02756.x; Miersch O, 1999, PHYTOCHEMISTRY, V50, P1147, DOI 10.1016/S0031-9422(98)00698-0; Miersch O, 2008, NEW PHYTOL, V177, P114, DOI 10.1111/j.1469-8137.2007.02252.x; Mueller MJ, 2006, PLANT J, V45, P472, DOI 10.1111/j.1365-313X.2005.02614.x; Olson DL, 2004, ANAL CHEM, V76, P2966, DOI 10.1021/ac035426l; Reymond P, 2004, PLANT CELL, V16, P3132, DOI 10.1105/tpc.104.026120; Reymond P, 2000, PLANT CELL, V12, P707, DOI 10.1105/tpc.12.5.707; Schilmiller AL, 2005, CURR OPIN PLANT BIOL, V8, P369, DOI 10.1016/j.pbi.2005.05.008; Staswick PE, 2004, PLANT CELL, V16, P2117, DOI 10.1105/tpc.104.023549; Stintzi A, 2000, P NATL ACAD SCI USA, V97, P10625, DOI 10.1073/pnas.190264497; Swiatek A, 2004, PLANT PHYSIOL, V135, P161, DOI 10.1104/pp.104.040501; Thorpe MR, 2007, PLANTA, V226, P541, DOI 10.1007/s00425-007-0503-5; Turner JG, 2002, PLANT CELL, V14, pS153, DOI 10.1105/tpc.000679; Walters DR, 2006, ANN BOT-LONDON, V97, P779, DOI 10.1093/aob/mcl034; Wasternack C, 2007, ANN BOT-LONDON, V100, P681, DOI 10.1093/aob/mcm079; Weber H, 1997, P NATL ACAD SCI USA, V94, P10473, DOI 10.1073/pnas.94.19.10473; Yan YX, 2007, PLANT CELL, V19, P2470, DOI 10.1105/tpc.107.050708	30	242	246	3	65	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16400	16407		10.1074/jbc.M801760200	http://dx.doi.org/10.1074/jbc.M801760200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18400744	hybrid			2022-12-25	WOS:000256497100016
J	Martayan, A; Sibilio, L; Setini, A; Lo Monaco, E; Tremante, E; Fruci, D; Colonna, M; Giacomini, P				Martayan, Aline; Sibilio, Leonardo; Setini, Andrea; Lo Monaco, Elisa; Tremante, Elisa; Fruci, Doriana; Colonna, Marco; Giacomini, Patrizio			N-linked glycosylation selectively regulates the generic folding of HLA-Cw1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-I; SITE-DIRECTED MUTAGENESIS; PEPTIDE-LOADING COMPLEX; ANTIGEN-PROCESSING TAP; SURFACE EXPRESSION; HEAVY-CHAINS; CELL-RECEPTOR; MOLECULES; CALRETICULIN; CALNEXIN	To resolve primary (glycosylation- assisted) from secondary (glycosylation- independent) quality control steps in the biosynthesis of HLA (human leukocyte antigen) class I glycoproteins, the unique N-linked glycosylation site of the HLA-Cw1 heavy chain was deleted by site-directed mutagenesis. The non-glycosylated Cw1S88G mutant was characterized by flow cytometry, pulse-chase, co-immunoprecipitation, and in vitro assembly assays with synthetic peptide ligands upon transfection in 721.221 and 721.220 cells. The former provide a full set of primary as well as secondary chaperoning interactions, whereas the latter are unable to perform secondary quality control (e. g. proper class I assembly with peptide antigens) as a result of a functional defect of the HLA-dedicated chaperone tapasin. In both transfectants, Cw1S88G displayed a loss/weakening in its generic chaperoning interaction with calreticulin and/or ERp57 and became redistributed toward calnexin, known to bind the most unfolded class I conformers. Despite this, and quite unexpectedly, a weak interaction with the HLA-dedicated chaperone TAP was selectively retained in 721.221. In addition, the ordered, stepwise acquisition of thermal stability/peptide binding was disrupted, resulting in a heterogeneous ensemble of Cw1S88G conformers with unorthodox and unprecedented peptide assembly features. Because a lack of glycosylation and a lack of tapasin-assisted peptide loading have distinct, complementary, and additive effects, the former is separable from (and upstream of) the latter, e. g. primary quality control is suggested to supervise a crucial, generic folding step preliminary to the acquisition of peptide receptivity.	[Martayan, Aline; Sibilio, Leonardo; Setini, Andrea; Lo Monaco, Elisa; Tremante, Elisa; Giacomini, Patrizio] Regina Elena Natl Canc Res Inst, Immunol Lab, Ctr Ric Sperimentale, I-00158 Rome, Italy; [Fruci, Doriana] Res Ctr Osped Pediat Bambino Gesu, I-00165 Rome, Italy; [Colonna, Marco] Washington Univ, Sch Med, Dept Pathol & Immunol, St Louis, MO 63110 USA	IRCCS Bambino Gesu; Washington University (WUSTL)	Giacomini, P (corresponding author), Regina Elena Natl Canc Res Inst, Immunol Lab, Ctr Ric Sperimentale, Via Messi Oro 156, I-00158 Rome, Italy.	giacomini@ifo.it	Fruci, Doriana/AAA-8218-2019; Giacomini, Patrizio/K-5217-2016; Tremante, Elisa/K-5288-2018	Fruci, Doriana/0000-0003-3388-7296; Giacomini, Patrizio/0000-0001-6109-1709; Tremante, Elisa/0000-0002-8584-9913; Colonna, Marco/0000-0001-5222-4987; SETINI, Andrea/0000-0001-8098-6671	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		Baba E, 2000, HUM IMMUNOL, V61, P1202, DOI 10.1016/S0198-8859(00)00184-1; BARBOSA JA, 1987, J EXP MED, V166, P1329, DOI 10.1084/jem.166.5.1329; BIX M, 1992, J EXP MED, V176, P829, DOI 10.1084/jem.176.3.829; BRODSKY FM, 1979, IMMUNOL REV, V47, P3, DOI 10.1111/j.1600-065X.1979.tb00288.x; Cresswell P, 2005, IMMUNOL REV, V207, P145, DOI 10.1111/j.0105-2896.2005.00316.x; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DENG WP, 1992, ANAL BIOCHEM, V200, P81, DOI 10.1016/0003-2697(92)90280-K; Ford S, 2004, J BIOL CHEM, V279, P16077, DOI 10.1074/jbc.M400456200; Gao B, 2002, IMMUNITY, V16, P99, DOI 10.1016/S1074-7613(01)00260-6; GREENWOOD R, 1994, J IMMUNOL, V153, P5525; GUSSOW D, 1987, IMMUNOGENETICS, V25, P313, DOI 10.1007/BF00404424; Harris MR, 1998, J IMMUNOL, V160, P5404; Harris MR, 2001, J IMMUNOL, V166, P6686, DOI 10.4049/jimmunol.166.11.6686; Harris MR, 2001, INT IMMUNOL, V13, P1275, DOI 10.1093/intimm/13.10.1275; Helenius A, 2001, SCIENCE, V291, P2364, DOI 10.1126/science.291.5512.2364; Lee N, 1998, J IMMUNOL, V160, P4951; Lewis JW, 1996, CURR BIOL, V6, P873, DOI 10.1016/S0960-9822(02)00611-5; Lian RH, 1998, J IMMUNOL, V161, P2301; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; Matsumoto N, 1998, IMMUNITY, V8, P245, DOI 10.1016/S1074-7613(00)80476-8; MIZUNO S, 1989, IMMUNOGENETICS, V29, P323, DOI 10.1007/BF00352842; Neisig A, 1996, J IMMUNOL, V156, P3196; ORTMANN B, 1994, NATURE, V368, P864, DOI 10.1038/368864a0; Park B, 2006, CELL, V127, P369, DOI 10.1016/j.cell.2006.08.041; Radcliffe CM, 2002, J BIOL CHEM, V277, P46415, DOI 10.1074/jbc.M202466200; RAJAGOPALAN S, 1994, J EXP MED, V180, P407, DOI 10.1084/jem.180.1.407; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; SANTOSAGUADO J, 1987, MOL CELL BIOL, V7, P982, DOI 10.1128/MCB.7.3.982; Schoenhals GJ, 1999, EMBO J, V18, P743, DOI 10.1093/emboj/18.3.743; SCOTT JE, 1995, J IMMUNOL, V155, P143; Setini A, 1996, HUM IMMUNOL, V46, P69, DOI 10.1016/0198-8859(96)00011-0; SHIMIZU Y, 1988, P NATL ACAD SCI USA, V85, P227, DOI 10.1073/pnas.85.1.227; SHIROISHI T, 1985, J IMMUNOL, V134, P623; Sibilio L, 2005, J IMMUNOL, V175, P6651, DOI 10.4049/jimmunol.175.10.6651; Sibilio L, 2008, J BIOL CHEM, V283, P1267, DOI 10.1074/jbc.M708068200; Solheim JC, 1997, J IMMUNOL, V158, P541; Solheim JC, 1997, J IMMUNOL, V158, P2236; VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997; Vassilakos A, 1996, EMBO J, V15, P1495, DOI 10.1002/j.1460-2075.1996.tb00493.x; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	40	6	6	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16469	16476		10.1074/jbc.M709175200	http://dx.doi.org/10.1074/jbc.M709175200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18420581	hybrid			2022-12-25	WOS:000256497100023
J	Singh, K; Chaturvedi, R; Asim, M; Barry, DP; Lewis, ND; Vitek, MP; Wilson, KT				Singh, Kshipra; Chaturvedi, Rupesh; Asim, Mohammad; Barry, Daniel P.; Lewis, Nuruddeen D.; Vitek, Michael P.; Wilson, Keith T.			The apolipoprotein E-mimetic peptide COG112 inhibits the inflammatory response to Citrobacter rodentium in colonic epithelial cells by preventing NF-kappa B activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENTEROPATHOGENIC ESCHERICHIA-COLI; INNATE IMMUNE-RESPONSE; BOWEL-DISEASE; HELICOBACTER-PYLORI; NITRIC-OXIDE; PROINFLAMMATORY CYTOKINES; MURINE MODEL; MACROPHAGE APOPTOSIS; ULCERATIVE-COLITIS; KINASE-ACTIVITY	Inflammatory bowel disease arises from the interplay between luminal bacteria and the colonic mucosa. Targeted inhibition of pro-inflammatory pathways without global immunosuppression is highly desirable. Apolipoprotein (apo) E has immunomodulatory effects and synthetically derived apoE-mimetic peptides are beneficial in models of sepsis and neuroinflammation. Citrobacter rodentium is the rodent equivalent of enteropathogenic Escherichia coli, and it causes colitis in mice by colonizing the surface of colonic epithelial cells and inducing signaling events. We have reported that mice deficient in inducible nitric-oxide (NO) synthase (iNOS) have attenuated C. rodentium-induced colitis. We used young adult mouse colon (YAMC) cells that mimic primary colonic epithelial cells to study effects of an antennapedia-linked apoE-mimetic peptide, COG112, on C. rodentium-activated cells. COG112 significantly attenuated induction of NO production, and iNOS mRNA and protein expression, in a concentration-dependent manner. COG112 inhibited the C. rodentium-stimulated induction of iNOS and the CXC chemokines KC and MIP-2 to the same degree as the NF-kappa B inhibitors MG132 or BAY 11-7082, and there was no additive effect when COG112 and these inhibitors were combined. COG112 significantly reduced nuclear translocation of NF-kappa B, when assessed by electromobility shift assay, immunoblotting, and immunofluorescence for p65. This correlated with inhibition of both C. rodentium-stimulated I kappa B-alpha phosphorylation and degradation, and I kappa B kinase activity, which occurred by inhibition of I kappa B kinase complex formation rather than by a direct effect on the enzyme itself. These studies indicate that apoE-mimetic peptides may have novel therapeutic potential by inhibiting NF-kappa B-driven proinflammatory epithelial responses to pathogenic colonic bacteria.	[Singh, Kshipra; Chaturvedi, Rupesh; Asim, Mohammad; Barry, Daniel P.; Lewis, Nuruddeen D.; Wilson, Keith T.] Vanderbilt Univ, Sch Med, Dept Med, Div Gastroenterol, Nashville, TN 37232 USA; [Lewis, Nuruddeen D.; Wilson, Keith T.] Vanderbilt Univ, Sch Med, Dept Canc Biol, Nashville, TN 37232 USA; [Singh, Kshipra; Chaturvedi, Rupesh; Asim, Mohammad; Barry, Daniel P.; Wilson, Keith T.] Vet Affairs Tennesse Valley Healthcare Syst, Nashville, TN 37212 USA; [Vitek, Michael P.] Cognosci Inc, Res Triangle Pk, NC 27709 USA	Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Wilson, KT (corresponding author), Vanderbilt Univ, Sch Med, Dept Med, Div Gastroenterol, 1030C MRB 4,2215B Garland Ave, Nashville, TN 37232 USA.	keith.wilson@vanderbilt.edu	Barry, Daniel P/B-5647-2008	Barry, Daniel P/0000-0002-3972-3914; Lewis, Nuruddeen/0000-0002-1233-6607; Wilson, Keith/0000-0003-4421-1830; Vitek, Michael/0000-0001-8140-8048	NCI NIH HHS [T32 CA009592] Funding Source: Medline; NIDDK NIH HHS [R41 DK075161, R01 DK053620, P30 DK058404] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009592] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK058404, R01DK053620, R41DK075161] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; Bussiere FI, 2005, J BIOL CHEM, V280, P2409, DOI 10.1074/jbc.C400498200; Chaturvedi R, 2004, J BIOL CHEM, V279, P40161, DOI 10.1074/jbc.M401370200; Chaturvedi R, 2007, INFECT IMMUN, V75, P4305, DOI 10.1128/IAI.00578-07; Cheng Y, 2005, J BIOL CHEM, V280, P22492, DOI 10.1074/jbc.C500122200; CHIAO PJ, 1994, P NATL ACAD SCI USA, V91, P28, DOI 10.1073/pnas.91.1.28; Clark M, 2007, GASTROENTEROLOGY, V133, P312, DOI 10.1053/j.gastro.2007.05.006; Cross RK, 2003, INFLAMM BOWEL DIS, V9, P179, DOI 10.1097/00054725-200305000-00006; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Elewaut D, 1999, J IMMUNOL, V163, P1457; Fichtner-Feigl S, 2005, J CLIN INVEST, V115, P3057, DOI 10.1172/JCI24792; Fukata M, 2005, AM J PHYSIOL-GASTR L, V288, pG1055, DOI 10.1152/ajpgi.00328.2004; Ghosh S, 2002, CELL, V109, pS81, DOI 10.1016/S0092-8674(02)00703-1; Gobert AP, 2004, J IMMUNOL, V173, P2109, DOI 10.4049/jimmunol.173.3.2109; Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; Higgins LM, 1999, SCIENCE, V285, P588, DOI 10.1126/science.285.5427.588; Higgins LM, 1999, INFECT IMMUN, V67, P3031, DOI 10.1128/IAI.67.6.3031-3039.1999; Jijon H, 2004, CELL SIGNAL, V16, P1023, DOI 10.1016/j.cellsig.2004.02.005; Jobin C, 1999, J IMMUNOL, V163, P3474; JUNG HC, 1995, J CLIN INVEST, V95, P55, DOI 10.1172/JCI117676; Kamthong PJ, 2001, BIOCHEM J, V356, P525, DOI 10.1042/0264-6021:3560525; Khan MA, 2006, INFECT IMMUN, V74, P2522, DOI 10.1128/IAI.74.5.2522-2536.2006; KOPP E, 1994, SCIENCE, V265, P956, DOI 10.1126/science.8052854; Kundu JK, 2006, CARCINOGENESIS, V27, P1465, DOI 10.1093/carcin/bgi349; Laskowitz DT, 2007, J NEUROTRAUM, V24, P1093, DOI 10.1089/neu.2006.0192; Laskowitz DT, 2000, J LIPID RES, V41, P613; Laskowitz DT, 2001, EXP NEUROL, V167, P74, DOI 10.1006/exnr.2001.7541; Li FQ, 2006, J PHARMACOL EXP THER, V318, P956, DOI 10.1124/jpet.106.103671; Loftus CG, 2007, INFLAMM BOWEL DIS, V13, P254, DOI 10.1002/ibd.20029; Luperchio SA, 2001, MICROBES INFECT, V3, P333, DOI 10.1016/S1286-4579(01)01387-9; Lynch JR, 2003, J BIOL CHEM, V278, P48529, DOI 10.1074/jbc.M306923200; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Pierce JW, 1997, J BIOL CHEM, V272, P21096, DOI 10.1074/jbc.272.34.21096; Podolin PL, 2005, J PHARMACOL EXP THER, V312, P373, DOI 10.1124/jpet.104.074484; Rothwarf DM, 1998, NATURE, V395, P297, DOI 10.1038/26261; Sartor RB, 2006, NAT CLIN PRACT GASTR, V3, P390, DOI 10.1038/ncpgasthep0528; Savkovic SD, 2003, AM J PHYSIOL-CELL PH, V285, pC512, DOI 10.1152/ajpcell.00444.2002; Savkovic SD, 1997, AM J PHYSIOL-CELL PH, V273, pC1160, DOI 10.1152/ajpcell.1997.273.4.C1160; SCHAUER DB, 1995, J CLIN MICROBIOL, V33, P2064, DOI 10.1128/JCM.33.8.2064-2068.1995; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; Tebo JM, 2000, J BIOL CHEM, V275, P12987, DOI 10.1074/jbc.275.17.12987; Vallance BA, 2002, INFECT IMMUN, V70, P6424, DOI 10.1128/IAI.70.11.6424-6435.2002; Van Oosten MV, 2001, J BIOL CHEM, V276, P8820, DOI 10.1074/jbc.M009915200; Wahl C, 1998, J CLIN INVEST, V101, P1163, DOI 10.1172/JCI992; Wang Y, 2006, BRIT J PHARMACOL, V148, P814, DOI 10.1038/sj.bjp.0706784; WHITEHEAD RH, 1993, P NATL ACAD SCI USA, V90, P587, DOI 10.1073/pnas.90.2.587; WIDMER U, 1993, J IMMUNOL, V150, P4996; Xiao H, 2007, IMMUNITY, V26, P461, DOI 10.1016/j.immuni.2007.02.012; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7	51	45	50	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16752	16761		10.1074/jbc.M710530200	http://dx.doi.org/10.1074/jbc.M710530200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18417477	Green Published, hybrid			2022-12-25	WOS:000256497100052
J	Ross, HR; Napier, I; Connor, M				Ross, Hamish Redmond; Napier, Ian; Connor, Mark			Inhibition of recombinant human T-type calcium channels by Delta(9)-Tetrahydrocannabinol and cannabidiol	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONS IN-VITRO; CANNABINOID RECEPTOR; FUNCTIONAL EXPRESSION; CA2+ CHANNELS; CB1; MARIJUANA; THC; CLONING; CELLS; SLEEP	Delta(9)-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are the most prevalent biologically active constituents of Cannabis sativa. THC is the prototypic cannabinoid CB1 receptor agonist and is psychoactive and analgesic. CBD is also analgesic, but it is not a CB1 receptor agonist. Low voltage-activated T-type calcium channels, encoded by the Ca(V)3 gene family, regulate the excitability of many cells, including neurons involved in nociceptive processing. We examined the effects of THC and CBD on human CaV3 channels stably expressed in human embryonic kidney 293 cells and T-type channels in mouse sensory neurons using whole-cell, patch clamp recordings. At moderately hyperpolarized potentials, THC and CBD inhibited peak Ca(V)3.1 and Ca(V)3.2 currents with IC50 values of similar to 1 mu M but were less potent on Ca(V)3.3 channels. THC and CBD inhibited sensory neuron T-type channels by about 45% at 1 mu M. However, in recordings made from a holding potential of -70 mV, 100 nM THC or CBD inhibited more than 50% of the peak Ca(V)3.1 current. THC and CBD produced a significant hyperpolarizing shift in the steady state inactivation potentials for each of the Ca(V)3 channels, which accounts for inhibition of channel currents. Additionally, THC caused a modest hyperpolarizing shift in the activation of Ca(V)3.1 and Ca(V)3.2. THC but not CBD slowed Ca(V)3.1 and Ca(V)3.2 deactivation and inactivation kinetics. Thus, THC and CBD inhibit Ca(V)3 channels at pharmacologically relevant concentrations. However, THC, but not CBD, may also increase the amount of calcium entry following T-type channel activation by stabilizing open states of the channel.	[Ross, Hamish Redmond; Napier, Ian; Connor, Mark] Univ Sydney, Royal N Shore Hosp, Pain Management Res Inst, Kolling Inst, St Leonards, NSW 2065, Australia	Royal North Shore Hospital; University of Sydney; Kolling Institute of Medical Research	Connor, M (corresponding author), Univ Sydney, Royal N Shore Hosp, Pain Management Res Inst, Kolling Inst, Level 5,Main Block, St Leonards, NSW 2065, Australia.	markc@med.usyd.edu.au	Connor, Mark/A-4197-2008; Ritter, Stefanie L/D-9312-2012	Connor, Mark/0000-0003-2538-2001; 				Anderson MP, 2005, P NATL ACAD SCI USA, V102, P1743, DOI 10.1073/pnas.0409644102; Barann M, 2002, BRIT J PHARMACOL, V137, P589, DOI 10.1038/sj.bjp.0704829; Bisogno T, 2001, BRIT J PHARMACOL, V134, P845, DOI 10.1038/sj.bjp.0704327; Borgland SL, 2001, J PHYSIOL-LONDON, V536, P35, DOI 10.1111/j.1469-7793.2001.t01-1-00035.x; Bourinet E, 2005, EMBO J, V24, P315, DOI 10.1038/sj.emboj.7600515; Brunet B, 2006, FORENSIC SCI INT, V161, P169, DOI 10.1016/j.forsciint.2006.04.018; CAULFIELD MP, 1992, BRIT J PHARMACOL, V106, P231, DOI 10.1111/j.1476-5381.1992.tb14321.x; Chemin J, 2001, EMBO J, V20, P7033, DOI 10.1093/emboj/20.24.7033; Clark AJ, 2004, NEUROLOGY, V62, P2098, DOI 10.1212/01.WNL.0000127707.07621.72; COMPTON DR, 1992, J PHARMACOL EXP THER, V260, P201; Costa B, 2007, EUR J PHARMACOL, V556, P75, DOI 10.1016/j.ejphar.2006.11.006; Cribbs LL, 2000, FEBS LETT, V466, P54, DOI 10.1016/S0014-5793(99)01756-1; Cribbs LL, 1998, CIRC RES, V83, P103, DOI 10.1161/01.RES.83.1.103; ElSohly MA, 2005, LIFE SCI, V78, P539, DOI 10.1016/j.lfs.2005.09.011; Engels FK, 2007, EUR J CANCER, V43, P2638, DOI 10.1016/j.ejca.2007.09.010; FEINBERG I, 1976, CLIN PHARMACOL THER, V19, P782; GAONI Y, 1964, J AM CHEM SOC, V86, P1646, DOI 10.1021/ja01062a046; Gomora JC, 2002, BIOPHYS J, V83, P229, DOI 10.1016/S0006-3495(02)75164-3; Gorter RW, 2005, NEUROLOGY, V64, P917, DOI 10.1212/01.WNL.0000152845.09088.28; Gross DW, 2004, NEUROLOGY, V62, P2095, DOI 10.1212/01.WNL.0000127623.03766.75; Hall W, 2000, AUST NZ J PUBL HEAL, V24, P503, DOI 10.1111/j.1467-842X.2000.tb00500.x; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Heady TN, 2001, JPN J PHARMACOL, V85, P339, DOI 10.1254/jjp.85.339; Huestis MA, 2004, J ANAL TOXICOL, V28, P394, DOI 10.1093/jat/28.6.394; Jarai Z, 1999, P NATL ACAD SCI USA, V96, P14136, DOI 10.1073/pnas.96.24.14136; Jordt SE, 2004, NATURE, V427, P260, DOI 10.1038/nature02282; KARLER R, 1974, LIFE SCI, V15, P931, DOI 10.1016/0024-3205(74)90009-5; Kim D, 2003, SCIENCE, V302, P117, DOI 10.1126/science.1088886; Lan RX, 1999, J MED CHEM, V42, P769, DOI 10.1021/jm980363y; LEMBERGER L, 1980, ANNU REV PHARMACOL, V20, P151, DOI 10.1146/annurev.pa.20.040180.001055; MATSUDA LA, 1990, NATURE, V346, P561, DOI 10.1038/346561a0; MUNRO S, 1993, NATURE, V365, P61, DOI 10.1038/365061a0; Mura P, 2005, J ANAL TOXICOL, V29, P842, DOI 10.1093/jat/29.8.842; Murillo-Rodriguez E, 2006, FEBS LETT, V580, P4337, DOI 10.1016/j.febslet.2006.04.102; Neeper MP, 2007, J BIOL CHEM, V282, P15894, DOI 10.1074/jbc.M608287200; Perez-Reyes E, 2003, PHYSIOL REV, V83, P117, DOI 10.1152/physrev.00018.2002; PEREZREYES M, 1973, EXPERIENTIA, V29, P1368, DOI 10.1007/BF01922823; Pertwee RG, 2008, BRIT J PHARMACOL, V153, P199, DOI 10.1038/sj.bjp.0707442; PETRZILKA T, 1969, HELV CHIM ACTA, V52, P1102, DOI 10.1002/hlca.19690520427; Roberts LA, 2008, NEUROPHARMACOLOGY, V54, P172, DOI 10.1016/j.neuropharm.2007.05.024; Ryberg E, 2007, BRIT J PHARMACOL, V152, P1092, DOI 10.1038/sj.bjp.0707460; Tao Q, 1998, J PHARMACOL EXP THER, V285, P651; Tarabova B, 2006, J PHARMACOL EXP THER, V317, P418, DOI 10.1124/jpet.105.095463; Teesson M, 2006, DRUG ALCOHOL DEPEN, V81, P149, DOI 10.1016/j.drugalcdep.2005.06.007; Thomas A, 2007, BRIT J PHARMACOL, V150, P613, DOI 10.1038/sj.bjp.0707133; Todorovic SM, 2001, NEURON, V31, P75, DOI 10.1016/S0896-6273(01)00338-5; Traboulsie A, 2007, J PHYSIOL-LONDON, V578, P159, DOI 10.1113/jphysiol.2006.114496; TSAKIRIDOU E, 1995, J NEUROSCI, V15, P3110, DOI 10.1523/jneurosci.15-04-03110.1995; Varvel SA, 2006, PSYCHOPHARMACOLOGY, V186, P226, DOI 10.1007/s00213-006-0356-9; Varvel SA, 2005, J PHARMACOL EXP THER, V314, P329, DOI 10.1124/jpet.104.080739; Vaughan CW, 2000, MOL PHARMACOL, V57, P288; Ware MA, 2003, PAIN, V102, P211, DOI 10.1016/S0304-3959(02)00400-1; Zimmer A, 1999, P NATL ACAD SCI USA, V96, P5780, DOI 10.1073/pnas.96.10.5780	53	110	111	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16124	16134		10.1074/jbc.M707104200	http://dx.doi.org/10.1074/jbc.M707104200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18390906	hybrid, Green Published			2022-12-25	WOS:000256332500071
J	Byon, CH; Javed, A; Dai, Q; Kappes, JC; Clemens, TL; Darley-Usmar, VM; McDonald, JM; Chen, YB				Byon, Chang Hyun; Javed, Amjad; Dai, Qun; Kappes, John C.; Clemens, Thomas L.; Darley-Usmar, Victor M.; McDonald, Jay M.; Chen, Yabing			Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE-CELLS; LOW-DENSITY-LIPOPROTEIN; PROMOTING OSTEOBLASTIC DIFFERENTIATION; ACTIVATOR INHIBITOR TYPE-1; GROWTH-FACTOR-I; HYDROGEN-PEROXIDE; ALKALINE-PHOSPHATASE; ENDOTHELIAL FUNCTION; REGULATES RUNX2; EMERGING ROLE	Oxidative stress plays a critical role in the pathogenesis of atherosclerosis including the formation of lipid laden macrophages and the development of inflammation. However, oxidative stress-induced molecular signaling that regulates the development of vascular calcification has not been investigated in depth. Osteogenic differentiation of vascular smooth muscle cells (VSMC) is critical in the development of calcification in atherosclerotic lesions. An important contributor to oxidative stress in atherosclerotic lesions is the formation of hydrogen peroxide from diverse sources in vascular cells. In this study we defined molecular signaling that is operative in the H2O2-induced VSMC calcification. We found that H2O2 promotes a phenotypic switch of VSMC from contractile to osteogenic phenotype. This response was associated with an increased expression and transactivity of Runx2, a key transcription factor for osteogenic differentiation. The essential role of Runx2 in oxidative stress-induced VSMC calcification was further confirmed by Runx2 depletion and overexpression. Inhibition of Runx2 using short hairpin RNA blocked VSMC calcification, and adenovirus-mediated overexpression of Runx2 alone induced VSMC calcification. Inhibition of H2O2-activated AKT signaling blocked VSMC calcification and Runx2 induction concurrently. This blockage did not cause VSMC apoptosis. Taken together, our data demonstrate a critical role for AKT-mediated induction of Runx2 in oxidative stress-induced VSMC calcification.	[Byon, Chang Hyun] Univ Alabama Birmingham, Dept Cell Biol, Birmingham, AL 35294 USA; [Dai, Qun; Kappes, John C.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA; [Kappes, John C.; Clemens, Thomas L.; Darley-Usmar, Victor M.; McDonald, Jay M.; Chen, Yabing] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA; [Javed, Amjad] Univ Alabama Birmingham, Inst Oral Res, Birmingham, AL 35294 USA; [Javed, Amjad; Clemens, Thomas L.; McDonald, Jay M.; Chen, Yabing] Univ Alabama Birmingham, Ctr Metab Bone Dis, Birmingham, AL 35294 USA; [Darley-Usmar, Victor M.; Chen, Yabing] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL 35294 USA; [Kappes, John C.; McDonald, Jay M.] Vet Affairs Med Ctr, Res Serv, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA)	Chen, YB (corresponding author), 1530,3rd Ave S,533 LHRB, Birmingham, AL 35294 USA.	ybchen@uab.edu	Darley-Usmar, Victor/F-7656-2010	Javed, Amjad/0000-0002-0847-8266; Darley-Usmar, Victor/0000-0001-8921-7086	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058031] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR046031, R03AR055339] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG030228] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 58031] Funding Source: Medline; NIAMS NIH HHS [P30 AR046031, P30 AR 046031, R03 AR055339] Funding Source: Medline; NIA NIH HHS [R01 AG 030228, R01 AG030228-04, R01 AG030228] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aikawa E, 2007, CIRCULATION, V115, P377, DOI 10.1161/CIRCULATIONAHA.106.654913; Arai M, 2007, IUBMB LIFE, V59, P27, DOI 10.1080/15216540601156188; Ardanaz N, 2006, EXP BIOL MED, V231, P237; BANKS LM, 1994, EUR J CLIN INVEST, V24, P813, DOI 10.1111/j.1365-2362.1994.tb02024.x; BOSTROM K, 1995, AM J CARDIOL, V75, pB88, DOI 10.1016/0002-9149(95)80020-S; Cai H, 2005, CARDIOVASC RES, V68, P26, DOI 10.1016/j.cardiores.2005.06.021; CAREW TE, 1987, P NATL ACAD SCI USA, V84, P7725, DOI 10.1073/pnas.84.21.7725; Chen NX, 2006, KIDNEY INT, V70, P1046, DOI 10.1038/sj.ki.5001663; Chen YB, 2006, AM J PATHOL, V169, P1833, DOI 10.2353/ajpath.2006.060234; Chen YB, 2006, ARTERIOSCL THROM VAS, V26, P1777, DOI 10.1161/01.ATV.0000227514.50065.2a; Chen YB, 2004, J CELL BIOCHEM, V92, P178, DOI 10.1002/jcb.20058; Chen YB, 2000, ARTERIOSCL THROM VAS, V20, P2696, DOI 10.1161/01.ATV.20.12.2696; Cheng SL, 2003, J BIOL CHEM, V278, P45969, DOI 10.1074/jbc.M306972200; Clarke M, 2006, AM J NEPHROL, V26, P531, DOI 10.1159/000097815; Collin-Osdoby P, 2004, CIRC RES, V95, P1046, DOI 10.1161/01.RES.0000149165.99974.12; Cool SM, 2005, STEM CELLS DEV, V14, P632, DOI 10.1089/scd.2005.14.632; Cseko C, 2004, J APPL PHYSIOL, V97, P1130, DOI 10.1152/japplphysiol.00106.2004; Davies JD, 2005, J BIOL CHEM, V280, P3911, DOI 10.1074/jbc.M410075200; DUCY P, 1995, MOL CELL BIOL, V15, P1858; Ducy P, 1997, CELL, V89, P747, DOI 10.1016/S0092-8674(00)80257-3; Engelse MA, 2001, CARDIOVASC RES, V52, P281, DOI 10.1016/S0008-6363(01)00375-3; Fernandes R, 2006, MOL VIS, V12, P1526; Fujita T, 2004, J CELL BIOL, V166, P85, DOI 10.1083/jcb.200401138; GALLOP PM, 1980, NEW ENGL J MED, V302, P1460, DOI 10.1056/NEJM198006263022608; Gutierrez J, 2006, CIRC RES, V99, P924, DOI 10.1161/01.RES.0000248212.86638.e9; Hayashi K, 2006, MOL CELL BIOL, V26, P9456, DOI 10.1128/MCB.00759-06; Huang JC, 2004, J BONE MINER RES, V19, P235, DOI 10.1359/JBMR.0301226; Inada M, 1999, DEV DYNAM, V214, P279, DOI 10.1002/(SICI)1097-0177(199904)214:4<279::AID-AJA1>3.0.CO;2-W; Ishida K, 2005, INT J MOL MED, V16, P689; Iyemere VP, 2006, J INTERN MED, V260, P192, DOI 10.1111/j.1365-2796.2006.01692.x; Johnson RC, 2006, CIRC RES, V99, P1044, DOI 10.1161/01.RES.0000249379.55535.21; KEANEY JF, 1995, J CLIN INVEST, V95, P2520, DOI 10.1172/JCI117953; Komori T, 2002, J CELL BIOCHEM, V87, P1, DOI 10.1002/jcb.10276; LaHair MM, 2006, ANTIOXID REDOX SIGN, V8, P1749, DOI 10.1089/ars.2006.8.1749; Lee DH, 2006, CELL BIOL TOXICOL, V22, P39, DOI 10.1007/s10565-006-0018-z; Lee MH, 2005, J BIOL CHEM, V280, P35579, DOI 10.1074/jbc.M502267200; Li WG, 2001, J BIOL CHEM, V276, P29251, DOI 10.1074/jbc.M102124200; Lian JB, 2004, CRIT REV EUKAR GENE, V14, P1; Liberman M, 2008, ARTERIOSCL THROM VAS, V28, P463, DOI 10.1161/ATVBAHA.107.156745; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Miano JM, 2004, P NATL ACAD SCI USA, V101, P17132, DOI 10.1073/pnas.0406041101; Mody N, 2001, FREE RADICAL BIO MED, V31, P509, DOI 10.1016/S0891-5849(01)00610-4; Mori K, 1999, ARTERIOSCL THROM VAS, V19, P2112, DOI 10.1161/01.ATV.19.9.2112; Nakagami H, 2006, HYPERTENSION, V48, P112, DOI 10.1161/01.HYP.0000225426.12101.15; Nakamura A, 2007, BONE, V40, P305, DOI 10.1016/j.bone.2006.09.001; Pagani F, 2005, J Endocrinol Invest, V28, P8; Peng XD, 2003, GENE DEV, V17, P1352, DOI 10.1101/gad.1089403; Proudfoot D, 2002, CIRCULATION, V106, P3044, DOI 10.1161/01.CIR.0000041429.83465.41; Qin SF, 2003, BIOCHEMISTRY-US, V42, P2995, DOI 10.1021/bi0205911; Qu Q, 1998, BONE, V22, P201, DOI 10.1016/S8756-3282(97)00276-7; Radcliff K, 2005, CIRC RES, V96, P398, DOI 10.1161/01.RES.0000157671.47477.71; Rattazzi M, 2005, ARTERIOSCL THROM VAS, V25, P1420, DOI 10.1161/01.ATV.0000166600.58468.1b; Sato M, 2005, ARTERIOSCL THROM VAS, V25, P341, DOI 10.1161/01.ATV.0000152608.29351.8f; Scheidegger KJ, 1997, J BIOL CHEM, V272, P21609, DOI 10.1074/jbc.272.34.21609; SCHMIDT AM, 1995, J CLIN INVEST, V96, P1395, DOI 10.1172/JCI118175; SPRAGUE SM, 1993, AM J PHYSIOL, V264, pF882, DOI 10.1152/ajprenal.1993.264.5.F882; Steitz SA, 2001, CIRC RES, V89, P1147, DOI 10.1161/hh2401.101070; STINSON RA, 1994, CLIN BIOCHEM, V27, P49, DOI 10.1016/0009-9120(94)90011-6; Stocker R, 2004, PHYSIOL REV, V84, P1381, DOI 10.1152/physrev.00047.2003; Tanaka T, 2008, MOL CELL BIOL, V28, P1147, DOI 10.1128/MCB.01771-07; Towler DA, 2006, ANN NY ACAD SCI, V1068, P327, DOI 10.1196/annals.1346.036; Trion A, 2004, AM HEART J, V147, P808, DOI 10.1016/j.ahj.2003.10.047; Tyson KL, 2003, ARTERIOSCL THROM VAS, V23, P489, DOI 10.1161/01.ATV.0000059406.92165.31; Ueyama T, 2003, MOL CELL BIOL, V23, P9222, DOI 10.1128/MCB.23.24.9222-9232.2003; Wada T, 1999, CIRC RES, V84, P166, DOI 10.1161/01.RES.84.2.166; Wesche-Soldato DE, 2005, BLOOD, V106, P2295, DOI 10.1182/blood-2004-10-4086; WITZTUM JL, 1994, LANCET, V344, P793, DOI 10.1016/S0140-6736(94)92346-9; Wu XY, 2000, MOL THER, V2, P47, DOI 10.1006/mthe.2000.0095; Yet SF, 2003, FASEB J, V17, P1759, DOI 10.1096/fj.03-0187fje; Yin TT, 2000, CIRCULATION, V102, P2636, DOI 10.1161/01.cir.102.21.2636; Zhao ZR, 2005, MOL THER, V12, P247, DOI 10.1016/j.ymthe.2005.03.009; Zoccali C, 2004, J AM SOC NEPHROL, V15, pS77, DOI 10.1097/01.ASN.0000093240.84097.FE	72	458	490	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15319	15327		10.1074/jbc.M800021200	http://dx.doi.org/10.1074/jbc.M800021200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18378684	Green Published, hybrid			2022-12-25	WOS:000256232000050
J	Takahashi, K; Hayashi, N; Shimokawa, T; Umehara, N; Kaminogawa, S; Ra, C				Takahashi, Kyoko; Hayashi, Natsuko; Shimokawa, Toshibumi; Umehara, Nagayoshi; Kaminogawa, Shuichi; Ra, Chisei			Cooperative regulation of Fc receptor gamma-chain gene expression by multiple transcription factors, including Sp1, GABP, and Elf-1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYSICAL ASSOCIATION; PROMOTER; ACTIVATE; C/EBP; SUBUNIT; PROTEIN; BETA; INVOLVEMENT; HOMODIMER; CELLS	The Fc receptor gamma-chain (FcR gamma), which was first identified as a constituent of the high affinity IgE receptor, associates with various cell surface receptors to mediate intracellular signals. We identified three transcriptional enhancer elements in the 5' region of the human FcR gamma gene; one of the cis-elements was recognized by the transcription factor Sp-1 and another was recognized by GABP or Elf-1. The sequence of the other element was similar to a binding motif of the C/EBP family. Overexpression experiments showed that these transcription factors cooperatively activated the FcR gamma promoter. Furthermore, inactivation of the GABP-binding site by nucleotide substitutions as well as repression of GABP alpha expression by RNA interference reduced Sp1-mediated transactivation of the FcR gamma promoter, demonstrating that Sp1 and GABP synergistically activated the FcR gamma promoter. This synergistic activation was suggested to require physical interaction between the two transcription factors, because the Ets domain of GABP alpha was demonstrated to directly bind Sp1. On the other hand, GABP and Elf-1, whose recognition sequences overlapped, were shown to bind the FcR gamma gene with similar affinity in the context of chromatin, although Elf-1 exerted weaker enhancer activity for FcR gamma gene expression than did GABP. Both were thought to compete for binding to the element, because additional expression of Elf-1 in combination with Sp1 and GABP reduced FcR gamma promoter activity. Such functional and physical interactions among transcription factors involved in the cooperative regulation of FcR gamma gene expression as revealed in this study will become promising targets for medical applications against various immune diseases involving FcR gamma.	[Ra, Chisei] Nihon Univ, Grad Sch Med Sci, Dept Mol Cell Immunol & Allergol, Adv Med Res Ctr,Itabashi Ku, Tokyo 1738610, Japan; [Takahashi, Kyoko; Kaminogawa, Shuichi] Nihon Univ, Coll Bioresource Sci, Kanagawa 2528510, Japan; [Hayashi, Natsuko] Tamagawa Univ, Dept Appl Biol Chem, Tokyo 1948610, Japan; [Umehara, Nagayoshi] Jikei Med Sch, Dept Obstet & Gynecol, Tokyo 1058461, Japan	Nihon University; Nihon University; Jikei University	Ra, C (corresponding author), Nihon Univ, Grad Sch Med Sci, Dept Mol Cell Immunol & Allergol, Adv Med Res Ctr,Itabashi Ku, 30-1 Oyaguchi Kamima Chi, Tokyo 1738610, Japan.	fcericra@med.nihon-u.ac.jp						BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BRINI AT, 1993, J BIOL CHEM, V268, P1355; Chiang BT, 2006, J BIOMED SCI, V13, P621, DOI 10.1007/s11373-006-9101-y; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; Galvagni F, 2001, J MOL BIOL, V306, P985, DOI 10.1006/jmbi.2000.4335; Gyrd-Hansen M, 2002, J NEUROL SCI, V197, P27, DOI 10.1016/S0022-510X(02)00038-2; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Hempel N, 2004, MOL PHARMACOL, V66, P1690, DOI 10.1124/mol.104.003350; Ishikawa S, 2004, INT IMMUNOL, V16, P1019, DOI 10.1093/intimm/dxh103; Jiang P, 2002, J BIOL CHEM, V277, P8989, DOI 10.1074/jbc.M105682200; Juang YT, 2007, J IMMUNOL, V179, P4884, DOI 10.4049/jimmunol.179.7.4884; Khanna-Gupta A, 2000, BLOOD, V95, P3734; Kim N, 2002, J EXP MED, V195, P201, DOI 10.1084/jem.20011681; KUSTER H, 1990, J BIOL CHEM, V265, P6448; LECONIAT M, 1990, IMMUNOGENETICS, V32, P183, DOI 10.1007/BF02114971; MASUDA M, 1993, J IMMUNOL, V151, P7188; Mocsai A, 2004, P NATL ACAD SCI USA, V101, P6158, DOI 10.1073/pnas.0401602101; MORTON HC, 1995, J BIOL CHEM, V270, P29781; Nuchprayoon I, 1997, BLOOD, V89, P4546, DOI 10.1182/blood.V89.12.4546; Osaki F, 2004, ATHEROSCLEROSIS, V176, P279, DOI 10.1016/j.atherosclerosis.2004.05.029; Payton SG, 2005, BBA-GENE STRUCT EXPR, V1727, P45, DOI 10.1016/j.bbaexp.2004.11.006; PFEFFERKORN LC, 1994, J IMMUNOL, V153, P3228; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; Rosmarin AG, 1998, J BIOL CHEM, V273, P13097, DOI 10.1074/jbc.273.21.13097; Rudge TL, 2002, EXP CELL RES, V274, P45, DOI 10.1006/excr.2001.5451; Saito K, 1995, J ALLERGY CLIN IMMUN, V96, P1152, DOI 10.1016/S0091-6749(95)70200-8; SCHOLL PR, 1993, P NATL ACAD SCI USA, V90, P8847, DOI 10.1073/pnas.90.19.8847; Shimokawa T, 2005, BLOOD, V106, P2534, DOI 10.1182/blood-2004-06-2413; Shirasaki F, 1999, ONCOGENE, V18, P7755, DOI 10.1038/sj.onc.1203360; Takahashi K, 2003, J IMMUNOL, V171, P2478, DOI 10.4049/jimmunol.171.5.2478; Takahashi K, 2006, J IMMUNOL, V177, P4605, DOI 10.4049/jimmunol.177.7.4605; Takai T, 1996, Int Rev Immunol, V13, P369, DOI 10.3109/08830189609061759; Tsuji M, 1997, J BIOL CHEM, V272, P23528, DOI 10.1074/jbc.272.38.23528; Tzeng SJ, 2005, J BIOMED SCI, V12, P741, DOI 10.1007/s11373-005-9002-5	34	22	23	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15134	15141		10.1074/jbc.M800498200	http://dx.doi.org/10.1074/jbc.M800498200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18378679	hybrid, Green Published			2022-12-25	WOS:000256232000029
J	Wong, CC; Gaspar-Maia, A; Ramalho-Santos, M; Pera, RAR				Wong, Connie C.; Gaspar-Maia, Alexandre; Ramalho-Santos, Miguel; Pera, Renee A. Reijo			High-Efficiency Stem Cell Fusion-Mediated Assay Reveals Sall4 as an Enhancer of Reprogramming	PLOS ONE			English	Article								Several methods allow reprogramming of differentiated somatic cells to embryonic stem cell-like cells. However, the process of reprogramming remains inefficient and the underlying molecular mechanisms are poorly understood. Here, we report the optimization of somatic cell fusion with embryonic stem cells in order to provide an efficient, quantitative assay to screen for factors that facilitate reprogramming. Following optimization, we achieved a reprogramming efficiency 15-590 fold higher than previous protocols. This allowed observation of cellular events during the reprogramming process. Moreover, we demonstrate that overexpression of the Spalt transcription factor, Sall4, which was previously identified as a regulator of embryonic stem cell pluripotency and early mouse development, can enhance reprogramming. The reprogramming activity of Sall4 is independent of an N-terminal domain implicated in recruiting the nucleosome remodeling and deacetylase corepressor complex, a global transcriptional repressor. These results indicate that improvements in reprogramming assays, including fusion assays, may allow the systematic identification and molecular characterization of enhancers of somatic cell reprogramming.	[Wong, Connie C.; Gaspar-Maia, Alexandre; Ramalho-Santos, Miguel; Pera, Renee A. Reijo] Univ Calif San Francisco, Inst Regenerat Med, San Francisco, CA USA; [Wong, Connie C.; Pera, Renee A. Reijo] Univ Calif San Francisco, Dept Obstet, Gynecol & Reprod Sci, San Francisco, CA USA; [Gaspar-Maia, Alexandre; Ramalho-Santos, Miguel] Univ Calif San Francisco, Diabetes Ctr, San Francisco, CA USA; [Gaspar-Maia, Alexandre] Univ Coimbra, Ctr Neurosci & Cell Biol, Doctoral Program Biomed & Expt Biol, Coimbra, Portugal	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Universidade de Coimbra	Ramalho-Santos, M (corresponding author), Univ Calif San Francisco, Inst Regenerat Med, San Francisco, CA USA.	mrsantos@diabetes.ucsf.edu; reneer@stanford.edu	Gaspar-Maia, Alexandre/AAY-5416-2020; Ramalho-Santos, Miguel/L-9092-2018	Gaspar-Maia, Alexandre/0000-0001-8528-5575; Ramalho-Santos, Miguel/0000-0003-0177-5556; Reijo Pera, Renee/0000-0002-6487-1329	UCSF Institute for Regeneration Medicine; Juvenile Diabetes Research Foundation; Stanford University Institute for Stem Cell Biology and Regenerative Medicine; California Institute of Regenerative Medicine	UCSF Institute for Regeneration Medicine; Juvenile Diabetes Research Foundation(Juvenile Diabetes Research Foundation); Stanford University Institute for Stem Cell Biology and Regenerative Medicine; California Institute of Regenerative Medicine(California Institute for Regenerative Medicine)	This research was supported by funds from the UCSF Institute for Regeneration Medicine and Juvenile Diabetes Research Foundation (to MRS) and from the Stanford University Institute for Stem Cell Biology and Regenerative Medicine, and the California Institute of Regenerative Medicine (to RARP). The funders were not directly involved in the study or the preparation of the manuscript.	Alberio R, 2006, REPRODUCTION, V132, P709, DOI 10.1530/rep.1.01077; Blelloch R, 2007, CELL STEM CELL, V1, P245, DOI 10.1016/j.stem.2007.08.008; Bohm J, 2007, BIOCHEM BIOPH RES CO, V356, P773, DOI 10.1016/j.bbrc.2007.03.050; Bowen NJ, 2004, BBA-GENE STRUCT EXPR, V1677, P52, DOI 10.1016/j.bbaexp.2003.10.010; CERVERA RP, 2007, CLIN PHARM THER; Cowan CA, 2005, SCIENCE, V309, P1369, DOI 10.1126/science.1116447; Deans B, 2003, CANCER RES, V63, P8181; Eilertsen KJ, 2007, ANIM REPROD SCI, V98, P129, DOI 10.1016/j.anireprosci.2006.10.019; Elling U, 2006, P NATL ACAD SCI USA, V103, P16319, DOI 10.1073/pnas.0607884103; FREI E, 1988, EMBO J, V7, P197, DOI 10.1002/j.1460-2075.1988.tb02800.x; Han DW, 2008, STEM CELLS, V26, P445, DOI 10.1634/stemcells.2007-0553; Hochedlinger K, 2003, NEW ENGL J MED, V349, P275, DOI 10.1056/NEJMra035397; Hochedlinger K, 2002, CURR OPIN CELL BIOL, V14, P741, DOI 10.1016/S0955-0674(02)00380-0; Hochedlinger K, 2006, NATURE, V441, P1061, DOI 10.1038/nature04955; JURGENS G, 1988, EMBO J, V7, P189, DOI 10.1002/j.1460-2075.1988.tb02799.x; Lauberth SM, 2006, J BIOL CHEM, V281, P23922, DOI 10.1074/jbc.M513461200; Li E, 2002, NAT REV GENET, V3, P662, DOI 10.1038/nrg887; Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760; Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014; Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199; Niwa H, 2007, DEVELOPMENT, V134, P635, DOI 10.1242/dev.02787; OKITA K, 2007, NATURE; Pan GJ, 2007, CELL RES, V17, P42, DOI 10.1038/sj.cr.7310125; Silva J, 2006, NATURE, V441, P997, DOI 10.1038/nature04914; Surani MA, 2007, CELL, V128, P747, DOI 10.1016/j.cell.2007.02.010; Surani MA, 2001, NATURE, V414, P122, DOI 10.1038/35102186; Sweetman D, 2006, DEV BIOL, V293, P285, DOI 10.1016/j.ydbio.2006.02.009; Tada M, 2001, CURR BIOL, V11, P1553, DOI 10.1016/S0960-9822(01)00459-6; Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024; Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284; WERNIG M, 2007, NATURE; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Wong C, 2003, NAT CELL BIOL, V5, P539, DOI 10.1038/ncb993; Wu Q, 2006, J BIOL CHEM, V281, P24090, DOI 10.1074/jbc.C600122200; Xia XF, 2007, STEM CELLS DEV, V16, P167, DOI 10.1089/scd.2006.0057; Yamanaka S, 2007, CELL STEM CELL, V1, P39, DOI 10.1016/j.stem.2007.05.012; Yang XZ, 2007, NAT GENET, V39, P295, DOI 10.1038/ng1973; Ying QL, 2003, CELL, V115, P281, DOI 10.1016/S0092-8674(03)00847-X; Yoshimizu T, 1999, DEV GROWTH DIFFER, V41, P675; Yu JY, 2006, STEM CELLS, V24, P168, DOI 10.1634/stemcells.2005-0292; Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481	41	55	57	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1955	10.1371/journal.pone.0001955	http://dx.doi.org/10.1371/journal.pone.0001955			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414659	gold, Green Submitted, Green Published			2022-12-25	WOS:000260867300008
J	Kinjo, AR; Nakamura, H				Kinjo, Akira R.; Nakamura, Haruki			Nature of Protein Family Signatures: Insights from Singular Value Analysis of Position-Specific Scoring Matrices	PLOS ONE			English	Article							ACID SUBSTITUTION MATRICES; SEQUENCE; PREDICTION; GENERATION; RESIDUES; FOLD; IDENTIFICATION; OPTIMIZATION; PARAMETERS; PROFILES	Position-specific scoring matrices (PSSMs) are useful for detecting weak homology in protein sequence analysis, and they are thought to contain some essential signatures of the protein families. In order to elucidate what kind of ingredients constitute such family-specific signatures, we apply singular value decomposition to a set of PSSMs and examine the properties of dominant right and left singular vectors. The first right singular vectors were correlated with various amino acid indices including relative mutability, amino acid composition in protein interior, hydropathy, or turn propensity, depending on proteins. A significant correlation between the first left singular vector and a measure of site conservation was observed. It is shown that the contribution of the first singular component to the PSSMs act to disfavor potentially but falsely functionally important residues at conserved sites. The second right singular vectors were highly correlated with hydrophobicity scales, and the corresponding left singular vectors with contact numbers of protein structures. It is suggested that sequence alignment with a PSSM is essentially equivalent to threading supplemented with functional information. In addition, singular vectors may be useful for analyzing and annotating the characteristics of conserved sites in protein families.	[Kinjo, Akira R.; Nakamura, Haruki] Osaka Univ, Inst Prot Res, Osaka, Japan	Osaka University	Kinjo, AR (corresponding author), Osaka Univ, Inst Prot Res, Osaka, Japan.	akinjo@protein.osaka-u.ac.jp		Kinjo, Akira/0000-0002-4006-8208	Japan Science and Technology Agency	Japan Science and Technology Agency(Japan Science & Technology Agency (JST))	Supported by Japan Science and Technology Agency, which played no role in the study but financial support.	ALTSCHUL SF, 1991, J MOL BIOL, V219, P555, DOI 10.1016/0022-2836(91)90193-A; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Aurora R, 1998, PROTEIN SCI, V7, P21, DOI 10.1002/pro.5560070103; Barber CB, 1996, ACM T MATH SOFTWARE, V22, P469, DOI 10.1145/235815.235821; BASHFORD D, 1987, J MOL BIOL, V196, P199, DOI 10.1016/0022-2836(87)90521-3; Bastolla U, 2005, PROTEINS, V58, P22, DOI 10.1002/prot.20240; BEGHIN F, 1975, ARCH INT PHYSIOL BIO, V83, P167; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BOWIE JU, 1990, PROTEINS, V7, P257, DOI 10.1002/prot.340070307; BUNDI A, 1979, BIOPOLYMERS, V18, P285, DOI 10.1002/bip.1979.360180206; Charton M, 1983, J THEOR BIOL, V111, P447; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; Doolittle R. F., 1986, URFS ORFS PRIMER ANA; Durbin R., 1999, BIOL SEQUENCE ANAL P; Eddy SR, 1996, CURR OPIN STRUC BIOL, V6, P361, DOI 10.1016/S0959-440X(96)80056-X; FAUCHERE JL, 1988, INT J PEPT PROT RES, V32, P269; Finn RD, 2006, NUCLEIC ACIDS RES, V34, pD247, DOI 10.1093/nar/gkj149; Fukuchi S, 2001, J MOL BIOL, V309, P835, DOI 10.1006/jmbi.2001.4718; GRANTHAM R, 1974, SCIENCE, V185, P862, DOI 10.1126/science.185.4154.862; GRIBSKOV M, 1987, P NATL ACAD SCI USA, V84, P4355, DOI 10.1073/pnas.84.13.4355; HENIKOFF S, 1992, P NATL ACAD SCI USA, V89, P10915, DOI 10.1073/pnas.89.22.10915; Horn RA., 1985, MATRIX ANAL; Ishida T, 2006, PROTEINS, V64, P940, DOI 10.1002/prot.21047; JONES DT, 1992, COMPUT APPL BIOSCI, V8, P275, DOI 10.1093/bioinformatics/8.3.275; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; Kann M, 2000, PROTEINS, V41, P498, DOI 10.1002/1097-0134(20001201)41:4<498::AID-PROT70>3.0.CO;2-3; Kawashima S, 1999, NUCLEIC ACIDS RES, V27, P368, DOI 10.1093/nar/27.1.368; KIDERA A, 1985, J PROTEIN CHEM, V4, P23, DOI 10.1007/BF01025492; Kinjo AR, 2008, CHEM PHYS LETT, V451, P132, DOI 10.1016/j.cplett.2007.12.005; Kinjo AR, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-401; Kinjo Akira R, 2005, Biophysics (Nagoya-shi), V1, P67, DOI 10.2142/biophysics.1.67; Kinjo AR, 2005, BIOINFORMATICS, V21, P2167, DOI 10.1093/bioinformatics/bti330; Kinjo AR, 2005, PROTEINS, V58, P158, DOI 10.1002/prot.20300; Kinjo AR, 2004, BIOINFORMATICS, V20, P2504, DOI 10.1093/bioinformatics/bth297; KLEIN P, 1984, BIOCHIM BIOPHYS ACTA, V787, P221, DOI 10.1016/0167-4838(84)90312-1; Koehl P, 1999, P NATL ACAD SCI USA, V96, P12524, DOI 10.1073/pnas.96.22.12524; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lecomte JTJ, 2005, CURR OPIN STRUC BIOL, V15, P290, DOI 10.1016/j.sbi.2005.05.008; LEVITT M, 1976, J MOL BIOL, V104, P59, DOI 10.1016/0022-2836(76)90004-8; Miyazawa S, 1999, PROTEINS, V34, P49; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAKAI K, 1988, PROTEIN ENG, V2, P93, DOI 10.1093/protein/2.2.93; NISHIKAWA K, 1986, J BIOCHEM-TOKYO, V100, P1043, DOI 10.1093/oxfordjournals.jbchem.a121783; NISHIKAWA K, 1980, INT J PEPT PROT RES, V16, P19; OOBATAKE M, 1977, J THEOR BIOL, V67, P567, DOI 10.1016/0022-5193(77)90058-3; Ota M, 1997, PROTEIN ENG, V10, P339, DOI 10.1093/protein/10.4.339; Ota M, 1997, FEBS LETT, V415, P129, DOI 10.1016/S0014-5793(97)01110-1; Pokarowski P, 2007, PROTEINS, V69, P379, DOI 10.1002/prot.21509; Porto M, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.218101; Qian B, 2002, PROTEINS, V48, P605, DOI 10.1002/prot.10132; RICHARDS FM, 1977, ANNU REV BIOPHYS BIO, V6, P151, DOI 10.1146/annurev.bb.06.060177.001055; Rosano C, 2000, J MOL BIOL, V303, P77, DOI 10.1006/jmbi.2000.4106; Rost B, 1999, PROTEIN ENG, V12, P85, DOI 10.1093/protein/12.2.85; ROYER WE, 1994, J MOL BIOL, V235, P657, DOI 10.1006/jmbi.1994.1019; Rudolph MG, 2003, ACTA CRYSTALLOGR D, V59, P290, DOI 10.1107/S0907444902021704; SNEATH PHA, 1966, J THEOR BIOL, V12, P157, DOI 10.1016/0022-5193(66)90112-3; Suzek BE, 2007, BIOINFORMATICS, V23, P1282, DOI 10.1093/bioinformatics/btm098; SWEET RM, 1983, J MOL BIOL, V171, P479, DOI 10.1016/0022-2836(83)90041-4; TAYLOR WR, 1986, J MOL BIOL, V188, P233, DOI 10.1016/0022-2836(86)90308-6; Thomas MC, 2006, ELEMENTS INFORM THEO; Tomii K, 1996, PROTEIN ENG, V9, P27, DOI 10.1093/protein/9.1.27; Wang GL, 2003, BIOINFORMATICS, V19, P1589, DOI 10.1093/bioinformatics/btg224; Wrabl JO, 2005, PROTEINS, V61, P523, DOI 10.1002/prot.20648; Yuan Z, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-248	65	8	8	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1963	10.1371/journal.pone.0001963	http://dx.doi.org/10.1371/journal.pone.0001963			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398479	Green Published, gold, Green Submitted			2022-12-25	WOS:000260795500032
J	Stavrum, R; Valvatne, H; Bo, TH; Jonassen, I; Hinds, J; Butcher, PD; Grewal, HMS				Stavrum, Ruth; Valvatne, Havard; Bo, Trond H.; Jonassen, Inge; Hinds, Jason; Butcher, Philip D.; Grewal, Harleen M. S.			Genomic Diversity among Beijing and non-Beijing Mycobacterium tuberculosis Isolates from Myanmar	PLOS ONE			English	Article							STRAINS; GENE; PREDOMINANCE; DIFFERENCE; VARIANCE; SEQUENCE; LINEAGE; FAMILY; YANGON	Background: The Beijing family of Mycobacterium tuberculosis is dominant in countries in East Asia. Genomic polymorphisms are a source of diversity within the M. tuberculosis genome and may account for the variation of virulence among M. tuberculosis isolates. Till date there are no studies that have examined the genomic composition of M. tuberculosis isolates from the high TB-burden country, Myanmar. Methodology/Principle Findings: Twenty-two M. tuberculosis isolates from Myanmar were screened on whole-genome arrays containing genes from M. tuberculosis H37Rv, M. tuberculosis CDC1551 and M. bovis AF22197. Screening identified 198 deletions or extra regions in the clinical isolates compared to H37Rv. Twenty-two regions differentiated between Beijing and non-Beijing isolates and were verified by PCR on an additional 40 isolates. Six regions (Rv0071-0074 [RD105], Rv1572-1576c [RD149], Rv1585c-1587c [RD149], MT1798-Rv1755c [RD152], Rv1761c [RD152] and Rv0279c) were deleted in Beijing isolates, of which 4 (Rv1572-1576c, Rv1585c-1587c, MT1798-Rv1755c and Rv1761c) were variably deleted among ST42 isolates, indicating a closer relationship between the Beijing and ST42 lineages. The TbD1 region, Mb1582-Mb1583 was deleted in Beijing and ST42 isolates. One M. bovis gene of unknown function, Mb3184c was present in all isolates, except 11 of 13 ST42 isolates. The CDC1551 gene, MT1360 coding for a putative adenylate cyclase, was present in all Beijing and ST42 isolates (except 1). The pks15/1 gene, coding for a putative virulence factor, was intact in all Beijing and non-Beijing isolates, except in ST42 and ST53 isolates. Conclusion: This study describes previously unreported deletions/extra regions in Beijing and non-Beijing M. tuberculosis isolates. The modern and highly frequent ST42 lineage showed a closer relationship to the hypervirulent Beijing lineage than to the ancient non-Beijing lineages. The pks15/1 gene was disrupted only in modern non-Beijing isolates. This is the first report of an in-depth analysis on the genomic diversity of M. tuberculosis isolates from Myanmar.	[Stavrum, Ruth; Valvatne, Havard; Grewal, Harleen M. S.] Univ Bergen, Gade Inst, Microbiol & Immunol Sect, Bergen, Norway; [Stavrum, Ruth; Valvatne, Havard; Grewal, Harleen M. S.] Haukeland Hosp, Dept Microbiol & Immunol, Bergen, Norway; [Bo, Trond H.; Jonassen, Inge] Univ Bergen, Bergen Ctr Computat Sci, Dept Informat, Bergen, Norway; [Hinds, Jason; Butcher, Philip D.] Univ London, Div Cell & Mol Med, Bacterial Microarray Grp, London, England	University of Bergen; University of Bergen; Haukeland University Hospital; University of Bergen; University of London	Grewal, HMS (corresponding author), Univ Bergen, Gade Inst, Microbiol & Immunol Sect, Bergen, Norway.	Harleen.Grewal@Gades.uib.no	Jonassen, Inge/AAC-7035-2020; Grewal, Harleen/ABC-5831-2020	Butcher, Philip/0000-0003-1223-9097; Jonassen, Inge/0000-0003-4110-0748; Hinds, Jason/0000-0002-2739-1908	Helse Vest; Norwegian Research Council; University of Bergen	Helse Vest; Norwegian Research Council(Research Council of NorwayEuropean Commission); University of Bergen	This study was funded by Helse Vest, the Norwegian Research Council and University of Bergen. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Betts JC, 2003, ANTIMICROB AGENTS CH, V47, P2903, DOI 10.1128/AAC.47.9.2903-2913.2003; Bifani PJ, 2002, TRENDS MICROBIOL, V10, P45, DOI 10.1016/S0966-842X(01)02277-6; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Camus JC, 2002, MICROBIOL-SGM, V148, P2967, DOI 10.1099/00221287-148-10-2967; Chan MY, 2001, EPIDEMIOL INFECT, V127, P169, DOI 10.1017/S0950268801005659; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Constant P, 2002, J BIOL CHEM, V277, P38148, DOI 10.1074/jbc.M206538200; Espitia C, 1999, MICROBIOL-UK, V145, P3487, DOI 10.1099/00221287-145-12-3487; Filliol I, 2002, EMERG INFECT DIS, V8, P1347, DOI 10.3201/eid0811.020125; Fleischmann RD, 2002, J BACTERIOL, V184, P5479, DOI 10.1128/JB.184.19.5479-5490.2002; Flynn JL, 2001, INFECT IMMUN, V69, P4195, DOI 10.1128/IAI.69.7.4195-4201.2001; Gagneux S, 2006, P NATL ACAD SCI USA, V103, P2869, DOI 10.1073/pnas.0511240103; Garnier T, 2003, P NATL ACAD SCI USA, V100, P7877, DOI 10.1073/pnas.1130426100; Gehring AJ, 2003, INFECT IMMUN, V71, P4487, DOI 10.1128/IAI.71.8.4487-4497.2003; Glynn JR, 2002, EMERG INFECT DIS, V8, P843; Gutierrez MC, 2006, EMERG INFECT DIS, V12, P1367, DOI 10.3201/eid1209.050017; Hinds J, 2002, METHOD MICROBIOL, V33, P83; Huber Wolfgang, 2002, Bioinformatics, V18 Suppl 1, pS96; Kremer K, 2004, J CLIN MICROBIOL, V42, P4040, DOI 10.1128/JCM.42.9.4040-4049.2004; Lillebaek T, 2003, EMERG INFECT DIS, V9, P1553, DOI 10.3201/eid0912.030276; Lopez B, 2003, CLIN EXP IMMUNOL, V133, P30, DOI 10.1046/j.1365-2249.2003.02171.x; Malik AN, 2005, LANCET INFECT DIS, V5, P174, DOI 10.1016/S1473-3099(05)01310-1; Mostowy S, 2002, J INFECT DIS, V186, P74, DOI 10.1086/341068; Musser JM, 2000, GENETICS, V155, P7; Phyu S, 2005, SCAND J INFECT DIS, V37, P846, DOI 10.1080/00365540500265065; Phyu S, 2003, J CLIN MICROBIOL, V41, P4907, DOI 10.1128/JCM.41.10.4907-4908.2003; Rao KR, 2005, J CLIN MICROBIOL, V43, P5978, DOI 10.1128/JCM.43.12.5978-5982.2005; Reed MB, 2004, NATURE, V431, P84, DOI 10.1038/nature02837; Rocke DM, 2003, BIOINFORMATICS, V19, P966, DOI 10.1093/bioinformatics/btg107; Stewart GR, 2002, MICROBIOL-SGM, V148, P3129, DOI 10.1099/00221287-148-10-3129; Supply P, 2006, J CLIN MICROBIOL, V44, P4498, DOI 10.1128/JCM.01392-06; Tsolaki AG, 2005, J CLIN MICROBIOL, V43, P3185, DOI 10.1128/JCM.43.7.3185-3191.2005; VANEMBDEN JDA, 1995, MYCOBACTERIUM BOVIS, P15; VANSOOLINGEN D, 1995, J CLIN MICROBIOL, V33, P3234, DOI 10.1128/JCM.33.12.3234-3238.1995; Warren RM, 2004, AM J RESP CRIT CARE, V169, P610, DOI 10.1164/rccm.200305-714OC; *WHO, WHO REP 2005 GLOB TU	37	15	16	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1973	10.1371/journal.pone.0001973	http://dx.doi.org/10.1371/journal.pone.0001973			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398483	gold, Green Accepted, Green Published			2022-12-25	WOS:000260795500036
J	Lamina, C; Bongardt, F; Kuchenhoff, H; Heid, IM				Lamina, Claudia; Bongardt, Friedhelm; Kuechenhoff, Helmut; Heid, Iris M.			Haplotype Reconstruction Error as a Classical Misclassification Problem: Introducing Sensitivity and Specificity as Error Measures	PLOS ONE			English	Article								Background: Statistically reconstructing haplotypes from single nucleotide polymorphism (SNP) genotypes, can lead to falsely classified haplotypes. This can be an issue when interpreting haplotype association results or when selecting subjects with certain haplotypes for subsequent functional studies. It was our aim to quantify haplotype reconstruction error and to provide tools for it. Methods and Results: By numerous simulation scenarios, we systematically investigated several error measures, including discrepancy, error rate, and R 2, and introduced the sensitivity and specificity to this context. We exemplified several measures in the KORA study, a large population-based study from Southern Germany. We find that the specificity is slightly reduced only for common haplotypes, while the sensitivity was decreased for some, but not all rare haplotypes. The overall error rate was generally increasing with increasing number of loci, increasing minor allele frequency of SNPs, decreasing correlation between the alleles and increasing ambiguity. Conclusions: We conclude that, with the analytical approach presented here, haplotype-specific error measures can be computed to gain insight into the haplotype uncertainty. This method provides the information, if a specific risk haplotype can be expected to be reconstructed with rather no or high misclassification and thus on the magnitude of expected bias in association estimates. We also illustrate that sensitivity and specificity separate two dimensions of the haplotype reconstruction error, which completely describe the misclassification matrix and thus provide the prerequisite for methods accounting for misclassification.	[Lamina, Claudia; Heid, Iris M.] Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol, Neuherberg, Germany; [Bongardt, Friedhelm; Heid, Iris M.] Ludwig Maximilians Univ Munchen, Inst Med Informat Processing, Biometry & Epidemiol, Munich, Germany; [Kuechenhoff, Helmut] Ludwig Maximilians Univ Munchen, Inst Statist, Stablab, Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; University of Munich	Lamina, C (corresponding author), Helmholtz Zentrum Munchen, German Res Ctr Environm Hlth, Inst Epidemiol, Neuherberg, Germany.	heid@helmholtz-muenchen.de	Kuchenhoff, Helmut/A-8291-2010; Lamina, Claudia/F-7608-2010	Lamina, Claudia/0000-0002-5398-5806; Kuchenhoff, Helmut/0000-0002-6372-2487	DFG; NGFN [PDN-S31T10]	DFG(German Research Foundation (DFG)); NGFN	This work was supported by the DFG grant within the SFB-386 (Analysis of discrete structure, project B10 Genetic epidemiological methods: Analysis of haplotype risk structure) and the NGFN grant PDN-S31T10.	Adkins RM, 2004, BMC GENET, V5, DOI 10.1186/1471-2156-5-22; Akey J, 2001, EUR J HUM GENET, V9, P291, DOI 10.1038/sj.ejhg.5200619; Carroll RJ, 2006, MEASUREMENT ERROR NO; Clark AG, 2004, GENET EPIDEMIOL, V27, P321, DOI 10.1002/gepi.20025; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; DEVLIN B, 1995, GENOMICS, V29, P311, DOI 10.1006/geno.1995.9003; Epstein MP, 2003, AM J HUM GENET, V73, P1316, DOI 10.1086/380204; EXCOFFIER L, 1995, MOL BIOL EVOL, V12, P921; Fallin D, 2000, AM J HUM GENET, V67, P947, DOI 10.1086/303069; Heid IM, 2006, DIABETES, V55, P375, DOI 10.2337/diabetes.55.02.06.db05-0747; Illig T, 2004, J CLIN ENDOCR METAB, V89, P5053, DOI 10.1210/jc.2004-0355; Illig T, 2003, DIABETES, V52, P2861, DOI 10.2337/diabetes.52.11.2861; Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233; Kraft P, 2005, GENET EPIDEMIOL, V28, P261, DOI 10.1002/gepi.20061; Kuchenhoff' H, 2006, BIOMETRICS, V62, P85, DOI 10.1111/j.1541-0420.2005.00396.x; Lake SL, 2003, HUM HERED, V55, P56, DOI 10.1159/000071811; Levenstien MA, 2006, PLOS GENET, V2, P1156, DOI 10.1371/journal.pgen.0020127; Lin DY, 2006, J AM STAT ASSOC, V101, P89, DOI 10.1198/016214505000000808; Little R.J.A., 2002, STAT ANAL MISSING DA; Martin ER, 2000, AM J HUM GENET, V67, P383, DOI 10.1086/303003; Morris RW, 2002, GENET EPIDEMIOL, V23, P221, DOI 10.1002/gepi.10200; Morrissey MJ, 1999, BIOMETRICS, V55, P338, DOI 10.1111/j.0006-341X.1999.00338.x; Niu TH, 2002, AM J HUM GENET, V70, P157, DOI 10.1086/338446; Nyholt DR, 2004, AM J HUM GENET, V74, P765, DOI 10.1086/383251; Schaid DJ, 2004, GENET EPIDEMIOL, V27, P348, DOI 10.1002/gepi.20037; Schaid DJ, 2002, AM J HUM GENET, V70, P425, DOI 10.1086/338688; Spinka C, 2005, GENET EPIDEMIOL, V29, P108, DOI 10.1002/gepi.20085; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501; Stram DO, 2003, HUM HERED, V55, P179, DOI 10.1159/000073202; THOMAS D, 1993, ANNU REV PUBL HEALTH, V14, P69, DOI 10.1146/annurev.pu.14.050193.000441; Wichmann HE, 2005, GESUNDHEITSWESEN, V67, pS26, DOI 10.1055/s-2005-858226; Xu HY, 2004, HUM HERED, V58, P63, DOI 10.1159/000083026; Zaykin DV, 2002, HUM HERED, V53, P79, DOI 10.1159/000057986; Zhao LP, 2003, AM J HUM GENET, V72, P1231, DOI 10.1086/375140	35	7	7	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1853	10.1371/journal.pone.0001853	http://dx.doi.org/10.1371/journal.pone.0001853			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365008	Green Published, Green Submitted, gold			2022-12-25	WOS:000260762400014
J	Fanta, S; Sonnenberg, M; Skorta, I; Duyster, J; Miething, C; Aulitzky, WE; van der Kuip, H				Fanta, S.; Sonnenberg, M.; Skorta, I.; Duyster, J.; Miething, C.; Aulitzky, W. E.; van der Kuip, H.			Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells	ONCOGENE			English	Article						imatinib mesylate; c-Abl; DNA repair; genetic stability	CHRONIC MYELOID-LEUKEMIA; TYROSINE KINASE INHIBITOR; IMATINIB MESYLATE; MUTATOR PHENOTYPE; DAMAGE; PHOSPHORYLATION; ASSOCIATION; ACTIVATION; GROWTH; STI571	Imatinib inhibits the kinase activity of Bcr-Abl and is currently the most effective drug for treatment of chronic myeloid leukemia (CML). Imatinib also blocks c-Abl, a physiological tyrosine kinase activated by a variety of stress signals including damaged DNA. We investigated the effect of pharmacological inhibition of c-Abl on the processing of irradiation-induced DNA damage in Bcr-Abl-negative cells. Cell lines and peripheral blood mononuclear cells (PBMCs) from healthy volunteers were treated with imatinib or dasatinib before gamma-irradiation. Inhibition of c-Abl caused an enhanced irradiation-induced mutation frequency and slowdown of DNA repair, whereas imatinib was ineffective in cells expressing a T315I variant of c-Abl. Mutation frequency and repair kinetics were also studied in c-Abl-/- murine embryonic fibroblasts (MEFs) retransfected with wild-type c-Abl (wt-Abl) or a kinase-defect variant of Abl (KD-Abl). Enhanced mutation frequency as well as delayed DNA repair was observed in cells expressing KD-Abl. These data indicate that pharmacological inhibition of c-Abl compromises DNA-damage response.	[Fanta, S.; Sonnenberg, M.; Skorta, I.; van der Kuip, H.] Dr Margarete Fischer Bosch Inst Clin Pharmacol, D-70376 Stuttgart, Germany; [Fanta, S.; Sonnenberg, M.; Skorta, I.; van der Kuip, H.] Univ Tubingen, Stuttgart, Germany; [Duyster, J.] Tech Univ Munich, Dept Internal Med 3, Munich, Germany; [Miething, C.] Cold Spring Harbor Lab, Ctr Canc, Cold Spring Harbor, NY 11724 USA; [Aulitzky, W. E.] Robert Bosch Krankenhaus, Dept Int Med Oncol & Hematol 2, Stuttgart, Germany	Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Eberhard Karls University of Tubingen; Technical University of Munich; University of Munich; Cold Spring Harbor Laboratory; Bosch; Robert Bosch Krankenhaus	van der Kuip, H (corresponding author), Dr Margarete Fischer Bosch Inst Clin Pharmacol, Auerbachstr 112, D-70376 Stuttgart, Germany.	heiko.van-der-kuip@ikp-stuttgart.de	Miething, Cornelius/F-9498-2014	Miething, Cornelius/0000-0003-4699-3805				Andersen MK, 2002, LEUKEMIA, V16, P1390, DOI 10.1038/sj.leu.2402634; Buchdunger E, 1996, CANCER RES, V56, P100; Canitrot Y, 1999, ONCOGENE, V18, P2676, DOI 10.1038/sj.onc.1202619; Carroll M, 1997, BLOOD, V90, P4947, DOI 10.1182/blood.V90.12.4947.4947_4947_4952; Cheng WH, 2003, MOL CELL BIOL, V23, P6385, DOI 10.1128/MCB.23.18.6385-6395.2003; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867; Foray N, 2002, MOL CELL BIOL, V22, P4020, DOI 10.1128/MCB.22.12.4020-4032.2002; Goldberg Z, 2002, EMBO J, V21, P3715, DOI 10.1093/emboj/cdf384; Heinrich MC, 2000, BLOOD, V96, P925, DOI 10.1182/blood.V96.3.925.015k50_925_932; Imam SZ, 2007, NUCLEIC ACIDS RES, V35, P4941, DOI 10.1093/nar/gkm386; Kerkela R, 2006, NAT MED, V12, P908, DOI 10.1038/nm1446; Kharbanda S, 1997, NATURE, V386, P732, DOI 10.1038/386732a0; Kharbanda S, 1998, ONCOGENE, V17, P3309, DOI 10.1038/sj.onc.1202571; Michor F, 2005, NATURE, V435, P1267, DOI 10.1038/nature03669; Moehring A, 2005, CELL DEATH DIFFER, V12, P627, DOI 10.1038/sj.cdd.4401608; Picard S, 2007, BLOOD, V109, P3496, DOI 10.1182/blood-2006-07-036012; Salloukh HF, 2000, LEUKEMIA, V14, P1401, DOI 10.1038/sj.leu.2401855; Shaul Y, 2005, CELL RES, V15, P33, DOI 10.1038/sj.cr.7290261; SINGH NP, 1988, EXP CELL RES, V175, P184, DOI 10.1016/0014-4827(88)90265-0; Terre C, 2004, LEUKEMIA, V18, P1340, DOI 10.1038/sj.leu.2403399; Uemura N, 2000, BLOOD, V96, P3294; van der Kuip H, 2004, LEUKEMIA RES, V28, P405, DOI 10.1016/j.leukres.2003.08.012; Wang JYJ, 2000, ONCOGENE, V19, P5643, DOI 10.1038/sj.onc.1203878; Wei G, 2005, J BIOL CHEM, V280, P12271, DOI 10.1074/jbc.M409522200; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Yuan ZM, 1998, J BIOL CHEM, V273, P3799, DOI 10.1074/jbc.273.7.3799	27	18	18	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 17	2008	27	31					4380	4384		10.1038/onc.2008.68	http://dx.doi.org/10.1038/onc.2008.68			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18362889				2022-12-25	WOS:000257691100013
J	Jeon, YJ; Kim, IK; Hong, SH; Nan, H; Kim, HJ; Lee, HJ; Masuda, ES; Meyuhas, O; Oh, BH; Jung, YK				Jeon, Y-J; Kim, I. K.; Hong, S-H; Nan, H.; Kim, H-J; Lee, H-J; Masuda, E. S.; Meyuhas, O.; Oh, B-H; Jung, Y-K			Ribosomal protein S6 is a selective mediator of TRAIL-apoptotic signaling	ONCOGENE			English	Article						TRAIL; apoptosis; ribosomal protein S6; S6 kinase 1; DR4; tumor cell	MESSENGER-RNA TRANSLATION; CELLS; PHOSPHORYLATION; RECEPTOR; FAMILY; LIGAND; IDENTIFICATION; INHIBITION; INDUCTION; PATHWAY	TRAIL (tumor necrosis factor-related apoptosis-inducing ligand) is a potent inducer of apoptosis in tumor cells and holds a promise as a therapeutic agent against cancer. To elucidate the death signaling evoked by TRAIL, we performed a functional genetic screening and rescued TRAIL-resistant Jurkat clones harboring ribosomal protein S6 (rpS6) cDNA in anti-sense frame. Reduction of rpS6 expression in Jurkat and HeLa cells attenuated apoptosis induced by TRAIL, but not those by other cell death signals, including tumor necrosis factor-a and cycloheximide, etoposide, doxorubicin, tunicamycin and staurosporine. Death receptor (DR) 4, but not DR5, was downregulated in rpS6 knockdown cells. Conversely, the sensitivity to TRAIL was increased by the ectopic expression of wild-type rpS6 and further by phospho-defective rpS6 mutant (S6-SS235,6AA), but not by phospho-mimic rpS6 mutant (S6-SS235,6DD). Also, unphosphorylatable rpS6 knock-in mouse embryo fibro-blasts (rpS6(P-/-) MEFs) were more sensitive to TRAIL than control MEFs. In addition, SKHep-1 tumor cells, which express less phospho-rpS6 and are more sensitive to TRAIL than other tumor cells, became effectively desensitized to TRAIL after rpS6 knockdown. These results suggest that rpS6, especially in its unphosphorylated form, is a selective mediator of TRAIL-induced apoptosis.	[Jeon, Y-J; Hong, S-H; Nan, H.; Kim, H-J; Lee, H-J; Jung, Y-K] Seoul Natl Univ, Sch Biol Sci, Biomax Inst, Seoul 151742, South Korea; [Kim, I. K.] Burnham Inst Med Res, La Jolla, CA USA; [Masuda, E. S.] Rigel Pharmaceut Inc, San Francisco, CA USA; [Meyuhas, O.] Hebrew Univ Jerusalem, Sch Med, Dept Biochem, IL-91010 Jerusalem, Israel; [Oh, B-H] Pohang Univ Sci & Technol, Dept Life Sci, Kyungbuk, South Korea	Seoul National University (SNU); Sanford Burnham Prebys Medical Discovery Institute; Hebrew University of Jerusalem; Pohang University of Science & Technology (POSTECH)	Jung, YK (corresponding author), Seoul Natl Univ, Sch Biol Sci, Biomax Inst, Seoul 151742, South Korea.	ykjung@snu.ac.kr	Lee, Ho-June/D-8855-2014	Lee, Ho-June/0000-0002-7019-2533; Jeon, Young-Jun/0000-0002-5998-9605; Masuda, Esteban/0000-0002-3175-2868; Jung, Yong-Keun/0000-0002-9686-3120				Ashkenazi A, 1999, J CLIN INVEST, V104, P155, DOI 10.1172/JCI6926; Beuvink I, 2005, CELL, V120, P747, DOI 10.1016/j.cell.2004.12.040; Fesik SW, 2005, NAT REV CANCER, V5, P876, DOI 10.1038/nrc1736; FRANCO R, 1990, J BIOL CHEM, V265, P4321; Harada H, 2001, P NATL ACAD SCI USA, V98, P9666, DOI 10.1073/pnas.171301998; Inoki K, 2005, NAT GENET, V37, P19, DOI 10.1038/ng1494; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kim IK, 2000, BIOCHEM BIOPH RES CO, V277, P311, DOI 10.1006/bbrc.2000.3673; Kim KI, 2003, BRIT J CANCER, V88, P910, DOI 10.1038/sj.bjc.6600795; KRIEG J, 1988, J BIOL CHEM, V263, P11473; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Pan GH, 1997, SCIENCE, V277, P815, DOI 10.1126/science.277.5327.815; Pan GH, 1997, SCIENCE, V276, P111, DOI 10.1126/science.276.5309.111; Panner A, 2005, MOL CELL BIOL, V25, P8809, DOI 10.1128/MCB.25.20.8809-8823.2005; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Pitt RM, 1996, J BIOL CHEM, V271, P12687, DOI 10.1074/jbc.271.22.12687; RAYMOND AD, 2005, CELL RES, V15, P430; Ren YG, 2004, MOL BIOL CELL, V15, P5064, DOI 10.1091/mbc.e04-03-0184; Ruvinsky I, 2005, GENE DEV, V19, P2199, DOI 10.1101/gad.351605; SHASHIREKHA S, 2005, MOL CELL BIOL, V25, P5404; Sheridan JP, 1997, SCIENCE, V277, P818, DOI 10.1126/science.277.5327.818; Stromberg T, 2004, BLOOD, V103, P3138, DOI 10.1182/blood-2003-05-1543; Wiley SR, 1995, IMMUNITY, V3, P673, DOI 10.1016/1074-7613(95)90057-8; Wu GS, 1997, NAT GENET, V17, P141, DOI 10.1038/ng1097-141	24	26	26	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4344	4352		10.1038/onc.2008.73	http://dx.doi.org/10.1038/onc.2008.73			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18362888				2022-12-25	WOS:000257691100009
J	Entchev, EV; Schwudke, D; Zagoriy, V; Matyash, V; Bogdanova, A; Habermann, B; Zhu, L; Shevchenko, A; Kurzchalia, TV				Entchev, Eugeni V.; Schwudke, Dominik; Zagoriy, Vyacheslav; Matyash, Vitali; Bogdanova, Aliona; Habermann, Bianca; Zhu, Lin; Shevchenko, Andrej; Kurzchalia, Teymuras V.			LET-767 is required for the production of branched chain and long chain fatty acids in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; MULTIPLE PRECURSOR; NUCLEAR RECEPTORS; GENOMIC ANALYSIS; CUTICULAR WAXES; GENE-EXPRESSION; DAUER FORMATION; LIFE-SPAN; REDUCTASE; IDENTIFICATION	LET-767 from Caenorhabditis elegans belongs to a family of short chain dehydrogenases/ reductases and is homologous to 17 beta-hydroxysterol dehydrogenases of type 3 and 3-ketoacyl-CoA reductases. Worms subjected to RNA interference (RNAi) of let-767 displayed multiple growth and developmental defects in the first generation and arrested in the second generation as L1 larvae. To determine the function of LET-767 in vivo, we exploited a biochemical complementation approach, in which let-767 (RNAi)-arrested larvae were rescued by feeding with compounds isolated from wild type worms. The arrest was only rescued by the addition of triacylglycerides extracted from worms but not from various natural sources, such as animal fats and plant oils. The mass spectrometric analyses showed alterations in the fatty acid content of triacylglycerides. Essential for the rescue were odd-numbered fatty acids with monomethyl branched chains. The rescue was improved when worms were additionally supplemented with long chain even-numbered fatty acids. Remarkably, let-767 completely rescued the yeast 3-ketoacyl-CoA reductase mutant (ybr159 Delta). Because worm ceramides exclusively contain a monomethyl branched chain sphingoid base, we also investigated ceramides in let-767 (RNAi). Indeed, the amount of ceramides was greatly reduced, and unusual sphingoid bases were observed. Taken together, we conclude that LET-767 is a major 3-ketoacyl-CoA reductase in C. elegans required for the bulk production of monomethyl branched and long chain fatty acids, and the developmental arrest in let-767 (RNAi) worms is caused by the deficiency of the former.	[Entchev, Eugeni V.; Schwudke, Dominik; Zagoriy, Vyacheslav; Matyash, Vitali; Bogdanova, Aliona; Habermann, Bianca; Zhu, Lin; Shevchenko, Andrej; Kurzchalia, Teymuras V.] Max Planck Inst Mol Cell Biol & Genet, D-01307 Dresden, Germany	Max Planck Society	Kurzchalia, TV (corresponding author), Max Planck Inst Mol Cell Biol & Genet, Pfotenhauerstr 108, D-01307 Dresden, Germany.	kurzchalia@mpi-cbg.de	Schwudke, Dominik/A-3472-2009; Entchev, Eugeni V/D-2606-2009; Schwudke, Dominik/B-3478-2013; Habermann, Bianca/N-4886-2016	Schwudke, Dominik/0000-0002-1379-9451; Habermann, Bianca/0000-0002-2457-7504; Entchev, Eugeni/0000-0003-0744-5929				Ashrafi K, 2003, NATURE, V421, P268, DOI 10.1038/nature01279; Athenstaedt K, 2000, J BIOL CHEM, V275, P235, DOI 10.1074/jbc.275.1.235; Baugh LR, 2005, DEVELOPMENT, V132, P1843, DOI 10.1242/dev.01782; Beaudoin F, 2000, P NATL ACAD SCI USA, V97, P6421, DOI 10.1073/pnas.110140197; Beaudoin F, 2002, J BIOL CHEM, V277, P11481, DOI 10.1074/jbc.M111441200; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Brock TJ, 2006, PLOS GENET, V2, P997, DOI 10.1371/journal.pgen.0020108; Brugger B, 1997, P NATL ACAD SCI USA, V94, P2339, DOI 10.1073/pnas.94.6.2339; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Chenna R, 2003, NUCLEIC ACIDS RES, V31, P3497, DOI 10.1093/nar/gkg500; CHITWOOD DJ, 1995, LIPIDS, V30, P567, DOI 10.1007/BF02537032; Desnoyers S, 2007, J ENDOCRINOL, V195, P271, DOI 10.1677/JOE-07-0248; Ekroos K, 2002, RAPID COMMUN MASS SP, V16, P1254, DOI 10.1002/rcm.705; Ekroos K, 2002, ANAL CHEM, V74, P941, DOI 10.1021/ac015655c; Entchev EV, 2005, SEMIN CELL DEV BIOL, V16, P175, DOI 10.1016/j.semcdb.2005.01.004; Felsenstein J., 1989, CLADISTICS, V5, P164, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FOLCH J, 1957, J BIOL CHEM, V226, P497; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; GEISSLER WM, 1994, NAT GENET, V7, P34, DOI 10.1038/ng0594-34; Gill MS, 2004, AGING CELL, V3, P413, DOI 10.1111/j.1474-9728.2004.00126.x; Han GS, 2002, J BIOL CHEM, V277, P35440, DOI 10.1074/jbc.M205620200; Held JM, 2006, AGING CELL, V5, P283, DOI 10.1111/j.1474-9726.2006.00218.x; Hill AA, 2000, SCIENCE, V290, P809, DOI 10.1126/science.290.5492.809; Kallberg Y, 2002, PROTEIN SCI, V11, P636, DOI 10.1110/ps.26902; Kamath RS, 2003, NATURE, V421, P231, DOI 10.1038/nature01278; KANEDA T, 1991, MICROBIOL REV, V55, P288, DOI 10.1128/MMBR.55.2.288-302.1991; Kniazeva M, 2004, PLOS BIOL, V2, P1446, DOI 10.1371/journal.pbio.0020257; Kniazeva M, 2003, GENETICS, V163, P159; Kuervers LM, 2003, MOL GENET GENOMICS, V270, P121, DOI 10.1007/s00438-003-0900-9; Kurzchalia TV, 2003, NAT CELL BIOL, V5, P684, DOI 10.1038/ncb0803-684; Leonard AE, 2004, PROG LIPID RES, V43, P36, DOI 10.1016/S0163-7827(03)00040-7; Lesa GM, 2003, J CELL SCI, V116, P4965, DOI 10.1242/jcs.00918; MADURO M, 1995, GENETICS, V141, P977; Matyash V, 2004, PLOS BIOL, V2, P1561, DOI 10.1371/journal.pbio.0020280; McKay RM, 2003, DEV CELL, V4, P131, DOI 10.1016/S1534-5807(02)00411-2; Moon YA, 2003, J BIOL CHEM, V278, P7335, DOI 10.1074/jbc.M211684200; Motola DL, 2006, CELL, V124, P1209, DOI 10.1016/j.cell.2006.01.037; Murphy CT, 2003, NATURE, V424, P277, DOI 10.1038/nature01789; Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352; Oelschlaegel T, 2005, CELL, V120, P773, DOI 10.1016/j.cell.2005.01.032; Puyaubert J, 2005, BBA-MOL CELL BIOL L, V1687, P152, DOI 10.1016/j.bbalip.2004.11.014; Rappleye Chad A, 2003, BMC Dev Biol, V3, P8, DOI 10.1186/1471-213X-3-8; Rossler H, 2003, MOL GENET GENOMICS, V269, P290, DOI 10.1007/s00438-003-0836-0; Schulz TJ, 2007, CELL METAB, V6, P280, DOI 10.1016/j.cmet.2007.08.011; Schwudke D, 2006, ANAL CHEM, V78, P585, DOI 10.1021/ac051605m; Schwudke D, 2007, ANAL CHEM, V79, P4083, DOI 10.1021/ac062455y; Sluder AE, 2001, TRENDS GENET, V17, P206, DOI 10.1016/S0168-9525(01)02242-9; Stewart HI, 1998, MOL GEN GENET, V260, P280, DOI 10.1007/PL00013816; THOMAS BJ, 1989, CELL, V56, P619, DOI 10.1016/0092-8674(89)90584-9; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Van Gilst M, 2002, CRIT REV EUKAR GENE, V12, P65; Vico P, 2002, YEAST, V19, P873, DOI 10.1002/yea.882; VOET D, 2006, FUNDAMENTALS BIOCH, P627; Watts JL, 2002, P NATL ACAD SCI USA, V99, P5854, DOI 10.1073/pnas.092064799; Wilm T, 1999, GENE, V229, P31, DOI 10.1016/S0378-1119(99)00043-8; Xu XJ, 2002, PLANT PHYSIOL, V128, P924, DOI 10.1104/pp.010621; Xu XJ, 1997, PLANT PHYSIOL, V115, P501, DOI 10.1104/pp.115.2.501; Zhang YM, 2000, NAT BIOTECHNOL, V18, P1314, DOI 10.1038/82449	58	61	65	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17550	17560		10.1074/jbc.M800965200	http://dx.doi.org/10.1074/jbc.M800965200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18390550	hybrid			2022-12-25	WOS:000256720600062
J	Pham, P; Smolka, MB; Calabrese, P; Landolph, A; Zhang, K; Zhou, H; Goodman, MF				Pham, Phuong; Smolka, Marcus B.; Calabrese, Peter; Landolph, Alice; Zhang, Ke; Zhou, Huilin; Goodman, Myron F.			Impact of phosphorylation and phosphorylation-null mutants on the activity and deamination specificity of activation-induced cytidine deaminase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; REPLICATION PROTEIN-A; SOMATIC HYPERMUTATION; IMMUNOGLOBULIN GENES; BINDING PROTEIN; AID; SEQUENCE; TARGET; MECHANISMS; EXPRESSION	Activation-induced cytidine deaminase (AID) initiates somatic hypermutation and class switch recombination in B cells by deaminating C -> U on transcribed DNA. Here we analyze the role of phosphorylation and phosphorylation-null mutants on the biochemical behavior of AID, including enzyme specific activity, processivity, deamination spectra, deamination motif specificity, and transcription-dependent deamination in the presence and absence of RPA. We show that a small fraction of recombinant human AID expressed in Sf9 insect cells is phosphorylated at previously identified residues Ser(38) and Thr(27) and also at Ser(41) and Ser(43). S43P AID has been identified in a patient with hyper-IgM immunodeficiency syndrome. Ser-substituted phosphorylation-null mutants (S38A, S41A, S43A, and S43P) exhibit wild type (WT) activity on single-stranded DNA. Deamination of transcribed double-stranded DNA is similar for WT and mutant AID and occurs with or without RPA. Although WT and AID mutants catalyze processive deamination favoring canonical WRC hot spot motifs (where W represents A/T and R is A/G), their deamination spectra differ significantly. The differences between the WT and AID mutants appear to be caused by the replacement of Ser as opposed to an absence of phosphorylation. The spectral differences reflect a marked change in deamination efficiencies in two motifs, GGC and AGC, which are preferred by mutant AID but disfavored by WT AID. Both motifs occur with exceptionally high frequency in human switch regions, suggesting a possible relationship between AID deamination specificity and a loss of antibody diversification.	[Pham, Phuong; Calabrese, Peter; Landolph, Alice; Goodman, Myron F.] Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; [Pham, Phuong; Calabrese, Peter; Landolph, Alice; Goodman, Myron F.] Univ So Calif, Dept Chem, Los Angeles, CA 90089 USA; [Smolka, Marcus B.; Zhou, Huilin] Univ Calif San Diego, Dept Cellular & Mol Med, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; [Zhang, Ke] Univ Calif Los Angeles, Sch Med, Dept Med, Div Clin Immunol Allergy, Los Angeles, CA 90095 USA	University of Southern California; University of Southern California; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Goodman, MF (corresponding author), Univ So Calif, Dept Biol Sci, RRI-201, Los Angeles, CA 90089 USA.	mgoodman@usc.edu		Zhou, Huilin/0000-0002-1350-4430	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R56ES013192, R01ES013192] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM021422, R01GM080469] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES013192] Funding Source: Medline; NIGMS NIH HHS [R01 GM080469-02, GM080469, R01 GM080469, R37GM21422] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barreto VM, 2005, J EXP MED, V202, P733, DOI 10.1084/jem.20051378; Basu U, 2005, NATURE, V438, P508, DOI 10.1038/nature04255; Basu U, 2007, ADV EXP MED BIOL, V596, P129; Besmer E, 2006, MOL CELL BIOL, V26, P4378, DOI 10.1128/MCB.02375-05; Bransteitter R, 2004, J BIOL CHEM, V279, P51612, DOI 10.1074/jbc.M408135200; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Chatterji M, 2007, J IMMUNOL, V179, P5274, DOI 10.4049/jimmunol.179.8.5274; Chaudhuri J, 2004, NATURE, V430, P992, DOI 10.1038/nature02821; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Chelico L, 2006, NAT STRUCT MOL BIOL, V13, P392, DOI 10.1038/nsmb1086; Di Nola JM, 2007, ANNU REV BIOCHEM, V76, P1, DOI 10.1146/annurev.biochem.76.061705.090740; Dickerson SK, 2003, J EXP MED, V197, P1291, DOI 10.1084/jem.20030481; Dorner T, 1998, IMMUNOL REV, V162, P161, DOI 10.1111/j.1600-065X.1998.tb01439.x; Fukita Y, 1998, IMMUNITY, V9, P105, DOI 10.1016/S1074-7613(00)80592-0; Goodman Myron F, 2007, Adv Immunol, V94, P127, DOI 10.1016/S0065-2776(06)94005-X; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; Ito S, 2004, P NATL ACAD SCI USA, V101, P1975, DOI 10.1073/pnas.0307335101; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; LOHMAN TM, 1986, BIOCHEMISTRY-US, V25, P21, DOI 10.1021/bi00349a004; MAIZELS N, 1995, CELL, V83, P9, DOI 10.1016/0092-8674(95)90227-9; McBride KM, 2006, P NATL ACAD SCI USA, V103, P8798, DOI 10.1073/pnas.0603272103; Muramatsu Masamichi, 2007, Adv Immunol, V94, P1, DOI 10.1016/S0065-2776(06)94001-2; Nambu Y, 2003, SCIENCE, V302, P2137, DOI 10.1126/science.1092481; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Pasqualucci L, 2006, P NATL ACAD SCI USA, V103, P395, DOI 10.1073/pnas.0509969103; Peters A, 1996, IMMUNITY, V4, P57, DOI 10.1016/S1074-7613(00)80298-8; Pham P, 2003, NATURE, V424, P103, DOI 10.1038/nature01760; Pham P, 2007, DNA REPAIR, V6, P689, DOI 10.1016/j.dnarep.2007.01.001; Rada C, 2002, P NATL ACAD SCI USA, V99, P7003, DOI 10.1073/pnas.092160999; RAJEWSKY K, 1987, SCIENCE, V238, P1088, DOI 10.1126/science.3317826; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; ROGOZIN IB, 1992, BIOCHIM BIOPHYS ACTA, V1171, P11, DOI 10.1016/0167-4781(92)90134-L; Shapiro GS, 2002, J IMMUNOL, V168, P2302, DOI 10.4049/jimmunol.168.5.2302; Shen HM, 2005, MOL CELL BIOL, V25, P10815, DOI 10.1128/MCB.25.24.10815-10821.2005; Shen HM, 2004, P NATL ACAD SCI USA, V101, P12997, DOI 10.1073/pnas.0404974101; Shinkura R, 2007, ADV EXP MED BIOL, V596, P71; Skalhegg BS, 2000, FRONT BIOSCI-LANDMRK, V5, pD678, DOI 10.2741/Skalhegg; Smith DS, 1996, J IMMUNOL, V156, P2642; Smolka MB, 2005, MOL CELL PROTEOMICS, V4, P1358, DOI 10.1074/mcp.M500115-MCP200; Sohail A, 2003, NUCLEIC ACIDS RES, V31, P2990, DOI 10.1093/nar/gkg464; Stavnezer J, 2000, CURR TOP MICROBIOL, V245, P127; Wakae K, 2006, INT IMMUNOL, V18, P41, DOI 10.1093/intimm/dxh347; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Yoshikawa K, 2002, SCIENCE, V296, P2033, DOI 10.1126/science.1071556; Zhu Yi, 2003, Journal of Medical and Dental Sciences, V50, P41	45	36	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17428	17439		10.1074/jbc.M802121200	http://dx.doi.org/10.1074/jbc.M802121200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18417471	Green Published, hybrid			2022-12-25	WOS:000256720600051
J	Cowieson, NP; King, G; Cookson, D; Ross, I; Huber, T; Hume, DA; Kobe, B; Martin, JL				Cowieson, Nathan P.; King, Gordon; Cookson, David; Ross, Ian; Huber, Thomas; Hume, David A.; Kobe, Bostjan; Martin, Jennifer L.			Cortactin adopts a globular conformation and bundles actin into sheets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN SECONDARY STRUCTURE; CIRCULAR-DICHROISM; ARP2/3 COMPLEX; F-ACTIN; PHOSPHORYLATION; BINDING; ACTIVATION; SRC; MIGRATION; SITES	Cortactin is a filamentous actin-binding protein that plays a pivotal role in translating environmental signals into coordinated rearrangement of the cytoskeleton. The dynamic reorganization of actin in the cytoskeleton drives processes including changes in cell morphology, cell migration, and phagocytosis. In general, structural proteins of the cytoskeleton bind in the N-terminal region of cortactin and regulatory proteins in the C-terminal region. Previous structural studies have reported an extended conformation for cortactin. It is therefore unclear how cortactin facilitates cross-talk between structural proteins and their regulators. In the study presented here, circular dichroism, chemical cross-linking, and small angle x-ray scattering are used to demonstrate that cortactin adopts a globular conformation, thereby bringing distant parts of the molecule into close proximity. In addition, the actin bundling activity of cortactin is characterized, showing that fully polymerized actin filaments are bundled into sheet-like structures. We present a low resolution structure that suggests how the various domains of cortactin interact to coordinate its array of binding partners at sites of actin branching.	[Cowieson, Nathan P.; King, Gordon; Ross, Ian; Hume, David A.; Kobe, Bostjan; Martin, Jennifer L.] Univ Queensland, Special Res Ctr Funct & Appl Genom, Inst Mol Biosci, Brisbane, Qld 4072, Australia; [Cowieson, Nathan P.; King, Gordon; Ross, Ian; Hume, David A.; Kobe, Bostjan; Martin, Jennifer L.] Univ Queensland, ARC, Brisbane, Qld 4072, Australia; [Ross, Ian] Univ Queensland, Cooperat Res Ctr Chron Inflammatory Dis, Brisbane, Qld 4072, Australia; [Huber, Thomas; Hume, David A.; Kobe, Bostjan; Martin, Jennifer L.] Univ Queensland, Sch Mol & Microbiol Sci, Brisbane, Qld 4072, Australia	University of Queensland; University of Queensland; University of Queensland; University of Queensland	Cowieson, NP (corresponding author), Monash Univ, Monash Ctr Synchrotron Sci, Clayton, Vic 3800, Australia.	nathan.cowieson@sync.monash.edu.Au	Ross, Ian/A-8622-2011; Kobe, Bostjan/D-1292-2009; Huber, Thomas/A-5278-2008; Hume, David A/C-7695-2013; King, Gordon/J-8718-2014; Martin, Jennifer L./A-6039-2010	Ross, Ian/0000-0002-2389-4292; Kobe, Bostjan/0000-0001-9413-9166; Huber, Thomas/0000-0002-3680-8699; Martin, Jennifer L./0000-0002-9225-8863; Hume, David/0000-0002-2615-1478				Bono H, 2002, NUCLEIC ACIDS RES, V30, P116, DOI 10.1093/nar/30.1.116; Boyle SN, 2007, CURR BIOL, V17, P445, DOI 10.1016/j.cub.2007.01.057; Cookson D, 2006, J SYNCHROTRON RADIAT, V13, P440, DOI 10.1107/S0909049506030184; Cosen-Binker LI, 2006, PHYSIOLOGY, V21, P352, DOI 10.1152/physiol.00012.2006; Cowieson NP, 2008, PROTEINS, V70, P1142, DOI 10.1002/prot.21631; Dominguez R, 2004, TRENDS BIOCHEM SCI, V29, P572, DOI 10.1016/j.tibs.2004.09.004; Egile C, 2005, PLOS BIOL, V3, P1902, DOI 10.1371/journal.pbio.0030383; Higgs HN, 2001, ANNU REV BIOCHEM, V70, P649, DOI 10.1146/annurev.biochem.70.1.649; Huber M, 2006, PHYS WORLD, V19, P16; Kinley AW, 2003, CURR BIOL, V13, P384, DOI 10.1016/S0960-9822(03)00107-6; Listwan P, 2005, ANAL BIOCHEM, V346, P327, DOI 10.1016/j.ab.2005.06.016; Liu JL, 1999, ONCOGENE, V18, P6700, DOI 10.1038/sj.onc.1203050; Martin KH, 2006, J CELL SCI, V119, P2851, DOI 10.1242/jcs03034; Martinez-Quiles N, 2004, MOL CELL BIOL, V24, P5269, DOI 10.1128/MCB.24.12.5269-5280.2004; McNiven MA, 2000, J CELL BIOL, V151, P187, DOI 10.1083/jcb.151.1.187; Mizutani K, 2002, CANCER RES, V62, P669; Mouradov D, 2006, PROTEIN ENG DES SEL, V19, P9, DOI 10.1093/protein/gzi070; Ouali M, 2000, PROTEIN SCI, V9, P1162, DOI 10.1110/ps.9.6.1162; Pant K, 2006, J MOL BIOL, V359, P840, DOI 10.1016/j.jmb.2006.03.065; ROST B, 1994, COMPUT APPL BIOSCI, V10, P53; Sangrar W, 2007, MOL CELL BIOL, V27, P6140, DOI 10.1128/MCB.01744-06; Sherman MB, 1999, J MOL BIOL, V294, P139, DOI 10.1006/jmbi.1999.3222; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Sreerama N, 2000, ANAL BIOCHEM, V287, P252, DOI 10.1006/abio.2000.4880; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Svergun DI, 1999, BIOPHYS J, V76, P2879, DOI 10.1016/S0006-3495(99)77443-6; SVERGUN DI, 1992, J APPL CRYSTALLOGR, V25, P495, DOI 10.1107/S0021889892001663; Tehrani S, 2007, P NATL ACAD SCI USA, V104, P11933, DOI 10.1073/pnas.0701077104; Uruno T, 2001, NAT CELL BIOL, V3, P259, DOI 10.1038/35060051; van Rossum AGSH, 2003, J BIOL CHEM, V278, P45672, DOI 10.1074/jbc.M306688200; Volkov VV, 2003, J APPL CRYSTALLOGR, V36, P860, DOI 10.1107/S0021889803000268; Weaver AM, 2002, CURR BIOL, V12, P1270, DOI 10.1016/S0960-9822(02)01035-7; Weaver AM, 2001, CURR BIOL, V11, P370, DOI 10.1016/S0960-9822(01)00098-7; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Woody AYM, 2003, BIOPOLYMERS, V72, P500, DOI 10.1002/bip.10488; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; Zhang CT, 1999, PROTEIN ENG, V12, P807, DOI 10.1093/protein/12.10.807; Zhu JW, 2007, J BIOL CHEM, V282, P16086, DOI 10.1074/jbc.M701997200	39	27	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16187	16193		10.1074/jbc.M708917200	http://dx.doi.org/10.1074/jbc.M708917200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18375393	Green Published, hybrid			2022-12-25	WOS:000256332500077
J	Fasanaro, P; D'Alessandra, Y; Di Stefano, V; Melchionna, R; Romani, S; Pompilio, G; Capogrossi, MC; Martelli, F				Fasanaro, Pasquale; D'Alessandra, Yuri; Di Stefano, Valeria; Melchionna, Roberta; Romani, Sveva; Pompilio, Giulio; Capogrossi, Maurizio C.; Martelli, Fabio			MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand Ephrin-A3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGET; ANGIOGENESIS; BIOGENESIS; ACTIVATION; EXPRESSION; MECHANISM; MEMBRANE; MIRNA; HIF	MicroRNAs (miRNAs) are small non-protein-coding RNAs that function as negative gene expression regulators. In the present study, we investigated miRNAs role in endothelial cell response to hypoxia. We found that the expression of miR-210 progressively increased upon exposure to hypoxia. miR-210 overexpression in normoxic endothelial cells stimulated the formation of capillary-like structures on Matrigel and vascular endothelial growth factor-driven cell migration. Conversely, miR-210 blockade via anti-miRNA transfection inhibited the formation of capillary-like structures stimulated by hypoxia and decreased cell migration in response to vascular endothelial growth factor. miR-210 overexpression did not affect endothelial cell growth in both normoxia and hypoxia. However, antimiR-210 transfection inhibited cell growth and induced apoptosis, in both normoxia and hypoxia. We determined that one relevant target of miR-210 in hypoxia was Ephrin-A3 since miR-210 was necessary and sufficient to down-modulate its expression. Moreover, luciferase reporter assays showed that Ephrin-A3 was a direct target of miR-210. Ephrin-A3 modulation by miR-210 had significant functional consequences; indeed, the expression of an Ephrin-A3 allele that is not targeted by miR-210 prevented miR-210-mediated stimulation of both tubulogenesis and chemotaxis. We conclude that miR-210 up-regulation is a crucial element of endothelial cell response to hypoxia, affecting cell survival, migration, and differentiation.	[Fasanaro, Pasquale; Melchionna, Roberta; Romani, Sveva; Capogrossi, Maurizio C.; Martelli, Fabio] IRCCS, Lab Patol Vascolare, Ist Dermopat Immacolata, I-00167 Rome, Italy; [D'Alessandra, Yuri; Pompilio, Giulio] IRCCS, Lab Biol Vascolare & Terapia Gen, Ctr Cardiol Monzino, I-20138 Milan, Italy; [Di Stefano, Valeria] IRCCS, Mol Cardiol Lab, Policlin San Donato, I-20097 Milan, Italy	IRCCS Istituto Dermopatico dell'Immacolata (IDI); IRCCS Centro Cardiologico Monzino; IRCCS Policlinico San Donato	Martelli, F (corresponding author), IRCCS, Lab Patol Vascolare, Ist Dermopat Immacolata, I-00167 Rome, Italy.	f.martelli@idi.it	Pompilio, Giulio/J-6701-2014; Melchionna, Roberta/AAZ-4111-2021; Huang, H/E-9490-2010; melchionna, Roberta/G-2479-2011; D'Alessandra, Yuri/K-4098-2016; Martelli, Fabio/AAL-3788-2020	Pompilio, Giulio/0000-0003-2581-5735; Melchionna, Roberta/0000-0002-8410-9681; D'Alessandra, Yuri/0000-0002-3440-2353; Martelli, Fabio/0000-0002-8624-7738				Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Camps C, 2008, CLIN CANCER RES, V14, P1340, DOI 10.1158/1078-0432.CCR-07-1755; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; DAVIS S, 1994, SCIENCE, V266, P816, DOI 10.1126/science.7973638; Donker RB, 2007, MOL HUM REPROD, V13, P273, DOI 10.1093/molehr/gam006; Giaccia AJ, 2004, GENE DEV, V18, P2183, DOI 10.1101/gad.1243304; Giannakakis A, 2008, CANCER BIOL THER, V7, P255, DOI 10.4161/cbt.7.2.5297; Guzy RD, 2006, EXP PHYSIOL, V91, P807, DOI 10.1113/expphysiol.2006.033506; Hebert C, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-5; Hua Z, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000116; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; KUBOTA Y, 1988, J CELL BIOL, V107, P1589, DOI 10.1083/jcb.107.4.1589; Kuijper S, 2007, TRENDS CARDIOVAS MED, V17, P145, DOI 10.1016/j.tcm.2007.03.003; Kulshreshtha R, 2008, CELL DEATH DIFFER, V15, P667, DOI 10.1038/sj.cdd.4402310; KULSHRESHTHA R, 2006, MOL CELL BIOL, V28, P28; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Luo FM, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-26; Mekhail K, 2004, CELL CYCLE, V3, P1027; PANDEY A, 1995, SCIENCE, V268, P567, DOI 10.1126/science.7536959; Pouyssegur J, 2006, NATURE, V441, P437, DOI 10.1038/nature04871; Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677; Rajewsky N, 2006, NAT GENET, V38, pS8, DOI 10.1038/ng1798; Sethupathy P, 2006, NAT METHODS, V3, P881, DOI 10.1038/NMETH954; Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460; Yamakawa M, 2003, CIRC RES, V93, P664, DOI 10.1161/01.RES.0000093984.48643.D7; Zaccagnini G, 2004, CIRCULATION, V109, P2917, DOI 10.1161/01.CIR.0000129309.58874.0F; Zamore PD, 2005, SCIENCE, V309, P1519, DOI 10.1126/science.1111444	27	704	765	1	53	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15878	15883		10.1074/jbc.M800731200	http://dx.doi.org/10.1074/jbc.M800731200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18417479	Green Published, hybrid			2022-12-25	WOS:000256332500046
J	Forsberg, LS; Carlson, RW				Forsberg, L. Scott; Carlson, Russell W.			Structural characterization of the primary O-antigenic polysaccharide of the Rhizobium leguminosarum 3841 lipopolysaccharide and identification of a new 3-acetimidoylamino-3-deoxyhexuronic acid glycosyl component - A unique O-methylated glycan of uniform size, containing 6-deoxy-3-O-methyl-D-talose, N-acetylquinovosamine, and rhizoaminuronic acid (3-acetimidoylamino-3-deoxy-D-gluco-hexuronic acid)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RHIZOBIUM-LEGUMINOSARUM; PSEUDOMONAS-AERUGINOSA; SP NGR234; BIOCHEMICAL-CHARACTERIZATION; CAPSULAR POLYSACCHARIDE; K-ANTIGENS; LIPID-A; ETLI; BIOSYNTHESIS; INFECTION	Rhizobium are Gram-negative bacteria that survive intracellularly, within host membrane-derived plant cell compartments called symbiosomes. Within the symbiosomes the bacteria differentiate to bacteroids, the active form that carries out nitrogen fixation. The progression from free-living bacteria to bacteroid is characterized by physiological and morphological changes at the bacterial surface, a phase shift with an altered array of cell surface glycoconjugates. Lipopolysaccharides undergo structural changes upon differentiation from the free living to the bacteroid (intracellular) form. The array of carbohydrate structures carried on lipopolysaccharides confer resistance to plant defense mechanisms and may serve as signals that trigger the plant to allow the infection to proceed. We have determined the structure of the major O-polysaccharide (OPS) isolated from free living Rhizobium leguminosarum 3841, a symbiont of Pisum sativum, using chemical methods, mass spectrometry, and NMR spectroscopy analysis. The OPS is composed of several unusual glycosyl residues, including 6-deoxy-3-O-methyl-D-talose and 2-acetamido-2deoxy-L-quinovosamine. In addition, a new glycosyl residue, 3-acetimidoylamino-3-deoxy-D-gluco-hexuronic acid was identified and characterized, a novel hexosaminuronic acid that does not have an amino group at the 2-position. The OPS is composed of three to four tetrasaccharide repeating units of -->4)-beta-DGlcp3NAmA-(1-->4)-[2-O-Ac-3-O-Me-alpha-D-6dTalp-(1-->3)]-alpha-L-Fucp(1-->3)-alpha-L-QuipNAc-(1-->. The unique 3-amino hexuronate residue, rhizoaminuronic acid, is an attractive candidate for selective inhibition of OPS synthesis.	[Forsberg, L. Scott; Carlson, Russell W.] Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30605 USA	University System of Georgia; University of Georgia	Carlson, RW (corresponding author), Univ Georgia, Complex Carbohydrate Res Ctr, Athens, GA 30605 USA.	rcarlson@ccrc.uga.edu			NIGMS NIH HHS [R01 GM039583, GM39583] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039583] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen CA, 1998, INFECT IMMUN, V66, P1008, DOI 10.1128/IAI.66.3.1008-1016.1998; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Becker A, 2005, MOL PLANT MICROBE IN, V18, P899, DOI 10.1094/MPMI-18-0899; BHAT UR, 1992, J BACTERIOL, V174, P2230, DOI 10.1128/JB.174.7.2230-2235.1992; BHAT UR, 1994, J BIOL CHEM, V269, P14402; BHAT UR, 1991, INT J SYST BACTERIOL, V41, P213; BRADLEY DJ, 1988, PLANTA, V173, P149, DOI 10.1007/BF00403006; Brewin N.J., 1998, RHIZOBIACEAE, P417; Broughton WJ, 2000, J BACTERIOL, V182, P5641, DOI 10.1128/JB.182.20.5641-5652.2000; Campbell GRO, 2002, P NATL ACAD SCI USA, V99, P3938, DOI 10.1073/pnas.062425699; CARLSON RW, 1987, J BACTERIOL, V169, P4923, DOI 10.1128/jb.169.11.4923-4928.1987; Catalano CM, 2004, ELECTROPHORESIS, V25, P519, DOI 10.1002/elps.200305711; CUMMINS CS, 1983, J BACTERIOL, V153, P1388, DOI 10.1128/JB.153.3.1388-1393.1983; D'Haeze W, 2004, TRENDS MICROBIOL, V12, P555, DOI 10.1016/j.tim.2004.10.009; D'Haeze W, 2007, J BIOL CHEM, V282, P17101, DOI 10.1074/jbc.M611669200; Dahiya P, 1998, MOL PLANT MICROBE IN, V11, P915, DOI 10.1094/MPMI.1998.11.9.915; DAVIS AL, 1991, J MAGN RESON, V94, P637, DOI 10.1016/0022-2364(91)90154-L; Ernst RK, 1999, SCIENCE, V286, P1561, DOI 10.1126/science.286.5444.1561; Forsberg LS, 1998, J BIOL CHEM, V273, P2747, DOI 10.1074/jbc.273.5.2747; Forsberg LS, 2003, J BIOL CHEM, V278, P51347, DOI 10.1074/jbc.M309016200; Forsberg LS, 1997, J BACTERIOL, V179, P5366, DOI 10.1128/jb.179.17.5366-5371.1997; Forsberg LS, 2000, J BIOL CHEM, V275, P18851, DOI 10.1074/jbc.M001090200; Fraysse N, 2002, GLYCOBIOLOGY, V12, P741, DOI 10.1093/glycob/cwf078; GERWIG GJ, 1979, CARBOHYD RES, V77, P1, DOI 10.1016/S0008-6215(00)83788-X; Gudlavalleti SK, 2003, J BIOL CHEM, V278, P3957, DOI 10.1074/jbc.M210491200; JANSSON PE, 1987, J CHEM SOC PERK T 1, P377, DOI 10.1039/p19870000377; KANNENBERG EL, 1994, J BACTERIOL, V176, P2021, DOI 10.1128/jb.176.7.2021-2032.1994; Kannenberg EL, 2001, MOL MICROBIOL, V39, P379, DOI 10.1046/j.1365-2958.2001.02225.x; KANNENBERG EL, 1998, RHIZOBIACEAE, P119; Kilcoyne M, 2005, CARBOHYD RES, V340, P2369, DOI 10.1016/j.carres.2005.07.007; Knirel YA, 2003, ADV CARBOHYD CHEM BI, V58, P371, DOI 10.1016/S0065-2318(03)58007-6; KNIREL YA, 1987, EUR J BIOCHEM, V167, P549, DOI 10.1111/j.1432-1033.1987.tb13372.x; Le Quere AJL, 2006, J BIOL CHEM, V281, P28981, DOI 10.1074/jbc.M513639200; MacLean LL, 2003, EUR J BIOCHEM, V270, P3440, DOI 10.1046/j.1432-1033.2003.03736.x; MACURA S, 1981, J MAGN RESON, V43, P259, DOI 10.1016/0022-2364(81)90037-8; Mathis R, 2005, P NATL ACAD SCI USA, V102, P2655, DOI 10.1073/pnas.0409816102; MAYER H, 1989, PURE APPL CHEM, V61, P1271, DOI 10.1351/pac198961071271; Mergaert P, 2006, P NATL ACAD SCI USA, V103, P5230, DOI 10.1073/pnas.0600912103; Messner P, 1997, FEMS MICROBIOL REV, V20, P25, DOI 10.1016/S0168-6445(97)00041-7; Miller WL, 2004, J BIOL CHEM, V279, P37551, DOI 10.1074/jbc.M404749200; Nedal A, 2004, APPL MICROBIOL BIOT, V64, P7, DOI 10.1007/s00253-003-1535-9; Noel KD, 2004, APPL ENVIRON MICROB, V70, P1537, DOI 10.1128/AEM.70.3.1537-1544.2004; Noel KD, 2000, J BACTERIOL, V182, P5317, DOI 10.1128/JB.182.19.5317-5324.2000; PAZUR JH, 1980, METHODS CARBOHYDR CH, V8, P107; Peschel A, 2002, TRENDS MICROBIOL, V10, P179, DOI 10.1016/S0966-842X(02)02333-8; Reuhs BL, 1998, APPL ENVIRON MICROB, V64, P4930; Reuhs BL, 2005, J BACTERIOL, V187, P6479, DOI 10.1128/JB.187.18.6479-6487.2005; Rocchetta HL, 1999, MICROBIOL MOL BIOL R, V63, P523, DOI 10.1128/MMBR.63.3.523-553.1999; Rosenberger CM, 2004, P NATL ACAD SCI USA, V101, P2422, DOI 10.1073/pnas.0304455101; Roth L. E., 1991, Microbial cell-cell interactions., P255; Sadovskaya I, 1998, EUR J BIOCHEM, V253, P319, DOI 10.1046/j.1432-1327.1998.2530319.x; Shashkov AS, 2002, CARBOHYD RES, V337, P1119, DOI 10.1016/S0008-6215(02)00101-5; TAO H, 1992, J BACTERIOL, V174, P2222, DOI 10.1128/JB.174.7.2222-2229.1992; Turska-Szewczuk A, 2009, MICROBIOL RES, V164, P163, DOI 10.1016/j.micres.2006.11.011; UMEZAWA S, 1967, B CHEM SOC JPN, V40, P2419, DOI 10.1246/bcsj.40.2419; Vedam V, 2006, J BACTERIOL, V188, P2126, DOI 10.1128/JB.188.6.2126-2133.2006; Vinogradov E, 2002, CARBOHYD RES, V337, P961; Wilkinson SG, 1996, PROG LIPID RES, V35, P283, DOI 10.1016/S0163-7827(96)00004-5; YAMADA H, 1980, CARBOHYD RES, V83, P377, DOI 10.1016/S0008-6215(00)84550-4; Young JPW, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-4-r34; Zahringer U, 1997, CARBOHYD RES, V300, P143, DOI 10.1016/S0008-6215(96)00304-7	61	22	24	0	7	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16037	16050		10.1074/jbc.M709615200	http://dx.doi.org/10.1074/jbc.M709615200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18387959	Green Published, hybrid			2022-12-25	WOS:000256332500062
J	Brown, AM; Baucum, AJ; Bass, MA; Colbran, RJ				Brown, Abigail M.; Baucum, Anthony J.; Bass, Martha A.; Colbran, Roger J.			Association of protein phosphatase 1 gamma(1) with spinophilin suppresses phosphatase activity in a Parkinson disease model	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRIATAL SYNAPTIC PLASTICITY; DOPA-INDUCED DYSKINESIA; LONG-TERM POTENTIATION; KINASE-II; POSTSYNAPTIC DENSITY; DENDRITIC SPINES; PHOSPHORYLATION; NEURABIN; ACTIN; ISOFORMS	Sustained nigrostriatal dopamine depletion increases the serine/ threonine phosphorylation of multiple striatal proteins that play a role in corticostriatal synaptic plasticity, including Thr(286) phosphorylation of calcium/calmodulin-dependent protein kinase II alpha ( CaMKII alpha). Mechanisms underlying these changes are unclear, but protein phosphatases play a critical role in the acute modulation of striatal protein phosphorylation. Here we show that dopamine depletion for periods ranging from 3 weeks to 10 months significantly reduces the total activity of protein phosphatase ( PP) 1, but not of PP2A, in whole lysates of rat striatum, as measured using multiple substrates, including Thr(286)-autophosphorylated CaMKII alpha. Striatal PP1 activity is partially inhibited by a fragment of the PP1-binding protein neurabin-I, Nb-(146-493), because of the selective inhibition of the PP1 gamma(1) isoform. The fraction of PP1 activity that is insensitive to Nb-(146-493) was unaffected by dopamine depletion, demonstrating that dopamine depletion specifically reduces the activity of PP1 isoforms that are sensitive to Nb-( 146-493) ( i. e. PP1 gamma(1)). However, total striatal levels of PP1 gamma(1) or any other PP1 isoform were unaffected by dopamine depletion, and our previous studies showed that total levels of the PP1 regulatory/ targeting proteins DARPP-32, spinophilin, and neurabin were also unchanged. Rather, co-immunoprecipitation experiments demonstrated that dopamine depletion increases the association of PP1 gamma(1) with spinophilin in striatal extracts. In combination, these data demonstrate that striatal dopamine depletion inhibits a specific synaptic phosphatase by increasing PP1 gamma(1) interaction with spinophilin, perhaps contributing to hyperphosphorylation of synaptic proteins and disruptions of synaptic plasticity and/or dendritic morphology.	[Brown, Abigail M.; Baucum, Anthony J.; Bass, Martha A.; Colbran, Roger J.] Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Nashville, TN 37232 USA; [Baucum, Anthony J.; Colbran, Roger J.] Vanderbilt Univ, Sch Med, Ctr Mol Neurosci, Nashville, TN 37232 USA; [Colbran, Roger J.] Vanderbilt Univ, Sch Med, Vanderbilt Kennedy Ctr Res Human Dev, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Colbran, RJ (corresponding author), Vanderbilt Univ, Sch Med, Dept Mol Physiol & Biophys, Rm 702 Light Hall, Nashville, TN 37232 USA.	roger.colbran@vanderbilt.edu	Baucum, Anthony/I-5109-2013; Colbran, Roger/AAU-7708-2021	Baucum, Anthony/0000-0002-4756-9865; Colbran, Roger/0000-0001-7401-8244; Brown, Abigail/0000-0001-9504-3465	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH063232, T32MH065215] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS044282] Funding Source: NIH RePORTER; NIMH NIH HHS [T32 MH 65215, R01 MH 63232] Funding Source: Medline; NINDS NIH HHS [P01 NS044282-010002, P01 NS044282, P01 NS 044282] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen PB, 2006, NEUROSCIENCE, V140, P897, DOI 10.1016/j.neuroscience.2006.02.067; Allen PB, 2004, PARKINSONISM RELAT D, V10, P287, DOI 10.1016/j.parkreldis.2004.02.016; Arbuthnott GW, 2000, J ANAT, V196, P587, DOI 10.1046/j.1469-7580.2000.19640587.x; Begley MJ, 2005, CURR OPIN STRUC BIOL, V15, P614, DOI 10.1016/j.sbi.2005.10.016; Blitzer RD, 1998, SCIENCE, V280, P1940, DOI 10.1126/science.280.5371.1940; Bordelon JR, 2005, CEREB CORTEX, V15, P1928, DOI 10.1093/cercor/bhi070; Brown AM, 2005, EUR J NEUROSCI, V22, P247, DOI 10.1111/j.1460-9568.2005.04190.x; Brown GP, 2000, J NEUROSCI, V20, P7880; Buchsbaum RJ, 2003, J BIOL CHEM, V278, P18833, DOI 10.1074/jbc.M207876200; Carmody LC, 2004, J BIOL CHEM, V279, P21714, DOI 10.1074/jbc.M402261200; CARMODY LC, 2008, IN PRESS FASEB J; Cenci MA, 2002, NAT REV NEUROSCI, V3, P574, DOI 10.1038/nrn877; Centonze D, 2001, EUR J NEUROSCI, V13, P1071, DOI 10.1046/j.0953-816x.2001.01485.x; Centonze D, 1999, J NEUROPHYSIOL, V82, P3575, DOI 10.1152/jn.1999.82.6.3575; Chergui K, 2004, P NATL ACAD SCI USA, V101, P2191, DOI 10.1073/pnas.0308652100; COHEN P, 1991, METHOD ENZYMOL, V201, P389; Colbran RJ, 2003, METHOD ENZYMOL, V366, P156; Colbran RJ, 1997, J NEUROCHEM, V69, P920; Day M, 2006, NAT NEUROSCI, V9, P251, DOI 10.1038/nn1632; Dunah AW, 2000, MOL PHARMACOL, V57, P342; Feng J, 2000, P NATL ACAD SCI USA, V97, P9287, DOI 10.1073/pnas.97.16.9287; Fleming IN, 1999, J BIOL CHEM, V274, P12753, DOI 10.1074/jbc.274.18.12753; Fukunaga K, 2000, J NEUROCHEM, V74, P807, DOI 10.1046/j.1471-4159.2000.740807.x; Grossman SD, 2004, J NEUROCHEM, V90, P317, DOI 10.1111/j.1471-4159.2004.02491.x; Hsieh-Wilson LC, 2003, J BIOL CHEM, V278, P1186, DOI 10.1074/jbc.M205754200; Hu XD, 2006, J NEUROCHEM, V98, P1841, DOI 10.1111/j.1471-4159.2006.04070.x; Ingham CA, 1998, J NEUROSCI, V18, P4732; Jonkers N, 2002, BRAIN RES, V926, P149, DOI 10.1016/S0006-8993(01)03147-X; Lisman J, 2002, NAT REV NEUROSCI, V3, P175, DOI 10.1038/nrn753; Liu F, 2005, EUR J NEUROSCI, V22, P1942, DOI 10.1111/j.1460-9568.2005.04391.x; MacMillan LB, 1999, J BIOL CHEM, V274, P35845, DOI 10.1074/jbc.274.50.35845; MCNEILL TH, 1988, BRAIN RES, V455, P148, DOI 10.1016/0006-8993(88)90124-2; Meshul CK, 1999, NEUROSCIENCE, V88, P1, DOI 10.1016/S0306-4522(98)00189-4; Norman ED, 2005, NEUROPHARMACOLOGY, V48, P311, DOI 10.1016/j.neuropharm.2004.09.018; Oh JD, 1999, BRAIN RES, V821, P433, DOI 10.1016/S0006-8993(99)01121-X; Oliver CJ, 2002, MOL CELL BIOL, V22, P4690, DOI 10.1128/MCB.22.13.4690-4701.2002; OUIMET CC, 1995, P NATL ACAD SCI USA, V92, P3396, DOI 10.1073/pnas.92.8.3396; Picconi B, 2004, J NEUROSCI, V24, P5283, DOI 10.1523/JNEUROSCI.1224-04.2004; Picconi B, 2003, NAT NEUROSCI, V6, P501, DOI 10.1038/nn1040; Pisani A, 2005, MOVEMENT DISORD, V20, P395, DOI 10.1002/mds.20394; Sarrouilhe D, 2006, BIOCHIMIE, V88, P1099, DOI 10.1016/j.biochi.2006.04.010; Schneider A, 2004, J BIOL CHEM, V279, P55833, DOI 10.1074/jbc.M409954200; SHIMA H, 1993, BIOCHEM BIOPH RES CO, V192, P1289, DOI 10.1006/bbrc.1993.1556; SILVA EFDE, 1995, J NEUROSCI, V15, P3375; Strack S, 1999, J COMP NEUROL, V413, P373; Strack S, 1997, J BIOL CHEM, V272, P13467, DOI 10.1074/jbc.272.21.13467; Strack S, 1997, J NEUROCHEM, V68, P2119; Strong MJ, 2005, J NEUROPATH EXP NEUR, V64, P649, DOI 10.1097/01.jnen.0000173889.71434.ea; Svenningsson P, 2004, ANNU REV PHARMACOL, V44, P269, DOI 10.1146/annurev.pharmtox.44.101802.121415; Terry-Lorenzo RT, 2005, MOL BIOL CELL, V16, P2349, DOI 10.1091/mbc.E04-12-1054; Terry-Lorenzo RT, 2002, J BIOL CHEM, V277, P27716, DOI 10.1074/jbc.M203365200; Weeber EJ, 2003, J NEUROSCI, V23, P2634; Westin JE, 2007, BIOL PSYCHIAT, V62, P800, DOI 10.1016/j.biopsych.2006.11.032; Wu LJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001407; Yan Z, 1999, NAT NEUROSCI, V2, P13, DOI 10.1038/4516; Zaja-Milatovic S, 2005, NEUROLOGY, V64, P545, DOI 10.1212/01.WNL.0000150591.33787.A4	56	25	26	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14286	14294		10.1074/jbc.M801377200	http://dx.doi.org/10.1074/jbc.M801377200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18372251	hybrid, Green Published			2022-12-25	WOS:000255941400015
J	Harkonen, T; Jussi, M; Jussi, I; Verevkin, M; Dmitrieva, L; Helle, E; Sagitov, R; Harding, KC				Harkonen, Tero; Jussi, Mart; Jussi, Ivar; Verevkin, Michail; Dmitrieva, Lilia; Helle, Eero; Sagitov, Roustam; Harding, Karin C.			Seasonal Activity Budget of Adult Baltic Ringed Seals	PLOS ONE			English	Article								Although ringed seals are important components in oceanic and fresh water ecosystems at high latitudes, little is known about how they exploit these harsh environments. Seasonal activity and diving behaviour of 19 adult Baltic ringed seals were studied by satellite telemetry. We elaborated an activity budget for ten months of the year, extending over the period from moult to the breeding season. Seals from three main regions showed explicit site fidelity and the distributions of animals tagged from different areas did not overlap, suggesting separate stocks. Both the mean duration and the mean depth of dives peaked in June and July. Seals spent 70% (females) to 85% (males) of their time diving in June and July which decreased to 50% in late autumn. Less than one percent of dives exceeded 10 min in females, while 10% of male dives lasted longer than 10 min in June to September. Less than one percent of dives lasted for more than 25 min. Both females and males were most active during day time and hauled out predominantly during the night. Activity patterns during the summer are suggested to be correlated to energy accumulation and prey availability. The information on seasonal activity budget is crucial for developing population energetic models where interactions between ringed seals and other trophic levels can be evaluated.	[Harkonen, Tero] Swedish Museum Nat Hist, S-10405 Stockholm, Sweden; [Jussi, Mart] Estonian Fund for Nature, Tartu, Estonia; [Jussi, Ivar] Estonian Marine Institute, Tallinn, Estonia; [Verevkin, Michail; Sagitov, Roustam] St Petersburg State Univ, St Petersburg, Russia; [Dmitrieva, Lilia] St Petersburg Naturalist Soc, St Petersburg, Russia; [Helle, Eero] Finnish Game & Fisheries Res Inst, Helsinki, Finland; [Harding, Karin C.] Gothenburg Univ, Dept Marine Ecol, Gothenburg, Sweden	Swedish Museum of Natural History; University of Tartu; Estonian Marine Institute; Saint Petersburg State University; Natural Resources Institute Finland (Luke); University of Gothenburg	Harkonen, T (corresponding author), Swedish Museum Nat Hist, S-10405 Stockholm, Sweden.	tero.harkonen@nrm.se	Harding, Karin/F-9957-2013	Harding, Karin/0000-0003-1527-0903	Wallenberg foundation; World Wide Fund for Nature (Sweden); Swedish Environment Protection Agency; Finnish Game Research Institute; Estonian Fund for Nature	Wallenberg foundation(European Commission); World Wide Fund for Nature (Sweden); Swedish Environment Protection Agency; Finnish Game Research Institute; Estonian Fund for Nature	This study was supported by the Wallenberg foundation, World Wide Fund for Nature (Sweden), The Swedish Environment Protection Agency, The Finnish Game Research Institute and the Estonian Fund for Nature.	Bergman A., 1985, FINNISH GAME RES, V44, P47; Born EW, 2004, ARCTIC, V57, P129; Born EW, 2002, MAR MAMMAL SCI, V18, P167, DOI 10.1111/j.1748-7692.2002.tb01026.x; Damgaard J, 1998, HYDROBIOLOGIA, V377, P9, DOI 10.1023/A:1003256906580; EBERHARDT LL, 1990, CAN J FISH AQUAT SCI, V47, P122, DOI 10.1139/f90-012; FOWLER CW, 1990, MAR MAMMAL SCI, V6, P171, DOI 10.1111/j.1748-7692.1990.tb00242.x; Gjertz I, 2000, POLAR BIOL, V23, P651, DOI 10.1007/s003000000143; Harding KC, 1999, AMBIO, V28, P619; Harkonen Tero, 1998, NAMMCO Scientific Publications, V1, P167; HEIDEJORGENSEN MP, 1992, ECOGRAPHY, V15, P56, DOI 10.1111/j.1600-0587.1992.tb00008.x; HELLE E, 1980, ANN ZOOL FENN, V17, P147; HELLE E, 1986, FINNISH GAME RES, V44, P28; JEVREJEVA S, 2002, REPORT SERIES GEOPHY, V44, P31; Kapel Finn O., 1998, NAMMCO Scientific Publications, V1, P211; Kelly BP, 1996, CAN J ZOOL, V74, P1547, DOI 10.1139/z96-169; Kunnasranta M., 2001, THESIS U JOENSUU FIN; Ojaveer E, 1988, BALTIC HERRINGS BIOL; Palo J., 2003, THESIS U HELSINKI FI; Ries EH, 1997, CAN J ZOOL, V75, P2063, DOI 10.1139/z97-840; Seina A, 1996, MERI, V27, P79; Soderberg S., 1972, SALENS FODOVAL SKADE; Stewart BS, 1996, MAR MAMMAL SCI, V12, P528; Teilmann J, 1999, CAN J ZOOL, V77, P1934, DOI 10.1139/cjz-77-12-1934; THOMPSON PM, 1989, J APPL ECOL, V26, P521, DOI 10.2307/2404078; Thompson PM, 1996, J APPL ECOL, V33, P1572, DOI 10.2307/2404795; Tollit DJ, 1998, J ZOOL, V244, P209, DOI 10.1111/j.1469-7998.1998.tb00026.x; TORMOSOV DD, 1978, FINN GAME RES, V37, P14; [No title captured]	28	21	22	0	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e2006	10.1371/journal.pone.0002006	http://dx.doi.org/10.1371/journal.pone.0002006			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414676	Green Submitted, Green Published, gold			2022-12-25	WOS:000260867300025
J	Kuhlman, SJ; Huang, ZJ				Kuhlman, Sandra J.; Huang, Z. Josh			High-Resolution Labeling and Functional Manipulation of Specific Neuron Types in Mouse Brain by Cre-Activated Viral Gene Expression	PLOS ONE			English	Article								We describe a method that combines Cre-recombinase knockin mice and viral-mediated gene transfer to genetically label and functionally manipulate specific neuron types in the mouse brain. We engineered adeno-associated viruses (AAVs) that express GFP, dsRedExpress, or channelrhodopsin (ChR2) upon Cre/loxP recombination-mediated removal of a transcription-translation STOP cassette. Fluorescent labeling was sufficient to visualize neuronal structures with synaptic resolution in vivo, and ChR2 expression allowed light activation of neuronal spiking. The structural dynamics of a specific class of neocortical neuron, the parvalbumin-containing (Pv) fast-spiking GABAergic interneuron, was monitored over the course of a week. We found that although the majority of Pv axonal boutons were stable in young adults, bouton additions and subtractions on axonal shafts were readily observed at a rate of 10.10% and 9.47%, respectively, over 7 days. Our results indicate that Pv inhibitory circuits maintain the potential for structural re-wiring in post-adolescent cortex. With the generation of an increasing number of Cre knockin mice and because viral transfection can be delivered to defined brain regions at defined developmental stages, this strategy represents a general method to systematically visualize the structure and manipulate the function of different cell types in the mouse brain.	[Kuhlman, Sandra J.; Huang, Z. Josh] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Huang, ZJ (corresponding author), Cold Spring Harbor Lab, POB 100, Cold Spring Harbor, NY 11724 USA.	huangj@cshl.edu	Kuhlman, Sandra/Q-1211-2015	Kuhlman, Sandra/0000-0003-0450-7282; Huang, Z. Josh/0000-0003-0592-028X	NARSAD; NIH; Mathes Foundation;  [MH070052-05]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH070052] Funding Source: NIH RePORTER	NARSAD(NARSAD); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Mathes Foundation; ; NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	NARSAD to S.J.K.; NIH and Mathes Foundation to Z.J.H.; supported in part by grant MH070052-05 to Karel Svoboda	Arlotta P, 2005, NEURON, V45, P207, DOI 10.1016/j.neuron.2004.12.036; Awatramani R, 2001, NAT GENET, V29, P257, DOI 10.1038/ng1101-257; Boyden ES, 2005, NAT NEUROSCI, V8, P1263, DOI 10.1038/nn1525; Branda CS, 2004, DEV CELL, V6, P7, DOI 10.1016/S1534-5807(03)00399-X; Cetin A, 2006, NAT PROTOC, V1, P3166, DOI 10.1038/nprot.2006.450; Chamberlin NL, 1998, BRAIN RES, V793, P169, DOI 10.1016/S0006-8993(98)00169-3; Chattopadhyaya B, 2004, J NEUROSCI, V24, P9598, DOI 10.1523/JNEUROSCI.1851-04.2004; Daly Thomas M, 2004, Methods Mol Biol, V246, P157; DeAngelis GC, 1999, J NEUROSCI, V19, P4046; Dittgen T, 2004, P NATL ACAD SCI USA, V101, P18206, DOI 10.1073/pnas.0407976101; Dong JY, 1996, HUM GENE THER, V7, P2101, DOI 10.1089/hum.1996.7.17-2101; Dumitriu D, 2007, CEREB CORTEX, V17, P81, DOI 10.1093/cercor/bhj126; Dymecki SM, 2007, NEURON, V54, P17, DOI 10.1016/j.neuron.2007.03.009; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; GONG S, 2003, GENE EXPRESSION ATLA, V425, P917; Grutzendler J, 2002, NATURE, V420, P812, DOI 10.1038/nature01276; Guo HL, 2000, BIOCHEM BIOPH RES CO, V273, P661, DOI 10.1006/bbrc.2000.2870; Hippenmeyer S, 2005, PLOS BIOL, V3, P878, DOI 10.1371/journal.pbio.0030159; HOLTMAAT AJ, 2004, IMAGING NEURONS, P624; Jiao YY, 2006, J NEUROSCI, V26, P8691, DOI 10.1523/JNEUROSCI.2478-06.2006; Kawaguchi Y, 2006, CEREB CORTEX, V16, P696, DOI 10.1093/cercor/bhj015; Knott GW, 2002, NEURON, V34, P265, DOI 10.1016/S0896-6273(02)00663-3; Lee WCA, 2006, PLOS BIOL, V4, P271, DOI 10.1371/journal.pbio.0040029; Lein ES, 2007, NATURE, V445, P168, DOI 10.1038/nature05453; Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107; Majewska AK, 2006, J NEUROSCI, V26, P3021, DOI 10.1523/JNEUROSCI.4454-05.2006; Nagel G, 2003, P NATL ACAD SCI USA, V100, P13940, DOI 10.1073/pnas.1936192100; Nelson SB, 2006, TRENDS NEUROSCI, V29, P339, DOI 10.1016/j.tins.2006.05.004; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Ohki K, 2005, NATURE, V433, P597, DOI 10.1038/nature03274; Oliva AA, 2000, J NEUROSCI, V20, P3354, DOI 10.1523/JNEUROSCI.20-09-03354.2000; Osten P, 2007, Handb Exp Pharmacol, P177; Passini Marco A, 2004, Methods Mol Biol, V246, P225; Pologruto TA, 2003, BIOMED ENG ONLINE, V2, DOI 10.1186/1475-925X-2-13; Rumpel S, 2005, SCIENCE, V308, P83, DOI 10.1126/science.1103944; Stosiek C, 2003, P NATL ACAD SCI USA, V100, P7319, DOI 10.1073/pnas.1232232100; Sugino K, 2006, NAT NEUROSCI, V9, P99, DOI 10.1038/nn1618; Trachtenberg JT, 2002, NATURE, V420, P788, DOI 10.1038/nature01273; van den Pol AN, 2004, NEURON, V42, P635, DOI 10.1016/S0896-6273(04)00251-X; Wang JH, 2007, P NATL ACAD SCI USA, V104, P13104, DOI 10.1073/pnas.0702778104; Yoshimura Y, 2005, NATURE, V433, P868, DOI 10.1038/nature03252	42	137	172	1	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e2005	10.1371/journal.pone.0002005	http://dx.doi.org/10.1371/journal.pone.0002005			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414675	Green Accepted, Green Submitted, Green Published, gold			2022-12-25	WOS:000260867300024
J	Jimenez-Diaz, L; Geranton, SM; Passmore, GM; Leith, JL; Fisher, AS; Berliocchi, L; Sivasubramaniam, AK; Sheasby, A; Lumb, BM; Hunt, SP				Jimenez-Diaz, Lydia; Geranton, Sandrine M.; Passmore, Gayle M.; Leith, J. Lianne; Fisher, Amy S.; Berliocchi, Laura; Sivasubramaniam, Anantha K.; Sheasby, Anne; Lumb, Bridget M.; Hunt, Stephen P.			Local Translation in Primary Afferent Fibers Regulates Nociception	PLOS ONE			English	Article							PROTEIN S6 PHOSPHORYLATION; MENTAL-RETARDATION PROTEIN; ROOT GANGLION NEURONS; SYNAPTIC PLASTICITY; MAMMALIAN TARGET; CENTRAL SENSITIZATION; MECHANICAL STIMULI; INFLAMMATORY PAIN; SIGNALING PATHWAY; RNA TRANSLATION	Recent studies have demonstrated the importance of local protein synthesis for neuronal plasticity. In particular, local mRNA translation through the mammalian target of rapamycin (mTOR) has been shown to play a key role in regulating dendrite excitability and modulating long-term synaptic plasticity associated with learning and memory. There is also increased evidence to suggest that intact adult mammalian axons have a functional requirement for local protein synthesis in vivo. Here we show that the translational machinery is present in some myelinated sensory fibers and that active mTOR-dependent pathways participate in maintaining the sensitivity of a subpopulation of fast-conducting nociceptors in vivo. Phosphorylated mTOR together with other downstream components of the translational machinery were localized to a subset of myelinated sensory fibers in rat cutaneous tissue. We then showed with electromyographic studies that the mTOR inhibitor rapamycin reduced the sensitivity of a population of myelinated nociceptors known to be important for the increased mechanical sensitivity that follows injury. Behavioural studies confirmed that local treatment with rapamycin significantly attenuated persistent pain that follows tissue injury, but not acute pain. Specifically, we found that rapamycin blunted the heightened response to mechanical stimulation that develops around a site of injury and reduced the long-term mechanical hypersensitivity that follows partial peripheral nerve damage - a widely used model of chronic pain. Our results show that the sensitivity of a subset of sensory fibers is maintained by ongoing mTOR-mediated local protein synthesis and uncover a novel target for the control of long-term pain states.	[Jimenez-Diaz, Lydia; Geranton, Sandrine M.; Berliocchi, Laura; Sivasubramaniam, Anantha K.; Sheasby, Anne; Hunt, Stephen P.] UCL, Dept Anat & Dev Biol, London, England; [Passmore, Gayle M.; Fisher, Amy S.] UCL, Dept Pharmacol, London, England; [Leith, J. Lianne; Lumb, Bridget M.] Dept Physiol, Bristol, Avon, England; [Jimenez-Diaz, Lydia] Univ Salamanca, Inst Neuroci Castilla Leon, Fac Med, Dept Fisiol, Salamanca, Spain; [Berliocchi, Laura] Ctr Expt Neurobiol Mondino Tor Vergata, IRRCS C Mondino, Rome, Italy	University of London; University College London; University of London; University College London; University of Salamanca	Hunt, SP (corresponding author), UCL, Dept Anat & Dev Biol, London, England.	hunt@ucl.ac.uk	Sivasubramaniam, Anantha Krishna/AHB-2476-2022; Jiménez-Diaz, Lydia/R-8383-2019	Sivasubramaniam, Anantha Krishna/0000-0002-2464-0104; Jiménez-Diaz, Lydia/0000-0001-9121-0334; Berliocchi, Laura/0000-0002-3014-1838; Hunt, Stephen/0000-0001-9453-5505; Lumb, Bridget/0000-0002-0268-6419	Wellcome Trust [065374]; Spanish MEC [JCI-2005-1775-25]	Wellcome Trust(Wellcome TrustEuropean Commission); Spanish MEC(Spanish Government)	This work was supported by research grants from the Wellcome Trust to the London Pain Consortium 065374 and JCI-2005-1775-25 from the Spanish MEC.	Bailey CH, 2004, NEURON, V44, P49, DOI 10.1016/j.neuron.2004.09.017; Banko JL, 2006, J NEUROSCI, V26, P2167, DOI 10.1523/JNEUROSCI.5196-05.2006; Basbaum AI, 2006, SCI AM, V294, P60, DOI 10.1038/scientificamerican0606-60; Bear MF, 2004, TRENDS NEUROSCI, V27, P370, DOI 10.1016/j.tins.2004.04.009; Ben Mamou C, 2006, NAT NEUROSCI, V9, P1237, DOI 10.1038/nn1778; Bester H, 1997, J COMP NEUROL, V383, P439; Carroll P, 1998, NAT NEUROSCI, V1, P42, DOI 10.1038/242; CHAN AW, 1992, J NEUROL NEUROSUR PS, V55, P56, DOI 10.1136/jnnp.55.1.56; Corradetti MN, 2006, ONCOGENE, V25, P6347, DOI 10.1038/sj.onc.1209885; Craner MJ, 2002, ANN NEUROL, V52, P786, DOI 10.1002/ana.10364; Decosterd I, 2000, PAIN, V87, P149, DOI 10.1016/S0304-3959(00)00276-1; Devor M, 2006, J PAIN, V7, pS3, DOI 10.1016/j.jpain.2005.09.006; Djouhri L, 2004, BRAIN RES REV, V46, P131, DOI 10.1016/j.brainresrev.2004.07.015; Duvarci S, 2006, EUR J NEUROSCI, V24, P249, DOI 10.1111/j.1460-9568.2006.04907.x; Foster DA, 2007, CANCER RES, V67, P1, DOI 10.1158/0008-5472.CAN-06-3016; Gilchrist HD, 1996, PAIN, V67, P179, DOI 10.1016/0304-3959(96)03104-1; Hanz S, 2003, NEURON, V40, P1095, DOI 10.1016/S0896-6273(03)00770-0; HARGREAVES K, 1988, PAIN, V32, P77, DOI 10.1016/0304-3959(88)90026-7; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Holz MK, 2005, CELL, V123, P569, DOI 10.1016/j.cell.2005.10.024; Hou LF, 2004, J NEUROSCI, V24, P6352, DOI 10.1523/JNEUROSCI.0995-04.2004; Hunt SP, 2001, NAT REV NEUROSCI, V2, P83, DOI 10.1038/35053509; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; Ji RR, 2003, TRENDS NEUROSCI, V26, P696, DOI 10.1016/j.tins.2003.09.017; Ji RR, 2001, NEUROBIOL DIS, V8, P1, DOI 10.1006/nbdi.2000.0360; Karim F, 2001, J NEUROSCI, V21, P3771, DOI 10.1523/JNEUROSCI.21-11-03771.2001; Klann E, 2004, LEARN MEMORY, V11, P365, DOI 10.1101/lm.79004; Klann E, 2004, NAT REV NEUROSCI, V5, P931, DOI 10.1038/nrn1557; Koenig E, 2000, J NEUROSCI, V20, P8390, DOI 10.1523/JNEUROSCI.20-22-08390.2000; Koltzenburg M, 2001, CURR OPIN NEUROL, V14, P641, DOI 10.1097/00019052-200110000-00014; Koltzenburg M, 1999, EUR J NEUROSCI, V11, P1698, DOI 10.1046/j.1460-9568.1999.00590.x; KRESS M, 1992, J NEUROPHYSIOL, V68, P581, DOI 10.1152/jn.1992.68.2.581; Lawson SN, 2002, J PHYSIOL-LONDON, V540, P989, DOI 10.1113/jphysiol.2001.013086; Lawson SN, 1996, J COMP NEUROL, V365, P355; Lawson SN, 1997, J PHYSIOL-LONDON, V505, P177, DOI 10.1111/j.1469-7793.1997.00177.x; Leith JL, 2007, J NEUROSCI, V27, P11296, DOI 10.1523/JNEUROSCI.2586-07.2007; Lewin GR, 2004, J NEUROBIOL, V61, P30, DOI 10.1002/neu.20078; Lumpkin EA, 2007, NATURE, V445, P858, DOI 10.1038/nature05662; Magerl W, 2001, BRAIN, V124, P1754, DOI 10.1093/brain/124.9.1754; Mannion RJ, 1999, P NATL ACAD SCI USA, V96, P9385, DOI 10.1073/pnas.96.16.9385; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; McMullan S, 2004, J NEUROSCI METH, V138, P133, DOI 10.1016/j.jneumeth.2004.03.020; McMullan S, 2006, PAIN, V124, P59, DOI 10.1016/j.pain.2006.03.015; Meyer RA, 2006, WALL MELZACKS TXB PA, V5, P3; Murashov AK, 2007, FASEB J, V21, P656, DOI 10.1096/fj.06-6155com; Oshiro N, 2004, GENES CELLS, V9, P359, DOI 10.1111/j.1356-9597.2004.00727.x; Pare M, 2001, J NEUROSCI, V21, P7236, DOI 10.1523/JNEUROSCI.21-18-07236.2001; Perlson E, 2005, NEURON, V45, P715, DOI 10.1016/j.neuron.2005.01.023; Piper M, 2004, ANNU REV CELL DEV BI, V20, P505, DOI 10.1146/annurev.cellbio.20.010403.111746; Price TJ, 2006, NEUROSCIENCE, V141, P2107, DOI 10.1016/j.neuroscience.2006.05.047; Price TJ, 2007, J NEUROSCI, V27, P13958, DOI 10.1523/JNEUROSCI.4383-07.2007; Raab-Graham KF, 2006, SCIENCE, V314, P144, DOI 10.1126/science.1131693; REEH PW, 1986, NEUROSCI LETT, V66, P141, DOI 10.1016/0304-3940(86)90180-1; Reiling JH, 2006, ONCOGENE, V25, P6373, DOI 10.1038/sj.onc.1209889; Rice FL, 1998, DEV BIOL, V198, P57, DOI 10.1006/dbio.1998.8861; Roux PP, 2007, J BIOL CHEM, V282, P14056, DOI 10.1074/jbc.M700906200; Ruvinsky I, 2006, TRENDS BIOCHEM SCI, V31, P342, DOI 10.1016/j.tibs.2006.04.003; Schratt GM, 2006, NATURE, V439, P283, DOI 10.1038/nature04367; Schratt GM, 2004, J NEUROSCI, V24, P7366, DOI 10.1523/JNEUROSCI.1739-04.2004; Sotelo-Silveira JR, 2006, TRAFFIC, V7, P508, DOI 10.1111/j.1600-0854.2006.00405.x; Sutton MA, 2006, CELL, V127, P49, DOI 10.1016/j.cell.2006.09.014; Suzuki R, 2002, NAT NEUROSCI, V5, P1319, DOI 10.1038/nn966; Takei N, 2004, J NEUROSCI, V24, P9760, DOI 10.1523/JNEUROSCI.1427-04.2004; TAL M, 1994, PAIN, V57, P375, DOI 10.1016/0304-3959(94)90013-2; Tang SJ, 2002, P NATL ACAD SCI USA, V99, P467, DOI 10.1073/pnas.012605299; TILLMAN DB, 1995, J PHYSIOL-LONDON, V485, P753, DOI 10.1113/jphysiol.1995.sp020766; Treede R D, 2000, Prog Brain Res, V129, P331; Tukey JW, 1977, EXPLORATORY DATA ANA; Verma P, 2005, J NEUROSCI, V25, P331, DOI 10.1523/JNEUROSCI.3073-04.2005; Weragoda RMS, 2007, J NEUROPHYSIOL, V98, P1231, DOI 10.1152/jn.01189.2006; Weragoda RMS, 2004, J NEUROSCI, V24, P10393, DOI 10.1523/JNEUROSCI.2329-04.2004; Wetzel C, 2007, NATURE, V445, P206, DOI 10.1038/nature05394; Willis D, 2005, J NEUROSCI, V25, P778, DOI 10.1523/JNEUROSCI.4235-04.2005; Willis DE, 2007, J CELL BIOL, V178, P965, DOI 10.1083/jcb.200703209; WOOLF CJ, 1983, NATURE, V306, P686, DOI 10.1038/306686a0; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; Wu KY, 2005, NATURE, V436, P1020, DOI 10.1038/nature03885; Zeitz KP, 2002, J NEUROSCI, V22, P1010, DOI 10.1523/JNEUROSCI.22-03-01010.2002; Zheng JQ, 2001, J NEUROSCI, V21, P9291, DOI 10.1523/JNEUROSCI.21-23-09291.2001; Ziegler EA, 1999, BRAIN, V122, P2245, DOI 10.1093/brain/122.12.2245	80	119	125	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1961	10.1371/journal.pone.0001961	http://dx.doi.org/10.1371/journal.pone.0001961			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398477	Green Published, gold, Green Submitted			2022-12-25	WOS:000260795500030
J	Thorrez, L; Van Deun, K; Tranchevent, LC; Van Lommel, L; Engelen, K; Marchal, K; Moreau, Y; Van Mechelen, I; Schuit, F				Thorrez, Lieven; Van Deun, Katrijn; Tranchevent, Leon-Charles; Van Lommel, Leentje; Engelen, Kristof; Marchal, Kathleen; Moreau, Yves; Van Mechelen, Iven; Schuit, Frans			Using Ribosomal Protein Genes as Reference: A Tale of Caution	PLOS ONE			English	Article								Background: Housekeeping genes are needed in every tissue as their expression is required for survival, integrity or duplication of every cell. Housekeeping genes commonly have been used as reference genes to normalize gene expression data, the underlying assumption being that they are expressed in every cell type at approximately the same level. Often, the terms "reference genes'' and "housekeeping genes'' are used interchangeably. In this paper, we would like to distinguish between these terms. Consensus is growing that housekeeping genes which have traditionally been used to normalize gene expression data are not good reference genes. Recently, ribosomal protein genes have been suggested as reference genes based on a meta-analysis of publicly available microarray data. Methodology/Principal Findings: We have applied several statistical tools on a dataset of 70 microarrays representing 22 different tissues, to assess and visualize expression stability of ribosomal protein genes. We confirmed the housekeeping status of these genes, but further estimated expression stability across tissues in order to assess their potential as reference genes. One- and two-way ANOVA revealed that all ribosomal protein genes have significant expression variation across tissues and exhibit tissue-dependent expression behavior as a group. Via multidimensional unfolding analysis, we visualized this tissue-dependency. In addition, we explored mechanisms that may cause tissue dependent effects of individual ribosomal protein genes. Conclusions/Significance: Here we provide statistical and biological evidence that ribosomal protein genes exhibit important tissue-dependent variation in mRNA expression. Though these genes are most stably expressed of all investigated genes in a meta-analysis they cannot be considered true reference genes.	[Thorrez, Lieven; Van Lommel, Leentje; Schuit, Frans] Katholieke Univ Leuven, Dept Mol Cell Biol, Gene Express Unit, Louvain, Belgium; [Thorrez, Lieven; Tranchevent, Leon-Charles; Moreau, Yves] Katholieke Univ Leuven, ESAT SCD, Dept Elect Engn, Louvain, Belgium; [Van Deun, Katrijn; Van Mechelen, Iven] Katholieke Univ Leuven, Dept Psychol, Louvain, Belgium; [Engelen, Kristof; Marchal, Kathleen] Katholieke Univ Leuven, Dept Microb & Mol Syst, Louvain, Belgium; [Thorrez, Lieven; Van Deun, Katrijn; Tranchevent, Leon-Charles; Van Lommel, Leentje; Engelen, Kristof; Marchal, Kathleen; Moreau, Yves; Van Mechelen, Iven; Schuit, Frans] KU Leuven Ctr Computat Syst Biol, SymBioSys, Louvain, Belgium	KU Leuven; KU Leuven; KU Leuven; KU Leuven; KU Leuven	Thorrez, L (corresponding author), Katholieke Univ Leuven, Dept Mol Cell Biol, Gene Express Unit, Louvain, Belgium.	frans.schuit@med.kuleuven.be	Thorrez, Lieven/A-2583-2011; Marchal, Kathleen/B-5001-2013; Marchal, Kathleen/O-7936-2017	Thorrez, Lieven/0000-0002-5896-6823; Marchal, Kathleen/0000-0002-2169-4588; Marchal, Kathleen/0000-0002-2169-4588; Moreau, Yves/0000-0002-4647-6560; Tranchevent, Leon-Charles/0000-0002-1257-4824; Engelen, Kristof/0000-0001-6215-1689	Katholieke Universiteit Leuven [GOA/2004/11]; Belgian Federal Science Policy Office; EU-RTD: ERNSI: FP6-MC-EST Bioptrain	Katholieke Universiteit Leuven(KU Leuven); Belgian Federal Science Policy Office(Belgian Federal Science Policy Office); EU-RTD: ERNSI: FP6-MC-EST Bioptrain	This research was supported by research grants from the Katholieke Universiteit Leuven (GOA 2004 11 to the FS laboratory, GOA AMBioRICS (2004 2009) and SymBioSys, CoE EF 05 007) and the Belgian Federal Science Policy Office (IUAP P6 25 BioMaGNet, 2007 2011). L. Tranchevent is funded by EU-RTD, ERNSI, FP6 MC EST Bioptrain. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Bachman NJ, 1997, GENOMICS, V42, P146, DOI 10.1006/geno.1997.4687; Borg I, 2010, MODERN MULTIDIMENSIO; Brinkhof B, 2006, ANAL BIOCHEM, V356, P36, DOI 10.1016/j.ab.2006.06.001; Butte AJ, 2001, PHYSIOL GENOMICS, V7, P95, DOI 10.1152/physiolgenomics.2001.7.2.95; Cooper GM, 2000, CELL MOL APPROACH; Cuccurese M, 2005, NUCLEIC ACIDS RES, V33, P5965, DOI 10.1093/nar/gki905; de Jonge HJM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000898; Dydensborg AB, 2006, AM J PHYSIOL-GASTR L, V290, pG1067, DOI 10.1152/ajpgi.00234.2005; Fromont-Racine M, 2003, GENE, V313, P17, DOI 10.1016/S0378-1119(03)00629-2; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Glare EM, 2002, THORAX, V57, P765, DOI 10.1136/thorax.57.9.765; Hsiao LL, 2001, PHYSIOL GENOMICS, V7, P97, DOI 10.1152/physiolgenomics.00040.2001; Kouadjo KE, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-127; Lee PD, 2002, GENOME RES, V12, P292, DOI 10.1101/gr.217802; Lee S, 2007, J BIOCHEM MOL BIOL, V40, P226; Maccoux LJ, 2007, BMC MOL BIOL, V8, DOI 10.1186/1471-2199-8-62; Nakao M, 2005, NUCLEIC ACIDS RES, V33, P2355, DOI 10.1093/nar/gki520; Peters IR, 2007, VET IMMUNOL IMMUNOP, V117, P55, DOI 10.1016/j.vetimm.2007.01.011; RUBIN AD, 1968, NATURE, V220, P196, DOI 10.1038/220196a0; Schoonjans L, 2003, STEM CELLS, V21, P90, DOI 10.1634/stemcells.21-1-90; Suzuki T, 2000, BIOTECHNIQUES, V29, P332, DOI 10.2144/00292rv02; Thellin O, 1999, J BIOTECHNOL, V75, P291, DOI 10.1016/S0168-1656(99)00163-7; Van Deun K, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-181; VanRaay TJ, 1996, GENOMICS, V37, P172, DOI 10.1006/geno.1996.0538	25	151	154	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1854	10.1371/journal.pone.0001854	http://dx.doi.org/10.1371/journal.pone.0001854			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365009	Green Published, gold			2022-12-25	WOS:000260762400015
J	Alm-Kristiansen, AH; Saether, T; Matre, V; Gilfillan, S; Dahle, O; Gabrielsen, OS				Alm-Kristiansen, A. H.; Saether, T.; Matre, V.; Gilfillan, S.; Dahle, O.; Gabrielsen, O. S.			FLASH acts as a co-activator of the transcription factor c-Myb and localizes to active RNA polymerase II foci	ONCOGENE			English	Article						FLASH; CASP8AP2; c-myb; PML; Cajal bodies; RNA polymerase II	PML NUCLEAR-BODIES; CAJAL BODIES; GLUCOCORTICOID-RECEPTOR; GENE-REGULATION; RAG-2 PROMOTER; FACTOR-BINDING; CELL-NUCLEUS; V-MYB; NF-M; CBP	The c-Myb oncoprotein is a DNA-binding transcription factor with a key role in early stages of hematopoiesis. To expand our knowledge of partners cooperating with c-Myb, we performed a yeast two-hybrid screening with full-length c-Myb as bait. Here, we report FLICE-associated huge protein (FLASH)/CASP8AP2 as a novel Myb-interacting protein. We show that FLASH interacts with the DNA-binding domain of c-Myb and enhances c-Myb-dependent reporter activity and expression of endogenous c-Myb target genes. Chromatin immunoprecipitation assays revealed that FLASH and c-Myb both associate with the MYC promoter region as well as with the intronic enhancer of the c-Myb target gene ADA. Furthermore, siRNA knock-down of FLASH or c-Myb both result in a reduction of MYC and ADA expression. The co-activator effect is mediated through the C-terminal part of FLASH, which binds c-Myb. The FLASH-induced enhancement is comparable with the increase seen with the c-Myb co-activator p300. We find FLASH localized in discrete nuclear speckles in several cell lines, co-localized with c-Myb in active RNA polymerase II foci. These results imply a novel molecular mechanism of regulation of c-Myb activity. We propose that c-Myb cooperates with FLASH in foci associated with active RNA polymerase II, leading to enhancement of Myb-dependent gene activation.	[Alm-Kristiansen, A. H.; Saether, T.; Matre, V.; Gilfillan, S.; Dahle, O.; Gabrielsen, O. S.] Univ Oslo, Dept Mol Biosci, N-0316 Oslo, Norway	University of Oslo	Gabrielsen, OS (corresponding author), Univ Oslo, Dept Mol Biosci, PB1041, N-0316 Oslo, Norway.	o.s.gabrielsen@imbv.uio.no		Saether, Thomas/0000-0003-4976-3810				Barcaroli D, 2006, P NATL ACAD SCI USA, V103, P14802, DOI 10.1073/pnas.0604225103; Barcaroli D, 2006, P NATL ACAD SCI USA, V103, P14808, DOI 10.1073/pnas.0604227103; Berge T, 2007, BLOOD CELL MOL DIS, V39, P278, DOI 10.1016/j.bcmd.2007.05.007; Boisvert FM, 2000, J CELL BIOL, V148, P283, DOI 10.1083/jcb.148.2.283; BURK O, 1993, EMBO J, V12, P2027, DOI 10.1002/j.1460-2075.1993.tb05852.x; Carpinelli MR, 2004, P NATL ACAD SCI USA, V101, P6553, DOI 10.1073/pnas.0401496101; Cioce M, 2005, ANNU REV CELL DEV BI, V21, P105, DOI 10.1146/annurev.cellbio.20.010403.103738; Dahle O, 2004, EXP CELL RES, V297, P118, DOI 10.1016/j.yexcr.2004.03.014; Dahle O, 2003, EUR J BIOCHEM, V270, P1338, DOI 10.1046/j.1432-1033.2003.03504.x; Dai P, 1996, GENE DEV, V10, P528, DOI 10.1101/gad.10.5.528; De Guzman RN, 2006, J MOL BIOL, V355, P1005, DOI 10.1016/j.jmb.2005.09.059; Dellaire G, 2004, BIOESSAYS, V26, P963, DOI 10.1002/bies.20089; Emambokus N, 2003, EMBO J, V22, P4478, DOI 10.1093/emboj/cdg434; ESS KC, 1995, MOL CELL BIOL, V15, P5707; Flotho C, 2006, BLOOD, V108, P1050, DOI 10.1182/blood-2006-01-0322; Fraser P, 2007, NATURE, V447, P413, DOI 10.1038/nature05916; Handwerger KE, 2006, TRENDS CELL BIOL, V16, P19, DOI 10.1016/j.tcb.2005.11.005; Imai Y, 1999, NATURE, V398, P777, DOI 10.1038/19709; Kasper LH, 2002, NATURE, V419, P738, DOI 10.1038/nature01062; Kino T, 2004, J STEROID BIOCHEM, V92, P357, DOI 10.1016/j.jsbmb.2004.09.003; Kino T, 2003, J BIOL CHEM, V278, P3023, DOI 10.1074/jbc.M209234200; Kittler R, 2004, NATURE, V432, P1036, DOI 10.1038/nature03159; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Lipsick JS, 1999, ONCOGENE, V18, P3047, DOI 10.1038/sj.onc.1202745; Milovic-Holm K, 2007, EMBO J, V26, P391, DOI 10.1038/sj.emboj.7601504; Miranda GA, 2002, MOL IMMUNOL, V38, P1151, DOI 10.1016/S0161-5890(02)00007-X; MUCENSKI ML, 1991, CELL, V65, P677, DOI 10.1016/0092-8674(91)90099-K; NESS SA, 1993, GENE DEV, V7, P749, DOI 10.1101/gad.7.5.749; Obradovic D, 2004, MOL PHARMACOL, V65, P761, DOI 10.1124/mol.65.3.761; Oelgeschlager M, 1996, EMBO J, V15, P2771, DOI 10.1002/j.1460-2075.1996.tb00637.x; Oh IH, 1999, ONCOGENE, V18, P3017, DOI 10.1038/sj.onc.1202839; Saether T, 2007, J BIOL CHEM, V282, P13994, DOI 10.1074/jbc.M700755200; Sakamoto H, 2006, BLOOD, V108, P896, DOI 10.1182/blood-2005-09-3846; Salomoni P, 2002, CELL, V108, P165, DOI 10.1016/S0092-8674(02)00626-8; Sandberg ML, 2005, DEV CELL, V8, P153, DOI 10.1016/j.devcel.2004.12.015; Schmidt M, 2000, MOL CELL BIOL, V20, P1970, DOI 10.1128/MCB.20.6.1970-1981.2000; Sexton T, 2007, NAT STRUCT MOL BIOL, V14, P1049, DOI 10.1038/nsmb1324; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; Sun J, 2005, J CELL SCI, V118, P4995, DOI 10.1242/jcs.02613; Vegiopoulos A, 2006, BLOOD, V107, P4703, DOI 10.1182/blood-2005-07-2968; Wang QF, 2000, MOL CELL BIOL, V20, P9203, DOI 10.1128/MCB.20.24.9203-9211.2000; Zimber A, 2004, CELL SIGNAL, V16, P1085, DOI 10.1016/j.cellsig.2004.03.020; Zor T, 2004, J MOL BIOL, V337, P521, DOI 10.1016/j.jmb.2004.01.038	43	40	42	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4644	4656		10.1038/onc.2008.105	http://dx.doi.org/10.1038/onc.2008.105			13	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408764				2022-12-25	WOS:000258236300003
J	Matsui, Y; Watanabe, J; Ikegawa, M; Kamoto, T; Ogawa, O; Nishiyama, H				Matsui, Y.; Watanabe, J.; Ikegawa, M.; Kamoto, T.; Ogawa, O.; Nishiyama, H.			Cancer-specific enhancement of cisplatin-induced cytotoxicity with triptolide through an interaction of inactivated glycogen synthase kinase-3 beta with p53	ONCOGENE			English	Article						urothelial cancer; cisplatin; triptolide; p53; p21; GSK3 beta	TUMOR-NECROSIS-FACTOR; KINASE-C-ALPHA; TRIPTERYGIUM-WILFORDII; INDUCED APOPTOSIS; BLADDER-CANCER; CELL-DEATH; SUSTAINED ACTIVATION; CARCINOMA-CELLS; DNA-DAMAGE; PROLIFERATION	To improve conventional chemotherapeutic efficacy, a combination use of traditional medicines is effective but detailed mechanisms have been rarely elucidated. In the this study, we attempted to clarify how triptolide (PG490), an oxygenated diterpene derived from a Chinese herb, enhances the cisplatin (CDDP)-induced cytotoxicity in urothelial cancer cells. Our results showed that a combined CDDP/triptolide therapy induced apoptosis in urothelial cancer cell lines with wild-type p53, but not in those with mutant-type p53 or normal human urothelium. As the mechanism, triptolide suppressed CDDP-induced p53 transcriptional activity, leading to p21 attenuation, which promoted apoptosis via the activation of c-Jun N-terminal kinase (JNK) and Bax. We further demonstrated that the functional regulation of p53 by triptolide was mediated by an intranuclear association of p53 with glycogen synthase kinase-3 beta (GSK3 beta), which was inactivated by protein kinase C (PKC). This modulation of the PKC-GSK3 beta axis by triptolide was observed in a cancer-specific manner. A mouse xenograft model also showed that a combined CDDP/triptolide therapy completely suppressed tumor growth without any side effects. We expect that cancer-specific enhancement of CDDP-induced cytotoxicity with triptolide may effectively overcome the resistance to a CDDP-based conventional chemotherapy as a treatment for urothelial cancer.	[Matsui, Y.; Watanabe, J.; Kamoto, T.; Ogawa, O.; Nishiyama, H.] Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, Kyoto 6608507, Japan; [Ikegawa, M.] Kyoto Prefectural Univ, Grad Sch Med Sci, Dept Genom Med Sci, Kyoto 606, Japan	Kyoto University; Kyoto Prefectural University	Ogawa, O (corresponding author), Kyoto Univ, Grad Sch Med, Dept Urol, Sakyo Ku, 54 Shogoin Kawaharacho, Kyoto 6608507, Japan.	ogawao@kuhp.kyoto-u.ac.jp	MATSUI, Yoshiyuki/I-2323-2019; Ikegawa, Masaya/AAG-5327-2020					Aaltonen V, 2006, J HISTOCHEM CYTOCHEM, V54, P795, DOI 10.1369/jhc.5A6839.2006; Asada M, 1999, EMBO J, V18, P1223, DOI 10.1093/emboj/18.5.1223; Bode AM, 2004, NAT REV CANCER, V4, P793, DOI 10.1038/nrc1455; Camacho-Carvajal MM, 2004, MOL CELL PROTEOMICS, V3, P176, DOI 10.1074/mcp.T300010-MCP200; Carter BZ, 2006, BLOOD, V108, P630, DOI 10.1182/blood-2005-09-3898; Chang WT, 2001, J BIOL CHEM, V276, P2221, DOI 10.1074/jbc.M009713200; Chen BJ, 2000, TRANSPLANTATION, V70, P1442, DOI 10.1097/00007890-200011270-00008; Cibere J, 2003, J RHEUMATOL, V30, P465; Cote RJ, 1997, NATURE, V385, P123, DOI 10.1038/385123b0; Coutts AS, 2005, BIOCHEM BIOPH RES CO, V331, P778, DOI 10.1016/j.bbrc.2005.03.150; Demidenko ZN, 2004, CANCER RES, V64, P3653, DOI 10.1158/0008-5472.CAN-04-0204; Erster S, 2004, MOL CELL BIOL, V24, P6728, DOI 10.1128/MCB.24.15.6728-6741.2004; Fidler JM, 2003, MOL CANCER THER, V2, P855; Gartel AL, 2002, MOL CANCER THER, V1, P639; Huang S, 2003, MOL CELL, V11, P1491, DOI 10.1016/S1097-2765(03)00180-1; Jiang XH, 2004, CANCER RES, V64, P5787, DOI 10.1158/0008-5472.CAN-03-1172; Jiang XH, 2001, ONCOGENE, V20, P8009, DOI 10.1038/sj.onc.1204981; Koivunen J, 2004, CANCER RES, V64, P5693, DOI 10.1158/0008-5472.CAN-03-3511; Kulikov R, 2005, MOL CELL BIOL, V25, P7170, DOI 10.1128/MCB.25.16.7170-7180.2005; KUPCHAN SM, 1972, J AM CHEM SOC, V94, P7194, DOI 10.1021/ja00775a078; Lam KS, 2003, ACCOUNTS CHEM RES, V36, P370, DOI 10.1021/ar0201299; Lee KY, 1999, J BIOL CHEM, V274, P13451, DOI 10.1074/jbc.274.19.13451; Lou YJ, 2005, LEUKEMIA RES, V29, P99, DOI 10.1016/j.leukres.2004.05.014; Mandil R, 2001, CANCER RES, V61, P4612; Mansouri A, 2003, J BIOL CHEM, V278, P19245, DOI 10.1074/jbc.M208134200; Matsui Y, 2007, CANCER RES, V67, P1212, DOI 10.1158/0008-5472.CAN-06-3283; Miyata Y, 2005, BIOCHEM BIOPH RES CO, V336, P1081, DOI 10.1016/j.bbrc.2005.08.247; Nishiyama H, 2004, EUR UROL, V45, P176, DOI 10.1016/j.eururo.2003.09.011; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Nogawa M, 2005, CANCER LETT, V217, P243, DOI 10.1016/j.canlet.2004.07.010; Qiu DM, 1999, J BIOL CHEM, V274, P13443, DOI 10.1074/jbc.274.19.13443; SARKIS AS, 1995, J CLIN ONCOL, V13, P1384, DOI 10.1200/JCO.1995.13.6.1384; Shamon LA, 1997, CANCER LETT, V112, P113, DOI 10.1016/S0304-3835(96)04554-5; SOUTHGATE J, 1994, LAB INVEST, V71, P583; Tan J, 2005, CANCER RES, V65, P9012, DOI 10.1158/0008-5472.CAN-05-1226; Wan CK, 2006, CANCER LETT, V241, P31, DOI 10.1016/j.canlet.2005.10.001; Watanabe J, 2006, ONCOGENE, V25, P2500, DOI 10.1038/sj.onc.1209162; Watcharasit P, 2003, J BIOL CHEM, V278, P48872, DOI 10.1074/jbc.M305870200; Watcharasit P, 2002, P NATL ACAD SCI USA, V99, P7951, DOI 10.1073/pnas.122062299; Weiss RH, 2003, CANCER CELL, V4, P425, DOI 10.1016/S1535-6108(03)00308-8; Weiss RH, 2003, CANCER LETT, V189, P39, DOI 10.1016/S0304-3835(02)00495-0; Yang SM, 2003, MOL CANCER THER, V2, P65	42	29	33	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4603	4614		10.1038/onc.2008.89	http://dx.doi.org/10.1038/onc.2008.89			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18391982				2022-12-25	WOS:000258077300009
J	Bonhomme, C; Calon, A; Martin, E; Robine, S; Neuville, A; Kedinger, M; Domon-Dell, C; Duluc, I; Freund, JN				Bonhomme, C.; Calon, A.; Martin, E.; Robine, S.; Neuville, A.; Kedinger, M.; Domon-Dell, C.; Duluc, I.; Freund, J-N			Cdx1, a dispensable homeobox gene for gut development with limited effect in intestinal cancer	ONCOGENE			English	Article						Cdx; intestine; cancer; development; mouse	DOWN-REGULATION; EXPRESSION; COLON; DIFFERENTIATION	The homeobox gene Cdx1 is involved in anteroposterior patterning in embryos and its expression selectively persists in the intestinal epithelium throughout life. In human colon cancers, Cdx1 is overexpressed in few cases and lost in the majority of adenocarcinomas. We used mouse models of gain and loss-of-function to investigate the role of Cdx1 in intestinal development and cancers. Transgenic mice overexpressing Cdx1 and knockout mice exhibited a morphologically normal intestine. Cell proliferation, specification into the four differentiated lineages and migration along the crypt-villus axis were unchanged compared to wild-type mice. Changing Cdx1 caused an inverse and dose-dependent modi. cation of the expression of the paralogous gene Cdx2, indicating that Cdx1. ne-tunes Cdx2 activity. Transgenenic and knockout mice failed to spontaneously develop tumours. Over-expressing Cdx1 was without incidence on the frequency of intestinal tumours induced chemically by azoxymethane treatment or genetically in Apc(Delta 14/+) mice. However, it augmented the severity of the tumours in Apc(Delta 14/+) mice. Inversely, the loss-of-function of Cdx1 in knockout mice was without incidence on the growth of tumours induced by azoxymethane. We conclude that Cdx1 is dispensable for intestinal development and that its overexpression could increase malignancy in early stages of tumourigenesis.	[Bonhomme, C.; Calon, A.; Martin, E.; Neuville, A.; Kedinger, M.; Domon-Dell, C.; Duluc, I.; Freund, J-N] INSERM U682, F-67200 Strasbourg, Bas Rhin, France; [Bonhomme, C.; Calon, A.; Martin, E.; Neuville, A.; Kedinger, M.; Domon-Dell, C.; Duluc, I.; Freund, J-N] Univ Louis Pasteur, Fac Med, Strasbourg, France; [Robine, S.] Inst Curie, CNRS, UMR144, F-75231 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Sorbonne Universite	Freund, JN (corresponding author), INSERM U682, 3 Ave Moliere, F-67200 Strasbourg, Bas Rhin, France.	jean-noel.freund@inserm.u-strasbg.fr	Calon, Alexandre/GPK-2061-2022; DULUC, Isabelle/AAA-7062-2022; Domon-Dell, Claire/P-2368-2017; Freund, Jean-Noel/R-4383-2016; Duluc, Isabelle/O-1972-2017	DULUC, Isabelle/0000-0001-8396-6385; Freund, Jean-Noel/0000-0002-0971-3774; Duluc, Isabelle/0000-0001-8396-6385; DOMON-DELL, Claire/0000-0002-8445-9593				Aoki K, 2003, NAT GENET, V35, P323, DOI 10.1038/ng1265; Bansal D, 2006, P NATL ACAD SCI USA, V103, P16924, DOI 10.1073/pnas.0604579103; Beck F, 1999, P NATL ACAD SCI USA, V96, P7318, DOI 10.1073/pnas.96.13.7318; Bonhomme C, 2003, GUT, V52, P1465, DOI 10.1136/gut.52.10.1465; Brabletz T, 2004, CANCER RES, V64, P6973, DOI 10.1158/0008-5472.CAN-04-1132; Domon-Dell C, 2003, ONCOGENE, V22, P7913, DOI 10.1038/sj.onc.1206756; Gross I, 2008, ONCOGENE, V27, P107, DOI 10.1038/sj.onc.1210601; Haigis K, 2006, J BIOL CHEM, V281, P638, DOI 10.1074/jbc.M509053200; Jonckheere N, 2007, J BIOL CHEM, V282, P22638, DOI 10.1074/jbc.M700905200; Lorentz O, 1997, J CELL BIOL, V139, P1553, DOI 10.1083/jcb.139.6.1553; Lynch J, 2000, J BIOL CHEM, V275, P4499, DOI 10.1074/jbc.275.6.4499; Mallo GV, 1997, INT J CANCER, V74, P35, DOI 10.1002/(SICI)1097-0215(19970220)74:1<35::AID-IJC7>3.0.CO;2-1; Mutoh H, 2004, GUT, V53, P1416, DOI 10.1136/gut.2003.032482; Pilozzi E, 2004, J PATHOL, V204, P289, DOI 10.1002/path.1641; Silberg DG, 2000, GASTROENTEROLOGY, V119, P961, DOI 10.1053/gast.2000.18142; Silberg DG, 1997, GASTROENTEROLOGY, V113, P478, DOI 10.1053/gast.1997.v113.pm9247467; Soubeyran P, 1999, GASTROENTEROLOGY, V117, P1326, DOI 10.1016/S0016-5085(99)70283-0; SUBRAMANIAN V, 1995, CELL, V83, P641, DOI 10.1016/0092-8674(95)90104-3; Vider BZ, 1997, BIOCHEM BIOPH RES CO, V232, P742, DOI 10.1006/bbrc.1997.6364	19	26	26	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4497	4502		10.1038/onc.2008.78	http://dx.doi.org/10.1038/onc.2008.78			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18372917				2022-12-25	WOS:000257881700012
J	Bonilla, M; Denicola, A; Novoselov, SV; Turanov, AA; Protasio, A; Izmendi, D; Gladyshev, VN; Salinas, G				Bonilla, Mariana; Denicola, Ana; Novoselov, Sergey V.; Turanov, Anton A.; Protasio, Anna; Izmendi, Darwin; Gladyshev, Vadim N.; Salinas, Gustavo			Platyhelminth mitochondrial and cytosolic redox homeostasis is controlled by a single thioredoxin glutathione reductase and dependent on selenium and glutathione	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MAMMALIAN THIOREDOXIN; PROTEIN GLUTATHIONYLATION; ECHINOCOCCUS-GRANULOSUS; SCHISTOSOMA-MANSONI; ANTIOXIDANT DEFENSE; REACTION-MECHANISM; OXIDATIVE STRESS; SELENOCYSTEINE; GENE	Platyhelminth parasites are a major health problem in developing countries. In contrast to their mammalian hosts, platyhelminth thiol-disulfide redox homeostasis relies on linked thioredoxin-glutathione systems, which are fully dependent on thioredoxin-glutathione reductase (TGR), a promising drug target. TGR is a homodimeric enzyme comprising a glutaredoxin domain and thioredoxin reductase (TR) domains with a C-terminal redox center containing selenocysteine ( Sec). In this study, we demonstrate the existence of functional linked thioredoxin- glutathione systems in the cytosolic and mitochondrial compartments of Echinococcus granulosus, the platyhelminth responsible for hydatid disease. The glutathione reductase (GR) activity of TGR exhibited hysteretic behavior regulated by the [GSSG]/[GSH] ratio. This behavior was associated with glutathionylation by GSSG and abolished by deglutathionylation. The K-m and k(cat) values for mitochondrial and cytosolic thioredoxins (9.5 mu M and 131 s(-1), 34 mu M and 197 s(-1), respectively) were higher than those reported for mammalian TRs. Analysis of TGR mutants revealed that the glutaredoxin domain is required for the GR activity but did not affect the TR activity. In contrast, both GR and TR activities were dependent on the Sec-containing redox center. The activity loss caused by the Sec-to-Cys mutation could be partially compensated by a Cys-to-Sec mutation of the neighboring residue, indicating that Sec can support catalysis at this alternative position. Consistent with the essential role of TGR in redox control, 2.5 mu M auranofin, a known TGR inhibitor, killed larval worms in vitro. These studies establish the selenium and glutathione-dependent regulation of cytosolic and mitochondrial redox homeostasis through a single TGR enzyme in platyhelminths.	[Denicola, Ana] Univ Republica, Fac Ciencias, Lab Fis Quim Biol, Montevideo 11400, Uruguay; [Novoselov, Sergey V.; Turanov, Anton A.; Gladyshev, Vadim N.] Univ Nebraska, Dept Biochem, Lincoln, NE 68588 USA; [Novoselov, Sergey V.; Turanov, Anton A.; Gladyshev, Vadim N.] Univ Nebraska, Redox Biol Ctr, Lincoln, NE 68588 USA; [Bonilla, Mariana; Izmendi, Darwin; Salinas, Gustavo] Univ Republica, Inst Higiene, Fac Quim, Fac Ciencias,Catedra Inmunol, Montevideo 11600, Uruguay	Universidad de la Republica, Uruguay; University of Nebraska System; University of Nebraska Lincoln; University of Nebraska System; University of Nebraska Lincoln; Universidad de la Republica, Uruguay	Salinas, G (corresponding author), Univ Republica, Inst Higiene, Fac Quim, Fac Ciencias,Catedra Inmunol, Avda A Navarro 3051,Piso 2, Montevideo 11600, Uruguay.	gsalin@fq.edu.uy	Gladyshev, Vadim N/J-6187-2013; Gladyshev, Vadim N/A-9894-2013; Protasio, Anna V./AAJ-8991-2020; Protasio, Anna/F-7751-2016	Protasio, Anna V./0000-0003-1723-800X; Protasio, Anna/0000-0003-1723-800X; Denicola, Ana/0000-0002-5181-9708; Novoselov, Sergey/0000-0003-0104-6492; Salinas, Gustavo/0000-0003-3350-3002; Bonilla, Mariana/0000-0002-9206-345X; Gladyshev, Vadim/0000-0002-0372-7016	FOGARTY INTERNATIONAL CENTER [R03TW006959] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM065204, R01GM065204] Funding Source: NIH RePORTER; FIC NIH HHS [TW 006959] Funding Source: Medline; NIGMS NIH HHS [GM 065204] Funding Source: Medline	FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agorio A, 2003, J BIOL CHEM, V278, P12920, DOI 10.1074/jbc.M209266200; Alger HM, 2002, INT J PARASITOL, V32, P1285, DOI 10.1016/S0020-7519(02)00108-X; Alger HM, 2002, MOL BIOCHEM PARASIT, V121, P129, DOI 10.1016/S0166-6851(02)00031-2; ANGELUCCI F, 2008, PROTEINS IN PRESS; [Anonymous], 2006, PREV CHEM HUM HELM C; Arner ESJ, 1999, J MOL BIOL, V292, P1003, DOI 10.1006/jmbi.1999.3085; Arner ESJ, 1999, METHOD ENZYMOL, V300, P226; Bar-Noy S, 2001, FREE RADICAL BIO MED, V30, P51, DOI 10.1016/S0891-5849(00)00448-2; Beer SM, 2004, J BIOL CHEM, V279, P47939, DOI 10.1074/jbc.M408011200; Biterova EI, 2005, P NATL ACAD SCI USA, V102, P15018, DOI 10.1073/pnas.0504218102; CARLBERG I, 1985, METHOD ENZYMOL, V113, P484; Chalar C, 1999, BIOCHEM BIOPH RES CO, V262, P302, DOI 10.1006/bbrc.1999.1168; Doenhoff Michael J, 2006, Expert Rev Anti Infect Ther, V4, P199, DOI 10.1586/14787210.4.2.199; Eckenroth B, 2006, BIOCHEMISTRY-US, V45, P5158, DOI 10.1021/bi0517887; Eckenroth BE, 2007, BIOCHEMISTRY-US, V46, P9472, DOI 10.1021/bi7004812; Fernandes AP, 2004, ANTIOXID REDOX SIGN, V6, P63, DOI 10.1089/152308604771978354; FRIEDEN C, 1970, J BIOL CHEM, V245, P5788; Gallogly MM, 2007, CURR OPIN PHARMACOL, V7, P381, DOI 10.1016/j.coph.2007.06.003; Gladwin MT, 2006, NAT CHEM BIOL, V2, P110, DOI 10.1038/nchembio0206-110; Gromer S, 2003, P NATL ACAD SCI USA, V100, P12618, DOI 10.1073/pnas.2134510100; Gromer S, 1998, J BIOL CHEM, V273, P20096, DOI 10.1074/jbc.273.32.20096; HOLMGREN A, 1979, J BIOL CHEM, V254, P9627; HOLMGREN A, 2006, SELENIUM ITS MOL BIO, P183; Johansson C, 2004, J BIOL CHEM, V279, P7537, DOI 10.1074/jbc.M312719200; Kelner MJ, 2000, BIOCHEM BIOPH RES CO, V269, P366, DOI 10.1006/bbrc.2000.2267; Kuntz AN, 2007, PLOS MED, V4, P1071, DOI 10.1371/journal.pmed.0040206; Lillig CH, 2003, J BIOL CHEM, V278, P22325, DOI 10.1074/jbc.M302304200; MANSOUR T, 2002, CHEMOTHERAPEUTIC TAR, P58; Miranda-Vizuete A, 1999, EUR J BIOCHEM, V261, P405, DOI 10.1046/j.1432-1327.1999.00286.x; Muller S, 1997, ARCH MICROBIOL, V168, P421, DOI 10.1007/s002030050517; Niwa T, 2007, J CHROMATOGR B, V855, P59, DOI 10.1016/j.jchromb.2006.12.029; Rendon JL, 2004, MOL BIOCHEM PARASIT, V133, P61, DOI 10.1016/j.molbiopara.2003.09.003; Rengby O, 2004, APPL ENVIRON MICROB, V70, P5159, DOI 10.1128/AEM.70.9.5159-5167.2004; Salinas G, 2004, TRENDS PARASITOL, V20, P340, DOI 10.1016/j.pt.2004.05.002; Sun QA, 1999, J BIOL CHEM, V274, P24522, DOI 10.1074/jbc.274.35.24522; Sun QA, 2005, BIOCHEMISTRY-US, V44, P14528, DOI 10.1021/bi051321w; Sun QA, 2001, P NATL ACAD SCI USA, V98, P3673, DOI 10.1073/pnas.051454398; Turanov AA, 2006, J BIOL CHEM, V281, P22953, DOI 10.1074/jbc.M604326200; Winyard PG, 2005, TRENDS BIOCHEM SCI, V30, P453, DOI 10.1016/j.tibs.2005.06.001; Zhong LW, 2000, J BIOL CHEM, V275, P18121, DOI 10.1074/jbc.M000690200	40	77	80	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17898	17907		10.1074/jbc.M710609200	http://dx.doi.org/10.1074/jbc.M710609200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18408002	Green Published, hybrid			2022-12-25	WOS:000256949200018
J	Golabek, AA; Dolzhanskaya, N; Walus, M; Wisniewski, KE; Kida, E				Golabek, Adam A.; Dolzhanskaya, Natalia; Walus, Marius; Wisniewski, Krystyna E.; Kida, Elizabeth			Prosegment of tripeptidyl peptidase I is a potent, slow-binding inhibitor of its cognate enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL CEROID-LIPOFUSCINOSIS; SERINE-CARBOXYL PROTEINASE; PROPROTEIN CONVERTASES; SUBTILISIN BPN'; CLN2 PROTEIN; GENE-PRODUCT; PROPEPTIDE; VITRO; VIVO; EXPRESSION	Tripeptidyl peptidase I (TPP I) is the first mammalian representative of a family of pepstatin-insensitive serine-carboxyl proteases, or sedolisins. The enzyme acts in lysosomes, where it sequentially removes tripeptides from the unmodified N terminus of small, unstructured polypeptides. Naturally occurring mutations in TPP I underlie a neurodegenerative disorder of childhood, classic late infantile neuronal ceroid lipofuscinosis (CLN2). Generation of mature TPP I is associated with removal of a long prosegment of 176 amino acid residues from the zymogen. Here we investigated the inhibitory properties of TPP I prosegment expressed and isolated from Escherichia coli toward its cognate protease. We show that the TPP I prosegment is a potent, slow-binding inhibitor of its parent enzyme, with an overall inhibition constant in the low nanomolar range. We also demonstrate the protective effect of the prosegment on alkaline pH-induced inactivation of the enzyme. Interestingly, the inhibitory properties of TPP I prosegment with the introduced classic late infantile neuronal ceroid lipofuscinosis disease-associated mutation, G77R, significantly differed from those revealed by wild-type prosegment in both the mechanism of interaction and the inhibitory rate. This is the first characterization of the inhibitory action of the sedolisin prosegment.	[Golabek, Adam A.; Dolzhanskaya, Natalia; Walus, Marius; Wisniewski, Krystyna E.; Kida, Elizabeth] New York State Inst Basic Res Dev Disabil, Dept Dev Neurobiol, Staten Isl, NY 10314 USA	Institute for Basic Research in Developmental Disabilities	Golabek, AA (corresponding author), 1050 Forest Hill Rd, Staten Isl, NY 10314 USA.	adamgolabek@gmail.com			NINDS NIH HHS [NS047355] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Basak A, 1997, J PEPT RES, V49, P596; Boudreault A, 1998, J BIOL CHEM, V273, P31574, DOI 10.1074/jbc.273.47.31574; CHENG Y, 1973, BIOCHEM PHARMACOL, V22, P3099; Comellas-Bigler M, 2004, STRUCTURE, V12, P1313, DOI 10.1016/j.str.2004.04.013; Copeland R. A., 2004, ENZYMES PRACTICAL IN; DUFOUR E, 1998, BIOCHIM BIOPHYS ACTA, V955, P58; EDER J, 1993, J MOL BIOL, V233, P293, DOI 10.1006/jmbi.1993.1507; EVIN G, 1984, P NATL ACAD SCI-BIOL, V81, P48, DOI 10.1073/pnas.81.1.48; Ezaki J, 2000, BIOCHEM BIOPH RES CO, V268, P904, DOI 10.1006/bbrc.2000.2207; FOX T, 1992, BIOCHEMISTRY-US, V31, P12571, DOI 10.1021/bi00165a005; FRIEDEN C, 1964, J BIOL CHEM, V239, P3522; Golabek AA, 2005, J BIOL CHEM, V280, P7550, DOI 10.1074/jbc.M412047200; Golabek AA, 2004, J BIOL CHEM, V279, P31058, DOI 10.1074/jbc.M400700200; Golabek AA, 2003, J BIOL CHEM, V278, P7135, DOI 10.1074/jbc.M211872200; Golabek AA, 2006, BIOL CHEM, V387, P1091, DOI 10.1515/BC.2006.135; Groves MR, 1998, PROTEINS, V32, P504, DOI 10.1002/(SICI)1097-0134(19980901)32:4<504::AID-PROT8>3.0.CO;2-F; Gutierrez-Gonzalez LH, 2006, ARCH BIOCHEM BIOPHYS, V446, P151, DOI 10.1016/j.abb.2005.12.005; Huang HW, 1997, PROTEIN ENG, V10, P1227, DOI 10.1093/protein/10.10.1227; Jean L, 2003, J BIOL CHEM, V278, P28572, DOI 10.1074/jbc.M303827200; Junaid MA, 2000, J NEUROCHEM, V74, P287, DOI 10.1046/j.1471-4159.2000.0740287.x; Khan AR, 1998, PROTEIN SCI, V7, P815; Kida E, 2001, J NEUROPATH EXP NEUR, V60, P280, DOI 10.1093/jnen/60.3.280; KITAMOTO Y, 1994, P NATL ACAD SCI USA, V91, P7588, DOI 10.1073/pnas.91.16.7588; Kurachi Y, 2001, ACTA NEUROPATHOL, V102, P20; Lesage G, 2001, FEBS LETT, V508, P332, DOI 10.1016/S0014-5793(01)03096-4; LI YY, 1995, J BIOL CHEM, V270, P25127, DOI 10.1074/jbc.270.42.25127; Lin L, 2001, J BIOL CHEM, V276, P2249, DOI 10.1074/jbc.M008562200; Lin L, 2001, BIOCHEM J, V357, P49, DOI 10.1042/0264-6021:3570049; MORRISON JF, 1988, ADV ENZYMOL RAMB, V61, P201; ODA K, 1994, J BIOL CHEM, V269, P26518; Oyama H, 2002, J BIOCHEM, V131, P757, DOI 10.1093/oxfordjournals.jbchem.a003162; Shinde U., 1995, INTRAMOLECULAR CHAPE, P1; Siezen RJ, 1997, PROTEIN SCI, V6, P501; Sleat DE, 1997, SCIENCE, V277, P1802, DOI 10.1126/science.277.5333.1802; Smyth MJ, 1996, J LEUKOCYTE BIOL, V60, P555, DOI 10.1002/jlb.60.5.555; Walus M, 2005, FEBS LETT, V579, P1383, DOI 10.1016/j.febslet.2005.01.035; WILLIAMS JW, 1979, BIOCHEMISTRY-US, V18, P2567, DOI 10.1021/bi00579a021; Wlodawer A, 2003, ACTA BIOCHIM POL, V50, P81; Wlodawer Alexander, 2003, BMC Struct Biol, V3, P8, DOI 10.1186/1472-6807-3-8; Zhong M, 1999, J BIOL CHEM, V274, P33913, DOI 10.1074/jbc.274.48.33913	40	12	12	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16497	16504		10.1074/jbc.M800458200	http://dx.doi.org/10.1074/jbc.M800458200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18411270	Green Published, hybrid			2022-12-25	WOS:000256497100026
J	Carnemolla, R; Ren, XF; Biswas, TK; Meredith, SC; Reardon, CA; Wang, JJ; Getz, GS				Carnemolla, Ronald; Ren, Xuefeng; Biswas, Tapan K.; Meredith, Stephen C.; Reardon, Catherine A.; Wang, Jianjun; Getz, Godfrey S.			The specific amino acid sequence between helices 7 and 8 influences the binding specificity of human apolipoprotein A-I for high density lipoprotein (HDL) subclasses - A potential for HDL preferential generation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-BOUND CONFORMATION; CHOLESTEROL LEVELS; CRYSTAL-STRUCTURE; HEART-DISEASE; PLASMA HDL; METABOLISM; ATHEROSCLEROSIS; EXPRESSION; DOMAIN; PARTICLES	Humans have two major high density lipoprotein (HDL) subfractions, HDL2 and HDL3, whereas mice have a monodisperse HDL profile. Epidemiological evidence has suggested that HDL2 is more atheroprotective; however, currently there is no direct experimental evidence to support this postulate. The amino acid sequence of apoA-I is a primary determinant of HDL subclass formation. The majority of the alpha-helical repeats in human apoA-I are proline-punctuated. A notable exception is the boundary between helices 7 and 8, which is located in the transitional segment between the stable N-terminal domain and the C-terminal hydrophobic domain. In this study we ask whether the substitution of a proline-containing sequence (PCS) separating other helices in human apoA-I for the non-proline-containing sequence (NPCS) between helices 7 and 8 (residues 184-190) influences HDL subclass association. The human apoA-I mutant with PCS2 replacing NPCS preferentially bound to HDL2. In contrast, the mutant where PCS3 replaced NPCS preferentially associated with HDL3. Thus, the specific amino acid sequence between helices 7 and 8 influences HDL subclass association. The wild-type and mutant proteins exhibited similar physicochemical properties except that the two mutants displayed greater lipid-associated stability versus wild-type human apoA-I. These results focus new attention on the influence of the boundary between helices 7 and 8 on the properties of apoA-I. The expression of these mutants in mice may result in the preferential generation of HDL2 or HDL3 and allow us to examine experimentally the anti-atherogenicity of the HDL subclasses.	[Carnemolla, Ronald; Biswas, Tapan K.; Meredith, Stephen C.; Reardon, Catherine A.; Getz, Godfrey S.] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA; [Carnemolla, Ronald; Reardon, Catherine A.; Getz, Godfrey S.] Univ Chicago, Comm Mol Metab & Nutr, Chicago, IL 60637 USA; [Ren, Xuefeng; Wang, Jianjun] Wayne State Univ, Dept Biochem & Mol Biol, Detroit, MI 48201 USA	University of Chicago; University of Chicago; Wayne State University	Getz, GS (corresponding author), Univ Chicago, Dept Pathol, MC 1089,5841 S Maryland Ave, Chicago, IL 60637 USA.	g-getz@uchicago.edu			NHLBI NIH HHS [R01 HL68661, 5T32 HL07237, R01 HL076620] Funding Source: Medline; NINDS NIH HHS [R01 NS042852] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL076620, T32HL007237, R01HL068661] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS042852] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ajees AA, 2006, P NATL ACAD SCI USA, V103, P2126, DOI 10.1073/pnas.0506877103; Assmann G, 2004, CIRCULATION, V109, P8, DOI 10.1161/01.CIR.0000131512.50667.46; Asztalos BF, 2004, CURR OPIN CARDIOL, V19, P385, DOI 10.1097/01.hco.0000126979.41946.7e; Barter PJ, 2004, CIRC RES, V95, P764, DOI 10.1161/01.RES.0000146094.59640.13; Barter PJ, 1997, CLIN EXP PHARMACOL P, V24, P286, DOI 10.1111/j.1440-1681.1997.tb01821.x; Bhat S, 2005, J BIOL CHEM, V280, P33015, DOI 10.1074/jbc.M505081200; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; CASTELLI WP, 1986, JAMA-J AM MED ASSOC, V256, P2835, DOI 10.1001/jama.256.20.2835; Davidson WS, 2007, J BIOL CHEM, V282, P22249, DOI 10.1074/jbc.R700014200; Davidson WS, 1996, P NATL ACAD SCI USA, V93, P13605, DOI 10.1073/pnas.93.24.13605; Frank PG, 2000, J LIPID RES, V41, P853; Klon AE, 2002, BIOCHEMISTRY-US, V41, P10895, DOI 10.1021/bi020315m; Kontush A, 2007, ARTERIOSCL THROM VAS, V27, P1843, DOI 10.1161/ATVBAHA.107.145672; Kozarsky KF, 1997, NATURE, V387, P414, DOI 10.1038/387414a0; Lazar KL, 2005, BIOCHEMISTRY-US, V44, P12681, DOI 10.1021/bi0509705; Lewis GF, 2006, CURR OPIN CARDIOL, V21, P345, DOI 10.1097/01.hco.0000231405.76930.a0; Martin DDO, 2006, J BIOL CHEM, V281, P20418, DOI 10.1074/jbc.M602077200; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; Mineo C, 2006, CIRC RES, V98, P1352, DOI 10.1161/01.RES.0000225982.01988.93; Mishra VK, 1996, BIOCHEMISTRY-US, V35, P11210, DOI 10.1021/bi960760f; MOWRI HO, 1992, J LIPID RES, V33, P1269; Rader DJ, 2006, J CLIN INVEST, V116, P3090, DOI 10.1172/JCI30163; Reardon CA, 2001, BIOCHEMISTRY-US, V40, P13670, DOI 10.1021/bi011451e; Ren XF, 2005, BIOCHEMISTRY-US, V44, P14907, DOI 10.1021/bi0508385; Reschly EJ, 2002, J BIOL CHEM, V277, P9645, DOI 10.1074/jbc.M107883200; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; Saito H, 2004, PROG LIPID RES, V43, P350, DOI 10.1016/j.plipres.2004.05.002; Saito H, 2004, J BIOL CHEM, V279, P20974, DOI 10.1074/jbc.M402043200; Singh IM, 2007, JAMA-J AM MED ASSOC, V298, P786, DOI 10.1001/jama.298.7.786; Sorci-Thomas MG, 1998, J BIOL CHEM, V273, P11776, DOI 10.1074/jbc.273.19.11776; Tanaka M, 2006, BIOCHEMISTRY-US, V45, P10351, DOI 10.1021/bi060726t; Thurberg BL, 1996, J BIOL CHEM, V271, P6062, DOI 10.1074/jbc.271.11.6062; Wang N, 2001, J BIOL CHEM, V276, P23742, DOI 10.1074/jbc.M102348200	34	11	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15779	15788		10.1074/jbc.M710244200	http://dx.doi.org/10.1074/jbc.M710244200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18385132	Green Published, hybrid			2022-12-25	WOS:000256332500035
J	Cartwright, AM; Lim, EK; Kleanthous, C; Bowles, DJ				Cartwright, Adam M.; Lim, Eng-Kiat; Kleanthous, Colin; Bowles, Dianna J.			A kinetic analysis of regiospecific glucosylation by two glycosyltransferases of Arabidopsis thaliana - Domain swapping to introduce new activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FLAVONOID GLUCOSYLTRANSFERASES; PLANT GLYCOSYLTRANSFERASES; SUBSTRATE-SPECIFICITY; MEDICAGO-TRUNCATULA; SORGHUM-BICOLOR; QUERCETIN; GLYCOSYLATION; ACID; MUTAGENESIS; GLYCOSIDES	Plant Family 1 glycosyltransferases (GTs) recognize a wide range of natural and non-natural scaffolds and have considerable potential as biocatalysts for the synthesis of small molecule glycosides. Regiospecificity of glycosylation is an important property, given that many acceptors have multiple potential glycosylation sites. This study has used a domain-swapping approach to explore the determinants of regiospecific glycosylation of two GTs of Arabidopsis thaliana, UGT74F1 and UGT74F2. The flavonoid quercetin was used as a model acceptor, providing five potential sites for O-glycosylation by the two GTs. As is commonly found for many plant GTs, both of these enzymes produce distinct multiple glycosides of quercetin. A high performance liquid chromatography method has been established to perform detailed steady-state kinetic analyses of these concurrent reactions. These data show the influence of each parameter in determining a GT product formation profile toward quercetin. Interestingly, construction and kinetic analyses of a series of UGT74F1/F2 chimeras have revealed that mutating a single amino acid distal to the active site, Asn-142, can lead to the development of a new GT with a more constrained regiospecificity. This ability to form the 4'-O-glucoside of quercetin is transferable to other flavonoid scaffolds and provides a basis for preparative scale production of flavonoid 4'-O-glucosides through the use of whole-cell biocatalysis.	[Cartwright, Adam M.; Lim, Eng-Kiat; Bowles, Dianna J.] Univ York, Ctr Novel Agr Prod, York YO10 5DD, N Yorkshire, England; [Kleanthous, Colin] Univ York, Dept Biol, York YO10 5DD, N Yorkshire, England	University of York - UK; University of York - UK	Bowles, DJ (corresponding author), Univ York, Ctr Novel Agr Prod, York YO10 5DD, N Yorkshire, England.	djb32@york.ac.uk			Biotechnology and Biological Sciences Research Council [BBS/B/13241] Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Bowles D, 2006, ANNU REV PLANT BIOL, V57, P567, DOI 10.1146/annurev.arplant.57.032905.105429; Brazier-Hicks M, 2007, P NATL ACAD SCI USA, V104, P20238, DOI 10.1073/pnas.0706421104; Browning AM, 2005, J PHARM PHARMACOL, V57, P1037, DOI 10.1211/0022357056514; Cao GH, 1997, FREE RADICAL BIO MED, V22, P749, DOI 10.1016/S0891-5849(96)00351-6; Carbone MN, 2007, CURR OPIN STRUC BIOL, V17, P454, DOI 10.1016/j.sbi.2007.08.005; Coutinho PM, 1999, ROY SOC CH, P3; Cuff JA, 1998, BIOINFORMATICS, V14, P892, DOI 10.1093/bioinformatics/14.10.892; Day AJ, 2003, BIOCHEM PHARMACOL, V65, P1199, DOI 10.1016/S0006-2952(03)00039-X; Day AJ, 2000, FREE RADICAL BIO MED, V29, P1234, DOI 10.1016/S0891-5849(00)00416-0; Ducros VMA, 2003, CHEM BIOL, V10, P619, DOI 10.1016/S1074-5521(03)00143-1; Erlund I, 2004, NUTR RES, V24, P851, DOI 10.1016/j.nutres.2004.07.005; Graefe EU, 2001, J CLIN PHARMACOL, V41, P492, DOI 10.1177/00912700122010366; Hall D, 2007, PLANT J, V49, P579, DOI 10.1111/j.1365-313X.2006.02987.x; Hancock SM, 2006, CURR OPIN CHEM BIOL, V10, P509, DOI 10.1016/j.cbpa.2006.07.015; Hansen KS, 2003, PHYTOCHEMISTRY, V64, P143, DOI 10.1016/S0031-9422(03)00261-9; He XZ, 2006, J BIOL CHEM, V281, P34441, DOI 10.1074/jbc.M605767200; HEMSLEY A, 1989, NUCLEIC ACIDS RES, V17, P6545, DOI 10.1093/nar/17.16.6545; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; Hoffmeister D, 2002, CHEM BIOL, V9, P287, DOI 10.1016/S1074-5521(02)00114-X; Hoffmeister D, 2001, CHEM BIOL, V8, P557, DOI 10.1016/S1074-5521(01)00039-4; Hollman PCH, 1997, FEBS LETT, V418, P152, DOI 10.1016/S0014-5793(97)01367-7; Hollman PCH, 2000, J SCI FOOD AGR, V80, P1081, DOI [10.1002/(SICI)1097-0010(20000515)80:7<1081::AID-JSFA566>3.0.CO;2-G, 10.1002/(SICI)1097-0010(20000515)80:7&lt;1081::AID-JSFA566&gt;3.0.CO;2-G]; Isayenkova J, 2006, PHYTOCHEMISTRY, V67, P1598, DOI 10.1016/j.phytochem.2006.06.026; Kamra P, 2005, NUCLEIC ACIDS RES, V33, pW220, DOI 10.1093/nar/gki449; Kelly SM, 2005, BBA-PROTEINS PROTEOM, V1751, P119, DOI 10.1016/j.bbapap.2005.06.005; Kohara A, 2007, PHYTOCHEMISTRY, V68, P478, DOI 10.1016/j.phytochem.2006.11.020; Kramer CM, 2003, PHYTOCHEMISTRY, V64, P1069, DOI 10.1016/S0031-9422(03)00507-7; Kubo A, 2004, ARCH BIOCHEM BIOPHYS, V429, P198, DOI 10.1016/j.abb.2004.06.021; Li LN, 2007, J MOL BIOL, V370, P951, DOI 10.1016/j.jmb.2007.05.036; Lim EK, 2005, TETRAHEDRON-ASYMMETR, V16, P143, DOI 10.1016/j.tetasy.2004.11.062; Lim EK, 2004, BIOTECHNOL BIOENG, V87, P623, DOI 10.1002/bit.20154; Lim EK, 2004, EMBO J, V23, P2915, DOI 10.1038/sj.emboj.7600295; Lim EK, 2003, GLYCOBIOLOGY, V13, P139, DOI 10.1093/glycob/cwg017; Lim EK, 2006, CHEMBIOCHEM, V7, P1181, DOI 10.1002/cbic.200600193; Masada S, 2007, FEBS LETT, V581, P2605, DOI 10.1016/j.febslet.2007.05.002; Mendez C, 2001, TRENDS BIOTECHNOL, V19, P449, DOI 10.1016/S0167-7799(01)01765-6; Modolo LV, 2007, PLANT MOL BIOL, V64, P499, DOI 10.1007/s11103-007-9167-6; Murota K, 2004, J AGR FOOD CHEM, V52, P1907, DOI 10.1021/jf035151a; Oka T, 2006, FEBS J, V273, P2645, DOI 10.1111/j.1742-4658.2006.05281.x; Thorsoe KS, 2005, PLANT PHYSIOL, V139, P664, DOI 10.1104/pp.105.063842; van der Woude H, 2004, CHEM RES TOXICOL, V17, P1520, DOI 10.1021/tx049826v; Vogt T, 1999, PLANT J, V19, P509, DOI 10.1046/j.1365-313X.1999.00540.x; Weis M, 2006, ANGEW CHEM INT EDIT, V45, P3534, DOI 10.1002/anie.200504505; Williams GJ, 2007, NAT CHEM BIOL, V3, P657, DOI 10.1038/nchembio.2007.28; Yang M, 2007, ANGEW CHEM INT EDIT, V46, P3885, DOI 10.1002/anie.200604177	45	48	53	2	22	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15724	15731		10.1074/jbc.M801983200	http://dx.doi.org/10.1074/jbc.M801983200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18378673	Green Published, hybrid			2022-12-25	WOS:000256332500028
J	Iwakura, Y; Nawa, H; Sora, I; Chao, MV				Iwakura, Yuriko; Nawa, Hiroyuki; Sora, Ichiro; Chao, Moses V.			Dopamine D1 receptor-induced signaling through TrkB receptors in striatal neurons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-COUPLED RECEPTORS; MEDIUM SPINY NEURONS; NERVE GROWTH-FACTOR; NEUROTROPHIN RECEPTORS; IN-VIVO; HIPPOCAMPAL-NEURONS; SURFACE EXPRESSION; GABAERGIC NEURONS; MUTANT MICE; BRAIN	In addition to its role as a neurotransmitter, dopamine can stimulate neurite outgrowth and morphological effects upon primary neurons. To investigate the signal transduction mechanisms used by dopamine in developing striatal neurons, we focused upon the effects of activating the dopamine D1 receptor. Using the D1 receptor agonist SKF38393, we found that Trk neurotrophin receptors were activated in embryonic day 18 striatal neurons. K-252a, a Trk tyrosine kinase inhibitor, and a dopamine D1 receptor antagonist could block the effects of SKF38393. The increase in TrkB phosphorylation was not the result of increased neurotrophin production. Induction of TrkB activity by SKF38393 was accompanied by the phosphorylation of several Trk signaling proteins, including phospholipase C gamma, Akt, and MAPK. Biotinylation experiments followed by immunostaining by phospho-TrkB-specific antibodies indicated that the mechanism involved increased TrkB surface expression by dopamine D1 receptor activation. This increase in cell surface TrkB expression was dependent upon an increase in intracellular Ca2+. These results indicate that stimulation of dopamine D1 receptors can be coupled to the neurotrophin receptor signaling to mediate the effects of dopamine upon striatal neurons.	[Iwakura, Yuriko; Chao, Moses V.] NYU, Sch Med,Dept Cell Biol Physiol & Neurosci, Skirball Inst Biomol Med, Mol Neurobiol Program,Kimmel Ctr, New York, NY 10016 USA; [Iwakura, Yuriko; Chao, Moses V.] NYU, Sch Med, Skirball Inst Biomol Med,Dept Psychiat, Mol Neurobiol Program,Kimmel Ctr, New York, NY 10016 USA; [Nawa, Hiroyuki] Niigata Univ, Div Mol Neurobiol, Brain Res Inst, Niigata 9518585, Japan; [Sora, Ichiro] Tohoku Univ, Grad Sch Med, Dept Biol Psychiat, Sendai, Miyagi 9808574, Japan	New York University; New York University; Niigata University; Tohoku University	Chao, MV (corresponding author), NYU, Sch Med,Dept Cell Biol Physiol & Neurosci, Skirball Inst Biomol Med, Mol Neurobiol Program,Kimmel Ctr, 540 1st Ave, New York, NY 10016 USA.	chao@saturn.med.nyu.edu	Iwakura, Yoichiro/E-5457-2011	Iwakura, Yoichiro/0000-0002-9934-5775; Chao, Moses/0000-0002-6969-3744	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD023315] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021072] Funding Source: NIH RePORTER; NICHD NIH HHS [HD23315] Funding Source: Medline; NINDS NIH HHS [NS21072] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ALTAR CA, 1994, EUR J NEUROSCI, V6, P1389, DOI 10.1111/j.1460-9568.1994.tb01001.x; Arevalo JC, 2004, EMBO J, V23, P2358, DOI 10.1038/sj.emboj.7600253; Arevalo JC, 2006, NEURON, V50, P549, DOI 10.1016/j.neuron.2006.03.044; Benraiss A, 2001, J NEUROSCI, V21, P6718, DOI 10.1523/JNEUROSCI.21-17-06718.2001; BERG MM, 1992, J BIOL CHEM, V267, P13; Berghuis P, 2005, P NATL ACAD SCI USA, V102, P19115, DOI 10.1073/pnas.0509494102; Bloch B, 2003, BIOL CELL, V95, P477, DOI 10.1016/S0248-4900(03)00080-7; Bustos G, 2004, BRAIN RES REV, V47, P126, DOI 10.1016/j.brainresrev.2004.05.002; Centonze D, 2003, J NEUROSCI, V23, P8506, DOI 10.1523/jneurosci.23-24-08506.2003; Chao MV, 2003, NAT REV NEUROSCI, V4, P299, DOI 10.1038/nrn1078; Do T, 2007, J NEUROCHEM, V100, P416, DOI 10.1111/j.1471-4159.2006.04249.x; DRAGO J, 1994, P NATL ACAD SCI USA, V91, P12564, DOI 10.1073/pnas.91.26.12564; Du J, 2000, J CELL BIOL, V150, P1423, DOI 10.1083/jcb.150.6.1423; Duman RS, 1997, ARCH GEN PSYCHIAT, V54, P597; EDWARDS RH, 1988, J BIOL CHEM, V263, P6810; Farber K, 2005, MOL CELL NEUROSCI, V29, P128, DOI 10.1016/j.mcn.2005.01.003; Gainetdinov RR, 2004, ANNU REV NEUROSCI, V27, P107, DOI 10.1146/annurev.neuro.27.070203.144206; Goldberg MS, 2005, NEURON, V45, P489, DOI 10.1016/j.neuron.2005.01.041; HernandezLopez S, 1997, J NEUROSCI, V17, P3334; HESS EJ, 1986, EUR J PHARMACOL, V121, P31, DOI 10.1016/0014-2999(86)90389-4; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; INGHAM CA, 1993, EXP BRAIN RES, V93, P17, DOI 10.1007/BF00227776; Ivkovic S, 1999, J NEUROSCI, V19, P5409; Ivkovic S, 1997, NEUROSCIENCE, V79, P509, DOI 10.1016/S0306-4522(96)00684-7; Iwakura Y, 2005, J NEUROCHEM, V93, P974, DOI 10.1111/j.1471-4159.2005.03073.x; Iwakura Y, 2001, J BIOL CHEM, V276, P40025, DOI 10.1074/jbc.M103125200; JACKSON DM, 1994, PHARMACOL THERAPEUT, V64, P291, DOI 10.1016/0163-7258(94)90041-8; Jassen AK, 2006, MOL PHARMACOL, V70, P71, DOI 10.1124/mol.105.021998; Jung AB, 1996, DEV BRAIN RES, V94, P133, DOI 10.1016/0165-3806(96)00035-1; KALIVAS PW, 1993, BRAIN RES REV, V18, P75, DOI 10.1016/0165-0173(93)90008-N; Kingsbury TJ, 2003, J BIOL CHEM, V278, P40744, DOI 10.1074/jbc.M303082200; Lee FS, 2001, P NATL ACAD SCI USA, V98, P3555, DOI 10.1073/pnas.061020198; Lessmann V, 2003, PROG NEUROBIOL, V69, P341, DOI 10.1016/S0301-0082(03)00019-4; LEWIS RM, 1990, J NEUROCHEM, V55, P1071, DOI 10.1111/j.1471-4159.1990.tb04600.x; Mayeux R, 2003, ANNU REV NEUROSCI, V26, P81, DOI 10.1146/annurev.neuro.26.043002.094919; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; Ming YL, 2006, J NEUROCHEM, V98, P1316, DOI 10.1111/j.1471-4159.2006.03961.x; Missale C, 1998, PHYSIOL REV, V78, P189, DOI 10.1152/physrev.1998.78.1.189; MIZUNO K, 1994, DEV BIOL, V165, P243, DOI 10.1006/dbio.1994.1250; Narisawa-Saito M, 2002, J BIOL CHEM, V277, P40901, DOI 10.1074/jbc.M202158200; Ohtani N, 2003, J NEUROSCI, V23, P2840; Pineda JR, 2005, J NEUROCHEM, V93, P1057, DOI 10.1111/j.1471-4159.2005.03047.x; Rajagopal R, 2004, J NEUROSCI, V24, P6650, DOI 10.1523/JNEUROSCI.0010-04.2004; Reuss B, 2001, MOL CELL NEUROSCI, V18, P197, DOI 10.1006/mcne.2001.1017; Schmidt U, 1996, NEUROSCIENCE, V74, P453, DOI 10.1016/0306-4522(96)00201-1; Schmidt U, 1998, MOL CELL NEUROSCI, V11, P9, DOI 10.1006/mcne.1998.0668; SIBLEY DR, 1982, LIFE SCI, V31, P637, DOI 10.1016/0024-3205(82)90764-0; SURMEIER DJ, 1995, NEURON, V14, P385, DOI 10.1016/0896-6273(95)90294-5; TSURUTA K, 1981, NATURE, V292, P463, DOI 10.1038/292463a0; Wiese S, 2007, P NATL ACAD SCI USA, V104, P17210, DOI 10.1073/pnas.0705267104; XU M, 1994, CELL, V79, P945, DOI 10.1016/0092-8674(94)90026-4; XU M, 1994, CELL, V79, P729, DOI 10.1016/0092-8674(94)90557-6; Yokomaku D, 2005, NEUROSCIENCE, V136, P1037, DOI 10.1016/j.neuroscience.2005.08.014	53	53	58	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15799	15806		10.1074/jbc.M801553200	http://dx.doi.org/10.1074/jbc.M801553200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18381284	Green Published, hybrid			2022-12-25	WOS:000256332500037
J	Wu, H; Min, JR; Zeng, H; McCloskey, DE; Ikeguchi, Y; Loppnau, P; Michael, AJ; Pegg, AE; Plotnikov, AN				Wu, Hong; Min, Jinrong; Zeng, Hong; McCloskey, Diane E.; Ikeguchi, Yoshihiko; Loppnau, Peter; Michael, Anthony J.; Pegg, Anthony E.; Plotnikov, Alexander N.			Crystal structure of human spermine synthase - Implications of substrate binding and catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLMETHIONINE DECARBOXYLASE; POLYAMINE BIOSYNTHESIS; BOVINE BRAIN; SACCHAROMYCES-CEREVISIAE; ANGSTROM RESOLUTION; MAMMALIAN-TISSUES; GENE; ARABIDOPSIS; SENSITIVITY; DEFICIENCY	The crystal structures of two ternary complexes of human spermine synthase (EC 2.5.1.22), one with 5'-methylthioadenosine and spermidine and the other with 5'-methylthioadenosine and spermine, have been solved. They show that the enzyme is a dimer of two identical subunits. Each monomer has three domains: a C-terminal domain, which contains the active site and is similar in structure to spermidine synthase; a central domain made up of four beta-strands; and an N-terminal domain with remarkable structural similarity to S-adenosylmethionine decarboxylase, the enzyme that forms the aminopropyl donor substrate. Dimerization occurs mainly through interactions between the N-terminal domains. Deletion of the N-terminal domain led to a complete loss of spermine synthase activity, suggesting that dimerization may be required for activity. The structures provide an outline of the active site and a plausible model for catalysis. The active site is similar to those of spermidine synthases but has a larger substrate-binding pocket able to accommodate longer substrates. Two residues (Asp(201) and Asp(276)) that are conserved in aminopropyltransferases appear to play a key part in the catalytic mechanism, and this role was supported by the results of site-directed mutagenesis. The spermine synthase center dot 5'-methylthioadenosine structure provides a plausible explanation for the potent inhibition of the reaction by this product and the stronger inhibition of spermine synthase compared with spermidine synthase. An analysis to trace possible evolutionary origins of spermine synthase is also described.	[McCloskey, Diane E.; Ikeguchi, Yoshihiko; Pegg, Anthony E.] Penn State Univ, Milton S Hershey Med Ctr, Dept Cellular & Mol Physiol, Coll Med, Hershey, PA 17033 USA; [Wu, Hong; Min, Jinrong; Zeng, Hong; Loppnau, Peter; Plotnikov, Alexander N.] Univ Toronto, Toronto, ON M5G 1L5, Canada; [Michael, Anthony J.] AFRC, Inst Food Res, Norwich NR4 7UA, Norfolk, England; [Plotnikov, Alexander N.] Univ Toronto, Dept Physiol, Toronto, ON M5S 1A8, Canada	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Penn State Health; University of Toronto; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Quadram Institute; University of East Anglia; University of Toronto	Pegg, AE (corresponding author), Penn State Univ, Milton S Hershey Med Ctr, Dept Cellular & Mol Physiol, Coll Med, Hershey, PA 17033 USA.	aep1@psu.edu; plotnikov@mssm.edu	Min, Jinrong/G-3449-2011	Min, Jinrong/0000-0001-5210-3130	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026290] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM26290] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Almrud JJ, 2000, J MOL BIOL, V295, P7, DOI 10.1006/jmbi.1999.3331; Basu I, 2007, J BIOL CHEM, V282, P21477, DOI 10.1074/jbc.M702287200; Bennett EM, 2002, BIOCHEMISTRY-US, V41, P14509, DOI 10.1021/bi026710u; Brooks WH, 2007, J CHEM INF MODEL, V47, P1897, DOI 10.1021/ci700005t; Cacciapuoti G, 2007, J BACTERIOL, V189, P6057, DOI 10.1128/JB.00151-07; Casero RA, 2007, NAT REV DRUG DISCOV, V6, P373, DOI 10.1038/nrd2243; Cason AL, 2003, EUR J HUM GENET, V11, P937, DOI 10.1038/sj.ejhg.5201072; Chattopadhyay MK, 2003, P NATL ACAD SCI USA, V100, P13869, DOI 10.1073/pnas.1835918100; Clay NK, 2005, PLANT PHYSIOL, V138, P767, DOI 10.1104/pp.104.055756; Dufe VT, 2007, J MOL BIOL, V373, P167, DOI 10.1016/j.jmb.2007.07.053; Dufe VT, 2005, FEBS LETT, V579, P6037, DOI 10.1016/j.febslet.2005.09.050; Ekstrom JL, 1999, STRUCTURE, V7, P583, DOI 10.1016/S0969-2126(99)80074-4; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Gerner EW, 2004, NAT REV CANCER, V4, P781, DOI 10.1038/nrc1454; HACKERT ML, 1997, COMPREHENSIVE BIOL C, P201; Hamasaki-Katagiri N, 1998, GENE, V210, P195, DOI 10.1016/S0378-1119(98)00027-4; HIBASAMI H, 1980, BIOCHEM J, V187, P419, DOI 10.1042/bj1870419; HOLM L, 1995, TRENDS BIOCHEM SCI, V20, P478, DOI 10.1016/S0968-0004(00)89105-7; Ikeguchi Y, 2006, J BIOCHEM, V139, P1, DOI 10.1093/jb/mvj019; Ikeguchi Y, 2004, BIOCHEM J, V381, P701, DOI 10.1042/BJ20040419; Ikeguchi Y, 2003, BIOCHEM J, V373, P885, DOI 10.1042/BJ20030246; Imai A, 2004, FEBS LETT, V556, P148, DOI 10.1016/S0014-5793(03)01395-4; Janne J, 2006, J BIOCHEM, V139, P155, DOI 10.1093/jb/mvj035; Knott JM, 2007, FEBS LETT, V581, P3081, DOI 10.1016/j.febslet.2007.05.074; Korhonen VP, 2001, MOL PHARMACOL, V59, P231, DOI 10.1124/mol.59.2.231; Korolev S, 2002, NAT STRUCT BIOL, V9, P27, DOI 10.1038/nsb737; Lang BF, 2002, CURR BIOL, V12, P1773, DOI 10.1016/S0960-9822(02)01187-9; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lu PK, 2007, PROTEINS, V67, P743, DOI 10.1002/prot.21315; Mackintosh CA, 2000, BIOCHEM J, V351, P439, DOI 10.1042/0264-6021:3510439; Martin JL, 2002, CURR OPIN STRUC BIOL, V12, P783, DOI 10.1016/S0959-440X(02)00391-3; Meyer RA, 1998, GENOMICS, V48, P289, DOI 10.1006/geno.1997.5169; Nilsson J, 2000, BIOCHEM J, V352, P381, DOI 10.1042/0264-6021:3520381; Nishimura K, 2002, GENES CELLS, V7, P41, DOI 10.1046/j.1356-9597.2001.00494.x; Ohnuma M, 2005, J BIOL CHEM, V280, P30073, DOI 10.1074/jbc.M413332200; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PAJULA RL, 1979, FEBS LETT, V99, P343, DOI 10.1016/0014-5793(79)80988-6; PAJULA RL, 1979, EUR J BIOCHEM, V101, P619, DOI 10.1111/j.1432-1033.1979.tb19756.x; Park MH, 2006, J BIOCHEM, V139, P161, DOI 10.1093/jb/mvj034; PEGG AE, 1995, INT J BIOCHEM CELL B, V27, P425, DOI 10.1016/1357-2725(95)00007-C; PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249; PEGG AE, 1969, BIOCHEM J, V115, P241, DOI 10.1042/bj1150241; Pendeville H, 2001, MOL CELL BIOL, V21, P6549, DOI 10.1128/MCB.21.19.6549-6558.2001; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Plotnikov AN, 1996, BIOORG KHIM+, V22, P489; Ptitsyn O.B., 1991, CONFORMATIONS FORCES, P155; RAINA A, 1984, BIOCHEM J, V219, P991, DOI 10.1042/bj2190991; Ricard G, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-22; Shantz L M, 1998, Methods Mol Biol, V79, P45; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tolbert WD, 2003, BIOCHEMISTRY-US, V42, P2386, DOI 10.1021/bi0268854; Tolbert WD, 2001, BIOCHEMISTRY-US, V40, P9484, DOI 10.1021/bi010735w; Toms AV, 2004, J BIOL CHEM, V279, P33837, DOI 10.1074/jbc.M403369200; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wallace HM, 2003, BIOCHEM J, V376, P1, DOI 10.1042/BJ20031327; Wiest L, 1998, Methods Mol Biol, V79, P51; Willert EK, 2007, P NATL ACAD SCI USA, V104, P8275, DOI 10.1073/pnas.0701111104; Wu H, 2007, BIOCHEMISTRY-US, V46, P8331, DOI 10.1021/bi602498k; Yamaguchi K, 2007, BIOCHEM BIOPH RES CO, V352, P486, DOI 10.1016/j.bbrc.2006.11.041	59	81	83	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16135	16146		10.1074/jbc.M710323200	http://dx.doi.org/10.1074/jbc.M710323200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18367445	hybrid, Green Published			2022-12-25	WOS:000256332500072
J	Mercado, J; Czajkowski, C				Mercado, Jose; Czajkowski, Cynthia			gamma-Aminobutyric acid (GABA) and pentobarbital induce different conformational rearrangements in the GABA(A) receptor alpha 1 and beta(2) pre-M1 regions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACETYLCHOLINE-RECEPTOR; ANESTHETIC ACTION; BINDING-SITE; A RECEPTOR; CHANNEL; SUBUNIT; ACTIVATION; CURRENTS; M2; DROSOPHILA	gamma-Aminobutyric acid (GABA) binding to GABA(A) receptors (GABA(A)Rs) triggers conformational movements in the alpha(1) and beta(2) pre-M1 regions that are associated with channel gating. At high concentrations, the barbiturate pentobarbital opens GABA(A)R channels with similar conductances as GABA, suggesting that their open state structures are alike. Little, however, is known about the structural rearrangements induced by barbiturates. Here, we examined whether pentobarbital activation triggers movements in the GABAAR pre-M1 regions. alpha(1)beta(2) GAB(A)Rs containing cysteine substitutions in the pre-M1 alpha(1) (K219C, K221C) and beta(2) (K213C, K215C) subunits were expressed in Xenopus oocytes and analyzed using two-electrode voltage clamp. The cysteine substitutions had little to no effect on GABA and pentobarbital EC50 values. Tethering chemically diverse thiol-reactive methanethiosulfonate reagents onto alpha(1)K219C and alpha(1)K221C affected GABA- and pentobarbital-activated currents differently, suggesting that the pre-M1 structural elements important for GABA and pentobarbital current activation are distinct. Moreover, pentobarbital altered the rates of cysteine modification by methanethiosulfonate reagents differently than GABA. For alpha(1)K221C1 beta(2) receptors, pentobarbital decreased the rate of cysteine modification whereas GABA had no effect. For alpha(1)beta(2)K215C receptors, pentobarbital had no effect whereas GABA increased the modification rate. The competitive GABA antagonist SR-95531 and a low, non-activating concentration of pentobarbital did not alter their modification rates, suggesting that the GABA- and pentobarbital-mediated changes in rates reflect gating movements. Overall, the data indicate that the pre-M1 region is involved in both GABA- and pentobarbital-mediated gating transitions. Pentobarbital, however, triggers different movements in this region than GABA, suggesting their activation mechanisms differ.	[Mercado, Jose; Czajkowski, Cynthia] Univ Wisconsin, Dept Physiol, Madison, WI 53706 USA; [Czajkowski, Cynthia] Univ Wisconsin, Neurosci Training Program, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Czajkowski, C (corresponding author), Univ Wisconsin, 601 Sci Dr, Madison, WI 53711 USA.	czajkowski@physiology.wisc.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS034727, R56NS034727] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 34727, R01 NS034727-13, R01 NS034727] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Amin J, 1999, MOL PHARMACOL, V55, P411; AMIN J, 1993, NATURE, V366, P565, DOI 10.1038/366565a0; Bali M, 2004, MOL PHARMACOL, V65, P68, DOI 10.1124/mol.65.1.68; Belelli D, 1997, P NATL ACAD SCI USA, V94, P11031, DOI 10.1073/pnas.94.20.11031; Belelli D, 1999, TRENDS PHARMACOL SCI, V20, P496, DOI 10.1016/S0165-6147(99)01405-4; Boileau AJ, 1998, MOL PHARMACOL, V53, P295, DOI 10.1124/mol.53.2.295; Chakrapani S, 2004, J GEN PHYSIOL, V123, P341, DOI 10.1085/jgp.200309004; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; HARRISON NL, 1993, MOL PHARMACOL, V44, P628; Holden JH, 2002, J BIOL CHEM, V277, P18785, DOI 10.1074/jbc.M111778200; JACKSON MB, 1982, J NEUROSCI, V2, P889; Kloda JH, 2007, MOL PHARMACOL, V71, P483, DOI 10.1124/mol.106.028662; Lee WY, 2005, NATURE, V438, P243, DOI 10.1038/nature04156; Lema GMC, 2006, J PHYSIOL-LONDON, V572, P183, DOI 10.1113/jphysiol.2005.099093; Li GD, 2006, J NEUROSCI, V26, P11599, DOI 10.1523/JNEUROSCI.3467-06.2006; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; MacDonald R L, 1992, Ion Channels, V3, P315; MACDONALD RL, 1989, J PHYSIOL-LONDON, V417, P483, DOI 10.1113/jphysiol.1989.sp017814; MATHERS DA, 1980, SCIENCE, V209, P507, DOI 10.1126/science.6248961; Mercado J, 2006, J NEUROSCI, V26, P2031, DOI 10.1523/JNEUROSCI.4555-05.2006; Mihic SJ, 1996, J PHARMACOL EXP THER, V277, P411; Mihic SJ, 1997, NATURE, V389, P385, DOI 10.1038/38738; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; Newell JG, 2004, J NEUROSCI, V24, P11226, DOI 10.1523/JNEUROSCI.3746-04.2004; Newell JG, 2003, J BIOL CHEM, V278, P13166, DOI 10.1074/jbc.M211905200; OLSEN RW, 1982, ANNU REV PHARMACOL, V22, P245, DOI 10.1146/annurev.pa.22.040182.001333; Pascual JM, 1998, J GEN PHYSIOL, V111, P717, DOI 10.1085/jgp.111.6.717; Pistis M, 1999, J PHYSIOL-LONDON, V515, P3, DOI 10.1111/j.1469-7793.1999.003ad.x; Rho JM, 1996, J PHYSIOL-LONDON, V497, P509, DOI 10.1113/jphysiol.1996.sp021784; Robertson GA, 1996, NEUROPHARMACOLOGY, V35, P841, DOI 10.1016/0028-3908(96)00113-X; Rosen A, 2007, BIOPHYS J, V92, P3130, DOI 10.1529/biophysj.106.094490; Serafini R, 2000, J PHYSIOL-LONDON, V524, P649, DOI 10.1111/j.1469-7793.2000.00649.x; Siegwart R, 2002, J NEUROCHEM, V80, P140, DOI 10.1046/j.0022-3042.2001.00682.x; Siegwart Roberta, 2003, BMC Pharmacol, V3, P13, DOI 10.1186/1471-2210-3-13; Sigel E, 1999, J NEUROCHEM, V73, P1758, DOI 10.1046/j.1471-4159.1999.731758.x; Wagner DA, 2001, J NEUROSCI, V21, P67, DOI 10.1523/JNEUROSCI.21-01-00067.2001; Zeller Anja, 2007, BMC Pharmacology, V7, P2, DOI 10.1186/1471-2210-7-2	37	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15250	15257		10.1074/jbc.M708638200	http://dx.doi.org/10.1074/jbc.M708638200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18387955	hybrid, Green Published			2022-12-25	WOS:000256232000043
J	Thorsell, AG; Persson, C; Voevodskaya, N; Busam, RD; Hammarstrom, M; Graslund, S; Graslund, A; Hallberg, BM				Thorsell, Ann-Gerd; Persson, Camilla; Voevodskaya, Nina; Busam, Robert D.; Hammarstrom, Martin; Graslund, Susanne; Graslund, Astrid; Hallberg, B. Martin			Structural and biophysical characterization of human myo-inositol oxygenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; RIBONUCLEOTIDE REDUCTASE; MOLECULAR-CLONING; MIXED-VALENT; IRON; PROTEIN; EXPRESSION; COMPLICATIONS; SPECTROSCOPY; COMPLEXES	Altered inositol metabolism is implicated in a number of diabetic complications. The first committed step in mammalian inositol catabolism is performed by myo-inositol oxygenase (MIOX), which catalyzes a unique four-electron dioxygen-dependent ring cleavage of myo-inositol to D-glucuronate. Here, we present the crystal structure of human MIOX in complex with myo-inosose-1 bound in a terminal mode to the MIOX diiron cluster site. Furthermore, from biochemical and biophysical results from N-terminal deletion mutagenesis we show that the N terminus is important, through coordination of a set of loops covering the active site, in shielding the active site during catalysis. EPR spectroscopy of the unliganded enzyme displays a two-component spectrum that we can relate to an open and a closed active site conformation. Furthermore, based on site-directed mutagenesis in combination with biochemical and biophysical data, we propose a novel role for Lys(127) in governing access to the diiron cluster.	[Thorsell, Ann-Gerd; Persson, Camilla; Busam, Robert D.; Hammarstrom, Martin; Graslund, Susanne; Hallberg, B. Martin] Karolinska Inst, Dept Med Biochem & Biophys, Struct Genom Consortium, SE-17177 Stockholm, Sweden; [Hallberg, B. Martin] Karolinska Inst, Med Nobel Inst, Dept Cell & Mol Biol, SE-17177 Stockholm, Sweden; [Voevodskaya, Nina; Graslund, Astrid] Stockholm Univ, Dept Biochem & Biophys, SE-10691 Stockholm, Sweden	Karolinska Institutet; Karolinska Institutet; Stockholm University	Hallberg, BM (corresponding author), Karolinska Inst, Dept Med Biochem & Biophys, Struct Genom Consortium, SE-17177 Stockholm, Sweden.	Martin.Hallberg@ki.se	Gräslund, Susanne/ABB-6339-2020; Hallberg, B. Martin/C-5361-2009	Hallberg, B. Martin/0000-0002-6781-0345; Graslund, Susanne/0000-0003-0077-8333	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Arner RJ, 2006, BIOCHEM BIOPH RES CO, V339, P816, DOI 10.1016/j.bbrc.2005.11.090; Arner RJ, 2004, BIOCHEM BIOPH RES CO, V324, P1386, DOI 10.1016/j.bbrc.2004.09.209; Arner RJ, 2001, BIOCHEM J, V360, P313, DOI 10.1042/bj3600313; ATKIN CL, 1973, J BIOL CHEM, V248, P7464; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; Brownt PM, 2006, P NATL ACAD SCI USA, V103, P15032, DOI 10.1073/pnas.0605143103; Cowtan K, 1999, ACTA CRYSTALLOGR D, V55, P1555, DOI 10.1107/S0907444999007416; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; GAYDA JP, 1976, BIOCHIM BIOPHYS ACTA, V434, P154, DOI 10.1016/0005-2795(76)90045-3; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Kim SH, 2006, J AM CHEM SOC, V128, P10374, DOI 10.1021/ja063602c; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lindqvist Y, 1996, EMBO J, V15, P4081, DOI 10.1002/j.1460-2075.1996.tb00783.x; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; NABER NI, 1986, BIOCHEMISTRY-US, V25, P7201, DOI 10.1021/bi00370a065; Nordlund P, 1995, CURR OPIN STRUC BIOL, V5, P758, DOI 10.1016/0959-440X(95)80008-5; NORDLUND P, 1990, NATURE, V345, P593, DOI 10.1038/345593a0; PEARCE LL, 1987, J AM CHEM SOC, V109, P7286, DOI 10.1021/ja00258a007; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; PORATH J, 1975, NATURE, V258, P598, DOI 10.1038/258598a0; ROSENZWEIG AC, 1993, NATURE, V366, P537, DOI 10.1038/366537a0; RUTTER R, 1984, BIOCHEMISTRY-US, V23, P6809, DOI 10.1021/bi00321a082; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; VANDUYNE GD, 1993, J MOL BIOL, V229, P105, DOI 10.1006/jmbi.1993.1012; WINEGRAD AI, 1987, DIABETES, V36, P396, DOI 10.2337/diab.36.3.396; Xing G, 2006, P NATL ACAD SCI USA, V103, P6130, DOI 10.1073/pnas.0508473103; Xing G, 2006, BIOCHEMISTRY-US, V45, P5402, DOI 10.1021/bi0526276; Xing G, 2006, BIOCHEMISTRY-US, V45, P5393, DOI 10.1021/bi0519607; Yang YS, 1997, J AM CHEM SOC, V119, P11832, DOI 10.1021/ja971896j	31	34	37	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15209	15216		10.1074/jbc.M800348200	http://dx.doi.org/10.1074/jbc.M800348200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18364358	Green Published, hybrid			2022-12-25	WOS:000256232000038
J	Thyagarajan, B; Lukacs, V; Rohacs, T				Thyagarajan, Baskaran; Lukacs, Viktor; Rohacs, Tibor			Hydrolysis of phosphatidylinositol 4,5-bisphosphate mediates calcium-induced inactivation of TRPV6 channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C ACTIVATION; CATION CHANNEL; ION CHANNELS; RECEPTOR; PIP2; CA2+; CELLS; INHIBITION; DESENSITIZATION; PHOSPHOINOSITIDES	TRPV6 is a member of the transient receptor potential superfamily of ion channels that facilitates Ca2+ absorption in the intestines. These channels display high selectivity for Ca2+, but in the absence of divalent cations they also conduct monovalent ions. TRPV6 channels have been shown to be inactivated by increased cytoplasmic Ca2+ concentrations. Here we studied the mechanism of this Ca2+ -induced inactivation. Monovalent currents through TRPV6 substantially decreased after a 40-s application of Ca butnotBa Wealsoshowthat Ca2+,but not Ba2+ ,influx via TRPV6 induces depletion of phos phatidylinositol 4,5-bisphosphate (PI(4,5)P-2 or PIN2) and the formation of inositol 1,4,5-trisphosphate. Dialysis of DiC(8) PI(4,5)P-2 through the patch pipette inhibited Ca2+ -dependent inactivation of TRPV6 currents in whole-cell patch clamp experiments. PI(4,5)P-2 also activated TRPV6 currents in excised patches. PI(4)P, the precursor of PI(4,5)P-2, neither activated TRPV6 in excised patches nor had any effect on Ca2+ -induced inactivation in whole-cell experiments. Conversion of PI(4,5)P-2 to PI(4)P by a rapamycin-inducible PI(4,5)P-2 5-phosphatase inhibited TRPV6 currents in whole-cell experiments. Inhibiting phosphatidylinositol 4 kinases with wortmannin decreased TRPV6 currents and Ca2+ entry into TRPV6-expressing cells. We propose that Ca2+ influx through TRPV6 activates phospholipase C and the resulting depletion of PI(4,5)P-2 contributes to the inactivation of TRPV6.	[Thyagarajan, Baskaran; Lukacs, Viktor; Rohacs, Tibor] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, Newark, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	Rohacs, T (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Physiol & Pharmacol, 185 S Orange Ave, Newark, NJ 07103 USA.	tibor.rohacs@umdnj.edu		Lukacs, Viktor/0000-0003-3652-5469	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS055159] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 055159, R01 NS055159] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abe J, 2006, NEUROSCI LETT, V397, P140, DOI 10.1016/j.neulet.2005.12.005; Balla A, 2006, TRENDS CELL BIOL, V16, P351, DOI 10.1016/j.tcb.2006.05.003; BALLA T, 1994, J BIOL CHEM, V269, P16101; Bianco SDC, 2007, J BONE MINER RES, V22, P274, DOI 10.1359/JBMR.061110; Bodding M, 2002, J BIOL CHEM, V277, P36656, DOI 10.1074/jbc.M202822200; Chuang HH, 2001, NATURE, V411, P957, DOI 10.1038/35082088; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Cui J, 2002, J BIOL CHEM, V277, P47175, DOI 10.1074/jbc.M205870200; Czirjak G, 2001, AM J PHYSIOL-CELL PH, V281, pC700, DOI 10.1152/ajpcell.2001.281.2.C700; Derler I, 2006, J PHYSIOL-LONDON, V577, P31, DOI 10.1113/jphysiol.2006.118661; Estacion M, 2001, J PHYSIOL-LONDON, V530, P1, DOI 10.1111/j.1469-7793.2001.0001m.x; Fischer W, 2005, N-S ARCH PHARMACOL, V371, P466, DOI 10.1007/s00210-005-1070-6; Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481; Gwanyanya A, 2006, AM J PHYSIOL-CELL PH, V291, pC627, DOI 10.1152/ajpcell.00074.2006; Hardie RC, 2007, J PHYSIOL-LONDON, V578, P9, DOI 10.1113/jphysiol.2006.118372; Hoenderop JGJ, 2005, PHYSIOL REV, V85, P373, DOI 10.1152/physrev.00003.2004; Hoenderop JGJ, 2001, J PHYSIOL-LONDON, V537, P747; Hoenderop JGJ, 2002, ANNU REV PHYSIOL, V64, P529, DOI 10.1146/annurev.physiol.64.081501.155921; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Lee J, 2005, J GEN PHYSIOL, V126, P439, DOI 10.1085/jgp.200509314; Liu BY, 2005, J NEUROSCI, V25, P1674, DOI 10.1523/JNEUROSCI.3632-04.2005; Liu D, 2003, P NATL ACAD SCI USA, V100, P15160, DOI 10.1073/pnas.2334159100; Lukacs V, 2007, J NEUROSCI, V27, P7070, DOI 10.1523/JNEUROSCI.1866-07.2007; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; Nijenhuis T, 2003, J AM SOC NEPHROL, V14, P2731, DOI 10.1097/01.ASN.0000094081.78893.E8; Nilius B, 2006, EMBO J, V25, P467, DOI 10.1038/sj.emboj.7600963; Nilius B, 2002, J BIOL CHEM, V277, P30852, DOI 10.1074/jbc.M202418200; Nilius B, 2001, CELL CALCIUM, V29, P417, DOI 10.1054/ceca.2001.0201; Nilius B, 2007, PHYSIOL REV, V87, P165, DOI 10.1152/physrev.00021.2006; Premkumar LS, 2005, J NEUROSCI, V25, P11322, DOI 10.1523/JNEUROSCI.3006-05.2005; Qu ZQ, 2000, J GEN PHYSIOL, V116, P825, DOI 10.1085/jgp.116.6.825; Rohacs T, 1999, J BIOL CHEM, V274, P36065, DOI 10.1074/jbc.274.51.36065; Rohacs T, 2005, NAT NEUROSCI, V8, P626, DOI 10.1038/nn1451; Rohacs T, 2007, PFLUG ARCH EUR J PHY, V453, P753, DOI 10.1007/s00424-006-0153-7; ROONEY TA, 1991, J BIOL CHEM, V266, P15068; Runnels LW, 2002, NAT CELL BIOL, V4, P329, DOI 10.1038/ncb781; Stein AT, 2006, J GEN PHYSIOL, V128, P509, DOI 10.1085/jgp.200609576; Suh BC, 2006, SCIENCE, V314, P1454, DOI 10.1126/science.1131163; van der Wal J, 2001, J BIOL CHEM, V276, P15337, DOI 10.1074/jbc.M007194200; Varnai P, 2006, J CELL BIOL, V175, P377, DOI 10.1083/jcb.200607116; Vennekens R, 2002, CELL CALCIUM, V31, P253, DOI 10.1016/S0143-4160(02)00055-6; Voets T, 2003, J GEN PHYSIOL, V121, P245, DOI 10.1085/jgp.20028752; Voets T, 2007, J PHYSIOL-LONDON, V582, P939, DOI 10.1113/jphysiol.2007.132522; WHITE MM, 1990, MOL PHARMACOL, V37, P720; Zhang HL, 2003, NEURON, V37, P963, DOI 10.1016/S0896-6273(03)00125-9; Zhang Z, 2005, J BIOL CHEM, V280, P39185, DOI 10.1074/jbc.M506965200; Zhuang LY, 2002, LAB INVEST, V82, P1755, DOI 10.1097/01.LAB.0000043910.41414.E7	47	56	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					14980	14987		10.1074/jbc.M704224200	http://dx.doi.org/10.1074/jbc.M704224200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18390907	Green Published, hybrid			2022-12-25	WOS:000256232000010
J	Almog, T; Lazar, S; Reiss, N; Etkovitz, N; Milch, E; Rahamim, N; Dobkin-Bekman, M; Rotem, R; Kalina, M; Ramon, J; Raziel, A; Brietbart, H; Seger, R; Naor, Z				Almog, Tal; Lazar, Shlomi; Reiss, Nachum; Etkovitz, Nir; Milch, Eyal; Rahamim, Nir; Dobkin-Bekman, Masha; Rotem, Ronit; Kalina, Moshe; Ramon, Jacob; Raziel, Arieh; Brietbart, Haim; Seger, Rony; Naor, Zvi			Identification of extracellular signal-regulated kinase 1/2 and p38 MAPK as regulators of human sperm motility and acrosome reaction and as predictors of poor spermatozoan quality	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GONADOTROPIN-RELEASING-HORMONE; MAMMALIAN SPERMATOZOA; MAP KINASE; MEIOTIC PROGRESSION; FLAGELLAR MOTILITY; COUPLED RECEPTORS; ACTIVATION; PHOSPHORYLATION; PROGESTERONE	Mature spermatozoa acquire progressive motility only after ejaculation. Their journey in the female reproductive tract also includes suppression of progressive motility, reactivation, capacitation, and hyperactivation of motility (whiplash), the mechanisms of which are obscure. MAPKs are key regulatory enzymes in cell signaling, participating in diverse cellular functions such as growth, differentiation, stress, and apoptosis. Here we report that ERK1/2 and p38MAPKare primarily localized to the tail of mature human spermatozoa. Surprisingly, c-Jun N-terminal kinase 1/2, which is thought to be ubiquitously expressed, could not be detected in mature human spermatozoa. ERK1/2 stimulation is downstream to protein kinase C (PKC) activation, which is also present in the human sperm tail (PKC beta I and PKC epsilon). ERK1/2 stimulates and p38 inhibits forward and hyperactivated motility, respectively. Both ERK1/2 and p38 MAPK are involved in the acrosome reaction. Using a proteomic approach, we identified ARHGAP6, a RhoGAP, as an ERK substrate in PMA-stimulated human spermatozoa. Inverse correlation was obtained between the relative expression level of ERK1 or the relative activation level of p38 and sperm motility, forward progression motility, sperm morphology, and viability. Therefore, increased expression of ERK1 and activated p38 can predict poor human sperm quality.	[Almog, Tal; Lazar, Shlomi; Reiss, Nachum; Rahamim, Nir; Dobkin-Bekman, Masha; Rotem, Ronit; Naor, Zvi] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel; [Etkovitz, Nir; Brietbart, Haim] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel; [Milch, Eyal] Chaim Sheba Med Ctr, Dept Urol, IL-52621 Tel Hashomer, Israel; [Raziel, Arieh] Tel Aviv Univ, Sackler Sch Med, Assaf Harofeh Med Ctr, Male Infertil & Vitro Fertilizat Unit, IL-69978 Tel Aviv, Israel; [Seger, Rony] Weizmann Inst Sci, Dept Regulat Biol, IL-76100 Rehovot, Israel; [Kalina, Moshe] Tel Aviv Univ, Sackler Sch Med, Assaf Harofeh Med Ctr, Dept Cell Biol & Histol, IL-69978 Tel Aviv, Israel	Tel Aviv University; Bar Ilan University; Chaim Sheba Medical Center; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Sackler Faculty of Medicine; Weizmann Institute of Science; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; Sackler Faculty of Medicine	Naor, Z (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Biochem, IL-69978 Tel Aviv, Israel.	zvin@tauex.tau.ac.il						Aitken RJ, 2006, INT J ANDROL, V29, P69, DOI 10.1111/j.1365-2605.2005.00630.x; Ashizawa K, 1997, BIOCHEM BIOPH RES CO, V240, P116, DOI 10.1006/bbrc.1997.7626; Baldi E, 1998, FRONT BIOSCI, V3, pD1051; Belanger LF, 2003, MOL CELL BIOL, V23, P4778, DOI 10.1128/MCB.23.14.4778-4787.2003; Bonfil D, 2004, ENDOCRINOLOGY, V145, P2228, DOI 10.1210/en.2003-1418; BREITBART H, 1992, BIOCHEM J, V281, P473, DOI 10.1042/bj2810473; Breitbart H, 1999, REV REPROD, V4, P151; Chen WY, 2005, FEBS LETT, V579, P4692, DOI 10.1016/j.febslet.2005.06.090; de Lamirande E, 2002, MOL HUM REPROD, V8, P124, DOI 10.1093/molehr/8.2.124; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; Di Agostino S, 2004, REPRODUCTION, V128, P25, DOI 10.1530/rep.1.00184; Dragileva E, 1999, BIOL REPROD, V61, P1226, DOI 10.1095/biolreprod61.5.1226; du Plessis SS, 2002, ANDROLOGIA, V34, P55; Eisenbach M, 2006, NAT REV MOL CELL BIO, V7, P276, DOI 10.1038/nrm1893; Garbers DL, 2001, NATURE, V413, P579, DOI 10.1038/35098164; Giroux S, 1999, CURR BIOL, V9, P369, DOI 10.1016/S0960-9822(99)80164-X; Gur Y, 2006, GENE DEV, V20, P411, DOI 10.1101/gad.367606; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Hamilton M, 2001, J BIOL CHEM, V276, P29079, DOI 10.1074/jbc.M102001200; Hirano Y, 2001, J ASSIST REPROD GEN, V18, P213; Ho HC, 2001, REPRODUCTION, V122, P519, DOI 10.1530/rep.0.1220519; Inaba K, 2003, ZOOL SCI, V20, P1043, DOI 10.2108/zsj.20.1043; Itoh Y, 2003, NATURE, V422, P173, DOI 10.1038/nature01478; KALINA M, 1995, J HISTOCHEM CYTOCHEM, V43, P439, DOI 10.1177/43.4.7897184; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Liu DY, 2002, MOL HUM REPROD, V8, P37, DOI 10.1093/molehr/8.1.37; Lu Q, 1999, ARCH ANDROLOGY, V43, P55, DOI 10.1080/014850199262733; Luconi M, 1998, MOL HUM REPROD, V4, P251, DOI 10.1093/molehr/4.3.251; MOHRI H, 1993, MOL REPROD DEV, V36, P221, DOI 10.1002/mrd.1080360214; Morita M, 2006, CELL MOTIL CYTOSKEL, V63, P459, DOI 10.1002/cm.20137; Mulvaney JM, 2000, J BIOL CHEM, V275, P14182, DOI 10.1074/jbc.275.19.14182; Murphy LO, 2006, TRENDS BIOCHEM SCI, V31, P268, DOI 10.1016/j.tibs.2006.03.009; Naor Z, 1997, TRENDS ENDOCRIN MET, V8, P337, DOI 10.1016/S1043-2760(97)00134-3; Naor Z, 2000, TRENDS ENDOCRIN MET, V11, P91, DOI 10.1016/S1043-2760(99)00232-5; Pages G, 1999, SCIENCE, V286, P1374, DOI 10.1126/science.286.5443.1374; Parinaud J, 1996, J CLIN ENDOCR METAB, V81, P1357, DOI 10.1210/jc.81.4.1357; Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153; Prakash SK, 2000, HUM MOL GENET, V9, P477, DOI 10.1093/hmg/9.4.477; Publicover S, 2007, NAT CELL BIOL, V9, P235, DOI 10.1038/ncb0307-235; Rhee K, 1997, DEVELOPMENT, V124, P2167; ROTEM R, 1992, ENDOCRINOLOGY, V131, P2235, DOI 10.1210/en.131.5.2235; ROTEM R, 1990, P NATL ACAD SCI USA, V87, P7305, DOI 10.1073/pnas.87.18.7305; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Sette C, 1999, J BIOL CHEM, V274, P33571, DOI 10.1074/jbc.274.47.33571; SPUNGIN B, 1995, J CELL SCI, V108, P2525; THONNEAU P, 1991, HUM REPROD, V6, P811, DOI 10.1093/oxfordjournals.humrep.a137433; VISCONTI PE, 1995, DEVELOPMENT, V121, P1139; WALENSKY LD, 1995, J CELL BIOL, V130, P857, DOI 10.1083/jcb.130.4.857; Weidinger S, 2005, HUM REPROD, V20, P456, DOI 10.1093/humrep/deh618; Wilsbacher JL, 2001, METHOD ENZYMOL, V332, P387; Wong CH, 2005, DEV BIOL, V286, P1, DOI 10.1016/j.ydbio.2005.08.001; World Health Organization (WHO), 1999, WHO LAB MANUAL EXAMI, V4th; YANAGIMACHI R, 1994, PHYSL REPROD, V0002, P00189; Yao Y, 2003, P NATL ACAD SCI USA, V100, P12759, DOI 10.1073/pnas.2134254100; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218; Zhang H, 2001, J BIOL CHEM, V276, P6905, DOI 10.1074/jbc.C000917200; ZWEIG MH, 1993, CLIN CHEM, V39, P561	57	90	99	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14479	14489		10.1074/jbc.M710492200	http://dx.doi.org/10.1074/jbc.M710492200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18372245	hybrid			2022-12-25	WOS:000255941400035
J	Suzuki, T; Kondo, S; Wakayama, T; Cizdziel, PE; Hayashizaki, Y				Suzuki, Takahiro; Kondo, Shinji; Wakayama, Teruhiko; Cizdziel, Paul E.; Hayashizaki, Yoshihide			Genome-Wide Analysis of Abnormal H3K9 Acetylation in Cloned Mice	PLOS ONE			English	Article							GENE-EXPRESSION; NUCLEAR TRANSFER; MOUSE EMBRYOS; TRICHOSTATIN-A; CLONING; LEPTIN; CELL; HUMAN-CHROMOSOME-21; TRANSCRIPTOME; PROMOTERS	Somatic nuclear transfer is a cloning technique that shows great promise in the application to regenerative medicine. Although cloned animals are genetically identical to their donor counterparts, abnormalities in phenotype and gene expression are frequently observed. One hypothesis is that the cause of these abnormalities is due to epigenetic aberration. In this report, we focused our analysis on the acetylation of histone H3 at lysine9 (H3K9Ac). Through the use of whole genome tiling arrays and quantitative PCR, we examined this epigenetic event and directly compared and assessed the differences between a cloned mouse (C1) and its parental nuclear donor (D1) counterpart. We identified 4720 regions of chromosomal DNA that showed notable differences in H3K9Ac and report here many genes identified in these hyper-and hypo-acetylated regions. Analysis of a second clone (C2) and its parental donor counterpart (D2) for H3K9Ac showed a high degree of similarity to the C1/D1 pair. This conservation of aberrant acetylation is suggestive of a reproducible epigenetic phenomenon that may lead to the frequent abnormalities observed in cloned mice, such as obesity. Furthermore, we demonstrated Crp which was identified as a hyper-acetylated gene in this study is related to the body mass, suggesting that Crp is a possible candidate of a cause for the abnormal obesity in cloned mice. In this, one of the first reports describing genome-wide epigenetic abberation between parental and nuclear transfer-cloned mammals, we propose that aberrant acetylation of histones (H3K9Ac) flanking promoter regions highly correlates with gene-expression and may itself be an epigenetic change that accounts for variable expression patterns observed in cloned animals.	[Suzuki, Takahiro; Kondo, Shinji; Cizdziel, Paul E.; Hayashizaki, Yoshihide] RIKEN, Yokohama Inst, Genom Sci Ctr, Genome Explorat Res Grp, Kanagawa, Japan; [Suzuki, Takahiro; Hayashizaki, Yoshihide] Yokohama City Univ, Int Grad Sch Arts & Sci, Div Genom Informat Resources, Supramol Biol, Yokohama, Kanagawa, Japan; [Wakayama, Teruhiko] RIKEN Kobe, Ctr Dev Biol, Lab Genom Reprogramming, Kobe, Hyogo, Japan; [Hayashizaki, Yoshihide] RIKEN, Discovery & Res Inst, Genome Sci Lab, Wako, Saitama, Japan; [Hayashizaki, Yoshihide] RIKEN Frontier Res Syst, Funct RNA Res Program, Wako, Saitama, Japan	RIKEN; Yokohama City University; RIKEN; RIKEN; RIKEN	Suzuki, T (corresponding author), RIKEN, Yokohama Inst, Genom Sci Ctr, Genome Explorat Res Grp, Kanagawa, Japan.	rgscerg@gsc.riken.jp	Suzuki, Takahiro/AAW-8509-2020; Hayashizaki, Yoshihide/N-6590-2015	Suzuki, Takahiro/0000-0002-0972-6911; 	Ministry of Education, Culture, Sports, Science, and Technology of the Japanese Government; RIKEN [15080211]	Ministry of Education, Culture, Sports, Science, and Technology of the Japanese Government(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); RIKEN	This work was supported in part by a Research Grant for the RIKEN Genome Exploration Research Project from the Ministry of Education, Culture, Sports, Science, and Technology of the Japanese Government to YH; a Grant of the Genome Network Project from the Ministry of Education, Culture, Sports, Science and Technology, Japan; The Strategic Program for R&D of RIKEN; Grant for the RIKEN Frontier Research System, Functional RNA research program and Scientific Research in Priority Areas (15080211) and a project for the realization of regenerative medicine from the Ministry of Education, Culture, Sports, Science and Technology of Japanese Government to TW.	Balbach ST, 2007, DEV BIOL, V308, P309, DOI 10.1016/j.ydbio.2007.05.034; Barker DJP, 2007, J INTERN MED, V261, P412, DOI 10.1111/j.1365-2796.2007.01809.x; Barker DJP, 2006, NAT CLIN PRACT NEPHR, V2, P700, DOI 10.1038/ncpneph0344; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bjorbaek C, 1999, J BIOL CHEM, V274, P30059, DOI 10.1074/jbc.274.42.30059; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; CHATOT CL, 1989, J REPROD FERTIL, V86, P679, DOI 10.1530/jrf.0.0860679; Chen K, 2006, NAT MED, V12, P425, DOI 10.1038/nm1372; Chen ZX, 2005, BIOCHEM CELL BIOL, V83, P438, DOI 10.1139/O05-138; Cheng J, 2005, SCIENCE, V308, P1149, DOI 10.1126/science.1108625; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Dodd IB, 2007, CELL, V129, P813, DOI 10.1016/j.cell.2007.02.053; Enright BP, 2003, BIOL REPROD, V69, P896, DOI 10.1095/biolreprod.103.017954; Farooqi IS, 2007, NAT MED, V13, P16, DOI 10.1038/nm0107-16; Florea L, 1998, GENOME RES, V8, P967, DOI 10.1101/gr.8.9.967; Gertler A, 2007, NAT MED, V13, P18, DOI 10.1038/nm0107-18; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Gura T, 1999, SCIENCE, V286, P881; Hasegawa Y, 2006, NUCLEIC ACIDS RES, V34, DOI 10.1093/nar/gkl497; Heintzman ND, 2007, NAT GENET, V39, P311, DOI 10.1038/ng1966; Humphreys D, 2002, P NATL ACAD SCI USA, V99, P12889, DOI 10.1073/pnas.192433399; Hutchinson WL, 2007, NAT MED, V13, P17, DOI 10.1038/nm0107-17; Inoue K, 2002, SCIENCE, V295, P297, DOI 10.1126/science.295.5553.297; Kampa D, 2004, GENOME RES, V14, P331, DOI 10.1101/gr.2094104; Kapranov P, 2002, SCIENCE, V296, P916, DOI 10.1126/science.1068597; Kent WJ, 2002, GENOME RES, V12, P656, DOI 10.1101/gr.229202; Kishigami S, 2006, BIOCHEM BIOPH RES CO, V340, P183, DOI 10.1016/j.bbrc.2005.11.164; Kishigami S, 2007, J REPROD DEVELOP, V53, P165, DOI 10.1262/jrd.18098; Kohda T, 2005, BIOL REPROD, V73, P1302, DOI 10.1095/biolreprod.105.044958; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McGregor GP, 1996, ENDOCRINOLOGY, V137, P1501, DOI 10.1210/en.137.4.1501; Nishida H, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-108; Nishida H, 2006, CHROMOSOME RES, V14, P203, DOI 10.1007/s10577-006-1036-7; Ohgane J, 2001, GENESIS, V30, P45, DOI 10.1002/gene.1031; Ohgane J, 2004, GENES CELLS, V9, P253, DOI 10.1111/j.1356-9597.2004.00720.x; Okazaki Y, 2002, NATURE, V420, P563, DOI 10.1038/nature01266; Roh TY, 2005, GENE DEV, V19, P542, DOI 10.1101/gad.1272505; SANDELIN A, 2007, NAT REV GENET; Senda S, 2007, CLONING STEM CELLS, V9, P293, DOI 10.1089/clo.2006.0050; Shimizu H, 1997, INT J OBESITY, V21, P536, DOI 10.1038/sj.ijo.0800437; Szmitko Paul E, 2006, J Cardiometab Syndr, V1, P66, DOI 10.1111/j.0197-3118.2006.05340.x; Tamashiro KLK, 2002, NAT MED, V8, P262, DOI 10.1038/nm0302-262; Tanaka S, 2001, BIOL REPROD, V65, P1813, DOI 10.1095/biolreprod65.6.1813; Tong GQ, 2006, CELL TISSUE RES, V325, P231, DOI 10.1007/s00441-006-0189-1; Wakayama S, 2005, J REPROD DEVELOP, V51, P765, DOI 10.1262/jrd.17061; Wakayama T, 1999, SEMIN CELL DEV BIOL, V10, P253, DOI 10.1006/scdb.1998.0267; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wakayama T, 1999, P NATL ACAD SCI USA, V96, P14984, DOI 10.1073/pnas.96.26.14984; Wakayama T, 2007, J REPROD DEVELOP, V53, P13, DOI 10.1262/jrd.18120; Yang FK, 2007, REPRODUCTION, V133, P219, DOI 10.1530/rep.1.01206; Yang JF, 2007, BIOL REPROD, V76, P36, DOI 10.1095/biolreprod.106.051383; Yu Y, 2007, REPRODUCTION, V133, P947, DOI 10.1530/REP-06-0358	52	19	22	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1905	10.1371/journal.pone.0001905	http://dx.doi.org/10.1371/journal.pone.0001905			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398451	Green Published, Green Submitted, gold			2022-12-25	WOS:000260795500001
J	Boutin, C; Diestel, S; Desoeuvre, A; Tiveron, MC; Cremer, H				Boutin, Camille; Diestel, Simone; Desoeuvre, Angelique; Tiveron, Marie-Catherine; Cremer, Harold			Efficient In Vivo Electroporation of the Postnatal Rodent Forebrain	PLOS ONE			English	Article								Functional gene analysis in vivo represents still a major challenge in biomedical research. Here we present a new method for the efficient introduction of nucleic acids into the postnatal mouse forebrain. We show that intraventricular injection of DNA followed by electroporation induces strong expression of transgenes in radial glia, neuronal precursors and neurons of the olfactory system. We present two proof-of-principle experiments to validate our approach. First, we show that expression of a human isoform of the neural cell adhesion molecule (hNCAM-140) in radial glia cells induces their differentiation into cells showing a neural precursor phenotype. Second, we demonstrate that p21 acts as a cell cycle inhibitor for postnatal neural stem cells. This approach will represent an important tool for future studies of postnatal neurogenesis and of neural development in general.	[Boutin, Camille; Diestel, Simone; Desoeuvre, Angelique; Tiveron, Marie-Catherine; Cremer, Harold] Univ Aix Marseille 2, CNRS, IBDML, Marseille, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Aix-Marseille Universite	Boutin, C (corresponding author), Univ Aix Marseille 2, CNRS, IBDML, Campus Luminy, Marseille, France.	cremer@ibdm.univ-mrs.fr	TIVERON, Marie-Catherine/AAR-1142-2020	Cremer, Harold/0000-0002-8673-5176	Fondation de France; Association Francaise contre les Myopathies; European Union; Agence Nationale de la Recherche	Fondation de France(Fondation de France); Association Francaise contre les Myopathies(Association Francaise contre les Myopathies); European Union(European Commission); Agence Nationale de la Recherche(French National Research Agency (ANR))	This work has been supported by grants from the Fondation de France (FDF), Association Francaise contre les Myopathies (AFM), the European Union through the Network of Excellence NeuroNE and the Agence Nationale de la Recherche (ANR) to HC.	Alvarez-Buylla A, 2002, J NEUROSCI, V22, P629, DOI 10.1523/JNEUROSCI.22-03-00629.2002; Chazal G, 2000, J NEUROSCI, V20, P1446; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Diestel S, 2007, J CELL SCI, V120, P4035, DOI 10.1242/jcs.019729; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Doetsch F, 1997, J NEUROSCI, V17, P5046; Hack I, 2002, NAT NEUROSCI, V5, P939, DOI 10.1038/nn923; Kim JH, 2005, J NEUROCHEM, V94, P417, DOI 10.1111/j.1471-4159.2005.03208.x; Kippin TE, 2005, GENE DEV, V19, P756, DOI 10.1101/gad.1272305; Konishi Y, 2004, SCIENCE, V303, P1026, DOI 10.1126/science.1093712; Lois C, 1996, SCIENCE, V271, P978, DOI 10.1126/science.271.5251.978; Matsuda T, 2004, P NATL ACAD SCI USA, V101, P16, DOI 10.1073/pnas.2235688100; Matsuda T, 2007, P NATL ACAD SCI USA, V104, P1027, DOI 10.1073/pnas.0610155104; Miller VM, 2005, CELL MOL NEUROBIOL, V25, P1195, DOI 10.1007/s10571-005-8447-4; Mir LM, 2005, ADV GENET, V54, P83, DOI 10.1016/S0065-2660(05)54005-7; MISSON JP, 1988, DEV BRAIN RES, V44, P95, DOI 10.1016/0165-3806(88)90121-6; Morin X, 2007, NAT NEUROSCI, V10, P1440, DOI 10.1038/nn1984; Nakamura H, 2004, MECH DEVELOP, V121, P1137, DOI 10.1016/j.mod.2004.05.013; Nelson SB, 2006, CURR OPIN NEUROBIOL, V16, P571, DOI 10.1016/j.conb.2006.08.006; Saito T, 2001, DEV BIOL, V240, P237, DOI 10.1006/dbio.2001.0439	20	108	108	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1883	10.1371/journal.pone.0001883	http://dx.doi.org/10.1371/journal.pone.0001883			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382666	gold, Green Published			2022-12-25	WOS:000260795400017
J	Kyere, SK; Joseph, PRB; Summers, MF				Kyere, Sampson K.; Joseph, Prem Raj B.; Summers, Michael F.			The p12 Domain Is Unstructured in a Murine Leukemia Virus p12-CA(N) Gag Construct	PLOS ONE			English	Article								The Gag polyproteins of gammaretroviruses contain a conserved p12 domain between MA and CA that plays critical roles in virus assembly, reverse transcription and nuclear integration. Here we show using nuclear magnetic resonance, that p12 is unstructured in a Moloney murine leukemia virus (MMLV) Gag fragment that includes the N-terminal domain of CA (p12-CA(N)). Furthermore, no long range interactions were observed between the domains, as has been previously predicted. Flexibility appears to be a common feature of Gag "late'' domains required for virus release during budding. Residues near the N-terminus of CA(N) that form a beta-hairpin in the mature CA protein are unfolded in p12-CA(N), consistent with proposals that hairpin formation helps trigger capsid assembly.	[Kyere, Sampson K.; Joseph, Prem Raj B.; Summers, Michael F.] Univ Maryland, Howard Hughes Med Inst, Dept Chem & Biochem, Baltimore, MD 21201 USA	Howard Hughes Medical Institute; University System of Maryland; University of Maryland Baltimore	Kyere, SK (corresponding author), Univ Maryland, Howard Hughes Med Inst, Dept Chem & Biochem, Baltimore, MD 21201 USA.	summers@hhmi.umbc.edu	Joseph, Prem Raj/E-8553-2010		NIH [AI30917, GM076979]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030917, R37AI030917] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM076979] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	Funding was received from the NIH (AI30917 to MFS and GM076979 to SKK).	Auerbach MR, 2003, P NATL ACAD SCI USA, V100, P11678, DOI 10.1073/pnas.2034020100; BOWERMAN B, 1989, GENE DEV, V3, P469, DOI 10.1101/gad.3.4.469; Campos-Olivas R, 2000, J MOL BIOL, V296, P633, DOI 10.1006/jmbi.1999.3475; COLICELLI J, 1988, J MOL BIOL, V199, P47, DOI 10.1016/0022-2836(88)90378-6; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Demirov DG, 2002, P NATL ACAD SCI USA, V99, P955, DOI 10.1073/pnas.032511899; Demirov DG, 2004, VIRUS RES, V106, P87, DOI 10.1016/j.virusres.2004.08.007; Freed EO, 1998, VIROLOGY, V251, P1, DOI 10.1006/viro.1998.9398; Gamble TR, 1996, CELL, V87, P1285, DOI 10.1016/S0092-8674(00)81823-1; Garrus JE, 2001, CELL, V107, P55, DOI 10.1016/S0092-8674(01)00506-2; Gitti RK, 1996, SCIENCE, V273, P231, DOI 10.1126/science.273.5272.231; GOTTLINGER HG, 1991, P NATL ACAD SCI USA, V88, P3195, DOI 10.1073/pnas.88.8.3195; GRZESIEK S, 1992, J MAGN RESON, V99, P201, DOI 10.1016/0022-2364(92)90169-8; GRZESIEK S, 1992, J AM CHEM SOC, V114, P6291, DOI 10.1021/ja00042a003; GRZESIEK S, 1992, J MAGN RESON, V96, P432, DOI 10.1016/0022-2364(92)90099-S; GRZESIEK S, 1993, J MAGN RESON SER B, V101, P114, DOI 10.1006/jmrb.1993.1019; HUANG MJ, 1995, J VIROL, V69, P6810, DOI 10.1128/JVI.69.11.6810-6818.1995; JOHNSON BA, 1994, J BIOMOL NMR, V4, P603, DOI 10.1007/BF00404272; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KAY LE, 1990, SCIENCE, V249, P411, DOI 10.1126/science.2377896; Khorasanizadeh S, 1999, J MOL BIOL, V291, P491, DOI 10.1006/jmbi.1999.2986; Le Blanc I, 2002, J VIROL, V76, P10024, DOI 10.1128/JVI.76.19.10024-10029.2002; Lee SK, 2005, J VIROL, V79, P4159, DOI 10.1128/JVI.79.7.4159-4169.2005; Martin-Serrano J, 2001, NAT MED, V7, P1313, DOI 10.1038/nm1201-1313; Momany C, 1996, NAT STRUCT BIOL, V3, P763, DOI 10.1038/nsb0996-763; Morita E, 2004, ANNU REV CELL DEV BI, V20, P395, DOI 10.1146/annurev.cellbio.20.010403.102350; Mortuza GB, 2004, NATURE, V431, P481, DOI 10.1038/nature02915; Oshima M, 2004, J VIROL, V78, P1411, DOI 10.1128/JVI.78.3.1411-1420.2004; Pornillos O, 2002, NAT STRUCT BIOL, V9, P812, DOI 10.1038/nsb856; Puffer BA, 1998, J VIROL, V72, P10218, DOI 10.1128/JVI.72.12.10218-10221.1998; Sundquist WI, 2004, MOL CELL, V13, P783, DOI 10.1016/S1097-2765(04)00129-7; Tang C, 2002, NAT STRUCT BIOL, V9, P537, DOI 10.1038/nsb806; Turner BG, 1999, J MOL BIOL, V285, P1, DOI 10.1006/jmbi.1998.2354; VerPlank L, 2001, P NATL ACAD SCI USA, V98, P7724, DOI 10.1073/pnas.131059198; von Schwedler UK, 1998, EMBO J, V17, P1555, DOI 10.1093/emboj/17.6.1555; Wang HT, 2002, J VIROL, V76, P8485, DOI 10.1128/JVI.76.16.8485-8493.2002; WILLS JW, 1994, J VIROL, V68, P6605, DOI 10.1128/JVI.68.10.6605-6618.1994; WISHART DS, 1994, J BIOMOL NMR, V4, P171; WISHART DS, 1995, J BIOMOL NMR, V5, P67, DOI 10.1007/BF00227471; Wuthrich K, 1986, NMR PROTEINS NUCL AC; Yasuda J, 1998, J VIROL, V72, P4095, DOI 10.1128/JVI.72.5.4095-4103.1998; Yeager M, 1998, P NATL ACAD SCI USA, V95, P7299, DOI 10.1073/pnas.95.13.7299; Yuan B, 1999, EMBO J, V18, P4700, DOI 10.1093/emboj/18.17.4700; Yuan B, 2000, J VIROL, V74, P7250, DOI 10.1128/JVI.74.16.7250-7260.2000; Yuan B, 2002, J VIROL, V76, P10801, DOI 10.1128/JVI.76.21.10801-10810.2002; Yueh A, 2003, J VIROL, V77, P1820, DOI 10.1128/JVI.77.3.1820-1829.2003	46	8	8	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1902	10.1371/journal.pone.0001902	http://dx.doi.org/10.1371/journal.pone.0001902			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382677	Green Submitted, Green Published, gold			2022-12-25	WOS:000260795400029
J	Yuan, SP; Fu, Y; Wang, XF; Shi, HB; Huang, YJ; Song, XM; Li, L; Song, N; Luo, YZ				Yuan, Shaopeng; Fu, Yan; Wang, Xiaofeng; Shi, Hubing; Huang, Yujie; Song, Xiaomin; Li, Ling; Song, Nan; Luo, Yongzhang			Voltage-dependent anion channel 1 is involved in endostatin-induced endothelial cell apoptosis	FASEB JOURNAL			English	Article						angiogenesis; endothelium; hexokinase; mitochondria; metabolism	PERMEABILITY TRANSITION PORE; HYPOXIA-INDUCIBLE FACTOR-1-ALPHA; CYTOCHROME-C RELEASE; HEXOKINASE-II; MITOCHONDRIAL BINDING; TUMOR ANGIOGENESIS; IN-VIVO; KINASE; GROWTH; DEATH	in endothelial cells, but the exact mechanism remains controversial. In the present study, we elucidate the mechanism of ES-induced endothelial cell apoptosis. Our results indicate that ES induces cytochrome c release and caspase-9 activation in human microvascular endothelial cells (HMECs) at the concentration of 1 mu M for 24 h, which initiates the apoptosis process. Further, ATP production, mitochondrial membrane potential, and tubule formation assays showed that ES promotes the mitochondrial permeability transition pore (mPTP) opening via voltage-dependent anion channel 1 (VDAC1), a major component of mitochondrial outer membrane. Knocking down VDAC1 by small interfering RNA attenuates ES-induced apoptosis, while overexpression of VDAC1 enhances the sensitivity of endothelial cells to ES. Moreover, we reveal that ES induces the reduction of hexokinase 2 (HK2), which, in turn, promotes VDAC1 phosphorylation and accumulation. Data from two-dimensional electrophoresis, immunoprecipitation, mPTP opening, and caspase-3 activation assays indicate that two serine residues of VDAC1, Ser-12 and Ser-103, can modulate VDAC1 protein level and thus the sensitivity to apoptosis stimuli. On the basis of these findings, we conclude that VDAC1 plays a vital role in modulating ES-induced endothelial cell apoptosis.	[Yuan, Shaopeng; Fu, Yan; Wang, Xiaofeng; Shi, Hubing; Huang, Yujie; Song, Xiaomin; Li, Ling; Song, Nan; Luo, Yongzhang] Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing Key Lab Prot Therapeut, Prot Chem Lab, Beijing 100084, Peoples R China	Tsinghua University	Luo, YZ (corresponding author), Tsinghua Univ, Dept Biol Sci & Biotechnol, Beijing Key Lab Prot Therapeut, Prot Chem Lab, Beijing 100084, Peoples R China.	protein@tsinghua.edu.cn	Song, Nan/T-9778-2018; Shi, Hubing/B-8445-2014	Song, Nan/0000-0002-7442-7475; Song, Xiaomin/0000-0002-2586-9285				Abdollahi A, 2004, MOL CELL, V13, P649, DOI 10.1016/S1097-2765(04)00102-9; Abu-Hamad S, 2006, P NATL ACAD SCI USA, V103, P5787, DOI 10.1073/pnas.0600103103; Adachi M, 2004, AM J PHYSIOL-GASTR L, V287, pG695, DOI 10.1152/ajpgi.00415.2003; Addison CL, 2005, BMC CELL BIOL, V6, DOI 10.1186/1471-2121-6-38; Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575; Baines CP, 2003, CIRC RES, V92, P873, DOI 10.1161/01.RES.0000069215.36389.8D; Banerjee J, 2006, J NEUROCHEM, V98, P670, DOI 10.1111/j.1471-4159.2006.03853.x; Carmeliet P, 1998, NATURE, V394, P485, DOI 10.1038/28867; Chan DA, 2002, J BIOL CHEM, V277, P40112, DOI 10.1074/jbc.M206922200; Crompton M, 1998, EUR J BIOCHEM, V258, P729, DOI 10.1046/j.1432-1327.1998.2580729.x; Davidson SM, 2007, CIRC RES, V100, P1128, DOI 10.1161/01.RES.0000261970.18328.1d; Dhanabal M, 1999, J BIOL CHEM, V274, P11721, DOI 10.1074/jbc.274.17.11721; Distler AM, 2007, BBA-PROTEINS PROTEOM, V1774, P628, DOI 10.1016/j.bbapap.2007.03.012; Dixelius J, 2000, BLOOD, V95, P3403, DOI 10.1182/blood.V95.11.3403.011k07_3403_3411; Don AS, 2003, CANCER CELL, V3, P497, DOI 10.1016/S1535-6108(03)00109-0; Ferrara N, 2005, NATURE, V438, P967, DOI 10.1038/nature04483; Folkman J, 2006, EXP CELL RES, V312, P594, DOI 10.1016/j.yexcr.2005.11.015; FOLKMAN J, 1995, NAT MED, V1, P27, DOI 10.1038/nm0195-27; Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7; HEIDEN, 2000, P NATL ACAD SCI USA, V97, P4666; Irani K, 2000, CIRC RES, V87, P179, DOI 10.1161/01.RES.87.3.179; Jacotot E, 1999, ANN NY ACAD SCI, V887, P18, DOI 10.1111/j.1749-6632.1999.tb07919.x; Jiang LW, 2001, AM J PHYSIOL-CELL PH, V280, pC1140, DOI 10.1152/ajpcell.2001.280.5.C1140; Kang HY, 2006, J BIOCHEM MOL BIOL, V39, P97; Khan ZA, 2006, BLOOD, V108, P915, DOI 10.1182/blood-2006-03-006478; Kim JW, 2007, MOL CELL BIOL, V27, P7381, DOI 10.1128/MCB.00440-07; Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994; Le Mellay V, 2002, BMC CELL BIOL, V3, DOI 10.1186/1471-2121-3-14; Marchetti P, 1996, J EXP MED, V184, P1155, DOI 10.1084/jem.184.3.1155; Olsen JV, 2006, CELL, V127, P635, DOI 10.1016/j.cell.2006.09.026; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Pastorino JG, 2005, CANCER RES, V65, P10545, DOI 10.1158/0008-5472.CAN-05-1925; Pastorino JG, 2003, CURR MED CHEM, V10, P1535, DOI 10.2174/0929867033457269; Pastorino JG, 2002, J BIOL CHEM, V277, P7610, DOI 10.1074/jbc.M109950200; Rapizzi E, 2002, J CELL BIOL, V159, P613, DOI 10.1083/jcb.200205091; Shi HB, 2007, BLOOD, V110, P2899, DOI 10.1182/blood-2007-01-064428; Shichiri M, 2001, FASEB J, V15, P1044, DOI 10.1096/fj.99-1083com; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Skovseth DK, 2005, BLOOD, V105, P1044, DOI 10.1182/blood-2004-03-1164; Sun L, 2008, MOL CELL BIOL, V28, P1007, DOI 10.1128/MCB.00224-07; Tsujimoto Y, 2000, CELL DEATH DIFFER, V7, P1174, DOI 10.1038/sj.cdd.4400780; Vieira HLA, 2000, CELL DEATH DIFFER, V7, P1146, DOI 10.1038/sj.cdd.4400778; Walter DH, 1998, CIRCULATION, V98, P1153, DOI 10.1161/01.CIR.98.12.1153; Yamaguchi N, 1999, EMBO J, V18, P4414, DOI 10.1093/emboj/18.16.4414; Yasuda S, 2004, J HEPATOL, V40, P117, DOI 10.1016/S0168-8278(03)00503-8; Zaid H, 2005, CELL DEATH DIFFER, V12, P751, DOI 10.1038/sj.cdd.4401599; Zheng YH, 2004, ONCOGENE, V23, P1239, DOI 10.1038/sj.onc.1207205	47	122	132	1	21	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2809	2820		10.1096/fj.08-107417	http://dx.doi.org/10.1096/fj.08-107417			12	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18381814				2022-12-25	WOS:000258089300021
J	Bheda, A; Creek, KE; Pirisi, L				Bheda, A.; Creek, K. E.; Pirisi, L.			Loss of p53 induces epidermal growth factor receptor promoter activity in normal human keratinocytes	ONCOGENE			English	Article						p53; EGFR promoter; HPV16; human keratinocytes; YY1; Sp1	TRANSCRIPTION FACTOR YY1; CERVICAL-CANCER; GENE; IDENTIFICATION; ACTIVATION; EXPRESSION; REGULATOR; BINDING; SP1; E6	Overexpression of the epidermal growth factor receptor (EGFR) in human papillomavirus type 16-immortalized human keratinocytes (HKc) is caused by the viral oncoprotein E6, which targets p53 for degradation. We have previously observed that expression of p53 RNAi in normal HKc is associated with an increase in EGFR mRNA and protein. We now report that p53 RNAi induces EGFR promoter activityup to approximately 10-fold in normal HKc, and this effect does not require intact p53 binding sites on the EGFR promoter. Exogenous wildtype p53 inhibits the EGFR promoter at low levels, and activates it at higher concentrations. Yin Yang 1 (YY1), which negatively regulates p53, induces EGFR promoter activity, and this effect is augmented by p53 RNAi. Intact p53 binding sites on the EGFR promoter are not required for activation by YY1. In addition, Sp1 and YY1 synergistically induce the EGFR promoter in normal HKc, indicating that Sp1 may recruit YY1 as a coactivator. Wild-type p53 suppressed Sp1- and YY1-mediated induction of the EGFR promoter. We conclude that acute loss of p53 in normal HKc induces EGFR expression by a mechanism that involves YY1 and Sp1 and does not require p53 binding to the EGFR promoter.	[Pirisi, L.] Univ S Carolina, Sch Med, S Carolina Canc Ctr, Dept Pathol Microbiol & Immunol,Basic Sci Labs, Columbia, SC 29203 USA	University of South Carolina; University of South Carolina System; University of South Carolina Columbia	Pirisi, L (corresponding author), Univ S Carolina, Sch Med, S Carolina Canc Ctr, Dept Pathol Microbiol & Immunol,Basic Sci Labs, 14 Richland Med Pk,Suite 500, Columbia, SC 29203 USA.	pirisi@med.sc.edu			NATIONAL CANCER INSTITUTE [R01CA089502, P20CA096427] Funding Source: NIH RePORTER; National Institute on Minority Health and Health Disparities [P20MD001770] Funding Source: NIH RePORTER; NCI NIH HHS [P20 CA096427-03, R01 CA089502, P20CA096427, P20 CA096427, R01CA89502, R01 CA089502-05] Funding Source: Medline; NIMHD NIH HHS [P20 MD001770, P20 MD001770-030002] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); National Institute on Minority Health and Health Disparities(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIMHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Minority Health & Health Disparities (NIMHD))		Ai WD, 2000, J VIROL, V74, P5198, DOI 10.1128/JVI.74.11.5198-5205.2000; Akerman GS, 2001, CANCER RES, V61, P3837; Arteaga CL, 2002, ONCOLOGIST, V7, P31; Baldwin A, 2004, J VIROL, V78, P3953, DOI 10.1128/JVI.78.8.3953-3964.2004; DEB SP, 1994, ONCOGENE, V9, P1341; Dykxhoorn DM, 2005, ANNU REV MED, V56, P401, DOI 10.1146/annurev.med.56.082103.104606; Gordon S, 2006, ONCOGENE, V25, P1125, DOI 10.1038/sj.onc.1209080; Gronroos E, 2004, P NATL ACAD SCI USA, V101, P12165, DOI 10.1073/pnas.0402283101; HALEY J, 1987, ONCOGENE RES, V1, P375; Hu GY, 1997, JNCI-J NATL CANCER I, V89, P1271, DOI 10.1093/jnci/89.17.1271; Innocente SA, 2005, FEBS LETT, V579, P1001, DOI 10.1016/j.febslet.2004.12.073; ISHII S, 1985, P NATL ACAD SCI USA, V82, P4920, DOI 10.1073/pnas.82.15.4920; Johnson AC, 2000, MOL MED, V6, P17, DOI 10.1007/BF03401931; KAGEYAMA R, 1988, J BIOL CHEM, V263, P6329; Kawada H, 2005, J INVEST DERMATOL, V124, P1206, DOI 10.1111/j.0022-202X.2005.23748.x; Kilic G, 1999, EUR J GYNAECOL ONCOL, V20, P167; LEE JS, 1993, P NATL ACAD SCI USA, V90, P6145, DOI 10.1073/pnas.90.13.6145; LudesMeyers JH, 1996, MOL CELL BIOL, V16, P6009; Mathur SP, 2001, AM J REPROD IMMUNOL, V46, P280, DOI 10.1034/j.1600-0897.2001.d01-14.x; PIRISI L, 1988, CARCINOGENESIS, V9, P1573, DOI 10.1093/carcin/9.9.1573; PIRISI L, 1987, J VIROL, V61, P1061, DOI 10.1128/JVI.61.4.1061-1066.1987; Sheikh MS, 1997, ONCOGENE, V15, P1095, DOI 10.1038/sj.onc.1201264; Shi Y, 1997, BBA-REV CANCER, V1332, pF49, DOI 10.1016/S0304-419X(96)00044-3; Sui GC, 2004, CELL, V117, P859, DOI 10.1016/j.cell.2004.06.004; Wang X, 2006, J CELL BIOL, V172, P409, DOI 10.1083/jcb.200510002; XU J, 1993, J BIOL CHEM, V268, P16065; Yakovleva T, 2004, BIOCHEM BIOPH RES CO, V318, P615, DOI 10.1016/j.bbrc.2004.04.065; Yao YL, 2001, MOL CELL BIOL, V21, P5979, DOI 10.1128/MCB.21.17.5979-5991.2001; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; Yu J, 1999, P NATL ACAD SCI USA, V96, P14517, DOI 10.1073/pnas.96.25.14517; Zhao RB, 2000, GENE DEV, V14, P981; ZYZAK LL, 1994, CELL GROWTH DIFFER, V5, P537	32	37	42	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4315	4323		10.1038/onc.2008.65	http://dx.doi.org/10.1038/onc.2008.65			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18391986	Green Accepted			2022-12-25	WOS:000257691100006
J	Nicolet, Y; Rubach, JK; Posewitz, MC; Amara, P; Mathevon, C; Atta, M; Fontecave, M; Fontecilla-Camps, JC				Nicolet, Yvain; Rubach, Jon K.; Posewitz, Matthew C.; Amara, Patricia; Mathevon, Carole; Atta, Mohamed; Fontecave, Marc; Fontecilla-Camps, Juan C.			X-ray structure of the [FeFe]-hydrogenase maturase HydE from Thermotoga maritima	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FE-ONLY HYDROGENASE; ACTIVE-SITE FE; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; BIOTIN SYNTHASE; RADICAL MECHANISMS; 4FE-4S CLUSTERS; CARBON-MONOXIDE; ENZYME MOAA; IN-VITRO	Maturation of the [FeFe]-hydrogenase active site depends on at least the expression of three gene products called HydE, HydF, and HydG. We have solved the high resolution structure of recombinant, reconstituted S-adenosine-L-methioninedependent HydE from Thermotoga maritima. Besides the conserved [Fe4S4] cluster involved in the radical-based reaction, this HydE was reported to have a second [ Fe4S4] cluster coordinated by three Cys residues. However, in our crystals, depending on the reconstitution and soaking conditions, this second cluster is either a [Fe2S2] center, with water occupying the fourth ligand site or is absent. We have carried out site-directed mutagenesis studies on the related HydE from Clostridium acetobutylicum, along with in silico docking and crystal soaking experiments, to define the active site region and three anion-binding sites inside a large, positive cavity, one of which binds SCN- with high affinity. Although the overall triose-phosphate isomerase-barrel structure of HydE is very similar to that of biotin synthase, the residues that line the internal cavity are significantly different in the two enzymes.	[Nicolet, Yvain; Amara, Patricia; Fontecilla-Camps, Juan C.] Univ Grenoble 1, CNRS, Cristallog & Cristallogenese Prot Lab, Inst Biol Struct JP Ebel,Commissariat Energie Ato, F-38027 Grenoble 1, France; [Rubach, Jon K.; Mathevon, Carole; Atta, Mohamed; Fontecave, Marc] Univ Grenoble 1, CNRS, Lab Chim & Biol Met, Inst Rech Technol & Sci Vivant,Commissariat Energ, F-38054 Grenoble 09, France; [Posewitz, Matthew C.] Colorado Sch Mines, Dept Chem & Geochem, Golden, CO 80401 USA	UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); CEA; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Colorado School of Mines	Fontecilla-Camps, JC (corresponding author), Univ Grenoble 1, CNRS, Cristallog & Cristallogenese Prot Lab, Inst Biol Struct JP Ebel,Commissariat Energie Ato, 41 Rue J Horowitz, F-38027 Grenoble 1, France.	juan.fontecilla@ibs.fr	Yvain, Nicolet/AAP-9763-2020	Yvain, Nicolet/0000-0002-4189-7067; Amara, Patricia/0000-0001-9634-7305				BAGLEY KA, 1995, BIOCHEMISTRY-US, V34, P5527, DOI 10.1021/bi00016a026; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berkessel A, 2001, CURR OPIN CHEM BIOL, V5, P486, DOI 10.1016/S1367-5931(00)00245-3; Berkovitch F, 2004, SCIENCE, V303, P76, DOI 10.1126/science.1088493; Blight SK, 2004, NATURE, V431, P333, DOI 10.1038/nature02895; Bock A, 2006, ADV MICROB PHYSIOL, V51, P1, DOI 10.1016/S0065-2911(06)51001-X; Brazzolotto X, 2006, J BIOL CHEM, V281, P769, DOI 10.1074/jbc.M510310200; Cicchillo RM, 2004, BIOCHEMISTRY-US, V43, P11770, DOI 10.1021/bi0488505; Dauter Z, 1997, BIOCHEMISTRY-US, V36, P16065, DOI 10.1021/bi972155y; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Fan HJ, 2001, J AM CHEM SOC, V123, P3828, DOI 10.1021/ja004120i; Forzi L, 2007, FEBS LETT, V581, P3317, DOI 10.1016/j.febslet.2007.06.028; Frey PA, 2001, ADV PROTEIN CHEM, V58, P1; Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430; Gloaguen F, 2001, J AM CHEM SOC, V123, P12518, DOI 10.1021/ja016071v; Graham DE, 2003, ARCH MICROBIOL, V180, P455, DOI 10.1007/s00203-003-0614-8; Hanzelmann P, 2006, P NATL ACAD SCI USA, V103, P6829, DOI 10.1073/pnas.0510711103; Hanzelmann P, 2004, P NATL ACAD SCI USA, V101, P12870, DOI 10.1073/pnas.0404624101; HARDER J, 1992, J BIOL CHEM, V267, P25548; Hinckley GT, 2006, BIOCHEMISTRY-US, V45, P3219, DOI 10.1021/bi0519497; Irwin JJ, 2005, J CHEM INF MODEL, V45, P177, DOI 10.1021/ci049714+; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; King PW, 2006, J BACTERIOL, V188, P2163, DOI 10.1128/JB.188.6.2163-2172.2006; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Layer G, 2003, EMBO J, V22, P6214, DOI 10.1093/emboj/cdg598; Lenz O, 2007, FEBS LETT, V581, P3322, DOI 10.1016/j.febslet.2007.06.027; Leonardi R, 2003, FEBS LETT, V539, P95, DOI 10.1016/S0014-5793(03)00204-7; Lepore BW, 2005, P NATL ACAD SCI USA, V102, P13819, DOI 10.1073/pnas.0505726102; Leslie AGW, 1999, ACTA CRYSTALLOGR D, V55, P1696, DOI 10.1107/S090744499900846X; Lyon EJ, 2004, J AM CHEM SOC, V126, P14239, DOI 10.1021/ja046818s; Mancia F, 1998, STRUCTURE, V6, P711, DOI 10.1016/S0969-2126(98)00073-2; McGlynn SE, 2007, J BIOL INORG CHEM, V12, P443, DOI 10.1007/s00775-007-0224-z; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Morris RJ, 2003, METHOD ENZYMOL, V374, P229, DOI 10.1016/S0076-6879(03)74011-7; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Nagy LE, 2007, BIOTECHNOL LETT, V29, P421, DOI 10.1007/s10529-006-9254-9; Nicolet Y, 2004, NUCLEIC ACIDS RES, V32, P4015, DOI 10.1093/nar/gkh728; Nicolet Y, 1999, STRUCTURE, V7, P13, DOI 10.1016/S0969-2126(99)80005-7; Nicolet Y, 2001, J AM CHEM SOC, V123, P1596, DOI 10.1021/ja0020963; Peters JW, 2006, FEBS LETT, V580, P363, DOI 10.1016/j.febslet.2005.12.040; Pierik AJ, 1998, EUR J BIOCHEM, V258, P572, DOI 10.1046/j.1432-1327.1998.2580572.x; Pierrel F, 2004, J BIOL CHEM, V279, P47555, DOI 10.1074/jbc.M408562200; Posewitz MC, 2004, J BIOL CHEM, V279, P25711, DOI 10.1074/jbc.M403206200; Reissmann S, 2003, SCIENCE, V299, P1067, DOI 10.1126/science.1080972; Roseboom W, 2005, FEBS LETT, V579, P469, DOI 10.1016/j.febslet.2004.12.013; Rubach JK, 2005, FEBS LETT, V579, P5055, DOI 10.1016/j.febslet.2005.07.092; Rubio LM, 2005, J BACTERIOL, V187, P405, DOI 10.1128/JB.187.2.405-414.2005; Schneider TR, 2002, ACTA CRYSTALLOGR D, V58, P1772, DOI 10.1107/S0907444902011678; SETO Y, 1995, ARCH BIOCHEM BIOPHYS, V321, P245, DOI 10.1006/abbi.1995.1392; Shima S, 2007, CHEM REC, V7, P37, DOI 10.1002/tcr.20111; Sofia HJ, 2001, NUCLEIC ACIDS RES, V29, P1097, DOI 10.1093/nar/29.5.1097; Srinivasan G, 2002, SCIENCE, V296, P1459, DOI 10.1126/science.1069588; Ugulava NB, 2002, J AM CHEM SOC, V124, P9050, DOI 10.1021/ja027004j; Ugulava NB, 2001, BIOCHEMISTRY-US, V40, P8352, DOI 10.1021/bi010463x; Vernede X, 1999, J APPL CRYSTALLOGR, V32, P505, DOI 10.1107/S0021889899002678; Vonrhein Clemens, 2007, Methods Mol Biol, V364, P215, DOI 10.1385/1-59745-266-1:215; VOORDOUW G, 1987, EUR J BIOCHEM, V162, P31, DOI 10.1111/j.1432-1033.1987.tb10537.x	57	104	105	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 4	2008	283	27					18861	18872		10.1074/jbc.M801161200	http://dx.doi.org/10.1074/jbc.M801161200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	319LR	18400755	hybrid			2022-12-25	WOS:000257165600043
J	Bahn, A; Hagos, Y; Reuter, S; Balen, D; Brzica, H; Krick, W; Burckhardt, BC; Sabolic, I; Burckhardt, G				Bahn, Andrew; Hagos, Yohannes; Reuter, Stefan; Balen, Daniela; Brzica, Hrvoje; Krick, Wolfgang; Burckhardt, Birgitta C.; Sabolic, Ivan; Burckhardt, Gerhard			Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORGANIC ANION TRANSPORTER; BRUSH-BORDER MEMBRANE; MOLECULAR-CLONING; FUNCTIONAL-CHARACTERIZATION; BASOLATERAL MEMBRANE; CATION TRANSPORTERS; EXPRESSION CLONING; GENDER-DIFFERENCES; PROXIMAL TUBULE; APICAL MEMBRANE	The orphan transporter hORCTL3 (human organic cation transporter like 3; SLC22A13) is highly expressed in kidneys and to a weaker extent in brain, heart, and intestine. hORCTL3-expressing Xenopus laevis oocytes showed uptake of [H-3]nicotinate, [H-3]p-aminohippurate, and [C-14]urate. Hence, hORCTL3 is an organic anion transporter, and we renamed it hOAT10. [H-3]icotinate transport by hOAT10 into X. laevis oocytes and into Caco-2 cells was saturable with Michaelis constants (Km) of 22 and 44 mu M, respectively, suggesting that hOAT10 may be the molecular equivalent of the postulated high affinity nicotinate transporter in kidneys and intestine. The pH dependence of hOAT10 suggests p-aminohippurate (-)/OH-, urate (-)/OH-, and nicotinate (-)/OH- exchange as possible transport modes. Urate inhibited [H-3]nicotinate transport by hOAT10 with an IC50 value of 759 mu M, assuming that hOAT10 represents a low affinity urate transporter. hOAT10-mediated [C-14]urate uptake was elevated by an exchange with L-lactate, pyrazinoate, and nicotinate. Surprisingly, we have detected urate -/glutathione exchange by hOAT10, consistent with an involvement of hOAT10 in the renal glutathione cycle. Uricosurics, diuretics, and cyclosporine A showed substantial interactions with hOAT10, of which cyclosporine A enhanced [C-14]urate uptake, providing the first molecular evidence for cyclosporine A-induced hyperuricemia.	[Bahn, Andrew; Hagos, Yohannes; Krick, Wolfgang; Burckhardt, Birgitta C.; Burckhardt, Gerhard] Zentrum Physiol, Abt Vegetat Physiol & Pathophysiol, D-37073 Gottingen, Germany; [Balen, Daniela; Brzica, Hrvoje; Sabolic, Ivan] Inst Med Res & Occupat Hlth, Unit Mol Toxicol, HR-10001 Zagreb, Croatia; [Reuter, Stefan] Univ Klinikum Munster, Med Klin & Poliklin D, D-48147 Munster, Germany	Institute for Medical Research & Occupational Health (IMROH); University of Munster	Bahn, A (corresponding author), Zentrum Physiol, Abt Vegetat Physiol & Pathophysiol, Humboldtallee 23, D-37073 Gottingen, Germany.	abahn@physiol.med.uni-goettingen.de						Alebouyeh M, 2003, J PHARMACOL SCI, V93, P430, DOI 10.1254/jphs.93.430; Anzai N, 2005, J PHARMACOL EXP THER, V315, P534, DOI 10.1124/jpet.105.088583; Anzai N, 2004, J BIOL CHEM, V279, P45942, DOI 10.1074/jbc.M406724200; Anzai N, 2006, J PHARMACOL SCI, V100, P411, DOI 10.1254/jphs.CRJ06006X; Anzai Naohiko, 2005, Curr Rheumatol Rep, V7, P227, DOI 10.1007/s11926-996-0044-0; Bahn A, 2002, MOL PHARMACOL, V62, P1128, DOI 10.1124/mol.62.5.1128; Bahn A, 2005, AM J PHYSIOL-CELL PH, V289, pC1075, DOI 10.1152/ajpcell.00619.2004; Bakhiya N, 2003, CELL PHYSIOL BIOCHEM, V13, P249, DOI 10.1159/000074539; Bonilla-Felix M, 2004, AM J PHYSIOL-RENAL, V287, pF1093, DOI 10.1152/ajprenal.00119.2004; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Burckhardt BC, 2003, REV PHYSIOL BIOCH P, V146, P95, DOI 10.1007/s10254-002-0003-8; Cha SH, 2000, J BIOL CHEM, V275, P4507, DOI 10.1074/jbc.275.6.4507; Enomoto A, 2002, NATURE, V417, P447, DOI 10.1038/nature742; Eraly SA, 2008, PHYSIOL GENOMICS, V33, P180, DOI 10.1152/physiolgenomics.00207.2007; Frey IM, 2007, PHYSIOL GENOMICS, V28, P301, DOI 10.1152/physiolgenomics.00193.2006; Gopal E, 2007, BBA-BIOMEMBRANES, V1768, P2690, DOI 10.1016/j.bbamem.2007.06.031; Gopal E, 2007, PHARM RES-DORDR, V24, P575, DOI 10.1007/s11095-006-9176-1; Graessler J, 2006, ARTHRITIS RHEUM, V54, P292, DOI 10.1002/art.21499; Hagos Y, 2007, J AM SOC NEPHROL, V18, P3101, DOI 10.1681/ASN.2007010106; Hagos Y, 2007, J AM SOC NEPHROL, V18, P430, DOI 10.1681/ASN.2006040415; Hara N, 2007, J BIOL CHEM, V282, P24574, DOI 10.1074/jbc.M610357200; Hasannejad H, 2004, J PHARMACOL EXP THER, V308, P1021, DOI 10.1124/jpet.103.059139; He WH, 2004, NATURE, V429, P188, DOI 10.1038/nature02488; Hediger MA, 2005, PHYSIOLOGY, V20, P125, DOI 10.1152/physiol.00039.2004; Hediger MA, 2004, PFLUG ARCH EUR J PHY, V447, P465, DOI 10.1007/s00424-003-1192-y; Hosoyamada M, 2004, J AM SOC NEPHROL, V15, P261, DOI 10.1097/01.ASN.0000107560.80107.19; HUANG XQ, 1994, COMPUT APPL BIOSCI, V10, P227; Jutabha P, 2003, J BIOL CHEM, V278, P27930, DOI 10.1074/jbc.M303210200; Kimura H, 2002, J PHARMACOL EXP THER, V301, P293, DOI 10.1124/jpet.301.1.293; Krick W, 2000, PFLUG ARCH EUR J PHY, V441, P125, DOI 10.1007/s004240000378; Kusuhara H, 1999, J BIOL CHEM, V274, P13675, DOI 10.1074/jbc.274.19.13675; Kutzing MK, 2008, J PHARMACOL EXP THER, V324, P1, DOI 10.1124/jpet.107.129031; Ljubojevic M, 2004, AM J PHYSIOL-RENAL, V287, pF124, DOI 10.1152/ajprenal.00029.2004; Ljubojevic M, 2007, AM J PHYSIOL-RENAL, V292, pF361, DOI 10.1152/ajprenal.00207.2006; MALO C, 1991, J MEMBRANE BIOL, V122, P127, DOI 10.1007/BF01872636; Miyazaki H, 2005, J AM SOC NEPHROL, V16, P3498, DOI 10.1681/ASN.2005030306; Nabokina SM, 2005, AM J PHYSIOL-CELL PH, V289, pC97, DOI 10.1152/ajpcell.00009.2005; Nishiwaki T, 1998, CYTOGENET CELL GENET, V83, P251, DOI 10.1159/000015197; Rizwan AN, 2007, PHARM RES-DORDR, V24, P450, DOI 10.1007/s11095-006-9181-4; Sabolic I, 2007, PFLUG ARCH EUR J PHY, V455, P397, DOI 10.1007/s00424-007-0308-1; Schnabolk GW, 2006, AM J PHYSIOL-RENAL, V291, pF314, DOI 10.1152/ajprenal.00497.2005; Sekine T, 1998, FEBS LETT, V429, P179, DOI 10.1016/S0014-5793(98)00585-7; Sekine T, 1997, J BIOL CHEM, V272, P18526, DOI 10.1074/jbc.272.30.18526; SHIMADA H, 1987, AM J PHYSIOL, V253, pF795, DOI 10.1152/ajprenal.1987.253.5.F795; Shin HJ, 2007, HEPATOLOGY, V45, P1046, DOI 10.1002/hep.21596; Sindic A, 2005, KIDNEY INT, V67, P1420; Sun W, 2001, BIOCHEM BIOPH RES CO, V283, P417, DOI 10.1006/bbrc.2001.4774; Sweet DH, 1997, J BIOL CHEM, V272, P30088, DOI 10.1074/jbc.272.48.30088; Takanaga H, 1996, J PHARM PHARMACOL, V48, P1073, DOI 10.1111/j.2042-7158.1996.tb05902.x; Thangaraju M, 2006, J BIOL CHEM, V281, P26769, DOI 10.1074/jbc.C600189200; Vitart V, 2008, NAT GENET, V40, P437, DOI 10.1038/ng.106; Wolff NA, 1997, FEBS LETT, V417, P287, DOI 10.1016/S0014-5793(97)01304-5; Wright SH, 2004, PHYSIOL REV, V84, P987, DOI 10.1152/physrev.00040.2003; Youngblood GL, 2004, AM J PHYSIOL-RENAL, V287, pF236, DOI 10.1152/ajprenal.00012.2004; Zurcher RM, 1996, NEPHROL DIAL TRANSPL, V11, P153, DOI 10.1093/oxfordjournals.ndt.a027032	55	142	154	4	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16332	16341		10.1074/jbc.M800737200	http://dx.doi.org/10.1074/jbc.M800737200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18411268	hybrid			2022-12-25	WOS:000256497100009
J	Bhattacharya, S; Zhang, HT; Debnath, AK; Cowburn, D				Bhattacharya, Shibani; Zhang, Hongtao; Debnath, Asim K.; Cowburn, David			Solution structure of a hydrocarbon stapled peptide inhibitor in complex with monomeric C-terminal domain of HIV-1 capsid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORSION ANGLE DYNAMICS; DIMERIZATION DOMAIN; ASSEMBLY INHIBITOR; PROTEIN; NMR; RESTRAINTS; HOMOLOGY; PROGRAM; DYANA	The human immunodeficiency virus type 1 (HIV-1) capsid protein plays a critical role in virus core particle assembly and is an important target for novel therapeutic strategies. In a previous study, we characterized the binding affinity of a hydrocarbon stapled helical peptide, NYAD-1, for the capsid protein (K-d similar to 1 mu M) and demonstrated its ability to penetrate the cell membrane (Zhang, H., Zhao, Q., Bhattacharya, S., Waheed, A. A., Tong, X., Hong, A., Heck, S., Goger, M., Cowburn, D., Freed, E. O., and Debnath, A. K. (2008) J. Mol. Biol. 378, 565-580). In cell-based assays, NYAD-1 colocalized with the Gag polyprotein during traffic to the plasma membrane and disrupted the formation of mature and immature virus particles in vitro systems. Here, we complement the cellular and biochemical data with structural characterization of the interactions between the capsid and a soluble peptide analogue, NYAD-13. Solution NMR methods were used to determine a high resolution structure of the complex between the inhibitor and a monomeric form of the C-terminal domain of the capsid protein (mCA-CTD). The intermolecular interactions are mediated by the packing of hydrophobic side chains at the buried interface and unperturbed by the presence of the olefinic chain on the solvent-exposed surface of the peptide. The results of the structural analysis provide valuable insight into the determinants for high affinity and selective inhibitors for HIV-1 particle assembly.	[Bhattacharya, Shibani; Cowburn, David] New York Struct Biol Ctr, New York, NY 10027 USA; [Zhang, Hongtao; Debnath, Asim K.] New York Blood Ctr, Lindsley F Kimball Res Inst, Lab Mol Modeling & Drug Design, New York, NY 10021 USA	New York Blood Center	Cowburn, D (corresponding author), New York Struct Biol Ctr, New York, NY 10027 USA.	dcadmin@nysbc.org	Cowburn, David/A-8448-2008	Cowburn, David/0000-0001-6770-7172	NIGMS NIH HHS [P41 GM066354, R01 GM047021-16, R01 GM047021, P41 GM-66354, P41 GM066354-05, P41 GM066354-01, R01 GM47021] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047021, P41GM066354] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alcaraz LA, 2007, BIOPHYS J, V93, P1264, DOI 10.1529/biophysj.106.101089; Bernal F, 2007, J AM CHEM SOC, V129, P2456, DOI 10.1021/ja0693587; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; De Clercq E, 2007, NAT REV DRUG DISCOV, V6, P1001, DOI 10.1038/nrd2424; Fogh Rasmus, 2002, Nature Structural Biology, V9, P416, DOI 10.1038/nsb0602-416; Gamble TR, 1997, SCIENCE, V278, P849, DOI 10.1126/science.278.5339.849; Ganser-Pornillos BK, 2007, CELL, V131, P70, DOI 10.1016/j.cell.2007.08.018; Guntert P, 1997, J MOL BIOL, V273, P283, DOI 10.1006/jmbi.1997.1284; Herrmann T, 2002, J MOL BIOL, V319, P209, DOI 10.1016/S0022-2836(02)00241-3; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; Keller R, 2004, THESIS ETH ZURICH; Kelly BN, 2007, J MOL BIOL, V373, P355, DOI 10.1016/j.jmb.2007.07.070; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Laskowski RA, 1996, J BIOMOL NMR, V8, P477, DOI 10.1007/BF00228148; Li Feng, 2005, Curr Opin Investig Drugs, V6, P148; Li S, 2000, NATURE, V407, P409, DOI 10.1038/35030177; Nilges M, 1997, J MOL BIOL, V269, P408, DOI 10.1006/jmbi.1997.1044; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Schafmeister CE, 2000, J AM CHEM SOC, V122, P5891, DOI 10.1021/ja000563a; Schuttelkopf AW, 2004, ACTA CRYSTALLOGR D, V60, P1355, DOI 10.1107/S0907444904011679; Sticht J, 2005, NAT STRUCT MOL BIOL, V12, P671, DOI 10.1038/nsmb964; Sundquist WI, 2007, CELL, V131, P17, DOI 10.1016/j.cell.2007.09.028; Tang C, 2003, J MOL BIOL, V327, P1013, DOI 10.1016/S0022-2836(03)00289-4; Ternois F, 2005, NAT STRUCT MOL BIOL, V12, P678, DOI 10.1038/nsmb967; von Schwedler UK, 2003, J VIROL, V77, P5439, DOI 10.1128/JVI.77.9.5439-5450.2003; Walensky LD, 2006, MOL CELL, V24, P199, DOI 10.1016/j.molcel.2006.08.020; Wong HC, 2008, BIOCHEMISTRY-US, V47, P2289, DOI 10.1021/bi7022128; Zhang H, 2008, J MOL BIOL, V378, P565, DOI 10.1016/j.jmb.2008.02.066; Zwahlen C, 1997, J AM CHEM SOC, V119, P6711, DOI 10.1021/ja970224q	30	83	88	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16274	16278		10.1074/jbc.C800048200	http://dx.doi.org/10.1074/jbc.C800048200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18417468	Green Published, hybrid			2022-12-25	WOS:000256497100002
J	Daugherty, KM; Goode, BL				Daugherty, Karen M.; Goode, Bruce L.			Functional surfaces on the p35/ARPC2 subunit of Arp2/3 complex required for cell growth, actin nucleation, and endocytosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALDRICH-SYNDROME PROTEIN; YEAST ACTIN; SACCHAROMYCES-CEREVISIAE; CONFORMATIONAL-CHANGES; INDIVIDUAL SUBUNITS; BINDING-ACTIVITY; ADP-ACTIN; IN-VIVO; WASP; POLYMERIZATION	The Arp2/3 complex is comprised of seven evolutionarily conserved subunits and upon activation by WASp or another nucleation promoting factor nucleates the formation of actin filaments. These events are critical for driving a wide range of cellular processes, including motility, endocytosis, and intracellular trafficking. However, an in depth understanding of the Arp2/3 complex activation and nucleation mechanism is still lacking. Here, we used a mutagenesis approach in Saccharomyces cerevisiae to dissect the structural and functional roles of the p35/ARPC2 subunit. Using integrated alleles that target conserved and solvent-exposed residues, we identified surfaces on p35/ARPC2 required for cell growth, actin organization, and endocytosis. In parallel, we purified the mutant Arp2/3 complexes and compared their actin assembly activities both in the presence and in the absence of WASp. The majority of alleles with defects mapped to one face of p35/ARPC2, where there was a close correlation between loss of actin nucleation and endocytosis. A second site required for nucleation and endocytosis was identified near the contact surface between p35/ARPC2 and p19/ARPC4. A third site was identified at a more distal conserved surface, which was critical for endocytosis but not nucleation. These findings pinpoint the key surfaces on p35/ARPC2 required for Arp2/3 complex-mediated actin assembly and cellular function and provide a higher resolution view of Arp2/3 structure and mechanism.	[Daugherty, Karen M.] Brandeis Univ, Dept Biochem, Waltham, MA 02454 USA; Rosenstiel Basic Med Sci Ctr, Waltham, MA 02454 USA	Brandeis University	Goode, BL (corresponding author), Brandeis Univ, Rosenstiel Basic Med Sci Res Ctr, Dept Biol, 415 South St, Waltham, MA 02454 USA.	goode@brandeis.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM063691, T32GM007596] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM63691, R01 GM063691, T32 GM007596] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		[Anonymous], 1991, Methods Enzymol, V194, P1; Baggett JJ, 2003, CURR PROTOC CELL BIO, V13, DOI [10.1002/0471143030.cb0413s20, DOI 10.1002/0471143030.CB0413S20]; Bailly M, 2001, CURR BIOL, V11, P620, DOI 10.1016/S0960-9822(01)00152-X; Beltzner CC, 2004, J MOL BIOL, V336, P551, DOI 10.1016/j.jmb.2003.12.017; Beltzner CC, 2008, J BIOL CHEM, V283, P7135, DOI 10.1074/jbc.M705894200; Carreno S, 2004, J CELL BIOL, V165, P781, DOI 10.1083/jcb.200403120; Chang FS, 2003, CURR BIOL, V13, P455, DOI 10.1016/S0960-9822(03)00131-3; DULIC V, 1991, METHOD ENZYMOL, V194, P697; Eitzen G, 2002, J CELL BIOL, V158, P669, DOI 10.1083/jcb.200204089; Goley ED, 2004, MOL CELL, V16, P269, DOI 10.1016/j.molcel.2004.09.018; Goley ED, 2006, NAT REV MOL CELL BIO, V7, P713, DOI 10.1038/nrm2026; Goode BL, 2002, METHOD ENZYMOL, V351, P433; Gournier H, 2001, MOL CELL, V8, P1041, DOI 10.1016/S1097-2765(01)00393-8; Higgs HN, 1999, BIOCHEMISTRY-US, V38, P15212, DOI 10.1021/bi991843+; Li R, 1997, J CELL BIOL, V136, P649, DOI 10.1083/jcb.136.3.649; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; MACHESKY LM, 1994, J CELL BIOL, V127, P107, DOI 10.1083/jcb.127.1.107; Madania A, 1999, MOL BIOL CELL, V10, P3521, DOI 10.1091/mbc.10.10.3521; Moreau V, 1997, MOL BIOL CELL, V8, P1361, DOI 10.1091/mbc.8.7.1361; Moseley JB, 2006, MICROBIOL MOL BIOL R, V70, P605, DOI 10.1128/MMBR.00013-06; Moseley JB, 2005, J BIOL CHEM, V280, P28023, DOI 10.1074/jbc.M503094200; Mullins RD, 1997, J CELL BIOL, V136, P331, DOI 10.1083/jcb.136.2.331; MUNN AL, 1994, J CELL BIOL, V127, P373, DOI 10.1083/jcb.127.2.373; POLLARD TD, 1986, J CELL BIOL, V103, P2747, DOI 10.1083/jcb.103.6.2747; POLLARD TD, 1984, J CELL BIOL, V99, P769, DOI 10.1083/jcb.99.3.769; Robinson RC, 2001, SCIENCE, V294, P1679, DOI 10.1126/science.1066333; Rodal AA, 2005, NAT STRUCT MOL BIOL, V12, P26, DOI 10.1038/nsmb870; Rodal AA, 2003, CURR BIOL, V13, P1000, DOI 10.1016/S0960-9822(03)00383-X; Rouiller I, 2008, J CELL BIOL, V180, P887, DOI 10.1083/jcb.200709092; Schaerer-Brodbeck C, 2000, MOL BIOL CELL, V11, P1113, DOI 10.1091/mbc.11.4.1113; Schaerer-Brodbeck C, 2000, J CELL SCI, V113, P521; Weaver AM, 2002, CURR BIOL, V12, P1270, DOI 10.1016/S0960-9822(02)01035-7; Welch MD, 2002, ANNU REV CELL DEV BI, V18, P247, DOI 10.1146/annurev.cellbio.18.040202.112133; Wen KK, 2005, J BIOL CHEM, V280, P24168, DOI 10.1074/jbc.M502024200; Winter D, 1997, CURR BIOL, V7, P519, DOI 10.1016/S0960-9822(06)00223-5; Winter DC, 1999, P NATL ACAD SCI USA, V96, P7288, DOI 10.1073/pnas.96.13.7288; Zalevsky J, 2001, CURR BIOL, V11, P1903, DOI 10.1016/S0960-9822(01)00603-0	37	25	26	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16950	16959		10.1074/jbc.M800783200	http://dx.doi.org/10.1074/jbc.M800783200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18381280	Green Published, hybrid			2022-12-25	WOS:000256497100072
J	Poh, TY; Pease, J; Young, JR; Bumstead, N; Kaiser, P				Poh, Tuang Yeow; Pease, James; Young, John R.; Bumstead, Nat; Kaiser, Pete			Re-evaluation of chicken CXCR1 determines the true gene structure - CXCLi1 (K60) and CXCLi2 (CAF/interleukin-8) are ligands for this receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISLET-ACTIVATING PROTEIN; HUMAN INTERLEUKIN-8 RECEPTOR; SPLICE JUNCTION SEQUENCES; PERTUSSIS TOXIN; IN-VIVO; SCANNING MUTAGENESIS; SIGNAL-TRANSDUCTION; GUANINE-NUCLEOTIDE; ANGIOGENIC FACTOR; PLATELET PROTEIN	The original report of chicken CXCR1 (Li, Q. J., Lu, S., Ye, R. D., and Martins-Green, M. (2000) Gene (Amst.) 257, 307-317) described it as a single exon gene, with two isoforms (differing in their start codon). In comparison with mammalian CXCR1, the reported chicken CXCR1 was longer at both the NH2 and COOH termini, and it lacked the conserved (C/S)CXNP motif present in the last transmembrane region of all known chemokine receptors. A re- evaluation of chicken CXCR1, comparing known expressed sequence tags with the chicken genome sequence, suggested that the gene contains two exons. We isolated a cDNA corresponding to our prediction, which was significantly different in sequence to the reported CXCR1. In particular, there were three frameshifts in our sequence, compared with the reported sequence, that restored higher identity in the COOH-terminal half of the protein to mammalian CXCR1 (61% total amino acid identity compared with 52% for the reported CXCR1), restored the (C/S) CXNP motif, and gave a predicted protein of the same length as mammalian CXCR1. In human, CXCR1 is the receptor for CXCL8. In the chicken, there are two syntenic genes, CXCLi1 and CXCLi2, which look equally like orthologues of human CXCL8. We demonstrate that both of these chemokines are ligands for chicken CXCR1. We also demonstrate that heterophils express chicken CXCR1 and that the receptor is G alpha(i) protein-linked.	[Poh, Tuang Yeow; Young, John R.; Bumstead, Nat; Kaiser, Pete] Inst Anim Hlth, Compton RG20 7NN, Berks, England; [Pease, James] Univ London Imperial Coll Sci Technol & Med, Leukocyte Biol Sect, NHLI Div, Fac Med, London SW7 2AZ, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Pirbright Institute; Imperial College London	Kaiser, P (corresponding author), Inst Anim Hlth, Compton RG20 7NN, Berks, England.	pete.kaiser@bbsrc.ac.uk	Pease, James/X-4521-2018	Pease, James/0000-0003-3749-0341	Biotechnology and Biological Sciences Research Council Funding Source: Medline	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))		Alter A, 2003, J IMMUNOL, V170, P4497, DOI 10.4049/jimmunol.170.9.4497; Auger GA, 2002, EUR J IMMUNOL, V32, P1052, DOI 10.1002/1521-4141(200204)32:4<1052::AID-IMMU1052>3.0.CO;2-L; BARKER KA, 1993, J VIROL, V67, P3528, DOI 10.1128/JVI.67.6.3528-3533.1993; BEDARD PA, 1987, P NATL ACAD SCI USA, V84, P6715, DOI 10.1073/pnas.84.19.6715; BOKOCH GM, 1983, J BIOL CHEM, V258, P2072; CODINA J, 1983, P NATL ACAD SCI-BIOL, V80, P4276, DOI 10.1073/pnas.80.14.4276; Damaj BB, 1996, J BIOL CHEM, V271, P12783, DOI 10.1074/jbc.271.22.12783; de Mendonca FL, 2005, J BIOL CHEM, V280, P4808, DOI 10.1074/jbc.M412267200; DeVries ME, 2006, J IMMUNOL, V176, P401, DOI 10.4049/jimmunol.176.1.401; Flynn G, 2003, J NEUROIMMUNOL, V136, P84, DOI 10.1016/S0165-5728(03)00009-2; Fu WX, 2005, CYTOKINE, V31, P9, DOI 10.1016/j.cyto.2005.02.005; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; Hillier LW, 2004, NATURE, V432, P695, DOI 10.1038/nature03154; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; Hughes S, 2000, ANIM GENET, V31, P418, DOI 10.1046/j.1365-2052.2000.00697.x; Kaiser P, 2005, J INTERF CYTOK RES, V25, P467, DOI 10.1089/jir.2005.25.467; Kaiser P, 1999, IMMUNOGENETICS, V49, P673, DOI 10.1007/s002510050664; KOGUT MH, 1995, J LEUKOCYTE BIOL, V57, P56, DOI 10.1002/jlb.57.1.56; Laurent F, 2001, INFECT IMMUN, V69, P2527, DOI 10.1128/IAI.69.4.2527-2534.2001; Lawson S, 2001, DEV COMP IMMUNOL, V25, P69, DOI 10.1016/S0145-305X(00)00044-6; LEE J, 1992, J BIOL CHEM, V267, P16283; Li QJ, 2005, J LEUKOCYTE BIOL, V77, P421, DOI 10.1189/jlb.0704398; Li QJ, 2000, GENE, V257, P307, DOI 10.1016/S0378-1119(00)00385-1; Martins-Green M, 1998, CYTOKINE, V10, P522, DOI 10.1006/cyto.1997.0311; Martins-Green M, 1998, CYTOKINE, V10, P819, DOI 10.1006/cyto.1998.0383; MartinsGreen M, 1996, CYTOKINE, V8, P448, DOI 10.1006/cyto.1996.0061; McNulty CA, 1999, AM J RESP CELL MOL, V20, P1251, DOI 10.1165/ajrcmb.20.6.3531; Moepps B, 2006, MOL IMMUNOL, V43, P897, DOI 10.1016/j.molimm.2005.06.043; MOLSKI TFP, 1984, BIOCHEM BIOPH RES CO, V124, P644, DOI 10.1016/0006-291X(84)91603-6; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OHSHIMA Y, 1987, J MOL BIOL, V195, P247, DOI 10.1016/0022-2836(87)90647-4; OHTA H, 1985, J BIOL CHEM, V260, P5771; OKAJIMA F, 1985, J BIOL CHEM, V260, P6761; OKAJIMA F, 1984, J BIOL CHEM, V259, P3863; Olson TS, 2002, AM J PHYSIOL-REG I, V283, pR7, DOI 10.1152/ajpregu.00738.2001; Ponath PD, 1996, J EXP MED, V183, P2437, DOI 10.1084/jem.183.6.2437; Richardson RM, 2003, J IMMUNOL, V170, P2904, DOI 10.4049/jimmunol.170.6.2904; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Schratzberger P, 1997, IMMUNOL LETT, V58, P167, DOI 10.1016/S0165-2478(97)00085-0; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Sick C, 2000, CYTOKINE, V12, P181, DOI 10.1006/cyto.1999.0543; Suetomi K, 2002, J BIOL CHEM, V277, P31563, DOI 10.1074/jbc.M204713200; SUGANO S, 1987, CELL, V49, P321, DOI 10.1016/0092-8674(87)90284-4; Tan JQ, 1997, J IMMUNOL, V158, P475; Tiffany HL, 1997, J EXP MED, V186, P165, DOI 10.1084/jem.186.1.165; Tregaskes CA, 2005, DEV COMP IMMUNOL, V29, P361, DOI 10.1016/j.dci.2004.09.001; TREGASKES CA, 1996, IMMUNOLOGICAL METHOD, P2295; Wang JC, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-45; Wigley P, 2002, MICROBES INFECT, V4, P1111, DOI 10.1016/S1286-4579(02)01635-0; Withanage GSK, 2004, INFECT IMMUN, V72, P2152, DOI 10.1128/IAI.72.4.2152-2159.2004; Xanthou G, 2003, EUR J IMMUNOL, V33, P2927, DOI 10.1002/eji.200324235	52	45	47	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16408	16415		10.1074/jbc.M800998200	http://dx.doi.org/10.1074/jbc.M800998200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18417470	hybrid			2022-12-25	WOS:000256497100017
J	Stuhlmeier, KM				Stuhlmeier, Karl M.			Hyaluronan production in synoviocytes as a consequence of viral infections - HAS1 activation by Epstein-Barr virus and synthetic double- and single-stranded viral RNA analogs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; ADENOVIRUS-MEDIATED EXPRESSION; RHEUMATOID-ARTHRITIS; ENDOTHELIAL-CELLS; POLY(C) TRACT; SYNOVIAL FIBROBLASTS; MAP KINASE; PATHWAY; DISEASE; TRANSCRIPTION	One of the hallmarks of arthritis is swollen joints containing unusually high quantities of hyaluronan. Intact hyaluronan molecules facilitate cell migration by acting as ligands for CD44. Hyaluronan degradation products, readily formed at sites of inflammation, also fuel inflammatory processes. Irrespective of whether viruses could be a cause of rheumatoid arthritis, there is clear evidence that links viral infections to this debilitating disease. For this study, live Epstein-Barr virus and a number of double-and single-stranded synthetic viral analogs were tested for their effectiveness as activators of hyaluronan (HA) synthesis. As shown herein, Epstein-Barr virus-treated fibroblast-like synoviocytes significantly increase HA production and release. Real time reverse transcription-PCR data show that HAS1 mRNA levels are significantly elevated in virus-treated cells, whereas mRNA levels for the genes HAS2 and HAS3 remain unchanged. As to the mechanism of virus-induced HAS1 transcription, data are presented that imply that among the double- and single-stranded polynucleotides tested, homopolymeric polycytidylic structures are the most potent inducers of HAS1 transcription and HA release, whereas homopolymeric polyinosinic acid is without effect. Analyses of virus-induced signal cascades, utilizing chemical inhibitors of MAPK and overexpressing mutated IKK and I kappa B, revealed that the MAPK p38 as well as the transcription factor NF-kappa B are essential for virus-induced activation of HAS1. The presented data implicate HAS1 as the culprit in unfettered HA release and point out targets in virus-induced signaling pathways that might allow for specific interventions in cases of unwanted and uncontrolled HA synthesis.	Ludwig Boltzmann Inst Rheumatol & Balneol, A-1100 Vienna, Austria	Ludwig Boltzmann Institute	Stuhlmeier, KM (corresponding author), Ludwig Boltzmann Inst Rheumatol & Balneol, Kurbadstr 10, A-1100 Vienna, Austria.	karlms@excite.com						Agren UM, 1997, FREE RADICAL BIO MED, V23, P996, DOI 10.1016/S0891-5849(97)00098-1; AHN BY, 1989, J VIROL, V63, P226, DOI 10.1128/JVI.63.1.226-232.1989; Alamanos Y, 2005, AUTOIMMUN REV, V4, P130, DOI 10.1016/j.autrev.2004.09.002; BIRD HA, 1999, CHALLENGES RHEUMATOI, P1; BLACK DN, 1979, NUCLEIC ACIDS RES, V6, P2381, DOI 10.1093/nar/6.7.2381; Blaschke S, 2000, J RHEUMATOL, V27, P866; Chaiamnuay Sumapa, 2005, Pathophysiology, V12, P203, DOI 10.1016/j.pathophys.2005.07.007; Costenbader KH, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1893; D'Addario M, 1999, FASEB J, V13, P2203, DOI 10.1096/fasebj.13.15.2203; de la Motte CA, 1999, J BIOL CHEM, V274, P30747, DOI 10.1074/jbc.274.43.30747; Deng GM, 2000, ARTHRITIS RHEUM-US, V43, P356, DOI 10.1002/1529-0131(200002)43:2<356::AID-ANR15>3.0.CO;2-J; DUKE GM, 1990, NATURE, V343, P474, DOI 10.1038/343474a0; GEILER T, 1994, ARTHRITIS RHEUM, V37, P1664, DOI 10.1002/art.1780371116; Jiang ZF, 2003, J BIOL CHEM, V278, P16713, DOI 10.1074/jbc.M300562200; Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017; Klareskog L, 2004, ANN RHEUM DIS, V63, P28, DOI 10.1136/ard.2004.028225; Laurent TC, 1996, ANN MED, V28, P241, DOI 10.3109/07853899609033126; Ma YY, 2005, CURR PHARM DESIGN, V11, P569, DOI 10.2174/1381612053381927; Markovic M, 2006, J MOL MED, V84, P821, DOI 10.1007/s00109-006-0089-6; Martin LR, 2000, J VIROL, V74, P3074, DOI 10.1128/JVI.74.7.3074-3081.2000; MELLOR EJC, 1985, J GEN VIROL, V66, P1919, DOI 10.1099/0022-1317-66-9-1919; MULLERLADNER U, 1995, RHEUM DIS CLIN N AM, V21, P675; NEWKIRK MM, 1994, BRIT J RHEUMATOL, V33, P317, DOI 10.1093/rheumatology/33.4.317; Noble PW, 1996, J EXP MED, V183, P2373, DOI 10.1084/jem.183.5.2373; Oitzinger W, 2001, BLOOD, V97, P1611, DOI 10.1182/blood.V97.6.1611; Pap T, 2000, ARTHRITIS RES, V2, P361, DOI 10.1186/ar113; Perl A, 1999, ANN RHEUM DIS, V58, P454, DOI 10.1136/ard.58.8.454; Saal JG, 1999, ARTHRITIS RHEUM-US, V42, P1485, DOI 10.1002/1529-0131(199907)42:7<1485::AID-ANR24>3.0.CO;2-7; Saklatvala J, 2004, CURR OPIN PHARMACOL, V4, P372, DOI 10.1016/j.coph.2004.03.009; Scheibner KA, 2006, J IMMUNOL, V177, P1272, DOI 10.4049/jimmunol.177.2.1272; Seemayer CA, 2003, AM J PATHOL, V162, P1549, DOI 10.1016/S0002-9440(10)64289-7; SIEBENLIST US, 1995, INDUCIBLE GENE EXPRE, P93; Stuhlmeier KM, 2007, J IMMUNOL, V179, P655, DOI 10.4049/jimmunol.179.1.655; Stuhlmeier KM, 2005, J BIOL CHEM, V280, P42766, DOI 10.1074/jbc.M503374200; Stuhlmeier KM, 2005, J IMMUNOL, V174, P7376, DOI 10.4049/jimmunol.174.11.7376; STUHLMEIER KM, 1994, EUR J IMMUNOL, V24, P2186, DOI 10.1002/eji.1830240938; Stuhlmeier KM, 2004, J BIOL CHEM, V279, P8753, DOI 10.1074/jbc.M303945200; Stuhlmeier KM, 2004, RHEUMATOLOGY, V43, P164, DOI 10.1093/rheumatology/keh014; Takeda T, 2000, ARTHRITIS RHEUM, V43, P1218, DOI 10.1002/1529-0131(200006)43:6<1218::AID-ANR4>3.0.CO;2-2; Takei M, 1997, INT IMMUNOL, V9, P739, DOI 10.1093/intimm/9.5.739; Termeer C, 2002, J EXP MED, V195, P99, DOI 10.1084/jem.20001858; TOSATO G, 1984, J CLIN INVEST, V73, P1789, DOI 10.1172/JCI111388; Turesson C, 2006, MAYO CLIN PROC, V81, P94, DOI 10.4065/81.1.94; Wrighton CJ, 1996, J EXP MED, V183, P1013, DOI 10.1084/jem.183.3.1013; Xiong AM, 2004, TRANSPLANTATION, V78, P41, DOI 10.1097/01.TP.0000129805.02631.EF	45	6	6	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16781	16789		10.1074/jbc.M801669200	http://dx.doi.org/10.1074/jbc.M801669200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18400745	hybrid			2022-12-25	WOS:000256497100055
J	Wolfrum, C; Howell, JJ; Ndungo, E; Stoffel, M				Wolfrum, Christian; Howell, Jessica J.; Ndungo, Esther; Stoffel, Markus			Foxa2 activity increases plasma high density lipoprotein levels by regulating apolipoprotein M	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRE-BETA-HDL; HEPATOCYTE NUCLEAR FACTOR-1-ALPHA; DEPENDENT DIABETES-MELLITUS; ELEVATED OXIDATIVE STRESS; CORONARY-ARTERY-DISEASE; INSULIN-RESISTANCE; A-I; ANTIOXIDATIVE ACTIVITY; MAGNETIC-RESONANCE; METABOLIC SYNDROME	Obesity, diabetes, insulin resistance, and hyperinsulinemia are frequently associated with a cluster of closely related lipid abnormalities such as low plasma levels of high density lipoprotein (HDL) and elevated levels of triglyceride, both known to increase the risk of developing atherosclerotic disease. The molecular mechanisms linking obesity, insulin resistance, and hyperinsulinemia to low HDL levels are incompletely understood. Here we demonstrate that insulin, through a Foxa2-mediated mechanism, inhibited the expression of apolipoprotein M(apoM), an important determinant of plasma pre-beta-HDL and alpha-HDL concentrations. Obese mice had decreased apoM expression and plasma pre-beta-HDL levels due to inactivation of Foxa2 in hyperinsulinemic states. Nuclear reexpression of Foxa2 with a phosphorylation-deficient mutant Foxa2T156A (Ad-T156A) activated apoM expression and increased plasma pre-beta-HDL and alpha-HDL levels. In contrast, haploinsufficient Foxa2(+/-) mice exhibited decreased hepatic apoM expression and plasma pre-beta-HDL and HDL levels. The increase in plasma HDL levels and pre-beta-HDL formation by Foxa2 was mediated exclusively by apoM, as constitutive active expression of Foxa2 in apoM(-/-) mice had no effect on plasma HDL levels. Our results identify a fundamental mechanism by which insulin regulates plasma HDL levels in physiological and insulin-resistant states and thus have important implications for novel therapeutic approaches to prevent atherosclerosis.	[Wolfrum, Christian; Howell, Jessica J.; Stoffel, Markus] ETH, Swiss Fed Inst Technol, Inst Mol Syst Biol, CH-8093 Zurich, Switzerland; [Wolfrum, Christian; Howell, Jessica J.; Stoffel, Markus] ETH, Competence Ctr Syst Physiol & Metab Dis, CH-8093 Zurich, Switzerland; [Howell, Jessica J.; Ndungo, Esther; Stoffel, Markus] Rockefeller Univ, New York, NY 10021 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Swiss Federal Institutes of Technology Domain; ETH Zurich; Rockefeller University	Stoffel, M (corresponding author), ETH, Swiss Fed Inst Technol, Inst Mol Syst Biol, HPTE73,Wolfgang Pauli Str 16, CH-8093 Zurich, Switzerland.	stoffel@imsb.biol.ethz.ch		Wolfrum, Christian/0000-0002-3862-6805; Ndungo, Esther/0000-0002-9975-7032; Stoffel, Markus/0000-0003-1304-5817				ALTABA ARI, 1993, MECH DEVELOP, V44, P91, DOI 10.1016/0925-4773(93)90060-B; ASZTALOS BF, 2005, ATHEROSCLEROSIS; Axler O, 2007, J LIPID RES, V48, P1772, DOI 10.1194/jlr.M700113-JLR200; Barrans A, 1996, BBA-LIPID LIPID MET, V1300, P73, DOI 10.1016/0005-2760(95)00236-7; BERLINER JA, 1995, CIRCULATION, V91, P2488, DOI 10.1161/01.CIR.91.9.2488; BRINTON EA, 1994, ARTERIOSCLER THROMB, V14, P707, DOI 10.1161/01.ATV.14.5.707; Cederberg A, 2003, CURR MOL MED, V3, P107, DOI 10.2174/1566524033361573; Christoffersen C, 2008, J BIOL CHEM, V283, P1839, DOI 10.1074/jbc.M704576200; Christoffersen C, 2006, J LIPID RES, V47, P1833, DOI 10.1194/jlr.M600055-JLR200; Deeb SS, 2003, J LIPID RES, V44, P1279, DOI 10.1194/jlr.R200017-JLR200; DeFronzo RA, 1996, J DIABETES COMPLICAT, V10, P243, DOI 10.1016/1056-8727(96)00046-3; Dujovne CA, 2001, AM HEART J, V142, P489, DOI 10.1067/mhj.2001.117510; ENERBACK S, 1992, MOL CELL BIOL, V12, P4622, DOI 10.1128/MCB.12.10.4622; Ferrannini E, 1999, EUR J CLIN INVEST, V29, P842; Festa A, 2005, CIRCULATION, V111, P3465, DOI 10.1161/CIRCULATIONAHA.104.512079; FIDGE N, 1980, METABOLISM, V29, P643, DOI 10.1016/0026-0495(80)90109-2; Garin MCB, 2005, J CLIN ENDOCR METAB, V90, P2264, DOI 10.1210/jc.2004-1295; Garvey WT, 2003, DIABETES, V52, P453, DOI 10.2337/diabetes.52.2.453; Gower BA, 2002, AM J CLIN NUTR, V76, P923, DOI 10.1093/ajcn/76.5.923; Hansel Boris, 2004, Semin Vasc Med, V4, P215, DOI 10.1055/s-2004-835381; HOROWITZ BS, 1993, J CLIN INVEST, V91, P1743, DOI 10.1172/JCI116384; Ioffe E, 1998, P NATL ACAD SCI USA, V95, P11852, DOI 10.1073/pnas.95.20.11852; Julius U, 2003, EXP CLIN ENDOCR DIAB, V111, P246, DOI 10.1055/s-2003-41284; Kim D, 2004, INTEGR FERROELECTR, V68, P75, DOI 10.1080/10584580490895671; Kontush A, 2005, ATHEROSCLEROSIS, V182, P277, DOI 10.1016/j.atherosclerosis.2005.03.001; Krentz AJ, 2003, DIABETES OBES METAB, V5, pS19, DOI 10.1046/j.1462-8902.2003.0310.x; Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201; Liang CP, 2001, J BIOL CHEM, V276, P49066, DOI 10.1074/jbc.M107250200; Lundasen T, 2003, J BIOL CHEM, V278, P43224, DOI 10.1074/jbc.M302645200; Luo GH, 2005, BBA-MOL CELL BIOL L, V1734, P198, DOI 10.1016/j.bbalip.2005.02.005; Marcil Michel, 2004, Expert Rev Cardiovasc Ther, V2, P417, DOI 10.1586/14779072.2.3.417; Miller M, 2004, CURR OPIN CARDIOL, V19, P380, DOI 10.1097/01.hco.0000126584.12520.b5; NISHINA PM, 1994, METABOLISM, V43, P549, DOI 10.1016/0026-0495(94)90194-5; Nobecourt E, 2005, DIABETOLOGIA, V48, P529, DOI 10.1007/s00125-004-1655-5; Postic C, 2004, DIABETES METAB, V30, P398, DOI 10.1016/S1262-3636(07)70133-7; Rezaee F, 2006, PROTEOMICS, V6, P721, DOI 10.1002/pmic.200500191; Richter S, 2003, DIABETES, V52, P2989, DOI 10.2337/diabetes.52.12.2989; Sasahara T, 1997, J LIPID RES, V38, P600; Shih DQ, 2001, NAT GENET, V27, P375, DOI 10.1038/86871; Silver DL, 2000, J CLIN INVEST, V105, P151, DOI 10.1172/JCI8087; Silver DL, 1999, J BIOL CHEM, V274, P4140, DOI 10.1074/jbc.274.7.4140; Soderlund S, 2005, J LIPID RES, V46, P1643, DOI 10.1194/jlr.M400480-JLR200; SYVANNE M, 1995, CIRCULATION, V92, P364, DOI 10.1161/01.CIR.92.3.364; SYVANNE M, 1995, J LIPID RES, V36, P573; Wolfrum C, 2003, P NATL ACAD SCI USA, V100, P11624, DOI 10.1073/pnas.1931483100; Wolfrum C, 2005, NAT MED, V11, P418, DOI 10.1038/nm1211; Wolfrum C, 2006, CELL METAB, V3, P99, DOI 10.1016/j.cmet.2006.01.001; Wolfrum C, 2004, NATURE, V432, P1027, DOI 10.1038/nature03047; Xu N, 2004, BIOCHEM BIOPH RES CO, V321, P916, DOI 10.1016/j.bbrc.2004.06.180; Yu YX, 2005, AM J MED SCI, V330, P227, DOI 10.1097/00000441-200511000-00005; Zimmet P, 2005, J ATHEROSCLER THROMB, V12, P295, DOI 10.5551/jat.12.295	51	58	64	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16940	16949		10.1074/jbc.M801930200	http://dx.doi.org/10.1074/jbc.M801930200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18381283	hybrid			2022-12-25	WOS:000256497100071
J	Bennett, MK; Datta, YKSS; Shin, DJ; Osborne, TF				Bennett, Mary K.; Datta, Young-Kyo Seo Shrimati; Shin, Dong-Ju; Osborne, Timothy F.			Selective binding of sterol regulatory element-binding protein isoforms and co-regulatory proteins to promoters for lipid metabolic genes in liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; FATTY-ACID SYNTHASE; THYROID-HORMONE REGULATION; TRANSCRIPTION FACTOR CREB; MESSENGER-RNA; IN-VIVO; FEEDBACK-REGULATION; NUCLEAR-PROTEIN; EXPRESSION; TARGET	Mice were subjected to different dietary manipulations to selectively alter expression of hepatic sterol regulatory element-binding protein 1 (SREBP-1) or SREBP-2. mRNA levels for key target genes were measured and compared with the direct binding of SREBP-1 and -2 to the associated promoters using isoform specific antibodies in chromatin immunoprecipitation studies. A diet supplemented with Zetia (ezetimibe) and lovastatin increased and decreased nuclear SREBP-2 and SREBP-1, respectively, whereas a fasting/refeeding protocol dramatically altered SREBP-1 but had modest effects on SREBP-2 levels. Binding of both SREBP-1 and -2 increased on promoters for 3-hydroxy-3-methylglutaryl-CoA reductase, fatty-acid synthase, and squalene synthase in livers of Zetia/lovastatin-treated mice despite the decline in total SREBP-1 protein. In contrast, only SREBP-2 binding was increased for the low density lipoprotein receptor promoter. Decreased SREBP-1 binding during fasting and a dramatic increase upon refeeding indicates that the lipogenic "overshoot" for fatty-acid synthase gene expression known to occur during high carbohydrate refeeding can be attributed to a similar overshoot in SREBP-1 binding. SREBP co-regulatory protein recruitment was also increased/decreased in parallel with associated changes in SREBP binding, and there were clear distinctions for different promoters in response to the dietary manipulations. Taken together, these studies reveal that there are alternative molecular mechanisms for activating SREBP target genes in response to the different dietary challenges of Zetia/lovastatin versus fasting/refeeding. This underscores the mechanistic flexibility that has evolved at the individual gene/promoter level to maintain metabolic homeostasis in response to shifting nutritional states and environmental fluctuations.	Univ Calif Irvine, Dept Biochem & Mol Biol, Sch Biol Sci, Irvine, CA 92697 USA; Univ Calif Irvine, Ctr Diabet Res & Treatment, Irvine, CA 92697 USA	University of California System; University of California Irvine; University of California System; University of California Irvine	Osborne, TF (corresponding author), Univ Calif Irvine, Dept Biochem & Mol Biol, Sch Biol Sci, 3244 McGaugh Hall, Irvine, CA 92697 USA.	tfosborn@uci.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048044] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48044] Funding Source: Medline; NIAAA NIH HHS [R01 AA026322] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Athanikar JN, 1998, P NATL ACAD SCI USA, V95, P4935, DOI 10.1073/pnas.95.9.4935; Athanikar JN, 1997, MOL CELL BIOL, V17, P5193, DOI 10.1128/MCB.17.9.5193; Bennett MK, 2004, J BIOL CHEM, V279, P37360, DOI 10.1074/jbc.M404693200; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; Brown MS, 1999, P NATL ACAD SCI USA, V96, P11041, DOI 10.1073/pnas.96.20.11041; BROWN MS, 1980, J LIPID RES, V21, P505; Casado M, 1999, J BIOL CHEM, V274, P2009, DOI 10.1074/jbc.274.4.2009; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; Datta S, 2006, J BIOL CHEM, V281, P807, DOI 10.1074/jbc.M511050200; Datta S, 2005, J BIOL CHEM, V280, P3338, DOI 10.1074/jbc.M411222200; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P1210, DOI 10.1073/pnas.91.4.1210; Garcia-Calvo M, 2005, P NATL ACAD SCI USA, V102, P8132, DOI 10.1073/pnas.0500269102; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; Guan GM, 1997, J BIOL CHEM, V272, P10295; Hannah VC, 2001, J BIOL CHEM, V276, P4365, DOI 10.1074/jbc.M007273200; Herzig S, 2001, NATURE, V413, P179, DOI 10.1038/35093131; Horton JD, 1998, P NATL ACAD SCI USA, V95, P5987, DOI 10.1073/pnas.95.11.5987; Ishii S, 2004, P NATL ACAD SCI USA, V101, P15597, DOI 10.1073/pnas.0405238101; KIM JB, 1995, MOL CELL BIOL, V15, P2582; Kim JB, 1998, J CLIN INVEST, V101, P1, DOI 10.1172/JCI1411; Kim TS, 1996, J NUTR, V126, P611, DOI 10.1093/jn/126.3.611; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Liang GS, 2002, J BIOL CHEM, V277, P9520, DOI 10.1074/jbc.M111421200; LISCUM L, 1983, J BIOL CHEM, V258, P8450; Magana MM, 2000, J BIOL CHEM, V275, P4726, DOI 10.1074/jbc.275.7.4726; MILLINDERVALLET.S, 1996, J BIOL CHEM, V271, P12247; Ngo TT, 2002, J BIOL CHEM, V277, P33901, DOI 10.1074/jbc.M202135200; Osborne TF, 1998, CURR OPIN LIPIDOL, V9, P137, DOI 10.1097/00041433-199804000-00010; Parker D, 1996, MOL CELL BIOL, V16, P694; Ravnskjaer K, 2007, EMBO J, V26, P2880, DOI 10.1038/sj.emboj.7601715; Repa JJ, 2000, GENE DEV, V14, P2819, DOI 10.1101/gad.844900; Repa JJ, 2002, J LIPID RES, V43, P1864, DOI 10.1194/jlr.M200144-JLR200; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Sato R, 1996, J BIOL CHEM, V271, P26461, DOI 10.1074/jbc.271.43.26461; SHENG ZQ, 1995, P NATL ACAD SCI USA, V92, P935, DOI 10.1073/pnas.92.4.935; Shimomura I, 1997, J CLIN INVEST, V99, P838, DOI 10.1172/JCI119247; Shin DJ, 2003, J BIOL CHEM, V278, P50047, DOI 10.1074/jbc.M309736200; Shin DJ, 2003, J BIOL CHEM, V278, P34114, DOI 10.1074/jbc.M305417200; Shin DJ, 2006, NUCLEIC ACIDS RES, V34, P3853, DOI 10.1093/nar/gkl506; Toth JI, 2004, MOL CELL BIOL, V24, P8288, DOI 10.1128/MCB.24.18.8288-8300.2004; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Xu W, 2007, EMBO J, V26, P2890, DOI 10.1038/sj.emboj.7601734; Yokoyama C., 1993, CELL, V75, P185	48	59	61	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15628	15637		10.1074/jbc.M800391200	http://dx.doi.org/10.1074/jbc.M800391200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18413311	Green Published, hybrid			2022-12-25	WOS:000256332500016
J	Sharina, IG; Jelen, F; Bogatenkova, EP; Thomas, A; Martin, E; Murad, F				Sharina, Iraida G.; Jelen, Filip; Bogatenkova, Elena P.; Thomas, Anthony; Martin, Emil; Murad, Ferid			alpha 1 soluble guanylyl cyclase (sGC) splice forms as potential regulators of human sGC activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPONTANEOUSLY HYPERTENSIVE-RATS; STABILIZING PROTEIN HUR; NITRIC-OXIDE RECEPTOR; DOWN-REGULATION; MESSENGER-RNA; SMOOTH-MUSCLE; SODIUM-NITROPRUSSIDE; EXPRESSION; SUBUNIT; ACTIVATION	Soluble guanylyl cyclase (sGC), a key protein in the NO/cGMP signaling pathway, is an obligatory heterodimeric protein composed of one alpha- and one beta-subunit. The alpha(1)/beta(1) sGC heterodimer is the predominant form expressed in various tissues and is regarded as the major isoform mediating NO-dependent effects such as vasodilation. We have identified three new a, sGC protein variants generated by alternative splicing. The 363 residue NI-a, sGC splice variant contains the regulatory domain, but lacks the catalytic domain. The shorter N2-alpha(1) sGC maintains 126 N-terminal residues and gains an additional 17 unique residues. The C-alpha(1) sGC variant lacks 240 N-terminal amino acids, but maintains a part of the regulatory domain and the entire catalytic domain. Q-PCR of N1-alpha(1), N2-alpha(1), sGC mRNA levels together with RT-PCR analysis for C-alpha(1) sGC demonstrated that the expression of the eel sGC splice forms vary in different human tissues indicative of tissue-specific regulation. Functional analysis of the N1-alpha(1) sGC demonstrated that this protein has a dominant-negative effect on the activity of sGC when co-expressed with the alpha(1)/beta(1) heterodimer. The C-alpha(1) sGC variant heterodimerizes with the 13, subunit and produces a fully functional NO- and BAY41-2272-sensitive enzyme. We also found that despite identical susceptibility to inhibition by ODQ, intracellular levels of the 54-kDa C-alpha(1) band did not change in response to ODQ treatments, while the level of 83 kDa alpha(1) band was significantly affected by ODQ. These studies suggest that modulation of the level and diversity of splice forms may represent novel mechanisms modulating the function of sGC in different human tissues.	[Sharina, Iraida G.; Jelen, Filip; Bogatenkova, Elena P.; Thomas, Anthony; Martin, Emil; Murad, Ferid] Univ Texas Houston, Sch Med, Brown Fdn Inst Mol Med, Houston, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston	Sharina, IG (corresponding author), Univ Texas Houston, Sch Med, Brown Fdn Inst Mol Med, Houston, TX 77030 USA.	iraida.g.sharina@uth.tmc.edu; ferid.murad@uth.tmc.edu	Sharina, Iraida/C-9888-2014	Martin, Emil/0000-0002-9094-4165	NHLBI NIH HHS [HL 088128, R01 HL088128] Funding Source: Medline; NIGMS NIH HHS [GM 061731] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL088128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061731] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams MD, 1996, CURR OPIN CELL BIOL, V8, P331, DOI 10.1016/S0955-0674(96)80006-8; Behrends S, 2000, BIOCHEM BIOPH RES CO, V271, P64, DOI 10.1006/bbrc.2000.2596; BEHRENDS S, 1995, J BIOL CHEM, V270, P21109, DOI 10.1074/jbc.270.36.21109; Budworth J, 1999, BIOCHEM BIOPH RES CO, V263, P696, DOI 10.1006/bbrc.1999.1444; Burgoyne JR, 2007, SCIENCE, V317, P1393, DOI 10.1126/science.1144318; Bustin SA, 2000, J MOL ENDOCRINOL, V25, P169, DOI 10.1677/jme.0.0250169; CHHAJLANI V, 1991, FEBS LETT, V290, P157, DOI 10.1016/0014-5793(91)81248-7; Friebe A, 2007, P NATL ACAD SCI USA, V104, P7699, DOI 10.1073/pnas.0609778104; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Hofmann F, 2006, PHYSIOL REV, V86, P1, DOI 10.1152/physrev.00015.2005; HUMBERT P, 1990, EUR J BIOCHEM, V190, P273, DOI 10.1111/j.1432-1033.1990.tb15572.x; Ibarra C, 2001, BRAIN RES, V907, P54, DOI 10.1016/S0006-8993(01)02588-4; Kagota S, 2001, BRIT J PHARMACOL, V134, P737, DOI 10.1038/sj.bjp.0704300; KATSUKI S, 1977, J CYCLIC NUCL PROT, V3, P23; KIMURA H, 1974, J BIOL CHEM, V249, P6910; Kloss S, 2005, HYPERTENSION, V45, P1200, DOI 10.1161/01.HYP.0000165674.58470.8f; Kloss S, 2004, MOL PHARMACOL, V65, P1440, DOI 10.1124/mol.65.6.1440; Kloss S, 2003, J BIOL CHEM, V278, P2377, DOI 10.1074/jbc.M206453200; Kloss S, 2000, HYPERTENSION, V35, P43; Koglin M, 2003, J BIOL CHEM, V278, P12590, DOI 10.1074/jbc.M212740200; Krumenacker JS, 2001, P NATL ACAD SCI USA, V98, P717, DOI 10.1073/pnas.98.2.717; Lee YC, 2000, P NATL ACAD SCI USA, V97, P10763, DOI 10.1073/pnas.190333697; Martin E, 2003, P NATL ACAD SCI USA, V100, P9208, DOI 10.1073/pnas.1633590100; Martin E, 2001, P NATL ACAD SCI USA, V98, P12938, DOI 10.1073/pnas.231486198; Mergia E, 2003, CELL SIGNAL, V15, P189, DOI 10.1016/S0898-6568(02)00078-5; Mergia E, 2006, J CLIN INVEST, V116, P1731, DOI 10.1172/JCI27657; MURAD F, 1986, J CLIN INVEST, V78, P1, DOI 10.1172/JCI112536; Nimmegeers S, 2007, CARDIOVASC RES, V76, P149, DOI 10.1016/j.cardiores.2007.06.002; Okamoto H, 2004, INT J BIOCHEM CELL B, V36, P472, DOI 10.1016/j.biocel.2003.08.003; Papapetropoulos A, 1996, BRIT J PHARMACOL, V118, P1359, DOI 10.1111/j.1476-5381.1996.tb15545.x; PAPAPETROPOULOS A, 1995, HYPERTENSION, V26, P696, DOI 10.1161/01.HYP.26.4.696; Papapetropoulos A, 1996, BRIT J PHARMACOL, V117, P147, DOI 10.1111/j.1476-5381.1996.tb15167.x; Pyriochou A, 2005, CELL SIGNAL, V17, P407, DOI 10.1016/j.cellsig.2004.09.008; RAPOPORT RM, 1983, NATURE, V306, P174, DOI 10.1038/306174a0; Ritter D, 2000, BIOCHEM J, V346, P811, DOI 10.1042/0264-6021:3460811; Rothkegel C, 2007, MOL PHARMACOL, V72, P1181, DOI 10.1124/mol.107.036368; Ruetten H, 1999, CIRC RES, V85, P534, DOI 10.1161/01.RES.85.6.534; Russwurm M, 1998, BIOCHEM J, V335, P125, DOI 10.1042/bj3350125; Shiga T, 2005, ZOOL SCI, V22, P735, DOI 10.2108/zsj.22.735; Stasch JP, 2006, J CLIN INVEST, V116, P2552, DOI 10.1172/JCI28371; Tamura N, 2003, J BIOL CHEM, V278, P48880, DOI 10.1074/jbc.M308680200; Wagner C, 2005, J BIOL CHEM, V280, P17687, DOI 10.1074/jbc.M412099200; Wang X, 1999, EMBO J, V18, P4549, DOI 10.1093/emboj/18.16.4549; Zabel U, 1998, BIOCHEM J, V335, P51, DOI 10.1042/bj3350051	45	42	43	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15104	15113		10.1074/jbc.M710269200	http://dx.doi.org/10.1074/jbc.M710269200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18381288	Green Published, hybrid			2022-12-25	WOS:000256232000025
J	Richard, B; Swanson, R; Schedin-Weiss, S; Ramirez, B; Izaguirre, G; Gettins, PGW; Olson, ST				Richard, Benjamin; Swanson, Richard; Schedin-Weiss, Sophia; Ramirez, Ben; Izaguirre, Gonzalo; Gettins, Peter G. W.; Olson, Steven T.			Characterization of the conformational alterations, reduced anticoagulant activity, and enhanced antiangiogenic activity of prelatent antithrombin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; HEPARIN-BINDING SITE; FACTOR-XA; PROTEINASE REACTIONS; RAPID INHIBITION; AFFINITY HEPARIN; TERNARY COMPLEX; MECHANISM; ANGIOGENESIS; THROMBIN	A conformationally altered prelatent form of antithrombin that possesses both anticoagulant and antiangiogenic activities is produced during the conversion of native to latent antithrombin (Larsson, H., Akerud, P., Nordling, K., Raub-Segall, E., ClaessonWelsh, L., and Bjork, I. (2001) J. Biol. Chem. 276, 11996 12002). Here, we show that the previously characterized prelatent antithrombin is a mixture of native antithrombin and a modified, true prelatent antithrombin that are resolvable by heparin-agarose chromatography. Kinetic analyses revealed that prelatent antithrombin is an intermediate in the conversion of native to latent antithrombin whose formation is favored by stabilizing anions of the Hofmeister series. Purified prelatent antithrombin had reduced anticoagulant function compared with native antithrombin, due to a reduced heparin affinity and consequent impaired ability of heparin to either bridge prelatent antithrombin and coagulation proteases in a ternary complex or to induce full conformational activation of the serpin. Significantly, prelatent antithrombin possessed an antiangiogenic activity more potent than that of latent antithrombin, based on the relative abilities of the two forms to inhibit endothelial cell growth. The prelatent form was conformationally altered from native antithrombin as judged from an attenuation of tryptophan fluorescence changes following heparin activation and a reduced thermal stability. The alterations are consistent with the limited structural changes involving strand 1C observed in a prelatent form of plasminogen activator inhibitor-1 (Dupont, D. M., Blouse, G. E., Hansen, M., Mathiasen, L., Kjelgaard, S., Jensen, J. K., Christensen, A., Gils, A., Declerck, P. J., Andreasen, P. A., and Wind, T. (2006) J. Biol. Chem. 281, 36071 -36081), since the H-1 NMR spectrum, electrophoretic mobility, and proteolytic susceptibility of prelatent antithrombin most resemble those of native rather than those of latent antithrombin. Together, these results demonstrate that limited conformational alterations of antithrombin that modestly reduce anticoagulant activity are sufficient to generate antiangiogenic activity.	[Richard, Benjamin; Swanson, Richard; Izaguirre, Gonzalo] Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA; [Ramirez, Ben; Gettins, Peter G. W.; Olson, Steven T.] Univ Illinois, Ctr Struct Biol, Chicago, IL 60612 USA; [Gettins, Peter G. W.] Univ Illinois, Dept Biochem & Mol Genet, Chicago, IL 60612 USA; [Schedin-Weiss, Sophia] Uppsala Univ, Dept Med Biochem & Microbiol, SE-75123 Uppsala, Sweden	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Uppsala University	Olson, ST (corresponding author), Univ Illinois, Ctr Mol Biol Oral Dis, Chicago, IL 60612 USA.	stolson@uic.edu		Schedin Weiss, Sophia/0000-0003-2143-7052; Richard, Benjamin/0000-0003-4531-1905	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL039888, R37HL049234, R01HL049234, R01HL039888, R29HL039888] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 49234, HL 39888] Funding Source: Medline; PHS HHS [P41 68944] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ATHA DH, 1985, BIOCHEMISTRY-US, V24, P6723, DOI 10.1021/bi00344a063; BJORK I, 1992, J BIOL CHEM, V267, P1976; BUSBY TF, 1981, J BIOL CHEM, V256, P2140; CHOAY J, 1983, BIOCHEM BIOPH RES CO, V116, P492, DOI 10.1016/0006-291X(83)90550-8; Church F. C., 2007, MOL CELLULAR ASPECTS, P509; Dawson DW, 1999, SCIENCE, V285, P245, DOI 10.1126/science.285.5425.245; Dementiev A, 2006, J BIOL CHEM, V281, P3452, DOI 10.1074/jbc.M510564200; Dementiev A, 2004, NAT STRUCT MOL BIOL, V11, P863, DOI 10.1038/nsmb810; Dupont DM, 2006, J BIOL CHEM, V281, P36071, DOI 10.1074/jbc.M606851200; EDSALL JT, 1984, BIOTHERMODYNAMICS ST; FISH WW, 1985, BIOCHEMISTRY-US, V24, P1510, DOI 10.1021/bi00327a033; GETTINS P, 1987, BIOCHEMISTRY-US, V26, P1391, DOI 10.1021/bi00379a027; Huntington JA, 2000, NATURE, V407, P923, DOI 10.1038/35038119; Huntington JA, 1996, BIOCHEMISTRY-US, V35, P8495, DOI 10.1021/bi9604643; Izaguirre G, 2006, J BIOL CHEM, V281, P13424, DOI 10.1074/jbc.M600415200; Izaguirre G, 2003, J BIOL CHEM, V278, P51433, DOI 10.1074/jbc.M309266200; Izaguirre G, 2007, J BIOL CHEM, V282, DOI 10.1074/jbc.M702462200; Jin L, 1997, P NATL ACAD SCI USA, V94, P14683, DOI 10.1073/pnas.94.26.14683; Johnson DJD, 2006, EMBO J, V25, P2029, DOI 10.1038/sj.emboj.7601089; JORDAN RE, 1987, SCIENCE, V237, P777, DOI 10.1126/science.3649921; Karlsson G, 2004, PROTEIN EXPRES PURIF, V33, P339, DOI 10.1016/j.pep.2003.10.008; Kisker O, 2001, CANCER RES, V61, P7298; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Larsson H, 2000, CANCER RES, V60, P6723; Larsson H, 2001, J BIOL CHEM, V276, P11996, DOI 10.1074/jbc.M010170200; LAWRENCE DA, 1994, BIOCHEMISTRY-US, V33, P3643, DOI 10.1021/bi00178a022; LEWIS SD, 1985, J BIOL CHEM, V260, P192; Li W, 2004, NAT STRUCT MOL BIOL, V11, P857, DOI 10.1038/nsmb811; LINDAHL U, 1980, P NATL ACAD SCI-BIOL, V77, P6551, DOI 10.1073/pnas.77.11.6551; Miao RQ, 2002, BLOOD, V100, P3245, DOI 10.1182/blood-2002-01-0185; MILETICH JP, 1981, METHOD ENZYMOL, V80, P221; NORDENMAN B, 1977, EUR J BIOCHEM, V78, P195, DOI 10.1111/j.1432-1033.1977.tb11730.x; O'Reilly MS, 1999, SCIENCE, V285, P1926, DOI 10.1126/science.285.5435.1926; OLSON ST, 1992, J BIOL CHEM, V267, P12528; OLSON ST, 1981, J BIOL CHEM, V256, P1073; OLSON ST, 1991, J BIOL CHEM, V266, P6353; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P331, DOI 10.1016/S1050-1738(02)00183-4; Olson ST, 2002, TRENDS CARDIOVAS MED, V12, P198, DOI 10.1016/S1050-1738(02)00160-3; OLSON ST, 1993, METHOD ENZYMOL, V222, P525; OWEN W G, 1973, Thrombosis Research, V3, P705, DOI 10.1016/0049-3848(73)90017-0; PROX D, 2003, WORLD J SURG, V68, P47; Rezaie AR, 1998, J BIOL CHEM, V273, P16824, DOI 10.1074/jbc.273.27.16824; Skinner R, 1998, J MOL BIOL, V283, P9, DOI 10.1006/jmbi.1998.2083; Skinner R, 1997, J MOL BIOL, V266, P601, DOI 10.1006/jmbi.1996.0798; STREUSAND VJ, 1995, J BIOL CHEM, V270, P9043, DOI 10.1074/jbc.270.16.9043; Turk B, 1997, BIOCHEMISTRY-US, V36, P6682, DOI 10.1021/bi9702492; VONHIPPE.PH, 1969, ACCOUNTS CHEM RES, V2, P257, DOI 10.1021/ar50021a001; Wardell MR, 1997, BIOCHEMISTRY-US, V36, P13133, DOI 10.1021/bi970664u; Zhang M, 2000, NAT MED, V6, P196, DOI 10.1038/72303; Zhang WQ, 2005, BLOOD, V106, P1621, DOI 10.1182/blood-2005-02-0547; Zhou AW, 1999, BLOOD, V94, P3388, DOI 10.1182/blood.V94.10.3388.422k20_3388_3396	51	13	15	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14417	14429		10.1074/jbc.M710327200	http://dx.doi.org/10.1074/jbc.M710327200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18375953	Green Published, hybrid			2022-12-25	WOS:000255941400029
J	Chiang, N; Schwab, JM; Fredman, G; Kasuga, K; Gelman, S; Serhan, CN				Chiang, Nan; Schwab, Jan M.; Fredman, Gabrielle; Kasuga, Kie; Gelman, Simon; Serhan, Charles N.			Anesthetics Impact the Resolution of Inflammation	PLOS ONE			English	Article								Background: Local and volatile anesthetics are widely used for surgery. It is not known whether anesthetics impinge on the orchestrated events in spontaneous resolution of acute inflammation. Here we investigated whether a commonly used local anesthetic (lidocaine) and a widely used inhaled anesthetic (isoflurane) impact the active process of resolution of inflammation. Methods and Findings: Using murine peritonitis induced by zymosan and a systems approach, we report that lidocaine delayed and blocked key events in resolution of inflammation. Lidocaine inhibited both PMN apoptosis and macrophage uptake of apoptotic PMN, events that contributed to impaired PMN removal from exudates and thereby delayed the onset of resolution of acute inflammation and return to homeostasis. Lidocaine did not alter the levels of specific lipid mediators, including pro-inflammatory leukotriene B-4, prostaglandin E-2 and anti-inflammatory lipoxin A(4), in the cell-free peritoneal lavages. Addition of a lipoxin A(4) stable analog, partially rescued lidocaine-delayed resolution of inflammation. To identify protein components underlying lidocaine's actions in resolution, systematic proteomics was carried out using nanospray-liquid chromatography-tandem mass spectrometry. Lidocaine selectively up-regulated pro-inflammatory proteins including S100A8/9 and CRAMP/LL-37, and down-regulated anti-inflammatory and some pro-resolution peptides and proteins including IL-4, IL-13, TGF-(alpha) over cap and Galectin-1. In contrast, the volatile anesthetic isoflurane promoted resolution in this system, diminishing the amplitude of PMN infiltration and shortening the resolution interval (Ri) similar to 50%. In addition, isoflurane down-regulated a panel of pro-inflammatory chemokines and cytokines, as well as proteins known to be active in cell migration and chemotaxis (i.e., CRAMP and cofilin-1). The distinct impact of lidocaine and isoflurane on selective molecules may underlie their opposite actions in resolution of inflammation, namely lidocaine delayed the onset of resoluion (T-max), while isoflurane shortened resolution interval (Ri). Conclusions: Taken together, both local and volatile anesthetics impact endogenous resolution program(s), altering specific resolution indices and selective cellular/molecular components in inflammation-resolution. Isoflurane enhances whereas lidocaine impairs timely resolution of acute inflammation.	[Chiang, Nan; Schwab, Jan M.; Fredman, Gabrielle; Kasuga, Kie; Gelman, Simon; Serhan, Charles N.] Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Chiang, N (corresponding author), Brigham & Womens Hosp, Dept Anesthesiol Perioperat & Pain Med, Ctr Expt Therapeut & Reperfus Injury, 75 Francis St, Boston, MA 02115 USA.	cnserhan@zeus.bwh.harvard.edu	Kasuga, Kie/D-2308-2013; Chiang, Nan/ABA-4924-2021	Kasuga, Kie/0000-0003-0489-194X; Chiang, Nan/0000-0003-1963-1585; Schwab, Jan/0000-0001-6784-4919	NIH [GM 38765, P50-DE016191]; German Research Council [Schw 1064/1-1]; Arthritis Foundation Postdoctoral Fellowship; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [P50DE016191] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038765, R01GM038765, R37GM038765] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); German Research Council(German Research Foundation (DFG)); Arthritis Foundation Postdoctoral Fellowship; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported in part by NIH grants GM 38765 and P50-DE016191 (CNS) and the German Research Council (DFG, Schw 1064/1-1) (JMS). Kie Kasuga is the recipient of an Arthritis Foundation Postdoctoral Fellowship.	Alam S, 2006, MOL IMMUNOL, V43, P1432, DOI 10.1016/j.molimm.2005.07.025; AZAD SS, 1993, J CLIN ANESTH, V5, P122, DOI 10.1016/0952-8180(93)90139-6; Bannenberg GL, 2005, J IMMUNOL, V174, P4345, DOI 10.4049/jimmunol.174.7.4345; Biteman B, 2007, FASEB J, V21, P2257, DOI 10.1096/fj.06-7918com; Brandt L, 1967, Scand J Haematol Suppl, V2, P1; Chow CC, 2005, SHOCK, V24, P74, DOI 10.1097/01.shk.0000168526.97716.f3; Cotran RS., 1999, ROBBINS PATHOLOGIC B, P1425; CULLEN BF, 1974, ANESTHESIOLOGY, V40, P142, DOI 10.1097/00000542-197402000-00009; de Klaver MJM, 2003, ANESTH ANALG, V97, P465, DOI 10.1213/01.ANE.0000073162.27208.E9; de Rossi LW, 2002, ANESTH ANALG, V95, P583, DOI 10.1097/00000539-200209000-00017; DesMarais V, 2005, J CELL SCI, V118, P19, DOI 10.1242/jcs.01631; Dias-Baruffi M, 2003, J BIOL CHEM, V278, P41282, DOI 10.1074/jbc.M306624200; Foell D, 2007, J LEUKOCYTE BIOL, V81, P28, DOI 10.1189/jlb.0306170; Gallos G, 2004, ANESTHESIOLOGY, V101, P902, DOI 10.1097/00000542-200410000-00015; Gil CD, 2006, INFLAMM RES, V55, P99, DOI 10.1007/s00011-005-0059-4; Gilroy DW, 1999, NAT MED, V5, P698, DOI 10.1038/9550; Godson C, 2000, J IMMUNOL, V164, P1663, DOI 10.4049/jimmunol.164.4.1663; Gogos CA, 2000, J INFECT DIS, V181, P176, DOI 10.1086/315214; GOLAN DE, 2007, PRINCIPLES PHARM PAT, P985; GOLDSTEIN IM, 1977, J EXP MED, V146, P483, DOI 10.1084/jem.146.2.483; Hawkins J Mel, 2002, Dent Clin North Am, V46, P719, DOI 10.1016/S0011-8532(02)00020-4; Hayes JK, 2004, ANESTH ANALG, V98, P999, DOI 10.1213/01.ANE.0000104584.91385.1D; Kurosaka K, 2005, J IMMUNOL, V174, P6257, DOI 10.4049/jimmunol.174.10.6257; Lee HT, 2004, AM J PHYSIOL-RENAL, V286, pF111, DOI 10.1152/ajprenal.00108.2003; Levy BD, 2001, NAT IMMUNOL, V2, P612, DOI 10.1038/89759; Maddox JE, 1996, J EXP MED, V183, P137, DOI 10.1084/jem.183.1.137; Mazzocco M, 2002, GENE, V291, P233, DOI 10.1016/S0378-1119(02)00602-9; Nascimento-Silva V, 2005, AM J PHYSIOL-CELL PH, V289, pC557, DOI 10.1152/ajpcell.00045.2005; Nathan C, 2002, NATURE, V420, P846, DOI 10.1038/nature01320; Plachinta RV, 2003, ANESTHESIOLOGY, V98, P89, DOI 10.1097/00000542-200301000-00017; Rossi AG, 2006, NAT MED, V12, P1056, DOI 10.1038/nm1468; Roth J, 2003, TRENDS IMMUNOL, V24, P155, DOI 10.1016/S1471-4906(03)00062-0; SALO M, 1992, ACTA ANAESTH SCAND, V36, P201, DOI 10.1111/j.1399-6576.1992.tb03452.x; SASAGAWA S, 1991, IMMUNOPHARM IMMUNOT, V13, P607, DOI 10.3109/08923979109019726; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Sawatzky DA, 2006, AM J PATHOL, V168, P33, DOI 10.2353/ajpath.2006.050058; Schwab JM, 2007, NATURE, V447, P869, DOI 10.1038/nature05877; Serhan CN, 2008, BRIT J PHARMACOL, V153, pS200, DOI 10.1038/sj.bjp.0707489; Serhan CN, 2007, FASEB J, V21, P325, DOI 10.1096/fj.06-7227rev; Serhan CN, 2007, ANNU REV IMMUNOL, V25, P101, DOI 10.1146/annurev.immunol.25.022106.141647; Serhan CN, 2002, J EXP MED, V196, P1025, DOI 10.1084/jem.20020760; Serhan CN, 2000, J EXP MED, V192, P1197, DOI 10.1084/jem.192.8.1197; Tamaki H, 2006, GASTROENTEROLOGY, V131, P1110, DOI 10.1053/j.gastro.2006.08.023; Taniguchi T, 1999, AM J EMERG MED, V17, P548, DOI 10.1016/S0735-6757(99)90194-8; Underhill DM, 2003, J ENDOTOXIN RES, V9, P176, DOI 10.1179/096805103125001586; Verleye M, 2000, PHARMACOL RES, V41, P539, DOI 10.1006/phrs.1999.0619; Walley ER, 1996, INFECT IMMUN, V64, P4733, DOI 10.1128/IAI.64.11.4733-4738.1996; WINYARD PG, 2003, INFLAMMATION PROTOCO, P378; Yregard L, 2003, BURNS, V29, P335, DOI 10.1016/S0305-4179(03)00006-8	49	97	101	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1879	10.1371/journal.pone.0001879	http://dx.doi.org/10.1371/journal.pone.0001879			16	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382663	Green Published, gold, Green Submitted			2022-12-25	WOS:000260795400014
J	Lahdesmaki, H; Rust, AG; Shmulevich, I				Lahdesmaki, Harri; Rust, Alistair G.; Shmulevich, Ilya			Probabilistic Inference of Transcription Factor Binding from Multiple Data Sources	PLOS ONE			English	Article							OPEN-ACCESS DATABASE; REGULATORY ELEMENTS; COMPUTATIONAL IDENTIFICATION; GENE-EXPRESSION; STATISTICAL SIGNIFICANCE; SAMPLING METHOD; SEQUENCE; SITES; PREDICTION; MODEL	An important problem in molecular biology is to build a complete understanding of transcriptional regulatory processes in the cell. We have developed a flexible, probabilistic framework to predict TF binding from multiple data sources that differs from the standard hypothesis testing (scanning) methods in several ways. Our probabilistic modeling framework estimates the probability of binding and, thus, naturally reflects our degree of belief in binding. Probabilistic modeling also allows for easy and systematic integration of our binding predictions into other probabilistic modeling methods, such as expression-based gene network inference. The method answers the question of whether the whole analyzed promoter has a binding site, but can also be extended to estimate the binding probability at each nucleotide position. Further, we introduce an extension to model combinatorial regulation by several TFs. Most importantly, the proposed methods can make principled probabilistic inference from multiple evidence sources, such as, multiple statistical models (motifs) of the TFs, evolutionary conservation, regulatory potential, CpG islands, nucleosome positioning, DNase hypersensitive sites, ChIP-chip binding segments and other (prior) sequence-based biological knowledge. We developed both a likelihood and a Bayesian method, where the latter is implemented with a Markov chain Monte Carlo algorithm. Results on a carefully constructed test set from the mouse genome demonstrate that principled data fusion can significantly improve the performance of TF binding prediction methods. We also applied the probabilistic modeling framework to all promoters in the mouse genome and the results indicate a sparse connectivity between transcriptional regulators and their target promoters. To facilitate analysis of other sequences and additional data, we have developed an on-line web tool, ProbTF, which implements our probabilistic TF binding prediction method using multiple data sources. Test data set, a web tool, source codes and supplementary data are available at: http://www.probtf.org.	[Lahdesmaki, Harri; Rust, Alistair G.; Shmulevich, Ilya] Inst Syst Biol, Seattle, WA USA	Institute for Systems Biology (ISB)	Lahdesmaki, H (corresponding author), Inst Syst Biol, Seattle, WA USA.	ishmulevich@systemsbiology.org		Rust, Alistair/0000-0001-7287-192X	NIH/NIGMS [R01 GM072855, P50 GM076547]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P50GM076547, R01GM072855] Funding Source: NIH RePORTER	NIH/NIGMS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))	This work was supported by grants R01 GM072855 and P50 GM076547 from NIH/NIGMS.	AMBESI I, 2006, BMC NEUROSCIENCE S1, V7, pS8; [Anonymous], 1999, MODELLING GENE EXPRE; Bailey T L, 1995, Proc Int Conf Intell Syst Mol Biol, V3, P21; BAILEY TL, 1994, P 2 INT C INT SYST M, P28; Bajic IV, 2006, IEEE T SIGNAL PROCES, V54, P2388, DOI 10.1109/TSP.2006.873739; Barash Y, 2005, BIOINFORMATICS, V21, P596, DOI 10.1093/bioinformatics/bti041; BARASH Y, 2003, P 7 ANN INT C COMP B; Beer MA, 2004, CELL, V117, P185, DOI 10.1016/S0092-8674(04)00304-6; Berger MF, 2006, NAT BIOTECHNOL, V24, P1429, DOI 10.1038/nbt1246; Bernard A, 2005, PACIFIC SYMPOSIUM ON BIOCOMPUTING 2005, P459; Beyer A, 2006, PLOS COMPUT BIOL, V2, P615, DOI 10.1371/journal.pcbi.0020070; Blanco E, 2006, NUCLEIC ACIDS RES, V34, pD63, DOI 10.1093/nar/gkj116; Brooks SP, 2003, J COMPUT GRAPH STAT, V12, P1, DOI 10.1198/1061860031347; Bulyk ML, 2002, NUCLEIC ACIDS RES, V30, P1255, DOI 10.1093/nar/30.5.1255; Cawley S, 2004, CELL, V116, P499, DOI 10.1016/S0092-8674(04)00127-8; Chen G, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-1-r4; CHEN T, 1999, P PAC S BIOC, V4, P29; Claverie JM, 1996, COMPUT APPL BIOSCI, V12, P431; Crawford GE, 2004, P NATL ACAD SCI USA, V101, P992, DOI 10.1073/pnas.0307540100; Davidson E. H., 2001, DEV EVOLUTION; de Hoon MJL, 2004, BIOINFORMATICS, V20, P101, DOI 10.1093/bioinformatics/bth927; Eisenstein M, 2005, NAT METHODS, V2, P5, DOI 10.1038/nmeth0105-5; Fawcett T, 2006, PATTERN RECOGN LETT, V27, P861, DOI 10.1016/j.patrec.2005.10.010; Friedman N, 2004, SCIENCE, V303, P799, DOI 10.1126/science.1094068; Frith MC, 2001, BIOINFORMATICS, V17, P878, DOI 10.1093/bioinformatics/17.10.878; Gordon DB, 2005, BIOINFORMATICS, V21, P3164, DOI 10.1093/bioinformatics/bti481; GuhaThakurta D, 2006, NUCLEIC ACIDS RES, V34, P3585, DOI 10.1093/nar/gkl372; Hallikas O, 2006, CELL, V124, P47, DOI 10.1016/j.cell.2005.10.042; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Heintzman ND, 2007, CELL MOL LIFE SCI, V64, P386, DOI 10.1007/s00018-006-6295-0; Hertzberg L, 2005, J COMPUT BIOL, V12, P314, DOI 10.1089/cmb.2005.12.314; Holloway DT, 2006, IBM J RES DEV, V50, P631, DOI 10.1147/rd.506.0631; Holloway Dustin T, 2005, Genome Inform, V16, P83; Huang HY, 2004, J COMPUT BIOL, V11, P1, DOI 10.1089/106652704773416858; Hughes JD, 2000, J MOL BIOL, V296, P1205, DOI 10.1006/jmbi.2000.3519; Husmeier D, 2003, BIOINFORMATICS, V19, P2271, DOI 10.1093/bioinformatics/btg313; Husmeier D, 2005, ADV INFO KNOW PROC, P17; Jensen ST, 2005, BIOINFORMATICS, V21, P3832, DOI 10.1093/bioinformatics/bti628; Kel-Margoulis OV, 2002, NUCLEIC ACIDS RES, V30, P332, DOI 10.1093/nar/30.1.332; Kellis M, 2003, NATURE, V423, P241, DOI 10.1038/nature01644; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; LAHDESMAKI H, 2007, P 5 IEEE INT WORKSH; LAWRENCE CE, 1993, SCIENCE, V262, P208, DOI 10.1126/science.8211139; Lee TI, 2002, SCIENCE, V298, P799, DOI 10.1126/science.1075090; Lehrach WP, 2006, BIOINFORMATICS, V22, P532, DOI 10.1093/bioinformatics/bti804; Levine M, 2003, NATURE, V424, P147, DOI 10.1038/nature01763; Liu X, 2001, Pac Symp Biocomput, P127; Liu XS, 2002, NAT BIOTECHNOL, V20, P835, DOI 10.1038/nbt717; MacIsaac KD, 2006, PLOS COMPUT BIOL, V2, P201, DOI 10.1371/journal.pcbi.0020036; Maerkl SJ, 2007, SCIENCE, V315, P233, DOI 10.1126/science.1131007; Marinescu VD, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-79; Montgomery SB, 2006, BIOINFORMATICS, V22, P637, DOI 10.1093/bioinformatics/btk027; Mukherjee S, 2004, NAT GENET, V36, P1331, DOI 10.1038/ng1473; NARLIKAR L, PLOS COMPUTATIONAL B; Narlikar L, 2007, LECT NOTES COMPUT SC, V4453, P107; Narlikar L, 2006, BIOINFORMATICS, V22, pE384, DOI 10.1093/bioinformatics/btl251; Pan W, 2006, BIOINFORMATICS, V22, P795, DOI 10.1093/bioinformatics/btl011; Qi Y, 2006, NAT BIOTECHNOL, V24, P963, DOI 10.1038/nbt1233; Quandt K, 1995, NUCLEIC ACIDS RES, V23, P4878, DOI 10.1093/nar/23.23.4878; Rajewsky N, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-30; REGULY T, 2006, J BIOL, V5; Reiss DJ, 2004, BIOINFORMATICS, V20, P274, DOI 10.1093/bioinformatics/bth922; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Robert PC, 2004, MONTE CARLO STAT MET; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012; Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pW249, DOI 10.1093/nar/gkh372; Segal E, 2003, BIOINFORMATICS, V19, pi273, DOI 10.1093/bioinformatics/btg1038; Segal E, 2006, NATURE, V442, P772, DOI 10.1038/nature04979; Siddharthan R, 2005, PLOS COMPUT BIOL, V1, P534, DOI 10.1371/journal.pcbi.0010067; Siepel A, 2005, GENOME RES, V15, P1034, DOI 10.1101/gr.3715005; Sinha S, 2006, BIOINFORMATICS, V22, pE454, DOI 10.1093/bioinformatics/btl227; Sinha S, 2003, BIOINFORMATICS, V19, pi292, DOI 10.1093/bioinformatics/btg1040; SMIT AFA, 1997, REPEATMASKER COMPUTE; STADEN R, 1984, NUCLEIC ACIDS RES, V12, P505, DOI 10.1093/nar/12.1Part2.505; Steck H., 2002, ADV NEURAL INFORM PR, P697; STORMO GD, 1982, NUCLEIC ACIDS RES, V10, P2997, DOI 10.1093/nar/10.9.2997; Tamada Y, 2003, BIOINFORMATICS, V19, pII227, DOI 10.1093/bioinformatics/btg1082; Taylor J, 2006, GENOME RES, V16, P1596, DOI 10.1101/gr.4537706; Thijs G, 2002, J COMPUT BIOL, V9, P447, DOI 10.1089/10665270252935566; Thijs G, 2001, BIOINFORMATICS, V17, P1113, DOI 10.1093/bioinformatics/17.12.1113; Thomas K, 2007, MOL CELL ENDOCRINOL, V270, P1, DOI 10.1016/j.mce.2007.03.001; Tompa M, 2005, NAT BIOTECHNOL, V23, P137, DOI 10.1038/nbt1053; Warren CL, 2006, P NATL ACAD SCI USA, V103, P867, DOI 10.1073/pnas.0509843102; Wasserman WW, 2004, NAT REV GENET, V5, P276, DOI 10.1038/nrg1315; Wilkinso D.J., 2006, STOCHASTIC MODELLING; Wingender E, 2000, NUCLEIC ACIDS RES, V28, P316, DOI 10.1093/nar/28.1.316; Wu TD, 2000, BIOINFORMATICS, V16, P233, DOI 10.1093/bioinformatics/16.3.233; Xie XH, 2005, NATURE, V434, P338, DOI 10.1038/nature03441; Yuh Chiou-Hwa, 2001, P73; Zhang LG, 2007, P NATL ACAD SCI USA, V104, P3061, DOI 10.1073/pnas.0611075104; Zhou Q, 2004, BIOINFORMATICS, V20, P909, DOI 10.1093/bioinformatics/bth006	91	36	38	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1820	10.1371/journal.pone.0001820	http://dx.doi.org/10.1371/journal.pone.0001820			24	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18364997	Green Published, Green Submitted, gold			2022-12-25	WOS:000260762400003
J	Nepal, RM; Zaheen, A; Basit, W; Li, L; Berger, SA; Martin, A				Nepal, R. M.; Zaheen, A.; Basit, W.; Li, L.; Berger, S. A.; Martin, A.			AID and RAG1 do not contribute to lymphomagenesis in E mu c-myc transgenic mice	ONCOGENE			English	Article						B cells; hypermutation; activation-induced cytidine deaminase; c-myc; lymphoma; RAG	CYTIDINE DEAMINASE AID; REACTIVE B-LYMPHOCYTES; SOMATIC HYPERMUTATION; CELL LYMPHOMAS; DNA BREAKS; TRANSLOCATIONS; EXPRESSION; REGION; MOUSE; GENE	DNA breaks caused by recombination-activating gene 1 (RAG1) and activation-induced cytidine deaminase (AID) induce c-myc/immunoglobulin (Ig) heavy chain chromosomal translocations and thereby stimulate lymphomagenesis. However, constitutive expression of c-myc alone is not sufficient to induce lymphomas. Because RAG1 and AID activity occurs outside of Ig genes, we assessed whether these enzymes provide the secondary genetic lesions in El c-myc transgenic mice to promote lymphoma development. We found that the tumor incidence and tumor phenotype in E mu c-myc transgenic mice is similar in AID(+/+), AID(+/-) and AID(-/-) backgrounds in both specific pathogen-free and conventional animal facilities, indicating that AID does not contribute to lymphoma development in E mu c-myc transgenic mice. To examine the role of RAG proteins in E mu c-myc mice, we examined E mu c-myc transgenic mice that harbor the Ig-HEL heavy- and light-chain transgenes, and thus have reduced RAG expression in B cells. We found that tumor incidence was not affected by these Ig transgenes. However, we found that RAG1(-/-) E mu c-myc mice exhibited accelerated tumor development compared to controls. This data combined with our finding that E mu c-myc mice lived longer in the conventional facility than in the specific pathogen-free facility suggest an immune-mediated activity that suppresses lymphoma development.	[Nepal, R. M.; Zaheen, A.; Basit, W.; Li, L.; Berger, S. A.; Martin, A.] Univ Toronto, Dept Immunol, Toronto, ON M5S 1A8, Canada; [Berger, S. A.] Univ Hlth Network, Arthritis & Autoimmun Res Ctr, Toronto, ON, Canada	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Martin, A (corresponding author), Univ Toronto, Dept Immunol, Med Sci Bldg 5265, Toronto, ON M5S 1A8, Canada.	alberto.martin@utoronto.ca		Martin, Alberto/0000-0002-0795-0418				ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; CREWS S, 1982, SCIENCE, V218, P1319, DOI 10.1126/science.7146913; Crouch EE, 2007, J EXP MED, V204, P1145, DOI 10.1084/jem.20061952; DALLAFAVERA R, 1982, P NATL ACAD SCI-BIOL, V79, P7824, DOI 10.1073/pnas.79.24.7824; Di Nola JM, 2007, ANNU REV BIOCHEM, V76, P1, DOI 10.1146/annurev.biochem.76.061705.090740; Dorsett Y, 2007, J EXP MED, V204, P2225, DOI 10.1084/jem.20070884; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Eischen CM, 1999, GENE DEV, V13, P2658, DOI 10.1101/gad.13.20.2658; Fang W, 1998, IMMUNITY, V9, P35, DOI 10.1016/S1074-7613(00)80586-5; Franco S, 2006, MOL CELL, V21, P201, DOI 10.1016/j.molcel.2006.01.005; Franco S, 2006, DNA REPAIR, V5, P1030, DOI 10.1016/j.dnarep.2006.05.024; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; HARRIS AW, 1988, J EXP MED, V167, P353, DOI 10.1084/jem.167.2.353; KORSMEYER SJ, 1992, ANNU REV IMMUNOL, V10, P785, DOI 10.1146/annurev.immunol.10.1.785; Kotani A, 2007, P NATL ACAD SCI USA, V104, P1616, DOI 10.1073/pnas.0610732104; MASON DY, 1992, INT IMMUNOL, V4, P163, DOI 10.1093/intimm/4.2.163; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Muschen M, 2000, J EXP MED, V192, P1833, DOI 10.1084/jem.192.12.1833; Pasqualucci L, 2001, NATURE, V412, P341, DOI 10.1038/35085588; Prasad VS, 1996, CYTOMETRY, V23, P131, DOI 10.1002/(SICI)1097-0320(19960201)23:2<131::AID-CYTO7>3.0.CO;2-N; Raghavan SC, 2004, NATURE, V428, P88, DOI 10.1038/nature02355; Ramiro AR, 2004, CELL, V118, P431, DOI 10.1016/j.cell.2004.08.006; Ramiro AR, 2006, NATURE, V440, P105, DOI 10.1038/nature04495; Shen HM, 1998, SCIENCE, V280, P1750, DOI 10.1126/science.280.5370.1750; Smith DP, 2005, ONCOGENE, V24, P3544, DOI 10.1038/sj.onc.1208399; VANLOHUIZEN M, 1991, CELL, V65, P737, DOI 10.1016/0092-8674(91)90382-9	27	24	24	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG	2008	27	34					4752	4756		10.1038/onc.2008.111	http://dx.doi.org/10.1038/onc.2008.111			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408759				2022-12-25	WOS:000258236300013
J	Yu, JS; Koujak, S; Nagase, S; Li, CM; Su, T; Wang, X; Keniry, M; Memeo, L; Rojtman, A; Mansukhani, M; Hibshoosh, H; Tycko, B; Parsons, R				Yu, J. S.; Koujak, S.; Nagase, S.; Li, C-M; Su, T.; Wang, X.; Keniry, M.; Memeo, L.; Rojtman, A.; Mansukhani, M.; Hibshoosh, H.; Tycko, B.; Parsons, R.			PCDH8, the human homolog of PAPC, is a candidate tumor suppressor of breast cancer	ONCOGENE			English	Article						PCDH8; protocadherin; breast cancer; tumor suppressor	TRANSCRIPTION FACTOR SNAIL; PARAXIAL PROTOCADHERIN; STRUCTURAL BASIS; CELL MOVEMENTS; CHROMOSOME 13Q; CADHERIN; MORPHOGENESIS; ADHESION; GENE; PROLIFERATION	Carcinoma is an altered state of tissue differentiation in which epithelial cells no longer respond to cues that keep them in their proper position. A break down in these cues has disastrous consequences not only in cancer but also in embryonic development when cells of various lineages must organize into discrete entities to form a body plan. Paraxial protocadherin (PAPC) is an adhesion protein with six cadherin repeats that organizes the formation and polarity of developing cellular structures in frog, fish and mouse embryos. Here we show that protocadherin-8 (PCDH8), the human ortholog of PAPC, is inactivated through either mutation or epigenetic silencing in a high fraction of breast carcinomas. Loss of PCDH8 expression is associated with loss of heterozygosity, partial promoter methylation, and increased proliferation. Complementation of mutant tumor cell line HCC2218 with wild-type PCDH8 inhibited its growth. Two tumor mutants, E146K and R343H, were defective for inhibition of cell growth and migration. Sur prisingly, the E146K mutant transformed the human mammary epithelial cell line MCF10A and sustained the expression of cyclin D1 and MYC without epidermal growth factor. We propose that loss of PCDH8 promotes oncogenesis in epithelial human cancers by disrupting cell-cell communication dedicated to tissue organization and repression of mitogenic signaling.	[Parsons, R.] Columbia Univ, Inst Canc Genet, Dept Pathol & Cell Biol, New York, NY 10032 USA; [Parsons, R.] Columbia Univ, Dept Med, New York, NY 10032 USA	Columbia University; Columbia University	Parsons, R (corresponding author), Columbia Univ, Inst Canc Genet, Dept Pathol & Cell Biol, 1130 St Nicholas Ave, New York, NY 10032 USA.	rep15@columbia.edu		Memeo, Lorenzo/0000-0003-4251-7203; Parsons, Ramon/0000-0002-6656-3514; Nagase, Satoru/0000-0001-5212-1128	NATIONAL CANCER INSTITUTE [R01CA082783] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA082783-05, R01 CA082783-04, R01 CA082783-07, R01 CA082783, R01 CA082783-06] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Batlle E, 2000, NAT CELL BIOL, V2, P84, DOI 10.1038/35000034; Berx G, 1998, HUM MUTAT, V12, P226, DOI 10.1002/(SICI)1098-1004(1998)12:4<226::AID-HUMU2>3.0.CO;2-D; Boggon TJ, 2002, SCIENCE, V296, P1308, DOI 10.1126/science.1071559; Cano A, 2000, NAT CELL BIOL, V2, P76, DOI 10.1038/35000025; Chou JL, 1999, BREAST CANCER RES TR, V55, P267, DOI 10.1023/A:1006217413089; Cox C, 2005, P NATL ACAD SCI USA, V102, P4542, DOI 10.1073/pnas.0408593102; Debnath J, 2003, J CELL BIOL, V163, P315, DOI 10.1083/jcb.200304159; Debnath J, 2003, METHODS, V30, P256, DOI 10.1016/S1046-2023(03)00032-X; Eiriksdottir G, 1998, EUR J CANCER, V34, P2076, DOI 10.1016/S0959-8049(98)00241-X; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Gumbiner BM, 2005, NAT REV MOL CELL BIO, V6, P622, DOI 10.1038/nrm1699; Hukriede NA, 2003, DEV CELL, V4, P83, DOI 10.1016/S1534-5807(02)00398-2; Imoto I, 2006, CANCER RES, V66, P4617, DOI 10.1158/0008-5472.CAN-05-4437; Kim SH, 1998, DEVELOPMENT, V125, P4681; Kim SH, 2000, CURR BIOL, V10, P821, DOI 10.1016/S0960-9822(00)00580-7; LISITSYN N, 1993, SCIENCE, V259, P946, DOI 10.1126/science.8438152; Medina A, 2004, EMBO J, V23, P3249, DOI 10.1038/sj.emboj.7600329; Melamed J, 1997, CLIN CANCER RES, V3, P1867; Muthuswamy SK, 2001, NAT CELL BIOL, V3, P785, DOI 10.1038/ncb0901-785; Nagar B, 1996, NATURE, V380, P360, DOI 10.1038/380360a0; Rhee J, 2003, DEV BIOL, V254, P248, DOI 10.1016/S0012-1606(02)00085-4; SHAPIRO L, 1995, NATURE, V374, P327, DOI 10.1038/374327a0; Sjoblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427; Suyama K, 2002, CANCER CELL, V2, P301, DOI 10.1016/S1535-6108(02)00150-2; Unterseher F, 2004, EMBO J, V23, P3259, DOI 10.1038/sj.emboj.7600332; WAZER DE, 1995, P NATL ACAD SCI USA, V92, P3687, DOI 10.1073/pnas.92.9.3687; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yin ZN, 1999, ONCOGENE, V18, P7576, DOI 10.1038/sj.onc.1203203; Ying J, 2006, ONCOGENE, V25, P1070, DOI 10.1038/sj.onc.1209154; Zhong Y, 1999, J CELL BIOL, V144, P351, DOI 10.1083/jcb.144.2.351	30	121	127	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG	2008	27	34					4657	4665		10.1038/onc.2008.101	http://dx.doi.org/10.1038/onc.2008.101			9	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	334QM	18408767	Green Accepted			2022-12-25	WOS:000258236300004
J	Thum, T; Borlak, J				Thum, Thomas; Borlak, Juergen			LOX-1 receptor blockade abrogates oxLDL-induced oxidative DNA damage and prevents activation of the transcriptional repressor Oct-1 in human coronary arterial endothelium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; OXIDIZED LDL; MITOCHONDRIAL-DNA; HYDROGEN-PEROXIDE; GENE-EXPRESSION; SMOOTH-MUSCLE; IN-VIVO; CELLS; PROMOTER; STRESS	Activation of the lectin-like oxLDL receptor (LOX-1) promotes atherosclerosis. Oxidized LDL (oxLDL) increases production of reactive oxygen species (ROS) and leads to the development of endothelial dysfunction. The molecular causes for oxLDL to induce oxidative DNA damage and metabolic dysfunction remain uncertain. Here we report treatment of cultured human coronary arterial endothelial cells (HCAEC) with oxLDL to cause oxidative DNA damage as determined by a 3-fold increase in 8-OH-desoxyguanosine adduct formation and a 4-fold induction of the growth arrest and DNA damage-inducible transcripts GADD45 and GADD153. Oxidative stress resulted in activation of Oct-1, a transcriptional repressor of various vascular cytochrome P450 (CYP) monooxygenases. Activation of Oct-1 was protein kinaseC(PKC)-mediated. Binding of Oct-1 to promoter sequences of CYP monooxygenases was increased upon treatment of HCAEC with oxLDL. This resulted in repressed production of endothelium-derived hyperpolarization factor 11,12-epoxyeicosatrieonic acid. Small interference RNA-mediated functional knockdown of Oct-1 prevented oxLDL-mediated silencing of CYP expression. Inhibition of LOX-1 attenuated oxLDL-mediated endothelial DNA damage, Oct-1/DNA binding, and reversed impaired production of EDHF. Taken collectively, oxLDL induced oxidative DNA damage and activation of Oct-1 to result in metabolic dysfunction of coronary arterial endothelium.	[Thum, Thomas; Borlak, Juergen] Fraunhofer Inst Toxicol & Expt Med, Ctr Drug Res & Med Biotechnol, D-30625 Hannover, Germany; [Thum, Thomas] Univ Wurzburg, Med Klin 1, D-97080 Wurzburg, Germany	Fraunhofer Gesellschaft; University of Wurzburg	Borlak, J (corresponding author), Fraunhofer Inst Toxicol & Expt Med, Ctr Drug Res & Med Biotechnol, Nikolai Fuchs Str 1, D-30625 Hannover, Germany.	borlak@item.fraunhofer.de		Thum, Thomas/0000-0003-4360-1511				Aikawa M, 2002, CIRCULATION, V106, P1390, DOI 10.1161/01.CIR.0000028465.52694.9B; Andreassi MG, 2003, TRENDS CARDIOVAS MED, V13, P270, DOI 10.1016/S1050-1738(03)00109-9; Ballinger SW, 2000, CIRC RES, V86, P960, DOI 10.1161/01.RES.86.9.960; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Bennett MR, 2001, CIRC RES, V88, P648, DOI 10.1161/hh0701.089955; Boulos S, 2007, J NEUROSCI RES, V85, P3089, DOI 10.1002/jnr.21429; Cai H, 2000, CIRC RES, V87, P840, DOI 10.1161/01.RES.87.10.840; Carpenter KLH, 2003, FEBS LETT, V553, P145, DOI 10.1016/S0014-5793(03)01007-X; Chen JW, 2006, BIOCHEM J, V393, P255, DOI 10.1042/BJ20050845; Chen JW, 2004, CIRC RES, V94, P370, DOI 10.1161/01.RES.0000113782.07824.BE; Chen KH, 2000, CARCINOGENESIS, V21, P1017, DOI 10.1093/carcin/21.5.1017; Cominacini L, 1998, J HYPERTENS, V16, P1913, DOI 10.1097/00004872-199816121-00010; DeFlora S, 1997, FASEB J, V11, P1021, DOI 10.1096/fasebj.11.12.9337155; Fadel BM, 1999, J BIOL CHEM, V274, P20376, DOI 10.1074/jbc.274.29.20376; Federici M, 2005, J CLIN INVEST, V115, P3494, DOI 10.1172/JCI26052; Fleming I, 2004, PHARMACOL RES, V49, P525, DOI 10.1016/j.phrs.2003.11.016; Gajdusek C, 2001, J CELL PHYSIOL, V188, P8, DOI 10.1002/jcp.1091; Galle J, 2001, KIDNEY INT, V59, pS120, DOI 10.1046/j.1523-1755.2001.59780120.x; GROENEN MAM, 1992, NUCLEIC ACIDS RES, V20, P4311, DOI 10.1093/nar/20.16.4311; Holvoet P, 1998, CIRCULATION, V98, P1487, DOI 10.1161/01.CIR.98.15.1487; Hu B, 2003, BIOCHEM BIOPH RES CO, V307, P1008, DOI 10.1016/S0006-291X(03)01295-6; Inoue K, 2005, CIRC RES, V97, P176, DOI 10.1161/01.RES.0000174286.73200.d4; Inoue T, 2001, CLIN CHIM ACTA, V305, P115, DOI 10.1016/S0009-8981(00)00426-5; Ishino S, 2007, ATHEROSCLEROSIS, V195, P48, DOI 10.1016/j.atherosclerosis.2006.11.031; Jang JH, 2002, ANN NY ACAD SCI, V973, P228, DOI 10.1111/j.1749-6632.2002.tb04639.x; Kataoka H, 1999, CIRCULATION, V99, P3110, DOI 10.1161/01.CIR.99.24.3110; Klaunig JE, 2004, ANNU REV PHARMACOL, V44, P239, DOI 10.1146/annurev.pharmtox.44.101802.121851; Lee SH, 2001, TRENDS CARDIOVAS MED, V11, P148, DOI 10.1016/S1050-1738(01)00094-9; Li DY, 2003, CIRCULATION, V107, P612, DOI 10.1161/01.CIR.0000047276.52039.FB; Li LX, 1998, ENDOTHELIUM-NEW YORK, V6, P1, DOI 10.3109/10623329809053400; Lin K, 2000, P NATL ACAD SCI USA, V97, P9385, DOI 10.1073/pnas.170282597; Loscalzo J, 2001, CIRC RES, V88, P756, DOI 10.1161/hh0801.089861; Low FM, 2007, BLOOD, V109, P2611, DOI 10.1182/blood-2006-09-048728; Mango R, 2005, CIRC RES, V97, P152, DOI 10.1161/01.RES.0000174563.62625.8e; Martinet W, 2002, CIRCULATION, V106, P927, DOI 10.1161/01.CIR.0000026393.47805.21; Mehta JL, 2007, CIRC RES, V100, P1634, DOI 10.1161/CIRCRESAHA.107.149724; Mehta JL, 2003, ARTERIOSCL THROM VAS, V23, P2203, DOI 10.1161/01.ATV.0000094411.98127.5F; Melaragno MG, 2004, J MOL CELL CARDIOL, V37, P881, DOI 10.1016/j.yjmcc.2004.06.018; Moriwaki H, 1998, ARTERIOSCL THROM VAS, V18, P1541, DOI 10.1161/01.ATV.18.10.1541; NICOL CJ, 1995, NAT GENET, V10, P181, DOI 10.1038/ng0695-181; Niehof M, 2001, J BIOL CHEM, V276, P9016, DOI 10.1074/jbc.M009284200; Outinen PA, 1998, BIOCHEM J, V332, P213, DOI 10.1042/bj3320213; Phillips K, 2000, J MOL BIOL, V302, P1023, DOI 10.1006/jmbi.2000.4107; Rundlof AK, 2001, J BIOL CHEM, V276, P30542, DOI 10.1074/jbc.M101452200; Saller F, 2006, BLOOD CELL MOL DIS, V36, P373, DOI 10.1016/j.bcmd.2005.12.038; Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0; Schmid H, 2003, KIDNEY INT, V64, P356, DOI 10.1046/j.1523-1755.2003.00074.x; Schubart DB, 1996, NATURE, V383, P538, DOI 10.1038/383538a0; Schwachtgen JL, 1998, BLOOD, V92, P1247, DOI 10.1182/blood.V92.4.1247.416k08_1247_1258; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; Sterling K, 1996, MOL PHARMACOL, V49, P329; Suzuki T, 2002, CLIN BIOCHEM, V35, P347, DOI 10.1016/S0009-9120(02)00326-0; Taddei F, 1997, SCIENCE, V278, P128, DOI 10.1126/science.278.5335.128; Taddei S, 2006, J AM COLL CARDIOL, V48, P508, DOI 10.1016/j.jacc.2006.04.074; Tanigawa H, 2006, ATHEROSCLEROSIS, V188, P245, DOI 10.1016/j.atherosclerosis.2005.10.046; Tantin D, 2005, CANCER RES, V65, P10750, DOI 10.1158/0008-5472.CAN-05-2399; Thum T, 2000, LANCET, V355, P979, DOI 10.1016/S0140-6736(00)99016-0; Thum T, 2004, CIRC RES, V94, pE1, DOI 10.1161/01.RES.0000110081.03480.E9; Thum T, 2000, FASEB J, V14, P740, DOI 10.1096/fasebj.14.5.740; Thum T, 2007, CIRC RES, V100, P434, DOI 10.1161/01.RES.0000257912.78915.af; Tong T, 2001, EXP CELL RES, V269, P64, DOI 10.1006/excr.2001.5312; Wei YH, 1998, ANN NY ACAD SCI, V854, P155, DOI 10.1111/j.1749-6632.1998.tb09899.x; Zhao HC, 2000, CANCER RES, V60, P6276; Zheng L, 2003, CELL, V114, P255, DOI 10.1016/S0092-8674(03)00552-X; Zmijewski JW, 2005, AM J PHYSIOL-HEART C, V289, pH852, DOI 10.1152/ajpheart.00015.2005	65	48	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19456	19464		10.1074/jbc.M708309200	http://dx.doi.org/10.1074/jbc.M708309200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18390905	hybrid			2022-12-25	WOS:000257387600032
J	Tajeddine, N; Galluzzi, L; Kepp, O; Hangen, E; Morselli, E; Senovilla, L; Araujo, N; Pinna, G; Larochette, N; Zamzami, N; Modjtahedi, N; Harel-Bellan, A; Kroemer, G				Tajeddine, N.; Galluzzi, L.; Kepp, O.; Hangen, E.; Morselli, E.; Senovilla, L.; Araujo, N.; Pinna, G.; Larochette, N.; Zamzami, N.; Modjtahedi, N.; Harel-Bellan, A.; Kroemer, G.			Hierarchical involvement of Bak, VDAC1 and Bax in cisplatin-induced cell death	ONCOGENE			English	Article						apoptosis; Bcl-2 family; caspases; mitochondria; non-small cell lung cancer (NSCLC); reactive oxygen species (ROS)	DEPENDENT ANION CHANNEL; MITOCHONDRIAL-MEMBRANE PERMEABILIZATION; ADENINE-NUCLEOTIDE TRANSLOCATOR; TRANSITION PORE; CYTOCHROME-C; LUNG-CANCER; APOPTOSIS; PROTEINS; DAMAGE; BCL-2	Following the screening of a battery of distinct small-interfering RNAs that target various components of the apoptotic machinery, we found that knockdown of the voltage-dependent anion channel 1 (VDAC1) was particularly efficient in preventing cell death induced by cisplatin (CDDP) in non-small cell lung cancer cells. Both the downregulation of VDAC1 and its chemical inhibition with 4,4'-diisothiocyanatostilbene-2,2'-disulfonic acid reduced the apoptosis-associated modi. cations induced by CDDP, including mitochondrial transmembrane potential dissipation and plasma membrane permeabilization. VDAC1 inhibition strongly reduced the CDDP-induced conformational activation of Bax, yet had no discernible effect on the activation of Bak, suggesting that VDAC1 acts downstream of Bak and upstream of Bax. Accordingly, knockdown of Bak abolished the activation of Bax, whereas Bax downregulation had no effect on Bak activation. In VDAC1-depleted cells, the failure of CDDP to activate Bax could be reversed by means of the Bcl-2/Bcl-XL antagonist ABT-737, which concomitantly restored CDDP cytotoxicity. Altogether, these results delineate a novel pathway for the induction of mitochondrial membrane permeabilization (MMP) in the course of CDDP-induced cell death that involves a hierarchical contribution of Bak, VDAC1 and Bax. Moreover, our data suggest that VDAC1 may act as a facultative regulator/effector of MMP, depending on the initial cytotoxic event.	[Tajeddine, N.; Galluzzi, L.; Kepp, O.; Hangen, E.; Morselli, E.; Senovilla, L.; Zamzami, N.; Modjtahedi, N.; Kroemer, G.] Inst Gustave Roussy, INSERM, U848, F-94805 Villejuif, France; [Tajeddine, N.; Galluzzi, L.; Kepp, O.; Hangen, E.; Morselli, E.; Senovilla, L.; Araujo, N.; Pinna, G.; Zamzami, N.; Modjtahedi, N.; Harel-Bellan, A.; Kroemer, G.] Univ Paris 11, Villejuif, France; [Araujo, N.; Pinna, G.; Harel-Bellan, A.] Inst Andre Lwoff, Lab Epigenet & Canc, CNRS, FRE 2944, Villejuif, France; [Larochette, N.] Inst Biol Physicochim, Lab Biol Cellulaire & Mol Secret, CNRS, UPR1929, F-75005 Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UNICANCER; Gustave Roussy; UDICE-French Research Universities; Universite Paris Saclay; Centre National de la Recherche Scientifique (CNRS); Centre National de la Recherche Scientifique (CNRS)	Kroemer, G (corresponding author), Inst Gustave Roussy, INSERM, U848, PR1,Pavillon Rech 1,39 Rue Camille Desmoulins, F-94805 Villejuif, France.	kroemer@igr.fr	MODJTAHEDI, Nazanine/D-4377-2017; KROEMER, Guido/B-4263-2013; Galluzzi, Lorenzo/AAH-3286-2021; Kepp, Oliver/N-2763-2017; Harel-Bellan, Annick/M-9795-2015; LAROCHETTE, Nathanael/R-4298-2017; Galluzzi, Lorenzo/K-2709-2012; Galluzzi, Lorenzo/AAG-6432-2019; Kepp, Oliver/GPX-8627-2022; Kroemer, Guido/AAY-9859-2020; Senovilla, Laura/AAX-5599-2021; Galluzzi, Lorenzo/AAG-6294-2019	KROEMER, Guido/0000-0002-9334-4405; Kepp, Oliver/0000-0002-6081-9558; LAROCHETTE, Nathanael/0000-0002-7936-678X; Galluzzi, Lorenzo/0000-0003-2257-8500; Senovilla, Laura/0000-0001-6887-2436; Harel-Bellan, Annick/0000-0002-2339-153X; PINNA, Guillaume/0000-0001-7841-7250; MODJTAHEDI, NAZANINE/0000-0002-1832-0710				Baines CP, 2007, NAT CELL BIOL, V9, P550, DOI 10.1038/ncb1575; Bartz SR, 2006, MOL CELL BIOL, V26, P9377, DOI 10.1128/MCB.01229-06; Belzacq AS, 2002, BIOCHIMIE, V84, P167, DOI 10.1016/S0300-9084(02)01366-4; Berndtsson M, 2007, INT J CANCER, V120, P175, DOI 10.1002/ijc.22132; Brenner C, 2006, ONCOGENE, V25, P4744, DOI 10.1038/sj.onc.1209609; Brenner C, 2000, ONCOGENE, V19, P329, DOI 10.1038/sj.onc.1203298; Castedo M, 2003, ANN NY ACAD SCI, V1010, P19, DOI 10.1196/annals.1299.004; Chandra D, 2005, J BIOL CHEM, V280, P19051, DOI 10.1074/jbc.M501391200; Cheng EHY, 2003, SCIENCE, V301, P513, DOI 10.1126/science.1083995; Cosaert J, 2002, BRIT J CANCER, V87, P825, DOI 10.1038/sj.bjc.6600540; Criollo A, 2007, APOPTOSIS, V12, P3, DOI 10.1007/s10495-006-0328-x; Galluzzi L, 2007, NAT CELL BIOL, V9, P487, DOI 10.1038/ncb0507-487; Galluzzi L, 2007, APOPTOSIS, V12, P803, DOI 10.1007/s10495-007-0720-1; Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950; Griffiths GJ, 1999, J CELL BIOL, V144, P903, DOI 10.1083/jcb.144.5.903; Grimm S, 2007, APOPTOSIS, V12, P841, DOI 10.1007/s10495-007-0747-3; Kepp O, 2007, EMBO J, V26, P825, DOI 10.1038/sj.emboj.7601533; Kroemer G, 2007, PHYSIOL REV, V87, P99, DOI 10.1152/physrev.00013.2006; Lalier L, 2007, APOPTOSIS, V12, P887, DOI 10.1007/s10495-007-0749-1; Lorenzo HK, 1999, CELL DEATH DIFFER, V6, P516, DOI 10.1038/sj.cdd.4400527; Mandic A, 2003, J BIOL CHEM, V278, P9100, DOI 10.1074/jbc.M210284200; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; Modjtahedi N, 2006, TRENDS CELL BIOL, V16, P264, DOI 10.1016/j.tcb.2006.03.008; Olaussen KA, 2006, NEW ENGL J MED, V355, P983, DOI 10.1056/NEJMoa060570; Oltersdorf T, 2005, NATURE, V435, P677, DOI 10.1038/nature03579; Perfettini JL, 2004, NAT CELL BIOL, V6, P386, DOI 10.1038/ncb0504-386; Ravagnan L, 2002, J CELL PHYSIOL, V192, P131, DOI 10.1002/jcp.10111; Reed JC, 2006, CELL DEATH DIFFER, V13, P1378, DOI 10.1038/sj.cdd.4401975; Rouge TD, 2007, CANCER RES, V67, P6253, DOI 10.1158/0008-5472.CAN-07-0538; Rudin CM, 2003, CANCER RES, V63, P312; Seve Pascal, 2005, Current Medicinal Chemistry - Anti-Cancer Agents, V5, P73, DOI 10.2174/1568011053352604; Shafir I, 1998, J BIOENERG BIOMEMBR, V30, P499, DOI 10.1023/A:1020598315287; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Shimizu S, 2000, ONCOGENE, V19, P4309, DOI 10.1038/sj.onc.1203788; Shimizu S, 2001, J CELL BIOL, V152, P237, DOI 10.1083/jcb.152.2.237; Shimizu S, 2000, J BIOL CHEM, V275, P12321, DOI 10.1074/jbc.275.16.12321; ShoshanBarmatz V, 1996, FEBS LETT, V386, P205, DOI 10.1016/0014-5793(96)00442-5; Siddik ZH, 2003, ONCOGENE, V22, P7265, DOI 10.1038/sj.onc.1206933; Tarze A, 2007, ONCOGENE, V26, P2606, DOI 10.1038/sj.onc.1210074; THINNES FP, 1990, BIOL CHEM H-S, V371, P1047, DOI 10.1515/bchm3.1990.371.2.1047; Wang GQ, 2001, J BIOL CHEM, V276, P34307, DOI 10.1074/jbc.M103526200; Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367; Zamzami N, 2005, BIOCHEM BIOPH RES CO, V331, P685, DOI 10.1016/j.bbrc.2005.04.013; ZAMZAMI N, 2003, METH MOL B, V282, P103; Zermati Y, 2007, MOL CELL, V28, P624, DOI 10.1016/j.molcel.2007.09.030; Zhang K, 2001, MOL PHARMACOL, V59, P837, DOI 10.1124/mol.59.4.837	47	168	176	1	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL	2008	27	30					4221	4232		10.1038/onc.2008.63	http://dx.doi.org/10.1038/onc.2008.63			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	324DB	18362892				2022-12-25	WOS:000257496800009
J	Bhoumik, A; Singha, N; O'Connell, MJ; Ronai, ZA				Bhoumik, Anindita; Singha, Netai; O'Connell, Matthew J.; Ronai, Ze'ev A.			Regulation of TIP60 by ATF2 modulates ATM activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-DAMAGE RESPONSE; HISTONE ACETYLASE COMPLEX; DOUBLE-STRAND BREAKS; S-PHASE CHECKPOINT; TRANSCRIPTION FACTOR-2; DEPENDENT PHOSPHORYLATION; REPAIR; PATHWAY; ACETYLTRANSFERASE; DEGRADATION	TIP60 (HTATIP) is a histone acetyltransferase (HAT) whose function is critical in regulating ataxia-telangiectasia mutated (ATM) activation, gene expression, and chromatin acetylation in DNA repair. Here we show that under non-stressed conditions, activating transcription factor-2 (ATF2) in cooperation with Cul3 ubiquitin ligase promotes degradation of TIP60, thereby attenuating its HAT activity. Inhibiting either ATF2 or Cul3 expression by small interfering RNA stabilizes the TIP60 protein. ATF2 association with TIP60 on chromatin is decreased following exposure to ionizing radiation (IR), resulting in enhanced TIP60 stability and activity. We also identified a panel of melanoma and prostate cancer cell lines whose ATF2 expression is inversely correlated with TIP60 levels and ATM activation after IR. Inhibition of ATF2 expression in these lines restored TIP60 protein levels and both basal and IR-induced levels of ATM activity. Our study provides novel insight into regulation of ATM activation by ATF2-dependent control of TIP60 stability and activity.	[Bhoumik, Anindita; Singha, Netai; Ronai, Ze'ev A.] Burnham Inst Med Res, Signal Transduct Program, La Jolla, CA 92037 USA; [O'Connell, Matthew J.] Mt Sinai Sch Med, Dept Oncol Sci, New York, NY 10029 USA	Sanford Burnham Prebys Medical Discovery Institute; Icahn School of Medicine at Mount Sinai	Ronai, ZA (corresponding author), Burnham Inst Med Res, Signal Transduct Program, La Jolla, CA 92037 USA.	ronai@burnham.org		RONAI, ZEEV/0000-0002-3859-0400	NCI NIH HHS [CA 099961, CA100076] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA099961, R01CA100076, R56CA100076] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson L, 2001, MOL CELL BIOL, V21, P1719, DOI 10.1128/MCB.21.5.1719-1729.2001; Bakkenist CJ, 2003, NATURE, V421, P499, DOI 10.1038/nature01368; Bao SD, 2001, NATURE, V411, P969, DOI 10.1038/35082110; Berger AJ, 2003, CANCER RES, V63, P8103; Berns K, 2004, NATURE, V428, P431, DOI 10.1038/nature02371; Bhoumik A, 2005, MOL CELL, V18, P577, DOI 10.1016/j.molcel.2005.04.015; Bhoumik A, 2002, J CLIN INVEST, V110, P643, DOI 10.1172/JCI200216081; Bird AW, 2002, NATURE, V419, P411, DOI 10.1038/nature01035; Brummelkamp TR, 2002, SCIENCE, V296, P550, DOI 10.1126/science.1068999; Chen MJ, 2001, J BIOL CHEM, V276, P16580, DOI 10.1074/jbc.M008871200; Cho SG, 2001, MOL CELL BIOL, V21, P8398, DOI 10.1128/MCB.21.24.8398-8413.2001; Firestein R, 1998, J BIOL CHEM, V273, P5892, DOI 10.1074/jbc.273.10.5892; FISHERADAMS G, 1995, EMBO J, V14, P1468, DOI 10.1002/j.1460-2075.1995.tb07133.x; Fuchs SY, 1999, MOL CELL BIOL, V19, P3289; Furukawa M, 2005, MOL CELL BIOL, V25, P162, DOI 10.1128/MCB.25.1.162-171.2005; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Legube G, 2002, EMBO J, V21, P1704, DOI 10.1093/emboj/21.7.1704; Li S, 2000, NATURE, V406, P210, DOI 10.1038/35018134; Lim DS, 2000, NATURE, V404, P613, DOI 10.1038/35007091; Lou ZK, 2003, NATURE, V421, P957, DOI 10.1038/nature01447; Matsuoka S, 1998, SCIENCE, V282, P1893, DOI 10.1126/science.282.5395.1893; Murr R, 2006, NAT CELL BIOL, V8, P91, DOI 10.1038/ncb1343; Nakanishi K, 2002, NAT CELL BIOL, V4, P913, DOI 10.1038/ncb879; Neuwald AF, 1999, GENOME RES, V9, P27; Ogryzko VV, 1998, CELL, V94, P35, DOI 10.1016/S0092-8674(00)81219-2; Ohtake F, 2007, NATURE, V446, P562, DOI 10.1038/nature05683; Putnik J, 2007, BBA-MOL BASIS DIS, V1772, P1211, DOI 10.1016/j.bbadis.2007.09.006; Qin S, 2002, MOL CELL BIOL, V22, P8353, DOI 10.1128/MCB.22.23.8353-8365.2002; Shiloh Y, 2003, NAT REV CANCER, V3, P155, DOI 10.1038/nrc1011; Siliciano JD, 1997, GENE DEV, V11, P3471, DOI 10.1101/gad.11.24.3471; Sorensen CS, 2003, CANCER CELL, V3, P247, DOI 10.1016/S1535-6108(03)00048-5; Sun YL, 2005, P NATL ACAD SCI USA, V102, P13182, DOI 10.1073/pnas.0504211102; Tamburini BA, 2005, MOL CELL BIOL, V25, P4903, DOI 10.1128/MCB.25.12.4903-4913.2005; van den Heuvel S, 2004, CURR BIOL, V14, pR59, DOI 10.1016/j.cub.2003.12.044; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7	38	45	52	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17605	17614		10.1074/jbc.M802030200	http://dx.doi.org/10.1074/jbc.M802030200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18397884	Green Published, hybrid			2022-12-25	WOS:000256720600067
J	Mionnet, C; Bogliolo, S; Arkowitz, RA				Mionnet, Cyril; Bogliolo, Stephanie; Arkowitz, Robert A.			Oligomerization regulates the localization of Cdc24, the Cdc42 activator in Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUANINE-NUCLEOTIDE-EXCHANGE; DBL HOMOLOGY DOMAIN; CELL POLARITY; SIGNAL-TRANSDUCTION; SCAFFOLD PROTEIN; STE5 SCAFFOLD; GROWTH SITE; SELECTION; COMPLEX; RAS	Guanine nucleotide exchange factor activation of Rho G-proteins is critical for cytoskeletal reorganization. In the yeast Saccharomyces cerevisiae, the sole guanine nucleotide exchange factor for the Rho G-protein Cdc42p, Cdc24p, is essential for its site-specific activation. Several mammalian exchange factors have been shown to oligomerize; however, the function of this homotypic interaction is unclear. Here we show that Cdc24p forms oligomers in yeast via its catalytic Db1 homology domain. Mutation of residues critical for Cdc24p oligomerization also perturbs the localization of this exchange factor yet does not alter its catalytic activity in vitro. Chemically induced oligomerization of one of these oligomerization-defective mutants partially restored its localization to the bud tip and nucleus. Furthermore, chemically induced oligomerization of wild-type Cdc24p does not affect in vitro exchange factor activity, yet it results in a decrease of activated Cdc42p in vivo and the presence of Cdc24p in the nucleus at all cell cycle stages. Together, our results suggest that Cdc24p oligomerization regulates Cdc42p activation via its localization.	[Mionnet, Cyril; Bogliolo, Stephanie; Arkowitz, Robert A.] Univ Nice, Inst Canc & Dev Biol, CNRS, Fac Sci Parc Valrose,UMR 6543, F-06108 Nice 2, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Cote d'Azur	Arkowitz, RA (corresponding author), Univ Nice, Inst Canc & Dev Biol, CNRS, Fac Sci Parc Valrose,UMR 6543, F-06108 Nice 2, France.	arkowitz@unice.fr	arkowitz, robert/ABC-1860-2021; mionnet, cyrille/P-9168-2016	arkowitz, robert/0000-0002-5216-5013; mionnet, cyrille/0000-0001-8431-3837				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Anborgh PH, 1999, MOL CELL BIOL, V19, P4611; Arkowitz RA, 1997, J CELL BIOL, V138, P17, DOI 10.1083/jcb.138.1.17; Barale S, 2006, MOL BIOL CELL, V17, P2824, DOI 10.1091/mbc.E05-11-1040; Bassilana M, 2006, EUKARYOT CELL, V5, P321, DOI 10.1128/EC.5.2.321-329.2006; Baumeister MA, 2006, BIOCHEM J, V400, P563, DOI 10.1042/BJ20061020; Bi F, 2001, MOL CELL BIOL, V21, P1463, DOI 10.1128/MCB.21.5.1463-1474.2001; Bose I, 2001, J BIOL CHEM, V276, P7176, DOI 10.1074/jbc.M010546200; Bower MJ, 1997, J MOL BIOL, V267, P1268, DOI 10.1006/jmbi.1997.0926; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Bustelo XR, 2002, FRONT BIOSCI, V7, pD24, DOI 10.2741/bustelo; Butty AC, 2002, EMBO J, V21, P1565, DOI 10.1093/emboj/21.7.1565; Chikumi H, 2004, ONCOGENE, V23, P233, DOI 10.1038/sj.onc.1207012; Douguet D, 2001, BIOINFORMATICS, V17, P752, DOI 10.1093/bioinformatics/17.8.752; Drees BL, 2001, J CELL BIOL, V154, P549, DOI 10.1083/jcb.200104057; Eisenhaure TM, 2003, J BIOL CHEM, V278, P30975, DOI 10.1074/jbc.M303277200; Feng YY, 1998, CURR BIOL, V8, P267, DOI 10.1016/S0960-9822(98)70108-3; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Gladfelter AS, 2002, J CELL BIOL, V156, P315, DOI 10.1083/jcb.200109062; Gulli MP, 2000, MOL CELL, V6, P1155, DOI 10.1016/S1097-2765(00)00113-1; Gulli MP, 2001, GENE DEV, V15, P365, DOI 10.1101/gad.876901; Inouye C, 1997, GENETICS, V147, P479; Inouye C, 1997, SCIENCE, V278, P103, DOI 10.1126/science.278.5335.103; Kim S, 2001, J BIOL CHEM, V276, P10581, DOI 10.1074/jbc.C000806200; Kozminski KG, 2003, MOL BIOL CELL, V14, P4958, DOI 10.1091/mbc.E03-06-0426; Kuma A, 2002, J BIOL CHEM, V277, P18619, DOI 10.1074/jbc.M111889200; Nern A, 2000, J CELL BIOL, V148, P1115, DOI 10.1083/jcb.148.6.1115; Nern A, 1999, J CELL BIOL, V144, P1187, DOI 10.1083/jcb.144.6.1187; Nern A, 1998, NATURE, V391, P195, DOI 10.1038/34458; Park HO, 2002, J BIOL CHEM, V277, P26721, DOI 10.1074/jbc.C200245200; Park HO, 1997, P NATL ACAD SCI USA, V94, P4463, DOI 10.1073/pnas.94.9.4463; PETERSON J, 1994, J CELL BIOL, V127, P1395, DOI 10.1083/jcb.127.5.1395; Ponting CP, 2002, TRENDS BIOCHEM SCI, V27, P10, DOI 10.1016/S0968-0004(01)02006-0; Rose M. D., 1991, METHODS YEAST GENETI; Rossman KL, 2002, EMBO J, V21, P1315, DOI 10.1093/emboj/21.6.1315; Rossman KL, 2005, NAT REV MOL CELL BIO, V6, P167, DOI 10.1038/nrm1587; Shimada Y, 2004, EMBO J, V23, P1051, DOI 10.1038/sj.emboj.7600124; Shimada Y, 2000, NAT CELL BIOL, V2, P117, DOI 10.1038/35000073; SPENCER DM, 1993, SCIENCE, V262, P1019, DOI 10.1126/science.7694365; Toenjes KA, 1999, CURR BIOL, V9, P1183, DOI 10.1016/S0960-9822(00)80022-6; Wang YM, 2005, J BIOL CHEM, V280, P13084, DOI 10.1074/jbc.M410461200; Wang YM, 2003, MOL BIOL CELL, V14, P2543, DOI 10.1091/mbc.E02-10-0699; WEINER MP, 1994, GENE, V151, P119, DOI 10.1016/0378-1119(94)90641-6; Wiget P, 2004, EMBO J, V23, P1063, DOI 10.1038/sj.emboj.7600123; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Yablonski D, 1996, P NATL ACAD SCI USA, V93, P13864, DOI 10.1073/pnas.93.24.13864; Zacharias DA, 2002, SCIENCE, V296, P913, DOI 10.1126/science.1068539; ZHENG Y, 1995, J BIOL CHEM, V270, P626, DOI 10.1074/jbc.270.2.626; ZHENG Y, 1994, J BIOL CHEM, V269, P2369; Zhu KJ, 2001, MOL CELL BIOL, V21, P425, DOI 10.1128/MCB.21.2.425-437.2001; Zhu KJ, 2000, J BIOL CHEM, V275, P25993, DOI 10.1074/jbc.M003780200	51	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17515	17530		10.1074/jbc.M800305200	http://dx.doi.org/10.1074/jbc.M800305200			16	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18378681	hybrid			2022-12-25	WOS:000256720600059
J	Nanashima, N; Akita, M; Yamada, T; Shimizu, T; Nakano, H; Fan, Y; Tsuchida, S				Nanashima, Naoki; Akita, Miki; Yamada, Toshiyuki; Shimizu, Takeshi; Nakano, Hajime; Fan, Yang; Tsuchida, Shigeki			The hairless phenotype of the Hirosaki hairless rat is due to the deletion of an 80-kb genomic DNA containing five basic keratin genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN TYPE-I; NORWAY RAT; MUTATION; FOLLICLE; EXPRESSION; MICE; MEMBERS; MOUSE; ARCHITECTURE; DISCOVERY	Most models of hereditary hypotrichosis are due to alterations in growth factors and transcription factors, and the examples of causative mutations in hair keratin genes are limited. The Hirosaki hairless rat (HHR) is a mutant strain spontaneously derived from Sprague-Dawley rats (SDRs). In this study, the locus of the responsible gene was examined by linkage analysis and mapped on chromosome 7q36. Because many basic keratin genes are clustered on 7q36, their expression was examined. Reverse transcription-PCR and genomic PCR indicated that the Kb21 (Krt81), -23 (Krt83), and -26 (Krt86) genes encoding basic hair keratins were not expressed and were deleted. Furthermore, 80-kb genomic DNA ranging from exon 9 of Kb25 (Krt85) to exon 9 of Krt2-25 was deleted. The breakpoints of these genes were within a 95-bp portion shared by the two genes, suggesting that deletion due to non-allelic homologous recombination occurred. Proteins identified as Kb21, Kb23, and Krt2-25 in SDR hairs by mass spectrometry were not detected in HHR. Instead, the product of a fusion gene became dominant in HHR. Because fusion occurred between the exons of the two genes with the same sequences, the product was identical to the wildtype Kb25 protein. By using immunohistochemistry, Kb21 was not detected in HHR hair follicles. Kb25 was expressed in the cortex in HHRs, whereas it was in the medulla in SDRs. This study clearly illustrates the importance of hair keratin genes in hair growth.	[Nanashima, Naoki; Akita, Miki; Yamada, Toshiyuki; Shimizu, Takeshi; Fan, Yang; Tsuchida, Shigeki] Hirosaki Univ, Grad Sch Med, Dept Biochem & Genome Biol, Hirosaki, Aomori 0368562, Japan; [Nanashima, Naoki] Hirosaki Univ, Grad Sch Hlth Sci, Dept Biomed Sci, Hirosaki, Aomori 0368564, Japan; [Akita, Miki; Nakano, Hajime] Hirosaki Univ, Grad Sch Med, Dept Dermatol, Hirosaki, Aomori 0368562, Japan	Hirosaki University; Hirosaki University; Hirosaki University	Tsuchida, S (corresponding author), Hirosaki Univ, Grad Sch Med, Dept Biochem & Genome Biol, 5 Zaifu Cho, Hirosaki, Aomori 0368562, Japan.	tsuchida@cc.hirosaki-u.ac.jp	Shimizu, Takeshi/ABE-6503-2020; Nanashima, Naoki/F-1302-2013; Tsuchida, Shigeki/L-3382-2013	Nanashima, Naoki/0000-0002-4729-3432; Tsuchida, Shigeki/0000-0002-4404-5599				CASTLE W. E., 1955, JOUR HEREDITY, V46, P9; Chrissluis RR, 2002, MOL GENET METAB, V76, P335, DOI 10.1016/S1096-7192(02)00103-8; FESTING MFW, 1978, NATURE, V274, P365, DOI 10.1038/274365a0; Godwin AR, 1998, GENE DEV, V12, P11, DOI 10.1101/gad.12.1.11; Hanada K, 1988, J Dermatol, V15, P257; HEID HW, 1986, DIFFERENTIATION, V32, P101, DOI 10.1111/j.1432-0436.1986.tb00562.x; Hesse M, 2004, EUR J CELL BIOL, V83, P19, DOI 10.1078/0171-9335-00354; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; INAZU M, 1984, LAB ANIM SCI, V34, P577; Kishimoto J, 2000, GENE DEV, V14, P1181; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Langbein L, 2005, INT REV CYTOL, V243, P1, DOI 10.1016/S0074-7696(05)43001-6; Langbein L, 2003, J INVEST DERMATOL, V120, P512, DOI 10.1046/j.1523-1747.2003.12087.x; Langbein L, 1999, J BIOL CHEM, V274, P19874, DOI 10.1074/jbc.274.28.19874; Langbein L, 2001, J BIOL CHEM, V276, P35123, DOI 10.1074/jbc.M103305200; LUETTEKE NC, 1993, CELL, V73, P263, DOI 10.1016/0092-8674(93)90228-I; Lupski JR, 2006, NAT GENET, V38, P974, DOI 10.1038/ng0906-974; MANN GB, 1993, CELL, V73, P249, DOI 10.1016/0092-8674(93)90227-H; MCLEAN WHI, 1995, CURR OPIN CELL BIOL, V7, P118; Millar SE, 1999, DEV BIOL, V207, P133, DOI 10.1006/dbio.1998.9140; Moemeka AN, 1998, J HERED, V89, P257, DOI 10.1093/jhered/89.3.257; Nanashima N, 2005, J BIOL CHEM, V280, P43010, DOI 10.1074/jbc.M509481200; NEHLS M, 1994, NATURE, V372, P103, DOI 10.1038/372103a0; PALM J, 1976, J HERED, V67, P284, DOI 10.1093/oxfordjournals.jhered.a108732; Panteleyev AA, 2001, COMPARATIVE MED, V51, P49; PEETERS JM, 1989, J IMMUNOL METHODS, V120, P133, DOI 10.1016/0022-1759(89)90298-6; Poirier C, 2002, GENETICS, V162, P831; ROBERTS E., 1940, JOUR INVEST DERMAL, V3, P1; Rogers MA, 2005, J INVEST DERMATOL, V124, P536, DOI 10.1111/j.0022-202X.2004.23530.x; Schorpp M, 2000, DEV DYNAM, V218, P537, DOI 10.1002/1097-0177(200007)218:3<537::AID-DVDY1007>3.0.CO;2-P; Schweizer J, 2006, J CELL BIOL, V174, P169, DOI 10.1083/jcb.200603161; Sharp AJ, 2006, NAT GENET, V38, P1038, DOI 10.1038/ng1862; Tong XM, 2006, GENE DEV, V20, P1353, DOI 10.1101/gad.1387406; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Wang ZL, 2003, J INVEST DERMATOL, V121, P1276, DOI 10.1111/j.1523-1747.2003.12644.x; Winter H, 1998, J INVEST DERMATOL, V111, P955, DOI 10.1046/j.1523-1747.1998.00456.x; Winter H, 1997, J BIOL CHEM, V272, P32345, DOI 10.1074/jbc.272.51.32345; Wojcik SM, 2001, J CELL BIOL, V154, P619, DOI 10.1083/jcb.200102079	38	26	27	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16868	16875		10.1074/jbc.M802539200	http://dx.doi.org/10.1074/jbc.M802539200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18420582	hybrid			2022-12-25	WOS:000256497100064
J	Chamberlain, MD; Chan, T; Oberg, JC; Hawrysh, AD; James, KM; Saxena, A; Xiang, J; Anderson, DH				Chamberlain, M. Dean; Chan, Tim; Oberg, Jennifer C.; Hawrysh, Andrea D.; James, Kristy M.; Saxena, Anurag; Xiang, Jim; Anderson, Deborah H.			Disrupted RabGAP function of the p85 subunit of phosphatidylinositol 3-kinase results in cell transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLATHRIN-MEDIATED ENDOCYTOSIS; SIGNAL-TRANSDUCTION PATHWAYS; RECEPTOR TYROSINE KINASES; DOWN-REGULATION; PHOSPHOINOSITIDE 3-KINASE; REGULATORY SUBUNIT; GTPASE ACTIVITY; PROTEIN; EXPRESSION; TRAFFICKING	Rab proteins regulate vesicle fusion events during the endocytosis, recycling, and degradation of activated receptor tyrosine kinases. The p85 alpha subunit of phosphatidylinositol 3-kinase has GTPase-activating protein activity toward Rab5 and Rab4, an activity severely reduced by a single point mutation (p85-R274A). Expression of p85-R274A resulted in increased plate-let-derived growth factor receptor (PDGFR) activation and downstream signaling (Akt and MAPK) and in decreased PDGFR degradation. We now report that the biological consequences of p85-R274A expression cause cellular transformation as determined by the following: aberrant morphological phenotype, loss of contact inhibition, growth in soft agar, and tumor formation in nude mice. Immunohistochemistry shows that the tumors contain activated PDGFR and high levels of activated Akt. Coexpression of a dominant negative Rab5-S34N mutant attenuated these transformed properties. Our results demonstrate that disruption of the RabGAP function of p85 alpha due to a single point mutation (R274A) is sufficient to cause cellular transformation via a phosphatidylinositol 3-kinase-independent mechanism partially reversed by Rab5-S34N expression. This critical new role for p85 in the regulation of Rab function suggests a novel role for p85 in controlling receptor signaling and trafficking through its effects on Rab GTPases.	[Chamberlain, M. Dean; Chan, Tim; Oberg, Jennifer C.; Hawrysh, Andrea D.; James, Kristy M.; Xiang, Jim; Anderson, Deborah H.] Saskatchewan Canc Agcy, Canc Res Unit, Hlth Res Div, Saskatoon, SK S7N 4H4, Canada; [Chamberlain, M. Dean; Oberg, Jennifer C.] Univ Saskatchewan, Dept Biochem, Saskatoon, SK S7N 5E5, Canada; [Xiang, Jim; Anderson, Deborah H.] Univ Saskatchewan, Dept Oncol, Saskatoon, SK S7N 5E5, Canada; [Chan, Tim; Saxena, Anurag] Univ Saskatchewan, Dept Pathol, Saskatoon, SK S7N 5E5, Canada	University of Saskatchewan; University of Saskatchewan; University of Saskatchewan; University of Saskatchewan	Anderson, DH (corresponding author), Saskatchewan Canc Agcy, Canc Res Unit, Hlth Res Div, Saskatoon, SK S7N 4H4, Canada.	deborah.anderson@saskcancer.ca	Chamberlain, Michael/A-9107-2016; Chamberlain, Michael Dean/AAX-1670-2021	Chamberlain, Michael/0000-0003-1813-8545; Chamberlain, Michael Dean/0000-0003-1813-8545				Alto NM, 2002, J CELL BIOL, V158, P659, DOI 10.1083/jcb.200204081; Amillet JM, 2006, HUM PATHOL, V37, P256, DOI 10.1016/j.humpath.2005.10.017; Anderson DH, 1998, ONCOGENE, V16, P2321, DOI 10.1038/sj.onc.1201780; Anderson DH, 2006, PROG LIPID RES, V45, P102, DOI 10.1016/j.plipres.2005.12.003; Bache KG, 2004, EMBO J, V23, P2707, DOI 10.1038/sj.emboj.7600292; Baynes KCR, 2000, DIABETOLOGIA, V43, P321, DOI 10.1007/s001250050050; Bizimungu C, 2003, BIOCHEM BIOPH RES CO, V310, P498, DOI 10.1016/j.bbrc.2003.09.051; Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225; Cairns CM, 2001, J IMMUNOL, V167, P57, DOI 10.4049/jimmunol.167.1.57; Ceresa BP, 2006, HISTOL HISTOPATHOL, V21, P987, DOI 10.14670/HH-21.987; Ceresa BP, 1998, MOL CELL BIOL, V18, P3862, DOI 10.1128/MCB.18.7.3862; Chamberlain MD, 2004, J BIOL CHEM, V279, P48607, DOI 10.1074/jbc.M409769200; Cheng KW, 2004, NAT MED, V10, P1251, DOI 10.1038/nm1125; Chow JC, 1998, J BIOL CHEM, V273, P4672, DOI 10.1074/jbc.273.8.4672; Clague MJ, 2001, J CELL SCI, V114, P3075; Crosetto N, 2005, FEBS LETT, V579, P3231, DOI 10.1016/j.febslet.2005.03.029; d'Azzo A, 2005, TRAFFIC, V6, P429, DOI 10.1111/j.1600-0854.2005.00294.x; Deneka M, 2003, CRIT REV BIOCHEM MOL, V38, P121, DOI 10.1080/713609214; Di Fiore PP, 2001, CELL, V106, P1, DOI 10.1016/S0092-8674(01)00428-7; Dikic I, 2003, CURR OPIN CELL BIOL, V15, P128, DOI 10.1016/S0955-0674(03)00004-8; Gebhardt C, 2005, AM J PATHOL, V167, P243, DOI 10.1016/S0002-9440(10)62969-0; Grandal MV, 2007, CARCINOGENESIS, V28, P1408, DOI 10.1093/carcin/bgm058; Haglund K, 2003, TRENDS BIOCHEM SCI, V28, P598, DOI 10.1016/j.tibs.2003.09.005; Hicke L, 2003, ANNU REV CELL DEV BI, V19, P141, DOI 10.1146/annurev.cellbio.19.110701.154617; Ignatiuk A, 2006, J BIOL CHEM, V281, P5956, DOI 10.1074/jbc.M510032200; Jimenez C, 1998, EMBO J, V17, P743, DOI 10.1093/emboj/17.3.743; Jucker M, 2002, LEUKEMIA, V16, P894, DOI 10.1038/sj.leu.2402484; King TR, 2000, J BIOL CHEM, V275, P36450, DOI 10.1074/jbc.M004720200; Kranenburg O, 1999, J BIOL CHEM, V274, P35301, DOI 10.1074/jbc.274.50.35301; Liu K, 1998, J BIOL CHEM, V273, P10087, DOI 10.1074/jbc.273.17.10087; LUTCKE A, 1994, J CELL SCI, V107, P3437; Luttrell LM, 1997, J BIOL CHEM, V272, P31648, DOI 10.1074/jbc.272.50.31648; Mak HHL, 2007, ONCOGENE, V26, P7213, DOI 10.1038/sj.onc.1210522; Markgraf DF, 2007, FEBS LETT, V581, P2125, DOI 10.1016/j.febslet.2007.01.090; Miaczynska M, 2004, CURR OPIN CELL BIOL, V16, P400, DOI 10.1016/j.ceb.2004.06.005; Mizoguchi M, 2004, BRAIN PATHOL, V14, P372, DOI 10.1111/j.1750-3639.2004.tb00080.x; Peschard P, 2003, CANCER CELL, V3, P519, DOI 10.1016/S1535-6108(03)00136-3; Philp AJ, 2001, CANCER RES, V61, P7426; Schmidlin F, 2001, J BIOL CHEM, V276, P25427, DOI 10.1074/jbc.M101688200; Sebastian S, 2006, BBA-REV CANCER, V1766, P120, DOI 10.1016/j.bbcan.2006.06.001; Shibata D, 2006, INT J CANCER, V119, P801, DOI 10.1002/ijc.21912; Sigismund S, 2004, CURR TOP MICROBIOL, V286, P149; Stenmark H, 2001, GENOME BIOL, V2; Thien CBF, 2001, NAT REV MOL CELL BIO, V2, P294, DOI 10.1038/35067100; Vieira AV, 1996, SCIENCE, V274, P2086, DOI 10.1126/science.274.5295.2086; Wang Y, 2004, J BIOL CHEM, V279, P8038, DOI 10.1074/jbc.M311494200; Wang Y, 2002, MOL CELL BIOL, V22, P7279, DOI 10.1128/MCB.22.20.7279-7290.2002; Waterman H, 2002, EMBO J, V21, P303, DOI 10.1093/emboj/21.3.303	48	35	36	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15861	15868		10.1074/jbc.M800941200	http://dx.doi.org/10.1074/jbc.M800941200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18387942	hybrid, Green Published			2022-12-25	WOS:000256332500044
J	Duret, G; Szymanski, M; Choi, KJ; Yeo, HJ; Delcour, AH				Duret, Guillaume; Szymanski, Michal; Choi, Kyoung-Jae; Yeo, Hye-Jeong; Delcour, Anne H.			The TpsB translocator HMW1B of Haemophilus influenzae forms a large conductance channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL OUTER-MEMBRANE; N-TERMINAL DOMAIN; ESCHERICHIA-COLI; 2-PARTNER SECRETION; PROTEIN SECRETION; CRYSTAL-STRUCTURE; TWIN-PORE; III SECRETION; OMP85 FAMILY; IMPORT PORE	The Haemophilus influenzae HMW1 adhesin is secreted via the two-partner secretion pathway and requires HMW1B for translocation across the outer membrane. HMW1B belongs to the Omp85-TpsB superfamily of transporters and consists of two structural domains, a C-terminal transmembrane beta-barrel and an N-terminal periplasmic domain. We investigated the electrophysiological properties of the purified full-length HMW1B and the C-terminal domain using planar lipid bilayers. Both the full-length and the truncated proteins formed conductive pores with a low open probability, two well defined conductance states, and other substates. The kinetic patterns of the two conductance states were distinct, with rapid and frequent transitions to the small conductance state and occasional and more prolonged openings to the large conductance state. The channel formed by the full-length HMW1B showed selectivity for cations, which decreased when measured at pH 5.2, suggesting the presence of acidic residues in the pore. The C-terminal domain of HMW1B was less stable and required reconstitution into liposomes prior to insertion in the bilayer. It formed a channel of smaller conductance but a similar gating pattern as the full-length protein, demonstrating the ability of the last 312 C-terminal amino acids to form a pore and suggesting that the periplasmic domain is not involved in occluding the pore, nor in controlling the inherent basal kinetics of the channel. The HMW1 pro-piece containing the secretion domain, although binding to the channel with high affinity, did not induce channel opening.	[Duret, Guillaume; Szymanski, Michal; Choi, Kyoung-Jae; Yeo, Hye-Jeong; Delcour, Anne H.] Univ Houston, Dept Biol & Biochem, Houston, TX 77204 USA	University of Houston System; University of Houston	Delcour, AH (corresponding author), Univ Houston, Dept Biol & Biochem, 369 Sci & Res Bldg 2, Houston, TX 77204 USA.	adelcour@uh.edu		Szymanski, Michal/0000-0001-9452-8508; Choi, Kyoungjae/0000-0001-9541-4182	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI068943] Funding Source: NIH RePORTER; NIAID NIH HHS [AI068943] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Ahting U, 1999, J CELL BIOL, V147, P959, DOI 10.1083/jcb.147.5.959; Andersen C, 2002, J MEMBRANE BIOL, V185, P83, DOI 10.1007/s00232-001-0113-2; Basle A, 2004, BBA-BIOMEMBRANES, V1664, P100, DOI 10.1016/j.bbamem.2004.04.009; Bond PJ, 2007, BIOPHYS J, V92, pL23, DOI 10.1529/biophysj.106.097311; Bredemeier R, 2007, J BIOL CHEM, V282, P1882, DOI 10.1074/jbc.M609598200; Burghout P, 2004, J BACTERIOL, V186, P4645, DOI 10.1128/JB.186.14.4645-4654.2004; Cascales E, 2003, NAT REV MICROBIOL, V1, P137, DOI 10.1038/nrmicro753; Clantin B, 2007, SCIENCE, V317, P957, DOI 10.1126/science.1143860; Conlan S, 2000, BIOCHEMISTRY-US, V39, P11845, DOI 10.1021/bi001065h; DELCOUR AH, 1989, J MEMBRANE BIOL, V112, P267, DOI 10.1007/BF01870957; Desvaux M, 2004, CURR ISSUES MOL BIOL, V6, P111; Dong CJ, 2006, NATURE, V444, P226, DOI 10.1038/nature05267; Duret G, 2007, CHANNELS, V1, P70, DOI 10.4161/chan.3983; Geme JWS, 1998, MOL MICROBIOL, V27, P617; Gentle IE, 2005, MOL MICROBIOL, V58, P1216, DOI 10.1111/j.1365-2958.2005.04906.x; Goetze TA, 2006, J BIOL CHEM, V281, P17989, DOI 10.1074/jbc.M600700200; Habib SJ, 2007, J CELL BIOL, V176, P77, DOI 10.1083/jcb.200602050; Hill K, 1998, NATURE, V395, P516, DOI 10.1038/26780; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hinnah SC, 2002, BIOPHYS J, V83, P899, DOI 10.1016/S0006-3495(02)75216-8; Holland IB, 2004, BBA-MOL CELL RES, V1694, P5, DOI 10.1016/j.bbamcr.2004.02.007; Jacob-Dubuisson F, 1999, J BIOL CHEM, V274, P37731, DOI 10.1074/jbc.274.53.37731; Koronakis V, 2000, NATURE, V405, P914, DOI 10.1038/35016007; Kostakioti M, 2005, J BACTERIOL, V187, P4306, DOI 10.1128/JB.187.13.4306-4314.2005; Li HL, 2004, J MOL BIOL, V344, P1397, DOI 10.1016/j.jmb.2004.10.008; Li HL, 2007, J BACTERIOL, V189, P7497, DOI 10.1128/JB.00541-07; Meli AC, 2006, J BIOL CHEM, V281, P158, DOI 10.1074/jbc.M508524200; Moslavac S, 2005, FEBS J, V272, P1367, DOI 10.1111/j.1742-4658.2005.04569.x; Mota LJ, 2005, FEMS MICROBIOL LETT, V252, P1, DOI 10.1016/j.femsle.2005.08.036; Nestorovich EM, 2003, BIOPHYS J, V85, P3718, DOI 10.1016/S0006-3495(03)74788-2; Nouwen N, 1999, P NATL ACAD SCI USA, V96, P8173, DOI 10.1073/pnas.96.14.8173; Oomen CJ, 2004, EMBO J, V23, P1257, DOI 10.1038/sj.emboj.7600148; Prilipov A, 1998, FEMS MICROBIOL LETT, V163, P65, DOI 10.1111/j.1574-6968.1998.tb13027.x; Prince SM, 2002, P NATL ACAD SCI USA, V99, P3417, DOI 10.1073/pnas.062630899; Pukatzki S, 2006, P NATL ACAD SCI USA, V103, P1528, DOI 10.1073/pnas.0510322103; Rehling P, 2003, SCIENCE, V299, P1747, DOI 10.1126/science.1080945; Rostovtseva TK, 2002, BIOPHYS J, V82, P160, DOI 10.1016/S0006-3495(02)75383-6; Saint N, 2000, FEMS MICROBIOL LETT, V190, P261, DOI 10.1111/j.1574-6968.2000.tb09296.x; Sanchez-Pulido L, 2003, TRENDS BIOCHEM SCI, V28, P523, DOI 10.1016/j.tibs.2003.08.003; Simonet VC, 2003, J BIOL CHEM, V278, P17539, DOI 10.1074/jbc.M301202200; Stegmeier JF, 2006, J BIOCHEM, V140, P275, DOI 10.1093/jb/mvj147; Surana NK, 2006, J BIOL CHEM, V281, P18051, DOI 10.1074/jbc.M600036200; Surana NK, 2004, P NATL ACAD SCI USA, V101, P14497, DOI 10.1073/pnas.0404679101; Thanassi DG, 2005, MOL MEMBR BIOL, V22, P63, DOI 10.1080/09687860500063290; Thanassi DG, 2002, J BACTERIOL, V184, P6260, DOI 10.1128/JB.184.22.6260-6269.2002; Tommassen J, 2007, SCIENCE, V317, P903, DOI 10.1126/science.1146518; Van Gelder P, 2000, BIOPHYS CHEM, V85, P153, DOI 10.1016/S0301-4622(99)00153-2; Vandeputte-Rutten L, 2001, EMBO J, V20, P5033, DOI 10.1093/emboj/20.18.5033; Yeo HJ, 2007, J BIOL CHEM, V282, P31076, DOI 10.1074/jbc.M705750200	49	13	13	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15771	15778		10.1074/jbc.M708970200	http://dx.doi.org/10.1074/jbc.M708970200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18403374	hybrid, Green Published			2022-12-25	WOS:000256332500034
J	Kajiya, M; Shiba, H; Fujita, T; Ouhara, K; Takeda, K; Mizuno, N; Kawaguchi, H; Kitagawa, M; Takata, T; Tsuji, K; Kurihara, H				Kajiya, Mikihito; Shiba, Hideki; Fujita, Tsuyoshi; Ouhara, Kazuhisa; Takeda, Katsuhiro; Mizuno, Noriyoshi; Kawaguchi, Hiroyuki; Kitagawa, Masae; Takata, Takashi; Tsuji, Koichiro; Kurihara, Hidemi			Brain-derived neurotrophic factor stimulates bone/cementum-related protein gene expression in cementoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; RECEPTOR TYROSINE KINASES; SIGNAL-TRANSDUCTION; OSTEOBLASTIC CELLS; EXTRACELLULAR-MATRIX; TRANSCRIPTION FACTOR; PERIODONTAL TISSUES; PARATHYROID-HORMONE; ENDOTHELIAL-CELLS; STAT3 ACTIVATION	Brain-derived neurotrophic factor (BDNF), recognized as essential in the developing nervous system, is involved in differentiation and proliferation in non-neuronal cells, such as endothelial cells, osteoblasts, and periodontal ligament cells. We have focused on the application of BDNF to the regeneration of periodontal tissue and indicated that BDNF promotes the regeneration of experimentally created periodontal defects. Cementoblasts form cementum, mineralized tissue, which is key to establishing a functional periodontium. The application of BDNF to the regeneration of periodontal tissue requires elucidation of the mechanism by which BDNF regulates the functions of cementoblasts. In this study, we examined how BDNF regulates the mRNA expression of bone/cementum-related proteins (alkaline phosphatase (ALP), osteopontin (OPN), and bone morphogenetic protein-2 (BMP-2) in cultures of immortalized human cementoblast-like (HCEM) cells. BDNF elevated the mRNA levels of ALP, OPN, and BMP-2 in HCEM cells. Small interfering RNA (siRNA) for TRKB, a high affinity receptor of BDNF, siRNA for ELK-1, which is a downstream target of ERK1/2, and PD98059, an ERK inhibitor, obviated the increase in the mRNA levels. BDNF increased the levels of phosphorylated ERK1/2 and Elk-1, and the blocking of BDNF signaling by treatment with siRNA for TRKB and PD98059 suppressed the phosphorylation of ERK1/2 and Elk-1. Furthermore, BDNF increased the levels of phosphorylated c-Raf, which activates the ERK signaling pathway. These findings provide the first evidence that the TrkB-c-Raf-ERK1/2-Elk-1 signaling pathway is required for the BDNF-inducedmRNAexpression of ALP, OPN, and BMP-2 in HCEM cells.	[Takata, Takashi] Hiroshima Univ, Grad Sch Biomed Sci, Dept Oral & Maxillofacial Pathobiol, Hiroshima 348553, Japan; [Kitagawa, Masae] Hiroshima Univ Hosp, Ctr Oral Clin Examinat, Hiroshima 348553, Japan; [Tsuji, Koichiro] Two Cells Co Ltd, Minami Ku, Hiroshima 348553, Japan; [Kajiya, Mikihito; Shiba, Hideki; Fujita, Tsuyoshi; Ouhara, Kazuhisa; Takeda, Katsuhiro; Mizuno, Noriyoshi; Kawaguchi, Hiroyuki; Kurihara, Hidemi] Hiroshima Univ, Grad Sch Biomed Sci, Dept Periodontol Med, Hiroshima 348553, Japan	Hiroshima University; Hiroshima University; Hiroshima University	Shiba, H (corresponding author), Hiroshima Univ, Grad Sch Biomed Sci, Dept Periodontol Med, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348553, Japan.	bashihi@hiroshima-u.ac.jp	Kajiya, Mikihito/A-4288-2018; Ouhara, Kazuhisa/G-5251-2019	Kajiya, Mikihito/0000-0001-6652-0007; 				Almeida RD, 2005, CELL DEATH DIFFER, V12, P1329, DOI 10.1038/sj.cdd.4401662; BARBACID M, 1994, J NEUROBIOL, V25, P1386, DOI 10.1002/neu.480251107; Bibel M, 1999, EMBO J, V18, P616, DOI 10.1093/emboj/18.3.616; Bibel M, 2000, GENE DEV, V14, P2919, DOI 10.1101/gad.841400; Boabaid F, 2004, J PERIODONTOL, V75, P1126, DOI 10.1902/jop.2004.75.8.1126; BOHM M, 1995, CELL GROWTH DIFFER, V6, P291; Chao MV, 2006, CLIN SCI, V110, P167, DOI 10.1042/CS20050163; Chen C, 2004, J BIOL CHEM, V279, P29121, DOI 10.1074/jbc.M313000200; CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915; Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716; DAHL LK, 1952, P SOC EXP BIOL MED, V80, P474, DOI 10.3181/00379727-80-19661; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; Debiais F, 1998, J BONE MINER RES, V13, P645, DOI 10.1359/jbmr.1998.13.4.645; Denhardt DT, 2003, CLIN EXP METASTAS, V20, P77, DOI 10.1023/A:1022550721404; Dereka XE, 2006, GROWTH FACTORS, V24, P260, DOI 10.1080/08977190601060990; EBENDAL T, 1992, J NEUROSCI RES, V32, P461, DOI 10.1002/jnr.490320402; El-Tanani M, 2001, J BIOL CHEM, V276, P41675, DOI 10.1074/jbc.M103966200; El-Tanani M, 2004, J BIOL CHEM, V279, P20794, DOI 10.1074/jbc.M311131200; FURUKAWA Y, 1984, J BIOL CHEM, V259, P1259; GONZALEZ FA, 1993, J CELL BIOL, V122, P1089, DOI 10.1083/jcb.122.5.1089; Hempstead BL, 2002, CURR OPIN NEUROBIOL, V12, P260, DOI 10.1016/S0959-4388(02)00321-5; Higuchi C, 2002, J BONE MINER RES, V17, P1785, DOI 10.1359/jbmr.2002.17.10.1785; Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629; Hurley MM, 1996, J BONE MINER RES, V11, P1256; Itoh S, 2006, BONE, V39, P505, DOI 10.1016/j.bone.2006.02.074; JING SQ, 1992, NEURON, V9, P1067, DOI 10.1016/0896-6273(92)90066-M; JOHNSON D, 1986, CELL, V47, P545, DOI 10.1016/0092-8674(86)90619-7; KATO Y, 1990, J BIOL CHEM, V265, P5903; Kerschensteiner M, 1999, J EXP MED, V189, P865, DOI 10.1084/jem.189.5.865; Kitagawa M, 2006, BONE, V39, P1035, DOI 10.1016/j.bone.2006.05.022; Kurihara H, 2003, J PERIODONTOL, V74, P76, DOI 10.1902/jop.2003.74.1.76; Lou J, 2000, BIOCHEM BIOPH RES CO, V268, P757, DOI 10.1006/bbrc.2000.2210; MACGROGAN D, 1992, J NEUROCHEM, V59, P1381, DOI 10.1111/j.1471-4159.1992.tb08451.x; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Murakami S, 2003, J PERIODONTAL RES, V38, P97, DOI 10.1034/j.1600-0765.2003.00640.x; Murakami S, 1999, J PERIODONTAL RES, V34, P425, DOI 10.1111/j.1600-0765.1999.tb02277.x; Nakagami H, 2001, HYPERTENSION, V37, P581, DOI 10.1161/01.HYP.37.2.581; Nakahashi T, 2000, FEBS LETT, V470, P113, DOI 10.1016/S0014-5793(00)01302-8; NAKANISHI T, 1994, BIOCHEM BIOPH RES CO, V198, P891, DOI 10.1006/bbrc.1994.1127; Nakayama K, 2003, J BONE MINER RES, V18, P827, DOI 10.1359/jbmr.2003.18.5.827; Nosrat CA, 1997, CELL TISSUE RES, V290, P569, DOI 10.1007/s004410050962; O'Brien CA, 1999, J BIOL CHEM, V274, P19301, DOI 10.1074/jbc.274.27.19301; OTTEN U, 1989, P NATL ACAD SCI USA, V86, P10059, DOI 10.1073/pnas.86.24.10059; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; San Miguel SM, 2005, J BIOL CHEM, V280, P37495, DOI 10.1074/jbc.M503861200; Sato Y, 2004, J PERIODONTOL, V75, P243, DOI 10.1902/jop.2004.75.2.243; Schindeler A, 2006, J BONE MINER RES, V21, P1331, DOI 10.1359/JBMR.060603; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; Slack SE, 2005, J COMP NEUROL, V489, P59, DOI 10.1002/cne.20606; Takeda K, 2005, TISSUE ENG, V11, P1618, DOI 10.1089/ten.2005.11.1618; Takeuchi Y, 1997, J BIOL CHEM, V272, P29309, DOI 10.1074/jbc.272.46.29309; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; UMBHAUER M, 1995, NATURE, V376, P58, DOI 10.1038/376058a0; Vesa J, 2000, J BIOL CHEM, V275, P24414, DOI 10.1074/jbc.M001641200; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; Xiao GZ, 2000, J BIOL CHEM, V275, P4453, DOI 10.1074/jbc.275.6.4453; Xiao GZ, 2002, J BIOL CHEM, V277, P36181, DOI 10.1074/JBC.m206057200; Xiao GZ, 2002, J BONE MINER RES, V17, P101, DOI 10.1359/jbmr.2002.17.1.101; Yamashiro T, 2001, BONE, V28, P404, DOI 10.1016/S8756-3282(01)00405-7; Yao Y, 2003, P NATL ACAD SCI USA, V100, P12759, DOI 10.1073/pnas.2134254100; Ye L, 2006, J ENDODONT, V32, P736, DOI 10.1016/j.joen.2006.01.007; You J, 2001, J BIOL CHEM, V276, P13365, DOI 10.1074/jbc.M009846200	62	47	52	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16259	16267		10.1074/jbc.M800668200	http://dx.doi.org/10.1074/jbc.M800668200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18390540	Green Published, hybrid			2022-12-25	WOS:000256332500084
J	Eminaga, S; Bennett, AM				Eminaga, Seda; Bennett, Anton M.			Noonan syndrome-associated SHP-2/Ptpn11 mutants enhance SIRP alpha and PZR tyrosyl phosphorylation and promote adhesion-mediated ERK activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GENOTYPE-PHENOTYPE CORRELATION; SOMATIC PTPN11 MUTATIONS; EPIDERMAL-GROWTH-FACTOR; PHOSPHATASE SHP-2; COMPLEX-FORMATION; CELL-MIGRATION; PROTEIN-KINASE; MOUSE MODEL; SHPS-1; FAMILY	Noonan syndrome (NS) is an autosomal dominant disorder that is associated with multiple developmental abnormalities. Activated mutations of the protein-tyrosine phosphatase, SHP-2/PTPN11, have been reported in similar to 50% of NS cases. Despite being activated, NS-associated SHP-2 mutants require plasma membrane proximity to evoke disease-associated signaling. Here we show that NS-associated SHP-2 mutants induce hypertyrosyl phosphorylation of the transmembrane glycoproteins, SIRP alpha (signal-regulatory protein alpha) and PZR (protein zero-related), resulting in their increased association with NS-associated SHP-2 mutants. NS-associated SHP-2 mutants enhanced SIRP alpha and PZR tyrosyl phosphorylation either by impairing SIRP alpha dephosphorylation or by promoting PZR tyrosyl phosphorylation. Importantly, during embryogenesis in a mouse model of NS, SIRP alpha and PZR were hypertyrosyl-phosphorylated and bound increased levels of the NS-associated SHP-2 mutant. SIRP alpha and PZR have been implicated in extracellular matrix-dependent signaling. Mouse embryonic fibroblasts derived from a mouse model of NS displayed enhanced ERK activation in response to fibronectin plating. Knockdown of SIRP alpha and PZR in these cells attenuated the enhanced activation of ERK following fibronectin plating. Thus, SIRP alpha and PZR serve as scaffolds that facilitate plasma membrane recruitment and signaling of NS-associated SHP-2 mutants.	[Eminaga, Seda; Bennett, Anton M.] Yale Univ, Sch Med, Dept Pharmacol, New Haven, CT 06520 USA	Yale University	Bennett, AM (corresponding author), Yale Univ, Sch Med, Dept Pharmacol, 333 Cedar St,SHM B226D, New Haven, CT 06520 USA.	anton.bennett@yale.edu		Bennett, Anton/0000-0001-5187-7599; Eminaga, Seda/0000-0002-5606-9678	NIAMS NIH HHS [R01 AR 46504] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR046504] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Araki T, 2004, NAT MED, V10, P849, DOI 10.1038/nm1084; Barclay AN, 2006, NAT REV IMMUNOL, V6, P457, DOI 10.1038/nri1859; Bennett AM, 1996, MOL CELL BIOL, V16, P1189; Bentires-Alj M, 2004, CANCER RES, V64, P8816, DOI 10.1158/0008-5472.CAN-04-1923; Chan RJ, 2005, BLOOD, V105, P3737, DOI 10.1182/blood-2004-10-4002; Chen BB, 2000, NAT GENET, V24, P296, DOI 10.1038/73528; Feng GS, 1999, EXP CELL RES, V253, P47, DOI 10.1006/excr.1999.4668; Fornaro M, 2006, J CELL BIOL, V175, P87, DOI 10.1083/jcb.200602029; Fragale A, 2004, HUM MUTAT, V23, P267, DOI 10.1002/humu.20005; Fujioka Y, 1996, MOL CELL BIOL, V16, P6887; HAUSDORFF SF, 1995, J BIOL CHEM, V270, P12965, DOI 10.1074/jbc.270.22.12965; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; Inagaki K, 2000, EMBO J, V19, P6721, DOI 10.1093/emboj/19.24.6721; Keilhack H, 2005, J BIOL CHEM, V280, P30984, DOI 10.1074/jbc.M504699200; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Kontaridis MI, 2002, MOL CELL BIOL, V22, P3875, DOI 10.1128/MCB.22.11.3875-3891.2002; Kontaridis MI, 2001, J CELL SCI, V114, P2187; Krenz M, 2005, CIRC RES, V97, P813, DOI 10.1161/01.RES.0000186194.06514.b0; Loh ML, 2004, BLOOD, V103, P2325, DOI 10.1182/blood-2003-09-3287; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; Mohi MG, 2005, CANCER CELL, V7, P179, DOI 10.1016/j.ccr.2005.01.010; Motegi S, 2003, EMBO J, V22, P2634, DOI 10.1093/emboj/cdg278; Musante L, 2003, EUR J HUM GENET, V11, P201, DOI 10.1038/sj.ejhg.5200935; Neel BG, 2003, TRENDS BIOCHEM SCI, V28, P284, DOI 10.1016/S0968-0004(03)00091-4; Niihori T, 2005, J HUM GENET, V50, P192, DOI 10.1007/s10038-005-0239-7; Noguchi T, 1996, J BIOL CHEM, V271, P27652, DOI 10.1074/jbc.271.44.27652; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; NOONAN JA, 1994, CLIN PEDIATR, V33, P548, DOI 10.1177/000992289403300907; NOONAN JA, 1968, AM J DIS CHILD, V116, P373, DOI 10.1001/archpedi.1968.02100020377005; O'Reilly AM, 2000, MOL CELL BIOL, V20, P299, DOI 10.1128/MCB.20.1.299-311.2000; Oh ES, 1999, MOL CELL BIOL, V19, P3205; Oshima K, 2002, FEBS LETT, V519, P1, DOI 10.1016/S0014-5793(02)02703-5; Ren Y, 2004, J BIOL CHEM, V279, P8497, DOI 10.1074/jbc.M312575200; Saxton TM, 2000, NAT GENET, V24, P420, DOI 10.1038/74279; Saxton TM, 1997, EMBO J, V16, P2352, DOI 10.1093/emboj/16.9.2352; Takada T, 1998, J BIOL CHEM, V273, P9234, DOI 10.1074/jbc.273.15.9234; Tartaglia M, 2005, ANNU REV GENOM HUM G, V6, P45, DOI 10.1146/annurev.genom.6.080604.162305; Tartaglia M, 2005, EUR J MED GENET, V48, P81, DOI 10.1016/j.ejmg.2005.03.001; Tartaglia M, 2001, NAT GENET, V29, P465, DOI 10.1038/ng772; Tartaglia M, 2003, NAT GENET, V34, P148, DOI 10.1038/ng1156; Tartaglia M, 2002, AM J HUM GENET, V70, P1555, DOI 10.1086/340847; Thiery JP, 2003, CURR OPIN GENET DEV, V13, P365, DOI 10.1016/S0959-437X(03)00088-1; Tiganis T, 2007, BIOCHEM J, V402, P1, DOI 10.1042/BJ20061548; Timms JF, 1999, CURR BIOL, V9, P927, DOI 10.1016/S0960-9822(99)80401-1; Tsuda M, 1998, J BIOL CHEM, V273, P13223, DOI 10.1074/jbc.273.21.13223; Uhlen P, 2006, P NATL ACAD SCI USA, V103, P2160, DOI 10.1073/pnas.0510876103; van den Berg TK, 2005, J IMMUNOL, V175, P7788, DOI 10.4049/jimmunol.175.12.7788; Wu CJ, 2001, ONCOGENE, V20, P6018, DOI 10.1038/sj.onc.1204699; Yang ID, 2006, NANOSC MICROSC THERM, V10, P1, DOI 10.1080/10893950500357921; Yu WM, 2006, J BIOL CHEM, V281, P5426, DOI 10.1074/jbc.M507622200; Zannettino ACW, 2003, BIOCHEM J, V370, P537, DOI 10.1042/BJ20020935; Zhang SQ, 2004, MOL CELL, V13, P341, DOI 10.1016/S1097-2765(04)00050-4; Zhang SQ, 2002, MOL CELL BIOL, V22, P4062, DOI 10.1128/MCB.22.12.4062-4072.2002; Zhao RX, 2000, J BIOL CHEM, V275, P5453, DOI 10.1074/jbc.275.8.5453; Zhao RX, 2002, J BIOL CHEM, V277, P7882, DOI 10.1074/jbc.M111914200; Zito CI, 2004, J CELL PHYSIOL, V199, P227, DOI 10.1002/jcp.10446	57	30	32	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15328	15338		10.1074/jbc.M801382200	http://dx.doi.org/10.1074/jbc.M801382200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18378677	Green Published, hybrid			2022-12-25	WOS:000256232000051
J	Bentley, ML; Lamb, EC; McCafferty, DG				Bentley, Matthew L.; Lamb, Erin C.; McCafferty, Dewey G.			Mutagenesis studies of substrate recognition and catalysis in the sortase A transpeptidase from Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NATIVE CHEMICAL LIGATION; GRAM-POSITIVE BACTERIA; SORTING SIGNAL BINDING; SURFACE-PROTEINS; CELL-WALL; LISTERIA-MONOCYTOGENES; SRTA GENE; VIRULENCE; COLONIZATION; PATHOGENESIS	The Staphylococcus aureus transpeptidase sortase A (SrtA) is responsible for anchoring a range of virulence- and colonization-associated proteins to the cell wall. SrtA recognizes substrates that contain a C-terminal LPXTGmotif. This sequence is cleaved following the threonine, and an amide bond is formed between the threonine and the pentaglycine cross-bridge of branched lipid II. Previous studies have implicated the beta 6/beta 7 loop region of SrtA in LPXTG recognition but have not systematically characterized this domain. To better understand the individual roles of the residues within this loop, we performed alanine-scanning mutagenesis. Val-168 and Leu-169 were found to be important for substrate recognition, and Glu-171 was also found to be important, consistent with its hypothesized role as a Ca2+-binding residue. Gly-167 and Asp-170 were dispensable for catalysis, as was Gln-172. The role of Arg-197 in SrtA has been the subject of much debate. To explore its role in catalysis, we used native chemical ligation to generate semi-synthetic SrtA in which we replaced Arg-197 with citrulline, a non-ionizable analog. This change resulted in a decrease of < 3-fold in k(cat)/K-m, indicating that Arg-197 utilizes a hydrogen bond, rather than an electrostatic interaction. Our results are consistent with a model for LPXTG recognition wherein the Leu-Pro sequence is recognized primarily by hydrophobic contacts with SrtA Val-168 and Leu-169, as well as a hydrogen bond from Arg-197. This model contradicts the previously proposed mechanism of binding predicted by the x-ray crystal structure of SrtA.	[Lamb, Erin C.; McCafferty, Dewey G.] Duke Univ, Dept Chem, Durham, NC 27708 USA; [Bentley, Matthew L.; McCafferty, Dewey G.] Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; [Bentley, Matthew L.; McCafferty, Dewey G.] Univ Penn, Sch Med, Johnson Res Fdn, Philadelphia, PA 19104 USA	Duke University; University of Pennsylvania; University of Pennsylvania	McCafferty, DG (corresponding author), Duke Univ, Dept Chem, B120 LSRC Bldg,Box 90317, Durham, NC 27708 USA.	dewey.mccaferty@duke.edu			NCRR NIH HHS [P41 RR006009] Funding Source: Medline; NIAID NIH HHS [R01 AI046611, AI 46611] Funding Source: Medline; NIGMS NIH HHS [T32 GM008275] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR006009] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046611] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008275] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alksne LE, 2000, CURR OPIN BIOTECH, V11, P625, DOI 10.1016/S0958-1669(00)00155-5; Appelbaum PC, 2006, CLIN MICROBIOL INFEC, V12, P16, DOI 10.1111/j.1469-0691.2006.01344.x; Appelbaum PC, 2006, CLIN MICROBIOL INFEC, V12, P3, DOI 10.1111/j.1469-0691.2006.01402.x; Appelbaum PC, 2007, INT J ANTIMICROB AG, V30, P398, DOI 10.1016/j.ijantimicag.2007.07.011; Barnett TC, 2002, J BACTERIOL, V184, P2181, DOI 10.1128/JB.184.8.2181-2191.2002; Bentley ML, 2007, J BIOL CHEM; Bierne H, 2002, MOL MICROBIOL, V43, P869, DOI 10.1046/j.1365-2958.2002.02798.x; Bolken TC, 2001, INFECT IMMUN, V69, P75, DOI 10.1128/IAI.69.1.75-80.2001; Clatworthy AE, 2007, NAT CHEM BIOL, V3, P541, DOI 10.1038/nchembio.2007.24; Dawson PE, 1997, METHOD ENZYMOL, V287, P34; DAWSON PE, 1994, SCIENCE, V266, P776, DOI 10.1126/science.7973629; FISCHETTI VA, 1990, MOL MICROBIOL, V4, P1603, DOI 10.1111/j.1365-2958.1990.tb02072.x; Frankel BA, 2005, BIOCHEMISTRY-US, V44, P11188, DOI 10.1021/bi050141j; Frankel BA, 2007, BIOCHEMISTRY-US, V46, P7269, DOI 10.1021/bi700448e; Garandeau C, 2002, INFECT IMMUN, V70, P1382, DOI 10.1128/IAI.70.3.1382-1390.2002; Hackeng TM, 1997, P NATL ACAD SCI USA, V94, P7845, DOI 10.1073/pnas.94.15.7845; Ilangovan U, 2001, P NATL ACAD SCI USA, V98, P6056, DOI 10.1073/pnas.101064198; IMPARL JM, 1995, ARCH BIOCHEM BIOPHYS, V318, P370, DOI 10.1006/abbi.1995.1242; Jantz D, 2003, J AM CHEM SOC, V125, P4960, DOI 10.1021/ja029671i; Kienhofer A, 2003, J AM CHEM SOC, V125, P3206, DOI 10.1021/ja0341992; Klevens RM, 2007, JAMA-J AM MED ASSOC, V298, P1763, DOI 10.1001/jama.298.15.1763; Klevens RM, 2006, EMERG INFECT DIS, V12, P1991; Kruger RG, 2004, BIOCHEMISTRY-US, V43, P1541, DOI 10.1021/bi035920j; Kruger RG, 2004, ANAL BIOCHEM, V326, P42, DOI 10.1016/j.ab.2003.10.023; Lalioui L, 2005, INFECT IMMUN, V73, P3342, DOI 10.1128/IAI.73.6.3342-3350.2005; Lee SF, 2003, INFECT IMMUN, V71, P676, DOI 10.1128/IAI.71.2.676-681.2003; Liew CK, 2004, FEBS LETT, V571, P221, DOI 10.1016/j.febslet.2004.06.070; Maresso AW, 2006, BIOMETALS, V19, P193, DOI 10.1007/s10534-005-4863-7; Marraffini LA, 2006, MICROBIOL MOL BIOL R, V70, P192, DOI 10.1128/MMBR.70.1.192-221.2006; Marraffini LA, 2004, J BIOL CHEM, V279, P37763, DOI 10.1074/jbc.M405282200; Mazmanian SK, 2002, P NATL ACAD SCI USA, V99, P2293, DOI 10.1073/pnas.032523999; Mazmanian SK, 2000, P NATL ACAD SCI USA, V97, P5510, DOI 10.1073/pnas.080520697; Mazmanian SK, 2001, MOL MICROBIOL, V40, P1049, DOI 10.1046/j.1365-2958.2001.02411.x; Metanis N, 2005, J AM CHEM SOC, V127, P5862, DOI 10.1021/ja050110b; Metanis N, 2004, J AM CHEM SOC, V126, P12726, DOI 10.1021/ja0463841; Naik MT, 2006, J BIOL CHEM, V281, P1817, DOI 10.1074/jbc.M506123200; Osaki M, 2002, J BACTERIOL, V184, P971, DOI 10.1128/jb.184.4.971-982.2002; Paterson GK, 2006, MICROBES INFECT, V8, P145, DOI 10.1016/j.micinf.2005.06.009; Perry AM, 2002, J BIOL CHEM, V277, P16241, DOI 10.1074/jbc.M109194200; Pritz S, 2007, J ORG CHEM, V72, P3909, DOI 10.1021/jo062331l; Ruzin A, 2002, J BACTERIOL, V184, P2141, DOI 10.1128/JB.184.8.2141-2147.2002; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; TANFORD C, 1962, J AM CHEM SOC, V84, P4240, DOI 10.1021/ja00881a009; Ton-That H, 2002, J BIOL CHEM, V277, P7447, DOI 10.1074/jbc.M109945200; Tsai YC, 2006, BIOCHEMISTRY-US, V45, P9675, DOI 10.1021/bi060993z; Yamaguchi M, 2006, MICROBES INFECT, V8, P2791, DOI 10.1016/j.micinf.2006.08.010; Zong YN, 2004, J BIOL CHEM, V279, P31383, DOI 10.1074/jbc.M401374200	47	59	62	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14762	14771		10.1074/jbc.M800974200	http://dx.doi.org/10.1074/jbc.M800974200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18375951	Green Published, hybrid			2022-12-25	WOS:000255941400064
J	Shenje, LT; Field, LJ; Pritchard, CA; Guerin, CJ; Rubart, M; Soonpaa, MH; Ang, KL; Galinanes, M				Shenje, Lincoln T.; Field, Loren J.; Pritchard, Catrin A.; Guerin, Christopher J.; Rubart, Michael; Soonpaa, Mark H.; Ang, Keng-Leong; Galinanes, Manuel			Lineage Tracing of Cardiac Explant Derived Cells	PLOS ONE			English	Article								Aims: Cultured cardiac explants produce a heterogeneous population of cells including a distinctive population of refractile cells described here as small round cardiac explant derived cells (EDCs). The aim of this study was to explore the source, morphology and cardiogenic potential of EDCs. Methods: Transgenic MLC2v-Cre/ZEG, and actin-eGFP mice were used for lineage-tracing of EDCs in vitro and in vivo. C57B16 mice were used as cell transplant recipients of EDCs from transgenic hearts, as well as for the general characterisation of EDCs. The activation of cardiac-specific markers were analysed by: immunohistochemistry with bright field and immunofluorescent microscopy, electron microscopy, PCR and RT-PCR. Functional engraftment of transplanted cells was further investigated with calcium transient studies. Results: Production of EDCs was highly dependent on the retention of blood-derived cells or factors in the cultured explants. These cells shared some characteristics of cardiac myocytes in vitro and survived engraftment in the adult heart in vivo. However, EDCs failed to differentiate into functional cardiac myocytes in vivo as demonstrated by the absence of stimulation-evoked intracellular calcium transients following transplantation into the peri-infarct zone. Conclusions: This study highlights that positive identification based upon one parameter alone such as morphology or immunofluorescene is not adequate to identify the source, fate and function of adult cardiac explant derived cells.	[Shenje, Lincoln T.; Ang, Keng-Leong; Galinanes, Manuel] Univ Leicester, Dept Cardiovasc Sci, Cardiac Surg Unit, Leicester, Leics, England; [Field, Loren J.; Rubart, Michael; Soonpaa, Mark H.] Indiana Univ, Sch Med, Krannert Inst Cardiol, Div Pediat Cardiol, Herman B Wells Ctr Pediat Res, Indianapolis, IN USA; [Pritchard, Catrin A.] Univ Leicester, Dept Biochem, Leicester, Leics, England; [Guerin, Christopher J.] Univ Leicester, MRC Toxicol Unit, Leicester, Leics, England	University of Leicester; Indiana University System; Indiana University-Purdue University Indianapolis; University of Leicester; University of Leicester	Shenje, LT (corresponding author), Univ Leicester, Dept Cardiovasc Sci, Cardiac Surg Unit, Leicester, Leics, England.	mg50@le.ac.uk	Guerin, Christopher/AAM-3233-2020; Galiñanes, Manuel/H-8195-2012	Pritchard, Catrin/0000-0003-1859-4487	Bristol Myer Squib Cardiovascular Prize Fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075165, R01HL083126] Funding Source: NIH RePORTER	Bristol Myer Squib Cardiovascular Prize Fellowship; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))	Bristol Myer Squib Cardiovascular Prize Fellowship 2003 (LTS)	Bedada FB, 2005, MOL CELL BIOL, V25, P9509, DOI 10.1128/MCB.25.21.9509-9519.2005; Chen J, 1998, J BIOL CHEM, V273, P1252, DOI 10.1074/jbc.273.2.1252; Fazel S, 2006, J CLIN INVEST, V116, P1865, DOI 10.1172/JCI27019; Koyanagi M, 2005, CIRC RES, V96, P1039, DOI 10.1161/01.RES.0000168650.23479.0c; Massberg S, 2007, CELL, V131, P994, DOI 10.1016/j.cell.2007.09.047; Messina E, 2004, CIRC RES, V95, P911, DOI 10.1161/01.RES.0000147315.71699.51; Murry CE, 2004, NATURE, V428, P664, DOI 10.1038/nature02446; Novak A, 2000, GENESIS, V28, P147, DOI 10.1002/1526-968X(200011/12)28:3/4<147::AID-GENE90>3.0.CO;2-G; Okabe M, 1997, FEBS LETT, V407, P313, DOI 10.1016/S0014-5793(97)00313-X; Planat-Benard V, 2004, CIRCULATION, V109, P656, DOI 10.1161/01.CIR.0000114522.38265.61; Rubart M, 2004, J CLIN INVEST, V114, P775, DOI 10.1172/JCI200421589; Rubart M, 2003, CIRC RES, V92, P1217, DOI 10.1161/01.RES.0000075089.39335.8C; Rubart M, 2003, AM J PHYSIOL-CELL PH, V284, pC1654, DOI 10.1152/ajpcell.00469.2002; Schulze M, 2005, GENE DEV, V19, P1787, DOI 10.1101/gad.339305; Smith RR, 2007, CIRCULATION, V115, P896, DOI 10.1161/CIRCULATIONAHA.106.655209; Steele A, 2005, J HEART LUNG TRANSPL, V24, P1930, DOI 10.1016/j.healun.2005.02.001	16	35	42	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1929	10.1371/journal.pone.0001929	http://dx.doi.org/10.1371/journal.pone.0001929			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414652	gold, Green Published, Green Submitted			2022-12-25	WOS:000260867300001
J	Gisselsson, D; Hakanson, U; Stoller, P; Marti, D; Jin, Y; Rosengren, AH; Stewenius, Y; Kahl, F; Panagopoulos, I				Gisselsson, David; Hakanson, Ulf; Stoller, Patrick; Marti, Dominik; Jin, Yuesheng; Rosengren, Anders H.; Stewenius, Ylva; Kahl, Fredrik; Panagopoulos, Ioannis			When the Genome Plays Dice: Circumvention of the Spindle Assembly Checkpoint and Near-Random Chromosome Segregation in Multipolar Cancer Cell Mitoses	PLOS ONE			English	Article							CENTROSOME AMPLIFICATION; GENETIC INSTABILITY; TELOMERE DYSFUNCTION; MITOTIC CHECKPOINT; ANEUPLOIDY; COMPLEX; KINASE; OVEREXPRESSION; TUMORIGENESIS; DUPLICATION	Background: Normal cell division is coordinated by a bipolar mitotic spindle, ensuring symmetrical segregation of chromosomes. Cancer cells, however, occasionally divide into three or more directions. Such multipolar mitoses have been proposed to generate genetic diversity and thereby contribute to clonal evolution. However, this notion has been little validated experimentally. Principal Findings: Chromosome segregation and DNA content in daughter cells from multipolar mitoses were assessed by multiphoton cross sectioning and fluorescence in situ hybridization in cancer cells and non-neoplastic transformed cells. The DNA distribution resulting from multipolar cell division was found to be highly variable, with frequent nullisomies in the daughter cells. Time-lapse imaging of H2B/GFP-labelled multipolar mitoses revealed that the time from the initiation of metaphase to the beginning of anaphase was prolonged and that the metaphase plates often switched polarity several times before metaphase-anaphase transition. The multipolar metaphase-anaphase transition was accompanied by a normal reduction of cellular cyclin B levels, but typically occurred before completion of the normal separase activity cycle. Centromeric AURKB and MAD2 foci were observed frequently to remain on the centromeres of multipolar ana-telophase chromosomes, indicating that multipolar mitoses were able to circumvent the spindle assembly checkpoint with some sister chromatids remaining unseparated after anaphase. Accordingly, scoring the distribution of individual chromosomes in multipolar daughter nuclei revealed a high frequency of nondisjunction events, resulting in a near-binomial allotment of sister chromatids to the daughter cells. Conclusion: The capability of multipolar mitoses to circumvent the spindle assembly checkpoint system typically results in a near-random distribution of chromosomes to daughter cells. Spindle multipolarity could thus be a highly efficient generator of genetically diverse minority clones in transformed cell populations.	[Gisselsson, David; Jin, Yuesheng; Stewenius, Ylva; Panagopoulos, Ioannis] Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden; [Gisselsson, David] Lund Univ Hosp, Dept Pathol, Lund, Sweden; [Hakanson, Ulf] Lund Univ, Div Solid State Phys, Nanometer Structure Consortium, Lund, Sweden; [Stoller, Patrick; Marti, Dominik] Univ Bern, Inst Appl Phys, Bern, Switzerland; [Rosengren, Anders H.] Lund Univ, Dept Clin Sci Malmo, Lund, Sweden; [Kahl, Fredrik] Lund Univ, Dept Math, Lund, Sweden	Lund University; Skane University Hospital; Lund University; Skane University Hospital; Lund University; University of Bern; Lund University; Lund University	Gisselsson, D (corresponding author), Univ Lund Hosp, Dept Clin Genet, S-22185 Lund, Sweden.	david.gisselsson@med.lu.se	Rosengren, Anders/E-8371-2012; Marti, Dominik/B-4856-2008; Hakanson, Ulf/A-1862-2009	Rosengren, Anders/0000-0002-9333-5736; Marti, Dominik/0000-0002-1745-3116; Stoller, Patrick/0000-0002-6620-1249; Panagopoulos, Ioannis/0000-0003-2159-5341	Swedish Children's Cancer Foundation; Swedish Cancer Society; Swedish Research Council; Swedish Medical Society; Swiss National Science Foundation [3152A0-100431]; Lund University Hospital Donation Funds; Gunnar Nilsson Cancer Foundation; Medical Faculty of Lund University; Crafoord Foundation; Erik-Philip Sorensen Foundation; Lundgren Foundation; Sward Foundation	Swedish Children's Cancer Foundation; Swedish Cancer Society(Swedish Cancer Society); Swedish Research Council(Swedish Research CouncilEuropean Commission); Swedish Medical Society; Swiss National Science Foundation(Swiss National Science Foundation (SNSF)European Commission); Lund University Hospital Donation Funds; Gunnar Nilsson Cancer Foundation; Medical Faculty of Lund University; Crafoord Foundation; Erik-Philip Sorensen Foundation; Lundgren Foundation; Sward Foundation	This study was supported by the Swedish Children's Cancer Foundation, the Swedish Cancer Society, the Swedish Research Council, the Swedish Medical Society, the Swiss National Science Foundation (Grant 3152A0-100431), the Lund University Hospital Donation Funds, the Gunnar Nilsson Cancer Foundation, the Medical Faculty of Lund University, the Crafoord Foundation, the Erik-Philip Sorensen Foundation, the Lundgren Foundation, and the Sward Foundation. The funders had no role in the conduct of the study, or in the collection, analysis, interpretation of the data, or in the preparation, review, or approval of the manuscript.	Alami J, 2003, INT J CANCER, V107, P365, DOI 10.1002/ijc.11429; Brito DA, 2006, CURR BIOL, V16, P1194, DOI 10.1016/j.cub.2006.04.043; Bylund L, 2004, CYTOGENET GENOME RES, V106, P28, DOI 10.1159/000078556; Cahill DP, 1998, NATURE, V392, P300, DOI 10.1038/32688; Carmena M, 2003, NAT REV MOL CELL BIO, V4, P842, DOI 10.1038/nrm1245; Chestukhin A, 2003, P NATL ACAD SCI USA, V100, P4574, DOI 10.1073/pnas.0730733100; CHNG WJ, 2007, BLOOD; Ciosk R, 1998, CELL, V93, P1067, DOI 10.1016/S0092-8674(00)81211-8; D'Assoro AB, 2002, BREAST CANCER RES TR, V75, P25, DOI 10.1023/A:1016550619925; Deng CX, 2001, MUTAT RES-FUND MOL M, V477, P183, DOI 10.1016/S0027-5107(01)00119-1; Duensing A, 2007, ONCOGENE, V26, P6280, DOI 10.1038/sj.onc.1210456; Duensing A, 2006, CELL CYCLE, V5, P2899, DOI 10.4161/cc.5.24.3567; Duensing S, 2000, P NATL ACAD SCI USA, V97, P10002, DOI 10.1073/pnas.170093297; DUENSING S, 2001, BIOCHIM BIOPHYS ACTA, V1471, P81; Emdad L, 2005, FRONT BIOSCI-LANDMRK, V10, P728; Ghadimi BM, 2000, GENE CHROMOSOME CANC, V27, P183, DOI 10.1002/(SICI)1098-2264(200002)27:2<183::AID-GCC10>3.0.CO;2-P; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Gisselsson D, 2001, P NATL ACAD SCI USA, V98, P12683, DOI 10.1073/pnas.211357798; Hansemann D., 1890, ARCH PATHOL ANAT PH, V119, P299, DOI DOI 10.1007/BF01882039; Iovino F, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-38; Jensen S, 2001, J CELL BIOL, V152, P27, DOI 10.1083/jcb.152.1.27; Jin YS, 2007, CLIN CANCER RES, V13, P1703, DOI 10.1158/1078-0432.CCR-06-2705; Kanda T, 1998, CURR BIOL, V8, P377, DOI 10.1016/S0960-9822(98)70156-3; Kaneko Y, 2000, GENE CHROMOSOME CANC, V29, P89, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1021>3.0.CO;2-Y; Klisch K, 2005, CELLS TISSUES ORGANS, V181, P103, DOI 10.1159/000091099; Landen CN, 2007, CLIN CANCER RES, V13, P4098, DOI 10.1158/1078-0432.CCR-07-0431; Lengauer C, 1997, NATURE, V386, P623, DOI 10.1038/386623a0; Lingle WL, 2002, P NATL ACAD SCI USA, V99, P1978, DOI 10.1073/pnas.032479999; Mattsson G, 2007, J MOL DIAGN, V9, P479, DOI 10.2353/jmoldx.2007.070041; Michaelis C, 1997, CELL, V91, P35, DOI 10.1016/S0092-8674(01)80007-6; Nasmyth K, 2005, CELL, V120, P739, DOI 10.1016/j.cell.2005.03.006; Nigg EA, 2002, NAT REV CANCER, V2, P815, DOI 10.1038/nrc924; Nigg EA, 2007, TRENDS CELL BIOL, V17, P215, DOI 10.1016/j.tcb.2007.03.003; PALITTI F, 1972, GENETICA, V43, P130; PERA F, 1969, CHROMOSOMA, V26, P337, DOI 10.1007/BF00326527; Quintyne NJ, 2005, SCIENCE, V307, P127, DOI 10.1126/science.1104905; Reiter R, 2006, CLIN CANCER RES, V12, P5136, DOI 10.1158/1078-0432.CCR-05-1650; RIZZONI M, 1974, CHROMOSOMA, V45, P151, DOI 10.1007/BF00362308; Saunders W, 2005, SEMIN CANCER BIOL, V15, P25, DOI 10.1016/j.semcancer.2004.09.003; Saunders WS, 2000, P NATL ACAD SCI USA, V97, P303, DOI 10.1073/pnas.97.1.303; Shinmura K, 2007, ONCOGENE, V26, P2939, DOI 10.1038/sj.onc.1210085; Steinbeck RG, 1998, BRIT J CANCER, V77, P1027, DOI 10.1038/bjc.1998.171; Stewenius Y, 2005, P NATL ACAD SCI USA, V102, P5541, DOI 10.1073/pnas.0408454102; Stewenius Y, 2007, CLIN CANCER RES, V13, P6593, DOI 10.1158/1078-0432.CCR-07-1081; Tanaka TU, 2002, CELL, V108, P317, DOI 10.1016/S0092-8674(02)00633-5; TEPLITZ RL, 1968, EXP CELL RES, V52, P379, DOI 10.1016/0014-4827(68)90479-5; Tutt A, 1999, CURR BIOL, V9, P1107, DOI 10.1016/S0960-9822(99)80479-5; Uhlmann F, 1999, NATURE, V400, P37, DOI 10.1038/21831; Wirth KG, 2006, J CELL BIOL, V172, P847, DOI 10.1083/jcb.200506119; Xu XL, 1999, MOL CELL, V3, P389, DOI 10.1016/S1097-2765(00)80466-9; Yamamoto Y, 2006, CLIN CANCER RES, V12, P2752, DOI 10.1158/1078-0432.CCR-05-0805; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zipfel WR, 2003, NAT BIOTECHNOL, V21, P1368, DOI 10.1038/nbt899	53	41	43	0	5	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1871	10.1371/journal.pone.0001871	http://dx.doi.org/10.1371/journal.pone.0001871			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18392149	Green Published, Green Submitted, gold			2022-12-25	WOS:000260795400011
J	Meadows, SK; Dressman, HK; Muramoto, GG; Himburg, H; Salter, A; Wei, ZZ; Ginsburg, G; Chao, NJ; Nevins, JR; Chute, JP				Meadows, Sarah K.; Dressman, Holly K.; Muramoto, Garrett G.; Himburg, Heather; Salter, Alice; Wei, ZhengZheng; Ginsburg, Geoff; Chao, Nelson J.; Nevins, Joseph R.; Chute, John P.			Gene Expression Signatures of Radiation Response Are Specific, Durable and Accurate in Mice and Humans	PLOS ONE			English	Article							RETRACTED ARTICLE. SEE; EXPOSURE; CELLS; LIPOPOLYSACCHARIDE; LYMPHOCYTES; BIOMARKERS; FREQUENCY; PATTERNS; P53	Background: Previous work has demonstrated the potential for peripheral blood (PB) gene expression profiling for the detection of disease or environmental exposures. Methods and Findings: We have sought to determine the impact of several variables on the PB gene expression profile of an environmental exposure, ionizing radiation, and to determine the specificity of the PB signature of radiation versus other genotoxic stresses. Neither genotype differences nor the time of PB sampling caused any lessening of the accuracy of PB signatures to predict radiation exposure, but sex difference did influence the accuracy of the prediction of radiation exposure at the lowest level (50 cGy). A PB signature of sepsis was also generated and both the PB signature of radiation and the PB signature of sepsis were found to be 100% specific at distinguishing irradiated from septic animals. We also identified human PB signatures of radiation exposure and chemotherapy treatment which distinguished irradiated patients and chemotherapy-treated individuals within a heterogeneous population with accuracies of 90% and 81%, respectively. Conclusions: We conclude that PB gene expression profiles can be identified in mice and humans that are accurate in predicting medical conditions, are specific to each condition and remain highly accurate over time.	[Meadows, Sarah K.; Muramoto, Garrett G.; Himburg, Heather; Salter, Alice; Chao, Nelson J.; Chute, John P.] Duke Univ, Med Ctr, Div Cell Therapy, Durham, NC 27706 USA; [Dressman, Holly K.; Wei, ZhengZheng; Nevins, Joseph R.] Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC USA; [Dressman, Holly K.; Ginsburg, Geoff; Nevins, Joseph R.; Chute, John P.] Duke Univ, Med Ctr, Inst Genome Sci & Policy, Durham, NC USA	Duke University; Duke University; Duke University	Meadows, SK (corresponding author), Duke Univ, Med Ctr, Div Cell Therapy, Durham, NC 27706 USA.	john.chute@duke.edu			National Institutes of Allergy and Infectious Diseases [AI-067798-01]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U19AI067798] Funding Source: NIH RePORTER	National Institutes of Allergy and Infectious Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))	This research was funded, in part, by grant AI-067798-01 from the National Institutes of Allergy and Infectious Diseases (JRN and JPC).	Alizadeh AA, 2000, NATURE, V403, P503, DOI 10.1038/35000501; Amundson SA, 2000, RADIAT RES, V154, P342, DOI 10.1667/0033-7587(2000)154[0342:IOPMBI]2.0.CO;2; Amundson SA, 2004, CANCER RES, V64, P6368, DOI 10.1158/0008-5472.CAN-04-1883; Amundson SA, 2001, RADIAT RES, V156, P657, DOI 10.1667/0033-7587(2001)156[0657:IOGEAA]2.0.CO;2; Baird AE, 2007, STROKE, V38, P694, DOI 10.1161/01.STR.0000250431.99687.7b; Boldrick JC, 2002, P NATL ACAD SCI USA, V99, P972, DOI 10.1073/pnas.231625398; Boolchand V, 2006, ANN INTERN MED, V145, P654, DOI 10.7326/0003-4819-145-9-200611070-00007; Cheng SH, 2006, J CLIN ONCOL, V24, P4594, DOI 10.1200/JCO.2005.02.5676; Dainiak N, 2002, EXP HEMATOL, V30, P513, DOI 10.1016/S0301-472X(02)00802-0; DAMLE R, 2007, BLOOD; Dressman HK, 2007, PLOS MED, V4, P690, DOI 10.1371/journal.pmed.0040106; Edwards CJ, 2007, MOL MED, V13, P40, DOI 10.2119/2006-000056.Edwards; Einstein AJ, 2007, CIRCULATION, V116, P1290, DOI 10.1161/CIRCULATIONAHA.107.688101; Falt S, 2003, CARCINOGENESIS, V24, P1837, DOI 10.1093/carcin/bgg134; Heller RA, 1997, P NATL ACAD SCI USA, V94, P2150, DOI 10.1073/pnas.94.6.2150; Hick RW, 2006, J IMMUNOL, V177, P169, DOI 10.4049/jimmunol.177.1.169; HIRAI Y, 1995, MUTAT RES-FUND MOL M, V329, P183, DOI 10.1016/0027-5107(95)00044-J; Horwitz PA, 2004, CIRCULATION, V110, P3815, DOI 10.1161/01.CIR.0000150539.72783.BF; Hsieh SC, 2002, ONCOGENE, V21, P3050, DOI 10.1038/sj.onc.1205417; Inoue K, 2005, FASEB J, V19, P533, DOI 10.1096/fj.05-3864fje; Iwamoto KS, 1998, J NATL CANCER I, V90, P1167, DOI 10.1093/jnci/90.15.1167; Jen KY, 2003, GENOME RES, V13, P2092, DOI 10.1101/gr.1240103; Kaiser J, 2003, SCIENCE, V302, P378, DOI 10.1126/science.302.5644.378; Lampe JW, 2004, CANCER EPIDEM BIOMAR, V13, P445; Lin BC, 2003, CLIN CHEM, V49, P1045, DOI 10.1373/49.7.1045; Mandel M, 2006, LUPUS, V15, P451, DOI 10.1191/0961203306lu2332oa; Martin KJ, 2001, P NATL ACAD SCI USA, V98, P2646, DOI 10.1073/pnas.041622398; Mettler FA, 2002, NEW ENGL J MED, V346, P1554, DOI 10.1056/NEJMra000365; Moore DH, 1997, RADIAT RES, V148, P463, DOI 10.2307/3579324; NEEL JV, 1990, ANNU REV GENET, V24, P327; Nevins JR, 2007, NAT REV GENET, V8, P601, DOI 10.1038/nrg2137; Patino WD, 2005, P NATL ACAD SCI USA, V102, P3423, DOI 10.1073/pnas.0408032102; Potti A, 2006, NAT MED, V12, P1294, DOI 10.1038/nm1491; Potti A, 2006, NEW ENGL J MED, V355, P570, DOI 10.1056/NEJMoa060467; POURNARA I, 2007, BMC BIOINFORMATICS, V23, P1; Ramilo O, 2007, BLOOD, V109, P2066, DOI 10.1182/blood-2006-02-002477; Rubins KH, 2004, P NATL ACAD SCI USA, V101, P15190, DOI 10.1073/pnas.0405759101; Seierstad T, 2007, RADIAT PROT DOSIM, V123, P246, DOI 10.1093/rpd/ncl141; TAKESHIMA Y, 1993, LANCET, V342, P1520, DOI 10.1016/S0140-6736(05)80087-X; Valenzuela HF, 2007, CANCER RES, V67, P6155, DOI 10.1158/0008-5472.CAN-05-4431; Waselenko JK, 2004, ANN INTERN MED, V140, P1037, DOI 10.7326/0003-4819-140-12-200406150-00015; Whitney AR, 2003, P NATL ACAD SCI USA, V100, P1896, DOI 10.1073/pnas.252784499; Yan H, 2002, SCIENCE, V297, P1143, DOI 10.1126/science.1072545	43	80	89	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1912	10.1371/journal.pone.0001912	http://dx.doi.org/10.1371/journal.pone.0001912			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382685	Green Published, gold			2022-12-25	WOS:000260795400037
J	Wagner, S; Storbeck, CJ; Roovers, K; Chaar, ZY; Kolodziej, P; Mckay, M; Sabourin, LA				Wagner, Simona; Storbeck, Chris J.; Roovers, Kristin; Chaar, Ziad Y.; Kolodziej, Piotr; Mckay, Marlene; Sabourin, Luc A.			FAK/src-Family Dependent Activation of the Ste20-Like Kinase SLK Is Required for Microtubule-Dependent Focal Adhesion Turnover and Cell Migration	PLOS ONE			English	Article								Cell migration involves a multitude of signals that converge on cytoskeletal reorganization, essential for development, immune responses and tissue repair. Using knockdown and dominant negative approaches, we show that the microtubule-associated Ste20-like kinase SLK is required for focal adhesion turnover and cell migration downstream of the FAK/c-src complex. Our results show that SLK co-localizes with paxillin, Rac1 and the microtubules at the leading edge of migrating cells and is activated by scratch wounding. SLK activation is dependent on FAK/c-src/MAPK signaling, whereas SLK recruitment to the leading edge is src-dependent but FAK independent. Our results show that SLK represents a novel focal adhesion disassembly signal.	[Wagner, Simona; Chaar, Ziad Y.; Sabourin, Luc A.] Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada; [Storbeck, Chris J.; Roovers, Kristin; Kolodziej, Piotr; Mckay, Marlene; Sabourin, Luc A.] Ottawa Hlth Res Inst, Canc Therapeut, Ottawa, ON, Canada	University of Ottawa; University of Ottawa; Ottawa Hospital Research Institute	Wagner, S (corresponding author), Univ Ottawa, Dept Cellular & Mol Med, Ottawa, ON, Canada.	lsabourin@ohri.ca			Canadian Institute for Health Research; MDAUSA; Premier's Research for Excellence Award; Canadian Heart and Stroke Foundation Fellowship; Canadian Breast Cancer Foundation; CIHR scholar award; OGSST; NSERC [studentship]	Canadian Institute for Health Research(Canadian Institutes of Health Research (CIHR)); MDAUSA(Muscular Dystrophy Association); Premier's Research for Excellence Award; Canadian Heart and Stroke Foundation Fellowship(Heart & Stroke Foundation of Canada); Canadian Breast Cancer Foundation(Canadian Cancer Society (CCS)); CIHR scholar award(Canadian Institutes of Health Research (CIHR)); OGSST; NSERC(Natural Sciences and Engineering Research Council of Canada (NSERC))	This work was supported by the Canadian Institute for Health Research, MDAUSA and a Premier's Research for Excellence Award. CJS is the recipient of a Canadian Heart and Stroke Foundation Fellowship. KR is supported by the Canadian Breast Cancer Foundation. LAS is the recipient of a CIHR scholar award. SW is supported by OGSST and NSERC studentship.	Angers-Loustau A, 1999, J CELL BIOL, V144, P1019, DOI 10.1083/jcb.144.5.1019; Arias-Salgado EG, 2003, P NATL ACAD SCI USA, V100, P13298, DOI 10.1073/pnas.2336149100; Arthur WT, 2000, CURR BIOL, V10, P719, DOI 10.1016/S0960-9822(00)00537-6; Bershadsky A, 1996, CURR BIOL, V6, P1279, DOI 10.1016/S0960-9822(02)70714-8; Brown MC, 2004, PHYSIOL REV, V84, P1315, DOI 10.1152/physrev.00002.2004; Brunton VG, 2005, CANCER RES, V65, P1335, DOI 10.1158/0008-5472.CAN-04-1949; Brunton VG, 2004, BBA-MOL CELL RES, V1692, P121, DOI 10.1016/j.bbamcr.2004.04.010; Chaar Z, 2006, J BIOL CHEM, V281, P28193, DOI 10.1074/jbc.M605665200; Cook TA, 1998, J CELL BIOL, V141, P175, DOI 10.1083/jcb.141.1.175; Enomoto T, 1996, CELL STRUCT FUNCT, V21, P317, DOI 10.1247/csf.21.317; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Etienne-Manneville S, 2001, CELL, V106, P489, DOI 10.1016/S0092-8674(01)00471-8; Ezratty EJ, 2005, NAT CELL BIOL, V7, P581, DOI 10.1038/ncb1262; Fincham VJ, 1998, EMBO J, V17, P81, DOI 10.1093/emboj/17.1.81; Hamadi A, 2005, J CELL SCI, V118, P4415, DOI 10.1242/jcs.02565; Hao W, 2006, J BIOL CHEM, V281, P3075, DOI 10.1074/jbc.M511744200; Huang C, 2004, J CELL SCI, V117, P4619, DOI 10.1242/jcs.01481; KAPLAN KB, 1994, EMBO J, V13, P4745, DOI 10.1002/j.1460-2075.1994.tb06800.x; Kaverina I, 1998, J CELL BIOL, V142, P181, DOI 10.1083/jcb.142.1.181; Kaverina I, 1999, J CELL BIOL, V146, P1033, DOI 10.1083/jcb.146.5.1033; Kaverina I, 2002, INT J BIOCHEM CELL B, V34, P746, DOI 10.1016/S1357-2725(01)00171-6; Laurent CE, 2004, MOL CELL BIOL, V24, P9351, DOI 10.1128/MCB.24.21.9351-9358.2004; McGarrigle D, 2006, J BIOL CHEM, V281, P10583, DOI 10.1074/jbc.M513002200; Mitra SK, 2006, CURR OPIN CELL BIOL, V18, P516, DOI 10.1016/j.ceb.2006.08.011; Mitra SK, 2005, NAT REV MOL CELL BIO, V6, P56, DOI 10.1038/nrm1549; O'Reilly PG, 2005, J BIOL CHEM, V280, P42383, DOI 10.1074/jbc.M510763200; Palazzo AF, 2004, SCIENCE, V303, P836, DOI 10.1126/science.1091325; Ren XD, 2000, J CELL SCI, V113, P3673; Rengifo-Cam W, 2004, ONCOGENE, V23, P289, DOI 10.1038/sj.onc.1207041; Sabourin LA, 2000, MOL CELL BIOL, V20, P684, DOI 10.1128/MCB.20.2.684-696.2000; Sabourin LA, 1999, ONCOGENE, V18, P7566, DOI 10.1038/sj.onc.1203119; Schaar DG, 1996, BRAIN RES, V721, P217, DOI 10.1016/0006-8993(96)00176-X; Schaller MD, 1999, MOL BIOL CELL, V10, P3489, DOI 10.1091/mbc.10.10.3489; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; Schaller MD, 2001, ONCOGENE, V20, P6459, DOI 10.1038/sj.onc.1204786; Schlaepfer DD, 1999, PROG BIOPHYS MOL BIO, V71, P435, DOI 10.1016/S0079-6107(98)00052-2; Schlaepfer DD, 1997, MOL CELL BIOL, V17, P1702, DOI 10.1128/MCB.17.3.1702; Schlaepfer DD, 2004, CURR OPIN GENET DEV, V14, P92, DOI 10.1016/j.gde.2003.12.002; Schwartz MA, 2006, CELL, V125, P1223, DOI 10.1016/j.cell.2006.06.015; Sieg DJ, 1999, J CELL SCI, V112, P2677; Sieg DJ, 1998, EMBO J, V17, P5933, DOI 10.1093/emboj/17.20.5933; Simon JR, 1998, J NEUROCYTOL, V27, P119, DOI 10.1023/A:1006999306413; Small JV, 2002, TRENDS CELL BIOL, V12, P112, DOI 10.1016/S0962-8924(01)02237-1; Storbeck CJ, 2004, MUSCLE NERVE, V29, P553, DOI 10.1002/mus.20000; Sulimenko V, 2006, J IMMUNOL, V176, P7243, DOI 10.4049/jimmunol.176.12.7243; Wagner S, 2002, J BIOL CHEM, V277, P37685, DOI 10.1074/jbc.M205899200; Webb DJ, 2002, NAT CELL BIOL, V4, pE97, DOI 10.1038/ncb0402-e97; Webb DJ, 2004, NAT CELL BIOL, V6, P154, DOI 10.1038/ncb1094; Wittmann T, 2003, J CELL BIOL, V161, P845, DOI 10.1083/jcb.200303082	50	42	42	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1868	10.1371/journal.pone.0001868	http://dx.doi.org/10.1371/journal.pone.0001868			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382658	Green Published, Green Submitted, gold			2022-12-25	WOS:000260795400008
J	Arora, P; Cuevas, BD; Russo, A; Johnson, GL; Trejo, J				Arora, P.; Cuevas, B. D.; Russo, A.; Johnson, G. L.; Trejo, J.			Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotes breast carcinoma cell invasion	ONCOGENE			English	Article						thrombin; GPCR; metalloprotease; MDA-MB-231; g protein	THROMBIN RECEPTOR; MONOCLONAL-ANTIBODY; CANCER; DESENSITIZATION; PROLIFERATION; CHEMOTHERAPY; MIGRATION; CLEAVAGE; REVEALS; FAMILY	Hyperactivation of ErbB signaling is implicated in metastatic breast cancer. However, the mechanisms that cause dysregulated ErbB signaling and promote breast carcinoma cell invasion remain poorly understood. One pathway leading to ErbB activation that remains unexplored in breast carcinoma cell invasion involves transactivation by G-protein-coupled receptors (GPCRs). Protease-activated receptor-1 (PAR1), a GPCR activated by extracellular proteases, is overexpressed in invasive breast cancer. PAR1 is also proposed to function in breast cancer invasion and metastasis, but how PAR1 contributes to these processes is not known. In this study, we report that proteolytic activation of PAR1 by thrombin induces persistent transactivation of EGFR and ErbB2/HER2 in invasive breast carcinoma, but not in normal mammary epithelial cells. PAR1-stimulated EGFR and ErbB2 transactivation leads to prolonged extracellular signal-regulated kinase-1 and -2 signaling and promotes breast carcinoma cell invasion. We also show that PAR1 signaling through G alpha(i/o) and metalloprotease activity is critical for ErbB transactivation and cellular invasion. Finally, we demonstrate that PAR1 expression in invasive breast carcinoma is essential for tumor growth in vivo assessed by mammary fat pad xenografts. These studies reveal a critical role for PAR1, a receptor activated by tumor-generated proteases, in hyperactivation of ErbB signaling that promotes breast carcinoma cell invasion.	[Arora, P.; Cuevas, B. D.; Russo, A.; Johnson, G. L.; Trejo, J.] Univ N Carolina, Sch Med, Lineberger Canc Res Ctr, Dept Pharmacol, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine	Trejo, J (corresponding author), Univ Calif San Diego, Sch Med, Dept Pharmacol, BSB 3018,9500 Gilman Dr, La Jolla, CA 92093 USA.	joann_trejo@med.unc.edu	, Pathology Services Core/CEZ-2246-2022	TREJO, JOANN/0000-0003-4405-6228	NHLBI NIH HHS [R01 HL073328, HL073328, R01 HL073328-06] Funding Source: Medline; NIDDK NIH HHS [R01 DK037871, DK37871] Funding Source: Medline; NIGMS NIH HHS [R37 GM030324, GM30324, R01 GM030324] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073328] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arora P, 2007, J CELL SCI, V120, P921, DOI 10.1242/jcs.03409; Asakura M, 2002, NAT MED, V8, P35, DOI 10.1038/nm0102-35; Bergmann S, 2006, ONCOL REP, V15, P889; Boire A, 2005, CELL, V120, P303, DOI 10.1016/j.cell.2004.12.018; Booden MA, 2004, MOL CELL BIOL, V24, P1990, DOI 10.1128/MCB.24.5.1990-1999.2004; Borrell-Pages M, 2003, EMBO J, V22, P1114, DOI 10.1093/emboj/cdg111; Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2; Cobleigh MA, 1999, J CLIN ONCOL, V17, P2639, DOI 10.1200/JCO.1999.17.9.2639; Darmoul D, 2004, MOL CANCER RES, V2, P514; Daub H, 1996, NATURE, V379, P557, DOI 10.1038/379557a0; Even-Ram S, 1998, NAT MED, V4, P909, DOI 10.1038/nm0898-909; Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0; Gschwind A, 2003, EMBO J, V22, P2411, DOI 10.1093/emboj/cdg231; Hart S, 2005, BIOL CHEM, V386, P845, DOI 10.1515/BC.2005.099; Kelly P, 2006, P NATL ACAD SCI USA, V103, P8173, DOI 10.1073/pnas.0510254103; Kuliopulos A, 1999, BIOCHEMISTRY-US, V38, P4572, DOI 10.1021/bi9824792; Lautrette A, 2005, NAT MED, V11, P867, DOI 10.1038/nm1275; Morris DR, 2006, CANCER RES, V66, P307, DOI 10.1158/0008-5472.CAN-05-1735; Nahta R, 2007, ONCOGENE, V26, P3637, DOI 10.1038/sj.onc.1210379; Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3; Noma T, 2007, J CLIN INVEST, V117, P2445, DOI 10.1172/JCI31901; Ohtsu H, 2006, AM J PHYSIOL-CELL PH, V291, pC1, DOI 10.1152/ajpcell.00620.2005; Paing MM, 2006, MOL CELL BIOL, V26, P3231, DOI 10.1128/MCB.26.8.3231-3242.2006; Paing MM, 2002, J BIOL CHEM, V277, P1292, DOI 10.1074/jbc.M109160200; Prenzel N, 1999, NATURE, V402, P884, DOI 10.1038/47260; PRICE JE, 1990, CANCER RES, V50, P717; Salah Z, 2007, MOL CANCER RES, V5, P229, DOI 10.1158/1541-7786.MCR-06-0261; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; Wetzker R, 2003, NAT REV MOL CELL BIO, V4, P651, DOI 10.1038/nrm1173; Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370; Yarden Y, 2001, ONCOLOGY-BASEL, V61, P1, DOI 10.1159/000055396	32	98	101	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4434	4445		10.1038/onc.2008.84	http://dx.doi.org/10.1038/onc.2008.84			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18372913	Green Published, Green Accepted			2022-12-25	WOS:000257881700006
J	Spirig, T; Tiaden, A; Kiefer, P; Buchrieser, C; Vorholt, JA; Hilbi, H				Spirig, Thomas; Tiaden, Andre; Kiefer, Patrick; Buchrieser, Carmen; Vorholt, Julia A.; Hilbi, Hubert			The Legionella autoinducer synthase LqsA produces an alpha-hydroxyketone signaling molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACANTHAMOEBA-CASTELLANII; STATIONARY-PHASE; 8-AMINO-7-OXONONANOATE SYNTHASE; TRANSMISSION PHENOTYPE; LEGIONNAIRES-DISEASE; PATHOGENIC BACTERIA; REGULATORY NETWORK; PNEUMOPHILA GENOME; COXIELLA-BURNETII; MASS-SPECTROMETRY	The opportunistic pathogen Legionella pneumophila replicates in human lung macrophages and in free- living amoebae. To accommodate the transfer between host cells, L. pneumophila switches from a replicative to a transmissive phase. L. pneumophila harbors a gene cluster homologous to the Vibrio cholerae cqsAS quorum sensing system, encoding a putative autoinducer synthase (lqsA) and a sensor kinase (lqsS), which flank a response regulator (lqsR). LqsR is an element of the L. pneumophila virulence regulatory network, which promotes pathogen-host cell interactions and inhibits entry into the replicative growth phase. Here, we show that lqsA functionally complements a V. cholerae cqsA autoinducer synthase deletion mutant and, upon expression in L. pneumophila or Escherichia coli, produces the diffusible signaling molecule LAI-1 (Legionella autoinducer-1). LAI-1 is distinct from CAI-1 (Cholerae autoinducer-1) and was identified as 3-hydroxypentadecan4- one using liquid chromatography coupled to high resolution tandem mass spectrometry. The activity of both LqsA and CqsA was abolished upon mutation of a conserved lysine, and covalent binding of the cofactor pyridoxal 5'-phosphate to this lysine was confirmed by mass spectrometry. Thus, LqsA and CqsA belong to a family of pyridoxal 5'-phosphate-dependent autoinducer synthases, which produce the alpha-hydroxyketone signaling molecules LAI-1 and CAI-1.	[Spirig, Thomas; Tiaden, Andre; Kiefer, Patrick; Vorholt, Julia A.; Hilbi, Hubert] ETH, Inst Microbiol, CH-8093 Zurich, Switzerland; [Buchrieser, Carmen] Inst Pasteur, CNRS, URA 2171, F-75724 Paris, France; [Buchrieser, Carmen] Inst Pasteur, Unite Biol Bacteries Intracellulaires, F-75724 Paris, France	Swiss Federal Institutes of Technology Domain; ETH Zurich; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Hilbi, H (corresponding author), Wolfgang Pauli Str 10, CH-8093 Zurich, Switzerland.	hilbi@micro.biol.ethz.ch	Hilbi, Hubert/AAU-5815-2020; Kiefer, Patrick/G-5138-2010; Vorholt, Julia/K-3514-2016	Hilbi, Hubert/0000-0002-5462-9301; Vorholt, Julia/0000-0002-6011-4910; Buchrieser, Carmen/0000-0003-3477-9190; Spirig, Thomas/0000-0001-8936-238X	NIAID NIH HHS [AI 044212] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI044212] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Albers U, 2005, MICROBIOL-SGM, V151, P167, DOI 10.1099/mic.0.27563-0; Albers U, 2007, MICROBIOL-SGM, V153, P3817, DOI 10.1099/mic.0.2007/009829-0; Alexeev D, 1998, J MOL BIOL, V284, P401, DOI 10.1006/jmbi.1998.2086; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bachman MA, 2004, INFECT IMMUN, V72, P2468, DOI 10.1128/IAI.72.5.2468-2476.2004; Bachman MA, 2001, MOL MICROBIOL, V40, P1201, DOI 10.1046/j.1365-2958.2001.02465.x; Bassler BL, 2002, CELL, V109, P421, DOI 10.1016/S0092-8674(02)00749-3; Bruggemann H, 2006, CURR OPIN MICROBIOL, V9, P86, DOI 10.1016/j.mib.2005.12.009; Bruggemann H, 2006, CELL MICROBIOL, V8, P1228, DOI 10.1111/j.1462-5822.2006.00703.x; Camilli A, 2006, SCIENCE, V311, P1113, DOI 10.1126/science.1121357; Cataldi TRI, 2008, J MASS SPECTROM, V43, P82, DOI 10.1002/jms.1275; Cazalet C, 2004, NAT GENET, V36, P1165, DOI 10.1038/ng1447; Chien MC, 2004, SCIENCE, V305, P1966, DOI 10.1126/science.1099776; Dorer MS, 2006, PLOS PATHOG, V2, P315, DOI 10.1371/journal.ppat.0020034; Eliot AC, 2004, ANNU REV BIOCHEM, V73, P383, DOI 10.1146/annurev.biochem.73.011303.074021; FEELEY JC, 1979, J CLIN MICROBIOL, V10, P437, DOI 10.1128/JCM.10.4.437-441.1979; Fields BS, 2002, CLIN MICROBIOL REV, V15, P506, DOI 10.1128/CMR.15.3.506-526.2002; Fuqua C, 2002, NAT REV MOL CELL BIO, V3, P685, DOI 10.1038/nrm907; Gal-Mor O, 2003, J BACTERIOL, V185, P4908, DOI 10.1128/JB.185.16.4908-4919.2003; Gal-Mor O, 2003, MICROB PATHOGENESIS, V34, P187, DOI 10.1016/S0882-4010(03)00027-5; GLOCKNER G, 2007, INT J MED M IN PRESS; Hales LM, 1999, J BACTERIOL, V181, P4879, DOI 10.1128/JB.181.16.4879-4889.1999; Hammer BK, 2002, MOL MICROBIOL, V44, P107, DOI 10.1046/j.1365-2958.2002.02884.x; Henke JM, 2004, J BACTERIOL, V186, P6902, DOI 10.1128/JB.186.20.6902-6914.2004; Heuner K, 2002, INFECT IMMUN, V70, P1604, DOI 10.1128/IAI.70.3.1604-1608.2002; Higgins DA, 2007, NATURE, V450, P883, DOI 10.1038/nature06284; Hilbi H, 2001, MOL MICROBIOL, V42, P603, DOI 10.1046/j.1365-2958.2001.02645.x; Hilbi H, 2007, ENVIRON MICROBIOL, V9, P563, DOI 10.1111/j.1462-2920.2007.01238.x; Hilbi H, 2006, CELL MICROBIOL, V8, P1697, DOI 10.1111/j.1462-5822.2006.00793.x; Jakober CA, 2006, ANAL CHEM, V78, P5086, DOI 10.1021/ac060301c; Kagan JC, 2002, NAT CELL BIOL, V4, P945, DOI 10.1038/ncb883; Kumari A, 2006, ANAL CHEM, V78, P7603, DOI 10.1021/ac061421n; Lynch D, 2003, FEMS MICROBIOL LETT, V219, P241, DOI 10.1016/S0378-1097(03)00050-8; Mampel J, 2006, APPL ENVIRON MICROB, V72, P2885, DOI 10.1128/AEM.72.4.2885-2895.2006; Masuda N, 2003, MOL MICROBIOL, V48, P699, DOI 10.1046/j.1365-2958.2003.03477.x; MCDADE JE, 1977, NEW ENGL J MED, V297, P1197, DOI 10.1056/NEJM197712012972202; Miller MB, 2002, CELL, V110, P303, DOI 10.1016/S0092-8674(02)00829-2; Molofsky AB, 2005, INFECT IMMUN, V73, P5720, DOI 10.1128/IAI.73.9.5720-5734.2005; Molofsky AB, 2004, MOL MICROBIOL, V53, P29, DOI 10.1111/j.1365-2958.2004.04129.x; Ninio S, 2007, TRENDS MICROBIOL, V15, P372, DOI 10.1016/j.tim.2007.06.006; Otto GP, 2004, MOL MICROBIOL, V51, P63, DOI 10.1046/j.1365-2958.2003.03826.x; Percudani R, 2003, EMBO REP, V4, P850, DOI 10.1038/sj.embor.embor914; Schmidt A, 2001, BIOCHEMISTRY-US, V40, P5151, DOI 10.1021/bi002204y; Schulze B, 2006, ANAL BIOCHEM, V348, P269, DOI 10.1016/j.ab.2005.10.021; Segal G, 1998, P NATL ACAD SCI USA, V95, P1669, DOI 10.1073/pnas.95.4.1669; Segal G, 2005, FEMS MICROBIOL REV, V29, P65, DOI 10.1016/j.femsre.2004.07.001; Sheehan KB, 2005, APPL ENVIRON MICROB, V71, P507, DOI 10.1128/AEM.71.1.507-511.2005; Tholey A, 2002, J MASS SPECTROM, V37, P963, DOI 10.1002/jms.355; Tiaden A, 2007, CELL MICROBIOL, V9, P2903, DOI 10.1111/j.1462-5822.2007.01005.x; Vendeville A, 2005, NAT REV MICROBIOL, V3, P383, DOI 10.1038/nrmicro1146; Vogel JP, 1998, SCIENCE, V279, P873, DOI 10.1126/science.279.5352.873; Weber Stefan S., 2006, PLoS Pathogens, V2, DOI 10.1371/journal.ppat.0020046; Webster SP, 2000, BIOCHEMISTRY-US, V39, P516, DOI 10.1021/bi991620j; Winzer K, 2003, ADV APPL MICROBIOL, V53, P291, DOI 10.1016/S0065-2164(03)53009-X; Zusman T, 2007, MOL MICROBIOL, V63, P1508, DOI 10.1111/j.1365-2958.2007.05604.x	55	81	82	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18113	18123		10.1074/jbc.M801929200	http://dx.doi.org/10.1074/jbc.M801929200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18411263	Green Published, hybrid			2022-12-25	WOS:000256949200040
J	Housley, MP; Rodgers, JT; Udeshi, ND; Kelly, TJ; Shabanowitz, J; Hunt, DF; Puigserver, P; Hart, GW				Housley, Michael P.; Rodgers, Joseph T.; Udeshi, Namrata D.; Kelly, Timothy J.; Shabanowitz, Jeffrey; Hunt, Donald F.; Puigserver, Pere; Hart, Gerald W.			O-GlcNAc regulates FoxO activation in response to glucose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED N-ACETYLGLUCOSAMINE; INSULIN-RESISTANCE; SEQUENCE-ANALYSIS; NUCLEOCYTOPLASMIC GLYCOSYLATION; HEXOSAMINE BIOSYNTHESIS; TRANSCRIPTION FACTORS; AKT ACTIVATION; X-CHROMOSOME; TRANSFERASE; PROTEINS	FoxO proteins are key transcriptional regulators of nutrient homeostasis and stress response. The transcription factor FoxO1 activates expression of gluconeogenic, including phosphoenolpyruvate carboxykinase and glucose-6-phosphatase, and also activates the expression of the oxidative stress response enzymes catalase and manganese superoxide dismutase. Hormonal and stress-dependent regulation of FoxO1 via acetylation, ubiquitination, and phosphorylation, are well established, but FoxOs have not been studied in the context of the glucose-derived O-linked beta-N-acetylglucosamine (O-GlcNAc) modification. Here we show that O-GlcNAc on hepatic FoxO1 is increased in diabetes. Furthermore, O-GlcNAc regulates FoxO1 activation in response to glucose, resulting in the paradoxically increased expression of gluconeogenic genes while concomitantly inducing expression of genes encoding enzymes that detoxify reactive oxygen species. GlcNAcylation of FoxO provides a new mechanism for direct nutrient control of transcription to regulate metabolism and stress response through control of FoxO1 activity.	[Housley, Michael P.; Hart, Gerald W.] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA; [Rodgers, Joseph T.; Kelly, Timothy J.; Puigserver, Pere] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; [Rodgers, Joseph T.; Kelly, Timothy J.; Puigserver, Pere] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; [Udeshi, Namrata D.; Shabanowitz, Jeffrey; Hunt, Donald F.] Univ Virginia, Dept Chem, Charlottesville, VA 22904 USA; [Hunt, Donald F.] Univ Virginia, Dept Pathol, Charlottesville, VA 22904 USA	Johns Hopkins University; Harvard University; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; University of Virginia; University of Virginia	Hart, GW (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA.	gwhart@jhmi.edu	Hunt, Donald F/I-6936-2012	Hunt, Donald F/0000-0003-2815-6368; Hart, Gerald/0000-0001-7812-4351; Rodgers, Joseph/0000-0002-6598-5520	NICHD NIH HHS [HD13563, R37 HD013563] Funding Source: Medline; NIDDK NIH HHS [R01 DK061671, DK61671] Funding Source: Medline; NIGMS NIH HHS [R01 GM037537, GM37537] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD013563, R37HD013563] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK061671] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037537] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Andrali SS, 2007, J BIOL CHEM, V282, P15589, DOI 10.1074/jbc.M701762200; Birnbaum MJ, 2008, SCIENCE, V319, P1348, DOI 10.1126/science.1155915; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Buse MG, 2006, AM J PHYSIOL-ENDOC M, V290, pE1, DOI 10.1152/ajpendo.00329.2005; Clark RJ, 2003, J BIOL CHEM, V278, P44230, DOI 10.1074/jbc.M303810200; Comer FI, 2001, ANAL BIOCHEM, V293, P169, DOI 10.1006/abio.2001.5132; Comer FI, 2001, BIOCHEMISTRY-US, V40, P7845, DOI 10.1021/bi0027480; Dentin R, 2008, SCIENCE, V319, P1402, DOI 10.1126/science.1151363; Dowell P, 2003, J BIOL CHEM, V278, P45485, DOI 10.1074/jbc.M309069200; Gross BJ, 2005, J AM CHEM SOC, V127, P14588, DOI 10.1021/ja0555217; HALTIWANGER RS, 1990, J BIOL CHEM, V265, P2563; Han I, 1997, MOL CELL BIOL, V17, P2550, DOI 10.1128/MCB.17.5.2550; Hanover JA, 2005, P NATL ACAD SCI USA, V102, P11266, DOI 10.1073/pnas.0408771102; Hart GW, 2007, NATURE, V446, P1017, DOI 10.1038/nature05815; Hartweck LM, 2002, GENETICS, V161, P1279; Hidaka S, 2002, FASEB J, V16, P509, DOI 10.1096/fj.01-0164com; Housley MP, 2006, FASEB J, V20, pA955; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; KELLY WG, 1989, CELL, V57, P243, DOI 10.1016/0092-8674(89)90962-8; KENYON C, 1993, NATURE, V366, P461, DOI 10.1038/366461a0; Kuo M, 2008, FEBS LETT, V582, P829, DOI 10.1016/j.febslet.2008.02.010; Lehmann R, 2000, ELECTROPHORESIS, V21, P3010, DOI 10.1002/1522-2683(20000801)21:14<3010::AID-ELPS3010>3.0.CO;2-C; Lehtinen MK, 2006, CELL, V125, P987, DOI 10.1016/j.cell.2006.03.046; Liu J, 2006, J MOL CELL CARDIOL, V40, P303, DOI 10.1016/j.yjmcc.2005.11.003; Liu J, 2007, AM J PHYSIOL-HEART C, V293, pH1391, DOI 10.1152/ajpheart.00285.2007; Love, 2005, SCI STKE, V2005, DOI DOI 10.1126/STKE.3122005RE13; MAGNUSSON I, 1992, J CLIN INVEST, V90, P1323, DOI 10.1172/JCI115997; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; Martin SE, 2000, ANAL CHEM, V72, P4266, DOI 10.1021/ac000497v; Matsuzaki H, 2003, P NATL ACAD SCI USA, V100, P11285, DOI 10.1073/pnas.1934283100; McClain DA, 2002, P NATL ACAD SCI USA, V99, P10695, DOI 10.1073/pnas.152346899; Mikesh LM, 2006, BBA-PROTEINS PROTEOM, V1764, P1811, DOI 10.1016/j.bbapap.2006.10.003; MONSIGNY M, 1980, EUR J BIOCHEM, V104, P147, DOI 10.1111/j.1432-1033.1980.tb04410.x; Nakae J, 2001, J CLIN INVEST, V108, P1359, DOI 10.1172/JCI200112876; O'Donnell N, 2004, MOL CELL BIOL, V24, P1680, DOI 10.1128/MCB.24.4.1680-1690.2004; Park SY, 2005, EXP MOL MED, V37, P220, DOI 10.1038/emm.2005.30; Plas DR, 2003, J BIOL CHEM, V278, P12361, DOI 10.1074/jbc.M213069200; Puig O, 2006, CELL CYCLE, V5, P503, DOI 10.4161/cc.5.5.2501; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Roos MD, 1997, MOL CELL BIOL, V17, P6472, DOI 10.1128/MCB.17.11.6472; Schroeder MJ, 2004, ANAL CHEM, V76, P3590, DOI 10.1021/ac0497104; Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497; Slawson C, 2005, J BIOL CHEM, V280, P32944, DOI 10.1074/jbc.M503396200; Syka JEP, 2004, P NATL ACAD SCI USA, V101, P9528, DOI 10.1073/pnas.0402700101; Tang ED, 1999, J BIOL CHEM, V274, P16741, DOI 10.1074/jbc.274.24.16741; TORRES CR, 1984, J BIOL CHEM, V259, P3308; Tothova Z, 2007, CELL, V128, P325, DOI 10.1016/j.cell.2007.01.003; TRAN H, 2003, SCI STKE, pRE5, DOI DOI 10.1126/STKE.2003.172.RE5; van der Horst A, 2007, NAT REV MOL CELL BIO, V8, P440, DOI 10.1038/nrm2190; Vosseller K, 2002, P NATL ACAD SCI USA, V99, P5313, DOI 10.1073/pnas.072072399; Yang XY, 2008, NATURE, V451, P964, DOI 10.1038/nature06668; Zachara NE, 2004, J BIOL CHEM, V279, P30133, DOI 10.1074/jbc.M403773200; Zachara NE, 2004, BBA-GEN SUBJECTS, V1673, P13, DOI 10.1016/j.bbagen.2004.03.016; Zhang FX, 2003, CELL, V115, P715, DOI 10.1016/S0092-8674(03)00974-7; Zhang WW, 2006, J BIOL CHEM, V281, P10105, DOI 10.1074/jbc.M600272200	56	240	252	0	32	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16283	16292		10.1074/jbc.M802240200	http://dx.doi.org/10.1074/jbc.M802240200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18420577	Green Published, hybrid			2022-12-25	WOS:000256497100004
J	Ishdorj, G; Graham, BA; Hu, XJ; Chen, J; Johnston, JB; Fang, XJ; Gibson, SB				Ishdorj, Ganchimeg; Graham, Bonnie A.; Hu, Xiaojie; Chen, Jing; Johnston, James B.; Fang, Xianjun; Gibson, Spencer B.			Lysophosphatidic acid protects cancer cells from histone deacetylase (HDAC) inhibitor-induced apoptosis through activation of HDAC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHRONIC LYMPHOCYTIC-LEUKEMIA; OVARIAN-CANCER; IN-VIVO; ACETYLATION; RECEPTORS; TRAIL; DEATH; LYSOPHOSPHOLIPIDS; EXPRESSION; SURVIVAL	Histone deacetylases (HDACs) catalyze the removal of acetyl groups from histones and contribute to transcriptional repression. In addition, the HDAC inhibitors induce apoptosis in cancer cells through alterations in histone acetylation and activation of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) apoptotic pathway. Lysophosphatidic acid (LPA) is a growth factor that promotes survival of cancer cells through activation of G protein-coupled receptors. Here we show that HDAC inhibitors can induce apoptosis through activation of the TRAIL apoptotic pathway, and LPA prevented HDAC inhibitor-induced apoptosis and increased TRAIL receptor DR4 (death receptor 4) protein expression. This was associated with increased HDAC1 recruitment to the DR4 promoter following LPA treatment and a reduction in HDAC inhibitor-induced histone acetylation in the DR4 promoter. In addition, LPA induces HDAC enzyme activity in a dose-and time-dependent manner, and this is associated with HDAC1 activation and increased binding of HDAC1 to HDAC2. Reducing the expression of HDAC1 significantly lowered LPA-induced HDAC activity and increased histone acetylation. LPA induction of HDAC activity was blocked by the LPA receptor antagonist, Ki16425, or by inhibiting receptor activation with pertussis toxin. Reducing the expression of the LPA receptor LPA(1) also blocked LPA-induced HDAC activation. In addition, LPA reduced histone acetyltransferase enzymatic activity. Finally, LPA attenuated the ability of the HDAC inhibitor to reduce HDAC activity. Thus, LPA enhances survival of cancer cells by increasing HDAC activity and reducing histone acetylation.	[Ishdorj, Ganchimeg; Graham, Bonnie A.; Hu, Xiaojie; Johnston, James B.; Gibson, Spencer B.] Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada; [Ishdorj, Ganchimeg; Gibson, Spencer B.] Univ Manitoba, Dept Biochem & Med Genet, Winnipeg, MB R3E 0V9, Canada; [Johnston, James B.] Univ Manitoba, Dept Internal Med, Winnipeg, MB R3E 0V9, Canada; [Chen, Jing; Fang, Xianjun] Virginia Commonwealth Univ, Dept Biochem & Mol Biol, Richmond, VA 23298 USA	University of Manitoba; University of Manitoba; University of Manitoba; Virginia Commonwealth University	Gibson, SB (corresponding author), Univ Manitoba, Manitoba Inst Cell Biol, Winnipeg, MB R3E 0V9, Canada.	gibsonsb@cc.umanitoba.ca		Gibson, Spencer/0000-0003-0119-732X	NATIONAL CANCER INSTITUTE [R01CA102196] Funding Source: NIH RePORTER; NCI NIH HHS [CA 102196] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ahringer J, 2000, TRENDS GENET, V16, P351, DOI 10.1016/S0168-9525(00)02066-7; Anliker B, 2004, J BIOL CHEM, V279, P20555, DOI 10.1074/jbc.R400013200; Ashburner BP, 2001, MOL CELL BIOL, V21, P7065, DOI 10.1128/MCB.21.20.7065-7077.2001; Chen LF, 2003, J MOL MED, V81, P549, DOI 10.1007/s00109-003-0469-0; Contos JJA, 2000, P NATL ACAD SCI USA, V97, P13384, DOI 10.1073/pnas.97.24.13384; Cress WD, 2000, J CELL PHYSIOL, V184, P1, DOI 10.1002/(SICI)1097-4652(200007)184:1<1::AID-JCP1>3.0.CO;2-7; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Fang XJ, 2002, BBA-MOL CELL BIOL L, V1582, P257, DOI 10.1016/S1388-1981(02)00179-8; Fang XJ, 2000, ANN NY ACAD SCI, V905, P188; Fulda S, 2005, CANCER BIOL THER, V4, P1113, DOI 10.4161/cbt.4.10.2100; Goetzl EJ, 2000, ANN NY ACAD SCI, V905, P177; Gray S. G., 2001, Current Molecular Medicine (Hilversum), V1, P401, DOI 10.2174/1566524013363537; Gregory PD, 2001, EXP CELL RES, V265, P195, DOI 10.1006/excr.2001.5187; Grozinger CM, 2002, CHEM BIOL, V9, P3, DOI 10.1016/S1074-5521(02)00092-3; Hassig CA, 1998, P NATL ACAD SCI USA, V95, P3519, DOI 10.1073/pnas.95.7.3519; Hu XJ, 2005, J BIOL CHEM, V280, P9498, DOI 10.1074/jbc.M410455200; Inoue S, 2004, CELL DEATH DIFFER, V11, pS193, DOI 10.1038/sj.cdd.4401535; Inoue S, 2006, CANCER RES, V66, P6785, DOI 10.1158/0008-5472.CAN-05-4563; Johnston JB, 2003, ONCOGENE, V22, P8356, DOI 10.1038/sj.onc.1207004; Kabore AF, 2006, APOPTOSIS, V11, P1175, DOI 10.1007/s10495-006-8048-9; Kang YC, 2004, CELL DEATH DIFFER, V11, P1287, DOI 10.1038/sj.cdd.4401489; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Liu L, 1999, MOL CELL BIOL, V19, P1202; Liu XG, 2004, CANCER RES, V64, P5078, DOI 10.1158/0008-5472.CAN-04-1195; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Luger K, 1998, CURR OPIN GENET DEV, V8, P140, DOI 10.1016/S0959-437X(98)80134-2; MacFarlane M, 2005, CELL DEATH DIFFER, V12, P773, DOI 10.1038/sj.cdd.4401649; Mahlknecht U, 2000, MOL MED, V6, P623, DOI 10.1007/BF03402044; Marks PA, 2001, NAT REV CANCER, V1, P194, DOI 10.1038/35106079; Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143; Nebbioso A, 2005, NAT MED, V11, P77, DOI 10.1038/nm1161; Ng HH, 2000, TRENDS BIOCHEM SCI, V25, P121; Ohta H, 2003, MOL PHARMACOL, V64, P994, DOI 10.1124/mol.64.4.994; Richon VM, 2002, CLIN CANCER RES, V8, P662; Sasagawa T, 1999, LIPIDS, V34, P17, DOI 10.1007/s11745-999-332-5; Sautin YY, 2001, AM J PHYSIOL-CELL PH, V281, pC2010, DOI 10.1152/ajpcell.00077.2001; Seligson DB, 2005, NATURE, V435, P1262, DOI 10.1038/nature03672; Shetty S, 2005, MOL CELL BIOL, V25, P5404, DOI 10.1128/MCB.25.13.5404-5416.2005; Shida D, 2003, CANCER RES, V63, P1706; Spiegelberg BD, 2005, J BIOL CHEM, V280, P41769, DOI 10.1074/jbc.M504066200; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Swarthout JT, 2000, CELL MOL LIFE SCI, V57, P1978, DOI 10.1007/PL00000678; Taplick J, 2001, J MOL BIOL, V308, P27, DOI 10.1006/jmbi.2001.4569; Timmermann S, 2001, CELL MOL LIFE SCI, V58, P728, DOI 10.1007/PL00000896; Urnov FD, 2002, EMBO REP, V3, P610, DOI 10.1093/embo-reports/kvf140; XU Y, 1995, BIOCHEM J, V309, P933, DOI 10.1042/bj3090933; Yang SH, 2001, MOL CELL BIOL, V21, P2802, DOI 10.1128/MCB.21.8.2802-2814.2001; Zhang CX, 2004, J EXP MED, V199, P763, DOI 10.1084/jem.20031619; Zhang XD, 2000, J IMMUNOL, V164, P3961, DOI 10.4049/jimmunol.164.8.3961; Zhong SP, 2003, ONCOGENE, V22, P5291, DOI 10.1038/sj.onc.1206507	50	27	30	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16818	16829		10.1074/jbc.M710177200	http://dx.doi.org/10.1074/jbc.M710177200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18408217	Green Published, hybrid			2022-12-25	WOS:000256497100059
J	Tone, Y; Pedersen, LC; Yamamoto, T; Izumikawa, T; Kitagawa, H; Nishihara, J; Tamura, J; Negishi, M; Sugahara, K				Tone, Yuko; Pedersen, Lars C.; Yamamoto, Tomoko; Izumikawa, Tomomi; Kitagawa, Hiroshi; Nishihara, Junko; Tamura, Jun-ichi; Negishi, Masahiko; Sugahara, Kazuyuki			2-O-phosphorylation of xylose and 6-O-sulfation of galactose in the protein linkage region of Glycosaminoglycans influence the glucuronyltransferase-I activity involved in the linkage region synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SULFATE HYBRID CHAINS; CHONDROITIN-POLYMERIZING FACTOR; GLAND EPITHELIAL-CELLS; EMBRYONIC PIG BRAIN; HEPARAN-SULFATE; MOLECULAR-CLONING; GROWTH-FACTOR; TETRASACCHARIDE SEQUENCE; NEURITOGENIC ACTIVITY; TUMOR SUPPRESSORS	Sulfated glycosaminoglycans (GAGs), including heparan sulfate and chondroitin sulfate, are synthesized on the so-called common GAG-protein linkage region (GlcUA beta 1-3Gal beta 1-3Gal beta 1-4Xyl beta 1-O-Ser) of core proteins, which is formed by the stepwise addition of monosaccharide residues by the respective specific glycosyltransferases. Glucuronyltransferase-I (GlcAT-I) is the key enzyme that completes the synthesis of this linkage region, which is a prerequisite for the conversion of core proteins to functional proteoglycans bearing GAGs. The Xyl and Gal residues in the linkage region can be modified by phosphorylation and sulfation, respectively, although the biological significance of these modifications remains to be clarified. Here we present evidence that these modifications can significantly influence the catalytic activity of GlcAT-I. Enzyme assays showed that the synthetic substrates, Gal-Gal-Xyl(2-O-phosphate)O-Ser and Gal-Gal(6-O-sulfate)-Xyl(2-O-phosphate)O-Ser, served as better substrates than the unmodified compound, whereas Gal(6-O-sulfate)-Gal-Xyl(2-O-phosphate)-O-Ser exhibited no acceptor activity. The crystal structure of the catalytic domain of GlcAT-I with UDP and Gal-Gal(6-O-sulfate)Xyl(2-O-phosphate)-O-Ser bound revealed that the Xyl(2-O-phosphate)O-Ser is disordered and the 6-O-sulfate forms interactions with Gln(318) from the second GlcAT-I monomer in the dimeric enzyme. The results indicate the possible involvement of these modifications in the processing and maturation of the growing linkage region oligosaccharide required for the assembly of GAG chains.	[Sugahara, Kazuyuki] Hokkaido Univ, Fac Adv Life Sci, Frontier Res Ctr Post Gen Sci & Technol, Grad Sch Life Sci,Lab Proteoglycan Signaling & Th, Sapporo, Hokkaido 0010021, Japan; [Tone, Yuko; Yamamoto, Tomoko; Izumikawa, Tomomi; Kitagawa, Hiroshi; Sugahara, Kazuyuki] Kobe Pharmaceut Univ, Dept Biochem, Higashinada Ku, Kobe, Hyogo 6588558, Japan; [Negishi, Masahiko] NIEHS, NIH, Reprod & Dev Toxicol Lab, Res Triangle Pk, NC 27709 USA; [Pedersen, Lars C.; Negishi, Masahiko] NIEHS, NIH, Struct Biol Lab, Res Triangle Pk, NC 27709 USA; [Nishihara, Junko; Tamura, Jun-ichi] Tottori Univ, Fac Reg Sci, Dept Reg Environm, Tottori 6808551, Japan	Hokkaido University; Kobe Pharmaceutical University; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Tottori University	Sugahara, K (corresponding author), Hokkaido Univ, Fac Adv Life Sci, Frontier Res Ctr Post Gen Sci & Technol, Grad Sch Life Sci,Lab Proteoglycan Signaling & Th, Sapporo, Hokkaido 0010021, Japan.	k-sugar@sci.hokudai.ac.jp	Negishi, Masahiko/F-7805-2019; Kitagawa, Hiroshi/AAJ-1344-2020; Pedersen, Lars/C-6173-2019	Negishi, Masahiko/0000-0002-2076-8928; Kitagawa, Hiroshi/0000-0002-9307-7079; Pedersen, Lars/0000-0002-4488-4077	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [Z01ES080040, ZIAES080040] Funding Source: NIH RePORTER; Intramural NIH HHS Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Bao XF, 2005, J BIOL CHEM, V280, P35318, DOI 10.1074/jbc.M507304200; Bao XF, 2005, J BIOL CHEM, V280, P9180, DOI 10.1074/jbc.M413423200; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Busse M, 2003, J BIOL CHEM, V278, P41333, DOI 10.1074/jbc.M308314200; DeBeer T, 1996, EUR J BIOCHEM, V240, P789; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Deepa SS, 2004, J BIOL CHEM, V279, P37368, DOI 10.1074/jbc.M403031200; DEWAARD P, 1992, J BIOL CHEM, V267, P6036; Fondeur-Gelinotte M, 2007, GLYCOBIOLOGY, V17, P857, DOI 10.1093/glycob/cwm055; FRANSSON LA, 1987, TRENDS BIOCHEM SCI, V12, P406, DOI 10.1016/0968-0004(87)90197-6; Gulberti S, 2005, J BIOL CHEM, V280, P1417, DOI 10.1074/jbc.M411552200; Izumikawa T, 2007, BIOCHEM J, V403, P545, DOI 10.1042/BJ20061876; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kakuda S, 2004, J BIOL CHEM, V279, P22693, DOI 10.1074/jbc.M400622200; Kim BT, 2003, J BIOL CHEM, V278, P41618, DOI 10.1074/jbc.M304831200; Kim BT, 2001, P NATL ACAD SCI USA, V98, P7176, DOI 10.1073/pnas.131188498; Kitagawa H, 1998, J BIOL CHEM, V273, P6615, DOI 10.1074/jbc.273.12.6615; Kitagawa H, 2003, J BIOL CHEM, V278, P23666, DOI 10.1074/jbc.M302493200; Kitagawa H, 1999, J BIOL CHEM, V274, P13933, DOI 10.1074/jbc.274.20.13933; Kitagawa H, 2001, J BIOL CHEM, V276, P38721, DOI 10.1074/jbc.M106871200; KOKENYESI R, 1994, J BIOL CHEM, V269, P12304; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P940; Lander A D, 1993, Curr Opin Neurobiol, V3, P716, DOI 10.1016/0959-4388(93)90143-M; Lander AD, 2000, J CELL BIOL, V148, P227, DOI 10.1083/jcb.148.2.227; Lauder RM, 2000, BIOCHEM J, V347, P339, DOI 10.1042/0264-6021:3470339; Li FC, 2007, J BIOL CHEM, V282, P2956, DOI 10.1074/jbc.M609296200; Lind T, 1998, J BIOL CHEM, V273, P26265, DOI 10.1074/jbc.273.41.26265; Lindahl U., 1972, GLYCOPROTEINS THEIR, P491; McCormick C, 1998, NAT GENET, V19, P158, DOI 10.1038/514; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; Morgenstern DA, 2002, PROG BRAIN RES, V137, P313; Moses J, 1999, EUR J BIOCHEM, V260, P879, DOI 10.1046/j.1432-1327.1999.00228.x; Nadanaka S, 1998, J BIOL CHEM, V273, P33728, DOI 10.1074/jbc.273.50.33728; Oohira A, 2000, ARCH BIOCHEM BIOPHYS, V374, P24, DOI 10.1006/abbi.1999.1598; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Ouzzine M, 2000, J BIOL CHEM, V275, P28254; Pedersen LC, 2000, J BIOL CHEM, V275, P34580, DOI 10.1074/jbc.M007399200; Pedersen LC, 2003, J BIOL CHEM, V278, P14420, DOI 10.1074/jbc.M210532200; Perrimon N, 2000, NATURE, V404, P725, DOI 10.1038/35008000; POOLE AR, 1986, BIOCHEM J, V236, P1; Roden L., 1980, BIOCH GLYCOPROTEINS, P267; Salmivirta M, 1996, FASEB J, V10, P1270, DOI 10.1096/fasebj.10.11.8836040; Senay C, 2000, EMBO REP, V1, P282, DOI 10.1093/embo-reports/kvd045; SUGAHARA K, 1995, J BIOL CHEM, V270, P7204, DOI 10.1074/jbc.270.13.7204; SUGAHARA K, 1992, J BIOL CHEM, V267, P6027; SUGAHARA K, 1988, J BIOL CHEM, V263, P10168; Sugahara K, 2000, CURR OPIN STRUC BIOL, V10, P518, DOI 10.1016/S0959-440X(00)00125-1; Sugahara K, 2003, CURR OPIN STRUC BIOL, V13, P612, DOI 10.1016/j.sbi.2003.09.011; Sugahara K, 2000, TRENDS GLYCOSCI GLYC, V12, P321, DOI 10.4052/tigg.12.321; Sugahara K, 2007, CURR OPIN STRUC BIOL, V17, P536, DOI 10.1016/j.sbi.2007.08.015; Tamura J, 1999, BIOORG MED CHEM LETT, V9, P1911, DOI 10.1016/S0960-894X(99)00300-5; Tamura J, 2001, J ORG CHEM, V66, P3074, DOI 10.1021/jo001540h; Tone Y, 1999, FEBS LETT, V459, P415, DOI 10.1016/S0014-5793(99)01287-9; Ueno M, 2001, J BIOL CHEM, V276, P29134, DOI 10.1074/jbc.M102089200; Wakabayashi H, 1999, J BIOL CHEM, V274, P5436, DOI 10.1074/jbc.274.9.5436	56	53	55	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16801	16807		10.1074/jbc.M709556200	http://dx.doi.org/10.1074/jbc.M709556200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18400750	Green Published, hybrid			2022-12-25	WOS:000256497100057
J	Betts, GN; van der Geer, P; Komives, EA				Betts, Gina N.; van der Geer, Peter; Komives, Elizabeth A.			Structural and functional consequences of tyrosine phosphorylation in the LRP1 cytoplasmic domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-RELATED PROTEIN; AMYLOID PRECURSOR PROTEIN; LIPOPROTEIN-RECEPTOR; SOLVENT ACCESSIBILITY; CORECEPTOR FUNCTION; NPXY MOTIFS; SHC; IDENTIFICATION; ACTIVATION; SUGGEST	The cytoplasmic domain of LRP1 contains two NPXY motifs that have been shown to interact with signaling proteins. In previous work, we showed that Tyr(4507) in the distal NPXY motif is phosphorylated by v-Src, whereas denaturation of the protein was required for phosphorylation of Tyr(4473) in the membrane-proximal NPXY motif. Amide H/D exchange studies reveal that the distal NPXY motif is fully solvent-exposed, whereas the proximal one is not. Phosphopeptide mapping combined with in vitro and in vivo kinase experiments show that Tyr(4473) can be phosphorylated, but only if Ty(r4507) is phosphorylated or substituted with glutamic acid. Amide H/D exchange experiments indicate that solvent accessibility increases across the entire LRP1 cytoplasmic region upon phosphorylation at Tyr(4507); in particular the NPXY4473 motif becomes much more exposed. This differential phosphorylation is functionally relevant: binding of Snx17, which is known to bind at the proximal NPXY motif, is inhibited by phosphorylation at Tyr(4473). Conversely, Shp2 binds most strongly when both of the NPXY motifs in LRP1 are phosphorylated.	[Betts, Gina N.; Komives, Elizabeth A.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; [van der Geer, Peter] San Diego State Univ, Dept Chem, San Diego, CA 92182 USA	University of California System; University of California San Diego; California State University System; San Diego State University	Komives, EA (corresponding author), Univ Calif San Diego, Dept Chem & Biochem, 9500 Gilman Dr, La Jolla, CA 92093 USA.	ekomives@ucsd.edu			NCI NIH HHS [CA78629] Funding Source: Medline; NIA NIH HHS [AG025343, R01 AG025343] Funding Source: Medline; NIDDK NIH HHS [T32-DK07233] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R29CA078629, R01CA078629] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007233] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG025343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Araki T, 2003, J BIOL CHEM, V278, P41677, DOI 10.1074/jbc.M306461200; Barnes H, 2003, ONCOGENE, V22, P3589, DOI 10.1038/sj.onc.1206504; Barnes H, 2001, J BIOL CHEM, V276, P19119, DOI 10.1074/jbc.M011437200; Boucher P, 2002, J BIOL CHEM, V277, P15507, DOI 10.1074/jbc.M200428200; Boucher P, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000448; Ferreiro DU, 2007, J MOL BIOL, V365, P1201, DOI 10.1016/j.jmb.2006.11.044; Goto JJ, 2002, J MOL NEUROSCI, V19, P37, DOI 10.1007/s12031-002-0008-4; Gotthardt M, 2000, J BIOL CHEM, V275, P25616, DOI 10.1074/jbc.M000955200; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hughes CA, 2001, J MOL BIOL, V307, P967, DOI 10.1006/jmbi.2001.4523; KLINGHOFFER RA, 1995, J BIOL CHEM, V270, P22208, DOI 10.1074/jbc.270.38.22208; Kroenke CD, 1997, BIOCHEMISTRY-US, V36, P8145, DOI 10.1021/bi9705669; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200; Lutz C, 2002, J BIOL CHEM, V277, P43143, DOI 10.1074/jbc.M204426200; Mandell JG, 1998, P NATL ACAD SCI USA, V95, P14705, DOI 10.1073/pnas.95.25.14705; Marzolo MP, 2003, TRAFFIC, V4, P273, DOI 10.1034/j.1600-0854.2003.00081.x; Meng TC, 2002, MOL CELL, V9, P387, DOI 10.1016/S1097-2765(02)00445-8; Newton CS, 2005, J BIOL CHEM, V280, P27872, DOI 10.1074/jbc.M505410200; O'Reilly AM, 1998, MOL CELL BIOL, V18, P161, DOI 10.1128/MCB.18.1.161; Pietrzik CU, 2002, EMBO J, V21, P5691, DOI 10.1093/emboj/cdf568; Pietrzik CU, 2004, J NEUROSCI, V24, P4259, DOI 10.1523/JNEUROSCI.5451-03.2004; Ramelot TA, 2001, J MOL BIOL, V307, P871, DOI 10.1006/jmbi.2001.4535; Roebroek AJM, 2006, MOL CELL BIOL, V26, P605, DOI 10.1128/MCB.26.2.605-616.2006; Seeliger MA, 2005, PROTEIN SCI, V14, P3135, DOI 10.1110/ps.051750905; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Strickland DK, 2003, J THROMB HAEMOST, V1, P1663, DOI 10.1046/j.1538-7836.2003.00330.x; Swertfeger DK, 2002, J BIOL CHEM, V277, P4141, DOI 10.1074/jbc.M109124200; THORPE GHG, 1986, METHOD ENZYMOL, V133, P331; Trommsdorff R, 1998, J BIOL CHEM, V273, P33556, DOI 10.1074/jbc.273.50.33556; Truhlar SME, 2006, J AM SOC MASS SPECTR, V17, P1490, DOI 10.1016/j.jasms.2006.07.023; van Kerkhof P, 2005, EMBO J, V24, P2851, DOI 10.1038/sj.emboj.7600756; VANDERGEER P, 1994, ELECTROPHORESIS, V15, P544, DOI 10.1002/elps.1150150173	34	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15656	15664		10.1074/jbc.M709514200	http://dx.doi.org/10.1074/jbc.M709514200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18381291	Green Published, hybrid			2022-12-25	WOS:000256332500019
J	Ma, CL; Soto, CS; Ohigashi, Y; Taylor, A; Bournas, V; Glawe, B; Udo, MK; DeGrado, WF; Lamb, RA; Pinto, LH				Ma, Chunlong; Soto, Cinque S.; Ohigashi, Yuki; Taylor, Albert; Bournas, Vasilios; Glawe, Brett; Udo, Maria K.; DeGrado, William F.; Lamb, Robert A.; Pinto, Lawrence H.			Identification of the pore-lining residues of the BM2 ion channel protein of influenza B virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CITRATE TRANSPORT PROTEIN; M2 PROTON CHANNEL; A VIRUS; TRANSMEMBRANE DOMAIN; SECONDARY STRUCTURE; OLIGOMERIC STATE; LIKELY COMPRISE; M(2) PROTEIN; H+ CHANNEL; SELECTIVITY	The influenza B virus BM2 proton-selective ion channel is essential for virus uncoating, a process that occurs in the acidic environment of the endosome. The BM2 channel causes acidification of the interior of the virus particle, which results in dissociation of the viral membrane protein from the ribonucleoprotein core. The BM2 protein is similar to the A/M2 protein ion channel of influenza A virus (A/M2) in that it contains an HXXXW motif. Unlike the A/M2 protein, the BM2 protein is not inhibited by the antiviral drug amantadine. We used mutagenesis to ascertain the pore-lining residues of the BM2 ion channel. The specific activity (relative to wild type), reversal voltage, and susceptibility to modification by (2-aminoethyl)-methane thiosulfonate and N-ethylmaleimide of cysteine mutant proteins were measured in oocytes. It was found that mutation of transmembrane domain residues Ser(9), Ser(12), Phe(13), Ser(16), His(19), and Trp(23) to cysteine were most disruptive for ion channel function. These cysteine mutants were also most susceptible to (2-aminoethyl)-methane thiosulfonate and N-ethylmaleimide modification. Furthermore, considerable amounts of dimer were formed in the absence of oxidative reagents when cysteine was introduced at positions Ser(9), Ser(12), Ser(16), or Trp(23). Based on these experimental data, a BM2 transmembrane domain model is proposed. The presence of polar residues in the pore is a probable explanation for the amantadine insensitivity of the BM2 protein and suggests that related but more polar compounds might serve as useful inhibitors of the protein.	[Ma, Chunlong; Ohigashi, Yuki; Taylor, Albert; Bournas, Vasilios; Glawe, Brett; Pinto, Lawrence H.] Northwestern Univ, Dept Neurobiol & Physiol, Evanston, IL 60208 USA; [Lamb, Robert A.] Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; [Lamb, Robert A.] Northwestern Univ, Howard Hughes Med Inst, Evanston, IL 60208 USA; [Soto, Cinque S.; DeGrado, William F.] Univ Penn, Sch Med, Dept Biochem & Biophys, Philadelphia, PA 19104 USA; [DeGrado, William F.] Univ Penn, Dept Chem, Philadelphia, PA 19104 USA; [Udo, Maria K.] Loyola Univ, Dept Phys, Chicago, IL 60626 USA	Northwestern University; Northwestern University; Howard Hughes Medical Institute; Northwestern University; University of Pennsylvania; University of Pennsylvania; Loyola University Chicago	Pinto, LH (corresponding author), Northwestern Univ, Dept Neurobiol & Physiol, Hogan Hall,2205 Tech Dr, Evanston, IL 60208 USA.	larry-pinto@northwestern.edu	Ma, Chunlong/AAT-7097-2021		Howard Hughes Medical Institute Funding Source: Medline; NIAID NIH HHS [R01 AI-20201, R01 AI-57363] Funding Source: Medline; NIGMS NIH HHS [R01 GM-56423] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020201, R01AI057363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056423] Funding Source: NIH RePORTER	Howard Hughes Medical Institute(Howard Hughes Medical Institute); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balannik V, 2008, J BIOL CHEM, V283, P4895, DOI 10.1074/jbc.M709433200; Bauer CM, 1999, VIROLOGY, V254, P196, DOI 10.1006/viro.1998.9552; BEUMER TL, 1995, TRENDS GENET, V11, P9, DOI 10.1016/S0168-9525(00)88978-7; CASTRUCCI MR, 1995, J VIROL, V69, P2725, DOI 10.1128/JVI.69.5.2725-2728.1995; Chizhmakov IV, 1996, J PHYSIOL-LONDON, V494, P329, DOI 10.1113/jphysiol.1996.sp021495; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P685, DOI 10.1107/S0365110X53001952; DAVIES WL, 1964, SCIENCE, V144, P862, DOI 10.1126/science.144.3620.862; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; Gandhi CS, 1999, J BIOL CHEM, V274, P5474, DOI 10.1074/jbc.274.9.5474; Hatta M, 2004, J VIROL, V78, P5576, DOI 10.1128/JVI.78.11.5576-5583.2004; Hay A.J., 1992, SEMIN VIROL, V3, P21, DOI DOI 10.1016/J.BMC.2015.06.030; Holmgren M, 1996, NEUROPHARMACOLOGY, V35, P797, DOI 10.1016/0028-3908(96)00129-3; Kaplan RS, 2000, J BIOL CHEM, V275, P12009, DOI 10.1074/jbc.275.16.12009; Kovacs FA, 2000, J MOL BIOL, V295, P117, DOI 10.1006/jmbi.1999.3322; Lamb R. A., 1994, RECEPTOR MEDIATED VI, P303; LEAR JD, 1988, SCIENCE, V240, P1177, DOI 10.1126/science.2453923; Lear JD, 1994, MEMBRANE PROTEIN STR, P335; Lin TI, 2001, J VIROL, V75, P3647, DOI 10.1128/JVI.75.8.3647-3656.2001; Ma CL, 2004, J BIOL CHEM, V279, P1533, DOI 10.1074/jbc.M310866200; MARTIN K, 1991, CELL, V67, P117, DOI 10.1016/0092-8674(91)90576-K; Mould JA, 2000, J BIOL CHEM, V275, P31038, DOI 10.1074/jbc.M003663200; Mould JA, 2003, DEV CELL, V5, P175, DOI 10.1016/S1534-5807(03)00190-4; Nishimura K, 2002, BIOCHEMISTRY-US, V41, P13170, DOI 10.1021/bi0262799; North B, 2001, J MOL BIOL, V311, P1081, DOI 10.1006/jmbi.2001.4900; Paterson RG, 2003, VIROLOGY, V306, P7, DOI 10.1016/S0042-6822(02)00083-1; Pinto LH, 2006, J BIOL CHEM, V281, P8997, DOI 10.1074/jbc.R500020200; Pinto LH, 1997, P NATL ACAD SCI USA, V94, P11301, DOI 10.1073/pnas.94.21.11301; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Sakaguchi T, 1997, P NATL ACAD SCI USA, V94, P5000, DOI 10.1073/pnas.94.10.5000; Schnell JR, 2008, NATURE, V451, P591, DOI 10.1038/nature06531; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SHIMBO K, 1996, BIOPHYS J, V70, P1336; Shuck K, 2000, J VIROL, V74, P7755, DOI 10.1128/JVI.74.17.7755-7761.2000; Song ZY, 2000, BIOPHYS J, V79, P767, DOI 10.1016/S0006-3495(00)76334-X; Stouffer AL, 2008, NATURE, V451, P596, DOI 10.1038/nature06528; Takeda M, 2002, J VIROL, V76, P1391, DOI 10.1128/JVI.76.3.1391-1399.2002; Tian CL, 2003, PROTEIN SCI, V12, P2597, DOI 10.1110/ps.03168503; Tian CL, 2002, BIOCHEMISTRY-US, V41, P11294, DOI 10.1021/bi025695q; Venkataraman P, 2005, J BIOL CHEM, V280, P21463, DOI 10.1074/jbc.M412406200; WANG C, 1993, J VIROL, V67, P5585, DOI 10.1128/JVI.67.9.5585-5594.1993; WANG C, 1994, VIROLOGY, V205, P133, DOI 10.1006/viro.1994.1628; Wang JF, 2001, PROTEIN SCI, V10, P2241, DOI 10.1110/ps.17901; Xiang ZX, 2001, J MOL BIOL, V311, P421, DOI 10.1006/jmbi.2001.4865	43	41	46	5	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15921	15931		10.1074/jbc.M710302200	http://dx.doi.org/10.1074/jbc.M710302200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18408016	Green Published, hybrid			2022-12-25	WOS:000256332500051
J	Malaga, W; Constant, P; Euphrasie, D; Cataldi, A; Daffe, M; Reyrat, JM; Guilhot, C				Malaga, Wladimir; Constant, Patricia; Euphrasie, Daniel; Cataldi, Angel; Daffe, Mamadou; Reyrat, Jean-Marc; Guilhot, Christophe			Deciphering the genetic bases of the structural diversity of phenolic glycolipids in strains of the Mycobacterium tuberculosis complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS; LEPRAE; PHTHIOCEROL; LIPOOLIGOSACCHARIDES; IDENTIFICATION; SEQUENCE; MARINUM	Phenolic glycolipids (PGL) play a major role in the virulence of mycobacteria, notably in strains of the Mycobacterium tuberculosis complex and in Mycobacterium leprae. The structure of the carbohydrate domain of these compounds is highly variable, and the genetic bases for these variations remain unknown. We demonstrated that the monoglycosylated PGL formed by Mycobacterium bovis differs from the triglycosylated PGL synthesized by M. tuberculosis (PGL-tb) because of the following two genetic defects: a frameshift mutation within the gene Rv2958c, encoding a glycosyltransferase involved in the transfer of the second rhamnosyl residue of the PGL-tb, and a deletion of a region that encompasses two genes, which encode a GDP-D-mannose 4,6-dehydratase and a GDP-4-keto-6-deoxy-D-mannose-3,5-epimerase/reductase, required for the formation of activated L-fucose. Expression of these three genes in M. bovis BCG allowed synthesis of PGL-tb in this recombinant strain. Additionally, we showed that all M. bovis, Mycobacterium microti, Mycobacterium pinnipedii, and some Mycobacterium africanum strains harbor the same frameshift mutation in their Rv2958c orthologs. Consistently, the structure of PGLs purified from M. africanum (harboring the Rv2958c mutation) and M. pinnipedii strains revealed that these compounds are monoglycosylated PGL. These findings explain the specificity of PGL-tb production by some strains of the M. tuberculosis complex and have important implications for our understanding of the evolution of this complex.	[Malaga, Wladimir; Constant, Patricia; Daffe, Mamadou; Guilhot, Christophe] Univ Toulouse 3, F-31077 Toulouse 4, France; [Malaga, Wladimir; Constant, Patricia; Daffe, Mamadou; Guilhot, Christophe] CNRS, Inst Pharmacol & Biol Struct, Unite Mixte Rech 5089, Dept Macanismes Mol Infect Mycobacteriennes, F-31077 Toulouse 4, France; [Euphrasie, Daniel; Reyrat, Jean-Marc] Univ Paris 05, Fac Med Rene Descartes, INSERM, Unite Pathogenie Infect Syst,U570, F-75730 Paris 15, France; [Cataldi, Angel] CNIA INTA, Inst Biotechnol, RA-1712 Castelar, Argentina	Universite de Toulouse; Universite Toulouse III - Paul Sabatier; Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Instituto Nacional de Tecnologia Agropecuaria (INTA)	Guilhot, C (corresponding author), Univ Toulouse 3, 205 Route Narbonne, F-31077 Toulouse 4, France.	Christophe.Guilhot@ipbs.fr						Belisle JT, 1998, METH MOL B, V101, P31, DOI 10.1385/0-89603-471-2:31; Brennan PJ, 1988, MICROBIAL LIPIDS, V1, P-298; Brosch R, 2002, P NATL ACAD SCI USA, V99, P3684, DOI 10.1073/pnas.052548299; Burguiere A, 2005, J BIOL CHEM, V280, P42124, DOI 10.1074/jbc.M507500200; Camacho LR, 2001, J BIOL CHEM, V276, P19845, DOI 10.1074/jbc.M100662200; Charlab R, 2001, LEPROSY REV, V72, P63; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Constant P, 2002, J BIOL CHEM, V277, P38148, DOI 10.1074/jbc.M206538200; DAFFE M, 1988, BIOCHIM BIOPHYS ACTA, V958, P443, DOI 10.1016/0005-2760(88)90230-5; DAFFE M, 1987, EUR J BIOCHEM, V167, P155, DOI 10.1111/j.1432-1033.1987.tb13317.x; DAFFE M, 1988, J GEN MICROBIOL, V134, P2049; DAFFE M, 1991, BIOCHEMISTRY-US, V30, P378, DOI 10.1021/bi00216a011; DAFFE M, 2000, GLYCOMICROBIOLOGY, P225, DOI DOI 10.1007/0-306-46821-2_8; Deshayes C, 2008, BMC EVOL BIOL, V8, DOI 10.1186/1471-2148-8-78; Guilhot C, 2008, MYCOBACTERIAL CELL ENVELOPE, P273; Kremer K, 1999, J CLIN MICROBIOL, V37, P2607, DOI 10.1128/JCM.37.8.2607-2618.1999; Laval F, 2001, ANAL CHEM, V73, P4537, DOI 10.1021/ac0105181; Le Dantec C, 2001, J BACTERIOL, V183, P2157, DOI 10.1128/JB.183.7.2157-2164.2001; Maki M, 2004, GLYCOBIOLOGY, V14, p1R, DOI 10.1093/glycob/cwh040; MEHRA V, 1984, NATURE, V308, P194, DOI 10.1038/308194a0; Miyamoto Y, 2007, J BACTERIOL, V189, P5515, DOI 10.1128/JB.00344-07; NEILL MA, 1988, J EXP MED, V167, P30, DOI 10.1084/jem.167.1.30; Ng V, 2000, CELL, V103, P511, DOI 10.1016/S0092-8674(00)00142-2; Perez E, 2004, J BIOL CHEM, V279, P42574, DOI 10.1074/jbc.M406246200; Pfyffer GE, 1998, EMERG INFECT DIS, V4, P631, DOI 10.3201/eid0404.980414; Reed MB, 2004, NATURE, V431, P84, DOI 10.1038/nature02837; Ren HP, 2007, MOL MICROBIOL, V63, P1345, DOI 10.1111/j.1365-2958.2007.05603.x; SCHLESINGER LS, 1991, J EXP MED, V174, P1031, DOI 10.1084/jem.174.5.1031; THURMAN PF, 1993, EUR J BIOCHEM, V212, P705, DOI 10.1111/j.1432-1033.1993.tb17708.x; Tsenova L, 2005, J INFECT DIS, V192, P98, DOI 10.1086/430614	30	25	28	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15177	15184		10.1074/jbc.M710275200	http://dx.doi.org/10.1074/jbc.M710275200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18390543	Green Published, hybrid			2022-12-25	WOS:000256232000034
J	Ruiz, A; Serrano, R; Arino, J				Ruiz, Amparo; Serrano, Raquel; Arino, Joaquin			Direct regulation of genes involved in glucose utilization by the calcium/calcineurin pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST SACCHAROMYCES-CEREVISIAE; INDIVIDUAL HEXOSE TRANSPORTERS; ACTIVATED PROTEIN-KINASE; TRANSCRIPTION FACTOR; ENA1 GENE; SIGNALING PATHWAY; MATING PHEROMONE; ALKALINE STRESS; ION HOMEOSTASIS; HXT GENES	Failure to use glucose as carbon source results in transcriptional activation of numerous genes whose expression is otherwise repressed. HXT2 encodes a yeast high affinity glucose transporter that is only expressed under conditions of glucose limitation. We show that HXT2 is rapidly and potently induced by environmental alkalinization, and this requires both the Snf1 and the calcineurin pathways. Regulation by calcineurin is mediated by the transcription factor Crz1, which rapidly translocates to the nucleus upon high pH stress, and acts through a previously unnoticed Crz1-binding element (calcineurin-dependent response element) in the HXT2 promoter (-507 GGGGCTG -501). We demonstrate that, in addition to HXT2, many other genes required for adaptation to glucose shortage, such as HXT7, MDH2, or ALD4, transcriptionally respond to calcium and high pH signaling through binding of Crz1 to their promoters. Therefore, calcineurin-dependent transcriptional regulation appears to be a common feature for many genes encoding carbohydrate-metabolizing enzymes. Remarkably, extracellular calcium allows growth of a snf1 mutant on low glucose in a calcineurin/Crz1-dependent manner, indicating that activation of calcineurin is sufficient to override a major deficiency in the glucose-repression pathway. We propose that alkalinization of the medium results in impaired glucose utilization and that activation of certain glucose-metabolizing genes by calcineurin contributes to yeast survival under this stress situation.	[Ruiz, Amparo; Serrano, Raquel; Arino, Joaquin] Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, E-08193 Barcelona, Spain; [Arino, Joaquin] Univ Autonoma Barcelona, Inst Biotecnol & Biomed, E-08193 Barcelona, Spain	Autonomous University of Barcelona; Autonomous University of Barcelona	Arino, J (corresponding author), Univ Autonoma Barcelona, Dept Bioquim & Biol Mol, Edificio 5,Campus Bellaterra, E-08193 Barcelona, Spain.	Joaquin.Arino@UAB.ES	Arino, Joaquin/D-3756-2011; Ruiz, Amparo/AAZ-2317-2021	Arino, Joaquin/0000-0002-6774-2987; Ruiz, Amparo/0000-0002-3947-4540; Arino Carmona, Joaquin/0000-0002-0390-4270				Adams A, 1997, METHODS YEAST GENETI; Alepuz PM, 1997, MOL MICROBIOL, V26, P91, DOI 10.1046/j.1365-2958.1997.5531917.x; Aramburu J, 2000, CURR TOP CELL REGUL, V36, P237; Boles E, 1997, FEMS MICROBIOL REV, V21, P85, DOI 10.1016/S0168-6445(97)00052-1; Boustany LM, 2002, GENE DEV, V16, P608, DOI 10.1101/gad.967602; Buziol S, 2002, FEMS YEAST RES, V2, P283, DOI 10.1016/S1567-1356(02)00113-7; Colombo S, 1998, EMBO J, V17, P3326, DOI 10.1093/emboj/17.12.3326; Cyert MS, 2003, BIOCHEM BIOPH RES CO, V311, P1143, DOI 10.1016/S0006-291X(03)01552-3; Cyert MS, 2001, ANNU REV GENET, V35, P647, DOI 10.1146/annurev.genet.35.102401.091302; Denis V, 2002, J CELL BIOL, V156, P29, DOI 10.1083/jcb.200111004; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Ferea TL, 1999, P NATL ACAD SCI USA, V96, P9721, DOI 10.1073/pnas.96.17.9721; Fischer M, 1997, FEBS LETT, V419, P259, DOI 10.1016/S0014-5793(97)01466-X; Gancedo JM, 1998, MICROBIOL MOL BIOL R, V62, P334, DOI 10.1128/MMBR.62.2.334-361.1998; Hong SP, 2007, J BIOL CHEM, V282, P16838, DOI 10.1074/jbc.M700146200; Hong SP, 2005, J BIOL CHEM, V280, P21804, DOI 10.1074/jbc.M501887200; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Idrissi FZ, 1998, J MOL BIOL, V284, P925, DOI 10.1006/jmbi.1998.2215; IIDA H, 1990, J BIOL CHEM, V265, P13391; Kafadar KA, 2004, EUKARYOT CELL, V3, P1147, DOI 10.1128/EC.3.5.1147-1153.2004; Kaniak A, 2004, EUKARYOT CELL, V3, P221, DOI 10.1128/EC.3.1.221-231.2004; Kim JH, 2006, J BIOL CHEM, V281, P26144, DOI 10.1074/jbc.M603636200; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; Lamb TM, 2003, MOL CELL BIOL, V23, P677, DOI 10.1128/MCB.23.2.677-686.2003; Lamb TM, 2001, J BIOL CHEM, V276, P1850, DOI 10.1074/jbc.M008381200; Liang H, 1996, MOL BIOL CELL, V7, P1953, DOI 10.1091/mbc.7.12.1953; Locke EG, 2000, MOL CELL BIOL, V20, P6686, DOI 10.1128/MCB.20.18.6686-6694.2000; Matheos DP, 1997, GENE DEV, V11, P3445, DOI 10.1101/gad.11.24.3445; Matsumoto TK, 2002, J BIOL CHEM, V277, P33075, DOI 10.1074/jbc.M205037200; Mendizabal I, 2001, MOL GENET GENOMICS, V265, P801, DOI 10.1007/s004380100474; Moser NJ, 1996, MOL CELL BIOL, V16, P4824; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4; OHSUMI Y, 1985, J BIOL CHEM, V260, P482; Ozcan S, 1996, MOL CELL BIOL, V16, P5536; Ozcan S, 1999, MICROBIOL MOL BIOL R, V63, P554; OZCAN S, 1995, MOL CELL BIOL, V15, P1564; Ozcan S, 1996, P NATL ACAD SCI USA, V93, P12428, DOI 10.1073/pnas.93.22.12428; Platara M, 2006, J BIOL CHEM, V281, P36632, DOI 10.1074/jbc.M606483200; REIFENBERGER E, 1995, MOL MICROBIOL, V16, P157, DOI 10.1111/j.1365-2958.1995.tb02400.x; Reifenberger E, 1997, EUR J BIOCHEM, V245, P324, DOI 10.1111/j.1432-1033.1997.00324.x; Reynolds A., 1997, CURRENT PROTOCOLS MO; Rodriguez C, 2003, FEMS YEAST RES, V3, P77, DOI 10.1016/S1567-1356(02)00156-3; Ruiz A, 2006, MOL MICROBIOL, V62, P263, DOI 10.1111/j.1365-2958.2006.05370.x; Santangelo GM, 2006, MICROBIOL MOL BIOL R, V70, P253, DOI 10.1128/MMBR.70.1.253-282.2006; Sanz P, 2007, FRONT BIOSCI-LANDMRK, V12, P2358, DOI 10.2741/2238; Schneper L, 2004, CURR OPIN MICROBIOL, V7, P624, DOI 10.1016/j.mib.2004.10.002; Schuller HJ, 2003, CURR GENET, V43, P139, DOI 10.1007/s00294-003-0381-8; Serrano R, 2002, MOL MICROBIOL, V46, P1319, DOI 10.1046/j.1365-2958.2002.03246.x; Serrano R, 2004, J BIOL CHEM, V279, P19698, DOI 10.1074/jbc.M313746200; Serrano R, 2006, J BIOL CHEM, V281, P39785, DOI 10.1074/jbc.M604497200; Stathopoulos AM, 1997, GENE DEV, V11, P3432, DOI 10.1101/gad.11.24.3432; Stathopoulos-Gerontides A, 1999, GENE DEV, V13, P798, DOI 10.1101/gad.13.7.798; Tsuzi D, 2004, FEBS LETT, V569, P301, DOI 10.1016/j.febslet.2004.05.077; van Helden J, 2003, NUCLEIC ACIDS RES, V31, P3593, DOI 10.1093/nar/gkg567; Viladevall L, 2004, J BIOL CHEM, V279, P43614, DOI 10.1074/jbc.M403606200; Wieczorke R, 1999, FEBS LETT, V464, P123, DOI 10.1016/S0014-5793(99)01698-1; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Withee JL, 1997, MOL BIOL CELL, V8, P263, DOI 10.1091/mbc.8.2.263; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Yoshimoto H, 2002, J BIOL CHEM, V277, P31079, DOI 10.1074/jbc.M202718200	60	44	44	1	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 16	2008	283	20					13923	13933		10.1074/jbc.M708683200	http://dx.doi.org/10.1074/jbc.M708683200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	299AM	18362157	hybrid			2022-12-25	WOS:000255728200046
J	Whitaker, D; Levi, DM; Kennedy, GJ				Whitaker, David; Levi, Dennis M.; Kennedy, Graeme J.			Integration across Time Determines Path Deviation Discrimination for Moving Objects	PLOS ONE			English	Article							MOTION; DIRECTION; ORIENTATION; PERCEPTION; MECHANISMS; SCALE; SPEED	Background: Human vision is vital in determining our interaction with the outside world. In this study we characterize our ability to judge changes in the direction of motion of objects-a common task which can allow us either to intercept moving objects, or else avoid them if they pose a threat. Methodology/Principal Findings: Observers were presented with objects which moved across a computer monitor on a linear path until the midline, at which point they changed their direction of motion, and observers were required to judge the direction of change. In keeping with the variety of objects we encounter in the real world, we varied characteristics of the moving stimuli such as velocity, extent of motion path and the object size. Furthermore, we compared performance for moving objects with the ability of observers to detect a deviation in a line which formed the static trace of the motion path, since it has been suggested that a form of static memory trace may form the basis for these types of judgment. The static line judgments were well described by a 'scale invariant' model in which any two stimuli which possess the same two-dimensional geometry (length/width) result in the same level of performance. Performance for the moving objects was entirely different. Irrespective of the path length, object size or velocity of motion, path deviation thresholds depended simply upon the duration of the motion path in seconds. Conclusions/Significance: Human vision has long been known to integrate information across space in order to solve spatial tasks such as judgment of orientation or position. Here we demonstrate an intriguing mechanism which integrates direction information across time in order to optimize the judgment of path deviation for moving objects.	[Whitaker, David; Kennedy, Graeme J.] Univ Bradford, Dept Optometry, Bradford BD7 1DP, W Yorkshire, England; [Levi, Dennis M.] Univ Calif, Sch Optometry, Helen Wills Neurosci Inst, Berkeley, CA USA	University of Bradford; University of California System; University of California Berkeley	Whitaker, D (corresponding author), Univ Bradford, Dept Optometry, Bradford BD7 1DP, W Yorkshire, England.	D.J.Whitaker@bradford.ac.uk			Research Fellowship from The Leverhulme Trust; National Eye Institute, NIH [R01EY01728, RO1 EY04776]; NATIONAL EYE INSTITUTE [R01EY004776, R01EY001728] Funding Source: NIH RePORTER	Research Fellowship from The Leverhulme Trust; National Eye Institute, NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))	DW was supported by a Research Fellowship from The Leverhulme Trust. DL was supported by Research grants R01EY01728 and RO1 EY04776 from the National Eye Institute, NIH.	ANDREWS DP, 1967, VISION RES, V7, P999, DOI 10.1016/0042-6989(67)90015-6; ANDREWS DP, 1973, VISION RES, V13, P599, DOI 10.1016/0042-6989(73)90026-6; BURR D, 1980, NATURE, V284, P164, DOI 10.1038/284164a0; Burr D, 2000, CURR BIOL, V10, pR440, DOI 10.1016/S0960-9822(00)00545-5; Burr DC, 2002, J NEUROSCI, V22, P8661; DZHAFAROV EN, 1993, PERCEPT PSYCHOPHYS, V54, P733, DOI 10.3758/BF03211798; Geisler WS, 1999, NATURE, V400, P65, DOI 10.1038/21886; Genova B, 2000, VISION RES, V40, P3049, DOI 10.1016/S0042-6989(00)00158-9; GRZYWACZ NM, 1995, VISION RES, V35, P3183, DOI 10.1016/0042-6989(95)00102-6; Heeley DW, 1998, EXP BRAIN RES, V120, P217, DOI 10.1007/s002210050395; Hohnsbein J, 1998, VISION RES, V38, P2569, DOI 10.1016/S0042-6989(98)00014-5; Joseph JS, 1997, VISION RES, V37, P3097, DOI 10.1016/S0042-6989(97)00068-0; KINGDOM FAA, 1995, VISION RES, V35, P79, DOI 10.1016/0042-6989(94)E0079-Z; Kingdom FAA, 1999, VISION RES, V39, P1477, DOI 10.1016/S0042-6989(98)00217-X; KLEIN SA, 1985, J OPT SOC AM A, V2, P1170, DOI 10.1364/JOSAA.2.001170; KOENDERINK JJ, 1988, J OPT SOC AM A, V5, P1136, DOI 10.1364/JOSAA.5.001136; KOOI FL, 1993, VISION RES, V33, P2347, DOI 10.1016/0042-6989(93)90112-A; Krekelberg B, 1999, VISION RES, V39, P2669, DOI 10.1016/S0042-6989(98)00287-9; SEKULER AB, 1990, PERCEPTION, V19, P181, DOI 10.1068/p190181; Skillen J, 2002, VISION RES, V42, P2447, DOI 10.1016/S0042-6989(02)00261-4; TOET A, 1987, VISION RES, V27, P441, DOI 10.1016/0042-6989(87)90092-7; Tong JL, 2007, PERCEPT PSYCHOPHYS, V69, P48, DOI 10.3758/BF03194452; Tripathy SP, 2004, J VISION, V4, P1020, DOI 10.1167/4.12.4; Tripathy SP, 2003, PERCEPTION, V32, P1403, DOI 10.1068/p5161; Vakrou C, 2007, J VISION, V7, DOI 10.1167/7.14.13; Watamaniuk SNJ, 2005, VISION RES, V45, P2993, DOI 10.1016/j.visres.2005.07.027; WATAMANIUK SNJ, 1995, VISION RES, V35, P65, DOI 10.1016/0042-6989(94)E0047-O; WESTHEIMER G, 1994, J NEUROPHYSIOL, V71, P33, DOI 10.1152/jn.1994.71.1.33; Whitaker D, 1998, VISION RES, V38, P3843, DOI 10.1016/S0042-6989(98)00104-7; Whitaker D, 2002, VISION RES, V42, P1137, DOI 10.1016/S0042-6989(02)00030-5; WILSON HR, 1986, VISION RES, V26, P453, DOI 10.1016/0042-6989(86)90188-4	31	7	7	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1930	10.1371/journal.pone.0001930	http://dx.doi.org/10.1371/journal.pone.0001930			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414653	Green Published, gold			2022-12-25	WOS:000260867300002
J	Li, ZJ; Zhang, SC; Liu, QH				Li, Zhaojie; Zhang, Shicui; Liu, Qinghui			Vitellogenin Functions as a Multivalent Pattern Recognition Receptor with an Opsonic Activity	PLOS ONE			English	Article								Background: Vitellogenin (Vg), a major reproductive protein, has been associated with infection-resistant response in fish. However, the underlying mechanisms by which Vg is involved in anti-infectious response are not understood. Methodology/Results: By both protein-microbe interaction analysis and enzyme-linked immunosorbent assay as well as phagocytosis test, we demonstrate for the first time that fish Vg acts as a pattern recognition molecule with multiple specificities that can recognize bacteria as well as fungus rather than self components from fish, and functions as an opsonin that can enhance macrophage phagocytosis. Conclusions: This study shows that fish Vg plays an integrative function in regulating immunity via its pleiotropic effects on both recognizing pathogen-associated molecular patterns and promoting macrophage phagocytosis. It also supports the notion that factors normally involved in control of female reproduction are associated with immunity in organisms that rely on Vg for oocyte development.	[Li, Zhaojie; Zhang, Shicui] Ocean Univ China, Dept Marine Biol, Qingdao, Peoples R China; [Liu, Qinghui] Chinese Acad Fisheries, Yellow Sea Fishery Res Inst, Qingdao, Peoples R China	Ocean University of China; Chinese Academy of Fishery Sciences; Yellow Sea Fisheries Research Institute, CAFS	Li, ZJ (corresponding author), Ocean Univ China, Dept Marine Biol, Qingdao, Peoples R China.	sczhang@ouc.edu.cn			Ministry of Science and Technology (MOST) [2006CB101805, 30730072]; Natural Science Foundation of China (NSFC)	Ministry of Science and Technology (MOST)(Ministry of Science and Technology, China); Natural Science Foundation of China (NSFC)(National Natural Science Foundation of China (NSFC))	This work was supported by grants (2006CB101805; 30730072) of Ministry of Science and Technology (MOST) and Natural Science Foundation of China (NSFC).	Akira S, 2006, CELL, V124, P783, DOI 10.1016/j.cell.2006.02.015; ALONSODEVELASCO E, 1994, VACCINE, V12, P1419, DOI 10.1016/0264-410X(94)90151-1; Amdam GV, 2006, BEHAV BRAIN RES, V169, P201, DOI 10.1016/j.bbr.2006.01.006; Amdam GV, 2004, J ECON ENTOMOL, V97, P741, DOI 10.1603/0022-0493(2004)097[0741:APIWHB]2.0.CO;2; Amdam GV, 2003, P NATL ACAD SCI USA, V100, P1799, DOI 10.1073/pnas.0333979100; ARUKWE A, 2003, COMP HEPATOL, V2, pE4; Avarre JC, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-3; Brown GD, 2003, IMMUNITY, V19, P311, DOI 10.1016/S1074-7613(03)00233-4; BYRNE BM, 1989, PROG BIOPHYS MOL BIO, V53, P33, DOI 10.1016/0079-6107(89)90005-9; Chen X, 2001, J BIOL CHEM, V276, P34617, DOI 10.1074/jbc.M103995200; CUTTING JA, 1973, ANAL BIOCHEM, V54, P386, DOI 10.1016/0003-2697(73)90367-9; DAVIS BJ, 1964, ANN NY ACAD SCI, V121, P404, DOI 10.1111/j.1749-6632.1964.tb14213.x; de Vlaming V L, 1977, Life Sci, V20, P1945, DOI 10.1016/0024-3205(77)90172-2; DELLACIOPPA G, 1987, INSECT BIOCHEM, V17, P401, DOI 10.1016/0020-1790(87)90002-3; DHADIALLA TS, 1990, J BIOL CHEM, V265, P9924; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; Garcia-Garcia E, 2002, J LEUKOCYTE BIOL, V72, P1092; Gordon S, 2002, CELL, V111, P927, DOI 10.1016/S0092-8674(02)01201-1; Guidugli KR, 2005, FEBS LETT, V579, P4961, DOI 10.1016/j.febslet.2005.07.085; Hiramatsu N, 2005, BIOCH MOLEC, V6, P431; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; Janeway CA, 2002, ANNU REV IMMUNOL, V20, P197, DOI 10.1146/annurev.immunol.20.083001.084359; Jiang HB, 2004, INSECT BIOCHEM MOLEC, V34, P89, DOI 10.1016/j.ibmb.2003.09.006; JOMORI T, 1992, FEBS LETT, V296, P283, DOI 10.1016/0014-5793(92)80305-Z; Kurata S, 2006, IMMUNOBIOLOGY, V211, P237, DOI 10.1016/j.imbio.2005.10.016; Levashina EA, 2001, CELL, V104, P709, DOI 10.1016/S0092-8674(01)00267-7; Nakamura A, 1999, BIOCHEM BIOPH RES CO, V264, P580, DOI 10.1006/bbrc.1999.1549; Nelson CM, 2007, PLOS BIOL, V5, P673, DOI 10.1371/journal.pbio.0050062; Peiser L, 2002, CURR OPIN IMMUNOL, V14, P123, DOI 10.1016/S0952-7915(01)00307-7; RABINOVITCH M, 1995, TRENDS CELL BIOL, V5, P85, DOI 10.1016/S0962-8924(00)88955-2; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Roos A, 2004, EUR J IMMUNOL, V34, P921, DOI 10.1002/eji.200424904; Roque ACA, 2004, J MOL RECOGNIT, V17, P262, DOI 10.1002/jmr.661; Royet J, 2004, MOL IMMUNOL, V41, P1063, DOI 10.1016/j.molimm.2004.06.009; Sappington TW, 1998, INSECT BIOCHEM MOLEC, V28, P277, DOI 10.1016/S0965-1748(97)00110-0; Seehuus SC, 2006, P NATL ACAD SCI USA, V103, P962, DOI 10.1073/pnas.0502681103; Shi XD, 2006, FISH SHELLFISH IMMUN, V20, P769, DOI 10.1016/j.fsi.2005.09.005; SHYU AB, 1986, P NATL ACAD SCI USA, V83, P3865, DOI 10.1073/pnas.83.11.3865; Soderhall K, 1998, CURR OPIN IMMUNOL, V10, P23, DOI 10.1016/S0952-7915(98)80026-5; Sun XT, 2001, COMP BIOCHEM PHYS B, V129, P121, DOI 10.1016/S1096-4959(01)00310-4; Tyler CR, 1996, REV FISH BIOL FISHER, V6, P287, DOI 10.1007/BF00122584; Yu XQ, 2003, DEV COMP IMMUNOL, V27, P189, DOI 10.1016/S0145-305X(02)00099-X; Yu YH, 2007, J IMMUNOL, V179, P8425, DOI 10.4049/jimmunol.179.12.8425; ZAPATA A, 1979, DEV COMP IMMUNOL, V3, P55, DOI 10.1016/S0145-305X(79)80006-3; ZAPATA A, 1981, DEV COMP IMMUNOL, V5, P685, DOI 10.1016/S0145-305X(81)80043-2; Zhang SC, 2005, FISH SHELLFISH IMMUN, V19, P93, DOI 10.1016/j.fsi.2004.10.008; Zou YM, 2006, BIOCHEM BIOPH RES CO, V351, P625, DOI 10.1016/j.bbrc.2006.10.091	48	124	133	2	24	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1940	10.1371/journal.pone.0001940	http://dx.doi.org/10.1371/journal.pone.0001940			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398466	Green Submitted, Green Published, gold			2022-12-25	WOS:000260795500017
J	Matsuzawa, D; Obata, T; Shirayama, Y; Nonaka, H; Kanazawa, Y; Yoshitome, E; Takanashi, J; Matsuda, T; Shimizu, E; Ikehira, H; Iyo, M; Hashimoto, K				Matsuzawa, Daisuke; Obata, Takayuki; Shirayama, Yukihiko; Nonaka, Hiroi; Kanazawa, Yoko; Yoshitome, Eiji; Takanashi, Junichi; Matsuda, Tsuyoshi; Shimizu, Eiji; Ikehira, Hiroo; Iyo, Masaomi; Hashimoto, Kenji			Negative Correlation between Brain Glutathione Level and Negative Symptoms in Schizophrenia: A 3T H-1-MRS Study	PLOS ONE			English	Article								Background: Glutathione (GSH), a major intracellular antioxidant, plays a role in NMDA receptor-mediated neurotransmission, which is involved in the pathophysiology of schizophrenia. In the present study, we aimed to investigate whether GSH levels are altered in the posterior medial frontal cortex of schizophrenic patients. Furthermore, we examined correlations between GSH levels and clinical variables in patients. Methods and Findings: Twenty schizophrenia patients and 16 age-and gender-matched normal controls were enrolled to examine the levels of GSH in the posterior medial frontal cortex by using 3T SIGNA EXCITE H-1-MRS with the spectral editing technique, MEGA-PRESS. Clinical variables of patients were assessed by the Global Assessment of Functioning (GAF), Scale for the Assessment of Negative Symptoms (SANS), Brief Psychiatric Rating Scale (BPRS), Drug-Induced Extra-Pyramidal Symptoms Scale (DIEPSS), and five cognitive performance tests (Word Fluency Test, Stroop Test, Trail Making Test, Wisconsin Card Sorting Test and Digit Span Distractibility Test). Levels of GSH in the posterior medial frontal cortex of schizophrenic patients were not different from those of normal controls. However, we found a significant negative correlation between GSH levels and the severity of negative symptoms (SANS total score and negative symptom subscore on BPRS) in patients. There were no correlations between brain GSH levels and scores on any cognitive performance test except Trail Making Test part A. Conclusion: These results suggest that GSH levels in the posterior medial frontal cortex may be related to negative symptoms in schizophrenic patients. Therefore, agents that increase GSH levels in the brain could be potential therapeutic drugs for negative symptoms in schizophrenia.	[Hashimoto, Kenji] Chiba Univ, Ctr Forensic Mental Hlth, Div Clin Neurosci, Chiba, Japan; [Matsuzawa, Daisuke; Shirayama, Yukihiko; Iyo, Masaomi] Chiba Univ, Grad Sch Med, Dept Psychiat, Chiba, Japan; [Matsuzawa, Daisuke; Obata, Takayuki; Nonaka, Hiroi; Kanazawa, Yoko; Yoshitome, Eiji; Ikehira, Hiroo] Natl Inst Radiol Sci, Mol Imaging Ctr, Dept Biophys, Chiba, Japan; [Matsuzawa, Daisuke; Shimizu, Eiji] Chiba Univ, Grad Sch Med, Dept Integrative Neurophysiol, Chiba, Japan; [Takanashi, Junichi] Kameda Med Ctr, Div Pediat, Chiba, Japan; [Matsuda, Tsuyoshi] GE Yokogawa Med Syst Ltd, Imaging Appl Tech Ctr, Tokyo, Japan	Chiba University; Chiba University; National Institutes for Quantum Science & Technology; Chiba University; General Electric	Hashimoto, K (corresponding author), Chiba Univ, Ctr Forensic Mental Hlth, Div Clin Neurosci, Chiba, Japan.	hashimoto@faculty.chiba-u.jp	Shimizu, Eiji/K-4637-2017; Obata, Takayuki/AAR-9820-2020; Hashimoto, Kenji/I-5800-2015	Shimizu, Eiji/0000-0002-6741-9338; Obata, Takayuki/0000-0001-7678-5033; Matsuzawa, Daisuke/0000-0003-0408-2608; Takanashi, Jun-ichi/0000-0002-1147-1938; Hashimoto, Kenji/0000-0002-8892-0439	Minister of Education, Culture, Sports, Science, and Technology of Japan	Minister of Education, Culture, Sports, Science, and Technology of Japan	This study was supported in part by grants from the Minister of Education, Culture, Sports, Science, and Technology of Japan (to K.H.).	ABDALLA DSP, 1986, CLIN CHEM, V32, P805; Akyol O, 2002, PROG NEURO-PSYCHOPH, V26, P995, DOI 10.1016/S0278-5846(02)00220-8; American Psychiatric Association, DIAGN STAT MAN MENT; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Ben Othmen L, 2008, PROG NEURO-PSYCHOPH, V32, P155, DOI 10.1016/j.pnpbp.2007.08.003; Carter CS, 1995, NEUROIMAGE, V2, P264, DOI 10.1006/nimg.1995.1034; Do KQ, 2000, EUR J NEUROSCI, V12, P3721, DOI 10.1046/j.1460-9568.2000.00229.x; Fukami G, 2004, BRAIN RES, V1016, P90, DOI 10.1016/j.brainres.2004.04.072; Goff DC, 2001, AM J PSYCHIAT, V158, P1367, DOI 10.1176/appi.ajp.158.9.1367; Gysin R, 2007, P NATL ACAD SCI USA, V104, P16621, DOI 10.1073/pnas.0706778104; Harada S, 2001, BIOCHEM BIOPH RES CO, V281, P267, DOI 10.1006/bbrc.2001.4347; Hashimoto K, 2003, ARCH GEN PSYCHIAT, V60, P572, DOI 10.1001/archpsyc.60.6.572; Hashimoto K, 2004, NEUROPSYCHOPHARMACOL, V29, P2018, DOI 10.1038/sj.npp.1300512; HASHIMOTO K, 2003, CURR MED CHEMCNS AGE, V60, P572; Hashimoto T, 2005, AM J MED GENET B, V135B, P5, DOI 10.1002/ajmg.b.30164; HASHIMOTO T, 2008, AM J MED B IN PRESS; Jacobsen JPR, 2005, NEUROSCIENCE, V132, P1055, DOI 10.1016/j.neuroscience.2005.01.059; Javitt DC, 1996, P NATL ACAD SCI USA, V93, P11962, DOI 10.1073/pnas.93.21.11962; JAVITT DC, 1991, AM J PSYCHIAT, V148, P1301; KOHR G, 1994, NEURON, V12, P1031, DOI 10.1016/0896-6273(94)90311-5; LAVOIE S, 2007, NEUROPSYCHO IN PRESS; Mahadik SP, 1996, SCHIZOPHR RES, V19, P1, DOI 10.1016/0920-9964(95)00049-6; Matsuzawa D, 2005, NEUROPSYCHOBIOLOGY, V52, P68, DOI 10.1159/000086607; Pae CU, 2004, PSYCHIAT GENET, V14, P147, DOI 10.1097/00041444-200409000-00005; REDDY R, 1991, BIOL PSYCHIAT, V30, P409, DOI 10.1016/0006-3223(91)90298-Z; Reitan RM, 1985, HALSTEAD REITAN NEUR; Satoh T, 2006, NEUROSCI RES, V55, P34, DOI 10.1016/j.neures.2006.01.002; Shad MU, 2006, SCHIZOPHR RES, V86, P54, DOI 10.1016/j.schres.2006.06.006; SUCHER NJ, 1991, J NEUROSCI RES, V30, P582, DOI 10.1002/jnr.490300316; Sumiyoshi C, 2005, SCHIZOPHR RES, V74, P91, DOI 10.1016/j.schres.2004.05.011; Tamminga CA, 1998, CRIT REV NEUROBIOL, V12, P21, DOI 10.1615/CritRevNeurobiol.v12.i1-2.20; Terpstra M, 2005, MAGN RESON MATER PHY, V18, P276, DOI 10.1007/s10334-005-0012-0; Terpstra M, 2003, MAGN RESON MED, V50, P19, DOI 10.1002/mrm.10499; Tosic M, 2006, AM J HUM GENET, V79, P586, DOI 10.1086/507566; Varga V, 1997, NEUROCHEM RES, V22, P1165, DOI 10.1023/A:1027377605054; Wilder-Willis KE, 2001, BIPOLAR DISORD, V3, P58, DOI 10.1034/j.1399-5618.2001.030202.x; Yao JK, 2006, DIS MARKERS, V22, P83, DOI 10.1155/2006/248387; Yao JK, 1999, BIOL PSYCHIAT, V45, P1512, DOI 10.1016/S0006-3223(98)00184-X; Yao JK, 2001, CNS DRUGS, V15, P287, DOI 10.2165/00023210-200115040-00004; Zhang XY, 2007, J CLIN PSYCHIAT, V68, P754, DOI 10.4088/JCP.v68n0513	40	150	154	0	14	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1944	10.1371/journal.pone.0001944	http://dx.doi.org/10.1371/journal.pone.0001944			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398470	Green Published, gold, Green Submitted			2022-12-25	WOS:000260795500021
J	Madeira, L; Galante, PAF; Budu, A; Azevedo, MF; Malnic, B; Garcia, CRS				Madeira, Luciana; Galante, Pedro A. F.; Budu, Alexandre; Azevedo, Mauro F.; Malnic, Bettina; Garcia, Celia R. S.			Genome-Wide Detection of Serpentine Receptor-Like Proteins in Malaria Parasites	PLOS ONE			English	Article							PLASMODIUM-FALCIPARUM; TOPOLOGY PREDICTION; COUPLED RECEPTORS; XANTHURENIC ACID; CALCIUM; PROTEOME; IDENTIFICATION; TRANSCRIPTOME; DISCOVERY; MELATONIN	Serpentine receptors comprise a large family of membrane receptors distributed over diverse organisms, such as bacteria, fungi, plants and all metazoans. However, the presence of serpentine receptors in protozoan parasites is largely unknown so far. In the present study we performed a genome-wide search for proteins containing seven transmembrane domains (7TM) in the human malaria parasite Plasmodium falciparum and identified four serpentine receptor-like proteins. These proteins, denoted PfSR1, PfSR10, PfSR12 and PfSR25, show membrane topologies that resemble those exhibited by members belonging to different families of serpentine receptors. Expression of the pfsrs genes was detected by Real Time PCR in P. falciparum intraerythrocytic stages, indicating that they potentially code for functional proteins. We also found corresponding homologues for the PfSRs in five other Plasmodium species, two primate and three rodent parasites. PfSR10 and 25 are the most conserved receptors among the different species, while PfSR1 and 12 are more divergent. Interestingly, we found that PfSR10 and PfSR12 possess similarity to orphan serpentine receptors of other organisms. The identification of potential parasite membrane receptors raises a new perspective for essential aspects of malaria parasite host cell infection.	[Budu, Alexandre; Azevedo, Mauro F.; Garcia, Celia R. S.] Univ Sao Paulo, Inst Bioci, Dept Fisiol, BR-05508 Sao Paulo, Brazil; [Madeira, Luciana] Univ Sao Paulo, Inst Ciencias Biomed, Dept Parasitol, Sao Paulo, Brazil; [Galante, Pedro A. F.; Malnic, Bettina] Univ Sao Paulo, Inst Quimi, Dept Bioquim, Sao Paulo, Brazil; [Galante, Pedro A. F.] Ludwig Inst Canc Res, Sao Paulo, Brazil	Universidade de Sao Paulo; Universidade de Sao Paulo; Universidade de Sao Paulo; Ludwig Institute for Cancer Research	Garcia, CRS (corresponding author), Univ Sao Paulo, Inst Bioci, Dept Fisiol, BR-05508 Sao Paulo, Brazil.	cgarcia@usp.br	4, INCT/H-4499-2013; Inbeqmedi, Inct/I-1929-2013; Galante, Pedro/U-8594-2019; Garcia, Celia R. S./A-4093-2011; Budu, Alexandre/F-6498-2013; Malnic, Bettina/A-4905-2008; Galante, Pedro A. F./C-6564-2012; Azevedo, Mauro/H-6180-2012	Galante, Pedro/0000-0002-4820-4155; Garcia, Celia R. S./0000-0003-2825-1701; Budu, Alexandre/0000-0002-7110-9754; Malnic, Bettina/0000-0002-5877-4784; Galante, Pedro A. F./0000-0002-4820-4155; Azevedo, Mauro/0000-0002-5233-2037	FAPESP [fellowship]; CNPq/Ministerio da Saude	FAPESP(Fundacao de Amparo a Pesquisa do Estado de Sao Paulo (FAPESP)); CNPq/Ministerio da Saude(Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ))	FAPESP; CNPq/Ministerio da Saude (Neglected Tropical Diseases Grant) to CRSG LM, PAFG, AB and MF received fellowship from FAPESP.	Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Anamika, 2005, PROTEINS, V58, P180, DOI 10.1002/prot.20278; Aravind L, 2003, CELL, V115, P771, DOI 10.1016/S0092-8674(03)01023-7; Bannister L, 2003, TRENDS PARASITOL, V19, P209, DOI 10.1016/S1471-4922(03)00086-2; Beraldo FH, 2005, J CELL BIOL, V170, P551, DOI 10.1083/jcb.200505117; Billker O, 1998, NATURE, V392, P289, DOI 10.1038/32667; Billker O, 2004, CELL, V117, P503, DOI 10.1016/S0092-8674(04)00449-0; Bockaert J, 1999, EMBO J, V18, P1723, DOI 10.1093/emboj/18.7.1723; Bozdech Z, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-17; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Brzostowski JA, 2001, TRENDS BIOCHEM SCI, V26, P291, DOI 10.1016/S0968-0004(01)01804-7; Carlton JM, 2002, NATURE, V419, P512, DOI 10.1038/nature01099; Daily JP, 2005, J INFECT DIS, V191, P1196, DOI 10.1086/428289; Escalante AA, 1998, P NATL ACAD SCI USA, V95, P8124, DOI 10.1073/pnas.95.14.8124; ESCALANTE AA, 1995, P NATL ACAD SCI USA, V92, P5793, DOI 10.1073/pnas.92.13.5793; Farias SL, 2005, MOL BIOCHEM PARASIT, V141, P71, DOI 10.1016/j.molbiopara.2005.01.015; FINN RD, 2007, NUCL ACIDS RES; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Garcia GE, 1998, J BIOL CHEM, V273, P12003, DOI 10.1074/jbc.273.20.12003; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gazarini ML, 2003, J CELL BIOL, V161, P103, DOI 10.1083/jcb.200212130; Goodstadt L, 2001, BIOINFORMATICS, V17, P845, DOI 10.1093/bioinformatics/17.9.845; Gunasekera AM, 2004, MOL BIOCHEM PARASIT, V136, P35, DOI 10.1016/j.molbiopara.2004.02.007; Hall RA, 1999, J CELL BIOL, V145, P927, DOI 10.1083/jcb.145.5.927; Hotta CT, 2000, NAT CELL BIOL, V2, P466, DOI 10.1038/35017112; Inoue Y, 2004, COMPUT BIOL CHEM, V28, P39, DOI 10.1016/j.compbiolchem.2003.11.003; Khan SM, 2005, CELL, V121, P675, DOI 10.1016/j.cell.2005.03.027; Krogh A, 2001, J MOL BIOL, V305, P567, DOI 10.1006/jmbi.2000.4315; Kumar S, 2001, BIOINFORMATICS, V17, P1244, DOI 10.1093/bioinformatics/17.12.1244; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Martin RE, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-3-r26; McConkey GA, 2004, TRENDS PARASITOL, V20, P60, DOI 10.1016/j.pt.2003.11.001; Melen K, 2003, J MOL BIOL, V327, P735, DOI 10.1016/S0022-2836(03)00182-7; Nielsen H, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P122; Otaki JM, 2001, J THEOR BIOL, V211, P77, DOI 10.1006/jtbi.2001.2272; Persson B, 1996, PROTEIN SCI, V5, P363; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; Quevillon E, 2003, GENE, V306, P13, DOI 10.1016/S0378-1119(03)00381-0; Salamov AA, 2000, GENOME RES, V10, P516, DOI 10.1101/gr.10.4.516; Snow RW, 2005, NATURE, V434, P214, DOI 10.1038/nature03342; Sonnhammer E L, 1998, Proc Int Conf Intell Syst Mol Biol, V6, P175; Tusnady GE, 2001, BIOINFORMATICS, V17, P849, DOI 10.1093/bioinformatics/17.9.849; Tusnady GE, 1998, J MOL BIOL, V283, P489, DOI 10.1006/jmbi.1998.2107; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; WALLIN E, 1995, PROTEIN ENG, V8, P693, DOI 10.1093/protein/8.7.693; Ward P, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-79; Yao H, 2005, PLANT MOL BIOL, V57, P445, DOI 10.1007/s11103-005-0271-1	48	39	39	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1889	10.1371/journal.pone.0001889	http://dx.doi.org/10.1371/journal.pone.0001889			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365025	gold, Green Published, Green Submitted			2022-12-25	WOS:000260762400031
J	Ogiwara, H; Kohno, T; Nakanishi, H; Nagayama, K; Sato, M; Yokota, J				Ogiwara, H.; Kohno, T.; Nakanishi, H.; Nagayama, K.; Sato, M.; Yokota, J.			Unbalanced translocation, a major chromosome alteration causing loss of heterozygosity in human lung cancer	ONCOGENE			English	Article						unbalanced translocation; loss of heterozygosity; lung adenocarcinoma; tumor suppressor gene; mitotic recombination	COLORECTAL CANCERS; DNA-DAMAGE; MOLECULAR PROCESSES; 9P21 DELETIONS; ALLELIC LOSS; MECHANISMS; INSTABILITY; GENE; P53; RETINOBLASTOMA	Loss of heterozygosity (LOH) is a major genetic event causing inactivation of tumor suppressor genes in human carcinogenesis. To elucidate chromosomal mechanisms causing LOH, 201 LOHs in 10 cases of human lung cancer, which were detected bya genome-wide single nucleotide polymorphism array analysis, were investigated for responsible chromosome alterations by integrating information on breakpoints for DNA copy number changes obtained by array-comparative genome hybridization and on numerical and structural chromosomal alterations obtained by spectral karyotyping. The majority(80%) of LOHs were partial chromosome LOHs caused by structural chromosomal alterations, while the remaining (20%) were whole chromosome LOHs caused by whole chromosome deletions. Unbalanced translocation was defined as the most frequent alteration, and it accounted for 30% of all LOHs. Three other structural alterations-interstitial deletion (19%), mitotic recombination (9%) and gene conversion (6%)-also contributed to the occurrence of LOH, while terminal deletion contributed to only a small subset (1%). Since unbalanced translocation is a common chromosomal alteration in lung cancer cells, the results in the present study strongly indicate that a considerable fraction of LOHs detected in lung cancer cells are caused by unbalanced translocation.	[Ogiwara, H.; Kohno, T.; Nakanishi, H.; Nagayama, K.; Sato, M.; Yokota, J.] Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, Tokyo 1040045, Japan	National Cancer Center - Japan	Yokota, J (corresponding author), Natl Canc Ctr, Res Inst, Div Biol, Chuo Ku, 1-1,Tsukiji 5 Chome, Tokyo 1040045, Japan.	jyokota@ncc.go.jp		Ogiwara, Hideaki/0000-0003-0860-1807				Abdel-Rahman WM, 2001, P NATL ACAD SCI USA, V98, P2538, DOI 10.1073/pnas.041603298; Adams J, 2005, CANCER RES, V65, P66; Bartkova J, 2005, NATURE, V434, P864, DOI 10.1038/nature03482; Bosco G, 1998, GENETICS, V150, P1037; CAVENEE WK, 1983, NATURE, V305, P779, DOI 10.1038/305779a0; COLVY T, 2004, WHO CLASSIFICATION T, P31; Florl AR, 2003, GENE CHROMOSOME CANC, V37, P141, DOI 10.1002/gcc.10192; Gaasenbeek M, 2006, CANCER RES, V66, P3471, DOI 10.1158/0008-5472.CAN-05-3285; Girard L, 2000, CANCER RES, V60, P4894; Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485; Grigorova M, 2005, CANCER GENET CYTOGEN, V162, P1, DOI 10.1016/j.cancergencyto.2005.03.007; JAMES CD, 1989, P NATL ACAD SCI USA, V86, P2858, DOI 10.1073/pnas.86.8.2858; Katsura Y, 2007, DNA REPAIR, V6, P639, DOI 10.1016/j.dnarep.2006.12.002; Kohno T, 2006, DNA REPAIR, V5, P1273, DOI 10.1016/j.dnarep.2006.05.021; LASKO D, 1991, ANNU REV GENET, V25, P281, DOI 10.1146/annurev.ge.25.120191.001433; Lieber MR, 2003, NAT REV MOL CELL BIO, V4, P712, DOI 10.1038/nrm1202; Masuda A, 2002, ONCOGENE, V21, P6884, DOI 10.1038/sj.onc.1205566; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; MORI N, 1989, CANCER RES, V49, P5130; NAYLOR SL, 1987, NATURE, V329, P451, DOI 10.1038/329451a0; Pennaneach V, 2006, MOL MICROBIOL, V59, P1357, DOI 10.1111/j.1365-2958.2006.05026.x; Phelps RM, 1996, J CELL BIOCHEM, P32; Robles AI, 2002, ONCOGENE, V21, P6898, DOI 10.1038/sj.onc.1205563; Roschke AV, 2003, CANCER RES, V63, P8634; SAKAMOTO H, 1986, P NATL ACAD SCI USA, V83, P3997, DOI 10.1073/pnas.83.11.3997; Sasaki S, 2003, ONCOGENE, V22, P3792, DOI 10.1038/sj.onc.1206589; Sato M, 2005, GENE CHROMOSOME CANC, V44, P405, DOI 10.1002/gcc.20253; Sato M, 2007, J THORAC ONCOL, V2, P327, DOI 10.1097/01.JTO.0000263718.69320.4c; Schmidt L, 1995, Cancer J Sci Am, V1, P191; Schrock E, 1996, SCIENCE, V273, P494, DOI 10.1126/science.273.5274.494; Sekido Y, 2003, ANNU REV MED, V54, P73, DOI 10.1146/annurev.med.54.101601.152202; Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546; Shiseki M, 1996, GENE CHROMOSOME CANC, V17, P71, DOI 10.1002/(SICI)1098-2264(199610)17:2<71::AID-GCC1>3.0.CO;2-Y; Takahashi T, 1999, ONCOGENE, V18, P4295, DOI 10.1038/sj.onc.1202807; Thiagalingam S, 2001, P NATL ACAD SCI USA, V98, P2698, DOI 10.1073/pnas.051625398; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Virmani AK, 1998, GENE CHROMOSOME CANC, V21, P308, DOI 10.1002/(SICI)1098-2264(199804)21:4<308::AID-GCC4>3.0.CO;2-2; Weinberg RA, 2007, BIOL CANC, P209; YOKOTA J, 1987, P NATL ACAD SCI USA, V84, P9252, DOI 10.1073/pnas.84.24.9252; Yokota J, 2004, CANCER SCI, V95, P197, DOI 10.1111/j.1349-7006.2004.tb02203.x; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308; Zhu CM, 2002, CELL, V109, P811, DOI 10.1016/S0092-8674(02)00770-5; ZHU X, 1992, CYTOGENET CELL GENET, V59, P248, DOI 10.1159/000133261	43	25	26	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	AUG 14	2008	27	35					4788	4797		10.1038/onc.2008.113	http://dx.doi.org/10.1038/onc.2008.113			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18408757				2022-12-25	WOS:000258445100004
J	Perotti, D; Gamba, B; Sardella, M; Spreafico, F; Terenziani, M; Collini, P; Pession, A; Nantron, M; Fossati-Bellani, F; Radice, P				Perotti, D.; Gamba, B.; Sardella, M.; Spreafico, F.; Terenziani, M.; Collini, P.; Pession, A.; Nantron, M.; Fossati-Bellani, F.; Radice, P.		AIEOP Wilms Tumor Study Grp	Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors	ONCOGENE			English	Article						Wilms' tumor; WTX; mutation analysis; tumor suppressor; chromosome X	BETA-CATENIN; MUTATIONS; HETEROZYGOSITY; RELAXATION; CANCER; LOCUS; 16Q	For many years the precise genetic etiology of the majority of Wilms' tumors has remained unexplained. Recently, the WTX gene, mapped to chromosome Xq11.1, has been reported to be lost or mutated in approximately one-third of Wilms' tumors. Moreover, in female cases, the somatically inactivated alleles were found to invariantly derive from the active chromosome X. Consequently, WTX has been proposed as a 'one-hit' tumor suppressor gene. To provide further insights on the contribution of WTX to the development of the disease, we have examined 102 Wilms' tumors, obtained from 43 male and 57 female patients. Quantitative PCR analyses detected WTX deletions in 5 of 45 (11%) tumors from males, whereas loss of heterozygosity at WTX-linked microsatellites was observed in 9 tumors from 50 informative females (19%). However, in the latter group, using a combination of HUMARA assay and bisulfite-modified DNA sequencing, we found that the deletion affected the active chromosome X only in two cases (4%). Sequence analyses detected an inactivating somatic mutation of WTX in a single tumor, in which a strongly reduced expression of the mutant allele respect to the wildtype allele was observed, a finding not consistent with its localization on the active chromosome X. Overall, a functional somatic nullizygosity of the WTX gene was ascertained only in seven of the Wilms' tumors included in the study ( approximately 7%). Our findings indicate that previously reported estimates on the proportion of Wilms' tumors due to WTX alterations should be reconsidered.	[Spreafico, F.; Terenziani, M.; Fossati-Bellani, F.] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, I-20133 Milan, Italy; [Collini, P.] Fdn IRCCS Ist Nazl Tumori, Dept Anat Pathol, I-20133 Milan, Italy; [Pession, A.] Policlin St Orsola Malpighi, Dept Pediat Oncol & Hematol, Bologna, Italy; [Nantron, M.] Ist Giannina Gaslini, Dept Pediat Hematol & Oncol, Genoa, Italy; [Radice, P.] IFOM Fdn Ist FIRC Oncol Mol, Milan, Italy; [Perotti, D.; Gamba, B.; Sardella, M.; Radice, P.] Fdn IRCCS Ist Nazl Tumori, Genet Susceptibil Canc Unit, Dept Expt Oncol & Labs, I-20133 Milan, Italy	Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Genoa; IRCCS Istituto Giannina Gaslini; IFOM - FIRC Institute of Molecular Oncology; Fondazione IRCCS Istituto Nazionale Tumori Milan	Perotti, D (corresponding author), Fdn IRCCS Ist Nazl Tumori, Genet Susceptibil Canc Unit, Dept Expt Oncol & Labs, Via Venezian 1, I-20133 Milan, Italy.	daniela.perotti@istitutotumori.mi.it	Terenziani, Monica/B-9562-2017; Pession, Andrea/O-3200-2013; Perotti, Daniela/C-2013-2017; Collini, Paola/K-7354-2016; Spreafico, Filippo/K-7813-2016; Radice, Paolo/O-3119-2013	Terenziani, Monica/0000-0002-7080-6718; Pession, Andrea/0000-0002-0379-9562; Perotti, Daniela/0000-0002-6703-2889; Collini, Paola/0000-0002-6158-210X; Spreafico, Filippo/0000-0002-5587-3509; Radice, Paolo/0000-0001-6298-4111	Associazione Italiana per la Ricerca sul Cancro Funding Source: Custom	Associazione Italiana per la Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro)		ALLEN RC, 1992, AM J HUM GENET, V51, P1229; den Dunnen JT, 2000, HUM MUTAT, V15, P7; Fukuzawa R, 2007, J CLIN PATHOL, V60, P1013, DOI 10.1136/jcp.2006.043083; GRUNDY PE, 1994, CANCER RES, V54, P2331; Han M, 2007, GENE CHROMOSOME CANC, V46, P909, DOI 10.1002/gcc.20476; Hing S, 2001, AM J PATHOL, V158, P393, DOI 10.1016/S0002-9440(10)63982-X; Hoglund M, 2004, CANCER GENET CYTOGEN, V150, P9, DOI 10.1016/j.cancergencyto.2003.08.017; Huff V, 2007, CANCER CELL, V11, P105, DOI 10.1016/j.ccr.2007.01.011; Klamt B, 1998, GENE CHROMOSOME CANC, V22, P287, DOI 10.1002/(SICI)1098-2264(199808)22:4<287::AID-GCC4>3.0.CO;2-R; KNUDSON AG, 1972, J NATL CANCER I, V48, P313; Koesters R, 1999, CANCER RES, V59, P3880; Koesters R, 2003, J PATHOL, V199, P68, DOI 10.1002/path.1248; Li CM, 2004, AM J PATHOL, V165, P1943, DOI 10.1016/S0002-9440(10)63246-4; Little M, 1997, HUM MUTAT, V9, P209, DOI 10.1002/(SICI)1098-1004(1997)9:3<209::AID-HUMU2>3.0.CO;2-2; Little SE, 2004, J CLIN ONCOL, V22, P4140, DOI 10.1200/JCO.2004.02.136; Maiti S, 2000, CANCER RES, V60, P6288; Major MB, 2007, SCIENCE, V316, P1043, DOI 10.1126/science/1141515; MAW MA, 1992, CANCER RES, V52, P3094; Nusse R, 2007, SCIENCE, V316, P988, DOI 10.1126/science.1143337; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; Perotti D, 2005, J PEDIAT HEMATOL ONC, V27, P197, DOI 10.1097/01.mph.0000161270.22313.2f; Perotti D, 2004, HUM MUTAT, V24, P400, DOI 10.1002/humu.20096; Perotti D, 2005, J PEDIAT HEMATOL ONC, V27, P521, DOI 10.1097/01.mph.0000184309.22583.66; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RADICE P, 1995, GENOMICS, V27, P497, DOI 10.1006/geno.1995.1082; RAINIER S, 1993, NATURE, V362, P747, DOI 10.1038/362747a0; REEVE AE, 1989, MOL CELL BIOL, V9, P1799, DOI 10.1128/MCB.9.4.1799; Rivera MN, 2007, SCIENCE, V315, P642, DOI 10.1126/science.1137509; RUTESHOUSER EC, 2007, GENE CHROMOSOME CANC, V43, P172; Schumacher V, 1997, P NATL ACAD SCI USA, V94, P3972, DOI 10.1073/pnas.94.8.3972; Vernon EG, 2003, ONCOGENE, V22, P1371, DOI 10.1038/sj.onc.1206332	31	50	52	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 31	2008	27	33					4625	4632		10.1038/onc.2008.93	http://dx.doi.org/10.1038/onc.2008.93			8	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18391980				2022-12-25	WOS:000258077300011
J	van der Weyden, L; Arends, MJ; Dovey, OM; Harrison, HL; Lefebvre, G; Conte, N; Gergely, FV; Bradley, A; Adams, DJ				van der Weyden, L.; Arends, M. J.; Dovey, O. M.; Harrison, H. L.; Lefebvre, G.; Conte, N.; Gergely, F. V.; Bradley, A.; Adams, D. J.			Loss of Rassf1a cooperates with Apc(Min) to accelerate intestinal tumourigenesis	ONCOGENE			English	Article						adenoma; adenocarcinoma; RASSF; APC; beta-catenin	TUMOR-SUPPRESSOR RASSF1A; COLORECTAL-CANCER; CODING VARIATION; MOUSE; MUTATIONS; NEOPLASIA; COMPLEX; GENOME; MICE; HYPERMETHYLATION	Promoter methylation of the RAS-association domain family 1, isoform A gene (RASSF1A) is one of the most frequent events found in human tumours. In this study we set out to test the hypothesis that loss of Rassf1a can cooperate with inactivation of the adenomatous polyposis coli (Apc) gene to accelerate intestinal tumourigenesis using the Apc-Min (Apc(Min/+)) mouse model, as mutational or deletional inactivation of APC is a frequent early event in the genesis of intestinal cancer. Further, loss of RASSF1A has also been reported to occur in premalignant adenomas of the bowel. RASSF1A has been implicated in an array of pivotal cellular processes, including regulation of the cell cycle, apoptosis, microtubule stability and most recently in the beta-catenin signalling pathway. By interbreeding isoform specific Rassf1a knockout mice with Apc(+/Min) mice, we showed that loss of Rassf1a results in a significant increase in adenomas of the small intestine and accelerated intestinal tumourigenesis leading to the earlier death of adenocarcinoma-bearing mice and decreased overall survival. Comparative genomic hybridization of adenomas from Rassf1a(-/-); Apc(+/Min) mice revealed no evidence of aneuploidy or gross chromosomal instability (no difference to adenomas from Rassf1a(+/+); Apc(+/Min) mice). Immunohistochemical analysis of adenomas revealed increased nuclear beta-catenin accumulation in adenomas from Rassf1a(-/-); Apc(+/Min) mice, compared to those from Rassf1a(+/+); Apc(+/Min) mice, but no differences in proliferation marker (Ki67) staining patterns. Collectively these data demonstrate cooperation between inactivation of Rassf1a and Apc resulting in accelerated intestinal tumourigenesis, with adenomas showing increased nuclear accumulation of beta-catenin, supporting a mechanistic link via loss of the known interaction of Rassf1 with beta-TrCP that usually mediates degradation of beta-catenin.	[van der Weyden, L.; Dovey, O. M.; Harrison, H. L.; Lefebvre, G.; Conte, N.; Bradley, A.; Adams, D. J.] Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; [Arends, M. J.] Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Cambridge CB2 2QQ, England; [Gergely, F. V.] Cambridge Res Inst, Dept Oncol, Li Ka Shing Ctr, Cambridge, England	Wellcome Trust Sanger Institute; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; CRUK Cambridge Institute; University of Cambridge	van der Weyden, L (corresponding author), Wellcome Trust Sanger Inst, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.	lvdw@sanger.ac.uk	van der Weyden, Louise/AAV-5711-2021	van der Weyden, Louise/0000-0002-0645-1879; Harrison, Hannah/0000-0002-0054-8047; Conte, Nathalie/0000-0002-1010-3121; Adams, David/0000-0001-9490-0306; Bradley, Allan/0000-0002-2349-8839; Gergely, Fanni/0000-0002-2441-8095	Cancer Research UK [A8449] Funding Source: Medline; Wellcome Trust [079643] Funding Source: Medline	Cancer Research UK(Cancer Research UK); Wellcome Trust(Wellcome TrustEuropean Commission)		Adams DJ, 2005, NAT GENET, V37, P532, DOI 10.1038/ng1551; Alberici P, 2007, AM J PATHOL, V170, P377, DOI 10.2353/ajpath.2007.060853; Carothers AM, 2001, J BIOL CHEM, V276, P39094, DOI 10.1074/jbc.M103450200; Chung YJ, 2004, GENOME RES, V14, P188, DOI 10.1101/gr.1878804; Cunningham F, 2006, NAT GENET, V38, P853, DOI 10.1038/ng0806-853a; Estrabaud E, 2007, CANCER RES, V67, P1054, DOI 10.1158/0008-5472.CAN-06-2530; GERDES J, 1984, J IMMUNOL, V133, P1710; Graubert TA, 2007, PLOS GENET, V3, DOI 10.1371/journal.pgen.0030003; Guo C, 2007, CURR BIOL, V17, P700, DOI 10.1016/j.cub.2007.02.055; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; Lee S, 2004, LAB INVEST, V84, P884, DOI 10.1038/labinvest.3700108; LUONGO C, 1994, CANCER RES, V54, P5947; MOSER AR, 1990, SCIENCE, V247, P322, DOI 10.1126/science.2296722; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; Oliveira C, 2005, ONCOGENE, V24, P7630, DOI 10.1038/sj.onc.1208906; Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; Taketo MM, 2004, NAT GENET, V36, P320, DOI 10.1038/ng0404-320; Tommasi S, 2005, CANCER RES, V65, P92; van Amerongen R, 2006, TRENDS GENET, V22, P678, DOI 10.1016/j.tig.2006.10.001; van der Weyden L, 2005, MOL CELL BIOL, V25, P8356, DOI 10.1128/MCB.25.18.8356-8367.2005; van der Weyden L, 2007, BBA-REV CANCER, V1776, P58, DOI 10.1016/j.bbcan.2007.06.003; van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466	25	22	22	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4503	4508		10.1038/onc.2008.94	http://dx.doi.org/10.1038/onc.2008.94			6	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18391979	Green Accepted			2022-12-25	WOS:000257881700013
J	Ono, N; Nakashima, K; Rittling, SR; Schipani, E; Hayata, T; Soma, K; Denhardt, DT; Kronenberg, HM; Ezura, Y; Noda, M				Ono, Noriaki; Nakashima, Kazuhisa; Rittling, Susan R.; Schipani, Ernestina; Hayata, Tadayoshi; Soma, Kunimichi; Denhardt, David T.; Kronenberg, Henry M.; Ezura, Yoichi; Noda, Masaki			Osteopontin negatively regulates parathyroid hormone receptor signaling in osteoblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYMPATHETIC-NERVOUS-SYSTEM; BONE-MINERAL DENSITY; STEM-CELL NICHE; COMPONENT; OSTEOPOROSIS; TERIPARATIDE; ENHANCEMENT; COMBINATION; SUPPRESSION; ACTIVATION	Systemic hormonal control exerts its effect through the regulation of local target tissues, which in turn regulate upstream signals in a feedback loop. The parathyroid hormone (PTH) axis is a well defined hormonal signaling system that regulates calcium levels and bone metabolism. To understand the interplay between systemic and local signaling in bone, we examined the effects of deficiency of the bone matrix protein osteopontin (OPN) on the systemic effects of PTH specifically within osteoblastic cell lineages. Parathyroid hormone receptor (PPR) transgenic mice expressing a constitutively active form of the receptor (caPPR) specifically in cells of the osteoblast lineage have a high bone mass phenotype. In these mice, OPN deficiency further increased bone mass. This increase was associated with conversion of the major intertrabecular cell population from hematopoietic cells to stromal/osteoblastic cells and parallel elevations in histomorphometric and biochemical parameters of bone formation and resorption. Treatment with small interfering RNA (siRNA) for osteopontin enhanced H223R mutant caPPR-induced cAMP-response element (CRE) activity levels by about 10-fold. Thus, in addition to the well known calcemic feedback system for PTH, local feedback regulation by the bone matrix protein OPN also plays a significant role in the regulation of PTH actions.	[Ono, Noriaki; Nakashima, Kazuhisa; Noda, Masaki] 21st Century Ctr Excellence Program Frontier Res, Chiyoda Ku, Tokyo 1010062, Japan; [Ono, Noriaki; Nakashima, Kazuhisa; Hayata, Tadayoshi; Ezura, Yoichi; Noda, Masaki] Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pharmacol, Chiyoda Ku, Tokyo 1010062, Japan; [Ono, Noriaki; Soma, Kunimichi] Tokyo Med & Dent Univ, Grad Sch, Bunkyo Ku, Tokyo 1138510, Japan; [Rittling, Susan R.] Forsyth Inst, Boston, MA 02115 USA; [Schipani, Ernestina; Kronenberg, Henry M.] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA; [Schipani, Ernestina; Kronenberg, Henry M.] Harvard Univ, Sch Med, Boston, MA 02114 USA; [Denhardt, David T.] Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08701 USA; [Noda, Masaki] Tokyo Med & Dent Univ, Adv Bone & Joint Sci ABJS Integrated Act Initiat, Tokyo 1010062, Japan; [Noda, Masaki] Tokyo Med & Dent Univ, Hard Tissue Genome Res Ctr, Tokyo 1010062, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU); Harvard University; Forsyth Institute; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Rutgers State University New Brunswick; Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Noda, M (corresponding author), Tokyo Med & Dent Univ, Med Res Inst, Dept Mol Pharmacol, Chiyoda Ku, 2-3-10 Kanda Surugadai, Tokyo 1010062, Japan.	noda.mph@mri.tmd.ac.jp	Ezura, Yoichi/L-9485-2016; Hayata, Tadayoshi/AAE-9712-2021	Nakashima, Kazuhisa/0000-0003-0491-2149	NIDCR NIH HHS [K99 DE022564] Funding Source: Medline; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [K99DE022564] Funding Source: NIH RePORTER	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Adams GB, 2007, NAT BIOTECHNOL, V25, P238, DOI 10.1038/nbt1281; Ashkar S, 2000, SCIENCE, V287, P860, DOI 10.1126/science.287.5454.860; AVIOLI LV, 1984, NEW ENGL J MED, V311, P47, DOI 10.1056/NEJM198407053110109; BELL NH, 1985, J CLIN INVEST, V76, P1, DOI 10.1172/JCI111930; Black DM, 2003, NEW ENGL J MED, V349, P1207, DOI 10.1056/NEJMoa031975; Calvi LM, 2001, J CLIN INVEST, V107, P277, DOI 10.1172/JCI11296; Calvi LM, 2003, NATURE, V425, P841, DOI 10.1038/nature02040; Cinamon U, 2006, BONE, V39, P420, DOI 10.1016/j.bone.2006.01.146; DELUCA HF, 1973, NEW ENGL J MED, V289, P359, DOI 10.1056/NEJM197308162890710; DEMPSTER DW, 1993, ENDOCR REV, V14, P690, DOI 10.1210/er.14.6.690; Denhardt DT, 1998, J CELL BIOCHEM, P92, DOI 10.1002/(SICI)1097-4644(1998)72:30/31+<92::AID-JCB13>3.0.CO;2-A; Denhardt DT, 2001, J CLIN INVEST, V107, P1055, DOI 10.1172/JCI12980; Elefteriou F, 2005, NATURE, V434, P514, DOI 10.1038/nature03398; Hodsman AB, 2005, ENDOCR REV, V26, P688, DOI 10.1210/er.2004-0006; Huang WB, 2004, BONE, V34, P799, DOI 10.1016/j.bone.2003.11.027; Ishijima M, 2001, J EXP MED, V193, P399, DOI 10.1084/jem.193.3.399; Jiang YB, 2003, J BONE MINER RES, V18, P1932, DOI 10.1359/jbmr.2003.18.11.1932; Katagiri YU, 1999, CANCER RES, V59, P219; Katayama Y, 2006, CELL, V124, P407, DOI 10.1016/j.cell.2005.10.041; Kitahara K, 2003, ENDOCRINOLOGY, V144, P2132, DOI 10.1210/en.2002-220996; Kondo H, 2005, J BIOL CHEM, V280, P30192, DOI 10.1074/jbc.M504179200; Kuznetsov SA, 2004, J CELL BIOL, V167, P1113, DOI 10.1083/jcb.200408079; Lin YH, 2001, J BIOL CHEM, V276, P46024, DOI 10.1074/jbc.M105132200; Marroquin CE, 2004, IMMUNOL LETT, V95, P109, DOI 10.1016/j.imlet.2004.06.001; Marx SJ, 2000, NEW ENGL J MED, V343, P1863, DOI 10.1056/NEJM200012213432508; Neer RM, 2001, NEW ENGL J MED, V344, P1434, DOI 10.1056/NEJM200105103441904; Nilsson SK, 2005, BLOOD, V106, P1232, DOI 10.1182/blood-2004-11-4422; Rittling SR, 1998, J BONE MINER RES, V13, P1101, DOI 10.1359/jbmr.1998.13.7.1101; Rosen CJ, 2001, J CLIN ENDOCR METAB, V86, P957, DOI 10.1210/jc.86.3.957; Rosen CJ, 2004, TRENDS ENDOCRIN MET, V15, P229, DOI 10.1016/j.tem.2004.05.005; ROSENBLATT M, 1986, NEW ENGL J MED, V315, P1004; Schipani E, 1996, NEW ENGL J MED, V335, P708, DOI 10.1056/NEJM199609053351004; Schluter KD, 1998, CARDIOVASC RES, V37, P34, DOI 10.1016/S0008-6363(97)00194-6; Stier S, 2005, J EXP MED, V201, P1781, DOI 10.1084/jem.20041992; Vestergaard P, 2007, OSTEOPOROSIS INT, V18, P45, DOI 10.1007/s00198-006-0204-0; Yoshitake H, 1999, P NATL ACAD SCI USA, V96, P8156, DOI 10.1073/pnas.96.14.8156; Zohar R, 2000, J CELL PHYSIOL, V184, P118, DOI 10.1002/(SICI)1097-4652(200007)184:1<118::AID-JCP13>3.3.CO;2-P	37	26	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19400	19409		10.1074/jbc.M800005200	http://dx.doi.org/10.1074/jbc.M800005200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18417476	Green Published, hybrid			2022-12-25	WOS:000257387600026
J	Richter, K; Soroka, J; Skalniak, L; Leskovar, A; Hessling, M; Reinstein, J; Buchner, J				Richter, Klaus; Soroka, Joanna; Skalniak, Lukasz; Leskovar, Adriane; Hessling, Martin; Reinstein, Jochen; Buchner, Johannes			Conserved conformational changes in the ATPase cycle of human Hsp90	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI HSP90; HEAT-SHOCK-PROTEIN; N-TERMINAL DOMAIN; IN-VIVO; CHAPERONE; BINDING; DIMERIZATION; HYDROLYSIS; ACTIVATION; NUCLEOTIDE	The dimeric molecular chaperone Hsp90 is required for the activation and stabilization of hundreds of substrate proteins, many of which participate in signal transduction pathways. The activation process depends on the hydrolysis of ATP by Hsp90. Hsp90 consists of a C-terminal dimerization domain, a middle domain, which may interact with substrate protein, and an N-terminal ATP-binding domain. A complex cycle of conformational changes has been proposed for the ATPase cycle of yeast Hsp90, where a critical step during the reaction requires the transient N-terminal dimerization of the two protomers. The ATPase cycle of human Hsp90 is less well understood, and significant differences have been proposed regarding key mechanistic aspects. ATP hydrolysis by human Hsp90 alpha and Hsp90 beta is 10-fold slower than that of yeast Hsp90. Despite these differences, our experiments suggest that the underlying enzymatic mechanisms are highly similar. In both cases, a concerted conformational rearrangement involving the N-terminal domains of both subunits is controlling the rate of ATP turnover, and N-terminal cross-talk determines the rate-limiting steps. Furthermore, similar to yeast Hsp90, the slow ATP hydrolysis by human Hsp90s can be stimulated up to over 100-fold by the addition of the co-chaperone Aha1 from either human or yeast origin. Together, our results show that the basic principles of the Hsp90 ATPase reaction are conserved between yeast and humans, including the dimerization of the N-terminal domains and its regulation by the repositioning of the ATP lid from its original position to a catalytically competent one.	[Richter, Klaus; Soroka, Joanna; Skalniak, Lukasz; Hessling, Martin; Buchner, Johannes] Tech Univ Munich, Ctr Integrated Prot Sci, D-85747 Garching, Germany; [Richter, Klaus; Soroka, Joanna; Skalniak, Lukasz; Hessling, Martin; Buchner, Johannes] Tech Univ Munich, Dept Chem, D-85747 Garching, Germany; [Leskovar, Adriane; Reinstein, Jochen] Max Planck Inst Med Res, Dept Biomol Mech, D-69120 Heidelberg, Germany	Technical University of Munich; Technical University of Munich; Max Planck Society	Buchner, J (corresponding author), Tech Univ Munich, Ctr Integrated Prot Sci, Lichtenbergstr 4, D-85747 Garching, Germany.	johannes.buchner@ch.tum.de	Buchner, Johannes/A-2651-2010; Richter, Klaus/A-2673-2010; Skalniak, Lukasz/C-6113-2013	Richter, Klaus/0000-0002-8952-9642; Skalniak, Lukasz/0000-0002-6707-6697; Buchner, Johannes/0000-0003-1282-7737				ALI JA, 1993, BIOCHEMISTRY-US, V32, P2717, DOI 10.1021/bi00061a033; Ali MMU, 2006, NATURE, V440, P1013, DOI 10.1038/nature04716; Chadli A, 2000, P NATL ACAD SCI USA, V97, P12524, DOI 10.1073/pnas.220430297; Chadli A, 2006, MOL CELL BIOL, V26, P1722, DOI 10.1128/MCB.26.5.1722-1730.2006; Dollins DE, 2007, MOL CELL, V28, P41, DOI 10.1016/j.molcel.2007.08.024; Frey S, 2007, J BIOL CHEM, V282, P35612, DOI 10.1074/jbc.M704647200; Hu XJ, 2003, FEBS LETT, V544, P268, DOI 10.1016/S0014-5793(03)00519-2; Huai Q, 2005, STRUCTURE, V13, P579, DOI 10.1016/j.str.2004.12.018; Immormino RM, 2004, J BIOL CHEM, V279, P46162, DOI 10.1074/jbc.M405253200; Jakob U, 1996, J BIOL CHEM, V271, P10035, DOI 10.1074/jbc.271.17.10035; Leskovar A, 2008, J BIOL CHEM, V283, P11677, DOI 10.1074/jbc.M709516200; McClellan AJ, 2007, CELL, V131, P121, DOI 10.1016/j.cell.2007.07.036; McLaughlin SH, 2004, J MOL BIOL, V344, P813, DOI 10.1016/j.jmb.2004.09.055; McLaughlin SH, 2002, J MOL BIOL, V315, P787, DOI 10.1006/jmbi.2001.5245; Meyer P, 2004, EMBO J, V23, P1402, DOI 10.1038/sj.emboj.7600141; Millson SH, 2007, FEBS J, V274, P4453, DOI 10.1111/j.1742-4658.2007.05974.x; MINAMI Y, 1991, J BIOL CHEM, V266, P10099; MINAMI Y, 1994, MOL CELL BIOL, V14, P1459, DOI 10.1128/MCB.14.2.1459; Obermann WMJ, 1998, J CELL BIOL, V143, P901, DOI 10.1083/jcb.143.4.901; Panaretou B, 1998, EMBO J, V17, P4829, DOI 10.1093/emboj/17.16.4829; Panaretou B, 2002, MOL CELL, V10, P1307, DOI 10.1016/S1097-2765(02)00785-2; Picard D, 2006, TRENDS ENDOCRIN MET, V17, P229, DOI 10.1016/j.tem.2006.06.003; Pratt WB, 2003, EXP BIOL MED, V228, P111, DOI 10.1177/153537020322800201; Prodromou C, 2000, EMBO J, V19, P4383, DOI 10.1093/emboj/19.16.4383; Prodromou C, 1999, EMBO J, V18, P754, DOI 10.1093/emboj/18.3.754; Richter K, 2006, J BIOL CHEM, V281, P11301, DOI 10.1074/jbc.M510142200; Richter K, 2004, J MOL BIOL, V342, P1403, DOI 10.1016/j.jmb.2004.07.064; Richter K, 2003, J BIOL CHEM, V278, P10328, DOI 10.1074/jbc.M213094200; Richter K, 2002, J BIOL CHEM, V277, P44905, DOI 10.1074/jbc.M208457200; Richter K, 2001, J BIOL CHEM, V276, P33689, DOI 10.1074/jbc.M103832200; RICHTER K, 2005, PROTEIN FOLDING HDB, P768; Shiau AK, 2006, CELL, V127, P329, DOI 10.1016/j.cell.2006.09.027; SMITH DF, 1992, J BIOL CHEM, V267, P1350; Sreedhar AS, 2004, FEBS LETT, V562, P11; Wegele H, 2003, J BIOL CHEM, V278, P39303, DOI 10.1074/jbc.M305751200; Wegele H, 2003, J BIOL CHEM, V278, P25970, DOI 10.1074/jbc.M301548200; Weikl T, 2000, J MOL BIOL, V303, P583, DOI 10.1006/jmbi.2000.4157; Weikl T, 1999, J MOL BIOL, V293, P685, DOI 10.1006/jmbi.1999.3172; WELCH WJ, 1985, ANN NY ACAD SCI, V455, P57, DOI 10.1111/j.1749-6632.1985.tb50403.x; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492	40	103	108	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17757	17765		10.1074/jbc.M800540200	http://dx.doi.org/10.1074/jbc.M800540200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18400751	hybrid			2022-12-25	WOS:000256949200003
J	Gissot, M; Ting, LM; Daly, TM; Bergman, LW; Sinnis, P; Kim, K				Gissot, Mathieu; Ting, Li-Min; Daly, Thomas M.; Bergman, Lawrence W.; Sinnis, Photini; Kim, Kami			High mobility group protein HMGB2 is a critical regulator of Plasmodium oocyst development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FALCIPARUM LIFE-CYCLE; MALARIA PARASITE; TRANSCRIPTION FACTORS; MOSQUITO TRANSMISSION; SEXUAL DEVELOPMENT; SURFACE PROTEIN; TRANSFORMATION; EXPRESSION; OOKINETE; BERGHEI	The sexual cycle of Plasmodium is required for transmission of malaria from mosquitoes to mammals, but how parasites induce the expression of genes required for the sexual stages is not known. We disrupted the Plasmodium yoelii gene encoding high mobility group nuclear factor hmgb2, which encodes a DNA-binding protein potentially implicated in transcriptional regulation of malaria gene expression. We investigated its function in vivo in the vertebrate and invertebrate hosts. Delta pyhmgb2 parasites develop into gametocytes but have drastic impairment of oocyst formation. A global transcriptome analysis of the Delta pyhmgb2 parasites identified similar to 30 genes whose expression is down-regulated in the similar to Delta pyhmgb2 parasites. These genes are conserved in all malaria species, and more than 90% of these genes show a peak of mRNA expression at the gametocyte stage. Surprisingly, the transcripts coding for the Plasmodium berghei orthologues of those genes are stored and translated in the ookinete stage. Therefore, sexual stage protein expression appears to be both transcriptionally and translationally regulated with Plasmodium HMGB2 acting as an important regulator of malaria sexual stage gene expression.	[Gissot, Mathieu; Ting, Li-Min; Kim, Kami] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA; [Gissot, Mathieu; Ting, Li-Min; Kim, Kami] Albert Einstein Coll Med, Dept Microbiol & Immunol, Bronx, NY 10461 USA; [Daly, Thomas M.; Bergman, Lawrence W.] Drexel Univ, Coll Med, Dept Microbiol & Immunol, Philadelphia, PA 19129 USA; [Sinnis, Photini] NYU, Sch Med, Dept Med Parasitol, New York, NY 10010 USA	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Drexel University; New York University	Kim, K (corresponding author), Albert Einstein Coll Med, Dept Med, Ullmann 1225,1300 Morris Pk Ave, Bronx, NY 10461 USA.	kkim@aecom.yu.edu	Gissot, Mathieu/AFN-3127-2022	Gissot, Mathieu/0000-0003-0047-8189; Kim, Kami/0000-0003-3384-152X	NIAID NIH HHS [R01 AI056840] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI056840] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Agresti A, 2003, CURR OPIN GENET DEV, V13, P170, DOI 10.1016/S0959-437X(03)00023-6; Alano P, 2007, MOL MICROBIOL, V66, P291, DOI 10.1111/j.1365-2958.2007.05904.x; Arai M, 2001, MOL BIOCHEM PARASIT, V116, P17, DOI 10.1016/S0166-6851(01)00299-7; Aravind L, 2003, CELL, V115, P771, DOI 10.1016/S0092-8674(03)01023-7; Balaji S, 2005, NUCLEIC ACIDS RES, V33, P3994, DOI 10.1093/nar/gki709; Billker O, 2004, CELL, V117, P503, DOI 10.1016/S0092-8674(04)00449-0; Briquet S, 2006, EUKARYOT CELL, V5, P672, DOI 10.1128/EC.5.4.672-682.2006; Callebaut I, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-100; Carter V, 2007, INT J PARASITOL, V37, P1221, DOI 10.1016/j.ijpara.2007.03.005; Dechering KJ, 1999, MOL CELL BIOL, V19, P967; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Gissot M, 2005, J MOL BIOL, V346, P29, DOI 10.1016/j.jmb.2004.11.045; Gissot M, 2007, PLOS PATHOG, V3, P709, DOI 10.1371/journal.ppat.0030077; Gutterson N, 2004, CURR OPIN PLANT BIOL, V7, P465, DOI 10.1016/j.pbi.2004.04.007; Hall N, 2005, SCIENCE, V307, P82, DOI 10.1126/science.1103717; Jongco AM, 2006, MOL BIOCHEM PARASIT, V146, P242, DOI 10.1016/j.molbiopara.2006.01.001; Khan SM, 2005, CELL, V121, P675, DOI 10.1016/j.cell.2005.03.027; KUMAR N, 1985, MOL BIOCHEM PARASIT, V14, P127, DOI 10.1016/0166-6851(85)90032-5; LaCount DJ, 2005, NATURE, V438, P103, DOI 10.1038/nature04104; Le Roch KG, 2004, GENOME RES, V14, P2308, DOI 10.1101/gr.2523904; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Mair GR, 2006, SCIENCE, V313, P667, DOI 10.1126/science.1125129; Mota MM, 2001, MOL BIOCHEM PARASIT, V113, P271, DOI 10.1016/S0166-6851(01)00228-6; PATON MG, 1993, MOL BIOCHEM PARASIT, V59, P263, DOI 10.1016/0166-6851(93)90224-L; Pradel G, 2004, J EXP MED, V199, P1533, DOI 10.1084/jem.20031274; Raine JD, 2007, PLOS PATHOG, V3, DOI 10.1371/journal.ppat.0030030; Shi QF, 2005, INFECT IMMUN, V73, P6363, DOI 10.1128/IAI.73.10.6363-6371.2005; Siden-Kiamos I, 2000, J CELL SCI, V113, P3419; Smyth G.K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027; Smyth GK, 2005, STAT BIOL HEALTH, P397, DOI 10.1007/0-387-29362-0_23; Tarun AS, 2008, P NATL ACAD SCI USA, V105, P305, DOI 10.1073/pnas.0710780104; Templeton TJ, 2004, GENOME RES, V14, P1686, DOI 10.1101/gr.2615304; Tomas AM, 2001, EMBO J, V20, P3975, DOI 10.1093/emboj/20.15.3975; Tsuboi T, 1997, INFECT IMMUN, V65, P2260, DOI 10.1128/IAI.65.6.2260-2264.1997; Voss TS, 2003, MOL MICROBIOL, V48, P1593, DOI 10.1046/j.1365-2958.2003.03528.x; Young JA, 2005, MOL BIOCHEM PARASIT, V143, P67, DOI 10.1016/j.molbiopara.2005.05.007	36	26	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17030	17038		10.1074/jbc.M801637200	http://dx.doi.org/10.1074/jbc.M801637200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18400754	Green Published, hybrid			2022-12-25	WOS:000256720600009
J	Fountain, SJ; Cao, LS; Young, MT; North, RA				Fountain, Samuel J.; Cao, Lishuang; Young, Mark T.; North, R. Alan			Permeation properties of a P2X receptor in the green algae Ostreococcus tauri	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL-CHARACTERIZATION; EXTRACELLULAR ATP; PERMEABILITY; CHANNELS; PHARMACOLOGY; FAMILY; CELLS	We have cloned a P2X receptor (OtP2X) from the green algae Ostreococcus tauri. The 42-kDa receptor shares similar to 28% identity with human P2X receptors and 23% with the Dictyostelium P2X receptor. ATP application evoked flickery single channel openings in outside-out membrane patches from human embryonic kidney 293 cells expressing OtP2X. Whole-cell recordings showed concentration-dependent cation currents reversing close to zero mV; ATP gave a half-maximal current at 250 mu m. alpha beta-Methylene-ATP evoked only small currents in comparison to ATP (EC50 > 5 mM). 2',3'-O-(4-Benzoylbenzoyl)-ATP, beta gamma-imido-ATP, ADP, and several other nucleotide triphosphates did not activate any current. The currents evoked by 300 mu m ATP were not inhibited by 100 mu m suramin, pyridoxal-phosphate-6-azophenyl-2',4'-disulfonic acid, 2',3'-O-(2,4,6-trinitrophenol)-ATP, or copper. Ion substitution experiments indicated permeabilities relative to sodium with the rank order calcium > choline > Tris > tetraethylammonium > N-methyl-D-glucosamine. However, OtP2X had a low relative calcium permeability (P-Ca/P-Na = 0.4) in comparison with other P2X receptors. This was due at least in part to the presence of an asparagine residue (Asn(353)) at a position in the second transmembrane domain in place of the aspartate that is completely conserved in all other P2X receptor subunits, because replacement of Asn(353) with aspartate increased calcium permeability by similar to 50%. The results indicate that the ability of ATP to gate cation permeation across membranes exists in cells that diverged in evolutionary terms from animals about I billion years ago.	[Fountain, Samuel J.; Cao, Lishuang; Young, Mark T.; North, R. Alan] Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	North, RA (corresponding author), Univ Manchester, Fac Life Sci, Oxford Rd, Manchester M13 9PT, Lancs, England.	alan.north@manchester.ac.uk	Fountain, Samuel J/C-2142-2011; Young, Mark T/E-8928-2010; North, Richard/GQA-6156-2022	Young, Mark T/0000-0002-9615-9002; 	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Agboh KC, 2004, J BIOL CHEM, V279, P41650, DOI 10.1074/jbc.M408203200; Bocquet N, 2007, NATURE, V445, P116, DOI 10.1038/nature05371; Chaumont S, 2004, J BIOL CHEM, V279, P29628, DOI 10.1074/jbc.M403940200; Chen GQ, 1999, NATURE, V402, P817, DOI 10.1038/45568; Derelle E, 2006, P NATL ACAD SCI USA, V103, P11647, DOI 10.1073/pnas.0604795103; Egan TM, 2006, PFLUG ARCH EUR J PHY, V452, P501, DOI 10.1007/s00424-006-0078-1; Evans RJ, 1996, J PHYSIOL-LONDON, V497, P413, DOI 10.1113/jphysiol.1996.sp021777; Fountain SJ, 2007, NATURE, V448, P200, DOI 10.1038/nature05926; Gever JR, 2006, PFLUG ARCH EUR J PHY, V452, P513, DOI 10.1007/s00424-006-0070-9; Khakh BS, 2006, NATURE, V442, P527, DOI 10.1038/nature04886; Kim SY, 2006, PLANT PHYSIOL, V142, P984, DOI 10.1104/pp.106.085670; Migita K, 2001, J BIOL CHEM, V276, P30934, DOI 10.1074/jbc.M103366200; North RA, 2000, ANNU REV PHARMACOL, V40, P563, DOI 10.1146/annurev.pharmtox.40.1.563; North RA, 2002, PHYSIOL REV, V82, P1013, DOI 10.1152/physrev.00015.2002; Palenik B, 2007, P NATL ACAD SCI USA, V104, P7705, DOI 10.1073/pnas.0611046104; Samways DSK, 2007, J GEN PHYSIOL, V129, P245, DOI 10.1085/jgp.200609677; Silberberg SD, 2005, J GEN PHYSIOL, V125, P347, DOI 10.1085/jgp.200409221; Surprenant A, 1996, SCIENCE, V272, P735, DOI 10.1126/science.272.5262.735; Virginio C, 1999, J PHYSIOL-LONDON, V519, P335, DOI 10.1111/j.1469-7793.1999.0335m.x; Virginio C, 1998, J PHYSIOL-LONDON, V510, P27, DOI 10.1111/j.1469-7793.1998.027bz.x	20	57	57	1	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15122	15126		10.1074/jbc.M801512200	http://dx.doi.org/10.1074/jbc.M801512200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18381285	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000256232000027
J	Shin, DJ; Osborne, TF				Shin, Dong-Ju; Osborne, Timothy F.			Peroxisome proliferator-activated receptor-gamma coactivator-1 alpha activation of CYP7A1 during food restriction and diabetes is still inhibited by small heterodimer partner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BILE-ACID BIOSYNTHESIS; ORPHAN NUCLEAR RECEPTOR; CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; 7 ALPHA-HYDROXYLASE; ELEMENT-BINDING PROTEIN; X-RECEPTOR; FEEDBACK-REGULATION; HEPATIC GLUCONEOGENESIS; RAT HEPATOCYTES; DOWN-REGULATION	Cholesterol 7 alpha-hydroxylase (CYP7A1) catalyzes the rate-limiting step in the classic pathway of hepatic bile acid biosynthesis from cholesterol. During fasting and in type I diabetes, elevated levels of peroxisome proliferator-activated receptor gamma-coactivator-1 alpha (PGC-1 alpha) induce expression of the Cyp7A1 gene and overexpression of PGC-1a in hepatoma cells stimulates bile acid synthesis. Using Ad-PGC-1 alpha-RNA interference to induce acute disruption of PGC-1 alpha in mice, here we show that PGC-1a is necessary for fasting-mediated induction of CYP7A1. Co-immunoprecipitation and promoter activation studies reveal that the induction of CYP7A1 is mediated by direct interaction between PGC-1a and the AF2 domain of liver receptor homolog-1 (LRH-1). In contrast, the very similar PGC-1 beta could not substitute for PGC-1a. We also show that transactivation of PGC-1 alpha and LRH-1 is repressed by the small heterodimer partner (SHP). Treatment of mice with GW4064, a synthetic agonist for farnesoid X receptor, induced SHP expression and decreased both the recruitment of PGC-1a to the Cyp7A1 promoter and the fasting-induced expression of CYP7A1 mRNA. These data suggest that PGC-1 alpha is an important co-activator for LRH-1 and that SHP targets the interaction between LRH-1 and PGC-1 alpha to inhibit CYP7A1 expression. Overall, these studies provide further evidence for the important role of PGC-1 alpha in bile acid homeostasis and suggest that pharmacological targeting of farnesoid X receptor in vivo can be used to reverse the increase in CYP7A1 associated with adverse metabolic conditions.	[Shin, Dong-Ju; Osborne, Timothy F.] Univ Calif Irvine, Dept Mol Biol & Biochem, Sch Biol Sci, Ctr Diabet Res & Treatment, Irvine, CA 92697 USA	University of California System; University of California Irvine	Osborne, TF (corresponding author), Univ Calif Irvine, Dept Mol Biol & Biochem, Sch Biol Sci, Ctr Diabet Res & Treatment, 3244 McGaugh Hall, Irvine, CA 92697 USA.	tfosborn@uci.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK071021] Funding Source: NIH RePORTER; NIAAA NIH HHS [R01 AA026322] Funding Source: Medline; NIDDK NIH HHS [DK 71021] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Boulias K, 2005, EMBO J, V24, P2624, DOI 10.1038/sj.emboj.7600728; Chiang JYL, 2002, ENDOCR REV, V23, P443, DOI 10.1210/er.2000-0035; Cooper AD, 1997, J BIOL CHEM, V272, P3444, DOI 10.1074/jbc.272.6.3444; Datta S, 2006, J BIOL CHEM, V281, P807, DOI 10.1074/jbc.M511050200; De Fabiani E, 2003, J BIOL CHEM, V278, P39124, DOI 10.1074/jbc.M305079200; De Fabiani E, 2001, J BIOL CHEM, V276, P30708, DOI 10.1074/jbc.M103270200; Dooley KA, 1999, J BIOL CHEM, V274, P5285, DOI 10.1074/jbc.274.9.5285; Fang SS, 2007, MOL CELL BIOL, V27, P1407, DOI 10.1128/MCB.00944-06; Glass CK, 2000, GENE DEV, V14, P121; Goodwin B, 2000, MOL CELL, V6, P517, DOI 10.1016/S1097-2765(00)00051-4; Gupta S, 2001, J BIOL CHEM, V276, P15816, DOI 10.1074/jbc.M010878200; Han SL, 2004, HEPATOLOGY, V39, P456, DOI 10.1002/hep.20043; Holt JA, 2003, GENE DEV, V17, P1581, DOI 10.1101/gad.1083503; Inagaki T, 2005, CELL METAB, V2, P217, DOI 10.1016/j.cmet.2005.09.001; Inoue Y, 2006, J LIPID RES, V47, P215, DOI 10.1194/jlr.M500430-JLR200; JELINEK DF, 1990, J BIOL CHEM, V265, P8190; Kobayashi M, 2007, DIABETES, V56, P239, DOI 10.2337/db06-0353; Lee YK, 2000, MOL CELL BIOL, V20, P187, DOI 10.1128/MCB.20.1.187-195.2000; Li TG, 2006, DRUG METAB DISPOS, V34, P756, DOI 10.1124/dmd.105.007575; Li Y, 2005, P NATL ACAD SCI USA, V102, P9505, DOI 10.1073/pnas.0501204102; LI YC, 1990, J BIOL CHEM, V265, P12012; Li-Hawkins J, 2002, J CLIN INVEST, V110, P1191, DOI 10.1172/JCI200216309; Lin JD, 2005, CELL METAB, V1, P361, DOI 10.1016/j.cmet.2005.05.004; Lu TT, 2000, MOL CELL, V6, P507, DOI 10.1016/S1097-2765(00)00050-2; Ma K, 2006, J CLIN INVEST, V116, P1102, DOI 10.1172/JCI25604; Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362; Mataki C, 2007, MOL CELL BIOL, V27, P8330, DOI 10.1128/MCB.00852-07; NESS GC, 1994, BBA-LIPID LIPID MET, V1214, P229, DOI 10.1016/0005-2760(94)90068-X; Nitta M, 1999, P NATL ACAD SCI USA, V96, P6660, DOI 10.1073/pnas.96.12.6660; Puigserver P, 1998, CELL, V92, P829, DOI 10.1016/S0092-8674(00)81410-5; Puigserver P, 2003, NATURE, V423, P550, DOI 10.1038/nature01667; Qiao DH, 2000, J BIOL CHEM, V275, P15090, DOI 10.1074/jbc.M908890199; Russell DW, 2003, ANNU REV BIOCHEM, V72, P137, DOI 10.1146/annurev.biochem.72.121801.161712; Safi R, 2005, CANCER RES, V65, P11762, DOI 10.1158/0008-5472.CAN-05-2792; SANCHEZ HB, 1995, J BIOL CHEM, V270, P1161, DOI 10.1074/jbc.270.3.1161; Seol W, 1996, SCIENCE, V272, P1336, DOI 10.1126/science.272.5266.1336; Shin DJ, 2003, J BIOL CHEM, V278, P50047, DOI 10.1074/jbc.M309736200; Shin DJ, 2006, NUCLEIC ACIDS RES, V34, P3853, DOI 10.1093/nar/gkl506; Stravitz RT, 1996, AM J PHYSIOL-GASTR L, V271, pG293, DOI 10.1152/ajpgi.1996.271.2.G293; TWISK J, 1995, HEPATOLOGY, V21, P501, DOI 10.1016/0270-9139(95)90113-2; Wang DP, 1996, J LIPID RES, V37, P1831; Weinsier R L, 1993, Obes Res, V1, P51; Yamagata K, 2007, INT J MOL MED, V19, P751; Yamakawa T, 2007, ENDOCR J, V54, P53, DOI 10.1507/endocrj.K05-098; Yoon JC, 2001, NATURE, V413, P131, DOI 10.1038/35093050; Zhang YQ, 2004, GENE DEV, V18, P157, DOI 10.1101/gad.1138104; Zhang YQ, 2006, P NATL ACAD SCI USA, V103, P1006, DOI 10.1073/pnas.0506982103	47	21	22	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15089	15096		10.1074/jbc.M710452200	http://dx.doi.org/10.1074/jbc.M710452200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18385139	Green Published, hybrid			2022-12-25	WOS:000256232000023
J	Ao, ZJ; Yu, Z; Wang, LN; Zheng, YF; Yao, XJ				Ao, Zhujun; Yu, Zhe; Wang, Lina; Zheng, Yingfeng; Yao, Xiaojian			Vpr14-88-Apobec3G Fusion Protein Is Efficiently Incorporated into Vif-Positive HIV-1 Particles and Inhibits Viral Infection	PLOS ONE			English	Article								Background: APOBEC3G (A3G), a deoxycytidine deaminase, is a potent host antiviral factor that can restrict HIV-1 infection. During Vif-negative HIV-1 replication, A3G is incorporated into HIV-1 particles, induces mutations in reverse transcribed viral DNA and inhibits reverse transcription. However, HIV-1 Vif counteracts A3G's activities by inducing its degradation and by blocking its incorporation into HIV-1 particles. Thus, it is interesting to elucidate a mechanism that would allow A3G to escape the effects of Vif in order to rescue its potent antiviral activity and to provide a possible novel therapeutic strategy for treating HIV-1 infection. Methods and Findings: In this study, we generated an R88-A3G fusion protein by fusing A3G to a virion-targeting polypeptide (R14-88) derived from HIV-1 Vpr protein and compared its antiviral effects relative to those of HA-tagged native A3G (HA-A3G). Our study showed that transient expression of the R88-A3G fusion protein in both Vif 2 and Vif(+) HIV-1 producing cells drastically inhibited viral infection in HeLa-CD4-CCR5-cells, CD4(+) C8166 T cells and human primary PBMCs. Moreover, we established CD4(+) C8166 T cell lines that stably express either R88-A3G or HA-A3G by transduction with VSV-G-pseudotyped lentiviral vector that harbor expression cassettes for R88-A3G or HA-A3G, respectively, and tested their susceptibility to Vif(+) HIV-1 infection. Our results clearly reveal that expression of R88-A3G in transduced CD4(+) C8166 cells significantly blocked Vif(+) HIV-1 infection. In an attempt to understand the mechanism underlying the antiviral activity of R88-A3G, we demonstrated that R88-A3G was efficiently incorporated into viral particles in the presence of Vif. Moreover, PCR analysis revealed that R88-A3G significantly inhibited viral cDNA synthesis during the early stage of Vif(+) virus infection. Conclusions: Our results clearly indicate that R88 delivers A3G into Vif(+) HIV-1 particles and inhibits infectivity and spread of the virions among CD4(+) T cells. This study provides evidence for an effective strategy to modify a host protein with innate anti-HIV-1 activity and rescue its potent anti-HIV potential in the presence of Vif. Further characterization and optimization of this system may lead to the development of an effective therapeutic approach against HIV-1 infection.	[Ao, Zhujun; Yu, Zhe; Wang, Lina; Zheng, Yingfeng; Yao, Xiaojian] Univ Manitoba, Fac Med, Dept Med Microbiol, Lab Mol Human Retrovirol, Winnipeg, MB, Canada	University of Manitoba	Ao, ZJ (corresponding author), Univ Manitoba, Fac Med, Dept Med Microbiol, Lab Mol Human Retrovirol, Winnipeg, MB, Canada.	yao2@cc.umanitoba.ca	Zheng, Yingfeng/AAE-2983-2022; Zheng, Yingfeng/CAE-9225-2022	Zheng, Yingfeng/0000-0002-0914-7864; Yao, Xiaojian/0000-0002-5022-1309	The Manitoba Medical Service Foundation [Basic Science Career Development Research Award]; CIHR [HPR85525]; CFI Leaders Opportunity Fund; University of Manitoba	The Manitoba Medical Service Foundation; CIHR(Canadian Institutes of Health Research (CIHR)); CFI Leaders Opportunity Fund(Canada Foundation for Innovation); University of Manitoba	X-J. Yao is the recipient of the Basic Science Career Development Research Award from The Manitoba Medical Service Foundation. This work was supported by CIHR HIV preventing grant (HPR85525), CFI Leaders Opportunity Fund, University Research Grants Program (URGP) from University of Manitoba, and the grant from The Manitoba Medical Service Foundation to X-J. Yao.	AGUIAR RS, 2007, J BIOL CHEM; Alce TM, 2004, J BIOL CHEM, V279, P34083, DOI 10.1074/jbc.C400235200; Ao Z, 2004, J VIROL, V78, P3170, DOI 10.1128/JVI.78.6.3170-3177.2004; Ao ZJ, 2007, J BIOL CHEM, V282, P13456, DOI 10.1074/jbc.M610546200; Ao ZJ, 2005, RETROVIROLOGY, V2, DOI 10.1186/1742-4690-2-62; Bishop KN, 2006, J VIROL, V80, P8450, DOI 10.1128/JVI.00839-06; Bogerd HP, 2004, P NATL ACAD SCI USA, V101, P3770, DOI 10.1073/pnas.0307713101; Burnett A, 2007, J VIROL, V81, P5000, DOI 10.1128/JVI.02237-06; Cen S, 2004, J BIOL CHEM, V279, P33177, DOI 10.1074/jbc.M402062200; Chiu YL, 2005, NATURE, V435, P108, DOI 10.1038/nature03493; Cohen GB, 1999, IMMUNITY, V10, P661, DOI 10.1016/S1074-7613(00)80065-5; Coker HA, 2007, DNA REPAIR, V6, P235, DOI 10.1016/j.dnarep.2006.10.001; Conticello SG, 2003, CURR BIOL, V13, P2009, DOI 10.1016/j.cub.2003.10.034; Doehle BP, 2005, J VIROL, V79, P8201, DOI 10.1128/JVI.79.13.8201-8207.2005; Fletcher TM, 1997, EMBO J, V16, P5123, DOI 10.1093/emboj/16.16.5123; Goncalves J, 1996, J VIROL, V70, P8701, DOI 10.1128/JVI.70.12.8701-8709.1996; Guo F, 2007, J VIROL, V81, P11322, DOI 10.1128/JVI.00162-07; Guo F, 2006, J VIROL, V80, P11710, DOI 10.1128/JVI.01038-06; Harris RS, 2003, CELL, V113, P803, DOI 10.1016/S0092-8674(03)00423-9; HE JL, 1995, J VIROL, V69, P6705, DOI 10.1128/JVI.69.11.6705-6711.1995; Holmes RK, 2007, J BIOL CHEM, V282, P2587, DOI 10.1074/jbc.M607298200; Huthoff H, 2007, J VIROL, V81, P3807, DOI 10.1128/JVI.02795-06; Kao S, 2003, J VIROL, V77, P11398, DOI 10.1128/JVI.77.21.11398-11407.2003; KAO S, 2004, RETROVIROLOGY, V1, P1; Kao S, 2007, VIROLOGY, V369, P329, DOI 10.1016/j.virol.2007.08.005; KIMPTON J, 1992, J VIROL, V66, P2232, DOI 10.1128/JVI.66.4.2232-2239.1992; Kobinger GP, 2001, NAT BIOTECHNOL, V19, P225, DOI 10.1038/85664; Kobinger GP, 1998, J VIROL, V72, P5441, DOI 10.1128/JVI.72.7.5441-5448.1998; KONDO E, 1995, J VIROL, V69, P2759, DOI 10.1128/JVI.69.5.2759-2764.1995; Kreisberg JF, 2006, J EXP MED, V203, P865, DOI 10.1084/jem.20051856; LAVALLEE C, 1994, J VIROL, V68, P1926; Lecossier D, 2003, SCIENCE, V300, P1112, DOI 10.1126/science.1083338; LEVY DN, 1993, CELL, V72, P541, DOI 10.1016/0092-8674(93)90073-Y; Li JL, 2004, J CELL BIOCHEM, V92, P560, DOI 10.1002/jcb.20082; LU YL, 1993, J VIROL, V67, P6542, DOI 10.1128/JVI.67.11.6542-6550.1993; Luo K, 2004, J VIROL, V78, P11841, DOI 10.1128/JVI.78.21.11841-11852.2004; Mangeat B, 2003, NATURE, V424, P99, DOI 10.1038/nature01709; Mangeat B, 2004, J BIOL CHEM, V279, P14481, DOI 10.1074/jbc.C400060200; Mariani R, 2003, CELL, V114, P21, DOI 10.1016/S0092-8674(03)00515-4; Marin M, 2003, NAT MED, V9, P1398, DOI 10.1038/nm946; Mehle A, 2004, J BIOL CHEM, V279, P7792, DOI 10.1074/jbc.M313093200; Newman ENC, 2005, CURR BIOL, V15, P166, DOI 10.1016/j.cub.2004.12.068; Nguyen KL, 2004, VIROLOGY, V319, P163, DOI 10.1016/j.virol.2003.11.021; Opi S, 2007, J VIROL, V81, P8236, DOI 10.1128/JVI.02694-06; Park IW, 1996, J ACQ IMMUN DEF SYND, V11, P341, DOI 10.1097/00042560-199604010-00004; PAXTON W, 1993, J VIROL, V67, P7229, DOI 10.1128/JVI.67.12.7229-7237.1993; Petersen-Mahrt S, 2005, IMMUNOL REV, V203, P80, DOI 10.1111/j.0105-2896.2005.00232.x; Popov S, 1998, EMBO J, V17, P909, DOI 10.1093/emboj/17.4.909; RE F, 1995, J VIROL, V69, P6859, DOI 10.1128/JVI.69.11.6859-6864.1995; ROGEL ME, 1995, J VIROL, V69, P882, DOI 10.1128/JVI.69.2.882-888.1995; Schafer A, 2004, VIROLOGY, V328, P163, DOI 10.1016/j.virol.2004.08.006; Schrofelbauer R, 2004, P NATL ACAD SCI USA, V101, P3927, DOI 10.1073/pnas.0307132101; Sheehy AM, 2003, NAT MED, V9, P1404, DOI 10.1038/nm945; Sheehy AM, 2002, NATURE, V418, P646, DOI 10.1038/nature00939; Simon JHM, 1996, J VIROL, V70, P5297, DOI 10.1128/JVI.70.8.5297-5305.1996; Stopak K, 2003, MOL CELL, V12, P591, DOI 10.1016/S1097-2765(03)00353-8; Svarovskaia ES, 2004, J BIOL CHEM, V279, P35822, DOI 10.1074/jbc.M405761200; Wu XY, 1996, VIROLOGY, V219, P307, DOI 10.1006/viro.1996.0253; Wu XY, 1997, EMBO J, V16, P5113, DOI 10.1093/emboj/16.16.5113; WU XY, 1995, J VIROL, V69, P3389, DOI 10.1128/JVI.69.6.3389-3398.1995; Xu HZ, 2004, P NATL ACAD SCI USA, V101, P5652, DOI 10.1073/pnas.0400830101; Yang Y, 2007, VIROLOGY; YAO XJ, 1995, VIROLOGY, V209, P615, DOI 10.1006/viro.1995.1293; Yao XJ, 1999, GENE THER, V6, P1590, DOI 10.1038/sj.gt.3300988; Yao XJ, 1998, J VIROL, V72, P4686, DOI 10.1128/JVI.72.6.4686-4693.1998; YAO XJ, 1995, J VIROL, V69, P7032, DOI 10.1128/JVI.69.11.7032-7044.1995; Yu XH, 2003, SCIENCE, V302, P1056, DOI 10.1126/science.1089591; Yu YK, 2004, GENE DEV, V18, P2867, DOI 10.1101/gad.1250204; Zennou W, 2004, J VIROL, V78, P12058, DOI 10.1128/JVI.78.21.12058-12061.2004; Zhang H, 2003, NATURE, V424, P94, DOI 10.1038/nature01707	70	33	33	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1995	10.1371/journal.pone.0001995	http://dx.doi.org/10.1371/journal.pone.0001995			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414671	Green Published, Green Submitted, gold			2022-12-25	WOS:000260867300020
J	Lamaziere, A; Wolf, C; Lambert, O; Chassaing, G; Trugnan, G; Ayala-Sanmartin, J				Lamaziere, Antonin; Wolf, Claude; Lambert, Olivier; Chassaing, Gerard; Trugnan, Germain; Ayala-Sanmartin, Jesus			The Homeodomain Derived Peptide Penetratin Induces Curvature of Fluid Membrane Domains	PLOS ONE			English	Article								Background: Protein membrane transduction domains that are able to cross the plasma membrane are present in several transcription factors, such as the homeodomain proteins and the viral proteins such as Tat of HIV-1. Their discovery resulted in both new concepts on the cell communication during development, and the conception of cell penetrating peptide vectors for internalisation of active molecules into cells. A promising cell penetrating peptide is Penetratin, which crosses the cell membranes by a receptor and metabolic energy-independent mechanism. Recent works have claimed that Penetratin and similar peptides are internalized by endocytosis, but other endocytosis-independent mechanisms have been proposed. Endosomes or plasma membranes crossing mechanisms are not well understood. Previously, we have shown that basic peptides induce membrane invaginations suggesting a new mechanism for uptake, "physical endocytosis''. Methodology/Principal Findings: Herein, we investigate the role of membrane lipid phases on Penetratin induced membrane deformations (liquid ordered such as in "raft'' microdomains versus disordered fluid "non-raft'' domains) in membrane models. Experimental data show that zwitterionic lipid headgroups take part in the interaction with Penetratin suggesting that the external leaflet lipids of cells plasma membrane are competent for peptide interaction in the absence of net negative charges. NMR and X-ray diffraction data show that the membrane perturbations (tubulation and vesiculation) are associated with an increase in membrane negative curvature. These effects on curvature were observed in the liquid disordered but not in the liquid ordered (raft-like) membrane domains. Conclusions/Significance: The better understanding of the internalisation mechanisms of protein transduction domains will help both the understanding of the mechanisms of cell communication and the development of potential therapeutic molecular vectors. Here we showed that the membrane targets for these molecules are preferentially the fluid membrane domains and that the mechanism involves the induction of membrane negative curvature. Consequences on cellular uptake are discussed.	[Lamaziere, Antonin; Wolf, Claude; Trugnan, Germain; Ayala-Sanmartin, Jesus] CHU St Antoine, UMR538, INSERM, Paris, France; [Lamaziere, Antonin; Wolf, Claude; Trugnan, Germain; Ayala-Sanmartin, Jesus] CHU St Antoine, Univ Pierre Marie Curie, Paris, France; [Lambert, Olivier] Univ Bordeaux 1, CNRS, CBMN, UMR 5248, Pessac, France; [Chassaing, Gerard] Univ Pierre Marie Curie, UMR CNRS 7613, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Saint-Antoine - APHP; UDICE-French Research Universities; Sorbonne Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Chemistry (INC); UDICE-French Research Universities; Universite de Bordeaux; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite	Lamaziere, A (corresponding author), CHU St Antoine, UMR538, INSERM, Paris, France.	jayala@chusa.jussieu.fr	Lamaziere, Antonin/AFM-0000-2022; Lamaziere, Antonin/AAH-2285-2022	Lambert, Olivier/0000-0002-5651-8082	ANR-PCV [06 139187]	ANR-PCV(French National Research Agency (ANR))	This work was supported by an ANR-PCV grant (06 139187)France.	Afonin S, 2006, CHEMPHYSCHEM, V7, P2134, DOI 10.1002/cphc.200600306; Andersson A, 2004, BBA-BIOMEMBRANES, V1661, P18, DOI 10.1016/j.bbamem.2003.11.014; Ayala-Sanmartin J, 2001, BBA-BIOMEMBRANES, V1510, P18, DOI 10.1016/S0005-2736(00)00262-5; Ayala-Sanmartin J, 2000, BIOCHEMISTRY-US, V39, P15190, DOI 10.1021/bi000764r; Baumgart T, 2003, NATURE, V425, P821, DOI 10.1038/nature02013; Bellet-Amalric E, 2000, BBA-BIOMEMBRANES, V1467, P131, DOI 10.1016/S0005-2736(00)00218-2; Berlose JP, 1996, EUR J BIOCHEM, V242, P372, DOI 10.1111/j.1432-1033.1996.0372r.x; Brown DA, 2000, J BIOL CHEM, V275, P17221, DOI 10.1074/jbc.R000005200; Bruston F, 2007, BIOPOLYMERS, V86, P42, DOI 10.1002/bip.20703; Caesar CEB, 2006, BIOCHEMISTRY-US, V45, P7682, DOI 10.1021/bi052095t; Cedric T, 2004, EUR BIOPHYS J BIOPHY, V33, P513, DOI 10.1007/s00249-004-0392-5; Christiaens B, 2002, EUR J BIOCHEM, V269, P2918, DOI 10.1046/j.1432-1033.2002.02963.x; Derossi D, 1996, J BIOL CHEM, V271, P18188, DOI 10.1074/jbc.271.30.18188; Dietz GPH, 2004, MOL CELL NEUROSCI, V27, P85, DOI 10.1016/j.mcn.2004.03.005; DUBOCHET J, 1988, Q REV BIOPHYS, V21, P129, DOI 10.1017/S0033583500004297; Fischer R, 2005, CHEMBIOCHEM, V6, P2126, DOI 10.1002/cbic.200500044; Fretz MM, 2007, BIOCHEM J, V403, P335, DOI 10.1042/BJ20061808; JOLIOT A, 1991, P NATL ACAD SCI USA, V88, P1864, DOI 10.1073/pnas.88.5.1864; Lamaziere A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000201; Lamaziere Antonin, 2006, Journal de la Societe de Biologie, V200, P229, DOI 10.1051/jbio:2006026; Lambert O, 2004, J BIOL CHEM, V279, P10872, DOI 10.1074/jbc.M313657200; Mae M, 2006, CURR OPIN PHARMACOL, V6, P509, DOI 10.1016/j.coph.2006.04.004; Magzoub M, 2002, BBA-BIOMEMBRANES, V1563, P53, DOI 10.1016/S0005-2736(02)00373-5; Mangavel C, 1998, BBA-BIOMEMBRANES, V1371, P265, DOI 10.1016/S0005-2736(98)00026-1; Menger FM, 2003, J AM CHEM SOC, V125, P2846, DOI 10.1021/ja021337z; Munro S, 2003, CELL, V115, P377, DOI 10.1016/S0092-8674(03)00882-1; Murriel Christopher L, 2006, Expert Opin Drug Deliv, V3, P739, DOI 10.1517/17425247.3.6.739; PEREZ F, 1994, MOL ENDOCRINOL, V8, P1278, DOI 10.1210/me.8.9.1278; Persson D, 2003, BIOCHEMISTRY-US, V42, P421, DOI 10.1021/bi026453t; Prochiantz A, 2000, CURR OPIN CELL BIOL, V12, P400, DOI 10.1016/S0955-0674(00)00108-3; Prochiantz A, 2003, NAT REV MOL CELL BIO, V4, P814, DOI 10.1038/nrm1227; Rothbard JB, 2005, ADV DRUG DELIVER REV, V57, P495, DOI 10.1016/j.addr.2004.10.003; Rothbard JB, 2004, J AM CHEM SOC, V126, P9506, DOI 10.1021/ja0482536; Roux A, 2005, EMBO J, V24, P1537, DOI 10.1038/sj.emboj.7600631; Terrone D, 2003, BIOCHEMISTRY-US, V42, P13787, DOI 10.1021/bi035293y; Thoren PEG, 2005, BIOPHYS CHEM, V114, P169, DOI 10.1016/j.bpc.2004.11.016; Veatch SL, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.268101; Volynsky PE, 2005, BIOCHEMISTRY-US, V44, P14626, DOI 10.1021/bi0514562	38	60	62	0	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1938	10.1371/journal.pone.0001938	http://dx.doi.org/10.1371/journal.pone.0001938			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398464	Green Published, Green Submitted, gold			2022-12-25	WOS:000260795500015
J	Forstmann, BU; Wolfensteller, U; Derrfuss, J; Neumann, J; Brass, M; Ridderinkhof, KR; von Cramon, DY				Forstmann, Birte U.; Wolfensteller, Uta; Derrfuss, Jan; Neumann, Jane; Brass, Marcel; Ridderinkhof, K. Richard; von Cramon, D. Yves			When the Choice Is Ours: Context and Agency Modulate the Neural Bases of Decision-Making	PLOS ONE			English	Article							MEDIAL FRONTAL-CORTEX; EVENT-RELATED FMRI; PREFRONTAL CORTEX; SOCIAL COGNITION; METAANALYSIS; BRAIN; SELF	The option to choose between several courses of action is often associated with the feeling of being in control. Yet, in certain situations, one may prefer to decline such agency and instead leave the choice to others. In the present functional magnetic resonance imaging (fMRI) study, we provide evidence that the neural processes involved in decision-making are modulated not only by who controls our choice options (agency), but also by whether we have a say in who is in control (context). The fMRI results are noteworthy in that they reveal specific contributions of the anterior frontomedian cortex (viz. BA 10) and the rostral cingulate zone (RCZ) in decision-making processes. The RCZ is engaged when conditions clearly present us with the most choice options. BA 10 is engaged in particular when the choice is completely ours, as well as when it is completely up to others to choose for us which in turn gives rise to an attribution of control to oneself or someone else, respectively. After all, it does not only matter whether we have any options to choose from, but also who decides on that.	[Forstmann, Birte U.; Ridderinkhof, K. Richard] Univ Amsterdam, Amsterdam Ctr Study Adapt Control Brain & Behav, Amsterdam, Netherlands; [Wolfensteller, Uta; Derrfuss, Jan; Neumann, Jane; Brass, Marcel; von Cramon, D. Yves] Max Planck Inst Human Cognitive & Brain Sci, Dept Cognitive Neurol, Leipzig, Germany; [Derrfuss, Jan] Inst Med, Res Ctr Juelich, Julich, Germany	University of Amsterdam; Max Planck Society; Helmholtz Association; Research Center Julich	Forstmann, BU (corresponding author), Univ Amsterdam, Amsterdam Ctr Study Adapt Control Brain & Behav, Amsterdam, Netherlands.	b.u.forstmann@uva.nl	Brass, Marcel/J-7082-2012; Forstmann, Birte/AAS-8515-2020; Wolfensteller, Uta/AAG-8921-2019; Derrfuss, Jan/J-3038-2012	Brass, Marcel/0000-0002-3364-4019; Derrfuss, Jan/0000-0002-8212-487X	NIH [R01 MH74457]; Netherlands Organization for Scientific Research [VICI grant]; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH074457] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); Netherlands Organization for Scientific Research(Netherlands Organization for Scientific Research (NWO)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	J.N.'s work is supported by the NIH (Grant Number: R01 MH74457). The work of B.U.F. and K.R.R. was afforded by a VICI grant from the Netherlands Organization for Scientific Research (NWO) to K.R.R.	Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Burock MA, 1998, NEUROREPORT, V9, P3735, DOI 10.1097/00001756-199811160-00030; Forstmann BU, 2006, J COGNITIVE NEUROSCI, V18, P388, DOI 10.1162/089892906775990589; FRISTON KJ, 1995, NEUROIMAGE, V2, P45, DOI 10.1006/nimg.1995.1007; Friston KJ, 1998, NEUROIMAGE, V7, P30, DOI 10.1006/nimg.1997.0306; Frith CD, 2006, NEURON, V50, P531, DOI 10.1016/j.neuron.2006.05.001; Gilbert SJ, 2006, J COGNITIVE NEUROSCI, V18, P932, DOI 10.1162/jocn.2006.18.6.932; Krawczyk DC, 2002, NEUROSCI BIOBEHAV R, V26, P631, DOI 10.1016/S0149-7634(02)00021-0; Lohmann G, 2001, COMPUT MED IMAG GRAP, V25, P449, DOI 10.1016/S0895-6111(01)00008-8; Mitchell JP, 2005, J COGNITIVE NEUROSCI, V17, P1306, DOI 10.1162/0898929055002418; Northoff G, 2006, NEUROIMAGE, V31, P440, DOI 10.1016/j.neuroimage.2005.12.002; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Picard N, 1996, CEREB CORTEX, V6, P342, DOI 10.1093/cercor/6.3.342; Ridderinkhof KR, 2004, SCIENCE, V306, P443, DOI 10.1126/science.1100301; Singer T, 2006, NEUROSCI BIOBEHAV R, V30, P855, DOI 10.1016/j.neubiorev.2006.06.011; Talairach J, 1988, CO PLANAR STEREOTAXI; Ullsperger M, 2001, NEUROIMAGE, V14, P1387, DOI 10.1006/nimg.2001.0935; Walton ME, 2004, NAT NEUROSCI, V7, P1259, DOI 10.1038/nn1339	18	15	15	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1899	10.1371/journal.pone.0001899	http://dx.doi.org/10.1371/journal.pone.0001899			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	370XC	18398450	Green Published, gold, Green Submitted			2022-12-25	WOS:000260795400026
J	Wilmes, P; Wexler, M; Bond, PL				Wilmes, Paul; Wexler, Margaret; Bond, Philip L.			Metaproteomics Provides Functional Insight into Activated Sludge Wastewater Treatment	PLOS ONE			English	Article								Background: Through identification of highly expressed proteins from a mixed culture activated sludge system this study provides functional evidence of microbial transformations important for enhanced biological phosphorus removal (EBPR). Methodology/Principal Findings: A laboratory-scale sequencing batch reactor was successfully operated for different levels of EBPR, removing around 25, 40 and 55 mg/l P. The microbial communities were dominated by the uncultured polyphosphate-accumulating organism "Candidatus Accumulibacter phosphatis''. When EBPR failed, the sludge was dominated by tetrad-forming alpha-Proteobacteria. Representative and reproducible 2D gel protein separations were obtained for all sludge samples. 638 protein spots were matched across gels generated from the phosphate removing sludges. 111 of these were excised and 46 proteins were identified using recently available sludge metagenomic sequences. Many of these closely match proteins from "Candidatus Accumulibacter phosphatis'' and could be directly linked to the EBPR process. They included enzymes involved in energy generation, polyhydroxyalkanoate synthesis, glycolysis, gluconeogenesis, glycogen synthesis, glyoxylate/TCA cycle, fatty acid beta oxidation, fatty acid synthesis and phosphate transport. Several proteins involved in cellular stress response were detected. Conclusions/Significance: Importantly, this study provides direct evidence linking the metabolic activities of "Accumulibacter'' to the chemical transformations observed in EBPR. Finally, the results are discussed in relation to current EBPR metabolic models.	[Wilmes, Paul; Bond, Philip L.] Univ East Anglia, Sch Environm Sci, Norwich, Norfolk, England; [Wexler, Margaret; Bond, Philip L.] Univ East Anglia, Sch Biol Sci, Norwich, Norfolk, England	University of East Anglia; University of East Anglia	Wilmes, P (corresponding author), Univ East Anglia, Sch Environm Sci, Norwich, Norfolk, England.	phil.bond@uq.edu.au	Wilmes, Paul/B-1707-2017; Wexler, Margaret/G-3423-2011; Bond, Philip/C-6046-2009; Bond, Philip/N-6649-2017	Wilmes, Paul/0000-0002-6478-2924; Bond, Philip/0000-0002-9025-4797	Anglian Water; School of Environmental Sciences Studentship; British Council Chevening Scholarship; short-term research scholarship from the German Academic Exchange Service; research scholarship from the Luxembourg Ministry of Culture, Higher Education and Research; Biotechnology and Biological Sciences Research Council [BB/D013348/1]; BBSRC [BB/D013348/1] Funding Source: UKRI	Anglian Water; School of Environmental Sciences Studentship; British Council Chevening Scholarship; short-term research scholarship from the German Academic Exchange Service; research scholarship from the Luxembourg Ministry of Culture, Higher Education and Research; Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); BBSRC(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC))	This project received financial support from Anglian Water. PW was supported by a School of Environmental Sciences Studentship, a British Council Chevening Scholarship, a short-term research scholarship from the German Academic Exchange Service and a research scholarship from the Luxembourg Ministry of Culture, Higher Education and Research. PLB and MW received support from the Biotechnology and Biological Sciences Research Council, grant reference no. BB/D013348/1.	Aldor AS, 2003, CURR OPIN BIOTECH, V14, P475, DOI 10.1016/j.copbio.2003.09.002; Baker-Austin C, 2005, MICROBIOL-SGM, V151, P2637, DOI 10.1099/mic.0.28076-0; Beer M, 2004, MICROBIOL-SGM, V150, P2267, DOI 10.1099/mic.0.26825-0; Benndorf D, 2007, ISME J, V1, P224, DOI 10.1038/ismej.2007.39; Blackall LL, 2002, ANTON LEEUW INT J G, V81, P681, DOI 10.1023/A:1020538429009; Bond PL, 1999, APPL ENVIRON MICROB, V65, P4077; BOND PL, 1995, APPL ENVIRON MICROB, V61, P1910, DOI 10.1128/AEM.61.5.1910-1916.1995; COMEAU Y, 1986, WATER RES, V20, P1511, DOI 10.1016/0043-1354(86)90115-6; Crocetti GR, 2000, APPL ENVIRON MICROB, V66, P1175, DOI 10.1128/AEM.66.3.1175-1182.2000; Crocetti GR, 2002, MICROBIOL-SGM, V148, P3353, DOI 10.1099/00221287-148-11-3353; Daims H, 1999, SYST APPL MICROBIOL, V22, P434, DOI 10.1016/S0723-2020(99)80053-8; DeLong EF, 2006, SCIENCE, V311, P496, DOI 10.1126/science.1120250; Falkentoft CM, 2002, WATER RES, V36, P491, DOI 10.1016/S0043-1354(01)00231-7; Filipe CDM, 2001, BIOTECHNOL BIOENG, V76, P32, DOI 10.1002/bit.1023; Gessesse A, 2003, WATER RES, V37, P3652, DOI 10.1016/S0043-1354(03)00241-0; Gygi SP, 2000, P NATL ACAD SCI USA, V97, P9390, DOI 10.1073/pnas.160270797; He S, 2006, WATER SCI TECHNOL, V54, P111, DOI 10.2166/wst.2006.378; Hesketh AR, 2002, MOL MICROBIOL, V46, P917, DOI 10.1046/j.1365-2958.2002.03219.x; Hesselmann RPX, 2000, WATER RES, V34, P3487, DOI 10.1016/S0043-1354(00)00092-0; Hesselmann RPX, 1999, SYST APPL MICROBIOL, V22, P454, DOI 10.1016/S0723-2020(99)80055-1; Hu QZ, 2005, J MASS SPECTROM, V40, P430, DOI 10.1002/jms.856; Hugenholtz P, 1998, J BACTERIOL, V180, P6793, DOI 10.1128/JB.180.24.6793-6793.1998; Kan Jinjun, 2005, Saline Syst, V1, P7, DOI 10.1186/1746-1448-1-7; Klaassens ES, 2007, APPL ENVIRON MICROB, V73, P1388, DOI 10.1128/AEM.01921-06; Lacerda CMR, 2007, J PROTEOME RES, V6, P1145, DOI 10.1021/pr060477v; Lee N, 2003, SYST APPL MICROBIOL, V26, P211, DOI 10.1078/072320203322346065; Lo I, 2007, NATURE, V446, P537, DOI 10.1038/nature05624; Louie TM, 2000, WATER RES, V34, P1507, DOI 10.1016/S0043-1354(99)00302-4; MANZ W, 1992, SYST APPL MICROBIOL, V15, P593, DOI 10.1016/S0723-2020(11)80121-9; Markowitz VM, 2006, NUCLEIC ACIDS RES, V34, pD344, DOI 10.1093/nar/gkj024; Maron PA, 2007, MICROB ECOL, V53, P486, DOI 10.1007/s00248-006-9196-8; Martin HG, 2006, NAT BIOTECHNOL, V24, P1263, DOI 10.1038/nbt1247; McMahon KD, 2002, APPL ENVIRON MICROB, V68, P4971, DOI 10.1128/AEM.68.10.4971-4978.2002; Mino T., 1987, BIOLOGICAL PHOSPHATE, P27; Oehmen A, 2005, BIOTECHNOL BIOENG, V91, P162, DOI 10.1002/bit.20500; Pereira H, 1996, WATER RES, V30, P2128, DOI 10.1016/0043-1354(96)00035-8; Ram RJ, 2005, SCIENCE, V308, P1915, DOI 10.1126/science. 1109070; Rehm BHA, 2006, BIOTECHNOL LETT, V28, P207, DOI 10.1007/s10529-005-5521-4; ROLLER C, 1994, MICROBIOL-UK, V140, P2849, DOI 10.1099/00221287-140-10-2849; Rutherford K, 2000, BIOINFORMATICS, V16, P944, DOI 10.1093/bioinformatics/16.10.944; Sato S, 2007, J BIOSCI BIOENG, V103, P38, DOI 10.1263/jbb.103.38; Schulze WX, 2005, OECOLOGIA, V142, P335, DOI 10.1007/s00442-004-1698-9; Seviour RJ, 2003, FEMS MICROBIOL REV, V27, P99, DOI 10.1016/S0168-6445(03)00021-4; Seviour RJ, 2000, ENVIRON MICROBIOL, V2, P581, DOI 10.1046/j.1462-2920.2000.00153.x; van Veen HW, 1997, ANTON LEEUW INT J G, V72, P299, DOI 10.1023/A:1000530927928; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Waltermann M, 2005, J BACTERIOL, V187, P3607, DOI 10.1128/JB.187.11.3607-3619.2005; WENTZEL MC, 1991, WATER SCI TECHNOL, V23, P567, DOI 10.2166/wst.1991.0506; Wilmes P, 2006, WATER SCI TECHNOL, V54, P217, DOI 10.2166/wst.2006.390; Wilmes P, 2006, TRENDS MICROBIOL, V14, P92, DOI 10.1016/j.tim.2005.12.006; Wilmes P, 2004, ENVIRON MICROBIOL, V6, P911, DOI 10.1111/j.1462-2920.2004.00687.x; Wong MT, 2004, MICROBIOL-SGM, V150, P3741, DOI 10.1099/mic.0.27291-0; Yagci N, 2003, BIOTECHNOL BIOENG, V84, P359, DOI 10.1002/bit.10765	53	123	132	0	75	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 12	2008	3	3							e1778	10.1371/journal.pone.0001778	http://dx.doi.org/10.1371/journal.pone.0001778			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	369VW	18392150	gold, Green Published			2022-12-25	WOS:000260723000031
J	Lockwood, WW; Chari, R; Coe, BP; Girard, L; MacAulay, C; Lam, S; Gazdar, AF; Minna, JD; Lam, WL				Lockwood, W. W.; Chari, R.; Coe, B. P.; Girard, L.; MacAulay, C.; Lam, S.; Gazdar, A. F.; Minna, J. D.; Lam, W. L.			DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers	ONCOGENE			English	Article						gene amplification; array CGH; gene expression; integrative analysis; lung cancer; EGFR signaling	COPY NUMBER ALTERATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; HIGH-RESOLUTION ANALYSIS; PATH ARRAY CGH; GENE-EXPRESSION; CELL-LINES; MICROARRAY ANALYSIS; CDNA MICROARRAYS; BREAST-CANCER; DEPENDENCY	Chromosomal translocation is the best-characterized genetic mechanism for oncogene activation. However, there are documented examples of activation by alternate mechanisms, for example gene dosage increase, though its prevalence is unclear. Here, we answered the fundamental question of the contribution of DNA amplification as a molecular mechanism driving oncogenesis. Comparing 104 cancer lines representing diverse tissue origins identified genes residing in amplification 'hotspots' and discovered an unexpected frequency of genes activated by this mechanism. The 3431 amplicons identified represent similar to 10 per hematological and similar to 36 per epithelial cancer genome. Many recurrently amplified oncogenes were previously known to be activated only by disease-specific translocations. The 135 hotspots identified contain 538 unique genes and are enriched for proliferation, apoptosis and linage-dependency genes, reflecting functions advantageous to tumor growth. Integrating gene dosage with expression data validated the downstream impact of the novel amplification events in both cell lines and clinical samples. For example, multiple downstream components of the EGFR-family-signaling pathway, including CDK5, AKT1 and SHC1, are overexpressed as a direct result of gene amplification in lung cancer. Our findings suggest that amplification is far more common a mechanism of oncogene activation than previously believed and that specific regions of the genome are hotspots of amplification.	[Lockwood, W. W.; Chari, R.; Coe, B. P.; Lam, W. L.] British Columbia Canc Res Ctr, Dept Canc Genet, Vancouver, BC V5Z 1L3, Canada; [Lockwood, W. W.; Chari, R.; Coe, B. P.; Lam, W. L.] British Columbia Canc Res Ctr, Dept Dev Biol, Vancouver, BC V5Z 1L3, Canada; [Girard, L.; Gazdar, A. F.; Minna, J. D.] Univ Texas SW Med Ctr Dallas, Hamon Ctr Therapeut Oncol Res, Dallas, TX 75390 USA; [MacAulay, C.; Lam, S.] British Columbia Canc Res Ctr, Dept Canc Imaging, Vancouver, BC V5Z 1L3, Canada	British Columbia Cancer Agency; British Columbia Cancer Agency; University of Texas System; University of Texas Southwestern Medical Center Dallas; British Columbia Cancer Agency	Lockwood, WW (corresponding author), British Columbia Canc Res Ctr, Dept Canc Genet, 675 W 10th Aveue, Vancouver, BC V5Z 1L3, Canada.	wlockwood@bccrc.ca	MacAulay, Calum/K-1795-2016; Chari, Raj/G-3285-2019; Chari, Rajagopal/B-6980-2008; Lockwood, William W/A-2879-2009; Coe, Bradley/A-2878-2009	Coe, Bradley/0000-0001-8471-4016; MacAulay, Calum/0000-0003-4440-2792	NCI NIH HHS [P50 CA070907, P50 CA070907-03S19001, P50 CA070907-09, P50 CA070907-11, P50 CA070907-110009, P50 CA070907-10] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA070907] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Albertson DG, 2006, TRENDS GENET, V22, P447, DOI 10.1016/j.tig.2006.06.007; Apergis GA, 1998, J BIOL CHEM, V273, P2917, DOI 10.1074/jbc.273.5.2917; Boersma-Vreugdenhil GR, 2004, BRIT J HAEMATOL, V126, P355, DOI 10.1111/j.1365-2141.2004.05050.x; Bublil EM, 2007, CURR OPIN CELL BIOL, V19, P124, DOI 10.1016/j.ceb.2007.02.008; Buttel I, 2004, ANN NY ACAD SCI, V1028, P14, DOI 10.1196/annals.1322.002; Chari R, 2006, BMC GENOMICS, V7, DOI 10.1186/1471-2164-7-324; Chi B, 2004, BMC BIOINFORMATICS, V5, DOI 10.1186/1471-2105-5-13; Coe BP, 2006, BRIT J CANCER, V94, P1927, DOI 10.1038/sj.bjc.6603167; Coe BP, 2007, GENOMICS, V89, P647, DOI 10.1016/j.ygeno.2006.12.012; Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478; Fabbro D, 1996, EUR J CANCER, V32A, P512, DOI 10.1016/0959-8049(95)00560-9; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Garnis C, 2006, INT J CANCER, V118, P1556, DOI 10.1002/ijc.21491; Garraway LA, 2006, NAT REV CANCER, V6, P593, DOI 10.1038/nrc1947; Greshock J, 2007, CANCER RES, V67, P3594, DOI 10.1158/0008-5472.CAN-06-3674; Heidenblad M, 2005, ONCOGENE, V24, P1794, DOI 10.1038/sj.onc.1208383; Hellman A, 2002, CANCER CELL, V1, P89, DOI 10.1016/S1535-6108(02)00017-X; Hemstrom TH, 2006, INT J CANCER, V119, P1028, DOI 10.1002/ijc.21927; Henderson LJ, 2005, BRIT J CANCER, V92, P1553, DOI 10.1038/sj.bjc.6602452; Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902; Hyman E, 2002, CANCER RES, V62, P6240; Ishkanian AS, 2004, NAT GENET, V36, P299, DOI 10.1038/ng1307; Khojasteh M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-274; Koizumi F, 2005, INT J CANCER, V116, P36, DOI 10.1002/ijc.20985; Lockwood WW, 2007, INT J CANCER, V120, P436, DOI 10.1002/ijc.22335; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; Myllykangas S, 2006, ONCOGENE, V25, P7324, DOI 10.1038/sj.onc.1209717; Myllykangas S, 2006, CANCER LETT, V232, P79, DOI 10.1016/j.canlet.2005.07.045; Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008; Pierotti MA, 1996, GENE CHROMOSOME CANC, V16, P1; Pollack JR, 2002, P NATL ACAD SCI USA, V99, P12963, DOI 10.1073/pnas.162471999; Roccato E, 2005, CANCER RES, V65, P2572, DOI 10.1158/0008-5472.CAN-04-4294; Squire JA, 2003, GENE CHROMOSOME CANC, V38, P215, DOI 10.1002/gcc.10273; Stenhouse G, 2004, J CLIN PATHOL, V57, P383, DOI 10.1136/jcp.2003.007138; Tanaka H, 2007, CANCER RES, V67, P6007, DOI 10.1158/0008-5472.CAN-06-4774; Tonon G, 2005, P NATL ACAD SCI USA, V102, P9625, DOI 10.1073/pnas.0504126102; WAHL GM, 1984, NATURE, V307, P516, DOI 10.1038/307516a0; Wang PW, 1999, GENOMICS, V59, P275, DOI 10.1006/geno.1999.5884; Watson SK, 2004, BMC GENOMICS, V5, DOI 10.1186/1471-2164-5-6; Watson SK, 2007, HUM GENET, V120, P795, DOI 10.1007/s00439-006-0251-9; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; Zhou BBS, 2006, CANCER CELL, V10, P39, DOI 10.1016/j.ccr.2006.05.024	43	87	89	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2008	27	33					4615	4624		10.1038/onc.2008.98	http://dx.doi.org/10.1038/onc.2008.98			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18391978	Green Accepted			2022-12-25	WOS:000258077300010
J	Zhang, D; Shimizu, T; Araki, N; Hirota, T; Yoshie, M; Ogawa, K; Nakagata, N; Takeya, M; Saya, H				Zhang, D.; Shimizu, T.; Araki, N.; Hirota, T.; Yoshie, M.; Ogawa, K.; Nakagata, N.; Takeya, M.; Saya, H.			Aurora A overexpression induces cellular senescence in mammary gland hyperplastic tumors developed in p53-deficient mice	ONCOGENE			English	Article						Aurora A; polyploidy; apoptosis; senescence; p16; DNA damage	CENTROSOME AMPLIFICATION; DNA-DAMAGE; MAMMALIAN-CELLS; BREAST-CANCER; ONCOGENIC RAS; KINASE; P53; ACTIVATION; CHECKPOINT; ENRICHMENT	Aurora A mitotic kinase is frequently overexpressed in various human cancers and is widely considered to be an oncoprotein. However, the cellular contexts in which Aurora A induces malignancy in vivo are still unclear. We previously reported a mouse model in which overexpression of human Aurora A in the mammary gland leads to small hyperplastic changes but not malignancy because of the induction of p53-dependent apoptosis. To study the additional factors required for Aurora A-associated tumorigenesis, we generated a new Aurora A overexpression mouse model that lacks p53. We present evidence here that Aurora A overexpression in primary mouse embryonic fibroblasts (MEFs) that lack p53 overrides postmitotic checkpoint and leads to the formation of multinucleated polyploid cells. Induction of Aurora A overexpression in the mammary glands of p53-deficient mice resulted in development of precancerous lesions that were histologically similar to atypical ductal hyperplasia in human mammary tissue and showed increased cellular senescence and p16 expression. We further observed DNA damage in p53-deficient primary MEFs after Aurora A overexpression. Our results suggest that Aurora A overexpression in mammary glands is insufficient for the development of malignant tumors in p53-deficient mice because of the induction of cellular senescence. Both p53 and p16 are critical in preventing mammary gland tumorigenesis in the Aurora A overexpression mouse model.	[Zhang, D.; Shimizu, T.; Araki, N.; Saya, H.] Kumamoto Univ, Grad Sch Med Sci, Dept Tumor Genet & Biol, Kumamoto, Japan; [Hirota, T.] Japanese Fdn Canc Res, Inst Canc, Dept Expt Pathol, Tokyo 170, Japan; [Yoshie, M.; Ogawa, K.] Asahikawa Med Coll, Dept Pathol, Asahikawa, Hokkaido 078, Japan; [Nakagata, N.] Kumamoto Univ, Ctr Anim Resources & Dev, Div Reprod Engn, Kumamoto, Japan; [Takeya, M.] Kumamoto Univ, Grad Sch Med Sci, Dept Cell Pathol, Kumamoto, Japan	Kumamoto University; Japanese Foundation for Cancer Research; Asahikawa Medical College; Kumamoto University; Kumamoto University	Saya, H (corresponding author), Keio Univ, Sch Med, Inst Adv Med Res, Div Gene Regulat,Shinjuku Ku, 35 Shinano Machi, Tokyo 1608582, Japan.	hsaya@a5.keio.jp	Saya, Hideyuki/J-4325-2013	Nakagata, Naomi/0000-0002-5737-9993				Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; Andreassen PR, 2001, MOL BIOL CELL, V12, P1315, DOI 10.1091/mbc.12.5.1315; Bischoff JR, 1998, EMBO J, V17, P3052, DOI 10.1093/emboj/17.11.3052; Bringold F, 2000, EXP GERONTOL, V35, P317, DOI 10.1016/S0531-5565(00)00083-8; Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X; Campisi J, 2001, TRENDS CELL BIOL, V11, pS27, DOI 10.1016/S0962-8924(01)02151-1; CHEN Q, 1995, P NATL ACAD SCI USA, V92, P4337, DOI 10.1073/pnas.92.10.4337; Collado M, 2005, NATURE, V436, P642, DOI 10.1038/436642a; Dimri GP, 2000, MOL CELL BIOL, V20, P273, DOI 10.1128/MCB.20.1.273-285.2000; DIMRI GP, 1995, P NATL ACAD SCI USA, V92, P9363, DOI 10.1073/pnas.92.20.9363; Ferbeyre G, 2002, MOL CELL BIOL, V22, P3497, DOI 10.1128/MCB.22.10.3497-3508.2002; Fujiwara T, 2005, NATURE, V437, P1043, DOI 10.1038/nature04217; Fukuda T, 2005, MOL CELL BIOL, V25, P5270, DOI 10.1128/MCB.25.12.5270-5281.2005; Giet R, 2005, TRENDS CELL BIOL, V15, P241, DOI 10.1016/j.tcb.2005.03.004; Goepfert TM, 2002, CANCER RES, V62, P4115; Gritsko TM, 2003, CLIN CANCER RES, V9, P1420; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Helmbold H, 2006, ONCOGENE, V25, P5257, DOI 10.1038/sj.onc.1209613; Hirota T, 2003, CELL, V114, P585, DOI 10.1016/S0092-8674(03)00642-1; Howe HL, 2001, J NATL CANCER I, V93, P824, DOI 10.1093/jnci/93.11.824; Jeng YM, 2004, CLIN CANCER RES, V10, P2065, DOI 10.1158/1078-0432.CCR-1057-03; KALLIONIEMI A, 1994, P NATL ACAD SCI USA, V91, P2156, DOI 10.1073/pnas.91.6.2156; KANEGAE Y, 1995, NUCLEIC ACIDS RES, V23, P3816, DOI 10.1093/nar/23.19.3816; Kunitoku N, 2003, DEV CELL, V5, P853, DOI 10.1016/S1534-5807(03)00364-2; Lee AC, 1999, J BIOL CHEM, V274, P7936, DOI 10.1074/jbc.274.12.7936; Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1; Lundberg AS, 2000, CURR OPIN CELL BIOL, V12, P705, DOI 10.1016/S0955-0674(00)00155-1; Marumoto T, 2005, NAT REV CANCER, V5, P42, DOI 10.1038/nrc1526; Marumoto T, 2003, J BIOL CHEM, V278, P51786, DOI 10.1074/jbc.M306275200; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Narita M, 2003, CELL, V113, P703, DOI 10.1016/S0092-8674(03)00401-X; Nigg EA, 2001, NAT REV MOL CELL BIO, V2, P21, DOI 10.1038/35048096; Robles SJ, 1998, ONCOGENE, V16, P1113, DOI 10.1038/sj.onc.1201862; Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320; Sakakura C, 2001, BRIT J CANCER, V84, P824, DOI 10.1054/bjoc.2000.1684; Sen S, 1997, ONCOGENE, V14, P2195, DOI 10.1038/sj.onc.1201065; Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; SYMONDS H, 1994, CELL, V78, P703, DOI 10.1016/0092-8674(94)90534-7; Tanaka T, 1999, CANCER RES, V59, P2041; te Poele RH, 2002, CANCER RES, V62, P1876; Vafa O, 2002, MOL CELL, V9, P1031, DOI 10.1016/S1097-2765(02)00520-8; Wang X, 2006, ONCOGENE, V25, P7148, DOI 10.1038/sj.onc.1209707; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602; Zhang DW, 2004, ONCOGENE, V23, P8720, DOI 10.1038/sj.onc.1208153; Zhou HY, 1998, NAT GENET, V20, P189, DOI 10.1038/2496; Zhu JY, 1998, GENE DEV, V12, P2997, DOI 10.1101/gad.12.19.2997	47	38	40	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4305	4314		10.1038/onc.2008.76	http://dx.doi.org/10.1038/onc.2008.76			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372918				2022-12-25	WOS:000257691100005
J	Cho, JA; Osenkowski, P; Zhao, HR; Kim, S; Toth, M; Cole, K; Aboukameel, A; Saliganan, A; Schuger, L; Bonfil, RD; Fridman, R				Cho, Jin-Ah; Osenkowski, Pamela; Zhao, Huiren; Kim, Seaho; Toth, Marta; Cole, Kristina; Aboukameel, Amro; Saliganan, Allen; Schuger, Lucia; Bonfil, R. Daniel; Fridman, Rafael			The inactive 44-kDa processed form of membrane type 1 matrix metalloproteinase (MT1-MMP) enhances proteolytic activity via regulation of endocytosis of active MT1-MMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; CELL-SURFACE; 1-MATRIX METALLOPROTEINASE; TISSUE INHIBITOR; I COLLAGEN; GELATINASE-A; PROMMP-2 ACTIVATION; MMP2 ACTIVATION; BINDING; EXPRESSION	Membrane type 1 (MT1) matrix metalloproteinase (MMP-14) is a membrane-tethered MMP considered to be a major mediator of pericellular proteolysis. MT1-MMP is regulated by a complex array of mechanisms, including processing and endocytosis that determine the pool of active proteases on the plasma membrane. Autocatalytic processing of active MT1-MMP generates an inactive membrane-tethered 44-kDa product (44-MT1) lacking the catalytic domain. This form preserves all other enzyme domains and is retained at the cell surface. Paradoxically, accumulation of the 44-kDa form has been associated with increased enzymatic activity. Here we report that expression of a recombinant 44-MT1 (Gly(285)-Val(582)) in HT1080 fibrosarcoma cells results in enhanced pro-MMP-2 activation, proliferation within a three-dimensional collagen I matrix, and tumor growth and lung metastasis in mice. Stimulation of pro-MMP-2 activation and growth in collagen I was also observed in other cell systems. Expression of 44-MT1 in HT1080 cells is associated with a delay in the rate of active MT1-MMP endocytosis resulting in higher levels of active enzyme at the cell surface. Consistently, deletion of the cytosolic domain obliterates the stimulatory effects of 44-MT1 on MT1-MMP activity. In contrast, deletion of the hinge turns the 44-MT1 form into a negative regulator of enzyme function in vitro and in vivo, suggesting a key role for the hinge region in the functional relationship between active and processed MT1-MMP. Together, these results suggest a novel role for the 44-kDa form of MT1-MMP generated during autocatalytic processing in maintaining the pool of active enzyme at the cell surface.	[Cho, Jin-Ah; Osenkowski, Pamela; Zhao, Huiren; Kim, Seaho; Toth, Marta; Cole, Kristina; Aboukameel, Amro; Saliganan, Allen; Schuger, Lucia; Bonfil, R. Daniel; Fridman, Rafael] Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, Detroit, MI 48201 USA; [Cho, Jin-Ah; Osenkowski, Pamela; Zhao, Huiren; Kim, Seaho; Toth, Marta; Cole, Kristina; Aboukameel, Amro; Saliganan, Allen; Schuger, Lucia; Bonfil, R. Daniel; Fridman, Rafael] Wayne State Univ, Barbara Ann Karmanos Canc Inst, Proteases & Canc Program, Detroit, MI 48201 USA	Barbara Ann Karmanos Cancer Institute; Wayne State University; Barbara Ann Karmanos Cancer Institute; Wayne State University	Fridman, R (corresponding author), Wayne State Univ, Sch Med, Dept Pathol, Barbara Ann Karmanos Canc Inst, 540 E Canfield Ave, Detroit, MI 48201 USA.	rfridman@med.wayne.edu		Bonfil, R. Daniel/0000-0002-1605-8317	NCI NIH HHS [P30 CA022453, P30CA22453, NCI-CA61986] Funding Source: Medline; NIEHS NIH HHS [P30ES06639, P30 ES006639] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061986, P30CA022453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006639] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Annabi B, 2001, BIOCHEM J, V353, P547, DOI 10.1042/0264-6021:3530547; Annabi B, 2002, BBA-MOL CELL RES, V1542, P209, DOI 10.1016/S0167-4889(01)00187-2; Annabi B, 2001, BIOCHEM J, V359, P325, DOI 10.1042/0264-6021:3590325; Arroyo AG, 2007, CURR PHARM DESIGN, V13, P1787, DOI 10.2174/138161207780831284; Aznavoorian S, 2001, CANCER RES, V61, P6264; Barbolina MV, 2008, SEMIN CELL DEV BIOL, V19, P24, DOI 10.1016/j.semcdb.2007.06.008; Barbolina MV, 2007, J BIOL CHEM, V282, P4924, DOI 10.1074/jbc.M608428200; Belkaid A, 2007, NEOPLASIA, V9, P332, DOI 10.1593/neo.07142; Budd DC, 1999, J BIOL CHEM, V274, P12355, DOI 10.1074/jbc.274.18.12355; Butler GS, 2007, CURR PHARM DESIGN, V13, P263, DOI 10.2174/138161207779313524; Cowell S, 1998, BIOCHEM J, V331, P453, DOI 10.1042/bj3310453; D'Alessio S, 2008, J BIOL CHEM, V283, P87, DOI 10.1074/jbc.M705492200; Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9; Ellerbroek SM, 1999, CANCER RES, V59, P1635; Ellerbroek SM, 2001, J BIOL CHEM, V276, P24833, DOI 10.1074/jbc.M005631200; Filippov S, 2005, J EXP MED, V202, P663, DOI 10.1084/jem.20050607; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; FUERST TR, 1987, MOL CELL BIOL, V7, P2538, DOI 10.1128/MCB.7.7.2538; Galvez BG, 2002, J CELL BIOL, V159, P509, DOI 10.1083/jcb.200205026; Galvez BG, 2001, J BIOL CHEM, V276, P37491, DOI 10.1074/jbc.M104094200; Genis L, 2006, CANCER METAST REV, V25, P77, DOI 10.1007/s10555-006-7891-z; Gervasi DC, 1996, BIOCHEM BIOPH RES CO, V228, P530, DOI 10.1006/bbrc.1996.1694; Gingras D, 2000, BBA-MOL CELL RES, V1497, P341, DOI 10.1016/S0167-4889(00)00071-9; Golubkov VS, 2005, J BIOL CHEM, V280, P25079, DOI 10.1074/jbc.M502779200; GOTTLIEB TA, 1993, J CELL BIOL, V120, P695, DOI 10.1083/jcb.120.3.695; Guo P, 2005, AM J PATHOL, V166, P877, DOI 10.1016/S0002-9440(10)62308-5; Haseneen NA, 2003, AM J PHYSIOL-LUNG C, V284, pL541, DOI 10.1152/ajplung.00290.2002; Hernandez-Barrantes S, 2000, J BIOL CHEM, V275, P12080, DOI 10.1074/jbc.275.16.12080; Hernandez-Barrantes S, 2002, SEMIN CANCER BIOL, V12, P131, DOI 10.1006/scbi.2001.0421; Holmbeck K, 2004, J CELL PHYSIOL, V200, P11, DOI 10.1002/jcp.20065; Hotary KB, 2003, CELL, V114, P33, DOI 10.1016/S0092-8674(03)00513-0; Hotary K, 2006, GENE DEV, V20, P2673, DOI 10.1101/gad.1451806; Inaki N, 2004, J HEART LUNG TRANSPL, V23, P218, DOI 10.1016/S1053-2498(03)00112-8; Itoh Y, 2004, TRENDS BIOCHEM SCI, V29, P285, DOI 10.1016/j.tibs.2004.04.001; Itoh Y, 2001, EMBO J, V20, P4782, DOI 10.1093/emboj/20.17.4782; Itoh Y, 2006, J CELL PHYSIOL, V206, P1, DOI 10.1002/jcp.20431; Itoh Y, 2006, MOL BIOL CELL, V17, P5390, DOI 10.1091/mbc.e06-08-0740; Kazes I, 2000, BLOOD, V96, P3064, DOI 10.1182/blood.V96.9.3064.h8003064_3064_3069; Konttinen YT, 1998, MATRIX BIOL, V17, P585, DOI 10.1016/S0945-053X(98)90110-X; Koshikawa N, 2000, J CELL BIOL, V148, P615, DOI 10.1083/jcb.148.3.615; Lafleur MA, 2006, J BIOL CHEM, V281, P6826, DOI 10.1074/jbc.M513084200; Lee HJ, 2006, MOL BIOL CELL, V17, P4812, DOI 10.1091/mbc.E06-06-0486; Lehti K, 2000, J BIOL CHEM, V275, P15006, DOI 10.1074/jbc.M910220199; Lehti K, 1998, BIOCHEM J, V334, P345, DOI 10.1042/bj3340345; Lehti K, 2002, J BIOL CHEM, V277, P8440, DOI 10.1074/jbc.M109128200; Li H, 1998, MOL CARCINOGEN, V22, P84; Lohi J, 1996, EUR J BIOCHEM, V239, P239, DOI 10.1111/j.1432-1033.1996.0239u.x; Maquoi E, 2003, BIOCHEM J, V373, P19, DOI 10.1042/BJ20030170; Maquoi E, 1998, FEBS LETT, V424, P262, DOI 10.1016/S0014-5793(98)00187-2; Maquoi E, 2000, EXP CELL RES, V261, P348, DOI 10.1006/excr.2000.5063; Marks MS, 1996, J CELL BIOL, V135, P341, DOI 10.1083/jcb.135.2.341; Munshi HG, 2004, J BIOL CHEM, V279, P39042, DOI 10.1074/jbc.M404958200; Munshi HG, 2002, J BIOL CHEM, V277, P41480, DOI 10.1074/jbc.M207695200; Nagase H, 2006, CARDIOVASC RES, V69, P562, DOI 10.1016/j.cardiores.2005.12.002; Nonaka T, 2005, MOL CANCER THER, V4, P1157, DOI 10.1158/1535-7163.MCT-05-0127; Olson MW, 1997, J BIOL CHEM, V272, P29975, DOI 10.1074/jbc.272.47.29975; Osenkowski P, 2005, J BIOL CHEM, V280, P26160, DOI 10.1074/jbc.M414379200; Osenkowski P, 2004, J CELL PHYSIOL, V200, P2, DOI 10.1002/jcp.20064; Preaux AM, 1999, HEPATOLOGY, V30, P944, DOI 10.1002/hep.510300432; Ratnikov BI, 2002, J BIOL CHEM, V277, P7377, DOI 10.1074/jbc.M109580200; Remacle A, 2003, J CELL SCI, V116, P3905, DOI 10.1242/jcs.00710; Remacle AG, 2006, J BIOL CHEM, V281, P16897, DOI 10.1074/jbc.M600295200; Rozanov DV, 2004, J BIOL CHEM, V279, P4260, DOI 10.1074/jbc.M311569200; Sato H, 2005, CANCER SCI, V96, P212, DOI 10.1111/j.1349-7006.2005.00039.x; Savinov AY, 2007, IUBMB LIFE, V59, P6, DOI 10.1080/15216540601187795; Savinov AY, 2006, FASEB J, V20, P1793, DOI 10.1096/fj.06-6207com; Seiki M, 2003, CANCER LETT, V194, P1, DOI 10.1016/S0304-3835(02)00699-7; Stanton H, 1998, J CELL SCI, V111, P2789; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; Tam EM, 2004, P NATL ACAD SCI USA, V101, P6917, DOI 10.1073/pnas.0305862101; Tam EM, 2002, J BIOL CHEM, V277, P39005, DOI 10.1074/jbc.M206874200; Theret N, 1999, HEPATOLOGY, V30, P462, DOI 10.1002/hep.510300236; Toth M, 2002, J BIOL CHEM, V277, P26340, DOI 10.1074/jbc.M200655200; Toth M, 2000, J BIOL CHEM, V275, P41415, DOI 10.1074/jbc.M006871200; Toth M, 1997, CANCER RES, V57, P3159; Wang X, 2004, J BIOL CHEM, V279, P9331, DOI 10.1074/jbc.M312369200; Warren RA, 1997, J BIOL CHEM, V272, P2116; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; Wu XY, 2005, DEV CELL, V9, P185, DOI 10.1016/j.devcel.2005.06.006; Wu YI, 2004, J BIOL CHEM, V279, P8278, DOI 10.1074/jbc.M311870200; Zhuge Y, 2001, J BIOL CHEM, V276, P16248, DOI 10.1074/jbc.M010190200; Zijlstra A, 2002, CANCER RES, V62, P7083; Zucker S, 2004, EXP CELL RES, V293, P164, DOI 10.1016/j.yexcr.2003.10.007; Zucker S, 2003, CURR TOP DEV BIOL, V54, P1, DOI 10.1016/S0070-2153(03)54004-2; Zucker S, 2002, LAB INVEST, V82, P1673, DOI 10.1097/01.LAB.0000041713.74852.2A	85	25	26	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17391	17405		10.1074/jbc.M708943200	http://dx.doi.org/10.1074/jbc.M708943200			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18413312	Green Published, hybrid			2022-12-25	WOS:000256720600048
J	Debler, EW; Muller, R; Hilvert, D; Wilson, IA				Debler, Erik W.; Mueller, Roger; Hilvert, Donald; Wilson, Ian A.			Conformational isomerism can limit antibody catalysis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYSICAL ORGANIC-CHEMISTRY; CRYSTAL-STRUCTURE; ENZYME CATALYSIS; STRUCTURAL BASIS; BENZISOXAZOLES; EVOLUTION; BINDING; TRANSITION; DIVERSITY; DYNAMICS	Ligand binding to enzymes and antibodies is often accompanied by protein conformational changes. Although such structural adjustments may be conducive to enzyme catalysis, much less is known about their effect on reactions promoted by engineered catalytic antibodies. Crystallographic and pre-steady state kinetic analyses of antibody 34E4, which efficiently promotes the conversion of benzisoxazoles to salicylonitriles, show that the resting catalyst adopts two interconverting active-site conformations, only one of which is competent to bind substrate. In the predominant isomer, the indole side chain of Trp(L91) occupies the binding site and blocks ligand access. Slow conformational isomerization of this residue, on the same time scale as catalytic turnover, creates a deep and narrow binding site that can accommodate substrate and promote proton transfer using Glu(H50) as a carboxylate base. Although 34E4 is among the best catalysts for the deprotonation of benzisoxazoles, its efficiency appears to be significantly limited by this conformational plasticity of its active site. Future efforts to improve this antibody might profitably focus on stabilizing the active conformation of the catalyst. Analogous strategies may also be relevant to other engineered proteins that are limited by an unfavorable conformational pre-equilibrium.	[Mueller, Roger; Hilvert, Donald] ETH, Organ Chem Lab, CH-8093 Zurich, Switzerland; [Debler, Erik W.; Wilson, Ian A.] Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; [Debler, Erik W.; Wilson, Ian A.] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	ETH Zurich; Scripps Research Institute; Scripps Research Institute	Hilvert, D (corresponding author), ETH, Organ Chem Lab, Honggerberg HCI F339, CH-8093 Zurich, Switzerland.	hilvert@org.chem.ethz.ch; wilson@scripps.edu	Debler, Erik/D-1794-2013	Debler, Erik/0000-0002-2587-2150	NIGMS NIH HHS [R01 GM038273, GM38273] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038273, R01GM038273] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AlLazikani B, 1997, J MOL BIOL, V273, P927, DOI 10.1006/jmbi.1997.1354; Berman HM, 2000, NUCLEIC ACIDS RES, V28, P235, DOI 10.1093/nar/28.1.235; Boehr DD, 2006, CHEM REV, V106, P3055, DOI 10.1021/cr050312q; CASEY ML, 1973, J ORG CHEM, V38, P2294, DOI 10.1021/jo00953a006; CHARBONNIER JB, 1995, P NATL ACAD SCI USA, V92, P11721, DOI 10.1073/pnas.92.25.11721; Debler EW, 2005, P NATL ACAD SCI USA, V102, P4984, DOI 10.1073/pnas.0409207102; Fersht A., 1998, STRUCTURE MECH PROTE, P147; FOOTE J, 1994, P NATL ACAD SCI USA, V91, P10370, DOI 10.1073/pnas.91.22.10370; GOLINELLIPIMPANEAU B, 1994, STRUCTURE, V2, P175, DOI 10.1016/S0969-2126(00)00019-8; Gruber K, 1999, BIOCHEMISTRY-US, V38, P7062, DOI 10.1021/bi990210s; Hammes GG, 2002, BIOCHEMISTRY-US, V41, P8221, DOI 10.1021/bi0260839; Hammes-Schiffer S, 2006, ANNU REV BIOCHEM, V75, P519, DOI 10.1146/annurev.biochem.75.103004.142800; Hilvert D, 2000, ANNU REV BIOCHEM, V69, P751, DOI 10.1146/annurev.biochem.69.1.751; Hu YF, 2004, J AM CHEM SOC, V126, P8197, DOI 10.1021/ja0490727; James LC, 2005, P NATL ACAD SCI USA, V102, P12730, DOI 10.1073/pnas.0500909102; James LC, 2003, SCIENCE, V299, P1362, DOI 10.1126/science.1079731; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPLUS M, 1984, ADV BIOPHYS, V18, P165, DOI 10.1016/0065-227X(84)90011-X; KEMP DS, 1975, J AM CHEM SOC, V97, P7312, DOI 10.1021/ja00858a018; KEMP DS, 1973, J AM CHEM SOC, V95, P6670, DOI 10.1021/ja00801a024; LANCET D, 1976, P NATL ACAD SCI USA, V73, P3549, DOI 10.1073/pnas.73.10.3549; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lindner AB, 1999, J MOL BIOL, V285, P421, DOI 10.1006/jmbi.1998.2309; Lovell SC, 2000, PROTEINS, V40, P389, DOI 10.1002/1097-0134(20000815)40:3<389::AID-PROT50>3.0.CO;2-2; Lovell SC, 2003, PROTEINS, V50, P437, DOI 10.1002/prot.10286; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Olsson MHM, 2006, CHEM REV, V106, P1737, DOI 10.1021/cr040427e; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Padlan EA, 1996, ADV PROTEIN CHEM, V49, P57, DOI 10.1016/S0065-3233(08)60488-X; PADLAN EA, 1994, MOL IMMUNOL, V31, P169, DOI 10.1016/0161-5890(94)90001-9; SCHULTZ PG, 1995, SCIENCE, V269, P1835, DOI 10.1126/science.7569920; Seebeck FP, 2005, J AM CHEM SOC, V127, P1307, DOI 10.1021/ja044647l; STEWART JD, 1995, NATURE, V375, P388, DOI 10.1038/375388a0; Storoni LC, 2004, ACTA CRYSTALLOGR D, V60, P432, DOI 10.1107/S0907444903028956; Sundberg EJ, 2003, ADV PROTEIN CHEM, V61, P119; TAIRA K, 1988, J MED CHEM, V31, P129, DOI 10.1021/jm00396a019; THORN SN, 1995, NATURE, V373, P228, DOI 10.1038/373228a0; Ulrich HD, 1997, NATURE, V389, P271, DOI 10.1038/38470; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; Wedemayer GJ, 1997, J MOL BIOL, V268, P390, DOI 10.1006/jmbi.1997.0974; Wedemayer GJ, 1997, SCIENCE, V276, P1665, DOI 10.1126/science.276.5319.1665; WILSON IA, 1994, CURR OPIN STRUC BIOL, V4, P857, DOI 10.1016/0959-440X(94)90267-4; Yin J, 2003, J MOL BIOL, V330, P651, DOI 10.1016/S0022-2836(03)00631-4; Zhu XY, 2006, STRUCTURE, V14, P205, DOI 10.1016/j.str.2005.10.014; Zhu XY, 2003, J MOL BIOL, V329, P69, DOI 10.1016/S0022-2836(03)00406-6; Zimmermann J, 2006, P NATL ACAD SCI USA, V103, P13722, DOI 10.1073/pnas.0603282103	46	10	10	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16554	16560		10.1074/jbc.M710256200	http://dx.doi.org/10.1074/jbc.M710256200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18417480	Green Published, hybrid			2022-12-25	WOS:000256497100032
J	Williams, G; Wood, A; Williams, EJ; Gao, Y; Mercado, ML; Katz, A; Joseph-McCarthy, D; Bates, B; Ling, HP; Aulabaugh, A; Zaccardi, J; Xie, YH; Pangalos, MN; Walsh, FS; Doherty, P				Williams, Gareth; Wood, Andrew; Williams, Emma-Jane; Gao, Ying; Mercado, Mary L.; Katz, Alan; Joseph-McCarthy, Diane; Bates, Brian; Ling, Huai-Ping; Aulabaugh, Ann; Zaccardi, Joe; Xie, Yuhong; Pangalos, Menelas N.; Walsh, Frank S.; Doherty, Patrick			Ganglioside inhibition of neurite outgrowth requires Nogo receptor function - Identification of interaction sites and development of novel antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYELIN-ASSOCIATED GLYCOPROTEIN; AXON REGENERATION; NEURONS; BINDING; LIGAND; MAG; ASSOCIATION; SPECIFICITY; ANTIBODIES; P75(NTR)	Gangliosides are key players in neuronal inhibition, with antibody-mediated clustering of gangliosides blocking neurite outgrowth in cultures and axonal regeneration post injury. In this study we show that the ganglioside GT1b can form a complex with the Nogo-66 receptor NgR1. The interaction is shown by analytical ultracentrifugation sedimentation and is mediated by the sialic acid moiety on GT1b, with mutations in FRG motifs on NgR1 attenuating the interaction. One FRG motif was developed into a cyclic peptide (N-Ac (CLQKFRGSSC) under bar -NH2) antagonist of GT1b, reversing the GT1b antibody inhibition of cerebellar granule cell neurite outgrowth. Interestingly, the peptide also antagonizes neurite outgrowth inhibition mediated by soluble forms of the myelin-associated glycoprotein (MAG). Structure function analysis of the peptide point to the conserved FRG triplet being the minimal functional motif, and mutations within this motif inhibit NgR1 binding to both GT1b and MAG. Finally, using gene ablation, we show that the cerebellar neuron response to GT1b antibodies and soluble MAG is indeed dependent on NgR1 function. The results suggest that gangliosides inhibit neurite outgrowth by interacting with FRG motifs in the NgR1 and that this interaction can also facilitate the binding of MAG to the NgR1. Furthermore, the results point to a rational strategy for developing novel ganglioside antagonists.	[Williams, Gareth; Williams, Emma-Jane; Doherty, Patrick] Kings Coll London, Wolfson Ctr Age Related Dis, London SE1 1UL, England; [Wood, Andrew; Gao, Ying; Mercado, Mary L.; Katz, Alan; Joseph-McCarthy, Diane; Bates, Brian; Ling, Huai-Ping; Aulabaugh, Ann; Zaccardi, Joe; Xie, Yuhong; Pangalos, Menelas N.; Walsh, Frank S.] Wyeth Ayerst Res, Neurosci Discovery, Princeton, NJ 08543 USA	University of London; King's College London; Pfizer	Doherty, P (corresponding author), Kings Coll London, Wolfson Ctr Age Related Dis, Wolfson Wing Hodgkin Bldg, London SE1 1UL, England.	patrick.doherty@kcl.ac.uk	Doherty, Patrick/A-8752-2008; Williams, Gareth/B-3202-2010	Williams, Gareth/0000-0001-9205-4943; Doherty, Patrick/0000-0002-0407-5689				Barton WA, 2003, EMBO J, V22, P3291, DOI 10.1093/emboj/cdg325; Chaudhry N, 2007, J CEREBR BLOOD F MET, V27, P1096, DOI 10.1038/sj.jcbfm.9600407; Chivatakarn O, 2007, J NEUROSCI, V27, P7117, DOI 10.1523/JNEUROSCI.1541-07.2007; Collins BE, 1997, J BIOL CHEM, V272, P1248, DOI 10.1074/jbc.272.2.1248; DeBellard ME, 1996, MOL CELL NEUROSCI, V7, P89, DOI 10.1006/mcne.1996.0007; DOHERTY P, 1995, NEURON, V14, P57, DOI 10.1016/0896-6273(95)90240-6; DOHERTY P, 1993, J CELL BIOL, V122, P181, DOI 10.1083/jcb.122.1.181; Domeniconi M, 2002, NEURON, V35, P283, DOI 10.1016/S0896-6273(02)00770-5; FORMISANO S, 1979, BIOCHEMISTRY-US, V18, P1119, DOI 10.1021/bi00573a028; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Fujitani M, 2005, J NEUROCHEM, V94, P15, DOI 10.1111/j.1471-4159.2005.03121.x; He XLL, 2003, NEURON, V38, P177, DOI 10.1016/S0896-6273(03)00232-0; Hruby VJ, 2002, NAT REV DRUG DISCOV, V1, P847, DOI 10.1038/nrd939; Kim JE, 2004, NEURON, V44, P439, DOI 10.1016/j.neuron.2004.10.015; Laue T.M., 1992, ANAL ULTRACENTRIFUGA, P90; Lauren J, 2007, J BIOL CHEM, V282, P5715, DOI 10.1074/jbc.M609797200; Lehmann HC, 2007, J NEUROSCI, V27, P27, DOI 10.1523/JNEUROSCI.4017-06.2007; Liu BP, 2002, SCIENCE, V297, P1190, DOI 10.1126/science.1073031; MCKERRACHER L, 1994, NEURON, V13, P805, DOI 10.1016/0896-6273(94)90247-X; Mehta NR, 2007, J BIOL CHEM, V282, P27875, DOI 10.1074/jbc.M704055200; Meiri KF, 1998, J NEUROSCI, V18, P10429; Mi S, 2004, NAT NEUROSCI, V7, P221, DOI 10.1038/nn1188; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; O'Gorman S, 1997, P NATL ACAD SCI USA, V94, P14602, DOI 10.1073/pnas.94.26.14602; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Tang S, 1997, MOL CELL NEUROSCI, V9, P333, DOI 10.1006/mcne.1997.0633; Tang S, 1997, J CELL BIOL, V138, P1355, DOI 10.1083/jcb.138.6.1355; Venkatesh K, 2005, J NEUROSCI, V25, P808, DOI 10.1523/JNEUROSCI.4464-04.2005; Vinson M, 2001, J BIOL CHEM, V276, P20280, DOI 10.1074/jbc.M100345200; Vyas AA, 2002, P NATL ACAD SCI USA, V99, P8412, DOI 10.1073/pnas.072211699; WALSH FS, 1991, J NEUROIMMUNOL, V34, P43, DOI 10.1016/0165-5728(91)90097-Q; Wang B, 1998, COMP BIOCHEM PHYS A, V119, P435, DOI 10.1016/S1095-6433(97)00445-5; Wang KC, 2002, NATURE, V420, P74, DOI 10.1038/nature01176; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Williams E, 2000, J BIOL CHEM, V275, P4007, DOI 10.1074/jbc.275.6.4007; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; Williams EJ, 2001, J BIOL CHEM, V276, P43879, DOI 10.1074/jbc.M105876200; Williams G, 2005, J BIOL CHEM, V280, P5862, DOI 10.1074/jbc.M411121200; Willison HJ, 2002, BRAIN, V125, P2591, DOI 10.1093/brain/awf272; Wong ST, 2002, NAT NEUROSCI, V5, P1302, DOI 10.1038/nn975; Yamashita T, 2002, J CELL BIOL, V157, P565, DOI 10.1083/jcb.200202010	41	34	43	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16641	16652		10.1074/jbc.M802067200	http://dx.doi.org/10.1074/jbc.M802067200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18411262	hybrid			2022-12-25	WOS:000256497100041
J	Bertolesi, GE; Michaiel, G; McFarlane, S				Bertolesi, Gabriel E.; Michaiel, George; McFarlane, Sarah			Two heparanase splicing variants with distinct properties are necessary in early Xenopus development	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST-GROWTH-FACTOR; DIFFERENTIAL STRUCTURAL REQUIREMENTS; MAMMALIAN HEPARANASE; SULFATE PROTEOGLYCANS; ENDOGLYCOSIDASE HEPARANASE; ENZYMATIC-ACTIVITY; ENDOTHELIAL-CELLS; BASEMENT-MEMBRANE; GENE CLONING; EXPRESSION	Heparanase is an endoglycosidase that cleaves heparan sulfate (HS) side chains from heparan sulfate proteoglycans (HSPGs) present in extracellular matrix and cell membranes. Although HSPGs have many functions during development, little is known of the role of the enzyme that degrades HS, heparanase. We cloned and characterized the expression of two heparanase splicing variants from Xenopus laevis and studied their function in early embryonic development. The heparanase gene (termed xHpa) spans over 15 kb and consists of at least 12 exons. The long heparanase (XHpaL) cDNA encodes a 531-amino acid protein, whereas the short splicing variant (XHpaS) results in a protein with the same open reading frame but missing 58 amino acids as a consequence of a skipped exon 4. Comparative studies of both isoforms using heterologous expression systems showed: 1) XHpaL is enzymatically active, whereas XHpaS is not; 2) XHpaL and XHpaS interact with heparin and HS; 3) both proteins traffic through the endoplasmic reticulum and Golgi apparatus, but XHpaL is secreted into the medium, whereas XHpaS remains associated with the membrane as a consequence of the loss of three glycosylation sites; 4) overexpression of XHpaS but not XHpaL increases cell adhesion of glioma cells to HS-coated surfaces; 5) XHpaL and XHpaS mRNA and protein levels vary as development progresses; 6) specific antisense knock-down of both XHpaL and XHpaS, but not XHpaL alone, results in failure of embryogenesis to proceed. Interestingly, rescue experiments suggest that the two heparanases regulate the same developmental processes, but via different mechanisms.	[Bertolesi, Gabriel E.; Michaiel, George; McFarlane, Sarah] Univ Calgary, Hotchkiss Brain Inst, Dept Cell Biol & Anat, Calgary, AB T2N 4N1, Canada	University of Calgary	McFarlane, S (corresponding author), 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	smcfarla@ucalgary.ca	Bertolesi, Gabriel/S-7058-2019	Michaiel, George/0000-0002-7817-9085				Abboud-Jarrous G, 2005, J BIOL CHEM, V280, P13568, DOI 10.1074/jbc.M413370200; Allen BL, 2003, J CELL BIOL, V163, P637, DOI 10.1083/jcb.200307053; AVIEZER D, 1994, J BIOL CHEM, V269, P114; BARTLETT MR, 1995, IMMUNOL CELL BIOL, V73, P113, DOI 10.1038/icb.1995.19; Bellaiche Y, 1998, NATURE, V394, P85, DOI 10.1038/27932; Ben-Zaken O, 2007, BIOCHEM BIOPH RES CO, V361, P829, DOI 10.1016/j.bbrc.2007.06.188; Binari RC, 1997, DEVELOPMENT, V124, P2623; Casu B, 2001, ADV CARBOHYD CHEM BI, V57, P159, DOI 10.1016/S0065-2318(01)57017-1; Dong J, 2000, GENE, V253, P171, DOI 10.1016/S0378-1119(00)00251-1; Galli A, 2003, DEVELOPMENT, V130, P4919, DOI 10.1242/dev.00706; GILAT D, 1995, J EXP MED, V181, P1929, DOI 10.1084/jem.181.5.1929; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; Goldschmidt O, 2003, FASEB J, V17, P1015, DOI 10.1096/fj.02-0773com; Goldshmidt O, 2004, J PATHOL, V203, P594, DOI 10.1002/path.1554; Goldshmidt O, 2002, P NATL ACAD SCI USA, V99, P10031, DOI 10.1073/pnas.152070599; Goldshmidt O, 2002, EXP CELL RES, V281, P50, DOI 10.1006/excr.2002.5651; Goldshmidt O, 2001, J BIOL CHEM, V276, P29178, DOI 10.1074/jbc.M102462200; Hacker U, 2005, NAT REV MOL CELL BIO, V6, P530, DOI 10.1038/nrm1681; Hulett MD, 2000, BIOCHEMISTRY-US, V39, P15659, DOI 10.1021/bi002080p; Hulett MD, 1999, NAT MED, V5, P803, DOI 10.1038/10525; Johnson KG, 2004, CURR BIOL, V14, P499, DOI 10.1016/j.cub.2004.02.005; Kizaki K, 2003, PLACENTA, V24, P424, DOI 10.1053/plac.2002.0909; Kreuger J, 2006, J CELL BIOL, V174, P323, DOI 10.1083/jcb.200604035; Lennox KA, 2006, OLIGONUCLEOTIDES, V16, P26, DOI 10.1089/oli.2006.16.26; Levy-Adam F, 2005, J BIOL CHEM, V280, P20457, DOI 10.1074/jbc.M414546200; Levy-Adam F, 2003, BIOCHEM BIOPH RES CO, V308, P885, DOI 10.1016/S0006-291X(03)01478-5; Lindahl U, 1998, J BIOL CHEM, V273, P24979, DOI 10.1074/jbc.273.39.24979; McKenzie E, 2003, BIOCHEM J, V373, P423, DOI 10.1042/BJ20030318; Miao HQ, 2002, PROTEIN EXPRES PURIF, V26, P425, DOI 10.1016/S1046-5928(02)00558-2; MOSCATELLI D, 1987, J CELL PHYSIOL, V131, P123, DOI 10.1002/jcp.1041310118; Nadav L, 2002, J CELL SCI, V115, P2179; Nasser NJ, 2007, BIOCHEM BIOPH RES CO, V354, P33, DOI 10.1016/j.bbrc.2006.12.189; Nasser NJ, 2005, P NATL ACAD SCI USA, V102, P15161, DOI 10.1073/pnas.0507279102; Ohkawara B, 2003, DEVELOPMENT, V130, P2129, DOI 10.1242/dev.00435; Parish CR, 1998, IMMUNOL CELL BIOL, V76, P104, DOI 10.1046/j.1440-1711.1998.00722.x; Rapraeger AC, 2001, SEMIN CELL DEV BIOL, V12, P107, DOI 10.1006/scdb.2000.0239; Revel A, 2005, FERTIL STERIL, V83, P580, DOI 10.1016/j.fertnstert.2004.11.008; Rozenberg GF, 2001, ELECTROPHORESIS, V22, P3, DOI 10.1002/1522-2683(200101)22:1<3::AID-ELPS3>3.0.CO;2-G; Shteper PJ, 2003, ONCOGENE, V22, P7737, DOI 10.1038/sj.onc.1207056; Simizu S, 2004, J BIOL CHEM, V279, P2697, DOI 10.1074/jbc.M300541200; Sindelka R, 2006, DEV DYNAM, V235, P754, DOI 10.1002/dvdy.20665; Sotnikov I, 2004, J IMMUNOL, V172, P5185, DOI 10.4049/jimmunol.172.9.5185; Toyoshima M, 1999, J BIOL CHEM, V274, P24153, DOI 10.1074/jbc.274.34.24153; Vlodavsky I, 2002, SEMIN CANCER BIOL, V12, P121, DOI 10.1006/scbi.2001.0420; Vlodavsky I, 1999, NAT MED, V5, P793, DOI 10.1038/10518; VLODAVSKY I, 1991, TRENDS BIOCHEM SCI, V16, P268, DOI 10.1016/0968-0004(91)90102-2; Vreys V, 2007, J CELL MOL MED, V11, P427, DOI 10.1111/j.1582-4934.2007.00039.x; Walz A, 1997, DEVELOPMENT, V124, P2421; Xu XL, 2007, J BIOL CHEM, V282, P2363, DOI 10.1074/jbc.M604218200; Yamane Y, 1998, J BIOL CHEM, V273, P7375, DOI 10.1074/jbc.273.13.7375; Zcharia E, 2005, FASEB J, V19, P211, DOI 10.1096/fj.04-1970com; Zcharia E, 2005, AM J PATHOL, V166, P999, DOI 10.1016/S0002-9440(10)62321-8; Zetser A, 2003, CANCER RES, V63, P7733	54	11	11	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16004	16016		10.1074/jbc.M708525200	http://dx.doi.org/10.1074/jbc.M708525200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18397881	Green Published, hybrid			2022-12-25	WOS:000256332500059
J	Thomas, SN; Zhu, F; Schnaar, RL; Alves, CS; Konstantopoulos, K				Thomas, Susan N.; Zhu, Fei; Schnaar, Ronald L.; Alves, Christina S.; Konstantopoulos, Konstantinos			Carcinoembryonic antigen and CD44 variant isoforms cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin in shear flow	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P-SELECTIN; COLORECTAL-CARCINOMA; TUMOR-METASTASIS; GLYCOPROTEIN LIGANDS; SIALYL LEWIS(A); CANCER CELLS; LUNG-CANCER; EXPRESSION; PLATELETS; ENDOTHELIUM	Selectin-mediated adhesion of tumor cells to platelets, leukocytes, and endothelial cells may regulate their hematogenous dissemination in the microvasculature. We recently identified CD44 variant isoforms (CD44v) as functional P-, but not E- or L-, selectin ligands on colon carcinoma cells. Moreover, an similar to 180-kDa sialofucosylated glycoprotein(s) mediated selectin binding in CD44-knockdown cells. Using immunoaffinity chromatography and tandem mass spectrometry, we identify this glycoprotein as the carcinoembryonic antigen (CEA). Blot rolling assays and flow-based adhesion assays using microbeads coated with CEA immunopurified from LS174T colon carcinoma cells and selectins as substrate reveal that CEA possesses E- and L-, but not P-, selectin ligand activity. CEA on CD44-knockdown LS174T cells exhibits higher HECA-452 immunoreactivity than CEA on wild-type cells, suggesting that CEA functions as an alternative acceptor for selectin-binding glycans. The enhanced expression of HECA-452 reactive epitopes on CEA from CD44-knockdown cells correlates with the increased CEA avidity for E- but not L-selectin. Through the generation of stable knockdown cell lines, we demonstrate that CEA serves as an auxiliary L-selectin ligand, which stabilizes L-selectin-dependent cell rolling against fluid shear. Moreover, CEA and CD44v cooperate to mediate colon carcinoma cell adhesion to E- and L-selectin at elevated shear stresses. The novel finding that CEA is an E- and L-selectin ligand may explain the enhanced metastatic potential associated with tumor cell CEA overexpression and the supportive role of selectins in metastasis.	[Thomas, Susan N.; Zhu, Fei; Alves, Christina S.; Konstantopoulos, Konstantinos] Johns Hopkins Univ, Dept Chem & Biomol Engn, Baltimore, MD 21218 USA; [Schnaar, Ronald L.] Johns Hopkins Univ, Dept Pharmacol & Neurosci, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University	Konstantopoulos, K (corresponding author), Johns Hopkins Univ, Dept Chem & Biomol Engn, 3400 N Charles St, Baltimore, MD 21218 USA.	kkonsta1@jhu.edu	Thomas, Susan/A-9947-2009; Thomas, Susan/B-4592-2016; Schnaar, Ronald L/S-8967-2016; Konstantopoulos, Konstantinos/A-7045-2011	Thomas, Susan/0000-0003-4651-232X; Schnaar, Ronald L/0000-0002-7701-5484; 	NATIONAL CANCER INSTITUTE [R01CA101135] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA101135] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ANOSTARIO M, 1994, ANAL BIOCHEM, V221, P317, DOI 10.1006/abio.1994.1419; Biancone L, 1996, J EXP MED, V183, P581, DOI 10.1084/jem.183.2.581; Blumenthal RD, 2005, CANCER RES, V65, P8809, DOI 10.1158/0008-5472.CAN-05-0420; Borsig L, 2004, NEWS PHYSIOL SCI, V19, P16, DOI 10.1152/nips.01450.2003; Borsig L, 2002, P NATL ACAD SCI USA, V99, P2193, DOI 10.1073/pnas.261704098; Borsig L, 2001, P NATL ACAD SCI USA, V98, P3352, DOI 10.1073/pnas.061615598; Burdick MM, 2004, AM J PHYSIOL-CELL PH, V287, pC539, DOI 10.1152/ajpcell.00450.2003; Burdick MM, 2003, AM J PHYSIOL-CELL PH, V284, pC977, DOI 10.1152/ajpcell.00423.2002; Burdick MM, 2001, BIOCHEM BIOPH RES CO, V284, P42, DOI 10.1006/bbrc.2001.4899; Hammarstrom S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119; Hanley WD, 2005, CANCER RES, V65, P5812, DOI 10.1158/0008-5472.CAN-04-4557; Hanley WD, 2006, FASEB J, V20, P337, DOI 10.1096/fj.05-4574fje; HASHINO J, 1994, CLIN EXP METASTAS, V12, P324, DOI 10.1007/BF01753839; Jadhav S, 2002, AM J PHYSIOL-CELL PH, V283, pC1133, DOI 10.1152/ajpcell.00104.2002; Jadhav S, 2001, J IMMUNOL, V167, P5986, DOI 10.4049/jimmunol.167.10.5986; Kannagi R, 2004, CANCER SCI, V95, P377, DOI 10.1111/j.1349-7006.2004.tb03219.x; Kaytes PS, 1998, BIOCHEMISTRY-US, V37, P10514, DOI 10.1021/bi9730846; Kim JC, 1999, INT J CANCER, V82, P880, DOI 10.1002/(SICI)1097-0215(19990909)82:6<880::AID-IJC18>3.0.CO;2-S; Kim YJ, 1999, AM J PATHOL, V155, P461, DOI 10.1016/S0002-9440(10)65142-5; Kim YJ, 1998, P NATL ACAD SCI USA, V95, P9325, DOI 10.1073/pnas.95.16.9325; KUIJPERS TW, 1992, J CELL BIOL, V118, P457, DOI 10.1083/jcb.118.2.457; Laubli H, 2006, CANCER RES, V66, P1536, DOI 10.1158/0008-5472.CAN-05-3121; Li L, 2001, BIOCHEM BIOPH RES CO, V288, P637, DOI 10.1006/bbrc.2001.5806; MANNORI G, 1995, CANCER RES, V55, P4425; Mannori G, 1997, AM J PATHOL, V151, P233; McCarty OJT, 2000, BLOOD, V96, P1789, DOI 10.1182/blood.V96.5.1789.h8001789_1789_1797; McCarty OJT, 2002, BIOPHYS J, V83, P836, DOI 10.1016/S0006-3495(02)75212-0; Minami S, 2001, CANCER RES, V61, P2732; NAKAMORI S, 1993, CANCER RES, V53, P3632; NAKAYAMA T, 1995, CANCER, V75, P2051, DOI 10.1002/1097-0142(19950415)75:8<2051::AID-CNCR2820750804>3.0.CO;2-4; Napier SL, 2007, J BIOL CHEM, V282, P3433, DOI 10.1074/jbc.M607219200; Sato M, 1997, ANTICANCER RES, V17, P3505; Somers WS, 2000, CELL, V103, P467, DOI 10.1016/S0092-8674(00)00138-0; STONE JP, 1993, J CLIN INVEST, V92, P804, DOI 10.1172/JCI116654; TIBBETTS LM, 1993, CANCER, V71, P315, DOI 10.1002/1097-0142(19930115)71:2<315::AID-CNCR2820710208>3.0.CO;2-B; VARKI A, 1997, J CLIN INVEST, V100, P31	36	130	134	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15647	15655		10.1074/jbc.M800543200	http://dx.doi.org/10.1074/jbc.M800543200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18375392	hybrid, Green Published			2022-12-25	WOS:000256332500018
J	Janssen, T; Husson, SJ; Lindemans, M; Mertens, I; Rademakers, S; Donck, KV; Geysen, J; Jansen, G; Schoofs, L				Janssen, Tom; Husson, Steven J.; Lindemans, Marleen; Mertens, Inge; Rademakers, Suzanne; Donck, Kris Ver; Geysen, Johan; Jansen, Gert; Schoofs, Liliane			Functional characterization of three G protein-coupled receptors for pigment dispersing factors in Caenorhabditis elegans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPEPTIDE; DROSOPHILA; PDF; CLOCK; SENSITIVITY; ACTIVATION; VARIANTS; RHYTHMS	Here, we report the identification, cloning, and functional characterization of three Caenorhabditis elegans G protein-coupled pigment dispersing factor (PDF) receptors, which we designated as Ce_PDFR-1a, -b, and -c. They represent three splice isoforms of the same gene (C13B9.4), which share a high degree of similarity with the Drosophila PDF receptor and are distantly related to the mammalian vasoactive intestinal peptide receptors (VPAC2) and calcitonin receptors. In a reverse pharmacological screen, three bioactive C elegans neuropeptides, which were recently identified as the Drosophila PDF orthologues, were able to activate these receptors in a dose-dependent manner with nanomolar potency (isoforms a and b). Integrated green fluorescent protein reporter constructs reveal the expression of these PDF receptors in all body wall muscle cells and many head and tail neurons involved in the integration of environmental stimuli and the control of locomotion. Using a custom data analysis system, we demonstrate the involvement of this newly discovered neuropeptide signaling system in the regulation of locomotor behavior. Overexpression of PDF-2 phenocopies the locomotor defects of a PDF-1 null mutant, suggesting that they elicit opposite effects on locomotion through the identified PDF receptors. Our findings strengthen the hypothesis that the PDF signaling system, which imposes the circadian clock rhythm on behavior in Drosophila, has been functionally conserved throughout the protostomian evolutionary lineage.	[Janssen, Tom; Husson, Steven J.; Lindemans, Marleen; Mertens, Inge; Schoofs, Liliane] Katholieke Univ Leuven, Dept Biol, Funct Genom & Proteom Unit, B-3000 Louvain, Belgium; [Rademakers, Suzanne; Jansen, Gert] Erasmus MC, Ctr Biomed Genet, MGC Dept Cell Biol & Genet, NL-3000 DR Rotterdam, Netherlands; [Donck, Kris Ver; Geysen, Johan] Maia Scientif, B-2440 Geel, Belgium	KU Leuven; Erasmus University Rotterdam; Erasmus MC	Janssen, T (corresponding author), Katholieke Univ Leuven, Dept Biol, Funct Genom & Proteom Unit, B-3000 Louvain, Belgium.	Tom_Janssen@bio.kuleuven.be	Janssen, Tom/AAC-1849-2020; schoofs, liliane/ABD-2943-2020; Mertens, Inge/N-9787-2018; Jansen, Gert/HCI-8852-2022; Schoofs, Liliane/F-2815-2010	Mertens, Inge/0000-0002-4888-3485; Jansen, Gert/0000-0002-7524-171X; Schoofs, Liliane/0000-0002-1673-432X				BROWN ED, 1994, J HELMINTHOL, V68, P105, DOI 10.1017/S0022149X00013602; CHALFIE M, 1985, J NEUROSCI, V5, P956; Conner AC, 2004, BIOCHEM SOC T, V32, P843, DOI 10.1042/BST0320843; Geusebroek JM, 2001, INT J COMPUT VISION, V43, P99, DOI 10.1023/A:1011118718821; Harmar AJ, 2001, GENOME BIOL, V2; Hasegawa K, 2005, CHRONOBIOL INT, V22, P1, DOI 10.1081/CBI-200038149; Helfrich-Forster C, 2000, J NEUROSCI, V20, P3339, DOI 10.1523/JNEUROSCI.20-09-03339.2000; Hendricks JC, 2000, NEURON, V25, P129, DOI 10.1016/S0896-6273(00)80877-6; Husson SJ, 2005, BIOCHEM BIOPH RES CO, V335, P76, DOI 10.1016/j.bbrc.2005.07.044; Husson SJ, 2007, PROG NEUROBIOL, V82, P33, DOI 10.1016/j.pneurobio.2007.01.006; Hyun S, 2005, NEURON, V48, P267, DOI 10.1016/j.neuron.2005.08.025; IWASAKI K, 1995, P NATL ACAD SCI USA, V92, P10317, DOI 10.1073/pnas.92.22.10317; Keane J, 2003, GENETICS, V164, P153; Keating CD, 2003, CURR BIOL, V13, P1715, DOI 10.1016/j.cub.2003.09.003; Kubiak TM, 2003, J BIOL CHEM, V278, P33724, DOI 10.1074/jbc.M304861200; Kubiak TM, 2003, J BIOL CHEM, V278, P42115, DOI 10.1074/jbc.M304056200; Lear BC, 2005, NEURON, V48, P221, DOI 10.1016/j.neuron.2005.09.008; Lindeberg T., 1994, SCALE SPACE THEORY C; LIU KS, 1995, NEURON, V14, P79, DOI 10.1016/0896-6273(95)90242-2; Mertens I, 2005, NEURON, V48, P213, DOI 10.1016/j.neuron.2005.09.009; Mertens I, 2005, BIOCHEM BIOPH RES CO, V330, P967, DOI 10.1016/j.bbrc.2005.03.071; Mertens I, 2004, FEBS LETT, V573, P55, DOI 10.1016/j.febslet.2004.07.058; Mertens I, 2006, PEPTIDES, V27, P1291, DOI 10.1016/j.peptides.2005.11.017; Parkinson J, 2004, NAT GENET, V36, P1259, DOI 10.1038/ng1472; Pichon G, 2004, CR BIOL, V327, P1087, DOI 10.1016/j.crvi.2004.09.008; RAO KR, 1993, ANN NY ACAD SCI, V680, P78, DOI 10.1111/j.1749-6632.1993.tb19676.x; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Rogers C, 2003, NAT NEUROSCI, V6, P1178, DOI 10.1038/nn1140; Saigusa T, 2002, CURR BIOL, V12, pR46, DOI 10.1016/S0960-9822(01)00669-8; Sato S, 2002, ZOOL SCI, V19, P821, DOI 10.2108/zsj.19.821; Simmer F, 2003, PLOS BIOL, V1, P77, DOI 10.1371/journal.pbio.0000012; THOMAS JH, 1990, GENETICS, V124, P855; WICKS SR, 1995, J NEUROSCI, V15, P2434, DOI 10.1523/JNEUROSCI.15-03-02434.1995; Zhao BB, 2003, J NEUROSCI, V23, P5319	34	48	54	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15241	15249		10.1074/jbc.M709060200	http://dx.doi.org/10.1074/jbc.M709060200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18390545	Green Published, hybrid			2022-12-25	WOS:000256232000042
J	Schiefelbein, D; Goren, I; Fisslthaler, B; Schmidt, H; Geisslinger, G; Pfeilschifter, J; Frank, S				Schiefelbein, Dana; Goren, Itamar; Fisslthaler, Beate; Schmidt, Helmut; Geisslinger, Gerd; Pfeilschifter, Josef; Frank, Stefan			Biphasic regulation of HMG-CoA reductase expression and activity during wound healing and its functional role in the control of keratinocyte angiogenic and proliferative responses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOTHELIAL GROWTH-FACTOR; CUTANEOUS BARRIER FUNCTION; INDUCIBLE NITRIC-OXIDE; DIABETIC OB/OB MICE; DENOVO STEROLOGENESIS; SIGNALING PATHWAYS; CULTURED KERATINOCYTES; ANTIINFLAMMATORY ROLE; PERMEABILITY BARRIER; CELL-PROLIFERATION	In this study, we determined the regulation and potential function of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR) during skin repair in mice. Upon skin injury, healthy mice exhibited a biphasic increase in HMGR expression and activity with elevated levels at days 3 and 13 post-wounding. In situ hybridization revealed wound margin keratinocytes as a cellular source of HMGR expression. In vitro experiments using cultured HaCaT keratinocytes uncovered epidermal growth factor (EGF), transforming growth factor (TGF)-alpha, and insulin as potent co-inducers of HMGR activity and vascular endothelial growth factor (VEGF) in the cells. Insulin-, but not EGF-mediated VEGF protein expression was functionally connected to co-induced HMGR activity, as simvastatin restrictively interfered only with insulin-induced translation of VEGF mRNA by inhibition of eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) phosphorylation. Functional ablation of insulin-induced sterol regulatory element-binding protein (SREBP)-2 by siRNA abolished HMGR expression and insulin-triggered VEGF protein release from keratinocytes. Simvastatin also blocked proliferation of cultured keratinocytes. The observed inhibitory effects of simvastatin on keratinocyte VEGF expression and proliferation could be reversed by mevalonate, the product of HMGR enzymatic activity. In accordance, simvastatin-mediated inhibition of HMGR activity in acutely regenerating tissue of wounded mice was paralleled by a marked loss of VEGF protein expression and disturbances of normal proliferation processes in wound margin keratinocytes during skin repair.	[Schiefelbein, Dana; Goren, Itamar; Schmidt, Helmut; Geisslinger, Gerd; Pfeilschifter, Josef; Frank, Stefan] Univ Frankfurt, Klinikum JW Goethe, ZAFES, Pharmazentrum Frankfurt, D-60590 Frankfurt, Germany; [Fisslthaler, Beate] Univ Frankfurt, Klinikum Johann Wolfgang, Zentrum Physiol, D-60590 Frankfurt, Germany	Goethe University Frankfurt; Goethe University Frankfurt	Frank, S (corresponding author), Univ Frankfurt, Klinikum JW Goethe, ZAFES, Pharmazentrum Frankfurt, Theodor Stern Kai 7, D-60590 Frankfurt, Germany.	S.Frank@em.uni-frankfurt.de						Bengoechea-Alonso MT, 2007, CURR OPIN CELL BIOL, V19, P215, DOI 10.1016/j.ceb.2007.02.004; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BROWN LF, 1992, J EXP MED, V176, P1375, DOI 10.1084/jem.176.5.1375; Carlin CM, 2007, AM J RESP CELL MOL, V37, P447, DOI 10.1165/rcmb.2007-0012OC; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P159; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Denoyelle C, 2001, CARCINOGENESIS, V22, P1139, DOI 10.1093/carcin/22.8.1139; FEINGOLD KR, 1990, J CLIN INVEST, V86, P1738, DOI 10.1172/JCI114899; FEINGOLD KR, 1983, J INVEST DERMATOL, V81, P365, DOI 10.1111/1523-1747.ep12519974; FEINGOLD KR, 1982, J LAB CLIN MED, V100, P405; Frank S, 1999, FASEB J, V13, P2002, DOI 10.1096/fasebj.13.14.2002; FRANK S, 1995, J BIOL CHEM, V270, P12607, DOI 10.1074/jbc.270.21.12607; Frank S, 2000, J CLIN INVEST, V106, P501, DOI 10.1172/JCI9148; GERDES J, 1984, J IMMUNOL, V133, P1710; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; Goren I, 2006, AM J PATHOL, V168, P765, DOI 10.2353/ajpath.2006.050293; GRUBAUER G, 1987, J LIPID RES, V28, P746; GRUBAUER G, 1989, J LIPID RES, V30, P89; Harris IR, 1998, J LIPID RES, V39, P412; Harris IR, 1997, J INVEST DERMATOL, V109, P783, DOI 10.1111/1523-1747.ep12340962; Harris IR, 2000, J INVEST DERMATOL, V114, P83, DOI 10.1046/j.1523-1747.2000.00822.x; Istvan ES, 2001, SCIENCE, V292, P1160, DOI 10.1126/science.1059344; Jiang ZY, 2003, J BIOL CHEM, V278, P31964, DOI 10.1074/jbc.M303314200; Kampfer H, 1999, J INVEST DERMATOL, V113, P369, DOI 10.1046/j.1523-1747.1999.00704.x; Kampfer H, 2001, LAB INVEST, V81, P361, DOI 10.1038/labinvest.3780244; Kotamraju S, 2007, CANCER RES, V67, P7386, DOI 10.1158/0008-5472.CAN-07-0993; LAMPE MA, 1983, J LIPID RES, V24, P120; Lauer G, 2000, J INVEST DERMATOL, V115, P12, DOI 10.1046/j.1523-1747.2000.00036.x; Leung BP, 2003, J IMMUNOL, V170, P1524, DOI 10.4049/jimmunol.170.3.1524; Liao JK, 2002, J CLIN INVEST, V110, P285, DOI 10.1172/JCI200216421; Madlener M, 1996, BIOCHEM J, V320, P659, DOI 10.1042/bj3200659; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; McKay A, 2004, J IMMUNOL, V172, P2903, DOI 10.4049/jimmunol.172.5.2903; MENON GK, 1985, J LIPID RES, V26, P418; PASTORE S, 2007, J INVESTIG IN PRESS; PROKSCH E, 1990, J CLIN INVEST, V85, P874, DOI 10.1172/JCI114514; Rodwell V W, 1976, Adv Lipid Res, V14, P1; Segrelles C, 2004, CARCINOGENESIS, V25, P1137, DOI 10.1093/carcin/bgh132; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Stallmeyer B, 1999, J INVEST DERMATOL, V113, P1090, DOI 10.1046/j.1523-1747.1999.00784.x; Stallmeyer B, 2001, DIABETOLOGIA, V44, P471, DOI 10.1007/s001250051645; Taniguchi CM, 2006, NAT REV MOL CELL BIO, V7, P85, DOI 10.1038/nrm1837; Treins C, 2002, J BIOL CHEM, V277, P27975, DOI 10.1074/jbc.M204152200; Vrtovsnik F, 1997, KIDNEY INT, V52, P1016, DOI 10.1038/ki.1997.423; Walker K, 2005, CURR OPIN GENET DEV, V15, P62, DOI 10.1016/j.gde.2004.11.001; WEINDEL K, 1992, BIOCHEM BIOPH RES CO, V183, P1167, DOI 10.1016/S0006-291X(05)80313-4; Werner S, 2003, PHYSIOL REV, V83, P835, DOI 10.1152/physrev.2003.83.3.835; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	49	18	18	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15479	15490		10.1074/jbc.M709841200	http://dx.doi.org/10.1074/jbc.M709841200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18390541	Green Published, hybrid			2022-12-25	WOS:000256232000066
J	Volkow, ND; Fowler, JS; Wang, GJ; Telang, F; Logan, J; Wong, C; Ma, J; Pradhan, K; Benveniste, H; Swanson, JM				Volkow, Nora D.; Fowler, Joanna S.; Wang, Gene-Jack; Telang, Frank; Logan, Jean; Wong, Christopher; Ma, Jim; Pradhan, Kith; Benveniste, Helene; Swanson, James M.			Methylphenidate Decreased the Amount of Glucose Needed by the Brain to Perform a Cognitive Task	PLOS ONE			English	Article								The use of stimulants (methylphenidate and amphetamine) as cognitive enhancers by the general public is increasing and is controversial. It is still unclear how they work or why they improve performance in some individuals but impair it in others. To test the hypothesis that stimulants enhance signal to noise ratio of neuronal activity and thereby reduce cerebral activity by increasing efficiency, we measured the effects of methylphenidate on brain glucose utilization in healthy adults. We measured brain glucose metabolism (using Positron Emission Tomography and 2-deoxy-2[18F] fluoro-D-glucose) in 23 healthy adults who were tested at baseline and while performing an accuracy-controlled cognitive task (numerical calculations) given with and without methylphenidate (20 mg, oral). Sixteen subjects underwent a fourth scan with methylphenidate but without cognitive stimulation. Compared to placebo methylphenidate significantly reduced the amount of glucose utilized by the brain when performing the cognitive task but methylphenidate did not affect brain metabolism when given without cognitive stimulation. Whole brain metabolism when the cognitive task was given with placebo increased 21% whereas with methylphenidate it increased 11% (50% less). This reflected both a decrease in magnitude of activation and in the regions activated by the task. Methylphenidate's reduction of the metabolic increases in regions from the default network (implicated in mind-wandering) was associated with improvement in performance only in subjects who activated these regions when the cognitive task was given with placebo. These results corroborate prior findings that stimulant medications reduced the magnitude of regional activation to a task and in addition document a "focusing'' of the activation. This effect may be beneficial when neuronal resources are diverted (i.e., mind-wandering) or impaired (i.e., attention deficit hyperactivity disorder), but it could be detrimental when brain activity is already optimally focused. This would explain why methylphenidate has beneficial effects in some individuals and contexts and detrimental effects in others.	[Volkow, Nora D.] Natl Inst Drug Abuse, Bethesda, MD 20892 USA; [Volkow, Nora D.; Telang, Frank; Ma, Jim] Natl Inst Alcohol Abuse & Alcoholism, Bethesda, MD USA; [Fowler, Joanna S.; Wang, Gene-Jack; Logan, Jean; Wong, Christopher; Pradhan, Kith; Benveniste, Helene] Brookhaven Natl Lab, Med Dept, Upton, NY USA; [Swanson, James M.] Univ Calif Irvine, Child Dev Ctr, Irvine, CA USA	National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); United States Department of Energy (DOE); Brookhaven National Laboratory; University of California System; University of California Irvine	Volkow, ND (corresponding author), Natl Inst Drug Abuse, Bethesda, MD 20892 USA.	nvolkow@nida.nih.gov		Logan, Jean/0000-0002-6993-9994	Intramural Research Program of the NIH (National Institutes on Alcoholism and Alcohol Abuse); Department of Energy Office of Biological and Environmental Research [DE-AC01-76CH00016]; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [Z01AA000550, ZIAAA000550] Funding Source: NIH RePORTER	Intramural Research Program of the NIH (National Institutes on Alcoholism and Alcohol Abuse)(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); Department of Energy Office of Biological and Environmental Research(United States Department of Energy (DOE)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))	This research was supported in part by the Intramural Research Program of the NIH (National Institutes on Alcoholism and Alcohol Abuse) and by the Department of Energy (Office of Biological and Environmental Research, contract DE-AC01-76CH00016).	Collins DL, 1995, HUM BRAIN MAPP, V3, P190, DOI 10.1002/hbm.460030304; Conners C K, 2002, J Atten Disord, V6 Suppl 1, pS17; CONNERS CK, 1966, J NERV MENT DIS, V142, P429, DOI 10.1097/00005053-196605000-00005; Elliott R, 1997, PSYCHOPHARMACOLOGY, V131, P196, DOI 10.1007/s002130050284; Fan J, 2005, NEUROIMAGE, V26, P471, DOI 10.1016/j.neuroimage.2005.02.004; Fox MD, 2005, P NATL ACAD SCI USA, V102, P9673, DOI 10.1073/pnas.0504136102; FOX PT, 1986, P NATL ACAD SCI USA, V83, P1140, DOI 10.1073/pnas.83.4.1140; Friston K. J., 1995, HUMAN BRAIN MAPPING, V2, P189, DOI DOI 10.1002/HBM.460020402; GINSBERG MD, 1988, ANN NEUROL, V23, P152, DOI 10.1002/ana.410230208; Gjedde A, 2002, J CEREBR BLOOD F MET, V22, P1, DOI 10.1097/00004647-200201000-00001; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Hirata A, 2006, J NEUROSCI, V26, P4426, DOI 10.1523/JNEUROSCI.5298-05.2006; KEELER JD, 1989, P NATL ACAD SCI USA, V86, P1712, DOI 10.1073/pnas.86.5.1712; Kiyatkin EA, 1996, J NEUROPHYSIOL, V75, P142, DOI 10.1152/jn.1996.75.1.142; Kiyatkin EA, 2002, BEHAV BRAIN RES, V137, P27, DOI 10.1016/S0166-4328(02)00283-8; Kuczenski R, 1997, J NEUROCHEM, V68, P2032; Lancaster JL, 2000, HUM BRAIN MAPP, V10, P120, DOI 10.1002/1097-0193(200007)10:3<120::AID-HBM30>3.0.CO;2-8; Mason MF, 2007, SCIENCE, V315, P393, DOI 10.1126/science.1131295; MATOCHIK JA, 1994, AM J PSYCHIAT, V151, P658; Mattay VS, 2000, NEUROIMAGE, V12, P268, DOI 10.1006/nimg.2000.0610; Mehta MA, 2000, J NEUROSCI, V20; PORRINO LJ, 1983, ARCH GEN PSYCHIAT, V40, P688; Rapoport J L, 2002, J Atten Disord, V6 Suppl 1, pS57; ROLLS ET, 1984, NEUROSCIENCE, V12, P1201, DOI 10.1016/0306-4522(84)90014-9; Sahakian B, 2007, NATURE, V450, P1157, DOI 10.1038/4501157a; Schweitzer JB, 2004, BIOL PSYCHIAT, V56, P597, DOI 10.1016/j.biopsych.2004.07.011; Seamans JK, 2004, PROG NEUROBIOL, V74, P1, DOI 10.1016/j.pneurobio.2004.05.006; SRINIVAS NR, 1991, PROG NEURO-PSYCHOPH, V15, P213, DOI 10.1016/0278-5846(91)90083-D; Talairach J., 1988, COPLANAR STEREOTAXIC; Teicher MH, 2003, J CHILD ADOL PSYCHOP, V13, P41, DOI 10.1089/104454603321666180; Volkow ND, 2004, AM J PSYCHIAT, V161, P1173, DOI 10.1176/appi.ajp.161.7.1173; Volkow ND, 2008, NATURE, V451, P520, DOI 10.1038/451520a; WANG GJ, 1993, RADIOLOGY, V186, P59, DOI 10.1148/radiology.186.1.8416587; WEBER K, 1985, PSYCHOPHARMACOLOGY, V85, P231, DOI 10.1007/BF00428421; WOODWARD DJ, 1979, FED PROC, V38, P2109	35	85	86	1	11	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e2017	10.1371/journal.pone.0002017	http://dx.doi.org/10.1371/journal.pone.0002017			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414677	Green Published, Green Submitted, gold			2022-12-25	WOS:000260867300026
J	Millen, SJ; Uys, PW; Hargrove, J; van Helden, PD; Williams, BG				Millen, Stephen J.; Uys, Pieter W.; Hargrove, John; van Helden, Paul D.; Williams, Brian G.			The Effect of Diagnostic Delays on the Drop-Out Rate and the Total Delay to Diagnosis of Tuberculosis	PLOS ONE			English	Article								Background: Numerous patient and healthcare system-related delays contribute to the overall delay experienced by patients from onset of TB symptoms to diagnosis and treatment. Such delays are critical as infected individuals remain untreated in the community, providing more opportunities for transmission of the disease and adversely affecting the epidemic. Methodology/Principal Findings: We present an analysis of the factors that contribute to the overall delay in TB diagnosis and treatment, in a resource-poor setting. Impact on the distribution of diagnostic delay times was assessed for various factors, the sensitivity of the diagnostic method being found to be the most significant. A linear relationship was found between the sensitivity of the test and the predicted mean delay time, with an increase in test sensitivity resulting in a reduced mean delay time and a reduction in the drop-out rate. Conclusions/Significance: The results show that in a developing country a number of delay factors, particularly the low sensitivity of the initial sputum smear microscopy test, potentially increase total diagnostic delay times experienced by TB patients significantly. The results reinforce the urgent need for novel diagnostic methods, both for smear positive and negative TB, that are highly sensitive, accessible and point of care, in order to reduce mean delay times.	[Millen, Stephen J.; Uys, Pieter W.; Hargrove, John] Univ Stellenbosch, DST NRF Ctr Excellence Epidemiol Modelling & Anal, Western Cape, South Africa; [Uys, Pieter W.; van Helden, Paul D.] Stellenbosch Univ, Fac Hlth Sci, DST/NRF Ctr Excellence Biomed TB Res, MRC Ctr Mol & Cell Biol, Western Cape, South Africa; [Williams, Brian G.] WHO, Stop TB, Geneva, Switzerland	National Research Foundation - South Africa; Stellenbosch University; National Research Foundation - South Africa; Stellenbosch University; World Health Organization	Millen, SJ (corresponding author), Univ Stellenbosch, DST NRF Ctr Excellence Epidemiol Modelling & Anal, Western Cape, South Africa.	edserve@iafrica.com		Williams, Brian/0000-0002-3174-4876	Stellenbosch University; MRC; NRF	Stellenbosch University; MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NRF	Funding was provided by Stellenbosch University, MRC and NRF for this work.	Asch S, 1998, AM J RESP CRIT CARE, V157, P1244, DOI 10.1164/ajrccm.157.4.9709071; Auer C, 2000, TROP MED INT HEALTH, V5, P648, DOI 10.1046/j.1365-3156.2000.00615.x; Behr MA, 1999, LANCET, V353, P444, DOI 10.1016/S0140-6736(98)03406-0; Crampin AC, 2001, INT J TUBERC LUNG D, V5, P994; El-Sony A, 2002, INT J TUBERC LUNG D, V6, P91; GEBRE N, 1995, T ROY SOC TROP MED H, V89, P191, DOI 10.1016/0035-9203(95)90491-3; Golub JE, 2006, INT J TUBERC LUNG D, V10, P24; Harries AD, 2000, INT J TUBERC LUNG D, V4, P36; Hudson CP, 2000, INT J TUBERC LUNG D, V4, P240; Lambert ML, 2005, TROP MED INT HEALTH, V10, P945, DOI 10.1111/j.1365-3156.2005.01485.x; Phillips L, 2004, PEDIATRICS, V113, pE514, DOI 10.1542/peds.113.6.e514; Selvakumar N, 2002, J CLIN MICROBIOL, V40, P3017, DOI 10.1128/JCM.40.8.3017-3020.2002; Sherman LF, 1999, INT J TUBERC LUNG D, V3, P1088; Verver S, 2004, INT J EPIDEMIOL, V33, P351, DOI 10.1093/ije/dyh021; Wandwalo ER, 2000, INT J TUBERC LUNG D, V4, P133; WHO, 2006, GLOB TUB CONTR; Wilkinson D, 1997, T ROY SOC TROP MED H, V91, P420, DOI 10.1016/S0035-9203(97)90263-7	17	35	35	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1933	10.1371/journal.pone.0001933	http://dx.doi.org/10.1371/journal.pone.0001933			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398459	Green Published, gold			2022-12-25	WOS:000260795500010
J	Muftuoglu, M; Kusumoto, R; Speina, E; Beck, G; Cheng, WH; Bohr, VA				Muftuoglu, Meltem; Kusumoto, Rika; Speina, Elzbieta; Beck, Gad; Cheng, Wen-Hsing; Bohr, Vilhelm A.			Acetylation Regulates WRN Catalytic Activities and Affects Base Excision DNA Repair	PLOS ONE			English	Article								Background: The Werner protein (WRN), defective in the premature aging disorder Werner syndrome, participates in a number of DNA metabolic processes, and we have been interested in the possible regulation of its function in DNA repair by post-translational modifications. Acetylation mediated by histone acetyltransferases is of key interest because of its potential importance in aging, DNA repair and transcription. Methodology/Principal Findings: Here, we have investigated the p300 acetylation mediated changes on the function of WRN in base excision DNA repair (BER). We show that acetylation of WRN increases in cells treated with methyl methanesulfonate (MMS), suggesting that acetylation of WRN may play a role in response to DNA damage. This hypothesis is consistent with our findings that acetylation of WRN stimulates its catalytic activities in vitro and in vivo, and that acetylated WRN enhances pol beta-mediated strand displacement DNA synthesis more than unacetylated WRN. Furthermore, we show that cellular exposure to the histone deacetylase inhibitor sodium butyrate stimulates long patch BER in wild type cells but not in WRN depleted cells, suggesting that acetylated WRN participates significantly in this process. Conclusion/Significance: Collectively, these results provide the first evidence for a specific role of p300 mediated WRN acetylation in regulating its function during BER.	[Muftuoglu, Meltem; Kusumoto, Rika; Speina, Elzbieta; Beck, Gad; Cheng, Wen-Hsing; Bohr, Vilhelm A.] NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA; [Speina, Elzbieta] Polish Acad Sci, Inst Biochem & Biophys, Warsaw, Poland	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Polish Academy of Sciences; Institute of Biochemistry & Biophysics - Polish Academy of Sciences	Bohr, VA (corresponding author), NIA, Lab Mol Gerontol, NIH, Baltimore, MD 21224 USA.	vbohr@nih.gov	Bohr, Vilhelm/AAP-5931-2020; Speina, Elzbieta/ABB-3371-2021; Muftuoglu, Meltem/AAG-5004-2019	Muftuoglu, Meltem/0000-0001-5372-4780	NATIONAL INSTITUTE ON AGING [Z01AG000721, ZIAAG000727, ZIAAG000726, Z01AG000727, ZIAAG000721, Z01AG000726] Funding Source: NIH RePORTER	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Ahn B, 2004, J BIOL CHEM, V279, P53465, DOI 10.1074/jbc.M409624200; Ataian Y, 2006, BIOCHEM CELL BIOL, V84, P490, DOI 10.1139/O06-075; Beard BC, 2003, P NATL ACAD SCI USA, V100, P7465, DOI 10.1073/pnas.1330328100; Bhakat KK, 2006, MOL CELL BIOL, V26, P1654, DOI 10.1128/MCB.26.5.1654-1665.2006; Bhakat KK, 2004, NUCLEIC ACIDS RES, V32, P3033, DOI 10.1093/nar/gkh632; Bhakat KK, 2003, EMBO J, V22, P6299, DOI 10.1093/emboj/cdg595; Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Blander G, 2002, J BIOL CHEM, V277, P50934, DOI 10.1074/jbc.M210479200; Blank A, 2004, DNA REPAIR, V3, P629, DOI 10.1016/j.dnarep.2004.02.003; Bohr VA, 2005, MUTAT RES-FUND MOL M, V577, P252, DOI 10.1016/j.mrfmmm.2005.03.021; Brosh RM, 2001, EMBO J, V20, P5791; Chafin DR, 2000, EMBO J, V19, P5492, DOI 10.1093/emboj/19.20.5492; Cheng WH, 2003, MOL CELL BIOL, V23, P6385, DOI 10.1128/MCB.23.18.6385-6395.2003; Davie JR, 2003, J NUTR, V133, p2485S, DOI 10.1093/jn/133.7.2485S; DI GE, 2004, AMINO ACIDS, V26, P435; DRESLER SL, 1985, BIOCHEMISTRY-US, V24, P6861, DOI 10.1021/bi00345a019; Eberharter A, 2002, EMBO REP, V3, P224, DOI 10.1093/embo-reports/kvf053; Ehrenhofer-Murray AE, 2004, EUR J BIOCHEM, V271, P2335, DOI 10.1111/j.1432-1033.2004.04162.x; Harrigan JA, 2006, NUCLEIC ACIDS RES, V34, P745, DOI 10.1093/nar/gkj475; Harrigan JA, 2003, J BIOL CHEM, V278, P22686, DOI 10.1074/jbc.M213103200; Hasan S, 2002, J MOL MED, V80, P463, DOI 10.1007/s00109-002-0341-7; Hasan S, 2002, MOL CELL, V10, P1213, DOI 10.1016/S1097-2765(02)00745-1; Hasan S, 2001, MOL CELL, V7, P1221, DOI 10.1016/S1097-2765(01)00272-6; Hasan S, 2001, NATURE, V410, P387, DOI 10.1038/35066610; Huang SR, 2000, NUCLEIC ACIDS RES, V28, P2396, DOI 10.1093/nar/28.12.2396; Huggins CF, 2002, MOL CELL, V10, P1201, DOI 10.1016/S1097-2765(02)00736-0; Imamura O, 2002, ONCOGENE, V21, P954, DOI 10.1038/sj.onc.1205143; Kamath-Loeb AS, 1998, J BIOL CHEM, V273, P34145, DOI 10.1074/jbc.273.51.34145; Karmakar P, 2002, J BIOL CHEM, V277, P18291, DOI 10.1074/jbc.M111523200; Kouzarides T, 1999, CURR OPIN GENET DEV, V9, P40, DOI 10.1016/S0959-437X(99)80006-9; Laine JP, 2003, CANCER RES, V63, P7136; Lindahl T, 2000, MUTAT RES-REV MUTAT, V462, P129, DOI 10.1016/S1383-5742(00)00024-7; Martin GM, 2000, NATURE, V408, P263, DOI 10.1038/35041705; Martin GM, 1999, J AM GERIATR SOC, V47, P1136, DOI 10.1111/j.1532-5415.1999.tb05240.x; Mostoslavsky R, 2006, CELL, V124, P315, DOI 10.1016/J.CEL.2005.11.044; Munshi A, 2005, CLIN CANCER RES, V11, P4912, DOI 10.1158/1078-0432.CCR-04-2088; Nakatani Y, 2001, GENES CELLS, V6, P79, DOI 10.1046/j.1365-2443.2001.00411.x; Nilsen H, 2002, EMBO J, V21, P5943, DOI 10.1093/emboj/cdf581; Opresko PL, 2003, CARCINOGENESIS, V24, P791, DOI 10.1093/carcin/bgg034; Orren DK, 1999, NUCLEIC ACIDS RES, V27, P3557, DOI 10.1093/nar/27.17.3557; Poot M, 2002, FASEB J, V16, P757, DOI 10.1096/fj.01-0906fje; Porcu M, 2005, TRENDS PHARMACOL SCI, V26, P94, DOI 10.1016/j.tips.2004.12.009; RAMANATHAN B, 1989, J BIOL CHEM, V264, P11026; Saha RN, 2006, CELL DEATH DIFFER, V13, P539, DOI 10.1038/sj.cdd.4401769; SHARMA A, 2007, J BIOL CHEM; Sharma S, 2003, J BIOL CHEM, V278, P23487, DOI 10.1074/jbc.M212798200; Shevelev IV, 2002, NAT REV MOL CELL BIO, V3, P364, DOI 10.1038/nrm804; SMERDON MJ, 1983, BIOCHEMISTRY-US, V22, P3516, DOI 10.1021/bi00283a033; SMERDON MJ, 1982, J BIOL CHEM, V257, P13441; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Stoilov L, 2000, INT J RADIAT BIOL, V76, P1485, DOI 10.1080/09553000050176243; Szekely AM, 2005, MOL CELL BIOL, V25, P10492, DOI 10.1128/MCB.25.23.10492-10506.2005; Tini M, 2002, MOL CELL, V9, P265, DOI 10.1016/S1097-2765(02)00453-7; von Kobbe C, 2004, FASEB J, V18, P1970, DOI 10.1096/fj.04-1895fje; von Kobbe C, 2004, NUCLEIC ACIDS RES, V32, P4003, DOI 10.1093/nar/gkh721; von Kobbe C, 2003, J BIOL CHEM, V278, P52997, DOI 10.1074/jbc.M308338200; White NR, 2006, J PEDIATR GASTR NUTR, V42, P134, DOI 10.1097/01.mpg.0000189345.31010.89	57	28	28	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1918	10.1371/journal.pone.0001918	http://dx.doi.org/10.1371/journal.pone.0001918			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398454	Green Published, Green Submitted, gold			2022-12-25	WOS:000260795500005
J	Chen, LW; Tredget, EE; Wu, PYG; Wu, YJ				Chen, Liwen; Tredget, Edward E.; Wu, Philip Y. G.; Wu, Yaojiong			Paracrine Factors of Mesenchymal Stem Cells Recruit Macrophages and Endothelial Lineage Cells and Enhance Wound Healing	PLOS ONE			English	Article								Bone marrow derived mesenchymal stem cells (BM-MSCs) have been shown to enhance wound healing; however, the mechanisms involved are barely understood. In this study, we examined paracrine factors released by BM-MSCs and their effects on the cells participating in wound healing compared to those released by dermal fibroblasts. Analyses of BM-MSCs with Real-Time PCR and of BM-MSC-conditioned medium by antibody-based protein array and ELISA indicated that BM-MSCs secreted distinctively different cytokines and chemokines, such as greater amounts of VEGF-alpha, IGF-1, EGF, keratinocyte growth factor, angiopoietin-1, stromal derived factor-1, macrophage inflammatory protein-1alpha and beta and erythropoietin, compared to dermal fibroblasts. These molecules are known to be important in normal wound healing. BM-MSC-conditioned medium significantly enhanced migration of macrophages, keratinocytes and endothelial cells and proliferation of keratinocytes and endothelial cells compared to fibroblast-conditioned medium. Moreover, in a mouse model of excisional wound healing, where concentrated BM-MSC-conditioned medium was applied, accelerated wound healing occurred compared to administration of pre-conditioned or fibroblast-conditioned medium. Analysis of cell suspensions derived from the wound by FACS showed that wounds treated with BM-MSC-conditioned medium had increased proportions of CD4/80-postive macrophages and Flk-1-, CD34- or c-kit-positive endothelial (progenitor) cells compared to wounds treated with pre-conditioned medium or fibroblast-conditioned medium. Consistent with the above findings, immunohistochemical analysis of wound sections showed that wounds treated with BM-MSC-conditioned medium had increased abundance of macrophages. Our results suggest that factors released by BM-MSCs recruit macrophages and endothelial lineage cells into the wound thus enhancing wound healing.	[Chen, Liwen; Tredget, Edward E.; Wu, Yaojiong] Univ Alberta, Dept Surg, Fac Med & Dent, Edmonton, AB, Canada; [Wu, Philip Y. G.] Univ Hong Kong, Li Ka Shing Fac Med, Hong Kong, Peoples R China; [Wu, Yaojiong] Shenzhen Univ, Sch Med, Shenzhen, Peoples R China	University of Alberta; University of Hong Kong; Shenzhen University	Chen, LW (corresponding author), Univ Alberta, Dept Surg, Fac Med & Dent, Edmonton, AB, Canada.	yjwu2005@yahoo.com			Firefighters Burn Trust Fund; University of Alberta Hospital Foundation; SZU R/D Fund of Shenzhen University	Firefighters Burn Trust Fund; University of Alberta Hospital Foundation(University of Alberta); SZU R/D Fund of Shenzhen University	Firefighters Burn Trust Fund, the University of Alberta Hospital Foundation and the SZU R/D Fund of Shenzhen University supported the study.	Amado LC, 2005, P NATL ACAD SCI USA, V102, P11474, DOI 10.1073/pnas.0504388102; Amirbekian V, 2007, P NATL ACAD SCI USA, V104, P961, DOI 10.1073/pnas.0606281104; ARNOLD F, 1991, PHARMACOL THERAPEUT, V52, P407, DOI 10.1016/0163-7258(91)90034-J; Boulton AJM, 2005, LANCET, V366, P1719, DOI 10.1016/S0140-6736(05)67698-2; Caldelari R, 2000, J INVEST DERMATOL, V114, P1064, DOI 10.1046/j.1523-1747.2000.00960-4.x; Colter DC, 2000, P NATL ACAD SCI USA, V97, P3213, DOI 10.1073/pnas.070034097; DANON D, 1989, P NATL ACAD SCI USA, V86, P2018, DOI 10.1073/pnas.86.6.2018; Dewald O, 2005, CIRC RES, V96, P881, DOI 10.1161/01.RES.0000163017.13772.3a; DiPietro LA, 1998, J CLIN INVEST, V101, P1693, DOI 10.1172/JCI1020; Dominici M, 2006, CYTOTHERAPY, V8, P315, DOI 10.1080/14653240600855905; Dupasquier M, 2004, J INVEST DERMATOL, V123, P876, DOI 10.1111/j.0022-202X.2004.23427.x; Falanga V, 2005, LANCET, V366, P1736, DOI 10.1016/S0140-6736(05)67700-8; Fathke C, 2004, STEM CELLS, V22, P812, DOI 10.1634/stemcells.22-5-812; Galeano M, 2004, DIABETES, V53, P2509, DOI 10.2337/diabetes.53.9.2509; Galiano RD, 2004, WOUND REPAIR REGEN, V12, P485, DOI 10.1111/j.1067-1927.2004.12404.x; Ghahary A, 2005, J INVEST DERMATOL, V124, P170, DOI 10.1111/j.0022-202X.2004.23521.x; Harada M, 2005, NAT MED, V11, P305, DOI 10.1038/nm1199; Hasegawa T, 2005, J DERMATOL, V32, P715, DOI 10.1111/j.1346-8138.2005.tb00831.x; Hintermann E, 2001, J CELL BIOL, V153, P465, DOI 10.1083/jcb.153.3.465; Keating A, 2006, CURR OPIN HEMATOL, V13, P419, DOI 10.1097/01.moh.0000245697.54887.6f; Keller Evan T., 1996, Frontiers in Bioscience (online), V1, pD340; Kinnaird T, 2004, CIRCULATION, V109, P1543, DOI 10.1161/01.CIR.0000124062.31102.57; Lamalice L, 2007, CIRC RES, V100, P782, DOI 10.1161/01.RES.0000259593.07661.1e; Lamme EN, 2002, WOUND REPAIR REGEN, V10, P152, DOI 10.1046/j.1524-475X.2002.10901.x; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Mayer H, 2005, J CELL BIOCHEM, V95, P827, DOI 10.1002/jcb.20462; Miller GE, 2006, P NATL ACAD SCI USA, V103, P5496, DOI 10.1073/pnas.0506312103; Park IW, 2001, BLOOD, V97, P352, DOI 10.1182/blood.V97.2.352; PIERCE GF, 1989, P NATL ACAD SCI USA, V86, P2229, DOI 10.1073/pnas.86.7.2229; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Rafii S, 2003, NAT MED, V9, P702, DOI 10.1038/nm0603-702; SBOISMOUTHON C, 2006, FASEB J; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Urbanek K, 2005, CIRC RES, V97, P663, DOI 10.1161/01.RES.0000183733.53101.11; Urbich C, 2004, CIRC RES, V95, P343, DOI 10.1161/01.RES.0000137877.89448.78; Welch S, 2002, CIRC RES, V90, P641, DOI 10.1161/01.RES.0000013780.77774.75; WU Y, 2007, MESENCHYMAL STEM CEL, P2007; Xing LP, 2005, IMMUNOL REV, V208, P19, DOI 10.1111/j.0105-2896.2005.00336.x; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126	39	1142	1218	11	80	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1886	10.1371/journal.pone.0001886	http://dx.doi.org/10.1371/journal.pone.0001886			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382669	Green Published, Green Submitted, gold			2022-12-25	WOS:000260795400020
J	Figueroa, ME; Reimers, M; Thompson, RF; Ye, K; Li, YS; Selzer, RR; Fridriksson, J; Paietta, E; Wiernik, P; Green, RD; Greally, JM; Melnick, A				Figueroa, Maria E.; Reimers, Mark; Thompson, Reid F.; Ye, Kenny; Li, Yushan; Selzer, Rebecca R.; Fridriksson, Jakob; Paietta, Elisabeth; Wiernik, Peter; Green, Roland D.; Greally, John M.; Melnick, Ari			An Integrative Genomic and Epigenomic Approach for the Study of Transcriptional Regulation	PLOS ONE			English	Article							DNA METHYLATION PATTERNS; GENE-EXPRESSION; PROMOTER HYPERMETHYLATION; HISTONE MODIFICATIONS; CANCER; CHROMATIN; METHYLTRANSFERASE; DEMETHYLATION	The molecular heterogeneity of acute leukemias and other tumors constitutes a major obstacle towards understanding disease pathogenesis and developing new targeted- therapies. Aberrant gene regulation is a hallmark of cancer and plays a central role in determining tumor phenotype. We predicted that integration of different genome-wide epigenetic regulatory marks along with gene expression levels would provide greater power in capturing biological differences between leukemia subtypes. Gene expression, cytosine methylation and histone H3 lysine 9 (H3K9) acetylation were measured using high-density oligonucleotide microarrays in primary human acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) specimens. We found that DNA methylation and H3K9 acetylation distinguished these leukemias of distinct cell lineage, as expected, but that an integrative analysis combining the information from each platform revealed hundreds of additional differentially expressed genes that were missed by gene expression arrays alone. This integrated analysis also enhanced the detection and statistical significance of biological pathways dysregulated in AML and ALL. Integrative epigenomic studies are thus feasible using clinical samples and provide superior detection of aberrant transcriptional programming than single-platform microarray studies.	[Figueroa, Maria E.; Li, Yushan; Melnick, Ari] Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10467 USA; [Reimers, Mark] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA; [Thompson, Reid F.; Greally, John M.] Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY USA; [Ye, Kenny] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY USA; [Selzer, Rebecca R.; Fridriksson, Jakob; Green, Roland D.] Roche NimbleGen Inc, Madison, WI USA; [Paietta, Elisabeth; Wiernik, Peter] Our Lady of Mercy Comprehensive Canc Ctr, Bronx, NY USA; [Greally, John M.] Albert Einstein Coll Med, Dept Med, Bronx, NY USA	Yeshiva University; Albert Einstein College of Medicine; Virginia Commonwealth University; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Roche Holding; Yeshiva University; Albert Einstein College of Medicine	Figueroa, ME (corresponding author), Albert Einstein Coll Med, Dept Dev & Mol Biol, Bronx, NY 10467 USA.	jgreally@aecom.yu.edu; amelnick@aecom.yu.edu	Greally, John/AAF-9540-2019; Figueroa, Maria/AAE-8662-2019; Ye, Kenny/GSM-7731-2022; Ye, Kenny/U-2341-2019; Melnick, Ari/AAA-5763-2020	Greally, John/0000-0001-6069-7960; Ye, Kenny/0000-0002-1466-855X; Thompson, Reid/0000-0003-3661-5296; Figueroa, Maria Eugenia/0000-0003-4887-4981	ASH Fellow Scholar Award; NCI [R01 CA104348]; Chemotherapy Foundation; Sam Waxman Cancer Research Foundation; G&P Foundation; Leukemia and Lymphoma Society Scholar; National Institutes of Health [R01 HD044078]; NIH MSTP [GM007288]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD044078] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA104348] Funding Source: NIH RePORTER	ASH Fellow Scholar Award; NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Chemotherapy Foundation; Sam Waxman Cancer Research Foundation; G&P Foundation; Leukemia and Lymphoma Society Scholar(Leukemia and Lymphoma Society); National Institutes of Health(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH MSTP(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	Maria E. Figueroa is supported by an ASH Fellow Scholar Award. Ari M. Melnick is supported by NCI R01 CA104348, the Chemotherapy Foundation, the Sam Waxman Cancer Research Foundation, and the G&P Foundation and is a Leukemia and Lymphoma Society Scholar. John M. Greally is supported by a grant from the National Institutes of Health (NIH) (R01 HD044078). Reid F. Thompson is supported by NIH MSTP Training Grant GM007288.	Armstrong SA, 2002, NAT GENET, V30, P41, DOI 10.1038/ng765; Baylin SB, 2006, NAT REV CANCER, V6, P107, DOI 10.1038/nrc1799; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Brell M, 2005, CLIN CANCER RES, V11, P5167, DOI 10.1158/1078-0432.CCR-05-0230; BRINKMAN AB, 2007, NUCL ACIDS RES; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Chakrabarti SK, 2002, J BIOL CHEM, V277, P13286, DOI 10.1074/jbc.M111857200; Culhane AC, 2005, BIOINFORMATICS, V21, P2789, DOI 10.1093/bioinformatics/bti394; Ehrich M, 2005, P NATL ACAD SCI USA, V102, P15785, DOI 10.1073/pnas.0507816102; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Esteller M, 1999, CANCER RES, V59, P793; Fellenberg K, 2001, P NATL ACAD SCI USA, V98, P10781, DOI 10.1073/pnas.181597298; Gebhard C, 2006, CANCER RES, V66, P6118, DOI 10.1158/0008-5472.CAN-06-0376; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Herman JG, 1998, P NATL ACAD SCI USA, V95, P6870, DOI 10.1073/pnas.95.12.6870; Herman JG, 2003, NEW ENGL J MED, V349, P2042, DOI 10.1056/NEJMra023075; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kent WJ, 2002, GENOME RES, V12, P996, DOI 10.1101/gr.229102; Khulan B, 2006, GENOME RES, V16, P1046, DOI 10.1101/gr.5273806; Kurdistani SK, 2004, CELL, V117, P721, DOI 10.1016/j.cell.2004.05.023; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; McGarvey KM, 2006, CANCER RES, V66, P3541, DOI 10.1158/0008-5472.CAN-05-2481; Melki JR, 1999, CANCER RES, V59, P3730; Melki JR, 2002, SEMIN CANCER BIOL, V12, P347, DOI 10.1016/S1044-579X(02)00055-X; Misra J, 2002, GENOME RES, V12, P1112, DOI 10.1101/gr.225302; Oberley MJ, 2004, METHOD ENZYMOL, V376, P315; Paz MF, 2004, CLIN CANCER RES, V10, P4933, DOI 10.1158/1078-0432.CCR-04-0392; Reimers M, 2005, BMC BIOINFORMATICS, V6, DOI 10.1186/1471-2105-6-166; Rosenwald A, 2002, NEW ENGL J MED, V346, P1937, DOI 10.1056/NEJMoa012914; Selzer RR, 2005, GENE CHROMOSOME CANC, V44, P305, DOI 10.1002/gcc.20243; Shi HD, 2003, CANCER RES, V63, P2164; Taylor KH, 2007, CANCER RES, V67, P2617, DOI 10.1158/0008-5472.CAN-06-3993; Team. RDC, 2007, R LANG ENV STAT COMP; Tessema M, 2003, LEUKEMIA, V17, P910, DOI 10.1038/sj.leu.2402891; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Wu JJ, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-131; Zinn RL, 2007, CANCER RES, V67, P194, DOI 10.1158/0008-5472.CAN-06-3396	40	69	72	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1882	10.1371/journal.pone.0001882	http://dx.doi.org/10.1371/journal.pone.0001882			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365023	gold, Green Published, Green Submitted			2022-12-25	WOS:000260762400029
J	Goncalves, LA; Almeida, P; Mota, MM; Penha-Goncalves, C				Goncalves, Ligia Antunes; Almeida, Paulo; Mota, Maria Manuel; Penha-Goncalves, Carlos			Malaria Liver Stage Susceptibility Locus Identified on Mouse Chromosome 17 by Congenic Mapping	PLOS ONE			English	Article								Host genetic variants are known to confer resistance to Plasmodium blood stage infection and to control malaria severity both in humans and mice. This work describes the genetic mapping of a locus for resistance to liver stage parasite in the mouse. First, we show that decreased susceptibility to the liver stage of Plasmodium berghei in the BALB/c mouse strain is attributable to intra-hepatic factors and impacts on the initial phase of blood stage infection. We used QTL mapping techniques to identify a locus controlling this susceptibility phenotype (LOD score 4.2) on mouse chromosome 17 (belr1 locus). Furthermore, analysis of congenic mouse strains delimited the belr1 locus boundaries distally to the H2 region. Quantification of parasites in the liver of infected congenic mice strongly suggested that the belr1 locus represents a genetic factor controlling the expansion of P. berghei in the hepatic tissue. The mapping of belr1 locus raises the hypothesis that host gene variation is able to control the progression of Plasmodium liver stage infection and opens the possibility that the human genomic region orthologue to belr1 may contain genes that confer resistance to the human malaria liver stage.	[Goncalves, Ligia Antunes; Almeida, Paulo; Mota, Maria Manuel; Penha-Goncalves, Carlos] Inst Gulbenkian Ciencias, Oeiras, Portugal; [Mota, Maria Manuel] Univ Lisbon, Inst Med Mol, Unidade Malaria, Lisbon, Portugal	Instituto Gulbenkian de Ciencia; Universidade de Lisboa	Goncalves, LA (corresponding author), Inst Gulbenkian Ciencias, Oeiras, Portugal.	cpenha@igc.gulbenkian.pt	Gonçalves, Lígia Antunes/F-6242-2014; Mota, Maria/AAF-2048-2019; Penha-Goncalves, Carlos/F-4640-2012	Gonçalves, Lígia Antunes/0000-0001-9804-6899; Penha-Goncalves, Carlos/0000-0001-7225-1907; Mota, Maria Manuel/0000-0002-2858-1041; Almeida, Paulo/0000-0002-9279-2353	Fundacao para a Ciencia e Tecnologia	Fundacao para a Ciencia e Tecnologia(Portuguese Foundation for Science and TechnologyEuropean Commission)	Financial support through grant from Fundacao para a Ciencia e Tecnologia. The funders had no role in the design and conduct of the study, in the collection, analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.	Bagot S, 2002, P NATL ACAD SCI USA, V99, P9919, DOI 10.1073/pnas.152215199; BENNETT S, 1993, T ROY SOC TROP MED H, V87, P286, DOI 10.1016/0035-9203(93)90130-I; Broman KW, 2003, BIOINFORMATICS, V19, P889, DOI 10.1093/bioinformatics/btg112; Burt RA, 2002, INFECT IMMUN, V70, P4750, DOI 10.1128/IAI.70.8.4750-4753.2002; Burt RA, 1999, IMMUNOGENETICS, V50, P278, DOI 10.1007/s002510050603; Campino S, 2005, GENES IMMUN, V6, P416, DOI 10.1038/sj.gene.6364219; Carrolo M, 2003, NAT MED, V9, P1363, DOI 10.1038/nm947; Flori L, 2005, GENES IMMUN, V6, P472, DOI 10.1038/sj.gene.6364231; Foote SJ, 1997, NAT GENET, V17, P380, DOI 10.1038/ng1297-380; Fortin A, 1997, NAT GENET, V17, P382, DOI 10.1038/ng1297-382; Fortin A, 2002, HUM MOL GENET, V11, P2469, DOI 10.1093/hmg/11.20.2469; Fortin A, 2001, P NATL ACAD SCI USA, V98, P10793, DOI 10.1073/pnas.191288998; Hernandez-Valladares M, 2005, TRENDS PARASITOL, V21, P352, DOI 10.1016/j.pt.2005.06.010; Hernandez-Valladares M, 2004, MAMM GENOME, V15, P390, DOI 10.1007/s00335-004-3042-4; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; HILL AVS, 1992, NATURE, V360, P434, DOI 10.1038/360434a0; Huh CG, 2004, P NATL ACAD SCI USA, V101, P4477, DOI 10.1073/pnas.0306068101; KHAN ZM, 1991, INFECT IMMUN, V59, P2529, DOI 10.1128/IAI.59.8.2529-2534.1991; Lederberg J, 1999, GENETICS, V153, P1; Leiriao P, 2005, CELL MICROBIOL, V7, P603, DOI 10.1111/j.1462-5822.2004.00490.x; Lin E, 2006, INFECT IMMUN, V74, P5814, DOI 10.1128/IAI.01690-05; McGuire W, 1999, J INFECT DIS, V179, P287, DOI 10.1086/314533; Min-Oo G, 2003, NAT GENET, V35, P357, DOI 10.1038/ng1260; Min-Oo G, 2007, J EXP MED, V204, P511, DOI 10.1084/jem.20061252; Min-Oo G, 2007, BLOOD CELL MOL DIS, V39, P63, DOI 10.1016/j.bcmd.2007.03.003; Nagayasu E, 2002, INFECT IMMUN, V70, P512, DOI 10.1128/IAI.70.2.512-516.2002; Ngonseu E, 1998, PARASITOLOGY, V117, P419, DOI 10.1017/S0031182098003333; Ohno T, 2004, IMMUNOGENETICS, V56, P675, DOI 10.1007/s00251-004-0739-1; Sepulveda N, 2007, HEREDITY, V99, P173, DOI 10.1038/sj.hdy.6800979; Silvie O, 2003, NAT MED, V9, P93, DOI 10.1038/nm808; van de Sand C, 2005, MOL MICROBIOL, V58, P731, DOI 10.1111/j.1365-2958.2005.04888.x; WEISS WR, 1989, J IMMUNOL, V143, P4263	32	17	17	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1874	10.1371/journal.pone.0001874	http://dx.doi.org/10.1371/journal.pone.0001874			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365019	Green Submitted, gold, Green Published			2022-12-25	WOS:000260762400025
J	Wang, B; Xiao, ZF; Chen, B; Han, J; Gao, Y; Zhang, J; Zhao, WX; Wang, X; Dai, JW				Wang, Bin; Xiao, Zhifeng; Chen, Bing; Han, Jin; Gao, Yuan; Zhang, Jing; Zhao, Wenxue; Wang, Xia; Dai, Jianwu			Nogo-66 Promotes the Differentiation of Neural Progenitors into Astroglial Lineage Cells through mTOR-STAT3 Pathway	PLOS ONE			English	Article								Background: Neural stem/progenitor cells (NPCs) can differentiate into neurons, astrocytes and oligodendrocytes. NPCs are considered valuable for the cell therapy of injuries in the central nervous system (CNS). However, when NPCs are transplanted into the adult mammalian spinal cord, they mostly differentiate into glial lineage. The same results have been observed for endogenous NPCs during spinal cord injury. However, little is known about the mechanism of such fate decision of NPCs. Methodology/Principal Findings: In the present study, we have found that myelin protein and Nogo-66 promoted the differentiation of NPCs into glial lineage. NgR and mTOR-Stat3 pathway were involved in this process. Releasing NgR from cell membranes or blocking mTOR-STAT3 could rescue the enhanced glial differentiation by Nogo-66. Conclusions/Significance: These results revealed a novel function of Nogo-66 in the fate decision of NPCs. This discovery could have profound impact on the understanding of CNS development and could improve the therapy of CNS injuries.	[Wang, Bin; Xiao, Zhifeng; Chen, Bing; Han, Jin; Gao, Yuan; Zhang, Jing; Zhao, Wenxue; Wang, Xia; Dai, Jianwu] Chinese Acad Sci, Inst Genet & Dev Biol, Key Lab Mol Dev Biol, Beijing, Peoples R China	Chinese Academy of Sciences; Institute of Genetics & Developmental Biology, CAS	Wang, B (corresponding author), Chinese Acad Sci, Inst Genet & Dev Biol, Key Lab Mol Dev Biol, Beijing, Peoples R China.	jwdai@genetics.ac.cn	Zhao, Wenxue/I-7721-2013		NSFC [30688002]; Chinese Academy of Sciences [KSCX2-YW-R-133]; Ministry of Science and Technology of China [2006CB943601]	NSFC(National Natural Science Foundation of China (NSFC)); Chinese Academy of Sciences(Chinese Academy of Sciences); Ministry of Science and Technology of China(Ministry of Science and Technology, China)	This work was supported by grants from NSFC (30688002), Chinese Academy of Sciences (KSCX2-YW-R-133), and the Ministry of Science and Technology of China (2006CB943601)	Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Cao QL, 2001, EXP NEUROL, V167, P48, DOI 10.1006/exnr.2000.7536; Chen HH, 2007, NEUROBIOL AGING, V28, P1148, DOI 10.1016/j.neurobiolaging.2006.05.036; Craig CG, 1996, J NEUROSCI, V16, P2649; DAVIS AA, 1994, NATURE, V372, P263, DOI 10.1038/372263a0; DELOULME JC, 1991, J NEUROSCI RES, V29, P499, DOI 10.1002/jnr.490290410; Dergham P, 2002, J NEUROSCI, V22, P6570; Dodd DA, 2005, J BIOL CHEM, V280, P12494, DOI 10.1074/jbc.M411827200; Fournier AE, 2003, J NEUROSCI, V23, P1416, DOI 10.1523/JNEUROSCI.23-04-01416.2003; Fournier AE, 2001, NATURE, V409, P341, DOI 10.1038/35053072; Gossrau G, 2007, STEM CELLS, V25, P939, DOI 10.1634/stemcells.2006-0299; GrandPre T, 2002, NATURE, V417, P547, DOI 10.1038/417547a; Hamilton GS, 1998, J MED CHEM, V41, P5119, DOI 10.1021/jm980307x; Hapner SJ, 2006, DEV BIOL, V297, P182, DOI 10.1016/j.ydbio.2006.05.007; Johe KK, 1996, GENE DEV, V10, P3129, DOI 10.1101/gad.10.24.3129; Kuhn HG, 1997, J NEUROSCI, V17, P5820; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Prinjha R, 2000, NATURE, V403, P383, DOI 10.1038/35000287; Rajan P, 2003, J CELL BIOL, V161, P911, DOI 10.1083/jcb.200211021; Rajan P, 1998, J NEUROSCI, V18, P3620; Spencer T, 2003, CURR OPIN NEUROBIOL, V13, P133, DOI 10.1016/S0959-4388(03)00012-6; Weible MW, 2007, GLIA, V55, P1156, DOI 10.1002/glia.20539; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; Yang H, 2006, J NEUROSCI, V26, P2157, DOI 10.1523/JNEUROSCI.4070-05.2005	24	81	98	3	16	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1856	10.1371/journal.pone.0001856	http://dx.doi.org/10.1371/journal.pone.0001856			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365011	Green Published, Green Submitted, gold			2022-12-25	WOS:000260762400017
J	Brandt, N; Franke, K; Johannes, S; Buck, F; Harder, N; Hassel, B; Nitsch, R; Schumacher, S				Brandt, Nicola; Franke, Kristin; Johannes, Sascha; Buck, Friedrich; Harder, Soenke; Hassel, Burkhard; Nitsch, Robert; Schumacher, Stefan			B56 beta, a regulatory subunit of protein phosphatase 2A, interacts with CALEB/NGC-mediated dendritic branching	FASEB JOURNAL			English	Article						neuronal differentiation; dendritic tree elaboration; spine morphogenesis; Akt signaling; mass spectrometry	EGF FAMILY; BETA-CATENIN; RHO GTPASES; TENASCIN-R; MEMBER; IDENTIFICATION; EXPRESSION; DYNAMICS; SURVIVAL; 3-KINASE	The development of dendritic arbors is critical in neuronal circuit formation, as dendrites are the primary sites of synaptic input. Morphologically specialized dendritic protrusions called spines represent the main postsynaptic compartment for excitatory neuro-transmission. Recently, we demonstrated that chicken acidic leucine-rich epidermal growth factor (EGF) -like domain-containing brain protein/neuroglycanC(CALEB/ NGC), a neural member of the EGF family, mediates dendritic tree and spine complexity but that the signaling pathways in the respective processes differ. For a more detailed characterization of these signal transduction pathways, we performed a yeast two-hybrid screen to identify proteins that interact with CALEB/NGC. Our results show that B56 beta, a regulatory subunit of protein phosphatase 2A, interacts with CALEB/NGC and inhibits CALEB/NGC-mediated dendritic branching but not spine formation. Binding of B56 beta to CALEB/NGC was confirmed by several biochemical and immunocytochemical assays. Using affinity chromatography and mass spectrometry, we demonstrate that the whole protein phosphatase 2A trimer, including structural and catalytic subunits, binds to CALEB/NGC via B56 beta. We show that CALEB/NGC induces the phosphorylation of Akt in dendrites. Previously described to interfere with Akt signaling, B56 beta inhibits Akt phosphorylation and Akt-dependent dendritic branching but not Akt-independent spine formation induced by CALEB/NGC. Our results contribute to a better understanding of signaling specificity leading to neuronal process differentiation in sequential developmental events.	[Brandt, Nicola; Franke, Kristin; Johannes, Sascha; Nitsch, Robert; Schumacher, Stefan] Charite, Ctr Anat, Inst Cell Biol & Neurobiol, D-10117 Berlin, Germany; [Buck, Friedrich; Harder, Soenke] Univ Hosp Hamburg Eppendorf, Inst Clin Chem, Hamburg, Germany; [Hassel, Burkhard] Univ Hosp Hamburg Eppendorf, Inst Cell Biochem & Clin Neurobiol, Hamburg, Germany	Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Hamburg; University Medical Center Hamburg-Eppendorf; University of Hamburg; University Medical Center Hamburg-Eppendorf	Schumacher, S (corresponding author), Charite, Ctr Anat, Inst Cell Biol & Neurobiol, Charite Pl 1, D-10117 Berlin, Germany.	stefan.schumacher@charite.de	Nitsch, Robert/AAI-9129-2021	Harder, Sonke/0000-0002-6352-4771; Dr. Franke, Kristin/0000-0002-7402-4211; Brandt, Nicola/0000-0003-2483-9292				BANKER G, 1998, CULTURING NERVE CELL; Brandt N, 2007, EMBO J, V26, P2371, DOI 10.1038/sj.emboj.7601680; BREWER GJ, 1993, J NEUROSCI RES, V35, P567, DOI 10.1002/jnr.490350513; Ethell IM, 2005, PROG NEUROBIOL, V75, P161, DOI 10.1016/j.pneurobio.2005.02.003; Halpain S, 2005, PROG BRAIN RES, V147, P29, DOI 10.1016/S0079-6123(04)47003-4; Hassel B, 2003, J BIOL CHEM, V278, P40136, DOI 10.1074/jbc.M305577200; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; Jan YN, 2003, NEURON, V40, P229, DOI 10.1016/S0896-6273(03)00631-7; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jaworski J, 2005, J NEUROSCI, V25, P11300, DOI 10.1523/JNEUROSCI.2270-05.2005; Juttner R, 2005, NEURON, V46, P233, DOI 10.1016/j.neuron.2005.02.027; Kumar V, 2005, J NEUROSCI, V25, P11288, DOI 10.1523/JNEUROSCI.2284-05.2005; Leemhuis J, 2004, J BIOL CHEM, V279, P585, DOI 10.1074/jbc.M307066200; Letourneux C, 2006, EMBO J, V25, P727, DOI 10.1038/sj.emboj.7600980; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Li XH, 2001, EMBO J, V20, P4122, DOI 10.1093/emboj/20.15.4122; McCright B, 1996, J BIOL CHEM, V271, P22081, DOI 10.1074/jbc.271.36.22081; MCCRIGHT B, 1995, J BIOL CHEM, V270, P26123, DOI 10.1074/jbc.270.44.26123; Nakanishi K, 2006, J BIOL CHEM, V281, P24970, DOI 10.1074/jbc.M601498200; Newey SE, 2005, J NEUROBIOL, V64, P58, DOI 10.1002/neu.20153; Rocher G, 2007, J BIOL CHEM, V282, P5468, DOI 10.1074/jbc.M609712200; Ruvolo PP, 2002, J BIOL CHEM, V277, P22847, DOI 10.1074/jbc.M201830200; Schumacher S, 2003, J NEUROCHEM, V87, P1213, DOI 10.1046/j.1471-4159.2003.02112.x; Schumacher S, 2001, J BIOL CHEM, V276, P7337, DOI 10.1074/jbc.M007234200; Schumacher S, 1997, J CELL BIOL, V136, P895, DOI 10.1083/jcb.136.4.895; Seeling JM, 1999, SCIENCE, V283, P2089, DOI 10.1126/science.283.5410.2089; Whitford KL, 2002, ANNU REV NEUROSCI, V25, P127, DOI 10.1146/annurev.neuro.25.112701.142932; Yamamoto H, 2001, J BIOL CHEM, V276, P26875, DOI 10.1074/jbc.M100443200; YOUNG D, 1988, P NATL ACAD SCI USA, V85, P5339, DOI 10.1073/pnas.85.14.5339; Yu X, 2003, NAT NEUROSCI, V6, P1169, DOI 10.1038/nn1132; Yuste R, 2004, NAT REV NEUROSCI, V5, P24, DOI 10.1038/nrn1300; Zolnierowicz S, 1996, BIOCHEM J, V317, P187, DOI 10.1042/bj3170187	32	11	11	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2521	2533		10.1096/fj.07-096115	http://dx.doi.org/10.1096/fj.07-096115			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18385213				2022-12-25	WOS:000257292500043
J	Zhou, J; Werstuck, GH; Lhotak, S; Shi, YY; Tedesco, V; Trigatti, B; Dickhout, J; Majors, AK; DiBello, PM; Jacobsen, DW; Austin, RC				Zhou, Ji; Werstuck, Geoff H.; Lhotak, Sarka; Shi, Yuan Y.; Tedesco, Vivienne; Trigatti, Bernardo; Dickhout, Jeffrey; Majors, Alana K.; DiBello, Patricia M.; Jacobsen, Donald W.; Austin, Richard C.			Hyperhomocysteinemia induced by methionine supplementation does not independently cause atherosclerosis in C57BL/6J mice	FASEB JOURNAL			English	Article						homocysteine; inflammation; VLDL; atherogenesis; dietary intervention	ENDOPLASMIC-RETICULUM STRESS; LOW-DENSITY LIPOPROTEIN; CYSTATHIONINE BETA-SYNTHASE; PLASMA-LEVELS; ACCELERATES ATHEROSCLEROSIS; INDUCED ARTERIOSCLEROSIS; REDUCES ATHEROSCLEROSIS; QUANTITATIVE ASSESSMENT; CARDIOVASCULAR-DISEASE; CORONARY-ARTERY	A causal relationship between diet-induced hyperhomocysteinemia (HHcy)and accelerated atherosclerosis has been established in apolipoprotein E-deficient (apoE(-/-)) mice. However, it is not known whether the proatherogenic effect of HHcy in apoE(-/-) mice is independent of hyperlipidemia and/or deficiency of apoE. In this study, a comprehensive dietary approach using C57BL/6J mice was used to investigate whether HHcy is an independent risk factor for accelerated atherosclerosis or dependent on additional dietary factors that increase plasma lipids and/or inflammation. C57BL/6J mice at 4 wk of age were divided into 6 dietary groups: chow diet (C), chow diet + methionine (C + M), western-type diet (W), western-type diet + methionine (W + M), atherogenic diet (A), or atherogenic diet + methionine (A + M). After 2, 10, 20, or 40 wk on the diets, mice were sacrificed, and the levels of total plasma homocysteine, cysteine, and glutathione, as well as total plasma cholesterol and triglycerides were analyzed. Aortic root sections were examined for atherosclerotic lesions. HHcy was induced in all groups supplemented with methionine, compared to diet-matched control groups. Plasma total cholesterol was significantly increased in mice fed the W or A diet. However, the W diet increased LDL/IDL and HDL levels, while the A diet significantly elevated plasma VLDL and LDL/IDL levels without increasing HDL. No differences in plasma total cholesterol levels or lipid profiles were observed between methionine-supplemented groups and the diet-matched control groups. Early atherosclerotic lesions containing macrophage foam cells were only observed in mice fed the A or A + M diet. Furthermore, lesion size was significantly larger in the A + M group compared to the A group at 10 and 20 wk; however, mature lesions were never observed even after 40 wk on these diets. The presence of lymphocytes, increased hyaluronan staining, and the expression of endoplasmic reticulum (ER) stress markers were also increased in atherosclerotic lesions from the A + M group. Taken together, these results suggest that HHcy does not independently cause atherosclerosis in C57BL/6J mice even in the presence of increased total plasma lipids induced by the W diet. However, HHcy can accelerate atherosclerotic lesion development under dietary conditions that increase plasma VLDL levels and/or inflammation.	[Zhou, Ji; Werstuck, Geoff H.; Lhotak, Sarka; Shi, Yuan Y.; Dickhout, Jeffrey; Austin, Richard C.] Henderson Res Ctr, Hamilton, ON L8V 1C3, Canada; [Zhou, Ji; Werstuck, Geoff H.; Lhotak, Sarka; Shi, Yuan Y.; Dickhout, Jeffrey; Austin, Richard C.] McMaster Univ, Dept Med, Hamilton, ON, Canada; [Werstuck, Geoff H.; Tedesco, Vivienne; Trigatti, Bernardo] McMaster Univ, Dept Biochem & Biomed Sci, Hamilton, ON, Canada; [DiBello, Patricia M.; Jacobsen, Donald W.] Cleveland Clin, Lerner Res Inst, Dept Cell Biol, Cleveland, OH 44106 USA; [Jacobsen, Donald W.] Case Western Reserve Univ, Cleveland Clin Lerner Coll Med, Dept Mol Med, Cleveland, OH 44106 USA; [Austin, Richard C.] St Josephs Hosp, Div Nephrol, Hamilton, ON, Canada; [Majors, Alana K.] Cleveland Clin, Dept Pathobiol, Cleveland, OH 44106 USA	McMaster University; McMaster University; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; McGill University; McMaster University; Cleveland Clinic Foundation	Austin, RC (corresponding author), Henderson Res Ctr, 711 Concess St, Hamilton, ON L8V 1C3, Canada.	raustin@thrombosis.hhscr.org	Dickhout, Jeffrey/R-2606-2019	Trigatti, Bernardo (Dino) L./0000-0002-4556-119X	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052234, R37HL052234] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52234, R37 HL052234-14, R01 HL052234, R37 HL052234] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Bernstein H, 1999, TOXICOL LETT, V108, P37, DOI 10.1016/S0378-4274(99)00113-7; BOUSHEY CJ, 1995, JAMA-J AM MED ASSOC, V274, P1049, DOI 10.1001/jama.274.13.1049; Burke AP, 2002, ARTERIOSCL THROM VAS, V22, P1936, DOI 10.1161/01.ATV.0000035405.16217.86; Burleigh ME, 2005, BIOCHEM PHARMACOL, V70, P334, DOI 10.1016/j.bcp.2005.04.044; Chai S, 2005, CIRC RES, V96, P583, DOI 10.1161/01.RES.0000158963.37132.8b; Chen Zhoutao, 2002, Brain Res Gene Expr Patterns, V1, P89; Colgan SM, 2007, INT J BIOCHEM CELL B, V39, P1843, DOI 10.1016/j.biocel.2007.05.002; Dixon JL, 2002, J LIPID RES, V43, P1618, DOI 10.1194/jlr.M200134-JLR200; DONAHUE S, 1974, AM J PATHOL, V77, P167; Eikelboom JW, 1999, ANN INTERN MED, V131, P363, DOI 10.7326/0003-4819-131-5-199909070-00008; HARKER LA, 1976, J CLIN INVEST, V58, P731, DOI 10.1172/JCI108520; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; Hofmann MA, 2001, J CLIN INVEST, V107, P675, DOI 10.1172/JCI10588; Iciek M, 2004, ACTA BIOCHIM POL, V51, P815; JACOBSEN DW, 1994, CLIN CHEM, V40, P873; Ji C, 2003, GASTROENTEROLOGY, V124, P1488, DOI 10.1016/S0016-5085(03)00276-2; Kleemann R, 2003, CIRCULATION, V108, P1368, DOI 10.1161/01.CIR.0000086460.55494.AF; Kokame K, 1996, J BIOL CHEM, V271, P29659, DOI 10.1074/jbc.271.47.29659; Mack WJ, 1996, ARTERIOSCL THROM VAS, V16, P697, DOI 10.1161/01.ATV.16.5.697; Majors AK, 2003, J BIOL CHEM, V278, P47223, DOI 10.1074/jbc.M304871200; MALINOW MR, 1995, CLIN CHEM, V41, P173; Matthias D, 1996, ATHEROSCLEROSIS, V122, P201, DOI 10.1016/0021-9150(95)05740-4; MCCULLY KS, 1969, AM J PATHOL, V56, P111; McQuillan BM, 1999, CIRCULATION, V99, P2383, DOI 10.1161/01.CIR.99.18.2383; Monetti M, 2007, PHARMACOL RES, V55, P441, DOI 10.1016/j.phrs.2007.02.001; MUDD SH, 1985, AM J HUM GENET, V37, P1; Norata GD, 2007, ATHEROSCLEROSIS, V191, P265, DOI 10.1016/j.atherosclerosis.2006.05.047; Olszanecki R, 2005, J PHYSIOL PHARMACOL, V56, P627; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; REDDY GSR, 1982, METABOLISM, V31, P778, DOI 10.1016/0026-0495(82)90075-0; Rigotti A, 1997, P NATL ACAD SCI USA, V94, P12610, DOI 10.1073/pnas.94.23.12610; Rosenblatt D. S., 2001, METABOLIC MOL BASES, V8th, P3897; Rubba P, 2000, DEV CARDIOVASC MED, V230, P117; Sampedro MC, 2001, BIOCHEM BIOPH RES CO, V285, P393, DOI 10.1006/bbrc.2001.5202; Scalia R, 2001, CIRCULATION, V103, P2598; Smilde TJ, 1998, ARTERIOSCL THROM VAS, V18, P1958, DOI 10.1161/01.ATV.18.12.1958; Srivastava RAK, 2001, INT J BIOCHEM CELL B, V33, P1215, DOI 10.1016/S1357-2725(01)00080-2; Srivastava RAK, 2000, EUR J BIOCHEM, V267, P4272, DOI 10.1046/j.1432-1327.2000.01473.x; Stollenwerk MM, 2005, BIOCHEM BIOPH RES CO, V335, P603, DOI 10.1016/j.bbrc.2005.07.123; Stollenwerk MM, 2005, ATHEROSCLEROSIS, V179, P247, DOI 10.1016/j.atherosclerosis.2004.12.002; TATAMI R, 1981, CIRCULATION, V64, P1174, DOI 10.1161/01.CIR.64.6.1174; Vergnes L, 2003, J BIOL CHEM, V278, P42774, DOI 10.1074/jbc.M306022200; Wang H, 2003, BLOOD, V101, P3901, DOI 10.1182/blood-2002-08-2606; Werstuck GH, 2001, J CLIN INVEST, V107, P1263, DOI 10.1172/JCI11596; Wilcken DEL, 2000, DEV CARDIOVASC MED, V230, P5; Wilson KM, 2007, ARTERIOSCL THROM VAS, V27, P233, DOI 10.1161/01.ATV.0000251607.96118.af; Zhou J, 2005, CIRCULATION, V111, P1814, DOI 10.1161/01.CIR.0000160864.31351.C1; Zhou J, 2004, CIRCULATION, V110, P207, DOI 10.1161/01.CIR.0000134487.51510.97; Zhou J, 2003, ATHEROSCLEROSIS, V168, P255, DOI 10.1016/S0021-9150(03)00138-2; Zhou J, 2001, ARTERIOSCL THROM VAS, V21, P1470, DOI 10.1161/hq0901.096582; Zulli A, 2004, ATHEROSCLEROSIS, V176, P83, DOI 10.1016/j.atherosclerosis.2004.05.013	52	37	42	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	JUL	2008	22	7					2569	2578		10.1096/fj.07-105353	http://dx.doi.org/10.1096/fj.07-105353			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	321GK	18364397	Green Accepted			2022-12-25	WOS:000257292500048
J	Brunsing, R; Omori, SA; Weber, F; Bicknell, A; Friend, L; Rickert, R; Niwa, M				Brunsing, Ryan; Omori, Sidne A.; Weber, Frank; Bicknell, Alicia; Friend, Leslie; Rickert, Robert; Niwa, Maho			B- and T-cell development both involve activity of the unfolded protein response pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM STRESS; TRANSCRIPTION FACTOR XBP-1; ER STRESS; TRANSMEMBRANE PROTEIN; MESSENGER-RNA; TRANSLATIONAL CONTROL; STEM-CELLS; IN-VITRO; KINASE; IRE1	The unfolded protein response (UPR) signaling pathway regulates the functional capacity of the endoplasmic reticulum for protein folding. Beyond a role for UPR signaling during terminal differentiation of mature B cells to antibody-secreting plasma cells, the status or importance of UPR signaling during hematopoiesis has not been explored, due in part to difficulties in isolating sufficient quantities of cells at developmentally intermediate stages required for biochemical analysis. Following reconstitution of irradiated mice with hematopoietic cells carrying a fluorescent UPR reporter construct, we found that IRE1 nuclease activity for XBP1 splicing is active at early stages of T-and B-lymphocyte differentiation: in bone marrow pro-B cells and in CD4(+)CD8(+) double positive thymic T cells. IRE1 was not active in B cells at later stages. In T cells, IRE activity was not detected in the more mature CD4(+) T-cell population but was active in the CD8(+) cytotoxic T-cell population. Multiple signals are likely to be involved in activating IRE1 during lymphocyte differentiation, including rearrangement of antigen receptor genes. Our results show that reporter-transduced hematopoietic stem cells provide a quick and easy means to identify UPR signaling component activation in physiological settings.	[Omori, Sidne A.; Rickert, Robert] Burnham Inst, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute	Niwa, M (corresponding author), Univ Calif San Diego, Div Biol Sci, Mol Biol Sect, La Jolla, CA 92093 USA.	niwa@ucsd.edu	Longo, Kenneth A/A-5631-2010	Fitzpatrick, Sidne/0000-0002-5245-4624				Batard P, 2000, J CELL SCI, V113, P383; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bertolotti A, 2001, J CLIN INVEST, V107, P585, DOI 10.1172/JCI11476; Bicknell AA, 2007, J CELL BIOL, V177, P1017, DOI 10.1083/jcb.200702101; Calfon M, 2002, NATURE, V415, P92, DOI 10.1038/415092a; Chambers KT, 2007, AM J PHYSIOL-ENDOC M, V292, pE1052, DOI 10.1152/ajpendo.00274.2006; Chambers KT, 2006, DIABETES, V55, pA354; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; Cox JS, 1996, CELL, V87, P391, DOI 10.1016/S0092-8674(00)81360-4; Credle JJ, 2005, P NATL ACAD SCI USA, V102, P18773, DOI 10.1073/pnas.0509487102; DuRose JB, 2006, MOL BIOL CELL, V17, P3095, DOI 10.1091/mbc.E06-01-0055; Dzierzak E, 2002, IMMUNOL REV, V187, P126, DOI 10.1034/j.1600-065X.2002.18711.x; Fortunel N, 1998, J CELL SCI, V111, P1867; Fortunel N, 2000, STEM CELLS, V18, P102, DOI 10.1634/stemcells.18-2-102; Fortunel NO, 2003, ONCOL RES, V13, P445; Gass JN, 2002, J BIOL CHEM, V277, P49047, DOI 10.1074/jbc.M205011200; Giesen K, 2001, BLOOD, V98, p115B; Gunn KE, 2004, MOL IMMUNOL, V41, P919, DOI 10.1016/j.molimm.2004.04.023; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Harding HP, 2002, ANNU REV CELL DEV BI, V18, P575, DOI 10.1146/annurev.cellbio.18.011402.160624; Haze K, 1999, MOL BIOL CELL, V10, P3787, DOI 10.1091/mbc.10.11.3787; Iwakoshi NN, 2003, NAT IMMUNOL, V4, P321, DOI 10.1038/ni907; Iwawaki T, 2004, NAT MED, V10, P98, DOI 10.1038/nm970; Kaufman RJ, 1999, GENE DEV, V13, P1211, DOI 10.1101/gad.13.10.1211; Liu CY, 2000, J BIOL CHEM, V275, P24881, DOI 10.1074/jbc.M004454200; Liu CY, 2002, J BIOL CHEM, V277, P18346, DOI 10.1074/jbc.M112454200; MELCHERS F, 1994, ANNU REV IMMUNOL, V12, P209, DOI 10.1146/annurev.immunol.12.1.209; Mori K, 2000, CELL, V101, P451, DOI 10.1016/S0092-8674(00)80855-7; MORI K, 1993, CELL, V74, P743; Oyadomari S, 2001, P NATL ACAD SCI USA, V98, P10845, DOI 10.1073/pnas.191207498; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Reimold AM, 2001, NATURE, V412, P300, DOI 10.1038/35085509; Rumfelt LL, 2006, J EXP MED, V203, P675, DOI 10.1084/jem.20052444; Schmitt TM, 2004, NAT IMMUNOL, V5, P410, DOI 10.1038/ni1055; Shamu CE, 1996, EMBO J, V15, P3028, DOI 10.1002/j.1460-2075.1996.tb00666.x; Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4; Shen XH, 2001, CELL, V107, P893, DOI 10.1016/S0092-8674(01)00612-2; Shi YG, 1998, MOL CELL BIOL, V18, P7499, DOI 10.1128/MCB.18.12.7499; Starr TK, 2003, ANNU REV IMMUNOL, V21, P139, DOI 10.1146/annurev.immunol.21.120601.141107; Tirasophon W, 1998, GENE DEV, V12, P1812, DOI 10.1101/gad.12.12.1812; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Wang XZ, 1998, EMBO J, V17, P5708, DOI 10.1093/emboj/17.19.5708; Welihinda AK, 2000, J BIOL CHEM, V275, P3377, DOI 10.1074/jbc.275.5.3377; Ye J, 2000, MOL CELL, V6, P1355, DOI 10.1016/S1097-2765(00)00133-7; Yoshida H, 2001, CELL, V107, P881, DOI 10.1016/S0092-8674(01)00611-0; Yoshida H, 2001, MOL CELL BIOL, V21, P1239, DOI 10.1128/MCB.21.4.1239-1248.2001; Zhang KZ, 2005, J CLIN INVEST, V115, P268, DOI 10.1172/JCI200521848	47	72	75	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					17954	17961		10.1074/jbc.M801395200	http://dx.doi.org/10.1074/jbc.M801395200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18375386	hybrid			2022-12-25	WOS:000256949200024
J	Gangabadage, CS; Zdunek, J; Tessari, M; Nilsson, S; Olivecrona, G; Wijmenga, SS				Gangabadage, Chinthaka Saneth; Zdunek, Janusz; Tessari, Marco; Nilsson, Solveig; Olivecrona, Gunilla; Wijmenga, Sybren Sipke			Structure and dynamics of human apolipoprotein CIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAJOR COAT PROTEIN; C-III VARIANT; LIPOPROTEIN-LIPASE; LIPID-BINDING; A-I; EXCHANGEABLE APOLIPOPROTEIN; DETERGENT MICELLES; BACKBONE DYNAMICS; LDL RECEPTOR; SECONDARY STRUCTURE	Human apolipoprotein CIII (apoCIII) is a surface component of chylomicrons, very low density lipoproteins, and high density lipoproteins. ApoCIII inhibits lipoprotein lipase as well as binding of lipoproteins to cell surface heparan sulfate proteoglycans and receptors. High levels of apoCIII are often correlated with elevated levels of blood lipids (hypertriglyceridemia). Here, we report the three-dimensional NMR structure and dynamics of human apoCIII in complex with SDS micelles, mimicking its natural lipid-bound state. Thanks to residual dipolar coupling data, the first detailed view is obtained of the structure and dynamics of an intact apolipoprotein in its lipid-bound state. ApoCIII wraps around the micelle surface as a necklace of six similar to 10-residue amphipathic helices, which are curved and connected via semiflexible hinges. Three positively charged(Lys) residues line the polar faces of helices 1 and 2. Interestingly, their three-dimensional conformation is similar to that of the low density lipoprotein receptor binding motifs of apoE/B and the receptor-associated protein. At the C-terminal side of apoCIII, an array of negatively charged residues lines the polar faces of helices 4 and 5 and the adjacent flexible loop. Sequence comparison shows that this asymmetric charge distribution along the solvent-exposed face of apoCIII as well as other structural features are conserved among mammals. This structure provides a template for exploration of molecular mechanisms by which human apoCIII inhibits lipoprotein lipase and receptor binding.	[Gangabadage, Chinthaka Saneth; Tessari, Marco; Wijmenga, Sybren Sipke] Radboud Univ Nijmegen, Inst Mol & Mat, Dept Phys Chem Biophys Chem, NL-6525 ED Nijmegen, Netherlands; [Gangabadage, Chinthaka Saneth] Univ Ruhuna, Dept Chem, Matara, Sri Lanka; [Zdunek, Janusz] Umea Univ, Dept Med Biochem & Biophys, SE-90187 Umea, Sweden; [Nilsson, Solveig; Olivecrona, Gunilla] Umea Univ, Dept Med Biosci Physiol Chem, SE-90187 Umea, Sweden	Radboud University Nijmegen; University Ruhuna; Umea University; Umea University	Wijmenga, SS (corresponding author), Radboud Univ Nijmegen, Inst Mol & Mat, Dept Phys Chem Biophys Chem, Toernooiveld 1, NL-6525 ED Nijmegen, Netherlands.	S.Wijmenga@nmr.ru.nl	Tessari, Marco/F-9693-2015					Ajees AA, 2006, P NATL ACAD SCI USA, V103, P2126, DOI 10.1073/pnas.0506877103; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; BORGIAS BA, 1990, J MAGN RESON, V87, P475, DOI 10.1016/0022-2364(90)90305-S; Borhani DW, 1997, P NATL ACAD SCI USA, V94, P12291, DOI 10.1073/pnas.94.23.12291; Canutescu AA, 2003, PROTEIN SCI, V12, P963, DOI 10.1110/ps.0242703; Chou JJ, 2001, J BIOMOL NMR, V21, P377, DOI 10.1023/A:1013336502594; CLAVEY V, 1995, ARTERIOSCL THROM VAS, V15, P963, DOI 10.1161/01.ATV.15.7.963; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Ebara T, 1997, J CLIN INVEST, V99, P2672, DOI 10.1172/JCI119456; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; EISENBERG D, 1984, P NATL ACAD SCI-BIOL, V81, P140, DOI 10.1073/pnas.81.1.140; EISENBERG D, 1984, J MOL BIOL, V179, P125, DOI 10.1016/0022-2836(84)90309-7; Fan DP, 2003, J BIOL CHEM, V278, P21212, DOI 10.1074/jbc.M208486200; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fisher C, 2006, MOL CELL, V22, P277, DOI 10.1016/j.molcel.2006.02.021; Folmer RHA, 1997, J BIOMOL NMR, V9, P245, DOI 10.1023/A:1018670623695; Gursky O, 2005, CURR OPIN LIPIDOL, V16, P287, DOI 10.1097/01.mol.0000169348.61191.ac; Hatters DM, 2005, J BIOL CHEM, V280, P26477, DOI 10.1074/jbc.M503910200; HUMPHREY W, 1996, J MOL GRAPHICS, V14, P32; ITO Y, 1990, SCIENCE, V249, P790, DOI 10.1126/science.2167514; Jong MC, 1999, ARTERIOSCL THROM VAS, V19, P472, DOI 10.1161/01.ATV.19.3.472; Juntti-Berggren L, 2004, P NATL ACAD SCI USA, V101, P10090, DOI 10.1073/pnas.0403551101; Kaiser J, 2004, SCIENCE, V306, P1284; Kumar MS, 2002, BIOCHEMISTRY-US, V41, P11681, DOI 10.1021/bi026069w; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; Lambert DA, 2000, CLIN CHIM ACTA, V291, P19, DOI 10.1016/S0009-8981(99)00193-X; Larsson G, 2005, BIOPHYS J, V89, P1214, DOI 10.1529/biophysj.104.055780; Larsson G, 2003, J BIOMOL NMR, V27, P291, DOI 10.1023/A:1025836018993; Lins L, 2002, PROTEIN ENG, V15, P513, DOI 10.1093/protein/15.6.513; Liu HQ, 2000, J LIPID RES, V41, P1760; Liu HQ, 2000, BIOCHEMISTRY-US, V39, P9201, DOI 10.1021/bi0009441; Losonczi JA, 1999, J MAGN RESON, V138, P334, DOI 10.1006/jmre.1999.1754; MacRaild CA, 2004, BIOCHEMISTRY-US, V43, P8084, DOI 10.1021/bi049817l; MAEDA N, 1994, J BIOL CHEM, V269, P23610; Mascioni A, 2003, J AM CHEM SOC, V125, P12520, DOI 10.1021/ja0354824; Mesleh MF, 2003, J AM CHEM SOC, V125, P8928, DOI 10.1021/ja034211q; Narayanaswami V, 2000, BBA-MOL CELL BIOL L, V1483, P15, DOI 10.1016/S1388-1981(99)00176-6; Okon M, 2002, FEBS LETT, V517, P139, DOI 10.1016/S0014-5793(02)02600-5; Ottiger M, 1998, J MAGN RESON, V131, P373, DOI 10.1006/jmre.1998.1361; Papavoine CHM, 1997, BIOCHEMISTRY-US, V36, P4015, DOI 10.1021/bi962650e; Papavoine CHM, 1998, J MOL BIOL, V282, P401, DOI 10.1006/jmbi.1998.1860; Peters-Libeu CA, 2006, J BIOL CHEM, V281, P1073, DOI 10.1074/jbc.M510851200; Rozek A, 1999, BIOCHEMISTRY-US, V38, P14475, DOI 10.1021/bi982966h; Rudenko G, 2002, SCIENCE, V298, P2353, DOI 10.1126/science.1078124; Saito H, 2004, PROG LIPID RES, V43, P350, DOI 10.1016/j.plipres.2004.05.002; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; Schwieters CD, 2001, J MAGN RESON, V152, P288, DOI 10.1006/jmre.2001.2413; Segelke BW, 2000, PROTEIN SCI, V9, P886, DOI 10.1110/ps.9.5.886; SEGREST JP, 1992, J LIPID RES, V33, P141; Shen Y, 2002, J BIOL CHEM, V277, P4334, DOI 10.1074/jbc.M105421200; SPARROW JT, 1977, BIOCHEMISTRY-US, V16, P5427, DOI 10.1021/bi00644a004; Talmud PJ, 2002, HUM MOL GENET, V11, P3039, DOI 10.1093/hmg/11.24.3039; van Dijk KW, 2004, CURR OPIN LIPIDOL, V15, P239, DOI [10.1097/01.mol.00001300096.77252.1f, 10.1097/00041433-200406000-00002]; VONECKARDSTEIN A, 1991, J CLIN INVEST, V87, P1724, DOI 10.1172/JCI115190; VUISTER GW, 1993, J AM CHEM SOC, V115, P7772, DOI 10.1021/ja00070a024; Wang JJ, 2002, P NATL ACAD SCI USA, V99, P1188, DOI 10.1073/pnas.032565999; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; Williams DL, 2000, J BIOL CHEM, V275, P18897, DOI 10.1074/jbc.M002411200; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194; Xu SZ, 1997, J LIPID RES, V38, P1289; Zannis VI, 2006, J MOL MED, V84, P276, DOI 10.1007/s00109-005-0030-4; Zdunek J, 2003, BIOCHEMISTRY-US, V42, P1872, DOI 10.1021/bi0267184	64	62	67	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17416	17427		10.1074/jbc.M800756200	http://dx.doi.org/10.1074/jbc.M800756200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18408013	Green Published, hybrid			2022-12-25	WOS:000256720600050
J	Roach, TIA; Rebres, RA; Fraser, IDC; DeCamp, DL; Lin, KM; Sternweis, PC; Simon, MI; Seaman, WE				Roach, Tamara I. A.; Rebres, Robert A.; Fraser, Iain D. C.; DeCamp, Dianne L.; Lin, Keng-Mean; Sternweis, Paul C.; Simon, Mel I.; Seaman, William E.			Signaling and cross-talk by C5a and UDP in macrophages selectively use PLC beta 3 to regulate intracellular free calcium	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C-BETA; FIBER SYNAPSE ELIMINATION; G-ALPHA-Q; NUCLEOTIDE RECEPTORS; PHOSPHATIDYLINOSITOL 4,5-BISPHOSPHATE; HETEROLOGOUS POTENTIATION; PI 3-KINASE; ACTIVATION; SUBUNIT; RESPONSES	Studies in fibroblasts, neurons, and platelets have demonstrated the integration of signals from different G protein-coupled receptors (GPCRs) in raising intracellular free Ca2+. To study signal integration in macrophages, we screened RAW264.7 cells and bone marrow-derived macrophages (BMDM) for their Ca2+ response to GPCR ligands. We found a synergistic response to complement component 5a (C5a) in combination with uridine 5'-diphosphate (UDP), platelet activating factor (PAF), or lysophosphatidic acid (LPA). The C5a response was G alpha(i)-dependent, whereas the UDP, PAF, and LPA responses were G alpha(q)-dependent. Synergy between C5a and UDP, mediated by the C5a and P2Y6 receptors, required dual receptor occupancy, and affected the initial release of Ca2+ from intracellular stores as well as sustained Ca2+ levels. C5a and UDP synergized in generating inositol 1,4,5-trisphosphate, suggesting synergy in activating phospholipase C (PLC) beta. Macrophages expressed transcripts for three PLC beta isoforms (PLC beta 2, PLC beta 3, and PLC beta 4), but GPCR ligands selectively used these isoforms in Ca2+ signaling. C5a predominantly used PLC beta 3, whereas UDP used PLC beta 3 but also PLC beta 4. Neither ligand required PLC beta 2. Synergy between C5a and UDP likewise depended primarily on PLC beta 3. Importantly, the Ca2+ signaling deficiency observed in PLC beta 3-deficient BMDM was reversed by re-constitution with PLC beta 3. Neither phosphatidylinositol (PI) 3-kinase nor protein kinase C was required for synergy. In contrast to Ca2+, PI 3-kinase activation by C5a was inhibited by UDP, as was macropinocytosis, which depends on PI 3-kinase. PLC beta 3 may thus provide a selective target for inhibiting Ca2+ responses to mediators of inflammation, including C5a, UDP, PAF, and LPA.	[Roach, Tamara I. A.; Rebres, Robert A.] Vet Affairs Med Ctr, No Calif Inst Res & Educ, San Francisco, CA 94121 USA; [Seaman, William E.] Univ Calif San Francisco, Vet Affairs Med Ctr, San Francisco, CA 94121 USA; [Fraser, Iain D. C.; Simon, Mel I.] CALTECH, Div Biol, Pasadena, CA 91125 USA; [DeCamp, Dianne L.; Lin, Keng-Mean; Sternweis, Paul C.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA	Northern California Institute for Research & Education; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; US Department of Veterans Affairs; Veterans Health Administration (VHA); California Institute of Technology; University of Texas System; University of Texas Southwestern Medical Center Dallas	Roach, TIA (corresponding author), Vet Affairs Med Ctr, No Calif Inst Res & Educ, 111R,4150 Clement St, San Francisco, CA 94121 USA.	Tamara.Roach@ucsf.edu; Robert.Rebres@ucsf.edu; bseaman@medicine.ucsf.edu	Fraser, Iain DC/L-4735-2017	Fraser, Iain DC/0000-0003-2272-3907	Intramural NIH HHS [ZIA AI001106-01, ZIA AI001107-01] Funding Source: Medline; NIGMS NIH HHS [GM62114] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI001107] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [U54GM062114] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abrams CS, 2005, CURR OPIN HEMATOL, V12, P401, DOI 10.1097/01.moh.0000176681.18710.e3; Ballou LM, 2006, BIOCHEM J, V394, P557, DOI 10.1042/BJ20051493; Ballou LM, 2003, J BIOL CHEM, V278, P23472, DOI 10.1074/jbc.M212232200; Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155; Boeynaems JM, 2006, J INVEST DERMATOL, V126, P943, DOI 10.1038/sj.jid.5700233; Carafoli E, 2001, CRIT REV BIOCHEM MOL, V36, P107, DOI 10.1080/20014091074183; Conner SD, 2003, NATURE, V422, P37, DOI 10.1038/nature01451; Davignon I, 2000, MOL CELL BIOL, V20, P797, DOI 10.1128/MCB.20.3.797-804.2000; del Rey A, 2006, J BIOL CHEM, V281, P35147, DOI 10.1074/jbc.M607713200; Di Virgilio F, 2001, BLOOD, V97, P587, DOI 10.1182/blood.V97.3.587; Dianzani C, 2001, J LEUKOCYTE BIOL, V69, P1013; Erb L, 2006, PFLUG ARCH EUR J PHY, V452, P552, DOI 10.1007/s00424-006-0069-2; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; Feske S, 2007, NAT REV IMMUNOL, V7, P690, DOI 10.1038/nri2152; Fraser Iain, 2007, V365, P261; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; Hashimoto K, 2000, PROG BRAIN RES, V124, P31; Hawlisch H, 2004, MOL IMMUNOL, V41, P123, DOI 10.1016/j.molimm.2004.03.019; Hazeki O, 1998, LIFE SCI, V62, P1555, DOI 10.1016/S0024-3205(98)00106-4; Hwang JI, 2004, P NATL ACAD SCI USA, V101, P488, DOI 10.1073/pnas.0307549100; JHON DY, 1993, J BIOL CHEM, V268, P6654; Jiang HP, 1996, P NATL ACAD SCI USA, V93, P14598, DOI 10.1073/pnas.93.25.14598; JIANG HP, 1994, J BIOL CHEM, V269, P7593; Jiang HP, 1996, J BIOL CHEM, V271, P13430, DOI 10.1074/jbc.271.23.13430; Jiang HP, 1997, P NATL ACAD SCI USA, V94, P7971, DOI 10.1073/pnas.94.15.7971; Kano M, 1998, P NATL ACAD SCI USA, V95, P15724, DOI 10.1073/pnas.95.26.15724; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE CW, 1994, J BIOL CHEM, V269, P25335; Morita S, 2000, GENE THER, V7, P1063, DOI 10.1038/sj.gt.3301206; Natarajan M, 2006, NAT CELL BIOL, V8, P571, DOI 10.1038/ncb1418; Offermanns S, 1997, P NATL ACAD SCI USA, V94, P14089, DOI 10.1073/pnas.94.25.14089; Offermanns S, 1998, EMBO J, V17, P4304, DOI 10.1093/emboj/17.15.4304; PARK DG, 1993, J BIOL CHEM, V268, P4573; Rhee SG, 2001, ANNU REV BIOCHEM, V70, P281, DOI 10.1146/annurev.biochem.70.1.281; Riedemann NC, 2003, IMMUNITY, V19, P193, DOI 10.1016/S1074-7613(03)00206-1; Rock KL, 2005, IMMUNOL REV, V207, P166, DOI 10.1111/j.0105-2896.2005.00301.x; Rossi GR, 2003, HUM GENE THER, V14, P385, DOI 10.1089/104303403321208989; Runnels LW, 1999, BIOCHEMISTRY-US, V38, P1488, DOI 10.1021/bi9821519; Salmon P, 2000, BLOOD, V96, P3392; Sarndahl E, 1996, J BIOL CHEM, V271, P15267; Schmidt M, 1996, MOL PHARMACOL, V50, P1038; Schmidt M, 1996, N-S ARCH PHARMACOL, V354, P87, DOI 10.1007/BF00178707; Schmidt M, 1998, MOL PHARMACOL, V53, P1139; Selbie LA, 1998, TRENDS PHARMACOL SCI, V19, P87, DOI 10.1016/S0165-6147(97)01166-8; Skokowa J, 2005, J IMMUNOL, V174, P3041, DOI 10.4049/jimmunol.174.5.3041; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; STEPHENS L, 1993, BIOCHEM J, V296, P481, DOI 10.1042/bj2960481; SWANSON JA, 1985, J CELL BIOL, V100, P851, DOI 10.1083/jcb.100.3.851; SWANSON JA, 1995, TRENDS CELL BIOL, V5, P424, DOI 10.1016/S0962-8924(00)89101-1; Thelen M, 1997, ANN NY ACAD SCI, V832, P368, DOI 10.1111/j.1749-6632.1997.tb46265.x; Toms NJ, 1999, NEUROPHARMACOLOGY, V38, P1511, DOI 10.1016/S0028-3908(99)00090-8; Wang ZL, 2008, J CLIN INVEST, V118, P195, DOI 10.1172/JCI33139; Werry TD, 2003, J PHARMACOL EXP THER, V307, P661, DOI 10.1124/jpet.103.055632; Werry TD, 2002, BRIT J PHARMACOL, V135, P1199, DOI 10.1038/sj.bjp.0704566; Werry TD, 2003, BIOCHEM J, V374, P281, DOI 10.1042/BJ20030312; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; Xie W, 1999, P NATL ACAD SCI USA, V96, P10385, DOI 10.1073/pnas.96.18.10385; Yang CM, 2001, BIOCHEM J, V354, P439, DOI 10.1042/0264-6021:3540439; Yue CP, 2000, J BIOL CHEM, V275, P30220, DOI 10.1074/jbc.M004276200	59	33	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17351	17361		10.1074/jbc.M800907200	http://dx.doi.org/10.1074/jbc.M800907200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18411281	Green Published, hybrid			2022-12-25	WOS:000256720600044
J	Tsai, PC; Lee, SW; Liu, YW; Chu, CW; Chen, KY; Ho, JC; Lee, FJS				Tsai, Pei-Chin; Lee, Szu-Wei; Liu, Ya-Wen; Chu, Chih-Wen; Chen, Kuan-Yu; Ho, Jui-Chih; Lee, Fang-Jen S.			Afi1p functions as an Arf3p polarization-specific docking factor for development of polarity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-RIBOSYLATION FACTOR; SACCHAROMYCES-CEREVISIAE; PLASMA-MEMBRANE; BUDDING YEAST; PROTEIN; ACTIN; ROLES; TRAFFICKING; ENDOCYTOSIS; FAMILY	ADP-ribosylation factors (Arfs) are highly conserved small GTPases and are critical components of vesicle trafficking. Yeast Arf3p, despite its similarity to mammalian Arf6, is not required for endocytosis but is involved in polarity development. In this study, we identified an Arf3p interacting protein 1 (Afi1p), which, through its N-terminal conserved region, specifically interacts with GTP-bound Arf3p. Afi1p is distributed asymmetrically at the plasma membrane and is required for polarized distribution of Arf3p but not of an Arf3p guanine nucleotide-exchange factor, Yel1p. However, Afi1p is not required for targeting of Arf3p or Yel1p to the plasma membrane. Like arf3 mutant yeast, afi1 mutant yeast exhibited an abnormal budding pattern and partially delayed actin patch polarization. An Afi1p, (38)KLGP4A-Afi1p, mutated at the Arf3p-binding region, loses its ability to interact with Arf3p and maintain the polarized distribution of Arf3p. Although (38)KLGP4A-Afi1p still possessed a proper polarized distribution, it lost its ability to rescue actin patch polarization in afi1 mutant cells. Our findings demonstrate that Afi1p functions as an Arf3p polarization-specific adapter and participates in development of polarity.	[Tsai, Pei-Chin; Lee, Szu-Wei; Liu, Ya-Wen; Chu, Chih-Wen; Chen, Kuan-Yu; Ho, Jui-Chih; Lee, Fang-Jen S.] Natl Taiwan Univ Hosp, Dept Med Res, Taipei 100, Taiwan; [Tsai, Pei-Chin; Lee, Szu-Wei; Liu, Ya-Wen; Chu, Chih-Wen; Chen, Kuan-Yu; Ho, Jui-Chih; Lee, Fang-Jen S.] Natl Taiwan Univ, Sch Med, Inst Mol Med, Taipei 100, Taiwan	National Taiwan University; National Taiwan University Hospital; National Taiwan University	Lee, FJS (corresponding author), Natl Taiwan Univ Hosp, Dept Med Res, 7 Chung Shan SS Rd, Taipei 100, Taiwan.	fangjen@ntu.edu.tw		LEE, FANG-JEN/0000-0002-2167-2426; LIU, YA-WEN/0000-0003-0180-4142; Chu, Chih-Wen/0000-0002-0918-2301				Altschuler Y, 1999, J CELL BIOL, V147, P7, DOI 10.1083/jcb.147.1.7; BALCH WE, 1992, J BIOL CHEM, V267, P13053; Campbell RE, 2002, P NATL ACAD SCI USA, V99, P7877, DOI 10.1073/pnas.082243699; CHANT J, 1995, J CELL BIOL, V129, P751, DOI 10.1083/jcb.129.3.751; Chant T, 1999, ANNU REV CELL DEV BI, V15, P365, DOI 10.1146/annurev.cellbio.15.1.365; Costa R, 2005, BIOCHEM J, V387, P649, DOI 10.1042/BJ20041729; D'Souza-Schorey C, 2006, NAT REV MOL CELL BIO, V7, P347, DOI 10.1038/nrm1910; Donaldson JG, 2003, J BIOL CHEM, V278, P41573, DOI 10.1074/jbc.R300026200; GIETZ RD, 1988, GENE, V74, P535, DOI 10.1016/0378-1119(88)90186-2; Gillingham AK, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000842; Goldstein AL, 1999, YEAST, V15, P1541, DOI 10.1002/(SICI)1097-0061(199910)15:14<1541::AID-YEA476>3.3.CO;2-B; Golemis E A, 1997, Methods Mol Biol, V63, P197; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; Hernandez-Deviez DJ, 2004, MOL BIOL CELL, V15, P111, DOI 10.1091/mbc.E03-06-0410; Huang CF, 2003, MOL BIOL CELL, V14, P3834, DOI 10.1091/mbc.E03-01-0013; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Irazoqui JE, 2005, MOL BIOL CELL, V16, P1296, DOI 10.1091/mbc.E04-05-0430; Jackson CL, 2000, TRENDS CELL BIOL, V10, P60, DOI 10.1016/S0962-8924(99)01699-2; Lambert AA, 2007, FEMS YEAST RES, V7, P782, DOI 10.1111/j.1567-1364.2007.00239.x; LEE FJS, 1994, J BIOL CHEM, V269, P20931; Lee FJS, 1997, J BIOL CHEM, V272, P30998, DOI 10.1074/jbc.272.49.30998; Liu YW, 2006, J CELL SCI, V119, P3845, DOI 10.1242/jcs.03148; Longtine MS, 1998, YEAST, V14, P953, DOI 10.1002/(SICI)1097-0061(199807)14:10<953::AID-YEA293>3.3.CO;2-L; Madden K, 1998, ANNU REV MICROBIOL, V52, P687, DOI 10.1146/annurev.micro.52.1.687; Nie ZZ, 2003, CURR OPIN CELL BIOL, V15, P396, DOI 10.1016/S0955-0674(03)00071-1; Pearson CL, 2004, MOL BIOL CELL, V15, P3658, DOI 10.1091/mbc.E03-11-0803; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; Pruyne D, 2000, J CELL SCI, V113, P365; Ren B, 2000, SCIENCE, V290, P2306, DOI 10.1126/science.290.5500.2306; Sambrook J., 1989, MOL CLONING LAB MANU, V2; Sherman F., 1986, METHODS YEAST GENETI; Turner CE, 2001, CURR BIOL, V11, pR875, DOI 10.1016/S0960-9822(01)00521-8; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; Wysocka M, 2003, ACTA BIOCHIM POL, V50, P883; Zakrzewska E, 2003, GENETICS, V165, P985	35	10	13	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16915	16927		10.1074/jbc.M802550200	http://dx.doi.org/10.1074/jbc.M802550200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18397879	hybrid			2022-12-25	WOS:000256497100069
J	van Hemert, MJ; de Wilde, AH; Gorbalenya, AE; Snijder, EJ				van Hemert, Martijn J.; de Wilde, Adriaan H.; Gorbalenya, Alexander E.; Snijder, Eric J.			The in vitro RNA synthesizing activity of the isolated arterivirus replication/transcription complex is dependent on a host factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE HEPATITIS-VIRUS; EQUINE ARTERITIS VIRUS; RIBONUCLEIC ACID POLYMERASE; JAPANESE ENCEPHALITIS-VIRUS; CORONAVIRUS-INFECTED CELLS; DOUBLE-MEMBRANE VESICLES; NSP4 SERINE-PROTEASE; BROME MOSAIC-VIRUS; C VIRUS; VIRAL REPLICATION	The cytoplasmic replication of positive-stranded RNA viruses is associated with characteristic, virus-induced membrane structures that are derived from host cell organelles. We used the prototype arterivirus, equine arteritis virus (EAV), to gain insight into the structure and function of the replication/transcription complex (RTC) of nidoviruses. RTCs were isolated from EAV-infected cells, and their activity was studied using a newly developed in vitro assay for viral RNA synthesis, which reproduced the synthesis of both viral genome and subgenomic mRNAs. A detailed characterization of this system and its reaction products is described. RTCs isolated from cytoplasmic extracts by differential centrifugation were inactive unless supplemented with a cytosolic host protein factor, which, according to subsequent size fractionation analysis, has a molecular mass in the range of 59-70 kDa. This host factor was found to be present in a wide variety of eukaryotes. Several EAV replicase subunits cosedimented with newly made viral RNA in a heavy membrane fraction that contained all RNA-dependent RNA polymerase activity. This fraction contained the characteristic double membrane vesicles (DMVs) that were previously implicated in EAV RNA synthesis and could be immunolabeled for EAV nonstructural proteins (nsps). Replicase subunits directly involved in viral RNA synthesis (nsp9 and nsp10) or DMV formation (nsp2 and nsp3) exclusively cosedimented with the active RTC. Subgenomic mRNAs appeared to be released from the complex, whereas newly made genomic RNA remained more tightly associated. Taken together, our data strongly support a link between DMVs and the RNA-synthesizing machinery of arteriviruses.	[van Hemert, Martijn J.; de Wilde, Adriaan H.; Gorbalenya, Alexander E.; Snijder, Eric J.] Leiden Univ, Med Ctr, Mol Virol Lab, Dept Med Microbiol,Ctr Infect Dis, NL-2300 RC Leiden, Netherlands	Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC	Snijder, EJ (corresponding author), Leiden Univ, Med Ctr, Mol Virol Lab, Dept Med Microbiol,Ctr Infect Dis, LUMC E4-P,POB 9600, NL-2300 RC Leiden, Netherlands.	e.j.snijder@lumc.nl	Gorbalenya, Alexander E/J-4818-2012; Snijder, Eric J./E-6073-2018	Gorbalenya, Alexander E/0000-0002-4967-7341; Snijder, Eric J./0000-0003-3297-2309; van Hemert, Martijn/0000-0002-2617-9243				Ali N, 2002, J VIROL, V76, P12001, DOI 10.1128/JVI.76.23.12001-12007.2002; ARLINGHAUS RB, 1969, P NATL ACAD SCI USA, V62, P821, DOI 10.1073/pnas.62.3.821; BALTIMORE D, 1963, J BIOL CHEM, V238, P3395; BALTIMORE D, 1963, P NATL ACAD SCI USA, V49, P843, DOI 10.1073/pnas.49.6.843; BARTON DJ, 1993, J VIROL, V67, P822, DOI 10.1128/JVI.67.2.822-831.1993; BARTON DJ, 1991, J VIROL, V65, P1496, DOI 10.1128/JVI.65.3.1496-1506.1991; BARTON DJ, 1995, J VIROL, V69, P5516, DOI 10.1128/JVI.69.9.5516-5527.1995; Beerens N, 2007, J VIROL, V81, P8384, DOI 10.1128/JVI.00564-07; Bi WZ, 1998, J NEUROVIROL, V4, P594, DOI 10.3109/13550289809114226; Bost AG, 2000, J VIROL, V74, P3379, DOI 10.1128/JVI.74.7.3379-3387.2000; Bost AG, 2001, VIROLOGY, V285, P21, DOI 10.1006/viro.2001.0932; BRAYTON PR, 1982, J VIROL, V42, P847, DOI 10.1128/JVI.42.3.847-853.1982; BRAYTON PR, 1984, VIROLOGY, V133, P197, DOI 10.1016/0042-6822(84)90439-2; CHU PWG, 1987, VIROLOGY, V157, P330, DOI 10.1016/0042-6822(87)90275-3; CHU PWG, 1985, VIROLOGY, V140, P68, DOI 10.1016/0042-6822(85)90446-5; COMPTON SR, 1987, J VIROL, V61, P1814, DOI 10.1128/JVI.61.6.1814-1820.1987; Denison MR, 1999, J VIROL, V73, P6862, DOI 10.1128/JVI.73.8.6862-6871.1999; DENNIS DE, 1982, J VIROL, V42, P153, DOI 10.1128/JVI.42.1.153-164.1982; DEVRIES AAF, 1992, J VIROL, V66, P6294, DOI 10.1128/JVI.66.11.6294-6303.1992; Egger D, 2000, J VIROL, V74, P6570, DOI 10.1128/JVI.74.14.6570-6580.2000; EHRENFELD E, 1970, VIROLOGY, V40, P840, DOI 10.1016/0042-6822(70)90129-7; EHRENFELD E, 1981, J BIOL CHEM, V256, P2656; ETCHISON D, 1981, VIROLOGY, V111, P33, DOI 10.1016/0042-6822(81)90651-6; FRANKLIN RICHARD M., 1967, J VIROL, V1, P64; Goldsmith CS, 2004, EMERG INFECT DIS, V10, P320, DOI 10.3201/eid1002.030913; Gorbalenya AE, 2006, VIRUS RES, V117, P17, DOI 10.1016/j.virusres.2006.01.017; Gosert R, 2002, J VIROL, V76, P3697, DOI 10.1128/JVI.76.8.3697-3708.2002; GRUN JB, 1986, J VIROL, V60, P1113, DOI 10.1128/JVI.60.3.1113-1124.1986; Harcourt BH, 2004, J VIROL, V78, P13600, DOI 10.1128/JVI.78.24.13600-13612.2004; Hardy RW, 2003, J VIROL, V77, P2029, DOI 10.1128/JVI.77.3.2029-2037.2003; HARDY SF, 1979, P NATL ACAD SCI USA, V76, P4956, DOI 10.1073/pnas.76.10.4956; IGARASHI A, 1978, J GEN VIROL, V40, P531, DOI 10.1099/0022-1317-40-3-531; Ivanov KA, 2004, J VIROL, V78, P5619, DOI 10.1128/JVI.78.11.5619-5632.2004; Lai VCH, 2003, J VIROL, V77, P2295, DOI 10.1128/JVI.77.3.2295-2300.2003; Li ML, 2005, VIROLOGY, V341, P24, DOI 10.1016/j.virol.2005.07.007; Mackenzie J, 2005, TRAFFIC, V6, P967, DOI 10.1111/j.1600-0854.2005.00339.x; MAHY BWJ, 1983, J GEN VIROL, V64, P103, DOI 10.1099/0022-1317-64-1-103; Molenkamp R, 2000, J GEN VIROL, V81, P2491, DOI 10.1099/0022-1317-81-10-2491; Molenkamp R, 2000, J VIROL, V74, P3156, DOI 10.1128/JVI.74.7.3156-3165.2000; Ng LFP, 2002, J VIROL, V76, P6257, DOI 10.1128/JVI.76.12.6257-6267.2002; Ng ML, 2003, J GEN VIROL, V84, P3291, DOI 10.1099/vir.0.19505-0; Novoa RR, 2005, BIOL CELL, V97, P147, DOI 10.1042/BC20040058; Pasternak AO, 2006, J GEN VIROL, V87, P1403, DOI 10.1099/vir.0.81611-0; Pedersen KW, 1999, J VIROL, V73, P2016, DOI 10.1128/JVI.73.3.2016-2026.1999; Pol JMA, 1997, VET MICROBIOL, V55, P203, DOI 10.1016/S0378-1135(96)01329-6; POLATNICK J, 1967, VIROLOGY, V31, P601, DOI 10.1016/0042-6822(67)90188-2; Prentice E, 2004, J VIROL, V78, P9977, DOI 10.1128/JVI.78.18.9977-9986.2004; QUADT R, 1990, VIROLOGY, V178, P189, DOI 10.1016/0042-6822(90)90393-6; QURESHI AA, 1972, J VIROL, V9, P565, DOI 10.1128/JVI.9.4.565-573.1972; ROSENBER.H, 1972, P NATL ACAD SCI USA, V69, P3815, DOI 10.1073/pnas.69.12.3815; Salonen A, 2005, CURR TOP MICROBIOL, V285, P139; SAWICKI SG, 1986, J VIROL, V57, P328, DOI 10.1128/JVI.57.1.328-334.1986; SAWICKI SG, 1990, J VIROL, V64, P1050, DOI 10.1128/JVI.64.3.1050-1056.1990; Sawicki SG, 2007, J VIROL, V81, P20, DOI 10.1128/JVI.01358-06; Seybert A, 2000, J VIROL, V74, P9586, DOI 10.1128/JVI.74.20.9586-9593.2000; Shi ST, 2003, J VIROL, V77, P4160, DOI 10.1128/JVI.77.7.4160-4168.2003; Shi ST, 1999, J VIROL, V73, P5957, DOI 10.1128/JVI.73.7.5957-5969.1999; SNIJDER EJ, 1992, J VIROL, V66, P7040, DOI 10.1128/JVI.66.12.7040-7048.1992; SNIJDER EJ, 1994, J VIROL, V68, P5755, DOI 10.1128/JVI.68.9.5755-5764.1994; Snijder EJ, 1998, J GEN VIROL, V79, P961, DOI 10.1099/0022-1317-79-5-961; Snijder EJ, 2001, J GEN VIROL, V82, P985, DOI 10.1099/0022-1317-82-5-985; Snijder EJ, 2006, J VIROL, V80, P5927, DOI 10.1128/JVI.02501-05; SREEVALSAN T, 1969, J VIROL, V3, P599, DOI 10.1128/JVI.3.6.599-604.1969; Stertz S, 2007, VIROLOGY, V361, P304, DOI 10.1016/j.virol.2006.11.027; Sun JH, 1996, VIROLOGY, V226, P1, DOI 10.1006/viro.1996.0622; Svitkin YV, 2003, J VIROL, V77, P6551, DOI 10.1128/JVI.77.11.6551-6555.2003; TAKEGAMI T, 1989, VIRUS RES, V13, P337; Tijms MA, 2001, P NATL ACAD SCI USA, V98, P1889, DOI 10.1073/pnas.041390398; Tijms MA, 2007, J VIROL, V81, P10496, DOI 10.1128/JVI.00683-07; Tomassini JE, 2003, VIROLOGY, V313, P274, DOI 10.1016/S0042-6822(03)00314-3; Uchil PD, 2003, VIROLOGY, V307, P358, DOI 10.1016/S0042-6822(02)00130-7; van Aken D, 2006, J GEN VIROL, V87, P3473, DOI 10.1099/vir.0.82269-0; van der Meer Y, 1998, J VIROL, V72, P6689, DOI 10.1128/JVI.72.8.6689-6698.1998; van der Meer Y, 1999, J VIROL, V73, P7641, DOI 10.1128/JVI.73.9.7641-7657.1999; van Dinten LC, 1999, J VIROL, V73, P2027, DOI 10.1128/JVI.73.3.2027-2037.1999; van Marle G, 1999, J VIROL, V73, P5274, DOI 10.1128/JVI.73.7.5274-5281.1999; van Marle G, 1999, P NATL ACAD SCI USA, V96, P12056, DOI 10.1073/pnas.96.21.12056; vanDinten LC, 1996, J VIROL, V70, P6625, DOI 10.1128/JVI.70.10.6625-6633.1996; Warrilow D, 2000, ARCH VIROL, V145, P2163, DOI 10.1007/s007050070046; Wassenaar ALM, 1997, J VIROL, V71, P9313, DOI 10.1128/JVI.71.12.9313-9322.1997; Westaway EG, 1999, VIROLOGY, V258, P108, DOI 10.1006/viro.1999.9683; WOOD O, 1970, J GEN VIROL, V7, P129, DOI 10.1099/0022-1317-7-2-129; YIN FH, 1972, J VIROL, V10, P93, DOI 10.1128/JVI.10.1.93-98.1972	83	41	45	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16525	16536		10.1074/jbc.M708136200	http://dx.doi.org/10.1074/jbc.M708136200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18411274	hybrid			2022-12-25	WOS:000256497100029
J	Wang, D; Guo, MX; Hu, HM; Zhao, ZZ; Qiu, HL; Shao, HJ; Zhu, CG; Xue, L; Shi, YB; Li, WX				Wang, Di; Guo, Ming-Xiong; Hu, Hai-Ming; Zhao, Zhou-Zhou; Qiu, Hong-Ling; Shao, Huan-Jie; Zhu, Chen-Gang; Xue, Lu; Shi, Yun-Bo; Li, Wen-Xin			Human T-cell leukemia virus type 1 oncoprotein Tax represses ZNF268 expression through the cAMP-responsive element-binding protein/activating transcription factor pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROENKEPHALIN GENE PROMOTER; ZINC-FINGER GENE; 21-BASE-PAIR REPEATS; PROTEIN; HTLV-1; TRANSACTIVATION; IMMORTALIZATION; IDENTIFICATION; LYMPHOCYTES; INDUCTION	Expression of the human T-cell leukemia virus type 1 (HTLV-1) oncoprotein Tax is correlated with cellular transformation, contributing to the development of adult T-cell leukemia. In this study, we investigated the role of Tax in the regulation of the ZNF268 gene, which plays a role in the differentiation of blood cells and the pathogenesis of leukemia. We demonstrated that ZNF268 mRNA was repressed in HTLV-1-infected cells. We also showed that stable and transient expression of HTLV-1 Tax led to repression of ZNF268. In addition, by using reporter constructs that bear the human ZNF268 promoter and its mutants, we showed that Tax repressed ZNF268 promoter in a process dependent on a functional cAMP-responsive element. By using Tax, cAMP-responsive element-binding protein (CREB)-1, CREB-2, and their mutants, we further showed that Tax repressed ZNF268 through the CREB/activating transcription factor pathway. Electrophoretic mobility shift assays and chromatin immunoprecipitation demonstrated the formation of the complex of Tax(.)CREB-1 directly at the cAMP-responsive element both in vitro and in vivo. These findings suggest a role for ZNF268 in aberrant T-cell proliferation observed in HTLV-1-associated diseases.	[Wang, Di; Guo, Ming-Xiong; Hu, Hai-Ming; Zhao, Zhou-Zhou; Qiu, Hong-Ling; Shao, Huan-Jie; Zhu, Chen-Gang; Xue, Lu; Li, Wen-Xin] Wuhan Univ, State Key Lab Virol, Coll Life Sci, Wuhan 430072, Peoples R China; [Shi, Yun-Bo] NICHD, Sect Mol Morphogenesis, Lab Gene Regulat & Dev, NIH, Bethesda, MD 20892 USA	Wuhan University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Li, WX (corresponding author), Wuhan Univ, State Key Lab Virol, Coll Life Sci, Wuhan 430072, Peoples R China.	liwxlab@whu.edu.cn		Shi, Yun-Bo/0000-0002-6330-0639	Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001901] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001901] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALEXANDRE C, 1991, ONCOGENE, V6, P543; Amorino GP, 2003, J BIOL CHEM, V278, P29394, DOI 10.1074/jbc.M304012200; Azran Inbal, 2004, Retrovirology, V1, P20; Brauweiler A, 1997, VIROLOGY, V231, P135, DOI 10.1006/viro.1997.8509; Cox JM, 1995, CHEM BIOL, V2, P819, DOI 10.1016/1074-5521(95)90088-8; Fu W, 1997, J NEUROVIROL, V3, P16, DOI 10.3109/13550289709015789; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; Gebelein B, 2001, MOL CELL BIOL, V21, P928, DOI 10.1128/MCB.21.3.928-939.2001; Gou DM, 2001, BBA-GENE STRUCT EXPR, V1518, P306, DOI 10.1016/S0167-4781(01)00194-4; GRASSMANN R, 1992, J VIROL, V66, P4570, DOI 10.1128/JVI.66.7.4570-4575.1992; Guo MX, 2006, J BIOL CHEM, V281, P24623, DOI 10.1074/jbc.M602753200; HINUMA Y, 1981, P NATL ACAD SCI-BIOL, V78, P6476, DOI 10.1073/pnas.78.10.6476; HOSHINO H, 1985, VIROLOGY, V147, P223, DOI 10.1016/0042-6822(85)90244-2; ISHIGURO N, 1992, J EXP MED, V176, P981, DOI 10.1084/jem.176.4.981; JOSHI JB, 1992, P NATL ACAD SCI USA, V89, P1006, DOI 10.1073/pnas.89.3.1006; Kibler KV, 2001, J VIROL, V75, P2161, DOI 10.1128/JVI.75.5.2161-2173.2001; Krackhardt AM, 2002, BLOOD, V100, P2123, DOI 10.1182/blood-2002-02-0513; NAPOLITANO M, 1991, J BIOL CHEM, V266, P17531; Nguyen LQ, 2000, MOL ENDOCRINOL, V14, P1448, DOI 10.1210/me.14.9.1448; Pathak SK, 2004, J BIOL CHEM, V279, P55127, DOI 10.1074/jbc.M409885200; POIESZ BJ, 1980, P NATL ACAD SCI-BIOL, V77, P6815, DOI 10.1073/pnas.77.11.6815; Robek MD, 1999, J VIROL, V73, P4856, DOI 10.1128/JVI.73.6.4856-4865.1999; Shao HJ, 2006, INT J MOL MED, V18, P457; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; Sun Y, 2004, INT J MOL MED, V14, P971; Sun Y, 2003, IUBMB LIFE, V55, P127, DOI 10.1080/1521654031000110208; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; TANAKA A, 1990, P NATL ACAD SCI USA, V87, P1071, DOI 10.1073/pnas.87.3.1071; Trejo SR, 1996, J BIOL CHEM, V271, P14584, DOI 10.1074/jbc.271.24.14584; Tsukahara T, 1999, J VIROL, V73, P7981, DOI 10.1128/JVI.73.10.7981-7987.1999; Wycuff DR, 2005, FRONT BIOSCI-LANDMRK, V10, P620, DOI 10.2741/1558; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	34	14	16	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16299	16308		10.1074/jbc.M706426200	http://dx.doi.org/10.1074/jbc.M706426200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18375384	hybrid, Green Published			2022-12-25	WOS:000256497100006
J	Maeda, Y; Suzuki, T; Pan, XF; Chen, G; Pan, SQ; Bartman, T; Whitsett, JA				Maeda, Yutaka; Suzuki, Takuji; Pan, Xiufang; Chen, Gang; Pan, Songqin; Bartman, Thomas; Whitsett, Jeffrey A.			CUL2 is required for the activity of hypoxia-inducible factor and vasculogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-SUPPRESSOR PROTEIN; ENDOTHELIAL GROWTH-FACTOR; UBIQUITIN LIGASE; FACTOR (HIF)-1-ALPHA; GENE-EXPRESSION; TARGET GENE; HIF-ALPHA; COMPLEX; BINDING; SKP2	CULLIN 2 (CUL2) is a component of the ElonginB/C-CUL2-RBX-1-Von Hippel-Lindau (VHL) tumor suppressor complex that ubiquitinates and degrades hypoxia-inducible factor alpha (HIF alpha). HIF alpha is a transcription factor that mediates the expression of hypoxia-sensitive genes, including vascular endothelial growth factor (VEGF), which in turn regulates vasculogenesis. Whereas CUL2 participates in the degradation of HIF alpha, the potential role of CUL2 in the regulation of other cellular processes is less well established. In the present study, suppression of CUL2 expression by Cul2 siRNA inhibited HIF alpha transcriptional activation of the VEGF gene in vitro, indicating that CUL2 plays a role distinct from its known function in HIF alpha degradation. Because ARNT heterodimerizes with HIF alpha, we assessed whether CUL2 influenced ARNT expression. Cul2 siRNA inhibited the expression of endogenous ARNT. Ectopically expressed ARNT reversed the inhibition of HIF activity by Cul2 siRNA in the VEGF promoter, suggesting that CUL2 regulates HIF activation through ARNT. In 786-O cells lacking VHL, Cul2 siRNA suppressed the expression of both ARNT and VEGF, indicating that CUL2 regulates HIF activity independently of VHL. In transgenic zebrafish expressing GFP driven by the Flk promoter (a known HIF target), zCul2 morpholino blocked embryonic vasculogenesis in a manner similar to that caused by inhibition of VEGF-A. In the zebrafish embryos, zCul2 inhibited the expression of CUL2, VEGF, and Flk-GFP protein, indicating that CUL2 is required for expression of other vasculogenic HIF targets. Taken together, CUL2 is required for normal vasculogenesis, at least in part mediated by its regulation of HIF-mediated transcription.	[Maeda, Yutaka; Suzuki, Takuji; Pan, Xiufang; Chen, Gang; Bartman, Thomas; Whitsett, Jeffrey A.] Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, Cincinnati, OH 45229 USA; [Pan, Songqin] Univ Calif Riverside, WM Keck Prote Lab, Inst Integrat Genome Biol, Riverside, CA 92521 USA; [Pan, Songqin] Univ Calif Riverside, Dept Bot & Plant Sci, Riverside, CA 92521 USA	Cincinnati Children's Hospital Medical Center; University of California System; University of California Riverside; University of California System; University of California Riverside	Whitsett, JA (corresponding author), Cincinnati Childrens Hosp, Med Ctr, Div Pulm Biol, 3333 Burnet Ave,MLC 7029, Cincinnati, OH 45229 USA.	jeff.whitsett@cchmc.org	Bartman, Thomas/AAF-9698-2021; Bartman, Thomas/AAF-9709-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL090156] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL90156] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Arai T, 2003, P NATL ACAD SCI USA, V100, P9855, DOI 10.1073/pnas.1733908100; Beis D, 2005, DEVELOPMENT, V132, P4193, DOI 10.1242/dev.01970; Brower CS, 2002, P NATL ACAD SCI USA, V99, P10353, DOI 10.1073/pnas.162424199; Carter C, 2004, PLANT CELL, V16, P3285, DOI 10.1105/tpc.104.027078; Clifford SC, 1999, GENE CHROMOSOME CANC, V26, P20, DOI 10.1002/(SICI)1098-2264(199909)26:1<20::AID-GCC3>3.3.CO;2-Y; Clifford SC, 2001, ONCOGENE, V20, P5067, DOI 10.1038/sj.onc.1204602; Cockman ME, 2000, J BIOL CHEM, V275, P25733, DOI 10.1074/jbc.M002740200; Duerr EM, 1999, J CLIN ENDOCR METAB, V84, P3207, DOI 10.1210/jc.84.9.3207; Feng H, 1999, NAT CELL BIOL, V1, P486, DOI 10.1038/70272; Feng Y, 2003, CANCER RES, V63, P8726; Gstaiger M, 2001, P NATL ACAD SCI USA, V98, P5043, DOI 10.1073/pnas.081474898; Gunton JE, 2005, CELL, V122, P337, DOI 10.1016/j.cell.2005.05.027; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Kamura T, 2000, P NATL ACAD SCI USA, V97, P10430, DOI 10.1073/pnas.190332597; Kamura T, 1999, SCIENCE, V284, P657, DOI 10.1126/science.284.5414.657; Kamura T, 2004, GENE DEV, V18, P3055, DOI 10.1101/gad.1252404; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kodadek T, 2006, CELL, V127, P261, DOI 10.1016/j.cell.2006.10.002; Lisztwan J, 1999, GENE DEV, V13, P1822, DOI 10.1101/gad.13.14.1822; Lonergan KM, 1998, MOL CELL BIOL, V18, P732, DOI 10.1128/MCB.18.2.732; Maeda Y, 2006, J BIOL CHEM, V281, P9600, DOI 10.1074/jbc.M510435200; Maxwell PH, 1999, NATURE, V399, P271, DOI 10.1038/20459; Mukhopadhyay D, 1997, MOL CELL BIOL, V17, P5629, DOI 10.1128/MCB.17.9.5629; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Nasevicius A, 2000, YEAST, V17, P294, DOI 10.1002/1097-0061(200012)17:4<294::AID-YEA54>3.0.CO;2-5; O'Rourke JF, 1999, J BIOL CHEM, V274, P2060, DOI 10.1074/jbc.274.4.2060; Ohh M, 2000, NAT CELL BIOL, V2, P423, DOI 10.1038/35017054; Olenyuk BZ, 2004, P NATL ACAD SCI USA, V101, P16768, DOI 10.1073/pnas.0407617101; Park SK, 2003, MOL CELL BIOL, V23, P4959, DOI 10.1128/MCB.23.14.4959-4971.2003; PATTERSON C, 1995, J BIOL CHEM, V270, P23111, DOI 10.1074/jbc.270.39.23111; Pause A, 1997, P NATL ACAD SCI USA, V94, P2156, DOI 10.1073/pnas.94.6.2156; Petroski MD, 2005, NAT REV MOL CELL BIO, V6, P9, DOI 10.1038/nrm1547; Starostina NG, 2007, DEV CELL, V13, P127, DOI 10.1016/j.devcel.2007.05.008; Tanimoto K, 2000, EMBO J, V19, P4298, DOI 10.1093/emboj/19.16.4298; Tian H, 1997, GENE DEV, V11, P72, DOI 10.1101/gad.11.1.72; Uchida T, 2004, J BIOL CHEM, V279, P14871, DOI 10.1074/jbc.M400461200; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Wagner KF, 2004, AM J RESP CELL MOL, V31, P276, DOI 10.1165/rcmb.2003-0319OC; Warnecke C, 2004, FASEB J, V18, P1462, DOI 10.1096/fj.04-1640fje; Weir BA, 2007, NATURE, V450, P893, DOI 10.1038/nature06358; Wenger Roland H, 2005, Sci STKE, V2005, pre12, DOI 10.1126/stke.3062005re12; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Zheng N, 2002, NATURE, V416, P703, DOI 10.1038/416703a	46	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16084	16092		10.1074/jbc.M710223200	http://dx.doi.org/10.1074/jbc.M710223200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18372249	hybrid, Green Published			2022-12-25	WOS:000256332500067
J	Seo, HR; Kim, J; Bae, S; Soh, JW; Lee, YS				Seo, Haeng Ran; Kim, Joon; Bae, Sangwoo; Soh, Jae-Won; Lee, Yun-Sil			Cdk5-mediated phosphorylation of c-Myc on Ser-62 is essential in transcriptional activation of cyclin B1 by cyclin G1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE; DNA-DAMAGE; TRANSACTIVATION DOMAIN; PROTEIN STABILITY; TARGET GENES; E-BOX; P53; EXPRESSION; REPRESSION; INDUCTION	It has been reported previously that cyclin G1 enables cells to overcome radiation-induced G(2) arrest and increased cell death and that these effects are mediated by transcriptional activation of cyclin B1. In this study, we further investigated the mechanism by which cyclin G1 transcriptionally activates cyclin B1. Deletion or point mutations within the cyclin B1 promoter region revealed that the c-Myc binding site (E-box) is necessary for cyclin G1-mediated transcriptional activation of cyclin B1 to occur. In addition, the kinase activity of Cdk5 was increased by cyclin G1 overexpression, and Cdk5 directly phosphorylated c-Myc on Ser-62. Furthermore, cyclin G1 mediated increased radiosensitivity, and radiation-induced M phase arrest was attenuated when RNA interference of Cdk5 was treated. Taken together, the results of this study indicate that Cdk5 activation in cells that overexpress cyclin G1 leads to c-Myc phosphorylation on Ser-62, which is responsible for cyclin G1-mediated transcriptional activation of cyclin B1.	[Seo, Haeng Ran; Bae, Sangwoo; Lee, Yun-Sil] Korea Inst Radiol & Med Sci, Div Radiat Effect, Seoul 139706, South Korea; [Seo, Haeng Ran; Kim, Joon] Korea Univ, Sch Life Sci & Biotechnol, Seoul 139701, South Korea; [Soh, Jae-Won] Inha Univ, Dept Chem, Lab Signal Transduct, Inchon 402751, South Korea	Korea Institute of Radiological & Medical Sciences; Korea University; Inha University	Lee, YS (corresponding author), Korea Inst Radiol & Med Sci, Div Radiat Damage Control, 215-4 Gongneung Dong, Seoul 139706, South Korea.	yslee@kcch.re.kr	Lee, Yun-Sil/AAP-1378-2020	Lee, Yun-Sil/0000-0002-7538-8850				ANTONSSON C, 1995, J BIOL CHEM, V270, P13968, DOI 10.1074/jbc.270.23.13968; Baek WK, 2003, AM J OBSTET GYNECOL, V188, P634, DOI 10.1067/mob.2003.140; Bates S, 1996, ONCOGENE, V13, P1103; Benassi B, 2006, MOL CELL, V21, P509, DOI 10.1016/j.molcel.2006.01.009; BIBEN C, 1994, MOL CELL BIOL, V14, P3504, DOI 10.1128/MCB.14.5.3504; Brandeis M, 1996, EMBO J, V15, P5280, DOI 10.1002/j.1460-2075.1996.tb00913.x; Chang DW, 2000, MOL CELL BIOL, V20, P4309, DOI 10.1128/MCB.20.12.4309-4319.2000; Claassen GF, 1999, ONCOGENE, V18, P2925, DOI 10.1038/sj.onc.1202747; COGSWELL JP, 1995, MOL CELL BIOL, V15, P2782; Conzen SD, 2000, MOL CELL BIOL, V20, P6008, DOI 10.1128/MCB.20.16.6008-6018.2000; Dohna CLZ, 2000, FEBS LETT, V484, P77, DOI 10.1016/S0014-5793(00)02133-5; Farina A, 1996, ONCOGENE, V13, P1287; Fuhrmann G, 1999, MUTAT RES-REV MUTAT, V437, P205, DOI 10.1016/S1383-5742(99)00084-8; HARTWELL L, 1992, CELL, V71, P543, DOI 10.1016/0092-8674(92)90586-2; HARTWELL LH, 1994, SCIENCE, V266, P1821, DOI 10.1126/science.7997877; HENRIKSSON M, 1993, ONCOGENE, V8, P3199; Henriksson M, 1996, ADV CANCER RES, V68, P109, DOI 10.1016/S0065-230X(08)60353-X; Horne MC, 1997, J BIOL CHEM, V272, P12650, DOI 10.1074/jbc.272.19.12650; HUANG G, 1996, J W CHINA U MED SCI, V27, P5; HUNT N, 1993, SOC PSYCH PSYCH EPID, V28, P281, DOI 10.1007/BF00795908; HUNT T, 1992, J CELL BIOL, V116, P707, DOI 10.1083/jcb.116.3.707; Jensen MR, 1998, HEPATOLOGY, V28, P537, DOI 10.1002/hep.510280235; Kanaoka Y, 1997, FEBS LETT, V402, P73, DOI 10.1016/S0014-5793(96)01484-6; Kastan MB, 2001, ACTA ONCOL, V40, P686; Kimura SH, 2002, GENES CELLS, V7, P869, DOI 10.1046/j.1365-2443.2002.00564.x; Kimura SH, 1997, GENOMICS, V44, P179, DOI 10.1006/geno.1997.4873; Law W, 2001, ONCOGENE, V20, P1118, DOI 10.1038/sj.onc.1204226; Lee YJ, 2002, RADIAT RES, V157, P371, DOI 10.1667/0033-7587(2002)157[0371:IOARBL]2.0.CO;2; Littlewood T D, 1990, Adv Dent Res, V4, P69; LUTTERBACH B, 1994, MOL CELL BIOL, V14, P5510, DOI 10.1128/MCB.14.8.5510; Lutterbach B, 1999, J CELL BIOCHEM, V72, P483, DOI 10.1002/(SICI)1097-4644(19990315)72:4<483::AID-JCB4>3.0.CO;2-I; Menssen A, 2002, P NATL ACAD SCI USA, V99, P6274, DOI 10.1073/pnas.082005599; Nesbit CE, 1999, ONCOGENE, V18, P3004, DOI 10.1038/sj.onc.1202746; Obaya AJ, 1999, ONCOGENE, V18, P2934, DOI 10.1038/sj.onc.1202749; OKAMOTO K, 1994, EMBO J, V13, P4816, DOI 10.1002/j.1460-2075.1994.tb06807.x; Okamoto K, 1999, ONCOGENE, V18, P4606, DOI 10.1038/sj.onc.1202821; Okamoto K, 1996, MOL CELL BIOL, V16, P6593; Paulovich AG, 1997, CELL, V88, P315, DOI 10.1016/S0092-8674(00)81870-X; PULVERER BJ, 1994, ONCOGENE, V9, P59; Reimers L, 1999, J BIOL CHEM, V274, P11022, DOI 10.1074/jbc.274.16.11022; Sears R, 1999, MOL CELL, V3, P169, DOI 10.1016/S1097-2765(00)80308-1; Seo HR, 2006, CELL DEATH DIFFER, V13, P1475, DOI 10.1038/sj.cdd.4401822; SKOTZKO M, 1995, CANCER RES, V55, P5493; Smith ML, 1997, EXP CELL RES, V230, P61, DOI 10.1006/excr.1996.3402; Townsley FM, 1998, YEAST, V14, P747, DOI 10.1002/(SICI)1097-0061(19980615)14:8<747::AID-YEA271>3.0.CO;2-T; Watnick RS, 2003, CANCER CELL, V3, P219, DOI 10.1016/S1535-6108(03)00030-8; Yin XY, 2001, CANCER RES, V61, P6487; ZAUBERMAN A, 1995, ONCOGENE, V10, P2361; ZWICKER J, 1995, EMBO J, V14, P4514, DOI 10.1002/j.1460-2075.1995.tb00130.x	49	45	47	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15601	15610		10.1074/jbc.M800987200	http://dx.doi.org/10.1074/jbc.M800987200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18408012	Green Published, hybrid			2022-12-25	WOS:000256332500013
J	Chang, YW; Sun, YJ; Wang, C; Hsiao, CD				Chang, Yi-Wei; Sun, Yuh-Ju; Wang, Chung; Hsiao, Chwan-Deng			Crystal structures of the 70-kDa heat shock proteins in domain disjoining conformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUBSTRATE-BINDING; ESCHERICHIA-COLI; DNAK CHAPERONE; HSP70 CHAPERONES; ATPASE ACTIVITY; MECHANISM; HSC70; DISSOCIATION; ASSOCIATION; SPECIFICITY	The 70-kDa heat shock proteins (Hsp7os) are highly conserved ATP-dependent molecular chaperones composed of an N-terminal nucleotide binding domain (NBD) and a C-terminal protein substrate binding domain (SBD) in a bilobate structure. Interdomain communication and nucleotide-dependent structural motions are critical for Hsp70 chaperone functions. Our understanding of these functions remains elusive due to insufficient structural information on intact Hsp70s that represent the different states of the chaperone cycle. We report here the crystal structures of DnaK from Geobacillus kaustophilus HTA426 bound with ADP-Mg2+-P-i at 2.37 angstrom and the 70-kDa heat shock cognate protein from Rattus norvegicus bound with ADP-P-i at 3.5 angstrom. The NBD and SBD in these structures are significantly separated from each other, and they might depict the ADP-bound conformation. Moreover, a Trp reporter was introduced at the potential interface region between NBD and the interdomain linker of GkDnaK to probe environmental changes. Results from fluorescence measurements support the notion that substrate binding enhances the domain-disjoining behavior of Hsp70 chaperones.	[Chang, Yi-Wei; Wang, Chung; Hsiao, Chwan-Deng] Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan; [Sun, Yuh-Ju] Natl Tsing Hua Univ, Inst Bioinformat & Struct Biol, Hsinchu 300, Taiwan	Academia Sinica - Taiwan; National Tsing Hua University	Hsiao, CD (corresponding author), Acad Sinica, Inst Mol Biol, Taipei 115, Taiwan.	hsiao@gate.sinica.edu.tw	Hsiao, Chwan-Deng/AAZ-8869-2021; Chang, Yi-Wei/ABH-1418-2020; Hsiao, Chwan-Deng/D-7327-2013	Hsiao, Chwan-Deng/0000-0002-7012-1532; Chang, Yi-Wei/0000-0003-2391-473X; 				ANDERSON JV, 1994, PLANT PHYSIOL, V104, P1371, DOI 10.1104/pp.104.4.1371; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Benaroudj N, 1996, J BIOL CHEM, V271, P18471, DOI 10.1074/jbc.271.31.18471; BHATTACHARYYA T, 1995, J BIOL CHEM, V270, P1705, DOI 10.1074/jbc.270.4.1705; BLONDELGUINDI S, 1993, J BIOL CHEM, V268, P12730; BROWN CR, 1993, J CELL BIOL, V120, P1101, DOI 10.1083/jcb.120.5.1101; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BUCHBERGER A, 1995, J BIOL CHEM, V270, P16903, DOI 10.1074/jbc.270.28.16903; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CARLINO A, 1992, P NATL ACAD SCI USA, V89, P2081, DOI 10.1073/pnas.89.6.2081; Chou CC, 2003, J BIOL CHEM, V278, P30311, DOI 10.1074/jbc.M304563200; CREIGHTON TE, 1993, PROTEINS STRUCTURE M, P5; Cupp-Vickery JR, 2004, J MOL BIOL, V342, P1265, DOI 10.1016/j.jmb.2004.07.025; De los Rios P, 2006, P NATL ACAD SCI USA, V103, P6166, DOI 10.1073/pnas.0510496103; DeLano WL, 2002, PYMOL USERS MANUAL; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FREIDEN PJ, 1992, EMBO J, V11, P63, DOI 10.1002/j.1460-2075.1992.tb05028.x; Harrison CJ, 1997, SCIENCE, V276, P431, DOI 10.1126/science.276.5311.431; Hartl FU, 1996, NATURE, V381, P571, DOI 10.1038/381571a0; Jiang JW, 2005, MOL CELL, V20, P513, DOI 10.1016/j.molcel.2005.09.028; Laufen T, 1999, P NATL ACAD SCI USA, V96, P5452, DOI 10.1073/pnas.96.10.5452; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; Liu QL, 2007, CELL, V131, P106, DOI 10.1016/j.cell.2007.08.039; Mayer MP, 2000, NAT STRUCT BIOL, V7, P586; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Moro F, 2006, PROTEIN SCI, V15, P223, DOI 10.1110/ps.051732706; Neupert W, 2002, NAT REV MOL CELL BIO, V3, P555, DOI 10.1038/nrm878; OBrien MC, 1996, J BIOL CHEM, V271, P15874, DOI 10.1074/jbc.271.27.15874; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PALLEROS DR, 1993, FEBS LETT, V336, P124, DOI 10.1016/0014-5793(93)81624-9; PALLEROS DR, 1993, NATURE, V365, P664, DOI 10.1038/365664a0; Raviol H, 2006, EMBO J, V25, P2510, DOI 10.1038/sj.emboj.7601139; RICHARME G, 1993, J BIOL CHEM, V268, P24074; Rudiger S, 1997, NAT STRUCT BIOL, V4, P342, DOI 10.1038/nsb0597-342; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SCHMID D, 1994, SCIENCE, V263, P971, DOI 10.1126/science.8310296; SCHONFELD HJ, 1995, J BIOL CHEM, V270, P2183, DOI 10.1074/jbc.270.5.2183; Sriram M, 1997, STRUCTURE, V5, P403, DOI 10.1016/S0969-2126(97)00197-4; Swain JF, 2007, MOL CELL, V26, P27, DOI 10.1016/j.molcel.2007.02.020; TAKENAKA IM, 1995, J BIOL CHEM, V270, P19839, DOI 10.1074/jbc.270.34.19839; Wegele H, 2004, REV PHYSIOL BIOCH P, V151, P1, DOI 10.1007/s10254-003-0021-1; WILBANKS SM, 1995, BIOCHEMISTRY-US, V34, P12095, DOI 10.1021/bi00038a002; Young JC, 2004, NAT REV MOL CELL BIO, V5, P781, DOI 10.1038/nrm1492; Zhu XT, 1996, SCIENCE, V272, P1606, DOI 10.1126/science.272.5268.1606	45	72	75	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15502	15511		10.1074/jbc.M708992200	http://dx.doi.org/10.1074/jbc.M708992200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18400763	hybrid, Green Published			2022-12-25	WOS:000256232000068
J	Daimon, T; Taguchi, T; Meng, Y; Katsuma, S; Mita, K; Shimada, T				Daimon, Takaaki; Taguchi, Tomohiro; Meng, Yan; Katsuma, Susumu; Mita, Kazuei; Shimada, Toru			beta-fructofuranosidase genes of the silkworm, Bombyx mori - Insights into enzymatic adaptation of B. mori to toxic alkaloids in mulberry latex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANIMAL CELLULOSE SYNTHASE; SUGAR-MIMIC ALKALOIDS; SEQUENCE ALIGNMENT; KINETIC-PROPERTIES; LARVAL MIDGUT; BMCHI-H; PROTEIN; LOCALIZATION; BACTERIAL; MEMBRANE	Mulberry latex contains extremely high concentrations of alkaloidal sugar mimic glycosidase inhibitors, such as 1,4-dideoxy-1,4-imino-D-arabinitol (D-AB1) and 1-deoxynojirimycin (DNJ). Although these compounds do not harm the silkworm, Bombyx mori, a mulberry specialist, they are highly toxic to insects that do not normally feed on mulberry leaves. D-AB1 and DNJ are strong inhibitors of alpha-glucosidases (EC 3.2.1.20); however, they do not affect the activity of beta-fructofuranosidases (EC 3.2.1.26). Although alpha-glucosidase genes are found in a wide range of organisms, beta-fructofuranosidase genes have not been identified in any animals so far. In this study, we report the identification and characterization of beta-fructofuranosidase genes (BmSuc1 and BmSuc2) from B. mod. The BmSuc1 gene was highly expressed in the midgut and silk gland, whereas the expression of BmSuc2 gene was not detected. BmSuc1 encodes a functional beta-fructofuranosidase, whose enzymatic activity was not inhibited by DNJ or D-AB1. We also showed that BmSUC1 protein localized within the midgut goblet cell cavities. Collectively, our data clearly demonstrated that BmSuc1 serves as a sugar-digesting enzyme in the silkworm physiology. This anomalous presence of the beta-fructofuranosidase gene in the B. mori genome may partly explain why the silkworm can circumvent the mulberry's defense system.	[Daimon, Takaaki; Taguchi, Tomohiro; Meng, Yan; Katsuma, Susumu; Shimada, Toru] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Agr & Environm Biol, Bunkyo Ku, Tokyo 1138657, Japan; [Mita, Kazuei] Natl Inst Agrobiol Sci, Tsukuba, Ibaraki, Japan	University of Tokyo; National Institute of Agrobiological Sciences - Japan	Shimada, T (corresponding author), Univ Tokyo, Grad Sch Agr & Life Sci, Dept Agr & Environm Biol, Bunkyo Ku, Yayoi 1-1-1, Tokyo 1138657, Japan.	shimada@ss.ab.a.u-tokyo.ac.jp	Shimada, Toru/AAZ-2703-2021; Shimada, Toru/A-2033-2011; meng, yan/GSE-2653-2022; Meng, Yan/HGC-0394-2022	Shimada, Toru/0000-0002-5791-0000; Shimada, Toru/0000-0002-5791-0000; Daimon, Takaaki/0000-0002-8382-1132				Asano N, 2001, J AGR FOOD CHEM, V49, P4208, DOI 10.1021/jf010567e; AZUMA M, 1989, J EXP ZOOL, V251, P108, DOI 10.1002/jez.1402510113; Carneiro CNB, 2004, J INSECT PHYSIOL, V50, P1093, DOI 10.1016/j.jinsphys.2004.09.011; Daimon T, 2005, INSECT BIOCHEM MOLEC, V35, P1112, DOI 10.1016/j.ibmb.2005.05.005; Daimon T, 2003, INSECT BIOCHEM MOLEC, V33, P749, DOI 10.1016/S0965-1748(03)00084-5; Dussourd David E., 1993, P92; DUSSOURD DE, 1987, SCIENCE, V237, P898, DOI 10.1126/science.3616620; Emanuelsson O, 2007, NAT PROTOC, V2, P953, DOI 10.1038/nprot.2007.131; Hirayama C, 2007, INSECT BIOCHEM MOLEC, V37, P1348, DOI 10.1016/j.ibmb.2007.09.001; Konno K, 2006, P NATL ACAD SCI USA, V103, P1337, DOI 10.1073/pnas.0506944103; Konno K, 2004, PLANT J, V37, P370, DOI 10.1046/j.1365-313X.2003.01968.x; Krasikov VV, 2001, BIOCHEMISTRY-MOSCOW+, V66, P267, DOI 10.1023/A:1010243611814; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Mita K, 2004, DNA RES, V11, P27, DOI 10.1093/dnares/11.1.27; Mita K, 2003, P NATL ACAD SCI USA, V100, P14121, DOI 10.1073/pnas.2234984100; Mitsumasu K, 2005, INSECT MOL BIOL, V14, P501, DOI 10.1111/j.1365-2583.2005.00581.x; Nakashima K, 2004, DEV GENES EVOL, V214, P81, DOI 10.1007/s00427-003-0379-8; Nishida R, 2002, ANNU REV ENTOMOL, V47, P57, DOI 10.1146/annurev.ento.47.091201.145121; Parthasarathy R, 2005, GENE EXPR PATTERNS, V5, P323, DOI 10.1016/j.modgep.2004.10.006; Reddy A, 1996, J BIOL CHEM, V271, P13953, DOI 10.1074/jbc.271.24.13953; SANTOS CD, 1986, INSECT BIOCHEM, V16, P819, DOI 10.1016/0020-1790(86)90119-8; Sasakura Y, 2005, P NATL ACAD SCI USA, V102, P15134, DOI 10.1073/pnas.0503640102; SHIMADA S, 1975, INSECT BIOCHEM, V5, P653, DOI 10.1016/0020-1790(75)90046-3; SHIMADA S, 1975, INSECT BIOCHEM, V5, P357, DOI 10.1016/0020-1790(75)90072-4; SUMIDA M, 1994, COMP BIOCHEM PHYS B, V107, P273, DOI 10.1016/0305-0491(94)90050-7; SUMIDA M, 1994, COMP BIOCHEM PHYS A, V108, P255, DOI 10.1016/0300-9629(94)90093-0; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; TOYAMA K, 1909, STUDIES BOMBYX MORI; Tsuchida K, 2004, J INSECT PHYSIOL, V50, P363, DOI 10.1016/j.jinsphys.2004.02.006; Watanabe H, 1998, NATURE, V394, P330, DOI 10.1038/28527; Xia QY, 2004, SCIENCE, V306, P1937, DOI 10.1126/science.1102210; Zagrobelny M, 2004, PHYTOCHEMISTRY, V65, P293, DOI 10.1016/j.phytochem.2003.10.016	32	89	97	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15271	15279		10.1074/jbc.M709350200	http://dx.doi.org/10.1074/jbc.M709350200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18397891	hybrid, Green Published			2022-12-25	WOS:000256232000045
J	Cao, XF; Bennett, RL; May, WS				Cao, Xuefang; Bennett, Richard L.; May, W. Stratford			c-Myc and caspase-2 are involved in activating Bax during cytotoxic drug-induced apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRESS-INDUCED APOPTOSIS; CHANNEL-FORMING ACTIVITY; CYTOCHROME-C; MITOCHONDRIAL DYSFUNCTION; PROAPOPTOTIC BAX; ION-CHANNEL; CELL-DEATH; RELEASE; BCL-2; MEMBRANE	Activation of Bax following diverse cytotoxic stress has been shown to be an essential gateway to mitochondrial dysfunction and activation of the intrinsic apoptotic pathway characterized by cytochrome c release with caspase-9/-3 activation. Interestingly, c-Myc has been reported to promote apoptosis by destabilizing mitochondrial integrity in a Bax-dependent manner. Stress-induced activation of caspase-2 may also induce permeabilization of mitochondria with activation of the intrinsic death pathway. To test whether c-Myc and caspase-2 cooperate to activate Bax and thereby mediate intrinsic apoptosis, small interfering RNA was used to efficiently knock down the expression of c-Myc, caspase-2, and Apaf-1, an activating component in the apoptosome, in two human cancer cell lines, lung adenocarcinoma A-549 and osteosarcoma U2-OS cells. Under conditions when the expression of endogenous c-Myc, caspase-2, or Apaf-1 is reduced 80-90%, cisplatin (or etoposide)-induced apoptosis is significantly decreased. Biochemical studies reveal that the expression of c-Myc and caspase-2 is crucial for cytochrome c release from mitochondria during cytotoxic stress and that Apaf-1 is only required following cytochrome c release to activate caspases-9/-3. Although knockdown of c-Myc or caspase-2 does not affect Bax expression, caspase-2 is important for cytosolic Bax to integrate into the outer mitochondrial membrane, and c-Myc is critical for oligomerization of Bax once integrated into the membrane.	Univ Florida, Coll Med, Dept Med, Gainesville, FL 32610 USA; Univ Florida, Shands Canc Ctr, Gainesville, FL 32610 USA	State University System of Florida; University of Florida; State University System of Florida; University of Florida	May, WS (corresponding author), 1376 Mowry Rd,Canc Genet Res Complex 145,POB 1036, Gainesville, FL 32610 USA.	smay@ufl.edu	Bennett, Richard/ABF-9211-2021	Bennett, Richard/0000-0002-0243-2443	NATIONAL CANCER INSTITUTE [R01CA044649] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL054083] Funding Source: NIH RePORTER; NCI NIH HHS [CA 44649] Funding Source: Medline; NHLBI NIH HHS [R01 HL054083] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Adrain C, 2001, EMBO J, V20, P6627, DOI 10.1093/emboj/20.23.6627; Antonsson B, 2000, BIOCHEM J, V345, P271, DOI 10.1042/0264-6021:3450271; Antonsson B, 1997, SCIENCE, V277, P370, DOI 10.1126/science.277.5324.370; Antonsson B, 2001, J BIOL CHEM, V276, P11615, DOI 10.1074/jbc.M010810200; Cao XF, 2003, BLOOD, V102, P2605, DOI 10.1182/blood-2003-01-0211; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; Dansen TB, 2006, J BIOL CHEM, V281, P10890, DOI 10.1074/jbc.M513655200; Deng XM, 1998, J BIOL CHEM, V273, P34157, DOI 10.1074/jbc.273.51.34157; Ekert PG, 2001, J CELL BIOL, V152, P483, DOI 10.1083/jcb.152.3.483; Eskes R, 1998, J CELL BIOL, V143, P217, DOI 10.1083/jcb.143.1.217; EVAN G, 1994, PHILOS T R SOC B, V345, P269, DOI 10.1098/rstb.1994.0105; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; Finucane DM, 1999, J BIOL CHEM, V274, P2225, DOI 10.1074/jbc.274.4.2225; Goping IS, 1998, J CELL BIOL, V143, P207, DOI 10.1083/jcb.143.1.207; Granville DJ, 1999, AM J PATHOL, V155, P1021, DOI 10.1016/S0002-9440(10)65202-9; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Gross A, 1998, EMBO J, V17, P3878, DOI 10.1093/emboj/17.14.3878; Hengartner MO, 2000, NATURE, V407, P770, DOI 10.1038/35037710; Ito T, 1997, J BIOL CHEM, V272, P11671, DOI 10.1074/jbc.272.18.11671; Juin P, 1999, GENE DEV, V13, P1367, DOI 10.1101/gad.13.11.1367; Juin P, 2002, MOL CELL BIOL, V22, P6158, DOI 10.1128/MCB.22.17.6158-6169.2002; Jurgensmeier JM, 1998, P NATL ACAD SCI USA, V95, P4997, DOI 10.1073/pnas.95.9.4997; Lassus P, 2002, SCIENCE, V297, P1352, DOI 10.1126/science.1074721; Li P, 1997, CELL, V91, P479, DOI 10.1016/S0092-8674(00)80434-1; Minn AJ, 1997, NATURE, V385, P353, DOI 10.1038/385353a0; Mitchell KO, 2000, CANCER RES, V60, P6318; Nechushtan A, 1999, EMBO J, V18, P2330, DOI 10.1093/emboj/18.9.2330; Nomura M, 2003, J BIOL CHEM, V278, P2058, DOI 10.1074/jbc.M207880200; Read SH, 2002, J CELL BIOL, V159, P739, DOI 10.1083/jcb.200209004; Robertson JD, 2002, J BIOL CHEM, V277, P29803, DOI 10.1074/jbc.M204185200; Rosse T, 1998, NATURE, V391, P496, DOI 10.1038/35160; Sawada M, 2003, NAT CELL BIOL, V5, P352, DOI 10.1038/ncb955; Scaffidi C, 1998, EMBO J, V17, P1675, DOI 10.1093/emboj/17.6.1675; Scaffidi C, 1999, J BIOL CHEM, V274, P22532, DOI 10.1074/jbc.274.32.22532; Schendel SL, 1997, P NATL ACAD SCI USA, V94, P5113, DOI 10.1073/pnas.94.10.5113; Schlesinger PH, 1997, P NATL ACAD SCI USA, V94, P11357, DOI 10.1073/pnas.94.21.11357; Slee EA, 1999, J CELL BIOL, V144, P281, DOI 10.1083/jcb.144.2.281; Soucie EL, 2001, MOL CELL BIOL, V21, P4725, DOI 10.1128/MCB.21.14.4725-4736.2001; Suzuki M, 2000, CELL, V103, P645, DOI 10.1016/S0092-8674(00)00167-7; VanderHeiden MG, 1997, CELL, V91, P627, DOI 10.1016/S0092-8674(00)80450-X; Waterhouse NJ, 2001, J CELL BIOL, V153, P319, DOI 10.1083/jcb.153.2.319; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wood DE, 1999, J BIOL CHEM, V274, P8309, DOI 10.1074/jbc.274.12.8309; Zeller KI, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-10-r69; Zindy F, 1998, GENE DEV, V12, P2424, DOI 10.1101/gad.12.15.2424	45	50	53	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14490	14496		10.1074/jbc.M801107200	http://dx.doi.org/10.1074/jbc.M801107200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18375382	Green Published, hybrid			2022-12-25	WOS:000255941400036
J	Fung, SY; Yang, H; Chen, P				Fung, Shan Yu; Yang, Hong; Chen, P.			Sequence Effect of Self-Assembling Peptides on the Complexation and In Vitro Delivery of the Hydrophobic Anticancer Drug Ellipticine	PLOS ONE			English	Article								A special class of self-assembling peptides has been found to be capable of stabilizing the hydrophobic anticancer agent ellipticine in aqueous solution. Here we study the effect of peptide sequence on the complex formation and its anticancer activity in vitro. Three peptides, EAK16-II, EAK16-IV and EFK16-II, were selected to have either a different charge distribution (EAK16-II vs. EAK16-IV) or a varying hydrophobicity (EAK16-II vs. EFK16-II). Results on their complexation with ellipticine revealed that EAK16-II and EAK16-IV were able to stabilize protonated ellipticine or ellipticine microcrystals depending on the peptide concentration; EFK16-II could stabilize neutral ellipticine molecules and ellipticine microcrystals. These different molecular states of ellipticine were expected to affect ellipticine delivery. The anticancer activity of these complexes was tested against two cancer cell lines: A549 and MCF-7, and related to the cell viability. The viability results showed that the complexes with protonated ellipticine were effective in eradicating both cancer cells (viability<0.05), but their dilutions in water were not stable, leading to a fast decrease in their toxicity. In contrast, the complexes formulated with EFK16-II were relatively stable upon dilution, but their original toxicity was relatively low compared to that with protonated ellipticine. Overall, the charge distribution of the peptides seemed not to affect the complex formation and its therapeutic efficacy in vitro; however, the increase in hydrophobicity of the peptides significantly altered the state of stabilized ellipticine and increased the stability of the complexes. This work provides essential information for peptide sequence design in the development of self-assembling peptide-based delivery of hydrophobic anticancer drugs.	[Fung, Shan Yu; Yang, Hong; Chen, P.] Univ Waterloo, Dept Chem Engn, Waterloo, ON N2L 3G1, Canada	University of Waterloo	Chen, P (corresponding author), Univ Waterloo, Dept Chem Engn, Waterloo, ON N2L 3G1, Canada.	p4chen@cape.uwaterloo.ca	Fung, Shan-Yu/E-3477-2014; Yang, Hong/AAZ-1061-2020; Yang, Hong/E-3478-2014	Fung, Shan-Yu/0000-0002-4547-8740; Yang, Hong/0000-0002-6707-8481	Natural Sciences and Engineering Research Council of Canada (NSERC); Canada Foundation for Innovation (CFI); Canada Research Chairs (CRC)	Natural Sciences and Engineering Research Council of Canada (NSERC)(Natural Sciences and Engineering Research Council of Canada (NSERC)); Canada Foundation for Innovation (CFI)(Canada Foundation for Innovation); Canada Research Chairs (CRC)(Canada Research Chairs)	Support for this research has been provided by the Natural Sciences and Engineering Research Council of Canada (NSERC), Canada Foundation for Innovation (CFI) and the Canada Research Chairs (CRC) Program for one of the coauthors (PC).	Aggeli Amalia, 1999, Molecular Medicine Today, V5, P512, DOI 10.1016/S1357-4310(99)01610-X; Biswas ME, 2005, J COLLOID INTERF SCI, V286, P14, DOI 10.1016/j.jcis.2005.01.011; Bokhari MA, 2005, BIOMATERIALS, V26, P5198, DOI 10.1016/j.biomaterials.2005.01.040; Caplan MR, 2002, BIOMATERIALS, V23, P219, DOI 10.1016/S0142-9612(01)00099-0; CARDAMONE M, 1992, BIOCHEM J, V282, P589, DOI 10.1042/bj2820589; Davis ME, 2005, CIRCULATION, V111, P442, DOI 10.1161/01.CIR.0000153847.47301.80; Davis ME, 2006, P NATL ACAD SCI USA, V103, P8155, DOI 10.1073/pnas.0602877103; Eastoe J, 2000, ADV COLLOID INTERFAC, V85, P103, DOI 10.1016/S0001-8686(99)00017-2; Ellis-Behnke RG, 2006, P NATL ACAD SCI USA, V103, P5054, DOI 10.1073/pnas.0600559103; Ellis-Behnke RG, 2006, NANOMED-NANOTECHNOL, V2, P207, DOI 10.1016/j.nano.2006.08.001; Fung SY, 2007, COLLOID SURFACE B, V55, P200, DOI 10.1016/j.colsurfb.2006.12.002; Fung SY, 2006, J PHYS CHEM A, V110, P11446, DOI 10.1021/jp062778y; FUNG SY, 2005, HDB NANOSTRUCTURED B, P1; FUNG SY, 2008, ACS NANO UNPUB; Garbett Nichola C., 2004, Current Medicinal Chemistry - Anti-Cancer Agents, V4, P149, DOI 10.2174/1568011043482070; Gu FX, 2007, NANO TODAY, V2, P14, DOI 10.1016/S1748-0132(07)70083-X; Holmes TC, 2000, P NATL ACAD SCI USA, V97, P6728, DOI 10.1073/pnas.97.12.6728; Hong YS, 2003, BIOMACROMOLECULES, V4, P1433, DOI 10.1021/bm0341374; Hsieh PCH, 2006, CIRCULATION, V114, P637, DOI 10.1161/CIRCULATIONAHA.106.639831; Hsieh PCH, 2006, J CLIN INVEST, V116, P237, DOI 10.1172/JCI25878; Jun S, 2004, BIOPHYS J, V87, P1249, DOI 10.1529/biophysj.103.038166; Keyes-Baig C, 2004, J AM CHEM SOC, V126, P7522, DOI 10.1021/ja0381297; Kisiday J, 2002, P NATL ACAD SCI USA, V99, P9996, DOI 10.1073/pnas.142309999; Lakowicz JR, 1999, PRINCIPLES FLUORESCE; Lindgren M, 2005, BIOPHYS J, V88, P4200, DOI 10.1529/biophysj.104.049700; Liu JB, 2004, J PHARM SCI-US, V93, P132, DOI 10.1002/jps.10533; Lundberg P, 2003, J MOL RECOGNIT, V16, P227, DOI 10.1002/jmr.630; Nagai Y, 2006, J CONTROL RELEASE, V115, P18, DOI 10.1016/j.jconrel.2006.06.031; PROVENCHER SW, 1982, COMPUT PHYS COMMUN, V27, P213, DOI 10.1016/0010-4655(82)90173-4; Schwartz JJ, 2000, CURR OPIN MOL THER, V2, P162; Segers VF, 2007, CIRCULATION, V116, P69; SLAVIK J, 1982, BIOCHIM BIOPHYS ACTA, V694, P1, DOI 10.1016/0304-4157(82)90012-0; Temsamani J, 2004, DRUG DISCOV TODAY, V9, P1012, DOI 10.1016/S1359-6446(04)03279-9; Torrent J, 2004, BIOCHEMISTRY-US, V43, P7162, DOI 10.1021/bi049939d; Yang H, 2006, LANGMUIR, V22, P8553, DOI 10.1021/la061238p; Yang H, 2007, J AM CHEM SOC, V129, P12200, DOI 10.1021/ja073168u; ZHANG SG, 1994, BIOPOLYMERS, V34, P663, DOI 10.1002/bip.360340508; ZHANG SG, 1993, P NATL ACAD SCI USA, V90, P3334, DOI 10.1073/pnas.90.8.3334; ZHANG SG, 1995, BIOMATERIALS, V16, P1385, DOI 10.1016/0142-9612(95)96874-Y; Zhang SG, 2003, NAT BIOTECHNOL, V21, P1171, DOI 10.1038/nbt874	40	44	47	2	28	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1956	10.1371/journal.pone.0001956	http://dx.doi.org/10.1371/journal.pone.0001956			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398476	gold, Green Submitted, Green Published			2022-12-25	WOS:000260795500027
J	Beck, RMD; Godthelp, H; Weisbecker, V; Archer, M; Hand, SJ				Beck, Robin M. D.; Godthelp, Henk; Weisbecker, Vera; Archer, Michael; Hand, Suzanne J.			Australia's Oldest Marsupial Fossils and their Biogeographical Implications	PLOS ONE			English	Article							PLACENTAL MAMMALS; PHYLOGENETIC IMPLICATIONS; CLADISTIC-ANALYSIS; PETROSAL BONES; LATE PALEOCENE; SEQUENCES; METATHERIANS; ITABORAI; FEATURES; BOLIVIA	Background: We describe new cranial and post-cranial marsupial fossils from the early Eocene Tingamarra Local Fauna in Australia and refer them to Djarthia murgonensis, which was previously known only from fragmentary dental remains. Methodology/Principal Findings: The new material indicates that Djarthia is a member of Australidelphia, a pan-Gondwanan clade comprising all extant Australian marsupials together with the South American microbiotheres. Djarthia is therefore the oldest known crown-group marsupial anywhere in the world that is represented by dental, cranial and post-cranial remains, and the oldest known Australian marsupial by 30 million years. It is also the most plesiomorphic known australidelphian, and phylogenetic analyses place it outside all other Australian marsupials. Conclusions/Significance: As the most plesiomorphic and oldest unequivocal australidelphian, Djarthia may approximate the ancestral morphotype of the Australian marsupial radiation and suggests that the South American microbiotheres may be the result of back-dispersal from eastern Gondwana, which is the reverse of prevailing hypotheses.	[Beck, Robin M. D.; Godthelp, Henk; Weisbecker, Vera; Archer, Michael; Hand, Suzanne J.] Univ New S Wales, Sch Biol Earth & Environm Sci, Sydney, NSW, Australia	University of New South Wales Sydney	Beck, RMD (corresponding author), Univ New S Wales, Sch Biol Earth & Environm Sci, Sydney, NSW, Australia.	robin.beck@student.unsw.edu.au	Weisbecker, Vera/P-7088-2015; Weisbecker, Vera/AAC-4374-2022; Hand, Suzanne J/C-3853-2008	Weisbecker, Vera/0000-0003-2370-4046; Weisbecker, Vera/0000-0003-2370-4046; Hand, Suzanne/0000-0002-4940-3391; Beck, Robin/0000-0002-7050-7072; Archer, Michael/0000-0002-0304-4039	Leverhulme Trust [SAS/30110]; Australian Research Council; Queensland Parks and Wildlife Service; University of New South Wales; Queensland Museum; Australian Museum; UNSW [CREATE scholarship]	Leverhulme Trust(Leverhulme Trust); Australian Research Council(Australian Research Council); Queensland Parks and Wildlife Service; University of New South Wales; Queensland Museum; Australian Museum; UNSW	This work was supported by the Leverhulme Trust (Study Abroad Studentship SAS/30110 to R. Beck), the Australian Research Council, Queensland Parks and Wildlife Service, the University of New South Wales, the Queensland Museum, the Australian Museum, and Phil Creaser and the CREATE fund at UNSW (CREATE scholarship to R. Beck).	Amrine-Madsen H, 2003, MOL PHYLOGENET EVOL, V28, P186, DOI 10.1016/S1055-7903(03)00122-2; Archer Michael, 1999, Australian Mammalogy, V21, P1; Archer Michael, 1993, Kaupia Darmstaedter Beitraege zur Naturgeschichte, V3, P193; Beck RMD, 2008, J MAMMAL, V89, P175, DOI 10.1644/06-MAMM-A-437.1; Boles Walter E., 1999, Records of the Western Australian Museum Supplement, V57, P229; Couto C. de P., 1952, American Museum Novitates, VNo. 1567, P1; de Muizon C, 1999, GEOBIOS-LYON, V32, P483; Drummond AJ, 2007, ROUGH GUIDE BEAST 1; Drummond AJ, 2006, PLOS BIOL, V4, P699, DOI 10.1371/journal.pbio.0040088; Ekdale EG, 2004, ACTA PALAEONTOL POL, V49, P161; GODTHELP H, 1992, NATURE, V356, P514, DOI 10.1038/356514a0; Godthelp Henk, 1999, Journal of Mammalian Evolution, V6, P289, DOI 10.1023/A:1020517808869; Goin Francisco J., 1999, Journal of Mammalian Evolution, V6, P335, DOI 10.1023/A:1027357927460; HAND S, 1994, J VERTEBR PALEONTOL, V14, P375, DOI 10.1080/02724634.1994.10011565; Ho SYW, 2007, J AVIAN BIOL, V38, P409, DOI 10.1111/j.2007.0908-8857.04168.x; Kielan-Jaworowska Z., 2005, MAMMALS AGE DINOSAUR; Kitazoe Y, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000384; Ladeveze S, 2004, J VERTEBR PALEONTOL, V24, P202, DOI 10.1671/16; Ladeveze S, 2007, PALAEONTOLOGY, V50, P1123, DOI 10.1111/j.1475-4983.2007.00703.x; Ladeveze S, 2007, ZOOL J LINN SOC-LOND, V150, P85, DOI 10.1111/j.1096-3642.2007.00282.x; Lewis PO, 2001, SYST BIOL, V50, P913, DOI 10.1080/106351501753462876; MARSHALL LG, 1988, NATL GEOGR RES, V4, P23; McKenna MC, 1997, CLASSIFICATION MAMMA; Nylander J. A. A., 2004, MRMODELTEST V2; Phillips MJ, 2008, MOL PHYLOGENET EVOL, V46, P594, DOI 10.1016/j.ympev.2007.09.008; Phillips MJ, 2006, SYST BIOL, V55, P122, DOI 10.1080/10635150500481614; Posada D, 2004, SYST BIOL, V53, P793, DOI 10.1080/10635150490522304; Ronquist F, 2003, BIOINFORMATICS, V19, P1572, DOI 10.1093/bioinformatics/btg180; Rougier GW, 2007, AM MUS NOVIT, P1, DOI 10.1206/0003-0082(2007)507[1:NJMFPA]2.0.CO;2; Rougier GW, 1998, NATURE, V396, P459, DOI 10.1038/24856; Salisbury SW, 1996, ALCHERINGA, V20, P179, DOI 10.1080/03115519608619189; Sanchez-Villagra M, 2007, BIOL LETTERS, V3, P318, DOI 10.1098/rsbl.2007.0090; Sanchez-Villagra MR, 2002, J ZOOL SYST EVOL RES, V40, P26, DOI 10.1046/j.1439-0469.2002.00173.x; SANCHEZVILLAGRA MR, 1998, THESIS DUKE U DURHAM; Scanlon John D., 2005, Memoirs of the Queensland Museum, V51, P215; SEGALL W, 1969, ACTA ANAT, V72, P489; Swofford D.L., 2002, PAUP PHYLOGENETIC AN, DOI 10.1111/j.0014-3820.2002.tb00191.x; Szalay F.S., 1982, P621; Szalay F. S., 1994, EVOLUTIONARY HIST MA; Szalay Frederick S., 2001, Geodiversitas, V23, P139; van Rheede T, 2006, MOL BIOL EVOL, V23, P587, DOI 10.1093/molbev/msj064; Voss RS, 2003, B AM MUS NAT HIST, P1; Wible JR, 2007, NATURE, V447, P1003, DOI 10.1038/nature05854; Wible J.R., 1990, Journal of Vertebrate Paleontology, V10, P183; Wible John R., 2001, American Museum Novitates, V3322, P1, DOI 10.1206/0003-0082(2001)322<0001:EEERAP>2.0.CO;2; Woodburne Michael O., 1996, Journal of Mammalian Evolution, V3, P121, DOI 10.1007/BF01454359; Worthy TH, 2006, P NATL ACAD SCI USA, V103, P19419, DOI 10.1073/pnas.0605684103; Wroe S, 2000, J MAMMAL, V81, P1008, DOI 10.1644/1545-1542(2000)081<1008:CAODMP>2.0.CO;2	48	80	85	1	25	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1858	10.1371/journal.pone.0001858	http://dx.doi.org/10.1371/journal.pone.0001858			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365013	Green Submitted, Green Published, gold			2022-12-25	WOS:000260762400019
J	Vomel, M; Wegener, C				Voemel, Matthias; Wegener, Christian			Neuroarchitecture of Aminergic Systems in the Larval Ventral Ganglion of Drosophila melanogaster	PLOS ONE			English	Article							CENTRAL-NERVOUS-SYSTEM; CRUSTACEAN CARDIOACTIVE PEPTIDE; SEROTONIN-CONTAINING NEURONS; TARGETED GENE-EXPRESSION; TYROSINE-HYDROXYLASE; FRUIT-FLY; DOPA DECARBOXYLASE; LOCOMOTOR-ACTIVITY; MUSHROOM BODIES; IMMUNOCYTOCHEMICAL LOCALIZATION	Biogenic amines are important signaling molecules in the central nervous system of both vertebrates and invertebrates. In the fruit fly Drosophila melanogaster, biogenic amines take part in the regulation of various vital physiological processes such as feeding, learning/memory, locomotion, sexual behavior, and sleep/arousal. Consequently, several morphological studies have analyzed the distribution of aminergic neurons in the CNS. Previous descriptions, however, did not determine the exact spatial location of aminergic neurite arborizations within the neuropil. The release sites and pre-/postsynaptic compartments of aminergic neurons also remained largely unidentified. We here used gal4-driven marker gene expression and immunocytochemistry to map presumed serotonergic (5-HT), dopaminergic, and tyraminergic/octopaminergic neurons in the thoracic and abdominal neuromeres of the Drosophila larval ventral ganglion relying on Fasciclin2-immunoreactive tracts as three-dimensional landmarks. With tyrosine hydroxylase-(TH) or tyrosine decarboxylase 2 (TDC2)-specific gal4-drivers, we also analyzed the distribution of ectopically expressed neuronal compartment markers in presumptive dopaminergic TH and tyraminergic/octopaminergic TDC2 neurons, respectively. Our results suggest that thoracic and abdominal 5-HT and TH neurons are exclusively interneurons whereas most TDC2 neurons are efferent. 5-HT and TH neurons are ideally positioned to integrate sensory information and to modulate neuronal transmission within the ventral ganglion, while most TDC2 neurons appear to act peripherally. In contrast to 5-HT neurons, TH and TDC2 neurons each comprise morphologically different neuron subsets with separated in- and output compartments in specific neuropil regions. The three-dimensional mapping of aminergic neurons now facilitates the identification of neuronal network contacts and co-localized signaling molecules, as exemplified for DOPA decarboxylase-synthesizing neurons that co-express crustacean cardioactive peptide and myoinhibiting peptides.	[Voemel, Matthias; Wegener, Christian] Univ Marburg, Dept Biol, Emmy Noether Neuropeptide Grp, Marburg, Germany	Philipps University Marburg	Vomel, M (corresponding author), Univ Marburg, Dept Biol, Emmy Noether Neuropeptide Grp, Marburg, Germany.	wegener@staff.uni-marburg.de		Wegener, Christian/0000-0003-4481-3567	Deutsche Forschungsgemeinschaft [We 2652/2-2,3]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG))	This work was supported by the Deutsche Forschungsgemeinschaft (DFG We 2652/2-2,3) to CW.	Adolfsen B, 2004, J CELL BIOL, V166, P249, DOI 10.1083/jcb.200312054; Andretic R, 2005, CURR BIOL, V15, P1165, DOI 10.1016/j.cub.2005.05.025; Bader R, 2007, FLY, V1, P228, DOI 10.4161/fly.4749; Bate Michael, 1993, P1013; BIRMAN S, 1994, J BIOL CHEM, V269, P26559; Blenau W, 2001, ARCH INSECT BIOCHEM, V48, P13, DOI 10.1002/arch.1055; Blumenthal EM, 2005, AM J PHYSIOL-CELL PH, V289, pC1261, DOI 10.1152/ajpcell.00026.2005; Blumenthal EM, 2003, AM J PHYSIOL-CELL PH, V284, pC718, DOI 10.1152/ajpcell.00359.2002; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRAUNIG P, 1988, J COMP PHYSIOL A, V163, P835, DOI 10.1007/BF00604060; Brembs B, 2007, J NEUROSCI, V27, P11122, DOI 10.1523/JNEUROSCI.2704-07.2007; Brody T, 2000, J CELL BIOL, V150, pF83, DOI 10.1083/jcb.150.2.F83; BUDNIK V, 1988, J COMP NEUROL, V268, P400, DOI 10.1002/cne.902680309; BUDNIK V, 1987, J NEUROGENET, V4, P309, DOI 10.3109/01677068709102351; Campos-Ortega J, 1997, EMBRYONIC DEV DROSOP; Carr CM, 2007, EMBO REP, V8, P834, DOI 10.1038/sj.embor.7401051; Chang HY, 2006, MOL PSYCHIATR, V11, P99, DOI 10.1038/sj.mp.4001742; CLARK WC, 1978, MOL GEN GENET, V162, P287, DOI 10.1007/BF00268854; Cole SH, 2005, J BIOL CHEM, V280, P14948, DOI 10.1074/jbc.M414197200; Coleman CM, 2004, INVERTEBR NEUROSCI, V5, P85, DOI 10.1007/s10158-004-0031-y; Coleman CM, 2005, ARCH INSECT BIOCHEM, V59, P12, DOI 10.1002/arch.20050; Cooper RL, 1999, COMP BIOCHEM PHYS B, V122, P199, DOI 10.1016/S0305-0491(98)10160-8; Dasari S, 2006, J COMP PHYSIOL B, V176, P349, DOI 10.1007/s00360-005-0058-3; Davis MM, 2007, DEVELOPMENT, V134, P4395, DOI 10.1242/dev.009902; DIRCKSEN H, 1988, CELL TISSUE RES, V254, P347; Draper I, 2007, DEV NEUROBIOL, V67, P378, DOI 10.1002/dneu.20355; Estes PS, 2000, J NEUROGENET, V13, P233, DOI 10.3109/01677060009084496; Evans Peter D., 2005, Invertebrate Neuroscience, V5, P111, DOI 10.1007/s10158-005-0001-z; Ewer J, 2005, HORM BEHAV, V48, P418, DOI 10.1016/j.yhbeh.2005.05.018; Ewer J, 1996, J COMP NEUROL, V370, P330; Farooqui T, 2007, NEUROCHEM RES, V32, P1511, DOI 10.1007/s11064-007-9344-7; Fox LE, 2006, J NEUROSCI, V26, P1486, DOI 10.1523/JNEUROSCI.4749-05.2006; Friggi-Grelin F, 2003, GENESIS, V35, P260, DOI 10.1002/gene.1082; Friggi-Grelin F, 2003, J NEUROBIOL, V54, P618, DOI 10.1002/neu.10185; Ganguly-Fitzgerald I, 2006, SCIENCE, V313, P1775, DOI 10.1126/science.1130408; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Greer CL, 2005, J NEUROBIOL, V64, P239, DOI 10.1002/neu.20146; Grueber WB, 2007, DEVELOPMENT, V134, P55, DOI 10.1242/dev.02666; Hamasaka Y, 2005, J NEUROBIOL, V65, P225, DOI 10.1002/neu.20184; Han KA, 1998, J NEUROSCI, V18, P3650; Han KA, 1996, NEURON, V16, P1127, DOI 10.1016/S0896-6273(00)80139-7; Hardie SL, 2007, DEV NEUROBIOL, V67, P1396, DOI 10.1002/dneu.20459; Hauser F, 2006, PROG NEUROBIOL, V80, P1, DOI 10.1016/j.pneurobio.2006.07.005; Hiesinger PR, 2001, J COMP NEUROL, V429, P277, DOI 10.1002/1096-9861(20000108)429:2<277::AID-CNE8>3.0.CO;2-8; Hodgetts RB, 2006, ANNU REV ENTOMOL, V51, P259, DOI 10.1146/annurev.ento.51.110104.151143; Hoffman BJ, 1998, FRONT NEUROENDOCRIN, V19, P187, DOI 10.1006/frne.1998.0168; Ito K, 1998, LEARN MEMORY, V5, P52; Iyengar BG, 2006, J COMP NEUROL, V499, P583, DOI 10.1002/cne.21133; Kim YC, 2003, GENE EXPR PATTERNS, V3, P237, DOI 10.1016/S1567-133X(02)00098-4; KONRAD KD, 1987, DEV BIOL, V122, P172, DOI 10.1016/0012-1606(87)90343-5; Kume K, 2005, J NEUROSCI, V25, P7377, DOI 10.1523/JNEUROSCI.2048-05.2005; Kutsukake M, 2000, GENE, V245, P31, DOI 10.1016/S0378-1119(99)00569-7; Landgraf M, 2003, DEV BIOL, V260, P207, DOI 10.1016/S0012-1606(03)00215-X; Landgraf M, 2006, SEMIN CELL DEV BIOL, V17, P3, DOI 10.1016/j.semcdb.2005.11.007; Langley K, 1997, NEUROCHEM INT, V31, P739, DOI 10.1016/S0197-0186(97)00040-5; Lee HG, 2003, DEV BIOL, V264, P179, DOI 10.1016/j.ydbio.2003.07.018; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; Li H, 2000, CURR BIOL, V10, P211, DOI 10.1016/S0960-9822(00)00340-7; Lohr R, 2002, J NEUROSCI, V22, P10357; LUNDELL MJ, 1994, DEV BIOL, V165, P385, DOI 10.1006/dbio.1994.1261; Meldolesi J, 2004, TRENDS CELL BIOL, V14, P13, DOI 10.1016/j.tcb.2003.11.006; Meng JH, 2007, J CELL SCI, V120, P2864, DOI 10.1242/jcs.012211; Middleton CA, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-17; Monastirioti M, 1999, MICROSC RES TECHNIQ, V45, P106, DOI 10.1002/(SICI)1097-0029(19990415)45:2<106::AID-JEMT5>3.3.CO;2-V; Monastirioti M, 1996, J NEUROSCI, V16, P3900; Monastirioti M, 2003, DEV BIOL, V264, P38, DOI 10.1016/j.ydbio.2003.07.019; MONASTIRIOTI M, 1995, J COMP NEUROL, V356, P275, DOI 10.1002/cne.903560210; Mustard JA, 2005, ARCH INSECT BIOCHEM, V59, P103, DOI 10.1002/arch.20065; Nagaya Y, 2002, NEUROSCI LETT, V329, P324, DOI 10.1016/S0304-3940(02)00596-7; NASSEL DR, 1992, CELL TISSUE RES, V267, P147, DOI 10.1007/BF00318701; Nassel DR, 1996, PROG NEUROBIOL, V48, P325, DOI 10.1016/0301-0082(95)00048-8; Nassel DR, 1996, J NEUROSCI METH, V69, P3, DOI 10.1016/S0165-0270(96)00016-7; Neckameyer WS, 2007, GENES BRAIN BEHAV, V6, P756, DOI 10.1111/j.1601-183X.2007.00307.x; NECKAMEYER WS, 1993, J NEUROGENET, V8, P189, DOI 10.3109/01677069309083448; Neckameyer WS, 2005, STRESS, V8, P117, DOI 10.1080/10253890500147381; Nichols CD, 2007, DEV NEUROBIOL, V67, P752, DOI 10.1002/dneu.20370; NIRENBERG MJ, 1995, P NATL ACAD SCI USA, V92, P8773, DOI 10.1073/pnas.92.19.8773; Nishikawa K, 1999, BRAIN RES, V837, P67, DOI 10.1016/S0006-8993(99)01676-5; O'Donnell MJ, 2006, ARCH INSECT BIOCHEM, V63, P123, DOI 10.1002/arch.20148; Otsuna H, 2006, J COMP NEUROL, V497, P928, DOI 10.1002/cne.21015; Park JH, 2003, DEVELOPMENT, V130, P2645, DOI 10.1242/dev.00503; Pendleton RG, 2005, PHARMACOL BIOCHEM BE, V81, P849, DOI 10.1016/j.pbb.2005.06.008; Pendleton RG, 2002, BEHAV GENET, V32, P89, DOI 10.1023/A:1015279221600; Pfluger HJ, 2005, ARTHROPOD STRUCT DEV, V34, P379, DOI 10.1016/j.asd.2005.04.004; Predel R, 2001, PEPTIDES, V22, P199, DOI 10.1016/S0196-9781(00)00383-1; Raghu SV, 2007, J COMP NEUROL, V502, P598, DOI 10.1002/cne.21319; Rauschenbach IY, 2007, ARCH INSECT BIOCHEM, V65, P95, DOI 10.1002/arch.20183; Roeder T, 2003, ARCH INSECT BIOCHEM, V54, P1, DOI 10.1002/arch.10102; Roeder T, 2005, ANNU REV ENTOMOL, V50, P447, DOI 10.1146/annurev.ento.50.071803.130404; Santos JG, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000695; Saraswati S, 2004, J NEUROBIOL, V58, P425, DOI 10.1002/neu.10298; Schrader S, 2000, J COMP NEUROL, V425, P34; Schwaerzel M, 2003, J NEUROSCI, V23, P10495, DOI 10.1523/jneurosci.23-33-10495.2003; Soller M, 2006, CURR BIOL, V16, P1771, DOI 10.1016/j.cub.2006.07.055; SPORHASEEICHMANN U, 1992, CELL TISSUE RES, V268, P287, DOI 10.1007/BF00318798; Srivastava DP, 2005, J NEUROSCI, V25, P6145, DOI 10.1523/JNEUROSCI.1005-05.2005; STEVENSON PA, 1992, J COMP NEUROL, V315, P382, DOI 10.1002/cne.903150403; STEVENSON PA, 1995, COMP BIOCHEM PHYS A, V110, P203, DOI 10.1016/0300-9629(94)00152-J; SUGAMORI KS, 1995, FEBS LETT, V362, P131, DOI 10.1016/0014-5793(95)00224-W; Sykes PA, 2005, DEV BIOL, V286, P207, DOI 10.1016/j.ydbio.2005.07.025; Tsuboi T, 2004, J BIOL CHEM, V279, P47115, DOI 10.1074/jbc.M408179200; VALLES AM, 1986, J NEUROSCI, V6, P1482; VALLES AM, 1988, J COMP NEUROL, V268, P414, DOI 10.1002/cne.902680310; Vie A, 1999, J BIOL CHEM, V274, P16788, DOI 10.1074/jbc.274.24.16788; Wang J, 2004, NEURON, V43, P663, DOI 10.1016/j.neuron.2004.06.033; Wojcik SM, 2007, NEURON, V55, P11, DOI 10.1016/j.neuron.2007.06.013; Ye YZ, 2004, EUR J NEUROSCI, V20, P1001, DOI 10.1111/j.1460-9568.2004.03575.x; Yoshihara M, 2003, CURR OPIN NEUROBIOL, V13, P315, DOI 10.1016/S0959-4388(03)00063-1; Yoshihara M, 2002, NEURON, V36, P897, DOI 10.1016/S0896-6273(02)01065-6; Yuan Q, 2005, NEURON, V47, P115, DOI 10.1016/j.neuron.2005.05.027; Yuan Q, 2006, CURR BIOL, V16, P1051, DOI 10.1016/j.cub.2006.04.032; Zhang K, 2007, SCIENCE, V316, P1901, DOI 10.1126/science.1137357; Zhang YQ, 2002, GENESIS, V34, P142, DOI 10.1002/gene.10144; Zitnan D, 2007, GEN COMP ENDOCR, V153, P88, DOI 10.1016/j.ygcen.2007.04.002; Zlatic M, 2003, NEURON, V37, P41, DOI 10.1016/S0896-6273(02)01131-5	115	30	30	0	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1848	10.1371/journal.pone.0001848	http://dx.doi.org/10.1371/journal.pone.0001848			18	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365004	Green Submitted, Green Published, gold			2022-12-25	WOS:000260762400010
J	Gude, DR; Alvarez, SE; Paugh, SW; Mitra, P; Yu, JD; Griffiths, R; Barbour, SE; Milstien, S; Spiegel, S				Gude, David R.; Alvarez, Sergio E.; Paugh, Steven W.; Mitra, Poulami; Yu, JiaDe; Griffiths, Rachael; Barbour, Suzanne E.; Milstien, Sheldon; Spiegel, Sarah			Apoptosis induces expression of sphingosine kinase 1 to release sphingosine-1-phosphate as a "come-and-get-me" signal	FASEB JOURNAL			English	Article						chemotaxis; leukemia cells; monocytes; secretion	CELL-MIGRATION; LEUKEMIA-CELLS; 1-PHOSPHATE; FTY720; RECEPTOR; N,N-DIMETHYLSPHINGOSINE; GROWTH; PHOSPHORYLATION; IMMUNOMODULATOR; INVOLVEMENT	Sphingosine-1-phosphate (S1P) is a bioactive lipid that regulates myriad important cellular processes, including growth, survival, cytoskeleton rearrangements, motility, and immunity. Here we report that treatment of Jurkat and U937 leukemia cells with the pan-sphingosine kinase (SphK) inhibitor N,N-dimethylsphingosine to block S1P formation surprisingly caused a large increase in expression of SphK1 concomitant with induction of apoptosis. Another SphK inhibitor, D, L-threo-dihydrosphingosine, also induced apoptosis and produced dramatic increases in SphK1 expression. However, up-regulation of SphK1 was not a specific effect of its inhibition but rather was a consequence of apoptotic stress. The chemotherapeutic drug doxorubicin, a potent inducer of apoptosis in these cells, also stimulated SphK1 expression and activity and promoted S1P secretion. The caspase inhibitor ZVAD reduced not only doxorubicin-induced lethality but also the increased expression of SphK1 and secretion of S1P. Apoptotic cells secrete chemotactic factors to attract phagocytic cells, and we found that S1P potently stimulated chemotaxis of monocytic THP-1 and U937 cells and primary monocytes and macrophages. Collectively, our data suggest that apoptotic cells may upregulate SphK1 to produce and secrete S1P that serves as a "come-and-get-me" signal for scavenger cells to engulf them in order to prevent necrosis.	[Gude, David R.; Alvarez, Sergio E.; Paugh, Steven W.; Mitra, Poulami; Yu, JiaDe; Griffiths, Rachael; Barbour, Suzanne E.; Spiegel, Sarah] Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, Richmond, VA 23298 USA; [Gude, David R.; Alvarez, Sergio E.; Paugh, Steven W.; Mitra, Poulami; Yu, JiaDe; Griffiths, Rachael; Barbour, Suzanne E.; Spiegel, Sarah] Virginia Commonwealth Univ, Sch Med, Massey Canc Ctr, Richmond, VA 23298 USA; [Milstien, Sheldon] NIMH, NIH, Bethesda, MD 20892 USA	Virginia Commonwealth University; Virginia Commonwealth University; National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH)	Spiegel, S (corresponding author), Virginia Commonwealth Univ, Sch Med, Dept Biochem & Mol Biol, 1101 E Marshall St,2011 Sanger Hall, Richmond, VA 23298 USA.	sspiegel@vcu.edu	Nagarkatti-Gude, David/AAF-6996-2020; Yu, JiaDe/J-6683-2019; Paugh, Steven/A-7739-2008	Yu, JiaDe/0000-0002-0874-3170; Paugh, Steven/0000-0001-5697-9228	Intramural NIH HHS Funding Source: Medline; NCI NIH HHS [R01 CA061774, R01 CA61774] Funding Source: Medline; NIGMS NIH HHS [R37 GM043880] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA061774] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM043880] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [ZIAMH001039] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adrain C, 2006, J BIOL CHEM, V281, P8118, DOI 10.1074/jbc.M509361200; Ancellin N, 2002, J BIOL CHEM, V277, P6667, DOI 10.1074/jbc.M102841200; Baran Y, 2007, J BIOL CHEM, V282, P10922, DOI 10.1074/jbc.M610157200; Billich A, 2003, J BIOL CHEM, V278, P47408, DOI 10.1074/jbc.M307687200; Bonhoure E, 2006, LEUKEMIA, V20, P95, DOI 10.1038/sj.leu.2404023; Chiba K, 2005, PHARMACOL THERAPEUT, V108, P308, DOI 10.1016/j.pharmthera.2005.05.002; Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007; Cuvillier O, 2000, J BIOL CHEM, V275, P15691, DOI 10.1074/jbc.M000280200; Cuvillier O, 1996, NATURE, V381, P800, DOI 10.1038/381800a0; Cuvillier O, 2001, BLOOD, V98, P2828, DOI 10.1182/blood.V98.9.2828; Don AS, 2007, J BIOL CHEM, V282, P15833, DOI 10.1074/jbc.M609124200; Edsall LC, 1998, BIOCHEMISTRY-US, V37, P12892, DOI 10.1021/bi980744d; French KJ, 2003, CANCER RES, V63, P5962; Grimsley C, 2003, TRENDS CELL BIOL, V13, P648, DOI 10.1016/j.tcb.2003.10.004; Hait NC, 2005, J BIOL CHEM, V280, P29462, DOI 10.1074/jbc.M502922200; Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007; Hammad SM, 2006, PROSTAG OTH LIPID M, V79, P126, DOI 10.1016/j.prostaglandins.2005.12.004; Hla T, 2001, SCIENCE, V294, P1875, DOI 10.1126/science.1065323; Huwiler A, 2006, CURR PHARM DESIGN, V12, P4625, DOI 10.2174/138161206779010422; Jin ZQ, 2006, CARDIOVASC RES, V71, P725, DOI 10.1016/j.cardiores.2006.06.010; Johann AM, 2008, J IMMUNOL, V180, P1239, DOI 10.4049/jimmunol.180.2.1239; Jolly PS, 2004, J EXP MED, V199, P959, DOI 10.1084/jem.20030680; Kinchen JM, 2007, J CELL SCI, V120, P2143, DOI 10.1242/jcs.03463; Lauber K, 2003, CELL, V113, P717, DOI 10.1016/S0092-8674(03)00422-7; Li QF, 2007, ONCOGENE, V26, P7904, DOI 10.1038/sj.onc.1210587; Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015; Mitra P, 2007, METHOD ENZYMOL, V434, P257, DOI 10.1016/S0076-6879(07)34014-7; Mitra P, 2006, P NATL ACAD SCI USA, V103, P16394, DOI 10.1073/pnas.0603734103; Murakami N, 2004, J BIOL CHEM, V279, P42484, DOI 10.1074/jbc.M406561200; Neviani P, 2007, J CLIN INVEST, V117, P2408, DOI 10.1172/JCI31095; Ogretmen B, 2004, NAT REV CANCER, V4, P604, DOI 10.1038/nrc1411; OLIVERA A, 1993, NATURE, V365, P557, DOI 10.1038/365557a0; Olivera A, 2003, J BIOL CHEM, V278, P46452, DOI 10.1074/jbc.M308749200; Paugh SW, 2003, FEBS LETT, V554, P189, DOI 10.1016/S0014-5793(03)01168-2; Peter C, 2008, J BIOL CHEM, V283, P5296, DOI 10.1074/jbc.M706586200; Ravichandran KS, 2003, CELL, V113, P817, DOI 10.1016/S0092-8674(03)00471-9; Sanchez T, 2003, J BIOL CHEM, V278, P47281, DOI 10.1074/jbc.M306896200; Sanchez T, 2004, J CELL BIOCHEM, V92, P913, DOI 10.1002/jcb.20127; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; Schaub FJ, 2000, NAT MED, V6, P790, DOI 10.1038/77521; Singer II, 2005, J IMMUNOL, V175, P7151, DOI 10.4049/jimmunol.175.11.7151; Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103; Spiegel S, 2007, J BIOL CHEM, V282, P2125, DOI 10.1074/jbc.R600028200; Sugimoto N, 2003, MOL CELL BIOL, V23, P1534, DOI 10.1128/MCB.23.5.1534-1545.2003; Sweeney EA, 1996, INT J CANCER, V66, P358, DOI 10.1002/(SICI)1097-0215(19960503)66:3<358::AID-IJC16>3.0.CO;2-7; Taha TA, 2006, J BIOCHEM MOL BIOL, V39, P113; Taha TA, 2005, J BIOL CHEM, V280, P17196, DOI 10.1074/jbc.M413744200; Taha TA, 2004, J BIOL CHEM, V279, P20546, DOI 10.1074/jbc.M401259200; Taylor RC, 2007, J BIOL CHEM, V282, P15011, DOI 10.1074/jbc.M611051200; Treede I, 2007, J BIOL CHEM, V282, P27155, DOI 10.1074/jbc.M704408200; Truman LA, 2004, IMMUNOBIOLOGY, V209, P21, DOI 10.1016/j.imbio.2004.02.001; Vessey DA, 2007, J BIOCHEM MOL TOXIC, V21, P273, DOI 10.1002/jbt.20193; Wang F, 1999, J BIOL CHEM, V274, P35343, DOI 10.1074/jbc.274.50.35343; Weigert A, 2007, MOL BIOL CELL, V18, P3810, DOI 10.1091/mbc.E06-12-1096; Weigert A, 2006, BLOOD, V108, P1635, DOI 10.1182/blood-2006-04-014852; Wu CH, 2002, ONCOGENE, V21, P5160, DOI 10.1038/sj.onc.1205639	56	246	255	2	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2629	2638		10.1096/fj.08-107169	http://dx.doi.org/10.1096/fj.08-107169			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18362204	Green Published			2022-12-25	WOS:000258089300004
J	Kines, KJ; Morales, ME; Mann, VH; Gobert, GN; Brindley, PJ				Kines, Kristine J.; Morales, Maria E.; Mann, Victoria H.; Gobert, Geoffrey N.; Brindley, Paul J.			Integration of reporter transgenes into Schistosoma mansoni chromosomes mediated by pseudotyped murine leukemia virus	FASEB JOURNAL			English	Article						schistosome; transgenesis; VSVG; luciferase; provirus; functional genomics	HUMAN-BLOOD FLUKE; LONG TERMINAL REPEAT; PANTROPIC RETROVIRAL VECTORS; T-CELL LEUKEMIA; PIGGYBAC TRANSPOSON; RNA INTERFERENCE; GENE-TRANSFER; GERM-LINE; IN-VITRO; GENOME	The recent release of draft genome sequences of two of the major human schistosomes has underscored the pressing need to develop functional genomics approaches for these significant pathogens. The sequence information also makes feasible genome-scale investigation of transgene integration into schistosome chromosomes. Retrovirus-mediated transduction offers a means to establish transgenic lines of schistosomes, to elucidate schistosome gene function and expression, and to advance functional genomics approaches for these parasites. We investigated the utility of the Moloney murine leukemia retrovirus (MLV) pseudotyped with vesicular stomatitis virus glycoprotein (VSVG) for the transduction of Schistosoma mansoni and delivery of reporter transgenes into schistosome chromosomes. Schistosomula were exposed to virions of VSVG-pseudotyped MLV, after which genomic DNA was extracted from the transduced schistosomes. Southern hybridization analysis indicated the presence of proviral MLV retrovirus in the transduced schistosomes. Fragments of the MLV transgene and flanking schistosome sequences recovered using an anchored PCR-based approach demonstrated definitively that somatic transgenesis of schistosome chromosomes had taken place and, moreover, revealed widespread retrovirus integration into schistosome chromosomes. More specifically, MLV transgenes had inserted in the vicinity of genes encoding immunophilin, zinc finger protein Sma-Zic, and others, as well as near the endogenous schistosome retrotransposons, the fugitive and SR1. Proviral integration of the MLV transgene appeared to exhibit primary sequence site specificity, targeting a gGATcc-like motif. Reporter luciferase transgene activity driven by the schistosome actin gene promoter was expressed in the tissues of transduced schistosomula and adult schistosomes. Luciferase activity appeared to be developmentally expressed in schistosomula with increased activity observed after 1 to 2 wk in culture. These findings indicate the utility of VSVG-pseudotyped MLV for transgenesis of S. mansoni, herald a tractable pathway forward toward germline transgenesis and functional genomics of parasitic helminths, and provide the basis for comparative molecular pathogenesis studies of chromosomal lesions arising from retroviral integration into human compared with schistosome chromosomes.	[Kines, Kristine J.; Morales, Maria E.; Mann, Victoria H.; Gobert, Geoffrey N.; Brindley, Paul J.] George Washington Univ, Med Ctr, Dept Microbiol Immunol & Trop Med, Washington, DC 20037 USA; [Kines, Kristine J.; Morales, Maria E.; Mann, Victoria H.; Gobert, Geoffrey N.; Brindley, Paul J.] Tulane Univ, Hlth Sci Ctr, Dept Trop Med, New Orleans, LA 70118 USA; [Kines, Kristine J.; Morales, Maria E.; Mann, Victoria H.; Gobert, Geoffrey N.; Brindley, Paul J.] Queensland Inst Med Res, Div Infect Dis, Brisbane, Qld 4006, Australia; [Kines, Kristine J.; Morales, Maria E.; Mann, Victoria H.; Gobert, Geoffrey N.; Brindley, Paul J.] Tulane Univ, Hlth Sci Ctr, Program Biomed Sci, New Orleans, LA 70118 USA	George Washington University; Tulane University; QIMR Berghofer Medical Research Institute; Tulane University	Brindley, PJ (corresponding author), George Washington Univ, Med Ctr, Dept Microbiol Immunol & Trop Med, Ross Hall,Rm 448,2300 Eye St NW, Washington, DC 20037 USA.	mtmpjb@gwumc.edu	Gobert, Geoffrey/A-1468-2011; Gobert, Geoffrey/V-2985-2019	Brindley, Paul J./0000-0003-1765-0002; Gobert, Geoffrey/0000-0001-5884-6453	NIAID NIH HHS [R01 AI072773] Funding Source: Medline; PHS HHS [N0155270] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI072773] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alfa Ronald W., 2006, V129, P241; Amsterdam A, 2006, TRENDS GENET, V22, P473, DOI 10.1016/j.tig.2006.06.011; Balu B, 2005, P NATL ACAD SCI USA, V102, P16391, DOI 10.1073/pnas.0504679102; BASCH PF, 1981, J PARASITOL, V67, P179, DOI 10.2307/3280632; Boulo V, 2000, IN VITRO CELL DEV-AN, V36, P395, DOI 10.1290/1071-2690(2000)036<0395:IOCECO>2.0.CO;2; Braschi S, 2006, MOL CELL PROTEOMICS, V5, P347, DOI 10.1074/mcp.M500287-MCP200; Brindley PJ, 2007, INT J PARASITOL, V37, P465, DOI 10.1016/j.ijpara.2006.12.012; Brindley PJ, 2003, TRENDS PARASITOL, V19, P79, DOI 10.1016/S1471-4922(02)00061-2; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; Cioli D, 2004, INT J PARASITOL, V34, P979, DOI 10.1016/j.ijpara.2004.05.001; Copeland CS, 2003, J VIROL, V77, P6153, DOI 10.1128/JVI.77.11.6153-6166.2003; Correnti JA, 2005, MOL BIOCHEM PARASIT, V143, P209, DOI 10.1016/j.molbiopara.2005.06.007; Correnti JM, 2007, INT J PARASITOL, V37, P1107, DOI 10.1016/j.ijpara.2007.02.011; DeMarco R, 2005, BIOCHEM BIOPH RES CO, V333, P230, DOI 10.1016/j.bbrc.2005.05.080; Derse D, 2007, J VIROL, V81, P6731, DOI 10.1128/JVI.02752-06; Dirks C, 2001, J VIROL, V75, P6375, DOI 10.1128/JVI.75.14.6375-6383.2001; Drew AC, 1999, MOL BIOL EVOL, V16, P1256, DOI 10.1093/oxfordjournals.molbev.a026216; Drew AC, 1997, MOL BIOL EVOL, V14, P602, DOI 10.1093/oxfordjournals.molbev.a025799; Grant WN, 2006, INT J PARASITOL, V36, P475, DOI 10.1016/j.ijpara.2005.12.002; Grevelding CG, 2006, PARASITIC FLATWORMS: MOLECULAR BIOLOGY, BIOCHEMISTRY, IMMUNOLOGY AND PHYSIOLOGY, P149, DOI 10.1079/9780851990279.0149; Haas BJ, 2007, EXP PARASITOL, V117, P225, DOI 10.1016/j.exppara.2007.06.005; Handler AM, 2002, INSECT BIOCHEM MOLEC, V32, P1211, DOI 10.1016/S0965-1748(02)00084-X; Hotez PJ, 2006, LANCET, V368, P1865, DOI 10.1016/S0140-6736(06)69765-1; Hu W, 2004, TRENDS MOL MED, V10, P217, DOI 10.1016/j.molmed.2004.03.002; Johnson C, 2005, J VIROL, V79, P57, DOI 10.1128/JVI.79.1.57-66.2005; Kalinna BH, 2007, TRENDS PARASITOL, V23, P197, DOI 10.1016/j.pt.2007.03.007; Kines KJ, 2006, EXP PARASITOL, V112, P209, DOI 10.1016/j.exppara.2006.02.003; King CH, 2005, LANCET, V365, P1561, DOI 10.1016/S0140-6736(05)66457-4; Krautz-Peterson G, 2007, MOL BIOCHEM PARASIT, V153, P194, DOI 10.1016/j.molbiopara.2007.03.006; Kumar A, 2004, GENOME RES, V14, P1975, DOI 10.1101/gr.2875304; Laha T, 2005, BMC GENOMICS, V6, DOI 10.1186/1471-2164-6-154; Laha T, 2004, INT J PARASITOL, V34, P1365, DOI 10.1016/j.ijpara.2004.08.007; Lampe DJ, 1998, GENETICS, V149, P179; LAZDINS JK, 1982, EXP PARASITOL, V53, P39, DOI 10.1016/0014-4894(82)90090-X; Li XS, 2006, INT J PARASITOL, V36, P671, DOI 10.1016/j.ijpara.2005.12.007; Liu F, 2006, PLOS PATHOG, V2, P268, DOI 10.1371/journal.ppat.0020029; Lu JK, 1996, P NATL ACAD SCI USA, V93, P3482, DOI 10.1073/pnas.93.8.3482; Maksakova IA, 2006, PLOS GENET, V2, P1, DOI 10.1371/journal.pgen.0020002; Marrelli MT, 2007, P NATL ACAD SCI USA, V104, P5580, DOI 10.1073/pnas.0609809104; Matsubara T, 1996, P NATL ACAD SCI USA, V93, P6181, DOI 10.1073/pnas.93.12.6181; MCLAREN DJ, 1977, NATURE, V269, P147, DOI 10.1038/269147a0; Mitchell RS, 2004, PLOS BIOL, V2, P1127, DOI 10.1371/journal.pbio.0020234; Miyazaki M, 2007, J VIROL, V81, P5714, DOI 10.1128/JVI.02511-06; Morales ME, 2008, MOL BIOCHEM PARASIT, V157, P160, DOI 10.1016/j.molbiopara.2007.10.009; Morales ME, 2007, FASEB J, V21, P3479, DOI 10.1096/fj.07-8726com; Nabekura T, 2006, MOL THER, V13, P301, DOI 10.1016/j.ymthe.2005.09.021; Que XC, 1999, MOL BIOCHEM PARASIT, V99, P237, DOI 10.1016/S0166-6851(99)00021-3; SHOEMAKER C, 1981, J VIROL, V40, P164, DOI 10.1128/JVI.40.1.164-172.1981; Sivasubbu S, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-S1-S9; SPILIOTIS M, 2008, INT J PARASITOL, DOI DOI 10.1016/J.IJPARA.2007.4.002; SPOTILA LD, 1989, CHROMOSOMA, V97, P421, DOI 10.1007/BF00295025; Tamiya S, 1996, BLOOD, V88, P3065, DOI 10.1182/blood.V88.8.3065.bloodjournal8883065; Tran MH, 2006, NAT MED, V12, P835, DOI 10.1038/nm1430; Vu HN, 2008, MOL THER, V16, P308, DOI 10.1038/sj.mt.6300350; Wang DW, 2007, P NATL ACAD SCI USA, V104, P12428, DOI 10.1073/pnas.0705502104; Wilson MH, 2007, MOL THER, V15, P139, DOI 10.1038/sj.mt.6300028; Wu P, 1998, J VIROL, V72, P5919, DOI 10.1128/JVI.72.7.5919-5926.1998	57	55	59	0	4	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2936	2948		10.1096/fj.08-108308	http://dx.doi.org/10.1096/fj.08-108308			13	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18403630	Green Published			2022-12-25	WOS:000258089300034
J	Momota, H; Shih, AH; Edgar, M; Holland, E				Momota, H.; Shih, A. H.; Edgar, M. A.; Holland, E. C.			C-Myc and beta-catenin cooperate with loss of p53 to generate multiple members of the primitive neuroectodermal tumor family in mice	ONCOGENE			English	Article						c-Myc; beta-catenin; p53; primitive neuroectodermal tumor; mouse model	CHOROID-PLEXUS TUMORS; LARGE CELL/ANAPLASTIC MEDULLOBLASTOMAS; PEDIATRIC-ONCOLOGY-GROUP; NEURAL PROGENITORS; SONIC HEDGEHOG; ANAPLASTIC MEDULLOBLASTOMA; SOMATIC MUTATIONS; IN-VIVO; EXPRESSION; CELLS	Primitive neuroectodermal tumors ( PNETs) are a family of primary malignant brain tumors that include medulloblastomas. Although genetic models of a subset of medulloblastomas are documented over the past decade, the molecular basis of other subclasses of PNET remains unclear. As elevated c-Myc expression, activation of Wnt/beta-catenin signaling and dysfunction of p53 are seen in human PNETs, we investigated what role these abnormalities have in the formation of PNETs. Incorporating these abnormalities, we generated supratentorial PNET (sPNET) in mice using somatic cell gene transfer. We show that sPNETs arise from GFAP-expressing cells by forced c-Myc expression combined with p53 inactivation. beta-catenin activation promotes tumor progression and induces divergent differentiation. These c-Myc+beta-catenin-induced PNETs are histologically similar to large cell/anaplastic medulloblastomas and can occur in both cerebrum and cerebellum. Furthermore, we have obtained one PNET with marked epithelial differentiation having histological resemblance to choroid plexus carcinoma in this series. Our results in mice suggest that sPNET with varied differentiation and large cell/anaplastic medulloblastomas may be two tumor groups with similar genetic foundations. These data provide insights into the biology and classification of human PNETs and suggest that multiple tumor types or variants can be generated from a fixed set of genetic abnormalities.	[Momota, H.; Shih, A. H.; Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, New York, NY 10021 USA; [Edgar, M. A.] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; [Holland, E. C.] Mem Sloan Kettering Canc Ctr, Dept Surg Neusurg & Neurol, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center	Holland, E (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Canc Biol & Genet, 1275 York Ave, New York, NY 10021 USA.	hollande@mskcc.org			NATIONAL CANCER INSTITUTE [R01CA099489, R01CA100688] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA099489, R01 CA100688] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADESINA AM, 1994, CANCER RES, V54, P5649; ANWER UE, 1989, ARCH PATHOL LAB MED, V113, P84; Brown HG, 2000, J NEUROPATH EXP NEUR, V59, P857, DOI 10.1093/jnen/59.10.857; Carlotti CG, 2002, ACTA NEUROPATHOL, V103, P1; Dai C, 2001, GENE DEV, V15, P1913, DOI 10.1101/gad.903001; Eberhart CG, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-19; Eberhart CG, 2002, CANCER-AM CANCER SOC, V94, P552, DOI 10.1002/cncr.10189; Frank AJ, 2004, MOL BRAIN RES, V121, P137, DOI 10.1016/j.molbrainres.2003.11.016; Fults D, 2002, NEOPLASIA, V4, P32, DOI 10.1038/sj.neo.7900200; Gessl M, 2003, BRAIN PATHOL, V13, P409; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Green DR, 2002, CANCER CELL, V1, P19, DOI 10.1016/S1535-6108(02)00024-7; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hill TP, 2005, DEV CELL, V8, P727, DOI 10.1016/j.devcel.2005.02.013; Ho YS, 1996, CANCER LETT, V104, P103, DOI 10.1016/0304-3835(96)04238-3; Holland EC, 2000, NAT GENET, V25, P55, DOI 10.1038/75596; Holland EC, 1998, GENE DEV, V12, P3675, DOI 10.1101/gad.12.23.3675; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; JANZER RC, 1985, CLIN NEUROPATHOL, V4, P93; Jay V, 1996, ARCH PATHOL LAB MED, V120, P1061; Koch A, 2001, INT J CANCER, V93, P445, DOI 10.1002/ijc.1342; Kratz JE, 2002, BMC CANCER, V2, DOI 10.1186/1471-2407-2-33; Kraus JA, 2002, NEUROPATH APPL NEURO, V28, P325, DOI 10.1046/j.1365-2990.2002.00413.x; Leonard JR, 2001, J NEUROSURG, V95, P82, DOI 10.3171/jns.2001.95.1.0082; Louis DN, 2007, ACTA NEUROPATHOL, V114, P97, DOI 10.1007/s00401-007-0243-4; Marino S, 2000, GENE DEV, V14, P994; McCall TD, 2007, CANCER RES, V67, P5179, DOI 10.1158/0008-5472.CAN-06-4177; OHGAKI H, 1993, MOL CARCINOGEN, V8, P74, DOI 10.1002/mc.2940080203; Pauklin S, 2005, BIOCHEM BIOPH RES CO, V334, P386, DOI 10.1016/j.bbrc.2005.06.097; Pillai A, 2004, J NEUROSURG, V100, P1076, DOI 10.3171/jns.2004.100.6.1076; Rao G, 2003, NEOPLASIA, V5, P198, DOI 10.1016/S1476-5586(03)80052-0; Reifenberger J, 1998, J NEUROPATH EXP NEUR, V57, P179; Rostomily RC, 1997, CANCER RES, V57, P3526; Russo C, 1999, CANCER, V86, P331, DOI 10.1002/(SICI)1097-0142(19990715)86:2<331::AID-CNCR18>3.0.CO;2-#; SAYLORS RL, 1991, CANCER RES, V51, P4721; Sevenet N, 1999, HUM MOL GENET, V8, P2359, DOI 10.1093/hmg/8.13.2359; Shakhova O, 2006, CANCER RES, V66, P5190, DOI 10.1158/0008-5472.CAN-05-3545; Su XH, 2006, MOL CELL BIOL, V26, P1666, DOI 10.1128/MCB.26.5.1666-1678.2006; van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0; Vital A, 1998, J NEUROPATH EXP NEUR, V57, P1061, DOI 10.1097/00005072-199811000-00009; Weiner HL, 2002, CANCER RES, V62, P6385; Wetmore C, 2001, CANCER RES, V61, P513; YUASA H, 1993, NEUROSURGERY, V32, P131, DOI 10.1227/00006123-199301000-00021	43	38	39	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4392	4401		10.1038/onc.2008.81	http://dx.doi.org/10.1038/onc.2008.81			10	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18372915				2022-12-25	WOS:000257881700002
J	Pendas-Franco, N; Garcia, JM; Pena, C; Valle, N; Palmer, HG; Heinaniemi, M; Carlberg, C; Jimenez, B; Bonilla, F; Munoz, A; Gonzalez-Sancho, JM				Pendas-Franco, N.; Garcia, J. M.; Pena, C.; Valle, N.; Palmer, H. G.; Heinaeniemi, M.; Carlberg, C.; Jimenez, B.; Bonilla, F.; Munoz, A.; Gonzalez-Sancho, J. M.			DICKKOPF-4 is induced by TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1 alpha, 25-dihydroxyvitamin D-3	ONCOGENE			English	Article						DICKKOPF-4; vitamin D; colon cancer; Wnt; beta-catenin	WNT SIGNALING PATHWAY; COLORECTAL-CANCER; EPIGENETIC INACTIVATION; GENE FAMILY; VITAMIN-D; DIFFERENTIATION; PROTEIN; TARGET	Aberrant activation of the Wnt/beta-catenin signaling pathway is a hallmark of colon cancer. We show that the Wnt antagonist DICKKOPF-4 (DKK-4) gene is repressed by 1 alpha, 25-dihydroxyvitamin D-3 (1,25(OH)(2)D-3) in human colon cancer cells. This effect correlated with the inhibition of the DKK-4 promoter. Chromatin immunoprecipitation assays revealed that 1,25(OH)(2)D-3 induces early and transient binding of the vitamin D receptor (VDR) and the SMRT corepressor to the region adjacent to the transcription start site of DKK-4. Additionally, we demonstrate that the DKK-4 gene is a new downstream target of TCF/beta-catenin. Remarkably, expression of DKK-4 messenger RNA (mRNA) was not detected in a series of 29 human normal (N) colon biopsies but expression was upregulated in all the matched tumour (T) tissues. An inverse correlation existed between the expression of DKK-4 and VDR RNA in the Ts. Ectopic DKK-4 expression increased the migration and invasion properties of colon cancer cells and conditioned media (CM) from DKK-4-expressing cells enhanced the capacity to migrate and form capillary-like tubules of human primary microvascular endothelial cells. In conclusion, DKK-4 is upregulated in colon cancer and is associated with the acquisition of malignant properties by neoplastic cells. DKK-4 downregulation is a novel effect of 1,25(OH)(2)D-3 that may contribute to its anticancer action.	[Pendas-Franco, N.; Valle, N.; Jimenez, B.; Munoz, A.; Gonzalez-Sancho, J. M.] Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Dept Canc Biol, Consejo Super Invest Cient, E-28029 Madrid, Spain; [Garcia, J. M.; Pena, C.; Bonilla, F.] Hosp Univ Puerta Hierro, Madrid, Spain; [Palmer, H. G.] Cambridge Res Inst, Cambridge, England; [Heinaeniemi, M.; Carlberg, C.] Univ Luxembourg, Life Sci Res Unit, Luxembourg, Luxembourg; [Jimenez, B.; Gonzalez-Sancho, J. M.] Univ Autonoma Madrid, Fac Med, Dept Bioquim, E-28029 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Investigaciones Biomedicas Alberto Sols (IIBM); Hospital Puerta de Hierro-Majadahonda; CRUK Cambridge Institute; University of Cambridge; University of Luxembourg; Autonomous University of Madrid	Munoz, A (corresponding author), Univ Autonoma Madrid, Inst Invest Biomed Alberto Sols, Dept Canc Biol, Consejo Super Invest Cient, Arturo Duperier 4, E-28029 Madrid, Spain.	amunoz@iib.uam.es	Palmer, Héctor G./AAG-8332-2019; Cuenca, Benilde Jimenez/K-9959-2014; Munoz, Alberto/O-6393-2014; Heinäniemi, Merja/C-5051-2014; Gonzalez-Sancho, Jose/AAA-6010-2019; Valle, Noelia/AAA-2975-2019; Carlberg, Carsten/C-9075-2011; Heinaniemi, Merja/AAS-4530-2020; Seoane, Joan/AAG-9173-2019	Munoz, Alberto/0000-0003-3890-4251; Heinäniemi, Merja/0000-0001-6190-3439; Gonzalez-Sancho, Jose/0000-0001-5875-1964; Valle, Noelia/0000-0002-3377-5035; Carlberg, Carsten/0000-0003-2633-0684; Heinaniemi, Merja/0000-0001-6190-3439; Seoane, Joan/0000-0002-6541-5974; Jimenez Cuenca, Benilde/0000-0002-1806-6636; Palmer, Hector/0000-0002-9823-5638				Abu-Jawdeh G, 1999, LAB INVEST, V79, P439; Aguilera O, 2006, ONCOGENE, V25, P4116, DOI 10.1038/sj.onc.1209439; Aguilera O, 2007, CARCINOGENESIS, V28, P1877, DOI 10.1093/carcin/bgm094; Ballestar E, 2003, EMBO J, V22, P6335, DOI 10.1093/emboj/cdg604; Bazzi H, 2007, DEV BIOL, V305, P498, DOI 10.1016/j.ydbio.2007.02.035; Caneparo L, 2007, GENE DEV, V21, P465, DOI 10.1101/gad.406007; Dufourcq P, 2002, CIRCULATION, V106, P3097, DOI 10.1161/01.CIR.0000039342.85015.5C; Gonzalex-Sancho JM, 2005, ONCOGENE, V24, P1098, DOI 10.1038/sj.onc.1208303; Kawano Y, 2003, J CELL SCI, V116, P2627, DOI 10.1242/jcs.00623; Kimura-Yoshida C, 2005, DEV CELL, V9, P639, DOI 10.1016/j.devcel.2005.09.011; Krupnik VE, 1999, GENE, V238, P301, DOI 10.1016/S0378-1119(99)00365-0; Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126; Mao BY, 2003, GENE, V302, P179, DOI 10.1016/S0378-1119(02)01106-X; Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054; Ordonez-Moran P, 2005, FRONT BIOSCI-LANDMRK, V10, P2723, DOI 10.2741/1731; Palmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028; Pendas-Franco N, 2007, DIFFERENTIATION, V75, P193, DOI 10.1111/j.1432-0436.2006.00131.x; Polakis P, 2007, CURR OPIN GENET DEV, V17, P45, DOI 10.1016/j.gde.2006.12.007; Roth W, 2000, ONCOGENE, V19, P4210, DOI 10.1038/sj.onc.1203783; Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059; Sick S, 2006, SCIENCE, V314, P1447, DOI 10.1126/science.1130088; Vaisanen S, 2005, J MOL BIOL, V350, P65, DOI 10.1016/j.jmb.2005.04.057; Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034; Wang TT, 2005, MOL ENDOCRINOL, V19, P2685, DOI 10.1210/me.2005-0106; Xi Y, 2008, ONCOL REP, V19, P257	25	129	133	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 24	2008	27	32					4467	4477		10.1038/onc.2008.88	http://dx.doi.org/10.1038/onc.2008.88			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18408752				2022-12-25	WOS:000257881700009
J	Wang, X; Di, K; Zhang, X; Han, HY; Wong, YC; Leung, SCL; Ling, MT				Wang, X.; Di, K.; Zhang, X.; Han, H. Y.; Wong, Y. C.; Leung, S. C. L.; Ling, M-T			Id-1 promotes chromosomal instability through modification of APC/C activity during mitosis in response to microtubule disruption	ONCOGENE			English	Article						Id-1; mitosis; aneuploidy; Cdc20; Cdh1	LOOP-HELIX PROTEIN; SPINDLE ASSEMBLY CHECKPOINT; PROSTATE-CANCER; P16(INK4A) EXPRESSION; CELLULAR SENESCENCE; SIGNALING PATHWAY; OVEREXPRESSION; ACTIVATION; ID1; DIFFERENTIATION	Id-1 (Inhibitor of DNA binding/differential-1) plays a positive role in tumorigenesis through regulation of multiple signaling pathways. Recently, it is suggested that upregulation of Id-1 in cancer cells promotes chromosomal instability. However, the underlying molecular mechanism is not known. In this study, we report a novel function of Id-1 in regulation of mitosis through physical interaction with Cdc20 (cell division cycle protein 20) and Cdh1 (Cdc20 homolog 1). During early mitosis, Id-1 interacts with Cdc20 and RASSF1A (Ras association domain family 1A), leading to enhanced APC(Cdc20) activity, which in turn promotes cyclin B1/securin degradation and premature mitosis. During late mitosis, Id-1 binds to Cdh1 and disrupts the interaction between Cdh1 and APC, resulting in suppression of APC Cdh1 activity. On the other hand, overexpression of Cdh1 leads to Id-1 protein degradation, suggesting that Id-1 may also act as a substrate of APC(Cdh1). The negative effect of Id-1 on APC(Cdh1) results in suppression of APC(Cdh1)-induced Aurora A and Cdc20 degradation, leading to failure in cytokinesis. As a result, overexpression of Id-1 in human prostate epithelial cells leads to polyploidy in response to microtubule disruption, and this effect is abolished when Id-1 expression is suppressed using antisense technology. These results demonstrate a novel function of Id-1 in promoting chromosomal instability through modi. cation of APC/C activity during mitosis and provide a novel molecular mechanism accounted for the function of Id-1 as an oncogene.	[Wang, X.; Di, K.; Zhang, X.; Han, H. Y.; Wong, Y. C.; Leung, S. C. L.; Ling, M-T] Univ Hong Kong, Fac Med, Dept Anat, Canc Biol Grp, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Wang, X (corresponding author), Univ Hong Kong, Fac Med, Dept Anat, Canc Biol Grp, 1-F Bldg,21 Sassoon Road, Hong Kong, Hong Kong, Peoples R China.	xhwang@hkucc.hku.hk; patling@hkucc.hku.hk						Alani RM, 1999, P NATL ACAD SCI USA, V96, P9637, DOI 10.1073/pnas.96.17.9637; Alani RM, 2001, P NATL ACAD SCI USA, V98, P7812, DOI 10.1073/pnas.141235398; Anand S, 2003, CANCER CELL, V3, P51, DOI 10.1016/S1535-6108(02)00235-0; BARONE MV, 1994, P NATL ACAD SCI USA, V91, P4985, DOI 10.1073/pnas.91.11.4985; Bright RK, 1997, CANCER RES, V57, P995; Crane R, 2004, J CELL SCI, V117, P5975, DOI 10.1242/jcs.01418; Di K, 2006, BIOL CELL, V98, P523, DOI 10.1042/BC20060026; Fong S, 2003, P NATL ACAD SCI USA, V100, P13543, DOI 10.1073/pnas.2230238100; Forootan SS, 2007, HUM PATHOL, V38, P1321, DOI 10.1016/j.humpath.2007.02.011; HARA E, 1994, J BIOL CHEM, V269, P2139; Hasskarl J, 2004, ONCOGENE, V23, P1930, DOI 10.1038/sj.onc.1207310; Lasorella A, 2006, NATURE, V442, P471, DOI 10.1038/nature04895; Li Y, 1997, P NATL ACAD SCI USA, V94, P12431, DOI 10.1073/pnas.94.23.12431; Lin ML, 2001, STEM CELLS, V19, P205, DOI 10.1634/stemcells.19-3-205; Ling MT, 2006, DIFFERENTIATION, V74, P481, DOI 10.1111/j.1432-0436.2006.00083.x; Ling MT, 2003, ONCOGENE, V22, P4498, DOI 10.1038/sj.onc.1206693; Ling MT, 2002, ONCOGENE, V21, P8498, DOI 10.1038/sj.onc.1206007; Meraldi P, 2002, EMBO J, V21, P483, DOI 10.1093/emboj/21.4.483; Mondal G, 2007, CARCINOGENESIS, V28, P81, DOI 10.1093/carcin/bgl100; Nakayama KI, 2006, NAT REV CANCER, V6, P369, DOI 10.1038/nrc1881; Nickoloff BJ, 2000, J BIOL CHEM, V275, P27501; Ohtani N, 2001, NATURE, V409, P1067, DOI 10.1038/35059131; Ouyang XS, 2002, J UROLOGY, V167, P2598, DOI 10.1016/S0022-5347(05)65044-6; Perk J, 2005, NAT REV CANCER, V5, P603, DOI 10.1038/nrc1673; Peters JM, 2006, NAT REV MOL CELL BIO, V7, P644, DOI 10.1038/nrm1988; Prabhu S, 1997, MOL CELL BIOL, V17, P5888, DOI 10.1128/MCB.17.10.5888; Schindl M, 2003, CLIN CANCER RES, V9, P779; Schoppmann SF, 2003, INT J CANCER, V104, P677, DOI 10.1002/ijc.11009; Song MS, 2004, NAT CELL BIOL, V6, P129, DOI 10.1038/ncb1091; Tang J, 2002, LAB INVEST, V82, P1073, DOI 10.1097/01.LAB.0000022223.65962.3A; Tang ZY, 2004, MOL CELL, V16, P387, DOI 10.1016/j.molcel.2004.09.031; To-Ho KW, 2008, ONCOGENE, V27, P347, DOI 10.1038/sj.onc.1210633; Wong YC, 2004, APOPTOSIS, V9, P279, DOI 10.1023/B:APPT.0000025804.25396.79; Yuen HF, 2006, MODERN PATHOL, V19, P931, DOI 10.1038/modpathol.3800602; Zhang XM, 2007, CANCER SCI, V98, P308, DOI 10.1111/j.1349-7006.2007.00400.x; Zhang XM, 2006, INT J CANCER, V118, P2072, DOI 10.1002/ijc.21592; Zheng WJ, 2004, J BIOL CHEM, V279, P31524, DOI 10.1074/jbc.M400365200	37	20	20	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 24	2008	27	32					4456	4466		10.1038/onc.2008.87	http://dx.doi.org/10.1038/onc.2008.87			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	329PU	18372912				2022-12-25	WOS:000257881700008
J	Cao, XH; Antonyuk, SV; Seetharaman, SV; Whitson, LJ; Taylor, AB; Holloway, SP; Strange, RW; Doucette, PA; Valentine, JS; Tiwari, A; Hayward, LJ; Padua, S; Cohlberg, JA; Hasnain, SS; Hart, PJ				Cao, Xiaohang; Antonyuk, Svetlana V.; Seetharaman, Sai V.; Whitson, Lisa J.; Taylor, Alexander B.; Holloway, Stephen P.; Strange, Richard W.; Doucette, Peter A.; Valentine, Joan Selverstone; Tiwari, Ashutosh; Hayward, Lawrence J.; Padua, Shelby; Cohlberg, Jeffrey A.; Hasnain, S. Samar; Hart, P. John			Structures of the G85R variant of SOD1 in familial amyotrophic lateral sclerosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ZINC SUPEROXIDE-DISMUTASE; COPPER CHAPERONE CCS; ALS-LINKED SOD1; CU,ZN-SUPEROXIDE DISMUTASE; DIMER STABILITY; MOTOR-NEURONS; MOUSE MODEL; HUMAN CU; AGGREGATION; MUTATIONS	Mutations in the gene encoding human copper-zinc superoxide dismutase (SOD1) cause a dominant form of the progressive neurodegenerative disease amyotrophic lateral sclerosis. Transgenic mice expressing the human G85R SOD1 variant develop paralytic symptoms concomitant with the appearance of SOD1-enriched proteinaceous inclusions in their neural tissues. The process(es) through which misfolding or aggregation of G85R SOD1 induces motor neuron toxicity is not understood. Here we present structures of the human G85R SOD1 variant determined by single crystal x-ray diffraction. Alterations in structure of the metal-binding loop elements relative to the wild type enzyme suggest a molecular basis for the metal ion deficiency of the G85R SOD1 protein observed in the central nervous system of transgenic mice and in purified recombinant G85R SOD1. These findings support the notion that metal-deficient and/or disulfide-reduced mutant SOD1 species contribute to toxicity in SOD1-linked amyotrophic lateral sclerosis.	[Cao, Xiaohang; Seetharaman, Sai V.; Whitson, Lisa J.; Taylor, Alexander B.; Holloway, Stephen P.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA; [Cao, Xiaohang; Seetharaman, Sai V.; Whitson, Lisa J.; Taylor, Alexander B.; Holloway, Stephen P.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Xray Crystallog Core Lab, San Antonio, TX 78229 USA; [Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Ctr Geriatr Res Educ & Clin, Dept Vet Affairs, San Antonio, TX 78229 USA; [Antonyuk, Svetlana V.; Strange, Richard W.; Hasnain, S. Samar] SERC, Daresbury Lab, Mol Biophys Grp, Sci & Technol Facil Council, Warrington WA4 4AD, Cheshire, England; [Doucette, Peter A.; Valentine, Joan Selverstone] Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; [Tiwari, Ashutosh; Hayward, Lawrence J.] Univ Massachusetts, Sch Med, Dept Neurol, Worcester, MA 01655 USA; [Padua, Shelby; Cohlberg, Jeffrey A.] Calif State Univ Long Beach, Dept Chem & Biochem, Long Beach, CA 90840 USA	University of Texas System; University of Texas Health San Antonio; University of Texas System; University of Texas Health San Antonio; Geriatric Research Education & Clinical Center; University of Texas System; University of Texas Health San Antonio; US Department of Veterans Affairs; Veterans Health Administration (VHA); Audie L. Murphy Memorial Veterans Hospital; STFC Daresbury Laboratory; UK Research & Innovation (UKRI); Science & Technology Facilities Council (STFC); University of California System; University of California Los Angeles; University of Massachusetts System; University of Massachusetts Worcester; California State University System; California State University Long Beach	Hart, PJ (corresponding author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem, San Antonio, TX 78229 USA.	pjhart@biochem.uthscsa.edu	Antonyuk, Svetlana V/B-6002-2013; Antonyuk, Svetlana/W-5159-2019; Tiwari, Ashutosh/A-7458-2008	Antonyuk, Svetlana/0000-0002-2779-9946; Tiwari, Ashutosh/0000-0001-7373-349X; Taylor, Alexander/0000-0003-3517-6033; Hayward, Lawrence/0000-0003-0579-0358	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM028222] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS039112, R01NS044170, P01NS049134] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM28222] Funding Source: Medline; NINDS NIH HHS [NS049134, R01 NS039112, R01 NS044170, NS44170, R01 NS039112-08, NS39112] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Antonyuk S, 2005, PROTEIN SCI, V14, P1201, DOI 10.1110/ps.041256705; Arnesano F, 2004, J BIOL CHEM, V279, P47998, DOI 10.1074/jbc.M406021200; Banci L, 2003, BIOCHEMISTRY-US, V42, P9543, DOI 10.1021/bi034324m; BANCI L, 1991, EUR J BIOCHEM, V196, P123, DOI 10.1111/j.1432-1033.1991.tb15794.x; Bertini I, 1998, ADV INORG CHEM, V45, P127, DOI 10.1016/S0898-8838(08)60026-4; BORCHELT DR, 1995, J BIOL CHEM, V270, P3234, DOI 10.1074/jbc.270.7.3234; BORCHELT DR, 1994, P NATL ACAD SCI USA, V91, P8292, DOI 10.1073/pnas.91.17.8292; BRANDTS JF, 1975, BIOCHEMISTRY-US, V14, P4953, DOI 10.1021/bi00693a026; Brown NM, 2004, P NATL ACAD SCI USA, V101, P5518, DOI 10.1073/pnas.0401175101; Bruijn LI, 1997, NEURON, V18, P327, DOI 10.1016/S0896-6273(00)80272-X; Bruijn LI, 1998, SCIENCE, V281, P1851, DOI 10.1126/science.281.5384.1851; Bruijn LI, 2004, ANNU REV NEUROSCI, V27, P723, DOI 10.1146/annurev.neuro.27.070203.144244; Brunger AT, 1997, METHOD ENZYMOL, V277, P243, DOI 10.1016/S0076-6879(97)77015-0; Bush AI, 2000, CURR OPIN CHEM BIOL, V4, P184, DOI 10.1016/S1367-5931(99)00073-3; Corson LB, 1998, P NATL ACAD SCI USA, V95, P6361, DOI 10.1073/pnas.95.11.6361; Curtain CC, 2001, J BIOL CHEM, V276, P20466, DOI 10.1074/jbc.M100175200; DEISSEROTH A, 1970, PHYSIOL REV, V50, P319, DOI 10.1152/physrev.1970.50.3.319; DENG HX, 1993, SCIENCE, V261, P1047, DOI 10.1126/science.8351519; Doucette PA, 2004, J BIOL CHEM, V279, P54558, DOI 10.1074/jbc.M409744200; Elam JS, 2003, J BIOL CHEM, V278, P21032, DOI 10.1074/jbc.M300484200; Furukawa Y, 2004, EMBO J, V23, P2872, DOI 10.1038/sj.emboj.7600276; GALALELDEEN A, 2006, PROTEIN MISFOLDING C, P327; GETZOFF ED, 1983, NATURE, V306, P287, DOI 10.1038/306287a0; Hart PJ, 2006, CURR OPIN CHEM BIOL, V10, P131, DOI 10.1016/j.cbpa.2006.02.034; Hart PJ, 1998, PROTEIN SCI, V7, P545; Hayward LJ, 2002, J BIOL CHEM, V277, P15923, DOI 10.1074/jbc.M112087200; Jobling MF, 2001, BIOCHEMISTRY-US, V40, P8073, DOI 10.1021/bi0029088; Johnston JA, 2000, P NATL ACAD SCI USA, V97, P12571, DOI 10.1073/pnas.220417997; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Jonsson PA, 2006, BRAIN, V129, P451, DOI 10.1093/brain/awh704; Jonsson PA, 2004, BRAIN, V127, P73, DOI 10.1093/brain/awh005; Kiaei M, 2004, J NEUROSCI, V24, P7945, DOI 10.1523/JNEUROSCI.2000-04.2004; Lamzin V. S., 2001, INT TABLES CRYSTALLO, VF, P720; Lindberg MJ, 2004, P NATL ACAD SCI USA, V101, P15893, DOI 10.1073/pnas.0403979101; LITTLE C, 1968, BIOCHEM BIOPH RES CO, V31, P145, DOI 10.1016/0006-291X(68)90721-3; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; Murphy LM, 1997, STRUCTURE, V5, P371, DOI 10.1016/S0969-2126(97)00194-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARDO CA, 1995, P NATL ACAD SCI USA, V92, P954, DOI 10.1073/pnas.92.4.954; Potter SZ, 2007, J AM CHEM SOC, V129, P4575, DOI 10.1021/ja066690+; Rakhit R, 2004, J BIOL CHEM, V279, P15499, DOI 10.1074/jbc.M313295200; Rakhit R, 2007, NAT MED, V13, P754, DOI 10.1038/nm1559; Ratovitski T, 1999, HUM MOL GENET, V8, P1451, DOI 10.1093/hmg/8.8.1451; Ray SS, 2004, BIOCHEMISTRY-US, V43, P4899, DOI 10.1021/bi030246r; Ray SS, 2005, P NATL ACAD SCI USA, V102, P3639, DOI 10.1073/pnas.0408277102; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Reaume AG, 1996, NAT GENET, V13, P43, DOI 10.1038/ng0596-43; Rodriguez JA, 2005, P NATL ACAD SCI USA, V102, P10516, DOI 10.1073/pnas.0502515102; ROSEN DR, 1993, NATURE, V362, P59, DOI 10.1038/362059a0; Son M, 2007, P NATL ACAD SCI USA, V104, P6072, DOI 10.1073/pnas.0610923104; Strange RW, 2007, P NATL ACAD SCI USA, V104, P10040, DOI 10.1073/pnas.0703857104; Strange RW, 2006, J MOL BIOL, V356, P1152, DOI 10.1016/j.jmb.2005.11.081; Strange RW, 2003, J MOL BIOL, V328, P877, DOI 10.1016/S0022-2836(03)00355-3; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Valentine JS, 2005, ANNU REV BIOCHEM, V74, P563, DOI 10.1146/annurev.biochem.72.121801.161647; Wang J, 2007, J BIOL CHEM, V282, P345, DOI 10.1074/jbc.M604503200; Zetterstrom P, 2007, P NATL ACAD SCI USA, V104, P14157, DOI 10.1073/pnas.0700477104	59	76	79	0	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16169	16177		10.1074/jbc.M801522200	http://dx.doi.org/10.1074/jbc.M801522200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18378676	hybrid, Green Published			2022-12-25	WOS:000256332500075
J	Green, T; Grigorian, A; Klyuyeva, A; Tuganova, A; Luo, M; Popov, KM				Green, Todd; Grigorian, Alexei; Klyuyeva, Alla; Tuganova, Alina; Luo, Ming; Popov, Kirill M.			Structural and functional insights into the molecular mechanisms responsible for the regulation of pyruvate dehydrogenase kinase 2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE KINASE; LIPOYL-BEARING DOMAIN; PROTEIN; INHIBITION; DIHYDROLIPOAMIDE; PHOSPHORYLATION; TRANSACETYLASE; STIMULATION; EXPRESSION; ISOFORMS	PDHK2 is a mitochondrial protein kinase that phosphorylates pyruvate dehydrogenase complex, thereby down-regulating the oxidation of pyruvate. Here, we present the crystal structure of PDHK2 bound to the inner lipoyl-bearing domain of dihydrolipoamide transacetylase (L2) determined with or without bound adenylyl imidodiphosphate. Both structures reveal a PDHK2 dimer complexed with two L2 domains. Comparison with apo-PDHK2 shows that L2 binding causes rearrangements in PDHK2 structure that affect the L2- and E1-binding sites. Significant differences are found between PDHK2 and PDHK3 with respect to the structure of their lipoyllysine-binding cavities, providing the first structural support to a number of studies showing that these isozymes are markedly different with respect to their affinity for the L2 domain. Both structures display a novel type II potassium-binding site located on the PDHK2 interface with the L2 domain. Binding of potassium ion at this site rigidifies the interface and appears to be critical in determining the strength of L2 binding. Evidence is also presented that potassium ions are indispensable for the cross-talk between the nucleotide-and L2-binding sites of PDHK2. The latter is believed to be essential for the movement of PDHK2 along the surface of the transacetylase scaffold.	[Green, Todd; Luo, Ming] Univ Alabama Birmingham, Sch Med, Dept Microbiol, Birmingham, AL 35294 USA; [Grigorian, Alexei; Klyuyeva, Alla; Tuganova, Alina; Popov, Kirill M.] Univ Alabama Birmingham, Sch Dent, Dept Biochem & Mol Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Luo, M (corresponding author), Univ Alabama Birmingham, Sch Med, Dept Microbiol, 1025 18th St S, Birmingham, AL 35294 USA.	mingluo@uab.edu; kpopov@uab.edu		Green, Todd/0000-0003-1158-4710	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051262, R29GM051262] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM051262, GM051262] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adams PD, 2004, J SYNCHROTRON RADIAT, V11, P53, DOI 10.1107/S0909049503024130; Baker JC, 2000, J BIOL CHEM, V275, P15773, DOI 10.1074/jbc.M909488199; Bao HY, 2004, BIOCHEMISTRY-US, V43, P13432, DOI 10.1021/bi049488x; Bowker-Kinley MM, 1998, BIOCHEM J, V329, P191, DOI 10.1042/bj3290191; Cairns RA, 2007, P NATL ACAD SCI USA, V104, P9445, DOI 10.1073/pnas.0611662104; CATE RL, 1978, J BIOL CHEM, V253, P496; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; GUDI R, 1995, J BIOL CHEM, V270, P28989, DOI 10.1074/jbc.270.48.28989; Harris RA, 1997, J BIOL CHEM, V272, P19746, DOI 10.1074/jbc.272.32.19746; Hiromasa Y, 2006, J BIOL CHEM, V281, P12568, DOI 10.1074/jbc.M513514200; Hiromasa Y, 2003, J BIOL CHEM, V278, P33681, DOI 10.1074/jbc.M212733200; Hiromasa Y, 2008, BIOCHEMISTRY-US, V47, P2312, DOI 10.1021/bi7014772; Hiromasa Y, 2008, BIOCHEMISTRY-US, V47, P2298, DOI 10.1021/bi701475f; Jogl G, 2001, ACTA CRYSTALLOGR D, V57, P1127, DOI 10.1107/S0907444901006783; Kato M, 2005, EMBO J, V24, P1763, DOI 10.1038/sj.emboj.7600663; Kato M, 2007, STRUCTURE, V15, P992, DOI 10.1016/j.str.2007.07.001; Klyuyeva A, 2005, BIOCHEMISTRY-US, V44, P13573, DOI 10.1021/bi0505868; Knoechel TR, 2006, BIOCHEMISTRY-US, V45, P402, DOI 10.1021/bi051402s; Kolobova E, 2001, BIOCHEM J, V358, P69, DOI 10.1042/0264-6021:3580069; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Machius M, 2001, P NATL ACAD SCI USA, V98, P11218, DOI 10.1073/pnas.201220098; Murshudov GN, 1999, ACTA CRYSTALLOGR D, V55, P247, DOI 10.1107/S090744499801405X; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Page MJ, 2006, PHYSIOL REV, V86, P1049, DOI 10.1152/physrev.00008.2006; Patel MS, 2001, EXP MOL MED, V33, P191, DOI 10.1038/emm.2001.32; PAWELCZYK T, 1992, BIOCHEM J, V288, P369, DOI 10.1042/bj2880369; QUINN J, 1993, BIOCHEM J, V289, P81, DOI 10.1042/bj2890081; RANDLE PJ, 1995, P NUTR SOC, V54, P317, DOI 10.1079/PNS19950057; ROBERTSON JG, 1989, J BIOL CHEM, V264, P11626; Roche TE, 2007, CELL MOL LIFE SCI, V64, P830, DOI 10.1007/s00018-007-6380-z; ROCHE TE, 1974, BIOCHEM BIOPH RES CO, V59, P1341, DOI 10.1016/0006-291X(74)90461-6; Rowles J, 1996, J BIOL CHEM, V271, P22376, DOI 10.1074/jbc.271.37.22376; Steussy CN, 2001, J BIOL CHEM, V276, P37443, DOI 10.1074/jbc.M104285200; Sugden M. C., 2002, Current Drug Targets - Immune Endocrine and Metabolic Disorders, V2, P151, DOI 10.2174/1568008023340785; Tuganova A, 2005, BIOCHEM J, V387, P147, DOI 10.1042/BJ20040805; Tuganova A, 2002, BIOCHEM J, V366, P129, DOI 10.1042/BJ20020301; Tuganova A, 2001, J BIOL CHEM, V276, P17994, DOI 10.1074/jbc.M009327200; Tuganova A, 2007, BIOCHEMISTRY-US, V46, P8592, DOI 10.1021/bi700650k; Yang DQ, 1998, J BIOL CHEM, V273, P14130, DOI 10.1074/jbc.273.23.14130	39	25	28	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15789	15798		10.1074/jbc.M800311200	http://dx.doi.org/10.1074/jbc.M800311200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18387944	hybrid, Green Published			2022-12-25	WOS:000256332500036
J	Orr, AL; Huang, SS; Roberts, MA; Reed, JC; Li, SH; Li, XJ				Orr, Adam L.; Huang, Shanshan; Roberts, Meredith A.; Reed, John C.; Li, Shihua; Li, Xiao-Jiang			Sex-dependent effect of BAG1 in ameliorating motor deficits of Huntington disease transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ISCHEMIA-REPERFUSION INJURY; N-TERMINAL HUNTINGTIN; HEAT-SHOCK PROTEINS; MOUSE MODEL; POLYGLUTAMINE AGGREGATION; VENTROMEDIAL HYPOTHALAMUS; INTRANUCLEAR INCLUSIONS; CHAPERONE SUPPRESSION; CELLULAR TOXICITY; MUTANT HUNTINGTIN	The pathogenesis of Huntington disease (HD) is attributed to the misfolding of huntingtin (htt) caused by an expanded polyglutamine (polyQ) domain. Considerable effort has been devoted to identifying molecules that can prevent or reduce htt misfolding and the associated neuropathology. Although overexpression of chaperones is known to reduce htt cytotoxicity in cellular models, only modest protection is seen with Hsp70 overexpression in HD mouse models. Because the activity of Hsp70 is modulated by co-chaperones, an interesting issue is whether the in vivo effects of chaperones on polyQ protein toxicity are dependent on other modulators. In the present study, we focused on BAG1, a co-chaperone that interacts with Hsp70 and regulates its activity. Of htt mice expressing the N171-82Q mutant, we found that male N171-82Q mice show a greater deficit in rotarod performance than female N171-82Q mice. This sex-dependent motor deficit was improved by crossing N171-82Q mice with transgenic mice overexpressing BAG1 in neurons. Transgenic BAG1 also reduces the levels of mutant htt in synaptosomal fraction of male HD mice. Overexpression of BAG1 augmented the effects of Hsp70 by reducing aggregation of mutant htt in cultured cells and improving neurite outgrowth in htt-transfected PC12 cells. These findings suggest that the effects of chaperones on HD pathology are influenced by both their modulators and sex-dependent factors.	[Orr, Adam L.; Huang, Shanshan; Roberts, Meredith A.; Li, Shihua; Li, Xiao-Jiang] Emory Univ, Sch Med, Dept Human Genet, Atlanta, GA 30322 USA; [Reed, John C.] Burnham Inst Med Res, La Jolla, CA 92037 USA	Emory University; Sanford Burnham Prebys Medical Discovery Institute	Li, XJ (corresponding author), Emory Univ, Sch Med, Dept Human Genet, 615 Michael St, Atlanta, GA 30322 USA.	xiaoli@genetics.emory.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS045106, R01NS041669] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG015393, R01AG019206] Funding Source: NIH RePORTER; NCI NIH HHS [CA6739] Funding Source: Medline; NIA NIH HHS [AG019206, AG15393, R01 AG019206] Funding Source: Medline; NINDS NIH HHS [NS041669, NS045106, R01 NS041669] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adachi H, 2007, NEUROPATH APPL NEURO, V33, P135, DOI 10.1111/j.1365-2990.2007.00830.x; Al-Ramahi I, 2006, J BIOL CHEM, V281, P26714, DOI 10.1074/jbc.M601603200; Alberti S, 2003, CELL STRESS CHAPERON, V8, P225, DOI 10.1379/1466-1268(2003)008<0225:BNEFOH>2.0.CO;2; Arrasate M, 2004, NATURE, V431, P805, DOI 10.1038/nature02998; Bonini NM, 2002, P NATL ACAD SCI USA, V99, P16407, DOI 10.1073/pnas.152330499; Chan HYE, 2000, HUM MOL GENET, V9, P2811, DOI 10.1093/hmg/9.19.2811; Chang DTW, 2006, NEUROBIOL DIS, V22, P388, DOI 10.1016/j.nbd.2005.12.007; Cheung J, 2000, MOL ENDOCRINOL, V14, P939, DOI 10.1210/me.14.7.939; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Dorner JL, 2007, BEHAV BRAIN RES, V178, P90, DOI 10.1016/j.bbr.2006.12.004; DUYAO M, 1993, NAT GENET, V4, P387, DOI 10.1038/ng0893-387; Fekete A, 2006, AM J PHYSIOL-RENAL, V291, pF806, DOI 10.1152/ajprenal.00080.2006; Gutekunst CA, 1999, J NEUROSCI, V19, P2522; Hansson O, 2003, BRAIN RES, V970, P47, DOI 10.1016/S0006-8993(02)04275-0; Hay DG, 2004, HUM MOL GENET, V13, P1389, DOI 10.1093/hmg/ddh144; *HD COLL RES GROUP, 1993, CELL, V26, P971; Jana NR, 2000, HUM MOL GENET, V9, P2009, DOI 10.1093/hmg/9.13.2009; Jana NR, 2005, NEUROSCI LETT, V378, P171, DOI 10.1016/j.neulet.2004.12.031; Kermer P, 2003, BRAIN PATHOL, V13, P495; Kermer P, 2002, CELL DEATH DIFFER, V9, P405, DOI 10.1038/sj.cdd.4400972; Krebs CJ, 1999, P NATL ACAD SCI USA, V96, P1686, DOI 10.1073/pnas.96.4.1686; Li SH, 2003, J NEUROSCI, V23, P6956; Li SH, 1998, HUM MOL GENET, V7, P777, DOI 10.1093/hmg/7.5.777; Li SH, 2000, MOL CELL NEUROSCI, V16, P168, DOI 10.1006/mcne.2000.0858; Liman J, 2005, MOL CELL BIOL, V25, P3715, DOI 10.1128/MCB.25.9.3715-3725.2005; Lin CH, 2001, HUM MOL GENET, V10, P137, DOI 10.1093/hmg/10.2.137; Lu AG, 2002, J CEREBR BLOOD F MET, V22, P183, DOI 10.1097/00004647-200202000-00006; Miller VM, 2005, J NEUROSCI, V25, P9152, DOI 10.1523/JNEUROSCI.3001-05.2005; Nickerson M, 2006, J APPL PHYSIOL, V101, P566, DOI 10.1152/japplphysiol.00259.2006; OLAZABAL UE, 1992, BRAIN RES, V596, P311, DOI 10.1016/0006-8993(92)91563-T; Paroo Z, 2002, CIRC RES, V90, P911, DOI 10.1161/01.RES.0000016963.43856.B1; Paulson HL, 1999, AM J HUM GENET, V64, P339, DOI 10.1086/302269; Phillips GR, 2001, NEURON, V32, P63, DOI 10.1016/S0896-6273(01)00450-0; Rong J, 2006, J NEUROSCI, V26, P6019, DOI 10.1523/JNEUROSCI.1251-06.2006; Rubinsztein DC, 2002, TRENDS GENET, V18, P202, DOI 10.1016/S0168-9525(01)02625-7; Sakahira H, 2002, P NATL ACAD SCI USA, V99, P16412, DOI 10.1073/pnas.182426899; Schilling G, 1999, HUM MOL GENET, V8, P397, DOI 10.1093/hmg/8.3.397; Shinohara T, 2004, J MOL CELL CARDIOL, V37, P1053, DOI 10.1016/j.yjmcc.2004.09.006; Thorp DB, 2007, AM J PHYSIOL-REG I, V293, pR363, DOI 10.1152/ajpregu.00363.2006; Vacher C, 2005, HUM MOL GENET, V14, P3425, DOI 10.1093/hmg/ddi372; Van Raamsdonk JM, 2005, HUM MOL GENET, V14, P1379, DOI 10.1093/hmg/ddi147; Voss MR, 2003, AM J PHYSIOL-HEART C, V285, pH687, DOI 10.1152/ajpheart.01000.2002; Wang JJ, 2008, J CELL BIOL, V180, P1177, DOI 10.1083/jcb.200709080; Weydt P, 2006, CELL METAB, V4, P349, DOI 10.1016/j.cmet.2006.10.004; Wyttenbach A, 2002, HUM MOL GENET, V11, P1137, DOI 10.1093/hmg/11.9.1137; Yang SH, 2005, J NEUROBIOL, V62, P341, DOI 10.1002/neu.20103; Zhou H, 2003, J CELL BIOL, V163, P109, DOI 10.1083/jcb.200306038; Zhou H, 2001, J BIOL CHEM, V276, P48417, DOI 10.1074/jbc.M104140200; Zhou R, 2005, J NEUROSCI, V25, P4493, DOI 10.1523/JNEUROSCI.4530-04.2005	49	23	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16027	16036		10.1074/jbc.M710606200	http://dx.doi.org/10.1074/jbc.M710606200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18400759	hybrid, Green Published			2022-12-25	WOS:000256332500061
J	Huang, JH; Qi, Z; Wu, F; Kotula, L; Jiang, SB; Chen, YH				Huang, Jing-He; Qi, Zhi; Wu, Fan; Kotula, Leszek; Jiang, Shibo; Chen, Ying-Hua			Interaction of HIV-1 gp41 core with NPF motif in Epsin - Implication in endocytosis of HIV	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; CLATHRIN-MEDIATED ENDOCYTOSIS; ENVELOPE GLYCOPROTEIN; BINDING MOTIF; EH-DOMAIN; MONOCLONAL-ANTIBODY; MEMBRANE; PEPTIDE; FUSION; MOLECULES	The human immunodeficiency virus, type 1 (HIV-1), gp41 core plays an important role in fusion between viral and target cell membranes. We previously identified an HIV-1 gp41 core-binding motif HXXNPF (where X is any amino acid residue). In this study, we found that Asn, Pro, and Phe were the key residues for gp41 core binding. There are two NPF motifs in Epsin-l(470 - 499), a fragment of Epsin, which is an essential accessory factor of endocytosis that can dock to the plasma membrane by interacting with the lipid. Epsin-1-(470-499) bound significantly to the gp41 core formed by the polypeptide N36(L8)C34 and interacted with the recombinant soluble gp41 containing the core structure. A synthetic peptide containing the Epsin-1-(470 - 499) sequence could effectively block entry of HIV- 1 virions into SupT1 T cells via the endocytosis pathway. These results suggest that interaction between Epsin and the gp41 core, which may be present in the target cell membrane, is probably essential for endocytosis of HIV-1, an alternative pathway of HIV-1 entry into the target cell.	[Qi, Zhi; Kotula, Leszek; Jiang, Shibo] New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA; [Huang, Jing-He; Wu, Fan; Chen, Ying-Hua] Tsinghua Univ, Dept Biol, Immunol Lab, Prot Sci Lab,Minist Educ, Beijing 100084, Peoples R China; [Huang, Jing-He] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Parterns AIDS Res Ctr & Infect Dis Div, Boston, MA 02129 USA	New York Blood Center; Tsinghua University; Harvard University; Harvard Medical School; Massachusetts General Hospital	Jiang, SB (corresponding author), New York Blood Ctr, Lindsley F Kimball Res Inst, New York, NY 10065 USA.	sjiang@nybloodcenter.org; chenyh@mail.tsinghua.edu.cn	Huang, Jinghe/P-8068-2019; WU, FAN/GRX-1654-2022; chen, ying/HHS-8254-2022; Jiang, Shibo/L-4500-2014; Huang, Jinghe/O-1986-2015	Jiang, Shibo/0000-0001-8283-7135; Huang, Jinghe/0000-0002-1968-871X; Kotula, Leszek/0000-0002-7977-7124; Wu, Fan/0000-0003-4741-3948	NIAID NIH HHS [R01 AI046221] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI046221] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alfsen A, 2001, J IMMUNOL, V166, P6257, DOI 10.4049/jimmunol.166.10.6257; Benferhat R, 2008, MOL IMMUNOL, V45, P1963, DOI 10.1016/j.molimm.2007.10.036; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Boge M, 1998, J BIOL CHEM, V273, P15773, DOI 10.1074/jbc.273.25.15773; Bosch B, 2006, ANTIVIR RES, V69, P173, DOI 10.1016/j.antiviral.2005.12.004; Bristow CL, 2003, BLOOD, V102, P4479, DOI 10.1182/blood-2003-05-1635; Brodsky FM, 2001, ANNU REV CELL DEV BI, V17, P517, DOI 10.1146/annurev.cellbio.17.1.517; Byland R, 2007, MOL BIOL CELL, V18, P414, DOI 10.1091/mbc.E06-06-0535; Chan DC, 1997, CELL, V89, P263, DOI 10.1016/S0092-8674(00)80205-6; Chan DC, 1998, CELL, V93, P681, DOI 10.1016/S0092-8674(00)81430-0; Chen H, 1998, NATURE, V394, P793, DOI 10.1038/29555; Chen YH, 1999, AIDS, V13, P1021, DOI 10.1097/00002030-199906180-00003; CHEN YH, 1992, AIDS, V6, P533, DOI 10.1097/00002030-199206000-00002; Daecke J, 2005, J VIROL, V79, P1581, DOI 10.1128/JVI.79.3.1581-1594.2005; de Beer T, 2000, NAT STRUCT BIOL, V7, P1018, DOI 10.1038/80924; de Rosny E, 2004, J VIROL, V78, P2627, DOI 10.1128/JVI.78.5.2627-2631.2004; Dimitrov AS, 2003, BIOCHEMISTRY-US, V42, P14150, DOI 10.1021/bi035154g; Doria M, 1999, J CELL BIOL, V147, P1379, DOI 10.1083/jcb.147.7.1379; Hovanessian AG, 2004, IMMUNITY, V21, P617, DOI 10.1016/j.immuni.2004.08.015; Huang JH, 2007, BIOCHEM J, V403, P565, DOI 10.1042/BJ20061275; Huang JH, 2007, J BIOL CHEM, V282, P6143, DOI 10.1074/jbc.M607701200; Huang JH, 2006, FEBS LETT, V580, P4807, DOI 10.1016/j.febslet.2006.07.067; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Jiang S, 1998, J VIROL, V72, P10213, DOI 10.1128/JVI.72.12.10213-10217.1998; Kalthoff C, 2002, J BIOL CHEM, V277, P8209, DOI 10.1074/jbc.M111587200; LU M, 1995, NAT STRUCT BIOL, V2, P1075, DOI 10.1038/nsb1295-1075; Manes S, 2000, EMBO REP, V1, P190, DOI 10.1093/embo-reports/kvd025; Nakashima S, 1999, EMBO J, V18, P3629, DOI 10.1093/emboj/18.13.3629; Neurath AR, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-6; Pho MT, 2000, J VIROL, V74, P2288, DOI 10.1128/JVI.74.5.2288-2292.2000; Sackett K, 2003, J MOL BIOL, V333, P47, DOI 10.1016/j.jmb.2003.07.008; Salcini AE, 1997, GENE DEV, V11, P2239, DOI 10.1101/gad.11.17.2239; SATTENTAU QJ, 1993, PHILOS T R SOC B, V342, P59, DOI 10.1098/rstb.1993.0136; Schaeffer E, 2004, J VIROL, V78, P1375, DOI 10.1128/JVI.78.3.1375-1383.2004; Shu W, 2000, J BIOL CHEM, V275, P1839, DOI 10.1074/jbc.275.3.1839; Speth C, 1999, MOL IMMUNOL, V36, P619, DOI 10.1016/S0161-5890(99)00082-6; Stang E, 1997, MOL BIOL CELL, V8, P47, DOI 10.1091/mbc.8.1.47; Su SB, 1999, BLOOD, V93, P3885, DOI 10.1182/blood.V93.11.3885.411k19_3885_3892; Su SB, 1999, J IMMUNOL, V162, P5924; Wang H, 2006, J BIOL CHEM, V281, P14129, DOI 10.1074/jbc.M512511200; Weissenhorn W, 1997, NATURE, V387, P426, DOI 10.1038/387426a0; Wendland B, 1998, J CELL BIOL, V141, P71, DOI 10.1083/jcb.141.1.71; Yamabhai M, 1998, J BIOL CHEM, V273, P31401, DOI 10.1074/jbc.273.47.31401	43	11	12	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					14994	15002		10.1074/jbc.M800525200	http://dx.doi.org/10.1074/jbc.M800525200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18375383	Green Published, hybrid			2022-12-25	WOS:000256232000012
J	Soh, H; Goldstein, SAN				Soh, Heun; Goldstein, Steve A. N.			I-SA channel complexes include four subunits each of DPP6 and Kv4.2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POTASSIUM CHANNEL; K+ CHANNEL; 3-DIMENSIONAL STRUCTURE; ALPHA-SUBUNITS; BETA-SUBUNITS; PROTEIN DPPX; TRANSIENT; MODULATION; STOICHIOMETRY; ASSOCIATION	Kv4 potassium channels produce rapidly inactivating currents that regulate excitability of muscles and nerves. To reconstitute the neuronal A-type current I-SA, Kv4 subunits assemble with DPP6, a single transmembrane domain accessory subunit. DPP6 alters function-accelerating activation, inactivation, and recovery from inactivation-and increases surface expression. We sought here to determine the stoichiometry of Kv4 and DPP6 in complexes using functional and biochemical methods. First, wild type channels formed from subunit monomers were compared with channels carrying subunits linked in tandem to enforce 4:4 and 4:2 assemblies (Kv4.2-DPP6 and Kv4.2Kv4.2-DPP6). Next, channels were overexpressed and purified so that the molar ratio of subunits in complexes could be assessed by direct amino acid analysis. Both biophysical and biochemical methods indicate that ISA channels carry four subunits each of Kv4.2 and DPP6.	[Goldstein, Steve A. N.] Univ Chicago, Pritzker Sch Med, Div Biol Sci, Dept Pediat, Chicago, IL 60637 USA; [Goldstein, Steve A. N.] Univ Chicago, Pritzker Sch Med, Div Biol Sci, Inst Mol Pediat Sci, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Goldstein, SAN (corresponding author), Univ Chicago, Pritzker Sch Med, Div Biol Sci, Dept Pediat, 5721 S Maryland Ave, Chicago, IL 60637 USA.	sangoldstein@uchicago.edu	Goldstein, Steven A./E-9817-2015	Goldstein, Steven A./0000-0001-5207-5061	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051851] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS058505] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL061657] Funding Source: Medline; NIGMS NIH HHS [GM 051851] Funding Source: Medline; NINDS NIH HHS [R01 NS058505] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abbott GW, 1998, Q REV BIOPHYS, V31, P357, DOI 10.1017/S0033583599003467; An WF, 2000, NATURE, V403, P553, DOI 10.1038/35000592; Brahmajothi MV, 1999, J GEN PHYSIOL, V113, P581, DOI 10.1085/jgp.113.4.581; Chen HJ, 2003, NEURON, V40, P15, DOI 10.1016/S0896-6273(03)00570-1; Clay JR, 2000, EUR BIOPHYS J BIOPHY, V29, P555, DOI 10.1007/s002490000091; Clement JP, 1997, NEURON, V18, P827, DOI 10.1016/S0896-6273(00)80321-9; Ding JP, 1998, BIOPHYS J, V74, P268, DOI 10.1016/S0006-3495(98)77785-9; Dixon JE, 1996, CIRC RES, V79, P659, DOI 10.1161/01.RES.79.4.659; Dougherty K, 2006, J GEN PHYSIOL, V128, P745, DOI 10.1085/jgp.200609668; Ficker E, 2003, CIRC RES, V92, pE87, DOI 10.1161/01.RES.0000079028.31393.15; Fiset C, 1997, J PHYSIOL-LONDON, V500, P51, DOI 10.1113/jphysiol.1997.sp021998; Gulbis JM, 2000, SCIENCE, V289, P123, DOI 10.1126/science.289.5476.123; Hinzpeter A, 2006, AM J PHYSIOL-CELL PH, V290, pC45, DOI 10.1152/ajpcell.00209.2005; Jentsch TJ, 2002, PHYSIOL REV, V82, P503, DOI 10.1152/physrev.00029.2001; Jerng HH, 2005, J PHYSIOL-LONDON, V568, P767, DOI 10.1113/jphysiol.2005.087858; Jerng HH, 2004, BIOPHYS J, V87, P2380, DOI 10.1529/biophysj.104.042358; Jerng HH, 1997, BIOPHYS J, V72, P163, DOI 10.1016/S0006-3495(97)78655-7; Johns DC, 1997, J BIOL CHEM, V272, P31598, DOI 10.1074/jbc.272.50.31598; Kaab S, 1998, CIRCULATION, V98, P1383, DOI 10.1161/01.CIR.98.14.1383; Kim LA, 2004, NEURON, V41, P513, DOI 10.1016/S0896-6273(04)00050-9; Kim LA, 2004, J BIOL CHEM, V279, P5549, DOI 10.1074/jbc.M311332200; KNAUS HG, 1994, J BIOL CHEM, V269, P17274; Liss B, 2001, EMBO J, V20, P5715, DOI 10.1093/emboj/20.20.5715; Malin SA, 2000, J NEUROSCI, V20, P5191, DOI 10.1523/JNEUROSCI.20-14-05191.2000; Mason HS, 2002, MOL PHARMACOL, V61, P285, DOI 10.1124/mol.61.2.285; Melman YF, 2004, NEURON, V42, P927, DOI 10.1016/j.neuron.2004.06.001; Morin TJ, 2008, P NATL ACAD SCI USA, V105, P1478, DOI 10.1073/pnas.0710366105; Nadal MS, 2003, NEURON, V37, P449, DOI 10.1016/S0896-6273(02)01185-6; Nadal MS, 2001, J PHYSIOL-LONDON, V537, P801; Petrecca K, 2000, J NEUROSCI, V20, P8736; Pioletti M, 2006, NAT STRUCT MOL BIOL, V13, P987, DOI 10.1038/nsmb1164; Ren XM, 2005, MOL CELL NEUROSCI, V29, P320, DOI 10.1016/j.mcn.2005.02.003; Rhodes KJ, 1997, J NEUROSCI, V17, P8246; Sampson LJ, 2003, J BIOL CHEM, V278, P41988, DOI 10.1074/jbc.M307479200; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Shyng SL, 1997, J GEN PHYSIOL, V110, P655, DOI 10.1085/jgp.110.6.655; Sokolova O, 2001, STRUCTURE, V9, P215, DOI 10.1016/S0969-2126(01)00578-0; Strop P, 2004, J MOL BIOL, V343, P1055, DOI 10.1016/j.jmb.2004.09.003; Tai KK, 1998, NATURE, V391, P605, DOI 10.1038/35416; Wang HY, 2007, NAT NEUROSCI, V10, P32, DOI 10.1038/nn1822; WANG KW, 1995, NEURON, V14, P1303, DOI 10.1016/0896-6273(95)90277-5; Wang YW, 2002, J NEUROSCI, V22, P1550, DOI 10.1523/JNEUROSCI.22-05-01550.2002; Zagha E, 2005, J BIOL CHEM, V280, P18853, DOI 10.1074/jbc.M410613200	43	26	27	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15072	15077		10.1074/jbc.M706964200	http://dx.doi.org/10.1074/jbc.M706964200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18364354	Green Published, hybrid			2022-12-25	WOS:000256232000021
J	Baitin, DM; Gruenig, MC; Cox, MM				Baitin, Dmitry M.; Gruenig, Marielle C.; Cox, Michael M.			SSB antagonizes RecX-RecA interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-STRANDED-DNA; ESCHERICHIA-COLI-RECA; STALLED REPLICATION FORKS; BINDING-PROTEIN SSB; C-TERMINUS; GENETIC-RECOMBINATION; SACCHAROMYCES-CEREVISIAE; NUCLEOPROTEIN FILAMENTS; DUPLEX DNA; IN-VITRO	The RecX protein of Escherichia coli inhibits the extension of RecA protein filaments on DNA, presumably by binding to and blocking the growing filament end. The direct binding of RecX protein to single-stranded DNA is weak, and previous reports suggested that direct binding to DNA did not explain the effects of RecX. We now demonstrate that elevated concentrations of SSB greatly moderate the effects of RecX protein. High concentrations of the yeast RPA protein have the same effect, suggesting that the effect is not species-specific or even specific to bacterial SSB proteins. A direct SSB-RecX interaction is thus unlikely. We suggest that SSB is blocking access to single-stranded DNA. The evident competition between RecX and SSB implies that the mechanism of RecX action may involve RecX binding to both RecA protein and to DNA. We speculate that the interaction of RecX protein and RecA may enable an enhanced DNA binding by RecX protein. The effects of SSB are increased if the SSB C terminus is removed.	[Baitin, Dmitry M.; Gruenig, Marielle C.; Cox, Michael M.] Univ Wisconsin Madison, Dept Biochem, Madison, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Cox, MM (corresponding author), Univ Wisconsin Madison, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA.	cox@biochem.wisc.edu	Baitin, Dmitry/G-1900-2014	Baitin, Dmitry/0000-0003-0022-1084	NIGMS NIH HHS [GM 32335, R01 GM032335] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032335] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Acharya N, 2002, J MOL BIOL, V318, P1251, DOI 10.1016/S0022-2836(02)00053-0; ALANI E, 1992, J MOL BIOL, V227, P54, DOI 10.1016/0022-2836(92)90681-9; Arenson TA, 1999, J MOL BIOL, V288, P391, DOI 10.1006/jmbi.1999.2705; BAGDASARIAN M, 1992, MOL MICROBIOL, V6, P885, DOI 10.1111/j.1365-2958.1992.tb01539.x; BAILONE A, 1988, MOL GEN GENET, V214, P389, DOI 10.1007/BF00330471; BENEDICT RC, 1988, J BIOL CHEM, V263, P15513; BENSON FE, 1994, EMBO J, V13, P5764, DOI 10.1002/j.1460-2075.1994.tb06914.x; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; Bork JM, 2001, J BIOL CHEM, V276, P45740, DOI 10.1074/jbc.M109247200; Bork JM, 2001, EMBO J, V20, P7313, DOI 10.1093/emboj/20.24.7313; Cadman CJ, 2004, NUCLEIC ACIDS RES, V32, P6378, DOI 10.1093/nar/gkh980; CLARK AJ, 1973, ANNU REV GENET, V7, P67, DOI 10.1146/annurev.ge.07.120173.000435; CLARK AJ, 1974, GENETICS, V78, P259; Cox JM, 2005, PLOS BIOL, V3, P231, DOI 10.1371/journal.pbio.0030052; Cox MM, 2007, CRIT REV BIOCHEM MOL, V42, P41, DOI 10.1080/10409230701260258; Cox MM, 2007, NAT REV MOL CELL BIO, V8, P127, DOI 10.1038/nrm2099; Cox MM, 2000, NATURE, V404, P37, DOI 10.1038/35003501; Cox MM, 2003, ANNU REV MICROBIOL, V57, P551, DOI 10.1146/annurev.micro.57.030502.090953; Cox MM, 2001, P NATL ACAD SCI USA, V98, P8173, DOI 10.1073/pnas.131004998; COX MM, 2006, TOPICS CURRENT GENET, P53; CRAIG NL, 1981, J BIOL CHEM, V256, P8039; Curth U, 1996, NUCLEIC ACIDS RES, V24, P2706, DOI 10.1093/nar/24.14.2706; DAVIS RW, 1980, ADV BACTERIAL GENET, P116; Drees JC, 2006, J BIOL CHEM, V281, P4708, DOI 10.1074/jbc.M513592200; Drees JC, 2004, J BIOL CHEM, V279, P52991, DOI 10.1074/jbc.M409050200; Drees JC, 2004, MOL CELL, V15, P789, DOI 10.1016/j.molcel.2004.08.026; DUNDERDALE HJ, 1994, CURR OPIN GENET DEV, V4, P221, DOI 10.1016/S0959-437X(05)80048-6; DUTREIX M, 1989, J BACTERIOL, V171, P2415, DOI 10.1128/jb.171.5.2415-2423.1989; Eggler AL, 2003, J BIOL CHEM, V278, P16389, DOI 10.1074/jbc.M212920200; ENNIS DG, 1985, P NATL ACAD SCI USA, V82, P3325, DOI 10.1073/pnas.82.10.3325; FLORY SS, 1984, COLD SPRING HARB SYM, V49, P513, DOI 10.1101/SQB.1984.049.01.058; Genschel J, 2000, BIOL CHEM, V381, P183, DOI 10.1515/BC.2000.025; GOLUB E, 1988, J BACTERIOL, V170, P4392, DOI 10.1128/jb.170.9.4392-4394.1988; Gulbis JM, 2004, EUR J BIOCHEM, V271, P439, DOI 10.1046/j.1432-1033.2003.03944.x; Handa P, 2001, J BIOL CHEM, V276, P16992, DOI 10.1074/jbc.M100393200; Hobbs MD, 2007, J BIOL CHEM, V282, P11058, DOI 10.1074/jbc.M611007200; HORII T, 1992, J MOL BIOL, V223, P105, DOI 10.1016/0022-2836(92)90719-Z; HOWARDFLANDERS P, 1984, NATURE, V309, P215, DOI 10.1038/309215a0; Joo C, 2006, CELL, V126, P515, DOI 10.1016/j.cell.2006.06.042; Kinebuchi T, 1997, BIOCHEMISTRY-US, V36, P6732, DOI 10.1021/bi961647s; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P81, DOI 10.1016/0022-2836(87)90629-2; KOWALCZYKOWSKI SC, 1987, J MOL BIOL, V193, P97, DOI 10.1016/0022-2836(87)90630-9; KOWALCZYKOWSKI SC, 1994, MICROBIOL REV, V58, P401, DOI 10.1128/MMBR.58.3.401-465.1994; Kowalczykowski SC, 2000, TRENDS BIOCHEM SCI, V25, P156, DOI 10.1016/S0968-0004(00)01569-3; Kuzminov A, 1999, MICROBIOL MOL BIOL R, V63, P751, DOI 10.1128/MMBR.63.4.751-813.1999; KUZMINOV A, 1995, MOL MICROBIOL, V16, P373, DOI 10.1111/j.1365-2958.1995.tb02403.x; LAVERY PE, 1992, J BIOL CHEM, V267, P9315; Li ZF, 1997, P NATL ACAD SCI USA, V94, P11221, DOI 10.1073/pnas.94.21.11221; LINDSLEY JE, 1989, J MOL BIOL, V205, P695, DOI 10.1016/0022-2836(89)90315-X; LINDSLEY JE, 1990, J BIOL CHEM, V265, P9043; LOHMAN TM, 1985, J BIOL CHEM, V260, P3594; Lusetti SL, 2006, MOL CELL, V21, P41, DOI 10.1016/j.molcel.2005.11.011; Lusetti SL, 2002, ANNU REV BIOCHEM, V71, P71, DOI 10.1146/annurev.biochem.71.083101.133940; Lusetti SL, 2004, J BIOL CHEM, V279, P30037, DOI 10.1074/jbc.M403064200; Lusetti SL, 2003, J BIOL CHEM, V278, P16381, DOI 10.1074/jbc.M212916200; Lusetti SL, 2003, J BIOL CHEM, V278, P16372, DOI 10.1074/jbc.M212917200; Ma YJ, 2004, J BIOL CHEM, V279, P19035, DOI 10.1074/jbc.M311738200; MESSING J, 1982, GENE, V19, P269, DOI 10.1016/0378-1119(82)90016-6; MESSING J, 1983, METHOD ENZYMOL, V101, P20; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; MORRICAL SW, 1986, BIOCHEMISTRY-US, V25, P1482, DOI 10.1021/bi00355a003; MUNIYAPPA K, 1984, P NATL ACAD SCI-BIOL, V81, P2757, DOI 10.1073/pnas.81.9.2757; NEUENDORF SK, 1986, J BIOL CHEM, V261, P8276; OGAWA T, 1993, SCIENCE, V259, P1896, DOI 10.1126/science.8456314; PUGH BF, 1988, J MOL BIOL, V203, P479, DOI 10.1016/0022-2836(88)90014-9; PUGH BF, 1987, J BIOL CHEM, V262, P1326; REGISTER JC, 1985, J BIOL CHEM, V260, P2308; Richard DJ, 2004, NUCLEIC ACIDS RES, V32, P1065, DOI 10.1093/nar/gkh259; Roy R, 2007, J MOL BIOL, V369, P1244, DOI 10.1016/j.jmb.2007.03.079; Sandler SJ, 1996, NUCLEIC ACIDS RES, V24, P2125, DOI 10.1093/nar/24.11.2125; Savvides SN, 2004, PROTEIN SCI, V13, P1942, DOI 10.1110/ps.04661904; Sehorn MG, 2004, CELL CYCLE, V3, P1375, DOI 10.4161/cc.3.11.1364; Shan Q, 1997, J MOL BIOL, V265, P519, DOI 10.1006/jmbi.1996.0748; Shan Q, 1996, J BIOL CHEM, V271, P5712, DOI 10.1074/jbc.271.10.5712; Shan Q, 1996, J MOL BIOL, V257, P756, DOI 10.1006/jmbi.1996.0200; Shereda RD, 2007, J BIOL CHEM, V282, P19247, DOI 10.1074/jbc.M608011200; Shinagawa H, 1996, EXS, V77, P221; Shinohara A, 1997, GENES CELLS, V2, P615, DOI 10.1046/j.1365-2443.1997.1480347.x; Stohl EA, 2003, J BIOL CHEM, V278, P2278, DOI 10.1074/jbc.M210496200; Sugiyama T, 1997, J BIOL CHEM, V272, P7940, DOI 10.1074/jbc.272.12.7940; SWEASY JB, 1990, J BACTERIOL, V172, P3030, DOI 10.1128/jb.172.6.3030-3036.1990; TEMPLIN A, 1978, J BACTERIOL, V134, P590, DOI 10.1128/JB.134.2.590-596.1978; UMEZU K, 1994, J BIOL CHEM, V269, P30005; VanLoock MS, 2003, J MOL BIOL, V333, P345, DOI 10.1016/j.jmb.2003.08.053; WALKER GC, 1995, TRENDS BIOCHEM SCI, V20, P416, DOI 10.1016/S0968-0004(00)89091-X; WILLIAMS KR, 1983, J BIOL CHEM, V258, P3346; WITKIN EM, 1991, BIOCHIMIE, V73, P133, DOI 10.1016/0300-9084(91)90196-8; Witte G, 2003, NUCLEIC ACIDS RES, V31, P4434, DOI 10.1093/nar/gkg498; Wu Y, 2004, MOL CELL, V15, P423, DOI 10.1016/j.molcel.2004.07.014; Yang SX, 2001, J MOL BIOL, V314, P1077, DOI 10.1006/jmbi.2000.5213; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X	91	15	15	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14198	14204		10.1074/jbc.M801511200	http://dx.doi.org/10.1074/jbc.M801511200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18385131	Green Accepted, Green Published, hybrid			2022-12-25	WOS:000255941400005
J	Lanternier, F; Cohen-Akenine, A; Palmerini, F; Feger, F; Yang, Y; Zermati, Y; Barete, S; Sans, B; Baude, C; Ghez, D; Suarez, F; Delarue, R; Casassus, P; Bodemer, C; Catteau, A; Soppelsa, F; Hanssens, K; Arock, M; Sobol, H; Fraitag, S; Canioni, D; Moussy, A; Launay, JM; Dubreuil, P; Hermine, O; Lortholary, O				Lanternier, Fanny; Cohen-Akenine, Annick; Palmerini, Fabienne; Feger, Frederic; Yang, Ying; Zermati, Yael; Barete, Stephane; Sans, Beatrix; Baude, Cedric; Ghez, David; Suarez, Felipe; Delarue, Richard; Casassus, Philippe; Bodemer, Christine; Catteau, Adeline; Soppelsa, Frederique; Hanssens, Katia; Arock, Michel; Sobol, Hagay; Fraitag, Sylvie; Canioni, Daniele; Moussy, Alain; Launay, Jean Marie; Dubreuil, Patrice; Hermine, Olivier; Lortholary, Olivier		AFIRMM Network	Phenotypic and Genotypic Characteristics of Mastocytosis According to the Age of Onset	PLOS ONE			English	Article								Adult's mastocytosis is usually associated with persistent systemic involvement and c-kit 816 mutation, while pediatrics disease is mostly limited to the skin and often resolves spontaneously. We prospectively included 142 adult patients with histologically proven mastocytosis. We compared phenotypic and genotypic features of adults patients whose disease started during childhood (Group 1, n = 28) with those of patients whose disease started at adult's age (Group 2, n = 114). Genotypic analysis was performed on skin biopsy by sequencing of c-kit exons 17 and 8 to 13. According to WHO classification, the percentage of systemic disease was similar (75 vs. 73%) in 2 groups. C-kit 816 mutation was found in 42% and 77% of patients in groups 1 and 2, respectively (p < 0.001). 816 c-kit mutation was associated with systemic mastocytosis in group 2 (87% of patients with systemic mastocytosis vs. 45% with cutaneous mastocytosis, p = 0.0001). Other c-kit activating mutations were found in 23% of patients with mastocytosis' onset before the age of 5, 0% between 6 and 15 years and 2% at adults' age (p < 0.001). In conclusion, pathogenesis of mastocytosis significantly differs according to the age of disease's onset. Our data may have major therapeutic relevance when considering c-kit-targeted therapy.	[Lanternier, Fanny; Lortholary, Olivier] Univ Paris 05, Serv Malad Infect & Trop, Ctr Reference Mastocytoses, Hop Necker Enfants Malad,Ctr Infectol Necker Past, Paris, France; [Cohen-Akenine, Annick; Baude, Cedric; Catteau, Adeline; Soppelsa, Frederique; Hanssens, Katia; Moussy, Alain] AFIRMM Network, Paris, France; [Palmerini, Fabienne; Yang, Ying; Dubreuil, Patrice] Hematopoiise Mol Fonct, U599, Inserm, Ctr Rech Cancerol Marseille, Marseille, France; [Palmerini, Fabienne; Yang, Ying; Sobol, Hagay; Dubreuil, Patrice] Inst Paoli Calmettes, Dept Biopathol, Marseille, France; [Palmerini, Fabienne; Yang, Ying; Dubreuil, Patrice] Univ Aix Marseille 2, Marseille, France; [Feger, Frederic; Arock, Michel] Ecole Normale Superieure Cachan, CNRS UMR8113, Lab Biotechnol Pharmacol Genet Appl, Cachan, France; [Barete, Stephane] Hop Tenon, Ctr reference mastocytoses, Serv Dermatol, Paris, France; [Sans, Beatrix] Hop Purpan, Serv Dermatol, Toulouse, France; [Ghez, David; Suarez, Felipe; Delarue, Richard; Hermine, Olivier] Univ Paris 05, Hop Necker Enfants malades, Ctr reference mastocytoses, IFR Necker, Serv Hematol, Paris, France; [Casassus, Philippe] Hop Avicenne, Serv Hematol, Bobigny, France; [Bodemer, Christine] Univ Paris 05, Hop Necker Enfants malades, Ctr reference mastocytoses, IFR Necker, Serv Dermatol, Paris, France; [Fraitag, Sylvie; Canioni, Daniele] Hop Necker Enfants Malad, Serv Anatomopathol, Paris, France; [Zermati, Yael; Launay, Jean Marie] Hop Lariboisiere, Serv Biochim, Paris, France; [Hermine, Olivier] CNRS, UMR 8147, Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; UNICANCER; Institut Paoli-Calmette (IPC); UDICE-French Research Universities; Aix-Marseille Universite; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); UDICE-French Research Universities; Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Tenon - APHP; UDICE-French Research Universities; Sorbonne Universite; CHU de Toulouse; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Avicenne - APHP; Universite Paris 13; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS)	Lanternier, F (corresponding author), Univ Paris 05, Serv Malad Infect & Trop, Ctr Reference Mastocytoses, Hop Necker Enfants Malad,Ctr Infectol Necker Past, Paris, France.	hermine@necker.fr; olivier.lortholary@nck.aphp.fr	Hermine, Olivier/Q-7072-2018; dubreuil, patrice/F-5346-2011; Lanternier, Fanny/AAQ-2815-2021; Dubreuil, Patrice/V-4816-2019	dubreuil, patrice/0000-0003-1155-1150; Dubreuil, Patrice/0000-0003-1155-1150; Hermine, Olivier/0000-0003-2574-3874				AZANA JM, 1994, PEDIATR DERMATOL, V11, P102, DOI 10.1111/j.1525-1470.1994.tb00560.x; Buttner C, 1998, J INVEST DERMATOL, V111, P1227, DOI 10.1046/j.1523-1747.1998.00414.x; CZARNETZKI BM, 1988, J AM ACAD DERMATOL, V18, P45, DOI 10.1016/S0190-9622(88)70007-9; Escribano L, 1998, BLOOD, V91, P2731, DOI 10.1182/blood.V91.8.2731.2731_2731_2736; Fearfield LA, 2001, BRIT J DERMATOL, V144, P561, DOI 10.1046/j.1365-2133.2001.04084.x; Fraitag-Spinner S, 2007, ANN DERMATOL VENER, V134, P589, DOI 10.1016/S0151-9638(07)89281-7; FURITSU T, 1993, J CLIN INVEST, V92, P1736, DOI 10.1172/JCI116761; GARCIAMONTERO AC, 2006, BLOOD, P2006; Hartmann K, 2000, HEMATOL ONCOL CLIN N, V14, P625, DOI 10.1016/S0889-8588(05)70299-9; Hartmann K, 2005, GASTROENTEROLOGY, V129, P1042, DOI 10.1053/j.gastro.2005.06.060; Horny HP, 2001, LEUKEMIA RES, V25, P543, DOI 10.1016/S0145-2126(01)00021-2; Hup MMA, 2002, J EUR ACAD DERMATOL, V16, P115, DOI 10.1046/j.1468-3083.2002.00370.x; IEMURA A, 1994, AM J PATHOL, V144, P321; Longley BJ, 1999, P NATL ACAD SCI USA, V96, P1609, DOI 10.1073/pnas.96.4.1609; MEKORI YA, 1993, J IMMUNOL, V151, P3775; NAGATA H, 1995, P NATL ACAD SCI USA, V92, P10560, DOI 10.1073/pnas.92.23.10560; RODERMUND OE, 1978, DERMATOL MONATSSCHR, V164, P493; Valent P, 2003, BRIT J HAEMATOL, V122, P695, DOI 10.1046/j.1365-2141.2003.04575.x; Valent P, 2001, LEUKEMIA RES, V25, P603, DOI 10.1016/S0145-2126(01)00038-8; Worobec AS, 1998, CANCER, V83, P2120, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2120::AID-CNCR10>3.0.CO;2-C; Yanagihori H, 2005, J MOL DIAGN, V7, P252, DOI 10.1016/S1525-1578(10)60552-1; Zhang LY, 2006, LEUKEMIA RES, V30, P373, DOI 10.1016/j.leukres.2005.08.015	22	69	70	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1906	10.1371/journal.pone.0001906	http://dx.doi.org/10.1371/journal.pone.0001906			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18404201	Green Published, gold			2022-12-25	WOS:000260795500002
J	Ma, XT; Tarone, AM; Li, WY				Ma, Xiaotu; Tarone, Aaron M.; Li, Wenyuan			Mapping Genetically Compensatory Pathways from Synthetic Lethal Interactions in Yeast	PLOS ONE			English	Article							SACCHAROMYCES-CEREVISIAE; CHITIN SYNTHESIS; DELETION; NETWORK	Background: Synthetic lethal genetic interaction analysis has been successfully applied to predicting the functions of genes and their pathway identities. In the context of synthetic lethal interaction data alone, the global similarity of synthetic lethal interaction patterns between two genes is used to predict gene function. With physical interaction data, such as protein-protein interactions, the enrichment of physical interactions within subsets of genes and the enrichment of synthetic lethal interactions between those subsets of genes are used as an indication of compensatory pathways. Result: In this paper, we propose a method of mapping genetically compensatory pathways from synthetic lethal interactions. Our method is designed to discover pairs of gene-sets in which synthetic lethal interactions are depleted among the genes in an individual set and where such gene-set pairs are connected by many synthetic lethal interactions. By its nature, our method could select compensatory pathway pairs that buffer the deleterious effect of the failure of either one, without the need of physical interaction data. By focusing on compensatory pathway pairs where genes in each individual pathway have a highly homogenous cellular function, we show that many cellular functions have genetically compensatory properties. Conclusion: We conclude that synthetic lethal interaction data are a powerful source to map genetically compensatory pathways, especially in systems lacking physical interaction information, and that the cellular function network contains abundant compensatory properties.	[Ma, Xiaotu; Tarone, Aaron M.; Li, Wenyuan] Univ So Calif, Dept Biol Sci, Mol & Computat Biol Program, Los Angeles, CA 90089 USA	University of Southern California	Ma, XT (corresponding author), Univ So Calif, Dept Biol Sci, Mol & Computat Biol Program, Los Angeles, CA 90089 USA.	xma@usc.edu	Tarone, Aaron/I-6483-2012	Tarone, Aaron/0000-0003-0965-7634	NIH [P50 HG 002790]; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [P50HG002790] Funding Source: NIH RePORTER	NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))	This work is partly supported by NIH grant P50 HG 002790	Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Boone C, 2007, NAT REV GENET, V8, P437, DOI 10.1038/nrg2085; Davierwala AP, 2005, NAT GENET, V37, P1147, DOI 10.1038/ng1640; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Harbison CT, 2004, NATURE, V431, P99, DOI 10.1038/nature02800; Ito T, 2000, P NATL ACAD SCI USA, V97, P1143, DOI 10.1073/pnas.97.3.1143; Kanehisa M, 2006, NUCLEIC ACIDS RES, V34, pD354, DOI 10.1093/nar/gkj102; KARP G, 1999, CELL MOL BIOL, P292; Kelley R, 2005, NAT BIOTECHNOL, V23, P561, DOI 10.1038/nbt1096; Lesage G, 2005, BMC GENET, V6, DOI 10.1186/1471-2156-6-8; Milo R, 2002, SCIENCE, V298, P824, DOI 10.1126/science.298.5594.824; Munro S, 2001, FEBS LETT, V498, P223, DOI 10.1016/S0014-5793(01)02488-7; Nash R, 2007, NUCLEIC ACIDS RES, V35, pD468, DOI 10.1093/nar/gkl931; Osmond BC, 1999, P NATL ACAD SCI USA, V96, P11206, DOI 10.1073/pnas.96.20.11206; Schuldiner M, 2005, CELL, V123, P507, DOI 10.1016/j.cell.2005.08.031; Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303; Stark C, 2006, NUCLEIC ACIDS RES, V34, pD535, DOI 10.1093/nar/gkj109; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Ulitsky I, 2007, MOL SYST BIOL, V3, DOI 10.1038/msb4100144; Wiggins CAR, 1998, P NATL ACAD SCI USA, V95, P7945, DOI 10.1073/pnas.95.14.7945; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; Ye P, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100034; Yoko-o T, 2003, GLYCOBIOLOGY, V13, P581, DOI 10.1093/glycob/cwg063	25	34	35	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1922	10.1371/journal.pone.0001922	http://dx.doi.org/10.1371/journal.pone.0001922			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398455	gold, Green Published, Green Submitted			2022-12-25	WOS:000260795500006
J	Stensmyr, MC; Stieber, R; Hansson, BS				Stensmyr, Marcus C.; Stieber, Regina; Hansson, Bill S.			The Cayman Crab Fly Revisited - Phylogeny and Biology of Drosophila endobranchia	PLOS ONE			English	Article							POPULATION; EVOLUTION; SOFTWARE; DIPTERA; DDC	Background: The majority of all known drosophilid flies feed on microbes. The wide spread of microorganisms consequently mean that drosophilids also can be found on a broad range of substrates. One of the more peculiar types of habitat is shown by three species of flies that have colonized land crabs. In spite of their intriguing lifestyle, the crab flies have remained poorly studied. Perhaps the least investigated of the three crab flies is the Cayman Island endemic Drosophila endobranchia. Apart from its life cycle very little is known about this species, including its phylogenetic position, which has remained unresolved due to a cryptic set of characteristics. Principal Findings: Based on molecular data, corroborated by a re-analysis of the morphological make up, we have resolved the phylogenetic position of D. endobranchia and show that it somewhat surprisingly belongs to the large Neotropical repleta radiation, and should be considered as an aberrant member of the canalinea species group. Furthermore we also provide additional data on the behavior of these remarkable flies. Conclusion: Our findings reveal that the two Caribbean crab flies are not as distantly related as first thought, as both species are members of the derived repleta radiation. That this lineage has given rise to two species with the same odd type of breeding substrate is curious and prompts the question of what aspects of their shared ancestry has made these flies suitable for a life on (and inside) land crabs. Knowledge of the phylogenetic position of D. endobranchia will allow for comparative explorations and will aid in efforts aimed at understanding processes involved in drastic host shifts and extreme specialization.	[Stensmyr, Marcus C.; Stieber, Regina; Hansson, Bill S.] Max Planck Inst Chem Ecol, Dept Evolutionary Neuroethol, Jena, Germany	Max Planck Society	Stensmyr, MC (corresponding author), Max Planck Inst Chem Ecol, Dept Evolutionary Neuroethol, Jena, Germany.	mstensmyr@ice.mpg.de	Hansson, Bill S/G-2774-2013	Hansson, Bill S/0000-0002-4811-1223; Stensmyr, Marcus/0000-0003-4009-9212	Max Planck Society	Max Planck Society(Max Planck SocietyFoundation CELLEX)	This work was supported by the Max Planck Society	Bonacum J, 2005, MOL PHYLOGENET EVOL, V37, P73, DOI 10.1016/j.ympev.2005.03.008; CARSON HL, 1974, P NATL ACAD SCI USA, V71, P3517, DOI 10.1073/pnas.71.9.3517; CARSON HL, 1968, ANN ENTOMOL SOC AM, V61, P675, DOI 10.1093/aesa/61.3.675; Clayton F.E., 1957, U TEXAS PUBLS, V5721, P125; Duda O., 1927, Archiv fuer Naturgeschichte Berlin, V91, P1; Gershenson S, 1928, GENETICS, V13, P488; Grimaldi D.A., 1988, P183; Hall T.A., 1999, NUCL ACIDS S SERIES, V41, P95, DOI [DOI 10.1021/BK-1999-0734.CH008, citeulike-article-id:691774, 10.12691/ajmr-6-4-3]; HAMPTON L, CARSON PAPERS AM PHI; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Jaenike J, 1996, AM NAT, V148, P237, DOI 10.1086/285923; Klaus AV, 2003, J MICROSC-OXFORD, V212, P107, DOI 10.1046/j.1365-2818.2003.01235.x; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Liu H, 1992, MOL PHYLOGENET EVOL, V1, P41, DOI 10.1016/1055-7903(92)90034-E; Malloch J. R., 1926, Proceedings of the United States National Museum, V68, P1; Medeiros Hermes Fonsêca de, 2004, Biota Neotrop., V4, P01, DOI 10.1590/S1676-06032004000100005; PIPKIN SB, 1965, AM MIDL NAT, V74, P1, DOI 10.2307/2423115; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Ratcov V, 2007, IHERINGIA SER ZOOL, V97, P336, DOI 10.1590/S0073-47212007000300019; Remsen J, 2002, MOL PHYLOGENET EVOL, V24, P249, DOI 10.1016/S1055-7903(02)00226-9; Rudolfs W., 1922, B NEW JERSEY AGR EXP, V367, P1; Stensmyr MC, 2007, CURR BIOL, V17, pR743, DOI 10.1016/j.cub.2007.06.015; Sturtevant AH, 1921, CARNEGIE I WASH YR B, V301, P1, DOI [DOI 10.5962/BHL.TITLE.33564, 10.5962/bhl.title.33564]; Suh GSB, 2004, NATURE, V431, P854, DOI 10.1038/nature02980; Swofford D.L., 2002, PAUP PHYLOGENETIC AN; Tatarenkov A, 1999, J MOL EVOL, V48, P445, DOI 10.1007/PL00006489; Tatarenkov A, 2001, MOL PHYLOGENET EVOL, V20, P321, DOI 10.1006/mpev.2001.0967; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Throckmorton L.H., 1975, P421; Throckmorton LH, 1962, U TEXAS PUBL, V6205, P207, DOI DOI 10.1016/J.YMPEV.2011.04.012; VILELA C R, 1990, Mitteilungen der Schweizerischen Entomologischen Gesellschaft, V63, P1; Wheeler M.R., 1957, U TEXAS PUBL, V5721, P79; Wheeler M.R., 1970, CATALOGUE DIPTERA AM; Xia X, 2001, J HERED, V92, P371, DOI 10.1093/jhered/92.4.371	34	8	8	2	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1942	10.1371/journal.pone.0001942	http://dx.doi.org/10.1371/journal.pone.0001942			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398468	Green Submitted, Green Published, gold			2022-12-25	WOS:000260795500019
J	Wang, HR; Liang, SY; Burgdorf, J; Wess, J; Yeomans, J				Wang, Haoran; Liang, Shuyin; Burgdorf, Jeffrey; Wess, Jurgen; Yeomans, John			Ultrasonic Vocalizations Induced by Sex and Amphetamine in M2, M4, M5 Muscarinic and D2 Dopamine Receptor Knockout Mice	PLOS ONE			English	Article								Adult mice communicate by emitting ultrasonic vocalizations (USVs) during the appetitive phases of sexual behavior. However, little is known about the genes important in controlling call production. Here, we study the induction and regulation of USVs in muscarinic and dopaminergic receptor knockout (KO) mice as well as wild-type controls during sexual behavior. Female mouse urine, but not female rat or human urine, induced USVs in male mice, whereas male urine did not induce USVs in females. Direct contact of males with females is required for eliciting high level of USVs in males. USVs (25 to 120 kHz) were emitted only by males, suggesting positive state; however human-audible squeaks were produced only by females, implying negative state during male-female pairing. USVs were divided into flat and frequency-modulated calls. Male USVs often changed from continuous to broken frequency-modulated calls after initiation of mounting. In M2 KO mice, USVs were lost in about 70-80% of the mice, correlating with a loss of sexual interaction. In M5 KO mice, mean USVs were reduced by almost 80% even though sexual interaction was vigorous. In D2 KOs, the duration of USVs was extended by 20%. In M4 KOs, no significant differences were observed. Amphetamine dose-dependently induced USVs in wild-type males (most at 0.5 mg/kg i.p.), but did not elicit USVs in M5 KO or female mice. These studies suggest that M2 and M5 muscarinic receptors are needed for male USV production during male-female interactions, likely via their roles in dopamine activation. These findings are important for the understanding of the neural substrates for positive affect.	[Wang, Haoran; Liang, Shuyin; Yeomans, John] Univ Toronto, Dept Psychol, CTBC, Toronto, ON M5S 1A1, Canada; [Burgdorf, Jeffrey] Northwestern Univ, Falk Ctr Mol Therapeut, Evanston, IL USA; [Wess, Jurgen] NIH, NIDDK, Lab Bioorgan Chem, Bethesda, MD USA	University of Toronto; Northwestern University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wang, HR (corresponding author), Univ Toronto, Dept Psychol, CTBC, Toronto, ON M5S 1A1, Canada.	haoranw@psych.toronto.edu; yeomans@psych.toronto.edu	Burgdorf, Jeffrey S/G-9552-2012		CIHR; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK031133] Funding Source: NIH RePORTER	CIHR(Canadian Institutes of Health Research (CIHR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	CIHR grants to JY	Adell A, 2004, NEUROSCI BIOBEHAV R, V28, P415, DOI 10.1016/j.neubiorev.2004.05.001; Basile AS, 2002, P NATL ACAD SCI USA, V99, P11452, DOI 10.1073/pnas.162371899; Blanchard DC, 2001, NEUROSCI BIOBEHAV R, V25, P205, DOI 10.1016/S0149-7634(01)00009-4; Brennan PA, 2004, HORM BEHAV, V46, P231, DOI 10.1016/j.yhbeh.2004.01.010; Brudzynski SM, 2007, BEHAV BRAIN RES, V182, P261, DOI 10.1016/j.bbr.2007.03.004; Burgdorf J, 2005, BEHAV GENET, V35, P67, DOI 10.1007/s10519-004-0856-5; BYATT S, 1986, HORM BEHAV, V20, P60, DOI 10.1016/0018-506X(86)90029-2; Ciucci MR, 2007, BEHAV BRAIN RES, V182, P284, DOI 10.1016/j.bbr.2007.02.020; D'Amato FR, 2001, BEHAV NEUROSCI, V115, P834, DOI 10.1037//0735-7044.115.4.834; Dockstader CL, 2001, EUR J NEUROSCI, V13, P995, DOI 10.1046/j.1460-9568.2001.01455.x; Ehret G, 2005, BEHAV GENET, V35, P19, DOI 10.1007/s10519-004-0853-8; EHRET G, 1987, NATURE, V325, P249, DOI 10.1038/325249a0; El-Khodor BF, 2004, INT J DEV NEUROSCI, V22, P405, DOI 10.1016/j.ijdevneu.2004.06.001; Enard W, 2002, NATURE, V418, P869, DOI 10.1038/nature01025; Fallon S, 2007, NEUROCHEM RES, V32, P1772, DOI 10.1007/s11064-007-9343-8; FLYNN DD, 1995, J NEUROCHEM, V64, P1888; Forster GL, 2002, J NEUROSCI, V22, DOI 10.1523/JNEUROSCI.22-01-j0001.2002; Fride E, 2005, BEHAV PHARMACOL, V16, P431, DOI 10.1097/00008877-200509000-00016; Garcia-Alloza M, 2005, NEUROPSYCHOLOGIA, V43, P442, DOI 10.1016/j.neuropsychologia.2004.06.007; Gomeza J, 1999, P NATL ACAD SCI USA, V96, P1692, DOI 10.1073/pnas.96.4.1692; Gomeza J, 1999, P NATL ACAD SCI USA, V96, P10483, DOI 10.1073/pnas.96.18.10483; Guo ZS, 2007, CHEM SENSES, V32, P463, DOI 10.1093/chemse/bjm015; Hahn ME, 2002, BEHAV GENET, V32, P267, DOI 10.1023/A:1019728813891; Hahn ME, 1998, BEHAV GENET, V28, P315, DOI 10.1023/A:1021679615792; Hahn ME, 1997, BEHAV GENET, V27, P133, DOI 10.1023/A:1025637408900; Holy TE, 2005, PLOS BIOL, V3, P2177, DOI 10.1371/journal.pbio.0030386; Hull EM, 2007, HORM BEHAV, V52, P45, DOI 10.1016/j.yhbeh.2007.03.030; Hurst JL, 2001, NATURE, V414, P631, DOI 10.1038/414631a; Ikemoto S, 1997, J NEUROSCI, V17, P8580; Jarskog LF, 2007, ANNU REV MED, V58, P49, DOI 10.1146/annurev.med.58.060904.084114; Kelly MA, 1997, NEURON, V19, P103, DOI 10.1016/S0896-6273(00)80351-7; Kimoto H, 2005, NATURE, V437, P898, DOI 10.1038/nature04033; Knutson B, 2002, PSYCHOL BULL, V128, P961, DOI 10.1037//0033-2909.128.6.961; Ko SW, 2005, MOL PAIN, V1, DOI 10.1186/1744-8069-1-10; Maldonado R, 1997, NATURE, V388, P586, DOI 10.1038/41567; MCINTOSH TK, 1978, NATURE, V272, P163, DOI 10.1038/272163a0; Miller AD, 2005, NEUROSCIENCE, V136, P531, DOI 10.1016/j.neuroscience.2005.08.035; Moles A, 2004, SCIENCE, V304, P1983, DOI 10.1126/science.1095943; Moles A, 2000, ANIM BEHAV, V60, P689, DOI 10.1006/anbe.2000.1504; Moles A, 2007, BEHAV BRAIN RES, V182, P223, DOI 10.1016/j.bbr.2007.01.020; Niva Y, 2007, ANN NY ACAD SCI, V1104, P357, DOI 10.1196/annals.1390.018; Panksepp JB, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000351; Petrulis A, 2005, NEUROSCIENCE, V130, P259, DOI 10.1016/j.neuroscience.2004.09.001; Picker JD, 2006, NEUROREPORT, V17, P541, DOI 10.1097/01.wnr.0000208995.38695.2f; POMERANTZ SM, 1983, PHYSIOL BEHAV, V31, P91, DOI 10.1016/0031-9384(83)90101-4; Portfors CV, 2007, J AM ASSOC LAB ANIM, V46, P28; Raedler TJ, 2007, MOL PSYCHIATR, V12, P232, DOI 10.1038/sj.mp.4001924; ROBERTS LH, 1975, ULTRASONICS, V13, P83, DOI 10.1016/0041-624X(75)90052-9; Roubertoux PL, 1996, BEHAV GENET, V26, P427, DOI 10.1007/BF02359487; SALES GD, 1972, ANIM BEHAV, V20, P88, DOI 10.1016/S0003-3472(72)80177-5; Sanjuan J, 2006, PSYCHIAT GENET, V16, P67, DOI 10.1097/01.ypg.0000185029.35558.bb; SCATTONI ML, 2007, BEHAV BRAIN RES; Schehka S, 2007, J COMP PHYSIOL A, V193, P845, DOI 10.1007/s00359-007-0236-8; Shu WG, 2005, P NATL ACAD SCI USA, V102, P9643, DOI 10.1073/pnas.0503739102; SIPOS ML, 1995, PHYSIOL BEHAV, V58, P529, DOI 10.1016/0031-9384(95)00089-2; SIPOS ML, 1992, BEHAV NEURAL BIOL, V58, P138, DOI 10.1016/0163-1047(92)90375-E; Takeuchi J, 2002, PHARMACOL BIOCHEM BE, V72, P117, DOI 10.1016/S0091-3057(01)00725-0; Thompson RN, 2007, J EXP BIOL, V210, P1406, DOI 10.1242/jeb.02753; Thornton LM, 2005, BEHAV GENET, V35, P73, DOI 10.1007/s10519-004-0857-4; Tzavaral ET, 2003, MOL PSYCHIATR, V8, P673, DOI 10.1038/sj.mp.4001270; VILARO MT, 1990, NEUROSCI LETT, V114, P154, DOI 10.1016/0304-3940(90)90064-G; Wang HR, 2007, GENOMICS, V89, P59, DOI 10.1016/j.ygeno.2006.07.009; Wang HR, 2004, NEUROPSYCHOPHARMACOL, V29, P2126, DOI 10.1038/sj.npp.1300502; Wess J, 2003, RECEPTOR CHANNEL, V9, P279, DOI 10.3109/10606820308262; White NR, 1998, PHYSIOL BEHAV, V63, P467, DOI 10.1016/S0031-9384(97)00484-8; Winslow JT, 2000, HORM BEHAV, V37, P145, DOI 10.1006/hbeh.1999.1566; Wintink AJ, 2001, PHARMACOL BIOCHEM BE, V70, P317, DOI 10.1016/S0091-3057(01)00615-3; Wohr M, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0001365; Yeomans J, 2001, LIFE SCI, V68, P2449, DOI 10.1016/S0024-3205(01)01038-4; Yeomans JS, 2000, J NEUROSCI, V20, P8861; Zeesman S, 2006, AM J MED GENET A, V140A, P509, DOI 10.1002/ajmg.a.31110; Zhang WL, 2002, J NEUROSCI, V22, P6347; ZIPPELIUS HM, 1956, NATURWISSENSCHAFTEN, V43, P501	73	94	96	0	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1893	10.1371/journal.pone.0001893	http://dx.doi.org/10.1371/journal.pone.0001893			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382674	gold, Green Submitted, Green Published			2022-12-25	WOS:000260795400025
J	Wee, KB; Pramono, ZAD; Wang, JL; MacDorman, KF; Lai, PS; Yee, WC				Wee, Keng Boon; Pramono, Zacharias Aloysius Dwi; Wang, Jian Li; MacDorman, Karl F.; Lai, Poh San; Yee, Woon Chee			Dynamics of Co-Transcriptional Pre-mRNA Folding Influences the Induction of Dystrophin Exon Skipping by Antisense Oligonucleotides	PLOS ONE			English	Article							DUCHENNE MUSCULAR-DYSTROPHY; SECONDARY STRUCTURE; SPLICING ENHANCERS; NONSENSE MUTATION; SYSTEMIC DELIVERY; GENE-EXPRESSION; IN-VITRO; RESTORATION; PREDICTION; DIAGNOSIS	Antisense oligonucleotides (AONs) mediated exon skipping offers potential therapy for Duchenne muscular dystrophy. However, the identification of effective AON target sites remains unsatisfactory for lack of a precise method to predict their binding accessibility. This study demonstrates the importance of co-transcriptional pre-mRNA folding in determining the accessibility of AON target sites for AON induction of selective exon skipping in DMD. Because transcription and splicing occur in tandem, AONs must bind to their target sites before splicing factors. Furthermore, co-transcriptional pre-mRNA folding forms transient secondary structures, which redistributes accessible binding sites. In our analysis, to approximate transcription elongation, a "window of analysis'' that included the entire targeted exon was shifted one nucleotide at a time along the pre-mRNA. Possible co-transcriptional secondary structures were predicted using the sequence in each step of transcriptional analysis. A nucleotide was considered "engaged'' if it formed a complementary base pairing in all predicted secondary structures of a particular step. Correlation of frequency and localisation of engaged nucleotides in AON target sites accounted for the performance (efficacy and efficiency) of 94% of 176 previously reported AONs. Four novel insights are inferred: (1) the lowest frequencies of engaged nucleotides are associated with the most efficient AONs; (2) engaged nucleotides at 39 or 59 ends of the target site attenuate AON performance more than at other sites; (3) the performance of longer AONs is less attenuated by engaged nucleotides at 39 or 59 ends of the target site compared to shorter AONs; (4) engaged nucleotides at 39 end of a short target site attenuates AON efficiency more than at 59 end.	[Wee, Keng Boon] Bioinformat Inst, Singapore, Singapore; [Pramono, Zacharias Aloysius Dwi; Wang, Jian Li; Yee, Woon Chee] Natl Neurosci Inst, Neuromuscul Res Lab, Singapore, Singapore; [Yee, Woon Chee] Natl Neurosci Inst, Dept Neurol, Singapore, Singapore; [MacDorman, Karl F.] Indiana Univ, Sch Informat, Indianapolis, IN USA; [Lai, Poh San] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Paediat, Singapore, Singapore; [Wee, Keng Boon] Natl Univ Singapore, Ctr Life Sci, Grad Sch Integrat Sci & Engn, Singapore, Singapore	Agency for Science Technology & Research (A*STAR); A*STAR - Bioinformatics Institute (BII); National Neuroscience Institute (NNI); National Neuroscience Institute (NNI); Indiana University System; Indiana University-Purdue University Indianapolis; National University of Singapore; National University of Singapore	Wee, KB (corresponding author), Bioinformat Inst, Singapore, Singapore.	dwi_pramono@nni.com.sg	MacDorman, Karl/AAH-4483-2020; wang, jian/GVS-0711-2022	MacDorman, Karl/0000-0003-1093-4184; 	National Medical Research Council of Singapore [NMRC/0938/2005]; SingHealth [NHGA-STP/04022]; A*STAR Graduate Scholarship	National Medical Research Council of Singapore(National Medical Research Council, Singapore); SingHealth(SingHealth); A*STAR Graduate Scholarship(Agency for Science Technology & Research (A*STAR))	Grants from the National Medical Research Council of Singapore (NMRC/0938/2005) and SingHealth (NHGA-STP/04022) supported this study. K.B. Wee is a recipient of an A*STAR Graduate Scholarship. There is no financial interest in this manuscript from any of the above funding organizations.	Aartsma-Rus A, 2002, NEUROMUSCULAR DISORD, V12, pS71, DOI 10.1016/S0960-8966(02)00086-X; Aartsma-Rus A, 2005, OLIGONUCLEOTIDES, V15, P284, DOI 10.1089/oli.2005.15.284; Aartsma-Rus A, 2004, AM J HUM GENET, V74, P83, DOI 10.1086/381039; Aartsma-Rus A, 2006, MOL THER, V14, P401, DOI 10.1016/j.ymthe.2006.02.022; ALBERTS B, 2002, MOL BIOL CELL, P317; Alter J, 2006, NAT MED, V12, P175, DOI 10.1038/nm1345; Bentley D, 2002, CURR OPIN CELL BIOL, V14, P336, DOI 10.1016/S0955-0674(02)00333-2; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; Blencowe BJ, 2000, TRENDS BIOCHEM SCI, V25, P106, DOI 10.1016/S0968-0004(00)01549-8; BOYLE J, 1980, J MOL BIOL, V139, P601, DOI 10.1016/0022-2836(80)90051-0; Cartegni L, 2002, NAT REV GENET, V3, P285, DOI 10.1038/nrg775; Cartegni L, 2003, NUCLEIC ACIDS RES, V31, P3568, DOI 10.1093/nar/gkg616; Chalk AM, 2002, BIOINFORMATICS, V18, P1567, DOI 10.1093/bioinformatics/18.12.1567; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Ding Y, 2003, NUCLEIC ACIDS RES, V31, P7280, DOI 10.1093/nar/gkg938; DOMINSKI Z, 1993, P NATL ACAD SCI USA, V90, P8673, DOI 10.1073/pnas.90.18.8673; EPERON LP, 1988, CELL, V54, P393, DOI 10.1016/0092-8674(88)90202-4; Errington SJ, 2003, J GENE MED, V5, P518, DOI 10.1002/jgm.361; Fairbrother WG, 2002, SCIENCE, V297, P1007, DOI 10.1126/science.1073774; Fall Abbie M, 2006, Genet Vaccines Ther, V4, P3, DOI 10.1186/1479-0556-4-3; Far RKK, 2003, NUCLEIC ACIDS RES, V31, P4417, DOI 10.1093/nar/gkg649; Flamm C, 2000, RNA, V6, P325, DOI 10.1017/S1355838200992161; Goldstrohm AC, 2001, GENE, V277, P31, DOI 10.1016/S0378-1119(01)00695-3; Gorman L, 2000, J BIOL CHEM, V275, P35914, DOI 10.1074/jbc.M006259200; Graveley BR, 1999, CURR BIOL, V9, pR6, DOI 10.1016/S0960-9822(99)80032-3; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Harding PL, 2007, MOL THER, V15, P157, DOI 10.1038/sj.mt.6300006; Harlepp S, 2003, EUR PHYS J E, V12, P605, DOI 10.1140/epje/e2004-00033-4; Knudsen B, 2003, NUCLEIC ACIDS RES, V31, P3423, DOI 10.1093/nar/gkg614; KRAMER FR, 1981, NUCLEIC ACIDS RES, V9, P5109, DOI 10.1093/nar/9.19.5109; Lam BJ, 2002, RNA, V8, P1233, DOI 10.1017/S1355838202028030; Lehmann MJ, 2000, NUCLEIC ACIDS RES, V28, P2597, DOI 10.1093/nar/28.13.2597; Lu QL, 2005, P NATL ACAD SCI USA, V102, P198, DOI 10.1073/pnas.0406700102; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Mann CJ, 2001, P NATL ACAD SCI USA, V98, P42, DOI 10.1073/pnas.011408598; Mathews DH, 1999, J MOL BIOL, V288, P911, DOI 10.1006/jmbi.1999.2700; Matsuo M, 1996, BRAIN DEV-JPN, V18, P167, DOI 10.1016/0387-7604(96)00007-1; Matsuo M, 2005, Acta Myol, V24, P110; Matsuo M, 2002, IUBMB LIFE, V53, P147, DOI 10.1080/15216540212333; McClorey G, 2006, NEUROMUSCULAR DISORD, V16, P583, DOI 10.1016/j.nmd.2006.05.017; McClorey G, 2006, GENE THER, V13, P1373, DOI 10.1038/sj.gt.3302800; Mercatante DR, 2001, CURR CANCER DRUG TAR, V1, P211, DOI 10.2174/1568009013334124; Meyer IM, 2004, BMC MOL BIOL, V5, DOI 10.1186/1471-2199-5-10; Muntoni Francesco, 2005, Neuromuscul Disord, V15, P450, DOI 10.1016/j.nmd.2005.02.007; Neugebauer KM, 2002, J CELL SCI, V115, P3865, DOI 10.1242/jcs.00073; Nowakowski J., 1999, OXFORD HDB NUCL ACID, P567; OSHEIM YN, 1985, CELL, V43, P143, DOI 10.1016/0092-8674(85)90019-4; Pramono ZAD, 1996, BIOCHEM BIOPH RES CO, V226, P445, DOI 10.1006/bbrc.1996.1375; Proudfoot NJ, 2002, CELL, V108, P501, DOI 10.1016/S0092-8674(02)00617-7; *R DEV COR TEAM, 2004, R LANG ENV STAT COMP; Repsilber D, 1999, RNA, V5, P574, DOI 10.1017/S1355838299982018; Sazani P, 2003, J CLIN INVEST, V112, P481, DOI 10.1172/JCI200319547; Sczakiel G, 2000, FRONT BIOSCI, V5, pD194, DOI 10.2741/Sczakiel; Staley JP, 1998, CELL, V92, P315, DOI 10.1016/S0092-8674(00)80925-3; Surono A, 2004, HUM GENE THER, V15, P749, DOI 10.1089/1043034041648444; Suwanmanee T, 2002, MOL THER, V6, P718, DOI 10.1006/mthe.2002.0805; Takeshima Y, 2006, PEDIATR RES, V59, P690, DOI 10.1203/01.pdr.0000215047.51278.7c; TENNYSON CN, 1995, NAT GENET, V9, P184, DOI 10.1038/ng0295-184; van Deutekom JCT, 2003, NAT REV GENET, V4, P774, DOI 10.1038/nrg1180; van Deutekom JCT, 2001, HUM MOL GENET, V10, P1547, DOI 10.1093/hmg/10.15.1547; Vetrini F, 2006, HUM MUTAT, V27, P420, DOI 10.1002/humu.20303; Vickers TA, 2000, NUCLEIC ACIDS RES, V28, P1340, DOI 10.1093/nar/28.6.1340; Wang JH, 2005, NUCLEIC ACIDS RES, V33, P5053, DOI 10.1093/nar/gki810; Wells DJ, 2006, J MUSCLE RES CELL M, V27, P387, DOI 10.1007/s10974-006-9081-6; Wilton SD, 2005, CURR GENE THER, V5, P467, DOI 10.2174/156652305774329249; Wilton SD, 2005, NEUROMUSCULAR DISORD, V15, P399, DOI 10.1016/j.nmd.2005.03.003; Wilton SD, 1999, NEUROMUSCULAR DISORD, V9, P330, DOI 10.1016/S0960-8966(99)00010-3; Wilton SD, 2007, MOL THER, V15, P1288, DOI 10.1038/sj.mt.6300095; WUARIN J, 1994, MOL CELL BIOL, V14, P7219, DOI 10.1128/MCB.14.11.7219; Zuker M, 2003, NUCLEIC ACIDS RES, V31, P3406, DOI 10.1093/nar/gkg595	70	33	34	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1844	10.1371/journal.pone.0001844	http://dx.doi.org/10.1371/journal.pone.0001844			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365002	Green Published, Green Submitted, gold			2022-12-25	WOS:000260762400008
J	Han, J; Hou, W; Goldstein, LA; Lu, CS; Stolz, DB; Yin, XM; Rabinowich, H				Han, Jie; Hou, Wen; Goldstein, Leslie A.; Lu, Caisheng; Stolz, Donna B.; Yin, Xiao-Ming; Rabinowich, Hannah			Involvement of protective autophagy in TRAIL resistance of apoptosis-defective tumor cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEDIATED MITOCHONDRIAL APOPTOSIS; DEATH RECEPTORS; SUPPRESSOR FUNCTION; ARP2/3 COMPLEX; CANCER-CELLS; GRANZYME-B; BAX; INHIBITION; CORTACTIN; CASPASE-8	Targeting TRAIL receptors with either recombinant TRAIL or agonistic DR4-or DR5-specific antibodies has been considered a promising treatment for cancer, particularly due to the preferential apoptotic susceptibility of tumor cells over normal cells to TRAIL. However, the realization that many tumors are unresponsive to TRAIL treatment has stimulated interest in identifying apoptotic agents that when used in combination with TRAIL can sensitize tumor cells to TRAIL-mediated apoptosis. Our studies suggest that various apoptosis defects that block TRAIL-mediated cell death at different points along the apoptotic signaling pathway shift the signaling cascade from default apoptosis toward cytoprotective autophagy. We also obtained evidence that inhibition of such a TRAIL-mediated autophagic response by specific knockdown of autophagic genes initiates an effective mitochondrial apoptotic response that is caspase-8-dependent. Currently, the molecular mechanisms linking disabled autophagy to mitochondrial apoptosis are not known. Our analysis of the molecular mechanisms involved in the shift from protective autophagy to apoptosis in response to TRAIL sheds new light on the negative regulation of apoptosis by the autophagic process and by some of its individual components.	[Rabinowich, Hannah] Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Pittsburgh, PA 15213 USA; [Han, Jie; Hou, Wen; Goldstein, Leslie A.; Lu, Caisheng; Yin, Xiao-Ming; Rabinowich, Hannah] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15213 USA; [Stolz, Donna B.] Univ Pittsburgh, Sch Med, Dept Cell Biol & Physiol, Pittsburgh, PA 15213 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Rabinowich, H (corresponding author), Univ Pittsburgh, Inst Canc, Hillman Canc Ctr, Res Pavil Rm G17C,5117 Ctr Ave, Pittsburgh, PA 15213 USA.	rabinow@pitt.edu			NATIONAL CANCER INSTITUTE [R01CA111786, R01CA109285] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA109285, R01 CA111786] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abdel-Rahman WM, 1999, ONCOGENE, V18, P2139, DOI 10.1038/sj.onc.1202589; Almasan A, 2003, CYTOKINE GROWTH F R, V14, P337, DOI 10.1016/S1359-6101(03)00029-7; Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833; Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Boya P, 2005, MOL CELL BIOL, V25, P1025, DOI 10.1128/MCB.25.3.1025-1040.2005; Brimmell M, 1998, ONCOGENE, V16, P1803, DOI 10.1038/sj.onc.1201704; Carew JS, 2007, BLOOD, V110, P313, DOI 10.1182/blood-2006-10-050260; Cheng JR, 2006, MOL CANCER THER, V5, P1844, DOI 10.1158/1535-7163.MCT-06-0050; Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001; Deng YB, 2002, GENE DEV, V16, P33, DOI 10.1101/gad.949602; French LE, 1999, NAT MED, V5, P146, DOI 10.1038/5505; Furuya N, 2005, AUTOPHAGY, V1, P46, DOI 10.4161/auto.1.1.1542; Goley ED, 2006, NAT REV MOL CELL BIO, V7, P713, DOI 10.1038/nrm2026; Gonzalez-Polo RA, 2005, J CELL SCI, V118, P3091, DOI 10.1242/jcs.02447; Han J, 2006, J BIOL CHEM, V281, P10153, DOI 10.1074/jbc.M510349200; Han J, 2005, J BIOL CHEM, V280, P16383, DOI 10.1074/jbc.M411377200; Han J, 2004, J BIOL CHEM, V279, P22020, DOI 10.1074/jbc.M313234200; Han J, 2007, J BIOL CHEM, V282, P16223, DOI 10.1074/jbc.M611186200; Huang Y, 2007, TOXICOL APPL PHARM, V224, P284, DOI 10.1016/j.taap.2006.12.007; Kataoka T, 1998, J IMMUNOL, V161, P3936; Kischkel FC, 2000, IMMUNITY, V12, P611, DOI 10.1016/S1074-7613(00)80212-5; Klionsky DJ, 2008, AUTOPHAGY, V4, P151, DOI 10.4161/auto.5338; Kondo Y, 2005, NAT REV CANCER, V5, P726, DOI 10.1038/nrc1692; LeBlanc H, 2002, NAT MED, V8, P274, DOI 10.1038/nm0302-274; Levine B, 2005, J CLIN INVEST, V115, P2679, DOI 10.1172/JCI26390; Levine B, 2007, NATURE, V446, P745, DOI 10.1038/446745a; Liang XH, 2001, CANCER RES, V61, P3443; Lum JJ, 2005, CELL, V120, P237, DOI 10.1016/j.cell.2004.11.046; Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239; Maiuri MC, 2007, EMBO J, V26, P2527, DOI 10.1038/sj.emboj.7601689; Mills KR, 2004, P NATL ACAD SCI USA, V101, P3438, DOI 10.1073/pnas.0400443101; Mizushima N, 2007, AUTOPHAGY, V3, P542, DOI 10.4161/auto.4600; Monastyrska I, 2008, MOL BIOL CELL, V19, P1962, DOI 10.1091/mbc.E07-09-0892; Park KJ, 2007, CANCER RES, V67, P7327, DOI 10.1158/0008-5472.CAN-06-4766; Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992; Ravi R, 2002, CANCER RES, V62, P1583; Ricci MS, 2007, CANCER CELL, V12, P66, DOI 10.1016/j.ccr.2007.05.006; Rothsschild BL, 2006, CANCER RES, V66, P8017, DOI 10.1158/0008-5472.CAN-05-4490; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Sprick MR, 2000, IMMUNITY, V12, P599, DOI 10.1016/S1074-7613(00)80211-3; Tanida I, 2005, AUTOPHAGY, V1, P84, DOI 10.4161/auto.1.2.1697; Weed SA, 2001, ONCOGENE, V20, P6418, DOI 10.1038/sj.onc.1204783; Weed SA, 2000, J CELL BIOL, V151, P29, DOI 10.1083/jcb.151.1.29; Yu L, 2004, SCIENCE, V304, P1500, DOI 10.1126/science.1096645; Zhang LD, 2005, CANCER GENE THER, V12, P228, DOI 10.1038/sj.cgt.7700792	45	161	175	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19665	19677		10.1074/jbc.M710169200	http://dx.doi.org/10.1074/jbc.M710169200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18375389	hybrid, Green Published			2022-12-25	WOS:000257387600052
J	Tan, JAT; Sun, YJ; Song, J; Chen, Y; Krontiris, TG; Durrin, LK				Tan, Joseph-Anthony T.; Sun, Yujie; Song, Jing; Chen, Yuan; Krontiris, Theodore G.; Durrin, Linda K.			SUMO conjugation to the matrix attachment region-binding protein, special AT-rich sequence-binding protein-1 (SATB1), targets SATB1 to promyelocytic nuclear bodies where it undergoes caspase cleavage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; IN-VIVO; GENE-EXPRESSION; YEAST SEPTINS/; PORE COMPLEX; CELL-CYCLE; T-CELLS; PML; APOPTOSIS; LOCALIZATION	SATB1 (special AT-rich sequence-binding protein-1) provides a key link between DNA loop organization, chromatin modification/remodeling, and association of transcription factors at matrix attachment regions (MARs). To investigate the role of SATB1 in cellular events, we performed a yeast two-hybrid screen that identified SUMO-1, Ubc9, and protein inhibitor of activated STAT (PIAS) family members as SATB1 interaction partners. These proteins, working in concert, enhanced SUMO conjugation to lysine-744 of SATB1. Overexpression of SUMO or PIAS in Jurkat cells, which express high levels of endogenous SATB1, exhibited enhanced caspase cleavage of this MAR-associating protein. Sumoylation-deficientSATB1(SATB1(K744R)) failed to display the characteristic caspase cleavage pattern; however, fusion of SUMO in-frame to SATB1(K744R) restored cleavage. A SUMO-independent interaction of inactive caspase-6 and SATB1 was noted. A subset of total cellular SATB1 localized into promyelocytic leukemia nuclear bodies where enhanced SATB1 cleavage was detected subsequent to caspase activation. These results reveal a novel sumoylation-directed caspase cleavage of this key regulatory molecule. The role of regulated proteolysis of SATB1 may be to control transcription in immune cells during normal cell functions or to assist in efficient and rapid clearance of nonfunctional or potentially damaging immune cells.	[Tan, Joseph-Anthony T.; Sun, Yujie; Krontiris, Theodore G.; Durrin, Linda K.] City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Med, Duarte, CA 91010 USA; [Song, Jing; Chen, Yuan] City Hope Natl Med Ctr, Beckman Res Inst, Div Immunol, Duarte, CA 91010 USA; [Song, Jing] City Hope Natl Med Ctr, Beckman Res Inst, Grad Sch Biol Sci, Duarte, CA 91010 USA	City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope; City of Hope; Beckman Research Institute of City of Hope	Durrin, LK (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Med, 1500 E Duarte Rd, Duarte, CA 91010 USA.	ldurrin@coh.org			NATIONAL CANCER INSTITUTE [K01CA097283, R01CA051985, R01CA094595] Funding Source: NIH RePORTER; NCI NIH HHS [CA 94595, CA 51985, K01 CA 097283-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alarcon-Vargas D, 2002, CANCER BIOL THER, V1, P237, DOI 10.4161/cbt.74; Alcalay M, 1998, MOL CELL BIOL, V18, P1084, DOI 10.1128/MCB.18.2.1084; Alvarez JD, 2000, GENE DEV, V14, P521; Baliga BC, 2003, J BIOL CHEM, V278, P4899, DOI 10.1074/jbc.M211512200; Bernardi R, 2003, ONCOGENE, V22, P9048, DOI 10.1038/sj.onc.1207106; Bernardi R, 2007, NAT REV MOL CELL BIO, V8, P1006, DOI 10.1038/nrm2277; Besnault-Mascard L, 2005, ONCOGENE, V24, P3268, DOI 10.1038/sj.onc.1208448; Bischof O, 2006, MOL CELL, V22, P783, DOI 10.1016/j.molcel.2006.05.016; Bossis G, 2006, CELL DIV, V1, DOI 10.1186/1747-1028-1-13; Cai ST, 2006, NAT GENET, V38, P1278, DOI 10.1038/ng1913; Cai ST, 2003, NAT GENET, V34, P42, DOI 10.1038/ng1146; Cao TY, 1998, J CELL SCI, V111, P1319; Cathelin S, 2006, J BIOL CHEM, V281, P17779, DOI 10.1074/jbc.M600537200; CORMACK B, 1999, CURRENT PROTOCOLS MO, V4, P1; de Belle I, 1998, J CELL BIOL, V141, P335, DOI 10.1083/jcb.141.2.335; de Botton S, 2002, BLOOD, V100, P1310, DOI 10.1182/blood-2002-03-0686; Desterro JMP, 1998, MOL CELL, V2, P233, DOI 10.1016/S1097-2765(00)80133-1; Desterro JMP, 1997, FEBS LETT, V417, P297, DOI 10.1016/S0014-5793(97)01305-7; DICKINSON LA, 1992, CELL, V70, P631, DOI 10.1016/0092-8674(92)90432-C; Dobreva G, 2003, GENE DEV, V17, P3048, DOI 10.1101/gad.1153003; Duprez E, 1999, J CELL SCI, V112, P381; Everett RD, 1999, J CELL SCI, V112, P3443; Everett RD, 1999, J CELL SCI, V112, P4581; Fischer U, 2003, CELL DEATH DIFFER, V10, P76, DOI 10.1038/sj.cdd.4401160; Galande S, 2001, MOL CELL BIOL, V21, P5591, DOI 10.1128/MCB.21.16.5591-5604.2001; Gocke CB, 2005, J BIOL CHEM, V280, P5004, DOI 10.1074/jbc.M411718200; Gohring F, 1997, EMBO J, V16, P7361, DOI 10.1093/emboj/16.24.7361; Gotzmann J, 2000, CELL DEATH DIFFER, V7, P425, DOI 10.1038/sj.cdd.4400668; Hay RT, 2005, MOL CELL, V18, P1, DOI 10.1016/j.molcel.2005.03.012; Hayashi N, 2006, NEUROSCI LETT, V397, P5, DOI 10.1016/j.neulet.2005.11.057; Hofmann TG, 2003, CELL DEATH DIFFER, V10, P1290, DOI 10.1038/sj.cdd.4401313; HU ZB, 1993, LEUKEMIA, V7, P1817; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; Ishov AM, 1999, J CELL BIOL, V147, P221, DOI 10.1083/jcb.147.2.221; Johnson ES, 2004, ANNU REV BIOCHEM, V73, P355, DOI 10.1146/annurev.biochem.73.011303.074118; Johnson ES, 2001, CELL, V106, P735, DOI 10.1016/S0092-8674(01)00491-3; Kagey MH, 2003, CELL, V113, P127, DOI 10.1016/S0092-8674(03)00159-4; Kahyo T, 2001, MOL CELL, V8, P713, DOI 10.1016/S1097-2765(01)00349-5; KAUFMANN SH, 1993, CANCER RES, V53, P3976; Kumar P, 2007, NAT CELL BIOL, V9, P45, DOI 10.1038/ncb1516; Lamkanfi M, 2007, CELL DEATH DIFFER, V14, P44, DOI 10.1038/sj.cdd.4402047; Mahajan R, 1997, CELL, V88, P97, DOI 10.1016/S0092-8674(00)81862-0; Mahajan R, 1998, J CELL BIOL, V140, P259, DOI 10.1083/jcb.140.2.259; Matunis MJ, 1996, J CELL BIOL, V135, P1457, DOI 10.1083/jcb.135.6.1457; Melchior F, 2003, TRENDS BIOCHEM SCI, V28, P612, DOI 10.1016/j.tibs.2003.09.002; Minty A, 2000, J BIOL CHEM, V275, P36316, DOI 10.1074/jbc.M004293200; NERVI C, 1992, CANCER RES, V52, P3687; Olson NE, 2003, J IMMUNOL, V170, P6065, DOI 10.4049/jimmunol.170.12.6065; Pavan KP, 2006, MOL CELL, V22, P231, DOI 10.1016/j.molcel.2006.03.010; Rebe C, 2007, BLOOD, V109, P1442, DOI 10.1182/blood-2006-03-011585; Rodriguez MS, 1999, EMBO J, V18, P6455, DOI 10.1093/emboj/18.22.6455; Rodriguez MS, 2001, J BIOL CHEM, V276, P12654, DOI 10.1074/jbc.M009476200; Sabbagh L, 2004, J IMMUNOL, V173, P5425, DOI 10.4049/jimmunol.173.9.5425; Saitoh H, 2000, J BIOL CHEM, V275, P6252, DOI 10.1074/jbc.275.9.6252; Seo J, 2005, J BIOL CHEM, V280, P24600, DOI 10.1074/jbc.M414076200; Shannon MF, 2003, NAT GENET, V34, P4, DOI 10.1038/ng0503-4; Siegel RM, 2006, NAT REV IMMUNOL, V6, P308, DOI 10.1038/nri1809; Song J, 2004, P NATL ACAD SCI USA, V101, P14373, DOI 10.1073/pnas.0403498101; Sordet O, 2002, BLOOD, V100, P4446, DOI 10.1182/blood-2002-06-1778; Sun YJ, 2006, CELL BIOL INT, V30, P244, DOI 10.1016/j.cellbi.2005.10.025; Takahashi Y, 2001, GENE, V275, P223, DOI 10.1016/S0378-1119(01)00662-X; Takahashi Y, 2004, ONCOGENE, V23, P2819, DOI 10.1038/sj.onc.1207533; Tang J, 2005, CANCER BIOL THER, V4, P645, DOI 10.4161/cbt.4.6.1729; Tatham MH, 2001, J BIOL CHEM, V276, P35368, DOI 10.1074/jbc.M104214200; Weger S, 2005, FEBS LETT, V579, P5007, DOI 10.1016/j.febslet.2005.07.088; Yasui D, 2002, NATURE, V419, P641, DOI 10.1038/nature01084; Zimber A, 2004, CELL SIGNAL, V16, P1085, DOI 10.1016/j.cellsig.2004.03.020; Zong RT, 2000, EMBO J, V19, P4123, DOI 10.1093/emboj/19.15.4123	68	37	41	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18124	18134		10.1074/jbc.M800512200	http://dx.doi.org/10.1074/jbc.M800512200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18408014	Green Published, hybrid			2022-12-25	WOS:000256949200041
J	Levitin, F; Weiss, M; Hahn, Y; Stern, O; Papke, RL; Matusik, R; Nandana, SR; Ziv, R; Pichinuk, E; Salame, S; Bera, T; Vincent, J; Lee, B; Pastan, I; Wreschner, DH				Levitin, Fiana; Weiss, Mordechai; Hahn, Yoonsoo; Stern, Omer; Papke, Roger L.; Matusik, Robert; Nandana, Srinivas R.; Ziv, Ravit; Pichinuk, Edward; Salame, Sharbel; Bera, Tapan; Vincent, James; Lee, Byungkook; Pastan, Ira; Wreschner, Daniel H.			PATE gene clusters code for multiple, secreted TFP/Ly-6/uPAR proteins that are expressed in reproductive and neuron-rich tissues and possess neuromodulatory activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTOR; VENOM ALPHA-NEUROTOXINS; ACROSOME REACTION; HUMAN SPERM; PLASMINOGEN-ACTIVATOR; SEQUENCE ALIGNMENT; SEMINAL-VESICLE; HUMAN SP-10; SNAKE; TOXINS	We report here syntenic loci in humans and mice incorporating gene clusters coding for secreted proteins each comprising 10 cysteine residues. These conform to three-fingered protein/Ly-6/urokinase-type plasminogen activator receptor (uPAR) domains that shape three-fingered proteins (TFPs). The founding gene is PATE, expressed primarily in prostate and less in testis. We have identified additional human PATE-like genes (PATE-M, PATE-DJ, and PATE-B) that co-localize with the PATE locus, code for novel secreted PATE-like proteins, and show selective expression in prostate and/ or testis. Anti-PATE-B-specific antibodies demonstrated the presence of PATE-B in the region of the sperm acrosome and at high levels on malignant prostatic epithelial cells. The syntenic mouse Pate-like locus encompasses 14 active genes coding for secreted proteins, which are all, except for Pate-P and Pate-Q, expressed primarily in prostate and/ or testis. Pate-P and Pate-Q are expressed solely in placental tissue. Castration up-regulates prostate expression of mouse Pate-Band Pate-E, whereas testosterone ablates this induced expression. The sequence similarity between TFP/Ly-6/uPAR proteins that modulate activity of nicotinic acetylcholine receptors and the PATE (Pate)-like proteins stimulated us to see whether these proteins possess analogous activity. Pharmacological studies showed significant modulation of the nicotinic acetylcholines by the PATE-B, Pate-C, and Pate-P proteins. In concert with these findings, certain PATE (Pate)-like genes were extensively expressed in neuron-rich tissues. Taken together, our findings indicate that in addition to participation of the PATE (Pate)-like genes in functions related to fertility and reproduction, some of them likely act as important modulators of neural transmission.	[Levitin, Fiana; Stern, Omer; Ziv, Ravit; Pichinuk, Edward; Salame, Sharbel; Wreschner, Daniel H.] Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Ramat Aviv, Israel; [Weiss, Mordechai] Assaf Harofeh Med Ctr, Dept Endocrinol, IL-70300 Zerifin, Israel; [Papke, Roger L.] Univ Florida, Dept Pharmacol & Therapeut, Gainesville, FL 32610 USA; [Hahn, Yoonsoo; Bera, Tapan; Vincent, James; Lee, Byungkook; Pastan, Ira; Wreschner, Daniel H.] NCI, NIH, Bethesda, MD 20892 USA; [Matusik, Robert; Nandana, Srinivas R.] Vanderbilt Univ, Med Ctr, Nashville, TN 37232 USA; [Wreschner, Daniel H.] Geneswitch Technol LLC, Waban, MA 02468 USA	Tel Aviv University; Shamir Medical Center (Assaf Harofeh); Tel Aviv University; State University System of Florida; University of Florida; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Vanderbilt University	Wreschner, DH (corresponding author), Tel Aviv Univ, Dept Cell Res & Immunol, IL-69978 Ramat Aviv, Israel.	danielhw@post.tau.ac.il	pastan, ira/P-9319-2019	pastan, ira/0000-0002-9223-0270; Pichinuk, Eddy/0000-0001-8488-8710; Matusik, Robert/0000-0003-2057-9892; Wreschner, Daniel/0000-0003-2102-2164; HAHN, YOONSOO/0000-0003-4273-9842	NATIONAL CANCER INSTITUTE [Z01BC010298] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057481] Funding Source: NIH RePORTER; Intramural NIH HHS [Z01 BC010298-10] Funding Source: Medline; NIGMS NIH HHS [R01 GM057481] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adermann K, 1999, PROTEIN SCI, V8, P810, DOI 10.1110/ps.8.4.810; Arredondo J, 2006, J CELL PHYSIOL, V208, P238, DOI 10.1002/jcp.20661; Bera TK, 2002, P NATL ACAD SCI USA, V99, P3058, DOI 10.1073/pnas.052713699; Bray C, 2005, MOL HUM REPROD, V11, P881, DOI 10.1093/molehr/gah245; Bray C, 2005, BIOL REPROD, V73, P807, DOI 10.1095/biolreprod.105.042184; Bray C, 2002, BIOL REPROD, V67, P782, DOI 10.1095/biolreprod.102.004580; Chimienti F, 2003, HUM MOL GENET, V12, P3017, DOI 10.1093/hmg/ddg320; CORONEL CE, 1992, J BIOL CHEM, V267, P20909; FOSTER JA, 1994, BIOL REPROD, V51, P1222, DOI 10.1095/biolreprod51.6.1222; FREEMERMAN AJ, 1995, MOL REPROD DEV, V41, P100, DOI 10.1002/mrd.1080410115; Fry BG, 2003, J MOL EVOL, V57, P110, DOI 10.1007/s00239-003-2461-2; HERR JC, 1990, BIOL REPROD, V42, P377, DOI 10.1095/biolreprod42.2.377; Ibanez-Tallon I, 2002, NEURON, V33, P893, DOI 10.1016/S0896-6273(02)00632-3; KOLBE HVJ, 1993, J BIOL CHEM, V268, P16458; Kumar P, 2005, J BIOL CHEM, V280, P25928, DOI 10.1074/jbc.M502435200; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Levitin F, 2005, J BIOL CHEM, V280, P33374, DOI 10.1074/jbc.M506047200; Luo CW, 2001, J BIOL CHEM, V276, P6913, DOI 10.1074/jbc.M006954200; Meizel S, 2004, BIOL REV, V79, P713, DOI 10.1017/S1464793103006407; Menez A, 1998, TOXICON, V36, P1557, DOI 10.1016/S0041-0101(98)00148-2; Nirthanan S, 2004, J PHARMACOL SCI, V94, P1, DOI 10.1254/jphs.94.1; Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042; Papke RL, 2002, BRIT J PHARMACOL, V137, P49, DOI 10.1038/sj.bjp.0704833; PLOUG M, 1994, FEBS LETT, V349, P163, DOI 10.1016/0014-5793(94)00674-1; Ploug M, 2003, CURR PHARM DESIGN, V9, P1499, DOI 10.2174/1381612033454630; Satomi Y, 2004, FEBS LETT, V576, P51, DOI 10.1016/j.febslet.2004.08.061; Soler-Garcia AA, 2005, REPRODUCTION, V129, P515, DOI 10.1530/rep.1.00576; Son JH, 2003, BIOL REPROD, V68, P1348, DOI 10.1095/biolreprod.102.011163; Southan C, 2002, PROTEOMICS, V2, P187, DOI 10.1002/1615-9861(200202)2:2<187::AID-PROT187>3.0.CO;2-A; Stokes C, 2004, MOL PHARMACOL, V66, P14, DOI 10.1124/mol.66.1.14; TREMEAU O, 1995, J BIOL CHEM, V270, P9362, DOI 10.1074/jbc.270.16.9362; Tsetlin V, 1999, EUR J BIOCHEM, V264, P281, DOI 10.1046/j.1432-1327.1999.00623.x; Tsetlin VI, 2004, FEBS LETT, V557, P9, DOI 10.1016/S0014-5793(03)01454-6; Tsuji H, 2003, GENOMICS, V81, P26, DOI 10.1016/S0888-7543(02)00025-3	34	47	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16928	16939		10.1074/jbc.M801454200	http://dx.doi.org/10.1074/jbc.M801454200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18387948	hybrid, Green Published			2022-12-25	WOS:000256497100070
J	Morii, M; Yamauchi, M; Ichikawa, T; Fujii, T; Takahashi, Y; Asano, S; Takeguchi, N; Sakai, H				Morii, Magotoshi; Yamauchi, Masashi; Ichikawa, Tomohiko; Fujii, Takuto; Takahashi, Yuji; Asano, Shinji; Takeguchi, Noriaki; Sakai, Hideki			Involvement of the H3O+-Lys-164-Gln-161-Glu-345 charge transfer pathway in proton transport of gastric H+, K+-ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CRYSTAL-STRUCTURE; BINDING-SITES; TRANSMEMBRANE SEGMENT; H+,K+-ATPASE ACTIVITY; MUTATIONAL ANALYSIS; MOLECULAR-DYNAMICS; CALCIUM-PUMP; MUTAGENESIS; H,K-ATPASE; CONFORMATION	Gastric H+, K+-ATPase is shown to transport 2 mol of H+/mol of ATP hydrolysis in isolated hog gastric vesicles. We studied whether the H+ transport mechanism is due to charge transfer and/or transfer of hydronium ion (H3O+). From transport of [O-18]H2O, 1.8 mol of water molecule/mol of ATP hydrolysis was found to be transported. We performed a molecular dynamics simulation of the three-dimensional structure model of the H+, K+-ATPase alpha-subunit at E-1 conformation. It predicts the presence of a charge transfer pathway from hydronium ion in cytosolic medium to Glu-345 in cation binding site 2 (H3O+-Lys-164-Gln-161-Glu-345). No charge transport pathway was formed in mutant Q161L, E345L, and E345D. Alternative pathways (H3O+-Gln-161-Glu-345) in mutant K164L and (H3O+-Arg-105-Gln-161-Gln-345) in mutant E345Q were formed. The H+, K+-ATPase activity in these mutants reflected the presence and absence of charge transfer pathways. We also found charge transfer from sites 2 to 1 via a water wire and a charge transfer pathway (H3O+-Asn-794-Glu-797). These results suggest that protons are charge-transferred from the cytosolic side to H2O in sites 2 and 1, the H2O comes from cytosolic medium, and H3O+ in the sites are transported into lumen during the conformational transition from E1P to E2P.	[Morii, Magotoshi; Yamauchi, Masashi; Ichikawa, Tomohiko; Fujii, Takuto; Takahashi, Yuji; Takeguchi, Noriaki; Sakai, Hideki] Toyama Univ, Grad Sch Med & Pharmaceut Sci, Dept Pharmaceut Physiol, Toyama 9300194, Japan; [Asano, Shinji] Ritsumeikan Univ, Coll Informat Sci & Engn, Dept Mol Physiol, Shiga 5258577, Japan	University of Toyama; Ritsumeikan University	Morii, M (corresponding author), Suzuka Univ Med Sci, Fac Pharmaceut Sci, Phys Chem Lab, 3500-3 Minamitamagaki Cho, Suzuka, Mie 5138670, Japan.	morii@suzuka-u.ac.jp		Asano, Shinji/0000-0003-1443-8970				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Asano S, 2000, J BIOCHEM, V127, P993, DOI 10.1093/oxfordjournals.jbchem.a022716; Asano S, 2004, J BIOL CHEM, V279, P13968, DOI 10.1074/jbc.M308934200; ASANO S, 1994, BIOCHEM J, V299, P59, DOI 10.1042/bj2990059; Asano S, 1997, J BIOL CHEM, V272, P17668, DOI 10.1074/jbc.272.28.17668; Asano S, 1996, J BIOL CHEM, V271, P2740, DOI 10.1074/jbc.271.5.2740; Asano S, 2001, J BIOL CHEM, V276, P31265, DOI 10.1074/jbc.M103698200; CRAIG H, 1961, SCIENCE, V133, P1702, DOI 10.1126/science.133.3465.1702; Hermsen HPH, 2000, BIOCHEMISTRY-US, V39, P1330, DOI 10.1021/bi991396y; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; Kamiya K, 2007, J AM CHEM SOC, V129, P9663, DOI 10.1021/ja070464y; KEELING DJ, 1989, J BIOL CHEM, V264, P5545; KHORANA HG, 1988, J BIOL CHEM, V263, P7439; Kimura T, 2002, J BIOCHEM, V131, P923, DOI 10.1093/oxfordjournals.jbchem.a003183; Koenderink JB, 2004, J BIOL CHEM, V279, P16417, DOI 10.1074/jbc.M400020200; Morii M, 1996, J BIOL CHEM, V271, P4068; Morth JP, 2007, NATURE, V450, P1043, DOI 10.1038/nature06419; MUNSON K, 2007, J CLIN GASTROENTE S2, V41, P226; Munson K, 2007, BIOCHEMISTRY-US, V46, P5398, DOI 10.1021/bi062305h; NAGLE JF, 1978, P NATL ACAD SCI USA, V75, P298, DOI 10.1073/pnas.75.1.298; Ogawa H, 2002, P NATL ACAD SCI USA, V99, P15977, DOI 10.1073/pnas.202622299; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; Pedersen BP, 2007, NATURE, V450, P1111, DOI 10.1038/nature06417; RABON EC, 1993, J BIOL CHEM, V268, P8012; RABON EC, 1982, J BIOL CHEM, V257, P6296; Rost B, 2004, NUCLEIC ACIDS RES, V32, pW321, DOI 10.1093/nar/gkh377; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; Suzuki H, 1997, J BIOL CHEM, V272, P10429; Swarts HGP, 2005, J BIOL CHEM, V280, P11488, DOI 10.1074/jbc.M412321200; Swarts HGP, 1996, J BIOL CHEM, V271, P29764, DOI 10.1074/jbc.271.47.29764; Swarts HGP, 2001, J BIOL CHEM, V276, P36909, DOI 10.1074/jbc.M103945200; TAKEGUCHI N, 1983, J BIOL CHEM, V258, P3094; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Toyoshima C, 2004, NATURE, V432, P361, DOI 10.1038/nature02981; Toyoshima C, 2000, NATURE, V405, P647, DOI 10.1038/35015017; WALLMARK B, 1980, J BIOL CHEM, V255, P5313; YODA A, 1970, BIOCHEM BIOPH RES CO, V40, P880, DOI 10.1016/0006-291X(70)90985-X	38	13	15	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16876	16884		10.1074/jbc.M800563200	http://dx.doi.org/10.1074/jbc.M800563200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18403373	hybrid			2022-12-25	WOS:000256497100065
J	Narasimhan, J; Joyce, BR; Naguleswaran, A; Smith, AT; Livingston, MR; Dixon, SE; Coppens, I; Wek, RC; Sullivan, WJ				Narasimhan, Jana; Joyce, Bradley R.; Naguleswaran, Arunasalam; Smith, Aaron T.; Livingston, Meredith R.; Dixon, Stacy E.; Coppens, Isabelle; Wek, Ronald C.; Sullivan, William J., Jr.			Translation regulation by eukaryotic initiation factor-2 kinases in the development of latent cysts in Toxoplasma gondii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; FACTOR 2-ALPHA; ACTIVATION; STRESS; ER; CELLS; GCN4; PKR; AUTOPHOSPHORYLATION; DIMERIZATION	A key problem in the treatment of numerous pathogenic eukaryotes centers on their development into latent forms during stress. For example, the opportunistic protist Toxoplasma gondii converts to latent cysts (bradyzoites) responsible for recrudescence of disease. We report that Toxoplasma eukaryotic initiation factor-2 alpha (TgIF2 alpha) is phosphorylated during stress and establish that protozoan parasites utilize translation control to modulate gene expression during development. Importantly, TgIF2 alpha remains phosphorylated in bradyzoites, explaining how these cells maintain their quiescent state. Furthermore, we have characterized novel eIF2 kinases; one in the endoplasmic reticulum and a likely regulator of the unfolded protein response (TgIF2K-A) and another that is a probable responder to cytoplasmic stresses (TgIF2K-B). Significantly, our data suggest that 1) the regulation of protein translation through eIF2 kinases is associated with development, 2) eIF2 alpha phosphorylation is employed by cells to maintain a latent state, and 3) endoplasmic reticulum and cytoplasmic stress responses evolved in eukaryotic cells before the early diverging Apicomplexa. Given its importance to pathogenesis, eIF2 kinase-mediated stress responses may provide opportunities for novel therapeutics.	[Narasimhan, Jana; Joyce, Bradley R.; Naguleswaran, Arunasalam; Smith, Aaron T.; Livingston, Meredith R.; Dixon, Stacy E.; Sullivan, William J., Jr.] Indiana Univ, Sch Med, Dept Pharmacol & Toxicol, Indianapolis, IN 46202 USA; [Narasimhan, Jana; Joyce, Bradley R.; Wek, Ronald C.] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [Coppens, Isabelle] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Mol Microbiol & Immunol, Baltimore, MD 21205 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Sullivan, WJ (corresponding author), 635 Barnhill Dr,MS A-525, Indianapolis, IN 46202 USA.	wjsulliv@iupui.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049164, R01GM064350] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01GM64350, R01GM49164] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Barber GN, 2005, CELL DEATH DIFFER, V12, P563, DOI 10.1038/sj.cdd.4401643; Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014; Bhatti MM, 2005, J BIOL CHEM, V280, P5902, DOI 10.1074/jbc.M410656200; Black MW, 2000, MICROBIOL MOL BIOL R, V64, P607, DOI 10.1128/MMBR.64.3.607-623.2000; Boyce M, 2005, SCIENCE, V307, P935, DOI 10.1126/science.1101902; Chen JJ, 2007, BLOOD, V109, P2693, DOI 10.1182/blood-2006-08-041830; Dar AC, 2005, CELL, V122, P887, DOI 10.1016/j.cell.2005.06.044; Dever TE, 2002, CELL, V108, P545, DOI 10.1016/S0092-8674(02)00642-6; ENDO T, 1982, EXP PARASITOL, V53, P179, DOI 10.1016/0014-4894(82)90059-5; Fang Rui, 2003, BMC Dev Biol, V3, P3, DOI 10.1186/1471-213X-3-3; Folsch H, 2001, J CELL BIOL, V152, P595, DOI 10.1083/jcb.152.3.595; Fox BA, 2002, NATURE, V415, P926, DOI 10.1038/415926a; Hager KM, 1999, J CELL SCI, V112, P2631; Harding HP, 1999, NATURE, V397, P271, DOI 10.1038/16729; Hinnebusch AG, 2005, ANNU REV MICROBIOL, V59, P407, DOI 10.1146/annurev.micro.59.031805.133833; Kissinger JC, 2003, NUCLEIC ACIDS RES, V31, P234, DOI 10.1093/nar/gkg072; KOZAK M, 1991, J BIOL CHEM, V266, P19867; Lieberman Linda A, 2002, Int Rev Immunol, V21, P373, DOI 10.1080/08830180213281; Lu LR, 2001, MOL CELL BIOL, V21, P7971, DOI 10.1128/MCB.21.23.7971-7980.2001; Luk FCY, 2008, MOL BIOCHEM PARASIT, V157, P169, DOI 10.1016/j.molbiopara.2007.10.012; Ma K, 2002, J BIOL CHEM, V277, P18728, DOI 10.1074/jbc.M200903200; Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006; Mohrle JJ, 1997, BIOCHEM J, V328, P677; Moraes MCS, 2007, EUKARYOT CELL, V6, P1979, DOI 10.1128/EC.00249-07; Padyana AK, 2005, J BIOL CHEM, V280, P29289, DOI 10.1074/jbc.M504096200; PROSTKO CR, 1993, MOL CELL BIOCHEM, V128, P255, DOI 10.1007/BF01076776; Rai M, 2006, DIFFERENTIATION, V74, P583, DOI 10.1111/j.1432-0436.2006.00085.x; RAMIREZ M, 1991, MOL CELL BIOL, V11, P3027, DOI 10.1128/MCB.11.6.3027; Reiner DS, 2001, CELL MICROBIOL, V3, P459, DOI 10.1046/j.1462-5822.2001.00129.x; Romano PR, 1998, MOL CELL BIOL, V18, P2282, DOI 10.1128/MCB.18.4.2282; Sadler AJ, 2007, CURR TOP MICROBIOL, V316, P253; SOETE M, 1994, EXP PARASITOL, V78, P361, DOI 10.1006/expr.1994.1039; Sullivan WJ, 2004, BIOCHEM J, V380, P523, DOI 10.1042/BJ20040262; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Tripathi G, 2002, EMBO J, V21, P5448, DOI 10.1093/emboj/cdf507; Weiss LM, 2000, FRONT BIOSCI-LANDMRK, V5, pD391, DOI 10.2741/Weiss; Wek RC, 2006, BIOCHEM SOC T, V34, P7, DOI 10.1042/BST0340007; Wek RC, 2007, ANTIOXID REDOX SIGN, V9, P2357, DOI 10.1089/ars.2007.1764; Yung SC, 2003, J PARASITOL, V89, P767, DOI 10.1645/GE-88R; Zhang F, 2001, J BIOL CHEM, V276, P24946, DOI 10.1074/jbc.M102108200	40	87	90	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16591	16601		10.1074/jbc.M800681200	http://dx.doi.org/10.1074/jbc.M800681200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18420584	Green Published, hybrid			2022-12-25	WOS:000256497100036
J	Lau, TL; Dua, V; Ulmer, TS				Lau, Tong-Lay; Dua, Varun; Ulmer, Tobias S.			Structure of the integrin alpha IIb transmembrane segment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DETERGENT MICELLES; DIPOLAR COUPLINGS; NMR-SPECTROSCOPY; CHEMICAL-SHIFTS; PROTEIN NMR; ATCUN MOTIF; RELAXATION; MEMBRANE; REFINEMENT; AFFINITY	Integrin cell-adhesion receptors transduce signals bidirectionally across the plasma membrane via the single-pass transmembrane segments of each alpha and beta subunit. While the beta 3 transmembrane segment consists of a linear 29-residue alpha-helix, the structure of the alpha IIb transmembrane segment reveals a linear 24-residue alpha-helix (Ile-966-Lys-989) followed by a backbone reversal that packs Phe-992-Phe-993 against the transmembrane helix. The length of the alpha IIb transmembrane helix implies the absence of a significant transmembrane helix tilt in contrast to its partnering beta 3 subunit. Sequence alignment shows Gly-991-Phe-993 to be fully conserved among all 18 human integrin alpha subunits, suggesting that their unusual structural motif is prototypical for integrin alpha subunits. The alpha IIb transmembrane structure demonstrates a level of complexity within the membrane that is beyond simple transmembrane helices and forms the structural basis for assessing the extent of structural and topological rearrangements upon alpha IIb-beta 3 association, i.e. integrin transmembrane signaling.	Univ So Calif, Keck Sch Med, Dept Biochem & Mol Biol, Los Angeles, CA 90033 USA; Univ So Calif, Keck Sch Med, Zilkha Neurogenet Inst, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Ulmer, TS (corresponding author), 1501 San Pablo St,ZNI 111, Los Angeles, CA 90033 USA.	tulmer@usc.edu			NHLBI NIH HHS [R01 HL089726-01A1, R01 HL089726] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL089726] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Armulik A, 1999, J BIOL CHEM, V274, P37030, DOI 10.1074/jbc.274.52.37030; Chamberlain AK, 2004, BIOPHYS J, V87, P3460, DOI 10.1529/biophysj.104.044024; Chou JJ, 2000, J BIOMOL NMR, V18, P101, DOI 10.1023/A:1008358318863; Chou JJ, 2001, J BIOMOL NMR, V21, P377, DOI 10.1023/A:1013336502594; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; Donaldson LW, 2001, J AM CHEM SOC, V123, P9843, DOI 10.1021/ja011241p; GarciaGuerra R, 1996, PLATELETS, V7, P195, DOI 10.3109/09537109609023579; Gehring K, 1998, J MAGN RESON, V135, P185, DOI 10.1006/jmre.1998.1543; GRAY TM, 1984, J MOL BIOL, V175, P75, DOI 10.1016/0022-2836(84)90446-7; Grishaev A, 2004, J AM CHEM SOC, V126, P7281, DOI 10.1021/ja0319994; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Harford C, 1997, ACCOUNTS CHEM RES, V30, P123, DOI 10.1021/ar9501535; Hu JS, 1997, J AM CHEM SOC, V119, P1803, DOI 10.1021/ja963625z; Hu JS, 1997, J BIOMOL NMR, V9, P323, DOI 10.1023/A:1018691228238; Hughes PE, 1996, J BIOL CHEM, V271, P6571, DOI 10.1074/jbc.271.12.6571; Hunsicker-Wang LM, 2005, ACTA CRYSTALLOGR D, V61, P340, DOI 10.1107/S0907444904033906; Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6; Jaroniec CP, 2004, J BIOMOL NMR, V30, P181, DOI 10.1023/B:JNMR.0000048946.71249.2f; Karplus PA, 1996, PROTEIN SCI, V5, P1406, DOI 10.1002/pro.5560050719; Kontaxis G, 2000, J MAGN RESON, V143, P184, DOI 10.1006/jmre.1999.1979; Kuszewski J, 2000, J MAGN RESON, V146, P249, DOI 10.1006/jmre.2000.2142; Lau TL, 2008, BIOCHEMISTRY-US, V47, P4008, DOI 10.1021/bi800107a; Li W, 2005, P NATL ACAD SCI USA, V102, P1424, DOI 10.1073/pnas.0409334102; Lin Z, 2006, ANGEW CHEM INT EDIT, V45, P1960, DOI 10.1002/anie.200503558; LIPARI G, 1982, J AM CHEM SOC, V104, P4546, DOI 10.1021/ja00381a009; Luo BH, 2005, P NATL ACAD SCI USA, V102, P3679, DOI 10.1073/pnas.0409440102; Luo BH, 2004, PLOS BIOL, V2, P776, DOI 10.1371/journal.pbio.0020153; Papiz MZ, 2003, J MOL BIOL, V326, P1523, DOI 10.1016/S0022-2836(03)00024-X; Partridge AW, 2005, J BIOL CHEM, V280, P7294, DOI 10.1074/jbc.M412701200; Pervushin K, 1997, P NATL ACAD SCI USA, V94, P12366, DOI 10.1073/pnas.94.23.12366; Prosser RS, 2006, BIOCHEMISTRY-US, V45, P8453, DOI 10.1021/bi060615u; SANDERS CR, 1995, BIOCHEMISTRY-US, V34, P4030, DOI 10.1021/bi00012a022; Schwieters CD, 2003, J MAGN RESON, V160, P65, DOI 10.1016/S1090-7807(02)00014-9; SPERA S, 1991, J AM CHEM SOC, V113, P5490, DOI 10.1021/ja00014a071; Stefansson A, 2004, J BIOL CHEM, V279, P21200, DOI 10.1074/jbc.M400771200; Tycko R, 2000, J AM CHEM SOC, V122, P9340, DOI 10.1021/ja002133q; Ulmer TS, 2005, J BIOL CHEM, V280, P9595, DOI 10.1074/jbc.M411805200; Ulmer TS, 2004, J MAGN RESON, V166, P190, DOI 10.1016/j.jmr.2003.10.012; Ulmer TS, 2003, J AM CHEM SOC, V125, P9179, DOI 10.1021/ja0350684; Vinogradova O, 2002, CELL, V110, P587, DOI 10.1016/S0092-8674(02)00906-6; Wang YJ, 2004, J BIOMOL NMR, V28, P327, DOI 10.1023/B:JNMR.0000015397.82032.2a; WIENER MC, 1992, BIOPHYS J, V61, P434, DOI 10.1016/S0006-3495(92)81849-0; Wimley WC, 1996, NAT STRUCT BIOL, V3, P842, DOI 10.1038/nsb1096-842; Zhu JQ, 2007, BLOOD, V110, P2475, DOI 10.1182/blood-2007-03-080077	45	70	73	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16162	16168		10.1074/jbc.M801748200	http://dx.doi.org/10.1074/jbc.M801748200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18417472	Green Published, hybrid			2022-12-25	WOS:000256332500074
J	MacPartlin, M; Zeng, SX; Lu, H				MacPartlin, Mary; Zeng, Shelya X.; Lu, Hua			Phosphorylation and stabilization of TAp63 gamma by I kappa B kinase-beta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UBIQUITIN-PROTEASOME PATHWAY; HAY-WELLS-SYNDROME; DNA-DAMAGE; IKK-ALPHA; P53 HOMOLOG; C-ABL; TRANSCRIPTIONAL ACTIVITY; EPIDERMAL MORPHOGENESIS; FOOT MALFORMATION; PROTEIN STABILITY	Post-translational modification of the p53 family members is key to their regulation. Here we report the phosphorylation of TAp63 gamma, but not Delta Np63 gamma, by I kappa B kinase beta (IKK beta). Activation of IKK beta by gamma radiation or tumor necrosis factor-alpha led to increased TAp63 gamma protein levels in cells. IKK beta, but not its kinase-defective mutant IKK beta-K44A, led to this observed stabilization of TAp63 gamma. This stabilization of TAp63 gamma in response to gamma radiation was significantly decreased in the absence of IKK beta. Phosphorylation of TAp63 gamma blocks ubiquitylation and possible degradation of this protein. We postulate that phosphorylation of TAp63 gamma by IKK beta stabilizes the TAp63 gamma protein by blocking ubiquitylation-dependent degradation of this protein.	[Zeng, Shelya X.; Lu, Hua] Indiana Univ, Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA; [MacPartlin, Mary] Oregon Hlth & Sci Univ, Ctr Hematol Malignancies, Inst Canc, Portland, OR 97239 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Oregon Health & Science University	Lu, H (corresponding author), Indiana Univ, Sch Med, Dept Biochem & Mol Biol, 635 Barnhill Dr,MS4053, Indianapolis, IN 46202 USA.	hualu@iupui.edu			NCI NIH HHS [CA93614, CA127724, CA 095441, CA 079721] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA079721, R01CA127724, R01CA093614, R01CA095441] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agami R, 1999, NATURE, V399, P809; ALKALAY I, 1995, P NATL ACAD SCI USA, V92, P10599, DOI 10.1073/pnas.92.23.10599; Avantaggiati ML, 1997, CELL, V89, P1175, DOI 10.1016/S0092-8674(00)80304-9; Bell S, 2003, CELL SIGNAL, V15, P1, DOI 10.1016/S0898-6568(02)00080-3; Candi E, 2006, J CELL SCI, V119, P4617, DOI 10.1242/jcs.03265; Celli J, 1999, CELL, V99, P143, DOI 10.1016/S0092-8674(00)81646-3; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; Delhase M, 1999, SCIENCE, V284, P309, DOI 10.1126/science.284.5412.309; DiDonato JA, 1997, NATURE, V388, P548, DOI 10.1038/41493; Fallis LH, 1999, APOPTOSIS, V4, P99, DOI 10.1023/A:1009614726059; Flores ER, 2007, CELL CYCLE, V6, P300, DOI 10.4161/cc.6.3.3793; Furuya K, 2007, J BIOL CHEM, V282, P18365, DOI 10.1074/jbc.M610522200; Gallegos JR, 2008, J BIOL CHEM, V283, P66, DOI 10.1074/jbc.M704686200; Ghioni P, 2005, CELL CYCLE, V4, P183, DOI 10.4161/cc.4.1.1359; Giaccia AJ, 1998, GENE DEV, V12, P2973, DOI 10.1101/gad.12.19.2973; Gu W, 1997, CELL, V90, P595, DOI 10.1016/S0092-8674(00)80521-8; HACKER H, 2006, SCI STKE, DOI DOI 10.1126/STKE.3572006RE13; Higashimoto Y, 2000, J BIOL CHEM, V275, P23199, DOI 10.1074/jbc.M002674200; Hirao A, 2000, SCIENCE, V287, P1824, DOI 10.1126/science.287.5459.1824; Hu YL, 1999, SCIENCE, V284, P316, DOI 10.1126/science.284.5412.316; Huang YP, 2004, CELL CYCLE, V3, P1587, DOI 10.4161/cc.3.12.1290; Ianakiev P, 2000, AM J HUM GENET, V67, P59, DOI 10.1086/302972; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; Karin M, 1999, ONCOGENE, V18, P6867, DOI 10.1038/sj.onc.1203219; Koster MI, 2004, GENE DEV, V18, P126, DOI 10.1101/gad.1165104; Koster MI, 2006, DEV BIOL, V289, P253, DOI 10.1016/j.ydbio.2005.10.041; KUERBITZ SJ, 1992, P NATL ACAD SCI USA, V89, P7491, DOI 10.1073/pnas.89.16.7491; Lakin ND, 1999, ONCOGENE, V18, P7644, DOI 10.1038/sj.onc.1203015; Lee FS, 1998, P NATL ACAD SCI USA, V95, P9319, DOI 10.1073/pnas.95.16.9319; Lee SH, 2004, P NATL ACAD SCI USA, V101, P17416, DOI 10.1073/pnas.0408061101; Li J, 1998, J BIOL CHEM, V273, P30736, DOI 10.1074/jbc.273.46.30736; Li NX, 1998, P NATL ACAD SCI USA, V95, P13012, DOI 10.1073/pnas.95.22.13012; Lill NL, 1997, J VIROL, V71, P129, DOI 10.1128/JVI.71.1.129-137.1997; MacPartlin M, 2005, J BIOL CHEM, V280, P30604, DOI 10.1074/jbc.M503352200; McGrath JA, 2001, HUM MOL GENET, V10, P221, DOI 10.1093/hmg/10.3.221; Mercurio F, 1997, SCIENCE, V278, P860, DOI 10.1126/science.278.5339.860; Mercurio F, 1999, MOL CELL BIOL, V19, P1526; Michael D, 2002, CURR OPIN GENET DEV, V12, P53, DOI 10.1016/S0959-437X(01)00264-7; Mills AA, 1999, NATURE, V398, P708, DOI 10.1038/19531; O'Mahony A, 2000, MOL CELL BIOL, V20, P1170, DOI 10.1128/MCB.20.4.1170-1178.2000; Okada Y, 2002, EXP CELL RES, V276, P194, DOI 10.1006/excr.2002.5535; Osada M, 1998, NAT MED, V4, P839, DOI 10.1038/nm0798-839; Pasparakis M, 2002, NATURE, V417, P861, DOI 10.1038/nature00820; Prens E, 1996, AM J PATHOL, V148, P1493; Regnier CH, 1997, CELL, V90, P373, DOI 10.1016/S0092-8674(00)80344-X; Rossi M, 2006, P NATL ACAD SCI USA, V103, P12753, DOI 10.1073/pnas.0603449103; Sakaguchi K, 1998, GENE DEV, V12, P2831, DOI 10.1101/gad.12.18.2831; Sanchez-Prieto R, 2002, ONCOGENE, V21, P974, DOI 10.1038/sj.onc.1205134; Serber Z, 2002, MOL CELL BIOL, V22, P8601, DOI 10.1128/MCB.22.24.8601-8611.2002; Shieh SY, 1997, CELL, V91, P325, DOI 10.1016/S0092-8674(00)80416-X; Sil AK, 2004, NATURE, V428, P660, DOI 10.1038/nature02421; Suh EK, 2006, NATURE, V444, P624, DOI 10.1038/nature05337; Takeda K, 1999, SCIENCE, V284, P313, DOI 10.1126/science.284.5412.313; Unger T, 1999, ONCOGENE, V18, P3205, DOI 10.1038/sj.onc.1202656; van Bokhoven H, 2001, AM J HUM GENET, V69, P481, DOI 10.1086/323123; Westfall MD, 2005, CELL CYCLE, V4, P710, DOI 10.4161/cc.4.5.1685; Westfall MD, 2003, MOL CELL BIOL, V23, P2264, DOI 10.1128/MCB.23.7.2264-2276.2003; Woronicz JD, 1997, SCIENCE, V278, P866, DOI 10.1126/science.278.5339.866; Wu C, 2003, J BIOL CHEM, V278, P31980, DOI 10.1074/jbc.M304278200; Xirodimas D, 2001, ONCOGENE, V20, P4972, DOI 10.1038/sj.onc.1204656; Yamaoka S, 1998, CELL, V93, P1231, DOI 10.1016/S0092-8674(00)81466-X; Yang A, 1999, NATURE, V398, P714, DOI 10.1038/19539; Yang AN, 1998, MOL CELL, V2, P305, DOI 10.1016/S1097-2765(00)80275-0; Ying HQ, 2005, MOL CELL BIOL, V25, P6154, DOI 10.1128/MCB.25.14.6154-6164.2005; Yuan ZM, 1999, NATURE, V399, P814, DOI 10.1038/21704; Zandi E, 1997, CELL, V91, P243, DOI 10.1016/S0092-8674(00)80406-7; Zandi E, 1998, SCIENCE, V281, P1360, DOI 10.1126/science.281.5381.1360; Zeng SX, 2002, EMBO J, V21, P5487, DOI 10.1093/emboj/cdf540	68	19	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15754	15761		10.1074/jbc.M801394200	http://dx.doi.org/10.1074/jbc.M801394200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18411264	Green Published, hybrid			2022-12-25	WOS:000256332500032
J	Rajapaksha, WRAKJS; Wang, DY; Davies, JN; Chen, L; Zamponi, GW; Fisher, TE				Rajapaksha, W. R. A. Kosala J. S.; Wang, Daoyi; Davies, Jonathan N.; Chen, Lina; Zamponi, Gerald W.; Fisher, Thomas E.			Novel splice variants of rat Ca(V)2.1 that lack much of the synaptic protein interaction site are expressed in neuroendocrine cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPRAOPTIC MAGNOCELLULAR NEURONS; PRESYNAPTIC CALCIUM-CHANNELS; P/Q-TYPE CHANNEL; N-TYPE; CA2+ CHANNELS; ALPHA(1A) SUBUNITS; SYNTAXIN; TRANSMISSION; CURRENTS; IDENTIFICATION	Voltage-gated Ca2+ channels are responsible for the activation of the Ca2+ influx that triggers exocytotic secretion. The synaptic protein interaction (synprint) site found in the II-III loop of Ca(V)2.1 and Ca(V)2.2 mediates a physical association with synaptic proteins that may be crucial for fast neurotransmission and axonal targeting. We report here the use of nested PCR to identify two novel splice variants of rat Ca(V)2.1 that lack much of the synprint site. Furthermore, we compare immunofluorescence data derived from antibodies directed against sequences in the Ca(V)2.1 synprint site and carboxyl terminus to show that channel variants lacking a portion of the synprint site are expressed in two types of neuroendocrine cells. Immunofluorescence data also suggest that such variants are properly targeted to neuroendocrine terminals. When expressed in a mammalian cell line, both splice variants yielded Ca2+ currents, but the variant containing the larger of the two deletions displayed a reduced current density and a marked shift in the voltage dependence of inactivation. These results have important implications for Ca(V)2.1 function and for the mechanisms of Ca(V)2.1 targeting in neurons and neuroendocrine cells.	[Rajapaksha, W. R. A. Kosala J. S.; Wang, Daoyi; Fisher, Thomas E.] Univ Saskatchewan, Dept Physiol, Coll Med, Saskatoon, SK S7N 5E5, Canada; [Davies, Jonathan N.; Chen, Lina; Zamponi, Gerald W.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB T2N 4N1, Canada	University of Saskatchewan; University of Calgary	Fisher, TE (corresponding author), Univ Saskatchewan, Dept Physiol, Coll Med, 107 Wiggins Rd, Saskatoon, SK S7N 5E5, Canada.	thomas.fisher@usask.ca	Davies, Jonathan/GPW-9712-2022	Davies, Jonathan/0000-0001-7838-126X; Zamponi, Gerald W./0000-0002-0644-9066; Fisher, Thomas/0000-0003-3890-2774				Arikkath J, 2003, CURR OPIN NEUROBIOL, V13, P298, DOI 10.1016/S0959-4388(03)00066-7; Beedle AM, 2004, NAT NEUROSCI, V7, P118, DOI 10.1038/nn1180; BEZPROZVANNY I, 1995, NATURE, V378, P623, DOI 10.1038/378623a0; Bourinet E, 1999, NAT NEUROSCI, V2, P407, DOI 10.1038/8070; Brice NL, 1999, J PHYSIOL-LONDON, V515, P685, DOI 10.1111/j.1469-7793.1999.685ab.x; Catterall WA, 2000, ANNU REV CELL DEV BI, V16, P521, DOI 10.1146/annurev.cellbio.16.1.521; Dolphin AC, 2003, J BIOENERG BIOMEMBR, V35, P599, DOI 10.1023/B:JOBB.0000008026.37790.5a; Fisher TE, 1995, J PHYSIOL-LONDON, V489, P383, DOI 10.1113/jphysiol.1995.sp021059; Fisher TE, 2000, FEBS LETT, V482, P131, DOI 10.1016/S0014-5793(00)02043-3; FISHER TE, 1995, J PHYSIOL-LONDON, V486, P571, DOI 10.1113/jphysiol.1995.sp020835; Fisher TE, 2001, PROG BIOPHYS MOL BIO, V77, P269, DOI 10.1016/S0079-6107(01)00017-7; Foehring RC, 1996, J NEUROPHYSIOL, V76, P977, DOI 10.1152/jn.1996.76.2.977; Glasgow E, 1999, ENDOCRINOLOGY, V140, P5391, DOI 10.1210/en.140.11.5391; Hans M, 1999, BIOPHYS J, V76, P1384, DOI 10.1016/S0006-3495(99)77300-5; Hu QP, 2005, GENES CELLS, V10, P87, DOI 10.1111/j.1365-2443.2005.00820.x; Joux N, 2001, J NEUROENDOCRINOL, V13, P638, DOI 10.1046/j.1365-2826.2001.00679.x; Jurkat-Rott K, 2004, J PHYSIOL-LONDON, V554, P609, DOI 10.1113/jphysiol.2003.052712; Kaneko S, 2002, J NEUROSCI, V22, P82, DOI 10.1523/JNEUROSCI.22-01-00082.2002; Krovetz HS, 2000, J NEUROSCI, V20, P7564; Lipscombe D, 2002, MOL NEUROBIOL, V26, P21, DOI 10.1385/MN:26:1:021; Liu HY, 1996, J NEUROSCI, V16, P7557; Maximov A, 2002, J NEUROSCI, V22, P6939; Maximov A, 1999, J BIOL CHEM, V274, P24453, DOI 10.1074/jbc.274.35.24453; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; Mochida S, 2003, P NATL ACAD SCI USA, V100, P2813, DOI 10.1073/pnas.262787299; Mochida S, 2003, P NATL ACAD SCI USA, V100, P2819, DOI 10.1073/pnas.262787699; Mochida S, 1996, NEURON, V17, P781, DOI 10.1016/S0896-6273(00)80209-3; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; OLIET SHR, 1992, J PHYSIOL-LONDON, V455, P291, DOI 10.1113/jphysiol.1992.sp019302; Rettig J, 1996, P NATL ACAD SCI USA, V93, P7363, DOI 10.1073/pnas.93.14.7363; Rigato F., 2005, V1, P82; Sakurai T, 1996, J CELL BIOL, V134, P511, DOI 10.1083/jcb.134.2.511; Sheng ZH, 1998, J BIOENERG BIOMEMBR, V30, P335, DOI 10.1023/A:1021985521748; Soong TW, 2002, J NEUROSCI, V22, P10142; Spafford JD, 2003, CURR OPIN NEUROBIOL, V13, P308, DOI 10.1016/S0959-4388(03)00061-8; Spafford JD, 2003, J BIOL CHEM, V278, P4258, DOI 10.1074/jbc.M211076200; STARR TVB, 1991, P NATL ACAD SCI USA, V88, P5621, DOI 10.1073/pnas.88.13.5621; Szabo Z, 2006, EUR J NEUROSCI, V24, P709, DOI 10.1111/j.1460-9568.2006.04947.x; TAKAHASHI T, 1993, NATURE, V366, P156, DOI 10.1038/366156a0; Tsunemi T, 2002, J BIOL CHEM, V277, P7214, DOI 10.1074/jbc.M108222200; Wang G, 1997, J PHYSIOL-LONDON, V502, P351, DOI 10.1111/j.1469-7793.1997.351bk.x; WHEELER DB, 1994, SCIENCE, V264, P107, DOI 10.1126/science.7832825; Wiser O, 1996, EMBO J, V15, P4100, DOI 10.1002/j.1460-2075.1996.tb00785.x; Yokoyama CT, 2005, MOL CELL NEUROSCI, V28, P1, DOI 10.1016/j.mcn.2004.08.019; Zhang WB, 2007, J PHYSIOL-LONDON, V580, P181, DOI 10.1113/jphysiol.2006.126680; Zhong HJ, 1999, NAT NEUROSCI, V2, P939, DOI 10.1038/14721	46	13	13	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15997	16003		10.1074/jbc.M710544200	http://dx.doi.org/10.1074/jbc.M710544200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18390553	Green Published, hybrid			2022-12-25	WOS:000256332500058
J	Lee, HJ; Cho, JS; Lambacher, N; Lee, J; Lee, SJ; Lee, TH; Gartner, A; Koo, HS				Lee, Hyojin; Cho, Jeong Soo; Lambacher, Nils; Lee, Jieun; Lee, Se-Jin; Lee, Tae Hoon; Gartner, Anton; Koo, Hyeon-Sook			The Caenorhabditis elegans AMP-activated protein kinase AAK-2 is phosphorylated by LKB1 and is required for resistance to oxidative stress and for normal motility and foraging behavior	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-ELEGANS; NERVOUS-SYSTEM; LIFE-SPAN; UPSTREAM; PATHWAY; PROLIFERATION; RESTRICTION; NEURONS	AAK-2 is one of two a isoforms of the AMP-activated protein kinase in Caenorhabditis elegans and is involved in life span maintenance, stress responses, and germ cell cycle arrest upon dauer entry. We found that AAK-2 was phosphorylated at threonine 243 in response to paraquat treatment and that this phosphorylation depends on PAR-4, the C elegans LKB1 homologue. Both aak-2 mutation and par-4 knockdown increased the sensitivity of C. elegans worms to paraquat, and the double deficiency did not further increase sensitivity, indicating that aak-2 and par-4 act in a linear pathway. Both mutations also slowed body bending during locomotion and failed to reduce head oscillation in response to anterior touch. Consistent with this abnormal motility and behavioral response, expression of the AAK-2::green fluorescent protein fusion protein was observed in the ventral cord, some neurons, body wall muscle, pharynx, vulva, somatic gonad, and excretory cell. Our study suggests that AMPK can influence the behavior of C. elegans worms in addition to its well known function in metabolic control.	[Lee, Hyojin; Cho, Jeong Soo; Lee, Jieun; Lee, Se-Jin; Lee, Tae Hoon; Koo, Hyeon-Sook] Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120749, South Korea; [Lambacher, Nils; Gartner, Anton] Univ Dundee, Sch Life Sci, Wellcome Trust Ctr Gene Regulat & Express, Dundee DD1 5EH, Scotland	Yonsei University; University of Dundee	Koo, HS (corresponding author), Yonsei Univ, Coll Sci, Dept Biochem, Seoul 120749, South Korea.	kooh@yonsei.ac.kr		Gartner, Anton/0000-0003-4639-9902; Koo, Hyeon-Sook/0000-0002-5712-3875; LEE, TAE HOON/0000-0001-6396-9378	Cancer Research UK Funding Source: Medline; Intramural NIH HHS [Z01 BC010615] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010615] Funding Source: NIH RePORTER	Cancer Research UK(Cancer Research UK); Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alkema MJ, 2005, NEURON, V46, P247, DOI 10.1016/j.neuron.2005.02.024; Apfeld J, 2004, GENE DEV, V18, P3004, DOI 10.1101/gad.1255404; Carling D, 2005, BIOCHIMIE, V87, P87, DOI 10.1016/j.biochi.2004.10.017; Castello PR, 2007, J BIOL CHEM, V282, P14186, DOI 10.1074/jbc.M700827200; Dasgupta B, 2007, P NATL ACAD SCI USA, V104, P7217, DOI 10.1073/pnas.0610068104; Greer EL, 2007, CURR BIOL, V17, P1646, DOI 10.1016/j.cub.2007.08.047; Hardie DG, 2004, J CELL SCI, V117, P5479, DOI 10.1242/jcs.01540; Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hunt-Newbury R, 2007, PLOS BIOL, V5, P1981, DOI 10.1371/journal.pbio.0050237; Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200; Jansen G, 1997, NAT GENET, V17, P119, DOI 10.1038/ng0997-119; Jones RG, 2005, MOL CELL, V18, P283, DOI 10.1016/j.molcel.2005.03.027; Kamath RS, 2001, GENOME BIOL, V2, DOI 10.1186/gb-2000-2-1-research0002; Kindt KS, 2007, NAT NEUROSCI, V10, P568, DOI 10.1038/nn1886; Kuramoto N, 2007, NEURON, V53, P233, DOI 10.1016/j.neuron.2006.12.015; Lee JH, 2007, NATURE, V447, P1017, DOI 10.1038/nature05828; MADURO M, 1995, GENETICS, V141, P977; Mirouse V, 2007, J CELL BIOL, V177, P387, DOI 10.1083/jcb.200702053; Motoshima H, 2006, J PHYSIOL-LONDON, V574, P63, DOI 10.1113/jphysiol.2006.108324; Narbonne P, 2006, DEVELOPMENT, V133, P611, DOI 10.1242/dev.02232; Proszkowiec-Weglarz M, 2006, COMP BIOCHEM PHYS B, V143, P92, DOI 10.1016/j.cbpb.2005.10.009; Salt I, 1998, BIOCHEM J, V334, P177, DOI 10.1042/bj3340177; Schulz TJ, 2007, CELL METAB, V6, P280, DOI 10.1016/j.cmet.2007.08.011; Shaw RJ, 2004, P NATL ACAD SCI USA, V101, P3329, DOI 10.1073/pnas.0308061100; Timmons L, 1998, NATURE, V395, P854, DOI 10.1038/27579; Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05; Tsalik EL, 2003, J NEUROBIOL, V56, P178, DOI 10.1002/neu.10245; Viollet B, 2003, J CLIN INVEST, V111, P91, DOI 10.1172/JCI200316567; Watts JL, 2000, DEVELOPMENT, V127, P1467; Woods A, 2003, CURR BIOL, V13, P2004, DOI 10.1016/j.cub.2003.10.031; Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005; Zheng B, 2007, P NATL ACAD SCI USA, V104, P819, DOI 10.1073/pnas.0610157104	33	59	65	2	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					14988	14993		10.1074/jbc.M709115200	http://dx.doi.org/10.1074/jbc.M709115200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18408008	hybrid, Green Published			2022-12-25	WOS:000256232000011
J	Nissim, I; Horyn, O; Nissim, I; Daikhin, Y; Wehrli, SL; Yudkoff, M				Nissim, Itzhak; Horyn, Oksana; Nissim, Ilana; Daikhin, Yevgeny; Wehrli, Suzanne L.; Yudkoff, Marc			3-isobutylmethylxanthine inhibits hepatic urea synthesis - Protection by agmatine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PERFUSED-RAT-LIVER; MITOCHONDRIAL CARBAMYL-PHOSPHATE; ACID CYCLE; METABOLISM; MECHANISM; IFOSFAMIDE; ORNITHINE; NITROGEN; AMMONIA	We previously showed that agmatine stimulated hepatic ureagenesis. In this study, we sought to determine whether the action of agmatine is mediated via cAMP signaling. A pilot experiment demonstrated that the phosphodiesterase inhibitor, 3-isobutylmethylxanthine (IBMX), inhibited urea synthesis albeit increased [cAMP]. Thus, we hypothesized that IBMX inhibits hepatic urea synthesis independent of [cAMP]. We further theorized that agmatine would negate the IBMX action and improve ureagenesis. Experiments were carried out with isolated mitochondria and (NH4Cl)-N-15 to trace [N-15] citrulline production or [5-N-15]glutamine and a rat liver perfusion system to trace ureagenesis. The results demonstrate that IBMX induced the following: (i) inhibition of the mitochondrial respiratory chain and diminished 0, consumption during liver perfusion; (ii) depletion of the phosphorylation potential and overall hepatic energetic capacity; (iii) inhibition of [N-15] citrulline synthesis; and (iv) inhibition of urea output in liver perfusion with little effect on [N-acetylglutamate]. The results indicate that IBMX directly and specifically inhibited complex I of the respiratory chain and carbamoyl-phosphate synthase-I (CPS-I), with an EC50 about 0.6 mm despite a significant elevation of hepatic [cAMP]. Perfusion of agmatine with IBMX stimulated 0, consumption, restored hepatic phosphorylation potential, and significantly stimulated ureagenesis. The action of agmatine may signify a cascade effect initiated by increased oxidative phosphorylation and greater ATP synthesis. In addition, agmatine may prevent IBMX from binding to one or more active site(s) of CPS-I and thus protect against inhibition of CPS-I. Together, the data may suggest a new experimental application of IBMX in studies of CPS-I malfunction and the use of agmatine as intervention therapy.	[Nissim, Itzhak; Horyn, Oksana; Nissim, Ilana; Daikhin, Yevgeny; Wehrli, Suzanne L.; Yudkoff, Marc] Univ Penn, Sch Med, Childrens Hosp Philadelphia, Dept Pediat,Div Child Dev Rehabil Med & Metab Dis, Philadelphia, PA 19104 USA	University of Pennsylvania; Childrens Hospital of Philadelphia	Nissim, I (corresponding author), Abramson Pediat Res Ctr, Div Child Dev, Rm 510C,34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.				NCRR NIH HHS [U54 RR 019453] Funding Source: Medline; NICHD NIH HHS [HD 26971] Funding Source: Medline; NIDDK NIH HHS [DK 047870, DK 53761] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026971] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [U54RR019453] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053761, R01DK047870, R56DK053761] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bender AT, 2006, PHARMACOL REV, V58, P488, DOI 10.1124/pr.58.3.5; BEYLOT M, 1995, J BIOL CHEM, V270, P1509, DOI 10.1074/jbc.270.4.1509; Brosnan JT, 1996, J BIOL CHEM, V271, P16199, DOI 10.1074/jbc.271.27.16199; Brosnan JT, 2001, J BIOL CHEM, V276, P31876, DOI 10.1074/jbc.M103890200; BROSNAN JT, 1995, ADV ENZYME REGUL, V35, P131, DOI 10.1016/0065-2571(94)00003-L; Burgess SC, 2008, J BIOL CHEM, V283, P1670, DOI 10.1074/jbc.M706540200; CAREY GB, 1993, BIOCHEM J, V292, P241, DOI 10.1042/bj2920241; COHEN NS, 1982, J BIOL CHEM, V257, P6898; COHEN NS, 1980, J BIOL CHEM, V255, P248; Conti M, 2007, ANNU REV BIOCHEM, V76, P481, DOI 10.1146/annurev.biochem.76.060305.150444; Dousa TP, 1999, KIDNEY INT, V55, P29, DOI 10.1046/j.1523-1755.1999.00233.x; ERNSTBERNHARD K, 2004, J BIOL CHEM, V279, P54479; Exton J H, 1968, Adv Enzyme Regul, V6, P391, DOI 10.1016/0065-2571(68)90024-1; FAHIEN LA, 1964, J BIOL CHEM, V239, P1935; Fiermonte G, 1999, BIOCHEM J, V344, P953, DOI 10.1042/0264-6021:3440953; GEN L, 1994, SCIENCE, V263, P12231; Grigorieff N, 1999, CURR OPIN STRUC BIOL, V9, P476, DOI 10.1016/S0959-440X(99)80067-0; Jaworek D., 1985, METHOD ENZYMAT AN, V7, P340; Jaworek D, 1974, METHODS ENZYMATIC AN, P2127, DOI 10.1016/B978-0-12-091304-6.50066-5; JONES BN, 1983, J CHROMATOGR, V266, P471, DOI 10.1016/S0021-9673(01)90918-5; KAWAMOTO S, 1985, BIOCHEM J, V232, P329, DOI 10.1042/bj2320329; Kothe M, 1997, P NATL ACAD SCI USA, V94, P12348, DOI 10.1073/pnas.94.23.12348; Krebs H A, 1969, Adv Enzyme Regul, V7, P397, DOI 10.1016/0065-2571(69)90030-2; MCGARRY JD, 1971, J BIOL CHEM, V246, P1149; MCGIVAN JD, 1976, BIOCHEM J, V154, P415, DOI 10.1042/bj1540415; MEIJER AJ, 1990, PHYSIOL REV, V70, P701, DOI 10.1152/physrev.1990.70.3.701; Nissim I, 2006, J BIOL CHEM, V281, P8486, DOI 10.1074/jbc.M506984200; Nissim I, 2005, J BIOL CHEM, V280, P17715, DOI 10.1074/jbc.M500607200; Nissim I, 2003, BIOCHEM J, V376, P179, DOI 10.1042/BJ20030997; Nissim I, 1999, J BIOL CHEM, V274, P28958, DOI 10.1074/jbc.274.41.28958; Nissim I, 2002, AM J PHYSIOL-ENDOC M, V283, pE1123, DOI 10.1152/ajpendo.00246.2002; Nissim I, 1996, KIDNEY INT, V49, P684, DOI 10.1038/ki.1996.97; Nissim I, 2006, CANCER RES, V66, P7824, DOI 10.1158/0008-5472.CAN-06-1043; Orrenius S, 2007, DRUG METAB REV, V39, P443, DOI 10.1080/03602530701468516; PRADELLES P, 1989, ANAL CHEM, V61, P447, DOI 10.1021/ac00180a014; Saeed-Kothe A, 2002, J BIOL CHEM, V277, P7231, DOI 10.1074/jbc.M110926200; Thoden JB, 2004, PROTEIN SCI, V13, P2398, DOI 10.1110/ps.04822704; VERA AV, 2005, ANTIOXID REDOX SIGN, V7, P1140; Wehrli SL, 2001, NMR BIOMED, V14, P192, DOI 10.1002/nbm.694; Weinberg JM, 2000, AM J PHYSIOL-RENAL, V279, pF927, DOI 10.1152/ajprenal.2000.279.5.F927; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; Williamson J R, 1968, Adv Enzyme Regul, V6, P67, DOI 10.1016/0065-2571(68)90008-3	42	8	8	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15063	15071		10.1074/jbc.M800163200	http://dx.doi.org/10.1074/jbc.M800163200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18375388	Green Published, hybrid			2022-12-25	WOS:000256232000020
J	Luo, YG; Lin, SJ; Zhang, J; Cooke, HA; Bruner, SD; Shen, B				Luo, Yinggang; Lin, Shuangjun; Zhang, Jian; Cooke, Heather A.; Bruner, Steven D.; Shen, Ben			Regiospecific O-methylation of naphthoic acids catalyzed by NcsB1, an O-methyltransferase involved in the biosynthesis of the enediyne antitumor antibiotic neocarzinostatin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA CROSS-LINKING; AZINOMYCIN-B; APO-NEOCARZINOSTATIN; SEQUENCE SELECTIVITY; STREPTOMYCES-CARZINOSTATICUS; CHROMOPHORE; MECHANISM; BINDING; PROTEIN; ALKYLATION	Neocarzinostatin, a clinical anticancer drug, is the archetypal member of the chromoprotein family of enediyne antitumor antibiotics that are composed of a nonprotein chromophore and an apoprotein. The neocarzinostatin chromophore consists of a nine-membered enediyne core, a deoxyaminosugar, and a naphthoic acid moiety. We have previously cloned and sequenced the neocarzinostatin biosynthetic gene cluster and proposed that the biosynthesis of the naphthoic acid moiety and its incorporation into the neocarzinostatin chromophore are catalyzed by five enzymes NcsB, NcsB1, NcsB2, NcsB3, and NcsB4. Here we report the biochemical characterization of NcsB1, unveiling that: (i) NcsB1 is an S-adenosyl-L-methionine-dependent O-methyltransferase; (ii) NcsB1 catalyzes regiospecific methylation at the 7-hydroxy group of its native substrate, 2,7-dihydroxy-5-methyl-1-naphthoic acid; (iii) NcsB1 also recognizes other dihydroxynaphthoic acids as substrates and catalyzes regiospecific O-methylation; and (iv) the carboxylate and its ortho-hydroxy groups of the substrate appear to be crucial for NcsB1 substrate recognition and binding, and O-methylation takes place only at the free hydroxy group of these dihydroxynaphthoic acids. These findings establish that NcsB1 catalyzes the third step in the biosynthesis of the naphthoic acid moiety of the neocarzinostatin chromophore and further support the early proposal for the biosynthesis of the naphthoic acid and its incorporation into the neocarzinostatin chromophore with free naphthoic acids serving as intermediates. NcsB1 represents another opportunity that can now be exploited to produce novel neocarzinostatin analogs by engineering neocarzinostatin biosynthesis or applying directed biosynthesis strategies.	[Luo, Yinggang; Lin, Shuangjun; Zhang, Jian; Shen, Ben] Univ Wisconsin, Div Pharmaceut Sci, Madison, WI 53705 USA; [Shen, Ben] Univ Wisconsin, Natl Cooperat Drug Discovery Grp, Madison, WI 53705 USA; [Shen, Ben] Univ Wisconsin, Dept Chem, Madison, WI 53705 USA; [Luo, Yinggang] Chinese Acad Sci, Chengdu Inst Biol, Ctr Nat Prod Res, Chengdu 610041, Peoples R China; [Bruner, Steven D.] Boston Coll, Dept Chem, Chestnut Hill, MA 02467 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Chinese Academy of Sciences; Chengdu Institute of Biology, CAS; Boston College	Shen, B (corresponding author), Univ Wisconsin, Div Pharmaceut Sci, Madison, WI 53705 USA.	bshen@pharmacy.wisc.edu		Cooke, Heather/0000-0001-9742-5993	NATIONAL CANCER INSTITUTE [R01CA078747, U19CA113297] Funding Source: NIH RePORTER; NCI NIH HHS [CA 78747, CA 113297] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcaro S, 2002, J MED CHEM, V45, P861, DOI 10.1021/jm011040w; Alcaro S, 2000, J MED CHEM, V43, P2783, DOI 10.1021/jm990362l; Baker JR, 2007, CHEMBIOCHEM, V8, P704, DOI 10.1002/cbic.200600534; Caddick S, 2006, J AM CHEM SOC, V128, P4204, DOI 10.1021/ja058419i; Casely-Hayford MA, 2005, BIOORG MED CHEM LETT, V15, P653, DOI 10.1016/j.bmcl.2004.11.037; Coleman RS, 2002, J AM CHEM SOC, V124, P13008, DOI 10.1021/ja025563k; Coleman RS, 2002, ORG LETT, V4, P3545, DOI 10.1021/ol0267275; Cooke HA, 2007, J AM CHEM SOC, V129, P7728, DOI 10.1021/ja071886a; Coque JJR, 2003, APPL ENVIRON MICROB, V69, P5089, DOI 10.1128/AEM.69.9.5089-5095.2003; Dalhoff C, 2006, NAT CHEM BIOL, V2, P31, DOI 10.1038/nchembio754; David-Cordonnier MH, 2006, CHEMBIOCHEM, V7, P1658, DOI 10.1002/cbic.200600244; EDO K, 1985, TETRAHEDRON LETT, V26, P331, DOI 10.1016/S0040-4039(01)80810-8; GOLDBERG IH, 1987, FREE RADICAL BIO MED, V3, P41, DOI 10.1016/0891-5849(87)90038-4; Gruschow S, 2007, J AM CHEM SOC, V129, P6470, DOI 10.1021/ja0700193; Hartley JA, 2000, ANGEW CHEM INT EDIT, V39, P3467; Ibdah M, 2003, J BIOL CHEM, V278, P43961, DOI 10.1074/jbc.M304932200; ISHIDA N, 1965, J ANTIBIOT, V18, P68; Ji N, 2004, ORG LETT, V6, P4551, DOI 10.1021/ol048075l; Kennedy DR, 2007, P NATL ACAD SCI USA, V104, P17632, DOI 10.1073/pnas.0708274104; Kennedy DR, 2007, CANCER RES, V67, P773, DOI 10.1158/0008-5472.CAN-06-2893; Landreau CAS, 2004, ORG LETT, V6, P3505, DOI 10.1021/ol048653y; LEE SH, 1989, BIOCHEMISTRY-US, V28, P1019, DOI 10.1021/bi00429a015; LePla RC, 2005, ORG BIOMOL CHEM, V3, P1174, DOI 10.1039/b502188j; Liu W, 2005, CHEM BIOL, V12, P293, DOI 10.1016/j.chembiol.2004.12.013; Maeda H, 2001, ADV DRUG DELIVER REV, V46, P169, DOI 10.1016/S0169-409X(00)00134-4; MAEDA H, 1975, CANCER RES, V35, P554; MAEDA H, 1980, EUR J CANCER, V16, P723, DOI 10.1016/0014-2964(80)90215-7; Miyagawa N, 2003, BIOCHEM BIOPH RES CO, V306, P87, DOI 10.1016/S0006-291X(03)00925-2; ODA T, 1989, ANTICANCER RES, V9, P261; Pfefferle C, 1997, J ANTIBIOT, V50, P1067, DOI 10.7164/antibiotics.50.1067; POVIRK LF, 1981, BIOCHEMISTRY-US, V20, P4007, DOI 10.1021/bi00517a009; Sambrook J, 2001, MOL CLONING LAB MANU; SCHLENK F, 1975, BIOCHIM BIOPHYS ACTA, V385, P312, DOI 10.1016/0304-4165(75)90359-1; SHAFIEE A, 1994, EUR J BIOCHEM, V225, P755, DOI 10.1111/j.1432-1033.1994.00755.x; Shen B, 2003, CURR MED CHEM, V10, P2317, DOI 10.2174/0929867033456701; Smith AL, 1996, J MED CHEM, V39, P2103, DOI 10.1021/jm9600398; Sthapit B, 2004, FEBS LETT, V566, P201, DOI 10.1016/j.febslet.2004.04.033; TAKAHASHI K, 1994, TETRAHEDRON, V50, P1327, DOI 10.1016/S0040-4020(01)80621-9; Urbaniak MD, 2004, J MED CHEM, V47, P4710, DOI 10.1021/jm040790d; Urbaniak MD, 2002, BIOCHEMISTRY-US, V41, P11731, DOI 10.1021/bi0262146; XI Z, 1999, COMPREHENSIVE NATURA, P533; Xu J, 2003, ARCH BIOCHEM BIOPHYS, V411, P277, DOI 10.1016/S0003-9861(03)00004-3; Yoon Y, 2005, BBA-GENE STRUCT EXPR, V1730, P85, DOI 10.1016/j.bbaexp.2005.06.005; Zang H, 2000, BIOCHEMISTRY-US, V39, P14968, DOI 10.1021/bi001998d; ZEIN N, 1993, P NATL ACAD SCI USA, V90, P2822, DOI 10.1073/pnas.90.7.2822; Zhang C, 2006, CHEMBIOCHEM, V7, P795, DOI 10.1002/cbic.200500504; Zhao N, 2007, PHYTOCHEMISTRY, V68, P1537, DOI 10.1016/j.phytochem.2007.03.041	47	18	19	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14694	14702		10.1074/jbc.M802206200	http://dx.doi.org/10.1074/jbc.M802206200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18387946	Green Published, hybrid			2022-12-25	WOS:000255941400058
J	Rosenberg, A; Kanner, BI				Rosenberg, Alex; Kanner, Baruch I.			The substrates of the gamma-aminobutyric acid transporter GAT-1 induce structural rearrangements around the interface of transmembrane domains 1 and 6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAIRED CYSTEINE MUTAGENESIS; DEPENDENT NEUROTRANSMITTER TRANSPORTERS; CL-COTRANSPORT FUNCTION; GABA TRANSPORTER; RAT-BRAIN; SEROTONIN TRANSPORTER; BACTERIAL HOMOLOG; ION-BINDING; GLYCINE TRANSPORTERS; XENOPUS OOCYTES	The sodium- and chloride-coupled gamma-aminobutyric acid ( GABA) transporter GAT-1 is essential for efficient synaptic transmission by this neurotransmitter. GAT-1 is the first cloned member of the neurotransmitter-sodium-symporter family. Here we address the idea that during transport the extracellular halves of transmembrane domains (TM) 1 and 6, TM 1b/TM 6a, move relative to the binding pocket. Therefore, we have probed the aqueous accessibility of TM 6a and its proximity to TM 1b in the presence and absence of its substrates. Cysteines were introduced, one by one, at all TM 6a positions. In several mutants, transport activity was inhibited by the impermeant sulfhydryl reagent ( 2-trimethylammonium) methanethiosulfonate, whereas wild type GAT-1 was basically insensitive. This inhibition was potentiated by sodium, whereas GABA was protective. Moreover, we used paired cysteine mutagenesis in conjunction with treatments with copper(II)(1,10-phenanthroline)(3) (CuPh). CuPh did not affect the activity of wild type GAT-1 but potently inhibited transport by the TM 6a mutant D287C. Such inhibition was not observed with D287C/C74A, indicating that Asp-287 is close to Cys-74 of TM 1b. Inhibition of transport of D287C by CuPh, but not by ( 2-trimethylammonium) methanethiosulfonate, was potentiated when sodium and GABA were both removed. Thus, the degree of inhibition by CuPh is not a simple function of the accessibility of the individual cysteines but also involves structural rearrangements around the TM 1b/TM 6a interface.	[Rosenberg, Alex; Kanner, Baruch I.] Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, IL-91120 Jerusalem, Israel	Hebrew University of Jerusalem	Kanner, BI (corresponding author), Hebrew Univ Jerusalem, Hadassah Med Sch, Dept Biochem, POB 12272, IL-91120 Jerusalem, Israel.	kannerb@cc.huji.ac.il		Rosenberg, Alex/0000-0001-9672-1360				Androutsellis-Theotokis A, 2003, J BIOL CHEM, V278, P12703, DOI 10.1074/jbc.M206563200; Benitah JP, 1996, P NATL ACAD SCI USA, V93, P7392, DOI 10.1073/pnas.93.14.7392; Bennett ER, 1997, J BIOL CHEM, V272, P1203, DOI 10.1074/jbc.272.2.1203; Brocke L, 2002, J BIOL CHEM, V277, P3985, DOI 10.1074/jbc.M107735200; Chen JG, 2000, P NATL ACAD SCI USA, V97, P1044, DOI 10.1073/pnas.97.3.1044; Chen JG, 1997, BIOCHEMISTRY-US, V36, P1479, DOI 10.1021/bi962256g; Dodd JR, 2007, J BIOL CHEM, V282, P15528, DOI 10.1074/jbc.M611705200; Forrest LR, 2007, P NATL ACAD SCI USA, V104, P12761, DOI 10.1073/pnas.0705600104; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; GUASTELLA J, 1990, SCIENCE, V249, P1303, DOI 10.1126/science.1975955; Henry LK, 2003, J BIOL CHEM, V278, P37052, DOI 10.1074/jbc.M305514200; Hilgemann DW, 1999, J GEN PHYSIOL, V114, P459, DOI 10.1085/jgp.114.3.459; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kanner BI, 2003, J BIOL CHEM, V278, P3705, DOI 10.1074/jbc.M210525200; KANNER BI, 1994, J EXP BIOL, V196, P237; KAVANAUGH MP, 1992, J BIOL CHEM, V267, P22007; KEYNAN S, 1988, BIOCHEMISTRY-US, V27, P12, DOI 10.1021/bi00401a003; KEYNAN S, 1992, BIOCHEMISTRY-US, V31, P1974, DOI 10.1021/bi00122a011; KLEINBERGERDORON N, 1994, J BIOL CHEM, V269, P3063; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Lu CC, 1999, J GEN PHYSIOL, V114, P429, DOI 10.1085/jgp.114.3.429; Mager S, 1996, J NEUROSCI, V16, P5405; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; Mari SA, 2006, CELL MOL LIFE SCI, V63, P100, DOI 10.1007/s00018-005-5512-6; Nelson N, 1998, J NEUROCHEM, V71, P1785; PerezGarcia MT, 1996, P NATL ACAD SCI USA, V93, P300, DOI 10.1073/pnas.93.1.300; Quick M, 2006, J BIOL CHEM, V281, P26444, DOI 10.1074/jbc.M602438200; RADIAN R, 1986, J BIOL CHEM, V261, P5437; Roux MJ, 2001, J BIOL CHEM, V276, P17699, DOI 10.1074/jbc.M009196200; Singh SK, 2007, NATURE, V448, P952, DOI 10.1038/nature06038; Vandenberg RJ, 2007, J BIOL CHEM, V282, P14447, DOI 10.1074/jbc.M609158200; Yamashita A, 2005, NATURE, V437, P215, DOI 10.1038/nature03978; Yernool D, 2004, NATURE, V431, P811, DOI 10.1038/nature03018; Yu N, 1998, FEBS LETT, V426, P174, DOI 10.1016/S0014-5793(98)00333-0; Zhang YW, 2006, J BIOL CHEM, V281, P36213, DOI 10.1074/jbc.M605468200; Zhou YG, 2004, J BIOL CHEM, V279, P13800, DOI 10.1074/jbc.M311579200; Zhou YG, 2006, J BIOL CHEM, V281, P22092, DOI 10.1074/jbc.M602319200; Zhou Z, 2007, SCIENCE, V317, P1390, DOI 10.1126/science.1147614; Zomot E, 2005, J BIOL CHEM, V280, P25512, DOI 10.1074/jbc.M503864200; Zomot E, 2003, J BIOL CHEM, V278, P42950, DOI 10.1074/jbc.M209307200; Zomot E, 2007, NATURE, V449, P726, DOI 10.1038/nature06133	42	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14376	14383		10.1074/jbc.M801093200	http://dx.doi.org/10.1074/jbc.M801093200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18381286	hybrid			2022-12-25	WOS:000255941400024
J	Ageta, H; Murayama, A; Migishima, R; Kida, S; Tsuchida, K; Yokoyama, M; Inokuchi, K				Ageta, Hiroshi; Murayama, Akiko; Migishima, Rika; Kida, Satoshi; Tsuchida, Kunihiro; Yokoyama, Minesuke; Inokuchi, Kaoru			Activin in the Brain Modulates Anxiety-Related Behavior and Adult Neurogenesis	PLOS ONE			English	Article								Activin, a member of the transforming growth factor-beta superfamily, is an endocrine hormone that regulates differentiation and proliferation of a wide variety of cells. In the brain, activin protects neurons from ischemic damage. In this study, we demonstrate that activin modulates anxiety-related behavior by analyzing ACM4 and FSM transgenic mice in which activin and follistatin (which antagonizes the activin signal), respectively, were overexpressed in a forebrain-specific manner under the control of the alpha CaMKII promoter. Behavioral analyses revealed that FSM mice exhibited enhanced anxiety compared to wild-type littermates, while ACM4 mice showed reduced anxiety. Importantly, survival of newly formed neurons in the subgranular zone of adult hippocampus was significantly decreased in FSM mice, which was partially rescued in ACM4/FSM double transgenic mice. Our findings demonstrate that the level of activin in the adult brain bi-directionally influences anxiety-related behavior. These results further suggest that decreases in postnatal neurogenesis caused by activin inhibition affect an anxiety-related behavior in adulthood. Activin and its signaling pathway may represent novel therapeutic targets for anxiety disorder as well as ischemic brain injury.	[Ageta, Hiroshi; Murayama, Akiko; Migishima, Rika; Yokoyama, Minesuke; Inokuchi, Kaoru] Mitsubishi Kagaku Inst Life Sci, Tokyo, Japan; [Ageta, Hiroshi; Murayama, Akiko; Kida, Satoshi; Inokuchi, Kaoru] CREST, Japan Sci & Technol Corp, Kawaguchi, Japan; [Kida, Satoshi; Inokuchi, Kaoru] Yokohama Natl Univ, Grad Sch Environm & Informat Sci, Yokohama, Kanagawa, Japan; Tokyo Univ Agr, Dept Biosci, Tokyo, Japan; [Tsuchida, Kunihiro] Fujita Hlth Univ, Inst Comprehensive Med Sci, Div Therapies Against Intractable Dis, Aichi, Japan; [Yokoyama, Minesuke] Niigata Univ, Brain Res Inst, Niigata, Japan	Mitsubishi Kagaku Institute of Life Sciences (MITILS); Japan Science & Technology Agency (JST); Yokohama National University; Tokyo University of Agriculture; Fujita Health University; Niigata University	Ageta, H (corresponding author), Mitsubishi Kagaku Inst Life Sci, Tokyo, Japan.	kaoru@mitils.jp	Inokuchi, Kaoru/AAI-9693-2020; Tsuchida, Kunihiro/A-4501-2012	Inokuchi, Kaoru/0000-0002-5393-3133; Tsuchida, Kunihiro/0000-0002-3983-5756	MEXT of the Japanese Government [Grant-in-Aid]	MEXT of the Japanese Government(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT))	This work was supported by the Special Coordinate Funds for Promoting Science and Technology from MEXT of the Japanese Government (K.I.), and in part by a Grant-in-Aid for Scientific Research on Priority Areas Neural Circuit Project, Advanced Brain Science Project, and Molecular Brain Science, from MEXT of the Japanese Government (K.I.).	ANDREASSON K, 1995, NEUROSCIENCE, V69, P781, DOI 10.1016/0306-4522(95)00245-E; Bilezikjian LM, 2006, REPRODUCTION, V132, P207, DOI 10.1530/rep.1.01073; BRINSTER RL, 1985, P NATL ACAD SCI USA, V82, P4438, DOI 10.1073/pnas.82.13.4438; CAMERON VA, 1994, ENDOCRINOLOGY, V134, P799, DOI 10.1210/en.134.2.799; Cryan JF, 2005, NAT REV DRUG DISCOV, V4, P775, DOI 10.1038/nrd1825; Dow AL, 2005, J NEUROSCI, V25, P4908, DOI 10.1523/JNEUROSCI.5155-04.2005; Dranovsky A, 2006, BIOL PSYCHIAT, V59, P1136, DOI 10.1016/j.biopsych.2006.03.082; Earnheart JC, 2007, J NEUROSCI, V27, P3845, DOI 10.1523/JNEUROSCI.3609-06.2007; Fukazawa' Y, 2003, NEURON, V38, P447, DOI 10.1016/S0896-6273(03)00206-X; Funaba M, 1997, J NEUROENDOCRINOL, V9, P105, DOI 10.1046/j.1365-2826.1997.00558.x; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Guo QX, 1998, MOL ENDOCRINOL, V12, P96, DOI 10.1210/mend.12.1.0053; Hirao K, 1998, J BIOL CHEM, V273, P21105, DOI 10.1074/jbc.273.33.21105; Hogan B, 1994, MANIPULATING MOUSE E; Ikegami S, 2000, NEUROSCIENCE, V98, P637, DOI 10.1016/S0306-4522(00)00161-5; Inokuchi K, 1996, FEBS LETT, V382, P48, DOI 10.1016/0014-5793(96)00135-4; Kalueff AV, 2007, BEHAV BRAIN RES, V179, P1, DOI 10.1016/j.bbr.2007.01.023; Kempermann G, 2002, EUR J NEUROSCI, V16, P129, DOI 10.1046/j.1460-9568.2002.02042.x; Kida S, 2002, NAT NEUROSCI, V5, P348, DOI 10.1038/nn819; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; Matsuo R, 2001, BIOCHEM BIOPH RES CO, V289, P479, DOI 10.1006/bbrc.2001.5975; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Mirescu C, 2004, NAT NEUROSCI, V7, P841, DOI 10.1038/nn1290; Munz B, 1999, EMBO J, V18, P5205, DOI 10.1093/emboj/18.19.5205; Nakagawa S, 2002, J NEUROSCI, V22, P3673; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Shoji H, 2000, J BIOL CHEM, V275, P5485, DOI 10.1074/jbc.275.8.5485; Shoji-Kasai Y, 2007, J CELL SCI, V120, P3830, DOI 10.1242/jcs.012450; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Spear LP, 2000, NEUROSCI BIOBEHAV R, V24, P417, DOI 10.1016/S0149-7634(00)00014-2; Stansfield KH, 2007, PHARMACOL BIOCHEM BE, V86, P637, DOI 10.1016/j.pbb.2007.02.008; Sugino Hiromu, 1997, Journal of Medical Investigation, V44, P1; Tang YP, 1999, NATURE, V401, P63, DOI 10.1038/43432; Tretter YP, 2000, NAT MED, V6, P812, DOI 10.1038/77548; Wankell M, 2001, EMBO J, V20, P5361, DOI 10.1093/emboj/20.19.5361; Wong ML, 2004, NAT REV DRUG DISCOV, V3, P136, DOI 10.1038/nrd1303	39	85	86	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1869	10.1371/journal.pone.0001869	http://dx.doi.org/10.1371/journal.pone.0001869			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382659	gold, Green Published, Green Submitted			2022-12-25	WOS:000260795400009
J	Alphonse, MP; Saffar, AS; Shan, L; HayGlass, KT; Simons, FER; Gounni, AS				Alphonse, Martin P.; Saffar, Arash S.; Shan, Lianyu; HayGlass, Kent T.; Simons, F. Estelle R.; Gounni, Abdelilah S.			Regulation of the High Affinity IgE Receptor (Fc epsilon RI) in Human Neutrophils: Role of Seasonal Allergen Exposure and Th-2 Cytokines	PLOS ONE			English	Article								The high affinity IgE receptor, Fc epsilon RI, plays a key role in the immunological pathways involved in allergic asthma. Previously we have demonstrated that human neutrophils isolated from allergic asthmatics express a functional Fc epsilon RI, and therefore it was of importance to examine the factors regulating its expression. In this study, we found that neutrophils from allergic asthmatics showed increased expression of Fc epsilon RI-alpha chain surface protein, total protein and mRNA compared with those from allergic non asthmatics and healthy donors (p<0.001). Interestingly, in neutrophils isolated from allergic asthmatics, Fc epsilon RI-alpha chain surface protein and mRNA expression were significantly greater during the pollen season than outside the pollen season (n = 9, P = 0.001), an effect which was not observed either in the allergic non asthmatic group or the healthy donors (p>0.05). Allergen exposure did not affect other surface markers of neutrophils such as CD16/Fc gamma RIII or IL-17R. In contrast to stimulation with IgE, neutrophils incubated with TH2 cytokines IL-9, GM-CSF, and IL-4, showed enhanced Fc epsilon RI-alpha chain surface expression. In conclusion, these results suggest that enhanced Fc epsilon RI expression in human neutrophils from allergic asthmatics during the pollen season can make them more susceptible to the biological effects of IgE, providing a possible new mechanism by which neutrophils contribute to allergic asthma.	[Alphonse, Martin P.; Saffar, Arash S.; Shan, Lianyu; HayGlass, Kent T.; Simons, F. Estelle R.; Gounni, Abdelilah S.] Univ Manitoba, Fac Med, Dept Immunol, Winnipeg, MB R3E 0W3, Canada; [HayGlass, Kent T.; Simons, F. Estelle R.] Univ Manitoba, Fac Med, Dept Pediat & Child Hlth, Winnipeg, MB, Canada	University of Manitoba; University of Manitoba	Gounni, AS (corresponding author), Univ Manitoba, Fac Med, Dept Immunol, Winnipeg, MB R3E 0W3, Canada.	gounni@cc.umanitoba.ca	Gounni, Abdelilah Soussi/AAH-3456-2020; Alphonse, Martin/AAP-4397-2021	Alphonse, Martin/0000-0003-3447-1284; HayGlass, Kent/0000-0002-4621-7737; Gounni, Abdelilah/0000-0003-1265-6560; Soussi Gounni, Abdelilah/0000-0002-7282-0388	Canadian Institutes of Health Research (CIHR); CIHR sponsored National Training Program in Allergy and Asthma (NTPAA) [studentships]; Manitoba Health Research Council; HSCF Olenick award for excellence in immunology research	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); CIHR sponsored National Training Program in Allergy and Asthma (NTPAA)(Canadian Institutes of Health Research (CIHR)); Manitoba Health Research Council; HSCF Olenick award for excellence in immunology research	This work was supported by grants from the Canadian Institutes of Health Research (CIHR). ASS is supported by studentships from CIHR sponsored National Training Program in Allergy and Asthma (NTPAA), Manitoba Health Research Council and the HSCF Olenick award for excellence in immunology research. The sponsors of the study had no role in study design, collection, analysis or interpretation of data, writing of the report, or in the final decision to submit this report for publication.	BRADLEY BL, 1991, J ALLERGY CLIN IMMUN, V88, P661, DOI 10.1016/0091-6749(91)90160-P; BURROWS B, 1989, NEW ENGL J MED, V320, P271, DOI 10.1056/NEJM198902023200502; Campbell AM, 1998, AM J RESP CELL MOL, V19, P92, DOI 10.1165/ajrcmb.19.1.2648; Ennis M, 2003, CURR ALLERGY ASTHM R, V3, P159, DOI 10.1007/s11882-003-0029-2; FAHY JV, 1995, J ALLERGY CLIN IMMUN, V95, P843, DOI 10.1016/S0091-6749(95)70128-1; FURUICHI K, 1985, P NATL ACAD SCI USA, V82, P1522, DOI 10.1073/pnas.82.5.1522; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; Gounni AS, 2001, FASEB J, V15, P940, DOI 10.1096/fj.00-0378com; Holgate ST, 2006, LANCET, V368, P780, DOI 10.1016/S0140-6736(06)69288-X; Kelly EAB, 2000, AM J RESP CRIT CARE, V162, P1157; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; Kraft S, 1998, J IMMUNOL, V161, P1000; Lantz CS, 1997, J IMMUNOL, V158, P2517; LAVABREBERTRAND T, 1994, LEUKEMIA, V8, P1557; MacGlashan D, 1998, BLOOD, V91, P1633, DOI 10.1182/blood.V91.5.1633.1633_1633_1643; MacGlashan D, 2001, J LEUKOCYTE BIOL, V70, P207; MALVEAUX FJ, 1978, J CLIN INVEST, V62, P176, DOI 10.1172/JCI109103; Maurer D, 1996, J IMMUNOL, V157, P607; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; Monteseirin J, 2003, INT ARCH ALLERGY IMM, V131, P174, DOI 10.1159/000071483; Monteseirin J, 2001, CLIN EXP ALLERGY, V31, P889, DOI 10.1046/j.1365-2222.2001.01083.x; Monteseirin J, 2004, J LEUKOCYTE BIOL, V76, P692, DOI 10.1189/jlb.0903441; Nechansky A, 1997, HYBRIDOMA, V16, P441, DOI 10.1089/hyb.1997.16.441; Nguyen LT, 2005, RESP MED, V99, P200, DOI 10.1016/j.rmed.2004.06.007; Nocker RET, 1999, INT ARCH ALLERGY IMM, V119, P45, DOI 10.1159/000024174; Novak N, 2001, J IMMUNOL, V167, P797, DOI 10.4049/jimmunol.167.2.797; O'Byrne PM, 2003, CHEST, V123, p411S, DOI 10.1378/chest.123.3_suppl.411S; Ordonez CL, 2000, AM J RESP CRIT CARE, V161, P1185, DOI 10.1164/ajrccm.161.4.9812061; Peebles RS, 1998, J ALLERGY CLIN IMMUN, V101, P265, DOI 10.1016/S0091-6749(98)70392-6; Peebles RS, 2001, CLIN EXP ALLERGY, V31, P239; Qian X, 2003, DIAGN MOL PATHOL, V12, P1, DOI 10.1097/00019606-200303000-00001; QUARTO R, 1985, MOL IMMUNOL, V22, P1045, DOI 10.1016/0161-5890(85)90107-5; Saffar AS, 2007, J IMMUNOL, V178, P2535, DOI 10.4049/jimmunol.178.4.2535; Terada N, 1995, J ALLERGY CLIN IMMUN, V96, P1161, DOI 10.1016/S0091-6749(95)70201-6; Xia HZ, 1997, J IMMUNOL, V159, P2911; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Yamaguchi M, 1999, J IMMUNOL, V162, P5455; Yamaoka KA, 1996, INT IMMUNOL, V8, P479, DOI 10.1093/intimm/8.4.479; Yano K, 1997, LAB INVEST, V77, P185	39	21	24	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1921	10.1371/journal.pone.0001921	http://dx.doi.org/10.1371/journal.pone.0001921			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382690	gold, Green Submitted, Green Published			2022-12-25	WOS:000260795400043
J	Ma, XL; Hibbert, B; White, D; Seymour, R; Whitman, SC; O'Brien, ER				Ma, Xiaoli; Hibbert, Benjamin; White, Dawn; Seymour, Richard; Whitman, Stewart C.; O'Brien, Edward R.			Contribution of Recipient-Derived Cells in Allograft Neointima Formation and the Response to Stent Implantation	PLOS ONE			English	Article							SMOOTH-MUSCLE-CELLS; ENDOTHELIAL PROGENITOR CELLS; GROWTH-FACTOR; MONONUCLEAR-CELLS; VASA VASORUM; BLOOD-CELLS; ORIGIN; ATHEROSCLEROSIS; VASCULOPATHY; ANGIOPLASTY	Allograft coronary disease is the dominant cause of increased risk of death after cardiac transplantation. While the percutaneous insertion of stents is the most efficacious revascularization strategy for allograft coronary disease there is a high incidence of stent renarrowing. We developed a novel rabbit model of sex-mismatched allograft vascular disease as well as the response to stent implantation. In situ hybridization for the Y-chromosome was employed to detect male cells in the neointima of stented allograft, and the population of recipient derived neointimal cells was measured by quantitative polymerase chain reaction and characterized by immunohistochemistry. To demonstrate the participation of circulatory derived cells in stent neointima formation we infused ex vivo labeled peripheral blood mononuclear cells into native rabbit carotid arteries immediately after stenting. Fourteen days after stenting the neointima area was 58% greater in the stented vs. non-stented allograft segments (p = 0.02). Male cells were detected in the neointima of stented female-to-male allografts. Recipient-derived cells constituted 72.1 +/- 5.7% and 81.5 +/- 4.2% of neointimal cell population in the non-stented and stented segments, respectively and the corresponding proliferation rates were only 2.7 +/- 0.5% and 2.3 +/- 0.2%. Some of the recipient-derived neointimal cells were of endothelial lineage. The ex vivo tagged cells constituted 9.0 +/- 0.4% of the cells per high power field in the stent neointima 14 days after stenting. These experiments provide important quantitative data regarding the degree to which host-derived blood-borne cells contribute to neointima formation in allograft vasculopathy and the early response to stent implantation.	[Ma, Xiaoli; Hibbert, Benjamin; White, Dawn; Seymour, Richard; Whitman, Stewart C.; O'Brien, Edward R.] Univ Ottawa, Inst Heart, Vasc Biol Lab, Ottawa, ON, Canada	University of Ottawa; University of Ottawa Heart Institute	Ma, XL (corresponding author), Univ Ottawa, Inst Heart, Vasc Biol Lab, Ottawa, ON, Canada.	eobrien@ottawaheart.ca	O'Brien, Edward R/J-6621-2013	O'Brien, Edward R/0000-0003-1039-9425	Canadian Institutes of Health Research (CIHR) [36383]; Medtronic [36383]; Heart and Stroke Foundation of Ontario [New Investigator]; Great-West Life and London Life Research salary award	Canadian Institutes of Health Research (CIHR)(Canadian Institutes of Health Research (CIHR)); Medtronic(Medtronic); Heart and Stroke Foundation of Ontario(Heart & Stroke Foundation of Ontario); Great-West Life and London Life Research salary award	This work is supported by an operating grant to EOB (UOP #36383) that is jointly funded by the Canadian Institutes of Health Research (CIHR) and Medtronic. SCW is a New Investigator of the Heart and Stroke Foundation of Ontario and the recipient of the Great-West Life and London Life Research salary award. EOB holds a Research Chair that is jointly funded by the CIHR and Medtronic.	Aranda JM, 2002, J HEART LUNG TRANSPL, V21, P860, DOI 10.1016/S1053-2498(02)00413-8; ASAHARA T, 1995, CIRCULATION, V91, P2793, DOI 10.1161/01.CIR.91.11.2793; Bentzon JF, 2006, ARTERIOSCL THROM VAS, V26, P2696, DOI 10.1161/01.ATV.0000247243.48542.9d; Benza RL, 2004, J AM COLL CARDIOL, V43, P1973, DOI 10.1016/j.jacc.2004.02.045; Byrne P, 2002, BIOTECHNIQUES, V32, P279; Caplice NM, 2003, P NATL ACAD SCI USA, V100, P4754, DOI 10.1073/pnas.0730743100; CLARKE JA, 1965, J ANAT, V99, P877; De Leon H, 2001, CIRCULATION, V104, P1591, DOI 10.1161/circ.104.14.1591; FEIGL W, 1985, VIRCHOWS ARCH A, V406, P133, DOI 10.1007/BF00737081; Froeschl M, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P103, DOI 10.2174/1568006043481293; Glaser R, 2002, CIRCULATION, V106, P17, DOI 10.1161/01.CIR.0000021923.58307.8F; Hibbert B, 2003, TRENDS CARDIOVAS MED, V13, P322, DOI 10.1016/j.tcm.2003.09.002; Hillebrands JL, 2005, TRENDS CARDIOVAS MED, V15, P1, DOI 10.1016/j.tcm.2004.10.002; Hillebrands JL, 2003, ARTERIOSCL THROM VAS, V23, P380, DOI 10.1161/01.ATV.0000059337.60393.64; Hillebrands JL, 2001, J CLIN INVEST, V107, P1411, DOI 10.1172/JCI10233; Hoofnagle MH, 2006, ARTERIOSCL THROM VAS, V26, P2579, DOI 10.1161/01.ATV.0000249623.79871.bc; Hristov M, 2003, TRENDS CARDIOVAS MED, V13, P201, DOI 10.1016/S1050-1738(03)00077-X; Jabs A, 2005, J VASC RES, V42, P174, DOI 10.1159/000084406; Jimenez DF, 2005, TRANSPLANTATION, V79, P142, DOI 10.1097/01.TP.0000144468.71962.AA; Jonas M, 2006, J AM COLL CARDIOL, V48, P453, DOI 10.1016/j.jacc.2006.01.081; KENNEDY LJ, 1971, NEW ENGL J MED, V285, P884, DOI 10.1056/NEJM197110142851603; Lowe HC, 2003, CATHETER CARDIO INTE, V60, P515, DOI 10.1002/ccd.10705; Ma XL, 2004, J LEUKOCYTE BIOL, V75, P1016, DOI 10.1189/jlb.1203618; MARTIN JF, 1991, EUR J CLIN INVEST, V21, P355, DOI 10.1111/j.1365-2362.1991.tb01382.x; McBride C, 2003, CYTOTHERAPY, V5, P7, DOI 10.1080/14653240310000038; Minami E, 2005, CIRCULATION, V112, P2951, DOI 10.1161/CIRCULATIONAHA.105.576017; Nowak G, 2004, CIRCULATION, V110, P3699, DOI 10.1161/01.CIR.0000143626.16576.51; OBRIEN ER, 1994, AM J PATHOL, V145, P883; Peters BA, 2005, NAT MED, V11, P261, DOI 10.1038/nm1200; Quaini F, 2002, NEW ENGL J MED, V346, P5, DOI 10.1056/NEJMoa012081; Religa P, 2005, CARDIOVASC RES, V65, P535, DOI 10.1016/j.cardiores.2004.10.011; ROSS R, 1993, NATURE, V362, P801, DOI 10.1038/362801a0; Schnetzler B, 2000, J HEART LUNG TRANSPL, V19, P557, DOI 10.1016/S1053-2498(00)00115-7; SCHWARTZ SM, 1995, CIRC RES, V77, P445, DOI 10.1161/01.RES.77.3.445; Simper D, 2003, CIRCULATION, V108, P143, DOI 10.1161/01.CIR.0000081703.34526.5D; Simper D, 2002, CIRCULATION, V106, P1199, DOI 10.1161/01.CIR.0000031525.61826.A8; Simpson L, 2005, J HEART LUNG TRANSPL, V24, P1211, DOI 10.1016/j.healun.2004.10.005; TAKESHITA S, 1995, AM J PATHOL, V147, P1649; Wang LJ, 2002, LIVER TRANSPLANT, V8, P822, DOI 10.1053/jlts.2002.34891; Werner N, 2003, CIRC RES, V93, pE17, DOI 10.1161/01.RES.0000083812.30141.74; WU MHD, 1995, J VASC SURG, V21, P862, DOI 10.1016/S0741-5214(05)80019-9; Yan BPY, 2005, CARDIOVASC REVASCULA, V6, P38, DOI 10.1016/j.carrev.2005.04.003; Yeh ETH, 2003, CIRCULATION, V108, P2070, DOI 10.1161/01.CIR.0000099501.52718.70	43	9	11	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1894	10.1371/journal.pone.0001894	http://dx.doi.org/10.1371/journal.pone.0001894			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365026	Green Submitted, Green Published, gold			2022-12-25	WOS:000260762400032
J	Wang, JF; Meng, JH; Lawrence, GW; Zurawski, TH; Sasse, A; Bodeker, MO; Gilmore, MA; Fernandez-Salas, E; Francis, J; Steward, LE; Aoki, KR; Dolly, JO				Wang, Jiafu; Meng, Jianghui; Lawrence, Gary W.; Zurawski, Tomas H.; Sasse, Astrid; Bodeker, MacDara O.; Gilmore, Marcella A.; Fernandez-Salas, Ester; Francis, Joseph; Steward, Lance E.; Aoki, K. Roger; Dolly, J. Oliver			Novel chimeras of botulinum neurotoxins A and E unveil contributions from the binding, translocation, and protease domains to their functional characteristics	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOXIN TYPE-A; CLOSTRIDIAL NEUROTOXINS; TRANSMITTER RELEASE; SYNAPTOTAGMIN-I; SEROTYPE-A; INHIBITION; EXOCYTOSIS; RECEPTOR; DISULFIDE; MARGINS	Hyperexcitability disorders of cholinergically innervated muscles are treatable with botulinum neurotoxin (BoNT) A. The seven serotypes (A-G) potently block neurotransmission by binding to presynaptic receptors, undergoing endocytosis, transferring to the cytosol, and inactivating proteins essential for vesicle fusion. Although BoNT/A and BoNT/E cleave SNAP-25, albeit at distinct sites, BoNT/E blocks neurotransmission faster and more potently. To identify the domains responsible for these characteristics, the C-terminal heavy chain portions of BoNT/A and BoNT/E were exchanged to create chimeras AE and EA. After high yield expression in Escherichia coli, these single chain chimeras were purified by two-step chromatography and activated by conversion to disulfide-linked dichains. In vitro, each entered neurons, cleaved SNAP-25, and blocked neuromuscular transmission while causing flaccid paralysis in vivo. Acidification-dependent translocation of the light chain to the cytosol occurred more rapidly for BoNT/E and EA than for BoNT/A and AE because the latter pair remained susceptible for longer to inhibitors of the vesicular proton pump, and BoNT/A proved less sensitive. The receptor-binding and protease domains do not seem to be responsible for the speeds of intoxication; rather the N-terminal halves of their heavy chains are implicated, with dissimilar rates of cytosolic transfer of the light chains being due to differences in pH sensitivity. AE produced the most persistent muscle weakening and therefore has therapeutic potential. Thus, proof of principle is provided for tailoring the pharmacological properties of these toxins by protein engineering.	[Wang, Jiafu; Meng, Jianghui; Lawrence, Gary W.; Zurawski, Tomas H.; Sasse, Astrid; Bodeker, MacDara O.; Dolly, J. Oliver] Dublin City Univ, Int Ctr Neurotherapeut, Dublin 9, Ireland; [Gilmore, Marcella A.; Fernandez-Salas, Ester; Francis, Joseph; Steward, Lance E.; Aoki, K. Roger] Allergan Pharmaceut Inc, Irvine, CA 92623 USA	Dublin City University; AbbVie; Allergan	Dolly, JO (corresponding author), Dublin City Univ, Int Ctr Neurotherapeut, Dublin 9, Ireland.	oliver.dolly@dcu.ie	Wang, Jiafu/AAX-9388-2020; Dolly, Oliver/G-1532-2012; Meng, Jianghui/H-4302-2014; Dolly, Oliver/ABH-6677-2020; Lawrence, Gary/F-3949-2012; Sasse, Astrid/A-4690-2015	Wang, Jiafu/0000-0002-3654-4400; Dolly, Oliver/0000-0002-0861-5320; Dolly, Oliver/0000-0002-0861-5320; Meng, Jianghui/0000-0002-3107-4200; Sasse, Astrid/0000-0001-8214-8946				Aoki KR, 2002, TOXICON, V40, P923, DOI 10.1016/S0041-0101(02)00086-7; Aoki KR, 2001, TOXICON, V39, P1815, DOI 10.1016/S0041-0101(01)00101-5; ARNON SS, 2002, SCI THERAPEUTIC ASPE, P145; Barnes MP, 2007, CLINICAL USES OF BOTULINUM TOXINS, P1, DOI 10.1017/CBO9780511544842.001; Chaddock JA, 2002, PROTEIN EXPRES PURIF, V25, P219, DOI 10.1016/S1046-5928(02)00002-5; CULLCANDY SG, 1976, J PHYSIOL-LONDON, V260, P177, DOI 10.1113/jphysiol.1976.sp011510; DEPAIVA A, 1993, J BIOL CHEM, V268, P20838; DEPAIVA A, 1993, J NEUROCHEM, V61, P2338, DOI 10.1111/j.1471-4159.1993.tb07482.x; Dolly JO, 2007, CLINICAL USES OF BOTULINUM TOXINS, P9, DOI 10.1017/CBO9780511544842.002; DOLLY JO, 1994, SEMIN NEUROSCI, V6, P149; Dong M, 2006, SCIENCE, V312, P592, DOI 10.1126/science.1123654; Dong M, 2003, J CELL BIOL, V162, P1293, DOI 10.1083/jcb.200305098; Eleopra R, 1998, NEUROSCI LETT, V256, P135, DOI 10.1016/S0304-3940(98)00775-7; Fischer A, 2008, J BIOL CHEM, V283, P3997, DOI 10.1074/jbc.M707917200; Fischer A, 2007, J BIOL CHEM, V282, P29604, DOI 10.1074/jbc.M703619200; Fischer A, 2007, P NATL ACAD SCI USA, V104, P10447, DOI 10.1073/pnas.0700046104; Foran PG, 2003, J BIOL CHEM, V278, P1363, DOI 10.1074/jbc.M209821200; Foster KA, 2006, NEUROTOX RES, V9, P101, DOI 10.1007/BF03354881; Francis JW, 2000, J NEUROCHEM, V74, P2528, DOI 10.1046/j.1471-4159.2000.0742528.x; Gerona RRL, 2000, J BIOL CHEM, V275, P6328, DOI 10.1074/jbc.275.9.6328; Keller JE, 2004, BIOCHEMISTRY-US, V43, P526, DOI 10.1021/bi0356698; Lacy DB, 1998, NAT STRUCT BIOL, V5, P898, DOI 10.1038/2338; Lawrence G, 2007, J PHARMACOL EXP THER, V320, P410, DOI 10.1124/jpet.106.108829; Lawrence GW, 1997, BIOCHEMISTRY-US, V36, P3061, DOI 10.1021/bi9622478; Mahanthappa N. K., 1998, CULTURING NERVE CELL, P289; Mahrhold S, 2006, FEBS LETT, V580, P2011, DOI 10.1016/j.febslet.2006.02.074; MAISEY EA, 1988, EUR J BIOCHEM, V177, P683, DOI 10.1111/j.1432-1033.1988.tb14423.x; Meng JH, 2007, J CELL SCI, V120, P2864, DOI 10.1242/jcs.012211; Meunier FA, 2003, MOL CELL NEUROSCI, V22, P454, DOI 10.1016/S1044-7431(02)00016-7; Montecucco C, 2004, TRENDS MICROBIOL, V12, P442, DOI 10.1016/j.tim.2004.08.002; Nishiki T, 1996, FEBS LETT, V378, P253, DOI 10.1016/0014-5793(95)01471-3; Rummel A, 2004, J BIOL CHEM, V279, P30865, DOI 10.1074/jbc.M403945200; Rummel A, 2007, P NATL ACAD SCI USA, V104, P359, DOI 10.1073/pnas.0609713104; Sakaba T, 2005, SCIENCE, V309, P491, DOI 10.1126/science.1112645; SCHMID MF, 1993, NATURE, V364, P827, DOI 10.1038/364827a0; Shone CC, 1995, CURR TOP MICROBIOL, V195, P143; SIMPSON LL, 1980, J PHARMACOL EXP THER, V212, P16; SIMPSON LL, 1983, J PHARMACOL EXP THER, V224, P135; SIMPSON LL, 1994, J PHARMACOL EXP THER, V269, P256; Studier FW, 2005, PROTEIN EXPRES PURIF, V41, P207, DOI 10.1016/j.pep.2005.01.016; Swaminathan S, 2000, ACTA CRYSTALLOGR D, V56, P1024, DOI 10.1107/S0907444900006764; Williams D., 2006, NEUROTOX RES, V9, P239; Xu T, 1998, NAT NEUROSCI, V1, P192, DOI 10.1038/642	43	89	99	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					16993	17002		10.1074/jbc.M710442200	http://dx.doi.org/10.1074/jbc.M710442200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18400760	hybrid			2022-12-25	WOS:000256720600005
J	Hackbarth, JS; Galvez-Peralta, M; Dai, NT; Loegering, DA; Peterson, KL; Meng, XW; Karnitz, LM; Kaufmann, SH				Hackbarth, Jennifer S.; Galvez-Peralta, Marina; Dai, Nga T.; Loegering, David A.; Peterson, Kevin L.; Meng, Xue W.; Karnitz, Larry M.; Kaufmann, Scott H.			Mitotic phosphorylation stimulates DNA relaxation activity of human topoisomerase I	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MYELOGENOUS LEUKEMIA-CELLS; MAMMALIAN-CELLS; EUKARYOTIC TOPOISOMERASE; RELIGATION REACTIONS; TERMINAL DOMAIN; CAMPTOTHECIN; CLEAVAGE; ENZYME; CYCLE	Human DNA topoisomerase I (topo I) is an essential mammalian enzyme that regulates DNA supercoiling during transcription and replication. In addition, topo I is specifically targeted by the anticancer compound camptothecin and its derivatives. Previous studies have indicated that topo I is a phosphoprotein and that phosphorylation stimulates its DNA relaxation activity. The locations of most topo I phosphorylation sites have not been identified, preventing a more detailed examination of this modification. To address this issue, mass spectrometry was used to identify four topo I residues that are phosphorylated in intact cells: Ser(10), Ser(21), Ser(112), and Ser(394). Immunoblotting using anti-phosphoepitope antibodies demonstrated that these sites are phosphorylated during mitosis. In vitro kinase assays demonstrated that Ser10 can be phosphorylated by casein kinase II, Ser21 can be phosphorylated by protein kinase C alpha, and Ser(112) and Ser(394) can be phosphorylated by Cdk1. When wild type topo I was pulled down from mitotic cells and dephosphorylated with alkaline phosphatase, topo I activity decreased 2-fold. Likewise, topo I polypeptide with all four phosphorylation sites mutated to alanine exhibited 2-fold lower DNA relaxation activity than wild type topo I after isolation from mitotic cells. Further mutational analysis demonstrated that Ser21 phosphorylation was responsible for this change. Consistent with these results, wild type topo I (but not S21A topo I) exhibited increased sensitivity to camptothecin-induced trapping on DNA during mitosis. Collectively these results indicate that topo I is phosphorylated during mitosis at multiple sites, one of which enhances DNA relaxation activity in vitro and interaction with DNA in cells.	[Galvez-Peralta, Marina; Dai, Nga T.; Loegering, David A.; Peterson, Kevin L.; Meng, Xue W.; Karnitz, Larry M.; Kaufmann, Scott H.] Mayo Clin, Div Oncol Res, Mayo Grad Sch, Rochester, MN 55905 USA; [Hackbarth, Jennifer S.] Mayo Clin, Dept Biochem & Mol Biol, Mayo Grad Sch, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Kaufmann, SH (corresponding author), Mayo Clin, Div Oncol Res, Mayo Grad Sch, Guggenheim 1342C,200 1st St SW, Rochester, MN 55905 USA.	Kaufmann.scott@mayo.edu		Kaufmann, Scott/0000-0002-4900-7145	NATIONAL CANCER INSTITUTE [R01CA073709] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA73709, R01 CA073709] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN P, 1985, P NATL ACAD SCI USA, V82, P3164, DOI 10.1073/pnas.82.10.3164; ALSNER J, 1992, J BIOL CHEM, V267, P12408; Blajeski AL, 2001, EXP CELL RES, V270, P277, DOI 10.1006/excr.2001.5349; Brenneisen P, 2002, ANN NY ACAD SCI, V973, P31, DOI 10.1111/j.1749-6632.2002.tb04602.x; Buckwalter CA, 1996, CANCER RES, V56, P1674; BURDEN DA, 1993, BIOCHEM J, V293, P297, DOI 10.1042/bj2930297; BURDEN DA, 1994, BIOCHEMISTRY-US, V33, P14651, DOI 10.1021/bi00253a001; CARDELLINI E, 1993, BIOCHEM J, V291, P303, DOI 10.1042/bj2910303; CARDELLINI E, 1994, BIOL CHEM H-S, V375, P255, DOI 10.1515/bchm3.1994.375.4.255; CARDENAS ME, 1993, J CELL SCI, V104, P533; Champoux JJ, 2001, ANNU REV BIOCHEM, V70, P369, DOI 10.1146/annurev.biochem.70.1.369; CHAMPOUX JJ, 1976, P NATL ACAD SCI USA, V73, P3488, DOI 10.1073/pnas.73.10.3488; CODERONI S, 1990, MOL BIOL REP, V14, P35, DOI 10.1007/BF00422713; CORBETT AH, 1993, J BIOL CHEM, V268, P14394; COVEY JM, 1989, CANCER RES, V49, P5016; DARPA P, 1995, EXP CELL RES, V217, P125, DOI 10.1006/excr.1995.1071; DURBAN E, 1985, EMBO J, V4, P2921, DOI 10.1002/j.1460-2075.1985.tb04024.x; DURBAN E, 1983, BIOCHEM BIOPH RES CO, V111, P897, DOI 10.1016/0006-291X(83)91384-0; FROELICHAMMON SJ, 1995, J BIOL CHEM, V270, P21429, DOI 10.1074/jbc.270.37.21429; GASSER SM, 1992, ANTON LEEUW INT J G, V62, P15, DOI 10.1007/BF00584459; Hackbarth JS, 2004, BIOTECHNIQUES, V37, P835; Hann C, 1998, J BIOL CHEM, V273, P8425, DOI 10.1074/jbc.273.14.8425; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HENDRICKS CB, 1992, CANCER RES, V52, P2268; HSIANG YH, 1989, CANCER RES, V49, P5077; Isaacs RJ, 1998, BBA-GENE STRUCT EXPR, V1400, P121, DOI 10.1016/S0167-4781(98)00131-6; KAUFMANN SH, 1989, CANCER RES, V49, P5870; Kaufmann SH, 1997, BLOOD, V89, P2098, DOI 10.1182/blood.V89.6.2098; Kaufmann SH, 2001, ANAL BIOCHEM, V296, P283, DOI 10.1006/abio.2001.5313; Keller DM, 2001, MOL CELL, V7, P283, DOI 10.1016/S1097-2765(01)00176-9; KJELDSEN E, 1992, J MOL BIOL, V228, P1025, DOI 10.1016/0022-2836(92)90310-G; Koster DA, 2007, NATURE, V448, P213, DOI 10.1038/nature05938; MADDEN KR, 1992, CANCER RES, V52, P525; MEISENHELDER JT, 1999, CURRENT PROTOCOLS MO; Mesa RA, 2005, BLOOD, V106, P318, DOI 10.1182/blood-2004-09-3523; Meyer KN, 1997, J CELL BIOL, V136, P775, DOI 10.1083/jcb.136.4.775; Mo YY, 2000, J BIOL CHEM, V275, P41107, DOI 10.1074/jbc.M003135200; MULLER MT, 1985, EMBO J, V4, P1237, DOI 10.1002/j.1460-2075.1985.tb03766.x; Park SY, 2005, CANCER RES, V65, P3894, DOI 10.1158/0008-5472.CAN-04-4014; POMMIER Y, 1990, J BIOL CHEM, V265, P9418; PORTER SE, 1989, NUCLEIC ACIDS RES, V17, P8521, DOI 10.1093/nar/17.21.8521; Pourquier P, 2001, CANCER RES, V61, P53; Redinbo MR, 1998, SCIENCE, V279, P1504, DOI 10.1126/science.279.5356.1504; SAHYOUN N, 1986, P NATL ACAD SCI USA, V83, P1603, DOI 10.1073/pnas.83.6.1603; SAMUELS DS, 1992, J BIOL CHEM, V267, P11156; SAMUELS DS, 1994, BBA-MOL CELL RES, V1223, P77, DOI 10.1016/0167-4889(94)90075-2; SAMUELS DS, 1989, FEBS LETT, V259, P57, DOI 10.1016/0014-5793(89)81493-0; Schorl C, 2007, METHODS, V41, P143, DOI 10.1016/j.ymeth.2006.07.022; SHERO JH, 1986, SCIENCE, V231, P737, DOI 10.1126/science.3003910; SHIOZAKI K, 1992, J CELL BIOL, V119, P1023, DOI 10.1083/jcb.119.5.1023; Stewart L, 1997, J MOL BIOL, V269, P355, DOI 10.1006/jmbi.1997.1056; Stewart L, 1996, J BIOL CHEM, V271, P7593, DOI 10.1074/jbc.271.13.7593; SVEJSTRUP JQ, 1991, J MOL BIOL, V222, P669, DOI 10.1016/0022-2836(91)90503-X; SVEJSTRUP JQ, 1990, J BIOL CHEM, V265, P12529; TSEDINH YC, 1984, NATURE, V312, P785, DOI 10.1038/312785a0; TURMAN MA, 1993, BIOCHEM MED METAB B, V50, P210, DOI 10.1006/bmmb.1993.1063; Wang JC, 2002, NAT REV MOL CELL BIO, V3, P430, DOI 10.1038/nrm831; Yu DH, 2004, J BIOL CHEM, V279, P51851, DOI 10.1074/jbc.M404396200	58	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16711	16722		10.1074/jbc.M802246200	http://dx.doi.org/10.1074/jbc.M802246200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18408216	Green Published, hybrid			2022-12-25	WOS:000256497100048
J	Huysamen, C; Willment, JA; Dennehy, KM; Brown, GD				Huysamen, Cristal; Willment, Janet A.; Dennehy, Kevin M.; Brown, Gordon D.			CLEC9A is a novel activation C-type lectin-like receptor expressed on BDCA3(+) dendritic cells and a subset of monocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MACROPHAGE MANNOSE RECEPTOR; HUMAN PERIPHERAL-BLOOD; BETA-GLUCAN RECEPTOR; IMMUNE RECOGNITION; INNATE IMMUNITY; GENE-COMPLEX; DECTIN-1; PHAGOCYTOSIS; INDUCTION; KINASE	We describe here the first characterization of CLEC9A, a group V C-type lectin-like receptor located in the "Dectin-1 cluster" of related receptors, which are encoded within the natural killer (NK)-gene complex. Expression of human CLEC9A is highly restricted in peripheral blood, being detected only on BDCA3(+) dendritic cells and on a small subset of CD14(+) CD16(-) monocytes. CLEC9A is expressed at the cell surface as a glycosylated dimer and can mediate endocytosis, but not phagocytosis. CLEC9A possesses a cytoplasmic immunoreceptor tyrosine-based activation-like motif that can recruit Syk kinase, and we demonstrate, using receptor chimeras, that this receptor can induce proinflammatory cytokine production. These data indicate that CLEC9A functions as an activation receptor.	[Huysamen, Cristal; Willment, Janet A.; Dennehy, Kevin M.; Brown, Gordon D.] Univ Cape Town, Div Immunol, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa	University of Cape Town	Brown, GD (corresponding author), Univ Cape Town, Div Immunol, Inst Infect Dis & Mol Med, ZA-7925 Cape Town, South Africa.	gordon.brown@mweb.co.za	brown, gordon/B-4249-2012	Willment, Janet/0000-0002-7040-0857; brown, gordon/0000-0002-0287-5383	Wellcome Trust [070018, 076114] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Brown GD, 2002, J EXP MED, V196, P407, DOI 10.1084/jem.20020470; Brown GD, 2003, J EXP MED, V197, P1119, DOI 10.1084/jem.20021890; Brown GD, 2006, NAT REV IMMUNOL, V6, P33, DOI 10.1038/nri1745; Brown GD, 2001, NATURE, V413, P36, DOI 10.1038/35092620; Carter RW, 2006, J IMMUNOL, V177, P2276, DOI 10.4049/jimmunol.177.4.2276; Dennehy KM, 2008, EUR J IMMUNOL, V38, P500, DOI 10.1002/eji.200737741; Dzionek A, 2000, J IMMUNOL, V165, P6037, DOI 10.4049/jimmunol.165.11.6037; EZEKOWITZ RAB, 1990, J EXP MED, V172, P1785, DOI 10.1084/jem.172.6.1785; Fuller GLJ, 2007, J BIOL CHEM, V282, P12397, DOI 10.1074/jbc.M609558200; Geissmann F, 2003, IMMUNITY, V19, P71, DOI 10.1016/S1074-7613(03)00174-2; Graham LM, 2006, J IMMUNOL METHODS, V314, P164, DOI 10.1016/j.jim.2006.05.013; Gross O, 2006, NATURE, V442, P651, DOI 10.1038/nature04926; Hao L, 2006, P NATL ACAD SCI USA, V103, P3192, DOI 10.1073/pnas.0511280103; Herre J, 2004, BLOOD, V104, P4038, DOI 10.1182/blood-2004-03-1140; Iizuka K, 2003, NAT IMMUNOL, V4, P801, DOI 10.1038/ni954; INDIK ZK, 1995, BLOOD, V86, P4389, DOI 10.1182/blood.V86.12.4389.bloodjournal86124389; Ito M, 2006, J EXP MED, V203, P289, DOI 10.1084/jem.20051986; Le Cabec V, 2005, J LEUKOCYTE BIOL, V77, P934, DOI 10.1189/jlb.1204705; LeibundGut-Landmann S, 2007, NAT IMMUNOL, V8, P630, DOI 10.1038/ni1460; MacDonald KPA, 2002, BLOOD, V100, P4512, DOI 10.1182/blood-2001-11-0097; Marshall ASJ, 2004, J BIOL CHEM, V279, P14792, DOI 10.1074/jbc.M313127200; PASSLICK B, 1989, BLOOD, V74, P2527, DOI 10.1182/blood.V74.7.2527.2527; Piccioli D, 2007, BLOOD, V109, P5371, DOI 10.1182/blood-2006-08-038422; Pyz E, 2006, ANN MED, V38, P242, DOI 10.1080/07853890600608985; Ravetch JV, 2000, SCIENCE, V290, P84, DOI 10.1126/science.290.5489.84; Robinson MJ, 2006, NAT IMMUNOL, V7, P1258, DOI 10.1038/ni1417; Rogers NC, 2005, IMMUNITY, V22, P507, DOI 10.1016/j.immuni.2005.03.004; Sato Katsuaki, 2007, Allergol Int, V56, P183, DOI 10.2332/allergolint.R-06-139; Sobanov Y, 2001, EUR J IMMUNOL, V31, P3493, DOI 10.1002/1521-4141(200112)31:12<3493::AID-IMMU3493>3.0.CO;2-9; Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175; Strzelecka-Kiliszek A, 2002, J IMMUNOL, V169, P6787, DOI 10.4049/jimmunol.169.12.6787; Suzuki-Inoue K, 2006, BLOOD, V107, P542, DOI 10.1182/blood-2005-05-1994; Taylor PR, 2005, ANNU REV IMMUNOL, V23, P901, DOI 10.1146/annurev.immunol.23.021704.115816; Underhill DM, 2005, BLOOD, V106, P2543, DOI 10.1182/blood-2005-03-1239; Weis WI, 1998, IMMUNOL REV, V163, P19, DOI 10.1111/j.1600-065X.1998.tb01185.x; Willment JA, 2005, EUR J IMMUNOL, V35, P1539, DOI 10.1002/eji.200425725; Yokoyama WM, 2003, NAT REV IMMUNOL, V3, P304, DOI 10.1038/nri1055; Yokozeki T, 2003, J IMMUNOL, V171, P1328, DOI 10.4049/jimmunol.171.3.1328; Zelensky AN, 2005, FEBS J, V272, P6179, DOI 10.1111/j.1742-4658.2005.05031.x	39	233	249	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16693	16701		10.1074/jbc.M709923200	http://dx.doi.org/10.1074/jbc.M709923200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18408006	hybrid, Green Published			2022-12-25	WOS:000256497100046
J	Tessari, I; Bisaglia, M; Valle, F; Samori, B; Bergantino, E; Mammi, S; Bubacco, L				Tessari, Isabella; Bisaglia, Marco; Valle, Francesco; Samori, Bruno; Bergantino, Elisabetta; Mammi, Stefano; Bubacco, Luigi			The reaction of alpha-synuclein with tyrosinase - Possible implications for Parkinson disease	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHAPERONE-MEDIATED AUTOPHAGY; HUMAN SUBSTANTIA-NIGRA; CELL-DEATH; SELECTIVE NEURODEGENERATION; SECONDARY STRUCTURE; OXIDATIVE STRESS; 11-MER REPEATS; DOPAMINE; NEUROMELANIN; PROTEINS	Oxidative stress appears to be directly involved in the pathogenesis of Parkinson disease. Several different pathways have been identified for the production of oxidative stress conditions in nigral dopaminergic neurons, including a pathological accumulation of cytosolic dopamine with the subsequent production of toxic reactive oxygen species or the formation of highly reactive quinone species. On these premises, tyrosinase, a key copper enzyme known for its role in the synthesis of melanin in skin and hair, has been proposed to take part in the oxidative chemistry related to Parkinson disease. A study is herein presented of the in vitro reactivity of tyrosinase with alpha-synuclein, aimed at defining the molecular basis of their synergistic toxic effect. The results presented here indicate that, in conformity with the stringent specificity of tyrosinase, the exposed tyrosine sidechains are the reactive centers of alpha-synuclein. The reactivity of alpha-synuclein depends on whether it is free or membrane bound, and the chemical modifications on the tyrosinase-treated alpha-synuclein strongly influence its aggregation properties. On the basis of our results, we propose a cytotoxic model which includes a possible new toxic role for alpha-synuclein exacerbated by its direct chemical modification by tyrosinase.	[Tessari, Isabella; Bisaglia, Marco; Bergantino, Elisabetta; Bubacco, Luigi] Univ Padua, Dept Biol, I-35121 Padua, Italy; [Mammi, Stefano] Univ Padua, Dept Chem Sci, I-35121 Padua, Italy; [Valle, Francesco; Samori, Bruno] Univ Bologna, Dept Biochem, I-40126 Bologna, Italy	University of Padua; University of Padua; University of Bologna	Bubacco, L (corresponding author), Univ Padua, Dept Biol, Via Trieste 75, I-35121 Padua, Italy.	luigi.bubacco@unipd.it	Bubacco, Luigi/B-5602-2012; Valle, Francesco/H-8549-2014; Tessari, Isabella/K-7847-2016	Bubacco, Luigi/0000-0001-7927-9208; Valle, Francesco/0000-0001-5793-7206; Tessari, Isabella/0000-0002-5823-645X				Apetri MM, 2006, J MOL BIOL, V355, P63, DOI 10.1016/j.jmb.2005.10.071; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; Berman SB, 1999, J NEUROCHEM, V73, P1127, DOI 10.1046/j.1471-4159.1999.0731127.x; Bisaglia M, 2005, BIOCHEMISTRY-US, V44, P329, DOI 10.1021/bi048448q; Bisaglia M, 2006, BIOPOLYMERS, V84, P310, DOI 10.1002/bip.20440; Bisaglia M, 2007, J BIOL CHEM, V282, P15597, DOI 10.1074/jbc.M610893200; Bubacco L, 2000, J MOL CATAL B-ENZYM, V8, P27, DOI 10.1016/S1381-1177(99)00064-8; Bussell R, 2004, BIOCHEMISTRY-US, V43, P4810, DOI 10.1021/bi036135+; Bussell R, 2003, J MOL BIOL, V329, P763, DOI 10.1016/S0022-2836(03)00520-5; Cabin DE, 2002, J NEUROSCI, V22, P8797; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Conway KA, 2000, P NATL ACAD SCI USA, V97, P571, DOI 10.1073/pnas.97.2.571; Corti O, 2005, CR BIOL, V328, P131, DOI 10.1016/j.crvi.2004.10.009; Cuervo AM, 2004, SCIENCE, V305, P1292, DOI 10.1126/science.1101738; Davidson WS, 1998, J BIOL CHEM, V273, P9443, DOI 10.1074/jbc.273.16.9443; Elsworth JD, 1997, EXP NEUROL, V144, P4, DOI 10.1006/exnr.1996.6379; Fedorow H, 2005, PROG NEUROBIOL, V75, P109, DOI 10.1016/j.pneurobio.2005.02.001; Foppoli C, 1997, BBA-GEN SUBJECTS, V1334, P200, DOI 10.1016/S0304-4165(96)00093-1; Fornai F, 2003, J NEUROSCI, V23, P8955; FORNSTEDT B, 1986, NEUROPHARMACOLOGY, V25, P451, DOI 10.1016/0028-3908(86)90242-X; Glaser CB, 2005, BBA-PROTEINS PROTEOM, V1703, P157, DOI 10.1016/j.bbapap.2004.10.008; Greggio E, 2005, J NEUROCHEM, V93, P246, DOI 10.1111/j.1471-4159.2005.03019.x; GRIESINGER C, 1988, J AM CHEM SOC, V110, P7870, DOI 10.1021/ja00231a044; Haavik J, 1997, J NEUROCHEM, V69, P1720; Hardy J, 2006, ANN NEUROL, V60, P389, DOI 10.1002/ana.21022; Hasegawa T, 2006, FEBS LETT, V580, P2147, DOI 10.1016/j.febslet.2006.03.018; HASTINGS TG, 1995, J NEUROCHEM, V64, P919; HIRSCH EC, 1993, EUR NEUROL, V33, P52, DOI 10.1159/000118538; Horcas I, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2432410; ITO S, 1988, BIOCHEM PHARMACOL, V37, P1707, DOI 10.1016/0006-2952(88)90432-7; Jao CC, 2004, P NATL ACAD SCI USA, V101, P8331, DOI 10.1073/pnas.0400553101; Jenner P, 1998, MOVEMENT DISORD, V13, P24; Kahn V, 1998, PIGM CELL RES, V11, P24, DOI 10.1111/j.1600-0749.1998.tb00707.x; Krishnan S, 2003, BIOCHEMISTRY-US, V42, P829, DOI 10.1021/bi026528t; Lashuel HA, 2006, Q REV BIOPHYS, V39, P167, DOI 10.1017/S0033583506004422; LaVoie MJ, 2005, NAT MED, V11, P1214, DOI 10.1038/nm1314; Lotharius J, 2002, J BIOL CHEM, V277, P38884, DOI 10.1074/jbc.M205518200; Martinez-Vicente M, 2008, J CLIN INVEST, V118, P777, DOI 10.1172/JCI32806; MATTAMMAL MB, 1995, J NEUROCHEM, V64, P1645; Murphy DD, 2000, J NEUROSCI, V20, P3214, DOI 10.1523/JNEUROSCI.20-09-03214.2000; Okun MR, 1996, PHYSIOL CHEM PHYS ME, V28, P91; PAZ MA, 1991, J BIOL CHEM, V266, P689; RABEY JM, 1990, J NEURAL TRANSM-PARK, V2, P1, DOI 10.1007/BF02251241; ROSEI MA, 1994, BIOCHEM BIOPH RES CO, V200, P344, DOI 10.1006/bbrc.1994.1454; Souza JM, 2000, J BIOL CHEM, V275, P18344, DOI 10.1074/jbc.M000206200; Sulzer D, 2000, P NATL ACAD SCI USA, V97, P11869, DOI 10.1073/pnas.97.22.11869; Sulzer D, 1999, NEUROTOX RES, V1, P181, DOI 10.1007/BF03033289; Tief K, 1998, MOL BRAIN RES, V53, P307, DOI 10.1016/S0169-328X(97)00301-X; Ulmer TS, 2005, J BIOL CHEM, V280, P9595, DOI 10.1074/jbc.M411805200; Uversky VN, 2000, PROTEINS, V41, P415, DOI 10.1002/1097-0134(20001115)41:3<415::AID-PROT130>3.3.CO;2-Z; Weinreb PH, 1996, BIOCHEMISTRY-US, V35, P13709, DOI 10.1021/bi961799n; Xu J, 2002, NAT MED, V8, P600, DOI 10.1038/nm0602-600; Xu RD, 1996, ARCH BIOCHEM BIOPHYS, V329, P56, DOI 10.1006/abbi.1996.0191; Xu YM, 1997, MOL BRAIN RES, V45, P159, DOI 10.1016/S0169-328X(96)00308-7; Zecca L, 2006, NEUROLOGY, V67, pS8, DOI 10.1212/WNL.67.7_suppl_2.S8; Zecca L, 2003, TRENDS NEUROSCI, V26, P578, DOI 10.1016/j.tins.2003.08.009	57	105	106	2	27	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16808	16817		10.1074/jbc.M709014200	http://dx.doi.org/10.1074/jbc.M709014200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18390556	hybrid			2022-12-25	WOS:000256497100058
J	Zhang, WZ; Cheng, GZ; Gong, JL; Hermanto, U; Zong, CS; Chan, J; Cheng, JQ; Wang, LH				Zhang, Weizhou; Cheng, George Zhi; Gong, Jianli; Hermanto, Ulrich; Zong, Cong Susan; Chan, Joseph; Cheng, Jin Quan; Wang, Lu-Hai			RACK1 and CIS mediate the degradation of BimEL in cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FAMILY-MEMBER BIM; ANCHORAGE-INDEPENDENT GROWTH; BH3-ONLY PROTEIN BIM; PROAPOPTOTIC ACTIVITY; SCAFFOLD PROTEIN; T-CELLS; APOPTOSIS; BCL-2; ACTIVATION; RECEPTOR	RACK1 is a 7-WD motif-containing protein with numerous downstream effectors regulating various cellular functions. Using a yeast two-hybrid screen, we identified dynein light chain 1 as a novel interacting partner of RACK1. Additionally, we demonstrated that RACK1 formed a complex with DLC1 and Bim, specifically BimEL, in the presence of apoptotic agents. Upon paclitaxel treatment, RACK1, DLC1, and CIS mediated the degradation of BimEL through the ElonginB/C-Cullin2-CIS ubiquitin-protein isopeptide ligase complex. We further showed that RACK1 conferred paclitaxel resistance to breast cancer cells in vitro and in vivo. Finally, we observed an inverse correlation between CIS and BimEL levels in both ovarian and breast cancer cell lines and specimens. Our study suggests a role of RACK1 in protecting cancer cells from apoptosis by regulating the degradation of BimEL, which together with CIS could play an important role of drug resistance in chemotherapy.	[Zhang, Weizhou; Cheng, George Zhi; Gong, Jianli; Chan, Joseph; Wang, Lu-Hai] Mt Sinai Sch Med, Dept Microbiol, New York, NY 10029 USA; [Hermanto, Ulrich] Univ Texas Houston, MD Anderson Canc Ctr, Dept Radiol, Houston, TX 77030 USA; [Zong, Cong Susan] Univ Texas Houston, MD Anderson Canc Ctr, Dept Mol & Cellular Oncol, Houston, TX 77030 USA; [Cheng, Jin Quan] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Pathol, Tampa, FL 33612 USA	Icahn School of Medicine at Mount Sinai; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; University of Texas System; University of Texas Health Science Center Houston; UTMD Anderson Cancer Center; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Wang, LH (corresponding author), Mt Sinai Sch Med, Dept Microbiol, 1 Gustave L Levy Pl,Box 1124, New York, NY 10029 USA.	lu-hai.wang@mssm.edu	Gong, Jianli/G-1212-2011; Wang, Lu-Hai/E-3986-2010		NATIONAL CANCER INSTITUTE [R01CA029339] Funding Source: NIH RePORTER; NCI NIH HHS [CA29339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adachi M, 2005, CELL DEATH DIFFER, V12, P192, DOI 10.1038/sj.cdd.4401529; Akiyama T, 2003, EMBO J, V22, P6653, DOI 10.1093/emboj/cdg635; Berns H, 2000, FASEB J, V14, P2549, DOI 10.1096/fj.99-1038com; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Bouillet P, 2002, NATURE, V415, P922, DOI 10.1038/415922a; Ceci M, 2003, NATURE, V426, P579, DOI 10.1038/nature02160; Cheng GZ, 2007, CANCER RES, V67, P1979, DOI 10.1158/0008-5472.CAN-06-1479; Dickens M, 1997, SCIENCE, V277, P693, DOI 10.1126/science.277.5326.693; Dijkers PF, 2000, CURR BIOL, V10, P1201, DOI 10.1016/S0960-9822(00)00728-4; Fomenkov A, 2004, CELL CYCLE, V3, P1285, DOI 10.4161/cc.3.10.1155; Fukazawa H, 2004, MOL CANCER THER, V3, P1281; Gomez-Bougie P, 2005, EUR J IMMUNOL, V35, P971, DOI 10.1002/eji.200425878; Harada H, 2004, P NATL ACAD SCI USA, V101, P15313, DOI 10.1073/pnas.0406837101; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Kamizono S, 2001, J BIOL CHEM, V276, P12530, DOI 10.1074/jbc.M010074200; Kortum RL, 2004, MOL CELL BIOL, V24, P4407, DOI 10.1128/MCB.24.10.4407-4416.2004; Li R, 2005, CELL DEATH DIFFER, V12, P292, DOI 10.1038/sj.cdd.4401554; Li SL, 2000, J EXP MED, V191, P985, DOI 10.1084/jem.191.6.985; Liu YV, 2007, MOL CELL, V25, P207, DOI 10.1016/j.molcel.2007.01.001; Lopez-Bergami P, 2005, MOL CELL, V19, P309, DOI 10.1016/j.molcel.2005.06.025; Matsumoto A, 1999, MOL CELL BIOL, V19, P6396; McCahill A, 2002, MOL PHARMACOL, V62, P1261, DOI 10.1124/mol.62.6.1261; Mollinedo F, 2003, APOPTOSIS, V8, P413, DOI 10.1023/A:1025513106330; Mourtacla-Maarabouni M, 2005, J LEUKOCYTE BIOL, V78, P503, DOI 10.1189/jlb.0205070; O'Reilly LA, 2000, AM J PATHOL, V157, P449, DOI 10.1016/S0002-9440(10)64557-9; Ozaki T, 2003, ONCOGENE, V22, P3231, DOI 10.1038/sj.onc.1206382; Putcha GV, 2003, NEURON, V38, P899, DOI 10.1016/S0896-6273(03)00355-6; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Qi XJ, 2006, J BIOL CHEM, V281, P813, DOI 10.1074/jbc.M505546200; Raccurt M, 2003, BRIT J CANCER, V89, P524, DOI 10.1038/sj.bjc.6601115; Reginato MJ, 2005, MOL CELL BIOL, V25, P4591, DOI 10.1128/MCB.25.11.4591-4601.2005; Sang NL, 2001, J BIOL CHEM, V276, P27026, DOI 10.1074/jbc.M010346200; Sengupta J, 2004, NAT STRUCT MOL BIOL, V11, P957, DOI 10.1038/nsmb822; Song CY, 2008, J BIOL CHEM, V283, P4004, DOI 10.1074/jbc.M704512200; Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200; Tan TT, 2005, CANCER CELL, V7, P227, DOI 10.1016/j.ccr.2005.02.008; Tauchi T, 2001, EXP HEMATOL, V29, P356, DOI 10.1016/S0301-472X(00)00673-1; Uttamsingh S, 2003, J BIOL CHEM, V278, P18798, DOI 10.1074/jbc.M211522200; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Willems AR, 2004, BBA-MOL CELL RES, V1695, P133, DOI 10.1016/j.bbamcr.2004.09.027; Zhang WZ, 2006, MOL CELL BIOL, V26, P413, DOI 10.1128/MCB.26.2.413-424.2006	41	50	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16416	16426		10.1074/jbc.M802360200	http://dx.doi.org/10.1074/jbc.M802360200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18420585	hybrid, Green Published			2022-12-25	WOS:000256497100018
J	Abdel-Ghany, SE; Pilon, M				Abdel-Ghany, Salah E.; Pilon, Marinus			MicroRNA-mediated systemic down-regulation of copper protein expression in response to low copper availability in arabidopsis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SUPEROXIDE-DISMUTASE; CHLOROPHYLL FLUORESCENCE; PHOTOSYNTHETIC APPARATUS; MULTICOPPER OXIDASE; FUNCTIONAL HOMOLOG; PLANT MICRORNAS; LACCASE CDNAS; GENE FAMILY; IDENTIFICATION; HOMEOSTASIS	In plants, copper is an essential micronutrient required for photosynthesis. Two of the most abundant copper proteins, plastocyanin and copper/zinc superoxide dismutase, are found in chloroplasts. Whereas plastocyanin is essential for photo-autotrophic growth, copper/zinc superoxide dismutase is dispensable and in plastids can be replaced by an iron superoxide dismutase when copper is limiting. The down-regulation of copper/zinc superoxide dismutase expression in response to low copper involves a microRNA, miR398. Interestingly, in Arabidopsis and other plants, three additional microRNA families, miR397, miR408, and miR857, are predicted to target the transcripts for the copper protein plantacyanin and members of the laccase copper protein family. We confirmed the predicted targets of miR397, miR408, and miR857 experimentally by cleavage site analysis. To study the spatial expression pattern of these microRNAs and the effect of copper on their expression, we analyzed Arabidopsis grown hydroponically on different copper regimes. On low amounts of copper the plants accumulated miR397, miR408, and miR857. The microRNA expression pattern was negatively correlated with the accumulation of transcripts for plantacyanin and laccases. Furthermore, the expression of other laccases that are not predicted targets for known microRNAs was similarly regulated in response to copper. For some of these laccases, the regulation was disrupted in a microRNA maturation mutant *(hen1-1), suggesting the presence of other copper-regulated microRNAs. Thus, in Arabidopsis, microRNA-mediated down-regulation is a general mechanism to regulate nonessential copper proteins. We propose that this mechanism allows plants to save copper for the most essential functions during limited copper supply.	[Abdel-Ghany, Salah E.; Pilon, Marinus] Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA; [Abdel-Ghany, Salah E.; Pilon, Marinus] Colorado State Univ, Program Mol Plant Biol, Ft Collins, CO 80523 USA; [Abdel-Ghany, Salah E.] Zagazig Univ, Dept Bot, Fac Sci, Zagazig 44519, Egypt	Colorado State University; Colorado State University; Egyptian Knowledge Bank (EKB); Zagazig University	Pilon, M (corresponding author), Colorado State Univ, Dept Biol, Ft Collins, CO 80523 USA.	pilon@lamar.colostate.edu						Abdel-Ghany SE, 2005, FEBS LETT, V579, P2307, DOI 10.1016/j.febslet.2005.03.025; Abdel-Ghany SE, 2005, PLANT CELL, V17, P1233, DOI 10.1105/tpc.104.030452; Allen E, 2005, CELL, V121, P207, DOI 10.1016/j.cell.2005.04.004; Allen E, 2004, NAT GENET, V36, P1282, DOI 10.1038/ng1478; ALT J, 1983, EMBO J, V2, P979, DOI 10.1002/j.1460-2075.1983.tb01531.x; Andersson U, 2003, PLANT PHYSIOL, V132, P811, DOI 10.1104/pp.102.019281; Asada K, 1999, ANNU REV PLANT PHYS, V50, P601, DOI 10.1146/annurev.arplant.50.1.601; Axtell MJ, 2005, PLANT CELL, V17, P1658, DOI 10.1105/tpc.105.032185; AYALA MB, 1992, PHYSIOL PLANTARUM, V84, P1, DOI 10.1034/j.1399-3054.1992.840101.x; BAO W, 1993, SCIENCE, V260, P672, DOI 10.1126/science.260.5108.672; BASZYNSKI T, 1978, Z PFLANZENPHYSIOL, V89, P207, DOI 10.1016/S0044-328X(78)80012-9; Baumberger N, 2005, P NATL ACAD SCI USA, V102, P11928, DOI 10.1073/pnas.0505461102; Bonnet E, 2004, P NATL ACAD SCI USA, V101, P11511, DOI 10.1073/pnas.0404025101; BOVY A, 1992, MOL MICROBIOL, V6, P1507, DOI 10.1111/j.1365-2958.1992.tb00871.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Buhtz A, 2008, PLANT J, V53, P739, DOI 10.1111/j.1365-313X.2007.03368.x; Cai XN, 2006, J EXP BOT, V57, P2563, DOI 10.1093/jxb/erl022; Chen XM, 2002, DEVELOPMENT, V129, P1085; Chiou TJ, 2006, PLANT CELL, V18, P412, DOI 10.1105/tpc.105.038943; Chiou TJ, 2007, PLANT CELL ENVIRON, V30, P323, DOI 10.1111/j.1365-3040.2007.01643.x; Cohu CM, 2007, PHYSIOL PLANTARUM, V129, P747, DOI 10.1111/j.1399-3054.2007.00879.x; Czechowski T, 2004, PLANT J, V38, P366, DOI 10.1111/j.1365-313X.2004.02051.x; DEAN JFD, 1994, HOLZFORSCHUNG, V48, P21, DOI 10.1515/hfsg.1994.48.s1.21; Dong J, 2005, PLANT PHYSIOL, V138, P778, DOI 10.1104/pp.105.063388; Fahlgren N, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000219; Fujii H, 2005, CURR BIOL, V15, P2038, DOI 10.1016/j.cub.2005.10.016; HENRIQUES FS, 1989, J PLANT PHYSIOL, V135, P453, DOI 10.1016/S0176-1617(89)80103-8; Himelblau E, 1998, PLANT PHYSIOL, V117, P1227, DOI 10.1104/pp.117.4.1227; HOAGLAND DR, 1938, WATER CULTURE METHOD, P347; Hoopes JT, 2004, PLANT PHYSIOL BIOCH, V42, P27, DOI 10.1016/j.plaphy.2003.10.011; Jones-Rhoades MW, 2006, ANNU REV PLANT BIOL, V57, P19, DOI 10.1146/annurev.arplant.57.032905.105218; Jones-Rhoades MW, 2004, MOL CELL, V14, P787, DOI 10.1016/j.molcel.2004.05.027; Kasschau KD, 2003, DEV CELL, V4, P205, DOI 10.1016/S1534-5807(03)00025-X; Kieselbach T, 1998, J BIOL CHEM, V273, P6710, DOI 10.1074/jbc.273.12.6710; Kliebenstein DJ, 1998, PLANT PHYSIOL, V118, P637, DOI 10.1104/pp.118.2.637; Knoetzel H, 2002, FEBS LETT, V510, P145, DOI 10.1016/S0014-5793(01)03253-7; LaFayette PR, 1999, PLANT MOL BIOL, V40, P23, DOI 10.1023/A:1026437406859; LI HH, 1995, J BIOL CHEM, V270, P23504, DOI 10.1074/jbc.270.40.23504; Liang MX, 2006, PLANTA, V224, P1185, DOI 10.1007/s00425-006-0300-6; Lu C, 2005, SCIENCE, V309, P1567, DOI 10.1126/science.1114112; Lu SF, 2005, PLANT CELL, V17, P2186, DOI 10.1105/tpc.105.033456; Marschner H, 1995, MINERAL NUTR HIGHER, P333; Maxwell K, 2000, J EXP BOT, V51, P659, DOI 10.1093/jexbot/51.345.659; McCaig BC, 2005, PLANTA, V221, P619, DOI 10.1007/s00425-004-1472-6; Miller JD, 1999, PLANT PHYSIOL, V120, P1015, DOI 10.1104/pp.120.4.1015; Muller P, 2001, PLANT PHYSIOL, V125, P1558, DOI 10.1104/pp.125.4.1558; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; MURPHY A, 1995, PLANT PHYSIOL, V108, P29, DOI 10.1104/pp.108.1.29; Pant BD, 2008, PLANT J, V53, P731, DOI 10.1111/j.1365-313X.2007.03363.x; Park W, 2002, CURR BIOL, V12, P1484, DOI 10.1016/S0960-9822(02)01017-5; Patsikka E, 2002, PLANT PHYSIOL, V129, P1359, DOI 10.1104/pp.004788; Philippar K, 2007, P NATL ACAD SCI USA, V104, P678, DOI 10.1073/pnas.0610062104; Pilon M, 2006, CURR OPIN PLANT BIOL, V9, P256, DOI 10.1016/j.pbi.2006.03.007; Puig S, 2007, PLANT CELL ENVIRON, V30, P271, DOI 10.1111/j.1365-3040.2007.01642.x; Ranocha P, 2002, PLANT PHYSIOL, V129, P145, DOI 10.1104/pp.010988; Ridge PG, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001378; Rolland N, 1999, P NATL ACAD SCI USA, V96, P5464, DOI 10.1073/pnas.96.10.5464; RYDEN LG, 1993, J MOL EVOL, V36, P41, DOI 10.1007/BF02407305; Sancenon V, 2003, PLANT MOL BIOL, V51, P577, DOI 10.1023/A:1022345507112; Sato Y, 2001, J PLANT RES, V114, P147, DOI 10.1007/PL00013978; SCHREIBER U, 1986, PHOTOSYNTH RES, V10, P51, DOI 10.1007/BF00024185; Schubert M, 2002, J BIOL CHEM, V277, P8354, DOI 10.1074/jbc.M108575200; Shikanai T, 2003, PLANT CELL, V15, P1333, DOI 10.1105/tpc.011817; STERJIADES R, 1992, PLANT PHYSIOL, V99, P1162, DOI 10.1104/pp.99.3.1162; Sunkar R, 2005, PLANT CELL, V17, P1397, DOI 10.1105/tpc.105.031682; Sunkar R, 2004, PLANT CELL, V16, P2001, DOI 10.1105/tpc.104.022830; Sunkar R, 2006, PLANT CELL, V18, P2051, DOI 10.1105/tpc.106.041673; Weigel M, 2003, J BIOL CHEM, V278, P31286, DOI 10.1074/jbc.M302876200; Yamasaki H, 2007, J BIOL CHEM, V282, P16369, DOI 10.1074/jbc.M700138200; ZHANG L, 1992, J BIOL CHEM, V267, P19054	70	387	425	3	100	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15932	15945		10.1074/jbc.M801406200	http://dx.doi.org/10.1074/jbc.M801406200			14	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18408011	hybrid, Green Published			2022-12-25	WOS:000256332500052
J	Davis, AJ; Yan, Z; Martinez, B; Mumby, MC				Davis, Anthony J.; Yan, Zhen; Martinez, Bobbie; Mumby, Marc C.			Protein phosphatase 2A is targeted to cell division control protein 6 by a calcium-binding regulatory subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE PATHWAY; DNA-REPLICATION; HUMAN-CELLS; SUBCELLULAR-LOCALIZATION; B''/PR72 SUBUNIT; MAMMALIAN CDC6; NAKED CUTICLE; IMPORTIN-BETA; PHOSPHORYLATION; IDENTIFICATION	The cell division control protein 6 (Cdc6) is essential for formation of pre-replication complexes at origins of DNA replication. Phosphorylation of Cdc6 by cyclin-dependent kinases inhibits ubiquitination of Cdc6 by APC/C-cdh1 and degradation by the proteasome. Experiments described here show that the PR70 member of the PPP2R3 family of regulatory subunits targets protein phosphatase 2A (PP2A) to Cdc6. Interaction with Cdc6 is mediated by residues within the C terminus of PR70, whereas interaction with PP2A requires N-terminal sequences conserved within the PPP2R3 family. Two functional EF-hand calcium-binding motifs mediate a calcium-enhanced interaction of PR70 with PP2A. Calcium has no effect on the interaction of PR70 with Cdc6 but enhances the association of PP2A with Cdc6 through its effects on PR70. Knockdown of PR70 by RNA interference results in an accumulation of endogenous and expressed Cdc6 protein that is dependent on the cyclin-dependent protein kinase phosphorylation sites on Cdc6. Knockdown of PR70 also causes G(1) arrest, suggesting that PR70 function is critical for progression into S phase. These observations indicate that PP2A can be targeted in a calcium-regulated manner to Cdc6 via the PR70 subunit, where it plays a role in regulating protein phosphorylation and stability.	[Davis, Anthony J.; Martinez, Bobbie; Mumby, Marc C.] Univ Texas SW Med Ctr Dallas, Dept Pharmacol, Dallas, TX 75390 USA; [Yan, Zhen] Duke Univ, Med Ctr, Dept Med, Div Cardiol, Durham, NC 27710 USA	University of Texas System; University of Texas Southwestern Medical Center Dallas; Duke University	Mumby, MC (corresponding author), Univ Texas SW Med Ctr Dallas, Dept Pharmacol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	marc.mumby@utsouthwestern.edu		Davis, Anthony/0000-0003-0184-3651; Yan, Zhen/0000-0002-4826-9813	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007062, R01GM049505] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49505, T32 GM07062] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahn JH, 2007, P NATL ACAD SCI USA, V104, P9876, DOI 10.1073/pnas.0703589104; Alexandrow MG, 2004, MOL CELL BIOL, V24, P1614, DOI 10.1128/MCB.24.4.1614-1627.2004; Ali A, 2004, GENE DEV, V18, P249, DOI 10.1101/gad.1176004; Bayliss R, 2000, CELL, V102, P99, DOI 10.1016/S0092-8674(00)00014-3; Bayliss R, 2002, J BIOL CHEM, V277, P50597, DOI 10.1074/jbc.M209037200; Bell SP, 2002, ANNU REV BIOCHEM, V71, P333, DOI 10.1146/annurev.biochem.71.110601.135425; Coverley D, 2000, J CELL SCI, V113, P1929; Creyghton MP, 2006, P NATL ACAD SCI USA, V103, P5397, DOI 10.1073/pnas.0507237103; Creyghton MP, 2005, GENE DEV, V19, P376, DOI 10.1101/gad.328905; Delmolino LM, 2001, J BIOL CHEM, V276, P26947, DOI 10.1074/jbc.M101870200; Diffley JFX, 2004, CURR BIOL, V14, pR778, DOI 10.1016/j.cub.2004.09.019; Duursma A, 2005, MOL CELL BIOL, V25, P6937, DOI 10.1128/MCB.25.16.6937-6947.2005; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Harper JW, 2002, GENE DEV, V16, P2179, DOI 10.1101/gad.1013102; Herbig U, 2000, MOL BIOL CELL, V11, P4117, DOI 10.1091/mbc.11.12.4117; Janssens V, 2003, J BIOL CHEM, V278, P10697, DOI 10.1074/jbc.M211717200; Janssens V, 2001, BIOCHEM J, V353, P417, DOI 10.1042/0264-6021:3530417; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Li XH, 2002, EUR J BIOCHEM, V269, P546, DOI 10.1046/j.0014-2956.2001.02680.x; Li XH, 2002, MOL CELL BIOL, V22, P3674, DOI 10.1128/MCB.22.11.3674-3684.2002; Mailand N, 2005, CELL, V122, P915, DOI 10.1016/j.cell.2005.08.013; MARUYAMA K, 1984, J BIOCHEM-TOKYO, V95, P511, DOI 10.1093/oxfordjournals.jbchem.a134633; Mendez J, 2000, MOL CELL BIOL, V20, P8602, DOI 10.1128/MCB.20.22.8602-8612.2000; MUMBY MC, 1985, J BIOL CHEM, V260, P3763; Pearson GW, 2006, MOL CELL BIOL, V26, P3039, DOI 10.1128/MCB.26.8.3039-3047.2006; Pelizon C, 2000, GENE DEV, V14, P2526, DOI 10.1101/gad.176300; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Silverstein AM, 2002, P NATL ACAD SCI USA, V99, P4221, DOI 10.1073/pnas.072071699; SILVERSTEIN AM, 2003, HDB CELLULAR SIGNALI, P405; SONTAG E, 1993, CELL, V75, P887, DOI 10.1016/0092-8674(93)90533-V; Stevens I, 2003, EUR J BIOCHEM, V270, P376, DOI 10.1046/j.1432-1033.2003.03398.x; Strack S, 2002, J BIOL CHEM, V277, P20750, DOI 10.1074/jbc.M202992200; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; Virshup DM, 2000, CURR OPIN CELL BIOL, V12, P180, DOI 10.1016/S0955-0674(99)00074-5; Voorhoeve PM, 1999, ONCOGENE, V18, P515, DOI 10.1038/sj.onc.1202316; Williams RS, 1997, P NATL ACAD SCI USA, V94, P142, DOI 10.1073/pnas.94.1.142; Yan Z, 2000, MOL CELL BIOL, V20, P1021, DOI 10.1128/MCB.20.3.1021-1029.2000; Yan Z, 1998, P NATL ACAD SCI USA, V95, P3603, DOI 10.1073/pnas.95.7.3603	39	30	32	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16104	16114		10.1074/jbc.M710313200	http://dx.doi.org/10.1074/jbc.M710313200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18397887	Green Published, hybrid			2022-12-25	WOS:000256332500069
J	Ding, YS; Williams, RM; Sherman, DH				Ding, Yousong; Williams, Robert M.; Sherman, David H.			Molecular analysis of a 4-dimethylallyltryptophan synthase from Malbranchea aurantiaca	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASPERGILLUS-FUMIGATUS; DIMETHYLALLYLTRYPTOPHAN SYNTHASE; BIOCHEMICAL-CHARACTERIZATION; CLAVICEPS-PURPUREA; NATURAL-PRODUCTS; STRUCTURAL BASIS; COMMITTED STEP; BIOSYNTHESIS; PRENYLTRANSFERASE; PURIFICATION	Prenyltransferases are widely distributed in prokaryotes and eukaryotes and play critical roles in cell signaling, protein trafficking, and elaboration of complex molecules in secondary metabolism. Numerous prenylated natural products have been isolated from diverse microorganisms, including bacteria and fungi. These complex metabolites possess a wide range of biological activities, with some showing promise as medicinal agents. On the other hand, many prenylated secondary metabolites have been described as toxins such as ergot alkaloids that have potent psychotropic activity. We have characterized a new prenyltransferase isolated from genomic DNA of Malbranchea aurentiaca RRC1813. Enzyme specificity was investigated with a series of amino acid substrates revealing its function as a 4-dimethylallyltryptophan synthase. Polypeptide sequence alignment analysis showed that it groups with a new class of prenyltransferase enzymes that lack the typical (N/D) DXXD motif found in these polypeptides. MaPT activity was not dependent on a divalent cation cofactor, although it was reversibly inactivated by 5mM EDTA. Analysis of kinetic parameters showed reduced enzyme efficiency upon simple modification of L-Trp. Moreover, D-Trp had 0.5% relative activity and functioned as a competitive inhibitor with a K-i of 40.41 mu M. Finally, Thr-105, Asp-179, Lys-189, and Lys-261 in MaPT were serially mutated, and the resulting lesions displayed low or complete loss of activity. This study provides a detailed characterization of a prenyltransferase in Malbranchea species, reveals two enzyme inhibitors, and through site-directed mutagenesis identified several key amino acid residues in catalysis, yielding new insights into this important yet understudied class of natural product biosynthetic enzymes.	[Ding, Yousong; Sherman, David H.] Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA; [Ding, Yousong; Sherman, David H.] Univ Michigan, Dept Med Chem, Ann Arbor, MI 48109 USA; [Sherman, David H.] Univ Michigan, Dept Microbiol & Immunol, Ann Arbor, MI 48109 USA; [Sherman, David H.] Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; [Williams, Robert M.] Colorado State Univ, Dept Chem, Ft Collins, CO 80523 USA; Univ Colorado Canc Ctr, Aurora, CO 80045 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Colorado State University; University of Colorado System; University of Colorado Anschutz Medical Campus	Sherman, DH (corresponding author), Univ Michigan, Inst Life Sci, 210 Wash Tenaw Ave, Ann Arbor, MI 48109 USA.	davidhs@lsi.umich.edu	Ding, Yousong/F-2629-2010		NCI NIH HHS [R01 CA070375, CA070375] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA070375] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balibar CJ, 2007, NAT CHEM BIOL, V3, P584, DOI 10.1038/nchembio.2007.20; BHATTACHARYYA DK, 1994, BIOCHEM J, V298, P281, DOI 10.1042/bj2980281; Carvajal N, 2004, J INORG BIOCHEM, V98, P1465, DOI 10.1016/j.jinorgbio.2004.05.005; CHAN HTC, 1992, FEMS MICROBIOL LETT, V96, P231, DOI 10.1111/j.1574-6968.1992.tb05422.x; CHEN AJ, 1994, PROTEIN SCI, V3, P600; CHIUNG YM, 1993, J ANTIBIOT, V46, P1819, DOI 10.7164/antibiotics.46.1819; CRESS WA, 1981, J BIOL CHEM, V256, P917; Edwards DJ, 2004, J AM CHEM SOC, V126, P11432, DOI 10.1021/ja047876g; GEBLER JC, 1992, J AM CHEM SOC, V114, P7354, DOI 10.1021/ja00045a004; GEBLER JC, 1992, ARCH BIOCHEM BIOPHYS, V296, P308, DOI 10.1016/0003-9861(92)90577-J; Gin AS, 1996, ANN PHARMACOTHER, V30, P615, DOI 10.1177/106002809603000610; Grundmann A, 2005, MICROBIOL-SGM, V151, P2199, DOI 10.1099/mic.0.27962-0; Haagen Y, 2007, FEBS LETT, V581, P2889, DOI 10.1016/j.febslet.2007.05.031; Keller NP, 2005, NAT REV MICROBIOL, V3, P937, DOI 10.1038/nrmicro1286; Kremer A, 2007, MICROBIOL-SGM, V153, P3409, DOI 10.1099/mic.0.2007/009019-0; Kuzuyama T, 2005, NATURE, V435, P983, DOI 10.1038/nature03668; Lam KS, 2007, TRENDS MICROBIOL, V15, P279, DOI 10.1016/j.tim.2007.04.001; Liang PH, 2002, EUR J BIOCHEM, V269, P3339, DOI 10.1046/j.1432-1033.2002.03014.x; LIU YG, 1995, GENOMICS, V25, P674, DOI 10.1016/0888-7543(95)80010-J; Martinez-Luis S, 2006, TETRAHEDRON, V62, P1817, DOI 10.1016/j.tet.2005.11.047; Martinez-Luis S, 2005, PHYTOCHEMISTRY, V66, P1012, DOI 10.1016/j.phytochem.2005.03.005; Ohara K, 2006, PLANT CELL PHYSIOL, V47, P581, DOI 10.1093/pcp/pcj025; Pelaez F., 2005, HDB IND MYCOLOGY; Peraica M, 1999, B WORLD HEALTH ORGAN, V77, P754; Pojer F, 2003, P NATL ACAD SCI USA, V100, P2316, DOI 10.1073/pnas.0337708100; Sambrook J, 2001, MOL CLONING LAB MANU; Schlegel B, 2003, J ANTIBIOT, V56, P792, DOI 10.7164/antibiotics.56.792; Schlegel B, 2003, J ANTIBIOT, V56, P917, DOI 10.7164/antibiotics.56.917; SHAH MM, 1992, J BIOL CHEM, V267, P21564; Spurgeon David, 2007, BMJ, V335, P961, DOI 10.1136/bmj.39388.619780.DB; Starks CM, 1997, SCIENCE, V277, P1815, DOI 10.1126/science.277.5333.1815; Steffan N, 2007, CHEMBIOCHEM, V8, P1298, DOI 10.1002/cbic.200700107; TSAI HF, 1995, BIOCHEM BIOPH RES CO, V216, P119, DOI 10.1006/bbrc.1995.2599; Unsold IA, 2006, CHEMBIOCHEM, V7, P158, DOI 10.1002/cbic.200500318; Unsold IA, 2005, MICROBIOL-SGM, V151, P1499, DOI 10.1099/mic.0.27759-0; Walsh C, 2003, NAT REV MICROBIOL, V1, P65, DOI 10.1038/nrmicro727; Walsh CT, 2007, ACS CHEM BIOL, V2, P296, DOI 10.1021/cb700094s; Wildung MR, 1996, J BIOL CHEM, V271, P9201, DOI 10.1074/jbc.271.16.9201; Wu Z, 1999, BIOCHEMISTRY-US, V38, P11239, DOI 10.1021/bi990583t; Yin WB, 2007, CHEMBIOCHEM, V8, P1154, DOI 10.1002/cbic.200700079	40	40	42	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16068	16076		10.1074/jbc.M801991200	http://dx.doi.org/10.1074/jbc.M801991200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18390548	Green Published, hybrid			2022-12-25	WOS:000256332500065
J	Fuhrken, PG; Apostolidis, PA; Lindsey, S; Miller, WM; Papoutsakis, ET				Fuhrken, Peter G.; Apostolidis, Pani A.; Lindsey, Stephan; Miller, William M.; Papoutsakis, Eleftherios T.			Tumor suppressor protein p53 regulates megakaryocytic polyploidization and apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-LINE K562; ERYTHROLEUKEMIA-CELLS; DESIGNED HAIRPINS; HL-60 CELLS; WILD-TYPE; DIFFERENTIATION; GENE; EXPRESSION; STRESS; TUMORIGENESIS	The molecular mechanisms underlying differentiation of hematopoietic stem cells into megakaryocytes are poorly understood. Tumor suppressor protein p53 can act as a transcription factor affecting both cell cycle control and apoptosis, and we have previously shown that p53 is activated during terminal megakaryocytic (Mk) differentiation of the CHRF-288-11 (CHRF) cell line. Here, we use RNA interference to reduce p53 expression in CHRF cells and show that reduced p53 activity leads to a greater fraction of polyploid cells, higher mean and maximum ploidy, accelerated DNA synthesis, and delayed apoptosis and cell death upon phorbol 12-myristate 13-acetate-induced Mk differentiation. In contrast, reduced p53 expression did not affect the ploidy or DNA synthesis of CHRF cells in the absence of phorbol 12-myristate 13-acetate stimulation. Furthermore, primary Mk cells from cultures initiated with p53-null mouse bone marrow mononuclear cells displayed higher ploidy compared with wild-type controls. Quantitative reverse transcription-PCR analysis of p53-knockdown CHRF cells, compared with the "scrambled" control CHRF cells, revealed that six known transcriptional targets of p53 (BBC3, BAX, TP53I3, TP53INP1, MDM2, and P21) were down-regulated, whereas BCL2 expression, which is known to be negatively affected by p53, was up-regulated. These studies show that the functional role of the intrinsic activation of p53 during Mk differentiation is to control polyploidization and the transition to endomitosis by impeding cell cycling and promoting apoptosis.	[Fuhrken, Peter G.; Apostolidis, Pani A.; Miller, William M.; Papoutsakis, Eleftherios T.] Northwestern Univ, Dept Chem & Biol Engn, Evanston, IL 60208 USA; [Apostolidis, Pani A.; Lindsey, Stephan; Papoutsakis, Eleftherios T.] Univ Delaware, Dept Chem Engn, Newark, DE 19711 USA; [Apostolidis, Pani A.; Lindsey, Stephan; Papoutsakis, Eleftherios T.] Univ Delaware, Delaware Biotechnol Inst, Newark, DE 19711 USA	Northwestern University; University of Delaware; University of Delaware	Papoutsakis, ET (corresponding author), Univ Delaware, Delaware Biotechnol Inst, 15 Innovat Way, Newark, DE 19711 USA.	papoutsakis@dbi.udel.edu	Papoutsakis, Eleftherios/B-7612-2009; Miller, William M/B-7650-2009; Papoutsakis, Eleftherios T/A-5254-2010; Lindsey, Stephan/E-4358-2012	Miller, William/0000-0003-0750-6314	NHLBI NIH HHS [HL48276] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048276] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Almog N, 1997, BBA-REV CANCER, V1333, pF1, DOI 10.1016/S0304-419X(97)00012-7; Aylon Y, 2006, GENE DEV, V20, P2687, DOI 10.1101/gad.1447006; Baccini V, 2001, BLOOD, V98, P3274, DOI 10.1182/blood.V98.12.3274; BANERJEE D, 1995, CELL GROWTH DIFFER, V6, P1405; Boden D, 2004, NUCLEIC ACIDS RES, V32, P1154, DOI 10.1093/nar/gkh278; Campomenosi P, 2001, ONCOGENE, V20, P3573, DOI 10.1038/sj.onc.1204468; Chen C, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-384; Chylicki K, 2000, CELL GROWTH DIFFER, V11, P315; Datta NS, 2002, EXP HEMATOL, V30, P158, DOI 10.1016/S0301-472X(01)00780-9; de Botton S, 2002, BLOOD, V100, P1310, DOI 10.1182/blood-2002-03-0686; Di JA, 1996, J EXP MED, V183, P1923, DOI 10.1084/jem.183.4.1923; Duensing A, 2005, BIOCHEM BIOPH RES CO, V331, P694, DOI 10.1016/j.bbrc.2005.03.157; EHINGER M, 1995, CELL GROWTH DIFFER, V6, P9; Fuhrken PG, 2007, EXP HEMATOL, V35, P476, DOI 10.1016/j.exphem.2006.10.017; Herault O, 1999, BRIT J HAEMATOL, V104, P530, DOI 10.1046/j.1365-2141.1999.01203.x; Horie K, 2002, J RADIAT RES, V43, P353, DOI 10.1269/jrr.43.353; Horvath MM, 2007, PLOS GENET, V3, P1284, DOI 10.1371/journal.pgen.0030127; Jagelska E, 2002, J IMMUNOL METHODS, V267, P227, DOI 10.1016/S0022-1759(02)00182-5; Jiang F, 2002, BLOOD, V99, P3579, DOI 10.1182/blood.V99.10.3579; JOHNSON P, 1993, MOL CELL BIOL, V13, P1456, DOI 10.1128/MCB.13.3.1456; Kramer A, 2002, LEUKEMIA, V16, P767, DOI 10.1038/sj.leu.2402454; LANE DP, 1992, NATURE, V358, P15, DOI 10.1038/358015a0; MAHDI T, 1995, J CELL SCI, V108, P1287; Margolis RL, 2003, J CELL BIOCHEM, V88, P673, DOI 10.1002/jcb.10411; Mattia G, 2002, BLOOD, V99, P888, DOI 10.1182/blood.V99.3.888; McManus MT, 2002, RNA, V8, P842, DOI 10.1017/S1355838202024032; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; Olivier M, 2002, HUM MUTAT, V19, P607, DOI 10.1002/humu.10081; Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525; Ravid K, 2002, J CELL PHYSIOL, V190, P7, DOI 10.1002/jcp.10035; Ritchie A, 1996, STEM CELLS, V14, P330, DOI 10.1002/stem.140330; Sanz C, 2001, EXP HEMATOL, V29, P728, DOI 10.1016/S0301-472X(01)00635-X; Soddu S, 1996, J CELL BIOL, V134, P193, DOI 10.1083/jcb.134.1.193; SODDU S, 1994, BLOOD, V83, P2230, DOI 10.1182/blood.V83.8.2230.bloodjournal8382230; Stiewe T, 2007, NAT REV CANCER, V7, P165, DOI 10.1038/nrc2072; SUGIMOTO K, 1992, BLOOD, V79, P2378, DOI 10.1182/blood.V79.9.2378.2378; Tomasin R, 2001, J BIOL CHEM, V276, P44185, DOI 10.1074/jbc.M105647200; Tomasini R, 2003, J BIOL CHEM, V278, P37722, DOI 10.1074/jbc.M301979200; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wlodarski P, 1998, BLOOD, V91, P2998, DOI 10.1182/blood.V91.8.2998.2998_2998_3006; Yang H, 2002, STEM CELLS, V20, P320, DOI 10.1634/stemcells.20-4-320; Yu J, 2003, CANCER CELL, V4, P248, DOI 10.1016/S1535-6108(03)00249-6; Zeng Y, 2002, MOL CELL, V9, P1327, DOI 10.1016/S1097-2765(02)00541-5; Zhan QM, 2005, MUTAT RES-FUND MOL M, V569, P133, DOI 10.1016/j.mrfmmm.2004.06.055	44	32	35	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15589	15600		10.1074/jbc.M801923200	http://dx.doi.org/10.1074/jbc.M801923200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18397889	Green Published, hybrid			2022-12-25	WOS:000256332500012
J	Lionaki, E; Lousa, CD; Baud, C; Vougioukalaki, M; Panayotou, G; Tokatlidis, K				Lionaki, Eirini; Lousa, Carine de Marcos; Baud, Catherine; Vougioukalaki, Maria; Panayotou, George; Tokatlidis, Kostas			The essential function of Tim12 in vivo is ensured by the assembly interactions of its C-terminal domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL INTERMEMBRANE SPACE; ADP/ATP CARRIER; PROTEIN IMPORT; COMPLEX; CHAPERONE; MIA40; TRANSLOCASE; RECOGNITION; RESIDUES; SUBUNIT	The small Tims chaperone hydrophobic precursors across the mitochondrial intermembrane space. Tim9 and Tim10 form the soluble TIM10 complex that binds precursors exiting from the outer membrane. Tim12 functions downstream, as the only small Tim peripherally attached on the inner membrane. We show that Tim12 has an intrinsic affinity for inner mitochondrial membrane lipids, in contrast to the other small Tims. We find that the C-terminal end of Tim12 is essential in vivo. Its deletion crucially abolishes assembly of Tim12 in complexes with the other Tims. The N-terminal end contains targeting information and also mediates direct binding of Tim12 to the transmembrane segments of the carrier substrates. These results provide a molecular basis for the concept that the essential role of Tim12 relies on its unique assembly properties that allow this subunit to bridge the soluble and membrane-embedded translocases in the carrier import pathway.	[Lionaki, Eirini; Lousa, Carine de Marcos; Baud, Catherine; Vougioukalaki, Maria; Tokatlidis, Kostas] Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion 71110, Crete, Greece; [Lionaki, Eirini; Vougioukalaki, Maria] Univ Crete, Dept Biol, Iraklion 71409, Crete, Greece; [Panayotou, George] Biomed Sci Res Ctr Alexander Fleming, Vari 16672, Greece; [Tokatlidis, Kostas] Univ Crete, Dept Mat Sci & Technol, Iraklion 71003, Crete, Greece	Foundation for Research & Technology - Hellas (FORTH); University of Crete; Alexander Fleming Biomedical Sciences Research Center; University of Crete	Tokatlidis, K (corresponding author), Fdn Res & Technol Hellas, Inst Mol Biol & Biotechnol, Iraklion 71110, Crete, Greece.	tokatlid@imbb.forth.gr	Vougioukalaki, Maria/AAN-3587-2020	Vougioukalaki, Maria/0000-0001-9868-820X; Baud, Catherine/0000-0002-0816-9092; De Marcos Lousa, Carine/0000-0002-5041-6261; Tokatlidis, Kostas/0000-0001-6295-8183; LIONAKI, EIRINI/0000-0002-7689-0463				Adam A, 1999, EMBO J, V18, P313, DOI 10.1093/emboj/18.2.313; Allen S, 2003, J BIOL CHEM, V278, P38505, DOI 10.1074/jbc.M306027200; BARTLETT GR, 1959, J BIOL CHEM, V234, P469; Baud C, 2007, PROTEIN PEPTIDE LETT, V14, P597; Chacinska A, 2004, EMBO J, V23, P3735, DOI 10.1038/sj.emboj.7600389; Curran SP, 2002, EMBO J, V21, P942, DOI 10.1093/emboj/21.5.942; Gentle IE, 2007, MOL BIOL EVOL, V24, P1149, DOI 10.1093/molbev/msm031; GLICK BS, 1992, CELL, V69, P809, DOI 10.1016/0092-8674(92)90292-K; Koehler CM, 1998, SCIENCE, V279, P369, DOI 10.1126/science.279.5349.369; Luciano P, 2001, EMBO J, V20, P4099, DOI 10.1093/emboj/20.15.4099; Mesecke N, 2005, CELL, V121, P1059, DOI 10.1016/j.cell.2005.04.011; Milenkovic D, 2007, J BIOL CHEM, V282, P22472, DOI 10.1074/jbc.M703294200; Muller JM, 2008, MOL BIOL CELL, V19, P226, DOI 10.1091/mbc.E07-08-0814; Sideris DP, 2007, MOL MICROBIOL, V65, P1360, DOI 10.1111/j.1365-2958.2007.05880.x; Sirrenberg C, 1998, NATURE, V391, P912, DOI 10.1038/36136; TZAMARIAS D, 1994, NATURE, V369, P758, DOI 10.1038/369758a0; Vergnolle MAS, 2007, J MOL BIOL, V371, P1315, DOI 10.1016/j.jmb.2007.06.025; Vergnolle MAS, 2005, J MOL BIOL, V351, P839, DOI 10.1016/j.jmb.2005.06.010; Vial S, 2002, J BIOL CHEM, V277, P36100, DOI 10.1074/jbc.M202310200; Webb CT, 2006, MOL CELL, V21, P123, DOI 10.1016/j.molcel.2005.11.010; Weiss C, 1999, P NATL ACAD SCI USA, V96, P8890, DOI 10.1073/pnas.96.16.8890	21	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15747	15753		10.1074/jbc.M800350200	http://dx.doi.org/10.1074/jbc.M800350200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18387953	hybrid, Green Published			2022-12-25	WOS:000256332500031
J	Pace, JM; Wiese, M; Drenguis, AS; Kuznetsova, N; Leikin, S; Schwarze, U; Chen, D; Mooney, SH; Unger, S; Byers, PH				Pace, James M.; Wiese, Mary; Drenguis, Andrea S.; Kuznetsova, Natalia; Leikin, Sergey; Schwarze, Ulrike; Chen, Diana; Mooney, Suzanne H.; Unger, Sheila; Byers, Peter H.			Defective C-propeptides of the pro alpha 2(I) chain of type I procollagen impede molecular assembly and result in osteogenesis imperfecta	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL PROPEPTIDE; COLLAGEN MUTATION DATABASE; FRAMESHIFT MUTATION; LETHAL VARIANT; ALPHA-1 CHAIN; TRIPLE-HELIX; GENE; SUBSTITUTION; DISRUPTION; CYSTEINE	Type I procollagen is a heterotrimer composed of two pro alpha 1(I) chains and one pro alpha 2(I) chain, encoded by the COL1A1 and COL1A2 genes, respectively. Mutations in these genes usually lead to dominantly inherited forms of osteogenesis imperfecta (OI) by altering the triple helical domains, but a few affect sequences in the pro alpha 1(I) C-terminal propeptide (C-propeptide), and one, which has a phenotype only in homozygotes, alters the pro alpha 2(I) C-propeptide. Here we describe four dominant mutations in the COL1A2 gene that alter sequences of the pro alpha 2(I) C-propeptide in individuals with clinical features of a milder form of the disease, OI type IV. Three of the four appear to interfere with disulfide bonds that stabilize the C-propeptide conformation and its interaction with other chains in the trimer. Cultured cells synthesized pro alpha 2(I) chains that were slow to assemble with pro alpha 1(I) chains to form heterotrimers and that were retained intracellularly. Some alterations led to the uncharacteristic formation of pro alpha 1(I) homotrimers. These findings show that the C-propeptide of pro alpha 2(I), like that of the pro alpha 1(I) C-propeptide, is essential for efficient assembly of type I procollagen heterotrimers. The milder OI phenotypes likely reflect a diminished amount of normal type I procollagen, small populations of overmodified heterotrimers, and pro alpha 1(I) homotrimers that are compatible with normal skeletal growth.	[Pace, James M.; Wiese, Mary; Drenguis, Andrea S.; Schwarze, Ulrike; Chen, Diana; Mooney, Suzanne H.; Byers, Peter H.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA; [Kuznetsova, Natalia; Leikin, Sergey] NICHD, Sect Phys Biochem, NIH, Bethesda, MD 20892 USA; [Unger, Sheila] Univ Freiburg, Inst Human Genet, D-79085 Freiburg, Germany; [Byers, Peter H.] Univ Washington, Dept Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); University of Freiburg; University of Washington; University of Washington Seattle	Byers, PH (corresponding author), Univ Washington, Dept Pathol, Box 357470, Seattle, WA 98195 USA.	pbyers@u.washington.edu	Leikin, Sergey/A-5518-2008; unger, sheila/E-9177-2015	Leikin, Sergey/0000-0001-7095-0739; Byers, Peter H./0000-0001-7786-7030	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000256] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000256] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041223] Funding Source: NIH RePORTER; NIAMS NIH HHS [5R01AR041223-13] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Alvares K, 1999, BIOCHEMISTRY-US, V38, P5401, DOI 10.1021/bi9821824; BATEMAN JF, 1989, J BIOL CHEM, V264, P10960; BONADIO J, 1985, J BIOL CHEM, V260, P1734; BONADIO J, 1985, NATURE, V316, P363, DOI 10.1038/316363a0; Byers PH, 2002, CONNECTIVE TISSUE IT, P385; Campbell BG, 2001, J BONE MINER RES, V16, P1147, DOI 10.1359/jbmr.2001.16.6.1147; Chamberlain JR, 2004, SCIENCE, V303, P1198, DOI 10.1126/science.1088757; CHESSLER SD, 1993, J BIOL CHEM, V268, P18218; CHESSLER SD, 1993, J BIOL CHEM, V268, P18226; Dalgleish R, 1998, NUCLEIC ACIDS RES, V26, P253, DOI 10.1093/nar/26.1.253; Dalgleish R, 1997, NUCLEIC ACIDS RES, V25, P181, DOI 10.1093/nar/25.1.181; Doyle SA, 1998, J CELL BIOCHEM, V71, P233; Fisher LW, 1995, ACTA ORTHOP SCAND, V66, P61, DOI 10.3109/17453679509157649; Fitzgerald J, 1999, J BIOL CHEM, V274, P27392, DOI 10.1074/jbc.274.39.27392; Forlino A, 1998, MATRIX BIOL, V17, P575, DOI 10.1016/S0945-053X(98)90109-3; JIMENEZ SA, 1977, BIOCHEM BIOPH RES CO, V78, P1354, DOI 10.1016/0006-291X(77)91441-3; Kivirikko KI, 1998, ADV ENZYMOL RAMB, V72, P325; Korkko J, 1998, P NATL ACAD SCI USA, V95, P1681, DOI 10.1073/pnas.95.4.1681; LEES JF, 1994, J BIOL CHEM, V269, P24354; Lees JF, 1997, EMBO J, V16, P908, DOI 10.1093/emboj/16.5.908; Lim AL, 1998, J CELL BIOCHEM, V71, P216, DOI 10.1002/(SICI)1097-4644(19981101)71:2<216::AID-JCB7>3.3.CO;2-K; McAlinden A, 2003, J BIOL CHEM, V278, P42200, DOI 10.1074/jbc.M302429200; MCBRIDE DJ, 1994, GENOMICS, V20, P135, DOI 10.1006/geno.1994.1141; Myllyharju J, 2001, ANN MED, V33, P7, DOI 10.3109/07853890109002055; Oliver JE, 1996, HUM MUTAT, V7, P318, DOI 10.1002/(SICI)1098-1004(1996)7:4<318::AID-HUMU5>3.3.CO;2-S; Pace JM, 2002, J MED GENET, V39, P23, DOI 10.1136/jmg.39.1.23; Pace JM, 2001, J MED GENET, V38, P443, DOI 10.1136/jmg.38.7.443; PIHLAJANIEMI T, 1984, J BIOL CHEM, V259, P2941; RAGHUNATH M, 1994, J MOL BIOL, V236, P940, DOI 10.1006/jmbi.1994.1199; Schwarze U, 2004, AM J HUM GENET, V74, P917, DOI 10.1086/420794; UITTO J, 1979, ARCH BIOCHEM BIOPHYS, V192, P371, DOI 10.1016/0003-9861(79)90105-X; VOGEL BE, 1987, J BIOL CHEM, V262, P14737; VOGEL BE, 1988, J BIOL CHEM, V263, P19249; WILLING MC, 1990, J CLIN INVEST, V85, P282, DOI 10.1172/JCI114424; Yang W, 1997, BIOCHEMISTRY-US, V36, P6930, DOI 10.1021/bi970051h	35	45	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					16061	16067		10.1074/jbc.M801982200	http://dx.doi.org/10.1074/jbc.M801982200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18375391	Green Published, hybrid			2022-12-25	WOS:000256332500064
J	Respuela, P; Ferella, M; Rada-Iglesias, A; Aslund, L				Respuela, Patricia; Ferella, Marcela; Rada-Iglesias, Alvaro; Aslund, Lena			Histone acetylation and methylation at sites initiating divergent polycistronic transcription in Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPLICED LEADER RNA; GENE; BRUCEI; GENOME; DNA; PROMOTER; EXPRESSION; TERMINATION; COMPLEXES; SEQUENCE	Trypanosomes are ancient eukaryotic parasites in which the protein-coding genes, organized in large polycistronic clusters on both strands, are transcribed from as yet unidentified promoters. In an effort to reveal transcriptional initiation sites, we examined the Trypanosoma cruzi genome for histone modification patterns shown to be linked to active genes in various organisms. Here, we show that acetylated and methylated histones were found to be enriched at strand switch regions of divergent gene arrays, not at convergent clusters or intra-and intergenic regions within clusters. The modified region showed a bimodular profile with two peaks centered over the 5'-regions of the gene pair flanking the strand switch region. This pattern, which demarcates polycistronic transcription units originating from bidirectional initiation sites, is likely to be common in kinetoplastid parasites as well as in other organisms with polycistronic transcription. In contrast, no acetylation was found at promoters of the highly expressed rRNA and spliced leader genes or satellite DNA or at tested retrotransposonal elements. These results reveal, for the first time, the presence of specific epigenetic marks in T. cruzi with potential implications for transcriptional regulation; they indicate that both histone modifications and bidirectional transcription are evolutionarily conserved.	[Respuela, Patricia; Rada-Iglesias, Alvaro; Aslund, Lena] Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, SE-75185 Uppsala, Sweden; [Ferella, Marcela] Karolinska Inst, Dept Cell & Mol Biol, Program Genom & Bioinformat, SE-17177 Stockholm, Sweden	Uppsala University; Karolinska Institutet	Aslund, L (corresponding author), Uppsala Univ, Rudbeck Lab, Dept Genet & Pathol, SE-75185 Uppsala, Sweden.	lena.aslund@genpat.uu.se		Rada-Iglesias, Alvaro/0000-0001-7137-1341; Respuela, Patricia/0000-0002-9719-7860				Andrews KT, 2000, INT J PARASITOL, V30, P761, DOI 10.1016/S0020-7519(00)00043-6; ASLUND L, 1994, MOL BIOCHEM PARASIT, V65, P317, DOI 10.1016/0166-6851(94)90082-5; BENAMAR MF, 1991, NUCLEIC ACIDS RES, V19, P5857, DOI 10.1093/nar/19.21.5857; Bernstein BE, 2005, CELL, V120, P169, DOI 10.1016/j.cell.2005.01.001; Blumenthal Thomas, 2004, Briefings in Functional Genomics & Proteomics, V3, P199, DOI 10.1093/bfgp/3.3.199; Buscaglia CA, 2006, NAT REV MICROBIOL, V4, P229, DOI 10.1038/nrmicro1351; CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0; da Cunha JPC, 2006, MOL BIOCHEM PARASIT, V150, P268, DOI 10.1016/j.molbiopara.2006.08.012; Chen NS, 2006, GENOME RES, V16, P606, DOI 10.1101/gr.4515306; Clayton CE, 2002, EMBO J, V21, P1881, DOI 10.1093/emboj/21.8.1881; DiPaolo C, 2005, MOL CELL, V17, P441, DOI 10.1016/j.molcel.2004.12.022; El-Sayed NM, 2005, SCIENCE, V309, P409, DOI 10.1126/science.1112631; Elias MCQB, 2001, MOL BIOCHEM PARASIT, V112, P79, DOI 10.1016/S0166-6851(00)00349-2; Figueroa-Angulo E, 2003, FEMS MICROBIOL LETT, V225, P221, DOI 10.1016/S0378-1097(03)00516-0; Freitas-Junior LH, 2005, CELL, V121, P25, DOI 10.1016/j.cell.2005.01.037; Garcia-Salcedo JA, 2003, EMBO J, V22, P5851, DOI 10.1093/emboj/cdg553; Gissot M, 2007, PLOS PATHOG, V3, P709, DOI 10.1371/journal.ppat.0030077; Gromak N, 2006, MOL CELL BIOL, V26, P3986, DOI 10.1128/MCB.26.10.3986-3996.2006; Hall N, 2003, NUCLEIC ACIDS RES, V31, P4864, DOI 10.1093/nar/gkg674; Hitchcock RA, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-44; Ingram AK, 2002, MOL MICROBIOL, V45, P89, DOI 10.1046/j.1365-2958.2002.03018.x; Janzen CJ, 2006, MOL CELL, V23, P497, DOI 10.1016/j.molcel.2006.06.027; Janzen CJ, 2006, FEBS LETT, V580, P2306, DOI 10.1016/j.febslet.2006.03.044; KENDALL G, 1990, EMBO J, V9, P2751, DOI 10.1002/j.1460-2075.1990.tb07462.x; Kruglyak S, 2000, TRENDS GENET, V16, P109, DOI 10.1016/S0168-9525(99)01941-1; Lee CK, 2004, NAT GENET, V36, P900, DOI 10.1038/ng1400; Liu CL, 2005, PLOS BIOL, V3, P1753, DOI 10.1371/journal.pbio.0030328; Lowell JE, 2005, J CELL SCI, V118, P5721, DOI 10.1242/jcs.02688; Lowell JE, 2004, J CELL SCI, V117, P5937, DOI 10.1242/jcs.01515; Mandava V, 2008, BIOCHEM BIOPH RES CO, V368, P846, DOI 10.1016/j.bbrc.2008.01.144; Mandava V, 2007, MOL BIOCHEM PARASIT, V156, P41, DOI 10.1016/j.molbiopara.2007.07.005; Martinez-Calvillo S, 2003, MOL CELL, V11, P1291, DOI 10.1016/S1097-2765(03)00143-6; Martinez-Calvillo S, 2004, EUKARYOT CELL, V3, P506, DOI 10.1128/EC.3.2.506-517.2004; Martinez-Calvillo S, 2007, INT J PARASITOL, V37, P491, DOI 10.1016/j.ijpara.2006.11.019; Murray PJ, 2001, BIOORG MED CHEM LETT, V11, P773, DOI 10.1016/S0960-894X(01)00049-X; Navarro M, 1999, EMBO J, V18, P2265, DOI 10.1093/emboj/18.8.2265; Nunes LR, 1997, GENE, V188, P157, DOI 10.1016/S0378-1119(96)00726-3; Obado SO, 2005, GENOME RES, V15, P36, DOI 10.1101/gr.2895105; Ouaissi M, 2006, J BIOMED BIOTECHNOL, DOI 10.1155/JBB/2006/13474; Palenchar JB, 2006, MOL BIOCHEM PARASIT, V146, P135, DOI 10.1016/j.molbiopara.2005.12.008; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Rada-Iglesias A, 2005, HUM MOL GENET, V14, P3435, DOI 10.1093/hmg/ddi378; Rando OJ, 2007, CURR OPIN GENET DEV, V17, P94, DOI 10.1016/j.gde.2007.02.006; Ruan JP, 2004, MOL CELL BIOL, V24, P9610, DOI 10.1128/MCB.24.21.9610-9618.2004; Saksouk N, 2005, MOL CELL BIOL, V25, P10301, DOI 10.1128/MCB.25.23.10301-10314.2005; Schimanski B, 2004, NUCLEIC ACIDS RES, V32, P700, DOI 10.1093/nar/gkh231; Siegel TN, 2008, MOL MICROBIOL, V67, P762, DOI 10.1111/j.1365-2958.2007.06079.x; SLOOF P, 1983, J MOL BIOL, V167, P1, DOI 10.1016/S0022-2836(83)80031-X; SOLARI AJ, 1980, CHROMOSOMA, V78, P239, DOI 10.1007/BF00328395; Sullivan WJ, 2006, CELL MICROBIOL, V8, P1850, DOI 10.1111/j.1462-5822.2006.00818.x; Trinklein ND, 2004, GENOME RES, V14, P62, DOI 10.1101/gr.1982804; Vazquez M, 1999, GENE, V239, P207, DOI 10.1016/S0378-1119(99)00387-X; VILLANUEVA MS, 1991, MOL CELL BIOL, V11, P6139, DOI 10.1128/MCB.11.12.6139; Yuan GC, 2005, SCIENCE, V309, P626, DOI 10.1126/science.1112178; Zink D, 2006, CHROMOSOMA, V115, P273, DOI 10.1007/s00412-006-0062-8	55	70	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15884	15892		10.1074/jbc.M802081200	http://dx.doi.org/10.1074/jbc.M802081200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18400752	Green Published, hybrid			2022-12-25	WOS:000256332500047
J	Savistchenko, J; Krzewska, J; Fay, N; Melki, R				Savistchenko, Jimmy; Krzewska, Joanna; Fay, Nicolas; Melki, Ronald			Molecular chaperones and the assembly of the prion Ure2p in vitro	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN URE2; INFECTIOUS PROTEIN; YEAST; DOMAIN; HSP70; FIBRILS; PROPAGATION; NITROGEN; HSP104	The protein Ure2 from Saccharomyces cerevisiae possesses prion properties at the origin of the [URE3] trait. In vivo, a high molecular weight form of inactive Ure2p is associated to [URE3]. The faithful and continued propagation of [URE3] is dependent on the expression levels of molecular chaperones from the Hsp100, -70, and -40 families; however, so far, their role is not fully documented. Here we investigate the effects of molecular chaperones from the Hsp40, Hsp70, Hsp90, and Hsp100 families and the chaperonin CCT/Tric on the assembly of full-length Ure2p. We show that Hsp104p greatly stimulates Ure2p aggregation, whereas Ssa1p, Ydj1p, Sis1p, and Hsp82p inhibit aggregation to different extents. The nature of the high molecular weight Ure2p species that forms in the presence of the different molecular chaperones and their nucleotide dependence is described. We show that Hsp104p favors the aggregation of Ure2p into non-fibrillar high molecular weight particles, whereas Ssa1p, Ydj1p, Sis1p, and Hsp82p sequester Ure2p in spherical oligomers. Using fluorescently labeled full-length Ure2p and Ure2p-(94-354) and fluorescence polarization, we show that Ssa1p binding to Ure2p is ATP-dependent, whereas that of Hsp104p is not. We also show that Ssa1p preferentially interacts with the N-terminal domain of Ure2p that is critical for prion propagation, whereas Ydj1p preferentially interacts with the C-terminal domain of the protein, and we discuss the significance of this observation. Finally, the affinities of Ssa1p, Ydj1p, and Hsp104p for Ure2p are determined. Our in vitro observations bring new insight into the mechanism by which molecular chaperones influence the propagation of [URE3].	[Savistchenko, Jimmy; Krzewska, Joanna; Fay, Nicolas; Melki, Ronald] CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Paris Saclay	Melki, R (corresponding author), CNRS, Lab Enzymol & Biochim Struct, F-91198 Gif Sur Yvette, France.	melki@lebs.cnrs-gif.fr	Savistchenko, Jimmy/A-6448-2011	Wolak, Joanna/0000-0003-1068-1770				Bai M, 2004, J BIOL CHEM, V279, P50025, DOI 10.1074/jbc.M406612200; Bousset L, 2001, BIOCHEMISTRY-US, V40, P13564, DOI 10.1021/bi011007b; Bousset L, 2002, EMBO J, V21, P2903, DOI 10.1093/emboj/cdf303; Bousset L, 2001, STRUCTURE, V9, P39, DOI 10.1016/S0969-2126(00)00553-0; Brachmann A, 2005, EMBO J, V24, P3082, DOI 10.1038/sj.emboj.7600772; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Cooper TG, 2002, FEMS MICROBIOL REV, V26, P223, DOI 10.1111/j.1574-6976.2002.tb00612.x; COSCHIGANO PW, 1991, MOL CELL BIOL, V11, P822, DOI 10.1128/MCB.11.2.822; COURCHESNE WE, 1988, J BACTERIOL, V170, P708, DOI 10.1128/jb.170.2.708-713.1988; CYR DM, 1995, FEBS LETT, V359, P129, DOI 10.1016/0014-5793(95)00024-4; Dougan DA, 2002, FEBS LETT, V529, P6, DOI 10.1016/S0014-5793(02)03179-4; Fay N, 2005, J BIOL CHEM, V280, P37149, DOI 10.1074/jbc.M506917200; Fay N, 2003, J BIOL CHEM, V278, P30199, DOI 10.1074/jbc.M303000200; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; Goloubinoff P, 1999, P NATL ACAD SCI USA, V96, P13732, DOI 10.1073/pnas.96.24.13732; Jiang Y, 2004, J BIOL CHEM, V279, P3361, DOI 10.1074/jbc.M310494200; Jones GW, 2005, BIOESSAYS, V27, P823, DOI 10.1002/bies.20267; King CY, 2004, NATURE, V428, P319, DOI 10.1038/nature02391; Krzewska J, 2006, EMBO J, V25, P822, DOI 10.1038/sj.emboj.7600985; Krzewska J, 2007, J BIOL CHEM, V282, P1679, DOI 10.1074/jbc.M608110200; LACROUTE F, 1971, J BACTERIOL, V106, P519, DOI 10.1128/JB.106.2.519-522.1971; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz JR, 1999, PRINCIPLES FLUORESCE, P291, DOI 10.1007/978-1-4757-3061-6; Lian HY, 2007, J BIOL CHEM, V282, P11931, DOI 10.1074/jbc.M606856200; Loovers HM, 2007, GENETICS, V175, P621, DOI 10.1534/genetics.106.066019; Lu Z, 1998, J BIOL CHEM, V273, P5970, DOI 10.1074/jbc.273.10.5970; Lu Z, 1998, J BIOL CHEM, V273, P27824, DOI 10.1074/jbc.273.43.27824; MASISON DC, 1995, SCIENCE, V270, P93, DOI 10.1126/science.270.5233.93; McParland VJ, 2000, BIOCHEMISTRY-US, V39, P8735, DOI 10.1021/bi000276j; Melki R, 1997, BIOCHEMISTRY-US, V36, P5817, DOI 10.1021/bi962830o; MITCHELL AP, 1984, MOL CELL BIOL, V4, P2758, DOI 10.1128/MCB.4.12.2758; Moriyama H, 2000, MOL CELL BIOL, V20, P8916, DOI 10.1128/MCB.20.23.8916-8922.2000; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Perrett S, 1999, J MOL BIOL, V290, P331, DOI 10.1006/jmbi.1999.2872; Prodromou C, 1996, PROTEINS, V25, P517, DOI 10.1002/prot.13; Ranson N, 2006, PROTEIN SCI, V15, P2481, DOI 10.1110/ps.062215206; Roberts BT, 2004, YEAST, V21, P107, DOI 10.1002/yea.1062; Schwimmer C, 2002, MOL CELL BIOL, V22, P3590, DOI 10.1128/MCB.22.11.3590-3598.2002; Shorter J, 2006, MOL CELL, V23, P425, DOI 10.1016/j.molcel.2006.05.042; Speransky VV, 2001, J CELL BIOL, V153, P1327, DOI 10.1083/jcb.153.6.1327; Tanaka M, 2004, NATURE, V428, P323, DOI 10.1038/nature02392; Taylor KL, 1999, SCIENCE, V283, P1339, DOI 10.1126/science.283.5406.1339; Thual C, 1999, J BIOL CHEM, V274, P13666, DOI 10.1074/jbc.274.19.13666; Thual C, 2001, BIOCHEMISTRY-US, V40, P1764, DOI 10.1021/bi001916l; Tuite MF, 2003, NAT REV MOL CELL BIO, V4, P878, DOI 10.1038/nrm1247; Umland TC, 2001, P NATL ACAD SCI USA, V98, P1459, DOI 10.1073/pnas.041607898; Wanker EE, 1999, METHOD ENZYMOL, V309, P375; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170	48	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15732	15739		10.1074/jbc.M800728200	http://dx.doi.org/10.1074/jbc.M800728200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18400756	Green Published, hybrid			2022-12-25	WOS:000256332500029
J	Tanaka, H; Homma, K; White, HD; Yanagida, T; Ikebe, M				Tanaka, Hiroto; Homma, Kazuaki; White, Howard D.; Yanagida, Toshio; Ikebe, Mitsuo			Smooth muscle myosin phosphorylated at single head shows sustained mechanical activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGHT-CHAIN PHOSPHORYLATION; ACTIN-FILAMENT; CONTRACTION; MEROMYOSIN; PHOSPHATASE; MOLECULE; MOTOR; ADP; ASYMMETRY; CALCIUM	Smooth muscle contraction is regulated by the phosphorylation of myosin. It is well known that tonic smooth muscles can maintain force with low energy consumption (latch state); however, the molecular mechanism underlying this phenomenon is unresolved. Here we show that single-head phosphorylated smooth myosin (SHPMII) exhibits fast (similar to 24s(-1)) and slow prolonged (similar to 1s(-1)) actin interactions, whereas double-head phosphorylated myosin (DHPMII) predominantly exhibits the fast (similar to 29s(-1)) interaction, suggesting that the phosphorylated head of SHPMII is mechanically as active as that of DHPMII. Both the fast and the slow actin interactions of SHPMII support the positive net mechanical displacement of actin. The actin translocating velocity of SHPMII was much slower than that of DHPMII, which is consistent with the slow actin interaction of SHPMII. We propose that the "latch state" can be explained by the motor characteristics of SHPMII that is present during the sustained phase of contraction.	[Homma, Kazuaki; Ikebe, Mitsuo] Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA; [Tanaka, Hiroto] Japan Sci & Technol Agcy, PRESTO, Tokyo 1020075, Japan; [Tanaka, Hiroto] Tohoku Univ, IMRAM, Sendai, Miyagi 9808577, Japan; [White, Howard D.] Eastern Virginia Med Sch, Dept Physiol Sci, Norfolk, VA 23507 USA; [Yanagida, Toshio] Osaka Univ, Soft Biosyst Grp, Lab Nanobiol, Grad Sch Frontier Biosci, Osaka 5650871, Japan	University of Massachusetts System; University of Massachusetts Worcester; Japan Science & Technology Agency (JST); Tohoku University; Eastern Virginia Medical School; Osaka University	Ikebe, M (corresponding author), Univ Massachusetts, Sch Med, Dept Physiol, Worcester, MA 01655 USA.	mitsuo.ikebe@umassmed.edu	Yanagida, Toshio/D-1919-2009		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073050] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL073050] Funding Source: Medline; NIAMS NIH HHS [AR41653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADELSTEIN RS, 1987, AM J CARDIOL, V59, pB4, DOI 10.1016/0002-9149(87)90076-2; Berger CEM, 2001, J BIOL CHEM, V276, P23240, DOI 10.1074/jbc.M100524200; BERNE RM, 2004, PHYSIOLOGY, P255; Cremo CR, 1998, BIOCHEMISTRY-US, V37, P1969, DOI 10.1021/bi9722406; DILLON PF, 1981, SCIENCE, V211, P495, DOI 10.1126/science.6893872; Ellison PA, 2000, J BIOL CHEM, V275, P15142, DOI 10.1074/jbc.275.20.15142; Ellison PA, 2003, J BIOL CHEM, V278, P4410, DOI 10.1074/jbc.M211016200; FINER JT, 1994, NATURE, V368, P113, DOI 10.1038/368113a0; HAI CM, 1989, ANNU REV PHYSIOL, V51, P285, DOI 10.1146/annurev.physiol.51.1.285; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, P423; Ikebe M, 1998, J BIOL CHEM, V273, P17702, DOI 10.1074/jbc.273.28.17702; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; Ishijima A, 1998, CELL, V92, P161, DOI 10.1016/S0092-8674(00)80911-3; KAMM KE, 1989, ANNU REV PHYSIOL, V51, P299; Kitamura K, 1999, NATURE, V397, P129, DOI 10.1038/16403; KITAZAWA T, 1991, P NATL ACAD SCI USA, V88, P9307, DOI 10.1073/pnas.88.20.9307; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; KITAZAWA T, 1991, ADV EXP MED BIOL, V304, P97; Komatsu S, 2000, J BIOL CHEM, V275, P34512, DOI 10.1074/jbc.M003019200; Komatsu S, 2007, MOL BIOL CELL, V18, P5081, DOI 10.1091/mbc.E06-12-1076; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; MOORE EDW, 1991, ADV EXP MED BIOL, V304, P171; Nakamura K, 2007, CIRC RES, V101, P712, DOI 10.1161/CIRCRESAHA.107.153981; Ogawa Y, 1998, ADV EXP MED BIOL, V453, P241; Ogut O, 2003, J MOL CELL CARDIOL, V35, P347, DOI 10.1016/S0022-2828(03)00045-2; Rovner AS, 2006, BIOCHEMISTRY-US, V45, P5280, DOI 10.1021/bi060154c; Sata M, 1996, BIOCHEMISTRY-US, V35, P11113, DOI 10.1021/bi960435s; SOMLYO AP, 1989, FASEB J, V3, P2266, DOI 10.1096/fasebj.3.11.2506092; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; Somlyo AV, 2004, PHILOS T R SOC B, V359, P1921, DOI 10.1098/rstb.2004.1562; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; Tanaka H, 1998, BIOPHYS J, V75, P1886, DOI 10.1016/S0006-3495(98)77629-5; Tanaka H, 2002, NATURE, V415, P192, DOI 10.1038/415192a; TRYBUS KM, 1985, J BIOL CHEM, V260, P5988; Wendt T, 1999, J CELL BIOL, V147, P1385, DOI 10.1083/jcb.147.7.1385; Wendt T, 2001, P NATL ACAD SCI USA, V98, P4361, DOI 10.1073/pnas.071051098	36	13	13	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15611	15618		10.1074/jbc.M710597200	http://dx.doi.org/10.1074/jbc.M710597200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18408003	Green Published, hybrid			2022-12-25	WOS:000256332500014
J	Tran, K; Gralla, JD				Tran, Khiem; Gralla, Jay D.			Control of the timing of promoter escape and RNA catalysis by the transcription factor IIB fingertip	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE ACTIVE-CENTER; START SITE SELECTION; FACTOR-TFIIB; IN-VITRO; PREINITIATION COMPLEX; CONFORMATIONAL-CHANGE; STRUCTURAL BASIS; INITIATION; ELONGATION; DNA	Transcription factor IIB (TFIIB) recruits RNA polymerase II to promoters and inserts a finger domain into its active site, with unknown consequences. Here we show that that the tip of this finger is important for two transcription initiation functions. First, TFIIB acts as a catalytic cofactor for initial RNA bond formation. It does so via a pair of fingertip aspartates that can bind magnesium, placing TFIIB within a family of proteins that insert finger domains to alter the catalytic functions of RNA polymerase. Second, the TFIIB fingertip mediates the timing of the release of TFIIB that is associated with appropriate promoter escape. These initiation requirements may assist in RNA quality control by minimizing functional synthesis when RNA polymerase becomes inappropriately associated with the genome without having been recruited there by TFIIB.	Univ Calif Los Angeles, Dept Chem & Biochem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gralla, JD (corresponding author), 607 Charles E Young Dr E, Los Angeles, CA 90095 USA.	gralla@mbi.ucla.edu			NIGMS NIH HHS [GM49048] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049048] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURATOWSKI S, 1993, P NATL ACAD SCI USA, V90, P5633, DOI 10.1073/pnas.90.12.5633; Bushnell DA, 2004, SCIENCE, V303, P983, DOI 10.1126/science.1090838; CARPOUSIS AJ, 1985, J MOL BIOL, V183, P165, DOI 10.1016/0022-2836(85)90210-4; CARPOUSIS AJ, 1980, BIOCHEMISTRY-US, V19, P3245, DOI 10.1021/bi00555a023; Cashel M, 2003, J BIOL CHEM, V278, P5539, DOI 10.1074/jbc.M211430200; CHANDLER DW, 1981, NUCLEIC ACIDS RES, V9, P6031, DOI 10.1093/nar/9.22.6031; Chen HT, 2004, CELL, V119, P169, DOI 10.1016/j.cell.2004.09.028; Chen HT, 2007, NAT STRUCT MOL BIOL, V14, P696, DOI 10.1038/nsmb1272; Cho EJ, 2001, GENE DEV, V15, P3319, DOI 10.1101/gad.935901; Deng WS, 2005, GENE DEV, V19, P2418, DOI 10.1101/gad.342405; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; Dvir A, 2002, BBA-GENE STRUCT EXPR, V1577, P208, DOI 10.1016/S0167-4781(02)00453-0; Freire-Picos MA, 2005, NUCLEIC ACIDS RES, V33, P5045, DOI 10.1093/nar/gki825; Grossmann JG, 2001, BIOCHEMISTRY-US, V40, P6267, DOI 10.1021/bi0028946; Holstege FCP, 1997, EMBO J, V16, P7468, DOI 10.1093/emboj/16.24.7468; JEON CJ, 1994, P NATL ACAD SCI USA, V91, P9106, DOI 10.1073/pnas.91.19.9106; JIANG Y, 1993, MOL CELL BIOL, V13, P4572, DOI 10.1128/MCB.13.8.4572; JIANG Y, 1995, J BIOL CHEM, V270, P27332, DOI 10.1074/jbc.270.45.27332; Johnson KM, 2004, METHOD ENZYMOL, V380, P207; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; Kulbachinskiy A, 2006, J BIOL CHEM, V281, P18273, DOI 10.1074/jbc.C600060200; Laptenko O, 2003, EMBO J, V22, P6322, DOI 10.1093/emboj/cdg610; Murakami KS, 2002, SCIENCE, V296, P1280, DOI 10.1126/science.1069594; Opalka N, 2003, CELL, V114, P335, DOI 10.1016/S0092-8674(03)00600-7; Pal M, 2005, MOL CELL, V19, P101, DOI 10.1016/j.molcel.2005.05.024; Panov KI, 2006, EMBO J, V25, P3310, DOI 10.1038/sj.emboj.7601221; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; Raffaelle M, 2005, MOL CELL, V20, P357, DOI 10.1016/j.molcel.2005.10.011; ROBERTS SGE, 1994, NATURE, V371, P717, DOI 10.1038/371717a0; Santangelo TJ, 2007, J MOL BIOL, V367, P344, DOI 10.1016/j.jmb.2006.12.069; Singh BN, 2007, MOL CELL, V27, P806, DOI 10.1016/j.molcel.2007.07.013; Sosunova E, 2003, P NATL ACAD SCI USA, V100, P15469, DOI 10.1073/pnas.2536698100; Steinmetz EJ, 2006, MOL CELL, V24, P735, DOI 10.1016/j.molcel.2006.10.023; Struhl K, 2007, NAT STRUCT MOL BIOL, V14, P103, DOI 10.1038/nsmb0207-103; Tubon TC, 2004, MOL CELL BIOL, V24, P2863, DOI 10.1128/MCB.24.7.2863-2874.2004; Werner F, 2005, MOL CELL BIOL, V25, P8344, DOI 10.1128/MCB.25.18.8344-8355.2005; Wu WH, 1999, GENETICS, V153, P643; Yudkovsky N, 2000, NATURE, V408, P225, DOI 10.1038/35041603; ZAWEL L, 1995, GENE DEV, V9, P1479, DOI 10.1101/gad.9.12.1479; Zaychikov E, 1996, SCIENCE, V273, P107, DOI 10.1126/science.273.5271.107; Zhang DY, 2002, NUCLEIC ACIDS RES, V30, P3078, DOI 10.1093/nar/gkf422; Zheng L, 2004, EUR J BIOCHEM, V271, P792, DOI 10.1111/j.1432-1033.2004.03983.x	42	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15665	15671		10.1074/jbc.M801439200	http://dx.doi.org/10.1074/jbc.M801439200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18411280	hybrid, Green Published			2022-12-25	WOS:000256332500020
J	Korpal, M; Lee, ES; Hu, GH; Kang, YB				Korpal, Manav; Lee, Esther S.; Hu, Guohong; Kang, Yibin			The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BREAST-CANCER; MICRORNA EXPRESSION; COLORECTAL-CANCER; TUMOR INVASION; MAMMARY-TUMOR; METASTASIS; GENES; MORPHOGENESIS; PROGRESSION; SIP1	MicroRNAs are small non-coding RNA molecules that can regulate gene expression by interacting with multiple mRNAs and inducing either translation suppression or degradation of mRNA. Recently, several miRNAs were identified as either promoters or suppressors of metastasis. However, it is unclear in which step(s) of the multistep metastatic cascade these miRNAs play a defined functional role. To study the functional importance of miRNAs in epithelial-mesenchymal transition (EMT), a process thought to initiate metastasis by enhancing the motility of tumor cells, we used a well established in vitro EMT assay: transforming growth factor-beta-induced EMT in NMuMG murine mammary epithelial cells. We found that members of the miR-200 family, organized as two clusters in the genome, were repressed during EMT. Overexpression of each miRNA individually or as clusters in NMuMG cells hindered EMT by enhancing E-cadherin expression through direct targeting of ZEB1 and ZEB2, which encode transcriptional repressors of E-cadherin. In the 4TO7 mouse carcinoma cell line, which expresses low levels of endogenous E-cadherin and displays a mesenchymal phenotype, ectopic expression of the miR-200 family miRNAs significantly increased E-cadherin expression and altered cell morphology to an epithelial phenotype. Furthermore, ectopic expression of each miR-200 miRNA cluster significantly reduced the in vitro motility of 4TO7 cells in migration assays. These results suggested that loss of expression of the miR-200 family members may play a critical role in the repression of E-cadherin by ZEB1 and ZEB2 during EMT, thereby enhancing migration and invasion during cancer progression.	[Korpal, Manav; Lee, Esther S.; Hu, Guohong; Kang, Yibin] Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Princeton University	Kang, YB (corresponding author), Princeton Univ, Dept Mol Biol, Washington Rd,LTL 255, Princeton, NJ 08544 USA.	ykang@princeton.edu	huang, nqi/F-7238-2011	Kang, Yibin/0000-0002-1626-6730; Hu, Guohong/0000-0002-2980-5166	NCI NIH HHS [R01 CA141062] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA141062] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856; ASLAKSON CJ, 1992, CANCER RES, V52, P1399; Baskerville S, 2005, RNA, V11, P241, DOI 10.1261/rna.7240905; Christoffersen NR, 2007, RNA, V13, P1172, DOI 10.1261/rna.586807; Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840; GREGORY PA, 2008, NAT CELL BIOL; Huang QH, 2008, NAT CELL BIOL, V10, P202, DOI 10.1038/ncb1681; Huber MA, 2004, J CLIN INVEST, V114, P569, DOI 10.1172/JCI200421358; Hurteau GJ, 2007, CANCER RES, V67, P7972, DOI 10.1158/0008-5472.CAN-07-1058; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Imamichi Y, 2007, ONCOGENE, V26, P2381, DOI 10.1038/sj.onc.1210012; Johnson SM, 2005, CELL, V120, P635, DOI 10.1016/j.cell.2005.01.014; Lee Y, 2003, NATURE, V425, P415, DOI 10.1038/nature01957; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; Ma L, 2007, NATURE, V449, P682, DOI 10.1038/nature06174; Maeda G, 2005, INT J ONCOL, V27, P1535; Miyoshi T, 2006, DEV DYNAM, V235, P1941, DOI 10.1002/dvdy.20799; Muraoka RS, 2002, J CLIN INVEST, V109, P1551, DOI 10.1172/JCI200215234; Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016; Spoelstra NS, 2006, CANCER RES, V66, P3893, DOI 10.1158/0008-5472.CAN-05-2881; Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487; Thiery JP, 2003, CURR OPIN CELL BIOL, V15, P740, DOI 10.1016/j.ceb.2003.10.006; Wienholds E, 2005, SCIENCE, V309, P310, DOI 10.1126/science.1114519; Yang J, 2004, CELL, V117, P927, DOI 10.1016/j.cell.2004.06.006; Yi R, 2006, NAT GENET, V38, P356, DOI 10.1038/ng1744; Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803; Zhu SM, 2008, CELL RES, V18, P350, DOI 10.1038/cr.2008.24	28	1274	1357	5	127	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					14910	14914		10.1074/jbc.C800074200	http://dx.doi.org/10.1074/jbc.C800074200			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18411277	Green Published, hybrid			2022-12-25	WOS:000256232000002
J	Kyosseva, SV; Harris, EN; Weigel, PH				Kyosseva, Svetlana V.; Harris, Edward N.; Weigel, Paul H.			The hyaluronan receptor for endocytosis mediates hyaluronan-dependent signal transduction via extracellular signal-regulated kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-KINASE; LIVER ENDOTHELIAL-CELLS; TRANSCRIPTIONAL ACTIVATION; CANCER PROGRESSION; OVARIAN-CANCER; BINDING; EXPRESSION; ACID; HARE; PURIFICATION	The hyaluronan (HA) receptor for endocytosis (HARE) mediates the endocytotic clearance of HA and other glycosaminoglycans from lymph and blood. Two isoforms of human HARE, 315- and 190-kDa, are highly expressed in sinusoidal endothelial cells of liver, lymph node, and spleen; HARE is also in specialized cells in the eye, heart, brain, and kidney. Here we determined whether HA binding to HARE initiates intracellular signaling in Flp-In 293 cells stably expressing either the 315- and 190-kDa HARE or the 190-kDa HARE alone. HARE was co-immunoprecipitated with extracellular signal-regulated kinase 1 and 2 (ERK1/2), c-Jun N-terminal protein kinase (JNK), and p38 members of the mitogen-activated protein kinase signaling cascade. ERK phosphorylation increased in a dose- and time-dependent manner when HA was added to cells expressing full-length or 190-kDa HARE, but not cells with vector-only or a HARE(Delta Link) construct with greatly decreased (similar to 90%) HA uptake. HA did not induce phosphorylation of JNK or p38. A maximum increase in phospho-ERK1/2 occurred within 30 min at 5 mu g/ml HA, and the response was dampened at >20 mu g/ml HA. HA binding did not increase the level of HARE-ERK complexes, but did increase HARE phosphorylation. These findings demonstrate a novel functional response, when HARE binds HA, that leads to activation of ERK1/2, important mediators of intracellular signal transduction.	Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73190 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Weigel, PH (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73190 USA.	paul-weigel@ouhsc.edu	Harris, Edward N/A-1596-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM069961] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 69961] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adachi H, 2002, J BIOL CHEM, V277, P34264, DOI 10.1074/jbc.M204277200; Anttila MA, 2000, CANCER RES, V60, P150; Bastow ER, 2005, J BIOL CHEM, V280, P11749, DOI 10.1074/jbc.M414495200; BERTRAND P, 1992, INT J CANCER, V52, P1, DOI 10.1002/ijc.2910520102; Bourguignon LYW, 2007, J BIOL CHEM, V282, P19426, DOI 10.1074/jbc.M610054200; Bourguignon LYW, 2005, J BIOL CHEM, V280, P11961, DOI 10.1074/jbc.M411985200; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; Day AJ, 2002, J BIOL CHEM, V277, P4585, DOI 10.1074/jbc.R100036200; Entwistle J, 1996, J CELL BIOCHEM, V61, P569, DOI 10.1002/(SICI)1097-4644(19960616)61:4<569::AID-JCB10>3.0.CO;2-B; Falkowski M, 2003, HISTOCHEM CELL BIOL, V120, P361, DOI 10.1007/s00418-003-0585-5; FRASER JRE, 1983, CELL TISSUE RES, V233, P285; Fujita Y, 2002, FEBS LETT, V528, P101, DOI 10.1016/S0014-5793(02)03262-3; HAMERMAN D, 1965, BIOCHIM BIOPHYS ACTA, V101, P343, DOI 10.1016/0926-6534(65)90013-8; Hamilton SR, 2007, J BIOL CHEM, V282, P16667, DOI 10.1074/jbc.M702078200; Hansen B, 2005, EXP CELL RES, V303, P160, DOI 10.1016/j.yexcr.2004.09.017; Harris EN, 2007, J BIOL CHEM, V282, P2785, DOI 10.1074/jbc.M607787200; Harris EN, 2004, J BIOL CHEM, V279, P36201, DOI 10.1074/jbc.M405322200; Hascall VC, 2004, BBA-GEN SUBJECTS, V1673, P3, DOI 10.1016/j.bbagen.2004.02.013; HAYNES PA, 1994, J BIOL CHEM, V269, P33146; Khaldoyanidi S, 1999, BLOOD, V94, P940, DOI 10.1182/blood.V94.3.940.415k27_940_949; Kim SK, 2007, PHARMACOL THERAPEUT, V113, P88, DOI 10.1016/j.pharmthera.2006.07.004; Kyosseva SV, 2004, INT REV NEUROBIOL, V59, P201; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURENT TC, 1992, FASEB J, V6, P2397, DOI 10.1096/fasebj.6.7.1563592; Laurent TC, 1996, ANN MED, V28, P241, DOI 10.3109/07853899609033126; Lee JY, 2000, CURR OPIN CELL BIOL, V12, P581, DOI 10.1016/S0955-0674(00)00135-6; MCGARY CT, 1989, BIOCHEM J, V257, P875, DOI 10.1042/bj2570875; McPherson PS, 2001, TRAFFIC, V2, P375, DOI 10.1034/j.1600-0854.2001.002006375.x; Mellman I, 1996, ANNU REV CELL DEV BI, V12, P575, DOI 10.1146/annurev.cellbio.12.1.575; Ohno S, 2006, J BIOL CHEM, V281, P17952, DOI 10.1074/jbc.M602750200; Pierce KL, 2000, P NATL ACAD SCI USA, V97, P1489, DOI 10.1073/pnas.97.4.1489; Politz O, 2002, BIOCHEM J, V362, P155, DOI 10.1042/0264-6021:3620155; RAJA RH, 1984, ANAL BIOCHEM, V139, P168, DOI 10.1016/0003-2697(84)90402-0; Seyfried NT, 2005, J BIOL CHEM, V280, P5435, DOI 10.1074/jbc.M411297200; SMEDSROD B, 1988, CELL TISSUE RES, V253, P39; Stern R, 2006, EUR J CELL BIOL, V85, P699, DOI 10.1016/j.ejcb.2006.05.009; Termeer C, 2003, TRENDS IMMUNOL, V24, P112, DOI 10.1016/S1471-4906(03)00029-2; Tool BP, 2001, SEMIN CELL DEV BIOL, V12, P79, DOI 10.1006/scdb.2000.0244; Toole BP, 1990, CURR OPIN CELL BIOL, V2, P839, DOI 10.1016/0955-0674(90)90081-O; Toole BP, 2004, NAT REV CANCER, V4, P528, DOI 10.1038/nrc1391; Turley EA, 2002, J BIOL CHEM, V277, P4589, DOI 10.1074/jbc.R100038200; Ulbrich SE, 2004, MOL CELL ENDOCRINOL, V214, P9, DOI 10.1016/j.mce.2003.12.002; Wang C, 1998, CLIN CANCER RES, V4, P567; Weigel JA, 2003, J BIOL CHEM, V278, P9808, DOI 10.1074/jbc.M211462200; Weigel PH, 2002, BBA-GEN SUBJECTS, V1572, P341, DOI 10.1016/S0304-4165(02)00318-5; Zhang SW, 1998, J BIOL CHEM, V273, P11342, DOI 10.1074/jbc.273.18.11342; Zhou B, 1999, J BIOL CHEM, V274, P33831, DOI 10.1074/jbc.274.48.33831; Zhou B, 2003, GLYCOBIOLOGY, V13, P339, DOI 10.1093/glycob/cwg029; Zhou B, 2002, MOL BIOL CELL, V13, P2853, DOI 10.1091/mbc.02-03-0048; Zhou B, 2000, J BIOL CHEM, V275, P37733, DOI 10.1074/jbc.M003030200	52	35	35	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15047	15055		10.1074/jbc.M709921200	http://dx.doi.org/10.1074/jbc.M709921200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18387958	Green Published, hybrid			2022-12-25	WOS:000256232000018
J	Rardin, MJ; Wiley, SE; Murphy, AN; Pagliarini, DJ; Dixon, JE				Rardin, Matthew J.; Wiley, Sandra E.; Murphy, Anne N.; Pagliarini, David J.; Dixon, Jack E.			Dual specificity phosphatases 18 and 21 target to opposing sides of the mitochondrial inner membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE COMPLEX; RAT-LIVER MITOCHONDRIA; CYTOCHROME-C; PHOSPHATASE; PHOSPHORYLATION; APOPTOSIS; RELEASE; PURIFICATION; DEGRADATION; MECHANISM	Although large-scale approaches have identified numerous mitochondrial phosphoproteins, little is known about the mitochondrial kinases and phosphatases that regulate these phosphoproteins. Here, we identify two members of the atypical dual specificity phosphatases (DSP), DSP18 and DSP21, that are localized in mitochondria. Although DSP18 is widely expressed in several mammalian tissues, DSP21 is selectively expressed in the testes. We demonstrate that DSP18 and DSP21 are targeted to mitochondria by cryptic internal localization signals. Sub-fractionation of mitochondria demonstrated that DSP18 is located in the intermembrane space as a peripheral membrane protein of the inner membrane. In contrast, subfractionation of rat testis mitochondria revealed DSP21 is localized to the matrix as a peripheral membrane protein of the inner membrane. Moreover, we demonstrate that a previously reported substrate for DSP18, the stress-activated protein kinase, does not localize to mitochondria in several different tissues, making it an unlikely substrate for DSP18. Finally, we show that induction of apoptosis by treatment with staurosporine causes translocation of DSP18 from the intermembrane space into the cytosol similar to other apoptogenic factors such as cytochrome c. This work rigorously demonstrates the unique location of two highly similar DSPs on opposing sides of the mitochondrial inner membrane.	[Rardin, Matthew J.; Wiley, Sandra E.; Murphy, Anne N.; Dixon, Jack E.] Univ Calif San Diego, Dept Pharmacol, La Jolla, CA 92093 USA; [Rardin, Matthew J.; Wiley, Sandra E.; Murphy, Anne N.; Dixon, Jack E.] Univ Calif San Diego, Dept Cell & Mol Med, La Jolla, CA 92093 USA; [Rardin, Matthew J.; Wiley, Sandra E.; Murphy, Anne N.; Dixon, Jack E.] Univ Calif San Diego, Dept Chem & Biochem, La Jolla, CA 92093 USA; [Rardin, Matthew J.] Univ Calif San Diego, Biomed Sci Grad Program, La Jolla, CA 92093 USA; [Dixon, Jack E.] Univ Calif San Diego, Howard Hughes Med Inst, La Jolla, CA 92093 USA; [Pagliarini, David J.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02114 USA; [Pagliarini, David J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; Howard Hughes Medical Institute; University of California System; University of California San Diego; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Dixon, JE (corresponding author), Univ Calif San Diego, Dept Pharmacol, 9500 Gilman Dr, La Jolla, CA 92093 USA.	jedixon@ucsd.edu	; Murphy, Anne N/H-3217-2016	Wiley, Sandra/0000-0003-3979-2474; Pagliarini, David J./0000-0002-0001-0087; Murphy, Anne N/0000-0002-5222-9902	NIGMS NIH HHS [2T32 GM 07752-25, T32 GM007752] Funding Source: Medline; PHS HHS [NIH 18849] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007752] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alonso A, 2004, TOP CURR GENET, V5, P333; Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Alonso A, 2004, J BIOL CHEM, V279, P35768, DOI 10.1074/jbc.M403412200; Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bossy-Wetzel E, 2000, METHOD ENZYMOL, V322, P235; Brookes PS, 2004, AM J PHYSIOL-CELL PH, V287, pC817, DOI 10.1152/ajpcell.00139.2004; Cardone L, 2004, MOL CELL BIOL, V24, P4613, DOI 10.1128/MCB.24.11.4613-4626.2004; Cardone L, 2002, J MOL BIOL, V320, P663, DOI 10.1016/S0022-2836(02)00479-5; COOK KG, 1983, FEBS LETT, V157, P59, DOI 10.1016/0014-5793(83)81116-8; COULDWELL WT, 1994, FEBS LETT, V345, P43, DOI 10.1016/0014-5793(94)00415-3; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DENU JM, 1995, J BIOL CHEM, V270, P3796, DOI 10.1074/jbc.270.8.3796; Diekert K, 1999, P NATL ACAD SCI USA, V96, P11752, DOI 10.1073/pnas.96.21.11752; Duchen Michael R., 2004, Molecular Aspects of Medicine, V25, P365, DOI 10.1016/j.mam.2004.03.001; Feliciello A, 2005, CELL SIGNAL, V17, P279, DOI 10.1016/j.cellsig.2004.09.009; Goldstein JC, 2000, NAT CELL BIOL, V2, P156, DOI 10.1038/35004029; Green DR, 2005, CELL, V121, P671, DOI 10.1016/j.cell.2005.05.019; Holness MJ, 2003, BIOCHEM SOC T, V31, P1143; Hood KL, 2002, BIOCHEM BIOPH RES CO, V298, P545, DOI 10.1016/S0006-291X(02)02488-9; Horbinski C, 2005, FREE RADICAL BIO MED, V38, P2, DOI 10.1016/j.freeradbiomed.2004.09.030; Hunter T, 2000, CELL, V100, P113, DOI 10.1016/S0092-8674(00)81688-8; Jeong DG, 2006, ACTA CRYSTALLOGR D, V62, P582, DOI 10.1107/S0907444906010109; Johnson  D., 1967, METHOD ENZYMOL, V10, P94, DOI DOI 10.1016/0076-6879(67)10018-9; Kim SA, 2002, J BIOL CHEM, V277, P4526, DOI 10.1074/jbc.M111087200; Koppen M, 2007, CRIT REV BIOCHEM MOL, V42, P221, DOI 10.1080/10409230701380452; LAPIDUS RG, 1993, ARCH BIOCHEM BIOPHYS, V306, P246, DOI 10.1006/abbi.1993.1507; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LINN TC, 1969, P NATL ACAD SCI USA, V62, P234, DOI 10.1073/pnas.62.1.234; Liou W, 1996, HISTOCHEM CELL BIOL, V106, P41, DOI 10.1007/BF02473201; Livigni A, 2006, MOL BIOL CELL, V17, P263, DOI 10.1091/mbc.e05-09-0827; Marin-Garcia J, 2004, J MOL MED, V82, P565, DOI 10.1007/s00109-004-0567-7; Mehrle A, 2006, NUCLEIC ACIDS RES, V34, pD415, DOI 10.1093/nar/gkj139; Melov S, 2004, TRENDS NEUROSCI, V27, P601, DOI 10.1016/j.tins.2004.08.004; Neupert W, 1997, ANNU REV BIOCHEM, V66, P863, DOI 10.1146/annurev.biochem.66.1.863; Pagliarini DJ, 2006, TRENDS BIOCHEM SCI, V31, P26, DOI 10.1016/j.tibs.2005.11.005; Pagliarini DJ, 2005, MOL CELL, V19, P197, DOI 10.1016/j.molcel.2005.06.008; Pagliarini DJ, 2004, J BIOL CHEM, V279, P38590, DOI 10.1074/jbc.M404959200; PEDERSEN PL, 1978, J BIOL CHEM, V253, P2176; Piergiacomi VA, 1996, MOL CELL BIOCHEM, V165, P121, DOI 10.1007/BF00229473; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; Rosini P, 2004, J BIOL CHEM, V279, P14016, DOI 10.1074/jbc.M305356200; Salvi M, 2005, FREE RADICAL BIO MED, V38, P1267, DOI 10.1016/j.freeradbiomed.2005.02.006; Salvi M, 2004, CELL MOL LIFE SCI, V61, P2393, DOI 10.1007/s00018-004-4211-z; Taylor GS, 1997, J BIOL CHEM, V272, P24054, DOI 10.1074/jbc.272.38.24054; Taylor GS, 2003, METHOD ENZYMOL, V366, P43; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; Tonks NK, 1996, CELL, V87, P365, DOI 10.1016/S0092-8674(00)81357-4; Truscott KN, 2003, CURR BIOL, V13, pR326, DOI 10.1016/S0960-9822(03)00239-2; Valente EM, 2004, SCIENCE, V304, P1158, DOI 10.1126/science.1096284; Visconti PE, 1998, BIOL REPROD, V59, P1, DOI 10.1095/biolreprod59.1.1; Wallace DC, 2005, ANNU REV GENET, V39, P359, DOI 10.1146/annurev.genet.39.110304.095751; Wang HG, 1996, CELL, V87, P629, DOI 10.1016/S0092-8674(00)81383-5; Wei MC, 2001, SCIENCE, V292, P727, DOI 10.1126/science.1059108; Wiland AM, 1996, J BIOL CHEM, V271, P33486, DOI 10.1074/jbc.271.52.33486; Wu QH, 2003, BBA-GENE STRUCT EXPR, V1625, P296, DOI 10.1016/S0167-4781(02)00629-2; Wu Q, 2006, FRONT BIOSCI-LANDMRK, V11, P2714, DOI 10.2741/2001; Wynn RM, 2004, STRUCTURE, V12, P2185, DOI 10.1016/j.str.2004.09.013; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	58	20	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15440	15450		10.1074/jbc.M709547200	http://dx.doi.org/10.1074/jbc.M709547200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18385140	hybrid, Green Published			2022-12-25	WOS:000256232000062
J	Bagautdinov, B; Matsuura, Y; Bagautdinova, S; Kunishima, N				Bagautdinov, Bagautdin; Matsuura, Yoshinori; Bagautdinova, Svetlana; Kunishima, Naoki			Protein biotinylation visualized by a complex structure of biotin protein ligase with a substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PYRUVATE-DEHYDROGENASE COMPLEX; PROPIONYL-COA CARBOXYLASE; POSTTRANSLATIONAL MODIFICATION; LIPOYL DOMAIN; ACETYL-COENZYME; CARRIER PROTEIN; 3-DIMENSIONAL STRUCTURE; SWINGING ARMS; IN-VIVO; PURIFICATION	Biotin protein ligase (BPL) catalyzes the biotinylation of the biotin carboxyl carrier protein (BCCP) only at a special lysine residue. Here we report the first structure of BPL.BCCP complex crystals, which are prepared using two BPL mutants: R48A and R48A/K111A. From a detailed structural characterization, it is likely that the mutants retain functionality as enzymes but have a reduced activity to produce the reaction intermediate biotinyl-5'-AMP. The observed biotin and partly disordered ATP in the mutant structures may act as a non-reactive analog of the substrates or biotinyl-5'-AMP, thereby providing the complex crystals. The four crystallographically independent BPL.BCCP complexes obtained can be classified structurally into three groups: the formation stages 1 and 2 with apo-BCCP and the product stage with biotinylated holo-BCCP. Residues responsible for the complex formation as well as for the biotinylation reaction have been identified. The C-terminal domain of BPL shows especially large conformational changes to accommodate BCCP, suggesting its functional importance. The formation stage 1 complex shows the closest distance between the carboxyl carbon of biotin and the special lysine of BCCP, suggesting its relevance to the unobserved reaction stage. Interestingly, bound ATP and biotin are also seen in the product stage, indicating that the substrates may be recruited into the product stage complex before the release of holo-BCCP, probably for the next reaction cycle. The existence of formation and product stages before and after the reaction stage would be favorable to ensure both the reaction efficiency and the extreme substrate specificity of the biotinylation reaction.	[Bagautdinov, Bagautdin; Matsuura, Yoshinori; Bagautdinova, Svetlana; Kunishima, Naoki] Harima Inst, RIKEN Spring Ctr 8, Sayo Cho, Hyogo 675148, Japan	RIKEN	Kunishima, N (corresponding author), Harima Inst, RIKEN Spring Ctr 8, 1-1-1 Kouto, Sayo Cho, Hyogo 675148, Japan.	kunisima@spring8.or.jp	Kunishima, Naoki/N-7464-2015; Bagautdinov, Bagautdin/GPP-2605-2022	Bagautdinov, Bagautdin/0000-0002-0310-1769; Kunishima, Naoki/0000-0001-9826-9902				Athappilly FK, 1995, STRUCTURE, V3, P1407, DOI 10.1016/S0969-2126(01)00277-5; Bagautdinov B, 2005, J MOL BIOL, V353, P322, DOI 10.1016/j.jmb.2005.08.032; Bagautdinov B, 2005, ACTA CRYSTALLOGR F, V61, P193, DOI 10.1107/S1744309104034360; Bagautdinov B, 2007, ACTA CRYSTALLOGR F, V63, P334, DOI 10.1107/S1744309107011967; Beckett D, 1997, METHOD ENZYMOL, V279, P362; Berg A, 1997, EUR J BIOCHEM, V244, P352, DOI 10.1111/j.1432-1033.1997.00352.x; Berg A, 1996, J MOL BIOL, V261, P432, DOI 10.1006/jmbi.1996.0474; BROCKLEHURST SM, 1993, PROTEIN SCI, V2, P626; Bruger AT, 1998, ACTA CRYSTALLOGR D, V54, P905; Chapman-Smith A, 1999, TRENDS BIOCHEM SCI, V24, P359, DOI 10.1016/S0968-0004(99)01438-3; Chapman-Smith A, 1999, J BIOL CHEM, V274, P1449, DOI 10.1074/jbc.274.3.1449; CHAPMANSMITH A, 1994, BIOCHEM J, V302, P881, DOI 10.1042/bj3020881; Clarke DJ, 2003, EUR J BIOCHEM, V270, P1277, DOI 10.1046/j.1432-1033.2003.03493.x; CRONAN JE, 1990, J BIOL CHEM, V265, P10327; Cronan JE, 2002, J BIOL CHEM, V277, P22520, DOI 10.1074/jbc.M201249200; Cronan JE, 2000, METHOD ENZYMOL, V326, P440; DARDEL F, 1993, J MOL BIOL, V229, P1037, DOI 10.1006/jmbi.1993.1103; de Boer E, 2003, P NATL ACAD SCI USA, V100, P7480, DOI 10.1073/pnas.1332608100; Gouet P, 1999, BIOINFORMATICS, V15, P305, DOI 10.1093/bioinformatics/15.4.305; Howarth M, 2005, P NATL ACAD SCI USA, V102, P7583, DOI 10.1073/pnas.0503125102; Jeanmougin F, 1998, TRENDS BIOCHEM SCI, V23, P403, DOI 10.1016/S0968-0004(98)01285-7; Jones DD, 2000, BIOCHEMISTRY-US, V39, P8448, DOI 10.1021/bi992978i; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; Kim DJ, 2005, J BIOL CHEM, V280, P38081, DOI 10.1074/jbc.M507284200; KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211; Kunishima N, 2005, J MOL BIOL, V352, P212, DOI 10.1016/j.jmb.2005.07.008; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEONDELRIO A, 1994, J BIOL CHEM, V269, P22964; Li YQ, 2006, FEBS LETT, V580, P1536, DOI 10.1016/j.febslet.2006.01.083; Ma QJ, 2006, P NATL ACAD SCI USA, V103, P8662, DOI 10.1073/pnas.0510436103; Menendez C, 1999, J BACTERIOL, V181, P1088, DOI 10.1128/JB.181.4.1088-1098.1999; Nenortas E, 1996, J BIOL CHEM, V271, P7559, DOI 10.1074/jbc.271.13.7559; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perham RN, 2000, ANNU REV BIOCHEM, V69, P961, DOI 10.1146/annurev.biochem.69.1.961; Polyak SW, 2001, J BIOL CHEM, V276, P3037, DOI 10.1074/jbc.M003968200; Polyak SW, 1999, J BIOL CHEM, V274, P32847, DOI 10.1074/jbc.274.46.32847; Reche P, 1998, BIOCHEM J, V329, P589, DOI 10.1042/bj3290589; Reche P, 1999, EMBO J, V18, P2673, DOI 10.1093/emboj/18.10.2673; Reche PA, 2000, FEBS LETT, V479, P93, DOI 10.1016/S0014-5793(00)01829-9; Reddy DV, 2000, BIOCHEMISTRY-US, V39, P2509, DOI 10.1021/bi9925367; Roberts EL, 1999, BIOCHEMISTRY-US, V38, P5045, DOI 10.1021/bi982466o; SHENOY BC, 1988, FASEB J, V2, P2396, DOI 10.1096/fasebj.2.8.3360240; SHENOY BC, 1992, J BIOL CHEM, V267, P18407; Stolz J, 1998, FEBS LETT, V440, P213, DOI 10.1016/S0014-5793(98)01454-9; TOH H, 1993, EUR J BIOCHEM, V215, P687, DOI 10.1111/j.1432-1033.1993.tb18080.x; Tong L, 2006, J CELL BIOCHEM, V99, P1476, DOI 10.1002/jcb.21077; Tozawa K, 2001, EUR J BIOCHEM, V268, P4908, DOI 10.1046/j.0014-2956.2001.02422.x; Ueno Go, 2006, Journal of Structural and Functional Genomics, V7, P15, DOI 10.1007/s10969-005-9005-5; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; WALLIS NG, 1994, J MOL BIOL, V236, P209, DOI 10.1006/jmbi.1994.1130; Weaver LH, 2001, PROTEIN SCI, V10, P2618, DOI 10.1110/ps.ps.32701; Weaver LH, 2001, P NATL ACAD SCI USA, V98, P6045, DOI 10.1073/pnas.111128198; WOOD HG, 1980, J BIOL CHEM, V255, P7397; Wood ZA, 2006, J MOL BIOL, V357, P509, DOI 10.1016/j.jmb.2005.12.066	54	42	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14739	14750		10.1074/jbc.M709116200	http://dx.doi.org/10.1074/jbc.M709116200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18372281	hybrid			2022-12-25	WOS:000255941400062
J	Craven, KB; Olivier, NB; Zagotta, WN				Craven, Kimberley B.; Olivier, Nelson B.; Zagotta, William N.			C-terminal movement during gating in cyclic nucleotide-modulated channels	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING DOMAIN; REGION; REARRANGEMENTS; MECHANISM; RING; SITE	Activation of cyclic nucleotide-modulated channels such as CNG and HCN channels is promoted by ligand-induced conformational changes in their C-terminal regions. The primary intersubunit interface of these C termini includes two salt bridges per subunit, formed between three residues (one positively charged and two negatively charged amino acids) that we term the SB triad. We previously hypothesized that the SB triad is formed in the closed channel and breaks when the channel opens. Here we tested this hypothesis by dynamically manipulating the SB triad in functioning CNGA1 channels. Reversing the charge at positions Arg-431 and Glu-462, two of the SB triad residues, by either mutation or application of charged reagents increased the favorability of channel opening. To determine how a charge reversal mutation in the SB triad structurally affects the channel, we solved the crystal structure of the HCN2 C-terminal region with the equivalent E462R mutation. The backbone structure of this mutant was very similar to that of wild type, but the SB triad was rearranged such that both salt bridges did not always form simultaneously, suggesting a mechanism for the increased ease of opening of the mutant channels. To prevent movement in the SB triad, we tethered two components of the SB triad region together with cysteine-reactive cross-linkers. Preventing normal movement of the SB triad region with short cross-linkers inhibited channel opening, whereas longer cross-linkers did not. These results support our hypothesis that the SB triad forms in the closed channel and indicate that this region expands as the channel opens.	[Zagotta, William N.] Univ Washington, Dept Physiol & Biophys, Howard Hughes Med Inst, Seattle, WA 98195 USA; [Olivier, Nelson B.] MIT, Dept Chem, Cambridge, MA 02139 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Massachusetts Institute of Technology (MIT)	Zagotta, WN (corresponding author), Univ Washington, Dept Physiol & Biophys, Howard Hughes Med Inst, Box 357290, Seattle, WA 98195 USA.	zagotta@u.washington.edu			NATIONAL EYE INSTITUTE [R01EY010329] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS038631] Funding Source: NIH RePORTER; Howard Hughes Medical Institute Funding Source: Medline; NEI NIH HHS [R01 EY 010329, R01 EY010329, R01 EY010329-15] Funding Source: Medline; NINDS NIH HHS [R01 NS 038631] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); Howard Hughes Medical Institute(Howard Hughes Medical Institute); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Armstrong N, 2006, CELL, V127, P85, DOI 10.1016/j.cell.2006.08.037; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen GQ, 1997, PROTEIN ENG, V10, P1061, DOI 10.1093/protein/10.9.1061; Craven KB, 2006, ANNU REV PHYSIOL, V68, P375, DOI 10.1146/annurev.physiol.68.040104.134728; Craven KB, 2004, J GEN PHYSIOL, V124, P663, DOI 10.1085/jgp.200409178; Emsley P, 2004, ACTA CRYSTALLOGR D, V60, P2126, DOI 10.1107/S0907444904019158; Flynn GE, 2007, STRUCTURE, V15, P671, DOI 10.1016/j.str.2007.04.008; Flynn GE, 2003, J GEN PHYSIOL, V121, P563, DOI 10.1085/jgp.200308819; FRENCH S, 1978, ACTA CRYSTALLOGR A, V34, P517, DOI 10.1107/S0567739478001114; GORDON SE, 1995, NEURON, V14, P857, DOI 10.1016/0896-6273(95)90229-5; GORDON SE, 1995, NEURON, V14, P177; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; Johnson JP, 2005, P NATL ACAD SCI USA, V102, P2742, DOI 10.1073/pnas.0408323102; Johnson JP, 2001, NATURE, V412, P917, DOI 10.1038/35091089; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KARPEN JW, 1988, P NATL ACAD SCI USA, V85, P1287, DOI 10.1073/pnas.85.4.1287; Kaupp UB, 2002, PHYSIOL REV, V82, P769, DOI 10.1152/physrev.00008.2002; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIMAN ER, 1992, NEURON, V9, P861, DOI 10.1016/0896-6273(92)90239-A; Loo TW, 2001, J BIOL CHEM, V276, P36877, DOI 10.1074/jbc.C100467200; Matulef K, 1999, NEURON, V24, P443, DOI 10.1016/S0896-6273(00)80857-0; Matulef K, 2002, NEURON, V36, P93, DOI 10.1016/S0896-6273(02)00878-4; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 2001, ACTA CRYSTALLOGR D, V57, P1445, DOI 10.1107/S0907444901014007; Rho SH, 2000, FEBS LETT, V478, P246, DOI 10.1016/S0014-5793(00)01863-9; Robinson RB, 2003, ANNU REV PHYSIOL, V65, P453, DOI 10.1146/annurev.physiol.65.092101.142734; Sunderman ER, 1999, J GEN PHYSIOL, V113, P601, DOI 10.1085/jgp.113.5.601; Taraska JW, 2007, NAT STRUCT MOL BIOL, V14, P854, DOI 10.1038/nsmb1281; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Wainger BJ, 2001, NATURE, V411, P805, DOI 10.1038/35081088; Zagotta WN, 2003, NATURE, V425, P200, DOI 10.1038/nature01922; ZAGOTTA WN, 1989, P NATL ACAD SCI USA, V86, P7243, DOI 10.1073/pnas.86.18.7243	35	52	53	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14728	14738		10.1074/jbc.M710463200	http://dx.doi.org/10.1074/jbc.M710463200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18367452	Green Published, hybrid			2022-12-25	WOS:000255941400061
J	Meuth, SG; Bittner, S; Meuth, P; Simon, OJ; Budde, T; Wiendl, H				Meuth, Sven G.; Bittner, Stefan; Meuth, Patrick; Simon, Ole J.; Budde, Thomas; Wiendl, Heinz			TWIK-related acid-sensitive K+ channel 1 (TASK1) and TASK3 critically influence T lymphocyte effector functions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; 2-PORE-DOMAIN POTASSIUM CHANNELS; MULTIPLE-SCLEROSIS; K+ CHANNEL; CALCIUM-DEPENDENCE; ION CHANNELS; CELL PROLIFERATION; KV1.3 CHANNELS; IMMUNE-SYSTEM; ZINC IONS	Two major K+ channels are expressed in T cells,(i) the voltage dependent K(V)1.3 channel and (ii) the Ca2+-activated K+ channel KCa3.1 (IKCa channel). Both critically influence T cell effector functions in vitro and animal models in vivo. Here we identify and characterize TWIK-related acid- sensitive potassium channel 1 (TASK1) and TASK3 as an important third K+ conductance on T lymphocytes. T lymphocytes constitutively express TASK1 and -3 protein. Application of semi-selective TASK blockers resulted in a significant reduction of cytokine production and cell proliferation. Interference with TASK channels on CD3(+) T cells revealed a dose- dependent reduction (similar to 40%) of an outward current in patch clamp recordings indicative of TASK channels, a finding confirmed by computational modeling. In vivo relevance of our findings was addressed in an experimental model of multiple sclerosis, adoptive transfer experimental autoimmune encephalomyelitis. Pre-treatment of myelin basic protein-specific encephalitogenic T lymphocytes with TASK modulators was associated with significant amelioration of the disease course in Lewis rats. These data introduce K2P channels as novel potassium conductance on T lymphocytes critically influencing T cell effector function and identify a possible molecular target for immunomodulation in T cell-mediated autoimmune disorders.	[Meuth, Sven G.; Bittner, Stefan; Simon, Ole J.; Wiendl, Heinz] Univ Wurzburg, Dept Neurol, D-97080 Wurzburg, Germany; [Budde, Thomas] Univ Munster, Inst Expt Epilepsy Res, D-48149 Munster, Germany; [Meuth, Patrick] Univ Munster, Inst Physiol 1, D-48149 Munster, Germany	University of Wurzburg; University of Munster; University of Munster	Meuth, SG (corresponding author), Univ Wurzburg, Dept Neurol, Josef Schneider Str 11, D-97080 Wurzburg, Germany.	meuth_s@klinik.uni-wuerzburg.de	Meuth, Sven G/HHM-8941-2022; Wiendl, Heinz/AAX-6041-2021	Meuth, Sven G/0000-0003-2571-3501; Bittner, Stefan/0000-0003-2179-3655; Wiendl, Heinz/0000-0003-4310-3432				Bean BP, 2007, NAT REV NEUROSCI, V8, P451, DOI 10.1038/nrn2148; Beeton C, 2005, NEUROSCIENTIST, V11, P550, DOI 10.1177/1073858405278016; Beeton C, 2005, MOL PHARMACOL, V67, P1369, DOI 10.1124/mol.104.008193; Beeton C, 2001, J IMMUNOL, V166, P936, DOI 10.4049/jimmunol.166.2.936; Beeton C, 2001, P NATL ACAD SCI USA, V98, P13942, DOI 10.1073/pnas.241497298; Beeton C, 2006, P NATL ACAD SCI USA, V103, P17414, DOI 10.1073/pnas.0605136103; Berg AP, 2007, J NEUROPHYSIOL, V97, P1546, DOI 10.1152/jn.01090.2006; Brown DA, 2000, CURR BIOL, V10, pR456, DOI 10.1016/S0960-9822(00)00532-7; Buckler KJ, 2000, J PHYSIOL-LONDON, V525, P135, DOI 10.1111/j.1469-7793.2000.00135.x; Cahalan MD, 2001, J CLIN IMMUNOL, V21, P235, DOI 10.1023/A:1010958907271; Cahalan MD, 1997, CURR OPIN BIOTECH, V8, P749, DOI 10.1016/S0958-1669(97)80130-9; Chandy KG, 2004, TRENDS PHARMACOL SCI, V25, P280, DOI 10.1016/j.tips.2004.03.010; CHANDY KG, 1984, J EXP MED, V160, P369, DOI 10.1084/jem.160.2.369; Chandy KG, 2001, TOXICON, V39, P1269, DOI 10.1016/S0041-0101(01)00120-9; Chen WC, 2006, HEARING RES, V222, P89, DOI 10.1016/j.heares.2006.09.002; Chen XD, 2006, P NATL ACAD SCI USA, V103, P3422, DOI 10.1073/pnas.0507710103; Czirjak G, 2003, MOL PHARMACOL, V63, P646, DOI 10.1124/mol.63.3.646; DECOURSEY TE, 1984, NATURE, V307, P465, DOI 10.1038/307465a0; DESCHUTTER E, 1994, J NEUROPHYSIOL, V71, P375, DOI 10.1152/jn.1994.71.1.375; DODT HU, 1990, BRAIN RES, V537, P333, DOI 10.1016/0006-8993(90)90380-T; Ghanshani S, 2000, J BIOL CHEM, V275, P37137, DOI 10.1074/jbc.M003941200; Goldstein SAN, 2001, NAT REV NEUROSCI, V2, P175, DOI 10.1038/35058574; GRISSMER S, 1993, J GEN PHYSIOL, V102, P601, DOI 10.1085/jgp.102.4.601; Hines ML, 1997, NEURAL COMPUT, V9, P1179, DOI 10.1162/neco.1997.9.6.1179; Kang DW, 2004, BIOCHEM BIOPH RES CO, V323, P323, DOI 10.1016/j.bbrc.2004.08.089; Kleinschnitz C., 2007, Endocrine Metabolic & Immune Disorders-Drug Targets, V7, P35; Leonoudakis D, 1998, J NEUROSCI, V18, P868; Lesage F, 2003, NEUROPHARMACOLOGY, V44, P1, DOI 10.1016/S0028-3908(02)00339-8; LEWIS RS, 1995, ANNU REV IMMUNOL, V13, P623, DOI 10.1146/annurev.iy.13.040195.003203; Logsdon NJ, 1997, J BIOL CHEM, V272, P32723, DOI 10.1074/jbc.272.52.32723; Maingret F, 2001, EMBO J, V20, P47, DOI 10.1093/emboj/20.1.47; Mathie A, 2007, J PHYSIOL-LONDON, V578, P377, DOI 10.1113/jphysiol.2006.121582; Meadows HJ, 2001, NEUROPHARMACOLOGY, V40, P551, DOI 10.1016/S0028-3908(00)00189-1; Meuth SG, 2006, MOL PHARMACOL, V69, P1468, DOI 10.1124/mol.105.020594; Meuth SG, 2003, J NEUROSCI, V23, P6460; Meuth SG, 2008, J NEUROIMMUNOL, V194, P62, DOI 10.1016/j.jneuroim.2007.11.013; Meuth SG, 2006, J NEUROPHYSIOL, V96, P1517, DOI 10.1152/jn.01212.2005; Musset B, 2006, J PHYSIOL-LONDON, V572, P639, DOI 10.1113/jphysiol.2006.106898; NEGULESCU PA, 1994, P NATL ACAD SCI USA, V91, P2873, DOI 10.1073/pnas.91.7.2873; NEHER E, 1992, METHOD ENZYMOL, V207, P123; Panyi G, 2004, TRENDS IMMUNOL, V25, P565, DOI 10.1016/j.it.2004.09.002; Prakriya M, 2003, CELL CALCIUM, V33, P311, DOI 10.1016/S0143-4160(03)00045-9; Prakriya M, 2006, J GEN PHYSIOL, V128, P373, DOI 10.1085/jgp.200609588; Rajan S, 2002, J PHYSIOL-LONDON, V545, P13, DOI 10.1113/jphysiol.2002.027052; SABATH DE, 1986, P NATL ACAD SCI USA, V83, P4739, DOI 10.1073/pnas.83.13.4739; SCHELL SR, 1987, J IMMUNOL, V139, P3224; Schmidt J, 2003, BRAIN, V126, P1895, DOI 10.1093/brain/awg176; Schwarz EC, 2007, EUR J IMMUNOL, V37, P2723, DOI 10.1002/eji.200737039; Teisseyre A, 2006, J PHYSIOL PHARMACOL, V57, P131; Teisseyre A, 2007, CELL MOL BIOL LETT, V12, P220, DOI 10.2478/s11658-006-0067-6; Tischner D, 2006, BRAIN, V129, P2635, DOI 10.1093/brain/awl213; Torborg CL, 2006, J NEUROSCI, V26, P7362, DOI 10.1523/JNEUROSCI.1257-06.2006; Vennekamp J, 2004, MOL PHARMACOL, V65, P1364, DOI 10.1124/mol.65.6.1364; Wulff H, 2003, J CLIN INVEST, V111, P1703, DOI 10.1172/JCI200316921; Wulff H, 2003, CURR OPIN DRUG DI DE, V6, P640	55	83	89	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14559	14570		10.1074/jbc.M800637200	http://dx.doi.org/10.1074/jbc.M800637200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18375952	hybrid			2022-12-25	WOS:000255941400044
J	Ali, GS; Prasad, KVSK; Hanumappa, M; Reddy, ASN				Ali, Gul Shad; Prasad, K. V. S. K.; Hanumappa, M.; Reddy, A. S. N.			Analyses of In Vivo Interaction and Mobility of Two Spliceosomal Proteins Using FRAP and BiFC	PLOS ONE			English	Article								U1-70K, a U1 snRNP-specific protein, and serine/arginine-rich (SR) proteins are components of the spliceosome and play critical roles in both constitutive and alternative pre-mRNA splicing. However, the mobility properties of U1-70K, its in vivo interaction with SR proteins, and the mobility of the U1-70K-SR protein complex have not been studied in any system. Here, we studied the in vivo interaction of U1-70K with an SR protein (SR45) and the mobility of the U1-70K/SR protein complex using bimolecular fluorescence complementation (BiFC) and fluorescence recovery after photobleaching (FRAP). Our results show that U1-70K exchanges between speckles and the nucleoplasmic pool very rapidly and that this exchange is sensitive to ongoing transcription and phosphorylation. BiFC analyses showed that U1-70K and SR45 interacted primarily in speckles and that this interaction is mediated by the RS1 or RS2 domain of SR45. FRAP analyses showed considerably slower recovery of the SR45/U1-70K complex than either protein alone indicating that SR45/U1-70K complexes remain in the speckles for a longer duration. Furthermore, FRAP analyses with SR45/U1-70K complex in the presence of inhibitors of phosphorylation did not reveal any significant change compared to control cells, suggesting that the mobility of the complex is not affected by the status of protein phosphorylation. These results indicate that U1-70K, like SR splicing factors, moves rapidly in the nucleus ensuring its availability at various sites of splicing. Furthermore, although it appears that U1-70K moves by diffusion its mobility is regulated by phosphorylation and transcription.	[Ali, Gul Shad; Prasad, K. V. S. K.; Hanumappa, M.; Reddy, A. S. N.] Colorado State Univ, Dept Biol, Program Mol Plant Biol, Ft Collins, CO 80523 USA	Colorado State University	Ali, GS (corresponding author), Colorado State Univ, Dept Biol, Program Mol Plant Biol, Ft Collins, CO 80523 USA.	reddy@colostate.edu		Reddy, Anireddy/0000-0002-4038-4091	Department of Energy [DE-FG02-04ER15556]; National Science Foundation	Department of Energy(United States Department of Energy (DOE)); National Science Foundation(National Science Foundation (NSF))	This work was supported by a grant from the Department of Energy (DE-FG02-04ER15556) and the National Science Foundation to ASNR.	ABEL S, 1994, PLANT J, V5, P421, DOI 10.1111/j.1365-313X.1994.00421.x; Ali GS, 2003, PLANT J, V36, P883, DOI 10.1046/j.1365-313X.2003.01932.x; Ali GS, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000471; Ali GS, 2006, J CELL SCI, V119, P3527, DOI 10.1242/jcs.03144; Anderie I, 2007, CELL BIOL INT, V31, P1131, DOI 10.1016/j.cellbi.2007.03.025; Ast G, 2004, NAT REV GENET, V5, P773, DOI 10.1038/nrg1451; AXELROD D, 1976, BIOPHYS J, V16, P1055, DOI 10.1016/S0006-3495(76)85755-4; Caceres JF, 1997, J CELL BIOL, V138, P225, DOI 10.1083/jcb.138.2.225; Cao WH, 1998, J BIOL CHEM, V273, P20629, DOI 10.1074/jbc.273.32.20629; Dye BT, 2001, EXP CELL RES, V263, P131, DOI 10.1006/excr.2000.5097; EPERON IC, 1993, EMBO J, V12, P3607, DOI 10.1002/j.1460-2075.1993.tb06034.x; Fang YD, 2004, MOL BIOL CELL, V15, P2664, DOI 10.1091/mbc.E04-02-0100; Golovkin M, 1996, PLANT CELL, V8, P1421, DOI 10.1105/tpc.8.8.1421; Golovkin M, 1998, PLANT CELL, V10, P1637, DOI 10.1105/tpc.10.10.1637; Golovkin M, 1999, J BIOL CHEM, V274, P36428, DOI 10.1074/jbc.274.51.36428; Graveley BR, 2001, TRENDS GENET, V17, P100, DOI 10.1016/S0168-9525(00)02176-4; Graveley BR, 2000, RNA, V6, P1197, DOI 10.1017/S1355838200000960; Guo YJ, 2005, J BIOL CHEM, V280, P1438, DOI 10.1074/jbc.M407593200; HEDLEY ML, 1995, P NATL ACAD SCI USA, V92, P11524, DOI 10.1073/pnas.92.25.11524; JAMISON SF, 1995, NUCLEIC ACIDS RES, V23, P3260, DOI 10.1093/nar/23.16.3260; Kerppola TK, 2006, NAT REV MOL CELL BIO, V7, P449, DOI 10.1038/nrm1929; KOHTZ JD, 1994, NATURE, V368, P119, DOI 10.1038/368119a0; Lamond AI, 1998, SCIENCE, V280, P547, DOI 10.1126/science.280.5363.547; Lorkovic ZJ, 2004, J BIOL CHEM, V279, P33890, DOI 10.1074/jbc.M400270200; Lorkovic ZJ, 2004, MOL BIOL CELL, V15, P3233, DOI 10.1091/mbc.E04-01-0055; Lorkovic ZJ, 2004, TRENDS PLANT SCI, V9, P565, DOI 10.1016/j.tplants.2004.10.003; Maniatis T, 2002, NATURE, V416, P499, DOI 10.1038/416499a; Maniatis T, 2002, NATURE, V418, P236, DOI 10.1038/418236a; MERMOUD JE, 1992, NUCLEIC ACIDS RES, V20, P5263, DOI 10.1093/nar/20.20.5263; Misteli T, 1999, CURR BIOL, V9, pR198, DOI 10.1016/S0960-9822(99)80128-6; Misteli T, 1998, J CELL BIOL, V143, P297, DOI 10.1083/jcb.143.2.297; Misteli T, 2001, SCIENCE, V291, P843, DOI 10.1126/science.291.5505.843; Nilsen TW, 2003, BIOESSAYS, V25, P1147, DOI 10.1002/bies.10394; Reddy ASN, 2007, ANNU REV PLANT BIOL, V58, P267, DOI 10.1146/annurev.arplant.58.032806.103754; Reddy ASN, 2004, TRENDS PLANT SCI, V9, P541, DOI 10.1016/j.tplants.2004.09.007; Reddy ASN, 2001, CRIT REV PLANT SCI, V20, P523, DOI 10.1016/S0735-2689(01)80004-6; ROMAC JMJ, 1994, MOL CELL BIOL, V14, P4662, DOI 10.1128/MCB.14.7.4662; Schmidt C, 2003, MOL CELL, V12, P1287, DOI 10.1016/S1097-2765(03)00390-3; Schmidt U, 2006, J CELL BIOL, V172, P373, DOI 10.1083/jcb.200503061; Sprague BL, 2004, BIOPHYS J, V86, P3473, DOI 10.1529/biophysj.103.026765; Stark H, 2001, NATURE, V409, P539, DOI 10.1038/35054102; TAZI J, 1992, J BIOL CHEM, V267, P4322; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; Tillemans V, 2005, PLANT J, V41, P567, DOI 10.1111/j.1365-313X.2004.02321.x; Tillemans V, 2006, PLANT CELL, V18, P3218, DOI 10.1105/tpc.106.044529; Walter M, 2004, PLANT J, V40, P428, DOI 10.1111/j.1365-313X.2004.02219.x; Wei XY, 1999, J CELL BIOL, V146, P543, DOI 10.1083/jcb.146.3.543; Will CL, 2001, CURR OPIN CELL BIOL, V13, P290, DOI 10.1016/S0955-0674(00)00211-8; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; WU JY, 1993, CELL, V75, P1061, DOI 10.1016/0092-8674(93)90316-I; Xiao SH, 1998, EMBO J, V17, P6359, DOI 10.1093/emboj/17.21.6359; Xiao SH, 1997, GENE DEV, V11, P334, DOI 10.1101/gad.11.3.334; ZAHLER AM, 1995, P NATL ACAD SCI USA, V92, P2642, DOI 10.1073/pnas.92.7.2642	53	25	28	1	9	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1953	10.1371/journal.pone.0001953	http://dx.doi.org/10.1371/journal.pone.0001953			13	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414657	Green Published, gold, Green Submitted			2022-12-25	WOS:000260867300006
J	Esnault, C; Boulesteix, M; Duchemin, JB; Koffi, AA; Chandre, F; Dabire, R; Robert, V; Simard, F; Tripet, F; Donnelly, MJ; Fontenille, D; Biemont, C				Esnault, Caroline; Boulesteix, Matthieu; Duchemin, Jean Bernard; Koffi, Alphonsine A.; Chandre, Fabrice; Dabire, Roch; Robert, Vincent; Simard, Frederic; Tripet, Frederic; Donnelly, Martin J.; Fontenille, Didier; Biemont, Christian			High Genetic Differentiation between the M and S Molecular Forms of Anopheles gambiae in Africa	PLOS ONE			English	Article								Background: Anopheles gambiae, a major vector of malaria, is widely distributed throughout sub-Saharan Africa. In an attempt to eliminate infective mosquitoes, researchers are trying to develop transgenic strains that are refractory to the Plasmodium parasite. Before any release of transgenic mosquitoes can be envisaged, we need an accurate picture of the differentiation between the two molecular forms of An. gambiae, termed M and S, which are of uncertain taxonomic status. Methodology/Principal Findings: Insertion patterns of three transposable elements (TEs) were determined in populations from Benin, Burkina Faso, Cameroon, Ghana, Ivory Coast, Madagascar, Mali, Mozambique, Niger, and Tanzania, using Transposon Display, a TE-anchored strategy based on Amplified Fragment Length Polymorphism. The results reveal a clear differentiation between the M and S forms, whatever their geographical origin, suggesting an incipient speciation process. Conclusions/Significance: Any attempt to control the transmission of malaria by An. gambiae using either conventional or novel technologies must take the M/S genetic differentiation into account. In addition, we localized three TE insertion sites that were present either in every individual or at a high frequency in the M molecular form. These sites were found to be located outside the chromosomal regions that are suspected of involvement in the speciation event between the two forms. This suggests that these chromosomal regions are either larger than previously thought, or there are additional differentiated genomic regions interspersed with undifferentiated regions.	[Esnault, Caroline; Boulesteix, Matthieu; Biemont, Christian] Univ Lyon 1, CNRS, Lab Biometrie & Biol Evolut, UMR 5558, F-69622 Villeurbanne, France; [Duchemin, Jean Bernard] Reseau Int Inst Pasteur, Ctr Rech Med Sanitaire, Niamey, Niger; [Koffi, Alphonsine A.] Inst Natl Sante Publique, Inst Pierre Richet, Abidjan, Cote Ivoire; [Chandre, Fabrice] CREC, Inst Rech Dev, Unite Rech, Cotonou, Benin; [Dabire, Roch] Inst Rech Sci Sante, Bobo Dioulasso, Burkina Faso; [Robert, Vincent] Museum Natl Histoire Naturelle, Unite Sci Museum, Inst Rech Dev, Unite Rech, Paris, France; [Robert, Vincent] Inst Pasteur, Antananarivo, Madagascar; [Simard, Frederic] Org Coordinat Endemies Afrique Centrale, Lab Rech Paludisme, Yaounde, Cameroon; [Simard, Frederic; Fontenille, Didier] Inst Rech Dev, Unite Rech, Montpellier, France; [Tripet, Frederic] Keele Univ, Sch Life Sci, Ctr Appl Entomol & Parasitol, Staffordshire, England; [Donnelly, Martin J.] Pembroke Place, Liverpool Sch Trop Med, Vector Grp, Liverpool, Merseyside, England	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Ecology & Environment (INEE); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; VetAgro Sup; Entomological Research Center of Cotonou (CREC); Institut de Recherche pour le Developpement (IRD); Institut de Recherche pour le Developpement (IRD); Museum National d'Histoire Naturelle (MNHN); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Madagascar; Institut de Recherche pour le Developpement (IRD); Keele University; Liverpool School of Tropical Medicine; University of Liverpool	Esnault, C (corresponding author), Univ Lyon 1, CNRS, Lab Biometrie & Biol Evolut, UMR 5558, F-69622 Villeurbanne, France.	biemont@biomserv.univ-lyon1.fr	Frederic, SIMARD/AFV-5001-2022; Chandre, Fabrice/Q-3429-2019; Tripet, Frederic/M-6693-2015; FONTENILLE, didier/G-4091-2013; Esnault, Caroline/C-7221-2015; Duchemin, Jean-Bernard/D-7000-2011; Dabire, Roch Kounbobr/ABF-3525-2020; SIMARD, Frederic/J-9489-2016; Duchemin, Jean-Bernard/AAE-8077-2020	Frederic, SIMARD/0000-0002-2871-5329; Chandre, Fabrice/0000-0002-1994-9705; Tripet, Frederic/0000-0002-7939-0712; Duchemin, Jean-Bernard/0000-0001-5044-4855; SIMARD, Frederic/0000-0002-2871-5329; Duchemin, Jean-Bernard/0000-0001-5044-4855; ROBERT, Vincent/0000-0003-1738-1842; Donnelly, Martin/0000-0001-5218-1497; FONTENILLE, didier/0000-0002-0544-3885	PAL+ program of the French Ministry of Research; CNRS	PAL+ program of the French Ministry of Research; CNRS(Centre National de la Recherche Scientifique (CNRS))	This work was supported by the PAL+ program of the French Ministry of Research and CNRS.	Amorosa LF, 2005, HEALTH PLACE, V11, P67, DOI 10.1016/j.healthplace.2004.06.003; Barnes MJ, 2005, INSECT MOL BIOL, V14, P353, DOI 10.1111/j.1365-2583.2005.00566.x; BOETE C, 2006, GENETICALLY MODIFIED, P174; Boulesteix M, 2007, MOL ECOL, V16, P441, DOI 10.1111/j.1365-294X.2006.03150.x; Casa AM, 2000, P NATL ACAD SCI USA, V97, P10083, DOI 10.1073/pnas.97.18.10083; Chandre F, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P319; Chessel D., 2004, R NEWS, V4, P5, DOI DOI 10.2307/3780087; della Torre A, 2002, SCIENCE, V298, P115, DOI 10.1126/science.1078170; della Torre A, 2005, INSECT BIOCHEM MOLEC, V35, P755, DOI 10.1016/j.ibmb.2005.02.006; EXCOFFIER L, 1992, GENETICS, V131, P479; Fanello C, 2003, INSECT MOL BIOL, V12, P241, DOI 10.1046/j.1365-2583.2003.00407.x; Fanello C, 2002, MED VET ENTOMOL, V16, P461, DOI 10.1046/j.1365-2915.2002.00393.x; Favia G, 2001, INSECT MOL BIOL, V10, P19, DOI 10.1046/j.1365-2583.2001.00236.x; Gentile G, 2001, INSECT MOL BIOL, V10, P25, DOI 10.1046/j.1365-2583.2001.00237.x; Guerreiro MPG, 2007, GENETICS, V175, P301, DOI 10.1534/genetics.106.064378; Johnson L, 2008, HEREDITY, V100, P5, DOI 10.1038/sj.hdy.6801064; Lehmann T, 2003, J HERED, V94, P133, DOI 10.1093/jhered/esg024; Machado CA, 2002, MOL BIOL EVOL, V19, P472, DOI 10.1093/oxfordjournals.molbev.a004103; MACPHERSON JM, 2008, MOL BIOL EV IN PRESS; Melayah D, 2001, PLANT J, V28, P159, DOI 10.1046/j.1365-313X.2001.01141.x; Mukabayire O, 2001, INSECT MOL BIOL, V10, P33, DOI 10.1046/j.1365-2583.2001.00238.x; PEAKALL R, 1995, MOL ECOL, V4, P135, DOI 10.1111/j.1365-294X.1995.tb00203.x; Slotman MA, 2007, MOL ECOL, V16, P639, DOI 10.1111/j.1365-294X.2006.03172.x; Slotman MA, 2006, GENETICS, V174, P2081, DOI 10.1534/genetics.106.059949; Stump AD, 2005, P NATL ACAD SCI USA, V102, P15930, DOI 10.1073/pnas.0508161102; Turner TL, 2007, MOL BIOL EVOL, V24, P2132, DOI 10.1093/molbev/msm143; Turner TL, 2005, PLOS BIOL, V3, P1572, DOI 10.1371/journal.pbio.0030285; Van den Broeck D, 1998, PLANT J, V13, P121, DOI 10.1046/j.1365-313X.1998.00004.x; Wang R, 2001, P NATL ACAD SCI USA, V98, P10769, DOI 10.1073/pnas.191003598; Wondji C, 2002, INSECT MOL BIOL, V11, P11, DOI 10.1046/j.0962-1075.2001.00306.x; Wondji C, 2005, J MED ENTOMOL, V42, P998, DOI 10.1603/0022-2585(2005)042[0998:SAPOTA]2.0.CO;2; Wu CI, 2004, NAT REV GENET, V5, P114, DOI 10.1038/nrg1269; Yawson AE, 2007, GENETICS, V175, P751, DOI 10.1534/genetics.106.065888; Zampicinini G, 2004, GENOME, V47, P1154, DOI [10.1139/g04-066, 10.1139/G04-066]	34	27	27	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1968	10.1371/journal.pone.0001968	http://dx.doi.org/10.1371/journal.pone.0001968			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414665	Green Published, Green Accepted, gold			2022-12-25	WOS:000260867300014
J	Paaby, AB; Schmidt, PS				Paaby, Annalise B.; Schmidt, Paul S.			Functional Significance of Allelic Variation at methuselah, an Aging Gene in Drosophila	PLOS ONE			English	Article							EXTENDED LIFE-SPAN; QUANTITATIVE TRAIT GENE; ADAPTIVE EVOLUTION; MUTANT; MELANOGASTER; LONGEVITY; EXTENSION; DIAPAUSE; HISTORY; EXPRESSION	Background: Longevity and age-specific patterns of mortality are complex traits that vary within and among taxa. Multiple candidate genes for aging have been identified in model systems by extended longevity mutant phenotypes, including the G-protein coupled receptor methuselah (mth) in D. melanogaster. These genes offer important insights into the mechanisms of lifespan determination and have been major targets of interest in the biology of aging. However, it is largely unknown whether these genes contribute to genetic variance for lifespan in natural populations, and consequently contribute to lifespan evolution. Methodology/Principle Findings: For a gene to contribute to genetic variance for a particular trait, it must meet two criteria: natural allelic variation and functional differences among variants. Previous work showed that mth varies significantly among wild populations; here we assess the functional significance of wild-derived mth alleles on lifespan, fecundity and stress resistance using a quantitative complementation scheme. Our results demonstrate that mth alleles segregating in nature have a functional effect on all three traits. Conclusions/Significance: These results suggest that allelic variation at mth contributes to observed differences in lifespan and correlated phenotypes in natural populations, and that evaluation of genetic diversity at candidate genes for aging can be a fruitful approach to identifying loci contributing to lifespan evolution.	[Paaby, Annalise B.; Schmidt, Paul S.] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA	University of Pennsylvania	Paaby, AB (corresponding author), Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.	paaby@sas.upenn.edu		Paaby, Annalise/0000-0003-1422-047X	Binns-Williams Scholarship; NSF	Binns-Williams Scholarship; NSF(National Science Foundation (NSF))	Funding for this work was provided by a Binns-Williams Scholarship to ABP and by an NSF grant to PSS. These sources played no other role in the study.	Baldal EA, 2006, EXP GERONTOL, V41, P1126, DOI 10.1016/j.exger.2006.08.014; Carbone MA, 2006, CURR BIOL, V16, P912, DOI 10.1016/j.cub.2006.03.051; Clancy DJ, 2001, SCIENCE, V292, P104, DOI 10.1126/science.1057991; Cvejic S, 2004, NAT CELL BIOL, V6, P540, DOI 10.1038/ncb1133; De Luca M, 2003, NAT GENET, V34, P429, DOI 10.1038/ng1218; Duvernell DD, 2003, MOL ECOL, V12, P1277, DOI 10.1046/j.1365-294X.2003.01841.x; Geiger-Thornsberry GL, 2004, MECH AGEING DEV, V125, P179, DOI 10.1016/j.mad.2003.12.008; Hwangbo DS, 2004, NATURE, V429, P562, DOI 10.1038/nature02549; Ja WW, 2007, NAT CHEM BIOL, V3, P415, DOI 10.1038/nchembio.2007.2; Jenkins NL, 2004, P ROY SOC B-BIOL SCI, V271, P2523, DOI 10.1098/rspb.2004.2897; Landry CR, 2005, GENETICS, V171, P1813, DOI 10.1534/genetics.105.047449; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; Mackay TFC, 2002, MECH AGEING DEV, V123, P95, DOI 10.1016/S0047-6374(01)00330-X; Marden JH, 2003, P NATL ACAD SCI USA, V100, P3369, DOI 10.1073/pnas.0634985100; Mockett RJ, 2006, EXP GERONTOL, V41, P566, DOI 10.1016/j.exger.2006.03.015; Nuzhdin SV, 2005, GENETICS, V170, P719, DOI 10.1534/genetics.104.038331; Parkes TL, 1998, NAT GENET, V19, P171, DOI 10.1038/534; Partridge L, 2005, CELL, V120, P461, DOI 10.1016/j.cell.2005.01.026; Pasyukova EG, 2004, AGING CELL, V3, P297, DOI 10.1111/j.1474-9728.2004.00114.x; Pasyukova EG, 2000, GENETICS, V156, P1129; Petrosyan A, 2007, BEHAV GENET, V37, P585, DOI 10.1007/s10519-007-9159-y; Promislow DEL, 1996, GENETICS, V143, P839; Rogina B, 2000, SCIENCE, V290, P2137, DOI 10.1126/science.290.5499.2137; ROSE MR, 1981, GENETICS, V97, P187; Schmidt PS, 2006, EVOLUTION, V60, P1602, DOI 10.1111/j.0014-3820.2006.tb00505.x; Schmidt PS, 2005, EVOLUTION, V59, P2616, DOI 10.1111/j.0014-3820.2005.tb00974.x; Schmidt PS, 2005, EVOLUTION, V59, P1721, DOI 10.1111/j.0014-3820.2005.tb01821.x; Schmidt PS, 2000, P NATL ACAD SCI USA, V97, P10861, DOI 10.1073/pnas.190338897; SCHMIDT PS, 2008, EVOLUTION IN PRESS; Song W, 2002, NEURON, V36, P105, DOI 10.1016/S0896-6273(02)00932-7; Spencer CC, 2005, J HERED, V96, P513, DOI 10.1093/jhered/esi071; Spencer CC, 2003, AGING CELL, V2, P123, DOI 10.1046/j.1474-9728.2003.00044.x; Tatar M, 2001, SCIENCE, V292, P107, DOI 10.1126/science.1057987; Tatar M, 2003, SCIENCE, V299, P1346, DOI 10.1126/science.1081447; Trotta V, 2006, BMC EVOL BIOL, V6, DOI 10.1186/1471-2148-6-67; Vermeulen CJ, 2007, EXP GERONTOL, V42, P153, DOI 10.1016/j.exger.2006.09.014; Wallenfang MR, 2006, AGING CELL, V5, P297, DOI 10.1111/j.1474-9726.2006.00221.x; West AP, 2001, P NATL ACAD SCI USA, V98, P3744, DOI 10.1073/pnas.051625298; WILLIAMS GC, 1957, EVOLUTION, V11, P398, DOI 10.1111/j.1558-5646.1957.tb02911.x; Wilson RH, 2006, GENETICS, V173, P1455, DOI 10.1534/genetics.105.055111	40	40	45	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1987	10.1371/journal.pone.0001987	http://dx.doi.org/10.1371/journal.pone.0001987			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414670	Green Submitted, Green Published, gold			2022-12-25	WOS:000260867300019
J	Bharti, N; Xia, YC; Bjornstad, ON; Grenfell, BT				Bharti, Nita; Xia, Yingcun; Bjornstad, Ottar N.; Grenfell, Bryan T.			Measles on the Edge: Coastal Heterogeneities and Infection Dynamics	PLOS ONE			English	Article							SPATIAL HIERARCHIES; GRAVITY MODEL; SPREAD; WAVES; RATES	Mathematical models can help elucidate the spatio-temporal dynamics of epidemics as well as the impact of control measures. The gravity model for directly transmitted diseases is currently one of the most parsimonious models for spatial epidemic spread. This model uses distance-weighted, population size-dependent coupling to estimate host movement and disease incidence in metapopulations. The model captures overall measles dynamics in terms of underlying human movement in pre-vaccination England and Wales (previously established). In spatial models, edges often present a special challenge. Therefore, to test the model's robustness, we analyzed gravity model incidence predictions for coastal cities in England and Wales. Results show that, although predictions are accurate for inland towns, they significantly underestimate coastal persistence. We examine incidence, outbreak seasonality, and public transportation records, to show that the model's inaccuracies stem from an underestimation of total contacts per individual along the coast. We rescue this predicted 'edge effect' by increasing coastal contacts to approximate the number of per capita inland contacts. These results illustrate the impact of 'edge effects' on epidemic metapopulations in general and illustrate directions for the refinement of spatiotemporal epidemic models.	[Bharti, Nita; Bjornstad, Ottar N.; Grenfell, Bryan T.] Penn State Univ, Dept Biol, University Pk, PA 16802 USA; [Xia, Yingcun] Natl Univ Singapore, Dept Stat & Appl Probability, Singapore, Singapore; [Bjornstad, Ottar N.] Penn State Univ, Dept Entomol, University Pk, PA USA; [Bjornstad, Ottar N.; Grenfell, Bryan T.] NIH, Fogarty Int Ctr, Bethesda, MD USA; [Bharti, Nita; Bjornstad, Ottar N.; Grenfell, Bryan T.] Penn State Univ, Ctr Infect Dis Dynamics, University Pk, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National University of Singapore; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; National Institutes of Health (NIH) - USA; NIH Fogarty International Center (FIC); Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Bharti, N (corresponding author), Penn State Univ, Dept Biol, University Pk, PA 16802 USA.	nita@psu.edu	Bjornstad, Ottar N/I-4518-2012	Xia, Yingcun/0000-0002-0309-8635; Bharti, Nita/0000-0003-1940-7794	department of biology at Penn State; Center for Infectious Disease Dynamics	department of biology at Penn State; Center for Infectious Disease Dynamics	Funding was provided by the department of biology at Penn State and the Center for Infectious Disease Dynamics. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript	ANDERSON R M, 1991; BARTLETT MS, 1957, J R STAT SOC SER A-G, V120, P48, DOI 10.2307/2342553; Bjornstad ON, 2002, ECOL MONOGR, V72, P169, DOI 10.1890/0012-9615(2002)072[0169:DOMEES]2.0.CO;2; Bolker BM, 1996, P NATL ACAD SCI USA, V93, P12648, DOI 10.1073/pnas.93.22.12648; British Railways Board, 1963, RESH BRIT RAILW; Brockmann D, 2006, NATURE, V439, P462, DOI 10.1038/nature04292; CLIFF AD, 1993, MEASLES HIST GEOGRAP, pR20; CREIGHTON C, 1965, HIST EPIDEMICS BRIT; Ferguson NM, 2005, NATURE, V437, P209, DOI 10.1038/nature04017; Ferrari MJ, 2008, NATURE, V451, P679, DOI 10.1038/nature06509; Ferrari MJ, 2006, AM NAT, V168, P294, DOI 10.1086/506917; Glass K, 2002, EPIDEMIOL INFECT, V128, P491, DOI 10.1017/S0950268802006829; GRENFELL BT, 1995, P ROY SOC B-BIOL SCI, V259, P97, DOI 10.1098/rspb.1995.0015; Grenfell BT, 2001, NATURE, V414, P716, DOI 10.1038/414716a; GRENFELL BT, 1985, J HYG-CAMBRIDGE, V95, P419, DOI 10.1017/S0022172400062859; Keeling MJ, 2001, SCIENCE, V294, P813, DOI 10.1126/science.1065973; Real LA, 2005, J HERED, V96, P253, DOI 10.1093/jhered/esi031; SAVILL NJ, 2006, BMC VET RES, V2; SHEAIL J, 1976, GEOGR J, V142, P257, DOI 10.2307/1796600; Viboud C, 2006, SCIENCE, V312, P447, DOI 10.1126/science.1125237; WALTON JK, 1981, ECON HIST REV, V34, P249; Xia YC, 2004, AM NAT, V164, P267, DOI 10.1086/422341	22	20	20	1	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1941	10.1371/journal.pone.0001941	http://dx.doi.org/10.1371/journal.pone.0001941			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398467	Green Submitted, Green Published, gold			2022-12-25	WOS:000260795500018
J	Lozier, J; McCright, B; Gridley, T				Lozier, Julie; McCright, Brent; Gridley, Thomas			Notch Signaling Regulates Bile Duct Morphogenesis in Mice	PLOS ONE			English	Article							ALAGILLE-SYNDROME; LIVER DEVELOPMENT; HUMAN JAGGED1; MUTATIONS; DIFFERENTIATION; DEFECTS; GENE; HEPATOCYTE; MODELS; LIGAND	Background: Alagille syndrome is a developmental disorder caused predominantly by mutations in the Jagged1 (JAG1) gene, which encodes a ligand for Notch family receptors. A characteristic feature of Alagille syndrome is intrahepatic bile duct paucity. We described previously that mice doubly heterozygous for Jag1 and Notch2 mutations are an excellent model for Alagille syndrome. However, our previous study did not establish whether bile duct paucity in Jag1/Notch2 double heterozygous mice resulted from impaired differentiation of bile duct precursor cells, or from defects in bile duct morphogenesis. Methodology/Principal Findings: Here we characterize embryonic biliary tract formation in our previously described Jag1/Notch2 double heterozygous Alagille syndrome model, and describe another mouse model of bile duct paucity resulting from liver-specific deletion of the Notch2 gene. Conclusions/Significance: Our data support a model in which bile duct paucity in Notch pathway loss of function mutant mice results from defects in bile duct morphogenesis rather than cell fate specification.	[Lozier, Julie; McCright, Brent; Gridley, Thomas] Jackson Lab, Bar Harbor, ME 04609 USA	Jackson Laboratory	Lozier, J (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.	tom.gridley@jax.org			National Institute of Diabetes and Digestive and Kidney Diseases [DK066387]; National Institute of Neurological Disorders and Stroke [NS036437]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK066387] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS036437] Funding Source: NIH RePORTER	National Institute of Diabetes and Digestive and Kidney Diseases(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); National Institute of Neurological Disorders and Stroke(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))	This work was funded by grants for the National Institute of Diabetes and Digestive and Kidney Diseases (DK066387; TG) and the National Institute of Neurological Disorders and Stroke (NS036437; TG). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	ALAGILLE D, 1987, J PEDIATR-US, V110, P195, DOI 10.1016/S0022-3476(87)80153-1; Bray SJ, 2006, NAT REV MOL CELL BIO, V7, P678, DOI 10.1038/nrm2009; Carlton VEH, 2004, ANN MED, V36, P606, DOI 10.1080/07853890410018916; Clotman F, 2006, CELL CYCLE, V5, P168, DOI 10.4161/cc.5.2.2341; Clotman F, 2005, GENE DEV, V19, P1849, DOI 10.1101/gad.340305; Clotman F, 2002, DEVELOPMENT, V129, P1819; Coffinier C, 2002, DEVELOPMENT, V129, P1829; Duncan SA, 2003, MECH DEVELOP, V120, P19, DOI 10.1016/S0925-4773(02)00328-3; Ehebauer M, 2006, SCIENCE, V314, P1414, DOI 10.1126/science.1134042; Emerick KM, 1999, HEPATOLOGY, V29, P822, DOI 10.1002/hep.510290331; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Kodama Y, 2004, GASTROENTEROLOGY, V127, P1775, DOI 10.1053/j.gastro.2004.09.004; Lazaridis KN, 2004, GASTROENTEROLOGY, V127, P1565, DOI 10.1053/j.gastro.2004.08.006; Lemaigre F, 2004, CURR OPIN GENET DEV, V14, P582, DOI 10.1016/j.gde.2004.08.004; Lemaigre FP, 2003, MECH DEVELOP, V120, P81; Li LH, 1997, NAT GENET, V16, P243, DOI 10.1038/ng0797-243; Loomes KM, 2007, HEPATOLOGY, V45, P323, DOI 10.1002/hep.21460; McCright B, 2001, DEVELOPMENT, V128, P491; McCright B, 2006, GENESIS, V44, P29, DOI 10.1002/gene.20181; McCright B, 2002, DEVELOPMENT, V129, P1075; McDaniell R, 2006, AM J HUM GENET, V79, P169, DOI 10.1086/505332; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Postic C, 2000, GENESIS, V26, P149, DOI 10.1002/(SICI)1526-968X(200002)26:2<149::AID-GENE16>3.0.CO;2-V; Postic C, 1999, J BIOL CHEM, V274, P305, DOI 10.1074/jbc.274.1.305; SHIOJIRI N, 1992, ANAT EMBRYOL, V185, P17, DOI 10.1007/BF00213597; Spinner Nancy B., 2004, P461; Strick-Marchand H, 2003, MECH DEVELOP, V120, P89, DOI 10.1016/S0925-4773(02)00335-0; Sund NJ, 2000, MOL CELL BIOL, V20, P5175, DOI 10.1128/MCB.20.14.5175-5183.2000; Tanimizu N, 2004, J CELL SCI, V117, P3165, DOI 10.1242/jcs.01169; Warthen DM, 2006, HUM MUTAT, V27, P436, DOI 10.1002/humu.20310; Xue YZ, 1999, HUM MOL GENET, V8, P723, DOI 10.1093/hmg/8.5.723; Zaret KS, 2002, NAT REV GENET, V3, P499, DOI 10.1038/nrg837	32	98	107	0	4	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1851	10.1371/journal.pone.0001851	http://dx.doi.org/10.1371/journal.pone.0001851			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365007	Green Published, gold, Green Submitted			2022-12-25	WOS:000260762400013
J	Winter, PM; Schmieder, AH; Caruthers, SD; Keene, JL; Zhang, HY; Wickline, SA; Lanza, GM				Winter, Patrick M.; Schmieder, Anne H.; Caruthers, Shelton D.; Keene, Jeffery L.; Zhang, Huiying; Wickline, Samuel A.; Lanza, Gregory M.			Minute dosages of alpha(nu)beta(3)-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits	FASEB JOURNAL			English	Article						MRI; cancer; drug delivery; molecular imaging	ENDOTHELIAL-CELL ANERGY; IN-VIVO; COLORECTAL-CANCER; BREAST-CANCER; INTEGRIN ALPHA(V)BETA(3); INHIBITOR TNP-470; CONTRAST AGENT; METHIONINE AMINOPEPTIDASES; VITRONECTIN RECEPTOR; SELECTIVE-INHIBITION	Fumagillin suppresses angiogenesis in cancer models and clinical trials, but it is associated with neurotoxicity at systemic doses. In this study, alpha(nu)beta(3)-targeted fumagillin nanoparticles were used to suppress the neovasculature and inhibit Vx-2 adenocarcinoma development using minute drug doses. Tumorbearing rabbits were treated on days 6, 9, and 12 postimplantation with alpha(nu)beta(3)-targeted fumagillin nanoparticles (30 mu g/kg), alpha(nu)beta(3)-targeted nanoparticles without drug, nontargeted fumagillin nanoparticles (30 mu g/kg) or saline. On day 16, MRI was performed with alpha(nu)beta(3)-targeted paramagnetic nanoparticles to quantify tumor size and assess neovascularity. Tumor volume was reduced among rabbits receiving alpha(nu)beta(3)-targeted fumagillin nanoparticles (470 +/- 120 mm(3)) compared with the three control groups: nontargeted fumagillin nanoparticles (1370 +/- 300 mm3, P<0.05), alpha(nu)beta(3)-targeted nanoparticles without drug (1080 +/- 180 mm(3), P<0.05) and saline (980 +/- 80 mm(3), P<0.05). MR molecular imaging of control rabbits ( no fumagillin) revealed a predominant peripheral distribution of neovascularity representing 7.2% of the tumor rim volume, which decreased to 2.8% (P<0.05) with alpha(nu)beta(3)-targeted fumagillin nanoparticle treatment. Microscopically, the tumor parenchyma tended to show T-cell infiltration after targeted fumagillin treatment, which was not appreciated in control animals. These results suggest that alpha(nu)beta(3)-targeted fumagillin nanoparticles could provide a safe and effective means to deliver MetAP2 inhibitors alone or in combination with cytotoxic or immunotherapy.	[Winter, Patrick M.; Schmieder, Anne H.; Caruthers, Shelton D.; Zhang, Huiying; Wickline, Samuel A.; Lanza, Gregory M.] Washington Univ, Sch Med, St Louis, MO 63108 USA; [Caruthers, Shelton D.] Philips Med Syst, Andover, MA USA; [Keene, Jeffery L.] Kereos Inc, St Louis, MO USA	Washington University (WUSTL); Philips; Philips Healthcare	Winter, PM (corresponding author), Washington Univ, Sch Med, Campus Box 8215,4320 Forest Pk Ave, St Louis, MO 63108 USA.	patrick@cvu.wustl.edu		Winter, Patrick/0000-0001-5975-5465	NATIONAL CANCER INSTITUTE [U54CA119342, U54CA136398] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073646, R01HL078631] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB001704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS059302] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-27031-16, U54 CA119342, N01-CO-37007, CA-119342, U54 CA136398] Funding Source: Medline; NHLBI NIH HHS [R01 HL078631, R01 HL073646, HL-78631, HL-73646] Funding Source: Medline; NIAID NIH HHS [N01CO37007] Funding Source: Medline; NIBIB NIH HHS [R01 EB001704, EB-01704] Funding Source: Medline; NINDS NIH HHS [R01 NS059302] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Alghisi GC, 2006, ENDOTHELIUM-J ENDOTH, V13, P113, DOI 10.1080/10623320600698037; ARFIN SM, 1995, P NATL ACAD SCI USA, V92, P7714, DOI 10.1073/pnas.92.17.7714; Baeten CIM, 2006, CLIN GASTROENTEROL H, V4, P1351, DOI 10.1016/j.cgh.2006.08.005; Bergers G, 1999, SCIENCE, V284, P808, DOI 10.1126/science.284.5415.808; Bhargava P, 1999, CLIN CANCER RES, V5, P1989; Borgstrom P, 1997, J CLIN INVEST, V99, P2246, DOI 10.1172/JCI119399; Cai WB, 2006, CANCER RES, V66, P9673, DOI 10.1158/0008-5472.CAN-06-1480; Carreiras F, 1996, GYNECOL ONCOL, V62, P260, DOI 10.1006/gyno.1996.0225; Castronovo V, 1996, EUR J CANCER, V32A, P2520, DOI 10.1016/S0959-8049(96)00388-7; Chen XY, 2004, BIOCONJUGATE CHEM, V15, P41, DOI 10.1021/bc0300403; CHERESH DA, 1991, BIOCHEM SOC T, V19, P835, DOI 10.1042/bst0190835; Cohen MH, 2007, ONCOLOGIST, V12, P356, DOI 10.1634/theoncologist.12-3-356; Coleman PJ, 2004, J MED CHEM, V47, P4829, DOI 10.1021/jm049874c; Crowder KC, 2005, ULTRASOUND MED BIOL, V31, P1693, DOI 10.1016/j.ultrasmedbio.2005.07.022; DENICHILO MO, 1993, P NATL ACAD SCI USA, V90, P2517, DOI 10.1073/pnas.90.6.2517; Dirkx AEM, 2003, CANCER RES, V63, P2322; Dirkx AEM, 2006, FASEB J, V20, P621, DOI 10.1096/fj.05-4493com; Eerola AK, 2000, CLIN CANCER RES, V6, P1875; Flacke S, 2001, CIRCULATION, V104, P1280, DOI 10.1161/hc3601.094303; Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263; Friedlander M, 1996, P NATL ACAD SCI USA, V93, P9764, DOI 10.1073/pnas.93.18.9764; Giantonio BJ, 2006, ANN ONCOL, V17, P1399, DOI 10.1093/annonc/mdl161; Griffioen A W, 1998, Angiogenesis, V2, P235, DOI 10.1023/A:1009237324501; Griffioen AW, 1999, INT J CANCER, V80, P315, DOI 10.1002/(SICI)1097-0215(19990118)80:2<315::AID-IJC23>3.0.CO;2-L; Griffith EC, 1998, P NATL ACAD SCI USA, V95, P15183, DOI 10.1073/pnas.95.26.15183; Harris TD, 2003, CANCER BIOTHER RADIO, V18, P627, DOI 10.1089/108497803322287727; Harris TD, 2006, BIOCONJUGATE CHEM, V17, P1294, DOI 10.1021/bc060063s; Helluin O, 2000, J BIOL CHEM, V275, P18337, DOI 10.1074/jbc.M001529200; Hess SD, 2003, J IMMUNOL, V170, P400, DOI 10.4049/jimmunol.170.1.400; Holig P, 2004, PROTEIN ENG DES SEL, V17, P433, DOI 10.1093/protein/gzh055; Hu G, 2007, INT J CANCER, V120, P1951, DOI 10.1002/ijc.22581; Imagawa Y, 2004, AURIS NASUS LARYNX, V31, P239, DOI 10.1016/j.anl.2004.03.008; Itoh H, 1997, J VASC SURG, V25, P1061, DOI 10.1016/S0741-5214(97)70130-7; Jackaman C, 2003, J IMMUNOL, V171, P5051, DOI 10.4049/jimmunol.171.10.5051; Janssen ML, 2002, CANCER RES, V62, P6146; Kageshita T, 2000, INT J CANCER, V89, P153, DOI 10.1002/(SICI)1097-0215(20000320)89:2<153::AID-IJC9>3.0.CO;2-1; Konno H, 1996, CANCER-AM CANCER SOC, V77, P1736; Kudelka AP, 1998, NEW ENGL J MED, V338, P991, DOI 10.1056/NEJM199804023381412; Lanza GM, 2002, CIRCULATION, V106, P2842, DOI 10.1161/01.CIR.0000044020.27990.32; Li LY, 2004, INT J RADIAT ONCOL, V58, P1215, DOI 10.1016/j.ijrobp.2003.10.057; LIS LJ, 1982, BIOPHYS J, V37, P657; Liu SP, 1998, SCIENCE, V282, P1324, DOI 10.1126/science.282.5392.1324; Logothetis CJ, 2001, CLIN CANCER RES, V7, P1198; Lowther WT, 2000, BBA-PROTEIN STRUCT M, V1477, P157, DOI 10.1016/S0167-4838(99)00271-X; McQuade P, 2004, BIOCONJUGATE CHEM, V15, P988, DOI 10.1021/bc049961j; Meoli DF, 2004, J CLIN INVEST, V113, P1684, DOI 10.1172/JCI200420352; Mizutani N, 2004, Breast Dis, V20, P81; Mulder WJM, 2007, FASEB J, V21, P378, DOI 10.1096/fj.06-6791com; Offodile R, 1999, TUMORI, V85, P51, DOI 10.1177/030089169908500111; Okaji Y, 2006, EJSO, V32, P363, DOI 10.1016/j.ejso.2006.01.016; Onthank DC, 2004, BIOCONJUGATE CHEM, V15, P235, DOI 10.1021/bc034108q; Plum Stacy M, 2004, Curr Opin Investig Drugs, V5, P1243; Posey JA, 2001, CANCER BIOTHER RADIO, V16, P125, DOI 10.1089/108497801300189218; Preda A, 2004, J MAGN RESON IMAGING, V20, P865, DOI 10.1002/jmri.20184; Reynolds LE, 2002, NAT MED, V8, P27, DOI 10.1038/nm0102-27; Roberts TPL, 2002, ACAD RADIOL, V9, pS261, DOI 10.1016/S1076-6332(03)80452-X; Rosen MA, 2007, CLIN CANCER RES, V13, p770S, DOI 10.1158/1078-0432.CCR-06-1921; Sadeghi MM, 2004, CIRCULATION, V110, P84, DOI 10.1161/01.CIR.0000133319.84326.70; Schmieder AH, 2005, MAGN RESON MED, V53, P621, DOI 10.1002/mrm.20391; Shukla R, 2005, CHEM COMMUN, P5739, DOI 10.1039/b507350b; Shusterman S, 2001, CLIN CANCER RES, V7, P977; Sin N, 1997, P NATL ACAD SCI USA, V94, P6099, DOI 10.1073/pnas.94.12.6099; Sipkins DA, 1998, NAT MED, V4, P623, DOI 10.1038/nm0598-623; SOMAN NR, 2008, NANO LETT; Tran HT, 2004, CANCER CHEMOTH PHARM, V54, P308, DOI 10.1007/s00280-004-0816-z; Tromp SC, 2000, INT IMMUNOL, V12, P671, DOI 10.1093/intimm/12.5.671; Turetschek K, 2003, EUR J NUCL MED MOL I, V30, P448, DOI 10.1007/s00259-002-1000-5; Turk BE, 1999, CHEM BIOL, V6, P823, DOI 10.1016/S1074-5521(99)80129-X; Wang JY, 2000, J CELL BIOCHEM, V77, P465, DOI 10.1002/(SICI)1097-4644(20000601)77:3<465::AID-JCB11>3.3.CO;2-D; Weissleder R, 2001, BIOCONJUGATE CHEM, V12, P213, DOI 10.1021/bc000091p; Wild R, 2000, MICROVASC RES, V59, P368, DOI 10.1006/mvre.1999.2233; Winter PM, 2003, CANCER RES, V63, P5838; Ye YP, 2006, J MED CHEM, V49, P2268, DOI 10.1021/jm050947h; Zhang CF, 2007, CANCER RES, V67, P1555, DOI 10.1158/0008-5472.CAN-06-1668; Zhang XZ, 2006, J NUCL MED, V47, P113	75	86	89	0	3	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2758	2767		10.1096/fj.07-103929	http://dx.doi.org/10.1096/fj.07-103929			10	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18362202	Green Published			2022-12-25	WOS:000258089300016
J	Unger, K; Malisch, E; Thomas, G; Braselmann, H; Walch, A; Jackl, G; Lewis, P; Lengfelder, E; Bogdanova, T; Wienberg, J; Zitzelsberger, H				Unger, K.; Malisch, E.; Thomas, G.; Braselmann, H.; Walch, A.; Jackl, G.; Lewis, P.; Lengfelder, E.; Bogdanova, T.; Wienberg, J.; Zitzelsberger, H.			Array CGH demonstrates characteristic aberration signatures in human papillary thyroid carcinomas governed by RET/PTC	ONCOGENE			English	Article						papillary thyroid carcinoma; array CGH; RET/PTC; candidate genes; tumour development; aberration signature	COMPARATIVE GENOMIC HYBRIDIZATION; TUMOR-SUPPRESSOR GENE; SQUAMOUS-CELL CARCINOMA; HIGH PREVALENCE; PROSTATE-CANCER; DOWN-REGULATION; BREAST-CANCER; EXPRESSION; RET; REARRANGEMENTS	The aim of this study is to investigate additional genetic alterations in papillary thyroid carcinomas (PTCs) with known RET/PTC rearrangements. We applied array-based comparative genomic hybridization (array CGH) to 33 PTC (20 PTC from adults, 13 post-Chernobyl PTC from children) with known RET/PTC status. Principal component analysis and hierarchical cluster analysis identified cases with similar aberration patterns. Significant deviations between tumour-groups were obtained by statistical testing (Fisher's exact test in combination with Benjamini-Hochberg FDR-controlling procedure). FISH analysis on FFPE sections was applied to validate the array CGH data. Deletions were found more frequently in RET/PTC-positive and RET/PTC-negative tumours than amplifications. Specific aberration signatures were identified that discriminated between RET/PTC-positive and RET/PTC-negative cases (aberrations on chromosomes 1p, 3q, 4p, 7p, 9p/q, 10q, 12q, 13q and 21q). In addition, childhood and adult RET/PTC-positive cases differ significantly for a deletion on the distal part of chromosome 1p. There are additional alterations in RET/PTC-positive tumours, which may act as modifiers of RET activation. In contrast, alterations in RET/PTC-negative tumours indicate alternative routes of tumour development. The data presented serve as a starting point for further studies on gene expression and function of genes identified in this study.	[Unger, K.; Malisch, E.; Braselmann, H.; Jackl, G.; Zitzelsberger, H.] Deutsch Forschungszentrum Gesundheit & Umwelt Gmb, Inst Mol Strahlenbiol, Helmholtz Zentrum Munchen, D-85764 Neuherberg, Germany; [Unger, K.; Thomas, G.] Hammersmith Hosp, Dept Histopathol, London W12 0HS, England; [Walch, A.] Deutsch Forschungszentrum Gesundheit & Umwelt Gmb, Helmholtz Zentrum Munchen, Inst Pathol, D-85764 Neuherberg, Germany; [Lewis, P.] Swansea Univ, Swansea Med Sch, Swansea, W Glam, Wales; [Lengfelder, E.] Univ Munich, Inst Strahlenbiol, Munich, Germany; [Bogdanova, T.] Ukraine Acad Med Sci, Inst Endocrinol & Metab, Kiev, Ukraine; [Wienberg, J.] Univ Munich, Dept Biol 2, Munich, Germany	Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Imperial College London; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Swansea University; University of Munich; National Academy of Medical Sciences of Ukraine; V. P. Komissarenko Institute of Endocrinology & Metabolism of the National Academy of Medical Science of Ukraine; University of Munich	Zitzelsberger, H (corresponding author), Helmholtz Zentrum Munchen, Inst Mol Radiobiol, Ingolstadter Landstr 1, D-85764 Neuherberg, Germany.	zitzelsberger@helmholtz-muenchen.de	Walch, Axel/B-4554-2012; Unger, Kristian/F-3730-2018	Walch, Axel/0000-0001-5578-4023; Unger, Kristian/0000-0002-0374-2320; Bogdanova, Tetiana/0000-0001-5119-0236				Adolphe C, 2006, CANCER RES, V66, P2081, DOI 10.1158/0008-5472.CAN-05-2146; Azuma K, 2005, ONCOGENE, V24, P4754, DOI 10.1038/sj.onc.1208654; Camacho-Vanegas O, 2007, INT J CANCER, V121, P1390, DOI 10.1002/ijc.22809; Chang M, 2005, EMBO J, V24, P2024, DOI 10.1038/sj.emboj.7600684; Cheung CC, 2000, J CLIN ENDOCR METAB, V85, P878, DOI 10.1210/jc.85.2.878; Chunduru S, 2002, J NEURO-ONCOL, V60, P201, DOI 10.1023/A:1021130620178; Ciampi R, 2007, ENDOCRINOLOGY, V148, P936, DOI 10.1210/en.2006-0921; COLLINS CM, 1996, P INT SOC MAGN RES M, V1, P253; Corson TW, 2007, GENE CHROMOSOME CANC, V46, P617, DOI 10.1002/gcc.20457; De Falco V, 2005, ONCOGENE, V24, P6303, DOI 10.1038/sj.onc.1208776; De Lellis R.A., 2004, WHO CLASSIFICATION T, V3rd; Demichelis F, 2007, ONCOGENE, V26, P4596, DOI 10.1038/sj.onc.1210237; Dickinson RE, 2004, BRIT J CANCER, V91, P2071, DOI 10.1038/sj.bjc.6602222; Djeu JY, 2002, CLIN CANCER RES, V8, P636; Dong M, 2007, J CLIN INVEST, V117, P206, DOI 10.1172/JCI29293; Doyon Y, 2006, MOL CELL, V21, P51, DOI 10.1016/j.molcel.2005.12.007; Duquette ML, 2007, CANCER RES, V67, P2586, DOI 10.1158/0008-5472.CAN-06-2419; Elisei R, 2001, J CLIN ENDOCR METAB, V86, P3211, DOI 10.1210/jc.86.7.3211; Engers R, 2006, BRIT J CANCER, V95, P1081, DOI 10.1038/sj.bjc.6603385; Fiegler H, 2003, GENE CHROMOSOME CANC, V36, P361, DOI 10.1002/gcc.10155; Finn SP, 2004, VIRCHOWS ARCH, V445, P396, DOI 10.1007/s00428-004-1070-9; GRIECO M, 1990, CELL, V60, P557, DOI 10.1016/0092-8674(90)90659-3; Hammarsund M, 2004, FEBS LETT, V556, P75, DOI 10.1016/S0014-5793(03)01371-1; Hou P, 2007, CLIN CANCER RES, V13, P1161, DOI 10.1158/1078-0432.CCR-06-1125; Hou W, 2005, CLIN CANCER RES, V11, P5595, DOI 10.1158/1078-0432.CCR-05-0384; Hu SY, 2006, INT J CANCER, V119, P2322, DOI 10.1002/ijc.22110; Huang H, 2007, J CANCER RES CLIN, V133, P761, DOI 10.1007/s00432-007-0221-1; Hupe P, 2004, BIOINFORMATICS, V20, P3413, DOI 10.1093/bioinformatics/bth418; ISHIZAKA Y, 1991, ONCOGENE, V6, P1667; JHIANG SM, 1994, J LAB CLIN MED, V123, P331; Jimenez-Velasco A, 2005, LEUKEMIA, V19, P2347, DOI 10.1038/sj.leu.2403974; Kadota M, 2003, ONCOL REP, V10, P35; Kitamura Y, 1999, J CLIN ENDOCR METAB, V84, P4043, DOI 10.1210/jc.84.11.4043; Klugbauer S, 1995, ONCOGENE, V11, P2459; Konishi T, 2006, ONCOGENE, V25, P3160, DOI 10.1038/sj.onc.1209342; La Rosa P, 2006, BIOINFORMATICS, V22, P2066, DOI 10.1093/bioinformatics/btl359; Li L, 2007, J CELL BIOCHEM, V102, P1368, DOI 10.1002/jcb.21593; Louhelainen JP, 2006, ONCOGENE, V25, P2409, DOI 10.1038/sj.onc.1209228; NAGATA S, 1994, ADV IMMUNOL, V57, P129, DOI 10.1016/S0065-2776(08)60672-0; Neuvial P, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-264; Nielsen SJ, 2001, NATURE, V412, P561, DOI 10.1038/35087620; O'Donnell KA, 2006, MOL CELL BIOL, V26, P2373, DOI 10.1128/MCB.26.6.2373-2386.2006; Okawa ER, 2008, ONCOGENE, V27, P803, DOI 10.1038/sj.onc.1210675; PIEROTTI MA, 1992, P NATL ACAD SCI USA, V89, P1616, DOI 10.1073/pnas.89.5.1616; Powell N, 2005, J PATHOL, V205, P558, DOI 10.1002/path.1736; Puxeddu E, 2005, ENDOCR-RELAT CANCER, V12, P319, DOI 10.1677/erc.1.00947; Rabes HM, 2000, CLIN CANCER RES, V6, P1093; Repana K, 2006, ANTICANCER RES, V26, P4949; Rhoden KJ, 2006, J CLIN ENDOCR METAB, V91, P2414, DOI 10.1210/jc.2006-0240; Rhoden KJ, 2004, LAB INVEST, V84, P1557, DOI 10.1038/labinvest.3700198; Richter H, 2004, THYROID, V14, P1061, DOI 10.1089/thy.2004.14.1061; Riedl SJ, 2007, NAT REV MOL CELL BIO, V8, P405, DOI 10.1038/nrm2153; Rouveirol C, 2006, BIOINFORMATICS, V22, P849, DOI 10.1093/bioinformatics/btl004; Santoro M, 2004, CELL MOL LIFE SCI, V61, P2954, DOI 10.1007/s00018-004-4276-8; Shan ZH, 2004, ONCOGENE, V23, P6612, DOI 10.1038/sj.onc.1207857; Singh B, 2000, SURGERY, V128, P888, DOI 10.1067/msy.2000.110847; Smida J, 1999, INT J CANCER, V80, P32, DOI 10.1002/(SICI)1097-0215(19990105)80:1<32::AID-IJC7>3.3.CO;2-C; Takakura S, 2001, INT J ONCOL, V18, P817; Tan XQ, 1998, TRENDS CELL BIOL, V8, P116, DOI 10.1016/S0962-8924(97)01208-7; Thomas GA, 1999, J CLIN ENDOCR METAB, V84, P4232, DOI 10.1210/jc.84.11.4232; Torosyan Y, 2006, CANCER RES, V66, P9609, DOI 10.1158/0008-5472.CAN-06-1574; Unger K, 2006, BRIT J CANCER, V94, P1472, DOI 10.1038/sj.bjc.6603109; Unger K, 2004, J CLIN ENDOCR METAB, V89, P4272, DOI 10.1210/jc.2003-031870; van Beers EH, 2006, BRIT J CANCER, V94, P333, DOI 10.1038/sj.bjc.6602889; Wang YG, 2007, J CLIN ENDOCR METAB, V92, P2387, DOI 10.1210/jc.2006-2019; Worthylake DK, 2000, NATURE, V408, P682, DOI 10.1038/35047014; Wreesmann VB, 2007, ORL-J OTO-RHIN-LARYN, V69, P218, DOI 10.1159/000101542; Yang LC, 2005, ONCOGENE, V24, P697, DOI 10.1038/sj.onc.1208179; Yoo NJ, 2007, APMIS, V115, P354, DOI 10.1111/j.1600-0463.2007.apm_632.x; Zhang Q, 2005, J HISTOCHEM CYTOCHEM, V53, P1371, DOI 10.1369/jhc.4A6508.2005	70	33	42	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	JUL 31	2008	27	33					4592	4602		10.1038/onc.2008.99	http://dx.doi.org/10.1038/onc.2008.99			11	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	332IS	18408749				2022-12-25	WOS:000258077300008
J	Kumar, A; Deshane, JS; Crossman, DK; Bolisetty, S; Yan, BS; Kramnik, I; Agarwal, A; Steyn, AJC				Kumar, Ashwani; Deshane, Jessy S.; Crossman, David K.; Bolisetty, Subhashini; Yan, Bo-Shiun; Kramnik, Igor; Agarwal, Anupam; Steyn, Adrie J. C.			Heme oxygenase-1-derived carbon monoxide induces the Mycobacterium tuberculosis dormancy regulon	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRIC-OXIDE SYNTHASE; GENE-EXPRESSION; OXIDATIVE STRESS; HYPOXIC RESPONSE; OXYGENASE; MACROPHAGES; METALLOPORPHYRINS; INDUCTION; REGULATOR; SENSOR	The mechanisms that allow Mycobacterium tuberculosis (Mtb) to persist in human tissue for decades and to then abruptly cause disease are not clearly understood. Regulatory elements thought to assist Mtb to enter such a state include the heme two-component sensor kinases DosS and DosT and the cognate response regulator DosR. We have demonstrated previously that O-2, nitric oxide (NO), and carbon monoxide (CO) are regulatory ligands of DosS and DosT. Here, we show that in addition to O-2 and NO, CO induces the complete Mtb dormancy (Dos) regulon. Notably, we demonstrate that CO is primarily sensed through DosS to induce the Dosregulon, whereas DosT plays a less prominent role. We also show that Mtb infection of macrophage cells significantly increases the expression, protein levels, and enzymatic activity of heme oxygenase-1 (HO-1, the enzyme that produces CO), in an NO-independent manner. Furthermore, exploiting HO-1(+/+) and HO-1(-/-) bone marrow-derived macrophages, we demonstrate that physiologically relevant levels of CO induce the Dos regulon. Finally, we demonstrate that increased HO-1 mRNA and protein levels are produced in the lungs of Mtb-infected mice. Our data suggest that during infection, O-2, NO, and CO are being sensed concurrently rather than independently via DosS and DosT. We conclude that CO, a previously unrecognized host factor, is a physiologically relevant Mtb signal capable of inducing the Dos regulon, which introduces a new paradigm for understanding the molecular basis of Mtb persistence.	[Kumar, Ashwani; Crossman, David K.; Steyn, Adrie J. C.] Univ Alabama, Dept Microbiol, Ctr Nephrol Res & Training, Birmingham, AL 35294 USA; [Deshane, Jessy S.; Bolisetty, Subhashini; Agarwal, Anupam] Univ Alabama, Dept Med, Ctr Nephrol Res & Training, Birmingham, AL 35294 USA; [Yan, Bo-Shiun; Kramnik, Igor] Harvard Univ, Sch Publ Hlth, Dept Immunol & Infect Dis, Boston, MA 02115 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; Harvard University; Harvard T.H. Chan School of Public Health	Steyn, AJC (corresponding author), 845 19th St S,BBRB Rm 308, Birmingham, AL 35294 USA.	asteyn@uab.edu	Bolisetty, Subhashini/F-6496-2011; Kumar, Ashwani/AAU-5045-2020	Kumar, Ashwani/0000-0002-6240-6810; Kramnik, Igor/0000-0001-6511-9246; Crossman, David/0000-0002-0981-169X; Yan, Bo-Shiun/0000-0002-9613-4788; Steyn, Adrie JC/0000-0001-9177-8827	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL059836, R01HL068157] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI058131, T32AI007041, R56AI058131] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK075532, R01DK059600] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 068157, HL 059836, R01 HL059836] Funding Source: Medline; NIAID NIH HHS [T32 AI 07041, P01 AI056296, AI 058131] Funding Source: Medline; NIDDK NIH HHS [DK 59600, DK 75532] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Abraham NG, 2005, FREE RADICAL BIO MED, V39, P1, DOI 10.1016/j.freeradbiomed.2005.03.010; Alcaraz MJ, 2003, CURR PHARM DESIGN, V9, P2541, DOI 10.2174/1381612033453749; ALLEY EW, 1995, GENE, V158, P247, DOI 10.1016/0378-1119(94)00892-V; BALLA G, 1992, J BIOL CHEM, V267, P18148; Blumenthal SB, 2005, FASEB J, V19, P1272, DOI 10.1096/fj.04-3259com; Boon C, 2002, J BACTERIOL, V184, P6760, DOI 10.1128/JB.184.24.6760-6767.2002; Butcher PD, 1998, METH MOL B, V101, P285, DOI 10.1385/0-89603-471-2:285; Cosma CL, 2003, ANNU REV MICROBIOL, V57, P641, DOI 10.1146/annurev.micro.57.030502.091033; Deshane J, 2007, J EXP MED, V204, P605, DOI 10.1084/jem.20061609; Devadas K, 2006, J IMMUNOL, V176, P4252, DOI 10.4049/jimmunol.176.7.4252; Dulak J, 2003, ACTA BIOCHIM POL, V50, P31; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Fenton MJ, 1997, INFECT IMMUN, V65, P5149, DOI 10.1128/IAI.65.12.5149-5156.1997; Flynn JL, 1998, J IMMUNOL, V160, P1796; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; Ioanoviciu A, 2007, BIOCHEMISTRY-US, V46, P4250, DOI 10.1021/bi602422p; King GA, 2003, APPL ENVIRON MICROB, V69, P7257, DOI 10.1128/AEM.69.12.7257-7265.2003; Kumar A, 2007, P NATL ACAD SCI USA, V104, P11568, DOI 10.1073/pnas.0705054104; Lin Q, 2007, J BIOL CHEM, V282, P20621, DOI 10.1074/jbc.M607954200; MacMicking JD, 1997, P NATL ACAD SCI USA, V94, P5243, DOI 10.1073/pnas.94.10.5243; Maines MD, 1997, ANNU REV PHARMACOL, V37, P517, DOI 10.1146/annurev.pharmtox.37.1.517; MAINES MD, 1988, FASEB J, V2, P2557, DOI 10.1096/fasebj.2.10.3290025; Malhotra V, 2004, FEMS MICROBIOL LETT, V231, P237, DOI 10.1016/S0378-1097(04)00002-3; MEFFERT MK, 1994, NEURON, V13, P1225, DOI 10.1016/0896-6273(94)90060-4; Morse D, 2002, AM J RESP CELL MOL, V27, P8, DOI 10.1165/ajrcmb.27.1.4862; Ohno H, 2003, CELL MICROBIOL, V5, P637, DOI 10.1046/j.1462-5822.2003.00307.x; Pamplona A, 2007, NAT MED, V13, P703, DOI 10.1038/nm1586; Pan H, 2005, NATURE, V434, P767, DOI 10.1038/nature03419; Pang XH, 2007, MICROBIOL-SGM, V153, P1229, DOI 10.1099/mic.0.29281-0; Piantadosi CA, 2002, ANTIOXID REDOX SIGN, V4, P259, DOI 10.1089/152308602753666316; Reed MB, 2007, J BACTERIOL, V189, P2583, DOI 10.1128/JB.01670-06; Roberts DM, 2004, J BIOL CHEM, V279, P23082, DOI 10.1074/jbc.M401230200; Rodriguez GM, 2002, INFECT IMMUN, V70, P3371, DOI 10.1128/IAI.70.7.3371-3381.2002; Rustad TR, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0001502; Sardiwal S, 2005, J MOL BIOL, V353, P929, DOI 10.1016/j.jmb.2005.09.011; Schnappinger D, 2003, J EXP MED, V198, P693, DOI 10.1084/jem.20030846; Sherman DR, 2001, P NATL ACAD SCI USA, V98, P7534, DOI 10.1073/pnas.121172498; Singh A, 2007, P NATL ACAD SCI USA, V104, P11562, DOI 10.1073/pnas.0700490104; Sousa EHS, 2007, PROTEIN SCI, V16, P1708, DOI 10.1110/ps.072897707; TENHUNEN R, 1969, J BIOL CHEM, V244, P6388; TENHUNEN R, 1968, P NATL ACAD SCI USA, V61, P748, DOI 10.1073/pnas.61.2.748; Tracz MJ, 2007, J AM SOC NEPHROL, V18, P414, DOI 10.1681/ASN.2006080894; Tremblay GA, 2007, INT J TUBERC LUNG D, V11, P722; Voskuil MI, 2003, J EXP MED, V198, P705, DOI 10.1084/jem.20030205; Wayne LG, 2001, ANNU REV MICROBIOL, V55, P139, DOI 10.1146/annurev.micro.55.1.139	45	173	270	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 27	2008	283	26					18032	18039		10.1074/jbc.M802274200	http://dx.doi.org/10.1074/jbc.M802274200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	316KU	18400743	Green Published, hybrid			2022-12-25	WOS:000256949200032
J	Fiedler, LR; Schonherr, E; Waddington, R; Niland, S; Seidler, DG; Aeschlimann, D; Eble, JA				Fiedler, Lorna R.; Schoenherr, Elke; Waddington, Rachel; Niland, Stephan; Seidler, Daniela G.; Aeschlimann, Daniel; Eble, Johannes A.			Decorin regulates endothelial cell motility on collagen I through activation of insulin-like growth factor I receptor and modulation of alpha 2 beta 1 integrin activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DERMATAN SULFATE PROTEOGLYCAN; PROTEODERMATAN SULFATE; SIGNALING PATHWAYS; CAPILLARY LUMEN; TUBE FORMATION; BINDING; ADHESION; EXPRESSION; MIGRATION; ANGIOGENESIS	The proteoglycan decorin is expressed by sprouting but not quiescent endothelial cells, and angiogenesis is dysregulated in its absence. Previously, we have shown that decorin core protein can bind to and activate insulin-like growth factor-I receptor (IGF-IR) in endothelial cells. In this study, we show that decorin promotes alpha 2 beta 1 integrin-dependent endothelial cell adhesion and migration on fibrillar collagen type I. We provide evidence that decorin modulates cell-matrix interaction in this context by stimulating cytoskeletal and focal adhesion reorganization through activation of the IGF-IR and the small GTPase Rac. Further, the glycosaminoglycan moiety of decorin interacts with alpha 2 beta 1, but not alpha 1 beta 1 integrin, at a site distinct from the collagen I-binding A-domain, to allosterically modulate collagen I-binding activity of the integrin. We propose that induction of decorin expression in angiogenic, as opposed to quiescent, endothelial cells promotes a motile phenotype in an interstitial collagen I-rich environment by both signaling through IGF-IR and influencing alpha 2 beta 1 integrin activity.	[Fiedler, Lorna R.; Schoenherr, Elke; Waddington, Rachel; Aeschlimann, Daniel] Cardiff Univ, Sch Dent, Matrix Biol & Tissue Repair Res Unit, Cardiff CF14 4XY, Wales; [Niland, Stephan; Eble, Johannes A.] Frankfurt Univ Hosp, Ctr Mol Med, Excellence Cluster Cardiopulm Syst, D-60590 Frankfurt, Germany; [Seidler, Daniela G.] Univ Hosp Muenster, Dept Physiol Chem & Pathobiochem, D-48149 Munster, Germany	Cardiff University; Goethe University Frankfurt; Goethe University Frankfurt Hospital; University of Munster	Fiedler, LR (corresponding author), Cardiff Univ, Sch Dent, Matrix Biol & Tissue Repair Res Unit, Heath Pk, Cardiff CF14 4XY, Wales.	fiedlerlr@cardiff.ac.uk; AeschlimannDP@cardiff.ac.uk	Fiedler, Lorna/A-1158-2009; Waddington, Rachel/AAG-5177-2020	Waddington, Rachel/0000-0001-5878-1434; Aeschlimann, Daniel/0000-0003-0930-7706; Fiedler, Lorna/0000-0003-3118-6410				Ameye L, 2002, GLYCOBIOLOGY, V12, p107R, DOI 10.1093/glycob/cwf065; Arnaout MA, 2005, ANNU REV CELL DEV BI, V21, P381, DOI 10.1146/annurev.cellbio.21.090704.151217; Bayless KJ, 2002, J CELL SCI, V115, P1123; Bhide VM, 2005, J BIOL CHEM, V280, P23103, DOI 10.1074/jbc.M410060200; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BLOCHBERGER TC, 1992, J BIOL CHEM, V267, P20613; Cao YM, 2005, BIOCHEM BIOPH RES CO, V328, P560, DOI 10.1016/j.bbrc.2005.01.010; Clemmons DR, 2005, MOL ENDOCRINOL, V19, P1, DOI 10.1210/me.2004-0376; Danielson KG, 1997, J CELL BIOL, V136, P729, DOI 10.1083/jcb.136.3.729; Davies CD, 2001, MICROVASC RES, V62, P26, DOI 10.1006/mvre.2001.2311; Davis GE, 1996, EXP CELL RES, V224, P39, DOI 10.1006/excr.1996.0109; Derwin KA, 2001, J ORTHOP RES, V19, P269, DOI 10.1016/S0736-0266(00)00032-2; Eble JA, 2003, BIOCHEM J, V376, P77, DOI 10.1042/BJ20030373; Eble JA, 2001, J BIOL CHEM, V276, P12274, DOI 10.1074/jbc.M009338200; EDGELL CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3734, DOI 10.1073/pnas.80.12.3734; Emsley J, 2000, CELL, V101, P47, DOI 10.1016/S0092-8674(00)80622-4; GLOSSL J, 1984, J BIOL CHEM, V259, P4144; Grant DS, 2002, ONCOGENE, V21, P4765, DOI 10.1038/sj.onc.1205595; Guidetti G, 2002, BLOOD, V100, P1707, DOI 10.1182/blood.V100.5.1707.h81702001707_1707_1714; Haas TL, 1998, J BIOL CHEM, V273, P3604, DOI 10.1074/jbc.273.6.3604; HAUSSER H, 1992, J BIOL CHEM, V267, P11559; HEYN MP, 1975, BIOCHEMISTRY-US, V14, P2962, DOI 10.1021/bi00684a026; Imai K, 1997, BIOCHEM J, V322, P809, DOI 10.1042/bj3220809; Iozzo RV, 1997, CRIT REV BIOCHEM MOL, V32, P141, DOI 10.3109/10409239709108551; Jarvelainen H, 2006, WOUND REPAIR REGEN, V14, P443, DOI 10.1111/j.1743-6109.2006.00150.x; JARVELAINEN HT, 1992, EXP CELL RES, V203, P395, DOI 10.1016/0014-4827(92)90013-X; Johnson MS, 2003, MOL B INT U, P1; Keene DR, 2000, J BIOL CHEM, V275, P21801, DOI 10.1074/jbc.C000278200; Kinsella MG, 2000, J BIOL CHEM, V275, P13924, DOI 10.1074/jbc.275.18.13924; Knight CG, 2000, J BIOL CHEM, V275, P35, DOI 10.1074/jbc.275.1.35; Korff T, 1998, J CELL BIOL, V143, P1341, DOI 10.1083/jcb.143.5.1341; Liu WL, 2001, ENDOCRINOLOGY, V142, P1710, DOI 10.1210/en.142.5.1710; Lynch L, 2005, MOL BIOL CELL, V16, P51, DOI 10.1091/mbc.E04-05-0399; Nelimarkka L, 2001, AM J PATHOL, V158, P345, DOI 10.1016/S0002-9440(10)63975-2; Parrizas M, 1997, ENDOCRINOLOGY, V138, P1427, DOI 10.1210/en.138.4.1427; Rottner K, 1999, CURR BIOL, V9, P640, DOI 10.1016/S0960-9822(99)80286-3; SAMPAIO LD, 1988, BIOCHEM J, V254, P757; Schonherr E, 2005, J BIOL CHEM, V280, P15767, DOI 10.1074/jbc.M500451200; Schonherr E, 1999, EUR J CELL BIOL, V78, P44, DOI 10.1016/S0171-9335(99)80006-5; Schonherr E, 2004, J VASC RES, V41, P499, DOI 10.1159/000081806; Schonherr E, 2001, J BIOL CHEM, V276, P40687, DOI 10.1074/jbc.M105426200; SCOTT JE, 1985, BIOSCIENCE REP, V5, P71, DOI 10.1007/BF01117443; Scott JE, 1997, BIOCHEM SOC T, V25, pS663, DOI 10.1042/bst025s663; Stephens P, 2004, J CELL SCI, V117, P3389, DOI 10.1242/jcs.01188; Strazynski M, 2004, J BIOL CHEM, V279, P21266, DOI 10.1074/jbc.M309782200; Sulochana KN, 2005, J BIOL CHEM, V280, P27935, DOI 10.1074/jbc.M414320200; Suzuki-Inoue K, 2001, BLOOD, V98, P3708, DOI 10.1182/blood.V98.13.3708; Sweeney SM, 2003, J BIOL CHEM, V278, P30516, DOI 10.1074/jbc.M304237200; Tenni R, 2002, EUR J BIOCHEM, V269, P1428, DOI 10.1046/j.1432-1033.2002.02784.x; TUCKWELL D, 1995, J CELL SCI, V108, P1629; Tufvesson E, 2003, J CELL SCI, V116, P4857, DOI 10.1242/jcs.00808; Urbich C, 2005, J MOL CELL CARDIOL, V39, P733, DOI 10.1016/j.yjmcc.2005.07.003; WINNEMOLLER M, 1991, EUR J CELL BIOL, V54, P10; Zhang XH, 2005, BREAST CANCER RES TR, V93, P159, DOI 10.1007/s10549-005-4626-8	54	79	80	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17406	17415		10.1074/jbc.M710025200	http://dx.doi.org/10.1074/jbc.M710025200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18413316	hybrid			2022-12-25	WOS:000256720600049
J	Lewis, MJ; Meehan, M; Owen, P; Woof, JM				Lewis, Melanie J.; Meehan, Mary; Owen, Peter; Woof, Jenny M.			A common theme in interaction of bacterial immunoglobulin-binding proteins with immunoglobulins illustrated in the equine system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FC-ALPHA-RI; STREPTOCOCCUS-EQUI; SUBSP EQUI; FIBRINOGEN-BINDING; STAPHYLOCOCCUS-AUREUS; COMPLEMENT ACTIVATION; CLASSICAL PATHWAY; MUCOSAL ANTIBODY; IMMUNE-RESPONSES; IGG SUBCLASSES	The M protein of Streptococcus equi subsp. equi known as fibrinogen-binding protein (FgBP) is a cell wall-associated protein with antiphagocytic activity that binds IgG. Recombinant versions of the seven equine IgG subclasses were used to investigate the subclass specificity of FgBP. FgBP bound predominantly to equine IgG4 and IgG7, with little or no binding to the other subclasses. Competitive binding experiments revealed that FgBP could inhibit the binding of staphylococcal protein A and streptococcal protein G to both IgG4 and IgG7, implicating the Fc interdomain region in binding to FgBP. To identify which of the two IgG Fc domains contributed to the interaction with FgBP, we tested two human IgG1/IgA1 domain swap mutants and found that both domains are required for full binding, with the CH3 domain playing a critical role. The binding site for FgBP was further localized using recombinant equine IgG7 antibodies with single or double point mutations to residues lying at the CH2-CH3 interface. We found that interaction of FgBP with equine IgG4 and IgG7 was able to disrupt C1q binding and antibody-mediated activation of the classical complement pathway, demonstrating an effective means by which S. equi may evade the immune response. The mode of interaction of FgBP with IgG fits a common theme for bacterial Ig-binding proteins. Remarkably, for those interactions studied in detail, it emerges that all the Ig-binding proteins target the CH2-CH3 domain interface, regardless of specificity for IgG or IgA, streptococcal or staphylococcal origin, or host species (equine or human).	[Lewis, Melanie J.; Woof, Jenny M.] Univ Dundee, Ninewells Hosp, Sch Med, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland; [Meehan, Mary; Owen, Peter] Trinity Coll Dublin, Moyne Inst Preventat Med, Dept Microbiol, Dublin 2, Ireland	University of Dundee; Trinity College Dublin	Woof, JM (corresponding author), Univ Dundee, Ninewells Hosp, Sch Med, Div Pathol & Neurosci, Dundee DD1 9SY, Scotland.	j.m.woof@dundee.ac.uk			Wellcome Trust [074863] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Abi-Rached L, 2007, J IMMUNOL, V178, P7943, DOI 10.4049/jimmunol.178.12.7943; AKERSTROM B, 1986, J BIOL CHEM, V261, P240; Berge A, 1997, J BIOL CHEM, V272, P20774, DOI 10.1074/jbc.272.33.20774; BOSCHWITZ JS, 1994, MICROB PATHOGENESIS, V17, P121, DOI 10.1006/mpat.1994.1058; BOSCHWITZ JS, 1994, INFECT IMMUN, V62, P3515, DOI 10.1128/IAI.62.8.3515-3520.1994; BRUGGEMANN M, 1987, J EXP MED, V166, P1351, DOI 10.1084/jem.166.5.1351; BURTON DR, 1992, ADV IMMUNOL, V51, P1, DOI 10.1016/S0065-2776(08)60486-1; BURTON DR, 1985, MOL IMMUNOL, V22, P161, DOI 10.1016/0161-5890(85)90151-8; Carlsson F, 2005, MOL MICROBIOL, V56, P28, DOI 10.1111/j.1365-2958.2005.04527.x; DEISENHOFER J, 1981, BIOCHEMISTRY-US, V20, P2361, DOI 10.1021/bi00512a001; DeLano WL, 2000, SCIENCE, V287, P1279, DOI 10.1126/science.287.5456.1279; Flock M, 2006, VACCINE, V24, P4144, DOI 10.1016/j.vaccine.2006.02.016; Flock M, 2004, INFECT IMMUN, V72, P3228, DOI 10.1128/IAI.72.6.3228-3236.2004; GALAN JE, 1986, INFECT IMMUN, V54, P202, DOI 10.1128/IAI.54.1.202-206.1986; GALAN JE, 1985, INFECT IMMUN, V47, P623, DOI 10.1128/IAI.47.3.623-628.1985; GALAN JE, 1987, INFECT IMMUN, V55, P3181; Ghetie V, 2000, ANNU REV IMMUNOL, V18, P739, DOI 10.1146/annurev.immunol.18.1.739; Harrington DJ, 2002, MICROBES INFECT, V4, P501, DOI 10.1016/S1286-4579(02)01565-4; Herr AB, 2003, NATURE, V423, P614, DOI 10.1038/nature01685; JONSSON H, 1995, INFECT IMMUN, V63, P2968, DOI 10.1128/IAI.63.8.2968-2975.1995; LANCET D, 1978, BIOCHEM BIOPH RES CO, V85, P608, DOI 10.1016/0006-291X(78)91206-8; Lewis MJ, 2008, MOL IMMUNOL, V45, P818, DOI 10.1016/j.molimm.2007.06.158; Lindmark H, 1999, RES VET SCI, V66, P93, DOI 10.1053/rvsc.1998.0250; Meehan M, 2001, MICROBIOL-SGM, V147, P3311, DOI 10.1099/00221287-147-12-3311; Meehan M, 2002, FEMS MICROBIOL LETT, V206, P81, DOI 10.1111/j.1574-6968.2002.tb10990.x; Meehan M, 1998, MICROBIOL-UK, V144, P993, DOI 10.1099/00221287-144-4-993; Meehan M, 2000, MICROBIOL-SGM, V146, P1187, DOI 10.1099/00221287-146-5-1187; Meehan M, 2000, FEMS MICROBIOL LETT, V190, P317, DOI 10.1111/j.1574-6968.2000.tb09305.x; MORTON HC, 1993, J IMMUNOL, V151, P4743; Newton JR, 2000, EQUINE VET J, V32, P515, DOI 10.2746/042516400777584721; Nitsche-Schmitz DP, 2007, J BIOL CHEM, V282, P17530, DOI 10.1074/jbc.M702612200; Pleass RJ, 1999, J BIOL CHEM, V274, P23508, DOI 10.1074/jbc.274.33.23508; Pleass RJ, 2001, J BIOL CHEM, V276, P8197, DOI 10.1074/jbc.M009396200; Ramsland PA, 2007, P NATL ACAD SCI USA, V104, P15051, DOI 10.1073/pnas.0706028104; RECHT B, 1982, J IMMUNOL, V127, P917; SAUERERIKSSON AE, 1995, STRUCTURE, V3, P265, DOI 10.1016/S0969-2126(01)00157-5; Sheoran AS, 1997, VET IMMUNOL IMMUNOP, V59, P239, DOI 10.1016/S0165-2427(97)00074-3; Sheoran AS, 2000, AM J VET RES, V61, P1099, DOI 10.2460/ajvr.2000.61.1099; Taylor S. D., 2006, Clinical Techniques in Equine Practice, V5, P211, DOI 10.1053/j.ctep.2006.03.016; TIMONEY JF, 1985, INFECT IMMUN, V48, P29, DOI 10.1128/IAI.48.1.29-34.1985; Timoney JF, 2004, VET RES, V35, P397, DOI 10.1051/vetres:2004025; Timoney JF, 1997, INFECT IMMUN, V65, P3600, DOI 10.1128/IAI.65.9.3600-3605.1997; VANLOGHEM E, 1982, SCAND J IMMUNOL, V15, P275; Wagner B, 2006, DEV COMP IMMUNOL, V30, P155, DOI 10.1016/j.dci.2005.06.008; Wagner B, 2004, J IMMUNOL, V173, P3230, DOI 10.4049/jimmunol.173.5.3230; Wagner B, 2002, IMMUNOGENETICS, V54, P353, DOI 10.1007/s00251-002-0458-4; Waller A, 2007, VACCINE, V25, P3629, DOI 10.1016/j.vaccine.2007.01.060; Wines BD, 2006, J BIOL CHEM, V281, P1389, DOI 10.1074/jbc.M509334200; Wines BD, 2000, J IMMUNOL, V164, P5313, DOI 10.4049/jimmunol.164.10.5313; WOLBINK GJ, 1993, J IMMUNOL METHODS, V163, P67, DOI 10.1016/0022-1759(93)90240-8	50	30	33	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17615	17623		10.1074/jbc.M709844200	http://dx.doi.org/10.1074/jbc.M709844200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18411272	hybrid, Green Published			2022-12-25	WOS:000256720600068
J	Llovera, RE; de Tullio, M; Alonso, LG; Leissring, MA; Kaufman, SB; Roher, AE; Gay, GD; Morelli, L; Castano, EM				Llovera, Ramiro E.; de Tullio, Matias; Alonso, Leonardo G.; Leissring, Malcolm A.; Kaufman, Sergio B.; Roher, Alex E.; Gay, Gonzalo de Prat; Morelli, Laura; Castano, Eduardo M.			The catalytic domain of insulin-degrading enzyme forms a denaturant-resistant complex with amyloid beta peptide - Implications for Alzheimer disease pathogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							A-BETA; FIBRIL FORMATION; IN-VIVO; PROTEIN; BRAIN; DEGRADATION; PROTEOLYSIS; AGGREGATION; SOLUBILITY; NEPRILYSIN	Insulin-degrading enzyme (IDE) is central to the turnover of insulin and degrades amyloid beta(A beta) in the mammalian brain. Biochemical and genetic data support the notion that IDE may play a role in late onset Alzheimer disease (AD), and recent studies suggest an association between AD and diabetes mellitus type 2. Here we show that a natively folded recombinant IDE was capable of forming a stable complex with A beta that resisted dissociation after treatment with strong denaturants. This interaction was also observed with rat brain IDE and detected in an SDS-soluble fraction from AD cortical tissue. A beta sequence 17-27, known to be crucial in amyloid assembly, was sufficient to form a stable complex with IDE. Monomeric as opposed to aggregated A beta was competent to associate irreversibly with IDE following a very slow kinetics (t(1/2) similar to 45 min). Partial denaturation of IDE as well as preincubation with a 10-fold molar excess of insulin prevented complex formation, suggesting that the irreversible interaction of A beta takes place with at least part of the substrate binding site of the protease. Limited proteolysis showed that A beta remained bound to a similar to 25-kDa N-terminal fragment of IDE in an SDS-resistant manner. Mass spectrometry after in gel digestion of the IDE.A beta complex showed that peptides derived from the region that includes the catalytic site of IDE were recovered with A beta. Taken together, these results are suggestive of an unprecedented mechanism of conformation-dependent substrate binding that may perturb A beta clearance, insulin turnover, and promote AD pathogenesis.	[Llovera, Ramiro E.; de Tullio, Matias; Alonso, Leonardo G.; Gay, Gonzalo de Prat; Morelli, Laura; Castano, Eduardo M.] Consejo Nacl Invest Cient & Tecn, Inst Invest Bioquim Buenos Aires, Fdn Inst Leloir, Buenos Aires, DF, Argentina; [Leissring, Malcolm A.] Scripps Florida, Dept Biomed Sci, Jupiter, FL 33458 USA; [Kaufman, Sergio B.] Univ Buenos Aires, Inst Quim & Fisicoquim Biol CONICET, Buenos Aires, DF, Argentina; [Kaufman, Sergio B.] Univ Buenos Aires, Fac Farm & Bioquim, Dept Quim Biol, RA-1113 Buenos Aires, DF, Argentina; [Roher, Alex E.] Sun Hlth Res inst, Sun City, AZ 85351 USA	Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); Leloir Institute; State University System of Florida; University of Florida; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University of Buenos Aires; University of Buenos Aires; Banner Research; Banner Health; Banner Sun Health Research Institute	Castano, EM (corresponding author), Consejo Nacl Invest Cient & Tecn, Inst Invest Bioquim Buenos Aires, Fdn Inst Leloir, 435 Av Patricias Argentinas,C1405BWE, Buenos Aires, DF, Argentina.	ecastano@leloir.org.ar	LEISSRING, MALCOLM/AAW-5361-2021	LEISSRING, MALCOLM/0000-0001-7185-4255; Kaufman, Sergio Benjamin/0000-0002-8763-4086; Alonso, Leonardo Gabriel/0000-0002-0596-703X; Prat Gay, Gonzalo/0000-0001-5748-6863	NIA NIH HHS [R21 AG025070] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AULD DS, 2004, HDB PROTEOLYTIC ENZY, P268; Bernstein HG, 1999, NEUROSCI LETT, V263, P161, DOI 10.1016/S0304-3940(99)00135-4; Caccamo A, 2005, NEUROBIOL AGING, V26, P645, DOI 10.1016/j.neurobiolaging.2004.06.013; Castano EM, 1996, J BIOL CHEM, V271, P32185, DOI 10.1074/jbc.271.50.32185; Chauhan VPS, 1999, BIOCHEM BIOPH RES CO, V258, P241, DOI 10.1006/bbrc.1999.0623; Chen YR, 2006, J BIOL CHEM, V281, P24414, DOI 10.1074/jbc.M602363200; Cook DG, 2003, AM J PATHOL, V162, P313, DOI 10.1016/S0002-9440(10)63822-9; Eckman EA, 2003, J BIOL CHEM, V278, P2081, DOI 10.1074/jbc.C200642200; ESCH FS, 1990, SCIENCE, V248, P1122, DOI 10.1126/science.2111583; Farris W, 2003, P NATL ACAD SCI USA, V100, P4162, DOI 10.1073/pnas.0230450100; GOREVIC PD, 1987, BIOCHEM BIOPH RES CO, V147, P854, DOI 10.1016/0006-291X(87)91008-4; GOWING E, 1994, J BIOL CHEM, V269, P10987; HARIGAYA Y, 1995, BIOCHEM BIOPH RES CO, V211, P1015, DOI 10.1006/bbrc.1995.1912; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; HILBICH C, 1992, J MOL BIOL, V228, P460, DOI 10.1016/0022-2836(92)90835-8; Hughes SR, 1998, P NATL ACAD SCI USA, V95, P3275, DOI 10.1073/pnas.95.6.3275; Iwata N, 2001, SCIENCE, V292, P1550, DOI 10.1126/science.1059946; Kurochkin IV, 2001, TRENDS BIOCHEM SCI, V26, P421, DOI 10.1016/S0968-0004(01)01876-X; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Leissring MA, 2003, J BIOL CHEM, V278, P37314, DOI 10.1074/jbc.M305627200; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Liu RT, 2004, BIOCHEMISTRY-US, V43, P6959, DOI 10.1021/bi049933o; Luchsinger JA, 2004, NEUROLOGY, V63, P1187, DOI 10.1212/01.WNL.0000140292.04932.87; Luhrs T, 2005, P NATL ACAD SCI USA, V102, P17342, DOI 10.1073/pnas.0506723102; Makarova KS, 1999, PROTEIN SCI, V8, P2537; Miller BC, 2003, P NATL ACAD SCI USA, V100, P6221, DOI 10.1073/pnas.1031520100; Morelli L, 2005, BIOCHEM BIOPH RES CO, V332, P808, DOI 10.1016/j.bbrc.2005.05.020; Morelli L, 2004, J BIOL CHEM, V279, P56004, DOI 10.1074/jbc.M407283200; Morelli L, 2003, J BIOL CHEM, V278, P23221, DOI 10.1074/jbc.M300276200; Morelli L, 2002, NEUROCHEM RES, V27, P1387, DOI 10.1023/A:1021679817756; Munson GW, 2000, BIOCHEMISTRY-US, V39, P16119, DOI 10.1021/bi0017475; O'Nuallain B, 2005, BIOCHEMISTRY-US, V44, P12709, DOI 10.1021/bi050927h; O'Nuallain B, 2004, J BIOL CHEM, V279, P17490, DOI 10.1074/jbc.M311300200; Oefner C, 2000, J MOL BIOL, V296, P341, DOI 10.1006/jmbi.1999.3492; Perez A, 2000, NEUROCHEM RES, V25, P247, DOI 10.1023/A:1007527721160; Qiu WQ, 2006, NEUROBIOL AGING, V27, P190, DOI 10.1016/j.neurobiolaging.2005.01.004; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; ROTH RA, 2004, HDB PROTEOLYTIC ENZY, P868; Safavi A, 1996, BIOCHEMISTRY-US, V35, P14318, DOI 10.1021/bi960582q; Saric T, 2003, MOL CELL ENDOCRINOL, V204, P11, DOI 10.1016/S0303-7207(03)00154-0; SCHWARZMAN AL, 1994, P NATL ACAD SCI USA, V91, P8368, DOI 10.1073/pnas.91.18.8368; Shen YQ, 2006, NATURE, V443, P870, DOI 10.1038/nature05143; SHII K, 1986, DIABETES, V35, P675, DOI 10.2337/diabetes.35.6.675; Shinall H, 2005, BIOCHEMISTRY-US, V44, P15345, DOI 10.1021/bi050650l; Soto C, 1998, NAT MED, V4, P822, DOI 10.1038/nm0798-822; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; Sudoh S, 2002, BIOCHEMISTRY-US, V41, P1091, DOI 10.1021/bi011193l; Vepsalainen S, 2007, J MED GENET, V44, DOI 10.1136/jmg.2006.048470; Wang HY, 2000, J BIOL CHEM, V275, P5626, DOI 10.1074/jbc.275.8.5626; Wang L, 2006, ENERG FUEL, V20, P1287, DOI 10.1021/ef050268h; WISNIEWSKI HM, 1989, ACTA NEUROPATHOL, V78, P22, DOI 10.1007/BF00687398; Wood SJ, 1996, J MOL BIOL, V256, P870, DOI 10.1006/jmbi.1996.0133; Zhang S, 2000, J STRUCT BIOL, V130, P130, DOI 10.1006/jsbi.2000.4288	53	31	40	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 20	2008	283	25					17039	17048		10.1074/jbc.M706316200	http://dx.doi.org/10.1074/jbc.M706316200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	313DF	18411275	hybrid, Green Published			2022-12-25	WOS:000256720600010
J	Bross, P; Naundrup, S; Hansen, J; Nielsen, MN; Christensen, JH; Kruhoffer, M; Palmfeldt, J; Corydon, TJ; Gregersen, N; Ang, D; Georgopoulos, C; Nielsen, KL				Bross, Peter; Naundrup, Soren; Hansen, Jakob; Nielsen, Marit Nyholm; Christensen, Jane Hvarregaard; Kruhoffer, Mogens; Palmfeldt, Johan; Corydon, Thomas Juhl; Gregersen, Niels; Ang, Debbie; Georgopoulos, Costa; Nielsen, Kare Lehmann			The Hsp60-(p.V98I) mutation associated with hereditary spastic paraplegia SPG13 compromises chaperonin function both in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; EXPRESSION; GENE; GROEL; PROTEIN; HSP60; PURIFICATION; RING	We have previously reported the association of a mutation (c.292G > A/p.V98I) in the human HSPD1 gene that encodes the mitochondrial Hsp60 chaperonin with a dominantly inherited form of hereditary spastic paraplegia. Here, we show that the purified Hsp60-(p.V98I) chaperonin displays decreased ATPase activity and exhibits a strongly reduced capacity to promote folding of denatured malate dehydrogenase in vitro. To test its in vivo functions, we engineered a bacterial model system that lacks the endogenous chaperonin genes and harbors two plasmids carrying differentially inducible operons with human Hsp10 and wild-type Hsp60 or Hsp10 and Hsp60-(p.V98I), respectively. Ten hours after shutdown of the wild-type chaperonin operon and induction of the Hsp60-(p.V98I)/Hsp10 mutant operon, bacterial cell growth was strongly inhibited. No globally increased protein aggregation was observed, and microarray analyses showed that a number of genes involved in metabolic pathways, some of which are essential for robust aerobic growth, were strongly up-regulated in Hsp60-(p.V98I)-expressing bacteria, suggesting that the growth arrest was caused by defective folding of some essential proteins. Co-expression of Hsp60-(p.V98I) and wild-type Hsp60 exerted a dominant negative effect only when the chaperonin genes were expressed at relatively low levels. Based on our in vivo and in vitro data, we propose that the major effect of heterozygosity for the Hsp60(p.V98I) mutation is a moderately decreased activity of chaperonin complexes composed of mixed wild-type and Hsp60( p.V98I) mutant subunits.	[Naundrup, Soren; Nielsen, Kare Lehmann] Aalborg Univ, Dept Biotechnol Chem & Environm Engn, DK-9000 Aalborg, Denmark; [Corydon, Thomas Juhl] Univ Aarhus, Inst Human Genet, DK-8000 Aarhus, Denmark; [Ang, Debbie; Georgopoulos, Costa] Ctr Med Univ Geneva, Dept Microbiol & Mol Med, CH-1211 Geneva, Switzerland; [Bross, Peter; Hansen, Jakob; Nielsen, Marit Nyholm; Christensen, Jane Hvarregaard; Kruhoffer, Mogens; Palmfeldt, Johan; Gregersen, Niels] Aarhus Univ Hosp, Res Unit Mol Med, Mol Diagnost Lab, DK-8200 Aarhus, Denmark	Aalborg University; Aarhus University; University of Geneva; Aarhus University	Bross, P (corresponding author), Aarhus Univ Hosp, Res Unit Mol Med, Mol Diagnost Lab, Brendstrupgaardsvej 100, DK-8200 Aarhus, Denmark.	peter.bross@KI.au.dk	Hansen, Jakob/W-1318-2017; Bross, Peter/B-7219-2013; Hansen, Jakob/F-7034-2013; Nielsen, Kåre Lehmann L/A-1181-2013	Hansen, Jakob/0000-0002-4115-2858; Bross, Peter/0000-0001-9526-8525; Nielsen, Kåre Lehmann L/0000-0002-5598-4401; Christensen, Jane Hvarregaard/0000-0002-0009-2991; Palmfeldt, Johan/0000-0001-5585-639X; Corydon, Thomas Juhl/0000-0003-3588-6350				Bearson S, 1997, FEMS MICROBIOL LETT, V147, P173, DOI 10.1016/S0378-1097(96)00503-4; Bross P, 2004, TOP CURR GENET, V8, P97; CARLIER MF, 1981, BIOCHEMISTRY-US, V20, P1918, DOI 10.1021/bi00510a030; Chapman E, 2006, P NATL ACAD SCI USA, V103, P15800, DOI 10.1073/pnas.0607534103; CHENG MY, 1989, NATURE, V337, P620, DOI 10.1038/337620a0; Corydon TJ, 1998, BIOCHEM J, V331, P309, DOI 10.1042/bj3310309; Crosby AH, 2002, AM J HUM GENET, V71, P1009, DOI 10.1086/344206; Danziger O, 2003, P NATL ACAD SCI USA, V100, P13797, DOI 10.1073/pnas.2333925100; DeLuca GC, 2004, NEUROPATH APPL NEURO, V30, P576, DOI 10.1111/j.1365-2990.2004.00587.x; Depienne C, 2007, CURR OPIN NEUROL, V20, P674, DOI 10.1097/WCO.0b013e3282f190ba; DICKSON R, 1994, J BIOL CHEM, V269, P26858; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; FAYET O, 1989, J BACTERIOL, V171, P1379, DOI 10.1128/JB.171.3.1379-1385.1989; Fink JK, 2006, CURR NEUROL NEUROSCI, V6, P65, DOI 10.1007/s11910-996-0011-1; Gerdes SY, 2003, J BACTERIOL, V185, P5673, DOI 10.1128/JB.185.19.5673-5684.2003; HALLBERG EM, 1993, MOL CELL BIOL, V13, P3050, DOI 10.1128/MCB.13.5.3050; Hansen JJ, 2002, AM J HUM GENET, V70, P1328, DOI 10.1086/339935; HORWICH AL, 1993, CELL, V74, P909, DOI 10.1016/0092-8674(93)90470-B; Horwich AL, 2006, CHEM REV, V106, P1917, DOI 10.1021/cr040435v; Kamireddi M, 1997, PROTEIN EXPRES PURIF, V11, P47, DOI 10.1006/prep.1997.0764; Kerner MJ, 2005, CELL, V122, P209, DOI 10.1016/j.cell.2005.05.028; KUO MS, 1986, CARBOHYD RES, V156, P173, DOI 10.1016/S0008-6215(00)90109-5; Lesley SA, 2002, PROTEIN ENG, V15, P153, DOI 10.1093/protein/15.2.153; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Martinez-Antonio A, 2003, CURR OPIN MICROBIOL, V6, P482, DOI 10.1016/j.mib.2003.09.002; MILLER AD, 1993, BIOCHEM J, V291, P139, DOI 10.1042/bj2910139; Nielsen KL, 1998, MOL CELL, V2, P93, DOI 10.1016/S1097-2765(00)80117-3; Perezgasga L, 1999, FEBS LETT, V456, P269, DOI 10.1016/S0014-5793(99)00963-1; Richmond CS, 1999, NUCLEIC ACIDS RES, V27, P3821, DOI 10.1093/nar/27.19.3821; Rye HS, 1997, NATURE, V388, P792, DOI 10.1038/42047; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VENNER TJ, 1990, DNA CELL BIOL, V9, P545, DOI 10.1089/dna.1990.9.545; Viitanen PV, 1998, METHOD ENZYMOL, V290, P203, DOI 10.1016/S0076-6879(98)90020-9; Zheng M, 2001, J BACTERIOL, V183, P4562, DOI 10.1128/JB.183.15.4562-4570.2001; Zwir I, 2005, P NATL ACAD SCI USA, V102, P2862, DOI 10.1073/pnas.0408238102	35	68	71	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15694	15700		10.1074/jbc.M800548200	http://dx.doi.org/10.1074/jbc.M800548200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18400758	Green Published, hybrid			2022-12-25	WOS:000256332500024
J	Lin, CH; Chang, HS; Yu, WCY				Lin, Ching-Hui; Chang, Hung-Shu; Yu, Winston C. Y.			USP11 stabilizes HPV-16E7 and further modulates the E7 biological activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; UBIQUITIN-PROTEASOME PATHWAY; DEUBIQUITINATING ENZYMES; FUNCTIONAL-CHARACTERIZATION; DEPENDENT DEGRADATION; HUMAN KERATINOCYTES; PROTEIN; ONCOPROTEIN; GENE; TRANSFORMATION	HPV-16E7 is a major transforming protein, which has been implicated in the development of cervical cancer. The stability of E7 is thus important to ensure its fully functional status. Using the yeast two-hybrid system, we found that USP11 (ubiquitin-specific protease 11), a member of a protein family that cleaves polyubiquitin chains and/or ubiquitin precursors, interacts and forms a specific complex with HPV-16E7. Our results indicate that the USP11 can greatly increase the steady state level of HPV-16E7 by reducing ubiquitination and attenuating E7 degradation. In contrast, a catalytically inactive mutant of USP11 abolished the deubiquitinating ability and returned E7 to a normal rate of degradation. Moreover, USP11 not only protected E7 from ubiquitination but also influenced E7 function as a modulator of cell growth status. These results suggest that USP11 plays an important role in regulating the levels of E7 protein and subsequently affects the biological function of E7 as well as its contribution to cell transformation by HPV-16E7.	[Chang, Hung-Shu] Natl Cheng Kung Univ, Dept Life Sci, Tainan 701, Taiwan; [Lin, Ching-Hui; Yu, Winston C. Y.] Natl Hlth Res Inst, Zhunan Town 350, Miaoli County, Taiwan	National Cheng Kung University; National Health Research Institutes - Taiwan	Chang, HS (corresponding author), Natl Cheng Kung Univ, Dept Life Sci, 1 Univ Rd, Tainan 701, Taiwan.	hschang@mail.ncku.edu.tw; winston@nhri.org.tw	Yu, C.Y./E-3666-2010					Amerik AY, 2004, BBA-MOL CELL RES, V1695, P189, DOI 10.1016/j.bbamcr.2004.10.003; ANDERSEN MW, 1981, BIOCHEMISTRY-US, V20, P1100, DOI 10.1021/bi00508a009; Antinore MJ, 1996, EMBO J, V15, P1950, DOI 10.1002/j.1460-2075.1996.tb00546.x; Baker RT, 1999, GENOMICS, V59, P264, DOI 10.1006/geno.1999.5879; Borodovsky A, 2002, CHEM BIOL, V9, P1149, DOI 10.1016/S1074-5521(02)00248-X; Burch AD, 2004, J VIROL, V78, P7175, DOI 10.1128/JVI.78.13.7175-7185.2004; Chang HS, 2004, AM J PATHOL, V165, P1535, DOI 10.1016/S0002-9440(10)63411-6; Chelbi-Alix MK, 1999, ONCOGENE, V18, P935, DOI 10.1038/sj.onc.1202366; Chung CH, 1999, BIOCHEM BIOPH RES CO, V266, P633, DOI 10.1006/bbrc.1999.1880; Derynck R, 2003, NATURE, V425, P577, DOI 10.1038/nature02006; Everett RD, 1998, EMBO J, V17, P7161, DOI 10.1093/emboj/17.24.7161; Funk JO, 1997, GENE DEV, V11, P2090, DOI 10.1101/gad.11.16.2090; GREENFIELD I, 1991, P NATL ACAD SCI USA, V88, P11217, DOI 10.1073/pnas.88.24.11217; Guccione E, 2002, VIROLOGY, V293, P20, DOI 10.1006/viro.2001.1290; Helt AM, 2001, J VIROL, V75, P6737, DOI 10.1128/JVI.75.15.6737-6747.2001; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; HUANG YZ, 1995, SCIENCE, V270, P1828, DOI 10.1126/science.270.5243.1828; HUGHES FJ, 1993, NUCLEIC ACIDS RES, V21, P5817, DOI 10.1093/nar/21.25.5817; Ideguchi H, 2002, BIOCHEM J, V367, P87, DOI 10.1042/BJ20011851; JEWERS RJ, 1992, J VIROL, V66, P1329, DOI 10.1128/JVI.66.3.1329-1335.1992; Kamio M, 2004, ONCOGENE, V23, P3107, DOI 10.1038/sj.onc.1207453; Kim JH, 2003, J BIOCHEM, V134, P9, DOI 10.1093/jb/mvg107; MANSUR CP, 1993, BIOCHIM BIOPHYS ACTA, V1155, P323, DOI 10.1016/0304-419X(93)90013-3; Massimi P, 2001, MOL CELL BIOCHEM, V227, P137, DOI 10.1023/A:1013145814186; MCINTYRE MC, 1993, J VIROL, V67, P3142, DOI 10.1128/JVI.67.6.3142-3150.1993; Nakamura M, 1998, J CELL BIOL, V143, P1041, DOI 10.1083/jcb.143.4.1041; Nijman SMB, 2005, CELL, V123, P773, DOI 10.1016/j.cell.2005.11.007; Oh KJ, 2004, J VIROL, V78, P5338, DOI 10.1128/JVI.78.10.5338-5346.2004; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; Parkinson J, 1999, J VIROL, V73, P650, DOI 10.1128/JVI.73.1.650-657.1999; Pei XF, 1998, CARCINOGENESIS, V19, P1481, DOI 10.1093/carcin/19.8.1481; Phillips AC, 1997, J GEN VIROL, V78, P905, DOI 10.1099/0022-1317-78-4-905; Pickart CM, 2004, BBA-MOL CELL RES, V1695, P55, DOI 10.1016/j.bbamcr.2004.09.019; Reinstein E, 2000, ONCOGENE, V19, P5944, DOI 10.1038/sj.onc.1203989; Rey O, 2000, VIROLOGY, V268, P372, DOI 10.1006/viro.1999.0175; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SELVEY LA, 1994, J GEN VIROL, V75, P1647, DOI 10.1099/0022-1317-75-7-1647; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; Swanson DA, 1996, HUM MOL GENET, V5, P533, DOI 10.1093/hmg/5.4.533; Wang J, 2001, ONCOGENE, V20, P4740, DOI 10.1038/sj.onc.1204655; Wilkinson KD, 2000, SEMIN CELL DEV BIOL, V11, P141, DOI 10.1006/scdb.2000.0164; Wilkinson KD, 1997, FASEB J, V11, P1245, DOI 10.1096/fasebj.11.14.9409543; Wing SS, 2003, INT J BIOCHEM CELL B, V35, P590, DOI 10.1016/S1357-2725(02)00392-8; Zhu Y, 1996, P NATL ACAD SCI USA, V93, P3275, DOI 10.1073/pnas.93.8.3275; zur Hausen H, 1996, BIOCHIM BIOPHYS ACTA, V1288, P55; Zwerschke W, 1999, P NATL ACAD SCI USA, V96, P1291, DOI 10.1073/pnas.96.4.1291; Zwerschke W, 2000, J BIOL CHEM, V275, P9534, DOI 10.1074/jbc.275.13.9534	48	44	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15681	15688		10.1074/jbc.M708278200	http://dx.doi.org/10.1074/jbc.M708278200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18408009	Green Published, hybrid			2022-12-25	WOS:000256332500022
J	Murali, A; Li, XJ; Ranjith-Kumar, CT; Bhardwaj, K; Holzenburg, A; Li, PW; Kao, CC				Murali, Ayaluru; Li, Xiaojun; Ranjith-Kumar, C. T.; Bhardwaj, Kanchan; Holzenburg, Andreas; Li, Pingwei; Kao, C. Cheng			Structure and function of LGP2, a DEX(D/H) helicase that regulates the innate immunity response	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TOLL-LIKE RECEPTORS; RIG-I; CRYSTAL-STRUCTURE; RNA; VIRUS; DOMAIN; ACTIVATION; EXPRESSION; MECHANISM; PATHWAYS	RNA recognition receptors are important for detection of and response to viral infections. RIG-I and MDA5 are cytoplasmic DEX(D/H) helicase proteins that can induce signaling in response to RNA ligands, including those from viral infections. LGP2, a homolog of RIG-I and MDA5 without the caspase recruitment domain required for signaling, plays an important role in modulating signaling by MDA5 and RIG-I, presumably through heterocomplex formation and/or by serving as a sink for RNAs. Here we demonstrate that LGP2 can be coexpressed with RIG-I to inhibit activation of the NF-kappa B reporter expression and that LGP2 protein produced in insect cells can bind both single-and double-stranded RNA (dsRNA), with higher affinity and cooperativity for dsRNA. Electron microscopy and image reconstruction were used to determine the shape of the LGP2 monomer in the absence of dsRNA and of the dimer complexed to a 27-bp dsRNA. LGP2 has striking structural similarity to the helicase domain of the superfamily 2 DNA helicase, Hef.	[Murali, Ayaluru; Li, Xiaojun; Ranjith-Kumar, C. T.; Bhardwaj, Kanchan; Holzenburg, Andreas; Li, Pingwei; Kao, C. Cheng] Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; [Holzenburg, Andreas] Texas A&M Univ, Dept Biol, College Stn, TX 77843 USA; [Holzenburg, Andreas] Texas A&M Univ, Microscopy & Imaging Ctr, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station	Kao, CC (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA.	ckao@tamu.edu	Li, Xiaojun/J-4460-2012; Kumar CT, Ranjith/J-5701-2016; Murali, Ayaluru/G-3401-2014; Bhardwaj, Kanchan/CAH-2291-2022	Li, Xiaojun/0000-0001-8528-8258; Murali, Ayaluru/0000-0001-6406-6840; Bhardwaj, Kanchan/0000-0002-7331-7717	NIAID NIH HHS [1R01AI073335] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI073335] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Caruthers JM, 2002, CURR OPIN STRUC BIOL, V12, P123, DOI 10.1016/S0959-440X(02)00298-1; Cordin O, 2006, GENE, V367, P17, DOI 10.1016/j.gene.2005.10.019; Cui S, 2008, MOL CELL, V29, P169, DOI 10.1016/j.molcel.2007.10.032; Eisenacher K, 2007, IMMUNOBIOLOGY, V212, P701, DOI 10.1016/j.imbio.2007.09.007; Gaspari AA, 2006, J AM ACAD DERMATOL, V54, pS67, DOI 10.1016/j.jaad.2005.10.057; Hornung V, 2006, SCIENCE, V314, P994, DOI 10.1126/science.1132505; Johnson CL, 2006, TRENDS IMMUNOL, V27, P1, DOI 10.1016/j.it.2005.11.004; Kao CC, 2000, J VIROL, V74, P11121, DOI 10.1128/JVI.74.23.11121-11128.2000; Kobayashi T, 2006, NAT IMMUNOL, V7, P123, DOI 10.1038/ni0206-123; Komuro A, 2006, J VIROL, V80, P12332, DOI 10.1128/JVI.01325-06; Kossen K, 2002, J MOL BIOL, V324, P625, DOI 10.1016/S0022-2836(02)01140-3; Lee MS, 2007, MOL CELLS, V23, P1; Lee MS, 2007, ANNU REV BIOCHEM, V76, P447, DOI 10.1146/annurev.biochem.76.060605.122847; Ludtke SJ, 1999, J STRUCT BIOL, V128, P82, DOI 10.1006/jsbi.1999.4174; Meylan E, 2006, MOL CELL, V22, P561, DOI 10.1016/j.molcel.2006.05.012; Nallagatla SR, 2007, SCIENCE, V318, P1455, DOI 10.1126/science.1147347; Nishino T, 2005, STRUCTURE, V13, P143, DOI 10.1016/j.str.2004.11.008; Park HH, 2007, CELL, V128, P533, DOI 10.1016/j.cell.2007.01.019; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Pichlmair A, 2006, SCIENCE, V314, P997, DOI 10.1126/science.1132998; Ranjith-Kumar CT, 2007, J BIOL CHEM, V282, P17696, DOI 10.1074/jbc.M700209200; Rixon FJ, 2003, ADV PROTEIN CHEM, V64, P379; Rothenfusser S, 2005, J IMMUNOL, V175, P5260, DOI 10.4049/jimmunol.175.8.5260; Saito T, 2007, P NATL ACAD SCI USA, V104, P582, DOI 10.1073/pnas.0606699104; Saito T, 2007, CURR OPIN IMMUNOL, V19, P17, DOI 10.1016/j.coi.2006.11.003; Sun J, 2007, P NATL ACAD SCI USA, V104, P1354, DOI 10.1073/pnas.0610542104; Takahasi K, 2008, MOL CELL, V29, P428, DOI 10.1016/j.molcel.2007.11.028; tenOever BR, 2006, IMMUNITY, V24, P510, DOI 10.1016/j.immuni.2006.05.006; Underhill DM, 2004, CURR OPIN IMMUNOL, V16, P483, DOI 10.1016/j.coi.2004.05.012; Venkataraman T, 2007, J IMMUNOL, V178, P6444, DOI 10.4049/jimmunol.178.10.6444; Vilasco M, 2006, HEPATOLOGY, V44, P1635, DOI 10.1002/hep.21432; VITOUR D, 2007, SCI STKE, pPE20, DOI DOI 10.1126/STKE.38442007PE20; Yoneyama M, 2005, J IMMUNOL, V175, P2851, DOI 10.4049/jimmunol.175.5.2851; Yoneyama M, 2007, J BIOL CHEM, V282, P15315, DOI 10.1074/jbc.R700007200; Zhou ZH, 2003, ADV PROTEIN CHEM, V64, P93	35	64	66	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15825	15833		10.1074/jbc.M800542200	http://dx.doi.org/10.1074/jbc.M800542200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18411269	Green Published, hybrid			2022-12-25	WOS:000256332500040
J	Cun, SJ; Li, HY; Ge, RG; Lin, MCM; Sun, HZ				Cun, Shujian; Li, Hongyan; Ge, Ruiguang; Lin, Marie C. M.; Sun, Hongzhe			A histidine-rich and cysteine-rich metal-binding domain at the C terminus of heat shock protein A from Helicobacter pylori - Implication for nickel homeostasis and bismuth susceptibility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; UREASE; GENE; PURIFICATION; RESISTANCE; MATURATION; SEQUENCE; FEATURES; GROES; NIKR	HspA, a member of the GroES chaperonin family, is a small protein found in Helicobacter pylori with a unique histidine- and cysteine-rich domain at the C terminus. In this work, we overexpressed, purified, and characterized this protein both in vitro and in vivo. The apo form of the protein binds 2.10 +/- 0.07 Ni2+ or 1.98 +/- 0.08 Bi3+ ions/monomer with a dissociation constant (K-d) of 1.1 or 5.9 x 10(-19) mu M, respectively. Importantly, Ni2+ can reversibly bind to the protein, as the bound nickel can be released either in the presence of a chelating ligand, e.g. EDTA, or at an acidic pH (pH(1/2) 3.8 +/- 0.2). In contrast, Bi3+ binds almost irreversibly to the protein. Both gel filtration chromatography and native electrophoresis demonstrated that apo-HspA exists as a heptamer in solution. Unexpectedly, binding of Bi3+ to the protein altered its quaternary structure from a heptamer to a dimer, indicating that bismuth may interfere with the biological functions of HspA. When cultured in Ni2+-supplemented M9 minimal medium, Escherichia coli BL21(DE3) cells expressing wild-type HspA or the C-terminal deletion mutant clearly indicated that the C terminus might protect cells from high concentrations of external Ni2+. However, an opposite phenomenon was observed when the same E, coli hosts were grown in Bi3+-supplemented medium. HspA may therefore play a dual role: to facilitate nickel acquisition by donating Ni2+ to appropriate proteins in a nickel-deficient environment and to carry out detoxification via sequestration of excess nickel. Meanwhile, HspA can be a potential target of the bismuth anti-ulcer drug against H. pylori.	[Sun, Hongzhe] Univ Hong Kong, Dept Chem, Hong Kong, Hong Kong, Peoples R China; Univ Hong Kong, Open Lab Chem Biol, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Sun, HZ (corresponding author), Univ Hong Kong, Dept Chem, Pokfulam Rd, Hong Kong, Hong Kong, Peoples R China.	hsun@hku.hk	/D-3123-2009	/0000-0001-6697-6899				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; Bakkes PJ, 2005, P NATL ACAD SCI USA, V102, P8144, DOI 10.1073/pnas.0500048102; Battistoni A, 2001, J BIOL CHEM, V276, P30315, DOI 10.1074/jbc.M010527200; Bauerfeind P, 1997, GUT, V40, P25, DOI 10.1136/gut.40.1.25; Benoit SL, 2007, MICROBIOL-SGM, V153, P1474, DOI 10.1099/mic.0.2006/003228-0; Bonshtien AL, 2007, J BIOL CHEM, V282, P4463, DOI 10.1074/jbc.M606433200; Brayman TG, 1996, J BACTERIOL, V178, P5410, DOI 10.1128/jb.178.18.5410-5416.1996; Bulaj G, 1998, BIOCHEMISTRY-US, V37, P8965, DOI 10.1021/bi973101r; Burk RF, 2005, ANNU REV NUTR, V25, P215, DOI 10.1146/annurev.nutr.24.012003.132120; Contreras M, 2003, MOL MICROBIOL, V49, P947, DOI 10.1046/j.1365-2958.2003.03621.x; Covacci A, 1999, SCIENCE, V284, P1328, DOI 10.1126/science.284.5418.1328; de Castro E, 2006, NUCLEIC ACIDS RES, V34, pW362, DOI 10.1093/nar/gkl124; De Pina K, 1999, J BACTERIOL, V181, P670, DOI 10.1128/JB.181.2.670-674.1999; Domenico P, 1996, J ANTIMICROB CHEMOTH, V38, P1031, DOI 10.1093/jac/38.6.1031; Dosanjh NS, 2006, CURR OPIN CHEM BIOL, V10, P123, DOI 10.1016/j.cbpa.2006.02.011; DUNN BE, 1992, INFECT IMMUN, V60, P1946, DOI 10.1128/IAI.60.5.1946-1951.1992; Ge RG, 2006, BIOCHEM J, V393, P285, DOI 10.1042/BJ20051160; Ge RG, 2007, J BIOL INORG CHEM, V12, P831, DOI 10.1007/s00775-007-0237-7; Ge RG, 2007, ACCOUNTS CHEM RES, V40, P267, DOI 10.1021/ar600001b; Guerinot ML, 2000, BBA-BIOMEMBRANES, V1465, P190, DOI 10.1016/S0005-2736(00)00138-3; GUPTA RS, 1995, MOL MICROBIOL, V15, P1, DOI 10.1111/j.1365-2958.1995.tb02216.x; GUPTA RS, 1993, J MOL EVOL, V37, P573; Hendricks JK, 1997, J BACTERIOL, V179, P5892, DOI 10.1128/jb.179.18.5892-5902.1997; Henkel G, 2004, CHEM REV, V104, P801, DOI 10.1021/cr020620d; Hulo N, 2006, NUCLEIC ACIDS RES, V34, pD227, DOI 10.1093/nar/gkj063; KANDROR O, 1994, J BIOL CHEM, V269, P23575; Kansau I, 1996, MOL MICROBIOL, V22, P1013, DOI 10.1046/j.1365-2958.1996.01536.x; Kansau I, 1996, ALIMENT PHARM THERAP, V10, P51, DOI 10.1046/j.1365-2036.1996.22164005.x; LEE MH, 1993, PROTEIN SCI, V2, P1042, DOI 10.1002/pro.5560020617; Li HY, 1996, J BIOL CHEM, V271, P9483, DOI 10.1074/jbc.271.16.9483; Li W, 2003, J AM CHEM SOC, V125, P12408, DOI 10.1021/ja037019x; Maier RJ, 1996, FEMS MICROBIOL LETT, V141, P71; Maier RJ, 2007, BIOMETALS, V20, P655, DOI 10.1007/s10534-006-9061-8; MARSHALL BJ, 1984, LANCET, V1, P1311; Mehta N, 2003, J BACTERIOL, V185, P726, DOI 10.1128/JB.185.3.726-734.2003; Mobley HLT, 1999, HELICOBACTER, V4, P162, DOI 10.1046/j.1523-5378.1999.99286.x; MOBLEY HLT, 1995, MOL MICROBIOL, V16, P97, DOI 10.1111/j.1365-2958.1995.tb02395.x; Olson JW, 2002, SCIENCE, V298, P1788, DOI 10.1126/science.1077123; PARSONNET J, 1991, JNCI-J NATL CANCER I, V83, P640, DOI 10.1093/jnci/83.9.640; PETIT G, 1997, IUPAC STABILITY CONS; Phillips RH, 2000, HELICOBACTER, V5, P176, DOI 10.1046/j.1523-5378.2000.00028.x; Rice P, 2000, TRENDS GENET, V16, P276, DOI 10.1016/S0168-9525(00)02024-2; SARKAR B, 1987, PROG FOOD NUTR SCI, V11, P363; Schreiter ER, 2003, NAT STRUCT BIOL, V10, P794, DOI 10.1038/nsb985; Scott DR, 1998, GASTROENTEROLOGY, V114, P58, DOI 10.1016/S0016-5085(98)70633-X; Seshadri S, 2007, J BACTERIOL, V189, P4120, DOI 10.1128/JB.01245-06; Stibrany RT, 2005, INORG CHEM, V44, P8234, DOI 10.1021/ic050114h; SUERBAUM S, 1994, MOL MICROBIOL, V14, P959, DOI 10.1111/j.1365-2958.1994.tb01331.x; Suerbaum S, 2002, NEW ENGL J MED, V347, P1175, DOI 10.1056/NEJMra020542; Sun HZ, 1999, J BIOL CHEM, V274, P29094, DOI 10.1074/jbc.274.41.29094; Sun HZ, 2003, J INORG BIOCHEM, V94, P114, DOI 10.1016/S0162-0134(02)00649-9; Tang YC, 2006, CELL, V125, P903, DOI 10.1016/j.cell.2006.04.027; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; Wilkins MR, 1999, METH MOL B, V112, P531	55	87	92	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15142	15151		10.1074/jbc.M800591200	http://dx.doi.org/10.1074/jbc.M800591200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18364351	Green Published, hybrid			2022-12-25	WOS:000256232000030
J	Labalette, C; Nouet, Y; Sobczak-Thepot, J; Armengol, C; Levillayer, F; Gendron, MC; Renard, CA; Regnault, B; Chen, J; Buendia, MA; Wei, Y				Labalette, Charlotte; Nouet, Yann; Sobczak-Thepot, Joelle; Armengol, Carolina; Levillayer, Florence; Gendron, Marie-Claude; Renard, Claire-Angelique; Regnault, Beatrice; Chen, Ju; Buendia, Marie-Annick; Wei, Yu			The LIM-only protein FHL2 regulates cyclin D1 expression and cell proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTIONAL COACTIVATOR FHL2; BETA-CATENIN; INTERACTS; GENE; ACETYLATION; DEFICIENCY; ACTIVATION; MEMBRANE; NUCLEUS; BINDING	The LIM-only protein FHL2 acts as a transcriptional modulator that positively or negatively regulates multiple signaling pathways. We recently reported that FHL2 cooperates with CREB-binding protein/p300 in the activation of beta-catenin/T cell factor target gene cyclin D1. In this paper, we demonstrate that FHL2 is associated with the cyclin D I promoter at the T cell factor/CRE site, providing evidence that cyclin D1 is a direct target of FHL2. We show that deficiency of FHL2 greatly reduces the proliferative capacity of spontaneously immortalized mouse fibroblasts, which is associated with decreased expression of cyclin D1 and p16(INK4a), and hypophosphorylation of Rb. Reexpression of FHL2 in FHL2-null fibroblasts efficiently restores cyclin D1 levels and cell proliferative capacity, indicating that FHL2 is critical for cyclin D1 activation and cell growth. Moreover, ectopic cyclin D1 expression is sufficient to override growth inhibition of immortalized FHL2-null fibroblasts. Gene expression profiling revealed that FHL2 deficiency triggers a broad change of the cell cycle program that is associated with down-regulation of several G(1)/S and G(2)/M cyclins, E2F transcription factors, and DNA replication machinery, thus correlating with reduced cell proliferation. This change also involves down-regulation of the negative cell cycle regulators, particularly INK4 inhibitors, which could counteract the decreased expression of cyclins, allowing cells to grow. Our study illustrates that FHL2 can act on different aspects of the cell cycle program to finely regulate cell proliferation.	[Labalette, Charlotte; Nouet, Yann; Armengol, Carolina; Levillayer, Florence; Renard, Claire-Angelique; Buendia, Marie-Annick; Wei, Yu] Inst Pasteur, Unite Oncogenese & Virol Mol, F-75015 Paris, France; [Regnault, Beatrice] Inst Pasteur, PT Puce ADN, F-75015 Paris, France; [Labalette, Charlotte; Nouet, Yann; Armengol, Carolina; Levillayer, Florence; Renard, Claire-Angelique; Buendia, Marie-Annick; Wei, Yu] INSERM, U579, F-75015 Paris, France; [Sobczak-Thepot, Joelle] Univ Paris 06, CNRS, UMR7098, F-75005 Paris, France; [Gendron, Marie-Claude] Inst Jacques Monod, F-75005 Paris, France; [Chen, Ju] Univ Calif San Diego, Dept Med, Inst Mol Med, La Jolla, CA 92093 USA	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Institut National de la Sante et de la Recherche Medicale (Inserm); Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Cite; University of California System; University of California San Diego	Wei, Y (corresponding author), Inst Pasteur, Unite Oncogenese & Virol Mol, 28 Rue Dr Roux, F-75015 Paris, France.	ywei@pasteur.fr	Armengol, Carol/D-5253-2014; Sobczak, Joelle/HHZ-5610-2022; Chen, Ju/E-5579-2011; Wei, Yu/A-7289-2016	Armengol, Carol/0000-0002-3723-7760; REGNAULT, Beatrice/0000-0002-3914-1914; Sobczak, Joelle/0000-0001-7180-2789; ARMENGOL, CAROLINA/0000-0002-4690-4027				Chen DH, 2003, CANCER RES, V63, P6626; Chu PH, 2000, MOL CELL BIOL, V20, P7460, DOI 10.1128/MCB.20.20.7460-7462.2000; Cougot D, 2007, J BIOL CHEM, V282, P4277, DOI 10.1074/jbc.M606774200; Fimia GM, 2000, MOL CELL BIOL, V20, P8613, DOI 10.1128/MCB.20.22.8613-8622.2000; Frank SR, 2001, GENE DEV, V15, P2069, DOI 10.1101/gad.906601; Gabriel B, 2004, ANTICANCER RES, V24, P921; Gunther T, 2005, EMBO J, V24, P3049, DOI 10.1038/sj.emboj.7600773; Hervy M, 2006, CURR OPIN CELL BIOL, V18, P524, DOI 10.1016/j.ceb.2006.08.006; Johannessen M, 2006, CELL MOL LIFE SCI, V63, P268, DOI 10.1007/s00018-005-5438-z; Kong YF, 2001, CIRCULATION, V103, P2731; Labalette C, 2004, MOL CELL BIOL, V24, P10689, DOI 10.1128/MCB.24.24.10689-10702.2004; Levy L, 2004, MOL CELL BIOL, V24, P3404, DOI 10.1128/MCB.24.8.3404-3414.2004; Martin B, 2002, J CELL BIOL, V159, P113, DOI 10.1083/jcb.200202075; Martin BT, 2007, CELL CYCLE, V6, P1779, DOI 10.4161/cc.6.14.4448; McLoughlin P, 2002, J BIOL CHEM, V277, P37045, DOI 10.1074/jbc.M203336200; Morlon A, 2003, P NATL ACAD SCI USA, V100, P3977, DOI 10.1073/pnas.0735923100; Muller JM, 2000, EMBO J, V19, P359, DOI 10.1093/emboj/19.3.359; Muller JM, 2002, EMBO J, V21, P736, DOI 10.1093/emboj/21.4.736; Paul C, 2006, ONCOGENE, V25, P5475, DOI 10.1038/sj.onc.1209567; Philippar U, 2004, MOL CELL, V16, P867, DOI 10.1016/j.molcel.2004.11.039; Purcell NH, 2004, MOL CELL BIOL, V24, P1081, DOI 10.1128/MCB.24.3.1081-1095.2004; Scholl FA, 2000, J CELL BIOL, V151, P495, DOI 10.1083/jcb.151.3.495; Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Wei Y, 2003, J BIOL CHEM, V278, P5188, DOI 10.1074/jbc.M207216200; Wixler V, 2000, J BIOL CHEM, V275, P33669, DOI 10.1074/jbc.M002519200; Wixler V, 2007, J CELL BIOL, V177, P163, DOI 10.1083/jcb.200606043; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570; Yu QY, 2001, NATURE, V411, P1017, DOI 10.1038/35082500; Zindy F, 1997, ONCOGENE, V15, P203, DOI 10.1038/sj.onc.1201178	30	38	38	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15201	15208		10.1074/jbc.M800708200	http://dx.doi.org/10.1074/jbc.M800708200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18378678	Green Published, hybrid			2022-12-25	WOS:000256232000037
J	Levin, SE; Zhang, C; Kadlecek, TA; Shokat, KM; Weiss, A				Levin, Susan E.; Zhang, Chao; Kadlecek, Theresa A.; Shokat, Kevan M.; Weiss, Arthur			Inhibition of ZAP-70 kinase activity via an analog-sensitive allele blocks T cell receptor and CD28 superagonist signaling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; ANTIGEN RECEPTOR; PHOSPHOLIPASE C-GAMMA-1; FAMILY KINASES; ACTIVATION; GENE; EXPRESSION; SELECTION; MUTATION; COMPLEX	ZAP-70 is a cytoplasmic protein tyrosine kinase that is required for T cell antigen receptor (TCR) signaling. Both mice and humans deficient in ZAP-70 fail to develop functional T cells, thus demonstrating its necessity for T cell development and function. There is currently no highly specific, cell-permeable, small molecule inhibitor for ZAP-70; therefore, we generated a mutant ZAP-70 allele that retains kinase activity but is sensitive to inhibition by a mutant-specific inhibitor. We validated the chemical genetic inhibitor system in Jurkat T cell lines, where the inhibitor blocked ZAP-70-dependent TCR signaling in cells expressing the analog-sensitive allele. Interestingly, the inhibitor also ablated CD28 superagonist signaling, thereby demonstrating the utility of this system in dissecting the requirement for ZAP-70 in alternative mechanisms of T cell activation. Thus, we have developed the first specific chemical means of inhibiting ZAP-70 in cells, which serves as a valuable toot for studying the function of ZAP-70 in T cells.	[Levin, Susan E.; Weiss, Arthur] Univ Calif San Francisco, Dept Med, Biomed Sci Grad Program, San Francisco, CA 94143 USA; [Levin, Susan E.; Weiss, Arthur] Univ Calif San Francisco, Dept Microbiol, Biomed Sci Grad Program, San Francisco, CA 94143 USA; [Levin, Susan E.; Weiss, Arthur] Univ Calif San Francisco, Dept Immunol, Biomed Sci Grad Program, San Francisco, CA 94143 USA; [Weiss, Arthur] Univ Calif San Francisco, Rosalind Russell Med Res Ctr Arthritis, San Francisco, CA 94143 USA; [Zhang, Chao; Shokat, Kevan M.] Univ Calif San Francisco, Dept Cell & Mol Pharmacol, San Francisco, CA 94143 USA; [Levin, Susan E.; Zhang, Chao; Kadlecek, Theresa A.; Shokat, Kevan M.; Weiss, Arthur] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco	Weiss, A (corresponding author), 513 Parnassus Ave,Box 0795, San Francisco, CA 94143 USA.	aweiss@medicine.ucsf.edu		Kadlecek, Theresa/0000-0002-1020-8169	Howard Hughes Medical Institute Funding Source: Medline	Howard Hughes Medical Institute(Howard Hughes Medical Institute)		ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Berg LJ, 2005, ANNU REV IMMUNOL, V23, P549, DOI 10.1146/annurev.immunol.22.012703.104743; Bishop AC, 2000, NATURE, V407, P395, DOI 10.1038/35030148; Bishop AC, 1999, J AM CHEM SOC, V121, P627, DOI 10.1021/ja983267v; Bogin Y, 2007, P NATL ACAD SCI USA, V104, P6638, DOI 10.1073/pnas.0609771104; Brdicka T, 2002, J EXP MED, V196, P1617, DOI 10.1084/jem.20021405; Brdicka T, 2005, MOL CELL BIOL, V25, P4924, DOI 10.1128/MCB.25.12.4924-4933.2005; Burkard ME, 2007, P NATL ACAD SCI USA, V104, P4383, DOI 10.1073/pnas.0701140104; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; Cohen P, 2002, NAT REV DRUG DISCOV, V1, P309, DOI 10.1038/nrd773; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; Deindl S, 2007, CELL, V129, P735, DOI 10.1016/j.cell.2007.03.039; Dennehy KM, 2007, J IMMUNOL, V178, P1363, DOI 10.4049/jimmunol.178.3.1363; Dennehy KM, 2003, INT IMMUNOL, V15, P655, DOI 10.1093/intimm/dxg063; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; GELFAND EW, 1995, J EXP MED, V182, P1057, DOI 10.1084/jem.182.4.1057; Goldberg DR, 2003, J MED CHEM, V46, P1337, DOI 10.1021/jm020446l; Griffith CE, 1998, J BIOL CHEM, V273, P10771, DOI 10.1074/jbc.273.17.10771; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; Jin L, 2004, J BIOL CHEM, V279, P42818, DOI 10.1074/jbc.M407096200; Knight ZA, 2005, CHEM BIOL, V12, P621, DOI 10.1016/j.chembiol.2005.04.011; Koretzky GA, 2006, NAT REV IMMUNOL, V6, P67, DOI 10.1038/nri1750; Lin J, 2001, J BIOL CHEM, V276, P29588, DOI 10.1074/jbc.M102221200; MARTH JD, 1985, CELL, V43, P393, DOI 10.1016/0092-8674(85)90169-2; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; Nishikawa K, 2000, MOL CELL, V6, P969, DOI 10.1016/S1097-2765(05)00085-7; Poulin B, 2005, P NATL ACAD SCI USA, V102, P4276, DOI 10.1073/pnas.0409590102; Rassenti LZ, 2004, NEW ENGL J MED, V351, P893, DOI 10.1056/NEJMoa040857; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; Roose JP, 2007, MOL CELL BIOL, V27, P2732, DOI 10.1128/MCB.01882-06; Rosenwald A, 2001, J EXP MED, V194, P1639, DOI 10.1084/jem.194.11.1639; Sakaguchi N, 2003, NATURE, V426, P454, DOI 10.1038/nature02119; Salvador JM, 2005, NAT IMMUNOL, V6, P390, DOI 10.1038/ni1177; Shan XC, 2001, MOL CELL BIOL, V21, P7137, DOI 10.1128/MCB.21.21.7137-7149.2001; SIEH M, 1994, MOL CELL BIOL, V14, P4435, DOI 10.1128/MCB.14.7.4435; Suntharalingam G, 2006, NEW ENGL J MED, V355, P1018, DOI 10.1056/NEJMoa063842; Tomlinson MG, 2004, MOL CELL BIOL, V24, P2455, DOI 10.1128/MCB.24.6.2455-2466.2004; VANOERS NSC, 1995, J EXP MED, V182, P1585, DOI 10.1084/jem.182.5.1585; Wardenburg JB, 1996, J BIOL CHEM, V271, P19641, DOI 10.1074/jbc.271.33.19641; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; Williams BL, 1999, EMBO J, V18, P1832, DOI 10.1093/emboj/18.7.1832; Williams BL, 1998, MOL CELL BIOL, V18, P1388, DOI 10.1128/MCB.18.3.1388; Wong WSF, 2005, CURR OPIN PHARMACOL, V5, P264, DOI 10.1016/j.coph.2005.01.009; Zhang C, 2005, NAT METHODS, V2, P435, DOI 10.1038/NMETH764; Zhang WG, 2000, J BIOL CHEM, V275, P23355, DOI 10.1074/jbc.M000404200; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhao QH, 1999, MOL CELL BIOL, V19, P948	48	42	43	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15419	15430		10.1074/jbc.M709000200	http://dx.doi.org/10.1074/jbc.M709000200			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18378687	hybrid, Green Published			2022-12-25	WOS:000256232000060
J	Numata, T; Okada, Y				Numata, Tomohiro; Okada, Yasunobu			Proton conductivity through the human TRPM7 channel and its molecular determinants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ION CHANNELS; CAPSAICIN RECEPTOR; PH; PERMEABILITY; SENSITIVITY; HOMEOSTASIS; CURRENTS; BARRIER; PROTEIN; CELLS	TRPM7 is a divalent cation-permeable channel that is ubiquitously expressed. Recently, mouse TRPM7 has been shown to be sensitive to, and even permeable to, protons when heterologously expressed. Here we have demonstrated that human TRPM7 expressed either heterologously or endogenously also exhibits proton conductivity. The gene silencing of TRPM7 by small interfering RNA suppressed H+ currents in human cervical epithelial HeLa cells. In HEK293T cells transfected with human TRPM7, the inward proton conductance was suppressed by extracellular Mg2+ or Ca2+ with IC50 values of 0.5 and 1.9 mm, respectively. Anomalous mole fraction behavior of H+ currents in the presence of Mg2+ or Ca2+ indicated that these divalent cations compete with protons for binding sites. Systematic mutation of negatively charged amino acid residues within the putative pore-forming region of human TRPM7 into the neutral amino acid alanine was tested. E1047A resulted in non-functional channels, and D1054A abolished proton conductance, whereas E1052A and D1059A only partially reduced proton conductivity. Thus, it is concluded that Asp-1054 is an essential determinant of the proton conductivity, whereas Glu-1047 might be required for channel formation, and the remaining negatively charged amino acids in the pore region (Glu-1052 and Asp- 1059) may play a facilitating role in the proton conductivity of human TRPM7. It is suggested that proton conductivity of endogenous human TRPM7 plays a role in physiologically/ pathologically acidic situations.	[Numata, Tomohiro; Okada, Yasunobu] Natl Inst Physiol Sci, Dept Cell Physiol, Okazaki, Aichi 4448585, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)	Okada, Y (corresponding author), Natl Inst Physiol Sci, Dept Cell Physiol, Okazaki, Aichi 4448585, Japan.	okada@nips.ac.jp	Numata, Tomohiro/AAW-2453-2020; Numata, Tomohiro/AAC-2330-2021	Numata, Tomohiro/0000-0002-5719-4884; Numata, Tomohiro/0000-0002-5719-4884				Aarts M, 2003, CELL, V115, P863, DOI 10.1016/S0092-8674(03)01017-1; ALLEN A, 1993, PHYSIOL REV, V73, P823, DOI 10.1152/physrev.1993.73.4.823; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; CHESLER M, 1992, TRENDS NEUROSCI, V15, P396, DOI 10.1016/0166-2236(92)90191-A; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Clark K, 2006, EMBO J, V25, P290, DOI 10.1038/sj.emboj.7600931; Decoursey TE, 2003, PHYSIOL REV, V83, P475, DOI 10.1152/physrev.00028.2002; Elias PM, 2007, SEMIN IMMUNOPATHOL, V29, P3, DOI 10.1007/s00281-007-0060-9; Elizondo MR, 2005, CURR BIOL, V15, P667, DOI 10.1016/j.cub.2005.02.050; Garcia-Closas M, 1999, AM J OBSTET GYNECOL, V180, P1060, DOI 10.1016/S0002-9378(99)70595-8; GILBERTSON TA, 1992, J GEN PHYSIOL, V100, P803, DOI 10.1085/jgp.100.5.803; GRINSTEIN S, 1991, CLIN BIOCHEM, V24, P241, DOI 10.1016/0009-9120(91)80014-T; Hanano T, 2004, J PHARMACOL SCI, V95, P403, DOI 10.1254/jphs.FP0040273; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; He Y, 2005, CIRC RES, V96, P207, DOI 10.1161/01.RES.0000152967.88472.3e; HILLE B, 2003, ION CHANNELS EXCITAB; Holzer P, 2003, CURR OPIN PHARMACOL, V3, P618, DOI 10.1016/j.coph.2003.06.008; JACOBUS WE, 1977, NATURE, V265, P756, DOI 10.1038/265756a0; Jiang JM, 2005, J GEN PHYSIOL, V126, P137, DOI 10.1085/jgp.200409185; Kim BJ, 2005, GASTROENTEROLOGY, V129, P1504, DOI 10.1053/j.gastro.2005.08.016; Kim D, 2003, TRENDS PHARMACOL SCI, V24, P648, DOI 10.1016/j.tips.2003.10.008; Krapivinsky G, 2006, NEURON, V52, P485, DOI 10.1016/j.neuron.2006.09.033; LANG W R, 1955, Obstet Gynecol Surv, V10, P546; Lardner A, 2001, J LEUKOCYTE BIOL, V69, P522; Lesage F, 2000, AM J PHYSIOL-RENAL, V279, pF793, DOI 10.1152/ajprenal.2000.279.5.F793; Li MJ, 2007, J BIOL CHEM, V282, P25817, DOI 10.1074/jbc.M608972200; Liu D, 2005, J BIOL CHEM, V280, P20691, DOI 10.1074/jbc.M414072200; Minke B, 2002, PHYSIOL REV, V82, P429, DOI 10.1152/physrev.00001.2002; Monteilh-Zoller MK, 2003, J GEN PHYSIOL, V121, P49, DOI 10.1085/jgp.20028740; Montell C, 2002, CELL, V108, P595, DOI 10.1016/S0092-8674(02)00670-0; Montell C, 2001, Sci STKE, V2001, pre1, DOI 10.1126/stke.2001.90.re1; Montell Craig, 2005, Sci STKE, V2005, pre3, DOI 10.1126/stke.2722005re3; MOZHAYEVA GN, 1983, PFLUG ARCH EUR J PHY, V396, P163, DOI 10.1007/BF00615521; Nadler MJS, 2001, NATURE, V411, P590, DOI 10.1038/35079092; NEDERGAARD M, 1991, AM J PHYSIOL, V260, pR581, DOI 10.1152/ajpregu.1991.260.3.R581; Numata T, 2007, AM J PHYSIOL-CELL PH, V292, pC460, DOI 10.1152/ajpcell.00367.2006; Numata T, 2007, CELL PHYSIOL BIOCHEM, V19, P1, DOI 10.1159/000099187; Ramsey IS, 2006, NATURE, V440, P1213, DOI 10.1038/nature04700; REHNCRONA S, 1985, ANN EMERG MED, V14, P770, DOI 10.1016/S0196-0644(85)80055-X; Revici E., 1949, B I APPL BIOL, V1, P21; Runnels LW, 2001, SCIENCE, V291, P1043, DOI 10.1126/science.1058519; Sasaki M, 2006, SCIENCE, V312, P589, DOI 10.1126/science.1122352; Schmid-Wendtner MH, 2006, SKIN PHARMACOL PHYS, V19, P296, DOI 10.1159/000094670; Schmitz C, 2003, CELL, V114, P191, DOI 10.1016/S0092-8674(03)00556-7; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; Soyombo AA, 2006, J BIOL CHEM, V281, P7294, DOI 10.1074/jbc.M508211200; Starace DM, 2004, NATURE, V427, P548, DOI 10.1038/nature02270; Su D, 2006, J BIOL CHEM, V281, P39852, DOI 10.1074/jbc.M606543200; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; TOMLINSON FH, 1993, STROKE, V24, P2030, DOI 10.1161/01.STR.24.12.2030; Topala CN, 2007, CELL CALCIUM, V41, P513, DOI 10.1016/j.ceca.2006.10.003; Waldmann R, 1999, ANN NY ACAD SCI, V868, P67, DOI 10.1111/j.1749-6632.1999.tb11274.x; Wemmie JA, 2006, TRENDS NEUROSCI, V29, P578, DOI 10.1016/j.tins.2006.06.014; Yeh BI, 2003, J BIOL CHEM, V278, P51044, DOI 10.1074/jbc.M306326200	54	27	27	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15097	15103		10.1074/jbc.M709261200	http://dx.doi.org/10.1074/jbc.M709261200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18390554	Green Published, hybrid			2022-12-25	WOS:000256232000024
J	Li, W; Liu, Y; Mukhtar, MM; Gong, R; Pan, Y; Rasool, ST; Gao, YC; Kang, L; Hao, Q; Peng, GQ; Chen, YN; Chen, X; Wu, JG; Zhu, Y				Li, Wei; Liu, Yan; Mukhtar, Muhammad Mahmood; Gong, Rui; Pan, Ying; Rasool, Sahibzada T.; Gao, Yecheng; Kang, Lei; Hao, Qian; Peng, Guiqing; Chen, Yanni; Chen, Xin; Wu, Jianguo; Zhu, Ying			Activation of Interleukin-32 Pro-Inflammatory Pathway in Response to Influenza A Virus Infection	PLOS ONE			English	Article								Background: Interleukin (IL)-32 is a recently described pro-inflammatory cytokine that has been reported to be induced by bacteria treatment in culture cells. Little is known about IL-32 production by exogenous pathogens infection in human individuals. Methods and Findings: In this study, we found that IL-32 level was increased by 58.2% in the serum samples from a cohort of 108 patients infected by influenza A virus comparing to that of 115 healthy individuals. Another pro-inflammatory factor cyclooxygenase (COX)-2-associated prostaglandin E2 was also upregulated by 2.7-fold. Expression of IL-32 in influenza A virus infected A549 human lung epithelial cells was blocked by either selective COX-2 inhibitor NS398 or Aspirin, a known anti-inflammatory drug, indicating IL-32 was induced through COX-2 in the inflammatory cascade. Interestingly, we found that COX-2-associate PGE2 production activated by influenza virus infection was significantly suppressed by over-expression of IL-32 but increased by IL-32-specific siRNA, suggesting there was a feedback mechanism between IL-32 and COX-2. Conclusions: IL-32 is induced by influenza A virus infection via COX- 2 in the inflammatory cascade. Our results provide that IL-32 is a potential target for anti-inflammatory medicine screening.	[Li, Wei; Liu, Yan; Mukhtar, Muhammad Mahmood; Gong, Rui; Pan, Ying; Rasool, Sahibzada T.; Gao, Yecheng; Kang, Lei; Hao, Qian; Peng, Guiqing; Chen, Yanni; Chen, Xin; Wu, Jianguo; Zhu, Ying] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China	Wuhan University	Li, W (corresponding author), Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Peoples R China.	wu9988@vip.sina.com; yingzhu@whu.edu.cn	Rasool, Sahibzada/M-4508-2016	Rasool, Sahibzada/0000-0002-6115-8499; Wu, Jianguo/0000-0002-8326-2895	National Natural Science Foundation of China [30570066]; Major State Basic Research Development Program of China [2007CB512803, 2005CB523010]; National High-Tech Research and Development Program of China [2006AA02A306]; Hubei Provincial Science Foundation for Distinguished Youth Scholar; Ph.D. Program Foundation of Ministry of Education of China [20050486012]	National Natural Science Foundation of China(National Natural Science Foundation of China (NSFC)); Major State Basic Research Development Program of China(National Basic Research Program of China); National High-Tech Research and Development Program of China(National High Technology Research and Development Program of China); Hubei Provincial Science Foundation for Distinguished Youth Scholar; Ph.D. Program Foundation of Ministry of Education of China(Ministry of Education, China)	This work was supported by research grants from the National Natural Science Foundation of China (No. 30570066), the Major State Basic Research Development Program of China (973 project No. 2007CB512803 and No. 2005CB523010), the National High-Tech Research and Development Program of China (863 project No. 2006AA02A306), Hubei Provincial Science Foundation for Distinguished Youth Scholar to Zhu Y, and the Ph.D. Program Foundation of Ministry of Education of China (No. 20050486012). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Carey MA, 2005, J IMMUNOL, V175, P6878, DOI 10.4049/jimmunol.175.10.6878; Ciencewicki J, 2006, AM J PHYSIOL-LUNG C, V290, pL1154, DOI 10.1152/ajplung.00318.2005; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; Coruzzi Gabriella, 2007, Acta Biomed, V78, P96; Deng WG, 2003, J BIOL CHEM, V278, P4770, DOI 10.1074/jbc.M209286200; Eliopoulos AG, 1999, J BIOL CHEM, V274, P16085, DOI 10.1074/jbc.274.23.16085; Gilroy DW, 2001, AM J PHYSIOL-CELL PH, V281, pC188, DOI 10.1152/ajpcell.2001.281.1.C188; Goodwin DC, 1999, FASEB J, V13, P1121, DOI 10.1096/fasebj.13.10.1121; Guillot L, 2005, J BIOL CHEM, V280, P5571, DOI 10.1074/jbc.M410592200; Heitmeier MR, 1998, J BIOL CHEM, V273, P15301, DOI 10.1074/jbc.273.24.15301; Hinz B, 2002, J PHARMACOL EXP THER, V300, P367, DOI 10.1124/jpet.300.2.367; Iniguez MA, 2000, J BIOL CHEM, V275, P23627, DOI 10.1074/jbc.M001381200; Jacobs BL, 1996, VIROLOGY, V219, P339, DOI 10.1006/viro.1996.0259; Joosten LAB, 2006, P NATL ACAD SCI USA, V103, P3298, DOI 10.1073/pnas.0511233103; Kim SH, 2005, IMMUNITY, V22, P131, DOI 10.1016/j.immuni.2004.12.003; Kundu M, 2006, PLOS MED, V3, P1210, DOI 10.1371/journal.pmed.0030274; Kutchera W, 1996, P NATL ACAD SCI USA, V93, P4816, DOI 10.1073/pnas.93.10.4816; Lara-Pezzi E, 2002, J CLIN INVEST, V110, P1831, DOI 10.1172/JCI200215887; Le Goffic R, 2007, J IMMUNOL, V178, P3368, DOI 10.4049/jimmunol.178.6.3368; Liu M, 2007, FASEB J, V21, P1586, DOI 10.1096/fj.06-6589com; Maggi LB, 2000, EMBO J, V19, P3630, DOI 10.1093/emboj/19.14.3630; Marnett LJ, 1999, J BIOL CHEM, V274, P22903, DOI 10.1074/jbc.274.33.22903; Mizumura K, 2003, CLIN EXP ALLERGY, V33, P1244, DOI 10.1046/j.1365-2222.2003.01750.x; Naesdall J, 2006, DRUG SAFETY, V29, P119; Nath A, 1999, J BIOL CHEM, V274, P17098, DOI 10.1074/jbc.274.24.17098; Netea MG, 2005, P NATL ACAD SCI USA, V102, P16309, DOI 10.1073/pnas.0508237102; Netea MG, 2006, PLOS MED, V3, P1310, DOI 10.1371/journal.pmed.0030277; Novick D, 2006, P NATL ACAD SCI USA, V103, P3316, DOI 10.1073/pnas.0511206103; SAMUELSSON B, 1987, DRUGS, V33, P2, DOI 10.2165/00003495-198700331-00003; Shoda H, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar2074; Steer SA, 2003, J IMMUNOL, V170, P1070, DOI 10.4049/jimmunol.170.2.1070; Steer SA, 2006, J IMMUNOL, V177, P3413, DOI 10.4049/jimmunol.177.5.3413; Subbaramaiah K, 1996, CANCER RES, V56, P4424; Traynor TR, 2004, LIFE SCI, V74, P2563, DOI 10.1016/j.lfs.2003.10.010; VANE JR, 1994, P NATL ACAD SCI USA, V91, P2046, DOI 10.1073/pnas.91.6.2046; White William B, 2007, Subcell Biochem, V42, P145; Wu Kenneth K, 2003, Semin Vasc Med, V3, P107; Yan XH, 2006, INT J BIOCHEM CELL B, V38, P1417, DOI 10.1016/j.biocel.2006.02.003; Zhu Y, 2002, J BIOL CHEM, V277, P6923, DOI 10.1074/jbc.M108075200	39	84	93	0	7	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 16	2008	3	4							e1985	10.1371/journal.pone.0001985	http://dx.doi.org/10.1371/journal.pone.0001985			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	371XZ	18414668	Green Submitted, Green Published, gold			2022-12-25	WOS:000260867300017
J	Novikova, SI; He, F; Bai, J; Cutrufello, NJ; Lidow, MS; Undieh, AS				Novikova, Svetlana I.; He, Fang; Bai, Jie; Cutrufello, Nicholas J.; Lidow, Michael S.; Undieh, Ashiwel S.			Maternal Cocaine Administration in Mice Alters DNA Methylation and Gene Expression in Hippocampal Neurons of Neonatal and Prepubertal Offspring	PLOS ONE			English	Article							X-CHROMOSOME INACTIVATION; EMBRYONIC STEM-CELLS; CPG ISLANDS; IMPRINTED GENES; IN-UTERO; METHYLTRANSFERASE GENE; MAMMALIAN DEVELOPMENT; CHROMATIN-STRUCTURE; CEREBRAL-CORTEX; NERVOUS-SYSTEM	Previous studies documented significant behavioral changes in the offspring of cocaine-exposed mothers. We now explore the hypothesis that maternal cocaine exposure could alter the fetal epigenetic machinery sufficiently to cause lasting neurochemical and functional changes in the offspring. Pregnant CD1 mice were administered either saline or 20 mg/kg cocaine twice daily on gestational days 8-19. Male pups from each of ten litters of the cocaine and control groups were analyzed at 3 (P3) or 30 (P30) days postnatum. Global DNA methylation, methylated DNA immunoprecipitation followed by CGI(2) microarray profiling and bisulfite sequencing, as well as quantitative real-time RT-PCR gene expression analysis, were evaluated in hippocampal pyramidal neurons excised by laser capture microdissection. Following maternal cocaine exposure, global DNA methylation was significantly decreased at P3 and increased at P30. Among the 492 CGIs whose methylation was significantly altered by cocaine at P3, 34% were hypermethylated while 66% were hypomethylated. Several of these CGIs contained promoter regions for genes implicated in crucial cellular functions. Endogenous expression of selected genes linked to the abnormally methylated CGIs was correspondingly decreased or increased by as much as 4-19-fold. By P30, some of the cocaine-associated effects at P3 endured, reversed to opposite directions, or disappeared. Further, additional sets of abnormally methylated targets emerged at P30 that were not observed at P3. Taken together, these observations indicate that maternal cocaine exposure during the second and third trimesters of gestation could produce potentially profound structural and functional modifications in the epigenomic programs of neonatal and prepubertal mice.	[Novikova, Svetlana I.; He, Fang; Bai, Jie; Cutrufello, Nicholas J.; Lidow, Michael S.] Univ Maryland, Dept Biomed Sci, Lab Neurogenom & Prote, Baltimore, MD 21201 USA; [Novikova, Svetlana I.; Undieh, Ashiwel S.] Thomas Jefferson Univ, Sch Pharm, Dept Pharmaceut Sci, Lab Integrat Neuropharmacol, Philadelphia, PA USA	University System of Maryland; University of Maryland Baltimore; Jefferson University	Undieh, AS (corresponding author), Univ Maryland, Dept Biomed Sci, Lab Neurogenom & Prote, Baltimore, MD 21201 USA.	ashiwel.undieh@jefferson.edu	Undieh, Ashiwel/ABG-4004-2020	Undieh, Ashiwel/0000-0003-1823-5230	United States National Institutes of Health/National Institute on Drug Abuse [R01DA08057, R01DA17614]; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA017614, R01DA008057] Funding Source: NIH RePORTER	United States National Institutes of Health/National Institute on Drug Abuse(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)	Supported by United States National Institutes of Health/National Institute on Drug Abuse Grants R01DA08057 and R01DA17614.	ANTEQUERA F, 1993, P NATL ACAD SCI USA, V90, P11995, DOI 10.1073/pnas.90.24.11995; Antequera F, 1999, CURR BIOL, V9, pR661, DOI 10.1016/S0960-9822(99)80418-7; ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; Attwood JT, 2002, CELL MOL LIFE SCI, V59, P241, DOI 10.1007/s00018-002-8420-z; Baraban SC, 1999, DEV BRAIN RES, V117, P213, DOI 10.1016/S0165-3806(99)00106-6; Baraban SC, 1997, J NEUROPHYSIOL, V77, P126, DOI 10.1152/jn.1997.77.1.126; Bashkatova V, 2005, NEUROREPORT, V16, P1217, DOI 10.1097/00001756-200508010-00017; BECK S, 2003, EPIGENOME MOL HIDE S; Bird A, 2002, GENE DEV, V16, P6, DOI 10.1101/gad.947102; Bonthius DJ, 2004, BRAIN RES PROTOC, V14, P45, DOI 10.1016/j.brainresprot.2004.09.003; Bosc C, 2003, BIOCHEMISTRY-US, V42, P12125, DOI 10.1021/bi0352163; Brown CJ, 2001, SEMIN REPROD MED, V19, P125, DOI 10.1055/s-2001-15392; Capo-chichi CD, 2005, DEV BIOL, V286, P574, DOI 10.1016/j.ydbio.2005.07.037; Chang SC, 2006, FRONT BIOSCI-LANDMRK, V11, P852, DOI 10.2741/1842; Charron F, 2001, GENE DEV, V15, P2702, DOI 10.1101/gad.915701; Cone-Wesson B, 2005, J COMMUN DISORD, V38, P279, DOI 10.1016/j.jcomdis.2005.02.004; Costello JF, 2001, J MED GENET, V38, P285, DOI 10.1136/jmg.38.5.285; Crandall JE, 2004, CEREB CORTEX, V14, P665, DOI 10.1093/cercor/bhh027; Cross SH, 1997, GENOMICS, V40, P454, DOI 10.1006/geno.1996.4598; Cunliffe VT, 2003, GENE, V305, P141, DOI 10.1016/S0378-1119(03)00386-X; Curradi M, 2002, MOL CELL BIOL, V22, P3157, DOI 10.1128/MCB.22.9.3157-3173.2002; Doerfler W, 2005, BIOCHEMISTRY-MOSCOW+, V70, P505, DOI 10.1007/s10541-005-0145-9; Ehrlich M, 2003, J CELL BIOCHEM, V88, P899, DOI 10.1002/jcb.10464; Faherty CJ, 2003, DEV BRAIN RES, V141, P55, DOI 10.1016/S0165-3806(02)00642-9; Fan GP, 2001, ADV EXP MED BIOL, V499, P195; Fernandez-Gonzalez R, 2004, P NATL ACAD SCI USA, V101, P5880, DOI 10.1073/pnas.0308560101; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; GARMAISE D, 2005, HIV AIDS POLICY LAW, V10, P16; GARRO AJ, 1991, ALCOHOL CLIN EXP RES, V15, P395, DOI 10.1111/j.1530-0277.1991.tb00536.x; Geiduschek EP, 2001, J MOL BIOL, V310, P1, DOI 10.1006/jmbi.2001.4732; GOTO K, 1994, DIFFERENTIATION, V56, P39, DOI 10.1046/j.1432-0436.1994.56120039.x; Goto T, 1998, MICROBIOL MOL BIOL R, V62, P362, DOI 10.1128/MMBR.62.2.362-378.1998; Guenatri M, 2004, J CELL BIOL, V166, P493, DOI 10.1083/jcb.200403109; Guerrero-Bosagna C, 2005, EVOL DEV, V7, P341, DOI 10.1111/j.1525-142X.2005.05033.x; Harvey JA, 2004, NEUROSCI BIOBEHAV R, V27, P751, DOI 10.1016/j.neubiorev.2003.11.006; Hashimshony T, 2003, NAT GENET, V34, P187, DOI 10.1038/ng1158; He F, 2006, NEUROTOXICOL TERATOL, V28, P198, DOI 10.1016/j.ntt.2005.12.003; Heard E, 2004, CURR OPIN CELL BIOL, V16, P247, DOI 10.1016/j.ceb.2004.03.005; Holliday R, 2002, METHODS, V27, P179, DOI 10.1016/S1046-2023(02)00072-5; Hope VD, 2005, ADDICTION, V100, P1701, DOI 10.1111/j.1360-0443.2005.01244.x; Hsieh J, 2004, CURR OPIN GENET DEV, V14, P461, DOI 10.1016/j.gde.2004.07.006; Hu JF, 1998, MOL ENDOCRINOL, V12, P220, DOI 10.1210/me.12.2.220; JOHANSON CE, 1989, PHARMACOL REV, V41, P3; Jones PA, 2001, SCIENCE, V293, P1068, DOI 10.1126/science.1063852; Ke ZJ, 2003, J NEUROPATH EXP NEUR, V62, P195, DOI 10.1093/jnen/62.2.195; Keller RW, 2000, ANN NY ACAD SCI, V909, P217; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; Li K, 2002, J BIOL CHEM, V277, P47052, DOI 10.1074/jbc.M205374200; Lidow MS, 2003, DEV BRAIN RES, V147, P23, DOI 10.1016/j.devbrainres.2003.09.001; Little JZ, 1998, DEV BRAIN RES, V110, P115, DOI 10.1016/S0165-3806(98)00100-X; Ma S, 2003, MOL CELL BIOL, V23, P6936, DOI 10.1128/MCB.23.19.6936-6943.2003; March JC, 2006, EUR ADDICT RES, V12, P33, DOI 10.1159/000088581; McCabe MT, 2005, CANCER RES, V65, P3624, DOI 10.1158/0008-5472.CAN-04-2158; McLachlan JA, 2001, TOXICOL LETT, V120, P161, DOI 10.1016/S0378-4274(01)00295-8; Meaney Michael J, 2005, Dialogues Clin Neurosci, V7, P103; Meehan RR, 2003, SEMIN CELL DEV BIOL, V14, P53, DOI 10.1016/S1084-9521(02)00137-4; Millar CB, 2002, SCIENCE, V297, P403, DOI 10.1126/science.1073354; MONK M, 1987, NATURE, V328, P203, DOI 10.1038/328203a0; Nakahira E, 2005, J COMP NEUROL, V483, P329, DOI 10.1002/cne.20441; Nakai D, 2004, AGING CELL, V3, P273, DOI 10.1111/j.1474-9728.2004.00116.x; Nakai D, 2001, BIOCHEM BIOPH RES CO, V289, P463, DOI 10.1006/bbrc.2001.5977; Niculescu MD, 2004, J NEUROCHEM, V89, P1252, DOI 10.1111/j.1471-4159.2004.02414.x; Novikova SI, 2005, SYNAPSE, V56, P105, DOI 10.1002/syn.20134; Novikova SI, 2005, NEUROTOXICOL TERATOL, V27, P3, DOI 10.1016/j.ntt.2004.08.004; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Paoloni-Giacobino A, 2006, CYTOGENET GENOME RES, V113, P116, DOI 10.1159/000090822; Paul S, 2003, CELL MOL LIFE SCI, V60, P2465, DOI 10.1007/s00018-003-3123-7; Peirson SN, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng073; RAZIN A, 1984, P NATL ACAD SCI-BIOL, V81, P2275, DOI 10.1073/pnas.81.8.2275; Reed MG, 2001, J MICROSC-OXFORD, V202, P473, DOI 10.1046/j.1365-2818.2001.00830.x; Reik W, 2003, THERIOGENOLOGY, V59, P21, DOI 10.1016/S0093-691X(02)01269-4; Reinhart B, 2002, MOL CELL BIOL, V22, P2089, DOI 10.1128/MCB.22.7.2089-2098.2002; Reinhart B, 2006, MOL CELL BIOL, V26, P8347, DOI 10.1128/MCB.00981-06; Reinoso BS, 1996, J NEUROSCI RES, V43, P439, DOI 10.1002/(SICI)1097-4547(19960215)43:4<439::AID-JNR5>3.0.CO;2-G; Ren JQ, 2004, INT J DEV NEUROSCI, V22, P309, DOI 10.1016/j.ijdevneu.2004.05.003; REZNIKOV KY, 1991, ADV ANAT EMBRYOL CEL, V122, P1; Rubinfeld H, 2005, MOL BIOTECHNOL, V31, P151, DOI 10.1385/MB:31:2:151; Schiller Cassandra, 2005, Pediatr Nurs, V31, P427; Seeburg DP, 2005, ONCOGENE, V24, P292, DOI 10.1038/sj.onc.1208277; Shimozaki K, 2005, J NEUROCHEM, V93, P432, DOI 10.1111/j.1471-4159.2005.03031.x; Siegfried Z, 1999, NAT GENET, V22, P203, DOI 10.1038/9727; Sjoholt G, 2004, MOL PSYCHIATR, V9, P621, DOI 10.1038/sj.mp.4001460; Smit AFA, 1996, CURR OPIN GENET DEV, V6, P743, DOI 10.1016/S0959-437X(96)80030-X; Smith SS, 2000, J MOL BIOL, V302, P1, DOI 10.1006/jmbi.2000.4046; Soga T, 2002, BBA-GENE STRUCT EXPR, V1579, P173, DOI 10.1016/S0167-4781(02)00546-8; *SUBST AB MENT HLT, 2005, NAT SURV DRUG US HLT, P1; Sugden PH, 2003, J MOL CELL CARDIOL, V35, P871, DOI 10.1016/S0022-2828(03)00153-6; Teter B, 1996, GLIA, V17, P195; Thomassin H, 2001, EMBO J, V20, P1974, DOI 10.1093/emboj/20.8.1974; Tichopad A, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng122; Vercelli D, 2004, J ALLERGY CLIN IMMUN, V113, P381, DOI 10.1016/j.jaci.2004.01.752; Vickaryous N, 2005, REPROD FERT DEVELOP, V17, P335, DOI 10.1071/RD04133; Warnecke PM, 1997, NUCLEIC ACIDS RES, V25, P4422, DOI 10.1093/nar/25.21.4422; Waterland RA, 2004, NUTRITION, V20, P63, DOI 10.1016/j.nut.2003.09.011; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; Weber M, 2005, NAT GENET, V37, P853, DOI 10.1038/ng1598; Williams J, 2006, SUBST USE MISUSE, V41, P489, DOI 10.1080/10826080500521755; Wilson IM, 2006, CELL CYCLE, V5, P155, DOI 10.4161/cc.5.2.2367; Yan QS, 2004, BRAIN RES, V1009, P228, DOI 10.1016/j.brainres.2004.02.052; Yoon S, 2006, GROWTH FACTORS, V24, P21, DOI 10.1080/02699050500284218	101	91	96	0	13	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1919	10.1371/journal.pone.0001919	http://dx.doi.org/10.1371/journal.pone.0001919			15	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382688	Green Published, gold			2022-12-25	WOS:000260795400041
J	Yuan, RR; Maeda, Y; Li, WP; Lu, W; Cook, S; Dowling, P				Yuan, RuiRong; Maeda, Yasuhiro; Li, Weiping; Lu, Wei; Cook, Stuart; Dowling, Peter			Erythropoietin: A Potent Inducer of Peripheral Immuno/Inflammatory Modulation in Autoimmune EAE	PLOS ONE			English	Article							REGULATORY T-CELLS; CUTTING EDGE; CD4 CELLS; CYTOKINE; IL-17; INFLAMMATION; TOLERANCE; RESPONSES; SELECTION; PEPTIDES	Background: Beneficial effects of short-term erythropoietin (EPO) therapy have been demonstrated in several animal models of acute neurologic injury, including experimental autoimmune encephalomyelitis (EAE)-the animal model of multiple sclerosis. We have found that EPO treatment substantially reduces the acute clinical paralysis seen in EAE mice and this improvement is accompanied by a large reduction in the mononuclear cell infiltration and downregulation of glial MHC class II expression within the inflamed CNS. Other reports have recently indicated that peripherally generated anti-inflammatory CD4(+)Foxp3(+) regulatory T cells (Tregs) and the IL17-producing CD4+ T helper cell (Th17) subpopulations play key antagonistic roles in EAE pathogenesis. However, no information regarding the effects of EPO therapy on the behavior of the general mononuclear-lymphocyte population, Tregs or Th17 cells in EAE has emerged. Methods and Findings: We first determined in vivo that EPO therapy markedly suppressed MOG specific T cell proliferation and sharply reduced the number of reactive dendritic cells (CD11c positive) in EAE lymph nodes during both inductive and later symptomatic phases of MOG(35-55) induced EAE. We then determined the effect in vivo of EPO on numbers of peripheral Treg cells and Th17 cells. We found that EPO treatment modulated immune balance in both the periphery and the inflamed spinal cord by promoting a large expansion in Treg cells, inhibiting Th17 polarization and abrogating proliferation of the antigen presenting dendritic cell population. Finally we utilized tissue culture assays to show that exposure to EPO in vitro similarly downregulated MOG-specific T cell proliferation and also greatly suppressed T cell production of pro-inflammatory cytokines. Conclusions: Taken together, our findings reveal an important new locus whereby EPO induces substantial long-term tissue protection in the host through signaling to several critical subsets of immune cells that reside in the peripheral lymphatic system.	[Yuan, RuiRong; Maeda, Yasuhiro; Li, Weiping; Lu, Wei; Cook, Stuart; Dowling, Peter] New Jersey Hlth Care Syst, Dept Vet Affairs, E Orange, NJ USA; [Yuan, RuiRong; Maeda, Yasuhiro; Cook, Stuart; Dowling, Peter] UMDNJ New Jersey Med Sch, Dept Neurosci & Neurol, Newark, NJ USA	New Jersey Department of Health & Senior Services; Rutgers State University New Brunswick; Rutgers State University Medical Center	Yuan, RR (corresponding author), New Jersey Hlth Care Syst, Dept Vet Affairs, E Orange, NJ USA.	dowlinpc@umdnj.edu	黎, 伟/GXM-4040-2022; li, wj/HGD-7322-2022		VA Merit Review; Segal Foundation; New Jersey State Commission on Cancer Research; National MS Society	VA Merit Review(US Department of Veterans Affairs); Segal Foundation; New Jersey State Commission on Cancer Research; National MS Society(National Multiple Sclerosis Society)	This work was supported by a VA Merit Review, the Segal Foundation, New Jersey State Commission on Cancer Research and the National MS Society.	Adembri C, 2008, CRIT CARE MED, V36, P975, DOI 10.1097/CCM.0B013E3181644343; Agnello D, 2002, BRAIN RES, V952, P128, DOI 10.1016/S0006-8993(02)03239-0; Baldwin KK, 1999, J IMMUNOL, V163, P689; Brines M, 2006, KIDNEY INT, V70, P246, DOI 10.1038/sj.ki.5001546; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; Brines ML, 2000, P NATL ACAD SCI USA, V97, P10526, DOI 10.1073/pnas.97.19.10526; Bynoe MS, 2003, IMMUNITY, V19, P317, DOI 10.1016/S1074-7613(03)00239-5; Chen Y, 2006, J CLIN INVEST, V116, P1317, DOI 10.1172/JCI25308; Chitnis T, 2003, IMMUNOL RES, V28, P223, DOI 10.1385/IR:28:3:223; Crawford J, 2007, J CLIN ONCOL, V25, P1021, DOI 10.1200/JCO.2006.08.8153; Cuzzocrea S, 2005, ARTHRITIS RHEUM, V52, P940, DOI 10.1002/art.20875; Dong C, 2006, NAT REV IMMUNOL, V6, P329, DOI 10.1038/nri1807; Erbayraktar S, 2003, P NATL ACAD SCI USA, V100, P6741, DOI 10.1073/pnas.1031753100; Fernandez-Martin A, 2006, EUR J IMMUNOL, V36, P318, DOI 10.1002/eji.200535430; Fontenot JD, 2017, J IMMUNOL, V198, P986, DOI 10.1038/ni904; Ford ML, 2005, EUR J IMMUNOL, V35, P76, DOI 10.1002/eji.200425660; Fujikado N, 2008, NAT MED, V14, P176, DOI 10.1038/nm1697; Furuzawa-Carballeda J, 2007, AUTOIMMUN REV, V6, P169, DOI 10.1016/j.autrev.2006.10.002; Govermant Joan, 2005, Current Drug Targets - Inflammation and Allergy, V4, P239, DOI 10.2174/1568010053586264; Grasso G, 2005, NEUROSURGERY, V56, P821, DOI 10.1227/01.NEU.0000156493.00904.7E; Henke M, 2006, J CLIN ONCOL, V24, P4708, DOI 10.1200/JCO.2006.06.2737; Hirota K, 2007, J EXP MED, V204, P41, DOI 10.1084/jem.20062259; Hofstetter HH, 2007, J IMMUNOL, V178, P1372, DOI 10.4049/jimmunol.178.3.1372; Hofstetter HH, 2005, CELL IMMUNOL, V237, P123, DOI 10.1016/j.cellimm.2005.11.002; Hofstetter HH, 2005, J NEUROIMMUNOL, V170, P105, DOI 10.1016/j.jneuroim.2005.09.004; Huseby ES, 2001, J EXP MED, V194, P669, DOI 10.1084/jem.194.5.669; Johnson AJ, 2007, INT REV NEUROBIOL, V79, P73, DOI 10.1016/S0074-7742(07)79004-9; Kassiotis G, 2003, J EXP MED, V197, P1007, DOI 10.1084/jem.20021812; Kim JM, 2007, NAT IMMUNOL, V8, P191, DOI 10.1038/ni1428; Kohm AP, 2002, J IMMUNOL, V169, P4712, DOI 10.4049/jimmunol.169.9.4712; Komiyama Y, 2006, J IMMUNOL, V177, P566, DOI 10.4049/jimmunol.177.1.566; Korn T, 2007, NAT MED, V13, P423, DOI 10.1038/nm1564; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; Leyland-Jones B, 2005, J CLIN ONCOL, V23, P5960, DOI 10.1200/JCO.2005.06.150; Li WP, 2004, ANN NEUROL, V56, P767, DOI 10.1002/ana.20274; McDole J, 2006, NEUROL RES, V28, P256, DOI 10.1179/016164106X98125; Ponomarev ED, 2004, J IMMUNOL, V173, P1587, DOI 10.4049/jimmunol.173.3.1587; Ponomarev ED, 2007, J IMMUNOL, V178, P39, DOI 10.4049/jimmunol.178.1.39; Reddy J, 2005, J IMMUNOL, V175, P5591, DOI 10.4049/jimmunol.175.9.5591; Reddy J, 2004, P NATL ACAD SCI USA, V101, P15434, DOI 10.1073/pnas.0404444101; Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178; Sebzda E, 1999, ANNU REV IMMUNOL, V17, P829, DOI 10.1146/annurev.immunol.17.1.829; Steinman L, 2001, J EXP MED, V194, pF27, DOI 10.1084/jem.194.5.F27; Stockinger B, 1999, Adv Immunol, V71, P229; Stockinger B, 2007, CURR OPIN IMMUNOL, V19, P281, DOI 10.1016/j.coi.2007.04.005; Stranges PB, 2007, IMMUNITY, V26, P629, DOI 10.1016/j.immuni.2007.03.016; Sun DM, 2003, INT IMMUNOL, V15, P261, DOI 10.1093/intimm/dxg023; Sun DM, 2001, J IMMUNOL, V166, P7579, DOI 10.4049/jimmunol.166.12.7579; Suryani S, 2007, J NEUROIMMUNOL, V183, P96, DOI 10.1016/j.jneuroim.2006.11.023; Sutton C, 2006, J EXP MED, V203, P1685, DOI 10.1084/jem.20060285; Viglietta V, 2004, J EXP MED, V199, P971, DOI 10.1084/jem.20031579; WEKERLE H, 1994, ANN NEUROL, V36, pS47, DOI 10.1002/ana.410360714; YUAN R, 2005, ANN NEUROL, V58, pA20; Yuan RR, 2004, BLOOD, V104, P2397, DOI 10.1182/blood-2004-01-0324; Zheng Y, 2007, NAT IMMUNOL, V8, P457, DOI 10.1038/ni1455	55	77	83	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1924	10.1371/journal.pone.0001924	http://dx.doi.org/10.1371/journal.pone.0001924			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382691	Green Published, Green Submitted, gold			2022-12-25	WOS:000260795400044
J	Polager, S; Ofir, M; Ginsberg, D				Polager, S.; Ofir, M.; Ginsberg, D.			E2F1 regulates autophagy and the transcription of autophagy genes	ONCOGENE			English	Article						E2F; autophagy; LC3; ATG1; DRAM	PROGRAMMED CELL-DEATH; APOPTOSIS; TARGET; PATHWAYS; ROLES; YEAST; DRAM; P53	The retinoblastoma pathway is often inactivated in human tumors resulting in deregulated E2F activity that can induce both proliferation and cell death. Although the role of E2F in apoptosis is well characterized, little is known regarding its putative participation in other cell death pathways. We show here that activation of E2F1 upregulates the expression off our autophagy genes microtubule-associated protein-1 light chain-3 (LC3), autophagy-related gene-1 (ATG1), ATG5 and damage-regulated autophagy modulator (DRAM). E2F1-mediated induction of LC3, ATG1 and DRAM is direct and indeed, endogenous E2F1 can be found bound to regions encompassing the promoters of these genes. Regulation of ATG5 by E2F1 is indirect. Importantly, we demonstrate that E2F1 activation enhances autophagy and conversely, reducing endogenous E2F1 expression inhibits DNA damage-induced autophagy. These studies identify E2F1 as a transcriptional regulator of autophagy, and for the first time establish a role for E2F1 in DNA damage-induced autophagy.	[Polager, S.; Ofir, M.; Ginsberg, D.] Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel	Bar Ilan University	Ginsberg, D (corresponding author), Bar Ilan Univ, Mina & Everard Goodman Fac Life Sci, IL-52900 Ramat Gan, Israel.	ginsbed@mail.biu.ac.il		ginsberg, doron/0000-0002-1257-4920				Baehrecke EH, 2005, NAT REV MOL CELL BIO, V6, P505, DOI 10.1038/nrm1666; Crighton D, 2007, CELL DEATH DIFFER, V14, P1071, DOI 10.1038/sj.cdd.4402108; Crighton D, 2006, CELL, V126, P121, DOI 10.1016/j.cell.2006.05.034; DeGregori J, 2006, CURR MOL MED, V6, P739; Dimova DK, 2005, ONCOGENE, V24, P2810, DOI 10.1038/sj.onc.1208612; Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011; Feng ZH, 2005, P NATL ACAD SCI USA, V102, P8204, DOI 10.1073/pnas.0502857102; Fortin A, 2004, J BIOL CHEM, V279, P28706, DOI 10.1074/jbc.M400376200; Ginsberg D, 2002, FEBS LETT, V529, P122, DOI 10.1016/S0014-5793(02)03270-2; Gozuacik D, 2007, CURR TOP DEV BIOL, V78, P217, DOI 10.1016/S0070-2153(06)78006-1; Hershko T, 2004, J BIOL CHEM, V279, P8627, DOI 10.1074/jbc.M312866200; Kabeya Y, 2000, EMBO J, V19, P5720, DOI 10.1093/emboj/19.21.5720; Kirisako T, 1999, J CELL BIOL, V147, P435, DOI 10.1083/jcb.147.2.435; Klionsky DJ, 2000, SCIENCE, V290, P1717, DOI 10.1126/science.290.5497.1717; Reef S, 2006, MOL CELL, V22, P463, DOI 10.1016/j.molcel.2006.04.014; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; Shimizu S, 2004, NAT CELL BIOL, V6, P1221, DOI 10.1038/ncb1192; Stevens C, 2004, DNA REPAIR, V3, P1071, DOI 10.1016/j.dnarep.2004.03.034; Tracy K, 2007, MOL CELL BIOL, V27, P6229, DOI 10.1128/MCB.02246-06; Tsuneoka M, 2003, CELL STRUCT FUNCT, V28, P195; Vigo E, 1999, MOL CELL BIOL, V19, P6379; Weinmann AS, 2001, MOL CELL BIOL, V21, P6820, DOI 10.1128/MCB.21.20.6820-6832.2001; WU XW, 1994, P NATL ACAD SCI USA, V91, P3602, DOI 10.1073/pnas.91.9.3602	23	194	200	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232			ONCOGENE	Oncogene	AUG 14	2008	27	35					4860	4864		10.1038/onc.2008.117	http://dx.doi.org/10.1038/onc.2008.117			5	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	337OJ	18408756				2022-12-25	WOS:000258445100011
J	Hu, XY; He, WX; Diaconu, CD; Tang, XY; Kidd, GJ; Macklin, WB; Trapp, BD; Yan, RQ				Hu, Xiangyou; He, Wanxia; Diaconu, Claudiu; Tang, Xiaoying; Kidd, Grahame J.; Macklin, Wendy B.; Trapp, Bruce D.; Yan, Riqiang			Genetic deletion of BACE1 in mice affects remyelination of sciatic nerves	FASEB JOURNAL			English	Article						neuregulin; myelin; nerve crush; alpha-secretase; gamma-secretase	AMYLOID PRECURSOR PROTEIN; BETA-SECRETASE ACTIVITY; MYELIN SHEATH THICKNESS; PERIPHERAL-NERVE; ALZHEIMERS-DISEASE; A-BETA; WALLERIAN DEGENERATION; EXPRESSION; NEUREGULIN-1; AXONS	BACE1 is a promising therapeutic and preventive target for Alzheimer's disease because it is essential for amyloid deposition. However, the recent demonstration of BACE1 in modulating developmental myelination in both peripheral and central nervous systems raises a concern of its effect on myelin maintenance or remyelination, and inhibition of these processes will potentially be detrimental to the BACE1 inhibitor users who are susceptible to myelination diseases such as adult peripheral nerve injury or multiple sclerosis. In this report, we investigated the role of BACE1 during peripheral nerve remyelination in wildtype (WT) and BACE1-null mice. We show here that genetic deletion of BACE1 affects sciatic nerve remyelination. The impaired remyelination appears to stem from the loss of neuregulin-1 cleavage by BACE1. To demonstrate a direct cleavage of neuregulin-1 by BACE1, we have identified a BACE1 cleavage site that turns out be highly conserved among neuregulin-1 paralogues. Moreover, we show that neuregulin-1 family member neuregulin-3 is also cleavable by BACE1. We hypothesize that the BACE1-cleaved extracellular domain of axonal neuregulin-1, perhaps neuregulin-3 as well, binds to Schwann cell ErbB receptors, which in turn regulate remyelination. Pharmacological inhibition of BACE1 should be carefully monitored to avoid alteration of signaling pathway that regulates remyelination.	[Hu, Xiangyou; He, Wanxia; Diaconu, Claudiu; Tang, Xiaoying; Kidd, Grahame J.; Macklin, Wendy B.; Trapp, Bruce D.; Yan, Riqiang] Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Yan, RQ (corresponding author), Cleveland Clin Fdn, Lerner Res Inst, Dept Neurosci, 9500 Euclid Ave, Cleveland, OH 44195 USA.	yanr@ccf.org	Messier, Claude/A-2322-2008	Messier, Claude/0000-0002-4791-1763; Yan, Riqiang/0000-0001-7195-7617; Kidd, Grahame/0000-0003-3956-2206	NATIONAL INSTITUTE ON AGING [R01AG025493] Funding Source: NIH RePORTER; NIA NIH HHS [R01 AG025493, AG025493] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Akassoglou K, 2003, NEUROSCI LETT, V338, P185, DOI 10.1016/S0304-3940(02)01387-3; Arnett HA, 2004, SCIENCE, V306, P2111, DOI 10.1126/science.1103709; Brady SF, 2004, BIOORG MED CHEM LETT, V14, P601, DOI 10.1016/j.bmcl.2003.11.061; Cai HB, 2001, NAT NEUROSCI, V4, P233, DOI 10.1038/85064; Carroll SL, 1997, J NEUROSCI, V17, P1642; Carteron C, 2006, J CELL SCI, V119, P898, DOI 10.1242/jcs.02799; Chang WP, 2004, J NEUROCHEM, V89, P1409, DOI 10.1111/j.1471-4159.2004.02452.x; Chen S, 2006, J NEUROSCI, V26, P3079, DOI 10.1523/JNEUROSCI.3785-05.2006; FAWCETT JW, 1990, ANNU REV NEUROSCI, V13, P43, DOI 10.1146/annurev.neuro.13.1.43; Fukumoto H, 2004, AM J PATHOL, V164, P719, DOI 10.1016/S0002-9440(10)63159-8; Funakoshi H, 1998, P NATL ACAD SCI USA, V95, P5269, DOI 10.1073/pnas.95.9.5269; Haney CA, 1999, J CELL BIOL, V146, P1173, DOI 10.1083/jcb.146.5.1173; He WX, 2004, NAT MED, V10, P959, DOI 10.1038/nm1088; Hu XY, 2006, NAT NEUROSCI, V9, P1520, DOI 10.1038/nn1797; Hussain I, 1999, MOL CELL NEUROSCI, V14, P419, DOI 10.1006/mcne.1999.0811; Kao SC, 2004, J BIOL CHEM, V279, P1942, DOI 10.1074/jbc.M309219200; LEBLANC AC, 1990, J NEUROSCI RES, V26, P317, DOI 10.1002/jnr.490260308; Lemke G., 2006, SCI STKE, V2006, pe11; Lu QR, 2002, CELL, V109, P75, DOI 10.1016/S0092-8674(02)00678-5; Luo Y, 2001, NAT NEUROSCI, V4, P231, DOI 10.1038/85059; MARTINI R, 1995, J NEUROSCI, V15, P4488; McConlogue L, 2007, J BIOL CHEM, V282, P26326, DOI 10.1074/jbc.M611687200; Michailov GV, 2004, SCIENCE, V304, P700, DOI 10.1126/science.1095862; MORGANHUGHES JA, 1968, ARCH NEUROL-CHICAGO, V19, P598, DOI 10.1001/archneur.1968.00480060068009; Navel KA, 2006, CURR OPIN NEUROBIOL, V16, P492, DOI 10.1016/j.conb.2006.08.008; Ozaki M, 2004, J NEUROCHEM, V91, P176, DOI 10.1111/j.1471-4159.2004.02719.x; Pietrak BL, 2005, ANAL BIOCHEM, V342, P144, DOI 10.1016/j.ab.2005.04.019; Roberds SL, 2001, HUM MOL GENET, V10, P1317, DOI 10.1093/hmg/10.12.1317; ROSENBLUTH J, 1980, J COMP NEUROL, V193, P729, DOI 10.1002/cne.901930310; SCHRODER JM, 1972, BRAIN RES, V45, P49, DOI 10.1016/0006-8993(72)90215-6; Selkoe DJ, 2005, ARCH NEUROL-CHICAGO, V62, P192, DOI 10.1001/archneur.62.2.192; Singer O, 2005, NAT NEUROSCI, V8, P1343, DOI 10.1038/nn1531; Sinha S, 1999, NATURE, V402, P537, DOI 10.1038/990114; Sisodia SS, 2002, NAT REV NEUROSCI, V3, P281, DOI 10.1038/nrn785; SMITH GM, 1993, EXP NEUROL, V121, P239, DOI 10.1006/exnr.1993.1091; Takebayashi H, 2002, CURR BIOL, V12, P1157, DOI 10.1016/S0960-9822(02)00926-0; Taveggia C, 2005, NEURON, V47, P681, DOI 10.1016/j.neuron.2005.08.017; Tomasselli AG, 2003, J NEUROCHEM, V84, P1006, DOI 10.1046/j.1471-4159.2003.01597.x; Turner RT, 2002, BIOCHEMISTRY-US, V41, P8742, DOI 10.1021/bi025926t; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735; WEBSTER HDF, 1962, J CELL BIOL, V12, P361; Willem M, 2006, SCIENCE, V314, P664, DOI 10.1126/science.1132341; WONG E, 1992, J NEUROCHEM, V58, P2212, DOI 10.1111/j.1471-4159.1992.tb10966.x; Yan RQ, 1999, NATURE, V402, P533, DOI 10.1038/990107; Yan RQ, 2001, J BIOL CHEM, V276, P36788, DOI 10.1074/jbc.M104350200; Yang LB, 2003, NAT MED, V9, P3, DOI 10.1038/nm0103-3; Yin XH, 2006, J CELL BIOL, V172, P469, DOI 10.1083/jcb.200509174; Yue T, 2006, J NEUROSCI, V26, P1275, DOI 10.1523/JNEUROSCI.4717-05.2006; Zanazzi G, 2001, J CELL BIOL, V152, P1289, DOI 10.1083/jcb.152.6.1289; Zhang DX, 1997, P NATL ACAD SCI USA, V94, P9562, DOI 10.1073/pnas.94.18.9562; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3	51	145	151	0	10	FEDERATION AMER SOC EXP BIOL	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA	0892-6638			FASEB J	Faseb J.	AUG	2008	22	8					2970	2980		10.1096/fj.08-106666	http://dx.doi.org/10.1096/fj.08-106666			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18413858	Green Published			2022-12-25	WOS:000258089300037
J	Kleinau, G; Jaeschke, H; Mueller, S; Raaka, BM; Neumann, S; Paschke, R; Krause, G				Kleinau, Gunnar; Jaeschke, Holger; Mueller, Sandra; Raaka, Bruce M.; Neumann, Susanne; Paschke, Ralf; Krause, Gerd			Evidence for cooperative signal triggering at the extracellular loops of the TSH receptor	FASEB JOURNAL			English	Article						glycoprotein hormone receptors; activation mechanism; signal transduction; endocrinology	THYROID-STIMULATING HORMONE; LEUCINE-RICH REPEATS; SITE-DIRECTED MUTAGENESIS; THYROTROPIN RECEPTOR; CRYSTAL-STRUCTURE; GONADOTROPIN RECEPTORS; CONSTITUTIVE ACTIVITY; CHORIONIC-GONADOTROPIN; TRANSMEMBRANE DOMAIN; SOMATIC MUTATIONS	The mechanisms governing transition of the thyroid stimulating hormone (TSH) receptor (TSHR) from basal to active conformations are poorly understood. Considering that constitutively activating mutations (CAMs) and inactivating mutations in each of the extracellular loops (ECLs) trigger only partial TSHR activation or inactivation, respectively, we hypothesized that full signaling occurs via multiple extracellular signal propagation events. Therefore, individual CAMs in the extracellular region were combined to create double and triple mutants. In support of our hypothesis, combinations of mutants in the ECLs are in some cases additive, while in others they are even synergistic, with triple mutant I486A/I568V/V656F exhibiting a 70-fold increase in TSH-independent signaling. The proximity but likely different spatial orientation of the residues of activating and inactivating mutations in each ECL supports a dual functionality to facilitate signal induction and conduction, respectively. This is the first report for G-protein coupled receptors, suggesting that multiple and cooperative signal propagating events at all three ECLs are required for full receptor activation. Our findings provide new insights concerning molecular signal transmission from extracellular domains toward the transmembrane helix bundle of the glycoprotein hormone receptors.	[Kleinau, Gunnar; Krause, Gerd] Leibniz Inst Mol Pharmacol, D-13125 Berlin, Germany; [Jaeschke, Holger; Mueller, Sandra; Paschke, Ralf] Univ Klinikum Leipzig, Dept Med, Leipzig, Germany; [Raaka, Bruce M.; Neumann, Susanne] NIDDK, NIH, Clin Endocrinol Branch, Bethesda, MD USA	Leibniz Forschungsinstitut furr Molekulare Pharmakologie (FMP); Leipzig University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Krause, G (corresponding author), Leibniz Inst Mol Pharmacol, Robert Rossle Str 10, D-13125 Berlin, Germany.	gkrause@fmp-berlin.de	Kleinau, Gunnar/GPX-6330-2022; Horstmann, Britta/C-2154-2008		Intramural NIH HHS Funding Source: Medline	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA)		Aarons EJ, 2001, VIROLOGY, V287, P382, DOI 10.1006/viro.2001.1046; Ballesteros JA, 2001, J BIOL CHEM, V276, P29171, DOI 10.1074/jbc.M103747200; Bhowmick N, 1996, MOL ENDOCRINOL, V10, P1147, DOI 10.1210/me.10.9.1147; Bhowmick N, 1999, ENDOCRINOLOGY, V140, P4558, DOI 10.1210/en.140.10.4558; Bogerd J, 2007, MOL CELL ENDOCRINOL, V260, P144, DOI 10.1016/j.mce.2006.01.019; Bonomi M, 2006, MOL ENDOCRINOL, V20, P3351, DOI 10.1210/me.2005-0521; BRAUN T, 1991, EMBO J, V10, P1885, DOI 10.1002/j.1460-2075.1991.tb07714.x; Case D. A., 2002, AMBER 7; Chen CR, 2003, ENDOCRINOLOGY, V144, P3821, DOI 10.1210/en.2003-0430; Cherezov V, 2007, SCIENCE, V318, P1258, DOI 10.1126/science.1150577; Claeysen S, 2002, FEBS LETT, V517, P195, DOI 10.1016/S0014-5793(02)02620-0; Claus M, 2005, ENDOCRINOLOGY, V146, P5197, DOI 10.1210/en.2005-0713; Claus M, 2005, THYROID, V15, P1089, DOI 10.1089/thy.2005.15.1089; Costagliola S, 2002, EMBO J, V21, P504, DOI 10.1093/emboj/21.4.504; Dragic T, 1998, J VIROL, V72, P279, DOI 10.1128/JVI.72.1.279-285.1998; Fan QR, 2007, MOL CELL ENDOCRINOL, V260, P73, DOI 10.1016/j.mce.2005.12.055; Fan QR, 2005, NATURE, V433, P269, DOI 10.1038/nature03206; Fuhrer D, 1997, J CLIN ENDOCR METAB, V82, P3885, DOI 10.1210/jc.82.11.3885; Galet C, 2005, MOL ENDOCRINOL, V19, P1263, DOI 10.1210/me.2004-0410; Gromoll J, 2000, J CLIN ENDOCR METAB, V85, P2281, DOI 10.1210/jc.85.6.2281; Gudermann T, 2005, EXP CLIN ENDOCR DIAB, V113, P245, DOI 10.1055/s-2005-865679; Ho SC, 2005, MOL CELL ENDOCRINOL, V245, P158, DOI 10.1016/j.mce.2005.11.008; Ho SC, 2001, ENDOCRINOLOGY, V142, P2760, DOI 10.1210/en.142.7.2760; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; Jaeschke H, 2006, ENDOCRINOLOGY, V147, P1753, DOI 10.1210/en.2005-1138; Karges B, 2005, MOL ENDOCRINOL, V19, P2086, DOI 10.1210/me.2004-0378; Kleinau G, 2004, J BIOL CHEM, V279, P51590, DOI 10.1074/jbc.M404748200; Kleinau G, 2007, MOL ENDOCRINOL, V21, P574, DOI 10.1210/me.2006-0309; Kleinau G, 2007, J BIOL CHEM, V282, P518, DOI 10.1074/jbc.M606176200; KOSUGI S, 1991, J BIOL CHEM, V266, P19413; LASKOWSKI RA, 1993, J MOL BIOL, V231, P1049, DOI 10.1006/jmbi.1993.1351; Lawson Z, 2004, BIOCHEM SOC T, V32, P1048, DOI 10.1042/BST0321048; Lee B, 1999, J BIOL CHEM, V274, P9617, DOI 10.1074/jbc.274.14.9617; Leitolf H, 2000, J BIOL CHEM, V275, P27457; Lin W, 2007, MOL CELL ENDOCRINOL, V260, P83, DOI 10.1016/j.mce.2006.06.012; Morgenthaler NG, 2007, J CLIN ENDOCR METAB, V92, P1058, DOI 10.1210/jc.2006-2213; MUELLER S, 2007, EXP CLIN ENDOCR S1, V115, P33; Mueller S, 2006, J BIOL CHEM, V281, P31638, DOI 10.1074/jbc.M604770200; Muller T, 2003, J CLIN ENDOCR METAB, V88, P2242, DOI 10.1210/jc.2002-021946; Nakabayashi K, 2003, MOL CELL ENDOCRINOL, V202, P139, DOI 10.1016/S0303-7207(03)00075-3; Neumann S, 2005, EUR J ENDOCRINOL, V152, P625, DOI 10.1530/eje.1.01891; Nishi S, 2002, J BIOL CHEM, V277, P3958, DOI 10.1074/jbc.M109617200; Nurwakagari P, 2007, J MOL ENDOCRINOL, V38, P259, DOI 10.1677/jme.1.02160; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; PARMA J, 1995, MOL ENDOCRINOL, V9, P725, DOI 10.1210/me.9.6.725; Parnot C, 2002, TRENDS ENDOCRIN MET, V13, P336, DOI 10.1016/S1043-2760(02)00628-8; Rapoport B, 1998, ENDOCR REV, V19, P673, DOI 10.1210/er.19.6.673; Rapoport B, 2007, THYROID, V17, P911, DOI 10.1089/thy.2007.0170; Rasmussen SGF, 2007, NATURE, V450, P383, DOI 10.1038/nature06325; Salom D, 2006, P NATL ACAD SCI USA, V103, P16123, DOI 10.1073/pnas.0608022103; Sanders J, 2007, THYROID, V17, P699, DOI 10.1089/thy.2007.0041; Sanders J, 2007, THYROID, V17, P395, DOI 10.1089/thy.2007.0034; Sanders J, 2006, THYROID, V16, P1195, DOI 10.1089/thy.2006.16.1195; Sangkuhl K, 2002, J BIOL CHEM, V277, P47748, DOI 10.1074/jbc.M203491200; Smits G, 2003, EMBO J, V22, P2692, DOI 10.1093/emboj/cdg260; Srinivasan S, 2004, J CLIN INVEST, V114, P1158, DOI 10.1172/JCI200421927; Standfuss J, 2007, J MOL BIOL, V372, P1179, DOI 10.1016/j.jmb.2007.03.007; Szkudlinski MW, 1996, NAT BIOTECHNOL, V14, P1257, DOI 10.1038/nbt1096-1257; Szkudlinski MW, 2002, PHYSIOL REV, V82, P473, DOI 10.1152/physrev.00031.2001; Tonacchera M, 1996, J CLIN ENDOCR METAB, V81, P547, DOI 10.1210/jc.81.2.547; Vassart G, 2004, TRENDS BIOCHEM SCI, V29, P119, DOI 10.1016/j.tibs.2004.01.006; Vischer HF, 2003, J BIOL CHEM, V278, P15505, DOI 10.1074/jbc.M300634200; Vlaeminck-Guillem V, 2002, MOL ENDOCRINOL, V16, P736, DOI 10.1210/me.16.4.736; Zhang M, 2000, ENDOCRINOLOGY, V141, P3514, DOI 10.1210/en.141.9.3514; ZHANG ML, 1995, BIOCHEM BIOPH RES CO, V211, P205, DOI 10.1006/bbrc.1995.1797	65	39	42	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0892-6638	1530-6860		FASEB J	Faseb J.	AUG	2008	22	8					2798	2808		10.1096/fj.07-104711	http://dx.doi.org/10.1096/fj.07-104711			11	Biochemistry & Molecular Biology; Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology	332NI	18381815	Green Published			2022-12-25	WOS:000258089300020
J	Hirabayashi, S; Nakagawa, K; Sumita, K; Hidaka, S; Kawai, T; Ikeda, M; Kawata, A; Ohno, K; Hata, Y				Hirabayashi, S.; Nakagawa, K.; Sumita, K.; Hidaka, S.; Kawai, T.; Ikeda, M.; Kawata, A.; Ohno, K.; Hata, Y.			Threonine 74 of MOB1 is a putative key phosphorylation site by MST2 to form the scaffold to activate nuclear Dbf2-related kinase 1	ONCOGENE			English	Article						NDR kinase; Hippo pathway; mammalian sterile 20-like kinase 2; Mps one binder 1	CELL-CYCLE EXIT; TUMOR-SUPPRESSOR; PROMOTES APOPTOSIS; PROTEIN-KINASE; NDR KINASES; HIPPO; DROSOPHILA; PROLIFERATION; SALVADOR; GROWTH	Mammalian nuclear Dbf2-related (NDR) kinases (LATS1 and 2, NDR1 and 2) play a role in cell proliferation, apoptosis and morphological changes. These kinases are regulated by mammalian sterile 20-like kinases (MSTs) and Mps one binder (MOB) 1. Okadaic acid (OA), which activates MST2, facilitates the complex formation of MOB1, MST2 and NDR1 in HEK293FT cells. The in vitro biochemical study demonstrates the phosphorylation of MOB1 by MST2. The phosphorylated MOB1 alone is capable to partially activate NDR1 in vitro, but MST2 is also required for the full activation. The knockdown of MOB1 or MST2 abolishes the OA-induced NDR1 activation in HEK293FT cells. Among MOB1 mutants, in which each serine or threonine residue is replaced with alanine, MOB1 T74A and T181A mutants fail to activate NDR1. Thr74, but not Thr181, is phosphorylated by MST2 in vitro, although MOB1 is also phosphorylated by MST2 at other site(s). The interaction of MOB1 T74A with NDR1 is barely enhanced by OA treatment. These findings indicate that the phosphorylation of MOB1 at Thr74 by MST2 is essential to make a complex of MOB1, MST2 and NDR1, and to fully activate NDR1.	[Hirabayashi, S.; Nakagawa, K.; Sumita, K.; Hidaka, S.; Kawai, T.; Ikeda, M.; Kawata, A.; Hata, Y.] Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, Tokyo 1138519, Japan; [Sumita, K.; Ohno, K.] Tokyo Med & Dent Univ, Grad Sch Med, Dept Neurosurg, Tokyo 1138519, Japan	Tokyo Medical & Dental University (TMDU); Tokyo Medical & Dental University (TMDU)	Hata, Y (corresponding author), Tokyo Med & Dent Univ, Grad Sch Med, Dept Med Biochem, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138519, Japan.	yuhammch@tmd.ac.jp	Sumita, Kazutaka/AAI-1553-2019					Bichsel SJ, 2004, J BIOL CHEM, V279, P35228, DOI 10.1074/jbc.M404542200; Bothos J, 2005, CANCER RES, V65, P6568, DOI 10.1158/0008-5472.CAN-05-0862; Chan EH, 2005, ONCOGENE, V24, P2076, DOI 10.1038/sj.onc.1208445; Creasy CL, 1995, GENE, V167, P303, DOI 10.1016/0378-1119(95)00653-2; Edgar BA, 2006, CELL, V124, P267, DOI 10.1016/j.cell.2006.01.005; Hariharan IK, 2006, CURR BIOL, V16, pR1037, DOI 10.1016/j.cub.2006.11.012; Harvey KF, 2003, CELL, V114, P457, DOI 10.1016/S0092-8674(03)00557-9; He Y, 2005, MOL BIOL CELL, V16, P4139, DOI 10.1091/mbc.e05-01-0018; Hergovich A, 2005, MOL CELL BIOL, V25, P8259, DOI 10.1128/MCB.25.18.8259-8272.2005; Hergovich A, 2006, NAT REV MOL CELL BIO, V7, P253, DOI 10.1038/nrm1891; Hergovich A, 2006, BIOCHEM BIOPH RES CO, V345, P50, DOI 10.1016/j.bbrc.2006.03.244; Ikeda M, 2007, EXP CELL RES, V313, P1484, DOI 10.1016/j.yexcr.2007.02.013; Jia JH, 2003, GENE DEV, V17, P2514, DOI 10.1101/gad.1134003; Lai ZC, 2005, CELL, V120, P675, DOI 10.1016/j.cell.2004.12.036; Lee KK, 2002, J BIOL CHEM, V277, P12351, DOI 10.1074/jbc.M108138200; Luca FC, 1998, MOL BIOL CELL, V9, P29, DOI 10.1091/mbc.9.1.29; Pantalacci S, 2003, NAT CELL BIOL, V5, P921, DOI 10.1038/ncb1051; Stavridi ES, 2003, STRUCTURE, V11, P1163, DOI 10.1016/S0969-2126(03)00182-5; Stegert MR, 2005, MOL CELL BIOL, V25, P11019, DOI 10.1128/MCB.25.24.11019-11029.2005; Tapon N, 2002, CELL, V110, P467, DOI 10.1016/S0092-8674(02)00824-3; Udan RS, 2003, NAT CELL BIOL, V5, P914, DOI 10.1038/ncb1050; Valverde P, 2000, BIOCHEM BIOPH RES CO, V276, P990, DOI 10.1006/bbrc.2000.3582; Wei X, 2007, EMBO J, V26, P1772, DOI 10.1038/sj.emboj.7601630; Wu S, 2003, CELL, V114, P445, DOI 10.1016/S0092-8674(03)00549-X	24	46	51	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4281	4292		10.1038/onc.2008.66	http://dx.doi.org/10.1038/onc.2008.66			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18362890				2022-12-25	WOS:000257691100003
J	Wischermann, K; Popp, S; Moshir, S; Scharfetter-Kochanek, K; Wlaschek, M; de Gruijl, F; Hartschuh, W; Greinert, R; Volkmer, B; Faust, A; Rapp, A; Schmezer, P; Boukamp, P				Wischermann, K.; Popp, S.; Moshir, S.; Scharfetter-Kochanek, K.; Wlaschek, M.; de Gruijl, F.; Hartschuh, W.; Greinert, R.; Volkmer, B.; Faust, A.; Rapp, A.; Schmezer, P.; Boukamp, P.			UVA radiation causes DNA strand breaks, chromosomal aberrations and tumorigenic transformation in HaCaT skin keratinocytes	ONCOGENE			English	Article						DNA double strand breaks; tumor formation; chromosomal aberrations; telomere length; radiation regimes	OXIDATIVE STRESS; IN-VITRO; H2AX PHOSPHORYLATION; COMET ASSAY; HUMAN-CELLS; DAMAGE; PROGRESSION; REPAIR; TUMOR; OVEREXPRESSION	The role of UVA-radiation-the major fraction in sunlight-in human skin carcinogenesis is still elusive. We here report that different UVA exposure regime (4 x 5 J/cm(2) per week or 1 x 20 J/cm(2) per week) caused tumorigenic conversion (tumors in nude mice) of the HaCaT skin keratinocytes. While tumorigenicity was not associated with general telomere shortening, we found new chromosomal changes characteristic for each recultivated tumor. Since this suggested a nontelomere-dependent relationship between UVA irradiation and chromosomal aberrations, we investigated for alternate mechanisms of UVA-dependent genomic instability. Using the alkaline and neutral comet assay as well as gamma-H2AX foci formation on irradiated HaCaT cells (20-60 J/cm(2)), we show a dosedependent and long lasting induction of DNA single and double (ds) strand breaks. Extending this to normal human skin keratinocytes, we demonstrate a comparable damage response and, additionally, a significant induction and maintenance of micronuclei (MN) with more acentric fragments (indicative of ds breaks) than entire chromosomes particularly 5 days post irradiation. Thus, physiologically relevant UVA doses cause long-lasting DNA strand breaks, a prerequisite for chromosomal aberration that most likely contribute to tumorigenic conversion of the HaCaT cells. Since normal keratinocytes responded similarly, UVA may likewise contribute to the complex karyotype characteristic for human skin carcinomas.	[Wischermann, K.; Popp, S.; Moshir, S.; Boukamp, P.] German Canc Res Ctr, Div Genet Skin Carcinogenesis, D-69120 Heidelberg, Germany; [Scharfetter-Kochanek, K.; Wlaschek, M.] Univ Ulm, Dept Dermatol & Allerg Dis, Ulm, Germany; [de Gruijl, F.] Leiden Univ, Med Ctr, Dept Dermatol, Leiden, Netherlands; [Hartschuh, W.] Heidelberg Univ, Dept Dermatol, D-6900 Heidelberg, Germany; [Greinert, R.; Volkmer, B.; Faust, A.] Dermatol Ctr, Mol Cell Biol Div, Buxtehude, Germany; [Rapp, A.] Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; [Schmezer, P.] German Canc Res Ctr, Div Toxicol & Canc Risk Factors, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ); Ulm University; Leiden University; Leiden University Medical Center (LUMC); Leiden University - Excl LUMC; Ruprecht Karls University Heidelberg; University of Oxford; Helmholtz Association; German Cancer Research Center (DKFZ)	Boukamp, P (corresponding author), German Canc Res Ctr, Div Genet Skin Carcinogenesis, Neuenheimer Feld 280,Postfach 101949, D-69120 Heidelberg, Germany.	P.Boukamp@DKFZ-Heidelberg.de	Rapp, Alexander/F-5327-2012	Rapp, Alexander/0000-0001-9108-3929				ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; Armstrong BK, 2001, J PHOTOCH PHOTOBIO B, V63, P8, DOI 10.1016/S1011-1344(01)00198-1; Bleuel K, 1999, P NATL ACAD SCI USA, V96, P2065, DOI 10.1073/pnas.96.5.2065; Boukamp P, 1997, GENE CHROMOSOME CANC, V19, P201, DOI 10.1002/(SICI)1098-2264(199708)19:4<201::AID-GCC1>3.0.CO;2-0; BOUKAMP P, 1990, CANCER RES, V50, P2840; BOUKAMP P, 1995, ONCOGENE, V11, P961; BOUKAMP P, 1988, J CELL BIOL, V106, P761, DOI 10.1083/jcb.106.3.761; BOUKAMP P, 1990, DIFFERENTIATION, V44, P150, DOI 10.1111/j.1432-0436.1990.tb00548.x; Boukamp P, 1999, ONCOGENE, V18, P5638, DOI 10.1038/sj.onc.1202934; Boukamp Petra, 2005, J Dtsch Dermatol Ges, V3, P493, DOI 10.1111/j.1610-0387.2005.05037.x; Burnworth B, 2006, ONCOGENE, V25, P4399, DOI 10.1038/sj.onc.1209474; Cadet J, 2005, MUTAT RES-FUND MOL M, V571, P3, DOI 10.1016/j.mrfmmm.2004.09.012; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; COHEN J, 1960, EDUC PSYCHOL MEAS, V20, P37, DOI 10.1177/001316446002000104; de Gruijl FR, 2002, SKIN PHARMACOL APPL, V15, P316, DOI 10.1159/000064535; Emri G, 2000, J INVEST DERMATOL, V115, P435, DOI 10.1046/j.1523-1747.2000.00057.x; *FED OFF RAD PROT, 2006, CONT SOL UV MON GERM; Fenech M, 2000, MUTAT RES-FUND MOL M, V455, P81, DOI 10.1016/S0027-5107(00)00065-8; Fenech M, 2002, TOXICOLOGY, V181, P411, DOI 10.1016/S0300-483X(02)00480-8; Figueroa R, 2000, CANCER RES, V60, P2770; Folkman J, 1991, Princess Takamatsu Symp, V22, P339; Garinis GA, 2005, EMBO J, V24, P3952, DOI 10.1038/sj.emboj.7600849; He YY, 2006, ONCOGENE, V25, P3680, DOI 10.1038/sj.onc.1209384; Ikehata H, 2004, MUTAT RES-FUND MOL M, V556, P11, DOI 10.1016/j.mrfmmm.2004.06.038; Ikehata H, 2003, MUTAGENESIS, V18, P511, DOI 10.1093/mutage/geg030; Ikehata H, 2007, PHOTOCHEM PHOTOBIOL, V83, P196, DOI 10.1562/2006-02-28-IR-822; Kielbassa C, 1997, CARCINOGENESIS, V18, P811, DOI 10.1093/carcin/18.4.811; Krude T, 1999, EXP CELL RES, V247, P148, DOI 10.1006/excr.1998.4342; LEHMAN TA, 1993, CARCINOGENESIS, V14, P833, DOI 10.1093/carcin/14.5.833; Limoli CL, 2002, P NATL ACAD SCI USA, V99, P233, DOI 10.1073/pnas.231611798; Marti TM, 2006, P NATL ACAD SCI USA, V103, P9891, DOI 10.1073/pnas.0603779103; Murnane JP, 2004, BIOESSAYS, V26, P1164, DOI 10.1002/bies.20125; MUTZHAS MF, 1981, J INVEST DERMATOL, V76, P42, DOI 10.1111/1523-1747.ep12524813; Obermueller E, 2004, CANCER RES, V64, P7801, DOI 10.1158/0008-5472.CAN-03-3301; Oikawa S, 1999, FEBS LETT, V453, P365, DOI 10.1016/S0014-5793(99)00748-6; Olive PL, 1999, INT J RADIAT BIOL, V75, P395, DOI 10.1080/095530099140311; OLIVE PL, 1993, RADIAT RES, V136, P130, DOI 10.2307/3578650; Parangi S, 1996, P NATL ACAD SCI USA, V93, P2002, DOI 10.1073/pnas.93.5.2002; Phillipson RP, 2002, FREE RADICAL BIO MED, V32, P474, DOI 10.1016/S0891-5849(01)00829-2; Popp S, 2002, INT J CANCER, V99, P352, DOI 10.1002/ijc.10321; Popp S, 2000, J INVEST DERMATOL, V115, P1095, DOI 10.1046/j.1523-1747.2000.00173.x; Rapp A, 2000, J PHOTOCH PHOTOBIO B, V56, P109, DOI 10.1016/S1011-1344(00)00052-X; Rapp A, 2004, J CELL SCI, V117, P4935, DOI 10.1242/jcs.01355; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Rothkamm K, 2003, P NATL ACAD SCI USA, V100, P5057, DOI 10.1073/pnas.0830918100; Sedelnikova OA, 2002, RADIAT RES, V158, P486, DOI 10.1667/0033-7587(2002)158[0486:QDOIID]2.0.CO;2; Skobe M, 1998, P NATL ACAD SCI USA, V95, P1050, DOI 10.1073/pnas.95.3.1050; Tefferi A, 2005, MAYO CLIN PROC, V80, P390, DOI 10.4065/80.3.390; Thompson LH, 2004, MOL B INT U, P107; Von Zglinicki T, 2000, FREE RADICAL BIO MED, V28, P64, DOI 10.1016/S0891-5849(99)00207-5; Wischermann K, 2007, MUTAT RES-GEN TOX EN, V630, P122, DOI 10.1016/j.mrgentox.2007.02.009; Wondrak GT, 2006, PHOTOCH PHOTOBIO SCI, V5, P215, DOI 10.1039/b504573h	52	65	69	0	4	SPRINGERNATURE	LONDON	CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND	0950-9232	1476-5594		ONCOGENE	Oncogene	JUL 17	2008	27	31					4269	4280		10.1038/onc.2008.70	http://dx.doi.org/10.1038/onc.2008.70			12	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics & Heredity	326WY	18372922				2022-12-25	WOS:000257691100002
J	Schumann, S; Saggu, M; Moller, N; Anker, SD; Lendzian, F; Hildebrandt, P; Leimkuhler, S				Schumann, Silvia; Saggu, Miguel; Moeller, Nadine; Anker, Stefan D.; Lendzian, Friedhelm; Hildebrandt, Peter; Leimkuehler, Silke			The mechanism of assembly and cofactor insertion into Rhodobacter capsulatus xanthine dehydrogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLYBDENUM-COFACTOR; QUINALDINE 4-OXIDASE; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; PROTEIN VARIANTS; OXIDASE; CATALYSIS; ENZYMES; REDOX; XDHC	Rhodobacter capsulatus xanthine dehydrogenase (XDH) is a molybdo-flavoprotein that is highly homologous to the homodimeric mammalian xanthine oxidoreductase. However, the bacterial enzyme has an (alpha beta)(2) heterotetrameric structure, and the cofactors were identified to be located on two different polypeptides. We have analyzed the mechanism of cofactor insertion and subunit assembly of R. capsulatus XDH, using engineered subunits with appropriate substitutions in the interfaces. In an (alpha beta) heterodimeric XDH containing the XdhA and XdhB subunits, the molybdenum cofactor (Moco) was shown to be absent, indicating that dimerization of the (alpha beta) subunits has to precede Moco insertion. In an (alpha beta)(2) XDH heterotetramer variant, including only one active Moco-center, the active (alpha beta) site of the chimeric enzyme was shown to be fully active, revealing that the two subunits act independent without cooperativity. Amino acid substitutions at two cysteine residues coordinating FeSI of the two [2Fe-2S] clusters of the enzyme demonstrate that an incomplete assembly of FeSI impairs the formation of the XDH (alpha beta)(2) heterotetramer and, thus, insertion of Moco into the enzyme. The results reveal that the insertion of the different redox centers into R. capsulatus XDH takes place sequentially. Dimerization of two (alpha beta) dimers is necessary for insertion of sulfurated Moco into apo-XDH, the last step of XDH maturation.	[Schumann, Silvia; Moeller, Nadine; Leimkuehler, Silke] Univ Potsdam, Inst Biochem & Biol, D-14476 Potsdam, Germany; [Saggu, Miguel; Moeller, Nadine; Lendzian, Friedhelm; Hildebrandt, Peter] Tech Univ Berlin, Inst Chem, D-10623 Berlin, Germany; [Anker, Stefan D.] Charite CVK, Dept Cardiol, Div Appl Cachexia Res, D-13353 Berlin, Germany	University of Potsdam; Technical University of Berlin; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Leimkuhler, S (corresponding author), Univ Potsdam, Inst Biochem & Biol, Karl Liebknecht Str 24-25, D-14476 Potsdam, Germany.	sleim@uni-potsdam.de	Hildebrandt, Peter/J-5658-2014; Saggu, Miguel/B-1224-2009	Hildebrandt, Peter/0000-0003-1030-5900; Leimkuhler, Silke/0000-0003-3238-2122				Canne C, 1997, BIOCHEMISTRY-US, V36, P9780, DOI 10.1021/bi970581d; Choi EY, 2004, J INORG BIOCHEM, V98, P841, DOI 10.1016/j.jinorgbio.2003.11.010; Enroth C, 2000, P NATL ACAD SCI USA, V97, P10723, DOI 10.1073/pnas.97.20.10723; Hille R, 1996, CHEM REV, V96, P2757, DOI 10.1021/cr950061t; HUNT J, 1993, J BIOL CHEM, V268, P18685; JOHNSON JL, 1991, J BIOL CHEM, V266, P12140; JOHNSON JL, 1984, J BIOL CHEM, V259, P5414; Kappl R, 2006, BIOCHEMISTRY-US, V45, P14853, DOI 10.1021/bi061185a; Kisker C, 1997, ANNU REV BIOCHEM, V66, P233, DOI 10.1146/annurev.biochem.66.1.233; KOMAI H, 1969, J BIOL CHEM, V244, P1692; Leimkuhler S, 1998, MOL MICROBIOL, V27, P853, DOI 10.1046/j.1365-2958.1998.00733.x; Leimkuhler S, 1999, J BACTERIOL, V181, P2745; Leimkuhler S, 2004, J BIOL CHEM, V279, P40437, DOI 10.1074/jbc.M405778200; Leimkuhler S, 2003, J BIOL CHEM, V278, P20802, DOI 10.1074/jbc.M303091200; MCCORD JM, 1985, NEW ENGL J MED, V312, P159; Neumann M, 2007, J BIOL CHEM, V282, P28493, DOI 10.1074/jbc.M704020200; Neumann M, 2007, BIOCHEMISTRY-US, V46, P9586, DOI 10.1021/bi700630p; Neumann M, 2006, J BIOL CHEM, V281, P15701, DOI 10.1074/jbc.M601617200; Nishino T, 2005, J BIOL CHEM, V280, P24888, DOI 10.1074/jbc.M501830200; NISHINO T, 1994, J BIOCHEM, V116, P1; PALMER G, 1969, J BIOL CHEM, V244, P2614; Palmer T, 1996, MOL MICROBIOL, V20, P875, DOI 10.1111/j.1365-2958.1996.tb02525.x; Parschat K, 2001, BBA-PROTEIN STRUCT M, V1544, P151, DOI 10.1016/S0167-4838(00)00214-4; RAJAGOPALAN KV, 1996, ESCHERICHIA COLI SAL, P674; Schindelin H, 1996, SCIENCE, V272, P1615, DOI 10.1126/science.272.5268.1615; STESMANS A, 1989, PHYS REV B, V39, P2864, DOI 10.1103/PhysRevB.39.2864; Stoll S, 2006, J MAGN RESON, V178, P42, DOI 10.1016/j.jmr.2005.08.013; Tai LA, 2004, BIOCHEMISTRY-US, V43, P4869, DOI 10.1021/bi035467b; Truglio JJ, 2002, STRUCTURE, V10, P115, DOI 10.1016/S0969-2126(01)00697-9; Wilson HL, 2006, BIOCHEMISTRY-US, V45, P2149, DOI 10.1021/bi051609l; Xiang Q, 1996, BIOCHEMISTRY-US, V35, P5441, DOI 10.1021/bi952880d	31	30	30	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16602	16611		10.1074/jbc.M709894200	http://dx.doi.org/10.1074/jbc.M709894200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18390908	hybrid			2022-12-25	WOS:000256497100037
J	Raynard, S; Zhao, WX; Bussen, W; Lu, L; Ding, YY; Busygina, V; Meetei, AR; Sung, P				Raynard, Steven; Zhao, Weixing; Bussen, Wendy; Lu, Lucy; Ding, Yang-Yang; Busygina, Valeria; Meetei, Amom Ruhikanta; Sung, Patrick			Functional role of BLAP75 in BLM-topoisomerase III alpha-dependent Holliday junction processing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOMS-SYNDROME HELICASE; SYNDROME GENE-PRODUCT; HOMOLOGOUS RECOMBINATION; GENOME STABILITY; RECQ HELICASES; D-LOOPS; COMPLEX; RMI1/NCE4; PROTEINS; PROMOTES	The BLAP75 protein combines with the BLM helicase and topoisomerase (Topo) III alpha to form an evolutionarily conserved complex, termed the BTB complex, that functions to regulate homologous recombination. BLAP75 binds DNA, associates with both BLM and Topo III alpha, and enhances the ability of the BLM-Topo III alpha pair to branch migrate the Holliday junction (HJ) or dissolve the double Holliday junction (dHJ) structure to yield non-crossover recombinants. Here we seek to understand the relevance of the biochemical attributes of BLAP75 in HJ processing. With the use of a series of BLAP75 protein fragments, we show that the evolutionarily conserved N-terminal third of BLAP75 mediates complex formation with BLM and Topo III alpha and that the DNA binding activity resides in the C-terminal third of this novel protein. Interestingly, the N-terminal third of BLAP75 is just as adept as the full-length protein in the promotion of dHJ dissolution and HJ unwinding by BLM-Topo III alpha. Thus, the BLAP75 DNA binding activity is dispensable for the ability of the BTB complex to process the HJ in vitro. Lastly, we show that a BLAP75 point mutant (K166A), defective in Topo III alpha interaction, is unable to promote dHJ dissolution and HJ unwinding by BLM-Topo III alpha. This result provides proof that the functional integrity of the BTB complex is contingent upon the interaction of BLAP75 with Topo III alpha.	[Raynard, Steven; Zhao, Weixing; Bussen, Wendy; Lu, Lucy; Ding, Yang-Yang; Busygina, Valeria; Sung, Patrick] Yale Univ, Sch Med, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; [Meetei, Amom Ruhikanta] Univ Cincinnati, Coll Med, Div Expt Hematol & Canc Biol, Cincinnati Childrens Res Fdn, Cincinnati, OH 45229 USA	Yale University; Cincinnati Children's Hospital Medical Center; Cincinnati Children's Hospital Research Foundation; University System of Ohio; University of Cincinnati	Sung, P (corresponding author), Yale Univ, Sch Med, Dept Mol Biophys & Biochem, C130 Sterling Hall Med,333 Cedar St, New Haven, CT 06520 USA.	patrick.sung@yale.edu	zhao, weixing/H-3154-2013	zhao, weixing/0000-0001-5746-3696; Ding, Yang-Yang/0000-0003-1588-2571	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL084082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015632, R01ES015252] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL084082] Funding Source: Medline; NIEHS NIH HHS [ES015252, ES015632] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		Adams MD, 2003, SCIENCE, V299, P265, DOI 10.1126/science.1077198; Bachrati CZ, 2006, NUCLEIC ACIDS RES, V34, P2269, DOI 10.1093/nar/gkl258; Bugreev DV, 2007, GENE DEV, V21, P3085, DOI 10.1101/gad.1609007; Bussen W, 2007, J BIOL CHEM, V282, P31484, DOI 10.1074/jbc.M706116200; CHAGANTI RS, 1974, P NATL ACAD SCI USA, V71, P4508, DOI 10.1073/pnas.71.11.4508; Chang M, 2005, EMBO J, V24, P2024, DOI 10.1038/sj.emboj.7600684; Chen CF, 2007, J BIOL CHEM, V282, P28971, DOI 10.1074/jbc.M705427200; Cheok CF, 2005, BIOCHEM SOC T, V33, P1456, DOI 10.1042/BST0331456; ELLIS NA, 1995, CELL, V83, P655, DOI 10.1016/0092-8674(95)90105-1; FU TJ, 1994, J MOL BIOL, V236, P91, DOI 10.1006/jmbi.1994.1121; GERMAN J, 1993, MEDICINE, V72, P393, DOI 10.1097/00005792-199311000-00003; Hickson ID, 2003, NAT REV CANCER, V3, P169, DOI 10.1038/nrc1012; Hirano S, 2005, EMBO J, V24, P418, DOI 10.1038/sj.emboj.7600534; Hu Y, 2007, GENE DEV, V21, P3073, DOI 10.1101/gad.1609107; Karow JK, 2000, P NATL ACAD SCI USA, V97, P6504, DOI 10.1073/pnas.100448097; KUHN EM, 1986, CANCER GENET CYTOGEN, V22, P1, DOI 10.1016/0165-4608(86)90132-9; Macris MA, 2006, DNA REPAIR, V5, P172, DOI 10.1016/j.dnarep.2005.09.005; Meetei AR, 2003, MOL CELL BIOL, V23, P3417, DOI 10.1128/MCB.23.10.3417-3426.2003; Mullen JR, 2005, MOL CELL BIOL, V25, P4476, DOI 10.1128/MCB.25.11.4476-4487.2005; Osman F, 2005, MOL CELL BIOL, V25, P8084, DOI 10.1128/MCB.25.18.8084-8096.2005; Raynard S, 2006, J BIOL CHEM, V281, P13861, DOI 10.1074/jbc.C600051200; Sung P, 2006, NAT REV MOL CELL BIO, V7, P739, DOI 10.1038/nrm2008; Theobald DL, 2003, ANNU REV BIOPH BIOM, V32, P115, DOI 10.1146/annurev.biophys.32.110601.142506; van Brabant AJ, 2000, BIOCHEMISTRY-US, V39, P14617, DOI 10.1021/bi0018640; Wu L, 2006, P NATL ACAD SCI USA, V103, P4068, DOI 10.1073/pnas.0508295103; Wu L, 2003, NATURE, V426, P870, DOI 10.1038/nature02253; Yin JH, 2005, EMBO J, V24, P1465, DOI 10.1038/sj.emboj.7600622	27	60	62	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15701	15708		10.1074/jbc.M802127200	http://dx.doi.org/10.1074/jbc.M802127200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18390547	hybrid, Green Published			2022-12-25	WOS:000256332500025
J	Petersen, SV; Kristensen, T; Petersen, JS; Ramsgaard, L; Oury, TD; Crapo, JD; Nielsen, NC; Enghild, JJ				Petersen, Steen V.; Kristensen, Torsten; Petersen, Jane S.; Ramsgaard, Lasse; Oury, Tim D.; Crapo, James D.; Nielsen, Niels C.; Enghild, Jan J.			The folding of human active and inactive extracellular superoxide dismutases is an intracellular event	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING DOMAIN; N-TERMINAL DOMAIN; EC-SOD; OXIDATIVE FRAGMENTATION; PEPTIDE MIXTURES; HUMAN PROTEIN; COPPER; METAL; CHAPERONE; SEQUENCE	Human extracellular superoxide dismutase (EC-SOD) is a tetrameric glycoprotein responsible for the removal of superoxide generated in the extracellular space. Two different folding variants of EC-SOD exist based on the disulfide bridge connectivity, resulting in enzymatically active (aEC-SOD) and inactive (iEC-SOD) subunits. As a consequence of this, the assembly of the EC-SOD tetramers produces molecules with variable activity and may represent a way to regulate the antioxidant level in the extracellular space. To determine whether the formation of these two folding variants is an intra- or extracellular event, we analyzed the biosynthesis in human embryonic kidney 293 cells expressing wild-type EC-SOD. These analyses revealed that both folding variants were present in the intra- and extracellular spaces, suggesting that the formation is an intracellular event. To further analyze the biosynthesis, we constructed mutants with the capacity to generate only aEC-SOD (C195S) or iEC-SOD (C45S). The expression of these suggested that the cellular biosynthetic machinery supported the secretion of aEC-SOD but not iEC-SOD. The coexpression of these two mutants did not affect the expression pattern. This study shows that generation of the EC-SOD folding variants is an intracellular event that depends on a free cysteine residue not involved in disulfide bonding.	[Petersen, Steen V.; Kristensen, Torsten; Petersen, Jane S.; Ramsgaard, Lasse; Enghild, Jan J.] Univ Aarhus, Dept Mol Biol, Ctr Insoluble Prot Structure inSPIN, DK-8000 Aarhus C, Denmark; [Nielsen, Niels C.] Univ Aarhus, Dept Chem, Interdisciplinary Nanosci Ctr iNANO, DK-8000 Aarhus C, Denmark; [Ramsgaard, Lasse; Oury, Tim D.] Univ Pittsburgh, Sch Med, Dept Pathol, Pittsburgh, PA 15261 USA; [Crapo, James D.] Natl Jewish Med & Res Ctr, Dept Med, Denver, CO 80206 USA	Aarhus University; Aarhus University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; National Jewish Health	Enghild, JJ (corresponding author), Univ Aarhus, Dept Mol Biol, Ctr Insoluble Prot Structure inSPIN, Gustav Wieds Vej 10C, DK-8000 Aarhus C, Denmark.	jje@mb.au.dk		Enghild, Jan Johannes/0000-0001-9292-9172; Vang Petersen, Steen/0000-0002-9338-911X; Nielsen, Niels Chr./0000-0003-2978-4366				ADACHI T, 1992, ARCH BIOCHEM BIOPHYS, V297, P155, DOI 10.1016/0003-9861(92)90654-F; Arnesano F, 2005, STRUCTURE, V13, P713, DOI 10.1016/j.str.2005.02.015; Banci L, 2006, J BIOL CHEM, V281, P2333, DOI 10.1074/jbc.M506497200; Bowler RP, 2002, J BIOL CHEM, V277, P16505, DOI 10.1074/jbc.M105409200; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; Chen VM, 2006, BIOCHEMISTRY-US, V45, P12020, DOI 10.1021/bi061271a; Due AV, 2006, FEBS LETT, V580, P1485, DOI 10.1016/j.febslet.2006.01.081; Ellgaard L, 2005, EMBO REP, V6, P28, DOI 10.1038/sj.embor.7400311; Enghild JJ, 1999, J BIOL CHEM, V274, P14818, DOI 10.1074/jbc.274.21.14818; Fattman CL, 2001, FREE RADICAL BIO MED, V31, P1198, DOI 10.1016/S0891-5849(01)00699-2; Gao F, 2008, J BIOL CHEM, V283, P6058, DOI 10.1074/jbc.M709273200; Gitschier J, 1998, NAT STRUCT BIOL, V5, P47, DOI 10.1038/nsb0198-47; Gobom J, 1999, J MASS SPECTROM, V34, P105, DOI 10.1002/(SICI)1096-9888(199902)34:2<105::AID-JMS768>3.0.CO;2-4; HJALMARSSON K, 1987, P NATL ACAD SCI USA, V84, P6340, DOI 10.1073/pnas.84.18.6340; Hoffmann JH, 2004, EMBO J, V23, P160, DOI 10.1038/sj.emboj.7600016; Jeney V, 2005, CIRC RES, V96, P723, DOI 10.1161/01.RES.0000162001.57896.66; Lamb AL, 2001, NAT STRUCT BIOL, V8, P751, DOI 10.1038/nsb0901-751; MARKLUND SL, 1982, P NATL ACAD SCI-BIOL, V79, P7634, DOI 10.1073/pnas.79.24.7634; MARKLUND SL, 1984, J CLIN INVEST, V74, P1398, DOI 10.1172/JCI111550; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; Matthias LJ, 2002, NAT IMMUNOL, V3, P727, DOI 10.1038/ni815; MCCORD JM, 1969, J BIOL CHEM, V244, P6049; O'Halloran TV, 2000, J BIOL CHEM, V275, P25057, DOI 10.1074/jbc.R000006200; OLIN KL, 1995, AM J CLIN NUTR, V61, P1263, DOI 10.1093/ajcn/61.6.1263; Olsen DA, 2004, J BIOL CHEM, V279, P22152, DOI 10.1074/jbc.M401180200; OURY TD, 1994, LAB INVEST, V70, P889; Oury TD, 1996, BIOCHEM J, V317, P51, DOI 10.1042/bj3170051; Oury TD, 1996, FREE RADICAL BIO MED, V20, P957, DOI 10.1016/0891-5849(95)02222-8; Palumaa P, 2004, BIOCHEM J, V382, P307, DOI 10.1042/BJ20040360; PEAR WS, 1993, P NATL ACAD SCI USA, V90, P8392, DOI 10.1073/pnas.90.18.8392; Petersen SV, 2005, BIOCHEM J, V385, P427, DOI 10.1042/BJ20041218; Petersen SV, 2004, BIOCHEMISTRY-US, V43, P14275, DOI 10.1021/bi048526+; Petersen SV, 2004, J BIOL CHEM, V279, P13705, DOI 10.1074/jbc.M310217200; Petersen SV, 2003, P NATL ACAD SCI USA, V100, P13875, DOI 10.1073/pnas.2436143100; Pufahl RA, 1997, SCIENCE, V278, P853, DOI 10.1126/science.278.5339.853; Qin ZY, 2006, FASEB J, V20, P334, DOI 10.1096/fj.05-4564fje; SANDSTROM J, 1992, J BIOL CHEM, V267, P18205; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P379; Schmidt B, 2006, BIOCHEMISTRY-US, V45, P7429, DOI 10.1021/bi0603064; Stenlund P, 1997, PROTEIN SCI, V6, P2350; TAINER JA, 1982, J MOL BIOL, V160, P181, DOI 10.1016/0022-2836(82)90174-7; Tibell LAE, 1996, BBA-PROTEIN STRUCT M, V1292, P47, DOI 10.1016/0167-4838(95)00189-1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Turano C, 2002, J CELL PHYSIOL, V193, P154, DOI 10.1002/jcp.10172; Wernimont AK, 2000, NAT STRUCT BIOL, V7, P766	45	19	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15031	15036		10.1074/jbc.M801548200	http://dx.doi.org/10.1074/jbc.M801548200			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18385137	hybrid, Green Published			2022-12-25	WOS:000256232000016
J	Yang, BX; Zador, Z; Verkman, AS				Yang, Baoxue; Zador, Zsolt; Verkman, A. S.			Glial cell aquaporin-4 overexpression in transgenic mice accelerates cytotoxic brain swelling	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASTROCYTE-SPECIFIC EXPRESSION; FIBRILLARY ACIDIC PROTEIN; WATER CHANNEL AQUAPORIN-4; NERVOUS-SYSTEM; EDEMA; MODEL; INJURY; RAT; DELETION; GENE	Aquaporin-4 (AQP4) is a water transport protein expressed in glial cell plasma membranes, including glial cell foot processes lining the blood-brain barrier. AQP4 deletion in mice reduces cytotoxic brain edema produced by different pathologies. To determine whether AQP4 is rate-limiting for brain water accumulation and whether altered AQP4 expression, as occurs in various pathologies, could have functional importance, we generated mice that overexpressed AQP4 in brain glial cells by a transgenic approach using the glial fibrillary acid protein promoter. Overexpression of AQP4 protein in brain by similar to 2.3-fold did not affect mouse survival, appearance, or behavior, nor did it affect brain anatomy or intracranial pressure (ICP). However, following acute water intoxication produced by intraperitoneal water injection, AQP4-overexpressing mice had an accelerated progression of cytotoxic brain swelling, with ICP elevation of 20 +/- 2 mmHg at 10 min, often producing brain herniation and death. In contrast, ICP elevation was 14 +/- 2 mmHg at 10 min in control mice and 9.8 +/- 2 mmHg in AQP4 knockout mice. The deduced increase in brain water content correlated linearly with brain AQP4 protein expression. We conclude that AQP4 expression is rate-limiting for brain water accumulation, and thus, that altered AQP4 expression can be functionally significant.	[Verkman, A. S.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Verkman, AS (corresponding author), Univ Calif San Francisco, Dept Med, 1246 Hlth Sci E Tower, San Francisco, CA 94143 USA.	Alan.Verkman@ucsf.edu		Zador, Zsolt/0000-0001-9767-3372; zador, zsolt/0000-0003-4297-616X	NATIONAL EYE INSTITUTE [R01EY013574] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL073856, R01HL059198] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R37EB000415, R01EB000415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK035124, P30DK072517, R01DK035124] Funding Source: NIH RePORTER; NEI NIH HHS [EY 13574] Funding Source: Medline; NHLBI NIH HHS [HL 59198, HL 73856] Funding Source: Medline; NIBIB NIH HHS [EB 00415] Funding Source: Medline; NIDDK NIH HHS [DK 35124, DK 72517] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Amiry-Moghaddam M, 2004, FASEB J, V18, P542, DOI 10.1096/fj.03-0869fje; Amiry-Moghaddam M, 2003, P NATL ACAD SCI USA, V100, P13615, DOI 10.1073/pnas.2336064100; Badaut J, 2003, ACTA NEUROCHIR SUPPL, V86, P495; Badaut J, 2006, FASEB J, V20, P2423, DOI 10.1096/fj.06-1104ufm; BESNARD F, 1991, J BIOL CHEM, V266, P18877; Bloch O, 2005, J NEUROCHEM, V95, P254, DOI 10.1111/j.1471-4159.2005.03362.x; Bloch O, 2006, J CEREBR BLOOD F MET, V26, P1527, DOI 10.1038/sj.jcbfm.9600306; BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994; Brenner Michael, 1996, Methods (Orlando), V10, P351, DOI 10.1006/meth.1996.0113; Cornet A, 2001, P NATL ACAD SCI USA, V98, P13306, DOI 10.1073/pnas.231474098; de Leeuw B, 2006, J NEUROSCI RES, V83, P744, DOI 10.1002/jnr.20776; Forman MS, 2005, J NEUROSCI, V25, P3539, DOI 10.1523/JNEUROSCI.0081-05.2005; Fryclenlund DS, 2006, P NATL ACAD SCI USA, V103, P13532, DOI 10.1073/pnas.0605796103; Fu XM, 2007, GLIA, V55, P935, DOI 10.1002/glia.20515; Furman CS, 2003, P NATL ACAD SCI USA, V100, P13609, DOI 10.1073/pnas.2235843100; Ghabriel MN, 2006, ACTA NEUROCHIR SUPPL, V96, P402; Hindinger C, 2005, J NEUROSCI RES, V82, P20, DOI 10.1002/jnr.20616; Ke CS, 2001, NEUROSCI LETT, V301, P21, DOI 10.1016/S0304-3940(01)01589-0; Kiening KL, 2002, NEUROSCI LETT, V324, P105, DOI 10.1016/S0304-3940(02)00180-5; Lee Y, 2008, GLIA, V56, P481, DOI 10.1002/glia.20622; Ma TH, 1997, J CLIN INVEST, V100, P957, DOI 10.1172/JCI231; Manley GT, 2000, NAT MED, V6, P159, DOI 10.1038/72256; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; Meng SZ, 2004, EUR J NEUROSCI, V19, P2261, DOI 10.1111/j.0953-816X.2004.03315.x; Neal CJ, 2007, J NEUROTRAUM, V24, P1609, DOI 10.1089/neu.2007.0301; Pagenstecher A, 2000, J IMMUNOL, V164, P4481, DOI 10.4049/jimmunol.164.9.4481; Papadopoulos MC, 2004, FASEB J, V18, P1291, DOI 10.1096/fj.04-1723fje; Papadopoulos MC, 2005, J BIOL CHEM, V280, P13906, DOI 10.1074/jbc.M413627200; Prevot V, 2003, J NEUROSCI, V23, P230; Rash JE, 1998, P NATL ACAD SCI USA, V95, P11981, DOI 10.1073/pnas.95.20.11981; Saadoun S, 2002, J NEUROL NEUROSUR PS, V72, P262, DOI 10.1136/jnnp.72.2.262; Satoh J, 2007, NEUROPATHOLOGY, V27, P245, DOI 10.1111/j.1440-1789.2007.00774.x; Smith JD, 1998, NEUROBIOL AGING, V19, P407, DOI 10.1016/S0197-4580(98)00076-1; Su M, 2004, NEUROCHEM RES, V29, P2075, DOI 10.1007/s11064-004-6881-1; Sun YL, 1998, J NEUROSCI, V18, P3261; Thiagarajah JR, 2005, J NEUROSCI RES, V80, P293, DOI 10.1002/jnr.20439; Verkman AS, 2006, BBA-BIOMEMBRANES, V1758, P1085, DOI 10.1016/j.bbamem.2006.02.018; Wang CY, 2006, GENE THER, V13, P1447, DOI 10.1038/sj.gt.3302771; Warth A, 2007, J NEUROSCI RES, V85, P1336, DOI 10.1002/jnr.21224; Yang BX, 1997, J BIOL CHEM, V272, P16140, DOI 10.1074/jbc.272.26.16140; Zhuo L, 1997, DEV BIOL, V187, P36, DOI 10.1006/dbio.1997.8601	41	140	171	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15280	15286		10.1074/jbc.M801425200	http://dx.doi.org/10.1074/jbc.M801425200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18375385	Green Published, hybrid			2022-12-25	WOS:000256232000046
J	Orlando, K; Zhang, J; Zhang, XY; Yue, P; Chiang, T; Bi, E; Guo, W				Orlando, Kelly; Zhang, Jian; Zhang, Xiaoyu; Yue, Peng; Chiang, Teresa; Bi, Erfei; Guo, Wei			Regulation of Gic2 localization and function by phosphatidylinositol 4,5-bisphosphate during the establishment of cell polarity in budding yeast	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMA-MEMBRANE; BINDING-PROTEIN; N-WASP; CDC42; EXOCYST; DOMAINS; GROWTH; IDENTIFICATION; POLARIZATION; ORGANIZATION	Establishment of cell polarity is important for a wide range of biological processes, from asymmetric cell growth in budding yeast to neurite formation in neurons. In the yeast Saccharomyces cerevisiae, the small GTPase Cdc42 controls polarized actin organization and exocytosis toward the bud. Gic2, a Cdc42 effector, is targeted to the bud tip and plays an important role in early bud formation. The GTP-bound Cdc42 interacts with Gic2 through the Cdc42/Rac interactive binding domain located at the N terminus of Gic2 and activates Gic2 during bud emergence. Here we identify a polybasic region in Gic2 adjacent to the Cdc42/Rac interactive binding domain that directly interacts with phosphatidylinositol 4,5-bisphosphate in the plasma membrane. We demonstrate that this interaction is necessary for the polarized localization of Gic2 to the bud tip and is important for the function of Gic2 in cell polarization. We propose that phosphatidylinositol 4,5-bisphosphate and Cdc42 act in concert to regulate polarized localization and function of Gic2 during polarized cell growth in the budding yeast.	[Orlando, Kelly; Zhang, Jian; Zhang, Xiaoyu; Yue, Peng; Chiang, Teresa; Guo, Wei] Univ Penn, Dept Biol, Philadelphia, PA 19104 USA; [Bi, Erfei] Univ Penn, Dept Cell & Dev Biol, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania	Guo, W (corresponding author), Univ Penn, Dept Biol, Philadelphia, PA 19104 USA.	guowei@sas.upenn.edu	Zhang, xiaoyu/GXA-3206-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM064690, R01GM059216, F32GM082012] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 64690, GM 59216, F32 GM 082012] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balla A, 2005, MOL BIOL CELL, V16, P1282, DOI 10.1091/mbc.E04-07-0578; Brown JL, 1997, GENE DEV, V11, P2972, DOI 10.1101/gad.11.22.2972; BURBELO PD, 1995, J BIOL CHEM, V270, P29071, DOI 10.1074/jbc.270.49.29071; Chen GC, 1997, GENE DEV, V11, P2958, DOI 10.1101/gad.11.22.2958; Desrivieres S, 1998, J BIOL CHEM, V273, P15787, DOI 10.1074/jbc.273.25.15787; Etienne-Manneville S, 2004, J CELL SCI, V117, P1291, DOI 10.1242/jcs.01115; GOUD B, 1988, CELL, V53, P753, DOI 10.1016/0092-8674(88)90093-1; He B, 2007, EMBO J, V26, P4053, DOI 10.1038/sj.emboj.7601834; Hokanson DE, 2006, P NATL ACAD SCI USA, V103, P3118, DOI 10.1073/pnas.0505685103; Isakoff SJ, 1998, EMBO J, V17, P5374, DOI 10.1093/emboj/17.18.5374; Iwase M, 2006, MOL BIOL CELL, V17, P1110, DOI 10.1091/mbc.E05-08-0793; Jaquenoud M, 2000, MOL CELL BIOL, V20, P6244, DOI 10.1128/MCB.20.17.6244-6258.2000; Jaquenoud M, 1998, EMBO J, V17, P5360, DOI 10.1093/emboj/17.18.5360; Johnson DI, 1999, MICROBIOL MOL BIOL R, V63, P54, DOI 10.1128/MMBR.63.1.54-105.1999; Klein DE, 1998, J BIOL CHEM, V273, P27725, DOI 10.1074/jbc.273.42.27725; Liu JL, 2007, MOL BIOL CELL, V18, P4483, DOI 10.1091/mbc.E07-05-0461; McLaughlin S, 2002, ANNU REV BIOPH BIOM, V31, P151, DOI 10.1146/annurev.biophys.31.082901.134259; MUMBERG D, 1995, GENE, V156, P119, DOI 10.1016/0378-1119(95)00037-7; Papayannopoulos V, 2005, MOL CELL, V17, P181, DOI 10.1016/j.molcel.2004.11.054; Park HO, 2007, MICROBIOL MOL BIOL R, V71, P48, DOI 10.1128/MMBR.00028-06; Prehoda KE, 2000, SCIENCE, V290, P801, DOI 10.1126/science.290.5492.801; Pruyne D, 2000, J CELL SCI, V113, P571; Pruyne D, 2004, ANNU REV CELL DEV BI, V20, P559, DOI 10.1146/annurev.cellbio.20.010403.103108; Rohatgi R, 2000, J CELL BIOL, V150, P1299, DOI 10.1083/jcb.150.6.1299; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; Stefan CJ, 2002, MOL BIOL CELL, V13, P542, DOI 10.1091/mbc.01-10-0476; Takahashi S, 2007, MOL BIOL CELL, V18, P4945, DOI 10.1091/mbc.E07-07-0676; Wild AC, 2004, J BIOL CHEM, V279, P17101, DOI 10.1074/jbc.M314035200; Zajac A, 2005, MOL BIOL CELL, V16, P1500, DOI 10.1091/mbc.E04-10-0896; Zhang XY, 2008, J CELL BIOL, V180, P145, DOI 10.1083/jcb.200704128; Zhang XY, 2001, J BIOL CHEM, V276, P46745, DOI 10.1074/jbc.M107464200	31	24	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14205	14212		10.1074/jbc.M708178200	http://dx.doi.org/10.1074/jbc.M708178200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18387956	Green Published, hybrid			2022-12-25	WOS:000255941400006
J	Volgushev, M; Malyshev, A; Balaban, P; Chistiakova, M; Volgushev, S; Wolf, F				Volgushev, Maxim; Malyshev, Aleksey; Balaban, Pavel; Chistiakova, Marina; Volgushev, Stanislav; Wolf, Fred			Onset Dynamics of Action Potentials in Rat Neocortical Neurons and Identified Snail Neurons: Quantification of the Difference	PLOS ONE			English	Article								The generation of action potentials (APs) is a key process in the operation of nerve cells and the communication between neurons. Action potentials in mammalian central neurons are characterized by an exceptionally fast onset dynamics, which differs from the typically slow and gradual onset dynamics seen in identified snail neurons. Here we describe a novel method of analysis which provides a quantitative measure of the onset dynamics of action potentials. This method captures the difference between the fast, step-like onset of APs in rat neocortical neurons and the gradual, exponential-like AP onset in identified snail neurons. The quantitative measure of the AP onset dynamics, provided by the method, allows us to perform quantitative analyses of factors influencing the dynamics.	[Volgushev, Maxim; Malyshev, Aleksey; Chistiakova, Marina] Univ Connecticut, Dept Phychol, Storrs, CT 06269 USA; [Volgushev, Maxim; Chistiakova, Marina] Ruhr Univ Bochum, Fac Med, Dept Neurophysiol, Bochum, Germany; [Volgushev, Stanislav] Ruhr Univ Bochum, Fac Math 3, Bochum, Germany; [Volgushev, Maxim; Malyshev, Aleksey; Balaban, Pavel] Russian Acad Sci, Inst Higher Nervous Activity & Neurophysiol, Moscow, Russia; [Wolf, Fred] Univ Gottingen, Bernstein Ctr Computat Neurosci, Fac Phys, MPI Dynam & Self Org, Gottingen, Germany	University of Connecticut; Ruhr University Bochum; Ruhr University Bochum; Institute of Higher Nervous Activity & Neurophysiology of RAS; Russian Academy of Sciences; Max Planck Society; University of Gottingen	Volgushev, M (corresponding author), Univ Connecticut, Dept Phychol, Storrs, CT 06269 USA.	maxim.volgushev@uconn.edu	Balaban, Pavel M/I-5811-2014; Volgushev, Maxim/AAO-6793-2020; Wolf, Fred/D-5771-2011; Malyshev, Alexey/P-2775-2015; Malyshev, Aleksey/R-8471-2018	Balaban, Pavel M/0000-0001-9248-8207; Volgushev, Maxim/0000-0002-8080-1136; Wolf, Fred/0000-0002-7068-3762; Malyshev, Aleksey/0000-0002-4633-7691	Deutsche Forschungsgemeinschaft; SFB 509 TPA5; FoRUM-Programm F475-2005; BMBF; Human Frontier Science Program [RGP0063/2003-C102]	Deutsche Forschungsgemeinschaft(German Research Foundation (DFG)); SFB 509 TPA5; FoRUM-Programm F475-2005; BMBF(Federal Ministry of Education & Research (BMBF)); Human Frontier Science Program(Human Frontier Science Program)	The work preformed in author's labs is supported by the grants from Deutsche Forschungsgemeinschaft, SFB 509 TPA5, FoRUM-Programm F475-2005 and the BMBF to MV, and from the Human Frontier Science Program, RGP0063/2003-C102 and the BMBF to FW.	Alle H, 2006, SCIENCE, V311, P1290, DOI 10.1126/science.1119055; Antic S, 2000, J PHYSIOL-LONDON, V527, P55, DOI 10.1111/j.1469-7793.2000.00055.x; Balaban PM, 2002, NEUROSCI BIOBEHAV R, V26, P597, DOI 10.1016/S0149-7634(02)00022-2; Baranauskas G, 2006, J NEUROSCI, V26, P671, DOI 10.1523/JNEUROSCI.2283-05.2006; Beck O, 2005, J NEUROPHYSIOL, V94, P363, DOI 10.1152/jn.01287.2004; Clark BA, 2005, NAT NEUROSCI, V8, P137, DOI 10.1038/nn1390; Colbert CM, 2002, NAT NEUROSCI, V5, P533, DOI 10.1038/nn857; COOMBS JS, 1957, J PHYSIOL-LONDON, V139, P198, DOI 10.1113/jphysiol.1957.sp005887; Dayan P., 2001, THEORETICAL NEUROSCI, P460; Destexhe A, 1999, J NEUROPHYSIOL, V81, P1531, DOI 10.1152/jn.1999.81.4.1531; DODT HU, 1990, BRAIN RES, V537, P333, DOI 10.1016/0006-8993(90)90380-T; FATT P, 1957, J NEUROPHYSIOL, V20, P61, DOI 10.1152/jn.1957.20.1.61; FUORTES MGF, 1957, J GEN PHYSIOL, V40, P735, DOI 10.1085/jgp.40.5.735; Hille B., 2001, ION CHANNELS EXCITAB, P813; HODGKIN AL, 1952, J PHYSIOL-LONDON, V116, P424, DOI 10.1113/jphysiol.1952.sp004716; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HODGKIN AL, 1952, J PHYSIOL-LONDON, V116, P449, DOI 10.1113/jphysiol.1952.sp004717; Khaliq ZM, 2006, J NEUROSCI, V26, P1935, DOI 10.1523/JNEUROSCI.4664-05.2006; Mainen ZF, 1995, NEURON, V15, P1427, DOI 10.1016/0896-6273(95)90020-9; Meeks JP, 2005, J PHYSIOL-LONDON, V566, P425, DOI 10.1113/jphysiol.2005.089086; NAUNDORF B, 2006, UNIQUE FEATURES ACTI, P1060; Palmer LM, 2006, J NEUROSCI, V26, P1854, DOI 10.1523/JNEUROSCI.4812-05.2006; Shu YS, 2007, J NEUROPHYSIOL, V97, P746, DOI 10.1152/jn.00922.2006; STUART G, 1994, NEURON, V13, P703, DOI 10.1016/0896-6273(94)90037-X; STUART GJ, 1994, NATURE, V367, P69, DOI 10.1038/367069a0; TAUC L, 1962, J GEN PHYSIOL, V45, P1099, DOI 10.1085/jgp.45.6.1099; TAUC L, 1962, J GEN PHYSIOL, V45, P1077, DOI 10.1085/jgp.45.6.1077; Volgushev M, 2000, J PHYSIOL-LONDON, V522, P59, DOI 10.1111/j.1469-7793.2000.0059m.x; Wang XJ, 2003, J NEUROPHYSIOL, V89, P3279, DOI 10.1152/jn.00242.2003; Zecevic D, 1996, NATURE, V381, P322, DOI 10.1038/381322a0	30	12	12	0	0	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1962	10.1371/journal.pone.0001962	http://dx.doi.org/10.1371/journal.pone.0001962			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398478	Green Published, gold			2022-12-25	WOS:000260795500031
J	Wang, SJ; Szalay, MS; Zhang, CS; Csermely, P				Wang, Shijun; Szalay, Mate S.; Zhang, Changshui; Csermely, Peter			Learning and Innovative Elements of Strategy Adoption Rules Expand Cooperative Network Topologies	PLOS ONE			English	Article							PRISONERS-DILEMMA GAME; SOCIAL DILEMMAS; EVOLUTIONARY GAMES; MAINTENANCE; TRANSITIONS; DYNAMICS; GRAPHS	Cooperation plays a key role in the evolution of complex systems. However, the level of cooperation extensively varies with the topology of agent networks in the widely used models of repeated games. Here we show that cooperation remains rather stable by applying the reinforcement learning strategy adoption rule, Q-learning on a variety of random, regular, small-word, scale-free and modular network models in repeated, multi-agent Prisoner's Dilemma and Hawk-Dove games. Furthermore, we found that using the above model systems other long-term learning strategy adoption rules also promote cooperation, while introducing a low level of noise (as a model of innovation) to the strategy adoption rules makes the level of cooperation less dependent on the actual network topology. Our results demonstrate that long-term learning and random elements in the strategy adoption rules, when acting together, extend the range of network topologies enabling the development of cooperation at a wider range of costs and temptations. These results suggest that a balanced duo of learning and innovation may help to preserve cooperation during the re-organization of real-world networks, and may play a prominent role in the evolution of self-organizing, complex systems.	[Szalay, Mate S.; Csermely, Peter] Semmelweis Univ, Dept Med Chem, Budapest, Hungary; [Wang, Shijun; Zhang, Changshui] Tsinghua Univ, Dept Automat, Beijing, Peoples R China	Semmelweis University; Tsinghua University	Csermely, P (corresponding author), Semmelweis Univ, Dept Med Chem, Budapest, Hungary.	csermely@puskin.sote.hu	Wang, Shijun/E-5005-2010; Csermely, Peter/J-2067-2017	Csermely, Peter/0000-0001-9234-0659	EU [FP6-518230]; Hungarian Science Foundation [OTKA- K69105]; Hungarian National Research Initiative [NKFP-1A/056/2004, KKK-0015/3.0]	EU(European Commission); Hungarian Science Foundation(Orszagos Tudomanyos Kutatasi Alapprogramok (OTKA)); Hungarian National Research Initiative	Work in the authors' laboratory was supported by research grants from the EU (FP6-518230), Hungarian Science Foundation (OTKA- K69105) and the Hungarian National Research Initiative (NKFP-1A/056/2004 and KKK-0015/3.0). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Aumann RJ, 2006, P NATL ACAD SCI USA, V103, P17075, DOI 10.1073/pnas.0608329103; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Batagelj V., 1998, CONNECTIONS, V21, P47, DOI DOI 10.1017/CB09780511996368; Cohen MD, 2001, RATION SOC, V13, P5, DOI 10.1177/104346301013001001; Csermely P, 2006, WEAK LINKS STABILIZE; Derenyi I, 2004, PHYSICA A, V334, P583, DOI 10.1016/j.physa.2003.10.083; Durrett R, 2006, RANDOM GRAPH DYNAMIC; Ebel H, 2002, PHYS REV E, V66, DOI 10.1103/PhysRevE.66.056118; FEIGEL A, 2006, EVOLUTION COOPERATIO; Fu F, 2007, PHYS LETT A, V371, P58, DOI 10.1016/j.physleta.2007.05.116; Girvan M, 2002, P NATL ACAD SCI USA, V99, P7821, DOI 10.1073/pnas.122653799; Goyal S, 2005, GAME ECON BEHAV, V50, P178, DOI 10.1016/j.geb.2004.01.005; GRANOVETTER M, 1985, AM J SOCIOL, V91, P481, DOI 10.1086/228311; Hauert C, 2004, NATURE, V428, P643, DOI 10.1038/nature02360; Holme P, 2006, PHYS REV LETT, V96, DOI 10.1103/PhysRevLett.96.098701; Kirschner M, 1998, P NATL ACAD SCI USA, V95, P8420, DOI 10.1073/pnas.95.15.8420; Kovacs IA, 2005, FEBS LETT, V579, P2254, DOI 10.1016/j.febslet.2005.03.056; Leskovec J, 2007, ACM T WEB, V1, DOI 10.1145/1232722.1232727; Luthi L, 2007, LECT NOTES ARTIF INT, V4648, P545; Macy MW, 2002, P NATL ACAD SCI USA, V99, P7214, DOI 10.1073/pnas.082097399; Macy MW, 2002, P NATL ACAD SCI USA, V99, P7229, DOI 10.1073/pnas.092080099; Masuda N, 2007, P R SOC B, V274, P1815, DOI 10.1098/rspb.2007.0294; McNamara JM, 2004, NATURE, V428, P745, DOI 10.1038/nature02432; Michod RE, 2006, P NATL ACAD SCI USA, V103, P9113, DOI 10.1073/pnas.0601080103; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; NOWAK MA, 1994, P NATL ACAD SCI USA, V91, P4877, DOI 10.1073/pnas.91.11.4877; Nowak MA, 2006, SCIENCE, V314, P1560, DOI 10.1126/science.1133755; Ohtsuki H, 2006, NATURE, V441, P502, DOI 10.1038/nature04605; Pacheco JM, 2006, PLOS COMPUT BIOL, V2, P1634, DOI 10.1371/journal.pcbi.0020178; Rong ZH, 2007, PHYS REV E, V76, DOI 10.1103/PhysRevE.76.027101; Sandholm TW, 1996, BIOSYSTEMS, V37, P147, DOI 10.1016/0303-2647(95)01551-5; Santos FC, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.098104; Santos FC, 2006, PLOS COMPUT BIOL, V2, P1284, DOI 10.1371/journal.pcbi.0020140; Skyrms B., 2004, STAG HUNT EVOLUTION, DOI DOI 10.1017/CBO9781139165228; Sutton R. S., 1999, REINFORCEMENT LEARNI; Szabo G, 2007, PHYS REP, V446, P97, DOI 10.1016/j.physrep.2007.04.004; Szolnoki A, 2008, PHYSICA A, V387, P2075, DOI 10.1016/j.physa.2007.11.021; Tan Ming, 1993, P 10 INT C MACH LEAR, V10, P330, DOI DOI 10.1016/B978-1-55860-307-3.50049-6; Tang CL, 2006, EUR PHYS J B, V53, P411, DOI 10.1140/epjb/e2006-00395-2; Tomassini M, 2006, PHYS REV E, V73, DOI 10.1103/PhysRevE.73.016132; Tomassini M, 2007, INT J MOD PHYS C, V18, P1173, DOI 10.1142/S0129183107011212; Traulsen A, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000270; Vukov J, 2008, PHYS REV E, V77, DOI 10.1103/PhysRevE.77.026109; WATKINS CJCH, 1992, MACH LEARN, V8, P279, DOI 10.1007/BF00992698; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918	46	58	59	0	27	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1917	10.1371/journal.pone.0001917	http://dx.doi.org/10.1371/journal.pone.0001917			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	370XD	18398453	Green Published, Green Submitted, gold			2022-12-25	WOS:000260795500004
J	Cheng, N; de Wetering, CIV; Knudson, CM				Cheng, Ningli; van de Wetering, Christopher I.; Knudson, C. Michael			p27 Deficiency Cooperates with Bcl-2 but Not Bax to Promote T-Cell Lymphoma	PLOS ONE			English	Article								The effect of Bcl-2 on oncogenesis is complex and expression may either delay or accelerate oncogenesis. The pro-oncogenic activity is attributed to its well characterized anti-apoptotic function while the anti-oncogenic function has been attributed to its inhibition of cellular proliferation. Recent studies demonstrate that p27 may mediate the effects of Bcl-2 on cellular proliferation. We hypothesized that p27 may suppress tumor formation by Bcl-2 family members. To test this hypothesis, cell cycle inhibition and lymphoma development were examined in Lck-Bcl-2 and Lck-Bax38/1 transgenic mice deficient in p27. Strikingly, p27 deficiency synergistically cooperates with Bcl-2 to increase T cell hyperplasia and development of spontaneous T cell lymphomas. Within 1 year, >90% of these mice had developed thymic T cell lymphomas. This high penetrance contrasts with a one year incidence of <5% of thymic lymphoma in Lck-Bcl-2 or p27 -/- mice alone. In contrast, p27 deficiency had no effect on tumor formation in Lck-Bax38/1 transgenic mice, another model of T cell lymphoma. Histologically the lymphomas in p27 -/- Lck-Bcl-2 mice are lymphoblastic and frequently involve multiple organs suggesting an aggressive phenotype. Interestingly, in mature splenic T cells, Bcl-2 largely retains its anti-proliferative function even in the absence of p27. T cells from p27 -/- Lck-Bcl-2 mice show delayed kinetics of CDK2 Thr-160 phosphorylation. This delay is associated with a delay in the up regulation of both Cyclin D2 and D3. These data demonstrate a complex relationship between the Bcl-2 family, cellular proliferation, and oncogenesis and demonstrate that p27 up-regulation is not singularly important in the proliferative delay observed in T cells expressing Bcl-2 family members. Nonetheless, the results indicate that p27 is a critical tumor suppressor in the context of Bcl-2 expression.	[Cheng, Ningli; van de Wetering, Christopher I.; Knudson, C. Michael] Univ Iowa, Roy J & Lucille P Carver Coll Med, Dept Pathol, Program Mol & Cell Biol, Iowa City, IA USA	University of Iowa	Cheng, N (corresponding author), Univ Iowa, Roy J & Lucille P Carver Coll Med, Dept Pathol, Program Mol & Cell Biol, Iowa City, IA USA.	c-knudson@uiowa.edu		Knudson, Charles Michael/0000-0003-3964-5466	National Research Service Award (NRSA) predoctoral fellowship [F31CA103363]; NIH [1RO1CA104695, 1RO1CA88967]; NATIONAL CANCER INSTITUTE [R01CA104695, R01CA088967, F31CA103363] Funding Source: NIH RePORTER	National Research Service Award (NRSA) predoctoral fellowship(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))	CIvdW was supported in part by a National Research Service Award (NRSA) predoctoral fellowship grant #F31CA103363. This work was supported by NIH grants 1RO1CA104695 and 1RO1CA88967 (C.M.K.). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Alao JP, 2007, MOL CANCER, V6, DOI 10.1186/1476-4598-6-24; BAKHSHI A, 1985, CELL, V41, P899, DOI 10.1016/S0092-8674(85)80070-2; Breckenridge DG, 2004, CURR OPIN CELL BIOL, V16, P647, DOI 10.1016/j.ceb.2004.09.009; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; Buglioni S, 1999, INT J CANCER, V84, P545, DOI 10.1002/(SICI)1097-0215(19991222)84:6<545::AID-IJC1>3.0.CO;2-2; Callagy GM, 2006, CLIN CANCER RES, V12, P2468, DOI 10.1158/1078-0432.CCR-05-2719; Chao DT, 1998, ANNU REV IMMUNOL, V16, P395, DOI 10.1146/annurev.immunol.16.1.395; Cheng NL, 2004, ONCOGENE, V23, P3770, DOI 10.1038/sj.onc.1207478; CLEARY ML, 1985, P NATL ACAD SCI USA, V82, P7439, DOI 10.1073/pnas.82.21.7439; de la Coste A, 1999, CANCER RES, V59, P5017; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Emerson DK, 2005, J BIOL CHEM, V280, P3233, DOI 10.1074/jbc.M411672200; Engedal N, 2006, J IMMUNOL, V177, P2851, DOI 10.4049/jimmunol.177.5.2851; Fero ML, 1998, NATURE, V396, P177, DOI 10.1038/24179; Geisen C, 2003, ONCOGENE, V22, P1724, DOI 10.1038/sj.onc.1206340; Greider C, 2002, ONCOGENE, V21, P7765, DOI 10.1038/sj.onc.1205928; Gurova KV, 2002, CANCER BIOL THER, V1, P39, DOI 10.4161/cbt.1.1.39; Hadzic T, 2005, J IMMUNOL, V175, P7965, DOI 10.4049/jimmunol.175.12.7965; Harris MH, 2000, CELL DEATH DIFFER, V7, P1182, DOI 10.1038/sj.cdd.4400781; Holmes JK, 2001, EUR J BIOCHEM, V268, P4647, DOI 10.1046/j.1432-1327.2001.02392.x; Huang DCS, 1997, EMBO J, V16, P4628, DOI 10.1093/emboj/16.15.4628; Janumyan YM, 2003, EMBO J, V22, P5459, DOI 10.1093/emboj/cdg533; Kaklamanis L, 1998, BRIT J CANCER, V77, P1864, DOI 10.1038/bjc.1998.310; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Knudson CM, 2001, CANCER RES, V61, P659; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Kuwana T, 2003, CURR OPIN CELL BIOL, V15, P691, DOI 10.1016/j.ceb.2003.10.004; LINETTE GP, 1995, BLOOD, V86, P1255, DOI 10.1182/blood.V86.4.1255.bloodjournal8641255; Linette GP, 1996, P NATL ACAD SCI USA, V93, P9545, DOI 10.1073/pnas.93.18.9545; Luke JJ, 2003, CELL DEATH DIFFER, V10, P740, DOI 10.1038/sj.cdd.4401233; MacCarthy-Morrogh L, 1999, BIOCHEM SOC T, V27, P785, DOI 10.1042/bst0270785; Manne U, 1997, INT J CANCER, V74, P346, DOI 10.1002/(SICI)1097-0215(19970620)74:3<346::AID-IJC19>3.0.CO;2-9; Martin-Caballero J, 2004, ONCOGENE, V23, P8231, DOI 10.1038/sj.onc.1207863; Martins CP, 2002, EMBO J, V21, P3739, DOI 10.1093/emboj/cdf364; MARVEL J, 1994, ONCOGENE, V9, P1117; Meterissian SH, 2001, ANN SURG ONCOL, V8, P533, DOI 10.1245/aso.2001.8.6.533; Murphy KL, 1999, ONCOGENE, V18, P6597, DOI 10.1038/sj.onc.1203099; Nakayama K, 1998, BIOESSAYS, V20, P1020, DOI 10.1002/(SICI)1521-1878(199812)20:12<1020::AID-BIES8>3.0.CO;2-D; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; OFNER D, 1995, BRIT J CANCER, V72, P981, DOI 10.1038/bjc.1995.446; OReilly LA, 1997, J IMMUNOL, V159, P2301; OReilly LA, 1997, INT IMMUNOL, V9, P1291, DOI 10.1093/intimm/9.9.1291; OReilly LA, 1996, EMBO J, V15, P6979, DOI 10.1002/j.1460-2075.1996.tb01090.x; Philipp-Staheli J, 2004, ONCOGENE, V23, P905, DOI 10.1038/sj.onc.1207220; Rathmell JC, 2000, MOL CELL, V6, P683, DOI 10.1016/S1097-2765(00)00066-6; Rossiter H, 2001, CANCER RES, V61, P3619; Roussel MF, 1999, ONCOGENE, V18, P5311, DOI 10.1038/sj.onc.1202998; Schmitt CA, 2002, CANCER CELL, V1, P289, DOI 10.1016/S1535-6108(02)00047-8; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; Sharpless NE, 2001, NATURE, V413, P86, DOI 10.1038/35092592; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SILVESTRINI R, 1994, J NATL CANCER I, V86, P499, DOI 10.1093/jnci/86.7.499; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; TSUJIMOTO Y, 1985, SCIENCE, V229, P1390, DOI 10.1126/science.3929382; Vairo G, 2000, MOL CELL BIOL, V20, P4745, DOI 10.1128/MCB.20.13.4745-4753.2000; Vairo G, 1996, ONCOGENE, V13, P1511; van de Wetering CI, 2007, CANCER RES, V67, P8081, DOI 10.1158/0008-5472.CAN-07-1666	57	8	8	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1911	10.1371/journal.pone.0001911	http://dx.doi.org/10.1371/journal.pone.0001911			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382684	Green Submitted, Green Published, gold			2022-12-25	WOS:000260795400036
J	Nosil, P; Sandoval, CP				Nosil, Patrik; Sandoval, Cristina P.			Ecological Niche Dimensionality and the Evolutionary Diversification of Stick Insects	PLOS ONE			English	Article							HOST-PLANT ADAPTATION; REPRODUCTIVE ISOLATION; HABITAT PREFERENCE; SPECIES BOUNDARY; SYMPATRIC SPECIATION; DISRUPTIVE SELECTION; ADAPTIVE DIVERGENCE; NATURAL-SELECTION; VISUAL PREDATION; SANTA-ROSALIA	The degree of phenotypic divergence and reproductive isolation between taxon pairs can vary quantitatively, and often increases as evolutionary divergence proceeds through various stages, from polymorphism to population differentiation, ecotype and race formation, speciation, and post-speciational divergence. Although divergent natural selection promotes divergence, it does not always result in strong differentiation. For example, divergent selection can fail to complete speciation, and distinct species pairs sometimes collapse ('speciation in reverse'). Widely-discussed explanations for this variability concern genetic architecture, and the geographic arrangement of populations. A less-explored possibility is that the degree of phenotypic and reproductive divergence between taxon pairs is positively related to the number of ecological niche dimensions (i.e., traits) subject to divergent selection. Some data supporting this idea stem from laboratory experimental evolution studies using Drosophila, but tests from nature are lacking. Here we report results from manipulative field experiments in natural populations of herbivorous Timema stick insects that are consistent with this 'niche dimensionality' hypothesis. In such insects, divergent selection between host plants might occur for cryptic colouration (camouflage to evade visual predation), physiology (to detoxify plant chemicals), or both of these niche dimensions. We show that divergent selection on the single niche dimension of cryptic colouration can result in ecotype formation and intermediate levels of phenotypic and reproductive divergence between populations feeding on different hosts. However, greater divergence between a species pair involved divergent selection on both niche dimensions. Although further replication of the trends reported here is required, the results suggest that dimensionality of selection may complement genetic and geographic explanations for the degree of diversification in nature.	[Nosil, Patrik] Univ British Columbia, Dept Zool, Vancouver, BC, Canada; [Sandoval, Cristina P.] Univ Calif Santa Barbara, Marine Sci Inst, Santa Barbara, CA USA	University of British Columbia; University of California System; University of California Santa Barbara	Nosil, P (corresponding author), Univ British Columbia, Dept Zool, Vancouver, BC, Canada.	pnosil@zoology.ubc.ca			Natural Science and Engineering Research Council of Canada	Natural Science and Engineering Research Council of Canada(Natural Sciences and Engineering Research Council of Canada (NSERC))	Financial support was provided by the Natural Science and Engineering Research Council of Canada.	Akaike H., 1973, P 2 INT S INF THEOR, VI, P610, DOI DOI 10.1007/978-1-4612-1694-0_15; Arnold M. L., 1997, NATURAL HYBRIDIZATIO; Beltran M, 2002, MOL BIOL EVOL, V19, P2176, DOI 10.1093/oxfordjournals.molbev.a004042; Berlocher SH, 2002, ANNU REV ENTOMOL, V47, P773, DOI 10.1146/annurev.ento.47.091201.145312; Bernays E. A., 1994, Host-plant selection by phytophagous insects.; Bolnick DI, 2007, EVOLUTION, V61, P2229, DOI 10.1111/j.1558-5646.2007.00179.x; Bond AB, 2002, NATURE, V415, P609, DOI 10.1038/415609a; BOUGHMAN JW, 2002, TRENDS ECOL EVOL, V10, P1; Bradshaw HD, 2003, NATURE, V426, P176, DOI 10.1038/nature02106; Bull V, 2006, BMC BIOL, V4, DOI 10.1186/1741-7007-4-11; Carleton KL, 2005, MOL ECOL, V14, P4341, DOI 10.1111/j.1365-294X.2005.02735.x; Chase J.M., 2009, ECOLOGICAL NICHES LI; COYNE JA, 1989, EVOLUTION, V43, P362, DOI 10.1111/j.1558-5646.1989.tb04233.x; Coyne JA, 2004, SPECIATION, V37; Crespi BJ, 2000, J EVOLUTION BIOL, V13, P249, DOI 10.1046/j.1420-9101.2000.00164.x; Dambroski HR, 2007, J EVOLUTION BIOL, V20, P2101, DOI 10.1111/j.1420-9101.2007.01435.x; de Queiroz K, 2005, P NATL ACAD SCI USA, V102, P6600, DOI 10.1073/pnas.0502030102; Dijkstra PD, 2007, J EVOLUTION BIOL, V20, P496, DOI 10.1111/j.1420-9101.2006.01266.x; Dijkstra PD, 2005, BEHAV ECOL SOCIOBIOL, V58, P136, DOI 10.1007/s00265-005-0919-5; Dopman EB, 2005, P NATL ACAD SCI USA, V102, P14706, DOI 10.1073/pnas.0502054102; Dres M, 2002, PHILOS T R SOC B, V357, P471, DOI 10.1098/rstb.2002.1059; Elton C. S., 1927, ANIMAL ECOLOGY; FELSENSTEIN J, 1981, EVOLUTION, V35, P124, DOI 10.1111/j.1558-5646.1981.tb04864.x; Forister ML, 2007, J EVOLUTION BIOL, V20, P985, DOI 10.1111/j.1420-9101.2007.01310.x; Funk DJ, 2006, P NATL ACAD SCI USA, V103, P3209, DOI 10.1073/pnas.0508653103; Funk DJ, 2002, GENETICA, V116, P251, DOI 10.1023/A:1021236510453; Funk DJ, 1998, EVOLUTION, V52, P1744, DOI [10.2307/2411347, 10.1111/j.1558-5646.1998.tb02254.x]; FUTUYMA DJ, 1995, EVOLUTION, V49, P797, DOI 10.1111/j.1558-5646.1995.tb02316.x; Gavrilets S, 2004, FITNESS LANDSCAPES O; Geraldes A, 2006, GENETICS, V173, P919, DOI 10.1534/genetics.105.054106; Gray SM, 2007, TRENDS ECOL EVOL, V22, P71, DOI 10.1016/j.tree.2006.10.005; Grinnell J., 1917, Auk Cambridge Mass, V34; Harmon LJ, 2005, EVOLUTION, V59, P409; Hawthorne DJ, 2001, NATURE, V412, P904, DOI 10.1038/35091062; Hendry AP, 2004, EVOLUTION, V58, P2319; Hendry AP, 2001, EVOLUTION, V55, P459, DOI 10.1554/0014-3820(2001)055[0459:PMATAD]2.0.CO;2; HUBBS CL, 1955, SYST ZOOL, V4, P1, DOI 10.2307/2411933; HUTCHINSON GE, 1957, COLD SPRING HARB SYM, V22, P415, DOI 10.1101/SQB.1957.022.01.039; HUTCHINSON GE, 1959, AM NAT, V93, P145, DOI 10.1086/282070; Jiggins CD, 2000, TRENDS ECOL EVOL, V15, P250, DOI 10.1016/S0169-5347(00)01873-5; Kirkpatrick M, 2002, AM NAT, V159, pS22, DOI 10.1086/338370; Law JH, 2002, MOL ECOL, V11, P1471, DOI 10.1046/j.1365-294X.2002.01547.x; Mallet J, 2007, BMC EVOL BIOL, V7, DOI 10.1186/1471-2148-7-28; MAYR E, 1947, EVOLUTION, V1, P263, DOI 10.2307/2405327; Mayr E., 1963, ANIMAL SPECIES EVOLU, P797; Muller HJ, 1942, BIOL S, V6, P71; Noor MAF, 2001, P NATL ACAD SCI USA, V98, P12084, DOI 10.1073/pnas.221274498; Nosil P, 2002, NATURE, V417, P440, DOI 10.1038/417440a; Nosil P, 2006, J EVOLUTION BIOL, V19, P929, DOI 10.1111/j.1420-9101.2005.01035.x; Nosil P, 2006, AM NAT, V167, pE66, DOI 10.1086/499383; Nosil P, 2004, P ROY SOC B-BIOL SCI, V271, P1521, DOI 10.1098/rspb.2004.2751; Nosil P, 2004, EVOLUTION, V58, P102, DOI 10.1111/j.0014-3820.2004.tb01577.x; Nosil P, 2003, P ROY SOC B-BIOL SCI, V270, P1911, DOI 10.1098/rspb.2003.2457; Nosil P, 2005, EVOLUTION, V59, P705; NOSIL P, 2008, ECOLOGY SPECIATION, P20; Nosil P, 2008, EVOLUTION, V62, P316, DOI 10.1111/j.1558-5646.2007.00299.x; Nosil P, 2007, AM NAT, V169, P151, DOI 10.1086/510634; Nosil P, 2006, CURR BIOL, V16, pR806, DOI 10.1016/j.cub.2006.08.038; Nosil P, 2006, P NATL ACAD SCI USA, V103, P9090, DOI 10.1073/pnas.0601575103; Olendorf R, 2006, NATURE, V441, P633, DOI 10.1038/nature04646; Ortiz-Barrientos D, 2005, SCIENCE, V310, P1467, DOI 10.1126/science.1121260; Ortiz-Barrientos D, 2002, GENETICA, V116, P167, DOI 10.1023/A:1021296829109; Pianka E.R., 2011, EVOL ECOL; Putnam AS, 2007, EVOLUTION, V61, P912, DOI 10.1111/j.1558-5646.2007.00076.x; Rice WR, 1987, EVOL ECOL, V1, P301, DOI 10.1007/BF02071555; RICE WR, 1988, AM NAT, V131, P911, DOI 10.1086/284831; RICE WR, 1990, EVOLUTION, V44, P1140, DOI 10.1111/j.1558-5646.1990.tb05221.x; RICE WR, 1985, EVOLUTION, V39, P645, DOI 10.1111/j.1558-5646.1985.tb00401.x; RICE WR, 1993, EVOLUTION, V47, P1637, DOI [10.2307/2410209, 10.1111/j.1558-5646.1993.tb01257.x]; Richmond JQ, 2007, P ROY SOC B-BIOL SCI, V274, P1701, DOI 10.1098/rspb.2007.0364; Rieseberg LH, 2001, TRENDS ECOL EVOL, V16, P351, DOI 10.1016/S0169-5347(01)02187-5; Roe AD, 2007, MOL ECOL, V16, P3617, DOI 10.1111/j.1365-294X.2007.03412.x; Rueffler C, 2006, TRENDS ECOL EVOL, V21, P238, DOI 10.1016/j.tree.2006.03.003; Rundle HD, 2005, ECOL LETT, V8, P336, DOI 10.1111/j.1461-0248.2004.00715.x; SANDOVAL CP, 1994, BIOL J LINN SOC, V52, P341; Sandoval CP, 2005, EVOLUTION, V59, P2405; SANDOVAL CP, 1994, EVOLUTION, V48, P1866, DOI 10.1111/j.1558-5646.1994.tb02220.x; SANDOVAL CP, 2000, SW NAT, V45, P19; SCHLUTER D, 1995, AM NAT, V146, P292, DOI 10.1086/285799; Schluter D., 2000, ECOLOGY ADAPTIVE RAD; Schoener T.W., 1989, P79; Seehausen O, 1997, SCIENCE, V277, P1808, DOI 10.1126/science.277.5333.1808; SEEHAUSEN O, 2008, MOL ECOL IN PRESS; SEEHAUSEN O, 2008, ECOLOGY SPECIATION, P20; Sinervo B, 2002, HEREDITY, V89, P329, DOI 10.1038/sj.hdy.6800148; Svensson EI, 2005, AM NAT, V165, P567, DOI 10.1086/429278; SVENSSON EI, 2008, EVOL ECOL IN PRESS; Taylor EB, 2006, MOL ECOL, V15, P343, DOI 10.1111/j.1365-294X.2005.02794.x; Via S, 2001, TRENDS ECOL EVOL, V16, P381, DOI 10.1016/S0169-5347(01)02188-7; VICKERY VR, 1993, CAN ENTOMOL, V125, P657, DOI 10.4039/Ent125657-4; Vines TH, 2003, EVOLUTION, V57, P1876; Wiens JJ, 2005, ANNU REV ECOL EVOL S, V36, P519, DOI 10.1146/annurev.ecolsys.36.102803.095431; Wu CI, 2001, J EVOLUTION BIOL, V14, P851, DOI 10.1046/j.1420-9101.2001.00335.x	93	69	72	1	51	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1907	10.1371/journal.pone.0001907	http://dx.doi.org/10.1371/journal.pone.0001907			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382680	Green Accepted, Green Published, Green Submitted, gold			2022-12-25	WOS:000260795400032
J	Ndam, NT; Bischoff, E; Proux, C; Lavstsen, T; Salanti, A; Guitard, J; Nielsen, MA; Coppee, JY; Gaye, A; Theander, T; David, PH; Deloron, P				Ndam, Nicaise Tuikue; Bischoff, Emmanuel; Proux, Caroline; Lavstsen, Thomas; Salanti, Ali; Guitard, Juliette; Nielsen, Morten A.; Coppee, Jean-Yves; Gaye, Alioune; Theander, Thor; David, Peter H.; Deloron, Philippe			Plasmodium falciparum Transcriptome Analysis Reveals Pregnancy Malaria Associated Gene Expression	PLOS ONE			English	Article							VARIANT SURFACE-ANTIGENS; CHONDROITIN SULFATE; INFECTED ERYTHROCYTES; PLACENTAL MALARIA; ANTIBODIES; CHILDREN; ADHERENCE; PARASITES; DYNAMICS; ADHESIVE	Background: Pregnancy-associated malaria (PAM) causing maternal anemia and low birth weight is among the multiple manifestations of Plasmodium falciparum malaria. Infected erythrocytes (iEs) can acquire various adhesive properties that mediate the clinical severity of malaria. Recent advances on the molecular basis of virulence and immune evasion have helped identify var2csa as a PAM-specific var gene. Methodology/Principal Findings: The present study presents a genome-wide microarray transcript analysis of 18 P. falciparum parasite isolates freshly collected from the placenta. The proportion of PAM over-expressed genes located in subtelomeric regions as well as that of PAM over-expressed genes predicted to be exported were higher than expected compared to the whole genome. The identification of novel parasite molecules with specificity to PAM and which are likely involved in host-pathogen interactions and placental tropism is described. One of these proteins, PFI1785w, was further characterized as the product of a two-exon PHIST gene, and was more often recognized by serum samples from P. falciparum-exposed women than from men. Conclusions/Significance: These findings suggest that other parasite proteins, such as PFI1785w, may contribute beside VAR2CSA to the pathogenesis of PAM. These data may be very valuable for future vaccine development.	[Ndam, Nicaise Tuikue; Guitard, Juliette; Deloron, Philippe] Univ Paris 05, UR010, Fac Pharm, IRD, Paris, France; [Bischoff, Emmanuel; Proux, Caroline; Coppee, Jean-Yves] Inst Pasteur, Plate Forme 2, Paris, France; [Lavstsen, Thomas; Salanti, Ali; Nielsen, Morten A.; Theander, Thor] Univ Copenhagen, Ctr Med Parasitol, Copenhagen, Denmark; [Gaye, Alioune] Ctr Sante Roi Baudoin Guediawaye, Dakar, Senegal; [David, Peter H.] Inst Pasteur, URA CNRS 2581, Unite Immunol Mol Parasites, Paris, France	Institut de Recherche pour le Developpement (IRD); UDICE-French Research Universities; Universite Paris Cite; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Copenhagen; Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Ndam, NT (corresponding author), Univ Paris 05, UR010, Fac Pharm, IRD, Paris, France.	Nicaise.Ndam@ird.fr	Guitard, Juliette/AAE-6344-2019; Deloron, Philippe/G-6305-2010; Bischoff, Emmanuel/F-1197-2011; Theander, Thor/F-6714-2015	Guitard, Juliette/0000-0002-9782-3577; Deloron, Philippe/0000-0003-4705-2484; Bischoff, Emmanuel/0000-0003-4655-4247; Theander, Thor/0000-0002-3509-7514; Nielsen, Morten Agertoug/0000-0003-2668-4992; Lavstsen, Thomas/0000-0002-3044-4249; Tuikue Ndam, Nicaise/0000-0003-2646-2513; Salanti, Ali/0000-0003-2207-5575	Commission of the European Union [QLK2-CT-2001-01302]; Delegation Generale pour l'Armement [DGA n 22120/DSP/SREAF, n 04 34 025]; Programme PAL+/Fonds National pour la Science; Institut Pasteur; Programme Genopole; Fondation Recherche Medicale; SSVF	Commission of the European Union(European Commission); Delegation Generale pour l'Armement; Programme PAL+/Fonds National pour la Science; Institut Pasteur(European Commission); Programme Genopole; Fondation Recherche Medicale; SSVF	The work received financial support from the Commission of the European Union (grant QLK2-CT-2001-01302, PAMVAC), the Delegation Generale pour l'Armement (DGA n 22120/DSP/SREAF and n 04 34 025), the Programme PAL+/Fonds National pour la Science, the Institut Pasteur, and the Programme Genopole. NTN was supported by a postdoctoral grant from the Fondation Recherche Medicale. AS is supported by a postdoctoral grant from SSVF.	Beeson JG, 2007, AM J TROP MED HYG, V77, P22, DOI 10.4269/ajtmh.2007.77.22; Beeson JG, 1999, J INFECT DIS, V180, P464, DOI 10.1086/314899; Brabin BJ, 2004, PLACENTA, V25, P359, DOI 10.1016/j.placenta.2003.10.019; Craig A, 2001, MOL BIOCHEM PARASIT, V115, P129, DOI 10.1016/S0166-6851(01)00275-4; Daily JP, 2005, J INFECT DIS, V191, P1196, DOI 10.1086/428289; Duffy MF, 2005, MOL MICROBIOL, V56, P774, DOI 10.1111/j.1365-2958.2005.04577.x; Duffy MF, 2006, INFECT IMMUN, V74, P4875, DOI 10.1128/IAI.01978-05; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; FRANCIS SE, 2007, INFECT IMMUN; Fried M, 1998, J MOL MED-JMM, V76, P162, DOI 10.1007/s001090050205; Fried M, 1996, SCIENCE, V272, P1502, DOI 10.1126/science.272.5267.1502; Fried M, 1998, NATURE, V395, P851, DOI 10.1038/27570; Fried M, 2007, MOL BIOCHEM PARASIT, V155, P57, DOI 10.1016/j.molbiopara.2007.05.010; Gentleman RC, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-10-r80; Gowda ASP, 2007, J BIOL CHEM, V282, P916, DOI 10.1074/jbc.M604741200; Haase RN, 2006, INFECT IMMUN, V74, P3035, DOI 10.1128/IAI.74.5.3035-3038.2006; Jafari-Guemouri S, 2006, MICROBES INFECT, V8, P1663, DOI 10.1016/j.micinf.2006.01.023; Jensen ATR, 2004, J EXP MED, V199, P1179, DOI 10.1084/jem.20040274; Kyes S, 2001, ANNU REV MICROBIOL, V55, P673, DOI 10.1146/annurev.micro.55.1.673; Kyriacou HM, 2006, MOL BIOCHEM PARASIT, V150, P211, DOI 10.1016/j.molbiopara.2006.08.005; Lasonder E, 2002, NATURE, V419, P537, DOI 10.1038/nature01111; Maubert B, 1999, INFECT IMMUN, V67, P5367, DOI 10.1128/IAI.67.10.5367-5371.1999; Moore JM, 1997, J IMMUNOL METHODS, V209, P93, DOI 10.1016/S0022-1759(97)00162-2; Ndam NGT, 2006, J INFECT DIS, V193, P713, DOI 10.1086/500146; Ndam NGT, 2005, J INFECT DIS, V192, P331, DOI 10.1086/430933; PLOWE CV, 1995, AM J TROP MED HYG, V52, P565, DOI 10.4269/ajtmh.1995.52.565; Ralph SA, 2005, GENOME BIOL, V6, DOI 10.1186/gb-2005-6-11-r93; Ricke CH, 2000, J IMMUNOL, V165, P3309, DOI 10.4049/jimmunol.165.6.3309; Salanti A, 2004, J EXP MED, V200, P1197, DOI 10.1084/jem.20041579; Salanti A, 2003, MOL MICROBIOL, V49, P179, DOI 10.1046/j.1365-2958.2003.03570.x; Sanders PR, 2005, J BIOL CHEM, V280, P40169, DOI 10.1074/jbc.M509631200; Sargeant TJ, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-2-r12; Staalsoe T, 1999, CYTOMETRY, V35, P329, DOI 10.1002/(SICI)1097-0320(19990401)35:4&lt;329::AID-CYTO5&gt;3.0.CO;2-Y; Staalsoe T, 2003, PARASITE IMMUNOL, V25, P421, DOI 10.1111/j.1365-3024.2003.00652.x; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; Treutiger CJ, 1997, NAT MED, V3, P1405, DOI 10.1038/nm1297-1405; Viebig NK, 2005, EMBO REP, V6, P775, DOI 10.1038/sj.embor.7400466	37	42	43	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1855	10.1371/journal.pone.0001855	http://dx.doi.org/10.1371/journal.pone.0001855			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365010	gold, Green Submitted, Green Published			2022-12-25	WOS:000260762400016
J	Ptitsyn, A				Ptitsyn, Andrey			Stochastic Resonance Reveals "Pilot Light'' Expression in Mammalian Genes	PLOS ONE			English	Article								Background: Microarrays are widely used for estimation of expression of thousands of genes in a biological sample. The resolution ability of this method is limited by the background noise. Low expressed genes are detected with insufficient reliability and expression of many genes is never detected at all. Methodology/Principal Findings: We have applied the principles of stochastic resonance to detect expression of genes from microarray signals below the background noise level. We report the periodic pattern detected in genes called "Absent'' by traditional analysis. The pattern is consistent with expression of the conventionally detected genes and specific to the tissue of origin. This effect is corroborated by the analysis of oscillating gene expression in mouse (M. musculus) and yeast (S. cerevisae). Conclusion/Significance: Most genes usually considered silent are in fact expressed at a very low level. Stochastic resonance can be applied to detect changes in expression pattern of low-expressed genes as well as for the validation of the probe performance in microarrays.			Ptitsyn, A (corresponding author), Colorado State Univ, Coll Vet Med & Biomed Sci, Dept Microbiol Immunol & Pathol, Ctr Bioinformat, Ft Collins, CO 80523 USA.	Andrey.Ptitsyn@colostate.edu		Ptitsyn, Andrey/0000-0003-1196-8757				Allison DB, 2006, NAT REV GENET, V7, P55, DOI 10.1038/nrg1749; BENZI R, 1981, J PHYS A-MATH GEN, V14, pL453, DOI 10.1088/0305-4470/14/11/006; Gonze D, 2002, P NATL ACAD SCI USA, V99, P673, DOI 10.1073/pnas.022628299; Greenwood PE, 1999, PHYS REV E, V60, P4687, DOI 10.1103/PhysRevE.60.4687; Guenther MG, 2007, CELL, V130, P77, DOI 10.1016/j.cell.2007.05.042; Havel PJ, 2000, P NUTR SOC, V59, P359, DOI 10.1017/S0029665100000410; Irizarry RA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng015; Li C, 2001, P NATL ACAD SCI USA, V98, P31, DOI 10.1073/pnas.011404098; Martinez-Merlos MT, 2004, J ENDOCRINOL, V181, P53, DOI 10.1677/joe.0.1810053; Priestley M. B., 1981, SPECTRAL ANAL TIME S, V1; Ptitsyn AA, 2007, PLOS COMPUT BIOL, V3, P1108, DOI 10.1371/journal.pcbi.0030120; Ptitsyn AA, 2006, PLOS COMPUT BIOL, V2, P126, DOI 10.1371/journal.pcbi.0020016; Ptitsyn AA, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S2-S10; Quackenbush J, 2002, NAT GENET, V32, P496, DOI 10.1038/ng1032; Refinetti Roberto, 2005, J Circadian Rhythms, V3, P4, DOI 10.1186/1740-3391-3-4; SAVITZKY A, 1964, ANAL CHEM, V36, P1627, DOI 10.1021/ac60214a047; Storch KF, 2002, NATURE, V417, P78, DOI 10.1038/nature744; Storey JD, 2003, P NATL ACAD SCI USA, V100, P9440, DOI 10.1073/pnas.1530509100; Tu BP, 2005, SCIENCE, V310, P1152, DOI 10.1126/science.1120499; Wichert S, 2004, BIOINFORMATICS, V20, P5, DOI 10.1093/bioinformatics/btg364; Zvonic S, 2006, DIABETES, V55, P962, DOI 10.2337/diabetes.55.04.06.db05-0873; Zvonic S, 2007, J BONE MINER RES, V22, P357, DOI 10.1359/jbmr.061114	22	7	7	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1842	10.1371/journal.pone.0001842	http://dx.doi.org/10.1371/journal.pone.0001842			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365000	gold, Green Published, Green Submitted			2022-12-25	WOS:000260762400006
J	Das, R; Mazhab-Jafari, MT; Chowdhury, S; SilDas, S; Selvaratnam, R; Melacini, G				Das, Rahul; Mazhab-Jafari, Mohammad T.; Chowdhury, Somenath; SilDas, Soumita; Selvaratnam, Rajeevan; Melacini, Giuseppe			Entropy-driven cAMP-dependent allosteric control of inhibitory interactions in exchange proteins directly activated by cAMP	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHEMICAL-SHIFT ANISOTROPY; PULSED-FIELD GRADIENTS; N-15 NMR RELAXATION; CYCLIC-AMP; BINDING DOMAIN; KINASE-A; GLOBULAR-PROTEINS; RI-ALPHA; DYNAMICS; EPAC	Exchange proteins directly activated by cAMP (EPACs) are guanine nucleotide-exchange factors for the small GTPases Rap1 and Rap2 and represent a key receptor for the ubiquitous cAMP second messenger in eukaryotes. The cAMP-dependent activation of apoEPAC is typically rationalized in terms of a preexisting equilibrium between inactive and active states. Structural and mutagenesis analyses have shown that one of the critical determinants of the EPAC activation equilibrium is a cluster of salt bridges formed between the catalytic core and helices alpha 1 and alpha 2 at the N terminus of the cAMP binding domain and commonly referred to as ionic latch (IL). The IL stabilizes the inactive states in a closed topology in which access to the catalytic domain is sterically occluded by the regulatory moiety. However, it is currently not fully understood how the IL is allosterically controlled by cAMP. Chemical shift mapping studies consistently indicate that cAMP does not significantly perturb the structure of the IL spanning sites within the regulatory region, pointing to cAMP-dependent dynamic modulations as a key allosteric carrier of the cAMP-signal to the IL sites. Here, we have therefore investigated the dynamic profiles of the EPAC1 cAMP binding domain in its apo, cAMP-bound, and Rp-cAMPS phosphorothioate antagonist-bound forms using several N-15 relaxation experiments. Based on the comparative analysis of dynamics in these three states, we have proposed a model of EPAC activation that incorporates the dynamic features allosterically modulated by cAMP and shows that cAMP binding weakens the IL by increasing its entropic penalty due to dynamic enhancements.	[Melacini, Giuseppe] McMaster Univ, Dept Chem, Hamilton, ON L8S 4M1, Canada; McMaster Univ, Dept Biochem, Hamilton, ON L8S 4M1, Canada; McMaster Univ, Dept Biomed Sci, Hamilton, ON L8S 4M1, Canada	McMaster University; McMaster University; McMaster University	Melacini, G (corresponding author), McMaster Univ, Dept Chem, 1280 Main St W, Hamilton, ON L8S 4M1, Canada.	melacin@mcmaster.ca	Das, Rahul/AAU-5123-2020; Chowdhury, Somenath/I-7846-2015; SELVARATNAM, RAJEEVAN/H-5289-2011	Das, Rahul/0000-0001-7841-8229; SELVARATNAM, RAJEEVAN/0000-0003-4457-616X; Chowdhury, Somenath/0000-0002-3693-1427; Mazhab-Jafari, Mohammad T./0000-0003-0207-5877				Abu-Abed M, 2007, PROTEINS, V69, P112, DOI 10.1002/prot.21446; Atkinson RA, 2004, PROG NUCL MAG RES SP, V44, P141, DOI 10.1016/j.pnmrs.2004.01.001; Berman HM, 2005, P NATL ACAD SCI USA, V102, P45, DOI 10.1073/pnas.0408579102; Bernado P, 2002, J BIOMOL NMR, V23, P139, DOI 10.1023/A:1016359412284; Bos JL, 2006, TRENDS BIOCHEM SCI, V31, P680, DOI 10.1016/j.tibs.2006.10.002; Brock M, 2007, J BIOL CHEM, V282, P32256, DOI 10.1074/jbc.M706231200; Cavanagh J., 1996, PROTEIN NMR SPECTROS; Clayton GM, 2004, CELL, V119, P615, DOI 10.1016/j.cell.2004.10.030; COOPER A, 1984, EUR BIOPHYS J BIOPHY, V11, P103, DOI 10.1007/BF00276625; Das R, 2007, P NATL ACAD SCI USA, V104, P93, DOI 10.1073/pnas.0609033103; Das R, 2007, J BIOL CHEM, V282, P581, DOI 10.1074/jbc.M607706200; Das R, 2006, J AM CHEM SOC, V128, P8406, DOI 10.1021/ja060046d; DAYIE KT, 1994, J MAGN RESON SER A, V111, P121, DOI 10.1006/jmra.1994.1236; de la Torre JG, 2001, BIOPHYS CHEM, V93, P159, DOI 10.1016/S0301-4622(01)00218-6; de Rooij J, 1998, NATURE, V396, P474, DOI 10.1038/24884; DELAGLIO F, 1995, J BIOMOL NMR, V6, P277, DOI 10.1007/BF00197809; DeLano W.L., 2002, PYMOL MOL GRAPHICS S; DiPilato LM, 2004, P NATL ACAD SCI USA, V101, P16513, DOI 10.1073/pnas.0405973101; Eghbalnia HR, 2005, J BIOMOL NMR, V32, P219, DOI 10.1007/s10858-005-7944-6; FARROW NA, 1994, BIOCHEMISTRY-US, V33, P5984, DOI 10.1021/bi00185a040; Fischer MWF, 1998, PROG NUCL MAG RES SP, V33, P207, DOI 10.1016/S0079-6565(98)00023-5; Goddard T. D., 2006, SPARKY 3; GRZESIEK S, 1993, J AM CHEM SOC, V115, P12593, DOI 10.1021/ja00079a052; Harper SM, 2008, J BIOL CHEM, V283, P6501, DOI 10.1074/jbc.M707849200; Houben K, 2005, J MOL BIOL, V349, P621, DOI 10.1016/j.jmb.2005.04.007; Kannan N, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-12-r264; Kawasaki H, 1998, SCIENCE, V282, P2275, DOI 10.1126/science.282.5397.2275; KAY LE, 1992, J MAGN RESON, V97, P359, DOI 10.1016/0022-2364(92)90320-7; Kim C, 2005, SCIENCE, V307, P690, DOI 10.1126/science.1104607; Kim C, 2007, CELL, V130, P1032, DOI 10.1016/j.cell.2007.07.018; Kim C, 2006, EUR J CELL BIOL, V85, P651, DOI 10.1016/j.ejcb.2006.02.004; Kneller JM, 2002, J AM CHEM SOC, V124, P1852, DOI 10.1021/ja017461k; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kraemer A, 2001, J MOL BIOL, V306, P1167, DOI 10.1006/jmbi.2001.4444; Kroenke CD, 1999, J AM CHEM SOC, V121, P10119, DOI 10.1021/ja9909273; Lefevre JF, 1996, BIOCHEMISTRY-US, V35, P2674, DOI 10.1021/bi9526802; Li J, 2007, MOL ENDOCRINOL, V21, P159, DOI 10.1210/me.2006-0340; Mazhab-Jafari MT, 2007, J AM CHEM SOC, V129, P14482, DOI 10.1021/ja0753703; MCKNIGHT GS, 1988, RECENT PROG HORM RES, V44, P307; Mei FC, 2005, MOL BIOSYST, V1, P325, DOI 10.1039/b511267b; Mei FC, 2002, J BIOL CHEM, V277, P11497, DOI 10.1074/jbc.M110856200; Mulder FAA, 1999, J MOL BIOL, V292, P111, DOI 10.1006/jmbi.1999.3034; Mulder FAA, 2004, BIOCHEMISTRY-US, V43, P5930, DOI 10.1021/bi0495331; Mulder FAA, 2001, J AM CHEM SOC, V123, P967, DOI 10.1021/ja003447g; Palmer AG, 2001, METHOD ENZYMOL, V339, P204, DOI 10.1016/S0076-6879(01)39315-1; PENG JW, 1992, BIOCHEMISTRY-US, V31, P8571, DOI 10.1021/bi00151a027; Popovych N, 2006, NAT STRUCT MOL BIOL, V13, P831, DOI 10.1038/nsmb1132; Qiao JB, 2002, J BIOL CHEM, V277, P26581, DOI 10.1074/jbc.M203571200; Rehmann H, 2006, NATURE, V439, P625, DOI 10.1038/nature04468; Rehmann H, 2003, NAT STRUCT BIOL, V10, P26, DOI 10.1038/nsb878; Rehmann H, 2007, NAT REV MOL CELL BIO, V8, P63, DOI 10.1038/nrm2082; Renner C, 2002, J BIOMOL NMR, V23, P23, DOI 10.1023/A:1015385910220; Sattler M, 1999, PROG NUCL MAG RES SP, V34, P93, DOI 10.1016/S0079-6565(98)00025-9; Stevens SY, 2001, NAT STRUCT BIOL, V8, P947, DOI 10.1038/nsb1101-947; SU Y, 1995, SCIENCE, V269, P807, DOI 10.1126/science.7638597; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; Tollinger M, 2001, J AM CHEM SOC, V123, P11341, DOI 10.1021/ja011300z; Wang ZP, 2006, MOL CELL BIOL, V26, P2130, DOI 10.1128/MCB.26.6.2130-2145.2006; Yip GNB, 2004, J MAGN RESON, V171, P25, DOI 10.1016/j.jmr.2004.06.021	59	58	58	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 11	2008	283	28					19691	19703		10.1074/jbc.M802164200	http://dx.doi.org/10.1074/jbc.M802164200			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	322PK	18411261	hybrid			2022-12-25	WOS:000257387600054
J	Hartley, DM; Zhao, CH; Speier, AC; Woodard, GA; Li, SM; Li, ZL; Walz, T				Hartley, Dean M.; Zhao, Chaohui; Speier, Austin C.; Woodard, Gavitt A.; Li, Shaomin; Li, Zongli; Walz, Thomas			Transglutaminase induces protofibril-like amyloid beta-protein assemblies that are protease-resistant and inhibit long-term potentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INSULIN-DEGRADING ENZYME; CENTRAL-NERVOUS-SYSTEM; ALZHEIMERS-DISEASE; TISSUE TRANSGLUTAMINASE; CROSS-LINKING; A-BETA; IN-VIVO; FIBRIL FORMATION; ELECTROPHYSIOLOGICAL CHANGES; NEURODEGENERATIVE DISEASES	An increasing body of evidence suggests that soluble assemblies of amyloid beta-protein (A beta) play an important role in the initiation of Alzheimer disease (AD). In vitro studies have found that synthetic A beta can form soluble aggregates through self-assembly, but this process requires A beta concentrations 100- to 1000-fold greater than physiological levels. Tissue transglutaminase (TGase) has been implicated in neurodegeneration and can cross-link A beta. Here we show that TGase induces rapid aggregation of A beta within 0.5-30 min, which was not observed with chemical cross-linkers. Both A beta 40 and A beta 42 are good substrates for TGase but show different aggregation patterns. Guinea pig and human TGase induced similar A beta aggregation patterns, and oligomerization was observed with A beta 40 concentrations as low as 50 nM. The formed A beta 40 species range from 5 to 6 nm spheres to curvilinear structures of the same width, but up to 100 nm in length, that resemble the previously described self-assembled A beta protofibrils. TGase-induced A beta 40 assemblies are resistant to a 1-h incubation with either neprilysin or insulin degrading enzyme, whereas the monomer is rapidly degraded by both proteases. In support of these species being pathological, TGase-induced A beta 40 assemblies (100 nM) inhibited long term potentiation recorded in the CA1 region of mouse hippocampus slices. Our data suggest that TGase can contribute to AD by initiating A beta oligomerization and aggregation at physiological levels, by reducing the clearance of A beta due to the generation of protease-resistant A beta species, and by forming A beta assemblies that inhibit processes involved in memory and learning. Our data suggest that TGase might constitute a specific therapeutic target for slowing or blocking the progression of AD.	[Hartley, Dean M.; Zhao, Chaohui] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA; [Speier, Austin C.; Woodard, Gavitt A.] Harvard Univ, Fac Arts & Sci, Harvard Coll, Cambridge, MA 02138 USA; [Li, Shaomin; Li, Zongli; Walz, Thomas] Harvard Univ, Sch Med, Dept Neurol & Cell Biol, Boston, MA 02115 USA	Rush University; Harvard University; Harvard University; Harvard Medical School	Hartley, DM (corresponding author), Rush Univ, Med Ctr, Dept Neurol Sci, 1735W Harrison St,Rm 316, Chicago, IL 60612 USA.	dean_hartley@rush.edu	Li, Zongli/AAB-9100-2020	Walz, Thomas/0000-0003-2606-2835	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM062580] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG019770] Funding Source: NIH RePORTER; NIA NIH HHS [AG19770] Funding Source: Medline; NIGMS NIH HHS [P01 GM062580] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson WW, 2001, J NEUROSCI METH, V108, P71, DOI 10.1016/S0165-0270(01)00374-0; Bitan G, 2003, P NATL ACAD SCI USA, V100, P330, DOI 10.1073/pnas.222681699; Bonelli RM, 2002, NEUROBIOL DIS, V11, P106, DOI 10.1006/nbdi.2002.0535; Case A, 2003, BIOCHEMISTRY-US, V42, P9466, DOI 10.1021/bi030084z; Case A, 2007, BIOCHEMISTRY-US, V46, P1106, DOI 10.1021/bi061787u; Chen JSK, 1999, INT J BIOCHEM CELL B, V31, P817, DOI 10.1016/S1357-2725(99)00045-X; Citron BA, 2005, MOL BRAIN RES, V135, P122, DOI 10.1016/j.molbrainres.2004.12.009; Citron BA, 2001, J BIOL CHEM, V276, P3295, DOI 10.1074/jbc.M004776200; Conway KA, 1998, NAT MED, V4, P1318, DOI 10.1038/3311; Cooke SF, 2006, BRAIN, V129, P1659, DOI 10.1093/brain/awl082; D'Souza DR, 2006, NEUROSCI LETT, V409, P5, DOI 10.1016/j.neulet.2006.08.003; DAVIES GE, 1970, P NATL ACAD SCI USA, V66, P651, DOI 10.1073/pnas.66.3.651; Deshpande A, 2006, J NEUROSCI, V26, P6011, DOI 10.1523/JNEUROSCI.1189-06.2006; DUDEK SM, 1994, BRAIN RES, V651, P129, DOI 10.1016/0006-8993(94)90688-2; Duval E, 2005, BIOORG MED CHEM LETT, V15, P1885, DOI 10.1016/j.bmcl.2005.02.005; Eckman EA, 2005, BIOCHEM SOC T, V33, P1101, DOI 10.1042/BST0331101; El-Amouri SS, 2007, BRAIN RES, V1152, P191, DOI 10.1016/j.brainres.2007.03.072; Fagan AM, 2006, ANN NEUROL, V59, P512, DOI 10.1002/ana.20730; GENTILE V, 1991, J BIOL CHEM, V266, P478; Goldsbury C, 2005, J MOL BIOL, V352, P282, DOI 10.1016/j.jmb.2005.07.029; Griffin M, 2002, BIOCHEM J, V368, P377, DOI 10.1042/BJ20021234; Harper JD, 1997, ANNU REV BIOCHEM, V66, P385, DOI 10.1146/annurev.biochem.66.1.385; Harper JD, 1997, CHEM BIOL, V4, P951, DOI 10.1016/S1074-5521(97)90303-3; Harper JD, 1997, CHEM BIOL, V4, P119, DOI 10.1016/S1074-5521(97)90255-6; Hartley DM, 1999, J NEUROSCI, V19, P8876, DOI 10.1523/JNEUROSCI.19-20-08876.1999; Hoshi M, 2003, P NATL ACAD SCI USA, V100, P6370, DOI 10.1073/pnas.1237107100; Huang SM, 2006, J BIOL CHEM, V281, P17941, DOI 10.1074/jbc.M601372200; IKURA K, 1993, FEBS LETT, V326, P109, DOI 10.1016/0014-5793(93)81772-R; Iwata N, 2000, NAT MED, V6, P143, DOI 10.1038/72237; JARRETT JT, 1993, BIOCHEMISTRY-US, V32, P4693, DOI 10.1021/bi00069a001; Johnson GVW, 1997, BRAIN RES, V751, P323, DOI 10.1016/S0006-8993(96)01431-X; Junn E, 2003, P NATL ACAD SCI USA, V100, P2047, DOI 10.1073/pnas.0438021100; Kahlem P, 1998, MOL CELL, V1, P595, DOI 10.1016/S1097-2765(00)80059-3; Kanemitsu H, 2003, NEUROSCI LETT, V350, P113, DOI 10.1016/S0304-3940(03)00898-X; Karpuj MV, 1999, P NATL ACAD SCI USA, V96, P7388, DOI 10.1073/pnas.96.13.7388; Kawahara M, 2000, J BIOL CHEM, V275, P14077, DOI 10.1074/jbc.275.19.14077; Kim SY, 1999, J BIOL CHEM, V274, P30715, DOI 10.1074/jbc.274.43.30715; Klyubin I, 2004, EUR J NEUROSCI, V19, P2839, DOI 10.1111/j.1460-9568.2004.03389.x; Konno T, 2005, J BIOL CHEM, V280, P17520, DOI 10.1074/jbc.M413988200; Konno T, 2005, BIOCHEMISTRY-US, V44, P2072, DOI 10.1021/bi047722d; KUROCHKIN IV, 1994, FEBS LETT, V345, P33, DOI 10.1016/0014-5793(94)00387-4; Lacor PN, 2004, J NEUROSCI, V24, P10191, DOI 10.1523/JNEUROSCI.3432-04.2004; Lambert MP, 1998, P NATL ACAD SCI USA, V95, P6448, DOI 10.1073/pnas.95.11.6448; Lansbury PT, 2006, NATURE, V443, P774, DOI 10.1038/nature05290; Lashuel HA, 2003, J MOL BIOL, V332, P795, DOI 10.1016/S0022-2836(03)00927-6; Lashuel HA, 2002, NATURE, V418, P291, DOI 10.1038/418291a; Leissring MA, 2003, NEURON, V40, P1087, DOI 10.1016/S0896-6273(03)00787-6; Leissring MA, 2003, J BIOL CHEM, V278, P37314, DOI 10.1074/jbc.M305627200; Lesne S, 2006, NATURE, V440, P352, DOI 10.1038/nature04533; Lesort M, 2000, PROG NEUROBIOL, V61, P439, DOI 10.1016/S0301-0082(99)00052-0; Li SM, 2006, J NEUROSCI, V26, P1721, DOI 10.1523/JNEUROSCI.3990-05.2006; Lomakin A, 1996, P NATL ACAD SCI USA, V93, P1125, DOI 10.1073/pnas.93.3.1125; Lue LF, 1999, AM J PATHOL, V155, P853, DOI 10.1016/S0002-9440(10)65184-X; Madani R, 2006, J NEUROSCI RES, V84, P1871, DOI 10.1002/jnr.21074; Mazur-Kolecka B, 2006, BRAIN RES, V1124, P10, DOI 10.1016/j.brainres.2006.09.064; McLean CA, 1999, ANN NEUROL, V46, P860, DOI 10.1002/1531-8249(199912)46:6<860::AID-ANA8>3.0.CO;2-M; MILLER ML, 1995, J NEUROCHEM, V65, P1760; Mucke L, 2000, J NEUROSCI, V20, P4050, DOI 10.1523/jneurosci.20-11-04050.2000; Muma NA, 2007, J NEUROPATH EXP NEUR, V66, P258, DOI 10.1097/nen.0b013e31803d3b02; Necula M, 2007, J BIOL CHEM, V282, P10311, DOI 10.1074/jbc.M608207200; Nemes Z, 2001, NEUROBIOL AGING, V22, P403, DOI 10.1016/S0197-4580(01)00224-X; NITSCH RM, 1995, ANN NEUROL, V37, P512, DOI 10.1002/ana.410370414; Ohi Melanie, 2004, Biol Proced Online, V6, P23, DOI 10.1251/bpo70; Petkova AT, 2002, P NATL ACAD SCI USA, V99, P16742, DOI 10.1073/pnas.262663499; PIKE CJ, 1993, J NEUROSCI, V13, P1676; Piper JL, 2002, BIOCHEMISTRY-US, V41, P386, DOI 10.1021/bi011715x; Qiu WQ, 1998, J BIOL CHEM, V273, P32730, DOI 10.1074/jbc.273.49.32730; Quist A, 2005, P NATL ACAD SCI USA, V102, P10427, DOI 10.1073/pnas.0502066102; Rowan MJ, 2005, BIOCHEM SOC T, V33, P563, DOI 10.1042/BST0330563; Samuels SC, 1999, NEUROLOGY, V52, P547, DOI 10.1212/WNL.52.3.547; Siegel SJ, 2007, BIOCHEMISTRY-US, V46, P1503, DOI 10.1021/bi061853s; Srinivasan R, 2003, J MOL BIOL, V333, P1003, DOI 10.1016/j.jmb.2003.09.001; Tanzi RE, 2004, NEURON, V43, P605, DOI 10.1016/j.neuron.2004.08.024; TERRY RD, 1991, ANN NEUROL, V30, P572, DOI 10.1002/ana.410300410; Townsend M, 2006, J PHYSIOL-LONDON, V572, P477, DOI 10.1113/jphysiol.2005.103754; Urbanc B, 2004, P NATL ACAD SCI USA, V101, P17345, DOI 10.1073/pnas.0408153101; Vekrellis K, 2000, J NEUROSCI, V20, P1657; Wakshlag JJ, 2006, PROTEIN J, V25, P83, DOI 10.1007/s10930-006-0009-1; Walsh DM, 2005, J NEUROSCI, V25, P2455, DOI 10.1523/JNEUROSCI.4391-04.2005; Walsh DM, 1997, J BIOL CHEM, V272, P22364, DOI 10.1074/jbc.272.35.22364; Walsh DM, 1999, J BIOL CHEM, V274, P25945, DOI 10.1074/jbc.274.36.25945; Walsh DM, 2002, NATURE, V416, P535, DOI 10.1038/416535a; Wang HW, 2002, BRAIN RES, V924, P133, DOI 10.1016/S0006-8993(01)03058-X; Wang QW, 2004, J NEUROSCI, V24, P6049, DOI 10.1523/JNEUROSCI.0233-04.2004; Whalen BM, 2005, NEUROBIOL DIS, V20, P254, DOI 10.1016/j.nbd.2005.03.007; Ye CP, 2004, NEUROSCI LETT, V366, P320, DOI 10.1016/j.neulet.2004.05.060; Ye CP, 2003, NEUROBIOL DIS, V13, P177, DOI 10.1016/S0969-9961(03)00068-8; Zainelli GM, 2005, J NEUROPATH EXP NEUR, V64, P58, DOI 10.1093/jnen/64.1.58; Zhang W, 1998, ACTA NEUROPATHOL, V96, P395, DOI 10.1007/s004010050910	89	68	76	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 13	2008	283	24					16790	16800		10.1074/jbc.M802215200	http://dx.doi.org/10.1074/jbc.M802215200			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	309YW	18397883	hybrid, Green Published			2022-12-25	WOS:000256497100056
J	Guo, C; Whitmarsh, AJ				Guo, Chun; Whitmarsh, Alan J.			The beta-arrestin-2 scaffold protein promotes c-jun N-terminal kinase-3 activation by binding to its nonconserved N terminus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR EXPORT SIGNAL; BETA-ARRESTINS; MAP KINASES; DOCKING INTERACTIONS; JNK3; APOPTOSIS; TRANSDUCTION; SPECIFICITY; MOTIF; IDENTIFICATION	The c-Jun N-terminal kinase (JNK) mitogen-activated protein kinase (MAPK) signaling pathway mediates stress responses in cells. JNK activity is regulated by a protein kinase cascade consisting of a MAPK kinase (MKK) and a MAPK kinase kinase (MAPKKK). beta-Arrestin-2 acts as a scaffold by directly binding to the JNK3 isoform and also by recruiting MKK4 and the MAPKKK apoptosis-signaling kinase-1 (ASK1). In this study, we demonstrate by co-precipitation that the extended N-terminal region of JNK3 mediates binding to the C terminus of beta-arrestin-2 and that the N terminus of JNK3 is required for its activation via beta-arrestin-2. We have used site-specific mutagenesis to identify key residues within the N terminus of JNK3 that are essential for binding and demonstrate that this region represents an independent beta-arrestin-2 binding motif that can be fused to other MAPKs and permit their recruitment to the scaffold complex. In addition, we demonstrate that JNK3 recruits MKK4 to the beta-arrestin-2 scaffold complex by binding to the MAPK docking domain (D-domain) located within the N terminus of MKK4. These findings uncover molecular determinants of beta-arrestin-2 scaffold complex assembly and assign a previously unrecognized role for the unique extended N terminus of JNK3.	[Guo, Chun; Whitmarsh, Alan J.] Univ Manchester, Fac Life Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Whitmarsh, AJ (corresponding author), Univ Manchester, Fac Life Sci, Michael Smith Bldg,Oxford Rd, Manchester M13 9PT, Lancs, England.	alan.j.whitmarsh@manchester.ac.uk	Guo, Chun/AAM-5894-2020	Guo, Chun/0000-0002-1540-3166; Whitmarsh, Alan/0000-0003-1184-6610	Biotechnology and Biological Sciences Research Council [BB/C512302/1] Funding Source: Medline; Medical Research Council [G0400620] Funding Source: Medline; Wellcome Trust Funding Source: Medline; MRC [G0400620] Funding Source: UKRI	Biotechnology and Biological Sciences Research Council(UK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Wellcome Trust(Wellcome Trust); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Barr RK, 2004, J BIOL CHEM, V279, P43178, DOI 10.1074/jbc.M405900200; Davis RJ, 2000, CELL, V103, P239, DOI 10.1016/S0092-8674(00)00116-1; DeWire SM, 2007, ANNU REV PHYSIOL, V69, P483, DOI 10.1146/annurev.physiol.69.022405.154749; Gupta S, 1996, EMBO J, V15, P2760, DOI 10.1002/j.1460-2075.1996.tb00636.x; Heo JS, 2004, EMBO J, V23, P2185, DOI 10.1038/sj.emboj.7600212; Ho DT, 2003, J BIOL CHEM, V278, P32662, DOI 10.1074/jbc.M304229200; Kuan CY, 2003, P NATL ACAD SCI USA, V100, P15184, DOI 10.1073/pnas.2336254100; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; Kyriakis JM, 2001, PHYSIOL REV, V81, P807, DOI 10.1152/physrev.2001.81.2.807; Lefkowitz RJ, 2006, MOL CELL, V24, P643, DOI 10.1016/j.molcel.2006.11.007; Ma L, 2007, J CELL SCI, V120, P213, DOI 10.1242/jcs.03338; MATSUMOTO H, 1994, NEURON, V12, P997, DOI 10.1016/0896-6273(94)90309-3; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Miller WE, 2001, J BIOL CHEM, V276, P27770, DOI 10.1074/jbc.M102264200; MOHIT AA, 1995, NEURON, V14, P67, DOI 10.1016/0896-6273(95)90241-4; Mooney LM, 2004, J BIOL CHEM, V279, P11843, DOI 10.1074/jbc.M311841200; Morishima Y, 2001, J NEUROSCI, V21, P7551, DOI 10.1523/JNEUROSCI.21-19-07551.2001; Morrison DK, 2003, ANNU REV CELL DEV BI, V19, P91, DOI 10.1146/annurev.cellbio.19.111401.091942; Scott MGH, 2002, J BIOL CHEM, V277, P37693, DOI 10.1074/jbc.M207552200; Sharrocks AD, 2000, TRENDS BIOCHEM SCI, V25, P448, DOI 10.1016/S0968-0004(00)01627-3; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; Takemoto-Kimura S, 2003, J BIOL CHEM, V278, P18597, DOI 10.1074/jbc.M300578200; Takemoto-Kimura S, 2007, NEURON, V54, P755, DOI 10.1016/j.neuron.2007.05.021; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Tanoue T, 2000, NAT CELL BIOL, V2, P110, DOI 10.1038/35000065; Tanoue TJ, 2003, CELL SIGNAL, V15, P455, DOI 10.1016/S0898-6568(02)00112-2; Tournier C, 1999, MOL CELL BIOL, V19, P1569; Wang P, 2003, J BIOL CHEM, V278, P11648, DOI 10.1074/jbc.M208109200; Wayman GA, 2006, NEURON, V50, P897, DOI 10.1016/j.neuron.2006.05.008; Whitmarsh AJ, 2006, BIOCHEM SOC T, V34, P828, DOI 10.1042/BST0340828; Whitmarsh AJ, 1998, SCIENCE, V281, P1671, DOI 10.1126/science.281.5383.1671; Willoughby EA, 2005, J BIOL CHEM, V280, P25651, DOI 10.1074/jbc.M501926200; Xu ZH, 2003, EMBO J, V22, P252, DOI 10.1093/emboj/cdg021; Yang DD, 1997, NATURE, V389, P865, DOI 10.1038/39899; Yasuda J, 1999, MOL CELL BIOL, V19, P7245	35	40	46	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15903	15911		10.1074/jbc.M710006200	http://dx.doi.org/10.1074/jbc.M710006200			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18408005	hybrid, Green Published			2022-12-25	WOS:000256332500049
J	Stuible, M; Dube, N; Tremblay, ML				Stuible, Matthew; Dube, Nadia; Tremblay, Michel L.			PTP1B regulates cortactin tyrosine phosphorylation by targeting Tyr(446)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATASE 1B; CORTICAL CYTOSKELETON; ACTIN CYTOSKELETON; SIGNALING NETWORKS; MASS-SPECTROMETRY; CELL-MIGRATION; BREAST-CANCER; LEPTIN ACTION; IDENTIFICATION; KINASE	The emergence of protein-tyrosine phosphatase 1B (PTP1B) as a potential drug target for treatment of diabetes, obesity, and cancer underlies the importance of understanding its full range of cellular functions. Here, we have identified cortactin, a central regulator of actin cytoskeletal dynamics, as a substrate of PTP1B. A trapping mutant of PTP1B binds cortactin at the phosphorylation site Tyr(446), the regulation and function of which have not previously been characterized. We show that phosphorylation of cortactin Tyr(446) is induced by hyperosmolarity and potentiates apoptotic signaling during prolonged hyperosmotic stress. This study advances the importance of Tyr(446) in the regulation of cortactin and provides a potential mechanism to explain the effects of PTP1B on processes including cell adhesion, migration, and tumorigenesis.	[Tremblay, Michel L.] McGill Univ, McGill Canc Ctr, Montreal, PQ H3G 1Y6, Canada; McGill Univ, Dept Biochem, Montreal, PQ H3G 1Y6, Canada	McGill University; McGill University	Tremblay, ML (corresponding author), McGill Univ, McGill Canc Ctr, 3655 Prom Sir William Osler, Montreal, PQ H3G 1Y6, Canada.	michel.tremblay@mcgill.ca						Alonso A, 2004, CELL, V117, P699, DOI 10.1016/j.cell.2004.05.018; Amanchy R, 2005, J PROTEOME RES, V4, P1661, DOI 10.1021/pr050134h; Arias-Salgado EG, 2005, J CELL BIOL, V170, P837, DOI 10.1083/jcb.200503125; Bence KK, 2006, NAT MED, V12, P917, DOI 10.1038/nm1435; Bentires-Alj M, 2007, CANCER RES, V67, P2420, DOI 10.1158/0008-5472.CAN-06-4610; Bjorge JD, 2000, J BIOL CHEM, V275, P41439, DOI 10.1074/jbc.M004852200; Blanchetot C, 2005, METHODS, V35, P44, DOI 10.1016/j.ymeth.2004.07.007; Buday L, 2007, BBA-REV CANCER, V1775, P263, DOI 10.1016/j.bbcan.2006.12.002; Burg MB, 2007, PHYSIOL REV, V87, P1441, DOI 10.1152/physrev.00056.2006; Cheng A, 2002, DEV CELL, V2, P497, DOI 10.1016/S1534-5807(02)00149-1; Cheng A, 2001, J BIOL CHEM, V276, P25848, DOI 10.1074/jbc.M009734200; Di Ciano C, 2002, AM J PHYSIOL-CELL PH, V283, pC850, DOI 10.1152/ajpcell.00018.2002; Dube N, 2004, P NATL ACAD SCI USA, V101, P1834, DOI 10.1073/pnas.0304242101; Elchebly M, 1999, SCIENCE, V283, P1544, DOI 10.1126/science.283.5407.1544; Fan LZ, 2004, BIOCHEM J, V380, P581, DOI 10.1042/BJ20040178; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; Head JA, 2003, MOL BIOL CELL, V14, P3216, DOI 10.1091/mbc.e02-11-0753; Hinsby AM, 2003, MOL CELL PROTEOMICS, V2, P29, DOI 10.1074/mcp.M200075-MCP200; Huang C, 1998, J BIOL CHEM, V273, P25770, DOI 10.1074/jbc.273.40.25770; Julien SG, 2007, NAT GENET, V39, P338, DOI 10.1038/ng1963; Kapus A, 2000, J BIOL CHEM, V275, P32289, DOI 10.1074/jbc.M003172200; Lua BL, 2005, FEBS LETT, V579, P577, DOI 10.1016/j.febslet.2004.12.055; Lunn JA, 2007, J BIOL CHEM, V282, P10370, DOI 10.1074/jbc.M607780200; Montalibet J, 2006, J BIOL CHEM, V281, P5258, DOI 10.1074/jbc.M511546200; Rush J, 2005, NAT BIOTECHNOL, V23, P94, DOI 10.1038/nbt1046; Selbach M, 2005, TRENDS MICROBIOL, V13, P181, DOI 10.1016/j.tim.2005.02.007; Simoncic PD, 2002, CURR BIOL, V12, P446, DOI 10.1016/S0960-9822(02)00697-8; Stuible M, 2007, CHEMBIOCHEM, V8, P179, DOI 10.1002/cbic.200600287; van Rossum AGSH, 2003, J BIOL CHEM, V278, P45672, DOI 10.1074/jbc.M306688200; Wang YG, 2006, EMBO J, V25, P5058, DOI 10.1038/sj.emboj.7601384; Wolf-Yadlin A, 2007, P NATL ACAD SCI USA, V104, P5860, DOI 10.1073/pnas.0608638104; Wolf-Yadlin A, 2006, MOL SYST BIOL, V2, DOI 10.1038/msb4100094; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113; Zhang Y, 2005, MOL CELL PROTEOMICS, V4, P1240, DOI 10.1074/mcp.M500089-MCP200; Zhang ZY, 2006, J BIOL CHEM, V281, P1746, DOI 10.1074/jbc.M509590200	35	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15740	15746		10.1074/jbc.M710534200	http://dx.doi.org/10.1074/jbc.M710534200			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18387954	Green Published, hybrid			2022-12-25	WOS:000256332500030
J	Wang, HY; Ghosh, A; Baigude, H; Yang, CS; Qiu, LH; Xia, XG; Zhou, HX; Rana, TM; Xu, ZS				Wang, Hongyan; Ghosh, Animesh; Baigude, Huricha; Yang, Chao-shun; Qiu, Linghua; Xia, Xugang; Zhou, Hongxia; Rana, Tariq M.; Xu, Zuoshang			Therapeutic gene silencing delivered by a chemically modified small interfering RNA against mutant SOD1 slows amyotrophic lateral sclerosis progression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTISENSE OLIGONUCLEOTIDES; MAMMALIAN-CELLS; IN-VIVO; MODIFIED SIRNAS; MOTOR-NEURONS; MICE; EXPRESSION; ALS; DEGENERATION; PERSISTENT	Inherited neurodegenerative diseases, such as Huntington disease and subset of Alzheimer disease, Parkinson disease, and amyotrophic lateral sclerosis, are caused by the mutant genes that have gained undefined properties that harm cells in the nervous system, causing neurodegeneration and clinical phenotypes. Lowering the mutant gene expression is predicted to slow the disease progression and produce clinical benefit. Administration of small interfering RNA (siRNA) can silence specific genes. However, long term delivery of siRNA to silence the mutant genes, a requirement for treatment of these chronic central nervous system (CNS) diseases, remains a critical unsolved issue. Here we designed and tested a chemically stabilized siRNA against human Cu,Zn-superoxide dismutase (SOD1) in a mouse model for amyotrophic lateral sclerosis. We show that the modified siRNA has enhanced stability and retains siRNA activity. Administration of this siRNA at the disease onset by long term infusion into the CNS resulted in widespread distribution of this siRNA, knocked down the mutant SOD1 expression, slowed the disease progression, and extended the survival. These results bring RNA interference therapy one step closer to its clinical application for treatment of chronic, devastating, and fatal CNS disorders.	[Wang, Hongyan; Ghosh, Animesh; Baigude, Huricha; Yang, Chao-shun; Qiu, Linghua; Xia, Xugang; Zhou, Hongxia; Rana, Tariq M.; Xu, Zuoshang] Univ Massachusetts, Sch Med, Dept Mol Pharmacol & Biochem, Worcester, MA 01605 USA; [Ghosh, Animesh; Baigude, Huricha; Yang, Chao-shun; Rana, Tariq M.] Univ Massachusetts, Sch Med, Chem Biol Program, Worcester, MA 01605 USA; [Xu, Zuoshang] Univ Massachusetts, Sch Med, Neurosci Program, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Rana, TM (corresponding author), 364 Plantat St, Worcester, MA 01605 USA.	Tariq.rana@umassmed.edu; zuoshang.xu@umassmed.edu		Yang, Chao-Shun/0000-0002-1532-3377	NINDS NIH HHS [R01NS048145, R21NS053770] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS048145, R21NS053770] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baigude H, 2007, ACS CHEM BIOL, V2, P237, DOI 10.1021/cb7000582; Bertrand JR, 2002, BIOCHEM BIOPH RES CO, V296, P1000, DOI 10.1016/S0006-291X(02)02013-2; Boillee S, 2006, SCIENCE, V312, P1389, DOI 10.1126/science.1123511; Boudreau RL, 2006, CURR TOP DEV BIOL, V75, P73, DOI 10.1016/S0070-2153(06)75003-7; Braasch DA, 2004, BIOORG MED CHEM LETT, V14, P1139, DOI 10.1016/j.bmcl.2003.12.074; Bumcrot D, 2006, NAT CHEM BIOL, V2, P711, DOI 10.1038/nchembio839; Caplen NJ, 2001, P NATL ACAD SCI USA, V98, P9742, DOI 10.1073/pnas.171251798; Chiu YL, 2003, RNA, V9, P1034, DOI 10.1261/rna.5103703; Chiu YL, 2002, MOL CELL, V10, P549, DOI 10.1016/S1097-2765(02)00652-4; Clement AM, 2003, SCIENCE, V302, P113, DOI 10.1126/science.1086071; DiFiglia M, 2007, P NATL ACAD SCI USA, V104, P17204, DOI 10.1073/pnas.0708285104; Dorn G, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh044; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elchuri S, 2005, ONCOGENE, V24, P367, DOI 10.1038/sj.onc.1208207; Far RKK, 2003, NUCLEIC ACIDS RES, V31, P4417, DOI 10.1093/nar/gkg649; FLENNIKEN AM, 1988, J VIROL, V62, P3077, DOI 10.1128/JVI.62.9.3077-3083.1988; Gewirtz AM, 2007, J CLIN INVEST, V117, P3612, DOI 10.1172/JCI34274; Gonzalez-Alegre P, 2007, NAT CLIN PRACT NEURO, V3, P394, DOI 10.1038/ncpneuro0551; Grimm D, 2006, NATURE, V441, P537, DOI 10.1038/nature04791; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; GURNEY ME, 1994, NEW ENGL J MED, V331, P1721, DOI 10.1056/NEJM199412223312516; Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191; Hummon AB, 2007, BIOTECHNIQUES, V42, P467, DOI 10.2144/000112401; Hwang S, 2003, J BIOL CHEM, V278, P39092, DOI 10.1074/jbc.M301749200; Jackson AL, 2006, RNA, V12, P1197, DOI 10.1261/rna.30706; Jackson AL, 2004, TRENDS GENET, V20, P521, DOI 10.1016/j.tig.2004.08.006; John M, 2007, NATURE, V449, P745, DOI 10.1038/nature06179; Jonsson PA, 2006, BRAIN, V129, P451, DOI 10.1093/brain/awh704; Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081; Kumar P, 2007, NATURE, V448, P39, DOI 10.1038/nature05901; Mello CC, 2004, NATURE, V431, P338, DOI 10.1038/nature02872; Miyagishi M, 2003, ANTISENSE NUCLEIC A, V13, P1, DOI 10.1089/108729003764097296; Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122; PAPAIOANNOU VE, 1993, LAB ANIM SCI, V43, P189; Rana TM, 2007, NAT REV MOL CELL BIO, V8, P23, DOI 10.1038/nrm2085; Rise MT, 2000, ARCH MED RES, V31, P237, DOI 10.1016/S0188-4409(00)00061-8; Semizarov D, 2003, P NATL ACAD SCI USA, V100, P6347, DOI 10.1073/pnas.1131959100; SHAH K, 1994, BIOCONJUGATE CHEM, V5, P508, DOI 10.1021/bc00030a005; Smith RA, 2006, J CLIN INVEST, V116, P2290, DOI 10.1172/JCI25424; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Wu WP, 2004, J NEUROSCI METH, V133, P65, DOI 10.1016/j.jneumeth.2003.09.015; Xia XG, 2006, NEUROBIOL DIS, V23, P578, DOI 10.1016/j.nbd.2006.04.019; Xu ZS, 2000, AMYOTROPH LATERAL SC, V1, P225, DOI 10.1080/14660820050515052	43	52	74	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 6	2008	283	23					15845	15852		10.1074/jbc.M800834200	http://dx.doi.org/10.1074/jbc.M800834200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	307QD	18367449	Green Published, hybrid			2022-12-25	WOS:000256332500042
J	Fowler, JD; Brown, JA; Johnson, KA; Suo, Z				Fowler, Jason D.; Brown, Jessica A.; Johnson, Kenneth A.; Suo, Zucai			Kinetic investigation of the inhibitory effect of gemcitabine on DNA polymerization catalyzed by human mitochondrial DNA polymerase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL LUNG-CANCER; PHASE-II TRIAL; OVARIAN-CANCER; MOUSE L; EXPRESSION; FIDELITY; FIALURIDINE; TOXICITY; 2,2-DIFLUORODEOXYCYTIDINE; CHEMOTHERAPY	Gemcitabine, 2'-deoxy-2',2'-difluorocytidine (dFdC), is a drug approved for use against various solid tumors. Clinically, this moderately toxic nucleoside analog causes peripheral neuropathy, hematological dysfunction, and pulmonary toxicity in cancer patients. Although these side effects closely mimic symptoms of mitochondrial dysfunction, there is no direct evidence to show gemcitabine interferes with mitochondrial DNA replication catalyzed by human DNA polymerase gamma. Here we employed presteady state kinetic methods to directly investigate the incorporation of the 5'-triphosphorylated form of gemcitabine (dFdCTP), the excision of the incorporated monophosphorylated form (dFdCMP), and the bypass of template base dFdC catalyzed by human DNA polymerase gamma. Opposite template base dG, dFdCTP was incorporated with a 432-fold lower efficiency than dCTP. Although dFdC is not a chain terminator, the incorporated dFdCMP decreased the incorporation efficiency of the next 2 correct nucleotides by 214- and 7-fold, respectively. Moreover, the primer 3'-dFdCMP was excised with a 50-fold slower rate than the matched 3'-dCMP. When dFdC was encountered as a template base, DNA polymerase gamma paused at the lesion and one downstream position but eventually elongated the primer to full-length product. These pauses were because of a 1,000-fold decrease in nucleotide incorporation efficiency. Interestingly, the polymerase fidelity at these pause sites decreased by 2 orders of magnitude. Thus, our pre-steady state kinetic studies provide direct evidence demonstrating the inhibitory effect of gemcitabine on the activity of human mitochondrial DNA polymerase.	[Fowler, Jason D.; Brown, Jessica A.; Suo, Zucai] Ohio State Univ, Dept Biochem, Ohio State Biochem Program, Columbus, OH 43210 USA; [Suo, Zucai] Ohio State Univ, Ohio State Biophys Program, Mol Cell & Dev Biol Program, Ctr Comprehens Canc, Columbus, OH 43210 USA; [Johnson, Kenneth A.] Univ Texas, Inst Cell & Mol Biol, Dept Chem & Biochem, Austin, TX 78712 USA	University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University of Texas System; University of Texas Austin	Suo, Z (corresponding author), 740 Biolog Sci,484 W 12th Ave, Columbus, OH 43210 USA.	suo.3@osu.edu	Brown, Jessica/E-2172-2017		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008512, R01GM079403, R01GM044613] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM044613, R01 GM044613-18, R01 GM079403, R01 GM079403-01A2, GM 044613, 5T32 GM 008512-11, GM 079403] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Airoldi M, 2006, PANCREAS, V32, P44, DOI 10.1097/01.mpa.0000191649.47667.06; Blackstock AW, 2001, CLIN CANCER RES, V7, P3263; BOGENHAGEN D, 1977, CELL, V11, P719, DOI 10.1016/0092-8674(77)90286-0; BOGENHAGEN D, 1974, J BIOL CHEM, V249, P7991; Bogenhagen DF, 1999, AM J HUM GENET, V64, P1276, DOI 10.1086/302392; BRAHAMS D, 1994, LANCET, V343, P1494, DOI 10.1016/S0140-6736(94)92599-2; Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403; CATIMEL G, 1994, ANN ONCOL, V5, P543, DOI 10.1093/oxfordjournals.annonc.a058910; Crino L, 1999, J CLIN ONCOL, V17, P3522, DOI 10.1200/JCO.1999.17.11.3522; Dalbagni G, 2006, J CLIN ONCOL, V24, P2729, DOI 10.1200/JCO.2005.05.2720; Davidson JD, 2004, CANCER RES, V64, P3761, DOI 10.1158/0008-5472.CAN-03-3363; Dormann AJ, 1998, LANCET, V351, P644, DOI 10.1016/S0140-6736(05)78426-9; Dumontet C, 2001, BRIT J HAEMATOL, V113, P772, DOI 10.1046/j.1365-2141.2001.02795.x; Einhorn LH, 1999, J CLIN ONCOL, V17, P509, DOI 10.1200/JCO.1999.17.2.509; Ferraro P, 2006, P NATL ACAD SCI USA, V103, P18586, DOI 10.1073/pnas.0609020103; Fiala KA, 2006, J BIOL CHEM, V281, P19038, DOI 10.1074/jbc.M601178200; Fracasso PM, 1999, J NATL CANCER I, V91, P1779, DOI 10.1093/jnci/91.20.1779; Graves SW, 1998, BIOCHEMISTRY-US, V37, P6050, DOI 10.1021/bi972685u; HEINEMANN V, 1992, CANCER RES, V52, P533; HEINEMANN V, 1995, SEMIN ONCOL, V22, P11; HUANG P, 1991, CANCER RES, V51, P6110; Johnson AA, 2000, BIOCHEMISTRY-US, V39, P1702, DOI 10.1021/bi992104w; Johnson AA, 2001, J BIOL CHEM, V276, P38097; Johnson AA, 2001, J BIOL CHEM, V276, P38090; Johnson AA, 2001, J BIOL CHEM, V276, P40847, DOI 10.1074/jbc.M106743200; JOHNSON MD, 1992, PHYSICIAN SPORTSMED, V20, P60, DOI 10.1080/00913847.1992.11947449; Konerding D, 2002, BIOCHEMISTRY-US, V41, P839, DOI 10.1021/bi015678l; Kubicka S, 2001, HEPATO-GASTROENTEROL, V48, P783; Lee HR, 2006, J BIOL CHEM, V281, P36236, DOI 10.1074/jbc.M607964200; LEWIS W, 1995, NAT MED, V1, P417, DOI 10.1038/nm0595-417; Lorusso D, 2006, ANN ONCOL, V17, pV188, DOI 10.1093/annonc/mdj979; Mackey JR, 1998, CANCER RES, V58, P4349; Mackey JR, 1999, JNCI-J NATL CANCER I, V91, P1876, DOI 10.1093/jnci/91.21.1876; Marce S, 2006, HAEMATOL-HEMATOL J, V91, P895; MCKENZIE R, 1995, NEW ENGL J MED, V333, P1099, DOI 10.1056/NEJM199510263331702; Morandi P, 2006, ANN ONCOL, V17, pV177, DOI 10.1093/annonc/mdj977; Mutch DG, 2003, GYNECOL ONCOL, V90, pS8, DOI 10.1016/S0090-8258(03)00338-X; Neff T, 1996, EXP HEMATOL, V24, P1340; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Pfisterer J, 2006, J CLIN ONCOL, V24, P4699, DOI 10.1200/JCO.2006.06.0913; Plunkett W, 1996, SEMIN ONCOL, V23, P3; PLUNKETT W, 1995, SEMIN ONCOL, V22, P3; REIS RJS, 1983, J BIOL CHEM, V258, P9078; Richardson KA, 2004, BIOCHEM PHARMACOL, V68, P2337, DOI 10.1016/j.bcp.2004.07.042; Roettger MP, 2004, BIOCHEMISTRY-US, V43, P13827, DOI 10.1021/bi048782m; Ruiz van Haperen V W, 1993, Biochem Pharmacol, V46, P762, DOI 10.1016/0006-2952(93)90566-F; Sallah S, 2001, BRIT J HAEMATOL, V113, P185, DOI 10.1046/j.1365-2141.2001.02743.x; SeminoMora C, 1997, LAB INVEST, V76, P487; Shao J, 2006, CURR CANCER DRUG TAR, V6, P409, DOI 10.2174/156800906777723949; Shirai T, 2006, LUNG CANCER, V52, P181, DOI 10.1016/j.lungcan.2006.01.004; Song SW, 2003, J BIOL CHEM, V278, P43893, DOI 10.1074/jbc.C300401200; Ukai A, 2006, GENES CELLS, V11, P111, DOI 10.1111/j.1365-2443.2006.00922.x; Verstappen CCP, 2003, J NEURO-ONCOL, V63, P201, DOI 10.1023/A:1023952106955	53	22	23	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 30	2008	283	22					15339	15348		10.1074/jbc.M800310200	http://dx.doi.org/10.1074/jbc.M800310200			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	306EV	18378680	Green Published, Green Accepted, hybrid			2022-12-25	WOS:000256232000052
J	Xu, JM; Chen, YJ; Lu, RJ; Cottingham, C; Jiao, K; Wang, Q				Xu, Jianmin; Chen, Yunjia; Lu, Roujian; Cottingham, Christopher; Jiao, Kai; Wang, Qin			Protein kinase A phosphorylation of spinophilin modulates its interaction with the alpha(2A)-adrenergic receptor (AR) and alters temporal properties of alpha(2A)AR internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3RD INTRACELLULAR LOOP; ALPHA(2)-ADRENERGIC RECEPTORS; BETA-2-ADRENERGIC RECEPTOR; ADRENERGIC-RECEPTOR; DOPAMINE-RECEPTOR; COUPLED RECEPTORS; BINDING-PROTEIN; CELL-SURFACE; F-ACTIN; DESENSITIZATION	Spinophilin plays critical roles in regulating trafficking and signaling of the alpha(2)-adrenergic receptor (AR) both in vitro and in vivo (Wang, Q., Zhao, J., Brady, A. E., Feng, J., Allen, P. B., Lefkowitz, R. J., Greengard, P., and Limbird, L. E. (2004) Science 304, 1940 -1944). In the present study, we demonstrate that protein kinase A (PKA) phosphorylation of spinophilin modulates the spinophilin-alpha(2A)AR interaction to regulate alpha(2A)AR internalization. Activation of PKA by forskolin abolishes the agonist-enhanced interaction between spinophilin and the alpha(2A)AR, and this event can be blocked by Ser -> Ala mutations at the PKA phosphorylation sites of spinophilin. In addition, a Ser 3 Asp mutation that mimics the phosphorylated state at the PKA phosphorylation site Ser-177, which is located within the alpha(2A)AR binding region of spinophilin, is sufficient to block the spinophilin-alpha(2A)AR interaction in intact cells. In cells expressing mutant spinophilin carrying the S177D mutation, agonist-induced internalization of the alpha(2A)ARis accelerated and enhanced, as revealed by both intact cell enzyme-linked immunosorbent assay and quantitative immunofluorescent studies. Furthermore, activation of PKA by forskolin enhances agonist-induced internalization of the alpha(2A)AR in cells expressing wild type spinophilin, but not in cells lacking spinophilin or expressing the spinophilin mutant Sp177D. These results strongly support that PKA phosphorylation of spinophilin is functionally relevant in regulating alpha(2A)AR trafficking. Therefore, modulation of spinophilin-receptor interaction through phosphorylation of spinophilin may represent a novel mechanism whereby PKA regulates G protein-coupled receptor trafficking.	[Xu, Jianmin; Chen, Yunjia; Lu, Roujian; Cottingham, Christopher; Wang, Qin] Univ Alabama, Dept Physiol & Biophys, Birmingham, AL 35294 USA; [Jiao, Kai] Univ Alabama, Dept Genet, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Wang, Q (corresponding author), 958 MCLM,1918 Univ Blvd, Birmingham, AL 35294 USA.	qinwang@uab.edu		Jiao, Kai/0000-0002-5415-9020; Wang, Qin/0000-0002-1079-5914				Allen PB, 1997, P NATL ACAD SCI USA, V94, P9956, DOI 10.1073/pnas.94.18.9956; Brady AE, 2003, J BIOL CHEM, V278, P32405, DOI 10.1074/jbc.M304195200; Brady AE, 2005, MOL PHARMACOL, V67, P1690, DOI 10.1124/mol.104.005215; DeGraff JL, 2002, J BIOL CHEM, V277, P43247, DOI 10.1074/jbc.M207495200; Ferguson SSG, 2001, PHARMACOL REV, V53, P1; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; Futter M, 2005, P NATL ACAD SCI USA, V102, P3489, DOI 10.1073/pnas.0409802102; Grossman SD, 2004, J NEUROCHEM, V90, P317, DOI 10.1111/j.1471-4159.2004.02491.x; Hsieh-Wilson LC, 2003, J BIOL CHEM, V278, P1186, DOI 10.1074/jbc.M205754200; JewellMotz EA, 1996, J BIOL CHEM, V271, P18082, DOI 10.1074/jbc.271.30.18082; LEE NH, 1993, J BIOL CHEM, V268, P7949; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIMBIRD LE, 1988, FASEB J, V2, P2686, DOI 10.1096/fasebj.2.11.2840317; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MacMillan LB, 1999, J BIOL CHEM, V274, P35845, DOI 10.1074/jbc.274.50.35845; Martini L, 2007, CURR OPIN NEUROBIOL, V17, P556, DOI 10.1016/j.conb.2007.10.004; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; Rapacciuolo A, 2003, J BIOL CHEM, V278, P35403, DOI 10.1074/jbc.M305675200; Richman JG, 1998, AM J PHYSIOL-CELL PH, V274, pC654, DOI 10.1152/ajpcell.1998.274.3.C654; Richman JG, 2001, J BIOL CHEM, V276, P15003, DOI 10.1074/jbc.M011679200; Satoh A, 1998, J BIOL CHEM, V273, P3470, DOI 10.1074/jbc.273.6.3470; Smith FD, 1999, J BIOL CHEM, V274, P19894, DOI 10.1074/jbc.274.28.19894; Ventura ALM, 2000, J PHARMACOL EXP THER, V293, P426; von Zastrow M, 2007, CURR OPIN CELL BIOL, V19, P436, DOI 10.1016/j.ceb.2007.04.021; Wang Q, 2004, SCIENCE, V304, P1940, DOI 10.1126/science.1098274; Wang Q, 2002, J BIOL CHEM, V277, P50589, DOI 10.1074/jbc.M208503200; Wang Q, 2007, BIOCHEM PHARMACOL, V73, P1135, DOI 10.1016/j.bcp.2006.12.024; Wang XH, 2005, NAT CELL BIOL, V7, P405, DOI 10.1038/ncb1237; WILSON AL, 1990, J BIOL CHEM, V265, P17318; Wu GY, 1997, J BIOL CHEM, V272, P17836, DOI 10.1074/jbc.272.28.17836; Zhang N, 2006, BLOOD, V108, P38, DOI 10.1182/blood-2005-06-2599; ZHOU XM, 1991, J BIOL CHEM, V266, P7462	32	17	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 23	2008	283	21					14516	14523		10.1074/jbc.M710340200	http://dx.doi.org/10.1074/jbc.M710340200			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	302BL	18367453	hybrid			2022-12-25	WOS:000255941400039
J	Forbes, ML; Horsey, E; Hiller, NL; Buchinsky, FJ; Hayes, JD; Compliment, JM; Hillman, T; Ezzo, S; Shen, K; Keefe, R; Barbadora, K; Post, JC; Hu, FZ; Ehrlich, GD				Forbes, Michael L.; Horsey, Edward; Hiller, N. Luisa; Buchinsky, Farrel J.; Hayes, Jay D.; Compliment, James M.; Hillman, Todd; Ezzo, Suzanne; Shen, Kai; Keefe, Randy; Barbadora, Karen; Post, J. Christopher; Hu, Fen Ze; Ehrlich, Garth D.			Strain-Specific Virulence Phenotypes of Streptococcus pneumoniae Assessed Using the Chinchilla laniger Model of Otitis Media	PLOS ONE			English	Article								Background: Streptococcus pneumoniae [Sp] infection is associated with local and systemic disease. Our current understanding of the differential contributions of genetic strain variation, serotype, and host response to disease phenotype is incomplete. Using the chinchilla model of otitis media [OM] we investigated the disease phenotype generated by the laboratory strain TIGR4 and each of thirteen clinical strains (BS68-75, BS290, BS291, BS293, BS436 and BS437); eleven of the thirteen strains have been genomically sequenced. Methodology/Principal Findings: For each strain 100 colony forming units were injected bilaterally into the tympanic bullae of 6 young adult chinchillas under general anesthesia. All animals were examined daily for local and systemic disease by a blinded observer. Pneumatic otoscopy was used to evaluate local disease, and behavioral assessments served as the measure of systemic disease. Virulence scoring was performed using a 4-point scale to assess four clinical parameters [severity and rapidity of local disease onset; and severity and rapidity of systemic disease onset] during a 10-day evaluation period. Highly significant variation was observed among the strains in their ability to cause disease and moribundity. Conclusions/Significance: As expected, there was a significant correlation between the rapidity of systemic disease onset and severity of systemic disease; however, there was little correlation between the severity of otoscopic changes and severity of systemic disease. Importantly, it was observed that different strains of the same serotype produced as broad an array of disease phenotypes as did strains of different serotypes. We attribute these phenotypic differences among the strains to the high degree of genomic plasticity that we have previously documented.	[Forbes, Michael L.; Horsey, Edward; Hiller, N. Luisa; Buchinsky, Farrel J.; Hayes, Jay D.; Compliment, James M.; Hillman, Todd; Ezzo, Suzanne; Shen, Kai; Keefe, Randy; Post, J. Christopher; Hu, Fen Ze; Ehrlich, Garth D.] Allegheny General Hosp, Allegheny Singer Res Inst, Ctr Genom Sci, Pittsburgh, PA USA; [Forbes, Michael L.] Allegheny General Hosp, Dept Pediat, Pittsburgh, PA USA; [Buchinsky, Farrel J.; Post, J. Christopher] Allegheny General Hosp, Dept Surg, Pittsburgh, PA USA; [Buchinsky, Farrel J.; Post, J. Christopher; Hu, Fen Ze; Ehrlich, Garth D.] Drexel Univ, Coll Med, Dept Microbiol & Immunol, Pittsburgh, PA USA; [Hillman, Todd] Allegheny General Hosp, Dept Neurosurg, Pittsburgh, PA USA; [Barbadora, Karen] Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA USA	Allegheny General Hospital; Allegheny General Hospital; Allegheny General Hospital; Drexel University; Allegheny General Hospital; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Ehrlich, GD (corresponding author), Allegheny General Hosp, Allegheny Singer Res Inst, Ctr Genom Sci, Pittsburgh, PA USA.	gehrlich@wpahs.org	Hiller, N. Luisa/A-3739-2016; Buchinsky, Farrel/AAC-2080-2020	Hiller, N. Luisa/0000-0001-6572-1368; Buchinsky, Farrel/0000-0002-2830-6023; Ehrlich, Garth/0000-0003-1140-6594	Allegheny General Hospital/Allegheny Singer Research Institute; Health Resources and Services Administration; NIH-NIDCD [DC02148, DC04173, DC05659]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC005659, R01DC002148, R01DC004173] Funding Source: NIH RePORTER	Allegheny General Hospital/Allegheny Singer Research Institute; Health Resources and Services Administration(United States Department of Health & Human ServicesUnited States Health Resources & Service Administration (HRSA)); NIH-NIDCD(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))	This work was supported by Allegheny General Hospital/Allegheny Singer Research Institute and grants from the Health Resources and Services Administration and the NIH-NIDCD: DC02148 (GDE), DC04173 (GDE), and DC05659 (JCP). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Adderson EE, 2000, MOL GENET METAB, V71, P451, DOI 10.1006/mgme.2000.3025; Aul JJ, 1998, ANN OTO RHINOL LARYN, V107, P508; Bentley SD, 2007, PLOS GENET, V3, P230, DOI 10.1371/journal.pgen.0030023; BLUESTONE CD, 2000, OTITIS MEDIA INFANTS; Bondy J, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.6.e72; BREDIUS RGM, 1994, J INFECT DIS, V170, P848, DOI 10.1093/infdis/170.4.848; Brogden KA, 2005, LANCET, V365, P253, DOI 10.1016/S0140-6736(05)70155-0; Bruckner R, 2004, INT J MED MICROBIOL, V294, P157, DOI 10.1016/j.ijmm.2004.06.019; Buchinsky FJ, 2007, BMC MICROBIOL, V7, DOI 10.1186/1471-2180-7-56; Dinarello CA, 1997, CHEST, V112, p321S, DOI 10.1378/chest.112.6_Supplement.321S; Ehrlich GD, 2005, CLIN ORTHOP RELAT R, P20, DOI 10.1097/01.blo.0000175124.52590.c0; Ehrlich GD, 2002, JAMA-J AM MED ASSOC, V287, P1710, DOI 10.1001/jama.287.13.1710; Elden LM, 1998, J OTOLARYNGOL, V27, P9; Gibot S, 2002, CRIT CARE MED, V30, P969, DOI 10.1097/00003246-200205000-00003; Grohmann U, 2000, J IMMUNOL, V164, P4197, DOI 10.4049/jimmunol.164.8.4197; Hiller NL, 2007, J BACTERIOL, V189, P8186, DOI 10.1128/JB.00690-07; Hoffman JA, 2003, PEDIATRICS, V112, P1095, DOI 10.1542/peds.112.5.1095; Hogg JS, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-6-r103; Holmes CL, 2003, CHEST, V124, P1103, DOI 10.1378/chest.124.3.1103; JACOBS NM, 1991, AM J DIS CHILD, V145, P70, DOI 10.1001/archpedi.1991.02160010076019; Kaplan B, 1997, PEDIATR INFECT DIS J, V16, pS9, DOI 10.1097/00006454-199702001-00003; Klein JO, 2000, PEDIATR INFECT DIS J, V19, P383, DOI 10.1097/00006454-200004000-00034; Klugman KP, 2001, CURR OPIN INFECT DIS, V14, P173, DOI 10.1097/00001432-200104000-00011; Kornelisse RF, 1996, J INFECT DIS, V173, P1148, DOI 10.1093/infdis/173.5.1148; Lacroix-Desmazes S, 2005, P NATL ACAD SCI USA, V102, P4109, DOI 10.1073/pnas.0500586102; Martens P, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-21; McCool TL, 2002, J EXP MED, V195, P359, DOI 10.1084/jem.20011576; McKessar SJ, 2007, J BACTERIOL, V189, P1342, DOI 10.1128/JB.01170-06; Mira JP, 1999, JAMA-J AM MED ASSOC, V282, P561, DOI 10.1001/jama.282.6.561; Perez-Caballero D, 2004, J IMMUNOL, V173, P6899, DOI 10.4049/jimmunol.173.11.6899; POST JC, 1995, JAMA-J AM MED ASSOC, V273, P1598, DOI 10.1001/jama.273.20.1598; Post JC, 1996, AM J OTOLARYNG, V17, P106, DOI 10.1016/S0196-0709(96)90005-8; Ratner AJ, 2005, P NATL ACAD SCI USA, V102, P3429, DOI 10.1073/pnas.0500599102; Schaaf BM, 2003, AM J RESP CRIT CARE, V168, P476, DOI 10.1164/rccm.200210-1164OC; Shen K, 2006, INFECT IMMUN, V74, P321, DOI 10.1128/IAI.74.1.321-330.2006; Shen K, 2005, INFECT IMMUN, V73, P3479, DOI 10.1128/IAI.73.6.3479-3491.2005; Stuber F, 1996, CRIT CARE MED, V24, P381, DOI 10.1097/00003246-199603000-00004; Tan TQ, 2002, PEDIATR ANN, V31, P241, DOI 10.3928/0090-4481-20020401-08; Tettelin H, 2005, P NATL ACAD SCI USA, V102, P13950, DOI 10.1073/pnas.0506758102; Wang XR, 2002, J IMMUNOL, V168, P810, DOI 10.4049/jimmunol.168.2.810; Watanabe E, 2005, CRIT CARE MED, V33, P89, DOI 10.1097/01.CCM.0000150025.79100.7D; Wizemann TM, 2001, INFECT IMMUN, V69, P1593, DOI 10.1128/IAI.69.3.1593-1598.2001	42	35	35	0	3	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 9	2008	3	4							e1969	10.1371/journal.pone.0001969	http://dx.doi.org/10.1371/journal.pone.0001969			11	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XD	18398481	Green Published, gold, Green Submitted			2022-12-25	WOS:000260795500034
J	McErlean, P; Shackelton, LA; Andrews, E; Webster, DR; Lambert, SB; Nissen, MD; Sloots, TP; Mackay, IM				McErlean, Peter; Shackelton, Laura A.; Andrews, Emily; Webster, Dale R.; Lambert, Stephen B.; Nissen, Michael D.; Sloots, Theo P.; Mackay, Ian M.			Distinguishing Molecular Features and Clinical Characteristics of a Putative New Rhinovirus Species, Human Rhinovirus C (HRV C)	PLOS ONE			English	Article							DENSITY-LIPOPROTEIN RECEPTOR; POLYMERASE-CHAIN-REACTION; CELLULAR RECEPTOR; 3-DIMENSIONAL STRUCTURE; PROTOTYPE STRAINS; PROTEIN VP1; SEQUENCE; ILLNESS; RECOMBINATION; POLIOVIRUS	Background: Human rhinoviruses (HRVs) are the most frequently detected pathogens in acute respiratory tract infections (ARTIs) and yet little is known about the prevalence, recurrence, structure and clinical impact of individual members. During 2007, the complete coding sequences of six previously unknown and highly divergent HRV strains were reported. To catalogue the molecular and clinical features distinguishing the divergent HRV strains, we undertook, for the first time, in silico analyses of all available polyprotein sequences and performed retrospective reviews of the medical records of cases in which variants of the prototype strain, HRV-QPM, had been detected. Methodology/Principle Findings: Genomic analyses revealed that the six divergent strains, residing within a clade we previously called HRV A2, had the shortest polyprotein of all picornaviruses investigated. Structure-based amino acid alignments identified conserved motifs shared among members of the genus Rhinovirus as well as substantive deletions and insertions unique to the divergent strains. Deletions mostly affected regions encoding proteins traditionally involved in antigenicity and serving as HRV and HEV receptor footprints. Because the HRV A2 strains cannot yet be cultured, we created homology models of predicted HRV-QPM structural proteins. In silico comparisons confirmed that HRV-QPM was most closely related to the major group HRVs. HRV-QPM was most frequently detected in infants with expiratory wheezing or persistent cough who had been admitted to hospital and required supplemental oxygen. It was the only virus detected in 65% of positive individuals. These observations contributed to an objective clinical impact ranging from mild to severe. Conclusions: The divergent strains did not meet classification requirements for any existing species of the genus Rhinovirus or Enterovirus. HRV A2 strains should be partitioned into at least one new species, putatively called Human rhinovirus C, populated by members detected with high frequency, from individuals with respiratory symptoms requiring hospital admission.	[McErlean, Peter; Andrews, Emily; Lambert, Stephen B.; Nissen, Michael D.; Sloots, Theo P.; Mackay, Ian M.] Royal Childrens Hosp, Sir Albert Sakzewski Virus Res Ctr, Queensland Paediat Infect Dis Lab, Brisbane, Qld, Australia; [McErlean, Peter; Andrews, Emily; Lambert, Stephen B.; Nissen, Michael D.; Sloots, Theo P.; Mackay, Ian M.] Univ Queensland, Clin & Med Virology Ctr, Brisbane, Qld, Australia; [Shackelton, Laura A.] Penn State Univ, Ctr Infect Dis Dynam, Dept Biol, Mueller Lab, University Pk, PA USA; [Webster, Dale R.] Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA USA; [Webster, Dale R.] Univ Calif San Francisco, Biol & Med Informat Program, San Francisco, CA USA; [Webster, Dale R.] Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA USA; [Nissen, Michael D.; Sloots, Theo P.] Royal Brisbane Hosp Campus, Queensland Hlth Pathol Serv, Div Microbiol, Brisbane, Qld, Australia; [Nissen, Michael D.; Sloots, Theo P.] Royal Childrens Hosp, Dept Paediat & Child Hlth, Brisbane, Qld, Australia	Royal Children's Hospital Brisbane; University of Queensland; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; Queensland Health; Royal Brisbane & Women's Hospital; Royal Children's Hospital Brisbane	McErlean, P (corresponding author), Royal Childrens Hosp, Sir Albert Sakzewski Virus Res Ctr, Queensland Paediat Infect Dis Lab, Brisbane, Qld, Australia.	ian.mackay@uq.edu.au	Lambert, Stephen B/B-8348-2008; Sloots, Theo P/E-6118-2011; Lambert, Stephen/N-7819-2019; McErlean, Peter/O-5187-2016; Mackay, Ian M/B-2537-2010; Nissen, Michael D/M-6823-2013	Lambert, Stephen B/0000-0002-2709-193X; Lambert, Stephen/0000-0002-2709-193X; Mackay, Ian M/0000-0003-3598-2350; Nissen, Michael D/0000-0003-1686-3313	NHMRC [455905]; Royal Children's Hospital Foundation [912-011, 922-202]; Woolworth's Fresh Futures Programme; SASVRC PhD Scholarship	NHMRC(National Health and Medical Research Council (NHMRC) of Australia); Royal Children's Hospital Foundation; Woolworth's Fresh Futures Programme; SASVRC PhD Scholarship	This work was supported by NHMRC Project grant 455905 and the Royal Children's Hospital Foundation grants 912-011 and 922-202 sponsored by the Woolworth's Fresh Futures Programme. PM was supported by a SASVRC PhD Scholarship.	ANDRIES K, 1990, J VIROL, V64, P1117, DOI 10.1128/JVI.64.3.1117-1123.1990; Arden KE, 2006, J MED VIROL, V78, P1232, DOI 10.1002/jmv.20689; Bartlett NW, 2008, NAT MED, V14, P199, DOI 10.1038/nm1713; Belnap DM, 2000, P NATL ACAD SCI USA, V97, P73, DOI 10.1073/pnas.97.1.73; Bhella D, 2004, J BIOL CHEM, V279, P8325, DOI 10.1074/jbc.M311334200; Bialasiewicz S, 2008, J CLIN VIROL, V41, P63, DOI 10.1016/j.jcv.2007.11.001; BLAAS D, 1987, PROTEINS, V2, P263, DOI 10.1002/prot.340020402; Blom N, 1996, PROTEIN SCI, V5, P2203, DOI 10.1002/pro.5560051107; Brown B, 2003, J VIROL, V77, P8973, DOI 10.1128/JVI.77.16.8973-8984.2003; GAMA RE, 1989, J MED VIROL, V28, P73, DOI 10.1002/jmv.1890280204; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Hall T, 1999, NUCL ACIDS S SER, V41, P95, DOI DOI 10.1021/BK-1999-0734.CH008; HAMPARIAN VV, 1987, VIROLOGY, V159, P191; Hayden FG, 2004, REV MED VIROL, V14, P17, DOI 10.1002/rmv.406; He YN, 2001, NAT STRUCT BIOL, V8, P874, DOI 10.1038/nsb1001-874; Hewat EA, 2000, EMBO J, V19, P6317, DOI 10.1093/emboj/19.23.6317; HOFER F, 1994, P NATL ACAD SCI USA, V91, P1839, DOI 10.1073/pnas.91.5.1839; HORSNELL C, 1995, J GEN VIROL, V76, P2549, DOI 10.1099/0022-1317-76-10-2549; Khan AG, 2007, J VIROL, V81, P4625, DOI 10.1128/JVI.02160-06; Kiang D, 2007, J CLIN VIROL, V38, P227, DOI 10.1016/j.jcv.2006.12.016; Kistler A, 2007, J INFECT DIS, V196, P817, DOI 10.1086/520816; Kistler AL, 2007, VIROL J, V4, DOI 10.1186/1743-422X-4-40; Kolatkar PR, 1999, EMBO J, V18, P6249, DOI 10.1093/emboj/18.22.6249; Kumar S, 2004, BRIEF BIOINFORM, V5, P150, DOI 10.1093/bib/5.2.150; Kusel MMH, 2006, PEDIATR INFECT DIS J, V25, P680, DOI 10.1097/01.inf.0000226912.88900.a3; Laine P, 2006, J GEN VIROL, V87, P129, DOI 10.1099/vir.0.81137-0; Lamson D, 2006, J INFECT DIS, V194, P1398, DOI 10.1086/508551; Lau SKP, 2007, J INFECT DIS, V196, P986, DOI 10.1086/521310; Ledford RM, 2005, ANTIVIR RES, V68, P135, DOI 10.1016/j.antiviral.2005.08.003; Ledford RM, 2004, J VIROL, V78, P3663, DOI 10.1128/JVI.78.7.3663-3674.2004; Lee WM, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000966; Lole KS, 1999, J VIROL, V73, P152, DOI 10.1128/JVI.73.1.152-160.1999; Lukashev AN, 2005, J GEN VIROL, V86, P3281, DOI 10.1099/vir.0.81264-0; Marlovits TC, 1998, J VIROL, V72, P10246, DOI 10.1128/JVI.72.12.10246-10250.1998; McErlean P, 2007, J CLIN VIROL, V39, P67, DOI 10.1016/j.jcv.2007.03.012; MORI J, 1994, J MED VIROL, V44, P323, DOI 10.1002/jmv.1890440403; Neumann E, 2003, J VIROL, V77, P8504, DOI 10.1128/JVI.77.15.8504-8511.2003; Oberste MS, 2004, J GEN VIROL, V85, P2577, DOI 10.1099/vir.0.79925-0; OLIVEIRA MA, 1993, STRUCTURE, V1, P51, DOI 10.1016/0969-2126(93)90008-5; PALMENBERG AC, 2002, ALIGNMENTS COMP PROF, V42, P149; Papadopoulos NG, 2000, J INFECT DIS, V181, P1875, DOI 10.1086/315513; Pettersen EF, 2004, J COMPUT CHEM, V25, P1605, DOI 10.1002/jcc.20084; Racaniello V.R., 2001, FIELDS VIROLOGY, P455; Rieder Elizabeth, 2002, P61; ROSEN L, 1965, BACTERIOL REV, V29, P173, DOI 10.1128/MMBR.29.2.173-184.1965; Rossmann MG, 2000, VIROLOGY, V269, P239, DOI 10.1006/viro.2000.0258; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; Savolainen C, 2004, J GEN VIROL, V85, P2271, DOI 10.1099/vir.0.79897-0; Savolainen C, 2002, J GEN VIROL, V83, P333, DOI 10.1099/0022-1317-83-2-333; Shepherd CM, 2006, NUCLEIC ACIDS RES, V34, pD386, DOI 10.1093/nar/gkj032; Simmonds P, 2006, J VIROL, V80, P483, DOI 10.1128/JVI.80.1.483-493.2006; Sloots TP, 2006, EMERG INFECT DIS, V12, P1263, DOI 10.3201/eid1708.051239; Stanway G, 2005, VIRUS TAXONOMY, P757; STIRK HJ, 1994, PROTEIN ENG, V7, P47, DOI 10.1093/protein/7.1.47; Stuart AD, 2002, J VIROL, V76, P7694, DOI 10.1128/JVI.76.15.7694-7704.2002; Tapparel C, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-224; Verdaguer N, 2000, J MOL BIOL, V300, P1179, DOI 10.1006/jmbi.2000.3943; Vlasak M, 2005, J VIROL, V79, P7389, DOI 10.1128/JVI.79.12.7389-7395.2005; Vlasak M, 2003, J VIROL, V77, P6923, DOI 10.1128/JVI.77.12.6923-6930.2003; Wainwright C, 2003, NEW ENGL J MED, V349, P27, DOI 10.1056/NEJMoa022226; Xiao C, 2001, J VIROL, V75, P2444, DOI 10.1128/JVI.75.5.2444-2451.2001	61	115	118	0	6	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1847	10.1371/journal.pone.0001847	http://dx.doi.org/10.1371/journal.pone.0001847			12	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382652	gold, Green Published, Green Submitted			2022-12-25	WOS:000260795400002
J	Quelard, D; Lavergne, E; Hendaoui, I; Elamaa, H; Tiirola, U; Heljasvaara, R; Pihlajaniemi, T; Clement, B; Musso, O				Quelard, Delphine; Lavergne, Elise; Hendaoui, Ismail; Elamaa, Harri; Tiirola, Ulla; Heljasvaara, Ritva; Pihlajaniemi, Taina; Clement, Bruno; Musso, Orlando			A Cryptic Frizzled Module in Cell Surface Collagen 18 Inhibits Wnt/beta-Catenin Signaling	PLOS ONE			English	Article								Collagens contain cryptic polypeptide modules that regulate major cell functions, such as cell proliferation or death. Collagen XVIII (C18) exists as three amino terminal end variants with specific amino terminal polypeptide modules. We investigated the function of the variant 3 of C18 (V3C18) containing a frizzled module (FZC18), which carries structural identity with the extracellular cysteine-rich domain of the frizzled receptors. We show that V3C18 is a cell surface heparan sulfate proteoglycan, its topology being mediated by the FZC18 module. V3C18 mRNA was expressed at low levels in 21 normal adult human tissues. Its expression was up-regulated in fibrogenesis and in small well-differentiated liver tumors, but decreased in advanced human liver cancers. Low FZC18 immunostaining in liver cancer nodules correlated with markers of high Wnt/beta-catenin activity. V3C18 (M(r) = 170 kD) was proteolytically processed into a cell surface FZC18-containing 50 kD glycoprotein precursor that bound Wnt3a in vitro through FZC18 and suppressed Wnt3a-induced stabilization of beta-catenin. Ectopic expression of either FZC18 ( 35 kD) or its 50 kD precursor inhibited Wnt/beta-catenin signaling in colorectal and liver cancer cell lines, thus downregulating major cell cycle checkpoint gatekeepers cyclin D1 and c-myc and reducing tumor cell growth. By contrast, full-length V3C18 was unable to inhibit Wnt signaling. In summary, we identified a cell-surface signaling pathway whereby FZC18 inhibits Wnt/beta-catenin signaling. The signal, encrypted within cell-surface C18, is released by enzymatic processing as an active frizzled (c) under bar ysteine-(r) under bar ich (d) under bar omain (CRD) that reduces cancer cell growth. Thus, extracellular matrix controls Wnt signaling through a collagen-embedded CRD behaving as a cell-surface sensor of proteolysis, conveying feedback cues to control cancer cell fate.	[Quelard, Delphine; Lavergne, Elise; Hendaoui, Ismail; Clement, Bruno; Musso, Orlando] Univ Rennes 1, INSERM, U620, Rennes, France; [Elamaa, Harri; Tiirola, Ulla; Heljasvaara, Ritva; Pihlajaniemi, Taina] Univ Oulu, Dept Med Biochem & Mol Biol, Biocenter, Oulu, Finland	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite de Rennes; University of Oulu	Quelard, D (corresponding author), Univ Rennes 1, INSERM, U620, Rennes, France.	orlando.musso@rennes.inserm.fr	Clement, Bruno/E-5546-2016; Musso, Orlando/N-5756-2017	Clement, Bruno/0000-0001-8827-146X; Pihlajaniemi, Taina/0000-0002-1664-9045; Musso, Orlando/0000-0001-8881-6925; Heljasvaara, Ritva/0000-0003-4763-3844	Inserm; Universite de Rennes 1; ARC [5158]; Region Bretagne; INCA; Finnish Centre of Excellence Program of Academy of Finland [44843]	Inserm(Institut National de la Sante et de la Recherche Medicale (Inserm)European Commission); Universite de Rennes 1; ARC(Australian Research Council); Region Bretagne(Region Bretagne); INCA(Institut National du Cancer (INCA) France); Finnish Centre of Excellence Program of Academy of Finland(Academy of Finland)	Inserm, Universite de Rennes 1, ARC #5158, Region Bretagne, INCA 2007 and Finnish Centre of Excellence Program of Academy of Finland #44843	Bafico A, 1999, J BIOL CHEM, V274, P16180, DOI 10.1074/jbc.274.23.16180; Bafico A, 2004, CANCER CELL, V6, P497, DOI 10.1016/j.ccr.2004.09.032; BENEDETTI EL, 1967, J CELL SCI, V2, P499; Benhamouche S, 2006, DEV CELL, V10, P759, DOI 10.1016/j.devcel.2006.03.015; Bornstein P, 2002, CURR OPIN CELL BIOL, V14, P608, DOI 10.1016/S0955-0674(02)00361-7; Caldwell GM, 2004, CANCER RES, V64, P883, DOI 10.1158/0008-5472.CAN-03-1346; Chen SQ, 2001, J CELL BIOL, V152, P87, DOI 10.1083/jcb.152.1.87; Chien AJ, 2007, FRONT BIOSCI-LANDMRK, V12, P448, DOI 10.2741/2074; Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018; Colnot S, 2004, P NATL ACAD SCI USA, V101, P17216, DOI 10.1073/pnas.0404761101; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847; DeAlmeida VI, 2007, CANCER RES, V67, P5371, DOI 10.1158/0008-5472.CAN-07-0266; Elamaa H, 2003, MATRIX BIOL, V22, P427, DOI 10.1016/S0945-053X(03)00073-8; Gripon P, 2002, P NATL ACAD SCI USA, V99, P15655, DOI 10.1073/pnas.232137699; Hausmann G, 2007, NAT REV MOL CELL BIO, V8, P331, DOI 10.1038/nrm2141; He BA, 2005, ONCOGENE, V24, P3054, DOI 10.1038/sj.onc.1208511; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; Hsu SC, 1998, MOL CELL BIOL, V18, P4807, DOI 10.1128/MCB.18.8.4807; King KL, 1998, ANNU REV PHYSIOL, V60, P601, DOI 10.1146/annurev.physiol.60.1.601; KOVACEVIC Z, 1983, PHYSIOL REV, V63, P547, DOI 10.1152/physrev.1983.63.2.547; Laurent-Puig P, 2006, ONCOGENE, V25, P3778, DOI 10.1038/sj.onc.1209547; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; LeJossic C, 1996, EUR J BIOCHEM, V238, P400, DOI 10.1111/j.1432-1033.1996.0400z.x; Lietard J, 2000, HEPATOLOGY, V32, P1377, DOI 10.1053/jhep.2000.20066; Loeppen S, 2002, CANCER RES, V62, P5685; Melkonyan HS, 1997, P NATL ACAD SCI USA, V94, P13636, DOI 10.1073/pnas.94.25.13636; Michineau S, 2006, BIOCHEMISTRY-US, V45, P2699, DOI 10.1021/bi051674v; Mikels AJ, 2006, ONCOGENE, V25, P7461, DOI 10.1038/sj.onc.1210053; MURAGAKI Y, 1995, P NATL ACAD SCI USA, V92, P8763, DOI 10.1073/pnas.92.19.8763; Musso O, 1998, HEPATOLOGY, V28, P98, DOI 10.1002/hep.510280115; Musso O, 2001, CANCER RES, V61, P45; Musso O, 2001, HEPATOLOGY, V33, P868, DOI 10.1053/jhep.2001.23189; OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6; Orford K, 1999, J CELL BIOL, V146, P855, DOI 10.1083/jcb.146.4.855; Overall CM, 2007, NAT REV MOL CELL BIO, V8, P245, DOI 10.1038/nrm2120; Prange W, 2003, J PATHOL, V201, P250, DOI 10.1002/path.1448; Rehn M, 1996, GENOMICS, V32, P436, DOI 10.1006/geno.1996.0139; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; REHN M, 1994, P NATL ACAD SCI USA, V91, P4234, DOI 10.1073/pnas.91.10.4234; Rehn M, 2001, P NATL ACAD SCI USA, V98, P1024, DOI 10.1073/pnas.031564998; Saarela J, 1998, AM J PATHOL, V153, P611, DOI 10.1016/S0002-9440(10)65603-9; Sasaki T, 1998, EMBO J, V17, P4249, DOI 10.1093/emboj/17.15.4249; Shih YL, 2006, CANCER, V107, P579, DOI 10.1002/cncr.22023; Suzuki H, 2004, NAT GENET, V36, P417, DOI 10.1038/ng1330; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; VALLET V, 1995, MOL CELL BIOL, V15, P5453; van de Wetering M, 2003, EMBO REP, V4, P609, DOI 10.1038/sj.embor.embor865; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Xu YK, 1998, CURR BIOL, V8, pR405, DOI 10.1016/S0960-9822(98)70262-3; You L, 2004, ONCOGENE, V23, P6170, DOI 10.1038/sj.onc.1207844; You ZB, 2002, J CELL BIOL, V157, P429, DOI 10.1083/jcb.200201110; Zi XL, 2005, CANCER RES, V65, P9762, DOI 10.1158/0008-5472.CAN-05-0103; Zucman-Rossi J, 2007, ONCOGENE, V26, P774, DOI 10.1038/sj.onc.1209824	54	43	48	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1878	10.1371/journal.pone.0001878	http://dx.doi.org/10.1371/journal.pone.0001878			14	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382662	Green Published, gold, Green Submitted			2022-12-25	WOS:000260795400013
J	Sato, F; Jin, Z; Schulmann, K; Wang, J; Greenwald, BD; Ito, T; Kan, T; Hamilton, JP; Yang, J; Paun, B; David, S; Olaru, A; Cheng, Y; Mori, Y; Abraham, JM; Yfantis, HG; Wu, TT; Fredericksen, MB; Wang, KK; Canto, M; Romero, Y; Feng, Z; Meltzer, SJ				Sato, Fumiaki; Jin, Zhe; Schulmann, Karsten; Wang, Jean; Greenwald, Bruce D.; Ito, Tetsuo; Kan, Takatsugu; Hamilton, James P.; Yang, Jian; Paun, Bogdan; David, Stefan; Olaru, Alexandru; Cheng, Yulan; Mori, Yuriko; Abraham, John M.; Yfantis, Harris G.; Wu, Tsung-Teh; Fredericksen, Mary B.; Wang, Kenneth K.; Canto, Marcia; Romero, Yvonne; Feng, Ziding; Meltzer, Stephen J.			Three-Tiered Risk Stratification Model to Predict Progression in Barrett's Esophagus Using Epigenetic and Clinical Features	PLOS ONE			English	Article								Background: Barrett's esophagus predisposes to esophageal adenocarcinoma. However, the value of endoscopic surveillance in Barrett's esophagus has been debated because of the low incidence of esophageal adenocarcinoma in Barrett's esophagus. Moreover, high inter-observer and sampling-dependent variation in the histologic staging of dysplasia make clinical risk assessment problematic. In this study, we developed a 3-tiered risk stratification strategy, based on systematically selected epigenetic and clinical parameters, to improve Barrett's esophagus surveillance efficiency. Methods and Findings: We defined high-grade dysplasia as endpoint of progression, and Barrett's esophagus progressor patients as Barrett's esophagus patients with either no dysplasia or low-grade dysplasia who later developed high-grade dysplasia or esophageal adenocarcinoma. We analyzed 4 epigenetic and 3 clinical parameters in 118 Barrett's esophagus tissues obtained from 35 progressor and 27 non-progressor Barrett's esophagus patients from Baltimore Veterans Affairs Maryland Health Care Systems and Mayo Clinic. Based on 2-year and 4-year prediction models using linear discriminant analysis (area under the receiver-operator characteristic (ROC) curve: 0.8386 and 0.7910, respectively), Barrett's esophagus specimens were stratified into high-risk (HR), intermediate-risk (IR), or low-risk (LR) groups. This 3-tiered stratification method retained both the high specificity of the 2-year model and the high sensitivity of the 4-year model. Progression-free survivals differed significantly among the 3 risk groups, with p = 0.0022 (HR vs. IR) and p<0.0001 (HR or IR vs. LR). Incremental value analyses demonstrated that the number of methylated genes contributed most influentially to prediction accuracy. Conclusions: This 3-tiered risk stratification strategy has the potential to exert a profound impact on Barrett's esophagus surveillance accuracy and efficiency.	[Sato, Fumiaki; Jin, Zhe; Wang, Jean; Ito, Tetsuo; Kan, Takatsugu; Hamilton, James P.; Yang, Jian; Paun, Bogdan; David, Stefan; Olaru, Alexandru; Cheng, Yulan; Mori, Yuriko; Abraham, John M.; Canto, Marcia; Meltzer, Stephen J.] Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Baltimore, MD 21205 USA; [Sato, Fumiaki; Jin, Zhe; Schulmann, Karsten; Greenwald, Bruce D.; Ito, Tetsuo; Kan, Takatsugu; Hamilton, James P.; Yang, Jian; Paun, Bogdan; David, Stefan; Olaru, Alexandru; Cheng, Yulan; Mori, Yuriko; Abraham, John M.; Meltzer, Stephen J.] Univ Maryland, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Baltimore, MD USA; [Schulmann, Karsten] Ruhr Univ Bochum, Med Dept, Bochum, Germany; [Yfantis, Harris G.] Baltimore Veterans Affairs Maryland Hlth Care Syst, Dept Anatom Pathol, Baltimore, MD USA; [Wu, Tsung-Teh] Mayo Clin Fdn, Dept Pathol, Rochester, MN USA; [Fredericksen, Mary B.; Wang, Kenneth K.; Romero, Yvonne] Mayo Clin Fdn, Div Gastroenterol & Hepatol, Rochester, MN USA; [Feng, Ziding] Fred Hutchinson Canc Res Ctr, Public Hlth Sci Div, Seattle, WA USA; [Sato, Fumiaki] Kyoto Univ, Grad Sch Pharmaceut Sci, Dept Nanobio Drug Discovery, Kyoto, Japan	Johns Hopkins University; University System of Maryland; University of Maryland Baltimore; Ruhr University Bochum; Mayo Clinic; Mayo Clinic; Fred Hutchinson Cancer Center; Kyoto University	Sato, F (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Gastroenterol & Hepatol, Baltimore, MD 21205 USA.	fsato@pharm.kyoto-u.ac.jp	Schulmann, Karsten/N-2230-2016		USPHS [CA85069, CA01808, CA 98450, CA106763, CA097048, CA111603]; Mildred Scheel Foundation of German Cancer Aid; NATIONAL CANCER INSTITUTE [R21CA098450, R01CA097048, R21CA106763, R01CA001808, R01CA111603, U01CA085069] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK067872] Funding Source: NIH RePORTER	USPHS(United States Department of Health & Human ServicesUnited States Public Health Service); Mildred Scheel Foundation of German Cancer Aid(Deutsche Krebshilfe); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))	USPHS grants CA85069, CA01808, CA 98450, CA106763, CA097048, CA111603, and the Mildred Scheel Foundation of German Cancer Aid (Deutsche Krebshilfe). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abe M, 2005, CANCER RES, V65, P828; Alikhan M, 1999, GASTROINTEST ENDOSC, V50, P23, DOI 10.1016/S0016-5107(99)70339-1; Barr H, 2002, GUT, V51, P313, DOI 10.1136/gut.51.3.313; Barrett MT, 1999, NAT GENET, V22, P106, DOI 10.1038/8816; Brock MV, 2003, CLIN CANCER RES, V9, P2912; *BUR USC, 2006, MONTHL POSTC RES POP; Cameron AJ, 1997, AM J GASTROENTEROL, V92, P586; Cameron AJ, 1998, MAYO CLIN PROC, V73, P457; Clark GWB, 1996, DIGEST DIS, V14, P213, DOI 10.1159/000171554; Conio M, 2003, AM J GASTROENTEROL, V98, P1931, DOI 10.1016/S0002-9270(03)00629-4; Corley DA, 2002, GASTROENTEROLOGY, V122, P633, DOI 10.1053/gast.2002.31879; Cossentino Mark J, 2003, Semin Gastrointest Dis, V14, P128; Eaden J, 2001, J PATHOL, V194, P152, DOI 10.1002/path.876; Eads CA, 2001, CANCER RES, V61, P3410; Eads CA, 2000, CANCER RES, V60, P5021; Eisen GM, 2002, GASTROINTEST ENDOSC, V55, P784, DOI 10.1016/S0016-5107(02)70404-5; HAMEETEMAN W, 1989, GASTROENTEROLOGY, V96, P1249, DOI 10.1016/S0016-5085(89)80011-3; Johnston MH, 2005, NAT CLIN PRACT GASTR, V2, P323, DOI 10.1038/ncpgasthep0214; Katz D, 1998, AM J GASTROENTEROL, V93, P536; Kondo Y, 2004, CANCER METAST REV, V23, P29, DOI 10.1023/A:1025806911782; LEVINE DS, 1993, GASTROENTEROLOGY, V105, P40, DOI 10.1016/0016-5085(93)90008-Z; MELTZER SJ, 1994, CANCER RES, V54, P3379; Montgomery E, 2001, HUM PATHOL, V32, P379, DOI 10.1053/hupa.2001.23511; Montgomery E, 2001, HUM PATHOL, V32, P368, DOI 10.1053/hupa.2001.23510; Ogino S, 2006, GUT, V55, P1000, DOI 10.1136/gut.2005.082933; Pepe MS, 2001, J NATL CANCER I, V93, P1054, DOI 10.1093/jnci/93.14.1054; Playford RJ, 2002, GUT, V51, P314, DOI 10.1136/gut.51.3.314; Rabinovitch PS, 2001, AM J GASTROENTEROL, V96, P3071, DOI 10.1111/j.1572-0241.2001.05261.x; Reid BJ, 2001, AM J GASTROENTEROL, V96, P2839; REID BJ, 1988, HUM PATHOL, V19, P166, DOI 10.1016/S0046-8177(88)80344-7; Ronkainen J, 2005, GASTROENTEROLOGY, V129, P1825, DOI 10.1053/j.gastro.2005.08.053; Rudolph RE, 2000, ANN INTERN MED, V133, P748, DOI 10.7326/0003-4819-133-9-200011070-00026; Rugge M, 2000, AM J SURG PATHOL, V24, P167, DOI 10.1097/00000478-200002000-00001; Sato F, 2006, CANCER-AM CANCER SOC, V106, P483, DOI 10.1002/cncr.21657; Sato F, 2005, CANCER-AM CANCER SOC, V103, P1596, DOI 10.1002/cncr.20938; Sato F, 2002, CANCER RES, V62, P1148; Sato F, 2002, CANCER RES, V62, P6820; Schulmann K, 2005, ONCOGENE, V24, P4138, DOI 10.1038/sj.onc.1208598; Shaheen NJ, 2004, GUT, V53, P1736, DOI 10.1136/gut.2003.033837; Skacel M, 2000, AM J GASTROENTEROL, V95, P3383; Spechler SJ, 2002, NEW ENGL J MED, V346, P836, DOI 10.1056/NEJMcp012118; Srivastava A, 2007, AM J GASTROENTEROL, V102, P483, DOI 10.1111/j.1572-0241.2007.01073.x; STREITZ JM, 1993, J THORAC CARDIOV SUR, V105, P383; STREITZ JM, 1993, J THORAC CARDIOVASC, V105, P387; Takubo K, 2002, SUPERFICIAL ESOPHAGEAL NEOPLASM: PATHOLOGY, DIAGNOSIS, AND THERAPY, P141; Tannapfel A, 2004, DIGEST DIS, V22, P126, DOI 10.1159/000080311; van Rijnsoever M, 2002, GUT, V51, P797, DOI 10.1136/gut.51.6.797; Weston AP, 1999, AM J GASTROENTEROL, V94, P3413, DOI 10.1111/j.1572-0241.1999.01602.x; Zingg JM, 1997, CARCINOGENESIS, V18, P869, DOI 10.1093/carcin/18.5.869	49	59	60	0	2	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	APR 2	2008	3	4							e1890	10.1371/journal.pone.0001890	http://dx.doi.org/10.1371/journal.pone.0001890			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370XC	18382671	Green Published, gold, Green Submitted			2022-12-25	WOS:000260795400022
J	Lutz, A; Brefczynski-Lewis, J; Johnstone, T; Davidson, RJ				Lutz, Antoine; Brefczynski-Lewis, Julie; Johnstone, Tom; Davidson, Richard J.			Regulation of the Neural Circuitry of Emotion by Compassion Meditation: Effects of Meditative Expertise	PLOS ONE			English	Article							BRAIN; COGNITION; EMPATHY	Recent brain imaging studies using functional magnetic resonance imaging (fMRI) have implicated insula and anterior cingulate cortices in the empathic response to another's pain. However, virtually nothing is known about the impact of the voluntary generation of compassion on this network. To investigate these questions we assessed brain activity using fMRI while novice and expert meditation practitioners generated a loving-kindness-compassion meditation state. To probe affective reactivity, we presented emotional and neutral sounds during the meditation and comparison periods. Our main hypothesis was that the concern for others cultivated during this form of meditation enhances affective processing, in particular in response to sounds of distress, and that this response to emotional sounds is modulated by the degree of meditation training. The presentation of the emotional sounds was associated with increased pupil diameter and activation of limbic regions (insula and cingulate cortices) during meditation (versus rest). During meditation, activation in insula was greater during presentation of negative sounds than positive or neutral sounds in expert than it was in novice meditators. The strength of activation in insula was also associated with self-reported intensity of the meditation for both groups. These results support the role of the limbic circuitry in emotion sharing. The comparison between meditation vs. rest states between experts and novices also showed increased activation in amygdala, right temporo-parietal junction (TPJ), and right posterior superior temporal sulcus (pSTS) in response to all sounds, suggesting, greater detection of the emotional sounds, and enhanced mentation in response to emotional human vocalizations for experts than novices during meditation. Together these data indicate that the mental expertise to cultivate positive emotion alters the activation of circuitries previously linked to empathy and theory of mind in response to emotional stimuli.	[Lutz, Antoine; Davidson, Richard J.] Univ Wisconsin, Madison, WI 53706 USA; [Brefczynski-Lewis, Julie] West Virginia Univ, Morgantown, WV USA; [Johnstone, Tom] Univ Reading, Reading, England	University of Wisconsin System; University of Wisconsin Madison; West Virginia University; University of Reading	Lutz, A (corresponding author), Univ Wisconsin, Madison, WI 53706 USA.	alutz@wisc.edu; rjdavids@wisc.edu	Johnstone, Tom/C-5909-2011; LUTZ, Antoine/AAE-5114-2020	Johnstone, Tom/0000-0001-8635-8158; LUTZ, Antoine/0000-0002-0258-3233; Davidson, Richard/0000-0002-8506-4964	NCCAM [U01AT002114-01A1]; Fyssen foundation; NIMH [P50-MH069315]; NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE [U01AT002114] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH069315] Funding Source: NIH RePORTER	NCCAM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); Fyssen foundation; NIMH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL CENTER FOR COMPLEMENTARY &ALTERNATIVE MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Complementary & Alternative Medicine); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))	Support was provided by NCCAM U01AT002114-01A1, Fyssen foundation to AL and NIMH P50-MH069315 to RJD, and by gifts from Adrianne and Edwin Cook-Ryder, Bryant Wangard and Ralph Robinson, Keith and Arlene Bronstein and the John W. Kluge Foundation. No funders or sponsors participated in the design or conduct of the study, or in the analysis, and interpretation of the data, or in the preparation, review, or approval of the manuscript.	Beatty J., 2000, HDB PSYCHOPHYSIOLOGY, P142; Bradley MM, 2000, PSYCHOPHYSIOLOGY, V37, P204, DOI 10.1111/1469-8986.3720204; Brefczynski-Lewis JA, 2007, P NATL ACAD SCI USA, V104, P11483, DOI 10.1073/pnas.0606552104; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; COXRW, 1996, COMPUT BIOMED RES, V29, P162; Dalai Lama, 1995, WORLD TIBETAN BUDDHI; Dalgleish T, 2004, NAT REV NEUROSCI, V5, P583, DOI 10.1038/nrn1432; Damasio A, 2001, NATURE, V413, P781, DOI 10.1038/35101669; Damasio Antonio, 1999, FEELING WHAT HAPPENS; Davidson RJ, 2004, PHILOS T R SOC B, V359, P1395, DOI 10.1098/rstb.2004.1510; de Vignemont F, 2006, TRENDS COGN SCI, V10, P435, DOI 10.1016/j.tics.2006.08.008; Gethin Rupert., 1998, FDN BUDDHISM; Gusnard DA, 2001, NAT REV NEUROSCI, V2, P685, DOI 10.1038/35094500; Jaffer FA, 1997, JMRI-J MAGN RESON IM, V7, P1122, DOI 10.1002/jmri.1880070627; JEZZARD P, 1995, MAGNET RESON MED, V34, P65, DOI 10.1002/mrm.1910340111; Lazar SW, 2005, NEUROREPORT, V16, P1893, DOI 10.1097/01.wnr.0000186598.66243.19; Lutz A, 2004, P NATL ACAD SCI USA, V101, P16369, DOI 10.1073/pnas.0407401101; Maguire EA, 2000, P NATL ACAD SCI USA, V97, P4398, DOI 10.1073/pnas.070039597; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Preston S. D., 2002, BEHAV BRAIN SCI, V25, P20, DOI [10.1017/S0140525X02380014, DOI 10.1017/S0140525X023]; Preston SD, 2002, BEHAV BRAIN SCI, V25, P1, DOI 10.1017/S0140525X02000018; Ruby P, 2004, J COGNITIVE NEUROSCI, V16, P988, DOI 10.1162/0898929041502661; RUBY P, 2007, SENSORIMOTOR FDN HIG; Saxe R, 2006, CURR OPIN NEUROBIOL, V16, P235, DOI 10.1016/j.conb.2006.03.001; Singer T, 2004, SCIENCE, V303, P1157, DOI 10.1126/science.1093535; Singer T, 2006, NATURE, V439, P466, DOI 10.1038/nature04271; Sommerville JA, 2006, PSYCHON B REV, V13, P179, DOI 10.3758/BF03193831; Tankersley D, 2007, NAT NEUROSCI, V10, P150, DOI 10.1038/nn1833; Urry HL, 2006, J NEUROSCI, V26, P4415, DOI 10.1523/JNEUROSCI.3215-05.2006	29	479	491	4	150	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1897	10.1371/journal.pone.0001897	http://dx.doi.org/10.1371/journal.pone.0001897			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	370KZ	18365029	Green Submitted, gold, Green Published			2022-12-25	WOS:000260762400035
J	Murrell, A; Ito, Y; Verde, G; Huddleston, J; Woodfine, K; Silengo, MC; Spreafico, F; Perotti, D; De Crescenzo, A; Sparago, A; Cerrato, F; Riccio, A				Murrell, Adele; Ito, Yoko; Verde, Gaetano; Huddleston, Joanna; Woodfine, Kathryn; Silengo, Margherita Cirillo; Spreafico, Filippo; Perotti, Daniela; De Crescenzo, Agostina; Sparago, Angela; Cerrato, Flavia; Riccio, Andrea			Distinct Methylation Changes at the IGF2-H19 Locus in Congenital Growth Disorders and Cancer	PLOS ONE			English	Article								Background: Differentially methylated regions (DMRs) are associated with many imprinted genes. In mice methylation at a DMR upstream of the H19 gene known as the Imprint Control region (IC1) is acquired in the male germline and influences the methylation status of DMRs 100 kb away in the adjacent Insulin-like growth factor 2 (Igf2) gene through long-range interactions. In humans, germline-derived or post-zygotically acquired imprinting defects at IC1 are associated with aberrant activation or repression of IGF2, resulting in the congenital growth disorders Beckwith-Wiedemann (BWS) and Silver-Russell (SRS) syndromes, respectively. In Wilms tumour and colorectal cancer, biallelic expression of IGF2 has been observed in association with loss of methylation at a DMR in IGF2. This DMR, known as DMR0, has been shown to be methylated on the silent maternal IGF2 allele presumably with a role in repression. The effect of IGF2 DMR0 methylation changes in the aetiology of BWS or SRS is unknown. Methodology/Principal Findings: We analysed the methylation status of the DMR0 in BWS, SRS and Wilms tumour patients by conventional bisulphite sequencing and pyrosequencing. We show here that, contrary to previous reports, the IGF2 DMR0 is actually methylated on the active paternal allele in peripheral blood and kidney. This is similar to the IC1 methylation status and is inconsistent with the proposed silencing function of the maternal IGF2 allele. Beckwith-Wiedemann and Silver-Russell patients with IC1 methylation defects have similar methylation defects at the IGF2 DMR0, consistent with IC1 regulating methylation at IGF2 in cis. In Wilms tumour, however, methylation profiles of IC1 and IGF2 DMR0 are indicative of methylation changes occurring on both parental alleles rather than in cis. Conclusions/Significance: These results support a model in which DMR0 and IC1 have opposite susceptibilities to global hyper and hypomethylation during tumorigenesis independent of the parent of origin imprint. In contrast, during embryogenesis DMR0 is methylated or demethylated according to the germline methylation imprint at the IC1, indicating different mechanisms of imprinting loss in neoplastic and non-neoplastic cells.	[Murrell, Adele; Ito, Yoko; Huddleston, Joanna; Woodfine, Kathryn] Univ Cambridge, CRUK Cambridge Res Inst, Dept Oncol, Cambridge, England; [Verde, Gaetano; De Crescenzo, Agostina; Sparago, Angela; Cerrato, Flavia; Riccio, Andrea] Seconda Univ Napoli, Dipartimento Sci Ambientali, Caserta, Italy; [De Crescenzo, Agostina; Sparago, Angela; Cerrato, Flavia; Riccio, Andrea] CNR, Inst Genet & Biophys, Naples, Italy; [Silengo, Margherita Cirillo] Univ Turin, Dipartimento Sci Pediatriche Adolescenza, Turin, Italy; [Spreafico, Filippo] Fdn IRCCS Ist Nazionale Tumori, Dept Med Oncol, Pediat Oncol Unit, Milan, Italy; [Perotti, Daniela] Fdn IRCCS Ist Nazionale Tumori, Dept Expt Oncol & Lab, Milan, Italy	CRUK Cambridge Institute; University of Cambridge; Universita della Campania Vanvitelli; Consiglio Nazionale delle Ricerche (CNR); Istituto di Genetica e Biofisica "Adriano Buzzati-Traverso" (IGB-CNR); University of Turin; Fondazione IRCCS Istituto Nazionale Tumori Milan; Fondazione IRCCS Istituto Nazionale Tumori Milan	Murrell, A (corresponding author), Univ Cambridge, CRUK Cambridge Res Inst, Dept Oncol, Cambridge, England.	amm207@cam.ac.uk	Spreafico, Filippo/K-7813-2016; Verde, Gaetano/U-2749-2017; Perotti, Daniela/C-2013-2017; Sparago, Angela/O-8324-2015; Riccio, Andrea/A-4991-2015; Riccio, Andrea/AAY-7571-2020	Spreafico, Filippo/0000-0002-5587-3509; Verde, Gaetano/0000-0003-4768-0165; Perotti, Daniela/0000-0002-6703-2889; Sparago, Angela/0000-0003-4352-945X; Riccio, Andrea/0000-0001-7990-3576; Riccio, Andrea/0000-0001-7990-3576; Murrell, adele/0000-0003-2647-3511; Silengo, Margherita/0000-0002-6255-1532	CRUK Senior Cancer Research Fellowship; Societa Italiana di Cancerologia; Fondazione Pezcoller fellowship; AICR; MIUR PRIN 2005; Istituto Superiore di Sanita; Associazione Italiana Ricerca sul Cancro; Telethon-Italia [GGP04072]; Associazione Bianca Garavaglia, Busto Arsizio, Varese, Italy	CRUK Senior Cancer Research Fellowship; Societa Italiana di Cancerologia; Fondazione Pezcoller fellowship; AICR; MIUR PRIN 2005(Ministry of Education, Universities and Research (MIUR)Research Projects of National Relevance (PRIN)); Istituto Superiore di Sanita; Associazione Italiana Ricerca sul Cancro(Fondazione AIRC per la ricerca sul cancro); Telethon-Italia(Fondazione Telethon); Associazione Bianca Garavaglia, Busto Arsizio, Varese, Italy	This work was supported by CRUK Senior Cancer Research Fellowship (A.M.) and Societa Italiana di Cancerologia and Fondazione Pezcoller fellowship (F.C) and grants from AICR (A.M.), MIUR PRIN 2005 (A.R.), Istituto Superiore di Sanita (A.R.), Associazione Italiana Ricerca sul Cancro (A.R. and D.P.), Telethon-Italia Grant No. GGP04072 (A.R.), and the Associazione Bianca Garavaglia, Busto Arsizio, Varese, Italy (D.P.).	Bell AC, 2000, NATURE, V405, P482, DOI 10.1038/35013100; Bliek J, 2006, AM J HUM GENET, V78, P604, DOI 10.1086/502981; Byun HM, 2007, CANCER RES, V67, P10753, DOI 10.1158/0008-5472.CAN-07-0329; Constancia M, 2000, NAT GENET, V26, P203, DOI 10.1038/79930; Cooper MJ, 1996, J UROLOGY, V155, P2120, DOI 10.1016/S0022-5347(01)66120-2; Cooper WN, 2005, EUR J HUM GENET, V13, P1025, DOI 10.1038/sj.ejhg.5201463; Cui HM, 2002, CANCER RES, V62, P6442; Delaval K, 2006, BIOESSAYS, V28, P453, DOI 10.1002/bies.20407; Esteller M, 2002, J PATHOL, V196, P1, DOI 10.1002/path.1024; FEIL R, 1994, DEVELOPMENT, V120, P2933; Feinberg AP, 2004, NAT REV CANCER, V4, P143, DOI 10.1038/nrc1279; Hark AT, 2000, NATURE, V405, P486, DOI 10.1038/35013106; Kanduri C, 2000, CURR BIOL, V10, P853, DOI 10.1016/S0960-9822(00)00597-2; Kurukuti S, 2006, P NATL ACAD SCI USA, V103, P10684, DOI 10.1073/pnas.0600326103; Lopes S, 2003, HUM MOL GENET, V12, P295, DOI 10.1093/hmg/ddg022; Monk D, 2006, HUM MOL GENET, V15, P1259, DOI 10.1093/hmg/ddl041; Moore T, 1997, P NATL ACAD SCI USA, V94, P12509, DOI 10.1073/pnas.94.23.12509; Murphy SK, 2006, MOL CANCER RES, V4, P283, DOI 10.1158/1541-7786.MCR-05-0138; Murrell A, 2004, NAT GENET, V36, P889, DOI 10.1038/ng1402; Murrell A, 2001, EMBO REP, V2, P1101, DOI 10.1093/embo-reports/kve248; Netchine I, 2007, J CLIN ENDOCR METAB, V92, P3148, DOI 10.1210/jc.2007-0354; Okamoto K, 1997, P NATL ACAD SCI USA, V94, P5367, DOI 10.1073/pnas.94.10.5367; Pant V, 2004, MOL CELL BIOL, V24, P3497, DOI 10.1128/MCB.24.8.3497-3504.2004; Smith AC, 2007, PEDIATR RES, V61, p43R, DOI 10.1203/pdr.0b013e3180457660; Sparago A, 2004, NAT GENET, V36, P958, DOI 10.1038/ng1410; Sparago A, 2007, HUM MOL GENET, V16, P254, DOI 10.1093/hmg/ddl448; Sullivan MJ, 1999, ONCOGENE, V18, P7527, DOI 10.1038/sj.onc.1203096; Szabo PE, 2000, CURR BIOL, V10, P607, DOI 10.1016/S0960-9822(00)00489-9; Thorvaldsen JL, 2006, MOL CELL BIOL, V26, P1245, DOI 10.1128/MCB.26.4.1245-1258.2006; Thorvaldsen JL, 1998, GENE DEV, V12, P3693, DOI 10.1101/gad.12.23.3693; Ulaner GA, 2003, HUM MOL GENET, V12, P535, DOI 10.1093/hmg/ddg034; Weksberg R, 2001, HUM MOL GENET, V10, P2989, DOI 10.1093/hmg/10.26.2989	32	84	86	0	15	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1849	10.1371/journal.pone.0001849	http://dx.doi.org/10.1371/journal.pone.0001849			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	370KZ	18365005	Green Published, Green Submitted, gold			2022-12-25	WOS:000260762400011
J	Okanoya, K; Tokimoto, N; Kumazawa, N; Hihara, S; Iriki, A				Okanoya, Kazuo; Tokimoto, Naoko; Kumazawa, Noriko; Hihara, Sayaka; Iriki, Atsushi			Tool-Use Training in a Species of Rodent: The Emergence of an Optimal Motor Strategy and Functional Understanding	PLOS ONE			English	Article							OCTODON-DEGUS; CALEDONIAN CROWS; MIRROR NEURONS; BODY SCHEMA; INTELLIGENCE; EVOLUTION; CORTEX; MONKEYS; PRIMATES; BEHAVIOR	Background: Tool use is defined as the manipulation of an inanimate object to change the position or form of a separate object. The expansion of cognitive niches and tool-use capabilities probably stimulated each other in hominid evolution. To understand the causes of cognitive expansion in humans, we need to know the behavioral and neural basis of tool use. Although a wide range of animals exhibit tool use in nature, most studies have focused on primates and birds on behavioral or psychological levels and did not directly address questions of which neural modifications contributed to the emergence of tool use. To investigate such questions, an animal model suitable for cellular and molecular manipulations is needed. Methodology/Principal Findings: We demonstrated for the first time that rodents can be trained to use tools. Through a step-by-step training procedure, we trained degus (Octodon degus) to use a rake-like tool with their forelimbs to retrieve otherwise out-of-reach rewards. Eventually, they mastered effective use of the tool, moving it in an elegant trajectory. After the degus were well trained, probe tests that examined whether they showed functional understanding of the tool were performed. Degus did not hesitate to use tools of different size, colors, and shapes, but were reluctant to use the tool with a raised nonfunctional blade. Thus, degus understood the functional and physical properties of the tool after extensive training. Conclusions/Significance: Our findings suggest that tool use is not a specific faculty resulting from higher intelligence, but is a specific combination of more general cognitive faculties. Studying the brains and behaviors of trained rodents can provide insights into how higher cognitive functions might be broken down into more general faculties, and also what cellular and molecular mechanisms are involved in the emergence of such cognitive functions.	[Okanoya, Kazuo; Tokimoto, Naoko] RIKEN, Brain Sci Inst, Lab Biolinguist, Saitama, Japan; [Tokimoto, Naoko; Kumazawa, Noriko; Hihara, Sayaka; Iriki, Atsushi] RIKEN, Brain Sci Inst, Lab Symbolic Cognit Dev, Saitama, Japan	RIKEN; RIKEN	Okanoya, K (corresponding author), RIKEN, Brain Sci Inst, Lab Biolinguist, Saitama, Japan.	iriki@brain.riken.jp	Okanoya, Kazuo/F-8528-2010		MEXT, JAPAN [18020035, 18019040]; RIKEN	MEXT, JAPAN(Ministry of Education, Culture, Sports, Science and Technology, Japan (MEXT)); RIKEN	Work supported by a Grant-in-Aid for Scientific Research on Priority Areas, System study on higher-order brain functions, from MEXT, JAPAN, #18020035 to AI and 18019040 to KO. NT was supported by a Special Postdoctoral Research Program from RIKEN.	Ambrose SH, 2001, SCIENCE, V291, P1748, DOI 10.1126/science.1059487; Beck B. B., 1980, ANIMAL TOOL BEHAV US; Braun K, 2000, NEUROSCIENCE, V95, P309; Emery NJ, 2006, PHILOS T R SOC B, V361, P23, DOI 10.1098/rstb.2005.1736; Emery NJ, 2004, SCIENCE, V306, P1903, DOI 10.1126/science.1098410; Ferrari PF, 2005, J COGNITIVE NEUROSCI, V17, P212, DOI 10.1162/0898929053124910; Fujita K, 2003, J EXP PSYCHOL ANIM B, V29, P233, DOI 10.1037/0097-7403.29.3.233; FULK GW, 1976, J MAMMAL, V57, P495, DOI 10.2307/1379298; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Hauser MD, 1997, COGNITION, V64, P285, DOI 10.1016/S0010-0277(97)00028-0; Hihara S, 2003, PHYSIOL BEHAV, V78, P427, DOI 10.1016/S0031-9384(02)01006-5; Hihara S, 2006, NEUROPSYCHOLOGIA, V44, P2636, DOI 10.1016/j.neuropsychologia.2005.11.020; Hunt GR, 1996, NATURE, V379, P249, DOI 10.1038/379249a0; Iriki A, 1996, NEUROREPORT, V7, P2325; Iriki A, 2006, CURR OPIN NEUROBIOL, V16, P660, DOI 10.1016/j.conb.2006.10.008; Ishibashi H, 2000, CAN J PHYSIOL PHARM, V78, P958, DOI 10.1139/cjpp-78-11-958; Lewis JW, 2006, NEUROSCIENTIST, V12, P211, DOI 10.1177/1073858406288327; Maravita A, 2004, TRENDS COGN SCI, V8, P79, DOI 10.1016/j.tics.2003.12.008; OWNING DH, 1977, BEHAVIOUR, V62, P50; Reader SM, 2002, P NATL ACAD SCI USA, V99, P4436, DOI 10.1073/pnas.062041299; Rioult-Pedotti MS, 1998, NAT NEUROSCI, V1, P230, DOI 10.1038/678; Rocamora N, 1996, J NEUROSCI, V16, P3991; Santos LR, 2006, ANIM COGN, V9, P94, DOI 10.1007/s10071-005-0001-8; Schaefer M, 2004, NEUROREPORT, V15, P1293, DOI 10.1097/01.wnr.0000129573.36301.db; Shuster Gabriela, 1998, ANIM COGN, V1, P71, DOI [10.1007/s100710050009, DOI 10.1007/S100710050009]; Taylor AH, 2007, CURR BIOL, V17, P1504, DOI 10.1016/j.cub.2007.07.057; Tebbich S, 2004, ANIM BEHAV, V67, P689, DOI 10.1016/j.anbehav.2003.08.003; Tokimoto N, 2004, JPN PSYCHOL RES, V46, P255, DOI 10.1111/j.1468-5584.2004.00257.x; van Schaik CP, 1999, J HUM EVOL, V36, P719, DOI 10.1006/jhev.1999.0304; Wan H, 2001, EUR J NEUROSCI, V14, P118, DOI 10.1046/j.0953-816x.2001.01625.x; WILSON SC, 1982, DEV PSYCHOBIOL, V15, P257, DOI 10.1002/dev.420150309; WILSON SC, 1974, AM ZOOL, V14, P341; WOODS C A, 1975, Mammalian Species, V67, P1	33	45	47	1	12	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	185 BERRY ST, STE 1300, SAN FRANCISCO, CA 94107 USA	1932-6203			PLOS ONE	PLoS One	MAR 26	2008	3	3							e1860	10.1371/journal.pone.0001860	http://dx.doi.org/10.1371/journal.pone.0001860			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	370KZ	18365015	gold, Green Submitted, Green Published			2022-12-25	WOS:000260762400021
